{"meta":{"query_hash":"6147ccd71970","filters":{"topic":"Cancer Immunotherapy and Biomarkers"},"cohort_total":2980,"direct_labels_cover":12,"predictions_cover":2980,"exported":2980,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/6147ccd71970","api":"https://metacan.xera.ac/api/v1/cohort?topic=Cancer+Immunotherapy+and+Biomarkers"},"results":[{"id":"W106357471","doi":"10.4049/jimmunol.178.supp.88.26","title":"The inverse agonist activity of soluble CTLA-4 ligands requires oligomerization of this receptor and CD28 expression (88.26)","year":2007,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"CD28; Receptor; Chemistry; Cell biology; T cell; Agonist; CTLA-4; Inverse agonist; T-cell receptor; Ligand (biochemistry); Biochemistry; Biology; In vitro; Cytotoxic T cell; Immunology; Immune system","score_opus":0.015520475560532954,"score_gpt":0.27517769530768327,"score_spread":0.25965721974715034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W106357471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917959,0.005165183,0.00021654846,0.0018372103,0.0005064804,0.00011269769,0.0000013693465,0.0000058777277,0.0003587343],"genre_scores_gemma":[0.98759323,0.0117328465,0.000118010335,0.00007987154,0.00007733448,6.02065e-7,7.0972965e-7,0.000012012411,0.00038539054],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99901223,0.000111702655,0.00048008832,0.000058870548,0.00017850645,0.00015858353],"domain_scores_gemma":[0.9984033,0.00034755954,0.00080680096,0.00022829315,0.00018522184,0.000028788638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015788532,0.000092158,0.00029330037,0.000099453384,0.00014508946,0.0000057833317,0.00016079676,0.00010550197,0.00005828915],"category_scores_gemma":[0.00015203725,0.00004769272,0.000092151575,0.00016930907,0.0006281599,0.00009867859,0.000050143393,0.00023413808,9.612806e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014094842,0.00007824927,0.0008354777,0.000024211342,0.00023330025,0.000001897687,0.0013068551,8.356125e-7,0.9600956,0.000016270207,0.0009819844,0.022330482],"study_design_scores_gemma":[0.0019636487,0.0011968295,0.018028628,0.00019940206,0.00008535781,0.00017103444,0.0008158766,0.000007723731,0.97104925,0.00005725911,0.0063767834,0.000048197428],"about_ca_topic_score_codex":0.00010571173,"about_ca_topic_score_gemma":0.000028103857,"teacher_disagreement_score":0.022282284,"about_ca_system_score_codex":0.00004833995,"about_ca_system_score_gemma":0.00011771699,"threshold_uncertainty_score":0.23144813},"labels":[],"label_agreement":null},{"id":"W1127933869","doi":"10.1097/cji.0000000000000089","title":"Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents","year":2015,"lang":"en","type":"article","venue":"Journal of Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Clinical trial; Oncology; Drug development; Cancer; Chemotherapy; Disease; Immunotherapy; Drug; Internal medicine; Pharmacology","score_opus":0.23698800890256355,"score_gpt":0.4567935504305351,"score_spread":0.21980554152797155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1127933869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95859426,0.021520222,0.013830816,0.0021587855,0.0025134168,0.0011524676,0.00002049658,0.000014538028,0.00019499625],"genre_scores_gemma":[0.9819757,0.006272272,0.009297997,0.0018283552,0.00040279413,0.000019258092,0.0000022337865,0.000043390646,0.0001580497],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99642277,0.0005091588,0.0021535577,0.00015187301,0.00053047383,0.00023215343],"domain_scores_gemma":[0.9976811,0.00055255095,0.00089865486,0.00028074437,0.00045561258,0.0001313286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030157499,0.00018159692,0.00085477775,0.0002875505,0.000030117919,0.000024748395,0.0001449865,0.00016344656,0.00077986706],"category_scores_gemma":[0.00033219624,0.00013965383,0.00030197084,0.00025449943,0.0002485829,0.00013568152,0.000010441762,0.0004286355,0.000004202064],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80622023,0.0036391285,0.028531572,0.000051289324,0.0030512311,0.0003006702,0.002938926,0.00041520572,0.03561335,0.00023377175,0.014065684,0.10493895],"study_design_scores_gemma":[0.7433259,0.034670796,0.1829468,0.001372572,0.00047320826,0.00094375684,0.0010678809,0.00061772077,0.007243648,0.00304973,0.023614004,0.0006740187],"about_ca_topic_score_codex":0.00012862482,"about_ca_topic_score_gemma":0.000009255297,"teacher_disagreement_score":0.15441523,"about_ca_system_score_codex":0.00023643592,"about_ca_system_score_gemma":0.0018343617,"threshold_uncertainty_score":0.8538997},"labels":[],"label_agreement":null},{"id":"W1136136811","doi":"10.1158/1538-7445.am2015-256","title":"Abstract 256: Identification of additional cancers likely to respond to anti-PD-1 therapy (pembrolizumab): Evaluation of PD-L1 expression in a large molecular tumor profiling gene expression database","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University College of the North","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Melanoma; Cancer; PD-L1; Oncology; Internal medicine; Database; Cancer research; Immunotherapy","score_opus":0.1575729984442325,"score_gpt":0.463054980766536,"score_spread":0.3054819823223035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1136136811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921824,0.0029600263,0.0002353076,0.00040769437,0.00015714532,0.0023063899,0.0015965399,0.000014779381,0.00013972541],"genre_scores_gemma":[0.99643445,0.00031470874,0.001010469,0.0001536553,0.00013188619,0.001258837,0.0005792189,0.00003941385,0.0000773373],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9953846,0.00044151006,0.00069958856,0.0005546497,0.0024657678,0.00045389638],"domain_scores_gemma":[0.9969915,0.00012974584,0.00021858122,0.0006688293,0.0017161096,0.00027520204],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005428395,0.00017389824,0.00034721696,0.0008403823,0.0000755012,0.000024387424,0.0002863276,0.000096234326,0.001269867],"category_scores_gemma":[0.0007701871,0.00015487091,0.0000832829,0.0012104425,0.00009987742,0.00021316946,0.00010668843,0.00029996858,0.000012555838],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017538833,0.00023829885,0.0009524902,0.00015747585,0.000032803462,0.000015050828,0.0009530114,0.00071752054,0.9682708,0.000005888004,0.006952104,0.004165744],"study_design_scores_gemma":[0.005449822,0.00033819757,0.03826834,0.0014328768,0.000012899621,0.0000035168632,0.00056522025,0.00028488,0.9519706,0.000039073537,0.0014905764,0.00014401646],"about_ca_topic_score_codex":0.00081463356,"about_ca_topic_score_gemma":0.00010704512,"teacher_disagreement_score":0.03731585,"about_ca_system_score_codex":0.0012528626,"about_ca_system_score_gemma":0.0029324892,"threshold_uncertainty_score":0.9996431},"labels":[],"label_agreement":null},{"id":"W1478180867","doi":"10.1016/j.ejca.2015.06.072","title":"P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Monoclonal antibody; Melanoma; Antibody; Monoclonal; Oncology; Internal medicine; Cancer research; Immunotherapy; Immunology; Cancer","score_opus":0.031577964653606364,"score_gpt":0.33412338809626674,"score_spread":0.3025454234426604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1478180867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99437153,0.0015278639,0.000018527691,0.00086729525,0.0007172403,0.00020087587,0.000014272655,0.000006174835,0.0022761885],"genre_scores_gemma":[0.99857056,0.00025757775,0.00013790501,0.00047770984,0.00031762794,3.833382e-7,0.000006318032,0.000035898516,0.00019604545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765027,0.00045154453,0.0009360085,0.00015585532,0.00060302933,0.00020329106],"domain_scores_gemma":[0.99828595,0.00004514381,0.0007541881,0.00027197693,0.00048002272,0.00016270461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011551043,0.00015843575,0.00047986113,0.00011439326,0.000028041723,0.000013824519,0.0002901382,0.000036339006,0.00013733859],"category_scores_gemma":[0.00010598187,0.0000871303,0.00021048314,0.00032423777,0.00020943541,0.00010060258,0.00004805033,0.0004123819,0.0000059793156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017365336,0.0005211893,0.9549696,0.000015886499,0.0003644721,0.00013751817,0.00038676118,0.000050205348,0.00092282676,0.0000035597293,0.004933164,0.020329496],"study_design_scores_gemma":[0.02446861,0.0015863768,0.94523245,0.00048571525,0.00012240814,0.000053823653,0.000056009743,0.000012463666,0.00052690227,0.0000017210679,0.027348494,0.000105047104],"about_ca_topic_score_codex":0.00004697473,"about_ca_topic_score_gemma":0.00001624589,"teacher_disagreement_score":0.022415329,"about_ca_system_score_codex":0.000117424584,"about_ca_system_score_gemma":0.00056044216,"threshold_uncertainty_score":0.35530704},"labels":[],"label_agreement":null},{"id":"W1488432447","doi":"10.1186/1479-5876-13-s1-o6","title":"Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma","year":2015,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Royal Victoria Regional Health Centre; BC Cancer Agency","funders":"","keywords":"Dacarbazine; Nivolumab; Melanoma; Medicine; Oncology; Overall survival; Internal medicine; Metastatic melanoma; Cancer research; Immunotherapy; Cancer","score_opus":0.015103153828286971,"score_gpt":0.2616498349889505,"score_spread":0.24654668116066353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1488432447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893002,0.001297988,0.0003252537,0.007410614,0.00041168736,0.0002915244,0.0000091200545,0.0000097249695,0.00094391056],"genre_scores_gemma":[0.99783444,0.00004567193,0.0013318596,0.00030374274,0.00027697842,0.0000021141068,0.000056072917,0.000019083476,0.00013005937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982769,0.000048654205,0.00063920487,0.00012453644,0.00074195466,0.00016873429],"domain_scores_gemma":[0.9987595,0.00007727039,0.00027938248,0.00011465592,0.0005770022,0.00019216619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004854968,0.00015383758,0.000498734,0.00027720933,0.000019479821,0.000004037046,0.00008324508,0.0000682164,0.00013836264],"category_scores_gemma":[0.00008102807,0.00009556974,0.000067291476,0.00038351733,0.00010943651,0.00016498637,0.0000032750875,0.0002406204,0.0000012915959],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12210496,0.0006529332,0.8389246,0.00006067897,0.0005218513,0.000106965184,0.0010718185,0.000115475705,0.0047027688,0.000043540324,0.00081048894,0.030883914],"study_design_scores_gemma":[0.0763247,0.008120201,0.9102559,0.00056701334,0.00015867256,0.000075890785,0.00014769225,0.00014304304,0.00018850136,0.00007728063,0.0038200382,0.000121074336],"about_ca_topic_score_codex":0.00006240135,"about_ca_topic_score_gemma":0.00007406304,"teacher_disagreement_score":0.071331285,"about_ca_system_score_codex":0.0001348563,"about_ca_system_score_gemma":0.00033154336,"threshold_uncertainty_score":0.38972208},"labels":[],"label_agreement":null},{"id":"W1495108757","doi":"10.1080/2162402x.2015.1016709","title":"The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade","year":2015,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Blockade; Immune system; Cancer research; CD8; PD-L1; Tumor microenvironment; Immunotherapy; T cell; Medicine; Cell; Radiation therapy; Acquired immune system; Immunology; Biology; Receptor; Internal medicine","score_opus":0.02045912337141762,"score_gpt":0.26386041447586994,"score_spread":0.24340129110445233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1495108757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87428325,0.10100233,0.000022842716,0.022792844,0.0004294193,0.0006868028,0.00035899208,0.00012052113,0.00030297408],"genre_scores_gemma":[0.97165835,0.010716082,0.00005859001,0.0027091613,0.000053556534,0.00011815899,0.0007261371,0.00006870729,0.013891271],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99733955,0.0007448097,0.0005719063,0.00050247525,0.0003262479,0.00051504106],"domain_scores_gemma":[0.9982063,0.00040042607,0.00042260732,0.0005446596,0.00029165213,0.00013436185],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00086817594,0.00035292265,0.00048520992,0.00013008721,0.00040893766,0.000058322094,0.00022538159,0.0002624533,0.000074909156],"category_scores_gemma":[0.00018591543,0.000278185,0.00009674377,0.000549802,0.0005587483,0.00011153614,0.000037846752,0.00047897466,0.000007364537],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04858776,0.00026964044,0.00029154756,0.0000053790664,0.0003611323,0.000025060413,0.00046917735,6.854534e-7,0.8021436,0.0000075661987,0.145607,0.0022314873],"study_design_scores_gemma":[0.012005011,0.0016114447,0.009158619,0.000034653498,0.00006236624,0.00009285307,0.0011229104,0.000108962384,0.25236097,0.000010734525,0.72311014,0.00032134846],"about_ca_topic_score_codex":0.0014328791,"about_ca_topic_score_gemma":0.00009062776,"teacher_disagreement_score":0.57750314,"about_ca_system_score_codex":0.0005386617,"about_ca_system_score_gemma":0.00051268464,"threshold_uncertainty_score":0.99996704},"labels":[],"label_agreement":null},{"id":"W1517732299","doi":"10.1186/s40425-015-0066-0","title":"Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Cancer Institute","keywords":"Ipilimumab; Medicine; Liver transplantation; Melanoma; Transplantation; Metastatic melanoma; Oncology; Internal medicine; Cancer; Immunotherapy; Cancer research","score_opus":0.020230095732515482,"score_gpt":0.3295934070659579,"score_spread":0.3093633113334424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1517732299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814464,0.016169209,0.00044231126,0.0010094126,0.00013717555,0.00058753206,0.00003632912,0.0000027834596,0.00016885354],"genre_scores_gemma":[0.9836422,0.014903114,0.0010085248,0.0002607754,0.00005924974,0.000016566773,0.0000037093812,0.000016080736,0.000089773945],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989262,0.000055914734,0.0005477499,0.00009259601,0.000246198,0.00013130707],"domain_scores_gemma":[0.9991751,0.00017467127,0.0003092165,0.00012711145,0.00017506257,0.000038881626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069591845,0.00010508849,0.00035452683,0.0001356492,0.000034850837,0.0000057140915,0.00010145815,0.00004991657,0.000031951215],"category_scores_gemma":[0.000025215919,0.00006860367,0.00013419645,0.00019702587,0.00006107279,0.00008075929,0.0000032641224,0.00009690248,8.1234965e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12052128,0.0002035777,0.00694514,0.0003411545,0.00024534846,0.000005206236,0.02171,0.00024390059,0.2835704,0.000029405845,0.000159284,0.5660253],"study_design_scores_gemma":[0.075836964,0.0069531538,0.6948488,0.0020642264,0.00032926898,0.000300286,0.0032531864,0.00013931753,0.19953966,0.00013473057,0.016313538,0.0002868712],"about_ca_topic_score_codex":0.0003325869,"about_ca_topic_score_gemma":0.00013482846,"teacher_disagreement_score":0.68790364,"about_ca_system_score_codex":0.000089379784,"about_ca_system_score_gemma":0.0001584405,"threshold_uncertainty_score":0.27975768},"labels":[],"label_agreement":null},{"id":"W1542041702","doi":"10.1111/j.1365-2249.2010.04147.x","title":"Survival in rectal cancer is predicted by T cell infiltration of tumour-associated lymphoid nodules","year":2010,"lang":"en","type":"article","venue":"Clinical & Experimental Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Edmonton Civic Employees Charitable Assistance Fund","keywords":"Biology; Pathology; CD3; Immune system; Lymphatic system; T cell; Dendritic cell; CD8; Immunology; Medicine","score_opus":0.024033154550021394,"score_gpt":0.36079200644691295,"score_spread":0.33675885189689153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1542041702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993323,0.002803129,0.000002049303,0.00047771804,0.0018597902,0.00034493796,0.0001300821,0.000046181744,0.001013094],"genre_scores_gemma":[0.9978914,0.0008189126,0.00006380329,0.0005338202,0.00010022084,0.000055162043,0.00017257764,0.00002650627,0.00033755825],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99804044,0.0001696026,0.00095723994,0.00035775336,0.00017703614,0.000297902],"domain_scores_gemma":[0.99906516,0.00020358585,0.00030749937,0.00027372764,0.00008151296,0.000068489724],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039504157,0.00019065218,0.00058176566,0.000082556326,0.00004213931,0.000008041104,0.00016111601,0.00046881216,0.001332297],"category_scores_gemma":[0.00013270328,0.0001763327,0.00020646505,0.00022911935,0.0005906719,0.00008098614,0.000057987898,0.0004893148,0.00000904826],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022701758,0.001729836,0.1560513,0.00000715081,0.0001538874,0.0000051217667,0.0003403864,6.022495e-8,0.8365015,0.00000751528,0.0015441513,0.0013889736],"study_design_scores_gemma":[0.008082009,0.0011640232,0.23479146,0.000047057227,0.000028367771,0.000010349008,0.00038006477,0.0000318114,0.75358,0.0000072071875,0.0017323024,0.00014536621],"about_ca_topic_score_codex":0.0016007235,"about_ca_topic_score_gemma":0.00017218251,"teacher_disagreement_score":0.082921475,"about_ca_system_score_codex":0.00013825065,"about_ca_system_score_gemma":0.00021833135,"threshold_uncertainty_score":0.9995806},"labels":[],"label_agreement":null},{"id":"W1591498347","doi":"10.1158/1538-7445.am2014-2987","title":"Abstract 2987: Evaluation of CTLA-4 blockage with sequential metronomic chemotherapy for the treatment of preclinical breast cancer","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Ipilimumab; Cyclophosphamide; Breast cancer; Chemotherapy; Paclitaxel; Internal medicine; Bolus (digestion); Oncology; Combination therapy; Cancer; Immunotherapy","score_opus":0.16587068743173164,"score_gpt":0.4865170146534458,"score_spread":0.32064632722171416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1591498347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906222,0.0042012683,0.00008377348,0.0026599944,0.0001279832,0.00189712,0.00012538927,0.0000074322625,0.0002748126],"genre_scores_gemma":[0.99478686,0.00335153,0.00005999153,0.000050088096,0.0004591116,0.00090657757,0.00001058782,0.000028040924,0.00034719278],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982996,0.00012920448,0.0003165828,0.00025823968,0.00072276656,0.00027359521],"domain_scores_gemma":[0.9981848,0.0004482958,0.00014250456,0.00040675767,0.00075517135,0.00006249591],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022133065,0.00012031511,0.00033261825,0.000100191566,0.00008263721,0.0000116146275,0.00014118371,0.000074036776,0.0014729311],"category_scores_gemma":[0.000030088037,0.00006765348,0.00016269089,0.0002275216,0.00040073352,0.000034488563,0.000008332798,0.00011021227,0.0000011117617],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02823901,0.000726701,0.01279332,0.0002494143,0.00178785,3.258563e-7,0.0007582289,0.00033296362,0.16376983,0.0000273332,0.0015391804,0.78977585],"study_design_scores_gemma":[0.033332933,0.0048852405,0.45557886,0.00063883944,0.0007989718,0.0000075836865,0.00027665892,0.004292717,0.47524694,0.000075199096,0.024645729,0.00022033132],"about_ca_topic_score_codex":0.0038532694,"about_ca_topic_score_gemma":0.0008741137,"teacher_disagreement_score":0.7895555,"about_ca_system_score_codex":0.0006592546,"about_ca_system_score_gemma":0.0010959663,"threshold_uncertainty_score":0.99943984},"labels":[],"label_agreement":null},{"id":"W1606039500","doi":"10.1158/1538-7445.am2015-ct104","title":"Abstract CT104: Efficacy of pembrolizumab (MK-3475) and relationship with PD-L1 expression in patients with non-small cell lung cancer: Findings from KEYNOTE-001)","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Lung cancer; Oncology; Cancer; Response Evaluation Criteria in Solid Tumors; Clinical trial; Disease; Progressive disease; Immunotherapy","score_opus":0.04928253500601571,"score_gpt":0.3471469764546767,"score_spread":0.297864441448661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1606039500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99460644,0.0031526282,0.00000854816,0.00032551732,0.000067883615,0.0010769974,0.00007951768,0.000016376809,0.0006660758],"genre_scores_gemma":[0.9985575,0.00038582322,0.00017828445,0.000054097563,0.00008111875,0.00016427625,0.000073302486,0.000046208337,0.00045940012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782026,0.00008507463,0.00031967775,0.00045657405,0.00085975364,0.00045868207],"domain_scores_gemma":[0.9985372,0.0002924233,0.00011686132,0.0003876539,0.00041512915,0.00025077807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049793505,0.00019760503,0.000355702,0.00031000556,0.000101869875,0.00003557483,0.00017255041,0.00015044278,0.00021475542],"category_scores_gemma":[0.00006496844,0.00014068186,0.00003392468,0.00057162845,0.0002675716,0.00015208218,0.000066424174,0.00062485907,0.0000038154235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040184468,0.00036829183,0.93858826,0.00028167482,0.00006849843,0.000016556662,0.0021462082,0.000058578065,0.013321681,0.0000010890795,0.0030737887,0.0018909018],"study_design_scores_gemma":[0.027315494,0.00073730975,0.9494702,0.0019000282,0.0000393411,8.2825665e-7,0.0003710213,0.000034198965,0.019317755,0.000007924701,0.00062692125,0.00017892524],"about_ca_topic_score_codex":0.0113692675,"about_ca_topic_score_gemma":0.0010590628,"teacher_disagreement_score":0.012868975,"about_ca_system_score_codex":0.0006071133,"about_ca_system_score_gemma":0.000966627,"threshold_uncertainty_score":0.9952141},"labels":[],"label_agreement":null},{"id":"W1703213295","doi":"10.2147/dddt.s78036","title":"Spotlight on pembrolizumab in the treatment of advanced melanoma","year":2015,"lang":"en","type":"review","venue":"Drug Design Development and Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Melanoma; Metastatic melanoma; Food and drug administration; Immune system; Immunotherapy; Disease; Cancer; Drug; Immune checkpoint; Oncology; Immunology; Cancer research; Internal medicine; Pharmacology","score_opus":0.08665092685978829,"score_gpt":0.3368170679676156,"score_spread":0.2501661411078273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1703213295","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023506975,0.99460775,0.00000508735,0.000095443684,0.00011716341,0.002171033,0.000004546778,0.000017316012,0.00063096074],"genre_scores_gemma":[0.000133184,0.9977085,0.0005105703,0.00013577181,0.000058332153,0.00038853323,0.00006392332,0.000039393577,0.00096178945],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99837655,0.00022395505,0.0005544347,0.00031453092,0.00030640693,0.00022411291],"domain_scores_gemma":[0.9991852,0.00018941195,0.0002186699,0.0003163903,0.000034873836,0.000055420016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005091771,0.00042448353,0.0012910276,0.00024576794,0.00004855628,0.000016184453,0.00014777404,0.00013580598,0.00003233482],"category_scores_gemma":[0.0000031116706,0.00021162131,0.0001970345,0.00030014332,0.000060984225,0.000024951152,0.0000053225913,0.0001114492,0.000010430108],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021194187,0.00044242453,0.00000823013,0.00046624124,0.00036252307,0.00004027714,0.0036324176,9.215763e-8,0.000003826537,0.00001693937,0.0003044834,0.9926031],"study_design_scores_gemma":[0.0049986932,0.0011215205,0.000087816756,0.0025495742,0.00009145744,0.000043246517,0.00010504551,3.175289e-7,0.00028567866,0.00002000829,0.9904679,0.00022876299],"about_ca_topic_score_codex":0.000009970238,"about_ca_topic_score_gemma":0.000003863965,"teacher_disagreement_score":0.99237436,"about_ca_system_score_codex":0.00027314737,"about_ca_system_score_gemma":0.00069907727,"threshold_uncertainty_score":0.8629667},"labels":[],"label_agreement":null},{"id":"W1781387617","doi":"10.1080/2162402x.2015.1050575","title":"B7-H4 is a positive regulator of antitumor immunity","year":2015,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Regulator; Negative regulator; Cancer research; Immunity; Medicine; Immune system; T cell; Immunology; Biology; Signal transduction; Cell biology; Genetics; Gene","score_opus":0.030064290279245134,"score_gpt":0.3041757713370558,"score_spread":0.2741114810578107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1781387617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97935116,0.0054612705,0.000032348744,0.0021090284,0.00038229994,0.00024438032,0.00002768625,0.000045621626,0.012346213],"genre_scores_gemma":[0.9959428,0.00025278475,0.0004873986,0.0009570785,0.000054354317,0.000009683284,0.000028337325,0.000019358662,0.0022482232],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99901885,0.000087639055,0.0003173492,0.00018226416,0.00016154977,0.00023235379],"domain_scores_gemma":[0.99899393,0.00004364024,0.00015803725,0.0005023751,0.00023683727,0.00006518457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028443598,0.00014008688,0.00042980496,0.00013433932,0.00004324354,0.0000048903535,0.00014377123,0.0001592575,0.00031684394],"category_scores_gemma":[0.00006574925,0.000120579185,0.00014352037,0.00026462908,0.00041017245,0.00006318849,0.00006452556,0.00019720031,0.00005626175],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02146277,0.0012523668,0.030349132,0.00011208507,0.0019118905,0.00014458924,0.007708407,5.142786e-7,0.8570412,0.0015647227,0.021067716,0.05738465],"study_design_scores_gemma":[0.014919581,0.00570629,0.5427169,0.00034253014,0.0002480826,0.0010609746,0.003133779,0.000025537849,0.32902032,0.0006568443,0.10174999,0.00041912522],"about_ca_topic_score_codex":0.0011858105,"about_ca_topic_score_gemma":0.000019313038,"teacher_disagreement_score":0.5280208,"about_ca_system_score_codex":0.0001493531,"about_ca_system_score_gemma":0.00033167127,"threshold_uncertainty_score":0.49170762},"labels":[],"label_agreement":null},{"id":"W1811235998","doi":"10.1111/ecc.12398","title":"Patterns of practice in oncology: is progress reaching our practice?","year":2015,"lang":"en","type":"letter","venue":"European Journal of Cancer Care","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Reimbursement; Anticipation (artificial intelligence); Enthusiasm; Intensive care medicine; Clinical Practice; Audit; Disease; Family medicine; Health care; Internal medicine","score_opus":0.037849446120564095,"score_gpt":0.3774756749990305,"score_spread":0.3396262288784664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1811235998","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046501555,0.09173908,0.000013555441,0.88544786,0.0024342407,0.00046584973,0.0001362642,0.000015060952,0.015097932],"genre_scores_gemma":[0.083046235,0.015372809,0.0025395919,0.88156974,0.015761556,0.000012734953,0.000081894075,0.0003041916,0.0013112426],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99564797,0.0015032504,0.0012058342,0.0002768579,0.0010399456,0.00032616645],"domain_scores_gemma":[0.994168,0.00018633815,0.003151956,0.0003979398,0.0019780055,0.0001177608],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0021996521,0.00032376387,0.0009000454,0.0003878792,0.000030455598,0.000040198567,0.00038875357,0.0002359921,0.00006072115],"category_scores_gemma":[0.00055679056,0.00025914586,0.00034536945,0.00020943503,0.000050107785,0.00035008133,0.0000706955,0.003344186,0.000006026296],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004425256,0.000110146495,0.0022315506,0.0006097195,0.00090078637,0.020236438,0.018658862,0.0000021969292,0.00008714804,1.4693853e-7,0.7231666,0.2295712],"study_design_scores_gemma":[0.004698416,0.0021059662,0.0015301354,0.00422311,0.00093142857,0.0021972246,0.012571396,3.410358e-7,0.00013983557,5.839199e-7,0.9713705,0.0002310735],"about_ca_topic_score_codex":0.00027888897,"about_ca_topic_score_gemma":0.000030668467,"teacher_disagreement_score":0.24820393,"about_ca_system_score_codex":0.0012565929,"about_ca_system_score_gemma":0.0018805106,"threshold_uncertainty_score":0.99998605},"labels":[],"label_agreement":null},{"id":"W1848988387","doi":"10.3747/co.22.2418","title":"Increased Treatment-Related Toxicity Subsequent to an Anti–PD-1 Agent","year":2015,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Toxicity; Pharmacology; Bioinformatics; Internal medicine; Biology","score_opus":0.1724611190938377,"score_gpt":0.42649890711237987,"score_spread":0.25403778801854215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1848988387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913866,0.0019328101,0.00004296627,0.0016792392,0.0018984376,0.0007445415,0.000023918594,0.00011558305,0.0021759034],"genre_scores_gemma":[0.99800754,0.00029583107,0.0001612612,0.0006969845,0.000255009,0.00007781369,0.00016841573,0.000021852667,0.00031532574],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99858576,0.00017517927,0.00035082526,0.00035144744,0.00019402623,0.00034274068],"domain_scores_gemma":[0.9987925,0.00003236044,0.00009283577,0.00036133334,0.00012309832,0.0005978597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033443962,0.00020170592,0.00043400147,0.00014407822,0.000052815165,0.000012260587,0.000106284875,0.00014350032,0.0003286367],"category_scores_gemma":[0.000058310583,0.00015748522,0.00012825974,0.00026314874,0.000091180664,0.00005934477,0.00003169467,0.00012883783,0.00018143034],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011673254,0.009971402,0.1032139,0.00006571575,0.0006699803,0.00038480927,0.005568319,0.000018296536,0.084803514,0.00019384152,0.02820956,0.7552274],"study_design_scores_gemma":[0.015749836,0.011686789,0.07515829,0.0000748324,0.00023416306,0.00019504245,0.0004448039,0.00018615749,0.011879132,0.00006698926,0.88401175,0.0003122051],"about_ca_topic_score_codex":0.0003604993,"about_ca_topic_score_gemma":0.00018122763,"teacher_disagreement_score":0.8558022,"about_ca_system_score_codex":0.0016537242,"about_ca_system_score_gemma":0.000688517,"threshold_uncertainty_score":0.64220613},"labels":[],"label_agreement":null},{"id":"W1859257957","doi":"10.1002/path.4287","title":"Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours","year":2013,"lang":"en","type":"review","venue":"The Journal of Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1347,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Labex Immuno-Oncology; Cancer Research Institute; Qatar National Research Fund; Institut National de la Santé et de la Recherche Médicale; Institut National Du Cancer; Assistance publique-Hôpitaux de Paris; Fonds National de la Recherche Luxembourg; European Commission; Pathological Society of Great Britain and Ireland; National Center for Advancing Translational Sciences; Japan Association for Chemical Innovation; Society for Immunotherapy of Cancer","keywords":"Medicine; Oncology; Colorectal cancer; Cancer staging; Cancer; Stage (stratigraphy); Internal medicine; Immune system; TNM staging system; Neoplasm staging; Immunology; Biology","score_opus":0.07554092438918289,"score_gpt":0.3444991782666527,"score_spread":0.26895825387746986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1859257957","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015836606,0.9720396,0.000026592383,0.010149895,0.0009481442,0.00083342416,0.00000803317,0.0000017419239,0.00015597303],"genre_scores_gemma":[0.017979167,0.98112017,0.000024678986,0.00016259046,0.00055988523,0.000017216718,0.000004104197,0.000017015838,0.00011517868],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963945,0.0018221663,0.0011814394,0.00009750664,0.00035219215,0.00015220296],"domain_scores_gemma":[0.9964116,0.00027931106,0.0023341207,0.00076005625,0.00020175846,0.000013161213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043226373,0.0001839607,0.000941911,0.00013520362,0.00006266793,0.000006688682,0.0008620316,0.00016957475,0.00006792713],"category_scores_gemma":[0.00020399195,0.000055316716,0.000525918,0.00043842278,0.0006121949,0.00003527933,0.000050883813,0.00082125375,0.0000028515499],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006148531,0.00021176843,0.00007709629,0.0016547687,0.00035441713,0.000016888744,0.0030886335,0.0000019178547,0.009541974,0.0004274011,0.006111385,0.9778989],"study_design_scores_gemma":[0.0014166702,0.0014296093,0.042813905,0.006669599,0.004022362,0.01858344,0.0036217158,0.0000042361503,0.0006523213,0.0004944717,0.9201011,0.00019058054],"about_ca_topic_score_codex":0.00006103554,"about_ca_topic_score_gemma":0.000011960963,"teacher_disagreement_score":0.97770834,"about_ca_system_score_codex":0.00010464489,"about_ca_system_score_gemma":0.00041876594,"threshold_uncertainty_score":0.35679847},"labels":[],"label_agreement":null},{"id":"W1899263436","doi":"10.1080/2162402x.2015.1021537","title":"Identification of characteristic TRB V usage in HBV-associated HCC by using differential expression profiling analysis","year":2015,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Hepatocellular carcinoma; Liver cancer; T-cell receptor; Antigen; Cancer; clone (Java method); Biology; Immune system; Cancer research; Immunology; T cell; Medicine; Gene; Genetics","score_opus":0.03060118265010576,"score_gpt":0.312870143548007,"score_spread":0.28226896089790127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1899263436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977719,0.00077617634,0.00083507964,0.000065787804,0.00023701397,0.00020365282,0.000028779423,0.000022597722,0.000059019538],"genre_scores_gemma":[0.9992744,0.00007058188,0.000060418908,0.000024033436,0.000020351787,0.000013260659,0.00026289863,0.000012409543,0.000261675],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987147,0.00015989534,0.0005540539,0.00021666905,0.00016423264,0.00019046161],"domain_scores_gemma":[0.999207,0.000037435548,0.00037067867,0.0002532412,0.000098332705,0.000033289216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003628798,0.00011427004,0.0004882965,0.0003192486,0.000030692703,0.000009528445,0.00009358288,0.00017749428,0.00009550242],"category_scores_gemma":[0.00013110833,0.000103177495,0.00011583783,0.0005987357,0.00009807893,0.000068807814,0.000031677595,0.00014298921,0.0000036873491],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011451748,0.0002877467,0.05095821,0.000016517894,0.00035708322,0.000004507207,0.00041386692,0.0000039533443,0.9448192,0.000002245437,0.000031385767,0.001960085],"study_design_scores_gemma":[0.0064709997,0.00041084937,0.50885314,0.00018178191,0.000838683,0.000011803748,0.0007196285,0.004659045,0.47743058,0.00002612007,0.00016297154,0.00023442633],"about_ca_topic_score_codex":0.00041878244,"about_ca_topic_score_gemma":0.000030422947,"teacher_disagreement_score":0.46738863,"about_ca_system_score_codex":0.00029091473,"about_ca_system_score_gemma":0.000106966785,"threshold_uncertainty_score":0.4207456},"labels":[],"label_agreement":null},{"id":"W1932095640","doi":"10.7759/cureus.344","title":"Abscopal Effects: Case Report and Emerging Opportunities","year":2015,"lang":"en","type":"article","venue":"Cureus","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre; Trillium Health Centre; Western University","funders":"","keywords":"Abscopal effect; Medicine; Bystander effect; Immune system; Lung cancer; Hepatocellular carcinoma; Radiation therapy; Immunotherapy; Cancer research; Oncology; Immunology; Internal medicine","score_opus":0.0723776465769782,"score_gpt":0.3281939128873106,"score_spread":0.2558162663103324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1932095640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744361,0.010575716,0.000051438503,0.00096375815,0.00049831386,0.00017133926,0.0000023498078,0.00006155192,0.0132394],"genre_scores_gemma":[0.99555415,0.00031555077,0.00027278656,0.00057903735,0.00021578246,0.000012732557,0.000011230463,0.000013978739,0.0030247716],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9995141,0.000014843487,0.00013537442,0.00011741944,0.00010448581,0.00011380081],"domain_scores_gemma":[0.9995706,0.000022063801,0.00004407293,0.00017885439,0.000047384154,0.00013699871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023097846,0.00007679437,0.00013067052,0.000029666036,0.000038811315,0.000013429255,0.000019182582,0.00004007767,0.000048207447],"category_scores_gemma":[0.00007119232,0.00006249553,0.00003072525,0.000042273947,0.0000662527,0.000059960974,0.000018578217,0.000055687335,0.0000029810974],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014475143,0.00016133697,0.011733105,0.00037715986,0.00048511368,0.79505134,0.0047946624,4.568206e-7,0.006171956,0.00025631255,0.069087386,0.11043368],"study_design_scores_gemma":[0.0060833967,0.0011111321,0.003932894,0.00028120668,0.00026022,0.62248445,0.0073698596,0.00009400411,0.0050682775,0.00022365517,0.3527169,0.0003740008],"about_ca_topic_score_codex":0.0004783147,"about_ca_topic_score_gemma":0.000046116333,"teacher_disagreement_score":0.28362948,"about_ca_system_score_codex":0.000048138423,"about_ca_system_score_gemma":0.000097801596,"threshold_uncertainty_score":0.25484937},"labels":[],"label_agreement":null},{"id":"W1936207051","doi":"10.1038/mt.2015.156","title":"Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses","year":2015,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Cancer Institute; National Institute for Health and Care Research; Cancer Research UK","keywords":"Blockade; Innate immune system; Acquired immune system; Immune system; Biology; Immunology; Cancer research; Medicine; Virology; Receptor; Internal medicine","score_opus":0.026425680771000437,"score_gpt":0.27133376228427203,"score_spread":0.2449080815132716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1936207051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624818,0.032608073,0.0005758798,0.002805518,0.0000620203,0.0009322196,0.000010254931,0.00007177182,0.00045245487],"genre_scores_gemma":[0.98986024,0.005715452,0.0006858834,0.0033822523,0.00003304012,0.000062354775,0.000012826941,0.000052970947,0.00019495458],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985667,0.00021259928,0.0002560987,0.0003628036,0.0003367074,0.0002650862],"domain_scores_gemma":[0.99917144,0.000064544016,0.00014420644,0.0002916978,0.00021714605,0.000110954534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040870634,0.0002788484,0.0004364904,0.00010989307,0.000101755046,0.000059973536,0.000082597195,0.000088526416,0.000014372395],"category_scores_gemma":[0.0000296625,0.00019955586,0.00006580458,0.0002519289,0.00032323273,0.00014639071,0.000018935722,0.00017276483,0.0000023707591],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.064268395,0.00037625883,0.004086488,0.0000169979,0.00085797743,0.0003328724,0.002331808,0.0000010152122,0.9120198,0.0010236787,0.00007514389,0.0146095585],"study_design_scores_gemma":[0.07703633,0.0120045375,0.10462618,0.00025359282,0.00010673814,0.0007647625,0.00086134305,0.00011697242,0.78396803,0.002315382,0.017185174,0.00076097384],"about_ca_topic_score_codex":0.00033681546,"about_ca_topic_score_gemma":0.000004143523,"teacher_disagreement_score":0.12805179,"about_ca_system_score_codex":0.00005640042,"about_ca_system_score_gemma":0.00014532082,"threshold_uncertainty_score":0.8137651},"labels":[],"label_agreement":null},{"id":"W1944579984","doi":"10.1093/annonc/mdu342.3","title":"Phase I Study of Nivolumab in Combination with Ipilimumab in Metastatic Renal Cell Carcinoma (Mrcc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Renal cell carcinoma; Pneumonitis; Internal medicine; Adverse effect; Melanoma; Common Terminology Criteria for Adverse Events; Oncology; Gastroenterology; Cancer; Immunotherapy; Cancer research; Lung","score_opus":0.058387123618302054,"score_gpt":0.37296636802090927,"score_spread":0.3145792444026072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1944579984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967714,0.00020051697,0.000019994586,0.000576796,0.000038101956,0.0004907631,0.0000026361954,0.000004132051,0.0018956857],"genre_scores_gemma":[0.99951357,0.000028005119,0.00011493659,0.00022688508,0.000008050847,0.000023720528,0.000008315244,0.0000088944125,0.00006762919],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988764,0.0002194048,0.0004392388,0.00015490224,0.00015605809,0.0001539814],"domain_scores_gemma":[0.9993269,0.00012801331,0.00022197326,0.00018112011,0.00011104306,0.000030940453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064832286,0.000089389956,0.0004714667,0.00028512662,0.000010128865,0.0000013703464,0.000070302216,0.00004887912,0.000039044706],"category_scores_gemma":[0.000031344414,0.00007327309,0.000039539027,0.0003077502,0.00008981374,0.00004350785,0.000013563528,0.00010908851,9.6988e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10382765,0.119593054,0.2062301,0.0007473016,0.00045441237,0.00039798315,0.02082129,0.00008593666,0.14374949,0.00015198589,0.0024224191,0.40151837],"study_design_scores_gemma":[0.20559831,0.2478912,0.4761208,0.00016530449,0.00014303208,0.000036660447,0.0050243116,0.000590166,0.06114808,0.00018706957,0.002875636,0.00021944054],"about_ca_topic_score_codex":0.00141568,"about_ca_topic_score_gemma":0.0018178,"teacher_disagreement_score":0.4012989,"about_ca_system_score_codex":0.00004971686,"about_ca_system_score_gemma":0.00016804847,"threshold_uncertainty_score":0.29879898},"labels":[],"label_agreement":null},{"id":"W1954282217","doi":"10.1007/s00428-015-1787-7","title":"The immune response in cancer: from immunology to pathology to immunotherapy","year":2015,"lang":"en","type":"review","venue":"Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institut National Du Cancer; Université Paris Descartes; Institute of Cancer Research; Institut National de la Santé et de la Recherche Médicale","keywords":"Immune system; Immunotherapy; Tumor microenvironment; Tumor immunology; Immunology; Medicine; Cancer immunotherapy; Cancer; Immunity; Internal medicine","score_opus":0.06939017325699584,"score_gpt":0.43217659184815105,"score_spread":0.36278641859115524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1954282217","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022639707,0.96309316,0.00012621828,0.005355917,0.0023973635,0.0047748964,0.00059494114,0.0002789902,0.00073879294],"genre_scores_gemma":[0.0020901854,0.9874804,0.0015899868,0.0042302087,0.0008438432,0.0019947754,0.0006360619,0.00028781098,0.00084675197],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98646206,0.004795615,0.003255115,0.002414772,0.00082252006,0.0022499321],"domain_scores_gemma":[0.9885024,0.005680342,0.0011343017,0.0037255017,0.00028435065,0.00067309913],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0063187443,0.0018723153,0.0061747706,0.0012640684,0.00047400637,0.00009493969,0.002770579,0.0015855647,0.00017345077],"category_scores_gemma":[0.0026899506,0.0011599633,0.0014216701,0.002254269,0.0018220383,0.00010709824,0.0011629972,0.0035178908,0.0004782983],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026928095,0.00045337237,0.00005841509,0.0004594262,0.0022133184,0.001137021,0.0015483191,0.000011395502,0.008815717,0.00014579647,0.0034328701,0.95479625],"study_design_scores_gemma":[0.004495256,0.0048347823,0.003927947,0.005748796,0.0011280176,0.00012761183,0.00064405706,0.000010149027,0.00024177037,0.0008526618,0.9767057,0.0012832966],"about_ca_topic_score_codex":0.0018877838,"about_ca_topic_score_gemma":0.0002781696,"teacher_disagreement_score":0.9732728,"about_ca_system_score_codex":0.0009842804,"about_ca_system_score_gemma":0.0036371367,"threshold_uncertainty_score":0.99971056},"labels":[],"label_agreement":null},{"id":"W1962016368","doi":"10.1080/2162402x.2015.1085146","title":"PD-1 expression on dendritic cells suppresses CD8<sup>+</sup>T cell function and antitumor immunity","year":2015,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Lethbridge","keywords":"Granzyme B; Cytotoxic T cell; Adoptive cell transfer; CD8; Perforin; Cancer research; Granzyme; Dendritic cell; CD11c; Immune system; T cell; Immunology; Biology; In vitro; Phenotype","score_opus":0.022566461775047106,"score_gpt":0.26425986540270396,"score_spread":0.24169340362765684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1962016368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98545253,0.005736531,0.00008021285,0.0005245144,0.00070038147,0.000335095,0.000014497189,0.00011171335,0.007044507],"genre_scores_gemma":[0.9955295,0.00085583446,0.00024783573,0.0007632352,0.00013280104,0.000029374673,0.000052688425,0.00003546143,0.0023532996],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99857044,0.0001923732,0.00031059107,0.0003519919,0.00020979643,0.0003648225],"domain_scores_gemma":[0.9989746,0.0001401891,0.000107342625,0.00054255006,0.000113976515,0.00012131498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028648562,0.00024546846,0.00040269483,0.0001830569,0.00014890844,0.000029862937,0.00013509976,0.0002481672,0.0003306379],"category_scores_gemma":[0.00005933562,0.00020651451,0.0000897126,0.00016872295,0.00028595194,0.00013239236,0.00009260649,0.00040107607,0.00015101433],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009109458,0.0006699347,0.0030011053,0.00011993756,0.000113503615,0.0000670373,0.00086488837,0.000021146632,0.96898884,0.0000607351,0.010568068,0.006415325],"study_design_scores_gemma":[0.019948145,0.008937595,0.042086765,0.00055026513,0.00028882225,0.00043880244,0.005253101,0.00019056382,0.7480464,0.00043581723,0.17311476,0.00070897327],"about_ca_topic_score_codex":0.0002803741,"about_ca_topic_score_gemma":0.000007459559,"teacher_disagreement_score":0.22094247,"about_ca_system_score_codex":0.00014287248,"about_ca_system_score_gemma":0.00017791189,"threshold_uncertainty_score":0.84214175},"labels":[],"label_agreement":null},{"id":"W1965640635","doi":"10.1371/journal.pone.0113597","title":"Comparison of Immunity in Mice Cured of Primary/Metastatic Growth of EMT6 or 4THM Breast Cancer by Chemotherapy or Immunotherapy","year":2014,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Toronto General Hospital","funders":"","keywords":"Metastasis; Immunotherapy; Medicine; Cancer research; Primary tumor; Chemotherapy; Cancer; Lymph node; Immunology; Pathology; Internal medicine","score_opus":0.0468575567930148,"score_gpt":0.30776841345077427,"score_spread":0.2609108566577595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965640635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521095,0.002903109,0.00007672573,0.00072113134,0.000037261416,0.0006661828,0.00018893245,0.000020371112,0.00017531491],"genre_scores_gemma":[0.99426466,0.003147477,0.0015603063,0.00043151196,0.000031041338,0.000043855354,0.0000465133,0.00004789971,0.00042675922],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99795496,0.00015889952,0.00093570084,0.00021485011,0.0004846914,0.00025086667],"domain_scores_gemma":[0.9984247,0.00023383313,0.00060568884,0.00041732108,0.00026436526,0.00005405605],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045209983,0.00022852691,0.0013200548,0.00018245023,0.000025996274,0.000004706833,0.00024110479,0.00009859875,0.000964128],"category_scores_gemma":[0.00004819157,0.00016809361,0.00013033439,0.00059452176,0.00026798726,0.00007991044,0.000022216991,0.00021153336,0.0000011916978],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030129831,0.007016613,0.065760635,0.0016920167,0.0012387808,8.2347617e-7,0.0017460928,5.962824e-7,0.88010573,0.0000052058554,0.00051895244,0.011784708],"study_design_scores_gemma":[0.013845824,0.0017763027,0.17891769,0.0018965288,0.0002211832,0.0000072580897,0.0002645709,0.00020529759,0.8024944,0.000018276492,0.00013134988,0.00022133123],"about_ca_topic_score_codex":0.004191648,"about_ca_topic_score_gemma":0.00028274552,"teacher_disagreement_score":0.11315706,"about_ca_system_score_codex":0.00013877488,"about_ca_system_score_gemma":0.00027047208,"threshold_uncertainty_score":0.9999491},"labels":[],"label_agreement":null},{"id":"W1966329636","doi":"10.1007/s00018-013-1339-8","title":"Positive and negative influence of the matrix architecture on antitumor immune surveillance","year":2013,"lang":"en","type":"review","venue":"Cellular and Molecular Life Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"Ligue Contre le Cancer; Fondazione Italiana per la Ricerca sul Cancro; Association pour la Recherche sur le Cancer","keywords":"Extracellular matrix; Immune system; Reticular connective tissue; Stroma; Metastasis; Cell biology; Tumor microenvironment; Cancer research; Antigen; Biology; Immunology; Chemistry; Cancer; Medicine; Pathology; Internal medicine; Immunohistochemistry","score_opus":0.013380681031996052,"score_gpt":0.29186989270909036,"score_spread":0.2784892116770943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966329636","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07089164,0.92757756,0.0000216436,0.00023422425,0.00008572083,0.00087716244,0.00002836336,0.000007669427,0.00027600222],"genre_scores_gemma":[0.035429366,0.9639972,0.00012525069,0.00025120165,0.000027560442,0.000020395515,0.000006010246,0.000015095897,0.00012796423],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984859,0.00020877682,0.00034732162,0.00041670218,0.0003341058,0.00020714394],"domain_scores_gemma":[0.9990961,0.00014882356,0.0003094261,0.0002967149,0.00006125444,0.00008771289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038292122,0.00027682568,0.0008393827,0.00012316156,0.00016520101,0.000036983653,0.00023806337,0.00011969995,0.000011005676],"category_scores_gemma":[0.00013440235,0.00014676822,0.0002539638,0.00048007286,0.001400838,0.000035632904,0.00010467371,0.0002500133,0.0000020830198],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002994636,0.00018359888,0.00039894733,0.019139493,0.0011339536,0.00010483633,0.0009690923,0.000032502212,0.058840547,0.0010972155,0.00017592795,0.9176244],"study_design_scores_gemma":[0.004920011,0.004903514,0.014298916,0.09858438,0.0025784262,0.0011504836,0.00066397793,0.00006862485,0.06751296,0.0009850084,0.8013092,0.0030244715],"about_ca_topic_score_codex":0.00013358584,"about_ca_topic_score_gemma":0.0000021174865,"teacher_disagreement_score":0.91459996,"about_ca_system_score_codex":0.000017414292,"about_ca_system_score_gemma":0.0003359968,"threshold_uncertainty_score":0.5985034},"labels":[],"label_agreement":null},{"id":"W1968086967","doi":"10.1016/j.ygyno.2010.05.016","title":"Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (αE/β7 Integrin) in high-grade serous ovarian cancer","year":2010,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Victoria","funders":"BC Cancer Agency; Canadian Institutes of Health Research; U.S. Department of Defense","keywords":"Medicine; Ovarian cancer; Serous fluid; CD8; Integrin; Serous ovarian cancer; Cancer research; Lymphocyte; Cancer; Immunology; Pathology; Antigen; Internal medicine; Receptor","score_opus":0.018536711274206336,"score_gpt":0.30159073171386325,"score_spread":0.2830540204396569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968086967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988822,0.0003032912,0.000066255896,0.0049028997,0.0030507355,0.0010246444,0.000017082633,0.000048926264,0.0017641942],"genre_scores_gemma":[0.9943868,0.0003579144,0.0018918372,0.0019268307,0.00038324192,0.00026141468,0.000017060196,0.00002609984,0.00074883475],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99796885,0.00028253742,0.0006653556,0.0003917106,0.0002164907,0.00047504582],"domain_scores_gemma":[0.99837184,0.0006058024,0.00040060375,0.0004209907,0.00012842196,0.0000723368],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011229619,0.00024302382,0.0005707457,0.00016772181,0.00011189123,0.00002015573,0.00028550794,0.0005388025,0.001639216],"category_scores_gemma":[0.00023571264,0.00015843908,0.00012313528,0.00038005473,0.00047956448,0.0000999856,0.000081588354,0.0006975883,0.000016226297],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033289485,0.0005154728,0.019407177,0.00007720466,0.0001591876,0.00007518905,0.0010728287,0.00002492247,0.7851408,0.00046506332,0.0011036466,0.18862954],"study_design_scores_gemma":[0.0147628,0.0021409828,0.733754,0.00014141275,0.00021870217,0.00013497227,0.00084342575,0.0004332741,0.13828199,0.001386075,0.10745956,0.00044284787],"about_ca_topic_score_codex":0.0022507901,"about_ca_topic_score_gemma":0.0056904145,"teacher_disagreement_score":0.71434677,"about_ca_system_score_codex":0.0008439195,"about_ca_system_score_gemma":0.0010861522,"threshold_uncertainty_score":0.9992734},"labels":[],"label_agreement":null},{"id":"W1971607318","doi":"10.1097/coh.0b013e3280ebb5c9","title":"Programmed death 1: a critical regulator of T-cell function and a strong target for immunotherapies for chronic viral infections","year":2007,"lang":"en","type":"article","venue":"Current Opinion in HIV and AIDS","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada); Canadian Institutes of Health Research; McGill University; Université de Montréal; Hôpital Saint-Luc","funders":"","keywords":"Cytotoxic T cell; Immune system; T cell; CD8; Regulator; Immunology; Cytokine; Blockade; Cell biology; Peripheral tolerance; Immunotherapy; Cancer research; Biology; Receptor","score_opus":0.03614048517179607,"score_gpt":0.3523486376190999,"score_spread":0.3162081524473038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971607318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7636042,0.068247266,0.16223934,0.00038995958,0.0028575882,0.002451755,0.00010706249,0.000053457952,0.000049337592],"genre_scores_gemma":[0.9961854,0.0008767034,0.002287801,0.000009690886,0.00033440135,0.00018214117,0.00007789377,0.000013873123,0.000032075102],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99929434,0.000011891089,0.0002595058,0.00016724294,0.00006953226,0.00019746825],"domain_scores_gemma":[0.99964345,0.00012217293,0.000049017337,0.00008075609,0.0000577252,0.000046866648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029046755,0.00010139313,0.0001839591,0.00012839684,0.00007241591,0.000013442849,0.000019384535,0.000062141975,0.000011381847],"category_scores_gemma":[0.000030710493,0.00008747517,0.00007974549,0.000090493704,0.00011716645,0.00006600037,0.0000090707435,0.000071912764,1.0013279e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013415455,0.0019614429,0.17305547,0.007429157,0.00023292478,1.8219629e-7,0.0007766412,0.0000031075797,0.048097685,0.022060968,0.0010163912,0.7319506],"study_design_scores_gemma":[0.06026079,0.0307572,0.41389552,0.0033946652,0.00032099395,0.000038243972,0.0011315505,0.0037518889,0.0154124675,0.0064648087,0.46367097,0.000900927],"about_ca_topic_score_codex":0.000008965657,"about_ca_topic_score_gemma":0.0000021314472,"teacher_disagreement_score":0.73104966,"about_ca_system_score_codex":0.000055894834,"about_ca_system_score_gemma":0.00006274973,"threshold_uncertainty_score":0.3567134},"labels":[],"label_agreement":null},{"id":"W1971998672","doi":"10.1371/journal.pone.0082406","title":"Markers of T Cell Infiltration and Function Associate with Favorable Outcome in Vascularized High-Grade Serous Ovarian Carcinoma","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital; University of Victoria; BC Cancer Agency","funders":"BC Cancer Agency; LOEWE Zentrum AdRIA; Canadian Institutes of Health Research; Ovarian Cancer Canada; University of Victoria","keywords":"Granzyme B; FOXP3; Tumor microenvironment; CD8; Tumor-infiltrating lymphocytes; Cancer research; Biology; CD31; Serous fluid; ELISPOT; Immune system; Medicine; Immunology; Pathology; Angiogenesis","score_opus":0.023316157445347808,"score_gpt":0.2066590575990691,"score_spread":0.1833429001537213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971998672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980081,0.00018678079,0.00005509801,0.0005133022,0.000025986754,0.000662531,0.0000040989494,0.00002374073,0.00052036566],"genre_scores_gemma":[0.99743265,0.000053594547,0.0015457008,0.00020651822,0.000023471139,0.000046034933,0.000027960452,0.0000170589,0.0006470046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909794,0.000053577383,0.00026396898,0.00016757849,0.00025635547,0.00016057966],"domain_scores_gemma":[0.99954534,0.000034578785,0.00012363099,0.00017247387,0.00007476774,0.00004923175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021033833,0.00011015393,0.000323426,0.000106433516,0.000029813533,0.00001757483,0.00003099035,0.0000905256,0.00013811202],"category_scores_gemma":[0.000015938032,0.00008987283,0.00003672659,0.00021088931,0.000041685296,0.0001335536,0.000009066558,0.00012487704,0.0000053561953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018749571,0.0006912283,0.606203,0.00026974405,0.00036161102,0.0000036258332,0.00017548697,0.0000012541037,0.38986114,0.000008186079,0.000033944012,0.0005158143],"study_design_scores_gemma":[0.007851262,0.0008645276,0.9423977,0.00013763981,0.00027811198,0.000002322451,0.0001600576,0.00022703886,0.047912274,0.000044216285,0.000012635153,0.000112192225],"about_ca_topic_score_codex":0.0051481016,"about_ca_topic_score_gemma":0.00021665839,"teacher_disagreement_score":0.34194887,"about_ca_system_score_codex":0.00009434345,"about_ca_system_score_gemma":0.000052100586,"threshold_uncertainty_score":0.77824235},"labels":[],"label_agreement":null},{"id":"W1974571784","doi":"10.1016/j.annder.2014.09.084","title":"Traitement par anticorps anti-PD-1 : pembrolizumab (MK-3475) chez 411 patients (pts) atteints de mélanome métastatique","year":2014,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gynecology","score_opus":0.02833442453355193,"score_gpt":0.3155192893932378,"score_spread":0.28718486485968586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974571784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9529008,0.010899789,0.00512575,0.024425877,0.0018018793,0.0011012395,0.00028563268,0.00042417547,0.0030348408],"genre_scores_gemma":[0.96086836,0.01472999,0.0029597923,0.019594425,0.00040633403,0.00016648906,0.0003501237,0.00014025612,0.00078420294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915479,0.0021653112,0.0014418643,0.0011197346,0.00063255365,0.0030926822],"domain_scores_gemma":[0.9959307,0.0012823411,0.0006734501,0.001103558,0.00032051493,0.000689468],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025263764,0.0010210343,0.0015506416,0.00042665497,0.00033910625,0.00019058671,0.0010066505,0.0011405351,0.00075091224],"category_scores_gemma":[0.0016690035,0.0009899891,0.00065374485,0.0005892339,0.0011610875,0.00039617624,0.0003091683,0.0012013982,0.0004415622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002275449,0.0022130287,0.8303647,0.0017481277,0.0012514632,0.0015612607,0.0026600205,0.00017087569,0.010366292,0.0016760508,0.07217987,0.073532864],"study_design_scores_gemma":[0.00977169,0.0016770614,0.8098275,0.0012172854,0.00053202186,0.0015586626,0.00081120763,0.00181618,0.02415301,0.0019322761,0.145403,0.0013001022],"about_ca_topic_score_codex":0.00061800645,"about_ca_topic_score_gemma":0.0001649311,"teacher_disagreement_score":0.07322314,"about_ca_system_score_codex":0.0014512745,"about_ca_system_score_gemma":0.002175416,"threshold_uncertainty_score":0.99925506},"labels":[],"label_agreement":null},{"id":"W1976113809","doi":"10.1158/1538-7445.tumimm2012-b51","title":"Abstract B51: Synergistic effects of αCTLA-4 and radiotherapy in the treatment of prostate cancer.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Blockade; Radiation therapy; Oncology; Prostate; Internal medicine; Cancer; Androgen deprivation therapy; Tramp; Castration; Urology; External beam radiotherapy; Receptor; Hormone","score_opus":0.0402545338470468,"score_gpt":0.39681315848190984,"score_spread":0.35655862463486304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976113809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9458134,0.050906587,8.156416e-7,0.0014406004,0.00006909952,0.0015460956,0.000011996395,0.000004607297,0.00020677599],"genre_scores_gemma":[0.9394278,0.059069905,0.000016472955,0.00006869037,0.00008004353,0.00089987746,0.000002375124,0.000014501996,0.00042033478],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988569,0.000099298195,0.00022337776,0.00018121477,0.0003612444,0.00027796032],"domain_scores_gemma":[0.9991093,0.00038419163,0.000059388203,0.000260933,0.00013212822,0.000054035085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032631762,0.00010398995,0.00027904124,0.00014893012,0.000040417137,0.000014508819,0.00009929821,0.000051300733,0.0003440145],"category_scores_gemma":[0.000024072195,0.000060153277,0.000054932996,0.00037693605,0.00037322802,0.000041841016,0.000007127707,0.00012709797,0.0000013350842],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018644836,0.00045111903,0.034016915,0.0010315799,0.000224836,0.00002385518,0.005221536,0.000006016154,0.6824631,0.000022788317,0.0015848851,0.27308884],"study_design_scores_gemma":[0.0074536605,0.0028176035,0.7365269,0.0009817582,0.000034918467,0.000003474359,0.00059005566,0.000046514804,0.24315456,0.000086971195,0.0081841275,0.00011946027],"about_ca_topic_score_codex":0.025004731,"about_ca_topic_score_gemma":0.00047941972,"teacher_disagreement_score":0.70251,"about_ca_system_score_codex":0.00029219294,"about_ca_system_score_gemma":0.00027234844,"threshold_uncertainty_score":0.9814879},"labels":[],"label_agreement":null},{"id":"W1982488143","doi":"10.1056/nejmoa1501824","title":"Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6228,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Oncology; Internal medicine; PD-L1; Cancer; Immunotherapy","score_opus":0.03835118192736064,"score_gpt":0.3276515059079407,"score_spread":0.28930032398058003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982488143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86722606,0.1024158,0.0027164663,0.023594908,0.0020552508,0.0007461062,0.000008374918,0.0000066109337,0.0012304416],"genre_scores_gemma":[0.97241217,0.01565502,0.00049994385,0.00066097715,0.0072612627,0.000012973593,0.0000035550324,0.000022030952,0.0034720444],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990266,0.000024496238,0.0004352391,0.000075140604,0.00029467075,0.00014386783],"domain_scores_gemma":[0.9987973,0.00022861386,0.00032918918,0.00015628796,0.00028979089,0.0001988251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004998445,0.00012220808,0.00044522533,0.00008966957,0.000029192703,0.0000033843937,0.000095479525,0.000044607088,0.00012510942],"category_scores_gemma":[0.00005411094,0.000054510947,0.00014661832,0.00011119865,0.00008148873,0.000025557254,0.0000037505663,0.00008615374,2.8930208e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044569235,0.00046246505,0.014868972,0.00019929958,0.0014503298,0.00007734124,0.012406938,0.00009923793,0.024675336,0.000011729034,0.08878027,0.81239885],"study_design_scores_gemma":[0.34025288,0.01902882,0.0072766156,0.00070160686,0.00219337,0.0006185323,0.0011427847,0.0006779204,0.010541881,0.000055614113,0.61739725,0.00011271371],"about_ca_topic_score_codex":0.000722827,"about_ca_topic_score_gemma":0.00010031729,"teacher_disagreement_score":0.81228614,"about_ca_system_score_codex":0.00016411855,"about_ca_system_score_gemma":0.00061074307,"threshold_uncertainty_score":0.22228919},"labels":[],"label_agreement":null},{"id":"W1982948257","doi":"10.1503/cjs.028009","title":"Foxp3+ regulatory T cells and the formation of portal vein tumour thrombus in patients with hepatocellular carcinoma","year":2011,"lang":"en","type":"article","venue":"Canadian Journal of Surgery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Natural Science Foundation of Guangdong Province; National Natural Science Foundation of China","keywords":"Medicine; Hepatocellular carcinoma; FOXP3; Infiltration (HVAC); Immunohistochemistry; Gastroenterology; Internal medicine; Portal vein; CD8; Survival rate; Oncology; Pathology; Immune system; Immunology","score_opus":0.02012307381126568,"score_gpt":0.1787106003966847,"score_spread":0.15858752658541903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982948257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983181,0.0010358237,0.000005283361,0.00008967025,0.00015046788,0.00012861256,0.0000066749253,8.889592e-7,0.0002645002],"genre_scores_gemma":[0.9997622,0.000033265787,0.000027588198,0.00012488646,0.00002412584,7.1694205e-7,0.0000030810775,0.000008881579,0.000015281945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992316,0.000041646268,0.00038770484,0.00005107093,0.00014563678,0.00014236275],"domain_scores_gemma":[0.9992886,0.000038596947,0.00029235965,0.00009820893,0.00012583037,0.00015636669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052771735,0.000073721996,0.00027461984,0.00026050894,0.000030820112,0.0000060550897,0.00004316909,0.000039149818,0.00006939694],"category_scores_gemma":[0.000018703624,0.00004619264,0.00008218295,0.00013221362,0.00019253124,0.00013807308,0.0000025117283,0.00010656513,2.4878187e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014938301,0.000021389262,0.9950747,0.000041225398,0.000042881482,0.00015521288,0.0012003027,2.6071987e-7,0.00026202018,0.000016038752,0.0006372861,0.0010548484],"study_design_scores_gemma":[0.0023841758,0.00012864712,0.9922065,0.00021161788,0.000040453917,0.000098312776,0.0003115372,0.000015047051,0.004341836,0.00002202547,0.00018272432,0.0000570957],"about_ca_topic_score_codex":0.004337987,"about_ca_topic_score_gemma":0.0024843395,"teacher_disagreement_score":0.004079816,"about_ca_system_score_codex":0.00006963809,"about_ca_system_score_gemma":0.00069152244,"threshold_uncertainty_score":0.65577674},"labels":[],"label_agreement":null},{"id":"W1983134388","doi":"10.1158/1538-7445.am2014-ct105","title":"Abstract CT105: MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Monoclonal antibody; Immunohistochemistry; Cohort; Cancer; Antibody; Immunology","score_opus":0.032183674932666294,"score_gpt":0.3776240989429154,"score_spread":0.3454404240102491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983134388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993221,0.0019381364,0.00038195643,0.0014699189,0.00028804917,0.0016275739,0.00018827278,0.00004734045,0.0008377597],"genre_scores_gemma":[0.99446434,0.0017746157,0.00033290673,0.0002296682,0.00070654467,0.0006068879,0.00004136734,0.00007316898,0.0017704766],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997215,0.00011489343,0.00028405644,0.00067619915,0.0008592024,0.0008506846],"domain_scores_gemma":[0.9981958,0.0004128199,0.00023296973,0.00037741175,0.0005285017,0.00025246645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001512047,0.0002789525,0.00049552403,0.00023320908,0.00040860366,0.00012405956,0.00019902704,0.00017726338,0.0002719637],"category_scores_gemma":[0.000092711685,0.00021794363,0.00012336165,0.000384215,0.00017450389,0.00022758849,0.0000637761,0.00064726116,0.000005626783],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005661466,0.00017279455,0.132278,0.0010005477,0.00014029053,0.00001447888,0.00022162874,0.000011957176,0.8458335,0.000003985138,0.0089632375,0.005698122],"study_design_scores_gemma":[0.005602102,0.00044823007,0.47004154,0.0011961107,0.00007400462,0.0000047301996,0.00008459217,0.00068307103,0.5115155,0.000008293524,0.01005639,0.00028547356],"about_ca_topic_score_codex":0.0033698285,"about_ca_topic_score_gemma":0.0005161909,"teacher_disagreement_score":0.33776355,"about_ca_system_score_codex":0.0008273321,"about_ca_system_score_gemma":0.00091891026,"threshold_uncertainty_score":0.88874835},"labels":[],"label_agreement":null},{"id":"W1986589602","doi":"10.1016/j.cyto.2008.07.275","title":"212 Programmed death-1 pathway inhibit γ-common cytokines signal–driven T-cell Proliferation and Survival","year":2008,"lang":"en","type":"article","venue":"Cytokine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Signal pathway; Programmed cell death; Cell biology; Cancer research; Cell growth; Signal transduction; Cell survival; SIGNAL (programming language); Chemistry; Apoptosis; Biology; Computer science; Biochemistry","score_opus":0.02680521580584125,"score_gpt":0.2566378623217977,"score_spread":0.22983264651595645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986589602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438316,0.0008130961,0.0001438797,0.0009053061,0.00014568138,0.000842108,0.000021016236,0.00015691723,0.0025888472],"genre_scores_gemma":[0.9963892,0.00044489672,0.000604784,0.00043240422,0.00039095507,0.00008592191,0.00012869672,0.000042029864,0.0014811283],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99856466,0.00006012436,0.00036311263,0.0003559066,0.00032777313,0.00032840206],"domain_scores_gemma":[0.9992928,0.000051971878,0.00011390615,0.00027136714,0.00011461797,0.0001553206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001967057,0.00024691498,0.00039316554,0.00012489011,0.00018491672,0.000028354856,0.00007481744,0.00014159772,0.000114401635],"category_scores_gemma":[0.000022202361,0.00020154518,0.000110501824,0.00025922208,0.00019140249,0.00012310111,0.00004102758,0.00019096614,0.000017269022],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004382702,0.0008372815,0.23099431,0.0002800952,0.00017415083,0.0003804161,0.0014651807,0.0000032174303,0.72160494,0.00012009908,0.0017318312,0.038025767],"study_design_scores_gemma":[0.017300395,0.0028656395,0.19227,0.00028800138,0.00017953772,0.0011094492,0.00027350607,0.0006116403,0.7058328,0.000111172034,0.07833331,0.00082458643],"about_ca_topic_score_codex":0.000105216364,"about_ca_topic_score_gemma":0.000058883943,"teacher_disagreement_score":0.07660148,"about_ca_system_score_codex":0.000087943896,"about_ca_system_score_gemma":0.00014779145,"threshold_uncertainty_score":0.82187736},"labels":[],"label_agreement":null},{"id":"W1990675339","doi":"10.1016/s0140-6736(14)60958-2","title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1761,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Ipilimumab; Internal medicine; Clinical endpoint; Adverse effect; Refractory (planetary science); Cohort; Clinical trial; Melanoma; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Surgery; Phases of clinical research; Cancer; Immunotherapy","score_opus":0.03062678598511109,"score_gpt":0.32420648103584115,"score_spread":0.29357969505073006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990675339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99322927,0.0011938427,0.000058177877,0.00060520077,0.00020480578,0.0026673528,0.000020957496,0.00006452423,0.0019558643],"genre_scores_gemma":[0.9979113,0.0004900259,0.00029260968,0.00014935255,0.0004923126,0.00039312383,0.000061880324,0.00003106901,0.00017834219],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99827164,0.0002129461,0.00052090763,0.00030190265,0.00030429897,0.00038831873],"domain_scores_gemma":[0.99867237,0.00023231075,0.00027894674,0.00069255923,0.000047758556,0.0000760688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006192448,0.0002622988,0.0014069846,0.000091000846,0.00005576897,0.000016866004,0.00019057085,0.00008784483,0.00015058785],"category_scores_gemma":[0.000047021567,0.0001424546,0.00018725838,0.00023308686,0.00016686668,0.000054666107,0.000014325976,0.00017849567,0.000008606577],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8761943,0.0018535486,0.020521512,0.000053843814,0.0004718666,0.0000066891926,0.0007566937,0.000006860146,0.01661519,0.000016941938,0.000350249,0.08315232],"study_design_scores_gemma":[0.9253135,0.012053501,0.020014714,0.0001847429,0.00028858747,0.000014784442,0.00015793278,0.00024389074,0.007890371,0.000011945879,0.033624638,0.00020141155],"about_ca_topic_score_codex":0.0003805471,"about_ca_topic_score_gemma":0.00012657992,"teacher_disagreement_score":0.082950905,"about_ca_system_score_codex":0.00018995162,"about_ca_system_score_gemma":0.00014542836,"threshold_uncertainty_score":0.580913},"labels":[],"label_agreement":null},{"id":"W1990951986","doi":"10.1097/cji.0000000000000055","title":"Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-α (IFN-α) in Operable Renal Cell Carcinoma (RCC)","year":2014,"lang":"fr","type":"article","venue":"Journal of Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Amgen","keywords":"Renal cell carcinoma; Medicine; Adjuvant; Interleukin 2; Interferon; Cancer research; Oncology; Internal medicine; Cytokine; Immunology","score_opus":0.011849089476180793,"score_gpt":0.25664498185556045,"score_spread":0.24479589237937965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990951986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80498296,0.17869782,0.0016912086,0.0033256016,0.008320073,0.00051070884,0.000023134162,0.000018095261,0.0024303745],"genre_scores_gemma":[0.9579197,0.022909984,0.0012369581,0.0029426047,0.0024579512,0.000013799813,0.000008659211,0.00016380484,0.012346497],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99397844,0.0007238646,0.0028678658,0.00047971797,0.00078932196,0.001160779],"domain_scores_gemma":[0.99666893,0.00036298367,0.00140004,0.00080601353,0.00041929056,0.00034276204],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0032780615,0.00072699034,0.0017002672,0.0008336931,0.00013248135,0.00017302418,0.0009341149,0.00046806267,0.00307526],"category_scores_gemma":[0.000095260664,0.0006190083,0.0009300173,0.0006475369,0.00043568318,0.00062483613,0.00008612682,0.0017549649,0.00014014043],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043527074,0.0016259057,0.003122084,0.0005390529,0.0007513358,0.00073734624,0.008535447,0.00032985516,0.45203143,0.000051555257,0.013798459,0.47495046],"study_design_scores_gemma":[0.108066946,0.030382583,0.0391698,0.016680053,0.0004271187,0.0044166776,0.0043245987,0.004453625,0.15989487,0.0002760373,0.6299869,0.00192081],"about_ca_topic_score_codex":0.0013108383,"about_ca_topic_score_gemma":0.00019964957,"teacher_disagreement_score":0.6161884,"about_ca_system_score_codex":0.002124885,"about_ca_system_score_gemma":0.0012206635,"threshold_uncertainty_score":0.9996261},"labels":[],"label_agreement":null},{"id":"W1996863944","doi":"10.1038/ncomms6241","title":"Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression","year":2014,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":995,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Natural Science Foundation of China; National Institutes of Health; Cancer Prevention and Research Institute of Texas","keywords":"Immunosuppression; Metastasis; Epithelial–mesenchymal transition; Cancer research; microRNA; CD8; Cell; Biology; PD-L1; Cancer; Immunology; Medicine; Immunotherapy; Immune system; Internal medicine; Gene","score_opus":0.009676409783834309,"score_gpt":0.27150452317627083,"score_spread":0.2618281133924365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996863944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8416599,0.13935827,0.00090710336,0.01358481,0.0003501789,0.001216061,0.00021406643,0.00014647035,0.0025631192],"genre_scores_gemma":[0.9907873,0.0026596482,0.0050629377,0.0010645536,0.000036710848,0.00002637105,0.00013125755,0.00002818102,0.00020303944],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986004,0.0002802352,0.00045097535,0.00024046894,0.00022447674,0.00020344913],"domain_scores_gemma":[0.99742746,0.00023934443,0.00029268628,0.0016928281,0.00025129275,0.000096370364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004095939,0.00020408348,0.00042349126,0.000124482,0.00022961761,0.000022958986,0.00049191987,0.00033435927,0.00011127244],"category_scores_gemma":[0.00008038833,0.00016258103,0.0001580038,0.0003011471,0.00028471582,0.000106022,0.0001705901,0.0007768333,0.000004703399],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010386967,0.00024893592,0.0015120644,0.000056026354,0.00010065795,6.6302397e-7,0.000322481,4.3015393e-7,0.9815618,0.00005391327,0.010110503,0.004993839],"study_design_scores_gemma":[0.007854748,0.00041949624,0.057469666,0.0005740769,0.00039001007,0.00006657598,0.00020932089,0.0013073103,0.8197008,0.00016406982,0.11151454,0.00032938004],"about_ca_topic_score_codex":0.00009104714,"about_ca_topic_score_gemma":0.000019159632,"teacher_disagreement_score":0.16186099,"about_ca_system_score_codex":0.0000481803,"about_ca_system_score_gemma":0.00005928811,"threshold_uncertainty_score":0.66298616},"labels":[],"label_agreement":null},{"id":"W2000145027","doi":"10.1097/cji.0b013e31823735d6","title":"Ipilimumab in Treatment-naive and Previously Treated Patients with Metastatic Melanoma","year":2011,"lang":"en","type":"article","venue":"Journal of Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Moncton Hospital","funders":"National Comprehensive Cancer Network; Bristol-Myers Squibb","keywords":"Ipilimumab; Medicine; Internal medicine; Placebo; Clinical endpoint; Diarrhea; Gastroenterology; Clinical trial; Oncology; Surgery; Cancer; Immunotherapy; Pathology","score_opus":0.020619749534033782,"score_gpt":0.2517715644603501,"score_spread":0.2311518149263163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000145027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923521,0.0066852444,0.000019231533,0.00007924103,0.000060423616,0.00042048778,0.0000038548196,0.000007834603,0.00037155868],"genre_scores_gemma":[0.9936047,0.0045098416,0.0014254373,0.00019915237,0.000024335835,0.000008954689,0.000003558666,0.00003028629,0.00019369299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893516,0.000071125825,0.00048446693,0.00012268842,0.00019037118,0.00019619838],"domain_scores_gemma":[0.9992436,0.000041137595,0.0003465535,0.00016625247,0.00013126554,0.00007119558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018309685,0.00018950457,0.00048750232,0.00024656113,0.00003154782,0.000013905101,0.000068352325,0.000043897442,0.00020879092],"category_scores_gemma":[0.0000074524905,0.0001103727,0.00011728394,0.00019439308,0.000087857545,0.00016139507,0.0000039461333,0.00011323341,0.0000017887498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056288473,0.0020357857,0.7480576,0.000032129665,0.002203001,0.00024319599,0.007409944,3.4126487e-7,0.005783737,0.0000069997,0.00008224128,0.17785656],"study_design_scores_gemma":[0.050557207,0.01840611,0.9206859,0.00044120848,0.00021778005,0.00036203503,0.0003560954,0.0000035012017,0.0068061543,0.000040681545,0.0019419043,0.00018143893],"about_ca_topic_score_codex":0.00025046882,"about_ca_topic_score_gemma":0.000038204078,"teacher_disagreement_score":0.17767513,"about_ca_system_score_codex":0.0002026722,"about_ca_system_score_gemma":0.00012343058,"threshold_uncertainty_score":0.4500868},"labels":[],"label_agreement":null},{"id":"W2000227671","doi":"10.1016/j.ijrobp.2014.08.206","title":"Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy","year":2014,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Bevacizumab; Oncology; non-small cell lung cancer (NSCLC); Chemotherapy; Internal medicine; Lung cancer; Immunotherapy; Cancer","score_opus":0.011472624027194081,"score_gpt":0.3019271566340644,"score_spread":0.2904545326068703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000227671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95825624,0.0005168127,0.034391128,0.0043674354,0.0006125245,0.0013914611,0.00003798481,0.000041373805,0.000385036],"genre_scores_gemma":[0.9884585,0.0026206803,0.004306152,0.0028542413,0.00090630964,0.00016602282,0.0000986912,0.00008455672,0.0005048523],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997929,0.000158775,0.00082614215,0.0003913776,0.00029976162,0.00039495475],"domain_scores_gemma":[0.9969462,0.00034914765,0.00137454,0.00022024712,0.0009892794,0.000120548946],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062097417,0.00035746934,0.00077809015,0.00028242133,0.0000870418,0.00004348644,0.00038459658,0.00028190788,0.00009449038],"category_scores_gemma":[0.00006095842,0.0002502292,0.00021461432,0.0003276137,0.00019737384,0.00026850434,0.000015412508,0.0004043226,0.0000037641285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.077303566,0.0022346028,0.45256045,0.00012104175,0.0022960994,0.00006522528,0.0022139184,0.0010307591,0.016720725,0.0010528499,0.0019981328,0.44240263],"study_design_scores_gemma":[0.40154332,0.052897524,0.2859507,0.0032578935,0.0011693346,0.0012739472,0.0007519028,0.052927215,0.07656913,0.002512613,0.119041234,0.002105176],"about_ca_topic_score_codex":0.00027210897,"about_ca_topic_score_gemma":0.0002120127,"teacher_disagreement_score":0.44029745,"about_ca_system_score_codex":0.0015359743,"about_ca_system_score_gemma":0.0013338883,"threshold_uncertainty_score":0.999995},"labels":[],"label_agreement":null},{"id":"W2000664994","doi":"10.3727/000000006783981837","title":"Suppression of Human T-Cell Responses to β-Cells by Activation of B7-H4 Pathway","year":2006,"lang":"en","type":"article","venue":"Cell Transplantation","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"University of Minnesota; University of Miami","keywords":"Molecular biology; T cell; Transfection; Biology; Flow cytometry; CD8; Cell culture; Cell biology; Cell cycle; Cell growth; Antigen; Cell; Immune system; Immunology; Biochemistry","score_opus":0.011164156825803432,"score_gpt":0.2545066499768505,"score_spread":0.24334249315104708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000664994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948916,0.00012759166,0.0014826634,0.00006620736,0.00006793008,0.00033768246,0.000111869755,0.000018350707,0.0028960973],"genre_scores_gemma":[0.99705684,0.0001235368,0.00030290594,0.000059192353,0.00002711314,0.000009402012,0.00038031174,0.000014532015,0.0020261684],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991693,0.00005011359,0.00032289332,0.00014787534,0.00020523596,0.000104604034],"domain_scores_gemma":[0.99957424,0.000065023094,0.00013413056,0.00013664449,0.000059215465,0.00003076122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001275382,0.00009739765,0.00016631167,0.00012415122,0.000036360532,0.000004130675,0.000049131442,0.00007900497,0.00009620666],"category_scores_gemma":[0.000001594817,0.00008804577,0.00007053158,0.00015936482,0.00003532818,0.00006172338,0.0000021198407,0.000052213592,0.000003037522],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004316513,0.000283795,0.0018798833,0.0005155841,0.000008129061,0.0000021436015,0.0005795902,0.000013721491,0.9899499,0.0000057579737,0.0016938552,0.00075111864],"study_design_scores_gemma":[0.002466505,0.0005138168,0.017975358,0.0002111735,0.00004636023,0.0000016334376,0.0000882317,0.000005215467,0.97758585,0.000013225652,0.0010084442,0.000084199106],"about_ca_topic_score_codex":0.00041920456,"about_ca_topic_score_gemma":0.000013463006,"teacher_disagreement_score":0.016095474,"about_ca_system_score_codex":0.000026983562,"about_ca_system_score_gemma":0.000034376826,"threshold_uncertainty_score":0.35904023},"labels":[],"label_agreement":null},{"id":"W2009098155","doi":"10.1186/bcr3072","title":"Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer","year":2011,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":351,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; BC Cancer Agency","funders":"BC Cancer Agency; Canadian Institutes of Health Research; Office of Defense Programs; BC Cancer Foundation; U.S. Department of Defense","keywords":"Anthracycline; Surgical oncology; Breast cancer; Medicine; Oncology; Estrogen receptor; Chemotherapy; Internal medicine; Cancer; Estrogen; Cancer research; Tumor-infiltrating lymphocytes; Immunotherapy","score_opus":0.05764511822765091,"score_gpt":0.37794657747861515,"score_spread":0.32030145925096426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009098155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835122,0.0008639227,0.000016485372,0.012235727,0.00021836325,0.0016442065,0.0008642018,0.000111922054,0.000532951],"genre_scores_gemma":[0.9945524,0.0004891068,0.0007358937,0.001858734,0.00052041374,0.0012761962,0.000014693716,0.00011538026,0.00043719538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99554414,0.00061374286,0.0006373645,0.0008489032,0.0011691273,0.0011867089],"domain_scores_gemma":[0.9976208,0.00040426728,0.00014165268,0.00067209324,0.000677012,0.0004841512],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002460524,0.00038911507,0.0005746893,0.0007645074,0.00023873664,0.000064472224,0.0004498948,0.00016683059,0.006371752],"category_scores_gemma":[0.00015951348,0.00033870226,0.0001872037,0.0020880785,0.0005093108,0.00020363368,0.0000846028,0.00062379363,0.000054276577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29738995,0.00091258343,0.30496544,0.00021691747,0.0003498715,0.00017248906,0.0039655017,0.000034656194,0.24556667,0.000012448905,0.004263952,0.14214951],"study_design_scores_gemma":[0.0118114585,0.00068917917,0.83834434,0.0018538326,0.000023881672,0.00020857762,0.0011598347,0.00028216388,0.14301609,0.000021263295,0.002160016,0.0004293923],"about_ca_topic_score_codex":0.045515057,"about_ca_topic_score_gemma":0.0015707229,"teacher_disagreement_score":0.53337884,"about_ca_system_score_codex":0.0023295751,"about_ca_system_score_gemma":0.0038413373,"threshold_uncertainty_score":0.9999065},"labels":[],"label_agreement":null},{"id":"W2011044258","doi":"10.1158/1538-7445.am2014-ct104","title":"Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Monoclonal antibody; Antibody; Dosing; Pharmacodynamics; Internal medicine; CD8; Immunohistochemistry; Gastroenterology; Immunology; Pharmacokinetics; Immune system","score_opus":0.055149924063105524,"score_gpt":0.4019696920424806,"score_spread":0.3468197679793751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011044258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99692535,0.0003987166,0.000069305504,0.0005892569,0.00016760919,0.0006954122,0.000034174172,0.00001187141,0.0011082778],"genre_scores_gemma":[0.9993167,0.00013242279,0.000067605804,0.000045373454,0.00008824557,0.000041118947,0.00000921502,0.000025862584,0.0002734594],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99778,0.0002068773,0.0004060575,0.00032042962,0.00091516646,0.00037146904],"domain_scores_gemma":[0.998656,0.00023899839,0.0002430856,0.0005345139,0.00025014082,0.0000772747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013461227,0.00015591351,0.0004434116,0.00025261266,0.00009969399,0.000014202504,0.00026115394,0.00009170725,0.00024931307],"category_scores_gemma":[0.00013445206,0.00009633813,0.000113279966,0.00067910843,0.000461187,0.00014320396,0.00008376881,0.00056930794,0.0000042446345],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003120419,0.00015254623,0.44932392,0.00024168867,0.000027952077,0.00000663188,0.00012228213,0.00004769529,0.5449212,0.000014771507,0.00012960218,0.0018912824],"study_design_scores_gemma":[0.00203546,0.0002483649,0.6922691,0.00077008567,0.000011305173,0.0000078823805,0.00008396992,0.00019075266,0.3038929,0.000012293113,0.00039950365,0.00007836811],"about_ca_topic_score_codex":0.0036560458,"about_ca_topic_score_gemma":0.00034664728,"teacher_disagreement_score":0.24294516,"about_ca_system_score_codex":0.00020731242,"about_ca_system_score_gemma":0.00044575497,"threshold_uncertainty_score":0.55268717},"labels":[],"label_agreement":null},{"id":"W2011991703","doi":"10.4137/cmed.s22469","title":"Immune Checkpoint Inhibitor Therapy Associated Hypophysitis","year":2015,"lang":"en","type":"review","venue":"Clinical Medicine Insights Endocrinology and Diabetes","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Ipilimumab; Hypophysitis; Medicine; Hypopituitarism; Adverse effect; Immunology; Immune system; Clinical trial; Internal medicine; Oncology; Immunotherapy; Pituitary gland; Hormone","score_opus":0.11376405994812568,"score_gpt":0.3994367352887917,"score_spread":0.28567267534066604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011991703","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009203111,0.9835522,3.7777897e-7,0.0008586606,0.0025368298,0.0012282351,0.000014863551,0.00018600015,0.002419704],"genre_scores_gemma":[0.0016138523,0.9933447,0.000024641642,0.0013317756,0.0023375652,0.00016864219,0.00033468453,0.00009548314,0.0007486212],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945378,0.00076639716,0.002595951,0.0009676269,0.00037393664,0.000758298],"domain_scores_gemma":[0.99568313,0.0018697251,0.00096194906,0.000763846,0.00025991185,0.00046143323],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00085269246,0.0008344736,0.0059093884,0.00037653992,0.00014271216,0.000017496977,0.0002775544,0.0011048184,0.00017864037],"category_scores_gemma":[0.0013489572,0.00049897947,0.0009767248,0.00048331625,0.0022038058,0.000077153534,0.00015631031,0.0015886317,0.000074217125],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022857008,0.00041050193,0.00037044933,0.0021656326,0.002167461,0.00016779009,0.00006465646,2.9611293e-9,0.00003407075,0.000056136494,0.0034755631,0.99085915],"study_design_scores_gemma":[0.007846995,0.004416019,0.002053841,0.015473374,0.0017337928,0.00010332641,0.000031868076,0.0000015452428,0.000040529394,0.00044666944,0.9673493,0.00050277665],"about_ca_topic_score_codex":0.000037450358,"about_ca_topic_score_gemma":0.000005437204,"teacher_disagreement_score":0.9903564,"about_ca_system_score_codex":0.00014204587,"about_ca_system_score_gemma":0.0005625234,"threshold_uncertainty_score":0.9997462},"labels":[],"label_agreement":null},{"id":"W2017999136","doi":"10.1002/path.2866","title":"<i>In situ</i> immune response after neoadjuvant chemotherapy for breast cancer predicts survival","year":2011,"lang":"en","type":"article","venue":"The Journal of Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":223,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ligue Contre le Cancer; Institut National de la Santé et de la Recherche Médicale; CNIB; Fondation de France; Association pour la Recherche sur le Cancer","keywords":"Breast cancer; Oncology; Chemotherapy; Medicine; Immune system; Internal medicine; Neoadjuvant therapy; Cancer; In situ; Immunology","score_opus":0.019973371361201572,"score_gpt":0.2847484247620868,"score_spread":0.2647750534008852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017999136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838155,0.0039127734,0.00024894855,0.010727833,0.0008465012,0.0002726455,0.000033365846,0.0000060729117,0.00013638152],"genre_scores_gemma":[0.99457854,0.0016532037,0.00033174644,0.0026860407,0.0003116658,0.000017249518,4.7191895e-7,0.00002436934,0.00039669545],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99877745,0.0002706499,0.0004715589,0.0000919391,0.00014267884,0.00024571116],"domain_scores_gemma":[0.9991264,0.00015591834,0.00027116446,0.00025375208,0.00013783494,0.000054950124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022289362,0.0001266956,0.00037834377,0.000118732845,0.000032195607,0.0000033469391,0.00020279431,0.00009998695,0.00043996886],"category_scores_gemma":[0.000042939795,0.00007429537,0.0001777081,0.0001176998,0.00016945858,0.000072189716,0.000023196157,0.00023322545,0.0000027399194],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34043533,0.00026264918,0.0045556547,0.000027078955,0.00018085475,0.0006420281,0.004818511,7.9112476e-7,0.63544244,0.00000531781,0.0012107114,0.01241867],"study_design_scores_gemma":[0.011468803,0.0018769683,0.94398403,0.00017977293,0.00015236251,0.0076506417,0.0004160297,0.000005337603,0.030255985,0.0002466558,0.0036441034,0.00011930798],"about_ca_topic_score_codex":0.00005548288,"about_ca_topic_score_gemma":0.00005290224,"teacher_disagreement_score":0.9394284,"about_ca_system_score_codex":0.00008729649,"about_ca_system_score_gemma":0.00018921595,"threshold_uncertainty_score":0.48173508},"labels":[],"label_agreement":null},{"id":"W2018305351","doi":"10.1016/j.cyto.2007.07.120","title":"115 Impaired T Cell Function and CD8 Memory Maintenance in a Novel Interleukin-7 Receptor α Knock-in Mouse","year":2007,"lang":"en","type":"article","venue":"Cytokine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Function (biology); CD8; Knockout mouse; Gene knockin; Interleukin 2; Interleukin 15; Cell biology; Biology; Receptor; Immunology; Interleukin; Immune system; Genetics; Cytokine; Gene","score_opus":0.012986525234125105,"score_gpt":0.24278379614152099,"score_spread":0.22979727090739588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018305351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957582,0.00076942693,0.00057948334,0.0005364782,0.00028002297,0.00035346986,0.000011943882,0.000042782172,0.0016682119],"genre_scores_gemma":[0.99389136,0.00014468908,0.00041871777,0.0008586837,0.00012894097,0.000014122448,0.000019532516,0.000024653427,0.0044993116],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989281,0.00001540048,0.00034582987,0.00027279535,0.0001270016,0.00031086794],"domain_scores_gemma":[0.999562,0.00004445883,0.00007304398,0.00020527272,0.000036058605,0.00007913372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054127333,0.00015113277,0.0002481337,0.00024057602,0.000021418471,0.000010140828,0.000055568446,0.00010752733,0.00014468352],"category_scores_gemma":[0.000035516878,0.00013081374,0.00005628281,0.0003174058,0.00007579337,0.000075594166,0.000027073927,0.00020503538,0.000012628236],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008414204,0.00031470117,0.01574482,0.000086078915,0.000020974181,0.00003445622,0.00062948494,0.0000019011155,0.9534603,0.000009795282,0.0012833866,0.01999995],"study_design_scores_gemma":[0.03638986,0.0018005878,0.52481925,0.0007720379,0.000046541256,0.00013626413,0.0021533892,0.0003330953,0.3718054,0.00004326261,0.061117183,0.00058310817],"about_ca_topic_score_codex":0.00040941295,"about_ca_topic_score_gemma":0.00082861056,"teacher_disagreement_score":0.58165485,"about_ca_system_score_codex":0.00037402555,"about_ca_system_score_gemma":0.00007113039,"threshold_uncertainty_score":0.533443},"labels":[],"label_agreement":null},{"id":"W2018652183","doi":"10.1038/nrclinonc.2013.153","title":"The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma","year":2013,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":198,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Medicine; Ipilimumab; Immunotherapy; Melanoma; Intensive care medicine; Clinical trial; Oncology; Cancer; Internal medicine; Cancer research","score_opus":0.1545630070054307,"score_gpt":0.5229324565085092,"score_spread":0.3683694495030785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018652183","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003841184,0.9722426,0.00002723118,0.0037180032,0.0025032733,0.020892818,0.00048949907,0.000016386031,0.00007178791],"genre_scores_gemma":[0.0000048824195,0.9862137,0.0015824004,0.0017688356,0.0009318324,0.0073723337,0.00009712556,0.00011485847,0.0019140377],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928637,0.0007795048,0.0048488737,0.0006569255,0.0003153735,0.0005356309],"domain_scores_gemma":[0.9734431,0.020070108,0.0047177863,0.0012236384,0.00045183147,0.00009351677],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0033529606,0.00077013177,0.0066468082,0.00005782386,0.00023295078,0.00001621339,0.000608732,0.0016945822,0.00013614354],"category_scores_gemma":[0.0003905714,0.000309343,0.011239315,0.00026213194,0.0008296306,0.000011429676,0.000022501816,0.0009539586,0.000006709123],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005447401,0.0011326752,0.0000042101483,0.0051143994,0.009964572,0.000002125833,0.000077016,1.5772164e-7,0.000029072904,0.00011704489,0.033142973,0.94496834],"study_design_scores_gemma":[0.0068297465,0.018013913,0.000012562871,0.005057579,0.004241005,0.000040334435,0.000036750756,0.000007490382,0.00002493169,0.000038523445,0.96543044,0.00026669662],"about_ca_topic_score_codex":0.00009475034,"about_ca_topic_score_gemma":0.00009370643,"teacher_disagreement_score":0.9447017,"about_ca_system_score_codex":0.0009923978,"about_ca_system_score_gemma":0.0023493238,"threshold_uncertainty_score":0.99993587},"labels":[],"label_agreement":null},{"id":"W2019090872","doi":"10.1371/journal.pone.0006412","title":"Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors","year":2009,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":435,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia; Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"CD20; FOXP3; Serous fluid; Immune system; MHC class I; CD8; Tissue microarray; MHC class II; Pathology; Immunology; Medicine; Cancer research; Biology; Immunohistochemistry; T cell","score_opus":0.02298917801614598,"score_gpt":0.2629354833330571,"score_spread":0.23994630531691113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019090872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99274224,0.005234785,0.000004465904,0.00072145707,0.000020244603,0.0010908066,0.000050908537,0.0000276127,0.00010750825],"genre_scores_gemma":[0.99868554,0.00061924633,0.0001573506,0.00021025923,0.00002031724,0.00004728467,0.000060190723,0.000013700969,0.00018614087],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984961,0.00010234651,0.0006252979,0.00023834883,0.00031741083,0.00022048542],"domain_scores_gemma":[0.999074,0.00022554534,0.0002656647,0.00025856882,0.00010392571,0.0000722864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024281236,0.00018443352,0.0010782636,0.00041968288,0.000035120407,0.000019343659,0.000075546996,0.00009973972,0.00008542737],"category_scores_gemma":[0.0001707803,0.00014498562,0.00012401785,0.0010603048,0.00006338777,0.0000781057,0.000011593311,0.00012783008,0.0000015853161],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010116857,0.0020352653,0.43306333,0.0057736756,0.013263763,0.000041353924,0.00297583,0.0000082812785,0.5414778,0.00009392318,0.0000084352705,0.00024668055],"study_design_scores_gemma":[0.0015011615,0.00072604266,0.9317476,0.009880199,0.005886266,0.000005084873,0.00032614009,0.0001312507,0.049564447,0.00007274005,1.5989404e-7,0.00015886295],"about_ca_topic_score_codex":0.0036149411,"about_ca_topic_score_gemma":0.00025150392,"teacher_disagreement_score":0.49868432,"about_ca_system_score_codex":0.0001222947,"about_ca_system_score_gemma":0.00006625446,"threshold_uncertainty_score":0.5912342},"labels":[],"label_agreement":null},{"id":"W2020946925","doi":"10.1158/1538-7445.tumimm2012-b88","title":"Abstract B88: Clinical significance of FOXP3+ T cell heterogeneity in ovarian cancer.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"","keywords":"FOXP3; Interleukin-7 receptor; IL-2 receptor; CD8; T-cell receptor; CD28; Tumor-infiltrating lymphocytes; Cancer research; Biology; Immunology; Flow cytometry; Medicine; T cell; Immune system","score_opus":0.16749013932249332,"score_gpt":0.47606689554371295,"score_spread":0.3085767562212196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020946925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98794496,0.005411771,0.0000074083523,0.0018563474,0.00030061396,0.0012801501,0.000037702877,0.000017416342,0.003143631],"genre_scores_gemma":[0.9925809,0.0049952446,0.00009793816,0.0002997341,0.00033016255,0.00067975646,0.0000062432982,0.000033889395,0.00097614084],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997247,0.00020771248,0.00072407746,0.00049334543,0.00068481284,0.00064309564],"domain_scores_gemma":[0.9983646,0.00029551744,0.00013344942,0.00055319426,0.0004179929,0.00023523782],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00177108,0.00016200148,0.00047913464,0.00022828572,0.00006811396,0.000028231585,0.00031211323,0.00020455077,0.004417229],"category_scores_gemma":[0.00008577345,0.00013808356,0.00018430273,0.0007257368,0.0005279143,0.000118190634,0.00007360358,0.0007993335,0.00007072865],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021481498,0.00050921325,0.27151233,0.00049643515,0.00011509986,0.000028105274,0.00020218319,0.000013127772,0.65208155,0.000012833536,0.013129305,0.059751693],"study_design_scores_gemma":[0.0034198205,0.00028768188,0.7737681,0.000334296,0.0000121052535,0.0000018454433,0.00014925514,0.000032164156,0.214028,0.000066295426,0.0077473316,0.00015309028],"about_ca_topic_score_codex":0.03611681,"about_ca_topic_score_gemma":0.0027755783,"teacher_disagreement_score":0.5022558,"about_ca_system_score_codex":0.0004277333,"about_ca_system_score_gemma":0.0011614765,"threshold_uncertainty_score":0.99649286},"labels":[],"label_agreement":null},{"id":"W2021399325","doi":"10.1016/j.coi.2015.02.004","title":"New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer","year":2015,"lang":"en","type":"review","venue":"Current Opinion in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia; BC Cancer Agency","funders":"BC Cancer Foundation; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Research Society; U.S. Department of Defense","keywords":"Ovarian cancer; Biology; Immune system; Immunity; CD8; Immunology; Immunotherapy; Tumor microenvironment; Cancer; Cancer research; Genetics","score_opus":0.06537923650083952,"score_gpt":0.37354882571972675,"score_spread":0.30816958921888726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021399325","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010387534,0.9931602,0.0000234685,0.00017308409,0.0039756093,0.0014838013,0.0000274463,0.00002078793,0.000096868585],"genre_scores_gemma":[0.00023587757,0.998903,0.000066487875,0.000023461804,0.00027190233,0.00019108005,0.00017671485,0.00004903719,0.00008245489],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99749684,0.0006243578,0.001002949,0.00041550735,0.00016079504,0.00029955665],"domain_scores_gemma":[0.9982817,0.0001516158,0.00064027304,0.0007402354,0.00009835412,0.00008781234],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034740762,0.00043619375,0.0017012235,0.00032410084,0.00006911865,0.000014654623,0.00042583022,0.00032506642,0.00010516316],"category_scores_gemma":[0.00005276401,0.00029381498,0.00022487406,0.0005130225,0.00037373937,0.000037698443,0.00020924657,0.0009281211,0.000007723978],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029174524,0.000093089555,0.00009490714,0.006754739,0.00042176005,0.000001394298,0.0005778589,1.1010251e-7,0.0001104535,0.00019502598,0.0038378853,0.987621],"study_design_scores_gemma":[0.0020622334,0.00027879092,0.0023625877,0.013389886,0.00023162627,0.00011479323,0.00004862496,0.0000017293938,0.000008392691,0.0003450386,0.98089015,0.00026611303],"about_ca_topic_score_codex":0.0027130006,"about_ca_topic_score_gemma":0.000082449296,"teacher_disagreement_score":0.98735493,"about_ca_system_score_codex":0.00057012634,"about_ca_system_score_gemma":0.0024737918,"threshold_uncertainty_score":0.9999514},"labels":[],"label_agreement":null},{"id":"W2022776477","doi":"10.3747/co.22.2666","title":"Erratum: Tumour Inflammatory Response: Adding Fuel to the Fire?","year":2015,"lang":"en","type":"erratum","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Inflammatory response; Inflammation; Immunology","score_opus":0.08424768518374746,"score_gpt":0.3911208971878037,"score_spread":0.3068732120040562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022776477","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013864688,0.279539,0.00003001358,0.06222493,0.42727086,0.004933702,0.00045731722,0.0005386289,0.2111409],"genre_scores_gemma":[0.011292112,0.016907634,0.00023114662,0.009641185,0.041755747,0.0014747322,0.0020237127,0.00046428846,0.91620946],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969109,0.00056466437,0.0006927911,0.0006083671,0.0005854024,0.00063783355],"domain_scores_gemma":[0.997801,0.00025805872,0.0003815712,0.0008361737,0.00036671068,0.00035650635],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019831196,0.00048550728,0.00089766213,0.0002796649,0.00015154773,0.000040732888,0.0005542451,0.0007829084,0.0004050835],"category_scores_gemma":[0.0007660029,0.00033722975,0.00034105548,0.0004444219,0.00023477197,0.000047566424,0.0002431163,0.002116185,0.00050317217],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009980816,0.00015768438,0.000096276424,0.00025841038,0.00018264969,0.000109871304,0.0011938319,4.5608923e-7,0.00029558802,0.000008525495,0.9236902,0.064025685],"study_design_scores_gemma":[0.0021122838,0.0013677364,0.0048050345,0.0008717516,0.00019540142,0.00021368748,0.00034075114,0.000023244276,0.000011003191,0.000037618312,0.98965645,0.00036506166],"about_ca_topic_score_codex":0.000021508387,"about_ca_topic_score_gemma":0.00015110541,"teacher_disagreement_score":0.7050685,"about_ca_system_score_codex":0.0017018985,"about_ca_system_score_gemma":0.0047483174,"threshold_uncertainty_score":0.999908},"labels":[],"label_agreement":null},{"id":"W2023261164","doi":"10.1002/cyto.b.20631","title":"CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non‐Hodgkin lymphoma","year":2011,"lang":"en","type":"article","venue":"Cytometry Part B Clinical Cytometry","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Follicular lymphoma; CD80; Lymphoma; Stromal cell; Cancer research; B cell; Non-Hodgkin's lymphoma; Immune system; Immunology; Biology; Pathology; Medicine; Antibody; Cytotoxic T cell; CD40","score_opus":0.06757683355857153,"score_gpt":0.333105368117879,"score_spread":0.26552853455930747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023261164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916578,0.00068919186,0.00025914217,0.00022456616,0.0015398187,0.00095128483,0.0002384949,0.00012589991,0.0043138284],"genre_scores_gemma":[0.9896687,0.0017753323,0.0015157298,0.004827556,0.0005602008,0.00006622338,0.000026049136,0.00012291786,0.001437287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939859,0.00031687017,0.0020954572,0.0015448311,0.00088948244,0.001167482],"domain_scores_gemma":[0.9963623,0.0008661514,0.00051455514,0.0013654713,0.000114669,0.0007768388],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024698647,0.0007281292,0.0016158746,0.0013569028,0.00014397732,0.000077089564,0.0004995729,0.00081555085,0.001537478],"category_scores_gemma":[0.00023491822,0.00060787395,0.0006362843,0.0022688154,0.0006452915,0.00021422845,0.00024704472,0.0007032266,0.00041437196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027639098,0.009606916,0.47428414,0.00075233885,0.0012642988,0.002481089,0.0012165956,0.0000012103553,0.36958572,0.00006805874,0.024937425,0.08816309],"study_design_scores_gemma":[0.016021535,0.005253194,0.58341134,0.00097458524,0.0002320834,0.000078182486,0.0004046629,0.00013743734,0.37545666,0.00005524431,0.01697647,0.0009986437],"about_ca_topic_score_codex":0.00021209703,"about_ca_topic_score_gemma":0.0000129689615,"teacher_disagreement_score":0.10912717,"about_ca_system_score_codex":0.00022240818,"about_ca_system_score_gemma":0.00022149186,"threshold_uncertainty_score":0.99963725},"labels":[],"label_agreement":null},{"id":"W2030838608","doi":"10.1186/2051-1426-2-s3-o3","title":"Toward cell transfer immunotherapy against patient-specific mutations in gastrointestinal cancers","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Immunotherapy; Medicine; Somatic cell; Cancer research; Melanoma; Metastatic melanoma; Gastrointestinal cancer; Cancer; Colorectal cancer; Immunology; Internal medicine; Biology; Gene; Genetics","score_opus":0.02094606342333718,"score_gpt":0.2891011124387091,"score_spread":0.26815504901537196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030838608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9617922,0.021323148,0.011938663,0.0015248721,0.0010670152,0.0011287467,0.00007898693,0.00003953329,0.0011068387],"genre_scores_gemma":[0.9794901,0.013641935,0.003977693,0.0017417823,0.00036439495,0.00019492561,0.00002303943,0.000117980526,0.000448128],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99742657,0.0000953791,0.0011267258,0.0003144235,0.00047446467,0.00056241197],"domain_scores_gemma":[0.9986994,0.00015259271,0.00034172132,0.00032332703,0.00035892095,0.00012402379],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052928686,0.00035364483,0.00068732246,0.0004155356,0.00017255565,0.00005395784,0.00025086908,0.00011256359,0.00060045964],"category_scores_gemma":[0.000015108866,0.0003045373,0.0006307262,0.00040757348,0.00021531903,0.00019684187,0.000006687594,0.00045587652,0.0000025999584],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016213527,0.00035917116,0.00466021,0.00014241404,0.00027816178,0.000011249705,0.00276671,0.0007648841,0.6090558,0.00005269798,0.0013767267,0.36431843],"study_design_scores_gemma":[0.07210882,0.010526521,0.045777712,0.004100943,0.00013974328,0.00065924745,0.0027643957,0.0011336807,0.23004621,0.0007626741,0.6305563,0.0014237516],"about_ca_topic_score_codex":0.00028818642,"about_ca_topic_score_gemma":0.000080820995,"teacher_disagreement_score":0.62917954,"about_ca_system_score_codex":0.00077254337,"about_ca_system_score_gemma":0.00059024605,"threshold_uncertainty_score":0.9999407},"labels":[],"label_agreement":null},{"id":"W2037265356","doi":"10.1089/jir.2010.0158","title":"Interferon: Current Status and Future Prospects in Cancer Therapy","year":2011,"lang":"en","type":"review","venue":"Journal of Interferon & Cytokine Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Cancer stem cell; Stem cell; Cancer research; Cancer; Immune system; Cancer cell; Biology; Cytotoxic T cell; Immunology; Glioma; Breast cancer; Medicine; In vitro; Cell biology","score_opus":0.2091841969159689,"score_gpt":0.4830847894529224,"score_spread":0.2739005925369535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037265356","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031886771,0.99349046,0.0000020577068,0.00042801953,0.0012087955,0.0012114713,0.000028046496,0.000009548281,0.00043292713],"genre_scores_gemma":[0.0011178781,0.9957358,0.000028615867,0.000036458623,0.0025552567,0.000091917354,0.000009514888,0.00009510345,0.00032944384],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99574596,0.0005590035,0.001559269,0.00044904966,0.0008559412,0.0008307869],"domain_scores_gemma":[0.9976123,0.00016693315,0.0006965288,0.00044095973,0.0007174119,0.00036585843],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0022699554,0.00051920215,0.002320569,0.0018089481,0.000063142754,0.000091336355,0.0004665844,0.00036975488,0.0008741285],"category_scores_gemma":[0.000059536986,0.000320884,0.000605423,0.00092247606,0.00029497786,0.00017945607,0.00018144978,0.0038883046,0.000011407432],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007158938,0.00044570153,0.00021707501,0.0071822656,0.0005685995,0.00012851236,0.0005675395,1.3331433e-8,0.00007806079,0.000024776626,0.0037060028,0.97992253],"study_design_scores_gemma":[0.002854391,0.0059265587,0.00037997722,0.044538196,0.00013445244,0.00055079063,0.0001680899,5.9010284e-7,0.00008052288,0.000022832039,0.94509375,0.0002498273],"about_ca_topic_score_codex":0.00020933693,"about_ca_topic_score_gemma":0.00011407353,"teacher_disagreement_score":0.9796727,"about_ca_system_score_codex":0.001575124,"about_ca_system_score_gemma":0.0020144675,"threshold_uncertainty_score":0.9999243},"labels":[],"label_agreement":null},{"id":"W2039566737","doi":"10.1016/j.ijrobp.2014.08.023","title":"Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)","year":2014,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Lung cancer; Adjuvant therapy; Oncology; Immunohistochemistry; Antibody; Phases of clinical research; Adjuvant; Clinical trial; Cancer; Adverse effect; Immunology","score_opus":0.014270829290972299,"score_gpt":0.3494862013988176,"score_spread":0.3352153721078453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039566737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99473715,0.0003032675,0.0023535737,0.00075465295,0.001050526,0.00029975362,0.000030449086,0.0000068900044,0.00046374428],"genre_scores_gemma":[0.9950851,0.0026415677,0.0006934059,0.000859685,0.0006586757,0.0000058389683,0.000023244374,0.000018130462,0.00001434916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985263,0.00022585939,0.0006951667,0.00019200664,0.00020817063,0.00015250353],"domain_scores_gemma":[0.99777853,0.0004104679,0.0010959537,0.00010898601,0.000526207,0.00007983677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059961784,0.00015534823,0.00052082364,0.00012134827,0.000030491521,0.000007897673,0.00017072244,0.0001949189,0.00004234675],"category_scores_gemma":[0.00009422909,0.00011960222,0.00014141818,0.00011625263,0.00020545073,0.00016892212,0.000027187662,0.0004018689,0.0000010133383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013793661,0.0005738187,0.6195689,0.0000072162247,0.0003227182,0.0000028141992,0.0001753834,0.000057551046,0.0014144036,0.00006069796,0.000030234973,0.36399257],"study_design_scores_gemma":[0.035076596,0.0057648853,0.95103717,0.00014145793,0.00007574134,0.000010629928,0.000022621192,0.0007283111,0.0035015272,0.00017874717,0.003323901,0.00013843284],"about_ca_topic_score_codex":0.00008327665,"about_ca_topic_score_gemma":0.0000233757,"teacher_disagreement_score":0.36385414,"about_ca_system_score_codex":0.00033996365,"about_ca_system_score_gemma":0.0005948831,"threshold_uncertainty_score":0.48772368},"labels":[],"label_agreement":null},{"id":"W2041507780","doi":"10.1007/s00262-010-0861-x","title":"Phenotypic characterization of chronic inflammation in a rare case of endobronchial carcinoma","year":2010,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame; Centre Hospitalier de l’Université de Montréal","funders":"Institut Du Cancer de Montréal","keywords":"Phenotype; Inflammation; Medicine; Carcinoma; Pathology; Biology; Internal medicine; Genetics; Gene","score_opus":0.009713388647332986,"score_gpt":0.2675888687790458,"score_spread":0.2578754801317128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041507780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911427,0.006454042,0.00009201452,0.00035564473,0.0010119975,0.00071101217,0.00004959512,0.00003039605,0.00015262926],"genre_scores_gemma":[0.99686563,0.0024138973,0.00009947365,0.000072927694,0.0001915347,0.00014103872,0.000073005715,0.00003940089,0.000103071994],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984277,0.00008417855,0.00079667085,0.00026968657,0.00012561798,0.00029616145],"domain_scores_gemma":[0.9986958,0.00004968207,0.00048919406,0.0005565591,0.00018069675,0.000028070106],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024634722,0.00022627984,0.0005711998,0.00036058237,0.00005193301,0.000006327758,0.00016642064,0.0003021305,0.0010891419],"category_scores_gemma":[0.000022203603,0.00021549653,0.00016540603,0.00044709785,0.00041873945,0.00015876305,0.000024669134,0.00041856294,0.0000028990737],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042435904,0.00013746168,0.016389193,0.00010811422,0.0002290691,0.00004772391,0.0011982844,0.0000015849345,0.8220762,0.0001696144,0.000004053685,0.15539509],"study_design_scores_gemma":[0.008680452,0.0006328094,0.30747133,0.00013646613,0.000038111575,0.0005374267,0.00009883233,0.00009885918,0.6797565,0.000040308,0.0023356136,0.0001732796],"about_ca_topic_score_codex":0.001636362,"about_ca_topic_score_gemma":0.0007794509,"teacher_disagreement_score":0.29108214,"about_ca_system_score_codex":0.00022379884,"about_ca_system_score_gemma":0.00058848027,"threshold_uncertainty_score":0.999824},"labels":[],"label_agreement":null},{"id":"W2043730939","doi":"10.1007/s00262-008-0534-1","title":"MSI-H colorectal cancers preferentially retain and expand intraepithelial lymphocytes rather than peripherally derived CD8+ T cells","year":2008,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; McGill University Health Centre","funders":"","keywords":"Intraepithelial lymphocyte; CD8; Colorectal cancer; Cancer research; Medicine; Biology; Immunology; Internal medicine; Immune system; Cancer","score_opus":0.01566053570161138,"score_gpt":0.25379718272415674,"score_spread":0.23813664702254536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043730939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92928547,0.06620925,0.0001391555,0.000835552,0.001350319,0.0010923309,0.00006720591,0.0002355953,0.0007851438],"genre_scores_gemma":[0.88030046,0.113312855,0.00047855012,0.0017902825,0.0003386273,0.0004306148,0.0000372054,0.00015951485,0.0031519143],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968331,0.0002371722,0.0007710531,0.00086981995,0.00035217378,0.00093672075],"domain_scores_gemma":[0.99844986,0.00010980968,0.00035103838,0.0006987415,0.00023133335,0.00015919363],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002582815,0.00070434815,0.0010401591,0.0002428104,0.00055619265,0.0000634556,0.00039289164,0.0005284764,0.0023500342],"category_scores_gemma":[0.000018695559,0.000620802,0.0003557478,0.00037295368,0.0016888139,0.0002535032,0.000079874764,0.0005188634,0.000024754167],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02182587,0.00015735901,0.008618989,0.000041495477,0.0022699672,0.0000617183,0.0047721574,0.0000088024235,0.9256681,0.000022511795,0.0010869793,0.03546605],"study_design_scores_gemma":[0.027601028,0.0026998501,0.19004977,0.00029696018,0.00020310855,0.00080435973,0.0008315184,0.00007891922,0.72646004,0.00006195425,0.049730953,0.0011815185],"about_ca_topic_score_codex":0.0024420682,"about_ca_topic_score_gemma":0.00035286037,"teacher_disagreement_score":0.19920804,"about_ca_system_score_codex":0.0011004178,"about_ca_system_score_gemma":0.0017394497,"threshold_uncertainty_score":0.9996243},"labels":[],"label_agreement":null},{"id":"W2045776411","doi":"10.3747/co.22.2303","title":"Tumour Inflammatory Response: Adding Fuel to the Fire?","year":2015,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Canadian Hospice Palliative Care Association; Bruyère; University of Ottawa","funders":"","keywords":"Medicine; Inflammatory response; Immune system; Key (lock); Carcinogen; Inflammation; Bioinformatics; Immunology; Computational biology; Cancer research; Biology; Computer security; Computer science; Genetics","score_opus":0.12038300606392814,"score_gpt":0.40791233393905857,"score_spread":0.2875293278751304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045776411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96330476,0.008588191,0.000046789803,0.021109654,0.0033871857,0.0005176486,0.00000860282,0.00007173526,0.0029654254],"genre_scores_gemma":[0.9959054,0.00019023102,0.00012308455,0.0018767178,0.0008469651,0.00009679697,0.000009919134,0.000018030558,0.00093288295],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99900216,0.00019415985,0.00022241205,0.00017182645,0.00017771358,0.00023171952],"domain_scores_gemma":[0.99924284,0.00016049869,0.00006621946,0.00024890972,0.00010269722,0.00017885331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010475228,0.00010384403,0.00019046583,0.00006691425,0.000053505242,0.000010301183,0.00014184973,0.000070291695,0.00012665906],"category_scores_gemma":[0.00037710532,0.00006831216,0.00007591432,0.00018837013,0.00008013831,0.000030540996,0.00006516656,0.00020847778,0.00026455047],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02810774,0.0002852097,0.010395657,0.000062693834,0.00009650964,0.00007794042,0.0053526787,0.0000056914196,0.012387369,0.000099191086,0.5645037,0.37862563],"study_design_scores_gemma":[0.0021038635,0.00078616926,0.0385568,0.0000627417,0.000024519237,0.00008945813,0.0005611105,0.000034575445,0.00033268012,0.00002308991,0.957342,0.00008296399],"about_ca_topic_score_codex":0.000009537988,"about_ca_topic_score_gemma":0.00003199968,"teacher_disagreement_score":0.39283833,"about_ca_system_score_codex":0.00043614794,"about_ca_system_score_gemma":0.0006149409,"threshold_uncertainty_score":0.34003493},"labels":[],"label_agreement":null},{"id":"W2046441958","doi":"10.1007/s11912-012-0284-2","title":"Programmed Death 1 Pathway inhibition in Metastatic Renal Cell Cancer and Prostate Cancer","year":2012,"lang":"en","type":"review","venue":"Current Oncology Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Prostate cancer; Renal cell carcinoma; Blockade; Programmed cell death; Cancer; Antibody; Cancer research; Immune system; PD-L1; Internal medicine; Pharmacology; Receptor; Apoptosis; Immunotherapy; Immunology","score_opus":0.14096055466489077,"score_gpt":0.4332371818489932,"score_spread":0.2922766271841024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046441958","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004332906,0.9897129,0.0000020374378,0.00011083002,0.002027553,0.003469648,0.00006598039,0.00004660063,0.00023153952],"genre_scores_gemma":[0.0006014755,0.99382913,0.0000785692,0.000058019228,0.00036481858,0.0040649516,0.00044395737,0.000064478816,0.00049460965],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99694115,0.00020708739,0.0013253676,0.00066821976,0.0002660035,0.00059216423],"domain_scores_gemma":[0.9980189,0.000070666545,0.0012606398,0.00032764577,0.000097732096,0.00022442472],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008492668,0.0005058403,0.0020218303,0.0003144572,0.00005793715,0.000020406962,0.000037022448,0.00031702427,0.00017207762],"category_scores_gemma":[0.000024257148,0.0003697312,0.0003170809,0.00038540585,0.000169078,0.00009089312,0.00006324035,0.0007492094,0.0000036912638],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000118257965,0.0005977174,0.0022229068,0.018152157,0.00021111759,0.0010961989,0.00025212846,9.049484e-8,0.000021705762,0.0000015082402,0.00051894074,0.9768073],"study_design_scores_gemma":[0.0011930672,0.00028395772,0.00044148968,0.015854107,0.0021496622,0.002097271,0.000015343234,6.705192e-7,0.00004133248,0.000013590828,0.9776021,0.00030738066],"about_ca_topic_score_codex":0.00030995824,"about_ca_topic_score_gemma":0.00035717606,"teacher_disagreement_score":0.9770832,"about_ca_system_score_codex":0.0012204364,"about_ca_system_score_gemma":0.003067455,"threshold_uncertainty_score":0.9998755},"labels":[],"label_agreement":null},{"id":"W2048296690","doi":"10.1007/s00262-015-1689-1","title":"Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report","year":2015,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"Cancer Research UK","keywords":"Nivolumab; Pembrolizumab; Medicine; Diabetes mellitus; Ipilimumab; Immunology; Type 1 diabetes; Adverse effect; Immune system; Insulin; Antibody; Immunotherapy; Internal medicine; Endocrinology","score_opus":0.04472514907973334,"score_gpt":0.30520106641164596,"score_spread":0.2604759173319126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048296690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7595817,0.23579676,0.000056998408,0.0015231364,0.0011481082,0.0010183709,0.000023226197,0.00022844336,0.00062326336],"genre_scores_gemma":[0.933065,0.060684305,0.0007757774,0.0031064295,0.00024614405,0.00057139667,0.000054442695,0.00014814567,0.0013483773],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99678475,0.00019430066,0.00089175237,0.0008561692,0.0003700773,0.00090295135],"domain_scores_gemma":[0.9976767,0.00009073117,0.00042921823,0.0011738573,0.00037012083,0.00025937852],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008249446,0.00060184015,0.0009985047,0.00030128684,0.00025144397,0.000095229276,0.00026926596,0.0004753643,0.00031905205],"category_scores_gemma":[0.000042474483,0.00051034486,0.0002707311,0.00044301705,0.0005993055,0.00021826736,0.00008078657,0.00059377594,0.000024984789],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011902422,0.0012688929,0.07408907,0.0001001082,0.0037410494,0.02506712,0.004106839,0.000004907109,0.36504737,0.00004636298,0.0016202335,0.5130056],"study_design_scores_gemma":[0.09944972,0.007856263,0.09497809,0.0004289801,0.00045832095,0.1201861,0.0041247224,0.00014787797,0.22656266,0.00044719406,0.44259238,0.0027676867],"about_ca_topic_score_codex":0.0015357629,"about_ca_topic_score_gemma":0.000041004503,"teacher_disagreement_score":0.51023793,"about_ca_system_score_codex":0.00043444743,"about_ca_system_score_gemma":0.0007660238,"threshold_uncertainty_score":0.9997348},"labels":[],"label_agreement":null},{"id":"W2049241540","doi":"10.1158/1538-7445.tumimm2012-b76","title":"Abstract B76: CD8+FoxP3+ T cells: A new player in the immune response to ovarian cancer.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"FOXP3; Tumor-infiltrating lymphocytes; Biology; CD8; Population; Immunology; Immunohistochemistry; Cancer research; Immune system; Pathology; Medicine","score_opus":0.08648452376026432,"score_gpt":0.41508885413319574,"score_spread":0.3286043303729314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049241540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93130165,0.006813315,0.0000052397527,0.057316132,0.0003228144,0.0019475517,0.000022428441,0.000030918225,0.0022399416],"genre_scores_gemma":[0.9835356,0.001337052,0.00008106756,0.002529464,0.00054438383,0.0011875412,0.000004565457,0.000046544665,0.0107337935],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99694765,0.00034418845,0.00040509217,0.00045385925,0.00096952356,0.0008797192],"domain_scores_gemma":[0.9981393,0.00048702338,0.000052312003,0.00079345645,0.0002369845,0.00029088728],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027876322,0.00020160925,0.00030906024,0.0004062953,0.00018619974,0.00014853753,0.0005826999,0.00014645296,0.010467161],"category_scores_gemma":[0.0001660615,0.000137024,0.00012205647,0.0014094897,0.00017250018,0.00014146764,0.000094691444,0.00088417804,0.0005071378],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013229704,0.00011131249,0.00071280333,0.00006379971,0.00008485053,0.00007054333,0.003545755,0.000017377342,0.8041736,0.000016658283,0.11085882,0.06711481],"study_design_scores_gemma":[0.0053413757,0.0006342572,0.5157366,0.00076862087,0.000019063487,0.000019811408,0.0021319715,0.000016161455,0.13409074,0.00015234365,0.3407643,0.00032479956],"about_ca_topic_score_codex":0.09997059,"about_ca_topic_score_gemma":0.0030335977,"teacher_disagreement_score":0.6700828,"about_ca_system_score_codex":0.00082401466,"about_ca_system_score_gemma":0.0018726181,"threshold_uncertainty_score":0.9904374},"labels":[],"label_agreement":null},{"id":"W2052590920","doi":"10.4161/onci.1.1.17824","title":"PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy","year":2012,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Versus Arthritis; Rosetrees Trust","keywords":"Cytotoxic T cell; Immunotherapy; T-cell receptor; Effector; Ligand (biochemistry); Downregulation and upregulation; Stimulation; Cancer research; Co-stimulation; Function (biology); Antigen presentation; Cell biology; Chemistry; Receptor; T cell; Immunology; Medicine; Immune system; Biology; Neuroscience; Biochemistry; CD28; In vitro","score_opus":0.022328723385317426,"score_gpt":0.30892876758755883,"score_spread":0.2866000442022414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052590920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989368,0.0061749625,0.00020345517,0.00086125755,0.000804335,0.00047026877,0.000007892023,0.00012922054,0.0019805573],"genre_scores_gemma":[0.99680835,0.000731682,0.00034246422,0.0012234211,0.00034623823,0.00003098618,0.00007736438,0.000043171265,0.00039632802],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99858904,0.000089276036,0.00041723214,0.00027225926,0.00017166948,0.000460521],"domain_scores_gemma":[0.9991033,0.00009840874,0.0001847653,0.00041943154,0.00011210947,0.00008199405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003814331,0.00024179695,0.0004478425,0.00019651295,0.00018453164,0.00002426094,0.000090285204,0.00022614932,0.00036698626],"category_scores_gemma":[0.00005348016,0.00021224169,0.00010942794,0.0002285558,0.00017719688,0.00024438972,0.000026943866,0.00023828453,0.000092667375],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017699817,0.00021663978,0.119402125,0.000023821307,0.00026971122,0.0000056417234,0.0008144709,0.0000013088829,0.83074844,0.00015727508,0.00052474614,0.046065833],"study_design_scores_gemma":[0.0051669786,0.0005039189,0.91377896,0.000054307497,0.00005232298,0.00029222507,0.00016247037,0.0000942138,0.03663148,0.00004997075,0.042963933,0.00024921307],"about_ca_topic_score_codex":0.0002173588,"about_ca_topic_score_gemma":0.0000052788378,"teacher_disagreement_score":0.79437685,"about_ca_system_score_codex":0.00014907774,"about_ca_system_score_gemma":0.000098260476,"threshold_uncertainty_score":0.86549646},"labels":[],"label_agreement":null},{"id":"W2057187391","doi":"10.1158/1078-0432.ccr-10-0505","title":"Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells","year":2010,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":302,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Tremelimumab; Medicine; Exemestane; Internal medicine; Breast cancer; Oncology; Adverse effect; Cancer; FOXP3; Immune system; Pharmacology; Immunology; Immunotherapy; Ipilimumab; Aromatase","score_opus":0.054415058311515815,"score_gpt":0.40782249443378715,"score_spread":0.3534074361222713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057187391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979362,0.00008572922,6.265546e-7,0.00037020093,0.00010324953,0.0013694874,0.000063115294,0.0000100447405,0.00006136548],"genre_scores_gemma":[0.99912167,0.0004471158,0.000055985085,0.000049951705,0.000021630536,0.00018841837,0.000039455543,0.00002517829,0.00005059933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802774,0.00016351436,0.00047377855,0.0004169849,0.00062444044,0.00029354362],"domain_scores_gemma":[0.9987441,0.00029164215,0.00017074838,0.00026758207,0.00040996133,0.00011597423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053009705,0.00014787563,0.00038627305,0.00026032396,0.000050169547,0.000011596703,0.000059914422,0.00016660834,0.00009271831],"category_scores_gemma":[0.00007011871,0.00009714919,0.000033828845,0.0005954188,0.00023655404,0.00010823469,0.000022068234,0.00050884206,6.371296e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042748142,0.0025951657,0.75504726,0.000028218841,0.0000400465,0.000005134703,0.00023156322,0.00010738557,0.016335472,0.0000029271243,0.000022506967,0.1828362],"study_design_scores_gemma":[0.031237416,0.0072308127,0.95196015,0.00089770614,0.0000128534075,3.1548592e-7,0.00006108012,0.0003776691,0.008008643,0.000007814637,0.00009637908,0.00010919355],"about_ca_topic_score_codex":0.0018622049,"about_ca_topic_score_gemma":0.0036474494,"teacher_disagreement_score":0.19691288,"about_ca_system_score_codex":0.00048949244,"about_ca_system_score_gemma":0.00035996814,"threshold_uncertainty_score":0.3961629},"labels":[],"label_agreement":null},{"id":"W2057270791","doi":"10.4161/onci.23687","title":"Victories and deceptions in tumor immunology","year":2013,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tumor immunology; Medicine; Immunology; Immune system; Immunotherapy","score_opus":0.00815938468256729,"score_gpt":0.252433483791686,"score_spread":0.2442740991091187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057270791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98620456,0.0065987976,0.000013182636,0.0032502583,0.00027962684,0.0002914874,0.0000016980273,0.00005164564,0.003308763],"genre_scores_gemma":[0.9961334,0.001441005,0.00044197615,0.00087294116,0.000036538477,0.000113215356,0.000009964572,0.000014206425,0.0009367863],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992118,0.000046811325,0.00023824572,0.00019218301,0.000047805286,0.00026318044],"domain_scores_gemma":[0.999588,0.000060087434,0.00004901873,0.00022739584,0.000046462977,0.000029010616],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000057511494,0.00011612445,0.00026863517,0.00017300817,0.000043618522,0.000012317499,0.00006605349,0.00012010623,0.0013384135],"category_scores_gemma":[0.000039513114,0.000100620295,0.000041828618,0.0001890959,0.0003725584,0.00009112234,0.000047607853,0.00020630386,0.00016632618],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001187432,0.00031540822,0.1372533,0.00003693511,0.0003156477,0.00006170953,0.0023100993,2.2202893e-7,0.75345045,0.0022640235,0.0013655293,0.10143923],"study_design_scores_gemma":[0.002805798,0.0005372149,0.9278499,0.000041351464,0.000015556918,0.0004929772,0.0009278508,0.000009015614,0.0018035852,0.00061231566,0.064777985,0.00012646859],"about_ca_topic_score_codex":0.0012322653,"about_ca_topic_score_gemma":0.00020116253,"teacher_disagreement_score":0.7905966,"about_ca_system_score_codex":0.00009779379,"about_ca_system_score_gemma":0.00008172184,"threshold_uncertainty_score":0.9995745},"labels":[],"label_agreement":null},{"id":"W2059881829","doi":"10.1159/000353408","title":"Melanoma-Associated Retinopathy Treated with Ipilimumab Therapy","year":2013,"lang":"en","type":"article","venue":"Dermatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Ipilimumab; Medicine; Melanoma; Vitiligo; Nivolumab; Dermatology; Adverse effect; Autoimmunity; Immunology; Ocular Melanoma; Immunotherapy; Oncology; Internal medicine; Disease; Immune system; Cancer research","score_opus":0.011410729582122565,"score_gpt":0.23423995301311012,"score_spread":0.22282922343098757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059881829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98873997,0.0008186581,0.000010750686,0.0039273393,0.000070064576,0.0004816481,0.0000033212368,0.00016313638,0.0057850922],"genre_scores_gemma":[0.995906,0.00021368405,0.00007836341,0.0026546142,0.000017464683,0.00008689414,0.0000574421,0.000026999884,0.00095857197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990696,0.000077672725,0.00022068454,0.00021100372,0.000120096294,0.00030098727],"domain_scores_gemma":[0.99941695,0.000048687893,0.000091605194,0.00025804952,0.000107731226,0.00007695231],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00004551498,0.00016105246,0.0003517047,0.00008786266,0.00006455422,0.000015112101,0.00007475478,0.00015741441,0.0011283018],"category_scores_gemma":[0.000012985785,0.00010731516,0.000072135525,0.000222378,0.00013779207,0.000058577,0.000009048868,0.00012665501,0.00017989319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068472014,0.00080127205,0.8248529,0.000046973746,0.001448211,0.00076913094,0.00090652076,3.3723424e-7,0.09161467,0.00013157268,0.03394036,0.038640857],"study_design_scores_gemma":[0.018339897,0.0015201946,0.90352154,0.000080141705,0.00008560076,0.0036821528,0.00024613712,0.0001303585,0.044054072,0.0000835705,0.027887553,0.0003688018],"about_ca_topic_score_codex":0.0003686172,"about_ca_topic_score_gemma":0.000028374367,"teacher_disagreement_score":0.07866863,"about_ca_system_score_codex":0.000056460405,"about_ca_system_score_gemma":0.00006650538,"threshold_uncertainty_score":0.9997848},"labels":[],"label_agreement":null},{"id":"W2062135418","doi":"10.1016/j.jim.2009.06.004","title":"Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients","year":2009,"lang":"en","type":"article","venue":"Journal of Immunological Methods","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":261,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal; Hôpital Notre-Dame","funders":"Institut Du Cancer de Montréal; Université de Montréal","keywords":"Prostate cancer; CD68; Immune system; Prostate; Prostatectomy; Medicine; CD20; Androgen deprivation therapy; FOXP3; CD8; Androgen; Oncology; Internal medicine; Cancer research; Cancer; Immunohistochemistry; Immunology; Hormone","score_opus":0.017524658707443817,"score_gpt":0.32470196334589796,"score_spread":0.30717730463845416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062135418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955998,0.0020634462,0.0005155588,0.0010068475,0.00032872232,0.0004137014,0.0000052236614,0.000005170791,0.000061540035],"genre_scores_gemma":[0.9883556,0.0028298637,0.008373372,0.00034783524,0.000030583204,0.0000058959326,0.0000050284584,0.0000067965557,0.000045038058],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982103,0.00042605476,0.0008946372,0.0000989996,0.00021642992,0.00015355626],"domain_scores_gemma":[0.9986028,0.00008300945,0.00087684765,0.0001514208,0.00025724087,0.000028697494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087287766,0.000120430945,0.00040570358,0.00011813281,0.000037381567,0.000012539636,0.00014405946,0.00011206673,0.000065164946],"category_scores_gemma":[0.00025513605,0.00006734726,0.00017377088,0.00041221164,0.00009408346,0.00013599584,0.000018276929,0.00034358143,3.3664796e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022583613,0.0003744696,0.019545637,0.000017845736,0.000039128936,0.0000024511196,0.00044542586,0.0000028122479,0.7901241,0.000005147545,0.0000021663204,0.18718244],"study_design_scores_gemma":[0.0021638954,0.0010206169,0.57472575,0.00016396903,0.000031237396,0.000009740792,0.000045017186,0.0000115322655,0.4214464,0.00011397853,0.00022114639,0.000046666522],"about_ca_topic_score_codex":0.000013049634,"about_ca_topic_score_gemma":7.1700237e-7,"teacher_disagreement_score":0.55518013,"about_ca_system_score_codex":0.000128988,"about_ca_system_score_gemma":0.00012450914,"threshold_uncertainty_score":0.27463415},"labels":[],"label_agreement":null},{"id":"W2062536536","doi":"10.1016/j.clinbiochem.2012.07.067","title":"Suivi des patients sous coumadin par autocontrôle à domicile de l'inr – Experience au CHUM","year":2012,"lang":"fr","type":"article","venue":"Clinical Biochemistry","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"CD8; Lung cancer; Tissue microarray; Concordance; Adenocarcinoma; Molecular biology; Medicine; Cancer research; clone (Java method); Immune system; Pathology; Fluorescence in situ hybridization; Cancer; Immunohistochemistry; Biology; Gene; Internal medicine; Immunology","score_opus":0.04057346484974996,"score_gpt":0.3691277131015028,"score_spread":0.32855424825175283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062536536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9633473,0.027429689,0.000071739916,0.0005124431,0.004151945,0.00044453808,0.00011599326,0.000070931615,0.0038553753],"genre_scores_gemma":[0.9815621,0.0020290324,0.00037471822,0.0014789102,0.0041361055,0.00008903611,0.00007971857,0.000049655817,0.010200773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99578136,0.00016098435,0.0011212822,0.00056232285,0.00032234562,0.0020516734],"domain_scores_gemma":[0.9969063,0.0005779492,0.00032295682,0.0007353046,0.00014264336,0.001314877],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019311549,0.00039264082,0.0006425782,0.000024877185,0.00023611556,0.000040457446,0.0003589976,0.0008203239,0.0020851463],"category_scores_gemma":[0.0019438526,0.00037591875,0.0005153132,0.00019593436,0.0023481664,0.00015318069,0.00012558828,0.00058558263,0.00029677898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018042466,0.0028079187,0.84980094,0.0004655617,0.00030057714,0.000018923263,0.0018122636,5.4199717e-7,0.053932358,0.0000074707277,0.025827095,0.0632221],"study_design_scores_gemma":[0.0120234005,0.0007949877,0.41920543,0.0017473527,0.000385512,0.00006439933,0.0011439021,0.000119856835,0.38602683,0.000057252022,0.17753176,0.0008993249],"about_ca_topic_score_codex":0.00038119312,"about_ca_topic_score_gemma":0.000013039658,"teacher_disagreement_score":0.43059555,"about_ca_system_score_codex":0.0012648279,"about_ca_system_score_gemma":0.0010435174,"threshold_uncertainty_score":0.9998693},"labels":[],"label_agreement":null},{"id":"W2065416322","doi":"10.4161/21645515.2014.980707","title":"Vaccines versus immunotherapy: Overview of approaches in deciding between options","year":2014,"lang":"en","type":"review","venue":"Human Vaccines & Immunotherapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Immunotherapy; Medicine; Monoclonal antibody; Modalities; Immunology; Scope (computer science); Antibody; Immune system; Computer science","score_opus":0.31160837997972607,"score_gpt":0.4237224810339045,"score_spread":0.1121141010541784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065416322","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014733457,0.9947647,0.000063095096,0.00008049056,0.000610198,0.002142036,0.00006420513,0.0001411554,0.0006608065],"genre_scores_gemma":[0.0017475158,0.9952972,0.00038682288,0.00009963227,0.00067310117,0.0002531177,0.00050290173,0.00039674775,0.0006429957],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938446,0.00056139525,0.0031973296,0.00096346805,0.0005693712,0.00086380745],"domain_scores_gemma":[0.9951708,0.0008579843,0.0016597621,0.0020179302,0.00017115804,0.00012238462],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013710919,0.0013494707,0.0057568178,0.0013085939,0.00023207019,0.00008839326,0.000970075,0.000990587,0.0004626966],"category_scores_gemma":[0.000046088135,0.001133054,0.002128362,0.0015502577,0.00015022799,0.00016790218,0.00015616462,0.0010547562,0.000035655114],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009908504,0.00040039694,0.00094656524,0.018775525,0.0039070975,0.0000075005437,0.0002653792,0.0000011832301,0.00015512771,0.000541824,0.00013175048,0.9738768],"study_design_scores_gemma":[0.009467938,0.00086380384,0.002652335,0.022156084,0.0029528253,0.000055500062,0.000076037955,0.000006247252,0.000062628715,0.00010795694,0.96050316,0.0010955036],"about_ca_topic_score_codex":0.00018790457,"about_ca_topic_score_gemma":0.000103017825,"teacher_disagreement_score":0.9727813,"about_ca_system_score_codex":0.00056984724,"about_ca_system_score_gemma":0.00048752013,"threshold_uncertainty_score":0.9999256},"labels":[],"label_agreement":null},{"id":"W2066567958","doi":"10.1620/tjem.191.113","title":"Infiltration of CD8+ T cells in Non-Small Cell Lung Cancer is Associated with Dedifferentiation of Cancer Cells, but not with Prognosis","year":2000,"lang":"en","type":"article","venue":"The Tohoku Journal of Experimental Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Lung cancer; Adenocarcinoma; CD8; Colorectal cancer; Cancer cell; Cytotoxic T cell; Medicine; Immunohistochemistry; Cancer; Infiltration (HVAC); Cell; Carcinoma; Pathology; Cancer research; Immunity; Immune system; Biology; Internal medicine; Oncology; Immunology; In vitro","score_opus":0.01366215114457797,"score_gpt":0.27776769065636886,"score_spread":0.2641055395117909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066567958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919794,0.005977893,0.000019183459,0.0009343139,0.00015931088,0.00058296556,0.000019378645,0.0000046372456,0.00032288802],"genre_scores_gemma":[0.99696255,0.0019550526,0.0000967099,0.00044421543,0.0001608787,0.00003066723,0.0000061040428,0.000025135587,0.0003186674],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99824035,0.000069473805,0.0007425359,0.00014086494,0.0006065785,0.00020022235],"domain_scores_gemma":[0.9986502,0.000073619995,0.0008297189,0.00015404588,0.00021393827,0.00007850684],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033313117,0.00020403962,0.00059336954,0.00015709766,0.000038840466,0.000005384064,0.00014507232,0.00007743479,0.0014816995],"category_scores_gemma":[0.0000048182733,0.00010891075,0.00008313013,0.00036558343,0.00024749083,0.000097082506,0.000008546668,0.00023350904,3.274665e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008247107,0.0005597424,0.020703452,0.000100670964,0.00044326435,0.000014190639,0.007960806,0.00008792646,0.9596838,5.053976e-7,0.0005431124,0.0016554749],"study_design_scores_gemma":[0.009872067,0.0030977512,0.03850159,0.002728788,0.00044701324,0.000018246508,0.0019612352,0.00023783828,0.9429845,7.958123e-7,0.00003788021,0.00011229422],"about_ca_topic_score_codex":0.0024828678,"about_ca_topic_score_gemma":0.0002540379,"teacher_disagreement_score":0.017798137,"about_ca_system_score_codex":0.0002681865,"about_ca_system_score_gemma":0.00022865119,"threshold_uncertainty_score":0.9994311},"labels":[],"label_agreement":null},{"id":"W2066794455","doi":"10.1016/j.cyto.2011.07.248","title":"PS2-085 Understanding anti-tumor immunity in breast cancer: Characterization the influence of B7-H4 in T cell responses to tumor antigens","year":2011,"lang":"en","type":"article","venue":"Cytokine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Breast cancer; Antigen; Immunity; Tumor associated antigen; Tumor cells; Cancer research; Immunology; Biology; Cancer; Immune system; Medicine; Internal medicine; Immunotherapy","score_opus":0.039267189403425565,"score_gpt":0.2749985727734916,"score_spread":0.23573138337006605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066794455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981137,0.00013103006,0.000047405163,0.0008459457,0.00009289564,0.00046860773,0.00011990221,0.000018795025,0.00016174301],"genre_scores_gemma":[0.9986106,0.00036024832,0.000032643362,0.0008642753,0.000031297222,0.00002615906,0.000012488837,0.000018489813,0.000043785738],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989153,0.00010466235,0.00038539656,0.00018777672,0.00016334333,0.00024353065],"domain_scores_gemma":[0.9993536,0.00005246296,0.00015380081,0.00032761885,0.00006262158,0.00004990213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004564384,0.00014086695,0.00028566652,0.0002774552,0.000057162513,0.000009467163,0.00016624581,0.000039993218,0.00014189919],"category_scores_gemma":[0.000034044253,0.00010652926,0.000050647202,0.0008005068,0.00012691456,0.00011256445,0.0000458411,0.00017315462,0.0000036973956],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035046588,0.00012387305,0.36071518,0.000058307185,0.000014097834,0.00003081965,0.0017766383,0.0000067305973,0.63344616,0.000016810114,0.000013595607,0.00029309854],"study_design_scores_gemma":[0.001440139,0.00013671645,0.9159844,0.00044206125,0.00001543256,0.000039164435,0.0006670703,0.000021103986,0.08092032,0.000013348257,0.00020935218,0.00011087766],"about_ca_topic_score_codex":0.0034347156,"about_ca_topic_score_gemma":0.00043322195,"teacher_disagreement_score":0.55526924,"about_ca_system_score_codex":0.00025191478,"about_ca_system_score_gemma":0.00016713967,"threshold_uncertainty_score":0.5192286},"labels":[],"label_agreement":null},{"id":"W2066973044","doi":"10.1016/j.ygyno.2007.03.035","title":"B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression","year":2007,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Ovarian cancer; Stage (stratigraphy); Medicine; Cancer; Biomarker; Internal medicine; Oncology; Ovarian carcinoma; Gastroenterology; Pathology; Biology","score_opus":0.02423244268222373,"score_gpt":0.3356432818737014,"score_spread":0.31141083919147766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066973044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992251,0.0011020466,0.000037073132,0.0014471106,0.00040518332,0.00053916284,0.000044490567,0.000026004165,0.0041479543],"genre_scores_gemma":[0.99359304,0.0011864124,0.00042167777,0.0032373543,0.000070848386,0.000046994435,0.0000060013813,0.000015187387,0.0014224745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838054,0.00007263503,0.00052690925,0.00039246533,0.00021102683,0.0004163992],"domain_scores_gemma":[0.9989663,0.00032845125,0.0002551055,0.00027397444,0.000062046725,0.00011414398],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007463052,0.00018396233,0.00053626846,0.0002303327,0.00005205163,0.000006656745,0.00012365582,0.0004972012,0.0028422833],"category_scores_gemma":[0.00007295607,0.00014904686,0.0000887969,0.00024795096,0.00020481442,0.00006587212,0.00009413206,0.00030550561,0.000004549105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046277866,0.0005447495,0.64415336,0.000105105064,0.00010874404,0.0002037005,0.0031111378,0.0000013032494,0.2989966,0.000040939885,0.0029901424,0.04511642],"study_design_scores_gemma":[0.007022414,0.0014003053,0.85426724,0.00007185265,0.000036204652,0.00001017878,0.00047569594,0.000014492442,0.07904619,0.00009427553,0.05741442,0.00014674183],"about_ca_topic_score_codex":0.0036744347,"about_ca_topic_score_gemma":0.0025922544,"teacher_disagreement_score":0.21995042,"about_ca_system_score_codex":0.0004143164,"about_ca_system_score_gemma":0.0002512453,"threshold_uncertainty_score":0.9980692},"labels":[],"label_agreement":null},{"id":"W2070462086","doi":"10.1158/1078-0432.ovca13-ia26","title":"Abstract IA26: Protective immune networks in ovarian cancer","year":2013,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Ovarian cancer; Immune system; CD8; Antigen; Cancer; Immunology; Cytotoxic T cell; Biology; Cancer research; Medicine; Internal medicine; Genetics","score_opus":0.18369874708787964,"score_gpt":0.513201799612445,"score_spread":0.3295030525245654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070462086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9528132,0.016417168,0.00005611588,0.019606503,0.0009974552,0.004222511,0.000015395477,0.00006287155,0.005808746],"genre_scores_gemma":[0.98696333,0.006751771,0.000053578973,0.00081209344,0.0011191794,0.0024797998,0.000007167203,0.000046322875,0.001766758],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9966421,0.00033729651,0.00090251496,0.000600419,0.00065392704,0.00086370116],"domain_scores_gemma":[0.9979143,0.00062247616,0.000116817624,0.0005580229,0.00050499704,0.00028340062],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034736842,0.000187553,0.00054496387,0.00021538511,0.00013545572,0.000069055335,0.00030452615,0.0003663044,0.009046887],"category_scores_gemma":[0.0003980158,0.0001476498,0.00024259496,0.00096950616,0.0006150452,0.00015529727,0.00012374492,0.002263337,0.00015722583],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009797149,0.0010612588,0.19073686,0.00024463193,0.00053951924,0.00011737234,0.00035337923,0.00009263175,0.016511325,0.00006140426,0.022315223,0.75816923],"study_design_scores_gemma":[0.0048380853,0.00048117136,0.9807178,0.0006496257,0.000013776081,0.000003613956,0.00016433733,0.00045961057,0.0011039767,0.00028982523,0.011084713,0.00019347393],"about_ca_topic_score_codex":0.052332357,"about_ca_topic_score_gemma":0.0026120779,"teacher_disagreement_score":0.78998095,"about_ca_system_score_codex":0.000621951,"about_ca_system_score_gemma":0.0009798554,"threshold_uncertainty_score":0.99185896},"labels":[],"label_agreement":null},{"id":"W2070606570","doi":"10.1385/ir:28:1:49","title":"Cytotoxic T-Lymphocyte Antigen-4 and Programmed Death-1 Function as Negative Regulators of Lymphocyte Activation","year":2003,"lang":"en","type":"review","venue":"Immunologic Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Cytotoxic T cell; Lymphocyte; Immunology; Immune system; Biology; Antigen; T lymphocyte; Cell biology; Receptor; Effector; T cell; Biochemistry; In vitro","score_opus":0.16048229458349386,"score_gpt":0.43758349068348346,"score_spread":0.2771011960999896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070606570","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012776323,0.98147404,0.000011861792,0.00005572418,0.00020998812,0.0036501708,0.000012108909,0.00007300665,0.0017367832],"genre_scores_gemma":[0.0036312917,0.99311376,0.00016063095,0.000033841592,0.00007870967,0.00052489847,0.00009590658,0.00007745299,0.0022835033],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99537444,0.0011629534,0.0009511579,0.00081021705,0.00093332917,0.0007679288],"domain_scores_gemma":[0.9972383,0.0006422632,0.0005446997,0.00087618246,0.00057167315,0.00012690053],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021571792,0.0005268054,0.001791806,0.0010043012,0.00028767908,0.000077227116,0.00029249725,0.0009160443,0.00023389167],"category_scores_gemma":[0.00064179086,0.00038249177,0.0004897757,0.0018487024,0.0009304035,0.00015470198,0.00015434573,0.00085685286,0.000053356907],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026613744,0.00019005947,0.0000430644,0.0045618163,0.0012287728,0.000022822669,0.000090308415,5.604863e-8,0.0016948641,0.00023253402,0.00012887784,0.98914546],"study_design_scores_gemma":[0.0034464265,0.002986703,0.0011676705,0.0111408895,0.00031948055,0.00036243544,0.00026154588,0.0000023971406,0.003863256,0.00040411646,0.975633,0.00041207392],"about_ca_topic_score_codex":0.0006932484,"about_ca_topic_score_gemma":0.000003315716,"teacher_disagreement_score":0.98873335,"about_ca_system_score_codex":0.0016570099,"about_ca_system_score_gemma":0.0026682755,"threshold_uncertainty_score":0.9998627},"labels":[],"label_agreement":null},{"id":"W2071040673","doi":"10.1158/0008-5472.sabcs13-p5-13-06","title":"Abstract P5-13-06: Seasonal variation in onset of inflammatory breast cancer: Evidence of an infectious trigger","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Inflammatory breast cancer; Breast cancer; Rash; Internal medicine; Cancer; Referral; Disease; Oncology; Dermatology; Family medicine","score_opus":0.05104685611728175,"score_gpt":0.39490904172381397,"score_spread":0.3438621856065322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071040673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99426156,0.0032429586,0.000002610751,0.001366281,0.00010506554,0.0007752328,0.000058011407,0.000016140038,0.00017215394],"genre_scores_gemma":[0.99626976,0.0028561002,0.00001457773,0.00007162872,0.00016610375,0.00036107487,0.000007048271,0.000021261078,0.00023242726],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979676,0.00017405613,0.00044443223,0.00027829083,0.00077501027,0.000360597],"domain_scores_gemma":[0.9983894,0.00024566174,0.0001507365,0.00035823556,0.00072278304,0.0001331824],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013313284,0.00012251624,0.0003104441,0.00037368076,0.000049573817,0.000020922695,0.00017961813,0.00013311511,0.0029712995],"category_scores_gemma":[0.000108772285,0.000106640946,0.000079581645,0.0007295627,0.0002859758,0.00038503628,0.00003936256,0.00041495764,0.000018958644],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004571678,0.00035960204,0.32051596,0.0011424369,0.00016913807,0.000017475792,0.001230164,0.00008262564,0.61294913,0.000015997985,0.0026870775,0.056258682],"study_design_scores_gemma":[0.0019616727,0.00024369817,0.9800745,0.0015086344,0.000013917651,0.000018598073,0.0001067606,0.0001578307,0.015469618,0.000065864944,0.00027863032,0.00010023575],"about_ca_topic_score_codex":0.038065545,"about_ca_topic_score_gemma":0.0031692751,"teacher_disagreement_score":0.6595586,"about_ca_system_score_codex":0.0006193328,"about_ca_system_score_gemma":0.0016694579,"threshold_uncertainty_score":0.9979401},"labels":[],"label_agreement":null},{"id":"W2071355800","doi":"10.4161/21624011.2014.944056","title":"Transcriptional profiling of whole blood: a rich source of immune biomarkers in cancer","year":2014,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Medicine; Tremelimumab; Immunotherapy; Cancer immunotherapy; Peripheral blood; Immune system; Cancer; Immunology; Whole blood; Gene expression profiling; Immune Dysfunction; Oncology; Internal medicine; Gene expression; Gene; Biology; Ipilimumab","score_opus":0.015273027825085274,"score_gpt":0.2774577912047784,"score_spread":0.26218476337969315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071355800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857,0.011481425,0.00019060924,0.00080464536,0.00022287041,0.0002626704,0.000012907956,0.00001981509,0.0013050513],"genre_scores_gemma":[0.9980815,0.0005180187,0.00079473446,0.0001091126,0.000034016546,0.000042074167,0.000024434645,0.000019670992,0.00037644582],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987032,0.00009743151,0.0006061692,0.00020459673,0.00015210552,0.0002365183],"domain_scores_gemma":[0.99931145,0.00007970281,0.00022077264,0.00027629576,0.0000891535,0.000022604241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043737344,0.00013456955,0.0005046515,0.00026117163,0.000023538545,0.000001962341,0.00013234882,0.00016983117,0.00021373658],"category_scores_gemma":[0.000046271995,0.00012174543,0.00015605216,0.0003810008,0.00033256656,0.000040333518,0.00002113211,0.00017276563,0.0000031442692],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024760112,0.00037870897,0.03870962,0.00016057932,0.00056995865,0.000002280864,0.00051453593,0.000011124597,0.93141025,0.000206993,0.000021768836,0.025538163],"study_design_scores_gemma":[0.014067553,0.0016959412,0.46345177,0.0006455321,0.000251339,0.000081404214,0.0008161857,0.00021673669,0.5043589,0.00011127081,0.014054544,0.00024883132],"about_ca_topic_score_codex":0.0018997836,"about_ca_topic_score_gemma":0.00011180415,"teacher_disagreement_score":0.42705137,"about_ca_system_score_codex":0.00006587752,"about_ca_system_score_gemma":0.00018875784,"threshold_uncertainty_score":0.49646342},"labels":[],"label_agreement":null},{"id":"W2071543540","doi":"10.1615/critrevoncog.2013010597","title":"Immunosenescence and Cancer","year":2013,"lang":"en","type":"review","venue":"Critical Reviews™ in Oncogenesis","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Université de Sherbrooke","funders":"Canadian Institutes of Health Research","keywords":"Immunosenescence; Immune system; Cancer; Context (archaeology); Immunology; Acquired immune system; Biology; Inflammation; Tumor microenvironment; Cancer research; Medicine; Genetics","score_opus":0.12174932931236014,"score_gpt":0.45333479837289653,"score_spread":0.3315854690605364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071543540","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014108174,0.9966446,0.0000082110955,0.00037414755,0.00041307686,0.0019999677,0.00002699539,0.000027978775,0.00049090246],"genre_scores_gemma":[0.00000371401,0.99629235,0.0004503975,0.00065229676,0.00027790075,0.0016083642,0.000020189025,0.00007387304,0.00062089006],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99698025,0.0003171358,0.0013050986,0.0006596684,0.00023710977,0.00050071505],"domain_scores_gemma":[0.99837697,0.0005423706,0.00015785857,0.00059189583,0.00008640851,0.0002444716],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00060025946,0.00056821224,0.0034777499,0.00020926008,0.000060833172,0.000049751987,0.00021080059,0.00043169086,0.0009910151],"category_scores_gemma":[0.0007575939,0.00039143054,0.000704984,0.00057984906,0.00036491966,0.00008431412,0.00009377596,0.00041408997,0.00022138834],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020899937,0.000070856535,0.000028264498,0.056028165,0.00006721476,0.000037762955,0.0000102225185,8.436965e-10,0.000020712027,0.00005064015,0.0010084893,0.94265676],"study_design_scores_gemma":[0.00028516448,0.00007038754,0.000059816815,0.093593575,0.0011216606,0.00017414903,0.0000056225604,7.671648e-7,0.000006288191,0.00001137972,0.90430486,0.00036629892],"about_ca_topic_score_codex":0.00029273183,"about_ca_topic_score_gemma":0.000016773776,"teacher_disagreement_score":0.9422905,"about_ca_system_score_codex":0.00036775335,"about_ca_system_score_gemma":0.0004633684,"threshold_uncertainty_score":0.9999222},"labels":[],"label_agreement":null},{"id":"W2073815834","doi":"10.4021//jmc.v4i1.886","title":"Ipilimumab Associated Autoimmune Alveolitis Responding to Corticosteroids","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Ipilimumab; Melanoma; Metastatic melanoma; Incidence (geometry); Nivolumab; Drug; Immunology; Immunotherapy; Immune system; Dermatology; Oncology; Cancer research; Pharmacology","score_opus":0.03574798075258941,"score_gpt":0.34339942928615436,"score_spread":0.30765144853356496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073815834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822427,0.0053901933,0.00010021543,0.010393003,0.0012941597,0.00010414528,0.000005426252,0.000019291765,0.00045083946],"genre_scores_gemma":[0.9936741,0.00039148342,0.00014694883,0.0040574796,0.0008064088,0.0000022368718,0.0000030935666,0.000017888087,0.0009003482],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973631,0.00011742805,0.0006890738,0.000078373225,0.0013787723,0.00037327947],"domain_scores_gemma":[0.99833924,0.00039889078,0.00026964984,0.00014270369,0.00015828073,0.0006912197],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020868678,0.00011843669,0.00042113243,0.0003953494,0.000060229373,0.00001968698,0.00015207184,0.00016117815,0.0021723139],"category_scores_gemma":[0.0040009874,0.000085290005,0.0002326401,0.00048712213,0.00007458967,0.00014311889,0.000044491168,0.0003940601,0.000023442104],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033974912,0.003931831,0.17234844,0.00023539414,0.0028356127,0.011481706,0.005712992,0.000001707467,0.09210873,0.00039833577,0.19575778,0.48121256],"study_design_scores_gemma":[0.012137119,0.0049472935,0.6628363,0.0027689685,0.00045223077,0.023846354,0.0013546266,0.000026755888,0.0056358506,0.000020730917,0.2856553,0.00031847254],"about_ca_topic_score_codex":0.000041430252,"about_ca_topic_score_gemma":0.0000055912087,"teacher_disagreement_score":0.49048787,"about_ca_system_score_codex":0.00029852576,"about_ca_system_score_gemma":0.0003291471,"threshold_uncertainty_score":0.99873984},"labels":[],"label_agreement":null},{"id":"W2076669505","doi":"10.1158/1078-0432.ccr-13-3368","title":"Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer","year":2014,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Biology; Ovarian cancer; Breast cancer; Cancer research; Population; Somatic hypermutation; Immune system; Metastasis; Cancer; B cell; Immunology; Antibody; Medicine; Genetics","score_opus":0.1014426997593371,"score_gpt":0.4251543637597016,"score_spread":0.3237116640003645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076669505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936756,0.0035082223,0.000015649814,0.0011954348,0.00023021168,0.0008599831,0.000029281236,0.000020140202,0.00046551452],"genre_scores_gemma":[0.99727476,0.001309367,0.00016980067,0.00038554872,0.00045443815,0.000080737016,0.000011790652,0.00004244906,0.0002711073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973473,0.00036504303,0.00045654186,0.0005679248,0.0007039335,0.00055925146],"domain_scores_gemma":[0.9983792,0.0005384642,0.00009329985,0.0003499782,0.00038846684,0.000250594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001741481,0.00017155988,0.00040665633,0.00019718394,0.00012702664,0.000056229957,0.0001591627,0.00020900698,0.00044172182],"category_scores_gemma":[0.00013265104,0.00012314739,0.00006735468,0.0006130528,0.0005971542,0.00008147965,0.000081498125,0.0009912625,0.000006554528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01113744,0.0006007565,0.9231073,0.00012457713,0.00005943602,0.000012005375,0.00008168023,0.000010561305,0.0005711046,0.000017470375,0.00097226445,0.06330536],"study_design_scores_gemma":[0.009673577,0.00117901,0.97950053,0.00058482646,0.000029367484,0.0000029511828,0.000032185344,0.00025373182,0.000121544246,0.000036334608,0.008412852,0.00017310961],"about_ca_topic_score_codex":0.0021460352,"about_ca_topic_score_gemma":0.0007130309,"teacher_disagreement_score":0.06313225,"about_ca_system_score_codex":0.00025502246,"about_ca_system_score_gemma":0.0005331902,"threshold_uncertainty_score":0.50218046},"labels":[],"label_agreement":null},{"id":"W2076911781","doi":"10.1016/j.vetimm.2009.10.006","title":"Structure and function of programmed death (PD) molecules","year":2009,"lang":"en","type":"review","venue":"Veterinary Immunology and Immunopathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Biology; Cell biology; Immune system; T cell; Acquired immune system; Programmed cell death; Autoimmunity; Cytokine; Immune tolerance; Peripheral tolerance; Phosphorylation; Immunology; Apoptosis; Genetics","score_opus":0.034935847125709026,"score_gpt":0.31582494228307895,"score_spread":0.28088909515736993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076911781","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.054953676,0.94353634,0.00002053189,0.000045710414,0.00039831956,0.0008332472,0.000046695102,0.000055332683,0.000110169865],"genre_scores_gemma":[0.0064063054,0.9924662,0.00047269664,0.000108234046,0.0000537838,0.000060520502,0.0002509797,0.000047918285,0.00013333689],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99782544,0.000368563,0.00076229416,0.0005647466,0.00008399483,0.0003949588],"domain_scores_gemma":[0.9988118,0.00008657743,0.00045862485,0.0005294359,0.0000632515,0.000050306884],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020266717,0.00054507155,0.0021263703,0.00039966518,0.00011702266,0.000014056025,0.0001444933,0.0010341728,0.000058832688],"category_scores_gemma":[0.00003334214,0.00042951142,0.0002789653,0.0002165074,0.00073466793,0.000066336484,0.00014130815,0.00065612636,0.0000028677714],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024991878,0.00010150112,0.000035424775,0.0038174582,0.0006230596,0.00024631346,0.00007618008,5.029538e-9,0.011282515,0.00012089187,0.000011603385,0.98118585],"study_design_scores_gemma":[0.0024035866,0.017912183,0.010114252,0.004476616,0.0020821327,0.037394654,0.000053684962,5.6524556e-7,0.00010618955,0.00021248753,0.92473453,0.0005091351],"about_ca_topic_score_codex":0.000017119033,"about_ca_topic_score_gemma":6.4792266e-7,"teacher_disagreement_score":0.9806767,"about_ca_system_score_codex":0.000050549217,"about_ca_system_score_gemma":0.00016706766,"threshold_uncertainty_score":0.99981564},"labels":[],"label_agreement":null},{"id":"W2078265158","doi":"10.1016/j.jss.2003.08.012","title":"Tumor immunity in the context of autoimmunity","year":2003,"lang":"en","type":"article","venue":"Journal of Surgical Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Nod; Autoimmunity; NOD mice; Immune system; Immunology; CD8; Insulitis; Biology; Context (archaeology); Clonal deletion; Medicine; T cell; Endocrinology; Diabetes mellitus; T-cell receptor","score_opus":0.1176537339592473,"score_gpt":0.42580165985606466,"score_spread":0.3081479258968174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078265158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832409,0.003477666,0.0000016016251,0.0027198114,0.000060941897,0.00015220643,0.0000013798023,0.0000013192647,0.010344155],"genre_scores_gemma":[0.998289,0.0013258486,0.000036243455,0.000117478296,0.00003720154,0.0000020841353,4.025726e-7,0.000005452273,0.00018628479],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968192,0.0013669165,0.00053632865,0.000054625507,0.0009803388,0.00024256844],"domain_scores_gemma":[0.99756664,0.0014528008,0.00013713635,0.000251562,0.00052037585,0.00007146673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012557982,0.00006241284,0.0003088873,0.0002570971,0.000074886724,0.00001572049,0.00026714624,0.00005162053,0.00052313047],"category_scores_gemma":[0.0008974409,0.00003363596,0.00019000625,0.00071451307,0.00039289938,0.00006150862,0.000023256169,0.0013092624,0.0000044366343],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12342493,0.017153496,0.20299588,0.0011068843,0.0016745923,0.017178314,0.02444896,0.000009888429,0.21138816,0.028149394,0.036120337,0.33634916],"study_design_scores_gemma":[0.018947424,0.004856318,0.34128803,0.00091396406,0.000038595732,0.0059604337,0.024022173,0.000018265135,0.027281107,0.0015062003,0.57500184,0.00016565439],"about_ca_topic_score_codex":0.00027259052,"about_ca_topic_score_gemma":0.00001575266,"teacher_disagreement_score":0.5388815,"about_ca_system_score_codex":0.0001146267,"about_ca_system_score_gemma":0.00051388546,"threshold_uncertainty_score":0.57279116},"labels":[],"label_agreement":null},{"id":"W2079482233","doi":"10.3389/fonc.2014.00288","title":"Immunotherapy for Lung Cancer: Has it Finally Arrived?","year":2014,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Lung cancer; Immunotherapy; Medicine; Cancer; Cancer immunotherapy; Oncology; Cancer research; Intensive care medicine; Internal medicine","score_opus":0.053372608556973324,"score_gpt":0.4062673542064971,"score_spread":0.3528947456495238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079482233","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000024548472,0.980473,0.0062885713,0.002471812,0.0061949017,0.0031406723,0.00010051079,0.000048049373,0.0012800638],"genre_scores_gemma":[0.0000010447106,0.9810593,0.009598166,0.0023725918,0.000919885,0.002143742,0.00021633468,0.00012720581,0.0035617228],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971328,0.00024640863,0.0011515801,0.0006528306,0.00018253428,0.00063387817],"domain_scores_gemma":[0.99830294,0.00029226314,0.0006544312,0.0005586618,0.00008752717,0.000104158025],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007907471,0.00055324234,0.003886428,0.0005407699,0.00011039896,0.000026660722,0.00042775564,0.0010913003,0.0003072757],"category_scores_gemma":[0.0000731462,0.00045955493,0.0011096697,0.00036559507,0.00032093274,0.00004061744,0.000037079077,0.00063847424,0.000005395008],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012864238,0.00009063902,0.00006897349,0.006979103,0.0009494019,0.000020748996,0.00012184469,5.106266e-7,0.000002521499,0.000007925573,0.30633467,0.6841372],"study_design_scores_gemma":[0.0049826396,0.0010036184,0.000018905748,0.0089897495,0.0010133588,0.000060425646,0.00004038485,0.00009916723,0.0000013489683,0.000034511453,0.9833179,0.0004379791],"about_ca_topic_score_codex":0.00015446234,"about_ca_topic_score_gemma":0.00016079862,"teacher_disagreement_score":0.68369925,"about_ca_system_score_codex":0.0025788327,"about_ca_system_score_gemma":0.003204671,"threshold_uncertainty_score":0.9997856},"labels":[],"label_agreement":null},{"id":"W2079548788","doi":"10.1097/00006676-200401000-00023","title":"CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma","year":2003,"lang":"en","type":"article","venue":"Pancreas","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":529,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cegep de Sept Iles","funders":"","keywords":"Tumor-infiltrating lymphocytes; CD8; Pancreatic cancer; Immunohistochemistry; Adenocarcinoma; CD3; Stage (stratigraphy); Medicine; Internal medicine; Cancer; Pathology; Immune system; Oncology; Immunology; Biology","score_opus":0.006871070795815766,"score_gpt":0.20493600467899692,"score_spread":0.19806493388318117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079548788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926978,0.0037794616,0.000036401845,0.00005964462,0.00007889972,0.001406066,0.000038348844,0.00006694994,0.0018364495],"genre_scores_gemma":[0.9965443,0.00008617864,0.0023963933,0.0004830842,0.000076378186,0.00019139885,0.000012998508,0.00008674592,0.00012251106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975363,0.00018997725,0.00058374676,0.00053848897,0.0005638769,0.00058763643],"domain_scores_gemma":[0.9980695,0.0005398804,0.00043665804,0.0005162946,0.00025934324,0.00017827796],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040913816,0.00046365356,0.00069549173,0.000101698635,0.0002939286,0.0000853102,0.00015844034,0.00007443978,0.00011708227],"category_scores_gemma":[0.0001855097,0.00027404426,0.000116517,0.00044149338,0.0004832117,0.00017983554,0.000028563092,0.00017731791,0.0000044298586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024109434,0.00019838465,0.9634261,0.00052072934,0.00050335797,0.000038514518,0.0011070209,0.0000033656356,0.030022833,0.000095627234,0.000035136043,0.0016379618],"study_design_scores_gemma":[0.017070578,0.0039021904,0.544863,0.00213724,0.0013698189,0.00060229184,0.0052330056,0.0002009525,0.42323452,0.000043221004,0.000454858,0.00088829594],"about_ca_topic_score_codex":0.0009356998,"about_ca_topic_score_gemma":0.00010475835,"teacher_disagreement_score":0.4185631,"about_ca_system_score_codex":0.00019056523,"about_ca_system_score_gemma":0.00052541104,"threshold_uncertainty_score":0.99997115},"labels":[],"label_agreement":null},{"id":"W2083455294","doi":"10.1016/j.ijrobp.2014.08.024","title":"Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)","year":2014,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Gemcitabine; Carboplatin; Pemetrexed; Internal medicine; Lung cancer; Chemotherapy; Oncology; Paclitaxel; Pneumonitis; Urology; Cisplatin; Gastroenterology; Cancer; Immunotherapy; Lung","score_opus":0.010113055749289576,"score_gpt":0.29832298477297836,"score_spread":0.2882099290236888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083455294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98028797,0.00050452835,0.012572649,0.0040091015,0.0012555227,0.00056026154,0.000023190694,0.000026864464,0.00075994217],"genre_scores_gemma":[0.9931244,0.0005853635,0.002854648,0.0024816007,0.0006985677,0.00004856607,0.00009708063,0.00004740319,0.000062357205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790215,0.00020020301,0.0009255394,0.00032954838,0.00032692373,0.0003156249],"domain_scores_gemma":[0.9976632,0.0003281884,0.0011957649,0.00018979817,0.0005263774,0.00009667471],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007552969,0.0002896865,0.0006699838,0.0004316219,0.00005122569,0.000029207262,0.00035451556,0.0002896349,0.00008762144],"category_scores_gemma":[0.0000600899,0.0002528217,0.00018374066,0.00039188974,0.00014937419,0.00026810408,0.000021697819,0.00061004236,0.000004959427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008230592,0.0012783491,0.7859834,0.00004761122,0.00032718544,0.000036801943,0.0007744358,0.0064658066,0.030442933,0.0004705588,0.00037350526,0.16556886],"study_design_scores_gemma":[0.16364716,0.00603838,0.696633,0.0014064224,0.00019650257,0.000110299305,0.0002820598,0.06273117,0.047434095,0.0011861129,0.019459667,0.0008751258],"about_ca_topic_score_codex":0.0002472739,"about_ca_topic_score_gemma":0.00024143938,"teacher_disagreement_score":0.16469373,"about_ca_system_score_codex":0.0016429775,"about_ca_system_score_gemma":0.0011235113,"threshold_uncertainty_score":0.99999243},"labels":[],"label_agreement":null},{"id":"W2089604735","doi":"10.1111/aji.12308","title":"Enrichment of LAG-3, but not PD-1, on Double Negative T Cells at the Female Genital Tract","year":2014,"lang":"en","type":"article","venue":"American Journal of Reproductive Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada; University of Manitoba","funders":"Canadian Institutes of Health Research; Manitoba Health Research Council","keywords":"Lag; Genital tract; Biology; Medicine; Andrology; Internal medicine; Physiology; Computer science","score_opus":0.014394850297273958,"score_gpt":0.2737245620625059,"score_spread":0.25932971176523195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089604735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925679,0.0010602159,0.000053827724,0.003880072,0.0006849221,0.00027391448,0.000008225891,0.000008241833,0.0014626671],"genre_scores_gemma":[0.99671197,0.00041077365,0.0003345171,0.00047073283,0.00037007098,0.000007694184,0.000001793606,0.000023207986,0.0016692575],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981494,0.00029380285,0.0006156026,0.00033357224,0.0003302262,0.00027738136],"domain_scores_gemma":[0.99727356,0.00036425155,0.0012418265,0.0006640342,0.00040049976,0.000055825032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093236275,0.00020518102,0.00068721705,0.00017223727,0.00010356258,0.000007349419,0.00024218176,0.000053262636,0.00019963531],"category_scores_gemma":[0.00017463327,0.00012726495,0.00031919303,0.0003240858,0.0015658231,0.000074741496,0.000057270376,0.0004319204,0.000023841882],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035696898,0.00055418897,0.0024101378,0.0000124532835,0.0013337659,0.00003570312,0.0026603874,0.00003559321,0.8900801,0.00006291149,0.00044620887,0.06667168],"study_design_scores_gemma":[0.003816957,0.00993089,0.08764128,0.000060602953,0.00017011868,0.0013585413,0.003891637,0.0000017099617,0.8832834,0.00003712556,0.00966057,0.0001472143],"about_ca_topic_score_codex":0.00031648236,"about_ca_topic_score_gemma":0.000003485614,"teacher_disagreement_score":0.08523113,"about_ca_system_score_codex":0.00026342119,"about_ca_system_score_gemma":0.00015198412,"threshold_uncertainty_score":0.57693404},"labels":[],"label_agreement":null},{"id":"W2094417916","doi":"10.1007/s00280-010-1379-9","title":"Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of Calgary; McGill University; Dr. H. Bliss Murphy Cancer Centre; Saskatchewan Cancer Agency; Aptose Biosciences (Canada); Alberta Cancer Foundation","funders":"","keywords":"Medicine; Nimotuzumab; Chills; Rash; Toxicity; Internal medicine; Lung cancer; Regimen; Oncology; Gastroenterology; Radiation therapy; Phases of clinical research; Surgery; Cancer; Epidermal growth factor receptor","score_opus":0.030605001814380035,"score_gpt":0.4110274883242362,"score_spread":0.38042248650985616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094417916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870829,0.004047579,0.00020446586,0.0011404825,0.0018143152,0.0051257005,0.00052943657,0.000018446986,0.000036676625],"genre_scores_gemma":[0.9742936,0.017748462,0.00028789093,0.005293462,0.00089775934,0.0009695238,0.00006145357,0.00009145035,0.00035640335],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973851,0.0001562224,0.00074113614,0.00065060594,0.0002794172,0.00078755064],"domain_scores_gemma":[0.998339,0.00031218375,0.0004618233,0.00028487996,0.00019415372,0.00040793355],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00057220925,0.00045392456,0.0009625147,0.00017087847,0.00019126425,0.000030456109,0.0003223936,0.00032375587,0.002086994],"category_scores_gemma":[0.00000891935,0.0002666938,0.00020698439,0.00038930748,0.0006570937,0.0001014383,0.000016169484,0.00073281507,2.1298123e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44526672,0.0040446375,0.27743754,0.00033560308,0.0010709781,0.00004286729,0.00125724,0.000017769731,0.13941002,0.0000035887701,0.0021846849,0.12892835],"study_design_scores_gemma":[0.71370006,0.0117513975,0.05131566,0.00044557868,0.00032851181,0.000018279537,0.0000776342,0.002506786,0.11578197,0.000002051365,0.10340435,0.00066772784],"about_ca_topic_score_codex":0.02209356,"about_ca_topic_score_gemma":0.03269015,"teacher_disagreement_score":0.26843333,"about_ca_system_score_codex":0.00031265581,"about_ca_system_score_gemma":0.0035898727,"threshold_uncertainty_score":0.99997854},"labels":[],"label_agreement":null},{"id":"W2095327463","doi":"10.3747/co.20.1265","title":"Immune Toxicities and Long Remission Duration after Ipilimumab Therapy for Metastatic Melanoma: Two Illustrative Cases","year":2013,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Moncton Hospital; University of British Columbia; Dalhousie University; BC Cancer Agency","funders":"","keywords":"Ipilimumab; Medicine; Melanoma; Internal medicine; Alopecia universalis; Oncology; Response Evaluation Criteria in Solid Tumors; Supraclavicular lymph nodes; Cancer; Surgery; Breast cancer; Immunotherapy; Progressive disease; Scalp; Chemotherapy; Cancer research","score_opus":0.08490885959279917,"score_gpt":0.39579348745939963,"score_spread":0.3108846278666004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095327463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9732115,0.022660948,0.0004771104,0.0015525992,0.0005645816,0.0013379563,0.000015591278,0.000028870678,0.0001508256],"genre_scores_gemma":[0.99598616,0.0021747758,0.00042372875,0.00021950649,0.00017225655,0.00057970604,0.00006245583,0.000015159326,0.00036622753],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99907184,0.00008330905,0.00033462516,0.00021596468,0.00009187413,0.00020236101],"domain_scores_gemma":[0.99929595,0.00023933621,0.00012970899,0.00013260433,0.00013464972,0.00006776015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017604644,0.00015397392,0.00031739182,0.000076307115,0.00008499813,0.000022673428,0.000037504,0.00005845207,0.00051569217],"category_scores_gemma":[0.000055651442,0.00010973288,0.00009207519,0.00006998317,0.0001717354,0.00013405595,0.000015621938,0.000107980275,0.00000661168],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011789739,0.00071012846,0.0071688155,0.00026487102,0.00033057024,0.000038176804,0.0028824487,4.5828008e-7,0.058415484,0.00007994554,0.0029087267,0.91541064],"study_design_scores_gemma":[0.08466295,0.027807198,0.53153986,0.0012117332,0.00083238236,0.0020951803,0.0096343495,0.001810625,0.08903879,0.0023512891,0.24756423,0.0014513998],"about_ca_topic_score_codex":0.000059716287,"about_ca_topic_score_gemma":0.000051596206,"teacher_disagreement_score":0.91395926,"about_ca_system_score_codex":0.00013850743,"about_ca_system_score_gemma":0.00013170534,"threshold_uncertainty_score":0.5646467},"labels":[],"label_agreement":null},{"id":"W2095826876","doi":"10.1016/s1470-2045(09)70334-1","title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1187,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Ipilimumab; Adverse effect; Clinical endpoint; Internal medicine; Melanoma; Clinical trial; Intention-to-treat analysis; Phases of clinical research; Randomized controlled trial; Gastroenterology; Surgery; Immunotherapy; Cancer","score_opus":0.03300815461349548,"score_gpt":0.35211559063508846,"score_spread":0.31910743602159297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095826876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99089503,0.00051970675,0.00002110932,0.0016994162,0.000135964,0.004800705,0.000006296145,0.00008791396,0.0018338652],"genre_scores_gemma":[0.9975108,0.00014774122,0.00025549784,0.0015407886,0.00014526749,0.0001880558,0.00003379962,0.000025728734,0.00015234885],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99826956,0.00023680396,0.0004245672,0.00034658684,0.00023764117,0.00048482872],"domain_scores_gemma":[0.998999,0.00015016468,0.00019934418,0.00049923017,0.00008243728,0.00006984211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056647003,0.00025381809,0.0008265198,0.00014240059,0.00009655743,0.000016920601,0.00020541376,0.000105239116,0.00009288111],"category_scores_gemma":[0.00001877505,0.00014807764,0.00008670743,0.00045325755,0.00008662756,0.00008944559,0.000014337707,0.00030594118,0.000008896756],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85710865,0.005183978,0.037369754,0.000011163377,0.00031331062,0.000068053916,0.0032286004,0.000035427758,0.00088707823,0.0000058915157,0.00009378365,0.09569432],"study_design_scores_gemma":[0.8226077,0.010962223,0.16329266,0.00006380224,0.00014714956,0.000009921631,0.00052935246,0.00009203379,0.00030878372,0.000010864622,0.0017985522,0.00017694492],"about_ca_topic_score_codex":0.00009706428,"about_ca_topic_score_gemma":0.00023774666,"teacher_disagreement_score":0.12592292,"about_ca_system_score_codex":0.00032586025,"about_ca_system_score_gemma":0.00012745145,"threshold_uncertainty_score":0.6038431},"labels":[],"label_agreement":null},{"id":"W2096064375","doi":"10.1101/gr.165985.113","title":"Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival","year":2014,"lang":"en","type":"review","venue":"Genome Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":617,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of Victoria; Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; National Institutes of Health; U.S. Department of Defense","keywords":"Biology; CTL*; Missense mutation; Epitope; Major histocompatibility complex; Cytotoxic T cell; Human leukocyte antigen; Genome; Genetics; Antigen; Mutation; Gene; Immunology; Cancer research; CD8","score_opus":0.16260585556539953,"score_gpt":0.40206131265082984,"score_spread":0.2394554570854303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096064375","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002719893,0.9918433,0.00012708941,0.000108360844,0.00008194613,0.0034120337,0.002229456,0.000092505994,0.0018333502],"genre_scores_gemma":[0.00035595286,0.98892933,0.00016152652,0.00011922873,0.0002038131,0.00075637334,0.0052297083,0.00020113669,0.004042934],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.9907586,0.0022523724,0.0014564588,0.0014093004,0.0027006133,0.0014226717],"domain_scores_gemma":[0.99515176,0.00070852385,0.00059431413,0.0020487604,0.00080318487,0.0006934313],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0041513266,0.0008743502,0.006931863,0.0018219796,0.00035655306,0.00014920667,0.0007350497,0.00044240046,0.0050782347],"category_scores_gemma":[0.00013813337,0.00054053613,0.0037292421,0.0049923426,0.0005488791,0.00005611598,0.00025920788,0.0017723473,0.0002577195],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023908867,0.0007758306,0.00006287899,0.016977288,0.87456256,0.0007324758,0.00030684588,0.000007568495,0.00022198475,0.000009241078,0.0027777674,0.10117469],"study_design_scores_gemma":[0.0007867777,0.0011002673,0.00016452293,0.00030353141,0.18247649,0.00008802492,0.000035790665,0.000009989709,0.00000207384,0.0000012075733,0.8145747,0.00045662152],"about_ca_topic_score_codex":0.0014193159,"about_ca_topic_score_gemma":0.00009420442,"teacher_disagreement_score":0.8117969,"about_ca_system_score_codex":0.00072945474,"about_ca_system_score_gemma":0.0016525232,"threshold_uncertainty_score":0.9997046},"labels":[],"label_agreement":null},{"id":"W2098048487","doi":"10.1111/j.1365-2559.2011.03846.x","title":"Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade","year":2011,"lang":"en","type":"article","venue":"Histopathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Susan G. Komen","keywords":"Univariate analysis; Breast cancer; Medicine; Lymphocyte; Pathology; Tissue microarray; Oncology; CD8; Stromal cell; Internal medicine; Estrogen receptor; Cancer; Immunohistochemistry; Multivariate analysis; Immune system; Immunology","score_opus":0.027465749790784845,"score_gpt":0.2618293170452825,"score_spread":0.23436356725449767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098048487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877769,0.01090946,0.000023409533,0.00025826925,0.0002228723,0.00031540016,0.000052096475,0.00003412347,0.0004074654],"genre_scores_gemma":[0.99655527,0.0017093815,0.0012014415,0.00024268244,0.00003790342,0.000105954685,0.000012053449,0.000018763032,0.00011657865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874955,0.0001066875,0.00034553316,0.00034441066,0.00011175125,0.00034207973],"domain_scores_gemma":[0.9994525,0.000050591392,0.00015534797,0.00020051467,0.000042503383,0.00009855739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017845555,0.00016313123,0.00043404367,0.00014747963,0.0000325515,0.0000020380749,0.000080881844,0.00015963342,0.0005359786],"category_scores_gemma":[0.000035652014,0.0001375711,0.00006345191,0.00016700245,0.00040872255,0.00004035303,0.000028410026,0.00013459516,0.00000411861],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031984944,0.00028386698,0.80765986,0.000089327994,0.000012498739,0.00015379272,0.0011476384,1.945404e-7,0.17790502,0.00012541351,0.00017045111,0.00925341],"study_design_scores_gemma":[0.0023546198,0.0005208639,0.98872477,0.00007698875,0.0000639392,0.0005047536,0.00014953528,0.000007089368,0.004426396,0.000079723904,0.0029408224,0.00015050435],"about_ca_topic_score_codex":0.0022121598,"about_ca_topic_score_gemma":0.00025849591,"teacher_disagreement_score":0.18106487,"about_ca_system_score_codex":0.0003831203,"about_ca_system_score_gemma":0.0002676364,"threshold_uncertainty_score":0.586859},"labels":[],"label_agreement":null},{"id":"W2098068164","doi":"10.1038/ncomms5051","title":"2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy","year":2014,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"David Geffen School of Medicine, University of California, Los Angeles; National Cancer Institute; Medisinske fakultet, Universitetet i Oslo; Institute of Biomedical Sciences, Academia Sinica; Medical Research Council; University of California, San Francisco; National Institutes of Health; Akershus Universitetssykehus; Fakultet Medicinskih Nauka, Univerziteta U Kragujevcu; Changhua Christian Hospital; China Medical University; QIMR Berghofer Medical Research Institute; Norges Forskningsråd; Universitetet i Oslo; National Breast Cancer Foundation; Seoul National University; Genome Institute of Singapore; Leids Universitair Medisch Centrum; National Health and Medical Research Council; Oulun Yliopisto; Universiti Malaya; Vetenskapsrådet; St Vincent's Hospital Melbourne; Academia Sinica; Kuopion Yliopistollinen Sairaala; Karolinska Institutet; Bundesministerium für Bildung und Forschung; Ovarian Cancer Research Fund; Ministerio de Economía y Competitividad; Kementerian Sains, Teknologi dan Inovasi; Deutsche Krebshilfe; University of Toronto; King's College London; Academy of Finland; Cancer Council Victoria; University of Melbourne; Stockholms Läns Landsting; National Science Council; Ministério da Ciência, Tecnologia e Inovação; Universiteit Leiden; Cancer Australia; Cancer Research Institute; Agency for Science, Technology and Research; KWF Kankerbestrijding; University of Southern California; National University of Singapore; Cancer Research UK; Canadian Institutes of Health Research; University of Southampton; Biocenter, University of Oulu; National Institute for Health and Care Research; University Hospital Southampton NHS Foundation Trust; Deutsches Krebsforschungszentrum; Helsingin ja Uudenmaan Sairaanhoitopiiri; Breast Cancer Research Foundation; University of Cambridge; College of Medicine, Seoul National University; Susan G. Komen for the Cure; Taiwan Biobank; Itä-Suomen Yliopisto; Breast Cancer Campaign; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Helsingin Yliopisto; Erasmus Universitair Medisch Centrum Rotterdam; European Commission; Cancerfonden","keywords":"Breast cancer; Medicine; Oncology; Single-nucleotide polymorphism; Hazard ratio; Internal medicine; Cancer; Genotyping; Population; Genome-wide association study; Biology; Genotype; Gene; Genetics","score_opus":0.012942137819047133,"score_gpt":0.2871066166888206,"score_spread":0.27416447886977346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098068164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667379,0.0014778511,0.000034416033,0.026743392,0.000056402656,0.0026831352,0.0010330098,0.00020831244,0.0010255551],"genre_scores_gemma":[0.99190795,0.0006849429,0.0025039886,0.0031546857,0.000042275078,0.0006974118,0.0006474021,0.000056359095,0.00030496507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904656,0.00008007941,0.00019126381,0.00023938059,0.00022117943,0.00022154923],"domain_scores_gemma":[0.99791425,0.00022517605,0.00021542644,0.0007917016,0.0007738786,0.000079570025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012985735,0.00020389365,0.00028602345,0.00006169049,0.00026702552,0.000026542572,0.0003286636,0.00024358531,0.00008463104],"category_scores_gemma":[0.00005044405,0.00013672856,0.000092237766,0.0005081608,0.0002256071,0.00008099304,0.00002557426,0.00039642872,0.0000023138564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052341134,0.0016198365,0.94046104,0.00003154143,0.002351031,1.376835e-7,0.0009904209,6.79798e-7,0.0014144906,0.00012467823,0.027279595,0.020492421],"study_design_scores_gemma":[0.012975564,0.0013673414,0.92719173,0.0005700275,0.0004055006,0.000006177752,0.00010146141,0.00014301288,0.007377634,0.000013209715,0.04950182,0.00034650226],"about_ca_topic_score_codex":0.00023220539,"about_ca_topic_score_gemma":0.0008210149,"teacher_disagreement_score":0.025170043,"about_ca_system_score_codex":0.0002829229,"about_ca_system_score_gemma":0.00015706995,"threshold_uncertainty_score":0.5575629},"labels":[],"label_agreement":null},{"id":"W2099842815","doi":"10.1158/1078-0432.ccr-13-2147","title":"Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer","year":2013,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of Victoria; Simon Fraser University; University of British Columbia","funders":"","keywords":"Ovarian cancer; ELISPOT; CD8; Epitope; Biology; Ovarian tumor; Cancer; Cancer research; Nonsynonymous substitution; Primary tumor; T cell; Immune system; Mutation; Cytotoxic T cell; Immunology; Medicine; Antibody; Metastasis; Genetics; Gene; Genome","score_opus":0.08844247405143725,"score_gpt":0.46397425790737373,"score_spread":0.3755317838559365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099842815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781946,0.0065521346,0.0000025381953,0.011810639,0.0009970003,0.001770142,0.0002152141,0.000024747458,0.00043296337],"genre_scores_gemma":[0.9931325,0.0025800315,0.00011118021,0.0011408598,0.0006399397,0.00068167754,0.000012501213,0.000038995473,0.0016623582],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9965998,0.00049437943,0.00076548324,0.00056704984,0.0010200309,0.0005532346],"domain_scores_gemma":[0.99790925,0.00040892686,0.00017555921,0.00073893723,0.00045726515,0.00031005437],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014520707,0.00016634949,0.0004950122,0.00007432548,0.00015740094,0.00003936528,0.00048174817,0.00012943933,0.0029146334],"category_scores_gemma":[0.00023172706,0.0001038346,0.00021965265,0.0006871451,0.00047765768,0.000065227876,0.00030677638,0.0008028128,0.000054465967],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065099164,0.00050240895,0.24195355,0.00028575372,0.00020630339,0.000008249806,0.00020237459,0.0000018599328,0.5222403,0.0000016576274,0.07940044,0.14868723],"study_design_scores_gemma":[0.002860317,0.0004685894,0.887836,0.0010344533,0.000015681435,0.0000013287058,0.00004861103,0.000019746532,0.06682391,0.000029835524,0.04069714,0.00016442941],"about_ca_topic_score_codex":0.0072728484,"about_ca_topic_score_gemma":0.00040116571,"teacher_disagreement_score":0.6458824,"about_ca_system_score_codex":0.00045524962,"about_ca_system_score_gemma":0.00074751495,"threshold_uncertainty_score":0.9993378},"labels":[],"label_agreement":null},{"id":"W2100184048","doi":"10.1186/s12967-014-0373-0","title":"PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation","year":2015,"lang":"en","type":"review","venue":"Journal of Translational Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"National Natural Science Foundation of China","keywords":"Immunotherapy; PD-L1; Lung cancer; Cancer research; Tyrosine kinase; In vivo; Medicine; Immune system; Mutation; Cancer; Cancer immunotherapy; Tyrosine-kinase inhibitor; Immunology; Oncology; Biology; Internal medicine; Gene; Receptor; Genetics","score_opus":0.04536202438563518,"score_gpt":0.34464966156230276,"score_spread":0.29928763717666756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100184048","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025125558,0.9933209,0.0002913522,0.0020242247,0.00036034518,0.00089407386,0.00002397942,0.0000063559633,0.0005662351],"genre_scores_gemma":[0.004352442,0.9936445,0.00042864657,0.00015402195,0.00090295327,0.000027864395,0.00011133704,0.00004827251,0.0003299845],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99746555,0.00009662255,0.0012555008,0.0002214373,0.00077892054,0.00018199443],"domain_scores_gemma":[0.9980597,0.00021508164,0.0009934749,0.00010640893,0.00044330544,0.00018205988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011007069,0.00032908772,0.0014675147,0.00064692134,0.000038173057,0.000009673047,0.000092449125,0.0002690727,0.00013250648],"category_scores_gemma":[0.000036971673,0.00020296479,0.00017562382,0.0005198317,0.000075036645,0.00017377875,0.0000046073706,0.00068097364,0.0000012769559],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031826203,0.00017891785,0.0008527285,0.01822242,0.0008749581,0.00041242447,0.0019809164,0.00008246637,0.00013688744,0.000031928823,0.0007903296,0.9732534],"study_design_scores_gemma":[0.027349215,0.0026995018,0.009371164,0.15219004,0.0053520934,0.0035817353,0.00022002723,0.00068673067,0.000027267337,0.000083242005,0.7977856,0.00065338635],"about_ca_topic_score_codex":0.000046206544,"about_ca_topic_score_gemma":0.00005963765,"teacher_disagreement_score":0.97260004,"about_ca_system_score_codex":0.00032957018,"about_ca_system_score_gemma":0.0015070783,"threshold_uncertainty_score":0.8276664},"labels":[],"label_agreement":null},{"id":"W2100553040","doi":"10.4049/jimmunol.1002050","title":"MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis","year":2011,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":262,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Melanoma; Major histocompatibility complex; MHC class I; Immune system; Cancer research; Biology; Immunology; MAPK/ERK pathway; MHC class II; Cell biology; Signal transduction","score_opus":0.02522357029395691,"score_gpt":0.2622211369994825,"score_spread":0.2369975667055256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100553040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95839113,0.016670274,0.0002935567,0.021584585,0.00065129786,0.00037194684,0.000013016662,0.000014666165,0.0020095184],"genre_scores_gemma":[0.9890258,0.001919602,0.00027520498,0.0045294836,0.00008972747,0.000009972566,0.0000014267114,0.000019873949,0.0041289567],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99860543,0.00020644392,0.00055501424,0.0001193054,0.00019001943,0.00032381053],"domain_scores_gemma":[0.9988938,0.00014040689,0.00027610324,0.00032490175,0.00027519258,0.00008957925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012296371,0.00016147763,0.00043054772,0.00017432171,0.00020095227,0.000010196641,0.00038912118,0.00010316111,0.00022426363],"category_scores_gemma":[0.00018228889,0.00010238863,0.0001246437,0.00028410286,0.00009885886,0.000058916594,0.00010880599,0.00035553417,0.000041569638],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019435087,0.00019421674,0.00028821683,0.000013620408,0.0011874955,0.000011508748,0.0032945396,4.5568459e-7,0.8896085,0.00018335167,0.08203656,0.0037464153],"study_design_scores_gemma":[0.0029197803,0.0028163265,0.010615264,0.00020366772,0.00019998693,0.00009624686,0.000884879,3.2679634e-7,0.65151995,0.00008432142,0.33054185,0.00011740569],"about_ca_topic_score_codex":0.000044690118,"about_ca_topic_score_gemma":0.00003405386,"teacher_disagreement_score":0.2485053,"about_ca_system_score_codex":0.00017518907,"about_ca_system_score_gemma":0.000101795275,"threshold_uncertainty_score":0.41752872},"labels":[],"label_agreement":null},{"id":"W2101338052","doi":"10.1158/2326-6066.cir-14-0113","title":"B7-H4 Expression by Nonhematopoietic Cells in the Tumor Microenvironment Promotes Antitumor Immunity","year":2014,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute; University Health Network; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"Canada Research Chairs","keywords":"Immune system; Cancer research; Downregulation and upregulation; Biology; Tumor microenvironment; Carcinogenesis; Cancer immunotherapy; Cancer; Immunity; Immunology; Acquired immune system; MHC class I; Immunotherapy; Major histocompatibility complex; Gene; Genetics","score_opus":0.03392099231862885,"score_gpt":0.3403574733914932,"score_spread":0.30643648107286436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101338052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763126,0.016904997,0.00002266631,0.004499184,0.00021927069,0.0010513911,0.000018757602,0.000027299642,0.000943865],"genre_scores_gemma":[0.9938695,0.003425356,0.00007772624,0.00078653375,0.00009052999,0.0004972227,0.000025608073,0.000034953424,0.0011926016],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968769,0.001004459,0.00038740237,0.00043549534,0.0005112096,0.0007845546],"domain_scores_gemma":[0.99846154,0.00036001435,0.00008888382,0.0009444323,0.00008074658,0.00006439478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023625966,0.00021623464,0.00038105252,0.00021777992,0.0003260649,0.000043845597,0.00062980026,0.0001478185,0.0006857525],"category_scores_gemma":[0.00009039784,0.00014521705,0.000108176944,0.0004953143,0.0010583445,0.00007669289,0.00018508607,0.0011709989,0.000105183084],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001314426,0.0004344509,0.005927424,0.00010492343,0.00006360042,0.0000263078,0.000995434,4.831676e-7,0.972973,0.0000149113,0.013524176,0.004620853],"study_design_scores_gemma":[0.003730506,0.0009608176,0.038853396,0.00047967213,0.000021075628,0.000114211965,0.0016047221,0.000029373428,0.84464866,0.00011028025,0.10922502,0.00022228414],"about_ca_topic_score_codex":0.0009565684,"about_ca_topic_score_gemma":0.00004605632,"teacher_disagreement_score":0.12832437,"about_ca_system_score_codex":0.00031579417,"about_ca_system_score_gemma":0.00016198563,"threshold_uncertainty_score":0.7508509},"labels":[],"label_agreement":null},{"id":"W2102986151","doi":"10.1158/2326-6066.cir-13-0155","title":"CD4 T Cells Require ICOS-Mediated PI3K Signaling to Increase T-Bet Expression in the Setting of Anti-CTLA-4 Therapy","year":2013,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"National Cancer Institute; U.S. Department of Defense","keywords":"CTLA-4; Immunotherapy; Medicine; Cancer research; Immunology; Cell biology; T cell; Immune system; Biology","score_opus":0.0604348810993394,"score_gpt":0.37876869473358404,"score_spread":0.3183338136342446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102986151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98122376,0.010289404,0.000012252667,0.0060535017,0.00018703805,0.0016175443,0.000020813757,0.000029573424,0.0005660952],"genre_scores_gemma":[0.99381715,0.00369225,0.00012645104,0.0011666857,0.0001362971,0.0006469138,0.000026247166,0.000036878766,0.00035112628],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99678355,0.0008816801,0.00053432956,0.00042459668,0.000590581,0.0007852478],"domain_scores_gemma":[0.99781364,0.00080869754,0.000121473895,0.00070298585,0.00045610833,0.00009711788],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023483166,0.00020459632,0.00045736885,0.00051778875,0.000195306,0.00004013221,0.00057681085,0.00024359416,0.0014194367],"category_scores_gemma":[0.00023304674,0.00013594708,0.00010744873,0.0013978335,0.00044464163,0.00017467751,0.00014456506,0.0008407299,0.0000802074],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020866438,0.0001927863,0.012467293,0.000061724975,0.00010887375,0.000019743526,0.0030679004,0.0000070562814,0.95557636,0.0000049397945,0.0047227517,0.021683937],"study_design_scores_gemma":[0.0046629063,0.0010099855,0.11240892,0.0007425884,0.000010228629,0.000020693753,0.0037722092,0.000057664955,0.86493623,0.00007183247,0.012086454,0.00022031034],"about_ca_topic_score_codex":0.0052596754,"about_ca_topic_score_gemma":0.000060509785,"teacher_disagreement_score":0.099941626,"about_ca_system_score_codex":0.0002224261,"about_ca_system_score_gemma":0.0004604357,"threshold_uncertainty_score":0.9994934},"labels":[],"label_agreement":null},{"id":"W2106728539","doi":"10.1158/1078-0432.ccr-11-3216","title":"The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature","year":2012,"lang":"en","type":"review","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":434,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Value (mathematics); Cancer; Medicine; Pathology; Oncology; Internal medicine; Statistics","score_opus":0.3397851811151872,"score_gpt":0.5872416934896351,"score_spread":0.24745651237444788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106728539","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002280381,0.9926517,2.0035203e-7,0.0025212762,0.0008224528,0.0032229517,0.0001578754,0.000009479122,0.00038602078],"genre_scores_gemma":[0.0006705052,0.9961792,0.000026389267,0.00050006143,0.0009267976,0.0013612409,0.000013642163,0.000061326784,0.00026079637],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99128604,0.0032093644,0.0027312038,0.00054305245,0.0014045134,0.00082585047],"domain_scores_gemma":[0.98486125,0.012107906,0.0006677411,0.001222291,0.0009370768,0.0002037064],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.011462279,0.0003660083,0.0025677106,0.00014679533,0.00018008203,0.000039212515,0.0010128438,0.00041698356,0.0002463584],"category_scores_gemma":[0.0108326115,0.00017186206,0.0014038534,0.0024170075,0.0020968223,0.00006200011,0.0003273293,0.0026918154,0.0000050004364],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034232886,0.00020994706,0.002513969,0.23208696,0.0002540766,0.000011642341,0.000055320805,3.1281413e-8,0.0000031859993,0.00019640347,0.0021263724,0.76219976],"study_design_scores_gemma":[0.00048413104,0.00021766094,0.0010493958,0.43128875,0.00054130174,0.00003103842,0.000017763823,0.0000020013028,0.000010189381,0.000031367454,0.56620675,0.000119648495],"about_ca_topic_score_codex":0.0006985194,"about_ca_topic_score_gemma":0.00017467192,"teacher_disagreement_score":0.76208013,"about_ca_system_score_codex":0.0006225743,"about_ca_system_score_gemma":0.006947468,"threshold_uncertainty_score":0.999609},"labels":[],"label_agreement":null},{"id":"W2107380545","doi":"10.1186/bcr3148","title":"CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer","year":2012,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":433,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University Health Centre; Centre for Advancing Health Outcomes; McGill University; University of British Columbia","funders":"Michael Smith Health Research BC; Canadian Breast Cancer Research Alliance; Susan G. Komen; National Cancer Institute; Sanofi","keywords":"Surgical oncology; Breast cancer; Infiltration (HVAC); Medicine; Basal (medicine); Tumor-infiltrating lymphocytes; Oncology; Pathology; CD8; Internal medicine; Cancer; Immunology; Immune system","score_opus":0.05920947704377097,"score_gpt":0.3825326707427997,"score_spread":0.32332319369902873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107380545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98617566,0.0049166437,0.000009432562,0.005588933,0.00048421873,0.0014401855,0.0004909307,0.00007090472,0.0008231037],"genre_scores_gemma":[0.99306107,0.0026707612,0.000036505124,0.001234034,0.0009581112,0.0010439161,0.000057801815,0.0000756007,0.0008622082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99578065,0.00030545748,0.00047580997,0.0005864107,0.0015176523,0.0013340329],"domain_scores_gemma":[0.9982852,0.00008670537,0.00011764167,0.0005853867,0.00034390402,0.0005811647],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001784508,0.00028928753,0.0003938082,0.000670304,0.00025796826,0.00010744621,0.00032019604,0.0002613897,0.0055714976],"category_scores_gemma":[0.0000245017,0.00025215003,0.00010453911,0.0013339546,0.00028223352,0.0007146994,0.000104915816,0.0006743948,0.0001225085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006264034,0.00085534906,0.87899286,0.0002776686,0.00017302351,0.000025516843,0.0019691952,0.000006359108,0.021705166,0.000028506363,0.004215231,0.085487075],"study_design_scores_gemma":[0.0043780133,0.00016481387,0.981445,0.000583797,0.00004172529,0.00031449163,0.0005677915,0.00012750505,0.004610254,0.000018149616,0.0074421493,0.00030629072],"about_ca_topic_score_codex":0.039176628,"about_ca_topic_score_gemma":0.0044244933,"teacher_disagreement_score":0.102452144,"about_ca_system_score_codex":0.0024542608,"about_ca_system_score_gemma":0.0027063226,"threshold_uncertainty_score":0.9999931},"labels":[],"label_agreement":null},{"id":"W2110156824","doi":"10.1200/jco.2013.49.6158","title":"Is Tremelimumab Beneficial in Advanced Melanoma?","year":2013,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Jonsson Comprehensive Cancer Center; University of California, Los Angeles","keywords":"Tremelimumab; Medicine; Melanoma; Oncology; Ipilimumab; Internal medicine; Cancer; Immunotherapy; Cancer research","score_opus":0.1169966416220452,"score_gpt":0.4530544913705417,"score_spread":0.3360578497484965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110156824","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15278658,0.0031401035,0.0000068014133,0.83323836,0.0050683254,0.00034392602,0.000010477945,0.0000085871725,0.005396851],"genre_scores_gemma":[0.01450276,0.004824244,0.0013280847,0.9583754,0.017558381,0.000009348274,0.000017429338,0.00005755452,0.0033268207],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938666,0.0004146037,0.0044301827,0.00030679497,0.00058080174,0.00040097823],"domain_scores_gemma":[0.99406385,0.0017523243,0.0032936672,0.00032450745,0.0004001847,0.00016546225],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0021234683,0.0002888357,0.0030826111,0.00036875956,0.000021970976,0.000012159418,0.00033272008,0.0027609193,0.002081218],"category_scores_gemma":[0.0009928402,0.00020470795,0.0014477713,0.00018726168,0.0002140045,0.000102874415,0.000042216627,0.005744162,0.000080776306],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008179566,0.0003913452,0.0025718359,0.00006422961,0.00048025354,0.0025867647,0.00004890694,5.332674e-7,0.00006497517,0.0000010707452,0.7094096,0.27620092],"study_design_scores_gemma":[0.015392856,0.012215603,0.038802143,0.00039131005,0.0003051723,0.0005285512,0.00003127697,0.000008198828,0.000026738557,0.00016606526,0.9319482,0.00018391752],"about_ca_topic_score_codex":0.00009790147,"about_ca_topic_score_gemma":0.00005511272,"teacher_disagreement_score":0.276017,"about_ca_system_score_codex":0.00045386158,"about_ca_system_score_gemma":0.0027723215,"threshold_uncertainty_score":0.99883103},"labels":[],"label_agreement":null},{"id":"W2110660168","doi":"10.1158/2326-6066.cir-14-0239","title":"PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer","year":2015,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Victoria; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"CD8; Biology; Tumor microenvironment; Cancer research; Ovarian cancer; Cytotoxic T cell; Flow cytometry; Antigen; Tumor-infiltrating lymphocytes; Immunology; Immune system; Cancer; In vitro","score_opus":0.11156452962012832,"score_gpt":0.40350539865578133,"score_spread":0.29194086903565303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110660168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756294,0.011887719,0.0000069368148,0.008243327,0.0005283109,0.0012451783,0.000072218754,0.00006233151,0.002324608],"genre_scores_gemma":[0.99169767,0.0034708083,0.000086593835,0.0008056964,0.0003055092,0.0007074593,0.000017530032,0.000057246456,0.0028514739],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99695086,0.0004138377,0.00044136884,0.00065822393,0.00057725544,0.0009584215],"domain_scores_gemma":[0.9983756,0.00022614196,0.000099338504,0.0005287124,0.00052295846,0.00024725517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014133984,0.00026450207,0.00055556855,0.00047607344,0.0002112721,0.00007874326,0.00031128406,0.00036383918,0.00051118014],"category_scores_gemma":[0.00024001807,0.00022790532,0.000064981854,0.00067671953,0.0011184764,0.00011059241,0.00015713427,0.0012635355,0.000038404105],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0190316,0.0006500254,0.050446797,0.00019762921,0.00051196857,0.00033090115,0.0018423215,0.000027542586,0.89074576,0.00067320786,0.018239094,0.017303148],"study_design_scores_gemma":[0.047199283,0.008428607,0.36552367,0.003909137,0.00016213836,0.000118841956,0.004024394,0.0003374606,0.3876644,0.0021920975,0.1790741,0.0013658936],"about_ca_topic_score_codex":0.0078890845,"about_ca_topic_score_gemma":0.0010684595,"teacher_disagreement_score":0.5030814,"about_ca_system_score_codex":0.0008192094,"about_ca_system_score_gemma":0.0012674684,"threshold_uncertainty_score":0.9987175},"labels":[],"label_agreement":null},{"id":"W2111521405","doi":"10.1158/1535-7163.mct-11-1014","title":"CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Mesothelioma Applied Research Foundation","keywords":"Blockade; Mesothelioma; Chemotherapy; Cancer research; Repopulation; Medicine; Cancer; Biology; Oncology; Immunology; Internal medicine; Pathology; Cell biology; Receptor; Stem cell","score_opus":0.018637470073894474,"score_gpt":0.2933234176663179,"score_spread":0.27468594759242343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111521405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629168,0.03515303,0.00007464644,0.0008737163,0.00019328202,0.0005027948,0.000014044801,0.000024590658,0.0002471073],"genre_scores_gemma":[0.991501,0.0063893534,0.00019601449,0.0014328047,0.00014801933,0.00008872583,0.000003858562,0.000055461955,0.00018475897],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99851,0.000085588516,0.000516732,0.00023293465,0.00028778077,0.00036698073],"domain_scores_gemma":[0.9992192,0.000033518696,0.0002696179,0.00034104008,0.00006834477,0.00006827136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032404138,0.00023855275,0.00034352034,0.00009835441,0.00006606809,0.000019570061,0.0001047474,0.0001234825,0.00013861673],"category_scores_gemma":[0.00000389957,0.00017876062,0.000119615,0.00034578386,0.00011358079,0.00011178585,0.000036814785,0.0001897352,4.5779265e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006588066,0.00012623012,0.0618564,0.00020306779,0.00017932893,0.0000036859665,0.0032023024,0.00004340696,0.92056787,0.000006112498,0.0000067063356,0.013146064],"study_design_scores_gemma":[0.0029694058,0.00009639228,0.062240534,0.00029331044,0.000103082646,0.000019809737,0.00033256126,0.00018372638,0.93191785,0.00001231901,0.0016424966,0.00018852239],"about_ca_topic_score_codex":0.0012619646,"about_ca_topic_score_gemma":0.0001781213,"teacher_disagreement_score":0.028763676,"about_ca_system_score_codex":0.0002106945,"about_ca_system_score_gemma":0.0000739316,"threshold_uncertainty_score":0.7289647},"labels":[],"label_agreement":null},{"id":"W2111877246","doi":"10.1111/nyas.12180","title":"Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma","year":2013,"lang":"en","type":"review","venue":"Annals of the New York Academy of Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":307,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pyrogenesis (Canada)","funders":"National Cancer Institute","keywords":"Ipilimumab; Medicine; Melanoma; Oncology; Internal medicine; Clinical trial; Adverse effect; Immunotherapy; Cancer; Immunology; Cancer research","score_opus":0.2503677468678624,"score_gpt":0.41097273322376177,"score_spread":0.16060498635589937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111877246","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00092893443,0.9952459,0.000093961484,0.0007762699,0.0000981629,0.0026464353,0.00003752547,0.0000056342983,0.00016720557],"genre_scores_gemma":[0.0007710158,0.9852673,0.012795352,0.0001433488,0.000062673476,0.0001704179,0.0000034559512,0.000020981075,0.0007654695],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974555,0.00005140375,0.001282436,0.00033073247,0.0005851956,0.00029473263],"domain_scores_gemma":[0.99735516,0.00043481356,0.0018007141,0.0002851804,0.00007578204,0.000048326012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088951,0.00033657718,0.0016262438,0.00016502773,0.00014246572,0.000007576266,0.0010127211,0.00021687183,0.000024990246],"category_scores_gemma":[0.000026731803,0.00014564638,0.0010342057,0.0007450173,0.001120049,0.000057377136,0.000051803796,0.000119895085,5.497147e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027748296,0.00031886343,0.000003963988,0.003050071,0.0010910819,5.995149e-9,0.00088711426,0.000006432231,0.002592827,0.00009264381,0.00027262242,0.9914069],"study_design_scores_gemma":[0.0013150868,0.0008911649,0.00019115422,0.0060290485,0.0006811887,0.0000074121685,0.00038813683,0.000022038006,0.025350908,0.000065426786,0.9648841,0.00017431164],"about_ca_topic_score_codex":0.00007954901,"about_ca_topic_score_gemma":0.0000013817187,"teacher_disagreement_score":0.9912326,"about_ca_system_score_codex":0.000043663164,"about_ca_system_score_gemma":0.0008761575,"threshold_uncertainty_score":0.5939287},"labels":[],"label_agreement":null},{"id":"W2112121482","doi":"10.1016/s1470-2045(15)70076-8","title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2666,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"National Institutes of Health; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Open label; Medicine; Nivolumab; Oncology; Chemotherapy; Internal medicine; Ipilimumab; Randomized controlled trial; Immunotherapy; Cancer","score_opus":0.05803676378711036,"score_gpt":0.3752254400827541,"score_spread":0.31718867629564373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112121482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98230904,0.0010480715,0.0000060482075,0.0036368757,0.0005850302,0.009512851,0.000028259547,0.00004919258,0.0028246061],"genre_scores_gemma":[0.9936758,0.00046165872,0.00047281646,0.0014604217,0.00041828217,0.002877564,0.000060291244,0.000049961312,0.0005231707],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978956,0.00040204023,0.00052001374,0.00038738665,0.00027084592,0.00052410614],"domain_scores_gemma":[0.9986183,0.0002262894,0.00032333424,0.0005623119,0.00013673933,0.00013301772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008499426,0.0003240201,0.0017268931,0.000084179796,0.00006261166,0.00004530974,0.0003079918,0.00015717978,0.00014333453],"category_scores_gemma":[0.00007141629,0.00017363168,0.00009712103,0.00024954963,0.00022945176,0.00012703107,0.00004423072,0.00018063726,0.000016055223],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92947155,0.005111363,0.0019595388,0.00001318586,0.0008096154,0.00007856489,0.000819838,0.0000016111674,0.00026483016,0.000005621738,0.00083226763,0.06063199],"study_design_scores_gemma":[0.905581,0.05465214,0.0021153914,0.00007474726,0.00022721932,0.000008712235,0.00009579988,0.00006879399,0.00037418402,0.00001079027,0.036587715,0.00020352949],"about_ca_topic_score_codex":0.00013211323,"about_ca_topic_score_gemma":0.00020118506,"teacher_disagreement_score":0.060428463,"about_ca_system_score_codex":0.00074691576,"about_ca_system_score_gemma":0.000615879,"threshold_uncertainty_score":0.7080494},"labels":[],"label_agreement":null},{"id":"W2112648444","doi":"10.1093/annonc/mdu191","title":"Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":790,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; University of British Columbia; BC Cancer Agency; Ontario Institute for Cancer Research","funders":"NIHR Cambridge Biomedical Research Centre; Academy of Medical Sciences; Pathological Society of Great Britain and Ireland; Breast Cancer Campaign; Cancer Research UK; National Institute for Health and Care Research; Sanofi","keywords":"Medicine; Breast cancer; Hazard ratio; Oncology; Estrogen receptor; Internal medicine; CD8; FOXP3; Cytotoxic T cell; Immunohistochemistry; Proportional hazards model; Pathology; Cancer; Immunology; Confidence interval; Immune system; Biology","score_opus":0.049513549492197446,"score_gpt":0.3511729877674861,"score_spread":0.3016594382752887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112648444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98931944,0.00009281089,0.000006885311,0.005417531,0.0001557707,0.00014061072,0.00003127596,0.0000063138905,0.004829382],"genre_scores_gemma":[0.9982054,0.0005063904,0.000021719698,0.0008812862,0.00013142948,0.000007733281,0.000033735254,0.00000595648,0.00020629846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928576,0.00010375866,0.0002434205,0.0001076845,0.00012450946,0.00013486354],"domain_scores_gemma":[0.99944085,0.00014325675,0.00019139037,0.00006655506,0.00012174071,0.00003620965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049740216,0.000062405525,0.0002465017,0.00007390149,0.000016658318,0.0000032737994,0.000028905959,0.00013794564,0.00006177571],"category_scores_gemma":[0.000049738217,0.000056891502,0.000034592013,0.000081963924,0.000031585536,0.000054794105,0.000010498544,0.00008116977,0.000001936261],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004920103,0.00013336142,0.88074684,0.000027858527,0.000055223307,2.5688442e-7,0.00016377239,6.299319e-7,0.002442811,0.0000066294024,0.0014736097,0.11445697],"study_design_scores_gemma":[0.003082419,0.0009300129,0.9726734,0.00002954518,0.000030013014,5.659285e-7,0.000022504317,0.000011677703,0.0016846539,0.000043165248,0.021439282,0.000052762734],"about_ca_topic_score_codex":0.0009949892,"about_ca_topic_score_gemma":0.0010444482,"teacher_disagreement_score":0.11440421,"about_ca_system_score_codex":0.00008726107,"about_ca_system_score_gemma":0.00007931817,"threshold_uncertainty_score":0.2319968},"labels":[],"label_agreement":null},{"id":"W2116458075","doi":"10.1016/j.jss.2005.11.155","title":"The intratumoral microenvironment permits insulinoma development despite initial protection by autoreactive CD8+ T cells","year":2006,"lang":"en","type":"article","venue":"Journal of Surgical Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"CD8; Autoimmunity; Biology; Cytotoxic T cell; Immunology; NOD mice; Immune system; Transgene; Immune tolerance; Nod; T cell; Priming (agriculture); Tumor microenvironment; Antigen; Cancer research; Clonal deletion; T-cell receptor; Endocrinology; Diabetes mellitus","score_opus":0.04382113345263774,"score_gpt":0.34130889572974266,"score_spread":0.29748776227710494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116458075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99231553,0.0021854504,0.00004618109,0.003669439,0.00018371013,0.00039120507,0.0000028653387,0.0000057200723,0.0011999274],"genre_scores_gemma":[0.99666876,0.00091515784,0.00015603233,0.000035309648,0.00047018047,0.000019436411,0.0000033155643,0.000015108343,0.0017167235],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975133,0.0002553413,0.00054709497,0.00014366336,0.0011448659,0.00039572848],"domain_scores_gemma":[0.99907637,0.00022480449,0.00017203523,0.00011713241,0.0002634255,0.00014621264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022820341,0.00011419574,0.0002110708,0.00013529697,0.00032918417,0.00008056996,0.00014788473,0.00009361068,0.00010947935],"category_scores_gemma":[0.00003893117,0.00006728612,0.0001291388,0.00025541135,0.00031569807,0.00009404252,0.00004569887,0.0008937397,0.000021030422],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020709772,0.001052253,0.0009896257,0.000043063337,0.0002317594,0.0011248635,0.00034221724,0.000004554514,0.73305464,0.000033043183,0.019832857,0.22258136],"study_design_scores_gemma":[0.0033957541,0.0012060776,0.024631454,0.00012111603,0.000012704632,0.00069178175,0.00019531374,0.000021807535,0.28286,0.000055949542,0.6867118,0.00009622531],"about_ca_topic_score_codex":0.000079308564,"about_ca_topic_score_gemma":0.0000082759125,"teacher_disagreement_score":0.66687894,"about_ca_system_score_codex":0.0007671316,"about_ca_system_score_gemma":0.0004801128,"threshold_uncertainty_score":0.3882904},"labels":[],"label_agreement":null},{"id":"W2117878645","doi":"10.1158/1078-0432.ccr-09-0265","title":"Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody","year":2009,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1648,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; York University; Chemotherapy Foundation; Breast Cancer Research Foundation; U.S. Department of Defense","keywords":"Abscopal effect; Radiation therapy; Medicine; CD8; Cancer research; Antibody; Immunotherapy; Growth inhibition; Nasopharyngeal carcinoma; Carcinoma; Dose fractionation; Regimen; Immune system; Oncology; Internal medicine; Immunology; Cell growth; Biology","score_opus":0.12192583124804135,"score_gpt":0.4906271966923983,"score_spread":0.36870136544435694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117878645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868281,0.00272725,0.00002518188,0.0075471997,0.00048254264,0.0015322489,0.000035616067,0.0001937503,0.0006281238],"genre_scores_gemma":[0.99268234,0.0028293477,0.00021588021,0.00234718,0.0008515308,0.00008144534,0.00022114861,0.000074432864,0.0006966804],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99473494,0.0011240487,0.00094822986,0.0008820029,0.0014091646,0.0009016391],"domain_scores_gemma":[0.99618536,0.0015777381,0.00022699975,0.000871111,0.00064229395,0.0004965005],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004085281,0.0003704131,0.0010272167,0.00037824115,0.000330253,0.00014582704,0.00045238013,0.00045285546,0.0011493141],"category_scores_gemma":[0.00055157,0.0002637548,0.000263881,0.0010139912,0.0009102729,0.00031348603,0.00003994117,0.0017744275,0.000047170863],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.093185395,0.0018933241,0.026671974,0.00007414523,0.000557245,0.0002080646,0.00020583303,0.0000038114163,0.79587173,0.000007674221,0.0017302539,0.079590544],"study_design_scores_gemma":[0.03568558,0.05304797,0.7715359,0.0006714952,0.000113833565,0.00006426429,0.0001284587,0.00037127288,0.1254942,0.00005284534,0.01221507,0.00061912264],"about_ca_topic_score_codex":0.0016430228,"about_ca_topic_score_gemma":0.00007898942,"teacher_disagreement_score":0.7448639,"about_ca_system_score_codex":0.00042574634,"about_ca_system_score_gemma":0.0009944,"threshold_uncertainty_score":0.99998146},"labels":[],"label_agreement":null},{"id":"W2118342755","doi":"10.1200/jco.2013.51.3002","title":"Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Center for Advancing Translational Sciences; National Institute of Environmental Health Sciences; National Cancer Institute","keywords":"Medicine; Melanoma; Tumor-infiltrating lymphocytes; Breslow Thickness; Hazard ratio; Population; Oncology; Cancer; Internal medicine; Stage (stratigraphy); Relative survival; Cancer registry; Confidence interval; Cancer research; Immunotherapy; Breast cancer; Biology","score_opus":0.0648592495248592,"score_gpt":0.3470578250292431,"score_spread":0.2821985755043839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118342755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942601,0.0012477015,0.000010721731,0.0033174157,0.00022194666,0.00070546387,0.0000028689706,0.0000047212966,0.00022909875],"genre_scores_gemma":[0.99692816,0.00034226498,0.00031432085,0.0021532131,0.00018320548,0.000022072092,0.000008201995,0.000017893695,0.000030676892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955494,0.0012176567,0.002099469,0.00025218964,0.00062348915,0.00025781378],"domain_scores_gemma":[0.9959898,0.0022721523,0.0013348752,0.0002149607,0.000064871645,0.00012331767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048216553,0.0001891168,0.0011215294,0.0001768315,0.00005383915,0.000028955597,0.00019084226,0.00021813017,0.00014482629],"category_scores_gemma":[0.00021430757,0.0001127434,0.00016631,0.00020895425,0.00013132542,0.00011999337,0.000026444066,0.00071835757,0.0000033432605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033903548,0.002148439,0.96332383,0.000008117655,0.00022638465,0.00053996185,0.0003364077,0.00002423866,0.0001599799,0.0000031516872,0.00007915378,0.029759996],"study_design_scores_gemma":[0.021761172,0.008673109,0.9670386,0.000085947366,0.00009702563,0.00014395741,0.0008895912,0.00009828319,0.000018188479,0.000032454354,0.0010385256,0.00012316706],"about_ca_topic_score_codex":0.0006226451,"about_ca_topic_score_gemma":0.00069405034,"teacher_disagreement_score":0.029636828,"about_ca_system_score_codex":0.00065689103,"about_ca_system_score_gemma":0.0006950839,"threshold_uncertainty_score":0.45975426},"labels":[],"label_agreement":null},{"id":"W2118775322","doi":"10.4049/jimmunol.0804089","title":"Antigen Specificity Determines the Pro- or Antitumoral Nature of CD8+ T Cells","year":2009,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Biotechnology and Biological Sciences Research Council; Wellcome Trust","keywords":"Cytotoxic T cell; CD8; Cancer research; Immunology; Tumor progression; Biology; Melanoma; Antigen; Tumor microenvironment; Interleukin 21; Tumor cells; In vitro; Cancer; Biochemistry","score_opus":0.01921931285139673,"score_gpt":0.28882280794708415,"score_spread":0.26960349509568743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118775322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98195237,0.010831658,0.000027873682,0.0060252873,0.0005831172,0.0001854796,0.0000026851933,0.000006004775,0.00038554042],"genre_scores_gemma":[0.9923186,0.005993644,0.00015802427,0.00089744484,0.0002436984,3.0441933e-7,5.06471e-7,0.000007624738,0.0003802024],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99895746,0.00014361923,0.00047125499,0.0000622205,0.00018464147,0.00018081829],"domain_scores_gemma":[0.99885297,0.00012868759,0.00050020684,0.0003098122,0.0001876276,0.000020705509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066302606,0.000116744224,0.00035736227,0.00008586928,0.00008185764,0.000007677253,0.00037759938,0.0001267028,0.0001629717],"category_scores_gemma":[0.000054165313,0.000046927904,0.0001676811,0.00020889574,0.0002709383,0.000058614103,0.000023217715,0.00057378336,0.0000035024502],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012819213,0.00014962982,0.00069366494,0.000010335523,0.00029456278,0.0000660499,0.00055772974,0.0000016691099,0.9689597,0.000047539288,0.0022277397,0.01417218],"study_design_scores_gemma":[0.0031594324,0.0044757286,0.23603591,0.00022159624,0.00016863787,0.005313555,0.0009321439,0.00001060897,0.7198088,0.0002454708,0.029505584,0.00012250713],"about_ca_topic_score_codex":0.000018912957,"about_ca_topic_score_gemma":0.0000085685115,"teacher_disagreement_score":0.24915087,"about_ca_system_score_codex":0.000032990672,"about_ca_system_score_gemma":0.00015725913,"threshold_uncertainty_score":0.24928351},"labels":[],"label_agreement":null},{"id":"W2118982164","doi":"10.1056/nejmoa1305133","title":"Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma","year":2013,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3395,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Medicine; Ipilimumab; Rash; Adverse effect; Melanoma; Internal medicine; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Cohort; Cancer; Confidence interval; Surgery; Immunotherapy; Chemotherapy; Phases of clinical research","score_opus":0.010636992930751725,"score_gpt":0.25383211996041916,"score_spread":0.24319512702966742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118982164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973516,0.004573677,0.00006300444,0.02011194,0.00015807041,0.00019270793,9.913615e-7,0.0000071973823,0.0013764214],"genre_scores_gemma":[0.99489576,0.0014487713,0.00041604473,0.0013219111,0.00095308525,0.0000012470339,0.0000014501577,0.000014865236,0.000946888],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99879587,0.000083796636,0.0004975513,0.000110217035,0.00033229004,0.00018026485],"domain_scores_gemma":[0.99910283,0.00021299144,0.00021851085,0.0001265037,0.000119760814,0.0002194156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006799507,0.00013714323,0.00051024626,0.00026959344,0.000028767818,0.000009656992,0.0000673879,0.000041284442,0.0005252414],"category_scores_gemma":[0.00016676886,0.00007307549,0.000034614983,0.0001989206,0.00016216758,0.00011296382,0.000009831941,0.00028116253,0.000002701523],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13120972,0.00017609145,0.28535083,0.0001677294,0.0004993716,0.0027954332,0.0035661084,0.000005718526,0.053569946,0.000106093146,0.012053581,0.51049936],"study_design_scores_gemma":[0.13517395,0.00595129,0.7709969,0.0014343049,0.000119145036,0.0136598395,0.0005620619,0.000021869457,0.0007064075,0.00010695077,0.07114492,0.00012233622],"about_ca_topic_score_codex":0.00064517267,"about_ca_topic_score_gemma":0.000113345544,"teacher_disagreement_score":0.51037705,"about_ca_system_score_codex":0.000057432975,"about_ca_system_score_gemma":0.00023064026,"threshold_uncertainty_score":0.57510257},"labels":[],"label_agreement":null},{"id":"W2119301589","doi":"10.1186/1479-5876-10-205","title":"Cancer classification using the Immunoscore: a worldwide task force","year":2012,"lang":"en","type":"review","venue":"Journal of Translational Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":803,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Princess Margaret Cancer Centre; Institute for Research in Immunology and Cancer; University Health Network; Ontario Institute for Cancer Research","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Institut National Du Cancer; Japan Association for Chemical Innovation; Society for Immunotherapy of Cancer; Cancer Research Institute","keywords":"Medicine; Oncology; Cancer; Biomarker; Immune system; Internal medicine; Immunology","score_opus":0.15273547994574574,"score_gpt":0.41347780407888707,"score_spread":0.26074232413314136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119301589","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000030049456,0.9911535,0.001155786,0.0053365966,0.0014520929,0.0005840937,0.000023531136,0.0000074291365,0.00025692998],"genre_scores_gemma":[0.00064711133,0.9940421,0.0004101594,0.00042246646,0.003913359,0.000018569557,0.000049881728,0.000050557162,0.00044578902],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970221,0.00015939804,0.001556327,0.00015083508,0.00086880114,0.00024255815],"domain_scores_gemma":[0.9973113,0.00041426165,0.0015566734,0.00026692788,0.00031785909,0.00013299163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011885692,0.00032917433,0.001466003,0.00037020986,0.00011860309,0.000012219321,0.00025595873,0.00020772107,0.0006058844],"category_scores_gemma":[0.000050060415,0.0001623833,0.0007342238,0.00058648834,0.0002706153,0.00014209494,0.000007302153,0.0007972104,0.000003077891],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005518465,0.000064088665,0.0000750432,0.003001876,0.0014199677,0.000010924486,0.00032675976,0.0000029073278,0.00052392745,0.00007672464,0.0009161476,0.9930298],"study_design_scores_gemma":[0.001585902,0.00016428734,0.00069401984,0.027376037,0.007533068,0.0014801243,0.000054301625,0.00003535641,0.0000030628605,0.00004687079,0.9608768,0.00015012198],"about_ca_topic_score_codex":0.000045213666,"about_ca_topic_score_gemma":0.000008785173,"teacher_disagreement_score":0.9928797,"about_ca_system_score_codex":0.00031205363,"about_ca_system_score_gemma":0.0011200262,"threshold_uncertainty_score":0.66340095},"labels":[],"label_agreement":null},{"id":"W2120431466","doi":"10.1093/annonc/mdu450","title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3136,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia; University Health Network","funders":"","keywords":"Medicine; Tumor-infiltrating lymphocytes; H&E stain; Breast cancer; Oncology; Medical physics; Cancer; Pathology; Internal medicine; Immunotherapy; Staining","score_opus":0.08993888139496703,"score_gpt":0.42382210720944913,"score_spread":0.3338832258144821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120431466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680704,0.0011788808,0.000059457565,0.022843778,0.00057769485,0.00029498976,0.000036982914,0.000011815529,0.0069259834],"genre_scores_gemma":[0.99645966,0.0018737204,0.0001509087,0.0012342755,0.00013989866,0.000051663865,0.00005719033,0.000008259383,0.000024444164],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987235,0.00028616257,0.00045127366,0.0001427518,0.0002464063,0.00014990904],"domain_scores_gemma":[0.99882907,0.0003141205,0.00035659826,0.00016636436,0.00030074717,0.00003312276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025697383,0.000077734716,0.00020938272,0.000089682166,0.000054948567,0.000009053675,0.00014688646,0.00006001882,0.00030232078],"category_scores_gemma":[0.00012120231,0.000060550872,0.000060281123,0.0001317501,0.00011438827,0.00010183997,0.000018722048,0.00008369033,0.0000013210597],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010889545,0.00022574925,0.03689572,0.000010225605,0.00010773412,3.4698692e-7,0.0003293404,0.000031691965,0.026517479,0.00020666135,0.008277467,0.92630863],"study_design_scores_gemma":[0.01335192,0.0028456696,0.584641,0.0008675837,0.00017592614,0.00012006139,0.0018726409,0.028089544,0.029674748,0.0011702902,0.3368494,0.00034126508],"about_ca_topic_score_codex":0.0011396364,"about_ca_topic_score_gemma":0.001033477,"teacher_disagreement_score":0.9259674,"about_ca_system_score_codex":0.00016050962,"about_ca_system_score_gemma":0.00025482307,"threshold_uncertainty_score":0.33102006},"labels":[],"label_agreement":null},{"id":"W2120570504","doi":"10.1200/jco.2011.41.4912","title":"Method to Our Madness or Madness in Our Methods? Pitfalls in Trial Methodology","year":2012,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Ipilimumab; Medicine; Carboplatin; Oncology; Clinical trial; Internal medicine; Chemotherapy; Regimen; Chemotherapy regimen; Immunotherapy; Cancer; Cisplatin","score_opus":0.5324042848346785,"score_gpt":0.6436033727356764,"score_spread":0.11119908790099786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120570504","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009707223,0.0014444393,0.020520646,0.94338477,0.022297611,0.0018505523,0.00001659133,0.000019151665,0.0007590232],"genre_scores_gemma":[0.00033662538,0.00067066844,0.47102657,0.4968832,0.02694867,0.00006593138,0.000011008192,0.000099867095,0.0039574536],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9624094,0.025672799,0.009193615,0.0007513887,0.0008126152,0.0011601968],"domain_scores_gemma":[0.97516596,0.0179027,0.005148838,0.0006834364,0.00052566716,0.00057338056],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.0770725,0.000646494,0.008639244,0.0016396111,0.0000311326,0.000022890368,0.0009158681,0.005902021,0.0004178535],"category_scores_gemma":[0.01645374,0.00043316273,0.0018833727,0.0009345482,0.000099923185,0.00016572043,0.00021195602,0.011020065,0.000055573186],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33177385,0.0012635307,0.0008399187,0.00016090913,0.00080961036,0.005919257,0.00020202692,0.000002852582,0.00027125597,0.000004334436,0.3764628,0.28228968],"study_design_scores_gemma":[0.11003929,0.017466517,0.00972675,0.00051855046,0.00079205394,0.0019743666,0.0005565945,0.0000044431295,0.000102436476,0.00030431926,0.8580743,0.00044036002],"about_ca_topic_score_codex":0.00033677978,"about_ca_topic_score_gemma":0.0002722299,"teacher_disagreement_score":0.48161152,"about_ca_system_score_codex":0.0010814817,"about_ca_system_score_gemma":0.00585778,"threshold_uncertainty_score":0.999812},"labels":[],"label_agreement":null},{"id":"W2120620347","doi":"10.1158/1078-0432.ccr-06-1772","title":"Standard Treatments Induce Antigen-Specific Immune Responses in Prostate Cancer","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Prostate cancer; Antigen; Immune system; Prostate-specific antigen; Medicine; Immunology; Immunotherapy; Autoantibody; Cancer; Hormonal therapy; Carcinoembryonic antigen; Cancer research; Radiation therapy; Internal medicine; Antibody","score_opus":0.2743677418458901,"score_gpt":0.5638471543117376,"score_spread":0.2894794124658475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120620347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9529193,0.039615933,0.00000524534,0.0040981607,0.0006395444,0.0012471834,0.00008286025,0.000043214135,0.0013485546],"genre_scores_gemma":[0.880004,0.11335393,0.000110091474,0.00036009197,0.0004916639,0.00021252492,0.000014101969,0.0000503434,0.005403233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99557304,0.00048230795,0.0011295625,0.00068667246,0.001098609,0.0010298257],"domain_scores_gemma":[0.99747896,0.0010114713,0.00012315734,0.0006182046,0.0004575071,0.0003107131],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008900846,0.00021650083,0.00062138785,0.0004676104,0.00017991653,0.000049695092,0.00025561222,0.00022862255,0.0013441618],"category_scores_gemma":[0.00033662605,0.00017216953,0.0002236215,0.0014022391,0.0007787144,0.000105516105,0.00010795732,0.0012429068,0.000050473656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09378262,0.00049188046,0.49077296,0.00004507589,0.00021807927,0.00047433452,0.00043848332,6.037462e-7,0.022856396,0.000019337713,0.004133473,0.38676676],"study_design_scores_gemma":[0.008158648,0.0013103796,0.7498134,0.0004790346,0.000009836628,0.000007987631,0.00033234095,0.0000017694632,0.017925702,0.00005393448,0.22174375,0.00016325293],"about_ca_topic_score_codex":0.0034581101,"about_ca_topic_score_gemma":0.001697426,"teacher_disagreement_score":0.3866035,"about_ca_system_score_codex":0.0012791165,"about_ca_system_score_gemma":0.0015370483,"threshold_uncertainty_score":0.99956876},"labels":[],"label_agreement":null},{"id":"W2123176392","doi":"10.1158/2326-6066.cir-14-0191","title":"Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody","year":2015,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":409,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Phoenix Technologies (Canada); Arbutus Biopharma (Canada); University of British Columbia","funders":"AstraZeneca","keywords":"Monoclonal antibody; Cancer research; CD80; Cancer immunotherapy; Antibody; T cell; Immunotherapy; In vivo; Cytotoxicity; PD-L1; Immune system; Chemistry; In vitro; Cytotoxic T cell; Pharmacology; Immunology; Biology; CD40; Biochemistry","score_opus":0.09984791139134354,"score_gpt":0.4369662327177876,"score_spread":0.3371183213264441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123176392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930021,0.0040403404,0.00010354842,0.0017987293,0.00039638742,0.0004176078,0.000048562142,0.0000291693,0.00016354906],"genre_scores_gemma":[0.9939095,0.004768263,0.00003165737,0.000082852086,0.00015658882,0.000061106424,0.00028588754,0.000021967306,0.0006822207],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983486,0.00023333207,0.0003633694,0.00033018267,0.00039910205,0.000325408],"domain_scores_gemma":[0.9985959,0.00005234905,0.000121344216,0.0003909705,0.00071869494,0.000120718694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012388449,0.00011578432,0.00029597865,0.00032627108,0.00012221484,0.00003011038,0.00016491009,0.00016805499,0.00012257184],"category_scores_gemma":[0.000109099834,0.00010467052,0.000035941794,0.0004778263,0.0008764258,0.00020259374,0.00006906702,0.00030222503,0.0000116491965],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025932654,0.00013139771,0.03324335,0.0000724006,0.00014980095,0.000009617264,0.00067386683,2.8894098e-7,0.9467163,0.00012818097,0.000111271496,0.016170278],"study_design_scores_gemma":[0.002754759,0.0009078312,0.76369,0.0001247417,0.000043653297,0.00009179986,0.00048336518,0.00032387025,0.22526273,0.0001318842,0.006050597,0.00013475104],"about_ca_topic_score_codex":0.00045025768,"about_ca_topic_score_gemma":0.000013260823,"teacher_disagreement_score":0.73044664,"about_ca_system_score_codex":0.0001608338,"about_ca_system_score_gemma":0.0006029046,"threshold_uncertainty_score":0.426834},"labels":[],"label_agreement":null},{"id":"W2125885282","doi":"10.1200/jco.2014.58.1967","title":"Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1023,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Medicine; Carboplatin; Chemotherapy; Oncology; Human Epidermal Growth Factor Receptor 2; Triple-negative breast cancer; Internal medicine; Triple negative; Breast cancer; Cancer research; Epidermal growth factor receptor; Receptor; Pathology; Cancer; Cisplatin","score_opus":0.038043498804686264,"score_gpt":0.38585307086776915,"score_spread":0.3478095720630829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125885282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929476,0.00017166442,0.000056565095,0.005848472,0.0001869841,0.00043615844,0.000014538836,0.000008487396,0.0003295739],"genre_scores_gemma":[0.986546,0.00023056501,0.0058333636,0.006814192,0.00043151737,0.000008821954,0.0000013622642,0.000026785345,0.00010740596],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9967146,0.0009280184,0.0015297362,0.00028640847,0.0002701657,0.00027110506],"domain_scores_gemma":[0.9943917,0.003742065,0.0011318447,0.00011418516,0.0002523782,0.00036784803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031092798,0.0002198564,0.0015784353,0.00018871427,0.00007208447,0.00001958715,0.00008915266,0.00019196363,0.000079823534],"category_scores_gemma":[0.0015920874,0.00013638876,0.000121333054,0.0002020757,0.00040970178,0.00014174976,0.00002665201,0.0005538995,4.977374e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49122003,0.0003557883,0.21504247,0.00006094875,0.00049598614,0.0002568779,0.0031368716,0.00000294172,0.045746796,0.000008006648,0.00027334577,0.24339993],"study_design_scores_gemma":[0.03981677,0.028893119,0.9237468,0.00057769305,0.0000833264,0.0015986795,0.0007623758,0.00007340961,0.0030592699,0.000017001677,0.001169731,0.00020180558],"about_ca_topic_score_codex":0.000512038,"about_ca_topic_score_gemma":0.00055129617,"teacher_disagreement_score":0.70870435,"about_ca_system_score_codex":0.0006870827,"about_ca_system_score_gemma":0.0021998468,"threshold_uncertainty_score":0.55617726},"labels":[],"label_agreement":null},{"id":"W2128452678","doi":"10.7150/jca.9485","title":"The Cause and Prevention of Anastomotic Recurrence following Colectomy: An Immunohistochemical Approach for Detecting Transforming Colonocytes","year":2014,"lang":"en","type":"article","venue":"Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision BioLogic (Canada)","funders":"","keywords":"Immunohistochemistry; Medicine; Colectomy; Anastomosis; Colorectal cancer; Monoclonal antibody; Malignancy; Biopsy; Cancer; Antigen; Pathology; Lesion; Gastroenterology; Antibody; Internal medicine; Surgery; Immunology","score_opus":0.02491660797874683,"score_gpt":0.3389587847977495,"score_spread":0.31404217681900265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128452678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786793,0.0084414715,0.0122183645,0.00013781429,0.00020071401,0.00027222396,0.0000011800989,0.0000035948458,0.000045337332],"genre_scores_gemma":[0.9966915,0.00047477012,0.0026146967,0.00003317807,0.00012761475,0.000017392906,6.8872976e-7,0.000009733001,0.000030378344],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992694,0.000037730988,0.00034871584,0.00007656493,0.00014669081,0.00012086486],"domain_scores_gemma":[0.9993429,0.00013253173,0.0002854216,0.0000792796,0.00011444053,0.00004539635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078684534,0.00007125924,0.00022752117,0.00004723969,0.00010952745,0.000015709385,0.00006819407,0.000045036337,0.0000023682085],"category_scores_gemma":[0.000095969895,0.00004766192,0.00015582623,0.000092151175,0.00006307612,0.00012800645,0.0000044550293,0.0001245393,1.0223034e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060524815,0.000078411744,0.0029868232,0.0002495373,0.0005182524,0.0000011541892,0.0011466302,0.000020849744,0.4694247,0.000022267453,0.000043288182,0.5194556],"study_design_scores_gemma":[0.03449844,0.0155394925,0.03382294,0.004576194,0.0034928496,0.0006312738,0.003618609,0.015250468,0.8674739,0.0010982953,0.019258317,0.00073924783],"about_ca_topic_score_codex":0.000021684642,"about_ca_topic_score_gemma":0.00003050368,"teacher_disagreement_score":0.5187164,"about_ca_system_score_codex":0.000113029164,"about_ca_system_score_gemma":0.00015055107,"threshold_uncertainty_score":0.19435968},"labels":[],"label_agreement":null},{"id":"W2129958914","doi":"10.1016/j.jcjo.2014.10.010","title":"New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient","year":2015,"lang":"en","type":"letter","venue":"Canadian Journal of Ophthalmology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ipilimumab; Medicine; Melanoma; Blockade; Oncology; Internal medicine; Cytotoxic T cell; Adverse effect; Cancer; Immunotherapy; Immunology; Cancer research; Receptor","score_opus":0.02860723322264029,"score_gpt":0.2641670588661218,"score_spread":0.2355598256434815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129958914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8950859,0.009321008,0.0000016484622,0.09219289,0.00092746044,0.0004332701,0.00008783936,0.0000042919078,0.0019457443],"genre_scores_gemma":[0.95946085,0.000087058426,0.0007171559,0.03530523,0.001103653,0.000016220043,0.00009285142,0.00013733517,0.0030796349],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99748904,0.0002409689,0.0008222292,0.00030703552,0.00039741627,0.00074334105],"domain_scores_gemma":[0.99798256,0.00008692117,0.0006027757,0.00038412353,0.0002694745,0.0006741542],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027395043,0.00042017462,0.001086805,0.0012058156,0.000062452316,0.000036800753,0.0003088142,0.00047917484,0.002267051],"category_scores_gemma":[0.000050255592,0.00032617702,0.00023205543,0.000368711,0.00020479261,0.00008177573,0.00001013318,0.0017896658,0.000010915395],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034849155,0.00004249196,0.021268267,0.00010660183,0.00123266,0.5360564,0.0011139731,0.000009254228,0.00016367229,2.9830989e-7,0.43478248,0.0017389932],"study_design_scores_gemma":[0.009615244,0.005889025,0.026805572,0.00066011475,0.00016668279,0.8050651,0.0001937005,8.2494e-7,0.00041643038,0.000065466134,0.1506829,0.00043891423],"about_ca_topic_score_codex":0.018574163,"about_ca_topic_score_gemma":0.0014374848,"teacher_disagreement_score":0.28409958,"about_ca_system_score_codex":0.0010397739,"about_ca_system_score_gemma":0.008982501,"threshold_uncertainty_score":0.99991906},"labels":[],"label_agreement":null},{"id":"W2130030995","doi":"10.1038/nri3790","title":"Clinical blockade of PD1 and LAG3 — potential mechanisms of action","year":2014,"lang":"en","type":"review","venue":"Nature reviews. Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":640,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Blockade; Context (archaeology); T cell; Cancer research; Receptor; Immune system; Programmed cell death; Medicine; Biology; Immunology; Apoptosis; Internal medicine; Biochemistry","score_opus":0.049452779629603386,"score_gpt":0.42533070793796024,"score_spread":0.37587792830835687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130030995","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027280426,0.9964512,0.0002027693,0.00008963948,0.0016071263,0.0013942004,0.000025714062,0.000020552267,0.00018151975],"genre_scores_gemma":[0.00009557911,0.9980067,0.00089387666,0.00015325185,0.00030614168,0.000044092776,0.000119960125,0.000048050628,0.0003323351],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99600065,0.0008542202,0.0021950512,0.0004962343,0.00019923928,0.00025459027],"domain_scores_gemma":[0.99680585,0.00022888693,0.0019953537,0.0007741519,0.0001380475,0.000057709927],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0015930701,0.00044716656,0.0054662307,0.0002624615,0.00003348431,0.000004430359,0.00026145566,0.0026288454,0.00016735391],"category_scores_gemma":[0.00034759325,0.00030361197,0.0015839434,0.0003379423,0.00037128336,0.000029700444,0.00010472351,0.001865754,0.00001632289],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029082267,0.00010518797,0.0000019605004,0.02947996,0.0010730369,0.000004922336,0.000004677618,2.14953e-9,0.00070376514,0.00023931109,0.0006023704,0.967494],"study_design_scores_gemma":[0.001107514,0.0008068269,0.000055091627,0.020492028,0.0025687127,0.0005590891,0.000004345252,4.1315462e-7,0.00011928067,0.000076662574,0.9740032,0.00020683545],"about_ca_topic_score_codex":0.000014888003,"about_ca_topic_score_gemma":0.0000037677348,"teacher_disagreement_score":0.97340083,"about_ca_system_score_codex":0.00006154483,"about_ca_system_score_gemma":0.00025798162,"threshold_uncertainty_score":0.9999416},"labels":[],"label_agreement":null},{"id":"W2132290857","doi":"10.1158/2326-6066.cir-14-0215","title":"Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma","year":2015,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":468,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; York University; National Cancer Institute; National Heart, Lung, and Blood Institute; University of Pennsylvania","keywords":"Medicine; Pancreatic cancer; Immunotherapy; Immune checkpoint; Tumor microenvironment; Cancer research; Immunology; T cell; CTLA-4; Immunity; Immune system; Cancer; Internal medicine","score_opus":0.10303665455813443,"score_gpt":0.365672754383077,"score_spread":0.26263609982494257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132290857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96454954,0.031661812,0.0000027271624,0.0019138551,0.0001836173,0.00058113463,0.000022545393,0.000013475489,0.0010712832],"genre_scores_gemma":[0.99535286,0.0029110694,0.00014336032,0.00006540458,0.000055191358,0.000102590806,0.000008126269,0.000020624644,0.0013407427],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981532,0.0003980308,0.00034307275,0.00034390917,0.00031394942,0.0004478121],"domain_scores_gemma":[0.99881697,0.000236155,0.000071509945,0.00041625986,0.00032575818,0.00013333315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013685243,0.00015458875,0.0004823725,0.00043822444,0.00009896764,0.000018177536,0.00015489671,0.00016234726,0.00002736232],"category_scores_gemma":[0.00019793084,0.00014046027,0.00003384228,0.00066642236,0.00080841035,0.0000860572,0.00018457035,0.000553226,0.0000025999939],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007901107,0.00009724981,0.14869793,0.00021414553,0.000101930906,0.00001288635,0.0020363582,3.4036103e-7,0.83644867,0.00004140766,0.0003040859,0.004143869],"study_design_scores_gemma":[0.005720284,0.0010274978,0.9146021,0.0002275864,0.000027582457,0.000025260522,0.0033911322,0.00001343606,0.070688285,0.00020154791,0.003913026,0.0001622826],"about_ca_topic_score_codex":0.0074035237,"about_ca_topic_score_gemma":0.0012006985,"teacher_disagreement_score":0.7659041,"about_ca_system_score_codex":0.00033937042,"about_ca_system_score_gemma":0.00047964326,"threshold_uncertainty_score":0.99920624},"labels":[],"label_agreement":null},{"id":"W2137481383","doi":"10.1093/jnci/djn508","title":"Melanoma Vaccines: Possible Progress After Years of Frustration?","year":2009,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Melanoma; Immunotherapy; Cancer; Immune system; Disease; Cancer immunotherapy; Immunology; Internal medicine; Cancer research","score_opus":0.026159132914100942,"score_gpt":0.33379668381470634,"score_spread":0.3076375509006054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137481383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847568,0.0029347073,0.000014632393,0.010044869,0.0011454691,0.00017230399,0.00002478471,0.0000052586247,0.0009011739],"genre_scores_gemma":[0.99629295,0.0001964745,0.000501817,0.0015686901,0.0010017682,0.000005158475,0.0000015503614,0.0000050837134,0.00042651873],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99874794,0.000018494846,0.00041434052,0.00007104108,0.0006521156,0.00009605932],"domain_scores_gemma":[0.9989012,0.000014626632,0.00037525696,0.00008754978,0.00057662284,0.000044755445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025973291,0.00007763442,0.00019672325,0.000119728706,0.000037377195,0.000015643773,0.00016257919,0.000054992775,0.00013330966],"category_scores_gemma":[0.00005538602,0.000051360195,0.00019549315,0.00028562133,0.000077716126,0.00022945333,0.000009811098,0.00016409866,0.0000011811375],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041808646,0.0021831365,0.31975847,0.00040350822,0.0032423227,0.00022688172,0.0023261379,0.0011579597,0.09752179,0.004258375,0.10837875,0.418734],"study_design_scores_gemma":[0.0027733573,0.00035157404,0.9423915,0.00038107738,0.00010672166,0.00025586443,0.000016356984,0.000016748347,0.0078095947,0.00082512165,0.044992965,0.000079129175],"about_ca_topic_score_codex":0.00001868505,"about_ca_topic_score_gemma":0.000029266846,"teacher_disagreement_score":0.62263304,"about_ca_system_score_codex":0.0002158442,"about_ca_system_score_gemma":0.0008281,"threshold_uncertainty_score":0.2094408},"labels":[],"label_agreement":null},{"id":"W2137661208","doi":"10.1002/ibd.21485","title":"MD-2","year":2010,"lang":"en","type":"letter","venue":"Inflammatory Bowel Diseases","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine","score_opus":0.010784251004385294,"score_gpt":0.2493637147175029,"score_spread":0.2385794637131176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137661208","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06752734,0.016815145,0.0000075765506,0.89248604,0.0056118136,0.002090061,0.0010643816,0.0011692358,0.013228398],"genre_scores_gemma":[0.0015541305,0.0007422799,0.000050268405,0.9732092,0.012593962,0.00017070948,0.0011020367,0.0001687513,0.01040868],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99803555,0.000048378643,0.00042217018,0.0004760981,0.00056244596,0.00045536796],"domain_scores_gemma":[0.9984968,0.00008336139,0.00020245415,0.000927651,0.00010942369,0.00018033662],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.000069696194,0.00044315198,0.00045811883,0.00021250808,0.00010304414,0.0000663731,0.00025335109,0.0015413502,0.0030069367],"category_scores_gemma":[0.0000634128,0.00037937556,0.0005931909,0.00008800272,0.00031140214,0.000088630055,0.00005198421,0.0025832597,0.00043264142],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000588485,0.000045815876,0.007024012,0.0007326767,0.00032066205,0.0040963762,0.000023849638,6.382016e-8,0.0009012928,0.000003579638,0.9832407,0.003022446],"study_design_scores_gemma":[0.0012008105,0.00006520934,0.044161208,0.0003198606,0.000408629,0.00009580416,0.000006821241,0.0000017487256,0.00018174872,0.00006737241,0.9530741,0.00041669403],"about_ca_topic_score_codex":0.000023344319,"about_ca_topic_score_gemma":0.00000855499,"teacher_disagreement_score":0.08072314,"about_ca_system_score_codex":0.00011264969,"about_ca_system_score_gemma":0.0006104663,"threshold_uncertainty_score":0.99986583},"labels":[],"label_agreement":null},{"id":"W2139591061","doi":"10.1158/0008-5472.can-11-1620","title":"Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1645,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; U.S. Public Health Service","keywords":"Immune system; Cancer; Cancer research; Receptor; Antibody; Immunology; Ipilimumab; Biology; Inhibitory postsynaptic potential; CD8; Blockade; Cancer cell; Immune tolerance; Knockout mouse; Immunotherapy; Neuroscience; Biochemistry","score_opus":0.05320576067752921,"score_gpt":0.33173856694882153,"score_spread":0.27853280627129234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139591061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98162043,0.009819899,0.00011532317,0.001041398,0.000321171,0.00088737987,0.000012639349,0.00007015327,0.0061116205],"genre_scores_gemma":[0.9909682,0.0009364513,0.0004917078,0.00022893744,0.00024271014,0.00021052358,0.000012440577,0.0000565451,0.0068524815],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99780554,0.00013133853,0.00036701112,0.00048564887,0.0005900924,0.0006203992],"domain_scores_gemma":[0.99876815,0.000037952934,0.000054711873,0.0005038261,0.0003521006,0.0002832433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010205683,0.0001965667,0.0003184398,0.00029814508,0.0002067191,0.00004644561,0.00016990265,0.00012844893,0.0009115214],"category_scores_gemma":[0.00006944034,0.00016821732,0.00009830853,0.0005510032,0.00038521533,0.000092278075,0.00016290466,0.00047013938,0.00007827401],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008841645,0.00016816387,0.0003424487,0.00022015224,0.00009766652,0.000077862394,0.00068321853,9.30288e-7,0.95604295,0.00015845317,0.0018309557,0.031535555],"study_design_scores_gemma":[0.0046554804,0.0032723881,0.12128033,0.00093041296,0.00009991222,0.000055706358,0.0004875717,0.00008472286,0.83171123,0.0004161405,0.036540482,0.000465609],"about_ca_topic_score_codex":0.0015720703,"about_ca_topic_score_gemma":0.000055880246,"teacher_disagreement_score":0.124331705,"about_ca_system_score_codex":0.0002548077,"about_ca_system_score_gemma":0.00035436658,"threshold_uncertainty_score":0.998052},"labels":[],"label_agreement":null},{"id":"W2140369740","doi":"10.1128/jvi.02034-13","title":"Differential Impact of PD-1 and/or Interleukin-10 Blockade on HIV-1-Specific CD4 T Cell and Antigen-Presenting Cell Functions","year":2013,"lang":"en","type":"article","venue":"Journal of Virology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; Massachusetts General Hospital","keywords":"Blockade; Biology; Immunotherapy; Immunology; T cell; Interleukin 2; Immune system; Cancer research; Receptor","score_opus":0.0155827842367759,"score_gpt":0.27251083401128884,"score_spread":0.25692804977451295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140369740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972989,0.001044206,0.00009999368,0.00047704228,0.0002773529,0.00012577322,0.0000071470495,0.0000047228023,0.0006648861],"genre_scores_gemma":[0.9970271,0.0012148805,0.00009561801,0.00008783982,0.0002926781,0.0000015345895,0.0000024423714,0.000014170795,0.0012637606],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99905103,0.000054840806,0.00044150825,0.0001270674,0.00013138143,0.00019418598],"domain_scores_gemma":[0.9991832,0.000115990675,0.00036502955,0.00013438278,0.00008805792,0.00011334737],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010961629,0.00013452023,0.000386135,0.0002369663,0.000049608218,0.000019104446,0.00007105047,0.0001119937,0.0026776139],"category_scores_gemma":[0.000014441547,0.00008479887,0.00018445129,0.00007695806,0.00015231084,0.00007038501,0.000034442215,0.00027951278,0.000013005585],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054273135,0.00033514632,0.022792354,0.000039168615,0.00020512097,0.00003519886,0.00029397517,0.000004009303,0.9577072,0.0000010352737,0.008640553,0.0045189233],"study_design_scores_gemma":[0.0111152865,0.011174126,0.86099154,0.00014113635,0.00021377264,0.0012908279,0.0004971606,0.00024930268,0.101920895,0.000042777756,0.012148384,0.0002147656],"about_ca_topic_score_codex":0.000044024575,"about_ca_topic_score_gemma":0.0000035134015,"teacher_disagreement_score":0.8557863,"about_ca_system_score_codex":0.0000400975,"about_ca_system_score_gemma":0.000055143853,"threshold_uncertainty_score":0.9982341},"labels":[],"label_agreement":null},{"id":"W2142959209","doi":"10.1186/1479-5876-9-214","title":"Defining the critical hurdles in cancer immunotherapy","year":2011,"lang":"en","type":"editorial","venue":"Journal of Translational Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Université de Montréal; Institute for Research in Immunology and Cancer; Ontario Institute for Cancer Research; BC Cancer Agency; McMaster University","funders":"National Cancer Institute; Society for Immunotherapy of Cancer","keywords":"Medicine; Immunotherapy; Summit; Cancer immunotherapy; Clinical trial; Cancer; Alternative medicine; Engineering ethics; Pathology; Internal medicine","score_opus":0.026256083378911346,"score_gpt":0.3608865586302095,"score_spread":0.3346304752512982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142959209","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006967114,0.24894561,0.000316542,0.037634015,0.7109201,0.00032371702,0.00006466914,0.000019432257,0.0010792332],"genre_scores_gemma":[0.022380585,0.03466715,0.0010217793,0.0015251008,0.93979555,0.000029162045,0.0000693603,0.00014388353,0.00036745108],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966855,0.00012419466,0.0012877407,0.00018223931,0.0014636522,0.00025666942],"domain_scores_gemma":[0.9963551,0.0022351772,0.0004957413,0.00020208466,0.0006136867,0.00009817301],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015765395,0.0002838732,0.0008777417,0.00039523878,0.000058925438,0.000011744905,0.00028734296,0.00045724152,0.001149916],"category_scores_gemma":[0.0006865699,0.00015752848,0.00032417057,0.00029308844,0.0004988123,0.00010619843,0.0000064107726,0.0016547685,0.0000022333506],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0108451,0.00021526127,0.0011979457,0.0002611775,0.00077843526,0.00015482954,0.0024720333,0.000006688719,0.00090829504,0.0004914752,0.95351696,0.029151807],"study_design_scores_gemma":[0.007449199,0.0011173049,0.009061392,0.0045820074,0.00041411002,0.00014908251,0.00014704696,0.000009265872,0.00005324339,0.0009882792,0.9758559,0.00017317043],"about_ca_topic_score_codex":0.00041331362,"about_ca_topic_score_gemma":0.000116091454,"teacher_disagreement_score":0.22887546,"about_ca_system_score_codex":0.0001583266,"about_ca_system_score_gemma":0.0013888625,"threshold_uncertainty_score":0.9997632},"labels":[],"label_agreement":null},{"id":"W2148493216","doi":"10.14740/gr594e","title":"Infectious Colitis Associated With Ipilimumab Therapy","year":2014,"lang":"en","type":"article","venue":"Gastroenterology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ipilimumab; Medicine; Colitis; Internal medicine; Diarrhea; Immunology; Adverse effect; Abdominal pain; Oncology; Gastroenterology; Cancer; Immunotherapy","score_opus":0.040552200473297544,"score_gpt":0.337131993018761,"score_spread":0.29657979254546346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148493216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99358094,0.000075793265,0.00012194786,0.0020087927,0.000085067564,0.00040309658,0.0000046779674,0.00007799091,0.0036416994],"genre_scores_gemma":[0.997117,0.0001463039,0.000032290078,0.0015827677,0.000093829156,0.000085691216,0.00002520939,0.000026108843,0.00089080795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978809,0.00056553556,0.00016948224,0.00028557022,0.00040543734,0.0006930946],"domain_scores_gemma":[0.9990492,0.00017160013,0.00004426396,0.0003184971,0.0002880271,0.0001284334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013539401,0.000121228455,0.00026926294,0.00022737302,0.000162855,0.000022731923,0.00011876783,0.00010924459,0.0003425457],"category_scores_gemma":[0.0001334224,0.00008936202,0.000070228554,0.0002791493,0.00051342807,0.000039561688,0.00003544053,0.0004807488,0.00003635059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023384709,0.0004406141,0.9527887,0.000013379401,0.00046320635,0.000039941697,0.0001652462,0.0000012711118,0.0056758793,0.000044753262,0.0047630933,0.0122191785],"study_design_scores_gemma":[0.011681484,0.009477638,0.97162944,0.000059467562,0.000011352478,0.00020787586,0.000042773107,0.000058483267,0.0003836194,0.00007230076,0.0063208826,0.00005466225],"about_ca_topic_score_codex":0.00013745722,"about_ca_topic_score_gemma":0.0004963959,"teacher_disagreement_score":0.018840732,"about_ca_system_score_codex":0.00015617578,"about_ca_system_score_gemma":0.000089089,"threshold_uncertainty_score":0.37506354},"labels":[],"label_agreement":null},{"id":"W2154610258","doi":"10.4049/jimmunol.170.3.1257","title":"Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production","year":2003,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":962,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Cytokine; T cell; Cell biology; Chemistry; CD28; PD-L1; Biology; Molecular biology; Immunology; Immune system; Immunotherapy","score_opus":0.013589798274912388,"score_gpt":0.2543486964007138,"score_spread":0.2407588981258014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154610258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99406075,0.0037190805,0.000074408505,0.0013931452,0.0003375918,0.00018585587,4.6196257e-7,0.000004892982,0.00022382429],"genre_scores_gemma":[0.995042,0.0043467768,0.00022118136,0.00008909226,0.000081595485,0.0000022356135,5.477694e-7,0.000008748224,0.00020781468],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99923193,0.00010347281,0.00033352152,0.00006978971,0.0001331006,0.00012816148],"domain_scores_gemma":[0.9992356,0.000102052414,0.00036270538,0.00014054346,0.00013800936,0.00002110255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055669906,0.0000890373,0.00022944338,0.00011763604,0.000052208565,0.00000449435,0.00006435806,0.00006819772,0.000024219911],"category_scores_gemma":[0.00008678969,0.000053894863,0.000058129786,0.00013528402,0.0001486944,0.00005210981,0.000006549359,0.00021840518,0.0000010237128],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033506132,0.00020848564,0.00021769103,0.000035387067,0.00016313295,0.000002569074,0.00045543318,0.0000028347388,0.9891716,0.000026341724,0.00008030064,0.006285593],"study_design_scores_gemma":[0.0017366331,0.0024922106,0.0048737098,0.00014487402,0.00011540171,0.00047110155,0.0004412806,0.00000100534,0.9870514,0.000087467764,0.002537038,0.000047842008],"about_ca_topic_score_codex":0.000012048905,"about_ca_topic_score_gemma":0.000001557678,"teacher_disagreement_score":0.006237751,"about_ca_system_score_codex":0.00004403033,"about_ca_system_score_gemma":0.00008000127,"threshold_uncertainty_score":0.21977687},"labels":[],"label_agreement":null},{"id":"W2154753744","doi":"10.1093/annonc/mdu205","title":"A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Toronto; University of Alberta","funders":"","keywords":"Tremelimumab; Medicine; Tolerability; Gemcitabine; Internal medicine; Oncology; Pancreatic cancer; Chemotherapy; Gastroenterology; Cancer; Adverse effect; Immunotherapy; Ipilimumab","score_opus":0.041193015539834725,"score_gpt":0.3675221896947738,"score_spread":0.32632917415493906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154753744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965023,0.00015358206,0.000083141465,0.0015280511,0.000056449393,0.0012095975,0.000012503054,0.0000073616065,0.0004470349],"genre_scores_gemma":[0.99874055,0.00023829001,0.000288371,0.0004937302,0.000023679304,0.000108429194,0.000057384368,0.0000177161,0.000031849177],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99863553,0.0001785659,0.0005460071,0.00019650071,0.00024957984,0.00019381885],"domain_scores_gemma":[0.9989377,0.00016907605,0.00043670277,0.00017400923,0.00024154676,0.00004091925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005020084,0.00014441521,0.00066775567,0.0002958443,0.000013064753,0.0000026539235,0.00006036698,0.00007807962,0.00008128395],"category_scores_gemma":[0.00006471608,0.00010357423,0.000056345638,0.0004436697,0.00014605084,0.00009194277,0.0000066396938,0.000104894694,5.248646e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5894599,0.012043388,0.0568247,0.00020611205,0.00038785997,0.0000073184406,0.0015409798,0.000045438846,0.00370829,0.00008787647,0.00011721414,0.33557093],"study_design_scores_gemma":[0.56146693,0.06506621,0.36635196,0.00045257478,0.0001404723,0.000002658847,0.00013535662,0.0005375356,0.004583063,0.00014220057,0.00096423354,0.00015681492],"about_ca_topic_score_codex":0.001159313,"about_ca_topic_score_gemma":0.0012979616,"teacher_disagreement_score":0.3354141,"about_ca_system_score_codex":0.00011117299,"about_ca_system_score_gemma":0.00028381785,"threshold_uncertainty_score":0.42236346},"labels":[],"label_agreement":null},{"id":"W2154754594","doi":"10.14740/jem.v5i5.287","title":"Ipilimumab-Induced Hypophysitis May Not Affect All Pituitary Cell Lines: A Case Report","year":2015,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Hypophysitis; Medicine; Ipilimumab; Hypopituitarism; Internal medicine; Central hypothyroidism; Adrenal insufficiency; Endocrinology; Pituitary gland; Hormone; Cancer; Immunotherapy","score_opus":0.047519239671677434,"score_gpt":0.3201074683246486,"score_spread":0.27258822865297117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154754594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794619,0.014670042,0.000023149512,0.0029336466,0.0017406462,0.00016818238,0.000005675973,0.000019046169,0.0009777008],"genre_scores_gemma":[0.99422723,0.0015585041,0.0008179862,0.0014723674,0.0010239986,0.000004905594,0.0000039099373,0.000020668445,0.000870449],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99849385,0.00012443474,0.0006125169,0.00020152419,0.00022833009,0.00033936318],"domain_scores_gemma":[0.9986775,0.00009143332,0.00042725817,0.00025440645,0.00026342183,0.00028600503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044114573,0.00020199973,0.00066444045,0.00024317042,0.000057207577,0.0000136083445,0.00008461998,0.0001226089,0.000039097446],"category_scores_gemma":[0.00014560678,0.00014951466,0.00024080352,0.0001200097,0.000117368385,0.00015861106,0.000042253087,0.00045342022,0.0000064975184],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009528411,0.0006579715,0.0014013876,0.00011701984,0.0015167992,0.5684983,0.0015345714,0.0000030523213,0.3501651,0.00015677577,0.013803299,0.052617297],"study_design_scores_gemma":[0.012136449,0.0011103324,0.012765634,0.00005050067,0.0008540359,0.75651747,0.00067435054,0.0000054172183,0.07759329,0.00011232911,0.1379688,0.00021141142],"about_ca_topic_score_codex":0.00021104112,"about_ca_topic_score_gemma":0.000016011392,"teacher_disagreement_score":0.2725718,"about_ca_system_score_codex":0.000041525298,"about_ca_system_score_gemma":0.0002750546,"threshold_uncertainty_score":0.6097031},"labels":[],"label_agreement":null},{"id":"W2155901347","doi":"10.1186/s13058-014-0432-8","title":"Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration","year":2014,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McGill University; University of British Columbia","funders":"Michael Smith Health Research BC; Susan G. Komen; National Cancer Institute; Sanofi","keywords":"Surgical oncology; Estrogen receptor; Cytotoxic T cell; Cancer research; Infiltration (HVAC); Epidermal growth factor receptor; Breast cancer; FOXP3; Medicine; Human Epidermal Growth Factor Receptor 2; Oncology; Receptor; Internal medicine; Biology; Cancer; Immunology; Immune system","score_opus":0.03460279391486393,"score_gpt":0.34208285504600217,"score_spread":0.30748006113113824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155901347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99523306,0.0019203079,0.000012252492,0.00073921256,0.00012085633,0.0012117838,0.0005431614,0.000035343317,0.00018402179],"genre_scores_gemma":[0.9973452,0.0014687922,0.00009046787,0.000097103955,0.00028407248,0.00055709743,0.000052238058,0.00005354773,0.00005146661],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99659526,0.00047912946,0.0006089271,0.00068884296,0.0008505957,0.0007772145],"domain_scores_gemma":[0.9983331,0.00042879523,0.0002501722,0.00028128308,0.0003791812,0.00032746315],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008209328,0.00032356393,0.00052341545,0.0003723671,0.00023234298,0.00007657682,0.00015294578,0.00014092926,0.0005984727],"category_scores_gemma":[0.000100426754,0.00027619238,0.00007074315,0.00051508937,0.00046098782,0.00023233224,0.00008213867,0.0005005131,0.000003366896],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020220787,0.00017392173,0.39574185,0.00051414565,0.00003097919,0.0000027251806,0.00033300574,0.0000042708325,0.5691425,0.000047863567,0.00020785509,0.03177876],"study_design_scores_gemma":[0.0051050205,0.00064188516,0.64629775,0.0016729701,0.000020669924,0.000045481036,0.0003008675,0.00011760515,0.34516263,0.000016906475,0.000325993,0.00029223502],"about_ca_topic_score_codex":0.009102108,"about_ca_topic_score_gemma":0.0003562716,"teacher_disagreement_score":0.2505559,"about_ca_system_score_codex":0.0006710453,"about_ca_system_score_gemma":0.0007381793,"threshold_uncertainty_score":0.999969},"labels":[],"label_agreement":null},{"id":"W2156375860","doi":"10.1158/1078-0432.ccr-13-1877","title":"Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer","year":2013,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":418,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia; BC Cancer Agency","funders":"","keywords":"CD8; Tumor-infiltrating lymphocytes; Serous fluid; Cancer research; Ovarian cancer; Immunotherapy; Intraepithelial lymphocyte; Biology; Antigen; Pathology; Cancer; Immunology; Medicine; Immune system; Internal medicine","score_opus":0.11773343481620593,"score_gpt":0.43122414660490305,"score_spread":0.31349071178869714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156375860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98502195,0.0033937914,0.0000045827455,0.008642268,0.00041564275,0.001638947,0.000037974583,0.00007235577,0.00077247206],"genre_scores_gemma":[0.993714,0.00096856535,0.000085240514,0.001492878,0.00079924776,0.0010620498,0.000020817259,0.00008273074,0.0017744944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935333,0.0021142731,0.0010275717,0.00077359803,0.0014958385,0.0010554185],"domain_scores_gemma":[0.99483585,0.0030552542,0.00035085413,0.000778399,0.00064091984,0.00033870165],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0059308074,0.00031646475,0.00079831027,0.00019677695,0.00041922994,0.00022931109,0.00049458415,0.00026082812,0.0025540118],"category_scores_gemma":[0.0017469829,0.0002010468,0.00014461628,0.0011594024,0.00094357843,0.00021797803,0.00017159902,0.001512545,0.000028342894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071066767,0.0005089479,0.93080187,0.00018600654,0.00062246306,0.000387453,0.0006939349,0.00004782065,0.013564349,0.000012182784,0.013628516,0.03243978],"study_design_scores_gemma":[0.0086175855,0.0004176127,0.98080176,0.0021179474,0.00006029064,0.000012811698,0.0014537534,0.00027398576,0.004511032,0.00007211429,0.0013708619,0.0002902537],"about_ca_topic_score_codex":0.16006236,"about_ca_topic_score_gemma":0.028014448,"teacher_disagreement_score":0.1320479,"about_ca_system_score_codex":0.0014497826,"about_ca_system_score_gemma":0.0021155851,"threshold_uncertainty_score":0.9983578},"labels":[],"label_agreement":null},{"id":"W2159116335","doi":"10.4049/jimmunol.181.9.6595","title":"Carcinoembryonic Antigen-Specific but Not Antiviral CD4+ T Cell Immunity Is Impaired in Pancreatic Carcinoma Patients","year":2008,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Carcinoembryonic antigen; Immunity; Immune system; Epitope; Medicine; Pancreatic cancer; Immunology; T cell; Cytokine; Cytotoxic T cell; Cellular immunity; Tumor microenvironment; Antigen; Cancer research; Cancer; Biology; Internal medicine; In vitro","score_opus":0.022602557747609695,"score_gpt":0.23713889565946789,"score_spread":0.2145363379118582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159116335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98276776,0.01537524,0.000010904754,0.0006441736,0.00047706717,0.00028993576,0.000010130106,0.000011408128,0.000413354],"genre_scores_gemma":[0.98127306,0.017817004,0.00005400867,0.00045449162,0.00009657964,0.0000023615412,0.000005109464,0.000029673774,0.00026773717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977446,0.00044556902,0.0008906359,0.00014342352,0.0003200802,0.00045565233],"domain_scores_gemma":[0.9984137,0.00018241021,0.0005582572,0.000542452,0.00024895568,0.000054218635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006693137,0.00024764848,0.00069026917,0.00033596277,0.00020051026,0.000008373033,0.00042154055,0.00016877419,0.00016736265],"category_scores_gemma":[0.000034381148,0.00016521227,0.00028897173,0.00038913824,0.00047723769,0.00013764543,0.000078442645,0.00080226175,0.000030252588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013850391,0.0006691752,0.5629443,0.000023847502,0.00029969707,0.00022346276,0.0050018206,9.794506e-7,0.41199303,0.0000028690538,0.0013680034,0.0036224236],"study_design_scores_gemma":[0.0076141697,0.0018332915,0.8815743,0.00007763935,0.000052473206,0.0010059956,0.00079641707,0.000007440015,0.10585609,0.000013440091,0.0010239157,0.00014483403],"about_ca_topic_score_codex":0.0009896369,"about_ca_topic_score_gemma":0.00001774391,"teacher_disagreement_score":0.31862998,"about_ca_system_score_codex":0.00029132335,"about_ca_system_score_gemma":0.00033780534,"threshold_uncertainty_score":0.67371607},"labels":[],"label_agreement":null},{"id":"W2162527475","doi":"10.1136/jech.2004.020404","title":"Public health practitioners can learn from the weather forecasters","year":2004,"lang":"en","type":"article","venue":"Journal of Epidemiology & Community Health","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Canada; University of Ottawa","funders":"National Health and Medical Research Council; Medical Research Council; University of Edinburgh","keywords":"Immunostaining; Antibody; Medicine; Molecular biology; Immunohistochemistry; Pathology; Internal medicine; Biology; Immunology","score_opus":0.24716937637306471,"score_gpt":0.4119884672841188,"score_spread":0.1648190909110541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162527475","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33762372,0.009102739,0.0022974142,0.64984196,0.000467833,0.00027491953,0.000023547376,0.00001814557,0.00034971078],"genre_scores_gemma":[0.82335055,0.0073077534,0.0039480054,0.16489705,0.0003586047,0.000004146889,0.000052666648,0.000023975022,0.00005723199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99371797,0.0040161023,0.0013605244,0.00013240095,0.00019650934,0.000576474],"domain_scores_gemma":[0.99335545,0.003299034,0.0019379846,0.00074516184,0.00019115735,0.00047122742],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01662999,0.00017528265,0.0009248482,0.00013697204,0.0007445567,0.000012274124,0.00037997364,0.00013109176,0.00010892919],"category_scores_gemma":[0.002806774,0.00010864801,0.00031082137,0.00024415785,0.00038810074,0.0001317779,0.00005217399,0.002340243,0.0000061762153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00606375,0.0029596088,0.44506085,0.0003367713,0.0033990191,0.00003890703,0.038743623,0.00044913782,0.00035224526,0.0039711595,0.15751049,0.34111443],"study_design_scores_gemma":[0.007132994,0.00613811,0.54502416,0.0009220347,0.000059968315,0.0010393219,0.012682313,0.000021889362,0.000011238211,0.006847687,0.41993383,0.0001864752],"about_ca_topic_score_codex":0.068781845,"about_ca_topic_score_gemma":0.021167835,"teacher_disagreement_score":0.48572683,"about_ca_system_score_codex":0.0016052643,"about_ca_system_score_gemma":0.0038023603,"threshold_uncertainty_score":0.9999614},"labels":[],"label_agreement":null},{"id":"W2162794483","doi":"10.1007/s10549-015-3269-7","title":"The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis","year":2015,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Exemestane; Breast cancer; Internal medicine; Oncology; Tamoxifen; Adjuvant; Immune system; Endocrine system; FOXP3; Hormone; Hormone receptor; Cancer; Gastroenterology; Immunology","score_opus":0.019819838874036568,"score_gpt":0.31346079668735405,"score_spread":0.2936409578133175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162794483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97049856,0.02463632,2.665889e-7,0.0008464553,0.000015018959,0.0028643298,0.001072781,0.000014305338,0.000051951272],"genre_scores_gemma":[0.9839968,0.014512981,0.0000075253306,0.000013660539,0.000036445097,0.0011909734,0.0000732952,0.000028670607,0.0001396672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99774295,0.00029446415,0.00034063726,0.00052780414,0.0006054999,0.00048866845],"domain_scores_gemma":[0.99857306,0.00018676296,0.00013049565,0.00026294307,0.00057376764,0.00027297786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003689321,0.00031055245,0.00062999234,0.00032131036,0.00020302973,0.00005831403,0.00007516514,0.000034815974,0.00001675607],"category_scores_gemma":[0.000012630795,0.00016290102,0.000042608233,0.0009978904,0.0005731219,0.00010922499,0.000060542527,0.00016572338,3.500767e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08502907,0.0033746134,0.8684005,0.000016177188,0.0046114083,0.00004983245,0.002059792,0.0000029715125,0.00100586,0.0000025545844,0.000026886546,0.03542029],"study_design_scores_gemma":[0.019741103,0.027384188,0.9481418,0.00017792168,0.0006516486,0.00006950229,0.0029679576,0.000060457864,0.0006232877,0.000005313142,0.000029472134,0.00014733917],"about_ca_topic_score_codex":0.063344784,"about_ca_topic_score_gemma":0.004749545,"teacher_disagreement_score":0.07974127,"about_ca_system_score_codex":0.00063327944,"about_ca_system_score_gemma":0.00042335177,"threshold_uncertainty_score":0.9428925},"labels":[],"label_agreement":null},{"id":"W2163800023","doi":"10.2174/187152806778256089","title":"The TGF-&amp;#946; 1/Foxp3 Regulatory Axis in Immune Self-Tolerance: Implications for Health and Disease","year":2006,"lang":"en","type":"review","venue":"Inflammation & Allergy - Drug Targets","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; Canada Research Chairs; McGill University","keywords":"FOXP3; Peripheral tolerance; IL-2 receptor; Immune tolerance; Immune system; Transcription factor; Regulatory T cell; Transforming growth factor; Immunology; Population; Biology; Disease; Cytokine; Cancer research; Cell biology; T cell; Medicine; Genetics; Gene; Internal medicine","score_opus":0.023217044903484536,"score_gpt":0.32902099854541117,"score_spread":0.30580395364192664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163800023","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001881099,0.9858232,0.0001160636,0.009788603,0.00031871378,0.0033339947,0.00012818867,0.00012681205,0.0001762987],"genre_scores_gemma":[0.00009986193,0.9932387,0.00054889,0.00031241533,0.0004625929,0.0018476727,0.0016555745,0.00008827507,0.0017460558],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99690586,0.00021180928,0.0015503517,0.00055446976,0.0002683942,0.0005091275],"domain_scores_gemma":[0.9974945,0.0003272357,0.0008489948,0.0008740455,0.00015199008,0.00030322274],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000870928,0.00049037626,0.0011898833,0.000258556,0.0004912602,0.00007760291,0.0002499915,0.00020921836,0.000017912818],"category_scores_gemma":[0.0001135029,0.00036660722,0.0005164564,0.000353724,0.00014563311,0.0001373233,0.000051623872,0.00031069317,0.000010368159],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005111418,0.00012365068,0.00006335593,0.0100755235,0.0005112211,0.0000021407104,0.00055131846,0.000010195149,0.000007742587,0.0012720571,0.023962777,0.96290886],"study_design_scores_gemma":[0.0014247292,0.00003984256,0.0036662188,0.0035795553,0.00011548844,0.000013697113,0.000020966176,0.000026207996,0.0000012795919,0.00049523654,0.9902839,0.00033284957],"about_ca_topic_score_codex":0.00012001958,"about_ca_topic_score_gemma":0.00048400406,"teacher_disagreement_score":0.9663212,"about_ca_system_score_codex":0.0005934088,"about_ca_system_score_gemma":0.0017314875,"threshold_uncertainty_score":0.9998786},"labels":[],"label_agreement":null},{"id":"W2166662937","doi":"10.1056/nejmoa1504030","title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"National Cancer Institute","keywords":"Nivolumab; Ipilimumab; Medicine; Melanoma; Oncology; Metastatic melanoma; Internal medicine; Dermatology; Immunotherapy; Cancer research; Cancer","score_opus":0.036930186456582546,"score_gpt":0.29790483512648624,"score_spread":0.2609746486699037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166662937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97747844,0.006373357,0.000075603806,0.014499058,0.00042379939,0.00017658275,9.4678717e-7,0.000012284955,0.00095991255],"genre_scores_gemma":[0.9934939,0.002271473,0.0003248501,0.001154035,0.0011816771,0.0000010074001,0.000003754159,0.00001929427,0.0015500088],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99870986,0.00008286629,0.00055625994,0.00011740396,0.00035758008,0.00017604828],"domain_scores_gemma":[0.99902546,0.00012857353,0.00021769828,0.00013607544,0.00014642622,0.00034574818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089454395,0.00015236282,0.00057960156,0.00029395256,0.000018909463,0.00000817655,0.00007915643,0.000078425306,0.00026984236],"category_scores_gemma":[0.0002019967,0.000085492866,0.000043158514,0.00029034002,0.00012191275,0.000082793485,0.000008885978,0.00024918962,0.000001576891],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21288332,0.00028113934,0.079466075,0.000057888705,0.0004624344,0.0018392024,0.0068590064,0.0000062384684,0.01006321,0.000041130446,0.027082203,0.6609582],"study_design_scores_gemma":[0.7747108,0.02703359,0.076209016,0.0013665326,0.00023722404,0.005967267,0.0015777284,0.00019017029,0.0012021614,0.00067715184,0.110592686,0.00023567548],"about_ca_topic_score_codex":0.00062965957,"about_ca_topic_score_gemma":0.00023300403,"teacher_disagreement_score":0.6607225,"about_ca_system_score_codex":0.00012220358,"about_ca_system_score_gemma":0.00040093248,"threshold_uncertainty_score":0.3486298},"labels":[],"label_agreement":null},{"id":"W2167510443","doi":"10.1158/1538-7445.tumimm2012-a88","title":"Abstract A88: Identification of factors modulating sensitivity to T cell infiltration in the breast cancer setting via next-generation sequencing.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Breast cancer; Immune system; Infiltration (HVAC); CD8; Immunohistochemistry; Medicine; Immunotherapy; Pathology; Transcriptome; Cancer; Cancer research; Biology; Immunology; Internal medicine; Gene; Gene expression","score_opus":0.1369984323469261,"score_gpt":0.3841539225332614,"score_spread":0.2471554901863353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167510443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953507,0.00021982146,0.00017908862,0.0028433453,0.00011514038,0.0011136206,0.000033290922,0.000013270605,0.0001317188],"genre_scores_gemma":[0.9989984,0.0001027065,0.0000448842,0.00018802313,0.0002822649,0.00025447365,0.000036502046,0.00001728894,0.000075431424],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998149,0.00022146715,0.000412587,0.00027400258,0.00063099485,0.00031199804],"domain_scores_gemma":[0.9988703,0.00016707118,0.0001305677,0.00029048155,0.00047747305,0.000064089196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019041145,0.000112102665,0.0001603548,0.00022521077,0.00015628811,0.00009684744,0.00009988221,0.00008182755,0.00025258015],"category_scores_gemma":[0.00007180126,0.00008339339,0.00005377143,0.0007137549,0.000077447345,0.00031812277,0.000021905624,0.000327501,0.000010498731],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009512969,0.000036273996,0.022493817,0.000109755936,0.000015271065,0.0000016527698,0.002888549,0.0008402648,0.9407255,0.0000023826362,0.00047696102,0.03231446],"study_design_scores_gemma":[0.00033833165,0.00003638518,0.55118465,0.00013064929,0.00000740886,0.0000050694034,0.0016178407,0.006273366,0.4402795,0.000012523908,0.000032593594,0.00008167058],"about_ca_topic_score_codex":0.043252826,"about_ca_topic_score_gemma":0.0028792624,"teacher_disagreement_score":0.5286908,"about_ca_system_score_codex":0.00069651287,"about_ca_system_score_gemma":0.00036521023,"threshold_uncertainty_score":0.96311826},"labels":[],"label_agreement":null},{"id":"W2168572010","doi":"10.1158/1078-0432.ccr-12-0234","title":"CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27− Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":547,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Antigen; CD20; Biology; CD8; Immunology; Tumor-infiltrating lymphocytes; Ovarian cancer; CD5; Cancer research; Cancer","score_opus":0.14974751668996145,"score_gpt":0.4592862070979238,"score_spread":0.30953869040796234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168572010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98867476,0.0063742213,0.000008128084,0.0018934392,0.0002515173,0.0014402557,0.000022651258,0.00004510469,0.0012899446],"genre_scores_gemma":[0.9941526,0.0014331848,0.0010355331,0.0008222764,0.0010854653,0.00054763467,0.000008539075,0.00007778152,0.00083698105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99596477,0.0006402156,0.000715738,0.00071315665,0.00082552235,0.0011405947],"domain_scores_gemma":[0.9979576,0.00050133886,0.00013443314,0.0004694541,0.00032395014,0.0006132109],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0044572004,0.00027576188,0.00063643843,0.00018362058,0.00021645005,0.000091271235,0.00023719552,0.00025878914,0.0011049699],"category_scores_gemma":[0.00021706661,0.00020192095,0.000101676276,0.0006107337,0.00088154746,0.00033043293,0.00011570112,0.0011227177,0.000017546994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022709528,0.0011977644,0.85399616,0.00036409462,0.00027467287,0.00007942126,0.0021986794,0.000007919507,0.03142251,0.000033872882,0.00079545967,0.086919926],"study_design_scores_gemma":[0.01867274,0.0059556304,0.8619871,0.0021619303,0.00020088481,0.000074196214,0.002489716,0.0009659861,0.089592285,0.000113557595,0.016823763,0.00096217846],"about_ca_topic_score_codex":0.00964436,"about_ca_topic_score_gemma":0.0045910887,"teacher_disagreement_score":0.08595774,"about_ca_system_score_codex":0.0005120459,"about_ca_system_score_gemma":0.001442585,"threshold_uncertainty_score":0.99980813},"labels":[],"label_agreement":null},{"id":"W2169351454","doi":"10.1093/annonc/mdv182","title":"A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors","year":2015,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":247,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Adverse effect; Tolerability; Clinical trial; Internal medicine; Regimen; MEDLINE; Oncology","score_opus":0.33926319126792126,"score_gpt":0.5585464306597261,"score_spread":0.21928323939180483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169351454","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038793348,0.99193555,8.215775e-7,0.00037408818,0.0007814871,0.005647202,0.00003354868,0.000012529042,0.0008268476],"genre_scores_gemma":[0.0003068514,0.99888176,0.000058091122,0.00013819354,0.00008027522,0.0002009501,0.00011288898,0.00004585079,0.00017514123],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9431364,0.005513553,0.050073028,0.0004287443,0.0005197278,0.0003285604],"domain_scores_gemma":[0.93317944,0.0020703159,0.062756464,0.001050698,0.0008246269,0.00011846349],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.11638736,0.00044787323,0.02276523,0.00049805234,0.000011927089,0.0000013092324,0.00031953838,0.0010042222,0.00015896643],"category_scores_gemma":[0.051485706,0.0003038167,0.007784983,0.0008677396,0.00033974912,0.000042719254,0.00013315697,0.00072811573,0.0000082451925],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005036207,0.0006701205,0.000008265635,0.7606428,0.0025925334,0.000081771504,0.00009041876,8.686374e-8,0.00004381836,0.00000607287,0.00052809267,0.23483239],"study_design_scores_gemma":[0.0024823037,0.0027222633,0.000031586405,0.8673376,0.0050948444,0.00027757118,0.000100669124,9.0945184e-7,0.00010213708,0.000014769307,0.12163946,0.00019589161],"about_ca_topic_score_codex":0.00023373943,"about_ca_topic_score_gemma":0.000007109828,"teacher_disagreement_score":0.23463649,"about_ca_system_score_codex":0.00022792492,"about_ca_system_score_gemma":0.0036782487,"threshold_uncertainty_score":0.9999414},"labels":[],"label_agreement":null},{"id":"W2171898561","doi":"10.1186/s13000-014-0204-x","title":"Medullary colon cancer presenting with total necrosis of all regional lymph node metastases: morphologic description of a presumed immune-mediated event","year":2014,"lang":"en","type":"article","venue":"Diagnostic Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medullary cavity; Pathology; Lymph node; Medicine; Adenocarcinoma; Colorectal cancer; Cancer; Histology; Lymph; Internal medicine","score_opus":0.023901024231911757,"score_gpt":0.2758838694810149,"score_spread":0.25198284524910314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171898561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941089,0.0035384884,0.00060194643,0.0007473966,0.00022144963,0.0005443642,0.00011629136,0.00003373001,0.00008742672],"genre_scores_gemma":[0.9968936,0.0010136937,0.0008860373,0.0005647016,0.000052016676,0.00023358293,0.0002607542,0.000025156425,0.000070446236],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99818784,0.00027727708,0.0005812031,0.00033274107,0.00029125236,0.0003296771],"domain_scores_gemma":[0.99787086,0.0010298108,0.00047790626,0.00035462112,0.0001883501,0.00007844039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052727986,0.00020568987,0.0006233224,0.00015168301,0.000039478255,0.0000049989035,0.00012491262,0.00016392687,0.00013779388],"category_scores_gemma":[0.0010663823,0.00015850869,0.00015759852,0.00023549203,0.00042684237,0.00006205208,0.000055180175,0.00012704606,0.000003277061],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005001023,0.0009472482,0.30898964,0.00042499168,0.00073182886,0.00026615,0.0010324038,0.00033165826,0.67868173,0.000042165702,0.001009894,0.0025412762],"study_design_scores_gemma":[0.0068061943,0.0011071598,0.95552003,0.00047372843,0.00067573955,0.0005873376,0.00016834088,0.0006107519,0.033269886,0.00005849124,0.0004998626,0.00022248487],"about_ca_topic_score_codex":0.0011345362,"about_ca_topic_score_gemma":0.000048140726,"teacher_disagreement_score":0.6465304,"about_ca_system_score_codex":0.000083179584,"about_ca_system_score_gemma":0.0001685013,"threshold_uncertainty_score":0.64637965},"labels":[],"label_agreement":null},{"id":"W2172841661","doi":"10.1016/j.ejcsup.2015.08.017","title":"T93","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer Supplements","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tumor microenvironment; Metastasis; Immune system; Oncology; FOXP3; Chemotherapy; Primary tumor; Cytokine; Breast cancer; Cancer; Cancer research; Internal medicine; Immunology","score_opus":0.050557843673313306,"score_gpt":0.3394336238279792,"score_spread":0.2888757801546659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172841661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93003374,0.016103597,0.0007962962,0.008464921,0.0036676456,0.00029838688,0.000049157206,0.000029349172,0.0405569],"genre_scores_gemma":[0.9939479,0.00077529857,0.0011389903,0.0016837787,0.00088424556,9.56951e-7,0.0000052088976,0.000029225588,0.0015343915],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99887455,0.00010191423,0.00040889077,0.00007379013,0.0003900907,0.0001507769],"domain_scores_gemma":[0.999187,0.0000064299925,0.00024535623,0.00012420138,0.00022866517,0.00020834609],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00078274315,0.00008735213,0.00017688035,0.000089763984,0.000021894377,0.000017924993,0.00012835208,0.000008739454,0.0011413019],"category_scores_gemma":[0.000022973396,0.00006480878,0.00011396558,0.000109924906,0.00003352112,0.000091885624,0.000024221712,0.00012564794,0.00003248444],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006188999,0.00019579855,0.0897434,0.000036809313,0.00083882816,0.0009922382,0.001375369,0.000010823675,0.009632147,0.000012491029,0.6991048,0.19186834],"study_design_scores_gemma":[0.008429155,0.0010768679,0.028448572,0.0001462567,0.00009763497,0.00019434834,0.00024091457,0.000002894042,0.0037185417,0.000009727683,0.9575561,0.00007897902],"about_ca_topic_score_codex":0.000025162319,"about_ca_topic_score_gemma":0.0000070002193,"teacher_disagreement_score":0.25845134,"about_ca_system_score_codex":0.00013597851,"about_ca_system_score_gemma":0.00023351192,"threshold_uncertainty_score":0.9997718},"labels":[],"label_agreement":null},{"id":"W2173070859","doi":"10.1186/2051-1426-3-s2-p259","title":"Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM)","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université de Montréal; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Ipilimumab; Carboplatin; Medicine; Paclitaxel; Metastatic melanoma; Internal medicine; Oncology; Stage (stratigraphy); Melanoma; Biomarker; Nivolumab; Chemotherapy; Immunotherapy; Cancer; Cisplatin; Cancer research","score_opus":0.03410340619736896,"score_gpt":0.33195909338164753,"score_spread":0.2978556871842786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2173070859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98197407,0.015306121,0.00009994563,0.00010528908,0.000265175,0.001958613,0.0002392466,0.000011934316,0.000039606108],"genre_scores_gemma":[0.99753004,0.00071019767,0.0007014645,0.000074468764,0.000035660603,0.00012025366,0.000029650477,0.000077018325,0.0007212571],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99739337,0.00012233759,0.0010640537,0.00031389523,0.0007281774,0.0003781815],"domain_scores_gemma":[0.99781746,0.00018499499,0.00096138497,0.00038055924,0.00051449455,0.00014110893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071755395,0.00036605718,0.0011160002,0.00035289713,0.00013669538,0.000037427126,0.00018906809,0.000085963664,0.00035053],"category_scores_gemma":[0.00003324106,0.00021915945,0.00012340161,0.00050359755,0.00020609667,0.00028619712,0.000030898915,0.00028249063,1.4335997e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67901665,0.0076588574,0.19069134,0.00016874347,0.0072400826,0.000048613598,0.016364,0.00009147608,0.03314797,0.0000030003873,0.0002630528,0.06530621],"study_design_scores_gemma":[0.52905244,0.11956892,0.31930456,0.0021452704,0.0010531426,0.000052149517,0.015394424,0.00050635834,0.008979232,0.00006331206,0.003128497,0.00075169414],"about_ca_topic_score_codex":0.005229787,"about_ca_topic_score_gemma":0.0017642741,"teacher_disagreement_score":0.14996421,"about_ca_system_score_codex":0.0002690943,"about_ca_system_score_gemma":0.0006396037,"threshold_uncertainty_score":0.8937063},"labels":[],"label_agreement":null},{"id":"W2175480754","doi":"10.1001/jamaoncol.2015.4685","title":"PD-L1 Testing in Cancer","year":2015,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Oncology; Internal medicine","score_opus":0.12754339395627157,"score_gpt":0.3985948787585825,"score_spread":0.27105148480231095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2175480754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92222416,0.0016896148,0.0000075462012,0.01292841,0.0005428139,0.00017971903,0.0000024280469,0.000037398444,0.06238792],"genre_scores_gemma":[0.9891535,0.000090404545,0.0012554765,0.0073463446,0.00046488913,0.000056828605,0.000004083371,0.000012747876,0.0016157102],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993701,0.000044637927,0.00017793805,0.00013190928,0.00009008239,0.00018531086],"domain_scores_gemma":[0.9995781,0.000101011865,0.00005353067,0.000110217814,0.000077551726,0.00007956524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035562392,0.00006502014,0.00019475016,0.00007624747,0.00001361356,0.0000053999406,0.00005041582,0.00013212644,0.00016823581],"category_scores_gemma":[0.00025442833,0.00005410543,0.000029584946,0.0002527772,0.00005905236,0.000040755993,0.000020868218,0.00016733554,0.000030041949],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003890615,0.00024278185,0.21174966,0.00002934516,0.000048343525,0.0002929324,0.001048976,0.000011894261,0.016858963,0.00003896666,0.040998224,0.7247893],"study_design_scores_gemma":[0.008962834,0.0012892316,0.33545008,0.00009689325,0.000023305278,0.00016992474,0.00043626656,0.0002628586,0.0010124,0.00013398637,0.6520588,0.000103426864],"about_ca_topic_score_codex":0.002656299,"about_ca_topic_score_gemma":0.0010826987,"teacher_disagreement_score":0.72468585,"about_ca_system_score_codex":0.00061178673,"about_ca_system_score_gemma":0.0007012192,"threshold_uncertainty_score":0.40155473},"labels":[],"label_agreement":null},{"id":"W2177919716","doi":"10.1158/2326-6066.cir-15-0051","title":"Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer","year":2015,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; Public Health Ontario; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Breast cancer; Medicine; Oncology; Internal medicine; Proportional hazards model; Univariate analysis; Survival analysis; Pathology; Cancer; Multivariate analysis; Gastroenterology","score_opus":0.055572904644834754,"score_gpt":0.3663105896333311,"score_spread":0.3107376849884963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2177919716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831502,0.011122397,0.0000018580694,0.0030201578,0.0009997183,0.0005538918,0.00029480425,0.000020858035,0.0008361479],"genre_scores_gemma":[0.99418783,0.0044593336,0.000013761164,0.000054615735,0.00019728809,0.00018487276,0.000036647838,0.000031867017,0.0008338105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738634,0.0004001343,0.0005397737,0.0003547872,0.00078193634,0.0005370615],"domain_scores_gemma":[0.9979799,0.00013651037,0.00015770594,0.0006889541,0.00085339556,0.00018352851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013727222,0.00017267538,0.0005093421,0.0005007539,0.00004232313,0.000009984653,0.00044401918,0.00018025834,0.00058649335],"category_scores_gemma":[0.00015496925,0.00015358129,0.0001087219,0.001037103,0.0010763372,0.00012774237,0.0001818372,0.00041142997,0.000009076744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030743344,0.00043754003,0.60743284,0.00025581763,0.00047158627,0.000032813496,0.0010022732,0.000042366733,0.34887183,0.000108680695,0.0053055496,0.005295377],"study_design_scores_gemma":[0.013778508,0.0010827564,0.6094215,0.0008058834,0.000098176926,0.000035627316,0.0016227411,0.000050130137,0.36979392,0.00044881273,0.0025979201,0.0002640514],"about_ca_topic_score_codex":0.011290128,"about_ca_topic_score_gemma":0.00023738557,"teacher_disagreement_score":0.0209221,"about_ca_system_score_codex":0.0008244256,"about_ca_system_score_gemma":0.0034754984,"threshold_uncertainty_score":0.9952938},"labels":[],"label_agreement":null},{"id":"W2193279488","doi":"10.6004/jnccn.2014.0105","title":"Ipilimumab-Induced Hypophysitis and Uveitis in a Patient With Metastatic Melanoma and a History of Ipilimumab-Induced Skin Rash","year":2014,"lang":"en","type":"article","venue":"Journal of the National Comprehensive Cancer Network","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"National Comprehensive Cancer Network; Pfizer","keywords":"Ipilimumab; Medicine; Rash; Hypophysitis; Uveitis; Adverse effect; Melanoma; Internal medicine; Immunology; Nivolumab; Immune system; Dermatology; Oncology; Immunotherapy; Pituitary gland; Cancer research","score_opus":0.02845236996536298,"score_gpt":0.26629667061326306,"score_spread":0.23784430064790008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2193279488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98867315,0.00940938,0.000015006478,0.0008526889,0.0005215543,0.0002857208,0.000007244462,0.0000035112184,0.00023171924],"genre_scores_gemma":[0.99694926,0.00044026438,0.0003968909,0.0018361162,0.00029916404,0.000012089928,0.0000013086741,0.000018549845,0.000046333254],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99837136,0.00019107918,0.0005159008,0.000163644,0.0005835412,0.00017446777],"domain_scores_gemma":[0.99812645,0.00033864332,0.0006557012,0.00010822597,0.00068998436,0.00008100169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021924605,0.00017122635,0.00051192933,0.00014411352,0.000050904826,0.000009553368,0.00009700682,0.000050834595,0.000035186556],"category_scores_gemma":[0.00005264663,0.00011454069,0.00011684683,0.0002492094,0.00014095688,0.00009665321,0.000041755306,0.00028408758,1.9074092e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06416489,0.0015719068,0.05435269,0.0017612501,0.008491883,0.00031436648,0.015605278,0.009718775,0.38105363,0.001178957,0.0743862,0.38740018],"study_design_scores_gemma":[0.028686415,0.005153669,0.91779363,0.00425533,0.00068067934,0.0023501255,0.0007351675,0.0027171783,0.004090056,0.0016708627,0.031261817,0.00060507096],"about_ca_topic_score_codex":0.00018407451,"about_ca_topic_score_gemma":0.00016952379,"teacher_disagreement_score":0.86344093,"about_ca_system_score_codex":0.00066353136,"about_ca_system_score_gemma":0.00046450205,"threshold_uncertainty_score":0.46708336},"labels":[],"label_agreement":null},{"id":"W2194675780","doi":"10.1158/2326-6066.cir-15-0141","title":"Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma","year":2015,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Melanoma; Immunotherapy; Pathology; Immunology; Oncology; Immune system; Cancer research","score_opus":0.11306137541957614,"score_gpt":0.4120534297064699,"score_spread":0.2989920542868938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2194675780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635419,0.025927322,0.00019131004,0.007101906,0.00029184815,0.0014612237,0.000048732752,0.000056357967,0.001379378],"genre_scores_gemma":[0.98077154,0.002104359,0.0004520302,0.00021498419,0.00028279438,0.0029893755,0.000059523067,0.000044860306,0.0130805345],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998486,0.000113706665,0.00019482327,0.00035336337,0.00030323907,0.0005489101],"domain_scores_gemma":[0.9986441,0.00010264939,0.000044771914,0.00038018046,0.0007132516,0.000115014554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005273543,0.0001571371,0.00028634773,0.00024513717,0.00012743103,0.000024829233,0.00010977045,0.00016645507,0.00021593289],"category_scores_gemma":[0.000034694207,0.00011083076,0.000086228545,0.00035922238,0.00043596476,0.00008464833,0.00003167595,0.0002041235,0.000040054543],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2176852,0.000985485,0.099527374,0.0001657889,0.0042815767,0.00023285155,0.004746503,0.0000048442243,0.05892446,0.0002730338,0.017979298,0.59519356],"study_design_scores_gemma":[0.044303793,0.030658562,0.09670339,0.00029742016,0.0003005619,0.0003282166,0.0021894702,0.00024147013,0.055916727,0.00038760187,0.76816386,0.00050893746],"about_ca_topic_score_codex":0.0008605258,"about_ca_topic_score_gemma":0.00058587414,"teacher_disagreement_score":0.75018454,"about_ca_system_score_codex":0.001353709,"about_ca_system_score_gemma":0.0012553041,"threshold_uncertainty_score":0.45195472},"labels":[],"label_agreement":null},{"id":"W2201788027","doi":"10.1007/s11523-015-0396-3","title":"Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis","year":2015,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Prostate; Adenocarcinoma; Prostate adenocarcinoma; Prostatic adenocarcinoma; Pathology; Lymphocyte; Castration; Prostate cancer; Oncology; Internal medicine; Cancer","score_opus":0.03854617420081482,"score_gpt":0.3205983842461482,"score_spread":0.28205221004533343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2201788027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927978,0.005708605,0.000053342897,0.00028850822,0.00016489488,0.00036233966,0.00010014793,0.000043493103,0.00048090093],"genre_scores_gemma":[0.99675333,0.0002035392,0.0019828132,0.00037419438,0.000113233684,0.000042483884,0.00031770862,0.000020579322,0.0001921393],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99849606,0.00022344638,0.00042550525,0.00037722944,0.00025969424,0.00021804786],"domain_scores_gemma":[0.99891865,0.00008256857,0.00021914575,0.00036761924,0.00017905935,0.00023292491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032285275,0.00018264461,0.0005457874,0.0002568861,0.000055062057,0.000011297275,0.00008719926,0.00018870452,0.00023566424],"category_scores_gemma":[0.00005036666,0.00015105557,0.00007360542,0.00036252636,0.00017784137,0.00011696638,0.000031501986,0.00011985935,0.000010448957],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027095536,0.00045810494,0.01514818,0.00003795163,0.0006354932,0.00021948467,0.0058912346,0.000042372994,0.9364212,0.000012135086,0.0012072597,0.01283104],"study_design_scores_gemma":[0.02086211,0.013595516,0.41939357,0.00013054667,0.0018153911,0.000035161647,0.007088773,0.00045300595,0.5180161,0.00024492727,0.017854411,0.0005104787],"about_ca_topic_score_codex":0.00083910936,"about_ca_topic_score_gemma":0.00067350996,"teacher_disagreement_score":0.41840512,"about_ca_system_score_codex":0.00030664422,"about_ca_system_score_gemma":0.00053560146,"threshold_uncertainty_score":0.61598676},"labels":[],"label_agreement":null},{"id":"W2204209053","doi":"10.1136/gutjnl-2015-310814","title":"Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma","year":2015,"lang":"en","type":"article","venue":"Gut","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":469,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Biomedical Research Council; National Medical Research Council; Medical Research Council; Servier; Agency for Science, Technology and Research; Genentech; Partenariat Canadien Contre Le Cancer","keywords":"Flow cytometry; CD40; Hepatocellular carcinoma; CD38; Immunophenotyping; Granzyme B; Cancer research; Immunohistochemistry; Immunofluorescence; Biology; CD19; Granzyme; Pathology; CD3; Immune system; CD34; T cell; Medicine; Immunology; CD8; Cytotoxic T cell; Perforin; Stem cell; In vitro; Antibody","score_opus":0.03675056090626577,"score_gpt":0.2951979399451888,"score_spread":0.258447379038923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2204209053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99668396,0.001066409,0.000076963915,0.00048438951,0.00017800403,0.00042136645,0.000008020822,0.000016496511,0.0010644206],"genre_scores_gemma":[0.99934167,0.000023090244,0.00018175987,0.00010670534,0.00018032396,0.000010534936,0.0000078257135,0.000010246269,0.0001378647],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993032,0.000054451175,0.00022708888,0.000119491866,0.00017660025,0.00011915371],"domain_scores_gemma":[0.9994972,0.000075985525,0.00014107882,0.00015073057,0.00006763008,0.00006739737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034318064,0.00008786295,0.00019181108,0.0000340774,0.000042141597,0.000016177575,0.000050345523,0.000049947743,0.000017830065],"category_scores_gemma":[0.000018078123,0.00005400868,0.000053496773,0.000073741365,0.00008177843,0.00005554896,0.00002027109,0.00011360522,0.0000054042225],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005708251,0.00002756953,0.10789791,0.00004832629,0.000053294145,0.0000074582354,0.00075439806,6.658606e-7,0.8741285,0.000005305048,0.0008238926,0.015681837],"study_design_scores_gemma":[0.0030519448,0.0007660361,0.03492854,0.00021551107,0.00013941267,0.000027419754,0.00092396064,0.00088374177,0.94687873,0.00002266857,0.012056352,0.00010567437],"about_ca_topic_score_codex":0.00019617441,"about_ca_topic_score_gemma":0.0000032271857,"teacher_disagreement_score":0.07296937,"about_ca_system_score_codex":0.000026807038,"about_ca_system_score_gemma":0.000063541025,"threshold_uncertainty_score":0.22024101},"labels":[],"label_agreement":null},{"id":"W2219463573","doi":"10.1016/s1470-2045(15)00554-9","title":"TIME for a successful cancer vaccine in NSCLC?","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Pembrolizumab; Nivolumab; Docetaxel; Oncology; Lung cancer; Internal medicine; Clinical trial; Chemotherapy; Clinical endpoint; Cancer; Immunotherapy; Phases of clinical research","score_opus":0.055105661926996514,"score_gpt":0.3677829949587555,"score_spread":0.312677333031759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2219463573","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00582178,0.005293079,0.0000067318833,0.97964585,0.0010450643,0.0013978537,0.00018367542,0.00006118299,0.0065447995],"genre_scores_gemma":[0.00057784293,0.0012010005,0.00015431154,0.9591843,0.018599888,0.00089670497,0.0003878122,0.00007853964,0.018919598],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99826896,0.00018501129,0.00039557568,0.00034602793,0.00020420561,0.0006002177],"domain_scores_gemma":[0.9986427,0.00038526874,0.00023566057,0.00056465244,0.0001313085,0.00004041133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009910007,0.00027226098,0.0012423524,0.00013312517,0.000040583665,0.000011674169,0.00039879195,0.0008280278,0.0008857682],"category_scores_gemma":[0.00006896558,0.00017004937,0.00017356875,0.00021374116,0.00012200652,0.000027716053,0.000053328647,0.0012285657,0.00006980103],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007467036,0.000042667732,0.00030634692,0.00021601163,0.000262603,0.0001601908,0.00024411053,0.0000013811352,0.00034504873,0.0000028046218,0.9783917,0.012560111],"study_design_scores_gemma":[0.011687802,0.0007709252,0.0007434237,0.00021826389,0.00020068858,0.000107953754,0.000022462884,0.000060684506,0.000044492717,0.00017676842,0.98576593,0.00020058679],"about_ca_topic_score_codex":0.0007450464,"about_ca_topic_score_gemma":0.0007935152,"teacher_disagreement_score":0.020461531,"about_ca_system_score_codex":0.0008902824,"about_ca_system_score_gemma":0.0009984811,"threshold_uncertainty_score":0.96985406},"labels":[],"label_agreement":null},{"id":"W2220506303","doi":"10.1097/jto.0000000000000526","title":"Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?","year":2015,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Immunohistochemistry; Medicine; Biomarker; Lung cancer; Companion diagnostic; Monoclonal antibody; Cancer; Oncology; Antibody; clone (Java method); Immunotherapy; Internal medicine; Pathology; Immunology; Biology","score_opus":0.049017193594614844,"score_gpt":0.4799286196516864,"score_spread":0.43091142605707156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2220506303","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025815065,0.9932495,0.0000018332926,0.001113483,0.0013781067,0.0009027026,0.000020416925,0.000009018929,0.0007434838],"genre_scores_gemma":[0.00006298845,0.9957381,0.00028833846,0.0003202287,0.00034870458,0.000098844816,0.000016958838,0.000057081103,0.0030687577],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99638826,0.0003277153,0.002044401,0.00031602677,0.00043663033,0.0004869811],"domain_scores_gemma":[0.9969886,0.0001833924,0.0019811213,0.00034630919,0.0002869179,0.00021365979],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022753845,0.0004395776,0.0034298117,0.0006325469,0.000025216446,0.000053952783,0.00036504006,0.00072600297,0.00035160757],"category_scores_gemma":[0.0000949063,0.00032916892,0.00069067697,0.00063357066,0.00013484707,0.00023119748,0.00006375289,0.0017470318,0.000010760562],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0032074566,0.0003306052,0.00013706253,0.009139209,0.000595442,0.0013918502,0.00055467756,4.216558e-7,0.00008430732,1.0428017e-7,0.008648841,0.97591],"study_design_scores_gemma":[0.001845413,0.0007492665,0.00003949075,0.043039817,0.0011091263,0.0024538708,0.00012730526,0.000004252807,0.00006566185,0.000018435014,0.9502733,0.000274108],"about_ca_topic_score_codex":0.00012488777,"about_ca_topic_score_gemma":0.000071736606,"teacher_disagreement_score":0.9756359,"about_ca_system_score_codex":0.005593837,"about_ca_system_score_gemma":0.006441243,"threshold_uncertainty_score":0.999916},"labels":[],"label_agreement":null},{"id":"W2234024195","doi":"10.1007/s00262-015-1785-2","title":"8th Annual Canadian Cancer Immunotherapy Consortium (CCIC) Symposium 2015—May 20–22, Vancouver, Canada","year":2016,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Cancer immunotherapy; Cancer; Immunotherapy; Library science; Medicine; Internal medicine; Computer science","score_opus":0.009294974100002554,"score_gpt":0.2674305215908344,"score_spread":0.25813554749083184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2234024195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42204428,0.39052698,0.00039240578,0.11619096,0.04788168,0.0057296976,0.006413855,0.0014899111,0.00933023],"genre_scores_gemma":[0.7149323,0.1830105,0.00022850398,0.029086627,0.0013083317,0.0019917178,0.00012438967,0.0008033705,0.06851425],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936076,0.0003056709,0.0014790047,0.0013980784,0.00076285587,0.0024468238],"domain_scores_gemma":[0.9956387,0.00026859046,0.0006899001,0.002001013,0.0008280385,0.00057370187],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052717864,0.0012124114,0.0015890963,0.00063855504,0.0005996,0.00006987892,0.0011160207,0.0008275993,0.009460021],"category_scores_gemma":[0.00003884998,0.0009249245,0.00057641073,0.00089179346,0.0011701011,0.0004935925,0.000079261066,0.00082687725,0.00006292167],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009263131,0.0002023022,0.017789384,0.000049196133,0.0051997635,0.00016203614,0.00056966796,0.0000090192525,0.46211123,0.000101704594,0.3650274,0.13951516],"study_design_scores_gemma":[0.015936866,0.00066627003,0.021857316,0.0005172519,0.00017109266,0.00016218964,0.00037093644,0.000005485104,0.04602073,0.000067946086,0.91294265,0.0012812505],"about_ca_topic_score_codex":0.94758916,"about_ca_topic_score_gemma":0.9801768,"teacher_disagreement_score":0.5479153,"about_ca_system_score_codex":0.0060136,"about_ca_system_score_gemma":0.017526714,"threshold_uncertainty_score":0.99932015},"labels":[],"label_agreement":null},{"id":"W2256341952","doi":"10.1200/jco.2015.63.0970","title":"Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":361,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fondation Gustave Roussy; Canadian Cancer Society Research Institute; Institut Gustave-Roussy; National Cancer Institute; Institut National Du Cancer; Princess Margaret Cancer Foundation; Sanofi","keywords":"Medicine; Lung cancer; Internal medicine; Hazard ratio; Proportional hazards model; Cisplatin; Oncology; Adjuvant; Chemotherapy; Gastroenterology; Confidence interval","score_opus":0.04683284203138601,"score_gpt":0.42856472358863434,"score_spread":0.38173188155724835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2256341952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944017,0.0015224006,0.00007802504,0.001573808,0.0009097582,0.00038953597,0.0000020817613,0.0000035527146,0.0011191614],"genre_scores_gemma":[0.9970511,0.0013736801,0.00024649952,0.00049803057,0.0005097824,0.000014898991,3.8480533e-7,0.000012102464,0.0002934831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971031,0.00042003766,0.0019190288,0.00013158927,0.00022682134,0.00019941285],"domain_scores_gemma":[0.9944416,0.0037018335,0.0013736961,0.00013423829,0.00021674675,0.00013184204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038517695,0.00010686,0.0011024148,0.00015457378,0.000013438649,0.0000033129497,0.000118597025,0.0002101078,0.00021225293],"category_scores_gemma":[0.0025026598,0.000056880905,0.00032209046,0.00019181539,0.00014295668,0.00008575125,0.00001915015,0.00030673906,0.0000035632181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03810779,0.00050814456,0.8187844,0.00027464767,0.00023354572,0.0002801115,0.00006287997,0.000010813086,0.056476016,0.0000023066802,0.0017298254,0.08352953],"study_design_scores_gemma":[0.067854345,0.04149085,0.8413135,0.0025060747,0.0007073568,0.00031455114,0.000033437154,0.0003564497,0.03811988,0.00003402751,0.0071102204,0.00015933107],"about_ca_topic_score_codex":0.00016846383,"about_ca_topic_score_gemma":0.0001915559,"teacher_disagreement_score":0.0833702,"about_ca_system_score_codex":0.00061850064,"about_ca_system_score_gemma":0.0036286002,"threshold_uncertainty_score":0.6436981},"labels":[],"label_agreement":null},{"id":"W2264465777","doi":"10.3111/13696998.2016.1151432","title":"Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada); McMaster University; McGill University; Golder Associates (Canada)","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Erlotinib; Nivolumab; Docetaxel; Quality-adjusted life year; Oncology; Lung cancer; Quality of life (healthcare); Cost effectiveness; Survival analysis; Internal medicine; Cancer; Immunotherapy; Epidermal growth factor receptor; Risk analysis (engineering)","score_opus":0.13854774319199728,"score_gpt":0.36274728020138175,"score_spread":0.22419953700938447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264465777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99279994,0.0018801275,0.0012908233,0.0033703344,0.00024729886,0.00036224106,0.000035436886,7.0382316e-7,0.000013110409],"genre_scores_gemma":[0.9987219,0.0006617942,0.0005178958,0.000029311419,0.000042942313,0.000008869304,0.0000012700423,0.0000089619725,0.0000070674655],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99852467,0.000035841735,0.0010345259,0.000095996336,0.00019539565,0.00011354943],"domain_scores_gemma":[0.9987001,0.00047879387,0.00053883856,0.00012102991,0.00006669628,0.00009457331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013373378,0.00009611607,0.000693582,0.0000850237,0.000013288797,0.0000023034513,0.0000997529,0.000055148153,0.000051289888],"category_scores_gemma":[0.00011935863,0.00005413628,0.00011767705,0.000023076438,0.000058718208,0.000048896185,0.00000976942,0.0000508001,4.9336847e-8],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008029884,0.00040045913,0.061296925,0.00012915075,0.0007106159,0.000001152422,0.0010097591,0.05062151,0.00086037425,0.00011197902,0.0000276606,0.87680054],"study_design_scores_gemma":[0.030407859,0.0024688123,0.047741685,0.00036560107,0.00038847598,0.00002455189,0.0014272777,0.9121131,0.0043873736,0.0002214359,0.00032011216,0.00013372698],"about_ca_topic_score_codex":0.018301222,"about_ca_topic_score_gemma":0.37507817,"teacher_disagreement_score":0.8766668,"about_ca_system_score_codex":0.000792122,"about_ca_system_score_gemma":0.0019365749,"threshold_uncertainty_score":0.988236},"labels":[],"label_agreement":null},{"id":"W2266375522","doi":"10.1038/srep10665","title":"RETRACTED ARTICLE: Tumor-specific Th2 responses inhibit growth of CT26 colon-cancer cells in mice via converting intratumor regulatory T cells to Th9 cells","year":2015,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":true,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Natural Science Foundation of China","keywords":"Colorectal cancer; Cancer research; Cancer cell; Cancer; Biology; Cell biology; Genetics","score_opus":0.020252591481691014,"score_gpt":0.2632350724266665,"score_spread":0.2429824809449755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2266375522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98842514,0.0010381737,0.000020734808,0.00054884824,0.008468544,0.0010513943,0.000013964401,0.00007218973,0.00036102548],"genre_scores_gemma":[0.9963631,0.00002325524,0.000421598,0.0004799845,0.00017283813,0.00004479738,0.000012212986,0.000044948232,0.0024372612],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99564904,0.0001842619,0.0014537526,0.0010109752,0.0010841221,0.0006178382],"domain_scores_gemma":[0.99696344,0.00011860069,0.00072696223,0.0009418664,0.00084309874,0.00040604695],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0040736035,0.0002946105,0.0005972542,0.0005288398,0.00011962642,0.000109683075,0.00019116318,0.00017170804,0.00028561288],"category_scores_gemma":[0.00021387894,0.0002685304,0.00015988712,0.0018681277,0.00053084525,0.00023182193,0.0000941764,0.00037106103,0.00004737826],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025755623,0.00025079702,0.0025775302,0.000091353366,0.000034544923,0.00068819546,0.0016204871,0.000028521321,0.92294544,0.0000028393395,0.068502456,0.00068224943],"study_design_scores_gemma":[0.0012209723,0.00017351942,0.008013434,0.0004828081,0.000037143865,0.00018359988,0.0004823136,0.00007503848,0.9803978,0.00012964188,0.008507388,0.0002963438],"about_ca_topic_score_codex":0.00031921183,"about_ca_topic_score_gemma":0.00009017663,"teacher_disagreement_score":0.059995066,"about_ca_system_score_codex":0.00047811551,"about_ca_system_score_gemma":0.0009782959,"threshold_uncertainty_score":0.9999767},"labels":[],"label_agreement":null},{"id":"W2266538010","doi":"10.1200/jop.2015.009506","title":"Immune Checkpoint Inhibition: A New Era in Lymphoma Treatment","year":2016,"lang":"en","type":"letter","venue":"Journal of Oncology Practice","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Lymphoma; Immune checkpoint; MEDLINE; Immune system; Immunotherapy; Immunology; Cancer research","score_opus":0.03336243968436687,"score_gpt":0.34616070707025215,"score_spread":0.3127982673858853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2266538010","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036418305,0.0070799477,0.00003542762,0.9746458,0.0016317795,0.00034047378,0.0000061888563,0.000010310747,0.012608247],"genre_scores_gemma":[0.0012455977,0.019576902,0.004211255,0.93453944,0.021117179,0.00002151109,0.000027035372,0.000085521475,0.019175585],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972645,0.00041476055,0.0013142496,0.0002293465,0.0004180932,0.0003590667],"domain_scores_gemma":[0.99588287,0.0010631129,0.0023328403,0.00030863925,0.00030146135,0.000111061214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010829754,0.00031145237,0.0010984852,0.0004746333,0.00004041119,0.000024161147,0.00012333774,0.0010230265,0.00081275974],"category_scores_gemma":[0.00045685636,0.0002012225,0.000533479,0.00020032939,0.0001112042,0.00037574643,0.000027010004,0.0013102036,0.000069782196],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013579522,0.00055246253,0.00003418867,0.000043451637,0.0011774385,0.027696095,0.00038058765,1.251027e-7,0.0045223315,0.0000019172853,0.66334385,0.288668],"study_design_scores_gemma":[0.021714794,0.0082107745,0.00090038806,0.0007459611,0.0007420069,0.03857328,0.00012467327,2.7389683e-7,0.0013049805,0.00005186855,0.9274546,0.00017641562],"about_ca_topic_score_codex":0.00031589338,"about_ca_topic_score_gemma":0.000022071423,"teacher_disagreement_score":0.2884916,"about_ca_system_score_codex":0.004537801,"about_ca_system_score_gemma":0.005330263,"threshold_uncertainty_score":0.9992836},"labels":[],"label_agreement":null},{"id":"W2266680384","doi":"10.1016/j.jcjo.2015.09.008","title":"Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: Case report","year":2016,"lang":"en","type":"letter","venue":"Canadian Journal of Ophthalmology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Pembrolizumab; Cataracts; Medicine; Ophthalmology; Uveitis; Internal medicine; Cancer","score_opus":0.026582145236937697,"score_gpt":0.2771705996565969,"score_spread":0.2505884544196592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2266680384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7567673,0.0022993437,5.072698e-7,0.23518977,0.0017760526,0.00036759317,0.00022767998,0.000004202113,0.0033675916],"genre_scores_gemma":[0.83012736,0.000017470567,0.000108564185,0.15825765,0.0037253362,0.000012632655,0.00007017513,0.00011070602,0.0075700847],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99744314,0.00014984624,0.000962809,0.00043763002,0.00023589461,0.0007706874],"domain_scores_gemma":[0.99718356,0.00010084429,0.0006744435,0.0005553847,0.0004233965,0.0010623876],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044340303,0.00042266076,0.0010446412,0.0009492886,0.00014437994,0.00005880173,0.00023643606,0.0010633345,0.0027518265],"category_scores_gemma":[0.00020461288,0.00034667828,0.00027459097,0.00016614214,0.00017761879,0.00013476201,0.000031420685,0.001698187,0.000022020122],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004864528,0.0000045392026,0.0006781136,0.000114422975,0.00037265875,0.76447135,0.00016003648,2.4615211e-8,0.0005540224,2.1515125e-7,0.23075752,0.0024006544],"study_design_scores_gemma":[0.0017330823,0.0012473569,0.003979142,0.00039827588,0.00015199734,0.72189486,0.000045243723,4.103593e-8,0.00013169623,0.000017154483,0.2701202,0.0002809131],"about_ca_topic_score_codex":0.011681915,"about_ca_topic_score_gemma":0.0005935594,"teacher_disagreement_score":0.076932125,"about_ca_system_score_codex":0.00063257356,"about_ca_system_score_gemma":0.0067053298,"threshold_uncertainty_score":0.9998985},"labels":[],"label_agreement":null},{"id":"W2270731020","doi":"10.1007/s00439-015-1616-8","title":"Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium","year":2015,"lang":"en","type":"article","venue":"Human Genetics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; McGill University; University of Toronto; Royal Victoria Hospital; Université Laval; Centre hospitalier universitaire de Québec","funders":"National Cancer Institute; Universitätsklinikum Hamburg-Eppendorf; Instituto de Salud Carlos III; Cancer Council South Australia; Medical Research Council; National Institutes of Health; Akershus Universitetssykehus; Guy's and St Thomas' NHS Foundation Trust; Deutschen Konsortium für Translationale Krebsforschung; Gesellschaft der Freunde der Medizinischen Hochschule Hannover; Rheinische Friedrich-Wilhelms-Universität Bonn; Ministero dello Sviluppo Economico; Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail; Institut National Du Cancer; National Health and Medical Research Council; Oulun Yliopisto; Deutsche Krebshilfe; Medizinischen Hochschule Hannover; Norges Forskningsråd; Universitetet i Bergen; Kuopion Yliopistollinen Sairaala; Ovarian Cancer Research Fund; Bundesministerium für Bildung und Forschung; Ministerio de Economía y Competitividad; Stichting Tegen Kanker; Deutsche Gesetzliche Unfallversicherung; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; King's College London; Academy of Finland; Cancer Australia; Agence Nationale de la Recherche; Robert Bosch Stiftung; Yorkshire Cancer Research; VicHealth; National Breast Cancer Foundation; Cancer Council Western Australia; European Commission; Fondation du cancer du sein du Québec; Breakthrough Breast Cancer; National Institute for Health and Care Research; Susan G. Komen; McGill University Health Centre; University of California, Irvine; Kreftforeningen; David F. and Margaret T. Grohne Family Foundation; Cancer Research UK; Hamburger Krebsgesellschaft; Itä-Suomen Yliopisto; Ministère du Développement Économique, de l’Innovation et de l’Exportation; Lon V. Smith Foundation; European Social Fund; Agency for Science, Technology and Research; Cancer Council Tasmania; Francis Crick Institute; Canadian Institutes of Health Research; Sigrid Juséliuksen Säätiö; General Secretariat for Research and Technology; Medisinske fakultet, Universitetet i Oslo; Ligue Contre le Cancer; Deutsches Krebsforschungszentrum; Breast Cancer Research Foundation; McGill University; Helsingin ja Uudenmaan Sairaanhoitopiiri; Cancer Council NSW; Susan G. Komen for the Cure; KWF Kankerbestrijding; Nordic Cancer Union; Herlev Hospital; University of Southern California; Associazione Italiana per la Ricerca sul Cancro; Beckman Research Institute, City of Hope; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Fondation de France; Universitetet i Oslo; Sundhed og Sygdom, Det Frie Forskningsråd; Cancer Council Victoria; California Department of Public Health; Haukeland Universitetssjukehus; U.S. Department of Health and Human Services; University of Cambridge","keywords":"Biology; Breast cancer; Human genetics; Genetic variation; Gene; Immunosuppression; Cancer; Genetics; Genetic association; Oncology; Bioinformatics; Genotype; Single-nucleotide polymorphism; Immunology; Medicine","score_opus":0.023883128228848225,"score_gpt":0.28878199986822195,"score_spread":0.2648988716393737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2270731020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769024,0.02028749,0.0000130407325,0.0013454016,0.00009335973,0.00049840705,0.0008384923,0.000009585321,0.000011822696],"genre_scores_gemma":[0.9961636,0.002950744,0.00003488182,0.00051525026,0.0001719999,0.00006412963,0.00004777788,0.0000142625895,0.000037359765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839264,0.00031147443,0.00044341251,0.00028229688,0.0003755382,0.00019466614],"domain_scores_gemma":[0.99867004,0.00032780404,0.00033307163,0.0003628272,0.00024830434,0.000057928373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005735895,0.00017052943,0.00039938377,0.00009842857,0.000114015806,0.000055822125,0.00011363007,0.00012613254,0.00013465069],"category_scores_gemma":[0.00004500351,0.00010544394,0.00009225171,0.0003421745,0.00014426968,0.000040385654,0.00004190996,0.00012525462,2.7401722e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007967176,0.00009730062,0.8793135,0.000018884226,0.0012074257,0.0000042416737,0.0031026693,0.00009070673,0.10596584,0.000004392234,0.00015409435,0.009244182],"study_design_scores_gemma":[0.0027639573,0.00010362219,0.9918143,0.00007544539,0.002366014,0.000016895747,0.00093881454,0.0009480604,0.0006414566,0.00004184455,0.00016801129,0.00012154439],"about_ca_topic_score_codex":0.016739083,"about_ca_topic_score_gemma":0.017917385,"teacher_disagreement_score":0.11250079,"about_ca_system_score_codex":0.0001961602,"about_ca_system_score_gemma":0.00017879179,"threshold_uncertainty_score":0.99983215},"labels":[],"label_agreement":null},{"id":"W2270816365","doi":"10.18632/oncotarget.7235","title":"Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis","year":2016,"lang":"en","type":"article","venue":"Oncotarget","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":184,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Cancer research; Immune system; Metastasis; PD-L1; Immune checkpoint; Medicine; Prostate cancer; Docetaxel; Immunotherapy; Cytotoxic T cell; Cancer; Cancer cell; Doxorubicin; Metastatic breast cancer; Programmed cell death; Immunology; Apoptosis; Breast cancer; Chemotherapy; Biology; Internal medicine; In vitro","score_opus":0.010318956986923023,"score_gpt":0.22565251283641738,"score_spread":0.21533355584949435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2270816365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931078,0.00026371435,0.00009958787,0.0022403682,0.000085639986,0.00040470314,0.000063900334,0.000037793507,0.0036964912],"genre_scores_gemma":[0.99734753,0.00004447649,0.0002658,0.00049103465,0.00003663074,0.000026000444,0.000024117264,0.000029020099,0.0017353724],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987316,0.00008689562,0.0003523646,0.00021905363,0.00037739266,0.00023267398],"domain_scores_gemma":[0.99879277,0.0001236263,0.0004194438,0.0004247905,0.00017830449,0.000061059516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004088551,0.00017889118,0.00037221584,0.000051933148,0.00007308041,0.000008594418,0.00014804608,0.0000630947,0.000494796],"category_scores_gemma":[0.00016503008,0.00008894167,0.00019211855,0.00032362284,0.00021470935,0.000087040185,0.000025220657,0.00010853114,0.000006031653],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004217824,0.000261222,0.024105376,0.00005417407,0.0003227229,0.0000045004163,0.00012062645,4.4393425e-7,0.96915597,0.000019783807,0.0012702321,0.00046715513],"study_design_scores_gemma":[0.0047244234,0.0002027312,0.32256487,0.0003995175,0.000109855784,0.0000033067586,0.00008563447,0.000005728934,0.6675857,0.000021990938,0.0041849446,0.00011133816],"about_ca_topic_score_codex":0.0003724651,"about_ca_topic_score_gemma":0.000046996814,"teacher_disagreement_score":0.3015703,"about_ca_system_score_codex":0.00030618958,"about_ca_system_score_gemma":0.00032124997,"threshold_uncertainty_score":0.54176694},"labels":[],"label_agreement":null},{"id":"W2273658812","doi":"10.5489/cuaj.3418","title":"A primer on tumour immunology and prostate cancer immunotherapy","year":2016,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Manitoba; Queen's University","funders":"","keywords":"Immunotherapy; Primer (cosmetics); Tumor immunology; Prostate cancer; Immunology; Cancer; Medicine; Prostate; Cancer immunotherapy; Cancer immunology; Immune system; Internal medicine; Chemistry","score_opus":0.02090399646087607,"score_gpt":0.29500373627729154,"score_spread":0.27409973981641544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273658812","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005115505,0.9878113,0.0000011908343,0.009709253,0.0007211844,0.00061224226,0.00013674374,0.000040088176,0.00045642228],"genre_scores_gemma":[0.0002511548,0.99270684,0.000016282134,0.0037857275,0.0006999636,0.00008353989,0.000019917154,0.00006909562,0.002367512],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99763703,0.00035975818,0.0006782765,0.00035398646,0.00028665102,0.0006843066],"domain_scores_gemma":[0.9981958,0.00023068165,0.0007868144,0.00016996978,0.00016895663,0.00044772378],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00070058584,0.00039514736,0.0012929888,0.0004082746,0.00022394868,0.00009223059,0.00016606139,0.00077770243,0.0010244471],"category_scores_gemma":[0.00017620016,0.00023572259,0.0004926634,0.00021972149,0.00009354194,0.000056769422,0.000014659958,0.0011432135,0.000065367334],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027415148,0.000027655711,0.0013765235,0.00013414759,0.0013230894,0.000085302425,0.00003951266,2.7681127e-8,0.00002461315,0.000037059493,0.006710903,0.989967],"study_design_scores_gemma":[0.0014632004,0.00055131636,0.0068882764,0.0023788565,0.00026612115,0.0006424421,0.000005799433,1.9138807e-7,0.0000016731219,0.00007356734,0.9874561,0.0002724609],"about_ca_topic_score_codex":0.00088683655,"about_ca_topic_score_gemma":0.0001871236,"teacher_disagreement_score":0.98969454,"about_ca_system_score_codex":0.0030466104,"about_ca_system_score_gemma":0.002287873,"threshold_uncertainty_score":0.9998888},"labels":[],"label_agreement":null},{"id":"W2285287574","doi":"10.4137/bic.s31805","title":"Imaging Biomarkers in Immunotherapy","year":2016,"lang":"en","type":"review","venue":"Biomarkers in Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Immunotherapy; Medicine; Biomarker; Mechanism (biology); Molecular imaging; Cancer immunotherapy; Immune system; Immune checkpoint; Cancer; Medical physics; Immunology; Internal medicine; Biology","score_opus":0.04149395003205605,"score_gpt":0.3756862328049298,"score_spread":0.33419228277287377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285287574","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000049534603,0.990507,0.000011307363,0.00067461934,0.0018999077,0.0023943805,0.00017345534,0.000106377935,0.004183391],"genre_scores_gemma":[0.000059421378,0.9967435,0.0001773848,0.0005439788,0.00036235305,0.0011254579,0.00007889914,0.00025471344,0.00065430434],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948887,0.00034029369,0.0018182625,0.0012800269,0.00055043714,0.0011222651],"domain_scores_gemma":[0.9976986,0.00031166736,0.0006320711,0.0011060629,0.00006775157,0.00018381419],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011874171,0.0010649106,0.0028415974,0.0019358936,0.00006865813,0.000061841216,0.00057369465,0.0006676521,0.0018576299],"category_scores_gemma":[0.000054050455,0.0007785793,0.0012004273,0.0020312546,0.00043630996,0.00019081727,0.00010535161,0.0005707026,0.00008342724],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015224309,0.00016084412,0.0021259715,0.005714606,0.002283777,0.0002797268,0.00006540672,2.7504473e-8,0.00013924546,0.0000060682996,0.0059173843,0.9817845],"study_design_scores_gemma":[0.005008202,0.00006675298,0.000986018,0.07377779,0.00025500442,0.00014420724,0.000043297674,0.0000042740235,0.00001555907,0.000019845094,0.91878945,0.0008896243],"about_ca_topic_score_codex":0.0015591972,"about_ca_topic_score_gemma":0.00037615126,"teacher_disagreement_score":0.98089486,"about_ca_system_score_codex":0.0037745016,"about_ca_system_score_gemma":0.0018857423,"threshold_uncertainty_score":0.99946654},"labels":[],"label_agreement":null},{"id":"W2287768841","doi":"10.5858/arpa.2015-0506-sa","title":"Programmed Death Ligand-1 Immunohistochemistry— A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society","year":2016,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Immunohistochemistry; Companion diagnostic; Lung cancer; Medicine; Immune system; Cancer; Antibody; Antigen; Cancer research; Pathology; Oncology; Immunology; Internal medicine","score_opus":0.020107788065184793,"score_gpt":0.29936978486064,"score_spread":0.27926199679545516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287768841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9508903,0.023164652,0.0013655662,0.019974636,0.0005172958,0.0014683825,0.0005124524,0.00007992217,0.0020268126],"genre_scores_gemma":[0.9913788,0.002716139,0.0038091184,0.0009074186,0.00040304146,0.00015611511,0.000040990184,0.000049617294,0.000538783],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978243,0.0001879954,0.0007003133,0.0006113184,0.00025644017,0.00041961504],"domain_scores_gemma":[0.99733114,0.00078131515,0.0005885646,0.0008962647,0.0002623017,0.00014038246],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00046771197,0.00033087237,0.0008946965,0.00008630167,0.00009675106,0.0000016304654,0.00039542268,0.0002657387,0.00009103149],"category_scores_gemma":[0.00066613883,0.00018110273,0.00044208096,0.00024902466,0.0032241428,0.00004630895,0.00011327845,0.00025861448,9.0449925e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034029104,0.00031368984,0.005235442,0.00013320557,0.0003649767,0.00013003241,0.008087008,9.2880754e-8,0.9653343,0.0005907097,0.00076833734,0.015639273],"study_design_scores_gemma":[0.04928268,0.011120715,0.22931966,0.005060761,0.0024919177,0.0010557259,0.024305843,0.00003411815,0.6254618,0.025894301,0.024714593,0.0012578969],"about_ca_topic_score_codex":0.0001866133,"about_ca_topic_score_gemma":0.000020427728,"teacher_disagreement_score":0.33987254,"about_ca_system_score_codex":0.00012750337,"about_ca_system_score_gemma":0.0006939558,"threshold_uncertainty_score":0.99948853},"labels":[],"label_agreement":null},{"id":"W2298279588","doi":"10.1136/jclinpath-2015-203493","title":"Tumour infiltrating lymphocytes and stromal CD68 in early stage HER2 positive breast cancer","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Oncology; Trastuzumab; Tumor-infiltrating lymphocytes; Internal medicine; CD68; Neoadjuvant therapy; Chemotherapy; Stromal cell; Population; Cancer; Pathology; Immunohistochemistry; Immunotherapy","score_opus":0.03308781809818559,"score_gpt":0.3790408154642046,"score_spread":0.34595299736601903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2298279588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932319,0.0008971741,0.000042826006,0.0051651294,0.0003684625,0.00008271684,0.000038631853,0.000004849225,0.00016833453],"genre_scores_gemma":[0.99559665,0.0023972332,0.00031360236,0.0010046415,0.00052093674,0.0000017956291,3.3635416e-7,0.000011567616,0.00015324708],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819,0.0002382095,0.0010585753,0.00015654249,0.00015474904,0.00020191839],"domain_scores_gemma":[0.99845773,0.0006192643,0.0005575239,0.000089202214,0.00014266638,0.00013360355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012770433,0.0001078546,0.00057623116,0.00009990347,0.000023071114,0.000009440575,0.00007147247,0.00016191874,0.00013702991],"category_scores_gemma":[0.00032798242,0.00006295397,0.00016426745,0.000081063234,0.0002675537,0.00013093042,0.000025125215,0.00029461322,0.0000023254659],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007115499,0.00014752189,0.87805146,0.000012841045,0.00008845233,0.0011225892,0.0001573003,2.6001675e-7,0.033142455,0.000019742587,0.00010645654,0.08003541],"study_design_scores_gemma":[0.008673929,0.00177644,0.9858608,0.00044447766,0.000041441308,0.0018104019,0.0001015056,0.0000031087538,0.0008599745,0.000054733195,0.00029646396,0.000076713884],"about_ca_topic_score_codex":0.0001397339,"about_ca_topic_score_gemma":0.00009898235,"teacher_disagreement_score":0.107809335,"about_ca_system_score_codex":0.000086351574,"about_ca_system_score_gemma":0.0003429701,"threshold_uncertainty_score":0.25671884},"labels":[],"label_agreement":null},{"id":"W2300386653","doi":"10.1016/j.ygyno.2016.03.008","title":"PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer","year":2016,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":341,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Victoria","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; BC Cancer Agency; Health Canada; BC Cancer Foundation; U.S. Department of Defense","keywords":"Cancer research; FOXP3; Tissue microarray; Ovarian cancer; Medicine; CD8; Tumor-infiltrating lymphocytes; Granzyme B; Immune system; IL-2 receptor; Immune checkpoint; Immunohistochemistry; Cancer; Immunology; Immunotherapy; T cell; Internal medicine","score_opus":0.020426850567280583,"score_gpt":0.2798248234885831,"score_spread":0.2593979729213025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300386653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915027,0.0004014267,0.000021238193,0.0060925344,0.00027176956,0.0007410642,0.000034223336,0.00008252947,0.00085248967],"genre_scores_gemma":[0.9946339,0.0004101205,0.0011529472,0.0025076836,0.000064545726,0.00029527943,0.000007085564,0.000023164175,0.0009052607],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982995,0.00020145481,0.0003730382,0.000457436,0.00016253808,0.0005060517],"domain_scores_gemma":[0.9987761,0.00060377544,0.0002731453,0.00016735539,0.00007181761,0.000107818],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046679453,0.00022058835,0.00056697364,0.00011772026,0.000111385634,0.000015257452,0.000098295044,0.00029679562,0.0009407246],"category_scores_gemma":[0.00014815156,0.000127684,0.000058293932,0.00028959117,0.0002100799,0.0001009502,0.000048269223,0.00021828916,0.0000078360845],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024888576,0.0008371643,0.44057116,0.000059927006,0.00025634145,0.0006007962,0.0006868109,0.000003869581,0.5095878,0.000025021003,0.004459339,0.0404229],"study_design_scores_gemma":[0.023907054,0.00814109,0.79077584,0.00094921765,0.00021234961,0.00016162808,0.00061642495,0.000046934732,0.16296157,0.0002944551,0.01137495,0.0005584571],"about_ca_topic_score_codex":0.0007275551,"about_ca_topic_score_gemma":0.0017688917,"teacher_disagreement_score":0.3502047,"about_ca_system_score_codex":0.00075594377,"about_ca_system_score_gemma":0.00041878398,"threshold_uncertainty_score":0.9999725},"labels":[],"label_agreement":null},{"id":"W2301237000","doi":"10.4103/0366-6999.178964","title":"Partial Remission of Hepatic Metastatic Lesion but Complicated with Secondary and Refractory Fever Lead by Nivolumab in a Patient with Lung Adenocarcinoma Presenting Gefitinib Acquired Resistance","year":2016,"lang":"en","type":"letter","venue":"Chinese Medical Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nivolumab; Lung cancer; Gefitinib; Internal medicine; Response Evaluation Criteria in Solid Tumors; Adenocarcinoma; Regimen; Oncology; Radiology; Gastroenterology; Surgery; Chemotherapy; Cancer; Phases of clinical research; Epidermal growth factor receptor; Immunotherapy","score_opus":0.013241507430789293,"score_gpt":0.26687213688935635,"score_spread":0.25363062945856707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301237000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89293295,0.011061382,0.00027728284,0.09465798,0.00015448449,0.00059949583,0.000062916784,0.000023911962,0.00022959383],"genre_scores_gemma":[0.9533201,0.0013158512,0.0005866839,0.041536245,0.0013225228,0.000048227634,0.00024546759,0.00014989011,0.0014750377],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99579173,0.00038069143,0.0011015984,0.00051766477,0.0016713478,0.0005369846],"domain_scores_gemma":[0.99779606,0.0003827207,0.0009424195,0.00037630595,0.0001921518,0.0003103716],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061121176,0.00047693917,0.0011198629,0.0002595172,0.0001373057,0.000038281873,0.00023567457,0.00041491297,0.000508494],"category_scores_gemma":[0.00023761633,0.00024549698,0.00013320302,0.0002734965,0.00056337664,0.00016020905,0.00007265224,0.0018327802,0.0000010840506],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029110685,0.0005982649,0.080778465,0.005296746,0.0017176532,0.025093766,0.0017261754,2.742503e-7,0.027815983,3.8450202e-7,0.76615274,0.06170885],"study_design_scores_gemma":[0.125551,0.009253285,0.3031941,0.13294461,0.0027093042,0.054819576,0.0008515759,0.0013206198,0.0078409985,0.0002614352,0.35701355,0.004239951],"about_ca_topic_score_codex":0.000097383934,"about_ca_topic_score_gemma":0.000045302135,"teacher_disagreement_score":0.40913922,"about_ca_system_score_codex":0.00025523952,"about_ca_system_score_gemma":0.00092587876,"threshold_uncertainty_score":0.9999997},"labels":[],"label_agreement":null},{"id":"W2313945592","doi":"10.1097/md.0000000000001631","title":"Tumor-Infiltrating Immune Cells Are Associated With Prognosis of Gastric Cancer","year":2015,"lang":"en","type":"article","venue":"Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"West China Hospital, Sichuan University; Sichuan University; National High-tech Research and Development Program; University of Toronto; National Natural Science Foundation of China","keywords":"Medicine; Nomogram; Hazard ratio; Immune system; Cancer; Internal medicine; Stromal cell; CD8; Oncology; Gastroenterology; Pathology; Confidence interval; Immunology","score_opus":0.03340432335839933,"score_gpt":0.27976868022472806,"score_spread":0.24636435686632874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313945592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866419,0.0058385786,0.000035026726,0.004658137,0.0002957142,0.00046431762,0.000014538909,0.00006426193,0.0019875686],"genre_scores_gemma":[0.99814785,0.00011824048,0.00015140226,0.0006184041,0.00020371011,0.000043317403,0.000021277729,0.000025783344,0.00067003357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986261,0.000043070882,0.00039819,0.00018903261,0.0005008328,0.00024276694],"domain_scores_gemma":[0.9988737,0.000065685614,0.0003890413,0.00020603676,0.00032249052,0.00014306264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004720882,0.0001640045,0.00052734546,0.00013224669,0.00003267089,0.0000039618217,0.00008391201,0.000051292944,0.00027026076],"category_scores_gemma":[0.0001924373,0.00010288168,0.00005392989,0.00070554385,0.00022913024,0.000045804056,0.000013559075,0.00015770273,0.0000024164926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004729064,0.0006244247,0.5544032,0.00039074372,0.0012712178,0.00022667441,0.003949042,0.000025140314,0.38426825,0.0000078606945,0.029798808,0.020305604],"study_design_scores_gemma":[0.035744105,0.009733901,0.6734919,0.011790401,0.0013677545,0.00019884606,0.011160349,0.00035619977,0.24536927,0.000020919793,0.010192382,0.0005739748],"about_ca_topic_score_codex":0.001049651,"about_ca_topic_score_gemma":0.00013513265,"teacher_disagreement_score":0.13889897,"about_ca_system_score_codex":0.00016822718,"about_ca_system_score_gemma":0.00024572786,"threshold_uncertainty_score":0.4195393},"labels":[],"label_agreement":null},{"id":"W2315061030","doi":"10.1158/1078-0432.tcme10-b13","title":"Abstract B13: TIA1+ and FOXP3+ tumor infiltrating lymphocytes are positive prognostic factors in estrogen receptor negative breast cancer","year":2010,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Breast cancer; Medicine; Tissue microarray; FOXP3; Oncology; Estrogen receptor; Cancer; Internal medicine; Tumor-infiltrating lymphocytes; Pathology; Immune system; Immunology; Immunotherapy","score_opus":0.10158320996902187,"score_gpt":0.4645544918253545,"score_spread":0.36297128185633265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315061030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99350005,0.0012763018,4.1851834e-7,0.0028936118,0.00043940608,0.0011187149,0.0003603726,0.00003814067,0.00037296664],"genre_scores_gemma":[0.9970858,0.0012125134,0.000104974846,0.00038236042,0.00071217224,0.0003024229,0.000020202118,0.00004708729,0.00013243186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996979,0.00025348985,0.0007291422,0.00068185746,0.0006455536,0.00071097584],"domain_scores_gemma":[0.9960997,0.0024974246,0.00021040083,0.00031200144,0.00048449164,0.00039596445],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018112515,0.00025532267,0.00056868105,0.00020648903,0.00020081292,0.00009022092,0.00021257396,0.00027258476,0.0012836973],"category_scores_gemma":[0.0015146402,0.00019906418,0.00015543304,0.0005774831,0.0010941282,0.00018011706,0.000110931454,0.0019320012,0.000016627075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040272046,0.0002599936,0.9342728,0.00012486738,0.00016064565,0.000053537682,0.00045560673,7.447933e-7,0.019790003,0.000012614524,0.0007038238,0.040138144],"study_design_scores_gemma":[0.0035426768,0.00045099625,0.9826199,0.0009308379,0.000029099265,0.000024426528,0.0010724554,0.000034599114,0.010467437,0.000044664786,0.0005620095,0.0002209357],"about_ca_topic_score_codex":0.01318721,"about_ca_topic_score_gemma":0.006280788,"teacher_disagreement_score":0.048347045,"about_ca_system_score_codex":0.00040066178,"about_ca_system_score_gemma":0.0015381391,"threshold_uncertainty_score":0.99962926},"labels":[],"label_agreement":null},{"id":"W2319847690","doi":"10.1158/1538-7445.am2012-sy32-03","title":"Abstract SY32-03: Promoting tissue-specific antitumor immunity","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Immunology; Adoptive cell transfer; CD8; Antigen; Biology; Immunity; Immune system; T cell; Autoimmunity; Cytotoxic T cell; Acquired immune system; Cancer research; In vitro","score_opus":0.1527286173809832,"score_gpt":0.44578536235398164,"score_spread":0.29305674497299844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319847690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9609866,0.02488677,0.0000047951653,0.0014275301,0.00046205206,0.0006561767,0.000014141092,0.00006731274,0.011494625],"genre_scores_gemma":[0.9931254,0.0031926036,0.00009417923,0.00010962534,0.001075864,0.00012809629,0.00001639781,0.000041891562,0.0022159698],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.997759,0.000112634974,0.00026645503,0.00024378943,0.0007114785,0.0009066588],"domain_scores_gemma":[0.9987897,0.000115782714,0.000054545464,0.00051431597,0.00025251723,0.0002730904],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002159318,0.00014401121,0.00024157827,0.00020690852,0.0003231358,0.00005752787,0.0002177942,0.00010090246,0.0046412344],"category_scores_gemma":[0.00007772162,0.00011977427,0.00008299346,0.00060891424,0.00029843877,0.00021343978,0.00008759427,0.0007757982,0.0004266242],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009621449,0.00027374594,0.012614733,0.00028011698,0.00008654768,0.000030159645,0.0013197137,1.6880665e-7,0.8787653,0.0000725461,0.01383976,0.0917551],"study_design_scores_gemma":[0.0013867391,0.00019876425,0.25041014,0.0004422214,0.000011520562,0.000045659133,0.00050620874,0.0000020298073,0.34998477,0.00002011247,0.39681068,0.00018114653],"about_ca_topic_score_codex":0.0010495922,"about_ca_topic_score_gemma":0.000028543645,"teacher_disagreement_score":0.5287805,"about_ca_system_score_codex":0.00047306815,"about_ca_system_score_gemma":0.00028536512,"threshold_uncertainty_score":0.99626863},"labels":[],"label_agreement":null},{"id":"W2320562015","doi":"10.1097/00054725-201212001-00091","title":"Adalimumab Sustains Deep Remission for 3 Years: Data From CHARM and ADHERE","year":2012,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Adalimumab; Charm (quantum number); Medicine; Dermatology; Immunology; Tumor necrosis factor alpha; Physics; Particle physics","score_opus":0.0308382027264529,"score_gpt":0.30278200582482445,"score_spread":0.2719438030983716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320562015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772365,0.020678557,0.000064872525,0.00025589194,0.00026479698,0.00053533807,0.00070898404,0.00009586238,0.00015919341],"genre_scores_gemma":[0.99645776,0.0006015679,0.00021580975,0.00053768005,0.0008951364,0.000044154534,0.00081680727,0.00003791198,0.0003931654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904853,0.000026876773,0.000208169,0.00025876053,0.00017438867,0.00028325513],"domain_scores_gemma":[0.9988858,0.000096669006,0.0000761098,0.0005972836,0.000041261836,0.00030285213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001272154,0.00014408783,0.00017432112,0.00004638092,0.00007727959,0.00002840379,0.00014595651,0.00007990529,0.00041748036],"category_scores_gemma":[0.00011780444,0.00012571448,0.00007162695,0.000043329983,0.00008761031,0.00030924432,0.000103605016,0.00006298519,0.000016256841],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012549845,0.0005458546,0.8299846,0.000773344,0.0006359017,0.0001114608,0.0012154479,5.181344e-7,0.010595995,0.00009765358,0.056756932,0.08673247],"study_design_scores_gemma":[0.0031659065,0.00006344958,0.8359642,0.0001759968,0.0002524611,0.000006985232,0.00063961436,0.00016878919,0.0003228542,0.0000881305,0.15896222,0.00018938172],"about_ca_topic_score_codex":0.000045866618,"about_ca_topic_score_gemma":0.000015529971,"teacher_disagreement_score":0.10220528,"about_ca_system_score_codex":0.000060840684,"about_ca_system_score_gemma":0.00012342424,"threshold_uncertainty_score":0.5126487},"labels":[],"label_agreement":null},{"id":"W2324887817","doi":"10.1136/gutjnl-2013-304907.440","title":"PWE-152 Selective Loss of Oncofoetal Antigen 5T4-Specific T Cell Response Correlates with Progression of Colorectal Cancer","year":2013,"lang":"en","type":"article","venue":"Gut","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"ELISPOT; Medicine; FOXP3; Antigen; Epitope; Colorectal cancer; Immunotherapy; Immune system; T cell; Immunology; Human leukocyte antigen; Cancer; Oncology; Cancer research; Internal medicine","score_opus":0.00855937621058479,"score_gpt":0.2680033741995602,"score_spread":0.25944399798897544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324887817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948379,0.0030847513,0.000018270382,0.00021457998,0.00012947018,0.00068714516,0.000020226113,0.000023008057,0.0009846783],"genre_scores_gemma":[0.9980451,0.0004903488,0.00040100198,0.000031212134,0.000037919977,0.000057743124,0.000008818607,0.00002150657,0.0009063773],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99904084,0.000065699045,0.00025220137,0.00019443718,0.00025109423,0.00019572675],"domain_scores_gemma":[0.9992461,0.00008766834,0.0002073359,0.00015924033,0.00024041324,0.00005923628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016357128,0.00013423117,0.00030048232,0.000088556466,0.000038964266,0.000008020051,0.00007436816,0.00009654124,0.0003916817],"category_scores_gemma":[0.000011098688,0.00009070655,0.000079733734,0.0002992505,0.00028094524,0.00009393942,0.000018821233,0.00012868058,0.0000125566],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03388308,0.00025948783,0.14378364,0.000072017305,0.00014973509,0.000014958277,0.0013889106,0.0000053851672,0.811395,0.0000033889376,0.0021247966,0.006919588],"study_design_scores_gemma":[0.0029817421,0.0024271926,0.4657064,0.00036375455,0.000036070913,0.000030044666,0.0003253858,0.000044344146,0.52587086,0.0000063349794,0.0020938155,0.00011406007],"about_ca_topic_score_codex":0.00040412118,"about_ca_topic_score_gemma":0.00003200858,"teacher_disagreement_score":0.32192275,"about_ca_system_score_codex":0.000100686026,"about_ca_system_score_gemma":0.00027306774,"threshold_uncertainty_score":0.428864},"labels":[],"label_agreement":null},{"id":"W2325101533","doi":"10.5114/ceji.2012.32713","title":"Editorial&lt;br&gt;Affiliation of the J Project Group to the Central European Journal of Immunology","year":2013,"lang":"en","type":"article","venue":"Central European Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tumor immunology; Clinical immunology; Library science; Medicine; Immunology; Political science; Immunotherapy; Immune system; Computer science","score_opus":0.01058765519944586,"score_gpt":0.22803953638926078,"score_spread":0.21745188118981493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325101533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.921387,0.00508186,0.00047368748,0.0064480733,0.06451139,0.00068874133,0.000011644415,0.000015117253,0.0013824695],"genre_scores_gemma":[0.98111486,0.0020143094,0.00036134262,0.0005867825,0.01565614,0.0000013691421,0.000004115076,0.000062919666,0.00019818048],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9943794,0.0025417374,0.0017316835,0.0001807561,0.0005128669,0.0006535774],"domain_scores_gemma":[0.9963818,0.00012946191,0.001974224,0.00052605395,0.00086651003,0.00012193053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022801065,0.00028042504,0.0006221991,0.00026156008,0.00015651522,0.00005037536,0.0011330061,0.00008186302,0.00022883622],"category_scores_gemma":[0.0005610762,0.00015280541,0.0006015534,0.0004491083,0.0004619853,0.00022318425,0.0001808786,0.00095382845,0.000037127436],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059646834,0.00044172202,0.001881351,0.000036479934,0.0016942443,0.000098767734,0.0032782445,0.00003225774,0.76389533,0.0000963389,0.16027161,0.062308975],"study_design_scores_gemma":[0.006298499,0.0047057364,0.51713246,0.00040484392,0.0002652786,0.0019250663,0.0010244234,0.0000060978305,0.007597457,0.000013418152,0.46043724,0.00018949095],"about_ca_topic_score_codex":0.000051698396,"about_ca_topic_score_gemma":0.000007116092,"teacher_disagreement_score":0.7562979,"about_ca_system_score_codex":0.00024373285,"about_ca_system_score_gemma":0.00039570674,"threshold_uncertainty_score":0.6231224},"labels":[],"label_agreement":null},{"id":"W2330297703","doi":"10.1371/journal.pone.0152448","title":"Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control Studies","year":2016,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Meta-analysis; Genetic model; Allele; Oncology; Population; Internal medicine; Medicine; Subgroup analysis; Cancer; Genetics; Biology; Bioinformatics; Gene","score_opus":0.2284101046551634,"score_gpt":0.36380856355775804,"score_spread":0.13539845890259464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330297703","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019878254,0.99402773,0.000019389667,0.0008189127,0.00007440718,0.0038107948,0.0008582668,0.00010496925,0.00008675142],"genre_scores_gemma":[0.00051802467,0.9902712,0.00041618393,0.00061132474,0.000470091,0.004626377,0.000042542117,0.000120849225,0.002923412],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9956076,0.00082130654,0.0012071315,0.0009000099,0.0007901035,0.0006738582],"domain_scores_gemma":[0.9950704,0.0014804687,0.0012878993,0.0014917229,0.00035549598,0.00031403598],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014183648,0.00087306177,0.007011593,0.00044122976,0.00034849448,0.00007604748,0.00040619055,0.00032175833,0.0017344118],"category_scores_gemma":[0.00048830593,0.00039028376,0.0059074913,0.001112399,0.00026822512,0.00007025482,0.000104065315,0.00061438995,0.00005230788],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023570548,0.0007393261,0.00010522344,0.0055827457,0.8220284,0.0005160314,0.00021462211,6.422112e-8,0.00001802508,0.0000027348806,0.00023257907,0.17032456],"study_design_scores_gemma":[0.0013815025,0.00015519527,0.000008359046,0.003292173,0.90814185,0.00010158243,0.000081697915,0.000007434643,0.000050710638,0.000009223273,0.0863102,0.00046005796],"about_ca_topic_score_codex":0.002824061,"about_ca_topic_score_gemma":0.0012638277,"teacher_disagreement_score":0.1698645,"about_ca_system_score_codex":0.0005527198,"about_ca_system_score_gemma":0.0007107256,"threshold_uncertainty_score":0.9998549},"labels":[],"label_agreement":null},{"id":"W2334317896","doi":"10.1136/gutjnl-2013-304907.439","title":"PWE-151 Cell-Mediated Immune Recognition of Cea Is Associated with Early Tumour Recurrence Following Resection of Colorectal Cancer","year":2013,"lang":"en","type":"article","venue":"Gut","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Colorectal cancer; Immune system; FOXP3; Oncology; Antigen; Cancer; Internal medicine; Population; Disease; Gastroenterology; Immunology","score_opus":0.015858119845614627,"score_gpt":0.2521093454213413,"score_spread":0.23625122557572664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334317896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99716395,0.0008660771,0.000011933614,0.00017915691,0.00027619817,0.0004893461,0.000058627043,0.000030165971,0.00092454295],"genre_scores_gemma":[0.9989691,0.00024675965,0.0000756953,0.000059166105,0.000030984138,0.000068216825,0.00008601811,0.000018956956,0.00044510982],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99893045,0.00005530787,0.0003484988,0.00017812874,0.00029380366,0.00019381914],"domain_scores_gemma":[0.9991432,0.00008109383,0.00031094777,0.00011784617,0.00030012085,0.00004679479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021199159,0.00012215722,0.00031408953,0.000110024375,0.00004428163,0.00001131527,0.00006218702,0.00011277842,0.0003804081],"category_scores_gemma":[0.0000845595,0.00010013772,0.0001257854,0.000477786,0.00007484986,0.00017893576,0.000012154413,0.00015255071,0.000013245873],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018656167,0.00017266179,0.028517075,0.00007492254,0.00031236815,0.000004584797,0.0010648926,6.205414e-7,0.9612432,2.0598115e-7,0.00064415013,0.006099662],"study_design_scores_gemma":[0.004210952,0.0019316993,0.5197915,0.0011122219,0.00016043556,0.000004411302,0.00026573607,0.0000912617,0.47218874,0.000016963444,0.00007047684,0.00015561387],"about_ca_topic_score_codex":0.0061327037,"about_ca_topic_score_gemma":0.00019994874,"teacher_disagreement_score":0.49127442,"about_ca_system_score_codex":0.00013049415,"about_ca_system_score_gemma":0.00014995848,"threshold_uncertainty_score":0.92708546},"labels":[],"label_agreement":null},{"id":"W2338494814","doi":"10.1001/jama.2016.4059","title":"Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma","year":2016,"lang":"en","type":"article","venue":"JAMA","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1062,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Ipilimumab; Pembrolizumab; Internal medicine; Melanoma; Oncology; Clinical endpoint; Clinical trial; Cohort; Immunotherapy; Cancer","score_opus":0.0041691266039237855,"score_gpt":0.21522916485977373,"score_spread":0.21106003825584993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338494814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982867,0.000043462496,0.00001893835,0.0009910492,0.00003764572,0.00020727352,0.000021868647,0.00001579341,0.00037721818],"genre_scores_gemma":[0.99842995,0.000015894098,0.000119837285,0.00009420348,0.000021293325,0.000009195484,0.000003939587,0.000012523458,0.001293184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99934626,0.00005739792,0.00011799691,0.00012299091,0.00024029007,0.00011504287],"domain_scores_gemma":[0.99938893,0.0001463123,0.00015259735,0.0001255006,0.00014613764,0.00004051698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020378453,0.00007626929,0.00016299516,0.000044465334,0.000022508084,0.000006152574,0.000026086012,0.00003716436,0.000046995916],"category_scores_gemma":[0.00010669498,0.00003924783,0.000019924426,0.00008758447,0.00006201164,0.00010738561,0.000007785242,0.000038590533,0.0000011899693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.090523854,0.000057865458,0.88009155,0.000017477707,0.00012262317,0.0000057066686,0.000102512924,6.496965e-8,0.007527703,0.0000028920638,0.00018197438,0.021365779],"study_design_scores_gemma":[0.022473026,0.0019067648,0.96896195,0.0002281199,0.000041850817,0.0000032211365,0.0000429337,0.0000010995549,0.004692279,0.0000025615423,0.0015762724,0.00006989023],"about_ca_topic_score_codex":0.000032921896,"about_ca_topic_score_gemma":0.00006184404,"teacher_disagreement_score":0.088870436,"about_ca_system_score_codex":0.00011185732,"about_ca_system_score_gemma":0.00005806735,"threshold_uncertainty_score":0.160048},"labels":[],"label_agreement":null},{"id":"W2339737660","doi":"10.1007/s00280-016-3026-6","title":"The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Gemcitabine; Erlotinib; Medicine; Pancreatic cancer; Internal medicine; Interstitial lung disease; Gastroenterology; Lung cancer; Oncology; Incidence (geometry); Cancer; Lung; Epidermal growth factor receptor","score_opus":0.008902987812251021,"score_gpt":0.2873161042179896,"score_spread":0.27841311640573857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339737660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98871577,0.003765334,0.000025592182,0.0059719384,0.0002677708,0.0011044353,0.000085393396,0.00002327302,0.000040483148],"genre_scores_gemma":[0.9907035,0.006131787,0.000009907509,0.002508321,0.00006939036,0.00026697098,0.000014371524,0.00003704208,0.0002586598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987395,0.00008596896,0.00030067447,0.000342198,0.00020672625,0.00032495512],"domain_scores_gemma":[0.99912816,0.00019398426,0.00025746075,0.00014071156,0.00014765492,0.00013199961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015445864,0.0002458012,0.0004317575,0.00008486837,0.00010987947,0.0000119792985,0.00008893609,0.00008765677,0.00046511216],"category_scores_gemma":[0.000014018005,0.00013593424,0.000042355063,0.0002387613,0.00038751838,0.00012545618,0.000018705074,0.00014300793,2.190469e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12224436,0.0005396227,0.6718639,0.0002673157,0.0017555448,0.000014511256,0.0020687906,0.0000062612626,0.07026951,0.000021525304,0.0013260569,0.12962258],"study_design_scores_gemma":[0.08648861,0.0020013945,0.87355685,0.001220796,0.0004909062,0.0000023924963,0.00009743524,0.0003869766,0.033653803,0.000039367485,0.0016751486,0.00038631182],"about_ca_topic_score_codex":0.0002380301,"about_ca_topic_score_gemma":0.00033406858,"teacher_disagreement_score":0.20169292,"about_ca_system_score_codex":0.00036291653,"about_ca_system_score_gemma":0.00028308074,"threshold_uncertainty_score":0.5543238},"labels":[],"label_agreement":null},{"id":"W2339872372","doi":"10.1158/2326-6074.tumimm14-a69","title":"Abstract A69: The immunological environment in triple negative breast cancer; impact on clinical outcomes towards a prognostic clinical test","year":2015,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Occupational Cancer Research Centre","funders":"","keywords":"Tumor microenvironment; Stromal cell; CD8; Laser capture microdissection; Stroma; Cytotoxic T cell; Triple-negative breast cancer; Tumor-infiltrating lymphocytes; Breast cancer; Gene signature; Cancer research; Immunotherapy; Biology; Cancer; Medicine; Immunology; Immune system; Internal medicine; Gene expression; Immunohistochemistry; Gene; Genetics","score_opus":0.2470849145066478,"score_gpt":0.5129981754542506,"score_spread":0.2659132609476028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339872372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9587508,0.010258634,0.0000015169373,0.026743712,0.0010083109,0.002078991,0.00019711508,0.00006011096,0.0009008198],"genre_scores_gemma":[0.9753611,0.02117017,0.000027487666,0.00092149957,0.00045181296,0.0010502756,0.000020913805,0.00005199269,0.0009447557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940059,0.0014215062,0.0014307736,0.0009264048,0.00093934033,0.0012760401],"domain_scores_gemma":[0.99379355,0.004173886,0.00027672743,0.0010853404,0.00034932134,0.00032118327],"candidate_categories":["sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0071095494,0.0004428587,0.0011723299,0.00031351656,0.00025794777,0.00006174242,0.0008084161,0.00068899314,0.0016717287],"category_scores_gemma":[0.002922302,0.00024383163,0.00061407115,0.00074112194,0.0033826146,0.00011610878,0.00033818133,0.0037161328,0.00026659574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01961525,0.0019252432,0.78651416,0.00001398355,0.0011190148,0.0001422447,0.00036171006,0.000011093936,0.00050353474,0.000012619176,0.003984071,0.18579707],"study_design_scores_gemma":[0.011336165,0.004782664,0.97790015,0.00022347127,0.00006170231,0.000077636294,0.0008530865,0.000037285703,0.00014915984,0.00016881315,0.004150914,0.0002589471],"about_ca_topic_score_codex":0.007855298,"about_ca_topic_score_gemma":0.00034336862,"teacher_disagreement_score":0.19138598,"about_ca_system_score_codex":0.0018855928,"about_ca_system_score_gemma":0.0030026855,"threshold_uncertainty_score":0.9993296},"labels":[],"label_agreement":null},{"id":"W2340166080","doi":"10.1371/journal.pone.0153954","title":"PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC","year":2016,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"Cancer Council Victoria; Medical Research Council; National Health and Medical Research Council; State Government of Victoria; Canadian Institutes of Health Research; Government of Ontario; Ontario Institute for Cancer Research; American Society of Clinical Oncology","keywords":"Medicine; Tissue microarray; KRAS; PD-L1; Immunohistochemistry; Tumor-infiltrating lymphocytes; Internal medicine; Oncology; Lung cancer; Cohort; Cancer; Pathology; Colorectal cancer; Immunotherapy","score_opus":0.0283528547707599,"score_gpt":0.2459529121478783,"score_spread":0.21760005737711838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340166080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99388856,0.0011437376,0.0000020127418,0.0013503826,0.000023281678,0.0005029713,0.000005821517,0.000062138184,0.003021116],"genre_scores_gemma":[0.9975887,0.0003110791,0.000559839,0.0004831662,0.00007541243,0.0000599721,0.0000043547875,0.000021359407,0.00089609827],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990039,0.000047247024,0.00023857557,0.000225008,0.0002402366,0.00024502023],"domain_scores_gemma":[0.9993562,0.0002667921,0.000063206586,0.0001770727,0.000055111468,0.00008163637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021374089,0.000119586235,0.00023503295,0.00011963706,0.000039265728,0.000017299419,0.000052323117,0.00005298689,0.00029820635],"category_scores_gemma":[0.000703922,0.0000821122,0.000030283181,0.0002223956,0.00011192354,0.000085704785,0.000024378667,0.00007586532,0.000025714064],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045283604,0.0004409546,0.22181466,0.00018401812,0.00022737517,0.00007489069,0.00019508501,1.2281032e-8,0.75772136,0.000012797911,0.0001573317,0.014643118],"study_design_scores_gemma":[0.011462403,0.0013374984,0.7637514,0.0061331214,0.00015217422,0.00008924285,0.00025225498,0.00007131957,0.21606365,0.00011097152,0.00028384392,0.00029211098],"about_ca_topic_score_codex":0.00023499578,"about_ca_topic_score_gemma":0.00007871101,"teacher_disagreement_score":0.54193676,"about_ca_system_score_codex":0.00013463355,"about_ca_system_score_gemma":0.00015811544,"threshold_uncertainty_score":0.33484384},"labels":[],"label_agreement":null},{"id":"W2340583087","doi":"10.1158/1538-7445.sabcs15-p3-07-32","title":"Abstract P3-07-32: Tumour infiltrating lymphocyte (TIL) and chemokine gene signature predicts for benefit of anthracycline-containing chemotherapy in breast cancer patients","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Breast cancer; Anthracycline; Gene signature; Tumor-infiltrating lymphocytes; Oncology; Cancer research; Cancer; Internal medicine; Medicine; CTL*; Chemokine; Immunology; Biology; Immune system; Immunotherapy; Gene expression; Gene; CD8","score_opus":0.03309062105273057,"score_gpt":0.3593285938650032,"score_spread":0.3262379728122726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340583087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98862743,0.0058786348,0.000012616786,0.0035488268,0.0001429817,0.0011125688,0.0005060564,0.000023244853,0.00014761595],"genre_scores_gemma":[0.988646,0.009860875,0.00011780806,0.0003086555,0.00039515525,0.00036127563,0.000024176768,0.000060611816,0.00022547261],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9977145,0.000032909084,0.00052979344,0.0004887223,0.0005916124,0.0006424254],"domain_scores_gemma":[0.998475,0.0003047498,0.00018682754,0.0002592866,0.000609018,0.0001650854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008089856,0.00022942496,0.00046748598,0.0002725825,0.000106707404,0.000025014911,0.00018243822,0.00020057797,0.0004409579],"category_scores_gemma":[0.00009950597,0.00016237925,0.000100072524,0.00038955774,0.00028103433,0.0001893801,0.000051020765,0.00028104242,0.0000011718336],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013191019,0.0001653076,0.11165563,0.00029793722,0.00011495496,0.0000051886714,0.0004232459,0.000004462619,0.6459595,0.0000061103106,0.00039143345,0.22778524],"study_design_scores_gemma":[0.021064186,0.00062184857,0.59868497,0.0026704266,0.000021864877,0.000010371404,0.00014760635,0.00009540101,0.37490362,0.000064889326,0.0014814122,0.00023338845],"about_ca_topic_score_codex":0.0017260546,"about_ca_topic_score_gemma":0.00030164674,"teacher_disagreement_score":0.48702934,"about_ca_system_score_codex":0.0007360899,"about_ca_system_score_gemma":0.00064234406,"threshold_uncertainty_score":0.6621634},"labels":[],"label_agreement":null},{"id":"W2341303931","doi":"10.1093/annonc/mdw178","title":"Anti-PD-1-associated organizing pneumonia in a responding melanoma patient","year":2016,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Pembrolizumab; Medicine; Ipilimumab; Pneumonitis; Internal medicine; Melanoma; Nivolumab; Lung cancer; Cancer; Oncology; Immunotherapy; Lung; Cancer research","score_opus":0.058271392711950115,"score_gpt":0.34924950369503355,"score_spread":0.29097811098308346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341303931","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3952163,0.00096487656,8.279762e-7,0.59841436,0.00052673114,0.00034637374,0.00006466737,0.00003087943,0.0044349795],"genre_scores_gemma":[0.33036956,0.0015146477,0.000043237498,0.6646179,0.0009469441,0.000031357027,0.00015124587,0.00009092565,0.0022341646],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759233,0.0003121965,0.0008018499,0.0003961669,0.0003056293,0.0005918403],"domain_scores_gemma":[0.99830097,0.0004127554,0.00066667714,0.00034928278,0.00022013966,0.000050157618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060974987,0.00027973598,0.0011355188,0.0008239052,0.00003730598,0.000007148422,0.00018219004,0.0012533369,0.000376963],"category_scores_gemma":[0.00027667655,0.00021994919,0.00024506354,0.0005216583,0.00014956662,0.00004897588,0.0000715792,0.00084976165,0.000031317108],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017615157,0.00019063853,0.005398035,0.00014618393,0.0005945072,0.0027103154,0.00068330765,6.5665844e-8,0.05976496,0.0000057341977,0.8701937,0.058551013],"study_design_scores_gemma":[0.002500859,0.0036907273,0.013562041,0.0010536616,0.0000599554,0.00010233036,0.000054129876,8.163905e-7,0.0060164304,0.000054022825,0.97266436,0.00024064587],"about_ca_topic_score_codex":0.00018125137,"about_ca_topic_score_gemma":0.000050389022,"teacher_disagreement_score":0.10247066,"about_ca_system_score_codex":0.0003744816,"about_ca_system_score_gemma":0.0006108299,"threshold_uncertainty_score":0.96668816},"labels":[],"label_agreement":null},{"id":"W2342082201","doi":"10.1017/cjn.2016.34","title":"Immunological Aspects of Malignant Gliomas","year":2016,"lang":"en","type":"review","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immunotherapy; Glioma; Immune system; Glioblastoma; Melanoma; Brain tumor; Medicine; Cancer; Pathological; Tumor immunology; Cancer immunotherapy; Neuroimmunology; Immunology; Cancer research; Pathology; Internal medicine","score_opus":0.0617574829878396,"score_gpt":0.322110316937866,"score_spread":0.2603528339500264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2342082201","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.097099915,0.89543533,0.000006390238,0.0012908994,0.0014063148,0.0003954447,0.00004642172,0.00001799932,0.0043013],"genre_scores_gemma":[0.04751415,0.95064586,0.0004974551,0.00078494975,0.00046428028,0.000005373456,7.60133e-7,0.000029099037,0.00005806842],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924437,0.001447843,0.0024336302,0.00078755437,0.0011631051,0.0017241952],"domain_scores_gemma":[0.99316,0.001069417,0.0028796375,0.0003304643,0.00063139247,0.0019290695],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["sts"],"category_scores_codex":[0.0052866777,0.000732519,0.0027625007,0.0023269532,0.0014269936,0.00033894373,0.0027886247,0.00069945323,0.0006758613],"category_scores_gemma":[0.002229425,0.0003693663,0.0016273602,0.0023437971,0.013736686,0.0005333791,0.000111203655,0.0018447873,0.000009548185],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005277332,0.00012506513,0.011077567,0.0007699509,0.00034652135,0.0277812,0.0001347317,0.000009535122,0.00004444977,0.0020996144,0.0009875239,0.9560961],"study_design_scores_gemma":[0.00073389447,0.12004421,0.0031296236,0.0059163393,0.00054623943,0.17654745,0.000065918946,0.0000068195477,0.000044252025,0.005242012,0.6870641,0.0006591452],"about_ca_topic_score_codex":0.0005348997,"about_ca_topic_score_gemma":0.005109335,"teacher_disagreement_score":0.95543694,"about_ca_system_score_codex":0.0005869812,"about_ca_system_score_gemma":0.014946758,"threshold_uncertainty_score":0.99987584},"labels":[],"label_agreement":null},{"id":"W2345807343","doi":"10.1097/cco.0000000000000291","title":"Immune-mediated respiratory adverse events of checkpoint inhibitors","year":2016,"lang":"en","type":"review","venue":"Current Opinion in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca; Pfizer","keywords":"Medicine; Pneumonitis; Adverse effect; Myasthenia gravis; Context (archaeology); Respiratory failure; Immune system; Immunology; Internal medicine; Lung","score_opus":0.11351410201309228,"score_gpt":0.4429251145201638,"score_spread":0.3294110125070715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345807343","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006197689,0.9830028,0.0000043420637,0.00010137441,0.014934703,0.001408445,0.00009561301,0.000031562984,0.00035920052],"genre_scores_gemma":[0.000013938516,0.9984567,0.000016121174,0.000024332376,0.00085337437,0.0002503121,0.00025271272,0.000050353374,0.00008216842],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963887,0.0004348926,0.0020604583,0.00046714756,0.00027939715,0.00036941044],"domain_scores_gemma":[0.997758,0.00028612622,0.0012310434,0.0005099306,0.00009931267,0.00011558643],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008936147,0.0004139584,0.0023225388,0.00069663156,0.00002466905,0.0000011107566,0.00024368304,0.0006741118,0.00039598058],"category_scores_gemma":[0.0002453143,0.0002914401,0.00089974055,0.0005232329,0.00023101825,0.000048750662,0.0001226711,0.0006187064,0.00015008434],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045571377,0.00046615183,0.00014297209,0.018507976,0.00017898687,0.0000041945727,0.00005974983,1.7782888e-8,0.000036791862,0.000013761409,0.0038259933,0.9763077],"study_design_scores_gemma":[0.0035930767,0.0006773154,0.00030770327,0.070472494,0.00011101595,0.000026104331,0.000017719267,2.2488133e-7,0.000010722177,0.0000076128995,0.9245339,0.00024210177],"about_ca_topic_score_codex":0.000014019184,"about_ca_topic_score_gemma":0.000002013523,"teacher_disagreement_score":0.9760656,"about_ca_system_score_codex":0.0012733706,"about_ca_system_score_gemma":0.0021996116,"threshold_uncertainty_score":0.99995375},"labels":[],"label_agreement":null},{"id":"W2346388928","doi":"10.1093/annonc/mdu338.62","title":"A Phase 1/2 Study of Ipilimumab in Women with Metastatic or Recurrent Hpv-Related Cervical Carcinoma: a Study of the Princess Margaret and Chicago N01 Consortia","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Ipilimumab; Medicine; Oncology; Internal medicine; Response Evaluation Criteria in Solid Tumors; Immunotherapy; Cancer; Progressive disease; Phases of clinical research; Clinical trial; Chemotherapy; Immunology","score_opus":0.06180391013388024,"score_gpt":0.3804247568531686,"score_spread":0.31862084671928836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346388928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972659,0.00026306268,9.957851e-7,0.00071641715,0.00005761776,0.0014684304,0.000008813149,0.000005176054,0.00021363772],"genre_scores_gemma":[0.99960726,0.000056958368,0.000015901553,0.00019274118,0.0000070885067,0.00008428077,0.0000012807749,0.00001079102,0.000023707984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981002,0.0005342433,0.0006897436,0.00023272591,0.0002371162,0.00020593843],"domain_scores_gemma":[0.9987735,0.0002614279,0.00043074784,0.00032691637,0.00014537666,0.00006203583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008549383,0.00013837701,0.0007943277,0.00013102805,0.000025452322,0.0000021921535,0.00014293728,0.000058920214,0.00010064081],"category_scores_gemma":[0.000094694944,0.00007609224,0.000036313446,0.00040667588,0.00028505796,0.000027626564,0.00006995154,0.00018032562,1.7509795e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2343898,0.105231404,0.33493468,0.00081211666,0.00333034,0.00014497143,0.09224857,0.000011099001,0.00465581,0.000037320213,0.00024652694,0.22395736],"study_design_scores_gemma":[0.067703076,0.14294724,0.76925737,0.00011090996,0.0002502505,0.000044306784,0.018337043,0.000066905035,0.000728924,0.00002798486,0.00042541313,0.000100564015],"about_ca_topic_score_codex":0.00055915705,"about_ca_topic_score_gemma":0.0015769381,"teacher_disagreement_score":0.43432269,"about_ca_system_score_codex":0.000039978142,"about_ca_system_score_gemma":0.00025390578,"threshold_uncertainty_score":0.31029516},"labels":[],"label_agreement":null},{"id":"W2346934180","doi":"10.1007/s12282-016-0698-z","title":"Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication","year":2016,"lang":"en","type":"review","venue":"Breast Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Fonds de Recherche du Québec - Santé; Canadian Cancer Society","keywords":"Tumor microenvironment; Medicine; Breast cancer; Immune system; Tumor-infiltrating lymphocytes; Immunotherapy; FOXP3; Immune checkpoint; Cancer; Immunology; Melanoma; Cancer research; Internal medicine","score_opus":0.02245801690494804,"score_gpt":0.3378021954832067,"score_spread":0.3153441785782587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346934180","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002006492,0.9926119,0.000027668828,0.0024160414,0.0003872004,0.001300932,0.001197909,0.000025475592,0.00002639473],"genre_scores_gemma":[0.0023842622,0.9948903,0.0000027088977,0.00043953062,0.0009441933,0.0008301315,0.00016348336,0.00005553902,0.0002898634],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99795496,0.00020316799,0.0008774071,0.0004924249,0.0001945172,0.00027752013],"domain_scores_gemma":[0.9988259,0.00008727245,0.0005219211,0.00044668492,0.000049865772,0.00006836228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042848598,0.00035882278,0.00091868086,0.00012976573,0.00009067749,0.00004578021,0.0001740907,0.00032181505,0.00053645374],"category_scores_gemma":[0.0000057822876,0.00020324867,0.00030440427,0.00031752014,0.00020543416,0.00011987713,0.000036642137,0.0003466694,0.00002169673],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003157059,0.00007880978,0.003339222,0.0013664837,0.00024747752,0.000002206988,0.000034401528,8.313262e-9,0.0010228669,0.0000019225577,0.000057252444,0.9935337],"study_design_scores_gemma":[0.0008318192,0.000029048244,0.3806443,0.008033582,0.00043775034,0.0010783988,0.000008191709,8.088401e-7,0.000011500141,0.0000013646466,0.60873085,0.0001924185],"about_ca_topic_score_codex":0.0006540959,"about_ca_topic_score_gemma":0.00012774284,"teacher_disagreement_score":0.9933412,"about_ca_system_score_codex":0.0004456951,"about_ca_system_score_gemma":0.00031942062,"threshold_uncertainty_score":0.82882404},"labels":[],"label_agreement":null},{"id":"W2397716952","doi":"10.1016/j.jval.2016.03.1611","title":"Cost-Effectiveness of Pembrolizumab (Keytruda®) Versus Ipilimumab in Patients with Advanced Melanoma in Canada","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Merck Canada Inc. (Canada); Université de Montréal","funders":"","keywords":"Ipilimumab; Pembrolizumab; Medicine; Clinical trial; Internal medicine; Oncology; Cancer; Immunotherapy","score_opus":0.028858743836033228,"score_gpt":0.2887272278546563,"score_spread":0.2598684840186231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397716952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99738485,0.00053251605,0.000005060144,0.00032688555,0.000267102,0.0013269272,0.00003019412,0.0000061385326,0.00012032465],"genre_scores_gemma":[0.9995682,0.00016902332,0.000057196154,0.000099076504,0.000008699887,0.00006399521,0.000009813754,0.000017066382,0.000006914202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846596,0.0002519158,0.00041830275,0.00023964826,0.0002744382,0.00034972417],"domain_scores_gemma":[0.999134,0.00037303683,0.00013252924,0.0002348388,0.00004409161,0.00008150359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041499457,0.00012902255,0.0004171668,0.00018307849,0.000013438374,0.0000013196383,0.00007490274,0.000042719264,0.000021586791],"category_scores_gemma":[0.00006029025,0.000088605404,0.000023595805,0.00040798896,0.00004203517,0.0000609989,0.000013143752,0.000113557595,7.377526e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.068626925,0.00022662498,0.8719839,0.00044115246,0.000022782004,0.000017819146,0.00015163345,0.00021089715,0.00018206918,0.000026041178,0.00001574965,0.05809441],"study_design_scores_gemma":[0.055470873,0.0018794088,0.9392464,0.002224045,0.0000029691964,0.0000014600815,0.00009053541,0.000035046454,0.00065925665,0.000010054872,0.00027932934,0.000100610516],"about_ca_topic_score_codex":0.8303211,"about_ca_topic_score_gemma":0.7156386,"teacher_disagreement_score":0.11468248,"about_ca_system_score_codex":0.0041060247,"about_ca_system_score_gemma":0.0031852697,"threshold_uncertainty_score":0.99971706},"labels":[],"label_agreement":null},{"id":"W2398137018","doi":"10.1158/1557-3265.ovca15-b72","title":"Abstract B72: Long-term survival and outcome update on patients (pts) with recurrent ovarian cancer who received Ipilimumab post GVAX vaccine.","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ipilimumab; Medicine; Internal medicine; Ovarian cancer; Oncology; Cancer; Nivolumab; Cancer immunotherapy; Immunotherapy; Immunology","score_opus":0.15463686632635967,"score_gpt":0.48019858411441674,"score_spread":0.3255617177880571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398137018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781578,0.0013255227,0.0000043229275,0.017357735,0.001033407,0.0011359229,0.00025761625,0.00004943388,0.00067823794],"genre_scores_gemma":[0.98133326,0.015020779,0.000016588223,0.001028226,0.0007414777,0.00019886192,0.000038920276,0.00007427849,0.0015476173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99559945,0.00037553016,0.000962415,0.0009874887,0.0012152146,0.0008599142],"domain_scores_gemma":[0.99653876,0.0010279114,0.0002225137,0.0007652547,0.00089601515,0.0005495497],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022663255,0.0003339691,0.0007622448,0.00021945775,0.00022398785,0.00007303149,0.00033106472,0.00026618852,0.0031065494],"category_scores_gemma":[0.0005238173,0.00018939721,0.00019040094,0.00040040625,0.00049440406,0.00016003191,0.00014608252,0.0010121702,0.00009413687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039588556,0.00047818586,0.61978894,0.00012398383,0.0002762336,0.000036419056,0.00003964997,1.3953321e-7,0.00039782087,0.000010582373,0.002233914,0.33702555],"study_design_scores_gemma":[0.019661821,0.003249132,0.9645742,0.0016331855,0.000062758205,0.000002615643,0.000025990537,0.0000018967951,0.00024990796,0.00001494998,0.01023358,0.00028992488],"about_ca_topic_score_codex":0.0012332977,"about_ca_topic_score_gemma":0.003646025,"teacher_disagreement_score":0.34478527,"about_ca_system_score_codex":0.0006271016,"about_ca_system_score_gemma":0.00068324467,"threshold_uncertainty_score":0.99780476},"labels":[],"label_agreement":null},{"id":"W2402033264","doi":"10.1016/j.jval.2016.03.1491","title":"Real-World Comparison of Metastatic Melanoma Treatments between Academic and Community Hospitals in Canada: A Retrospective Study","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Ipilimumab; Medicine; Dabrafenib; Dacarbazine; Pembrolizumab; Trametinib; Internal medicine; Vemurafenib; Nivolumab; Oncology; Melanoma; Immunotherapy; Chemotherapy; Metastatic melanoma; Cancer","score_opus":0.08628646098148093,"score_gpt":0.38129555611284605,"score_spread":0.2950090951313651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402033264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966199,0.0010215964,0.0000014066824,0.001067031,0.000045818786,0.0010825052,0.00006492449,0.0000071789304,0.00008962986],"genre_scores_gemma":[0.99930006,0.0004936896,0.00006107136,0.00005767696,0.000012112111,0.000027086751,0.0000052558585,0.000011722313,0.000031310843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784195,0.0008217425,0.0006953154,0.00016266922,0.00023340361,0.00024494273],"domain_scores_gemma":[0.9989538,0.00043219532,0.00025139234,0.00024708404,0.000018833773,0.00009667957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010399222,0.00012485434,0.0007255119,0.00019306794,0.00005576747,0.0000017120111,0.000080943835,0.000028505481,0.000009335989],"category_scores_gemma":[0.00006897748,0.00008661997,0.000023878267,0.0003631842,0.000059459257,0.00004071439,0.000028858844,0.0003563647,3.010015e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000363217,0.00027175472,0.98752624,0.000091434216,0.00012135825,0.0000059387667,0.0034968425,0.000001102451,0.00014711627,0.000008668672,0.000035194058,0.007931123],"study_design_scores_gemma":[0.0051134713,0.0021023958,0.98863584,0.00059105485,0.000035067795,0.0000013390576,0.0030359314,0.000017033366,0.00029089404,0.00009468622,0.000010780438,0.000071537426],"about_ca_topic_score_codex":0.9895824,"about_ca_topic_score_gemma":0.8922011,"teacher_disagreement_score":0.0973813,"about_ca_system_score_codex":0.0023707906,"about_ca_system_score_gemma":0.0011582817,"threshold_uncertainty_score":0.61995345},"labels":[],"label_agreement":null},{"id":"W2402915536","doi":"10.1093/annonc/mdv527.02","title":"315O_PR Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Tolerability; Internal medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Adverse effect; Phases of clinical research; Surgery; Gastroenterology; Clinical trial; Cancer; Immunotherapy","score_opus":0.06563245932026754,"score_gpt":0.3743396067828195,"score_spread":0.308707147462552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402915536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99670833,0.00025368904,0.000003942429,0.0006313191,0.00009503667,0.000741124,0.00038833526,0.00000699065,0.001171211],"genre_scores_gemma":[0.9995369,0.000040948824,0.000056943994,0.00022378647,0.000031359265,0.000010251682,0.00006809938,0.000011073115,0.000020665864],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9987113,0.00019847522,0.0004262481,0.00028024305,0.00020242341,0.00018130537],"domain_scores_gemma":[0.9989431,0.00014231575,0.00031079593,0.00022536192,0.00027927232,0.00009918745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004044239,0.00014342036,0.0006419319,0.0001366196,0.000018579287,0.0000031011737,0.00007714345,0.000085741674,0.000012451885],"category_scores_gemma":[0.00008796984,0.000112332316,0.000048355258,0.0001615333,0.0002281965,0.00010647592,0.000061596555,0.00014739197,6.428922e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6918357,0.016147697,0.22501792,0.000034682114,0.00047536404,0.00017657854,0.0070118355,6.134753e-7,0.0036771914,0.000002603871,0.00065940217,0.05496039],"study_design_scores_gemma":[0.108933404,0.045119528,0.8374209,0.000090604,0.00006739952,0.0000070151964,0.00067209103,0.000012135561,0.0072865873,0.00000804348,0.0002909959,0.00009132486],"about_ca_topic_score_codex":0.0035510615,"about_ca_topic_score_gemma":0.00056167954,"teacher_disagreement_score":0.612403,"about_ca_system_score_codex":0.00008712728,"about_ca_system_score_gemma":0.00033405208,"threshold_uncertainty_score":0.5368166},"labels":[],"label_agreement":null},{"id":"W2403393996","doi":"10.1158/1538-7445.sabcs15-s5-07","title":"Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Breast cancer; Oncology; Cancer; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Progressive disease; Immunotherapy; Clinical trial; Disease","score_opus":0.01529012457989496,"score_gpt":0.32621919828278506,"score_spread":0.3109290737028901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2403393996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992351,0.0017090277,0.00000419056,0.001857566,0.000088234716,0.0025243359,0.0007707496,0.000020494143,0.00067440816],"genre_scores_gemma":[0.99541974,0.0033837631,0.000082401435,0.00008712957,0.00008313731,0.00045829517,0.000035915917,0.000067999994,0.00038162665],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.996532,0.0003123483,0.00061410025,0.0007729049,0.00093512563,0.0008335018],"domain_scores_gemma":[0.99769706,0.0007326727,0.00021220896,0.00041732096,0.00070368295,0.00023706972],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00064668834,0.0003536935,0.00072485616,0.00048784984,0.000121726735,0.00002044994,0.0002351656,0.00020416088,0.00097059936],"category_scores_gemma":[0.00012153652,0.00024227177,0.00008975551,0.00089392555,0.0008504353,0.00029999999,0.0001233924,0.0006045493,0.000011030717],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47658446,0.00102526,0.27218983,0.00026386883,0.0004743553,0.000053038733,0.00213472,0.000030212655,0.044852473,0.000017242546,0.00027246145,0.2021021],"study_design_scores_gemma":[0.04390439,0.0023442816,0.9221922,0.0047376817,0.000029945168,0.0000064976807,0.00029477556,0.0000041351473,0.02601561,0.00001527993,0.00017088426,0.00028432137],"about_ca_topic_score_codex":0.0045379763,"about_ca_topic_score_gemma":0.0006534737,"teacher_disagreement_score":0.65000236,"about_ca_system_score_codex":0.0017142456,"about_ca_system_score_gemma":0.0010350513,"threshold_uncertainty_score":0.99994266},"labels":[],"label_agreement":null},{"id":"W2404115445","doi":"10.1158/1538-7445.sabcs15-s1-01","title":"Abstract S1-01: Analysis of molecular prognostic factors associated with tumor immune and stromal microenvironment in BEATRICE, an open-label phase 3 trial in early triple-negative breast cancer (eTNBC)","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Gene signature; Breast cancer; Population; Oncology; Immune system; Biomarker; Stromal cell; Medicine; Cancer research; Proportional hazards model; Internal medicine; Triple-negative breast cancer; CD8; Cancer; Immunology; Biology; Gene expression; Gene; Genetics","score_opus":0.07188113592461359,"score_gpt":0.3979305673090321,"score_spread":0.3260494313844185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2404115445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951899,0.0011140283,0.000002631709,0.00037880475,0.00003563721,0.0024090358,0.0008334331,0.000008225998,0.000028311542],"genre_scores_gemma":[0.9987113,0.00052001356,0.000016215048,0.00002214961,0.000025256884,0.0005147878,0.000053177548,0.00003558183,0.00010151329],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972473,0.0003051422,0.0005660647,0.00056813064,0.00071893726,0.0005944728],"domain_scores_gemma":[0.99877375,0.00032258718,0.00022545004,0.00034335154,0.00015053769,0.00018432458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010048117,0.0002334421,0.00076420465,0.00089755206,0.00006694235,0.000051859457,0.00029650223,0.0001031074,0.0006867415],"category_scores_gemma":[0.0001406311,0.00015416631,0.00006608579,0.002070389,0.00044859597,0.00025753284,0.00009740397,0.00036510846,8.831368e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14977024,0.0027377622,0.25378606,0.000043825938,0.0018552842,0.00012802574,0.00074604474,0.000007296638,0.58140904,0.0000018015876,0.000015779366,0.009498811],"study_design_scores_gemma":[0.1430954,0.0029350019,0.820534,0.00061147125,0.0003004906,0.0000010831329,0.00028689989,0.000022579936,0.03201649,0.0000046881455,0.000010774818,0.00018115739],"about_ca_topic_score_codex":0.023531439,"about_ca_topic_score_gemma":0.0062272563,"teacher_disagreement_score":0.5667479,"about_ca_system_score_codex":0.0012168677,"about_ca_system_score_gemma":0.0006579929,"threshold_uncertainty_score":0.98297095},"labels":[],"label_agreement":null},{"id":"W2409661721","doi":"","title":"Colon polyps and cytokines: emerging immunological mechanisms.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Cytotoxic T cell; Immune system; Immunology; Medicine; Colorectal cancer; CD8; Cancer research; CTL*; T cell; Cancer; Biology; Internal medicine; In vitro","score_opus":0.019799343633740356,"score_gpt":0.23433297386894109,"score_spread":0.21453363023520072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409661721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9701954,0.006831476,0.000389263,0.0023151406,0.0004522427,0.00094344426,0.000003981263,0.00012646378,0.018742582],"genre_scores_gemma":[0.9971193,0.0005550429,0.00038486742,0.0009371636,0.00003081883,0.00032214203,0.000002806304,0.000011203392,0.0006366186],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992709,0.000034717657,0.00014110991,0.00017357264,0.00010870936,0.00027097674],"domain_scores_gemma":[0.99971265,0.000027355532,0.000036955356,0.00013471277,0.000013792969,0.00007451972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022475094,0.00009628676,0.00016202743,0.00005808348,0.000063717045,0.000015691503,0.000035502926,0.00007781275,0.000091548354],"category_scores_gemma":[0.00006736526,0.00007429068,0.000052221538,0.00014028087,0.00006367296,0.000037642043,0.000013910567,0.000093190916,0.00000297595],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026197173,0.00024651224,0.006375643,0.0000817525,0.0003988054,0.00010097636,0.0002757261,2.2195837e-7,0.123603575,0.007504127,0.000689526,0.8581034],"study_design_scores_gemma":[0.008387847,0.00038542892,0.6797929,0.000040833373,0.00015448776,0.0006183136,0.000656163,0.000009131084,0.11711251,0.0019423737,0.190462,0.00043801367],"about_ca_topic_score_codex":0.000022008491,"about_ca_topic_score_gemma":0.0000024451513,"teacher_disagreement_score":0.8576654,"about_ca_system_score_codex":0.000038074035,"about_ca_system_score_gemma":0.000018625633,"threshold_uncertainty_score":0.3029486},"labels":[],"label_agreement":null},{"id":"W2412466530","doi":"10.1158/1538-7445.am2015-4303","title":"Abstract 4303: Programmed death ligand 1 (PD-L1) expression in paired melanoma tumor samples","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University College of the North","funders":"","keywords":"Concordance; Immunohistochemistry; Medicine; Melanoma; Internal medicine; Confidence interval; Gastroenterology; Pathology; Oncology; Cancer research","score_opus":0.22448888422165203,"score_gpt":0.4316842909616055,"score_spread":0.20719540673995346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2412466530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875373,0.0073652347,0.000005108532,0.0019296573,0.00017676018,0.0009927333,0.000018558194,0.000060021597,0.0019145746],"genre_scores_gemma":[0.99720526,0.0005097766,0.00025484603,0.0002013022,0.0003230322,0.0005205694,0.00002832699,0.000039261533,0.0009176408],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975406,0.00012327904,0.00032685374,0.00041598937,0.00089247944,0.0007008086],"domain_scores_gemma":[0.99875355,0.00013860696,0.00005744951,0.00041550785,0.00028554496,0.00034933956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016961145,0.00016449702,0.00031204504,0.00030124796,0.00009217571,0.0000652385,0.00021796394,0.00011260264,0.00030116382],"category_scores_gemma":[0.0002551291,0.00012639342,0.00008305019,0.00058528874,0.00019676733,0.0001142901,0.00008011277,0.0005027542,0.00003636794],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018086959,0.00059030455,0.1814936,0.00039631338,0.0001100275,0.0005437972,0.002322625,0.0000044500252,0.6668038,0.000024664727,0.029362136,0.100261375],"study_design_scores_gemma":[0.009898647,0.0009928093,0.42592108,0.0015289646,0.000015814683,0.000046346886,0.0017334127,0.000025644455,0.41252515,0.00029272787,0.14669143,0.00032797465],"about_ca_topic_score_codex":0.0042011943,"about_ca_topic_score_gemma":0.0007965812,"teacher_disagreement_score":0.2542786,"about_ca_system_score_codex":0.0006910398,"about_ca_system_score_gemma":0.001142187,"threshold_uncertainty_score":0.6350977},"labels":[],"label_agreement":null},{"id":"W2417272722","doi":"","title":"Cytokines in cancer and immunity--fifth joint ICS and ISICR meeting. 21-25 October 2004, San Juan, Puerto Rico.","year":2004,"lang":"en","type":"article","venue":"PubMed","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Joint (building); Immunity; Cancer; Geography; Gerontology; Immunology; Environmental ethics; Medicine; Engineering; Immune system; Civil engineering; Internal medicine; Philosophy","score_opus":0.027897598283416338,"score_gpt":0.256999022943361,"score_spread":0.22910142465994468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2417272722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97339225,0.018631017,0.0000074755108,0.004947082,0.0002402308,0.00081580895,0.000013285071,0.000047657668,0.0019051849],"genre_scores_gemma":[0.9925721,0.0043925187,0.00012419627,0.0017480437,0.00016077202,0.00047403885,0.000009851163,0.000030458583,0.00048797645],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987039,0.00003839302,0.00032519276,0.00029305895,0.00019600724,0.00044342177],"domain_scores_gemma":[0.99943906,0.000042531115,0.00009303904,0.00022235182,0.00004587374,0.00015715319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040623493,0.00020789316,0.00035318916,0.00017796399,0.00009000586,0.000044815777,0.00006401895,0.00011648335,0.00002994122],"category_scores_gemma":[0.00008175943,0.00017236928,0.00005907789,0.00032549663,0.00017193312,0.000114870054,0.000060601124,0.0002422547,0.0000017225651],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004223517,0.0007621844,0.27935997,0.0006147212,0.0005873234,0.00020503456,0.0035129418,0.000023862685,0.03412425,0.000078059435,0.0036672626,0.6728409],"study_design_scores_gemma":[0.007212865,0.000083000974,0.959777,0.00019705787,0.00007258891,0.00006874776,0.00023957132,0.00000798958,0.008139234,0.0001570278,0.023786886,0.00025801876],"about_ca_topic_score_codex":0.006067797,"about_ca_topic_score_gemma":0.001833652,"teacher_disagreement_score":0.68041706,"about_ca_system_score_codex":0.00018970964,"about_ca_system_score_gemma":0.00008489066,"threshold_uncertainty_score":0.91727346},"labels":[],"label_agreement":null},{"id":"W2430573464","doi":"10.1186/s40425-016-0142-0","title":"Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Clinical trial; Common Rule; Medicine; Government (linguistics); Declaration; Cancer immunotherapy; Standardization; Cancer; Immunotherapy; Alternative medicine; Engineering ethics; Informed consent; Political science; Pathology; Law; Internal medicine","score_opus":0.03576900875414307,"score_gpt":0.36246891781178425,"score_spread":0.3266999090576412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2430573464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7196866,0.042926926,0.002276346,0.22623204,0.002319116,0.005662674,0.00077325315,0.000032500422,0.00009051025],"genre_scores_gemma":[0.7672882,0.15948956,0.0025280733,0.046954755,0.0028191635,0.0039355424,0.000017154296,0.00040451824,0.01656301],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99770683,0.00007713595,0.00084800285,0.0002580884,0.0006094353,0.00050052983],"domain_scores_gemma":[0.9974293,0.00047379214,0.00088565605,0.00057865353,0.00055807317,0.00007449139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015369246,0.00032903132,0.00064804876,0.00010124561,0.00042035608,0.00003977385,0.00052316114,0.000118520125,0.00080460374],"category_scores_gemma":[0.00002490441,0.00014149719,0.000991967,0.00025132837,0.00025956784,0.00008210238,0.000021414748,0.00020237154,0.0000014959413],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02351696,0.0002021942,0.0005920183,0.000101263475,0.002729637,2.7493724e-7,0.0021109988,0.000015601154,0.5523962,0.00012081953,0.045316212,0.37289786],"study_design_scores_gemma":[0.009877154,0.002951359,0.004234076,0.0010210124,0.00013223379,0.0000060332763,0.0005259054,0.000019529612,0.33279195,0.00033121213,0.6478982,0.00021136872],"about_ca_topic_score_codex":0.0005359559,"about_ca_topic_score_gemma":0.00050296815,"teacher_disagreement_score":0.602582,"about_ca_system_score_codex":0.00056154,"about_ca_system_score_gemma":0.0004999012,"threshold_uncertainty_score":0.88098466},"labels":[],"label_agreement":null},{"id":"W2461149012","doi":"10.1200/jco.2013.31.15_suppl.8072","title":"A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Pemetrexed; Internal medicine; Carboplatin; Regimen; Pneumonitis; Chemotherapy; Gemcitabine; Chemotherapy regimen; Lung cancer; Vinorelbine; Phases of clinical research; Oncology; Gastroenterology; Cancer; Cisplatin; Lung; Immunotherapy","score_opus":0.05354189609253231,"score_gpt":0.4133180934351775,"score_spread":0.3597761973426452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461149012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912364,0.00065020606,0.00012542169,0.002962437,0.0014610812,0.00258426,0.00001564225,0.000018404648,0.0009461852],"genre_scores_gemma":[0.99122804,0.0008976978,0.0010931147,0.005504357,0.000766323,0.000087920125,0.000010102819,0.00008467557,0.00032774106],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99278265,0.0004989653,0.0047618947,0.00054583274,0.0007727889,0.0006378826],"domain_scores_gemma":[0.9927234,0.0011711138,0.004117054,0.00054937514,0.0009943239,0.0004447164],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024720863,0.0004873536,0.003158247,0.0004762919,0.00007146638,0.000030179413,0.0005471187,0.0007053334,0.0016329741],"category_scores_gemma":[0.00023091651,0.00037428451,0.00088383886,0.0005677172,0.0003106487,0.00022870357,0.000054778528,0.0014830088,0.000013135513],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11384483,0.06203807,0.5719007,0.00032135734,0.0020683953,0.00025870412,0.0038516982,0.00021654992,0.0060729417,0.000001441489,0.016016614,0.22340867],"study_design_scores_gemma":[0.4690957,0.06254989,0.45038927,0.0007778362,0.00057409174,0.000024933703,0.0012413956,0.002596315,0.0030793578,0.000016589027,0.009113374,0.0005412177],"about_ca_topic_score_codex":0.0023117447,"about_ca_topic_score_gemma":0.00050664885,"teacher_disagreement_score":0.3552509,"about_ca_system_score_codex":0.0009275375,"about_ca_system_score_gemma":0.0038697391,"threshold_uncertainty_score":0.9998709},"labels":[],"label_agreement":null},{"id":"W2464620827","doi":"10.1200/jco.2016.66.9861","title":"Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":447,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Pemetrexed; Carboplatin; Tolerability; Gemcitabine; Lung cancer; Oncology; Internal medicine; Cisplatin; Chemotherapy; Paclitaxel; Adverse effect; Cancer; Immunotherapy","score_opus":0.06176889032220338,"score_gpt":0.424635470981647,"score_spread":0.3628665806594436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464620827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98032814,0.00070737046,0.0027269148,0.014901805,0.00041024014,0.0007352623,0.000010368782,0.000004320901,0.00017559587],"genre_scores_gemma":[0.9901904,0.003071555,0.005049092,0.0008619676,0.0002802976,0.0000490887,0.00000279956,0.000020982025,0.00047385864],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979666,0.00006703631,0.0014714038,0.00015320818,0.00016798855,0.0001737944],"domain_scores_gemma":[0.9965015,0.001409372,0.0015150313,0.00014011453,0.0003334626,0.00010049836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007934341,0.00013220894,0.0010825493,0.00012013133,0.00001955834,0.000002296959,0.000081686514,0.00021343918,0.00012877809],"category_scores_gemma":[0.000109494504,0.00006993033,0.00032384586,0.000121617784,0.00011748732,0.00005894275,0.000003925778,0.00012150599,3.6142313e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17878795,0.0062543573,0.15290467,0.00013314071,0.0005158485,0.000050658884,0.00019729779,0.00013048631,0.0091301855,0.000006192299,0.00060354744,0.65128565],"study_design_scores_gemma":[0.5029155,0.15535109,0.24689975,0.0013770468,0.0005401635,0.000037913753,0.00009142532,0.0011639111,0.028795585,0.00008537974,0.06250433,0.00023791568],"about_ca_topic_score_codex":0.0000623852,"about_ca_topic_score_gemma":0.0006493477,"teacher_disagreement_score":0.65104777,"about_ca_system_score_codex":0.0005265014,"about_ca_system_score_gemma":0.0014844622,"threshold_uncertainty_score":0.2851676},"labels":[],"label_agreement":null},{"id":"W2465405903","doi":"10.1016/j.cllc.2016.06.006","title":"Immunotherapy Comes of Age in Lung Cancer","year":2016,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Immunosurveillance; Immunotherapy; Lung cancer; Immunology; Immune system; Immune checkpoint; Cancer; Vaccine therapy; Cytotoxic T cell; Oncology; Cancer research; Internal medicine; Biology","score_opus":0.0805236080097743,"score_gpt":0.49545136780202026,"score_spread":0.41492775979224594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2465405903","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001850144,0.99333084,0.0000078144785,0.00044374607,0.0025644114,0.0020400432,0.00027207826,0.00004599279,0.0011100871],"genre_scores_gemma":[0.000059155325,0.9913741,0.00004610166,0.00082726957,0.0011142889,0.0007535897,0.000043242348,0.00013514134,0.005647115],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953775,0.00033355257,0.002625263,0.0007431286,0.00039818953,0.00052236905],"domain_scores_gemma":[0.99684936,0.0009137174,0.0010619019,0.00090252387,0.000113839385,0.0001586328],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010369869,0.0005820283,0.0042771846,0.00027539095,0.000036728197,0.000015996256,0.00044864605,0.00086246827,0.0033965008],"category_scores_gemma":[0.00009960957,0.0003702657,0.0018724847,0.0005591387,0.00048494077,0.000064018896,0.00007926357,0.0008572994,0.000011968167],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009813677,0.00019471596,0.0082745515,0.017296322,0.0021101136,0.000051146828,0.000042610252,9.597017e-8,0.0000096183985,0.000016051772,0.014113381,0.95691],"study_design_scores_gemma":[0.0038358574,0.00014785724,0.0028271226,0.09228892,0.0009943012,0.0000072533508,0.000003859883,0.000003978669,0.0000035799796,0.0000068071968,0.89947224,0.00040820846],"about_ca_topic_score_codex":0.00047144183,"about_ca_topic_score_gemma":0.00036001662,"teacher_disagreement_score":0.95650184,"about_ca_system_score_codex":0.0009224263,"about_ca_system_score_gemma":0.0020616013,"threshold_uncertainty_score":0.99987495},"labels":[],"label_agreement":null},{"id":"W2466059604","doi":"10.1016/j.canlet.2016.06.023","title":"Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells","year":2016,"lang":"en","type":"article","venue":"Cancer Letters","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research; Dalhousie University; Canadian Cancer Society; Dalhousie Medical Research Foundation","keywords":"Apigenin; Jurkat cells; Cytotoxic T cell; Immune system; Cancer research; Biology; Chemistry; Molecular biology; T cell; Immunology; Biochemistry; In vitro","score_opus":0.019595907473079276,"score_gpt":0.26038791105989745,"score_spread":0.24079200358681818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2466059604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98787683,0.0032832094,0.00010396832,0.008097982,0.000097708624,0.00042128816,0.000024205498,0.000026236374,0.00006857703],"genre_scores_gemma":[0.99551696,0.00045819712,0.00008345813,0.002746499,0.0000971214,0.00008969436,0.000005312128,0.000021786722,0.0009809836],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99911475,0.000034235858,0.00020450115,0.00024832235,0.00017404082,0.00022416412],"domain_scores_gemma":[0.99944484,0.00003241876,0.0001077222,0.00031064122,0.000029687431,0.00007467731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013266019,0.00013977925,0.00019243607,0.000049431663,0.000079959194,0.000016384063,0.00010902974,0.00006772801,0.000027080232],"category_scores_gemma":[0.000004464085,0.00007381848,0.000062570965,0.000097322096,0.00018531905,0.00008523223,0.00004266945,0.00009059108,0.0000012107008],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026631574,0.00005352233,0.009941605,0.00005610462,0.00004006259,0.000004327114,0.00037043268,3.4863668e-8,0.9443832,0.0000035055048,0.030362198,0.014518677],"study_design_scores_gemma":[0.0042896303,0.00012186963,0.0051581506,0.00022618365,0.00003172589,0.000005777548,0.00003326368,4.345772e-7,0.97687817,0.0000050654576,0.0131398,0.00010995288],"about_ca_topic_score_codex":0.000263478,"about_ca_topic_score_gemma":0.000012706009,"teacher_disagreement_score":0.032494932,"about_ca_system_score_codex":0.00008034382,"about_ca_system_score_gemma":0.000051851337,"threshold_uncertainty_score":0.30102304},"labels":[],"label_agreement":null},{"id":"W2466658396","doi":"10.1080/2162402x.2016.1204507","title":"Intratumoral expression levels of <i>PD-L1</i>, <i>GZMA</i>, and <i>HLA-A</i> along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma","year":2016,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Regina","keywords":"Nivolumab; TIGIT; Perforin; Melanoma; Immune checkpoint; PD-L1; Granzyme; CD8; Immune system; Immunology; Cancer research; Tumor-infiltrating lymphocytes; Cytotoxic T cell; Medicine; Tumor microenvironment; Human leukocyte antigen; T cell; Immunotherapy; Antigen; Biology","score_opus":0.011640409059253743,"score_gpt":0.24676790515993152,"score_spread":0.2351274961006778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2466658396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99551356,0.0013137948,0.00022409759,0.0019394564,0.000091642585,0.00052006904,0.000052423944,0.000035181132,0.0003097779],"genre_scores_gemma":[0.99549496,0.00013765386,0.0027840643,0.0005361999,0.000019318915,0.00005632247,0.0000062563727,0.000043845972,0.0009214031],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979546,0.00034709825,0.00048727304,0.00045389443,0.00029842948,0.00045869141],"domain_scores_gemma":[0.99873114,0.00038262713,0.00025324812,0.00041502714,0.000115944735,0.00010199789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006453673,0.00028537874,0.00070089503,0.00027650205,0.00006216446,0.000011234552,0.00014248653,0.00013898706,0.00009026757],"category_scores_gemma":[0.00006592445,0.00016780318,0.00005995991,0.00037463888,0.0003332513,0.00014704998,0.0000773426,0.00020674514,0.000008818629],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074030094,0.00024924794,0.01709871,0.000048245747,0.00011653672,0.00023009378,0.0009289802,0.0000011116489,0.89736503,0.000007494348,0.00021966401,0.009704809],"study_design_scores_gemma":[0.01947753,0.008109247,0.42811024,0.0013702918,0.000099989185,0.00045315802,0.0006285831,0.0000019959134,0.53910637,0.00003300038,0.0022707821,0.00033880438],"about_ca_topic_score_codex":0.00033043747,"about_ca_topic_score_gemma":0.00034797334,"teacher_disagreement_score":0.41101155,"about_ca_system_score_codex":0.00021153444,"about_ca_system_score_gemma":0.00042832977,"threshold_uncertainty_score":0.6842815},"labels":[],"label_agreement":null},{"id":"W2468483329","doi":"10.1038/modpathol.2016.109","title":"Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group","year":2016,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":279,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Vancouver General Hospital; McMaster University","funders":"European Commission","keywords":"Medicine; Breast cancer; Concordance; Intraclass correlation; Internal medicine; Surgical oncology; Oncology; Biomarker; Cancer; Medical physics; Pathology","score_opus":0.06188627006501885,"score_gpt":0.35220671003961046,"score_spread":0.2903204399745916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2468483329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99255615,0.003177948,0.0000805246,0.0024842164,0.0006774865,0.00035679198,0.00009799654,0.000006282697,0.0005626003],"genre_scores_gemma":[0.99916416,0.0004993926,0.00011442006,0.00010566057,0.00003899216,0.000043986638,0.0000017696522,0.000010337188,0.000021249201],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99813503,0.0003973078,0.0006836955,0.00020387313,0.00042723824,0.00015288281],"domain_scores_gemma":[0.99835354,0.00030392036,0.00064882776,0.00032921563,0.00035407298,0.000010434703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023674148,0.0001098923,0.00038965335,0.000100371144,0.00004289556,0.0000019976603,0.00022563846,0.00007530939,0.000025046013],"category_scores_gemma":[0.00038737385,0.000054669716,0.00013839894,0.00020021907,0.00048204066,0.000040263105,0.00013668064,0.00006817402,9.698188e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048377244,0.00006694741,0.08911594,0.000029727467,0.00022735601,0.0000027047518,0.0018053008,0.000041491072,0.7582616,0.00003178453,0.000025035362,0.14555438],"study_design_scores_gemma":[0.022430615,0.00016476071,0.8189071,0.002228497,0.00021044919,0.00021394482,0.0010401881,0.0018545793,0.15158358,0.0010859476,0.00016089335,0.0001194743],"about_ca_topic_score_codex":0.00023983407,"about_ca_topic_score_gemma":0.0005740917,"teacher_disagreement_score":0.7297911,"about_ca_system_score_codex":0.0006452599,"about_ca_system_score_gemma":0.00040908222,"threshold_uncertainty_score":0.22293663},"labels":[],"label_agreement":null},{"id":"W2470412971","doi":"10.1038/npjbcancer.2016.22","title":"The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population","year":2016,"lang":"en","type":"article","venue":"npj Breast Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Cancer Agency; Cancer Research UK","keywords":"Subtyping; Breast cancer; Oncology; Medicine; Internal medicine; Population; Cancer; Cancer research","score_opus":0.009950373896513452,"score_gpt":0.28530443092892915,"score_spread":0.2753540570324157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470412971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98909754,0.0047544055,0.00025339,0.0022836558,0.0002403753,0.00035695825,0.0029342547,0.000027445443,0.000051978528],"genre_scores_gemma":[0.99646217,0.0029934878,0.000029090628,0.00016723979,0.000090132664,0.000072429626,0.000047833,0.000029316072,0.00010831711],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99818933,0.000101459984,0.0006271437,0.00029939206,0.00048017214,0.00030252466],"domain_scores_gemma":[0.9981527,0.0000990274,0.00061721593,0.0005393573,0.00048467537,0.00010706743],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018731914,0.00023142793,0.0007049521,0.00027547838,0.00009498047,0.000012428739,0.00016308865,0.00011056969,0.0010653592],"category_scores_gemma":[0.0000069516113,0.00012760826,0.00042144346,0.0009944437,0.00023081894,0.000090384594,0.00003679278,0.0000896568,0.0000018778384],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016957885,0.00020609656,0.34647578,0.00004867448,0.0073284805,0.000006806192,0.00018001525,0.000033640503,0.117080055,0.00004455722,0.000492258,0.5111458],"study_design_scores_gemma":[0.010466962,0.00013222432,0.98094314,0.00030775397,0.0030624706,0.000026231139,0.0000850577,0.00037404292,0.0037232228,0.000018119821,0.00068577676,0.0001749991],"about_ca_topic_score_codex":0.050782483,"about_ca_topic_score_gemma":0.0016409071,"teacher_disagreement_score":0.63446736,"about_ca_system_score_codex":0.00018517666,"about_ca_system_score_gemma":0.00016293277,"threshold_uncertainty_score":0.9998478},"labels":[],"label_agreement":null},{"id":"W2470583568","doi":"10.1093/annonc/mdw265","title":"Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Flatiron Health; Helsinn; Genentech; Celgene; Amgen; Pfizer; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Medicine; Nivolumab; Quality of life (healthcare); Phases of clinical research; Internal medicine; Oncology; Cancer; Nursing; Immunotherapy; Chemotherapy","score_opus":0.058747586539183036,"score_gpt":0.4089947964497547,"score_spread":0.3502472099105717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470583568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99432933,0.0005246093,7.0549163e-7,0.0029782508,0.000084129795,0.0015190858,0.0002988017,0.000009084216,0.0002559766],"genre_scores_gemma":[0.99932534,0.0002508009,0.000010204833,0.00025543928,0.000012803541,0.000033708675,0.000046141653,0.000011624826,0.00005391194],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9974143,0.0008281514,0.0010864929,0.00024842366,0.00022173522,0.00020093135],"domain_scores_gemma":[0.99699426,0.0013466519,0.0010377511,0.00043067234,0.00012887854,0.00006178869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012136756,0.00015936446,0.0010742444,0.0000777714,0.000025260104,8.165003e-7,0.0001014508,0.0000927318,0.000036397687],"category_scores_gemma":[0.00030422155,0.00007368573,0.00011066188,0.00018407215,0.00018942473,0.000036430734,0.000016842318,0.000072661234,0.0000017242653],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47918713,0.0075912285,0.11705659,0.000037841426,0.0009142449,0.0000056219465,0.0024905554,0.0000018173582,0.0022094685,0.0000033877093,0.00029281265,0.39020932],"study_design_scores_gemma":[0.22163238,0.18836893,0.5785328,0.00029069505,0.00005847872,3.3348525e-7,0.00027093675,0.000001158562,0.010352359,0.000008325129,0.00040813923,0.00007546952],"about_ca_topic_score_codex":0.0078876205,"about_ca_topic_score_gemma":0.001319498,"teacher_disagreement_score":0.4614762,"about_ca_system_score_codex":0.00012291384,"about_ca_system_score_gemma":0.00026138284,"threshold_uncertainty_score":0.9987189},"labels":[],"label_agreement":null},{"id":"W2471272049","doi":"10.1200/jco.2014.32.15_suppl.8020","title":"Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Rash; Lung cancer; Adverse effect; Immunohistochemistry; Cancer; Oncology; Incidence (geometry); Gastroenterology","score_opus":0.04064561755296586,"score_gpt":0.4091944623600961,"score_spread":0.36854884480713024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471272049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955856,0.0004511373,0.00015332972,0.0011415812,0.0005176074,0.00040864147,0.000004637141,0.0000041776248,0.0017332381],"genre_scores_gemma":[0.99280524,0.005050916,0.00066154334,0.00092119764,0.0003733187,0.0000033222666,0.0000015257776,0.000018142948,0.0001647906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959868,0.0007129813,0.0025591198,0.0002422699,0.00025711124,0.00024172604],"domain_scores_gemma":[0.99465674,0.0022029777,0.0023047926,0.00020155043,0.00035367516,0.00028027783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042873854,0.00016548198,0.0018632971,0.00011143452,0.00002393754,0.000004595217,0.00013253,0.00045309443,0.00007193103],"category_scores_gemma":[0.0007957009,0.00010482933,0.00036464867,0.00016825735,0.0003403479,0.000081524566,0.00003900451,0.00094013434,8.779307e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04997785,0.0022092476,0.6923264,0.00007363534,0.00029327688,0.000028493076,0.00006968869,0.0000033428084,0.00014322493,8.749507e-7,0.00033215256,0.25454175],"study_design_scores_gemma":[0.04125335,0.023833433,0.92452323,0.0004808869,0.0004984207,0.000021288834,0.000017951346,0.00028389046,0.0001782211,0.0000041708577,0.0087995,0.000105683706],"about_ca_topic_score_codex":0.00033268819,"about_ca_topic_score_gemma":0.0008540206,"teacher_disagreement_score":0.25443608,"about_ca_system_score_codex":0.00018271785,"about_ca_system_score_gemma":0.0012025222,"threshold_uncertainty_score":0.4274816},"labels":[],"label_agreement":null},{"id":"W2471534305","doi":"10.1016/j.lungcan.2016.06.026","title":"Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca; Pfizer","keywords":"Medicine; Nivolumab; Adverse effect; Lung cancer; Immune system; Cancer; Combination therapy; Toxicity; Oncology; Internal medicine; Immunology; Immunotherapy","score_opus":0.008072019970002274,"score_gpt":0.251468389813785,"score_spread":0.2433963698437827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471534305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98945755,0.0061878446,0.00019454173,0.0010896438,0.00010906157,0.001289484,0.000100064055,0.000059357768,0.0015124672],"genre_scores_gemma":[0.99224514,0.0017092878,0.00032948374,0.0008547332,0.000066683046,0.00093273364,0.0000109839975,0.000073242794,0.0037776958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832076,0.000045002264,0.0003116193,0.0004829512,0.00034211494,0.0004975835],"domain_scores_gemma":[0.99914557,0.000048892776,0.00016688023,0.00037335366,0.00012648919,0.00013883774],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007893961,0.00033133104,0.00048796352,0.00016313334,0.00006487434,0.000020664687,0.00010503398,0.00007418498,0.0009775478],"category_scores_gemma":[0.000003181098,0.00017741697,0.000089528636,0.0005670972,0.000101880505,0.00011632326,0.00001999904,0.00014757678,0.000004127954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02929897,0.000595778,0.82668597,0.0012569292,0.0021944852,0.0006801486,0.0034105051,0.00015557151,0.039306607,0.000003938219,0.008355578,0.08805555],"study_design_scores_gemma":[0.20103538,0.009466388,0.4558422,0.03749129,0.008074891,0.0008018486,0.0024458175,0.004193751,0.24397938,0.000010693583,0.031764608,0.0048937667],"about_ca_topic_score_codex":0.012944956,"about_ca_topic_score_gemma":0.012397001,"teacher_disagreement_score":0.37084374,"about_ca_system_score_codex":0.0011449987,"about_ca_system_score_gemma":0.0006136883,"threshold_uncertainty_score":0.9999357},"labels":[],"label_agreement":null},{"id":"W2476422824","doi":"10.1158/1538-7445.am2016-ct097","title":"Abstract CT097: A first-in-human phase I dose escalation study of the OX40 agonist MOXR0916 in patients with refractory solid tumors","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Immunotherapy; Internal medicine; Oncology; Agonist; Cohort; Adverse effect; Refractory (planetary science); Cancer; Gastroenterology; Urology; Receptor","score_opus":0.05143809461649836,"score_gpt":0.40633539807865404,"score_spread":0.3548973034621557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2476422824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971999,0.00012475607,3.3362045e-7,0.00065690815,0.00006152132,0.0014673254,0.000020216472,0.000008544077,0.00046050406],"genre_scores_gemma":[0.9993313,0.000053007145,0.0000016739169,0.000027441061,0.00005333392,0.00018329252,0.0000041493904,0.000023603076,0.00032223278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804425,0.0001210756,0.00037434665,0.0002941681,0.0008095887,0.00035654273],"domain_scores_gemma":[0.99903125,0.000106095205,0.000111064546,0.0004768682,0.00020570373,0.00006901149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007051663,0.00012036668,0.00024824584,0.0002533811,0.000119309974,0.000014574754,0.00020239946,0.00005796872,0.00032264224],"category_scores_gemma":[0.00006213092,0.00006251152,0.000043953656,0.00058812567,0.0002683782,0.00011133383,0.00005219432,0.00035260324,0.0000033295921],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0155921215,0.0051343,0.89144254,0.00013372373,0.0000883998,0.00002778683,0.0023734726,0.000009552436,0.055805422,0.0000057887014,0.00040592405,0.028980946],"study_design_scores_gemma":[0.022492666,0.0022015446,0.9689014,0.0009345818,0.000008307943,3.8052477e-7,0.0005492572,0.0000026395933,0.004221281,0.000008942707,0.0005913314,0.00008767283],"about_ca_topic_score_codex":0.0033392094,"about_ca_topic_score_gemma":0.007783757,"teacher_disagreement_score":0.077458836,"about_ca_system_score_codex":0.0007700637,"about_ca_system_score_gemma":0.00035561016,"threshold_uncertainty_score":0.5047908},"labels":[],"label_agreement":null},{"id":"W2477245600","doi":"10.1200/jco.2016.34.15_suppl.9513","title":"KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Ipilimumab; Internal medicine; Oncology; Family medicine; Immunotherapy; Cancer","score_opus":0.11140591642277498,"score_gpt":0.4643476528672035,"score_spread":0.3529417364444285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2477245600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99274105,0.0032879505,0.00021796017,0.0017477614,0.0011264826,0.00067478756,0.00001743718,0.0000069659695,0.00017963302],"genre_scores_gemma":[0.99389154,0.004226384,0.0010118482,0.00021652602,0.00042230388,0.000009934582,0.0000018804014,0.000023843708,0.00019572629],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962361,0.00034249178,0.0026066795,0.00024191916,0.00035655024,0.00021629749],"domain_scores_gemma":[0.9912105,0.005418573,0.00243198,0.00028161114,0.0004679412,0.0001893801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019475393,0.00018129236,0.0016962603,0.0001187895,0.00003708462,0.0000030033696,0.00019682026,0.00032709356,0.000104952596],"category_scores_gemma":[0.0017454671,0.000099582736,0.00047110024,0.0001059146,0.0002642558,0.00010466951,0.000045778335,0.00030518352,6.441251e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45913962,0.0057964954,0.0030559215,0.000037976457,0.00065937807,0.000016033779,0.00018999366,0.0000015527643,0.1526789,0.0000033210936,0.0023219394,0.37609884],"study_design_scores_gemma":[0.5390982,0.2671107,0.09363038,0.00053990015,0.00055730937,0.00007076773,0.0006518435,0.000014349756,0.036822382,0.00007863962,0.06119898,0.00022654686],"about_ca_topic_score_codex":0.000011835545,"about_ca_topic_score_gemma":0.0000128354495,"teacher_disagreement_score":0.3758723,"about_ca_system_score_codex":0.00008477764,"about_ca_system_score_gemma":0.00051880826,"threshold_uncertainty_score":0.40608662},"labels":[],"label_agreement":null},{"id":"W2477682166","doi":"10.1158/1538-7445.am2016-3261","title":"Abstract 3261: Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Cyclophosphamide; Paclitaxel; Chemotherapy; Breast cancer; Regimen; Oncology; Cancer; Bolus (digestion); Internal medicine; Pharmacology; Cancer research","score_opus":0.06897503347927765,"score_gpt":0.4399733878566051,"score_spread":0.3709983543773275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2477682166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99199533,0.0007301827,0.0000056184062,0.005679166,0.00008672689,0.0006107293,0.00011507332,0.00001889456,0.00075825624],"genre_scores_gemma":[0.99435544,0.0043177484,0.000010810041,0.00012625613,0.0003065722,0.00018311312,0.000003159178,0.00004307003,0.00065385323],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980928,0.00009291224,0.00036194854,0.00041199347,0.0005397848,0.00050056155],"domain_scores_gemma":[0.99879277,0.00029194617,0.00011042049,0.000356685,0.0002946136,0.00015356546],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00089168793,0.00018026576,0.00041883477,0.00037384237,0.000044168613,0.000013731953,0.0001624357,0.00013617489,0.0028899442],"category_scores_gemma":[0.00004155408,0.00009843674,0.00016134068,0.0005578116,0.0004281578,0.00010071873,0.00001881349,0.0003897728,0.000014759578],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06645164,0.00046177013,0.3804953,0.00012247595,0.0006133843,0.000012008491,0.0001545006,0.000013516222,0.4245895,0.000014984242,0.0032845705,0.12378634],"study_design_scores_gemma":[0.009507536,0.0014372943,0.9033603,0.0012741447,0.000016149519,0.000010494548,0.000030115127,0.0000071693794,0.08365407,0.000025478805,0.0005409858,0.00013626603],"about_ca_topic_score_codex":0.011716894,"about_ca_topic_score_gemma":0.00068220927,"teacher_disagreement_score":0.522865,"about_ca_system_score_codex":0.0017313206,"about_ca_system_score_gemma":0.0013022558,"threshold_uncertainty_score":0.99802154},"labels":[],"label_agreement":null},{"id":"W2478115115","doi":"10.1200/jco.2013.31.15_suppl.9009","title":"Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rash; Ipilimumab; Internal medicine; Adverse effect; Progressive disease; Gastroenterology; Melanoma; Toxicity; Phases of clinical research; Surgery; Disease; Cancer; Immunotherapy","score_opus":0.03772999889311207,"score_gpt":0.42130256588563464,"score_spread":0.38357256699252257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2478115115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956844,0.0005379549,0.00003864579,0.0019373996,0.00061858294,0.0004599249,0.0000050852254,0.000005440918,0.00071258645],"genre_scores_gemma":[0.9926462,0.0021885056,0.0038038068,0.0010117708,0.0002769808,0.0000018168821,0.000006951773,0.000018507219,0.000045468707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950143,0.00043776122,0.0036658426,0.00024976066,0.0003720506,0.00026028795],"domain_scores_gemma":[0.9948748,0.0020454458,0.0020765106,0.00022382621,0.00048097302,0.00029844046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023240177,0.00017492786,0.0019892042,0.0001561846,0.000025723022,0.000006575109,0.00016261222,0.00041863177,0.00018896797],"category_scores_gemma":[0.0010454239,0.00011109164,0.0003452401,0.00019363278,0.000562661,0.00018054052,0.000051583036,0.00093054085,0.0000061032542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052587412,0.0023537935,0.71674174,0.00002560959,0.0003598316,0.000055715132,0.000031117273,0.000004183792,0.00016861557,0.000011736506,0.00030693554,0.22735332],"study_design_scores_gemma":[0.061038673,0.027375087,0.9031253,0.0002770141,0.0001408375,0.000060206905,0.00003615125,0.000025145837,0.000022091997,0.000031976004,0.007759353,0.00010816621],"about_ca_topic_score_codex":0.000035175704,"about_ca_topic_score_gemma":0.000016136459,"teacher_disagreement_score":0.22724515,"about_ca_system_score_codex":0.000080541875,"about_ca_system_score_gemma":0.0008665647,"threshold_uncertainty_score":0.45301858},"labels":[],"label_agreement":null},{"id":"W2485024460","doi":"10.1158/1538-7445.am2016-4134","title":"Abstract 4134: Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Immunohistochemistry; Immune system; Tumor microenvironment; Medicine; Osteosarcoma; PD-L1; Immune checkpoint; Immunotherapy; Cancer research; CD68; Tumor-infiltrating lymphocytes; Antigen; Infiltration (HVAC); Antibody; Oncology; Internal medicine; Immunology","score_opus":0.05030626678690519,"score_gpt":0.35589875473078914,"score_spread":0.30559248794388394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2485024460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98526216,0.0068592858,0.0000024719573,0.0067109484,0.00004183758,0.0009295725,0.000010370451,0.0000069239086,0.00017643675],"genre_scores_gemma":[0.9967342,0.0024093853,0.000017333894,0.00017330553,0.000074525364,0.00039925787,0.000004124252,0.0000136668405,0.00017420771],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998574,0.00015583866,0.00025044172,0.00025229258,0.00042442748,0.00034300334],"domain_scores_gemma":[0.99933773,0.00025822883,0.0000518726,0.00027270446,0.000030519925,0.00004894752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010744447,0.000099534074,0.00015338487,0.00017234718,0.00007126855,0.000029147524,0.0001327584,0.000053476855,0.00027276692],"category_scores_gemma":[0.00009657824,0.000053368043,0.000030986,0.00024401705,0.0002323153,0.00009956695,0.000046511763,0.0002917234,0.000013037916],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015569667,0.00011312039,0.13318507,0.000086584834,0.0000073847013,0.00007267284,0.0005698165,3.5335876e-7,0.84046257,0.000002859707,0.0004199368,0.023522694],"study_design_scores_gemma":[0.002417576,0.00017135889,0.8716897,0.0014080364,0.000002989216,0.000018796723,0.00073489355,0.0000018574028,0.11994209,0.00003815587,0.0035059785,0.00006855818],"about_ca_topic_score_codex":0.0005035012,"about_ca_topic_score_gemma":0.00043963164,"teacher_disagreement_score":0.73850465,"about_ca_system_score_codex":0.00031564696,"about_ca_system_score_gemma":0.000115896786,"threshold_uncertainty_score":0.29866064},"labels":[],"label_agreement":null},{"id":"W2509111028","doi":"10.1158/0008-5472.can-16-0136","title":"Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Capecitabine; Medicine; Chemotherapy; In vivo; Cancer; Oncology; Pharmacology; Internal medicine; Cancer research; Colorectal cancer; Biology","score_opus":0.10186511112080873,"score_gpt":0.43537001063229597,"score_spread":0.3335048995114872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2509111028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770724,0.013573202,0.00003516703,0.008081668,0.00006039754,0.0009837257,0.0000033387576,0.000014585442,0.00017549976],"genre_scores_gemma":[0.9921597,0.0068703126,0.000048239166,0.0003099521,0.00012818501,0.00030584735,6.008603e-7,0.000016787524,0.00016035548],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982069,0.00034508418,0.00027765936,0.00030544875,0.00042046487,0.0004444461],"domain_scores_gemma":[0.9964699,0.0027085769,0.00006879176,0.0005876804,0.00011639153,0.000048614886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020954264,0.00011432341,0.00026511628,0.00017166609,0.0000725485,0.000016581227,0.0004427536,0.00008634425,0.00031375626],"category_scores_gemma":[0.00063775043,0.000055655968,0.000114220304,0.000647923,0.00050213706,0.00007289086,0.00006342436,0.00031657136,0.000022825756],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038211169,0.00013256642,0.009442439,0.00008977964,0.000054753655,0.0000064782853,0.00034379444,2.0224348e-7,0.7802256,0.000048182028,0.00030026134,0.20553488],"study_design_scores_gemma":[0.005357889,0.0007278561,0.7505397,0.0020740903,0.00000949437,0.000008737249,0.00014258487,0.000003947812,0.23954433,0.000051136794,0.0014485702,0.000091613794],"about_ca_topic_score_codex":0.0006102685,"about_ca_topic_score_gemma":0.000030480895,"teacher_disagreement_score":0.74109733,"about_ca_system_score_codex":0.00044321027,"about_ca_system_score_gemma":0.00030880424,"threshold_uncertainty_score":0.34354112},"labels":[],"label_agreement":null},{"id":"W2513322051","doi":"10.1182/blood.v126.23.4543.4543","title":"Evan's Syndrome Associated with Pembrolizumab Therapy in Metastatic Non-Small Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Carboplatin; Lung cancer; Internal medicine; Chemotherapy regimen; Cancer; Oncology; Surgery; Gastroenterology; Pathology; Chemotherapy; Immunotherapy","score_opus":0.023281058475851286,"score_gpt":0.27125456213981036,"score_spread":0.24797350366395907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513322051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98930365,0.007841618,0.000013743845,0.000300079,0.00009520016,0.0006496724,0.000016055901,0.000047133217,0.0017328201],"genre_scores_gemma":[0.9972683,0.0005378912,0.00014089348,0.00057873933,0.000031784057,0.00012388185,0.000022341197,0.000041869018,0.0012542618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988464,0.00006276095,0.00022947213,0.0002489768,0.00028894423,0.00032346052],"domain_scores_gemma":[0.9993863,0.00004159277,0.00010736729,0.00023776991,0.00009905454,0.00012791918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029452072,0.00019165511,0.00037511584,0.0001244579,0.00002708338,0.000019620204,0.000100997415,0.00006922877,0.00011377073],"category_scores_gemma":[0.000015944865,0.00013903946,0.0000721184,0.0003567517,0.00004643291,0.000060820243,0.000012918046,0.00017511417,0.000006738911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017236914,0.01114441,0.89221156,0.0005639708,0.006235962,0.004598294,0.010095459,0.0001309803,0.044824913,0.000012167768,0.0045491317,0.0083962465],"study_design_scores_gemma":[0.21693376,0.0072136894,0.7366178,0.0017388262,0.001607217,0.0006832045,0.0007810383,0.00072389096,0.030407814,0.000041804105,0.0021652943,0.0010856492],"about_ca_topic_score_codex":0.00095227826,"about_ca_topic_score_gemma":0.0005477057,"teacher_disagreement_score":0.19969684,"about_ca_system_score_codex":0.00018202902,"about_ca_system_score_gemma":0.0005712526,"threshold_uncertainty_score":0.56698644},"labels":[],"label_agreement":null},{"id":"W2513871868","doi":"10.1369/0022155416665338","title":"Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non–small Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Journal of Histochemistry & Cytochemistry","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"University of British Columbia; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Immunohistochemistry; Biomarker; Medicine; Tissue microarray; Lung cancer; Lymph node; PD-L1; Cancer; Oncology; Transcriptome; Lung; Pathology; Cancer research; Internal medicine; Gene expression; Biology; Immunotherapy; Gene","score_opus":0.03126597858926772,"score_gpt":0.32625956378311566,"score_spread":0.29499358519384794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513871868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846987,0.002922179,0.010299259,0.00055075984,0.00016259566,0.00046432833,0.000042644057,0.000015594986,0.00084391434],"genre_scores_gemma":[0.96990806,0.000117707576,0.028454935,0.00013693851,0.00037611133,0.00009242675,0.000017690974,0.00005052758,0.000845611],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99756205,0.00003804389,0.0013518003,0.000358298,0.00032054432,0.0003692572],"domain_scores_gemma":[0.9967638,0.00047342974,0.0014394677,0.0003523287,0.0007468424,0.0002241015],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010558348,0.000327287,0.00068432966,0.00015390677,0.000064731656,0.0000140398615,0.00017658083,0.00035516164,0.0001143422],"category_scores_gemma":[0.00054463564,0.00026181564,0.00038791265,0.0003936782,0.00024003805,0.0001307594,0.000040374096,0.0003205786,4.226275e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024697275,0.00011064371,0.009156607,0.0018421258,0.000104692735,0.000031845942,0.00020327236,0.000004927005,0.97452414,1.5179724e-7,0.00240324,0.009148621],"study_design_scores_gemma":[0.0068324264,0.00021212306,0.0052904673,0.0029766539,0.00025660286,0.00029261137,0.0001313881,0.00024420675,0.98299736,0.0000457857,0.00043160896,0.00028876786],"about_ca_topic_score_codex":0.00006452559,"about_ca_topic_score_gemma":0.0000025222132,"teacher_disagreement_score":0.018155677,"about_ca_system_score_codex":0.0011330723,"about_ca_system_score_gemma":0.0009852035,"threshold_uncertainty_score":0.99998343},"labels":[],"label_agreement":null},{"id":"W2513908572","doi":"10.1007/978-1-4939-3801-8_12","title":"Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies","year":2016,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Immune system; Context (archaeology); Medicine; Immune checkpoint; Cancer; Cancer research; Immunology; Immunotherapy; Biology; Internal medicine","score_opus":0.11265200890247054,"score_gpt":0.5397259188556498,"score_spread":0.4270739099531793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513908572","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6494545,0.006698207,0.33603284,0.006388038,0.00054398115,0.00071547145,0.000003281944,0.000013889399,0.00014982374],"genre_scores_gemma":[0.25143033,0.0007146675,0.74702704,0.0005489341,0.000047109384,0.00013259938,7.202108e-7,0.00002103382,0.00007757022],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99373305,0.0046921405,0.00077915855,0.0003918586,0.00010328267,0.00030052368],"domain_scores_gemma":[0.99748605,0.0016906662,0.00014758886,0.0005436827,0.00009047569,0.000041522795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0134289265,0.00017771834,0.00075995125,0.00021645117,0.000021496766,0.0000023573277,0.0001930583,0.0001640757,0.000036077774],"category_scores_gemma":[0.005269534,0.00009001036,0.00024735645,0.00051046227,0.00048129258,0.0000191995,0.00019474073,0.00022281881,0.0000022143986],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011644264,0.000080370795,0.003069876,0.000022288443,0.00013375763,0.000007678306,0.00019261462,8.347362e-7,0.682942,0.00006994952,0.0000059817985,0.31231025],"study_design_scores_gemma":[0.002191742,0.0006914035,0.032346655,0.0002290741,0.00004447744,0.000013437687,0.00009356057,0.00001529821,0.9603625,0.0020769956,0.0018159696,0.0001189112],"about_ca_topic_score_codex":0.00015470068,"about_ca_topic_score_gemma":0.000034484783,"teacher_disagreement_score":0.4109942,"about_ca_system_score_codex":0.0001341159,"about_ca_system_score_gemma":0.00010818291,"threshold_uncertainty_score":0.6308505},"labels":[],"label_agreement":null},{"id":"W2516660524","doi":"10.1200/jco.2016.34.15_suppl.9026","title":"Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Discontinuation; Internal medicine; Oncology; Cancer; Immunotherapy","score_opus":0.06154770022914629,"score_gpt":0.43853787942426264,"score_spread":0.37699017919511635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2516660524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955787,0.00015160555,0.000085756845,0.0022283122,0.0005234664,0.0011344057,0.000004499331,0.0000031642016,0.00029006472],"genre_scores_gemma":[0.9980896,0.00023699219,0.00027187756,0.00097066676,0.00027900113,0.000025102729,0.0000013568417,0.000014899429,0.00011048721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99669284,0.00043724448,0.002087932,0.00016491611,0.0004060147,0.00021106051],"domain_scores_gemma":[0.9939556,0.0034818684,0.0017410243,0.00025649194,0.00046619342,0.00009880255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024211458,0.00013273096,0.0012110354,0.00011869109,0.000028499026,0.0000038133253,0.00025455136,0.0001801967,0.00008153601],"category_scores_gemma":[0.0012936854,0.000054228174,0.0003125223,0.00014034218,0.0001776974,0.00009389331,0.000021226644,0.00033236013,0.0000015521556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2300427,0.010801066,0.46061733,0.000022016053,0.00042306326,0.00006731216,0.00019866017,8.186367e-7,0.0001957109,0.0000031138807,0.00040680534,0.2972214],"study_design_scores_gemma":[0.16591573,0.08262414,0.74809885,0.00017771742,0.00019820993,0.000031927073,0.00014939865,0.0000010343357,0.00001933404,0.000021761922,0.0027017575,0.00006014329],"about_ca_topic_score_codex":0.0000083103405,"about_ca_topic_score_gemma":0.00015564969,"teacher_disagreement_score":0.29716125,"about_ca_system_score_codex":0.00011504434,"about_ca_system_score_gemma":0.0006116277,"threshold_uncertainty_score":0.22113608},"labels":[],"label_agreement":null},{"id":"W2518422528","doi":"10.1634/theoncologist.2016-0164","title":"Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer","year":2016,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Nivolumab; Adverse effect; Tolerability; Lung cancer; Oncology; Chemotherapy; Immune system; Immunotherapy; Monoclonal antibody; Internal medicine; Intensive care medicine; Immunology; Antibody","score_opus":0.03120782614683579,"score_gpt":0.34147288587707575,"score_spread":0.31026505973023993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518422528","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021672653,0.9717781,7.2061493e-7,0.00008905067,0.00022336506,0.005379034,0.000022171418,0.000041615214,0.00079330994],"genre_scores_gemma":[0.014116152,0.9817603,0.000055258733,0.00000454344,0.00004746945,0.0013146492,0.000016939433,0.00004985392,0.0026347807],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.998,0.00021215183,0.00081071147,0.0003339754,0.00028996266,0.00035317012],"domain_scores_gemma":[0.9985762,0.00009026571,0.0008762006,0.00034994684,0.000054290653,0.000053061838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080184476,0.00036340283,0.0011911322,0.0001268499,0.00006870634,0.000005505658,0.0002035789,0.00029036473,0.000028085678],"category_scores_gemma":[0.000018245151,0.00018049173,0.00025281904,0.0004645463,0.0002266684,0.000037196594,0.00010197502,0.00034853947,0.0000018729926],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007513978,0.00038783334,0.0045053675,0.015667792,0.002085956,0.0001074885,0.00014847181,4.7726473e-7,0.000058750284,0.00000504222,0.00002423571,0.9762572],"study_design_scores_gemma":[0.02020069,0.0023711505,0.030102018,0.65653867,0.0071160337,0.000043991568,0.0004887935,0.00000637303,0.00048491804,0.000016858601,0.2813655,0.0012650058],"about_ca_topic_score_codex":0.0005806276,"about_ca_topic_score_gemma":0.00004821754,"teacher_disagreement_score":0.97499216,"about_ca_system_score_codex":0.0012276446,"about_ca_system_score_gemma":0.00031268457,"threshold_uncertainty_score":0.7360239},"labels":[],"label_agreement":null},{"id":"W2518519462","doi":"10.1016/j.ajur.2016.08.002","title":"Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?","year":2016,"lang":"en","type":"review","venue":"Asian journal of urology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Immune system; Immune checkpoint; Prostate cancer; Tumor microenvironment; Medicine; Cancer research; Cancer; Immunotherapy; Immunology; Internal medicine","score_opus":0.02116284273267214,"score_gpt":0.31324744570775187,"score_spread":0.2920846029750797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518519462","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043037618,0.9961015,0.000087050495,0.0013400012,0.0012568505,0.0005160364,0.00010403327,0.000005523945,0.0001586109],"genre_scores_gemma":[0.014222847,0.984845,0.0001512457,0.000090576,0.0003594246,0.000014356278,0.000004965114,0.000056045494,0.00025557776],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964687,0.00038784006,0.0022369847,0.00023373867,0.00035043972,0.0003222812],"domain_scores_gemma":[0.99585336,0.00021887338,0.0030174719,0.0004081737,0.00039947295,0.00010261548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088181027,0.00037016819,0.002830504,0.00041744896,0.000033675155,0.0000050081167,0.00039674094,0.00035928423,0.0007108465],"category_scores_gemma":[0.000034764063,0.00023573378,0.0013298707,0.00028464914,0.00044228067,0.00011223098,0.000028226299,0.0005617553,0.000009740173],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056354227,0.0002079717,0.000006452608,0.012667729,0.0015514963,0.00011552483,0.000842902,0.0000012820034,0.027001234,0.0000043714795,0.00022412936,0.95174146],"study_design_scores_gemma":[0.005439655,0.007195522,0.00014491439,0.060442105,0.0059164576,0.0015694125,0.00014550687,7.812937e-7,0.010043839,0.00006368663,0.9085803,0.00045780806],"about_ca_topic_score_codex":0.000040257204,"about_ca_topic_score_gemma":0.0000041241187,"teacher_disagreement_score":0.9512837,"about_ca_system_score_codex":0.000106455096,"about_ca_system_score_gemma":0.0014450483,"threshold_uncertainty_score":0.9612945},"labels":[],"label_agreement":null},{"id":"W2519347052","doi":"10.1016/j.jaci.2016.07.038","title":"Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma","year":2016,"lang":"en","type":"article","venue":"Journal of Allergy and Clinical Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Heart and Stroke Foundation","funders":"Genentech; Novartis Pharmaceuticals Corporation","keywords":"Omalizumab; Medicine; Confounding; Observational study; Hazard ratio; Asthma; Rate ratio; Cohort; Internal medicine; Cohort study; Adverse effect; Stroke (engine); Incidence (geometry); Pediatrics; Confidence interval; Immunoglobulin E; Immunology","score_opus":0.015007488901920383,"score_gpt":0.28064831959026404,"score_spread":0.26564083068834365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519347052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968038,0.0016046774,0.000062520914,0.00039088837,0.00042314193,0.0006146761,0.000008460626,0.000008131965,0.00008369587],"genre_scores_gemma":[0.9936813,0.0057736877,0.00014725857,0.00011040801,0.000118933334,0.000011234614,0.0000027252454,0.000019281764,0.00013513544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972573,0.00049884274,0.0012388799,0.0004416488,0.0003146444,0.00024867765],"domain_scores_gemma":[0.9985842,0.0003123734,0.00035320473,0.0003487161,0.00025781087,0.00014369923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015530832,0.00019771403,0.0009585475,0.00014889066,0.00006336355,0.0000146522525,0.00012425263,0.00023526716,0.00003061668],"category_scores_gemma":[0.0006459867,0.0001284143,0.0003319394,0.00013472281,0.00015834563,0.0001693887,0.00011533389,0.00038161015,0.0000027054002],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018067326,0.0007885568,0.9292381,0.0000029900873,0.011216394,0.00007222621,0.00048203804,0.000004224858,0.00007670963,0.0000012360902,0.00004574646,0.040004473],"study_design_scores_gemma":[0.032379102,0.0040300763,0.9615376,0.0003883451,0.00018876926,0.000059948088,0.00026382128,0.000005393,0.000036410267,0.00009621569,0.0008557329,0.00015859136],"about_ca_topic_score_codex":0.00065341115,"about_ca_topic_score_gemma":0.0007783738,"teacher_disagreement_score":0.03984588,"about_ca_system_score_codex":0.00013116462,"about_ca_system_score_gemma":0.000088617075,"threshold_uncertainty_score":0.52365834},"labels":[],"label_agreement":null},{"id":"W2523880687","doi":"10.1002/cam4.878","title":"The full blood count as a biomarker of outcome and toxicity in ipilimumab‐treated cutaneous metastatic melanoma","year":2016,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Ipilimumab; Medicine; Internal medicine; Toxicity; Gastroenterology; Lactate dehydrogenase; Melanoma; Clinical endpoint; Biomarker; Oncology; Cancer; Confidence interval; Proportional hazards model; Surgery; Clinical trial; Immunotherapy; Cancer research","score_opus":0.027871569787371667,"score_gpt":0.31468495001501,"score_spread":0.28681338022763836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523880687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96413565,0.02230115,0.000015308893,0.011704606,0.00024814086,0.000517755,0.00003005816,0.00002624444,0.0010210963],"genre_scores_gemma":[0.9884379,0.009172864,0.000021044943,0.00082303723,0.00008127829,0.00006193626,0.000003823523,0.00002322384,0.0013749034],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99834365,0.00007419327,0.00062696345,0.00029023594,0.00035385462,0.00031110476],"domain_scores_gemma":[0.9987379,0.00045483062,0.00019714997,0.00037119005,0.000112490095,0.00012647602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004972915,0.00021472438,0.00057477184,0.0001349243,0.00005995156,0.0000052130886,0.00011894789,0.0000671709,0.0007694869],"category_scores_gemma":[0.00024993782,0.00009686495,0.00006814618,0.00033767012,0.0007177618,0.000042098338,0.000028776709,0.0001022738,0.000004286432],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011143654,0.00017996262,0.14393166,0.00025605963,0.00092092017,0.00037878082,0.00062058674,1.3084687e-7,0.707747,0.00008875441,0.0016725174,0.13306],"study_design_scores_gemma":[0.11212085,0.014507496,0.5796319,0.009594261,0.004093147,0.0059485026,0.0024716614,0.00024198953,0.16356571,0.001011745,0.105404414,0.0014082821],"about_ca_topic_score_codex":0.0013574432,"about_ca_topic_score_gemma":0.0010155783,"teacher_disagreement_score":0.5441813,"about_ca_system_score_codex":0.0001624867,"about_ca_system_score_gemma":0.00013190828,"threshold_uncertainty_score":0.8425341},"labels":[],"label_agreement":null},{"id":"W2524109460","doi":"10.1007/s00262-016-1906-6","title":"Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model","year":2016,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Science Foundation Ireland","keywords":"FOXP3; Cytotoxic T cell; CD8; Cancer research; Immunology; Effector; Biology; Adjuvant; T cell; Antigen; Blocking antibody; Cytokine; Immune system; In vitro","score_opus":0.009830295630320715,"score_gpt":0.26167196302427037,"score_spread":0.25184166739394964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524109460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9262459,0.069187775,0.00018199252,0.002620082,0.00046777047,0.0011103847,0.00007801363,0.00006165606,0.00004641672],"genre_scores_gemma":[0.9292288,0.06817732,0.00007799824,0.0008320941,0.00008288281,0.00020147701,0.000004573157,0.000083270825,0.0013116192],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997526,0.00022593274,0.00080132874,0.00057251396,0.00023325243,0.0006410029],"domain_scores_gemma":[0.99838567,0.00038917174,0.00042921997,0.000589269,0.00014039881,0.00006624848],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045266442,0.0004807884,0.0009487394,0.00027694993,0.00014693549,0.000022448517,0.00034834276,0.00032097683,0.00033908742],"category_scores_gemma":[0.000026387777,0.00028060123,0.000240745,0.0004242408,0.00052820443,0.00018337712,0.00007947665,0.00040353835,0.000007554587],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011236581,0.000247174,0.0104744695,0.00010641173,0.00055277324,0.00000475421,0.0015554879,0.000022481066,0.9455037,0.000015503756,0.0003434161,0.029937247],"study_design_scores_gemma":[0.022260902,0.00059115246,0.04328091,0.00069729233,0.00009423036,0.000012886237,0.00024990155,0.00014896544,0.93129796,0.000029577706,0.0009825672,0.0003536689],"about_ca_topic_score_codex":0.0015852189,"about_ca_topic_score_gemma":0.00030384416,"teacher_disagreement_score":0.03280644,"about_ca_system_score_codex":0.00041606076,"about_ca_system_score_gemma":0.0004540472,"threshold_uncertainty_score":0.9999646},"labels":[],"label_agreement":null},{"id":"W2527905628","doi":"10.1056/nejmoa1606774","title":"Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Internal medicine; Hazard ratio; Oncology; Chemotherapy; Cancer; Gastroenterology; Confidence interval; Immunotherapy","score_opus":0.01779133937735275,"score_gpt":0.3044793150951555,"score_spread":0.2866879757178028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527905628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9016119,0.014987639,0.009559727,0.06621945,0.0036831181,0.00082313357,0.000024055313,0.000023775128,0.003067151],"genre_scores_gemma":[0.96840256,0.009804999,0.0008626743,0.0027798407,0.01206266,0.000014291983,0.000005484453,0.00005838128,0.0060091163],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985745,0.000035914152,0.00053815206,0.00017602547,0.00037311812,0.00030231324],"domain_scores_gemma":[0.99835,0.00043178248,0.00040019795,0.0001812927,0.00033752163,0.00029917806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057234516,0.00021597584,0.00058578304,0.000177865,0.00005823892,0.0000074473096,0.00014856402,0.00010221628,0.00081548234],"category_scores_gemma":[0.00010795377,0.00011156989,0.00020779816,0.00014551383,0.00012008462,0.000082111226,0.000009250748,0.0001848299,0.0000017951936],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14900182,0.00012857032,0.0030287222,0.00014086782,0.0010283482,0.00009506211,0.0017559894,0.0000017478632,0.2072444,0.000019503548,0.0667982,0.5707568],"study_design_scores_gemma":[0.70135766,0.010422176,0.014018816,0.0030908282,0.0011288062,0.0005931967,0.00024144909,0.000054452266,0.04767141,0.00009080141,0.22103593,0.00029445568],"about_ca_topic_score_codex":0.00016959688,"about_ca_topic_score_gemma":0.000050816157,"teacher_disagreement_score":0.57046235,"about_ca_system_score_codex":0.00026222566,"about_ca_system_score_gemma":0.0005432774,"threshold_uncertainty_score":0.89289594},"labels":[],"label_agreement":null},{"id":"W2528255331","doi":"10.20381/ruor-4870","title":"The Role of CD8+ T Cell Phenotype and Cytotoxicity on Cancer Immunotherapy","year":2011,"lang":"en","type":"dissertation","venue":"Library and Archives Canada (Government of Canada)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Cytotoxicity; Cancer immunotherapy; Cytotoxic T cell; Immunotherapy; Phenotype; CD8; Cancer; Cancer research; Biology; Immunology; Genetics; Immune system; Gene; In vitro","score_opus":0.003422302603073359,"score_gpt":0.17104341651885344,"score_spread":0.16762111391578008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528255331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7382533,0.01967557,5.4647603e-7,0.0005345045,0.00034357014,0.00043528312,0.00023188686,0.000009406422,0.24051593],"genre_scores_gemma":[0.9661291,0.012565245,0.000049792376,0.00065217155,0.000056093988,0.000021478125,0.0000252928,0.000048731632,0.02045207],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982818,0.000037160906,0.00032065803,0.00021736305,0.0009334484,0.00020959666],"domain_scores_gemma":[0.9991788,0.00015202624,0.00032009394,0.00023569961,0.0000015123389,0.000111818335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00001365879,0.00023291621,0.00035303645,0.0000230706,0.00013529738,0.00001036607,0.00014536266,0.00006211411,0.000053346237],"category_scores_gemma":[0.0000012765004,0.00016958598,0.000052761483,0.000055126984,0.00009969623,0.000063576845,0.000021036742,0.00019469215,8.8329216e-10],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04199517,0.0001269388,0.016436981,0.00093007175,0.0008391677,0.000021339969,0.00078671105,0.0000016314079,0.74427086,0.009477019,0.00062681513,0.18448728],"study_design_scores_gemma":[0.0010304572,0.00035296546,0.12299462,0.0004736132,0.000076132455,0.0000018773346,0.0035104356,0.00003647078,0.82420444,0.0005504566,0.046528213,0.00024030455],"about_ca_topic_score_codex":0.017038433,"about_ca_topic_score_gemma":0.06937658,"teacher_disagreement_score":0.22787583,"about_ca_system_score_codex":0.0000103104985,"about_ca_system_score_gemma":0.001915289,"threshold_uncertainty_score":0.9895072},"labels":[],"label_agreement":null},{"id":"W2528626295","doi":"10.1186/s40425-016-0168-3","title":"Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"Society for Immunotherapy of Cancer","keywords":"Immunotherapy; Medicine; Cancer immunotherapy; Melanoma; Immune system; Ipilimumab; Cancer; Renal cell carcinoma; Breast cancer; Oncology; Immunology; Cancer research; Internal medicine","score_opus":0.03410942348087324,"score_gpt":0.370393223925771,"score_spread":0.33628380044489775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528626295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7521126,0.21813616,0.0015310103,0.023674224,0.0020857095,0.0014996273,0.0001602549,0.000065938686,0.0007344556],"genre_scores_gemma":[0.8415075,0.14405236,0.0020749809,0.0034915996,0.0020910094,0.0003762839,0.000018377365,0.00031646775,0.006071449],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957543,0.00022634331,0.0017717262,0.0005893097,0.00085192855,0.00080639846],"domain_scores_gemma":[0.996037,0.0007755445,0.0013660633,0.0010201642,0.0006806978,0.00012052377],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020205677,0.00056791917,0.0010961558,0.0003032393,0.00036689875,0.00010558997,0.0006598484,0.00028280012,0.0018656263],"category_scores_gemma":[0.00015604791,0.0003202147,0.0010706985,0.00050681946,0.0005222421,0.00040964337,0.00003415985,0.0005269364,0.0000063359885],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030718757,0.0004489365,0.04473225,0.000028254894,0.003212087,0.00005712855,0.0058633396,0.000009431835,0.6126114,0.000067925524,0.021543387,0.2807071],"study_design_scores_gemma":[0.036306452,0.0011810837,0.32869953,0.0027009072,0.00015532544,0.0008336444,0.0020819225,0.000021418458,0.042893924,0.0021938956,0.5820542,0.0008776804],"about_ca_topic_score_codex":0.0036788643,"about_ca_topic_score_gemma":0.0007670326,"teacher_disagreement_score":0.56971747,"about_ca_system_score_codex":0.001007456,"about_ca_system_score_gemma":0.0009787502,"threshold_uncertainty_score":0.999925},"labels":[],"label_agreement":null},{"id":"W2529040040","doi":"10.1038/bjc.2016.308","title":"Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients","year":2016,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Internal medicine; Pembrolizumab; Complete response; Radiological weapon; Response Evaluation Criteria in Solid Tumors; Oncology; Hazard ratio; Immunotherapy; Melanoma; Lung cancer; Proportional hazards model; Progressive disease; Cancer; Surgery; Chemotherapy; Confidence interval; Cancer research","score_opus":0.04788620324865843,"score_gpt":0.3419081425565475,"score_spread":0.29402193930788906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529040040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974613,0.0013393577,0.00006444152,0.0004346395,0.00010141794,0.00021013351,0.00038217867,0.000003026462,0.0000034881143],"genre_scores_gemma":[0.99876577,0.00082029443,0.00024223556,0.000081822516,0.00003294736,0.000010289865,0.0000032824796,0.000012960912,0.000030413472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982157,0.00065889524,0.0005748632,0.00012603159,0.00027653572,0.00014802588],"domain_scores_gemma":[0.9988026,0.00031981355,0.0004167598,0.00009536241,0.00025321147,0.00011225305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081555994,0.00010502001,0.0006055814,0.00015813926,0.000025185227,0.00001276166,0.0000643162,0.000045224624,0.00008969609],"category_scores_gemma":[0.00019966901,0.00007322234,0.000073669755,0.00010724056,0.00005678385,0.00015926258,0.000010625303,0.000067903384,1.3951951e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06839099,0.000546032,0.8479434,0.000019417246,0.0002876,0.00014949133,0.0012317472,0.0000036657514,0.051498342,7.2039103e-7,0.000084822736,0.029843748],"study_design_scores_gemma":[0.0120570995,0.0064852913,0.97584397,0.0009515081,0.000096853735,0.000088262546,0.00032868475,0.000002441544,0.0035569763,0.0000052620644,0.00049521227,0.00008844651],"about_ca_topic_score_codex":0.0003955175,"about_ca_topic_score_gemma":0.001232285,"teacher_disagreement_score":0.12790054,"about_ca_system_score_codex":0.00026782783,"about_ca_system_score_gemma":0.00024779543,"threshold_uncertainty_score":0.29859206},"labels":[],"label_agreement":null},{"id":"W2529221862","doi":"10.1186/s40425-016-0171-8","title":"Antitumor activity of nivolumab on hemodialysis after renal allograft rejection","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Nivolumab; Hemodialysis; Ipilimumab; Transplantation; Immunosuppression; Internal medicine; Malignancy; Cancer; Intensive care medicine; Oncology; Immunotherapy","score_opus":0.015400382094347695,"score_gpt":0.31423989675110625,"score_spread":0.29883951465675856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529221862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908791,0.00393533,0.0020561407,0.0017587368,0.0007997385,0.0003743352,0.000052858664,0.000014187512,0.00012953277],"genre_scores_gemma":[0.9889188,0.007421188,0.0005050095,0.0003131049,0.00034535196,0.00006292084,0.0000010286055,0.000037924514,0.0023946862],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986412,0.000051044583,0.0005049908,0.0001854362,0.00037833434,0.00023901975],"domain_scores_gemma":[0.9986941,0.0000977685,0.00056883023,0.000278518,0.0003028569,0.00005792887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044520252,0.00017859912,0.00051211833,0.00025844976,0.00007946471,0.000011697854,0.00011077171,0.000108547334,0.000701312],"category_scores_gemma":[0.00002728804,0.0001103811,0.0006759212,0.00020259849,0.00016728685,0.0001531205,0.0000070242236,0.00013557565,9.2151856e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050138272,0.00019247849,0.0031856883,0.0000417012,0.00080362573,0.0000024497936,0.00008837605,0.00000250603,0.6707848,0.0000059319545,0.00096971984,0.2737845],"study_design_scores_gemma":[0.013474859,0.002918681,0.08670757,0.0010268091,0.00017979911,0.000046524146,0.000018842296,0.000010910573,0.83128464,0.0001237419,0.06401831,0.00018928676],"about_ca_topic_score_codex":0.00014590222,"about_ca_topic_score_gemma":0.000047125446,"teacher_disagreement_score":0.2735952,"about_ca_system_score_codex":0.00027898725,"about_ca_system_score_gemma":0.00024501095,"threshold_uncertainty_score":0.7678874},"labels":[],"label_agreement":null},{"id":"W2529567741","doi":"10.1200/jco.2016.34.2_suppl.256","title":"The relationship of B7H3 expression to androgen and prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Prostatectomy; Androgen receptor; Oncology; Prostate; Cohort; Internal medicine; Cancer; Metastasis","score_opus":0.067726577267008,"score_gpt":0.4298627577605361,"score_spread":0.36213618049352814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529567741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860924,0.004277309,0.000011238455,0.008633616,0.00045691853,0.00031241585,0.0000047142526,0.0000020996783,0.00020928608],"genre_scores_gemma":[0.9957175,0.002696593,0.0002578836,0.0003424054,0.00005852144,0.000008658301,2.3716053e-7,0.000007040506,0.0009111245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978766,0.00025372885,0.0014341569,0.00009704373,0.00020588451,0.00013260306],"domain_scores_gemma":[0.9950129,0.0035266168,0.001088314,0.00010784693,0.00017874631,0.00008558366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030025914,0.00006960294,0.0006652647,0.00008963565,0.00002264465,0.0000014521202,0.00007537601,0.00011859198,0.000025783624],"category_scores_gemma":[0.0027271796,0.000031387633,0.00014741429,0.00007001299,0.00018574279,0.00007048738,0.000033652443,0.0002666883,3.0382571e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012798226,0.00018482048,0.9506409,0.000030471283,0.00015950548,0.000015603719,0.0003540706,3.756037e-7,0.0069194967,0.000024729698,0.0014540191,0.027417744],"study_design_scores_gemma":[0.0093150055,0.0021368198,0.96635926,0.0005226378,0.00006005144,0.000020691443,0.00013905797,0.0000030934777,0.0008100647,0.00012235546,0.02046893,0.00004200784],"about_ca_topic_score_codex":0.00003822142,"about_ca_topic_score_gemma":0.00034386254,"teacher_disagreement_score":0.027375735,"about_ca_system_score_codex":0.00030229692,"about_ca_system_score_gemma":0.001145176,"threshold_uncertainty_score":0.32648858},"labels":[],"label_agreement":null},{"id":"W2531395888","doi":"10.1111/ajco.12524","title":"Convenor's Welcome","year":2016,"lang":"en","type":"article","venue":"Asia-Pacific Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Mentorship; Medical education; Oncology; Library science","score_opus":0.08744800783826183,"score_gpt":0.43538723783270594,"score_spread":0.3479392299944441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531395888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74201596,0.0022838097,0.00095567346,0.15941672,0.0102174375,0.00033287247,0.000010096854,0.000040225015,0.084727205],"genre_scores_gemma":[0.98804885,0.0026176448,0.0011349515,0.0014776409,0.002047966,0.0000018690253,6.951388e-7,0.000019276791,0.0046510766],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99684227,0.00031852498,0.0020796233,0.00018012885,0.00030478026,0.00027468504],"domain_scores_gemma":[0.9962842,0.0016193873,0.0011622418,0.00026699383,0.00032709324,0.00034007613],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003196496,0.00013582385,0.0010959368,0.00013312908,0.000034643814,0.0000067607752,0.00019668206,0.0003542131,0.0013246634],"category_scores_gemma":[0.0011172721,0.00007204447,0.0007187733,0.0001389668,0.00049704843,0.000108303866,0.000027286798,0.0004853036,0.00014634461],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017196009,0.0009099102,0.06757361,0.0000151598,0.0007780026,0.0007827434,0.00006710589,4.8712163e-8,0.007626378,0.00028622232,0.056893717,0.8478711],"study_design_scores_gemma":[0.012931266,0.008909258,0.10353103,0.00015639505,0.00015048406,0.0017888568,0.00023430403,7.5713683e-7,0.0007080889,0.00048843276,0.8710032,0.00009790286],"about_ca_topic_score_codex":0.00000441385,"about_ca_topic_score_gemma":0.0000049275386,"teacher_disagreement_score":0.8477732,"about_ca_system_score_codex":0.00016366031,"about_ca_system_score_gemma":0.001186266,"threshold_uncertainty_score":0.99958825},"labels":[],"label_agreement":null},{"id":"W2534319025","doi":"10.1158/1538-7445.tme16-ia23","title":"Abstract IA23: Deconvolution of the triple-negative breast cancer microenvironment","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University; Occupational Cancer Research Centre","funders":"","keywords":"Tumor microenvironment; Triple-negative breast cancer; Stromal cell; Breast cancer; CD8; Gene signature; Immune system; Cancer; Cancer research; Medicine; Biology; Oncology; Immunology; Internal medicine; Gene expression; Gene; Genetics","score_opus":0.05274078397056778,"score_gpt":0.3774184741006233,"score_spread":0.32467769013005554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534319025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97894174,0.0030275441,0.0000075752705,0.016150437,0.00029684446,0.0006780629,0.00025236342,0.000010176463,0.0006352482],"genre_scores_gemma":[0.988546,0.005888618,0.000011155066,0.00018327379,0.00020763515,0.00020189933,0.0000010234455,0.000019151435,0.0049412353],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984857,0.00008926913,0.00023593691,0.00025097743,0.0005720425,0.00036608125],"domain_scores_gemma":[0.9991518,0.00012225441,0.000089412315,0.00038601196,0.00016409848,0.000086409695],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005282934,0.00010457274,0.00017875808,0.00008856704,0.0001227343,0.000007902193,0.0002012603,0.00007371258,0.0042965272],"category_scores_gemma":[0.00004046542,0.000052674,0.00013235302,0.00030243583,0.0006810315,0.00006909316,0.0000691166,0.00021172984,0.000026663965],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026940654,0.00008707462,0.03223178,0.000076821656,0.00015697225,0.0000021979315,0.00019252628,8.5215726e-7,0.860422,0.00001794776,0.008633645,0.09548412],"study_design_scores_gemma":[0.0024555984,0.0000649793,0.69423956,0.00065127737,0.000017278813,0.000008893391,0.00010056636,0.0000011920986,0.29228753,0.00006224181,0.010045629,0.000065286185],"about_ca_topic_score_codex":0.004421448,"about_ca_topic_score_gemma":0.0006993707,"teacher_disagreement_score":0.66200775,"about_ca_system_score_codex":0.001106186,"about_ca_system_score_gemma":0.0005446624,"threshold_uncertainty_score":0.9966137},"labels":[],"label_agreement":null},{"id":"W2535232402","doi":"10.1158/1538-7445.tme16-a15","title":"Abstract A15: Mechanisms of CD8+ T cell immunosuppression in triple negative breast cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Triple-negative breast cancer; Stromal cell; Cancer research; Cytotoxic T cell; CD8; Estrogen receptor; Breast cancer; Stroma; Tumor microenvironment; Medicine; Immune system; Cancer; Biology; Pathology; Immunology; Internal medicine; Immunohistochemistry","score_opus":0.04951582192889033,"score_gpt":0.3846278011184199,"score_spread":0.33511197918952956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2535232402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892597,0.003399177,0.000043813274,0.0038263672,0.00033936862,0.0008491747,0.0002981559,0.00002225996,0.0019619563],"genre_scores_gemma":[0.99081445,0.0053474368,0.000053155687,0.00008014707,0.00012352344,0.00028175284,0.0000035892726,0.000033625947,0.0032623056],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979124,0.0001156419,0.00037403448,0.0003560997,0.00070931565,0.00053249625],"domain_scores_gemma":[0.99882627,0.00020793661,0.00010482079,0.00038785854,0.00035150917,0.00012159264],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008364493,0.0001515245,0.0003325947,0.00033050013,0.000072505616,0.000012610313,0.00023387233,0.0001412193,0.006975131],"category_scores_gemma":[0.000042725955,0.000094796545,0.00011156863,0.00062634714,0.00028052393,0.00013933865,0.00007778347,0.0003439433,0.000024449844],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067821704,0.00017146193,0.0025833016,0.00017400978,0.000054143344,0.000018273973,0.0003142946,0.0000010966334,0.9251279,0.000035394278,0.003487784,0.061250165],"study_design_scores_gemma":[0.006574201,0.00020833149,0.115385465,0.0017551294,0.0000108698305,0.00000603083,0.00032400986,0.0000045223824,0.8736214,0.0005389251,0.0014385588,0.00013253216],"about_ca_topic_score_codex":0.0095853945,"about_ca_topic_score_gemma":0.0007082092,"teacher_disagreement_score":0.11280216,"about_ca_system_score_codex":0.00070357416,"about_ca_system_score_gemma":0.00080256746,"threshold_uncertainty_score":0.9970099},"labels":[],"label_agreement":null},{"id":"W2536412330","doi":"10.1158/1538-7445.tme16-a18","title":"Abstract A18: Investigating the differential expressions of miRNAs and programmed-death-ligand-1 related to the T-bet positive tumor-infiltrating lymphocytes in axillary-node-negative breast cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Breast cancer; Tumor-infiltrating lymphocytes; Cancer research; Tumor microenvironment; Medicine; microRNA; Cancer; Biology; Immunotherapy; Internal medicine; Gene","score_opus":0.04818138646503195,"score_gpt":0.37586560232068045,"score_spread":0.3276842158556485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536412330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793123,0.0019534773,0.0000038525195,0.016749388,0.00010647627,0.0013445703,0.00020436467,0.000021512225,0.00030405397],"genre_scores_gemma":[0.997723,0.0008909317,0.000042019692,0.0003114211,0.00014074687,0.00062410027,0.000004331976,0.000033909968,0.00022953984],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99760777,0.00026865446,0.00045246084,0.00040454193,0.0006756337,0.0005909362],"domain_scores_gemma":[0.99802935,0.0009301123,0.00015103522,0.00035922864,0.00034584716,0.00018443236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009844553,0.00020400755,0.00031678143,0.00016258702,0.00036541524,0.000063326195,0.00027673994,0.000093424744,0.00027900928],"category_scores_gemma":[0.0003341064,0.00009383483,0.000082669845,0.0007296836,0.0008115997,0.000118351614,0.00016246883,0.00046166813,0.0000035009928],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017464563,0.000075107855,0.07485519,0.00010109343,0.00021070297,0.000020333742,0.0062602134,0.000006721596,0.85699034,0.000077305755,0.0006762737,0.058980275],"study_design_scores_gemma":[0.0031951645,0.00018160051,0.69883066,0.004559249,0.000030133968,0.000048399066,0.0022519527,0.000039549068,0.29026777,0.00016399992,0.00026387628,0.00016766439],"about_ca_topic_score_codex":0.013250039,"about_ca_topic_score_gemma":0.0013293141,"teacher_disagreement_score":0.62397546,"about_ca_system_score_codex":0.00048773582,"about_ca_system_score_gemma":0.0007879845,"threshold_uncertainty_score":0.9933208},"labels":[],"label_agreement":null},{"id":"W2540839950","doi":"10.21873/anticanres.11145","title":"Immune Blockade Inhibition in Breast Cancer","year":2016,"lang":"en","type":"review","venue":"Anticancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sault Area Hospital; NOSM University","funders":"","keywords":"Cancer; Breast cancer; Immune checkpoint; Medicine; Immunotherapy; Melanoma; Cancer immunotherapy; Ipilimumab; Blockade; Immune system; Oncology; Immunology; Cancer research; Internal medicine; Receptor","score_opus":0.12383466456606561,"score_gpt":0.48279634530928406,"score_spread":0.35896168074321844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2540839950","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017362111,0.99269307,0.0000013663528,0.0032411518,0.00025011686,0.0015009913,0.00020619562,0.000036589332,0.0018969069],"genre_scores_gemma":[0.00054186664,0.9946757,0.000009214563,0.00008647279,0.000805037,0.0007692943,0.000046170775,0.00009865153,0.0029675898],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99629974,0.000366982,0.0007863482,0.0006674534,0.0009543716,0.00092508737],"domain_scores_gemma":[0.9985074,0.00026616864,0.000144876,0.0006849672,0.0002441077,0.00015250806],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015385565,0.00036039134,0.0015500543,0.0009558907,0.00010913596,0.00004706513,0.00019568916,0.00041839053,0.003237151],"category_scores_gemma":[0.000042912736,0.00023462642,0.00048086283,0.0016073339,0.00049465394,0.0000924136,0.00014489354,0.0011834217,0.0003482407],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051382295,0.00012874887,0.000076765995,0.00916692,0.00024230372,0.00018335493,0.00003214376,1.0950897e-8,0.00027159054,0.000038318693,0.0022960268,0.98705],"study_design_scores_gemma":[0.001424033,0.0000884557,0.0006611627,0.09512736,0.00011347191,0.00027024248,0.00001553011,8.4511265e-7,0.00008366893,0.000029671324,0.90191895,0.00026658445],"about_ca_topic_score_codex":0.0021068726,"about_ca_topic_score_gemma":0.00012679485,"teacher_disagreement_score":0.9867834,"about_ca_system_score_codex":0.0016235411,"about_ca_system_score_gemma":0.0024231793,"threshold_uncertainty_score":0.99767405},"labels":[],"label_agreement":null},{"id":"W2541139800","doi":"10.1186/s12943-016-0551-1","title":"Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis","year":2016,"lang":"en","type":"review","venue":"Molecular Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":260,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canadian Centre for Applied Research in Cancer Control; Occupational Cancer Research Centre; BC Cancer Agency","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; University of British Columbia; Terry Fox Research Institute; Canadian Cancer Society; Michael Smith Health Research BC; National Sanitarium Association","keywords":"Tumor microenvironment; Metastasis; Lung cancer; Immune system; Cancer research; Biology; Carcinogenesis; Immunology; Inflammation; Context (archaeology); T cell; Tumor progression; Cancer; Regulatory T cell; Medicine; Pathology; IL-2 receptor","score_opus":0.015996327544215514,"score_gpt":0.35100789564145346,"score_spread":0.3350115680972379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2541139800","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003059566,0.99549985,0.000015217976,0.00017634788,0.00015263169,0.0008838106,0.000101308986,0.00001333025,0.00009793737],"genre_scores_gemma":[0.00040366533,0.9985019,0.00010835897,0.00013681817,0.00007167102,0.00034844535,0.000009534913,0.00006598417,0.00035361192],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983955,0.00010248485,0.00049859757,0.0004620914,0.0002743177,0.00026702663],"domain_scores_gemma":[0.9992125,0.000026801905,0.00031089297,0.00030909077,0.000050738316,0.00008994993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024092237,0.000350868,0.0012846205,0.00026371467,0.00003111132,0.000011866584,0.000081901504,0.00022662061,0.00023192393],"category_scores_gemma":[0.0000069805533,0.000232513,0.00023900134,0.00023808116,0.00020114562,0.00005044263,0.00007454708,0.00018511605,3.581536e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013117758,0.000023192082,0.00012701246,0.014178975,0.000577804,0.000038051752,0.00011729579,2.8154446e-7,0.0051698145,0.0000051989414,0.00056122715,0.97906995],"study_design_scores_gemma":[0.0011501918,0.000051101048,0.00010567228,0.06399884,0.0011316098,0.000018051063,0.000018822462,0.0000060360708,0.0039629303,0.000002741312,0.9292577,0.00029629914],"about_ca_topic_score_codex":0.00014829797,"about_ca_topic_score_gemma":0.00008942791,"teacher_disagreement_score":0.97877365,"about_ca_system_score_codex":0.00024505102,"about_ca_system_score_gemma":0.00040765083,"threshold_uncertainty_score":0.9481605},"labels":[],"label_agreement":null},{"id":"W2547629658","doi":"10.1038/pcan.2016.49","title":"Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis","year":2016,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prostate Cancer Canada; Genome British Columbia","funders":"National Cancer Institute","keywords":"Prostate cancer; Androgen receptor; Medicine; Cancer research; Immune checkpoint; Oncology; Cancer; Biology; Internal medicine; Immunotherapy","score_opus":0.013502321125658235,"score_gpt":0.2759243260925506,"score_spread":0.26242200496689233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547629658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797814,0.015842956,0.00009868581,0.0009948976,0.000066799934,0.001325608,0.001828376,0.000043696964,0.00001759095],"genre_scores_gemma":[0.9932136,0.005173363,0.00025483707,0.00023642949,0.000020962249,0.0006030586,0.0001851132,0.000036759837,0.00027587416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981813,0.00008612642,0.00058438786,0.00050024735,0.00031649394,0.00033148288],"domain_scores_gemma":[0.9988725,0.00013190173,0.0003163267,0.0002734749,0.0001649898,0.00024080984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020211536,0.00028652832,0.00063514453,0.00029375817,0.000090132555,0.000037101127,0.00006391275,0.000054076198,0.00020801189],"category_scores_gemma":[0.00003861787,0.00017172824,0.000090156806,0.0006004457,0.00033458605,0.00029304283,0.000024782483,0.00007329743,4.6205977e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01186188,0.00020724424,0.8864576,0.000581203,0.000312353,0.0000139798,0.0011774403,0.00007400158,0.01697772,0.0000073925034,0.000033857406,0.082295306],"study_design_scores_gemma":[0.015604487,0.0015238805,0.95603794,0.0021759542,0.0014515871,0.0000052521436,0.0009485166,0.0012521463,0.019612549,0.00015188861,0.0006710225,0.0005648045],"about_ca_topic_score_codex":0.0010004082,"about_ca_topic_score_gemma":0.000295906,"teacher_disagreement_score":0.0817305,"about_ca_system_score_codex":0.00012072285,"about_ca_system_score_gemma":0.0003605262,"threshold_uncertainty_score":0.70028746},"labels":[],"label_agreement":null},{"id":"W2547680646","doi":"10.1093/annonc/mdw435.39","title":"NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Nivolumab; Medicine; Internal medicine; Ipilimumab; Response Evaluation Criteria in Solid Tumors; Oncology; Docetaxel; Progression-free survival; Phases of clinical research; Chemotherapy; Adverse effect; Randomization; Gastroenterology; Randomized controlled trial; Surgery; Cancer; Immunotherapy","score_opus":0.12810382298844694,"score_gpt":0.4189531583647975,"score_spread":0.2908493353763506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547680646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97872937,0.0016211128,0.00079791853,0.012619531,0.00035728383,0.0048813415,0.000678806,0.000046296733,0.00026836735],"genre_scores_gemma":[0.99170643,0.0021492355,0.0016836588,0.0030402865,0.00025983946,0.000615519,0.00014655203,0.000082379076,0.00031608922],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967348,0.0002228089,0.0014485887,0.0005220052,0.00047426496,0.00059751485],"domain_scores_gemma":[0.9956117,0.0012862652,0.0015106621,0.00053850305,0.0007656205,0.00028722672],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013184301,0.00044499946,0.0016655253,0.00030731288,0.000074931646,0.000010966708,0.0002911854,0.00027606534,0.00023861969],"category_scores_gemma":[0.0005713183,0.0003095716,0.0006484712,0.00038636432,0.0006998622,0.00012643231,0.000027768278,0.00016672465,0.0000025940972],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53859466,0.006134148,0.00031016945,0.0004218225,0.0016673913,0.000012398512,0.00081910804,0.00000154202,0.18106773,0.000086563625,0.0018385411,0.26904592],"study_design_scores_gemma":[0.3154622,0.07723813,0.0007111248,0.0006523921,0.00020953282,0.0000076183674,0.0000652328,0.00008208126,0.5456101,0.00019402239,0.059500247,0.00026737156],"about_ca_topic_score_codex":0.0004844208,"about_ca_topic_score_gemma":0.00012490933,"teacher_disagreement_score":0.3645423,"about_ca_system_score_codex":0.00012563009,"about_ca_system_score_gemma":0.001666943,"threshold_uncertainty_score":0.9999356},"labels":[],"label_agreement":null},{"id":"W2549537687","doi":"10.1182/blood.v114.22.1953.1953","title":"CD80 (B7.1) Is Expressed On Both Malignant B Cells and Tumor Infiltrating T Cells in Non-Hodgkin's Lymphomas.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"CD80; Follicular lymphoma; Lymphoma; Cancer research; Mantle cell lymphoma; Biology; Rituximab; Immunology; Immune system; Medicine; Cytotoxic T cell; CD40; In vitro","score_opus":0.008733650523847126,"score_gpt":0.2353902096997596,"score_spread":0.2266565591759125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549537687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935183,0.0005211672,0.000008556986,0.00051629264,0.00010690455,0.00038994316,0.000022428701,0.00003834792,0.0048780763],"genre_scores_gemma":[0.9939739,0.00026068778,0.00064967276,0.004594088,0.00012830671,0.000012715558,0.0000047713215,0.000021191603,0.00035467694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99878204,0.000029511073,0.00031293984,0.00034163523,0.00021549872,0.00031836814],"domain_scores_gemma":[0.9994381,0.000048498867,0.00009704543,0.0002989291,0.000019479905,0.00009792082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001900883,0.00020494577,0.00031032783,0.00012300935,0.000054047247,0.000036894817,0.00008364732,0.00008371106,0.00010793199],"category_scores_gemma":[0.000009103503,0.00017220568,0.00007778557,0.00019058099,0.000046282603,0.000061746876,0.000014363974,0.00012343889,0.000013122188],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060713926,0.0006436437,0.0021956041,0.00005795217,0.00004242423,0.00020059056,0.0006896666,0.0000013210081,0.98593825,0.000008873677,0.0013958314,0.008218676],"study_design_scores_gemma":[0.0094297575,0.0010606406,0.034901537,0.00048800927,0.00005808658,0.000049398655,0.00015921661,0.000065254455,0.95102763,0.000028278788,0.0025068603,0.0002253371],"about_ca_topic_score_codex":0.00017541587,"about_ca_topic_score_gemma":0.000013462023,"teacher_disagreement_score":0.034910653,"about_ca_system_score_codex":0.000038021597,"about_ca_system_score_gemma":0.00006756238,"threshold_uncertainty_score":0.7022344},"labels":[],"label_agreement":null},{"id":"W2549800333","doi":"10.1158/0008-5472.can-16-1873","title":"PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Canadian Institutes of Health Research","keywords":"Trastuzumab; Immune system; Cancer research; Monoclonal antibody; Immunotherapy; Breast cancer; Medicine; Immunology; CD8; Cancer; CpG site; Acquired immune system; Innate immune system; Immune checkpoint; Antibody; Biology; Internal medicine","score_opus":0.04022546538509793,"score_gpt":0.3621033141185209,"score_spread":0.321877848733423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549800333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98436475,0.0036731577,0.000035584064,0.010120771,0.00006568153,0.0013132727,0.00020495658,0.00001999286,0.00020184048],"genre_scores_gemma":[0.9946817,0.0013722489,0.00015384943,0.000036112335,0.00017575592,0.0006859901,0.0000046926093,0.000040870873,0.002848743],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99832225,0.000051478262,0.00032282696,0.0003742993,0.00044177836,0.00048735685],"domain_scores_gemma":[0.99888587,0.00013945969,0.00006772399,0.00038935855,0.00031258108,0.0002049831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047654528,0.00016665636,0.00041606496,0.00024861368,0.00011132389,0.000018131259,0.00009205748,0.000060131446,0.00023170683],"category_scores_gemma":[0.000034431585,0.000089711,0.00010236099,0.00039929317,0.0003746227,0.000052299933,0.00003716839,0.000052099564,0.0000032924397],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02458091,0.00017369975,0.002997148,0.00017384776,0.00022598603,0.000022784734,0.0003334942,3.1198357e-7,0.91797024,0.00006244378,0.0005463146,0.052912842],"study_design_scores_gemma":[0.011230122,0.006333421,0.09273808,0.001926551,0.000054204404,0.00007070795,0.0005116644,0.0000019460551,0.8708405,0.000043109718,0.016049547,0.00020018287],"about_ca_topic_score_codex":0.0025304486,"about_ca_topic_score_gemma":0.00025497575,"teacher_disagreement_score":0.08974093,"about_ca_system_score_codex":0.00062941044,"about_ca_system_score_gemma":0.0005433962,"threshold_uncertainty_score":0.38252982},"labels":[],"label_agreement":null},{"id":"W2549925369","doi":"10.1002/eji.201646583","title":"Local checkpoint inhibition of CTLA‐4 as a monotherapy or in combination with anti‐PD1 prevents the growth of murine bladder cancer","year":2016,"lang":"en","type":"article","venue":"European Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prevention of Organ Failure; University of British Columbia","funders":"Seventh Framework Programme; Vetenskapsrådet; Göran Gustafssons Stiftelse för Naturvetenskaplig och Medicinsk Forskning; U.S. Food and Drug Administration; Lunds Universitet; Svenska Sällskapet för Medicinsk Forskning; Cancerfonden","keywords":"Biology; Bladder cancer; Cancer research; CTLA-4; Cancer; Pharmacology; Immunology; Immune system; T cell; Genetics","score_opus":0.013079942968868153,"score_gpt":0.25689917134006857,"score_spread":0.2438192283712004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549925369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99338317,0.0015043762,0.0012406114,0.003179264,0.00010920693,0.00018966351,0.0000033123642,0.000003883978,0.00038649258],"genre_scores_gemma":[0.9955747,0.0037132357,0.00008368609,0.00019998239,0.000037272857,0.000002193812,8.40867e-7,0.000022722346,0.00036532758],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99860173,0.00034350084,0.0006437104,0.00009514151,0.00018190587,0.0001340334],"domain_scores_gemma":[0.9988169,0.00006723106,0.00069358293,0.00015527832,0.0002442993,0.00002267128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069521804,0.00011208362,0.0003370246,0.00018465536,0.00001927529,0.0000029142395,0.00012466894,0.000032462383,0.00027902416],"category_scores_gemma":[0.000045467237,0.000050433933,0.00009253548,0.00021666432,0.0003670448,0.00009282409,0.000021224845,0.00016077008,0.0000022893546],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027352251,0.0005643552,0.0062495484,0.00004987422,0.0008270659,0.00016772204,0.0010997816,0.000004105921,0.88160837,0.0001032918,0.00018649136,0.081787124],"study_design_scores_gemma":[0.02414467,0.008410524,0.39418143,0.002073712,0.00008278364,0.000715425,0.00028733842,0.0000042040765,0.56867176,0.00009160767,0.0012267808,0.00010979478],"about_ca_topic_score_codex":0.000095556075,"about_ca_topic_score_gemma":0.000016233655,"teacher_disagreement_score":0.38793188,"about_ca_system_score_codex":0.000085545165,"about_ca_system_score_gemma":0.00016968428,"threshold_uncertainty_score":0.3055119},"labels":[],"label_agreement":null},{"id":"W2550419061","doi":"10.1007/s40259-016-0204-3","title":"Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors","year":2016,"lang":"en","type":"review","venue":"BioDrugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"Ontario Institute for Cancer Research","keywords":"Immune system; Immunology; Medicine; Adverse effect; Autoimmunity; Immunotherapy; Antibody; Immune checkpoint; Cytotoxic T cell; CTLA-4; Nivolumab; T cell; Biology; Pharmacology","score_opus":0.01959998934634755,"score_gpt":0.2869797453921792,"score_spread":0.26737975604583164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550419061","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00054581225,0.994088,0.000001615656,0.00018023055,0.0010180702,0.0017628546,0.00015270076,0.00022865819,0.002022059],"genre_scores_gemma":[0.00041727384,0.98412937,0.000023580033,0.00005259792,0.00018227097,0.00013998628,0.00065271836,0.000168749,0.014233465],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962163,0.00020937249,0.0017208777,0.00066173257,0.00056594535,0.00062577217],"domain_scores_gemma":[0.99731874,0.00012791666,0.0013556014,0.00087379874,0.00014218786,0.00018176774],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000787278,0.00082023186,0.0025080286,0.00036300655,0.00013050705,0.0000112789285,0.00030574395,0.00083578547,0.0009379983],"category_scores_gemma":[0.00012257243,0.00047580208,0.0018095218,0.00083292025,0.00023411523,0.00009572685,0.000096805816,0.0005966078,0.00062092085],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069075834,0.00039822698,0.000061345825,0.0044921134,0.0057951333,0.000127913,0.00014500783,1.5807897e-8,0.00031187906,0.0000075041694,0.0009730743,0.986997],"study_design_scores_gemma":[0.004549214,0.00037795454,0.00046145782,0.09405254,0.0017188154,0.00013704956,0.000030610954,2.4430733e-7,0.00015665623,0.000004643272,0.8978357,0.0006751343],"about_ca_topic_score_codex":0.0001009704,"about_ca_topic_score_gemma":0.0000050513863,"teacher_disagreement_score":0.98632187,"about_ca_system_score_codex":0.0010269943,"about_ca_system_score_gemma":0.0009373314,"threshold_uncertainty_score":0.99997526},"labels":[],"label_agreement":null},{"id":"W2551543699","doi":"10.1016/j.annder.2016.09.264","title":"Survie à 3 ans des patients traités pour mélanome métastatique par prembrolizumab (Keynote-001) et devenir des patients en réponse complète","year":2016,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gynecology; Ipilimumab; Cancer; Internal medicine; Immunotherapy","score_opus":0.046163004109673465,"score_gpt":0.3359234629200106,"score_spread":0.28976045881033713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551543699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662378,0.0096363025,0.005094727,0.0131639745,0.0010800717,0.0012299505,0.0015823672,0.00041583253,0.0015590065],"genre_scores_gemma":[0.96238494,0.021761103,0.005779598,0.007891569,0.00013712936,0.00019810887,0.00045960516,0.00015911109,0.0012288542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9901667,0.004079663,0.0014214854,0.0010543391,0.00057874277,0.0026990348],"domain_scores_gemma":[0.99300784,0.004171807,0.00059624977,0.00089800707,0.00068492326,0.0006411759],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001977313,0.0010623445,0.0013202808,0.0004187521,0.0003949539,0.00013498148,0.0009783648,0.0010640671,0.0005537004],"category_scores_gemma":[0.00354672,0.00083250797,0.00054792746,0.000557061,0.0021594104,0.00077316037,0.0003538981,0.00080345466,0.00041670172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005527711,0.002727343,0.80137295,0.0009398791,0.0009782022,0.00095475017,0.0036842434,0.000027260154,0.0031937817,0.00044968975,0.028333675,0.15181054],"study_design_scores_gemma":[0.013399732,0.0016848221,0.93055874,0.0019204443,0.00030527991,0.00077947415,0.00070553983,0.00007295335,0.0070857126,0.0058810106,0.036476787,0.0011295031],"about_ca_topic_score_codex":0.0009553944,"about_ca_topic_score_gemma":0.0015288205,"teacher_disagreement_score":0.15068105,"about_ca_system_score_codex":0.002115889,"about_ca_system_score_gemma":0.002702039,"threshold_uncertainty_score":0.9994126},"labels":[],"label_agreement":null},{"id":"W2552086545","doi":"10.1016/j.jtho.2016.08.110","title":"P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Discontinuation; Internal medicine; Antibody; Oncology; Gastroenterology; Immunotherapy; Cancer; Immunology","score_opus":0.017608884163936512,"score_gpt":0.3861327224011434,"score_spread":0.36852383823720686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552086545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99633217,0.00026081217,0.000119237855,0.0015579754,0.00031949446,0.0012009311,0.000006380728,0.0000038843914,0.00019911757],"genre_scores_gemma":[0.9989718,0.00009502652,0.0002810015,0.00031989906,0.00013078922,0.00003618212,0.0000018698539,0.000016983267,0.00014645768],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983497,0.00023592003,0.00071047706,0.00013739096,0.00034498915,0.000221472],"domain_scores_gemma":[0.9980542,0.00048392123,0.0008131987,0.00023888393,0.00035232527,0.000057490564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007898043,0.0001408538,0.00062350405,0.0002114236,0.000040708914,0.0000054668603,0.00023033733,0.00009706165,0.00007771624],"category_scores_gemma":[0.00013061058,0.0000619267,0.0001385209,0.00018480931,0.00009617655,0.000111456124,0.000018888308,0.00018105589,0.0000011978776],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26004365,0.006754052,0.20152828,0.00007928085,0.00047509008,0.0001309768,0.0013436863,0.0000022815593,0.004235454,0.000001683675,0.00035597713,0.52504957],"study_design_scores_gemma":[0.06319991,0.048326984,0.8841898,0.00039557263,0.00032463338,0.0001908065,0.0007531274,0.0000015137374,0.0004651378,0.000025245858,0.0020196917,0.00010762256],"about_ca_topic_score_codex":0.0000071598506,"about_ca_topic_score_gemma":0.00011167462,"teacher_disagreement_score":0.6826615,"about_ca_system_score_codex":0.00025550948,"about_ca_system_score_gemma":0.00028158084,"threshold_uncertainty_score":0.25252977},"labels":[],"label_agreement":null},{"id":"W2555459688","doi":"10.1093/annonc/mdw570","title":"Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Stanford Cancer Institute; National Cancer Institute; Anticancer Fund; Leukemia and Lymphoma Society","keywords":"CD137; Medicine; Oncology; Breast cancer; Nomogram; Internal medicine; Head and neck cancer; Immunotherapy; Cancer; Monoclonal antibody; Immunology; Antibody","score_opus":0.0583383124896076,"score_gpt":0.3665372311762007,"score_spread":0.3081989186865931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555459688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927839,0.000109389126,0.000010417497,0.004454554,0.00028292078,0.00025031532,0.000009114597,0.0000127605035,0.0020866187],"genre_scores_gemma":[0.9956289,0.0017606836,0.00006915949,0.0022352703,0.00009008764,0.000007803958,0.00001778446,0.000012679278,0.00017765895],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990771,0.000081102306,0.00032753017,0.00017670452,0.00013943626,0.00019816346],"domain_scores_gemma":[0.9993953,0.00012688486,0.00018764242,0.00015926856,0.00009250244,0.00003840761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031668457,0.00009942498,0.00027417237,0.00014816115,0.000020390271,0.0000028082122,0.000061876875,0.00012278584,0.00016653222],"category_scores_gemma":[0.000029658579,0.00006731557,0.00008394422,0.00011335282,0.00006493888,0.00008154925,0.000012345219,0.00006659933,0.000013342748],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005099691,0.00038463366,0.07446759,0.000009560735,0.00004010779,0.000003112424,0.00017413987,2.7672942e-7,0.4711716,0.000011457495,0.00037801484,0.44825983],"study_design_scores_gemma":[0.0044542924,0.0036260558,0.8027354,0.0002266311,0.0000031745624,0.0000013075228,0.000010505382,0.0000041104386,0.16440244,0.000036696903,0.024427801,0.00007158245],"about_ca_topic_score_codex":0.000035031833,"about_ca_topic_score_gemma":0.0000071012646,"teacher_disagreement_score":0.7282678,"about_ca_system_score_codex":0.00006455778,"about_ca_system_score_gemma":0.000076140954,"threshold_uncertainty_score":0.2745049},"labels":[],"label_agreement":null},{"id":"W2557730509","doi":"10.1016/j.jtho.2016.11.2228","title":"PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1254,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Celgene; AstraZeneca","keywords":"Immunohistochemistry; Medicine; Staining; Pathology; Companion diagnostic; Lung cancer; Cancer; Internal medicine","score_opus":0.04763398284113613,"score_gpt":0.4766245741671307,"score_spread":0.4289905913259946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557730509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754738,0.0051530064,0.0024160375,0.01213288,0.0020428288,0.00079400704,0.00048330918,0.000017796925,0.0014863295],"genre_scores_gemma":[0.99434125,0.0006373579,0.0024448233,0.00033520063,0.0007932545,0.000038251164,0.000012569775,0.000028816272,0.0013684682],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99734616,0.00027103224,0.0014247353,0.00025440456,0.00039634242,0.0003073234],"domain_scores_gemma":[0.99579066,0.00089122594,0.0021821302,0.0004969638,0.0005418003,0.00009718961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001990494,0.00021644759,0.00090896635,0.00011603514,0.000099906065,0.00001195515,0.00043784108,0.0002972332,0.00017589894],"category_scores_gemma":[0.0007369761,0.00011717488,0.00056731206,0.00019102753,0.0002837927,0.00009176498,0.0000745008,0.0004326063,0.0000010569928],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081707664,0.00080026407,0.0016284583,0.0001162794,0.0008706921,0.000022050785,0.00071745226,0.000004053292,0.702617,0.000003878523,0.03067177,0.18084048],"study_design_scores_gemma":[0.02984146,0.0040932093,0.009651,0.0027053899,0.0016976614,0.00040397287,0.0008791973,0.00043880657,0.74564284,0.00014455392,0.2041421,0.00035982195],"about_ca_topic_score_codex":0.00030711349,"about_ca_topic_score_gemma":0.000048282753,"teacher_disagreement_score":0.18048064,"about_ca_system_score_codex":0.0012575729,"about_ca_system_score_gemma":0.0017692336,"threshold_uncertainty_score":0.47782528},"labels":[],"label_agreement":null},{"id":"W2557786287","doi":"10.1093/neuonc/now212.100","title":"ATIM-35. RESULTS OF THE PHASE IB KEYNOTE-028 MULTI-COHORT TRIAL OF PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT PD-L1-POSITIVE GLIOBLASTOMA MULTIFORME (GBM)","year":2016,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Rash; Clinical endpoint; Cohort; Oncology; Surgery; Clinical trial; Gastroenterology; Immunotherapy; Cancer","score_opus":0.015537324857194883,"score_gpt":0.3030960722070924,"score_spread":0.2875587473498975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557786287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99460286,0.0000639894,0.000042678766,0.001124266,0.0007858595,0.0027757837,0.00023269937,0.000022591477,0.00034926346],"genre_scores_gemma":[0.99878544,0.00021816818,0.0002007238,0.00047958086,0.0000949126,0.00010130492,0.00001619632,0.000040408293,0.000063258056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973399,0.0003788895,0.0009888432,0.00047412165,0.00044650296,0.000371757],"domain_scores_gemma":[0.9978037,0.0005256992,0.0007506917,0.0005878124,0.00023908392,0.00009302606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037041516,0.00028410516,0.0007645766,0.00021653155,0.000050962393,0.000004103497,0.00024766565,0.00023175153,0.000055314882],"category_scores_gemma":[0.0002818493,0.0001532458,0.00022797218,0.00038624363,0.00045745485,0.00009021227,0.000057284997,0.00026531782,0.000004122655],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7231946,0.004010451,0.010118887,0.000022432001,0.00017889771,0.000014877859,0.00072182884,0.0000019123788,0.14267965,0.0000034127615,0.00029176503,0.118761316],"study_design_scores_gemma":[0.6651527,0.046952073,0.17260231,0.0003670894,0.00012298576,0.000017158673,0.000057701967,0.00007902625,0.10665966,0.0000044409317,0.0077683176,0.00021647927],"about_ca_topic_score_codex":0.00016134609,"about_ca_topic_score_gemma":0.00028334194,"teacher_disagreement_score":0.16248344,"about_ca_system_score_codex":0.00042847238,"about_ca_system_score_gemma":0.000469872,"threshold_uncertainty_score":0.6249182},"labels":[],"label_agreement":null},{"id":"W2560005855","doi":"10.1016/j.it.2016.11.005","title":"T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints","year":2016,"lang":"en","type":"review","venue":"Trends in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canada Research Chairs; Canadian Institutes of Health Research; Alberta Innovates - Health Solutions","keywords":"Immune system; Immunology; Glioblastoma; Medicine; Biology; Cancer research","score_opus":0.02997503648571365,"score_gpt":0.3369090748250731,"score_spread":0.30693403833935945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560005855","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010568768,0.99517685,0.0000024430128,0.00009216165,0.0005251214,0.00031467224,0.000026880638,0.000030385507,0.002774612],"genre_scores_gemma":[0.0023342983,0.9939845,0.000048408026,0.0000108729355,0.000060180748,0.00010582509,0.00005503978,0.000051407118,0.0033494283],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972223,0.00021493775,0.0015483677,0.00042450445,0.0001505658,0.00043930183],"domain_scores_gemma":[0.9984501,0.000167163,0.00066033826,0.00065308507,0.00004203459,0.000027256463],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042827782,0.0004239044,0.0024814,0.0025507777,0.000016994232,0.0000042970864,0.00029865472,0.00075139484,0.0010964851],"category_scores_gemma":[0.000053949403,0.00030650484,0.0005801351,0.0015709591,0.0003512144,0.000055353226,0.00011535515,0.00059385865,0.00007107618],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010699462,0.00029788679,0.000028306937,0.0026545196,0.00020247679,0.000056750858,0.00010733803,3.309248e-8,0.00066344446,0.000027599992,0.00021631227,0.9946754],"study_design_scores_gemma":[0.005565177,0.0009947298,0.0015863259,0.019830307,0.000254594,0.00023309639,0.000050503768,4.3941753e-7,0.00083503866,0.000024156105,0.97023886,0.0003867406],"about_ca_topic_score_codex":0.00017288594,"about_ca_topic_score_gemma":0.000047903166,"teacher_disagreement_score":0.9942886,"about_ca_system_score_codex":0.00054062967,"about_ca_system_score_gemma":0.00023054959,"threshold_uncertainty_score":0.9999387},"labels":[],"label_agreement":null},{"id":"W2560342953","doi":"10.1186/s40425-016-0191-4","title":"31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College; University Health Network; Princess Margaret Cancer Centre; Université Laval","funders":"National Center for Advancing Translational Sciences; lékařská fakulta Univerzity Karlovy; Radboud Universitair Medisch Centrum; Université Paris Descartes; EMD Serono; Kindai University; Radboud Universiteit; Karolinska Institutet; Institut National de la Santé et de la Recherche Médicale; Université Pierre et Marie Curie; Dr. Ralph and Marian Falk Medical Research Trust; Sidra Medicine; Graduate School, University of Maryland; Pennsylvania Department of Health; University of Bern; Univerzita Karlova v Praze; National Cancer Institute; Alliance for Cancer Gene Therapy; National Institutes of Health; Keio University; National Science Foundation","keywords":"Durvalumab; Lung cancer; CD8; Immunotherapy; Cancer immunotherapy; Oncology; Medicine; Cancer research; Internal medicine; Cancer; Immunology; Immune system; Nivolumab","score_opus":0.017529416612312148,"score_gpt":0.31854342246694217,"score_spread":0.30101400585463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560342953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94011396,0.054026708,0.0002006987,0.0027597721,0.0009659839,0.0014062858,0.00044247144,0.0000189902,0.000065142434],"genre_scores_gemma":[0.9526955,0.042603713,0.001090202,0.0006012314,0.00035404455,0.00019154235,0.000005342661,0.0001175432,0.0023409133],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974928,0.000054202395,0.0012403161,0.00025070255,0.0004879397,0.00047402718],"domain_scores_gemma":[0.996195,0.0003022224,0.0021854774,0.00030309608,0.00094814686,0.00006601424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013323566,0.00030552165,0.0008152646,0.00009139876,0.0002514346,0.000025934998,0.00029794237,0.00023485067,0.00010405296],"category_scores_gemma":[0.000056846413,0.00017383999,0.0014040037,0.00025272387,0.00044041625,0.00021065534,0.000024669831,0.00021055863,8.294323e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008109531,0.0002222386,0.01538448,0.00023075966,0.004113358,2.7794528e-7,0.0019115814,0.0000133327685,0.61233884,0.00001144016,0.0013407915,0.3563234],"study_design_scores_gemma":[0.05568094,0.0036685145,0.27152008,0.013994185,0.0010408344,0.000049883223,0.0012301999,0.00008578471,0.47685063,0.00068095414,0.17435646,0.0008415534],"about_ca_topic_score_codex":0.0010477845,"about_ca_topic_score_gemma":0.00024385093,"teacher_disagreement_score":0.35548183,"about_ca_system_score_codex":0.00031670392,"about_ca_system_score_gemma":0.00074280007,"threshold_uncertainty_score":0.7088989},"labels":[],"label_agreement":null},{"id":"W2560628113","doi":"10.15252/emmm.201606674","title":"PD‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy","year":2016,"lang":"en","type":"article","venue":"EMBO Molecular Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":225,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Medical Research Council; Wellcome; Royal Society; Kidani Memorial Trust; Cancer Research UK; Wellcome Trust","keywords":"Blockade; Pancreatic ductal adenocarcinoma; Cancer research; Radiation therapy; Adenocarcinoma; Medicine; Pancreatic carcinoma; Pancreatic cancer; Internal medicine; Oncology; Receptor; Cancer","score_opus":0.01059972384263337,"score_gpt":0.2804955575501925,"score_spread":0.26989583370755915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560628113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.957139,0.01473266,0.0038794463,0.022806332,0.00028743167,0.0005731935,0.000008283252,0.000055728575,0.00051792513],"genre_scores_gemma":[0.9925578,0.0008474636,0.0011971694,0.0030606436,0.00031849716,0.00004044599,0.000004816156,0.00004956747,0.0019236001],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99795175,0.00018047736,0.00052878144,0.0004019316,0.0005775291,0.00035955937],"domain_scores_gemma":[0.99859685,0.0002221479,0.00014494802,0.00065456174,0.00012351394,0.00025800001],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006857398,0.0002623025,0.0006609341,0.0003060794,0.000039674826,0.0000039466454,0.00019354856,0.000106486346,0.0012166161],"category_scores_gemma":[0.0004222799,0.00015591503,0.00016278395,0.00047310692,0.00036065886,0.00004161324,0.000026157575,0.00009496262,0.000022380387],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017455984,0.00007746244,0.004515224,0.00005916758,0.0003809439,0.0002657169,0.0008042533,2.825786e-7,0.9694089,0.00004084187,0.0016699872,0.005321225],"study_design_scores_gemma":[0.008333931,0.004075212,0.19340321,0.0013672769,0.00023094042,0.00035572328,0.00018616399,0.0000045793595,0.7797988,0.000055615634,0.01193939,0.00024913624],"about_ca_topic_score_codex":0.00014225382,"about_ca_topic_score_gemma":0.0000046317946,"teacher_disagreement_score":0.1896101,"about_ca_system_score_codex":0.00014387484,"about_ca_system_score_gemma":0.00017196545,"threshold_uncertainty_score":0.99969643},"labels":[],"label_agreement":null},{"id":"W2560700960","doi":"10.1002/cncr.30449","title":"Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting","year":2016,"lang":"en","type":"article","venue":"Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Amgen; Pfizer; Genentech; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Clinical trial; Head and neck squamous-cell carcinoma; Cancer; Head and neck cancer; Immunotherapy; Oncology; Cancer immunotherapy; Internal medicine","score_opus":0.1293711173762785,"score_gpt":0.4437406255949231,"score_spread":0.3143695082186446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560700960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86128706,0.13063405,0.00009536762,0.0045559765,0.0019620012,0.000569903,0.0005264937,0.00005709595,0.0003120509],"genre_scores_gemma":[0.9016129,0.092202924,0.0005312537,0.0023384893,0.002231003,0.00046283923,0.000016220703,0.00007823473,0.0005261468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99679744,0.00020216752,0.0013756498,0.0006483638,0.00050941075,0.00046698484],"domain_scores_gemma":[0.9979251,0.0005981382,0.0007202324,0.000288514,0.0002695387,0.00019845614],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014046466,0.00038562715,0.0012834448,0.0001587568,0.00020307569,0.000044794335,0.0001675446,0.00024173831,0.00074080174],"category_scores_gemma":[0.00022279812,0.00028122574,0.00024223347,0.0002606333,0.00042178822,0.00031056462,0.00007893545,0.0003090613,0.0000010390384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005596544,0.00006647357,0.54516274,0.00017060946,0.0014960469,0.000008965947,0.001005261,0.00009515225,0.08973922,0.00003402577,0.0027735818,0.35385138],"study_design_scores_gemma":[0.03416145,0.00045006536,0.66390854,0.016959583,0.00047046147,0.0000116150395,0.00028927962,0.00054921844,0.013308466,0.00017909358,0.26880822,0.000903999],"about_ca_topic_score_codex":0.025917988,"about_ca_topic_score_gemma":0.00502968,"teacher_disagreement_score":0.35294738,"about_ca_system_score_codex":0.00053364853,"about_ca_system_score_gemma":0.0009664933,"threshold_uncertainty_score":0.999964},"labels":[],"label_agreement":null},{"id":"W2560704457","doi":"10.1016/s1470-2045(16)30624-6","title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":961,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; Juravinski Cancer Centre; University of Toronto; McMaster University","funders":"National Cancer Institute; University of Oxford","keywords":"Nivolumab; Ipilimumab; Medicine; Tolerability; Internal medicine; Lung cancer; Oncology; Cancer; Surgery; Adverse effect; Immunotherapy","score_opus":0.08906368332496893,"score_gpt":0.43502498492940195,"score_spread":0.345961301604433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560704457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846685,0.00097119174,0.00013924694,0.005578604,0.00050478487,0.006190637,0.00043307838,0.000057448902,0.0014565157],"genre_scores_gemma":[0.9865239,0.002748437,0.0012613916,0.00074174337,0.00050557515,0.001851879,0.000055939985,0.000057718884,0.0062533855],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978866,0.00017156283,0.00068080844,0.0005446956,0.00017375576,0.0005425901],"domain_scores_gemma":[0.99783057,0.00043721157,0.00043599308,0.0009868011,0.0001849954,0.00012444658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088625256,0.00030718854,0.0011409156,0.00006967179,0.00017975635,0.000015966887,0.0005466697,0.00014390163,0.00012511974],"category_scores_gemma":[0.00007398571,0.00016516903,0.00008680905,0.00016615662,0.00017423432,0.000114346505,0.000118499745,0.00010818528,0.000008291192],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42255557,0.016206112,0.0012320387,0.0002137974,0.0015053928,0.000090895126,0.0051192855,0.00005194705,0.1997503,0.000012973055,0.002281403,0.35098028],"study_design_scores_gemma":[0.743577,0.09012265,0.0025951446,0.00037695683,0.0012648251,0.0000464164,0.001078899,0.0023346515,0.06256197,0.000042162355,0.095542185,0.0004571658],"about_ca_topic_score_codex":0.002656492,"about_ca_topic_score_gemma":0.0066185766,"teacher_disagreement_score":0.35052314,"about_ca_system_score_codex":0.0011257086,"about_ca_system_score_gemma":0.00076955545,"threshold_uncertainty_score":0.67353976},"labels":[],"label_agreement":null},{"id":"W2560764121","doi":"10.1080/10428194.2016.1265115","title":"Severe inflammatory myositis in a patient receiving concurrent nivolumab and azacitidine","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Nivolumab; Azacitidine; Medicine; Myositis; Nilotinib; Internal medicine; Ipilimumab; Oncology; Dermatology; Immunotherapy; Cancer; Myeloid leukemia","score_opus":0.007861848712363367,"score_gpt":0.2188114789362649,"score_spread":0.21094963022390154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560764121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93544054,0.018367965,0.00001284789,0.038288828,0.0014959709,0.0016872481,0.00033505302,0.00029962754,0.0040719225],"genre_scores_gemma":[0.6305825,0.020941822,0.0001907171,0.33359748,0.00549016,0.00064890774,0.0008378724,0.0005834134,0.0071271043],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939602,0.00022849748,0.0015393395,0.0017511225,0.0009800514,0.0015407793],"domain_scores_gemma":[0.9972651,0.0004521588,0.0006842234,0.0010012635,0.00017995274,0.00041728106],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00041531314,0.001374845,0.0018207503,0.0007833174,0.00029691384,0.00019650454,0.00034213567,0.0020991436,0.00029388975],"category_scores_gemma":[0.00008950967,0.0011794845,0.00042348204,0.00045319862,0.00077400607,0.00035765438,0.00033713583,0.0007226797,0.00004820343],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001315039,0.00004804799,0.0031337112,0.0014134097,0.00044081002,0.0047905603,0.001007925,4.0699612e-7,0.0015844294,0.000022133805,0.3273003,0.65894324],"study_design_scores_gemma":[0.030639015,0.0006959559,0.040725242,0.0069179744,0.0003130663,0.00667533,0.00022443941,0.00013777212,0.00096168154,0.00011161846,0.91075957,0.0018383281],"about_ca_topic_score_codex":0.0018111898,"about_ca_topic_score_gemma":0.00017621643,"teacher_disagreement_score":0.6571049,"about_ca_system_score_codex":0.0135232005,"about_ca_system_score_gemma":0.004219558,"threshold_uncertainty_score":0.9999002},"labels":[],"label_agreement":null},{"id":"W2562748814","doi":"10.1684/ejd.2016.2923","title":"A case of fulminant type 1 diabetes mellitus, with a precipitous decrease in pancreatic volume, induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4 polymorphisms","year":2017,"lang":"en","type":"letter","venue":"European Journal of Dermatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Research Foundation","funders":"","keywords":"Medicine; Nivolumab; Fulminant; Melanoma; Type 1 diabetes; Oncology; Internal medicine; Ipilimumab; Diabetes mellitus; Immunotherapy; Cancer research; Cancer; Endocrinology","score_opus":0.01539169536177042,"score_gpt":0.24662489762950254,"score_spread":0.2312332022677321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562748814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9728652,0.012840537,0.000058136367,0.013462296,0.0001519328,0.00037530027,0.00012420946,0.000004381406,0.000117983735],"genre_scores_gemma":[0.9941346,0.00069220754,0.00069282047,0.004022685,0.00014982518,0.0000055546766,0.00008133773,0.000070283364,0.00015066873],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9972529,0.0006417651,0.0012384495,0.00028750984,0.00022177381,0.00035760354],"domain_scores_gemma":[0.9965665,0.00027177404,0.0022001613,0.00049536163,0.00032985874,0.00013639114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005377942,0.00033393677,0.0020102342,0.0009256653,0.00006108892,0.000018984614,0.00026020673,0.00021369889,0.000044760138],"category_scores_gemma":[0.0002222431,0.00024078858,0.0003396632,0.00031741153,0.0003501474,0.00006886308,0.000040947278,0.0006073413,6.2621734e-7],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030049134,0.001309541,0.17938744,0.004405228,0.04427017,0.33654666,0.0034521185,0.000003368786,0.076290116,0.0000054468333,0.2885534,0.035727393],"study_design_scores_gemma":[0.068898916,0.03063331,0.12332755,0.012526348,0.080911376,0.4311741,0.00082510477,0.0010516943,0.04168081,0.000045565546,0.20592906,0.0029961688],"about_ca_topic_score_codex":0.00018455816,"about_ca_topic_score_gemma":0.00004428282,"teacher_disagreement_score":0.09462744,"about_ca_system_score_codex":0.0000550477,"about_ca_system_score_gemma":0.0003307042,"threshold_uncertainty_score":0.9819073},"labels":[],"label_agreement":null},{"id":"W2564318420","doi":"10.1186/s40425-016-0173-6","title":"31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Columbia College; Caprion (Canada)","funders":"National Institute of Neurological Disorders and Stroke; Stand Up To Cancer; National Institutes of Health; Knight Cancer Institute, Oregon Health and Science University; Cancer Research Society; European Commission; U.S. Department of Defense; Breast Cancer Research Foundation; Oregon Health and Science University; Prostate Cancer Foundation; Movember Foundation; Cancer League of Colorado; Harry J. Lloyd Charitable Trust; National Cancer Institute; Dendreon Pharmaceuticals; Melanoma Research Alliance; Susan G. Komen for the Cure; Pharmaceutical Research and Manufacturers of America Foundation; Amgen; Collins Medical Trust","keywords":"Prostate cancer; Immunotherapy; Cancer immunotherapy; Myeloid cells; Cancer; Medicine; Gerontology; Immunology; Oncology; Cancer research; Myeloid; Internal medicine","score_opus":0.019952623559447987,"score_gpt":0.3311051548978156,"score_spread":0.3111525313383676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564318420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89988714,0.091400534,0.00035133894,0.004167115,0.0015107943,0.0018932604,0.0007009511,0.000021814152,0.0000670273],"genre_scores_gemma":[0.8708895,0.11680655,0.0020311957,0.0014893578,0.0010398607,0.00064921135,0.000012905816,0.00022514455,0.0068562976],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975085,0.00007315964,0.0011729631,0.00026094288,0.0005080223,0.00047639798],"domain_scores_gemma":[0.99647254,0.00029025608,0.0017988053,0.00034682456,0.0010213739,0.000070185844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013129849,0.00031111165,0.0008677856,0.000083406485,0.0002491471,0.000021701648,0.00031616323,0.00019178921,0.00018194994],"category_scores_gemma":[0.00005574862,0.00017322678,0.0015685415,0.00027889266,0.00054769014,0.00018278218,0.000026130749,0.00019249598,9.1676924e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010848518,0.00029642868,0.026149144,0.00020623005,0.0051203384,1.9904527e-7,0.0017135028,0.0000048361367,0.5656192,0.000029348028,0.00601054,0.38400173],"study_design_scores_gemma":[0.07208356,0.004518243,0.056080986,0.010424612,0.0010560035,0.000039573417,0.0014510668,0.00006901456,0.42876703,0.00074239395,0.4239808,0.00078671786],"about_ca_topic_score_codex":0.00074414216,"about_ca_topic_score_gemma":0.0002509947,"teacher_disagreement_score":0.41797027,"about_ca_system_score_codex":0.00031723463,"about_ca_system_score_gemma":0.00083652046,"threshold_uncertainty_score":0.7063983},"labels":[],"label_agreement":null},{"id":"W2564586450","doi":"10.1158/1538-7445.am2015-570","title":"Abstract 570: PD-L1 expression in paired non-small cell lung cancer tumor samples","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University College of the North","funders":"","keywords":"Concordance; Medicine; Lung cancer; Immunohistochemistry; Internal medicine; PD-L1; Cancer; Confidence interval; Gastroenterology; Pathology; Oncology; Nuclear medicine; Immunotherapy","score_opus":0.14249879872615298,"score_gpt":0.41428909081230464,"score_spread":0.2717902920861517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564586450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749942,0.017978745,0.000015153199,0.0015296008,0.00039863662,0.0010140418,0.000049855615,0.000043986576,0.0039757933],"genre_scores_gemma":[0.99262,0.0023866966,0.00018997466,0.00037382488,0.0005556445,0.00073559774,0.00002127169,0.00005881216,0.003058193],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99730486,0.00012460536,0.00037759662,0.00051791023,0.0008628687,0.0008121356],"domain_scores_gemma":[0.9985345,0.00014982584,0.00008026965,0.00049772847,0.0003636734,0.00037402613],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014962186,0.00020910097,0.00036370213,0.00035545396,0.00011149692,0.00005631775,0.00030181935,0.0001367851,0.00131537],"category_scores_gemma":[0.00009675852,0.00017049273,0.00010537382,0.00069108186,0.00019437891,0.00012196596,0.00011492855,0.0007042914,0.00003398349],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007305214,0.00029705916,0.1169026,0.00076236925,0.000060761824,0.00021608916,0.002749385,0.000054758573,0.7664375,0.0000022255485,0.09180512,0.013406964],"study_design_scores_gemma":[0.011868639,0.00041340615,0.3487483,0.0031399054,0.000033312743,0.0000123773025,0.0027284066,0.00025908064,0.5520836,0.000057395686,0.08014969,0.00050587906],"about_ca_topic_score_codex":0.017960425,"about_ca_topic_score_gemma":0.0027097485,"teacher_disagreement_score":0.23184569,"about_ca_system_score_codex":0.0012934824,"about_ca_system_score_gemma":0.002121978,"threshold_uncertainty_score":0.99959755},"labels":[],"label_agreement":null},{"id":"W2564893835","doi":"10.1093/annonc/mdw372.09","title":"Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Clinical endpoint; Prostate cancer; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Cohort; Adenocarcinoma; Cancer; Prostate; Clinical trial; Phases of clinical research; Immunotherapy","score_opus":0.04219005847890556,"score_gpt":0.33884572222919324,"score_spread":0.2966556637502877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564893835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838497,0.0006083554,0.000019266654,0.012377168,0.00014106827,0.0021839235,0.0003704499,0.000020781155,0.0004292587],"genre_scores_gemma":[0.9976158,0.00017842639,0.0002028684,0.0011898276,0.00008689344,0.00016642752,0.000054541582,0.000021996095,0.0004832289],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.998729,0.00009446518,0.00041173407,0.0003099828,0.00019373276,0.00026110822],"domain_scores_gemma":[0.9981032,0.000769559,0.0002998633,0.00042705552,0.00034480417,0.00005553703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029075082,0.00014539559,0.0003568439,0.000041303574,0.00006942854,0.0000036940794,0.0001512861,0.00007900179,0.000025419366],"category_scores_gemma":[0.00020587147,0.00006725983,0.000093768045,0.000097993354,0.0001849974,0.000074107455,0.000039760842,0.00007069109,0.0000042247493],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.548891,0.002495423,0.11486348,0.00002130125,0.0005596954,0.000018784925,0.0026784895,9.1230044e-7,0.00097385864,0.000006707148,0.014722168,0.3147682],"study_design_scores_gemma":[0.049891837,0.09039187,0.82622063,0.00012637985,0.000114852286,0.000003758729,0.0005192918,0.000002102268,0.0015059047,0.00007794941,0.031035414,0.000109988956],"about_ca_topic_score_codex":0.00016115808,"about_ca_topic_score_gemma":0.00006669464,"teacher_disagreement_score":0.7113572,"about_ca_system_score_codex":0.000046142683,"about_ca_system_score_gemma":0.00022765133,"threshold_uncertainty_score":0.27427766},"labels":[],"label_agreement":null},{"id":"W2565502203","doi":"10.1158/1538-7445.am2015-5289","title":"Abstract 5289: The role of the immune system in lymph node positive ER+ breast cancer","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University","funders":"","keywords":"Breast cancer; Medicine; Tissue microarray; Lymph node; Immune system; Oncology; Estrogen receptor; Cancer; Population; Immunohistochemistry; Internal medicine; Stage (stratigraphy); Tamoxifen; Immunology; Biology","score_opus":0.043079388725031295,"score_gpt":0.36983007657160044,"score_spread":0.32675068784656913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565502203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9473624,0.03654689,5.8791613e-7,0.0060564866,0.00033869644,0.00082553364,0.00017932034,0.000017223803,0.008672859],"genre_scores_gemma":[0.99809104,0.000574333,0.0000027832648,0.00013174512,0.00024647874,0.00026450993,0.0000033676,0.000026266058,0.0006594818],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979118,0.00020553573,0.00031861546,0.00023617472,0.00088254345,0.000445312],"domain_scores_gemma":[0.9986195,0.00012131372,0.00009564612,0.0005648127,0.000498271,0.00010048136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015514607,0.00012794558,0.00026342957,0.00011698845,0.00012512377,0.000026749683,0.00042569597,0.000094796254,0.00021825198],"category_scores_gemma":[0.00003813103,0.00006832152,0.00012112919,0.0008118378,0.0004479934,0.00006529382,0.0001223983,0.0004489992,0.000013571204],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017506592,0.00040450643,0.24313717,0.00068599504,0.0007502459,0.000056212768,0.007535105,0.00017984759,0.60257524,0.0008829155,0.0037415808,0.12254461],"study_design_scores_gemma":[0.0030222468,0.000051774055,0.876907,0.0018827254,0.000028238052,0.00005821246,0.0067632375,0.00010349198,0.10655756,0.000045499946,0.004464862,0.00011515755],"about_ca_topic_score_codex":0.058655012,"about_ca_topic_score_gemma":0.0011785217,"teacher_disagreement_score":0.6337698,"about_ca_system_score_codex":0.0015988701,"about_ca_system_score_gemma":0.0017051339,"threshold_uncertainty_score":0.9476135},"labels":[],"label_agreement":null},{"id":"W2565843701","doi":"10.1158/1538-7445.am2015-2344","title":"Abstract 2344: The PD-1:PD-L1 pathway in the context of the osteosarcoma tumor microenvironment","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Immune system; Tumor microenvironment; Cancer research; PD-L1; Cancer; Tumor-infiltrating lymphocytes; Medicine; Antibody; Context (archaeology); Immunology; Biology; Immunotherapy; Internal medicine","score_opus":0.10120100545151116,"score_gpt":0.37393525672491523,"score_spread":0.27273425127340406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565843701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96390617,0.009615334,3.676242e-7,0.022345096,0.00018903578,0.0011499139,0.000035555564,0.0000056763547,0.0027528577],"genre_scores_gemma":[0.99612725,0.0004305276,0.0000037367263,0.0020102367,0.00017095798,0.00023643272,0.0000032535283,0.000018997109,0.0009986112],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99765676,0.0003641493,0.00029963983,0.00022310368,0.0010314909,0.00042483542],"domain_scores_gemma":[0.99865234,0.00028088107,0.00008275537,0.00080478046,0.00010412637,0.00007512425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028061308,0.00012397932,0.00019547984,0.00006668185,0.00014239634,0.00003239222,0.00067324477,0.00005267644,0.00031072582],"category_scores_gemma":[0.00010919374,0.000053375137,0.00012649671,0.00043649122,0.00082774536,0.000042117033,0.00012718809,0.00066550303,0.000032526408],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0111752255,0.00086311094,0.051378287,0.00031058918,0.0003103272,0.00016199195,0.02668108,0.000012494567,0.68501073,0.0003532142,0.09142562,0.13231735],"study_design_scores_gemma":[0.004433086,0.00046474882,0.37103367,0.00040638185,0.000017401731,0.000055840985,0.019524429,0.0000084010035,0.16100878,0.000143866,0.44276637,0.00013701683],"about_ca_topic_score_codex":0.004620254,"about_ca_topic_score_gemma":0.0014938789,"teacher_disagreement_score":0.52400196,"about_ca_system_score_codex":0.00045726885,"about_ca_system_score_gemma":0.00065170234,"threshold_uncertainty_score":0.6984473},"labels":[],"label_agreement":null},{"id":"W2566747056","doi":"10.1080/2162402x.2016.1257452","title":"Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer","year":2016,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":236,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Tumor-infiltrating lymphocytes; CD8; Immunohistochemistry; PD-L1; CD19; Immune system; Breast cancer; Infiltration (HVAC); Pathology; Flow cytometry; Lymphocyte; Stroma; Biology; Cancer research; Medicine; Cancer; Immunotherapy; Immunology; Internal medicine","score_opus":0.008638446302255718,"score_gpt":0.25263621476796555,"score_spread":0.24399776846570984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566747056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916213,0.0026446169,0.000111841,0.0048809065,0.00024164651,0.00021067377,0.000026840136,0.00006852889,0.00019363425],"genre_scores_gemma":[0.99617445,0.0024229547,0.00014899144,0.0008567299,0.00011439504,0.000025630527,0.000021357757,0.000026337682,0.00020914973],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990454,0.000075650285,0.00029528778,0.00026305253,0.000095911084,0.000224738],"domain_scores_gemma":[0.99940026,0.000069161215,0.00016671761,0.00020287791,0.000121769954,0.00003920309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011034042,0.00014584107,0.00028243853,0.00012593987,0.000094043826,0.000012851935,0.00006924793,0.00013966662,0.0005316643],"category_scores_gemma":[0.000027448932,0.000102692655,0.00002897632,0.00026086686,0.000159947,0.00012257503,0.00004312279,0.00010012321,0.000014539084],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014362149,0.00006755299,0.14095943,0.00002903593,0.000038654915,0.000028073806,0.00025672914,5.5630727e-7,0.8308833,0.000020228545,0.00022203248,0.026058184],"study_design_scores_gemma":[0.0068667014,0.00011976278,0.928979,0.001071461,0.000024124609,0.0007184194,0.0002280499,0.0000126469995,0.060039986,0.000023533594,0.0017487025,0.00016762121],"about_ca_topic_score_codex":0.00027503783,"about_ca_topic_score_gemma":0.000045525234,"teacher_disagreement_score":0.78801954,"about_ca_system_score_codex":0.00038659427,"about_ca_system_score_gemma":0.0001732365,"threshold_uncertainty_score":0.58213514},"labels":[],"label_agreement":null},{"id":"W2566878474","doi":"10.1158/2326-6074.tumimm14-ia22","title":"Abstract IA22: Regulation of metabolic plasticity in effector T cells","year":2015,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Effector; Cell biology; Biology; AMPK; T cell; Acquired immune system; Bioenergetics; Immune system; Kinase; Protein kinase A; Immunology; Mitochondrion","score_opus":0.09428215381281056,"score_gpt":0.40043620735981783,"score_spread":0.30615405354700725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566878474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98234373,0.014565718,0.000008185643,0.0005041791,0.00035006684,0.00048652585,0.000016767157,0.000016803404,0.0017079968],"genre_scores_gemma":[0.9977251,0.0013086167,0.0000531634,0.0000374153,0.00010319,0.00009996446,0.000010069257,0.000016798796,0.0006456609],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983864,0.00020294999,0.00033852924,0.00025081896,0.0004041538,0.00041719183],"domain_scores_gemma":[0.99894226,0.00026327366,0.00007828322,0.00028375178,0.00035114278,0.00008129071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010922296,0.00011270771,0.0003802597,0.0004508518,0.00003739206,0.000008008288,0.00016370173,0.00019304328,0.0005943869],"category_scores_gemma":[0.00021317299,0.00009670245,0.00007221602,0.0007157534,0.0005201195,0.000076484845,0.00005880993,0.000504996,0.000068024856],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075504985,0.000176314,0.02188892,0.00009174903,0.00019128031,0.000012943219,0.0005783348,0.000025246867,0.94690347,0.00010120538,0.0016613432,0.02081868],"study_design_scores_gemma":[0.0039695557,0.00033261036,0.61350006,0.00015478568,0.000015571706,0.00000763393,0.00019574253,0.000045558536,0.37060508,0.00008253833,0.01101183,0.00007906087],"about_ca_topic_score_codex":0.0025083341,"about_ca_topic_score_gemma":0.0002201414,"teacher_disagreement_score":0.59161115,"about_ca_system_score_codex":0.00025400333,"about_ca_system_score_gemma":0.00073219504,"threshold_uncertainty_score":0.650812},"labels":[],"label_agreement":null},{"id":"W2567743054","doi":"10.1016/j.jtho.2016.11.010","title":"PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Pemetrexed; Lung cancer; Internal medicine; Oncology; Chemotherapy; Quality of life (healthcare); Adverse effect; Progression-free survival; Tolerability; Cancer; Immunotherapy; Cisplatin","score_opus":0.09413103862692979,"score_gpt":0.4769493827011173,"score_spread":0.3828183440741875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567743054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96669096,0.0042056795,0.00067860534,0.026536485,0.0007067902,0.0006160159,0.00013740623,0.00001171438,0.00041632497],"genre_scores_gemma":[0.98681396,0.0014586006,0.00890156,0.0021696822,0.00032764603,0.000009503526,0.000054594304,0.000040880434,0.00022357206],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99696743,0.0002900033,0.0016974326,0.00033344055,0.0003546727,0.00035701293],"domain_scores_gemma":[0.99451625,0.0004679611,0.0034453517,0.0011235293,0.00022873742,0.00021817921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002575378,0.00022461517,0.0016039237,0.00019692948,0.00013332773,0.000023683224,0.0007732805,0.00027844557,0.0001952757],"category_scores_gemma":[0.0005612611,0.00016606873,0.00020949267,0.00011728021,0.0002965241,0.0003384152,0.000079938305,0.000537931,0.0000023981727],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82329047,0.00094658055,0.007538228,0.00028304086,0.00095959235,0.00006841699,0.0008703334,0.000012329134,0.012613795,0.000009941185,0.0042039603,0.14920335],"study_design_scores_gemma":[0.041103307,0.010863257,0.89854574,0.0011813256,0.00021123952,0.00030733112,0.00096380763,0.00023241834,0.0023953991,0.00051950914,0.0433749,0.00030174394],"about_ca_topic_score_codex":0.0017160311,"about_ca_topic_score_gemma":0.0010998141,"teacher_disagreement_score":0.89100754,"about_ca_system_score_codex":0.00045428856,"about_ca_system_score_gemma":0.0021408915,"threshold_uncertainty_score":0.6772086},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2567825448","doi":"10.1038/bjc.2016.429","title":"Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth","year":2017,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institute on Minority Health and Health Disparities; National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Blockade; Breast cancer; Oncology; Chemotherapy; Cancer; CTLA-4; Internal medicine; Immunology; Receptor; T cell; Immune system","score_opus":0.01793608759319667,"score_gpt":0.35102083915400556,"score_spread":0.3330847515608089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567825448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99331397,0.0041544596,0.000010166178,0.0016179474,0.00027711975,0.00017897668,0.00006514509,0.0000039940924,0.00037824595],"genre_scores_gemma":[0.9844888,0.014472968,0.000050038645,0.00024755218,0.00053869403,0.0000097802,9.4457937e-7,0.00002636127,0.00016485636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881786,0.00003552521,0.0005097682,0.00015454793,0.0002851794,0.00019709297],"domain_scores_gemma":[0.99858844,0.00003610513,0.00081372104,0.00018469593,0.0002717113,0.000105321444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034367782,0.00013472144,0.0005523454,0.00011991191,0.00006380907,0.000049478076,0.00017088102,0.000091776725,0.0006628444],"category_scores_gemma":[0.00003391497,0.000108246146,0.00027787164,0.00008624259,0.00019872317,0.00018864215,0.000009192498,0.00033786902,5.117371e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027276373,0.00034247592,0.66953593,0.00004441072,0.0009900527,0.00008568839,0.00006050879,0.00005582129,0.005414277,0.0000013821486,0.0014497784,0.29474333],"study_design_scores_gemma":[0.012911183,0.0013572099,0.9778302,0.0025656766,0.000109445435,0.0009240729,0.000014150536,0.000020058116,0.0036006824,0.00001128915,0.0005389362,0.0001171406],"about_ca_topic_score_codex":0.01391351,"about_ca_topic_score_gemma":0.0022674985,"teacher_disagreement_score":0.30829424,"about_ca_system_score_codex":0.0005234775,"about_ca_system_score_gemma":0.0007181555,"threshold_uncertainty_score":0.99265295},"labels":[],"label_agreement":null},{"id":"W2568149294","doi":"10.1016/j.jtho.2016.11.445","title":"MA09.03 Cisplatin/Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non-Squamous NSCLC: A CCTG Phase IB Study - IND.226","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa; University of Calgary; Hôpital Notre-Dame; Queen's University; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Pemetrexed; Durvalumab; Medicine; Carboplatin; Tremelimumab; Tolerability; Internal medicine; Cisplatin; Oncology; Gemcitabine; Chemotherapy; Pembrolizumab; Cancer; Immunotherapy; Adverse effect; Ipilimumab","score_opus":0.0332512173496041,"score_gpt":0.4461936429016305,"score_spread":0.41294242555202637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568149294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926324,0.00065982126,0.00010068544,0.0020876238,0.0009123633,0.0009224851,0.000006393691,0.000016031341,0.0026621867],"genre_scores_gemma":[0.99672097,0.00014642665,0.0018135818,0.0003641946,0.0003578521,0.000028245948,0.0000035156338,0.00004844738,0.0005167409],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971091,0.00027666698,0.0011664693,0.00034901546,0.00061298657,0.00048573597],"domain_scores_gemma":[0.9966156,0.00024260503,0.0018264814,0.00073309796,0.00034581352,0.0002363979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015906291,0.0003332798,0.0012876183,0.0005709634,0.00024422116,0.000064029366,0.0005061686,0.00023628905,0.00022406956],"category_scores_gemma":[0.00034537714,0.00023974768,0.0002460571,0.00030125224,0.00023981143,0.00039780655,0.000079392456,0.0008616819,0.000013096796],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1567167,0.008930001,0.03665657,0.00010200515,0.0007105273,0.006816308,0.0026976578,0.000018479026,0.031244531,0.0000022220172,0.00068715785,0.7554178],"study_design_scores_gemma":[0.20089889,0.15944889,0.5860558,0.0017279516,0.0017876289,0.006785071,0.014671609,0.000307817,0.011240032,0.00010733798,0.01599329,0.0009756884],"about_ca_topic_score_codex":0.00015419802,"about_ca_topic_score_gemma":0.0011472135,"teacher_disagreement_score":0.75444216,"about_ca_system_score_codex":0.0008031,"about_ca_system_score_gemma":0.0010192699,"threshold_uncertainty_score":0.9776627},"labels":[],"label_agreement":null},{"id":"W2568650842","doi":"10.1016/j.jtho.2016.11.1117","title":"P2.01-065 Quantification of Tumor-Immune Cell Spatial Relationships in the Lung Tumor Microenvironment Using Single Cell Profiling","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"KRAS; Tumor microenvironment; Immunohistochemistry; CD8; Medicine; Immune system; Pathology; Adenocarcinoma; T cell; Cancer research; Immunology; Internal medicine; Cancer","score_opus":0.06269955750267579,"score_gpt":0.37652949442402606,"score_spread":0.31382993692135025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568650842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99333066,0.0023499867,0.0011450504,0.0015866093,0.0004991263,0.00035380662,0.0000036648407,0.0000027740462,0.00072830875],"genre_scores_gemma":[0.99394405,0.000097155826,0.0055381022,0.00011517284,0.0002008963,0.000003335468,0.0000038386643,0.000015525144,0.000081906495],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981306,0.00038303685,0.00090724544,0.00013245687,0.0002628716,0.00018376095],"domain_scores_gemma":[0.99721277,0.0001861501,0.0020716416,0.00040628284,0.00008061155,0.000042547752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023394013,0.00012060528,0.00040967425,0.00016948354,0.00022069395,0.00002864198,0.00030011553,0.00009261486,0.000042637446],"category_scores_gemma":[0.00014004463,0.00008697219,0.00017284519,0.00008084471,0.00019493393,0.00014078297,0.000037503414,0.0005232043,0.000002776128],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003731926,0.0008960716,0.035828788,0.00017211233,0.000041913336,0.0001412885,0.00086674193,0.00014212278,0.95357305,0.000004677078,0.00011629433,0.004485004],"study_design_scores_gemma":[0.003162945,0.001864595,0.350822,0.0005375007,0.0004973971,0.0011019562,0.0030580915,0.0019251992,0.6329221,0.00006661809,0.0038561942,0.00018539374],"about_ca_topic_score_codex":0.00013401601,"about_ca_topic_score_gemma":0.000036118254,"teacher_disagreement_score":0.32065094,"about_ca_system_score_codex":0.00045009365,"about_ca_system_score_gemma":0.0002897414,"threshold_uncertainty_score":0.3546623},"labels":[],"label_agreement":null},{"id":"W2568802220","doi":"10.1016/j.jtho.2016.11.238","title":"OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Tolerability; Internal medicine; Adverse effect; Oncology; Ipilimumab; Docetaxel; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Population; Progression-free survival; Chemotherapy; Phases of clinical research; Immunotherapy; Clinical trial; Cancer","score_opus":0.025470528182510967,"score_gpt":0.3758445914173529,"score_spread":0.35037406323484194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568802220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99311185,0.0018376788,0.00011320874,0.0034378283,0.0007208258,0.0004654133,0.000019003292,0.000015653366,0.00027855625],"genre_scores_gemma":[0.99565876,0.0014480845,0.0016593437,0.00057615456,0.00020004869,0.000010087248,0.000011911195,0.000045883986,0.00038975058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801016,0.00009966563,0.00081899355,0.00029742758,0.0003728842,0.0004008828],"domain_scores_gemma":[0.99757606,0.00013885844,0.0013396904,0.00054100045,0.00020881782,0.00019558276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047049476,0.00029802235,0.0011319036,0.00023029283,0.00021131434,0.00006205908,0.00033845552,0.00024661154,0.00024168448],"category_scores_gemma":[0.00009727414,0.00021268062,0.00018127132,0.000083708466,0.00030224095,0.0004377896,0.00006927422,0.0004945139,0.00000630651],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06417533,0.0005825894,0.5662152,0.00005126884,0.00043811853,0.00024257046,0.0005036115,0.000008499941,0.0003744178,5.830633e-7,0.000073633615,0.3673342],"study_design_scores_gemma":[0.03685613,0.0053264364,0.954313,0.0005762531,0.0002068209,0.000101167374,0.00009371878,0.000040302148,0.00041052327,0.000041793526,0.0018044058,0.00022948925],"about_ca_topic_score_codex":0.00023816702,"about_ca_topic_score_gemma":0.0013755801,"teacher_disagreement_score":0.38809776,"about_ca_system_score_codex":0.00075975223,"about_ca_system_score_gemma":0.0003871152,"threshold_uncertainty_score":0.8672864},"labels":[],"label_agreement":null},{"id":"W2568885197","doi":"10.1016/j.jtho.2016.11.1825","title":"P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"David Geffen School of Medicine, University of California, Los Angeles; Deutsches Zentrum für Lungenforschung; Tel Aviv University","keywords":"Pembrolizumab; Medicine; Dosing; Pharmacokinetics; Lung cancer; non-small cell lung cancer (NSCLC); Population; Internal medicine; Area under the curve; Oncology; Adverse effect; Urology; Gastroenterology; Cancer; Immunotherapy","score_opus":0.049424323586636905,"score_gpt":0.42637060500342583,"score_spread":0.37694628141678893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568885197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862554,0.0090872515,0.0003072186,0.0021934907,0.0009251789,0.00085560064,0.00006774627,0.0000028156064,0.0003052608],"genre_scores_gemma":[0.9840283,0.009761493,0.004051896,0.00014790331,0.00029841452,0.000042569656,0.0000022411798,0.000025704287,0.001641494],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984308,0.00008161929,0.00089856866,0.00013986614,0.000214595,0.00023453316],"domain_scores_gemma":[0.995789,0.0005007104,0.0025751786,0.00051723147,0.0005322318,0.00008566453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043202628,0.00017914783,0.0009656297,0.0001401325,0.00010203931,0.0000097306,0.0002958684,0.00016314091,0.00011574837],"category_scores_gemma":[0.00010017181,0.00010686331,0.00056209473,0.00007698383,0.00027170192,0.00011587841,0.000027177668,0.00014388075,2.9732163e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12770607,0.0021644665,0.009583107,0.00065904495,0.0018190201,0.000063203115,0.00215756,0.00018392278,0.32346398,0.0000042862175,0.0028161653,0.5293792],"study_design_scores_gemma":[0.053039838,0.04970056,0.19960701,0.0020072744,0.0065669655,0.00043952637,0.0016551155,0.0016292142,0.4657739,0.00005103783,0.2191063,0.00042325506],"about_ca_topic_score_codex":0.0003909002,"about_ca_topic_score_gemma":0.00026885123,"teacher_disagreement_score":0.52895594,"about_ca_system_score_codex":0.00039978043,"about_ca_system_score_gemma":0.0010278556,"threshold_uncertainty_score":0.4357759},"labels":[],"label_agreement":null},{"id":"W2569537049","doi":"10.1038/modpathol.2016.221","title":"Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer","year":2017,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Calgary Laboratory Services","funders":"Alberta Innovates; Alberta Innovates - Health Solutions; Alberta Cancer Foundation","keywords":"Tissue microarray; CD8; Medicine; Immunohistochemistry; PD-L1; Cervical cancer; Chemoradiotherapy; Hazard ratio; Cancer; Pathology; Predictive marker; Immune system; Oncology; Immunotherapy; Cancer research; Internal medicine; Immunology; Confidence interval","score_opus":0.01535115698568248,"score_gpt":0.303202073314891,"score_spread":0.28785091632920856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569537049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996681,0.0018277398,0.00040539925,0.00018250059,0.00007989229,0.00037102815,0.00007367405,0.0000037417888,0.00037502332],"genre_scores_gemma":[0.9976205,0.0013120354,0.0007566848,0.000029888017,0.000016045316,0.000026384416,0.0000035552016,0.0000092629725,0.00022563389],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991795,0.000050387724,0.00028763784,0.00022879784,0.00011121888,0.00014247556],"domain_scores_gemma":[0.99919045,0.000055398817,0.00025977942,0.00038987037,0.00006835797,0.000036151458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008866253,0.00010827985,0.00041592252,0.000056956887,0.000025384454,0.000001923692,0.00009373194,0.000105250314,0.00004218236],"category_scores_gemma":[0.000017016704,0.00008292181,0.000055133805,0.00002691388,0.00037582094,0.000046989415,0.00006620939,0.00006145653,2.2881564e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053637023,0.00028506282,0.031860825,0.00010842119,0.00003124717,0.00004644524,0.0025134427,0.000064104024,0.93372613,0.0000073117662,0.0000074744876,0.025985833],"study_design_scores_gemma":[0.0027694365,0.0007943445,0.35543877,0.00033970262,0.000026171932,0.000010399064,0.000039721624,0.00031669476,0.6401059,0.00008524315,0.000025469239,0.0000481504],"about_ca_topic_score_codex":0.0006167154,"about_ca_topic_score_gemma":0.00032664338,"teacher_disagreement_score":0.32357794,"about_ca_system_score_codex":0.00004995214,"about_ca_system_score_gemma":0.00007534753,"threshold_uncertainty_score":0.33814535},"labels":[],"label_agreement":null},{"id":"W2569695288","doi":"10.1007/s00262-016-1950-2","title":"Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model","year":2017,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; Université de Montréal; Montreal Clinical Research Institute","funders":"Canadian Institutes of Health Research; Canadian Cancer Society","keywords":"T cell; Immune system; Cancer research; CD8; Immunotherapy; Immunology; Immunity; Cytotoxic T cell; Cancer immunotherapy; Cancer; Biology; Medicine; Internal medicine; In vitro","score_opus":0.016891490023701924,"score_gpt":0.2921629740460029,"score_spread":0.27527148402230095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569695288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92829335,0.06967123,0.000039336628,0.00039199425,0.00031321004,0.0009487083,0.00004682387,0.000040902498,0.00025442487],"genre_scores_gemma":[0.94888765,0.049609706,0.00014879237,0.00035868137,0.00002736263,0.00022111116,0.000008699851,0.000064211934,0.0006737853],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980429,0.00013265637,0.00056187855,0.00056233193,0.00018533334,0.0005149138],"domain_scores_gemma":[0.9978539,0.0001874209,0.0005363534,0.0012622079,0.000086947635,0.000073212046],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025000903,0.00049472507,0.0009821195,0.00031949807,0.00042734275,0.000049099577,0.0003176112,0.00018873574,0.00003881394],"category_scores_gemma":[0.00006621415,0.00037783018,0.0001506002,0.00012741954,0.0010548682,0.0001612006,0.00008869801,0.0003505781,0.0000022855534],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071622375,0.00079788413,0.014232701,0.00025202276,0.00025068605,0.00005713273,0.0009754928,0.000012145807,0.95444167,0.00006390748,0.000017854252,0.02173624],"study_design_scores_gemma":[0.02387958,0.0033877578,0.2512073,0.0010435731,0.00011102775,0.00004211691,0.00019675857,0.00051202875,0.7186666,0.00006643126,0.00040981936,0.00047701833],"about_ca_topic_score_codex":0.0029015304,"about_ca_topic_score_gemma":0.00009779319,"teacher_disagreement_score":0.23697458,"about_ca_system_score_codex":0.00034320707,"about_ca_system_score_gemma":0.00024900876,"threshold_uncertainty_score":0.9998674},"labels":[],"label_agreement":null},{"id":"W2572743968","doi":"10.1186/s12967-016-1095-2","title":"Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts","year":2017,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Hungarian Scientific Research Fund; Melanoma Research Alliance","keywords":"Bridge (graph theory); Immunotherapy; Medicine; Computer science; Immunology; Internal medicine; Immune system","score_opus":0.03614032860580018,"score_gpt":0.3221784287638414,"score_spread":0.2860381001580412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2572743968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89877236,0.028735163,0.00044119696,0.061758827,0.0010580105,0.0002764167,0.000018017472,0.000015158707,0.008924856],"genre_scores_gemma":[0.99100584,0.00506497,0.0007772887,0.0009487405,0.0016164515,0.00000158039,0.000008013116,0.00002504732,0.00055206934],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981466,0.00003469549,0.00085440336,0.00015348611,0.000606388,0.00020440861],"domain_scores_gemma":[0.9982721,0.0001845305,0.0008402883,0.0002615801,0.00026469704,0.00017679688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012048766,0.0001843115,0.000511025,0.00018310893,0.00025664477,0.00003839097,0.00019098572,0.00010199356,0.00027188164],"category_scores_gemma":[0.00015147628,0.00012583299,0.00016798633,0.00005086694,0.00035823704,0.00030495666,0.000008394359,0.0003040085,0.000004994002],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01841957,0.00040429822,0.115972444,0.00031298722,0.0022815594,0.0006018502,0.0030368443,0.000016873695,0.3430542,0.00016114739,0.03554235,0.48019588],"study_design_scores_gemma":[0.010631225,0.00084023614,0.941013,0.0016099071,0.000151473,0.0012902361,0.000029683766,0.000024013434,0.0012550942,0.0003397602,0.042687822,0.00012755029],"about_ca_topic_score_codex":0.00031669196,"about_ca_topic_score_gemma":0.000020860774,"teacher_disagreement_score":0.8250406,"about_ca_system_score_codex":0.00004096587,"about_ca_system_score_gemma":0.00026447253,"threshold_uncertainty_score":0.51313204},"labels":[],"label_agreement":null},{"id":"W2582960575","doi":"10.1093/annonc/mdx003","title":"PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University; University Health Network","funders":"Duke Clinical Research Institute; Fondation Gustave Roussy; Canadian Cancer Society Research Institute; Institut Gustave-Roussy; National Cancer Institute; Institut National Du Cancer; Ligue Contre le Cancer; Princess Margaret Cancer Foundation; AstraZeneca","keywords":"Medicine; Immunohistochemistry; Chemotherapy; Lung cancer; Oncology; Adjuvant; KRAS; Internal medicine; Pathology; Cancer; Colorectal cancer","score_opus":0.02672653027178159,"score_gpt":0.3590182722130548,"score_spread":0.33229174194127326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582960575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879507,0.0055570663,0.000033678,0.0020142368,0.00011522163,0.0012657477,0.00033082397,0.000014501592,0.0027180172],"genre_scores_gemma":[0.99623513,0.0012312742,0.00032698273,0.0005239038,0.00009177013,0.00031277147,0.000060379603,0.000038907532,0.0011788845],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840695,0.00004997234,0.00058813224,0.00039580386,0.00023458405,0.000324589],"domain_scores_gemma":[0.99793094,0.00010960654,0.0008753703,0.0006761023,0.0003271524,0.00008080584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025358124,0.00023233722,0.00073241803,0.00008096356,0.00007323585,0.000010612579,0.00036603562,0.00038208056,0.0005703252],"category_scores_gemma":[0.00008457308,0.00020030103,0.00015993723,0.00010063288,0.00026156518,0.00008987247,0.00007047659,0.00028105848,0.000001125965],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01307945,0.0009789735,0.04421193,0.00025891114,0.00023108591,0.000014423676,0.0011128277,0.0000014149759,0.9229481,2.5819824e-7,0.0064933975,0.010669234],"study_design_scores_gemma":[0.006738804,0.0013392995,0.23362431,0.0011314903,0.000050768525,0.000001294698,0.0001243326,0.00012735334,0.7547631,0.000022115239,0.0019343729,0.00014271431],"about_ca_topic_score_codex":0.0056490214,"about_ca_topic_score_gemma":0.00012615131,"teacher_disagreement_score":0.18941239,"about_ca_system_score_codex":0.00013923648,"about_ca_system_score_gemma":0.0005490821,"threshold_uncertainty_score":0.8539668},"labels":[],"label_agreement":null},{"id":"W2583641997","doi":"10.1016/s1470-2045(17)30003-7","title":"Adjuvant ipilimumab for stage III melanoma: the patient voice","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Ipilimumab; Medicine; Internal medicine; Melanoma; Discontinuation; Placebo; Adverse effect; Oncology; Adjuvant; Adjuvant therapy; Hazard ratio; Cancer; Gastroenterology; Immunotherapy; Pathology; Cancer research","score_opus":0.06020058253608758,"score_gpt":0.3461598513023324,"score_spread":0.28595926876624483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583641997","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051363246,0.0036472643,0.000042258547,0.9694189,0.002926593,0.002252573,0.00036730716,0.000068360554,0.016140444],"genre_scores_gemma":[0.0085595865,0.0010437315,0.00014781859,0.9419667,0.016942618,0.00076823623,0.0003801051,0.00008588958,0.03010528],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979599,0.0002674504,0.00042164492,0.00039808586,0.00028583387,0.00066709204],"domain_scores_gemma":[0.99662423,0.00086172286,0.00063714356,0.0017251282,0.00011585996,0.000035940906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008994337,0.0003365507,0.0011054764,0.00004904295,0.00047273547,0.00004310396,0.0008768646,0.00071148976,0.0002780311],"category_scores_gemma":[0.0001075525,0.00016041749,0.00037289795,0.000051059073,0.00054835214,0.00003009875,0.00013287671,0.0015634461,0.00006075862],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005822307,0.000046595498,0.00002713586,0.00018305029,0.0005476059,0.00021966528,0.0006878109,3.6073192e-7,0.00019585756,0.000026889873,0.9615363,0.030706419],"study_design_scores_gemma":[0.007692222,0.0019813005,0.0005610025,0.000105925785,0.00038934316,0.00021220127,0.0001295599,0.000018348817,0.00012320197,0.00012465964,0.98845226,0.00020996768],"about_ca_topic_score_codex":0.00035222486,"about_ca_topic_score_gemma":0.00021129644,"teacher_disagreement_score":0.030496452,"about_ca_system_score_codex":0.00038803738,"about_ca_system_score_gemma":0.0005236422,"threshold_uncertainty_score":0.6792482},"labels":[],"label_agreement":null},{"id":"W2586106096","doi":"10.1093/ecco-jcc/jjx002.593","title":"P468 Etrolizumab treatment improves histological activity as assessed by the Robarts histopathology index","year":2017,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Histopathology; Gastroenterology; Placebo; Internal medicine; Sigmoidoscopy; Colonoscopy; Histology; Hypoallergenic; Pathology; Colorectal cancer; Cancer","score_opus":0.020292991575627813,"score_gpt":0.303670368092277,"score_spread":0.2833773765166492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586106096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853233,0.003390395,0.00004554048,0.007719045,0.00033404527,0.0001355932,0.0000072514704,0.0000049778932,0.0030398408],"genre_scores_gemma":[0.9955269,0.0014771731,0.000023442963,0.0005485103,0.0001862496,0.0000072115345,6.3949904e-7,0.000007246295,0.0022226302],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99926436,0.00006196754,0.00022347829,0.000115773415,0.00016146344,0.00017297467],"domain_scores_gemma":[0.9990706,0.00005915334,0.0004448359,0.00024160788,0.000082560975,0.000101250254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002106423,0.00011846866,0.00035852884,0.000035201567,0.00032422907,0.000079044185,0.0001204565,0.000104209474,0.00009786479],"category_scores_gemma":[0.00006928577,0.000064419735,0.00016017216,0.000018408256,0.00033822033,0.00011352835,0.000023695471,0.000174017,0.0000011466439],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048466418,0.0010469476,0.018561957,0.00004464757,0.000506828,0.0025035397,0.00055543275,1.9132794e-7,0.040734027,0.00037569256,0.016743869,0.87046045],"study_design_scores_gemma":[0.0034011172,0.0023318455,0.8593297,0.0000270218,0.00010572689,0.0031282748,0.000054201064,0.000006804773,0.0015287484,0.00021441006,0.12980705,0.00006510595],"about_ca_topic_score_codex":0.000570104,"about_ca_topic_score_gemma":0.00007531435,"teacher_disagreement_score":0.87039536,"about_ca_system_score_codex":0.00024128017,"about_ca_system_score_gemma":0.00020146897,"threshold_uncertainty_score":0.26269606},"labels":[],"label_agreement":null},{"id":"W2586232813","doi":"10.1038/ncomms14369","title":"An unexpected N-terminal loop in PD-1 dominates binding by nivolumab","year":2017,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":260,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Chinese Academy of Sciences; National Natural Science Foundation of China; Salt Science Research Foundation","keywords":"Nivolumab; Pembrolizumab; Glycosylation; Monoclonal antibody; Immunotherapy; Immune checkpoint; Chemistry; PD-L1; Computational biology; Cancer research; Antibody; Immune system; Medicine; Biochemistry; Biology; Immunology","score_opus":0.022416853824153735,"score_gpt":0.36049839201310796,"score_spread":0.3380815381889542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586232813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97511303,0.012774351,0.000005024679,0.0073397066,0.0001489795,0.00029816013,0.000040042243,0.00006111057,0.004219585],"genre_scores_gemma":[0.99570936,0.0017270759,0.0012186845,0.00032156275,0.000036360172,0.00003622919,0.00024037744,0.000017982851,0.0006923886],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999242,0.000073588526,0.00020442414,0.00017504592,0.00012931823,0.00017563839],"domain_scores_gemma":[0.9968264,0.00007948563,0.00014482191,0.0028019797,0.0000814013,0.000065912805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002206205,0.00011503628,0.00018618684,0.00009597273,0.0005413584,0.00009179401,0.0010975016,0.00026218066,0.00007109437],"category_scores_gemma":[0.00012703301,0.00010670554,0.00006474551,0.00013672758,0.00027161685,0.0002128574,0.00012579892,0.00078444614,0.000014454251],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015627637,0.0016531363,0.15677825,0.000050303355,0.00020670937,0.00004649417,0.0013499844,2.907251e-7,0.7294824,0.0010254991,0.03593858,0.07190558],"study_design_scores_gemma":[0.012733104,0.0006078539,0.70727146,0.00074928615,0.00018183717,0.00022505352,0.0014915393,0.001880741,0.029236486,0.0001524976,0.24469538,0.0007747538],"about_ca_topic_score_codex":0.00036206024,"about_ca_topic_score_gemma":0.001190054,"teacher_disagreement_score":0.7002459,"about_ca_system_score_codex":0.00013310021,"about_ca_system_score_gemma":0.00008261639,"threshold_uncertainty_score":0.4351326},"labels":[],"label_agreement":null},{"id":"W2586934550","doi":"10.1093/annonc/mdw435.40","title":"KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Carboplatin; Medicine; Pemetrexed; Pembrolizumab; Oncology; Internal medicine; Gemcitabine; Lung cancer; Cisplatin; Chemotherapy; Cancer; Immunotherapy","score_opus":0.04888819655693708,"score_gpt":0.35420473796828106,"score_spread":0.30531654141134396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586934550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96093255,0.001253833,0.0037458844,0.029931094,0.00019776808,0.0025263121,0.000059218874,0.00011717929,0.0012361768],"genre_scores_gemma":[0.98261225,0.0017358811,0.0023935924,0.011342298,0.00027077075,0.0004651725,0.000058612837,0.00009634079,0.0010250888],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99762994,0.00006684486,0.0007441007,0.0005805197,0.00038357868,0.00059499044],"domain_scores_gemma":[0.9976398,0.00034629143,0.00069926836,0.0005579933,0.00059354305,0.0001631053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050443417,0.0003963466,0.000925122,0.00021154602,0.00011857785,0.000010644306,0.00021586013,0.00026096098,0.00057090574],"category_scores_gemma":[0.00012968399,0.00024400988,0.00034992516,0.00027919,0.00042232778,0.00014879987,0.000015950458,0.0001572844,0.000014826101],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43960628,0.001343683,0.002668954,0.00021516696,0.0004566264,0.00004050339,0.00023882376,0.000014090002,0.14404544,0.00007325443,0.002701967,0.4085952],"study_design_scores_gemma":[0.10673046,0.061517075,0.03597818,0.0010227158,0.000091190814,0.0002186785,0.000086193,0.00012366558,0.50079304,0.0007852267,0.29205173,0.0006018173],"about_ca_topic_score_codex":0.00009201727,"about_ca_topic_score_gemma":0.00008885571,"teacher_disagreement_score":0.4079934,"about_ca_system_score_codex":0.00017367772,"about_ca_system_score_gemma":0.0010761739,"threshold_uncertainty_score":0.9950434},"labels":[],"label_agreement":null},{"id":"W2587280945","doi":"10.1093/annonc/mdw372.03","title":"First evidence of significant clinical activity of PD-1 inhibitors in metastatic, castration resistant prostate cancer (mCRPC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Merck; Astellas Pharma US","keywords":"Enzalutamide; Medicine; Prostate cancer; Pembrolizumab; Internal medicine; Oncology; Clinical endpoint; Prostate-specific antigen; Cancer; Progressive disease; Urology; Androgen receptor; Clinical trial; Chemotherapy; Immunotherapy","score_opus":0.209904179058089,"score_gpt":0.47190292722071725,"score_spread":0.26199874816262825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587280945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860475,0.0012433806,0.000021717327,0.011899145,0.00015917789,0.00042459974,0.00004589952,0.0000045347842,0.00015404628],"genre_scores_gemma":[0.9921148,0.00734322,0.00023192629,0.00014217974,0.000038278224,0.000029286071,8.513971e-7,0.000007850681,0.00009160275],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982864,0.00022851872,0.0009008179,0.00020403256,0.0002028852,0.00017728974],"domain_scores_gemma":[0.9979035,0.0008735301,0.00068080565,0.00021187478,0.000275724,0.0000545584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015394619,0.00009806176,0.00061649526,0.000119090146,0.00001233872,0.0000011456914,0.000076862925,0.00010002163,0.00011008597],"category_scores_gemma":[0.00048472208,0.00006468317,0.00015140708,0.00021107876,0.00045121938,0.00010757685,0.000022331606,0.000093839364,9.301376e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031453136,0.00079386483,0.04137484,0.00036840283,0.00018912519,0.000026475487,0.00041174405,0.000003968517,0.73719674,0.000029259485,0.0012671195,0.18688533],"study_design_scores_gemma":[0.0039655273,0.009822022,0.4256671,0.0019493378,0.00007835514,0.000004712752,0.00013622882,0.000011878349,0.5534197,0.00009791777,0.0047468864,0.000100306126],"about_ca_topic_score_codex":0.0019851336,"about_ca_topic_score_gemma":0.0027250038,"teacher_disagreement_score":0.38429227,"about_ca_system_score_codex":0.00007144523,"about_ca_system_score_gemma":0.00081236265,"threshold_uncertainty_score":0.30009416},"labels":[],"label_agreement":null},{"id":"W2587327379","doi":"10.1093/annonc/mdx008","title":"Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Merck","keywords":"Medicine; Pembrolizumab; Oncology; Lung cancer; Internal medicine; First line therapy; Phases of clinical research; Clinical trial; Cancer; Immunotherapy","score_opus":0.044464290305860014,"score_gpt":0.40573394879088776,"score_spread":0.36126965848502773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587327379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880193,0.0011998406,0.00009148757,0.0038954017,0.00052662374,0.0031563013,0.00018806753,0.000015879092,0.002907122],"genre_scores_gemma":[0.9921461,0.0039656158,0.0003187882,0.0019523086,0.00032380453,0.0005061991,0.000082598424,0.000036763628,0.0006678667],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99871576,0.0000349053,0.00038764748,0.00032924724,0.00017027337,0.00036218535],"domain_scores_gemma":[0.9980817,0.00016977642,0.00065823464,0.00045272463,0.0005253944,0.00011219306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020477282,0.00021925117,0.000650619,0.00008369912,0.00024079264,0.000015552152,0.00022657697,0.00017353873,0.00013462639],"category_scores_gemma":[0.00006399638,0.00016391695,0.00022867334,0.000059035312,0.00020766309,0.00010924367,0.000028923687,0.00012743594,0.0000019138183],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76374084,0.0034996215,0.0028395301,0.00009883346,0.0005228788,0.000016282343,0.00060901936,0.0000039321712,0.002008303,0.0000059960134,0.0025811086,0.22407366],"study_design_scores_gemma":[0.697059,0.14627756,0.026788516,0.00031286362,0.00023005652,0.000006382758,0.00006947049,0.000106988984,0.041903414,0.000046660367,0.0868698,0.0003292826],"about_ca_topic_score_codex":0.00044733722,"about_ca_topic_score_gemma":0.00020523083,"teacher_disagreement_score":0.22374439,"about_ca_system_score_codex":0.00008923395,"about_ca_system_score_gemma":0.0006512694,"threshold_uncertainty_score":0.6684339},"labels":[],"label_agreement":null},{"id":"W2587330058","doi":"10.1016/j.ijrobp.2017.02.003","title":"Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy","year":2017,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Tolerability; PD-L1; CTLA-4; Oncology; Immune system; Internal medicine; Immunotherapy; Immunology; Adverse effect; T cell","score_opus":0.03636297625217191,"score_gpt":0.3574663870174011,"score_spread":0.3211034107652292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587330058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940511,0.0014115038,0.00013450661,0.0030877942,0.00065159216,0.00051365286,0.000026956344,0.0000037720258,0.00011911383],"genre_scores_gemma":[0.99685496,0.0024777222,0.00025860287,0.00010442365,0.00025653196,0.00001299116,0.000015761454,0.000009824324,0.000009172577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857664,0.00023978384,0.00064141146,0.00014472198,0.00030791853,0.00008954204],"domain_scores_gemma":[0.99614304,0.00018288029,0.0024887323,0.00020414259,0.00094040966,0.000040778206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091494253,0.00013788551,0.00039585188,0.00006289322,0.00009542552,0.000017527227,0.0001561959,0.00011070438,0.000023525694],"category_scores_gemma":[0.0002264447,0.0000837275,0.00014840039,0.000048612088,0.00048255795,0.00018018247,0.000029888937,0.00013602882,2.2066914e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042803977,0.00046583175,0.6463829,0.000008698731,0.00088796957,7.96022e-7,0.0013316529,0.000032880384,0.045193292,0.00013360743,0.0000088043635,0.30127314],"study_design_scores_gemma":[0.021799933,0.003028798,0.88363564,0.000102859616,0.00020561727,0.000016041637,0.00010896275,0.0017554911,0.087961845,0.0007953432,0.00051515637,0.00007431183],"about_ca_topic_score_codex":0.0001545063,"about_ca_topic_score_gemma":0.00001694775,"teacher_disagreement_score":0.3011988,"about_ca_system_score_codex":0.0004946511,"about_ca_system_score_gemma":0.00041987406,"threshold_uncertainty_score":0.3414308},"labels":[],"label_agreement":null},{"id":"W2587527428","doi":"10.1093/ecco-jcc/jjx002.010","title":"OP011 Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study","year":2017,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Refractory (planetary science); Cohort; Medicine; Open label; Tumor necrosis factor alpha; Internal medicine; Oncology; Clinical trial; Biology","score_opus":0.022741618593659352,"score_gpt":0.3169022185564893,"score_spread":0.29416059996282995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587527428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99748707,0.00034752855,2.6478202e-7,0.00036957164,0.00019530536,0.001464009,0.000009417665,8.9484183e-7,0.0001259593],"genre_scores_gemma":[0.9991902,0.000548649,0.0000047998856,0.00013992627,0.000037472837,0.000041433,6.5883756e-7,0.000008390455,0.000028471122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870926,0.00012243632,0.00057532307,0.00014592957,0.00028517042,0.00016190496],"domain_scores_gemma":[0.9991152,0.000033570013,0.00043555163,0.0002757545,0.00008033729,0.000059549486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078197673,0.00012985563,0.00036696342,0.00019437836,0.0001014847,0.00008726606,0.00022665974,0.00006000556,0.0000067780893],"category_scores_gemma":[0.000034029094,0.00007457033,0.000040898427,0.000111287474,0.00013028456,0.00025011998,0.00006216399,0.00017084519,1.10320656e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00893481,0.002414527,0.88201004,0.00002004093,0.00018107513,0.000071451475,0.0027965363,2.0580333e-7,0.0015009973,0.0000053432877,0.00002947027,0.1020355],"study_design_scores_gemma":[0.029145395,0.0066924295,0.9618002,0.00028219336,0.00006574847,0.000022548853,0.0010846617,0.0000026000976,0.00046871943,0.000013600972,0.00034836764,0.000073515745],"about_ca_topic_score_codex":0.0032596553,"about_ca_topic_score_gemma":0.0016652113,"teacher_disagreement_score":0.101961985,"about_ca_system_score_codex":0.0002489682,"about_ca_system_score_gemma":0.00015551099,"threshold_uncertainty_score":0.49276453},"labels":[],"label_agreement":null},{"id":"W2587867179","doi":"10.1093/annonc/mdw379.07","title":"PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Ipilimumab; Oncology; Hazard ratio; Cancer; Immunotherapy; Confidence interval","score_opus":0.04392144402831851,"score_gpt":0.37215963198604646,"score_spread":0.32823818795772797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587867179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864091,0.0035029815,0.00039352276,0.007314241,0.00013233881,0.0007330474,0.000044949596,0.000043697713,0.0014261086],"genre_scores_gemma":[0.9944955,0.0018260063,0.00087022304,0.0012499524,0.000052384345,0.00013132092,0.00002297667,0.000033645636,0.0013179583],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981371,0.00013085811,0.000630256,0.00047617435,0.000194638,0.00043097002],"domain_scores_gemma":[0.9985173,0.00043509895,0.0003188339,0.000394587,0.00019929577,0.00013488076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005941058,0.00022448669,0.0009818688,0.0005809933,0.00004692953,0.000006470835,0.00013461278,0.00028517927,0.0002858024],"category_scores_gemma":[0.00020258027,0.00015732917,0.00033096946,0.00056176144,0.0002463379,0.00013470514,0.00006441423,0.00008491477,0.0000047774615],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07516679,0.0005548751,0.007189464,0.00011389281,0.0018395191,0.000073638,0.0005773492,0.0000018360369,0.54648894,0.00003998984,0.0037777366,0.36417598],"study_design_scores_gemma":[0.12972315,0.022864748,0.32587415,0.0013010605,0.002299957,0.00023179536,0.0013284337,0.0008937782,0.30506352,0.0015855738,0.20776272,0.001071103],"about_ca_topic_score_codex":0.00034912265,"about_ca_topic_score_gemma":0.00053075206,"teacher_disagreement_score":0.36310485,"about_ca_system_score_codex":0.00015131336,"about_ca_system_score_gemma":0.00031555974,"threshold_uncertainty_score":0.64156973},"labels":[],"label_agreement":null},{"id":"W2588008593","doi":"10.1016/j.revmed.2017.01.004","title":"Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge","year":2017,"lang":"en","type":"review","venue":"La Revue de Médecine Interne","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-François d'Assise","funders":"","keywords":"Immunotherapy; Medicine; Pembrolizumab; Cancer immunotherapy; Autoimmunity; Melanoma; Oncology; Cancer; Metastatic melanoma; Adjuvant; Adverse effect; Nivolumab; Immunology; Internal medicine; Immune system; Cancer research","score_opus":0.135948062588993,"score_gpt":0.42953056223580544,"score_spread":0.29358249964681243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588008593","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021152361,0.9882435,0.00013083026,0.0018153029,0.0011698084,0.0014304719,0.00026864363,0.00027252483,0.006457354],"genre_scores_gemma":[0.00059410546,0.98573816,0.00024673858,0.00071050995,0.0013104543,0.0005553052,0.00040620734,0.0003669926,0.010071538],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967273,0.0003373879,0.0011833285,0.00080667884,0.0002774335,0.00066787854],"domain_scores_gemma":[0.9962021,0.00017020166,0.0007785492,0.002307833,0.0001308576,0.00041047038],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010888004,0.0008421096,0.0029577732,0.00048402898,0.00017206836,0.00015411492,0.0011382013,0.0005865566,0.001926296],"category_scores_gemma":[0.00011441278,0.00072737527,0.0010126139,0.00021707785,0.00017059238,0.00015162665,0.00021165686,0.0013726518,0.00005836732],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005428394,0.00034027227,0.000065292974,0.009049916,0.0012217436,0.00048660877,0.00044443845,1.7925635e-7,0.00009086707,0.000111224006,0.0012685017,0.98637813],"study_design_scores_gemma":[0.0020194715,0.00066686905,0.0011135305,0.041315634,0.0007730295,0.0009929672,0.00004376854,0.000011288358,0.0000042453353,0.000032821816,0.95234376,0.00068259554],"about_ca_topic_score_codex":0.0015388703,"about_ca_topic_score_gemma":0.00041890683,"teacher_disagreement_score":0.98569554,"about_ca_system_score_codex":0.0008074507,"about_ca_system_score_gemma":0.0012112686,"threshold_uncertainty_score":0.99951774},"labels":[],"label_agreement":null},{"id":"W2588061824","doi":"10.1038/ncomms14278","title":"Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma","year":2017,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Children's Hospital of Eastern Ontario; University of Ottawa","funders":"Ottawa Hospital Research Institute; Fondation Brain Canada; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; University of Ottawa","keywords":"Cytotoxic T cell; Immune system; Immune checkpoint; Cancer research; Innate immune system; Apoptosis; Cancer; Immunology; Cancer cell; CD8; Biology; Immunotherapy; In vitro; Biochemistry","score_opus":0.016171613828414783,"score_gpt":0.3029597928864098,"score_spread":0.28678817905799503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588061824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.948176,0.009568986,0.000023193194,0.03150131,0.00032014932,0.0011357267,0.00004223871,0.00017326402,0.009059094],"genre_scores_gemma":[0.98691595,0.0014449487,0.009797351,0.0009490698,0.000104257866,0.00009723108,0.00007091862,0.00005510584,0.0005651556],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985256,0.000095182615,0.00044671012,0.00027412776,0.0003325008,0.00032586476],"domain_scores_gemma":[0.99342763,0.000078176716,0.00034761045,0.005555912,0.00039722773,0.00019342569],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0005304737,0.00027358017,0.00038440275,0.00014341,0.0013108792,0.00014608106,0.0016948464,0.00031058633,0.000029080722],"category_scores_gemma":[0.00040022243,0.0002189394,0.00020365122,0.00034130015,0.0004596091,0.00015717252,0.00065713044,0.0015249412,0.00003912817],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046952227,0.0016767867,0.005961419,0.00013292271,0.0010381005,0.000057412974,0.0018745547,0.0000048132106,0.91722906,0.00078720844,0.0075293127,0.059013166],"study_design_scores_gemma":[0.006303045,0.0017422569,0.32378304,0.001727234,0.00036609414,0.00020055434,0.0007205186,0.00027072933,0.27019796,0.000066322296,0.39369473,0.00092752365],"about_ca_topic_score_codex":0.00026152458,"about_ca_topic_score_gemma":0.0010206847,"teacher_disagreement_score":0.6470311,"about_ca_system_score_codex":0.00020996311,"about_ca_system_score_gemma":0.00024161265,"threshold_uncertainty_score":0.9999893},"labels":[],"label_agreement":null},{"id":"W2588072385","doi":"10.1093/annonc/mdw379.18","title":"Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis; Pfizer; GlaxoSmithKline Australia; Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Discontinuation; Internal medicine; Nivolumab; Adverse effect; Regimen; Toxicity; Melanoma; Gastroenterology; Oncology; Immunotherapy; Cancer","score_opus":0.023034425118017395,"score_gpt":0.3101263806729594,"score_spread":0.287091955554942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588072385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943196,0.0004901387,0.000012806534,0.00210238,0.00006224671,0.0005122813,0.000021250878,0.000008846885,0.0024704027],"genre_scores_gemma":[0.9970313,0.0021692254,0.00017614473,0.000334706,0.000010464363,0.000019830244,0.000013425792,0.000011647849,0.00023330258],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991073,0.00007246918,0.00034247254,0.0001715447,0.00014532924,0.00016087286],"domain_scores_gemma":[0.99922544,0.000105139145,0.00024030502,0.00016668491,0.00022615858,0.000036287853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002338197,0.00010088838,0.0003759006,0.00012270901,0.00001811347,0.0000011175057,0.000057775855,0.00010148537,0.00012809389],"category_scores_gemma":[0.000031132004,0.00006287524,0.00004270298,0.00014654781,0.0002075164,0.00008900241,0.000015579228,0.00005327861,0.00000140155],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03940254,0.0010383296,0.106092654,0.000044878474,0.0001129732,0.0000033614185,0.00036646094,1.8436647e-7,0.01557248,0.00012485111,0.0003025608,0.83693874],"study_design_scores_gemma":[0.044739734,0.033820372,0.8707369,0.0002622987,0.000012799036,0.000006421729,0.000096931406,0.000004714779,0.038782053,0.00012838155,0.011299338,0.000110072666],"about_ca_topic_score_codex":0.000072360795,"about_ca_topic_score_gemma":0.00006966386,"teacher_disagreement_score":0.83682865,"about_ca_system_score_codex":0.00006141934,"about_ca_system_score_gemma":0.00014149249,"threshold_uncertainty_score":0.25639778},"labels":[],"label_agreement":null},{"id":"W2588106160","doi":"10.1093/annonc/mdw378.16","title":"Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Tolerability; Renal cell carcinoma; Adverse effect; Sunitinib; Oncology; Toxicity; Gastroenterology; Immunotherapy; Cancer","score_opus":0.06595504791265101,"score_gpt":0.36861642131899086,"score_spread":0.30266137340633986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588106160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953208,0.00019463754,0.0000057232533,0.0022401991,0.00006309078,0.0016147447,0.00008458039,0.000009814869,0.00046643504],"genre_scores_gemma":[0.9994719,0.00005539186,0.00003345493,0.00016768278,0.0000133379235,0.000063302396,0.00003112373,0.000016226513,0.00014758288],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9976579,0.00058507686,0.0008910379,0.00032468297,0.00029667362,0.00024463833],"domain_scores_gemma":[0.99842477,0.0003722861,0.0005047965,0.0004521038,0.0002042098,0.00004182834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012311548,0.0001679277,0.0006538706,0.00027402703,0.000027827553,0.0000038818985,0.00018913865,0.00006633805,0.0000863048],"category_scores_gemma":[0.000073406096,0.00009160877,0.000057248933,0.0004931057,0.00016984304,0.00008485072,0.00004354554,0.00014911317,0.0000027644244],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4224386,0.11209392,0.10986375,0.000087260705,0.0014715085,0.001031827,0.057487383,0.000022767312,0.15302111,0.000014806682,0.0035274578,0.13893962],"study_design_scores_gemma":[0.26574203,0.087675564,0.603561,0.00017447838,0.00022793122,0.000011767434,0.016487345,0.000082584935,0.024921002,0.000081605926,0.0008441545,0.00019050884],"about_ca_topic_score_codex":0.0066853175,"about_ca_topic_score_gemma":0.007286399,"teacher_disagreement_score":0.49369726,"about_ca_system_score_codex":0.00010537632,"about_ca_system_score_gemma":0.00030586516,"threshold_uncertainty_score":0.99992925},"labels":[],"label_agreement":null},{"id":"W2588999445","doi":"10.1093/annonc/mdw379.10","title":"Estimating the percentage of patients with advanced melanoma achieving long-term survival with pembrolizumab (Pembro) treatment in KEYNOTE-006","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Population; Confidence interval; Survival analysis; Ipilimumab; Internal medicine; Cancer; Immunotherapy","score_opus":0.03141026450130777,"score_gpt":0.33654428113419116,"score_spread":0.30513401663288336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588999445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967845,0.00024492064,0.00011090973,0.0013089874,0.00008294356,0.00055731134,0.0000218128,0.000010751077,0.0008778273],"genre_scores_gemma":[0.9989226,0.00015048565,0.00055418763,0.00016461917,0.00003236087,0.000033099095,0.000013774613,0.000019810637,0.00010905279],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988374,0.0001136113,0.00036995247,0.0002123269,0.00020351501,0.00026316362],"domain_scores_gemma":[0.9989872,0.00025092906,0.0003106437,0.00029063242,0.00011427066,0.000046319157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020077582,0.00016755001,0.00049519073,0.000088072455,0.000038216986,0.0000028206769,0.00010924551,0.00007188685,0.000082944316],"category_scores_gemma":[0.00002819776,0.000074178235,0.00007929138,0.00011811889,0.00025654602,0.00007784676,0.00002396516,0.00006721625,0.0000013633601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023949118,0.0007133826,0.6976515,0.00005541658,0.00022904253,0.000025685942,0.0005155126,0.000012377631,0.004114062,0.000008015114,0.000009148914,0.2727167],"study_design_scores_gemma":[0.017517513,0.0151209,0.9628628,0.00043894807,0.000062999476,0.000015668147,0.00009518449,0.000008172741,0.0034666725,0.0000037636064,0.0003068906,0.00010048398],"about_ca_topic_score_codex":0.00020513634,"about_ca_topic_score_gemma":0.0006653242,"teacher_disagreement_score":0.27261624,"about_ca_system_score_codex":0.00013508795,"about_ca_system_score_gemma":0.0002117293,"threshold_uncertainty_score":0.30249006},"labels":[],"label_agreement":null},{"id":"W2589078008","doi":"10.1093/annonc/mdw376.01","title":"Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Durvalumab; Internal medicine; Cohort; Nausea; Oncology; Gastroenterology; Cancer; Immunotherapy; Nivolumab","score_opus":0.023916400266900773,"score_gpt":0.3244297351281284,"score_spread":0.3005133348612276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589078008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973442,0.0006433138,0.0000027943254,0.0010377151,0.000118684235,0.0004973062,0.00009815038,0.000005500838,0.00025235984],"genre_scores_gemma":[0.99884313,0.0006793961,0.000041973206,0.00032819287,0.000020765225,0.0000023514583,0.00004537222,0.000012735788,0.000026070753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862397,0.00017754696,0.00057278847,0.00025075112,0.00018782684,0.00018709958],"domain_scores_gemma":[0.9989184,0.00018395153,0.00033697637,0.00033496754,0.0001583794,0.000067331595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032536648,0.00013228886,0.0005957333,0.00010318054,0.00002687569,0.00000149502,0.00010802783,0.0001752738,0.000065523964],"category_scores_gemma":[0.000073069525,0.00007883988,0.00007210411,0.00016194266,0.0004191984,0.000068472174,0.000072348696,0.000084868276,4.2483828e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010496596,0.0009840591,0.8327457,0.00004596977,0.000042531363,0.000004953634,0.00047882902,3.1740208e-7,0.12326633,0.000003159148,0.00023686577,0.03169472],"study_design_scores_gemma":[0.015517889,0.005419384,0.92320114,0.00014703948,0.000048956957,0.0000040383115,0.00006850145,0.000010513058,0.054526288,0.000015236431,0.00096222846,0.00007877211],"about_ca_topic_score_codex":0.0021705579,"about_ca_topic_score_gemma":0.00020133269,"teacher_disagreement_score":0.09045549,"about_ca_system_score_codex":0.000027637843,"about_ca_system_score_gemma":0.00016162854,"threshold_uncertainty_score":0.32812488},"labels":[],"label_agreement":null},{"id":"W2589103622","doi":"10.1016/j.cllc.2017.02.001","title":"Immune Checkpoint Inhibitors for Patients With Advanced Non–Small-Cell Lung Cancer: A Systematic Review","year":2017,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Atezolizumab; Pemetrexed; Nivolumab; Internal medicine; Oncology; Erlotinib; Lung cancer; Hazard ratio; Docetaxel; Adverse effect; Gefitinib; Chemotherapy; Erlotinib Hydrochloride; Epidermal growth factor receptor; Cancer; Immunotherapy; Confidence interval; Cisplatin","score_opus":0.0542220111495793,"score_gpt":0.43289833144204876,"score_spread":0.37867632029246945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589103622","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000057136836,0.9681483,0.000024470579,0.00024145957,0.0028197628,0.027932547,0.00044487737,0.000079269485,0.00025220946],"genre_scores_gemma":[0.000014769918,0.9779879,0.0002374036,0.0008437759,0.0009459504,0.015635593,0.00036871084,0.00026935586,0.0036965543],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99257386,0.00027446967,0.0044816164,0.0012988779,0.00058856525,0.00078264205],"domain_scores_gemma":[0.9912592,0.00071549363,0.004835337,0.0021715353,0.0006386427,0.00037977833],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017614784,0.0011131581,0.009390503,0.00014179184,0.00026414296,0.000075339885,0.0007982936,0.0007309461,0.00019732941],"category_scores_gemma":[0.0006757211,0.00069661124,0.003422855,0.00033300673,0.00026693498,0.00012658695,0.00015001792,0.0010387338,0.000013953925],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059620023,0.00029408932,0.00042808155,0.76083905,0.0024225593,0.000008093878,0.000015280706,1.1482704e-7,3.1975316e-7,3.962924e-7,0.0041808574,0.23121499],"study_design_scores_gemma":[0.0043061655,0.00053971953,0.00007367997,0.620988,0.023069283,0.0000045233755,0.0000029566522,0.0000113534115,0.0000015532452,2.9894036e-7,0.35040778,0.0005946839],"about_ca_topic_score_codex":0.00012192029,"about_ca_topic_score_gemma":0.000058926606,"teacher_disagreement_score":0.34622693,"about_ca_system_score_codex":0.001239896,"about_ca_system_score_gemma":0.0030111996,"threshold_uncertainty_score":0.9995485},"labels":[],"label_agreement":null},{"id":"W2589130880","doi":"10.1093/annonc/mdw383.16","title":"Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Durvalumab; Internal medicine; Pneumonitis; Discontinuation; Gastroenterology; Lung cancer; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Cancer; Surgery; Toxicity; Lung; Pembrolizumab; Immunotherapy","score_opus":0.05181691926919445,"score_gpt":0.4093947081574053,"score_spread":0.35757778888821085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589130880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977262,0.00014147039,0.0000066386456,0.00079319184,0.000099941164,0.0006893006,0.000028746517,0.0000017382316,0.0005127632],"genre_scores_gemma":[0.99921435,0.0004926711,0.000012714414,0.00016536588,0.000017189739,0.000008235552,4.5495133e-7,0.0000068402082,0.00008215584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989922,0.00017831268,0.0004260234,0.00015260109,0.00013029664,0.00012056341],"domain_scores_gemma":[0.9989624,0.00023063508,0.00039101,0.00022599756,0.00015625292,0.00003368235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005058339,0.00007960411,0.00046769218,0.000047133755,0.0000140896955,4.98238e-7,0.000080917685,0.00008512433,0.00003750567],"category_scores_gemma":[0.000041149728,0.000039719267,0.00006538428,0.00011972352,0.00023740678,0.000029282413,0.00004302944,0.00008885344,9.1899395e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034547962,0.0077820774,0.76479715,0.000052835632,0.00020026401,0.0000016358094,0.00044320858,2.9479838e-7,0.0030827262,4.803847e-7,0.00012894027,0.18896241],"study_design_scores_gemma":[0.045507442,0.019222146,0.927807,0.00018346166,0.00009015689,4.27321e-7,0.000092819944,0.000005527897,0.006539551,0.0000011387039,0.00050428376,0.000046084773],"about_ca_topic_score_codex":0.00088789134,"about_ca_topic_score_gemma":0.001066561,"teacher_disagreement_score":0.18891633,"about_ca_system_score_codex":0.00003330305,"about_ca_system_score_gemma":0.00029451915,"threshold_uncertainty_score":0.16197048},"labels":[],"label_agreement":null},{"id":"W2591800574","doi":"10.1158/1538-7445.sabcs16-p1-09-08","title":"Abstract P1-09-08: Predictive effect of cytotoxic tumor infiltrating lymphocytes in HER2-positive metastatic breast cancer: A correlative study with CCTG MA.31","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Partnership Against Cancer; University of Ottawa; Vancouver Coastal Health Research Institute; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Lapatinib; Trastuzumab; Medicine; Breast cancer; Oncology; Metastatic breast cancer; Internal medicine; Tissue microarray; Taxane; Cancer; Tumor-infiltrating lymphocytes; Immunotherapy","score_opus":0.036816695995706514,"score_gpt":0.396372866378245,"score_spread":0.35955617038253845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591800574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918997,0.0013697451,0.000005325214,0.00035846847,0.00012228031,0.003831121,0.00041157618,0.000026109143,0.0019756737],"genre_scores_gemma":[0.9975743,0.00031066168,0.000024128189,0.000031887914,0.00012957238,0.0016221377,0.000011314131,0.00005636997,0.00023961462],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966206,0.00043164458,0.0004981314,0.0006291431,0.0011146909,0.00070577645],"domain_scores_gemma":[0.99753034,0.00069321744,0.00039459992,0.0007000221,0.00049277325,0.00018902148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019436857,0.00033583117,0.0008454297,0.00037937236,0.00045071376,0.00010287422,0.0004193083,0.000074554424,0.0003062989],"category_scores_gemma":[0.00022376182,0.00024288497,0.00012168694,0.00056097814,0.0010220035,0.00033708024,0.00012730507,0.00078332616,0.000008580587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08822941,0.0011974402,0.8016578,0.0009704285,0.0023278128,0.0009177266,0.0079337405,0.00015641071,0.074000604,0.000010811387,0.00026588808,0.022331933],"study_design_scores_gemma":[0.015255635,0.006971937,0.91242176,0.0036187917,0.00019111176,0.00008219448,0.0039611435,0.00017606362,0.05703174,0.0000094089055,0.000023840974,0.00025639744],"about_ca_topic_score_codex":0.037082966,"about_ca_topic_score_gemma":0.0066215936,"teacher_disagreement_score":0.110763945,"about_ca_system_score_codex":0.001517806,"about_ca_system_score_gemma":0.0023196174,"threshold_uncertainty_score":0.99045616},"labels":[],"label_agreement":null},{"id":"W2592144107","doi":"10.1016/s1470-2045(17)30074-8","title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2408,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Guideline; Clinical trial; Medicine; Medical physics; Response Evaluation Criteria in Solid Tumors; Immunotherapy; Cancer; Intensive care medicine; Oncology; Internal medicine; Pathology","score_opus":0.8623875272759276,"score_gpt":0.6325735133841923,"score_spread":0.22981401389173528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592144107","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045233654,0.98602355,0.00024217449,0.005322613,0.0016004028,0.006041316,0.0005378904,0.000050149818,0.00013666535],"genre_scores_gemma":[0.0000020180644,0.9689936,0.020674385,0.002767974,0.0031763674,0.0021363564,0.00012491312,0.00010048696,0.002023891],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953505,0.0016178797,0.001952556,0.000417611,0.00012230272,0.0005391888],"domain_scores_gemma":[0.9759513,0.020703636,0.0016317893,0.0012187395,0.00045098198,0.000043549768],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.020591635,0.0004207717,0.005353143,0.00019059339,0.00020938966,0.00008925449,0.00062823476,0.0006114243,0.000033310425],"category_scores_gemma":[0.025401723,0.00024230272,0.00095107686,0.00015425762,0.00022029044,0.00005381668,0.0000633879,0.00034541028,0.0000053774556],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033729736,0.00006217045,0.000004426758,0.0038885102,0.000519349,0.0000119247015,0.000065733955,8.306854e-8,0.00018506774,0.000015354522,0.020008754,0.9415089],"study_design_scores_gemma":[0.008306851,0.0012825343,0.00004781538,0.008308829,0.0013929557,0.0001796262,0.000016313932,0.000041807747,0.0000065314375,0.00013789204,0.9800229,0.0002559164],"about_ca_topic_score_codex":0.00009149541,"about_ca_topic_score_gemma":0.000104667386,"teacher_disagreement_score":0.96001416,"about_ca_system_score_codex":0.00050188135,"about_ca_system_score_gemma":0.0016844468,"threshold_uncertainty_score":0.9880818},"labels":[],"label_agreement":null},{"id":"W2592196580","doi":"10.1186/s12885-017-3175-y","title":"Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial","year":2017,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":159,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; North York General Hospital","funders":"Medical Research Council; University of Glasgow; University of Dundee","keywords":"Medicine; Lung cancer; Lung cancer screening; Internal medicine; National Lung Screening Trial; Stage (stratigraphy); Cancer; Randomized controlled trial; Surgical oncology; Lung; Oncology","score_opus":0.0639721456365767,"score_gpt":0.45992217573099387,"score_spread":0.39595003009441715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592196580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6776245,0.00018338156,0.00056391675,0.00013414727,0.00032048562,0.32110265,0.000012292042,0.000014542953,0.00004408005],"genre_scores_gemma":[0.6252918,0.000013330219,0.00049404736,0.00004440549,0.00025362,0.37375677,2.1338693e-7,0.000026991784,0.00011882787],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99750024,0.00043450252,0.0009943916,0.00039767884,0.00030076705,0.00037239247],"domain_scores_gemma":[0.99745566,0.0011490863,0.0007602901,0.0004138329,0.00016461912,0.00005648908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003684373,0.0002697759,0.0016412303,0.00031041657,0.00032086566,0.00009034654,0.00017612307,0.00009131317,0.00007113547],"category_scores_gemma":[0.0016189254,0.00017168438,0.00042151517,0.00025291764,0.00008631773,0.00011661777,0.000054479104,0.00019840425,1.4192845e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8943808,0.00047615805,0.04337018,0.00028670725,0.0006086639,0.00006586119,0.002614954,0.000101321,0.05685006,0.0000019067288,0.000012321799,0.0012310519],"study_design_scores_gemma":[0.95910174,0.00086399424,0.00937158,0.0010679412,0.0009284226,0.000061759034,0.00083695794,0.01287391,0.014641417,0.000006181732,0.000033922868,0.00021216644],"about_ca_topic_score_codex":0.05704836,"about_ca_topic_score_gemma":0.06733261,"teacher_disagreement_score":0.06472093,"about_ca_system_score_codex":0.00035436117,"about_ca_system_score_gemma":0.0008388172,"threshold_uncertainty_score":0.94968617},"labels":[],"label_agreement":null},{"id":"W2592274279","doi":"10.1186/s40425-017-0223-8","title":"Systematic evaluation of immune regulation and modulation","year":2017,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; U.S. National Library of Medicine; National Cancer Institute; National Institutes of Health; Trent University; Sidra Medicine; Nottingham Trent University","keywords":"Immune system; Immunotherapy; Medicine; Computational biology; Tumor microenvironment; Identification (biology); Cancer immunotherapy; Task force; Cancer; Bioinformatics; Computer science; Immunology; Data science; Biology; Internal medicine; Political science","score_opus":0.13558746605105143,"score_gpt":0.4619861904541074,"score_spread":0.32639872440305595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592274279","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047728184,0.9949139,0.00017725625,0.000046893463,0.0008906836,0.0033813568,0.00003918546,0.000006060495,0.0000674256],"genre_scores_gemma":[0.0011743386,0.9973506,0.00022212429,0.000009023798,0.00023186015,0.00028275495,0.000031448137,0.00006185883,0.00063599943],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9967859,0.0002151601,0.0019390874,0.00018647294,0.0007173183,0.00015606581],"domain_scores_gemma":[0.99340636,0.00014567775,0.004913772,0.0005037901,0.0009914662,0.00003892268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034733238,0.00029143278,0.0024755513,0.0003640582,0.00016298628,0.00004232297,0.0001719087,0.00027920518,0.00013058071],"category_scores_gemma":[0.00015446109,0.00020652736,0.0010965149,0.000113595444,0.00012432807,0.00016295545,0.000010847911,0.00019359814,3.1266262e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006669785,0.000040271665,0.00000524996,0.121361434,0.0025221389,1.6753769e-7,0.000121182755,0.0000056209374,0.0008346707,0.000013795302,0.000048926435,0.8743796],"study_design_scores_gemma":[0.010479258,0.00095150166,0.0015033612,0.55943865,0.013679828,0.000348894,0.000055575096,0.0009702118,0.00033402065,0.0005351903,0.41121352,0.0004899952],"about_ca_topic_score_codex":0.000055717912,"about_ca_topic_score_gemma":0.000005430567,"teacher_disagreement_score":0.87388957,"about_ca_system_score_codex":0.0004226062,"about_ca_system_score_gemma":0.00093358086,"threshold_uncertainty_score":0.84219414},"labels":[],"label_agreement":null},{"id":"W2592573955","doi":"10.1158/1538-7445.sabcs16-pd5-08","title":"Abstract PD5-08: Expression of LAG-3 in breast cancer, and its association with subtype and outcome","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes","funders":"","keywords":"Breast cancer; Medicine; Immune checkpoint; Tumor-infiltrating lymphocytes; Context (archaeology); Cancer; Oncology; Breast carcinoma; Biomarker; Internal medicine; Pathology; Cancer research; Biology; Immunotherapy","score_opus":0.08472194768660533,"score_gpt":0.42787809987824466,"score_spread":0.3431561521916393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592573955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99047107,0.004166427,1.382046e-7,0.0042458083,0.000060154835,0.00028217986,0.000053112697,0.0000054369125,0.0007156658],"genre_scores_gemma":[0.99352455,0.0051531363,0.0000089133155,0.000037431208,0.000082358405,0.0000546769,0.0000022146542,0.000012861246,0.0011238606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989319,0.000031136642,0.00016308608,0.00020298517,0.00042446516,0.00024643398],"domain_scores_gemma":[0.9992851,0.00007210816,0.00013741471,0.00021055165,0.00021692965,0.00007787254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000782217,0.000078858975,0.000211923,0.00011153195,0.00014392559,0.00004134665,0.00009209442,0.000091883376,0.00018637699],"category_scores_gemma":[0.00007614464,0.000057429086,0.000017759152,0.000099527475,0.00012260975,0.00014360723,0.00005264059,0.00027449557,0.0000013202532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002454796,0.000032126656,0.7755486,0.00022963014,0.0000297319,0.000011717864,0.00018646398,4.3748403e-7,0.21274737,0.00000637705,0.00037703186,0.008375716],"study_design_scores_gemma":[0.0027387745,0.00008145396,0.95658755,0.0007113143,0.0000091142765,0.0000071227228,0.000084793624,0.0000084321155,0.038983073,0.000008855288,0.0007146012,0.00006491527],"about_ca_topic_score_codex":0.005651057,"about_ca_topic_score_gemma":0.0011563101,"teacher_disagreement_score":0.18103895,"about_ca_system_score_codex":0.0002944649,"about_ca_system_score_gemma":0.00023856909,"threshold_uncertainty_score":0.8542746},"labels":[],"label_agreement":null},{"id":"W2593839194","doi":"10.1016/j.urolonc.2017.01.017","title":"Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice","year":2017,"lang":"en","type":"review","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Centre for Applied Research in Cancer Control","keywords":"Nivolumab; Renal cell carcinoma; Clinical Practice; Medicine; Intensive care medicine; Oncology; Cancer research; Internal medicine; Immunotherapy; Cancer; Nursing","score_opus":0.25299152889040166,"score_gpt":0.4905502424194859,"score_spread":0.23755871352908425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593839194","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002640977,0.9874572,0.00014494784,0.0045617144,0.0007546216,0.004332215,0.000505851,0.00004719973,0.0019321314],"genre_scores_gemma":[0.000013621017,0.8234239,0.16881548,0.0012430594,0.00055159116,0.0021734198,0.0005647117,0.00003641525,0.0031777767],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99751914,0.00024673398,0.0010143546,0.0007319393,0.000102564605,0.00038524365],"domain_scores_gemma":[0.99276775,0.0051054563,0.0011121824,0.0005217463,0.00021946973,0.00027337772],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00081843114,0.00045065806,0.0018954589,0.000147652,0.0008521926,0.000059799848,0.00012305078,0.0008209377,0.000037182424],"category_scores_gemma":[0.0016962767,0.00033742483,0.00071744516,0.00007818495,0.000936088,0.00012775771,0.000030838055,0.00037617795,0.000007712415],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011919132,0.00082946627,0.00021967749,0.002016861,0.00065446214,0.00011384003,0.00012833948,7.1013085e-7,0.000005398629,0.0016197979,0.050999247,0.9422203],"study_design_scores_gemma":[0.0047504003,0.01271251,0.0000074037207,0.00056481996,0.0065072505,0.000897063,0.00005420767,0.000022677707,0.000007288805,0.00095233315,0.97322434,0.00029971852],"about_ca_topic_score_codex":0.000033171073,"about_ca_topic_score_gemma":0.00004008,"teacher_disagreement_score":0.9419206,"about_ca_system_score_codex":0.0004012836,"about_ca_system_score_gemma":0.0037500535,"threshold_uncertainty_score":0.9999078},"labels":[],"label_agreement":null},{"id":"W2594276295","doi":"10.1186/s40425-017-0225-6","title":"Immunotherapy biomarkers 2016: overcoming the barriers","year":2017,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"U.S. Food and Drug Administration; Society for Immunotherapy of Cancer","keywords":"Medicine; Immunotherapy; Data science; Computer science; Cancer; Internal medicine","score_opus":0.023611641771029142,"score_gpt":0.3512964664018322,"score_spread":0.32768482463080306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594276295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8230142,0.13148542,0.0017223064,0.029037444,0.008703107,0.0024403338,0.00014504029,0.00006930427,0.003382826],"genre_scores_gemma":[0.9029457,0.078319825,0.0017640588,0.0051703015,0.0016582248,0.00025252785,0.000006553052,0.00021890872,0.0096639125],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977775,0.00006629289,0.00083393423,0.00026796907,0.0005259477,0.000528317],"domain_scores_gemma":[0.9968598,0.00016339452,0.0013162892,0.001134012,0.00037547795,0.00015101985],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014065771,0.00033953396,0.0006430007,0.00016546939,0.0019167748,0.00027257702,0.0008982688,0.000177002,0.0012890479],"category_scores_gemma":[0.00011769422,0.00021405914,0.0010464897,0.000113066046,0.0007009051,0.00037899666,0.000034068104,0.0003945692,0.0000028702298],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028217752,0.00009904475,0.0130962245,0.00008427801,0.005201976,0.000008455126,0.001152577,0.000008169856,0.4349012,0.00011487931,0.026364986,0.49075046],"study_design_scores_gemma":[0.019093841,0.0010467843,0.071722806,0.0007903501,0.00022431607,0.00022569828,0.00059662835,0.0000969289,0.055828184,0.00075571705,0.84918123,0.0004375049],"about_ca_topic_score_codex":0.0006380151,"about_ca_topic_score_gemma":0.000046794798,"teacher_disagreement_score":0.82281625,"about_ca_system_score_codex":0.00030050156,"about_ca_system_score_gemma":0.000846788,"threshold_uncertainty_score":0.9996239},"labels":[],"label_agreement":null},{"id":"W2594457906","doi":"10.1158/1538-7445.sabcs16-p4-12-09","title":"Abstract P4-12-09: The immune response in triple negative breast cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Immune system; Breast cancer; Triple-negative breast cancer; Immunosuppression; Tumor microenvironment; Medicine; Chemokine; Immunology; Oncology; Cancer; Internal medicine","score_opus":0.09840107818208124,"score_gpt":0.4436234260459285,"score_spread":0.3452223478638473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594457906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9493359,0.0053144787,5.871405e-7,0.04004525,0.00043123346,0.0010768436,0.00012680344,0.000021010293,0.0036479319],"genre_scores_gemma":[0.98778176,0.0036472734,0.000007007703,0.0002622975,0.00040886807,0.00067754905,0.0000029827138,0.000037228972,0.007175036],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99757504,0.00028467493,0.00032555437,0.00038791835,0.00074271637,0.0006841027],"domain_scores_gemma":[0.9979061,0.00040835844,0.00013474969,0.0011551527,0.0002639255,0.00013171707],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033633017,0.00017214907,0.00031264537,0.00021443218,0.00077442435,0.00017390792,0.00068134087,0.00012698949,0.00304373],"category_scores_gemma":[0.00041204615,0.00011290723,0.00013828723,0.00031395932,0.0009621834,0.00017093451,0.00015960638,0.0009571728,0.000051208106],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17840804,0.00030966726,0.02931172,0.00018668557,0.0004227259,0.0002669462,0.003913224,0.000010634972,0.5961974,0.00006370929,0.01600788,0.17490135],"study_design_scores_gemma":[0.0049204812,0.00015933796,0.94595456,0.00054690975,0.0000127294325,0.00002113968,0.000598959,0.000018562698,0.031207697,0.00007565035,0.016346412,0.00013755177],"about_ca_topic_score_codex":0.057358008,"about_ca_topic_score_gemma":0.006951955,"teacher_disagreement_score":0.91664284,"about_ca_system_score_codex":0.0009592029,"about_ca_system_score_gemma":0.0015081877,"threshold_uncertainty_score":0.99786764},"labels":[],"label_agreement":null},{"id":"W2596767442","doi":"10.1016/s0735-1097(17)35753-4","title":"AN UNSUSPECTED CASE OF MYOCARDITIS ASSOCIATED WITH NIVOLUMAB USE","year":2017,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Nivolumab; Myocarditis; Cardiology; Internal medicine; Dermatology; Intensive care medicine; Cancer; Immunotherapy","score_opus":0.017409931202008115,"score_gpt":0.2873145441962156,"score_spread":0.2699046129942075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596767442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981215,0.00013221611,0.000053825584,0.00072048267,0.00026625363,0.000148125,0.00014493543,0.000004466698,0.00040817],"genre_scores_gemma":[0.99914974,0.0001334699,0.00029221876,0.000120046214,0.0001730784,0.0000011662562,0.000001081488,0.000016733888,0.00011247089],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874145,0.00030753342,0.000450514,0.00010509797,0.00023241971,0.00016295801],"domain_scores_gemma":[0.9962067,0.0001675439,0.002227026,0.0006853015,0.00063723454,0.000076189775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000459704,0.00011888561,0.0010600988,0.00010938248,0.0001327153,0.000008312605,0.00031705183,0.000056067664,0.000008680086],"category_scores_gemma":[0.0004904285,0.00007113043,0.0004146625,0.0001994148,0.0013334355,0.00011339702,0.00003626737,0.00021268785,1.14707525e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03290828,0.0003565898,0.81993324,0.000049964732,0.013643747,0.019796735,0.00034840865,0.00027919197,0.08730495,0.000077048564,0.015619832,0.009682015],"study_design_scores_gemma":[0.0050026076,0.005759272,0.94785416,0.00019681825,0.0007512268,0.034707878,0.0009377839,0.000028335422,0.0029759214,0.000027603595,0.0016460806,0.00011228458],"about_ca_topic_score_codex":0.0003634021,"about_ca_topic_score_gemma":0.00011059216,"teacher_disagreement_score":0.12792094,"about_ca_system_score_codex":0.00011951805,"about_ca_system_score_gemma":0.00038836748,"threshold_uncertainty_score":0.49130988},"labels":[],"label_agreement":null},{"id":"W2597647786","doi":"10.1126/science.aan1467","title":"Costimulation, a surprising connection for immunotherapy","year":2017,"lang":"en","type":"letter","venue":"Science","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Immunotherapy; Connection (principal bundle); Sensitivity (control systems); Medicine; Immunology; Immune system; Engineering","score_opus":0.040461514910811895,"score_gpt":0.34763419163759224,"score_spread":0.30717267672678034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597647786","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015050556,0.0028472035,0.008611367,0.9579267,0.0068440107,0.0030324769,0.00008037172,0.0002063368,0.0054009985],"genre_scores_gemma":[0.047750216,0.00033035956,0.0031105333,0.92096037,0.006735189,0.000101323545,0.00024965993,0.00010041915,0.020661926],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985781,0.000012418517,0.00020784578,0.0004316295,0.00043380883,0.0003362287],"domain_scores_gemma":[0.99866503,0.00009626717,0.0002445262,0.0006369453,0.00032397817,0.0000332669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072624284,0.00016188595,0.0002553492,0.00021827154,0.0006934355,0.0001967245,0.00031602403,0.00024161793,0.000081685685],"category_scores_gemma":[0.00018534901,0.00013694765,0.00015220286,0.0001816328,0.00067634805,0.00019631264,0.000017603792,0.00033465165,0.000011633472],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009010269,0.00002053928,0.00022029289,0.0001334882,0.000077906654,0.000028299028,0.0002030728,0.0000016617116,0.037606075,0.000008773269,0.89137125,0.069427595],"study_design_scores_gemma":[0.0014080211,0.00020848574,0.0026512844,0.00021055402,0.000029243696,0.00007298677,0.000009347356,0.00015156633,0.0028900893,0.00013838203,0.9920535,0.00017651424],"about_ca_topic_score_codex":0.00010086799,"about_ca_topic_score_gemma":0.000004338469,"teacher_disagreement_score":0.10068226,"about_ca_system_score_codex":0.0002814486,"about_ca_system_score_gemma":0.0007023122,"threshold_uncertainty_score":0.5584563},"labels":[],"label_agreement":null},{"id":"W2598873759","doi":"10.1200/jco.2015.33.15_suppl.1037","title":"Tumor infiltrating lymphocytes (TILs) in HER2 positive breast cancer: Evaluation according to the new recommendations by the international TILs working group 2014.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Tumor-infiltrating lymphocytes; Oncology; Trastuzumab; Kappa; Cancer; Pathology; Immunotherapy","score_opus":0.15832878338563722,"score_gpt":0.4891784860668536,"score_spread":0.3308497026812164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598873759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5769491,0.002080283,0.000560849,0.4117219,0.0053891772,0.00058167224,0.000016379172,0.000008681363,0.002691953],"genre_scores_gemma":[0.97917897,0.0005428434,0.0008903944,0.016725237,0.0025184888,0.000018415223,0.000008622055,0.000011417699,0.00010561697],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971956,0.0005704879,0.0014342705,0.00014471529,0.0004848706,0.00017002915],"domain_scores_gemma":[0.99644846,0.001686721,0.001115831,0.00012716845,0.00044147423,0.00018036409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009024062,0.00010278764,0.00044680721,0.00009304762,0.00006918538,0.00004448619,0.0003074047,0.000103941995,0.00023500311],"category_scores_gemma":[0.0020377673,0.000057177866,0.00019402633,0.00023256466,0.000072666735,0.00015996167,0.00005614129,0.00055931066,0.000008514309],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005641299,0.00022805862,0.051913634,0.0000013692539,0.00026387963,0.000012096581,0.00067364477,0.00010257332,0.00051007245,0.000018187979,0.1430101,0.79762506],"study_design_scores_gemma":[0.02572139,0.0043040426,0.42811826,0.0012082001,0.0004993018,0.0017016847,0.009452273,0.003838042,0.00029039232,0.0005123487,0.5240872,0.00026688125],"about_ca_topic_score_codex":0.0010461751,"about_ca_topic_score_gemma":0.0014184096,"teacher_disagreement_score":0.7973582,"about_ca_system_score_codex":0.001170669,"about_ca_system_score_gemma":0.0028013135,"threshold_uncertainty_score":0.496941},"labels":[],"label_agreement":null},{"id":"W2599175392","doi":"10.1200/jco.2015.33.15_suppl.8025","title":"First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Rash; Lung cancer; Pneumonitis; Tolerability; Neutropenia; Adverse effect; Oncology; Cancer; Gastroenterology; Chemotherapy; Immunotherapy; Lung","score_opus":0.05510212609985535,"score_gpt":0.4032218573776451,"score_spread":0.3481197312777897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599175392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98864245,0.0039683515,0.0025496082,0.003248249,0.0005178227,0.00076674967,0.0000054402226,0.00001193218,0.000289415],"genre_scores_gemma":[0.98475283,0.0058408584,0.008114396,0.0007477625,0.00025394355,0.000016265472,0.0000041056337,0.000040575906,0.00022923926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966308,0.00020249224,0.0021145884,0.00031074992,0.00042430573,0.00031709333],"domain_scores_gemma":[0.9955288,0.0012525968,0.0021214813,0.00026042626,0.00047684566,0.00035982454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017141312,0.00027240397,0.0018525354,0.00020077586,0.000048258757,0.000012194312,0.0001708784,0.00039497347,0.0000308751],"category_scores_gemma":[0.0003031789,0.00016399268,0.00021552756,0.00027021932,0.00027143376,0.00016998572,0.00003520668,0.0007718921,6.648703e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12852837,0.0018931864,0.8064829,0.00010238595,0.00037161692,0.0002011912,0.0006869587,0.0013853633,0.0013005981,0.0000020633402,0.00024446438,0.058800872],"study_design_scores_gemma":[0.114679575,0.023204064,0.85038555,0.0014796475,0.0004156267,0.00011392674,0.0003744215,0.0009519504,0.0015235258,0.000017705197,0.0066024344,0.00025155293],"about_ca_topic_score_codex":0.00024169385,"about_ca_topic_score_gemma":0.0008249541,"teacher_disagreement_score":0.058549322,"about_ca_system_score_codex":0.0002497416,"about_ca_system_score_gemma":0.0017639088,"threshold_uncertainty_score":0.6687428},"labels":[],"label_agreement":null},{"id":"W2600612550","doi":"10.1111/his.13224","title":"Immune modulator‐induced changes in the gastrointestinal tract","year":2017,"lang":"en","type":"letter","venue":"Histopathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Ontario Institute for Cancer Research","keywords":"Medicine; Library science; Gerontology; Computer science","score_opus":0.039696694932943984,"score_gpt":0.28884881750847935,"score_spread":0.24915212257553537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600612550","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10391885,0.0024966116,0.0000092457685,0.8857751,0.0012880918,0.0006928782,0.000026517413,0.000054631448,0.0057380977],"genre_scores_gemma":[0.19589946,0.00018629886,0.0002807806,0.7858911,0.0064421133,0.00025375836,0.0003915571,0.00012480652,0.010530132],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982795,0.00021277051,0.00032428824,0.00044376546,0.00025995536,0.00047972717],"domain_scores_gemma":[0.9983258,0.00009321433,0.00033344573,0.0011763624,0.000046591416,0.000024589881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000567904,0.0003254132,0.0006413203,0.0002423443,0.00013751983,0.000024198607,0.00050459197,0.0005076239,0.00021950973],"category_scores_gemma":[0.00010298457,0.00022929201,0.00022003568,0.00007172237,0.0002971711,0.000028509561,0.00003623757,0.002081282,0.00005028065],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007870181,0.00020563744,0.0061769183,0.00030841856,0.000010084836,0.05249856,0.0010697682,7.913478e-8,0.080672614,0.000009017046,0.8511736,0.007088311],"study_design_scores_gemma":[0.0011946573,0.0007432301,0.29516107,0.00029772936,0.000077019446,0.023825707,0.00003058981,0.0000025565087,0.00008226806,0.00002621232,0.67835724,0.0002017224],"about_ca_topic_score_codex":0.0002850282,"about_ca_topic_score_gemma":0.00011917209,"teacher_disagreement_score":0.28898415,"about_ca_system_score_codex":0.00024302588,"about_ca_system_score_gemma":0.00017491986,"threshold_uncertainty_score":0.9350257},"labels":[],"label_agreement":null},{"id":"W2603747793","doi":"10.1200/jco.2013.31.15_suppl.tps4593","title":"A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; BC Cancer Agency; University of Alberta; University of Calgary","funders":"","keywords":"Nivolumab; Medicine; Pazopanib; Ipilimumab; Sunitinib; Renal cell carcinoma; Tyrosine-kinase inhibitor; Internal medicine; Oncology; Pharmacology; Cancer; Immunotherapy","score_opus":0.07959710117448439,"score_gpt":0.4098850430227954,"score_spread":0.330287941848311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603747793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99746066,0.000086773616,0.000023060917,0.0005755598,0.0002279503,0.0012921084,0.0000050445633,0.0000052675337,0.00032355328],"genre_scores_gemma":[0.9985068,0.00006471612,0.0007718206,0.00041832673,0.0000781561,0.000027050028,0.000008219332,0.000028741424,0.0000961913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948338,0.00089727825,0.0030492852,0.00027528108,0.00062341767,0.0003209152],"domain_scores_gemma":[0.9952675,0.001210126,0.0023379496,0.00026839573,0.00070265646,0.00021337901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022297278,0.00023447389,0.0018742549,0.00046847484,0.000031655763,0.000013250779,0.0002146363,0.00018109345,0.00026599516],"category_scores_gemma":[0.00043493867,0.00013969878,0.00017476421,0.000567014,0.00024815067,0.00026086625,0.0000347565,0.0009191641,0.0000046551904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14820136,0.09100024,0.66323316,0.00012463493,0.00050322706,0.00097019476,0.0015798502,0.000020094634,0.0004191321,0.0000034098362,0.0005535079,0.093391165],"study_design_scores_gemma":[0.20639732,0.19793648,0.59211236,0.00023308885,0.00029568496,0.00007511667,0.002232323,0.000102137965,0.00019752767,0.000011729327,0.00027954238,0.00012669517],"about_ca_topic_score_codex":0.000921204,"about_ca_topic_score_gemma":0.001970754,"teacher_disagreement_score":0.10693624,"about_ca_system_score_codex":0.00031925688,"about_ca_system_score_gemma":0.0017485461,"threshold_uncertainty_score":0.5696751},"labels":[],"label_agreement":null},{"id":"W2604893395","doi":"10.3389/fonc.2017.00067","title":"Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer","year":2017,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Docetaxel; Nivolumab; Oncology; Atezolizumab; Lung cancer; Internal medicine; Chemotherapy; Cancer; Immunotherapy; Immune checkpoint; Targeted therapy","score_opus":0.0738078040686972,"score_gpt":0.4036445052378537,"score_spread":0.32983670116915653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604893395","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009463216,0.9810029,0.000035587622,0.00029094086,0.0007502361,0.008018918,0.000061741426,0.000015068684,0.00036133517],"genre_scores_gemma":[0.00065373053,0.9896773,0.0040233815,0.00015780638,0.00009713803,0.004689697,0.00020481087,0.000052883173,0.0004432326],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99751776,0.00034773108,0.00088469015,0.0005583579,0.00018616892,0.00050529855],"domain_scores_gemma":[0.9983538,0.00019317675,0.000793064,0.0005290212,0.000045958237,0.00008498435],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005353798,0.0005112864,0.002558767,0.0004256017,0.000074816235,0.000027294365,0.00017581467,0.00038018386,0.000012134397],"category_scores_gemma":[0.0000364914,0.00028878427,0.00032329143,0.00028197095,0.00022255839,0.000047006633,0.00002305373,0.00034864235,9.4658594e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003176893,0.0014432803,0.0009419698,0.0064006154,0.00042859383,0.0004857028,0.00093213643,8.358927e-7,0.000004285595,0.0000026809025,0.000754243,0.98542875],"study_design_scores_gemma":[0.010565982,0.0057754233,0.0003758601,0.0061571216,0.0019674678,0.00009291519,0.00029255843,0.000022901544,0.00006547212,0.000017712466,0.97438097,0.00028560057],"about_ca_topic_score_codex":0.0004270804,"about_ca_topic_score_gemma":0.0010562969,"teacher_disagreement_score":0.9851432,"about_ca_system_score_codex":0.001466645,"about_ca_system_score_gemma":0.0013312668,"threshold_uncertainty_score":0.9999564},"labels":[],"label_agreement":null},{"id":"W2606429310","doi":"10.1111/jdv.14284","title":"Oral lichenoid reactions associated with anti‐<scp>PD</scp>‐1/<scp>PD</scp>‐L1 therapies: clinicopathological findings","year":2017,"lang":"en","type":"letter","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Integre de Sante et de Services Sociaux de Laval","funders":"National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Cancer; Library science; Family medicine; Gerontology; Internal medicine","score_opus":0.03939686956812237,"score_gpt":0.3004152909291787,"score_spread":0.2610184213610563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606429310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7811037,0.0057427734,0.000024026289,0.20736955,0.001013255,0.00034002707,0.00004167954,0.000044696397,0.0043202913],"genre_scores_gemma":[0.81784683,0.006206857,0.0002537265,0.16531736,0.002141186,0.0000067539654,0.000038445087,0.00016450431,0.008024323],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.994043,0.0026364552,0.001602252,0.00051262893,0.0004532515,0.00075241056],"domain_scores_gemma":[0.99312234,0.0021336677,0.003891001,0.00048336995,0.00021264624,0.00015695873],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0018468542,0.0006134617,0.0020317018,0.0004254822,0.00048277524,0.000041719533,0.0011837961,0.0019041004,0.00002599635],"category_scores_gemma":[0.0021544213,0.00037298485,0.0006868594,0.00022585507,0.0025418454,0.00017069059,0.00026650395,0.006272994,0.000015996751],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003797501,0.00026287235,0.15292719,0.00023667155,0.002719322,0.0042945114,0.0010043408,0.0000022532497,0.0035060372,0.000046409885,0.833827,0.0007936419],"study_design_scores_gemma":[0.003942361,0.00039093982,0.3202805,0.0008558524,0.0011021543,0.03954099,0.0001507444,0.000003558286,0.0008259396,0.00024740162,0.6325409,0.00011868873],"about_ca_topic_score_codex":0.000006287779,"about_ca_topic_score_gemma":0.000001884891,"teacher_disagreement_score":0.2012861,"about_ca_system_score_codex":0.00008896825,"about_ca_system_score_gemma":0.0002841102,"threshold_uncertainty_score":0.9998722},"labels":[],"label_agreement":null},{"id":"W2606495925","doi":"10.1186/s13073-017-0424-2","title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","year":2017,"lang":"en","type":"article","venue":"Genome Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3730,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Prostate Cancer Foundation; Foundation Medicine; U.S. Department of Defense","keywords":"Microsatellite instability; Exome sequencing; Germline; Exome; Biology; Somatic cell; Germline mutation; PMS2; Cancer; Computational biology; Cancer research; Medicine; Oncology; Genetics; Gene; Mutation; Microsatellite; Allele","score_opus":0.030987939456910342,"score_gpt":0.33415935941470787,"score_spread":0.3031714199577975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606495925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792672,0.008650744,0.000016762617,0.0051331846,0.00012374419,0.00027541557,0.000109780005,0.000008664066,0.0064145],"genre_scores_gemma":[0.99607295,0.00041366034,0.000030894313,0.00036302052,0.0005188393,0.000023846906,0.000080624006,0.00001262637,0.002483524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868256,0.00003332742,0.0005020588,0.00019178413,0.000420395,0.00016990073],"domain_scores_gemma":[0.9983778,0.00007338512,0.0005688439,0.0007127429,0.00020282945,0.00006437182],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00060131354,0.00013142398,0.0006481502,0.00028873768,0.00019131368,0.000006824958,0.00032059624,0.00003544738,0.008092034],"category_scores_gemma":[0.00005462842,0.00007651476,0.00018519453,0.00034181704,0.00056165614,0.000034222572,0.00004159011,0.000093024064,0.0000014467198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010515138,0.00010747368,0.6141447,0.00030152206,0.0096959965,0.000035477427,0.006275127,0.00011620056,0.35059553,0.00024198828,0.0018722526,0.01556223],"study_design_scores_gemma":[0.0022811461,0.00034042457,0.9880122,0.00013558807,0.0025572537,0.000008643936,0.00073467137,0.00008326238,0.00088116585,0.000084980165,0.0047917953,0.00008888008],"about_ca_topic_score_codex":0.002945069,"about_ca_topic_score_gemma":0.00015373461,"teacher_disagreement_score":0.3738675,"about_ca_system_score_codex":0.000037557125,"about_ca_system_score_gemma":0.00008359781,"threshold_uncertainty_score":0.9928147},"labels":[],"label_agreement":null},{"id":"W2606571211","doi":"10.1007/s00262-017-1996-9","title":"The Summit for Cancer Immunotherapy (Summit4CI), June 26–29, 2016 Halifax, Canada","year":2017,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; BC Cancer Agency; Princess Margaret Cancer Centre; University of Guelph; Institute for Research in Immunology and Cancer; University of Alberta; Université de Montréal; Dalhousie University; University Health Network; University of Toronto","funders":"","keywords":"Summit; Immunotherapy; Cancer immunotherapy; Cancer; Medicine; Oncology; Geography; Internal medicine; Cartography","score_opus":0.021655016890104642,"score_gpt":0.30991624940816614,"score_spread":0.2882612325180615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606571211","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20421389,0.6535881,0.0004488478,0.10939339,0.024197388,0.005186524,0.00076464243,0.00073399144,0.0014732089],"genre_scores_gemma":[0.31628042,0.5769972,0.0004947795,0.01657322,0.0024528494,0.007724589,0.00011534669,0.0011334304,0.07822814],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952141,0.00017001132,0.0012475991,0.0010290626,0.0005986284,0.001740586],"domain_scores_gemma":[0.9939118,0.0004993288,0.0012246243,0.003512099,0.0006759674,0.00017619962],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0008810095,0.0009291854,0.0012784642,0.00015354458,0.003560936,0.00041253577,0.0021673152,0.00054017367,0.0007715031],"category_scores_gemma":[0.00013476193,0.000674601,0.0007648937,0.00024020506,0.001769859,0.00036121462,0.00013451942,0.0008245375,0.00002142259],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027582483,0.000220971,0.013684483,0.00008577367,0.008208374,0.00003437538,0.00040464272,0.0000071112026,0.1973598,0.00042453888,0.2012982,0.5506892],"study_design_scores_gemma":[0.014026227,0.00052351237,0.04665396,0.00034673733,0.0001585672,0.000033914523,0.0003179618,0.000031620748,0.030714571,0.00022993224,0.90615743,0.00080555445],"about_ca_topic_score_codex":0.42241493,"about_ca_topic_score_gemma":0.56716454,"teacher_disagreement_score":0.7048592,"about_ca_system_score_codex":0.0017993742,"about_ca_system_score_gemma":0.005238325,"threshold_uncertainty_score":0.99957055},"labels":[],"label_agreement":null},{"id":"W2607206237","doi":"10.1016/j.immuni.2017.04.003","title":"Two Strings in One Bow: PD-1 Negatively Regulates via Co-receptor CD28 on T Cells","year":2017,"lang":"en","type":"letter","venue":"Immunity","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Scopus; Humanities; Chemistry; Philosophy; MEDLINE; Biochemistry","score_opus":0.03740958560088624,"score_gpt":0.3043365376482639,"score_spread":0.26692695204737765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607206237","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70063335,0.001697313,0.000008687915,0.27023748,0.0020792303,0.0021867093,0.00060058123,0.00021929783,0.02233734],"genre_scores_gemma":[0.28397554,0.0017818828,0.0007995309,0.5999362,0.00785935,0.00024906266,0.004906912,0.0005193379,0.09997222],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975639,0.00028373522,0.00055095996,0.00048108277,0.0005353802,0.00058494735],"domain_scores_gemma":[0.99746585,0.0002811474,0.00051804597,0.0015429561,0.0001148577,0.00007713641],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00057473796,0.00053297303,0.00093806116,0.00035216572,0.00026857306,0.00009366773,0.00063056307,0.0008029123,0.0013549608],"category_scores_gemma":[0.00007650175,0.0004940474,0.00031961722,0.00016079773,0.00045534235,0.00012294641,0.00009388554,0.0034013218,0.0004747126],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029537801,0.00033404166,0.00037568988,0.00034350433,0.00052791607,0.00021048308,0.0005412026,7.7377246e-7,0.11929118,0.0000017903737,0.86297476,0.012444875],"study_design_scores_gemma":[0.0055486932,0.0007045498,0.01503674,0.0018738229,0.00010685779,0.00002206816,0.00004801086,0.0000052139553,0.12188982,0.000052384636,0.854104,0.0006078215],"about_ca_topic_score_codex":0.007916975,"about_ca_topic_score_gemma":0.00011077598,"teacher_disagreement_score":0.41665784,"about_ca_system_score_codex":0.00056107977,"about_ca_system_score_gemma":0.00025470302,"threshold_uncertainty_score":0.9997511},"labels":[],"label_agreement":null},{"id":"W2610248350","doi":"10.1093/annonc/mdx140.006","title":"Distinct immune microenvironments stratify triple-negative breast cancer and predict outcome","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; University of Toronto; McGill University","funders":"","keywords":"Triple-negative breast cancer; Tumor microenvironment; Immune system; Medicine; CD8; Cytotoxic T cell; Stroma; Cancer research; Tumor-infiltrating lymphocytes; Immunotherapy; Breast cancer; T cell; Immunology; Cancer; Biology; Internal medicine; Immunohistochemistry","score_opus":0.07393463096564874,"score_gpt":0.40217304690720296,"score_spread":0.32823841594155423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610248350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784264,0.0011385232,0.000003986767,0.015756242,0.00027293267,0.00032619733,0.0002462817,0.000009594268,0.0038198507],"genre_scores_gemma":[0.9956236,0.0019460737,0.00008379527,0.0007114381,0.0001007598,0.000025162914,0.000009403371,0.000011996936,0.0014877622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990717,0.000036191803,0.00036641135,0.0001994561,0.000117720716,0.00020851685],"domain_scores_gemma":[0.9990668,0.00005590966,0.00039759415,0.00034618398,0.00005235736,0.00008113078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025071634,0.00012964109,0.00044219577,0.000042358723,0.00014531211,0.00001311206,0.00013677576,0.00011854942,0.0003620182],"category_scores_gemma":[0.00006107439,0.0001029556,0.000105969855,0.000024364708,0.00060052023,0.00009169598,0.000067357716,0.0001318618,0.000004140651],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073198196,0.00045151947,0.6314211,0.00010685317,0.00071294646,0.000053204672,0.00035348578,1.5772592e-7,0.036211185,0.000023066079,0.0030585965,0.3202881],"study_design_scores_gemma":[0.0046656933,0.0011920044,0.9776401,0.000071064336,0.00007428304,0.0000761184,0.00007651318,0.000007593369,0.005602845,0.000057893423,0.010446737,0.00008917423],"about_ca_topic_score_codex":0.0013865099,"about_ca_topic_score_gemma":0.00019385602,"teacher_disagreement_score":0.346219,"about_ca_system_score_codex":0.00004758756,"about_ca_system_score_gemma":0.000107934175,"threshold_uncertainty_score":0.41984075},"labels":[],"label_agreement":null},{"id":"W2611286974","doi":"10.1038/bjc.2017.168","title":"Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies","year":2017,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University Belfast; Queen's University; Cancer Research UK; Health and Social Care Research and Development Division; Public Health Agency; Friends of the Cancer Centre","keywords":"Microsatellite instability; DNA methylation; Immune checkpoint; Colorectal cancer; Cancer research; Biology; Signet ring cell; Immunohistochemistry; Methylation; CpG site; Immune system; Cancer; Adenocarcinoma; Immunotherapy; Immunology; Genetics; Gene; Microsatellite; Gene expression; Allele","score_opus":0.013194118503054814,"score_gpt":0.2747363519693475,"score_spread":0.2615422334662927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611286974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88401425,0.11453027,0.00018722165,0.00033377163,0.00023192272,0.00054221845,0.00007326729,0.0000036353917,0.000083421335],"genre_scores_gemma":[0.992087,0.0055736685,0.0017576274,0.00005024952,0.0003351281,0.000050411967,0.0000036652386,0.000025851088,0.000116418545],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989942,0.000021605674,0.00048528836,0.00013013925,0.00019866294,0.00017014405],"domain_scores_gemma":[0.9987465,0.000028884802,0.00074685656,0.000087673994,0.00033053514,0.000059522838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031632467,0.000111235626,0.00035911883,0.00005548271,0.00014552119,0.00008676705,0.00011137006,0.000060681337,0.000077038974],"category_scores_gemma":[0.000049779854,0.0001101186,0.00017899225,0.000029600313,0.00015659444,0.00018271766,0.000025031324,0.00014245167,8.9896794e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024504424,0.000055459852,0.0052112076,0.0002884586,0.00035975233,0.00002689799,0.00029868406,0.000054916454,0.9544164,0.0000066369757,0.000045151985,0.036786005],"study_design_scores_gemma":[0.005922444,0.00046890994,0.0787079,0.0011616746,0.00014959964,0.00014326086,0.00030311232,0.00021663641,0.9118606,0.0000521625,0.0008806662,0.0001330333],"about_ca_topic_score_codex":0.00072423625,"about_ca_topic_score_gemma":0.00024199647,"teacher_disagreement_score":0.108956605,"about_ca_system_score_codex":0.00013116794,"about_ca_system_score_gemma":0.0004818743,"threshold_uncertainty_score":0.44905064},"labels":[],"label_agreement":null},{"id":"W2611551719","doi":"10.3747/co.24.3355","title":"Factors Influencing Treatment Selection and Survival in Advanced Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Lung cancer; Confidence interval; Internal medicine; Cancer; Performance status; Targeted therapy; Oncology","score_opus":0.1146620595225405,"score_gpt":0.4521266296929186,"score_spread":0.3374645701703781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611551719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933569,0.0043354887,0.000006929311,0.00038279512,0.0012329107,0.0002702877,0.000004304997,0.000016807626,0.00039358623],"genre_scores_gemma":[0.99664134,0.0030559974,0.00001621955,0.000021269972,0.00011211286,0.000053345047,0.0000052937576,0.0000075350827,0.00008691811],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99941874,0.00002915192,0.00014541499,0.0001804113,0.000059175774,0.00016711805],"domain_scores_gemma":[0.9996566,0.00003390476,0.00010612217,0.00012388699,0.000028687846,0.000050768434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000079703816,0.00010517077,0.00024566855,0.00006642248,0.00012120345,0.000013258112,0.00003970047,0.00006601358,0.000060575785],"category_scores_gemma":[0.000029786239,0.000078737736,0.000039998788,0.000039980758,0.000059834445,0.000078123434,0.00001751905,0.00009803995,5.161365e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047989163,0.00009793217,0.72897035,0.000027960277,0.000037765956,0.0000024387416,0.00055592647,0.00000212821,0.0041521555,0.000005851379,0.00002740955,0.2656402],"study_design_scores_gemma":[0.0045688273,0.00050556776,0.95859635,0.000101303885,0.00004781993,0.0000039520955,0.0001702255,0.00020636452,0.0015638061,0.000005876675,0.034149107,0.000080809106],"about_ca_topic_score_codex":0.00084315584,"about_ca_topic_score_gemma":0.0041649668,"teacher_disagreement_score":0.2655594,"about_ca_system_score_codex":0.0009068217,"about_ca_system_score_gemma":0.00019562358,"threshold_uncertainty_score":0.32108316},"labels":[],"label_agreement":null},{"id":"W2612327959","doi":"10.1186/s40425-017-0243-4","title":"Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy","year":2017,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":239,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Immunotherapy; Immune system; Medicine; Tumor microenvironment; Cancer immunotherapy; Cancer; Immunology; Baseline (sea); Biomarker; Bioinformatics; Oncology; Internal medicine; Biology","score_opus":0.18568744673297063,"score_gpt":0.511312647124004,"score_spread":0.3256252003910334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612327959","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041970628,0.9856511,0.00076816237,0.000471054,0.007969339,0.0039194343,0.0005892358,0.000051872776,0.00016010174],"genre_scores_gemma":[0.00009598084,0.991942,0.0021599631,0.00033751942,0.000885103,0.00031581943,0.0000923618,0.0003824697,0.0037887879],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9882935,0.0005085017,0.008485507,0.0007904231,0.0010641123,0.0008579456],"domain_scores_gemma":[0.98745966,0.0007789173,0.008479897,0.001965761,0.0009871126,0.00032863545],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0073253596,0.0011334062,0.007537948,0.0012757813,0.00044133927,0.00013400918,0.0016228682,0.001140027,0.0011850558],"category_scores_gemma":[0.0004419902,0.0008554443,0.008517291,0.0006504387,0.0006248005,0.00027341963,0.00009931051,0.0013992252,0.000011139998],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009432679,0.00043244293,0.0007254312,0.008424779,0.018694798,0.000017263867,0.0001693201,0.0000013847787,0.0012384447,0.000008607319,0.0033992447,0.9574556],"study_design_scores_gemma":[0.011070272,0.0019929642,0.0009496042,0.047302507,0.002556729,0.00031187534,0.0000459119,0.000008028744,0.00022029314,0.000047795093,0.9347539,0.0007401335],"about_ca_topic_score_codex":0.0003548739,"about_ca_topic_score_gemma":0.00002417648,"teacher_disagreement_score":0.95671546,"about_ca_system_score_codex":0.0006711661,"about_ca_system_score_gemma":0.0021800841,"threshold_uncertainty_score":0.999728},"labels":[],"label_agreement":null},{"id":"W2612554234","doi":"10.1093/annonc/mdx091.058","title":"An open-label phase 3b/4 safety trial of flat-dose nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré de Santé et de Services Sociaux du Bas-Saint-Laurent","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Discontinuation; Lung cancer; Adverse effect; Cohort; Cancer; Phases of clinical research; Chemotherapy; Immunotherapy","score_opus":0.061340445049482356,"score_gpt":0.41847537420991215,"score_spread":0.35713492916042977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612554234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905343,0.00046489315,0.000014303686,0.0007062158,0.00044884786,0.002195706,0.00010275602,0.000008908942,0.005524067],"genre_scores_gemma":[0.99745405,0.00091434503,0.00051781704,0.00052714074,0.0000913518,0.0000939078,0.000049413542,0.00003200292,0.00031994435],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982392,0.000100539095,0.0006858265,0.00037841342,0.00022714821,0.00036882824],"domain_scores_gemma":[0.9977644,0.00006948956,0.0008747249,0.00082654465,0.00034168278,0.00012313173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005196861,0.00021359201,0.0009360966,0.00013314668,0.00011361984,0.000016082997,0.0005799257,0.00019972927,0.00012086365],"category_scores_gemma":[0.0000488917,0.00017713441,0.00007058615,0.00012268091,0.00027442112,0.0002913018,0.00011620713,0.0002023505,0.0000012712577],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7196561,0.006865192,0.009557492,0.0001476646,0.00022505042,0.000026032125,0.0007516315,0.000011320327,0.0155823445,0.000005766052,0.00073215045,0.24643925],"study_design_scores_gemma":[0.8389813,0.06873744,0.06673099,0.0005044214,0.00015065735,0.0000019587962,0.00014061923,0.00026899742,0.017855152,0.000010233075,0.006330561,0.00028767218],"about_ca_topic_score_codex":0.0021268139,"about_ca_topic_score_gemma":0.0016390384,"teacher_disagreement_score":0.24615157,"about_ca_system_score_codex":0.00018867386,"about_ca_system_score_gemma":0.0013667651,"threshold_uncertainty_score":0.72233313},"labels":[],"label_agreement":null},{"id":"W2613260599","doi":"10.1080/21645515.2017.1322241","title":"A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors","year":2017,"lang":"en","type":"article","venue":"Human Vaccines & Immunotherapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Impact","funders":"","keywords":"Medicine; Adverse effect; Ipilimumab; Immune checkpoint; Melanoma; Pembrolizumab; Disease; Immune system; Intensive care medicine; Oncology; Immunology; Internal medicine; Immunotherapy; Cancer research","score_opus":0.049832303528381645,"score_gpt":0.35912917943561956,"score_spread":0.3092968759072379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613260599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814057,0.014000974,0.000024457002,0.0011428861,0.00037990903,0.0009835755,0.0000037544692,0.000014986852,0.002043759],"genre_scores_gemma":[0.9911669,0.0060732015,0.0016621931,0.00014311411,0.00011138283,0.0000443664,0.000012803768,0.000040256407,0.0007457836],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99732333,0.00011993289,0.0016601091,0.0003172024,0.00026832262,0.00031107248],"domain_scores_gemma":[0.99759376,0.00008695027,0.0008324825,0.0014007592,0.000052076597,0.000033991848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008264641,0.00028895237,0.00086700916,0.0001752008,0.00012459682,0.000031779244,0.00045237556,0.0001435734,0.00010875899],"category_scores_gemma":[0.000018235227,0.0002023022,0.00044734046,0.00017762624,0.00012726254,0.000100133526,0.000060127222,0.00024743617,0.00000258645],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008845366,0.0021090973,0.2157363,0.00016772513,0.0012150304,0.000067037974,0.0061191134,0.000009166463,0.03734188,0.00039228206,0.00011392967,0.7278831],"study_design_scores_gemma":[0.02373655,0.001997733,0.9502511,0.00063883903,0.00019697098,0.000013409942,0.001379488,0.00001841204,0.0093896445,0.0002631505,0.011899971,0.00021470837],"about_ca_topic_score_codex":0.0015788686,"about_ca_topic_score_gemma":0.00047405626,"teacher_disagreement_score":0.73451483,"about_ca_system_score_codex":0.0001521474,"about_ca_system_score_gemma":0.000097965174,"threshold_uncertainty_score":0.8249644},"labels":[],"label_agreement":null},{"id":"W2613800036","doi":"10.1126/sciimmunol.aan3864","title":"PD-1 and CTLA-4: Two checkpoints, one pathway?","year":2017,"lang":"en","type":"article","venue":"Science Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council","keywords":"CTLA-4; Immunity; Immunology; CD28; Cancer research; Cell biology; Biology; Immune system; T cell","score_opus":0.029723623865436706,"score_gpt":0.3230072836662338,"score_spread":0.2932836598007971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613800036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764372,0.0017468731,0.000023257815,0.005143733,0.0006014601,0.00016955269,0.0000021975723,0.000037661266,0.015838029],"genre_scores_gemma":[0.99721515,0.0004197351,0.0005491144,0.00050314143,0.00007032053,0.000009086172,0.0000012079026,0.000007387138,0.0012248454],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989463,0.000014833631,0.00015847234,0.0003356574,0.00018478127,0.00035994817],"domain_scores_gemma":[0.99893844,0.000018244265,0.00011917011,0.0007704529,0.0000827285,0.00007094793],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0006042792,0.00010066878,0.00020103189,0.000120631965,0.000737726,0.00009958879,0.00039582385,0.000059650145,0.00018960671],"category_scores_gemma":[0.00021593214,0.00008388957,0.00004196752,0.00012103485,0.0036498117,0.00027310557,0.00019344971,0.00015059805,0.00005606493],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034786382,0.000046035824,0.0050944937,0.0000065613835,0.000032900967,0.0000123734535,0.00016374132,1.6909599e-8,0.8659492,0.0008833728,0.00004235509,0.1274211],"study_design_scores_gemma":[0.0037315842,0.0005482301,0.69398534,0.00008186503,0.000021451493,0.00029663648,0.00015692347,0.00003123724,0.2853836,0.00093952194,0.014645193,0.00017838996],"about_ca_topic_score_codex":0.0005725442,"about_ca_topic_score_gemma":0.00004308936,"teacher_disagreement_score":0.6888909,"about_ca_system_score_codex":0.00007406543,"about_ca_system_score_gemma":0.00030714256,"threshold_uncertainty_score":0.9990617},"labels":[],"label_agreement":null},{"id":"W2613837566","doi":"10.26443/msurj.v10i1.121","title":"Immune Response Regulation has Therapeutic Potential in the Treatment of Cancer","year":2015,"lang":"en","type":"article","venue":"McGill Science Undergraduate Research Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; McGill University","keywords":"Immune system; Immunotherapy; Adoptive cell transfer; Immunology; Ipilimumab; Cancer immunotherapy; Cancer; Cytotoxic T cell; Cancer research; Tumor microenvironment; Medicine; T cell; CTL*; Immune checkpoint; Cancer cell; Biology; CD8; Internal medicine","score_opus":0.1667549721764681,"score_gpt":0.42810261344128636,"score_spread":0.26134764126481824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613837566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9316609,0.003632226,0.000041785766,0.06348808,0.00023108644,0.0004334081,0.0000040433647,0.0000066871225,0.0005017739],"genre_scores_gemma":[0.9959004,0.0033574705,0.00008216452,0.00008705031,0.00008520034,0.000019357483,7.009357e-7,0.00000851862,0.0004591394],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9961632,0.0007313541,0.00036532746,0.00020629096,0.002010154,0.00052367075],"domain_scores_gemma":[0.9985846,0.00016431132,0.00011799711,0.0003132407,0.0006398501,0.00017996397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00930755,0.00010509553,0.00019107047,0.0006461266,0.0007034946,0.00012428612,0.00035060215,0.000042539534,0.000033431956],"category_scores_gemma":[0.00016206333,0.0000576768,0.00011106633,0.0018979175,0.001390593,0.00023220337,0.000023537277,0.00027943007,0.0000054018083],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023792913,0.0010965479,0.0028878842,0.000012331963,0.00011295497,0.00017686574,0.0023531036,0.00030390322,0.8076962,0.0006086457,0.00047422713,0.16048437],"study_design_scores_gemma":[0.024793712,0.018797418,0.5951346,0.0005773161,0.00012532082,0.0020009943,0.00819395,0.004516809,0.18753693,0.023943411,0.13392243,0.00045708483],"about_ca_topic_score_codex":0.0013173323,"about_ca_topic_score_gemma":0.00015150137,"teacher_disagreement_score":0.6201593,"about_ca_system_score_codex":0.0014596776,"about_ca_system_score_gemma":0.0016632153,"threshold_uncertainty_score":0.54107827},"labels":[],"label_agreement":null},{"id":"W2613957521","doi":"10.1007/s00262-017-2009-8","title":"Cancer immunotherapy without frontiers: 2nd Annual Immuno-Oncology Meeting of the Centro de Investigación de Cancer en Sonora (CICS), Ciudad Obregón, Sonora México, Dec 2–4, 2016","year":2017,"lang":"es","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Cancer Agency; National Cancer Institute; National Institutes of Health; Augusta University; Moffitt Cancer Center; Georgia Research Alliance","keywords":"Cancer; Medicine; Immunotherapy; Oncology; Internal medicine","score_opus":0.016149254965996056,"score_gpt":0.3240649541124184,"score_spread":0.30791569914642236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613957521","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.538271,0.43055266,0.00033174054,0.016077723,0.010351847,0.002305998,0.0013001915,0.00024367866,0.0005651354],"genre_scores_gemma":[0.45069215,0.53161305,0.0012288175,0.0063302233,0.0023382264,0.001979443,0.000044782762,0.0007931647,0.0049801567],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9873727,0.0024717038,0.0031619584,0.0020620879,0.0010204255,0.0039111297],"domain_scores_gemma":[0.98676664,0.0006426485,0.0055744834,0.0053812847,0.0011898603,0.00044507897],"candidate_categories":["metaepi_narrow","sts","open_science","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","sts","research_integrity"],"category_scores_codex":[0.0032364521,0.0022778893,0.0039093904,0.0006811399,0.0025583964,0.0005653599,0.0058568376,0.0027728793,0.002171089],"category_scores_gemma":[0.0004557392,0.0019106084,0.0019034374,0.0008092752,0.007486152,0.0011015866,0.00081751216,0.0027203371,0.000019782095],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.017482521,0.00060175336,0.2788182,0.00030709864,0.012468905,0.000036201378,0.010339971,0.00010222373,0.43737143,0.00016184173,0.013381943,0.22892793],"study_design_scores_gemma":[0.026460098,0.0013512371,0.31523392,0.005497928,0.0012850334,0.00017238877,0.004469989,0.00027382254,0.12005307,0.00039478653,0.52276725,0.0020404945],"about_ca_topic_score_codex":0.07465032,"about_ca_topic_score_gemma":0.0035069315,"teacher_disagreement_score":0.5093853,"about_ca_system_score_codex":0.0084389625,"about_ca_system_score_gemma":0.015765117,"threshold_uncertainty_score":0.99958044},"labels":[],"label_agreement":null},{"id":"W2615312978","doi":"10.1056/nejmc1703047","title":"Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade","year":2017,"lang":"en","type":"letter","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Autoimmunity; Blockade; Toxicity; Pembrolizumab; Immunology; Immunotherapy; Internal medicine; Antibody; Immune system; Receptor","score_opus":0.015523292707906594,"score_gpt":0.2799860467626121,"score_spread":0.2644627540547055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615312978","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46600297,0.015172885,0.000038570244,0.5171559,0.0010345479,0.00022668699,0.000057535224,0.000007185234,0.00030372513],"genre_scores_gemma":[0.7366168,0.008002619,0.0007324552,0.20436285,0.023137722,0.0000038088747,0.00011069688,0.00018427748,0.026848802],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969864,0.00025807836,0.0013918097,0.00022092836,0.0008719609,0.00027083492],"domain_scores_gemma":[0.9958662,0.00061184104,0.0024689618,0.00054528395,0.00033874306,0.0001689736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023167464,0.00035044068,0.0018128449,0.00041329724,0.000048925867,0.000009131632,0.0003905927,0.00037007578,0.00037635682],"category_scores_gemma":[0.0009507809,0.00022954856,0.00026027497,0.00010408136,0.00086177443,0.00007789008,0.000053184376,0.0016671082,4.5018027e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03494171,0.00006969288,0.00070664025,0.0004234027,0.0007649612,0.0020007677,0.00081303436,1.0612815e-7,0.11796913,3.1065628e-7,0.829684,0.012626237],"study_design_scores_gemma":[0.06535263,0.0065916064,0.0040716357,0.0069593294,0.00079385913,0.0076630474,0.00008485159,0.0000020740029,0.0088516865,0.000031490727,0.8994089,0.00018890112],"about_ca_topic_score_codex":0.0004058348,"about_ca_topic_score_gemma":0.000008928666,"teacher_disagreement_score":0.31279305,"about_ca_system_score_codex":0.00011220295,"about_ca_system_score_gemma":0.0006052711,"threshold_uncertainty_score":0.9360719},"labels":[],"label_agreement":null},{"id":"W2615526152","doi":"10.1373/clinchem.2016.267849","title":"The Phoenix Rises: The Rebirth of Cancer Immunotherapy","year":2017,"lang":"en","type":"article","venue":"Clinical Chemistry","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; University Health Network","funders":"","keywords":"Phoenix; Immunotherapy; Cancer immunotherapy; Cancer; Medicine; Immunology; Oncology; Cancer research; Internal medicine; Pathology","score_opus":0.048343321276410556,"score_gpt":0.41786914685443666,"score_spread":0.3695258255780261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615526152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745479,0.008175867,0.000002078563,0.010635196,0.00044775885,0.0001734344,0.0000116684105,0.000029764919,0.005976317],"genre_scores_gemma":[0.9768086,0.015472841,0.000017849723,0.00070720253,0.00061511603,0.000030336236,0.0000019798265,0.000024255718,0.0063218367],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99890023,0.000028276243,0.0005077349,0.0001887794,0.00019427312,0.00018068735],"domain_scores_gemma":[0.99758875,0.00040436114,0.00043508888,0.0014218632,0.0000934422,0.00005648458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078304275,0.00011247815,0.00026157105,0.0000029074527,0.00036872883,0.000047473608,0.00059480185,0.00013177279,0.0002048863],"category_scores_gemma":[0.00042809578,0.00005402969,0.0003470847,0.000035401164,0.0012708969,0.000026286345,0.000064288964,0.00034101558,0.0000037585683],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009144923,0.00038177997,0.42671794,0.00016312693,0.0013891764,0.000012579042,0.00018679754,3.232563e-7,0.13254227,0.000024931756,0.032311074,0.39712507],"study_design_scores_gemma":[0.0038940595,0.00010622696,0.23094684,0.00018006578,0.00008990418,0.000010387445,0.0001539501,0.000018510365,0.114085644,0.00009760914,0.650293,0.0001238426],"about_ca_topic_score_codex":0.00014030715,"about_ca_topic_score_gemma":0.000016946713,"teacher_disagreement_score":0.6179819,"about_ca_system_score_codex":0.000030423878,"about_ca_system_score_gemma":0.00021316309,"threshold_uncertainty_score":0.46826723},"labels":[],"label_agreement":null},{"id":"W2615663954","doi":"10.1200/jco.2014.32.15_suppl.3057","title":"A systematic review of immune-related adverse event (irAE) reporting in clinical trials of immune checkpoint inhibitors (ICIs).","year":2014,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Clinical trial; Adverse effect; Consolidated Standards of Reporting Trials; Internal medicine; MEDLINE; Confidence interval; Systematic review","score_opus":0.27038554086918604,"score_gpt":0.5699617890490783,"score_spread":0.2995762481798923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615663954","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00085519656,0.98913306,0.0000140176935,0.00056868524,0.0043328516,0.0046979194,0.000008609142,0.000009080664,0.00038056207],"genre_scores_gemma":[0.0007354099,0.9974202,0.0003118961,0.00036701054,0.00083261664,0.000073042014,0.000020566707,0.000069680915,0.00016958374],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.77526426,0.018611109,0.20414259,0.0005076776,0.0010610136,0.00041335367],"domain_scores_gemma":[0.6956469,0.024147645,0.27760315,0.0011262953,0.001124892,0.00035110864],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","metaepi_broad","research_integrity"],"category_scores_codex":[0.37718326,0.0006253833,0.05124045,0.00063899276,0.000024118515,0.000004483997,0.00064081035,0.0023188028,0.00028578276],"category_scores_gemma":[0.35988414,0.00037159488,0.034231503,0.0008217558,0.00057903246,0.000083882056,0.00017064334,0.0038851008,0.000012402822],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027394847,0.0015421677,0.00007558413,0.6352636,0.0053757876,0.00037565795,0.00002433911,3.1621994e-7,0.000007767261,0.000005912426,0.0003113608,0.354278],"study_design_scores_gemma":[0.0115460465,0.0069270693,0.00049255055,0.8416497,0.019058999,0.0014823354,0.000050554085,0.0000036783388,0.0000063759308,0.00001833645,0.1185092,0.00025513384],"about_ca_topic_score_codex":0.000054498014,"about_ca_topic_score_gemma":0.000006873134,"teacher_disagreement_score":0.35402286,"about_ca_system_score_codex":0.00055535516,"about_ca_system_score_gemma":0.0071431603,"threshold_uncertainty_score":0.9998736},"labels":[{"model":"gemma","categories":["metaresearch","metaepi_broad"],"domain":"reporting","study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["metaresearch"],"domain":"reporting","study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W2615945276","doi":"10.6004/jnccn.2017.0075","title":"Immunotherapies for Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of the National Comprehensive Cancer Network","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Pembrolizumab; Atezolizumab; Medicine; Nivolumab; Immunotherapy; Oncology; Lung cancer; PD-L1; Internal medicine; Standard of care; First line; Cancer","score_opus":0.05760166304265469,"score_gpt":0.3876294147813151,"score_spread":0.3300277517386604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615945276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5109482,0.33738416,0.0010533825,0.121786416,0.023757542,0.0023764889,0.00023832281,0.00003542925,0.0024200974],"genre_scores_gemma":[0.9674984,0.0072743157,0.0012084652,0.012375221,0.009038585,0.0000831769,0.0000021504225,0.000044206216,0.0024754796],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987934,0.000032609285,0.00037583933,0.000107534106,0.0004968089,0.00019377108],"domain_scores_gemma":[0.99678016,0.00016098567,0.00096422527,0.00019557333,0.0018495057,0.000049553088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021391452,0.00013280477,0.00031280183,0.000044672754,0.0006159762,0.00007115821,0.00040915978,0.00006645426,0.00016862308],"category_scores_gemma":[0.000084599706,0.00008346921,0.00045026324,0.00007997764,0.00016954195,0.00014166006,0.00004696861,0.00022219936,3.2154205e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018234085,0.00014512827,0.056449834,0.0002832175,0.0062480457,0.000006633563,0.00051454525,0.014456927,0.029807713,0.0009032011,0.83305234,0.039898355],"study_design_scores_gemma":[0.0074111414,0.00020977894,0.42971143,0.0015568472,0.00038377414,0.000104734216,0.00005100599,0.0016894612,0.0018795625,0.0015091224,0.5552757,0.00021746119],"about_ca_topic_score_codex":0.00005222513,"about_ca_topic_score_gemma":0.00002322125,"teacher_disagreement_score":0.45655024,"about_ca_system_score_codex":0.00039067958,"about_ca_system_score_gemma":0.0005644602,"threshold_uncertainty_score":0.47376534},"labels":[],"label_agreement":null},{"id":"W2616513983","doi":"10.1016/j.jtho.2017.04.008","title":"Immune Signatures of Non–Small Cell Lung Cancer","year":2017,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Pembrolizumab; Medicine; Nivolumab; Atezolizumab; Oncology; Lung cancer; Internal medicine; Immunotherapy; Chemotherapy; PD-L1; Cancer","score_opus":0.02078147109960025,"score_gpt":0.3932704617069904,"score_spread":0.37248899060739016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616513983","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.105836295,0.112392284,0.00012239849,0.7568349,0.011166942,0.0009202045,0.0001002245,0.000016984204,0.012609739],"genre_scores_gemma":[0.16275547,0.029174494,0.007650743,0.6707866,0.048197415,0.00007180255,0.00012744257,0.00041747672,0.08081854],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99756444,0.0001896594,0.001195657,0.00022390546,0.00044814125,0.00037821737],"domain_scores_gemma":[0.9945427,0.00022537167,0.0040061474,0.000559292,0.000580652,0.000085803586],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00087120343,0.0003355041,0.0017542089,0.00044145132,0.00008130042,0.00002111167,0.00065005245,0.0016187656,0.00069755845],"category_scores_gemma":[0.00006924881,0.0002464677,0.00091016816,0.00009644735,0.0002633856,0.000074087104,0.000073009294,0.0033745859,0.0000033686617],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060294406,0.00016781778,0.00033609438,0.0017010669,0.0013381875,0.0036953888,0.00025865194,0.000004381335,0.053768106,1.0166409e-7,0.8769546,0.055746134],"study_design_scores_gemma":[0.0021175852,0.0022215892,0.0034174423,0.0020614103,0.0022351881,0.0010616769,0.000046914927,0.000015079718,0.018190613,0.000013215429,0.9683695,0.00024981308],"about_ca_topic_score_codex":0.00021161581,"about_ca_topic_score_gemma":0.00002263732,"teacher_disagreement_score":0.09141484,"about_ca_system_score_codex":0.0006153788,"about_ca_system_score_gemma":0.002390979,"threshold_uncertainty_score":0.99999875},"labels":[],"label_agreement":null},{"id":"W2621331192","doi":"10.1158/2326-6066.cir-17-0224","title":"Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology Keystone Symposia Meeting Summary","year":2017,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Institutes for BioMedical Research; California Institute of Technology; University of California, San Francisco; Memorial Sloan-Kettering Cancer Center; University of California, San Diego; National Cancer Institute; National Institutes of Health; Cancer Research Institute","keywords":"Tumor immunology; Immunotherapy; Medicine; Cancer immunotherapy; Mainstream; Cancer; Cancer immunology; Clinical Oncology; Immunology; Oncology; Internal medicine; Political science","score_opus":0.06634672360924461,"score_gpt":0.4207497187492648,"score_spread":0.3544029951400202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621331192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8160245,0.15857887,0.0000035721184,0.013333719,0.00094657036,0.0010059297,0.000028920467,0.00007055751,0.010007367],"genre_scores_gemma":[0.8616083,0.13223748,0.00014483297,0.0005591744,0.00032680825,0.0010412667,0.00001790019,0.000097930046,0.003966308],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99543667,0.0007283686,0.0007618799,0.0009955845,0.00044731857,0.0016301634],"domain_scores_gemma":[0.9969994,0.0005111,0.0005222324,0.0014419911,0.00038461795,0.00014066469],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.002525077,0.00043731972,0.0010769899,0.00083453197,0.001270991,0.00014312478,0.0009204115,0.0008076599,0.0006992012],"category_scores_gemma":[0.0003659704,0.00040988295,0.00016439182,0.0004598402,0.0033921034,0.0003077033,0.00063720637,0.0020890352,0.000023276853],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01600234,0.00031494815,0.12991953,0.0001436015,0.0014782124,0.00041455362,0.0022359455,0.0000068028917,0.5320088,0.00035788908,0.0010411863,0.3160762],"study_design_scores_gemma":[0.026625175,0.0027061147,0.7149136,0.0030083247,0.00011843555,0.00072637864,0.003386188,0.00025915142,0.03474244,0.00028088997,0.2122729,0.0009603761],"about_ca_topic_score_codex":0.02939554,"about_ca_topic_score_gemma":0.006862988,"teacher_disagreement_score":0.5849941,"about_ca_system_score_codex":0.002101221,"about_ca_system_score_gemma":0.0019432172,"threshold_uncertainty_score":0.9998353},"labels":[],"label_agreement":null},{"id":"W2621587943","doi":"10.1016/j.critrevonc.2017.06.001","title":"Biomarkers of response to PD-1/PD-L1 inhibition","year":2017,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":318,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute","funders":"U.S. Food and Drug Administration; University of Chicago; Bristol-Myers Squibb","keywords":"Medicine; PD-L1; Immunotherapy; Melanoma; Immune system; Oncology; Head and neck squamous-cell carcinoma; Lymphoma; Cytotoxic T cell; Cancer; Renal cell carcinoma; Head and neck cancer; Internal medicine; Cancer research; Antigen; Immunology; Biology","score_opus":0.17863256192961188,"score_gpt":0.5110149956100323,"score_spread":0.3323824336804204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621587943","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006814058,0.9870809,0.00006448149,0.0041863234,0.0011096471,0.0035937033,0.000059390095,0.000038583097,0.0037988801],"genre_scores_gemma":[0.00009369994,0.9949277,0.001849847,0.0014219303,0.00014876162,0.0010562014,0.00007232283,0.00008119052,0.0003483659],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918413,0.0026869674,0.0033266318,0.0010155647,0.00028933148,0.00084020314],"domain_scores_gemma":[0.99298567,0.003912156,0.00089529547,0.001610235,0.00020677836,0.00038986473],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0053125643,0.0007416423,0.008546156,0.0009886335,0.00011042615,0.000018964822,0.00053885265,0.001752151,0.0006198515],"category_scores_gemma":[0.01863114,0.00057721196,0.001468775,0.0006683765,0.0013969555,0.000079442405,0.00026127574,0.0009984825,0.00048593842],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004037524,0.00049702177,0.00001831274,0.03395081,0.0002203284,0.00090141094,0.00006746213,2.5289153e-9,0.00006702185,0.0015618207,0.013413741,0.9452645],"study_design_scores_gemma":[0.0013411961,0.0014056885,0.00003965809,0.090821646,0.00092478114,0.002766273,0.000022321006,4.0499856e-7,0.000035385638,0.00017161686,0.9020568,0.00041422818],"about_ca_topic_score_codex":0.00002635257,"about_ca_topic_score_gemma":0.000045209,"teacher_disagreement_score":0.9448503,"about_ca_system_score_codex":0.00094756635,"about_ca_system_score_gemma":0.0018187241,"threshold_uncertainty_score":0.99966794},"labels":[],"label_agreement":null},{"id":"W2622613223","doi":"10.1200/jco.2017.35.15_suppl.1088","title":"Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Breast cancer; Nausea; Cohort; Clinical endpoint; Cancer; Surgery; Clinical trial; Immunotherapy","score_opus":0.2259555002164314,"score_gpt":0.540515536048429,"score_spread":0.31456003583199754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622613223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98161966,0.0014788347,0.00026759075,0.011317902,0.0018185249,0.0020430458,0.0012177699,0.000007792348,0.00022891197],"genre_scores_gemma":[0.9899946,0.005273102,0.0010265209,0.0018019965,0.0014804024,0.000056799512,0.0000629019,0.000038668124,0.00026503394],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9950902,0.0005503491,0.0030117892,0.0004824385,0.0005662506,0.00029901013],"domain_scores_gemma":[0.98752964,0.0048135347,0.0052733924,0.0011075387,0.00097255845,0.00030332353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035880064,0.00028749442,0.002589001,0.00012622408,0.00023093312,0.000029946936,0.00096616347,0.00027263086,0.0005703062],"category_scores_gemma":[0.0031476668,0.00019584064,0.0006051205,0.00009323787,0.00058050227,0.0003841242,0.00017499039,0.0007595991,0.0000037524055],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6385007,0.027344776,0.02399877,0.000039976796,0.010672562,0.00048017473,0.0008399884,0.0000067163155,0.00037825122,0.000002724268,0.00840528,0.2893301],"study_design_scores_gemma":[0.2063365,0.14308019,0.63719803,0.00034976564,0.0031990074,0.0002838441,0.0010617432,0.00060552155,0.0004801135,0.0002683467,0.00692447,0.00021247147],"about_ca_topic_score_codex":0.0030565583,"about_ca_topic_score_gemma":0.0007726608,"teacher_disagreement_score":0.61319923,"about_ca_system_score_codex":0.00020283986,"about_ca_system_score_gemma":0.0023214214,"threshold_uncertainty_score":0.7986149},"labels":[],"label_agreement":null},{"id":"W2623329013","doi":"10.1002/hon.2438_50","title":"PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE <scp>B</scp>‐CELL LYMPHOMA (<scp>RRPMBCL</scp>): UPDATED RESULTS FROM THE <scp>KEYNOTE</scp>‐013 TRIAL","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Neutropenia; Internal medicine; Pembrolizumab; Regimen; Adverse effect; Population; Cohort; Refractory (planetary science); Surgery; Oncology; Gastroenterology; Toxicity; Cancer; Immunotherapy","score_opus":0.026721705012862557,"score_gpt":0.30302441348129183,"score_spread":0.2763027084684293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623329013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860274,0.0007392065,0.000019993768,0.00025259517,0.0010886514,0.003613667,0.00039564265,0.0001349645,0.007727851],"genre_scores_gemma":[0.99630946,0.0001955031,0.00024901927,0.0011990069,0.00037380523,0.0002492566,0.00072485994,0.000079760895,0.00061935745],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.992979,0.0011256974,0.0021028162,0.0013338136,0.0011849754,0.0012737212],"domain_scores_gemma":[0.987651,0.0074480763,0.0022916484,0.0018133566,0.00038914164,0.000406801],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015888186,0.00078628375,0.0023749296,0.00025167287,0.0005317579,0.00007771721,0.0012231531,0.0010892458,0.000057381418],"category_scores_gemma":[0.006228133,0.0004874528,0.00035657003,0.00045129293,0.0010062193,0.00027322437,0.0004897537,0.0010946124,0.00006583129],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30392435,0.2751453,0.24619499,0.00031771485,0.0025233212,0.0051956773,0.018272994,0.0000056342483,0.0037922051,0.00011748073,0.1285859,0.015924452],"study_design_scores_gemma":[0.56098384,0.03447393,0.3450088,0.00017355819,0.00044074064,0.00008236734,0.003688765,0.000039941468,0.00085425196,0.00006117423,0.054093447,0.000099176825],"about_ca_topic_score_codex":0.00045644323,"about_ca_topic_score_gemma":0.00038414213,"teacher_disagreement_score":0.2570595,"about_ca_system_score_codex":0.00056471274,"about_ca_system_score_gemma":0.00096005003,"threshold_uncertainty_score":0.9997577},"labels":[],"label_agreement":null},{"id":"W2624341173","doi":"10.1200/jco.2017.35.15_suppl.104","title":"Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Pharmacology; Pharmacodynamics; Immunogenicity; Adverse effect; Internal medicine; Pharmacokinetics; Cancer; Immunotherapy; Immunology; Immune system","score_opus":0.06905777210190539,"score_gpt":0.4292556546783504,"score_spread":0.360197882576445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624341173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997256,0.00016206803,0.00000544677,0.0011554412,0.00029924538,0.0010040592,0.000011446309,0.000004711883,0.00010157877],"genre_scores_gemma":[0.9988712,0.00029358946,0.0006130541,0.00009054941,0.000043280743,0.000011740557,0.0000049510104,0.00002302152,0.000048614926],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9953138,0.0003752114,0.0033468888,0.00030478273,0.0004245784,0.00023469594],"domain_scores_gemma":[0.9928683,0.0007900408,0.0053335708,0.0004082192,0.00044194513,0.00015791002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019529732,0.00020190139,0.0021055085,0.0002679459,0.000053021817,0.000012184526,0.00021891775,0.00022271965,0.000017192651],"category_scores_gemma":[0.0016104365,0.00014024241,0.00013901989,0.00021502675,0.0003684896,0.00024145664,0.000056771518,0.00073609356,4.8165674e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5970217,0.023475563,0.18389767,0.00011187069,0.0006899263,0.0010089221,0.0020343878,0.0000271196,0.09190329,0.0000011346043,0.000041674557,0.09978672],"study_design_scores_gemma":[0.15637198,0.17062908,0.66327405,0.0007510462,0.00016703618,0.00017644945,0.00066784746,0.00014156723,0.007644003,0.00000909186,0.00005281535,0.000115038216],"about_ca_topic_score_codex":0.00043778378,"about_ca_topic_score_gemma":0.00082232076,"teacher_disagreement_score":0.47937638,"about_ca_system_score_codex":0.00019840762,"about_ca_system_score_gemma":0.0012188286,"threshold_uncertainty_score":0.57189196},"labels":[],"label_agreement":null},{"id":"W2624483458","doi":"10.1200/jco.2017.35.15_suppl.1008","title":"Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Internal medicine; Breast cancer; Metastatic breast cancer; Oncology; Cancer; Tolerability; Adverse effect; Immunotherapy","score_opus":0.15072636432771547,"score_gpt":0.524890833082499,"score_spread":0.3741644687547835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624483458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99143237,0.0007748693,0.0001909932,0.0037140641,0.0012259654,0.0022381179,0.00008635658,0.000010711759,0.00032656273],"genre_scores_gemma":[0.9938853,0.0026752613,0.00091824756,0.0008914674,0.0007789584,0.00009624725,0.0000038220182,0.000041671687,0.0007090392],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.994874,0.0005717153,0.0034182176,0.00032723963,0.00046603143,0.00034279624],"domain_scores_gemma":[0.9903578,0.0018129839,0.0058671758,0.0005686745,0.0010733051,0.0003200373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003913015,0.0002755679,0.0029463253,0.00017745986,0.00017489847,0.000027005688,0.0004510808,0.00026329566,0.0003295922],"category_scores_gemma":[0.0017908085,0.00018481532,0.0010049652,0.00011973776,0.00047187658,0.0002175461,0.000035274825,0.00060125394,0.0000017891579],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40419716,0.023738638,0.105576575,0.00010839883,0.0099450005,0.00026427882,0.00084783474,0.000007882505,0.0014732608,0.000007371563,0.0046078917,0.44922572],"study_design_scores_gemma":[0.3244186,0.10567674,0.5544802,0.00030249104,0.003775705,0.00041695283,0.0005950746,0.0002613241,0.000735929,0.00013288794,0.008963955,0.00024011977],"about_ca_topic_score_codex":0.0009008944,"about_ca_topic_score_gemma":0.0004719401,"teacher_disagreement_score":0.44898558,"about_ca_system_score_codex":0.00029679367,"about_ca_system_score_gemma":0.0020970118,"threshold_uncertainty_score":0.753655},"labels":[],"label_agreement":null},{"id":"W2624782256","doi":"10.1002/cncr.30724","title":"Assessment of programmed death‐ligand 1 expression and tumor‐associated immune cells in pediatric cancer tissues","year":2017,"lang":"en","type":"article","venue":"Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Stand Up To Cancer; St. Baldrick's Foundation; Bristol-Myers Squibb","keywords":"Medicine; Immune system; Cancer; Programmed cell death; Cancer research; Ligand (biochemistry); Cancer cell; Apoptosis; Immunology; Receptor; Internal medicine; Genetics; Biology","score_opus":0.024100714238840887,"score_gpt":0.3511504466756715,"score_spread":0.32704973243683066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624782256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98182225,0.016343253,0.0000029978037,0.0003330289,0.00035972145,0.00047136543,0.000031090705,0.000018029921,0.00061828946],"genre_scores_gemma":[0.9865496,0.012256589,0.00012933208,0.000073449955,0.00014040632,0.00017663203,0.0000063022376,0.000019960815,0.0006476954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900305,0.000026888589,0.00029214812,0.00023454364,0.00020544985,0.00023793422],"domain_scores_gemma":[0.999194,0.000025361334,0.00032632236,0.00030645638,0.00008016127,0.00006765588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022186292,0.00014161826,0.0003703141,0.00008132952,0.00010344838,0.000033614386,0.000117001575,0.000082967796,0.00012711466],"category_scores_gemma":[0.00002561237,0.00011416783,0.00006110064,0.00009170975,0.000095961856,0.00009276377,0.000053702483,0.00014182439,4.6149512e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028219834,0.0001306137,0.7281986,0.0002063425,0.00005639839,0.000017578373,0.0002286261,0.0000019463246,0.25833708,0.00000320353,0.00033136387,0.012206067],"study_design_scores_gemma":[0.0035597435,0.00013236536,0.8731914,0.0005412243,0.00008751285,0.0000013892908,0.000046192737,0.00005065079,0.1205379,0.000010244081,0.0017176998,0.00012363633],"about_ca_topic_score_codex":0.0033264603,"about_ca_topic_score_gemma":0.00052507047,"teacher_disagreement_score":0.14499287,"about_ca_system_score_codex":0.00020206149,"about_ca_system_score_gemma":0.00026520647,"threshold_uncertainty_score":0.5028635},"labels":[],"label_agreement":null},{"id":"W2625448727","doi":"10.1158/1078-0432.ccr-17-0438","title":"<i>In Situ</i> Vaccination after Accelerated Hypofractionated Radiation and Surgery in a Mesothelioma Mouse Model","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Toronto General Hospital","funders":"","keywords":"Medicine; Radiation therapy; Immune system; Immunotherapy; Mesothelioma; Immune checkpoint; Blockade; Surgery; Oncology; Internal medicine; Immunology; Pathology","score_opus":0.2499333826277477,"score_gpt":0.5176092521322413,"score_spread":0.2676758695044936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625448727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98458546,0.0014441938,0.000009257211,0.012869988,0.00014169812,0.0004804049,0.000010621595,0.00001452287,0.00044383018],"genre_scores_gemma":[0.98693466,0.009762239,0.000034622477,0.0010793541,0.00016718921,0.0002359882,0.000010505103,0.000021162492,0.0017542552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998102,0.0002472218,0.0005395299,0.00038684966,0.00039720177,0.0003272146],"domain_scores_gemma":[0.998589,0.0005717105,0.00011650775,0.0003892337,0.00021816888,0.000115399285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034418227,0.00010327691,0.0003235623,0.00040701445,0.00012971544,0.00009647865,0.000115457646,0.00021110536,0.00026663317],"category_scores_gemma":[0.00089235714,0.00009227448,0.000078932295,0.00030051943,0.00015338678,0.00050215086,0.00005822439,0.0006092683,0.000011165189],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029269058,0.0007441892,0.619084,0.00015821074,0.00010188253,0.00013827595,0.00024280058,0.000031475614,0.031359226,0.000024589333,0.009023085,0.30982324],"study_design_scores_gemma":[0.0047015357,0.00010000152,0.9781411,0.00012445262,0.000008450083,0.0000033645508,0.000024850708,0.0059915595,0.007172367,0.00021667924,0.0033935711,0.000122015554],"about_ca_topic_score_codex":0.0020533588,"about_ca_topic_score_gemma":0.0022164246,"teacher_disagreement_score":0.3590572,"about_ca_system_score_codex":0.00032001745,"about_ca_system_score_gemma":0.00052350666,"threshold_uncertainty_score":0.37628442},"labels":[],"label_agreement":null},{"id":"W2625494135","doi":"","title":"Partially differentiated polyfunctional T cells dominate the periphery after tumor-infiltrating lymphocytes therapy for cancer","year":2016,"lang":"en","type":"article","venue":"Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Kite Pharma; Cancer Institute, University of Pittsburgh; Oregon Clinical and Translational Research Institute; Deutsches Zentrum für Lungenforschung; National Institutes of Health; M.J. Murdock Charitable Trust; Terry Fox Foundation; University of Pittsburgh; Midwest Athletes Against Childhood Cancer; National Institute of Allergy and Infectious Diseases; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Harry J. Lloyd Charitable Trust; Achievement Rewards for College Scientists Foundation; Dana-Farber/Harvard Cancer Center; National Science Foundation","keywords":"Cancer; Tumor-infiltrating lymphocytes; Cancer research; Cancer therapy; Tumor cells; Chemistry; Biology; Pathology; Medicine; Immunotherapy; Genetics","score_opus":0.013723032792461657,"score_gpt":0.22443513094057474,"score_spread":0.2107120981481131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625494135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97446537,0.0016900045,0.013104722,0.0048381337,0.00032532922,0.0020356574,0.00046946085,0.00024403194,0.0028272956],"genre_scores_gemma":[0.99002624,0.0023790062,0.002559308,0.00031282371,0.000090704714,0.0000041959356,0.000015962094,0.00004664581,0.0045651225],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9970578,0.00019720923,0.00054907514,0.00079022325,0.0007302924,0.00067537575],"domain_scores_gemma":[0.99694765,0.00084212254,0.0005720759,0.0008392279,0.00051586586,0.00028305617],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006139646,0.0004817839,0.0009501027,0.00025980768,0.00043777612,0.000020059018,0.00096524454,0.0005007648,0.004947531],"category_scores_gemma":[0.00009875257,0.00037498446,0.001036735,0.00063364016,0.0019247718,0.00029267493,0.0003495657,0.00040543173,0.000033974513],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050458208,0.0010966873,0.009311851,0.00020992999,0.0010204786,0.00018266702,0.00019221699,0.0000084367675,0.89593995,0.00040908795,0.010224067,0.030946435],"study_design_scores_gemma":[0.056568746,0.0057440004,0.54647946,0.0034228836,0.0025879552,0.00033061142,0.0025362682,0.00043393805,0.16216187,0.00065868354,0.21629167,0.002783932],"about_ca_topic_score_codex":0.0006733202,"about_ca_topic_score_gemma":0.001007367,"teacher_disagreement_score":0.73377806,"about_ca_system_score_codex":0.00070284575,"about_ca_system_score_gemma":0.000638589,"threshold_uncertainty_score":0.9998702},"labels":[],"label_agreement":null},{"id":"W2625997216","doi":"10.1371/journal.pone.0179536","title":"Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis","year":2017,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Meta-analysis; Medicine; Hazard ratio; Subgroup analysis; Internal medicine; Cochrane Library; Oncology; Confidence interval; Head and neck cancer; Cancer","score_opus":0.15630846122141334,"score_gpt":0.34221223106471577,"score_spread":0.18590376984330242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625997216","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038183928,0.9862477,5.6092654e-7,0.000036582616,0.000004166532,0.009774851,0.00008681817,0.00001089099,0.000020001868],"genre_scores_gemma":[0.0007706311,0.996328,0.00046404332,0.000051888102,0.000007670392,0.0020281882,0.00008770482,0.000037737114,0.0002241475],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9977234,0.00020520332,0.0009518673,0.00044275165,0.00046832112,0.00020846362],"domain_scores_gemma":[0.99770033,0.00011031435,0.0012567203,0.00068266474,0.00014389884,0.00010605543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040964078,0.00040555446,0.008727235,0.00023864998,0.000045485747,0.000030872536,0.00013373893,0.00014643588,0.000021168571],"category_scores_gemma":[0.00011400488,0.00021552596,0.0005378166,0.00035662597,0.0000766519,0.000055216326,0.00004883259,0.00019619294,5.8671174e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008753607,0.0009247487,0.0037976657,0.90897095,0.08401368,0.000004461362,0.00003799879,7.579095e-9,0.000001296656,1.5064478e-7,0.0000034955742,0.0021580365],"study_design_scores_gemma":[0.00080872193,0.00036890415,0.00059161795,0.370022,0.62774366,0.0000014279109,0.0000015858473,9.499341e-7,0.000010143484,2.8948654e-7,0.00029308785,0.00015759823],"about_ca_topic_score_codex":0.00015127273,"about_ca_topic_score_gemma":0.000048878388,"teacher_disagreement_score":0.54372996,"about_ca_system_score_codex":0.00006704715,"about_ca_system_score_gemma":0.00016235758,"threshold_uncertainty_score":0.8788894},"labels":[],"label_agreement":null},{"id":"W2627028493","doi":"10.1182/blood.v128.22.4172.4172","title":"Intratumoral Administration of the Immunotherapeutic Combination Anti-ctla4, Anti-cd137 and Anti-ox40: Comparison to Systemic Administration, Peri-Draining Lymph Node Injection, and Cellular Vaccine in a Mouse Lymphoma Model","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Cancer immunotherapy; Immunotherapy; Cancer research; Immune system; Systemic administration; Cancer; CD137; Immunology; Internal medicine; In vivo; Biology","score_opus":0.015068652019173867,"score_gpt":0.2570639547747318,"score_spread":0.24199530275555795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2627028493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960157,0.0011315326,0.0009395683,0.00101107,0.00010936188,0.0006827409,0.000023810497,0.000040933457,0.000045263438],"genre_scores_gemma":[0.99917996,0.0002018904,0.00017963779,0.00019621775,0.000041704854,0.000034622026,0.000014538758,0.00003113783,0.000120317505],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99832684,0.0001034361,0.00069429335,0.00036578524,0.0002671637,0.00024246714],"domain_scores_gemma":[0.9990948,0.00005215058,0.00028219563,0.00034978695,0.00014365278,0.00007741832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038495645,0.00023859314,0.00047996602,0.00019157442,0.00013243503,0.00005130481,0.00011277267,0.00014188098,0.000008890629],"category_scores_gemma":[0.000046398898,0.00016808255,0.00006691336,0.00035893606,0.00010370659,0.00017677456,0.000037568603,0.00007478115,9.2849e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007415743,0.00064922695,0.2629051,0.000157499,0.00009948402,0.000005370544,0.001024754,0.000029067696,0.7322207,0.00008887723,0.000013046262,0.0020653338],"study_design_scores_gemma":[0.019566108,0.00094246137,0.5294723,0.0011472481,0.00022354504,0.00058146374,0.00089187676,0.0038148512,0.44292185,0.000045114397,0.00003324269,0.00035998187],"about_ca_topic_score_codex":0.000082084654,"about_ca_topic_score_gemma":0.000042145784,"teacher_disagreement_score":0.28929883,"about_ca_system_score_codex":0.000097308184,"about_ca_system_score_gemma":0.0003273249,"threshold_uncertainty_score":0.68542075},"labels":[],"label_agreement":null},{"id":"W2635951006","doi":"10.1056/nejmoa1613493","title":"First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer","year":2017,"lang":"en","type":"letter","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2575,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Nivolumab; Docetaxel; Medicine; Oncology; Lung cancer; Chemotherapy; Internal medicine; Lung; Cancer; Stage (stratigraphy); Immunotherapy","score_opus":0.03511857503314067,"score_gpt":0.31992912677095625,"score_spread":0.28481055173781555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2635951006","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04110611,0.04746758,0.00020953335,0.900861,0.0074908813,0.00093648414,0.00005517494,0.00001914021,0.0018540967],"genre_scores_gemma":[0.026903387,0.1417814,0.00072521454,0.43783394,0.20925686,0.00005199118,0.00024887637,0.00037617216,0.18282217],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965493,0.00011062256,0.001404732,0.00037602076,0.0009963247,0.0005629824],"domain_scores_gemma":[0.9967663,0.00030269322,0.0016904168,0.00063546805,0.0003065901,0.000298498],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012481635,0.0005477635,0.0017639949,0.0006632486,0.000103548104,0.000032795102,0.00055053807,0.0006175087,0.0029882358],"category_scores_gemma":[0.00027596776,0.000326782,0.0002929675,0.00021377514,0.00019307966,0.000101225414,0.000049199087,0.003500634,0.000004040908],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011527697,0.00009888624,0.0031966679,0.0015685895,0.0004679885,0.010429609,0.0009680431,0.000010369074,0.00025417376,1.2637939e-7,0.8869211,0.084556736],"study_design_scores_gemma":[0.10931735,0.0032495377,0.0021537992,0.012413142,0.0007918507,0.0012054323,0.00004824705,0.000103817874,0.00007872848,0.000008937084,0.8703205,0.0003086572],"about_ca_topic_score_codex":0.0028589517,"about_ca_topic_score_gemma":0.0027133957,"teacher_disagreement_score":0.4630271,"about_ca_system_score_codex":0.00060301507,"about_ca_system_score_gemma":0.0017654616,"threshold_uncertainty_score":0.9999184},"labels":[],"label_agreement":null},{"id":"W2636042323","doi":"10.1016/j.ejca.2017.05.031","title":"Health-related quality of life results from the phase III CheckMate 067 study","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Genentech; Astellas Pharma; Merck Sharp and Dohme; Eisai; National Cancer Institute; Dendreon Pharmaceuticals; Incyte; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; LEO Pharma; Prometheus; Helsinn; Roche; EMD Serono; Novartis; GlaxoSmithKline; Merck; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Phase (matter); Medicine; Chemistry","score_opus":0.09786343728687633,"score_gpt":0.4043122046986372,"score_spread":0.30644876741176086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2636042323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.970482,0.008948975,0.000013670296,0.016821012,0.00080154504,0.00025369422,0.00008983203,0.000007636873,0.0025816448],"genre_scores_gemma":[0.9965693,0.0012454187,0.000033720975,0.0009705707,0.0005340966,7.4592083e-7,0.000003099932,0.000022336711,0.0006207478],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970673,0.00067528104,0.0015160121,0.00013818243,0.0004468671,0.00015638428],"domain_scores_gemma":[0.9959161,0.00010030161,0.0029538546,0.000630511,0.00024793018,0.00015126521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004533736,0.00012318093,0.0005540178,0.000036287012,0.00022616937,0.000041230258,0.00041669543,0.000017232669,0.00019830317],"category_scores_gemma":[0.00047785015,0.000071973496,0.00020044898,0.00006317498,0.00016618105,0.000099201054,0.000049377442,0.00031710486,0.0000055305086],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20477755,0.0026366792,0.055296678,0.00008869505,0.0058089932,0.00042783204,0.033703607,0.000029048548,0.026469294,0.000011936633,0.07759091,0.5931588],"study_design_scores_gemma":[0.059641246,0.0017578613,0.9087711,0.0005051081,0.00013154106,0.000012444871,0.0012007399,0.0000067843484,0.00054550456,0.0000062124723,0.0273211,0.00010033303],"about_ca_topic_score_codex":0.0036544139,"about_ca_topic_score_gemma":0.00025938347,"teacher_disagreement_score":0.85347444,"about_ca_system_score_codex":0.00007548539,"about_ca_system_score_gemma":0.00038044082,"threshold_uncertainty_score":0.5524405},"labels":[],"label_agreement":null},{"id":"W2652023138","doi":"10.1038/nrurol.2017.87","title":"Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach","year":2017,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Radiation therapy; SABR volatility model; Radioresistance; Renal cell carcinoma; Ablative case; Context (archaeology); Clinical trial; Oncology; Internal medicine","score_opus":0.0761896278512064,"score_gpt":0.3909135346657712,"score_spread":0.3147239068145648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2652023138","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004840944,0.9916011,0.00015992254,0.000101522164,0.0005907267,0.0052899593,0.000117157884,0.000026508664,0.0021082615],"genre_scores_gemma":[0.000020752434,0.9903257,0.005611028,0.0006087614,0.0010108392,0.0006374255,0.0005832065,0.00012137639,0.0010809021],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966083,0.00047988546,0.0013215364,0.00089927966,0.00021990176,0.0004711005],"domain_scores_gemma":[0.9955868,0.0001682813,0.0020333831,0.0019408271,0.00012476202,0.00014595031],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0013572647,0.0007021918,0.005563586,0.00026522996,0.00011446039,0.000016664877,0.00074823806,0.002214524,0.00007774507],"category_scores_gemma":[0.00015920492,0.00047117207,0.002030076,0.00021219028,0.00030238248,0.00006952176,0.00003682405,0.001428717,0.0000044330036],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007765116,0.00021324091,0.0000031071081,0.04649013,0.0002694822,0.000011303208,0.00002423077,3.4511224e-8,0.00005469825,0.000057634265,0.008249602,0.94385004],"study_design_scores_gemma":[0.0021886423,0.0013655113,0.000015344951,0.0025652484,0.002136387,0.00041925957,8.112555e-7,0.00000704817,0.000015030646,0.000012315772,0.9909038,0.0003705881],"about_ca_topic_score_codex":0.000013202819,"about_ca_topic_score_gemma":0.0000042894635,"teacher_disagreement_score":0.9826542,"about_ca_system_score_codex":0.00014092606,"about_ca_system_score_gemma":0.00057531643,"threshold_uncertainty_score":0.999774},"labels":[],"label_agreement":null},{"id":"W2685405318","doi":"10.1016/j.diabet.2017.05.005","title":"Combination avelumab and utomilumab immunotherapy can induce diabetic ketoacidosis","year":2017,"lang":"en","type":"letter","venue":"Diabetes & Metabolism","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Diabetic ketoacidosis; Avelumab; Medicine; Immunotherapy; Ketoacidosis; Diabetes mellitus; Immunology; Immunopathology; Intensive care medicine; Type 1 diabetes; Endocrinology; Immune system; Pembrolizumab","score_opus":0.014323892100799384,"score_gpt":0.2530380344837107,"score_spread":0.23871414238291133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2685405318","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5926486,0.042430922,0.000003063802,0.35784253,0.0027715955,0.0014909169,0.00028203346,0.00019368634,0.00233663],"genre_scores_gemma":[0.2716504,0.0072601573,0.00029768972,0.6948728,0.0061575603,0.0005812845,0.0018248027,0.0004453923,0.016909901],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965614,0.00021309654,0.0006614146,0.00089556864,0.00073216547,0.0009363201],"domain_scores_gemma":[0.99731773,0.0001644173,0.00064447126,0.0015008266,0.00022909124,0.0001434499],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005185183,0.00080836104,0.001628232,0.00050206005,0.0004149454,0.00032176453,0.00050152943,0.0012723043,0.00040858585],"category_scores_gemma":[0.00010543867,0.0007316414,0.00047331027,0.00020077356,0.00051535916,0.00019122404,0.00010313292,0.0018058042,0.000047568796],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031959705,0.00024176142,0.0043329643,0.0009021597,0.003351426,0.00015351069,0.0010082126,4.691517e-8,0.03742814,0.000058487116,0.7298705,0.2223332],"study_design_scores_gemma":[0.0067542563,0.00019290748,0.0713079,0.00049534475,0.00080125855,0.000019892339,0.000018937208,0.00002054964,0.009160781,0.0003599091,0.9100408,0.00082748244],"about_ca_topic_score_codex":0.00027349207,"about_ca_topic_score_gemma":0.0000066408347,"teacher_disagreement_score":0.3370303,"about_ca_system_score_codex":0.00019402777,"about_ca_system_score_gemma":0.00025078657,"threshold_uncertainty_score":0.99951345},"labels":[],"label_agreement":null},{"id":"W2703678370","doi":"10.1200/jco.2016.34.15_suppl.101","title":"A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Atezolizumab; Medicine; Agonist; Internal medicine; Antibody; Pharmacokinetics; Immunotherapy; Adverse effect; Oncology; Pharmacology; Cancer; Pembrolizumab; Immunology; Receptor","score_opus":0.03716742583024048,"score_gpt":0.4133332806145038,"score_spread":0.37616585478426334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2703678370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99344474,0.0001358582,0.000009453974,0.0051978603,0.00043647754,0.0006417074,0.0000030143124,0.000002376679,0.00012848653],"genre_scores_gemma":[0.9989686,0.00015496994,0.00006216265,0.00053814985,0.00019940725,0.0000067598476,3.4086062e-7,0.000009605805,0.000059986756],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99710524,0.0005270455,0.0017598292,0.00013214754,0.0003388421,0.00013688934],"domain_scores_gemma":[0.9966643,0.0011105209,0.0016878636,0.00020324028,0.0002504793,0.00008360052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019118694,0.00010644328,0.00092012325,0.000060916827,0.000046946127,0.000005309542,0.00013008126,0.0001130527,0.00002293173],"category_scores_gemma":[0.0009994562,0.000037304122,0.00017566244,0.0001495814,0.000548906,0.00009548642,0.000043049542,0.00036541084,6.1133835e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29776326,0.0097450735,0.23979612,0.000013652715,0.0003192,0.000034826757,0.00064530247,0.000002909897,0.00059571146,0.000012499785,0.00016010094,0.45091134],"study_design_scores_gemma":[0.19159855,0.03551963,0.7704545,0.00024964075,0.00014625346,0.000024696517,0.00025794018,0.000010619963,0.00012195256,0.00005519261,0.0015115683,0.000049412545],"about_ca_topic_score_codex":0.000032854987,"about_ca_topic_score_gemma":0.00015583729,"teacher_disagreement_score":0.5306584,"about_ca_system_score_codex":0.00011510781,"about_ca_system_score_gemma":0.00049248483,"threshold_uncertainty_score":0.2022467},"labels":[],"label_agreement":null},{"id":"W2715305028","doi":"10.1371/journal.pone.0179223","title":"Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2+:ERα- breast cancer","year":2017,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network","funders":"Cure Brain Cancer Foundation; Canadian Cancer Society","keywords":"Breast cancer; Immune system; Cell growth; Cell; Cancer research; Signal transduction; Identification (biology); Cancer; Biology; Medicine; Immunology; Internal medicine; Cell biology; Genetics","score_opus":0.02561423988688706,"score_gpt":0.27902034948527593,"score_spread":0.2534061095983889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2715305028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914001,0.0015958294,0.00005930378,0.005520951,0.00004371034,0.0012045727,0.00012676658,0.000013802694,0.000034934812],"genre_scores_gemma":[0.99827445,0.0002947579,0.00026425876,0.00009892302,0.000070971626,0.00032827756,0.000032745218,0.000016968072,0.00061867374],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990689,0.00005353282,0.00033047854,0.00021080108,0.00020173291,0.00013454024],"domain_scores_gemma":[0.99906665,0.0001421607,0.00017239283,0.00028760373,0.00028746307,0.000043753786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044386732,0.00009880345,0.00021408305,0.00008224474,0.00012226854,0.000054115757,0.00006895774,0.00011484298,0.000041546464],"category_scores_gemma":[0.00043728488,0.00009035076,0.00004180849,0.00006240482,0.00011413985,0.00015614775,0.000014313846,0.00010403955,0.0000020797982],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010109825,0.0012734885,0.015937833,0.000780864,0.000039736442,0.0000028321565,0.00070930785,3.194268e-7,0.9703627,0.000018354165,0.000060844137,0.0007038508],"study_design_scores_gemma":[0.0021592907,0.00035663476,0.29945004,0.0004932133,0.00013672191,0.0000040367045,0.00010090845,0.0004744224,0.6966151,0.00010491246,0.00001882311,0.00008591156],"about_ca_topic_score_codex":0.0001982564,"about_ca_topic_score_gemma":0.00015857366,"teacher_disagreement_score":0.2835122,"about_ca_system_score_codex":0.00005924106,"about_ca_system_score_gemma":0.00019474098,"threshold_uncertainty_score":0.36843973},"labels":[],"label_agreement":null},{"id":"W2715315455","doi":"10.1016/j.radonc.2017.06.006","title":"Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation","year":2017,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Radiation; Medicine; Neuroscience; Psychology; Physics; Optics","score_opus":0.013836673752474693,"score_gpt":0.31419587813930866,"score_spread":0.30035920438683394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2715315455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9589998,0.010768795,0.00013911007,0.027927835,0.00038719788,0.00041497685,0.000010354229,0.00007474797,0.0012771761],"genre_scores_gemma":[0.97905093,0.009400141,0.00075426645,0.008499967,0.0003595437,0.00005916762,0.000021139116,0.000023103112,0.0018317519],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991761,0.00007076114,0.00021523748,0.00025340603,0.00009607278,0.0001884647],"domain_scores_gemma":[0.99933106,0.0001188014,0.00016381915,0.0002591933,0.000031981068,0.00009515821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002827373,0.00014579242,0.0003493935,0.00009632529,0.00029953552,0.00006795712,0.000039824386,0.00020001247,0.0002855082],"category_scores_gemma":[0.000057374742,0.0001217587,0.00006446503,0.000045906363,0.00023284454,0.00019965583,0.000012280688,0.00011822306,0.0000029388757],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047441134,0.0001449533,0.29646638,0.000057931033,0.00032308366,0.00006445498,0.0013329582,3.9206896e-7,0.0144624505,0.00016136817,0.0061000763,0.67614186],"study_design_scores_gemma":[0.0075902715,0.00063856697,0.756055,0.000027161677,0.00003846508,0.0001243117,0.000032282165,0.00016682243,0.0008161574,0.00010093071,0.23427804,0.0001320182],"about_ca_topic_score_codex":0.00016860758,"about_ca_topic_score_gemma":0.00011102904,"teacher_disagreement_score":0.67600983,"about_ca_system_score_codex":0.0002577142,"about_ca_system_score_gemma":0.00010682636,"threshold_uncertainty_score":0.49651754},"labels":[],"label_agreement":null},{"id":"W2722553159","doi":"10.1053/j.ajkd.2017.04.026","title":"Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases","year":2017,"lang":"en","type":"article","venue":"American Journal of Kidney Diseases","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Ipilimumab; Nephrotic syndrome; Acute kidney injury; Pembrolizumab; Minimal change disease; Immunology; Focal segmental glomerulosclerosis; Interstitial nephritis; Kidney disease; Internal medicine; Nephrology; Proteinuria; Immune system; Immunotherapy; Kidney","score_opus":0.012299086631508912,"score_gpt":0.30035063145072927,"score_spread":0.28805154481922035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2722553159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99093765,0.0037845185,0.000036154222,0.0046038455,0.00019126062,0.00015621186,0.000083014376,0.000010218539,0.00019712196],"genre_scores_gemma":[0.996284,0.0013421025,0.00041908163,0.0014850402,0.00012525558,0.0000088461165,0.0000041356975,0.000028644938,0.00030289686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987078,0.000035054705,0.0005159576,0.0001395977,0.0004106326,0.00019099271],"domain_scores_gemma":[0.9966664,0.00006620106,0.0018836067,0.00058104086,0.0003069713,0.00049582886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013061734,0.00016414185,0.00066775543,0.0001303982,0.00012953172,0.000037612164,0.00024409824,0.000019670935,0.0003770339],"category_scores_gemma":[0.0005769635,0.00010802754,0.00028561277,0.0001284975,0.0010793956,0.00019785081,0.000020562167,0.000112669695,8.882427e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033671074,0.001283537,0.784288,0.00043870168,0.0070188046,0.0492143,0.0007608297,0.000009912514,0.013670924,0.0000115895855,0.015679635,0.09395272],"study_design_scores_gemma":[0.006696655,0.008275339,0.8779193,0.0036636435,0.0015936308,0.07369019,0.001451561,0.0000041587814,0.0018058912,0.0000250257,0.024530638,0.000343922],"about_ca_topic_score_codex":0.0014977967,"about_ca_topic_score_gemma":0.000009869106,"teacher_disagreement_score":0.09363137,"about_ca_system_score_codex":0.000083319246,"about_ca_system_score_gemma":0.0019618724,"threshold_uncertainty_score":0.4405235},"labels":[],"label_agreement":null},{"id":"W2725962181","doi":"10.1038/cr.2017.90","title":"Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function","year":2017,"lang":"en","type":"article","venue":"Cell Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":328,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research","funders":"Tsinghua University; National Natural Science Foundation of China; EMD Serono; National Science Foundation","keywords":"Cytotoxic T cell; Biology; Immune system; CD8; Cancer immunotherapy; Cancer research; Immune checkpoint; Immunotherapy; Immunology; Antibody; Immunity; In vitro; Biochemistry","score_opus":0.042037585227412994,"score_gpt":0.3243706694996745,"score_spread":0.28233308427226156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2725962181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98182017,0.0019260733,0.000044273736,0.00085290225,0.0002532552,0.0005631952,0.0000072935172,0.000017144443,0.014515693],"genre_scores_gemma":[0.9929113,0.00061359344,0.000016978192,0.00008976127,0.00013623659,0.000041137682,0.000010525513,0.000023984961,0.006156488],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982387,0.00013221885,0.00031884425,0.00025064553,0.0006947243,0.00036489544],"domain_scores_gemma":[0.99854255,0.00008820858,0.00018552286,0.00078654266,0.00032009784,0.00007710179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016058957,0.000113296504,0.00020100478,0.000108559325,0.00059027213,0.0000647388,0.0002503876,0.000086888685,0.00023547183],"category_scores_gemma":[0.00027279643,0.00007895538,0.00016687995,0.00021269836,0.000414685,0.00012182822,0.00013518297,0.00030270393,0.000041514486],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017646748,0.0001227334,0.00081969955,0.00021488564,0.000031118925,0.000006303228,0.00016355967,1.0934563e-7,0.99088466,0.000011226427,0.001805793,0.004175206],"study_design_scores_gemma":[0.0024633147,0.00040347825,0.026284155,0.0003487022,0.000018395445,0.000009177808,0.00025044117,0.000027434882,0.9670444,0.00008351397,0.0029899455,0.00007704706],"about_ca_topic_score_codex":0.0008987504,"about_ca_topic_score_gemma":0.000053677915,"teacher_disagreement_score":0.025464455,"about_ca_system_score_codex":0.0003438059,"about_ca_system_score_gemma":0.00031584938,"threshold_uncertainty_score":0.4539956},"labels":[],"label_agreement":null},{"id":"W2735019816","doi":"10.1016/j.mehy.2017.07.017","title":"Tumor-associated immune aggregates in oral cancer: Their cellular composition and potential prognostic significance","year":2017,"lang":"en","type":"article","venue":"Medical Hypotheses","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; University of British Columbia","funders":"","keywords":"Immune system; Immunotherapy; Cancer; Tumor microenvironment; Immunology; Biology; Basal cell; Cancer immunotherapy; Cancer research; Medicine; Pathology; Internal medicine","score_opus":0.02163821669145152,"score_gpt":0.27292653184986015,"score_spread":0.25128831515840866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735019816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98580134,0.008966977,0.000028889293,0.0042334436,0.000269358,0.00043637326,0.000024308409,0.000052080366,0.00018721263],"genre_scores_gemma":[0.99724823,0.001815291,0.000051600342,0.00049137854,0.00013488888,0.00006857859,0.000020350637,0.000024400426,0.00014530036],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99853,0.00009542172,0.00032975117,0.00029049307,0.00042106234,0.0003332891],"domain_scores_gemma":[0.999131,0.00015842692,0.00020223107,0.0002900258,0.000054136282,0.00016417127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005026265,0.00018787028,0.0004264959,0.000071770235,0.0002478496,0.00007782642,0.00021830178,0.00013708042,0.00039961684],"category_scores_gemma":[0.0005396144,0.00014047894,0.00009075882,0.0000832966,0.00061934825,0.00010568879,0.000065487446,0.00027753282,0.0000053345902],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035963973,0.0013556617,0.32439464,0.00032806315,0.0005067015,0.0016215302,0.0006864938,0.0000027710305,0.38846216,0.000042330787,0.00033026416,0.278673],"study_design_scores_gemma":[0.0062197084,0.00042096293,0.93614304,0.0023810305,0.00011019743,0.000090099114,0.00017871197,0.0011419049,0.05101178,0.00024241331,0.0017322602,0.00032787313],"about_ca_topic_score_codex":0.001988644,"about_ca_topic_score_gemma":0.0002863808,"teacher_disagreement_score":0.61174846,"about_ca_system_score_codex":0.000101144025,"about_ca_system_score_gemma":0.00020197169,"threshold_uncertainty_score":0.5728565},"labels":[],"label_agreement":null},{"id":"W2735569299","doi":"10.1016/j.ejca.2017.06.021","title":"Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis","year":2017,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Society for Medical Oncology; University of Toronto","keywords":"Ipilimumab; Medicine; Meta-analysis; Internal medicine; Adverse effect; Incidence (geometry); Odds ratio; Placebo; Confidence interval; Cancer; Randomized controlled trial; Cochrane Library; Oncology; Immunotherapy; Pathology","score_opus":0.11535894112813506,"score_gpt":0.392580623555264,"score_spread":0.27722168242712897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735569299","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010366284,0.9965369,6.080043e-7,0.000037010035,0.00004322772,0.0017259995,0.00034549888,0.000005005891,0.00026908642],"genre_scores_gemma":[0.002006668,0.99671096,0.00000993887,0.000051918436,0.000021644759,0.00007299509,0.00002067391,0.00006273496,0.0010424515],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99504685,0.0015918203,0.0024529477,0.00030688767,0.00040527075,0.00019623352],"domain_scores_gemma":[0.99179715,0.0000823685,0.0069054943,0.00065860717,0.00041920663,0.00013717003],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014875203,0.0005283522,0.010120654,0.0004561007,0.00004964442,0.000026094516,0.00024965862,0.00006910337,0.00040848224],"category_scores_gemma":[0.00008923545,0.00025007912,0.002801731,0.0006213956,0.00014033208,0.00009240612,0.00002208256,0.00034119585,0.0000017133816],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023706016,0.00020505574,0.0041575953,0.32217622,0.6316873,0.00014497728,0.00010470259,0.0000024312924,1.6393071e-7,1.3706597e-7,0.000052432562,0.04123193],"study_design_scores_gemma":[0.002118121,0.00084704376,0.00426036,0.11649464,0.85605145,0.00003271159,0.0000041256417,5.858684e-7,4.378195e-7,1.1164301e-7,0.019994339,0.00019605806],"about_ca_topic_score_codex":0.000966307,"about_ca_topic_score_gemma":0.00041690865,"teacher_disagreement_score":0.22436419,"about_ca_system_score_codex":0.0005267872,"about_ca_system_score_gemma":0.0005055697,"threshold_uncertainty_score":0.9999952},"labels":[],"label_agreement":null},{"id":"W2735830058","doi":"10.1684/ejd.2017.2973","title":"Azathioprine combination therapy for steroid-refractory hepatic immune system-related adverse events","year":2017,"lang":"en","type":"letter","venue":"European Journal of Dermatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Alberta Innovates - Health Solutions; American Association for the Study of Liver Diseases","keywords":"Medicine; Ipilimumab; Nivolumab; Pneumonitis; Pembrolizumab; Adverse effect; Immune system; Azathioprine; Immunology; Hepatitis; Cytotoxic T cell; Colitis; Pancreatitis; Internal medicine; Immunotherapy; Lung; Disease","score_opus":0.01799094243735956,"score_gpt":0.26592167029395036,"score_spread":0.24793072785659082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735830058","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3284724,0.02325828,0.0012730567,0.6229413,0.014761652,0.003206539,0.000085620544,0.00016723051,0.005833919],"genre_scores_gemma":[0.9307473,0.0020026346,0.00032602958,0.059777338,0.001968987,0.000014799692,0.00032061763,0.00028927223,0.0045530605],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965242,0.00088660815,0.001589759,0.00025307704,0.00038260283,0.00036373065],"domain_scores_gemma":[0.9955385,0.00015325079,0.0031448945,0.0006230524,0.00045762173,0.000082704304],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007915107,0.00038858055,0.001179168,0.00043203315,0.00017916229,0.000018764216,0.00055716303,0.00033968108,0.00007619599],"category_scores_gemma":[0.00009683655,0.0003064094,0.0007432487,0.000065388725,0.00015236382,0.00014604897,0.00004354439,0.001417249,0.00005782242],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014928309,0.0009999212,0.0037875539,0.004940635,0.010480073,0.06472993,0.0011995004,0.0000025995848,0.0135574695,0.00004774664,0.8543532,0.030973075],"study_design_scores_gemma":[0.026679384,0.002118308,0.010853548,0.0025833414,0.00057440734,0.039180312,0.00006104684,0.0000413213,0.0008738324,0.000019914569,0.9166094,0.00040516007],"about_ca_topic_score_codex":0.0000054125544,"about_ca_topic_score_gemma":3.0520894e-7,"teacher_disagreement_score":0.60227484,"about_ca_system_score_codex":0.0002216526,"about_ca_system_score_gemma":0.00023755102,"threshold_uncertainty_score":0.9999388},"labels":[],"label_agreement":null},{"id":"W2735904407","doi":"10.1038/bjc.2017.220","title":"HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer","year":2017,"lang":"en","type":"review","venue":"British Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":442,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Immune system; Tumor microenvironment; Immune checkpoint; CD8; Cancer; Immunology; Immunotherapy; Cancer research; Cancer cell; Medicine; Biology; Internal medicine","score_opus":0.07567563179933269,"score_gpt":0.39825864361742486,"score_spread":0.3225830118180922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735904407","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014658088,0.99557674,0.0000017417002,0.00021449085,0.0014190465,0.0008920622,0.00012216721,0.0000045041443,0.00030345024],"genre_scores_gemma":[0.00081806444,0.99686074,0.00007854019,0.00012527636,0.0009182915,0.00009488565,0.0000043071796,0.000062078354,0.0010378414],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99703187,0.00019655439,0.0017282988,0.00020111416,0.0005256651,0.00031652628],"domain_scores_gemma":[0.9961484,0.00026256594,0.0028590464,0.00033506955,0.00031096654,0.00008394772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010218109,0.0002968175,0.0022324757,0.00017310717,0.0001102698,0.00010889533,0.0005697033,0.00023971267,0.0005372389],"category_scores_gemma":[0.00027759245,0.0001932818,0.00080296054,0.00031950654,0.00024724336,0.0001475214,0.000051484814,0.0010311828,0.0000013540089],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037171796,0.00008450526,0.000169921,0.0078018843,0.00080082146,0.00053104095,0.00009111709,0.0000044402964,0.00007090719,9.314536e-7,0.0013399717,0.98873276],"study_design_scores_gemma":[0.0015195346,0.0002456489,0.0019593092,0.17572783,0.001387701,0.0028756093,0.00004685636,0.0000018165174,0.00006385074,0.000003210413,0.81597507,0.00019354458],"about_ca_topic_score_codex":0.005237087,"about_ca_topic_score_gemma":0.0025409346,"teacher_disagreement_score":0.9885392,"about_ca_system_score_codex":0.00038733298,"about_ca_system_score_gemma":0.0039468696,"threshold_uncertainty_score":0.7916944},"labels":[],"label_agreement":null},{"id":"W2736093966","doi":"10.1136/gutjnl-2017-314472.251","title":"PWE-006 Differential immune responses between proximal and distal colorectal cancer","year":2017,"lang":"en","type":"article","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Colorectal cancer; Immune system; Medicine; Dendritic cell; Lymph node; C-C chemokine receptor type 7; CD86; Lymph; Tumor microenvironment; Cancer research; Cancer; Pathology; T cell; Immunology; Internal medicine; Chemokine","score_opus":0.022998172268866537,"score_gpt":0.3180260084167092,"score_spread":0.29502783614784267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736093966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945229,0.00062075024,0.00006544999,0.0019889583,0.0002312699,0.00032543886,0.00006514761,0.000044908655,0.0021351182],"genre_scores_gemma":[0.9901328,0.00018645299,0.00007129128,0.00005899209,0.00033243455,0.00003423618,0.000017505878,0.000016871963,0.009149417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99919724,0.000023228346,0.0001857224,0.00021759927,0.00016080981,0.00021539249],"domain_scores_gemma":[0.9994748,0.000043436412,0.00009544354,0.000266949,0.000033921613,0.00008541467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010038296,0.00013911669,0.00027241927,0.000041249485,0.00032791708,0.00013546734,0.00010931354,0.00008309823,0.0005283817],"category_scores_gemma":[0.000043399283,0.00009971235,0.00008841509,0.000024394953,0.00033816876,0.00014589181,0.00008439669,0.00011472833,0.0000035197768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013153898,0.00008931363,0.4744025,0.000064401116,0.00039586154,0.000024445366,0.0002211062,8.403269e-9,0.456157,0.00009211313,0.0005758941,0.054823454],"study_design_scores_gemma":[0.003140119,0.00034525915,0.91171974,0.000064419306,0.00009456775,0.000013684464,0.00004617572,0.00001194304,0.081197925,0.000014764524,0.0032200757,0.00013131219],"about_ca_topic_score_codex":0.0016849424,"about_ca_topic_score_gemma":0.00018096023,"teacher_disagreement_score":0.43731725,"about_ca_system_score_codex":0.00005235373,"about_ca_system_score_gemma":0.000095819036,"threshold_uncertainty_score":0.57854086},"labels":[],"label_agreement":null},{"id":"W2736373206","doi":"10.1200/jco.2017.35.15_suppl.10525","title":"Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1<sup>+</sup> advanced, relapsed, or refractory solid tumor or lymphoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Response Evaluation Criteria in Solid Tumors; Refractory (planetary science); Internal medicine; Metastatic melanoma; Lymphoma; Phases of clinical research; Oncology; Melanoma; Cancer; Progressive disease; Disease; Surgery; Nuclear medicine; Clinical trial; Immunotherapy; Cancer research","score_opus":0.0674205008324529,"score_gpt":0.4443536176567062,"score_spread":0.37693311682425334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736373206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99618644,0.00042826182,0.000013632243,0.00051168416,0.0010726167,0.0012050765,0.000020783269,0.000017347267,0.00054415787],"genre_scores_gemma":[0.9933852,0.0022205177,0.0016082235,0.00095129537,0.000841227,0.000038644343,0.000004804032,0.00007128929,0.00087880867],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9925813,0.0006834722,0.0046380255,0.0005708377,0.000933793,0.00059259334],"domain_scores_gemma":[0.98855084,0.002521172,0.0066215605,0.0009575421,0.0008422226,0.00050664844],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024543738,0.000449251,0.0031766153,0.00045243555,0.00018194974,0.000027447788,0.0007708463,0.00045236354,0.00040478862],"category_scores_gemma":[0.0074631427,0.00024760835,0.0004792089,0.00038866384,0.0004306846,0.0005620115,0.00014822223,0.0010984986,0.000010251989],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59310395,0.03116002,0.07115124,0.00012778657,0.00049153465,0.003778843,0.0007059772,0.000041123145,0.000066183784,5.5577755e-7,0.000619747,0.29875305],"study_design_scores_gemma":[0.37374055,0.301103,0.30345818,0.00045894022,0.0008103082,0.00057914905,0.002536375,0.000113691916,0.000061869345,0.0000074024065,0.016788619,0.0003418972],"about_ca_topic_score_codex":0.00009094502,"about_ca_topic_score_gemma":0.0010529609,"teacher_disagreement_score":0.29841113,"about_ca_system_score_codex":0.0006264551,"about_ca_system_score_gemma":0.0054343063,"threshold_uncertainty_score":0.9999976},"labels":[],"label_agreement":null},{"id":"W2739577140","doi":"10.1158/1538-7445.am2017-lb-055","title":"Abstract LB-055: Overall survival and safety experience from an expanded access program (EAP) of nivolumab (NIVO) for patients with advanced melanoma (MEL) who progressed after prior ipilimumab (IPI) treatment","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; London Health Sciences Centre; McMaster University","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Expanded access; Adverse effect; Oncology; Melanoma; Stage (stratigraphy); Immunotherapy; Cancer","score_opus":0.06117101554433939,"score_gpt":0.43848929324547986,"score_spread":0.37731827770114046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739577140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930943,0.0014415615,0.00000529046,0.00023705508,0.00017097346,0.004445674,0.00033683225,0.00003798692,0.00023028941],"genre_scores_gemma":[0.9943517,0.0010727021,0.00046238178,0.000023001696,0.00017080728,0.0034744425,0.00008284659,0.00005631356,0.00030580172],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974683,0.000071109214,0.00036489434,0.00064616883,0.0007666411,0.00068287057],"domain_scores_gemma":[0.99790275,0.00012420262,0.00023119405,0.0009476896,0.0005123465,0.00028179967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002971997,0.00028586344,0.0005552643,0.000109757595,0.0004221844,0.00021534105,0.0004052369,0.00012925318,0.00024546226],"category_scores_gemma":[0.000060110608,0.00020332776,0.00010165096,0.000109578905,0.00069023774,0.0007524439,0.000115745475,0.000179076,6.099514e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11361209,0.0016251808,0.4153545,0.00024706183,0.00035811454,0.000014128064,0.0027175345,9.124723e-7,0.0034525618,0.0000040031014,0.000049688104,0.46256423],"study_design_scores_gemma":[0.024592238,0.0058531235,0.9459767,0.00065073115,0.000047859194,7.292732e-7,0.00040909485,0.000031051,0.018046487,0.000012915508,0.004126815,0.00025230195],"about_ca_topic_score_codex":0.0028985532,"about_ca_topic_score_gemma":0.0012954903,"teacher_disagreement_score":0.5306222,"about_ca_system_score_codex":0.00048619282,"about_ca_system_score_gemma":0.00046987674,"threshold_uncertainty_score":0.8291465},"labels":[],"label_agreement":null},{"id":"W2740164441","doi":"10.1158/1538-7445.am2017-575","title":"Abstract 575: PD-L1 positive tumor-infiltrating lymphocytes and mutational load in breast cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Breast cancer; Tumor-infiltrating lymphocytes; Medicine; PD-L1; Oncology; Immunotherapy; FOXP3; Internal medicine; Cancer; CD8; Immune system; Immune checkpoint; Immunology","score_opus":0.057195156088499045,"score_gpt":0.4192581731660861,"score_spread":0.36206301707758703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740164441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98396015,0.0048006955,7.8402144e-7,0.005834075,0.00013356093,0.00039273466,0.00017631841,0.000014302537,0.0046874047],"genre_scores_gemma":[0.99691886,0.0014812964,0.000033889602,0.00036206638,0.00036831497,0.00019186074,0.000008953623,0.000023004939,0.0006117397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982488,0.000048361006,0.00022630101,0.00035872398,0.0006600899,0.0004577022],"domain_scores_gemma":[0.99892145,0.00015614246,0.00009548716,0.00029578517,0.00039029957,0.00014084463],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00080312096,0.00013607494,0.00022509949,0.0001452906,0.0004549185,0.0001665937,0.00018081443,0.00007100876,0.0011846377],"category_scores_gemma":[0.000105567466,0.0001185206,0.00005131762,0.00015646813,0.0005480713,0.00023955156,0.00007329561,0.00037023742,0.000012135817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012765271,0.00019799938,0.43394887,0.00047054133,0.00032144462,0.0006679692,0.0021982454,0.000017956361,0.3765602,0.00015301048,0.004808341,0.16789013],"study_design_scores_gemma":[0.0035125988,0.00006710638,0.9773505,0.0009480972,0.000010101181,0.00011848861,0.0003738238,0.00007611063,0.016457986,0.000072164505,0.0008750499,0.00013797396],"about_ca_topic_score_codex":0.03407469,"about_ca_topic_score_gemma":0.0028979897,"teacher_disagreement_score":0.5434016,"about_ca_system_score_codex":0.0012534802,"about_ca_system_score_gemma":0.0019854142,"threshold_uncertainty_score":0.99972844},"labels":[],"label_agreement":null},{"id":"W2740300715","doi":"10.1158/1538-7445.am2017-5599","title":"Abstract 5599: Soluble PD-L1 as a surrogate biomarker of metastatic progression and resistance to antiangiogenic therapy","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Biomarker; Melanoma; Cancer; Cancer research; PD-L1; Tumor progression; Oncology; Immune checkpoint; Metastasis; Immunotherapy; Internal medicine; Biology","score_opus":0.14572625433992165,"score_gpt":0.47668867404966764,"score_spread":0.330962419709746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740300715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676389,0.021992993,0.000003736009,0.0055871313,0.00016918163,0.0010692016,0.000026785683,0.000020011124,0.003492056],"genre_scores_gemma":[0.9881611,0.007439029,0.00035023346,0.00014117717,0.00006997785,0.00018382195,0.0000054538277,0.00003614692,0.0036130967],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99793357,0.00008927527,0.00029351094,0.00041797728,0.00075112184,0.00051457493],"domain_scores_gemma":[0.99831206,0.00010857599,0.00015015657,0.0008256937,0.00037105588,0.00023249027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015695404,0.00015974973,0.00034757872,0.00024763448,0.00043144944,0.00011398434,0.00032333244,0.00007243705,0.0006331405],"category_scores_gemma":[0.00017868854,0.00012112782,0.00012118221,0.0002925276,0.0005717058,0.00015038352,0.00011968378,0.00021079362,0.000023237835],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018133415,0.00017480673,0.0079007875,0.0004165748,0.00044709668,0.00009493651,0.00055474223,1.4330875e-7,0.84852296,0.00006156943,0.009310313,0.11438267],"study_design_scores_gemma":[0.006945249,0.00088943256,0.50916415,0.0021030926,0.00004736255,0.000023247663,0.0002645278,0.000007268669,0.3792789,0.00042498743,0.100549884,0.00030187948],"about_ca_topic_score_codex":0.0014083677,"about_ca_topic_score_gemma":0.000490991,"teacher_disagreement_score":0.5012634,"about_ca_system_score_codex":0.00011781421,"about_ca_system_score_gemma":0.0005014228,"threshold_uncertainty_score":0.69324446},"labels":[],"label_agreement":null},{"id":"W2740476111","doi":"10.1001/jamaoncol.2017.2085","title":"Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer","year":2017,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of Ottawa; Ottawa Hospital; Queen's University; University of British Columbia","funders":"","keywords":"Medicine; Lapatinib; Taxane; Trastuzumab; Oncology; Internal medicine; Metastatic breast cancer; Breast cancer; Docetaxel; Tumor-infiltrating lymphocytes; Cancer; Immunotherapy","score_opus":0.01663913112658683,"score_gpt":0.33253364601581675,"score_spread":0.3158945148892299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740476111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927795,0.0005762086,0.0000019103475,0.0025740208,0.00014477562,0.00041322282,0.00006894592,0.000014440392,0.003427002],"genre_scores_gemma":[0.99854314,0.00012747038,0.00037209902,0.0006858682,0.000077160985,0.00009784082,0.0000053650347,0.000017135215,0.00007389035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869233,0.000119753066,0.00051156024,0.000231362,0.00015031666,0.00029468417],"domain_scores_gemma":[0.99888694,0.00029029502,0.000429493,0.0002764745,0.00006514405,0.00005162822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052143197,0.00014833857,0.00062918494,0.0001634029,0.0000762401,0.000020761487,0.00016579774,0.000097492295,0.00013696271],"category_scores_gemma":[0.00023215234,0.00012471939,0.0000999939,0.00011011987,0.00019809179,0.0001659065,0.000057186975,0.00021303922,0.000002369192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019413896,0.0002687596,0.85499644,0.000062851876,0.00013893483,0.0001326975,0.0012517144,0.000012198312,0.082985334,0.000020607671,0.000023462011,0.058165584],"study_design_scores_gemma":[0.00752886,0.0004252565,0.97399235,0.00044826992,0.00004880557,0.00019828691,0.0017211296,0.0006851727,0.014638801,0.00004758206,0.00015833454,0.00010717437],"about_ca_topic_score_codex":0.015794577,"about_ca_topic_score_gemma":0.008967754,"teacher_disagreement_score":0.11899587,"about_ca_system_score_codex":0.00071725284,"about_ca_system_score_gemma":0.0006085735,"threshold_uncertainty_score":0.9907593},"labels":[],"label_agreement":null},{"id":"W2740659912","doi":"10.1158/1538-7445.am2017-ct021","title":"Abstract CT021: Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Nivolumab; Medicine; Internal medicine; Immune system; Oncology; Hazard ratio; Context (archaeology); PD-L1; Immunotherapy; Gastroenterology; Cancer; Immunology; Confidence interval; Biology","score_opus":0.13261298521661807,"score_gpt":0.4479654569332892,"score_spread":0.31535247171667113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740659912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710485,0.02319696,0.000003042759,0.0008877518,0.00027668633,0.0006078703,0.00010002025,0.000055787157,0.0038234289],"genre_scores_gemma":[0.99123836,0.0038841402,0.00013012328,0.000071834715,0.0003011043,0.00015072506,0.000086721935,0.00005750478,0.004079473],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973248,0.00013606984,0.00046056253,0.0005714429,0.00079358165,0.00071349106],"domain_scores_gemma":[0.99800897,0.00011991196,0.00028603896,0.0010170524,0.00035007944,0.0002179735],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011132429,0.00025849795,0.0005501518,0.00015151313,0.00097040704,0.00032198505,0.00046369203,0.00018043254,0.001878572],"category_scores_gemma":[0.00022848931,0.00020662435,0.00018810965,0.00017022791,0.0005624159,0.00025996997,0.00025500136,0.0007830099,0.000022266993],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034041328,0.00016682966,0.013499347,0.00013755291,0.00020711131,0.000089722314,0.00040646215,0.0000017644182,0.97747207,0.0000013199393,0.0010253419,0.0035883524],"study_design_scores_gemma":[0.0035799968,0.00015375232,0.34716377,0.0005923033,0.000037651156,0.0000028832949,0.00040772549,0.000055649536,0.6460324,0.000036009777,0.0017581903,0.00017968618],"about_ca_topic_score_codex":0.01444583,"about_ca_topic_score_gemma":0.00014536326,"teacher_disagreement_score":0.33366442,"about_ca_system_score_codex":0.00044172432,"about_ca_system_score_gemma":0.00048018052,"threshold_uncertainty_score":0.99903387},"labels":[],"label_agreement":null},{"id":"W2741071796","doi":"10.1158/1538-7445.am2017-608","title":"Abstract 608: Augmenting and broadening T cell responses against mutated tumour neo-antigens","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"CTL*; Antigen; Immunology; Cytotoxic T cell; Immune system; Immunotherapy; Vaccination; Context (archaeology); Cancer immunotherapy; FOXP3; Tumor antigen; Cancer research; Biology; Medicine; CD8; In vitro; Genetics","score_opus":0.11606581956224846,"score_gpt":0.4364360629494028,"score_spread":0.32037024338715436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741071796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98361826,0.0041893143,0.000002369984,0.003009412,0.00018141851,0.00039521747,0.000019638177,0.000040746938,0.008543615],"genre_scores_gemma":[0.9867017,0.0033091025,0.00007284228,0.00016312173,0.00027915233,0.000047436737,0.0000075628323,0.00003729224,0.009381768],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981414,0.000082945255,0.00023966629,0.00038911973,0.0005395204,0.0006073659],"domain_scores_gemma":[0.9987978,0.00015306243,0.00011947124,0.0005128207,0.0002247657,0.00019213294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001323794,0.00014514285,0.00023481857,0.00020780116,0.0010648653,0.0002952686,0.00025439268,0.00009688414,0.00035385176],"category_scores_gemma":[0.00025314113,0.0001139015,0.000075129916,0.00014100967,0.00047109625,0.00016270166,0.00015268681,0.0005406838,0.000029366569],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027541043,0.00004065477,0.018984465,0.00018443656,0.000079453544,0.00022719709,0.000528374,0.0000011490539,0.9258714,0.0000021909952,0.0033444716,0.04798214],"study_design_scores_gemma":[0.0036445907,0.00017881811,0.5030547,0.00075063546,0.000024796971,0.00002683619,0.0007322084,0.00006191354,0.46265334,0.000016872324,0.028637484,0.00021780893],"about_ca_topic_score_codex":0.0019231687,"about_ca_topic_score_gemma":0.00012961555,"teacher_disagreement_score":0.48407024,"about_ca_system_score_codex":0.00019296892,"about_ca_system_score_gemma":0.0004724108,"threshold_uncertainty_score":0.8190191},"labels":[],"label_agreement":null},{"id":"W2741245320","doi":"10.1158/1538-7445.am2017-ct075","title":"Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067)","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Placebo; Hazard ratio; Oncology; Gastroenterology; Cancer; Immunotherapy; Confidence interval; Pathology","score_opus":0.06454676551010405,"score_gpt":0.3935429647153974,"score_spread":0.3289961992052933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741245320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99260795,0.00028858407,0.0000015763414,0.0005319189,0.00026971253,0.0027427175,0.0009340172,0.000029533003,0.0025940035],"genre_scores_gemma":[0.9973155,0.00072179356,0.00007316449,0.00002100841,0.00014957786,0.00032392095,0.0003420864,0.00006305497,0.0009898735],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99655527,0.0001492805,0.00064788805,0.00073143217,0.0011933119,0.00072281546],"domain_scores_gemma":[0.9972251,0.0002735664,0.00044829978,0.0013633205,0.00047181698,0.00021791687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006752751,0.00034235656,0.0008690629,0.0002611901,0.00028581574,0.0000894135,0.00042135076,0.00015733184,0.00035722338],"category_scores_gemma":[0.00013272035,0.00023661758,0.00012723393,0.0002544485,0.00057889376,0.0003103579,0.00007579215,0.0004300475,0.000007878902],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93391156,0.0028677795,0.010720823,0.000064356886,0.0006115,0.00012078672,0.00092623464,0.00000762927,0.010721288,0.0000063578773,0.00022902268,0.03981267],"study_design_scores_gemma":[0.7277348,0.019085763,0.24009226,0.0009072899,0.00007210392,9.853159e-7,0.0002304047,0.000028303404,0.010270478,0.00002360068,0.0012720166,0.0002820067],"about_ca_topic_score_codex":0.030924348,"about_ca_topic_score_gemma":0.011161885,"teacher_disagreement_score":0.22937144,"about_ca_system_score_codex":0.0009664787,"about_ca_system_score_gemma":0.0011399095,"threshold_uncertainty_score":0.97552884},"labels":[],"label_agreement":null},{"id":"W2741345495","doi":"10.1158/1538-7445.am2017-ct039","title":"Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Tolerability; Pharmacokinetics; Immunogenicity; Antibody; Pharmacodynamics; Immunotherapy; CD28; Internal medicine; Cancer; Oncology; Agonist; Pharmacology; T cell; Immunology; Adverse effect; Receptor; Immune system","score_opus":0.09170124266370266,"score_gpt":0.46638821067488734,"score_spread":0.3746869680111847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741345495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959918,0.00014821063,7.6068875e-7,0.00020145267,0.000029815616,0.0033812704,0.00003369163,0.000010003122,0.00020295753],"genre_scores_gemma":[0.99932355,0.00009609119,0.000038798644,0.00002285604,0.000016158327,0.00032592154,0.000070753194,0.00004068827,0.0000652057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977283,0.00014335623,0.0004039871,0.0005320207,0.0007288797,0.00046344358],"domain_scores_gemma":[0.9982822,0.000046244506,0.00025699372,0.00068243936,0.0005749348,0.00015716862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006819758,0.00020217372,0.00054210384,0.00039219222,0.0002710805,0.000167346,0.00042926558,0.00007666193,0.00003885065],"category_scores_gemma":[0.00007960606,0.00015741575,0.00001024681,0.000558204,0.00039503997,0.0005594955,0.00013195713,0.00049833057,7.2867755e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17526306,0.022605069,0.693554,0.0002680452,0.00016587494,0.00019865127,0.0025576132,0.0000034974014,0.06375692,0.000003344903,0.000022537903,0.041601405],"study_design_scores_gemma":[0.14504121,0.017911049,0.8296299,0.0008530805,0.00001619494,0.0000054308007,0.0009139559,0.000037906142,0.0053966697,0.0000049433443,0.000020178466,0.0001694849],"about_ca_topic_score_codex":0.0063727987,"about_ca_topic_score_gemma":0.012484534,"teacher_disagreement_score":0.13607591,"about_ca_system_score_codex":0.00034799264,"about_ca_system_score_gemma":0.00091448316,"threshold_uncertainty_score":0.9633808},"labels":[],"label_agreement":null},{"id":"W2741346996","doi":"10.3233/kca-170010","title":"Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward","year":2017,"lang":"en","type":"review","venue":"Kidney Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; McMaster University","funders":"ECOG-ACRIN Cancer Research Group; European Association of Urology; American College of Radiology Imaging Network; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Perioperative; Nephrectomy; Oncology; Adjuvant therapy; Internal medicine; Clinical trial; Surgery; Immunotherapy; Chemotherapy; Kidney; Cancer","score_opus":0.07852159444762236,"score_gpt":0.39968673167374524,"score_spread":0.3211651372261229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741346996","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026310929,0.9901512,0.000016743546,0.0015423726,0.000581217,0.003405407,0.00047674627,0.00002033234,0.003779662],"genre_scores_gemma":[0.00007323656,0.9890068,0.00004673663,0.00091136066,0.00031369433,0.0026343502,0.00014381771,0.00007782469,0.006792133],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980246,0.00010163083,0.0006436967,0.00048787575,0.00026617906,0.00047605316],"domain_scores_gemma":[0.9986206,0.00007660027,0.0003086671,0.0007369087,0.00003121107,0.00022596732],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028676365,0.00058973866,0.0019855383,0.00016020155,0.00026193654,0.00010332261,0.0002890316,0.00017893872,0.000632521],"category_scores_gemma":[0.00003393125,0.00030391244,0.000849223,0.00023948816,0.00018304297,0.00011433846,0.00001815578,0.0003620767,0.00003557982],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020838279,0.00009760275,0.000024695393,0.0042999806,0.0010109671,0.000085338324,0.0016882538,3.1248325e-7,0.0000055914697,0.000010774152,0.0019073308,0.9906608],"study_design_scores_gemma":[0.0028499612,0.00037687688,0.000040032264,0.022712277,0.0016342326,0.00008254757,0.00007549997,0.000008634015,0.000019570212,0.000006498469,0.9718605,0.0003333533],"about_ca_topic_score_codex":0.0024693008,"about_ca_topic_score_gemma":0.00063049584,"teacher_disagreement_score":0.9903274,"about_ca_system_score_codex":0.0014451116,"about_ca_system_score_gemma":0.003959899,"threshold_uncertainty_score":0.9999413},"labels":[],"label_agreement":null},{"id":"W2741722460","doi":"10.1158/1538-7445.am2017-ct070","title":"Abstract CT070: A open-label phase 3b/4 safety trial of flat-dose nivolumab in combination with ipilimumab in patients with advanced non-small cell lung cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré de Santé et de Services Sociaux du Bas-Saint-Laurent","funders":"","keywords":"Nivolumab; Medicine; Ipilimumab; Internal medicine; Oncology; Lung cancer; Adverse effect; Combination therapy; Discontinuation; Cancer; Immunotherapy","score_opus":0.057571217029514475,"score_gpt":0.4162801374752172,"score_spread":0.35870892044570274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741722460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906305,0.000754517,0.000006348629,0.00050354406,0.00019677482,0.005425888,0.00009037315,0.000010135056,0.0023818957],"genre_scores_gemma":[0.99708664,0.0010718966,0.00012410796,0.000045923953,0.000057673704,0.00086777617,0.00004703966,0.000057226673,0.0006417124],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99718493,0.000109551285,0.0005557037,0.0005872742,0.0009080088,0.00065451773],"domain_scores_gemma":[0.997921,0.00010590823,0.00035900227,0.0008840925,0.0005813502,0.00014867367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011677239,0.00025066372,0.00061582855,0.00038482083,0.0002525833,0.000103852675,0.00067445997,0.00014116096,0.0002165965],"category_scores_gemma":[0.00006504664,0.00019639371,0.000042838707,0.00054688705,0.00036837562,0.00046739198,0.00016374205,0.0006940511,0.0000023599503],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78007317,0.005097571,0.08137662,0.00060127355,0.00015188758,0.000053423104,0.0011071061,0.000023557826,0.023483975,0.0000056199174,0.00035098247,0.10767479],"study_design_scores_gemma":[0.6266828,0.0067111496,0.35112825,0.0027390362,0.0000356032,5.528665e-7,0.00019017066,0.0001485485,0.011670183,0.0000070465435,0.000421402,0.00026523936],"about_ca_topic_score_codex":0.014663556,"about_ca_topic_score_gemma":0.0115328,"teacher_disagreement_score":0.2697516,"about_ca_system_score_codex":0.0013363877,"about_ca_system_score_gemma":0.0022362126,"threshold_uncertainty_score":0.9918979},"labels":[],"label_agreement":null},{"id":"W2743419024","doi":"10.1093/annonc/mdx286","title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","year":2017,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":921,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Rash; Nivolumab; Immunology; Pneumonitis; Cancer; Immunotherapy; Lung","score_opus":0.1276813283897447,"score_gpt":0.41766562727838813,"score_spread":0.2899842988886434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743419024","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006649307,0.9944398,9.930897e-7,0.00035557136,0.0003925106,0.0034235106,0.000119266486,0.000011876947,0.0005915708],"genre_scores_gemma":[0.0024060255,0.99679726,0.0000189576,0.000072295596,0.000051573385,0.00014280513,0.00011669106,0.00005342549,0.00034093283],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9931529,0.0005903462,0.0052095773,0.00038648525,0.0003509851,0.00030969325],"domain_scores_gemma":[0.9897381,0.00028855342,0.008304123,0.0011736517,0.00040141746,0.00009415533],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027948348,0.00048413905,0.008362968,0.0003360725,0.00004181751,0.0000023749035,0.00042778975,0.000601493,0.00016520968],"category_scores_gemma":[0.00041881524,0.0003508773,0.0022918435,0.00021523572,0.0003262661,0.000069770336,0.00016239667,0.00043938344,0.000011982788],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023155726,0.00036224144,0.00001660614,0.8680839,0.0022010305,0.000038943548,0.00010329901,1.1181729e-8,0.0003502142,0.000014006812,0.00029408233,0.12830412],"study_design_scores_gemma":[0.0015317224,0.0017456486,0.0002147749,0.7563117,0.0029772818,0.00032977058,0.00004907003,2.3128419e-7,0.00028761732,0.000007953844,0.23632382,0.00022038196],"about_ca_topic_score_codex":0.00016558442,"about_ca_topic_score_gemma":0.000006503562,"teacher_disagreement_score":0.23602973,"about_ca_system_score_codex":0.000109777306,"about_ca_system_score_gemma":0.00064245146,"threshold_uncertainty_score":0.9998943},"labels":[],"label_agreement":null},{"id":"W2744685612","doi":"10.1097/pap.0000000000000161","title":"Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors","year":2017,"lang":"en","type":"review","venue":"Advances in Anatomic Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":799,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of British Columbia; University of Victoria; BC Cancer Agency","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Breast Cancer Research Foundation","keywords":"Medicine; Oncology; Tumor-infiltrating lymphocytes; Immunotherapy; Biomarker; Melanoma; Internal medicine; Cancer; Medical physics; Cancer research","score_opus":0.05062480522551941,"score_gpt":0.38405874683422947,"score_spread":0.33343394160871004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744685612","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37204605,0.622282,0.0001748242,0.00032825003,0.00023869335,0.0045438022,0.0003053316,0.000011348782,0.00006964343],"genre_scores_gemma":[0.49687427,0.46578068,0.035313305,0.00031228078,0.0002757709,0.0011323094,0.0001802228,0.00012356487,0.000007576407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99303305,0.0018310684,0.0023037535,0.0015982906,0.0003197086,0.00091413973],"domain_scores_gemma":[0.9894362,0.0073291934,0.0022365297,0.0007007295,0.000120723525,0.00017663231],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005171733,0.0009745901,0.0038906645,0.0007017198,0.00031529725,0.00015807079,0.00051708164,0.00041518582,0.000004108751],"category_scores_gemma":[0.0019312162,0.0007035153,0.00037179128,0.00041109734,0.0012689946,0.0004068938,0.0005332191,0.00093992666,5.0787513e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066943597,0.0004295014,0.5967037,0.026037663,0.000117642914,0.0036328372,0.0011769121,5.4495615e-7,0.003220685,0.00004463047,0.000044203996,0.3618973],"study_design_scores_gemma":[0.07493242,0.006215068,0.7445749,0.07350619,0.003477784,0.06470762,0.003725216,0.0018044494,0.00067818095,0.00066101796,0.02293951,0.0027776437],"about_ca_topic_score_codex":0.0009903196,"about_ca_topic_score_gemma":0.0009315208,"teacher_disagreement_score":0.35911965,"about_ca_system_score_codex":0.0008285005,"about_ca_system_score_gemma":0.0024078009,"threshold_uncertainty_score":0.9995416},"labels":[],"label_agreement":null},{"id":"W2745458550","doi":"10.21037/atm.2017.08.14","title":"EGFR mutation positive non-small cell lung cancer: can we identify predictors of benefit from immune checkpoint inhibitors","year":2017,"lang":"en","type":"letter","venue":"Annals of Translational Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Pembrolizumab; Atezolizumab; Nivolumab; Docetaxel; Medicine; Oncology; Epidermal growth factor receptor; Lung cancer; Internal medicine; Chemotherapy; Immunotherapy; Cancer; Cancer research","score_opus":0.029840213715639777,"score_gpt":0.31711278592186914,"score_spread":0.28727257220622937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745458550","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1688857,0.037230838,0.00010930031,0.78638536,0.0019287438,0.0013513911,0.003145274,0.000030938125,0.0009324519],"genre_scores_gemma":[0.8760151,0.016396662,0.0003525626,0.07385976,0.013497796,0.00017819834,0.015881643,0.00024054322,0.0035777166],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9960644,0.00006578888,0.0016492052,0.00057462696,0.0012485683,0.00039739432],"domain_scores_gemma":[0.9963894,0.00034461572,0.0016706525,0.0006180294,0.00085275754,0.00012454332],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045178327,0.00054171425,0.0014174647,0.0005012803,0.00011609077,0.000013104519,0.00037203578,0.00076394004,0.0006455607],"category_scores_gemma":[0.00005085247,0.00042316222,0.0006323509,0.0002201997,0.0005773717,0.00012550798,0.00002411271,0.00095136143,0.0000018182936],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008836192,0.00060937187,0.027504183,0.009570113,0.01147706,0.00076921505,0.01831266,0.00012926523,0.21346289,0.000010652926,0.6732011,0.03611731],"study_design_scores_gemma":[0.01920353,0.0025570006,0.47197357,0.04106759,0.005470861,0.000061400446,0.00041879274,0.00033353904,0.37741408,0.0011625327,0.07894523,0.0013918718],"about_ca_topic_score_codex":0.016565165,"about_ca_topic_score_gemma":0.00035357216,"teacher_disagreement_score":0.7125256,"about_ca_system_score_codex":0.00008650723,"about_ca_system_score_gemma":0.000596072,"threshold_uncertainty_score":0.999822},"labels":[],"label_agreement":null},{"id":"W2745601792","doi":"10.1200/jco.2017.35.15_suppl.9011","title":"KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Discontinuation; Internal medicine; Oncology; Cancer; Immunotherapy","score_opus":0.06695172355110598,"score_gpt":0.42704922656710764,"score_spread":0.36009750301600163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745601792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992025,0.00007722511,0.00011028556,0.0023963046,0.00075839745,0.00043341165,0.000014228878,0.00000955292,0.0041755517],"genre_scores_gemma":[0.9946301,0.00026343967,0.0028448084,0.0008255159,0.0006546277,0.000007345692,0.000011233553,0.000030372206,0.00073254574],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979012,0.00011070217,0.0011666254,0.00020104641,0.0003589513,0.0002614516],"domain_scores_gemma":[0.99558264,0.0007489133,0.0022524726,0.0003602596,0.00080105115,0.00025468162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010245511,0.00016706772,0.0012413833,0.00006298373,0.00013516059,0.000024275405,0.00023660641,0.00025804545,0.00010583064],"category_scores_gemma":[0.0010394666,0.0000928287,0.0003319519,0.000036877656,0.0003460992,0.00019561652,0.000023049493,0.0004596899,0.0000038779785],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42547795,0.0028137465,0.3969409,0.000029214245,0.0010413326,0.00012676087,0.000025344107,0.0000038198123,0.000081330516,0.000034041717,0.0019445478,0.17148103],"study_design_scores_gemma":[0.1126812,0.059316956,0.75007075,0.00016918489,0.0003408525,0.000042583226,0.000020691585,0.000009032765,0.00003789448,0.00003335083,0.07715861,0.00011887288],"about_ca_topic_score_codex":0.000039189403,"about_ca_topic_score_gemma":0.000074886135,"teacher_disagreement_score":0.3531299,"about_ca_system_score_codex":0.00013515682,"about_ca_system_score_gemma":0.00088812655,"threshold_uncertainty_score":0.37854445},"labels":[],"label_agreement":null},{"id":"W2747107882","doi":"10.1016/s0140-6736(17)31601-x","title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1239,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Ipilimumab; Medicine; Open label; Oncology; Open label study; Internal medicine; Clinical trial; Adverse effect; Immunotherapy; Cancer","score_opus":0.13387247519936102,"score_gpt":0.4107823894404024,"score_spread":0.2769099142410414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747107882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863697,0.00046356206,0.000039789786,0.0025871817,0.0009580092,0.004183849,0.00038332382,0.00003481789,0.0049797087],"genre_scores_gemma":[0.9966482,0.00022682012,0.0005381962,0.00016981238,0.0005573681,0.00019432225,0.00005732565,0.00003140136,0.0015765378],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982678,0.00012394249,0.00051094434,0.00037161075,0.00031307747,0.00041259825],"domain_scores_gemma":[0.99707437,0.00054786133,0.00051883585,0.0016336408,0.00014912366,0.00007618272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011172275,0.0002362768,0.00096177537,0.000037666006,0.0003900026,0.0001042479,0.0010313154,0.000067880566,0.000050182145],"category_scores_gemma":[0.0007838189,0.00015570568,0.00013773225,0.00005643666,0.00018005111,0.00017725718,0.00018482347,0.00017685286,0.0000067260316],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96220297,0.0021952444,0.00028846625,0.000075542084,0.00065984786,0.00001949652,0.0008875672,0.0000034714508,0.0067975875,0.000047787456,0.004157762,0.022664232],"study_design_scores_gemma":[0.97113764,0.0056389947,0.008268356,0.00013010616,0.0003917189,0.0000060109646,0.00044275942,0.00046266528,0.002311778,0.000048196667,0.010955732,0.00020603342],"about_ca_topic_score_codex":0.00055494916,"about_ca_topic_score_gemma":0.00038433901,"teacher_disagreement_score":0.0224582,"about_ca_system_score_codex":0.000084825944,"about_ca_system_score_gemma":0.00015695226,"threshold_uncertainty_score":0.6349494},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2751411673","doi":"10.1080/2162402x.2017.1371895","title":"A library-based screening method identifies neoantigen-reactive T cells in peripheral blood prior to relapse of ovarian cancer","year":2017,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of Victoria; Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Ovarian cancer; Peripheral blood; Cancer; Oncology; Peripheral; Immunology; Cancer research; Internal medicine","score_opus":0.023411737154730772,"score_gpt":0.329068476526905,"score_spread":0.30565673937217425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751411673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891647,0.0017424444,0.0010371772,0.0048156567,0.00058528734,0.0005890357,0.000042243697,0.000047437883,0.0019760071],"genre_scores_gemma":[0.96984637,0.0002835192,0.025174567,0.0009941321,0.0000979567,0.00010437673,0.000014048824,0.000051284343,0.003433736],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985411,0.00013832144,0.00043172148,0.00037978997,0.00015239436,0.0003566646],"domain_scores_gemma":[0.9986433,0.000101468315,0.00033445487,0.0007945358,0.00006297041,0.00006327947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003154741,0.0002057081,0.0005891454,0.00026096046,0.00016621828,0.000049809478,0.00037245374,0.00021803477,0.0008178461],"category_scores_gemma":[0.00007996319,0.00018965949,0.0001715162,0.00019001686,0.00022975438,0.00024087851,0.00012415466,0.00030097459,0.000009008747],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008754109,0.0002923211,0.025177853,0.00006816427,0.0005177744,0.00012905509,0.002226805,0.000025849433,0.8941481,0.000059566424,0.00027307626,0.06832729],"study_design_scores_gemma":[0.009037187,0.00077783497,0.441755,0.00058102806,0.0001506214,0.000031500018,0.0004704024,0.00010210779,0.53019434,0.000039485734,0.016610047,0.00025047784],"about_ca_topic_score_codex":0.006379052,"about_ca_topic_score_gemma":0.00057414157,"teacher_disagreement_score":0.41657713,"about_ca_system_score_codex":0.000073114745,"about_ca_system_score_gemma":0.0003859103,"threshold_uncertainty_score":0.96432614},"labels":[],"label_agreement":null},{"id":"W2751649617","doi":"10.1158/1078-0432.ccr-16-3066","title":"Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities","year":2017,"lang":"en","type":"editorial","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University College of the North","funders":"National Cancer Institute","keywords":"Dosing; Clinical trial; Medicine; Clinical study design; Intensive care medicine; Cancer; Immunotherapy; Oncology; Precision medicine; Internal medicine; Pathology","score_opus":0.8329008721661434,"score_gpt":0.6316473128910778,"score_spread":0.2012535592750656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751649617","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007816823,0.17802237,0.000007741365,0.017140657,0.791244,0.0029600784,0.00015798908,0.00008145122,0.009604049],"genre_scores_gemma":[0.0001793727,0.5362309,0.00012861613,0.00019387798,0.45225507,0.0005679458,0.00013082821,0.00007440624,0.010238938],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.987869,0.005098272,0.002563447,0.0014392181,0.0020596846,0.00097034295],"domain_scores_gemma":[0.95875245,0.03577537,0.0009001258,0.0018527458,0.0019573814,0.00076192745],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.036237545,0.00047507422,0.0022979896,0.00036721112,0.0005891684,0.00019167953,0.0009376512,0.0041504935,0.00039275314],"category_scores_gemma":[0.026795661,0.0003980137,0.0007616279,0.000097547374,0.0044611692,0.00015298184,0.0005250778,0.0063718213,0.000051541032],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15513246,0.00040963746,0.000006024536,0.00015536927,0.000576506,0.00013751714,0.00006615728,1.2670466e-8,0.0000030654728,0.000018095849,0.47196034,0.37153482],"study_design_scores_gemma":[0.07251761,0.018590346,0.00035651913,0.0008056182,0.0003125245,0.000007669758,0.00025780496,0.000006233068,0.000003095571,0.00022210674,0.90656984,0.00035061254],"about_ca_topic_score_codex":0.00033109012,"about_ca_topic_score_gemma":0.00044364028,"teacher_disagreement_score":0.43460953,"about_ca_system_score_codex":0.0005726833,"about_ca_system_score_gemma":0.017269112,"threshold_uncertainty_score":0.9998472},"labels":[],"label_agreement":null},{"id":"W2751752943","doi":"10.1007/s40273-017-0558-5","title":"Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Bristol-Myers Squibb (Canada); Augmentium Pharma Consulting (Canada)","funders":"Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Oncology; Survival analysis; Contouring; Clinical trial; Medical physics; Internal medicine; Statistics; Cancer; Mathematics; Computer science; Immunotherapy","score_opus":0.11388261087873913,"score_gpt":0.4255673181020439,"score_spread":0.31168470722330477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751752943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893189,0.00079775247,0.0059198295,0.0012963252,0.00022489886,0.0010464954,0.000071051174,0.0000075888524,0.0013171757],"genre_scores_gemma":[0.9976599,0.0006023838,0.0014015624,0.00013703924,0.000037265232,0.000058724505,0.00004953193,0.000010358814,0.00004320507],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99889773,0.00010235547,0.0005581879,0.00026035504,0.00005986294,0.00012150849],"domain_scores_gemma":[0.9984058,0.00023184218,0.00037370203,0.0009257817,0.00002278297,0.000040064748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002196255,0.00010732149,0.0005700125,0.00019851257,0.00011707405,0.000052314423,0.00039241154,0.000041962794,0.000028025192],"category_scores_gemma":[0.000035276076,0.00008159072,0.00008896616,0.000053839638,0.000077129414,0.0002128723,0.000121557656,0.000075455006,0.0000035020173],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006590827,0.0011947386,0.513946,0.007312671,0.02929788,0.0000027532826,0.025375536,0.36364815,0.00994277,0.0019961179,0.00055608706,0.040136456],"study_design_scores_gemma":[0.001938097,0.000022697064,0.027248088,0.00005642651,0.0012974225,0.0000026272687,0.0006777485,0.9683971,0.00013060503,0.000052827556,0.00008352992,0.00009284941],"about_ca_topic_score_codex":0.0017278313,"about_ca_topic_score_gemma":0.00020285389,"teacher_disagreement_score":0.6047489,"about_ca_system_score_codex":0.00020125149,"about_ca_system_score_gemma":0.00013574502,"threshold_uncertainty_score":0.3327173},"labels":[],"label_agreement":null},{"id":"W2752101014","doi":"10.1186/s12885-017-3634-5","title":"Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma","year":2017,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; BC Cancer Agency; Pancreas Centre (Canada); Abbotsford Veterinary Clinic; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Tissue microarray; Immunohistochemistry; Medicine; Adenocarcinoma; Surgical oncology; PD-L1; Pathology; Pancreatic cancer; Biomarker; Tumor-infiltrating lymphocytes; Cancer; Oncology; Cancer research; Internal medicine; Immunotherapy; Biology","score_opus":0.052520081596619604,"score_gpt":0.2972865866867426,"score_spread":0.24476650509012302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752101014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919737,0.0042027263,0.000006801409,0.00095665676,0.00034342377,0.0010974063,0.000079573496,0.000069202026,0.0012705049],"genre_scores_gemma":[0.9948067,0.000659404,0.00009566947,0.00014916646,0.00026321562,0.00025386922,0.00006257425,0.000060355935,0.0036490473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980445,0.00007515343,0.00034088086,0.00054473657,0.00045961302,0.0005351128],"domain_scores_gemma":[0.998412,0.000061382016,0.00028021797,0.0008322453,0.00014565254,0.0002684973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027273977,0.00029141814,0.0005024694,0.000118751,0.00022148291,0.00013006263,0.00023190337,0.00011526883,0.00036659674],"category_scores_gemma":[0.00011094897,0.0002274327,0.00014713363,0.00023481109,0.00020592859,0.00014056303,0.000049214264,0.00025057068,0.000008449983],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013871724,0.0003675827,0.96490693,0.00012424006,0.00020266474,0.0003618115,0.0005510754,0.0000013696822,0.016977994,0.0000045210404,0.0020019626,0.00062814716],"study_design_scores_gemma":[0.009710948,0.00034434436,0.9783358,0.0008035394,0.00019831919,0.000013222111,0.0001650839,0.00010801838,0.009265266,0.000020012643,0.00071511476,0.00032034324],"about_ca_topic_score_codex":0.0020174587,"about_ca_topic_score_gemma":0.0035508482,"teacher_disagreement_score":0.01342888,"about_ca_system_score_codex":0.00056958414,"about_ca_system_score_gemma":0.00079196284,"threshold_uncertainty_score":0.9274436},"labels":[],"label_agreement":null},{"id":"W2752227448","doi":"10.1056/nejmoa1709030","title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2207,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Medical Research Council; Cancer Research UK","keywords":"Ipilimumab; Nivolumab; Medicine; Melanoma; Adjuvant; Adjuvant therapy; Oncology; Internal medicine; Placebo; Immunotherapy; Chemotherapy; Cancer; Cancer research; Pathology","score_opus":0.05226193040225233,"score_gpt":0.3429099879807146,"score_spread":0.29064805757846224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752227448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746475,0.0036571836,0.000043553242,0.012651361,0.0023293134,0.0002269279,0.0000038985822,0.00001380158,0.006426458],"genre_scores_gemma":[0.9868551,0.0021236287,0.00018122737,0.00031576,0.0034990388,0.0000013536535,0.000004451913,0.00002324174,0.006996211],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99809355,0.00007887619,0.0007449483,0.00017081024,0.00061512593,0.00029667362],"domain_scores_gemma":[0.9981568,0.00023195836,0.0006408591,0.0004934237,0.00017946758,0.00029753213],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012058783,0.00019232825,0.0007476555,0.0003000624,0.00012737385,0.000024733426,0.00032556106,0.00011068715,0.0015919681],"category_scores_gemma":[0.0009630507,0.00011213444,0.00010707218,0.00014632016,0.00022875566,0.00017418031,0.000036121237,0.00053416047,0.0000040599525],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3534478,0.00023551131,0.014457427,0.0001150054,0.0006311891,0.0057281135,0.0029435332,0.0000035915682,0.026632125,0.000041756615,0.03425535,0.5615086],"study_design_scores_gemma":[0.62791187,0.014096352,0.13435568,0.0020806778,0.00026861642,0.0015583767,0.0010157418,0.00007219004,0.0018916362,0.000056821013,0.21647114,0.00022088412],"about_ca_topic_score_codex":0.0016594607,"about_ca_topic_score_gemma":0.0024515935,"teacher_disagreement_score":0.5612877,"about_ca_system_score_codex":0.0001979051,"about_ca_system_score_gemma":0.0005900005,"threshold_uncertainty_score":0.9993207},"labels":[],"label_agreement":null},{"id":"W2752475919","doi":"10.1158/1078-0432.ccr-16-3064","title":"From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely","year":2017,"lang":"en","type":"editorial","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Immunotherapy; Medicine; Clinical trial; Cancer immunotherapy; Cancer; Intensive care medicine; Immune system; Oncology; Immunology; Internal medicine","score_opus":0.4070754855804582,"score_gpt":0.6245596429953687,"score_spread":0.2174841574149105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752475919","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06884628,0.011200786,0.00021645256,0.014026607,0.89820325,0.0046129287,0.0018895693,0.0001395868,0.00086454913],"genre_scores_gemma":[0.00570349,0.025076618,0.0005356763,0.0006531398,0.9496882,0.0011565295,0.0014237292,0.0002483726,0.015514264],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9891413,0.0021420436,0.0026532842,0.0015230995,0.0034925293,0.0010477309],"domain_scores_gemma":[0.98205763,0.011329877,0.0009923705,0.0020515837,0.0029847145,0.00058383564],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.021438874,0.0005775013,0.0028510108,0.00057005143,0.0006114971,0.00051606045,0.0014051839,0.002031035,0.0013284651],"category_scores_gemma":[0.025974128,0.00048060584,0.00094033644,0.00054405374,0.00078439264,0.00017493802,0.0003521474,0.003799337,0.00030219508],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03677268,0.00044566373,0.00019030752,0.000111241236,0.0010378059,0.000058483587,0.00019856995,6.03403e-8,0.0013197578,0.0000050620547,0.7207076,0.23915277],"study_design_scores_gemma":[0.029375443,0.0034706667,0.0045040264,0.002554595,0.00015947658,7.4393205e-7,0.000045518766,0.000004815288,0.00070746784,0.00035885765,0.95829684,0.0005215632],"about_ca_topic_score_codex":0.010650214,"about_ca_topic_score_gemma":0.00053509074,"teacher_disagreement_score":0.2386312,"about_ca_system_score_codex":0.0014546892,"about_ca_system_score_gemma":0.007761404,"threshold_uncertainty_score":0.99976456},"labels":[],"label_agreement":null},{"id":"W2753127471","doi":"10.1158/1078-0432.ccr-16-3079","title":"Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies","year":2017,"lang":"en","type":"editorial","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Clinical trial; Medicine; Immunotherapy; Cancer; Cancer immunotherapy; Pillar; Clinical study design; Biomarker; Oncology; Intensive care medicine; Internal medicine; Biology","score_opus":0.7863942232871721,"score_gpt":0.6191165422598202,"score_spread":0.16727768102735197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753127471","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041275104,0.2667951,0.000028881463,0.008662346,0.7122771,0.0060162707,0.00018667048,0.00006876948,0.0018373276],"genre_scores_gemma":[0.0010080468,0.51378024,0.00025236304,0.00009870239,0.47931617,0.0012286204,0.00005100439,0.00010191886,0.0041629532],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918614,0.0021970696,0.0022701952,0.0013092847,0.0014094,0.00095266814],"domain_scores_gemma":[0.96853024,0.028123412,0.0006763166,0.0012717192,0.0010580522,0.0003402733],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.04119349,0.000433352,0.0020567102,0.00038748223,0.00038279814,0.00018815506,0.00072762894,0.002406235,0.00010009399],"category_scores_gemma":[0.015603025,0.00036135936,0.00066878414,0.00007779284,0.0023052366,0.0001380604,0.00026625663,0.004016875,0.0000051306683],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24460153,0.00026001484,0.000028969132,0.00035829068,0.00039221274,0.000036832564,0.00011496728,5.5092226e-8,0.000003887472,0.000016649647,0.36745614,0.38673046],"study_design_scores_gemma":[0.09527685,0.010380708,0.0008365698,0.002192768,0.00010700726,0.0000018126816,0.00028326444,0.000023825662,0.0000058062515,0.00036197502,0.8901853,0.0003441146],"about_ca_topic_score_codex":0.0005061265,"about_ca_topic_score_gemma":0.0007596428,"teacher_disagreement_score":0.52272916,"about_ca_system_score_codex":0.0002926795,"about_ca_system_score_gemma":0.0061210096,"threshold_uncertainty_score":0.99988383},"labels":[],"label_agreement":null},{"id":"W2753432434","doi":"10.1056/nejmoa1709684","title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5392,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Ipilimumab; Nivolumab; Medicine; Melanoma; Oncology; Internal medicine; Overall survival; Metastatic melanoma; Clinical trial; Immunotherapy; Cancer; Cancer research","score_opus":0.015926810965805293,"score_gpt":0.27898384675855475,"score_spread":0.26305703579274947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753432434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813718,0.0022290053,0.000046942678,0.013133784,0.00047366787,0.0001414866,8.948343e-7,0.0000058011337,0.0025966067],"genre_scores_gemma":[0.99626106,0.0013457217,0.00034580685,0.00033818188,0.00093121914,7.3072596e-7,0.0000019048007,0.000015049562,0.00076032395],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989033,0.000041119085,0.0003892347,0.00012531516,0.00036481547,0.0001762405],"domain_scores_gemma":[0.99895155,0.00009715693,0.00038961336,0.0002594485,0.000103060986,0.00019919177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066638796,0.00014311151,0.00056206435,0.00014152771,0.00007899645,0.00001812427,0.0001333875,0.000053001953,0.00010152591],"category_scores_gemma":[0.00017073823,0.00008419625,0.00004016894,0.000051142553,0.00020965772,0.00015748828,0.000018214505,0.0002903243,5.196884e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.105202444,0.00019336444,0.3421039,0.00011590204,0.00042966084,0.0017333532,0.0018426409,0.000004853407,0.020620566,0.00016788252,0.0026173862,0.524968],"study_design_scores_gemma":[0.33701077,0.008938366,0.6307694,0.0014027363,0.0001268012,0.0017221016,0.00023746112,0.000023727636,0.0004808143,0.00027948318,0.01887976,0.00012858864],"about_ca_topic_score_codex":0.00046409632,"about_ca_topic_score_gemma":0.0005175115,"teacher_disagreement_score":0.52483946,"about_ca_system_score_codex":0.000060539518,"about_ca_system_score_gemma":0.00018002422,"threshold_uncertainty_score":0.34334233},"labels":[],"label_agreement":null},{"id":"W2753687864","doi":"10.1200/jco.2017.35.15_suppl.e14587","title":"Effect of high-dose corticosteroids on CD4+ or CD8+ lymphocyte proliferation or IL-2 production after stimulation with pembrolizumab.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Pembrolizumab; Peripheral blood mononuclear cell; Prednisone; CD8; Immune system; Lymphocyte; Melanoma; Internal medicine; Stimulation; Immunology; IL-2 receptor; Pharmacology; Immunotherapy; Endocrinology; T cell; Cancer research; In vitro; Biology","score_opus":0.07150106635071538,"score_gpt":0.44700487998762045,"score_spread":0.3755038136369051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753687864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99426776,0.000065306645,0.000067860594,0.0030500263,0.0017423409,0.00061611144,0.000002717501,0.000008041116,0.00017982538],"genre_scores_gemma":[0.996471,0.0003384194,0.00050080963,0.0005251341,0.0014413665,0.000016952852,0.0000029153173,0.000019306226,0.0006841044],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99720395,0.00042890612,0.001585632,0.00020685414,0.00041786954,0.00015681669],"domain_scores_gemma":[0.99558467,0.00082748465,0.0026349647,0.0003854263,0.00043005956,0.00013738783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025014945,0.00015734007,0.0011088073,0.000112945665,0.00008572045,0.000022561897,0.00012362361,0.00027811065,0.0001489504],"category_scores_gemma":[0.0034328052,0.00007683764,0.00023188804,0.00006965185,0.00028473904,0.00024425233,0.000020407488,0.00037604113,0.0000059249123],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6229589,0.0006811021,0.036685176,0.00010454579,0.00033157456,0.00024138577,0.000053910877,0.000043546715,0.0016589713,0.0000025460718,0.00029178604,0.33694658],"study_design_scores_gemma":[0.048374142,0.1776132,0.75702846,0.0006289827,0.0006948291,0.0008535718,0.000010648772,0.00017536897,0.010541927,0.000016830378,0.003947035,0.000114984236],"about_ca_topic_score_codex":0.000024200972,"about_ca_topic_score_gemma":0.000111309426,"teacher_disagreement_score":0.7203433,"about_ca_system_score_codex":0.0002647535,"about_ca_system_score_gemma":0.0013643308,"threshold_uncertainty_score":0.41096365},"labels":[],"label_agreement":null},{"id":"W2753741461","doi":"10.1158/0008-5472.can-17-0707","title":"CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institut du Savoir Montfort; Centre Hospitalier de l’Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Medical Research Council; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Fonds De La Recherche Scientifique - FNRS; National Health and Medical Research Council; Breast Cancer Research Foundation; Susan G. Komen for the Cure","keywords":"Trastuzumab; Cancer research; Immune system; Stromal cell; Antibody; Cancer cell; Medicine; Monoclonal antibody; Breast cancer; Cancer; Immunology; Biology; Internal medicine","score_opus":0.1319793339646701,"score_gpt":0.4944404438853889,"score_spread":0.3624611099207188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753741461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94509095,0.007263843,0.000018177252,0.030258384,0.00033313752,0.0012458651,0.000025450472,0.000055655393,0.015708543],"genre_scores_gemma":[0.95962465,0.004934776,0.00020414715,0.0007930844,0.0006461357,0.00029293748,0.0000076196793,0.000048219517,0.0334484],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978066,0.00008973726,0.00020316272,0.00046961798,0.0007865025,0.00064434746],"domain_scores_gemma":[0.99789476,0.00006554206,0.00006461258,0.0013099625,0.0004181035,0.0002469994],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011513331,0.00015373774,0.00027335473,0.00017142648,0.0007958186,0.00022053526,0.00057927053,0.000099083336,0.00094025605],"category_scores_gemma":[0.00021250569,0.0001207924,0.00010411546,0.00028264528,0.00041232764,0.00013593589,0.00011574958,0.0003944397,0.00012494269],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008059503,0.0001638052,0.023643464,0.00014631801,0.00018457934,0.0000931734,0.0007247302,2.1457339e-7,0.8427351,0.00015043371,0.045437396,0.07866127],"study_design_scores_gemma":[0.0026010456,0.0005170637,0.2009431,0.0006113898,0.0000068541344,0.0000062064487,0.000102123646,0.000002442623,0.21456997,0.00018784424,0.5802581,0.0001938727],"about_ca_topic_score_codex":0.0016447151,"about_ca_topic_score_gemma":0.000720021,"teacher_disagreement_score":0.6281651,"about_ca_system_score_codex":0.00029338564,"about_ca_system_score_gemma":0.000540346,"threshold_uncertainty_score":0.999973},"labels":[],"label_agreement":null},{"id":"W2754718069","doi":"10.1080/2162402x.2017.1377873","title":"Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models","year":2017,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Saskatchewan","keywords":"Blockade; CD8; Monoclonal antibody; Cytotoxic T cell; CTLA-4; Cancer research; Immunotherapy; Medicine; T cell; Immune system; Blocking antibody; Cancer immunotherapy; Immunology; Immune checkpoint; Antibody; Receptor; Biology; In vitro; Internal medicine","score_opus":0.02885851850022436,"score_gpt":0.29853256680669993,"score_spread":0.26967404830647557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754718069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907496,0.0007800721,0.000058126334,0.0016085841,0.0003432528,0.0005438864,0.000015433217,0.000090819325,0.0058102547],"genre_scores_gemma":[0.9922273,0.00083288545,0.0005221224,0.00047425128,0.000059905295,0.00008871737,0.000022443255,0.00004540188,0.005726959],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983005,0.00010576031,0.0004700201,0.00040826018,0.00018921256,0.00052623876],"domain_scores_gemma":[0.99805313,0.000084501466,0.0003575305,0.0013330225,0.00010466866,0.00006714239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002892553,0.00031667322,0.0007561368,0.00022058416,0.0003250307,0.000073940275,0.00062984455,0.00016417952,0.00036533576],"category_scores_gemma":[0.00009467642,0.00022199412,0.00011071148,0.00014899141,0.0008418179,0.00031917766,0.00017318112,0.00055276917,0.00004014475],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10093893,0.0016327737,0.018484993,0.00018718351,0.00087045215,0.0013573564,0.0020954115,0.0000118044745,0.8599143,0.0003609409,0.00036694767,0.013778894],"study_design_scores_gemma":[0.050155856,0.014607248,0.26245037,0.001658481,0.00023122049,0.0020141648,0.0024427383,0.00085309835,0.6527712,0.000602947,0.010832267,0.0013804443],"about_ca_topic_score_codex":0.0047103907,"about_ca_topic_score_gemma":0.0037729107,"teacher_disagreement_score":0.24396536,"about_ca_system_score_codex":0.00023642498,"about_ca_system_score_gemma":0.00044274208,"threshold_uncertainty_score":0.90526575},"labels":[],"label_agreement":null},{"id":"W2754724354","doi":"10.1021/acs.biochem.7b00655","title":"The Too Many Faces of PD-L1: A Comprehensive Conformational Analysis Study","year":2017,"lang":"en","type":"article","venue":"Biochemistry","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Li Ka Shing Institute of Virology, University of Alberta; Kom op tegen Kanker; Alberta Cancer Foundation; Compute Canada; Kræftens Bekæmpelse","keywords":"Molecular dynamics; Chemistry; Computational biology; Binding site; Plasma protein binding; Binding pocket; Protein structure; Biophysics; Biology; Biochemistry; Computational chemistry","score_opus":0.02421401266249711,"score_gpt":0.32323873433014877,"score_spread":0.29902472166765165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754724354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951755,0.0006290819,0.00000903408,0.00054317893,0.000048347287,0.00014441661,0.000023070352,0.000008101942,0.0034192968],"genre_scores_gemma":[0.9980493,0.000082648534,0.000025996123,0.000077830635,0.00004294037,0.000010122285,0.000020312738,0.0000030186186,0.0016878227],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99941427,0.000007339224,0.00019155853,0.00009755462,0.00020210404,0.00008715966],"domain_scores_gemma":[0.99908745,0.000036912457,0.0002013346,0.0005194618,0.00012442673,0.000030434216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010198028,0.000073159645,0.00016788086,0.000019609028,0.00023941157,0.000041401974,0.00018394737,0.00003956735,0.00008231894],"category_scores_gemma":[0.000035226123,0.00004749854,0.00013726875,0.00006364039,0.00020232439,0.00002860259,0.0000422312,0.00005444453,0.0000032017379],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004195698,0.0006057044,0.32136023,0.00020057899,0.01062605,0.000018199122,0.001355443,0.0000040928717,0.6393598,0.000041244366,0.008863097,0.013369916],"study_design_scores_gemma":[0.0017610597,0.000100544574,0.8102504,0.000021578879,0.00038136257,0.000007058938,0.003247647,0.00012347124,0.17805283,0.0000052024625,0.005962869,0.00008600041],"about_ca_topic_score_codex":0.000102128826,"about_ca_topic_score_gemma":0.000007538426,"teacher_disagreement_score":0.48889014,"about_ca_system_score_codex":0.00002418786,"about_ca_system_score_gemma":0.00006437234,"threshold_uncertainty_score":0.19369341},"labels":[],"label_agreement":null},{"id":"W2754774331","doi":"10.1172/jci.insight.94308","title":"VISTA.COMP — an engineered checkpoint receptor agonist that potently suppresses T cell–mediated immune responses","year":2017,"lang":"en","type":"article","venue":"JCI Insight","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Sunnybrook Hospital; University of Toronto","funders":"University of Toronto; Canadian Institutes of Health Research; Sunnybrook Research Institute","keywords":"Immune checkpoint; Agonist; T cell; Cell biology; Receptor; Cancer research; Immune system; In vivo; Chemistry; Biology; Immunology; Immunotherapy; Biochemistry","score_opus":0.03036613902829853,"score_gpt":0.2799893687440375,"score_spread":0.24962322971573897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754774331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98204255,0.003274094,0.000047718666,0.0035367114,0.0013295028,0.0005450609,0.00012183011,0.00022182705,0.008880722],"genre_scores_gemma":[0.98934853,0.0010415851,0.0004990328,0.00043099606,0.0003465301,0.000039247356,0.0002903152,0.00006855049,0.007935214],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99826455,0.00008605285,0.00041268,0.00043323732,0.00038375502,0.00041970183],"domain_scores_gemma":[0.9978261,0.00009944454,0.00028125872,0.001439704,0.00012829417,0.00022521187],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002983946,0.00032314364,0.00048139857,0.0001521347,0.00051275216,0.00026724004,0.00044282197,0.00020566098,0.0011896935],"category_scores_gemma":[0.00019102758,0.0002622303,0.00023496909,0.00010383161,0.0002831829,0.00034911328,0.00009217088,0.00028940235,0.00013748907],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007831827,0.00051599793,0.0017598594,0.00012647719,0.0001885704,0.00016164193,0.00097100914,8.3683454e-7,0.97960025,0.000021032969,0.0055420063,0.0032804925],"study_design_scores_gemma":[0.0040183384,0.0006570415,0.104930274,0.00014699617,0.000071432914,0.000039164654,0.00021399958,0.00005904455,0.562407,0.000008663528,0.32711163,0.00033638984],"about_ca_topic_score_codex":0.00047631806,"about_ca_topic_score_gemma":0.000035826943,"teacher_disagreement_score":0.4171932,"about_ca_system_score_codex":0.00013997438,"about_ca_system_score_gemma":0.00021678727,"threshold_uncertainty_score":0.999983},"labels":[],"label_agreement":null},{"id":"W2755890634","doi":"10.1186/s12885-017-3615-8","title":"Analysis of B7-H4 expression in metastatic pleural adenocarcinoma and therapeutic potential of its antagonists","year":2017,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Government of Jiangsu Province; National Natural Science Foundation of China; Saskatchewan Cancer Agency","keywords":"Surgical oncology; Medicine; Adenocarcinoma; Oncology; Metastatic adenocarcinoma; Expression (computer science); Internal medicine; Cancer research; Cancer","score_opus":0.04765802514331017,"score_gpt":0.3463769819414301,"score_spread":0.2987189567981199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755890634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816299,0.017747253,0.00005998129,0.0001448474,0.000100966165,0.00019830654,0.0000482246,0.0000042941565,0.0000662043],"genre_scores_gemma":[0.99822515,0.0013358741,0.0001486291,0.000059123635,0.00002792765,0.000017754352,0.0000070033934,0.000009522534,0.00016902841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991693,0.00003910822,0.0002859133,0.00018061775,0.00019233835,0.00013273396],"domain_scores_gemma":[0.99928284,0.000025705436,0.00026870886,0.0003295748,0.000054748103,0.000038420283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015103494,0.000101334095,0.00042928368,0.00020895306,0.000051921717,0.0000128221145,0.00010505989,0.000041381634,0.00023971894],"category_scores_gemma":[0.000015803695,0.00007833112,0.00015120386,0.0001711671,0.00014536334,0.000060285198,0.000033773707,0.00006006034,2.6956684e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025144534,0.00006997174,0.6508781,0.00022587764,0.00069963327,0.00000780453,0.00034484922,0.000032291133,0.336824,0.000006038309,0.000024806615,0.008372225],"study_design_scores_gemma":[0.0024950523,0.00010762731,0.9396195,0.00017444526,0.0009994562,0.0000042937027,0.0001488769,0.0015558122,0.054721992,0.0000072249295,0.00008912315,0.00007660138],"about_ca_topic_score_codex":0.0011477816,"about_ca_topic_score_gemma":0.0009674002,"teacher_disagreement_score":0.28874144,"about_ca_system_score_codex":0.00004009706,"about_ca_system_score_gemma":0.00010179376,"threshold_uncertainty_score":0.31942502},"labels":[],"label_agreement":null},{"id":"W2756347613","doi":"10.18632/oncotarget.21003","title":"Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling","year":2017,"lang":"en","type":"article","venue":"Oncotarget","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Atorvastatin; PI3K/AKT/mTOR pathway; Downregulation and upregulation; Receptor; Cancer immunotherapy; Immune system; T cell; Immunotherapy; Biology; Cancer research; Effector; Cell biology; Signal transduction; Medicine; Immunology; Pharmacology; Biochemistry","score_opus":0.01620187261016697,"score_gpt":0.29360245449648575,"score_spread":0.2774005818863188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756347613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99368626,0.0016216694,0.0001262665,0.0010010661,0.00066523824,0.0003813598,0.00007272028,0.00015227804,0.002293166],"genre_scores_gemma":[0.990787,0.00025560058,0.0034994432,0.00040175588,0.0007150617,0.000033936467,0.00034026493,0.00007121352,0.0038956914],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99828243,0.00007446035,0.00040882832,0.0004299491,0.0003811915,0.00042314877],"domain_scores_gemma":[0.99872184,0.000087608634,0.00041029617,0.00048470212,0.00009875278,0.00019677416],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045400116,0.000275257,0.00040177768,0.00006196899,0.00067362346,0.00012246335,0.00023092184,0.00018408937,0.002036515],"category_scores_gemma":[0.00015837976,0.00022971563,0.00017433349,0.000059381146,0.00018215935,0.00029441967,0.000052389685,0.0002711783,0.000102571685],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013170326,0.0001024761,0.011465908,0.000047840967,0.000072918105,0.000009620349,0.00023800526,0.000001116654,0.78709173,0.000001423985,0.1977695,0.0018824068],"study_design_scores_gemma":[0.0022877967,0.00018544524,0.004938678,0.00034794805,0.000020349426,0.0000035744847,0.00018282194,0.000040519277,0.7600781,0.000009448492,0.23165959,0.00024577623],"about_ca_topic_score_codex":0.00014272706,"about_ca_topic_score_gemma":0.0000018546932,"teacher_disagreement_score":0.033890095,"about_ca_system_score_codex":0.00018874036,"about_ca_system_score_gemma":0.0001281905,"threshold_uncertainty_score":0.99887574},"labels":[],"label_agreement":null},{"id":"W2756695645","doi":"10.1111/cei.13060","title":"<i>In-vitro</i> effect of pembrolizumab on different T regulatory cell subsets","year":2017,"lang":"en","type":"article","venue":"Clinical & Experimental Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"United Arab Emirates University; Terry Fox Foundation","keywords":"FOXP3; Pembrolizumab; Cytotoxic T cell; Immunology; IL-2 receptor; Immune system; Biology; Antigen; T cell; Cancer research; Immunotherapy; In vitro","score_opus":0.026621508002461842,"score_gpt":0.38290973552263197,"score_spread":0.35628822752017014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756695645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98935413,0.0039968775,4.206441e-7,0.00045253226,0.0016132913,0.0004499999,0.0000067884175,0.000022701912,0.0041032396],"genre_scores_gemma":[0.9981201,0.00032981465,0.000014738274,0.00063884613,0.00013040518,0.00004419493,0.000013848144,0.000029079882,0.000678939],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99812675,0.0002382275,0.000727909,0.00041304377,0.00017149979,0.0003225793],"domain_scores_gemma":[0.9981007,0.0003097685,0.00035629977,0.0011345171,0.00001972394,0.00007901224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003529938,0.00024937015,0.000890209,0.00008018057,0.00010845844,0.000013111232,0.00033802172,0.00030803256,0.00027543976],"category_scores_gemma":[0.000086142514,0.0001868039,0.00044329005,0.000032032673,0.00096482143,0.000067747096,0.00014382595,0.00039644405,0.000061646366],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047363315,0.001484064,0.011320151,0.000034278164,0.00015901678,0.00006650115,0.00006832555,4.8359055e-8,0.9336481,0.000035307115,0.0006993449,0.005121509],"study_design_scores_gemma":[0.016395546,0.0056299814,0.17784819,0.00007699464,0.000031983924,0.00001990595,0.000033174816,0.00000361183,0.79833853,0.000008932421,0.0014841395,0.00012903004],"about_ca_topic_score_codex":0.000064344225,"about_ca_topic_score_gemma":0.0000017279694,"teacher_disagreement_score":0.16652805,"about_ca_system_score_codex":0.00013521693,"about_ca_system_score_gemma":0.000044694512,"threshold_uncertainty_score":0.76176417},"labels":[],"label_agreement":null},{"id":"W2757328282","doi":"10.1093/annonc/mdx557","title":"LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Fonds de Recherche du Québec - Santé; Canadian Cancer Society","keywords":"Medicine; Breast cancer; Oncology; Tumor-infiltrating lymphocytes; Internal medicine; Cancer; Hazard ratio; Immune checkpoint; Proportional hazards model; PD-L1; Tissue microarray; Immunohistochemistry; Estrogen receptor; Immunotherapy; Confidence interval","score_opus":0.059523721403723875,"score_gpt":0.40956022298624556,"score_spread":0.3500365015825217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757328282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98295283,0.0008071016,0.0000010989964,0.013301031,0.00019281554,0.00018745138,0.000023949307,0.000012520369,0.0025211712],"genre_scores_gemma":[0.9951822,0.002194461,0.00008895413,0.0021378656,0.00015600515,0.000018215014,0.000005020438,0.00001176767,0.00020551337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885017,0.000091321206,0.0004759461,0.00020470402,0.0001442819,0.00023355758],"domain_scores_gemma":[0.9984972,0.0003328438,0.0007344425,0.00020191107,0.0001627346,0.00007089447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000982929,0.00011258255,0.0005160209,0.000067482586,0.00009827094,0.00001889034,0.000098506374,0.00015733225,0.00006573272],"category_scores_gemma":[0.00026171975,0.00008854419,0.00006907126,0.00006690071,0.00026480044,0.00012014493,0.000034663863,0.00019482688,0.0000022205738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050516957,0.00017263935,0.9252747,0.00003778559,0.0001561617,0.00006052713,0.00019440091,0.0000018370014,0.0008222709,0.000018435172,0.0015675834,0.06664196],"study_design_scores_gemma":[0.005272945,0.0018487294,0.9871578,0.00035041638,0.000045345907,0.0001620379,0.0001875467,0.00012980419,0.0009771973,0.00003577664,0.0037306726,0.000101719226],"about_ca_topic_score_codex":0.0021638146,"about_ca_topic_score_gemma":0.0012035429,"teacher_disagreement_score":0.066540234,"about_ca_system_score_codex":0.0001358455,"about_ca_system_score_gemma":0.00056222896,"threshold_uncertainty_score":0.36107272},"labels":[],"label_agreement":null},{"id":"W2757427979","doi":"10.1200/jco.2017.35.15_suppl.9504","title":"Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Discontinuation; Medicine; Pembrolizumab; Population; Ipilimumab; Internal medicine; Family medicine; Cancer; Immunotherapy","score_opus":0.12402998275954939,"score_gpt":0.4848306160490523,"score_spread":0.3608006332895029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757427979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99449474,0.00016862413,0.000007690314,0.0025431288,0.00066014106,0.0012293897,0.000011057356,0.000006242665,0.00087900145],"genre_scores_gemma":[0.9981817,0.0002678587,0.00009145384,0.0010397831,0.0001924892,0.000026476799,0.0000073314195,0.000023050481,0.00016984095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99567443,0.0007871787,0.0023474344,0.0003093457,0.0005225948,0.00035904415],"domain_scores_gemma":[0.99509317,0.0014114561,0.0024070444,0.00067336904,0.0002471977,0.00016777987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018430148,0.00028690908,0.0021454683,0.00020515693,0.0001394492,0.000039760835,0.00054488593,0.00023881756,0.00008606073],"category_scores_gemma":[0.0007461807,0.00014663361,0.00043900148,0.0001262687,0.00037018288,0.00023369901,0.00005250654,0.0007968454,0.0000059418117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10298025,0.017503705,0.704962,0.000009398764,0.0006040829,0.0011441465,0.00081510504,0.0000021140847,0.000014409248,0.0000017695792,0.000060570776,0.17190245],"study_design_scores_gemma":[0.20845623,0.08026011,0.7094069,0.00011956239,0.0002736875,0.00006575194,0.00045991363,0.000012614781,0.000005310213,0.000009991198,0.000818171,0.00011173121],"about_ca_topic_score_codex":0.0002291124,"about_ca_topic_score_gemma":0.0021187812,"teacher_disagreement_score":0.17179072,"about_ca_system_score_codex":0.00052643515,"about_ca_system_score_gemma":0.00077600044,"threshold_uncertainty_score":0.5979545},"labels":[],"label_agreement":null},{"id":"W2760003250","doi":"10.3389/fimmu.2017.01215","title":"Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer","year":2017,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; University of Alberta; Alberta Cancer Foundation","keywords":"TIGIT; Blockade; Immune checkpoint; Immunology; Immune system; Cancer immunotherapy; Cancer; Immunotherapy; Medicine; Cytotoxic T cell; T cell; Receptor expression; Cancer research; Receptor; Biology; Internal medicine","score_opus":0.02333629337061027,"score_gpt":0.32310099062911135,"score_spread":0.2997646972585011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760003250","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011326839,0.9843798,0.00003974034,0.0002606746,0.0023710965,0.0013603055,0.00004929354,0.00003387547,0.00017835817],"genre_scores_gemma":[0.0015033634,0.99487513,0.0007971266,0.000047532,0.0002226628,0.0006691783,0.00003791446,0.0000691644,0.0017779279],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973217,0.00038393552,0.0008833594,0.0007035751,0.00013124538,0.0005761586],"domain_scores_gemma":[0.9986474,0.00012166128,0.0004623497,0.00064540224,0.00003465399,0.00008856932],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000656895,0.00049535156,0.0020395862,0.0009513575,0.00018230035,0.00004509293,0.0002458829,0.00069719454,0.00007101383],"category_scores_gemma":[0.00016620339,0.00044596853,0.00020716201,0.00026557577,0.0004991192,0.000104660634,0.0002709896,0.0010505306,0.000006195771],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022462266,0.00013169166,0.0023726688,0.0034172025,0.00027010796,0.000066177105,0.000543093,5.45491e-7,0.016628284,0.0000023854582,0.0014550996,0.97286654],"study_design_scores_gemma":[0.003465049,0.0007232472,0.0019153795,0.02425673,0.0001568132,0.00012657302,0.00018077786,0.0000061600645,0.00082372787,0.000012868357,0.96787417,0.00045852148],"about_ca_topic_score_codex":0.0005704394,"about_ca_topic_score_gemma":0.00009522238,"teacher_disagreement_score":0.972408,"about_ca_system_score_codex":0.0013796526,"about_ca_system_score_gemma":0.00093954377,"threshold_uncertainty_score":0.9997992},"labels":[],"label_agreement":null},{"id":"W2760807868","doi":"10.1016/j.apsb.2017.06.007","title":"Regulation of immune-related diseases by multiple factors of chromatin, exosomes, microparticles, vaccines, oxidative stress, dormancy, protein quality control, inflammation and microenvironment: a meeting report of 2017 International Workshop of the Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine on Tumor Immunology","year":2017,"lang":"en","type":"article","venue":"Acta Pharmaceutica Sinica B","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"National Key Research and Development Program of China; Canadian Institutes of Health Research; Chinese Academy of Medical Sciences; Medical Research Council; Zhengzhou University; Huazhong University of Science and Technology; National Natural Science Foundation of China; National Institutes of Health; Innovent Biologics; Ontario Institute for Cancer Research","keywords":"Immune system; Inflammation; Microvesicles; Immunology; Tumor microenvironment; Medicine; Disease; Immunotherapy; Cancer; Cancer immunotherapy; Biology; microRNA; Pathology; Internal medicine","score_opus":0.05773619731521537,"score_gpt":0.390365461417985,"score_spread":0.3326292641027696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760807868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99056554,0.0013921928,0.000019590121,0.0063574985,0.000088521534,0.0011893361,0.00033901603,0.0000060789494,0.000042204687],"genre_scores_gemma":[0.99936265,0.00035339518,0.00008407883,0.000036368776,0.000027531423,0.000033209144,0.00008237837,0.000011220418,0.000009167206],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969655,0.00023329005,0.0017774387,0.0002626547,0.0006064037,0.00015465998],"domain_scores_gemma":[0.993922,0.0010840496,0.0044014086,0.00030452426,0.00024156719,0.0000464645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014703866,0.00018950414,0.00070234906,0.0001274446,0.00011737859,0.000005522398,0.00043434775,0.00012348154,0.000066862376],"category_scores_gemma":[0.0045971847,0.00012126631,0.000117059964,0.0002474406,0.0023054879,0.00021504998,0.00015173436,0.00019565331,4.486177e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003423319,0.00031684397,0.13741755,0.00026782465,0.0006433619,6.094466e-7,0.00074170437,0.0000029554792,0.8560131,0.00009507444,0.00005140608,0.0010262335],"study_design_scores_gemma":[0.0054069734,0.00022759268,0.45965305,0.0011339722,0.00009260186,0.0000050137255,0.00025609383,0.0003272613,0.53272164,0.000067227294,0.00005018253,0.000058372807],"about_ca_topic_score_codex":0.0001623799,"about_ca_topic_score_gemma":0.000006349997,"teacher_disagreement_score":0.32329145,"about_ca_system_score_codex":0.000046431393,"about_ca_system_score_gemma":0.00016131226,"threshold_uncertainty_score":0.8494666},"labels":[],"label_agreement":null},{"id":"W2760849249","doi":"10.1186/s12967-017-1309-2","title":"Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016","year":2017,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Center for Advancing Translational Sciences; Society for Immunotherapy of Cancer","keywords":"Atezolizumab; Durvalumab; Nivolumab; Medicine; Immunotherapy; Pembrolizumab; Avelumab; Oncology; Immune checkpoint; Ipilimumab; Targeted therapy; Melanoma; Internal medicine; Cancer; Cancer research; Immunology","score_opus":0.04251446897132561,"score_gpt":0.34408954507010703,"score_spread":0.3015750760987814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760849249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72772545,0.072194606,0.0009589099,0.18933707,0.0014308898,0.00049785635,0.000023155782,0.000017738388,0.007814318],"genre_scores_gemma":[0.9892944,0.005192809,0.00093060744,0.0016059233,0.0023906962,0.000005117239,0.000013209472,0.00003656698,0.0005306444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975057,0.00009220998,0.0011066966,0.00021700979,0.0008442997,0.00023404868],"domain_scores_gemma":[0.9974639,0.00044251725,0.0010917704,0.0005681645,0.00035324236,0.000080400845],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017800714,0.00022405093,0.0006009804,0.0001607034,0.00027746032,0.000044928758,0.0004086459,0.000110784706,0.0009135818],"category_scores_gemma":[0.0003084361,0.00012870859,0.00030187264,0.00012722774,0.00050824275,0.0002924502,0.000010735783,0.00052138773,0.000003334577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032679476,0.0009371648,0.43436903,0.00005807943,0.004156936,0.001678905,0.032320794,0.000048318914,0.2929168,0.00040757985,0.02780702,0.17261988],"study_design_scores_gemma":[0.012649141,0.0003697362,0.9372555,0.0014953477,0.00009528058,0.0010605229,0.0008876354,0.000034446577,0.00048083748,0.001170069,0.044353016,0.00014848226],"about_ca_topic_score_codex":0.0020664334,"about_ca_topic_score_gemma":0.0002066519,"teacher_disagreement_score":0.5028864,"about_ca_system_score_codex":0.0001311647,"about_ca_system_score_gemma":0.0004251989,"threshold_uncertainty_score":0.9999997},"labels":[],"label_agreement":null},{"id":"W2760940301","doi":"10.1093/annonc/mdx363","title":"Relationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Clinical endpoint; Internal medicine; Response Evaluation Criteria in Solid Tumors; Clinical trial; Population; Oncology; Surrogate endpoint; Phases of clinical research; Cancer; Gastroenterology; Immunotherapy","score_opus":0.15942913122050914,"score_gpt":0.4775674784646882,"score_spread":0.3181383472441791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760940301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526423,0.0001861698,0.000011984302,0.0028481232,0.00019354273,0.0009896109,0.000028427614,0.000005518505,0.00047239603],"genre_scores_gemma":[0.9974969,0.00022292363,0.0015994844,0.00027481717,0.00008878058,0.000045842622,0.000005219117,0.000011744239,0.0002542861],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99790174,0.0004241695,0.0010824538,0.00023050267,0.00017673314,0.00018439724],"domain_scores_gemma":[0.9975161,0.0009358179,0.00076668675,0.0005020593,0.00017644792,0.00010290375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00292597,0.000108311826,0.0007432969,0.00019845892,0.00004500885,0.0000030552314,0.0001499926,0.0002560586,0.000036114263],"category_scores_gemma":[0.0034244987,0.000091928894,0.00014423764,0.00008853549,0.00037793664,0.000059046786,0.00009378432,0.00018939085,0.0000020147004],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5769384,0.00088101375,0.0866416,0.00007911134,0.000040885712,0.000028193715,0.0007280685,0.0000021857577,0.32405746,0.0000025528718,0.0010312044,0.009569366],"study_design_scores_gemma":[0.045046955,0.013010714,0.713211,0.00023784924,0.000032672542,0.000007855526,0.000094912626,0.000029057017,0.2265328,0.000036691225,0.0016799038,0.00007958775],"about_ca_topic_score_codex":0.00013209805,"about_ca_topic_score_gemma":0.000049029823,"teacher_disagreement_score":0.6265694,"about_ca_system_score_codex":0.000023343599,"about_ca_system_score_gemma":0.0004723402,"threshold_uncertainty_score":0.4099692},"labels":[],"label_agreement":null},{"id":"W2761091964","doi":"10.1093/annonc/mdx377","title":"Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Internal medicine; Nivolumab; Cohort; Post-hoc analysis; Oncology; Cancer; Immunotherapy","score_opus":0.05034381694852815,"score_gpt":0.33696388372828484,"score_spread":0.2866200667797567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761091964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996096,0.00010840167,0.000009254067,0.00271757,0.00008359636,0.0005857394,0.00006796981,0.0000051519596,0.00032629305],"genre_scores_gemma":[0.99854916,0.00082013995,0.00007513344,0.00025743787,0.000012616866,0.000014753422,0.000055272692,0.000012159051,0.00020329688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891025,0.00016038436,0.00044024963,0.00016690364,0.00017974293,0.0001424717],"domain_scores_gemma":[0.9982279,0.00017377894,0.00083506195,0.00036601088,0.00036864544,0.000028620636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038346904,0.00011182111,0.0005189207,0.00012533809,0.00007855722,0.0000055740525,0.00014660366,0.00009997759,0.00004630478],"category_scores_gemma":[0.00017618913,0.00007418381,0.000043731932,0.00010167449,0.0004592645,0.00014660804,0.00004097918,0.00008516256,4.0933642e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19622064,0.0014114071,0.36663285,0.00025146402,0.00032955257,0.000009450066,0.0021867657,0.0000013322939,0.26137823,0.000073771254,0.0001413511,0.1713632],"study_design_scores_gemma":[0.014746108,0.009456834,0.9508837,0.00028383255,0.000032000244,0.0000046559235,0.0001140712,0.000027967377,0.022193385,0.000025193387,0.0021568756,0.000075384036],"about_ca_topic_score_codex":0.00021870829,"about_ca_topic_score_gemma":0.0003111402,"teacher_disagreement_score":0.58425087,"about_ca_system_score_codex":0.000034093882,"about_ca_system_score_gemma":0.00015760117,"threshold_uncertainty_score":0.3025128},"labels":[],"label_agreement":null},{"id":"W2761156597","doi":"10.1093/annonc/mdx374.019","title":"Immune profile analysis of head and neck squamous cell carcinoma before and after neoadjuvant treatment with the IRX-2 regimen","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Tumor microenvironment; Immune system; CD8; Head and neck squamous-cell carcinoma; Immunotherapy; Chemokine; Tumor-infiltrating lymphocytes; Cancer research; T cell; Oncology; Pathology; Internal medicine; Immunology; Cancer; Head and neck cancer","score_opus":0.030849452074828518,"score_gpt":0.3311706744289176,"score_spread":0.3003212223540891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761156597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852002,0.0047406172,0.0000012208566,0.0075146514,0.000021318436,0.00032772156,0.000032439144,0.0000035784328,0.0021582446],"genre_scores_gemma":[0.99800843,0.00048680464,0.000096186806,0.00030764524,0.000024382363,0.000039041115,0.000010867726,0.000008559165,0.0010180646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993262,0.000038581988,0.00021330295,0.00017362765,0.00009007701,0.00015817302],"domain_scores_gemma":[0.9990488,0.000048395108,0.00029762977,0.00046603422,0.00009059717,0.000048539674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016583959,0.00011819794,0.00053490436,0.00009128187,0.00008689649,0.0000084198455,0.00007580952,0.00007895282,0.000060535043],"category_scores_gemma":[0.000006909809,0.000062943356,0.00011364451,0.000082173836,0.00045475163,0.000039291786,0.0000378703,0.00005215971,4.1312353e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022906804,0.0008948116,0.7174269,0.00015905302,0.0025174692,0.0001567931,0.006226177,0.0000011118988,0.012725173,0.000018906801,0.0007471016,0.23621969],"study_design_scores_gemma":[0.0043226983,0.016676242,0.9580842,0.000023473642,0.0010019362,0.00002675392,0.00034602487,0.00004908173,0.010961852,0.0000066863245,0.0084369965,0.000064022846],"about_ca_topic_score_codex":0.001986324,"about_ca_topic_score_gemma":0.0019875756,"teacher_disagreement_score":0.24065731,"about_ca_system_score_codex":0.00002389606,"about_ca_system_score_gemma":0.00010210345,"threshold_uncertainty_score":0.3002741},"labels":[],"label_agreement":null},{"id":"W2761191882","doi":"10.7759/cureus.1774","title":"The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors","year":2017,"lang":"en","type":"review","venue":"Cureus","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Adverse effect; Immune system; Immune checkpoint; Melanoma; Nivolumab; Immune dysregulation; Oncology; Immunology; Internal medicine; Immunotherapy; Cancer research","score_opus":0.06495064639638068,"score_gpt":0.3783761175569654,"score_spread":0.3134254711605847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761191882","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004038674,0.98196745,0.000024752138,0.0069651376,0.006243256,0.0026568286,0.000071323695,0.000038380145,0.001992502],"genre_scores_gemma":[0.00009509457,0.99570245,0.000026365391,0.00010034999,0.00087054947,0.000510192,0.0001718075,0.000063096944,0.0024601258],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969877,0.00018892462,0.0015719736,0.0004311379,0.0003934755,0.00042681597],"domain_scores_gemma":[0.995878,0.00006545437,0.0014851835,0.0020450077,0.00043065462,0.0000956896],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006846185,0.00046855377,0.0012870821,0.000071530274,0.00079167594,0.000067586276,0.0011036667,0.00026926177,0.00044993436],"category_scores_gemma":[0.00019315472,0.00024822785,0.0011376388,0.0005825192,0.00026446968,0.00010619914,0.0002213256,0.00047659242,0.000080882215],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008709514,0.00020622012,0.000002673605,0.00090452895,0.00072377204,0.0000021032902,0.00022656439,5.759223e-7,0.00049251574,0.00004667167,0.032775674,0.9645316],"study_design_scores_gemma":[0.0002952394,0.00024796173,0.0004717367,0.0059524314,0.0010624669,0.00001965599,0.00048668892,0.0000025073557,0.00005483019,0.00004379927,0.991094,0.0002687141],"about_ca_topic_score_codex":0.0002987181,"about_ca_topic_score_gemma":0.0002419647,"teacher_disagreement_score":0.9642629,"about_ca_system_score_codex":0.00031567545,"about_ca_system_score_gemma":0.00047817256,"threshold_uncertainty_score":0.999997},"labels":[],"label_agreement":null},{"id":"W2761452338","doi":"10.1093/annonc/mdx440.005","title":"Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":185,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tumor-infiltrating lymphocytes; Cohort; Internal medicine; Oncology; Breast cancer; Triple-negative breast cancer; Lymph node; Pembrolizumab; Cancer; Immunotherapy","score_opus":0.1800278887842173,"score_gpt":0.4355927975528641,"score_spread":0.2555649087686468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761452338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735937,0.0004964266,0.000018945384,0.022590654,0.00015185276,0.0006098506,0.0014426258,0.000018026136,0.0010779127],"genre_scores_gemma":[0.99656844,0.00008603065,0.0010492973,0.0016789321,0.00013478739,0.000058736245,0.00002437981,0.000024529178,0.00037489462],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99759036,0.000497306,0.00087155873,0.00043719652,0.00023562432,0.0003679236],"domain_scores_gemma":[0.99546874,0.0028747586,0.000707398,0.0005445735,0.0002203222,0.00018421818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016740017,0.0002250721,0.0007893217,0.00028925203,0.00020587776,0.000035346435,0.0002239877,0.00014192714,0.00006251775],"category_scores_gemma":[0.003912494,0.00020380455,0.00010906084,0.00021603839,0.00033606222,0.0002206808,0.00008877303,0.00025323092,0.0000076005986],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40504187,0.00035586412,0.35497954,0.00011984784,0.00063377165,0.00029906706,0.012889508,0.000027874366,0.024373801,0.000058772486,0.0026232284,0.19859686],"study_design_scores_gemma":[0.021365471,0.0014990055,0.96596634,0.00038622864,0.000093972325,0.000053998858,0.0006418939,0.000036939095,0.0073295175,0.00042972193,0.0020025908,0.00019434182],"about_ca_topic_score_codex":0.014798441,"about_ca_topic_score_gemma":0.002490331,"teacher_disagreement_score":0.61098677,"about_ca_system_score_codex":0.0002823111,"about_ca_system_score_gemma":0.0011900873,"threshold_uncertainty_score":0.9917621},"labels":[],"label_agreement":null},{"id":"W2761835542","doi":"10.1093/annonc/mdx374.056","title":"Pembrolizumab plus chemoradiation (CRT) for the treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Phase 3 KEYNOTE-412 trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Placebo; Regimen; Internal medicine; Head and neck squamous-cell carcinoma; Oncology; Surgery; Radiation therapy; Head and neck cancer; Immunotherapy; Cancer; Pathology","score_opus":0.0787968731189083,"score_gpt":0.4089477882456363,"score_spread":0.330150915126728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761835542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98817307,0.004518115,0.00007603765,0.0037759144,0.0003031535,0.0014486382,0.000047307803,0.000007728259,0.0016500201],"genre_scores_gemma":[0.99681896,0.0019630548,0.00017183377,0.0002881803,0.00021389883,0.00012310705,0.00001944298,0.000015339874,0.00038620728],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99908316,0.00004542346,0.00036891,0.0001941284,0.00010793361,0.00020041413],"domain_scores_gemma":[0.99852264,0.0003871404,0.00046678525,0.0004139954,0.000146557,0.000062887884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022212003,0.00014159553,0.00052387867,0.00005216473,0.00013471491,0.000010357153,0.00011702355,0.00014463694,0.00002582849],"category_scores_gemma":[0.0000949989,0.00009665649,0.00020562744,0.000034363467,0.00030047251,0.000058189515,0.000014331195,0.000051331037,6.905156e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48847836,0.0018708154,0.00027746416,0.0001072827,0.000121622266,0.000014496953,0.0008780567,0.000008534046,0.012858656,0.000030328365,0.0008716575,0.49448273],"study_design_scores_gemma":[0.6445132,0.10699482,0.014044743,0.00003096791,0.00030520838,0.00003374349,0.00020063683,0.00078160065,0.0968486,0.000083501516,0.13600966,0.0001533086],"about_ca_topic_score_codex":0.0003998446,"about_ca_topic_score_gemma":0.00012240768,"teacher_disagreement_score":0.4943294,"about_ca_system_score_codex":0.0000931705,"about_ca_system_score_gemma":0.00044673018,"threshold_uncertainty_score":0.39415374},"labels":[],"label_agreement":null},{"id":"W2762092110","doi":"10.1101/198101","title":"The interface of malignant and immunologic clonal dynamics in high-grade serous ovarian cancer","year":2017,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia; Canada's Michael Smith Genome Sciences Centre; Vancouver General Hospital; BC Cancer Agency; BC Children's Hospital","funders":"BC Cancer Foundation; Canada Research Chairs; Michael Smith Health Research BC; Genome British Columbia; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Research Society; Genome Canada","keywords":"Serous fluid; Ovarian cancer; Biology; CD8; Immune system; Cytotoxic T cell; Transcriptome; Cancer research; Cancer; Immunohistochemistry; Gene expression profiling; Gene; Immunology; Gene expression; Genetics","score_opus":0.015460263216432565,"score_gpt":0.2682839400726151,"score_spread":0.2528236768561825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762092110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97368217,0.02152705,0.000069813024,0.0023525415,0.0012649358,0.0007768593,0.00025511562,0.00006383613,0.00000771191],"genre_scores_gemma":[0.9847907,0.01423014,0.0005060158,0.00009412058,0.00013506642,0.0001541908,3.7357646e-7,0.000064355336,0.00002507411],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979615,0.00010705373,0.00059432304,0.0006182222,0.00027850908,0.00044035696],"domain_scores_gemma":[0.9976757,0.00007901159,0.00063107116,0.0012975527,0.00022043788,0.00009622798],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007217685,0.00041620372,0.00069476635,0.00016346252,0.00018880487,0.00011927387,0.0005259357,0.0004930944,0.000020128658],"category_scores_gemma":[0.000098755474,0.0003139466,0.00013132663,0.00017763033,0.000499672,0.00006561527,0.00043530404,0.00079985504,0.0000021207998],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030985775,0.00038056218,0.1559741,0.0012414125,0.0015389675,0.00018271599,0.000052765383,0.00003125644,0.8353468,0.0016407007,0.00021715488,0.0002949541],"study_design_scores_gemma":[0.0027091075,0.00019149405,0.9047552,0.0022131917,0.00019258495,2.1227807e-7,0.00001904884,0.00066887715,0.08608669,0.00000950713,0.0026440676,0.0005100492],"about_ca_topic_score_codex":0.0031240515,"about_ca_topic_score_gemma":0.00031408673,"teacher_disagreement_score":0.7492601,"about_ca_system_score_codex":0.00074955885,"about_ca_system_score_gemma":0.0007613117,"threshold_uncertainty_score":0.9999313},"labels":[],"label_agreement":null},{"id":"W2762153201","doi":"10.1016/j.semcancer.2017.10.003","title":"Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer","year":2017,"lang":"en","type":"review","venue":"Seminars in Cancer Biology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":432,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Advancing Health Outcomes","funders":"Centro de Investigación Biomédica en Red de Cáncer; Breast Cancer Research Foundation","keywords":"Medicine; Breast cancer; Oncology; Ductal carcinoma; Tumor-infiltrating lymphocytes; Internal medicine; Neoadjuvant therapy; Cancer; Immunotherapy","score_opus":0.1306686927296367,"score_gpt":0.43061170924415293,"score_spread":0.29994301651451627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762153201","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40793225,0.58316195,2.6031668e-7,0.0050809905,0.0014229213,0.0015157462,0.0006782441,0.000009444209,0.00019815308],"genre_scores_gemma":[0.36083868,0.6360243,0.000032849915,0.0008400307,0.00018189261,0.0018794005,0.00012683506,0.000048024944,0.000028016106],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99552685,0.00066140055,0.0017849403,0.0010892805,0.00026349333,0.00067403185],"domain_scores_gemma":[0.9974847,0.00050285686,0.0011096721,0.0007212773,0.00007384109,0.00010766117],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016409667,0.0006254478,0.001906525,0.0014135519,0.00007885512,0.0000397008,0.00063886814,0.00043881356,0.0001959591],"category_scores_gemma":[0.00011858633,0.00047458647,0.00021715277,0.0009198907,0.00031722704,0.00011125229,0.0003397857,0.0008402558,7.7671154e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062386557,0.0002458253,0.35327938,0.00042664647,0.000112739166,0.00048464112,0.00036056017,0.000010365236,0.00057851925,0.0000050355225,0.00018701375,0.63807064],"study_design_scores_gemma":[0.0051015397,0.0001854744,0.7691303,0.08771375,0.00008498458,0.0005361629,0.00022583334,0.000043800126,0.00007626103,0.000029233386,0.13623528,0.0006373754],"about_ca_topic_score_codex":0.019704351,"about_ca_topic_score_gemma":0.07090208,"teacher_disagreement_score":0.63743323,"about_ca_system_score_codex":0.005820308,"about_ca_system_score_gemma":0.002434949,"threshold_uncertainty_score":0.9997706},"labels":[],"label_agreement":null},{"id":"W2762414606","doi":"10.1093/annonc/mdx440.051","title":"ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Durvalumab; Neutropenia; Internal medicine; Gastroenterology; Adverse effect; Lung cancer; Chemotherapy; Surgery; Urology; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.03829033952117692,"score_gpt":0.3702188285745939,"score_spread":0.33192848905341693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762414606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819776,0.0020648865,0.0000068699596,0.0020161376,0.00028831908,0.0014911629,0.000055508044,0.000026935057,0.012072598],"genre_scores_gemma":[0.98923945,0.0035990295,0.00029468143,0.0016323453,0.000093311166,0.00021845514,0.000033495424,0.000051722676,0.004837512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979531,0.00009525967,0.00061163097,0.00047068283,0.00025682387,0.000612515],"domain_scores_gemma":[0.9978455,0.00010704147,0.00071502343,0.000761207,0.00041464632,0.0001566165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003241713,0.00031082396,0.0008798194,0.00018014575,0.00016190512,0.000025176189,0.0003452763,0.00027162614,0.00022095517],"category_scores_gemma":[0.00010452617,0.00022405761,0.00015773943,0.00018912852,0.00033239368,0.00019712669,0.00007011045,0.0002568981,0.0000079472575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040268086,0.0048019164,0.7649158,0.00058782136,0.00048883056,0.00017753837,0.0016242465,0.0000072216603,0.0020345734,0.0000056220015,0.0045366725,0.18055166],"study_design_scores_gemma":[0.052653693,0.01001497,0.88954425,0.0008680489,0.00015576524,0.000011272578,0.00017213981,0.00004529322,0.0050769923,0.000013074802,0.041098252,0.00034624466],"about_ca_topic_score_codex":0.003331792,"about_ca_topic_score_gemma":0.0062172427,"teacher_disagreement_score":0.18020542,"about_ca_system_score_codex":0.00025349748,"about_ca_system_score_gemma":0.0009961167,"threshold_uncertainty_score":0.91368043},"labels":[],"label_agreement":null},{"id":"W2762460629","doi":"10.1093/annonc/mdx374","title":"Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"MacroGenics; Genentech; AstraZeneca; Celgene; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Durvalumab; Head and neck squamous-cell carcinoma; Internal medicine; Clinical endpoint; Oncology; Immunotherapy; Regimen; Chemotherapy; Phases of clinical research; Radiation therapy; Cancer; Head and neck cancer; Clinical trial; Pembrolizumab","score_opus":0.16130445258756126,"score_gpt":0.4264112029151277,"score_spread":0.2651067503275664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762460629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892314,0.0028708086,0.00001227009,0.0037968154,0.0004170644,0.0015214179,0.00043213705,0.00001792332,0.0017001813],"genre_scores_gemma":[0.99790365,0.00014623778,0.000745259,0.0005265881,0.00015782278,0.0000760687,0.000098668635,0.000025461799,0.00032025957],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9983207,0.00013179683,0.0006210639,0.00043805147,0.00017066383,0.0003177487],"domain_scores_gemma":[0.99786556,0.0005178641,0.00060157455,0.00067535794,0.00020756968,0.00013205817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059337047,0.00020290393,0.0006595311,0.000104115425,0.000203519,0.000025368947,0.00020154889,0.000109882014,0.000039964812],"category_scores_gemma":[0.00046975986,0.00017843308,0.00015978607,0.000050198858,0.00025427656,0.00010002795,0.00008070931,0.00013671933,0.0000032762498],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3843017,0.029702818,0.004931696,0.00030556883,0.00038779608,0.000360468,0.006469677,6.629998e-7,0.013245406,0.000004221568,0.022441046,0.53784895],"study_design_scores_gemma":[0.19644336,0.5687387,0.14833057,0.00020443194,0.0008301198,0.0000852042,0.0026861297,0.00037989853,0.023702497,0.00030164153,0.05783622,0.000461249],"about_ca_topic_score_codex":0.0010963879,"about_ca_topic_score_gemma":0.0003120833,"teacher_disagreement_score":0.53903586,"about_ca_system_score_codex":0.000046170073,"about_ca_system_score_gemma":0.00022683588,"threshold_uncertainty_score":0.727629},"labels":[],"label_agreement":null},{"id":"W2762643147","doi":"10.1093/annonc/mdx364.015","title":"KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Triple-negative breast cancer; Placebo; Oncology; Breast cancer; Chemotherapy; Internal medicine; Adjuvant; Cancer; Alternative medicine; Immunotherapy; Pathology","score_opus":0.05267274810334072,"score_gpt":0.41567765299517073,"score_spread":0.36300490489183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762643147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.969497,0.0023836913,0.000039892904,0.016009778,0.0008431646,0.006488688,0.0005969164,0.000079973346,0.004060871],"genre_scores_gemma":[0.98089546,0.0066650477,0.00014975083,0.005944035,0.00041211944,0.0010070271,0.0000869095,0.00015281189,0.0046868525],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952319,0.00028310344,0.0015954843,0.0010782501,0.00077196205,0.0010392858],"domain_scores_gemma":[0.9941819,0.0006589857,0.0022545329,0.0015226118,0.0010114844,0.0003705313],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013242892,0.0008255578,0.0027878059,0.00030950367,0.00048304332,0.000054131433,0.0009794325,0.00061886146,0.001558343],"category_scores_gemma":[0.00032997693,0.00069596514,0.0008387632,0.0002813965,0.00083064544,0.00032040486,0.00012555788,0.00049719366,0.0000132009445],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6138034,0.009684311,0.0011075884,0.00016715426,0.003264929,0.000073115705,0.005134975,0.0000032720382,0.119092666,0.00001967836,0.06712094,0.18052799],"study_design_scores_gemma":[0.508128,0.061808366,0.014627969,0.00044843182,0.0005283833,0.00024010336,0.0032284635,0.00020573333,0.3221379,0.00020276078,0.08742824,0.0010156895],"about_ca_topic_score_codex":0.0073326887,"about_ca_topic_score_gemma":0.00063428184,"teacher_disagreement_score":0.2030452,"about_ca_system_score_codex":0.00033145654,"about_ca_system_score_gemma":0.001693944,"threshold_uncertainty_score":0.99954915},"labels":[],"label_agreement":null},{"id":"W2762651948","doi":"10.1093/annonc/mdx367.030","title":"Immune related adverse events (irAEs) in early phase immunotherapy (IO) trials: Implications for recommended phase 2 dose (RP2D) determination","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Discontinuation; Adverse effect; Internal medicine; Gastroenterology; Endocrine system; Surgery","score_opus":0.2148737949930711,"score_gpt":0.5153160146034517,"score_spread":0.30044221961038053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762651948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741636,0.0009734647,0.00025658845,0.02071747,0.0005105046,0.002049148,0.0001476783,0.000030920346,0.001150621],"genre_scores_gemma":[0.9953842,0.0020974854,0.0006897995,0.0007813258,0.00008519175,0.00035758232,0.00014543638,0.000032176173,0.00042679938],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99756384,0.00026920222,0.0014197308,0.00030648353,0.00010990897,0.0003308237],"domain_scores_gemma":[0.9969437,0.00047161558,0.0014559717,0.0007718586,0.00028005618,0.00007681462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003014059,0.00019531987,0.0009156885,0.00028034177,0.00020535555,0.0000096672275,0.00030955323,0.00030196994,0.00018250516],"category_scores_gemma":[0.00087134575,0.00017838042,0.00049522525,0.00013978414,0.00014210766,0.00024717266,0.00003293981,0.00018098984,0.0000068662675],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02934639,0.0030457636,0.0012647939,0.000035294473,0.00035900096,0.0000082074475,0.00076260214,3.8413876e-7,0.18381114,0.00009919221,0.00086606416,0.7804012],"study_design_scores_gemma":[0.31304216,0.033761177,0.42362645,0.000509572,0.00037182827,0.000101292506,0.0003346,0.00036935543,0.058118373,0.0062580486,0.1628339,0.000673245],"about_ca_topic_score_codex":0.0003375692,"about_ca_topic_score_gemma":0.00010800502,"teacher_disagreement_score":0.77972794,"about_ca_system_score_codex":0.0001268096,"about_ca_system_score_gemma":0.00029656396,"threshold_uncertainty_score":0.72741425},"labels":[],"label_agreement":null},{"id":"W2763004155","doi":"10.1016/j.ejca.2017.08.032","title":"Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Health Sciences Centre; Jewish General Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Alcohol and Drug Abuse Institute, University of Washington; Merck","keywords":"Ipilimumab; Pembrolizumab; Medicine; Oncology; Internal medicine; Melanoma; Immunotherapy; Cancer; Cancer research","score_opus":0.01614722972116736,"score_gpt":0.29094432069674336,"score_spread":0.27479709097557603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763004155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967468,0.00045618418,0.0000018104803,0.00015653831,0.00053929246,0.00072045275,0.000004368405,0.000004680184,0.0013698817],"genre_scores_gemma":[0.9996476,0.00009347859,0.000054965873,0.000054777498,0.000039594215,0.0000072401454,0.0000011820143,0.000034878412,0.00006626112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997847,0.00021156731,0.0010100962,0.00017770559,0.0005473085,0.00020631142],"domain_scores_gemma":[0.9976316,0.000056505163,0.001507052,0.0004359064,0.0002853646,0.000083553234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004794751,0.00018819301,0.0006890515,0.0002439647,0.00005484463,0.000022135897,0.00021651454,0.000022042394,0.00006466044],"category_scores_gemma":[0.00019701126,0.0001267424,0.00012971763,0.000119276316,0.00008245669,0.00019813827,0.000038479444,0.00025573198,8.4689594e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30845466,0.001032134,0.6333559,0.000016885595,0.00047922193,0.0003816497,0.0014489416,0.00004834285,0.0002606353,1.4139157e-7,0.000035365025,0.054486122],"study_design_scores_gemma":[0.31077358,0.0060979873,0.6817532,0.00031530843,0.00010286675,0.0000045779657,0.0003692727,0.0000021955977,0.00018978133,3.628938e-7,0.00029645322,0.00009440268],"about_ca_topic_score_codex":0.00014415922,"about_ca_topic_score_gemma":0.00033008622,"teacher_disagreement_score":0.05439172,"about_ca_system_score_codex":0.00019696061,"about_ca_system_score_gemma":0.00017549624,"threshold_uncertainty_score":0.51684046},"labels":[],"label_agreement":null},{"id":"W2763012859","doi":"10.1200/jco.2017.35.15_suppl.9093","title":"Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Clinical endpoint; Nivolumab; Oncology; Rash; Adverse effect; Diarrhea; Cohort; Ipilimumab; Gastroenterology; Clinical trial; Immunotherapy; Cancer","score_opus":0.17941705955805842,"score_gpt":0.4993057137901145,"score_spread":0.3198886542320561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763012859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974512,0.002670497,0.0002073292,0.018617362,0.0024793874,0.0006238091,0.000033791766,0.000014919664,0.00084094517],"genre_scores_gemma":[0.9825799,0.009307582,0.002161885,0.0019814149,0.0013785971,0.00002619305,0.000012570956,0.000034510904,0.0025173393],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969707,0.000104611114,0.0020285612,0.0003168345,0.0002601404,0.00031916858],"domain_scores_gemma":[0.9943565,0.0020302364,0.002461538,0.0005138065,0.00026825472,0.0003696437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011247005,0.00026226896,0.00208224,0.000078693185,0.00024148921,0.00004260862,0.00027962052,0.00043242075,0.00029684012],"category_scores_gemma":[0.0020731941,0.0001711647,0.0008972788,0.000027476277,0.0003982162,0.00021893115,0.000067141016,0.00039422122,0.000012975243],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.089788914,0.0015004581,0.13956328,0.000047719033,0.002141368,0.0005027054,0.000169425,0.0000031694487,0.0005780221,0.000012045222,0.00044825955,0.76524466],"study_design_scores_gemma":[0.115234084,0.032538515,0.7862044,0.00031534274,0.0010886414,0.00024581543,0.000060752747,0.00008147019,0.00045857657,0.0003476758,0.06321537,0.00020935954],"about_ca_topic_score_codex":0.00017591058,"about_ca_topic_score_gemma":0.00079940323,"teacher_disagreement_score":0.7650353,"about_ca_system_score_codex":0.00044617927,"about_ca_system_score_gemma":0.0010851414,"threshold_uncertainty_score":0.69798946},"labels":[],"label_agreement":null},{"id":"W2763214421","doi":"10.2147/tcrm.s144681","title":"A rare case of lung carcinoma acquires multidrug-resistant &lt;em&gt;Klebsiella pneumoniae&lt;/em&gt; pneumonia radiologically mimicking metastasis caused by nivolumab therapy-associated neutropenia","year":2017,"lang":"en","type":"article","venue":"Therapeutics and Clinical Risk Management","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Government of Jiangsu Province; National Natural Science Foundation of China; Saskatchewan Cancer Agency","keywords":"Medicine; Klebsiella pneumoniae; Nivolumab; Pneumonia; Neutropenia; Multiple drug resistance; Metastasis; Lung; Internal medicine; Pathology; Oncology; Microbiology; Chemotherapy; Drug resistance; Cancer; Immunotherapy; Escherichia coli","score_opus":0.039551006353837743,"score_gpt":0.32544344739257286,"score_spread":0.2858924410387351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763214421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848939,0.011399217,0.00006837761,0.0008685801,0.0003504176,0.0015003484,0.00025481114,0.00008895429,0.0005753523],"genre_scores_gemma":[0.9469367,0.050726425,0.00031084672,0.0010205277,0.00009558847,0.000055458342,0.000048403497,0.00008411711,0.0007218853],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9955124,0.0006247284,0.001573173,0.0009763855,0.0005660656,0.00074722624],"domain_scores_gemma":[0.9960706,0.0005024961,0.0014148883,0.0015079952,0.0002162137,0.00028777783],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00223069,0.0006211184,0.0014022993,0.00013994613,0.0008344594,0.00026849264,0.0006411488,0.0003615009,0.000111240755],"category_scores_gemma":[0.00010267326,0.00047503476,0.0006962245,0.00019300864,0.000638049,0.00013234743,0.00034103717,0.0004897833,0.0000061000055],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016168354,0.003659694,0.15329355,0.0003956792,0.016536565,0.0034214235,0.0018047222,0.000008637704,0.0759215,0.00029868042,0.0020688272,0.72642237],"study_design_scores_gemma":[0.03211289,0.00443583,0.9130663,0.00049608294,0.005355328,0.00012587495,0.0013442519,0.004335157,0.0017436377,0.00024846528,0.035386797,0.0013493474],"about_ca_topic_score_codex":0.00045398326,"about_ca_topic_score_gemma":0.0007304882,"teacher_disagreement_score":0.7597728,"about_ca_system_score_codex":0.00016955542,"about_ca_system_score_gemma":0.00007609166,"threshold_uncertainty_score":0.9997701},"labels":[],"label_agreement":null},{"id":"W2763417272","doi":"10.1093/annonc/mdx369.157","title":"KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Sorafenib; Medicine; Pembrolizumab; Internal medicine; Adverse effect; Placebo; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Oncology; Clinical trial; Surgery; Phases of clinical research; Cancer; Immunotherapy; Pathology; Alternative medicine","score_opus":0.09005920300160238,"score_gpt":0.42564074388608303,"score_spread":0.33558154088448067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763417272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893324,0.0022630591,0.0000812055,0.0012866221,0.0004458049,0.004005067,0.00023105169,0.000019032454,0.0023357759],"genre_scores_gemma":[0.99734086,0.0003250296,0.00025002542,0.00048619395,0.00015935939,0.00035926758,0.00010670633,0.000042831205,0.00092971936],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974879,0.0002198737,0.0011459212,0.00045247487,0.000264521,0.00042932967],"domain_scores_gemma":[0.9961089,0.00043764018,0.0013845167,0.0009131235,0.0010096302,0.00014620871],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00085208105,0.0003061903,0.002229439,0.00019223134,0.00019584913,0.000011667903,0.00035858483,0.00024065354,0.00033662145],"category_scores_gemma":[0.0005125523,0.00025602634,0.0006426794,0.00008377658,0.00056625635,0.00013338473,0.00008755484,0.0001863545,0.0000035773216],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89080447,0.0048288684,0.005233305,0.0006489603,0.0012104133,0.0001563687,0.0054654246,0.0000029306068,0.03620316,0.000028958611,0.0012122067,0.05420493],"study_design_scores_gemma":[0.7644432,0.05707903,0.003283771,0.00014997943,0.00077160506,0.00004352762,0.005337071,0.00021341137,0.14954743,0.00009322307,0.01873618,0.00030153754],"about_ca_topic_score_codex":0.0005651652,"about_ca_topic_score_gemma":0.00038218615,"teacher_disagreement_score":0.12636124,"about_ca_system_score_codex":0.00007791067,"about_ca_system_score_gemma":0.0005932662,"threshold_uncertainty_score":0.9999892},"labels":[],"label_agreement":null},{"id":"W2764006529","doi":"10.1200/jco.2017.35.15_suppl.9013","title":"A phamacoeconomic analysis of personalized dosing versus fixed dosing of pembrolizumab in first-line PD-L1 positive non-small cell lung cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dosing; Medicine; Pembrolizumab; Lung cancer; Population; Internal medicine; Oncology; Cancer; Immunotherapy","score_opus":0.08819770977649027,"score_gpt":0.45779028894337037,"score_spread":0.3695925791668801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764006529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916941,0.0023010513,0.00011732926,0.0028669292,0.0011657648,0.000217914,0.00002681852,0.0000024113817,0.0016077135],"genre_scores_gemma":[0.99420685,0.0040011327,0.0008578814,0.00037874252,0.00041321313,0.000003457059,0.000004351513,0.000016095859,0.000118303054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962404,0.00022789832,0.0028179162,0.00023457666,0.0002248888,0.00025434734],"domain_scores_gemma":[0.9920294,0.001923898,0.0051597054,0.00031576105,0.00039888214,0.0001723032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002424061,0.00017755535,0.0025859824,0.00043468404,0.00008306572,0.00001524991,0.0003290731,0.00034932917,0.000312896],"category_scores_gemma":[0.0007906117,0.00014465266,0.0013757445,0.00022289484,0.00045818283,0.00013882075,0.00006560336,0.0006218281,6.0754724e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39147574,0.003055315,0.4831864,0.00035436367,0.015055837,0.00043235577,0.0020302336,0.00093501894,0.019936081,0.000013852607,0.0005096838,0.08301514],"study_design_scores_gemma":[0.081572734,0.007842435,0.8900156,0.00075356936,0.0072305403,0.000027989356,0.00027941263,0.0070217717,0.0036577098,0.00000952729,0.0014044163,0.0001843142],"about_ca_topic_score_codex":0.0014975544,"about_ca_topic_score_gemma":0.0019790288,"teacher_disagreement_score":0.40682918,"about_ca_system_score_codex":0.0005281781,"about_ca_system_score_gemma":0.001677102,"threshold_uncertainty_score":0.5898764},"labels":[],"label_agreement":null},{"id":"W2764212839","doi":"10.1093/annonc/mdx380.002","title":"Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; University of Ottawa; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Discontinuation; Randomized controlled trial; Internal medicine; Adverse effect; Lung cancer; Surgery; Oncology; Cancer; Immunotherapy","score_opus":0.02308003937331568,"score_gpt":0.3364791698968296,"score_spread":0.31339913052351387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764212839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858757,0.00064218027,0.000025787514,0.0018131024,0.0002478896,0.0012627629,0.000041554045,0.000008014526,0.010082956],"genre_scores_gemma":[0.99715406,0.0012368371,0.0003155103,0.0004586781,0.00004465921,0.000087095344,0.000031617114,0.00001634957,0.00065518613],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99846417,0.00012048286,0.0007549873,0.00024462215,0.00017622515,0.00023948977],"domain_scores_gemma":[0.9977122,0.00018409261,0.0012004385,0.00042126508,0.00042969856,0.000052320895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007046175,0.00015139632,0.0010071418,0.00011951306,0.00005691473,0.000007058878,0.00016729545,0.0001575463,0.000037055903],"category_scores_gemma":[0.00024442925,0.00011572044,0.00014383248,0.00007883192,0.0002910737,0.00010697827,0.000032400287,0.00013217627,0.0000010756538],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8618175,0.0008608957,0.049777012,0.000196726,0.00025942823,0.000016134725,0.001614772,0.000016775537,0.0064167106,0.0000042710676,0.0022686422,0.076751135],"study_design_scores_gemma":[0.7228142,0.007274636,0.21802832,0.00076412916,0.00015119604,0.0000024287472,0.00014102973,0.00016700917,0.045898765,0.000010872617,0.0045567653,0.00019065558],"about_ca_topic_score_codex":0.002362406,"about_ca_topic_score_gemma":0.0013133334,"teacher_disagreement_score":0.1682513,"about_ca_system_score_codex":0.000088078916,"about_ca_system_score_gemma":0.0005175459,"threshold_uncertainty_score":0.47189426},"labels":[],"label_agreement":null},{"id":"W2765326687","doi":"10.1158/2326-6066.cir-17-0175","title":"Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence","year":2017,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"Rosetrees Trust; National Cancer Institute; National Institute for Health and Care Research; Cancer Research UK","keywords":"Subversion; Immune system; Tumor necrosis factor alpha; Immunotherapy; Immunology; Medicine; Cancer research; Biology; Political science","score_opus":0.058015048956315964,"score_gpt":0.3881521610682535,"score_spread":0.3301371121119375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765326687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92915136,0.06452041,0.000004207559,0.0025823715,0.00039832882,0.00039946302,0.000025927562,0.000018311846,0.002899628],"genre_scores_gemma":[0.9666458,0.03087319,0.00006588549,0.000039391005,0.00007269182,0.000053741365,0.0000075088656,0.00001965526,0.0022221538],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99826294,0.00019174349,0.0003113451,0.00039983378,0.00033140273,0.0005027036],"domain_scores_gemma":[0.9980731,0.00019570629,0.00021742783,0.0010090574,0.00042907128,0.00007563764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011621827,0.00015335677,0.00043776626,0.00020684919,0.00054904236,0.00004148475,0.0004904429,0.00013831754,0.00033583617],"category_scores_gemma":[0.00026424127,0.00013238825,0.000091308284,0.00018023053,0.0024146636,0.00013494612,0.0003282829,0.0005641572,0.000016902386],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052445354,0.00013955431,0.17154017,0.00029874942,0.00019492189,0.00003866257,0.00043372455,1.6589453e-7,0.7785404,0.000076824195,0.0010593173,0.042432997],"study_design_scores_gemma":[0.004159488,0.00086692616,0.7564965,0.0004089888,0.000016280244,0.000048102964,0.00044189687,0.000022548684,0.22700469,0.00010063564,0.01026954,0.00016443142],"about_ca_topic_score_codex":0.0019775128,"about_ca_topic_score_gemma":0.000100553465,"teacher_disagreement_score":0.5849563,"about_ca_system_score_codex":0.00013514342,"about_ca_system_score_gemma":0.00041493453,"threshold_uncertainty_score":0.88969284},"labels":[],"label_agreement":null},{"id":"W2765953690","doi":"10.1001/jamaoncol.2017.3290","title":"Dose-Response Association of CD8<sup>+</sup> Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer","year":2017,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":404,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Royal Alexandra Hospital; Vancouver General Hospital; Alberta Health Services; University of British Columbia; University of Calgary","funders":"National Center for Advancing Translational Sciences; Cancer Research UK; National Cancer Institute; National Center for Research Resources; Fogarty International Center; Francis Crick Institute","keywords":"Medicine; Tumor-infiltrating lymphocytes; Serous fluid; Oncology; CD8; Internal medicine; Ovarian cancer; Survival analysis; Immunotherapy; Cancer; Immune system; Immunology","score_opus":0.01761508240589437,"score_gpt":0.30840041665345425,"score_spread":0.29078533424755987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765953690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98590386,0.00031879888,0.0000023202956,0.012013783,0.00024759688,0.00028180686,0.00003819201,0.000023476196,0.0011701739],"genre_scores_gemma":[0.9972073,0.00017523304,0.0003315283,0.00078569585,0.00025158483,0.00003643701,0.000010088385,0.000019100431,0.0011830349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852836,0.00034475545,0.00039795038,0.00024283651,0.00019909134,0.0002870345],"domain_scores_gemma":[0.99838966,0.00067914446,0.00048646692,0.0002879552,0.000090013156,0.000066763765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015424142,0.00014405132,0.00052534643,0.00011614193,0.00013205007,0.000037953334,0.00013238957,0.0002567724,0.00021109458],"category_scores_gemma":[0.0008054337,0.00013202784,0.00006783303,0.00009780839,0.00013780234,0.00013739019,0.00005221096,0.0001916708,0.000007010498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034301277,0.00038378083,0.6150511,0.00012464833,0.0004555301,0.00024528604,0.0028564602,0.000057898225,0.26804054,0.000079175305,0.002484518,0.07591982],"study_design_scores_gemma":[0.017487414,0.0008719851,0.9647395,0.00015055823,0.00007792734,0.000056793506,0.00028201964,0.0012657479,0.0059139924,0.00005129246,0.008947015,0.00015575538],"about_ca_topic_score_codex":0.008452123,"about_ca_topic_score_gemma":0.0014236955,"teacher_disagreement_score":0.3496884,"about_ca_system_score_codex":0.001156443,"about_ca_system_score_gemma":0.00071654125,"threshold_uncertainty_score":0.9981507},"labels":[],"label_agreement":null},{"id":"W2766023480","doi":"10.1016/j.critrevonc.2017.10.009","title":"Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review","year":2017,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval; McGill University","funders":"","keywords":"Medicine; Concomitant; Clinical trial; Internal medicine; Systematic review; MEDLINE; Oncology; Radiation therapy; Immunotherapy; Hematology; Cancer","score_opus":0.11235881203892009,"score_gpt":0.42442660713128944,"score_spread":0.31206779509236937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766023480","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021142424,0.98726434,0.000007063357,0.00036999566,0.00034218357,0.011624372,0.000031358773,0.00002320897,0.00012606799],"genre_scores_gemma":[0.0002856079,0.99620956,0.0005924763,0.0006926576,0.000019834913,0.001999335,0.0000619664,0.000077848024,0.000060741237],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98896253,0.001995248,0.0069398726,0.0009647995,0.0003348972,0.00080265],"domain_scores_gemma":[0.99138,0.0037874435,0.0027428388,0.0015837534,0.0002578566,0.0002481508],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0025436012,0.0009803761,0.020146262,0.00049424043,0.00007168367,0.00003118395,0.0004781226,0.001133686,0.00010292312],"category_scores_gemma":[0.018855104,0.0005520249,0.00083848333,0.0005266151,0.0015890984,0.0001703522,0.0002774624,0.0012042123,0.000032317577],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070302514,0.0008450664,0.0006741982,0.9168569,0.00027733593,0.00077536143,0.000045068904,2.2121314e-9,6.6564775e-7,0.00032600234,0.00016252552,0.07933386],"study_design_scores_gemma":[0.0028931675,0.0021442783,0.00009979236,0.85575145,0.0034817208,0.003345291,0.000018959425,0.0000013232724,0.0000036253225,0.000021320024,0.13175012,0.00048894016],"about_ca_topic_score_codex":0.000027985056,"about_ca_topic_score_gemma":0.00011094074,"teacher_disagreement_score":0.1315876,"about_ca_system_score_codex":0.0006504523,"about_ca_system_score_gemma":0.0010616721,"threshold_uncertainty_score":0.9996931},"labels":[],"label_agreement":null},{"id":"W2766103705","doi":"10.1007/s41669-018-0112-1","title":"Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada); McGill University","funders":"Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Medicine; Pembrolizumab; Regimen; Internal medicine; Oncology; Progression-free survival; Cost effectiveness; Immunotherapy; Cancer; Chemotherapy","score_opus":0.023948478740535926,"score_gpt":0.33105219360357485,"score_spread":0.30710371486303895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766103705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992232,0.00012205694,0.0000022201446,0.0004613411,0.00035433134,0.0049003726,0.00013984775,0.0000039327165,0.0017838452],"genre_scores_gemma":[0.99851674,0.0001506462,0.00008926621,0.0002595723,0.000018077499,0.00035429015,0.00034662028,0.000024318888,0.0002404659],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990692,0.000026815213,0.00037602553,0.00026885959,0.0000979092,0.00016120287],"domain_scores_gemma":[0.9993241,0.0000711914,0.00024956313,0.00020711376,0.000096364536,0.000051695115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026627435,0.0001444538,0.0003724592,0.00007040766,0.000030218018,0.000016196384,0.00014667217,0.000027203163,0.00075009995],"category_scores_gemma":[0.000005731268,0.00013226268,0.00004619176,0.000038096372,0.000013507747,0.0002279716,0.000027708746,0.000036802823,0.00001283041],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09628028,0.0015450829,0.4573766,0.00025982744,0.0015391335,0.0000020946711,0.0007920453,0.039757762,0.00092539954,0.00018909926,0.0010570636,0.40027562],"study_design_scores_gemma":[0.47663832,0.009059108,0.2624628,0.0002862927,0.0007046829,0.000006469616,0.00048236066,0.19699495,0.02438547,0.00028584414,0.02788225,0.0008114814],"about_ca_topic_score_codex":0.44759476,"about_ca_topic_score_gemma":0.6351725,"teacher_disagreement_score":0.39946416,"about_ca_system_score_codex":0.006962179,"about_ca_system_score_gemma":0.0030710015,"threshold_uncertainty_score":0.9968499},"labels":[],"label_agreement":null},{"id":"W2766602219","doi":"10.1016/j.cjca.2017.09.025","title":"Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Nivolumab; Myocarditis; Fulminant; Ipilimumab; Immunotherapy; Complication; Cancer; Internal medicine; Incidence (geometry); Oncology","score_opus":0.0363093879874403,"score_gpt":0.2845153319284048,"score_spread":0.24820594394096449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766602219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.734479,0.083853915,0.008477504,0.06857898,0.025448186,0.0028193085,0.0005594674,0.000083086496,0.075700544],"genre_scores_gemma":[0.99452096,0.0007970972,0.00015212607,0.00022871116,0.0037572419,0.000009395268,0.000015291944,0.000028980903,0.00049018825],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99853915,0.00008206274,0.0005682186,0.0001854047,0.00012415588,0.0005010084],"domain_scores_gemma":[0.9978701,0.0000676852,0.0005687356,0.00049679965,0.00037288867,0.0006238001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009468049,0.00018552304,0.0010179497,0.00020203461,0.0003298951,0.000052338437,0.0003350974,0.00031847038,0.000021931748],"category_scores_gemma":[0.001058622,0.00016019605,0.001018382,0.00004447805,0.00035426382,0.000101482314,0.000017076296,0.00031939294,0.000004947608],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008431194,0.000036561534,0.11847385,0.00027665737,0.021227937,0.0044364245,0.0018516695,0.00020524341,0.027656674,0.00071701605,0.4117345,0.4049523],"study_design_scores_gemma":[0.008728775,0.00207999,0.3870428,0.00029940196,0.00043267824,0.0016696912,0.0001803224,0.0000048323423,0.0008050857,0.0007292989,0.5977575,0.00026959335],"about_ca_topic_score_codex":0.0035754307,"about_ca_topic_score_gemma":0.0024408337,"teacher_disagreement_score":0.4046827,"about_ca_system_score_codex":0.0004895947,"about_ca_system_score_gemma":0.0029696964,"threshold_uncertainty_score":0.6532605},"labels":[],"label_agreement":null},{"id":"W2766923414","doi":"10.1186/s40425-017-0290-x","title":"Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma","year":2017,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Hôpital Notre-Dame; Université du Québec à Montréal; Institute for Research in Immunology and Cancer; McGill University; Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"Bristol-Myers Squibb Canada; Réseau de cancérologie Rossy; Bristol-Myers Squibb","keywords":"Ipilimumab; Carboplatin; Medicine; Paclitaxel; Oncology; Melanoma; Internal medicine; Stage (stratigraphy); Blockade; Immune checkpoint; Chemotherapy; Immunotherapy; Cancer research; Cancer; Receptor; Cisplatin; Biology","score_opus":0.0230277490862044,"score_gpt":0.3553829253992408,"score_spread":0.3323551763130364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766923414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98132807,0.015156506,0.00038551664,0.0003114039,0.0006743197,0.0017578364,0.00018649155,0.000008494726,0.00019135648],"genre_scores_gemma":[0.9908253,0.0045322916,0.00021597723,0.00006679819,0.0001686918,0.0001538669,0.0000074842255,0.000054682267,0.003974893],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99759495,0.000087031214,0.0010951223,0.00030575562,0.0004934209,0.0004236988],"domain_scores_gemma":[0.9979107,0.00012724061,0.001170022,0.00047236026,0.00023548187,0.00008422995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010216548,0.00031012387,0.0010808539,0.00032827308,0.00030268787,0.00007220098,0.00030166018,0.00020319333,0.00046882217],"category_scores_gemma":[0.00006598277,0.0002152805,0.00023662695,0.00018293913,0.0005431052,0.00042466965,0.00004110079,0.0005052335,3.77492e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.786934,0.0010525263,0.0022378443,0.00021445222,0.00096216914,0.00005447149,0.0035480168,0.00016225876,0.1638057,0.000019388433,0.00007098018,0.040938184],"study_design_scores_gemma":[0.8331889,0.044850785,0.04752025,0.0025961443,0.00017984808,0.00006210901,0.003966191,0.0018629112,0.059502333,0.00009059368,0.005651886,0.0005280809],"about_ca_topic_score_codex":0.004946944,"about_ca_topic_score_gemma":0.0041285832,"teacher_disagreement_score":0.10430335,"about_ca_system_score_codex":0.0003898506,"about_ca_system_score_gemma":0.0008780247,"threshold_uncertainty_score":0.8778884},"labels":[],"label_agreement":null},{"id":"W2766962557","doi":"10.1158/0008-5472.can-17-0491","title":"Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Cancer Research UK; Wellcome Trust; Wellcome","keywords":"Blockade; Cancer; Antibody; Cancer therapy; Cancer research; Medicine; Immunology; Internal medicine; Receptor","score_opus":0.14389260925883182,"score_gpt":0.4744422395084106,"score_spread":0.33054963024957873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766962557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916856,0.0019597223,0.000048225953,0.0037867965,0.00018506893,0.0016272909,0.00007403488,0.0000127138255,0.000620502],"genre_scores_gemma":[0.9938328,0.0043936917,0.000026190208,0.00041520808,0.00025474027,0.00063992187,0.000013436552,0.000029912926,0.00039405256],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99828,0.00018444509,0.0002305343,0.00041214545,0.00050378736,0.00038909825],"domain_scores_gemma":[0.99884766,0.000039725775,0.0000875982,0.0005026876,0.00038723537,0.00013511788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008048668,0.00014258668,0.00029273008,0.00035092115,0.00019084293,0.0000525408,0.00022713664,0.00010224024,0.00038020714],"category_scores_gemma":[0.000041169274,0.00012331764,0.00008935215,0.00031813723,0.00027714553,0.00016523838,0.000034702523,0.00035138003,0.0000056111007],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072842385,0.0002302789,0.010009065,0.00008518708,0.00010537147,0.000020742094,0.0043490175,0.000005975544,0.91205627,0.0000127075355,0.00020093637,0.06564019],"study_design_scores_gemma":[0.003977356,0.0012026026,0.18895933,0.00064481515,0.000009071613,0.0000016666928,0.00021904628,0.000044486304,0.80361027,0.00006346049,0.0011570974,0.000110830086],"about_ca_topic_score_codex":0.033472598,"about_ca_topic_score_gemma":0.003682276,"teacher_disagreement_score":0.17895027,"about_ca_system_score_codex":0.0005052355,"about_ca_system_score_gemma":0.00027336582,"threshold_uncertainty_score":0.9729636},"labels":[],"label_agreement":null},{"id":"W2766985996","doi":"10.1097/pap.0000000000000162","title":"Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research","year":2017,"lang":"en","type":"review","venue":"Advances in Anatomic Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":720,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of British Columbia; University of Victoria; BC Cancer Agency","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Tumor-infiltrating lymphocytes; Oncology; Standardization; Immunotherapy; Biomarker; Medical physics; Response Evaluation Criteria in Solid Tumors; Internal medicine; Clinical trial; Cancer; Computer science; Biology","score_opus":0.12578917640441278,"score_gpt":0.4894863819423636,"score_spread":0.3636972055379508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766985996","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19527489,0.7961489,0.00031798513,0.0016305408,0.0002571251,0.0061535197,0.00018797185,0.000010266475,0.000018779552],"genre_scores_gemma":[0.19809908,0.77478397,0.022657016,0.000320098,0.00013165998,0.0037497873,0.00016417111,0.00009131052,0.0000029009327],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99184316,0.004049868,0.0017963056,0.0011795013,0.00029283518,0.0008383223],"domain_scores_gemma":[0.97880876,0.019118069,0.0012779667,0.00053029717,0.00019237655,0.000072536866],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.015565249,0.0005829577,0.0027569844,0.0006048706,0.0003336609,0.000286112,0.00046355097,0.00024765334,0.0000026994305],"category_scores_gemma":[0.008079808,0.00038910782,0.00024964052,0.0004342659,0.0012360051,0.00057770597,0.00030968915,0.0008862971,1.1555462e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015135089,0.00025436401,0.02944908,0.012613488,0.0003898759,0.0037971847,0.0018120931,4.982041e-7,0.0051812567,0.00015042724,0.000019952495,0.9311967],"study_design_scores_gemma":[0.0631383,0.0037218689,0.46412346,0.3049409,0.0030128406,0.08059573,0.025629865,0.0017549536,0.0006432026,0.005979274,0.043244783,0.003214814],"about_ca_topic_score_codex":0.00031794838,"about_ca_topic_score_gemma":0.0031863535,"teacher_disagreement_score":0.92798185,"about_ca_system_score_codex":0.0009980676,"about_ca_system_score_gemma":0.0027760866,"threshold_uncertainty_score":0.99985605},"labels":[],"label_agreement":null},{"id":"W2767221986","doi":"10.5858/arpa.2017-0041-ra","title":"Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II—The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer","year":2017,"lang":"en","type":"review","venue":"Archives of Pathology & Laboratory Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; BC Cancer Agency","funders":"","keywords":"Microsatellite instability; Pembrolizumab; Colorectal cancer; Context (archaeology); Immunotherapy; Cancer; Medicine; Oncology; DNA mismatch repair; Nivolumab; Immune checkpoint; Melanoma; Cancer immunotherapy; Internal medicine; Cancer research; Microsatellite; Biology; Genetics","score_opus":0.053962115133304726,"score_gpt":0.33750189250838913,"score_spread":0.2835397773750844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767221986","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47471425,0.5197216,4.657846e-7,0.00027027552,0.00007764841,0.0047556907,0.00039192959,0.00002506484,0.00004302409],"genre_scores_gemma":[0.21366411,0.7806074,0.000889683,0.00013609334,0.00017203487,0.004307989,0.000083796134,0.00012393654,0.0000149558255],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9951027,0.0005349361,0.0018368962,0.0012758437,0.0003264126,0.0009232376],"domain_scores_gemma":[0.9949221,0.0021560828,0.00165787,0.0006527371,0.00041538168,0.0001958426],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018735918,0.00095561944,0.0036502627,0.00046471722,0.00030120419,0.000028108067,0.00047544373,0.0005188483,0.000008994983],"category_scores_gemma":[0.000823134,0.0006112201,0.00020317415,0.0007997891,0.0024516776,0.00013193107,0.00018639666,0.0009924769,1.4608531e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004539562,0.00060191815,0.1319254,0.011274773,0.0006128291,0.00009346396,0.008736188,3.728736e-7,0.04332185,0.000021239779,0.0000013666148,0.79887104],"study_design_scores_gemma":[0.052207854,0.032595724,0.3559231,0.23279496,0.0047436063,0.00090283615,0.0031215537,0.0001661333,0.042965814,0.0011732607,0.26986855,0.003536625],"about_ca_topic_score_codex":0.002094625,"about_ca_topic_score_gemma":0.003371202,"teacher_disagreement_score":0.7953344,"about_ca_system_score_codex":0.00019146876,"about_ca_system_score_gemma":0.0020066488,"threshold_uncertainty_score":0.9996339},"labels":[],"label_agreement":null},{"id":"W2767287110","doi":"10.1016/s1470-2045(17)30690-3","title":"Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":349,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Quality of life (healthcare); Lung cancer; Discontinuation; Response Evaluation Criteria in Solid Tumors; Oncology; Clinical endpoint; Cancer; Clinical trial; Chemotherapy; Progressive disease; Immunotherapy; Nursing","score_opus":0.18616216440643962,"score_gpt":0.4962273689759054,"score_spread":0.3100652045694658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767287110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91165274,0.0010611933,0.00009745704,0.06862611,0.0029306712,0.0065281517,0.0003340748,0.000034705845,0.008734879],"genre_scores_gemma":[0.9901337,0.002504407,0.0013871811,0.0037818984,0.0007026153,0.0004729541,0.000191144,0.000036195193,0.0007899267],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997184,0.0004853861,0.0012421189,0.0004084145,0.00023073031,0.0004493856],"domain_scores_gemma":[0.9956933,0.00173261,0.001493737,0.00080476166,0.000168627,0.00010693764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032027632,0.00022200294,0.0014373505,0.000092525785,0.0002509063,0.000044575325,0.0008987804,0.00019487247,0.0000553449],"category_scores_gemma":[0.0021784748,0.00016322156,0.00016593825,0.00010108808,0.00034158496,0.00016050081,0.00011544837,0.00032263796,0.000005675601],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91526204,0.0017880724,0.000033287342,0.00004851667,0.0006152205,0.000009041111,0.0016373093,0.0000037492312,0.0019574775,0.0002770084,0.003323325,0.07504494],"study_design_scores_gemma":[0.958053,0.0065040262,0.0026915385,0.00019289774,0.00005534448,0.000008597883,0.00030353683,0.0004369573,0.00044704345,0.00012674267,0.031013735,0.00016658808],"about_ca_topic_score_codex":0.002048178,"about_ca_topic_score_gemma":0.0012608862,"teacher_disagreement_score":0.07848092,"about_ca_system_score_codex":0.00052398443,"about_ca_system_score_gemma":0.0008059217,"threshold_uncertainty_score":0.66559815},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2767905976","doi":"10.1016/j.jtho.2017.09.429","title":"OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Nivolumab; Medicine; Pemetrexed; Carboplatin; Chemotherapy; Gemcitabine; Internal medicine; Oncology; Cisplatin; Neutropenia; Surgery; Cancer; Immunotherapy","score_opus":0.03107285707539334,"score_gpt":0.40509584104625496,"score_spread":0.37402298397086164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767905976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9126274,0.0017900005,0.0050261472,0.07169034,0.0029193615,0.0012814935,0.00006277881,0.000060426584,0.004542053],"genre_scores_gemma":[0.96656173,0.00087668316,0.0236187,0.0046838247,0.0014111297,0.000037968686,0.000025750835,0.00008124933,0.0027029433],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980126,0.00006175558,0.0008865733,0.00026495356,0.0003211966,0.0004529072],"domain_scores_gemma":[0.9968092,0.00017486232,0.0017675252,0.00060962245,0.0004290306,0.00020979774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012157528,0.00027476813,0.000988146,0.00020015075,0.0003677829,0.00006634211,0.0004836671,0.0003113854,0.0005933132],"category_scores_gemma":[0.00019339024,0.00021849992,0.00051159126,0.00009586113,0.00024657373,0.00026103342,0.000038517985,0.00043555736,0.000020002002],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26629928,0.00087990344,0.0012672741,0.00041953914,0.0010708509,0.0002829672,0.00041896204,0.00025695426,0.044499356,0.000032435546,0.027815651,0.6567568],"study_design_scores_gemma":[0.06113664,0.009733895,0.0069840318,0.0007760606,0.00056815235,0.00075357157,0.00021478298,0.0012722893,0.05726826,0.00041455936,0.86038023,0.0004975156],"about_ca_topic_score_codex":0.000022828648,"about_ca_topic_score_gemma":0.00008717061,"teacher_disagreement_score":0.8325646,"about_ca_system_score_codex":0.00066862995,"about_ca_system_score_gemma":0.00083016016,"threshold_uncertainty_score":0.89101684},"labels":[],"label_agreement":null},{"id":"W2768791003","doi":"10.1093/annonc/mdx665.036","title":"KEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Head and neck squamous-cell carcinoma; Internal medicine; Placebo; Head and neck cancer; Oncology; Regimen; Phases of clinical research; Larynx; Response Evaluation Criteria in Solid Tumors; Urology; Cancer; Surgery; Clinical trial; Immunotherapy; Pathology","score_opus":0.06201928635590589,"score_gpt":0.39645764806864353,"score_spread":0.33443836171273766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768791003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895275,0.0014600427,0.0001294214,0.00383267,0.00037101452,0.001192993,0.000061769184,0.000013717322,0.003410862],"genre_scores_gemma":[0.99746686,0.0005246312,0.00051344244,0.0007338392,0.00024149001,0.00006995697,0.000041462077,0.000024787261,0.0003835038],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99864924,0.000061788895,0.000556414,0.00028303158,0.00016606107,0.00028347288],"domain_scores_gemma":[0.99821424,0.000258721,0.0006820848,0.00045923228,0.0002755905,0.000110102126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044508657,0.00017679276,0.0008196538,0.00010785158,0.000112882844,0.000012197428,0.00016531072,0.0002526594,0.000037275633],"category_scores_gemma":[0.00029750133,0.00016370484,0.00021005815,0.000054352884,0.00035205833,0.00011683337,0.000039186703,0.0001187642,0.0000013458675],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75850356,0.0015463989,0.0004571938,0.0004069777,0.000091139984,0.000032456486,0.00044625648,0.000006790649,0.055624165,0.000039571376,0.0036420817,0.17920339],"study_design_scores_gemma":[0.7076209,0.06306266,0.017174086,0.00008316437,0.00019609577,0.000059444792,0.00009949908,0.0005521686,0.14937253,0.00015768636,0.061373807,0.00024793757],"about_ca_topic_score_codex":0.00030586234,"about_ca_topic_score_gemma":0.00009263789,"teacher_disagreement_score":0.17895545,"about_ca_system_score_codex":0.00007391545,"about_ca_system_score_gemma":0.00065627875,"threshold_uncertainty_score":0.667569},"labels":[],"label_agreement":null},{"id":"W2769385365","doi":"10.1007/s10549-017-4575-z","title":"Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers","year":2017,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Education, Culture, Sports, Science and Technology; Alberta Innovates - Health Solutions; Japanese Breast Cancer Society","keywords":"Tumor-infiltrating lymphocytes; Estrogen receptor; Medicine; Oncology; Internal medicine; Breast cancer; Chemotherapy; Triple-negative breast cancer; Pathological; Estrogen; Cancer; Immunotherapy","score_opus":0.024877519237589796,"score_gpt":0.3231705649301975,"score_spread":0.29829304569260773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769385365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883888,0.0035043606,9.73608e-7,0.0035045582,0.00010801108,0.0027381182,0.0009771826,0.000043925273,0.00073410384],"genre_scores_gemma":[0.9910225,0.0044369265,0.0001427348,0.0001890732,0.00034519276,0.0033120562,0.000041630916,0.000059912738,0.00044993075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972539,0.00014692008,0.0003969245,0.00071783556,0.0006433186,0.0008411004],"domain_scores_gemma":[0.99862593,0.00011104298,0.00019381611,0.00043854688,0.00027793925,0.0003526911],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041222587,0.00039074023,0.000583006,0.00022645349,0.0005111765,0.00024693052,0.00020048351,0.0001109551,0.0002820861],"category_scores_gemma":[0.000016890897,0.00029193627,0.00013583316,0.00023013787,0.0007035373,0.00028393284,0.00007853529,0.00023591526,0.000010412683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03682909,0.0007552106,0.7344731,0.00038783174,0.0012051512,0.000439922,0.0016228134,0.0000018504256,0.01345578,0.000010684994,0.00026882155,0.21054973],"study_design_scores_gemma":[0.014485603,0.0016411564,0.9563091,0.0028238152,0.00006820571,0.001458432,0.00059252774,0.000049361846,0.021946702,0.000014167758,0.00030784303,0.0003030987],"about_ca_topic_score_codex":0.057467975,"about_ca_topic_score_gemma":0.0028194264,"teacher_disagreement_score":0.22183597,"about_ca_system_score_codex":0.005253383,"about_ca_system_score_gemma":0.0019504819,"threshold_uncertainty_score":0.99995327},"labels":[],"label_agreement":null},{"id":"W2770169340","doi":"10.2147/cmar.s147326","title":"Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200","year":2017,"lang":"en","type":"review","venue":"Cancer Management and Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Blockade; Immune checkpoint; Cancer research; Cancer; Immune system; Immunology; Biology; Medicine; Immunotherapy; Receptor; Internal medicine","score_opus":0.09535184495420482,"score_gpt":0.4029308205727563,"score_spread":0.3075789756185515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770169340","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003073946,0.9835774,2.471635e-7,0.00013724569,0.0000623938,0.0015048913,0.000015653413,0.0000021427543,0.011626117],"genre_scores_gemma":[0.0042859013,0.9904707,0.000019289077,0.000008403123,0.0001846896,0.000112560476,0.000005539465,0.000016427739,0.004896505],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99866676,0.000097726566,0.00036446503,0.00025423,0.00040014903,0.00021666494],"domain_scores_gemma":[0.99925137,0.000039433042,0.00023349372,0.0003509867,0.00008612387,0.000038596732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006771216,0.00015147592,0.0007114301,0.00024714507,0.00010561358,0.00003100626,0.00014779724,0.00008735834,0.000068671376],"category_scores_gemma":[0.000011706825,0.000085161155,0.00008662582,0.00022379655,0.0005990212,0.000030294994,0.00016481554,0.00027426274,4.24817e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005079269,0.00008763258,0.0008811704,0.027117148,0.00029895394,0.000028216895,0.00029088993,2.3766806e-7,0.00015022718,0.00014335712,0.0007276791,0.96976656],"study_design_scores_gemma":[0.0015735814,0.00018481341,0.0021643355,0.023739867,0.00024687732,0.000011803585,0.0003452692,0.0000037590983,0.0009786937,0.00007261394,0.9705597,0.000118656906],"about_ca_topic_score_codex":0.0004084834,"about_ca_topic_score_gemma":0.0003367104,"teacher_disagreement_score":0.96983206,"about_ca_system_score_codex":0.00010364165,"about_ca_system_score_gemma":0.00037517896,"threshold_uncertainty_score":0.3472771},"labels":[],"label_agreement":null},{"id":"W2770613715","doi":"10.1097/cmr.0000000000000410","title":"Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review","year":2017,"lang":"en","type":"article","venue":"Melanoma Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Immunosuppression; Adverse effect; Immunotherapy; Clinical trial; Population; Intensive care medicine; Melanoma; Cancer; Internal medicine; Oncology","score_opus":0.05101301996435191,"score_gpt":0.3477682834934246,"score_spread":0.29675526352907267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770613715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8231535,0.17260875,0.0000012838339,0.0020279957,0.000052058498,0.0011900774,0.000023815415,0.000009810466,0.0009326918],"genre_scores_gemma":[0.8954761,0.103198424,0.0001435971,0.00005455889,0.00007920168,0.0001147598,0.000030522042,0.00002571296,0.0008771043],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9978987,0.00020104581,0.0005257582,0.00042786522,0.00056643615,0.0003802196],"domain_scores_gemma":[0.9982135,0.000085202446,0.00020567745,0.0010164524,0.0003519201,0.00012723243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024364344,0.00019383116,0.00056388485,0.00024794682,0.0002034036,0.000068841095,0.00018024907,0.0001397999,0.00012764693],"category_scores_gemma":[0.00014287652,0.00012537732,0.00011363451,0.00034916768,0.00038815537,0.00013068694,0.000061324696,0.00056787976,0.0000028356142],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029278269,0.0007885036,0.087625325,0.0065671387,0.00043769248,0.7560265,0.005938669,3.9115015e-8,0.046434477,0.000030262661,0.000811273,0.06606187],"study_design_scores_gemma":[0.01951383,0.008420027,0.4246616,0.060840096,0.00011281651,0.410689,0.00055113353,0.000042579515,0.060473297,0.000026548823,0.014060429,0.00060863915],"about_ca_topic_score_codex":0.0017110697,"about_ca_topic_score_gemma":0.0005764485,"teacher_disagreement_score":0.34533748,"about_ca_system_score_codex":0.00009907693,"about_ca_system_score_gemma":0.00027971802,"threshold_uncertainty_score":0.51127386},"labels":[],"label_agreement":null},{"id":"W2770677081","doi":"10.1016/j.jtho.2016.11.1371","title":"P2.03b-089 CD1C in Lung Adenocarcinoma: Prognosis and Cellular Origin","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Immunohistochemistry; Dendritic cell; Cancer research; Adenocarcinoma; Immunosurveillance; Cancer; Lung cancer; Immune system; Myeloid; Immunology; Pathology; Internal medicine","score_opus":0.036107051764902164,"score_gpt":0.4116131324339759,"score_spread":0.37550608066907376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770677081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803393,0.007885798,0.00003778642,0.009430937,0.0006995937,0.0002032068,0.0000013632075,0.0000057597945,0.0013962421],"genre_scores_gemma":[0.996869,0.0006138254,0.0012942532,0.00035993507,0.0004391375,0.000005250567,8.811603e-7,0.000014726775,0.00040296227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988428,0.000103056016,0.00050615775,0.00014498703,0.00018666343,0.00021636221],"domain_scores_gemma":[0.99880636,0.000073671385,0.0006456393,0.0002355115,0.00011096134,0.00012787252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010280454,0.00012351366,0.0005208022,0.00020909727,0.000111907604,0.000040061484,0.00019678767,0.00018345937,0.000090045374],"category_scores_gemma":[0.00012290332,0.000094296855,0.00012994873,0.00007237961,0.00019794764,0.00017564284,0.00005190358,0.00041492327,0.0000032966586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009939398,0.0004507156,0.7308597,0.00024037488,0.00030150873,0.0027631528,0.0008658864,7.924178e-7,0.035035685,0.000026442596,0.003271434,0.21624492],"study_design_scores_gemma":[0.0047156685,0.0028946572,0.92188096,0.0004872325,0.0004033408,0.0026446574,0.00039360722,0.00011241795,0.012131973,0.00022558516,0.0539242,0.00018570916],"about_ca_topic_score_codex":0.00008443691,"about_ca_topic_score_gemma":0.00006377429,"teacher_disagreement_score":0.21605921,"about_ca_system_score_codex":0.00030215376,"about_ca_system_score_gemma":0.00036688402,"threshold_uncertainty_score":0.3845314},"labels":[],"label_agreement":null},{"id":"W2770798942","doi":"10.1001/jamaoncol.2017.3776","title":"Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma","year":2017,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Drug Research and Development; University Hospital; Juravinski Cancer Centre; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Ipilimumab; Response Evaluation Criteria in Solid Tumors; Internal medicine; Cervical cancer; Oncology; Cancer; Immunotherapy; Clinical trial; Phases of clinical research","score_opus":0.022603644146138538,"score_gpt":0.31995943085534284,"score_spread":0.2973557867092043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770798942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946479,0.000087289154,0.000005019642,0.0032138124,0.00006216668,0.00041060185,0.000016243137,0.000012097575,0.0015448426],"genre_scores_gemma":[0.99896216,0.0001454032,0.00014467954,0.00016866667,0.000024246621,0.000030597177,0.000005884184,0.000013315704,0.00050507183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891335,0.00015466115,0.00027419836,0.00022716697,0.00018291995,0.00024767802],"domain_scores_gemma":[0.99896646,0.00014015671,0.00048116787,0.00026532545,0.00007639725,0.000070478476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061899563,0.00012907459,0.00055990147,0.000086124615,0.00012601638,0.000018054734,0.00008288405,0.00012623983,0.00017120088],"category_scores_gemma":[0.000083013314,0.00008209154,0.000026200662,0.00010540371,0.0002078733,0.00013147332,0.00003692803,0.00025728706,0.0000013034729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2178663,0.0013579007,0.54520136,0.00037775206,0.0010220879,0.0005090098,0.0033606796,0.0000013396136,0.037417073,0.000065291824,0.00018969072,0.19263148],"study_design_scores_gemma":[0.022023087,0.0074533154,0.9656861,0.00014081788,0.00011990077,0.000080717145,0.0002797508,0.000033663644,0.00093639083,0.000020460822,0.0031180612,0.000107730775],"about_ca_topic_score_codex":0.00069549534,"about_ca_topic_score_gemma":0.0030153892,"teacher_disagreement_score":0.42048472,"about_ca_system_score_codex":0.00085910957,"about_ca_system_score_gemma":0.00030945917,"threshold_uncertainty_score":0.3347596},"labels":[],"label_agreement":null},{"id":"W2770837274","doi":"10.1016/j.jtho.2017.11.088","title":"P2.07-029 CheckMate 169: Safety/Efficacy of Nivolumab in Canadian Pretreated Advanced NSCLC (including Elderly and PS 2) Patients","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Royal Victoria Hospital; Lakeridge Health; Richmond Hospital; Dr. Georges-L.-Dumont University Hospital Centre; Interior Health; Thunder Bay Regional Health Sciences Centre; CancerCare Manitoba; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Hôpital Charles-Le Moyne; Cégep de Rimouski; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.023992013256225977,"score_gpt":0.39462491183558024,"score_spread":0.3706328985793543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770837274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99238753,0.0009425256,0.0000072479825,0.0023017116,0.000531907,0.00028133587,0.000012642429,0.000004460633,0.0035306585],"genre_scores_gemma":[0.9980282,0.0007464367,0.00069756055,0.00015448092,0.00008912145,0.0000020621912,0.0000046407654,0.000017870083,0.00025961816],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99844605,0.00010672583,0.0007506251,0.00015718311,0.00019872806,0.00034066447],"domain_scores_gemma":[0.9980825,0.00009670117,0.0010317707,0.0002748281,0.00024996052,0.00026420841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007716365,0.00014818525,0.0006596885,0.00036032553,0.00016662035,0.000020764663,0.0002159838,0.00019847832,0.00010700349],"category_scores_gemma":[0.0004440911,0.00012424987,0.00012381993,0.0001077939,0.00018748653,0.00021837409,0.00004093781,0.00033567575,0.0000026065811],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022412874,0.00033995288,0.17563225,0.00010760903,0.00024974832,0.00026416229,0.000913425,0.000005833131,0.0074723656,0.0000040837367,0.0003364928,0.7922612],"study_design_scores_gemma":[0.010083806,0.0044131675,0.96310407,0.00087697397,0.00015748687,0.00023481053,0.00021341887,0.00003853,0.002354184,0.00003457894,0.01834979,0.00013920404],"about_ca_topic_score_codex":0.014786519,"about_ca_topic_score_gemma":0.03980296,"teacher_disagreement_score":0.792122,"about_ca_system_score_codex":0.0008785733,"about_ca_system_score_gemma":0.0009566721,"threshold_uncertainty_score":0.9917741},"labels":[],"label_agreement":null},{"id":"W2771485561","doi":"10.5114/pjp.2017.71537","title":"Answer to the Teresa Pusiol comments to the paper “The association of tumor lymphocyte infiltration with clinico-pathological factor and survival in breast cancer” by Huszno &lt;i&gt;et al&lt;/i&gt;.","year":2017,"lang":"en","type":"letter","venue":"Polish Journal of Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pathological; Medicine; Breast cancer; Infiltration (HVAC); Pathology; Lymphocyte; Cancer; Internal medicine","score_opus":0.021543676230276667,"score_gpt":0.3063929708411228,"score_spread":0.2848492946108462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771485561","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37528962,0.0008302728,0.000020818221,0.6214863,0.00093488145,0.000552242,0.0007600364,0.00000488927,0.00012091164],"genre_scores_gemma":[0.2975416,0.0019893744,0.000052849955,0.69820225,0.0016215317,0.000059060014,0.000061706814,0.00004429715,0.0004273074],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99658173,0.0010552378,0.00091592455,0.0003133508,0.0006841274,0.0004496439],"domain_scores_gemma":[0.99691325,0.00052373833,0.0015780262,0.0005235833,0.0003664011,0.000095025134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002355491,0.00033436005,0.0008856697,0.00016239936,0.00018527002,0.00009313661,0.00060254976,0.0003855836,0.00010826144],"category_scores_gemma":[0.00033967776,0.00015596178,0.00019734062,0.00015979061,0.00026226236,0.00014087137,0.00010370243,0.0012044753,0.000003539195],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032021224,0.00011182536,0.0431721,0.000029873554,0.00029399898,0.0004681645,0.00160945,0.000003603675,0.024064042,0.000003786336,0.9224861,0.0045548906],"study_design_scores_gemma":[0.0026457598,0.00067971955,0.38691708,0.00025573597,0.0001424453,0.0015867666,0.0000582408,0.0000013764584,0.00009578051,0.000008092161,0.6074586,0.00015038917],"about_ca_topic_score_codex":0.0002222089,"about_ca_topic_score_gemma":0.0011017874,"teacher_disagreement_score":0.343745,"about_ca_system_score_codex":0.00044156244,"about_ca_system_score_gemma":0.00040076714,"threshold_uncertainty_score":0.6359937},"labels":[],"label_agreement":null},{"id":"W2771706601","doi":"10.1093/annonc/mdx711.077","title":"Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Head and neck squamous-cell carcinoma; Internal medicine; Placebo; Oncology; Head and neck cancer; Regimen; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Chemoradiotherapy; Urology; Cancer; Surgery; Clinical trial; Immunotherapy; Pathology","score_opus":0.06854208842948625,"score_gpt":0.4002969800796791,"score_spread":0.3317548916501929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771706601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98428696,0.002394703,0.00015937665,0.0067932718,0.00046178742,0.0014338166,0.00005032703,0.000028105786,0.0043916553],"genre_scores_gemma":[0.99582195,0.00065610604,0.000556867,0.0016585923,0.0003162419,0.00012256566,0.000055611832,0.000035560784,0.0007765159],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99851245,0.000070158574,0.00052377704,0.0003587953,0.00016577303,0.0003690303],"domain_scores_gemma":[0.998225,0.00027279364,0.0005709195,0.0005253799,0.00025227698,0.00015364075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048731238,0.000215129,0.0008054497,0.00011256815,0.00019068719,0.000027307686,0.00018578726,0.00028814623,0.000046965404],"category_scores_gemma":[0.00030941612,0.00019960447,0.00021476469,0.00005888913,0.0003180021,0.00015579295,0.00004487203,0.00015061484,0.0000038113612],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7036425,0.0019487806,0.0004765625,0.00036233003,0.00010084645,0.00007046194,0.0005362472,0.00000602069,0.033621356,0.000049759597,0.008560833,0.2506243],"study_design_scores_gemma":[0.6864308,0.062032897,0.015306617,0.000075989454,0.00019853853,0.00009907666,0.00010566921,0.0006696919,0.07078579,0.00019526434,0.16376981,0.00032983266],"about_ca_topic_score_codex":0.00033793523,"about_ca_topic_score_gemma":0.0001251309,"teacher_disagreement_score":0.25029448,"about_ca_system_score_codex":0.00010874995,"about_ca_system_score_gemma":0.0006711248,"threshold_uncertainty_score":0.8139634},"labels":[],"label_agreement":null},{"id":"W2772034086","doi":"10.29173/jchla/jabsc.v38i3.29349","title":"Mark your Calendars for CHLA/ABSC 2018 in St. John's, NL!","year":2017,"lang":"fr","type":"article","venue":"Journal of the Canadian Health Libraries Association / Journal de l Association de bilbiothèques de la santé du Canada","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Computer science","score_opus":0.011019844191075611,"score_gpt":0.28616146566475376,"score_spread":0.27514162147367816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772034086","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13395585,0.38302258,0.0002336308,0.44908392,0.02547922,0.0014592772,0.004315742,0.000023877072,0.0024258876],"genre_scores_gemma":[0.67913806,0.20991135,0.003553885,0.06303503,0.02036713,0.00003424769,0.000052809304,0.00025060656,0.023656864],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99125606,0.0026201247,0.0021720931,0.0002654997,0.0013922821,0.0022939432],"domain_scores_gemma":[0.9857099,0.002617863,0.008404645,0.00044338751,0.0010000286,0.0018241412],"candidate_categories":["metaresearch","metaepi_narrow","sts","scholarly_communication","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.016276369,0.00043626394,0.0011049922,0.00047133572,0.002752705,0.002228843,0.0012038716,0.0010209082,0.00048527456],"category_scores_gemma":[0.014360486,0.00040243438,0.00068049046,0.00039553456,0.00017260366,0.0015311987,0.000067040324,0.0024087103,0.0000016697029],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00039379162,0.00006190379,0.36991078,0.00014833361,0.0007230546,0.00020689226,0.001389676,0.00007673205,0.000018899866,0.00026007587,0.6208036,0.006006288],"study_design_scores_gemma":[0.003140703,0.00021081691,0.4037369,0.00095308025,0.00016993393,0.0006622825,0.0006411487,0.00023294406,0.00005270799,0.0013744609,0.58857423,0.00025083372],"about_ca_topic_score_codex":0.6870454,"about_ca_topic_score_gemma":0.91105705,"teacher_disagreement_score":0.5451822,"about_ca_system_score_codex":0.11051066,"about_ca_system_score_gemma":0.11645843,"threshold_uncertainty_score":0.9998928},"labels":[],"label_agreement":null},{"id":"W2772068066","doi":"10.1016/j.jcrc.2017.09.162","title":"Systematic review and metanalysis on the use of imaging for neuroprognostication after cardiac arrest","year":2017,"lang":"en","type":"article","venue":"Journal of Critical Care","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Colorectal cancer; Interleukin 17; Flow cytometry; Interleukin 22; Cancer; Interleukin; Internal medicine; Immunology; Pathology; Inflammation; Cytokine","score_opus":0.04663448741173449,"score_gpt":0.3508408852282545,"score_spread":0.30420639781652004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772068066","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1474421,0.68224376,0.0017395853,0.16289538,0.0013630242,0.0037494637,0.00022575496,0.000012775464,0.00032813664],"genre_scores_gemma":[0.9969999,0.0011081405,0.00021639005,0.0015684977,0.00007206236,0.000017618435,7.4546296e-7,0.0000067169967,0.000009934626],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9992586,0.000075816475,0.0003545402,0.00005912943,0.00018515534,0.000066761975],"domain_scores_gemma":[0.9983176,0.00058383227,0.00020694315,0.00027622315,0.0005691934,0.00004620735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003751062,0.000060434384,0.00043733473,0.00003231996,0.00006885902,0.000052912303,0.00006982537,0.00001506628,0.000011337547],"category_scores_gemma":[0.004980841,0.000031390504,0.00026991958,0.000026570942,0.00013282002,0.00009591867,0.000010140422,0.00007989388,2.870482e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002661997,0.000204651,0.013477254,0.9676512,0.0019137955,0.00013297505,0.0007505661,5.065189e-7,0.0041888827,0.0015019587,0.002221412,0.005294832],"study_design_scores_gemma":[0.00608943,0.0041828314,0.24899614,0.51110363,0.20502041,0.00061690685,0.0049051857,0.00048731014,0.009504947,0.00067590026,0.007439005,0.0009782814],"about_ca_topic_score_codex":0.0000034092752,"about_ca_topic_score_gemma":5.905219e-7,"teacher_disagreement_score":0.8495578,"about_ca_system_score_codex":0.00001984818,"about_ca_system_score_gemma":0.000026160216,"threshold_uncertainty_score":0.5962892},"labels":[],"label_agreement":null},{"id":"W2773701379","doi":"10.5114/pjp.2017.71536","title":"Comments on the article “The association of tumour lymphocyte infiltration with clinico-pathological factors and survival in breast cancer” by Huszno et al.","year":2017,"lang":"en","type":"letter","venue":"Polish Journal of Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pathological; Breast cancer; Medicine; Infiltration (HVAC); Pathology; Lymphocyte; Cancer; Internal medicine","score_opus":0.032498809318744507,"score_gpt":0.3220975471564721,"score_spread":0.2895987378377276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773701379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5600491,0.00023878038,0.00000271369,0.43909973,0.00027054868,0.00011909929,0.0001307774,0.0000020181546,0.0000872447],"genre_scores_gemma":[0.710933,0.0017348382,0.000008014877,0.28684995,0.00035129953,0.000006663692,0.00002632762,0.000016624383,0.000073238836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99798775,0.0006822602,0.00055319286,0.00015022341,0.0003963079,0.00023026922],"domain_scores_gemma":[0.9974612,0.0005680969,0.0015631673,0.0002041022,0.00016967133,0.00003377934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017277303,0.00018179786,0.00057814945,0.0000908764,0.00008077408,0.00003739803,0.00020254852,0.00031497612,0.000036048124],"category_scores_gemma":[0.00021577763,0.00008721907,0.00011592086,0.00006729894,0.00024204039,0.000078741556,0.00002451444,0.0012027351,5.4983406e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019678331,0.00013449889,0.498906,0.000023430837,0.00021516884,0.00044214257,0.0005637947,0.0000012784719,0.006217118,0.000007048886,0.49064222,0.0008794865],"study_design_scores_gemma":[0.004035675,0.0008830609,0.94512504,0.0003413247,0.00016386442,0.001232834,0.00017633538,0.0000036265494,0.0007018795,0.000034024983,0.04717873,0.00012359723],"about_ca_topic_score_codex":0.00034419954,"about_ca_topic_score_gemma":0.00011794482,"teacher_disagreement_score":0.44621906,"about_ca_system_score_codex":0.00027724344,"about_ca_system_score_gemma":0.00021485885,"threshold_uncertainty_score":0.52253526},"labels":[],"label_agreement":null},{"id":"W2773756552","doi":"10.14302/issn.2471-2175.jdrt-17-1760","title":"Blockade of Programmed Cell Death Protein-1 Pathway for the Treatment of Melanoma","year":2017,"lang":"en","type":"article","venue":"Journal of Dermatologic Research And Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Nivolumab; Pembrolizumab; Ipilimumab; Medicine; Melanoma; Dacarbazine; Oncology; Internal medicine; Blockade; Cancer; Adverse effect; Immune checkpoint; PD-L1; Immunotherapy; Cancer research","score_opus":0.1412676086609013,"score_gpt":0.3993332796148271,"score_spread":0.25806567095392585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773756552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670213,0.027491717,0.00003322852,0.0039749383,0.000044395852,0.0012010422,0.000006595613,0.0000021512212,0.00022465432],"genre_scores_gemma":[0.9724168,0.026620958,0.00056378124,0.000022541717,0.000074447446,0.000054528828,6.958219e-7,0.000007775542,0.00023843287],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988867,0.00007928257,0.00037767197,0.00008724013,0.00034288058,0.000226219],"domain_scores_gemma":[0.9984743,0.00025421666,0.0004628189,0.00031178066,0.00041734055,0.00007955039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072859396,0.000094664414,0.0003821748,0.000098761135,0.00022705269,0.0000358261,0.00022528016,0.000070497284,0.000016378372],"category_scores_gemma":[0.00005516108,0.000042273063,0.00020112246,0.000053201067,0.00039846843,0.000050628038,0.000011950265,0.0001180735,1.7041268e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035141986,0.003392636,0.07664317,0.00032395768,0.0013988487,0.00015896352,0.0012823695,2.3681007e-7,0.35878274,0.00022401295,0.0004472253,0.52220386],"study_design_scores_gemma":[0.013469543,0.02211287,0.02678675,0.00014237428,0.000031335567,0.00035860785,0.00047121104,0.000025278561,0.88069093,0.0013124483,0.054533362,0.00006530004],"about_ca_topic_score_codex":0.000054519252,"about_ca_topic_score_gemma":0.0000039729393,"teacher_disagreement_score":0.52213854,"about_ca_system_score_codex":0.000027472573,"about_ca_system_score_gemma":0.00021891078,"threshold_uncertainty_score":0.17463286},"labels":[],"label_agreement":null},{"id":"W2774081554","doi":"10.21037/atm.2017.11.26","title":"CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors","year":2018,"lang":"en","type":"letter","venue":"Annals of Translational Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institut National Du Cancer; Ligue Contre le Cancer; Institute of Cancer Research; Institut National de la Santé et de la Recherche Médicale","keywords":"Value (mathematics); Expression (computer science); Cancer research; Computational biology; Medicine; Biology; Computer science","score_opus":0.0854666628753438,"score_gpt":0.3470849359270449,"score_spread":0.26161827305170116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774081554","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12534894,0.020819489,0.000016275142,0.8517323,0.00025940282,0.0008348274,0.00011985895,0.000028576987,0.00084032473],"genre_scores_gemma":[0.40752733,0.0064838463,0.00085129455,0.572688,0.008256109,0.00014766578,0.0018853808,0.0001585087,0.0020018902],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99746275,0.00011568503,0.00084465614,0.00044477286,0.000818132,0.0003139979],"domain_scores_gemma":[0.9985093,0.0005579706,0.0002682321,0.0002602116,0.00032463466,0.000079637255],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057442975,0.0003413247,0.00083089195,0.00046017664,0.000042839274,0.000005557975,0.0001256619,0.00043280696,0.00062660634],"category_scores_gemma":[0.00027865707,0.0002465244,0.00012836925,0.00030067508,0.0005153212,0.00009394947,0.0000139787,0.00058954436,0.000003734469],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052030613,0.00018616673,0.006675391,0.0040430645,0.00032878804,0.00025541743,0.0015348805,0.0000042059773,0.05045221,0.0000440837,0.9258908,0.005381944],"study_design_scores_gemma":[0.010748218,0.0039020544,0.17889833,0.030374719,0.00040398538,0.00023287768,0.000112341324,0.00015560153,0.020652214,0.0020326907,0.7516774,0.0008095766],"about_ca_topic_score_codex":0.00018990034,"about_ca_topic_score_gemma":0.00001921624,"teacher_disagreement_score":0.2821784,"about_ca_system_score_codex":0.000014531918,"about_ca_system_score_gemma":0.00018595353,"threshold_uncertainty_score":0.9999987},"labels":[],"label_agreement":null},{"id":"W2776526327","doi":"10.1371/journal.pone.0189848","title":"Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma","year":2017,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":305,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Rutgers Cancer Institute of New Jersey; Merck; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Internal medicine; Gastroenterology; Adverse effect; Rectum; Colorectal cancer; Microsatellite instability; Oncology; Cancer; Immunotherapy","score_opus":0.013885717632349614,"score_gpt":0.2425488519917105,"score_spread":0.2286631343593609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2776526327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99834126,0.00008771124,9.315614e-7,0.00026097687,0.00003477614,0.00059788005,0.000027871642,0.000008007697,0.0006405871],"genre_scores_gemma":[0.9997205,0.000091825845,0.00005908891,0.000031084786,0.000015244326,0.0000046625473,0.000005725495,0.000012246944,0.000059609414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992714,0.000025789059,0.00013374792,0.0001719472,0.00024954297,0.00014757864],"domain_scores_gemma":[0.99931085,0.000019557096,0.00017826665,0.00039013094,0.0000672883,0.000033926513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000077365454,0.00010305618,0.00031643626,0.00003780829,0.000132184,0.000012308463,0.00011202702,0.00004174746,0.000015010818],"category_scores_gemma":[0.00004886812,0.00006565406,0.000033730776,0.00006916022,0.00024835966,0.00012400009,0.000057949423,0.00011834334,5.1819313e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0152226295,0.000929105,0.825413,0.00011447607,0.00010525334,0.0000037272982,0.00008568799,1.2212111e-7,0.15647678,0.0000032148264,0.0000014076614,0.0016445904],"study_design_scores_gemma":[0.009175741,0.00078777294,0.8944856,0.00040500617,0.000066855835,0.00000179895,0.000010424729,0.000027962824,0.09495313,0.0000013835443,0.000008467747,0.00007586679],"about_ca_topic_score_codex":0.00022973138,"about_ca_topic_score_gemma":0.000098602104,"teacher_disagreement_score":0.0690726,"about_ca_system_score_codex":0.00004815062,"about_ca_system_score_gemma":0.00007176827,"threshold_uncertainty_score":0.26772946},"labels":[],"label_agreement":null},{"id":"W2778781711","doi":"10.1007/978-3-319-67577-0_14","title":"Adaptive Resistance to Cancer Immunotherapy","year":2017,"lang":"en","type":"review","venue":"Advances in experimental medicine and biology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Immune system; Immunotherapy; Tumor microenvironment; Immunosuppression; Acquired immune system; Cancer immunotherapy; Biology; Immunology; Cancer; Cancer research; Immune tolerance","score_opus":0.13177734228979737,"score_gpt":0.49197449224339035,"score_spread":0.360197149953593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2778781711","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000042765165,0.99418575,0.000009311818,0.0005018071,0.00091920356,0.0011455121,0.0000252861,0.000037642618,0.0031327512],"genre_scores_gemma":[0.00033336654,0.9961901,0.0002821293,0.0011154232,0.0005446897,0.0006360413,0.000038601902,0.00005916561,0.00080050796],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981533,0.0000945965,0.00062984804,0.0006454509,0.000105831474,0.00037095387],"domain_scores_gemma":[0.9989244,0.00012538227,0.00032804348,0.0004681787,0.000029744648,0.00012426519],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020771108,0.0004659589,0.0021339254,0.00029465026,0.00008579522,0.000007512706,0.00024384337,0.00028094646,0.00014200604],"category_scores_gemma":[0.000038371036,0.00029800573,0.0001680057,0.00019315218,0.0006825269,0.00009176297,0.00007284083,0.0003036887,0.000004927407],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011243201,0.000059541642,0.000046980243,0.0009820401,0.00014591003,0.000027074564,0.0003083051,1.1251887e-8,0.00035011576,0.00015288683,0.00047394316,0.9963289],"study_design_scores_gemma":[0.0018321951,0.001323178,0.000019651176,0.020591121,0.00009123157,0.0000492281,0.00025670166,1.523063e-7,0.00009104243,0.000052887524,0.9753878,0.00030481847],"about_ca_topic_score_codex":0.0002185809,"about_ca_topic_score_gemma":0.00020962732,"teacher_disagreement_score":0.9960241,"about_ca_system_score_codex":0.00027812572,"about_ca_system_score_gemma":0.0001507022,"threshold_uncertainty_score":0.9999472},"labels":[],"label_agreement":null},{"id":"W2780073276","doi":"10.1200/jco.2017.35.15_suppl.e20504","title":"Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Durvalumab; Medicine; Internal medicine; Adverse effect; Discontinuation; Oncology; Phases of clinical research; Gastroenterology; Cancer; Clinical trial; Pembrolizumab; Immunotherapy","score_opus":0.1417976650562891,"score_gpt":0.5247077997151413,"score_spread":0.38291013465885215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2780073276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98803306,0.00023762022,0.00004880982,0.009013907,0.0013244019,0.00040398486,0.000061013416,0.000005209573,0.00087200885],"genre_scores_gemma":[0.9944749,0.00365675,0.0007564886,0.00036023077,0.0006157137,0.0000012647486,0.000006381207,0.000012955441,0.00011532954],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9939132,0.0007632122,0.0044793203,0.00032129695,0.00032608083,0.0001969086],"domain_scores_gemma":[0.9898389,0.004022193,0.0049644485,0.0005865461,0.0003196097,0.000268293],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009321496,0.00015961449,0.0023311162,0.00009924185,0.00008536811,0.000011636813,0.00029127835,0.00044312488,0.00009137645],"category_scores_gemma":[0.01285681,0.00011460783,0.00047194684,0.00008369772,0.0005932051,0.00020259141,0.000115212715,0.0012027064,0.0000016911282],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33940962,0.008840125,0.13488795,0.000006167685,0.00058408687,0.00043098346,0.00009904434,0.0000015917868,0.00024661288,7.304537e-7,0.00024134383,0.51525176],"study_design_scores_gemma":[0.16825096,0.034819443,0.77238524,0.00018399917,0.00030608932,0.000035455836,0.00011017384,0.0001966761,0.00008007603,0.000040438917,0.02350456,0.00008688194],"about_ca_topic_score_codex":0.000625107,"about_ca_topic_score_gemma":0.0025017383,"teacher_disagreement_score":0.6374973,"about_ca_system_score_codex":0.00011196107,"about_ca_system_score_gemma":0.00087965396,"threshold_uncertainty_score":0.9954583},"labels":[],"label_agreement":null},{"id":"W2781731864","doi":"10.1097/pas.0000000000001013","title":"Comprehensive Assessment of PD-L1 Staining Heterogeneity in Pulmonary Adenocarcinomas Using Tissue Microarrays","year":2018,"lang":"en","type":"article","venue":"The American Journal of Surgical Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Canada Research Chairs","keywords":"Staining; Tissue microarray; Pathology; Immunohistochemistry; Adenocarcinoma; Biopsy; Medicine; Lung; Lung cancer; Cancer; Internal medicine","score_opus":0.04135927412676696,"score_gpt":0.36455253939462257,"score_spread":0.32319326526785563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781731864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969132,0.0013756434,0.00032718922,0.0007940532,0.00015589627,0.00011820096,0.000004410886,0.0000040471177,0.00030736398],"genre_scores_gemma":[0.9966838,0.0003286014,0.0023259737,0.0004087843,0.00022805082,0.0000010203305,0.0000011372014,0.000014418788,0.000008221215],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99824923,0.0004745497,0.0006474841,0.00014725016,0.00022326194,0.0002582254],"domain_scores_gemma":[0.9985212,0.00021334073,0.00073008914,0.0002247474,0.0002311095,0.00007950626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007077932,0.00013526379,0.00072774687,0.00017849266,0.000053976084,0.0000049274395,0.00017737896,0.000045630695,0.00006710395],"category_scores_gemma":[0.000012828525,0.000087755034,0.00016338167,0.0003603163,0.0015435162,0.000041636267,0.0000590317,0.00033519987,0.0000010936805],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0126661295,0.00033286656,0.18760718,0.000036922105,0.00022852895,0.0047279997,0.0008952779,0.00005782539,0.7546825,0.00002423784,0.00002643905,0.038714133],"study_design_scores_gemma":[0.0032063774,0.0068990225,0.93254447,0.00021721599,0.00013306498,0.029707769,0.0026660108,0.00032062124,0.020200968,0.000060987037,0.0038622015,0.00018130269],"about_ca_topic_score_codex":0.00010632692,"about_ca_topic_score_gemma":0.000003655984,"teacher_disagreement_score":0.7449373,"about_ca_system_score_codex":0.00009549542,"about_ca_system_score_gemma":0.00018576455,"threshold_uncertainty_score":0.568715},"labels":[],"label_agreement":null},{"id":"W2783749923","doi":"10.1016/j.canlet.2018.01.039","title":"Extratumoral PD-1 blockade does not perpetuate obesity-associated inflammation in esophageal adenocarcinoma","year":2018,"lang":"en","type":"article","venue":"Cancer Letters","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Health Research Board","keywords":"Medicine; Immunotherapy; Inflammation; CD8; Adenocarcinoma; Cancer research; Internal medicine; Esophageal cancer; Blockade; Cancer; Oncology; Immunology; Immune system; Receptor","score_opus":0.014091125537719148,"score_gpt":0.2665815049040733,"score_spread":0.25249037936635416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2783749923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98332965,0.00045619585,0.00002474205,0.014718789,0.0007519982,0.00036806107,0.000021037014,0.000083450934,0.00024608392],"genre_scores_gemma":[0.99054843,0.00008341002,0.00008601028,0.007166924,0.0010439003,0.0000683453,0.000027760625,0.000030789844,0.0009444327],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99853486,0.00006745775,0.00035261177,0.0003449004,0.00028582677,0.00041432638],"domain_scores_gemma":[0.99942577,0.000028517441,0.00013228712,0.00025130252,0.00007216336,0.00008998154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023982821,0.00020788024,0.00030143827,0.00018150649,0.00009848778,0.000038100028,0.00012912143,0.00011211517,0.00050787715],"category_scores_gemma":[0.000028514045,0.00016797913,0.00011207909,0.0003551732,0.0002390953,0.00015296342,0.000025126797,0.00024898644,0.00004512191],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017964306,0.000054117838,0.30698574,0.00006398129,0.0001428981,0.000170557,0.0019368478,0.0000043537116,0.6785796,0.000012455734,0.0031588767,0.0070941118],"study_design_scores_gemma":[0.0035537512,0.0001537582,0.8221311,0.00021979344,0.00006357522,0.000013655974,0.000073607574,0.00016150482,0.17163248,0.0000141900055,0.0017573844,0.00022520519],"about_ca_topic_score_codex":0.00080316426,"about_ca_topic_score_gemma":0.0009993578,"teacher_disagreement_score":0.51514536,"about_ca_system_score_codex":0.00060790736,"about_ca_system_score_gemma":0.00014042894,"threshold_uncertainty_score":0.68499905},"labels":[],"label_agreement":null},{"id":"W2787710026","doi":"10.14740/jocmr3257w","title":"Isolated Adrenocorticotropic Hormone Deficiency and Severe Hypercalcemia After Destructive Thyroiditis in a Patient on Nivolumab Therapy With a Malignant Melanoma","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Nivolumab; Medicine; Adrenocorticotropic hormone; Melanoma; Thyroiditis; Internal medicine; Gastroenterology; Oncology; Hormone; Thyroid; Immunotherapy; Cancer; Cancer research","score_opus":0.07255713538036349,"score_gpt":0.4138338453290244,"score_spread":0.3412767099486609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787710026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98843443,0.007102955,0.000027139162,0.0030063752,0.00016383301,0.00049739314,0.0000025812185,0.000006127593,0.00075918966],"genre_scores_gemma":[0.9904782,0.007810518,0.000252096,0.0006722322,0.0006852555,0.00001439679,0.0000010273903,0.000024099843,0.000062164305],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9961969,0.00051642244,0.0013097823,0.00031922825,0.001209285,0.00044837504],"domain_scores_gemma":[0.99725443,0.0008805478,0.0003334052,0.00028730623,0.00089866266,0.0003456357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022060582,0.00018147577,0.0007913415,0.00048057508,0.000079956204,0.000016769158,0.00014355313,0.00018101215,0.00020846594],"category_scores_gemma":[0.00075620716,0.00009684518,0.0001080049,0.0006953409,0.0014060797,0.000095384574,0.00003944542,0.0012220431,0.000006549184],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22347055,0.0012851234,0.2325202,0.000057165005,0.00036271213,0.003279452,0.0026370126,2.6491264e-7,0.009071288,0.000024569526,0.0015974484,0.5256942],"study_design_scores_gemma":[0.02070272,0.1407192,0.830963,0.001778919,0.00004644013,0.0025056514,0.000971217,0.000056034063,0.0003920085,0.00022999643,0.001499639,0.00013517823],"about_ca_topic_score_codex":0.00014965265,"about_ca_topic_score_gemma":0.000046158017,"teacher_disagreement_score":0.5984428,"about_ca_system_score_codex":0.00015544638,"about_ca_system_score_gemma":0.00056158326,"threshold_uncertainty_score":0.53092366},"labels":[],"label_agreement":null},{"id":"W2787915872","doi":"10.7759/cureus.2238","title":"Abscopal Effect in a Stage IV Melanoma Patient who Progressed on Pembrolizumab","year":2018,"lang":"en","type":"article","venue":"Cureus","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Abscopal effect; Pembrolizumab; Radiation therapy; Melanoma; Lesion; Mucosal melanoma; Lung; Larynx; Radiology; Stage (stratigraphy); Immunotherapy; Surgery; Internal medicine; Cancer; Cancer research","score_opus":0.01182194189274016,"score_gpt":0.2919495731585549,"score_spread":0.28012763126581475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787915872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98609936,0.00090443983,0.0000029896291,0.0002728499,0.00032055977,0.0006626612,0.000009122368,0.000048045327,0.011679982],"genre_scores_gemma":[0.9982998,0.000041137453,0.000039653652,0.0006244223,0.00020388083,0.000065805834,0.000010443078,0.000021490807,0.00069338485],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99905795,0.000053876214,0.00019061123,0.00023117877,0.00021248624,0.00025389052],"domain_scores_gemma":[0.99948627,0.000039819297,0.00005897485,0.00031227944,0.000034860932,0.00006778667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013942223,0.0001465822,0.00023516724,0.00007286356,0.000041330415,0.000015489943,0.0000759724,0.00008436224,0.0005486705],"category_scores_gemma":[0.00003656324,0.00010801685,0.00007457925,0.00016444828,0.00010553289,0.000038070408,0.000020327803,0.00012121572,0.00008097123],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.122449294,0.0026106997,0.25757828,0.00080677785,0.00080700836,0.0011384928,0.010254025,0.000002430782,0.08818324,0.0005011386,0.036213104,0.4794555],"study_design_scores_gemma":[0.031963404,0.051530212,0.5530017,0.0017340627,0.00010039044,0.00006647584,0.0002545091,0.00040119916,0.17648385,0.000060139664,0.18370132,0.0007027257],"about_ca_topic_score_codex":0.00019501102,"about_ca_topic_score_gemma":0.00017921573,"teacher_disagreement_score":0.47875276,"about_ca_system_score_codex":0.00018354478,"about_ca_system_score_gemma":0.00007020021,"threshold_uncertainty_score":0.6007557},"labels":[],"label_agreement":null},{"id":"W2789017398","doi":"10.1038/nrclinonc.2018.27","title":"Cancer immunotherapy and the value of cure","year":2018,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":188,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Cancer immunotherapy; Clinical Oncology; Cancer; Internal medicine; Value (mathematics); Immune checkpoint; Intensive care medicine","score_opus":0.12489199908178489,"score_gpt":0.5402313480486471,"score_spread":0.41533934896686225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789017398","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000039541746,0.9900198,0.0000037306147,0.0026604487,0.0023390006,0.0036660465,0.000028216204,0.000029059667,0.00124976],"genre_scores_gemma":[0.000001053761,0.989523,0.0004976654,0.0067033293,0.0020814582,0.0003638338,0.000026145924,0.00008348865,0.00072004483],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99270666,0.0026668736,0.003442171,0.000630089,0.00025275725,0.0003014705],"domain_scores_gemma":[0.9927647,0.0032460922,0.0027072036,0.0009819702,0.00017639824,0.0001236407],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.007439287,0.0005249784,0.0085982075,0.00009950478,0.00005728,0.00000949315,0.00046741546,0.003145421,0.00027351166],"category_scores_gemma":[0.0011612155,0.00023067975,0.0031581258,0.00047885612,0.0020324949,0.000026641317,0.00010937343,0.003223932,0.000023365712],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015669735,0.00015330425,0.000016068814,0.010761309,0.0013820442,0.0000061725614,0.000025709858,9.451395e-10,2.749451e-7,0.0003908119,0.032418154,0.9532792],"study_design_scores_gemma":[0.004965538,0.001004092,0.000051206753,0.024186103,0.00369971,0.0001486072,0.0000027487065,6.7858844e-7,2.2270261e-7,0.00006304445,0.96566796,0.00021009438],"about_ca_topic_score_codex":0.00004251171,"about_ca_topic_score_gemma":0.000028958944,"teacher_disagreement_score":0.9530691,"about_ca_system_score_codex":0.00018781798,"about_ca_system_score_gemma":0.001612728,"threshold_uncertainty_score":0.99907565},"labels":[],"label_agreement":null},{"id":"W2789295860","doi":"10.1158/1538-7445.sabcs17-ot1-01-01","title":"Abstract OT1-01-01: IMpassion131: A phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC)","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Atezolizumab; Medicine; Internal medicine; Triple-negative breast cancer; Oncology; Taxane; Paclitaxel; Metastatic breast cancer; Chemotherapy; Breast cancer; Placebo; Cancer; Immunotherapy; Pathology; Pembrolizumab","score_opus":0.06763732471246466,"score_gpt":0.4113377107985923,"score_spread":0.3437003860861277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789295860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902647,0.00057315076,0.000042000338,0.00054293295,0.000101107325,0.007530788,0.0003583052,0.000072126,0.00051484787],"genre_scores_gemma":[0.99335134,0.0004114321,0.0002596348,0.0001534994,0.00015155038,0.0040080994,0.00006138474,0.00013695363,0.0014661087],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9946435,0.0003892797,0.00071542646,0.0011891385,0.0015992782,0.0014633565],"domain_scores_gemma":[0.9968486,0.00033920328,0.00030310443,0.00082099834,0.0011747943,0.00051330664],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00073193375,0.00068775273,0.0012805035,0.00059341284,0.0005082305,0.00014869218,0.0003422149,0.000102893326,0.0016872715],"category_scores_gemma":[0.000055628076,0.00037761667,0.00009019456,0.0021258418,0.0010160565,0.0005623262,0.00008760927,0.00077262206,0.000020334628],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77738047,0.007892428,0.15378015,0.00027858122,0.0026834551,0.0006666397,0.01323636,0.00016405077,0.0020468363,0.0000032230366,0.00082415855,0.04104367],"study_design_scores_gemma":[0.40572926,0.072309025,0.48657447,0.0048016026,0.00050547847,0.00008270462,0.021021815,0.00037352045,0.0058978484,0.000009946464,0.0015372755,0.0011570477],"about_ca_topic_score_codex":0.044815823,"about_ca_topic_score_gemma":0.081294574,"teacher_disagreement_score":0.3716512,"about_ca_system_score_codex":0.0034383556,"about_ca_system_score_gemma":0.0034602336,"threshold_uncertainty_score":0.99986756},"labels":[],"label_agreement":null},{"id":"W2789315292","doi":"10.1016/j.jacc.2018.02.037","title":"Myocarditis in Patients Treated With Immune Checkpoint Inhibitors","year":2018,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1542,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; Toronto General Hospital; University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institutes of Health; Kohlberg Foundation; Sarnoff Cardiovascular Research Foundation; Canadian Institutes of Health Research; Harvard University Center for AIDS Research; American Heart Association","keywords":"Medicine; Myocarditis; Immune system; Immune checkpoint; Immunology; Internal medicine; Immunotherapy","score_opus":0.006600490092082035,"score_gpt":0.23684055813455715,"score_spread":0.23024006804247513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789315292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99725187,0.0001865364,0.00001080619,0.0008598893,0.0002996976,0.00018351857,0.000021398868,0.0000031491454,0.0011831475],"genre_scores_gemma":[0.999149,0.000102090235,0.00014139805,0.0002020562,0.00031390015,0.0000020463574,7.8866833e-7,0.000013558829,0.0000751635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876,0.00017402275,0.00056480005,0.00009433944,0.00023914948,0.00016771254],"domain_scores_gemma":[0.9985323,0.00004731663,0.00079355953,0.0002455753,0.000336409,0.000044822653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034415248,0.0001128438,0.0008196366,0.00017306475,0.00003141366,0.0000016163679,0.00015033568,0.000040071103,0.000010734327],"category_scores_gemma":[0.000069468995,0.00006220328,0.0003565302,0.00058583374,0.0009168215,0.000035256006,0.00003214359,0.00017724211,9.090372e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017115593,0.00008286013,0.9587404,0.000012161459,0.0009947076,0.00010404476,0.00006508224,0.000011335023,0.01570697,0.0000036484407,0.0033273643,0.0038358038],"study_design_scores_gemma":[0.004828549,0.007024613,0.9679315,0.00016729825,0.00013229133,0.0006589067,0.00023957643,0.0000019002377,0.013509932,0.000008498295,0.005423635,0.00007328722],"about_ca_topic_score_codex":0.00007841348,"about_ca_topic_score_gemma":0.000009190946,"teacher_disagreement_score":0.012287045,"about_ca_system_score_codex":0.00015987514,"about_ca_system_score_gemma":0.00019168243,"threshold_uncertainty_score":0.3378067},"labels":[],"label_agreement":null},{"id":"W2789457030","doi":"10.1016/j.ijrobp.2017.12.021","title":"A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR","year":2018,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; Medicine; Tremelimumab; Head and neck squamous-cell carcinoma; Internal medicine; Immunotherapy; Oncology; Phases of clinical research; Cancer; Head and neck cancer; Gastroenterology; Clinical trial; Ipilimumab; Pembrolizumab","score_opus":0.040095039830471635,"score_gpt":0.37978140492283785,"score_spread":0.3396863650923662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789457030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957123,0.00038496178,0.0003299638,0.00027847514,0.00096898084,0.0020585745,0.00016315325,0.000008519946,0.000095109004],"genre_scores_gemma":[0.99762285,0.0001373164,0.0014207815,0.0003928704,0.00027025657,0.000047058802,0.000054653367,0.000021776244,0.00003241252],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99713314,0.00066318485,0.001262868,0.00031620808,0.00038636167,0.00023824742],"domain_scores_gemma":[0.99620616,0.00068155734,0.0016955792,0.0001654011,0.0011291619,0.00012212823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074782164,0.00027981435,0.001184027,0.00017768319,0.00006580949,0.00003422559,0.00037043818,0.00010278951,0.000099573066],"category_scores_gemma":[0.00043833378,0.0001782935,0.00009844284,0.00030165727,0.0004747941,0.00030481195,0.00009758895,0.0002778686,0.000002997826],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8358906,0.0156701,0.10007868,0.000035716937,0.0010590334,0.00008868383,0.0030190293,0.000017528704,0.00018094506,0.000040350566,0.00016047727,0.04375889],"study_design_scores_gemma":[0.9036132,0.04543239,0.0463785,0.00017544108,0.00048583784,0.00006720739,0.0008083735,0.002037512,0.00043730965,0.000118983655,0.0002452064,0.00020004564],"about_ca_topic_score_codex":0.00034970546,"about_ca_topic_score_gemma":0.0003841805,"teacher_disagreement_score":0.06772263,"about_ca_system_score_codex":0.0010801047,"about_ca_system_score_gemma":0.0010419709,"threshold_uncertainty_score":0.72705984},"labels":[],"label_agreement":null},{"id":"W2789989802","doi":"10.1038/s41598-018-22254-4","title":"Computationally-Guided Development of a Stromal Inflammation Histologic Biomarker in Lung Squamous Cell Carcinoma","year":2018,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"U.S. National Library of Medicine; National Institutes of Health; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Klarman Family Foundation; National Science Foundation","keywords":"Biomarker; Stromal cell; Medicine; Tissue microarray; Hazard ratio; Oncology; Pathology; Internal medicine; Inflammation; Lung; Lung cancer; Confidence interval; Immunohistochemistry; Biology","score_opus":0.02720305663599768,"score_gpt":0.28330635096087825,"score_spread":0.25610329432488055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789989802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947503,0.00023696004,0.00034441412,0.00011024615,0.0015494148,0.00038813546,8.069792e-7,0.000023700417,0.002595985],"genre_scores_gemma":[0.99452406,3.1460254e-7,0.004281491,0.00002634433,0.00003108039,0.000015065576,0.000083070016,0.000008235235,0.0010303437],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99809825,0.000032424145,0.0008462801,0.0003899902,0.00043578338,0.00019729088],"domain_scores_gemma":[0.9989417,0.000022865812,0.0003833687,0.00031954408,0.0002778516,0.00005467067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011453577,0.00010830911,0.00019645975,0.00033320228,0.00011987525,0.000026878912,0.000059515696,0.00006550276,0.00022459566],"category_scores_gemma":[0.000058628208,0.0000944665,0.00006447131,0.0005004987,0.00029787567,0.00007464508,0.000032600397,0.000050565443,0.0000074718073],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038047688,0.00020047932,0.13263713,0.0002108162,0.000020603453,0.00028496765,0.0030182675,0.000010675292,0.8461,0.000008473263,0.008645108,0.008483053],"study_design_scores_gemma":[0.0014279706,0.000108516724,0.7470548,0.00006828755,0.000023246632,0.00028704028,0.00014993237,0.0011889938,0.2363398,0.00015165069,0.013035088,0.00016466923],"about_ca_topic_score_codex":0.000048070582,"about_ca_topic_score_gemma":0.00007612783,"teacher_disagreement_score":0.6144177,"about_ca_system_score_codex":0.0002608968,"about_ca_system_score_gemma":0.0006842158,"threshold_uncertainty_score":0.3852232},"labels":[],"label_agreement":null},{"id":"W2790105191","doi":"10.1200/jco.2018.36.4_suppl.209","title":"KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Sorafenib; Internal medicine; Tolerability; Discontinuation; Hepatocellular carcinoma; Oncology; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Adverse effect; Gastroenterology; Progressive disease; Surgery; Clinical trial; Immunotherapy; Phases of clinical research; Disease; Cancer","score_opus":0.04166315873030817,"score_gpt":0.3684097563228039,"score_spread":0.32674659759249575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790105191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996858,0.00034000014,0.000048568483,0.00084612524,0.00028536012,0.0004712553,0.0000020326977,0.0000109217635,0.0011377184],"genre_scores_gemma":[0.99656284,0.00015044192,0.0014340932,0.0011905127,0.0004289556,0.000005607755,0.000005004128,0.00002966005,0.00019287028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969962,0.0002767384,0.0017319219,0.0002473505,0.00041573716,0.00033200116],"domain_scores_gemma":[0.9970252,0.00034766368,0.0013785425,0.00026449765,0.0007092102,0.00027492063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011193337,0.00019755751,0.0013608485,0.00016912966,0.000039441264,0.000008025982,0.00016295098,0.00029429182,0.00016808606],"category_scores_gemma":[0.0003269546,0.000113363596,0.00023860167,0.000309149,0.0004731322,0.00014031031,0.000021425189,0.0006587239,0.000009932465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17746541,0.0014440515,0.7658839,0.000018882338,0.00025237194,0.00042263506,0.00010416863,0.0000013790345,0.00008737582,0.0000026306643,0.0002656002,0.054051556],"study_design_scores_gemma":[0.06543103,0.086961746,0.8339954,0.00024688066,0.0002299327,0.00015757528,0.00004337754,0.000041205374,0.00027100867,0.0000106578955,0.012479828,0.00013136884],"about_ca_topic_score_codex":0.00006758607,"about_ca_topic_score_gemma":0.00013867357,"teacher_disagreement_score":0.11203439,"about_ca_system_score_codex":0.00028474513,"about_ca_system_score_gemma":0.0014807064,"threshold_uncertainty_score":0.46228334},"labels":[],"label_agreement":null},{"id":"W2790152927","doi":"10.1183/13993003.02072-2017","title":"Immunotherapy: a new standard of care in thoracic malignancies?","year":2018,"lang":"en","type":"article","venue":"European Respiratory Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Standard of care; Medicine; Immunotherapy; Intensive care medicine; Oncology; Internal medicine; Cancer","score_opus":0.02563767760734927,"score_gpt":0.31398697278678445,"score_spread":0.2883492951794352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790152927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9640841,0.015737284,0.00021015262,0.00016635447,0.00031695171,0.00016820214,0.000006942898,0.000023212371,0.019286802],"genre_scores_gemma":[0.9951797,0.00037098196,0.00082973036,0.0019002858,0.0010238439,6.7936867e-7,0.0000011327882,0.00005862604,0.0006350082],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99842685,0.00028525555,0.000544326,0.00016135139,0.0003370688,0.0002451726],"domain_scores_gemma":[0.99907595,0.000015534972,0.00024357448,0.00029582274,0.00023690335,0.00013220114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000970135,0.00014589608,0.00030237518,0.00024674498,0.00008874636,0.000034394558,0.00017875215,0.000040143645,0.0007873254],"category_scores_gemma":[0.000043601045,0.00011672587,0.00016656477,0.0003052631,0.00017079792,0.00009284164,0.000026619597,0.0002906874,0.000040415896],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03249078,0.0000885838,0.034328274,0.00010848529,0.00019759059,0.00076218136,0.0062649185,0.0000017095599,0.3349094,0.000028802677,0.011383096,0.5794362],"study_design_scores_gemma":[0.006881315,0.006375344,0.18343358,0.001105149,0.00003187595,0.0003490226,0.001193755,7.593367e-7,0.053289145,0.000023114635,0.7470954,0.00022155387],"about_ca_topic_score_codex":0.000007086567,"about_ca_topic_score_gemma":0.000023389768,"teacher_disagreement_score":0.7357123,"about_ca_system_score_codex":0.00017069063,"about_ca_system_score_gemma":0.00056409417,"threshold_uncertainty_score":0.8620661},"labels":[],"label_agreement":null},{"id":"W2790263900","doi":"10.1200/jco.2018.36.5_suppl.212","title":"Phase I trial of the programmed death receptor 1 (PD-1) inhibitor, BI 754091, in patients (pts) with advanced solid tumors.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Adverse effect; Cohort; Internal medicine; Oncology; Pharmacokinetics; In vivo; Pharmacology; Gastroenterology","score_opus":0.07473774142480086,"score_gpt":0.4593583504307734,"score_spread":0.3846206090059725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790263900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935853,0.000093217284,0.0000112946545,0.0024051138,0.0025760725,0.00080278976,0.0000039912757,0.000005306769,0.00051695196],"genre_scores_gemma":[0.9956656,0.00013366526,0.0013991264,0.0011563718,0.0015151319,0.000010629192,0.0000020219545,0.000016979262,0.00010043791],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99607944,0.00041755367,0.0026120527,0.00017283857,0.0004699381,0.00024819144],"domain_scores_gemma":[0.9959411,0.00054542546,0.002499388,0.00024317212,0.0005952063,0.00017570252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025073746,0.00014074206,0.0012860713,0.00010836541,0.00003589132,0.0000052671503,0.00021373547,0.00025738397,0.00010683816],"category_scores_gemma":[0.0020170058,0.00007239342,0.00041642258,0.00030994587,0.0005697209,0.00009086831,0.00003823042,0.00067256,0.0000035422793],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5775222,0.0102209775,0.037258424,0.000015183927,0.0002031215,0.000019826035,0.00012961647,3.1661222e-7,0.00082300993,0.0000042983625,0.0012535175,0.37254947],"study_design_scores_gemma":[0.5426683,0.27076563,0.090240344,0.00052884425,0.00017630497,0.0000328686,0.00010087673,0.000007208042,0.0033171475,0.000037783597,0.09200671,0.00011796544],"about_ca_topic_score_codex":0.000018879582,"about_ca_topic_score_gemma":0.00007022544,"teacher_disagreement_score":0.37243152,"about_ca_system_score_codex":0.00019501307,"about_ca_system_score_gemma":0.001725574,"threshold_uncertainty_score":0.30610943},"labels":[],"label_agreement":null},{"id":"W2790809604","doi":"10.1158/1078-0432.ccr-18-0380","title":"Biomarker Discovery from We to Me: Is Learning from Each Patient a New Approach?","year":2018,"lang":"en","type":"letter","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Cancer; Ovarian cancer; Biomarker discovery; Identification (biology); Mechanism (biology); Medicine; Biomarker; Computational biology; Immunotherapy; Internal medicine; Biology; Proteomics","score_opus":0.3369151465285287,"score_gpt":0.49592690996692385,"score_spread":0.15901176343839513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790809604","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.061432436,0.012255719,0.00040725057,0.91497654,0.0029736303,0.002527368,0.000985804,0.00013809114,0.004303191],"genre_scores_gemma":[0.0058859284,0.011256022,0.0016976638,0.8096716,0.046868827,0.00069697335,0.002667606,0.00043425997,0.120821156],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9907025,0.0014086685,0.0015019072,0.0023240438,0.0026979973,0.0013648953],"domain_scores_gemma":[0.9942819,0.0024363603,0.0003223025,0.0018007343,0.0004947551,0.000663948],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0019824726,0.0006182115,0.001496076,0.00045076612,0.00028046325,0.00034285162,0.00093020586,0.001961489,0.011913776],"category_scores_gemma":[0.0010114317,0.0004899897,0.0009122762,0.0009762749,0.0009024439,0.00015338731,0.00072049827,0.007567962,0.0013208035],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007737494,0.00017844282,0.0034475313,0.00011154681,0.0013578008,0.0001713802,0.0008428606,3.66523e-7,0.0005852858,2.7824402e-7,0.874122,0.11144501],"study_design_scores_gemma":[0.0030754486,0.0013023624,0.0051833056,0.0015397355,0.0002172427,0.0000034532509,0.00024106572,0.00007227932,0.00032715476,0.00013015166,0.9873441,0.00056370284],"about_ca_topic_score_codex":0.03198869,"about_ca_topic_score_gemma":0.00023607384,"teacher_disagreement_score":0.11651796,"about_ca_system_score_codex":0.0008799328,"about_ca_system_score_gemma":0.002602023,"threshold_uncertainty_score":0.9997552},"labels":[],"label_agreement":null},{"id":"W2790931951","doi":"10.1200/jco.2018.36.5_suppl.185","title":"Systemic immune signature of inflammation in metastatic melanoma (MM) patients treated with ipilimumab (IPI) and carboplatin/paclitaxel (CP).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame; Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Ipilimumab; Immune system; CD8; Gastroenterology; Neutrophil to lymphocyte ratio; Carboplatin; Inflammation; Immunology; Chemokine; Paclitaxel; Systemic inflammation; Log-rank test; Oncology; Lymphocyte; Survival analysis; Cancer; Chemotherapy; Immunotherapy","score_opus":0.04094894280871056,"score_gpt":0.378669652425957,"score_spread":0.33772070961724643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790931951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971772,0.0012125836,0.000015976697,0.0005076547,0.00028697404,0.00030870762,0.0000047666394,0.000004185791,0.00048195245],"genre_scores_gemma":[0.9986247,0.00034589123,0.00061377895,0.0001472878,0.00019616685,0.0000029439352,0.0000051944357,0.0000127151,0.000051328785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967576,0.0003967089,0.0022785347,0.0001366538,0.00028080077,0.00014967137],"domain_scores_gemma":[0.9963098,0.00083553226,0.002048315,0.00014566314,0.00055187236,0.00010881824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019005183,0.0001297078,0.0012593748,0.00019251765,0.000021084135,0.000004764567,0.00008283799,0.00025177145,0.00004870603],"category_scores_gemma":[0.00074737635,0.00008011232,0.00016629824,0.00022221729,0.0003194975,0.00010822886,0.000018027647,0.00046559479,0.000001438268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09417262,0.0013533278,0.72609776,0.0002849902,0.0015352551,0.00023283051,0.0011025531,0.0000057650313,0.027112043,0.000026127784,0.00021958018,0.14785713],"study_design_scores_gemma":[0.033747703,0.03674055,0.92461807,0.00085444725,0.00045658275,0.00031218695,0.00032913827,0.00014223692,0.0018890417,0.000043680815,0.0007620635,0.00010432547],"about_ca_topic_score_codex":0.000087743436,"about_ca_topic_score_gemma":0.0001011034,"teacher_disagreement_score":0.19852026,"about_ca_system_score_codex":0.00013888683,"about_ca_system_score_gemma":0.00056398293,"threshold_uncertainty_score":0.32668853},"labels":[],"label_agreement":null},{"id":"W2791091396","doi":"10.1200/jco.2018.36.5_suppl.7","title":"Tumor infiltrating lymphocyte recruitment in patients with early stage breast cancer after intramammary IRX-2 cytokine immunotherapy.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Immunotherapy; Breast cancer; Immune system; Tumor-infiltrating lymphocytes; FOXP3; Oncology; Internal medicine; CD8; Cancer; Immunology","score_opus":0.06041739771748082,"score_gpt":0.4064554422141759,"score_spread":0.34603804449669506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791091396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995258,0.0006125307,0.000024067953,0.0021078095,0.0010294142,0.00049105764,0.000027719598,0.000009036847,0.0004403974],"genre_scores_gemma":[0.9897639,0.00076036796,0.0013500268,0.0065547214,0.0013241563,0.000031594063,0.00000241451,0.00003242463,0.00018037567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964939,0.00029944305,0.00220331,0.00022749661,0.00043994372,0.00033595343],"domain_scores_gemma":[0.9971356,0.00035146187,0.001534855,0.00023082922,0.0005385354,0.00020875377],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018992329,0.00020207104,0.0011350954,0.00017111385,0.000039042796,0.000017773886,0.00016235614,0.00022470797,0.001051623],"category_scores_gemma":[0.0001349086,0.00012865265,0.00027420325,0.00025921312,0.00040403864,0.00019931335,0.00003121615,0.0006610423,0.0000081524295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12214526,0.0010602465,0.5819706,0.000015775862,0.00041253728,0.00022309349,0.00021784872,0.0000011486403,0.00024764644,0.0000014501804,0.00018567551,0.29351875],"study_design_scores_gemma":[0.031470064,0.019443737,0.9059252,0.0004213292,0.00008648558,0.0001165902,0.000055082604,0.000008681804,0.0001411556,0.00000762493,0.042185046,0.00013900515],"about_ca_topic_score_codex":0.00033862915,"about_ca_topic_score_gemma":0.00037347156,"teacher_disagreement_score":0.3239546,"about_ca_system_score_codex":0.0006904625,"about_ca_system_score_gemma":0.0019828894,"threshold_uncertainty_score":0.99986154},"labels":[],"label_agreement":null},{"id":"W2791290180","doi":"10.1016/s1470-2045(18)30144-x","title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":576,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute; Kite Pharma; EMD Serono; MacroGenics; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Internal medicine; Oncology; Lung cancer; Anaplastic lymphoma kinase; Response Evaluation Criteria in Solid Tumors; Cohort; Progressive disease; Cancer; Nivolumab; Anaplastic large-cell lymphoma; Immunotherapy; Chemotherapy; Lymphoma; Malignant pleural effusion","score_opus":0.13285510740048945,"score_gpt":0.45235716903037204,"score_spread":0.3195020616298826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791290180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843174,0.0005144307,0.00008992344,0.005767821,0.0009343648,0.005087559,0.000061268096,0.000086522465,0.0031407068],"genre_scores_gemma":[0.9801368,0.0006400453,0.001796787,0.0060132514,0.0021097192,0.0013425566,0.0000710707,0.00007026906,0.007819506],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99807215,0.00021339016,0.00044009124,0.0005207222,0.00015260067,0.0006010415],"domain_scores_gemma":[0.99844104,0.000220108,0.00023884555,0.0007874049,0.00018825635,0.00012432254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071149087,0.00031665855,0.0009313436,0.00006213387,0.00029301186,0.000055008248,0.0005194657,0.0001450491,0.0008080586],"category_scores_gemma":[0.00003266413,0.00017433007,0.00006400422,0.00020270573,0.00020324675,0.00011347145,0.000110488174,0.00015411372,0.000031169042],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39431208,0.05721429,0.005688755,0.00023454208,0.0024695238,0.0003394756,0.014692141,0.000008419827,0.30899167,0.000033326192,0.019243954,0.19677182],"study_design_scores_gemma":[0.3101373,0.3131844,0.0016180378,0.0001895102,0.0016699247,0.000175294,0.0021010481,0.0014852739,0.0501548,0.00007127991,0.31861204,0.00060107996],"about_ca_topic_score_codex":0.0013528867,"about_ca_topic_score_gemma":0.006361111,"teacher_disagreement_score":0.29936808,"about_ca_system_score_codex":0.000631496,"about_ca_system_score_gemma":0.0006696901,"threshold_uncertainty_score":0.8847675},"labels":[],"label_agreement":null},{"id":"W2791308824","doi":"10.1158/1078-0432.ccr-17-3452","title":"Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":387,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Breast cancer; Internal medicine; Oncology; Adverse effect; Cancer; Response Evaluation Criteria in Solid Tumors; Estrogen receptor; Nausea; Gastroenterology; Phases of clinical research; Toxicity; Immunotherapy","score_opus":0.06109298004932549,"score_gpt":0.4370445413124408,"score_spread":0.3759515612631153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791308824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526644,0.00032026606,0.0000062422714,0.0017581183,0.00020244041,0.0012121259,0.00085594814,0.000021141974,0.0003572971],"genre_scores_gemma":[0.9975245,0.0014366736,0.00013854347,0.00016546085,0.00034931063,0.00009610609,0.000025744328,0.00004557508,0.00021806554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99652165,0.0006016206,0.0006928317,0.0007261695,0.00081446784,0.0006432359],"domain_scores_gemma":[0.9972336,0.00057777815,0.00025982285,0.0003676374,0.0012625448,0.00029858548],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010278584,0.0002537565,0.0007856857,0.00021306821,0.00021267125,0.00002157816,0.00020703168,0.00018722023,0.0017766523],"category_scores_gemma":[0.0002780981,0.00019244803,0.0001247299,0.0007265909,0.0022720117,0.0002583296,0.00014340741,0.0008487088,0.000008762104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1027604,0.000735931,0.7898188,0.00014189919,0.00027764754,0.000004444007,0.00027629075,2.6983219e-7,0.007446384,0.00002485278,0.00040170358,0.098111324],"study_design_scores_gemma":[0.016126547,0.0035893533,0.9632673,0.0006955278,0.000027128328,0.000002130673,0.00006103801,0.000008211175,0.015413017,0.000013517358,0.00058453286,0.00021168613],"about_ca_topic_score_codex":0.0039902194,"about_ca_topic_score_gemma":0.0008644076,"teacher_disagreement_score":0.17344846,"about_ca_system_score_codex":0.0005867533,"about_ca_system_score_gemma":0.0007950383,"threshold_uncertainty_score":0.99913585},"labels":[],"label_agreement":null},{"id":"W2791467603","doi":"10.1158/1535-7163.mct-17-1091","title":"Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Canadian Cancer Society; Government of Canada","keywords":"Immune checkpoint; Cancer research; Cisplatin; CD8; Immune system; Biology; In vivo; Cancer; Cytotoxic T cell; Immunology; Immunotherapy; Chemotherapy; Genetics; In vitro","score_opus":0.027543629945367083,"score_gpt":0.33420471881669817,"score_spread":0.3066610888713311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791467603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955179,0.0023510861,0.000034011708,0.0008693771,0.00009552095,0.0005757919,0.000035463985,0.000030939125,0.00048987556],"genre_scores_gemma":[0.99726665,0.00028759163,0.00014387308,0.0019837725,0.00010830534,0.000064226886,0.000024542012,0.000058259586,0.00006278531],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811345,0.00011050034,0.00054495136,0.0003509646,0.00052506843,0.00035506077],"domain_scores_gemma":[0.998722,0.000056398818,0.0002266246,0.0004902518,0.0004071149,0.00009756527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033048444,0.00030144682,0.0004627734,0.00021825501,0.00003388509,0.0000133915955,0.00017284046,0.000143573,0.00044799584],"category_scores_gemma":[0.000039564395,0.000244146,0.00037035564,0.0005853204,0.00024215775,0.000043918746,0.000026313277,0.0002638287,0.000009888128],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024495738,0.00045951162,0.0024786054,0.000018445731,0.00067050726,0.000068144254,0.00074420066,0.000010585179,0.9328652,0.000025464613,0.000011512118,0.038152073],"study_design_scores_gemma":[0.0074860402,0.0029220774,0.11671976,0.0002556786,0.000053363237,0.000038666043,0.0000449896,0.00017729748,0.8716166,0.00013629129,0.0003059866,0.00024323032],"about_ca_topic_score_codex":0.002639514,"about_ca_topic_score_gemma":0.000024338853,"teacher_disagreement_score":0.11424115,"about_ca_system_score_codex":0.0008251561,"about_ca_system_score_gemma":0.0011531181,"threshold_uncertainty_score":0.99559855},"labels":[],"label_agreement":null},{"id":"W2791564187","doi":"10.1158/1538-7445.sabcs17-p3-05-12","title":"Abstract P3-05-12: VISTA expression on tumor-infiltrating lymphocytes in breast cancer: Clinical correlates and association with PD-1","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes","funders":"","keywords":"Tumor-infiltrating lymphocytes; Breast cancer; Immune checkpoint; Tissue microarray; Medicine; Immunohistochemistry; Oncology; Internal medicine; Cancer; PD-L1; Immune system; Antibody; Proportional hazards model; Cancer research; Immunotherapy; Immunology","score_opus":0.05990005739500917,"score_gpt":0.4214375950081101,"score_spread":0.3615375376131009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791564187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99391174,0.0011357844,0.0000021031435,0.0027129496,0.0002505848,0.00045198578,0.00004633745,0.00003315388,0.0014553302],"genre_scores_gemma":[0.9956105,0.0022999612,0.00003392997,0.00054397044,0.0007229626,0.0001225534,0.000008968861,0.000031976007,0.00062520907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773324,0.00016481694,0.00039019567,0.0004535142,0.00074806367,0.0005101831],"domain_scores_gemma":[0.9984955,0.00055520266,0.00015662693,0.00025063046,0.000381876,0.00016016299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018309283,0.00015805489,0.00031349625,0.00018136142,0.00021363512,0.00007804765,0.00011631004,0.00015855733,0.0005693836],"category_scores_gemma":[0.00016924833,0.00011605014,0.000045512086,0.00045297696,0.00035645018,0.00012844753,0.000044321318,0.00064185035,0.00001587324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0190095,0.00017834906,0.84941375,0.00012129494,0.000101232516,0.0000579864,0.00047726757,0.0000037731493,0.06962879,0.0000072979537,0.012141025,0.04885976],"study_design_scores_gemma":[0.0064587826,0.0013513482,0.9588013,0.003062421,0.000019548126,0.000036003938,0.00043239095,0.00022109611,0.024787428,0.00001719893,0.0046058707,0.00020657186],"about_ca_topic_score_codex":0.0037497438,"about_ca_topic_score_gemma":0.0012455251,"teacher_disagreement_score":0.109387614,"about_ca_system_score_codex":0.0013115386,"about_ca_system_score_gemma":0.0009347189,"threshold_uncertainty_score":0.62343514},"labels":[],"label_agreement":null},{"id":"W2791697169","doi":"10.1200/jco.2018.36.5_suppl.184","title":"Genomic and immune landscape of metastatic melanoma (MM) treated with pembrolizumab (PEM).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; TIGIT; Pembrolizumab; Internal medicine; CD8; Immunophenotyping; Gastroenterology; Oncology; Immune system; Immunotherapy; Cancer; Immunology; Flow cytometry","score_opus":0.06533237155806704,"score_gpt":0.4068555114984129,"score_spread":0.3415231399403459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791697169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99265885,0.002343773,0.000050101786,0.0014220465,0.00024442404,0.00012703234,0.0000032172472,0.000004526496,0.0031460505],"genre_scores_gemma":[0.99543715,0.00095591316,0.0023744253,0.0005336234,0.00041129423,0.0000011434026,0.0000015227045,0.000013737956,0.00027117695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976984,0.00022293479,0.0016255388,0.00012232552,0.00017995037,0.00015084744],"domain_scores_gemma":[0.9972394,0.00070383324,0.0014180857,0.00015664462,0.0003269761,0.00015505636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016344342,0.0001106168,0.0012846959,0.00011931779,0.000027653738,0.0000047739054,0.00009515035,0.00014132429,0.00036707846],"category_scores_gemma":[0.00030275361,0.000064434134,0.00024480122,0.00012572814,0.0005235651,0.000050622082,0.000021648175,0.00031474288,0.0000048256647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24709603,0.0021354442,0.3688362,0.00013063682,0.005274106,0.00085715234,0.00044790673,0.0000013675212,0.033101454,0.00007414291,0.0026020207,0.33944353],"study_design_scores_gemma":[0.03170041,0.0611709,0.8823457,0.00014232247,0.00094557676,0.00242892,0.00018026873,0.000056517558,0.0017359643,0.0000715847,0.019128582,0.00009329778],"about_ca_topic_score_codex":0.000049296636,"about_ca_topic_score_gemma":0.000044460063,"teacher_disagreement_score":0.51350945,"about_ca_system_score_codex":0.000046496818,"about_ca_system_score_gemma":0.0007916112,"threshold_uncertainty_score":0.40192518},"labels":[],"label_agreement":null},{"id":"W2791803000","doi":"10.1200/jco.2018.36.5_suppl.169","title":"Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Durvalumab; Medicine; Internal medicine; Discontinuation; Histology; Oncology; Gastroenterology; Cancer; Pembrolizumab; Immunotherapy","score_opus":0.06885531867939113,"score_gpt":0.4457146054494242,"score_spread":0.3768592867700331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791803000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892889,0.0006805658,0.0000691844,0.0036409264,0.0010137201,0.00020984499,0.0000045286424,0.000004821256,0.005087494],"genre_scores_gemma":[0.9920826,0.0026003097,0.003132325,0.0013155114,0.00055821077,0.0000013848498,0.0000024288488,0.000013668991,0.0002935795],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970007,0.0003407837,0.0021212904,0.00014643278,0.00022357354,0.00016723097],"domain_scores_gemma":[0.9975103,0.0006585659,0.0012229101,0.00014903473,0.0003279944,0.00013117291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003142907,0.00010436397,0.0011858471,0.000114947026,0.000019641224,0.000002920364,0.00010230937,0.00027469438,0.0005039093],"category_scores_gemma":[0.00059479824,0.00007414148,0.00023485266,0.00014729047,0.00041453924,0.0000921712,0.000022388629,0.0004441703,0.000003123738],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24766676,0.0015360115,0.09280973,0.000032404085,0.00055014674,0.00011909761,0.00025553067,0.0000021541562,0.014229267,0.00014077281,0.0023143294,0.6403438],"study_design_scores_gemma":[0.04592627,0.021226007,0.8280243,0.00017192795,0.0000698474,0.000118967924,0.00013211064,0.000086005755,0.0010028677,0.0002194057,0.10292557,0.000096662836],"about_ca_topic_score_codex":0.000046145455,"about_ca_topic_score_gemma":0.000105063555,"teacher_disagreement_score":0.73521465,"about_ca_system_score_codex":0.00009902854,"about_ca_system_score_gemma":0.0008650506,"threshold_uncertainty_score":0.55174536},"labels":[],"label_agreement":null},{"id":"W2791879337","doi":"10.1080/2162402x.2017.1423173","title":"Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen","year":2018,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Chemokine; Immune system; CD8; Cancer research; Immunotherapy; Tumor microenvironment; Medicine; Dendritic cell; CD68; Immunohistochemistry; Immunology; Biology","score_opus":0.007076286795418588,"score_gpt":0.24744590405908215,"score_spread":0.24036961726366357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791879337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98678565,0.0072407536,0.000027666496,0.00461684,0.00011967109,0.00058110553,0.000008339331,0.00004083024,0.0005791346],"genre_scores_gemma":[0.99580723,0.0015166765,0.00067913265,0.0013174618,0.0001433338,0.000119060285,0.000026659744,0.000036174166,0.00035425994],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987018,0.000138843,0.0003453551,0.00034751112,0.00014731709,0.00031917664],"domain_scores_gemma":[0.99920523,0.00007938049,0.0001578663,0.00044050987,0.0000737875,0.00004322839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036061936,0.00024476968,0.000405502,0.0001343618,0.00014017476,0.000030306057,0.000106448075,0.00017900244,0.00024197546],"category_scores_gemma":[0.000023387665,0.00014995308,0.000043933404,0.00022655503,0.000839247,0.00013426249,0.000054940043,0.0002899283,0.000009999365],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029682014,0.00013084765,0.018396912,0.000019885721,0.00010689726,0.00002090629,0.0024531349,6.402046e-8,0.90818954,0.000015778844,0.00018723929,0.04079676],"study_design_scores_gemma":[0.0131746465,0.003535989,0.8312244,0.0005344704,0.000028049311,0.0003502632,0.0006635449,0.0000209913,0.10858584,0.000033461172,0.041590855,0.00025753022],"about_ca_topic_score_codex":0.0009937601,"about_ca_topic_score_gemma":0.0002383879,"teacher_disagreement_score":0.81282747,"about_ca_system_score_codex":0.00009605489,"about_ca_system_score_gemma":0.000121303136,"threshold_uncertainty_score":0.6114909},"labels":[],"label_agreement":null},{"id":"W2791905160","doi":"10.14740/wjon1085w","title":"Autoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports","year":2018,"lang":"en","type":"review","venue":"World Journal of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pembrolizumab; Medicine; Ipilimumab; Type 1 diabetes; Diabetes mellitus; Internal medicine; Pneumonitis; Diabetic ketoacidosis; Nivolumab; Cancer; Oncology; Immunology; Immunotherapy; Lung; Endocrinology","score_opus":0.034164925736160104,"score_gpt":0.3562388457275644,"score_spread":0.32207391999140433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791905160","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014907194,0.99360865,0.0000010721988,0.0007040193,0.0009936142,0.0007937092,0.000013097098,0.000015448017,0.003721309],"genre_scores_gemma":[0.000099131714,0.99667436,0.00020438679,0.00074056466,0.00038893957,0.000025986848,0.000046779252,0.0000652272,0.0017546185],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948514,0.0006072707,0.0033809254,0.00029592204,0.00048726998,0.0003772281],"domain_scores_gemma":[0.9885441,0.00054164254,0.008965918,0.00060599326,0.0011699707,0.00017236828],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038511343,0.00042759435,0.0057201525,0.0007840904,0.000057103574,0.000017832866,0.00019359616,0.00034099733,0.0012653433],"category_scores_gemma":[0.0012289144,0.0002575752,0.0013829198,0.0013097553,0.00037897902,0.00012555564,0.000056148034,0.0009888764,0.0000027472015],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005795473,0.00056756503,0.000077539975,0.07079983,0.0056967223,0.044954356,0.00003827138,1.6830423e-8,0.0000041432972,0.000003041513,0.0830278,0.79425114],"study_design_scores_gemma":[0.0014008317,0.0025159407,0.000049452363,0.23342544,0.004919266,0.101667546,0.000003924867,1.0768048e-7,0.0000014800329,0.000004282069,0.6558625,0.00014924067],"about_ca_topic_score_codex":0.000019901858,"about_ca_topic_score_gemma":0.000085097905,"teacher_disagreement_score":0.7941019,"about_ca_system_score_codex":0.0010371107,"about_ca_system_score_gemma":0.004383393,"threshold_uncertainty_score":0.99998766},"labels":[],"label_agreement":null},{"id":"W2792522034","doi":"10.1016/j.semcancer.2018.02.005","title":"Immuno-oncology-101: overview of major concepts and translational perspectives","year":2018,"lang":"en","type":"review","venue":"Seminars in Cancer Biology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Immunotherapy; Immune system; Cancer immunotherapy; Medicine; Acquired immune system; Cancer; Immunology; Immune checkpoint; Bioinformatics; Cancer research; Oncology; Biology; Internal medicine","score_opus":0.08023712406347813,"score_gpt":0.45872948274763853,"score_spread":0.3784923586841604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792522034","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045117334,0.99665457,0.0000025708111,0.0002806735,0.00047478962,0.00080660527,0.00029493784,0.00001366517,0.0010209884],"genre_scores_gemma":[0.00019943411,0.9984341,0.00033252846,0.00012042664,0.00028696615,0.00019429528,0.00012810052,0.00003296507,0.00027117983],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981304,0.0002342469,0.00073214417,0.0005225464,0.00009663104,0.00028406625],"domain_scores_gemma":[0.99888235,0.00028916073,0.00040680915,0.00027774245,0.000091944734,0.00005199379],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043035412,0.00034362252,0.0019738092,0.00026744884,0.00003562872,0.0000036407534,0.00016456083,0.000685109,0.00087640045],"category_scores_gemma":[0.000032834203,0.00026429424,0.00035690903,0.00035660955,0.0011740515,0.000028817723,0.00004711061,0.0003140086,0.0000034483612],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004797836,0.00009828698,0.00036993338,0.006444418,0.00059979246,0.000008161071,0.00104927,1.06091775e-8,0.00016207542,0.00021899118,0.00087287754,0.9896964],"study_design_scores_gemma":[0.0015198682,0.0007912347,0.0002663226,0.019487318,0.0005414669,0.00015589266,0.00026917213,5.706941e-7,0.000028019416,0.00012246179,0.9765782,0.00023951636],"about_ca_topic_score_codex":0.00027598816,"about_ca_topic_score_gemma":0.00017867735,"teacher_disagreement_score":0.9894569,"about_ca_system_score_codex":0.00031752375,"about_ca_system_score_gemma":0.0011132377,"threshold_uncertainty_score":0.9999809},"labels":[],"label_agreement":null},{"id":"W2792770181","doi":"10.1016/j.cllc.2018.03.004","title":"Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy","year":2018,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Cancer Institute","keywords":"Medicine; Lung cancer; Immunotherapy; Cancer immunotherapy; Oncology; Intensive care medicine; Internal medicine; Cancer","score_opus":0.18685287426036798,"score_gpt":0.5488623498999278,"score_spread":0.36200947563955976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792770181","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042767182,0.99251556,0.000008111189,0.000709961,0.0044348105,0.0012720799,0.00012383382,0.000017580218,0.0004903793],"genre_scores_gemma":[0.0002158039,0.9954991,0.00003633222,0.0014995752,0.0010798662,0.00043229386,0.000040688003,0.000047472513,0.001148915],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967079,0.00041079076,0.0017306663,0.0005349624,0.0003672724,0.0002484092],"domain_scores_gemma":[0.99748856,0.00078754104,0.0007508515,0.00060261425,0.0003248839,0.000045542118],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001514867,0.00038076346,0.0018968068,0.0001310558,0.00006379957,0.000012781332,0.00050912396,0.0002887322,0.0010944346],"category_scores_gemma":[0.00029366394,0.00020473817,0.0008091982,0.00050007633,0.00096140715,0.000050446426,0.000091609094,0.00062992936,0.00002823983],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002193952,0.0002720377,0.0005234665,0.004324885,0.004406413,0.000018733448,0.00041186347,0.0000010009122,0.000003482079,0.000107529064,0.042701665,0.945035],"study_design_scores_gemma":[0.0009058051,0.00044858936,0.00028591507,0.045765568,0.0004889493,0.000008458385,0.00014043176,0.00001191162,0.000009188912,0.000017805894,0.9516848,0.00023261654],"about_ca_topic_score_codex":0.000031958356,"about_ca_topic_score_gemma":0.00007833019,"teacher_disagreement_score":0.94480234,"about_ca_system_score_codex":0.00027323485,"about_ca_system_score_gemma":0.00063318136,"threshold_uncertainty_score":0.9998187},"labels":[],"label_agreement":null},{"id":"W2792893181","doi":"10.1016/j.ctrv.2018.02.005","title":"Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC","year":2018,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Juravinski Cancer Centre; Montreal General Hospital; University of British Columbia; Royal Victoria Regional Health Centre; University of Alberta; Royal Victoria Hospital; University Health Network; University of Toronto; McMaster University; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"Pfizer Canada; Merck Canada; Pfizer; AstraZeneca Canada; Roche Canada","keywords":"Medicine; Biomarker; Cancer research; Oncology; Code (set theory); Internal medicine; Programming language; Genetics","score_opus":0.10290617840553892,"score_gpt":0.40395395192761063,"score_spread":0.3010477735220717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792893181","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021824615,0.9929266,0.0000085388,0.0002429334,0.00037108845,0.0051717455,0.00006974222,0.00003595784,0.0009551559],"genre_scores_gemma":[0.000035372992,0.99448174,0.00014983796,0.00027597597,0.00031350448,0.0036537277,0.00019102979,0.00007360683,0.00082519435],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99710435,0.00035007257,0.0011939877,0.0007681575,0.00020208655,0.00038135724],"domain_scores_gemma":[0.99821085,0.00010000681,0.00076205283,0.0007768578,0.000040887797,0.00010933647],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000580113,0.00072695606,0.0024075822,0.00017985326,0.00013650913,0.00004534029,0.00009766691,0.00027921182,0.00032354638],"category_scores_gemma":[0.000028893512,0.00035384714,0.0007782033,0.00051684276,0.00020212684,0.000100860234,0.00006082692,0.0002258466,0.000043108874],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000289136,0.000107256696,0.000022901986,0.007787736,0.00018352905,0.000024949102,0.00014113549,1.6398824e-8,0.00016144449,0.0000013479729,0.00164223,0.9896383],"study_design_scores_gemma":[0.002060945,0.00024468402,0.00010531505,0.112412915,0.0010918559,0.00013194238,0.000015607951,0.0000013711496,0.0001194727,0.0000041228855,0.88350916,0.00030260114],"about_ca_topic_score_codex":0.00019168387,"about_ca_topic_score_gemma":0.000235042,"teacher_disagreement_score":0.9893357,"about_ca_system_score_codex":0.0014006749,"about_ca_system_score_gemma":0.00033925567,"threshold_uncertainty_score":0.99989134},"labels":[],"label_agreement":null},{"id":"W2793126529","doi":"10.1158/2159-8290.cd-17-1327","title":"Genetic Mechanisms of Immune Evasion in Colorectal Cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":550,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Ontario Institute for Cancer Research","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Cancer Institute; U.S. National Library of Medicine; Ontario Ministry of Research and Innovation; Stand Up To Cancer; Dana-Farber/Harvard Cancer Center; Gary Bennett Family Fund; Parker Institute for Cancer Immunotherapy; American Association for Cancer Research; American Society of Clinical Oncology; National Center for Advancing Translational Sciences; National Human Genome Research Institute; Hope Foundation; National Institutes of Health; Conquer Cancer Foundation; Tower Cancer Research Foundation","keywords":"Evasion (ethics); Immune system; Colorectal cancer; Cancer; Biology; Computational biology; Immunology; Cancer research; Medicine; Genetics","score_opus":0.014185351286958477,"score_gpt":0.2869981973630584,"score_spread":0.27281284607609996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793126529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99101996,0.0062810667,0.00034127352,0.00033902255,0.0008678671,0.0003410422,0.000044513115,0.000016039889,0.0007492144],"genre_scores_gemma":[0.99620575,0.0023275274,0.00015191307,0.00040428468,0.00025418407,0.00011069424,0.0000053834574,0.000023438253,0.0005168456],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989694,0.000023619737,0.00033390577,0.00023574305,0.00020728572,0.00023009778],"domain_scores_gemma":[0.9995629,0.00001827078,0.00011862522,0.00018753325,0.000071181516,0.00004144992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001124578,0.00013359595,0.00030072514,0.00010827852,0.000031985535,0.00001088482,0.00009664975,0.000085260705,0.0007596885],"category_scores_gemma":[0.000010533776,0.00011068591,0.000121961624,0.0003226417,0.00019035352,0.00011396944,0.000035298133,0.00009260677,0.0000059099807],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032930945,0.0000979074,0.021657715,0.00010352096,0.00011091935,0.000009063815,0.0004042411,0.000009045723,0.95683426,0.00007911119,0.0003722165,0.017028928],"study_design_scores_gemma":[0.0023044103,0.00045407406,0.41764486,0.0005307346,0.000054320368,0.0000075663634,0.00013903543,0.00008125538,0.5778681,0.00022416288,0.00056476716,0.00012669581],"about_ca_topic_score_codex":0.0036926519,"about_ca_topic_score_gemma":0.0014902115,"teacher_disagreement_score":0.39598712,"about_ca_system_score_codex":0.00029453848,"about_ca_system_score_gemma":0.00040310874,"threshold_uncertainty_score":0.83180565},"labels":[],"label_agreement":null},{"id":"W2793304410","doi":"10.1097/cji.0000000000000213","title":"The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis","year":2018,"lang":"en","type":"review","venue":"Journal of Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Diarrhea; Colitis; Discontinuation; Ipilimumab; Relative risk; Gastroenterology; Incidence (geometry); Ulcerative colitis; Oncology; Immunology; Confidence interval; Immunotherapy; Cancer; Disease","score_opus":0.022225291073107372,"score_gpt":0.2951776078196416,"score_spread":0.2729523167465342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793304410","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002913405,0.99372345,0.000013225861,0.00014373798,0.00006596994,0.0030787678,0.000045959023,0.000005103153,0.00001036261],"genre_scores_gemma":[0.00068136235,0.9986345,0.00023297043,0.00014533139,0.00003166779,0.00011240841,0.0000074392024,0.00007010591,0.00008417438],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99450105,0.0010238915,0.0032960514,0.0002993766,0.0005906158,0.00028902633],"domain_scores_gemma":[0.99201924,0.00093165203,0.005751048,0.00074549817,0.00046768333,0.00008489696],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032294781,0.00059009885,0.008807501,0.0004929623,0.00012611684,0.000061463325,0.00029408,0.00018397975,0.00006140267],"category_scores_gemma":[0.00019222757,0.00026021138,0.002597887,0.0009789101,0.0003120558,0.00014471197,0.000032463045,0.0005267245,5.5004386e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048086564,0.00032797956,0.00038472534,0.34594113,0.5884115,0.000015573414,0.00035590975,2.266704e-7,0.000005169123,0.000004059655,0.000029729821,0.05971533],"study_design_scores_gemma":[0.009691819,0.005480407,0.0045507993,0.23494673,0.720279,0.00025731526,0.00008708332,7.5455847e-7,0.000024731611,0.00001892042,0.024045337,0.000617132],"about_ca_topic_score_codex":0.00005014584,"about_ca_topic_score_gemma":0.000048238166,"teacher_disagreement_score":0.13186748,"about_ca_system_score_codex":0.00019378406,"about_ca_system_score_gemma":0.00038505276,"threshold_uncertainty_score":0.99998504},"labels":[],"label_agreement":null},{"id":"W2793495237","doi":"10.1158/1538-7445.sabcs17-pd6-10","title":"Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC)","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Cohort; Triple-negative breast cancer; Clinical endpoint; Breast cancer; Metastatic breast cancer; Cancer; Response Evaluation Criteria in Solid Tumors; Progressive disease; Chemotherapy; Clinical trial; Immunotherapy","score_opus":0.0679343402304146,"score_gpt":0.4227587382644817,"score_spread":0.35482439803406707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793495237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96928877,0.0086779315,0.0002127393,0.005723311,0.00066857063,0.007784202,0.0020289612,0.00017626093,0.0054392293],"genre_scores_gemma":[0.9659118,0.007379084,0.00032259605,0.0010341988,0.0015033445,0.004093145,0.00012823052,0.00019564353,0.019431932],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9953823,0.00025707638,0.00067587226,0.0010433226,0.001176766,0.0014646653],"domain_scores_gemma":[0.99598587,0.000546373,0.00022608052,0.00077349984,0.002027115,0.00044104614],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014875405,0.0004960157,0.0008615394,0.00048813355,0.00061204605,0.00015179753,0.00045073216,0.00021491878,0.011073613],"category_scores_gemma":[0.00014172425,0.00040233895,0.00037713372,0.0011936985,0.0011983247,0.00028078863,0.00006840799,0.0006248132,0.00014359965],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30957258,0.0014096508,0.01554967,0.00153001,0.009161467,0.00018019226,0.0055661877,0.00002620021,0.15189466,0.00014610536,0.1560513,0.34891197],"study_design_scores_gemma":[0.06605431,0.007043747,0.56881917,0.0036545317,0.0010795784,0.00030768875,0.0011768771,0.0007468941,0.2325926,0.0007356675,0.115911804,0.001877132],"about_ca_topic_score_codex":0.015266002,"about_ca_topic_score_gemma":0.0021747448,"teacher_disagreement_score":0.5532695,"about_ca_system_score_codex":0.0019116639,"about_ca_system_score_gemma":0.0022406732,"threshold_uncertainty_score":0.9998428},"labels":[],"label_agreement":null},{"id":"W2794016097","doi":"10.1158/1538-7445.sabcs17-pd6-05","title":"Abstract PD6-05: Distinct tumor microenvironments stratify triple negative breast cancer into immune subtypes","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; McGill University Health Centre; University of Toronto","funders":"","keywords":"Triple-negative breast cancer; Tumor microenvironment; CD8; Immune system; Stroma; Cytotoxic T cell; Tumor-infiltrating lymphocytes; Cancer research; Breast cancer; Tumor progression; Medicine; T cell; Immunohistochemistry; Pathology; Biology; Cancer; Immunology; Internal medicine","score_opus":0.04269010630005453,"score_gpt":0.3853015084727795,"score_spread":0.34261140217272495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794016097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98812646,0.004316744,0.0000049447517,0.004095399,0.00058045913,0.0009231707,0.00026768498,0.00004583788,0.0016392746],"genre_scores_gemma":[0.9926913,0.0014726099,0.00007146609,0.00035298846,0.0011230997,0.00035683514,0.000030050529,0.00006149278,0.0038401987],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972418,0.00011671707,0.00042325773,0.0005935413,0.00083556504,0.00078911067],"domain_scores_gemma":[0.9986039,0.00011600839,0.00012402993,0.0005597291,0.00034135737,0.0002550024],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00072961336,0.00026225386,0.00038820927,0.00020042674,0.00045029147,0.000081481834,0.0003376538,0.00011199591,0.011220904],"category_scores_gemma":[0.000063293875,0.00021339118,0.0001485984,0.00060920924,0.0012872965,0.00017075348,0.00011973517,0.00062936265,0.0002362293],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011548075,0.00032815427,0.023284879,0.00025574135,0.0004979125,0.0000920617,0.0013723295,5.1889987e-7,0.8605143,0.00001075269,0.025244169,0.076851144],"study_design_scores_gemma":[0.0037930876,0.00049581967,0.74046516,0.000505649,0.000042139094,0.000041164545,0.00056607585,0.00001243135,0.23027776,0.00010719806,0.02342472,0.00026881823],"about_ca_topic_score_codex":0.023290126,"about_ca_topic_score_gemma":0.0031851714,"teacher_disagreement_score":0.71718025,"about_ca_system_score_codex":0.0011964502,"about_ca_system_score_gemma":0.0008397911,"threshold_uncertainty_score":0.989683},"labels":[],"label_agreement":null},{"id":"W2794109650","doi":"10.1016/j.cjca.2018.03.007","title":"Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Nivolumab; Fulminant; Myocarditis; Ipilimumab; Immune checkpoint; Immunology; Immune system; Immunotherapy; Internal medicine","score_opus":0.009829954080926817,"score_gpt":0.22797198263231927,"score_spread":0.21814202855139245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794109650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98643136,0.0026460988,0.0004164366,0.0022624005,0.0015360262,0.00015388601,0.000033131266,0.000008023857,0.006512608],"genre_scores_gemma":[0.99613047,0.00014951307,0.00022620824,0.0004401297,0.0026074026,0.0000029287057,0.000007104237,0.000024962346,0.000411308],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987751,0.00008378989,0.000441296,0.00014642389,0.000142841,0.00041054748],"domain_scores_gemma":[0.99862033,0.000026925636,0.00020698248,0.00026384217,0.00040836836,0.00047354764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044902985,0.00015446372,0.00061766885,0.0002873631,0.00012268969,0.000018574934,0.00013253595,0.0001479936,0.00015905937],"category_scores_gemma":[0.00006439694,0.000113884395,0.00030154985,0.00019958595,0.0006642327,0.00006653825,0.000007742166,0.00028184144,0.00002728464],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024242679,0.000037130725,0.37376732,0.00022195114,0.010764777,0.01622653,0.0036277017,0.000096640266,0.10530059,0.00008613561,0.28701195,0.1786166],"study_design_scores_gemma":[0.005425955,0.0057250927,0.35762316,0.00036829224,0.00031206963,0.021937536,0.00038559,0.000005168599,0.01373758,0.000054356395,0.5941546,0.00027061417],"about_ca_topic_score_codex":0.0020955645,"about_ca_topic_score_gemma":0.0029279075,"teacher_disagreement_score":0.30714265,"about_ca_system_score_codex":0.0003211639,"about_ca_system_score_gemma":0.002302751,"threshold_uncertainty_score":0.4644071},"labels":[],"label_agreement":null},{"id":"W2795067517","doi":"10.1016/j.cjca.2018.03.012","title":"Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area","year":2018,"lang":"en","type":"review","venue":"Canadian Journal of Cardiology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Cardiotoxicity; Myocarditis; Plasmapheresis; Internal medicine; Oncology; Heart failure; Immunology; Chemotherapy; Antibody","score_opus":0.031640776949221176,"score_gpt":0.29951474343573375,"score_spread":0.26787396648651257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795067517","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000108326945,0.99743396,0.0000048995043,0.000347109,0.0002937878,0.0012704534,0.0001980993,0.0000024069059,0.00034096916],"genre_scores_gemma":[0.00127181,0.99793905,0.000010855686,0.00030857173,0.00024458556,0.000051659506,0.00012177892,0.000026925687,0.000024765048],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99701595,0.0007880712,0.0016080412,0.00016714637,0.00018294483,0.00023783896],"domain_scores_gemma":[0.99657935,0.000089107365,0.0018494789,0.0005427379,0.0007121814,0.00022713923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001576693,0.0002501856,0.0034951149,0.000356867,0.000059338643,0.000015526686,0.00022650826,0.00025716267,0.000009676524],"category_scores_gemma":[0.0004499472,0.00013336522,0.0010978663,0.0008325327,0.0002212548,0.000048902108,0.000008878884,0.0005633787,6.0911066e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042919582,0.000011665586,0.0010804073,0.9853245,0.0043690903,0.0003574167,0.00040709798,9.801649e-7,0.0000055014343,0.000035084933,0.0050300728,0.0033352587],"study_design_scores_gemma":[0.0002733427,0.0002153794,0.00055831065,0.8538564,0.0031149022,0.0019987817,0.00004345564,1.7713259e-7,5.423123e-7,0.0000064216506,0.13980936,0.00012295306],"about_ca_topic_score_codex":0.000100194804,"about_ca_topic_score_gemma":0.0010970148,"teacher_disagreement_score":0.13477929,"about_ca_system_score_codex":0.00064075855,"about_ca_system_score_gemma":0.0037667486,"threshold_uncertainty_score":0.668205},"labels":[],"label_agreement":null},{"id":"W2795140780","doi":"10.3390/cancers10040102","title":"EBV+ and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8+ Intratumoral Lymphocytes","year":2018,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Cancer research; PD-L1; Medicine; CD8; Cytotoxic T cell; Microsatellite instability; Cancer; Immune system; Chemistry; Internal medicine; Immunotherapy; Immunology; Gene; Biochemistry","score_opus":0.010682773872450004,"score_gpt":0.24856174557058436,"score_spread":0.23787897169813435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795140780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98848295,0.008418706,0.0000534248,0.0006529304,0.0010834173,0.00038225175,0.00005141631,0.00009005263,0.0007848553],"genre_scores_gemma":[0.9920661,0.0036061192,0.0008119414,0.0017042782,0.00088215934,0.000058764952,0.000016056509,0.000042959153,0.0008116269],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998466,0.000037571637,0.00027697932,0.0005065097,0.0002585864,0.00045433152],"domain_scores_gemma":[0.99913186,0.00004548525,0.0001332077,0.00032015092,0.00010097993,0.00026834308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014192217,0.0002827756,0.00039213957,0.00014439956,0.00020480192,0.00005847823,0.00010526473,0.00013687175,0.0005100889],"category_scores_gemma":[0.000030053567,0.00023549702,0.000058309273,0.00032374557,0.0006817997,0.00016485955,0.00005511686,0.00015490098,0.000007866852],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021583997,0.000056126537,0.020876992,0.00055973924,0.00057540153,0.00016157309,0.0020941526,0.000021826689,0.73176503,0.00029931465,0.101969264,0.120036595],"study_design_scores_gemma":[0.036151428,0.005679249,0.27004978,0.0027759788,0.000636353,0.00040512905,0.0019526028,0.0011472168,0.49382675,0.0003307752,0.18517089,0.0018738221],"about_ca_topic_score_codex":0.0057377345,"about_ca_topic_score_gemma":0.00025889478,"teacher_disagreement_score":0.24917279,"about_ca_system_score_codex":0.00200034,"about_ca_system_score_gemma":0.0011045351,"threshold_uncertainty_score":0.960329},"labels":[],"label_agreement":null},{"id":"W2795354240","doi":"10.1080/2162402x.2018.1434468","title":"The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1","year":2018,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Blockade; PD-L1; Immunotherapy; Immune checkpoint; Immune system; Medicine; Cancer immunotherapy; Gut flora; Clinical efficacy; Immunology; Cancer research; Internal medicine; Receptor","score_opus":0.027641767298129286,"score_gpt":0.34032556835621924,"score_spread":0.31268380105808996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795354240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98014855,0.007857367,0.000028866922,0.008654957,0.0016210154,0.0004527653,0.000003852254,0.000055416327,0.0011771967],"genre_scores_gemma":[0.99534947,0.0011640046,0.0009581259,0.00057997106,0.00059775263,0.000015943577,0.00001209487,0.000034785182,0.0012878847],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975613,0.00028709057,0.00121298,0.00032505434,0.00014824895,0.00046535925],"domain_scores_gemma":[0.9971491,0.001160985,0.00053799484,0.00084384816,0.00026557795,0.000042467054],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.001756279,0.00023332381,0.0005111728,0.0000622436,0.0003994613,0.000022803393,0.00055317435,0.00021183283,0.00020728503],"category_scores_gemma":[0.0010720071,0.00012565246,0.00044662692,0.00029419156,0.003265919,0.00003263296,0.00021596243,0.00052453566,0.00007425406],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01014925,0.00032525178,0.008612275,0.000028192506,0.0007387766,0.00001748042,0.000754596,1.17755015e-7,0.8585491,0.00005988955,0.0045117578,0.116253294],"study_design_scores_gemma":[0.008114551,0.00427436,0.4641101,0.00038050528,0.00029924224,0.00085482013,0.0015306146,0.00007229559,0.1478135,0.00007389468,0.37214005,0.00033607378],"about_ca_topic_score_codex":0.00033175474,"about_ca_topic_score_gemma":0.00006326971,"teacher_disagreement_score":0.7107356,"about_ca_system_score_codex":0.000079908285,"about_ca_system_score_gemma":0.0002881588,"threshold_uncertainty_score":0.99944663},"labels":[],"label_agreement":null},{"id":"W2795389053","doi":"10.1200/jco.2018.36.4_suppl.614","title":"Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; FOLFOX; Internal medicine; Oncology; Stage (stratigraphy); Colorectal cancer; Oxaliplatin; Confidence interval; Hazard ratio; Proportional hazards model; Adjuvant; Gastroenterology; Cancer","score_opus":0.048153343294930304,"score_gpt":0.3961819419516077,"score_spread":0.3480285986566774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795389053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968036,0.00011989371,0.000029094437,0.0004758384,0.00049822073,0.0019869457,0.00002918941,0.000006270795,0.000050950537],"genre_scores_gemma":[0.9983748,0.0003080242,0.00040005316,0.0005824174,0.0002191225,0.000034187677,0.00001850408,0.00001386412,0.00004897832],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9955787,0.0003653866,0.0032105793,0.00019172914,0.00036203294,0.000291588],"domain_scores_gemma":[0.9957203,0.0008998945,0.0024607994,0.00018557871,0.00052168756,0.00021172852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002109156,0.00019578495,0.0016018206,0.00029111948,0.0000352938,0.000012575924,0.00014275225,0.0003222723,0.00007027917],"category_scores_gemma":[0.0020944905,0.0001226675,0.00014278248,0.0004312851,0.00030852458,0.00031244603,0.000039132014,0.0005760642,0.0000026228238],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6198536,0.002643051,0.28677756,0.00006468493,0.00015311198,0.00014474674,0.0008561248,0.000003042885,0.00018375053,0.0000013283184,0.00019461525,0.08912439],"study_design_scores_gemma":[0.328747,0.13581987,0.5315194,0.0005602523,0.00017304475,0.0000263074,0.00019856074,0.00012303358,0.00041284994,0.000004255157,0.0023054369,0.00010996757],"about_ca_topic_score_codex":0.0010787831,"about_ca_topic_score_gemma":0.0027938725,"teacher_disagreement_score":0.29110658,"about_ca_system_score_codex":0.00030264255,"about_ca_system_score_gemma":0.0017022827,"threshold_uncertainty_score":0.5002236},"labels":[],"label_agreement":null},{"id":"W2795424799","doi":"10.1200/jco.2017.35.15_suppl.3579","title":"Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; CD8; Stage (stratigraphy); Oncology; CD20; CD3; Immune system; Gastroenterology; Immunology; Immunohistochemistry","score_opus":0.05267206944974719,"score_gpt":0.3802259054741129,"score_spread":0.3275538360243657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795424799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962947,0.00064654293,0.000009669697,0.001084026,0.0004719025,0.00034889192,0.000027742495,0.00000404831,0.0011124895],"genre_scores_gemma":[0.9968072,0.0015997807,0.00041178736,0.000106655185,0.00011883488,0.0000031444338,0.000008789366,0.000021161986,0.0009226131],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99656624,0.00032070844,0.002143756,0.00019060305,0.00054397795,0.00023471097],"domain_scores_gemma":[0.99033934,0.0008754882,0.0073028766,0.00036614004,0.0009671725,0.00014900685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028464631,0.0001854563,0.0019386995,0.0000805437,0.000094332434,0.000012744919,0.00023205002,0.00035482374,0.000059783804],"category_scores_gemma":[0.0009606275,0.00011659105,0.00030906068,0.00009089514,0.0005414913,0.00017746117,0.000049852468,0.0005447338,5.0013546e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11317733,0.0020948348,0.8521904,0.0000801746,0.0015635752,0.00008757405,0.00012179106,9.603107e-7,0.0016498201,0.0000047182193,0.0002674828,0.028761355],"study_design_scores_gemma":[0.06719643,0.038280085,0.8892894,0.000391371,0.0006739499,0.00002271714,0.00021354151,0.000017426097,0.0010010193,0.000004395953,0.0028011003,0.00010860552],"about_ca_topic_score_codex":0.00063911895,"about_ca_topic_score_gemma":0.0005181426,"teacher_disagreement_score":0.045980904,"about_ca_system_score_codex":0.00026821232,"about_ca_system_score_gemma":0.00090331025,"threshold_uncertainty_score":0.47544453},"labels":[],"label_agreement":null},{"id":"W2795615530","doi":"10.1016/j.ejca.2018.02.027","title":"Rational design and identification of immuno-oncology drug combinations","year":2018,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Canada Research Chairs; University of Toronto; University Health Network; Institute of Cancer Research; Ontario Institute for Cancer Research","funders":"World Meteorological Organization","keywords":"Medicine; Clinical trial; Oncology; Drug; Cancer; Internal medicine; Prostate cancer; Gene expression profiling; Computational biology; Bioinformatics; Gene; Gene expression; Pharmacology; Biology; Genetics","score_opus":0.06265323624891216,"score_gpt":0.38105393028601253,"score_spread":0.31840069403710036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795615530","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000058739373,0.9967325,0.0011805338,0.00032353427,0.00073149503,0.0003021589,0.000016123457,0.0000039765596,0.0006509515],"genre_scores_gemma":[0.00028962194,0.9972877,0.00060853397,0.000063632186,0.00043401786,0.0000055125697,0.000011526017,0.000033128345,0.0012663599],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997686,0.00068243203,0.0011803127,0.00011747009,0.00024577352,0.00008799823],"domain_scores_gemma":[0.99726534,0.00014624203,0.0018533473,0.00015222035,0.00052614394,0.000056693887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020490286,0.00014784574,0.00076451787,0.00023928724,0.000051958043,0.000018657776,0.0001505096,0.000043695658,0.00017659931],"category_scores_gemma":[0.000073447685,0.00010857071,0.00027804298,0.00017927923,0.00020053782,0.00007447839,0.000021321324,0.00020853133,0.0000071955037],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002783489,0.00009402318,0.0000037409325,0.0013828108,0.00072231615,0.000023109093,0.00024613543,8.707035e-7,0.00027828699,0.00002496525,0.015606672,0.98133874],"study_design_scores_gemma":[0.0013942491,0.00041326386,0.0002373144,0.005761423,0.0010649239,0.00034259164,0.00002339443,0.0000032600176,0.00008492416,0.000011752331,0.99057305,0.000089879395],"about_ca_topic_score_codex":0.0000030261504,"about_ca_topic_score_gemma":0.0000010622155,"teacher_disagreement_score":0.98124886,"about_ca_system_score_codex":0.00019779742,"about_ca_system_score_gemma":0.0009139033,"threshold_uncertainty_score":0.4427385},"labels":[],"label_agreement":null},{"id":"W2796207838","doi":"10.1016/j.immuni.2018.03.023","title":"The Immune Landscape of Cancer","year":2018,"lang":"en","type":"article","venue":"Immunity","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6191,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Calgary; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"U.S. National Library of Medicine; National Institute of Environmental Health Sciences; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; National Institute of General Medical Sciences; Cancer Research Institute; National Human Genome Research Institute; U.S. Department of Defense","keywords":"Biology; Immune system; Neuroblastoma RAS viral oncogene homolog; Epigenetics; FOXP3; Cancer research; Immunology; Melanoma; Cancer; Epigenome; KRAS; Gene; Genetics; Gene expression; DNA methylation; Colorectal cancer","score_opus":0.01786348163548429,"score_gpt":0.3127203879480663,"score_spread":0.294856906312582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796207838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9721615,0.014393998,0.0000066625453,0.0011639562,0.00038024483,0.00012746658,0.000006080825,0.000021052056,0.0117390435],"genre_scores_gemma":[0.9966238,0.0012076476,0.000028678276,0.00016280304,0.0001296235,0.000010018878,0.000003179818,0.000007719125,0.0018265059],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99949926,0.0000365113,0.00017247637,0.00005593798,0.00010973954,0.00012607564],"domain_scores_gemma":[0.9993213,0.0000623096,0.00007218749,0.00039497289,0.00012774537,0.000021494516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029001743,0.00006006459,0.000121841564,0.000022793949,0.00018474285,0.0000076597735,0.00012608789,0.000036921112,0.0005869433],"category_scores_gemma":[0.000034625475,0.000035146168,0.00007982621,0.00016501051,0.00032104904,0.000022290022,0.000033046443,0.000106289495,0.000015200848],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077524413,0.00023413547,0.06825827,0.00007197761,0.0007885748,0.0000028842321,0.0016593246,2.168169e-7,0.54143083,0.00034443493,0.007193375,0.37226355],"study_design_scores_gemma":[0.0017028986,0.00041325935,0.63929045,0.00009897229,0.000054255914,0.000010274575,0.00043652672,0.00002513861,0.22823389,0.0000673975,0.1295911,0.000075824515],"about_ca_topic_score_codex":0.0024762957,"about_ca_topic_score_gemma":0.00039726557,"teacher_disagreement_score":0.57103217,"about_ca_system_score_codex":0.000022750972,"about_ca_system_score_gemma":0.000091716545,"threshold_uncertainty_score":0.64266175},"labels":[],"label_agreement":null},{"id":"W2796273564","doi":"10.1016/j.immuni.2018.03.018","title":"Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8+ T Cells","year":2018,"lang":"en","type":"article","venue":"Immunity","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Beijing Municipal Science and Technology Commission; Tsinghua University; National Natural Science Foundation of China","keywords":"Biology; Cytotoxic T cell; Myeloid cells; Inhibitory postsynaptic potential; CD8; Cancer research; Tumor cells; Myeloid; Cell biology; Immunology; Immune system; Genetics; Endocrinology; In vitro","score_opus":0.018677178484085618,"score_gpt":0.2652425557284374,"score_spread":0.2465653772443518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796273564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99133104,0.00058603706,0.00006596443,0.00006388259,0.00078408775,0.0004119084,0.000084553365,0.00009054943,0.006581977],"genre_scores_gemma":[0.99808156,0.00007228627,0.00020954848,0.00072366867,0.00026828767,0.000018181501,0.00006182273,0.000046637062,0.0005180274],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99813324,0.00021598287,0.0005683703,0.0003072188,0.00040268758,0.00037249713],"domain_scores_gemma":[0.9985843,0.00012522317,0.0002799915,0.0006539509,0.00024776568,0.00010881091],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055880664,0.0002824376,0.00046105144,0.00012181613,0.0002555181,0.000034745397,0.00021410156,0.00012677573,0.00073172635],"category_scores_gemma":[0.000048344806,0.0002581029,0.00017055217,0.0003079437,0.00047112527,0.00019735876,0.000044256198,0.00039536407,0.0000663363],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008076997,0.00030279125,0.0010219794,0.000118901204,0.00011671929,0.000008846877,0.00064691255,9.543738e-7,0.9810204,0.0000012305098,0.015258009,0.00069559243],"study_design_scores_gemma":[0.002308527,0.00073918264,0.0065610297,0.0002178109,0.00006929522,0.000018564937,0.0012270566,0.00003299075,0.98253363,0.0000043132213,0.006028587,0.00025901152],"about_ca_topic_score_codex":0.0021649878,"about_ca_topic_score_gemma":0.000017639839,"teacher_disagreement_score":0.009229422,"about_ca_system_score_codex":0.00010242023,"about_ca_system_score_gemma":0.00018465173,"threshold_uncertainty_score":0.9999871},"labels":[],"label_agreement":null},{"id":"W2796510657","doi":"10.1016/s1556-0864(18)30404-0","title":"130O Real-world prevalence of PD-L1 expression in locally advanced or metastatic non-small cell lung cancer (NSCLC): The global, multicentre EXPRESS study","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Oncology; Immunohistochemistry; Stage (stratigraphy); Real world data","score_opus":0.02686796737099981,"score_gpt":0.428025967513239,"score_spread":0.4011580001422392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796510657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921598,0.003548102,0.000418364,0.0007576478,0.00089696504,0.0013306737,0.000016824692,0.000008355952,0.00086325424],"genre_scores_gemma":[0.99038583,0.002356007,0.0053543733,0.00038802094,0.00026505822,0.00004211193,6.233309e-7,0.000021464526,0.0011864817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972627,0.0005450526,0.0011489211,0.0002576072,0.00043419583,0.0003515029],"domain_scores_gemma":[0.9973411,0.00037222783,0.0012799948,0.00039733716,0.00047658038,0.00013273429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013029817,0.000228178,0.00077471265,0.00018270462,0.000077286684,0.000012761779,0.0004527758,0.00009232269,0.00046176554],"category_scores_gemma":[0.000119003285,0.00012858244,0.0001766534,0.0005480854,0.00024233929,0.0001539389,0.00010095325,0.00039531017,0.0000023079508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24764977,0.007967064,0.28133112,0.002849116,0.0010025217,0.001266916,0.015305712,0.00039263777,0.20185082,0.0000015816447,0.004715793,0.23566693],"study_design_scores_gemma":[0.037868533,0.02766993,0.745055,0.011480429,0.003857725,0.0005136716,0.022757381,0.0018469923,0.13435449,0.000044062086,0.013792342,0.0007594212],"about_ca_topic_score_codex":0.00033754358,"about_ca_topic_score_gemma":0.003120224,"teacher_disagreement_score":0.4637239,"about_ca_system_score_codex":0.00072385836,"about_ca_system_score_gemma":0.001159138,"threshold_uncertainty_score":0.52434397},"labels":[],"label_agreement":null},{"id":"W2796582438","doi":"10.1056/nejmoa1801005","title":"Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6613,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Merck","keywords":"Pembrolizumab; Chemotherapy; Lung cancer; Medicine; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.019753106306839144,"score_gpt":0.31209189995984565,"score_spread":0.2923387936530065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796582438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96744037,0.0128305545,0.00095427054,0.014504154,0.0011250492,0.00030948946,0.0000016873249,0.00001000398,0.0028244131],"genre_scores_gemma":[0.9826633,0.004636517,0.0007557616,0.0038052788,0.0059487764,0.0000037032942,0.000002310034,0.00003242356,0.002151951],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983981,0.00006111371,0.0006819741,0.00015202485,0.00042663648,0.0002801472],"domain_scores_gemma":[0.99889904,0.00010238795,0.00035323363,0.00018687667,0.00021220079,0.00024625924],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008693945,0.00019444492,0.0006771708,0.00033363188,0.000036352427,0.0000084333005,0.00015335548,0.000061011007,0.0017469826],"category_scores_gemma":[0.00006349445,0.00012253797,0.00010815308,0.00036894463,0.00016411916,0.000070840135,0.00001055107,0.000355265,0.0000033463077],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06940269,0.00044720023,0.044273663,0.0006000112,0.0013019991,0.0012621572,0.021035604,0.000038029066,0.14603539,0.000021302278,0.09029123,0.62529075],"study_design_scores_gemma":[0.69949603,0.009623757,0.06971998,0.004369799,0.0011022327,0.003315863,0.0010661022,0.0015763515,0.01782194,0.00019573148,0.19126263,0.00044959597],"about_ca_topic_score_codex":0.001045888,"about_ca_topic_score_gemma":0.0004100194,"teacher_disagreement_score":0.63009334,"about_ca_system_score_codex":0.00025848424,"about_ca_system_score_gemma":0.00080821314,"threshold_uncertainty_score":0.99916553},"labels":[],"label_agreement":null},{"id":"W2796727977","doi":"10.1200/jco.2017.35.7_suppl.86","title":"Perspectives from the community setting: A retrospective chart review of nivolumab for previously treated non-small cell lung cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Windsor Regional Hospital; University of Windsor; Western University","funders":"","keywords":"Nivolumab; Medicine; Discontinuation; Lung cancer; Retrospective cohort study; Cancer; Internal medicine; Stage (stratigraphy); Oncology; Surgery; Immunotherapy","score_opus":0.10272184075221755,"score_gpt":0.469878250525866,"score_spread":0.3671564097736485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796727977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9007905,0.06545951,0.000055653323,0.029202739,0.00080609974,0.0011393058,0.00006358863,0.000006459377,0.0024761003],"genre_scores_gemma":[0.87479323,0.11892262,0.0011062595,0.0033575592,0.0013517342,0.000029249715,0.000005220144,0.000021990965,0.00041211845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969518,0.0006920272,0.0017826925,0.0001570346,0.00021740583,0.00019903283],"domain_scores_gemma":[0.99091697,0.0026626894,0.004602374,0.00064701197,0.0010383489,0.00013262128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060728327,0.0001515859,0.0017135969,0.000029630919,0.00029758178,0.000014615796,0.0005756927,0.00024207169,0.00016332847],"category_scores_gemma":[0.005053353,0.000089126166,0.0010114335,0.00005963468,0.0004985625,0.00008102439,0.00007491691,0.0011879663,8.1083334e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03879324,0.0044530737,0.6887076,0.0030695866,0.0048242114,0.00007606432,0.0070514,5.10573e-7,0.0035860646,0.00002599356,0.11929985,0.13011242],"study_design_scores_gemma":[0.017200686,0.012058134,0.9277676,0.009189447,0.0021085464,0.000040230232,0.0015332318,0.000048178248,0.0006135984,0.00010593525,0.029197706,0.00013673183],"about_ca_topic_score_codex":0.0016108437,"about_ca_topic_score_gemma":0.0005636159,"teacher_disagreement_score":0.23905998,"about_ca_system_score_codex":0.0003690658,"about_ca_system_score_gemma":0.0016385402,"threshold_uncertainty_score":0.60497004},"labels":[],"label_agreement":null},{"id":"W2797309423","doi":"10.1056/nejmoa1802357","title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1853,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Genentech; EUSA Pharma; Merck Sharp and Dohme; Eisai; Universiteit van Amsterdam; Incyte; LEO Pharma; Massachusetts Medical Society; Sun Pharma; Regeneron Pharmaceuticals; Syndax Pharmaceuticals; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Adjuvant; Placebo; Stage (stratigraphy); Medicine; Melanoma; Oncology; Internal medicine; Cancer research; Cancer; Biology; Immunotherapy; Pathology","score_opus":0.03049556086374712,"score_gpt":0.3167479901321354,"score_spread":0.2862524292683883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797309423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776355,0.0034636694,0.000104836814,0.0070579965,0.0019207962,0.00020884383,0.0000020583625,0.000015121983,0.009591165],"genre_scores_gemma":[0.9900509,0.000766306,0.00018275109,0.0005308668,0.0060340883,0.0000011172314,0.000005242668,0.000020133119,0.0024085988],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982115,0.000102162114,0.0006951235,0.00014725629,0.0005665971,0.0002773669],"domain_scores_gemma":[0.99872655,0.00023570177,0.00031239042,0.00021985087,0.00023127605,0.00027421143],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010955306,0.00016821978,0.00058647036,0.00039829317,0.00004267339,0.000007210888,0.00014968075,0.000095153664,0.0018833315],"category_scores_gemma":[0.00040166933,0.00010686758,0.000084463434,0.00037896552,0.00023217469,0.000086040425,0.000018231627,0.00042677362,0.000008039587],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.558945,0.00018996795,0.008292303,0.00007795201,0.0005687808,0.0019419874,0.005846172,0.000003567331,0.06385048,0.00009194964,0.04088935,0.31930247],"study_design_scores_gemma":[0.6657964,0.019127239,0.045565892,0.0012629387,0.0002053931,0.0017044899,0.00092286937,0.000077572986,0.0044835433,0.00006545214,0.260605,0.00018318051],"about_ca_topic_score_codex":0.00065655884,"about_ca_topic_score_gemma":0.000802197,"teacher_disagreement_score":0.3191193,"about_ca_system_score_codex":0.00018167276,"about_ca_system_score_gemma":0.00042982807,"threshold_uncertainty_score":0.9990291},"labels":[],"label_agreement":null},{"id":"W2797437320","doi":"10.1016/j.cjca.2018.04.010","title":"Immune Checkpoint Inhibitors: Game Changing Cancer Therapy With a Cardiac Cost. What Are the Mechanisms and Unresolved Questions in Cardiotoxicity?","year":2018,"lang":"en","type":"letter","venue":"Canadian Journal of Cardiology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Immune system; Cancer; Immune checkpoint; Immunotherapy; Cancer immunotherapy; Cardiotoxicity; Clinical trial; Antigen; Scopus; Immunology; Cancer research; Internal medicine; Chemotherapy; MEDLINE; Biology","score_opus":0.017624703683608425,"score_gpt":0.25030046947288903,"score_spread":0.23267576578928062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797437320","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.063086085,0.20486523,0.00066875544,0.72056997,0.007446527,0.0026229988,0.00026951672,0.000025056655,0.00044584024],"genre_scores_gemma":[0.6078314,0.07435017,0.00018249996,0.27696493,0.038953047,0.00046198565,0.00011673245,0.00033248984,0.0008067125],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99735034,0.00048644454,0.0006888642,0.0003506759,0.00030910727,0.0008145599],"domain_scores_gemma":[0.9980681,0.00013487086,0.0006039075,0.00048220527,0.00042643657,0.00028446855],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012156825,0.0004408478,0.0015934071,0.0009371165,0.00017344704,0.0001292784,0.00027221153,0.0007732188,0.000030175006],"category_scores_gemma":[0.00005569568,0.0002836857,0.0005896783,0.00044436415,0.00072856335,0.00016571523,0.000022471972,0.00198262,0.0000015726409],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064807357,0.00002148665,0.030758685,0.0006754495,0.022505159,0.016143346,0.010439117,0.0004797677,0.012971066,0.00004232668,0.8210812,0.07840166],"study_design_scores_gemma":[0.0026903767,0.0008163451,0.010874952,0.0032121672,0.0004197558,0.0021138836,0.0020000553,0.0000040531736,0.00084379956,0.00007110358,0.97654057,0.0004129282],"about_ca_topic_score_codex":0.006343675,"about_ca_topic_score_gemma":0.0049247434,"teacher_disagreement_score":0.5447454,"about_ca_system_score_codex":0.0009353867,"about_ca_system_score_gemma":0.002506733,"threshold_uncertainty_score":0.99996156},"labels":[],"label_agreement":null},{"id":"W2797461445","doi":"10.1101/303834","title":"TGF-β induced CXCL13 in CD8+ T cells is associated with tertiary lymphoid structures in cancer","year":2018,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"Universitair Medisch Centrum Groningen; Ministry of Earth Sciences; National Institute for Health and Care Research; Jan Kornelis de Cock Stichting; Wellcome Trust","keywords":"CXCL13; CD8; CXCR5; Immune system; Cancer research; Biology; Chemokine; Antigen; Immunology; Cell biology; Chemokine receptor","score_opus":0.0166229474333329,"score_gpt":0.24839261995956888,"score_spread":0.23176967252623598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797461445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946607,0.0021061362,0.0000075542066,0.00045902302,0.0010747042,0.0012546593,0.00025033642,0.00016979652,0.000017116527],"genre_scores_gemma":[0.99616927,0.00072861,0.00031630154,0.0019337385,0.00037381673,0.00029259984,0.0000012510621,0.00016951599,0.000014880763],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9965632,0.00016238513,0.00077157206,0.001161519,0.00056730444,0.00077402603],"domain_scores_gemma":[0.9977883,0.00005914087,0.0005109358,0.0010941228,0.00033112764,0.00021638568],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005795767,0.0007261097,0.001008064,0.0006586146,0.00007243517,0.00009723473,0.0004229011,0.000986356,0.00036329962],"category_scores_gemma":[0.00007197313,0.000652089,0.00016143295,0.0009739942,0.0001979449,0.000119104385,0.00020968974,0.0009905997,0.00001344059],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009437335,0.0002635606,0.22453615,0.00029854546,0.00047958826,0.00022497821,0.000084819716,0.000009113867,0.772227,0.0000033246715,0.0009174967,0.000011688324],"study_design_scores_gemma":[0.0034382674,0.00013412189,0.57488084,0.0021316602,0.00010759743,5.3349915e-8,0.0000048373454,0.00007530227,0.41789404,0.000001180951,0.0007405345,0.0005915676],"about_ca_topic_score_codex":0.0028130508,"about_ca_topic_score_gemma":0.00041442958,"teacher_disagreement_score":0.35433295,"about_ca_system_score_codex":0.0019085818,"about_ca_system_score_gemma":0.002138116,"threshold_uncertainty_score":0.999593},"labels":[],"label_agreement":null},{"id":"W2797759769","doi":"10.21037/jtd.2018.03.153","title":"Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer","year":2018,"lang":"en","type":"letter","venue":"Journal of Thoracic Disease","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Lung cancer; Internal medicine; Renal cell carcinoma; Personalized medicine; Nivolumab; Melanoma; Cancer; Immunotherapy; Cancer research; Bioinformatics","score_opus":0.02252735479224907,"score_gpt":0.35321522282883366,"score_spread":0.33068786803658456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797759769","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3731143,0.057372436,0.00020424176,0.5629302,0.0030144204,0.0021762713,0.00012834503,0.000023918072,0.0010358347],"genre_scores_gemma":[0.29459804,0.009585134,0.0007874881,0.6642297,0.021100383,0.00036601772,0.00023361585,0.0003615755,0.008738044],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963795,0.00021957234,0.0014834321,0.0004241553,0.00087485067,0.0006185094],"domain_scores_gemma":[0.9972297,0.00028002125,0.0013545791,0.00041232046,0.00040644285,0.0003169317],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012352566,0.0005243572,0.001507079,0.0012773888,0.00004456269,0.0000298282,0.00047306973,0.00067747413,0.0010277854],"category_scores_gemma":[0.0002899647,0.0003907984,0.00050060824,0.0006847463,0.00041977028,0.00013291821,0.000066786626,0.0024161257,0.0000048835277],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036455676,0.0013737931,0.13995385,0.007562931,0.0008995202,0.01786008,0.0022317031,0.00001054953,0.0033654694,2.4917153e-7,0.7827383,0.007547872],"study_design_scores_gemma":[0.036265444,0.0027455618,0.29765567,0.060938466,0.0049092844,0.0008412276,0.0008729131,0.00089967146,0.000136413,0.000055379965,0.5932597,0.0014202734],"about_ca_topic_score_codex":0.000458977,"about_ca_topic_score_gemma":0.00010996938,"teacher_disagreement_score":0.1894786,"about_ca_system_score_codex":0.0015910212,"about_ca_system_score_gemma":0.0032024612,"threshold_uncertainty_score":0.99988544},"labels":[],"label_agreement":null},{"id":"W2799536814","doi":"10.1016/j.intimp.2018.04.021","title":"The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: A systematic review and meta-analysis","year":2018,"lang":"en","type":"review","venue":"International Immunopharmacology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre; Université de Montréal","funders":"","keywords":"Nivolumab; Medicine; Pembrolizumab; Internal medicine; Ipilimumab; Incidence (geometry); Relative risk; Meta-analysis; Oncology; Gastroenterology; Cancer; Confidence interval; Immunotherapy","score_opus":0.03336400043589581,"score_gpt":0.3759060836385016,"score_spread":0.34254208320260576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799536814","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015336464,0.9920618,0.000011397413,0.0006849819,0.0003563511,0.0061382484,0.0004970317,0.000035350866,0.000061453095],"genre_scores_gemma":[0.0014480059,0.99427253,0.000020139623,0.0003100878,0.000042400665,0.0022036058,0.0004293958,0.000071060276,0.0012027542],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99541163,0.00082083244,0.0025437183,0.0004926616,0.00039119614,0.00033997867],"domain_scores_gemma":[0.99355054,0.0016294902,0.0036714757,0.00048859115,0.00060530717,0.000054600936],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019319312,0.00059586175,0.006543951,0.00041915727,0.00019141039,0.000038917562,0.00056414877,0.00019381059,0.00040680877],"category_scores_gemma":[0.0004602622,0.00029850483,0.003933427,0.0008139791,0.0005521523,0.00007049192,0.0000864247,0.00042132972,0.0000051155343],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004859387,0.00025989098,0.000011327916,0.07949224,0.9162477,0.0000072793537,0.00004432537,7.946304e-7,0.000033760924,0.000014874217,0.00062175293,0.002780101],"study_design_scores_gemma":[0.0027417587,0.00072564423,0.000047727768,0.01878995,0.91426975,0.00009614549,0.000017702378,0.000025248026,0.000042217845,0.000018973042,0.062875345,0.00034952053],"about_ca_topic_score_codex":0.00009988462,"about_ca_topic_score_gemma":0.000020723926,"teacher_disagreement_score":0.062253594,"about_ca_system_score_codex":0.0001953924,"about_ca_system_score_gemma":0.00027831382,"threshold_uncertainty_score":0.9999467},"labels":[],"label_agreement":null},{"id":"W2799632934","doi":"10.1097/pas.0000000000001084","title":"PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma","year":2018,"lang":"en","type":"article","venue":"The American Journal of Surgical Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Concordance; Staining; Immunohistochemistry; Medicine; Carcinoma; Antibody; Pathology; Bladder cancer; Tissue microarray; Intraclass correlation; Cancer; Oncology; Internal medicine; Immunology","score_opus":0.009376332697949283,"score_gpt":0.2598185263424308,"score_spread":0.2504421936444815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799632934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935786,0.0028246483,0.000010387737,0.0017344275,0.0002495232,0.00013564242,0.0000092219325,0.0000032865512,0.0014542665],"genre_scores_gemma":[0.99862134,0.00015420192,0.00008177581,0.0006065297,0.00032563327,0.0000030203755,5.045757e-7,0.000016647995,0.00019032277],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983657,0.0003770078,0.00059015834,0.00016480908,0.00024259755,0.00025969945],"domain_scores_gemma":[0.9984072,0.0003335435,0.00069021975,0.00033832478,0.0001524991,0.00007824732],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0008222818,0.00016037507,0.0006014365,0.00006726321,0.00007065141,0.000005673929,0.00030035287,0.00006212871,0.00009270597],"category_scores_gemma":[0.00005655408,0.00008774284,0.00020836019,0.0002860993,0.003064109,0.00003129496,0.00007608625,0.0004645141,0.0000018044366],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024470698,0.00033888296,0.17041786,0.000048106223,0.00006683099,0.0013860337,0.0019178675,0.0000018168736,0.78375083,0.000019816222,0.00065070076,0.016930541],"study_design_scores_gemma":[0.009707919,0.005143181,0.892412,0.00006303801,0.00016381156,0.014507269,0.0011906446,0.00002963081,0.073772445,0.000096733645,0.0026996862,0.00021363991],"about_ca_topic_score_codex":0.00018288809,"about_ca_topic_score_gemma":0.000004970653,"teacher_disagreement_score":0.72199416,"about_ca_system_score_codex":0.00007929834,"about_ca_system_score_gemma":0.0002355125,"threshold_uncertainty_score":0.999649},"labels":[],"label_agreement":null},{"id":"W2799996199","doi":"10.1136/jclinpath-2018-205143","title":"Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective","year":2018,"lang":"en","type":"review","venue":"Journal of Clinical Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Pembrolizumab; Immune system; Immunology; Hepatitis; Colitis; Avelumab; Immunotherapy","score_opus":0.12212967280919691,"score_gpt":0.4593344633350179,"score_spread":0.337204790525821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799996199","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025822813,0.97097933,0.000048552287,0.00048823692,0.0016886762,0.00053550774,0.000018319783,0.000021183803,0.00039740495],"genre_scores_gemma":[0.002221847,0.99183017,0.0025083572,0.00028351904,0.0029523992,0.00001023586,0.0000068187596,0.000064641994,0.00012201922],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929793,0.0011963636,0.004524762,0.00053824676,0.00035341844,0.0004079494],"domain_scores_gemma":[0.99321365,0.000993996,0.0042202054,0.0005065514,0.0007498209,0.0003157916],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005511842,0.0005204519,0.005055094,0.00035834263,0.00007129954,0.000027472313,0.0002873789,0.00073637534,0.000118980424],"category_scores_gemma":[0.005617779,0.00034110842,0.0022774376,0.0002646726,0.0010600167,0.00007575808,0.00015791411,0.0024431099,0.000034986864],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045223623,0.0007787204,0.00085762166,0.0036155186,0.00075099734,0.0054081054,0.00014215836,4.5242112e-9,0.00033611996,0.000036470825,0.0007383219,0.9828136],"study_design_scores_gemma":[0.009735961,0.0619914,0.018296042,0.07119173,0.0070443866,0.20247394,0.0005158922,0.0000029260418,0.00005303157,0.00070435775,0.6268861,0.0011042261],"about_ca_topic_score_codex":0.000012105173,"about_ca_topic_score_gemma":0.0000028821105,"teacher_disagreement_score":0.98170936,"about_ca_system_score_codex":0.00025854484,"about_ca_system_score_gemma":0.0013888627,"threshold_uncertainty_score":0.9999041},"labels":[],"label_agreement":null},{"id":"W2800200585","doi":"10.1186/s40425-018-0332-z","title":"Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Pembrolizumab; Medicine; Mucositis; Internal medicine; Esophagitis; Gastroenterology; Durvalumab; Oncology; Cancer; Radiation therapy; Surgery; Immunotherapy; Disease","score_opus":0.01402107771542368,"score_gpt":0.2911977492456359,"score_spread":0.27717667153021225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800200585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96577,0.03219998,0.000039224597,0.00083604857,0.00033867435,0.0005850488,0.00007302254,0.0000061412206,0.00015184825],"genre_scores_gemma":[0.996992,0.0016835316,0.000190407,0.00038260015,0.000084774256,0.000034728342,0.0000031504192,0.00004172603,0.00058707315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985416,0.00008218217,0.00060999894,0.00015303824,0.0003406233,0.0002725572],"domain_scores_gemma":[0.99861246,0.00013177816,0.0006018759,0.00024046379,0.00036938896,0.000044038778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043236004,0.00018832345,0.000566518,0.00015050852,0.00015263165,0.000019073103,0.00016727803,0.00007433666,0.00024634594],"category_scores_gemma":[0.000045325985,0.000117602154,0.00023385926,0.00035847406,0.00045021172,0.00011525628,0.000016390733,0.00021827375,1.378493e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07934641,0.001099238,0.4054796,0.0005376522,0.0049883425,0.000060492544,0.008797875,0.00003630474,0.29107386,0.00012485542,0.0015879917,0.20686737],"study_design_scores_gemma":[0.028763404,0.0035491807,0.9086361,0.0011450041,0.0002451251,0.0005816171,0.00031103293,0.00009768238,0.054189507,0.00019741165,0.0020722044,0.0002117383],"about_ca_topic_score_codex":0.0009119465,"about_ca_topic_score_gemma":0.00063749007,"teacher_disagreement_score":0.5031565,"about_ca_system_score_codex":0.00022068938,"about_ca_system_score_gemma":0.00042137792,"threshold_uncertainty_score":0.47956765},"labels":[],"label_agreement":null},{"id":"W2800568511","doi":"10.1186/s40425-018-0328-8","title":"Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Institutes of Health; National Cancer Institute; Melanoma Research Alliance","keywords":"Medicine; Immunotherapy; Melanoma; CTLA-4; Biomarker; Blockade; Oncology; Ipilimumab; Immune checkpoint; Predictive value; Immunology; Immune system; Internal medicine; T cell; Cancer research; Biology; Receptor","score_opus":0.015536892900585509,"score_gpt":0.32959102357534525,"score_spread":0.31405413067475973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800568511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98552555,0.007605517,0.0010747567,0.0018535594,0.0012192464,0.0021768329,0.0004535389,0.000023100463,0.00006792802],"genre_scores_gemma":[0.99346787,0.0030058275,0.0011431815,0.0010696277,0.00033167572,0.0002792783,0.000022543567,0.000104394705,0.0005755914],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975981,0.00011329704,0.00095010886,0.00040308444,0.00036981434,0.00056559325],"domain_scores_gemma":[0.99800223,0.0003248504,0.0004930537,0.00033556935,0.00069148163,0.00015281908],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001220328,0.0003673335,0.0008114344,0.00054929807,0.0002840548,0.000068723835,0.00023603602,0.00018188314,0.00022434875],"category_scores_gemma":[0.00013596739,0.0002929401,0.0003331938,0.00043731034,0.00032907038,0.00021311606,0.00002459281,0.00017821213,0.0000013906894],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21843538,0.00039648643,0.17336248,0.00009518983,0.0011433203,0.0000033167944,0.0019823643,0.0000017629922,0.48890355,0.0000044538674,0.0032881682,0.112383515],"study_design_scores_gemma":[0.026272012,0.0065555596,0.7948139,0.00068879017,0.000079466874,0.000036272697,0.0001457312,0.000121138495,0.052839924,0.000105852116,0.1179833,0.00035810936],"about_ca_topic_score_codex":0.00032094892,"about_ca_topic_score_gemma":0.00011966487,"teacher_disagreement_score":0.6214514,"about_ca_system_score_codex":0.00039939734,"about_ca_system_score_gemma":0.00041422257,"threshold_uncertainty_score":0.99995226},"labels":[],"label_agreement":null},{"id":"W2800654890","doi":"10.1016/j.cell.2018.03.073","title":"Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer","year":2018,"lang":"en","type":"article","venue":"Cell","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":385,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; Genome British Columbia; Canada's Michael Smith Genome Sciences Centre; Vancouver General Hospital; BC Children's Hospital; University of British Columbia","funders":"BC Cancer Foundation; Terry Fox Research Institute; Canada Research Chairs; Michael Smith Health Research BC; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Biology; Immune system; Ovarian cancer; Cancer immunology; CD8; Tumor microenvironment; Cancer; Cancer research; Immunology; Immunotherapy; Genetics","score_opus":0.013686842752185586,"score_gpt":0.26805049457920793,"score_spread":0.25436365182702236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800654890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921884,0.0031345095,0.00001679047,0.0004230176,0.00015504932,0.00009207766,0.000008830781,0.0000054430407,0.0039759115],"genre_scores_gemma":[0.9978602,0.0009023563,0.00014335493,0.00013822128,0.000031567502,0.0000043528603,0.000002662481,0.0000050303397,0.000912275],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996254,0.00001125312,0.0001262655,0.00009731296,0.000046322144,0.000093441624],"domain_scores_gemma":[0.9998151,0.000011551121,0.000042310705,0.00009009206,0.000025801988,0.00001516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008291226,0.000054312368,0.00011980704,0.000047429294,0.000012528865,0.0000032291236,0.000038576512,0.000047921127,0.00028036252],"category_scores_gemma":[0.000003363757,0.00004091836,0.000018730603,0.000083299856,0.00016783085,0.000017445613,0.000021251066,0.000052721494,0.0000028424922],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025218895,0.00014439104,0.07968886,0.00014052702,0.00006676127,0.000013199606,0.0008315565,3.6681448e-7,0.88928676,0.000095574454,0.0003371326,0.026872993],"study_design_scores_gemma":[0.004141227,0.0011020711,0.36980253,0.0003750237,0.000039544782,0.000026241629,0.0010889523,0.00076262135,0.61784345,0.00012339307,0.0045347842,0.00016012944],"about_ca_topic_score_codex":0.00088329276,"about_ca_topic_score_gemma":0.0005161295,"teacher_disagreement_score":0.29011366,"about_ca_system_score_codex":0.000075844946,"about_ca_system_score_gemma":0.000043866035,"threshold_uncertainty_score":0.3069773},"labels":[],"label_agreement":null},{"id":"W2800700360","doi":"10.14740/wjon1092w","title":"A Case Series of Two Patients Presenting With Pericardial Effusion as First Manifestation of Non-Small Cell Lung Cancer With <i>BRAF</i> Mutation and Expression Of PD-L1","year":2018,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pericardial effusion; Cardiac tamponade; Lung cancer; Pericardium; Pleural effusion; Cancer; Internal medicine; Radiology; Surgery","score_opus":0.009023069755485768,"score_gpt":0.2872121968814588,"score_spread":0.27818912712597305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800700360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99825174,0.00025613199,0.00013794548,0.00012749672,0.0001333232,0.00027592195,0.000005778915,0.0000019895938,0.00080967654],"genre_scores_gemma":[0.9967982,0.00015108261,0.002783725,0.000040444367,0.00011284081,0.000005135784,0.00000275411,0.0000119852275,0.00009381807],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99907225,0.000065535,0.00045255705,0.000097761935,0.00020800748,0.00010388381],"domain_scores_gemma":[0.9981503,0.00008994889,0.0010858519,0.000079160345,0.00054529257,0.000049485978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020676084,0.000095103795,0.00036334858,0.00017417913,0.000055634315,0.0000037154402,0.000038784994,0.000039599327,0.00004857355],"category_scores_gemma":[0.000015114283,0.00006351206,0.000049984894,0.00018857683,0.0002198899,0.00011629348,0.000020735566,0.00010158669,6.853304e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06952659,0.0009437077,0.66044414,0.0012507224,0.0003956748,0.0013788955,0.01731469,0.00018477158,0.2312962,0.0000041746616,0.00052215275,0.016738268],"study_design_scores_gemma":[0.04944907,0.039568998,0.31564656,0.003400857,0.0014345942,0.011898947,0.0034309702,0.0004001059,0.5721717,0.000016190093,0.0022582852,0.0003236988],"about_ca_topic_score_codex":0.00039927714,"about_ca_topic_score_gemma":0.0010614838,"teacher_disagreement_score":0.34479758,"about_ca_system_score_codex":0.000074107236,"about_ca_system_score_gemma":0.00024446406,"threshold_uncertainty_score":0.25899464},"labels":[],"label_agreement":null},{"id":"W2801510798","doi":"10.1158/1078-0432.ccr-17-2386","title":"Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":309,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Merck","keywords":"Medicine; Pembrolizumab; Internal medicine; Logistic regression; Univariate analysis; Proportional hazards model; Oncology; Post-hoc analysis; Gastroenterology; Stage (stratigraphy); Multivariate analysis; Cancer; Immunotherapy","score_opus":0.12898013682164816,"score_gpt":0.4481364110601866,"score_spread":0.31915627423853843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801510798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99606884,0.000105323365,0.00001965093,0.0007629272,0.00012742428,0.0024257281,0.00027451126,0.000036344205,0.00017923646],"genre_scores_gemma":[0.9973089,0.000052720272,0.00019879857,0.0006844335,0.0005265549,0.00034895932,0.000055987173,0.00006485641,0.0007587506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964729,0.00039380603,0.0005961107,0.0007610591,0.0010626463,0.00071346975],"domain_scores_gemma":[0.99667716,0.0011460991,0.00011665542,0.00053870527,0.0011741526,0.00034721193],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016513901,0.00023110138,0.0005555735,0.00015225887,0.00012840406,0.000050915718,0.00023866922,0.00015428438,0.0015474298],"category_scores_gemma":[0.0006496999,0.00014605004,0.00010026581,0.00049277645,0.00060513115,0.00012732307,0.00005177764,0.0005851606,0.000014026254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.123967186,0.0011837363,0.8597389,0.000081488324,0.00018472243,0.000026272799,0.00015586683,2.5886138e-7,0.00009614134,0.0000032605808,0.00057700824,0.013985192],"study_design_scores_gemma":[0.03276578,0.024293136,0.9382862,0.00031328673,0.000046110752,0.0000026228192,0.000056282177,0.00013786109,0.0005639842,0.000012084991,0.0033127975,0.00020987412],"about_ca_topic_score_codex":0.0016880957,"about_ca_topic_score_gemma":0.0034523068,"teacher_disagreement_score":0.09120141,"about_ca_system_score_codex":0.0003577612,"about_ca_system_score_gemma":0.0010731944,"threshold_uncertainty_score":0.99936527},"labels":[],"label_agreement":null},{"id":"W2801625460","doi":"10.1093/annonc/mdy126","title":"Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"Fondation de l'Hôpital général juif","keywords":"Medicine; Cytology; Immunohistochemistry; Lung cancer; Pathology; Immunostaining; Biopsy; Fixative; Cancer; Staining; Internal medicine","score_opus":0.08965536908357587,"score_gpt":0.42444060635135045,"score_spread":0.3347852372677746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801625460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834247,0.005277686,0.00018840551,0.0053897817,0.000456742,0.0010164187,0.00006353212,0.00002158231,0.004161146],"genre_scores_gemma":[0.9917088,0.00015191533,0.0029923634,0.0030772937,0.0003999481,0.00041242153,0.000018935945,0.000024491083,0.0012138382],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998823,0.000026863823,0.00041842114,0.00024517046,0.00006464756,0.00042192443],"domain_scores_gemma":[0.9985139,0.0005563531,0.00025228824,0.00017823314,0.0004488603,0.00005040591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045356926,0.00012200581,0.0005063631,0.000112611706,0.0000570352,0.0000026329476,0.000116092364,0.00026750824,0.00012691603],"category_scores_gemma":[0.00032322382,0.000113383554,0.00013186941,0.00017494697,0.00024370209,0.000030409024,0.00002822591,0.00011661491,0.0000010229529],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017906291,0.000658645,0.036109693,0.00059581443,0.0002127892,0.000011303669,0.0006408589,0.000003028273,0.79674745,0.000035584973,0.10480852,0.042270035],"study_design_scores_gemma":[0.016967827,0.013649516,0.023106134,0.00045689667,0.00019444653,0.000066462475,0.00042875373,0.0011984428,0.52852196,0.00042544547,0.41460833,0.00037576718],"about_ca_topic_score_codex":0.00057653786,"about_ca_topic_score_gemma":0.00033851617,"teacher_disagreement_score":0.30979982,"about_ca_system_score_codex":0.00013694109,"about_ca_system_score_gemma":0.00044237182,"threshold_uncertainty_score":0.4623647},"labels":[],"label_agreement":null},{"id":"W2802206159","doi":"10.1016/s0140-6736(18)30789-x","title":"International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2058,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Institut National de la Santé et de la Recherche Médicale; National Institutes of Health; Agence Nationale de la Recherche","keywords":"Medicine; Colorectal cancer; Oncology; Internal medicine; Cancer; Nomogram; Confounding; Proportional hazards model; Stage (stratigraphy); Immunotherapy; Clinical endpoint; Prognostic variable; Clinical trial","score_opus":0.07818886738008371,"score_gpt":0.3702558735660371,"score_spread":0.2920670061859534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802206159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862515,0.0004047723,0.000028250144,0.011514072,0.00031058714,0.0012273818,0.000048141592,0.0000061790224,0.0002091447],"genre_scores_gemma":[0.99912155,0.00018347913,0.00003188543,0.0001728862,0.00028310865,0.00010284691,0.0000045344154,0.0000047646035,0.00009493513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999535,0.00004736555,0.000160386,0.000071320675,0.00012475332,0.00006117048],"domain_scores_gemma":[0.9989525,0.00040577468,0.000198538,0.00027137616,0.0001663626,0.0000054559905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003823225,0.000046404428,0.00012400548,0.000012751623,0.00008324631,0.000008876285,0.00016955863,0.000018147388,0.000027541793],"category_scores_gemma":[0.0002114975,0.000020265508,0.00003262767,0.000089579196,0.0002739062,0.000013622798,0.000025634845,0.000047461144,3.3242392e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01623786,0.00038021023,0.4911587,0.00014799181,0.0011195093,2.2866865e-7,0.0078585055,0.0000044950675,0.4165193,0.0005187294,0.013040963,0.053013485],"study_design_scores_gemma":[0.003044957,0.0004221367,0.9653237,0.00010503426,0.00018893411,0.0000053022964,0.0011735368,0.0007350367,0.020259203,0.000083398736,0.0086263,0.000032456483],"about_ca_topic_score_codex":0.00019430259,"about_ca_topic_score_gemma":0.000081911785,"teacher_disagreement_score":0.474165,"about_ca_system_score_codex":0.000022689861,"about_ca_system_score_gemma":0.00005927533,"threshold_uncertainty_score":0.10092188},"labels":[],"label_agreement":null},{"id":"W2802224787","doi":"10.1016/j.jgo.2018.03.021","title":"Low levels of intra-tumoural T cells in breast cancer identify clinically frail patients with shorter disease-specific survival","year":2018,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"Vlaamse regering; Fonds Wetenschappelijk Onderzoek","keywords":"Medicine; Breast cancer; Internal medicine; Immune system; Oncology; Cancer; Disease; Immunology","score_opus":0.02360833839821771,"score_gpt":0.3231382878339344,"score_spread":0.2995299494357167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802224787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99517643,0.00037413466,0.000090552385,0.0016165809,0.0022833596,0.0002260666,0.00008361841,0.000004443162,0.00014479685],"genre_scores_gemma":[0.99722964,0.00063687086,0.0003530965,0.00038970454,0.0012708466,0.0000032765486,0.000002603001,0.000021775848,0.00009218146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976901,0.00016958738,0.0012391075,0.00018964092,0.00043412007,0.0002774646],"domain_scores_gemma":[0.9978756,0.00015350243,0.00092089415,0.00018723971,0.00066249486,0.00020027361],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00074829726,0.00016263309,0.00071981846,0.00028639942,0.000030576542,0.000011863717,0.00018644315,0.00014845641,0.0015120709],"category_scores_gemma":[0.000025882424,0.00011204039,0.0002044419,0.0004126978,0.00029205345,0.00013275116,0.000029817224,0.00033809492,0.000007151434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05811724,0.0017079575,0.8529989,0.00008094421,0.0003363401,0.00022239267,0.00033929697,0.000005259628,0.011657616,0.0000022018748,0.0053703175,0.069161505],"study_design_scores_gemma":[0.010066429,0.0032709,0.9820614,0.00017702098,0.0001577473,0.00006123274,0.000082814804,0.0000048435422,0.0003931381,0.000014063851,0.0035870755,0.000123343],"about_ca_topic_score_codex":0.000034927136,"about_ca_topic_score_gemma":0.0000693446,"teacher_disagreement_score":0.12906246,"about_ca_system_score_codex":0.00038199307,"about_ca_system_score_gemma":0.0010082074,"threshold_uncertainty_score":0.9994007},"labels":[],"label_agreement":null},{"id":"W2802450491","doi":"10.1016/s1470-2045(18)30287-0","title":"Body-mass index and metastatic melanoma outcomes","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Melanoma; Body mass index; Incidence (geometry); Oncology; Internal medicine; Population; Obesity; Cancer research; Environmental health","score_opus":0.05080202648312223,"score_gpt":0.3475610063345605,"score_spread":0.2967589798514383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802450491","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00980749,0.0015541259,0.000037418748,0.97330153,0.0009788985,0.0005823526,0.000059256054,0.00007334209,0.013605603],"genre_scores_gemma":[0.0093424935,0.0008195774,0.00045568575,0.9717417,0.006691253,0.00008531802,0.0001076847,0.000055074277,0.010701248],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983635,0.000289209,0.00032990906,0.0003210042,0.00023156949,0.00046480788],"domain_scores_gemma":[0.99851537,0.0005084723,0.00024136297,0.0006368563,0.000056968052,0.00004099032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061649305,0.00028917537,0.0012192464,0.00009669942,0.000090712965,0.000023242439,0.00027723194,0.0004934645,0.0006429042],"category_scores_gemma":[0.00006217856,0.00016054115,0.00015736854,0.000103096965,0.000575897,0.000025212266,0.0000665593,0.0011596432,0.00008054587],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012010984,0.000021066458,0.0056613293,0.00017827532,0.0010777833,0.00045552495,0.00012909986,1.9507842e-8,0.00020685836,0.000018642415,0.987425,0.0036252541],"study_design_scores_gemma":[0.0041515185,0.00088018423,0.021111965,0.000057736404,0.00044793583,0.00042377354,0.00003343813,0.000011028812,0.00003540814,0.0006215089,0.9720438,0.00018168954],"about_ca_topic_score_codex":0.00012333115,"about_ca_topic_score_gemma":0.00004327967,"teacher_disagreement_score":0.015450635,"about_ca_system_score_codex":0.00017533955,"about_ca_system_score_gemma":0.00023489061,"threshold_uncertainty_score":0.70393497},"labels":[],"label_agreement":null},{"id":"W2802467006","doi":"10.7150/jca.24200","title":"Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment","year":2018,"lang":"en","type":"article","venue":"Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Beijing Friendship Hospital, Capital Medical University; Capital Medical University","keywords":"Medicine; Internal medicine; Nivolumab; Relative risk; Gastroenterology; Pembrolizumab; Atezolizumab; Subgroup analysis; Ulcerative colitis; Confidence interval; Chemotherapy; Colitis; Cancer; Immunotherapy","score_opus":0.00663379225719941,"score_gpt":0.3010319427632782,"score_spread":0.2943981505060788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802467006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99096626,0.005930405,0.000049841554,0.0008204279,0.0008635755,0.000359303,0.000015476486,0.000009293068,0.0009854041],"genre_scores_gemma":[0.99516696,0.0034052841,0.0001757862,0.00020920909,0.0006032043,0.000014191044,0.0000013594629,0.00003471031,0.00038930762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775356,0.0001003556,0.0011911585,0.00014444886,0.00055012986,0.00026032218],"domain_scores_gemma":[0.9977283,0.000047370813,0.0014056691,0.0002162193,0.00050149154,0.000100983794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085542025,0.00018404731,0.0007495795,0.0002612225,0.000045527282,0.000022073293,0.00013027091,0.0001129852,0.0003686454],"category_scores_gemma":[0.000018571582,0.00012539847,0.00020659478,0.00043405718,0.00023270099,0.00013750608,0.00001149635,0.00038747463,0.0000014911226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.085236,0.0012563209,0.7321088,0.0007707393,0.005966112,0.00035554147,0.0051522534,0.00042267068,0.12796076,0.00008142522,0.009100283,0.031589113],"study_design_scores_gemma":[0.017238455,0.0053658504,0.9152371,0.0058873706,0.00026653387,0.00039821203,0.00090253574,0.00028886096,0.042636972,0.000029157709,0.011503462,0.00024546735],"about_ca_topic_score_codex":0.0018818809,"about_ca_topic_score_gemma":0.00023028319,"teacher_disagreement_score":0.18312833,"about_ca_system_score_codex":0.00060863304,"about_ca_system_score_gemma":0.00087496097,"threshold_uncertainty_score":0.5113601},"labels":[],"label_agreement":null},{"id":"W2802523646","doi":"10.1007/978-3-319-44870-1_77-1","title":"Immunosenescence and Cancer Immunotherapy at Old Age: Basics","year":2018,"lang":"en","type":"book-chapter","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North; Université de Sherbrooke","funders":"","keywords":"Immunosenescence; Medicine; Cancer; Immunotherapy; Clinical trial; Cancer immunotherapy; Immunology; Incidence (geometry); Oncology; Immune system; Internal medicine","score_opus":0.02274856465506976,"score_gpt":0.2774029600165726,"score_spread":0.25465439536150286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802523646","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011604925,0.10861261,0.000037549205,0.0021985865,0.0019427859,0.0016798656,0.00012672185,0.0005442357,0.8732527],"genre_scores_gemma":[0.0012561233,0.08165989,0.00025897418,0.004159642,0.0005675963,0.000026362006,0.0000519243,0.00019842497,0.91182107],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982653,0.000010575045,0.00044619522,0.0005768462,0.0003707403,0.00033032816],"domain_scores_gemma":[0.9987598,0.00004523455,0.00021378964,0.00072085194,0.0001398553,0.0001204882],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016195947,0.0005239259,0.00068086927,0.00013276128,0.00012301514,0.000043032396,0.0001564676,0.00051116303,0.016509904],"category_scores_gemma":[0.00000444365,0.00041879524,0.00027071874,0.000041034516,0.0006140951,0.000056706693,0.000100770485,0.00032234623,0.00011456141],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020239452,0.00017067733,0.002091307,0.0010100254,0.005966517,0.0006310695,0.002014077,1.14159256e-7,0.11292816,0.010671428,0.15444775,0.6898294],"study_design_scores_gemma":[0.0025496653,0.0004011595,0.002568483,0.0008174278,0.00016485443,0.00015615275,0.000013799113,0.0000024519586,0.0027046672,0.00050605956,0.9895869,0.0005284078],"about_ca_topic_score_codex":0.0004892258,"about_ca_topic_score_gemma":0.00031141582,"teacher_disagreement_score":0.83513916,"about_ca_system_score_codex":0.00040797683,"about_ca_system_score_gemma":0.00018407965,"threshold_uncertainty_score":0.9998264},"labels":[],"label_agreement":null},{"id":"W2803437699","doi":"10.1016/s1470-2045(18)30270-5","title":"Does a patient's sex predict the efficacy of cancer immunotherapy?","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Immunotherapy; Cancer; Lung cancer; Cancer immunotherapy; Pembrolizumab; Oncology; Internal medicine; Melanoma; Meta-analysis; Scopus; Nivolumab; Clinical trial; MEDLINE; Cancer research","score_opus":0.027200920113298246,"score_gpt":0.329764280774798,"score_spread":0.3025633606614998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803437699","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033383273,0.0076667634,0.0000046185573,0.9505314,0.003246214,0.0014724373,0.00022070343,0.0001295245,0.0033450488],"genre_scores_gemma":[0.01087825,0.009528354,0.00007523144,0.9472069,0.023628747,0.00037729187,0.000094510164,0.00014272988,0.008067943],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975398,0.0005135209,0.0005906529,0.0003695975,0.0004223742,0.0005640274],"domain_scores_gemma":[0.9970532,0.0007735636,0.00064485933,0.0013584038,0.00014278584,0.000027155918],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00065975543,0.00035283057,0.00114075,0.00007632902,0.0001276362,0.000017433385,0.0007500869,0.00072690233,0.0012455735],"category_scores_gemma":[0.000051067273,0.00012746429,0.00037779228,0.00022236771,0.0015714584,0.000023270028,0.000101235244,0.0015080787,0.000017404625],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005475748,0.00009004828,0.00068556645,0.00017666651,0.0015788976,0.000048560087,0.0019322261,4.5588214e-7,0.0020093853,0.0000049191817,0.9385976,0.049399905],"study_design_scores_gemma":[0.0047377674,0.0014999659,0.003949959,0.00024520204,0.00032302304,0.000056369994,0.000104810926,0.0000047358863,0.0015809987,0.00011153458,0.987205,0.00018058105],"about_ca_topic_score_codex":0.0009887604,"about_ca_topic_score_gemma":0.00016571609,"teacher_disagreement_score":0.04921932,"about_ca_system_score_codex":0.00030157404,"about_ca_system_score_gemma":0.0005841445,"threshold_uncertainty_score":0.9996674},"labels":[],"label_agreement":null},{"id":"W2803642760","doi":"10.1016/j.jtho.2018.05.015","title":"Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":179,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; McMaster University; Juravinski Cancer Centre","funders":"Gilead Sciences; Amgen; Pfizer; Samsung; Genentech; Celgene; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Erlotinib; Nivolumab; Oncology; Mutant; Internal medicine; Epidermal growth factor receptor; Cancer; Immunotherapy; Genetics; Gene","score_opus":0.012998529033252212,"score_gpt":0.36691182312771664,"score_spread":0.3539132940944644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803642760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99404216,0.00029315945,0.00009903921,0.00177053,0.0007904622,0.00028842027,0.0000026742694,0.000008943711,0.002704638],"genre_scores_gemma":[0.99542767,0.00005350369,0.002955351,0.00092135515,0.00033517805,0.0000031971788,0.000002197318,0.000019336572,0.00028218914],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986471,0.00010002567,0.00056707213,0.00013798715,0.00029358166,0.0002542634],"domain_scores_gemma":[0.9987393,0.00006306941,0.0005325525,0.00017034505,0.0003849925,0.00010975471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004892471,0.00012901587,0.00051744265,0.00024089238,0.000042666452,0.00000767462,0.0001308347,0.00012806118,0.00025618938],"category_scores_gemma":[0.00007136021,0.00008737395,0.00009905524,0.00029683977,0.00019540732,0.00013219062,0.000021367901,0.00032821533,0.00001350747],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20953792,0.0009954243,0.059903942,0.000051656207,0.00028573707,0.00034504512,0.0011021987,0.000006278004,0.005787284,0.000006274326,0.0014457147,0.72053254],"study_design_scores_gemma":[0.037283044,0.05255484,0.7740978,0.0010593074,0.00028715853,0.0010070134,0.000882486,0.000044167056,0.005776106,0.00007706073,0.1266061,0.0003249341],"about_ca_topic_score_codex":0.000017528746,"about_ca_topic_score_gemma":0.0001158157,"teacher_disagreement_score":0.7202076,"about_ca_system_score_codex":0.0008108007,"about_ca_system_score_gemma":0.00071114104,"threshold_uncertainty_score":0.35630062},"labels":[],"label_agreement":null},{"id":"W2804249484","doi":"10.1007/s10549-018-4785-z","title":"Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer","year":2018,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Cancer Research UK","keywords":"Medicine; Exemestane; Internal medicine; Oncology; Breast cancer; Hazard ratio; Tamoxifen; Cohort; Tumor-infiltrating lymphocytes; Adjuvant therapy; Univariate analysis; Cancer; Multivariate analysis; Immunotherapy; Confidence interval","score_opus":0.0863728712915903,"score_gpt":0.3953243361581453,"score_spread":0.308951464866555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804249484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98876387,0.004870135,0.00002336243,0.0032230169,0.00008839055,0.0018643257,0.0008836492,0.00002431834,0.00025894228],"genre_scores_gemma":[0.9867254,0.0102466075,0.00006938558,0.00006647253,0.00033517613,0.0021584688,0.0000337473,0.000032460735,0.00033229802],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982474,0.00008266935,0.0003300541,0.0004249928,0.00040238074,0.0005124972],"domain_scores_gemma":[0.99886376,0.00011852986,0.00009738602,0.00021138573,0.0005472466,0.00016170433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028250722,0.00022105643,0.00037514552,0.00029011455,0.00016018505,0.000037580805,0.00007335537,0.000062563646,0.0002613303],"category_scores_gemma":[0.0000114838695,0.00015553323,0.00009426778,0.0004585237,0.0004167629,0.00024642597,0.000025089068,0.0000782155,0.0000028111044],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10123647,0.0010789057,0.1460552,0.000103540915,0.0009133138,0.000034512203,0.0025202942,0.0000018762852,0.10103056,0.00006117469,0.0002447708,0.6467194],"study_design_scores_gemma":[0.02082606,0.009202042,0.88143975,0.00078644213,0.00005340997,0.00019980919,0.00080388313,0.00030762947,0.084998526,0.00022364841,0.00096564397,0.00019318481],"about_ca_topic_score_codex":0.044843983,"about_ca_topic_score_gemma":0.0032642256,"teacher_disagreement_score":0.7353845,"about_ca_system_score_codex":0.0008721356,"about_ca_system_score_gemma":0.0008783284,"threshold_uncertainty_score":0.9615165},"labels":[],"label_agreement":null},{"id":"W2804868005","doi":"10.1164/rccm.201712-2539pp","title":"The Immune Landscape of Non–Small-Cell Lung Cancer: Utility of Cytologic and Histologic Samples Obtained through Minimally Invasive Pulmonary Procedures","year":2018,"lang":"en","type":"review","venue":"American Journal of Respiratory and Critical Care Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Cytology; Lung; Pathology; Cancer; Internal medicine","score_opus":0.04179628408417865,"score_gpt":0.3518814988579138,"score_spread":0.3100852147737352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804868005","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.040427778,0.9579802,0.000016996932,0.0004795352,0.0001943281,0.0004935228,0.000047394886,0.000006225022,0.0003540313],"genre_scores_gemma":[0.19952954,0.7996225,0.00016491562,0.000333966,0.00028914277,0.000022205873,0.0000058934256,0.00002272329,0.0000091360425],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968049,0.00043316436,0.0016648981,0.0003442383,0.00042604128,0.0003267918],"domain_scores_gemma":[0.99491465,0.0021231172,0.0014808037,0.0003479836,0.00094115746,0.0001922988],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.000935681,0.0004248438,0.0029969432,0.00017820591,0.00015329149,0.000009315397,0.00031134704,0.00019484633,0.00006525292],"category_scores_gemma":[0.0015499473,0.00022074879,0.00040728014,0.000417769,0.005659138,0.00005568131,0.00008394173,0.00055914815,1.0769051e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043032686,0.00017117904,0.007093403,0.060149446,0.00082413177,0.0002863644,0.0014958585,2.1751847e-8,0.0007898288,0.00003862478,0.0008263427,0.92402154],"study_design_scores_gemma":[0.006997647,0.05440199,0.016362067,0.113990605,0.019360937,0.0037706797,0.04428585,0.0000064239475,0.0010624825,0.00014773758,0.73839545,0.0012181315],"about_ca_topic_score_codex":0.00011376955,"about_ca_topic_score_gemma":0.00003268248,"teacher_disagreement_score":0.9228034,"about_ca_system_score_codex":0.000073387535,"about_ca_system_score_gemma":0.0016371314,"threshold_uncertainty_score":0.9970469},"labels":[],"label_agreement":null},{"id":"W2804957255","doi":"10.1016/j.jtho.2018.05.013","title":"PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":807,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Intraclass correlation; Immunohistochemistry; Lung cancer; Internal medicine; Concordance; Pathology","score_opus":0.15394022752030842,"score_gpt":0.5666192394865217,"score_spread":0.41267901196621326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804957255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955139,0.00029316146,0.000046239158,0.0007058776,0.00067786843,0.00059483683,0.000015984606,0.000009681627,0.002142435],"genre_scores_gemma":[0.9975194,0.00022954449,0.001397401,0.00018712408,0.00054805446,0.000006869729,0.000004273589,0.000012151829,0.000095212396],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9957832,0.0006870411,0.0026900228,0.00027059854,0.00033588256,0.00023323092],"domain_scores_gemma":[0.996622,0.00056257023,0.0016116655,0.00051496975,0.0005529689,0.00013578036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065952833,0.00016242357,0.0011976702,0.00020112375,0.000040016082,0.000006197468,0.00027529645,0.00022779213,0.000101891135],"category_scores_gemma":[0.0013609927,0.00012441343,0.00032751178,0.00033011055,0.0006531575,0.00006063213,0.000068544556,0.00065764884,0.000003430333],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58992124,0.027130745,0.14136496,0.00025286493,0.0011282369,0.00041910468,0.0054368977,0.0000020372186,0.097932525,0.0000032319704,0.0049837045,0.13142444],"study_design_scores_gemma":[0.048175994,0.060883656,0.844979,0.0005835787,0.0005961601,0.00075330393,0.008385386,0.00006714664,0.014122504,0.00006104256,0.021101546,0.0002906719],"about_ca_topic_score_codex":0.0004950593,"about_ca_topic_score_gemma":0.00013307274,"teacher_disagreement_score":0.70361406,"about_ca_system_score_codex":0.0005601404,"about_ca_system_score_gemma":0.0020566527,"threshold_uncertainty_score":0.50734323},"labels":[],"label_agreement":null},{"id":"W2805371265","doi":"10.1186/s40164-018-0098-5","title":"Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report","year":2018,"lang":"en","type":"article","venue":"Experimental Hematology and Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Aplastic anemia; Neutropenia; Oncology; Cancer; Bone marrow; Immunotherapy; Chemotherapy","score_opus":0.012702777517378966,"score_gpt":0.3125096891512824,"score_spread":0.29980691163390344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805371265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932987,0.003712681,0.000027243295,0.00048724774,0.00016100916,0.0004877852,0.0000041275775,0.000020689322,0.0018004968],"genre_scores_gemma":[0.9966573,0.000011719178,0.0019525946,0.0011288583,0.000026666206,0.00011124038,0.000007445966,0.000013894794,0.00009024079],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9989159,0.00007027903,0.000325126,0.00036983882,0.00006565718,0.00025320082],"domain_scores_gemma":[0.999503,0.000093941875,0.00008403837,0.00015421667,0.000027210486,0.00013754673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011923627,0.0001595998,0.000452193,0.00014003426,0.00009631208,0.0000058434266,0.000025358177,0.00010692024,0.0002396282],"category_scores_gemma":[0.000016956776,0.00012556885,0.000022966615,0.00012340763,0.0004838715,0.000045672914,0.000056249268,0.00013838346,0.000007910462],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04694923,0.0020082716,0.0154658025,0.00028505616,0.00043256336,0.8578515,0.024834523,2.5001177e-7,0.024618812,0.00084056327,0.003234965,0.023478467],"study_design_scores_gemma":[0.009040708,0.0151097495,0.0017718195,0.00007672264,0.00005462624,0.9135223,0.0068061464,0.00002202121,0.049520746,0.000026599484,0.0038638625,0.00018468205],"about_ca_topic_score_codex":0.00028196603,"about_ca_topic_score_gemma":0.001199071,"teacher_disagreement_score":0.055670824,"about_ca_system_score_codex":0.00015259218,"about_ca_system_score_gemma":0.00017859908,"threshold_uncertainty_score":0.5120549},"labels":[],"label_agreement":null},{"id":"W2805530155","doi":"10.1097/cad.0000000000000661","title":"A case of severe Pembrolizumab-induced neutropenia","year":2018,"lang":"en","type":"article","venue":"Anti-Cancer Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Pembrolizumab; Medicine; Neutropenia; Immunosuppression; Adverse effect; Internal medicine; Immunology; Gastroenterology; Cancer; Chemotherapy; Immunotherapy","score_opus":0.02603540285744438,"score_gpt":0.3146937041468664,"score_spread":0.28865830128942205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805530155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861304,0.00055612205,0.0000040415885,0.0007471008,0.00043607136,0.00030760004,0.000027976788,0.000048318183,0.011742345],"genre_scores_gemma":[0.99577266,0.0003357018,0.00009938786,0.0011968883,0.00048724262,0.00002156943,0.000005599449,0.000031782594,0.0020491842],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989239,0.00003066702,0.0003026025,0.00027789117,0.00018406131,0.00028087196],"domain_scores_gemma":[0.99913156,0.000024189509,0.00013910157,0.00041811503,0.00019429614,0.000092711336],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013244365,0.00016886542,0.0003634896,0.00009710764,0.00009636379,0.000013257695,0.000107703854,0.00009504292,0.0012453579],"category_scores_gemma":[0.000009155416,0.00013924707,0.00015755858,0.00033210783,0.00019468437,0.000097217264,0.00004028894,0.00012609464,0.000054409164],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065450734,0.00035484432,0.010738926,0.00034884625,0.00080494065,0.0007203136,0.004519548,8.3360516e-7,0.8261752,0.0002151558,0.016218513,0.13335782],"study_design_scores_gemma":[0.022672337,0.0021857342,0.040451005,0.0007174664,0.0005316422,0.00604406,0.0016494283,0.00013035395,0.8559225,0.000077909186,0.06879282,0.0008247411],"about_ca_topic_score_codex":0.0031338716,"about_ca_topic_score_gemma":0.00021982075,"teacher_disagreement_score":0.13253307,"about_ca_system_score_codex":0.00008323551,"about_ca_system_score_gemma":0.0002487588,"threshold_uncertainty_score":0.99966764},"labels":[],"label_agreement":null},{"id":"W2805976333","doi":"10.1177/2513826x17751116","title":"A 60-Year-Old Female With Metastatic Malignant Melanoma of the Scalp Responding to Ipilimumab","year":2018,"lang":"en","type":"article","venue":"Plastic Surgery Case Studies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Regina Qu'Appelle Health Region; University of Saskatchewan","funders":"","keywords":"Ipilimumab; Medicine; Melanoma; Scalp; Oncology; Metastatic melanoma; Immunotherapy; Internal medicine; Cancer; Stage (stratigraphy); Dermatology; Surgery; Cancer research","score_opus":0.04572450805667622,"score_gpt":0.30422577579521126,"score_spread":0.25850126773853505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805976333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972815,0.00085047336,0.00005743485,0.00036864504,0.00087958516,0.0003070661,0.000034293873,0.000027138998,0.00019389608],"genre_scores_gemma":[0.9983506,0.000059978778,0.00029271885,0.0002475208,0.0001209078,0.000045637695,0.0000014594377,0.000023370168,0.00085780484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864644,0.00009346833,0.00037018736,0.00026623136,0.0003232723,0.00030042086],"domain_scores_gemma":[0.9963778,0.0028338889,0.00013996287,0.0003469018,0.00022473533,0.00007666295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005607735,0.0001917075,0.0005504813,0.00031972255,0.00020795895,0.000011086174,0.000059227237,0.000024814428,0.0000933887],"category_scores_gemma":[0.0013989662,0.00010324596,0.00014962486,0.0010192486,0.0004281171,0.000039478306,0.000078135155,0.00007323948,0.000022742943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13374902,0.0015115625,0.59357584,0.00357033,0.022168657,0.03502408,0.04150299,0.000043708835,0.08334026,0.0008269392,0.060650505,0.0240361],"study_design_scores_gemma":[0.02062418,0.013085395,0.46898043,0.020441586,0.007669075,0.051196318,0.107797466,0.0002638727,0.26866615,0.00016294817,0.03804481,0.0030677642],"about_ca_topic_score_codex":0.00006613565,"about_ca_topic_score_gemma":0.00017807656,"teacher_disagreement_score":0.18532589,"about_ca_system_score_codex":0.00009329819,"about_ca_system_score_gemma":0.00014351477,"threshold_uncertainty_score":0.42102483},"labels":[],"label_agreement":null},{"id":"W2806145489","doi":"10.1200/jco.2018.36.18_suppl.lba9000","title":"IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":220,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"Medicine; Carboplatin; Atezolizumab; Paclitaxel; Internal medicine; Docetaxel; Oncology; Population; Chemotherapy; Cisplatin; Cancer; Nivolumab; Immunotherapy","score_opus":0.053843135627837414,"score_gpt":0.4520079957856368,"score_spread":0.39816486015779934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806145489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896818,0.0043063443,0.000088044,0.0012151783,0.0007982283,0.0021899163,0.000051250066,0.000017084598,0.00165219],"genre_scores_gemma":[0.9918438,0.0050294464,0.0011500231,0.0012082888,0.00041451483,0.00003872621,0.00001591013,0.000050719147,0.00024852672],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98567694,0.0027981054,0.0092457915,0.0006395704,0.0010674428,0.0005721409],"domain_scores_gemma":[0.98090667,0.009990628,0.0066978545,0.00073553895,0.0012006421,0.00046868128],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013595607,0.0005284454,0.009121289,0.0011735564,0.00009209454,0.000016387417,0.00040244334,0.0007392917,0.0004723084],"category_scores_gemma":[0.0072084945,0.00034956128,0.001902603,0.0016495265,0.0014979689,0.0002364259,0.00012070822,0.001204257,0.0000015219201],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84618425,0.010048503,0.015650153,0.00007304301,0.009213973,0.00038748514,0.004483425,0.000017901844,0.004506634,0.000019183448,0.00016113122,0.1092543],"study_design_scores_gemma":[0.765241,0.10676883,0.11522012,0.00031507225,0.0047498727,0.00017775699,0.0041320957,0.00050994795,0.000395301,0.00013260865,0.0019842612,0.00037308867],"about_ca_topic_score_codex":0.0015372565,"about_ca_topic_score_gemma":0.0017876719,"teacher_disagreement_score":0.10888121,"about_ca_system_score_codex":0.0004420983,"about_ca_system_score_gemma":0.0026316165,"threshold_uncertainty_score":0.99989563},"labels":[],"label_agreement":null},{"id":"W2807849948","doi":"10.1158/1078-0432.ccr-18-0415","title":"Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":212,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Lung cancer; Confidence interval; Oncology; Melanoma; Proportional hazards model; Cachexia; Cancer; Immunotherapy; Cancer research","score_opus":0.1687627955113297,"score_gpt":0.5617169475500441,"score_spread":0.3929541520387144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807849948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97482085,0.017337363,0.000006281041,0.006180206,0.00042503307,0.0005263289,0.00011135321,0.000025768551,0.00056683744],"genre_scores_gemma":[0.97293556,0.021643037,0.000036445974,0.0005415429,0.00065918546,0.00016426736,0.000008652796,0.000033850676,0.0039774454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963646,0.000926727,0.00066695135,0.000505419,0.0009968766,0.00053944223],"domain_scores_gemma":[0.997331,0.00092738017,0.0002323105,0.00041904108,0.000855519,0.0002347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055498565,0.00015228368,0.00051404734,0.00012877313,0.00016914077,0.00002888966,0.0002000689,0.0002958771,0.0007193754],"category_scores_gemma":[0.00080204953,0.00013215448,0.00012573384,0.00046565253,0.0007789263,0.00009494197,0.00009968134,0.0007115397,0.000018221353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.112657554,0.0007272585,0.53081423,0.00026402881,0.00086396013,0.000009168268,0.0007584654,2.4412398e-7,0.06612864,0.000021595752,0.049461506,0.23829332],"study_design_scores_gemma":[0.009050836,0.0027803918,0.8732132,0.00026644074,0.00006606457,0.0000021466283,0.00014839343,0.00006740574,0.0086392015,0.000029415092,0.105574936,0.00016162248],"about_ca_topic_score_codex":0.0028449905,"about_ca_topic_score_gemma":0.0010736417,"teacher_disagreement_score":0.34239888,"about_ca_system_score_codex":0.00054959604,"about_ca_system_score_gemma":0.0008912818,"threshold_uncertainty_score":0.7876656},"labels":[],"label_agreement":null},{"id":"W2807902048","doi":"10.1158/1078-0432.ccr-18-1475","title":"Unexpected Benefits of Aging for Favorable Responses to PD-1 Blockade in Melanoma?","year":2018,"lang":"en","type":"letter","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"","keywords":"Blockade; Immunosenescence; Melanoma; Immune checkpoint; Cancer; Medicine; Immune system; CD8; PD-L1; Immunotherapy; Cancer research; Oncology; Immunology; Internal medicine; Receptor","score_opus":0.30777271043350346,"score_gpt":0.5352811957631706,"score_spread":0.2275084853296671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807902048","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3982045,0.0073798555,0.0000089582845,0.5897037,0.00088721904,0.002720478,0.0004710543,0.00004142378,0.00058284175],"genre_scores_gemma":[0.11343835,0.012075507,0.0026354727,0.72171277,0.04490271,0.0048564007,0.00069940893,0.00069857144,0.09898082],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.994742,0.00070064055,0.0013827119,0.0009734941,0.0011336701,0.001067496],"domain_scores_gemma":[0.99339104,0.0041099396,0.00022039798,0.00096602214,0.0011120088,0.0002005977],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005166763,0.0003011691,0.0012062707,0.0009770694,0.000109700544,0.000038785234,0.00059885444,0.001079377,0.000703854],"category_scores_gemma":[0.0024622586,0.00025979837,0.00043017,0.0013130037,0.0006616719,0.00004192728,0.00020336655,0.0026213177,0.000035531724],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01817964,0.0001641152,0.010200167,0.0008494367,0.00031227153,0.00007929662,0.00020187633,0.0000013560447,0.0013705553,0.000003190925,0.9535571,0.015081041],"study_design_scores_gemma":[0.004763089,0.0033421344,0.023118531,0.0030115244,0.0000707429,0.0000069308608,0.00007297772,0.000012971098,0.0057259323,0.000073444695,0.9594948,0.00030687317],"about_ca_topic_score_codex":0.0024838634,"about_ca_topic_score_gemma":0.0008672566,"teacher_disagreement_score":0.28476614,"about_ca_system_score_codex":0.00054995756,"about_ca_system_score_gemma":0.0020816135,"threshold_uncertainty_score":0.9999854},"labels":[],"label_agreement":null},{"id":"W2807947863","doi":"10.3390/cancers10060194","title":"TGF-β in T Cell Biology: Implications for Cancer Immunotherapy","year":2018,"lang":"en","type":"review","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":214,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Cancer Society Research Institute","keywords":"Immunosurveillance; Cancer immunotherapy; Immunotherapy; Biology; T cell; Transforming growth factor; Tumor microenvironment; Transforming growth factor beta; Context (archaeology); Cancer research; Immune system; Cytokine; Cancer; Immunology; Acquired immune system; Effector; Cell biology","score_opus":0.07548115491784751,"score_gpt":0.4103283441442401,"score_spread":0.33484718922639256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807947863","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026156518,0.9945381,0.00005999237,0.000256636,0.0009182805,0.0025298062,0.00053092116,0.00008065665,0.0010594481],"genre_scores_gemma":[0.000014807932,0.9927793,0.00025094362,0.00074390386,0.0006689499,0.003834295,0.0002736493,0.00014497925,0.0012891587],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99826425,0.00004809577,0.0006262923,0.00055973994,0.000059763173,0.00044183413],"domain_scores_gemma":[0.99875784,0.00012283558,0.00034214795,0.00060134183,0.0000951583,0.0000806756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022486351,0.00039427434,0.0013937878,0.00027803605,0.000063392064,0.00001566214,0.00027338605,0.00044250855,0.00019969778],"category_scores_gemma":[0.000013510526,0.00031382902,0.0006843102,0.0005257063,0.00021986515,0.000032225376,0.000019277788,0.00024741006,0.000012163799],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024226331,0.00001943671,0.00004947056,0.0051384154,0.00031670617,5.140456e-7,0.000063036874,3.8951478e-7,0.00011069868,0.000028857927,0.0118757505,0.9821545],"study_design_scores_gemma":[0.0016776461,0.00022360453,0.000042576627,0.0054937205,0.0003405606,0.000006370317,0.0000118799,0.0000025347754,0.00002609574,0.00004929454,0.99179786,0.00032785858],"about_ca_topic_score_codex":0.0008925931,"about_ca_topic_score_gemma":0.00030735595,"teacher_disagreement_score":0.9818266,"about_ca_system_score_codex":0.0040505887,"about_ca_system_score_gemma":0.004179739,"threshold_uncertainty_score":0.9999314},"labels":[],"label_agreement":null},{"id":"W2808437122","doi":"10.1186/s12911-018-0606-x","title":"A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions","year":2018,"lang":"en","type":"article","venue":"BMC Medical Informatics and Decision Making","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute of Environmental Health Sciences","keywords":"Tremelimumab; Ipilimumab; Immunological synapse; Monoclonal antibody; Antigen; Epitope; Blocking antibody; CD28; T cell; Cytotoxic T cell; CTLA-4; Antibody; Computational biology; Cell biology; Immunology; Chemistry; Biology; Immunotherapy; Immune system; CD8; T-cell receptor; Biochemistry; In vitro","score_opus":0.04137781716813687,"score_gpt":0.36913857972454966,"score_spread":0.3277607625564128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808437122","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2655013,0.00007700294,0.7327773,0.000103406666,0.00026769208,0.00043745554,0.0000032945247,0.000031106978,0.0008014724],"genre_scores_gemma":[0.7300682,0.00021916113,0.26390028,0.0050534657,0.00060912006,0.00005127484,0.000018861632,0.000026330104,0.000053300984],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9983145,0.00002253788,0.00067001,0.00012349739,0.00062097394,0.00024850204],"domain_scores_gemma":[0.99324507,0.0060925456,0.00015104972,0.00026232513,0.00012568124,0.00012335392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010971378,0.00015559331,0.00028050193,0.00012329781,0.0002921273,0.000094471936,0.0001250597,0.00012429067,0.00016384416],"category_scores_gemma":[0.00097464083,0.00008685879,0.00012904145,0.00018651185,0.00015384337,0.0000999908,0.000055727516,0.00022561052,0.00004939664],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062997285,0.00021000284,0.00025160366,0.0013906816,0.00022021247,0.000011327929,0.0030109894,0.0003015328,0.00048372534,0.004182727,0.0036851133,0.97995234],"study_design_scores_gemma":[0.0020112353,0.00038159548,0.000069808935,0.0030181152,0.000052284737,0.000093962444,0.00031882673,0.9850661,0.00027108172,0.003363476,0.0052317744,0.00012173417],"about_ca_topic_score_codex":0.0000016155147,"about_ca_topic_score_gemma":0.0000028053648,"teacher_disagreement_score":0.9847646,"about_ca_system_score_codex":0.00003532358,"about_ca_system_score_gemma":0.00013280501,"threshold_uncertainty_score":0.35419986},"labels":[],"label_agreement":null},{"id":"W2808572932","doi":"10.3747/co.25.3750","title":"Current Landscape of Immunotherapy for the Treatment of Metastatic Non-Small-Cell Lung Cancer","year":2018,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Peking University; Peking University People's Hospital; National Natural Science Foundation of China","keywords":"Pembrolizumab; Atezolizumab; Medicine; Nivolumab; Immunotherapy; Lung cancer; Oncology; Chemotherapy; Internal medicine; Clinical trial; Cancer","score_opus":0.16120865097227316,"score_gpt":0.4704134536338138,"score_spread":0.30920480266154066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808572932","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032889112,0.98975265,0.00033172863,0.000057584493,0.004219445,0.0047941483,0.00042813164,0.000012138325,0.000075306394],"genre_scores_gemma":[0.000019785277,0.9965128,0.00014078918,0.000014786095,0.0006537551,0.002226226,0.00020092544,0.000062130144,0.00016881802],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977793,0.00015057376,0.0011450418,0.00039440373,0.00018016095,0.00035048454],"domain_scores_gemma":[0.9971009,0.0007510556,0.0012292425,0.0006147243,0.00023975152,0.00006435581],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035760525,0.0004814646,0.0026736823,0.00021201982,0.00006439195,0.0000060741995,0.00029967583,0.00017818563,0.00034573322],"category_scores_gemma":[0.000012559031,0.0002582054,0.0015186224,0.00029962315,0.0002587911,0.000015410074,0.000024400995,0.00018640533,0.0000041234994],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089177757,0.0019975414,0.00011707575,0.027575811,0.0022566593,9.983404e-7,0.00053648103,1.9440617e-7,0.000012642388,0.000003818108,0.005783664,0.96082336],"study_design_scores_gemma":[0.006030793,0.0035253142,0.00003579972,0.0093147205,0.007304231,0.00001309977,0.000045260575,0.00006162851,0.000067676214,0.000003131964,0.97339153,0.00020683027],"about_ca_topic_score_codex":0.00005473251,"about_ca_topic_score_gemma":0.000043621378,"teacher_disagreement_score":0.96760786,"about_ca_system_score_codex":0.0005592678,"about_ca_system_score_gemma":0.0018784163,"threshold_uncertainty_score":0.999987},"labels":[],"label_agreement":null},{"id":"W2809644342","doi":"10.1101/352559","title":"Cancer stemness, intratumoral heterogeneity, and immune response across cancers","year":2018,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; BC Children's Hospital; University of British Columbia","funders":"","keywords":"Biology; Immune system; Cancer stem cell; Cancer research; Cancer; Stem cell; Tumor progression; Phenotype; Cancer cell; Tumor microenvironment; Transcriptome; Immunology; Gene expression; Gene; Genetics","score_opus":0.01974265339892695,"score_gpt":0.2846974147210584,"score_spread":0.26495476132213147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809644342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97144556,0.022904243,0.000043171083,0.0008932551,0.0025663574,0.0011146611,0.00071301375,0.00031508127,0.0000046855957],"genre_scores_gemma":[0.9932407,0.0037488402,0.0005911948,0.0007811156,0.0009839556,0.00043177285,7.6271215e-7,0.00019396006,0.000027711685],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9962902,0.0002386839,0.00077546603,0.001279532,0.0005175125,0.00089861534],"domain_scores_gemma":[0.99689066,0.000066165914,0.00052325794,0.0015364833,0.0005789917,0.00040441958],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013509643,0.0007786138,0.0010659802,0.00020205724,0.00031581678,0.00026460277,0.00041843602,0.00072773464,0.0001288873],"category_scores_gemma":[0.00011276455,0.00076289114,0.00027980105,0.0004934202,0.0007464324,0.00014679982,0.0006274183,0.0008794624,0.000020666148],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010066716,0.00011393901,0.03651355,0.00094997115,0.0009961143,0.00017544739,0.000057864523,0.0000052400383,0.94999766,0.000009177173,0.0010896686,0.000024631792],"study_design_scores_gemma":[0.0025304635,0.0002970052,0.5917206,0.0015881747,0.00023766221,2.9766463e-7,0.0000091388665,0.00007471307,0.3911617,5.238753e-7,0.011572494,0.00080727536],"about_ca_topic_score_codex":0.0013684737,"about_ca_topic_score_gemma":0.00009420378,"teacher_disagreement_score":0.558836,"about_ca_system_score_codex":0.0013429564,"about_ca_system_score_gemma":0.0023552517,"threshold_uncertainty_score":0.9994822},"labels":[],"label_agreement":null},{"id":"W2809754085","doi":"10.1136/esmoopen-2018-eacr25.913","title":"PO-401 Tumour stem cell characteristics are negatively associated with anti-cancer immunity in diverse solid cancers","year":2018,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Immunity; Cancer research; Cancer; Solid tumor; Stem cell; Medicine; Biology; Oncology; Immunology; Internal medicine; Immune system; Genetics","score_opus":0.038939276018340845,"score_gpt":0.3102179298636768,"score_spread":0.27127865384533595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809754085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943752,0.000071165385,0.000009356822,0.00048205085,0.00025657692,0.0007644297,0.00018537854,0.000033200853,0.0038226373],"genre_scores_gemma":[0.9944254,0.0002343802,0.000031834512,0.0011341521,0.000120212324,0.00005634406,0.000055690638,0.000035591253,0.00390636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986889,0.00011654489,0.0002947233,0.00029884183,0.00023538363,0.00036561085],"domain_scores_gemma":[0.99900085,0.00004589758,0.00034416624,0.000295069,0.00021465536,0.000099346],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003619615,0.00021994526,0.00051247014,0.00008852275,0.00018557157,0.000078201345,0.00036488817,0.00010777756,0.0009344017],"category_scores_gemma":[0.000022819813,0.00017756273,0.00005598495,0.0004238759,0.00024276215,0.00021918843,0.00015864761,0.00029206896,0.00003452254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011371565,0.000882847,0.9226052,0.00013278234,0.00091918954,0.00027556054,0.007249048,0.000005167909,0.03163799,0.0000069594735,0.00915971,0.01575394],"study_design_scores_gemma":[0.005713973,0.00054786913,0.9411125,0.0007600364,0.000076779565,0.000004378636,0.00198799,0.000038549704,0.046510592,0.0000033564702,0.0029700643,0.00027391707],"about_ca_topic_score_codex":0.018510878,"about_ca_topic_score_gemma":0.010607917,"teacher_disagreement_score":0.018507253,"about_ca_system_score_codex":0.0007415362,"about_ca_system_score_gemma":0.00054276834,"threshold_uncertainty_score":0.9999789},"labels":[],"label_agreement":null},{"id":"W2810339633","doi":"10.1158/1538-7445.am2018-4670","title":"Abstract 4670: Evidence of neoantigen-reactive T cell response in a case of relapsing, mismatch-repair gene proficient, colorectal cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; McGill University","funders":"","keywords":"Cancer research; T cell; Metastasis; CD8; Cancer; T-cell receptor; clone (Java method); Colorectal cancer; Biology; Antigen; Immunology; Medicine; Gene; Immune system; Genetics","score_opus":0.09864081204970468,"score_gpt":0.44366097450097436,"score_spread":0.34502016245126965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810339633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834936,0.014026903,0.000004072228,0.0005251308,0.00024864773,0.0011430825,0.00006812356,0.000025889847,0.00046452304],"genre_scores_gemma":[0.9968915,0.0016923118,0.00013920656,0.000053115455,0.00015233875,0.00023581559,0.0000020390462,0.000036152724,0.00079750584],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972945,0.00034487285,0.00057473144,0.0004907816,0.00070749014,0.000587639],"domain_scores_gemma":[0.99754286,0.0005942816,0.00022080795,0.0004757759,0.0010160103,0.00015027684],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030972376,0.00018033064,0.00043947672,0.00053783634,0.00011442285,0.000012232623,0.0002143866,0.00016665111,0.0011594091],"category_scores_gemma":[0.00037103117,0.00015686499,0.00016679279,0.001372928,0.0011050107,0.00013466469,0.000092091825,0.0004989571,0.00001332248],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07791796,0.00030983254,0.0134427035,0.00051819213,0.00010074462,0.0006257212,0.005057375,0.000005796132,0.8976266,0.0000020568914,0.0017176088,0.0026754406],"study_design_scores_gemma":[0.0023061812,0.002163286,0.07540273,0.0023464242,0.000030004978,0.00013120289,0.0013365383,0.00010376812,0.91517174,0.0000070358437,0.0008536033,0.00014746508],"about_ca_topic_score_codex":0.023517486,"about_ca_topic_score_gemma":0.0030407226,"teacher_disagreement_score":0.075611785,"about_ca_system_score_codex":0.00087822124,"about_ca_system_score_gemma":0.0025586132,"threshold_uncertainty_score":0.99975365},"labels":[],"label_agreement":null},{"id":"W2810901052","doi":"10.1158/1538-7445.am2018-1209","title":"Abstract 1209: Patterns of treatment with immune check point inhibitors and targeted therapy in patients with metastatic melanoma presumed BRAF V600 positive","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Ipilimumab; Pembrolizumab; Dabrafenib; Vemurafenib; Nivolumab; Trametinib; Internal medicine; Metastatic melanoma; Oncology; Melanoma; Targeted therapy; Combination therapy; Cancer; Immunotherapy; Cancer research; Kinase","score_opus":0.030878174585815075,"score_gpt":0.33888517476556507,"score_spread":0.30800700017974997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810901052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99606484,0.0017066814,0.0000027965339,0.00038541065,0.00003735368,0.0015444466,0.00009916085,0.000011080808,0.00014822457],"genre_scores_gemma":[0.99847937,0.00089292316,0.00005943161,0.000052847554,0.000053634172,0.00019969964,0.000046779234,0.000035868765,0.00017947178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983497,0.00010737151,0.00029077224,0.00034054162,0.00051241333,0.00039917396],"domain_scores_gemma":[0.9990283,0.00008554342,0.000103496015,0.0002946092,0.0003778511,0.00011017768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034413606,0.00019328341,0.00037635767,0.00025934802,0.000073404684,0.000021558686,0.00008333006,0.000051545667,0.0003657589],"category_scores_gemma":[0.000009915682,0.000115153925,0.00004405554,0.00037976765,0.00041262328,0.00010695959,0.000023449064,0.00019006092,0.0000021316503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061165884,0.0011124518,0.7701927,0.00016525107,0.001295265,0.00004700884,0.0056728716,0.0000011789989,0.07326516,0.0000032585601,0.00007582057,0.08700314],"study_design_scores_gemma":[0.014822401,0.0128725385,0.8072023,0.00056700286,0.000024399735,0.0000031762343,0.00039290127,0.0000031101574,0.16382399,0.0000041133426,0.00016871048,0.00011537067],"about_ca_topic_score_codex":0.011990184,"about_ca_topic_score_gemma":0.0014703359,"teacher_disagreement_score":0.090558834,"about_ca_system_score_codex":0.000495113,"about_ca_system_score_gemma":0.00043732816,"threshold_uncertainty_score":0.99458903},"labels":[],"label_agreement":null},{"id":"W2811030359","doi":"10.1016/j.clon.2018.05.005","title":"A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma","year":2018,"lang":"en","type":"article","venue":"Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Queen's University","funders":"Ontario Institute for Cancer Research; Ontario Ministry of Health and Long-Term Care; Canadian Institutes of Health Research; Government of Ontario; Institute for Clinical Evaluative Sciences","keywords":"Medicine; Hazard ratio; Internal medicine; Population; Confidence interval; Oncology; Radiation therapy; Systemic therapy; Targeted therapy; Melanoma; Surgery; Cancer; Cancer research","score_opus":0.14929682030100036,"score_gpt":0.48362354619962017,"score_spread":0.3343267258986198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811030359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972782,0.0004870798,0.0003730429,0.000393289,0.00029462,0.0010797144,0.000026535781,0.000014913831,0.00005261935],"genre_scores_gemma":[0.996799,0.00001253118,0.0026207906,0.00019475854,0.00013465993,0.00002655835,0.00003054263,0.00001813164,0.00016303758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814206,0.00031712698,0.0010019821,0.00022314137,0.00013373984,0.0001819386],"domain_scores_gemma":[0.9961423,0.002809552,0.00046357382,0.00027291305,0.0002132373,0.00009841979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012367149,0.00013294879,0.0010493773,0.00010240153,0.000042442767,0.0000038854905,0.000089975925,0.00012585212,0.00057482935],"category_scores_gemma":[0.00090677757,0.00008336322,0.00028074154,0.00021862552,0.00022486027,0.000025601357,0.0000144910255,0.00009883527,7.811168e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13301733,0.004554962,0.8041447,0.00012891165,0.0021608947,0.000008561409,0.0005721298,0.000011696481,0.0067272615,0.000011937423,0.00063970994,0.048021935],"study_design_scores_gemma":[0.03299186,0.083081655,0.8808097,0.000044773715,0.00036791113,0.0000018790099,0.0004296554,0.00083254045,0.00077769003,0.00008214765,0.0004880297,0.000092113434],"about_ca_topic_score_codex":0.0032445109,"about_ca_topic_score_gemma":0.0015670552,"teacher_disagreement_score":0.10002547,"about_ca_system_score_codex":0.000064697655,"about_ca_system_score_gemma":0.0013643695,"threshold_uncertainty_score":0.62939787},"labels":[],"label_agreement":null},{"id":"W2811161985","doi":"10.3747/co.25.4031","title":"Harmonization of PD-L1 Testing in Oncology: A Canadian Pathology Perspective","year":2018,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Impact; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre; University of British Columbia","funders":"","keywords":"Medicine; Head and neck squamous-cell carcinoma; Lung cancer; Oncology; PD-L1; Head and neck cancer; Cancer; Pathology; Bioinformatics; Medical physics; Internal medicine; Immunotherapy","score_opus":0.27593151557901757,"score_gpt":0.48730731010502504,"score_spread":0.21137579452600747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811161985","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021703968,0.9879661,0.000012927327,0.00028055234,0.001970505,0.0012569398,0.000070795744,0.00002397951,0.008201156],"genre_scores_gemma":[0.00020142579,0.9982897,0.00040647792,0.00012015015,0.0005174072,0.00016612037,0.00017467688,0.000044954522,0.0000790596],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974579,0.0004833507,0.0009310516,0.0005351958,0.00011893711,0.0004735674],"domain_scores_gemma":[0.997983,0.00039738076,0.00067010935,0.000323577,0.0004470656,0.00017886015],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00071506563,0.0003348975,0.0021284823,0.0009608239,0.000053549826,0.000004724237,0.00020548975,0.000810867,0.0002069743],"category_scores_gemma":[0.00082255993,0.0002889611,0.00029985298,0.0009975102,0.000433174,0.000030841613,0.00005515102,0.0007233943,0.000043994045],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00016403635,0.00031641056,0.0004596637,0.0031236485,0.0001321176,0.00018591392,0.00066845585,4.4624624e-8,0.0000054684483,0.00007223996,0.002127424,0.99274457],"study_design_scores_gemma":[0.0014406296,0.0017459382,0.00053838827,0.006797389,0.0005859215,0.00064591994,0.0002507431,0.000008839613,0.000001802084,0.000046732686,0.98772097,0.00021670994],"about_ca_topic_score_codex":0.009668585,"about_ca_topic_score_gemma":0.039735056,"teacher_disagreement_score":0.99252784,"about_ca_system_score_codex":0.006335385,"about_ca_system_score_gemma":0.01001202,"threshold_uncertainty_score":0.99995625},"labels":[],"label_agreement":null},{"id":"W2838357484","doi":"10.1093/annonc/mdy232","title":"Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":367,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Response Evaluation Criteria in Solid Tumors; Internal medicine; Prostate cancer; Oncology; Clinical endpoint; Cohort; Adverse effect; Progressive disease; Cancer; Urology; Surgery; Clinical trial; Disease; Immunotherapy","score_opus":0.06985392706225708,"score_gpt":0.4013476399603873,"score_spread":0.33149371289813023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2838357484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912642,0.0005741762,0.000011503965,0.004775171,0.00032416076,0.0013573768,0.000022481045,0.000010319983,0.0016605963],"genre_scores_gemma":[0.9973448,0.00007282074,0.00015953302,0.0013080555,0.000097772456,0.000050854855,0.0000029121052,0.000014472417,0.0009487868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990171,0.00005732897,0.0003797496,0.00018090925,0.000144859,0.00022000888],"domain_scores_gemma":[0.9989369,0.00011779972,0.00022668082,0.00031274604,0.00037024057,0.000035654983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003925452,0.00010232072,0.0003816715,0.00006760663,0.000059862683,0.0000020706245,0.0001621611,0.00008253736,0.00007164196],"category_scores_gemma":[0.00012747322,0.00006747011,0.00017409083,0.00019001964,0.00035735438,0.000037079786,0.00004821135,0.000077788165,0.0000029077062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16278616,0.005687639,0.3096102,0.0006071655,0.001801713,0.000021854616,0.017266987,0.000003071825,0.21251617,0.00040713258,0.051340222,0.23795168],"study_design_scores_gemma":[0.018781297,0.049619153,0.660506,0.00010722693,0.00016231163,0.00003550561,0.0013092041,0.0000145525,0.18725564,0.00032714568,0.08174423,0.00013771877],"about_ca_topic_score_codex":0.00007839741,"about_ca_topic_score_gemma":0.000064855165,"teacher_disagreement_score":0.35089582,"about_ca_system_score_codex":0.000032773885,"about_ca_system_score_gemma":0.000268593,"threshold_uncertainty_score":0.27513513},"labels":[],"label_agreement":null},{"id":"W2844479918","doi":"10.1016/j.semcancer.2018.07.001","title":"Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning","year":2018,"lang":"en","type":"review","venue":"Seminars in Cancer Biology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research; McGill University; University of British Columbia","funders":"Institute for Information and Communications Technology Promotion; Deutschen Konsortium für Translationale Krebsforschung; Berlin Center for Machine Learning; Deutsche Forschungsgemeinschaft; National Research Foundation; Banting and Best Diabetes Centre, University of Toronto; National Research Foundation of Korea; World Health Organization; Ministry of Science and ICT, South Korea; Breast Cancer Research Foundation","keywords":"Machine learning; Artificial intelligence; Computer science; Tumor-infiltrating lymphocytes; Standardization; Segmentation; Cancer; Medicine; Immunotherapy","score_opus":0.04520917337671387,"score_gpt":0.404199645825318,"score_spread":0.3589904724486041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2844479918","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0071653263,0.99104255,0.0001053853,0.0000251355,0.0006787039,0.0006460788,0.0001106089,0.000035577264,0.00019065893],"genre_scores_gemma":[0.0010646434,0.9953529,0.0022942745,0.00014189874,0.00043368337,0.00018056695,0.0003783435,0.00005449351,0.00009917742],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99791914,0.00017572287,0.0008998338,0.0005421177,0.00012567782,0.00033749422],"domain_scores_gemma":[0.9987405,0.00031519282,0.0005518833,0.00026037128,0.000058935475,0.00007312226],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004310509,0.00036359558,0.0016484152,0.00037376911,0.000048808175,0.000008742718,0.00018532011,0.00031416642,0.00028945465],"category_scores_gemma":[0.00021842925,0.00030185468,0.00025257046,0.00056510634,0.00015165187,0.00003173117,0.00008887738,0.00035688345,0.00001574474],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032051824,0.000034974368,0.002158527,0.003018604,0.00019313606,0.0000110525425,0.00022657147,0.000008511338,0.0006611685,0.000002247261,0.00008994447,0.99327475],"study_design_scores_gemma":[0.0013513766,0.0015424164,0.00015579928,0.10344098,0.0005006572,0.000075940974,0.00008654453,0.0006664867,0.0011381789,0.000022228085,0.89049333,0.00052604836],"about_ca_topic_score_codex":0.004083268,"about_ca_topic_score_gemma":0.0003080229,"teacher_disagreement_score":0.9927487,"about_ca_system_score_codex":0.0008329406,"about_ca_system_score_gemma":0.00069595856,"threshold_uncertainty_score":0.9999434},"labels":[],"label_agreement":null},{"id":"W2845852940","doi":"10.3748/wjg.v24.i25.2686","title":"Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond","year":2018,"lang":"en","type":"review","venue":"World Journal of Gastroenterology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Texas MD Anderson Cancer Center; Astellas Pharma; Broad Institute; National Cancer Institute; University of Rochester; Case Western Reserve University; University of Pittsburgh; Nationwide Children's Hospital; Memorial Sloan-Kettering Cancer Center; Vanderbilt University; University of Washington; BC Cancer Agency; Eli Lilly and Company; KU Leuven; Brown University; Van Andel Research Institute; University of Southern California","keywords":"Pembrolizumab; Microsatellite instability; Cancer; Medicine; Blockade; Oncology; Immunotherapy; PD-L1; Biomarker; Internal medicine; Cancer research; Receptor; Biology","score_opus":0.028792485852918857,"score_gpt":0.3592188708300455,"score_spread":0.3304263849771266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2845852940","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0059827473,0.99031967,0.00006267098,0.0006309544,0.0011998368,0.0016259452,0.00008823101,0.0000117832715,0.000078142075],"genre_scores_gemma":[0.00084640365,0.99468523,0.0030924352,0.00045917902,0.00056677865,0.00017145666,0.000044557284,0.00006918332,0.00006478406],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99595934,0.00038653534,0.0020866948,0.000514523,0.00021298301,0.0008399229],"domain_scores_gemma":[0.99709886,0.0002806683,0.0018117431,0.00030071416,0.00026237156,0.00024562443],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015114705,0.00058039103,0.0033863531,0.0011370414,0.00007767785,0.00003657774,0.0003372668,0.00030544514,0.0000373238],"category_scores_gemma":[0.0000610884,0.0004378273,0.00086401205,0.00037304507,0.00073029,0.0001735976,0.00010032313,0.0006442307,8.118166e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020848524,0.00037558633,0.016283588,0.0064195613,0.00115728,0.00016949473,0.00011452622,1.0714285e-7,0.000058728165,0.000003569589,0.0004936994,0.95407534],"study_design_scores_gemma":[0.008031016,0.00965215,0.0009500203,0.006753879,0.0013398235,0.0034550722,0.000045302546,0.0000013138192,0.00001608626,0.000045566852,0.9695389,0.00017083455],"about_ca_topic_score_codex":0.000020985417,"about_ca_topic_score_gemma":0.0016192148,"teacher_disagreement_score":0.9690452,"about_ca_system_score_codex":0.00075106137,"about_ca_system_score_gemma":0.0007281141,"threshold_uncertainty_score":0.99980736},"labels":[],"label_agreement":null},{"id":"W2883058590","doi":"10.1371/journal.pone.0199575","title":"Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis","year":2018,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Institute for Health and Care Research","keywords":"Atezolizumab; Medicine; Nivolumab; Docetaxel; Internal medicine; Pembrolizumab; Oncology; Adverse effect; Erlotinib; Ramucirumab; Meta-analysis; Lung cancer; Hazard ratio; Cancer; Confidence interval; Epidermal growth factor receptor; Immunotherapy","score_opus":0.1766601193131163,"score_gpt":0.36054780719679524,"score_spread":0.18388768788367896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883058590","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013059961,0.9790907,0.000013992965,0.000032591994,0.0000101537,0.02026041,0.00036082813,0.000020805137,0.000079930855],"genre_scores_gemma":[0.000034908873,0.99374723,0.0006524926,0.000119366654,0.000059027192,0.003256915,0.00031896276,0.000049294016,0.00176179],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9969508,0.0003764437,0.0015369393,0.0005888993,0.00023960929,0.00030728604],"domain_scores_gemma":[0.9967633,0.0006354559,0.0015513059,0.0006552911,0.0002532748,0.00014138328],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0006046688,0.0006211222,0.015882801,0.00016824571,0.00008713871,0.00001911462,0.00012936287,0.00019604721,0.000114292096],"category_scores_gemma":[0.000034300472,0.00037461103,0.0018134635,0.00081293005,0.00010709648,0.000026781394,0.00003495999,0.0001262882,0.0000019815493],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021834925,0.00040585198,0.000009941464,0.5817257,0.41702202,0.0000011929378,0.00011624901,6.309243e-8,0.0000020072623,1.634759e-7,0.00017590451,0.00032250132],"study_design_scores_gemma":[0.001543888,0.00045927748,0.000009737858,0.25804257,0.7383158,0.000003568664,0.000004207365,0.000029375913,0.000012634081,1.2925092e-7,0.0013631965,0.00021558457],"about_ca_topic_score_codex":0.000118967175,"about_ca_topic_score_gemma":0.000065584914,"teacher_disagreement_score":0.32368317,"about_ca_system_score_codex":0.00017623129,"about_ca_system_score_gemma":0.00018044974,"threshold_uncertainty_score":0.9998706},"labels":[],"label_agreement":null},{"id":"W2883803370","doi":"10.1093/jncics/pky021","title":"The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management","year":2018,"lang":"en","type":"review","venue":"JNCI Cancer Spectrum","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Endocrine system; Current (fluid); MEDLINE; Intensive care medicine; Internal medicine; Hormone","score_opus":0.05807851058393724,"score_gpt":0.36440259642873496,"score_spread":0.3063240858447977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883803370","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026821719,0.9877125,0.0001529365,0.00414685,0.0044991053,0.0029652433,0.00015862992,0.000020234504,0.00031767192],"genre_scores_gemma":[0.00024894034,0.9976062,0.00006932649,0.000056419663,0.0007921877,0.00064271095,0.000051711693,0.000047968988,0.0004845111],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99834806,0.000079978185,0.00069792196,0.000347205,0.00022230012,0.00030453285],"domain_scores_gemma":[0.9984399,0.00031222962,0.0006000187,0.0005719297,0.000026018735,0.000049892882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030541624,0.0003167342,0.00082188984,0.00008757391,0.0003199966,0.000041610936,0.00023590877,0.00006732959,0.000049546055],"category_scores_gemma":[0.00002368165,0.00016519205,0.0006441844,0.0002985931,0.0002337023,0.000029998484,0.00015395352,0.00028518433,0.000001635549],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018698706,0.000041327745,0.000011873307,0.009231904,0.0012725045,9.2763736e-7,0.000082216015,1.4547184e-8,0.000006424758,0.0006491373,0.009370415,0.97914624],"study_design_scores_gemma":[0.0012235567,0.00013574923,0.00011526159,0.024453472,0.001675755,0.0000056895296,0.000066203116,0.0000029934222,0.00034530013,0.0010034156,0.9707991,0.00017353117],"about_ca_topic_score_codex":0.00027587262,"about_ca_topic_score_gemma":0.0002494664,"teacher_disagreement_score":0.97897273,"about_ca_system_score_codex":0.0010164907,"about_ca_system_score_gemma":0.00022261425,"threshold_uncertainty_score":0.67363364},"labels":[],"label_agreement":null},{"id":"W2884098295","doi":"10.3389/fonc.2018.00269","title":"Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma","year":2018,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Immune checkpoint; Immune system; Immunotherapy; Hepatocellular carcinoma; Oncology; Cancer; PD-L1; Internal medicine; Biomarker; Ipilimumab; Clinical trial; Immunology; Cancer research; Biology","score_opus":0.014473705120868385,"score_gpt":0.2836439886567582,"score_spread":0.26917028353588984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884098295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820915,0.0056215758,0.00023940604,0.0008411546,0.004199637,0.000701076,0.0000033767221,0.000051210085,0.00625107],"genre_scores_gemma":[0.9950402,0.00042102745,0.0034123044,0.00015002649,0.0004376786,0.0000892802,0.000008784259,0.000037129274,0.00040358645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799514,0.00015134846,0.0006486305,0.0004607097,0.00021642297,0.0005277463],"domain_scores_gemma":[0.99920243,0.000042672196,0.00016296965,0.00039727156,0.000077090386,0.00011757028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071455806,0.00023183705,0.0006088069,0.00059069117,0.00006341498,0.000009059276,0.00018657275,0.00037832942,0.000112680485],"category_scores_gemma":[0.0001051273,0.00022738897,0.00015609775,0.00070432475,0.0005541246,0.00009494075,0.000068793204,0.00033193504,0.00001880064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011825202,0.00024051091,0.9226295,0.00003570961,0.00027213639,0.00038864894,0.0018030958,9.0324295e-7,0.028128859,0.0000064882884,0.0016885629,0.0329804],"study_design_scores_gemma":[0.0095829945,0.0039567673,0.8479058,0.00031914227,0.00006973135,0.00014160412,0.0040769037,0.0015829648,0.10895386,0.00035530768,0.02273867,0.00031625578],"about_ca_topic_score_codex":0.0012594692,"about_ca_topic_score_gemma":0.00004586776,"teacher_disagreement_score":0.080825,"about_ca_system_score_codex":0.001956111,"about_ca_system_score_gemma":0.00048477875,"threshold_uncertainty_score":0.9272653},"labels":[],"label_agreement":null},{"id":"W2884100356","doi":"10.1158/1078-0432.ccr-18-1481","title":"Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer","year":2018,"lang":"en","type":"review","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":523,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Victoria","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; Networks of Centres of Excellence of Canada; Michael Smith Health Research BC","keywords":"Cancer; Tumor cells; Cancer research; Medicine; Pathology; Human plasma; Cancer cell; Biology; Internal medicine; Chemistry","score_opus":0.3274036531060941,"score_gpt":0.5512920413785712,"score_spread":0.22388838827247715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884100356","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023014009,0.9719826,8.5498954e-7,0.00009712668,0.00059526565,0.0033670818,0.00025304104,0.000024752628,0.00066524016],"genre_scores_gemma":[0.0032215777,0.99297166,0.00010781481,0.00008071696,0.0011426011,0.0011279923,0.000020976186,0.00010430271,0.0012223523],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935822,0.0011193007,0.002343433,0.0011402236,0.0009396507,0.0008751816],"domain_scores_gemma":[0.9949513,0.0028711543,0.00066876353,0.0007286244,0.00045061304,0.0003295083],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005096012,0.0004588871,0.0027812182,0.0004669187,0.0001446847,0.000052870775,0.00049876585,0.00055427814,0.0007304748],"category_scores_gemma":[0.00046673467,0.00035818308,0.0005424988,0.0012421305,0.0020238967,0.00006296892,0.00022052249,0.0022698005,0.000022323407],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001127916,0.00052512425,0.0042198836,0.05519702,0.0005757733,0.00014387185,0.00015472368,5.617988e-7,0.0018602049,0.000011897588,0.008855876,0.92732716],"study_design_scores_gemma":[0.0023961454,0.0016681782,0.0007901482,0.06416312,0.00044746517,0.000013368416,0.00006858286,0.000017660703,0.001698837,0.000021955815,0.9282327,0.00048181726],"about_ca_topic_score_codex":0.0028949778,"about_ca_topic_score_gemma":0.0011486404,"teacher_disagreement_score":0.9268453,"about_ca_system_score_codex":0.0004908446,"about_ca_system_score_gemma":0.0033836,"threshold_uncertainty_score":0.999887},"labels":[],"label_agreement":null},{"id":"W2884366738","doi":"10.3390/cancers10080242","title":"The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy","year":2018,"lang":"en","type":"review","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Tumor microenvironment; Ovarian cancer; Immunotherapy; Cancer research; Microvesicles; Immune system; Cancer immunotherapy; Cancer-Associated Fibroblasts; Cancer; Medicine; Antigen; Immunology; Biology; microRNA; Internal medicine; Gene","score_opus":0.024514932119570152,"score_gpt":0.32400644937706574,"score_spread":0.29949151725749557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884366738","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019601846,0.9774088,9.230591e-7,0.0004943397,0.00051937706,0.0016335712,0.00025637326,0.00001533982,0.00006941411],"genre_scores_gemma":[0.0003389107,0.9958428,0.000028151097,0.0013676812,0.00024633034,0.00044490965,0.0000049859354,0.00007024013,0.001655972],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998119,0.0001694302,0.0005927838,0.00046317626,0.0003023715,0.0003532559],"domain_scores_gemma":[0.9985344,0.00026598226,0.00038569712,0.00061850535,0.00005836823,0.00013708945],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006285821,0.00039914824,0.0010093357,0.00013887184,0.00016118985,0.000024807865,0.00029274405,0.00014158644,0.00012825523],"category_scores_gemma":[0.00007100682,0.00024765285,0.0003004778,0.00028432958,0.00032388707,0.000027669634,0.000050550956,0.00025346605,0.00003072253],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017637534,0.000018269397,0.0000052233827,0.0022901034,0.00084450684,0.0000148632425,0.00035407895,0.00000444473,0.005139523,0.000010843532,0.0019975584,0.971683],"study_design_scores_gemma":[0.0011642013,0.0009095825,0.0003603386,0.01346937,0.00025081096,0.000031942105,0.000025727668,0.0000010574292,0.0009142925,0.0000017381058,0.98262185,0.00024907727],"about_ca_topic_score_codex":0.00032729522,"about_ca_topic_score_gemma":0.000039294697,"teacher_disagreement_score":0.9806243,"about_ca_system_score_codex":0.0022815273,"about_ca_system_score_gemma":0.0018191332,"threshold_uncertainty_score":0.99999756},"labels":[],"label_agreement":null},{"id":"W2884860818","doi":"10.1016/j.clon.2018.07.001","title":"Science in Focus: Biological Optimisation of Radiotherapy Fraction Size in an Era of Immune Oncology","year":2018,"lang":"en","type":"editorial","venue":"Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; National Institute for Health and Care Research; Cancer Research UK; Royal Marsden NHS Foundation Trust","keywords":"Medicine; Context (archaeology); Scopus; Radiation therapy; Oncology; Computational biology; Internal medicine; Bioinformatics; Biology; MEDLINE","score_opus":0.07248629511679035,"score_gpt":0.4739328655901497,"score_spread":0.40144657047335935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884860818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6508631,0.0011589222,0.000033607535,0.00095242314,0.3454322,0.00075031514,0.000021317883,0.000019601426,0.0007684927],"genre_scores_gemma":[0.48549348,0.028114384,0.013133565,0.0007214189,0.47194546,0.00011778864,0.00021144506,0.00008022506,0.00018223614],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99451756,0.00095250906,0.0029468997,0.00074618356,0.0004504599,0.00038636226],"domain_scores_gemma":[0.9895527,0.007446922,0.0017352278,0.0005752366,0.0005607787,0.00012917239],"candidate_categories":["sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008164292,0.00025670056,0.0022774728,0.0004372411,0.000032631015,0.0000056251,0.00046827586,0.003271772,0.00046792458],"category_scores_gemma":[0.007988693,0.00020787606,0.0003306523,0.00091016374,0.0035452852,0.00012794418,0.00007566321,0.0019160123,0.0000037744753],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.096922,0.011461281,0.023303125,0.0001757573,0.0002578883,0.00011186855,0.00076308806,0.00000718111,0.09842193,0.00003354638,0.07778838,0.69075394],"study_design_scores_gemma":[0.024193082,0.08472056,0.20077239,0.0005451491,0.00009558112,0.00001417894,0.0002651249,0.00013581025,0.0014721113,0.00024553438,0.687181,0.00035946726],"about_ca_topic_score_codex":0.0007096777,"about_ca_topic_score_gemma":0.0005227853,"teacher_disagreement_score":0.69039446,"about_ca_system_score_codex":0.0016846544,"about_ca_system_score_gemma":0.007509131,"threshold_uncertainty_score":0.9991665},"labels":[],"label_agreement":null},{"id":"W2884928681","doi":"10.1016/j.eururo.2018.07.004","title":"Re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients’ Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018;19:737–46","year":2018,"lang":"en","type":"review","venue":"European Urology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Meta-analysis; Immunotherapy; Gynecology; Oncology; Internal medicine; Cancer","score_opus":0.07941094937152471,"score_gpt":0.3713891982163465,"score_spread":0.2919782488448218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884928681","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011611071,0.98883593,0.000024977422,0.0039128233,0.00019879639,0.0053093336,0.00034526337,0.00013488778,0.0012263726],"genre_scores_gemma":[0.000031990996,0.92684233,0.000077141034,0.07055781,0.00012704752,0.00041473398,0.00030948195,0.00020870115,0.0014307799],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921935,0.0033911876,0.0021904863,0.0012113509,0.0004035993,0.00060987426],"domain_scores_gemma":[0.995534,0.0005830928,0.0018152044,0.001614542,0.00019066563,0.0002624713],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031526883,0.001011436,0.010692002,0.00036725064,0.00013199984,0.00008539542,0.00047630313,0.00025196135,0.0009349318],"category_scores_gemma":[0.0002762701,0.00064667466,0.0018973514,0.00067141326,0.0004754163,0.00007990875,0.00019364861,0.00071997364,0.00007808099],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006203824,0.00031474908,0.000129694,0.44189763,0.3486933,0.00014265382,0.0003446618,2.2390537e-7,0.0000018875077,0.000014221852,0.18200321,0.025837373],"study_design_scores_gemma":[0.0015381818,0.00065188855,0.00009875888,0.0066280463,0.31341255,0.000073457864,0.000005174228,7.097593e-7,8.363309e-8,6.178229e-7,0.6771938,0.0003967198],"about_ca_topic_score_codex":0.00009756973,"about_ca_topic_score_gemma":0.00006345939,"teacher_disagreement_score":0.4951906,"about_ca_system_score_codex":0.00015965274,"about_ca_system_score_gemma":0.00025183934,"threshold_uncertainty_score":0.99997836},"labels":[],"label_agreement":null},{"id":"W2884973113","doi":"10.1007/s00281-018-0697-6","title":"Does patient age influence anti-cancer immunity?","year":2018,"lang":"en","type":"review","venue":"Seminars in Immunopathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"","keywords":"Immunosenescence; Medicine; Cancer; Antibody; Immunity; Immune system; Blockade; Immunology; Immune checkpoint; Clinical trial; Immunotherapy; Oncology; Internal medicine","score_opus":0.02229103082045222,"score_gpt":0.33881870968777394,"score_spread":0.31652767886732175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884973113","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.054333154,0.94170153,4.7125803e-7,0.000050657552,0.0019336465,0.0013272982,0.00009725751,0.00007814343,0.00047786994],"genre_scores_gemma":[0.0004303726,0.9956679,0.00017179982,0.00039498546,0.00018820913,0.00053753867,0.00019358132,0.00012041172,0.0022952312],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962281,0.0005243034,0.0014192348,0.0007962688,0.0002831271,0.0007489941],"domain_scores_gemma":[0.99751776,0.00019491825,0.0006730177,0.0014094465,0.000120397985,0.00008446779],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006952295,0.00074330956,0.0028064705,0.00067051855,0.00012614956,0.000033866014,0.0005765916,0.00093303795,0.00051021116],"category_scores_gemma":[0.00016653453,0.00045884782,0.00064706506,0.00082206255,0.0009657238,0.00010296489,0.00031220578,0.0012007941,0.00016049265],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031855222,0.00026755148,0.000410705,0.0077331117,0.0002519345,0.0012396578,0.0007302769,1.4193637e-7,0.0010753963,0.0000040719674,0.00056600483,0.9874026],"study_design_scores_gemma":[0.00081039843,0.0006883862,0.00091222936,0.042221695,0.0004118061,0.0008215008,0.00011494269,1.8206336e-7,0.00019676196,0.00001740057,0.95324624,0.0005584717],"about_ca_topic_score_codex":0.00019135534,"about_ca_topic_score_gemma":0.00003367657,"teacher_disagreement_score":0.9868441,"about_ca_system_score_codex":0.0006003306,"about_ca_system_score_gemma":0.0005601198,"threshold_uncertainty_score":0.9997863},"labels":[],"label_agreement":null},{"id":"W2885084852","doi":"10.7759/cureus.3089","title":"Abscopal Effect after Palliative Radiation Therapy for Metastatic Adenocarcinoma of the Esophagus","year":2018,"lang":"en","type":"article","venue":"Cureus","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abscopal effect; Radiation therapy; Adenocarcinoma; Esophagus; Lymph; Oncology; Cancer; Esophageal cancer; Immunotherapy; Pathology; Internal medicine","score_opus":0.020726669885313024,"score_gpt":0.3132924596900973,"score_spread":0.29256578980478426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885084852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95417684,0.043172173,0.00021802372,0.00043088954,0.0005337439,0.0012855654,0.000031489377,0.00001556844,0.0001357192],"genre_scores_gemma":[0.99837315,0.00016738319,0.00021997839,0.0005976352,0.00026006982,0.00014653009,0.000006448995,0.000015783013,0.00021304103],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993745,0.000054228472,0.00016624,0.0001343781,0.00013865453,0.00013198759],"domain_scores_gemma":[0.99942744,0.00011328873,0.00009988081,0.00025162188,0.00008017858,0.00002759721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001977036,0.00010403666,0.00018877594,0.000024274943,0.000048698934,0.000006706307,0.00008349002,0.000039167317,0.00022292805],"category_scores_gemma":[0.000048074442,0.000058754755,0.00017198062,0.0001229069,0.00014556746,0.000036568676,0.0000097594,0.00004617087,0.000006188813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04788484,0.0005023625,0.7487894,0.000453068,0.002520695,0.0000092982045,0.008018138,0.0000010820103,0.041004643,0.00021709448,0.008143894,0.14245546],"study_design_scores_gemma":[0.005450021,0.0028589265,0.8461503,0.00006951763,0.00013799983,0.000004771707,0.000036198177,0.0000765834,0.14288637,0.00014421632,0.0021056673,0.00007947272],"about_ca_topic_score_codex":0.00005466202,"about_ca_topic_score_gemma":0.000023376293,"teacher_disagreement_score":0.14237599,"about_ca_system_score_codex":0.00006246851,"about_ca_system_score_gemma":0.000067678,"threshold_uncertainty_score":0.24409059},"labels":[],"label_agreement":null},{"id":"W2885286334","doi":"10.1158/1538-7445.am2018-ct075","title":"Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Sunnybrook Health Science Centre; Centre Intégré de Santé et de Services Sociaux des Laurentides; Health Sciences Centre; Santé Montérégie","funders":"","keywords":"Carboplatin; Medicine; Pembrolizumab; Placebo; Internal medicine; Oncology; Pemetrexed; Tolerability; Nausea; Population; Interim analysis; Cisplatin; Clinical trial; Chemotherapy; Cancer; Adverse effect; Immunotherapy; Pathology","score_opus":0.20242464594605009,"score_gpt":0.4864854517590442,"score_spread":0.2840608058129941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885286334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792759,0.005496708,0.00017362532,0.0011832191,0.00030007743,0.012693554,0.00008999512,0.00005223068,0.0007347076],"genre_scores_gemma":[0.9894989,0.0035361385,0.00020817237,0.00019669978,0.0005619998,0.0032230788,0.00003668601,0.00009759316,0.0026407398],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995855,0.00032384216,0.0009929386,0.00077486964,0.0012234895,0.0008298817],"domain_scores_gemma":[0.99529564,0.0022530523,0.00031330352,0.00072944025,0.001103726,0.00030481067],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004102607,0.00041019832,0.0014222863,0.0006705037,0.0004366137,0.00009808259,0.00035452654,0.0001516417,0.0025273622],"category_scores_gemma":[0.0005395791,0.0002767956,0.00027095847,0.0009815183,0.0010507223,0.00017295472,0.000096230884,0.0005042614,0.00001631541],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9449865,0.0017373352,0.00007178399,0.00054158526,0.0018049092,0.000040482795,0.0039305207,0.0000074606955,0.012158276,0.000022397,0.0018618427,0.032836866],"study_design_scores_gemma":[0.95420414,0.013105188,0.00025091754,0.0004435728,0.00027446655,0.000035750738,0.0022833762,0.0005267515,0.02353289,0.00010261194,0.0049234233,0.00031691891],"about_ca_topic_score_codex":0.0041684965,"about_ca_topic_score_gemma":0.0016161044,"teacher_disagreement_score":0.032519944,"about_ca_system_score_codex":0.00036408534,"about_ca_system_score_gemma":0.0013921768,"threshold_uncertainty_score":0.9999684},"labels":[],"label_agreement":null},{"id":"W2885330205","doi":"10.1158/1538-7445.am2018-ct163","title":"Abstract CT163: KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Head and neck squamous-cell carcinoma; Placebo; Internal medicine; Head and neck cancer; Regimen; Oncology; Phases of clinical research; Chemoradiotherapy; Radiation therapy; Cancer; Urology; Surgery; Chemotherapy; Immunotherapy; Pathology","score_opus":0.04528575789131785,"score_gpt":0.36670612020297155,"score_spread":0.3214203623116537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885330205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883449,0.0051153633,0.0001368422,0.0024789872,0.0003014824,0.0017010863,0.000062875624,0.00005802384,0.0018004525],"genre_scores_gemma":[0.99495786,0.0005603265,0.000348839,0.0004892639,0.0011028169,0.00040638293,0.00009547281,0.00006864273,0.0019703936],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997626,0.000046184872,0.00037264737,0.0005943219,0.0006319601,0.000728861],"domain_scores_gemma":[0.9982801,0.00017846399,0.00012122759,0.0004431247,0.0007097285,0.00026734933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065207673,0.00023280752,0.000405769,0.00026058205,0.00034284475,0.000079206955,0.00017087195,0.00020412372,0.0003483935],"category_scores_gemma":[0.00014187698,0.0002214449,0.000109720015,0.00049698894,0.00037907792,0.0002524616,0.000047882728,0.00035209107,0.000034301447],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10973626,0.00039603197,0.006707124,0.002121319,0.00010451141,0.000041156018,0.002634843,0.00005108706,0.71110004,0.00003515686,0.02447992,0.14259256],"study_design_scores_gemma":[0.07695229,0.006052916,0.27973637,0.00035848445,0.00009659072,0.000046824687,0.00044252208,0.0037759128,0.56794643,0.00019866232,0.06367476,0.00071821845],"about_ca_topic_score_codex":0.0013504296,"about_ca_topic_score_gemma":0.0004497835,"teacher_disagreement_score":0.27302924,"about_ca_system_score_codex":0.0011381675,"about_ca_system_score_gemma":0.0011471648,"threshold_uncertainty_score":0.90302616},"labels":[],"label_agreement":null},{"id":"W2885416623","doi":"10.1158/1538-7445.am2018-4768","title":"Abstract 4768: Characteristics of patients diagnosed de novo with AJCC7 stage III or regionally advanced cutaneous melanoma and trends in adjuvant therapy: An analysis of the SEER cancer registry in the United States","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Ipilimumab; Systemic therapy; Melanoma; Internal medicine; Radiation therapy; Cancer registry; Cancer; Stage (stratigraphy); Oncology; Adjuvant therapy; Nivolumab; Dabrafenib; Adjuvant; Surgery; Breast cancer; Immunotherapy; Vemurafenib; Metastatic melanoma","score_opus":0.04965723613258807,"score_gpt":0.38306094428132687,"score_spread":0.33340370814873876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885416623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978514,0.0004777578,0.0000015227727,0.0007524449,0.000030868978,0.0004449796,0.0003780308,0.000005187136,0.000057860667],"genre_scores_gemma":[0.9945981,0.0043482464,0.000014402494,0.00035545853,0.00004074617,0.00012775049,0.00013000022,0.000020933932,0.00036439364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806297,0.00022165962,0.00038954173,0.00029059473,0.0006688922,0.00036636423],"domain_scores_gemma":[0.9984357,0.0002876852,0.00022290308,0.000536138,0.0004489027,0.00006871204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006573674,0.0001546832,0.00041091748,0.0006082383,0.00007945846,0.000019856636,0.00031518872,0.00008466727,0.0003647724],"category_scores_gemma":[0.000057673213,0.00007868307,0.00006147098,0.0027994735,0.00074871903,0.0000632763,0.00003520578,0.00034367686,9.7041486e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03463075,0.0005186986,0.8994998,0.000104120045,0.00058527925,0.000108387365,0.009064488,0.00009698548,0.009269405,0.0000062060417,0.0001374786,0.0459784],"study_design_scores_gemma":[0.0042913756,0.0010459543,0.987711,0.00032357255,0.00007567999,0.0000045560373,0.0018484782,0.00023703603,0.002329508,0.000003333272,0.0020261675,0.00010334394],"about_ca_topic_score_codex":0.018793002,"about_ca_topic_score_gemma":0.04680954,"teacher_disagreement_score":0.08821119,"about_ca_system_score_codex":0.00029659024,"about_ca_system_score_gemma":0.0004654342,"threshold_uncertainty_score":0.98774093},"labels":[],"label_agreement":null},{"id":"W2885490407","doi":"10.1158/1538-7445.am2018-ct001","title":"Abstract CT001: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Population; Hazard ratio; Ipilimumab; Melanoma; Interim analysis; Surgery; Placebo; Oncology; Nivolumab; Gastroenterology; Clinical trial; Cancer; Immunotherapy; Confidence interval; Pathology","score_opus":0.12376313014069187,"score_gpt":0.41874513784396916,"score_spread":0.2949820077032773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885490407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98950386,0.0016243893,0.000025091706,0.001605911,0.0011322018,0.0029545121,0.0013769367,0.000046576864,0.0017305295],"genre_scores_gemma":[0.99375045,0.0023330024,0.000034368404,0.000068685375,0.0024344898,0.00023750636,0.00016467359,0.00005004063,0.0009267999],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960358,0.0004053379,0.0008594167,0.00076141476,0.0012214942,0.0007165342],"domain_scores_gemma":[0.99622834,0.0015900745,0.00032211165,0.0010777251,0.0005507957,0.0002309634],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028952048,0.00029022386,0.00062364066,0.00024268856,0.0005396758,0.000097553464,0.00036187377,0.00025524912,0.0015477681],"category_scores_gemma":[0.00030219392,0.00020538045,0.00015913133,0.0006522326,0.0012744054,0.00015691314,0.0001761193,0.0010198442,0.000020964608],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95095944,0.00030477322,0.000058477544,0.000047495076,0.0006878556,0.000031065694,0.0016418487,0.000004061831,0.023742763,0.000021628728,0.0039493926,0.018551212],"study_design_scores_gemma":[0.91476524,0.0069372132,0.020756634,0.0003526376,0.000185547,0.0000039504644,0.00044809494,0.000076941484,0.016563326,0.000030463932,0.03961729,0.00026265113],"about_ca_topic_score_codex":0.04799245,"about_ca_topic_score_gemma":0.008134977,"teacher_disagreement_score":0.039857473,"about_ca_system_score_codex":0.0005430028,"about_ca_system_score_gemma":0.00076550856,"threshold_uncertainty_score":0.999365},"labels":[],"label_agreement":null},{"id":"W2885581930","doi":"10.1016/j.humpath.2018.07.024","title":"Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types","year":2018,"lang":"en","type":"article","venue":"Human Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"AstraZeneca","keywords":"Concordance; Tissue microarray; Immunohistochemistry; Head and neck squamous-cell carcinoma; Genitourinary system; Medicine; Pathology; PD-L1; Carcinoma; Antibody; Head and neck; Immunotherapy; Oncology; Head and neck cancer; Internal medicine; Cancer; Immunology","score_opus":0.01831126202199016,"score_gpt":0.3563426486502356,"score_spread":0.33803138662824544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885581930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909962,0.008041492,0.000028946139,0.00006254296,0.00011249598,0.0001817236,0.000021503438,0.000016017004,0.0005390801],"genre_scores_gemma":[0.9990218,0.00013016119,0.0003339133,0.000048068225,0.00009331913,0.000004512228,0.000037118305,0.000011744974,0.0003193268],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99895525,0.000052402844,0.00031364735,0.00047630124,0.000068168774,0.00013423811],"domain_scores_gemma":[0.9989956,0.000024515502,0.00015397069,0.00066846784,0.00012776363,0.000029658151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045744688,0.00010740587,0.00032864622,0.00003901434,0.00007018842,0.000003958206,0.000056068628,0.00011975355,0.00006560338],"category_scores_gemma":[0.000079605576,0.00009834035,0.000034956276,0.000064337735,0.0008714792,0.000031370797,0.00006921128,0.00009170721,0.0000012429333],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017411454,0.00009837863,0.07508639,0.00033401288,0.000052714648,0.000032606924,0.0032017059,4.584273e-8,0.913591,0.000014144527,0.00005526973,0.0057925675],"study_design_scores_gemma":[0.0011283712,0.0016753128,0.79211706,0.00009631599,0.0000654136,0.0005779967,0.00016092707,0.000007950505,0.20360638,0.00014824979,0.0003219379,0.00009408954],"about_ca_topic_score_codex":0.00028945354,"about_ca_topic_score_gemma":0.0000338152,"teacher_disagreement_score":0.71703064,"about_ca_system_score_codex":0.000024781053,"about_ca_system_score_gemma":0.00003620008,"threshold_uncertainty_score":0.40102032},"labels":[],"label_agreement":null},{"id":"W2885806694","doi":"10.1158/1557-3265.ovca17-ia23","title":"Abstract IA23: How does the immune system contend with intratumoral heterogeneity in ovarian cancer?","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Immune system; Biology; Ovarian cancer; Antibody; Antigen; Immunology; Cancer research; Cancer; Genetics","score_opus":0.1845318137194227,"score_gpt":0.4851670211719057,"score_spread":0.30063520745248296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885806694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9679496,0.005389872,0.000009110897,0.023333758,0.00092306355,0.0011670818,0.00005101001,0.00004418491,0.0011322715],"genre_scores_gemma":[0.99531263,0.0013618035,0.00003486299,0.0004613469,0.0017690414,0.00039298402,0.000006243786,0.000040267463,0.00062081584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99664336,0.00048748736,0.00065625156,0.00060461054,0.0008306978,0.0007776127],"domain_scores_gemma":[0.99766964,0.0005379496,0.00015827706,0.00080545427,0.0006015718,0.00022713158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004566342,0.00021431672,0.0005881046,0.0001300566,0.00028716147,0.00012708172,0.00046215896,0.00020796146,0.00042068516],"category_scores_gemma":[0.00019882838,0.0001044575,0.00018442245,0.0007451593,0.0021366256,0.000109578024,0.00011167134,0.001362596,0.000023189612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08228239,0.0009039847,0.69346255,0.0010963132,0.0015400883,0.00068994536,0.00092997187,0.0000026800112,0.04614947,0.0005769121,0.006885433,0.16548026],"study_design_scores_gemma":[0.0074751116,0.001665924,0.9457055,0.0015589901,0.00004928661,0.00003969418,0.0014187939,0.000100879806,0.02561692,0.00002174505,0.016105484,0.00024172626],"about_ca_topic_score_codex":0.01371496,"about_ca_topic_score_gemma":0.025737833,"teacher_disagreement_score":0.2522429,"about_ca_system_score_codex":0.0005990039,"about_ca_system_score_gemma":0.0011794069,"threshold_uncertainty_score":0.9928528},"labels":[],"label_agreement":null},{"id":"W2885832508","doi":"10.1158/1538-7445.am2018-5530","title":"Abstract 5530: PD-L1 expression in patients screened for phase 2 head and neck squamous cell carcinoma clinical studies (HAWK and CONDOR)","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Concordance; Medicine; Biopsy; Immunohistochemistry; Head and neck squamous-cell carcinoma; Oncology; Internal medicine; Pathology; Biomarker; Primary tumor; Cancer; Head and neck cancer; Metastasis; Biology","score_opus":0.19271039759958067,"score_gpt":0.510435567361243,"score_spread":0.3177251697616623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885832508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98653007,0.011239777,0.0000023247744,0.0005126958,0.00018592093,0.0012206627,0.000059533475,0.000012136984,0.00023685845],"genre_scores_gemma":[0.9969883,0.0016772901,0.00012796771,0.00025872016,0.00034525763,0.00017632252,0.000016457143,0.00002498047,0.00038468535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825686,0.00010251105,0.00039980735,0.00045037066,0.00034738897,0.0004430542],"domain_scores_gemma":[0.9986299,0.00043683557,0.00006483229,0.00025662038,0.0004303094,0.00018144787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011067692,0.00014157896,0.00036634828,0.00016216225,0.00019235161,0.000029637013,0.000088583954,0.00012656291,0.00009466905],"category_scores_gemma":[0.00024847654,0.000109731904,0.00005603664,0.00018219021,0.00078084733,0.00009086833,0.000099121076,0.00030090375,0.0000033852273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07153076,0.0012244524,0.7072557,0.0009356063,0.00007907969,0.000027405053,0.0017420595,1.1350903e-7,0.07472845,0.0000034536251,0.024707695,0.1177652],"study_design_scores_gemma":[0.050170302,0.007526364,0.8806983,0.00043321212,0.000023683633,0.0000018041185,0.00079503236,0.00002765577,0.04667493,0.00004154672,0.0134232035,0.0001839223],"about_ca_topic_score_codex":0.0005064949,"about_ca_topic_score_gemma":0.00036984653,"teacher_disagreement_score":0.17344262,"about_ca_system_score_codex":0.000155489,"about_ca_system_score_gemma":0.00021763942,"threshold_uncertainty_score":0.44747373},"labels":[],"label_agreement":null},{"id":"W2886184165","doi":"10.1158/1538-7445.am2018-ct182","title":"Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advanced <i>BRAF</i> V600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Dabrafenib; Trametinib; Biomarker; CD8; Peripheral blood mononuclear cell; Internal medicine; Melanoma; Gastroenterology; Oncology; Cancer; Immunology; Cancer research; Immune system; Metastatic melanoma; Biology; MAPK/ERK pathway; Vemurafenib","score_opus":0.025198491763443628,"score_gpt":0.32818624777733774,"score_spread":0.3029877560138941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886184165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924985,0.0017727079,0.000003709183,0.0022107868,0.00007354122,0.0030285981,0.0001369413,0.000020006231,0.00025519135],"genre_scores_gemma":[0.9967468,0.0026938457,0.00001806026,0.00011597101,0.000026824655,0.000130298,0.00018657531,0.00004906781,0.00003258413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970591,0.00027056213,0.0005902571,0.0006395837,0.00083120813,0.0006092862],"domain_scores_gemma":[0.9979232,0.00085553026,0.00019176966,0.00056863995,0.000340432,0.00012041975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00146521,0.00030714984,0.0005718118,0.00024325194,0.00029092733,0.00007922888,0.00027077223,0.00014534855,0.00018055123],"category_scores_gemma":[0.00012513006,0.0001654151,0.000045470315,0.0013335058,0.0018720744,0.00017920868,0.00010228922,0.00042310468,0.0000022748904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030816767,0.00069526746,0.943991,0.00011912432,0.00036453392,0.00003074032,0.0014071335,0.000002013242,0.008695424,0.0000129999735,0.00026534716,0.0135996705],"study_design_scores_gemma":[0.02369082,0.0015607623,0.96492064,0.0017081323,0.00007252309,0.000010699674,0.00031356193,0.00005466958,0.0045594615,0.000013225813,0.0028789816,0.00021651351],"about_ca_topic_score_codex":0.006330185,"about_ca_topic_score_gemma":0.007249151,"teacher_disagreement_score":0.02092967,"about_ca_system_score_codex":0.00023297312,"about_ca_system_score_gemma":0.0002816168,"threshold_uncertainty_score":0.95693886},"labels":[],"label_agreement":null},{"id":"W2886229095","doi":"10.1080/2162402x.2018.1498439","title":"Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy","year":2018,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"Canadian Institutes of Health Research","keywords":"TIGIT; Immune system; Immunotherapy; Immune checkpoint; Medicine; Head and neck squamous-cell carcinoma; Cancer research; Antigen; Immunology; HPV infection; T cell; Head and neck cancer; Cancer; Oncology; Internal medicine; Cervical cancer","score_opus":0.03692625881733523,"score_gpt":0.3077519065233821,"score_spread":0.27082564770604683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886229095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97625226,0.012512304,0.00053824286,0.005174097,0.0007493954,0.0013399553,0.0005899916,0.00012916025,0.0027145764],"genre_scores_gemma":[0.993052,0.002720709,0.00059301005,0.001013681,0.00037818283,0.00054265984,0.00041473858,0.00007507804,0.0012099192],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983234,0.00006170796,0.00039412468,0.00059252314,0.00009163714,0.0005366284],"domain_scores_gemma":[0.99844253,0.0002967456,0.00024083983,0.0007944686,0.00013284899,0.00009256875],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000097800425,0.00040536,0.0006490788,0.00010387996,0.00046765638,0.000067764726,0.00020314331,0.00025429082,0.00052752736],"category_scores_gemma":[0.000019421785,0.00030645166,0.00021491681,0.00016058136,0.00097460387,0.000110092624,0.000040668354,0.00013944083,0.000028523958],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028189855,0.0007728597,0.06969957,0.000051748724,0.0028036055,0.000010703432,0.0075020436,4.2093475e-7,0.37443337,0.00026418464,0.0038034031,0.5124682],"study_design_scores_gemma":[0.016330656,0.0048133633,0.56570154,0.00007287676,0.00021670277,0.00007061891,0.00047163147,0.000082905935,0.013156124,0.00046378156,0.39821434,0.00040541895],"about_ca_topic_score_codex":0.005201817,"about_ca_topic_score_gemma":0.0031179206,"teacher_disagreement_score":0.5120628,"about_ca_system_score_codex":0.0006980109,"about_ca_system_score_gemma":0.00051184034,"threshold_uncertainty_score":0.9999388},"labels":[],"label_agreement":null},{"id":"W2886686678","doi":"10.1158/1538-7445.am2018-4693","title":"Abstract 4693: Characterization of the tumor immune microenvironment in head and neck squamous cell carcinoma (SCCHN)","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Tumor microenvironment; Immune system; Immunohistochemistry; FOXP3; Head and neck squamous-cell carcinoma; CD20; Medicine; CD8; Cancer research; PD-L1; Tumor-infiltrating lymphocytes; Immunotherapy; Pathology; Immunology; Cancer; Internal medicine; Head and neck cancer","score_opus":0.03359121070307398,"score_gpt":0.3265311620853214,"score_spread":0.29293995138224743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886686678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955949,0.0019056424,7.014865e-7,0.0012007916,0.00011674435,0.0005731223,0.000021262253,0.0000045813135,0.0005822591],"genre_scores_gemma":[0.9985307,0.0003875677,0.00000887653,0.0001566292,0.00012703327,0.000054019823,0.000006622148,0.000017720558,0.0007108375],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99887544,0.00006044485,0.00024290397,0.00021148247,0.00032501054,0.00028473831],"domain_scores_gemma":[0.9994588,0.00003018049,0.00006713931,0.00032392336,0.000068500114,0.000051443385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040930105,0.000088830035,0.00016439678,0.00010821151,0.000089365676,0.000013192138,0.00013105645,0.00004866185,0.00055089005],"category_scores_gemma":[0.000015387779,0.00006310952,0.00004486511,0.000294356,0.0004702709,0.00004677644,0.00007977991,0.0002418966,0.000008716715],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013515339,0.00010557933,0.08038937,0.00015934987,0.0000061967203,0.000006389408,0.0005436625,1.2007429e-7,0.9130558,0.0000017299906,0.00010120033,0.0042790836],"study_design_scores_gemma":[0.0013425389,0.00020488547,0.5925771,0.000100526246,0.0000035955115,0.00000422373,0.000057897276,0.000005712484,0.402929,0.0000025131476,0.0027342045,0.00003779636],"about_ca_topic_score_codex":0.0023982355,"about_ca_topic_score_gemma":0.0002331323,"teacher_disagreement_score":0.5121877,"about_ca_system_score_codex":0.00026030862,"about_ca_system_score_gemma":0.00018904744,"threshold_uncertainty_score":0.60318595},"labels":[],"label_agreement":null},{"id":"W2886698194","doi":"10.1158/1538-7445.am2018-2503","title":"Abstract 2503: Rational design of small-molecule immune checkpoints' inhibitors","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Monoclonal antibody; Rational design; Small molecule; Cancer; Immunotherapy; Immune system; Cancer immunotherapy; Medicine; Cancer research; Antibody; Cancer cell; Immunology; Chemistry; Biology; Internal medicine; Biochemistry","score_opus":0.11384304322974825,"score_gpt":0.4063370127493758,"score_spread":0.29249396951962753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886698194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98758304,0.0036173444,0.0005220452,0.0021867617,0.0003392476,0.00080475723,0.000017062437,0.00003167039,0.004898051],"genre_scores_gemma":[0.9964885,0.00041921233,0.00044868828,0.00013013858,0.0006396571,0.00010348578,0.000011935147,0.000027401145,0.0017309538],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99834526,0.00008926462,0.00033764387,0.0002525153,0.00060654106,0.00036877458],"domain_scores_gemma":[0.9987022,0.0001210022,0.00007347985,0.00032945094,0.00067180925,0.00010200115],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013662227,0.000107864624,0.00021019686,0.00021637359,0.0001357753,0.000020654908,0.00016839622,0.000099313,0.0032079685],"category_scores_gemma":[0.00013177289,0.00009135146,0.00009849746,0.00054047635,0.0006717737,0.000056850768,0.000050919538,0.00029685846,0.00007703459],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035501346,0.00011377517,0.0005109787,0.00009154674,0.00012861984,0.0000106001025,0.00030969086,0.000002851707,0.97818375,0.00004566659,0.008309954,0.008742436],"study_design_scores_gemma":[0.0019523326,0.0006426855,0.02195819,0.000306299,0.000012618491,0.00000850671,0.0001346187,0.000051588275,0.9689959,0.00006942662,0.0057641016,0.00010369598],"about_ca_topic_score_codex":0.0010512896,"about_ca_topic_score_gemma":0.000053836662,"teacher_disagreement_score":0.021447212,"about_ca_system_score_codex":0.0002443118,"about_ca_system_score_gemma":0.00097010063,"threshold_uncertainty_score":0.99770325},"labels":[],"label_agreement":null},{"id":"W2886819625","doi":"10.1016/j.jgo.2018.07.015","title":"The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population","year":2018,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Pembrolizumab; Internal medicine; Population; Context (archaeology); Adverse effect; Immunotherapy; Oncology; Lung cancer; Cancer; Renal cell carcinoma","score_opus":0.012597394628385489,"score_gpt":0.3136205981020948,"score_spread":0.3010232034737093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886819625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953218,0.0014437039,0.000005660131,0.0016392911,0.000692954,0.000204503,5.628939e-7,0.0000026678958,0.0006888731],"genre_scores_gemma":[0.9981137,0.0010907104,0.0002484253,0.00007669622,0.00040506272,0.0000016076624,5.8374513e-7,0.0000064851197,0.000056750378],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986058,0.000109834604,0.00092954055,0.00007383856,0.00015347559,0.00012749751],"domain_scores_gemma":[0.9987378,0.00018881551,0.00078537286,0.00010340018,0.00013975792,0.0000448168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088198873,0.000072904746,0.00033255632,0.00022841638,0.000049205533,0.000005741986,0.00005211358,0.00007609234,0.000040023268],"category_scores_gemma":[0.00012911044,0.00004461299,0.000101598576,0.0003491948,0.00012377264,0.000044349454,0.000024894607,0.00016031506,5.91637e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027802713,0.0011803155,0.10956368,0.00008178335,0.00030275766,0.00007059221,0.0035578127,0.0000041130247,0.25832066,0.00005353607,0.001997626,0.59706444],"study_design_scores_gemma":[0.005509971,0.00470674,0.96699333,0.0001013424,0.00006619943,0.00015613294,0.00020486083,0.000014185779,0.014944119,0.000067823166,0.00718056,0.000054706135],"about_ca_topic_score_codex":0.00042378192,"about_ca_topic_score_gemma":0.000357686,"teacher_disagreement_score":0.8574297,"about_ca_system_score_codex":0.00027270193,"about_ca_system_score_gemma":0.00017024594,"threshold_uncertainty_score":0.18192649},"labels":[],"label_agreement":null},{"id":"W2887292684","doi":"10.1097/pai.0000000000000698","title":"Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced Lung Non–Small Cell Lung Carcinomas","year":2018,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Biopsy; Internal medicine; Lung; Oncology; Sampling (signal processing); Immunohistochemistry; Cancer; Immunotherapy; Computer science","score_opus":0.01164686152847724,"score_gpt":0.28481472023975557,"score_spread":0.27316785871127836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887292684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806518,0.0022515832,0.0017254209,0.00017482544,0.00040271194,0.0011122491,0.000022378708,0.00005319373,0.013605869],"genre_scores_gemma":[0.9912966,0.00005694843,0.0052647963,0.0010447326,0.00007087839,0.00030996616,0.0001296334,0.00008897817,0.0017374816],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99726146,0.00004137315,0.00083501445,0.0008608048,0.00027084618,0.0007304769],"domain_scores_gemma":[0.9980979,0.00004730607,0.00033114708,0.001171809,0.00017656249,0.00017529332],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002620468,0.00049405335,0.000827221,0.00023927185,0.000088711175,0.00001539011,0.0004896829,0.00042161005,0.00028907732],"category_scores_gemma":[0.000028818687,0.000534562,0.00023891704,0.0005770612,0.00046035758,0.000026884167,0.00021564915,0.00044192508,0.000024649538],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003970592,0.00022843761,0.001831655,0.00035937695,0.00019003729,0.00015752565,0.0005201981,0.000008612823,0.9906323,0.000014984388,0.0007416541,0.0013446065],"study_design_scores_gemma":[0.0058615403,0.00044770318,0.01194543,0.00018039877,0.00017238304,0.00012182838,0.00049457396,0.00005784574,0.9795769,0.000013638797,0.0006579268,0.00046981702],"about_ca_topic_score_codex":0.00030817345,"about_ca_topic_score_gemma":0.0000030659494,"teacher_disagreement_score":0.011868387,"about_ca_system_score_codex":0.00060117757,"about_ca_system_score_gemma":0.0003849998,"threshold_uncertainty_score":0.9997106},"labels":[],"label_agreement":null},{"id":"W2887998811","doi":"10.3747/co.25.3976","title":"Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung Cancer","year":2018,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba; University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Malignancy; PD-L1; Immunotherapy; Clinical trial; Monoclonal antibody; Oncology; Disease; Targeted therapy; Internal medicine; Cancer; Blockade; Immune checkpoint; Antibody; Immunology; Receptor","score_opus":0.15336242665102887,"score_gpt":0.46283817367511737,"score_spread":0.30947574702408853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887998811","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013472077,0.98881656,0.00018291893,0.00040498492,0.005100057,0.004848198,0.00016737047,0.000016930528,0.00032827558],"genre_scores_gemma":[0.000016918615,0.99350303,0.00008530202,0.00008740093,0.0023940823,0.0027770908,0.00013410632,0.00005406833,0.00094800035],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980973,0.00016132675,0.0007826085,0.00040551246,0.00014749165,0.00040573816],"domain_scores_gemma":[0.99742615,0.0010341475,0.000760265,0.0005527086,0.00016563636,0.00006109598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000493971,0.00042213188,0.0015888076,0.00008305124,0.00019093373,0.000011058533,0.00034613025,0.00029674743,0.00031144283],"category_scores_gemma":[0.000032207765,0.00018621385,0.0010879502,0.00022603926,0.00031568916,0.000012755456,0.000044467957,0.00024394169,0.000010374871],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004177564,0.00054803106,0.000058616308,0.009931548,0.0010688726,0.0000017511262,0.0006370137,2.708701e-7,0.00000905775,0.0000028076877,0.031418487,0.9559058],"study_design_scores_gemma":[0.0022858777,0.0017440319,0.000022721564,0.0037930177,0.0050600544,0.000013719339,0.00010089403,0.00009626975,0.000025146392,0.0000016424151,0.9866791,0.00017755314],"about_ca_topic_score_codex":0.0001449028,"about_ca_topic_score_gemma":0.00008072966,"teacher_disagreement_score":0.95572823,"about_ca_system_score_codex":0.0010678887,"about_ca_system_score_gemma":0.0014358049,"threshold_uncertainty_score":0.75935805},"labels":[],"label_agreement":null},{"id":"W2888614982","doi":"10.1007/s00262-018-2231-z","title":"PD-1/PD-L1 co-inhibition shapes anticancer T cell immunodominance: facing the consequences of an immunological ménage à trois","year":2018,"lang":"fr","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Immunodominance; Virology; Biology; Immune system; Immunology; T cell","score_opus":0.025520738549925176,"score_gpt":0.3199907870929124,"score_spread":0.2944700485429872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888614982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5686856,0.41563603,0.0004393684,0.0051024696,0.0059426515,0.0014714049,0.0005104957,0.00015763596,0.0020543395],"genre_scores_gemma":[0.7722857,0.21550596,0.0005876972,0.0038773245,0.0015877549,0.0004573551,0.00011771378,0.0002104987,0.0053699915],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9910197,0.0016336716,0.0025356396,0.0015770728,0.0008456205,0.0023882783],"domain_scores_gemma":[0.9939516,0.00076489314,0.0018016434,0.0021579876,0.0011442074,0.00017962763],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","sts"],"category_scores_codex":[0.0022007027,0.0014249576,0.002201739,0.00048480296,0.0014069367,0.00019591949,0.0016407437,0.0014931641,0.013859473],"category_scores_gemma":[0.00014696173,0.0011166466,0.0010076785,0.0014341846,0.016363975,0.00092576485,0.00019884117,0.0017998058,0.0003619168],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020197092,0.0009278371,0.00092833274,0.00022374924,0.002520509,0.00007343627,0.0053110505,0.000013023542,0.8007598,0.00064509007,0.0016204616,0.1667796],"study_design_scores_gemma":[0.014308422,0.0073299184,0.033990726,0.0020561672,0.00058648735,0.00054616545,0.0059115617,0.00016616413,0.7882377,0.00059338636,0.14491418,0.0013591269],"about_ca_topic_score_codex":0.0076664393,"about_ca_topic_score_gemma":0.0002218343,"teacher_disagreement_score":0.2036001,"about_ca_system_score_codex":0.001346994,"about_ca_system_score_gemma":0.0017552326,"threshold_uncertainty_score":0.99989307},"labels":[],"label_agreement":null},{"id":"W2888679740","doi":"10.14740/jmc.v9i9.3131","title":"Pembrolizumab-Induced Hepatitis and Pancreatitis in a Patient With Stage IV Non-Small Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Nausea; Pembrolizumab; Vomiting; Acute pancreatitis; Internal medicine; Toxic hepatitis; Gastroenterology; Pancreatitis; Cancer; Hepatitis; Immunotherapy","score_opus":0.014850809918831994,"score_gpt":0.28535214945055326,"score_spread":0.2705013395317213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888679740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944657,0.00316644,0.000047566817,0.0014699472,0.00022871754,0.00018329325,0.000010848808,0.000005135957,0.00042236142],"genre_scores_gemma":[0.9932663,0.004710791,0.00019068268,0.0012698977,0.00042078007,0.000009097496,0.000001199702,0.000016024174,0.000115220675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984673,0.000049721635,0.000428887,0.0001303344,0.0007121486,0.00021157623],"domain_scores_gemma":[0.99908406,0.00012136326,0.0002389459,0.000104882136,0.00016063539,0.00029012832],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030496047,0.00013021452,0.00037407994,0.00014234018,0.000042853793,0.000018614328,0.000077410165,0.00011043519,0.0009898049],"category_scores_gemma":[0.00011404377,0.00008363834,0.00006238076,0.00016806908,0.00014893139,0.00007052287,0.000024304716,0.00030706363,9.932312e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012747101,0.00059746206,0.8191175,0.00059198105,0.00037267635,0.03400753,0.0037695824,8.9452965e-7,0.006755888,0.0000054897755,0.007938381,0.11409555],"study_design_scores_gemma":[0.043105204,0.027556464,0.8318636,0.009683021,0.00060478505,0.031006934,0.0022065812,0.0011863792,0.029499948,0.000008323868,0.022622146,0.0006566408],"about_ca_topic_score_codex":0.004765904,"about_ca_topic_score_gemma":0.0040860856,"teacher_disagreement_score":0.113438904,"about_ca_system_score_codex":0.00014942656,"about_ca_system_score_gemma":0.0006950184,"threshold_uncertainty_score":0.9999234},"labels":[],"label_agreement":null},{"id":"W2889599863","doi":"10.1200/jco.2017.35.15_suppl.tps3113","title":"INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Immunogenicity; Agonist; Immunotherapy; Pharmacokinetics; Antibody; CD28; Pharmacodynamics; Internal medicine; Oncology; Biomarker; Cytokine release syndrome; Cancer; Pharmacology; T cell; Immunology; Immune system; Chimeric antigen receptor; Adverse effect; Receptor","score_opus":0.12653220019038627,"score_gpt":0.5105342624420508,"score_spread":0.38400206225166456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889599863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783367,0.000049623348,0.0000054665124,0.00072596164,0.00016825553,0.0009857413,0.000004353248,0.0000022047723,0.00022473022],"genre_scores_gemma":[0.99903506,0.00008235072,0.0005328304,0.00025111213,0.00004710667,0.000009187332,0.000007366752,0.000016586426,0.000018419374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970352,0.0003299623,0.0018785383,0.0002404567,0.00033088046,0.00018492743],"domain_scores_gemma":[0.9959564,0.0002277011,0.0029342703,0.0003475838,0.00035359387,0.00018041738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017904518,0.00015292618,0.001620632,0.00018207794,0.00007301626,0.000036958285,0.00032452884,0.0001584856,0.000010874004],"category_scores_gemma":[0.0004950457,0.000100960606,0.000040498504,0.00011388206,0.00034472268,0.00046928664,0.00008238434,0.00057441,2.1041913e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2553465,0.054511543,0.58230513,0.000024542634,0.00017820255,0.00041861364,0.0004024548,0.000001021862,0.00045587716,0.0000027598321,0.000008409718,0.10634497],"study_design_scores_gemma":[0.24493602,0.15815191,0.59592694,0.00028855496,0.00007701611,0.00004772008,0.00032940495,0.000028909446,0.00005667352,0.000011866765,0.00007188776,0.000073118026],"about_ca_topic_score_codex":0.00017906411,"about_ca_topic_score_gemma":0.0016555991,"teacher_disagreement_score":0.10627185,"about_ca_system_score_codex":0.00011617716,"about_ca_system_score_gemma":0.0010293052,"threshold_uncertainty_score":0.41170537},"labels":[],"label_agreement":null},{"id":"W2889696341","doi":"10.1200/jco.2017.35.15_suppl.tps3621","title":"The CCTG CO.26 trial: A phase II randomized study of durvalumab plustremelimumab and best supportive care (BSC) vs BSC alone in patients with advanced colorectal carcinoma (CRC) refractory to standard therapies.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; University of Ottawa; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Durvalumab; Irinotecan; Tremelimumab; Internal medicine; Oncology; Colorectal cancer; Pembrolizumab; Oxaliplatin; Cancer; Immunotherapy; Ipilimumab","score_opus":0.05437149275475614,"score_gpt":0.44329688858097105,"score_spread":0.3889253958262149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889696341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99357545,0.0008360903,0.000005516733,0.0014216525,0.00086153223,0.0030977342,0.000026543143,0.000005582597,0.00016991605],"genre_scores_gemma":[0.9985307,0.0007151243,0.00021288324,0.00019289415,0.00022864014,0.0000471226,0.000003120447,0.000030449564,0.000039076058],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948826,0.0010587338,0.0028109178,0.00028456212,0.0006753407,0.00028787268],"domain_scores_gemma":[0.9921281,0.0024224934,0.0037987884,0.00042669318,0.0009670637,0.00025686057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044890135,0.00023564498,0.0029663052,0.00014022063,0.0002795731,0.000026566757,0.00030895002,0.00024181667,0.000039576465],"category_scores_gemma":[0.003844108,0.00012754435,0.0003692969,0.00009354654,0.0008674446,0.00015476145,0.00008559191,0.00076024316,5.965409e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82656646,0.006940631,0.047496963,0.000016287842,0.00096357206,0.00013742488,0.003932454,8.3705794e-7,0.0000632971,0.0000013410139,0.00014907477,0.11373167],"study_design_scores_gemma":[0.602886,0.24273838,0.14750066,0.000114829694,0.0003661675,0.000009554287,0.004066376,0.0000017302236,0.00006404834,0.000009183083,0.0021514383,0.00009160558],"about_ca_topic_score_codex":0.00019159411,"about_ca_topic_score_gemma":0.0011826275,"teacher_disagreement_score":0.23579775,"about_ca_system_score_codex":0.0003443197,"about_ca_system_score_gemma":0.0017145097,"threshold_uncertainty_score":0.5201108},"labels":[],"label_agreement":null},{"id":"W2889835879","doi":"10.4251/wjgo.v10.i9.221","title":"Immune blockade inhibitors and the radiation abscopal effect in gastrointestinal cancers","year":2018,"lang":"en","type":"editorial","venue":"World Journal of Gastrointestinal Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Essar Steel Algoma (Canada); Sault Area Hospital; NOSM University","funders":"","keywords":"Medicine; Immune system; Blockade; Abscopal effect; Immune checkpoint; Radiation therapy; Cancer; Cancer research; Immunotherapy; Melanoma; Immunology; Receptor; Internal medicine","score_opus":0.0060907739502511875,"score_gpt":0.2861549433960556,"score_spread":0.2800641694458044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889835879","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14639743,0.01883659,0.00031240194,0.01558276,0.8114151,0.0033665202,0.00008252129,0.00008943243,0.0039172648],"genre_scores_gemma":[0.051514417,0.0011879831,0.0064988667,0.0004658291,0.93841106,0.00006152901,0.00006350047,0.0001684376,0.0016283613],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99537486,0.00075136195,0.0019434182,0.00039937763,0.00088598003,0.000645006],"domain_scores_gemma":[0.99244076,0.003947503,0.002449643,0.00031192557,0.0006032016,0.00024697403],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0044459063,0.00056388695,0.0018873987,0.0009368519,0.00012705453,0.000058861642,0.00037838714,0.00021910391,0.00013420988],"category_scores_gemma":[0.0031882117,0.0003701011,0.00054540904,0.00057689723,0.0014801526,0.0001164691,0.00010216366,0.003086163,0.000007634838],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.123560496,0.00019578448,0.011251734,0.00031901494,0.00027615557,0.002051352,0.00024178985,0.00002098244,0.0036205621,0.0000073193514,0.8426924,0.015762437],"study_design_scores_gemma":[0.087068744,0.052500933,0.018370828,0.023712061,0.0014573771,0.047735065,0.00026136066,0.00019240931,0.0005506292,0.00013831827,0.7672947,0.0007175654],"about_ca_topic_score_codex":0.0007564066,"about_ca_topic_score_gemma":0.0011826649,"teacher_disagreement_score":0.126996,"about_ca_system_score_codex":0.0024380127,"about_ca_system_score_gemma":0.0034327647,"threshold_uncertainty_score":0.99987507},"labels":[],"label_agreement":null},{"id":"W2889956317","doi":"10.2174/1389450119666180911093143","title":"The Value of Biomarkers in Optimizing the Use of Immuno-oncologic Therapy","year":2018,"lang":"en","type":"article","venue":"Current Drug Targets","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Biomarker; Intensive care medicine; Immunotherapy; Value (mathematics); Precision medicine; Cancer; Internal medicine; Pathology; Computer science","score_opus":0.06221978956576248,"score_gpt":0.32591000633438993,"score_spread":0.2636902167686275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889956317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94463164,0.050909832,0.000058949,0.0017977012,0.0014763217,0.00078889204,0.000011850743,0.000020566915,0.00030423084],"genre_scores_gemma":[0.9863518,0.012738309,0.00047489445,0.00019208487,0.00012106244,0.000032665946,0.000008154458,0.000017260003,0.00006376735],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986343,0.00018044314,0.00048640138,0.0001797165,0.00025170416,0.00026746653],"domain_scores_gemma":[0.9986966,0.0003941719,0.0002611371,0.0004799278,0.00013640216,0.000031754495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008172235,0.00015241907,0.00028238038,0.00008630176,0.00013276056,0.000016116779,0.0002656531,0.000050005612,0.00006527084],"category_scores_gemma":[0.00010921293,0.00007558013,0.00018648326,0.0003810892,0.00076488644,0.000073407275,0.00005559222,0.0001674728,0.0000035806804],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014624578,0.0011922714,0.038820557,0.0001700235,0.001324666,0.000006777758,0.009323116,0.000051719184,0.16395955,0.00046526387,0.030795572,0.7392659],"study_design_scores_gemma":[0.008941287,0.0011749499,0.13780458,0.00086438865,0.00011028577,0.000018298668,0.0017153523,0.002372818,0.15499705,0.00030100349,0.69130945,0.00039053286],"about_ca_topic_score_codex":0.00021605525,"about_ca_topic_score_gemma":0.00003556881,"teacher_disagreement_score":0.7388754,"about_ca_system_score_codex":0.00007973134,"about_ca_system_score_gemma":0.0001454655,"threshold_uncertainty_score":0.30820683},"labels":[],"label_agreement":null},{"id":"W2889975327","doi":"10.1080/2162402x.2018.1504728","title":"Somatic mutation-associated T follicular helper cell elevation in lung adenocarcinoma","year":2018,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Occupational Cancer Research Centre","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"Germinal center; Biology; Immune system; B cell; Lung cancer; Adenocarcinoma; Immunology; Immunohistochemistry; Cancer research; Follicular phase; Affinity maturation; Antigen; Follicular dendritic cells; Cancer; T cell; Pathology; Antibody; Medicine; Antigen-presenting cell","score_opus":0.010534164007506785,"score_gpt":0.26721513923945933,"score_spread":0.25668097523195255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889975327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252343,0.0027245693,0.00010810112,0.00095252757,0.0003293908,0.00036212866,0.0000025439856,0.00006235599,0.0029349383],"genre_scores_gemma":[0.99745744,0.00009521598,0.00020804818,0.00066594343,0.00006485444,0.00004249931,0.00006713115,0.000022609029,0.0013762786],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998909,0.000096296644,0.0003482156,0.00022414552,0.00013478822,0.0002875811],"domain_scores_gemma":[0.9994114,0.000060445615,0.00013457928,0.00025728357,0.000109549685,0.000026746846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024142266,0.00013414619,0.00027521234,0.00020796015,0.00007374479,0.00001088758,0.00008829883,0.00020852924,0.0005717298],"category_scores_gemma":[0.00007636259,0.00012541011,0.000082204155,0.00041482953,0.00014499703,0.00007759204,0.000021480333,0.00015855972,0.00013755026],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022172807,0.0009158025,0.34803882,0.0001455081,0.0005180817,0.00020638095,0.0058624377,0.000002652851,0.6281429,0.00016472675,0.0018648056,0.011920594],"study_design_scores_gemma":[0.0070034117,0.0009956696,0.96339506,0.00013538351,0.00008077468,0.00008161428,0.00060983025,0.00079312775,0.024617327,0.00018860052,0.0019092591,0.00018992188],"about_ca_topic_score_codex":0.00051225664,"about_ca_topic_score_gemma":0.00024134787,"teacher_disagreement_score":0.61535627,"about_ca_system_score_codex":0.00038635932,"about_ca_system_score_gemma":0.00016034782,"threshold_uncertainty_score":0.62600404},"labels":[],"label_agreement":null},{"id":"W2890134385","doi":"10.1007/s00262-018-2244-7","title":"Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy","year":2018,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"Novartis Pharma; Klaus Tschira Stiftung; Roche; Merck Sharp and Dohme; Bristol-Myers Squibb","keywords":"Nivolumab; Pembrolizumab; Antibody; Immunotherapy; Flow cytometry; PD-L1; Medicine; Immunology; T cell; Mass cytometry; Immune system; Cancer research; Biology; Phenotype; Biochemistry","score_opus":0.027958930338670026,"score_gpt":0.3176974800295449,"score_spread":0.28973854969087487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890134385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830969,0.011511394,0.0003273011,0.0006581934,0.0021319184,0.0011491027,0.00005572457,0.000109779015,0.0009596706],"genre_scores_gemma":[0.98564255,0.011365783,0.00028663225,0.0016978367,0.0001699253,0.00016501917,0.00006040463,0.00012605762,0.00048575946],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965898,0.00025257058,0.0012607594,0.00074954866,0.00041034474,0.0007369888],"domain_scores_gemma":[0.99728775,0.00013680634,0.0007453315,0.0013242824,0.00044765658,0.00005818905],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00051509525,0.000537659,0.0009923382,0.00066013733,0.00021200234,0.000042347256,0.0005300927,0.00044800038,0.0012421092],"category_scores_gemma":[0.00003195991,0.0004872079,0.00031989272,0.00088973175,0.001056666,0.00026387346,0.000042299813,0.00049842923,0.00008092821],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02126118,0.0010060419,0.024603652,0.000042986198,0.0007321902,0.0000038232374,0.0013228813,0.0000142257095,0.857408,0.00008928485,0.00066588854,0.09284984],"study_design_scores_gemma":[0.015324825,0.0023098625,0.46414706,0.0005965618,0.000030270896,0.0000056635595,0.00015639086,0.00004668207,0.49400496,0.000048503884,0.022888802,0.0004404127],"about_ca_topic_score_codex":0.0006501049,"about_ca_topic_score_gemma":0.00003070541,"teacher_disagreement_score":0.43954343,"about_ca_system_score_codex":0.00048717554,"about_ca_system_score_gemma":0.00035637547,"threshold_uncertainty_score":0.99975795},"labels":[],"label_agreement":null},{"id":"W2890146145","doi":"10.1200/jco.2017.35.15_suppl.e21064","title":"Retrospective analysis of ipilimumab-induced diarrhea and/or colitis: A single centre review.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Clinical Oncology Group; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Ipilimumab; Medicine; Diarrhea; Internal medicine; Colitis; Discontinuation; Gastroenterology; Cancer","score_opus":0.1453140435504841,"score_gpt":0.4877604757531635,"score_spread":0.3424464322026794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890146145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97529846,0.0035842217,0.000011242396,0.017132748,0.0007057531,0.00019973468,0.000010553436,0.0000038693674,0.003053384],"genre_scores_gemma":[0.9783257,0.018091548,0.0004051326,0.002364631,0.0004024143,0.0000010611277,0.0000013603028,0.0000081511425,0.00039999667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970975,0.00027708465,0.0020178605,0.0001648129,0.00028234583,0.00016043184],"domain_scores_gemma":[0.99466515,0.0007130629,0.0034805443,0.00036703763,0.00055051275,0.0002236669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031217672,0.00010571522,0.0022943406,0.00013840714,0.00006767352,0.000010624487,0.00018159788,0.00024152486,0.00039199553],"category_scores_gemma":[0.0074215718,0.00006716189,0.0008754438,0.00018229178,0.00033471728,0.00009776772,0.000046953246,0.00045362127,0.0000014794256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046589453,0.003058253,0.5506406,0.0003943403,0.014335755,0.0007869197,0.00026293125,2.675937e-7,0.0029090086,0.00008240822,0.010340879,0.37059918],"study_design_scores_gemma":[0.0069883685,0.00951195,0.9541302,0.00097167987,0.004781612,0.00009220809,0.00006486249,0.000020555679,0.00020577712,0.00005318695,0.023106132,0.00007346643],"about_ca_topic_score_codex":0.00005220566,"about_ca_topic_score_gemma":0.00039273326,"teacher_disagreement_score":0.4034896,"about_ca_system_score_codex":0.00016969515,"about_ca_system_score_gemma":0.0007397621,"threshold_uncertainty_score":0.8884851},"labels":[],"label_agreement":null},{"id":"W2890208257","doi":"10.1200/jco.2018.36.15_suppl.e21577","title":"Pembrolizumab-induced immune related adverse events and survival outcomes in advanced melanoma.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Adverse effect; Internal medicine; Hazard ratio; Multivariate analysis; Pneumonitis; Lactate dehydrogenase; Melanoma; Gastroenterology; Immunotherapy; Cancer; Confidence interval","score_opus":0.07655993975475398,"score_gpt":0.45488470605453935,"score_spread":0.3783247662997854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890208257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894603,0.0004044331,0.0000051389684,0.004377217,0.0027561786,0.00016847246,0.0000011291255,0.000008081943,0.0028190818],"genre_scores_gemma":[0.9970028,0.0007311159,0.0005781087,0.00080668816,0.00029940854,0.0000016611156,0.0000010155907,0.00001480287,0.0005644393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99637693,0.00038346797,0.0025832045,0.0001738778,0.0002566496,0.00022586172],"domain_scores_gemma":[0.9971471,0.0009460174,0.0013022816,0.00018088473,0.00022873115,0.0001950007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032523868,0.00013692777,0.0014741082,0.00016283989,0.00003397047,0.0000018865499,0.0001269029,0.00039155295,0.00021539933],"category_scores_gemma":[0.0018931061,0.000094957846,0.00041003706,0.00017130909,0.00022416367,0.00012297831,0.000044760403,0.0007412203,0.000015040402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043685064,0.0011865817,0.7866551,0.00001753066,0.00072335434,0.0004462401,0.00023915213,6.2208636e-7,0.006336953,0.000039449165,0.0001046193,0.16056533],"study_design_scores_gemma":[0.03394854,0.013898303,0.94340163,0.00011564298,0.00011766279,0.00028075016,0.00017688329,0.00001796039,0.00019231069,0.00019196825,0.00756563,0.00009272258],"about_ca_topic_score_codex":0.000048441405,"about_ca_topic_score_gemma":0.00012370145,"teacher_disagreement_score":0.16047262,"about_ca_system_score_codex":0.00015350184,"about_ca_system_score_gemma":0.00072086556,"threshold_uncertainty_score":0.38722685},"labels":[],"label_agreement":null},{"id":"W2890261294","doi":"10.1093/annonc/mdz135","title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":840,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"Merck Sharp and Dohme; National Institute for Health and Care Research; Merck","keywords":"Medicine; Pembrolizumab; Ovarian cancer; Oncology; Internal medicine; Cancer; Phases of clinical research; Gynecology; Chemotherapy; Immunotherapy","score_opus":0.03553001180780957,"score_gpt":0.3693015059763449,"score_spread":0.33377149416853535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890261294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951013,0.00046734826,0.0000014806049,0.0023594298,0.00017547594,0.0011796445,0.00029022666,0.0000055911255,0.00041953352],"genre_scores_gemma":[0.99887806,0.00069375674,0.000031224026,0.00028806657,0.000024249359,0.0000168302,0.000027673448,0.000008972296,0.000031166044],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99886173,0.00014127849,0.00038078567,0.0002594382,0.0001877252,0.00016901831],"domain_scores_gemma":[0.99894744,0.0001988833,0.00035431175,0.00031886186,0.00014136653,0.000039136397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003516461,0.00012159128,0.000505354,0.00006181496,0.000037567785,0.0000020611285,0.00009457162,0.00006336725,0.000059419257],"category_scores_gemma":[0.00005291757,0.000076712575,0.000045311484,0.0001885993,0.00012781279,0.000070038084,0.000052159947,0.00015530946,4.9530905e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36108613,0.005710503,0.1525756,0.000029461302,0.0003124589,0.0000070081587,0.0023990797,0.00000692178,0.003527343,0.0000052099326,0.0002345242,0.47410578],"study_design_scores_gemma":[0.07304067,0.03593862,0.8835418,0.00018804135,0.000048045942,9.0663184e-7,0.00027665106,0.000014555674,0.0019945567,0.000007711286,0.0048671314,0.00008127078],"about_ca_topic_score_codex":0.0026529806,"about_ca_topic_score_gemma":0.0013165121,"teacher_disagreement_score":0.73096627,"about_ca_system_score_codex":0.00005616922,"about_ca_system_score_gemma":0.00025195166,"threshold_uncertainty_score":0.40105307},"labels":[],"label_agreement":null},{"id":"W2890296921","doi":"10.1038/s41392-018-0022-9","title":"The intracellular signalosome of PD-L1 in cancer cells","year":2018,"lang":"en","type":"review","venue":"Signal Transduction and Targeted Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":290,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Fundación Española para la Ciencia y la Tecnología; Universidad Pública de Navarra; Instituto de Salud Carlos III; Ministerio de Economía y Competitividad","keywords":"Intracellular; Cancer; Biology; Chemistry; Cell biology; Computational biology; Genetics","score_opus":0.04542014459269217,"score_gpt":0.32253754590274536,"score_spread":0.2771174013100532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890296921","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001160994,0.9967057,0.0000366571,0.00018658671,0.00060621696,0.0011429755,0.000051720606,0.000025521025,0.00008361922],"genre_scores_gemma":[0.0012796004,0.9975415,0.0000331356,0.00007866143,0.0004227154,0.0001251353,0.000038767557,0.00005482028,0.00042569384],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99806494,0.00021930363,0.00076922047,0.00038220137,0.00026705788,0.0002972539],"domain_scores_gemma":[0.9991742,0.000111589645,0.0002848911,0.00026003853,0.00008786702,0.000081418424],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004912562,0.00037720005,0.0010962096,0.00022563442,0.00011463923,0.000023641578,0.000143321,0.000319789,0.0012117982],"category_scores_gemma":[0.0000027275867,0.0002268415,0.0004796241,0.0005578509,0.00042396286,0.000054043223,0.0000056876625,0.00041853767,0.0000057383854],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015371913,0.00015367015,0.000005035927,0.0024287996,0.0007756828,0.0000068736654,0.00030036233,5.1819836e-7,0.016430166,0.00002203695,0.00026597976,0.97807366],"study_design_scores_gemma":[0.0016958471,0.0005530561,0.000020479463,0.0036930083,0.0002446477,0.000029432922,0.000059430604,0.000005735393,0.013486003,0.00006927241,0.9798928,0.0002503262],"about_ca_topic_score_codex":0.00015064025,"about_ca_topic_score_gemma":0.0000278457,"teacher_disagreement_score":0.9796268,"about_ca_system_score_codex":0.00009130037,"about_ca_system_score_gemma":0.00031848095,"threshold_uncertainty_score":0.9997012},"labels":[],"label_agreement":null},{"id":"W2890365096","doi":"10.1200/jco.2017.35.15_suppl.9085","title":"Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Durvalumab; Medicine; Internal medicine; Pneumonitis; Adverse effect; Rash; Gastroenterology; Clinical endpoint; Nausea; Oncology; Surgery; Nivolumab; Clinical trial; Cancer; Lung; Immunotherapy","score_opus":0.07735938050308919,"score_gpt":0.45217460592540987,"score_spread":0.3748152254223207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890365096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960225,0.0001843959,0.000035543988,0.001996972,0.0004070626,0.00045310424,0.000012559341,0.0000056027184,0.0008822334],"genre_scores_gemma":[0.99476403,0.0037042978,0.00052215933,0.00052419875,0.0001922261,0.00000141497,0.000003751496,0.000019591373,0.0002683472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99585825,0.0006743124,0.0026778309,0.0002455123,0.00031919903,0.00022490507],"domain_scores_gemma":[0.99385655,0.0010421157,0.004046979,0.0004286166,0.00037842075,0.00024730782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046531297,0.00017042951,0.0020032707,0.000108339475,0.000068345274,0.000013474497,0.00022935422,0.00047057684,0.00012244533],"category_scores_gemma":[0.0014135526,0.000107581756,0.0003808611,0.000083123276,0.000756859,0.00020993718,0.000045719178,0.0008849863,0.0000013439347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15075721,0.0022232023,0.5940465,0.000014131904,0.0005364151,0.00008108049,0.00003701227,7.0658086e-7,0.00006662053,0.0000023381183,0.00014017812,0.25209463],"study_design_scores_gemma":[0.06615296,0.02433061,0.8954834,0.00020444032,0.0002070222,0.000020961194,0.0000176194,0.000051633648,0.00005858083,0.000009570078,0.013365346,0.00009786918],"about_ca_topic_score_codex":0.0002298141,"about_ca_topic_score_gemma":0.00046170436,"teacher_disagreement_score":0.3014369,"about_ca_system_score_codex":0.00013760821,"about_ca_system_score_gemma":0.0010238407,"threshold_uncertainty_score":0.43870565},"labels":[],"label_agreement":null},{"id":"W2890444065","doi":"10.1200/jco.2018.36.15_suppl.tps6094","title":"Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Placebo; Internal medicine; Head and neck cancer; Head and neck squamous-cell carcinoma; Regimen; Oncology; Larynx; Phases of clinical research; Radiation therapy; Cancer; Urology; Surgery; Chemotherapy; Immunotherapy; Pathology","score_opus":0.06739899375646541,"score_gpt":0.43358376972508367,"score_spread":0.36618477596861826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890444065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877231,0.0011836451,0.00058977713,0.0077683055,0.0013077415,0.00095516077,0.000005878129,0.000010479272,0.0004559136],"genre_scores_gemma":[0.992481,0.00019043892,0.0011851694,0.003261674,0.0025614493,0.00001955282,0.0000061198994,0.000023768393,0.0002708514],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99719816,0.0002249175,0.0017728767,0.00024108612,0.00030635198,0.0002566044],"domain_scores_gemma":[0.9960617,0.0013243945,0.0015555769,0.00024206442,0.0005923331,0.00022395937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025336,0.00017169802,0.0011122734,0.00009033971,0.00013686968,0.000019439405,0.00016092772,0.00027078303,0.000053173026],"category_scores_gemma":[0.0012877347,0.000111207555,0.0003307599,0.00016476375,0.00031062792,0.00014175514,0.00002862688,0.00048028264,0.0000049898636],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44156858,0.0072178678,0.020342287,0.000121085635,0.00032980283,0.00015107002,0.0019154428,0.000024328736,0.0046694996,0.00001104762,0.010213298,0.51343566],"study_design_scores_gemma":[0.36714005,0.18532228,0.34896928,0.000050563296,0.0009563903,0.00041880138,0.000833723,0.0036063741,0.002547183,0.00012287374,0.08977042,0.0002620684],"about_ca_topic_score_codex":0.00005255425,"about_ca_topic_score_gemma":0.0001169114,"teacher_disagreement_score":0.5131736,"about_ca_system_score_codex":0.00030657824,"about_ca_system_score_gemma":0.0015154731,"threshold_uncertainty_score":0.45349124},"labels":[],"label_agreement":null},{"id":"W2890466450","doi":"10.1200/jco.2017.35.15_suppl.9523","title":"Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Internal medicine; Nivolumab; Gastroenterology; Adverse effect; Placebo; Immunotherapy; Cancer; Pathology","score_opus":0.14229025081470043,"score_gpt":0.4783152062342483,"score_spread":0.33602495541954785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890466450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951608,0.00034082506,0.000112490095,0.0025264532,0.0003478131,0.0005209898,0.000008705556,0.0000054630664,0.0009764424],"genre_scores_gemma":[0.9944866,0.0009377126,0.0035156172,0.00029926343,0.00017620531,0.000007568974,0.0000027127317,0.00001546599,0.00055885495],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9946254,0.0006802028,0.0037566486,0.00025482534,0.00037433038,0.00030858125],"domain_scores_gemma":[0.9922328,0.0020912187,0.004954233,0.00030226406,0.00022239091,0.00019707829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010805944,0.00019362918,0.0030963789,0.00019760593,0.000082877945,0.000013730988,0.00025993795,0.00022134154,0.00015146649],"category_scores_gemma":[0.0049862936,0.00012554368,0.0003216713,0.00014365227,0.00045611593,0.00017965735,0.00010519751,0.0007344464,5.0086675e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5844187,0.007883708,0.06961145,0.00010675114,0.0011558613,0.0059459037,0.00023092006,0.000019480902,0.0021656943,0.000023520824,0.00038054815,0.32805744],"study_design_scores_gemma":[0.30271077,0.08229205,0.6085392,0.0028282586,0.000433093,0.00070267613,0.00048750226,0.00019888458,0.00036712206,0.00008311916,0.0011908498,0.00016647193],"about_ca_topic_score_codex":0.0001126219,"about_ca_topic_score_gemma":0.0013736024,"teacher_disagreement_score":0.53892773,"about_ca_system_score_codex":0.00043277777,"about_ca_system_score_gemma":0.0010907259,"threshold_uncertainty_score":0.59694195},"labels":[],"label_agreement":null},{"id":"W2890487472","doi":"10.1200/jco.2017.35.15_suppl.4071","title":"Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Durvalumab; Internal medicine; Hepatocellular carcinoma; Interim analysis; Adverse effect; Gastroenterology; Sorafenib; Population; Clinical trial; Surgery; Oncology; Cancer; Immunotherapy","score_opus":0.08252898576785439,"score_gpt":0.42888099083417397,"score_spread":0.3463520050663196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890487472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99567753,0.00024446592,0.00005024186,0.0026171745,0.00059263164,0.00026256853,0.000004215676,0.000002289245,0.0005488949],"genre_scores_gemma":[0.99690855,0.0015674577,0.0006827731,0.0004666447,0.00028873538,7.732859e-7,7.5957223e-7,0.000014270324,0.00007001096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99666196,0.00044345148,0.0022153084,0.00019686196,0.0003110463,0.00017136113],"domain_scores_gemma":[0.99500024,0.0009659698,0.0031414954,0.00038607628,0.00029952583,0.00020671461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004382727,0.0001303192,0.001770183,0.000085250824,0.000058421607,0.0000091152815,0.00020179528,0.00038834428,0.000054174565],"category_scores_gemma":[0.0012085806,0.000084487176,0.00038201033,0.00004889853,0.00072669436,0.00015225567,0.000045465156,0.0008050353,8.718767e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.105227135,0.0016532412,0.68734527,0.000015538766,0.00029075664,0.00008912545,0.000028149363,2.0323974e-7,0.000044144068,0.0000043221635,0.00006932388,0.20523281],"study_design_scores_gemma":[0.05082581,0.022383383,0.9198634,0.00012290709,0.0001473106,0.000026893233,0.000013616167,0.00008088478,0.00007317177,0.000027105592,0.00635542,0.00008007538],"about_ca_topic_score_codex":0.00014657216,"about_ca_topic_score_gemma":0.000107992615,"teacher_disagreement_score":0.23251818,"about_ca_system_score_codex":0.00009959388,"about_ca_system_score_gemma":0.0009797731,"threshold_uncertainty_score":0.34975225},"labels":[],"label_agreement":null},{"id":"W2890555947","doi":"10.1200/jco.2018.36.15_suppl.12121","title":"Early mortality with immune checkpoint inhibitors (IOs) in solid tumors: An inconvenient truth?","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Randomized controlled trial; Internal medicine; Oncology; Melanoma; Cancer research","score_opus":0.09172081577637263,"score_gpt":0.45602678384590917,"score_spread":0.3643059680695365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890555947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943634,0.00021371714,0.000029699893,0.002130665,0.0015411242,0.00019522576,0.0000015239482,0.000010456746,0.0015141515],"genre_scores_gemma":[0.9954726,0.00013073959,0.00082783465,0.0011850797,0.0022943704,0.0000035902049,0.0000015177046,0.000019781106,0.000064501866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99525124,0.0004156431,0.0034009777,0.00023103914,0.000409452,0.00029164526],"domain_scores_gemma":[0.99660325,0.00041277832,0.0019081095,0.00030404827,0.00043411934,0.0003377157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057193907,0.00016389218,0.001466149,0.00017610691,0.000037498754,0.000013032782,0.00019438106,0.00032658412,0.00023454026],"category_scores_gemma":[0.0009200031,0.0001051229,0.00042612967,0.0002543291,0.00072400743,0.00019962652,0.00003932491,0.000959741,0.000013438934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.109892316,0.0077758576,0.7088623,0.000067785484,0.0013253224,0.0027104048,0.002030139,0.0000042373686,0.012836816,0.00006959763,0.0005447984,0.1538804],"study_design_scores_gemma":[0.014612003,0.05053233,0.9237606,0.00032788242,0.00013805614,0.000468112,0.00032828018,0.00003361635,0.0035263589,0.00017113221,0.0059724865,0.00012913554],"about_ca_topic_score_codex":0.00033362792,"about_ca_topic_score_gemma":0.00037727348,"teacher_disagreement_score":0.21489827,"about_ca_system_score_codex":0.0002554057,"about_ca_system_score_gemma":0.001842678,"threshold_uncertainty_score":0.42867872},"labels":[],"label_agreement":null},{"id":"W2890571864","doi":"10.1200/jco.2018.36.15_suppl.3586","title":"Prognostic immune scoring of colorectal cancer liver metastasis with MHC class-I expression combined to T cell quantification.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Colorectal cancer; CD8; Immune system; Chemotherapy; Major histocompatibility complex; Tissue microarray; Metastasis; Immunohistochemistry; Internal medicine; Oncology; Gastroenterology; Pathology; Cancer; Immunology","score_opus":0.11011219782431647,"score_gpt":0.4368056017572908,"score_spread":0.3266934039329743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890571864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939809,0.0010789259,0.0004596878,0.0023849087,0.0010546646,0.00035868035,0.0000050940043,0.000007770077,0.0006694002],"genre_scores_gemma":[0.9913417,0.0006549942,0.0067481836,0.00058448495,0.0004648779,0.000012111667,0.0000015132555,0.000017461252,0.0001746431],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972793,0.00024661198,0.0017893155,0.00018220926,0.00031234502,0.00019022576],"domain_scores_gemma":[0.99599165,0.0009689039,0.0017216064,0.00018382483,0.0009168378,0.00021715635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019285441,0.00012585719,0.0010607591,0.00014205276,0.000050270573,0.0000072144576,0.0001772126,0.00018860002,0.00035509153],"category_scores_gemma":[0.0007618367,0.00007890295,0.00026031188,0.00027747412,0.00037041938,0.00008870242,0.00004034499,0.00040235708,0.0000111081845],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14316146,0.00357106,0.12234616,0.00015419257,0.0010376724,0.00013366881,0.00061929825,0.00002175136,0.6126458,0.000026653133,0.0052987863,0.110983506],"study_design_scores_gemma":[0.013927833,0.063648574,0.65947866,0.0008629799,0.00080675905,0.00012628753,0.00026276615,0.00010019535,0.22899152,0.000013135123,0.03161681,0.0001644626],"about_ca_topic_score_codex":0.00008475338,"about_ca_topic_score_gemma":0.00007918181,"teacher_disagreement_score":0.5371325,"about_ca_system_score_codex":0.00012449708,"about_ca_system_score_gemma":0.0012932626,"threshold_uncertainty_score":0.38880032},"labels":[],"label_agreement":null},{"id":"W2890710292","doi":"10.1200/jco.2017.35.15_suppl.5581","title":"Immunologic and genomic characterization of high grade serous ovarian cancer (HGSOC) in patients (pts) treated with pembrolizumab (Pembro) in the phase II INSPIRE trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Cancer; Pathology; Immunotherapy","score_opus":0.08087035136110318,"score_gpt":0.41750179391872866,"score_spread":0.33663144255762545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890710292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947114,0.00018246955,0.0000022679924,0.004062537,0.00040861897,0.00054279255,0.000011055557,0.0000026255318,0.00007623201],"genre_scores_gemma":[0.9969967,0.0019698206,0.000051501054,0.0006960008,0.00021523054,0.000013394229,0.000008203379,0.0000104507435,0.00003868901],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9974804,0.00041854376,0.0015972317,0.00015320197,0.00018816278,0.00016246544],"domain_scores_gemma":[0.9968011,0.00026058976,0.0024813653,0.00025532788,0.00014413199,0.000057483863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015827084,0.00012692744,0.0010598078,0.0001339184,0.000085299376,0.000013798854,0.00023583797,0.00028229252,0.000037476944],"category_scores_gemma":[0.00041552438,0.000070109956,0.00013167992,0.00010315483,0.00031469006,0.00014217135,0.000037644015,0.00054579356,2.9386544e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4806172,0.005884933,0.27594602,0.000022944767,0.00031540607,0.00013000522,0.00044393333,0.0000013091268,0.0049031875,0.000011250171,0.000024104707,0.23169972],"study_design_scores_gemma":[0.24432895,0.033463724,0.72059876,0.00012305712,0.00011898223,0.00003256879,0.000033896853,0.000010611182,0.00008120094,0.000017832968,0.0011361436,0.000054278447],"about_ca_topic_score_codex":0.00083940505,"about_ca_topic_score_gemma":0.00037212495,"teacher_disagreement_score":0.44465274,"about_ca_system_score_codex":0.00017655532,"about_ca_system_score_gemma":0.0006094724,"threshold_uncertainty_score":0.2859001},"labels":[],"label_agreement":null},{"id":"W2890809656","doi":"10.1200/jco.2018.36.15_suppl.e15071","title":"Multi-platform characterization of cutaneous melanoma from patients treated with immune checkpoint inhibitors.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Royal Victoria Hospital; McGill University Health Centre; Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Melanoma; Immune system; Immunotherapy; Oncology; Eosinophil; Immune checkpoint; Pembrolizumab; Cancer research; Immunology; Internal medicine","score_opus":0.05367705653353559,"score_gpt":0.370737021129612,"score_spread":0.3170599645960764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890809656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979951,0.000066624394,0.00008498789,0.0004835214,0.0008298912,0.00018506033,0.000015845539,0.0000062599934,0.0003327257],"genre_scores_gemma":[0.99658215,0.00024465504,0.0017413908,0.00039518377,0.0008409961,0.000001222679,0.000031635078,0.000016249705,0.00014651561],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970295,0.00009656473,0.0023445217,0.00013160327,0.00025851533,0.00013932917],"domain_scores_gemma":[0.99608576,0.0002710474,0.0026330024,0.0001605397,0.00071168545,0.00013797382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064347807,0.000121611825,0.0010476877,0.000092824914,0.000028227532,0.000004655139,0.00009965709,0.0003030733,0.00034415358],"category_scores_gemma":[0.0003883665,0.00007470309,0.00031344738,0.00013437269,0.00032842383,0.00010108738,0.000020471005,0.0003375555,0.000011870137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081183,0.0035720952,0.4081694,0.00002021236,0.0011646792,0.00020267912,0.00032981957,1.2146572e-7,0.30507302,9.658075e-7,0.00011444479,0.2001696],"study_design_scores_gemma":[0.01878106,0.03818292,0.88501316,0.00024035979,0.00028892976,0.00016003328,0.000039112452,0.000049803824,0.047899656,0.0000049764717,0.009253686,0.000086323234],"about_ca_topic_score_codex":0.00011745734,"about_ca_topic_score_gemma":0.00004482459,"teacher_disagreement_score":0.47684377,"about_ca_system_score_codex":0.00012400192,"about_ca_system_score_gemma":0.00049579865,"threshold_uncertainty_score":0.37682402},"labels":[],"label_agreement":null},{"id":"W2890817079","doi":"10.1200/jco.2017.35.15_suppl.11607","title":"A technical feasibility report on correlative studies from the investigator-initiated phase II study of pembrolizumab (Pembro) immunological response evaluation (INSPIRE).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Biomarker; Breast cancer; Triple-negative breast cancer; Oncology; Cancer; Melanoma; Ovarian cancer; Internal medicine; Cancer research; Immunotherapy; Biology","score_opus":0.5247670049047602,"score_gpt":0.5941794047374243,"score_spread":0.069412399832664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890817079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98184204,0.0012384607,0.000008428363,0.013777447,0.0014846561,0.001184925,0.000011446839,0.00001490374,0.00043770892],"genre_scores_gemma":[0.9973373,0.0003823298,0.00027726075,0.001477921,0.00042254152,0.0000247355,0.000004142842,0.00001350009,0.000060282302],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9898346,0.004579598,0.004009787,0.00038997433,0.0009776966,0.00020834037],"domain_scores_gemma":[0.97819644,0.0113163795,0.007158104,0.0012509958,0.0018368068,0.00024127841],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02572631,0.00022437386,0.0019909288,0.000088574336,0.00042678165,0.000016023496,0.0005122675,0.00050273235,0.00011276119],"category_scores_gemma":[0.14652212,0.000120266195,0.0006449607,0.0001295821,0.0018956916,0.0001445488,0.00021795857,0.0016261323,0.0000032068306],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71609557,0.027126562,0.1210025,0.000010578811,0.0036729048,0.001995075,0.0017284455,0.000006856746,0.008616276,0.000017959552,0.0044769505,0.11525036],"study_design_scores_gemma":[0.06302256,0.13875502,0.79107255,0.00024061775,0.001202201,0.00038244738,0.0015698994,0.000055200984,0.00023946355,0.0005583742,0.0027985391,0.00010309975],"about_ca_topic_score_codex":0.00010122973,"about_ca_topic_score_gemma":0.000114473136,"teacher_disagreement_score":0.67007005,"about_ca_system_score_codex":0.00059238944,"about_ca_system_score_gemma":0.0036514343,"threshold_uncertainty_score":0.8916277},"labels":[],"label_agreement":null},{"id":"W2890982083","doi":"10.1007/s00262-018-2240-y","title":"International Symposium: Trailblazing in Cancer Immunotherapy, October 29–31, 2017, Pamplona, Spain","year":2018,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AstraZeneca Schweiz; Merck Sharp and Dohme; University of Toronto; Weill Cornell Medical College; Boehringer Ingelheim; Takeda Pharmaceuticals U.S.A.; University of Manchester; Fundación Ramón Areces; Roche; Merck; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Cancer immunotherapy; Cancer; Immunotherapy; Geography; Library science; Medicine; Computer science; Internal medicine","score_opus":0.027392093562318004,"score_gpt":0.3273475082277839,"score_spread":0.29995541466546594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890982083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8812268,0.08195209,0.00033764925,0.017754469,0.0078012124,0.001608463,0.00011393547,0.0005685444,0.008636863],"genre_scores_gemma":[0.75328976,0.2158477,0.0011214623,0.015727205,0.0024628837,0.0018317777,0.00013550326,0.0005047882,0.009078924],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954878,0.00023455068,0.0013139128,0.0011241403,0.00054207107,0.0012975369],"domain_scores_gemma":[0.99753416,0.00015592844,0.00050423195,0.0012352925,0.00044679706,0.00012359512],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008303114,0.0008097009,0.001115324,0.0006120383,0.0002843249,0.00011623869,0.0009916428,0.00066039414,0.0054902267],"category_scores_gemma":[0.000030218467,0.0007602663,0.0005221504,0.0009725117,0.0013465653,0.00046537802,0.00011074006,0.00097107794,0.00012568093],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014516375,0.00057127833,0.023900473,0.00003507356,0.0028332677,0.00006482628,0.003785972,0.000011714097,0.70480484,0.0000989968,0.005659091,0.2437181],"study_design_scores_gemma":[0.01785372,0.0011226861,0.12441703,0.0006937083,0.00007793127,0.0002418838,0.00039326685,0.0001410325,0.03576816,0.00011607554,0.8181715,0.0010030147],"about_ca_topic_score_codex":0.0051470525,"about_ca_topic_score_gemma":0.0011011271,"teacher_disagreement_score":0.8125124,"about_ca_system_score_codex":0.0017148207,"about_ca_system_score_gemma":0.0007708376,"threshold_uncertainty_score":0.99948484},"labels":[],"label_agreement":null},{"id":"W2891062831","doi":"10.1200/jco.2017.35.15_suppl.tps6090","title":"KEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Population; Internal medicine; Oncology; Head and neck squamous-cell carcinoma; Placebo; Chemoradiotherapy; Head and neck cancer; Radiation therapy; Cancer; Surgery; Pathology; Immunotherapy; Alternative medicine","score_opus":0.04883037949348787,"score_gpt":0.3914537141748603,"score_spread":0.3426233346813724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891062831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990685,0.0007080672,0.000051832736,0.0045968913,0.00062774925,0.00031134713,0.0000013337477,0.0000057440416,0.0030120357],"genre_scores_gemma":[0.99753124,0.0005748734,0.0011257594,0.00040930597,0.00023884309,0.000006975245,0.0000061918527,0.000019091638,0.00008773958],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9975537,0.00023313874,0.0014527888,0.00023291934,0.00030225766,0.0002251803],"domain_scores_gemma":[0.9965803,0.00093084894,0.0018462274,0.0002529997,0.0002197698,0.0001698753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018872956,0.00016122493,0.0010131324,0.00020885603,0.00006464208,0.000030275634,0.00015711114,0.00039031982,0.000019670886],"category_scores_gemma":[0.0013261422,0.0001310771,0.00013942488,0.00012632496,0.00024727162,0.00040632152,0.000028336242,0.00075724965,0.0000022333807],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3706916,0.002452431,0.3527015,0.000113901966,0.000060833983,0.00068857544,0.00038608207,0.00009534676,0.0017011645,0.000032617136,0.00018290349,0.2708931],"study_design_scores_gemma":[0.21824431,0.01579903,0.7620551,0.00009897425,0.000064963264,0.00012666853,0.000083876446,0.0007825069,0.00046316057,0.00006242559,0.0021037161,0.000115283314],"about_ca_topic_score_codex":0.00027906455,"about_ca_topic_score_gemma":0.0010422562,"teacher_disagreement_score":0.4093536,"about_ca_system_score_codex":0.0004613354,"about_ca_system_score_gemma":0.0012039278,"threshold_uncertainty_score":0.53451693},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2891159956","doi":"10.1200/jco.2018.36.15_suppl.e15052","title":"Characterization of two potential immunotherapeutics in tumor infiltrating lymphocytes (TILs) using flow cytometry and Meso Scale Discovery.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada)","funders":"","keywords":"Flow cytometry; Tumor-infiltrating lymphocytes; CD8; IL-2 receptor; CD28; T cell; Cancer research; Cytokine; Medicine; Immunophenotyping; Molecular biology; Proinflammatory cytokine; Immune system; Immunotherapy; Immunology; Biology; Inflammation","score_opus":0.06901335600157942,"score_gpt":0.438163824961048,"score_spread":0.36915046895946857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891159956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957577,0.00039746528,0.002278369,0.00041917607,0.0009252041,0.00011351248,0.0000051474917,0.000003257827,0.0001001674],"genre_scores_gemma":[0.9913496,0.00059363357,0.0058785095,0.0011658722,0.0009720176,5.135952e-7,0.000002201423,0.000013857091,0.000023801716],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99729544,0.00023268243,0.0019633307,0.00012556871,0.00022344224,0.00015951258],"domain_scores_gemma":[0.9976535,0.00034772587,0.0015503305,0.000114366725,0.00025570273,0.000078388235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020328984,0.000106445856,0.0008978612,0.00020741766,0.000034742396,0.000016500579,0.00008835006,0.0001637121,0.00006351027],"category_scores_gemma":[0.00034129928,0.00008066439,0.00021767506,0.0002482034,0.0004276102,0.00024422488,0.000031335723,0.00030519062,6.2911965e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011830831,0.00050713064,0.11188228,0.00003481189,0.00022829621,0.00006020153,0.00023440518,0.000005960299,0.7753967,0.0000043199616,0.0000054362463,0.09980964],"study_design_scores_gemma":[0.027198182,0.010850489,0.88991314,0.0006894524,0.00037916258,0.0014625706,0.00031957764,0.007684965,0.05941752,0.00010143442,0.0017929879,0.00019053834],"about_ca_topic_score_codex":0.000053733685,"about_ca_topic_score_gemma":0.000032678832,"teacher_disagreement_score":0.7780309,"about_ca_system_score_codex":0.00014856266,"about_ca_system_score_gemma":0.00096544327,"threshold_uncertainty_score":0.32893983},"labels":[],"label_agreement":null},{"id":"W2891383683","doi":"10.23889/ijpds.v3i4.639","title":"Population survival impact of new targeted and immune based therapies for metastatic or unresectable melanoma","year":2018,"lang":"en","type":"article","venue":"International Journal for Population Data Science","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Northeast Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Population; Hazard ratio; Cancer registry; Internal medicine; Cohort; Cancer; Oncology; Radiation therapy; Melanoma; Systemic therapy; Relative survival; Retrospective cohort study; Christian ministry; Confidence interval; Cancer research","score_opus":0.10322139556213399,"score_gpt":0.4381719238084799,"score_spread":0.3349505282463459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891383683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9574254,0.00032643473,0.03873017,0.000921957,0.0014615777,0.0005308652,0.00056787464,0.000014533679,0.000021142925],"genre_scores_gemma":[0.9759522,0.00003188191,0.022783583,0.00006919795,0.00033440726,0.0000033765034,0.0006283389,0.000011010348,0.0001860084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986167,0.000022303795,0.0004366321,0.00022421472,0.0005280969,0.00017206294],"domain_scores_gemma":[0.99853516,0.00014199702,0.00034967193,0.00023783342,0.0006413865,0.000093947114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012442133,0.00010215203,0.0001997031,0.0003173559,0.0002122574,0.0001302688,0.00043658714,0.000025791354,0.00023923004],"category_scores_gemma":[0.0006911619,0.000068940164,0.00009103364,0.00027744498,0.0001487631,0.0010011542,0.00005040915,0.00005118832,4.4956772e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05710156,0.0004784334,0.38372993,0.00012456115,0.001860383,0.000008051163,0.00095310423,0.00031738722,0.23743896,0.0018032895,0.005756316,0.31042802],"study_design_scores_gemma":[0.006740289,0.0018035267,0.9129914,0.0001631866,0.000098431185,0.00012734778,0.00013427396,0.070392154,0.0037811496,0.0014768271,0.0021250176,0.00016641522],"about_ca_topic_score_codex":0.0019927185,"about_ca_topic_score_gemma":0.00023545459,"teacher_disagreement_score":0.52926147,"about_ca_system_score_codex":0.00013632845,"about_ca_system_score_gemma":0.0004882401,"threshold_uncertainty_score":0.30124077},"labels":[],"label_agreement":null},{"id":"W2891579537","doi":"10.1200/jco.2018.36.15_suppl.4032","title":"Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Durvalumab; Medicine; Discontinuation; Adverse effect; Nausea; Vomiting; Internal medicine; Tolerability; Oncology; Blockade; Gastroenterology; Cancer; Surgery; Immunotherapy; Nivolumab","score_opus":0.051781930594670164,"score_gpt":0.433290098603136,"score_spread":0.3815081680084658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891579537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970656,0.00015390686,0.00009646326,0.0013166445,0.00068622536,0.0002006426,0.0000049938744,0.0000029710905,0.00047257703],"genre_scores_gemma":[0.9950609,0.0011457877,0.001909457,0.0011592397,0.0006676255,6.5256927e-7,6.7411014e-7,0.000012455964,0.000043209617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967468,0.00046856905,0.0021277128,0.00017967231,0.00029336437,0.0001839126],"domain_scores_gemma":[0.99655026,0.0009377156,0.0017549684,0.00016654548,0.00039258137,0.00019790547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003559561,0.00011632214,0.0014241803,0.00009915204,0.0000234413,0.000003117793,0.000101536105,0.00028916026,0.00012825821],"category_scores_gemma":[0.0005667576,0.00007458615,0.0002682214,0.00014276148,0.0008842254,0.000098652694,0.00002258537,0.0006810018,0.0000010785852],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15810035,0.001066832,0.5925855,0.000008141288,0.00032419834,0.000027662805,0.000043406886,4.1789824e-7,0.000030005394,0.0000022932898,0.00017920278,0.247632],"study_design_scores_gemma":[0.043862782,0.054457158,0.8958923,0.0001075558,0.000111649286,0.000024585039,0.000018561806,0.000025662315,0.000059130853,0.000014046046,0.0053723194,0.00005425813],"about_ca_topic_score_codex":0.00010860352,"about_ca_topic_score_gemma":0.0003224354,"teacher_disagreement_score":0.30330682,"about_ca_system_score_codex":0.00020598767,"about_ca_system_score_gemma":0.0015446668,"threshold_uncertainty_score":0.32579654},"labels":[],"label_agreement":null},{"id":"W2891694121","doi":"10.1200/jco.2017.35.15_suppl.9522","title":"Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Cohort; Expanded access; Oncology; Cancer; Immunotherapy","score_opus":0.0642788692201449,"score_gpt":0.4571803772239324,"score_spread":0.3929015080037875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891694121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980201,0.00007692061,0.000044166245,0.00063177774,0.0003564451,0.00044035216,0.000007690827,0.0000059800886,0.0004165396],"genre_scores_gemma":[0.9977839,0.00015431014,0.0017117191,0.00017890155,0.000096449934,0.0000092952705,0.00002833586,0.000015589847,0.00002147278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99678797,0.00040631593,0.0018038092,0.00023926316,0.0005236937,0.00023893839],"domain_scores_gemma":[0.9954785,0.00048111685,0.0029980156,0.00042500952,0.00044076293,0.0001765704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017540461,0.00016269593,0.0017556386,0.00032638936,0.000042751693,0.000029747505,0.00038488174,0.00027399007,0.0000764716],"category_scores_gemma":[0.000489537,0.00010744207,0.00026559582,0.00027477316,0.00028339037,0.00066633016,0.000047980582,0.0005679007,3.7288993e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.088956535,0.0062756827,0.74775785,0.000011310255,0.0009058914,0.00005321292,0.00013228414,0.000026785527,0.000023991392,0.0000042727897,0.000012074131,0.15584008],"study_design_scores_gemma":[0.07356782,0.02964808,0.8953498,0.00017112038,0.00049606356,0.00000330504,0.000100535355,0.00015149773,0.000045525525,0.000053539483,0.00029792514,0.0001147918],"about_ca_topic_score_codex":0.00086518266,"about_ca_topic_score_gemma":0.0063521382,"teacher_disagreement_score":0.1557253,"about_ca_system_score_codex":0.00024005327,"about_ca_system_score_gemma":0.00068199536,"threshold_uncertainty_score":0.43813604},"labels":[],"label_agreement":null},{"id":"W2891723502","doi":"10.1200/jco.2017.35.15_suppl.3058","title":"Immune related adverse events (irAE) with platinum chemotherapy (CT) with durvalumab (D) ± tremelimumab (T): CCTG IND226.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Centre Hospitalier de l’Université de Montréal; Kingston General Hospital; BC Cancer Agency; Ottawa Hospital; Princess Margaret Cancer Centre; Queen's University; McMaster University; Juravinski Cancer Centre; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Durvalumab; Adverse effect; Nivolumab; Immunotherapy; Cancer","score_opus":0.06334241880670663,"score_gpt":0.4143125597281582,"score_spread":0.3509701409214516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891723502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819141,0.0004965361,0.00005643725,0.009929777,0.0009795655,0.0004159943,0.0000027443214,0.000019899995,0.0061849216],"genre_scores_gemma":[0.99235606,0.0011136987,0.002308557,0.0011943185,0.00057096954,0.000005222779,0.000003550317,0.000051300918,0.0023963002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957642,0.00026521136,0.0027029954,0.00028805662,0.00062480813,0.00035472232],"domain_scores_gemma":[0.992856,0.0005338334,0.0051570944,0.00069717236,0.0004355323,0.0003203371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033333967,0.00027078966,0.001793938,0.00012816228,0.00022114892,0.000014127457,0.00044908657,0.0003427635,0.0006491221],"category_scores_gemma":[0.00078627374,0.00015835876,0.0006707804,0.000121824625,0.00064778293,0.0002891206,0.00004398818,0.0013479657,0.000023532775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31728438,0.0038085626,0.33755335,0.000060386024,0.005679293,0.0037744765,0.00037336734,0.000022474258,0.0021341634,0.00003917193,0.0019009307,0.32736942],"study_design_scores_gemma":[0.112382665,0.028668284,0.8157372,0.0005562708,0.0005146486,0.0029851734,0.00018436268,0.000039297618,0.00037823906,0.000088384826,0.038249187,0.00021632125],"about_ca_topic_score_codex":0.00008937342,"about_ca_topic_score_gemma":0.00008838893,"teacher_disagreement_score":0.4781838,"about_ca_system_score_codex":0.0002618087,"about_ca_system_score_gemma":0.002132932,"threshold_uncertainty_score":0.7107432},"labels":[],"label_agreement":null},{"id":"W2892170876","doi":"10.1080/2162402x.2018.1509820","title":"Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, <i>BRCA1</i>-like status, tumor-infiltrating immune cells and survival","year":2018,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute; University of Toronto; University Health Network","funders":"National Cancer Institute; National Institutes of Health; European Commission","keywords":"Tumor-infiltrating lymphocytes; Tissue microarray; Breast cancer; PD-L1; FOXP3; Cancer research; Immune system; Medicine; CD8; Estrogen receptor; Multiplex; Cancer; Immunohistochemistry; Oncology; Pathology; Biology; Internal medicine; Immunology; Immunotherapy; Bioinformatics","score_opus":0.0096826423141296,"score_gpt":0.31319507012572595,"score_spread":0.3035124278115964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892170876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99617076,0.0012753688,0.00035894272,0.00040186348,0.0007058296,0.00044357043,0.000048443162,0.000027864775,0.0005673483],"genre_scores_gemma":[0.9979665,0.0003168287,0.0011299207,0.0002790821,0.000051164934,0.000046015466,0.000049553724,0.000026895603,0.0001339881],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984064,0.00019547963,0.00052170735,0.00033491847,0.00017284698,0.0003686196],"domain_scores_gemma":[0.99913996,0.00008244326,0.00024926045,0.00029487524,0.00017866865,0.0000547729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005445605,0.00017891999,0.0004023002,0.0001337323,0.00008936863,0.00001799164,0.000080361635,0.0001423618,0.00014468306],"category_scores_gemma":[0.000025809291,0.00016587462,0.00005335551,0.0003662514,0.00021837855,0.00013104978,0.00006940827,0.00021142594,0.000004175605],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020843614,0.000105120125,0.040926334,0.000051453837,0.00007093497,0.00002265469,0.0014105254,0.000030870255,0.946758,0.000035349247,0.000038673013,0.008465765],"study_design_scores_gemma":[0.0031612234,0.00065770873,0.8428071,0.0003172468,0.00002362954,0.000048664817,0.0011998047,0.00012976068,0.15049565,0.000017316182,0.0009905524,0.00015134392],"about_ca_topic_score_codex":0.0028370572,"about_ca_topic_score_gemma":0.0005246774,"teacher_disagreement_score":0.8018808,"about_ca_system_score_codex":0.00027370936,"about_ca_system_score_gemma":0.0002675815,"threshold_uncertainty_score":0.67641705},"labels":[],"label_agreement":null},{"id":"W2892309170","doi":"10.1200/jco.2018.36.15_suppl.tps3120","title":"An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Cancer; Biomarker; Lung cancer; PD-L1; Oncology; Internal medicine; Immunotherapy","score_opus":0.10984176389203318,"score_gpt":0.48741888138114337,"score_spread":0.37757711748911016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892309170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994198,0.0005344235,0.0000101889045,0.00064447604,0.0012532583,0.0028544161,0.000017759203,0.00003085409,0.0004566283],"genre_scores_gemma":[0.99398535,0.000728941,0.0020277882,0.0023035516,0.0007259543,0.00004167145,0.000015937965,0.000073558265,0.00009722702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99418485,0.0013096189,0.002656551,0.0006565835,0.00059687847,0.0005955207],"domain_scores_gemma":[0.99457544,0.000718977,0.00251587,0.0005600171,0.0010351624,0.00059451914],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0039011613,0.0004218897,0.0021349108,0.00029869017,0.00019017253,0.00006790709,0.00071685057,0.00044287433,0.00017040884],"category_scores_gemma":[0.0002676789,0.00028216268,0.00015690638,0.0004723228,0.00038750764,0.0003812335,0.00009567697,0.0010516972,0.0000030612473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21210377,0.07128179,0.49626014,0.000021661575,0.0007058632,0.00029403524,0.0017265312,0.0000032163855,0.0016175766,3.0698754e-7,0.00054121413,0.21544388],"study_design_scores_gemma":[0.21349496,0.24254909,0.5372589,0.00048645938,0.0002538902,0.000010449638,0.0007349531,0.0017424724,0.0003254503,8.480084e-7,0.0028839854,0.0002585343],"about_ca_topic_score_codex":0.0006924058,"about_ca_topic_score_gemma":0.0017033996,"teacher_disagreement_score":0.21518534,"about_ca_system_score_codex":0.0003744747,"about_ca_system_score_gemma":0.0019927307,"threshold_uncertainty_score":0.99996305},"labels":[],"label_agreement":null},{"id":"W2892310829","doi":"10.1016/j.jtho.2018.09.006","title":"Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme; National Cancer Institute; National Institutes of Health; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Stage (stratigraphy); Oncology; Mutation; Cancer research; Lung; Gene; Basal cell; Internal medicine; Squamous-cell carcinoma of the lung; Carcinoma; Lung cancer; Gene mutation; Pathology; Genetics; Biology","score_opus":0.01350046462277225,"score_gpt":0.3431897313177978,"score_spread":0.3296892666950255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892310829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99627405,0.0012458107,0.0013135726,0.0003897241,0.00018061431,0.00047017587,0.0000053701415,0.0000037413795,0.0001169573],"genre_scores_gemma":[0.993708,0.00002181691,0.0057500033,0.00006411454,0.00029443632,0.000011830102,0.000004071608,0.000012889148,0.0001327963],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991212,0.00008483191,0.00040784976,0.00010858255,0.00015547834,0.00012208811],"domain_scores_gemma":[0.9988364,0.0001541958,0.000622594,0.00006511418,0.0002706746,0.000051043175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045267044,0.00008876218,0.0003067602,0.00021552404,0.00003696251,0.0000066205794,0.00005003626,0.00011636371,0.000024795358],"category_scores_gemma":[0.000049439543,0.00006227285,0.000058105645,0.00012573709,0.00010407408,0.0001030563,0.000010843911,0.00016164433,1.8640425e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09187168,0.00037523577,0.16980658,0.00059663574,0.0000812521,0.00031592872,0.0063902833,0.00016374433,0.6900611,0.0000025663235,0.00061566534,0.039719358],"study_design_scores_gemma":[0.008143587,0.023006067,0.42330208,0.00044585761,0.00035600242,0.00068001566,0.0017050931,0.0031736076,0.53758705,0.00003308513,0.0014112252,0.0001563174],"about_ca_topic_score_codex":0.000071165254,"about_ca_topic_score_gemma":0.000032565047,"teacher_disagreement_score":0.25349548,"about_ca_system_score_codex":0.00014730384,"about_ca_system_score_gemma":0.00021837038,"threshold_uncertainty_score":0.2539413},"labels":[],"label_agreement":null},{"id":"W2892330548","doi":"10.1200/jco.2017.35.15_suppl.3057","title":"Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Université de Montréal; Hôpital Notre-Dame; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Atezolizumab; Adverse effect; Internal medicine; Melanoma; Oncology; Gastroenterology; Cancer; Surgery; Immunotherapy; Pembrolizumab; Cancer research","score_opus":0.1440716241624101,"score_gpt":0.5033347753420615,"score_spread":0.3592631511796514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892330548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97748965,0.0005174027,0.00006287359,0.01548111,0.0016902373,0.0002361425,0.000006359688,0.0000068579047,0.004509364],"genre_scores_gemma":[0.990221,0.0053574634,0.0017241011,0.0016244788,0.0006029404,0.0000012392115,0.0000020719824,0.000017715154,0.00044899082],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9950584,0.0009114195,0.0032140568,0.00026039965,0.00028678478,0.00026889218],"domain_scores_gemma":[0.9932446,0.0024715608,0.0032907892,0.00041766113,0.0002100015,0.00036537385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009505594,0.00016655392,0.0022188956,0.00013286398,0.000105676256,0.000030384337,0.00028819955,0.0004226656,0.0002826458],"category_scores_gemma":[0.0053358823,0.00011703504,0.00061182864,0.00007748629,0.000812043,0.00021874165,0.00010285501,0.0013904482,0.0000130646],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.084652305,0.0017590353,0.24267748,0.000021387952,0.0010216275,0.0014135911,0.000037630176,4.1123118e-7,0.0002382363,0.000039960385,0.0017939978,0.66634434],"study_design_scores_gemma":[0.02939174,0.010933585,0.8147432,0.000107330525,0.00037391408,0.0006339374,0.000045539397,0.000098855955,0.0000586222,0.00011267841,0.14339723,0.000103350554],"about_ca_topic_score_codex":0.00014129108,"about_ca_topic_score_gemma":0.00035787144,"teacher_disagreement_score":0.666241,"about_ca_system_score_codex":0.00013632844,"about_ca_system_score_gemma":0.0014903287,"threshold_uncertainty_score":0.63879347},"labels":[],"label_agreement":null},{"id":"W2892397412","doi":"10.1200/jco.2018.36.30_suppl.260","title":"Safety and clinical efficacy of programmed cell death 1 antibodies (PD-1 Ab) in patients with advanced non-small cell lung cancer (NSCLC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; BC Cancer Agency","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Lung cancer; Pembrolizumab; Gastroenterology; Pneumonitis; Hazard ratio; Atezolizumab; Adverse effect; Clinical trial; Cancer; Proportional hazards model; Oncology; Surgery; Lung; Immunotherapy; Confidence interval","score_opus":0.039853733966512164,"score_gpt":0.42258185502727835,"score_spread":0.3827281210607662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892397412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99513763,0.0012291849,0.000087573346,0.0006902646,0.0009681039,0.0006495938,0.0000069187818,0.000006188685,0.0012245466],"genre_scores_gemma":[0.9864505,0.005712235,0.0062435986,0.0008708891,0.0005823454,0.0000029418438,0.0000032238675,0.00002450987,0.00010974929],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955497,0.0003263692,0.0031880708,0.00029301725,0.00031539664,0.00032748512],"domain_scores_gemma":[0.9947794,0.0016722946,0.0023604936,0.00022501132,0.00066917925,0.00029358655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026892903,0.00020069764,0.0017903448,0.00013361582,0.00004011486,0.0000066560883,0.00017429328,0.000405714,0.00007050081],"category_scores_gemma":[0.00057904783,0.00012866344,0.0003731887,0.00019620833,0.0006623669,0.00008901858,0.00005760219,0.0008442077,0.0000014420042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081543274,0.0033700755,0.75097424,0.00008321916,0.00027901228,0.000039042745,0.00013939968,0.0000017978801,0.00010975248,9.3041854e-7,0.00025139944,0.16320786],"study_design_scores_gemma":[0.05926115,0.033030275,0.8973853,0.00050060864,0.00040627734,0.000008870242,0.000065110384,0.000048506823,0.0002389436,0.0000030991428,0.008921592,0.00013029],"about_ca_topic_score_codex":0.00007722122,"about_ca_topic_score_gemma":0.00021490816,"teacher_disagreement_score":0.16307756,"about_ca_system_score_codex":0.00013374804,"about_ca_system_score_gemma":0.0016006328,"threshold_uncertainty_score":0.5246743},"labels":[],"label_agreement":null},{"id":"W2892903770","doi":"10.1080/14737140.2018.1528146","title":"Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review","year":2018,"lang":"en","type":"review","venue":"Expert Review of Anticancer Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Nivolumab; Atezolizumab; Cancer; Lung cancer; Internal medicine; Quality of life (healthcare); Oncology; Clinical trial; Systematic review; Melanoma; Ipilimumab; Head and neck cancer; MEDLINE; Intensive care medicine; Immunotherapy","score_opus":0.06345455502091561,"score_gpt":0.4126376919410446,"score_spread":0.349183136920129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892903770","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009969612,0.98597175,7.950599e-7,0.00070506835,0.00021105503,0.01279191,0.00010601923,0.00003503137,0.000078656645],"genre_scores_gemma":[0.000029799368,0.992686,0.000051048435,0.005082332,0.00011439268,0.0016455335,0.00019164594,0.00012152266,0.00007773585],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9897084,0.0015703076,0.006503514,0.00073857396,0.0009947589,0.0004843949],"domain_scores_gemma":[0.99200827,0.00024543353,0.00564476,0.001288753,0.0006034585,0.00020931872],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0023421617,0.00088446814,0.014650279,0.00028091198,0.000041886375,0.000007770416,0.00042762244,0.000273633,0.000561486],"category_scores_gemma":[0.00029449438,0.000500865,0.0014741139,0.0019524571,0.00037795212,0.000089190165,0.000035224424,0.00037565324,0.00000923957],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043333424,0.0005715766,0.00020782418,0.87115824,0.0015596084,0.000001948346,0.00011836081,1.8499079e-9,0.0000014251927,0.0000022545432,0.0037222838,0.122223124],"study_design_scores_gemma":[0.002166916,0.0011093571,0.000092516035,0.8330213,0.00072781,0.000008820586,0.0000072059197,1.0834877e-7,0.000006905077,3.8388228e-7,0.16246921,0.00038951772],"about_ca_topic_score_codex":0.0034011425,"about_ca_topic_score_gemma":0.00008840575,"teacher_disagreement_score":0.15874691,"about_ca_system_score_codex":0.00064942025,"about_ca_system_score_gemma":0.002133473,"threshold_uncertainty_score":0.99997824},"labels":[],"label_agreement":null},{"id":"W2893221436","doi":"10.1016/j.cllc.2018.09.005","title":"Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non–Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grand River Hospital; University of Victoria","funders":"AstraZeneca Canada","keywords":"Medicine; Nivolumab; Pembrolizumab; Internal medicine; Lung cancer; Adverse effect; Hazard ratio; Cohort; Common Terminology Criteria for Adverse Events; Proportional hazards model; Cancer; Oncology; Renal cell carcinoma; Immunotherapy","score_opus":0.019306177894472296,"score_gpt":0.3678977620764572,"score_spread":0.3485915841819849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893221436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997382,0.00081993215,0.0000848502,0.000063972104,0.00026789404,0.0011997541,0.00007503321,0.00001308959,0.000093472845],"genre_scores_gemma":[0.9979605,0.0012044504,0.00028505462,0.00009594536,0.00011656775,0.000100741214,0.000024234883,0.000026914195,0.00018557752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981286,0.000065801076,0.00081969006,0.0004874923,0.0002425653,0.00025583495],"domain_scores_gemma":[0.9985981,0.000107651205,0.0005180202,0.0003275719,0.00033836564,0.00011026879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001868715,0.000231631,0.00083688524,0.00024716067,0.000036747908,0.0000026822104,0.00008467123,0.00013179895,0.00022295583],"category_scores_gemma":[0.000050714265,0.00017348255,0.00028010595,0.0006221086,0.00024709947,0.0001065308,0.000042689506,0.00016164975,4.6248294e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03545334,0.001206001,0.9507586,0.00014597569,0.0023680432,0.0000019508063,0.0012046086,0.00004372999,0.0005025252,4.4882051e-7,0.00002474026,0.008290068],"study_design_scores_gemma":[0.042543977,0.002822033,0.9465124,0.0010241716,0.0027342264,1.9303481e-7,0.00014811975,0.0031699156,0.0008498704,4.1732883e-7,0.00003185129,0.00016280824],"about_ca_topic_score_codex":0.0016000535,"about_ca_topic_score_gemma":0.0022907148,"teacher_disagreement_score":0.00812726,"about_ca_system_score_codex":0.00088954176,"about_ca_system_score_gemma":0.00018599632,"threshold_uncertainty_score":0.70744133},"labels":[],"label_agreement":null},{"id":"W2893560583","doi":"10.1136/jclinpath-2018-205404","title":"Immune infiltrates and PD-L1 expression in treatment-naïve acinar prostatic adenocarcinoma: an exploratory analysis","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Prostate cancer; Immune checkpoint; Immune system; CD163; Immunosuppression; PD-L1; Medicine; CD68; Prostate; Immunotherapy; Adenocarcinoma; Blockade; Cancer; Cancer research; Immunology; Immunohistochemistry; Internal medicine; Macrophage; Biology; Receptor","score_opus":0.07382010503479558,"score_gpt":0.41083719913109973,"score_spread":0.33701709409630415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893560583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99502546,0.003789036,0.00008217147,0.00059035746,0.0002755761,0.00015153567,0.0000039756237,0.000007227654,0.00007468176],"genre_scores_gemma":[0.996122,0.0015230271,0.0014738387,0.00040118187,0.00039303073,0.00000523018,0.0000057158354,0.000012573177,0.00006342562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99748945,0.0005132351,0.0014172187,0.0002311636,0.00015127707,0.00019765315],"domain_scores_gemma":[0.9984042,0.0003195749,0.0006560151,0.00027262006,0.0001786655,0.00016893043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015823522,0.0001484404,0.0010006983,0.0003590572,0.00004573698,0.0000132406885,0.00008806123,0.00021011573,0.000118221935],"category_scores_gemma":[0.00032128664,0.00009725098,0.00030091163,0.00034435172,0.00044424945,0.00018808071,0.000023267232,0.0002973701,0.000004404278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012436655,0.0010072615,0.90436167,0.000020862866,0.0005083132,0.0010491064,0.0021923222,0.0000012934287,0.056402735,0.0000032544058,0.0000848106,0.021931702],"study_design_scores_gemma":[0.0074911616,0.014082602,0.97007555,0.000096775344,0.0006456266,0.0005437478,0.0010878079,0.000054924338,0.005271047,0.00014088758,0.0004078607,0.00010201079],"about_ca_topic_score_codex":0.000010960338,"about_ca_topic_score_gemma":0.000062806306,"teacher_disagreement_score":0.06571387,"about_ca_system_score_codex":0.000051807157,"about_ca_system_score_gemma":0.0001931707,"threshold_uncertainty_score":0.39657798},"labels":[],"label_agreement":null},{"id":"W2894609651","doi":"10.1073/pnas.1817652116","title":"Infiltration of CD8 <sup>+</sup> T cells into tumor cell clusters in triple-negative breast cancer","year":2019,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; McGill University; McGill University Health Centre","funders":"National Cancer Institute; V Foundation for Cancer Research; National Science Foundation","keywords":"Infiltration (HVAC); Cytotoxic T cell; CD8; Chemokine; Immunotherapy; Biology; Immune system; Immunology; Physics","score_opus":0.018550607151461302,"score_gpt":0.2909553893536397,"score_spread":0.2724047822021784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894609651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928931,0.00014463157,2.3579423e-7,0.0030550528,0.000029174851,0.0004462377,0.000026120926,0.000004391774,0.003401083],"genre_scores_gemma":[0.9986183,0.0000787332,0.0004392605,0.00051653205,0.000042113385,0.000012585083,1.8839984e-7,0.000004206042,0.00028807003],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99836785,0.0000077832465,0.00041753805,0.00020182473,0.00087909197,0.0001259361],"domain_scores_gemma":[0.9991163,0.00009361306,0.00048487273,0.000010492074,0.00026872373,0.000026005637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008941348,0.00009413483,0.00022291347,0.00024567268,0.000046099158,0.000008474228,0.00032226482,0.00006495279,0.00009194224],"category_scores_gemma":[0.000068111556,0.00006272587,0.00008842447,0.00096129446,0.00055605633,0.0003551468,0.000044971075,0.00014853103,0.0000012153617],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070342334,0.00010141691,0.049738254,0.00034858278,0.000025682897,7.1466584e-9,0.0017215031,0.0004938014,0.9452814,0.00038310912,0.0004910096,0.0007118267],"study_design_scores_gemma":[0.0017898136,0.000156748,0.15900359,0.00049669534,0.000019678937,0.000006988604,0.0016784325,0.004048644,0.8312237,0.0013971478,0.00008614829,0.00009237342],"about_ca_topic_score_codex":0.00022907193,"about_ca_topic_score_gemma":0.0000010292476,"teacher_disagreement_score":0.11405763,"about_ca_system_score_codex":0.000114418224,"about_ca_system_score_gemma":0.00014231636,"threshold_uncertainty_score":0.25578868},"labels":[],"label_agreement":null},{"id":"W2895006950","doi":"10.1073/pnas.1802166115","title":"Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)","year":2018,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":239,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Cancer Institute; Genentech; University of Texas Southwestern Medical Center; Japan Health Sciences Foundation","keywords":"Atezolizumab; Immune system; PD-L1; Cancer research; Immunotherapy; Lung cancer; Immunity; Biology; Immunology; Medicine; Oncology; Nivolumab","score_opus":0.01625751836405695,"score_gpt":0.28187168195601453,"score_spread":0.26561416359195755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895006950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99516225,0.0003086426,8.23869e-7,0.0038897288,0.000011404785,0.00037675974,0.000011685908,0.0000029892094,0.00023573343],"genre_scores_gemma":[0.9993702,0.00009498402,0.00023002707,0.00009056939,0.000026727783,0.000011738674,1.7964376e-7,0.000003119929,0.0001724241],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99894613,0.000015835916,0.0002528041,0.00016899534,0.0005245767,0.00009168406],"domain_scores_gemma":[0.99947804,0.00011157077,0.00025566018,0.000012663917,0.00011871567,0.000023330502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007373785,0.000081589475,0.00018521884,0.00012280652,0.00011017501,0.000012729251,0.00014124974,0.000037768463,0.000013765663],"category_scores_gemma":[0.0000711536,0.000037483827,0.000031209576,0.00035378386,0.0013201652,0.00011042541,0.000049040023,0.0000490823,1.1574316e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013563833,0.00004445422,0.0020723941,0.000025890275,0.000015873027,5.8578156e-9,0.0008846008,7.2041064e-7,0.98194534,0.00018384484,0.00010703575,0.0011560057],"study_design_scores_gemma":[0.0022591862,0.00047659723,0.27834105,0.00030535448,0.0000151241065,0.0000073559554,0.00020979706,0.00014291731,0.7176809,0.00042420576,0.00010208162,0.000035440684],"about_ca_topic_score_codex":0.000040266583,"about_ca_topic_score_gemma":2.7685735e-7,"teacher_disagreement_score":0.27626866,"about_ca_system_score_codex":0.00003827292,"about_ca_system_score_gemma":0.000033255063,"threshold_uncertainty_score":0.48642036},"labels":[],"label_agreement":null},{"id":"W2895403399","doi":"10.14740/gr1068w","title":"An Unusual Case of Gastritis in One Patient Receiving PD-1 Blocking Therapy: Coexisting Immune-Related Gastritis and Cytomegaloviral Infection","year":2018,"lang":"en","type":"article","venue":"Gastroenterology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pembrolizumab; Immune system; Blocking antibody; Adverse effect; Cancer; Nivolumab; Internal medicine; Immunology; Antibody; Gastroenterology; Immunotherapy","score_opus":0.06152513003388608,"score_gpt":0.3688140766210214,"score_spread":0.3072889465871353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895403399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983548,0.00045170513,0.000042160227,0.0002709224,0.00012655926,0.0005467025,0.000016308813,0.00003608998,0.00015477085],"genre_scores_gemma":[0.9988941,0.00044621137,0.00035696334,0.00008566482,0.00011057062,0.000039236977,0.000021875127,0.000029940455,0.000015415879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971565,0.00071392296,0.000650071,0.00043349806,0.00030159907,0.0007443891],"domain_scores_gemma":[0.99895036,0.00011438168,0.00014638167,0.00031287095,0.0003388553,0.00013717101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017998657,0.00016917939,0.00041972287,0.00073961425,0.00022223091,0.000031784737,0.000089923335,0.0001654826,0.00010742364],"category_scores_gemma":[0.00014526439,0.00017430678,0.00007329392,0.0005734216,0.0009734953,0.00015051973,0.00009756932,0.0006665221,0.000002630337],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008191039,0.0005175017,0.7737705,0.000056771398,0.00013066584,0.00065077195,0.0014755807,0.0000017464024,0.15707456,0.0000045141987,0.00002929016,0.058097072],"study_design_scores_gemma":[0.010045886,0.020783765,0.942138,0.0006577413,0.00002084296,0.00971535,0.00088545954,0.0005736435,0.014971191,0.000038571336,0.00004979471,0.0001197386],"about_ca_topic_score_codex":0.0048201,"about_ca_topic_score_gemma":0.0021356335,"teacher_disagreement_score":0.16836753,"about_ca_system_score_codex":0.0001798043,"about_ca_system_score_gemma":0.00008187028,"threshold_uncertainty_score":0.7286582},"labels":[],"label_agreement":null},{"id":"W2895608724","doi":"10.1007/s00259-018-4171-4","title":"FDG PET/CT for assessing tumour response to immunotherapy","year":2018,"lang":"en","type":"review","venue":"European Journal of Nuclear Medicine and Molecular Imaging","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":261,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Health and Medical Research Council; Medical Research Council; Associazione Italiana per la Ricerca sul Cancro","keywords":"Medicine; Immunotherapy; Timeline; Medical physics; Positron emission tomography; Immune system; Oncology; Nuclear medicine; Immunology","score_opus":0.038631461432770464,"score_gpt":0.3584516726275386,"score_spread":0.3198202111947681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895608724","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008338173,0.98992133,0.0008248282,0.0061464966,0.00055812945,0.00057078485,0.000005472092,0.000025731091,0.0011134241],"genre_scores_gemma":[0.00071195676,0.9819262,0.0049001114,0.010995125,0.0010620424,0.0000024077247,0.000008169514,0.00029878764,0.000095205025],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996965,0.00077322964,0.001185257,0.00034296027,0.00039176326,0.00034179923],"domain_scores_gemma":[0.99799734,0.00018868705,0.00085668155,0.0003571478,0.00029531427,0.00030480203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004048556,0.00043890858,0.0015824989,0.00068573357,0.00014550656,0.000100181824,0.00029930446,0.000012319831,0.00007509085],"category_scores_gemma":[0.0005195595,0.00030579802,0.0006604498,0.000289587,0.000226228,0.00010742037,0.000066770124,0.0004635624,0.00001511669],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025442166,0.000047306687,0.0000013597387,0.0022619346,0.0006390575,0.010886257,0.00038753552,3.901276e-8,0.013988516,0.0000042404517,0.04776053,0.921479],"study_design_scores_gemma":[0.0030801827,0.0013611936,0.000028453425,0.034061544,0.0010530041,0.025220854,0.00036297267,0.0000035134751,0.000018900126,0.0000027556778,0.93453825,0.00026835475],"about_ca_topic_score_codex":0.0000029793714,"about_ca_topic_score_gemma":4.7995652e-8,"teacher_disagreement_score":0.92121065,"about_ca_system_score_codex":0.00013055713,"about_ca_system_score_gemma":0.00026895327,"threshold_uncertainty_score":0.99993944},"labels":[],"label_agreement":null},{"id":"W2896068855","doi":"10.1093/annonc/mdy288.114","title":"Phase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated non-small cell lung cancer (NSCLC) and other solid tumors","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Boehringer Ingelheim (Canada); University of Alberta; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Response Evaluation Criteria in Solid Tumors; Microsatellite instability; Blockade; Internal medicine; Colorectal cancer; Oncology; Cancer research; Cancer; Phases of clinical research; Receptor; Clinical trial; Adverse effect; Biology; Microsatellite","score_opus":0.024037371716843267,"score_gpt":0.3505419665554048,"score_spread":0.32650459483856153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896068855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919605,0.003821044,0.000013456613,0.00014836002,0.00025826987,0.0031424668,0.00041011782,0.000028987857,0.0002167518],"genre_scores_gemma":[0.99628156,0.002263613,0.00020825388,0.00057120254,0.00004068079,0.00032751026,0.00006018344,0.00010799912,0.0001390104],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99624074,0.00027429173,0.0011933843,0.0008962209,0.00045516837,0.00094020413],"domain_scores_gemma":[0.99766684,0.00013253198,0.0009949673,0.0004316471,0.00056546205,0.00020857276],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005091555,0.00060753606,0.0020264809,0.0005893156,0.00010594258,0.00001933849,0.00025426495,0.00021195126,0.00015733982],"category_scores_gemma":[0.000024223096,0.00047009613,0.00010503188,0.0012219781,0.00061886356,0.0002316812,0.0000829419,0.00033548503,0.0000011907164],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05789696,0.0077640754,0.54806066,0.00059606216,0.0011574139,0.00016798475,0.012603216,0.00037853673,0.3588261,2.9333256e-7,0.0010418633,0.011506816],"study_design_scores_gemma":[0.14053494,0.06630923,0.16968274,0.0029734715,0.0007361735,0.000022163691,0.0053837704,0.001153984,0.6109263,0.0000016861666,0.001240004,0.0010355813],"about_ca_topic_score_codex":0.02957386,"about_ca_topic_score_gemma":0.03313514,"teacher_disagreement_score":0.37837794,"about_ca_system_score_codex":0.00057127385,"about_ca_system_score_gemma":0.0016518573,"threshold_uncertainty_score":0.99977505},"labels":[],"label_agreement":null},{"id":"W2896600825","doi":"10.1016/s1470-2045(18)30700-9","title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1409,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Medicine; Internal medicine; Oncology; Immunotherapy; Cancer","score_opus":0.059457284228469,"score_gpt":0.3855917897477813,"score_spread":0.3261345055193123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896600825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870612,0.0007673303,0.000044805096,0.00282389,0.0023739187,0.0031433688,0.00007041116,0.000114998715,0.0036000481],"genre_scores_gemma":[0.99394614,0.00091822835,0.0010971633,0.0008566226,0.0010848689,0.00025854167,0.00004600564,0.00006444114,0.0017280016],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964208,0.0005532781,0.0011547316,0.00055680436,0.00043573175,0.00087864464],"domain_scores_gemma":[0.9968739,0.0011628116,0.0005888959,0.00104268,0.00018957535,0.00014214455],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001466869,0.00042033056,0.002274485,0.00022323645,0.00014639842,0.000017662709,0.00052874006,0.00032731006,0.0011513],"category_scores_gemma":[0.0006880736,0.00027406582,0.00035417653,0.00054951006,0.000811893,0.00013123832,0.00013475811,0.00046289962,0.00009868885],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9536278,0.0014436648,0.0004076472,0.000089749155,0.00079047517,0.00011350821,0.0018764051,0.0000049150417,0.008165564,0.000032139167,0.0015735803,0.031874556],"study_design_scores_gemma":[0.9513123,0.015526126,0.0026232742,0.0001233043,0.00040074377,0.000051053634,0.0011377593,0.00051434047,0.004532529,0.00003452764,0.02342135,0.0003226896],"about_ca_topic_score_codex":0.00067046203,"about_ca_topic_score_gemma":0.003888741,"teacher_disagreement_score":0.031551868,"about_ca_system_score_codex":0.0008381379,"about_ca_system_score_gemma":0.00083742844,"threshold_uncertainty_score":0.99997115},"labels":[],"label_agreement":null},{"id":"W2896721818","doi":"10.1016/j.ijrobp.2018.07.630","title":"Impact of Palliative Radiation on Lymphocyte Count and Neutrophil-to-Lymphocyte Ratio in Patients Receiving PD-1 Inhibitors","year":2018,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Neutrophil to lymphocyte ratio; Internal medicine; Lung cancer; Lymphocyte; Radiation therapy; Gastroenterology; Cancer; Cohort; Oncology","score_opus":0.0156550724555801,"score_gpt":0.33505813105070276,"score_spread":0.31940305859512264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896721818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99619997,0.0002997455,0.0005583387,0.00070340256,0.0016199581,0.00033088351,0.00005413759,0.0000113788965,0.0002222181],"genre_scores_gemma":[0.99620444,0.0010265682,0.0003590662,0.00085893384,0.0014510883,0.0000074956856,0.000056070316,0.00002295427,0.000013382312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981855,0.00017968945,0.0008726073,0.00023188585,0.00032491787,0.00020541217],"domain_scores_gemma":[0.9974571,0.0002692989,0.0011346497,0.00012696431,0.00089419726,0.00011777428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049617735,0.00020645675,0.00048112604,0.0003953958,0.000052304335,0.000020662028,0.00017966694,0.00019698005,0.00003998311],"category_scores_gemma":[0.0003053716,0.00017306517,0.00019546982,0.0003034314,0.00019810963,0.00023272664,0.00003537356,0.00021805242,0.000010130423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008706901,0.0004673982,0.73101425,0.0000065379522,0.00052818755,0.0000060611146,0.0012679439,0.00034713914,0.00890722,0.00024948944,0.0004620144,0.24803688],"study_design_scores_gemma":[0.01592778,0.007846964,0.96511585,0.00018734644,0.000045479323,0.000014481842,0.00004147991,0.0009833983,0.0066106487,0.00040025407,0.002668657,0.00015766868],"about_ca_topic_score_codex":0.0001274568,"about_ca_topic_score_gemma":0.000015186834,"teacher_disagreement_score":0.2478792,"about_ca_system_score_codex":0.0032080344,"about_ca_system_score_gemma":0.0008702594,"threshold_uncertainty_score":0.83888984},"labels":[],"label_agreement":null},{"id":"W2896903565","doi":"10.1093/annonc/mdy283.083","title":"Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Randomization; Adverse effect; Intention-to-treat analysis; Randomized controlled trial; Surgery; Ipilimumab; Interim analysis; Gastroenterology; Cancer; Immunotherapy","score_opus":0.0451959082111775,"score_gpt":0.34429111020888037,"score_spread":0.2990952019977029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896903565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968029,0.00017620271,0.00007080464,0.00065610034,0.000114402705,0.0005192047,0.000057121753,0.000020184538,0.0015830236],"genre_scores_gemma":[0.9985434,0.00011808434,0.0005040512,0.00013851038,0.000061826424,0.00003871274,0.00015209959,0.00002848439,0.0004148711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982629,0.00011187238,0.0007289187,0.0003230107,0.00024700022,0.0003262889],"domain_scores_gemma":[0.99850017,0.00013278174,0.00050370704,0.0004892227,0.00029957198,0.000074547104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026218322,0.0002210942,0.00095127255,0.00043746273,0.000043550815,0.0000052868045,0.00018162736,0.00013327067,0.00015990302],"category_scores_gemma":[0.00009024207,0.00015744132,0.0003285045,0.0007748575,0.00022868709,0.00012159694,0.000055913857,0.000090317124,0.0000018074417],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19925779,0.00621741,0.48222926,0.00021212816,0.0037908335,0.00015503909,0.006753622,0.00009530957,0.0072760927,0.000009756213,0.00053063856,0.29347214],"study_design_scores_gemma":[0.10246202,0.12907197,0.66140485,0.0003742794,0.0018633369,0.000010567595,0.0013243555,0.0011247296,0.09570702,0.000024575422,0.0061969804,0.00043530305],"about_ca_topic_score_codex":0.0013494783,"about_ca_topic_score_gemma":0.012517913,"teacher_disagreement_score":0.29303682,"about_ca_system_score_codex":0.0002637106,"about_ca_system_score_gemma":0.00031276463,"threshold_uncertainty_score":0.69852895},"labels":[],"label_agreement":null},{"id":"W2897283341","doi":"10.1038/s41416-018-0220-9","title":"Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy","year":2018,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Institute of Cancer Research; Institut Du Cancer de Montréal; Institut National Du Cancer","keywords":"Oncology; Lung cancer; Internal medicine; Medicine; Cohort; Immunotherapy; PD-L1; Immunohistochemistry; Cancer; Pathology","score_opus":0.006954791000340693,"score_gpt":0.27787800787922173,"score_spread":0.27092321687888105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897283341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750506,0.024380974,0.000035459216,0.00006277413,0.000106665626,0.00025144243,0.000035223737,0.000001711985,0.000075123025],"genre_scores_gemma":[0.99268115,0.0069887433,0.00010093036,0.00009595286,0.00009969825,0.0000049781934,0.0000019545628,0.000010334593,0.0000162547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992127,0.000034862805,0.00035572433,0.00008910776,0.00020982079,0.00009778681],"domain_scores_gemma":[0.999226,0.00003440477,0.00032082899,0.000043316322,0.00033155404,0.000043900473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016710383,0.000068359936,0.00025745842,0.00009985055,0.000022200882,0.000011027007,0.00003897666,0.000041289568,0.00006690892],"category_scores_gemma":[0.000036746827,0.00006512673,0.00003154734,0.000111886766,0.00018643893,0.00013050943,0.000010481039,0.000088604196,4.3094182e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002643387,0.00019166668,0.5981621,0.00010945183,0.00012336143,0.000022549277,0.00068998133,0.000001297094,0.026871715,0.0000011516552,0.00010094701,0.3710824],"study_design_scores_gemma":[0.004487278,0.0012791707,0.96950644,0.0013712941,0.000055557393,0.0001719362,0.00015928266,0.00009673368,0.022263983,0.000054976117,0.0004950665,0.000058278245],"about_ca_topic_score_codex":0.0003045756,"about_ca_topic_score_gemma":0.000209082,"teacher_disagreement_score":0.37134436,"about_ca_system_score_codex":0.00005438383,"about_ca_system_score_gemma":0.00010465711,"threshold_uncertainty_score":0.2655791},"labels":[],"label_agreement":null},{"id":"W2897631076","doi":"10.1093/annonc/mdy374.041","title":"A phase I trial of BI 754091, a programmed death receptor 1 (PD-1) inhibitor, in patients with advanced solid tumors","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Pharmacokinetics; Internal medicine; Oncology; Cancer; Pharmacology","score_opus":0.05004048888174779,"score_gpt":0.39877375961944994,"score_spread":0.34873327073770216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897631076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965336,0.00011508629,0.000005490561,0.00087345653,0.00028129976,0.0013104001,0.000020323932,0.000016056492,0.00084429997],"genre_scores_gemma":[0.9982143,0.00007747864,0.0007826288,0.000562621,0.00016647506,0.000083209474,0.000034225584,0.00001782359,0.00006125352],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99858606,0.00008520967,0.00058930804,0.00022095202,0.00022338219,0.00029509285],"domain_scores_gemma":[0.99884367,0.00006403607,0.00039635456,0.0002256727,0.00038816058,0.00008210414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036528782,0.00013925263,0.0006227238,0.0001963286,0.000020827858,0.0000022868442,0.000088882625,0.00012833354,0.000112500944],"category_scores_gemma":[0.00013308626,0.00010431017,0.000102097656,0.0003518642,0.0003462627,0.00006452337,0.000022236074,0.00011013493,0.0000036815525],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6150658,0.008409459,0.007723352,0.000057292695,0.00016236327,0.000008412375,0.00064180564,1.464706e-7,0.010375703,0.000008173251,0.0014002927,0.3561472],"study_design_scores_gemma":[0.4771073,0.3306416,0.018314956,0.0004783078,0.000057451773,0.000005092678,0.00020448813,0.000005607356,0.107146785,0.000033657067,0.0657917,0.00021305942],"about_ca_topic_score_codex":0.00009280251,"about_ca_topic_score_gemma":0.00009556918,"teacher_disagreement_score":0.35593414,"about_ca_system_score_codex":0.000058129903,"about_ca_system_score_gemma":0.00047883805,"threshold_uncertainty_score":0.42536452},"labels":[],"label_agreement":null},{"id":"W2898096006","doi":"10.1016/j.jtho.2018.08.1726","title":"P3.04-19 Do Advanced Lung Cancer Patients Derive Similar Survival Benefits from Immunotherapy? A Systematic Review and Meta-Analysis","year":2018,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Meta-analysis; Lung cancer; Subgroup analysis; Oncology; Randomized controlled trial; Immunotherapy; Cancer; Confidence interval","score_opus":0.0676536742065104,"score_gpt":0.45838238290408695,"score_spread":0.39072870869757653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898096006","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013747625,0.99508804,0.000040808398,0.0006726696,0.0006951054,0.002812677,0.00046957083,0.0000145597105,0.00006906904],"genre_scores_gemma":[0.000035496058,0.9961221,0.0008680604,0.0019664455,0.0002527882,0.000258765,0.000071505165,0.0000897443,0.00033506262],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99285847,0.0018348028,0.0035779052,0.00057505775,0.0007393026,0.00041449038],"domain_scores_gemma":[0.990604,0.0009140976,0.0064750626,0.00078052713,0.0009332083,0.00029310808],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023549283,0.0008122621,0.017426638,0.0006799867,0.00011939473,0.000050086517,0.0005405514,0.0006082492,0.0015529137],"category_scores_gemma":[0.00032852116,0.00048085983,0.0057436097,0.0010741241,0.000183126,0.00016931446,0.00009688531,0.0007951825,0.0000070064884],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010930322,0.00024533112,0.00002939397,0.3724053,0.48781082,0.00007416449,0.00016382596,9.385742e-7,0.0000014731532,7.4489225e-7,0.0011380545,0.13703693],"study_design_scores_gemma":[0.00074217573,0.00096670474,0.000051058218,0.06515101,0.76697433,0.00015198906,0.000030681083,0.000001466597,7.539593e-7,0.0000047238386,0.16557635,0.00034871834],"about_ca_topic_score_codex":0.00008728316,"about_ca_topic_score_gemma":0.00013387275,"teacher_disagreement_score":0.30725428,"about_ca_system_score_codex":0.001171165,"about_ca_system_score_gemma":0.0011591087,"threshold_uncertainty_score":0.9997643},"labels":[],"label_agreement":null},{"id":"W2898119006","doi":"10.1093/annonc/mdy287.078","title":"KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; MorphoSys; Swedish Orphan Biovitrum; Astellas Pharma; Genentech; Symphogen; AstraZeneca; Amgen; Pfizer; Eisai; Merck; GlaxoSmithKline","keywords":"Medicine; Pembrolizumab; Head and neck squamous-cell carcinoma; Oncology; Head and neck; Internal medicine; Chemoradiotherapy; Basal cell; Phases of clinical research; Head and neck cancer; Radiation therapy; Chemotherapy; Cancer; Overall survival; Surgery; Immunotherapy","score_opus":0.04605862990792877,"score_gpt":0.3704412387882663,"score_spread":0.32438260888033754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898119006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99481666,0.0010237982,0.00015991754,0.001313667,0.00020964677,0.0015190456,0.00002841095,0.000020301775,0.00090857723],"genre_scores_gemma":[0.99789107,0.00013130004,0.0003870862,0.0010010003,0.00022755029,0.000078201636,0.000054973247,0.000025691823,0.00020315332],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99853134,0.00005629426,0.0006235491,0.00031958983,0.0001900166,0.0002791894],"domain_scores_gemma":[0.9984691,0.00014131962,0.00049529644,0.00029078094,0.0005015287,0.00010195888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034160973,0.00018174724,0.00074780005,0.00016840758,0.00007293163,0.0000051811526,0.00009579246,0.00017459717,0.000048139857],"category_scores_gemma":[0.00008888873,0.00017422835,0.000107768996,0.00022007248,0.00020081736,0.0001021339,0.000026663323,0.00009031718,0.0000018401855],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39362806,0.009732233,0.00504058,0.0007963724,0.00030663106,0.00003299104,0.010908304,0.00004538232,0.22852625,0.000024530149,0.008533072,0.34242558],"study_design_scores_gemma":[0.38278255,0.18447295,0.06384786,0.00007198817,0.00037002424,0.00006015887,0.0018493994,0.003408206,0.34203294,0.00007966609,0.020615602,0.0004086655],"about_ca_topic_score_codex":0.00047662717,"about_ca_topic_score_gemma":0.00026398222,"teacher_disagreement_score":0.3420169,"about_ca_system_score_codex":0.00011191215,"about_ca_system_score_gemma":0.000412042,"threshold_uncertainty_score":0.71048254},"labels":[],"label_agreement":null},{"id":"W2898201251","doi":"10.1093/annonc/mdy341.028","title":"The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: A systematic review","year":2018,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; MEDLINE; PsycINFO; CINAHL; Observational study; Clinical trial; Systematic review; Protocol (science); Cancer; Cochrane Library; Quality of life (healthcare); Family medicine; Alternative medicine; Psychological intervention; Internal medicine; Meta-analysis; Pathology; Psychiatry","score_opus":0.3139636080246317,"score_gpt":0.4635268026791106,"score_spread":0.14956319465447893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898201251","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010152197,0.9862743,6.808751e-7,0.0010179882,0.0006373468,0.010931918,0.00006766324,0.000010748816,0.000044154775],"genre_scores_gemma":[0.000087653745,0.9955309,0.00007059823,0.0011360497,0.000071833056,0.0027762768,0.000052978347,0.000049671795,0.00022404188],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99338263,0.00050205825,0.0050720675,0.0003625832,0.0003171315,0.00036354252],"domain_scores_gemma":[0.9925662,0.00061981456,0.0052604587,0.00094408594,0.00054928585,0.0000601329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022687232,0.00040257914,0.0054925424,0.00025432027,0.000049673734,0.000007727711,0.0002746663,0.00037231427,0.000030349775],"category_scores_gemma":[0.0009535158,0.00021897203,0.0014725481,0.0005591376,0.00032428064,0.00005122489,0.00006567696,0.00025273452,0.0000019214506],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084096665,0.00030806355,0.000024798806,0.49341458,0.001582149,0.000007237628,0.000096702184,1.4267449e-8,0.000011444692,0.000004747885,0.0011995671,0.5025097],"study_design_scores_gemma":[0.001068325,0.0027956688,0.000014968404,0.35340968,0.0008667415,0.00005010439,0.000019308327,6.624621e-7,0.00008906284,0.0000045792826,0.6415546,0.00012630028],"about_ca_topic_score_codex":0.00037042866,"about_ca_topic_score_gemma":0.0000843541,"teacher_disagreement_score":0.64035505,"about_ca_system_score_codex":0.00029324996,"about_ca_system_score_gemma":0.0011474586,"threshold_uncertainty_score":0.892942},"labels":[],"label_agreement":null},{"id":"W2898234770","doi":"10.1093/annonc/mdy289.062","title":"ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Ipilimumab; Internal medicine; Melanoma; Clinical endpoint; Refractory (planetary science); Phases of clinical research; Oncology; Progressive disease; Clinical trial; Gastroenterology; Immunotherapy; Chemotherapy; Cancer; Cancer research","score_opus":0.06381902280130473,"score_gpt":0.3998208149114062,"score_spread":0.33600179211010145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898234770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878015,0.0017932054,0.00003795465,0.0012248751,0.00025553076,0.0008673608,0.000014274794,0.000023505474,0.00798178],"genre_scores_gemma":[0.9982442,0.0006299409,0.00036362864,0.0003988126,0.00009376249,0.000040673487,0.000029301791,0.00002802102,0.00017163147],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99789727,0.00028557848,0.00079823827,0.00033020836,0.00029904777,0.00038964435],"domain_scores_gemma":[0.9978085,0.00057080697,0.00070946885,0.00039615948,0.00041364817,0.00010138693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000991708,0.00024537314,0.0019102421,0.000315719,0.000044722903,0.000004244076,0.00015382576,0.00021284465,0.00027944302],"category_scores_gemma":[0.00011122693,0.00016964441,0.00016203545,0.00043977832,0.0015448615,0.000097420205,0.000031129766,0.00023090612,0.000005513179],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9404801,0.0024696009,0.0016585711,0.00010135655,0.0010562821,0.00010943184,0.003092357,0.0000016082895,0.02589018,0.000025809382,0.001888341,0.02322636],"study_design_scores_gemma":[0.817569,0.057287,0.007102404,0.00043922936,0.00035369614,0.00006391225,0.0014865567,0.00013802129,0.10224462,0.000013812453,0.013035634,0.0002661033],"about_ca_topic_score_codex":0.0010607386,"about_ca_topic_score_gemma":0.0015894285,"teacher_disagreement_score":0.122911096,"about_ca_system_score_codex":0.00008130049,"about_ca_system_score_gemma":0.0005626725,"threshold_uncertainty_score":0.6917898},"labels":[],"label_agreement":null},{"id":"W2898263433","doi":"10.1016/j.jtho.2018.08.1727","title":"P3.04-20 Correlation of Immune-Related Adverse Events and Response from Immune Checkpoint Inhibitors in Patients with Advanced NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Immune system; Adverse effect; Oncology; Immune checkpoint; Correlation; Immunology; Internal medicine; Immunotherapy","score_opus":0.007345838563558819,"score_gpt":0.320942653332588,"score_spread":0.3135968147690292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898263433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99705356,0.0010146932,0.000048971455,0.00062036456,0.0007662618,0.00031874652,0.000008425646,0.000006387672,0.00016261249],"genre_scores_gemma":[0.99812573,0.00009467375,0.0014962453,0.000066856526,0.00006736882,0.0000024195424,0.000012054076,0.000018756562,0.0001159043],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99783313,0.0003138035,0.0012524723,0.0001497681,0.00027697385,0.00017387014],"domain_scores_gemma":[0.99779695,0.0001827336,0.0014131343,0.0001823698,0.0003457687,0.00007904004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011898488,0.00014899072,0.0005897055,0.0003291842,0.000040105715,0.0000020522755,0.00008789448,0.00020936421,0.00012073177],"category_scores_gemma":[0.000210658,0.00011110031,0.00014179469,0.00031429797,0.00023119945,0.00019324617,0.00003457303,0.00035773346,0.0000037258749],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49869037,0.0009581438,0.19021966,0.000035160236,0.00046872933,0.000068120826,0.0027602601,0.000026323321,0.15307027,7.894705e-7,0.000046650875,0.15365554],"study_design_scores_gemma":[0.013760916,0.013006795,0.9565365,0.0010501938,0.00018165787,0.000070085334,0.0005829122,0.00006195065,0.013550117,0.000048709633,0.0010313615,0.00011880064],"about_ca_topic_score_codex":0.000065512446,"about_ca_topic_score_gemma":0.00003199036,"teacher_disagreement_score":0.76631683,"about_ca_system_score_codex":0.0004235521,"about_ca_system_score_gemma":0.00036467653,"threshold_uncertainty_score":0.4530539},"labels":[],"label_agreement":null},{"id":"W2898272834","doi":"10.1016/j.jtho.2018.08.780","title":"P1.09-04 Optimization of PD-L1 Testing Specimen Flow in the Greater Hamilton, Ontario Region","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Histology; Immunohistochemistry; Medicine; Staining; Cytology; Lung cancer; Pathology; PD-L1; Internal medicine; Cancer; Immunotherapy","score_opus":0.05723737596441916,"score_gpt":0.375391455338915,"score_spread":0.3181540793744958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898272834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859885,0.0002226591,0.0016445597,0.0028945606,0.0005785364,0.00021320829,7.0554523e-7,0.0000052211853,0.008452052],"genre_scores_gemma":[0.97418064,0.00007257388,0.023096094,0.0010633154,0.00079307024,0.0000025936165,0.0000022135812,0.0000134911115,0.00077601086],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99872804,0.0001830906,0.0006123694,0.000100714286,0.00021457512,0.00016123685],"domain_scores_gemma":[0.9987667,0.00014137926,0.0005818838,0.00017711225,0.0002931092,0.000039818715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011043528,0.000098645134,0.00035896437,0.00019305482,0.00004597459,0.000009776402,0.00015544386,0.00013013891,0.00021381715],"category_scores_gemma":[0.00009833093,0.000060854352,0.00010494677,0.00028248402,0.00016345263,0.00009713085,0.000015330603,0.00029763192,0.0000030540127],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074292995,0.0017150068,0.18298754,0.00022990743,0.00085143524,0.0020165173,0.047257658,0.0026371928,0.031962547,0.00001512889,0.021475898,0.6345582],"study_design_scores_gemma":[0.009320815,0.025697593,0.81632483,0.0018142095,0.00087305304,0.01576575,0.0028939617,0.004477968,0.012277871,0.00031478383,0.10982771,0.00041147304],"about_ca_topic_score_codex":0.0007126053,"about_ca_topic_score_gemma":0.0019406069,"teacher_disagreement_score":0.6341467,"about_ca_system_score_codex":0.0005349812,"about_ca_system_score_gemma":0.00046392303,"threshold_uncertainty_score":0.24815685},"labels":[],"label_agreement":null},{"id":"W2898338151","doi":"10.1016/j.jtho.2018.08.1564","title":"P3.01-04 Immune Checkpoint Inhibitors (ICIs) in NSCLC: Immune Related Adverse Events (irAEs) and Outcomes. A Canadian Single Institution Experience","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adverse effect; Immune system; Oncology; Institution; Internal medicine; Immunology","score_opus":0.021264394917971916,"score_gpt":0.35837666064516016,"score_spread":0.3371122657271882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898338151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99099374,0.0012695282,0.000023887507,0.0038422362,0.001626425,0.00031979586,0.000006942779,0.000011608763,0.0019058287],"genre_scores_gemma":[0.99818057,0.00017990876,0.000559913,0.000523101,0.00016315636,0.00001072261,0.000006672765,0.000017688037,0.00035828742],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99768645,0.00014888927,0.0013521947,0.00019788282,0.00024430655,0.0003702883],"domain_scores_gemma":[0.9985552,0.000054560573,0.0007318629,0.00021605536,0.00018714242,0.00025522007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001121378,0.00019202898,0.0006332751,0.0006105658,0.00012032173,0.000008109104,0.0001500673,0.0002973904,0.0005702269],"category_scores_gemma":[0.00031109978,0.00015591951,0.00023380572,0.00045560428,0.00040042974,0.00027908626,0.000044220542,0.00047704863,0.000015395217],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02727281,0.0016600175,0.10366623,0.00014418339,0.00083791395,0.0025896686,0.017660644,0.000013875118,0.17748894,0.000034589637,0.0012740885,0.667357],"study_design_scores_gemma":[0.010078273,0.007226759,0.85791975,0.0015974962,0.00025853858,0.0052293614,0.006654724,0.000109305525,0.017025806,0.00013648745,0.09325606,0.00050741265],"about_ca_topic_score_codex":0.009480068,"about_ca_topic_score_gemma":0.01820466,"teacher_disagreement_score":0.75425357,"about_ca_system_score_codex":0.0016878495,"about_ca_system_score_gemma":0.00095788174,"threshold_uncertainty_score":0.99971056},"labels":[],"label_agreement":null},{"id":"W2898348027","doi":"10.1093/annonc/mdy424.054","title":"Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Oncology; Melanoma; Internal medicine; Immunotherapy; Cancer; Cancer research","score_opus":0.07025226007946675,"score_gpt":0.3951179964264698,"score_spread":0.324865736347003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898348027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957672,0.000505225,0.000004511611,0.00055514777,0.00058703497,0.000737969,0.000017325006,0.000007791751,0.0018178271],"genre_scores_gemma":[0.99767864,0.0015568286,0.000053725955,0.0002183855,0.00005246952,0.000024908733,0.000023936664,0.000014499161,0.000376617],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99841213,0.00017796649,0.0007705085,0.0001969557,0.00021985362,0.00022259446],"domain_scores_gemma":[0.9989111,0.0001660667,0.00045683063,0.00024221414,0.00018768867,0.00003612023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000813,0.00011692649,0.0008033543,0.00026892291,0.000012912025,0.0000013058798,0.00011887132,0.0001796811,0.00019613966],"category_scores_gemma":[0.00009300249,0.00011536115,0.00016081294,0.0002798308,0.00026032346,0.00007006352,0.00003308629,0.000096631025,0.0000020647954],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6544734,0.0021927957,0.0012209167,0.00004285046,0.00016382434,0.000022189397,0.002051787,0.000002051945,0.1248783,0.00010062467,0.00029448484,0.21455674],"study_design_scores_gemma":[0.80915457,0.059684154,0.039662506,0.0001879234,0.000026016,0.000010059212,0.00025615375,0.00013919504,0.07923193,0.00033745376,0.011143521,0.00016652471],"about_ca_topic_score_codex":0.0011239602,"about_ca_topic_score_gemma":0.0016180857,"teacher_disagreement_score":0.21439022,"about_ca_system_score_codex":0.00016054504,"about_ca_system_score_gemma":0.0003370509,"threshold_uncertainty_score":0.47042912},"labels":[],"label_agreement":null},{"id":"W2898353693","doi":"10.1093/annonc/mdy287.074","title":"IMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Oncology; Head and neck; Adjuvant; Internal medicine; Basal cell; Head and neck cancer; Adjuvant therapy; Cancer; Immunotherapy; Surgery; Nivolumab","score_opus":0.04919813182413135,"score_gpt":0.37082337033940665,"score_spread":0.3216252385152753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898353693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98681164,0.0074043074,0.00000638814,0.0006359291,0.00017799503,0.0019109112,0.000038457492,0.000006791762,0.0030075614],"genre_scores_gemma":[0.9960144,0.002627532,0.00005264078,0.0009991686,0.00005934057,0.0000816675,0.0000033709593,0.000025754336,0.00013612914],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997657,0.00050217827,0.0010381188,0.00028148707,0.0002747148,0.0002465008],"domain_scores_gemma":[0.99754375,0.0004687694,0.00088126026,0.00049551856,0.0005477176,0.00006300341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007950555,0.00023199238,0.0015955828,0.00016386442,0.000042211166,0.0000025604797,0.00018573673,0.00018399447,0.00048653086],"category_scores_gemma":[0.000069310336,0.00014431057,0.00036620058,0.00025536225,0.0012456357,0.000047340058,0.00005174018,0.00013969878,0.0000016303172],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8442559,0.006593639,0.006224579,0.00009282672,0.0006807725,0.000019680143,0.016653234,4.4265218e-7,0.053644877,0.00002910089,0.00036211664,0.07144281],"study_design_scores_gemma":[0.5607765,0.048656892,0.047213364,0.000088948414,0.00019526754,0.000024929892,0.0020825928,0.000019152341,0.33895305,0.00017482328,0.0016610428,0.00015345836],"about_ca_topic_score_codex":0.0027295894,"about_ca_topic_score_gemma":0.00022009587,"teacher_disagreement_score":0.28530815,"about_ca_system_score_codex":0.000024102652,"about_ca_system_score_gemma":0.00032832834,"threshold_uncertainty_score":0.5884814},"labels":[],"label_agreement":null},{"id":"W2898376257","doi":"10.1093/annonc/mdy424.043","title":"Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Eisai; Merck","keywords":"Medicine; Pembrolizumab; Ovarian cancer; Internal medicine; Oncology; BRCA mutation; Population; Cancer; Immunotherapy","score_opus":0.06020003525901501,"score_gpt":0.4252376011103097,"score_spread":0.3650375658512947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898376257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99516267,0.00018913292,0.000017486775,0.00294157,0.0001698772,0.0013236246,0.00014540294,0.000009332615,0.00004091332],"genre_scores_gemma":[0.997979,0.00018820808,0.0011486328,0.00042889165,0.000105332554,0.00006147988,0.000035679932,0.00001407584,0.000038739723],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9977219,0.00064342044,0.00071701297,0.00036913806,0.00034070748,0.0002078223],"domain_scores_gemma":[0.99782413,0.0006255076,0.00068078894,0.00033734934,0.00045223557,0.0000799989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016235486,0.0001406578,0.00049694837,0.00009148933,0.00008710003,0.000004199235,0.0001081523,0.00013593369,0.000021118263],"category_scores_gemma":[0.0005870447,0.000081889244,0.00004056414,0.00023798143,0.00012479401,0.000071823415,0.00007597047,0.00018488454,3.9850121e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69010806,0.0034405873,0.17243868,0.000008552949,0.00014459356,0.0000051420316,0.0040992294,0.0000043143677,0.056884933,1.7893532e-7,0.0008641994,0.07200152],"study_design_scores_gemma":[0.06823421,0.092307314,0.7610981,0.0006539602,0.00007075764,6.305052e-7,0.0005537658,0.000011497218,0.07419929,0.0000049634696,0.0027539954,0.000111504],"about_ca_topic_score_codex":0.00030407764,"about_ca_topic_score_gemma":0.00041356607,"teacher_disagreement_score":0.62187386,"about_ca_system_score_codex":0.000107110354,"about_ca_system_score_gemma":0.00032218124,"threshold_uncertainty_score":0.33393463},"labels":[],"label_agreement":null},{"id":"W2898394782","doi":"10.1093/annonc/mdy424.045","title":"KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Cetuximab; Carboplatin; Head and neck squamous-cell carcinoma; Internal medicine; Pembrolizumab; Interim analysis; Cisplatin; Phases of clinical research; Oncology; Chemotherapy; Gastroenterology; Head and neck cancer; Radiation therapy; Nuclear medicine; Randomized controlled trial; Urology; Cancer; Immunotherapy","score_opus":0.10538821966103608,"score_gpt":0.416188050832784,"score_spread":0.3107998311717479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898394782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934772,0.0023600115,0.0000662443,0.0012750971,0.00030007382,0.0013831045,0.000068316695,0.000014537994,0.0010553624],"genre_scores_gemma":[0.9984374,0.00023671937,0.0002818513,0.0005323643,0.00017363015,0.00006432144,0.00002483606,0.000023576134,0.00022532295],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9984479,0.00008383996,0.000681516,0.00030600274,0.00016924007,0.00031147944],"domain_scores_gemma":[0.99848,0.00028070385,0.0003851193,0.00032313817,0.000419747,0.00011126139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040828573,0.00018796122,0.0007676615,0.00018011637,0.000079859514,0.00000415995,0.000115971336,0.000100021876,0.00013816245],"category_scores_gemma":[0.00009892465,0.00016015267,0.0001442064,0.00019856641,0.0002988804,0.000049304945,0.000044214274,0.000103622806,0.0000021149174],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42143852,0.040501427,0.018016974,0.0021178485,0.00086637744,0.0001261262,0.01633296,0.0000028890513,0.022501511,0.00005538638,0.03297477,0.4450652],"study_design_scores_gemma":[0.25971416,0.5510615,0.025354026,0.0001488331,0.000774984,0.00013567304,0.0027297179,0.00069382566,0.04384604,0.000215447,0.11490177,0.00042399793],"about_ca_topic_score_codex":0.0005555235,"about_ca_topic_score_gemma":0.0010551778,"teacher_disagreement_score":0.5105601,"about_ca_system_score_codex":0.000035504352,"about_ca_system_score_gemma":0.00019021622,"threshold_uncertainty_score":0.6530837},"labels":[],"label_agreement":null},{"id":"W2898510460","doi":"10.1634/theoncologist.2018-0434","title":"Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"York University; AstraZeneca","keywords":"Medicine; Blockade; Rash; Immune checkpoint; Multidisciplinary approach; Immune system; Oncology; Internal medicine; Pharmacology; Immunology; Receptor","score_opus":0.029282654386571155,"score_gpt":0.28493885733428814,"score_spread":0.25565620294771696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898510460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98464686,0.00065556087,0.0001689134,0.008384595,0.000063733154,0.0023561667,0.000043822973,0.00011544696,0.0035649033],"genre_scores_gemma":[0.99397725,0.000023910556,0.0015378314,0.0011209858,0.00040947634,0.00027680275,0.00004321433,0.000044286367,0.0025662272],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9983741,0.00013516791,0.0003458293,0.00041576676,0.00034380183,0.00038530896],"domain_scores_gemma":[0.9984197,0.00024262763,0.00020920447,0.00086903287,0.00011367468,0.00014578673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023641017,0.0002991318,0.00043381413,0.000042723565,0.0003538109,0.00004989706,0.00032180373,0.00006734816,0.00011551176],"category_scores_gemma":[0.000072390685,0.000118861935,0.00011571652,0.00049497065,0.00086515583,0.00004106631,0.00015425896,0.0002441427,0.000030188303],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50326574,0.007262923,0.12381691,0.0001381493,0.0061756372,0.0014118192,0.059141133,0.0002073213,0.1728097,0.00002925583,0.08122859,0.044512846],"study_design_scores_gemma":[0.031943318,0.03031456,0.79365677,0.0010792421,0.001273124,0.0015383747,0.018054176,0.0010367215,0.07123514,0.000026036334,0.048964918,0.00087759324],"about_ca_topic_score_codex":0.0290534,"about_ca_topic_score_gemma":0.0032737518,"teacher_disagreement_score":0.6698399,"about_ca_system_score_codex":0.0002350266,"about_ca_system_score_gemma":0.0003471629,"threshold_uncertainty_score":0.9774122},"labels":[],"label_agreement":null},{"id":"W2898517298","doi":"10.1093/annonc/mdy424.074","title":"Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEYNOTE-407","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital","funders":"Merck Sharp and Dohme; Merck","keywords":"Medicine; Carboplatin; Paclitaxel; Placebo; Clinical endpoint; Pembrolizumab; Internal medicine; Tolerability; Quality of life (healthcare); Oncology; Clinical trial; Chemotherapy; Cancer; Adverse effect; Nursing; Cisplatin","score_opus":0.20006962575984466,"score_gpt":0.4352044458391081,"score_spread":0.23513482007926345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898517298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909964,0.0017205939,0.00011411812,0.0035159728,0.00015935789,0.0017143979,0.001564962,0.00001949762,0.00019470659],"genre_scores_gemma":[0.9947823,0.00018330925,0.0019996122,0.002247723,0.00005552204,0.000046764315,0.0005050082,0.00003416637,0.00014556778],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99685794,0.00043173987,0.0014410255,0.00051704934,0.00031462937,0.00043758945],"domain_scores_gemma":[0.9960139,0.001680301,0.0010034475,0.00073733466,0.00036832248,0.00019671829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015665857,0.00025016256,0.0014995928,0.00019232703,0.00006880231,0.0000067418555,0.00024700214,0.00019551128,0.00021767053],"category_scores_gemma":[0.001658481,0.0001688788,0.00007777364,0.00033272355,0.0006117446,0.00013780345,0.000108703665,0.00018196374,0.0000022076554],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88170236,0.0023820007,0.03206139,0.0011628583,0.0015567488,0.000020611345,0.0053207222,0.000004509622,0.0006177865,0.00005220136,0.013596318,0.06152251],"study_design_scores_gemma":[0.1791887,0.07793422,0.7281553,0.0007994285,0.0003476214,0.00002297411,0.0033470665,0.00097169,0.00064640085,0.0003368754,0.00763896,0.00061072776],"about_ca_topic_score_codex":0.0150007885,"about_ca_topic_score_gemma":0.013781814,"teacher_disagreement_score":0.70251364,"about_ca_system_score_codex":0.000121984835,"about_ca_system_score_gemma":0.0019005176,"threshold_uncertainty_score":0.99155843},"labels":[],"label_agreement":null},{"id":"W2898528000","doi":"10.1016/j.jtho.2018.08.635","title":"P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-line (1L) Treatment of Advanced NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Regimen; Internal medicine; Oncology; Adverse effect; Cohort; Expanded access; Lung cancer; Clinical endpoint; Cancer; Clinical trial; Immunotherapy","score_opus":0.028992896876272097,"score_gpt":0.39115500225825217,"score_spread":0.36216210538198007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898528000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680336,0.008111694,0.003587654,0.015108696,0.0024334153,0.0014968337,0.00009042072,0.000021737342,0.0011159185],"genre_scores_gemma":[0.99118125,0.0018829847,0.0049571665,0.0005302792,0.000833851,0.000026337526,0.000009624728,0.000035453355,0.0005430356],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978627,0.00010539885,0.0012273788,0.00018751105,0.00030660833,0.000310407],"domain_scores_gemma":[0.99682283,0.0006189356,0.001469326,0.000417094,0.00056572934,0.00010605437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083181943,0.00023284924,0.0010651614,0.0001915338,0.0001344433,0.0000052068167,0.00024345421,0.0002047847,0.00029544535],"category_scores_gemma":[0.00010797122,0.0001389203,0.00060586195,0.00026169635,0.00045465652,0.0000786888,0.000022684146,0.00016208396,0.000003352025],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27234322,0.0011730316,0.0003662223,0.00025612258,0.0013417458,0.000045807195,0.00093329337,0.00012562507,0.04489001,0.000015046702,0.0014539568,0.6770559],"study_design_scores_gemma":[0.05512088,0.06973945,0.013708851,0.0009044407,0.002278932,0.00057235657,0.0007750449,0.0025229088,0.25794816,0.00017203897,0.59594655,0.00031039494],"about_ca_topic_score_codex":0.000061307954,"about_ca_topic_score_gemma":0.00025363825,"teacher_disagreement_score":0.67674553,"about_ca_system_score_codex":0.00096672465,"about_ca_system_score_gemma":0.0011251073,"threshold_uncertainty_score":0.56650054},"labels":[],"label_agreement":null},{"id":"W2898540510","doi":"10.1016/j.jtho.2018.08.606","title":"P1.01-50 Real World Experience of Nivolumab in Patients with Metastatic Nonsmall Cell Lung Cancer (mNSCLC)","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Medicine; Internal medicine; Nivolumab; Lung cancer; Gastroenterology; Pneumonitis; Adverse effect; Cancer; Lung; Immunotherapy","score_opus":0.019155735096526506,"score_gpt":0.39141899903739846,"score_spread":0.37226326394087195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898540510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563617,0.00075190485,0.000078196405,0.0004137537,0.00053311215,0.00025654462,0.000006722259,0.0000046867685,0.0023188896],"genre_scores_gemma":[0.9945605,0.00023650887,0.004082203,0.00032064217,0.00017345321,0.000009416103,0.0000016336772,0.00001853082,0.0005971537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983909,0.00014324374,0.00071911665,0.00015073919,0.00034091313,0.0002550727],"domain_scores_gemma":[0.9984565,0.00009177838,0.00084149314,0.00018493719,0.00031834497,0.00010697211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004643602,0.00014163002,0.0006281276,0.00036676574,0.00003527799,0.0000063383864,0.0001695251,0.00006751503,0.0005541911],"category_scores_gemma":[0.000023823924,0.00009876192,0.00010806549,0.00044230284,0.00029246704,0.00013467381,0.000027153344,0.0002754901,0.000001752827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08435602,0.0021451323,0.79140055,0.00033415185,0.00051146036,0.0002058423,0.0071242563,0.000011619969,0.016416337,0.000004841076,0.0029518595,0.094537936],"study_design_scores_gemma":[0.012107074,0.010925457,0.940787,0.0011012221,0.0006153795,0.00009946725,0.0013394442,0.00008445668,0.0175337,0.000016169522,0.015127061,0.0002635244],"about_ca_topic_score_codex":0.00061959465,"about_ca_topic_score_gemma":0.002025361,"teacher_disagreement_score":0.1493865,"about_ca_system_score_codex":0.00056301145,"about_ca_system_score_gemma":0.0007517738,"threshold_uncertainty_score":0.60680044},"labels":[],"label_agreement":null},{"id":"W2898544736","doi":"10.1016/j.jtho.2018.08.1298","title":"P2.09-01 Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pathology; Medicine; Stromal cell; Infiltration (HVAC); Immune system; Cell; Lung; Carcinoma; Biology; Immunology; Internal medicine","score_opus":0.017575113156483683,"score_gpt":0.3574076070987257,"score_spread":0.339832493942242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898544736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950468,0.0007494093,0.0000976936,0.001052754,0.0009940796,0.00024173423,0.000010765338,0.000013630474,0.0017931531],"genre_scores_gemma":[0.99782085,0.00007649038,0.00019161837,0.0005871997,0.00048277396,0.00000425011,0.0000074700883,0.00002392637,0.00080543454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801344,0.00028575165,0.0009278026,0.00015358502,0.00029479334,0.00032465442],"domain_scores_gemma":[0.99835527,0.0001392634,0.0009198792,0.00019254071,0.00028294636,0.00011010117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012143429,0.00016239611,0.00057360064,0.00035182477,0.00006445909,0.000022379149,0.00016541484,0.00020602002,0.0004383077],"category_scores_gemma":[0.00011443837,0.0001364525,0.00020004444,0.00031457967,0.00011134088,0.00017730486,0.000028936622,0.00053202687,0.000013001259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01802822,0.0012355722,0.78167343,0.0001620643,0.00018387796,0.0016832572,0.0038937202,0.000004725227,0.16816252,0.0000038399644,0.0014107383,0.023558035],"study_design_scores_gemma":[0.0045582782,0.0073245103,0.9472375,0.00017555458,0.0001531535,0.00046199557,0.0007245551,0.00013698553,0.034715824,0.000016140175,0.004339644,0.00015586302],"about_ca_topic_score_codex":0.00067043095,"about_ca_topic_score_gemma":0.00054734683,"teacher_disagreement_score":0.16556408,"about_ca_system_score_codex":0.00096861576,"about_ca_system_score_gemma":0.00059136085,"threshold_uncertainty_score":0.5564371},"labels":[],"label_agreement":null},{"id":"W2898547276","doi":"10.1016/j.jtho.2018.08.564","title":"P1.01-08 Hyperresponsive Disease: A New Pattern of Response in NSCLC Patients Treated by Anti-PD-1/PD-L1","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Pembrolizumab; Medicine; Pemetrexed; Lung cancer; Adenocarcinoma; Internal medicine; Chemotherapy; Progressive disease; Oncology; Docetaxel; Surgery; Bone metastasis; Cancer; Gastroenterology; Metastasis; Immunotherapy; Cisplatin","score_opus":0.01899642676788839,"score_gpt":0.3821546776044433,"score_spread":0.36315825083655495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898547276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99288684,0.0014667335,0.00005720382,0.0045126425,0.00057431794,0.0002786751,0.00004484706,0.000008829042,0.00016989504],"genre_scores_gemma":[0.9970655,0.0002526273,0.00016247499,0.0013727319,0.0002668624,0.0000028952197,0.000011951603,0.000025531013,0.00083945267],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9975844,0.0006685643,0.00090320024,0.00019306746,0.00035700112,0.00029377665],"domain_scores_gemma":[0.99793005,0.00035551842,0.0007975397,0.00025937657,0.000367392,0.0002901439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095057837,0.00018834742,0.00072530576,0.00046240367,0.0000394837,0.0000093144545,0.00019614691,0.00019236653,0.00046192718],"category_scores_gemma":[0.00049995363,0.00014528629,0.00023450561,0.0004053393,0.00024718366,0.00012561768,0.00003998175,0.00030405688,0.000015705886],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46947503,0.0015074548,0.16780117,0.000057265697,0.00035546932,0.00056096434,0.0012532925,7.765968e-7,0.067669466,2.5949308e-7,0.03854319,0.25277564],"study_design_scores_gemma":[0.008409282,0.012326613,0.9110258,0.00058798847,0.00029164547,0.00020458139,0.00022797042,0.000018857389,0.008971236,0.000017377974,0.05775264,0.00016599912],"about_ca_topic_score_codex":0.00014366013,"about_ca_topic_score_gemma":0.000044717675,"teacher_disagreement_score":0.7432246,"about_ca_system_score_codex":0.00046189534,"about_ca_system_score_gemma":0.0011439521,"threshold_uncertainty_score":0.5924603},"labels":[],"label_agreement":null},{"id":"W2898605921","doi":"10.1016/j.jtho.2018.08.608","title":"P1.01-52 BR-34- Randomized Trial of Durvalumab and Tremelimumab +/- Platinum Chemotherapy in Patients with Metastatic Squamous or Non-Squamous NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Hôpital de l'Enfant-Jésus","funders":"","keywords":"Durvalumab; Tremelimumab; Medicine; Oncology; Pemetrexed; Internal medicine; Clinical endpoint; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Lung cancer; Cancer; Immunotherapy; Pembrolizumab; Progressive disease; Randomized controlled trial; Cisplatin; Ipilimumab","score_opus":0.018443874309196764,"score_gpt":0.3618502880888733,"score_spread":0.34340641377967657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898605921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956667,0.0003615521,0.00022763206,0.001013262,0.0006084116,0.0015066775,0.000008911527,0.000008155226,0.00059870305],"genre_scores_gemma":[0.99533135,0.00016289079,0.0032692805,0.0005954715,0.00033943512,0.000017582059,0.0000050413737,0.000037578633,0.00024135987],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969845,0.0005125526,0.0014684054,0.0002213531,0.00050395523,0.0003092353],"domain_scores_gemma":[0.99685025,0.00090545614,0.0014991609,0.00023740661,0.00037220767,0.00013551363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022979414,0.00026041028,0.0019606678,0.0004396632,0.000057322406,0.000014815576,0.00015489395,0.00017751999,0.00036183093],"category_scores_gemma":[0.00046493116,0.00015375913,0.0002631853,0.00036831608,0.00062941486,0.00013892868,0.000023134335,0.00035140282,0.0000019961196],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89054614,0.0016143165,0.0010085745,0.00009249192,0.0005251532,0.000080522994,0.001298361,0.0000011954565,0.0013721149,0.0000016921886,0.00034157457,0.10311784],"study_design_scores_gemma":[0.9419646,0.04187044,0.01129323,0.00028332867,0.00072831096,0.00031497635,0.00041278766,0.00009768573,0.0015188314,0.000058901915,0.0012724428,0.0001844646],"about_ca_topic_score_codex":0.00008915628,"about_ca_topic_score_gemma":0.00015136444,"teacher_disagreement_score":0.10293338,"about_ca_system_score_codex":0.00033051523,"about_ca_system_score_gemma":0.0007925323,"threshold_uncertainty_score":0.62701154},"labels":[],"label_agreement":null},{"id":"W2898607831","doi":"10.1093/annonc/mdy269.093","title":"Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Loss of heterozygosity; Human leukocyte antigen; Medicine; Immunology; Univariate analysis; Internal medicine; Allele; Oncology; Biology; Genetics; Antigen; Multivariate analysis","score_opus":0.06514329559478552,"score_gpt":0.400270124425917,"score_spread":0.33512682883113143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898607831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839605,0.0005393767,0.00014866634,0.0124132885,0.00011330246,0.00022341494,0.000022573671,0.000041806987,0.0025370428],"genre_scores_gemma":[0.99096733,0.0003008329,0.00081914366,0.007300046,0.00023721371,0.00000990846,0.0000065659524,0.000016681735,0.00034230054],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99875087,0.0001667937,0.00040557396,0.00027764673,0.00013368895,0.00026544888],"domain_scores_gemma":[0.99897814,0.00023072278,0.0001658131,0.00029490326,0.00022263553,0.00010779468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085537025,0.00012174783,0.00052162114,0.00023353005,0.00006213668,0.0000064709134,0.00009036673,0.00015205295,0.00014725141],"category_scores_gemma":[0.00021867723,0.00010604648,0.0001659319,0.00053734274,0.0002897697,0.000050385755,0.000068751535,0.000101612124,0.0000075921903],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14608254,0.00073884707,0.04812872,0.00006727226,0.0038360008,0.00006994812,0.006729489,0.000010764168,0.7154361,0.00007581917,0.009898227,0.0689263],"study_design_scores_gemma":[0.0058817393,0.018506141,0.6526079,0.000053978205,0.0007204624,0.00011797155,0.0004710783,0.00040841536,0.0498821,0.00010928307,0.27101985,0.0002210509],"about_ca_topic_score_codex":0.0003511506,"about_ca_topic_score_gemma":0.00040333162,"teacher_disagreement_score":0.665554,"about_ca_system_score_codex":0.00007697408,"about_ca_system_score_gemma":0.00020458669,"threshold_uncertainty_score":0.43244496},"labels":[],"label_agreement":null},{"id":"W2898717093","doi":"10.1001/jamaoncol.2018.4628","title":"Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC","year":2018,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":310,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Tremelimumab; Durvalumab; Medicine; Internal medicine; Head and neck squamous-cell carcinoma; Tolerability; Oncology; Immunotherapy; Adverse effect; Cancer; Head and neck cancer; Nivolumab; Ipilimumab","score_opus":0.021322078231398343,"score_gpt":0.31950666701340313,"score_spread":0.29818458878200477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898717093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966209,0.00010806427,0.000057017412,0.0006608581,0.000120522025,0.0012154214,0.000028830724,0.0000198761,0.0011685198],"genre_scores_gemma":[0.99587494,0.00014138862,0.0028569961,0.0005764759,0.00006775508,0.00003689537,0.000022582526,0.000028781207,0.0003941987],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99841535,0.0002023527,0.00047427506,0.00034797884,0.0002712812,0.00028877315],"domain_scores_gemma":[0.99870604,0.00037728355,0.00030434428,0.00026178005,0.00025392257,0.00009661275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033815016,0.00021768505,0.00074977416,0.00017163489,0.00005588786,0.00000836715,0.00008500717,0.00010429966,0.00042714656],"category_scores_gemma":[0.00019404537,0.00011458164,0.000039515056,0.0004533385,0.0006617668,0.00009258524,0.000033472734,0.00020296055,0.0000052214978],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6839135,0.0018215758,0.06570114,0.00016255524,0.00057768327,0.00005617364,0.004288066,9.669344e-7,0.000185074,0.000011388111,0.00030684326,0.24297498],"study_design_scores_gemma":[0.11300598,0.059897553,0.8158235,0.00090785895,0.0003147213,0.000081240316,0.0008846591,0.00009561415,0.0008349899,0.0000076280053,0.007909201,0.0002370408],"about_ca_topic_score_codex":0.00025309226,"about_ca_topic_score_gemma":0.0036327613,"teacher_disagreement_score":0.75012237,"about_ca_system_score_codex":0.00032035704,"about_ca_system_score_gemma":0.00066287105,"threshold_uncertainty_score":0.46769553},"labels":[],"label_agreement":null},{"id":"W2898788563","doi":"10.1186/s13046-018-0937-6","title":"Nobel committee honors tumor immunologists","year":2018,"lang":"en","type":"editorial","venue":"Journal of Experimental & Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Library science; Computer science","score_opus":0.16475649902268977,"score_gpt":0.5603450773387032,"score_spread":0.39558857831601346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898788563","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1098981,0.07704407,0.0000026091866,0.0011641866,0.809178,0.00074548344,0.00012779083,0.000027339232,0.001812453],"genre_scores_gemma":[0.0312011,0.017543769,0.0003222599,0.0004724767,0.9467592,0.00008218883,0.000043938504,0.00015216834,0.003422855],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.991001,0.0009909507,0.0026930263,0.00064757525,0.0037558458,0.00091161404],"domain_scores_gemma":[0.99193394,0.0026624808,0.0013477295,0.0008557499,0.0026597055,0.00054040656],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008321458,0.0004721202,0.0018179285,0.0005516027,0.00029726725,0.00014491871,0.0012074006,0.0011713207,0.0035840746],"category_scores_gemma":[0.002698658,0.00035178996,0.0013564572,0.0005544357,0.0025080715,0.00018261382,0.00043268767,0.006549235,0.00012256698],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031761095,0.0014207801,0.0009803188,0.00010349757,0.0012416237,0.0004905911,0.00016075805,4.267898e-8,0.013316459,0.0000018631504,0.9456392,0.0048837746],"study_design_scores_gemma":[0.009599659,0.012945603,0.0012022823,0.0017674401,0.00012940596,0.00009352096,0.00055865047,0.0000015756433,0.013847487,0.000029373161,0.95949763,0.00032737604],"about_ca_topic_score_codex":0.0011926544,"about_ca_topic_score_gemma":0.00008081109,"teacher_disagreement_score":0.13758127,"about_ca_system_score_codex":0.0019962743,"about_ca_system_score_gemma":0.00518609,"threshold_uncertainty_score":0.9998934},"labels":[],"label_agreement":null},{"id":"W2898845456","doi":"10.3747/co.25.4235","title":"Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Brief Review","year":2018,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Horizon Health Network; Moncton Hospital","funders":"","keywords":"Medicine; Discontinuation; Adverse effect; Immunosuppression; Intensive care medicine; Oncology; Internal medicine","score_opus":0.09874859782321654,"score_gpt":0.43080192981987575,"score_spread":0.3320533319966592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898845456","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000041433053,0.98992425,0.0000029708835,0.00018631737,0.005093827,0.0031084788,0.00006570056,0.00006476099,0.0015122372],"genre_scores_gemma":[0.000008801411,0.99768686,0.000049721057,0.000079332494,0.00048456664,0.00027941697,0.0006812968,0.00008793178,0.0006420516],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99396914,0.0005277268,0.0039698766,0.0006531305,0.00038035435,0.0004997465],"domain_scores_gemma":[0.99547815,0.00014715204,0.0028583384,0.0010511852,0.00030696424,0.00015821577],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001673522,0.0006766733,0.0049542445,0.00032663383,0.000060629987,0.0000021380943,0.0004230999,0.0007348918,0.0015695052],"category_scores_gemma":[0.0003308146,0.000514178,0.003348432,0.00084645004,0.00044896253,0.000057744033,0.00022370672,0.00095900544,0.00030410424],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022034929,0.00072422717,0.000008401529,0.12771463,0.0010340969,0.000019791294,0.00005808921,2.8725318e-9,0.000021047828,0.000006621303,0.006709809,0.86348295],"study_design_scores_gemma":[0.002123493,0.0009167956,0.000036518468,0.25110894,0.0032491013,0.0003341961,0.000008139205,3.8530035e-7,0.000018445475,0.0000073336373,0.7418919,0.0003047429],"about_ca_topic_score_codex":0.000041832427,"about_ca_topic_score_gemma":0.0000033119297,"teacher_disagreement_score":0.8631782,"about_ca_system_score_codex":0.0009641174,"about_ca_system_score_gemma":0.0018944106,"threshold_uncertainty_score":0.999731},"labels":[],"label_agreement":null},{"id":"W2898952978","doi":"10.3747/co.25.4002","title":"Radiation Therapy and Immunotherapy—A Potential Combination in Cancer Treatment","year":2018,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Immunotherapy; Radiation therapy; Cancer; Cancer treatment; Cancer immunotherapy; Bioinformatics; Cancer research; Internal medicine; Biology","score_opus":0.1610106313617224,"score_gpt":0.46343482192430085,"score_spread":0.30242419056257847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898952978","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024032039,0.9932128,0.000005642406,0.00019573425,0.002279922,0.0017182905,0.000029548468,0.000027323356,0.00012751907],"genre_scores_gemma":[0.00011913653,0.9981267,0.000013942153,0.00006368825,0.0005642066,0.0006220459,0.0002786557,0.00004004497,0.00017161336],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984317,0.00024128362,0.00056316296,0.0003960573,0.00012444002,0.00024337244],"domain_scores_gemma":[0.9992515,0.00006684335,0.0003500471,0.00022140646,0.000053896718,0.00005632682],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023028611,0.00034066814,0.0012858221,0.0003373421,0.000053548723,0.000016350657,0.000075817996,0.00036228757,0.00026590767],"category_scores_gemma":[0.000006883922,0.00024561255,0.0002942431,0.00024861438,0.00014448357,0.0000446815,0.000014498376,0.00021752447,0.000012969805],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057054695,0.00075572083,0.00018323415,0.0009925149,0.00030920884,0.000007521261,0.00020845255,1.922327e-8,0.0000066500443,0.000009749785,0.00058473455,0.9963716],"study_design_scores_gemma":[0.0073401127,0.002246864,0.0014865919,0.002402168,0.0002678777,0.000062400344,0.000009314841,0.000012673469,0.000004256469,0.000016487036,0.9859468,0.00020449472],"about_ca_topic_score_codex":0.00018070891,"about_ca_topic_score_gemma":0.000060347735,"teacher_disagreement_score":0.9961671,"about_ca_system_score_codex":0.0017764972,"about_ca_system_score_gemma":0.00079500204,"threshold_uncertainty_score":0.99999964},"labels":[],"label_agreement":null},{"id":"W2898987931","doi":"10.1126/sciimmunol.aav1872","title":"Developing combination immunotherapies against cancer that make sense","year":2018,"lang":"en","type":"letter","venue":"Science Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; Montreal Clinical Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Cancer immunotherapy; Sense (electronics); Cancer; Immunotherapy; Immunology; Medicine; Computational biology; Cancer research; Computer science; Biology; Internal medicine; Chemistry","score_opus":0.04042491318069269,"score_gpt":0.3169337651981892,"score_spread":0.27650885201749653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898987931","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15474603,0.012294818,0.00015235355,0.8203525,0.007872459,0.0009726133,0.000028192364,0.00026583124,0.0033151885],"genre_scores_gemma":[0.024799729,0.009556137,0.0011544385,0.9530124,0.0018891251,0.00018955005,0.00021526126,0.00012498708,0.00905838],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966995,0.00011171693,0.00048092005,0.00093669177,0.0007612185,0.0010099353],"domain_scores_gemma":[0.99791646,0.00009274451,0.00042262883,0.0010024898,0.0005247285,0.00004095148],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.00082369905,0.00047041004,0.0006639019,0.00083088846,0.00057750125,0.0001375366,0.00061112375,0.000834524,0.0003974345],"category_scores_gemma":[0.000081805374,0.00039979798,0.00020970944,0.001029667,0.004236915,0.0002063377,0.00018212586,0.0012171975,0.00012409946],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015331837,0.000116425384,0.0013293497,0.00035799938,0.0015712456,0.00066155614,0.0024088433,3.3006825e-7,0.31696278,0.00024693602,0.4490424,0.22576892],"study_design_scores_gemma":[0.0019019963,0.00034178072,0.010029329,0.0006472479,0.00006552168,0.00031712858,0.00017414687,0.000015715652,0.029260194,0.00023361499,0.9564527,0.00056060485],"about_ca_topic_score_codex":0.000484375,"about_ca_topic_score_gemma":0.000035204033,"teacher_disagreement_score":0.5074103,"about_ca_system_score_codex":0.0013609792,"about_ca_system_score_gemma":0.0023336636,"threshold_uncertainty_score":0.9998454},"labels":[],"label_agreement":null},{"id":"W2899030278","doi":"10.3747/co.25.4047","title":"Predictors of Immunotherapy-Induced Immune-Related Adverse Events","year":2018,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Hotel Dieu Hospital; Queen's University","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Pembrolizumab; Internal medicine; Renal cell carcinoma; Kidney cancer; Odds ratio; Adverse effect; Cancer; Lung cancer; Oncology; Immunotherapy","score_opus":0.052667878926980306,"score_gpt":0.3754606896998456,"score_spread":0.32279281077286526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899030278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98695177,0.0033191924,0.000028203813,0.00030728406,0.0051365457,0.0005011145,0.000010301994,0.000068713445,0.0036768985],"genre_scores_gemma":[0.99823016,0.00085557357,0.00006680229,0.00009970544,0.00030223097,0.00002605995,0.000033223565,0.000026376745,0.00035989753],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99845225,0.0001074382,0.0006842823,0.00025097447,0.0002114366,0.00029360267],"domain_scores_gemma":[0.9989483,0.000052970237,0.0003254249,0.00039228043,0.00019987037,0.00008119596],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003740951,0.00017813541,0.00046306796,0.0001710476,0.0000661444,0.0000011177357,0.00016397794,0.00020672036,0.0012537264],"category_scores_gemma":[0.000049004084,0.00014920665,0.00028166067,0.0003273762,0.00029651957,0.00005547514,0.000042793396,0.00023773733,0.00008650605],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010084791,0.0020820973,0.12179818,0.00013120053,0.0013681459,0.000012775691,0.00287984,2.9635515e-7,0.51242566,0.00009368307,0.0028038078,0.3463195],"study_design_scores_gemma":[0.023372559,0.009614946,0.507254,0.0006373407,0.0003116229,0.00013741448,0.0004330664,0.00009392491,0.07013226,0.00014965064,0.3874646,0.00039857204],"about_ca_topic_score_codex":0.000041450385,"about_ca_topic_score_gemma":0.0000089115,"teacher_disagreement_score":0.4422934,"about_ca_system_score_codex":0.0002559013,"about_ca_system_score_gemma":0.00034289132,"threshold_uncertainty_score":0.99965924},"labels":[],"label_agreement":null},{"id":"W2899204048","doi":"10.1038/s41467-018-06654-8","title":"TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure","year":2018,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":662,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"J.P. Bickell Foundation; Natural Sciences and Engineering Research Council of Canada; Princess Margaret Cancer Foundation; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Research Society; University of Calgary","keywords":"Extracellular matrix; Cancer; Blockade; Cancer research; Immune system; Biology; Gene; Immune checkpoint; Immunotherapy; Downregulation and upregulation; Cancer immunotherapy; Transforming growth factor; Immunology; Cell biology; Genetics; Receptor","score_opus":0.016676201844246067,"score_gpt":0.3261005842010016,"score_spread":0.3094243823567555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899204048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5551569,0.38786522,0.000076025644,0.053200167,0.0004673601,0.0016967886,0.00054508785,0.0004300781,0.00056240184],"genre_scores_gemma":[0.9757681,0.015087967,0.0041359803,0.0010234015,0.00020062218,0.00016285571,0.00064415345,0.000075478536,0.0029014791],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982144,0.00022251096,0.00049401243,0.00035738313,0.00032281128,0.00038886192],"domain_scores_gemma":[0.9971008,0.0002657843,0.0002554449,0.0016502894,0.0005752677,0.00015245726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049783743,0.00029407424,0.00043625597,0.00018318793,0.00065690535,0.000069315865,0.0006628568,0.0006865145,0.00059596193],"category_scores_gemma":[0.00020777408,0.0002684948,0.00017999124,0.0009532131,0.00031074297,0.000116781936,0.00024222021,0.00090385304,0.00002993389],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010570624,0.00047495455,0.0052897353,0.000034157907,0.0009459641,0.0000038548965,0.0013410485,0.000001820278,0.88951576,0.00024105357,0.040587686,0.0605069],"study_design_scores_gemma":[0.003906171,0.00080052397,0.099647924,0.0009592026,0.00018442713,0.000027045484,0.00023363391,0.00047404002,0.01483287,0.00007268185,0.8783497,0.0005117827],"about_ca_topic_score_codex":0.00059791876,"about_ca_topic_score_gemma":0.0037623104,"teacher_disagreement_score":0.8746829,"about_ca_system_score_codex":0.00037507474,"about_ca_system_score_gemma":0.00021394304,"threshold_uncertainty_score":0.99997675},"labels":[],"label_agreement":null},{"id":"W2899369036","doi":"10.3747/co.25.3840","title":"Current Landscape of Immunotherapy in the Treatment of Solid Tumours, with Future Opportunities and Challenges","year":2018,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":146,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; London Health Sciences Centre; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Immunotherapy; Clinical trial; Intensive care medicine; Disease; Biomarker; Standard of care; Cancer; Internal medicine; Biology","score_opus":0.2475213054108361,"score_gpt":0.4346991206377291,"score_spread":0.18717781522689297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899369036","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00075882353,0.9963955,8.011197e-7,0.0006059746,0.0007820513,0.0011278833,0.00010549423,0.00000820227,0.000215213],"genre_scores_gemma":[0.00008181608,0.9989181,0.0000139514505,0.000012092455,0.0006101269,0.00020098402,0.0001203836,0.000026939311,0.000015590374],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983514,0.00029689248,0.00064161205,0.00028088127,0.00018671516,0.00024247609],"domain_scores_gemma":[0.99869764,0.0001784506,0.00059836084,0.0003964216,0.000086127584,0.000042994347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035715676,0.00036401924,0.0019481232,0.00025821032,0.000029754423,0.000003709554,0.00016480133,0.00019845573,0.00005524494],"category_scores_gemma":[0.0000035416008,0.00017745324,0.00028877205,0.0001526732,0.0004380154,0.000021204187,0.000015781516,0.00020348368,8.447699e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007802707,0.0014397698,0.00008275942,0.009429526,0.0003616617,0.000012910706,0.0024872196,4.4644928e-9,4.2515146e-7,0.000070820955,0.00051284325,0.9848218],"study_design_scores_gemma":[0.002856612,0.0074821846,0.00039802442,0.010039723,0.0006958387,0.00019069144,0.0013086849,4.2087711e-7,0.0000021887954,0.000006192802,0.9768658,0.0001536219],"about_ca_topic_score_codex":0.000008256679,"about_ca_topic_score_gemma":0.0000661728,"teacher_disagreement_score":0.9846682,"about_ca_system_score_codex":0.00014742017,"about_ca_system_score_gemma":0.0006971039,"threshold_uncertainty_score":0.7236333},"labels":[],"label_agreement":null},{"id":"W2900483456","doi":"10.1093/annonc/mdy425.002","title":"Carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab in first-line metastatic squamous NSCLC: Results from the KEYNOTE-407 east Asia subgroup","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Medicine; Carboplatin; Pembrolizumab; Paclitaxel; Internal medicine; Clinical endpoint; Placebo; Oncology; Randomization; Taxane; Progression-free survival; Randomized controlled trial; Chemotherapy; Cancer; Cisplatin; Pathology; Immunotherapy; Breast cancer","score_opus":0.09552856974600375,"score_gpt":0.37292295093702754,"score_spread":0.2773943811910238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900483456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677161,0.0013517672,0.00009119416,0.021536047,0.0002893768,0.0010281145,0.00028586594,0.00005002842,0.007651489],"genre_scores_gemma":[0.9938346,0.00034263838,0.0009957766,0.0033889145,0.00043497098,0.00006467672,0.00009923694,0.000053043437,0.00078612106],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9969923,0.00032284067,0.0010443947,0.0005728547,0.0004481227,0.0006195015],"domain_scores_gemma":[0.99688566,0.0011814248,0.0005776256,0.0008026764,0.00039262473,0.00016001388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011491774,0.00036762588,0.001044501,0.00018178302,0.00014433265,0.00001973664,0.0003381166,0.00022106398,0.0003470475],"category_scores_gemma":[0.00075041223,0.00021273526,0.00018488026,0.0006375078,0.0010097271,0.000120041725,0.00007430418,0.00039675328,0.000033740565],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6936949,0.004737791,0.06156373,0.0003407256,0.003013095,0.0012908773,0.030729655,0.00004709365,0.012173805,0.00031428822,0.03640905,0.15568502],"study_design_scores_gemma":[0.14518893,0.10497848,0.4891525,0.0019820274,0.0012435265,0.0011331827,0.010413582,0.0018916546,0.01300724,0.0011131964,0.22834954,0.0015461579],"about_ca_topic_score_codex":0.00889128,"about_ca_topic_score_gemma":0.032586303,"teacher_disagreement_score":0.54850596,"about_ca_system_score_codex":0.0001354139,"about_ca_system_score_gemma":0.0007500843,"threshold_uncertainty_score":0.9977086},"labels":[],"label_agreement":null},{"id":"W2900524781","doi":"10.1007/s00384-018-3202-8","title":"Current status of immunotherapy in metastatic colorectal cancer","year":2018,"lang":"en","type":"review","venue":"International Journal of Colorectal Disease","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Immunotherapy; Colorectal cancer; Oncolytic virus; Cancer; Oncology; Internal medicine; Disease; Immunology","score_opus":0.04124469240618466,"score_gpt":0.40716206462102655,"score_spread":0.3659173722148419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900524781","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023662386,0.97210145,0.000012084375,0.000065298686,0.0029438436,0.00059163995,0.0005331154,0.000006754811,0.000083447376],"genre_scores_gemma":[0.0066976934,0.9924575,0.000098348864,0.000050168725,0.00047375512,0.000062048886,0.00008553268,0.000048823335,0.00002613224],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967077,0.00018191108,0.0016308648,0.00022660152,0.0009429074,0.00031005178],"domain_scores_gemma":[0.9969522,0.00019080669,0.0016513808,0.00013540982,0.00077757,0.00029263043],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036632852,0.0003537874,0.0015256745,0.0008733781,0.000017541071,0.000031339456,0.00045975734,0.00008824825,0.0007447323],"category_scores_gemma":[0.00020476426,0.00026131544,0.001303175,0.0003696198,0.00023166646,0.00013960933,0.000052827727,0.00044196972,0.000008247626],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01593422,0.00094667607,0.001631561,0.0026513957,0.0030450234,0.00034481665,0.0001527618,0.0000020836244,0.00007180298,0.000020694972,0.00082863244,0.97437036],"study_design_scores_gemma":[0.004328805,0.00078193494,0.009419035,0.03576993,0.0012319044,0.00020500719,0.000021903163,0.000016786931,0.00005072721,0.000074899144,0.94781697,0.00028211658],"about_ca_topic_score_codex":0.00009800039,"about_ca_topic_score_gemma":0.000038394242,"teacher_disagreement_score":0.9740882,"about_ca_system_score_codex":0.0011272527,"about_ca_system_score_gemma":0.0042604394,"threshold_uncertainty_score":0.9999839},"labels":[],"label_agreement":null},{"id":"W2900960610","doi":"10.1136/annrheumdis-2018-eular.6009","title":"THU0615 Immune related adverse events (IRAES) associated with checkpoint inhibitors: 12 cases from a single centre","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Adverse effect; Immunology; Internal medicine","score_opus":0.03060352778655538,"score_gpt":0.2698284226833359,"score_spread":0.23922489489678053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900960610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99442595,0.001957291,0.0000020536356,0.002113657,0.00026431773,0.000489126,0.00020262168,0.000070458875,0.00047449773],"genre_scores_gemma":[0.99835855,0.00013712973,0.000027746588,0.00041659252,0.00005001763,0.000009774823,0.000093707604,0.00003338223,0.00087309093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982293,0.00014151176,0.0006308484,0.00023460595,0.00046781253,0.0002958803],"domain_scores_gemma":[0.9982857,0.00020807072,0.0005713069,0.00058190554,0.00022368439,0.00012934553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019936025,0.0002281755,0.00045191435,0.000064247484,0.00012892211,0.000009711329,0.00019866176,0.00008028841,0.00072144694],"category_scores_gemma":[0.0007931492,0.00013797362,0.00040934383,0.00031539882,0.00035282667,0.00012473017,0.000074447686,0.00009082025,0.000027937696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049217924,0.024065053,0.6294063,0.0016324387,0.03273916,0.0003162934,0.019466035,0.00005204378,0.04441986,0.00009378673,0.075245276,0.12334583],"study_design_scores_gemma":[0.0075920373,0.0015362991,0.92742264,0.015571352,0.0011014229,0.000025635345,0.0018741362,0.00020071976,0.04277193,0.00082060735,0.0006142539,0.00046894557],"about_ca_topic_score_codex":0.00085570005,"about_ca_topic_score_gemma":0.00016168499,"teacher_disagreement_score":0.29801637,"about_ca_system_score_codex":0.00006513012,"about_ca_system_score_gemma":0.0001623267,"threshold_uncertainty_score":0.7899338},"labels":[],"label_agreement":null},{"id":"W2901601525","doi":"10.1158/2326-6066.cir-18-0136","title":"Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma","year":2018,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Universität Zürich; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Melanoma; Immunotherapy; T-cell receptor; Medicine; Blockade; Oncology; Immunology; Exact test; Internal medicine; Peripheral blood mononuclear cell; Proportional hazards model; Immune system; Cancer research; T cell; Biology; Receptor","score_opus":0.08599289826017605,"score_gpt":0.38266565641827377,"score_spread":0.29667275815809774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901601525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708518,0.019703316,0.0001547282,0.0034713368,0.0007255865,0.0023022129,0.000102012484,0.00011002482,0.0025790068],"genre_scores_gemma":[0.9864783,0.0037916221,0.0011703571,0.00056979066,0.0004496965,0.0019326793,0.00015824063,0.000071981034,0.0053773182],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970781,0.00027370974,0.00058737147,0.0007110341,0.00043667783,0.0009131006],"domain_scores_gemma":[0.99754953,0.00016692489,0.0001348782,0.0008666151,0.0011866783,0.00009538588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000981479,0.00026796697,0.000420076,0.00028708222,0.0007021278,0.00006602241,0.00032022226,0.00030375642,0.00058557506],"category_scores_gemma":[0.0001333244,0.00022867267,0.00020960176,0.0005413087,0.0013804797,0.00013890368,0.000062428575,0.0005386952,0.00003467235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009611737,0.00022834812,0.0028124484,0.00008354236,0.0008153506,0.000010063202,0.0021458801,0.000001008514,0.72287446,0.0001575017,0.001457609,0.25980207],"study_design_scores_gemma":[0.009962415,0.008636846,0.011425102,0.00032340875,0.00006958249,0.00008527041,0.0033009367,0.00023537254,0.79728144,0.0003004989,0.16786397,0.0005151835],"about_ca_topic_score_codex":0.00034489357,"about_ca_topic_score_gemma":0.0000948701,"teacher_disagreement_score":0.25928688,"about_ca_system_score_codex":0.00051339215,"about_ca_system_score_gemma":0.0008908359,"threshold_uncertainty_score":0.93250006},"labels":[],"label_agreement":null},{"id":"W2901903079","doi":"10.1093/annonc/mdy507","title":"Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma","year":2018,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":273,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Head and neck squamous-cell carcinoma; Immune system; Immune checkpoint; Biomarker; Immunotherapy; Oncology; Immunology; Head and neck cancer; Cancer research; Internal medicine; Cancer; Biology","score_opus":0.07791163796091786,"score_gpt":0.3930575096801219,"score_spread":0.315145871719204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901903079","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22678882,0.7696241,4.3039734e-7,0.0007485327,0.00034006734,0.0011779658,0.00005032027,0.0000109056455,0.0012588628],"genre_scores_gemma":[0.07197626,0.9269053,0.00023065302,0.00023505779,0.00010763183,0.00008105455,0.000038201488,0.000068006586,0.00035787374],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957967,0.0006740228,0.00226447,0.0005329279,0.00024100709,0.0004908641],"domain_scores_gemma":[0.9971307,0.0006686335,0.0010799642,0.0007187845,0.00023083619,0.00017107844],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025087944,0.0004719655,0.0032502862,0.0010528761,0.000033496064,0.0000059502313,0.00027274297,0.0007513616,0.00010025572],"category_scores_gemma":[0.00038108186,0.00039641373,0.0008435752,0.0008243409,0.000511902,0.000042955948,0.00019393372,0.00035053425,0.000016058239],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034479998,0.000999912,0.00033372117,0.016576147,0.00040517762,0.0002002392,0.000980435,7.454721e-8,0.011365383,0.0000022635015,0.003406814,0.93124986],"study_design_scores_gemma":[0.004255885,0.014640798,0.0061858385,0.0072584604,0.00030498175,0.000180537,0.00015933976,5.0153363e-7,0.005854532,0.0000064065302,0.96080947,0.00034327185],"about_ca_topic_score_codex":0.0015677395,"about_ca_topic_score_gemma":0.00011215956,"teacher_disagreement_score":0.95740265,"about_ca_system_score_codex":0.00021808805,"about_ca_system_score_gemma":0.0014421438,"threshold_uncertainty_score":0.9998488},"labels":[],"label_agreement":null},{"id":"W2902530914","doi":"10.1093/annonc/mdy517","title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":795,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Merck","keywords":"Medicine; Triple-negative breast cancer; Pembrolizumab; Metastatic breast cancer; Cohort; Oncology; Internal medicine; Breast cancer; Cancer; Immunotherapy","score_opus":0.07573474290946053,"score_gpt":0.43182966956319807,"score_spread":0.35609492665373754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902530914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99012625,0.0007494268,0.00004141766,0.004168656,0.00022978874,0.003858562,0.00029616465,0.000019525305,0.00051020144],"genre_scores_gemma":[0.99639934,0.000685634,0.000121556346,0.0013886152,0.00013261402,0.0004351469,0.000008966687,0.000027984615,0.00080013653],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99830025,0.00023098559,0.0006488647,0.00028918177,0.00022089716,0.00030981627],"domain_scores_gemma":[0.9980381,0.0002100099,0.00057108403,0.0004184167,0.0006921516,0.00007025407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063741376,0.00020323796,0.0008608242,0.00011955355,0.00013431726,0.0000037743555,0.0002128679,0.0000890158,0.00035912642],"category_scores_gemma":[0.0000875361,0.00012968984,0.000317444,0.00040028268,0.0005312828,0.00005420063,0.000034408928,0.000100849036,0.0000010526248],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27421674,0.018434143,0.041375373,0.00025742888,0.0108714085,0.00001711434,0.016858784,0.0000037208392,0.04823326,0.000056293586,0.022758685,0.56691706],"study_design_scores_gemma":[0.20160553,0.24083613,0.3127547,0.0005024321,0.00301289,0.0002268952,0.002842128,0.0004452532,0.19463257,0.00048764996,0.042061683,0.0005921448],"about_ca_topic_score_codex":0.0023829709,"about_ca_topic_score_gemma":0.00086339924,"teacher_disagreement_score":0.5663249,"about_ca_system_score_codex":0.00009807641,"about_ca_system_score_gemma":0.00065460725,"threshold_uncertainty_score":0.5288598},"labels":[],"label_agreement":null},{"id":"W2902540225","doi":"10.1155/2018/5837235","title":"The Adaptive Complexity of Cancer","year":2018,"lang":"en","type":"review","venue":"BioMed Research International","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"Ryerson University","keywords":"Immunosurveillance; Cancer; Disease; Immunosuppression; Medicine; Tumor microenvironment; Immune system; Acquired immune system; Bioinformatics; Immunology; Cancer research; Biology; Internal medicine","score_opus":0.46892114504629356,"score_gpt":0.5553741294137186,"score_spread":0.08645298436742499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902540225","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000069156627,0.9909241,0.000005863091,0.0011683202,0.00171565,0.0007396635,0.00037409778,0.000011206262,0.005054186],"genre_scores_gemma":[0.000026504005,0.99114573,0.000104993385,0.000020660726,0.0013794568,0.00022324646,0.000117943586,0.000023851584,0.0069576344],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974992,0.00024712933,0.0004857464,0.0002669458,0.0012006642,0.00030030802],"domain_scores_gemma":[0.9979655,0.0004382233,0.00022333334,0.00035065968,0.00093906926,0.00008321613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015452466,0.00015691653,0.00052553654,0.00039089145,0.00016296434,0.00003611791,0.0006281061,0.00015631926,0.00091251306],"category_scores_gemma":[0.0001873057,0.000084655585,0.00041273778,0.00056220917,0.002467358,0.000025614376,0.0001870672,0.00043480733,0.00006810855],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065534236,0.00007605544,0.0000060643783,0.0012236595,0.00165657,0.000006177397,0.00002686349,1.6820821e-9,0.000018649196,0.0010230214,0.061159104,0.9341485],"study_design_scores_gemma":[0.00039414968,0.00020067793,0.00009043083,0.0066378494,0.00007079968,0.000017496688,0.000027703469,0.00001025351,0.0000329805,0.00016498858,0.9922762,0.000076488206],"about_ca_topic_score_codex":0.00061981584,"about_ca_topic_score_gemma":0.00014813767,"teacher_disagreement_score":0.934072,"about_ca_system_score_codex":0.0006182531,"about_ca_system_score_gemma":0.0012320157,"threshold_uncertainty_score":0.9991378},"labels":[],"label_agreement":null},{"id":"W2902655481","doi":"10.1093/annonc/mdy518","title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":631,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Metastatic breast cancer; Breast cancer; Triple-negative breast cancer; Cohort; Oncology; Clinical endpoint; Adverse effect; Cancer; Clinical trial; Immunotherapy","score_opus":0.05724842178695039,"score_gpt":0.41755175223619245,"score_spread":0.36030333044924207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902655481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98821634,0.00096157275,0.00006912842,0.0049494435,0.00031644516,0.004069353,0.0005436026,0.000020477439,0.0008536317],"genre_scores_gemma":[0.99566734,0.000981009,0.0001616038,0.001748883,0.00016494398,0.0003647724,0.000015733058,0.000034331595,0.00086139725],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99800843,0.00028973017,0.00070807576,0.0003539212,0.00026610092,0.00037374865],"domain_scores_gemma":[0.99768597,0.00029210345,0.0006406608,0.0004495286,0.00084552285,0.00008620039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006636749,0.00024964326,0.0009461298,0.00013604871,0.00018164371,0.0000055215187,0.0002491269,0.00010859878,0.00038219447],"category_scores_gemma":[0.00008506741,0.00016502867,0.00034800865,0.00042286707,0.00068581785,0.00007533061,0.000048831065,0.0001316045,0.0000017458001],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35780403,0.019980514,0.033899352,0.00029915274,0.014214281,0.000032685755,0.020130733,0.0000084161675,0.04094805,0.00012406787,0.02335094,0.48920777],"study_design_scores_gemma":[0.17314035,0.21367937,0.3596962,0.00068350555,0.0032873554,0.00032304166,0.0034557753,0.00039520237,0.21913758,0.00055054016,0.02496914,0.0006819392],"about_ca_topic_score_codex":0.0026749908,"about_ca_topic_score_gemma":0.0008731129,"teacher_disagreement_score":0.48852584,"about_ca_system_score_codex":0.00013043999,"about_ca_system_score_gemma":0.0007559795,"threshold_uncertainty_score":0.6729674},"labels":[],"label_agreement":null},{"id":"W2902690248","doi":"10.3389/fimmu.2018.02737","title":"CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy","year":2018,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"Deutsche Forschungsgemeinschaft","keywords":"Blockade; Immunotherapy; CTLA-4; Immune system; Cancer research; Antibody; Autoimmunity; Monoclonal antibody; Effector; Immune checkpoint; Immunology; Motility; T cell; Peripheral tolerance; Receptor; Biology; Cell biology; Biochemistry","score_opus":0.0212571566540893,"score_gpt":0.3050628559414002,"score_spread":0.2838056992873109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902690248","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012891947,0.99218506,0.0030340792,0.00028451876,0.00059504475,0.00225882,0.0002429569,0.0000198543,0.00009049363],"genre_scores_gemma":[0.0008699048,0.99434775,0.0037286195,0.00013778152,0.00007727756,0.0004671688,0.00010354873,0.000043728956,0.00022424574],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99823684,0.00014022412,0.00082928484,0.00045597175,0.00005691659,0.00028074472],"domain_scores_gemma":[0.9986669,0.00018179492,0.00046906693,0.00053193094,0.00011175492,0.000038590995],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003884224,0.00032874855,0.001853809,0.00034011184,0.00007333707,0.000011794123,0.00016127162,0.00037912012,0.00001858467],"category_scores_gemma":[0.000053884996,0.00027812095,0.00028742923,0.00023301055,0.00074430334,0.000035456174,0.0000280534,0.00022815449,7.7072156e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018953932,0.00026249894,0.0035074481,0.0073136142,0.0013797538,0.000001619127,0.00021265667,1.5704812e-8,0.00086257694,0.00005412834,0.0039295717,0.98058075],"study_design_scores_gemma":[0.0054629706,0.0009639026,0.0047742724,0.0016888801,0.0005575338,0.0001145764,0.00007010707,0.0000131415845,0.000070866845,0.00030399158,0.98574376,0.00023601505],"about_ca_topic_score_codex":0.00006475055,"about_ca_topic_score_gemma":0.000014677224,"teacher_disagreement_score":0.98181415,"about_ca_system_score_codex":0.00014008708,"about_ca_system_score_gemma":0.00031357634,"threshold_uncertainty_score":0.9999671},"labels":[],"label_agreement":null},{"id":"W2902836632","doi":"10.1016/j.annder.2018.09.095","title":"Étude de phase II de l’administration de pembrolizumab (MK-3475) en monothérapie et en première ligne chez des patients présentant un carcinome épidermoïde cutané inopérable","year":2018,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Gynecology","score_opus":0.02772617595972393,"score_gpt":0.33872634232495613,"score_spread":0.3110001663652322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902836632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.961927,0.016023107,0.0045425845,0.012525805,0.0008717422,0.0012327433,0.00029876168,0.00045934677,0.0021189312],"genre_scores_gemma":[0.9621592,0.018999094,0.008313214,0.008633026,0.0006361984,0.00026627028,0.00031012073,0.0001511977,0.00053167314],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9912322,0.002500252,0.0013560046,0.0010700489,0.0005378319,0.0033036498],"domain_scores_gemma":[0.995777,0.0014131616,0.00062298606,0.0009984995,0.00039003041,0.00079833524],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0030267488,0.0010101132,0.0011668411,0.0004024079,0.0006683187,0.0002175669,0.001022725,0.0015216029,0.00040688174],"category_scores_gemma":[0.0022751535,0.0010219146,0.0005221726,0.00068192347,0.0015151779,0.00066500047,0.00040607236,0.0012512087,0.00008743701],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014785111,0.0072663473,0.7371722,0.0017376025,0.0023056888,0.0051783286,0.04134105,0.00015265982,0.11046675,0.001358009,0.02587215,0.05236412],"study_design_scores_gemma":[0.021558404,0.011386087,0.4458459,0.0017293443,0.0014098089,0.010758354,0.0066622836,0.0052603465,0.4640375,0.0065413048,0.022730134,0.0020805462],"about_ca_topic_score_codex":0.0011098798,"about_ca_topic_score_gemma":0.00072755554,"teacher_disagreement_score":0.35357076,"about_ca_system_score_codex":0.0037473992,"about_ca_system_score_gemma":0.0060156435,"threshold_uncertainty_score":0.99977463},"labels":[],"label_agreement":null},{"id":"W2903560348","doi":"10.20944/preprints201811.0609.v1","title":"Exploiting Autoimmunity Unleashed by an Off-Label Low-Dose Immune Checkpoint Blockade to Treat Advanced Cancer","year":2018,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Ipilimumab; Medicine; Immunotherapy; Adverse effect; Blockade; Cancer immunotherapy; Cancer; Nivolumab; Population; Immune checkpoint; Immunology; Autoimmunity; Immune system; Oncology; Internal medicine; Receptor","score_opus":0.09678417388093633,"score_gpt":0.3788941730114344,"score_spread":0.28210999913049806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903560348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858966,0.003962157,0.00006022983,0.001997116,0.0013777197,0.0026879099,0.00023145336,0.00064743415,0.0031394104],"genre_scores_gemma":[0.98509824,0.0031055093,0.00071507646,0.0009545247,0.0006554376,0.0013282852,0.0004918591,0.0002510572,0.007400005],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99417025,0.00032748957,0.0015838796,0.0020297167,0.0007945515,0.001094122],"domain_scores_gemma":[0.99423707,0.000083916755,0.0007876798,0.0037373053,0.0005344778,0.00061957666],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013531275,0.0010821908,0.0015665991,0.00034542815,0.0003591068,0.00006474025,0.001169362,0.00076317653,0.004446459],"category_scores_gemma":[0.00036523715,0.0010725434,0.0005653794,0.00049340836,0.00038599156,0.00023732592,0.0019480509,0.0017352129,0.0006688408],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065655843,0.0012708736,0.029564017,0.000708584,0.00065142126,0.000032145774,0.0030532465,0.000083683124,0.9140742,0.0000017603759,0.00019053085,0.04380399],"study_design_scores_gemma":[0.007061084,0.00043088058,0.19981286,0.002867927,0.00040259975,0.00003406526,0.0006056904,0.00032908382,0.77575344,0.000078897836,0.011373088,0.0012504106],"about_ca_topic_score_codex":0.0056461366,"about_ca_topic_score_gemma":0.00014720473,"teacher_disagreement_score":0.17024884,"about_ca_system_score_codex":0.0014665134,"about_ca_system_score_gemma":0.00087864726,"threshold_uncertainty_score":0.9991725},"labels":[],"label_agreement":null},{"id":"W2904424259","doi":"10.1016/j.ejca.2018.10.017","title":"Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Adverse effect; Discontinuation; Internal medicine; Incidence (geometry); Clinical trial; Confidence interval; Odds ratio; Surgery","score_opus":0.04551773507185558,"score_gpt":0.3870358535211918,"score_spread":0.3415181184493362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904424259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992565,0.0032554774,0.00068431196,0.0007694158,0.00095405336,0.00064631755,0.000016695958,0.000010987725,0.0010977647],"genre_scores_gemma":[0.9965134,0.0010162446,0.0011284318,0.00047995642,0.0005102398,0.000011704442,0.0000037918905,0.000052897485,0.00028333635],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99648213,0.0007505749,0.0019429356,0.00018255024,0.00032614914,0.00031565252],"domain_scores_gemma":[0.99814755,0.00016060377,0.0011476817,0.0001921901,0.00026614143,0.000085811356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069305887,0.00019625424,0.0007173959,0.00033420525,0.00006124985,0.000010857782,0.00019844297,0.00005058795,0.00038644372],"category_scores_gemma":[0.00017990703,0.00015473763,0.0004256197,0.00034705753,0.000079959944,0.00018820928,0.000018584686,0.0003568369,0.0000044453036],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06322264,0.0009664797,0.025812235,0.000046747195,0.0012641869,0.0002488858,0.003348331,0.000054271084,0.57221997,0.000014001727,0.00041345536,0.33238882],"study_design_scores_gemma":[0.15446234,0.0098864455,0.784561,0.0024852692,0.00023522852,0.00011397545,0.0005727244,0.00036782338,0.027093286,0.0000745334,0.019694733,0.00045263767],"about_ca_topic_score_codex":0.000104817074,"about_ca_topic_score_gemma":0.000054531585,"teacher_disagreement_score":0.75874877,"about_ca_system_score_codex":0.0004677132,"about_ca_system_score_gemma":0.00036064003,"threshold_uncertainty_score":0.6310017},"labels":[],"label_agreement":null},{"id":"W2904444972","doi":"10.1200/jco.2018.78.2276","title":"T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":992,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Clinical endpoint; Cancer; Response Evaluation Criteria in Solid Tumors; Lung cancer; KRAS; Clinical trial; Phases of clinical research; Immunotherapy; Colorectal cancer","score_opus":0.0401353546324534,"score_gpt":0.39514115414317325,"score_spread":0.35500579951071987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904444972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99742335,0.00037479668,0.000020350686,0.00061265106,0.000368212,0.0008077048,0.000020377493,0.000017700957,0.00035488405],"genre_scores_gemma":[0.99523336,0.00018241456,0.0026823527,0.00046652314,0.0011409271,0.000031596504,0.000028809249,0.000031316416,0.00020272372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99639183,0.00031262,0.0019446422,0.00036186207,0.0005744076,0.00041465703],"domain_scores_gemma":[0.9963824,0.0006542663,0.0016390572,0.0002048858,0.0007176774,0.00040171712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012940537,0.0002435736,0.0011217988,0.00013116375,0.00010681629,0.000027104632,0.00017015541,0.00035465756,0.000081251834],"category_scores_gemma":[0.00072384893,0.00015003872,0.00019607395,0.00022543268,0.0005888455,0.00017639682,0.00005785758,0.00067980646,0.0000035245885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19243583,0.0027878222,0.7453531,0.000072567054,0.00029442483,0.0004915149,0.0010264545,0.00001635311,0.013759069,4.1721958e-7,0.0027325186,0.041029923],"study_design_scores_gemma":[0.08046674,0.03153595,0.86304355,0.00076382497,0.00015538989,0.00021347008,0.00016046005,0.00011518547,0.017623885,0.00000820556,0.005725017,0.00018832787],"about_ca_topic_score_codex":0.00009138678,"about_ca_topic_score_gemma":0.000058411857,"teacher_disagreement_score":0.117690444,"about_ca_system_score_codex":0.00030716238,"about_ca_system_score_gemma":0.0017887414,"threshold_uncertainty_score":0.6118401},"labels":[],"label_agreement":null},{"id":"W2905172465","doi":"10.3747/co.25.4287","title":"Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort","year":2018,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada); Thunder Bay Regional Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Hospital; Institut universitaire de cardiologie et de pneumologie de Québec; Cegep de Saint Jerome; Regional Municipality of Durham; Royal Columbian Hospital; Dr. Georges-L.-Dumont University Hospital Centre; McGill University Health Centre; Juravinski Cancer Centre","funders":"Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Discontinuation; Cohort; Lung cancer; Internal medicine; Clinical trial; Randomized controlled trial; Cancer; Oncology; Demographics; Immunotherapy; Demography","score_opus":0.04051589643830278,"score_gpt":0.37682045576695133,"score_spread":0.33630455932864856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905172465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96562505,0.0025870765,0.0000043099794,0.000664798,0.0016694447,0.0006022661,0.00003193038,0.000012448257,0.028802702],"genre_scores_gemma":[0.9954714,0.0021633601,0.00007468437,0.00025440723,0.00039065394,0.00010003845,0.000026527578,0.000018813618,0.001500079],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988199,0.000028027232,0.00035904412,0.00025278618,0.0001057237,0.00043452985],"domain_scores_gemma":[0.9992589,0.000034041874,0.00012197385,0.00024485827,0.00014151944,0.00019871336],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026522257,0.00013105656,0.00039546128,0.00036636513,0.000041401516,0.0000035981757,0.00012149959,0.00011428885,0.0010431614],"category_scores_gemma":[0.000010510112,0.0001241011,0.00008141688,0.00042675665,0.00017485276,0.00002391743,0.000024222416,0.00019161178,0.000012344007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006566696,0.00021608504,0.94469666,0.00015176863,0.00007338521,0.000016680371,0.00061160425,7.811749e-7,0.002290347,0.00003089463,0.010721016,0.040534128],"study_design_scores_gemma":[0.0038662746,0.0005525439,0.76551956,0.00029520722,0.00011368822,0.0000068240206,0.00006114879,0.0004349088,0.00211806,0.0000106990465,0.2268793,0.00014181266],"about_ca_topic_score_codex":0.6115435,"about_ca_topic_score_gemma":0.95280105,"teacher_disagreement_score":0.34125757,"about_ca_system_score_codex":0.0017522956,"about_ca_system_score_gemma":0.0021554735,"threshold_uncertainty_score":0.99987},"labels":[],"label_agreement":null},{"id":"W2905201605","doi":"10.1016/j.ejca.2018.11.015","title":"Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":267,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McGill University Health Centre","funders":"AstraZeneca; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Head and neck; Basal cell; Oncology; Head and neck squamous-cell carcinoma; Internal medicine; Head and neck cancer; Surgery; Cancer; Immunotherapy","score_opus":0.0346955478729249,"score_gpt":0.3084686780840385,"score_spread":0.2737731302111136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905201605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965283,0.00095715746,0.000059388232,0.00026023635,0.00022352724,0.001525544,0.00017981346,0.0000112952575,0.00025473765],"genre_scores_gemma":[0.99759907,0.000017149963,0.0013544938,0.00037615706,0.00031856704,0.000018192834,0.000022874465,0.00008171709,0.00021179862],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976248,0.00031812524,0.00083370635,0.00038035694,0.0005442464,0.00029874215],"domain_scores_gemma":[0.998182,0.00013389635,0.0008713726,0.0002623287,0.0003759645,0.00017443352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006078098,0.00031204382,0.00054592174,0.00019576788,0.00013174968,0.00004665508,0.00015110701,0.000025816937,0.00009174229],"category_scores_gemma":[0.00006169832,0.00019542838,0.00010001404,0.0001700813,0.00010225019,0.00010381224,0.000021554946,0.0002573861,8.6129705e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81569594,0.023825394,0.030452594,0.000185379,0.00016134985,0.00037113143,0.012334548,0.000026117757,0.017449288,3.6419326e-8,0.005153936,0.09434427],"study_design_scores_gemma":[0.39341408,0.27820504,0.23889978,0.0022154672,0.0003281097,0.0000065519575,0.00091857626,0.00035418742,0.079419985,0.000001254399,0.0057944795,0.00044248748],"about_ca_topic_score_codex":0.00005287823,"about_ca_topic_score_gemma":0.0001387528,"teacher_disagreement_score":0.42228186,"about_ca_system_score_codex":0.0002127247,"about_ca_system_score_gemma":0.00024924843,"threshold_uncertainty_score":0.7969338},"labels":[],"label_agreement":null},{"id":"W2905817704","doi":"10.1186/s40425-018-0479-7","title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":571,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"Canadian Institutes of Health Research","keywords":"Immune system; Immunotherapy; Medicine; Melanoma; Phenotype; Immune checkpoint; Immunology; Cancer research; Cancer; Biology; Internal medicine; Gene","score_opus":0.015517749621850001,"score_gpt":0.3085602037906005,"score_spread":0.2930424541687505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905817704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759296,0.017950699,0.00006930343,0.004497126,0.00077578425,0.0006848673,0.000048042275,0.000020995416,0.00002358389],"genre_scores_gemma":[0.99247515,0.003902081,0.0018085479,0.0005420653,0.0005199033,0.00007279949,0.0000037131535,0.000049441685,0.0006263084],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99815613,0.00008035032,0.00077770953,0.00030473695,0.0003332834,0.00034778443],"domain_scores_gemma":[0.99856544,0.00027047584,0.0004121381,0.00019718731,0.0003926837,0.00016208779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010240142,0.0002786619,0.00058482133,0.0002704929,0.00031519812,0.000081646576,0.00011885209,0.00013323562,0.00022030504],"category_scores_gemma":[0.00014315828,0.00022135972,0.0001661119,0.00022253318,0.0006226259,0.00015441676,0.00004330808,0.00024407325,0.0000010929078],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1572043,0.00005530568,0.00038258475,0.000051071613,0.00055204955,0.000012308788,0.0015799609,0.0000033176016,0.79752576,0.00003760351,0.00019882157,0.04239691],"study_design_scores_gemma":[0.054383017,0.02263518,0.43643677,0.0021742487,0.00023040941,0.0008892004,0.00225591,0.000076902405,0.4389621,0.0004139387,0.040688075,0.0008542524],"about_ca_topic_score_codex":0.00037854037,"about_ca_topic_score_gemma":0.000025259073,"teacher_disagreement_score":0.43605417,"about_ca_system_score_codex":0.00022004051,"about_ca_system_score_gemma":0.0003591228,"threshold_uncertainty_score":0.9026787},"labels":[],"label_agreement":null},{"id":"W2905883696","doi":"10.1186/s40425-018-0480-1","title":"Taking the bull by the horn: the frontline use of infliximab for the treatment of immune checkpoint inhibitor-induced enterocolitis","year":2018,"lang":"en","type":"letter","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Infliximab; Medicine; Immune system; Enterocolitis; Adverse effect; Immune dysregulation; Immune checkpoint; CTLA-4; Immunology; Intensive care medicine; Sepsis; Ipilimumab; Cancer; Oncology; Tumor necrosis factor alpha; Internal medicine; Immunotherapy; T cell","score_opus":0.051706465511070686,"score_gpt":0.3364134831832456,"score_spread":0.28470701767217493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905883696","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15142371,0.2162927,0.0007749204,0.61233,0.006263268,0.011028576,0.001811788,0.000024112214,0.00005088484],"genre_scores_gemma":[0.21138844,0.3274901,0.0012783086,0.3773631,0.044639047,0.010070033,0.0004376617,0.0013157069,0.026017636],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99605745,0.00021286745,0.002010948,0.0003137085,0.0008159369,0.00058909354],"domain_scores_gemma":[0.9922419,0.001590363,0.003978933,0.0012599669,0.00089455926,0.00003426762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012035505,0.0006111672,0.0012730379,0.0001243883,0.0006151536,0.0001112576,0.0009396288,0.00044845277,0.00047060096],"category_scores_gemma":[0.00007888168,0.00023523552,0.002359488,0.00022569961,0.000900184,0.000112114234,0.000034186865,0.0008491174,4.9674526e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025378864,0.00042127902,0.000111028196,0.00033240902,0.012414239,0.000003347245,0.00473645,0.0000087758135,0.20870097,0.000004933598,0.50900215,0.23888555],"study_design_scores_gemma":[0.009425483,0.004309738,0.0012983221,0.000925571,0.0009803306,0.00008692615,0.00031081363,0.00004936075,0.12792692,0.00004637791,0.85442144,0.0002187389],"about_ca_topic_score_codex":0.003458555,"about_ca_topic_score_gemma":0.00016569105,"teacher_disagreement_score":0.34541926,"about_ca_system_score_codex":0.000590358,"about_ca_system_score_gemma":0.0005452445,"threshold_uncertainty_score":0.9592626},"labels":[],"label_agreement":null},{"id":"W2905948744","doi":"10.1158/1078-0432.ccr-18-1726","title":"SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Office of Extramural Research, National Institutes of Health; National Cancer Institute; Society of Memorial Sloan Kettering; National Institute of Diabetes and Digestive and Kidney Diseases; Stand Up To Cancer; Association for Academic Surgery; Memorial Sloan-Kettering Cancer Center; American Society of Colon and Rectal Surgeons; American College of Surgeons; U.S. Department of Veterans Affairs; Dana-Farber/Harvard Cancer Center; Howard Hughes Medical Institute","keywords":"Cohort; Medicine; Interquartile range; Colorectal cancer; Internal medicine; Oncology; Cancer; Immune system; Chemotherapy; Gastroenterology; Adjuvant therapy; Immunology","score_opus":0.07200764511862745,"score_gpt":0.4443375698646952,"score_spread":0.37232992474606774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905948744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99260354,0.004618774,0.0000014747241,0.00063308945,0.0003231203,0.00069433433,0.00006314968,0.000013890465,0.001048597],"genre_scores_gemma":[0.9918363,0.0072297244,0.00005044018,0.00011519595,0.00022026725,0.00015775122,0.000015454365,0.00002700291,0.00034787858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973528,0.00020132329,0.0007964709,0.00050273584,0.0006318182,0.0005148796],"domain_scores_gemma":[0.9979593,0.0005057284,0.00018822883,0.00027158266,0.00090228225,0.0001728569],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0015998702,0.00017195738,0.00056600856,0.00017586257,0.00009823287,0.00001990132,0.00020954217,0.0002012166,0.00044668658],"category_scores_gemma":[0.00033170698,0.00012728863,0.000083459905,0.0010622471,0.0033519387,0.00009751474,0.000097294054,0.00076846196,0.0000072100565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026796978,0.00044123264,0.9488724,0.00018601528,0.000119323115,0.00001990301,0.00029509387,3.743788e-7,0.0016663241,0.000020748212,0.000972412,0.020609204],"study_design_scores_gemma":[0.0075122993,0.0032840152,0.97143954,0.0013274578,0.000025054516,0.000004785317,0.00008703711,0.000033628963,0.013849329,0.00006577809,0.0022054298,0.00016563987],"about_ca_topic_score_codex":0.0022376762,"about_ca_topic_score_gemma":0.003252111,"teacher_disagreement_score":0.022567153,"about_ca_system_score_codex":0.00021008665,"about_ca_system_score_gemma":0.00085661263,"threshold_uncertainty_score":0.9993604},"labels":[],"label_agreement":null},{"id":"W2906917595","doi":"10.1007/s40265-018-1032-1","title":"Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer","year":2019,"lang":"en","type":"review","venue":"Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Nivolumab; Medicine; Pembrolizumab; Immune checkpoint; Blockade; Cancer; Oncology; Ipilimumab; Internal medicine; Atezolizumab; Immunotherapy; Microsatellite instability; Chemotherapy","score_opus":0.03974246553099459,"score_gpt":0.3481894594858245,"score_spread":0.30844699395482994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906917595","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008225032,0.9959686,1.2850975e-7,0.00013734763,0.00043043334,0.0015086252,0.000056808494,0.000009209491,0.001066385],"genre_scores_gemma":[0.0004880388,0.99760264,0.00001152599,0.000053152846,0.00028313685,0.0002836294,0.00009231083,0.00003341322,0.0011521676],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985062,0.00009885595,0.0007015337,0.00023672369,0.00023378828,0.00022290862],"domain_scores_gemma":[0.9990461,0.00008031479,0.00032327618,0.0005014419,0.00002185288,0.000027011421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024534718,0.00030019318,0.0014639924,0.00015087353,0.000017432472,0.000008189452,0.00014770913,0.0001527582,0.00015808306],"category_scores_gemma":[0.0000038522403,0.00015420362,0.0009261345,0.00032132532,0.0000741029,0.000017989272,0.000011436749,0.00016866197,0.0000253632],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013232788,0.0002758242,0.00003877275,0.005201685,0.00031355655,0.000017146753,0.0012932535,8.674527e-8,0.000012687872,0.00000307986,0.00020115638,0.99251044],"study_design_scores_gemma":[0.0015729637,0.0005120991,0.00018359652,0.009165459,0.0007816395,0.00002396007,0.00015828462,3.562569e-7,0.000094113064,0.0000011969373,0.98739827,0.000108063985],"about_ca_topic_score_codex":0.0010424341,"about_ca_topic_score_gemma":0.00002589411,"teacher_disagreement_score":0.9924024,"about_ca_system_score_codex":0.00048776262,"about_ca_system_score_gemma":0.00043192194,"threshold_uncertainty_score":0.6288241},"labels":[],"label_agreement":null},{"id":"W2907028960","doi":"10.1001/jamaoncol.2018.5904","title":"Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers","year":2019,"lang":"en","type":"review","venue":"JAMA Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":302,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Immunotherapy; Hazard ratio; Meta-analysis; Internal medicine; Randomized controlled trial; Observational study; Clinical trial; Oncology; MEDLINE; Cancer; Confidence interval","score_opus":0.018362684288729527,"score_gpt":0.32044378403258034,"score_spread":0.30208109974385083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907028960","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10541496,0.8919026,4.3649297e-7,0.00016348466,0.00039215595,0.001293661,0.000032333934,0.000007763476,0.00079258654],"genre_scores_gemma":[0.0043141367,0.9949275,0.00009621368,0.000048778522,0.00006547457,0.000052303905,0.0000699898,0.000031667445,0.0003938835],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979614,0.00022080034,0.0010735898,0.00028497103,0.0002457956,0.00021344543],"domain_scores_gemma":[0.997556,0.0004669578,0.001596261,0.0002443887,0.00009767197,0.00003874293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005513769,0.0002397163,0.0022938724,0.00020443599,0.0000102833965,0.0000023898954,0.00006943511,0.00048821108,0.0000379687],"category_scores_gemma":[0.00012792276,0.00017612067,0.00024376798,0.00025307914,0.00008600824,0.00003975018,0.00004229608,0.00037342843,0.000001139509],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025807025,0.00020490366,0.0017510263,0.008724434,0.00069025025,0.00001124707,0.00048573266,0.000004697609,0.00026172405,0.0000048213706,0.0000987222,0.98518175],"study_design_scores_gemma":[0.012374331,0.005002797,0.008336536,0.012592192,0.0008556556,0.000026903954,0.00023885498,0.000003137284,0.00022673454,0.0000020530708,0.96008635,0.00025445595],"about_ca_topic_score_codex":0.0012903893,"about_ca_topic_score_gemma":0.0003978213,"teacher_disagreement_score":0.9849273,"about_ca_system_score_codex":0.0021682358,"about_ca_system_score_gemma":0.0013489731,"threshold_uncertainty_score":0.71819925},"labels":[],"label_agreement":null},{"id":"W2908570680","doi":"10.1503/cmaj.180870","title":"Adverse events associated with immune checkpoint inhibitor treatment for cancer","year":2019,"lang":"en","type":"review","venue":"Canadian Medical Association Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Immune system; Cytotoxic T cell; Immune checkpoint; Immunity; Cancer; Immunology; Adverse effect; Programmed cell death 1; Medicine; Cancer research; Immunotherapy; Biology; PD-L1; Pharmacology; Internal medicine; In vitro","score_opus":0.03153973747778953,"score_gpt":0.32135271998383275,"score_spread":0.2898129825060432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908570680","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020434844,0.9918313,0.0000076011365,0.0031854508,0.002058421,0.0017926084,0.00056087866,0.000023529325,0.00033583405],"genre_scores_gemma":[0.00004025481,0.98752266,0.00003080911,0.0011793157,0.0020764235,0.00026536942,0.0003965732,0.00009340814,0.008395207],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996343,0.00020074376,0.0011129405,0.0003328683,0.0012466258,0.0007637943],"domain_scores_gemma":[0.99644595,0.00029074977,0.0012529073,0.00020785487,0.0005027748,0.0012997785],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013770023,0.00046260105,0.0019337812,0.00034656512,0.00023399133,0.000028319084,0.00019598233,0.0011695743,0.0026205077],"category_scores_gemma":[0.0006850641,0.00030942578,0.0012350949,0.00038282984,0.000038252274,0.00007406882,0.000009228509,0.00095063954,0.000067835106],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0001595417,0.00012029079,0.0005165178,0.0010546041,0.0054832506,0.00015823937,0.000084862455,2.8603054e-7,6.478308e-7,0.0000019007686,0.008637378,0.9837825],"study_design_scores_gemma":[0.0056818025,0.00062221516,0.0004152107,0.02488493,0.0023724735,0.00027328994,0.000048952807,0.000007585028,0.0000018881191,0.0000019446697,0.9653637,0.00032602082],"about_ca_topic_score_codex":0.0034373375,"about_ca_topic_score_gemma":0.028124753,"teacher_disagreement_score":0.98345643,"about_ca_system_score_codex":0.01725579,"about_ca_system_score_gemma":0.026248638,"threshold_uncertainty_score":0.9999358},"labels":[],"label_agreement":null},{"id":"W2908791713","doi":"10.1093/jncics/pky058","title":"Physical Activity and Colorectal Cancer Prognosis According to Tumor-Infiltrating T Cells","year":2018,"lang":"en","type":"article","venue":"JNCI Cancer Spectrum","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Gary Bennett Family Fund; General Hospital of People’s Liberation Army; American Association for Cancer Research; University of Tokyo; National Institutes of Health; Taiho Pharmaceutical; Huazhong University of Science and Technology; Keio University; Agios Pharmaceuticals; Harvard T.H. Chan School of Public Health; Five Prime Therapeutics; F. Hoffmann-La Roche; National Cancer Institute; Gilead Sciences; Yale University; Massachusetts General Hospital; Broad Institute; Sanofi; Zhejiang Chinese Medical University; Stand Up To Cancer; Entertainment Industry Foundation; Brigham and Women's Hospital; Yale Cancer Center; Pfizer; Eli Lilly and Company","keywords":"Colorectal cancer; Medicine; Hazard ratio; Microsatellite instability; Oncology; Internal medicine; KRAS; Cancer; Confidence interval; Proportional hazards model; Cancer research; Biology; Genetics","score_opus":0.01680627733881148,"score_gpt":0.31340372381757725,"score_spread":0.2965974464787658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908791713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925898,0.00027975562,0.000037362704,0.004200189,0.0007685293,0.000649241,0.000037616508,0.00010153691,0.0013360151],"genre_scores_gemma":[0.9956757,0.00012357751,0.0001728429,0.0011091715,0.002386886,0.00025026573,0.0000010335505,0.000039530576,0.00024099654],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986208,0.000025410569,0.00015212058,0.0004626746,0.00026991998,0.0004690871],"domain_scores_gemma":[0.9994303,0.000043184686,0.00010178441,0.00016980366,0.000059803664,0.00019514051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011233721,0.00023317082,0.0003754818,0.00008876954,0.00019518369,0.00006116184,0.00009347086,0.00005531365,0.00028310216],"category_scores_gemma":[0.000015152267,0.00020000999,0.00010541988,0.00042526308,0.00016783869,0.00013331033,0.000064888416,0.00020322164,0.000017152335],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024145525,0.00014000993,0.07129644,0.000075296426,0.00018135838,0.000014566768,0.0010031275,0.0000015763019,0.8503881,0.000020031837,0.0017384997,0.07272642],"study_design_scores_gemma":[0.0010841617,0.00087429397,0.14651601,0.00021488385,0.00008943487,0.000021034508,0.00019572591,0.00049223047,0.84751266,0.000017371165,0.002719425,0.00026274277],"about_ca_topic_score_codex":0.0049860533,"about_ca_topic_score_gemma":0.0018381068,"teacher_disagreement_score":0.07521957,"about_ca_system_score_codex":0.00041598192,"about_ca_system_score_gemma":0.00027608866,"threshold_uncertainty_score":0.8156171},"labels":[],"label_agreement":null},{"id":"W2908942081","doi":"10.2217/imt-2018-0167","title":"Immune Checkpoint Inhibitors and Non-Small-Cell Lung Cancer Management: 2018 Update","year":2019,"lang":"en","type":"editorial","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Pembrolizumab; Atezolizumab; Nivolumab; Medicine; Lung cancer; Oncology; Internal medicine; Docetaxel; Avelumab; Ipilimumab; Cancer; Immunotherapy","score_opus":0.005902408804642505,"score_gpt":0.2602707838035951,"score_spread":0.2543683749989526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908942081","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022737194,0.16446915,0.00008492187,0.00078513206,0.804007,0.0032126124,0.000293508,0.0001949664,0.0042155036],"genre_scores_gemma":[0.0025026167,0.4100301,0.0007919825,0.0012449007,0.5193053,0.0006859327,0.0010542268,0.0006822309,0.0637027],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99600554,0.000074775475,0.0011577191,0.0010802223,0.00086980464,0.0008119533],"domain_scores_gemma":[0.9974046,0.00014436782,0.00071116496,0.0013952185,0.00020760896,0.00013704717],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006821001,0.0009723294,0.001360811,0.00042014592,0.00019475994,0.00018618362,0.00048983155,0.0011990654,0.0007070253],"category_scores_gemma":[0.000012227676,0.00085362763,0.0006422207,0.0003760897,0.00023024391,0.0001532724,0.00016987398,0.0012082722,0.00011627466],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057201576,0.00025367658,0.00026916314,0.002330377,0.003031428,0.0000642323,0.000523633,0.0000013226932,0.03329525,0.000004446834,0.92914903,0.025357276],"study_design_scores_gemma":[0.01499165,0.00042321545,0.0009466347,0.0021894933,0.0005421899,0.000009025604,0.00010063827,0.000044962002,0.006820779,0.000009516677,0.97299147,0.0009304444],"about_ca_topic_score_codex":0.0015719784,"about_ca_topic_score_gemma":0.00003646023,"teacher_disagreement_score":0.2847017,"about_ca_system_score_codex":0.00068372994,"about_ca_system_score_gemma":0.0005788921,"threshold_uncertainty_score":0.99939144},"labels":[],"label_agreement":null},{"id":"W2910245285","doi":"10.1200/jco.18.00149","title":"Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1716,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Chemotherapy; Internal medicine; Hazard ratio; Oncology; Tolerability; Clinical endpoint; Chemotherapy regimen; Surgery; Cancer; Confidence interval; Randomized controlled trial; Immunotherapy; Adverse effect","score_opus":0.06235330001325926,"score_gpt":0.4207660967554982,"score_spread":0.3584127967422389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910245285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99615425,0.00026405405,0.0007487654,0.0010414886,0.00062321336,0.0009131513,0.00003169732,0.0000072859857,0.00021608041],"genre_scores_gemma":[0.9933583,0.0002205901,0.004803628,0.00091285387,0.00019412179,0.000020943715,0.00002513931,0.000032543845,0.000431885],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99656236,0.000117343174,0.0024109501,0.0002676988,0.00038885267,0.0002528068],"domain_scores_gemma":[0.994031,0.00074320164,0.003880802,0.00029701588,0.0008973403,0.0001506003],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001234685,0.00020865227,0.0022184371,0.00034246116,0.000023405895,0.0000047541344,0.00017885286,0.00027695403,0.0010463966],"category_scores_gemma":[0.00016847008,0.00012375865,0.00088531006,0.0005441471,0.00019715026,0.00008308437,0.000012494471,0.00038229438,7.94325e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7264834,0.0012470911,0.22946067,0.0003552974,0.006082542,0.000050960974,0.00014183926,0.001272324,0.01565949,0.0000012825619,0.00043951062,0.018805582],"study_design_scores_gemma":[0.23734902,0.08075658,0.6128643,0.0008317154,0.011465649,0.00004459859,0.00031892903,0.009887537,0.039129943,0.000004630272,0.006972005,0.000375071],"about_ca_topic_score_codex":0.00007450489,"about_ca_topic_score_gemma":0.00019208282,"teacher_disagreement_score":0.48913437,"about_ca_system_score_codex":0.00024177422,"about_ca_system_score_gemma":0.0030009018,"threshold_uncertainty_score":0.9998668},"labels":[],"label_agreement":null},{"id":"W2910269253","doi":"10.1158/1078-0432.ccr-18-2847","title":"Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Swim Across America; U.S. Food and Drug Administration; Herbert Irving Comprehensive Cancer Center, Columbia University","keywords":"Medicine; Oncology; Melanoma; Internal medicine; Proportional hazards model; Stage (stratigraphy); Receiver operating characteristic; Survival analysis; Cohort; Population; Area under the curve; Immunotherapy; Cancer; Cancer research; Biology","score_opus":0.14415378547743973,"score_gpt":0.45528315525464214,"score_spread":0.3111293697772024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910269253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871614,0.0046755127,0.000078125966,0.0010361725,0.0008356307,0.0049850023,0.00033550966,0.000057912606,0.0008347289],"genre_scores_gemma":[0.98468584,0.0014204831,0.0003721995,0.00006715707,0.00051421847,0.0010465168,0.00038196563,0.000057765472,0.011453832],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99624866,0.00028721933,0.0013510594,0.0006257509,0.0008934489,0.00059386133],"domain_scores_gemma":[0.9969385,0.00085285114,0.00032895867,0.000781194,0.00093069585,0.00016776168],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00446489,0.00020362892,0.0007357683,0.00024386561,0.00019877387,0.000029039054,0.00030692067,0.00031281222,0.0023640601],"category_scores_gemma":[0.0006705961,0.00016811001,0.0004199855,0.000636325,0.00041303196,0.00014443924,0.00017017697,0.0006300911,0.000034187695],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048093945,0.0016764328,0.3549527,0.0019298854,0.0011883794,0.000015140898,0.0005990407,0.000016022941,0.5256692,0.00016024162,0.0034901414,0.062208842],"study_design_scores_gemma":[0.025049148,0.017768037,0.4424938,0.0016432038,0.00024980164,0.00001762549,0.000424066,0.0013088515,0.48516592,0.00013395303,0.025350496,0.00039508045],"about_ca_topic_score_codex":0.0006388122,"about_ca_topic_score_gemma":0.000023321127,"teacher_disagreement_score":0.0875411,"about_ca_system_score_codex":0.00028077565,"about_ca_system_score_gemma":0.0011000272,"threshold_uncertainty_score":0.9985479},"labels":[],"label_agreement":null},{"id":"W2910583709","doi":"10.1371/journal.ppat.1007429","title":"Roles, function and relevance of LAG3 in HIV infection","year":2019,"lang":"en","type":"review","venue":"PLoS Pathogens","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research; Canadian Foundation for AIDS Research","keywords":"Immune system; Immunology; Immunity; Antibody; Biology; Phenotype; Human immunodeficiency virus (HIV); Gene; Genetics","score_opus":0.04777689860763594,"score_gpt":0.3014540003096937,"score_spread":0.25367710170205776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910583709","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024228527,0.9961711,0.0000130297,0.0000137550805,0.00015981257,0.00071785465,0.00005352832,0.0000209646,0.00042705843],"genre_scores_gemma":[0.0003497428,0.99884224,0.00004585011,0.00003273737,0.00009498073,0.000042576794,0.00010341364,0.00003190285,0.0004565435],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99901295,0.00006649843,0.00039816948,0.00025462024,0.0001404836,0.00012727655],"domain_scores_gemma":[0.99936694,0.000082012,0.00022978456,0.00025565075,0.000035412504,0.000030187308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015869294,0.00018673671,0.000943606,0.00020619734,0.000013161909,0.0000047593217,0.000029443992,0.0002376292,0.000045609948],"category_scores_gemma":[0.00005746802,0.0001494881,0.00019686938,0.0002703057,0.00003479768,0.000035152625,0.00001834655,0.00021420539,0.000024757384],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019800305,0.00011821652,0.0018766891,0.023922237,0.00019922806,0.000006034873,0.00003063467,1.220499e-7,0.0008023691,0.000013533785,0.00012486777,0.97270805],"study_design_scores_gemma":[0.00089249195,0.0002931688,0.002940912,0.021481149,0.0011866874,0.000041104777,0.0000065016425,0.000007348392,0.000024260022,0.000010902364,0.9729423,0.00017319382],"about_ca_topic_score_codex":0.000021773827,"about_ca_topic_score_gemma":0.00002871248,"teacher_disagreement_score":0.9728174,"about_ca_system_score_codex":0.00011157748,"about_ca_system_score_gemma":0.000133591,"threshold_uncertainty_score":0.60959476},"labels":[],"label_agreement":null},{"id":"W2911467060","doi":"10.1186/s13046-018-0999-5","title":"Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Experimental & Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; University of Toronto","keywords":"Triple-negative breast cancer; Paclitaxel; Medicine; Nintedanib; Oncology; Breast cancer; Internal medicine; Triple negative; Metastatic breast cancer; Antibody; Docetaxel; Cancer; Cancer research; Immunology","score_opus":0.23228886764235887,"score_gpt":0.569873010385426,"score_spread":0.33758414274306714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911467060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98837537,0.009448872,0.000012053177,0.0005606614,0.00015593697,0.0011574719,0.000086805616,0.000003832898,0.00019897721],"genre_scores_gemma":[0.98990124,0.00892853,0.0003911828,0.00019324101,0.00012500712,0.00004477054,0.000002878027,0.000036519006,0.00037665202],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99556744,0.00070154073,0.0018298127,0.00036160962,0.0011112689,0.00042830582],"domain_scores_gemma":[0.9965421,0.0014680993,0.0007714069,0.000327841,0.0006243009,0.00026626198],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030219855,0.00023590616,0.0014590794,0.00033399044,0.00003451227,0.000019564426,0.00026393952,0.0001383874,0.0021770783],"category_scores_gemma":[0.00014117704,0.00012380152,0.00046152988,0.0007071213,0.0008093548,0.00029858935,0.0000931713,0.0010073466,9.662194e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4205156,0.0042577316,0.41010487,0.0004613306,0.0028746128,0.00015127815,0.001827761,0.000047791447,0.14196143,0.000016980295,0.00018639464,0.017594235],"study_design_scores_gemma":[0.045615986,0.047065474,0.8798483,0.003969441,0.0002599151,0.00048109758,0.003976008,0.00075753435,0.017492045,0.00010601385,0.000110191715,0.00031801168],"about_ca_topic_score_codex":0.003386357,"about_ca_topic_score_gemma":0.00027172922,"teacher_disagreement_score":0.4697434,"about_ca_system_score_codex":0.0005598244,"about_ca_system_score_gemma":0.0033477405,"threshold_uncertainty_score":0.9987351},"labels":[],"label_agreement":null},{"id":"W2912094423","doi":"10.1200/jco.2019.37.4_suppl.327","title":"Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Hepatocellular carcinoma; Sorafenib; Gastroenterology; Cancer; Progressive disease; Clinical endpoint; Clinical trial; Oncology; Immunotherapy; Disease","score_opus":0.029937500286940696,"score_gpt":0.3545736872949904,"score_spread":0.3246361870080497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912094423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937174,0.0012982439,0.0000067009673,0.0013267806,0.00074967765,0.0004425833,0.0000043459604,0.000007233899,0.002447082],"genre_scores_gemma":[0.99623585,0.0010593015,0.0008453287,0.0014346335,0.00019829908,0.0000030080516,0.0000057126495,0.000025388446,0.00019250081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99698,0.0002129064,0.0018280891,0.00026144958,0.00037170626,0.00034585033],"domain_scores_gemma":[0.99760073,0.00036067938,0.0012488608,0.00023139874,0.0002684421,0.0002898589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013237932,0.00018243633,0.0013974104,0.00015622212,0.000030089132,0.000009501267,0.000121464785,0.00031807114,0.00021542881],"category_scores_gemma":[0.00032889255,0.00012437084,0.00023903177,0.00018692693,0.0002044746,0.0001722795,0.000041576994,0.00088676583,0.000013220516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04032399,0.0011350492,0.88874286,0.000059417678,0.00018674244,0.00023098546,0.0001350612,0.0000034213258,0.00014178963,0.000007846827,0.0002157883,0.06881702],"study_design_scores_gemma":[0.048562117,0.025176264,0.89324486,0.000275474,0.00010285905,0.0001630048,0.00014146602,0.00007757273,0.00011554643,0.00002234834,0.031980082,0.00013838027],"about_ca_topic_score_codex":0.00010320681,"about_ca_topic_score_gemma":0.000051875817,"teacher_disagreement_score":0.06867864,"about_ca_system_score_codex":0.00025984208,"about_ca_system_score_gemma":0.00083992264,"threshold_uncertainty_score":0.50716954},"labels":[],"label_agreement":null},{"id":"W2912271356","doi":"10.1200/jco.2019.37.4_suppl.670","title":"Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Durvalumab; Internal medicine; Adverse effect; Nausea; Population; Gastroenterology; Cancer; Oncology; Surgery; Nivolumab; Immunotherapy","score_opus":0.03658901201206075,"score_gpt":0.3932580590738272,"score_spread":0.35666904706176644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912271356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971523,0.00027107695,0.000021390511,0.0011903165,0.00059513474,0.00042904238,0.000007654308,0.0000037909851,0.00032923825],"genre_scores_gemma":[0.99646074,0.0014347497,0.00094711274,0.00091997447,0.00015135636,6.46103e-7,0.0000022972538,0.000016526477,0.00006662108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995511,0.0006873475,0.0030237508,0.00025536955,0.00032297583,0.00019959004],"domain_scores_gemma":[0.9953565,0.001725157,0.0021346463,0.00027327336,0.00032258022,0.0001878668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005083466,0.0001526193,0.002096997,0.000117522344,0.000015897172,0.0000049934424,0.0001286052,0.0003899387,0.0001507504],"category_scores_gemma":[0.0005654133,0.00009869351,0.00037562722,0.00017762372,0.0005108129,0.00013701993,0.000034962253,0.00095836585,0.0000027134831],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14451304,0.002503679,0.65186226,0.000030121826,0.00027613624,0.000017438504,0.00004723681,0.0000013974951,0.00017993376,0.000006294237,0.000017673134,0.20054479],"study_design_scores_gemma":[0.048673782,0.02916485,0.9146847,0.00025932805,0.00008624328,0.000023557153,0.000026774147,0.00001194579,0.00012229482,0.00004001976,0.006812466,0.0000940262],"about_ca_topic_score_codex":0.00010769457,"about_ca_topic_score_gemma":0.00009556141,"teacher_disagreement_score":0.26282245,"about_ca_system_score_codex":0.00015546073,"about_ca_system_score_gemma":0.0010765748,"threshold_uncertainty_score":0.4163676},"labels":[],"label_agreement":null},{"id":"W2912508355","doi":"10.1002/cncr.31997","title":"Hyperprogression with immunotherapy: Is it real?","year":2019,"lang":"en","type":"letter","venue":"Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research","keywords":"Medicine; Immunotherapy; Immunology; Immune system","score_opus":0.025622438843314447,"score_gpt":0.31229194550173583,"score_spread":0.2866695066584214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912508355","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0055988478,0.022307904,0.000008180143,0.9523002,0.0013450449,0.0011404359,0.00014105505,0.00010614128,0.017052202],"genre_scores_gemma":[0.0004612057,0.017527511,0.00010832072,0.8575454,0.0035495453,0.0001576965,0.00019849677,0.00015834527,0.12029353],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981064,0.00003440787,0.00029695113,0.00057190994,0.0005404421,0.0004498508],"domain_scores_gemma":[0.99866915,0.000042415373,0.00024248475,0.0008703296,0.00013482633,0.000040804665],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008792194,0.00043402016,0.0006717858,0.00012993341,0.00006737367,0.00003965375,0.00020349244,0.0007554547,0.007416673],"category_scores_gemma":[0.0000021953153,0.00028181906,0.0002566151,0.0002209379,0.00015455954,0.000060137565,0.00002239675,0.001126764,0.0001816757],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019251095,0.000025322557,0.0012813637,0.00041456043,0.00069004693,0.00021997641,0.00033719235,1.3312682e-7,0.0016788518,3.1290503e-7,0.96013427,0.033292837],"study_design_scores_gemma":[0.0029638342,0.0004469274,0.001035218,0.0023540845,0.00019518737,0.000099097815,0.00003726453,0.000004119234,0.00097423623,0.0000024921278,0.9914705,0.00041703615],"about_ca_topic_score_codex":0.00060747087,"about_ca_topic_score_gemma":0.000014234743,"teacher_disagreement_score":0.103241324,"about_ca_system_score_codex":0.0004298779,"about_ca_system_score_gemma":0.00070698804,"threshold_uncertainty_score":0.9999634},"labels":[],"label_agreement":null},{"id":"W2912997017","doi":"10.1158/1538-7445.sabcs18-p4-06-03","title":"Abstract P4-06-03: Unravelling triple-negative breast cancer tumor microenvironment heterogeneity using an integrative multiomic analysis","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Triple-negative breast cancer; Immune system; Tumor microenvironment; Breast cancer; Biology; Cancer research; Immune checkpoint; Stromal cell; Computational biology; Cancer; Oncology; Medicine; Immunotherapy; Immunology; Genetics","score_opus":0.07217865534394961,"score_gpt":0.4058792502545535,"score_spread":0.3337005949106039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912997017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953827,0.002066312,0.00009836953,0.0003897822,0.00019395119,0.0012421992,0.0004831795,0.000030731626,0.000112749745],"genre_scores_gemma":[0.99668765,0.0015527094,0.0002720767,0.00025734684,0.00026068688,0.0001679431,0.000060522434,0.00005609372,0.00068494264],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9968112,0.00025363098,0.00046566082,0.0008474524,0.00084335124,0.00077866367],"domain_scores_gemma":[0.99844253,0.00013583421,0.00017814376,0.00064436835,0.0003006618,0.00029847605],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009460457,0.00032157844,0.0006460217,0.00064356666,0.00025861565,0.00008768743,0.00029029444,0.00012533904,0.0040106415],"category_scores_gemma":[0.000020225722,0.00025680903,0.00035612262,0.001362723,0.0004057367,0.00024083153,0.00008408841,0.0007495912,0.00008795241],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041350196,0.00032042165,0.09215453,0.00012343032,0.0023952115,0.000031957454,0.0013939895,0.001438366,0.89246166,0.0000021234698,0.000109956134,0.005433313],"study_design_scores_gemma":[0.0049848347,0.00030257995,0.5508669,0.0006892905,0.00051187933,0.000030116778,0.0023267434,0.0072445427,0.43184832,0.00001396401,0.0006967089,0.0004841069],"about_ca_topic_score_codex":0.029618647,"about_ca_topic_score_gemma":0.0036905971,"teacher_disagreement_score":0.46061334,"about_ca_system_score_codex":0.0027468014,"about_ca_system_score_gemma":0.00068444246,"threshold_uncertainty_score":0.99998844},"labels":[],"label_agreement":null},{"id":"W2913035147","doi":"10.1111/jgs.15750","title":"Immune Checkpoint Inhibitors in Real‐World Treatment of Older Adults with Non–Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of the American Geriatrics Society","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York Central Hospital","funders":"Wilmot Cancer Institute, University of Rochester Medical Center; National Cancer Institute; National Institute on Aging; University of Rochester","keywords":"Medicine; Lung cancer; Immune system; Oncology; Immunotherapy; Cancer; Internal medicine; Immunology; Intensive care medicine","score_opus":0.0059394270270723215,"score_gpt":0.2518339255898166,"score_spread":0.24589449856274428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913035147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944393,0.0033631346,0.000012638153,0.0009510986,0.00037462963,0.0005642227,0.000007250679,0.000004946147,0.00028275547],"genre_scores_gemma":[0.9862256,0.0113398805,0.0010862397,0.00020466086,0.00022913732,0.000009993831,9.846734e-7,0.000030163917,0.00087331224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850035,0.000048388305,0.0006981351,0.00015711575,0.0003528065,0.00024319356],"domain_scores_gemma":[0.9977072,0.00006147754,0.0016590833,0.0003232802,0.00017730833,0.00007163928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030233298,0.00019364287,0.0006928439,0.0001055918,0.000033563636,0.000010283761,0.00017076031,0.000043867338,0.000053010637],"category_scores_gemma":[0.0000041939707,0.00010775623,0.0007625616,0.0010862703,0.00013998926,0.00005198608,0.000029921264,0.00022764187,6.160628e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006979964,0.0010488383,0.8874563,0.0003779019,0.0008572112,0.0000155603,0.012877664,0.00023296989,0.07670695,5.349736e-7,0.0014613676,0.0119847255],"study_design_scores_gemma":[0.014803508,0.0025203058,0.9229904,0.00092012377,0.0005220341,0.000040086674,0.0052024187,0.0002699421,0.051248144,0.0000015029701,0.0012421125,0.00023944135],"about_ca_topic_score_codex":0.0055583967,"about_ca_topic_score_gemma":0.00017559716,"teacher_disagreement_score":0.035534076,"about_ca_system_score_codex":0.0009010852,"about_ca_system_score_gemma":0.0005907627,"threshold_uncertainty_score":0.840267},"labels":[],"label_agreement":null},{"id":"W2913210476","doi":"10.3389/fimmu.2019.00108","title":"Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis","year":2019,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre; McGill University","funders":"","keywords":"Nivolumab; Medicine; Pneumonitis; Pembrolizumab; Ipilimumab; Internal medicine; Pneumonia; Gastroenterology; Lung cancer; Cancer; Immunotherapy; Lung","score_opus":0.030238788214397214,"score_gpt":0.30180289127396465,"score_spread":0.2715641030595674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913210476","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009141907,0.9923665,0.00009638905,0.00011640025,0.000151372,0.0067332103,0.00040387947,0.000023697348,0.000017160872],"genre_scores_gemma":[0.0002054899,0.99702406,0.00047549748,0.00006609038,0.000009100659,0.001333154,0.00024871307,0.00007981186,0.0005580825],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9953373,0.0008127763,0.0025231875,0.0006791183,0.00021159509,0.00043598586],"domain_scores_gemma":[0.9954625,0.00042614623,0.0030225432,0.00085562735,0.00017770898,0.00005550026],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0017231437,0.0007007634,0.017812565,0.0009795163,0.00006141387,0.000019979749,0.00023121486,0.0005134595,0.000022712451],"category_scores_gemma":[0.0005406473,0.00044918107,0.0025653036,0.0011771361,0.0004319923,0.000066426925,0.00008799103,0.00056374713,0.0000010195278],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015431365,0.00008922178,0.00008520651,0.5602105,0.43486345,0.000013196832,0.000093959905,1.2250872e-7,0.0000088942,0.0000022708623,0.00006075082,0.004418096],"study_design_scores_gemma":[0.001303942,0.00080740417,0.00017687779,0.099989645,0.89325416,0.00015340654,0.00011919947,0.0000072442053,0.0000083207115,0.0000126250325,0.0037339395,0.00043325417],"about_ca_topic_score_codex":0.0001706225,"about_ca_topic_score_gemma":0.000035432393,"teacher_disagreement_score":0.46022087,"about_ca_system_score_codex":0.00027425776,"about_ca_system_score_gemma":0.0002764732,"threshold_uncertainty_score":0.999796},"labels":[],"label_agreement":null},{"id":"W2913561945","doi":"10.1007/s10067-019-04451-2","title":"Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor–induced inflammatory arthritis","year":2019,"lang":"en","type":"article","venue":"Clinical Rheumatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Dalhousie University","funders":"","keywords":"Medicine; Hydroxychloroquine; Arthritis; Adverse effect; Internal medicine; Rheumatology; Rheumatoid arthritis; Inflammatory arthritis; Immunology; Oncology; Disease; Infectious disease (medical specialty)","score_opus":0.023382523300866622,"score_gpt":0.32725824787583374,"score_spread":0.30387572457496714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913561945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908001,0.0036452494,0.00009204462,0.0015980316,0.001610709,0.0018624509,0.000009101385,0.00006619121,0.00031616486],"genre_scores_gemma":[0.9954053,0.0026225743,0.00023838668,0.0011313923,0.00008758835,0.00017471424,0.000017310982,0.000042336742,0.00028038927],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974633,0.00012504816,0.0012544789,0.0005979915,0.00014339518,0.00041579505],"domain_scores_gemma":[0.9979974,0.00095327274,0.00032609256,0.00047197207,0.000091616545,0.00015963627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010771544,0.0002559136,0.0011115534,0.00010006285,0.00007681346,0.000018966597,0.00010465303,0.00040679562,0.000215165],"category_scores_gemma":[0.00043248865,0.00022681714,0.0003933611,0.000094901974,0.00025096972,0.0000769569,0.00011796936,0.00037979608,0.000112276495],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021204174,0.0006476372,0.41660064,0.0013601978,0.0015878349,0.00005901656,0.0011105733,5.6400745e-7,0.08776651,0.0003400097,0.0019432805,0.46737957],"study_design_scores_gemma":[0.07514662,0.011631969,0.7777959,0.003985681,0.00023846158,0.0012348288,0.0004985504,0.0008211375,0.06271338,0.0007239724,0.06411582,0.0010936422],"about_ca_topic_score_codex":0.00005793771,"about_ca_topic_score_gemma":0.000024380757,"teacher_disagreement_score":0.4662859,"about_ca_system_score_codex":0.000073535666,"about_ca_system_score_gemma":0.000117399984,"threshold_uncertainty_score":0.92493343},"labels":[],"label_agreement":null},{"id":"W2913874229","doi":"10.1200/jco.2019.37.4_suppl.481","title":"CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Toronto; Hôpital Charles-Le Moyne; University of Saskatchewan; Université de Montréal; Nova Scotia Cancer Centre; Hôpital du Sacré-Cœur de Montréal; University of Ottawa; McGill University; Saskatchewan Cancer Agency; University Health Network; Ottawa Hospital; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; BC Cancer Agency; Moncton Hospital","funders":"","keywords":"Medicine; Tremelimumab; Irinotecan; Internal medicine; Hazard ratio; Refractory (planetary science); Durvalumab; Oxaliplatin; Oncology; Colorectal cancer; Gastroenterology; Clinical endpoint; Randomized controlled trial; Cancer; Confidence interval; Immunotherapy; Ipilimumab; Nivolumab","score_opus":0.05959807721354623,"score_gpt":0.4340736936208993,"score_spread":0.3744756164073531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913874229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937831,0.0008054925,0.0000016574209,0.00017470376,0.0015716883,0.003148395,0.000014046114,0.000008419018,0.00049249973],"genre_scores_gemma":[0.9989529,0.00042493976,0.00015170124,0.0001169387,0.0002113323,0.000032033793,0.000011463913,0.00003618638,0.000062478735],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99405473,0.0012156349,0.0034284855,0.00035609043,0.000648095,0.000296974],"domain_scores_gemma":[0.99256647,0.0030417112,0.0031529744,0.00026056555,0.00072465884,0.000253619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028721683,0.00026983736,0.003936735,0.00027348258,0.000049088998,0.000006335103,0.00016335877,0.00035364542,0.00013893032],"category_scores_gemma":[0.0017768405,0.00017996391,0.00048068396,0.00021898648,0.00043712487,0.00016682746,0.000054654774,0.00088352105,0.000003079795],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9014241,0.018052343,0.02658985,0.00005112264,0.0011613497,0.00026671734,0.0033588507,0.0000046921164,0.0002581239,6.5659043e-7,0.00008574305,0.048746467],"study_design_scores_gemma":[0.62370235,0.333113,0.03687076,0.000118928816,0.000657355,0.000020306588,0.0047436845,0.0000133155245,0.00008885805,0.0000015002404,0.00055335637,0.00011660392],"about_ca_topic_score_codex":0.00020744021,"about_ca_topic_score_gemma":0.00041767658,"teacher_disagreement_score":0.31506068,"about_ca_system_score_codex":0.0005921019,"about_ca_system_score_gemma":0.0022003162,"threshold_uncertainty_score":0.7338716},"labels":[],"label_agreement":null},{"id":"W2913970282","doi":"10.14740/jmc.v10i2.3249","title":"Altered PD-L1 Expression in Non-Small Cell Lung Cancer Patient After Induction Chemotherapy: A Case Report","year":2019,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Immunotherapy; Chemotherapy; Lung cancer; PD-L1; Oncology; Modalities; Internal medicine; Treatment modality; Cancer","score_opus":0.014942137386285477,"score_gpt":0.2994622242925835,"score_spread":0.28452008690629804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913970282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914384,0.004242812,0.000047054607,0.0025526406,0.0012996979,0.00030966845,0.0000033411375,0.000006091106,0.00010029744],"genre_scores_gemma":[0.9963675,0.000930695,0.00020099284,0.0015541373,0.0006569452,0.00001856181,0.0000022805386,0.000020493924,0.00024838137],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99799526,0.00005948635,0.0007623864,0.00017429964,0.0008049561,0.00020361763],"domain_scores_gemma":[0.998932,0.00006725379,0.0004458048,0.00019443578,0.00012261466,0.00023786881],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006326421,0.00014319368,0.00037937806,0.00018495429,0.000021772044,0.000014495367,0.000073340896,0.00019741443,0.0027631358],"category_scores_gemma":[0.00010129495,0.00009675462,0.00017766037,0.00016467391,0.000044070606,0.000103462,0.000025538808,0.0004985278,0.0000025016825],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025971312,0.00163248,0.15171684,0.0008876316,0.00026737782,0.60365766,0.0046183206,0.000014671441,0.078473754,2.0192215e-7,0.028832348,0.1039274],"study_design_scores_gemma":[0.027302427,0.004140803,0.10765801,0.009650988,0.00029101886,0.69978046,0.0036801896,0.000529297,0.109559454,0.000007898537,0.036801796,0.0005976589],"about_ca_topic_score_codex":0.0005007836,"about_ca_topic_score_gemma":0.00010527353,"teacher_disagreement_score":0.10332974,"about_ca_system_score_codex":0.00024420157,"about_ca_system_score_gemma":0.00046738482,"threshold_uncertainty_score":0.9981485},"labels":[],"label_agreement":null},{"id":"W2914258217","doi":"10.1002/cncr.31999","title":"Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities","year":2019,"lang":"en","type":"article","venue":"Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Genentech; Servier; Astellas Pharma; MacroGenics; Agios Pharmaceuticals; Regeneron Pharmaceuticals; EMD Serono; Mersana Therapeutics; Karyopharm Therapeutics; PTC Therapeutics; Sanofi; GlaxoSmithKline; Amgen; Pfizer; MorphoSys; Celgene; Symphogen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Discontinuation; Immunotherapy; Internal medicine; Clinical trial; Oncology; Response Evaluation Criteria in Solid Tumors; Cancer; Disease; Adverse effect; Phases of clinical research","score_opus":0.024898809890380912,"score_gpt":0.36129843012811225,"score_spread":0.33639962023773134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914258217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722897,0.025017463,0.0000036322692,0.0008679351,0.0005600443,0.0009889049,0.000048695336,0.000044813965,0.00017882838],"genre_scores_gemma":[0.98874927,0.008536053,0.000019539166,0.00039915062,0.00013376838,0.00012667273,0.000023523322,0.00003055126,0.0019814514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983091,0.00021572942,0.0006813238,0.00028841896,0.00026807282,0.0002373864],"domain_scores_gemma":[0.99893194,0.00028369413,0.00037392933,0.00022953385,0.000076088414,0.000104781604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011415001,0.00016924138,0.00064727303,0.000094417155,0.000036083442,0.000031179006,0.0000589586,0.0001608951,0.00054341846],"category_scores_gemma":[0.00011278106,0.0001194662,0.00015813283,0.00020638136,0.000110611785,0.0001278562,0.000009826778,0.0002629424,0.0000089938885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019069565,0.00021876759,0.94433767,0.000046156543,0.00065245735,0.000015151993,0.0009123826,0.0000032557168,0.0034279425,0.000010174,0.00017687623,0.031129625],"study_design_scores_gemma":[0.030143518,0.001212125,0.9604394,0.0006910767,0.0001808344,0.0000029257176,0.00015462845,0.00010205272,0.0007765524,0.000030851974,0.0060586194,0.00020740177],"about_ca_topic_score_codex":0.0002111448,"about_ca_topic_score_gemma":0.00001793227,"teacher_disagreement_score":0.030922223,"about_ca_system_score_codex":0.00029789118,"about_ca_system_score_gemma":0.00029803553,"threshold_uncertainty_score":0.5950051},"labels":[],"label_agreement":null},{"id":"W2914282788","doi":"10.1172/jci96313","title":"Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":427,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Ontario Institute for Cancer Research; McGill University Health Centre; Montreal Neurological Institute and Hospital; University of Toronto; Centre Hospitalier de l’Université de Montréal; McGill University; Princess Margaret Cancer Centre; Occupational Cancer Research Centre","funders":"Merck Sharp and Dohme; National Cancer Institute; National Institutes of Health; University of Toronto; Québec Consortium for Drug Discovery; Ohio State University; McGill University Health Centre; Stand Up To Cancer; Faculty of Medicine, McGill University; McGill University; Deutsches Krebsforschungszentrum","keywords":"Stromal cell; Tumor microenvironment; Granzyme B; Triple-negative breast cancer; Immune system; Cancer research; CD8; Cytotoxic T cell; Biology; Granzyme; Laser capture microdissection; Immune checkpoint; Immunology; Breast cancer; Immunotherapy; Cancer; Gene expression; Perforin","score_opus":0.03719470121437023,"score_gpt":0.3412165992050687,"score_spread":0.30402189799069845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914282788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953357,0.00023836379,0.000071177994,0.0022609073,0.0012502659,0.00035620478,0.000017965787,0.000008537908,0.00046084909],"genre_scores_gemma":[0.9957467,0.00015855435,0.0015920958,0.0013133634,0.0005646696,0.0000024639962,0.000014364965,0.000018831415,0.00058898114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725074,0.00018827766,0.0017516426,0.00018304857,0.00045787115,0.00016845163],"domain_scores_gemma":[0.99752915,0.00028005638,0.0015838038,0.00020852646,0.00016433255,0.00023411367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001316255,0.000153728,0.00061547774,0.00007943972,0.00004175158,0.000026517693,0.00013237004,0.000111058114,0.0006828818],"category_scores_gemma":[0.00040967914,0.000116118834,0.00038624826,0.0001518962,0.00029058047,0.00023230887,0.000018412316,0.00051944616,0.000043076358],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013424336,0.0003753581,0.8071391,0.0001339003,0.0009958837,0.00008537944,0.0003695806,0.000059582813,0.13019292,0.000034886045,0.0026379724,0.044551127],"study_design_scores_gemma":[0.008204567,0.0016897235,0.97864753,0.0004852949,0.00016258369,0.000266917,0.00010588626,0.00022477892,0.008275257,0.00032157823,0.00148283,0.00013305411],"about_ca_topic_score_codex":0.00018078646,"about_ca_topic_score_gemma":0.000029343832,"teacher_disagreement_score":0.17150846,"about_ca_system_score_codex":0.00023484025,"about_ca_system_score_gemma":0.0007865246,"threshold_uncertainty_score":0.74770766},"labels":[],"label_agreement":null},{"id":"W2915186433","doi":"10.1126/sciadv.aav2437","title":"Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy","year":2019,"lang":"en","type":"article","venue":"Science Advances","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Cancer Institute","keywords":"Immunotherapy; In vivo; Cancer research; Immune system; Medicine; Computational biology; Biology; Immunology; Genetics","score_opus":0.008272262814606548,"score_gpt":0.30833175461955803,"score_spread":0.3000594918049515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915186433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99091095,0.004043085,0.0001491544,0.001696406,0.0010312634,0.0005313219,0.000004220381,0.000082548926,0.0015510306],"genre_scores_gemma":[0.9912543,0.00022864177,0.0033196453,0.0028213623,0.00009521795,0.000022685232,0.0000012163122,0.000016099546,0.0022407903],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980137,0.000042450614,0.00028056715,0.0005287594,0.0006229037,0.00051165523],"domain_scores_gemma":[0.9991001,0.000109131266,0.00010971719,0.0004072667,0.00013939067,0.0001344156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015718294,0.00016633539,0.00027082936,0.00025860273,0.00024039368,0.000075415715,0.000393878,0.00002536252,0.00048746605],"category_scores_gemma":[0.00018706417,0.00012659897,0.000079232464,0.0013380746,0.000435751,0.00069291773,0.000048431026,0.00010957484,0.0003058008],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038978334,0.00003547391,0.0056987144,0.000018690067,0.000009312888,0.000007559083,0.0004886904,0.000033657863,0.9678452,0.000009438416,0.00011691715,0.021838514],"study_design_scores_gemma":[0.001301348,0.0009832758,0.04873886,0.00019587815,0.0000050949952,0.000031829935,0.0011935474,0.000033553697,0.73826706,0.000050393617,0.20892929,0.00026984498],"about_ca_topic_score_codex":0.000023820083,"about_ca_topic_score_gemma":0.0000029656346,"teacher_disagreement_score":0.22957811,"about_ca_system_score_codex":0.00013365317,"about_ca_system_score_gemma":0.00040529078,"threshold_uncertainty_score":0.5337411},"labels":[],"label_agreement":null},{"id":"W2915663366","doi":"10.1097/cmr.0000000000000582","title":"A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma","year":2019,"lang":"en","type":"article","venue":"Melanoma Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Institute for Clinical Evaluative Sciences","funders":"Canadian Institutes of Health Research; Government of Ontario; Institute for Clinical Evaluative Sciences; Ontario Ministry of Health and Long-Term Care; Ontario Institute for Cancer Research","keywords":"Ipilimumab; Dacarbazine; Medicine; Internal medicine; Oncology; Population; Hazard ratio; Melanoma; Confidence interval; Cancer; Chemotherapy; Immunotherapy; Cancer research","score_opus":0.0696841004889453,"score_gpt":0.3957929849542213,"score_spread":0.326108884465276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915663366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99295616,0.00036027055,0.000009143535,0.00029021344,0.00012694954,0.0060173753,0.000046400204,0.000010726397,0.0001827793],"genre_scores_gemma":[0.99642783,0.000016834945,0.00006691918,0.000009932716,0.00003879368,0.0004723837,0.00002806625,0.000027936407,0.0029112904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784875,0.00044103593,0.0003998396,0.00027577757,0.0007062525,0.00032833955],"domain_scores_gemma":[0.9967863,0.002111354,0.0001182544,0.00071115035,0.00021748607,0.00005545536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00138405,0.00016298001,0.0005850882,0.00023784651,0.00012135541,0.000011933713,0.0002074337,0.00005189641,0.00059482525],"category_scores_gemma":[0.00023317832,0.00007790498,0.00022121613,0.0006683257,0.000059380727,0.000030626972,0.000032069172,0.00011694664,0.0000065993204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060847215,0.002800973,0.9152357,0.0011797668,0.0008942161,0.000009704421,0.00068784074,0.000099875164,0.0074961954,0.000008353357,0.00017580787,0.010564379],"study_design_scores_gemma":[0.08942339,0.1780925,0.56265324,0.00064602,0.00058612775,0.000012718977,0.001452895,0.0063558198,0.15712446,0.000038574526,0.0033441805,0.00027008652],"about_ca_topic_score_codex":0.0035919577,"about_ca_topic_score_gemma":0.0022055167,"teacher_disagreement_score":0.35258242,"about_ca_system_score_codex":0.00024625598,"about_ca_system_score_gemma":0.0002351882,"threshold_uncertainty_score":0.65129197},"labels":[],"label_agreement":null},{"id":"W2915708315","doi":"10.1200/jco.18.01998","title":"Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":398,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Nivolumab; Dosing; Oncology; Melanoma; Internal medicine; Metastatic melanoma; Clinical trial; Cancer; Immunotherapy; Cancer research","score_opus":0.09565285910935743,"score_gpt":0.4600113664279852,"score_spread":0.36435850731862773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915708315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956155,0.0001561804,0.000032430784,0.0016464846,0.00064590335,0.0016736486,0.000017159373,0.000002332161,0.00021036035],"genre_scores_gemma":[0.9984789,0.000048399084,0.0010363044,0.00022933324,0.00013369201,0.000013251164,0.000030578638,0.000011717345,0.000017810882],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964825,0.0006484829,0.0019280184,0.00017466521,0.0006254528,0.0001408722],"domain_scores_gemma":[0.9945594,0.0020607575,0.0023424742,0.00019538248,0.0007939041,0.00004806863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008597998,0.00010187951,0.0008664901,0.00010118634,0.000018959401,0.0000049825067,0.00010507274,0.0001471254,0.000021229502],"category_scores_gemma":[0.0016028619,0.00005657599,0.00014130567,0.00018233735,0.00010663801,0.00014006515,0.000010681057,0.00037236614,5.9741467e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81770813,0.003783114,0.020895462,0.000007635762,0.00022711519,0.000004620863,0.00033332917,0.00010476991,0.00022756297,0.000005107991,0.00008388896,0.15661928],"study_design_scores_gemma":[0.69307095,0.07319672,0.23105824,0.0003574982,0.00032615365,0.0000030096085,0.00015773908,0.00088439975,0.00012291531,0.00015109047,0.00061232643,0.000058955768],"about_ca_topic_score_codex":0.00010554326,"about_ca_topic_score_gemma":0.0005789916,"teacher_disagreement_score":0.21016277,"about_ca_system_score_codex":0.00037809336,"about_ca_system_score_gemma":0.0013515545,"threshold_uncertainty_score":0.29799116},"labels":[],"label_agreement":null},{"id":"W2915872017","doi":"10.3747/co.26.4130","title":"A Case of Nivolumab-Induced Acute-Onset Type 1 Diabetes Mellitus in Melanoma","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Nivolumab; Medicine; Type 1 diabetes; Diabetic ketoacidosis; Adverse effect; Internal medicine; Insulin; Diabetes mellitus; Fulminant; Endocrinology; Gastroenterology; Cancer; Immunotherapy","score_opus":0.06335165943507967,"score_gpt":0.3780011591664498,"score_spread":0.31464949973137013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915872017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99192494,0.0048632934,8.390629e-7,0.00024499002,0.0016479811,0.0004102314,0.000014549959,0.00001690303,0.00087625155],"genre_scores_gemma":[0.9990967,0.00052708195,0.000047535428,0.00010721772,0.000057239788,0.000016328597,0.000028238797,0.000011986441,0.000107676664],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990843,0.00007904564,0.00031295727,0.00020264773,0.000082379585,0.000238654],"domain_scores_gemma":[0.99939775,0.000107123764,0.00011172452,0.00025441445,0.000071299735,0.00005767271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021945598,0.00011313911,0.0004256334,0.00015616727,0.00001350635,0.000002765658,0.00007179897,0.00013041313,0.00060121977],"category_scores_gemma":[0.000031709293,0.00009708296,0.00008818905,0.00028271787,0.0000644277,0.000032781263,0.00003207755,0.00019433381,0.000055667653],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004997429,0.0014560317,0.42355227,0.00040173865,0.00042207426,0.00101721,0.0014840276,4.937877e-7,0.09112395,0.00006906833,0.0036261792,0.4718495],"study_design_scores_gemma":[0.0634525,0.034759574,0.3507338,0.0014802337,0.0011196384,0.008438825,0.0024489937,0.0015175856,0.10467779,0.00040738515,0.42950788,0.0014557805],"about_ca_topic_score_codex":0.00008490178,"about_ca_topic_score_gemma":0.000112131165,"teacher_disagreement_score":0.47039372,"about_ca_system_score_codex":0.00020337744,"about_ca_system_score_gemma":0.00026873845,"threshold_uncertainty_score":0.6582935},"labels":[],"label_agreement":null},{"id":"W2916289875","doi":"10.3747/co.26.4151","title":"Diabetes Mellitus Secondary to Treatment with Immune Checkpoint Inhibitors","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Immunotherapy; Adverse effect; Diabetes mellitus; Diabetic ketoacidosis; Immune system; Endocrine system; Type 1 diabetes; Type 2 Diabetes Mellitus; Immunology; Internal medicine; Endocrinology; Hormone","score_opus":0.030990536879095962,"score_gpt":0.32828062178367756,"score_spread":0.2972900849045816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916289875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97710764,0.013789272,0.000008300787,0.0021650107,0.0016818728,0.0009169008,0.0000111725,0.000054843473,0.004264957],"genre_scores_gemma":[0.9969285,0.00090950745,0.0001944497,0.00039875813,0.0002874142,0.0001411364,0.000056856592,0.000027699572,0.0010556782],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888,0.000041332078,0.00030971534,0.00030706314,0.00013074615,0.00033108992],"domain_scores_gemma":[0.9993415,0.00005109652,0.000092570575,0.00031589624,0.000057487818,0.00014145176],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014628706,0.00019269741,0.00045566718,0.000116768184,0.000035873545,0.000009207643,0.00006727067,0.00008537323,0.0010502381],"category_scores_gemma":[0.000006299995,0.00012893802,0.00014975763,0.00018217767,0.00007305747,0.000039040347,0.000029540099,0.00015295793,0.00031137493],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002985763,0.000973837,0.04504303,0.00013642915,0.00033025013,0.000016612907,0.0009733317,0.000001526474,0.065023266,0.00001424579,0.0011086827,0.88339305],"study_design_scores_gemma":[0.007297702,0.011877001,0.036680076,0.0001976165,0.00009640584,0.000026428395,0.00022838038,0.000012663661,0.05795913,0.00000960993,0.88542485,0.00019015223],"about_ca_topic_score_codex":0.000038264385,"about_ca_topic_score_gemma":0.000029887678,"teacher_disagreement_score":0.88431615,"about_ca_system_score_codex":0.00068261725,"about_ca_system_score_gemma":0.0003703885,"threshold_uncertainty_score":0.9998629},"labels":[],"label_agreement":null},{"id":"W2916442912","doi":"10.1101/565531","title":"A Mathematical Model for the Immune-Mediated Theory of Metastasis","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Immune system; Metastasis; Biology; Immunology; Immunotherapy; Mechanism (biology); Cancer; Cytotoxic T cell; Cancer metastasis; Cancer research; In vitro","score_opus":0.028608099195649182,"score_gpt":0.257520095057589,"score_spread":0.2289119958619398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916442912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59683645,0.04693606,0.3356875,0.0026304317,0.0021285743,0.0119624585,0.0031019412,0.0006265633,0.000090043075],"genre_scores_gemma":[0.9912541,0.0008951779,0.0065939203,0.00037493874,0.00014900786,0.00052803213,0.0000010724375,0.00014425923,0.00005949],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976489,0.000098894045,0.000817091,0.000573142,0.00043162264,0.00043036626],"domain_scores_gemma":[0.9963824,0.00064663636,0.00055300666,0.0018004577,0.00050141866,0.00011603801],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018009472,0.00046847918,0.0009954985,0.00018714654,0.00009121455,0.000046957164,0.0005145659,0.0004558397,0.00012835569],"category_scores_gemma":[0.00044892167,0.00032756676,0.00066269294,0.00029650194,0.00027253345,0.000053556352,0.00024311189,0.00053800055,0.000027744918],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038750514,0.00056549907,0.00040245074,0.0041346275,0.004229192,0.000008773445,0.000089021974,0.00037094473,0.9792928,0.006070561,0.0009293222,0.00003172409],"study_design_scores_gemma":[0.010023763,0.00057787454,0.024119496,0.0036881533,0.0055618095,1.6994453e-7,0.000055152555,0.21108569,0.73594606,0.0001990519,0.0069114836,0.0018313066],"about_ca_topic_score_codex":0.000012825232,"about_ca_topic_score_gemma":3.383084e-7,"teacher_disagreement_score":0.39441767,"about_ca_system_score_codex":0.0001721606,"about_ca_system_score_gemma":0.0010117466,"threshold_uncertainty_score":0.9999176},"labels":[],"label_agreement":null},{"id":"W2916451481","doi":"10.1200/jco.18.01042","title":"First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":596,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Cegep de Saint Jerome","funders":"Janssen Pharmaceuticals; Foundation Medicine; EMD Serono; Genentech; Eisai; Pfizer; Moderna; Incyte; Agios Pharmaceuticals; Syndax Pharmaceuticals; Takeda Oncology; Mirati Therapeutics; Acceleron; Clovis Oncology; TG Therapeutics; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Array BioPharma; Karyopharm Therapeutics; University of Pennsylvania; Amgen; Jounce Therapeutics; Ariad Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Sanofi; Celgene; Ignyta; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Ipilimumab; Internal medicine; Lung cancer; Oncology; Clinical endpoint; Cancer; Immunotherapy; Clinical trial","score_opus":0.03760860318418664,"score_gpt":0.4112338146753233,"score_spread":0.37362521149113664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916451481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824386,0.004496241,0.000037551938,0.010401442,0.0011328824,0.00087658345,0.000013574139,0.000013058943,0.0005900281],"genre_scores_gemma":[0.9909428,0.0027364208,0.0017907995,0.0026724937,0.00027739396,0.00003587153,0.0000101607575,0.000035563502,0.0014985303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99641705,0.0001658135,0.002277111,0.00034778315,0.000394304,0.0003979339],"domain_scores_gemma":[0.99635273,0.0013432765,0.0015084445,0.00018965386,0.00027508847,0.0003307871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019459985,0.00025616653,0.0016261567,0.00018957048,0.00004817901,0.000022403688,0.00019039375,0.00033953326,0.00021813343],"category_scores_gemma":[0.0005544803,0.00018924347,0.00041009576,0.00021484018,0.00021406633,0.00014941511,0.0000567187,0.0007464845,0.000009714373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058297772,0.0016177436,0.8195168,0.0004007319,0.0016267882,0.0007272246,0.000553528,0.00018506982,0.0055275434,0.000007683411,0.0022665616,0.1092726],"study_design_scores_gemma":[0.18524867,0.020765383,0.7137217,0.0011960049,0.00092700165,0.0007462597,0.0009973526,0.005190222,0.0018014973,0.00017682865,0.06857041,0.00065866974],"about_ca_topic_score_codex":0.0004957749,"about_ca_topic_score_gemma":0.00036474105,"teacher_disagreement_score":0.12695089,"about_ca_system_score_codex":0.0005188244,"about_ca_system_score_gemma":0.0022906363,"threshold_uncertainty_score":0.7717125},"labels":[],"label_agreement":null},{"id":"W2916647762","doi":"10.1038/s41591-019-0357-y","title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","year":2019,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":702,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Human Genome Research Institute","keywords":"Medicine; Melanoma; Blockade; Neoadjuvant therapy; Immune system; Oncology; Immune checkpoint; Adjuvant; Internal medicine; Immunotherapy; CD8; Pathological; Stage (stratigraphy); Tumor microenvironment; Adjuvant therapy; Cancer; Immunology; Cancer research; Receptor; Biology; Breast cancer","score_opus":0.02196290238046546,"score_gpt":0.3415913732103955,"score_spread":0.31962847082993007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916647762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97316927,0.0076935235,0.0000027933997,0.0070983497,0.0014676073,0.000738502,0.000010666423,0.000044092674,0.009775213],"genre_scores_gemma":[0.99213743,0.00034051348,0.00020742242,0.0023151888,0.00041420897,0.000009359461,0.000032902102,0.000028249682,0.004514716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765277,0.00009469176,0.00088682,0.0003889627,0.00063619285,0.00034057902],"domain_scores_gemma":[0.99847364,0.00043749777,0.00022611473,0.00059402606,0.00012572412,0.00014298855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011114295,0.00021951595,0.0010385475,0.00029785474,0.000017688773,0.0000034247241,0.00018943824,0.0005590558,0.0008681033],"category_scores_gemma":[0.00072865665,0.00014040837,0.00018478092,0.0005360126,0.00023379113,0.000057058987,0.000047463676,0.0010457543,0.00001871465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007327884,0.00077263394,0.87723404,0.00024883953,0.00030632003,0.00013208487,0.00047626102,9.27216e-7,0.09399995,0.000060660474,0.006483565,0.012956837],"study_design_scores_gemma":[0.024988111,0.0051923776,0.9065197,0.0014370229,0.00013562906,0.0000770755,0.00029139093,0.000063993866,0.009195891,0.000073070856,0.051840957,0.00018474682],"about_ca_topic_score_codex":0.00032146426,"about_ca_topic_score_gemma":0.00014426437,"teacher_disagreement_score":0.08480406,"about_ca_system_score_codex":0.000103614904,"about_ca_system_score_gemma":0.00016657032,"threshold_uncertainty_score":0.95051223},"labels":[],"label_agreement":null},{"id":"W2918152867","doi":"10.1080/2162402x.2019.1568812","title":"Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors","year":2019,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"","keywords":"Medicine; Melanoma; Immune checkpoint; Antibiotics; Immune system; Oncology; Immunotherapy; Cancer research; Immunology; Internal medicine; Biology; Microbiology","score_opus":0.007036063694775429,"score_gpt":0.23986660714244068,"score_spread":0.23283054344766524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2918152867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960928,0.0008299229,0.0000030241736,0.00020937521,0.00022139295,0.0009961801,0.00004623512,0.0000956501,0.0015054333],"genre_scores_gemma":[0.99868983,0.000083936844,0.00028611982,0.00005032435,0.000016524233,0.000007763196,0.00027851338,0.000060295988,0.00052670593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981319,0.000121850164,0.000551424,0.00037744927,0.00040793614,0.0004094936],"domain_scores_gemma":[0.99789315,0.00011719732,0.00074215326,0.00076442974,0.00041451462,0.00006854683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021757589,0.00031517155,0.0008608983,0.00016805054,0.00006163126,0.000008679244,0.00021421783,0.00026393254,0.00012990006],"category_scores_gemma":[0.00014682292,0.00020793316,0.00013553427,0.0005269086,0.00034828833,0.000087203254,0.00006972906,0.0002641192,0.0000111629415],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020842269,0.001279904,0.8853437,0.00007700783,0.0010482485,0.000038775153,0.00015436906,0.0000023449713,0.08442916,0.000008349215,0.000030023006,0.006745853],"study_design_scores_gemma":[0.025549179,0.0082961945,0.8725558,0.0014483035,0.00015962913,0.000020642425,0.00042349737,0.000008194623,0.09092364,0.0000036612387,0.00035200335,0.00025927462],"about_ca_topic_score_codex":0.00018736295,"about_ca_topic_score_gemma":0.00012915808,"teacher_disagreement_score":0.012787914,"about_ca_system_score_codex":0.00023578311,"about_ca_system_score_gemma":0.0002448735,"threshold_uncertainty_score":0.84792686},"labels":[],"label_agreement":null},{"id":"W2918622184","doi":"10.1016/j.euf.2019.02.014","title":"State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era","year":2019,"lang":"en","type":"review","venue":"European Urology Focus","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Immunotherapy; Renal cell carcinoma; Translational research; Kidney cancer; Biomarker; Modalities; Immune checkpoint; Therapeutic modalities; Oncology; Cancer; Cancer research; Internal medicine; Pathology","score_opus":0.04741992839791257,"score_gpt":0.27072297167210535,"score_spread":0.2233030432741928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2918622184","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032578383,0.9863949,0.0000058607825,0.0010699696,0.0003256147,0.0012887665,0.000042984997,0.000007965963,0.007606143],"genre_scores_gemma":[0.040282313,0.95842665,0.000026193184,0.0005097212,0.00026507684,0.000031171567,0.000049670987,0.000078180674,0.00033103328],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99642086,0.0018925733,0.000791045,0.00036617523,0.0002416518,0.00028770673],"domain_scores_gemma":[0.9986874,0.00019775913,0.00036491864,0.00071347045,0.000016871105,0.000019575695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012508741,0.00033676493,0.0009328826,0.0002087314,0.000036702797,0.000009936551,0.00061702094,0.00014234493,0.00006685431],"category_scores_gemma":[0.000005760168,0.00017355414,0.0005614583,0.00050219515,0.00022089046,0.000026017893,0.000035904995,0.0010275621,0.000024761379],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007573456,0.00017772317,0.00041809198,0.0012227374,0.00012272754,0.000062693915,0.0013437996,0.000007602637,0.000028660677,0.00003651627,0.00033396197,0.99548817],"study_design_scores_gemma":[0.0024784734,0.00031861005,0.03075735,0.00039954323,0.0002025122,0.0001917229,0.000026421427,0.000005202056,0.000008577243,0.000026834601,0.96539885,0.00018589945],"about_ca_topic_score_codex":0.000033349395,"about_ca_topic_score_gemma":0.0000632873,"teacher_disagreement_score":0.99530226,"about_ca_system_score_codex":0.00004614424,"about_ca_system_score_gemma":0.00034055175,"threshold_uncertainty_score":0.7077333},"labels":[],"label_agreement":null},{"id":"W2918666649","doi":"10.1136/bcr-2018-227995","title":"Immune checkpoint inhibitor-induced rheumatoid arthritis: insights into an increasingly common aetiology of polyarthritis","year":2019,"lang":"en","type":"article","venue":"BMJ Case Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Nivolumab; Medicine; Rheumatoid arthritis; Polyarthritis; Adverse effect; Immunotherapy; Immune system; Cancer; Oncology; Arthritis; Adjuvant; Internal medicine; Immunology","score_opus":0.014239565304620611,"score_gpt":0.28574649501172816,"score_spread":0.27150692970710755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2918666649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875106,0.008664433,0.000004567939,0.00021876363,0.00084018236,0.001148721,0.0000025214968,0.00009681637,0.0015133718],"genre_scores_gemma":[0.99809974,0.0010717553,0.00028158634,0.00015518341,0.0001429546,0.000052822717,0.00008314958,0.000047302878,0.00006551165],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.99720407,0.0001649597,0.0015080047,0.00048707754,0.00032835043,0.00030754105],"domain_scores_gemma":[0.9977498,0.00005922596,0.0007499945,0.0010674702,0.00019092111,0.00018256977],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00076138,0.000268394,0.0008719357,0.0002278122,0.00009705707,0.000020596357,0.00004897162,0.00027516534,0.00033661877],"category_scores_gemma":[0.00010754896,0.00024830014,0.00026375262,0.0002642243,0.0001583179,0.00019370021,0.000068782174,0.00024972108,0.000020027517],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018553999,0.00043934467,0.01455106,0.00016719567,0.00020661965,0.13602169,0.0013502372,7.27039e-7,0.75644183,0.000049410177,0.00007083779,0.08884565],"study_design_scores_gemma":[0.0039845393,0.002169593,0.030920183,0.0016463129,0.000030196015,0.68878794,0.00090209395,0.000027124184,0.26748854,0.00027114808,0.003365457,0.0004068667],"about_ca_topic_score_codex":0.009164838,"about_ca_topic_score_gemma":0.0013050735,"teacher_disagreement_score":0.55276626,"about_ca_system_score_codex":0.0001299354,"about_ca_system_score_gemma":0.00044436456,"threshold_uncertainty_score":0.9999969},"labels":[],"label_agreement":null},{"id":"W2919228285","doi":"10.1080/13696998.2019.1590842","title":"Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)","year":2019,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Western University; University of Alberta; William Osler Health System; Roche (Canada)","funders":"","keywords":"Atezolizumab; Docetaxel; Medicine; Nivolumab; Oncology; Lung cancer; Cost effectiveness; Clinical trial; Internal medicine; Chemotherapy; Cancer; Immunotherapy; Risk analysis (engineering)","score_opus":0.016275617865555925,"score_gpt":0.29182496836964344,"score_spread":0.2755493505040875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2919228285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99470866,0.0020022935,0.00021192785,0.0008115357,0.0012730194,0.0007304531,0.000043122338,0.0000013949344,0.00021758546],"genre_scores_gemma":[0.9967727,0.0020472517,0.00020122051,0.00067882176,0.00016376375,0.000011443269,0.0000056629356,0.00002120738,0.000097949705],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986449,0.000035853063,0.000767669,0.00013719784,0.0001903925,0.00022400176],"domain_scores_gemma":[0.9986664,0.00039396243,0.00048490742,0.00013866412,0.000119967925,0.00019610279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010168912,0.0001269603,0.00068865955,0.00010126957,0.0000113797105,0.0000046396226,0.00019971986,0.00012133332,0.0006998919],"category_scores_gemma":[0.000058197274,0.00010592898,0.0001705418,0.000071917115,0.000033355802,0.00006960239,0.00002171989,0.00030166368,5.542178e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1135269,0.0014690132,0.3815358,0.014854124,0.002774268,0.000328469,0.0015958154,0.013134026,0.059849814,0.00013659954,0.0060452577,0.4047499],"study_design_scores_gemma":[0.24104084,0.0061103455,0.35721663,0.014530039,0.0006625064,0.0006516216,0.003787612,0.059452605,0.2374733,0.00018548631,0.07747146,0.0014175641],"about_ca_topic_score_codex":0.05542929,"about_ca_topic_score_gemma":0.30446956,"teacher_disagreement_score":0.40333235,"about_ca_system_score_codex":0.001482991,"about_ca_system_score_gemma":0.007726778,"threshold_uncertainty_score":0.9978985},"labels":[],"label_agreement":null},{"id":"W2919559414","doi":"10.1016/j.ijrobp.2019.02.046","title":"Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities","year":2019,"lang":"en","type":"review","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Janssen Biotech; Eisai; Celldex Therapeutics; ViewRay; National Institutes of Health; Regeneron Pharmaceuticals; Varian Medical Systems; Focused Ultrasound Foundation; Chrysalis; Bayer; National Cancer Institute; Merck; Accuray; AbbVie; GlaxoSmithKline; Bristol-Myers Squibb; AstraZeneca; Pfizer; Roche; Philips; Boehringer Ingelheim; Elekta; Janssen Research and Development; Medtronic","keywords":"Medicine; Immunotherapy; Medical physics; Radiation therapy; Oncology; Immunology; Internal medicine; Immune system","score_opus":0.09821815658456183,"score_gpt":0.4284426080831474,"score_spread":0.33022445149858554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2919559414","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018273586,0.9732961,0.00015965919,0.00024111102,0.0069180164,0.00087645615,0.000043485263,0.000021218879,0.00017036045],"genre_scores_gemma":[0.0145140495,0.98176837,0.00015652152,0.0005091766,0.002696847,0.000017294275,0.00018734288,0.000059349368,0.00009105157],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99541515,0.0010843547,0.0025750517,0.00035692385,0.00036332395,0.00020517957],"domain_scores_gemma":[0.991254,0.0030024045,0.004644179,0.00031699988,0.00063727004,0.0001451848],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001157457,0.00041266627,0.0025362193,0.00036636696,0.000045269906,0.000029356275,0.00042985895,0.00089677866,0.00003951661],"category_scores_gemma":[0.0004836063,0.0003132231,0.0012057219,0.00014387359,0.0004448182,0.00027755043,0.00007611104,0.0010378184,0.000011135872],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011077133,0.0006334227,0.006453148,0.0008722356,0.0057637137,0.000040389492,0.000126799,4.0144354e-7,0.00004298881,0.0004758932,0.00033931172,0.984144],"study_design_scores_gemma":[0.009218094,0.004980982,0.0077288803,0.0030649053,0.0017617765,0.00034760335,0.00001604247,0.00004144359,0.000041393476,0.0004038231,0.9721013,0.0002937846],"about_ca_topic_score_codex":0.000010764307,"about_ca_topic_score_gemma":6.2610167e-7,"teacher_disagreement_score":0.9838502,"about_ca_system_score_codex":0.0006123707,"about_ca_system_score_gemma":0.0024473085,"threshold_uncertainty_score":0.999932},"labels":[],"label_agreement":null},{"id":"W2921210767","doi":"10.1158/2326-6066.cir-18-0517","title":"A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":262,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"Universitair Medisch Centrum Groningen; Wellcome Trust; Ministry of Earth Sciences; Academy of Medical Sciences; KWF Kankerbestrijding; National Institute for Health and Care Research; Jan Kornelis de Cock Stichting","keywords":"CXCL13; CD8; Biology; B cell; Immunology; T cell; Tumor microenvironment; Cancer research; Acquired immune system; Chemokine; CXCR5; Immune system; Population; Antibody; Chemokine receptor; Medicine","score_opus":0.09239662447523743,"score_gpt":0.3867133403020323,"score_spread":0.29431671582679486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921210767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750977,0.018417735,0.0000022363529,0.0020091853,0.00018295384,0.0018136278,0.000062575346,0.00003569026,0.0023782607],"genre_scores_gemma":[0.98046446,0.0035723213,0.000014782375,0.00033721403,0.000057684327,0.0006562094,0.00010364686,0.00004626555,0.014747391],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974011,0.00027047965,0.0003921829,0.0006068456,0.00063310174,0.0006962855],"domain_scores_gemma":[0.9989577,0.000100677746,0.00011789414,0.0003811861,0.00035410793,0.000088453475],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009261543,0.00023970942,0.00047933075,0.00032472805,0.00019760466,0.000038865073,0.00018712654,0.0002701665,0.002422738],"category_scores_gemma":[0.000018643543,0.00020098174,0.00008025221,0.00067020213,0.0003445351,0.00011922435,0.0000539949,0.0007500843,0.000022695744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044858446,0.00038824722,0.5179476,0.00015551996,0.00034116308,0.000033114,0.0014871866,0.000004806615,0.46698838,0.000019224766,0.0008569347,0.0072919796],"study_design_scores_gemma":[0.013613656,0.0014585746,0.9548168,0.00072194816,0.00006480907,0.000014790184,0.00035055206,0.000058891896,0.016169613,0.00007780848,0.012339793,0.00031274563],"about_ca_topic_score_codex":0.0136406515,"about_ca_topic_score_gemma":0.0051941425,"teacher_disagreement_score":0.45081878,"about_ca_system_score_codex":0.0016464574,"about_ca_system_score_gemma":0.0007457608,"threshold_uncertainty_score":0.9984892},"labels":[],"label_agreement":null},{"id":"W2921474571","doi":"10.14740/jocmr3750","title":"Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Medicine Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Adverse effect; Nivolumab; Ipilimumab; Pembrolizumab; Internal medicine; Type 1 diabetes; Myocarditis; Diabetes mellitus; Oncology; Immunotherapy; Cancer; Endocrinology","score_opus":0.1366829575598688,"score_gpt":0.48506569073782124,"score_spread":0.34838273317795243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921474571","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22248337,0.76708734,9.1558366e-7,0.0003905712,0.0015089941,0.008281558,0.000026527312,0.000019036659,0.00020169861],"genre_scores_gemma":[0.1789778,0.8183569,0.00006278023,0.000014511526,0.0019329527,0.00010160973,0.00002232273,0.00012674,0.00040439135],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9765444,0.004392303,0.012536961,0.0009657656,0.004624507,0.0009360759],"domain_scores_gemma":[0.9787739,0.0063965106,0.00947889,0.0011676851,0.0034006026,0.00078240153],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.03819105,0.00085230777,0.0105979415,0.002100942,0.00011882876,0.00002062573,0.0006873289,0.0013422568,0.000034512577],"category_scores_gemma":[0.04275667,0.0005327834,0.0027500715,0.0027708819,0.0019116853,0.00016694398,0.00042873636,0.005079898,0.000006270262],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031216301,0.008881447,0.0073582036,0.051675335,0.009926238,0.0013423631,0.0014564252,1.14192076e-7,0.0027023493,0.0000056399635,0.00168781,0.88374776],"study_design_scores_gemma":[0.1275386,0.17630687,0.030342584,0.52533764,0.009171102,0.0005519131,0.002617149,0.000005594229,0.004948168,0.00008086555,0.12199015,0.0011093663],"about_ca_topic_score_codex":0.000796879,"about_ca_topic_score_gemma":0.000035830417,"teacher_disagreement_score":0.8826384,"about_ca_system_score_codex":0.0013342,"about_ca_system_score_gemma":0.0045944313,"threshold_uncertainty_score":0.9999542},"labels":[],"label_agreement":null},{"id":"W2921797044","doi":"10.1016/s2213-2600(18)30500-9","title":"Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Canada; Pfizer Canada; Bristol-Myers Squibb Canada; Merck Sharp and Dohme; AstraZeneca Canada; Genentech; Boehringer Ingelheim; MedImmune; Merck; AbbVie; Novartis; Roche; Eli Lilly and Company","keywords":"Medicine; Pembrolizumab; Internal medicine; Clinical endpoint; Adverse effect; Lung cancer; Oncology; Cohort; Cancer; Clinical trial; Immunotherapy","score_opus":0.03974779098585332,"score_gpt":0.3540708388786967,"score_spread":0.3143230478928434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921797044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894212,0.0013117488,0.000003074737,0.0012240811,0.00044553247,0.0044874703,0.00016329935,0.000061450104,0.0028821286],"genre_scores_gemma":[0.9928964,0.00013367232,0.00006611551,0.0052208877,0.0007464505,0.00019368867,0.00018524118,0.000075400116,0.00048214788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970008,0.00026818996,0.0007170781,0.0007748154,0.0006763822,0.00056269515],"domain_scores_gemma":[0.99743,0.00016060223,0.00036532572,0.0016581629,0.00019564226,0.00019025846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011091981,0.0003998108,0.0010766762,0.0001541609,0.000110676054,0.000035093595,0.00081982237,0.00011122603,0.0006113311],"category_scores_gemma":[0.0000604604,0.00022827652,0.000025015173,0.00056415895,0.00016531524,0.00024118519,0.0001387342,0.00056974334,0.00002679649],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31715128,0.007964385,0.6159433,0.00016669017,0.00050338,0.00010736627,0.006493806,0.000035784757,0.018799288,0.0000054711136,0.010856757,0.021972505],"study_design_scores_gemma":[0.43619508,0.02120099,0.52750206,0.0009906795,0.0002641836,9.4529827e-7,0.0012367798,0.00013048708,0.0005456284,0.0000043680366,0.011547578,0.00038119662],"about_ca_topic_score_codex":0.0028097949,"about_ca_topic_score_gemma":0.0010505326,"teacher_disagreement_score":0.11904382,"about_ca_system_score_codex":0.00027315822,"about_ca_system_score_gemma":0.00032379176,"threshold_uncertainty_score":0.9308846},"labels":[],"label_agreement":null},{"id":"W2921861485","doi":"10.2217/imt-2018-0186","title":"Toxicity Patterns Associated with Chemotherapy/Immune Checkpoint Inhibitor Combinations: A Meta-Analysis","year":2019,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Meta-analysis; Chemotherapy; Toxicity; Medicine; Immune checkpoint; Immune system; Immunotherapy; Oncology; Immunology; Internal medicine","score_opus":0.0886360825971064,"score_gpt":0.34861315145748456,"score_spread":0.2599770688603782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921861485","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033008322,0.99391454,0.00030590265,0.00047666524,0.0002582156,0.003654605,0.00045314385,0.0002513571,0.00035549825],"genre_scores_gemma":[0.0006223688,0.987569,0.00014343724,0.001055551,0.00011111742,0.00081971596,0.0015071175,0.00032542314,0.00784627],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.994528,0.0005128727,0.0020566604,0.0011470481,0.0010136185,0.000741796],"domain_scores_gemma":[0.9950418,0.00043276892,0.0018760994,0.0021624325,0.0003539515,0.00013298815],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0012242859,0.001404346,0.009573022,0.0010581631,0.00019391521,0.00018606542,0.0006184266,0.00086736225,0.0032973746],"category_scores_gemma":[0.000044695233,0.0008994311,0.010873345,0.0027452216,0.00021120673,0.00017500957,0.00005310263,0.0009871207,0.000105536004],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007373414,0.0015423222,0.000037342892,0.0029947034,0.7517525,0.000030905998,0.00024214842,0.0000010358997,0.00009555613,0.000025774278,0.00013654055,0.2424038],"study_design_scores_gemma":[0.005719923,0.0010163783,0.00033599304,0.0026828882,0.3552176,0.00006120575,0.000032219854,0.000011912195,0.000133765,0.0000069131856,0.6337318,0.0010493891],"about_ca_topic_score_codex":0.0002761249,"about_ca_topic_score_gemma":0.00008178262,"teacher_disagreement_score":0.6335953,"about_ca_system_score_codex":0.00089178927,"about_ca_system_score_gemma":0.00075792655,"threshold_uncertainty_score":0.99987066},"labels":[],"label_agreement":null},{"id":"W2922202838","doi":"10.1093/jcag/gwz006.014","title":"A15 IMPACT OF DYSFUNCTIONAL MESENCHYMAL TELOCYTES IN THE DEVELOPMENT OF COLITIS ASSOCIATED CANCER.","year":2019,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Dysfunctional family; Mesenchymal stem cell; Cancer; Medicine; Cancer research; Internal medicine; Pathology; Clinical psychology","score_opus":0.01091314655962927,"score_gpt":0.26228305370573046,"score_spread":0.2513699071461012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922202838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953514,0.000048872338,0.0000017341467,0.0038282846,0.00034113938,0.00017261306,0.00006412695,6.9840416e-7,0.00019117806],"genre_scores_gemma":[0.99926436,0.000022037762,0.00004691263,0.00038744992,0.00004002923,0.000002327335,0.000005234515,0.000005812358,0.00022581554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830574,0.00025705964,0.000732699,0.000060283357,0.00041760993,0.00022659347],"domain_scores_gemma":[0.997698,0.00012060966,0.0015699485,0.000102959435,0.0004472428,0.00006121738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015148789,0.000083937804,0.00041320105,0.00023018023,0.00003473963,0.000004089022,0.00020021615,0.00010298317,0.00027840395],"category_scores_gemma":[0.00022433273,0.00005180359,0.00026075233,0.00021346123,0.0000557784,0.00004321974,0.000011133859,0.00022431616,6.039556e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014831141,0.00007881008,0.99121326,0.000016469852,0.00078594877,0.0000014283471,0.00069873896,0.000067432695,0.0028793486,0.0000067133,0.0025594176,0.00020929813],"study_design_scores_gemma":[0.0030420627,0.0009285801,0.994781,0.00014030337,0.00006373592,0.000024466683,0.00015005526,0.000016918337,0.0005243313,0.000014867838,0.0002881473,0.000025523259],"about_ca_topic_score_codex":0.014708405,"about_ca_topic_score_gemma":0.36502835,"teacher_disagreement_score":0.35031995,"about_ca_system_score_codex":0.0027056076,"about_ca_system_score_gemma":0.0022395547,"threshold_uncertainty_score":0.99185276},"labels":[],"label_agreement":null},{"id":"W2922930489","doi":"10.1016/j.bpobgyn.2019.03.005","title":"Immunotherapy of gynecological cancers","year":2019,"lang":"en","type":"review","venue":"Best Practice & Research Clinical Obstetrics & Gynaecology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Immunotherapy; Clinical trial; Oncology; Cancer; Regimen; Chemotherapy; Internal medicine; Intensive care medicine","score_opus":0.36611178096792507,"score_gpt":0.5696743345982737,"score_spread":0.20356255363034859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922930489","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000070207294,0.9590194,0.000010324589,0.0006598853,0.006648145,0.004403404,0.000079646314,0.000054031683,0.029054936],"genre_scores_gemma":[0.000112165806,0.9922257,0.00097498304,0.00079476455,0.0004372075,0.0003898491,0.00012472161,0.00016999136,0.004770638],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9838393,0.006707754,0.004277679,0.0016080586,0.0019950508,0.0015721929],"domain_scores_gemma":[0.8466596,0.14607036,0.002322234,0.002139404,0.0022978666,0.0005105643],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0151392715,0.0007552594,0.006124921,0.0015116148,0.00021538508,0.00008180822,0.0014447671,0.003276208,0.0068555917],"category_scores_gemma":[0.12197554,0.00057433,0.0025113148,0.0041538887,0.0020550166,0.00027197402,0.0006016898,0.0070028985,0.0014020877],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012927435,0.0031699901,0.0002950785,0.006446217,0.0025239526,0.0006729251,0.00003201154,2.473812e-7,0.0000011071864,0.0001833732,0.0054325657,0.9799498],"study_design_scores_gemma":[0.0042463266,0.014059077,0.0005484044,0.0010360702,0.0018798056,0.00020472823,0.00021572289,0.0000045723145,7.982853e-7,0.000027806473,0.97729844,0.00047825175],"about_ca_topic_score_codex":0.00030840733,"about_ca_topic_score_gemma":0.000024144943,"teacher_disagreement_score":0.97947156,"about_ca_system_score_codex":0.0033809503,"about_ca_system_score_gemma":0.014514193,"threshold_uncertainty_score":0.9996708},"labels":[],"label_agreement":null},{"id":"W2924316526","doi":"10.1172/jci125301","title":"Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital; McGill University; McGill University Health Centre; Université de Montréal; Jewish General Hospital","funders":"National Heart, Lung, and Blood Institute; Natural Sciences and Engineering Research Council of Canada; Krembil Foundation; Institut Du Cancer de Montréal; Institute of Cancer Research; Terry Fox Research Institute; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Fonds de Recherche du Québec - Santé; Mitacs; Lady Davis Institute for Medical Research; Qatar University; McGill University; Kidney Foundation of Canada; Society for Immunotherapy of Cancer","keywords":"Immune system; Context (archaeology); Immunology; Cancer; Immunogenicity; Tumor-infiltrating lymphocytes; Disease; Biology; Immunotherapy; Medicine; Pathology; Genetics","score_opus":0.08151032616132131,"score_gpt":0.3913902125593313,"score_spread":0.30987988639801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2924316526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961198,0.0019731352,0.00003084032,0.0010378889,0.00056005036,0.00022007467,0.000009261508,0.000019628089,0.000029298179],"genre_scores_gemma":[0.9961758,0.00025967302,0.0020559703,0.0010980448,0.00024974142,0.000002401877,0.000008273448,0.00001495513,0.00013511177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977412,0.0002307703,0.0014024527,0.00017211221,0.00027908693,0.00017433774],"domain_scores_gemma":[0.9972155,0.0011827452,0.0010417968,0.00018411712,0.00024761318,0.00012823782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025157174,0.000122374,0.0005583569,0.00006364825,0.00007018963,0.000046110225,0.000085317675,0.00013387771,0.0000594443],"category_scores_gemma":[0.0054410174,0.000089558205,0.0002361503,0.00012858499,0.00024155964,0.0002481801,0.000038925846,0.00031900156,0.0000107614605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004785463,0.00005132556,0.8479864,0.00012278638,0.00013706212,0.00009087388,0.0006661819,0.000015632908,0.12673935,0.00000520338,0.0001511573,0.01924857],"study_design_scores_gemma":[0.006899016,0.00096165965,0.9799222,0.0006109565,0.000055642144,0.0003268078,0.00074983743,0.0011145681,0.008345783,0.0002396907,0.00066342903,0.00011045804],"about_ca_topic_score_codex":0.0000232689,"about_ca_topic_score_gemma":0.0000039691954,"teacher_disagreement_score":0.13193576,"about_ca_system_score_codex":0.00010596971,"about_ca_system_score_gemma":0.00040187984,"threshold_uncertainty_score":0.6513799},"labels":[],"label_agreement":null},{"id":"W2924812697","doi":"10.1158/2326-6066.cir-18-0499","title":"Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma","year":2019,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Foundation","funders":"National Cancer Institute","keywords":"Immune system; Tumor microenvironment; Cytotoxic T cell; Tumor-infiltrating lymphocytes; Immunohistochemistry; CD8; Cancer research; Immune checkpoint; PD-L1; Immunotherapy; Cancer; T cell; Medicine; Immunology; Biology; Internal medicine","score_opus":0.040802647508878714,"score_gpt":0.35138590238406125,"score_spread":0.31058325487518257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2924812697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96780926,0.025198182,0.000013758698,0.0018554631,0.00066557305,0.0012690625,0.000019786065,0.00004721658,0.0031217046],"genre_scores_gemma":[0.99123245,0.001903493,0.00013093837,0.00022949025,0.000077323966,0.0003318649,0.000030460873,0.000051187282,0.0060127904],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972337,0.00031599368,0.00042826234,0.00058262533,0.00047158648,0.0009678716],"domain_scores_gemma":[0.99837905,0.00031211914,0.0000778511,0.00085835316,0.00028850813,0.00008410303],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009307881,0.00021946609,0.0005320659,0.000579908,0.00012137488,0.00002749546,0.0004061779,0.00036684025,0.0029953804],"category_scores_gemma":[0.00011890831,0.00019630384,0.00016351031,0.00084073463,0.00038559202,0.00011864476,0.0002237989,0.0011561501,0.00042280782],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007190585,0.00013968852,0.10179657,0.00011541599,0.00022311194,0.000103545644,0.00073537935,0.0000062026675,0.88004136,0.00026003917,0.0005915907,0.008796537],"study_design_scores_gemma":[0.014492441,0.0016781554,0.52505744,0.00047351193,0.00002440563,0.00011901773,0.002274679,0.0004323702,0.4322335,0.00056623784,0.022259992,0.00038822633],"about_ca_topic_score_codex":0.0027863958,"about_ca_topic_score_gemma":0.00015722212,"teacher_disagreement_score":0.44780782,"about_ca_system_score_codex":0.0006430953,"about_ca_system_score_gemma":0.00067543366,"threshold_uncertainty_score":0.99791604},"labels":[],"label_agreement":null},{"id":"W2929513598","doi":"10.1093/annonc/mdz113","title":"Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Roche (Canada); University of Toronto; University Health Network; Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"National Cancer Institute; Genentech","keywords":"Atezolizumab; Medicine; Tolerability; Internal medicine; Adverse effect; Oncology; Lung cancer; Rash; Discontinuation; Nivolumab; Gastroenterology; Cancer; Immunotherapy","score_opus":0.03361865556179713,"score_gpt":0.3662232353398603,"score_spread":0.3326045797780632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2929513598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966023,0.00004616102,6.8009655e-7,0.0002955002,0.000052332474,0.0011404697,0.000009399098,0.000008255438,0.0018448895],"genre_scores_gemma":[0.9994028,0.000014675263,0.00003653285,0.00036711694,0.000008077109,0.000018006509,0.000018293846,0.000014904699,0.00011956132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892366,0.00007912742,0.00040586645,0.00018235049,0.00021464987,0.00019436043],"domain_scores_gemma":[0.999101,0.000063531115,0.00030328607,0.00025638688,0.00023007659,0.000045745855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022046185,0.00012003286,0.00065607333,0.0001588224,0.000010979641,0.0000014952791,0.00008618588,0.00006119758,0.0001583473],"category_scores_gemma":[0.000013399097,0.0000806245,0.000039907598,0.00027111053,0.00011650234,0.00004147417,0.000019360776,0.00010494751,0.0000044119706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21693261,0.02833322,0.7278097,0.00010814544,0.00058243854,0.00005079699,0.0022042468,0.000010232426,0.0017542815,0.0000116197,0.0004932151,0.02170946],"study_design_scores_gemma":[0.106158555,0.27933487,0.6075041,0.00016608102,0.00005236998,0.0000059221443,0.0010437066,0.000008151945,0.0046543027,0.000004593373,0.00096055615,0.00010679785],"about_ca_topic_score_codex":0.00029525225,"about_ca_topic_score_gemma":0.00018951732,"teacher_disagreement_score":0.25100163,"about_ca_system_score_codex":0.000031200037,"about_ca_system_score_gemma":0.00021511051,"threshold_uncertainty_score":0.32877716},"labels":[],"label_agreement":null},{"id":"W2932619366","doi":"10.32471/exp-oncology.2312-8852.vol-41-no-1.12593","title":"Integral characteristic of the immune system state predicts breast cancer outcome","year":2019,"lang":"en","type":"article","venue":"Experimental Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immune system; Breast cancer; Medicine; Cancer; Proportional hazards model; Oncology; Internal medicine; Immunology","score_opus":0.01475253177779263,"score_gpt":0.32064518694125815,"score_spread":0.30589265516346553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2932619366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917449,0.0019026704,0.0000018496874,0.0006961824,0.0023342725,0.0006016232,0.000085995925,0.000032813765,0.0025997194],"genre_scores_gemma":[0.99743235,0.000024770592,0.00002000359,0.0003626012,0.000089023,0.00006319436,0.000008593447,0.000018483635,0.001980965],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99896586,0.000067889785,0.00042839517,0.00017154939,0.00016850136,0.00019783435],"domain_scores_gemma":[0.9993706,0.000026389826,0.00022548859,0.00029008315,0.0000391396,0.000048328784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013123387,0.00013274339,0.00042525303,0.000040247858,0.000034380933,0.00000454358,0.0001449636,0.0000806649,0.000869633],"category_scores_gemma":[0.0000031856384,0.00008148898,0.00017327319,0.00010656725,0.00015380685,0.000041291663,0.0000726049,0.00014777172,0.000037413774],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004116465,0.00028526594,0.08011152,0.00012731366,0.00020491313,0.000012437704,0.0010517853,6.550714e-7,0.9108771,0.0000893332,0.00014376333,0.002979416],"study_design_scores_gemma":[0.0051311394,0.0010248643,0.6317732,0.00029906232,0.000049493963,0.0003937159,0.001997656,0.000064345586,0.35359898,8.5686764e-7,0.0055443,0.00012240178],"about_ca_topic_score_codex":0.0007325345,"about_ca_topic_score_gemma":0.000012015516,"teacher_disagreement_score":0.55727816,"about_ca_system_score_codex":0.0007841418,"about_ca_system_score_gemma":0.00018962375,"threshold_uncertainty_score":0.9521871},"labels":[],"label_agreement":null},{"id":"W2933590268","doi":"10.1186/s40425-019-0519-y","title":"Correction to: 33rd Annual Meeting &amp; Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)","year":2019,"lang":"en","type":"erratum","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cancer Council South Australia; Stand Up To Cancer; National Institutes of Health; Government of South Australia; Melanoma Research Alliance; South Australian Health and Medical Research Institute; Johns Hopkins University; Damon Runyon Cancer Research Foundation","keywords":"Cancer immunotherapy; Library science; Medicine; Immunotherapy; Cancer; Computer science; Internal medicine","score_opus":0.025540044931796076,"score_gpt":0.34468516163508495,"score_spread":0.3191451167032889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2933590268","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12813939,0.5297921,0.0058825053,0.007767302,0.29748008,0.023483392,0.0050809407,0.00014111343,0.0022331837],"genre_scores_gemma":[0.020449776,0.26074332,0.0069638146,0.0034103375,0.008947653,0.0028799449,0.00038019518,0.0009463919,0.6952786],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953401,0.00010650325,0.0021010302,0.00057050976,0.001125196,0.00075665046],"domain_scores_gemma":[0.9922647,0.0002651206,0.0039482773,0.00095694145,0.0024531463,0.000111810274],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013516743,0.00074270816,0.0019758139,0.00025322803,0.0003119719,0.00006473967,0.00094720925,0.00075095793,0.00046123308],"category_scores_gemma":[0.00008485725,0.00052782486,0.0040684957,0.0006097275,0.00041715222,0.00019824396,0.00005910312,0.0011814898,7.01732e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023411438,0.00036658198,0.0017553286,0.0017076413,0.0071166055,1.4428241e-7,0.005086754,0.00008814106,0.11822059,0.0000052961177,0.59208024,0.25016123],"study_design_scores_gemma":[0.009058772,0.002844325,0.006168755,0.011831107,0.00073411316,0.000026818614,0.0006260947,0.00013579815,0.018943217,0.000069383444,0.94895816,0.0006034603],"about_ca_topic_score_codex":0.004013355,"about_ca_topic_score_gemma":0.0015765105,"teacher_disagreement_score":0.6930454,"about_ca_system_score_codex":0.0008769084,"about_ca_system_score_gemma":0.0035404016,"threshold_uncertainty_score":0.99971735},"labels":[],"label_agreement":null},{"id":"W2935069581","doi":"10.3389/fimmu.2019.00603","title":"The Tumor Immune Contexture of Prostate Cancer","year":2019,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":217,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Prostate Cancer Canada","keywords":"Prostate cancer; Immune system; Cancer; Prostate; Cancer research; Medicine; Oncology; Internal medicine; Immunology","score_opus":0.019959835952851602,"score_gpt":0.3105670794137507,"score_spread":0.2906072434608991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935069581","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000044221808,0.9913503,0.0000071312306,0.00023611539,0.0058546136,0.0019927183,0.000104203384,0.00002074408,0.0003899603],"genre_scores_gemma":[0.000017244087,0.9927844,0.000112707654,0.00008660667,0.000076188095,0.00036364736,0.00008973629,0.00006733939,0.006402168],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99765563,0.00023683187,0.001094921,0.0003728965,0.0001616482,0.00047805742],"domain_scores_gemma":[0.9981169,0.00014087356,0.0007791887,0.00085074914,0.000086943,0.000025359435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040806853,0.0004084405,0.002692654,0.00029466383,0.00006599523,0.000012645261,0.00047486482,0.00042998994,0.000072415794],"category_scores_gemma":[0.00006357757,0.00024504922,0.0006907446,0.0004880068,0.0006328372,0.000035530607,0.00009413028,0.0008849173,0.000014734185],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013974071,0.00005039632,0.00023022605,0.0054905578,0.001975336,0.000021165966,0.00013228881,8.844726e-8,0.000023290082,0.000031534928,0.010872811,0.9797749],"study_design_scores_gemma":[0.0018283782,0.0002572344,0.00020066538,0.011292031,0.00060732255,0.0000946189,0.00022682089,0.0000014324053,0.000021038717,0.00002293411,0.98522216,0.00022538591],"about_ca_topic_score_codex":0.00029527702,"about_ca_topic_score_gemma":0.000029014174,"teacher_disagreement_score":0.9795495,"about_ca_system_score_codex":0.00044201483,"about_ca_system_score_gemma":0.0011068109,"threshold_uncertainty_score":0.9992817},"labels":[],"label_agreement":null},{"id":"W2936287366","doi":"10.1016/j.berh.2019.03.009","title":"Checkpoint inhibitor-associated autoimmunity","year":2018,"lang":"en","type":"review","venue":"Best Practice & Research Clinical Rheumatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Clinical trial; Adverse effect; Immunotherapy; Internal medicine; Cancer; Arthritis; Randomized controlled trial; Autoimmunity; Oncology","score_opus":0.33456803091917403,"score_gpt":0.5781455320671951,"score_spread":0.24357750114802107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936287366","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034519137,0.9829408,0.0000048451825,0.0024403583,0.001845253,0.0022889175,0.00004404193,0.00016481084,0.009925817],"genre_scores_gemma":[0.00006105821,0.9950901,0.00036486745,0.00029069508,0.00040418847,0.00030843396,0.000288191,0.00017057889,0.0030218663],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9789955,0.012370681,0.0041102245,0.0013860697,0.0015720321,0.0015654727],"domain_scores_gemma":[0.9646721,0.027944855,0.002001798,0.0023023796,0.0023786032,0.00070027716],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity","insufficient_payload"],"category_scores_codex":[0.032831058,0.0007049039,0.005044065,0.0006924702,0.0005575421,0.00015506202,0.0010336032,0.0030020142,0.0011966932],"category_scores_gemma":[0.120472886,0.00055027,0.0019524826,0.0018011756,0.0034512528,0.0003096067,0.0009152718,0.008591469,0.005046344],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024363312,0.0053157825,0.00011728204,0.0071850047,0.0031089643,0.00043431923,0.00007303416,1.6006219e-9,8.1014986e-7,0.00014004526,0.050580192,0.9306082],"study_design_scores_gemma":[0.0026023786,0.0049282876,0.000034411612,0.027247088,0.0012399381,0.0023667635,0.00019545948,0.0000029787745,9.203988e-7,0.00006504802,0.9608712,0.00044550188],"about_ca_topic_score_codex":0.0018607216,"about_ca_topic_score_gemma":0.0001737636,"teacher_disagreement_score":0.9301627,"about_ca_system_score_codex":0.00096902164,"about_ca_system_score_gemma":0.007953565,"threshold_uncertainty_score":0.99971634},"labels":[],"label_agreement":null},{"id":"W2937841409","doi":"10.1016/j.lungcan.2019.04.009","title":"The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Immunohistochemistry; Biopsy; Pathology; Pembrolizumab; Metastasis; Serous fluid; Lung cancer; Oncology; Lung; Carcinoma; Serous membrane; Internal medicine; Radiology; Cancer; Immunotherapy","score_opus":0.006195992376352095,"score_gpt":0.270509923954496,"score_spread":0.2643139315781439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937841409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98849475,0.008076528,0.000033272907,0.0006373103,0.0006622319,0.0010596568,0.000023431148,0.000029082687,0.0009837376],"genre_scores_gemma":[0.9901581,0.001235772,0.00026792218,0.0012667316,0.000075870325,0.00021467899,0.000007642695,0.000033837186,0.0067394613],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99856746,0.000052774172,0.00033930628,0.00036424695,0.00027389283,0.00040232207],"domain_scores_gemma":[0.99903995,0.00015078105,0.00014876576,0.000511577,0.00007182585,0.00007712193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023718775,0.0002109441,0.00030339515,0.00007788539,0.000095300624,0.000035006473,0.00018517533,0.00006565488,0.00023411974],"category_scores_gemma":[0.000016193242,0.0001206307,0.00011187526,0.00025090436,0.00006069101,0.0001439626,0.000057195506,0.0002547535,0.000021193408],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023974609,0.000038823753,0.3619139,0.00035496536,0.00004193524,0.000018843237,0.001321965,0.00020297614,0.62915903,0.0000025267764,0.0005061532,0.0040414035],"study_design_scores_gemma":[0.006340711,0.0001544331,0.6156345,0.0010305583,0.0001147478,0.000005866817,0.0005070562,0.0024581666,0.362544,0.0000078586045,0.010870663,0.00033143046],"about_ca_topic_score_codex":0.0009837783,"about_ca_topic_score_gemma":0.0006536229,"teacher_disagreement_score":0.26661506,"about_ca_system_score_codex":0.00032531552,"about_ca_system_score_gemma":0.00022535949,"threshold_uncertainty_score":0.4919177},"labels":[],"label_agreement":null},{"id":"W2937848504","doi":"10.1186/s40425-018-0488-6","title":"Hyperspectral cell sociology reveals spatial tumor-immune cell interactions associated with lung cancer recurrence","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver Coastal Health; Canadian Centre for Applied Research in Cancer Control; Occupational Cancer Research Centre; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute","keywords":"Immune system; Tumor microenvironment; CD8; Cell; T cell; Cytotoxic T cell; Lung cancer; Biology; Cancer research; Adenocarcinoma; Pathology; Cancer; Medicine; Immunology; Internal medicine; In vitro","score_opus":0.013211437999701406,"score_gpt":0.320314737866742,"score_spread":0.3071032998670406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937848504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9491236,0.044366114,0.00030829853,0.0014103155,0.0026364853,0.0010529557,0.00012947425,0.000031053332,0.0009416733],"genre_scores_gemma":[0.98014706,0.008017587,0.00046688662,0.00097502634,0.00043852604,0.00015275284,0.000020971263,0.00008736027,0.009693819],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978736,0.0001024143,0.0007898615,0.00031779017,0.00037926988,0.0005370735],"domain_scores_gemma":[0.99770653,0.00020879344,0.0011170477,0.00031362657,0.00055636093,0.00009763333],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00049904326,0.00032737738,0.0008194851,0.00020396146,0.00020921817,0.00003508914,0.0002585965,0.00014240379,0.0029875862],"category_scores_gemma":[0.000020204114,0.00025039862,0.00053082383,0.00023439167,0.00021169115,0.0002043675,0.000014678301,0.0006627574,0.000003841393],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017798416,0.0005270318,0.05039003,0.0002482467,0.001757125,0.0000091529855,0.002158483,0.00011698044,0.91108066,0.000013755806,0.0049752896,0.010924816],"study_design_scores_gemma":[0.08189479,0.011877272,0.29801694,0.0070192697,0.0018268637,0.00048859447,0.0026581108,0.0014218679,0.50359917,0.00037418664,0.08864154,0.0021814264],"about_ca_topic_score_codex":0.0010391179,"about_ca_topic_score_gemma":0.00018187979,"teacher_disagreement_score":0.40748152,"about_ca_system_score_codex":0.00089457806,"about_ca_system_score_gemma":0.00087223644,"threshold_uncertainty_score":0.9999948},"labels":[],"label_agreement":null},{"id":"W2937981811","doi":"10.1001/jamaoncol.2018.7147","title":"Current Landscape of Immunotherapy in Breast Cancer","year":2019,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":409,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institutes of Health","keywords":"Medicine; Breast cancer; Immunotherapy; Oncology; Clinical trial; Cancer; Immune checkpoint; Internal medicine; Tumor microenvironment","score_opus":0.012827140362133293,"score_gpt":0.32467049464520614,"score_spread":0.31184335428307286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937981811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792,0.009159363,0.0000026491452,0.0061060446,0.00071263075,0.00029592143,0.000022333414,0.000013150488,0.004487924],"genre_scores_gemma":[0.9918062,0.00650137,0.000043922864,0.0011981933,0.00013528149,0.000031109725,0.00000904205,0.000012946428,0.000261915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992593,0.00004538501,0.000268013,0.00014963366,0.00010561682,0.0001720428],"domain_scores_gemma":[0.99956936,0.000053468342,0.00010579581,0.00018802803,0.00005413671,0.000029224042],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020656608,0.000085636224,0.00033621976,0.00012808247,0.0000075829053,0.0000030309493,0.00007654126,0.00011996035,0.0031275086],"category_scores_gemma":[0.0000038769404,0.000067631685,0.00009071302,0.00020841154,0.00004922587,0.000041460946,0.000015377831,0.00017950842,0.000030132027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006561253,0.00031253207,0.47334376,0.00007298115,0.00007101614,0.0000069397947,0.0003341161,0.0000026902858,0.051098526,0.00004397737,0.0032867165,0.4648655],"study_design_scores_gemma":[0.009262769,0.00043030758,0.7766059,0.0002042342,0.00001154214,0.000062108666,0.00010719391,0.000057381272,0.00095931726,0.00001948226,0.2122051,0.00007466418],"about_ca_topic_score_codex":0.0004515188,"about_ca_topic_score_gemma":0.00011158523,"teacher_disagreement_score":0.46479085,"about_ca_system_score_codex":0.00018518629,"about_ca_system_score_gemma":0.0003271179,"threshold_uncertainty_score":0.9977838},"labels":[],"label_agreement":null},{"id":"W2938546950","doi":"10.1093/annonc/mdz094.003","title":"Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Phases of clinical research; Oncology; Pemetrexed; Chemotherapy; Nuclear medicine; Clinical trial; Surgery; Cisplatin","score_opus":0.03306078952820038,"score_gpt":0.36945708844085207,"score_spread":0.33639629891265166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2938546950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992572,0.00013420322,0.0000020293032,0.00072324346,0.00009005409,0.006192212,0.000026793923,0.000015313512,0.00024412065],"genre_scores_gemma":[0.9985808,0.00006810435,0.00001015051,0.0010109313,0.000016096967,0.00014969066,0.00003913495,0.00004825663,0.00007683926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966529,0.0010131028,0.00092729356,0.00042321772,0.00059747725,0.00038601234],"domain_scores_gemma":[0.9974492,0.001115851,0.00050673046,0.0006850848,0.00019714364,0.000045950295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020608925,0.0003913543,0.001602219,0.00037273526,0.000036813977,0.0000085007805,0.00028257893,0.00006453509,0.0002245006],"category_scores_gemma":[0.00006408752,0.00021039492,0.00014867773,0.0005818858,0.00014108844,0.000080014244,0.000017979835,0.0002945915,0.000005252889],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30853158,0.021536931,0.65130854,0.000100025696,0.0010675569,0.00010419788,0.0027985866,0.00004966993,0.00034170126,0.0000019786432,0.000022908325,0.014136312],"study_design_scores_gemma":[0.16802487,0.24974781,0.58060473,0.00013331481,0.00012707707,0.000006848575,0.00063362194,0.00001765751,0.00043288796,0.0000014565488,0.00012058046,0.00014916412],"about_ca_topic_score_codex":0.0028487197,"about_ca_topic_score_gemma":0.0015589644,"teacher_disagreement_score":0.22821088,"about_ca_system_score_codex":0.00012430403,"about_ca_system_score_gemma":0.00016750292,"threshold_uncertainty_score":0.8579656},"labels":[],"label_agreement":null},{"id":"W2940105550","doi":"10.1016/j.jhepr.2019.02.001","title":"Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report","year":2019,"lang":"en","type":"article","venue":"JHEP Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Melanoma; Adverse effect; Immune checkpoint; Internal medicine; Immune system; Common Terminology Criteria for Adverse Events; Cancer; Oncology; Immunology; Immunotherapy; Cancer research","score_opus":0.010726329060093267,"score_gpt":0.2735513881588859,"score_spread":0.26282505909879267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2940105550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894383,0.0035794685,0.000016261089,0.0009676056,0.0013392569,0.0024255894,0.000016428909,0.00004808402,0.002169012],"genre_scores_gemma":[0.99128866,0.00025917706,0.00020884081,0.00016989849,0.00013830034,0.0002527298,0.00005865991,0.00003665259,0.0075871046],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99800175,0.00001885998,0.001184894,0.0003564726,0.00022034533,0.00021768648],"domain_scores_gemma":[0.99801123,0.00010584598,0.00064666255,0.0009917209,0.00015999142,0.000084541636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004909578,0.00019151744,0.00045754673,0.00009763327,0.0000734382,0.000013981621,0.00003855278,0.000120528224,0.00052781746],"category_scores_gemma":[0.00008324523,0.00012382209,0.0004461091,0.00018569827,0.000084380634,0.00006686185,0.0000193891,0.000091101356,0.000008174662],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008957367,0.0034994993,0.12326207,0.0007867339,0.005123946,0.26434812,0.01333685,0.000044972247,0.24183817,0.000023862007,0.011901021,0.32687736],"study_design_scores_gemma":[0.005553607,0.0059381383,0.046930797,0.00033441623,0.00042168953,0.20750046,0.0007983989,0.00006113614,0.12009312,0.00004895926,0.611949,0.00037021606],"about_ca_topic_score_codex":0.0047542104,"about_ca_topic_score_gemma":0.00020032671,"teacher_disagreement_score":0.600048,"about_ca_system_score_codex":0.00033359727,"about_ca_system_score_gemma":0.00035125721,"threshold_uncertainty_score":0.7186976},"labels":[],"label_agreement":null},{"id":"W2941729594","doi":"10.29245/2578-3009/2019/1.1167","title":"Commentary: Small Molecule Inhibition of PD-1 Transcription is an Effective Alternative to Antibody Blockade in Cancer Therapy","year":2019,"lang":"en","type":"article","venue":"Journal of Immunological Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"Cancer Research UK","keywords":"Blockade; Antibody; Small molecule; Cancer research; Cancer therapy; Cancer; Transcription (linguistics); Medicine; Chemistry; Pharmacology; Immunology; Internal medicine; Biochemistry; Receptor; Philosophy","score_opus":0.038448057503273084,"score_gpt":0.3467796508385664,"score_spread":0.3083315933352933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941729594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907231,0.0022876363,0.000062429826,0.006132887,0.00022887602,0.0004272875,0.000006004843,0.000004121734,0.00012770541],"genre_scores_gemma":[0.995165,0.0017806813,0.0002612421,0.0027221416,0.00004733525,0.0000064619912,0.0000013727362,0.0000034900208,0.000012259426],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99887395,0.00013548357,0.0003673064,0.00015828942,0.00029692304,0.0001680431],"domain_scores_gemma":[0.9994648,0.00005666318,0.00024141674,0.00007645494,0.000112408685,0.000048226593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069079094,0.00010255667,0.00031352602,0.00021113598,0.00003973071,0.000017171902,0.00016041404,0.000062214654,0.0002640024],"category_scores_gemma":[0.000015731084,0.000061971754,0.000119833974,0.00046618085,0.00020744113,0.00018725492,0.000013578646,0.00018838113,0.0000016414427],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003743484,0.00040431987,0.019212188,0.000007684102,0.000069157955,0.0000089823925,0.001430491,0.000034108212,0.94891924,0.000009132738,0.000027927514,0.026133263],"study_design_scores_gemma":[0.0035373464,0.011797568,0.32492915,0.0003717471,0.0000141165765,0.000027273396,0.0009501716,0.00005480724,0.6576728,0.00012975279,0.00042420177,0.00009102565],"about_ca_topic_score_codex":0.00085808826,"about_ca_topic_score_gemma":0.000034760436,"teacher_disagreement_score":0.30571696,"about_ca_system_score_codex":0.00013772323,"about_ca_system_score_gemma":0.0000537398,"threshold_uncertainty_score":0.2890641},"labels":[],"label_agreement":null},{"id":"W2942865184","doi":"10.3747/co.26.4393","title":"A Network Approach to Developing Immuno-Oncology Combinations in Canada","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Université de Montréal; William Osler Health System; Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; Jewish General Hospital","funders":"Terry Fox Research Institute; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Medicine; Excellence; Clinical trial; Biobank; Harmonization; Collaborative network; Leverage (statistics); Bioinformatics; Computer science; Internal medicine; Knowledge management; Political science; Artificial intelligence","score_opus":0.07811732958159477,"score_gpt":0.3635893323815424,"score_spread":0.2854720027999476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942865184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9508989,0.0033334668,0.00054295955,0.0066320235,0.0052027944,0.0014123709,0.0000061965893,0.000031147476,0.03194017],"genre_scores_gemma":[0.9942204,0.00021031388,0.0016520334,0.003234845,0.00016077183,0.0001707344,0.00006769311,0.000017602619,0.00026562047],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987344,0.00010600233,0.00036553794,0.00025869705,0.00013511915,0.00040021795],"domain_scores_gemma":[0.99941397,0.00013312553,0.00008600867,0.0002079995,0.00007383574,0.00008504103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030360388,0.00012612503,0.00041858683,0.000113729926,0.000042623236,0.000004701247,0.00013587286,0.00009380596,0.00011261402],"category_scores_gemma":[0.000031331867,0.00011825411,0.00004472218,0.0005014926,0.000031746305,0.000027662127,0.0000644319,0.00024981634,0.00003214298],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.003135976,0.0016769307,0.36084506,0.00030931484,0.00022634967,0.00004930409,0.0020304548,0.0003866082,0.0013425772,0.0054164934,0.10560446,0.51897645],"study_design_scores_gemma":[0.0048906626,0.00046777155,0.13262156,0.00010901597,0.000018939538,0.0000640412,0.00058240717,0.0003084428,0.000031389736,0.000097798016,0.86064035,0.00016761497],"about_ca_topic_score_codex":0.107336394,"about_ca_topic_score_gemma":0.39522323,"teacher_disagreement_score":0.7550359,"about_ca_system_score_codex":0.004967724,"about_ca_system_score_gemma":0.006134533,"threshold_uncertainty_score":0.99949974},"labels":[],"label_agreement":null},{"id":"W2943155654","doi":"10.1186/s40425-019-0542-z","title":"Radiotherapy enhances responses of lung cancer to CTLA-4 blockade","year":2019,"lang":"en","type":"letter","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Abscopal effect; Ipilimumab; Medicine; Radiation therapy; Immunotherapy; CTLA-4; Immune system; Lung cancer; Oncology; Clinical trial; Blockade; Immune checkpoint; Biological response modifiers; Immunology; Internal medicine; T cell; Receptor","score_opus":0.02045189570884703,"score_gpt":0.3664423344238244,"score_spread":0.34599043871497737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943155654","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10485345,0.29724178,0.00072102674,0.58368856,0.008424036,0.0036741823,0.0011525264,0.000048102578,0.00019634589],"genre_scores_gemma":[0.0037460527,0.23861152,0.003697912,0.661497,0.015468632,0.0009872977,0.000077271376,0.00069536467,0.07521895],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99551654,0.00016637813,0.001775642,0.0005689358,0.0011625208,0.00080998696],"domain_scores_gemma":[0.9955859,0.00053349807,0.0019768297,0.000825885,0.0009704651,0.000107430424],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008236044,0.00073935936,0.002215614,0.00092198775,0.00015673264,0.000062150335,0.00072989275,0.00090656034,0.0028016407],"category_scores_gemma":[0.000054793294,0.00059031503,0.0016113188,0.0005384806,0.0002610178,0.00015426647,0.00002551837,0.0014195632,0.0000019997563],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025888436,0.00008187284,0.00083587976,0.0011090075,0.0046576033,0.000014881135,0.0006376718,0.00002408191,0.3803986,0.0000010883784,0.55432963,0.032021224],"study_design_scores_gemma":[0.0072487546,0.0019613022,0.0010223379,0.0037305364,0.00048060433,0.00009440474,0.000033017477,0.000023328159,0.15050407,0.000024196444,0.8343296,0.0005478298],"about_ca_topic_score_codex":0.00081405824,"about_ca_topic_score_gemma":0.000027385757,"teacher_disagreement_score":0.27999994,"about_ca_system_score_codex":0.00095721975,"about_ca_system_score_gemma":0.002366094,"threshold_uncertainty_score":0.9996548},"labels":[],"label_agreement":null},{"id":"W2943439937","doi":"10.1097/nrl.0000000000000230","title":"Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors","year":2019,"lang":"en","type":"review","venue":"The Neurologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Collège Jean-de-Brébeuf; McGill University","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Chemotherapy; Confidence interval; Peripheral neuropathy; Immune system; Gastroenterology; Clinical trial; Relative risk; Randomized controlled trial; Oncology; Immunology","score_opus":0.08863043527797192,"score_gpt":0.32493105026709707,"score_spread":0.23630061498912514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943439937","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25436434,0.7424637,0.0000015197638,0.00071905315,0.0006211492,0.0016892285,0.000057654484,0.000028143375,0.000055170847],"genre_scores_gemma":[0.080614,0.9184688,0.0000063502525,0.00043055505,0.00010250702,0.00007399663,0.000018651408,0.000049469007,0.00023567691],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99633807,0.0010801788,0.0014346852,0.00040731,0.00036621152,0.00037355523],"domain_scores_gemma":[0.99587107,0.0016270499,0.0012099774,0.0012227478,0.000034153487,0.00003497873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007769223,0.0004756631,0.0025125626,0.00014918741,0.00007158476,0.000019901727,0.00055251253,0.000285027,0.000029169825],"category_scores_gemma":[0.00051742,0.00020192457,0.0015989547,0.0003276356,0.00076188834,0.00003507229,0.0002698407,0.0012087158,0.0000050599842],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021333912,0.0033966762,0.015275379,0.040378083,0.0069565065,0.0010152969,0.0023152796,0.00018451743,0.0054939864,0.0003197067,0.002985581,0.9003451],"study_design_scores_gemma":[0.006897262,0.014967363,0.060567778,0.020643579,0.010097184,0.00074313034,0.00017160585,0.00023383554,0.0018841614,0.00014448272,0.8822455,0.0014041337],"about_ca_topic_score_codex":0.00026417492,"about_ca_topic_score_gemma":0.00002723966,"teacher_disagreement_score":0.8989409,"about_ca_system_score_codex":0.00004205341,"about_ca_system_score_gemma":0.00012931289,"threshold_uncertainty_score":0.8234245},"labels":[],"label_agreement":null},{"id":"W2943665137","doi":"10.1186/s40425-019-0578-0","title":"Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Institute of Dental and Craniofacial Research","keywords":"Medicine; Cetuximab; Nivolumab; Pembrolizumab; Head and neck squamous-cell carcinoma; Internal medicine; Oncology; Docetaxel; Clinical trial; Immunotherapy; Head and neck cancer; Cancer","score_opus":0.06821629106114331,"score_gpt":0.4354250672816484,"score_spread":0.36720877622050513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943665137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783666,0.019301195,0.00004082142,0.00022834,0.0004850252,0.00131966,0.00018752963,0.000003142856,0.000067678346],"genre_scores_gemma":[0.992919,0.00634968,0.00017078078,0.00028931772,0.00005520437,0.000018631776,0.0000079916435,0.000023336985,0.0001660499],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964533,0.00037731818,0.0023179234,0.00025490363,0.00035873384,0.00023784551],"domain_scores_gemma":[0.99648046,0.0005532891,0.0022272605,0.00034080286,0.00032658954,0.00007157343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002299497,0.00024481452,0.002312767,0.0003784027,0.0000636783,0.00001655492,0.00017944293,0.00016160238,0.00018775927],"category_scores_gemma":[0.000045836325,0.00015675496,0.00091015594,0.00055575714,0.00028538847,0.00011222173,0.000020149822,0.00027359696,1.00668416e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06318129,0.0011610964,0.7103981,0.00018262755,0.002770033,6.8607307e-7,0.0028496836,0.000061220686,0.1872271,0.0000068805743,0.00017067253,0.031990655],"study_design_scores_gemma":[0.09768809,0.0035284965,0.8359793,0.0002799982,0.0009288666,0.0000035494154,0.00027981537,0.000867433,0.057440117,0.000040108185,0.0027774877,0.00018674337],"about_ca_topic_score_codex":0.00059529796,"about_ca_topic_score_gemma":0.000104743245,"teacher_disagreement_score":0.12978698,"about_ca_system_score_codex":0.00008548452,"about_ca_system_score_gemma":0.00024864843,"threshold_uncertainty_score":0.63922817},"labels":[],"label_agreement":null},{"id":"W2943722998","doi":"10.1016/bs.acr.2019.03.001","title":"Translation of cancer immunotherapy from the bench to the bedside","year":2019,"lang":"en","type":"review","venue":"Advances in cancer research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Immunosurveillance; Immunoediting; Cancer; Immune system; Tumor microenvironment; Cancer immunotherapy; Immunotherapy; Medicine; Immune checkpoint; Cancer immunology; Immunology; Internal medicine","score_opus":0.20448096674654492,"score_gpt":0.5420846857193639,"score_spread":0.33760371897281893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943722998","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014644644,0.99048954,0.000016731154,0.003745209,0.0008012883,0.0038432805,0.00035278525,0.000017984668,0.0005867054],"genre_scores_gemma":[0.00018296026,0.99589807,0.00007781506,0.00048258094,0.0006215599,0.002081278,0.00005243421,0.00010270408,0.0005005709],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99628866,0.00058673276,0.0008303737,0.000582859,0.0011413174,0.00057006883],"domain_scores_gemma":[0.9965171,0.0018170109,0.00024879345,0.0011402195,0.00021706588,0.00005978881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017144182,0.00034149992,0.001285927,0.00027591304,0.00011804514,0.00003628986,0.000967519,0.00023006139,0.000684792],"category_scores_gemma":[0.000056136,0.0001722897,0.000440058,0.001949463,0.00034527548,0.0001342141,0.00007898531,0.0012271758,0.00002427325],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007971356,0.00004517478,0.0003005437,0.0024239284,0.00032504034,0.0000024967517,0.0007713052,0.000029741146,0.0000662459,0.00001700084,0.001267616,0.99395376],"study_design_scores_gemma":[0.000876077,0.00018482035,0.00034067576,0.017214416,0.00015724039,0.0000021751978,0.00014708021,0.000005672848,0.00008017615,0.00006581563,0.98073894,0.00018690435],"about_ca_topic_score_codex":0.017637815,"about_ca_topic_score_gemma":0.018069234,"teacher_disagreement_score":0.99376684,"about_ca_system_score_codex":0.00075005105,"about_ca_system_score_gemma":0.0016469561,"threshold_uncertainty_score":0.9998484},"labels":[],"label_agreement":null},{"id":"W2943786262","doi":"10.3389/fimmu.2019.00993","title":"Editorial: Immune Outposts on the Inflammatory Frontier: Tertiary Lymphoid Structures as Targets for Immunotherapy of Cancer and Autoimmunity","year":2019,"lang":"en","type":"editorial","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Autoimmunity; Immunotherapy; Cancer immunotherapy; Immune system; Immunology; Tumor immunology; Medicine; Cancer; Internal medicine","score_opus":0.004946386947336442,"score_gpt":0.25901186526867126,"score_spread":0.2540654783213348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943786262","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018688196,0.12432089,0.000045730787,0.0006802161,0.8532189,0.0024086386,0.00045902422,0.00005875694,0.00011962264],"genre_scores_gemma":[0.004343192,0.07057571,0.0008821542,0.0006228588,0.9173776,0.001195578,0.0010030968,0.00040181066,0.0035980141],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959938,0.00035612227,0.0013520585,0.0007883115,0.00071879465,0.0007909477],"domain_scores_gemma":[0.9958593,0.0011050053,0.0010453818,0.0014923618,0.00044053578,0.000057394507],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011175463,0.0008477138,0.0020120877,0.00065959373,0.00021694897,0.0000471486,0.00089205964,0.002473792,0.00010970447],"category_scores_gemma":[0.0007353458,0.00063525164,0.0005462193,0.00024897838,0.0011166962,0.000122061356,0.00018072154,0.0018168954,0.000004426799],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025579657,0.00016028815,0.0025178185,0.00042229873,0.0032371883,0.000005131545,0.00083559484,0.0000031836057,0.012475871,0.00005453864,0.93502265,0.019685779],"study_design_scores_gemma":[0.011442616,0.0014071233,0.0077816034,0.0008082329,0.00024248286,0.0000078733265,0.000490149,0.000016672242,0.004362678,0.0009150107,0.97191805,0.0006075016],"about_ca_topic_score_codex":0.002490876,"about_ca_topic_score_gemma":0.000056644218,"teacher_disagreement_score":0.064158656,"about_ca_system_score_codex":0.0009302415,"about_ca_system_score_gemma":0.0019820018,"threshold_uncertainty_score":0.9996099},"labels":[],"label_agreement":null},{"id":"W2944068250","doi":"10.1186/s40425-019-0544-x","title":"Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratification","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Krembil Foundation; Université de Montréal; Institute for Research in Immunology and Cancer; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé; Natural Sciences and Engineering Research Council of Canada; Mitacs; Canadian Cancer Society Research Institute; Institute of Cancer Research; Institut Du Cancer de Montréal; Terry Fox Research Institute; Canada Foundation for Innovation","keywords":"Multiplex; Medicine; Immune system; Immune checkpoint; Profiling (computer programming); Lung cancer; Oncology; Risk stratification; Immunology; Immunotherapy; Internal medicine; Bioinformatics; Biology; Computer science","score_opus":0.017285490871467562,"score_gpt":0.31139325831436837,"score_spread":0.2941077674429008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944068250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9226211,0.047777332,0.016829016,0.0011743994,0.0017041806,0.009219604,0.00061534817,0.000023238184,0.000035829464],"genre_scores_gemma":[0.96755385,0.0065398067,0.021101195,0.0001714213,0.00020025304,0.0030708404,0.00021623871,0.000111484485,0.0010348795],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99710125,0.000041785417,0.00174439,0.00032540841,0.00035106047,0.00043608196],"domain_scores_gemma":[0.9958622,0.00040088565,0.0017132012,0.00038935008,0.0015632218,0.000071171446],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009833039,0.00034014322,0.000832026,0.00028169848,0.00021517956,0.00003795873,0.00022809676,0.00015844377,0.00016496805],"category_scores_gemma":[0.00007649969,0.00028103785,0.0008567574,0.000267401,0.00009426424,0.00014925822,0.000016563072,0.00019829615,3.8764134e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011869898,0.0009985022,0.0074593853,0.0021342165,0.0011402103,2.0777769e-7,0.0011544655,0.00065319665,0.9349947,0.00005953911,0.0002383201,0.039297376],"study_design_scores_gemma":[0.026870003,0.0038399224,0.01348119,0.0015910818,0.0005248592,0.000009374395,0.0010330166,0.014103465,0.9325553,0.00010971306,0.0054872897,0.00039475854],"about_ca_topic_score_codex":0.0002721843,"about_ca_topic_score_gemma":0.000032808046,"teacher_disagreement_score":0.044932827,"about_ca_system_score_codex":0.00041721322,"about_ca_system_score_gemma":0.0008226202,"threshold_uncertainty_score":0.9999642},"labels":[],"label_agreement":null},{"id":"W2944192183","doi":"10.1158/1538-7445.sabcs18-pd3-10","title":"Abstract PD3-10: Higher serum PD-L1 predicts for increased overall survival to lapatinib vs trastuzumab in the phase 3 CCTG MA.31 trial","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lapatinib; Trastuzumab; Taxane; Medicine; Internal medicine; Oncology; Metastatic breast cancer; Population; Biomarker; Breast cancer; Cancer","score_opus":0.11753207521934145,"score_gpt":0.44622672142565545,"score_spread":0.328694646206314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944192183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809888,0.000496431,0.000003288887,0.0064650327,0.00088528707,0.0055491733,0.00038496318,0.0000351285,0.0051918975],"genre_scores_gemma":[0.98845136,0.00014266728,0.000028381839,0.0011518316,0.0012938846,0.001396747,0.00009709809,0.000052484986,0.0073855654],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99676603,0.00024572777,0.00045787395,0.0005319024,0.0011523168,0.00084617507],"domain_scores_gemma":[0.9980453,0.000761742,0.00007310502,0.00064769946,0.00025673426,0.00021538732],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031086064,0.00022556445,0.00045727647,0.0002741575,0.00012914873,0.00009223303,0.00045669597,0.00017428522,0.0057633403],"category_scores_gemma":[0.0001903027,0.00015810035,0.00019232678,0.00060495513,0.00012047851,0.00011790683,0.000056663455,0.0005740352,0.00011888931],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7832549,0.0014605925,0.0027140048,0.00047648232,0.00028534138,0.00005325571,0.0013775942,0.000007748358,0.0681523,0.0001255987,0.1216733,0.020418864],"study_design_scores_gemma":[0.31121635,0.010627013,0.22073868,0.00061259355,0.000057964506,0.0000060552065,0.000559228,0.000058488757,0.008866311,0.00017375323,0.44664767,0.00043588894],"about_ca_topic_score_codex":0.0037730462,"about_ca_topic_score_gemma":0.000672389,"teacher_disagreement_score":0.47203857,"about_ca_system_score_codex":0.00065093854,"about_ca_system_score_gemma":0.0011532229,"threshold_uncertainty_score":0.9951455},"labels":[],"label_agreement":null},{"id":"W2944392072","doi":"10.1186/s40425-019-0541-0","title":"An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Institute of Cancer Research; Ontario Institute for Cancer Research; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"Terry Fox Research Institute; Ontario Ministry of Research, Innovation and Science; Canada Research Chairs; Government of Ontario; Ontario Institute for Cancer Research; Ontario Ministry of Research and Innovation; Princess Margaret Cancer Foundation","keywords":"Pembrolizumab; Medicine; Internal medicine; Immunophenotyping; Oncology; Immune system; CD8; Tumor-infiltrating lymphocytes; Interim analysis; Clinical trial; Immunotherapy; Immunology; Antigen","score_opus":0.10289923724578354,"score_gpt":0.4450525707470737,"score_spread":0.3421533335012902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944392072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991771,0.0032561272,0.000023587252,0.0015169935,0.00092029775,0.0023665417,0.000021894297,0.000020003778,0.00010358029],"genre_scores_gemma":[0.99775666,0.000556526,0.000053334777,0.0010388055,0.000114279836,0.00016886716,0.000010469142,0.000043410644,0.0002576394],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99698615,0.0006248405,0.0010940759,0.00026526727,0.0007888728,0.00024077031],"domain_scores_gemma":[0.99702454,0.00030317745,0.0010846654,0.0007193447,0.0007847266,0.000083544764],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003830035,0.00023446965,0.0005841233,0.00022916713,0.00014695605,0.000033335706,0.00030421678,0.00012661616,0.0014473146],"category_scores_gemma":[0.0003089126,0.00014248077,0.00033099347,0.00028335137,0.0001803749,0.00015764235,0.000012480709,0.0003539011,0.0000018360473],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21472621,0.0022603034,0.0031880324,0.000026290385,0.0013342239,0.000014795244,0.001964664,0.000046243513,0.7282369,0.000014911379,0.00045991113,0.04772749],"study_design_scores_gemma":[0.16980983,0.15450533,0.2574072,0.0017746276,0.00091831625,0.0010305119,0.008747362,0.0016600471,0.3591464,0.00047257636,0.04374772,0.00078010076],"about_ca_topic_score_codex":0.00013151625,"about_ca_topic_score_gemma":0.000009164392,"teacher_disagreement_score":0.36909053,"about_ca_system_score_codex":0.0003469537,"about_ca_system_score_gemma":0.0009894568,"threshold_uncertainty_score":0.9994655},"labels":[],"label_agreement":null},{"id":"W2944427520","doi":"10.1073/pnas.1819004116","title":"TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion","year":2019,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"National Cancer Institute; Canadian Institutes of Health Research; Genentech; Government of Canada; Cancer Prevention and Research Institute of Texas","keywords":"Blockade; Ipilimumab; Cancer research; Ligand (biochemistry); Medicine; Cancer; Immune checkpoint; CTLA-4; Cancer immunotherapy; Antibody; Receptor; Melanoma; Immunotherapy; Immunology; Pharmacology; Internal medicine; Immune system; T cell","score_opus":0.019729531133047026,"score_gpt":0.2974859262997659,"score_spread":0.27775639516671885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944427520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933905,0.00059452147,2.6661004e-7,0.001612149,0.00003040933,0.00025178544,0.000010892708,0.000008258125,0.004101189],"genre_scores_gemma":[0.9990331,0.00013600738,0.00033292465,0.00019375824,0.00006473974,0.0000026734217,3.7872843e-7,0.000004173953,0.00023227037],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983657,0.000006899274,0.0003685552,0.00019931322,0.0009267247,0.00013283484],"domain_scores_gemma":[0.99914986,0.000114288116,0.00050032244,0.000010145175,0.00019735073,0.000028046361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011268411,0.00009145802,0.000242582,0.00014022009,0.00007880535,0.000013750346,0.0003231721,0.00006807495,0.00002628623],"category_scores_gemma":[0.00029433917,0.000059412367,0.0000974035,0.0007008495,0.0007050012,0.00025420997,0.00004255365,0.000122141,8.887526e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043904674,0.00007812661,0.026870226,0.0001230797,0.000028821647,4.453095e-9,0.00010272744,0.0000017804326,0.9702534,0.0011965572,0.00033855304,0.0005676705],"study_design_scores_gemma":[0.0007316296,0.00016846137,0.16783008,0.00041026034,0.00002127818,0.00001570824,0.00010099917,0.00010906306,0.82958317,0.00075930543,0.00021333451,0.000056704135],"about_ca_topic_score_codex":0.000030478937,"about_ca_topic_score_gemma":5.391901e-8,"teacher_disagreement_score":0.14095984,"about_ca_system_score_codex":0.000034864985,"about_ca_system_score_gemma":0.00006575315,"threshold_uncertainty_score":0.25976062},"labels":[],"label_agreement":null},{"id":"W2944546179","doi":"10.1038/s41568-019-0145-5","title":"Going to extremes: determinants of extraordinary response and survival in patients with cancer","year":2019,"lang":"en","type":"review","venue":"Nature reviews. Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Disease; Cancer; Outcome (game theory); Intensive care medicine; Internal medicine","score_opus":0.048015793666906344,"score_gpt":0.39600519899684516,"score_spread":0.34798940532993883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944546179","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005762699,0.9890161,6.630261e-7,0.000053109816,0.000687045,0.004165283,0.00022154435,0.000012428985,0.00008112464],"genre_scores_gemma":[0.00018126731,0.99756646,0.00011933268,0.00032643226,0.00013424152,0.00054011354,0.000030148864,0.00009881179,0.0010031954],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99689686,0.0004057292,0.0010955638,0.000735255,0.00045783314,0.00040872855],"domain_scores_gemma":[0.99807304,0.00024551497,0.0007284382,0.00066007057,0.00014810641,0.00014481097],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009563076,0.00063744193,0.0039812583,0.00041759296,0.000030380812,0.000014451946,0.00023003692,0.00066636683,0.00020364422],"category_scores_gemma":[0.00015738797,0.00039772905,0.00040299646,0.0009805956,0.00008010851,0.00008643773,0.00007931748,0.00092736987,0.000010261671],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045831646,0.00007181596,0.02071459,0.04792522,0.00017085393,0.000014023295,0.00006610139,6.6090706e-8,0.0000044847843,4.4309766e-7,0.0010166945,0.92543256],"study_design_scores_gemma":[0.0015865258,0.00040182713,0.020302542,0.1730797,0.0008484678,0.000009222736,0.000003922065,2.4146794e-7,0.0000025770887,1.7274421e-7,0.8033973,0.00036750975],"about_ca_topic_score_codex":0.00013387475,"about_ca_topic_score_gemma":0.00042708602,"teacher_disagreement_score":0.92506504,"about_ca_system_score_codex":0.000633825,"about_ca_system_score_gemma":0.0010085058,"threshold_uncertainty_score":0.9998475},"labels":[],"label_agreement":null},{"id":"W2945057866","doi":"10.1038/s41568-019-0144-6","title":"Tertiary lymphoid structures in the era of cancer immunotherapy","year":2019,"lang":"en","type":"review","venue":"Nature reviews. Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1784,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Labex Immuno-Oncology; Sorbonne Université; Institut National de la Santé et de la Recherche Médicale; Institute of Cancer Research; Institut National Du Cancer; Association pour la Recherche sur le Cancer","keywords":"Immunotherapy; Cancer immunotherapy; Medicine; Cancer; Immunology; Internal medicine","score_opus":0.03471973675741632,"score_gpt":0.4036705072742845,"score_spread":0.3689507705168682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945057866","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003341615,0.99251634,9.122049e-7,0.0005676636,0.0016265332,0.004711389,0.00019098788,0.00003152852,0.00032124305],"genre_scores_gemma":[0.000031317068,0.99176735,0.00006801942,0.0054572327,0.00080063107,0.0012673864,0.00010288906,0.00015789954,0.0003473025],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961128,0.0005126209,0.0015941135,0.00067853095,0.0006211748,0.00048073108],"domain_scores_gemma":[0.99704236,0.0002386863,0.0012002656,0.0013527487,0.00010897874,0.000056991626],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009044133,0.0008356902,0.00417875,0.00024116905,0.00004278752,0.000030436517,0.0008381976,0.0012528237,0.0009976384],"category_scores_gemma":[0.000052937572,0.00042230924,0.0018571088,0.0011915442,0.00015869712,0.00007832537,0.000047621375,0.002656463,0.000013081338],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001881904,0.000057164252,0.00024777668,0.042974774,0.00066643144,0.000009435699,0.00016401865,1.9724867e-7,0.000029135883,0.000025119138,0.010188254,0.94544953],"study_design_scores_gemma":[0.0011945029,0.00006531036,0.0006496858,0.07433224,0.0013924186,0.00009647336,0.000011326508,3.7105244e-7,0.000015701213,0.000011442705,0.9218257,0.00040483053],"about_ca_topic_score_codex":0.0009847354,"about_ca_topic_score_gemma":0.00029781405,"teacher_disagreement_score":0.9450447,"about_ca_system_score_codex":0.00074264174,"about_ca_system_score_gemma":0.0016536678,"threshold_uncertainty_score":0.9999156},"labels":[],"label_agreement":null},{"id":"W2945884255","doi":"10.3390/cancers11050714","title":"Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy","year":2019,"lang":"en","type":"review","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Rural Affairs; Cancer Moonshot; Rexanna's Foundation; Moonshot Research and Development Program; LUNGevity Foundation; University of Texas MD Anderson Cancer Center; Cancer Prevention and Research Institute of Texas; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"Immunotherapy; Medicine; Epithelial–mesenchymal transition; Lung cancer; Cancer; Breast cancer; Melanoma; Metastasis; Cancer research; Cancer immunotherapy; Oncology; Cancer stem cell; Immunology; Internal medicine","score_opus":0.017832238606401443,"score_gpt":0.32858070690816404,"score_spread":0.3107484683017626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945884255","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000095347554,0.98440933,0.0013597053,0.0005431375,0.0013398165,0.011678898,0.0003198879,0.00005873546,0.00019512762],"genre_scores_gemma":[0.0021647175,0.9930611,0.00005920635,0.000384357,0.0009838532,0.002670909,0.00015100892,0.00012109106,0.0004037046],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99767566,0.00040668825,0.0007642074,0.0005060213,0.0002391878,0.00040821815],"domain_scores_gemma":[0.99726325,0.0014811379,0.00046200678,0.00061858166,0.00010635067,0.00006865905],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017171246,0.00051940663,0.0021444624,0.00013449385,0.00030086632,0.000077267025,0.0003361899,0.00027714658,0.00002035422],"category_scores_gemma":[0.000059267233,0.00025042513,0.0009897299,0.00035063495,0.00032975976,0.00005045309,0.00004151507,0.0004726991,0.000021012638],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002695712,0.0000036987074,0.0000017710181,0.016564626,0.0024431406,0.0000017956676,0.0015059963,0.000007137108,0.00013904349,0.00009277428,0.00044246292,0.9761018],"study_design_scores_gemma":[0.004744035,0.00040628,0.000017218634,0.023921143,0.0022806295,0.000051156305,0.00060997444,0.00004950684,0.0001197985,0.0000060827615,0.9674472,0.00034697112],"about_ca_topic_score_codex":0.0005544859,"about_ca_topic_score_gemma":0.000004970897,"teacher_disagreement_score":0.97575486,"about_ca_system_score_codex":0.0019483692,"about_ca_system_score_gemma":0.0006786588,"threshold_uncertainty_score":0.9999948},"labels":[],"label_agreement":null},{"id":"W2945998739","doi":"10.1158/1078-0432.ccr-19-0585","title":"Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":236,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Science and Technology Planning Project of Guangdong Province; National Key Research and Development Program of China; Sun Yat-sen University; National Natural Science Foundation of China","keywords":"Lung cancer; Medicine; Oncology; Internal medicine; Immunotherapy; Cancer; Copy-number variation; Cancer research; Gene; Biology; Genetics; Genome","score_opus":0.1172463546394366,"score_gpt":0.4609627422534374,"score_spread":0.3437163876140008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945998739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834629,0.0112720765,0.000018027786,0.0013248784,0.00093311403,0.0027527944,0.000083991035,0.000022584443,0.00012957392],"genre_scores_gemma":[0.9910864,0.0051751337,0.0003609245,0.00047915752,0.00033248737,0.0003226272,0.0000059653553,0.000060913346,0.0021763647],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99629164,0.000491383,0.0010757202,0.0007254059,0.0007228604,0.0006930192],"domain_scores_gemma":[0.99697244,0.0012955498,0.00016853434,0.00070063,0.00063228543,0.00023057169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027222876,0.00022832275,0.00077618106,0.0004990139,0.00007278147,0.0000381609,0.00043534389,0.00023964504,0.00059417204],"category_scores_gemma":[0.00018640707,0.00019489217,0.00024395791,0.0009013387,0.00042083114,0.000060278206,0.00023989352,0.0008393432,0.00003398605],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016302342,0.00021091539,0.4861114,0.0005203045,0.00016544532,0.000011877378,0.0009629649,0.00015522687,0.49295104,6.4310285e-7,0.00043737204,0.0021704766],"study_design_scores_gemma":[0.005979656,0.0009808459,0.94597685,0.0008403871,0.00004160662,0.0000024377948,0.0009574824,0.00038652742,0.040340394,0.000004927283,0.0042840946,0.00020481108],"about_ca_topic_score_codex":0.0034891386,"about_ca_topic_score_gemma":0.0004859866,"teacher_disagreement_score":0.45986545,"about_ca_system_score_codex":0.00044655442,"about_ca_system_score_gemma":0.0014932383,"threshold_uncertainty_score":0.7947472},"labels":[],"label_agreement":null},{"id":"W2946361462","doi":"10.1016/j.ctro.2019.05.001","title":"Computer-assisted image analysis of the tumor microenvironment on an oral tongue squamous cell carcinoma tissue microarray","year":2019,"lang":"en","type":"article","venue":"Clinical and Translational Radiation Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Princess Margaret Cancer Foundation","keywords":"Pathology; Tissue microarray; Tumor microenvironment; Stain; Immunohistochemistry; Medicine; Cytokeratin; Biology; Immune system; Staining; Immunology","score_opus":0.022415868483714282,"score_gpt":0.33496922307702437,"score_spread":0.3125533545933101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946361462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960747,0.00021584833,0.00017999753,0.002380087,0.00028000202,0.00035094444,0.000062869425,0.000007039133,0.0004485481],"genre_scores_gemma":[0.9968273,0.000027022294,0.0009903398,0.0017609952,0.000092859,0.000005252608,0.00014354257,0.000007590334,0.00014509543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987457,0.00021229376,0.0005251254,0.00026386848,0.00014677798,0.00010625158],"domain_scores_gemma":[0.99914795,0.000369727,0.00017925753,0.00019533219,0.00003323032,0.00007447981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032583717,0.00010036448,0.00038544319,0.00009162382,0.000046712637,0.000005976009,0.00007057527,0.00011145755,0.00045467442],"category_scores_gemma":[0.000008270447,0.000071311406,0.00022225195,0.00020716364,0.00021679241,0.000036630223,0.000008060283,0.0001439512,0.000010432876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035319694,0.0019122905,0.8322473,0.00004793042,0.0004065046,0.000008680901,0.00038970937,0.0002554561,0.04932747,0.00009263804,0.00025873265,0.111521326],"study_design_scores_gemma":[0.0049177413,0.0018244982,0.9745312,0.000004677047,0.00048965815,0.000008403892,0.000020782501,0.0026872735,0.0021963674,0.000013330131,0.013231089,0.00007499043],"about_ca_topic_score_codex":0.00004929123,"about_ca_topic_score_gemma":0.000057646022,"teacher_disagreement_score":0.14228389,"about_ca_system_score_codex":0.000035065445,"about_ca_system_score_gemma":0.00011686931,"threshold_uncertainty_score":0.4978366},"labels":[],"label_agreement":null},{"id":"W2946386783","doi":"10.1016/s1470-2045(19)30167-6","title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1681,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"F. Hoffmann-La Roche","keywords":"Carboplatin; Medicine; Paclitaxel; Atezolizumab; Chemotherapy; Oncology; Nab-paclitaxel; Open label; Internal medicine; Lung cancer; Cisplatin; Cancer; Randomized controlled trial; Nivolumab; Immunotherapy","score_opus":0.048483638906467647,"score_gpt":0.3745263839184664,"score_spread":0.3260427450119987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946386783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96768534,0.0011366642,0.0005747847,0.0072062244,0.00033774733,0.02202023,0.00008264299,0.000048754555,0.0009075878],"genre_scores_gemma":[0.9867935,0.001625546,0.0022427002,0.002967075,0.00028008406,0.0040318826,0.0001960679,0.0001121823,0.0017509314],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99742454,0.0002184191,0.000713366,0.0006279192,0.00028712663,0.0007285972],"domain_scores_gemma":[0.99759746,0.0008134393,0.00060436566,0.00068671687,0.00016855438,0.00012944343],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008126488,0.0005305943,0.0020577987,0.00014240602,0.00014968435,0.00006186465,0.00041415278,0.00016517162,0.0003009691],"category_scores_gemma":[0.000020889243,0.0003147473,0.00012890251,0.0004013135,0.00016897693,0.000112553185,0.000032862346,0.00026672045,0.0000090966505],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96773916,0.0068942425,0.0010051813,0.0003043417,0.0013081951,0.00006326105,0.0061034197,0.00030583754,0.0058303345,0.000008782099,0.00072054274,0.009716677],"study_design_scores_gemma":[0.926024,0.03383809,0.00055793393,0.00027515853,0.0006166384,0.000056270404,0.000587897,0.025125645,0.004592743,0.000017057639,0.007892759,0.000415774],"about_ca_topic_score_codex":0.00464751,"about_ca_topic_score_gemma":0.0066877445,"teacher_disagreement_score":0.04171515,"about_ca_system_score_codex":0.0016692925,"about_ca_system_score_gemma":0.0012568606,"threshold_uncertainty_score":0.99993044},"labels":[],"label_agreement":null},{"id":"W2946397648","doi":"10.1016/j.lungcan.2019.05.005","title":"Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"BC Cancer Foundation","keywords":"Medicine; Pembrolizumab; Clinical Practice; Oncology; Lung cancer; Internal medicine; Intensive care medicine; Cancer; Family medicine; Immunotherapy","score_opus":0.012976930031351913,"score_gpt":0.3767882010690081,"score_spread":0.3638112710376562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946397648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9312025,0.052170657,0.00014808027,0.005021975,0.0021163996,0.0033589108,0.00008764969,0.00006406461,0.0058298195],"genre_scores_gemma":[0.954983,0.02902815,0.0017890934,0.0052811224,0.00060154125,0.00048235577,0.00003002979,0.000084320964,0.0077203624],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980994,0.00007956887,0.0005926818,0.0005653325,0.00023298101,0.00043005365],"domain_scores_gemma":[0.9984113,0.0007098041,0.00023660986,0.0003700231,0.00013719684,0.00013504716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005547534,0.0002333591,0.000539505,0.000085185784,0.00006305052,0.00002262536,0.00011653542,0.00019179049,0.00041514295],"category_scores_gemma":[0.00012242315,0.00020475451,0.00015098818,0.000231214,0.0000728618,0.00021462631,0.00004316518,0.00034491866,0.0000051963834],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17782503,0.0010998168,0.49557084,0.0032192322,0.0011890548,0.00005322132,0.002002338,0.0004064187,0.021521434,0.00015013418,0.025581358,0.2713811],"study_design_scores_gemma":[0.06941635,0.0010271922,0.26722378,0.0015601914,0.0007315897,0.000032328357,0.0002593621,0.004933034,0.0014601079,0.000006213755,0.6526971,0.00065272884],"about_ca_topic_score_codex":0.0007896633,"about_ca_topic_score_gemma":0.00036733356,"teacher_disagreement_score":0.6271157,"about_ca_system_score_codex":0.0005327202,"about_ca_system_score_gemma":0.0006351893,"threshold_uncertainty_score":0.8349647},"labels":[],"label_agreement":null},{"id":"W2946430621","doi":"10.1016/s0167-8140(19)30648-6","title":"SP-0228 Circulating biomarkers tumor immune response","year":2019,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Immune system; Medicine; Immunology","score_opus":0.014339836315523451,"score_gpt":0.30174025437564994,"score_spread":0.2874004180601265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946430621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982451,0.010598112,0.00006552677,0.0034750495,0.00053950754,0.00056821096,0.000004379902,0.00007638208,0.00222179],"genre_scores_gemma":[0.9910989,0.000998653,0.0017616106,0.004397893,0.00017142242,0.00002212293,0.0000064119095,0.000042536543,0.0015004623],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99860084,0.00021423129,0.00036584397,0.00034420172,0.0001417644,0.00033310615],"domain_scores_gemma":[0.99906904,0.00031719843,0.00014258438,0.0003257488,0.00003560587,0.00010982595],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00091475697,0.00019107632,0.0005025462,0.00016830728,0.00009467766,0.000018853578,0.00008408893,0.0001656598,0.0014272343],"category_scores_gemma":[0.000036006597,0.00016228057,0.00016210864,0.00022575157,0.00018101347,0.00007074062,0.000017362585,0.0001872445,0.000027839229],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04267663,0.00016226374,0.021448163,0.000070098,0.0005523911,0.00013876849,0.00088005525,0.0000026069574,0.8362152,0.00006648256,0.0006179514,0.09716938],"study_design_scores_gemma":[0.018829582,0.005601369,0.4261462,0.00016048209,0.0000802977,0.0022094462,0.0006850443,0.0009470161,0.006185821,0.000043055155,0.5386806,0.00043106536],"about_ca_topic_score_codex":0.00009309099,"about_ca_topic_score_gemma":0.0000073231968,"teacher_disagreement_score":0.83002937,"about_ca_system_score_codex":0.0005341493,"about_ca_system_score_gemma":0.00027264474,"threshold_uncertainty_score":0.9994856},"labels":[],"label_agreement":null},{"id":"W2946456966","doi":"10.1016/j.jtho.2019.05.010","title":"Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":187,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; University of Ottawa; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"Astellas Pharma Global Development; Ipsen; Astellas Pharma; MedImmune; Daiichi-Sankyo; Celldex Therapeutics; Helsinn; University of Texas Southwestern Medical Center; Merck; Spectrum Pharmaceuticals; North Carolina GlaxoSmithKline Foundation; Novartis; Celgene; Pfizer; Biogen; GlaxoSmithKline; Roche; Takeda Pharmaceutical Company; AbbVie; Genentech; Aeglea BioTherapeutics; Biogen Idec; Merck Sharp and Dohme; Genzyme; Bayer Corporation; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Intuitive Surgical","keywords":"Medicine; Nivolumab; Clinical endpoint; Lung cancer; Quality of life (healthcare); Adverse effect; Internal medicine; Population; Incidence (geometry); Randomized controlled trial; Performance status; Cancer; Surgery; Immunotherapy; Nursing","score_opus":0.016731925908331845,"score_gpt":0.34291538502650565,"score_spread":0.3261834591181738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946456966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969937,0.0010347229,0.000008770741,0.00023789679,0.00018122251,0.0014700495,0.00002120641,0.000010532291,0.00004184887],"genre_scores_gemma":[0.99738103,0.000969771,0.0012063716,0.00025876108,0.00001806108,0.000011431107,0.000015685515,0.000042416472,0.000096485914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712527,0.00023498657,0.0013997174,0.00031593477,0.00049050973,0.00043357484],"domain_scores_gemma":[0.99635506,0.00017743604,0.002586812,0.00021477646,0.00039963945,0.00026625805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060902553,0.0002702206,0.0012057045,0.00028376,0.00007542903,0.000013098996,0.00009665858,0.00015537256,0.00006576015],"category_scores_gemma":[0.00005504561,0.00016073867,0.00004256045,0.00044484404,0.00016039873,0.00022439004,0.00006095552,0.00047333929,3.056268e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19796896,0.0006052357,0.712371,0.0006905146,0.00041666764,0.000035637917,0.0034003095,0.00014933001,0.00034759514,4.077715e-8,0.000030141648,0.08398455],"study_design_scores_gemma":[0.04344217,0.025012914,0.9276953,0.0021621978,0.00017545608,0.000053436335,0.0008296131,0.00008779568,0.00016856128,2.2619327e-7,0.00015190482,0.00022044516],"about_ca_topic_score_codex":0.00062993844,"about_ca_topic_score_gemma":0.0005908724,"teacher_disagreement_score":0.21532425,"about_ca_system_score_codex":0.0006377441,"about_ca_system_score_gemma":0.0016964388,"threshold_uncertainty_score":0.65547323},"labels":[],"label_agreement":null},{"id":"W2946531823","doi":"10.1016/s0167-8140(19)30873-4","title":"SP-0453 Targeting DNA repair to improve immunesurveillance and restrict cancer growth","year":2019,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"DNA; Cancer research; Computational biology; Medicine; Biology; Genetics","score_opus":0.008693742317565176,"score_gpt":0.29030860047688956,"score_spread":0.28161485815932435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946531823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9659496,0.026559453,0.000046819932,0.004835972,0.0007181608,0.00069800555,0.000012065286,0.00009284088,0.0010870867],"genre_scores_gemma":[0.9533167,0.030882873,0.002739544,0.009810773,0.0006475666,0.00009019546,0.000009096014,0.000055849352,0.0024474154],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99871755,0.000089505804,0.00030505075,0.00043976377,0.00011536748,0.00033274642],"domain_scores_gemma":[0.9993215,0.00015320933,0.00010449722,0.00022329159,0.000059329974,0.00013812764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046028453,0.00019185827,0.00050488557,0.000108940556,0.000086496126,0.000016685839,0.00006654156,0.0001845842,0.00028823718],"category_scores_gemma":[0.00003367134,0.00015702254,0.00009385288,0.00021398757,0.00010389759,0.00006151513,0.000026710895,0.00017654024,0.0000056549516],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009137491,0.00011952982,0.23862596,0.00021191717,0.00047129154,0.000045464527,0.001435744,0.0000017773802,0.6107337,0.00016446957,0.0075590634,0.13149357],"study_design_scores_gemma":[0.009818507,0.004821648,0.37618348,0.00011852515,0.00004923694,0.00017429964,0.00026527047,0.00028643737,0.006759406,0.00004518727,0.6010532,0.0004248033],"about_ca_topic_score_codex":0.0007440963,"about_ca_topic_score_gemma":0.000091773945,"teacher_disagreement_score":0.6039743,"about_ca_system_score_codex":0.00034847175,"about_ca_system_score_gemma":0.00017598497,"threshold_uncertainty_score":0.64031935},"labels":[],"label_agreement":null},{"id":"W2946620901","doi":"10.1016/j.ccell.2019.04.003","title":"Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation","year":2019,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Comisión Sectorial de Investigación Científica; Wellcome Trust; Agence Universitaire de la Francophonie; Universidad de la República Uruguay; Fundação de Amparo à Pesquisa do Estado de São Paulo; Agencia Nacional de Investigación e Innovación","keywords":"Inflammasome; Immunity; Immune system; Immune checkpoint; Cancer research; Immunology; Pharmacology; Medicine; Inflammation; Immunotherapy","score_opus":0.00848900030737249,"score_gpt":0.2534903114946767,"score_spread":0.24500131118730423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946620901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98693395,0.010712505,0.000016205913,0.00055824145,0.00028495767,0.00055639347,0.000008968721,0.000022631277,0.00090617704],"genre_scores_gemma":[0.99550825,0.0031701608,0.00006773352,0.00015999406,0.000078082434,0.00002119742,0.00002712573,0.000020398733,0.0009470433],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99895096,0.000049883813,0.0003733518,0.00020273737,0.00021150206,0.00021154173],"domain_scores_gemma":[0.99920666,0.00010528169,0.00030387007,0.00027707004,0.000065061475,0.00004203276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036654007,0.00015476554,0.00026899352,0.000032891927,0.000106779895,0.00002129348,0.00012969684,0.00006258624,0.00039267502],"category_scores_gemma":[0.000029031291,0.000110032764,0.00009233357,0.00016191945,0.00012547195,0.00015847263,0.000052298063,0.00019058079,0.000005172258],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092033984,0.000070779475,0.007982583,0.00020510236,0.00011516199,4.425072e-7,0.0009256747,0.000010039485,0.98512095,0.0000023124496,0.00035226528,0.004294348],"study_design_scores_gemma":[0.0031617137,0.00016494763,0.04155178,0.0003396276,0.000056523204,0.0000015950826,0.0011213842,0.000096895965,0.9471026,0.000003919632,0.00626056,0.00013843803],"about_ca_topic_score_codex":0.0019271962,"about_ca_topic_score_gemma":0.000009202507,"teacher_disagreement_score":0.038018335,"about_ca_system_score_codex":0.00015395969,"about_ca_system_score_gemma":0.000105010564,"threshold_uncertainty_score":0.44870058},"labels":[],"label_agreement":null},{"id":"W2946850150","doi":"10.1200/jco.2019.37.15_suppl.1086","title":"Hyperprogressive disease in advanced triple-negative breast cancer (aTNBC) treated with immunotherapy (IO).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Clinical trial; Confidence interval; Progressive disease; Cancer; Hazard ratio; Breast cancer; Disease; Oncology; Surgery","score_opus":0.03563998643533165,"score_gpt":0.42339137601618504,"score_spread":0.38775138958085337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946850150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877048,0.003022888,0.000006144832,0.007165166,0.00072845427,0.0006068073,0.000021803447,0.000010826746,0.0007330738],"genre_scores_gemma":[0.9908029,0.0048907176,0.00059395574,0.0024518762,0.00038900683,0.00002320794,0.0000029880987,0.000030385188,0.00081495673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970316,0.00034172632,0.0017286564,0.00025536318,0.00035695886,0.00028567368],"domain_scores_gemma":[0.9965038,0.0008713738,0.0016419325,0.00023983217,0.00043321468,0.0003098888],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010820011,0.00020504615,0.0015281386,0.00017231533,0.00002539749,0.000009115441,0.00017005026,0.00023357922,0.00094116124],"category_scores_gemma":[0.000249092,0.00012244681,0.00045756967,0.0003487915,0.0002787878,0.00019249953,0.000016019703,0.00080834277,0.00001367808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19523822,0.0013867264,0.5747299,0.000022312806,0.0006015486,0.0005487945,0.00009829676,0.00002817029,0.00081491284,0.0000053608405,0.00019518952,0.22633055],"study_design_scores_gemma":[0.05106142,0.010271212,0.9270616,0.00064658676,0.00017145103,0.00023571127,0.00017453567,0.000057335514,0.00013919297,0.000041771862,0.009984801,0.00015434698],"about_ca_topic_score_codex":0.00019900406,"about_ca_topic_score_gemma":0.00012080849,"teacher_disagreement_score":0.35233173,"about_ca_system_score_codex":0.00039084905,"about_ca_system_score_gemma":0.0025653564,"threshold_uncertainty_score":0.9999721},"labels":[],"label_agreement":null},{"id":"W2946988148","doi":"10.1016/j.lungcan.2019.05.027","title":"Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer","year":2019,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Juravinski Cancer Centre; McMaster University; Vancouver Hospital and Health Sciences Centre; University of Toronto; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"Merck Canada; AstraZeneca Canada","keywords":"Durvalumab; Medicine; Oncology; Lung cancer; Pneumonitis; Internal medicine; Chemoradiotherapy; Context (archaeology); Clinical trial; Adverse effect; Cancer; Nivolumab; Immunotherapy; Lung","score_opus":0.019804051459983922,"score_gpt":0.3242405323665668,"score_spread":0.3044364809065829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946988148","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037232072,0.98890567,0.0000080272,0.00013497671,0.0017459224,0.0032211416,0.00016428927,0.000046542646,0.002050208],"genre_scores_gemma":[0.0004875466,0.9726162,0.0000359702,0.00016205684,0.0007264881,0.0009556658,0.00017288029,0.00015212227,0.024691066],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970784,0.00007805041,0.0010513798,0.00080406875,0.00033487557,0.0006532174],"domain_scores_gemma":[0.998409,0.00008638139,0.00066743384,0.0006101114,0.000081520484,0.00014558288],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004605832,0.0006607216,0.0022143235,0.0003868545,0.000075268275,0.00006578476,0.00021326283,0.00057059625,0.0010282967],"category_scores_gemma":[0.000012947314,0.000557395,0.00050767587,0.0007367854,0.00007146882,0.000139702,0.0000979864,0.000774708,0.000009592742],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010452826,0.00019957431,0.006251302,0.20552127,0.0014063299,0.00006647737,0.0011338252,0.000026709135,0.0016091614,0.00000422905,0.008115609,0.77462023],"study_design_scores_gemma":[0.0056577157,0.00009173268,0.00070771924,0.04159258,0.0018869067,0.000011321618,0.000065156135,0.0004949918,0.00085004023,4.1116462e-7,0.9478544,0.0007870218],"about_ca_topic_score_codex":0.012917148,"about_ca_topic_score_gemma":0.0013284115,"teacher_disagreement_score":0.9397388,"about_ca_system_score_codex":0.0022430979,"about_ca_system_score_gemma":0.0019885164,"threshold_uncertainty_score":0.9998849},"labels":[],"label_agreement":null},{"id":"W2946993394","doi":"10.1200/jco.2019.37.15_suppl.e16038","title":"Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Rash; Adverse effect; Cancer; Lung cancer; Oncology; Gastroenterology","score_opus":0.028234575770547898,"score_gpt":0.3466008892436285,"score_spread":0.3183663134730806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946993394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969891,0.0001485842,0.0000063376942,0.0007758975,0.0006236321,0.000983482,0.000013997951,0.000010239481,0.00044877332],"genre_scores_gemma":[0.9982195,0.00013791947,0.0006997637,0.00023934689,0.000116653835,0.000011977851,0.000017793242,0.000046625486,0.0005104214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99129146,0.00074536446,0.006345461,0.000335966,0.0009084976,0.00037326282],"domain_scores_gemma":[0.9893834,0.0016134684,0.007475888,0.00034585546,0.000957116,0.0002242809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005948207,0.00030270166,0.0026820556,0.0002952351,0.00003047049,0.0000044068206,0.00020765506,0.0004969639,0.00024542576],"category_scores_gemma":[0.0009615298,0.00017652623,0.0008475496,0.0005125122,0.00023979551,0.00021631963,0.000038151396,0.0013487375,0.000013591378],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11908585,0.0034528198,0.8649791,0.00004618539,0.002413632,0.000115983705,0.00010534932,0.00006781475,0.00012210601,0.0000030899034,0.00003763586,0.009570448],"study_design_scores_gemma":[0.08143011,0.045159735,0.87049276,0.00060754,0.0011428236,0.000054415435,0.00016412933,0.000033711647,0.00026988838,0.00001155541,0.00044780227,0.00018553295],"about_ca_topic_score_codex":0.0003330813,"about_ca_topic_score_gemma":0.0001962878,"teacher_disagreement_score":0.041706912,"about_ca_system_score_codex":0.00057599746,"about_ca_system_score_gemma":0.0015440244,"threshold_uncertainty_score":0.7198531},"labels":[],"label_agreement":null},{"id":"W2947026438","doi":"10.1200/jco.2019.37.15_suppl.6000","title":"Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Cetuximab; Carboplatin; Population; Head and neck squamous-cell carcinoma; Pembrolizumab; Internal medicine; Interim analysis; Cisplatin; Oncology; Head and neck cancer; Urology; Nuclear medicine; Radiation therapy; Randomized controlled trial; Surgery; Cancer; Chemotherapy; Immunotherapy","score_opus":0.18097689072096435,"score_gpt":0.4906753055908003,"score_spread":0.30969841486983596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947026438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977633,0.00047535024,0.000068826295,0.0021061643,0.0009093439,0.018297708,0.000035893223,0.0000035943788,0.00047011283],"genre_scores_gemma":[0.9968789,0.00030060252,0.0006707556,0.00067248207,0.00046481285,0.0006580906,0.000006148642,0.000021263322,0.00032693215],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949431,0.00052449235,0.0035092356,0.00027284762,0.00049539894,0.00025493526],"domain_scores_gemma":[0.9918463,0.0030665887,0.0039233896,0.00042117946,0.0005637101,0.00017879314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029563224,0.00022166164,0.0024944367,0.0002870047,0.000049151033,0.0000086378595,0.0002933016,0.00027814286,0.00040627338],"category_scores_gemma":[0.0010373964,0.00012853589,0.0018341598,0.0005164907,0.00032184774,0.000070907394,0.000041364732,0.00057769223,0.0000013931065],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89593726,0.008069726,0.009284534,0.00024163057,0.0013667891,0.000018954399,0.00018114156,0.000017867917,0.0014577961,0.00002182714,0.0009655537,0.082436904],"study_design_scores_gemma":[0.6317196,0.20180285,0.077050336,0.00011609033,0.0023350876,0.000060469825,0.000087148605,0.0006318841,0.0018048729,0.00015022738,0.08409066,0.00015077199],"about_ca_topic_score_codex":0.00005265082,"about_ca_topic_score_gemma":0.00007366473,"teacher_disagreement_score":0.26421767,"about_ca_system_score_codex":0.00010381353,"about_ca_system_score_gemma":0.0016241582,"threshold_uncertainty_score":0.5241542},"labels":[],"label_agreement":null},{"id":"W2947197208","doi":"10.1200/jco.2019.37.15_suppl.e20506","title":"Pembrolizumab (Pem) for advanced non-small cell lung cancer (aNSCLC): Efficacy and safety in everyday clinical practice.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Hazard ratio; Proportional hazards model; Cohort; Population; Adverse effect; Pembrolizumab; Cancer; Gastroenterology; Oncology; Confidence interval; Immunotherapy","score_opus":0.05864685892664957,"score_gpt":0.4779817900254512,"score_spread":0.41933493109880166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947197208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755858,0.0053927284,0.00030465279,0.010211323,0.0038489276,0.0011725598,0.000008208678,0.000007682526,0.0034680932],"genre_scores_gemma":[0.9511991,0.024908883,0.01216935,0.008608946,0.0017040673,0.00002034188,0.0000035372896,0.00004305535,0.0013426896],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9946265,0.0005082785,0.00385907,0.000367385,0.00027733436,0.0003614163],"domain_scores_gemma":[0.98550683,0.011001954,0.002421046,0.00026376557,0.0004728803,0.00033350708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075637777,0.00020198322,0.0019594955,0.00013112673,0.000036060723,0.00001189604,0.00019501388,0.0006355663,0.00018187615],"category_scores_gemma":[0.0037607385,0.00014934315,0.00066736556,0.00016013972,0.00017851913,0.00020921303,0.00005234015,0.0013664181,0.000006672197],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29781172,0.0034693908,0.21221866,0.0002819759,0.0008104541,0.00021019319,0.00031075318,0.00006216735,0.0014700585,0.000019143665,0.005779417,0.47755605],"study_design_scores_gemma":[0.10076344,0.018064307,0.4940814,0.00043636435,0.000562719,0.00017838637,0.0002192018,0.00037101793,0.0000850103,0.00002267545,0.3850369,0.00017856609],"about_ca_topic_score_codex":0.000044128654,"about_ca_topic_score_gemma":0.00007854453,"teacher_disagreement_score":0.4773775,"about_ca_system_score_codex":0.0002826488,"about_ca_system_score_gemma":0.0029979006,"threshold_uncertainty_score":0.60900366},"labels":[],"label_agreement":null},{"id":"W2947202175","doi":"10.1200/jco.2019.37.15_suppl.9514","title":"Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cohort; Pembrolizumab; Ipilimumab; Discontinuation; Metastatic melanoma; Internal medicine; Melanoma; Tolerability; Toxicity; Oncology; Surgery; Cancer; Adverse effect; Immunotherapy; Cancer research","score_opus":0.05677921057621099,"score_gpt":0.4489293667916658,"score_spread":0.3921501562154548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947202175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905531,0.0009624462,0.00006638887,0.0012570675,0.002185921,0.00049141253,0.000037978796,0.000012103806,0.0044335835],"genre_scores_gemma":[0.99497193,0.0020786421,0.0008889243,0.0011794518,0.000452864,0.0000063581156,0.000014922172,0.00003180889,0.0003750702],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9931315,0.00057217956,0.0046029664,0.0003990987,0.0008665731,0.00042767668],"domain_scores_gemma":[0.9936608,0.0018326712,0.0030339276,0.00051348517,0.0006322208,0.0003268625],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0047578467,0.00027907226,0.0039848797,0.00084953505,0.00002855903,0.000011873305,0.00039082387,0.00057564536,0.0012782008],"category_scores_gemma":[0.001250469,0.00021389044,0.0016196676,0.00091324735,0.00032443836,0.00020998488,0.00008802785,0.0012608212,0.000017499924],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43696696,0.0019284111,0.42426223,0.00009741171,0.008288861,0.0010226384,0.00028082458,0.0006003319,0.004885264,0.00005467375,0.00057840516,0.12103398],"study_design_scores_gemma":[0.09893372,0.027657969,0.84871995,0.00026300916,0.0032326502,0.00025425444,0.00025236874,0.0010214609,0.00084940396,0.00012714883,0.018401502,0.0002865479],"about_ca_topic_score_codex":0.00020107476,"about_ca_topic_score_gemma":0.00036749558,"teacher_disagreement_score":0.42445773,"about_ca_system_score_codex":0.0008233792,"about_ca_system_score_gemma":0.0032669099,"threshold_uncertainty_score":0.99963474},"labels":[],"label_agreement":null},{"id":"W2947265946","doi":"10.1200/jco.2019.37.15_suppl.2507","title":"Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Nivolumab; Pharmacodynamics; Pharmacokinetics; Lymphoma; Gastroenterology; Oncology; Cancer; Immunotherapy","score_opus":0.061459076868332324,"score_gpt":0.4461295254891137,"score_spread":0.38467044862078137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947265946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979578,0.00008410881,0.00001245479,0.00035436067,0.00036278786,0.00096041855,0.0000025512293,0.0000038588187,0.00026163983],"genre_scores_gemma":[0.99870044,0.000100992904,0.00058637623,0.00041184685,0.000050163133,0.000010295709,0.0000042578654,0.000020434582,0.00011516841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99609435,0.0004023076,0.0025262865,0.0002178861,0.0005300686,0.0002291187],"domain_scores_gemma":[0.99640113,0.0007345208,0.0021506867,0.00021440018,0.00036683804,0.00013240776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017194847,0.00016902578,0.0017108833,0.00032120047,0.000013811829,0.000005094504,0.0001483052,0.00011273003,0.00012700945],"category_scores_gemma":[0.00041949033,0.000098282304,0.00012390039,0.00044164967,0.00015254632,0.00019113277,0.00002164572,0.00045815663,0.0000035621074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23393944,0.046674322,0.62394685,0.00007856126,0.00038881096,0.0007117438,0.00074411393,0.000097883734,0.00007518802,0.000003620024,0.000097228185,0.09324224],"study_design_scores_gemma":[0.21947807,0.23267077,0.54494697,0.0004914854,0.00013953912,0.00009353078,0.0013523892,0.00008743888,0.00007039791,0.000017463848,0.0005559422,0.00009601072],"about_ca_topic_score_codex":0.00007033488,"about_ca_topic_score_gemma":0.0008092428,"teacher_disagreement_score":0.18599644,"about_ca_system_score_codex":0.00032221602,"about_ca_system_score_gemma":0.0012776583,"threshold_uncertainty_score":0.4007836},"labels":[],"label_agreement":null},{"id":"W2947266573","doi":"10.1200/jco.2019.37.15_suppl.e14125","title":"Real-life use of nivolumab and pembrolizumab in four adult university teaching hospitals in Québec, Canada.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; McGill University; Centre Hospitalier de l’Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke; Centre hospitalier universitaire de Québec","funders":"","keywords":"Nivolumab; Pembrolizumab; Medicine; Discontinuation; Adverse effect; Population; Melanoma; Internal medicine; Renal cell carcinoma; Lung cancer; Cancer; Oncology; Immunotherapy","score_opus":0.04672971601381915,"score_gpt":0.3583926393468246,"score_spread":0.31166292333300544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947266573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99072504,0.00018814072,0.0000030152432,0.0076150126,0.00036253387,0.00012470479,0.0000029337405,0.000001609539,0.0009770215],"genre_scores_gemma":[0.9962981,0.0017045864,0.00032833,0.0011633472,0.000081116166,1.11240745e-7,3.8543763e-7,0.000006341595,0.00041771602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979645,0.00036398627,0.0012196475,0.000118173244,0.00019175834,0.00014195264],"domain_scores_gemma":[0.9972834,0.0014293656,0.0008743249,0.00011715653,0.00014247678,0.00015326646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013907007,0.00007723339,0.00095492136,0.00013840871,0.000012176377,0.000002526567,0.00009119095,0.00019954647,0.00004890621],"category_scores_gemma":[0.00178731,0.00006367486,0.00013776707,0.00009511919,0.000093914845,0.00011919677,0.000030477935,0.00071813416,4.7110882e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019897023,0.00027276995,0.95245725,0.00003772857,0.00013508927,0.0005149745,0.00014233863,0.000010124545,0.00025589054,0.000047519938,0.0034585076,0.022770789],"study_design_scores_gemma":[0.016204651,0.003172879,0.95116895,0.00019790421,0.00004586412,0.00008571693,0.000369692,0.000104075974,0.00000812087,0.000006894576,0.028574469,0.000060805094],"about_ca_topic_score_codex":0.7036803,"about_ca_topic_score_gemma":0.8366692,"teacher_disagreement_score":0.13298891,"about_ca_system_score_codex":0.0005979805,"about_ca_system_score_gemma":0.0071014888,"threshold_uncertainty_score":0.99852735},"labels":[],"label_agreement":null},{"id":"W2947279694","doi":"10.1186/s12935-019-0863-5","title":"The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis","year":2019,"lang":"en","type":"review","venue":"Cancer Cell International","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Key Research and Development Program of China; State Key Laboratory of Oncology in South China","keywords":"Medicine; Nasopharyngeal carcinoma; Hazard ratio; Meta-analysis; Internal medicine; Confidence interval; Oncology; Cochrane Library; Gastroenterology; Radiation therapy","score_opus":0.04530429487191686,"score_gpt":0.3201657543416139,"score_spread":0.27486145946969703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947279694","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015992369,0.99564004,0.0000049330592,0.000072900635,0.000080294936,0.0036723053,0.00019924472,0.0000046537484,0.00016571718],"genre_scores_gemma":[0.0045973617,0.9927516,0.00003448558,0.00014417936,0.000020281124,0.0011339177,0.000118218166,0.000025344676,0.0011746034],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9980113,0.00016996844,0.00083759567,0.00039899212,0.00043718654,0.00014494712],"domain_scores_gemma":[0.9982075,0.00031437134,0.0008657152,0.00035885503,0.00020216857,0.000051355062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034496584,0.00031027303,0.0029959676,0.00013035435,0.000032603602,0.000026904996,0.00021390045,0.000089078705,0.00021187894],"category_scores_gemma":[0.00003840825,0.00015144273,0.00055666803,0.00029733285,0.00010968345,0.00006778813,0.00005635552,0.00017821968,0.0000012573381],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031116637,0.00013000937,0.0026946168,0.94570214,0.04825309,0.000005283453,0.000073106305,6.081214e-7,0.000002201049,0.000004839745,0.00026208846,0.0025608577],"study_design_scores_gemma":[0.0018620125,0.00027430884,0.0031905212,0.09046452,0.8789547,0.000009395364,0.000028756003,0.000012335145,0.000011698397,0.000001799537,0.024776004,0.00041393714],"about_ca_topic_score_codex":0.00011787017,"about_ca_topic_score_gemma":0.000056595894,"teacher_disagreement_score":0.8552376,"about_ca_system_score_codex":0.00021184437,"about_ca_system_score_gemma":0.00022308901,"threshold_uncertainty_score":0.6175655},"labels":[],"label_agreement":null},{"id":"W2947290320","doi":"10.1634/theoncologist.2019-0027","title":"Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Toronto; University Health Network; Royal Victoria Hospital; University of Alberta; Royal Victoria Regional Health Centre; Juravinski Cancer Centre; Montreal General Hospital; McMaster University; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Pembrolizumab; Medicine; Atezolizumab; Oncology; Lung cancer; Internal medicine; Nivolumab; Bevacizumab; Pemetrexed; Anaplastic lymphoma kinase; Chemotherapy; Ipilimumab; Cancer; Immunotherapy; Cisplatin","score_opus":0.029609471225638256,"score_gpt":0.3227680076414282,"score_spread":0.2931585364157899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947290320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975667,0.0009138962,0.00006839034,0.012123469,0.0007327239,0.0011475995,0.000012424867,0.000045919092,0.009288603],"genre_scores_gemma":[0.9903433,0.00045957093,0.00012645066,0.001992748,0.000103606246,0.00015531972,0.000013104674,0.000020896508,0.0067850323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899036,0.000036246063,0.0003363287,0.00021553182,0.00015273022,0.00026880528],"domain_scores_gemma":[0.99921125,0.00019544661,0.00013311928,0.00036228777,0.000051763534,0.000046157373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044790964,0.0001549798,0.00032593563,0.000080148064,0.00009711964,0.000021470078,0.00017568422,0.00010576932,0.00043889912],"category_scores_gemma":[0.00003455734,0.000097168944,0.00012933345,0.00027019007,0.00011010334,0.00004034645,0.0000652258,0.00028431832,0.00006248389],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011612569,0.0011617824,0.9651487,0.0004578355,0.00016177965,0.000030725372,0.0022539445,0.00029857282,0.019803638,0.0000843875,0.0043237302,0.005113634],"study_design_scores_gemma":[0.018294044,0.0008263615,0.9397931,0.00056407176,0.00015479328,0.000013753264,0.0011562126,0.0019299933,0.0075415093,0.00008711338,0.029258525,0.00038053968],"about_ca_topic_score_codex":0.002545775,"about_ca_topic_score_gemma":0.0034594757,"teacher_disagreement_score":0.02535563,"about_ca_system_score_codex":0.00060686556,"about_ca_system_score_gemma":0.00021437356,"threshold_uncertainty_score":0.48056376},"labels":[],"label_agreement":null},{"id":"W2947320935","doi":"10.1200/jco.2019.37.15_suppl.3512","title":"CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Centre Hospitalier de l’Université de Montréal; University of Toronto; Hôpital Charles-Le Moyne; University of Saskatchewan; Université de Montréal; Hôpital du Sacré-Cœur de Montréal; University of Ottawa; McGill University; Saskatchewan Cancer Agency; University Health Network; Ottawa Hospital; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Nova Scotia Cancer Centre; Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; Moncton Hospital","funders":"","keywords":"Medicine; Hazard ratio; Durvalumab; Internal medicine; Confidence interval; Clinical endpoint; Tremelimumab; Gastroenterology; Microsatellite instability; Immunotherapy; Randomized controlled trial; Oncology; Cancer; Microsatellite; Allele; Genetics; Nivolumab; Biology","score_opus":0.04624605588599972,"score_gpt":0.4041748008360857,"score_spread":0.357928744950086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947320935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99829197,0.00041509356,0.0000018163562,0.000049956692,0.00013908975,0.0009618194,0.00011570183,0.0000033809301,0.000021194142],"genre_scores_gemma":[0.9994412,0.00020320286,0.00022369284,0.000012136249,0.0000342583,0.0000052509395,0.000059770227,0.000016659464,0.000003794467],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99575335,0.0007532799,0.002585034,0.00031887062,0.0003626697,0.00022681238],"domain_scores_gemma":[0.9952461,0.0014118883,0.0024317107,0.00016576961,0.0005508552,0.00019364478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017208093,0.00021852257,0.0023540934,0.00053574133,0.000025723182,0.000007957434,0.00007465275,0.0002084578,0.00008427894],"category_scores_gemma":[0.0008209632,0.00015585512,0.0002980156,0.0005364323,0.0004944438,0.00016529068,0.00003552364,0.0005215769,2.5982192e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70248914,0.0030679456,0.26069602,0.00009582189,0.0018623782,0.00015195349,0.0028847589,0.000013263733,0.005507631,8.273055e-8,0.0000033363235,0.02322765],"study_design_scores_gemma":[0.32552463,0.15630654,0.51311624,0.00007070891,0.0013324734,0.000031903106,0.0018576548,0.00029111648,0.0013529108,0.0000016954939,0.0000143077605,0.000099812016],"about_ca_topic_score_codex":0.0014506262,"about_ca_topic_score_gemma":0.0016857174,"teacher_disagreement_score":0.3769645,"about_ca_system_score_codex":0.000584177,"about_ca_system_score_gemma":0.0016363157,"threshold_uncertainty_score":0.6355587},"labels":[],"label_agreement":null},{"id":"W2947334480","doi":"10.1200/jco.2019.37.15_suppl.tps5597","title":"CALLA: Efficacy and safety of durvalumab with and following concurrent chemoradiotherapy (CCRT) versus CCRT alone in women with locally advanced cervical cancer: A phase III, randomized, double-blind, multicenter study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Durvalumab; Cervical cancer; Internal medicine; Clinical endpoint; Oncology; Cancer; Radiation therapy; Chemoradiotherapy; Urology; Randomized controlled trial; Nivolumab; Immunotherapy","score_opus":0.05282560527458163,"score_gpt":0.4371832909920048,"score_spread":0.3843576857174232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947334480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99228483,0.00296077,0.000094716066,0.0015253772,0.0006998143,0.0023282378,0.000002843909,0.0000064174214,0.000097007796],"genre_scores_gemma":[0.99474424,0.0038436076,0.0005535428,0.0005763906,0.00017274129,0.000045569966,0.000001297565,0.000026784921,0.000035813297],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960888,0.00041746456,0.002355436,0.00034318777,0.00047119934,0.00032388876],"domain_scores_gemma":[0.99569327,0.002099571,0.0014458207,0.00019998687,0.0002402372,0.0003211189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003626851,0.00025821378,0.003640527,0.0001476654,0.00003089303,0.00001207322,0.00012921132,0.00022193197,0.00011401365],"category_scores_gemma":[0.0001818371,0.00015317612,0.00022592668,0.00021506977,0.00047254836,0.00013315766,0.00003626361,0.00075321115,4.2919353e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.841618,0.0040412447,0.027703384,0.000062965184,0.0029357262,0.00022027851,0.0012846836,0.000036959067,0.00033961172,0.000001990911,0.000009975208,0.121745184],"study_design_scores_gemma":[0.9156161,0.04765339,0.032551553,0.000597435,0.00060729834,0.00007144914,0.0010588486,0.00017875586,0.000060123326,0.0000011241113,0.0014356134,0.0001683094],"about_ca_topic_score_codex":0.00017301788,"about_ca_topic_score_gemma":0.00044482254,"teacher_disagreement_score":0.121576875,"about_ca_system_score_codex":0.00035063075,"about_ca_system_score_gemma":0.0011819953,"threshold_uncertainty_score":0.6246341},"labels":[],"label_agreement":null},{"id":"W2947377968","doi":"10.1200/jco.2019.37.15_suppl.9561","title":"Correlation of immune-related adverse events with peripheral baseline immune markers and overall survival in patients with metastatic melanoma on ipilimumab and chemotherapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Ipilimumab; Internal medicine; Gastroenterology; Adverse effect; Melanoma; Rash; Immunotherapy; Cancer","score_opus":0.018448734506566245,"score_gpt":0.327820990103751,"score_spread":0.30937225559718473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947377968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99771094,0.00032221407,0.000032801334,0.00079688674,0.00036986553,0.0004507863,0.000004359727,0.0000034462073,0.00030869746],"genre_scores_gemma":[0.9980782,0.00046745906,0.000814948,0.00038386032,0.000029084917,0.0000015459444,0.0000098209275,0.000021141339,0.00019389068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99700814,0.0004191304,0.001861738,0.00018870854,0.0003575972,0.00016468651],"domain_scores_gemma":[0.99707055,0.00081949425,0.0016316602,0.00015824188,0.00021009258,0.00010996206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025137626,0.00017110254,0.0012605555,0.00014596534,0.000018024097,0.000002445853,0.000066236156,0.0001756211,0.00022293265],"category_scores_gemma":[0.0002115583,0.0001059345,0.00017137018,0.00013953114,0.00018767177,0.00013351357,0.000016048247,0.0005406974,0.0000011793958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18475506,0.0012751926,0.7829176,0.000048838676,0.0008686264,0.00003212809,0.0001539684,0.0000942174,0.00013405917,0.0000089890445,0.000013890278,0.029697392],"study_design_scores_gemma":[0.07779602,0.034674544,0.8856844,0.00042313573,0.00019538582,0.000049004837,0.00014875722,0.0005377982,0.0000139908625,0.000017923387,0.00035532308,0.00010373192],"about_ca_topic_score_codex":0.00006195577,"about_ca_topic_score_gemma":0.000027182126,"teacher_disagreement_score":0.10695904,"about_ca_system_score_codex":0.00012377185,"about_ca_system_score_gemma":0.00039104174,"threshold_uncertainty_score":0.43198836},"labels":[],"label_agreement":null},{"id":"W2947449715","doi":"10.1200/jco.2019.37.15_suppl.2599","title":"A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; University of Ottawa; University of Alberta; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Nausea; Avelumab; Adverse effect; Vomiting; Oncology; Gastroenterology; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.047685911572707365,"score_gpt":0.39437321195440667,"score_spread":0.3466873003816993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947449715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964267,0.00005020588,0.000018520359,0.001773716,0.00045842232,0.0009780588,0.0000011715986,0.0000025110417,0.0002906946],"genre_scores_gemma":[0.998197,0.000022051054,0.0007131849,0.000881506,0.000041938194,0.0000063687185,6.231122e-7,0.000012890058,0.00012441666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763507,0.00028408924,0.0013235743,0.00015296717,0.0004385247,0.00016574828],"domain_scores_gemma":[0.997465,0.0005034344,0.0013372686,0.00020756463,0.0003945348,0.00009218653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013081843,0.000109088076,0.000905383,0.00013650033,0.000023342809,0.000004734644,0.00018476523,0.000114452596,0.00005572972],"category_scores_gemma":[0.0003609193,0.000055982364,0.00012968128,0.00026703742,0.00008882941,0.000079938894,0.0000389273,0.000413129,0.0000028271568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039208066,0.0043960973,0.9013287,0.000023974846,0.00029052893,0.000028122968,0.0013314362,0.000049442708,0.0005426477,0.0000038727007,0.000080051796,0.05271708],"study_design_scores_gemma":[0.04602148,0.06167794,0.88943607,0.0004253974,0.00013090062,0.000018581015,0.0007212872,0.0000108622135,0.00015142947,0.00002054829,0.0013170486,0.00006845041],"about_ca_topic_score_codex":0.00006581252,"about_ca_topic_score_gemma":0.00040648394,"teacher_disagreement_score":0.05728184,"about_ca_system_score_codex":0.0002146003,"about_ca_system_score_gemma":0.00064140145,"threshold_uncertainty_score":0.22828946},"labels":[],"label_agreement":null},{"id":"W2947482799","doi":"10.1200/jco.2019.37.15_suppl.9014","title":"A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Nivolumab; Medicine; Ipilimumab; Internal medicine; Clinical endpoint; Lung cancer; Gastroenterology; Interim analysis; Response Evaluation Criteria in Solid Tumors; Biomarker; Phases of clinical research; Progression-free survival; Stage (stratigraphy); Oncology; Randomized controlled trial; Cancer; Immunotherapy; Clinical trial; Overall survival","score_opus":0.03816719068031371,"score_gpt":0.40792299775776353,"score_spread":0.3697558070774498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947482799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873433,0.0017584242,0.00007706542,0.00015515054,0.0019132299,0.008419235,0.00003456804,0.000020271478,0.00027875378],"genre_scores_gemma":[0.9978328,0.00033673758,0.00022868555,0.00020253423,0.00024875428,0.000136757,0.0000138058,0.000065662025,0.000934311],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934505,0.0010265955,0.0038263914,0.00052636035,0.000698847,0.00047125464],"domain_scores_gemma":[0.98886216,0.005155126,0.0039612446,0.0004308013,0.0012536905,0.00033698394],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045388867,0.00041807548,0.0042845695,0.0002736375,0.00010704829,0.000026085925,0.00025711127,0.00034691612,0.0001943133],"category_scores_gemma":[0.00087077694,0.00027438675,0.0006570784,0.00027466138,0.000276561,0.00021599987,0.000081673395,0.0006851032,0.0000024835606],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8686751,0.023066219,0.089876235,0.00033950416,0.0039189872,0.00008533798,0.0019509185,0.000018678222,0.00030047397,5.539975e-7,0.00127646,0.010491491],"study_design_scores_gemma":[0.8598092,0.11260597,0.018411163,0.00022607775,0.004175437,0.000010335483,0.0016644263,0.0013258267,0.000037838687,0.0000015823287,0.0014642284,0.00026787637],"about_ca_topic_score_codex":0.0009020496,"about_ca_topic_score_gemma":0.0006314191,"teacher_disagreement_score":0.08953975,"about_ca_system_score_codex":0.0005806678,"about_ca_system_score_gemma":0.0017395384,"threshold_uncertainty_score":0.99997085},"labels":[],"label_agreement":null},{"id":"W2947502981","doi":"10.1200/jco.2019.37.15_suppl.9584","title":"An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Adverse effect; Incidence (geometry); Internal medicine; Stage (stratigraphy); Clinical endpoint; Melanoma; Oncology; Clinical trial; Surgery; Cancer","score_opus":0.06504591594462274,"score_gpt":0.4566494913299082,"score_spread":0.39160357538528545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947502981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981808,0.000090237634,0.000014126434,0.0007794664,0.00043083128,0.0002926627,0.000013673476,0.0000074682957,0.0001907065],"genre_scores_gemma":[0.9970481,0.0009855125,0.00054225733,0.0006163764,0.00016500484,0.0000012393477,0.000019394862,0.000014116475,0.0006080466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99453294,0.0011295453,0.0033461016,0.0002545278,0.00050702406,0.00022986786],"domain_scores_gemma":[0.9914011,0.004062662,0.0035565447,0.00025880206,0.0004594622,0.00026143895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008383447,0.00013861271,0.0022663283,0.00042213572,0.000018080496,0.0000036092563,0.00015299393,0.0006065898,0.0004964359],"category_scores_gemma":[0.0030596482,0.00008786324,0.00047511738,0.0007811562,0.00013763149,0.00015146002,0.00002695285,0.000878699,0.000004696889],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09451724,0.0024593426,0.8893131,0.000022020185,0.0036235347,0.00015879699,0.0001435489,0.000040280644,0.0008412485,0.0000016872701,0.00010899394,0.008770179],"study_design_scores_gemma":[0.040809613,0.02294206,0.9305799,0.000121330144,0.0014796088,0.00001583564,0.00031224146,0.0013383598,0.000034153974,0.0000020873974,0.0022716399,0.000093151815],"about_ca_topic_score_codex":0.0001998645,"about_ca_topic_score_gemma":0.0013905856,"teacher_disagreement_score":0.053707626,"about_ca_system_score_codex":0.00029345145,"about_ca_system_score_gemma":0.0013112988,"threshold_uncertainty_score":0.5435625},"labels":[],"label_agreement":null},{"id":"W2947533513","doi":"10.1200/jco.2019.37.15_suppl.e20667","title":"Bone metastases as predictors of treatment response and rapidly progressive disease in NSCLC patients on PD-1/PD-L1 immune checkpoint inhibitors (ICI).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Progressive disease; Response Evaluation Criteria in Solid Tumors; Histology; Stage (stratigraphy); Metastasis; Disease; Cancer","score_opus":0.039780566048534166,"score_gpt":0.3993018404263666,"score_spread":0.35952127437783243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947533513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99195,0.003096526,3.5014867e-7,0.0029610335,0.0010769059,0.0007403302,0.000023707245,0.0000055730675,0.00014561138],"genre_scores_gemma":[0.9974835,0.0013279244,0.00010982198,0.0006120074,0.00024036983,0.000011517794,0.00000803101,0.000018584411,0.0001882529],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99550086,0.0008694086,0.0027753895,0.00023916413,0.00038907,0.00022610422],"domain_scores_gemma":[0.99509245,0.0019100866,0.0021538127,0.0002498285,0.00024056631,0.00035325316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028659115,0.00020298059,0.0015376956,0.0002898385,0.000021495107,0.000005970742,0.00008983938,0.0002250038,0.00017321887],"category_scores_gemma":[0.002617832,0.00012833033,0.00063187256,0.00017191705,0.00032250263,0.00009576242,0.000039350973,0.0004247881,0.00000784445],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4731587,0.0064974516,0.46269348,0.000055648637,0.0008246624,0.00054763944,0.0003169216,0.000007152589,0.0033006095,0.000005116619,0.0002829858,0.05230963],"study_design_scores_gemma":[0.034840386,0.08773282,0.860577,0.00063422084,0.0003744921,0.000039509014,0.00015848732,0.0000087257295,0.0024380973,0.000028612942,0.013062882,0.00010479904],"about_ca_topic_score_codex":0.00006824573,"about_ca_topic_score_gemma":0.000008891418,"teacher_disagreement_score":0.4383183,"about_ca_system_score_codex":0.0004145003,"about_ca_system_score_gemma":0.001774875,"threshold_uncertainty_score":0.52331585},"labels":[],"label_agreement":null},{"id":"W2947571627","doi":"10.1093/pch/pxz066.072","title":"73 Changes in Palivizumab usage in Canada 2005–2017 (Data from CARESS registry)","year":2019,"lang":"en","type":"article","venue":"Paediatrics & Child Health","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Sunnybrook Health Science Centre","funders":"","keywords":"Palivizumab; Bronchopulmonary dysplasia; Medicine; Pediatrics; Gestational age; Observational study; Respiratory system; Internal medicine; Pregnancy; Biology","score_opus":0.02767030854767094,"score_gpt":0.28627247798051525,"score_spread":0.2586021694328443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947571627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9217291,0.045787774,0.0000043419295,0.02703247,0.0013223443,0.001083291,0.0012502514,0.000028061942,0.0017623992],"genre_scores_gemma":[0.9730373,0.018100653,0.00010822992,0.00711174,0.0005669891,0.0000143303,0.00081619207,0.000031624204,0.00021296754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978125,0.000109483575,0.00045841525,0.0005458889,0.00043498163,0.00063872535],"domain_scores_gemma":[0.99822897,0.00014607198,0.00023741758,0.0011445059,0.000025361016,0.00021770106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006430172,0.00019916015,0.00051201414,0.00020460333,0.000057551184,0.000017079468,0.0004067572,0.00010806894,0.00026673105],"category_scores_gemma":[0.00006474938,0.00018703936,0.000034830748,0.00047651396,0.000022067405,0.00007058546,0.0001108708,0.00048242445,0.00001882479],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053648977,0.00009816487,0.9356784,0.00029991454,0.000031223055,0.00010907575,0.00054346066,0.00000574414,0.00003102212,0.000004962581,0.050864875,0.011796666],"study_design_scores_gemma":[0.0045322366,0.000119001255,0.89199924,0.00033494347,0.000016075648,0.000013515329,0.000533595,0.00022593592,0.000026471746,0.000009545782,0.10194416,0.00024529072],"about_ca_topic_score_codex":0.9722077,"about_ca_topic_score_gemma":0.99515176,"teacher_disagreement_score":0.051308207,"about_ca_system_score_codex":0.0017633972,"about_ca_system_score_gemma":0.004488903,"threshold_uncertainty_score":0.79631215},"labels":[],"label_agreement":null},{"id":"W2947602280","doi":"10.1093/pch/pxz066.071","title":"72 Use of Palivizumab in Canada; Data from the CARESS registry 2005–2017","year":2019,"lang":"en","type":"article","venue":"Paediatrics & Child Health","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Palivizumab; Medicine; Pediatrics; Observational study; Gestational age; Retinopathy of prematurity; Adverse effect; Respiratory system; Internal medicine; Pregnancy","score_opus":0.044357755120764446,"score_gpt":0.29360013630067255,"score_spread":0.2492423811799081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947602280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9226703,0.04549961,0.000014302367,0.025777807,0.0012196325,0.001067899,0.0030943023,0.000018767058,0.0006373862],"genre_scores_gemma":[0.9788871,0.01185602,0.00014092705,0.007792916,0.00041222936,0.000004406674,0.0007396177,0.000022489641,0.00014428882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822164,0.000107857006,0.0004842783,0.00034333012,0.0004344924,0.0004084172],"domain_scores_gemma":[0.99753565,0.00036752693,0.00031675468,0.0015999114,0.00004904364,0.00013113864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005733713,0.00013728923,0.00037635476,0.000056415596,0.00007470561,0.000018359688,0.00044963692,0.00007145556,0.0001174993],"category_scores_gemma":[0.00013585849,0.00009842799,0.000046737554,0.00028506416,0.00003603478,0.00010604148,0.00013131983,0.00037929774,0.0000067678197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048132916,0.00005820342,0.8070983,0.00014992591,0.000053630378,0.000012711682,0.00032481583,0.0000083893965,0.000015072917,0.000013430656,0.18665154,0.0051326314],"study_design_scores_gemma":[0.001986014,0.00006329851,0.8599523,0.0001864882,0.000029188071,0.000009862953,0.00038458253,0.00017072004,0.000013454783,0.0000060785874,0.13708575,0.00011227248],"about_ca_topic_score_codex":0.96714526,"about_ca_topic_score_gemma":0.947179,"teacher_disagreement_score":0.056216814,"about_ca_system_score_codex":0.00060004095,"about_ca_system_score_gemma":0.005319,"threshold_uncertainty_score":0.9435678},"labels":[],"label_agreement":null},{"id":"W2947606778","doi":"10.1200/jco.2019.37.15_suppl.9013","title":"KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Université de Sherbrooke","funders":"","keywords":"Pemetrexed; Medicine; Placebo; Oncology; Internal medicine; Pembrolizumab; Carboplatin; Docetaxel; Cisplatin; Chemotherapy; Cancer; Immunotherapy; Alternative medicine","score_opus":0.07164292177969342,"score_gpt":0.40844652258449093,"score_spread":0.33680360080479754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947606778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98884267,0.002821524,0.00029445943,0.0056708474,0.0002724879,0.0018478282,0.000012059485,0.000011197629,0.00022691434],"genre_scores_gemma":[0.989855,0.0011466637,0.0063120327,0.0018852891,0.00029605156,0.000046893187,0.000009152551,0.00004477698,0.00040417246],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99698955,0.0002778181,0.0016429828,0.00031478418,0.00045745057,0.00031740277],"domain_scores_gemma":[0.99491984,0.002149862,0.0019172115,0.00030427118,0.00048414269,0.00022470343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023566915,0.00029057133,0.0018268119,0.00013063844,0.0000620478,0.00002706209,0.00016963584,0.00027579552,0.000223455],"category_scores_gemma":[0.00031606844,0.00013577867,0.00025820764,0.00022514444,0.0006173302,0.00016111707,0.000045062643,0.00070601853,0.0000014190255],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8330375,0.00081574,0.010318985,0.00022578672,0.0015683245,0.00012757197,0.00059367594,0.000017457625,0.0030861115,0.000007143005,0.000837148,0.14936455],"study_design_scores_gemma":[0.5310026,0.21587832,0.17751026,0.0020373922,0.0027228564,0.00438672,0.0016254876,0.0059357127,0.006215976,0.000120268385,0.051772,0.000792444],"about_ca_topic_score_codex":0.000028329963,"about_ca_topic_score_gemma":0.00006716596,"teacher_disagreement_score":0.30203494,"about_ca_system_score_codex":0.00012922222,"about_ca_system_score_gemma":0.0016069725,"threshold_uncertainty_score":0.5536893},"labels":[],"label_agreement":null},{"id":"W2947692688","doi":"10.1200/jco.2019.37.15_suppl.e14006","title":"A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rash; Adverse effect; Internal medicine; Cancer; Antibody; Gastroenterology; Oncology; Immunology","score_opus":0.0930166138414748,"score_gpt":0.4811636294540753,"score_spread":0.3881470156126005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947692688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958448,0.00046121902,0.000025974005,0.0013564155,0.0012344262,0.0006998076,0.0000012386387,0.000005206619,0.00037092017],"genre_scores_gemma":[0.99802536,0.0006076587,0.00032775063,0.00060159835,0.00028424652,0.0000017825648,0.0000013613418,0.000012003949,0.00013821918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699736,0.00047759793,0.0018255634,0.00017362958,0.00036693015,0.00015893595],"domain_scores_gemma":[0.9968671,0.0007968916,0.001678898,0.0002669048,0.00024523493,0.00014492327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026837343,0.00012032757,0.0010268235,0.00008613498,0.00003907198,0.000008561094,0.00014238297,0.00025053334,0.00007569468],"category_scores_gemma":[0.00037981512,0.000066466215,0.0003585815,0.00017427566,0.00013996783,0.000090293164,0.00005556387,0.00056872336,0.000003215576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038715847,0.022287032,0.5826309,0.00007860104,0.00037819782,0.000113976865,0.0007467657,0.000007343074,0.103925005,0.000005371787,0.00029417584,0.25081682],"study_design_scores_gemma":[0.0684919,0.059511248,0.86331993,0.00012597808,0.00042890248,0.00012978507,0.00088923,0.00020064226,0.00091234763,0.00002494578,0.0058846595,0.00008045616],"about_ca_topic_score_codex":0.000055323086,"about_ca_topic_score_gemma":0.000017324768,"teacher_disagreement_score":0.28068903,"about_ca_system_score_codex":0.000052009815,"about_ca_system_score_gemma":0.00054653146,"threshold_uncertainty_score":0.27104133},"labels":[],"label_agreement":null},{"id":"W2947775394","doi":"10.1200/jco.19.00934","title":"Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1185,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Pembrolizumab; Overall survival; Lung cancer; Safety profile; Phases of clinical research; Survival rate; Cancer; Lung","score_opus":0.043142148027036545,"score_gpt":0.41046673368768,"score_spread":0.36732458566064347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947775394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949187,0.00021024927,0.000029526573,0.0013058098,0.0009149317,0.0018515184,0.00015322045,0.0000095617615,0.000606453],"genre_scores_gemma":[0.99621344,0.00030298793,0.00058253465,0.0011756493,0.0006551133,0.000024757146,0.00004631916,0.000037215934,0.00096199295],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9970221,0.0003070209,0.0016060671,0.0003336384,0.00043778145,0.00029338777],"domain_scores_gemma":[0.9940013,0.0028603072,0.0018614607,0.0003607323,0.00071879337,0.00019737585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013032042,0.00022876759,0.0013186085,0.00005239204,0.000065186054,0.000016433092,0.00024983738,0.00021376908,0.00014628078],"category_scores_gemma":[0.00032999556,0.00010953471,0.0002923182,0.00013279502,0.00011848277,0.000106476735,0.000028803035,0.0006702083,0.0000039863207],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5069,0.008801681,0.46186993,0.000018085047,0.001502027,0.00006349218,0.00034647324,0.000059909617,0.00012948478,5.651299e-7,0.0024625026,0.017845837],"study_design_scores_gemma":[0.31975245,0.08178364,0.583197,0.0001826613,0.00092204503,0.0000050776102,0.00037360657,0.00012387834,0.000040511266,0.0000028350664,0.013472104,0.00014416239],"about_ca_topic_score_codex":0.0005998812,"about_ca_topic_score_gemma":0.00067401817,"teacher_disagreement_score":0.18714756,"about_ca_system_score_codex":0.00021608344,"about_ca_system_score_gemma":0.0012272329,"threshold_uncertainty_score":0.44666958},"labels":[],"label_agreement":null},{"id":"W2947794723","doi":"10.1186/s40425-019-0602-4","title":"Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop","year":2019,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Caprion (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; University of Toronto; University Health Network","funders":"National Center for Advancing Translational Sciences; Society for Immunotherapy of Cancer; National Cancer Institute; Celgene","keywords":"Premise; Cancer; Cancer immunotherapy; Immune escape; Immune system; Immunotherapy; Computational biology; Bioinformatics; Medicine; Immunology; Psychology; Biology; Genetics","score_opus":0.11245442319226147,"score_gpt":0.4196030258259771,"score_spread":0.30714860263371563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947794723","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008758338,0.98927665,0.00008067281,0.0016285112,0.0034292236,0.0032795235,0.0013749361,0.000019092004,0.00003557502],"genre_scores_gemma":[0.00008630256,0.9949322,0.00026322072,0.00093329506,0.00090058375,0.0005907569,0.00007910612,0.00022175354,0.001992806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950481,0.00041781034,0.0026278098,0.00051626447,0.0008175917,0.0005724203],"domain_scores_gemma":[0.9919796,0.0020406838,0.0036367476,0.0011191888,0.0011206189,0.00010317075],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007721254,0.0008581903,0.0051298765,0.000331256,0.00020321307,0.00006713803,0.0010032769,0.00059785496,0.0016418556],"category_scores_gemma":[0.00007510874,0.0005136753,0.0041079177,0.000785823,0.00040471874,0.0001339865,0.00007639491,0.0010714633,0.0000055372407],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011995067,0.0001453044,0.000032144653,0.011421816,0.013960815,0.000008342686,0.00081137166,0.000007131185,0.0025457928,0.000008232348,0.0047228844,0.9543411],"study_design_scores_gemma":[0.004921595,0.00052979257,0.0003400935,0.084829465,0.004191369,0.000094415955,0.0003134148,0.0000034399914,0.00039328643,0.000037099817,0.9038746,0.00047144585],"about_ca_topic_score_codex":0.002090258,"about_ca_topic_score_gemma":0.0001005984,"teacher_disagreement_score":0.95386964,"about_ca_system_score_codex":0.0007559713,"about_ca_system_score_gemma":0.003377965,"threshold_uncertainty_score":0.9997315},"labels":[],"label_agreement":null},{"id":"W2947829857","doi":"10.1200/jco.2019.37.15_suppl.4012","title":"Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Nivolumab; Sorafenib; Gastroenterology; Hepatocellular carcinoma; Clinical endpoint; Randomized controlled trial; Adverse effect; Cancer; Immunotherapy","score_opus":0.047177588256687567,"score_gpt":0.3612129806940574,"score_spread":0.31403539243736983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947829857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99404055,0.0005133669,0.000011043717,0.0020432058,0.0014170307,0.0006221249,0.00001451714,0.000011769522,0.0013264104],"genre_scores_gemma":[0.9961723,0.0010691363,0.0006801333,0.0014344098,0.00025131268,0.000004532975,0.00003911979,0.00002955473,0.00031946637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99587405,0.00040643875,0.002560232,0.00032764624,0.0005490692,0.0002825896],"domain_scores_gemma":[0.9959422,0.0008951198,0.0020988614,0.00035975783,0.00051681773,0.00018729444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020625656,0.00020661809,0.0014091717,0.00017586666,0.000030143712,0.000011795518,0.00022095467,0.0004069723,0.00018682955],"category_scores_gemma":[0.0004429129,0.00014249737,0.0003565376,0.00024590222,0.0001487727,0.00021416813,0.00002886856,0.00087198237,0.000028160572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17986237,0.0027718905,0.6433387,0.000012763801,0.00026294414,0.00013864176,0.00025628303,0.000008314402,0.0009249151,0.0000072236285,0.00038684954,0.17202914],"study_design_scores_gemma":[0.1474484,0.04053158,0.7951231,0.00020452017,0.00006183172,0.00001896476,0.00011144142,0.00027832016,0.0005891951,0.00008373069,0.015403648,0.00014523366],"about_ca_topic_score_codex":0.00023353621,"about_ca_topic_score_gemma":0.0000656693,"teacher_disagreement_score":0.17188391,"about_ca_system_score_codex":0.0004180789,"about_ca_system_score_gemma":0.0009850803,"threshold_uncertainty_score":0.58108747},"labels":[],"label_agreement":null},{"id":"W2948248276","doi":"10.1200/jco.2019.37.18_suppl.lba9015","title":"Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Clinical endpoint; Oncology; Incidence (geometry); Clinical trial; Immunotherapy; Cancer","score_opus":0.04006387445179824,"score_gpt":0.3833419232587135,"score_spread":0.34327804880691526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948248276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954372,0.000104607614,0.000051797528,0.0012957703,0.0008962858,0.0006783063,0.000096492964,0.00001408888,0.0014254694],"genre_scores_gemma":[0.994888,0.0002705151,0.0017593291,0.001107576,0.00059072516,0.000005275935,0.00013580907,0.000037598154,0.0012051413],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9970377,0.00019540048,0.0017138128,0.0003174657,0.00044317075,0.00029245016],"domain_scores_gemma":[0.9946612,0.0022227264,0.0018329246,0.00030879863,0.00071508996,0.00025921914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008850321,0.00021097974,0.0014576241,0.00008554235,0.000035606998,0.000012830997,0.00017694809,0.00033418226,0.00020725424],"category_scores_gemma":[0.00056823675,0.000121779456,0.0003565863,0.00010247559,0.00016436812,0.00015857008,0.000021671844,0.0005588457,0.000015978505],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5712428,0.002219412,0.38091373,0.000021113283,0.0010012604,0.00009871761,0.000053062184,0.00001236777,0.0001263329,0.0000037802236,0.0011093428,0.04319808],"study_design_scores_gemma":[0.17516464,0.057223,0.75653666,0.00029936925,0.0003234938,0.000020468347,0.000033961926,0.000012447528,0.00004691589,0.000011854709,0.010185353,0.0001418321],"about_ca_topic_score_codex":0.00011109383,"about_ca_topic_score_gemma":0.000117229065,"teacher_disagreement_score":0.39607817,"about_ca_system_score_codex":0.000190184,"about_ca_system_score_gemma":0.0008025095,"threshold_uncertainty_score":0.4966022},"labels":[],"label_agreement":null},{"id":"W2949104201","doi":"10.1186/s13643-019-1047-z","title":"Immunotherapy with check-point inhibitors (CPI) in adult malignancies: a protocol for the systematic review of the quality of economic analyses","year":2019,"lang":"en","type":"article","venue":"Systematic Reviews","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University; CancerCare Manitoba; University of British Columbia","funders":"University of British Columbia","keywords":"Medicine; Protocol (science); Immunotherapy; Quality (philosophy); Intensive care medicine; Alternative medicine; Internal medicine; Cancer; Pathology","score_opus":0.07805868778301084,"score_gpt":0.40957988120037675,"score_spread":0.3315211934173659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949104201","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033100643,0.062125184,0.00013235207,0.0005980176,0.00013931202,0.93332934,0.0000146551865,0.000012074943,0.00033901917],"genre_scores_gemma":[0.030114166,0.008125113,0.00030960795,0.0014435882,0.00004775741,0.9590918,0.0000036364272,0.000060347164,0.0008040213],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99324214,0.0013583726,0.004495594,0.00025859493,0.00044795722,0.00019736527],"domain_scores_gemma":[0.9928702,0.0007964091,0.0042652376,0.0018085456,0.00023276013,0.000026842023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009886754,0.00030883664,0.003821803,0.00007286179,0.00003605703,0.000013827292,0.00043049513,0.000065023494,0.00009797421],"category_scores_gemma":[0.0009173333,0.00010823807,0.001034294,0.0004098099,0.000112525806,0.000070445945,0.000026172462,0.00010271483,0.000015391739],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032920975,0.00006592626,0.0004670809,0.9955347,0.0004370997,1.18954716e-7,0.00041764262,0.0000013474522,0.00231051,0.00012620943,0.00028095912,0.000029162751],"study_design_scores_gemma":[0.002719959,0.00029518362,0.00034670663,0.993026,0.0004966059,0.000022022696,0.0007508844,0.000053605047,0.0017488602,0.000011565941,0.000381036,0.000147536],"about_ca_topic_score_codex":0.00023335125,"about_ca_topic_score_gemma":0.00009081082,"teacher_disagreement_score":0.05400007,"about_ca_system_score_codex":0.00021051186,"about_ca_system_score_gemma":0.00025594098,"threshold_uncertainty_score":0.44138202},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"systematic_review","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["metaresearch"],"domain":"evaluation","study_design":"systematic_review","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W2949145033","doi":"10.1016/j.oooo.2019.02.110","title":"DIFFERENTIAL EXPRESSION OF PD1 AND PDL1 IN ORAL POTENTIALLY MALIGNANT LESIONS AND ORAL SQUAMOUS CELL CARCINOMA:A PILOT STUDY","year":2019,"lang":"en","type":"article","venue":"Oral Surgery Oral Medicine Oral Pathology and Oral Radiology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Basal cell; Medicine; Differential diagnosis; Oncology; Carcinoma; Oral Cancers; Malignant cells; Cancer research; Pathology; Internal medicine; Cancer","score_opus":0.03050009749651033,"score_gpt":0.27750737056015495,"score_spread":0.24700727306364462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949145033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99178296,0.004162998,0.000058620622,0.0012019179,0.0012959061,0.0013069018,0.000039363247,0.000062436324,0.00008890328],"genre_scores_gemma":[0.99729496,0.00066052604,0.0003776744,0.00078314333,0.00014702824,0.00004642663,0.00013416033,0.000067244735,0.0004888184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99474806,0.0013117809,0.0013568957,0.0012049732,0.00037729408,0.0010010157],"domain_scores_gemma":[0.9979181,0.00053921586,0.00043968376,0.00055948016,0.00013076361,0.00041273178],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015912799,0.0007359105,0.0027633323,0.000728359,0.00018967221,0.000019853462,0.00020033079,0.000500896,0.0007159651],"category_scores_gemma":[0.00020709142,0.00052737235,0.0001609258,0.0004659744,0.0016090659,0.00022283761,0.0002806504,0.0007436849,0.0000082157285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01324572,0.0010649478,0.767691,0.00024341367,0.000059637252,0.001577357,0.00056263857,0.0000016629155,0.19845775,0.000028938599,0.001506084,0.01556084],"study_design_scores_gemma":[0.018039223,0.019428149,0.9539189,0.00024602216,0.00044470886,0.002050194,0.0011866695,0.000096842494,0.0030101081,0.00017827246,0.0007335506,0.00066735747],"about_ca_topic_score_codex":0.0024766403,"about_ca_topic_score_gemma":0.00086013356,"teacher_disagreement_score":0.19544764,"about_ca_system_score_codex":0.00007377778,"about_ca_system_score_gemma":0.00017539188,"threshold_uncertainty_score":0.9997178},"labels":[],"label_agreement":null},{"id":"W2949244813","doi":"10.1016/j.lungcan.2019.06.012","title":"Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Merck Sharp and Dohme; Merck","keywords":"Medicine; Lung cancer; Oncology; Expression (computer science); Cancer; Ligand (biochemistry); Pathology; Cancer research; Internal medicine; Receptor","score_opus":0.017161885430112406,"score_gpt":0.34280352524772334,"score_spread":0.32564163981761096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949244813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98157924,0.010217617,0.000086344684,0.0002379158,0.000546466,0.00671574,0.00006967162,0.000042819924,0.0005042052],"genre_scores_gemma":[0.9879411,0.0048328065,0.0007228102,0.00030894284,0.00007165456,0.0016195677,0.0000058700075,0.000044410044,0.0044528325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762404,0.00013697933,0.0006468132,0.00057771086,0.00050672586,0.0005077289],"domain_scores_gemma":[0.9985328,0.00012779924,0.0003523718,0.0007165302,0.00015959846,0.00011093258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003657109,0.00033502607,0.00059661065,0.00009495734,0.00006360479,0.000031200365,0.00037192486,0.000064921755,0.0004489173],"category_scores_gemma":[0.000018781937,0.00020203198,0.00013748404,0.0006040578,0.00008183804,0.0001493855,0.00011125368,0.0002481384,0.0000021916899],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013066967,0.0010396197,0.92083377,0.0033558912,0.00034377322,0.0000346671,0.0027650644,0.00039135834,0.048876807,0.0000014103874,0.00044798676,0.008842669],"study_design_scores_gemma":[0.045541517,0.0018519586,0.8164268,0.012729729,0.0017661825,0.000007790393,0.0033317674,0.00887241,0.1052665,0.0000046918753,0.0033218013,0.00087886455],"about_ca_topic_score_codex":0.0058483826,"about_ca_topic_score_gemma":0.007023771,"teacher_disagreement_score":0.104407,"about_ca_system_score_codex":0.00067184505,"about_ca_system_score_gemma":0.00054428505,"threshold_uncertainty_score":0.88410443},"labels":[],"label_agreement":null},{"id":"W2949277199","doi":"10.1056/nejmc1903064","title":"Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy","year":2019,"lang":"en","type":"letter","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":220,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Alemtuzumab; Myocarditis; Immune system; Immunology; Antibody therapy; Internal medicine; Antibody; Monoclonal antibody","score_opus":0.021274083332279533,"score_gpt":0.28306428833792363,"score_spread":0.2617902050056441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949277199","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066380408,0.025983052,0.00063890073,0.95580864,0.0077735833,0.0013984774,0.00004560005,0.000030501844,0.0016832124],"genre_scores_gemma":[0.007254029,0.0076885875,0.00071090925,0.89089495,0.07217755,0.00002047876,0.00033452458,0.00021586637,0.020703092],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964742,0.00013807483,0.0015353743,0.0003359734,0.0010058052,0.0005105681],"domain_scores_gemma":[0.9970094,0.0007031816,0.0009819408,0.00054851087,0.0005191158,0.00023784068],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014693179,0.00051000295,0.0020740074,0.0006616698,0.00006491312,0.000021868458,0.00038365222,0.0007030134,0.0012843233],"category_scores_gemma":[0.0003271588,0.0003225715,0.00075166515,0.0003151571,0.00012625467,0.00007415235,0.000021409407,0.0019316929,0.000028037552],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072460864,0.000024845724,0.0000443208,0.00014829733,0.0016470093,0.0011950798,0.0005788116,0.00000252629,0.003310915,0.000002073179,0.78632957,0.19947046],"study_design_scores_gemma":[0.10818118,0.008923683,0.0009277218,0.002513108,0.00054964627,0.007926396,0.000045344706,0.0000036045985,0.00039144987,0.00014515144,0.870107,0.0002857273],"about_ca_topic_score_codex":0.00019098958,"about_ca_topic_score_gemma":0.000004304727,"teacher_disagreement_score":0.19918473,"about_ca_system_score_codex":0.00027937972,"about_ca_system_score_gemma":0.0008413041,"threshold_uncertainty_score":0.99992263},"labels":[],"label_agreement":null},{"id":"W2949515538","doi":"10.1016/j.ejca.2019.05.008","title":"Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":217,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Foundation Medicine; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Medicine; Oncology; Internal medicine; Lung cancer; Chemotherapy; Open label; Cancer; Immunotherapy; Clinical trial","score_opus":0.025837221785027956,"score_gpt":0.32123817474898925,"score_spread":0.2954009529639613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949515538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98513263,0.0037488448,0.000021584561,0.004651016,0.0017973351,0.0032187158,0.0001337003,0.000017187867,0.0012789925],"genre_scores_gemma":[0.9915171,0.0032975841,0.00031805612,0.0008506452,0.0007401135,0.0001060825,0.000064325846,0.00009914552,0.0030069288],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967621,0.00026048615,0.0014905626,0.00045075832,0.00066221674,0.00037386638],"domain_scores_gemma":[0.9969842,0.00035756067,0.0016859605,0.0004501919,0.00035143804,0.00017063874],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007201812,0.00043412205,0.0010131542,0.00012153198,0.00012858947,0.00010013725,0.00040690266,0.000052230625,0.0008977606],"category_scores_gemma":[0.00006529102,0.00025376625,0.00021627363,0.00029548578,0.0000845087,0.00023314975,0.000047232952,0.0003527733,0.0000100846855],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94241965,0.00091094,0.0004922486,0.000018947294,0.0020070968,0.00067202386,0.0036315739,0.003062141,0.00614513,4.482654e-7,0.00060683367,0.04003297],"study_design_scores_gemma":[0.96652955,0.009960557,0.004053315,0.00076551706,0.0006345913,0.000037295777,0.00060013036,0.0004394968,0.00538084,0.0000017290849,0.011267315,0.0003296897],"about_ca_topic_score_codex":0.0042021135,"about_ca_topic_score_gemma":0.0008734255,"teacher_disagreement_score":0.03970328,"about_ca_system_score_codex":0.0010840083,"about_ca_system_score_gemma":0.0014816495,"threshold_uncertainty_score":0.9999915},"labels":[],"label_agreement":null},{"id":"W2949917654","doi":"10.21037/atm.2019.05.86","title":"The PD-1/PD-L1 pathway in advanced prostate cancer—have we milked this cow?","year":2019,"lang":"en","type":"letter","venue":"Annals of Translational Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Prostate cancer; Medicine; Immunotherapy; Cancer; Oncology; PD-L1; Lung cancer; Internal medicine; Melanoma; Cancer research","score_opus":0.05676537123009357,"score_gpt":0.3445108657724363,"score_spread":0.2877454945423427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949917654","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035739557,0.06835837,0.000008316317,0.9222404,0.0009553564,0.0015721155,0.00038120814,0.000028269274,0.0028820198],"genre_scores_gemma":[0.03474297,0.080923304,0.00013156793,0.84383357,0.0044266228,0.00039118752,0.0020410328,0.00018082462,0.033328943],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99633116,0.00014578136,0.0011576976,0.00052254566,0.0012730731,0.00056975026],"domain_scores_gemma":[0.9974426,0.0009747171,0.00050998083,0.0005616921,0.00043984875,0.00007116639],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007912746,0.00047597926,0.0010498127,0.00033512714,0.00009455772,0.000009996068,0.00032138315,0.00051588425,0.0008603009],"category_scores_gemma":[0.0000945398,0.00030165908,0.00032626535,0.00039453624,0.00057154655,0.000098351804,0.000014460483,0.0013009716,0.00001422673],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0085090725,0.000077506236,0.001547491,0.0012065126,0.0007167653,0.00012995925,0.0020699736,0.00002654809,0.004173257,0.000036452228,0.9020674,0.07943902],"study_design_scores_gemma":[0.0060720127,0.0007480246,0.0066425456,0.0045245034,0.00010049642,0.000021800362,0.00011382263,0.00005741822,0.0014936065,0.0004803918,0.97944003,0.0003053449],"about_ca_topic_score_codex":0.0007251183,"about_ca_topic_score_gemma":0.00035595478,"teacher_disagreement_score":0.079133675,"about_ca_system_score_codex":0.00006408671,"about_ca_system_score_gemma":0.00069658156,"threshold_uncertainty_score":0.99994355},"labels":[],"label_agreement":null},{"id":"W2950359183","doi":"10.1073/pnas.1818210116","title":"Cancer stemness, intratumoral heterogeneity, and immune response across cancers","year":2019,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":607,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; BC Children's Hospital; University of British Columbia","funders":"Canadian Cancer Society","keywords":"Immune system; Cancer; Biology; Cancer research; Medicine; Oncology; Immunology; Internal medicine","score_opus":0.03707180813737486,"score_gpt":0.35300250061469934,"score_spread":0.31593069247732447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950359183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992507,0.0017383044,3.2679672e-8,0.004832253,0.000047913247,0.0002415268,0.000023976838,0.0000069138437,0.0006021216],"genre_scores_gemma":[0.9987561,0.00021603056,0.00009353599,0.0005226426,0.000041424173,0.000011523979,6.6130255e-8,0.000004063533,0.00035462505],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99869823,0.000006608337,0.00025414085,0.00019632706,0.0006932841,0.00015140988],"domain_scores_gemma":[0.9994589,0.000057699024,0.00027191624,0.000008945938,0.00017307169,0.000029431068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014081238,0.0000822474,0.00018602629,0.00006643636,0.00011582473,0.000019756393,0.00027213496,0.00006217025,0.000027688657],"category_scores_gemma":[0.00008533651,0.000051849416,0.000069211936,0.0004815424,0.0008764674,0.00022861706,0.00009222163,0.000118785785,5.5210165e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016596821,0.000016702592,0.08583661,0.00011908973,0.00004263267,7.661132e-9,0.0002665775,0.000008730298,0.9104684,0.00051411474,0.00017660232,0.0008908501],"study_design_scores_gemma":[0.0006279515,0.00011142348,0.5962172,0.00022013852,0.000010023781,0.000017158918,0.00027588554,0.00011102954,0.4015439,0.0004148009,0.00039601093,0.000054454842],"about_ca_topic_score_codex":0.0000925602,"about_ca_topic_score_gemma":7.758136e-7,"teacher_disagreement_score":0.5103806,"about_ca_system_score_codex":0.000103824386,"about_ca_system_score_gemma":0.00012250521,"threshold_uncertainty_score":0.32293805},"labels":[],"label_agreement":null},{"id":"W2950568943","doi":"10.1016/j.ejca.2019.05.020","title":"Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"EORTC Charitable Trust; European Organisation for Research and Treatment of Cancer; Merck","keywords":"Pembrolizumab; Medicine; Placebo; Stage (stratigraphy); Oncology; Melanoma; Internal medicine; Predictive value; Cancer; Immunotherapy; Pathology; Cancer research; Alternative medicine","score_opus":0.012460533648180939,"score_gpt":0.2876012665329937,"score_spread":0.2751407328848128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950568943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946205,0.0022622435,0.00007086406,0.00033297407,0.00037815177,0.0010493272,0.000072418654,0.0000042119354,0.0012093026],"genre_scores_gemma":[0.99792093,0.0014128593,0.000053821474,0.00010103601,0.00023236842,0.00000633319,0.0000046271725,0.000030985673,0.00023703217],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99704343,0.00093456195,0.0010497504,0.00018693953,0.00055485487,0.00023047802],"domain_scores_gemma":[0.99816304,0.00031340128,0.0010182483,0.00025024533,0.00018554358,0.000069509144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025279406,0.00017690302,0.00061417563,0.00032848638,0.00002839824,0.000016149588,0.00022470551,0.000039553313,0.00018343284],"category_scores_gemma":[0.00018804295,0.00011764127,0.00012555218,0.00038372312,0.00015314817,0.00013986044,0.00003897331,0.00052694173,7.1489694e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8905464,0.0007032461,0.06453826,0.00020722301,0.0005624463,0.0003322646,0.009133812,0.00038915244,0.015119966,0.0000282196,0.0003848983,0.018054152],"study_design_scores_gemma":[0.54523873,0.016201839,0.42561275,0.0021492525,0.00037858984,0.00006905854,0.0022834972,0.00067526166,0.004862488,0.000015736468,0.0022997842,0.00021299663],"about_ca_topic_score_codex":0.0005335506,"about_ca_topic_score_gemma":0.00006890413,"teacher_disagreement_score":0.36107448,"about_ca_system_score_codex":0.00013427655,"about_ca_system_score_gemma":0.0003634863,"threshold_uncertainty_score":0.47972718},"labels":[],"label_agreement":null},{"id":"W2950848761","doi":"10.1016/j.joco.2019.05.002","title":"Ocular adverse events with immune checkpoint inhibitors","year":2019,"lang":"en","type":"article","venue":"Journal of Current Ophthalmology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Foundation for Anesthesia Education and Research","keywords":"Medicine; Nivolumab; Pembrolizumab; Adverse effect; Ipilimumab; Atezolizumab; Uveitis; Durvalumab; Odds ratio; Adverse Event Reporting System; Internal medicine; Immunology; Cancer; Immunotherapy","score_opus":0.021931693678853732,"score_gpt":0.31234024952250966,"score_spread":0.29040855584365594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950848761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913278,0.0049469266,0.000027772727,0.00041965282,0.00226297,0.00024032097,0.0000016338187,0.0000058802293,0.00076703855],"genre_scores_gemma":[0.99891096,0.00016634983,0.00020446983,0.000035679335,0.00026484914,0.0000022892968,0.0000039708143,0.000018896573,0.00039255145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986033,0.000063085026,0.0006219101,0.00013648813,0.00035092255,0.00022428307],"domain_scores_gemma":[0.99889,0.0000290687,0.0005581893,0.00021701853,0.00019767931,0.00010803591],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042709702,0.00015605753,0.00047153785,0.00019625865,0.000024114595,0.0000027528008,0.00012244511,0.000083276136,0.00095386326],"category_scores_gemma":[0.00002384068,0.000102938284,0.00033155648,0.00018063709,0.00006674435,0.0001104371,0.00002633212,0.00039146587,0.00005061645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025155524,0.0017513564,0.8122464,0.00051299244,0.0015743668,0.0021123432,0.0005020726,0.00005703789,0.14469321,0.000047665366,0.0006157411,0.010731329],"study_design_scores_gemma":[0.02691992,0.013453187,0.78430045,0.0025203472,0.000504416,0.09777795,0.00049782504,0.000030667718,0.032854196,0.00018901298,0.040430203,0.00052181544],"about_ca_topic_score_codex":0.000006203792,"about_ca_topic_score_gemma":1.1838625e-7,"teacher_disagreement_score":0.11183902,"about_ca_system_score_codex":0.00012667345,"about_ca_system_score_gemma":0.00024979468,"threshold_uncertainty_score":0.9999594},"labels":[],"label_agreement":null},{"id":"W2951431887","doi":"10.1002/bjs.11204","title":"Mechanisms of immunogenicity in colorectal cancer","year":2019,"lang":"en","type":"review","venue":"British journal of surgery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Merck Sharp and Dohme; Medical Research Council Canada; Bowel Disease Research Foundation; Wellcome Trust; Royal College of Surgeons of England; National Institute for Health and Care Research; National Cancer Research Institute; Merck; The Wellcome Trust DBT India Alliance; Cancer Research UK; British Lung Foundation; Cancer Research Institute","keywords":"Medicine; Immunogenicity; Colorectal cancer; Immunotherapy; Cancer; Immune system; Adjuvant; Cancer immunotherapy; Disease; Oncology; Immunology; Internal medicine","score_opus":0.07172669906006864,"score_gpt":0.334562418243538,"score_spread":0.2628357191834694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951431887","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0071128076,0.9909477,0.000007841187,0.000015375219,0.0014197781,0.00031879524,0.00009138915,0.000004062237,0.0000821999],"genre_scores_gemma":[0.0014013846,0.9981711,0.000049278475,0.000046637462,0.00014805983,0.000010750476,0.000016285234,0.000044972632,0.00011151934],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972628,0.0001627247,0.0017619747,0.0001611814,0.00040909875,0.00024222114],"domain_scores_gemma":[0.9976393,0.00036024544,0.0016077332,0.00011822575,0.00020266548,0.00007180763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013457843,0.00021881491,0.0032630253,0.00045267696,0.000017493148,0.000019209741,0.00015649832,0.0003042104,0.00046886265],"category_scores_gemma":[0.00012258958,0.00020914893,0.0018493398,0.0004597145,0.0000701127,0.00008833671,0.00002876869,0.0006294064,0.0000034818506],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051079714,0.00014091044,0.00014654399,0.009623287,0.000827044,0.00092588196,0.000010029874,1.3924559e-7,0.0002490301,0.0000015806493,0.0013850305,0.9861797],"study_design_scores_gemma":[0.0020498692,0.0002604079,0.0062046787,0.3225827,0.0019630564,0.030915964,0.000041311305,5.601342e-7,0.00043203542,0.000033140444,0.6350202,0.00049606105],"about_ca_topic_score_codex":0.0007354161,"about_ca_topic_score_gemma":0.00007245868,"teacher_disagreement_score":0.9856837,"about_ca_system_score_codex":0.0003459409,"about_ca_system_score_gemma":0.002196885,"threshold_uncertainty_score":0.8528846},"labels":[],"label_agreement":null},{"id":"W2951643410","doi":"10.1159/000500856","title":"AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report","year":2019,"lang":"en","type":"article","venue":"Case Reports in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Alberta Hospital; Alberta Hospital Edmonton; University of Alberta","funders":"","keywords":"Pembrolizumab; Medicine; Pancytopenia; Ipilimumab; Nivolumab; Adverse effect; Prednisone; Internal medicine; Melanoma; Oncology; Immunosuppression; Anemia; Thrombocytopenic purpura; Immunotherapy; Immunology; Cancer; Immune system; Cancer research; Bone marrow","score_opus":0.036289360302867155,"score_gpt":0.37192401206101827,"score_spread":0.3356346517581511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951643410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99077135,0.0024715208,0.00007492803,0.00092770776,0.00023609301,0.0017674982,0.000011871293,0.000016952366,0.0037220845],"genre_scores_gemma":[0.99667674,0.00022672866,0.0014898266,0.0005131662,0.000025662624,0.00025437627,0.000031123076,0.000019713783,0.0007626837],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99854535,0.0000557108,0.0007888496,0.00034508994,0.00008497955,0.00018004638],"domain_scores_gemma":[0.99852645,0.00028080467,0.00047510478,0.00051047164,0.00013667853,0.000070480906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065198075,0.00012746314,0.00055009645,0.00013786247,0.000043337153,0.0000052755504,0.000021026432,0.000099884004,0.00015405442],"category_scores_gemma":[0.00012120827,0.00010673916,0.000107287306,0.0001326453,0.00013665135,0.000042854717,0.000020127001,0.00010375071,0.0000015775721],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027112723,0.00047022026,0.0076083373,0.00017042446,0.00025874222,0.9341412,0.00062351086,0.0000017192933,0.0090670185,0.00020940942,0.00042948776,0.044308625],"study_design_scores_gemma":[0.0049375934,0.001597301,0.0033888354,0.000039900227,0.000084802465,0.9246216,0.00038735385,0.000042062034,0.0013459473,0.0002802994,0.06317416,0.0001001645],"about_ca_topic_score_codex":0.00056512,"about_ca_topic_score_gemma":0.00020642608,"teacher_disagreement_score":0.06274467,"about_ca_system_score_codex":0.0001471721,"about_ca_system_score_gemma":0.0005361809,"threshold_uncertainty_score":0.43526965},"labels":[],"label_agreement":null},{"id":"W2952406594","doi":"10.1186/s40425-017-0215-8","title":"Gene expression markers of Tumor Infiltrating Leukocytes","year":2017,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":850,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"National Cancer Institute","keywords":"Immune system; Biology; Gene; Gene expression; Immunotherapy; Flow cytometry; Gene expression profiling; Computational biology; Genetics","score_opus":0.02844187749003703,"score_gpt":0.34877392438913074,"score_spread":0.3203320468990937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952406594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792354,0.017327879,0.0004146554,0.00075706636,0.0011088381,0.00044377957,0.000039697486,0.0000110396295,0.0006616112],"genre_scores_gemma":[0.98389083,0.0067924834,0.007371816,0.00034681862,0.00044783423,0.000042407908,0.000003045489,0.000051347837,0.0010534266],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985534,0.000026292011,0.00069215166,0.00014746339,0.00033768747,0.00024301666],"domain_scores_gemma":[0.99761957,0.000076361626,0.0014396938,0.00046654785,0.0003313131,0.00006649786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057170185,0.00017386777,0.0005128306,0.00012086677,0.00038695207,0.000051275612,0.00031525167,0.00007800613,0.0004571834],"category_scores_gemma":[0.00008526674,0.00013152618,0.00047237397,0.000051699364,0.00023707039,0.00023272658,0.00001942201,0.00018303143,3.3422455e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016123302,0.00007645488,0.013597809,0.00013421892,0.00048064117,0.000003546079,0.00021703659,0.000007828278,0.8709354,0.0000065917657,0.001504522,0.09691269],"study_design_scores_gemma":[0.007918112,0.0010919176,0.05380713,0.0011009371,0.000073592775,0.00009383353,0.0001565724,0.000035153033,0.91422725,0.000117040865,0.021228734,0.00014971847],"about_ca_topic_score_codex":0.00023396792,"about_ca_topic_score_gemma":0.000014461331,"teacher_disagreement_score":0.09676297,"about_ca_system_score_codex":0.0001183854,"about_ca_system_score_gemma":0.00036789197,"threshold_uncertainty_score":0.5363482},"labels":[],"label_agreement":null},{"id":"W2952869261","doi":"10.1101/430413","title":"Infiltration of CD8 <sup>+</sup> T cells into tumor-cell clusters in Triple Negative Breast Cancer","year":2018,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital; Occupational Cancer Research Centre; McGill University Health Centre","funders":"","keywords":"Infiltration (HVAC); CD8; Triple-negative breast cancer; Cytotoxic T cell; Pathology; Breast cancer; Cancer research; Chemistry; Biology; Immune system; Medicine; Cancer; Materials science; Immunology; Internal medicine","score_opus":0.01051378016856517,"score_gpt":0.23575737303894004,"score_spread":0.22524359287037488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952869261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948642,0.0013970853,0.0001477363,0.00042304487,0.00092467753,0.0016417368,0.0004441727,0.00011948099,0.000037829966],"genre_scores_gemma":[0.9955996,0.0009336885,0.0019017487,0.0005930521,0.00055552775,0.00027162154,0.0000012403777,0.00012297256,0.000020535725],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968707,0.00017921656,0.000997332,0.0009202588,0.0005162417,0.0005162598],"domain_scores_gemma":[0.9972479,0.000072722956,0.0007378083,0.001049499,0.0006716357,0.00022047861],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006617263,0.0006041276,0.0009580902,0.0005538296,0.000081981074,0.00006474755,0.0003805101,0.0005086223,0.0003322256],"category_scores_gemma":[0.000057492733,0.0006075198,0.0002665795,0.0008932665,0.00035933536,0.00017687837,0.00021045131,0.00074010954,0.000025190122],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002788627,0.0005119636,0.025178531,0.001943297,0.0003653206,0.000047875063,0.00030800697,0.00033071975,0.9666371,0.000007884004,0.0018598106,0.000020864189],"study_design_scores_gemma":[0.0059862975,0.0002975803,0.13134558,0.0026537522,0.00027250368,1.09240005e-7,0.000056422494,0.002480037,0.85434115,0.0000019599324,0.0016960852,0.0008685405],"about_ca_topic_score_codex":0.003056204,"about_ca_topic_score_gemma":0.000077642304,"teacher_disagreement_score":0.11229597,"about_ca_system_score_codex":0.0009890638,"about_ca_system_score_gemma":0.0017978415,"threshold_uncertainty_score":0.9996376},"labels":[],"label_agreement":null},{"id":"W2952953974","doi":"10.1016/j.jtho.2019.06.010","title":"Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"Foundation Medicine; EMD Serono; Eisai; Daiichi-Sankyo; Pfizer; Incyte; Genentech; IFM Therapeutics; Horizon Pharma; Exelixis; Regeneron Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Roche; Celgene; Novartis; AbbVie; MedImmune; Merck; Boehringer Ingelheim; Amgen; PharmaMar; Daiichi Sankyo Europe; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Common Terminology Criteria for Adverse Events; Tolerability; Adverse effect; Internal medicine; Oncology; Cohort; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.023076036204060287,"score_gpt":0.4132323152498739,"score_spread":0.3901562790458136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952953974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99764305,0.00027449525,0.00001908454,0.00060232065,0.0007166574,0.00036082766,0.0000024468857,0.0000031052664,0.00037802898],"genre_scores_gemma":[0.99894524,0.00015472018,0.00050919334,0.00016540881,0.000059467813,0.0000014699988,0.0000013181939,0.000011473134,0.00015170132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845994,0.00022974242,0.00073378853,0.00015943457,0.0002590976,0.00015797268],"domain_scores_gemma":[0.9985116,0.00024603042,0.0007348829,0.00019482101,0.00022229849,0.000090329166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010887347,0.000111147565,0.0008466617,0.00014699053,0.000012889817,0.000004502345,0.000095159565,0.00016143547,0.000101930316],"category_scores_gemma":[0.00009648885,0.000076660945,0.00015028399,0.00014562052,0.00015904849,0.00014755623,0.00004227351,0.00038591377,0.0000016524269],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057948824,0.00072521437,0.5836111,0.00008254353,0.0001111456,0.000021159174,0.000078749865,7.890966e-7,0.0009154579,4.458217e-7,0.000017085327,0.3564875],"study_design_scores_gemma":[0.014810499,0.014788374,0.96889144,0.00040344594,0.00011059729,0.00008969372,0.000040031402,0.0000041661106,0.0004270647,0.00001318495,0.0003459521,0.00007552023],"about_ca_topic_score_codex":0.000010160491,"about_ca_topic_score_gemma":0.000074857875,"teacher_disagreement_score":0.3852804,"about_ca_system_score_codex":0.00018837508,"about_ca_system_score_gemma":0.00035919953,"threshold_uncertainty_score":0.31261426},"labels":[],"label_agreement":null},{"id":"W2953499075","doi":"10.1111/his.13946","title":"Inter‐ and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma","year":2019,"lang":"en","type":"article","venue":"Histopathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Concordance; Medicine; Head and neck squamous-cell carcinoma; Intraclass correlation; Carcinoma; Oncology; PD-L1; clone (Java method); Cancer; Immunohistochemistry; Pathology; Head and neck cancer; Internal medicine; Immunotherapy; Biology","score_opus":0.01564064277270831,"score_gpt":0.23902073726632658,"score_spread":0.2233800944936183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953499075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991477,0.006709597,0.0000048534553,0.00024187611,0.00022278892,0.00075651775,0.000019771964,0.0000137866045,0.00055381336],"genre_scores_gemma":[0.99897724,0.00008169216,0.00028539202,0.00018342433,0.00005602208,0.000030292449,0.000011097742,0.000025537756,0.0003493069],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859464,0.000071408875,0.00039780422,0.00047469526,0.000119605866,0.00034187312],"domain_scores_gemma":[0.99938273,0.000039284594,0.00012301412,0.0002889471,0.000046877238,0.00011915119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025232116,0.0002310952,0.0005247224,0.00020653756,0.00003938413,0.000012350392,0.00006936182,0.00014713929,0.000032644362],"category_scores_gemma":[0.000010665847,0.00021009563,0.000053763917,0.00010915937,0.0002537825,0.0000632494,0.00009896825,0.00019684291,0.0000019713566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020835006,0.00012156699,0.90311843,0.00049093395,0.0000036074832,0.00020221346,0.0020983072,1.08392776e-7,0.08499231,0.000025495207,0.000018361352,0.0068451334],"study_design_scores_gemma":[0.008926385,0.0018982834,0.981507,0.00008624228,0.00005796122,0.0013168043,0.0002753578,0.000055731172,0.0048909206,0.000014592816,0.0007758779,0.00019486064],"about_ca_topic_score_codex":0.0021870104,"about_ca_topic_score_gemma":0.00043379216,"teacher_disagreement_score":0.08010139,"about_ca_system_score_codex":0.00012892635,"about_ca_system_score_gemma":0.00009359641,"threshold_uncertainty_score":0.8567451},"labels":[],"label_agreement":null},{"id":"W2953501806","doi":"10.1158/1538-7445.am2019-1500","title":"Abstract 1500: Mediators of CD8+ cytotoxic T lymphocyte infiltration in pancreatic cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Cytotoxic T cell; Pancreatic cancer; Chemokine; CCL5; CXCL9; CXCL10; Cancer research; CD8; Immune system; Immunotherapy; Immunology; Cancer immunotherapy; T cell; Medicine; Biology; Cancer; Internal medicine; IL-2 receptor","score_opus":0.04773726485834382,"score_gpt":0.3878654520946729,"score_spread":0.34012818723632904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953501806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886934,0.006939375,9.481094e-7,0.0005554033,0.0002734948,0.00091479684,0.000028800947,0.000018182895,0.0025755719],"genre_scores_gemma":[0.9910177,0.0072390866,0.000017142034,0.00014267948,0.00017980719,0.00028212674,0.000014123623,0.000029438286,0.0010778944],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979639,0.00008165506,0.00040395083,0.0003097304,0.0007870353,0.00045375002],"domain_scores_gemma":[0.99900776,0.00018009364,0.00009417258,0.00038231455,0.00022399165,0.00011167587],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009018654,0.0001343398,0.00036586382,0.00042005366,0.000039110688,0.000016976506,0.00016750763,0.00013720538,0.0046276366],"category_scores_gemma":[0.00006934609,0.00011408544,0.00009056232,0.00091239356,0.0001900316,0.00012803671,0.000032740983,0.0003433739,0.000061834035],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030994306,0.000089850524,0.19085479,0.0005640538,0.00010272266,0.000012999791,0.0006438705,0.000036493475,0.78842616,0.000029226576,0.0009663694,0.015174052],"study_design_scores_gemma":[0.006221998,0.0003484986,0.59681517,0.0014671749,0.000023072562,0.0000058616993,0.00052740885,0.000096763215,0.3882969,0.00005847086,0.005944383,0.00019427949],"about_ca_topic_score_codex":0.010672317,"about_ca_topic_score_gemma":0.0016850142,"teacher_disagreement_score":0.40596038,"about_ca_system_score_codex":0.0011282548,"about_ca_system_score_gemma":0.0017049368,"threshold_uncertainty_score":0.9962823},"labels":[],"label_agreement":null},{"id":"W2953512316","doi":"10.1158/1538-7445.am2019-ct188","title":"Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Discontinuation; Medicine; Family medicine; Internal medicine","score_opus":0.09129829141963566,"score_gpt":0.41869285483120017,"score_spread":0.3273945634115645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953512316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923188,0.0021756508,0.000007274864,0.00032126918,0.00043371352,0.003054645,0.00025993236,0.000034643228,0.0013940663],"genre_scores_gemma":[0.99721926,0.0002871198,0.00005052084,0.000110643996,0.00018555316,0.0003300763,0.000025326906,0.00007877594,0.0017127324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973303,0.00012158988,0.00046758645,0.0006444362,0.0008544791,0.00058161595],"domain_scores_gemma":[0.99803907,0.0006059843,0.0001427525,0.00070893596,0.00034325646,0.00015999608],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00071326765,0.00026212604,0.00071678765,0.00024300322,0.00011529265,0.00004308325,0.00028612957,0.00015097503,0.0016971596],"category_scores_gemma":[0.00006237231,0.00020974298,0.0001631806,0.00028057196,0.00021562252,0.0001184777,0.000109799934,0.0003837852,0.00002821795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04018651,0.0007693136,0.8475492,0.00050101074,0.0010819149,0.000017036293,0.0021218313,0.000005225117,0.08361174,0.0000285064,0.00038488128,0.023742847],"study_design_scores_gemma":[0.034563992,0.0020970623,0.94703996,0.000287889,0.00008032335,0.0000021025282,0.0044991225,0.000009331653,0.009984246,0.000043015043,0.0011451277,0.00024780526],"about_ca_topic_score_codex":0.0047251717,"about_ca_topic_score_gemma":0.0010861106,"teacher_disagreement_score":0.09949081,"about_ca_system_score_codex":0.00027966997,"about_ca_system_score_gemma":0.00033546903,"threshold_uncertainty_score":0.9992154},"labels":[],"label_agreement":null},{"id":"W2953914066","doi":"10.1158/1538-7445.sabcs18-463","title":"Abstract 463: Integrated digital pathology and transcriptome analysis identifies molecular mediators of T cell exclusion in ovarian cancer","year":2019,"lang":"en","type":"article","venue":"Clinical Research (Excluding Clinical Trials)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Ovarian cancer; Transcriptome; CD8; Cytotoxic T cell; Immunotherapy; Biology; Phenotype; Cancer research; Cancer; Ovarian carcinoma; Immune system; Pathology; Medicine; Immunology; Gene expression; In vitro; Gene; Genetics","score_opus":0.2873265918370317,"score_gpt":0.5490763127051037,"score_spread":0.261749720868072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953914066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935376,0.0021508636,0.00009009737,0.0013159673,0.0009971065,0.001171375,0.00010653842,0.000028835713,0.00060161913],"genre_scores_gemma":[0.9865563,0.012323165,0.0001123149,0.00022406565,0.00026403426,0.00003604496,0.00006223102,0.00003791709,0.0003839176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9890527,0.0032422969,0.004841731,0.0010946385,0.0010840064,0.0006845909],"domain_scores_gemma":[0.97715884,0.020322153,0.00071788335,0.0007659873,0.00052472664,0.00051038555],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.05107089,0.00028654246,0.0028558604,0.0009922879,0.00007084621,0.000084940104,0.00038545465,0.0008349984,0.001369715],"category_scores_gemma":[0.029508745,0.00021553328,0.0015533618,0.0022244367,0.0012113554,0.00018892446,0.00021468067,0.0020059487,0.00004922369],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020267654,0.0017991078,0.7006542,0.00038075572,0.0021614882,0.00038928507,0.00025409562,0.000009608146,0.21040308,0.00004796039,0.0005205004,0.06311226],"study_design_scores_gemma":[0.027163817,0.0025524863,0.95137566,0.0011322593,0.0010182591,0.0000070819424,0.0008474699,0.0005393306,0.010223035,0.0009628514,0.0036795987,0.00049814075],"about_ca_topic_score_codex":0.00040702528,"about_ca_topic_score_gemma":0.00012490952,"teacher_disagreement_score":0.25072145,"about_ca_system_score_codex":0.00012100561,"about_ca_system_score_gemma":0.00069768965,"threshold_uncertainty_score":0.9995432},"labels":[],"label_agreement":null},{"id":"W2954313053","doi":"10.1007/s11936-019-0731-6","title":"Cardiotoxicity of Immune Checkpoint Inhibitors","year":2019,"lang":"en","type":"article","venue":"Current Treatment Options in Cardiovascular Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Cardiotoxicity; Medicine; Myocarditis; Intensive care medicine; Fulminant; Case fatality rate; Cancer; Internal medicine; Epidemiology; Oncology; Chemotherapy","score_opus":0.027832467632892627,"score_gpt":0.2996907282748089,"score_spread":0.2718582606419163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954313053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7986631,0.19520113,0.0001224225,0.00031258882,0.0015740059,0.0014924502,0.000014373998,0.000048025002,0.002571942],"genre_scores_gemma":[0.9840049,0.015049489,0.00014345505,0.000013426142,0.0002981428,0.00011630805,0.000103256854,0.000027615886,0.00024336635],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977746,0.00010964689,0.0008041117,0.0004309529,0.0005931792,0.000287532],"domain_scores_gemma":[0.99855214,0.000047280395,0.00012658542,0.0010601626,0.00011353043,0.00010032026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079701934,0.00028786596,0.0012619069,0.00040038113,0.000034627177,0.000003843015,0.000092945826,0.00010279362,0.0002652889],"category_scores_gemma":[0.00004626203,0.0002069934,0.0015541004,0.0006580702,0.00021829024,0.0000636978,0.000030750558,0.00018260082,0.00003378833],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024726558,0.0034464682,0.20731449,0.001592295,0.014696624,0.00012783076,0.0026201531,0.0012168824,0.111671746,0.00033638132,0.000447142,0.6540573],"study_design_scores_gemma":[0.057377964,0.004655682,0.66341233,0.0052993163,0.003802924,0.0003640287,0.00149338,0.00028962345,0.056103103,0.000076407625,0.20632623,0.000798987],"about_ca_topic_score_codex":0.00044372387,"about_ca_topic_score_gemma":0.000007039881,"teacher_disagreement_score":0.6532583,"about_ca_system_score_codex":0.0006595588,"about_ca_system_score_gemma":0.00014743571,"threshold_uncertainty_score":0.8440946},"labels":[],"label_agreement":null},{"id":"W2954342804","doi":"10.1136/esmoopen-2019-000552","title":"Introducing a new ESMO Open article series: how I treat side effects of immunotherapy","year":2019,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Lung cancer; Internal medicine; Cancer immunotherapy; Clinical trial; Cancer; Melanoma; Pembrolizumab; Cancer research","score_opus":0.011755799005690694,"score_gpt":0.28289966512091025,"score_spread":0.27114386611521957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954342804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9631701,0.0009302401,0.000093437775,0.010488245,0.0005024519,0.0036796501,0.0000050407816,0.000044853496,0.021085994],"genre_scores_gemma":[0.9205202,0.00052212854,0.0034785436,0.0022345125,0.00021464228,0.00008486619,0.000024756477,0.00007370315,0.07284666],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998705,0.00008553516,0.00028473834,0.00040795392,0.00020889708,0.00030785633],"domain_scores_gemma":[0.9986487,0.000116236326,0.00016151938,0.00090569246,0.000058139824,0.00010969642],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039719918,0.00021204236,0.0006071904,0.00007113506,0.0000681545,0.00021638369,0.0007127823,0.00009595243,0.0014537434],"category_scores_gemma":[0.000066902234,0.0001696242,0.00012775317,0.00032468184,0.00006781903,0.0006451064,0.00029571712,0.00014608128,0.00010115089],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0200226,0.00048338313,0.023061657,0.00037879462,0.0010906456,0.00006233046,0.0044440576,0.000012519067,0.6385413,0.00036234251,0.031612,0.27992842],"study_design_scores_gemma":[0.024327671,0.0029938961,0.11076254,0.0011206435,0.00012377552,0.000094809955,0.00068771304,0.000042816955,0.7117042,0.00030648216,0.14740314,0.00043234538],"about_ca_topic_score_codex":0.015422682,"about_ca_topic_score_gemma":0.0005046518,"teacher_disagreement_score":0.27949604,"about_ca_system_score_codex":0.00011452869,"about_ca_system_score_gemma":0.0003148305,"threshold_uncertainty_score":0.9994591},"labels":[],"label_agreement":null},{"id":"W2954377994","doi":"10.1186/s40425-019-0640-y","title":"Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada); Ontario Institute for Cancer Research; Jewish General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"National Center for Advancing Translational Sciences; Society for Immunotherapy of Cancer; National Cancer Institute; Celgene","keywords":"Library science; Computer science; Psychology","score_opus":0.03021381831505963,"score_gpt":0.3515596864330823,"score_spread":0.3213458681180226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954377994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8122178,0.17154235,0.00038987029,0.007567683,0.0066289897,0.0014124663,0.00015355504,0.00001657554,0.00007075937],"genre_scores_gemma":[0.9190523,0.06865584,0.0005908987,0.00499262,0.00071366195,0.0002882806,0.000016732787,0.000109938184,0.005579724],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978699,0.00012661406,0.00092257163,0.00026395568,0.0004911943,0.00032574573],"domain_scores_gemma":[0.99692935,0.0008370946,0.0007799043,0.0004897873,0.0008870702,0.000076766264],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044754436,0.00027945184,0.00090095936,0.00016043747,0.00013986269,0.000035989302,0.00034495423,0.00012713135,0.0017632501],"category_scores_gemma":[0.00006362971,0.00018691516,0.00072753016,0.00051829114,0.00013036796,0.0001239123,0.00003063201,0.00036748234,0.0000049465734],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049091093,0.00012186507,0.005945721,0.00012709145,0.002482066,0.0000018175492,0.0028608753,0.00024835495,0.6332858,0.0000059787412,0.0126927495,0.2931366],"study_design_scores_gemma":[0.011035202,0.0016943214,0.18773723,0.0062642065,0.00042078036,0.000048703,0.0027176186,0.00015325703,0.1360693,0.00008712486,0.65338665,0.00038562494],"about_ca_topic_score_codex":0.004660668,"about_ca_topic_score_gemma":0.0003295873,"teacher_disagreement_score":0.6406939,"about_ca_system_score_codex":0.0003707363,"about_ca_system_score_gemma":0.0006543428,"threshold_uncertainty_score":0.99914926},"labels":[],"label_agreement":null},{"id":"W2954486272","doi":"10.1158/1538-7445.am2019-3141","title":"Abstract 3141: The relationship between BRAF/NRAS/KIT genomic driver mutations and anti-PD1 immunotherapy responses in patients with advanced melanoma","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Neuroblastoma RAS viral oncogene homolog; Medicine; Melanoma; Immunotherapy; Oncology; Internal medicine; Cancer; Ipilimumab; Hazard ratio; Cancer research; KRAS; Confidence interval","score_opus":0.053841706845501124,"score_gpt":0.37446927507133493,"score_spread":0.3206275682258338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954486272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942942,0.0020218168,0.0000024945018,0.0017255025,0.000065776214,0.0014098539,0.00005587426,0.000020227122,0.00040424633],"genre_scores_gemma":[0.99800783,0.0003630605,0.00005134484,0.0001343695,0.000057946374,0.000120878,0.000043465723,0.000039458722,0.0011816206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982935,0.00018314504,0.00027276945,0.00034491275,0.0005073807,0.0003982868],"domain_scores_gemma":[0.9981707,0.001058727,0.00007851803,0.00044107114,0.00017559115,0.00007539999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077536464,0.00014904703,0.0002486302,0.0002992396,0.00022636804,0.000055034317,0.00017814411,0.000094383206,0.0003644549],"category_scores_gemma":[0.00008441348,0.00009999195,0.000047189493,0.0006014973,0.0003477274,0.00017626991,0.00003778537,0.0005600942,0.000041572406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049134763,0.000058348607,0.9690792,0.000045616627,0.000098068675,0.0000043690047,0.0007810258,0.000010664184,0.012043055,0.000029633038,0.00010714037,0.012829402],"study_design_scores_gemma":[0.0065656365,0.00044840318,0.98877907,0.00023552703,0.000012555501,0.0000019049035,0.00024861298,0.0000020852476,0.00075134274,0.00006965421,0.0027530158,0.00013217116],"about_ca_topic_score_codex":0.0005774627,"about_ca_topic_score_gemma":0.00014532602,"teacher_disagreement_score":0.019699892,"about_ca_system_score_codex":0.00035598865,"about_ca_system_score_gemma":0.00042885967,"threshold_uncertainty_score":0.40775532},"labels":[],"label_agreement":null},{"id":"W2954619918","doi":"10.1158/1538-7445.am2019-ct200","title":"Abstract CT200: IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"Medicine; Atezolizumab; Internal medicine; Pemetrexed; Oncology; Population; Carboplatin; Progression-free survival; Docetaxel; Clinical endpoint; Paclitaxel; Bevacizumab; Randomized controlled trial; Chemotherapy; Cancer; Nivolumab; Cisplatin; Immunotherapy","score_opus":0.038004971061680104,"score_gpt":0.4185161436121033,"score_spread":0.3805111725504232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954619918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98696756,0.0049052434,0.000015063718,0.0004823274,0.00011702882,0.006862683,0.00016858886,0.00003438414,0.00044712742],"genre_scores_gemma":[0.9944226,0.0038832084,0.00012192609,0.00004620028,0.00009260222,0.0008250889,0.00006222045,0.000071784285,0.00047437655],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99529314,0.0004691208,0.0009711574,0.00090708357,0.0016622695,0.0006972393],"domain_scores_gemma":[0.9962544,0.0014542463,0.00033595366,0.0012033831,0.00050642114,0.00024559617],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027127059,0.00041166367,0.0020810913,0.0007385832,0.00015121819,0.00005664191,0.00039625002,0.00018405291,0.0016591481],"category_scores_gemma":[0.00032295234,0.00025300955,0.00022681353,0.0021272711,0.00047460143,0.00017357475,0.00012861537,0.0007155285,0.000004896579],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84114736,0.0021805088,0.09255953,0.00015590218,0.002751713,0.0001284298,0.005468319,0.00009791929,0.0177181,0.0000012020756,0.000027533295,0.03776349],"study_design_scores_gemma":[0.8705794,0.011818207,0.102552645,0.0010844469,0.000466569,0.000007693653,0.0060601356,0.0010857763,0.005469583,0.00003116788,0.0003474673,0.0004968666],"about_ca_topic_score_codex":0.037077874,"about_ca_topic_score_gemma":0.02538874,"teacher_disagreement_score":0.037266623,"about_ca_system_score_codex":0.00039754895,"about_ca_system_score_gemma":0.0009219271,"threshold_uncertainty_score":0.9999922},"labels":[],"label_agreement":null},{"id":"W2954741075","doi":"10.1158/1538-7445.pedca19-pr17","title":"Abstract PR17: Immunogenomic landscape of pediatric solid malignancies","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immune system; Cancer; Medicine; Synovial sarcoma; Cancer research; Sarcoma; Malignancy; Immunotherapy; Immunology; Biology; Pathology; Internal medicine","score_opus":0.0979179379956064,"score_gpt":0.39421207268108877,"score_spread":0.2962941346854824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954741075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.972533,0.0220398,0.0000033654226,0.0029448755,0.00010287547,0.00037555417,0.000041863655,0.000029066376,0.00192961],"genre_scores_gemma":[0.98942304,0.009069357,0.000031638254,0.0002982776,0.00071449485,0.000055093653,0.000010178404,0.000026199246,0.0003717537],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99854666,0.000038489165,0.00028802425,0.00024584337,0.00050581415,0.0003751879],"domain_scores_gemma":[0.9992043,0.000074364965,0.000067981244,0.00024582946,0.00026100402,0.00014657198],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004389398,0.00010456225,0.0002645553,0.00014642552,0.00007540156,0.000018702201,0.00020248067,0.000077560675,0.002151631],"category_scores_gemma":[0.000076243035,0.00008695842,0.00012003088,0.0006441497,0.00014385596,0.00005317135,0.0000667069,0.0003183528,0.00007197968],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003439982,0.00007093957,0.026564581,0.0006099905,0.00014885605,0.000032966607,0.0008977905,0.000006526282,0.94149,0.000014876169,0.021602204,0.005121286],"study_design_scores_gemma":[0.0066568647,0.0015502432,0.4659633,0.00027248394,0.000115568364,0.000014404856,0.001332441,0.00004387945,0.4698371,0.000045080797,0.05378412,0.00038449693],"about_ca_topic_score_codex":0.0002950543,"about_ca_topic_score_gemma":0.0000117746695,"teacher_disagreement_score":0.4716529,"about_ca_system_score_codex":0.000101633515,"about_ca_system_score_gemma":0.00073520886,"threshold_uncertainty_score":0.9987605},"labels":[],"label_agreement":null},{"id":"W2955080438","doi":"10.1158/1538-7445.sabcs18-4051","title":"Abstract 4051: First step for development of checkpoint inhibitors immune monitoring panels in human whole blood and peripheral mononuclear cells","year":2019,"lang":"en","type":"article","venue":"Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada)","funders":"","keywords":"Peripheral blood mononuclear cell; Immune system; Monoclonal antibody; Flow cytometry; Antibody; clone (Java method); Immunotherapy; Immunology; CD8; Cancer immunotherapy; Medicine; Biology; Cancer research; In vitro","score_opus":0.016738496301305677,"score_gpt":0.262972273895625,"score_spread":0.24623377759431933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955080438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960426,0.0025371725,0.000009727559,0.00013949507,0.00046277873,0.000619176,0.0000047389312,0.000022519098,0.00016177946],"genre_scores_gemma":[0.99801713,0.00016302326,0.0013235261,0.000014627871,0.00006124303,0.00004221446,0.000009653161,0.000030710522,0.00033788377],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987443,0.000015234093,0.0005962929,0.00025452478,0.000092733135,0.00029693317],"domain_scores_gemma":[0.9994636,0.00004603738,0.00017157604,0.00024262819,0.00004641269,0.000029738309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025233199,0.00017140992,0.00042273672,0.00013148239,0.00007287396,0.000011198625,0.000098199314,0.00017343623,0.00011261548],"category_scores_gemma":[0.000008515438,0.00016208949,0.0000956326,0.00008622425,0.000107519365,0.00006670517,0.00005744938,0.00018004762,0.0000071187524],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010514574,0.00021239808,0.011627503,0.0002083169,0.000248678,0.0000052662226,0.0023683354,0.000004226395,0.9744232,0.000006185348,0.0000057709804,0.009838655],"study_design_scores_gemma":[0.005627163,0.00051103265,0.37485203,0.00030632713,0.000022296568,0.000012215133,0.0010097618,0.0000046845375,0.6118338,0.000007467019,0.005667912,0.00014526547],"about_ca_topic_score_codex":0.00025854964,"about_ca_topic_score_gemma":0.000023079645,"teacher_disagreement_score":0.36322454,"about_ca_system_score_codex":0.00009167247,"about_ca_system_score_gemma":0.000078149744,"threshold_uncertainty_score":0.6609818},"labels":[],"label_agreement":null},{"id":"W2955224282","doi":"10.1093/annonc/mdz206","title":"The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?","year":2019,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":233,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Jewish General Hospital; Université de Montréal; McGill University Health Centre","funders":"Institut Du Cancer de Montréal; Agence Nationale de la Recherche","keywords":"Medicine; Dysbiosis; Microbiome; Cancer; Immunotherapy; Antibiotics; Oncology; Immunology; Internal medicine; Gut flora; Bioinformatics; Intensive care medicine; Microbiology","score_opus":0.13012124007633907,"score_gpt":0.4555019810436903,"score_spread":0.3253807409673512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955224282","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17449448,0.8217584,3.1643154e-7,0.00017555867,0.00017152677,0.0028041557,0.00022790238,0.000009395117,0.00035829953],"genre_scores_gemma":[0.049724855,0.9495614,0.0000074675363,0.00012173276,0.000026483698,0.000011060827,0.00004117355,0.000048321934,0.0004574591],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99795187,0.00023398273,0.00088041206,0.00028519644,0.00030726628,0.00034129395],"domain_scores_gemma":[0.9971741,0.0008907165,0.001230254,0.00040089744,0.00023832667,0.000065742264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019243897,0.00041279916,0.0025128936,0.0002724246,0.00002539058,0.0000074601753,0.00023469618,0.000384307,0.000082573315],"category_scores_gemma":[0.00010001822,0.00019244482,0.0006779806,0.00041007678,0.0001848582,0.000032295524,0.000027165937,0.000390976,0.0000044018952],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037632636,0.0011015461,0.14819005,0.0012397171,0.0036127504,0.000008830417,0.0002584943,0.0000013114085,0.0000058807127,0.000003017216,0.00032779315,0.84148735],"study_design_scores_gemma":[0.011399098,0.05331157,0.6582689,0.019777156,0.0009311487,0.0000137983925,0.000049289116,0.0000014165945,0.00017146037,0.000009341298,0.2555805,0.0004862778],"about_ca_topic_score_codex":0.0032200806,"about_ca_topic_score_gemma":0.00047262266,"teacher_disagreement_score":0.8410011,"about_ca_system_score_codex":0.00040365476,"about_ca_system_score_gemma":0.0026931432,"threshold_uncertainty_score":0.78476715},"labels":[],"label_agreement":null},{"id":"W2955241001","doi":"10.1158/1538-7445.am2019-2405","title":"Abstract 2405: B7H4 as a T cell inhibitory regulator in bladder cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"CD8; Cancer research; T cell; Transcriptome; Cytotoxic T cell; Cell growth; Biology; Cell; In vitro; Immunology; Medicine; Immune system; Gene expression; Gene; Genetics","score_opus":0.05003311348813792,"score_gpt":0.40121581435592696,"score_spread":0.351182700867789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955241001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9625284,0.013368109,1.8155265e-7,0.0021237151,0.00053731346,0.0009697841,0.000019691332,0.00003558301,0.020417241],"genre_scores_gemma":[0.967476,0.0028931664,0.000012523904,0.00070477865,0.0004981343,0.00032787689,0.000007918667,0.000054331987,0.02802526],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99745786,0.00008014816,0.00032119316,0.000512803,0.0008991329,0.0007288535],"domain_scores_gemma":[0.99886566,0.0001085113,0.00005830516,0.0005374172,0.00023371023,0.00019637203],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00089957914,0.00017816295,0.00031816418,0.00038802772,0.00007283261,0.00004105521,0.0002144751,0.00019548682,0.016571859],"category_scores_gemma":[0.000028985187,0.0001537967,0.0001190388,0.00076211855,0.00021232365,0.00012883644,0.000075493655,0.0008190829,0.00054385734],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004413342,0.00023423965,0.03478022,0.0005106996,0.00011316345,0.000093159404,0.00090032653,0.000018080913,0.8802554,0.000029316167,0.051469278,0.027182756],"study_design_scores_gemma":[0.009818855,0.0005841494,0.28281087,0.0014611678,0.000025300567,0.000015242226,0.001458397,0.000036424586,0.3914925,0.00012191285,0.31169623,0.00047896654],"about_ca_topic_score_codex":0.010763173,"about_ca_topic_score_gemma":0.001426581,"teacher_disagreement_score":0.48876294,"about_ca_system_score_codex":0.0010204568,"about_ca_system_score_gemma":0.0017461504,"threshold_uncertainty_score":0.9958242},"labels":[],"label_agreement":null},{"id":"W2955283109","doi":"10.1158/1078-0432.ccr-18-3944","title":"Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institutes of Health; Ono Pharmaceutical; National Cancer Institute; National Institute for Health and Care Research; Bristol-Myers Squibb","keywords":"Cetuximab; Nivolumab; Medicine; Head and neck; Head and neck squamous-cell carcinoma; Oncology; Basal cell; Internal medicine; Head and neck cancer; Cancer; Surgery; Immunotherapy; Colorectal cancer","score_opus":0.09167109629543041,"score_gpt":0.41982478930838263,"score_spread":0.3281536930129522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955283109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99504226,0.0022436131,2.7928422e-7,0.00057378557,0.00009598887,0.0019086768,0.000060988343,0.0000041391568,0.00007023924],"genre_scores_gemma":[0.99828255,0.0008046416,0.00004339584,0.00013417976,0.000015675943,0.00003947626,0.000008388321,0.000022201966,0.00064950756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759626,0.00041150252,0.00063232833,0.00042843123,0.0005449632,0.0003865361],"domain_scores_gemma":[0.9982165,0.000987891,0.00011834567,0.00040810983,0.00014662526,0.00012253912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013388391,0.00013970291,0.00050500757,0.00010902085,0.000049714166,0.000022702396,0.00014806922,0.000086200336,0.00012967607],"category_scores_gemma":[0.0003283913,0.000079258716,0.00005107414,0.0005278035,0.00047685127,0.00008561914,0.00013701434,0.00067030935,0.0000021342532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05462401,0.0011061247,0.91308784,0.00034443822,0.000022973065,0.0000056080517,0.00026806723,7.969841e-7,0.00018824697,9.3027626e-7,0.00046117842,0.029889783],"study_design_scores_gemma":[0.04304227,0.0044501633,0.9495954,0.0004693466,0.000021347021,0.0000012061877,0.00008004104,0.000053323944,0.00027226252,0.0000023540424,0.0019128108,0.00009949439],"about_ca_topic_score_codex":0.0025820297,"about_ca_topic_score_gemma":0.0017482607,"teacher_disagreement_score":0.03650754,"about_ca_system_score_codex":0.00019576371,"about_ca_system_score_gemma":0.00052150653,"threshold_uncertainty_score":0.39032736},"labels":[],"label_agreement":null},{"id":"W2955654457","doi":"10.1021/acsmedchemlett.9b00221","title":"<i>In Vitro</i> Assessment of Putative PD-1/PD-L1 Inhibitors: Suggestions of an Alternative Mode of Action","year":2019,"lang":"en","type":"article","venue":"ACS Medicinal Chemistry Letters","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"Canadian Cancer Society Research Institute; Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs; Michael Smith Health Research BC; University of Victoria","keywords":"Mode of action; In vitro; Action (physics); Pharmacology; Computational biology; Combinatorial chemistry; Chemistry; Computer science; Medicine; Information retrieval; Biology; Biochemistry; Physics","score_opus":0.012365480067953839,"score_gpt":0.3263274455219592,"score_spread":0.31396196545400534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955654457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996457,0.00006501009,0.0001597279,0.002218876,0.00016493385,0.0002522807,0.00005548172,0.000008504535,0.00061821577],"genre_scores_gemma":[0.99847794,0.00004594752,0.00061324245,0.00052037457,0.00014166729,0.000013655423,0.000107087784,0.000014652795,0.00006544841],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998584,0.00004054969,0.00049565325,0.00023142263,0.00048464315,0.00016374282],"domain_scores_gemma":[0.9990536,0.00010512074,0.00039313227,0.00026492597,0.00011722936,0.00006596502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002300856,0.00015185834,0.00043952055,0.00008575737,0.000011949804,0.0000019961653,0.00011313511,0.000083820494,0.00008722774],"category_scores_gemma":[0.000027892149,0.00013535816,0.00009933822,0.00023151253,0.00024890847,0.00012765585,0.000019551326,0.00024868562,5.357782e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001867127,0.00021234932,0.001523478,0.0005209588,0.00015523279,0.000015011604,0.0008856725,0.00012748272,0.99355143,0.0000030434662,0.00015105761,0.0009871478],"study_design_scores_gemma":[0.0031189597,0.00025565707,0.004299974,0.0004310443,0.00008456577,0.000029875635,0.0013195074,0.00033427982,0.9899245,0.000021937964,0.00007923219,0.000100486504],"about_ca_topic_score_codex":0.00077365147,"about_ca_topic_score_gemma":0.000003197082,"teacher_disagreement_score":0.003626959,"about_ca_system_score_codex":0.00020013646,"about_ca_system_score_gemma":0.00015678923,"threshold_uncertainty_score":0.55197453},"labels":[],"label_agreement":null},{"id":"W2955839328","doi":"10.1002/cncr.32190","title":"Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial","year":2019,"lang":"en","type":"article","venue":"Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Bristol-Myers Squibb; Ono Pharmaceutical; National Institute for Health and Care Research; University of Texas MD Anderson Cancer Center","keywords":"Medicine; Nivolumab; Response Evaluation Criteria in Solid Tumors; Internal medicine; Oncology; Randomized controlled trial; Clinical trial; Head and neck squamous-cell carcinoma; Target lesion; Immunotherapy; Phases of clinical research; Head and neck cancer; Cancer","score_opus":0.05610088972359639,"score_gpt":0.40369909282406696,"score_spread":0.34759820310047057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955839328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98836154,0.007814641,0.0000022709858,0.00020220061,0.00033064853,0.0031065987,0.000056676505,0.0000042523498,0.00012115477],"genre_scores_gemma":[0.9979928,0.0010934247,0.00011331395,0.00005436952,0.000028418028,0.00031365003,0.000021446569,0.000012626965,0.00036993294],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977272,0.00039461136,0.001154009,0.00030731686,0.00023296566,0.00018387202],"domain_scores_gemma":[0.99861425,0.0004104111,0.0005127826,0.00035379335,0.0000556278,0.000053124866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010178678,0.00017318416,0.001669967,0.00025192802,0.000015380303,0.00000600054,0.000077838806,0.00007732548,0.00027183298],"category_scores_gemma":[0.00012954908,0.00009075987,0.00051765237,0.0008877549,0.00018609189,0.000030738523,0.000024372148,0.00011861165,4.2815284e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89609426,0.0022229927,0.04386863,0.00018214685,0.00054987415,0.000010111422,0.00095278665,0.00000555127,0.0018991161,0.0000024554251,0.000030945797,0.054181136],"study_design_scores_gemma":[0.9548611,0.0049574017,0.031675722,0.0003281887,0.0022761438,0.0000017444021,0.00012674867,0.00212272,0.003269661,0.0000074674053,0.0002586178,0.00011446703],"about_ca_topic_score_codex":0.0019789939,"about_ca_topic_score_gemma":0.0027646832,"teacher_disagreement_score":0.058766864,"about_ca_system_score_codex":0.00024433312,"about_ca_system_score_gemma":0.00038857642,"threshold_uncertainty_score":0.370108},"labels":[],"label_agreement":null},{"id":"W2955877427","doi":"10.14740/jh507","title":"Bone Marrow Findings of Immune-Mediated Pure Red Cell Aplasia Following Anti-Programmed Cell Death Receptor-1 Therapy: A Report of Two Cases and Review of Literature","year":2019,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pure red cell aplasia; Lymphocytosis; Immunology; Bone marrow; Pancytopenia; Immune system","score_opus":0.012092972116947698,"score_gpt":0.2804414602021144,"score_spread":0.2683484880851667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955877427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75895244,0.23957752,0.0000023426294,0.0006365481,0.00027427857,0.00038637253,0.000008119011,0.000004830105,0.00015754133],"genre_scores_gemma":[0.9464516,0.05184914,0.0012699631,0.00017393783,0.000028226445,0.0000027447827,0.000028835766,0.000024292636,0.00017128378],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99741256,0.000128296,0.0017116535,0.00018482293,0.00034047756,0.00022216763],"domain_scores_gemma":[0.9968815,0.00025457935,0.0020656555,0.00033023025,0.0003859518,0.00008209016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001081514,0.0002076658,0.0017006241,0.00025983044,0.000019244573,0.000006170025,0.00012741098,0.00019804158,0.00017930819],"category_scores_gemma":[0.00022486188,0.00014814123,0.0005639405,0.0003936922,0.000094275536,0.00009628333,0.000027748154,0.00032704842,9.228116e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028391052,0.00041890584,0.14311543,0.009897543,0.0005543706,0.0019448528,0.0004312491,9.471383e-8,0.8377071,0.0000103084085,0.0022978028,0.0007832166],"study_design_scores_gemma":[0.02204827,0.0050088274,0.012608179,0.041222963,0.0007876286,0.05216003,0.00043060415,0.000004856407,0.85081714,0.00004144938,0.014485259,0.0003847997],"about_ca_topic_score_codex":0.000022709783,"about_ca_topic_score_gemma":0.0000010278513,"teacher_disagreement_score":0.18772838,"about_ca_system_score_codex":0.000032040753,"about_ca_system_score_gemma":0.00023885701,"threshold_uncertainty_score":0.60410243},"labels":[],"label_agreement":null},{"id":"W2955886650","doi":"10.1158/1538-7445.am2019-lb-225","title":"Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Oncology; Internal medicine; Triple-negative breast cancer; Breast cancer; Cohort; Tumor-infiltrating lymphocytes; Cancer; Gene signature; Gene expression; Immunotherapy; Gene; Biology","score_opus":0.017428781766807483,"score_gpt":0.35015654284941816,"score_spread":0.3327277610826107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955886650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911736,0.0018342135,0.000013315593,0.0019248804,0.00015392991,0.0037972233,0.00057995383,0.000028886416,0.0004939966],"genre_scores_gemma":[0.9978098,0.0004337953,0.00010953734,0.00042669536,0.000037180984,0.00059079984,0.000021587146,0.00008804923,0.00048253534],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9958346,0.0004915222,0.00052302994,0.00073782715,0.0016221707,0.0007908769],"domain_scores_gemma":[0.99751365,0.00045497122,0.00019079588,0.00064416585,0.0009027992,0.0002936059],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012798462,0.00034763748,0.00068296073,0.0010247432,0.000079148005,0.000037415193,0.0003676471,0.0001515114,0.0015252525],"category_scores_gemma":[0.0001545089,0.00027018637,0.00015555011,0.0019225097,0.00037523248,0.00018798118,0.000066532266,0.0006766712,0.000024163346],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.639742,0.0005804304,0.036323696,0.00028391415,0.0015323065,0.000074302305,0.002087669,0.00046625838,0.29967293,0.000009795158,0.0008845996,0.01834207],"study_design_scores_gemma":[0.030532725,0.005070049,0.86318964,0.0015564619,0.000063178915,0.0000050625918,0.00082270964,0.00005106198,0.09781509,0.00005811747,0.00047698704,0.00035894607],"about_ca_topic_score_codex":0.009780382,"about_ca_topic_score_gemma":0.0003474838,"teacher_disagreement_score":0.8268659,"about_ca_system_score_codex":0.0014213521,"about_ca_system_score_gemma":0.0020356677,"threshold_uncertainty_score":0.999975},"labels":[],"label_agreement":null},{"id":"W2955959842","doi":"10.1158/1538-7445.am2019-ct166","title":"Abstract CT166: A Phase I/II, open-label, two part study of GSK3359609 in combination with tremelimumab in participants with selected, advanced solid tumors","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Princess Margaret Cancer Centre","funders":"","keywords":"Tremelimumab; Medicine; Internal medicine; Oncology; Cancer; Ipilimumab; Immunotherapy; Pharmacology","score_opus":0.1232677421746893,"score_gpt":0.47346573222076316,"score_spread":0.3501979900460739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955959842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99451256,0.00044055836,7.17196e-7,0.0003257459,0.00004479294,0.0040064757,0.000012380596,0.000016705875,0.0006400389],"genre_scores_gemma":[0.9982485,0.00015698609,0.000028474835,0.000051260136,0.000022580829,0.0008913974,0.000018066034,0.000041390096,0.00054133893],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971832,0.00018145413,0.00051228306,0.00051844044,0.0008833875,0.00072125485],"domain_scores_gemma":[0.9986611,0.0001116596,0.00014765888,0.00047919268,0.0004725799,0.00012783353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001292041,0.00019368267,0.00058825285,0.0004572764,0.00008055172,0.00003662227,0.00030675804,0.00005301598,0.00043180623],"category_scores_gemma":[0.000052456126,0.00014391077,0.000015178114,0.002171285,0.00015253312,0.00028074067,0.00008836851,0.00054966495,0.000007226841],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20379099,0.033047717,0.26385626,0.00046974767,0.00046549056,0.00041460313,0.009657531,0.0003998166,0.41651398,0.000020397403,0.00042455268,0.07093892],"study_design_scores_gemma":[0.43017083,0.07965735,0.3894255,0.0053031174,0.000069029054,0.000021897058,0.011664966,0.00067899097,0.08136116,0.000030771742,0.00097236666,0.00064403575],"about_ca_topic_score_codex":0.0055236933,"about_ca_topic_score_gemma":0.020023497,"teacher_disagreement_score":0.3351528,"about_ca_system_score_codex":0.000581824,"about_ca_system_score_gemma":0.0012141258,"threshold_uncertainty_score":0.9978585},"labels":[],"label_agreement":null},{"id":"W2956547457","doi":"10.1200/jco.2019.37.8_suppl.82","title":"Real-world characterization of patients with cancer admitted with immune-related adverse events (irAEs).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Pembrolizumab; Nivolumab; Lung cancer; Adverse effect; Internal medicine; Cancer; Medical record; Pneumonitis; Pediatrics; Lung; Immunotherapy","score_opus":0.030311993426305844,"score_gpt":0.38111122616167636,"score_spread":0.3507992327353705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956547457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965681,0.000046690024,0.000009578037,0.0010457268,0.0009573746,0.00038837938,0.000011782182,0.0000068191675,0.0009655457],"genre_scores_gemma":[0.99703187,0.0006566648,0.00024160306,0.0005702968,0.00013395914,0.0000032757487,0.000028069126,0.000021796943,0.0013124482],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706334,0.0001883247,0.0020434447,0.00014640646,0.00039661588,0.00016184499],"domain_scores_gemma":[0.9954892,0.00023368945,0.00329633,0.00018940357,0.000652692,0.0001387236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009178986,0.00013075919,0.0011278451,0.0001548106,0.000017866678,0.0000013020364,0.00011220582,0.00020387057,0.00087556656],"category_scores_gemma":[0.00007584609,0.00007653254,0.00027407522,0.00031651088,0.00012622289,0.0001435415,0.000016840499,0.00048206415,0.000007887622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0641482,0.0011593429,0.91000295,0.00004153036,0.0010556218,0.000025367786,0.0000711804,0.0000071940262,0.004072244,0.0000070685983,0.00005262272,0.019356694],"study_design_scores_gemma":[0.026023159,0.014164923,0.9509106,0.00050740456,0.00035913874,0.000013499184,0.000023653958,0.000014964968,0.00036573707,0.0000034013574,0.007524543,0.000088976056],"about_ca_topic_score_codex":0.00011924005,"about_ca_topic_score_gemma":0.00009055648,"teacher_disagreement_score":0.040907666,"about_ca_system_score_codex":0.00017428507,"about_ca_system_score_gemma":0.0013674758,"threshold_uncertainty_score":0.958684},"labels":[],"label_agreement":null},{"id":"W2956756279","doi":"10.1200/jco.2019.37.8_suppl.85","title":"Comparison of care patterns for hospitalized immune-related adverse events (irAEs) between melanoma patients on combination immune checkpoint inhibitor (ICI) therapy versus ICI monotherapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Combination therapy; Ipilimumab; Nivolumab; Internal medicine; Adverse effect; Pneumonitis; Pembrolizumab; Cancer; Infliximab; Melanoma; Surgery; Immunotherapy","score_opus":0.07641191059100924,"score_gpt":0.4351657891211862,"score_spread":0.35875387853017693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956756279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99174094,0.0011225913,0.000030350504,0.0008808706,0.0044537005,0.0013987976,0.000037142927,0.000013606863,0.00032200755],"genre_scores_gemma":[0.9982295,0.00078212767,0.00020368882,0.00022836427,0.0003015727,0.000013686151,0.00010021139,0.000045709254,0.00009514573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940165,0.0003987815,0.004469876,0.00026811857,0.00056209165,0.00028462854],"domain_scores_gemma":[0.9927469,0.0013616411,0.004569237,0.0003447002,0.00082390965,0.00015362677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017354597,0.00027018014,0.0023659414,0.00021671785,0.00005242617,0.000004098019,0.00027625167,0.0006239928,0.00018891005],"category_scores_gemma":[0.00041000912,0.0002024613,0.0015921597,0.00016190566,0.0001364911,0.00012372807,0.00003255026,0.00070242584,0.000012741144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.123506516,0.0034364352,0.7710037,0.00009188411,0.0019008156,0.00000474792,0.0010153624,0.000010641372,0.0017934329,0.000012465277,0.00008714756,0.09713685],"study_design_scores_gemma":[0.11954555,0.09465206,0.77463,0.00040883545,0.00025390115,0.0000017781377,0.0006341506,0.000037534348,0.0057103145,0.000032198357,0.003928614,0.00016506058],"about_ca_topic_score_codex":0.00007397342,"about_ca_topic_score_gemma":0.000008226957,"teacher_disagreement_score":0.09697179,"about_ca_system_score_codex":0.00044883104,"about_ca_system_score_gemma":0.00047839587,"threshold_uncertainty_score":0.82561326},"labels":[],"label_agreement":null},{"id":"W2956922351","doi":"10.1158/1078-0432.ccr-19-0298","title":"Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Juravinski Cancer Centre; Spinal Cord Injury BC; Canadian Cancer Society; Espace pour la vie","funders":"Innate Pharma","keywords":"Medicine; Nausea; Vomiting; Pharmacodynamics; Internal medicine; Adverse effect; Cohort; Tolerability; Gastroenterology; Cancer; Cervical cancer; Endometrial cancer; Response Evaluation Criteria in Solid Tumors; Pharmacokinetics; Clinical trial; Phases of clinical research","score_opus":0.14237343410683095,"score_gpt":0.4662813181220757,"score_spread":0.32390788401524473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956922351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99042696,0.0011327744,1.6945589e-7,0.00044678999,0.000519734,0.007288494,0.000057093333,0.000005716393,0.00012227427],"genre_scores_gemma":[0.99822456,0.000839178,0.000013520883,0.00014679873,0.00008340895,0.00049117947,0.0000067883166,0.000024110806,0.00017046089],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99534655,0.0012793315,0.0012557127,0.0005053491,0.0011196655,0.00049339357],"domain_scores_gemma":[0.996943,0.0014125683,0.0004110415,0.00057219283,0.0004809484,0.00018022401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068125497,0.0001733922,0.0011067021,0.00028926454,0.000117212265,0.000017151786,0.00027616255,0.00020885297,0.00036269412],"category_scores_gemma":[0.0011006856,0.000100652105,0.00015705284,0.00091562135,0.0004598754,0.000077952805,0.000105410145,0.00065581704,0.0000012729753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13723756,0.0009783863,0.8309926,0.00010830068,0.00023401923,0.000003887546,0.00043590815,0.000016254291,0.00030420852,0.0000053052545,0.00008359016,0.02959996],"study_design_scores_gemma":[0.12788081,0.009769474,0.8604103,0.0005619153,0.00007279093,2.446798e-7,0.000586656,0.000015518728,0.00009064453,0.000014658646,0.00049214886,0.00010485086],"about_ca_topic_score_codex":0.16626701,"about_ca_topic_score_gemma":0.36601573,"teacher_disagreement_score":0.19974874,"about_ca_system_score_codex":0.0006002825,"about_ca_system_score_gemma":0.0021459328,"threshold_uncertainty_score":0.8392849},"labels":[],"label_agreement":null},{"id":"W2957094860","doi":"10.1007/s00259-019-04412-6","title":"Inflammatory response to the anti PD-L1 drug, atezolizumab, masquerades as breast implant rupture","year":2019,"lang":"en","type":"article","venue":"European Journal of Nuclear Medicine and Molecular Imaging","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Atezolizumab; Medicine; Breast implant; Drug; Implant; Internal medicine; Dermatology; Pharmacology; Surgery; Pembrolizumab; Cancer; Immunotherapy","score_opus":0.005183033422075557,"score_gpt":0.23499392861244017,"score_spread":0.22981089519036463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2957094860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89594704,0.0027834815,0.000025410469,0.09788586,0.00034847928,0.00020375646,0.0000025101965,0.000018750892,0.0027846938],"genre_scores_gemma":[0.9637067,0.0003238319,0.00014164689,0.03524665,0.00034614294,2.4889147e-7,0.0000015140615,0.000062996616,0.00017030312],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99828273,0.00042895105,0.0004556269,0.00018342467,0.0004080021,0.00024126444],"domain_scores_gemma":[0.99904406,0.000055568806,0.0002242393,0.00030463052,0.00013806118,0.00023342809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017641472,0.00019020373,0.00033029958,0.00022810047,0.00009367461,0.00004349068,0.00020992676,0.000016345508,0.00019613502],"category_scores_gemma":[0.00009496822,0.00011256364,0.00013019664,0.00016554986,0.00013896349,0.00009055136,0.00007596949,0.00038698083,0.00007843904],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010925781,0.000038632694,0.0020454484,0.00007003492,0.000253929,0.008000982,0.0063602757,0.000005421325,0.8637885,0.000039095896,0.0837623,0.02470959],"study_design_scores_gemma":[0.005345098,0.00096054486,0.08577271,0.0014490085,0.0001471121,0.033958428,0.004738744,0.000025008017,0.0010954998,0.000006304617,0.86630654,0.00019498053],"about_ca_topic_score_codex":0.000014443811,"about_ca_topic_score_gemma":2.7038763e-7,"teacher_disagreement_score":0.862693,"about_ca_system_score_codex":0.000044885506,"about_ca_system_score_gemma":0.00007543115,"threshold_uncertainty_score":0.45902118},"labels":[],"label_agreement":null},{"id":"W2958648554","doi":"10.1186/s40425-019-0662-5","title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":738,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Center for Advancing Translational Sciences; University of Texas MD Anderson Cancer Center; National Institute for Health and Care Research; Cancer Research UK; Yale University; Society for Immunotherapy of Cancer; Università degli Studi di Milano; Brigham and Women's Hospital; Yale Cancer Center; Memorial Sloan-Kettering Cancer Center","keywords":"Pembrolizumab; Medicine; Nivolumab; Head and neck squamous-cell carcinoma; Oncology; Internal medicine; Immunotherapy; Cancer; Head and neck cancer; Population","score_opus":0.02314064955390921,"score_gpt":0.33343247864077485,"score_spread":0.31029182908686564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958648554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.790246,0.19892289,0.00013313814,0.0037360727,0.0014492159,0.004876777,0.00059778476,0.0000064173696,0.00003172795],"genre_scores_gemma":[0.88735527,0.10700372,0.00060385844,0.00079288136,0.00024729135,0.0008251852,0.0000066181337,0.00012890917,0.003036241],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99692214,0.000086805616,0.0015719372,0.0003176359,0.00056975335,0.0005317052],"domain_scores_gemma":[0.99467266,0.001542063,0.0021019725,0.00085436594,0.0007753607,0.000053560638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009401458,0.00046185256,0.0010724323,0.00008809796,0.00047989291,0.00003376973,0.00047833283,0.00017585425,0.00013007197],"category_scores_gemma":[0.000014287259,0.000227224,0.0023758041,0.00023327266,0.00063578534,0.00005502466,0.000014781383,0.00019607155,1.2923817e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10086498,0.0012326423,0.011761172,0.0006887403,0.0061990824,2.3461318e-7,0.0064315167,0.00029657263,0.60567796,0.00015251918,0.0037661763,0.26292843],"study_design_scores_gemma":[0.0661817,0.019177442,0.041730758,0.00059860013,0.00059673353,0.000013093886,0.002135157,0.0004246919,0.4815457,0.00029506176,0.38692397,0.0003771151],"about_ca_topic_score_codex":0.0015838358,"about_ca_topic_score_gemma":0.00023429436,"teacher_disagreement_score":0.3831578,"about_ca_system_score_codex":0.00051309983,"about_ca_system_score_gemma":0.00095399586,"threshold_uncertainty_score":0.9265926},"labels":[],"label_agreement":null},{"id":"W2958944135","doi":"10.1200/jco.2019.37.8_suppl.100","title":"CheckMate 384: Phase IIIb/IV trial of nivolumab (nivo) 480 mg Q4W versus 240 mg Q2W after ≤ 12 months of nivo in previously treated advanced NSCLC.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Southlake Regional Health Center","funders":"","keywords":"Medicine; Dosing; Interim analysis; Nivolumab; Internal medicine; Safety profile; Pharmacokinetics; Randomized controlled trial; Gastroenterology; Oncology; Adverse effect; Cancer; Immunotherapy","score_opus":0.07353088413689789,"score_gpt":0.4558853785881979,"score_spread":0.3823544944513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958944135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896701,0.0022989735,0.000009529612,0.0010642156,0.0030393666,0.0010347064,0.000015969144,0.000010843709,0.0028563263],"genre_scores_gemma":[0.99344474,0.0041525806,0.0005861539,0.0004009068,0.00061852235,0.00001549804,0.000005985178,0.000034494733,0.00074109173],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99377394,0.0005631758,0.004425616,0.0003118369,0.0005207173,0.00040472424],"domain_scores_gemma":[0.99398065,0.0016440854,0.0032796757,0.0004446139,0.0003911076,0.00025990108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003254562,0.000265177,0.0028582213,0.00029276175,0.000016906873,0.0000055514383,0.00028750798,0.0006453362,0.0008272304],"category_scores_gemma":[0.0014558225,0.00019940537,0.0011290322,0.00029786504,0.00034627324,0.00019448993,0.000053858326,0.0008783173,0.000013658052],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80064803,0.004803677,0.007103477,0.00010052044,0.0007042387,0.0002733605,0.0002431902,0.0000068598533,0.011083733,0.0000037671955,0.00056563545,0.17446348],"study_design_scores_gemma":[0.7893275,0.11017343,0.04999927,0.00082590774,0.00076503,0.00008919811,0.00028990116,0.00012673925,0.0020623014,0.00003442441,0.04604936,0.00025693045],"about_ca_topic_score_codex":0.00015263612,"about_ca_topic_score_gemma":0.00026816773,"teacher_disagreement_score":0.17420655,"about_ca_system_score_codex":0.00032857122,"about_ca_system_score_gemma":0.0015913419,"threshold_uncertainty_score":0.9057593},"labels":[],"label_agreement":null},{"id":"W2960346100","doi":"10.1016/bs.mie.2019.05.040","title":"DIY: Visualizing the immune landscape of tumors using transcriptome and methylome data","year":2019,"lang":"en","type":"article","venue":"Methods in enzymology on CD-ROM/Methods in enzymology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"Canadian Institutes of Health Research","keywords":"Immune system; Transcriptome; Immune checkpoint; Tumor microenvironment; Biology; Computational biology; Tumor-infiltrating lymphocytes; Immunotherapy; Cancer research; Immunology; Gene; Genetics; Gene expression","score_opus":0.09687006259291128,"score_gpt":0.4599538056504083,"score_spread":0.363083743057497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2960346100","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9610361,0.01559694,0.017932182,0.00097473705,0.0018566027,0.0012784494,0.000041470452,0.0000640248,0.001219491],"genre_scores_gemma":[0.38368836,0.0006526155,0.61390996,0.0012452488,0.00010931206,0.000052572854,0.000037924,0.00009507921,0.0002089241],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9857148,0.009743251,0.0018722982,0.0013532944,0.00030717032,0.001009201],"domain_scores_gemma":[0.9901689,0.0068444433,0.0005814611,0.0021956908,0.00008970519,0.00011978948],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.01957621,0.000606461,0.0022820102,0.001197557,0.00010785142,0.000020166606,0.0010662555,0.0008041623,0.00050192315],"category_scores_gemma":[0.0017203533,0.00046703735,0.00024045398,0.0014430404,0.0011383033,0.00017412873,0.00048115055,0.0014980778,0.000005604179],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036725895,0.0004239245,0.025325002,0.0002714007,0.000369381,0.00013890858,0.0020930383,0.00006268312,0.9005552,0.0015589808,0.00004083647,0.06548808],"study_design_scores_gemma":[0.01979789,0.004607887,0.7902103,0.0011150524,0.00063216244,0.0036755027,0.0052059675,0.004570321,0.14852184,0.008869312,0.011186205,0.001607541],"about_ca_topic_score_codex":0.001085603,"about_ca_topic_score_gemma":0.00023077517,"teacher_disagreement_score":0.7648853,"about_ca_system_score_codex":0.00017931839,"about_ca_system_score_gemma":0.0002541364,"threshold_uncertainty_score":0.99977815},"labels":[],"label_agreement":null},{"id":"W2961180278","doi":"10.1177/0825859719858341","title":"Programmed Death 1 Inhibitor–Induced Hypothyroidism on the Palliative Care Unit: Case Report","year":2019,"lang":"en","type":"article","venue":"Journal of Palliative Care","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus; University of British Columbia","funders":"","keywords":"Pembrolizumab; Medicine; Palliative care; Hypoglycemia; Intensive care medicine; Antithyroid drugs; Programmed cell death 1; Cancer; Internal medicine; Immunotherapy; Disease; Nursing; Graves' disease; PD-L1","score_opus":0.075040839142177,"score_gpt":0.35188902025305085,"score_spread":0.27684818111087384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961180278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899759,0.0037956396,0.000013877843,0.0017455596,0.000844589,0.0010100015,0.000030768068,0.000020363408,0.0025632617],"genre_scores_gemma":[0.99774885,0.00016525507,0.00021330133,0.00087902683,0.00052152143,0.000021656035,0.000022883876,0.000041721858,0.0003858009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978197,0.00015816894,0.0007103286,0.00027082776,0.00071936526,0.0003216159],"domain_scores_gemma":[0.9965076,0.0002835099,0.0009393176,0.00043155567,0.001658351,0.00017965978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035233295,0.00030201816,0.0005366594,0.00015712371,0.00016152329,0.000051278086,0.00017369109,0.00016647606,0.00014645426],"category_scores_gemma":[0.00029601587,0.00017590582,0.0004816924,0.00034757683,0.0000768599,0.000090061825,0.000034617402,0.00076452363,0.000020140033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012351334,0.00064102624,0.66247344,0.0007476706,0.0035093953,0.12686174,0.10158339,0.000026141826,0.04937927,0.00046671275,0.0043338165,0.037626065],"study_design_scores_gemma":[0.017215397,0.012450614,0.5353417,0.0033213797,0.00083852303,0.007139628,0.29798818,0.000018927944,0.0857822,0.000103241386,0.03890368,0.0008965777],"about_ca_topic_score_codex":0.000083456776,"about_ca_topic_score_gemma":0.00007969314,"teacher_disagreement_score":0.19640478,"about_ca_system_score_codex":0.00067523785,"about_ca_system_score_gemma":0.00057954603,"threshold_uncertainty_score":0.7173231},"labels":[],"label_agreement":null},{"id":"W2961644267","doi":"10.1186/s40425-019-0643-8","title":"Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer; Yale Cancer Center; Li Ka Shing Foundation; National Cancer Institute; National Institutes of Health; National Science Foundation; Yale University; AstraZeneca; Symphogen; Memorial Sloan-Kettering Cancer Center; National Center for Advancing Translational Sciences; Chugai Pharmaceutical","keywords":"Erlotinib; Infiltration (HVAC); Medicine; Immune system; Cancer research; Mutant; Lung; Oncology; Immunology; Internal medicine; Epidermal growth factor receptor; Biology; Receptor; Gene","score_opus":0.008928297133187109,"score_gpt":0.3020364498705301,"score_spread":0.293108152737343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961644267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97809285,0.019130934,0.000055118297,0.00030710682,0.00090834143,0.0013297674,0.00010293797,0.000018493034,0.000054454587],"genre_scores_gemma":[0.9916406,0.0063716513,0.0003853516,0.0002894345,0.00013268038,0.000057434776,0.000033716366,0.00008183295,0.0010072744],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99721307,0.000085948486,0.0015354627,0.0002448738,0.0005481679,0.00037250877],"domain_scores_gemma":[0.9976677,0.00022239966,0.0013642485,0.00031637895,0.00034443857,0.00008488878],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000813569,0.00031205348,0.00091618934,0.00034143365,0.00007344681,0.00002274199,0.00022848258,0.00015845078,0.0011997995],"category_scores_gemma":[0.000042165702,0.00021562011,0.00034599705,0.00040002025,0.00014129058,0.00025433395,0.000015222866,0.0003510663,0.000001916522],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04117475,0.00024540213,0.017209578,0.0003630371,0.0004884477,0.0000121076755,0.0008342642,0.00020637093,0.92820776,0.0000029666771,0.0007190978,0.010536204],"study_design_scores_gemma":[0.021677593,0.0023224968,0.021791589,0.0031360348,0.00007990761,0.00009003975,0.0004314618,0.0010111459,0.9382583,0.000019004621,0.01087062,0.0003118409],"about_ca_topic_score_codex":0.0003367716,"about_ca_topic_score_gemma":0.000063109284,"teacher_disagreement_score":0.01949716,"about_ca_system_score_codex":0.0004111368,"about_ca_system_score_gemma":0.00090839766,"threshold_uncertainty_score":0.99971324},"labels":[],"label_agreement":null},{"id":"W2962502275","doi":"10.3899/jrheum.190084","title":"Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist","year":2019,"lang":"en","type":"review","venue":"The Journal of Rheumatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Vancouver General Hospital; Jewish General Hospital; McGill University; University of Calgary; University of Alberta; University of British Columbia","funders":"","keywords":"Medicine; Adverse effect; Immune system; Cancer; Immunotherapy; Myositis; Cancer immunotherapy; Arthritis; Immunology; Ipilimumab; Oncology; Internal medicine","score_opus":0.048961324049465724,"score_gpt":0.36408193166326386,"score_spread":0.3151206076137981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2962502275","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029206276,0.99158025,0.00009544639,0.0031863344,0.0013717146,0.0033747815,0.000028800569,0.00003538012,0.000035230274],"genre_scores_gemma":[0.00029381918,0.99821866,0.000037881706,0.0005561944,0.000013985898,0.00014561534,0.000026045847,0.00016210375,0.00054567825],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995125,0.0010188039,0.0026305532,0.0002427034,0.0004676262,0.0005152972],"domain_scores_gemma":[0.9867713,0.0043565487,0.007462047,0.00081680476,0.0005268851,0.00006645045],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0041982234,0.00060616474,0.004518556,0.00019063854,0.00022801137,0.000009860092,0.0008698324,0.0004461558,0.00022948775],"category_scores_gemma":[0.00085691316,0.0002475969,0.001674666,0.00061568187,0.00036577592,0.00011357936,0.000058564674,0.0014295287,0.000013268183],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007212196,0.000403913,0.0012824099,0.066923894,0.048870772,0.000032839456,0.00059411454,0.00001274593,0.000007258937,0.0000749824,0.0135255605,0.8610593],"study_design_scores_gemma":[0.004089057,0.0007416317,0.00009639971,0.24552627,0.01215304,0.019964179,0.00011845518,0.000010449794,7.4635994e-7,0.00001110089,0.71699286,0.00029582874],"about_ca_topic_score_codex":0.00038875954,"about_ca_topic_score_gemma":0.00006402817,"teacher_disagreement_score":0.8607635,"about_ca_system_score_codex":0.0004799261,"about_ca_system_score_gemma":0.002205726,"threshold_uncertainty_score":0.9999976},"labels":[],"label_agreement":null},{"id":"W2963393430","doi":"10.3390/cancers11071009","title":"Somatic Alteration Burden Involving Non-Cancer Genes Predicts Prognosis in Early-Stage Non-Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"NIHR Sheffield Biomedical Research Centre; Canadian Institutes of Health Research; National Institute for Health and Care Research; Princess Margaret Cancer Foundation","keywords":"Somatic cell; Lung cancer; Cancer; Gene; Hazard ratio; Oncology; Stage (stratigraphy); Phenotype; Biology; Immunotherapy; Disease; Transcriptome; Immune system; Survival analysis; Cancer research; Proportional hazards model; Internal medicine; Immunology; Medicine; Gene expression; Genetics; Confidence interval","score_opus":0.014746357189210815,"score_gpt":0.26760398289950155,"score_spread":0.25285762571029075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963393430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838089,0.011270526,0.00006416049,0.00038805034,0.001150306,0.002121975,0.00003788997,0.000058882626,0.001099325],"genre_scores_gemma":[0.98728156,0.005950915,0.00021205869,0.00053756626,0.0005399266,0.0009924776,0.00002561714,0.00006795942,0.0043919045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981212,0.00003631191,0.00046934656,0.00051708485,0.0003325597,0.0005234659],"domain_scores_gemma":[0.9991535,0.000041408493,0.00021788395,0.00034263366,0.00010583473,0.00013877355],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020867435,0.000301982,0.00046093087,0.00021967382,0.00007453873,0.000064615146,0.00018261537,0.00017039414,0.00081836036],"category_scores_gemma":[0.000007396891,0.0002796108,0.00014353644,0.00046148902,0.00006271241,0.000243072,0.000043187254,0.00025476966,0.000024180672],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073267746,0.00003539698,0.79713494,0.0019143695,0.00021540948,0.000022060314,0.005936929,0.0049199606,0.18073782,0.0000015469568,0.0009961813,0.007352696],"study_design_scores_gemma":[0.016607003,0.0008429297,0.59618735,0.007546083,0.0004617258,0.0000075946314,0.002293002,0.15059468,0.215851,0.0000075104626,0.008333876,0.0012672581],"about_ca_topic_score_codex":0.015415829,"about_ca_topic_score_gemma":0.0017830865,"teacher_disagreement_score":0.20094761,"about_ca_system_score_codex":0.002578983,"about_ca_system_score_gemma":0.0014540975,"threshold_uncertainty_score":0.9999656},"labels":[],"label_agreement":null},{"id":"W2963476376","doi":"10.1016/s1470-2045(19)30388-2","title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1153,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"Merck Sharp and Dohme; Les Laboratories Pierre Fabre; Merck; Meso Scale Diagnostics; Roche; British Microcirculation Society; Amgen","keywords":"Ipilimumab; Pembrolizumab; Post-hoc analysis; Open label; Medicine; Post hoc; Oncology; Internal medicine; Clinical trial; Immunotherapy; Cancer","score_opus":0.04835099458072202,"score_gpt":0.3901170919169451,"score_spread":0.3417660973362231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963476376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764865,0.000868357,0.0000017031892,0.0040186634,0.0014034907,0.008194679,0.00019730403,0.00008014354,0.008749179],"genre_scores_gemma":[0.99524987,0.00046536903,0.0003580199,0.002116715,0.00048472604,0.00033760542,0.00022944155,0.00004963147,0.00070861063],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963122,0.0010947612,0.000905788,0.00071272906,0.00032463358,0.00064987765],"domain_scores_gemma":[0.99613106,0.0018642851,0.00041951227,0.001296699,0.000146143,0.00014231299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017737034,0.0003504626,0.0018477615,0.00012106525,0.00011261271,0.00005782685,0.0008537883,0.00021483163,0.00057625386],"category_scores_gemma":[0.00042211125,0.00023242015,0.00010341095,0.00027041952,0.00013863425,0.00023082951,0.0001917475,0.0005255613,0.00019706391],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9470787,0.0052267807,0.00060905074,0.00001207628,0.0006599836,0.00016835945,0.003352647,0.000013068284,0.014997446,0.000023177208,0.00066833926,0.027190346],"study_design_scores_gemma":[0.939757,0.03466911,0.0054983757,0.000060151313,0.0003012871,0.000015311196,0.004935682,0.0005993159,0.00024293912,0.000022913631,0.013622421,0.00027553376],"about_ca_topic_score_codex":0.0017867284,"about_ca_topic_score_gemma":0.0033827967,"teacher_disagreement_score":0.029442329,"about_ca_system_score_codex":0.0004988312,"about_ca_system_score_gemma":0.00044677278,"threshold_uncertainty_score":0.94778186},"labels":[],"label_agreement":null},{"id":"W2963703029","doi":"10.1097/coc.0000000000000577","title":"Association Between Smoking and Survival Benefit of Immunotherapy in Advanced Malignancies","year":2019,"lang":"en","type":"review","venue":"American Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Confidence interval; Internal medicine; Immunotherapy; Meta-analysis; Randomized controlled trial; Oncology; Clinical trial; Cancer","score_opus":0.11228883707839485,"score_gpt":0.4767912794818843,"score_spread":0.3645024424034895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963703029","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.051608704,0.9463054,0.000010309674,0.00043938198,0.00092525786,0.00032637097,0.000019003597,0.000003925474,0.00036166605],"genre_scores_gemma":[0.0031361547,0.99534655,0.0006106927,0.00022090651,0.00044318705,0.0000041342782,0.000007888916,0.000034763743,0.00019573337],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99452215,0.00073407125,0.0038774887,0.00023035394,0.00037968342,0.00025626677],"domain_scores_gemma":[0.9854838,0.0056151072,0.008334559,0.00021305597,0.00024971506,0.00010376651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004832202,0.00025038002,0.006978116,0.00030442135,0.000014940138,0.000006081249,0.00020628372,0.00046944353,0.00004188263],"category_scores_gemma":[0.00078068214,0.00018300212,0.0011139738,0.00041364686,0.00032240053,0.000063983665,0.00003707999,0.0011232517,0.0000015440544],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013721822,0.0001378654,0.073116854,0.0007007513,0.0021458692,0.000020967362,0.000047664587,2.5385722e-7,0.000004135236,0.000004753269,0.000036076217,0.92241263],"study_design_scores_gemma":[0.0047382764,0.009511859,0.0833287,0.008877326,0.0016621237,0.00007058358,0.00011712685,2.2863625e-7,0.000001146423,0.00002110591,0.8915043,0.00016724637],"about_ca_topic_score_codex":0.00007509553,"about_ca_topic_score_gemma":0.000020368809,"teacher_disagreement_score":0.9222454,"about_ca_system_score_codex":0.0005002956,"about_ca_system_score_gemma":0.0014575953,"threshold_uncertainty_score":0.746261},"labels":[],"label_agreement":null},{"id":"W2964839871","doi":"10.14740/jocmr3886","title":"Profiling of Target Molecules for Immunotherapy in Mesenchymal Tumors","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care; Vanderbilt University Medical Center; Vanderbilt University","keywords":"Medicine; Mesenchymal stem cell; Profiling (computer programming); Immunotherapy; Cancer research; Pathology; Immunology; Immune system","score_opus":0.17043926031219475,"score_gpt":0.5377524395820596,"score_spread":0.3673131792698649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964839871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828953,0.0051522157,0.00029522518,0.008210262,0.00056078995,0.00091297406,0.0000031020575,0.0000038356975,0.0019663027],"genre_scores_gemma":[0.9903954,0.0021160222,0.00567629,0.00034986917,0.0009443959,0.000009896129,0.0000034438383,0.000028325318,0.00047633736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99542075,0.00040802805,0.0023885844,0.00019636007,0.0012109532,0.00037531924],"domain_scores_gemma":[0.99471027,0.0031000045,0.00061292003,0.00029475513,0.0011058415,0.00017620927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01714225,0.000120644065,0.001208778,0.0006110925,0.00002479875,0.000005175232,0.00028387076,0.00016333806,0.0003950862],"category_scores_gemma":[0.0039719706,0.00007550849,0.0003928846,0.00057409616,0.00047305302,0.00007703662,0.000029363231,0.0010742269,0.0000038411126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.070435055,0.0012726773,0.5659409,0.0009909725,0.0006735302,0.00016490427,0.00054212427,0.000019076471,0.2765113,0.0005962881,0.004325096,0.07852805],"study_design_scores_gemma":[0.12235095,0.0869775,0.5912861,0.013792664,0.00013752522,0.0005777492,0.0066507175,0.002578202,0.11311683,0.0057605137,0.056255933,0.0005152966],"about_ca_topic_score_codex":0.000045171713,"about_ca_topic_score_gemma":0.0000026023974,"teacher_disagreement_score":0.16339448,"about_ca_system_score_codex":0.00007822861,"about_ca_system_score_gemma":0.0009485986,"threshold_uncertainty_score":0.59411955},"labels":[],"label_agreement":null},{"id":"W2964957722","doi":"10.1007/978-1-4939-9597-4_25","title":"Immunoproteomic Biomarkers: From Publication to Personalized Medicine","year":2019,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Context (archaeology); Biomarker; Personalized medicine; Immunotherapy; Medicine; Precision medicine; Disease; Immune system; Computer science; Data science; Computational biology; Immunology; Bioinformatics; Internal medicine; Biology; Pathology","score_opus":0.025247280066798078,"score_gpt":0.40406318647660316,"score_spread":0.3788159064098051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964957722","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.519315,0.005081938,0.45275944,0.01574553,0.0007873687,0.0015984029,0.00001547271,0.000076760494,0.0046200915],"genre_scores_gemma":[0.025819732,0.00013578043,0.96224326,0.010369116,0.00010276295,0.00016112396,0.00023069093,0.00004220161,0.0008953239],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99802744,0.00064626016,0.00041760286,0.00049703417,0.00011068776,0.000300946],"domain_scores_gemma":[0.99896365,0.00017606013,0.00010102748,0.0005852116,0.00008861583,0.00008544177],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015742282,0.00018191738,0.00048209072,0.0003617971,0.000022233142,0.0000085008,0.00019798081,0.00021897508,0.002325019],"category_scores_gemma":[0.00050023996,0.00014558631,0.00011569492,0.0005840537,0.00015694542,0.000026708809,0.000060657796,0.0001754974,0.00008944111],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014432693,0.00003607442,0.0053299004,0.000012727638,0.00017989938,0.0000061327078,0.00023857063,1.9392876e-7,0.92395955,0.0004946672,0.00021722873,0.06808177],"study_design_scores_gemma":[0.013033597,0.0018258118,0.037527822,0.00031907935,0.0001148595,0.00005343316,0.0004908085,0.00022528593,0.7440486,0.0046236054,0.1971901,0.0005470095],"about_ca_topic_score_codex":0.0010550987,"about_ca_topic_score_gemma":0.0000070756505,"teacher_disagreement_score":0.5094838,"about_ca_system_score_codex":0.00015695626,"about_ca_system_score_gemma":0.000077250195,"threshold_uncertainty_score":0.998587},"labels":[],"label_agreement":null},{"id":"W2965019135","doi":"10.1038/s41379-019-0327-4","title":"“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy","year":2019,"lang":"en","type":"review","venue":"Modern Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McMaster University; BC Cancer Agency; McGill University Health Centre; Institut universitaire de cardiologie et de pneumologie de Québec; Dalhousie University; Hamilton Health Sciences; University of Toronto; Saskatchewan Health; University Health Network; Université Laval; University of Saskatchewan; Saskatchewan Health Authority","funders":"National Center for Advancing Translational Sciences","keywords":"Interchangeability; Medicine; Medical physics; Meta-analysis; Data extraction; Diagnostic accuracy; MEDLINE; Grading (engineering); Pathology; Data mining; Computer science; Internal medicine","score_opus":0.19305812754960316,"score_gpt":0.4155887077541432,"score_spread":0.22253058020454003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965019135","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004876708,0.99656194,0.00047220307,0.000052780037,0.00014761194,0.0010460311,0.00070993387,0.000021392045,0.00050041964],"genre_scores_gemma":[0.004271425,0.99353224,0.00018951375,0.00009542937,0.000034522298,0.00028478165,0.00060908665,0.000057804114,0.0009252101],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9966489,0.0004098127,0.0015979495,0.0007184066,0.00031405463,0.00031089524],"domain_scores_gemma":[0.99383646,0.002571783,0.0014132418,0.0019003089,0.00021655954,0.00006166811],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008890392,0.0005174965,0.008580123,0.0005670517,0.000019315497,0.000004853497,0.00042731734,0.0006816758,0.0012713579],"category_scores_gemma":[0.0012544381,0.0003741051,0.0073446087,0.00069665845,0.0003641888,0.000030956606,0.00015322378,0.00044856308,0.000016249227],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045122,0.0005900147,0.00003747444,0.043970864,0.41200155,0.00013050156,0.00059129,0.000003906698,0.002470516,0.000009897714,0.0002000893,0.5395427],"study_design_scores_gemma":[0.0005912971,0.00034135816,0.00006455314,0.001171646,0.89119554,0.0002182885,0.000018803361,0.000032161886,0.00014813754,0.00003859115,0.10582826,0.0003513682],"about_ca_topic_score_codex":0.00009656215,"about_ca_topic_score_gemma":0.000009128761,"teacher_disagreement_score":0.5391913,"about_ca_system_score_codex":0.00019875896,"about_ca_system_score_gemma":0.0003998263,"threshold_uncertainty_score":0.9998711},"labels":[],"label_agreement":null},{"id":"W2965089489","doi":"10.1016/s1470-2045(19)30171-8","title":"Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":204,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Research Council; Weill Cornell Medical College; Genentech; Labex Immuno-Oncology; European Research Area Network on Cardiovascular Diseases; PharmaMar; Institut Universitaire de France; Chancellerie des Universités de Paris; Cancéropôle Ile de France; Ligue Contre le Cancer; Fondation pour la Recherche Médicale; Fondation pour la recherche juridique; U.S. Department of Defense; European Commission; Institut National de la Santé et de la Recherche Médicale; Bayer HealthCare; Servier; AstraZeneca; Institut National Du Cancer; Fondation Leducq; Agence Nationale de la Recherche; E-Rare; Bristol-Myers Squibb; Direction Générale de l’offre de Soins; Association pour la Recherche sur le Cancer; Seerave Foundation","keywords":"Radioimmunotherapy; Immunotherapy; Medicine; Radiation therapy; Toxicity; Oncology; Internal medicine; Cancer; Immunology; Monoclonal antibody; Antibody","score_opus":0.15012238987139914,"score_gpt":0.43593377494448915,"score_spread":0.28581138507309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965089489","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013534584,0.9934805,0.00001917669,0.00079748215,0.0005298209,0.0011743905,0.000019925397,0.000031426312,0.0025937909],"genre_scores_gemma":[0.00018958989,0.99727803,0.0006664989,0.0006551443,0.0006693744,0.000027301416,0.000017374055,0.00004998723,0.00044670235],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998164,0.00033565995,0.00063735445,0.00033488407,0.0001833583,0.0003447608],"domain_scores_gemma":[0.9978686,0.00072070834,0.00056888873,0.00074955367,0.000049039332,0.00004319155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012415752,0.0002984938,0.003153604,0.00012347236,0.00006569167,0.000014660252,0.00026406578,0.00036151896,0.00016878745],"category_scores_gemma":[0.000064456726,0.00017407694,0.00033015778,0.0002908142,0.0004066157,0.000027337484,0.00006878718,0.00054806995,0.000009231953],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013025504,0.00008249911,0.0000061925716,0.0077666026,0.0008284284,0.00000811045,0.00026860123,8.90108e-7,0.0004673424,0.0000499554,0.001120994,0.98809785],"study_design_scores_gemma":[0.003429644,0.00074293156,0.000109596695,0.009243932,0.0011206234,0.00040633258,0.000020102128,0.0000072207954,0.00005700501,0.0000068332647,0.9846777,0.00017807784],"about_ca_topic_score_codex":0.000057432608,"about_ca_topic_score_gemma":0.000002635877,"teacher_disagreement_score":0.98791975,"about_ca_system_score_codex":0.0002878789,"about_ca_system_score_gemma":0.00069460797,"threshold_uncertainty_score":0.70986515},"labels":[],"label_agreement":null},{"id":"W2965354595","doi":"10.1016/j.lungcan.2019.07.033","title":"PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Law Foundation of British Columbia","keywords":"Medicine; Cytology; Concordance; Lung cancer; Histology; Lung; Lymph; Pathology; Radiology; Internal medicine","score_opus":0.017871589380297107,"score_gpt":0.2916921288345026,"score_spread":0.2738205394542055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965354595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94959307,0.0070161712,0.000021170064,0.0023299376,0.0012332966,0.0009402897,0.00003691466,0.00003780424,0.038791336],"genre_scores_gemma":[0.98852324,0.0007623775,0.00015936492,0.0030932452,0.0004905005,0.00013216806,0.000004879518,0.000048223417,0.006786001],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986229,0.00004376077,0.00033273068,0.00035279867,0.00024805745,0.00039976113],"domain_scores_gemma":[0.9988072,0.00026326257,0.00022837431,0.0005039582,0.00013098122,0.000066245324],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021599805,0.00022476932,0.0004034117,0.00008120438,0.000072597635,0.000011951494,0.0002005157,0.0001260217,0.002647819],"category_scores_gemma":[0.00002149269,0.0001512887,0.00014703693,0.00033636822,0.0001023873,0.00003464003,0.000045019347,0.00030394786,0.000025176983],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002389773,0.00015622875,0.46270773,0.00087365456,0.0005926698,0.000020811709,0.0012307062,0.000262993,0.49710327,0.000076159995,0.023714224,0.010871777],"study_design_scores_gemma":[0.008097918,0.00088784186,0.7848752,0.0026270968,0.00065703114,0.000027762571,0.00048811632,0.008085609,0.16286694,0.000020205227,0.030673243,0.0006930291],"about_ca_topic_score_codex":0.002918254,"about_ca_topic_score_gemma":0.0004534066,"teacher_disagreement_score":0.33423632,"about_ca_system_score_codex":0.0003823603,"about_ca_system_score_gemma":0.00035917468,"threshold_uncertainty_score":0.9982639},"labels":[],"label_agreement":null},{"id":"W2965511029","doi":"10.1158/1535-7163.mct-19-0132","title":"Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Pembrolizumab; Immunotherapy; Medicine; Adverse effect; Internal medicine; Oncology; Blockade; Antibody; Multiplex; Immune checkpoint; Toxicity; Immune system; Immunology; Cancer; Receptor; Bioinformatics; Biology","score_opus":0.0194290354595217,"score_gpt":0.27511367244459595,"score_spread":0.25568463698507427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965511029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807024,0.011330118,0.00028542336,0.003165969,0.00072932936,0.0012903592,0.00022669214,0.00012278243,0.0021469004],"genre_scores_gemma":[0.97598314,0.002075885,0.00014308032,0.014020316,0.00016788283,0.0002427313,0.00003196393,0.00009864049,0.0072363857],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981757,0.000070599395,0.00031631073,0.0005137201,0.00043464222,0.0004890671],"domain_scores_gemma":[0.9988579,0.000019523975,0.00011009176,0.00069794024,0.00019049703,0.00012403508],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000074974036,0.000391112,0.00044382655,0.00010263147,0.00007209331,0.00005128566,0.00013507881,0.00021483912,0.0021866078],"category_scores_gemma":[0.0000019061002,0.00031559114,0.00034439043,0.00026013356,0.00013035732,0.000064813015,0.000030402782,0.00018869559,0.00025200503],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033732742,0.00079570536,0.03955435,0.0002247488,0.007456375,0.00027012578,0.003021647,0.00008713541,0.8737724,0.00004686614,0.0005993218,0.040438604],"study_design_scores_gemma":[0.019564938,0.0046414165,0.05019957,0.00036670384,0.0013966167,0.000076793105,0.00017780416,0.002940483,0.5447735,0.00010230719,0.37496153,0.0007983439],"about_ca_topic_score_codex":0.0004990983,"about_ca_topic_score_gemma":0.000016039283,"teacher_disagreement_score":0.3743622,"about_ca_system_score_codex":0.0007880723,"about_ca_system_score_gemma":0.00050552934,"threshold_uncertainty_score":0.9999296},"labels":[],"label_agreement":null},{"id":"W2966365653","doi":"10.3390/cancers11081080","title":"Regulation of Immunity in Breast Cancer","year":2019,"lang":"en","type":"review","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"University of Manitoba; Natural Sciences and Engineering Research Council of Canada; CancerCare Manitoba Foundation; Research Manitoba","keywords":"Breast cancer; Immune system; Immunotherapy; Tumor microenvironment; Cancer; Carcinogenesis; Medicine; Immunity; Cancer immunotherapy; Immunology; Cancer research; Internal medicine","score_opus":0.054065762377098946,"score_gpt":0.3608675591086607,"score_spread":0.30680179673156177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966365653","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001878801,0.9970035,9.2693415e-7,0.00005225888,0.00052198116,0.0007651607,0.00017468429,0.000012831139,0.0012808039],"genre_scores_gemma":[0.000396815,0.99813396,0.000012025113,0.00006903616,0.00012119146,0.00009010526,0.000094183924,0.000037308997,0.0010453792],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998853,0.00006346284,0.00051262823,0.0002219611,0.00017092,0.00017802171],"domain_scores_gemma":[0.9990747,0.000041429255,0.00035765223,0.00042776598,0.000060003313,0.000038463644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017825057,0.0002204351,0.0013324311,0.00023269463,0.000013745414,0.00000425808,0.0001223959,0.00024256404,0.0007965948],"category_scores_gemma":[0.0000058562723,0.00017667247,0.0003779446,0.0005276544,0.00008983444,0.000041481828,0.00002101838,0.00028112702,0.000010461367],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002910529,0.000010610338,0.0001446833,0.021175617,0.00023784931,0.0000016092135,0.000055274682,0.0000067782976,0.000041107127,0.0000070504775,0.001104956,0.9769234],"study_design_scores_gemma":[0.0009321421,0.000042535063,0.003431131,0.041440457,0.0005371741,0.00003474888,0.000024163473,0.000009560838,0.000008926447,0.00000258691,0.95335156,0.00018500589],"about_ca_topic_score_codex":0.0042741923,"about_ca_topic_score_gemma":0.00014629027,"teacher_disagreement_score":0.9767384,"about_ca_system_score_codex":0.0036360978,"about_ca_system_score_gemma":0.0034164304,"threshold_uncertainty_score":0.95082694},"labels":[],"label_agreement":null},{"id":"W2966885713","doi":"10.3390/cancers11081150","title":"Association between PD-1 and PD-L1 Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies","year":2019,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Akademia Wychowania Fizycznego im. Jerzego Kukuczki w Katowicach; Research Manitoba","keywords":"Odds ratio; Internal medicine; Meta-analysis; Medicine; Allele; Gastroenterology; Case-control study; Genetic model; Cancer; Genotype; Programmed cell death 1; Confidence interval; Oncology; PD-L1; Gene; Genetics; Biology; Immunotherapy","score_opus":0.03468073863171975,"score_gpt":0.31282038492006287,"score_spread":0.2781396462883431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966885713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8641278,0.13343033,0.000009725775,0.0014447679,0.00007165722,0.00042011685,0.00037898423,0.0000060853963,0.00011052173],"genre_scores_gemma":[0.98874116,0.0101460945,0.0000229179,0.00031564923,0.00003984946,0.00004506815,0.000003180072,0.000008290772,0.0006777768],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9989891,0.0001354958,0.0003409326,0.0001851768,0.00021815753,0.00013113655],"domain_scores_gemma":[0.9983672,0.0007018991,0.0005394517,0.00021769223,0.00013835989,0.00003540452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008493943,0.00012296857,0.0012751528,0.00012486847,0.000051174433,0.0000062155627,0.00004362095,0.00006369298,0.00015371274],"category_scores_gemma":[0.00008708295,0.00007089231,0.0004806832,0.00038387076,0.00023031519,0.000039579147,0.000016407548,0.0000935923,2.8436162e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016327047,0.0000045050515,0.4157673,0.00008225421,0.57609206,0.000003138253,0.001963805,0.00011534456,0.0007035386,0.000015375495,0.000316719,0.00330324],"study_design_scores_gemma":[0.008219086,0.00020272091,0.28483865,0.000028569253,0.7024263,0.0000058509345,0.0016256039,0.00052563293,0.0012482475,0.00004123563,0.00070558296,0.00013250648],"about_ca_topic_score_codex":0.015061829,"about_ca_topic_score_gemma":0.0026522218,"teacher_disagreement_score":0.13092867,"about_ca_system_score_codex":0.00041084812,"about_ca_system_score_gemma":0.00013136947,"threshold_uncertainty_score":0.991497},"labels":[],"label_agreement":null},{"id":"W2967093625","doi":"10.1186/s40425-019-0700-3","title":"PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"FujiFilm VisualSonics (Canada)","funders":"Leids Universitair Medisch Centrum; H2020 Marie Skłodowska-Curie Actions; KWF Kankerbestrijding; European Commission","keywords":"Tumor microenvironment; Immunotherapy; Cancer immunotherapy; Blockade; Immune system; Cancer research; Mass cytometry; Medicine; CD8; T cell; Immune checkpoint; Flow cytometry; In vivo; Colorectal cancer; Cancer; Immunology; Receptor; Biology; Internal medicine; Phenotype","score_opus":0.014173682057967981,"score_gpt":0.320614542574468,"score_spread":0.3064408605165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967093625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763529,0.019681007,0.0001038285,0.0007329245,0.0018036555,0.0008360367,0.000026622194,0.000030700423,0.00043234453],"genre_scores_gemma":[0.9816013,0.00499142,0.004906642,0.0019310771,0.0010248192,0.00011265473,0.0000068705504,0.00011928514,0.005305918],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981761,0.0000665792,0.00067614985,0.00027532395,0.00038868788,0.00041718475],"domain_scores_gemma":[0.99862564,0.00025554493,0.0005149512,0.00023687347,0.00023149497,0.00013548616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007946784,0.00026931494,0.0006029726,0.00021919383,0.00028290582,0.00007574925,0.00015592533,0.00010384044,0.0007983982],"category_scores_gemma":[0.0000678383,0.00022242557,0.00025974392,0.00020349643,0.00008622265,0.0002647751,0.00001861743,0.00033290355,0.0000027117608],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071950597,0.00006437599,0.01700647,0.00019261322,0.00050975545,0.0000017764289,0.001837826,0.00006210394,0.92355835,0.000005224562,0.0032663317,0.046300087],"study_design_scores_gemma":[0.007212264,0.0011234275,0.00803571,0.0010827242,0.000040113402,0.000097622666,0.0013256586,0.000058850917,0.70606697,0.000028570441,0.2746403,0.00028780184],"about_ca_topic_score_codex":0.00021012442,"about_ca_topic_score_gemma":0.0000074474697,"teacher_disagreement_score":0.27137396,"about_ca_system_score_codex":0.00033199615,"about_ca_system_score_gemma":0.0004007958,"threshold_uncertainty_score":0.90702516},"labels":[],"label_agreement":null},{"id":"W2967398918","doi":"10.1016/s1470-2045(19)30407-3","title":"Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":365,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Bristol-Myers Squibb; Ono Pharmaceutical; European Society for Medical Oncology; Cancer Research Society; American Association for Cancer Research","keywords":"Nivolumab; Medicine; Docetaxel; Lung cancer; Internal medicine; Oncology; Clinical trial; Survival analysis; Cancer; Progressive disease; Chemotherapy; Immunotherapy","score_opus":0.011169927419285955,"score_gpt":0.26970985525713,"score_spread":0.258539927837844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967398918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928929,0.00037305802,0.000032065745,0.00087510556,0.00010493563,0.001468242,0.000019212614,0.00004323859,0.0041912496],"genre_scores_gemma":[0.99706036,0.00028985977,0.00033811654,0.0006684382,0.0000862784,0.00013283356,0.000053537413,0.000032953827,0.0013376522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984831,0.0001708017,0.00027110946,0.00036340638,0.00022797793,0.00048358666],"domain_scores_gemma":[0.9989225,0.00010292378,0.00022104074,0.000569071,0.00011941084,0.00006500104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035758788,0.00022035206,0.0009798359,0.00015959954,0.00004702067,0.000011673656,0.00021442054,0.000114432056,0.00030986883],"category_scores_gemma":[0.0000063703847,0.00012431196,0.00010239463,0.0009948253,0.00009018908,0.000050339593,0.00003158708,0.00027722304,0.000012772232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03486811,0.0002796736,0.9581072,0.00008981333,0.001668724,0.000021668837,0.00058435916,0.0002833709,0.000527874,0.0000027203025,0.00015845503,0.003408036],"study_design_scores_gemma":[0.042462863,0.0034572675,0.949221,0.0001464404,0.0017667353,0.0000037669645,0.00021475037,0.00040126126,0.00021330756,0.0000014009156,0.0018966885,0.0002144917],"about_ca_topic_score_codex":0.0015540118,"about_ca_topic_score_gemma":0.0073091737,"teacher_disagreement_score":0.008886168,"about_ca_system_score_codex":0.00048839836,"about_ca_system_score_gemma":0.0003408858,"threshold_uncertainty_score":0.5069295},"labels":[],"label_agreement":null},{"id":"W2968230578","doi":"10.1186/s40425-019-0698-6","title":"Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; National Institutes of Health; National Cancer Institute; Irving Medical Center, Columbia University; National Institute of Dental and Craniofacial Research; University of Texas MD Anderson Cancer Center","keywords":"Medicine; Tumor microenvironment; Cancer research; Immune checkpoint; Immune system; Cytotoxic T cell; T cell; Immunology; Immunotherapy; Biology","score_opus":0.012831285176136567,"score_gpt":0.28629095324417336,"score_spread":0.2734596680680368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968230578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9248024,0.07155423,0.0011456091,0.0010347144,0.00048753238,0.0008840531,0.000024748673,0.000009290394,0.000057391724],"genre_scores_gemma":[0.95562476,0.041333236,0.0013481906,0.0004465845,0.00013090279,0.00003524339,0.000009992323,0.000055687306,0.0010154183],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984366,0.000027716933,0.0008035895,0.00019520955,0.00031025417,0.00022659416],"domain_scores_gemma":[0.9987977,0.000049392274,0.00069922,0.00026220916,0.00014107255,0.000050383045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045096115,0.0002110185,0.00057603745,0.00018785475,0.000073862924,0.000018411374,0.000078687604,0.00012623407,0.00070036465],"category_scores_gemma":[0.0000029697476,0.00017100901,0.00039172583,0.00012910862,0.00013453414,0.00014790791,0.000008833323,0.0001684308,6.8193947e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008520571,0.00014375977,0.008062794,0.00016463874,0.0008705897,4.317529e-7,0.00056197273,0.00011787318,0.8310085,0.0000636566,0.00002632721,0.15045887],"study_design_scores_gemma":[0.022545217,0.0033956203,0.3137943,0.0009763866,0.0001706156,0.00014788524,0.00026800775,0.0007157206,0.6315638,0.0009105256,0.025175558,0.00033637145],"about_ca_topic_score_codex":0.00011656121,"about_ca_topic_score_gemma":0.0000062675476,"teacher_disagreement_score":0.30573153,"about_ca_system_score_codex":0.00028472007,"about_ca_system_score_gemma":0.00009862136,"threshold_uncertainty_score":0.7668502},"labels":[],"label_agreement":null},{"id":"W2969057008","doi":"10.1371/journal.pone.0221301","title":"Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade","year":2019,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"LEO Pharma; Klaus Tschira Stiftung; Seqirus; Les Laboratories Pierre Fabre; Celgene; Sanofi; Amgen; Pfizer; Deutsche Forschungsgemeinschaft; King's College London; Bristol-Myers Squibb","keywords":"Medicine; Blockade; Oncology; Internal medicine; Melanoma; Ipilimumab; Confounding; Immune checkpoint; CD8; Nivolumab; Biomarker; Immunology; Immune system; Cancer; Immunotherapy; Cancer research; Biology; Receptor","score_opus":0.03544868439431686,"score_gpt":0.2406301466911236,"score_spread":0.20518146229680673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969057008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98761564,0.00094098883,0.00002367008,0.0011034067,0.00009682166,0.0006964658,0.000017919709,0.000077432465,0.009427678],"genre_scores_gemma":[0.9528349,0.000101294594,0.0007200549,0.0011923707,0.00006257702,0.000029494471,0.000021477592,0.000046967507,0.044990882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845934,0.00003936598,0.00034622508,0.00033181327,0.00043991202,0.0003833512],"domain_scores_gemma":[0.99925673,0.000048971284,0.00010886822,0.00043376788,0.000054715743,0.00009693184],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016802382,0.0002304568,0.000488004,0.00012321542,0.000039584214,0.000026634867,0.00013016602,0.00013749093,0.0019152906],"category_scores_gemma":[0.000009638642,0.00017733019,0.00008219351,0.0002519339,0.000101596444,0.00010708024,0.000027828806,0.00034533083,0.00017798576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028159353,0.0012491293,0.7537909,0.00034529244,0.00043506804,0.00009131266,0.0008270904,0.00003026991,0.24013795,0.000066523055,0.00007639829,0.00013409063],"study_design_scores_gemma":[0.026838835,0.003710359,0.91943204,0.0012987079,0.00048199485,0.000049869774,0.0025727719,0.0014966214,0.040367533,0.00007818519,0.0026406841,0.0010323721],"about_ca_topic_score_codex":0.00063146715,"about_ca_topic_score_gemma":0.00029802954,"teacher_disagreement_score":0.19977042,"about_ca_system_score_codex":0.0002789568,"about_ca_system_score_gemma":0.00014080694,"threshold_uncertainty_score":0.9989971},"labels":[],"label_agreement":null},{"id":"W2969365775","doi":"10.1016/j.lungcan.2019.08.016","title":"Erratum to “The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma” [Lung Cancer 132 (June) (2019) 36–38]","year":2019,"lang":"en","type":"erratum","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Nivolumab; Atezolizumab; Medicine; Pembrolizumab; ROS1; Lung cancer; Durvalumab; Oncology; Internal medicine; Cancer; Cancer research; Immunotherapy; Adenocarcinoma","score_opus":0.009040041164799914,"score_gpt":0.28580558810533935,"score_spread":0.27676554694053945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969365775","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56981695,0.26469052,0.0003899371,0.010369714,0.123902865,0.015217996,0.002959787,0.0003606541,0.01229158],"genre_scores_gemma":[0.1724444,0.024821006,0.0006086675,0.011441724,0.0034232459,0.004011648,0.00070303073,0.00057633244,0.78196996],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935698,0.00023519839,0.0014085659,0.0018994184,0.0012625371,0.0016244646],"domain_scores_gemma":[0.9958832,0.00020296333,0.0009357625,0.0021036707,0.00045269268,0.0004216907],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00061456306,0.0013706888,0.0019488046,0.0006641929,0.00028461093,0.00016168537,0.0010888834,0.00079759915,0.0011266195],"category_scores_gemma":[0.00007597003,0.00092555885,0.0005885359,0.0012076611,0.00016090025,0.00037432805,0.00038896775,0.0025373544,0.000060967915],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048857844,0.00013802196,0.023672692,0.0045097424,0.00046834498,0.00013239235,0.0041248165,0.0010338785,0.06958783,9.660287e-7,0.8896171,0.0018284462],"study_design_scores_gemma":[0.010205181,0.0003845211,0.11011778,0.020468738,0.002064639,0.00002552209,0.0006552895,0.004815893,0.029099636,0.000005481121,0.8193402,0.0028170669],"about_ca_topic_score_codex":0.012573814,"about_ca_topic_score_gemma":0.0130610885,"teacher_disagreement_score":0.76967835,"about_ca_system_score_codex":0.0026961353,"about_ca_system_score_gemma":0.0030325104,"threshold_uncertainty_score":0.9999044},"labels":[],"label_agreement":null},{"id":"W2969970780","doi":"10.1101/743989","title":"Coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mathematical Institute, University of Oxford; Juno Therapeutics; School of Medicine, Stanford University; Defence Science and Technology Laboratory; Hamilton Health Sciences Foundation; University of Oxford; Cancer Research UK; Inselspital, Universitätsspital Bern; Parker Institute for Cancer Immunotherapy; National Institutes of Health; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Lady Tata Memorial Trust; U.S. Department of Defense; Silicon Valley Community Foundation; University of Bern; Celgene; Pfizer; Bill and Melinda Gates Foundation; Kenneth Rainin Foundation; Cancer Research Institute; National Science Foundation","keywords":"Immune system; Colorectal cancer; Immunity; Biology; Cancer research; Tumor microenvironment; Cellular immunity; Computational biology; Cancer; Immunology; Genetics","score_opus":0.017321113005867257,"score_gpt":0.2405803256426975,"score_spread":0.22325921263683024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969970780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809671,0.011948353,0.00008939725,0.0011094043,0.0026690485,0.0022502532,0.0006084832,0.00029131272,0.00006665086],"genre_scores_gemma":[0.99528724,0.0025651709,0.00014773781,0.000723778,0.0005342713,0.00039133537,0.0000060616535,0.0001924034,0.00015201925],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99642694,0.00033774468,0.00075055956,0.00108046,0.0005660923,0.0008382048],"domain_scores_gemma":[0.9964109,0.00014796658,0.00070080586,0.0017979335,0.00065695326,0.0002854507],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008438428,0.0008636396,0.0010973172,0.00020721207,0.00038757257,0.00018445765,0.0007434206,0.0007817063,0.00093026785],"category_scores_gemma":[0.00013950923,0.0006799342,0.00047617182,0.00052841974,0.0005160404,0.00012613137,0.0007792596,0.0016459014,0.00019861216],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016999714,0.00020794032,0.054544143,0.000642095,0.0011414848,0.00015720939,0.000041438478,0.00006527811,0.9388218,0.000020747853,0.0026539706,0.0000039483843],"study_design_scores_gemma":[0.0022096639,0.0002278569,0.29499057,0.0008950057,0.00046867726,1.4986885e-7,0.000012071097,0.00020675904,0.695595,6.7448093e-7,0.0046635107,0.0007300507],"about_ca_topic_score_codex":0.0021439856,"about_ca_topic_score_gemma":0.00012076204,"teacher_disagreement_score":0.24322677,"about_ca_system_score_codex":0.0015975899,"about_ca_system_score_gemma":0.003183774,"threshold_uncertainty_score":0.999983},"labels":[],"label_agreement":null},{"id":"W2970304599","doi":"10.1200/jco.2013.31.15_suppl.9032","title":"Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Queen Elizabeth II Health Sciences Centre; Baker Hughes (Canada); Ottawa Hospital; BC Cancer Agency; Queen's University; Hôpital Notre-Dame; Royal Victoria Hospital; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Dacarbazine; Internal medicine; Rash; Gastroenterology; Adverse effect; Phases of clinical research; Nausea; Population; Neutropenia; Melanoma; Hazard ratio; Surgery; Toxicity; Oncology; Chemotherapy; Confidence interval","score_opus":0.11078690434279748,"score_gpt":0.4519686521981819,"score_spread":0.3411817478553844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970304599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99549025,0.00022263247,0.000016349542,0.0010824286,0.001173817,0.0018776004,0.000006775831,0.000003472209,0.00012668823],"genre_scores_gemma":[0.99819565,0.00024095165,0.0010450953,0.00021741878,0.000089705,0.000025178739,0.000006397711,0.0000165725,0.00016305136],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99130666,0.0016755562,0.005962095,0.00024728183,0.0005630581,0.00024532466],"domain_scores_gemma":[0.9891529,0.0046434873,0.004955233,0.0002969378,0.00074910815,0.00020230378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063268715,0.00021480414,0.0036511938,0.00035733916,0.000026424796,0.000005656775,0.00024403966,0.00016969038,0.00028610745],"category_scores_gemma":[0.0060342564,0.000112890535,0.0005387774,0.00036433834,0.00035264998,0.00011921781,0.000067168985,0.00080739544,0.000002717767],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7464124,0.041515183,0.0066070235,0.000047227204,0.001439394,0.00012707707,0.0013269725,0.0000020625357,0.00004031897,0.0000013787471,0.000976386,0.2015046],"study_design_scores_gemma":[0.63922787,0.221543,0.13604449,0.0005984695,0.00070124835,0.000037637506,0.00056482485,0.000030034107,0.00003976746,0.00003080694,0.001090006,0.00009188474],"about_ca_topic_score_codex":0.00023269137,"about_ca_topic_score_gemma":0.0002741611,"teacher_disagreement_score":0.20141272,"about_ca_system_score_codex":0.0001680292,"about_ca_system_score_gemma":0.0012541773,"threshold_uncertainty_score":0.7224004},"labels":[],"label_agreement":null},{"id":"W2970405984","doi":"10.1038/s41598-019-48826-6","title":"Comprehensive in vitro characterization of PD-L1 small molecule inhibitors","year":2019,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northern Alberta Institute of Technology; University of Alberta","funders":"National Institute of Environmental Health Sciences; University of Alberta; Alberta Cancer Foundation","keywords":"Peptidomimetic; Small molecule; In vitro; Drug discovery; PD-L1; Immunotherapy; Mode of action; Chemistry; Cancer immunotherapy; Computational biology; Cytotoxicity; Immune system; Pharmacology; Cancer research; Peptide; Biochemistry; Biology; Immunology","score_opus":0.013036107235970632,"score_gpt":0.24121008052459333,"score_spread":0.2281739732886227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970405984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99530596,0.00011568666,0.000007850564,0.000115636234,0.0032735507,0.0004762814,0.0000023872412,0.000017238004,0.000685404],"genre_scores_gemma":[0.9974909,0.0000069943308,0.000055344182,0.00008244224,0.000026360676,0.000006757024,0.00015555092,0.000009725092,0.0021659685],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988215,0.000020780846,0.0004251914,0.00033585148,0.00024907562,0.00014757404],"domain_scores_gemma":[0.99915355,0.000007639738,0.00024179569,0.00043264808,0.00013127484,0.000033070562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031146934,0.000081577164,0.00020729277,0.0002015158,0.000024678217,0.000023982291,0.000036963447,0.000052625557,0.00019318933],"category_scores_gemma":[0.000010311583,0.00007177763,0.00008343729,0.0004603927,0.00010271136,0.000060933922,0.000023187567,0.00006398046,0.000014490751],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027745904,0.00006307528,0.012339119,0.00007076495,0.000014400095,0.00008007286,0.00024287733,7.250388e-7,0.9839376,0.0000013235884,0.00016276447,0.0028098198],"study_design_scores_gemma":[0.0005223152,0.000050355204,0.0679468,0.000095262185,0.000008474228,0.0000849094,0.00009359734,0.00002607088,0.91866636,0.00002489853,0.0124083245,0.00007260194],"about_ca_topic_score_codex":0.00006535287,"about_ca_topic_score_gemma":0.000005261695,"teacher_disagreement_score":0.065271206,"about_ca_system_score_codex":0.000052316977,"about_ca_system_score_gemma":0.00013998825,"threshold_uncertainty_score":0.29270068},"labels":[],"label_agreement":null},{"id":"W2970408575","doi":"10.1111/his.13983","title":"Intratumoral heterogeneity in programmed death‐ligand 1 immunoreactivity is associated with variation in non‐small cell lung carcinoma histotype","year":2019,"lang":"en","type":"article","venue":"Histopathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Adenocarcinoma; Carcinoma; Medicine; Pathology; Lung cancer; Lung; Adenocarcinoma of the lung; Oncology; Internal medicine; Cancer","score_opus":0.011569482378800048,"score_gpt":0.23320282036518977,"score_spread":0.22163333798638973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970408575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966067,0.00080880796,0.000042137668,0.00016937974,0.00024663028,0.0008843293,0.000007758135,0.000033396882,0.0012008516],"genre_scores_gemma":[0.99884003,0.000022962333,0.00015554464,0.00036849864,0.00002179555,0.00006986273,0.00005356819,0.000028604114,0.00043914496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857813,0.0001413494,0.00032778177,0.00042829977,0.00013626732,0.00038819635],"domain_scores_gemma":[0.9993262,0.000042471216,0.00018014955,0.00033596862,0.00006317493,0.000052031897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004666799,0.00020595663,0.00048505113,0.0002319298,0.000032751752,0.000009415208,0.00009336177,0.0002341832,0.000042999804],"category_scores_gemma":[0.00002343214,0.0001879262,0.00007410353,0.00034145213,0.00007312437,0.000071743074,0.000023801893,0.00036093857,0.00001182163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002239779,0.0004439859,0.778147,0.00005920898,0.000008528647,0.00034918002,0.0015553179,0.0000017662823,0.21669292,0.000006681237,0.00003099328,0.00046463852],"study_design_scores_gemma":[0.006333434,0.00088193925,0.98526305,0.00007395742,0.000048456757,0.00012555302,0.000034574205,0.00026512233,0.006470455,0.000011737718,0.00029072925,0.00020100489],"about_ca_topic_score_codex":0.0016071225,"about_ca_topic_score_gemma":0.0020476072,"teacher_disagreement_score":0.21022247,"about_ca_system_score_codex":0.0011912795,"about_ca_system_score_gemma":0.00024595932,"threshold_uncertainty_score":0.7663408},"labels":[],"label_agreement":null},{"id":"W2970704131","doi":"10.1186/s40169-019-0241-x","title":"New therapeutic targets for cancer: the interplay between immune and metabolic checkpoints and gut microbiota","year":2019,"lang":"en","type":"review","venue":"Clinical and Translational Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Immune system; Immunosurveillance; Tumor microenvironment; Immune checkpoint; Cancer research; Biology; Cancer; Immunotherapy; Pembrolizumab; Immunology; Medicine","score_opus":0.1249707252379751,"score_gpt":0.45914901077438797,"score_spread":0.3341782855364129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970704131","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010919486,0.9855868,0.00027987306,0.011541482,0.00053180335,0.001711743,0.00016415137,0.000014227768,0.00006070763],"genre_scores_gemma":[0.0006205296,0.9953332,0.00024172066,0.0009193959,0.0015766635,0.000054907865,0.00026935618,0.000040837847,0.0009434221],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99783266,0.00011332764,0.0011635369,0.000497272,0.00017293576,0.00022025764],"domain_scores_gemma":[0.9974335,0.0018092672,0.00028467915,0.00023525192,0.000057707457,0.0001796272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009172339,0.0003767502,0.002212531,0.00009111463,0.000102142556,0.00001707253,0.00011980101,0.00033887397,0.00018449633],"category_scores_gemma":[0.000060932492,0.0001917822,0.00036500095,0.00014027033,0.00068023725,0.000039067345,0.000026028725,0.00048236482,0.000002509707],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039155863,0.00001912318,0.0011047978,0.0034347004,0.0016139275,8.563374e-7,0.00012545504,4.911626e-9,0.000016532986,0.00013312427,0.00053011335,0.9926298],"study_design_scores_gemma":[0.00491576,0.00038879138,0.031380706,0.007329445,0.005494462,0.00006067922,0.000012679989,0.0000049944388,0.0000012124302,0.00036549012,0.94984543,0.00020035179],"about_ca_topic_score_codex":0.00009668055,"about_ca_topic_score_gemma":0.000019542003,"teacher_disagreement_score":0.99242944,"about_ca_system_score_codex":0.000007772184,"about_ca_system_score_gemma":0.00032705872,"threshold_uncertainty_score":0.7820651},"labels":[],"label_agreement":null},{"id":"W2970707725","doi":"10.3747/co.26.4853","title":"The Role of Metronomic Chemotherapy in the Era of Cancer Immunotherapy: An Oncologist’s Perspective","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chemotherapy; Cancer; Oncology; Immunotherapy; Internal medicine; Perspective (graphical); Pharmacology","score_opus":0.03671572125204746,"score_gpt":0.39995118406278946,"score_spread":0.363235462810742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970707725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9473578,0.04588741,0.0000038461553,0.0032028886,0.00065676734,0.0008194579,0.000009594813,0.000013747063,0.0020485076],"genre_scores_gemma":[0.9898306,0.009514086,0.000040595092,0.00033063444,0.00011853148,0.00009676268,0.000004185436,0.000020695401,0.000043899763],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987222,0.00024386983,0.00041332698,0.00021683131,0.00016743998,0.00023633169],"domain_scores_gemma":[0.99877954,0.00030456323,0.00030858876,0.0004507346,0.00013203574,0.000024522762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007853372,0.00014053265,0.00043635783,0.000071003036,0.00003720562,0.0000064139444,0.00034482343,0.0001050475,0.00023441495],"category_scores_gemma":[0.000020110088,0.00007771847,0.00017386963,0.0002512274,0.00037207027,0.00004703129,0.000019340527,0.00037165123,0.0000032012829],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009576667,0.0015065991,0.13844831,0.000031290405,0.0003384518,9.3820444e-7,0.009464512,0.000008398081,0.051306803,0.0022079186,0.00028140208,0.7868287],"study_design_scores_gemma":[0.010975281,0.004723901,0.47543365,0.000116359966,0.00007685312,0.000013019312,0.025009591,0.00024316477,0.011260095,0.0011177749,0.4708435,0.00018681237],"about_ca_topic_score_codex":0.0016139026,"about_ca_topic_score_gemma":0.0010200415,"teacher_disagreement_score":0.7866419,"about_ca_system_score_codex":0.0006660218,"about_ca_system_score_gemma":0.00057643006,"threshold_uncertainty_score":0.31692672},"labels":[],"label_agreement":null},{"id":"W2971177723","doi":"10.5430/jst.v9n2p38","title":"Potential prognostic value of PD-L1 and FOXP3 as predictors of relapse in breast cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Solid Tumors","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; FOXP3; Immunohistochemistry; Oncology; Internal medicine; Pathological; Cancer; Stage (stratigraphy); Tissue microarray; Breast carcinoma; Immunology; Immune system; Biology","score_opus":0.004813739765190261,"score_gpt":0.2548815043058475,"score_spread":0.2500677645406572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971177723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968031,0.0016477767,0.0000034571153,0.0006978172,0.00043313316,0.00021913597,0.000025753026,0.0000028869222,0.00016691307],"genre_scores_gemma":[0.9987295,0.0007894091,0.000057656594,0.00009434995,0.00015007268,0.0000017477428,9.201962e-7,0.000014974307,0.00016133768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986788,0.000037654114,0.00067401666,0.0000982707,0.00035854633,0.000152691],"domain_scores_gemma":[0.999023,0.000040575047,0.00057334185,0.00010987848,0.00016544726,0.000087729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035342632,0.00010730266,0.0004787385,0.0002314369,0.000011073564,0.0000040246673,0.00008297322,0.00006418668,0.00019311834],"category_scores_gemma":[0.000039256345,0.00008020667,0.00014136388,0.0001938069,0.00011567879,0.00010762704,0.000021181198,0.00021384761,0.0000011405486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008410755,0.00029595592,0.87701136,0.00040096827,0.00034844133,0.00015341166,0.0007648912,0.00015386022,0.110292606,0.000017823028,0.00045594817,0.0016939676],"study_design_scores_gemma":[0.0048614005,0.0011861024,0.98026186,0.0019439326,0.00016306217,0.0017627666,0.00041642808,0.0001194312,0.0090443,0.00005832919,0.00010172541,0.00008067855],"about_ca_topic_score_codex":0.00028422262,"about_ca_topic_score_gemma":0.000007957026,"teacher_disagreement_score":0.103250474,"about_ca_system_score_codex":0.00007298716,"about_ca_system_score_gemma":0.0003559377,"threshold_uncertainty_score":0.32707334},"labels":[],"label_agreement":null},{"id":"W2971312062","doi":"10.3747/co.26.4859","title":"Pembrolizumab-Induced Obstructive Bronchiolitis in a Patient With Stage IV Non-Small-Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Pembrolizumab; Medicine; Pneumonitis; Bronchiolitis; Lung cancer; Immune system; Immunology; Immunotherapy; Internal medicine; Lung; Virus","score_opus":0.03610401448437293,"score_gpt":0.34371464164154314,"score_spread":0.3076106271571702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971312062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862208,0.0028431667,0.00001615718,0.00021182749,0.0015800918,0.0013807024,0.00003032298,0.000027969782,0.0076890076],"genre_scores_gemma":[0.99828047,0.0004988773,0.000088238565,0.00023987335,0.00012740724,0.00023135323,0.000026932608,0.00003025508,0.00047661082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854404,0.000074099524,0.00033485578,0.00041739515,0.00018878543,0.00044085077],"domain_scores_gemma":[0.9992437,0.0000650585,0.00018750891,0.00028948952,0.000100967256,0.00011329967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000089188594,0.00022396339,0.0004825686,0.00015984314,0.00003283793,0.000008852075,0.000104490835,0.00014285576,0.0005578368],"category_scores_gemma":[0.0000073499314,0.00017685261,0.00009055641,0.0002486541,0.00006547436,0.000058285073,0.00004719158,0.00040499103,0.000025969759],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011171137,0.0013107493,0.66528875,0.00087593513,0.0002625133,0.00024219774,0.007280911,0.000030441384,0.026620753,0.00004933918,0.0007355704,0.28613174],"study_design_scores_gemma":[0.03925681,0.005622848,0.8330114,0.0010630868,0.00019195404,0.00016746629,0.0024474976,0.0010673109,0.0076291566,0.000011896183,0.10887891,0.00065167964],"about_ca_topic_score_codex":0.00070507993,"about_ca_topic_score_gemma":0.0008253902,"teacher_disagreement_score":0.28548005,"about_ca_system_score_codex":0.001185049,"about_ca_system_score_gemma":0.0008402301,"threshold_uncertainty_score":0.721184},"labels":[],"label_agreement":null},{"id":"W2971320602","doi":"10.1002/med.21632","title":"Targeting B7‐1 in immunotherapy","year":2019,"lang":"en","type":"review","venue":"Medicinal Research Reviews","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Alberta Cancer Foundation","keywords":"CD80; CD28; Cytotoxic T cell; Immunotherapy; Immune system; Cancer immunotherapy; T cell; Antigen; Biology; Immunology; CD86; Immunological synapse; Co-stimulation; Autoimmunity; Peripheral tolerance; Monoclonal antibody; Cell biology; T-cell receptor; Antibody; CD40; Biochemistry","score_opus":0.3734383938238347,"score_gpt":0.5411864163707715,"score_spread":0.16774802254693677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971320602","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000022915117,0.98548627,0.000010635135,0.00031957898,0.00048589372,0.007076422,0.000008461651,0.000028928906,0.0065814937],"genre_scores_gemma":[8.869559e-7,0.98973864,0.00017809308,0.00035162334,0.0007831988,0.00084304897,0.00016043967,0.00012935721,0.007814715],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99179494,0.0022321253,0.0022212146,0.0009121958,0.0016276406,0.0012118638],"domain_scores_gemma":[0.99690855,0.00090524915,0.00045866022,0.0012739111,0.00019530629,0.00025833727],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.016549794,0.0006478512,0.0052777636,0.0013467524,0.00010986287,0.000047522644,0.00069881056,0.0005239321,0.0022573816],"category_scores_gemma":[0.0016086447,0.00040056263,0.0011718578,0.0024777255,0.00036133965,0.00008430861,0.00013611904,0.0032241154,0.002049033],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023537775,0.000104105064,0.000022874632,0.061027043,0.00013461034,0.00014867207,0.00008181262,8.62911e-9,0.000020393596,0.000015803525,0.026242802,0.9119665],"study_design_scores_gemma":[0.001182938,0.00056175375,0.000014239701,0.13060533,0.00017144,0.00014186339,0.000039935654,0.000002390557,6.422555e-7,0.0000085918355,0.86698484,0.00028601603],"about_ca_topic_score_codex":0.00032900425,"about_ca_topic_score_gemma":0.000021639009,"teacher_disagreement_score":0.91168046,"about_ca_system_score_codex":0.0012436141,"about_ca_system_score_gemma":0.0016270152,"threshold_uncertainty_score":0.9998446},"labels":[],"label_agreement":null},{"id":"W2971391427","doi":"10.1080/2162402x.2019.1659092","title":"Aberrant upregulation of PDK1 in ovarian cancer cells impairs CD8<sup>+</sup> T cell function and survival through elevation of PD-L1","year":2019,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Hong Kong; University of Ottawa","keywords":"Ovarian cancer; Cancer research; Downregulation and upregulation; CD8; Cancer cell; Gene knockdown; Cell growth; T cell; Cytotoxic T cell; Chemistry; Biology; Cancer; Apoptosis; Medicine; Internal medicine; Immune system; Immunology; In vitro; Biochemistry","score_opus":0.012666189428212179,"score_gpt":0.2560772161786536,"score_spread":0.2434110267504414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971391427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945332,0.0020769963,0.00019878734,0.0003341503,0.0004553072,0.00046919886,0.000013776823,0.000014639699,0.0019039914],"genre_scores_gemma":[0.9980675,0.0009236647,0.00018227345,0.000085235835,0.000039761908,0.000016933192,0.000039776747,0.000018509789,0.00062634307],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988292,0.000099928046,0.0004774218,0.00024206446,0.000154143,0.00019724878],"domain_scores_gemma":[0.9992599,0.000080727295,0.00026430545,0.00028083508,0.00009755221,0.000016689353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029299635,0.00014310086,0.0004388015,0.00014725211,0.000021606049,0.0000034609743,0.000060926683,0.00022427441,0.0006232059],"category_scores_gemma":[0.00000908392,0.00013090124,0.000077307595,0.0002874813,0.00013620684,0.00012659357,0.000025604228,0.0001527505,0.000007898076],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057210564,0.00019694137,0.07449158,0.00021654353,0.00013772375,9.764178e-7,0.0016045223,0.0002655536,0.91096646,0.0002247342,0.00007797133,0.0060959654],"study_design_scores_gemma":[0.009515551,0.0014341173,0.8616793,0.00022711424,0.00010336532,0.000007991947,0.0013247804,0.0008610514,0.1223162,0.0002835479,0.002074855,0.00017209718],"about_ca_topic_score_codex":0.0039128894,"about_ca_topic_score_gemma":0.0001617137,"teacher_disagreement_score":0.7886502,"about_ca_system_score_codex":0.00013955544,"about_ca_system_score_gemma":0.00015533094,"threshold_uncertainty_score":0.6823667},"labels":[],"label_agreement":null},{"id":"W2972020095","doi":"10.21037/jtd.2019.08.88","title":"Hyperprogressive disease with immunotherapy: new directions","year":2019,"lang":"en","type":"letter","venue":"Journal of Thoracic Disease","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Immunotherapy; Disease; Immunology; Internal medicine; Immune system","score_opus":0.015072834552670335,"score_gpt":0.31191218710268365,"score_spread":0.2968393525500133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972020095","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010686203,0.09288717,0.00019310627,0.8916442,0.002333055,0.0011652729,0.00021597558,0.00007619537,0.00079881673],"genre_scores_gemma":[0.009873041,0.00931309,0.0013016567,0.8787193,0.018651593,0.00004433416,0.0003184369,0.00040833565,0.08137021],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997334,0.00013491184,0.00068939145,0.00034789427,0.0010839027,0.0004099041],"domain_scores_gemma":[0.9969965,0.000118173986,0.0011120234,0.000770363,0.0003982682,0.0006046673],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019855573,0.00049004325,0.0008787066,0.00046641025,0.000097519674,0.000118692216,0.0003378595,0.00024848862,0.0008988845],"category_scores_gemma":[0.00008797917,0.00032323314,0.0010042342,0.00035996365,0.0001665427,0.0002436899,0.000027578919,0.001575705,0.00005520393],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031729106,0.00031327768,0.0045220805,0.0010303608,0.0019194742,0.008078838,0.00006268904,0.0000051171914,0.00006323575,6.9232385e-7,0.9092708,0.043004278],"study_design_scores_gemma":[0.0022505766,0.0007044575,0.014438363,0.005259979,0.002578721,0.00049461547,0.000025227968,0.0000052541086,0.00002935026,0.000059438422,0.973725,0.0004290078],"about_ca_topic_score_codex":0.000020856785,"about_ca_topic_score_gemma":9.380823e-7,"teacher_disagreement_score":0.08357408,"about_ca_system_score_codex":0.00031484436,"about_ca_system_score_gemma":0.003793131,"threshold_uncertainty_score":0.999922},"labels":[],"label_agreement":null},{"id":"W2972289446","doi":"10.1016/j.jtho.2019.08.2503","title":"Impact of Specimen Characteristics on PD-L1 Testing in Non–Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Recommendations","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Université Laval; Montreal Heart Institute","funders":"AstraZeneca","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; PD-L1; Cancer; Biopsy; Immunohistochemistry; clone (Java method); Pathology; Immunotherapy","score_opus":0.04424345787969483,"score_gpt":0.4129967866273894,"score_spread":0.3687533287476946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972289446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950653,0.00015190018,0.000027883618,0.0013029712,0.00078890723,0.00040323543,0.000027333374,0.0000044267886,0.0022280624],"genre_scores_gemma":[0.99680173,0.00011949316,0.0023906117,0.00015474232,0.00029509712,0.00000428816,0.0000056261642,0.00001957623,0.00020883593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818605,0.00021105762,0.001036771,0.00013352095,0.00021858787,0.00021403868],"domain_scores_gemma":[0.9963882,0.0008162086,0.0020610038,0.00023408588,0.00043878326,0.000061742365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011681509,0.00014864022,0.0006065174,0.0002642293,0.000043473065,0.000009326267,0.00020201794,0.00013755153,0.0002435612],"category_scores_gemma":[0.00047562475,0.000101410515,0.00021388663,0.0005394545,0.000057325342,0.00008768825,0.000043081225,0.0004909787,0.0000022525421],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036017997,0.0005212677,0.5964222,0.00023064244,0.00017944166,0.000014462262,0.0007411869,0.00031499425,0.29676807,7.6353666e-7,0.00056907476,0.10063614],"study_design_scores_gemma":[0.0018390126,0.0032721255,0.9635128,0.0016897816,0.0002584384,0.00014725969,0.00024460623,0.0009906703,0.027492944,0.000014862474,0.00042728227,0.00011022576],"about_ca_topic_score_codex":0.000312712,"about_ca_topic_score_gemma":0.000024696703,"teacher_disagreement_score":0.3670906,"about_ca_system_score_codex":0.00091785897,"about_ca_system_score_gemma":0.0010045042,"threshold_uncertainty_score":0.41354007},"labels":[],"label_agreement":null},{"id":"W2972981028","doi":"10.1016/j.hbpd.2019.09.007","title":"PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review","year":2019,"lang":"en","type":"review","venue":"Hepatobiliary & pancreatic diseases international","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Essar Steel Algoma (Canada); Sault Area Hospital; NOSM University","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Pembrolizumab; Meta-analysis; Oncology; Adverse effect; Hepatocellular carcinoma; Confidence interval; MEDLINE; Immunotherapy; Cancer","score_opus":0.05643517063371303,"score_gpt":0.33667569194800867,"score_spread":0.28024052131429567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972981028","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022020064,0.992732,0.000025808757,0.00018264155,0.00025138404,0.005768076,0.00055317336,0.00005434329,0.0002123868],"genre_scores_gemma":[0.001426137,0.99176794,0.000057994024,0.0009688565,0.00010879764,0.0021904863,0.0012964596,0.0000959062,0.00208742],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9948366,0.0005951991,0.0022852297,0.0010258956,0.0008980813,0.00035899534],"domain_scores_gemma":[0.9969559,0.0005144975,0.00097064057,0.0011732873,0.00015192885,0.00023376549],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00068973936,0.0008756333,0.009487339,0.00108143,0.00004424339,0.00007670312,0.00043506612,0.00025118032,0.0017233477],"category_scores_gemma":[0.00020983304,0.00060139806,0.006040506,0.0011633806,0.00016822704,0.00015898146,0.0001073704,0.00034043472,0.00007419826],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001388892,0.00032955664,0.010649484,0.7843276,0.19865005,0.00020859044,0.000026275533,1.8769828e-7,3.9154855e-7,0.00003157371,0.00039281332,0.0052445694],"study_design_scores_gemma":[0.0008550591,0.00008508205,0.000283277,0.15690988,0.7893491,0.00013362676,0.000015756566,0.0002203172,7.1841794e-7,0.000013342236,0.0515369,0.000596937],"about_ca_topic_score_codex":0.0003628732,"about_ca_topic_score_gemma":0.00001910041,"teacher_disagreement_score":0.62741774,"about_ca_system_score_codex":0.0005215278,"about_ca_system_score_gemma":0.00052090414,"threshold_uncertainty_score":0.99964374},"labels":[],"label_agreement":null},{"id":"W2973542609","doi":"10.14740/wjon1214","title":"Current Immune-Related Molecular Approach in Combating Nasopharyngeal Cancer","year":2019,"lang":"en","type":"review","venue":"World Journal of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immune system; Medicine; Cytotoxic T cell; Nasopharyngeal carcinoma; Carcinogenesis; Cancer; Immunology; Antigen; Cancer research; Cancer cell; Epstein–Barr virus; Suppressor; Radiation therapy; Virus; Biology; Internal medicine; Genetics","score_opus":0.0625944814858261,"score_gpt":0.40697200929612015,"score_spread":0.34437752781029407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973542609","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021203993,0.9929383,0.0000097138445,0.00021301048,0.0024810503,0.0007462333,0.000007040039,0.0000073586466,0.0033852835],"genre_scores_gemma":[0.00034858333,0.9984311,0.0002615543,0.00013782665,0.00029017162,0.000032923876,0.000028453016,0.000057334484,0.00041204318],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964599,0.00043146088,0.002172167,0.00025594782,0.00031941885,0.0003611157],"domain_scores_gemma":[0.99712455,0.00019207965,0.0021815288,0.00025619316,0.0001350896,0.00011054312],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011646384,0.00036969152,0.0034250694,0.0009998588,0.000027692986,0.000012395766,0.00032043128,0.00032474333,0.00029929186],"category_scores_gemma":[0.000034769495,0.00026918214,0.0011856345,0.00088206335,0.000105749095,0.000054532517,0.000062699,0.002127141,0.000012732095],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043535474,0.00038920387,0.00011340277,0.006984139,0.0009409176,0.00031997633,0.00009156488,0.000007816208,0.000029202072,0.000036643964,0.00080296816,0.9898488],"study_design_scores_gemma":[0.0043041045,0.0006105318,0.00017433787,0.023561662,0.001519898,0.0014136139,0.00001798895,0.000012359631,0.0000025448103,0.000008885132,0.96815264,0.00022143574],"about_ca_topic_score_codex":0.000034860943,"about_ca_topic_score_gemma":0.00001609716,"teacher_disagreement_score":0.98962736,"about_ca_system_score_codex":0.001634647,"about_ca_system_score_gemma":0.002776522,"threshold_uncertainty_score":0.99997604},"labels":[],"label_agreement":null},{"id":"W2973896058","doi":"10.1200/jco.2013.31.15_suppl.4060","title":"Prognostic value of an immune score combining intra- and peritumoral T-cell subset density in patients with pancreatic adenocarcinoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; CD8; Immune system; Gastroenterology; Internal medicine; T cell; Tissue microarray; Adenocarcinoma; Proportional hazards model; Univariate analysis; FOXP3; Pathology; Immunohistochemistry; Oncology; Cancer; Multivariate analysis; Immunology","score_opus":0.03771683548251378,"score_gpt":0.34086053746602357,"score_spread":0.3031437019835098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973896058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99823004,0.0005985173,0.0000064064197,0.00047197862,0.00020640958,0.00038413788,0.0000015030781,0.0000033687054,0.00009761865],"genre_scores_gemma":[0.9976551,0.00011621033,0.0017082535,0.00039996486,0.000086850996,0.0000033266635,0.0000038753437,0.000012570578,0.00001387321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997487,0.00033404073,0.0016051623,0.00014448895,0.00024523103,0.00018407805],"domain_scores_gemma":[0.9975826,0.0006203169,0.001123058,0.00014906884,0.00032829025,0.00019666899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013375108,0.000120063414,0.0011895576,0.00010728225,0.000022870203,0.0000085751035,0.000100211015,0.0001822695,0.00006838552],"category_scores_gemma":[0.0005119947,0.00007897271,0.00012650274,0.00012473448,0.0003522708,0.00015619172,0.00002700189,0.000557398,0.000001219397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011721356,0.0019081988,0.973058,0.000067226356,0.00013084945,0.00009875121,0.0002004617,0.0000015157893,0.0006094315,0.0000059463027,0.00004574732,0.012152512],"study_design_scores_gemma":[0.019131657,0.029753145,0.94980377,0.0002900733,0.00022025299,0.00011841783,0.00021817634,0.00009409888,0.00020055774,0.00005988464,0.000030728446,0.0000792301],"about_ca_topic_score_codex":0.00020838139,"about_ca_topic_score_gemma":0.0000379348,"teacher_disagreement_score":0.027844945,"about_ca_system_score_codex":0.00006966798,"about_ca_system_score_gemma":0.0005758014,"threshold_uncertainty_score":0.3220414},"labels":[],"label_agreement":null},{"id":"W2974885357","doi":"10.1093/jncics/pkz071","title":"Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index","year":2019,"lang":"en","type":"article","venue":"JNCI Cancer Spectrum","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"American Society of Clinical Oncology","keywords":"Medicine; Hazard ratio; Internal medicine; Confidence interval; Multivariate analysis; Oncology; Cohort; Clinical trial; Proportional hazards model; Progression-free survival; Overall survival","score_opus":0.04345991597609218,"score_gpt":0.3606200229043465,"score_spread":0.31716010692825436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974885357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99498045,0.0018779973,0.00004769859,0.0007427926,0.0006058608,0.0008987343,0.000008128125,0.000016866687,0.0008214906],"genre_scores_gemma":[0.9989597,0.00035732271,0.00011254089,0.000086486056,0.00009658895,0.000082297796,0.000011463493,0.000014981484,0.0002785877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986777,0.000106655025,0.0005741625,0.00022015744,0.00021062922,0.0002106998],"domain_scores_gemma":[0.99937576,0.00014681327,0.00024151114,0.00015486828,0.000035347,0.00004571642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097146106,0.0001266751,0.00057571934,0.00017644027,0.000019067093,0.000010791648,0.000058493795,0.00010162661,0.00038973632],"category_scores_gemma":[0.00006547078,0.00010566952,0.00006210756,0.00025719748,0.000051721898,0.000069070564,0.000023702014,0.00012210442,0.0000056735453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015080929,0.00054477644,0.7991985,0.00023373532,0.00039345145,0.000021600492,0.0035705538,0.0000045339443,0.05886773,0.00008272111,0.00008655239,0.121914886],"study_design_scores_gemma":[0.02845377,0.0019722572,0.79290605,0.00041931614,0.000093943396,0.000019310855,0.000432559,0.000078237266,0.15905397,0.00008870942,0.016235039,0.00024684356],"about_ca_topic_score_codex":0.0012080502,"about_ca_topic_score_gemma":0.0004431469,"teacher_disagreement_score":0.12166804,"about_ca_system_score_codex":0.00038114772,"about_ca_system_score_gemma":0.0007113034,"threshold_uncertainty_score":0.4309078},"labels":[],"label_agreement":null},{"id":"W2977365200","doi":"10.1093/annonc/mdz255","title":"Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Adjuvant; Oncology; Internal medicine; Stage (stratigraphy); Melanoma; Biomarker; Immunotherapy; Cancer; Cancer research","score_opus":0.09707293265296456,"score_gpt":0.3960347247990392,"score_spread":0.2989617921460746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977365200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98434556,0.0017028424,0.0000012819712,0.004769493,0.001020346,0.0014901258,0.00024974463,0.0000354829,0.0063851457],"genre_scores_gemma":[0.9963733,0.0013876264,0.00004912553,0.00059036264,0.00021399707,0.000025824236,0.00016947808,0.00002849063,0.001161779],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974881,0.00033744925,0.0009114405,0.00051186624,0.00030267655,0.00044847935],"domain_scores_gemma":[0.99736434,0.001278361,0.00042702048,0.00067035074,0.00014995762,0.00010998263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012950256,0.0002460732,0.0008564906,0.0001734484,0.000065365675,0.000016723418,0.0002416838,0.0003221512,0.0006216926],"category_scores_gemma":[0.00038721273,0.00017760838,0.0001684669,0.00038191117,0.00032672592,0.00009438957,0.00010775791,0.00032965702,0.000025965648],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90283835,0.0011047649,0.00020416998,0.000022285285,0.00053284917,0.00008404526,0.0015278826,9.907583e-7,0.033343535,0.000024453353,0.009952332,0.050364364],"study_design_scores_gemma":[0.8454774,0.019772708,0.02852303,0.00017598987,0.0001204053,0.000009139755,0.0012485498,0.00017343619,0.0059001967,0.000023825854,0.09832055,0.00025476151],"about_ca_topic_score_codex":0.0033347593,"about_ca_topic_score_gemma":0.00093767414,"teacher_disagreement_score":0.08836822,"about_ca_system_score_codex":0.00010387665,"about_ca_system_score_gemma":0.00043132823,"threshold_uncertainty_score":0.724266},"labels":[],"label_agreement":null},{"id":"W2977396843","doi":"10.1097/pai.0000000000000800","title":"Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)","year":2019,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan; Saskatchewan Health Authority; Calgary Laboratory Services; St. Michael's Hospital; Jewish General Hospital; University of Manitoba; Juravinski Cancer Centre; University of British Columbia; University of Calgary; McGill University Health Centre; McGill University; BC Cancer Agency; University of Alberta; Université Laval; Dalhousie University; Royal University Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Oncology; Cancer; Internal medicine; Lung cancer; Biomarker; Clinical trial; Disease; Guideline; Pathology","score_opus":0.05631065346560763,"score_gpt":0.35510117340578673,"score_spread":0.2987905199401791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977396843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99183565,0.002128565,0.00039022198,0.0014858465,0.0005968931,0.0026175964,0.0006822823,0.000039629587,0.0002233026],"genre_scores_gemma":[0.9818649,0.00009209337,0.01346735,0.00192499,0.000113046146,0.0014151082,0.0008717232,0.000056659403,0.00019411091],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970279,0.00014580085,0.0012722678,0.00060084945,0.000179941,0.00077324215],"domain_scores_gemma":[0.9950356,0.0016047918,0.0011185288,0.00042072634,0.0017186499,0.000101732905],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027104858,0.00031694697,0.0007711426,0.000095177566,0.0002633161,0.000027305277,0.0002565701,0.0008839902,0.000032898337],"category_scores_gemma":[0.0060550314,0.00028826634,0.0002881744,0.0004264211,0.00024372882,0.000041576768,0.000045156274,0.00029557705,0.0000019832203],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023728737,0.000117167314,0.06215334,0.000085987784,0.00032091382,0.00000675382,0.0003344411,0.000015495601,0.9217362,0.00003123868,0.0030889187,0.009736708],"study_design_scores_gemma":[0.031377304,0.0056898035,0.3970548,0.00047750145,0.001550041,0.00012698439,0.0040428224,0.0007275579,0.49450397,0.0025447556,0.060096998,0.0018074778],"about_ca_topic_score_codex":0.0488529,"about_ca_topic_score_gemma":0.013980946,"teacher_disagreement_score":0.42723218,"about_ca_system_score_codex":0.0044317143,"about_ca_system_score_gemma":0.0013892927,"threshold_uncertainty_score":0.99995697},"labels":[],"label_agreement":null},{"id":"W2977680118","doi":"10.1093/annonc/mdz253.023","title":"A phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lag; Phase (matter); Internal medicine; Oncology","score_opus":0.0580734026653386,"score_gpt":0.4154281216832031,"score_spread":0.3573547190178645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977680118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620724,0.00044932886,0.000009290908,0.0011060267,0.00016023777,0.0014633067,0.000020175441,0.000025530386,0.00055885507],"genre_scores_gemma":[0.99823874,0.0009826932,0.00008317052,0.00039578276,0.000031189767,0.000022076118,0.00006331365,0.00003182242,0.00015122921],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979794,0.00023152921,0.0007019137,0.00042965225,0.00031934076,0.00033818537],"domain_scores_gemma":[0.99857855,0.00016028257,0.00044331868,0.00044806258,0.000268538,0.000101244084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008350589,0.00023505824,0.0011499369,0.00044707645,0.000040012386,0.000010001834,0.00015639774,0.00018789362,0.00018229414],"category_scores_gemma":[0.000044719316,0.00017714134,0.000068006215,0.0005739112,0.00023542545,0.00021750588,0.000053001157,0.00020342672,0.0000043934356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039451838,0.04062281,0.4839122,0.0006558012,0.0010416233,0.0004749756,0.00415679,0.000031096984,0.39079797,0.00007742459,0.0005243182,0.038253147],"study_design_scores_gemma":[0.080247365,0.1352549,0.747572,0.0005006012,0.00023152797,0.00026168433,0.0056749424,0.00049626245,0.027227178,0.000021571572,0.0021291394,0.00038281557],"about_ca_topic_score_codex":0.00081424974,"about_ca_topic_score_gemma":0.00037774778,"teacher_disagreement_score":0.36357078,"about_ca_system_score_codex":0.000038457707,"about_ca_system_score_gemma":0.0002977931,"threshold_uncertainty_score":0.72236145},"labels":[],"label_agreement":null},{"id":"W2977739337","doi":"10.1093/annonc/mdz244.036","title":"Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Durvalumab; Tremelimumab; Medicine; Carboplatin; Tolerability; Internal medicine; Chemotherapy; Gemcitabine; Pemetrexed; Vinorelbine; Oncology; Cisplatin; Adverse effect; Cancer; Immunotherapy; Pembrolizumab; Ipilimumab","score_opus":0.16481319092961788,"score_gpt":0.4216233194782329,"score_spread":0.256810128548615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977739337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98998165,0.0009214795,0.0000011236959,0.0064157974,0.0002089181,0.0015375661,0.00021640904,0.0000063060347,0.0007107774],"genre_scores_gemma":[0.9971474,0.0008910516,0.000025695226,0.0015070532,0.00005569068,0.000027484912,0.0002674639,0.00001821122,0.000059971513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981681,0.00047828682,0.00059893855,0.00029690505,0.00024950132,0.00020827889],"domain_scores_gemma":[0.9985229,0.00040143923,0.0004097388,0.00045769484,0.00014314865,0.000065071115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019268846,0.0001456594,0.000785327,0.00014369005,0.000036661826,0.000009646836,0.00026020617,0.00011164651,0.00071154296],"category_scores_gemma":[0.000048477177,0.00009555621,0.00003365187,0.00033625466,0.00012707895,0.00008800408,0.00003918147,0.00017318458,0.0000014701426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06737325,0.0036426962,0.5954252,0.00008575644,0.003236641,0.00004403206,0.008083035,0.000027231396,0.03429279,0.00005168247,0.011653429,0.27608427],"study_design_scores_gemma":[0.07754154,0.010635067,0.87879455,0.00014788822,0.00024145255,0.0000071894824,0.0025114089,0.00039647103,0.0026259047,0.000043885157,0.026859686,0.00019497311],"about_ca_topic_score_codex":0.4160529,"about_ca_topic_score_gemma":0.6984433,"teacher_disagreement_score":0.28336936,"about_ca_system_score_codex":0.00008846225,"about_ca_system_score_gemma":0.000626698,"threshold_uncertainty_score":0.7790896},"labels":[],"label_agreement":null},{"id":"W2978014264","doi":"10.1097/cad.0000000000000653","title":"DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy","year":2018,"lang":"en","type":"article","venue":"Anti-Cancer Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Occupational Cancer Research Centre","funders":"","keywords":"Docetaxel; Taxane; Paclitaxel; Medicine; Triple-negative breast cancer; Immunotherapy; Breast cancer; Pharmacology; Metastatic breast cancer; Chemotherapy; Cancer; Cancer research; Oncology; Internal medicine","score_opus":0.03358925432978724,"score_gpt":0.33690315042350005,"score_spread":0.30331389609371284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978014264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768506,0.006185541,0.00012461898,0.012186321,0.00046953393,0.0029513838,0.0010694141,0.00004065619,0.00012187486],"genre_scores_gemma":[0.9813159,0.010834622,0.00052110915,0.001900213,0.0006799502,0.0013133552,0.000013026778,0.000067593064,0.0033541906],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982521,0.000041833508,0.0004628415,0.000538666,0.00028864696,0.00041590774],"domain_scores_gemma":[0.99852467,0.00028493936,0.00022359412,0.00048757432,0.00036082487,0.00011841823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019327433,0.0003508182,0.00073746766,0.00009245209,0.00030012775,0.000054647484,0.00015934806,0.0001101248,0.00075511914],"category_scores_gemma":[0.000016851303,0.00019707439,0.00020495693,0.00038672567,0.00097127556,0.00009202993,0.000019181269,0.00008340012,0.0000058642563],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067821234,0.0022306906,0.08025618,0.0005443753,0.007489074,0.0000106659245,0.035958666,0.000006704679,0.19186014,0.000049887978,0.016257698,0.5975147],"study_design_scores_gemma":[0.036749348,0.011826733,0.28934625,0.0014105536,0.0013534176,0.00006337891,0.0024305482,0.00047243593,0.5001361,0.000032607488,0.15527512,0.00090351107],"about_ca_topic_score_codex":0.006879272,"about_ca_topic_score_gemma":0.00058210763,"teacher_disagreement_score":0.5966112,"about_ca_system_score_codex":0.0001707827,"about_ca_system_score_gemma":0.0005321138,"threshold_uncertainty_score":0.999734},"labels":[],"label_agreement":null},{"id":"W2978136097","doi":"10.1158/1078-0432.ccr-19-0526","title":"An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Agonist; Medicine; Blockade; Receptor; Pharmacology; CD8; Cancer research; Oncology; Internal medicine; Immunology; Immune system","score_opus":0.07808303389853102,"score_gpt":0.4868528207522376,"score_spread":0.4087697868537066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978136097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946736,0.00008498422,0.000025813566,0.00032991078,0.000084567866,0.0014717933,0.00003581555,0.0000131097295,0.003280419],"genre_scores_gemma":[0.9978789,0.00010104221,0.0012036598,0.00016693644,0.000055941888,0.000109428904,0.00008029662,0.000019690911,0.00038407088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997725,0.00013822276,0.0006586088,0.00040190152,0.00071196957,0.00036428],"domain_scores_gemma":[0.9985545,0.00016460079,0.0001194415,0.00041279336,0.0005649767,0.00018364158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012273018,0.00014324898,0.00051130814,0.00021310954,0.00005749269,0.000026529646,0.00020959578,0.00010828943,0.00011952707],"category_scores_gemma":[0.00017088527,0.00009746341,0.000079946876,0.00072945113,0.00041073505,0.0001952751,0.000049365706,0.0005644457,0.000011273023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10290026,0.0022532262,0.82291806,0.00025325062,0.0001349957,0.000005760794,0.0014381456,0.0001335175,0.0017249268,0.00012673555,0.00026237196,0.06784875],"study_design_scores_gemma":[0.006456227,0.015604177,0.97006536,0.00054594385,0.0000103448365,0.0000010719618,0.0016363028,0.00023190725,0.0041120825,0.000006903108,0.0011715599,0.00015812153],"about_ca_topic_score_codex":0.0002475866,"about_ca_topic_score_gemma":0.00021574776,"teacher_disagreement_score":0.1471473,"about_ca_system_score_codex":0.00020178175,"about_ca_system_score_gemma":0.0008921721,"threshold_uncertainty_score":0.39744425},"labels":[],"label_agreement":null},{"id":"W2978163142","doi":"10.1503/cmaj.190244","title":"Enteritis with immune checkpoint inhibitor use","year":2019,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Ipilimumab; Medicine; Biopsy; Melanoma; Wide local excision; Axilla; Lymph; Positron emission tomography; Lymph node; Radiology; Pathology; Immune system; Immunotherapy; Internal medicine; Cancer research; Immunology; Cancer; Breast cancer","score_opus":0.005923663059332946,"score_gpt":0.21632689823661028,"score_spread":0.21040323517727733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978163142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96957195,0.00033699718,0.000017268741,0.026790923,0.0009317433,0.0001777876,0.000017837332,0.00001666054,0.0021388594],"genre_scores_gemma":[0.981904,0.00028388438,0.00014972614,0.011659887,0.0009843658,0.000004410279,0.000018678465,0.00002291392,0.004972158],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981435,0.00005574382,0.0003520087,0.000121557285,0.0009654179,0.0003618056],"domain_scores_gemma":[0.99848944,0.000050026825,0.00016108263,0.00011193381,0.0002491773,0.0009383115],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007470698,0.00010192623,0.0002270052,0.00013162786,0.000096520176,0.000094314135,0.00008287225,0.00022302585,0.010844596],"category_scores_gemma":[0.00026469288,0.00007887528,0.00012468388,0.00017818199,0.0000315479,0.00015436878,0.000006527411,0.0006262187,0.00020677336],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010814186,0.00012813718,0.8230856,0.00005481763,0.0010687717,0.0020137439,0.0006598139,8.097782e-7,0.0059955027,0.000050408282,0.088928215,0.07693275],"study_design_scores_gemma":[0.0050752903,0.0004160547,0.3215331,0.00046570858,0.000034247103,0.0023242715,0.00027340068,0.000028674536,0.0006180397,0.0000056142107,0.6690751,0.00015053245],"about_ca_topic_score_codex":0.004059049,"about_ca_topic_score_gemma":0.009950842,"teacher_disagreement_score":0.58014685,"about_ca_system_score_codex":0.0012512478,"about_ca_system_score_gemma":0.0024173544,"threshold_uncertainty_score":0.9900596},"labels":[],"label_agreement":null},{"id":"W2978186977","doi":"10.1093/annonc/mdz240.110","title":"Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Open label; Oncology; Immunotherapy; Neoadjuvant therapy; Internal medicine; Randomized controlled trial; Cancer; Breast cancer","score_opus":0.09962862780967344,"score_gpt":0.4323160443553067,"score_spread":0.3326874165456333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978186977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98174274,0.00180721,0.00005135664,0.0037280188,0.00029208267,0.0071856934,0.000025917396,0.000071826034,0.005095162],"genre_scores_gemma":[0.98221576,0.0036334714,0.0018950423,0.007047116,0.0001992037,0.00045790133,0.00009722696,0.0001091693,0.0043451074],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99697036,0.000611189,0.00085362344,0.00058569724,0.00043291852,0.0005462217],"domain_scores_gemma":[0.9974883,0.00029320034,0.00073254615,0.0008682106,0.00043475462,0.0001829675],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016319558,0.00043792307,0.0024885882,0.00020213034,0.00013733284,0.00004290787,0.0005495238,0.00028011453,0.0026522686],"category_scores_gemma":[0.000034982364,0.00023576152,0.00017466178,0.00040294518,0.00055684365,0.0003197865,0.00006146709,0.0003061319,0.000011486669],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83114624,0.007539463,0.00012598306,0.000025973313,0.0019185323,0.000058674104,0.0015275541,0.0000023970301,0.029672194,0.00004832949,0.00071706675,0.12721758],"study_design_scores_gemma":[0.7059697,0.23289002,0.00010321339,0.00013093658,0.00009546967,0.00013002126,0.00026450003,0.000110633504,0.008322885,0.000030982566,0.051668502,0.0002831742],"about_ca_topic_score_codex":0.0012748912,"about_ca_topic_score_gemma":0.00030886577,"teacher_disagreement_score":0.22535056,"about_ca_system_score_codex":0.0000675742,"about_ca_system_score_gemma":0.001608408,"threshold_uncertainty_score":0.9982594},"labels":[],"label_agreement":null},{"id":"W2978458313","doi":"10.1093/annonc/mdz253.018","title":"Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Solid tumor; Immunotherapy; Cancer","score_opus":0.012197201427352979,"score_gpt":0.30922483837680625,"score_spread":0.2970276369494533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978458313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996717,0.000047265818,0.0000023081088,0.0015229192,0.000022175398,0.0006095377,0.000019099774,0.000009475254,0.0010502356],"genre_scores_gemma":[0.9989686,0.000023198434,0.00018342001,0.00026217077,0.00000958639,0.000019533536,0.00006708718,0.000018101,0.00044829276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876374,0.0000834253,0.00037408728,0.00020027938,0.0003298426,0.0002486063],"domain_scores_gemma":[0.99884486,0.00015136099,0.00046184735,0.00011827589,0.0003884502,0.00003517607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021364736,0.0001448642,0.0006319697,0.0002497509,0.000009997678,0.0000024419226,0.00006432802,0.000104857456,0.00006587398],"category_scores_gemma":[0.00004321418,0.00009741767,0.000044356337,0.00039153913,0.000059722486,0.00009830784,0.000007910633,0.00013969372,0.0000027060285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03944294,0.0006160138,0.95408845,0.00004456125,0.00028155523,0.000015974712,0.00041894193,0.00046044088,0.0016573142,0.0000053526296,0.000058020232,0.0029104252],"study_design_scores_gemma":[0.027676279,0.014860314,0.95261735,0.00019238285,0.000044659642,0.0000067362953,0.000155826,0.000036000147,0.0041651134,0.000010448635,0.000121401754,0.00011348425],"about_ca_topic_score_codex":0.00043751352,"about_ca_topic_score_gemma":0.0010483023,"teacher_disagreement_score":0.0142443,"about_ca_system_score_codex":0.0002185463,"about_ca_system_score_gemma":0.00041236053,"threshold_uncertainty_score":0.39725775},"labels":[],"label_agreement":null},{"id":"W2978507674","doi":"10.1093/annonc/mdz253.094","title":"Results from a randomised phase I/II trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; Medicine; Nivolumab; Oncology; Internal medicine; Phases of clinical research; Clinical trial; Immunotherapy; Cancer","score_opus":0.08317332167414404,"score_gpt":0.3884031649587813,"score_spread":0.30522984328463726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978507674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894155,0.0015244822,0.000026006124,0.0028572464,0.0006725939,0.0031453695,0.00045357243,0.000027311538,0.0018779155],"genre_scores_gemma":[0.9967441,0.0014985079,0.00042650805,0.0005745794,0.00022312561,0.000030723677,0.00012449094,0.000056162753,0.00032180632],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941077,0.0016353801,0.0019414136,0.00085493946,0.0007465196,0.0007140174],"domain_scores_gemma":[0.99481815,0.0020904425,0.0016831623,0.00089517084,0.0003308913,0.00018219196],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0056745596,0.000479117,0.0024838408,0.00036355972,0.00018462453,0.000022251314,0.00039227476,0.000337811,0.00031833723],"category_scores_gemma":[0.00067322125,0.00036859323,0.00052200496,0.00056436454,0.00060616643,0.00022281337,0.00020155721,0.00066466694,0.000012146166],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.564537,0.0025043264,0.00078478066,0.00018723114,0.00029768504,0.00007134371,0.0017066183,0.000029685725,0.41793588,0.0000024638957,0.0008938423,0.011049145],"study_design_scores_gemma":[0.70247173,0.04294544,0.049364448,0.00032009528,0.00067479984,0.000042423304,0.0007276437,0.0031007975,0.19712794,0.000039984847,0.002728773,0.00045589783],"about_ca_topic_score_codex":0.004085728,"about_ca_topic_score_gemma":0.00025075593,"teacher_disagreement_score":0.22080792,"about_ca_system_score_codex":0.00011098013,"about_ca_system_score_gemma":0.0011835203,"threshold_uncertainty_score":0.9998766},"labels":[],"label_agreement":null},{"id":"W2978537230","doi":"10.1093/annonc/mdz252.011","title":"Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Head and neck squamous-cell carcinoma; Agonist; Oncology; Head and neck; Internal medicine; Cancer research; Receptor; Cancer; Immunotherapy; Head and neck cancer; Surgery","score_opus":0.034317671288232106,"score_gpt":0.29838349818667054,"score_spread":0.26406582689843844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978537230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99073094,0.00345546,8.097406e-7,0.0013987725,0.00019270745,0.0011839644,0.000057397603,0.000019580291,0.0029603604],"genre_scores_gemma":[0.9975987,0.0008769317,0.00021063304,0.00072666333,0.00004024306,0.000033530294,0.00019610848,0.00003579201,0.00028139],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776363,0.00022666108,0.00073231506,0.00063986436,0.0002588502,0.0003786896],"domain_scores_gemma":[0.9985044,0.00042451822,0.00037350302,0.00041536716,0.00014246788,0.00013972828],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005809153,0.00027499342,0.0008094449,0.00037739842,0.000044259352,0.000013011876,0.00010198754,0.00044036048,0.000050629435],"category_scores_gemma":[0.000050392973,0.00025167954,0.00005313808,0.000316874,0.00019940526,0.00017609907,0.00007720835,0.00041628367,0.0000066871303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25632682,0.0047338596,0.46138296,0.00057963474,0.000068671514,0.000327655,0.0065377024,0.000083188,0.23532638,0.000007197107,0.0048244665,0.029801458],"study_design_scores_gemma":[0.057812918,0.023812719,0.8423783,0.00033796325,0.000043838227,0.00004610548,0.000641796,0.0002964357,0.07155918,0.000036986094,0.0027324543,0.00030127825],"about_ca_topic_score_codex":0.0048890267,"about_ca_topic_score_gemma":0.0007682202,"teacher_disagreement_score":0.38099536,"about_ca_system_score_codex":0.00015547046,"about_ca_system_score_gemma":0.0005024084,"threshold_uncertainty_score":0.99999356},"labels":[],"label_agreement":null},{"id":"W2978821325","doi":"10.1093/annonc/mdz253.081","title":"Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Oncology; Cancer; Population","score_opus":0.039236838387144014,"score_gpt":0.363956153621469,"score_spread":0.32471931523432496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978821325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888741,0.00020770603,0.000013685825,0.0029532455,0.00022695676,0.00051268155,0.000028840666,0.000009488195,0.00717333],"genre_scores_gemma":[0.998507,0.00038505674,0.00017452928,0.0006511557,0.000031852596,0.000019072508,0.000006060381,0.00001238004,0.0002128522],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99882627,0.0001311128,0.00043373264,0.00019471445,0.00018563245,0.0002285664],"domain_scores_gemma":[0.99901307,0.00017445268,0.00032608508,0.0002125725,0.00021628891,0.000057511435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058324373,0.00011824014,0.00063046,0.00019360089,0.000008162344,0.0000013391889,0.00007912804,0.00010301886,0.0002282761],"category_scores_gemma":[0.00013268832,0.00010146919,0.00017966743,0.00023265232,0.00018307669,0.00007583626,0.000031725518,0.00017077585,0.000008690022],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10300482,0.0030757175,0.06480315,0.000921215,0.0011784157,0.0000809187,0.0018883094,0.000042402273,0.7296225,0.00009294763,0.004801515,0.09048808],"study_design_scores_gemma":[0.008988816,0.021347474,0.42188615,0.00047171974,0.00009912907,0.00004103555,0.0012584022,0.0003774664,0.543108,0.00013947532,0.0021162906,0.00016603812],"about_ca_topic_score_codex":0.00043841865,"about_ca_topic_score_gemma":0.00011815234,"teacher_disagreement_score":0.357083,"about_ca_system_score_codex":0.00007772912,"about_ca_system_score_gemma":0.00037584576,"threshold_uncertainty_score":0.41377935},"labels":[],"label_agreement":null},{"id":"W2979163050","doi":"10.3389/fonc.2019.00969","title":"IL-27, IL-30, and IL-35: A Cytokine Triumvirate in Cancer","year":2019,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Immune system; Cytokine; Immunotherapy; Cancer immunotherapy; Tumor microenvironment; Immunology; Context (archaeology); Cancer; Biology; Cytotoxic T cell; Cancer research; Medicine; In vitro; Genetics","score_opus":0.050900349227122436,"score_gpt":0.3746382043595906,"score_spread":0.32373785513246817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979163050","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025710493,0.98887604,0.000024249892,0.00057644944,0.005162835,0.0019767217,0.0003289046,0.000029658979,0.002768056],"genre_scores_gemma":[0.000023849963,0.9925257,0.00065638154,0.0009077698,0.0004172976,0.0003645077,0.0001195375,0.00008558412,0.004899366],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969932,0.00036139964,0.0010721062,0.00075524696,0.00019881639,0.00061926036],"domain_scores_gemma":[0.9987375,0.000162057,0.00047055734,0.00046993987,0.00004069892,0.000119215176],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00070612115,0.0005435905,0.003674886,0.00087910116,0.000029798983,0.000015883921,0.00025761378,0.00113674,0.00033930177],"category_scores_gemma":[0.00006648662,0.0004469281,0.00034612356,0.0007210529,0.00028832583,0.00006545985,0.00009417473,0.0010495335,0.00003459025],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011092274,0.00016756482,0.0009641443,0.0064259386,0.00035070322,0.00025580166,0.00017534576,5.0904123e-7,0.000011479428,0.000005903296,0.058887124,0.9316462],"study_design_scores_gemma":[0.005573833,0.00087622576,0.0003329597,0.0062999055,0.0006817432,0.00012604252,0.00008899512,0.000017783372,0.000003178504,0.000025661157,0.98555005,0.00042361295],"about_ca_topic_score_codex":0.00063360686,"about_ca_topic_score_gemma":0.00039266303,"teacher_disagreement_score":0.9312226,"about_ca_system_score_codex":0.002340524,"about_ca_system_score_gemma":0.0019797215,"threshold_uncertainty_score":0.99979824},"labels":[],"label_agreement":null},{"id":"W2979257942","doi":"10.1093/annonc/mdz394.080","title":"Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Chemotherapy; First line therapy; Internal medicine; Cancer; Immunotherapy","score_opus":0.07576311777996377,"score_gpt":0.3943962022662226,"score_spread":0.3186330844862588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979257942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98497397,0.008471017,0.000014491615,0.0052679274,0.000051480347,0.00074678677,0.000007749679,0.000007370477,0.00045922512],"genre_scores_gemma":[0.9925791,0.0045592557,0.000278173,0.0023042574,0.000026934948,0.000059343132,0.000011455698,0.000017986018,0.00016346906],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998295,0.00021040314,0.0006745967,0.00029103033,0.0002366403,0.00029230816],"domain_scores_gemma":[0.99882066,0.00031931186,0.00032308014,0.00037221814,0.000118199634,0.000046530728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087083894,0.0001916998,0.000883332,0.00046791357,0.000016361695,0.000007156482,0.00014283665,0.00015169708,0.00059323723],"category_scores_gemma":[0.00004292318,0.00012277008,0.00023928942,0.00093510415,0.00026747806,0.00008137497,0.000031581498,0.00022482697,0.0000026454286],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.090791844,0.0018262704,0.24204695,0.00020594348,0.0009978784,0.000055198274,0.0026943951,0.000027167485,0.051309686,0.00001719488,0.00015342682,0.609874],"study_design_scores_gemma":[0.02334658,0.007869503,0.93071765,0.00021556021,0.00018477216,0.000048279126,0.00040820587,0.00084649445,0.030884545,0.00016518157,0.005099395,0.00021381813],"about_ca_topic_score_codex":0.0006095562,"about_ca_topic_score_gemma":0.0005340853,"teacher_disagreement_score":0.6886707,"about_ca_system_score_codex":0.000047244914,"about_ca_system_score_gemma":0.00021363261,"threshold_uncertainty_score":0.6495532},"labels":[],"label_agreement":null},{"id":"W2979775428","doi":"10.1038/s41523-019-0130-x","title":"Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer","year":2019,"lang":"en","type":"review","venue":"npj Breast Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Metastatic breast cancer; Blockade; Breast cancer; Oncology; Cancer; Chemotherapy; PD-L1; Internal medicine; Antibody; Clinical Practice; Radiation therapy; Immunotherapy; Immunology; Receptor","score_opus":0.10722042243326235,"score_gpt":0.36058413776115533,"score_spread":0.253363715327893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979775428","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00077754253,0.9834521,0.000009044062,0.007435637,0.001175337,0.0030141599,0.0026865075,0.00009668737,0.0013530247],"genre_scores_gemma":[0.0038954853,0.98738307,0.0001287594,0.0016208532,0.0010371839,0.0019944478,0.00070804014,0.00026485338,0.0029673104],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99539477,0.00034393277,0.0012360865,0.0011822418,0.000930522,0.0009124724],"domain_scores_gemma":[0.9977137,0.0001359753,0.00078527216,0.0009652404,0.0001683734,0.00023147005],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005968225,0.0010477789,0.0031181234,0.0006392491,0.00009829521,0.000096123134,0.0004837482,0.00046344736,0.0034280487],"category_scores_gemma":[0.000008465719,0.0008419104,0.0009463478,0.0010374464,0.00025480348,0.00024111029,0.000118797885,0.0011103875,0.00008623681],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091990386,0.00056415476,0.002572788,0.01821264,0.002115454,0.000031277537,0.00017655603,0.000004131736,0.000018677018,0.000039277944,0.0018093268,0.97353584],"study_design_scores_gemma":[0.0099992,0.00015000279,0.03609817,0.047100563,0.007296721,0.0013983822,0.00012211749,0.00007913535,0.000024607538,0.00003215488,0.8959525,0.0017464529],"about_ca_topic_score_codex":0.009157009,"about_ca_topic_score_gemma":0.0016216707,"teacher_disagreement_score":0.97178936,"about_ca_system_score_codex":0.0023029337,"about_ca_system_score_gemma":0.0019350067,"threshold_uncertainty_score":0.9994032},"labels":[],"label_agreement":null},{"id":"W2980047572","doi":"10.3389/fonc.2019.01040","title":"Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis","year":2019,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Hazard ratio; Oncology; Internal medicine; Medicine; Subgroup analysis; Meta-analysis; Confidence interval; Stage (stratigraphy); Breast cancer; Immune system; Cancer; Immunology; Biology","score_opus":0.12881900735781493,"score_gpt":0.4115773061812036,"score_spread":0.28275829882338865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980047572","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000110593646,0.9960849,0.0004264668,0.00012778958,0.0008121968,0.001929528,0.00006607399,0.000012050096,0.00043035034],"genre_scores_gemma":[0.00011125393,0.99510485,0.0028157553,0.00019618795,0.000071160204,0.00077120075,0.00022711336,0.000041516705,0.00066094496],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99705803,0.0005097747,0.0013028432,0.0005463379,0.00025200503,0.00033103186],"domain_scores_gemma":[0.99821156,0.000258917,0.0009114165,0.0004975854,0.000069676564,0.000050841874],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007274961,0.00037866077,0.0070488113,0.0017272094,0.000013504177,0.0000050364333,0.00023529292,0.0007091968,0.00026760978],"category_scores_gemma":[0.000101393416,0.0002898709,0.0021673727,0.0022861727,0.0001277225,0.00004561382,0.00004335975,0.00036157886,0.0000041342514],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074030267,0.0003432548,0.0021514867,0.0067722406,0.12310229,0.000041872543,0.00015886042,0.00005996824,0.000007337187,0.000007415809,0.0013835939,0.8652314],"study_design_scores_gemma":[0.0016372091,0.0003748167,0.00038379023,0.00078261667,0.22473325,0.000013586342,0.00003753371,0.00011237688,0.000012959393,0.000011336784,0.77167726,0.00022329873],"about_ca_topic_score_codex":0.0017269886,"about_ca_topic_score_gemma":0.00027359943,"teacher_disagreement_score":0.86500806,"about_ca_system_score_codex":0.003261584,"about_ca_system_score_gemma":0.0029545734,"threshold_uncertainty_score":0.99995536},"labels":[],"label_agreement":null},{"id":"W2980072580","doi":"10.4081/oncol.2019.425","title":"Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review","year":2019,"lang":"en","type":"article","venue":"Oncology Reviews","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Triple-negative breast cancer; Neutropenia; Oncology; Internal medicine; Adverse effect; PD-L1; Breast cancer; Cancer; Immunotherapy; Chemotherapy","score_opus":0.034481868574456155,"score_gpt":0.3339692933621759,"score_spread":0.2994874247877197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980072580","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38532203,0.5855195,0.0000012374865,0.0010868462,0.0001602449,0.02721834,0.000045959223,0.000015219363,0.00063062453],"genre_scores_gemma":[0.19699472,0.7981249,0.0006038507,0.00079976633,0.000058432495,0.0029622822,0.00004508366,0.000030423682,0.00038053183],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9966153,0.00091358076,0.0015569543,0.0003768512,0.00022204452,0.00031526765],"domain_scores_gemma":[0.9975036,0.0005050126,0.0012040632,0.00054418313,0.00016182191,0.00008136031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009367795,0.0003541864,0.0028978686,0.000098102806,0.000039780694,0.000007018598,0.00016777609,0.00015606357,0.00004591062],"category_scores_gemma":[0.000048971928,0.0001858022,0.00038575145,0.00049372716,0.00017566164,0.000039325332,0.000023736056,0.00016423158,0.000009407942],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008585488,0.008384204,0.030642234,0.7109355,0.0009872844,0.00005894782,0.0084432885,4.4821584e-7,0.014655947,0.000033454122,0.0011260493,0.21614718],"study_design_scores_gemma":[0.09453541,0.037968457,0.06560579,0.50375336,0.013022658,0.0009336012,0.0041945516,0.00004573025,0.02323462,0.000022806755,0.2552194,0.0014636109],"about_ca_topic_score_codex":0.00049440196,"about_ca_topic_score_gemma":0.00009911095,"teacher_disagreement_score":0.25409338,"about_ca_system_score_codex":0.000351961,"about_ca_system_score_gemma":0.000308411,"threshold_uncertainty_score":0.7576794},"labels":[],"label_agreement":null},{"id":"W2980236107","doi":"10.1016/j.smim.2019.101295","title":"Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications","year":2019,"lang":"en","type":"review","venue":"Seminars in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"University of Leeds; Cancer Research UK; Wellcome Trust; Wellcome","keywords":"TIGIT; Blockade; GSK-3; Immunotherapy; Cancer immunotherapy; Immune checkpoint; Immune system; Cancer research; Receptor; Glycogen synthase; Cytotoxic T cell; Biology; Immunology; Medicine; Signal transduction; Internal medicine; Glycogen; Cell biology; Biochemistry","score_opus":0.045284025094739444,"score_gpt":0.34750597229373315,"score_spread":0.3022219471989937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980236107","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005200573,0.993229,0.0000055493956,0.0000999881,0.00015360315,0.001024153,0.00003496446,0.000015283269,0.00023692203],"genre_scores_gemma":[0.0060648485,0.99303234,0.00007742499,0.00003156384,0.00002353557,0.00009592912,0.00010057722,0.000033102668,0.0005406526],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986907,0.00013929234,0.0005476805,0.00035628426,0.00007609271,0.00018995166],"domain_scores_gemma":[0.9988772,0.00026253358,0.0003504502,0.0004392801,0.000043495536,0.00002702877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022539328,0.00024577798,0.0011141426,0.00032582335,0.000037117592,0.0000058894043,0.000103408835,0.00048453882,0.0000736114],"category_scores_gemma":[0.00004325199,0.00019719343,0.0001265201,0.00024734833,0.0001744213,0.000047535545,0.00008237006,0.00025944578,0.000005720988],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033273455,0.000052517917,0.00006762017,0.0057586757,0.00022394265,0.0000028617692,0.00017051725,2.414104e-8,0.02582216,0.0001403501,0.000053452637,0.96737516],"study_design_scores_gemma":[0.0020446249,0.00063699216,0.0031652907,0.037168935,0.0009626272,0.0010409486,0.00012133396,0.0000062607965,0.0013249076,0.00018727827,0.95296305,0.0003777231],"about_ca_topic_score_codex":0.000016399832,"about_ca_topic_score_gemma":0.0000021729925,"teacher_disagreement_score":0.96699744,"about_ca_system_score_codex":0.00009688341,"about_ca_system_score_gemma":0.0001651785,"threshold_uncertainty_score":0.80413145},"labels":[],"label_agreement":null},{"id":"W2980239782","doi":"10.1111/sji.12821","title":"Exploiting autoimmunity unleashed by low‐dose immune checkpoint blockade to treat advanced cancer","year":2019,"lang":"en","type":"review","venue":"Scandinavian Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Ipilimumab; Medicine; Blockade; Immune checkpoint; Autoimmunity; Immunotherapy; Cancer; Immunology; Immune system; Cancer immunotherapy; Adoptive cell transfer; Adverse effect; T cell; Internal medicine; Receptor","score_opus":0.037896893878331145,"score_gpt":0.3511225220488142,"score_spread":0.31322562817048305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980239782","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011469164,0.98357344,0.000028115099,0.00058627175,0.0023698634,0.0014054567,0.00013070741,0.000048781243,0.00038823063],"genre_scores_gemma":[0.0015562013,0.99337155,0.00023424522,0.00017222992,0.00037451927,0.00010815856,0.000103325074,0.00019255433,0.0038872012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945593,0.00049840874,0.0029127186,0.0005646436,0.00048142945,0.0009834964],"domain_scores_gemma":[0.9951973,0.00023331131,0.0027646006,0.0010726118,0.00042484023,0.00030735697],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00088859926,0.0009919127,0.005186376,0.0009663449,0.00020234493,0.00006073951,0.0009427572,0.00077286956,0.0010515421],"category_scores_gemma":[0.00021308022,0.0007596686,0.0021225754,0.000982197,0.0003150728,0.00021107045,0.00020287008,0.0021576097,0.00012088445],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032798627,0.0002917119,0.0000228632,0.0055106333,0.0023678287,0.0001727574,0.00034510583,0.0000017623157,0.025307361,0.0000021987767,0.0006217667,0.9620761],"study_design_scores_gemma":[0.008220803,0.0035247293,0.00035931118,0.07793436,0.003151561,0.0033813526,0.00049553934,8.700791e-7,0.002893677,0.000009024828,0.8990965,0.000932274],"about_ca_topic_score_codex":0.00026238686,"about_ca_topic_score_gemma":0.000005564304,"teacher_disagreement_score":0.96114385,"about_ca_system_score_codex":0.0020110246,"about_ca_system_score_gemma":0.0015988149,"threshold_uncertainty_score":0.99986166},"labels":[],"label_agreement":null},{"id":"W2980270483","doi":"10.1098/rsob.190061","title":"miR-149-3p reverses CD8 <sup>+</sup> T-cell exhaustion by reducing inhibitory receptors and promoting cytokine secretion in breast cancer cells","year":2019,"lang":"en","type":"article","venue":"Open Biology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Natural Science Foundation of China","keywords":"Biology; CD8; Cytotoxic T cell; Cancer research; BTLA; Immune system; T cell; Downregulation and upregulation; Immunology; Receptor; Cytokine; Cancer cell; Cancer; Cell biology; Biochemistry","score_opus":0.010692740885410675,"score_gpt":0.2675119685262619,"score_spread":0.25681922764085124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980270483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99477786,0.0009809469,0.0000039512083,0.0012430692,0.0003913056,0.00095092185,0.00006321795,0.000020643178,0.001568105],"genre_scores_gemma":[0.9953195,0.0013581025,0.00023672884,0.00050695275,0.0001592362,0.000055185283,0.00017245635,0.000025545169,0.0021662947],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987167,0.00013121165,0.00032178327,0.0004685516,0.00007606965,0.00028565867],"domain_scores_gemma":[0.99949044,0.000042532287,0.00015121128,0.00020035954,0.000047656486,0.000067805],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004923265,0.00017646146,0.00034481313,0.00010421468,0.00005957298,0.000026870248,0.00011643907,0.00022223999,0.0009722572],"category_scores_gemma":[0.000010152901,0.00015178404,0.000041867366,0.00020483449,0.000101811806,0.0001580155,0.00009815004,0.00021756138,0.000021478605],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013119255,0.00008465709,0.035089117,0.00012040524,0.00003138534,0.0000022068155,0.00060706877,0.000007748399,0.94014364,0.0000024665403,0.0066932356,0.015906159],"study_design_scores_gemma":[0.01870584,0.0019636517,0.02928658,0.0030322834,0.00014837024,0.00022231447,0.0030480588,0.001261512,0.7274778,0.00004418271,0.2137042,0.0011052184],"about_ca_topic_score_codex":0.0061840946,"about_ca_topic_score_gemma":0.000060853246,"teacher_disagreement_score":0.21266583,"about_ca_system_score_codex":0.00022499582,"about_ca_system_score_gemma":0.00011345075,"threshold_uncertainty_score":0.999941},"labels":[],"label_agreement":null},{"id":"W2981145234","doi":"10.1016/j.mbs.2019.108269","title":"Mathematical modelling of cancer stem cell-targeted immunotherapy","year":2019,"lang":"en","type":"article","venue":"Mathematical Biosciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; Western University","funders":"","keywords":"Cancer stem cell; Immunotherapy; Adoptive cell transfer; Cancer research; Cancer; Cytotoxic T cell; Cancer immunotherapy; Stem cell; Biology; Immunology; Medicine; Immune system; T cell; In vitro; Internal medicine; Cell biology","score_opus":0.032081027937635787,"score_gpt":0.2874517461124516,"score_spread":0.2553707181748158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981145234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97435814,0.0019385573,0.008315808,0.0006878956,0.00018039477,0.0006154728,0.000011063453,0.00006195939,0.013830696],"genre_scores_gemma":[0.99029005,0.00025458966,0.00628566,0.00024267231,0.000028883678,0.00002596431,0.0000012706148,0.000019519559,0.0028513898],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99816406,0.000029648347,0.000556805,0.0003090388,0.0006077927,0.00033268364],"domain_scores_gemma":[0.99912554,0.00014521241,0.00016951893,0.0003821448,0.00007774704,0.00009983804],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000467296,0.0001876986,0.0005190311,0.000115897936,0.00005737697,0.000030352467,0.0002516184,0.00010447275,0.0028242778],"category_scores_gemma":[0.0000074401964,0.0001225932,0.00021310744,0.0004451849,0.0004134836,0.000101625315,0.000033744887,0.000120585086,0.00016785906],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011145527,0.0014630693,0.003625396,0.0025426843,0.00024417182,0.000008011697,0.0034897788,0.00024533636,0.95114243,0.014207353,0.00020726107,0.021709973],"study_design_scores_gemma":[0.005976534,0.0018891738,0.0018167672,0.002237426,0.0002192246,0.00006766903,0.0039335694,0.1446783,0.80666065,0.028967202,0.0025496006,0.0010038982],"about_ca_topic_score_codex":0.000025684632,"about_ca_topic_score_gemma":6.75172e-7,"teacher_disagreement_score":0.14448178,"about_ca_system_score_codex":0.000048138,"about_ca_system_score_gemma":0.0001369393,"threshold_uncertainty_score":0.9980873},"labels":[],"label_agreement":null},{"id":"W2981420871","doi":"10.1016/j.jtho.2019.08.555","title":"MA07.11 Survival Outcomes Based on Gender of Advanced Nonsmall Cell Lung Cancer Patients Treated with Pembrolizumab or Nivolumab in Everyday Clinical Practice","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"","keywords":"Medicine; Nivolumab; Pembrolizumab; Internal medicine; Lung cancer; Cohort; Discontinuation; Oncology; Performance status; Cancer; Proportional hazards model; Immunotherapy","score_opus":0.031015507604992963,"score_gpt":0.43560339426023886,"score_spread":0.4045878866552459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981420871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941799,0.00027739131,0.000034799526,0.001136754,0.0010230284,0.0005773126,0.000014846981,0.000008025993,0.002747962],"genre_scores_gemma":[0.9950946,0.00024617178,0.0020946178,0.0013759529,0.00009063756,0.000009492524,0.000005881213,0.000034820994,0.0010478409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99707085,0.000585978,0.001240135,0.0002554964,0.0005480919,0.0002994632],"domain_scores_gemma":[0.99618435,0.0012398653,0.0015723575,0.00028549708,0.00058318296,0.0001347459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012107868,0.00022674132,0.0011812178,0.00031002238,0.00002408574,0.0000069961216,0.00017871376,0.00025667867,0.00048760851],"category_scores_gemma":[0.0002967846,0.00013898124,0.0002635067,0.000335536,0.00009384263,0.00018559977,0.000022174672,0.0005720076,0.0000045817237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19734856,0.0029854986,0.7815945,0.00018571754,0.0003228469,0.00025102083,0.00015732026,0.0002426326,0.0006510261,6.6446813e-7,0.00042081592,0.015839392],"study_design_scores_gemma":[0.03412576,0.017994616,0.933931,0.000494214,0.0006695919,0.00008163515,0.00043472744,0.00038733112,0.0009261981,9.3013773e-7,0.010739723,0.00021429246],"about_ca_topic_score_codex":0.00015939228,"about_ca_topic_score_gemma":0.0002817297,"teacher_disagreement_score":0.1632228,"about_ca_system_score_codex":0.00075247505,"about_ca_system_score_gemma":0.0016831814,"threshold_uncertainty_score":0.56674904},"labels":[],"label_agreement":null},{"id":"W2981423664","doi":"10.1016/j.jtho.2019.08.1673","title":"P2.09-24 IASLC Global Survey for Pathologists on PD-L1 Testing for Non-Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Lung cancer; Durvalumab; Quality assurance; Oncology; Medical physics; Cancer; Internal medicine; Pathology; Immunotherapy; External quality assessment","score_opus":0.05809206462201901,"score_gpt":0.4309762567463521,"score_spread":0.3728841921243331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981423664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887676,0.0014616003,0.0012978701,0.0018782177,0.0036639147,0.0011490933,0.00015307077,0.00001524219,0.001613393],"genre_scores_gemma":[0.9818331,0.0001535971,0.012837381,0.0024534038,0.0010052737,0.00005929963,0.00001839792,0.00003890349,0.0016006513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982681,0.00015525994,0.00070592895,0.0002541411,0.00019645512,0.00042006143],"domain_scores_gemma":[0.99699277,0.0011290011,0.0008991805,0.00021486224,0.00062651705,0.00013769898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022603814,0.00020950729,0.0007503161,0.0001137834,0.000076095705,0.000020134026,0.0002207176,0.00028997083,0.00007716555],"category_scores_gemma":[0.00044752267,0.00015828222,0.00034209015,0.00022783244,0.000066027,0.000063770436,0.000029929073,0.00030677306,0.0000064767473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09193702,0.0010590926,0.46143928,0.0013039683,0.00061213993,0.0001850686,0.00041981906,0.00017190524,0.051277183,0.000007648641,0.04104705,0.35053983],"study_design_scores_gemma":[0.015703667,0.032478347,0.87311935,0.001333707,0.0009992761,0.0010927736,0.00043186077,0.0017203185,0.010977394,0.00017070034,0.06138662,0.00058599043],"about_ca_topic_score_codex":0.00013685225,"about_ca_topic_score_gemma":0.00022806496,"teacher_disagreement_score":0.41168007,"about_ca_system_score_codex":0.0009781242,"about_ca_system_score_gemma":0.0011459215,"threshold_uncertainty_score":0.64545614},"labels":[],"label_agreement":null},{"id":"W2981451418","doi":"10.1016/j.jtho.2019.08.1582","title":"P2.04-77 Hyperprogression with Immunotherapy in Metastatic Non-Small Cell Lung Cancer: Hôpital Charles-LeMoyne Experience","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Pembrolizumab; Nivolumab; Lung cancer; Immunotherapy; Internal medicine; Cancer; Retrospective cohort study; Oncology; Disease; Cancer immunotherapy; Pathological; Medical record","score_opus":0.014374700161792254,"score_gpt":0.37626157438802665,"score_spread":0.3618868742262344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981451418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816902,0.014229796,0.00017767257,0.0016313175,0.00085239456,0.0006324743,0.0000040818068,0.000010901187,0.0007711065],"genre_scores_gemma":[0.98882616,0.0042703613,0.005138989,0.00078071497,0.00018320914,0.000037436166,0.0000027055708,0.00004023334,0.0007202063],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99807316,0.00015978309,0.00076783425,0.0002502139,0.00036091384,0.00038809708],"domain_scores_gemma":[0.99846137,0.00012093751,0.000819658,0.00027871857,0.00018589533,0.00013340467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007271877,0.00024344704,0.0008783054,0.00032661343,0.00004680581,0.00002195184,0.00025943218,0.0001382055,0.00060705794],"category_scores_gemma":[0.000011189535,0.0001602183,0.00020322445,0.0003882169,0.00012521005,0.00020659096,0.000030237663,0.00055210316,0.000008583115],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04978101,0.0016833643,0.26696756,0.0005301637,0.0005787947,0.0014227134,0.009110206,0.000098459146,0.29380342,0.0000025353925,0.00062280544,0.37539896],"study_design_scores_gemma":[0.061042704,0.048464645,0.522254,0.010367537,0.0014922336,0.0115401205,0.030935878,0.00277419,0.19988388,0.000056398734,0.10914575,0.0020426472],"about_ca_topic_score_codex":0.00012015627,"about_ca_topic_score_gemma":0.00007194416,"teacher_disagreement_score":0.3733563,"about_ca_system_score_codex":0.0006324494,"about_ca_system_score_gemma":0.00096546276,"threshold_uncertainty_score":0.6646859},"labels":[],"label_agreement":null},{"id":"W2981476024","doi":"10.1016/j.jtho.2019.08.1556","title":"P2.04-51 A 6-Gene Immune Genomic Signature (IGS) Predicts Resistance to Nivolumab [NIV] in Advanced Pretreated NSCLC: Results of PRINCiPe Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Nivolumab; Medicine; Internal medicine; Oncology; Immunotherapy; Gene; Log-rank test; Cancer research; Cancer; Overall survival; Biology; Genetics","score_opus":0.013452686025996505,"score_gpt":0.35171045269305967,"score_spread":0.33825776666706314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981476024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98766506,0.0048656776,0.000025558953,0.0025684624,0.0013027565,0.0014438616,0.0000388406,0.000016617636,0.002073148],"genre_scores_gemma":[0.99138886,0.0004912245,0.003412783,0.00034625537,0.00032635155,0.000014788361,0.0000152327075,0.000036770256,0.003967713],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99670327,0.00033015513,0.0017789918,0.00033454594,0.00045648153,0.00039655817],"domain_scores_gemma":[0.99716336,0.00027498344,0.0014740749,0.0005047093,0.00040639818,0.00017649737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017576077,0.0002473371,0.001244258,0.0005478152,0.000032270542,0.000009760257,0.0003587035,0.00041580125,0.000119108765],"category_scores_gemma":[0.00046713202,0.00020165052,0.00033023494,0.0006805014,0.00008919762,0.00014791536,0.00006352999,0.00070914824,0.000011500755],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5779872,0.0005084336,0.0004441384,0.00010542154,0.00023497448,0.00020295999,0.0007113552,0.00009386465,0.39447066,0.0000021460048,0.0008990571,0.02433981],"study_design_scores_gemma":[0.3387006,0.055489346,0.19875152,0.00439721,0.00065646035,0.0008839753,0.0009770235,0.00008427547,0.24837802,0.0001105367,0.15081094,0.00076009193],"about_ca_topic_score_codex":0.000036464604,"about_ca_topic_score_gemma":0.00016992216,"teacher_disagreement_score":0.23928659,"about_ca_system_score_codex":0.001036797,"about_ca_system_score_gemma":0.0012120875,"threshold_uncertainty_score":0.82230693},"labels":[],"label_agreement":null},{"id":"W2981525398","doi":"10.1016/j.jtho.2019.08.586","title":"MA11.04 Platinum Doublet + Durvalumab +/- Tremelimumab in Patients with Advanced NSCLC: A CCTG Phase IB Study - IND.226","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Durvalumab; Internal medicine; Rash; Carboplatin; Tremelimumab; Gemcitabine; Oncology; Tolerability; Adverse effect; Pemetrexed; Nausea; Gastroenterology; Chemotherapy; Cisplatin; Nivolumab; Cancer; Ipilimumab; Immunotherapy","score_opus":0.01567304170146937,"score_gpt":0.38731438004835966,"score_spread":0.3716413383468903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981525398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956896,0.00030665848,0.000019273275,0.0007565284,0.0007938785,0.0011813848,0.000007869653,0.000014006272,0.0012308247],"genre_scores_gemma":[0.9981603,0.000036635956,0.0007954022,0.00046121,0.00014351704,0.000013533262,0.000009581975,0.000035663797,0.0003441281],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975493,0.0002540293,0.0009808852,0.00026634792,0.0005832619,0.00036617665],"domain_scores_gemma":[0.99816924,0.00012903036,0.0009116884,0.00033141286,0.00031041112,0.00014821398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083316164,0.0002463181,0.0009617732,0.00045493385,0.00004396091,0.0000179681,0.00021309542,0.00017390064,0.0005258398],"category_scores_gemma":[0.000056574398,0.00017227838,0.0001590164,0.0004525995,0.00007566954,0.00026292074,0.000040205665,0.00065039453,0.000024242383],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30678344,0.011628989,0.28549805,0.00008503727,0.0006784834,0.0005766728,0.0021815402,0.000037050413,0.004592576,0.0000021170972,0.00049571897,0.38744032],"study_design_scores_gemma":[0.19302745,0.13933375,0.6430934,0.00079547265,0.00055454095,0.0004820284,0.0053511597,0.00004016886,0.0012605281,0.000034189852,0.01556221,0.00046508643],"about_ca_topic_score_codex":0.00003500545,"about_ca_topic_score_gemma":0.00011147834,"teacher_disagreement_score":0.38697526,"about_ca_system_score_codex":0.00075894414,"about_ca_system_score_gemma":0.00065403566,"threshold_uncertainty_score":0.70253086},"labels":[],"label_agreement":null},{"id":"W2981822363","doi":"10.1016/j.jtho.2019.08.1527","title":"P2.04-22 Programmed Death 1-mRNA Expression Predicts Benefit to Anti-PD1 Monotherapy in a Prospective Cohort of Advanced NSCLC","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Medicine; Oncology; Cohort; Internal medicine; Prospective cohort study","score_opus":0.013894854399624543,"score_gpt":0.3731552329488857,"score_spread":0.35926037854926113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981822363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929876,0.0013814692,0.00011146441,0.0011989825,0.0006564582,0.0017369458,0.000006273619,0.000017066162,0.0019037662],"genre_scores_gemma":[0.9914831,0.0005426357,0.0066738203,0.00046881108,0.00017752772,0.00004783262,0.0000033967433,0.00003384734,0.00056900823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785084,0.00011686608,0.0009623199,0.00027451184,0.00044626664,0.000349177],"domain_scores_gemma":[0.9982192,0.000118818774,0.0008204357,0.00029770963,0.00036283347,0.00018101452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009784988,0.00021118499,0.0010311368,0.00043651168,0.000027513288,0.0000099673,0.00022202371,0.00023712723,0.00020261348],"category_scores_gemma":[0.00008524953,0.00015817866,0.00024094735,0.0004532599,0.0000666494,0.00017207462,0.000041287094,0.0004251088,0.000006427167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049210645,0.0010126235,0.39509583,0.00010671556,0.00028889053,0.0001231392,0.0011311984,0.00009227252,0.32017228,0.000009585643,0.00024941258,0.2325074],"study_design_scores_gemma":[0.009125046,0.012343377,0.8575308,0.0014665724,0.00012912147,0.00043666645,0.00055050175,0.00004048062,0.10375866,0.00016742868,0.014249733,0.000201612],"about_ca_topic_score_codex":0.00004114237,"about_ca_topic_score_gemma":0.000028585717,"teacher_disagreement_score":0.46243498,"about_ca_system_score_codex":0.0006426956,"about_ca_system_score_gemma":0.0004879298,"threshold_uncertainty_score":0.64503384},"labels":[],"label_agreement":null},{"id":"W2981839573","doi":"10.1093/annonc/mdz295","title":"Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration","year":2019,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Chemotherapy; Oncology; Internal medicine; Pemetrexed; Cancer; Immunotherapy; Cisplatin","score_opus":0.06686532430890642,"score_gpt":0.3997437970675532,"score_spread":0.3328784727586468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981839573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97710186,0.0014069083,0.00057238503,0.0004818078,0.016164556,0.0025072766,0.0017112095,0.0000021198318,0.00005190082],"genre_scores_gemma":[0.99045396,0.0024446119,0.0006869569,0.0000906424,0.0051578665,0.0006581059,0.00036141765,0.00003388174,0.00011256168],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981426,0.00009674543,0.00078695576,0.00033232805,0.00047250142,0.00016887952],"domain_scores_gemma":[0.9959086,0.0014855777,0.0014092266,0.0003097557,0.00085552083,0.000031309264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006069833,0.00022067555,0.00073380367,0.00015733152,0.000033999248,0.000003912249,0.00024544858,0.0003762035,0.000018027544],"category_scores_gemma":[0.00013957174,0.00013231955,0.00015627175,0.00010065298,0.0001710629,0.00010040452,0.000035386325,0.00016741379,9.106534e-9],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25998527,0.0014419737,0.0008532205,0.002629357,0.0005456905,0.0000011937829,0.0035217316,0.00016007843,0.5422091,0.000020228332,0.14573967,0.042892504],"study_design_scores_gemma":[0.023386069,0.022237072,0.0031038169,0.0059337434,0.00030933553,0.0000045924594,0.001349913,0.0013460433,0.9308282,0.000037071048,0.011200341,0.00026377564],"about_ca_topic_score_codex":0.00076890225,"about_ca_topic_score_gemma":0.0011021633,"teacher_disagreement_score":0.38861915,"about_ca_system_score_codex":0.00011790126,"about_ca_system_score_gemma":0.0012207922,"threshold_uncertainty_score":0.53958344},"labels":[],"label_agreement":null},{"id":"W2982040065","doi":"10.1016/j.jtho.2019.08.424","title":"OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Ipilimumab; Cohort; Internal medicine; Nivolumab; Discontinuation; Oncology; Adverse effect; Cancer; Immunotherapy","score_opus":0.015037087101347242,"score_gpt":0.3432745938222109,"score_spread":0.32823750672086366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982040065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951262,0.00027218356,0.000036835754,0.001375858,0.00051732565,0.00042617565,0.00000867956,0.000008025374,0.0022287015],"genre_scores_gemma":[0.99602807,0.0000716816,0.002500516,0.0005275242,0.0003858838,0.000004114956,0.0000053679373,0.000029229494,0.00044763385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987733,0.0000665485,0.0004990761,0.00017360436,0.00025803127,0.00022945572],"domain_scores_gemma":[0.998992,0.000055258417,0.00051506236,0.00017119589,0.00016925347,0.00009722849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002889414,0.00016134074,0.0005428407,0.00023797007,0.000047350506,0.000012658935,0.00008427538,0.00012359329,0.00043304238],"category_scores_gemma":[0.000023496514,0.00010651187,0.00006659902,0.00023372477,0.00009519519,0.00017239027,0.00001887006,0.00031482603,0.000009357315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11848512,0.001101706,0.6706893,0.00011605856,0.00029243284,0.00009896071,0.0008141178,0.00016225928,0.00041772547,0.000015929216,0.0006418794,0.20716453],"study_design_scores_gemma":[0.024717752,0.015700106,0.9193359,0.00072853465,0.0002006251,0.00037576552,0.00030579857,0.00005594561,0.0002246023,0.000073286144,0.0380533,0.00022836459],"about_ca_topic_score_codex":0.00003351874,"about_ca_topic_score_gemma":0.0006957463,"teacher_disagreement_score":0.24864665,"about_ca_system_score_codex":0.00034841473,"about_ca_system_score_gemma":0.00023765383,"threshold_uncertainty_score":0.47415102},"labels":[],"label_agreement":null},{"id":"W2982152775","doi":"10.1002/jcp.29300","title":"Single peptides and combination modalities for triple negative breast cancer","year":2019,"lang":"en","type":"review","venue":"Journal of Cellular Physiology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Triple-negative breast cancer; Oncolytic virus; Immunotherapy; Breast cancer; Immune system; Adjuvant; Tumor microenvironment; Medicine; Cancer research; Cancer immunotherapy; Antigen; Cancer; Immunology; Oncology; Internal medicine","score_opus":0.0565307822319558,"score_gpt":0.3349470306537033,"score_spread":0.2784162484217475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982152775","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018898974,0.99639827,0.00005034492,0.00018257259,0.0007113926,0.0006193674,0.000094112715,0.000004135187,0.000049916518],"genre_scores_gemma":[0.0019431983,0.9962232,0.00009350868,0.00009225236,0.0005776389,0.000023283412,0.000040070303,0.00003210525,0.00097470375],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988822,0.00011299747,0.0005785956,0.00015256854,0.00011570676,0.0001579311],"domain_scores_gemma":[0.99838805,0.00021955343,0.0009670374,0.000120042285,0.0002548973,0.000050393457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021669276,0.00021344794,0.0015996618,0.00017330429,0.000038878345,0.0000132350915,0.000085758846,0.00020599386,0.000064964166],"category_scores_gemma":[0.00002716497,0.00014382006,0.0005683989,0.00008846797,0.000120762714,0.000072479736,0.000017697275,0.00022852652,0.0000013974599],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021665744,0.00025572322,0.0000037185328,0.022516977,0.0019140939,0.0000072932594,0.00023646964,6.2472003e-7,0.021661598,0.00009900389,0.0021117514,0.94902617],"study_design_scores_gemma":[0.0051173214,0.002104568,0.0001917136,0.012150413,0.0026026347,0.0005999199,0.00016262963,0.000017520875,0.0007498667,0.00072844,0.9752856,0.00028936763],"about_ca_topic_score_codex":0.000028130366,"about_ca_topic_score_gemma":0.0000019102881,"teacher_disagreement_score":0.97317386,"about_ca_system_score_codex":0.00018020193,"about_ca_system_score_gemma":0.0003785927,"threshold_uncertainty_score":0.58648115},"labels":[],"label_agreement":null},{"id":"W2982207199","doi":"10.1136/bcr-2019-231211","title":"Acute kidney injury from immune checkpoint inhibitor use","year":2019,"lang":"en","type":"article","venue":"BMJ Case Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regina General Hospital; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Acute kidney injury; Immune system; Nivolumab; Immunosuppression; Adverse effect; Vomiting; Immunology; Internal medicine; Immunotherapy","score_opus":0.01732741314848113,"score_gpt":0.30094354520138933,"score_spread":0.2836161320529082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982207199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946213,0.00026495033,0.0000103358125,0.00091334165,0.0017538782,0.001031008,0.000074601325,0.00010833983,0.0012222445],"genre_scores_gemma":[0.9909889,0.00009467962,0.0005033129,0.0013743747,0.00040937754,0.000044089247,0.00022244449,0.000044800407,0.006317987],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.9982038,0.00003038304,0.00077575684,0.00042053065,0.0003098257,0.0002597182],"domain_scores_gemma":[0.99827415,0.000028873408,0.00035802883,0.0010154382,0.00009313382,0.00023036782],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035070447,0.00020663114,0.00041567697,0.000088971334,0.00005161319,0.000045820663,0.0000271211,0.00015451315,0.0018796948],"category_scores_gemma":[0.00013792247,0.0001709742,0.00029387962,0.00017123175,0.00005283932,0.00017836147,0.000060551047,0.0001906759,0.00014183723],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024720856,0.000138696,0.0126137,0.000055837445,0.000616423,0.4043434,0.00020221708,8.69492e-8,0.5575944,0.0000017173519,0.016560953,0.005400447],"study_design_scores_gemma":[0.0027634199,0.0004475042,0.020245645,0.00062017556,0.00036408362,0.47953823,0.000097257565,0.000025313067,0.29593694,0.000036458383,0.19946815,0.000456823],"about_ca_topic_score_codex":0.0022050492,"about_ca_topic_score_gemma":0.000009554353,"teacher_disagreement_score":0.26165748,"about_ca_system_score_codex":0.00014620881,"about_ca_system_score_gemma":0.00038154988,"threshold_uncertainty_score":0.99903274},"labels":[],"label_agreement":null},{"id":"W2982248538","doi":"10.1016/j.jtho.2019.08.904","title":"P1.04-01 Body Mass Index and Age Do Not Influence Survival in Patients with Lung Cancers Treated with PD1/PDL1 Immune Checkpoint Inhibitors","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Body mass index; Internal medicine; Proportional hazards model; Hazard ratio; Oncology; Lung cancer; Overweight; Univariate analysis; Confidence interval; Retrospective cohort study; Multivariate analysis","score_opus":0.007379600913020159,"score_gpt":0.3108634258425638,"score_spread":0.3034838249295437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982248538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99761444,0.00044159612,0.000010032533,0.000518426,0.00033193294,0.00049164105,0.000005781624,0.000010535627,0.00057562476],"genre_scores_gemma":[0.998952,0.00015967949,0.00027293526,0.00023754353,0.00009055078,0.0000069169255,0.0000056365607,0.00003143637,0.0002433255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803907,0.00016181142,0.000762284,0.00024359171,0.00045068876,0.0003425293],"domain_scores_gemma":[0.9985041,0.000098460405,0.00079281157,0.0002255222,0.00022631527,0.00015278948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000723378,0.00024432447,0.0008514712,0.00034071956,0.00004196989,0.000027325104,0.0001340901,0.00020505131,0.00009415226],"category_scores_gemma":[0.000033026114,0.00015871745,0.00009334622,0.00041928838,0.00021278918,0.00024254904,0.00003072106,0.00060786086,0.0000021265564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072244056,0.00023644786,0.8952114,0.00011632119,0.000405936,0.00041779922,0.00037549378,0.00011076368,0.017969506,0.0000010704225,0.000034189,0.012877033],"study_design_scores_gemma":[0.011675466,0.007184,0.97434795,0.00082133565,0.00017922546,0.00017549432,0.0004069876,0.000037424234,0.0037896924,0.000004141393,0.0011706206,0.00020768635],"about_ca_topic_score_codex":0.00059898826,"about_ca_topic_score_gemma":0.00023051069,"teacher_disagreement_score":0.079136536,"about_ca_system_score_codex":0.0011836782,"about_ca_system_score_gemma":0.00067986874,"threshold_uncertainty_score":0.647231},"labels":[],"label_agreement":null},{"id":"W2982449517","doi":"10.1038/s41523-019-0133-7","title":"If we build it they will come: targeting the immune response to breast cancer","year":2019,"lang":"en","type":"review","venue":"npj Breast Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":208,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Tumor microenvironment; Immune system; Immunotherapy; Immunology; Antigen presentation; Breast cancer; Cancer research; Medicine; Antigen; Cancer immunotherapy; Cancer; Biology; T cell; Internal medicine","score_opus":0.025922347459563594,"score_gpt":0.3392283886206269,"score_spread":0.3133060411610633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982449517","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000116845156,0.9513222,0.000007974931,0.03901526,0.0026174563,0.0029121013,0.0033932505,0.00012300216,0.0004919246],"genre_scores_gemma":[0.00083632657,0.9818176,0.000033231907,0.0034016075,0.002528298,0.0013453483,0.00009705704,0.00029738373,0.0096431505],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950051,0.00058924453,0.0013178068,0.0010917508,0.0009131516,0.0010830023],"domain_scores_gemma":[0.99644685,0.0004587909,0.0007775944,0.0016287438,0.00036426642,0.0003237601],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015060086,0.0011133829,0.0028381574,0.0003399605,0.00032016425,0.00013019309,0.0009976977,0.0005951751,0.0064256294],"category_scores_gemma":[0.000048829857,0.0006677328,0.0013972297,0.0009428874,0.0002183715,0.0001730868,0.00028826998,0.0012390987,0.00032398102],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0082718255,0.000098399716,0.00015835113,0.006647615,0.0016854492,0.000032345983,0.0004308575,0.000006638724,0.0002373214,0.000008852787,0.031185888,0.9512364],"study_design_scores_gemma":[0.0016423394,0.0001013397,0.002209356,0.040737204,0.0018618391,0.0010751217,0.0001243729,0.0000046166124,0.000008780255,0.0000031943594,0.9514269,0.00080489763],"about_ca_topic_score_codex":0.0060931956,"about_ca_topic_score_gemma":0.0002407547,"teacher_disagreement_score":0.9504316,"about_ca_system_score_codex":0.0021432212,"about_ca_system_score_gemma":0.0029611941,"threshold_uncertainty_score":0.9995774},"labels":[],"label_agreement":null},{"id":"W2982501627","doi":"10.1093/jnci/djz208","title":"Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach","year":2019,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":204,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University","funders":"KU Leuven; McGill University; Breast Cancer Research Foundation","keywords":"Biology; Immune system; Tumor microenvironment; Stromal cell; Cancer research; Phenotype; Breast cancer; Transcriptome; Triple-negative breast cancer; Comparative genomic hybridization; Androgen receptor; Gene expression profiling; Cancer; Immunology; Gene; Gene expression; Genetics; Chromosome; Prostate cancer","score_opus":0.045564374662300504,"score_gpt":0.32655625385423154,"score_spread":0.280991879191931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982501627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98993516,0.0017188378,0.00014779376,0.003731725,0.0026465661,0.0007664692,0.0003337088,0.000010759391,0.00070895685],"genre_scores_gemma":[0.99032784,0.001546139,0.0028125604,0.0028026125,0.0013851993,0.00006638252,0.000012546527,0.000029352992,0.0010173537],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980191,0.000076669516,0.0005398245,0.00023640395,0.0009089001,0.00021910602],"domain_scores_gemma":[0.9987648,0.000020755015,0.00056338805,0.00017806029,0.00034027538,0.00013268813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003737713,0.00023336071,0.00044453112,0.00013673311,0.00013514837,0.000037391277,0.00025426756,0.00006688386,0.00034824584],"category_scores_gemma":[0.00001955404,0.00013921128,0.00040956025,0.00022224645,0.00014042438,0.00032184384,0.000035294524,0.0002374953,0.000004138351],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.093672715,0.0061358777,0.07439083,0.00056604017,0.016597541,0.00011311866,0.00557136,0.2323607,0.41421872,0.00029237536,0.007207451,0.14887327],"study_design_scores_gemma":[0.08819243,0.0027150274,0.57718885,0.0019813592,0.0021601727,0.006098009,0.0007866804,0.010057845,0.20604515,0.0002516505,0.103125505,0.0013972936],"about_ca_topic_score_codex":0.0007461645,"about_ca_topic_score_gemma":0.00009147744,"teacher_disagreement_score":0.502798,"about_ca_system_score_codex":0.0029511622,"about_ca_system_score_gemma":0.0015537926,"threshold_uncertainty_score":0.7717187},"labels":[],"label_agreement":null},{"id":"W2982897711","doi":"10.1016/j.cell.2019.10.028","title":"B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer","year":2019,"lang":"en","type":"article","venue":"Cell","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":481,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institute of Environmental Health Sciences; Canadian Institutes of Health Research; Susan G. Komen; Breast Cancer Research Foundation","keywords":"Biology; Cancer research; Mutation; Breast cancer; Follicular phase; Cancer; Immunology; Genetics; Cell biology; Gene","score_opus":0.006973579470186499,"score_gpt":0.22835992651501105,"score_spread":0.22138634704482454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982897711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99733925,0.0006329961,0.000018955567,0.0008902292,0.00024189279,0.00065366394,0.00006896799,0.000015332127,0.00013871393],"genre_scores_gemma":[0.99653393,0.00029539372,0.00015932997,0.00028033636,0.00006903968,0.000026990072,0.000007946179,0.000027699365,0.002599357],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99894375,0.000061609055,0.0003166166,0.00026180007,0.00021674237,0.00019950031],"domain_scores_gemma":[0.99945664,0.000046814763,0.00009245944,0.00023295995,0.00006756576,0.00010355185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003464053,0.00014265045,0.0002834143,0.00017904902,0.000013478646,0.000009734314,0.000059501956,0.0001022405,0.00019119531],"category_scores_gemma":[0.0000036063102,0.00012344483,0.00006935262,0.00021838942,0.000039501883,0.00007960663,0.00002539012,0.000096312055,0.000026414886],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00593787,0.00006501467,0.00035125285,0.00014194584,0.000025416472,0.00001465743,0.0029625753,0.0015440655,0.9877909,8.0079076e-7,0.00029026272,0.0008752816],"study_design_scores_gemma":[0.0040440816,0.00021515216,0.0049170335,0.00018481507,0.00003142486,0.00000591801,0.00054315623,0.00075650576,0.98836714,0.000012437617,0.0007655032,0.00015684376],"about_ca_topic_score_codex":0.002288357,"about_ca_topic_score_gemma":0.000052706862,"teacher_disagreement_score":0.0045657805,"about_ca_system_score_codex":0.00013724004,"about_ca_system_score_gemma":0.00011002782,"threshold_uncertainty_score":0.5033934},"labels":[],"label_agreement":null},{"id":"W2983284890","doi":"10.1200/jco.19.02107","title":"Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1014,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Pembrolizumab; Cohort; Colorectal cancer; Tolerability; Oncology; Microsatellite instability; Irinotecan; Progression-free survival; Clinical endpoint; Oxaliplatin; Response Evaluation Criteria in Solid Tumors; Cancer; Surgery; Phases of clinical research; Adverse effect; Chemotherapy; Clinical trial; Immunotherapy","score_opus":0.13532950797617835,"score_gpt":0.49091004164502033,"score_spread":0.355580533668842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983284890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931742,0.0019878151,0.000002274912,0.0010518968,0.0016095774,0.0017698791,0.000030025843,0.000011322877,0.0003630102],"genre_scores_gemma":[0.99657595,0.0017529853,0.0006027542,0.0005501934,0.00015036597,0.00003017022,0.0000071782115,0.000027813161,0.00030257864],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9936345,0.0009558199,0.004162657,0.00042427346,0.00046302634,0.00035970582],"domain_scores_gemma":[0.99492556,0.0013984713,0.0025915534,0.0004199415,0.00040956933,0.00025491609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003820299,0.00027674585,0.0029881997,0.00025145826,0.000056778706,0.000015084491,0.0003741621,0.0002678471,0.0004275306],"category_scores_gemma":[0.000507247,0.00018949957,0.00048947334,0.00040988703,0.0002532552,0.00018825477,0.00013887882,0.0007231069,0.000008112178],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30828568,0.27554083,0.109711416,0.0001365581,0.0032452112,0.00075984723,0.003551851,0.000030292704,0.030067269,0.000016059486,0.00036786028,0.26828712],"study_design_scores_gemma":[0.391169,0.46919036,0.0983146,0.0003664415,0.0011430394,0.00025912223,0.0023708676,0.00018207573,0.00162534,0.00004792332,0.03506525,0.00026599792],"about_ca_topic_score_codex":0.0019762977,"about_ca_topic_score_gemma":0.0015043253,"teacher_disagreement_score":0.26802114,"about_ca_system_score_codex":0.00097004947,"about_ca_system_score_gemma":0.0031735327,"threshold_uncertainty_score":0.7727568},"labels":[],"label_agreement":null},{"id":"W2985618399","doi":"10.1007/s11523-019-00689-7","title":"High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Essar Steel Algoma (Canada); Sault Area Hospital","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Breast cancer; Internal medicine; Mutation; Immunology; Cancer; Genetics; Gene","score_opus":0.022687232918031704,"score_gpt":0.2912074542816495,"score_spread":0.2685202213636178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985618399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891472,0.0035820098,0.000005542009,0.0059552114,0.00023531665,0.0005594228,0.00009656068,0.000048814985,0.00036994976],"genre_scores_gemma":[0.99530524,0.0005394347,0.00013390034,0.0029986654,0.00009751995,0.000055237873,0.000030546962,0.000029562605,0.00080988166],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988394,0.0002618575,0.0003034664,0.00022917065,0.00013204907,0.00023407167],"domain_scores_gemma":[0.9993098,0.00027081772,0.000153681,0.00014990356,0.00005450607,0.000061306244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057580223,0.00014922486,0.00035531752,0.00022005975,0.00005460921,0.000016097722,0.00004889587,0.00014738849,0.0005886182],"category_scores_gemma":[0.000019493607,0.00013232882,0.00003995223,0.0001608139,0.00015696642,0.00006717394,0.000014067923,0.00016775406,0.000005467014],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.073299155,0.00031029913,0.32311845,0.00013322182,0.0015716475,0.00023034263,0.02330229,0.000056671845,0.35257465,0.0007511871,0.00096979615,0.22368228],"study_design_scores_gemma":[0.012695258,0.0022086066,0.91335696,0.00009804192,0.00007947833,0.00040035538,0.0042611444,0.00034761164,0.0006262399,0.0003006734,0.06535532,0.0002703245],"about_ca_topic_score_codex":0.0027575644,"about_ca_topic_score_gemma":0.0001766306,"teacher_disagreement_score":0.5902385,"about_ca_system_score_codex":0.0006022614,"about_ca_system_score_gemma":0.00052740757,"threshold_uncertainty_score":0.64449567},"labels":[],"label_agreement":null},{"id":"W2986516670","doi":"10.1182/blood-2019-130647","title":"Evaluation of T-Cell Compartment By Complex Multiparameter Flow Cytometry Reveals Distinct Patterns of T-Cell Exhaustion in DLBCL, FL and HL Patients","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Lymphoma; Immunophenotyping; CD8; Cancer research; T cell; Follicular lymphoma; Diffuse large B-cell lymphoma; Medicine; Flow cytometry; Immunotherapy; Immunology; Oncology; Internal medicine; Immune system","score_opus":0.02785331893501828,"score_gpt":0.2852168885162989,"score_spread":0.2573635695812806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986516670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99809456,0.00038504982,0.000032074615,0.000014714911,0.00007397946,0.0009550496,0.00014892063,0.0000062649683,0.00028941213],"genre_scores_gemma":[0.99912214,0.000042879426,0.00039518718,0.00004719703,0.000011594831,0.000019829731,0.00028628766,0.000012141973,0.00006276206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986127,0.00011193777,0.00041716956,0.00020282618,0.0005215282,0.0001338559],"domain_scores_gemma":[0.9993005,0.000060695853,0.00021647237,0.00021731092,0.00016395222,0.000041092593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058278197,0.00011987575,0.00032075495,0.00011673761,0.000011811206,0.000004817075,0.000049198614,0.00006326922,0.00020386945],"category_scores_gemma":[0.000025109926,0.000104712584,0.000058143723,0.00013186966,0.000032400676,0.00004089593,0.000022890516,0.00006508825,0.000004887779],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034902783,0.0024862376,0.7031575,0.00028545654,0.00005640078,3.3289749e-7,0.00016111493,0.000003333171,0.29091835,1.17739006e-7,0.00013347054,0.0024486682],"study_design_scores_gemma":[0.02679547,0.0007250728,0.84758097,0.00019922406,0.00027441554,0.0000011033385,0.00006708862,0.0013792454,0.12282318,0.0000036928832,0.000051237905,0.00009927874],"about_ca_topic_score_codex":0.00013233066,"about_ca_topic_score_gemma":0.000017776523,"teacher_disagreement_score":0.16809516,"about_ca_system_score_codex":0.00006240282,"about_ca_system_score_gemma":0.000030007457,"threshold_uncertainty_score":0.42700553},"labels":[],"label_agreement":null},{"id":"W2987040069","doi":"10.3390/cancers11111713","title":"The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors","year":2019,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northern Alberta Institute of Technology; University of Calgary","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Cohort; Retrospective cohort study; Lung cancer; Oncology; Immune system; Gastroenterology; Confidence interval; Immunology","score_opus":0.006033555498873084,"score_gpt":0.23608792513150706,"score_spread":0.23005436963263398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987040069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99592024,0.0010824885,0.0000027215515,0.0004117463,0.0003318239,0.0016298791,0.000011758294,0.000055945555,0.00055338244],"genre_scores_gemma":[0.99863577,0.00007517879,0.0000110914825,0.00007234459,0.000031108964,0.00013698371,0.000053185955,0.00006014381,0.0009241657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810416,0.000054513883,0.0005188412,0.00035945958,0.0004482242,0.0005148316],"domain_scores_gemma":[0.9989571,0.00010650053,0.00025188283,0.0004742133,0.00012501272,0.000085300075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002495408,0.00032090052,0.0005955894,0.00012326396,0.000119947945,0.00004648868,0.0001753241,0.0000776427,0.000057602374],"category_scores_gemma":[0.000036049332,0.00017263553,0.00012543329,0.00046845753,0.0002872659,0.00013162885,0.00003769865,0.0002891089,0.0000075565154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0086227,0.00008554858,0.9867962,0.000090130154,0.000379369,0.000014474079,0.0004961725,0.000083639534,0.00084494025,0.000004895317,0.000032439053,0.0025494695],"study_design_scores_gemma":[0.010307629,0.0012792822,0.981989,0.00079378224,0.00009694192,0.0000036852653,0.0012432819,0.00015030353,0.0036787177,0.0000024188357,0.00016485895,0.00029009057],"about_ca_topic_score_codex":0.0032638987,"about_ca_topic_score_gemma":0.0005046193,"teacher_disagreement_score":0.004807213,"about_ca_system_score_codex":0.0013183595,"about_ca_system_score_gemma":0.0005261134,"threshold_uncertainty_score":0.70398724},"labels":[],"label_agreement":null},{"id":"W2987813669","doi":"10.1007/s40674-019-00131-z","title":"Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments","year":2019,"lang":"en","type":"review","venue":"Current Treatment Options in Rheumatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Jewish General Hospital; University of Calgary; McGill University; University of British Columbia; Vancouver General Hospital; University of Alberta","funders":"","keywords":"Medicine; Ipilimumab; Adverse effect; Nivolumab; Cancer; Disease; Clinical trial; Pembrolizumab; Myositis; Contraindication; Immunology; Intensive care medicine; Internal medicine; Oncology; Immunotherapy; Alternative medicine; Pathology","score_opus":0.07909071008148343,"score_gpt":0.39219993052725,"score_spread":0.31310922044576656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987813669","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026034815,0.99137,0.0000046469445,0.00009436749,0.00073462253,0.004722228,0.0003515987,0.000042764146,0.00007625845],"genre_scores_gemma":[0.00025424123,0.99541706,0.00007830935,0.0000055625806,0.000007270234,0.0015120191,0.0023611933,0.000055933,0.00030844088],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9963512,0.00045560175,0.0020506827,0.000572116,0.00019990085,0.00037054604],"domain_scores_gemma":[0.99755996,0.0003730969,0.0011649531,0.0007052689,0.000102606406,0.000094134986],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028986455,0.0006720955,0.0038459823,0.00056929816,0.00006891924,0.0000043536215,0.00014076276,0.0003027583,0.00021010554],"category_scores_gemma":[0.00013980363,0.00046584848,0.0010770505,0.00066462636,0.00017338914,0.00008421299,0.000071717855,0.00026860274,0.00005105416],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103874714,0.0038724095,0.0021234073,0.20923378,0.0041827057,0.000007395022,0.00029402628,3.0822372e-7,0.0000016255467,0.00007866331,0.00018044884,0.77992135],"study_design_scores_gemma":[0.009944817,0.0010935741,0.0022123633,0.74032086,0.0070935218,0.00053856656,0.00014621699,0.00002280061,0.000004507629,0.00003368878,0.23797703,0.0006120286],"about_ca_topic_score_codex":0.00012443503,"about_ca_topic_score_gemma":0.000016121716,"teacher_disagreement_score":0.77930933,"about_ca_system_score_codex":0.0009400787,"about_ca_system_score_gemma":0.00068759033,"threshold_uncertainty_score":0.99977934},"labels":[],"label_agreement":null},{"id":"W2988353924","doi":"10.1158/0008-5472.can-19-1108","title":"CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; McGill University; McGill University Health Centre","funders":"Government of Canada; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Research Society","keywords":"CD44; Cancer research; Triple-negative breast cancer; Carcinogenesis; Regulator; Lung cancer; Biology; Small hairpin RNA; PD-L1; Breast cancer; Cancer; Downregulation and upregulation; Gene knockdown; Immune system; Medicine; Immunology; Cell; Oncology; Immunotherapy; Internal medicine; Cell culture; Gene","score_opus":0.033775768281425686,"score_gpt":0.35367727695887174,"score_spread":0.31990150867744604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988353924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806082,0.016340915,0.0000011104141,0.0012871166,0.00017393446,0.0008929442,0.0000144271025,0.000021480386,0.00065982423],"genre_scores_gemma":[0.9953586,0.0027106942,0.000008126157,0.00017277128,0.00014825883,0.00014220909,0.000005836425,0.000022956398,0.0014305458],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985614,0.00009306455,0.00016799447,0.0003907914,0.00039728716,0.0003894943],"domain_scores_gemma":[0.9994395,0.00006978145,0.00003494438,0.0001899858,0.00013528933,0.00013053023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005987479,0.00011986183,0.00021495516,0.0002590821,0.00008755212,0.00003928745,0.000063102176,0.000075592645,0.0006041661],"category_scores_gemma":[0.00002366306,0.00009715409,0.000026208141,0.0004219262,0.00011333633,0.00015161451,0.00007586452,0.0003861282,0.000011014512],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007942745,0.00004107101,0.12050799,0.00067326945,0.000053256797,0.000025601945,0.00053588074,0.0000020546781,0.837178,0.000029324528,0.001978899,0.031031922],"study_design_scores_gemma":[0.011301561,0.00097560626,0.8519269,0.0036430813,0.000039417646,0.000198149,0.001193963,0.00066711893,0.119226225,0.000092651644,0.010328771,0.00040653246],"about_ca_topic_score_codex":0.0017346015,"about_ca_topic_score_gemma":0.00022473482,"teacher_disagreement_score":0.7314189,"about_ca_system_score_codex":0.0005232942,"about_ca_system_score_gemma":0.00039810996,"threshold_uncertainty_score":0.6615195},"labels":[],"label_agreement":null},{"id":"W2988973848","doi":"10.1158/1078-0432.ccr-18-3717","title":"A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"GlaxoSmithKline Biologicals; Agence Nationale de la Recherche","keywords":"Melanoma; Medicine; Gene signature; Oncology; Lymph node; Immunotherapy; Internal medicine; Lung cancer; Cancer; Adjuvant therapy; Cancer research; Gene expression; Gene; Biology","score_opus":0.06522862528922822,"score_gpt":0.42706495668085354,"score_spread":0.3618363313916253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988973848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97689027,0.014230866,0.0000032526586,0.0049373675,0.00037309754,0.0027637756,0.00015204784,0.000012997484,0.00063632755],"genre_scores_gemma":[0.98797584,0.008116467,0.00012117215,0.0012057055,0.000422365,0.00054515933,0.000016026546,0.000047805333,0.0015494776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99517065,0.0009846959,0.0010776158,0.0007526338,0.0011046889,0.00090970186],"domain_scores_gemma":[0.9956949,0.0027110341,0.0002572013,0.00081956753,0.0003766208,0.00014069748],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007521993,0.00023494389,0.00078502035,0.00031274417,0.00009175678,0.00003928035,0.0006438605,0.0004100164,0.0009818603],"category_scores_gemma":[0.000597988,0.00015731079,0.00023192655,0.001448186,0.00027403134,0.00007763695,0.00019853802,0.0027054357,0.000021879587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008208222,0.00046505852,0.93916774,0.00075827155,0.00012872634,0.00007920092,0.0018702613,0.000056107627,0.028631989,0.0000043356695,0.004254971,0.016375143],"study_design_scores_gemma":[0.009762331,0.0014320454,0.95456576,0.0015229703,0.000086120606,0.000004846535,0.0009869281,0.0019166339,0.027936986,0.000044918386,0.0014932654,0.00024720666],"about_ca_topic_score_codex":0.039068934,"about_ca_topic_score_gemma":0.010035667,"teacher_disagreement_score":0.029033268,"about_ca_system_score_codex":0.0004008488,"about_ca_system_score_gemma":0.00146403,"threshold_uncertainty_score":0.9999314},"labels":[],"label_agreement":null},{"id":"W2989217594","doi":"10.1097/ccm.0000000000004087","title":"Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer","year":2019,"lang":"en","type":"review","venue":"Critical Care Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Toronto General Hospital","funders":"National Cancer Institute","keywords":"Medicine; Adverse effect; Cytokine release syndrome; Immunotherapy; Cancer; Cancer immunotherapy; Immunology; Internal medicine; Chimeric antigen receptor","score_opus":0.0665410540857086,"score_gpt":0.4045305031470224,"score_spread":0.3379894490613138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989217594","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000113657574,0.99427825,0.0000700064,0.00077415654,0.000699011,0.0020755532,0.00067748496,0.000052897572,0.001258966],"genre_scores_gemma":[0.010266659,0.98697084,0.00024970516,0.0005416574,0.00025694378,0.00052577944,0.00068956456,0.000104458166,0.00039439264],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99741495,0.00010969522,0.0007960513,0.00058144715,0.0005884372,0.00050943205],"domain_scores_gemma":[0.9974971,0.00089939515,0.00014768304,0.00045015904,0.0008349264,0.00017076702],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002113352,0.00057554996,0.0026736415,0.00021934621,0.00010573777,0.000019826673,0.0001750468,0.00037724912,0.00037391332],"category_scores_gemma":[0.0003239837,0.00037154547,0.00036120522,0.0003005429,0.0013458424,0.000054771604,0.000043428627,0.0003312163,0.0000012554069],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007071668,0.000071475435,0.000047146557,0.25776458,0.0017011394,0.00006494123,0.0017778111,3.2805122e-8,0.000006916158,0.00078209594,0.0007687173,0.736308],"study_design_scores_gemma":[0.0062770657,0.004360685,0.0005689672,0.189859,0.016808134,0.000049386825,0.024015367,0.0000027025724,0.00002677646,0.000038191134,0.7572881,0.0007056394],"about_ca_topic_score_codex":0.00008306426,"about_ca_topic_score_gemma":0.000021114136,"teacher_disagreement_score":0.7565194,"about_ca_system_score_codex":0.00039888042,"about_ca_system_score_gemma":0.00028657762,"threshold_uncertainty_score":0.99987364},"labels":[],"label_agreement":null},{"id":"W2989838587","doi":"10.1093/annonc/mdz417","title":"Effects of immune architecture on response to adjuvant capecitabine in triple negative breast cancer (FinXX trial)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Capecitabine; Triple-negative breast cancer; Adjuvant; Oncology; Breast cancer; Internal medicine; Immune system; Cancer; Immunology; Colorectal cancer","score_opus":0.02178207769440861,"score_gpt":0.3528573360992954,"score_spread":0.33107525840488683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989838587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97931474,0.0011412986,0.0000027791696,0.016604653,0.00049317355,0.0017720857,0.00005163113,0.0000090442945,0.0006105759],"genre_scores_gemma":[0.99593395,0.00034113223,0.00007324584,0.0025290102,0.00007941664,0.000103966384,0.000003934337,0.000017855731,0.0009174852],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99843925,0.0003398503,0.0005281364,0.00023842657,0.00019235745,0.0002619657],"domain_scores_gemma":[0.9983916,0.00087271375,0.000248111,0.00027664847,0.0001373645,0.00007352999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007574225,0.00015492439,0.00083188235,0.0003542958,0.000012129836,0.0000016006354,0.000121326,0.00015574347,0.00030296776],"category_scores_gemma":[0.00025536754,0.0001198794,0.00019165529,0.00043541662,0.00009517549,0.000023049022,0.000032154476,0.00020414469,0.00001288208],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59389174,0.0006335221,0.0002824582,0.00013198961,0.00012722537,0.000025882942,0.0011310058,0.000024561707,0.3096957,0.000008888141,0.0006239646,0.09342304],"study_design_scores_gemma":[0.15379167,0.050616268,0.45441732,0.00092198455,0.000059713577,0.000032970867,0.00023264406,0.000008146412,0.32606313,0.00009807559,0.013547258,0.00021082078],"about_ca_topic_score_codex":0.0012765372,"about_ca_topic_score_gemma":0.0002600385,"teacher_disagreement_score":0.45413485,"about_ca_system_score_codex":0.00011626277,"about_ca_system_score_gemma":0.00043930946,"threshold_uncertainty_score":0.488854},"labels":[],"label_agreement":null},{"id":"W2990849834","doi":"10.1016/s1470-2045(19)30693-x","title":"Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"School of Medicine, Stanford University; Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino; Penn State Health Children's Hospital; F. Hoffmann-La Roche; Pfizer","keywords":"Atezolizumab; Medicine; Adverse effect; Internal medicine; Clinical trial; Population; Phases of clinical research; Lymphoma; Clinical endpoint; Incidence (geometry); Surgery; Pediatrics; Cancer; Immunotherapy","score_opus":0.012094129770249843,"score_gpt":0.3121682710117557,"score_spread":0.3000741412415059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990849834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913092,0.0017683783,0.00001518118,0.0010142388,0.0001492747,0.005283452,0.00008381966,0.000080577665,0.00029585525],"genre_scores_gemma":[0.9970819,0.000856804,0.0003428829,0.0006125431,0.00031626143,0.00021808136,0.000082620965,0.000051340834,0.0004375599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820906,0.00017125277,0.00035266698,0.0005177851,0.00017474029,0.00057447446],"domain_scores_gemma":[0.9988739,0.00018658378,0.00024086452,0.00048652283,0.00008789783,0.0001242209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052901974,0.00032200164,0.0009540382,0.00008796677,0.0001548098,0.000038704697,0.00018213589,0.00014226294,0.00003515971],"category_scores_gemma":[0.000028689523,0.0001950806,0.00007683644,0.00017684637,0.000204977,0.00007809277,0.000066726716,0.00009827774,0.000008579088],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22053054,0.003517711,0.45514652,0.0002809037,0.0017774167,0.0001469765,0.01501442,0.000002080047,0.003104107,0.000015099704,0.002942428,0.2975218],"study_design_scores_gemma":[0.22912332,0.02011545,0.7423343,0.00025018616,0.0007912181,0.0014543178,0.00218711,0.0006786172,0.00074210064,0.000010072048,0.0019625511,0.00035077537],"about_ca_topic_score_codex":0.0011906413,"about_ca_topic_score_gemma":0.0010071481,"teacher_disagreement_score":0.29717103,"about_ca_system_score_codex":0.00023544554,"about_ca_system_score_gemma":0.00022399182,"threshold_uncertainty_score":0.7955156},"labels":[],"label_agreement":null},{"id":"W2991173919","doi":"10.1186/s40425-019-0783-x","title":"Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial","year":2019,"lang":"en","type":"letter","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"National Cancer Institute; Chemotherapy Foundation; Breast Cancer Research Foundation; U.S. Department of Defense","keywords":"Blockade; Medicine; Concomitant; Immunotherapy; Oncology; Cyclophosphamide; Immune system; Doxorubicin; Radiation therapy; Internal medicine; Cisplatin; Clinical trial; Chemotherapy; Immunology; Receptor","score_opus":0.04260303808485426,"score_gpt":0.39823958657665026,"score_spread":0.355636548491796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991173919","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18680817,0.04081974,0.00045313008,0.7566952,0.0105833,0.003908783,0.00059833203,0.000037452286,0.00009588768],"genre_scores_gemma":[0.02349484,0.037265588,0.0017663823,0.8396256,0.04175267,0.0018193397,0.00022380354,0.00059408054,0.05345767],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961154,0.00025429518,0.0014072793,0.0005694438,0.0009663634,0.0006872113],"domain_scores_gemma":[0.99637496,0.0008030693,0.0011099582,0.0010635336,0.00056559057,0.00008286914],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010517123,0.00061301555,0.0013439184,0.00038420944,0.0003458475,0.00025892493,0.00084233837,0.0007761515,0.0010861596],"category_scores_gemma":[0.00009980089,0.00041572025,0.0011493634,0.00047593497,0.0001549877,0.0002062945,0.00004755358,0.0020409469,0.000022209082],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.241466,0.00007349304,0.000011662427,0.00007431645,0.0023101796,0.000010448558,0.0012115734,0.000017051076,0.16565701,0.0000027800602,0.52039605,0.06876945],"study_design_scores_gemma":[0.020581858,0.0036408477,0.0011374445,0.0015373223,0.00036293187,0.00006926815,0.00041293848,0.000001215485,0.030638743,0.00013954398,0.94099367,0.00048423265],"about_ca_topic_score_codex":0.0017055896,"about_ca_topic_score_gemma":0.00012332048,"teacher_disagreement_score":0.4205976,"about_ca_system_score_codex":0.0007692403,"about_ca_system_score_gemma":0.0024624404,"threshold_uncertainty_score":0.9998295},"labels":[],"label_agreement":null},{"id":"W2993064651","doi":"10.1136/jnnp-2019-abn-2.176","title":"208 Immune checkpoint inhibitor-related neurotoxicity: a case series","year":2019,"lang":"en","type":"article","venue":"Journal of Neurology Neurosurgery & Psychiatry","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity; Royal Ottawa Mental Health Centre","funders":"","keywords":"Medicine; Aseptic meningitis; Nivolumab; Ipilimumab; Discontinuation; Myositis; myalgia; Adverse effect; Neurotoxicity; Brachial Plexopathy; Meningitis; Internal medicine; Oncology; Immune system; Immunology; Immunotherapy; Surgery","score_opus":0.00914409779592389,"score_gpt":0.2450454443059332,"score_spread":0.2359013465100093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993064651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9549991,0.0018965605,0.0000026593384,0.026946632,0.015258037,0.00042616608,0.0000066782327,0.00005973238,0.00040442438],"genre_scores_gemma":[0.987772,0.00056551496,0.0000970196,0.010176738,0.00065191364,0.000005358644,0.0000025067195,0.00008470749,0.000644282],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.99657816,0.00032279687,0.0017693028,0.0004138806,0.00041320256,0.00050267746],"domain_scores_gemma":[0.99761003,0.00017274919,0.0011880767,0.000590995,0.0001967028,0.00024143433],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007326958,0.0003745421,0.0009752611,0.00054588343,0.00011722061,0.000039190163,0.00019368362,0.00030816774,0.0004996593],"category_scores_gemma":[0.00011552366,0.00031415347,0.000955462,0.0005700832,0.00021924353,0.00033209036,0.00006421153,0.0014984265,0.000057887693],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029409055,0.0011510125,0.37456986,0.0002571118,0.0005767724,0.03378066,0.00016422718,0.000041266892,0.5479826,0.00005422171,0.010124847,0.0018884159],"study_design_scores_gemma":[0.007053537,0.008419463,0.22961955,0.00019817946,0.00026746513,0.7179623,0.000081883336,0.00004369778,0.006361259,0.0002082425,0.029386364,0.00039806828],"about_ca_topic_score_codex":0.000011929507,"about_ca_topic_score_gemma":0.000005648057,"teacher_disagreement_score":0.68418163,"about_ca_system_score_codex":0.000027784592,"about_ca_system_score_gemma":0.00045442145,"threshold_uncertainty_score":0.99993104},"labels":[],"label_agreement":null},{"id":"W2993545890","doi":"10.1158/1535-7163.targ-19-c027","title":"Abstract C027: A Phase I, dose finding study of BI 754111, an anti-LAG-3 antibody, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumors: preliminary results from the microsatellite stable (MSS) metastatic colorectal cancer (mCRC) cohort","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); University of Alberta","funders":"","keywords":"Blockade; Medicine; Antibody; Monoclonal antibody; Immune checkpoint; Lung cancer; Cancer; Cancer research; Internal medicine; T cell; Oncology; Immune system; Pharmacology; Immunology; Receptor","score_opus":0.01862583428759236,"score_gpt":0.3292702647812341,"score_spread":0.31064443049364177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993545890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923378,0.0020129918,0.00004130347,0.00013166806,0.00019023717,0.004685355,0.00052838895,0.00004600461,0.00002623276],"genre_scores_gemma":[0.99718463,0.000795862,0.00022713102,0.0003917468,0.000024996476,0.00014996756,0.001085319,0.00012731462,0.000013004592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961252,0.0003213681,0.001026634,0.0009561314,0.0009031228,0.0006675415],"domain_scores_gemma":[0.9978005,0.00012647216,0.00074323436,0.00088361785,0.00032433422,0.00012180566],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006265486,0.00058358826,0.0010640488,0.00033875945,0.00012005717,0.00008673734,0.00040375532,0.00013566099,0.000054776116],"category_scores_gemma":[0.000010740282,0.00041680012,0.000095153155,0.001186082,0.00023845721,0.0004982439,0.00005736296,0.0004910258,0.00000143515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045904294,0.0060800873,0.5553299,0.000100135876,0.0008728093,0.00013108375,0.0046469998,0.0019123212,0.37737638,0.0000012299956,0.0000013614133,0.0076434086],"study_design_scores_gemma":[0.051084477,0.012788553,0.8585028,0.0012556479,0.00046023368,0.0000055622395,0.0022798753,0.0012910896,0.07171465,0.0000066934676,0.00006319376,0.00054723874],"about_ca_topic_score_codex":0.008262068,"about_ca_topic_score_gemma":0.0025469845,"teacher_disagreement_score":0.30566174,"about_ca_system_score_codex":0.00038566472,"about_ca_system_score_gemma":0.00054403476,"threshold_uncertainty_score":0.9998284},"labels":[],"label_agreement":null},{"id":"W2994379966","doi":"10.1097/coc.0000000000000650","title":"Analysis of Heterogeneity in Survival Benefit of Immunotherapy in Oncology According to Patient Demographics and Performance Status","year":2019,"lang":"en","type":"review","venue":"American Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Confidence interval; Meta-analysis; Randomized controlled trial; Subgroup analysis; Oncology","score_opus":0.1313721123070089,"score_gpt":0.4929832975669688,"score_spread":0.3616111852599599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994379966","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5899094,0.40927082,0.000011361406,0.00007624383,0.0003439493,0.00030880838,0.000019058862,0.000001247763,0.000059121034],"genre_scores_gemma":[0.17813385,0.82067436,0.0008095453,0.00028913756,0.000053372903,0.000007394945,0.000007491128,0.000022596454,0.0000022698325],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9923578,0.0010828982,0.005500949,0.00034054377,0.0003467297,0.00037106758],"domain_scores_gemma":[0.98966247,0.0035300222,0.0059569916,0.0003623686,0.00027663048,0.00021153066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003837657,0.00030402467,0.0098009845,0.0020273302,0.0000122458505,0.000003346384,0.0002725393,0.00043025755,0.000023429233],"category_scores_gemma":[0.00039302977,0.00022723737,0.0016321243,0.0026991928,0.00063000614,0.000051441162,0.000085782645,0.0010840945,5.0408164e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064861956,0.0005687892,0.29688722,0.00048182067,0.0030996099,0.0000272803,0.00012485692,0.000028584294,0.0000051670413,0.0000013964426,0.0000017752544,0.6922873],"study_design_scores_gemma":[0.007195726,0.075653635,0.4652822,0.0071953423,0.006113051,0.0001416428,0.0008973837,0.000066229615,0.0000038731537,0.0000025814154,0.43704107,0.00040726503],"about_ca_topic_score_codex":0.00039372675,"about_ca_topic_score_gemma":0.00066792633,"teacher_disagreement_score":0.69188005,"about_ca_system_score_codex":0.00042710657,"about_ca_system_score_gemma":0.0020553397,"threshold_uncertainty_score":0.9266471},"labels":[],"label_agreement":null},{"id":"W2995123342","doi":"10.1016/j.jtho.2019.12.107","title":"PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee","year":2019,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":345,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Genentech; Takeda Pharmaceuticals U.S.A.; Meso Scale Diagnostics; AbbVie; Chugai Pharmaceutical; Roche; EMD Serono; Novartis; MedImmune; Agilent Technologies; GlaxoSmithKline; Merck; Bayer; Bayer Corporation; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Medicine; Companion diagnostic; Lung cancer; Immunohistochemistry; Oncology; Cancer; Clinical trial; Pathology; Internal medicine","score_opus":0.08695334608872189,"score_gpt":0.500247038117566,"score_spread":0.4132936920288441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995123342","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005454417,0.99013954,0.000059185943,0.0041949144,0.0028108973,0.0014400199,0.00019528918,0.000008267546,0.00060642866],"genre_scores_gemma":[0.00009119249,0.99420345,0.0017385086,0.0011025649,0.002110725,0.00008789107,0.000018358898,0.00006405061,0.00058328884],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969927,0.0007243744,0.0013529207,0.0003224963,0.0002229553,0.0003845363],"domain_scores_gemma":[0.9929663,0.0038678914,0.002205569,0.0003762069,0.0005014521,0.000082613806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018985507,0.00036426002,0.0029834083,0.00029805533,0.00007564048,0.000019358968,0.00047774788,0.0006780794,0.000205676],"category_scores_gemma":[0.0007444787,0.00021144951,0.0009490091,0.0003998429,0.0001785769,0.00006919771,0.00007626995,0.0015329377,0.000006296207],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002654363,0.00015595036,0.00040506036,0.0020487022,0.001100324,0.00027233196,0.0006147987,0.0000022879904,0.000035763987,0.000006866596,0.015556855,0.9771467],"study_design_scores_gemma":[0.0017302705,0.0018072174,0.001452168,0.016774304,0.004811712,0.002028957,0.00069800304,0.000023428365,0.000003340532,0.000101538724,0.9703251,0.00024392828],"about_ca_topic_score_codex":0.00045137305,"about_ca_topic_score_gemma":0.00027940574,"teacher_disagreement_score":0.9769028,"about_ca_system_score_codex":0.0025700396,"about_ca_system_score_gemma":0.0035398046,"threshold_uncertainty_score":0.86226606},"labels":[],"label_agreement":null},{"id":"W2995658490","doi":"10.1007/s00262-019-02453-2","title":"The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies","year":2019,"lang":"en","type":"review","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Antibiotics; Internal medicine; Oncology; Meta-analysis; Observational study; Hazard ratio; Proportional hazards model; Confidence interval; Microbiology","score_opus":0.26229063664934493,"score_gpt":0.4919036307089502,"score_spread":0.22961299405960528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995658490","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008667735,0.991686,9.343035e-7,0.000662944,0.00042948787,0.0061287857,0.00019316522,0.000018263385,0.000013675343],"genre_scores_gemma":[0.00022945489,0.9980425,0.000019173105,0.00042869532,0.000013370962,0.00033599636,0.000058942776,0.00007812068,0.0007937038],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9906758,0.002324687,0.005461618,0.00067776866,0.0004436847,0.00041643024],"domain_scores_gemma":[0.985798,0.007874232,0.004000407,0.0019966613,0.0002983574,0.000032352047],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.004867727,0.000919901,0.024491562,0.00064531027,0.00009032972,0.000015178085,0.00066097116,0.00059506734,0.00011493807],"category_scores_gemma":[0.0008692907,0.00044678134,0.007912004,0.0015315489,0.0011067309,0.000048454916,0.00011544999,0.00089232676,0.0000052111313],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007281466,0.00011370937,0.00068274955,0.33905467,0.64851236,0.0000032733822,0.000060963357,7.1712105e-7,0.000025711563,0.000022914837,0.000018699302,0.010776045],"study_design_scores_gemma":[0.0025740005,0.0023372404,0.0020372018,0.074928895,0.9010222,0.0000218498,0.00004075011,0.0000014654412,0.000091769354,0.000004114169,0.016501091,0.00043939534],"about_ca_topic_score_codex":0.0000946789,"about_ca_topic_score_gemma":0.000027420896,"teacher_disagreement_score":0.2641258,"about_ca_system_score_codex":0.00029882972,"about_ca_system_score_gemma":0.0004426313,"threshold_uncertainty_score":0.9997984},"labels":[],"label_agreement":null},{"id":"W2995697375","doi":"10.1172/jci.insight.133501","title":"Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy","year":2019,"lang":"en","type":"article","venue":"JCI Insight","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovation Cluster (Canada)","funders":"Ono Pharmaceutical; Japan Agency for Medical Research and Development; Japan Society for the Promotion of Science; Sysmex Corporation; Bristol-Myers Squibb","keywords":"Nivolumab; Biomarker; Immune system; CD8; Immunotherapy; Immune checkpoint; T cell; Cancer; Metabolite; Metabolomics; Medicine; Oncology; Cancer research; Internal medicine; Immunology; Biology; Bioinformatics; Biochemistry","score_opus":0.015450282092576782,"score_gpt":0.2837239727465045,"score_spread":0.26827369065392775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995697375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9186881,0.070407584,0.00015444649,0.0052419486,0.0015046031,0.0022017518,0.000042335854,0.00007887164,0.0016803152],"genre_scores_gemma":[0.98970276,0.0067216773,0.0001415563,0.0008227347,0.000121184865,0.00019876283,0.000022891643,0.00005866231,0.002209766],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988346,0.000036368427,0.0004121639,0.00021836461,0.00026550042,0.0002329885],"domain_scores_gemma":[0.9988842,0.00019365724,0.00023267373,0.00048027208,0.00017571087,0.000033496526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030601938,0.00018169316,0.00040244922,0.00013076539,0.000078203884,0.000018527498,0.00019221386,0.000111701,0.0004996424],"category_scores_gemma":[0.000018563873,0.00011503167,0.00032009548,0.00038254075,0.00013234667,0.000087755645,0.00002066656,0.00011170417,0.000010288322],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004526983,0.00024594573,0.0034883842,0.0000896135,0.0015709511,6.9301353e-7,0.0008577205,0.0000026402486,0.9396645,0.00053820136,0.00115424,0.04786014],"study_design_scores_gemma":[0.008319585,0.00044996873,0.14015755,0.00012192126,0.00017240061,0.0000066874486,0.00020707116,0.0002634088,0.4062178,0.000035444562,0.44387692,0.00017125423],"about_ca_topic_score_codex":0.00060787,"about_ca_topic_score_gemma":0.000023795985,"teacher_disagreement_score":0.53344667,"about_ca_system_score_codex":0.00007388047,"about_ca_system_score_gemma":0.00015961369,"threshold_uncertainty_score":0.5470734},"labels":[],"label_agreement":null},{"id":"W2995798653","doi":"10.1093/annonc/mdz452","title":"Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+ T cells (PD1tR) driven by tumour CD155","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Immunotherapy; CD8; Cytotoxic T cell; Cancer research; Immunology; Antigen; Immune system; Biology; In vitro; Biochemistry","score_opus":0.02463949322853559,"score_gpt":0.31302863989151836,"score_spread":0.28838914666298276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995798653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744414,0.0014408522,0.000018590696,0.014258529,0.0003246626,0.0007279155,0.00016520837,0.000050122337,0.008572703],"genre_scores_gemma":[0.9678737,0.00084307865,0.0003427528,0.014505607,0.00007219833,0.0000385288,0.0000595624,0.000046456687,0.01621811],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980248,0.00013208127,0.0005269115,0.00043092069,0.000369497,0.00051577034],"domain_scores_gemma":[0.998479,0.00018725834,0.00038386698,0.0004605945,0.0003460902,0.00014317688],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043486393,0.00026218576,0.00083325314,0.00013328585,0.000058534886,0.00001272603,0.00025566615,0.0002641442,0.0013763115],"category_scores_gemma":[0.000032991455,0.00021499857,0.000178123,0.0004136199,0.00015399596,0.00007967667,0.000033518383,0.00023072428,0.00011043527],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012882877,0.00073926704,0.0070042643,0.000050814553,0.00094013574,0.000051828723,0.0009349593,0.000005819499,0.7073834,0.000043551612,0.2633223,0.0066407784],"study_design_scores_gemma":[0.009690048,0.012077952,0.05652756,0.00040877974,0.00007615267,0.000017100401,0.00021147315,0.0000069740827,0.33964622,0.000074743635,0.5808268,0.00043619098],"about_ca_topic_score_codex":0.00032121816,"about_ca_topic_score_gemma":0.00021353028,"teacher_disagreement_score":0.3677372,"about_ca_system_score_codex":0.00015611803,"about_ca_system_score_gemma":0.00036819789,"threshold_uncertainty_score":0.9995366},"labels":[],"label_agreement":null},{"id":"W2996471497","doi":"10.1016/j.jval.2019.09.226","title":"PCN29 COMPARATIVE EFFICACY OF NIVOLUMAB VERSUS RELEVANT TREATMENTS IN PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A SYSTEMATIC LITERATURE REVIEW AND INDIRECT TREATMENT COMPARISON OF RANDOMIZED CONTROLLED TRIALS (RCTS)","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Nivolumab; Medicine; Docetaxel; Internal medicine; Oncology; Hazard ratio; Atezolizumab; Lung cancer; Erlotinib; Randomized controlled trial; Population; Cancer; Confidence interval; Immunotherapy; Epidermal growth factor receptor","score_opus":0.050520128968875665,"score_gpt":0.3839835827175796,"score_spread":0.33346345374870395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996471497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5319887,0.4488454,0.0000019431416,0.0001194518,0.000142758,0.018744778,0.00003901819,0.000008678594,0.00010926762],"genre_scores_gemma":[0.81365526,0.18470794,0.0002274582,0.000050960258,0.000012011822,0.0010722571,0.00004076874,0.000019444802,0.00021388981],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9921671,0.003409338,0.0034292254,0.00039788007,0.0002855924,0.00031086983],"domain_scores_gemma":[0.99215984,0.004771054,0.0024574662,0.00038168865,0.00012807183,0.00010190402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003798441,0.00038940267,0.012256144,0.0003825308,0.000025717438,0.000009951386,0.00008001099,0.0001282739,0.00003091662],"category_scores_gemma":[0.0005235331,0.00023139572,0.00061190384,0.00062689144,0.000064171145,0.000049258946,0.000012635072,0.00017024588,0.0000010519915],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7847365,0.0021316493,0.011012376,0.178608,0.0041009225,0.000011210877,0.016092636,0.0004610227,0.001664488,0.0000066650696,0.000041254687,0.0011332565],"study_design_scores_gemma":[0.7596986,0.0029059735,0.002570605,0.22459823,0.0025621178,0.0000034270702,0.00037308031,0.0053005214,0.0018155326,0.0000011832242,0.000005479193,0.00016521975],"about_ca_topic_score_codex":0.0026307777,"about_ca_topic_score_gemma":0.0001808851,"teacher_disagreement_score":0.28166655,"about_ca_system_score_codex":0.0009226788,"about_ca_system_score_gemma":0.00065194716,"threshold_uncertainty_score":0.94360435},"labels":[],"label_agreement":null},{"id":"W2996522289","doi":"10.3390/cancers12010038","title":"Structure and Optimization of Checkpoint Inhibitors","year":2019,"lang":"en","type":"review","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; Tremelimumab; Avelumab; Nivolumab; Pembrolizumab; Medicine; Pharmacokinetics; Ipilimumab; Immune checkpoint; Drug; Pharmacology; Cancer research; Immunotherapy; Cancer; Internal medicine","score_opus":0.02967208556251453,"score_gpt":0.31462716188615436,"score_spread":0.2849550763236398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996522289","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000040222203,0.99839294,0.000026853546,0.000014552096,0.0004905971,0.00062962,0.000071737224,0.000012291554,0.00032116994],"genre_scores_gemma":[0.000033838023,0.99888057,0.0003769277,0.000050621205,0.00015138034,0.000011123244,0.00010921479,0.000033024215,0.00035329536],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991865,0.000019741687,0.00035449976,0.0002118732,0.000120254364,0.00010708938],"domain_scores_gemma":[0.9993823,0.000019856467,0.00029399016,0.00021980204,0.00003896308,0.000045099754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000058571233,0.00019096403,0.0009512943,0.00011109648,0.000014074552,0.0000063006246,0.0000487834,0.00022478489,0.00023530933],"category_scores_gemma":[0.000012729544,0.00013999507,0.00022840787,0.00019794908,0.000089616085,0.000025972151,0.000017361986,0.0001564954,0.0000011551045],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090353395,0.000002317488,0.000005882482,0.029997624,0.0003194009,0.0000017267031,0.000058880352,0.0001357154,0.000017938688,0.0000038401354,0.00085936073,0.96850693],"study_design_scores_gemma":[0.00062888185,0.00012539784,0.0000036853537,0.01525483,0.00085836434,0.000039055685,0.000019953604,0.000055869594,0.000071383656,0.0000012545561,0.9827846,0.00015666836],"about_ca_topic_score_codex":0.00008031669,"about_ca_topic_score_gemma":0.0000034564118,"teacher_disagreement_score":0.9819253,"about_ca_system_score_codex":0.00072511064,"about_ca_system_score_gemma":0.0011615986,"threshold_uncertainty_score":0.57088333},"labels":[],"label_agreement":null},{"id":"W2997299711","doi":"10.1186/s40425-019-0816-5","title":"High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Stromal cell; Tumor microenvironment; Immune system; Cancer research; Immune checkpoint; Biology; Granzyme B; Ovarian cancer; CD8; Immunology; Cancer; Immunotherapy","score_opus":0.014381859020029834,"score_gpt":0.28372799322185854,"score_spread":0.26934613420182874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997299711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99523324,0.0028803262,0.000018983217,0.00056575,0.00035275414,0.00073748315,0.00018497545,0.000007790398,0.00001869274],"genre_scores_gemma":[0.99652785,0.0023020646,0.00036046607,0.0003425483,0.00007737674,0.000044720382,0.000013660246,0.000040514293,0.00029080067],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99853647,0.000051263174,0.0005863176,0.00021799692,0.00035553778,0.00025242474],"domain_scores_gemma":[0.9987116,0.000120139426,0.00075727614,0.00016261463,0.00019427079,0.000054098593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027838323,0.00023090816,0.00066015066,0.00022265111,0.00007729325,0.000024377885,0.000084763466,0.00010240434,0.00024631235],"category_scores_gemma":[0.000009972999,0.00016732098,0.00011347036,0.0001826492,0.00010355272,0.00016752261,0.000012028561,0.0002047747,1.4753277e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037210044,0.000276511,0.054230325,0.000096007345,0.0005520957,0.000002149975,0.00053039077,0.00006209496,0.8977163,0.000010590135,0.000120497694,0.009192994],"study_design_scores_gemma":[0.02254075,0.0027155438,0.44975904,0.002268154,0.00006669283,0.000009135624,0.00015568345,0.00006857521,0.5215901,0.00002879413,0.00063744606,0.00016005177],"about_ca_topic_score_codex":0.0008874718,"about_ca_topic_score_gemma":0.000062468185,"teacher_disagreement_score":0.39552873,"about_ca_system_score_codex":0.00020564311,"about_ca_system_score_gemma":0.0001729431,"threshold_uncertainty_score":0.6823152},"labels":[],"label_agreement":null},{"id":"W2997563701","doi":"10.1016/j.cllc.2019.11.004","title":"Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non–small-cell Lung Cancer: A Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Cancer Care Ontario; Western University","funders":"","keywords":"Medicine; Meta-analysis; Lung cancer; Oncology; Nivolumab; Internal medicine; Immune system; Cancer; Immunotherapy; Immunology","score_opus":0.04228492074617649,"score_gpt":0.3698276433116152,"score_spread":0.3275427225654387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997563701","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001272849,0.98773026,0.000006537242,0.00021158122,0.00041373025,0.008921066,0.0013705703,0.00003160642,0.000041779353],"genre_scores_gemma":[0.00044564472,0.9959383,0.00009440428,0.0003803053,0.0001435895,0.002231533,0.00038296237,0.00011975126,0.00026353126],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99187946,0.00052071025,0.005215585,0.0012518074,0.0007061533,0.0004262567],"domain_scores_gemma":[0.99408424,0.0007667599,0.0033920375,0.0011303442,0.00030903012,0.00031761316],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0012149919,0.00094064017,0.019166112,0.00026504605,0.000042946278,0.000023986302,0.00041650838,0.00050171,0.0005214786],"category_scores_gemma":[0.0002131846,0.00057571195,0.0045902,0.0017941209,0.00020081639,0.00008173291,0.0001693849,0.00095463684,0.0000018030184],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055770803,0.00029565292,0.018884027,0.73007756,0.24109901,0.000011939109,0.000071493654,0.0000032834832,3.6289651e-7,2.6957971e-7,0.00010085612,0.008897842],"study_design_scores_gemma":[0.0028416368,0.00033794463,0.0031211567,0.17164475,0.81512,4.9516547e-7,0.000011421212,0.000020882491,0.0000019911147,2.6241693e-7,0.0063725132,0.00052699086],"about_ca_topic_score_codex":0.0012292347,"about_ca_topic_score_gemma":0.0006081946,"teacher_disagreement_score":0.574021,"about_ca_system_score_codex":0.00055895647,"about_ca_system_score_gemma":0.0009257005,"threshold_uncertainty_score":0.99966943},"labels":[],"label_agreement":null},{"id":"W2997720498","doi":"10.1001/jamaoncol.2019.5570","title":"Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo","year":2020,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":436,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pharmacyclics; Genentech; Merck Canada; Deutschen Konsortium für Translationale Krebsforschung; Radboud Universitair Medisch Centrum; Melanoma Institute Australia; Amgen; Radboud Universiteit; Universitat de Barcelona; Astellas Pharma; Les Laboratories Pierre Fabre; European Organisation for Research and Treatment of Cancer; SkylineDx; Sun Pharma; Peter MacCallum Cancer Centre; Syndax Pharmaceuticals; Regeneron Pharmaceuticals; Endocyte; Array BioPharma; Aix-Marseille Université; InflaRx; Pfizer; Incyte; F. Hoffmann-La Roche; Sanofi; GlaxoSmithKline; NeraCare; University of Sydney; Medizinischen Hochschule Hannover; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Internal medicine; Adverse effect; Placebo; Randomized controlled trial; Clinical trial; Melanoma; Oncology; Surgery; Cancer; Immunotherapy; Pathology","score_opus":0.014428608379705823,"score_gpt":0.2701461534137153,"score_spread":0.25571754503400945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997720498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98826694,0.00008076887,0.00006082262,0.0063334564,0.00036369427,0.0022857527,0.00011627829,0.000065593245,0.0024267011],"genre_scores_gemma":[0.9958522,0.00014579482,0.00025427315,0.0008584603,0.00014026815,0.00012031416,0.00019962472,0.000032290638,0.0023968308],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99757797,0.0006024794,0.00067551085,0.00039823187,0.0004016485,0.0003441372],"domain_scores_gemma":[0.9978319,0.0009342015,0.00054669596,0.0002357995,0.00020832547,0.00024309046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000988694,0.00023627475,0.0010889282,0.00010579202,0.00009885826,0.0000108767235,0.00014018142,0.00035878044,0.00041975066],"category_scores_gemma":[0.0014868836,0.0001679179,0.00014344086,0.0003713865,0.00011485334,0.00014360313,0.00010370825,0.00037652132,0.000022979331],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5861143,0.00012118685,0.3975838,0.000043286916,0.0015398607,0.000036449495,0.0026006699,0.0000031562581,0.00006455532,0.000004970158,0.0018195531,0.0100681735],"study_design_scores_gemma":[0.43638495,0.0031452444,0.5519953,0.00011062636,0.000448348,0.0000026547643,0.00030672713,0.00004619257,0.000072304116,0.000010516167,0.007286671,0.00019046891],"about_ca_topic_score_codex":0.00041672218,"about_ca_topic_score_gemma":0.00025696808,"teacher_disagreement_score":0.15441146,"about_ca_system_score_codex":0.00062298635,"about_ca_system_score_gemma":0.00029817072,"threshold_uncertainty_score":0.6847493},"labels":[],"label_agreement":null},{"id":"W2997965122","doi":"10.1126/sciimmunol.aaz8128","title":"A new perspective in cancer immunotherapy: PD-1 on myeloid cells takes center stage in orchestrating immune checkpoint blockade","year":2020,"lang":"en","type":"letter","venue":"Science Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Blockade; Immune checkpoint; Immunotherapy; Cancer immunotherapy; Myeloid cells; Stage (stratigraphy); Cancer research; Immune system; Perspective (graphical); PD-L1; Myeloid; Immunology; Biology; Medicine; Internal medicine; Computer science; Receptor","score_opus":0.027189659761894767,"score_gpt":0.30830801922973833,"score_spread":0.2811183594678436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997965122","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1360214,0.013383021,0.000026470505,0.8413485,0.0028958898,0.0022634468,0.00008243425,0.0002481873,0.0037305902],"genre_scores_gemma":[0.2043933,0.009275984,0.0025925708,0.76309127,0.0044489056,0.0007088772,0.00015370139,0.0006584616,0.01467694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9947486,0.00022245788,0.0011533925,0.0015788455,0.00079716573,0.0014995252],"domain_scores_gemma":[0.99806166,0.00015956454,0.0005452983,0.00095872453,0.0001676041,0.00010716093],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00068078743,0.00075800763,0.0012755881,0.0013322366,0.00015584844,0.00012246662,0.0011440135,0.00077871606,0.00077534385],"category_scores_gemma":[0.00014610875,0.00067919784,0.0003598526,0.0022693318,0.0015036446,0.0002466929,0.00014068579,0.004306371,0.000057952755],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030263031,0.00020953466,0.00067376415,0.000102650396,0.00023672155,0.001381579,0.007212287,0.00001268801,0.97131246,0.000027310305,0.0074362634,0.008368431],"study_design_scores_gemma":[0.021002177,0.0043771383,0.037159923,0.0036139954,0.000084682084,0.00031401738,0.009700317,0.00014268869,0.50690657,0.0003395741,0.41393155,0.0024273908],"about_ca_topic_score_codex":0.018936051,"about_ca_topic_score_gemma":0.0005617389,"teacher_disagreement_score":0.46440592,"about_ca_system_score_codex":0.0033987216,"about_ca_system_score_gemma":0.0039164457,"threshold_uncertainty_score":0.9995659},"labels":[],"label_agreement":null},{"id":"W2998098600","doi":"10.2147/lctt.s184380","title":"&lt;p&gt;Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non–Small Cell Lung Cancer: Emerging Mechanisms and Perspectives&lt;/p&gt;","year":2020,"lang":"en","type":"review","venue":"Lung Cancer Targets and Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer research; Oncology; Lung cancer; Stage (stratigraphy); Internal medicine; Immune checkpoint; Cancer; Immunotherapy; Biology","score_opus":0.022841948297249465,"score_gpt":0.30830290289875933,"score_spread":0.2854609546015099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998098600","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008997824,0.9904509,0.0003587854,0.00080332474,0.0008980921,0.0058012246,0.00051873934,0.000051456445,0.00021767641],"genre_scores_gemma":[0.0010095405,0.9928499,0.00024774502,0.00011731604,0.00074491446,0.0023548526,0.00007165747,0.0001779786,0.002426105],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970519,0.00009282316,0.00095469423,0.00093397143,0.00033343362,0.00063319417],"domain_scores_gemma":[0.9981184,0.00020469823,0.00078703626,0.0005294518,0.00016313103,0.00019726835],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035187666,0.00091037777,0.0025132666,0.00018686737,0.00038480916,0.000075903976,0.0002312928,0.00031466302,0.00039371106],"category_scores_gemma":[0.000006339877,0.0005567569,0.0009594647,0.00041406706,0.00019235934,0.00008030412,0.000054689524,0.00027699812,3.1095476e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002854755,0.0003802661,0.00003758796,0.012711801,0.0065348805,0.000021007994,0.008132443,0.000006134151,0.010366493,0.00018658719,0.0006970979,0.95807093],"study_design_scores_gemma":[0.007994151,0.0015283473,0.000036294943,0.004517377,0.0023956816,0.000009904517,0.00045643395,0.0005976831,0.0037578857,0.000012123259,0.97808284,0.0006113022],"about_ca_topic_score_codex":0.0018037019,"about_ca_topic_score_gemma":0.0003105072,"teacher_disagreement_score":0.9773857,"about_ca_system_score_codex":0.00081400305,"about_ca_system_score_gemma":0.0008532311,"threshold_uncertainty_score":0.9996884},"labels":[],"label_agreement":null},{"id":"W2998527695","doi":"10.1016/j.rmra.2019.11.456","title":"CheckMate 817 : nivolumab + ipilimumab en première ligne chez des patients atteints d’un cancer bronchique non à petites cellules (CBNPC) avancé avec un ECOG PS 2 et autres populations particulières","year":2020,"lang":"fr","type":"article","venue":"Revue des Maladies Respiratoires Actualités","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Gynecology","score_opus":0.04118215612072727,"score_gpt":0.29169111322118113,"score_spread":0.25050895710045384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998527695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.912765,0.0735298,0.00019783487,0.00808261,0.0014329648,0.0016284372,0.0010133219,0.00027764993,0.001072351],"genre_scores_gemma":[0.956435,0.027554344,0.0016439349,0.0025467311,0.002027933,0.00040327088,0.00038038607,0.000297175,0.0087111695],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9931695,0.0010352712,0.0018775992,0.0014465279,0.0007056867,0.0017654548],"domain_scores_gemma":[0.9962954,0.00058635254,0.0007902931,0.0009826269,0.0005135556,0.0008317655],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00068489555,0.0012504992,0.0015626034,0.00026608523,0.00093584834,0.00033558428,0.0007200719,0.00071580155,0.006696794],"category_scores_gemma":[0.0011237357,0.0012304473,0.00076706684,0.00091092393,0.0014049484,0.0008366807,0.0004309446,0.0008894856,0.00023714181],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058582528,0.0017128796,0.20065899,0.0125580225,0.0029080454,0.0002944985,0.092750005,0.0009560102,0.05106388,0.00052699604,0.004562798,0.6261496],"study_design_scores_gemma":[0.013416448,0.0041690264,0.5028936,0.016523078,0.0020874667,0.000108790504,0.0046499083,0.00569172,0.17822713,0.00064748153,0.2683636,0.0032217326],"about_ca_topic_score_codex":0.0017761661,"about_ca_topic_score_gemma":0.004588939,"teacher_disagreement_score":0.6229279,"about_ca_system_score_codex":0.0011799412,"about_ca_system_score_gemma":0.00036929615,"threshold_uncertainty_score":0.99901456},"labels":[],"label_agreement":null},{"id":"W2998936402","doi":"10.1158/0008-5472.can-19-2039","title":"Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Center for Advancing Translational Sciences; National Institute of General Medical Sciences; Social Sciences and Humanities Research Council of Canada; National Institutes of Health; National Cancer Institute; Melanoma Research Alliance","keywords":"Melanoma; Tumor microenvironment; Biomarker; Immune system; Transcriptome; Computational biology; Cancer research; Medicine; Biology; Immunology; Genetics; Gene; Gene expression","score_opus":0.07578532127632648,"score_gpt":0.35455211334266906,"score_spread":0.2787667920663426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998936402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9189607,0.07118205,0.0001166546,0.008589972,0.00006191815,0.0008410383,0.00016297275,0.000014300153,0.00007041098],"genre_scores_gemma":[0.9935685,0.0051934887,0.0003397741,0.00042714202,0.000051715448,0.000087555316,0.00014628458,0.000025775342,0.00015981152],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99881184,0.00005905379,0.00023682394,0.00037263738,0.000274776,0.0002448972],"domain_scores_gemma":[0.99941385,0.00011054716,0.000060874136,0.00026251187,0.00007652508,0.00007567689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060301827,0.00010933261,0.0002617985,0.00011934987,0.00013662918,0.000057290676,0.00016506233,0.0000330289,0.000026967216],"category_scores_gemma":[0.000046577738,0.00009583902,0.000040278428,0.00018063099,0.0003413427,0.00015555127,0.00014779034,0.00015494823,3.9333997e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003081871,0.000045322977,0.010959752,0.001452255,0.00012822969,0.0000070127226,0.0007037447,1.1361776e-7,0.9409334,0.00001752596,0.0018071091,0.04086365],"study_design_scores_gemma":[0.012289367,0.0006428789,0.5759783,0.0015094295,0.00022227081,0.000084280735,0.0016866685,0.0007874853,0.38180637,0.00027185027,0.024386114,0.00033498267],"about_ca_topic_score_codex":0.00046265172,"about_ca_topic_score_gemma":0.000038849827,"teacher_disagreement_score":0.56501853,"about_ca_system_score_codex":0.000085793814,"about_ca_system_score_gemma":0.00013819843,"threshold_uncertainty_score":0.3908202},"labels":[],"label_agreement":null},{"id":"W2999626196","doi":"10.1016/j.immuni.2019.08.004","title":"The Immune Landscape of Cancer","year":2019,"lang":"en","type":"erratum","venue":"Immunity","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":801,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Calgary; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; Cancer Research Institute; Henry M. Jackson Foundation; U.S. Department of Defense","keywords":"Biology; Immune system; Cancer; Computational biology; Immunology; Cancer research; Genetics","score_opus":0.015569977086122991,"score_gpt":0.29816710591699525,"score_spread":0.28259712883087224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999626196","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024153868,0.65917945,0.0000024580966,0.0031433043,0.058385577,0.0012889985,0.0002669708,0.00008691079,0.25349244],"genre_scores_gemma":[0.04197168,0.07982755,0.000012114013,0.0003314789,0.0010388842,0.000063414795,0.0004659944,0.000084798594,0.8762041],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99865586,0.00009698425,0.0004636293,0.00016563438,0.00034374185,0.000274178],"domain_scores_gemma":[0.9980067,0.00014374183,0.00038707943,0.0012232973,0.00020217868,0.000037024718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046683394,0.00024435407,0.00059812434,0.00007982497,0.00016995045,0.000022635248,0.00041781206,0.0003924341,0.0008859253],"category_scores_gemma":[0.00006380761,0.00014944351,0.00039162795,0.00023657503,0.0002302141,0.000028020157,0.000107667685,0.0011921619,0.000036240126],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022448583,0.000104293504,0.0014497435,0.0005338462,0.0012777952,0.000003950877,0.00022525458,3.3041522e-7,0.004102498,0.000022223217,0.94796646,0.04206876],"study_design_scores_gemma":[0.001341038,0.00021598594,0.057074603,0.0008521914,0.00022270926,0.000010038479,0.00020175324,0.0000120448085,0.0017368131,0.000013363213,0.9381512,0.00016829841],"about_ca_topic_score_codex":0.0055738618,"about_ca_topic_score_gemma":0.00049853144,"teacher_disagreement_score":0.62271166,"about_ca_system_score_codex":0.000107026084,"about_ca_system_score_gemma":0.0008844089,"threshold_uncertainty_score":0.9700261},"labels":[],"label_agreement":null},{"id":"W2999687281","doi":"10.1016/j.jgo.2020.01.006","title":"Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab","year":2020,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia","funders":"BC Cancer Agency","keywords":"Medicine; Pembrolizumab; Nivolumab; Internal medicine; Lung cancer; Cohort; Propensity score matching; Adverse effect; Odds ratio; Cancer; Cohort study; Retrospective cohort study; Oncology; Immunotherapy","score_opus":0.008176792538313046,"score_gpt":0.25560216531257907,"score_spread":0.24742537277426602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999687281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99791825,0.00093887025,0.00002090405,0.00048181356,0.00020056736,0.00028995785,0.000010215804,0.0000034549134,0.0001359795],"genre_scores_gemma":[0.9975377,0.0017406677,0.0004841714,0.000033753797,0.000038620103,0.0000035874455,0.0000031777784,0.000013279071,0.00014506759],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984697,0.00015639569,0.00077642687,0.00012522955,0.0003122477,0.0001600159],"domain_scores_gemma":[0.9976603,0.0001865329,0.0017552343,0.00006668159,0.00026229472,0.000068993395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032239032,0.0001221192,0.0007526323,0.00016109148,0.000021342217,0.0000016911853,0.000080572165,0.00012649375,0.000109910776],"category_scores_gemma":[0.00009979849,0.00007816109,0.0000716921,0.00046539566,0.00004502609,0.00010786668,0.000020205838,0.0002559665,1.0489516e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054911245,0.00038420284,0.93410236,0.00023765818,0.00041838508,0.000054627188,0.0014826156,0.000033966335,0.0046756254,2.9867925e-7,0.000035726356,0.0036632682],"study_design_scores_gemma":[0.03010239,0.007486751,0.9608133,0.00028413805,0.00036907542,0.000012233398,0.00040220396,0.00005243909,0.00027231063,0.0000013373523,0.00011423263,0.00008958881],"about_ca_topic_score_codex":0.000115463954,"about_ca_topic_score_gemma":0.00023873057,"teacher_disagreement_score":0.026710916,"about_ca_system_score_codex":0.00042255782,"about_ca_system_score_gemma":0.00059824926,"threshold_uncertainty_score":0.31873167},"labels":[],"label_agreement":null},{"id":"W3000106048","doi":"10.1002/cncr.32692","title":"Development of the Functional Assessment of Cancer Therapy–Immune Checkpoint Modulator (FACT‐ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs","year":2020,"lang":"en","type":"article","venue":"Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; University of Alberta; St. Michael's Hospital; Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"Department of Medicine, University of Toronto; University of Toronto","keywords":"Medicine; Quality of life (healthcare); Thematic analysis; Focus group; Cancer; Family medicine; Qualitative research; Internal medicine; Nursing","score_opus":0.051507144514421205,"score_gpt":0.30126922885925245,"score_spread":0.24976208434483124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000106048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950033,0.0022320189,0.00007694125,0.0012077999,0.00009137359,0.0011276433,0.00019336324,0.0000127014455,0.000054904456],"genre_scores_gemma":[0.9983473,0.00013123277,0.00018965077,0.0008375427,0.000042804866,0.00032709353,0.000010562911,0.000030440888,0.00008338458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977981,0.00007872402,0.0007461035,0.00033606676,0.0008148139,0.00022619212],"domain_scores_gemma":[0.99839944,0.000021751122,0.0006137882,0.00031025946,0.0005214922,0.00013327532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022501606,0.00024683008,0.00078674546,0.00006308379,0.000047953177,0.000004823888,0.000150669,0.00008572869,0.0004911622],"category_scores_gemma":[0.000019650663,0.000143224,0.00011992077,0.00073046953,0.00014002764,0.00005898322,0.000036760335,0.00017753193,1.6794273e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016010132,0.00042934428,0.89629054,0.0002773891,0.00073400995,3.0739403e-7,0.0014700647,0.0008384291,0.07950519,0.0000023938958,0.00010203116,0.00434017],"study_design_scores_gemma":[0.0077567035,0.00035721716,0.85064393,0.0010753191,0.000045888763,8.0673e-8,0.00019310549,0.000043062428,0.13929446,2.993483e-7,0.00042778364,0.00016211953],"about_ca_topic_score_codex":0.0047322325,"about_ca_topic_score_gemma":0.006268107,"teacher_disagreement_score":0.059789274,"about_ca_system_score_codex":0.00061114226,"about_ca_system_score_gemma":0.0017690747,"threshold_uncertainty_score":0.7153752},"labels":[],"label_agreement":null},{"id":"W3000340261","doi":"10.1158/1055-9965.epi-19-0953","title":"Association of Serum Immunoglobulin Levels with Solid Cancer: A Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; National Institute for Health and Care Research; Medical Research Council Canada; Cancer Research UK; National Institute on Handicapped Research","keywords":"Medicine; Meta-analysis; Antibody; Confidence interval; Internal medicine; Cancer; Cochrane Library; Observational study; Immunoglobulin G; Immunology; Oncology","score_opus":0.14847380577691877,"score_gpt":0.4401395295933584,"score_spread":0.2916657238164396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000340261","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000026405335,0.98784876,0.00024698596,0.0052635795,0.00013299617,0.0056066457,0.0008195485,0.00005734925,0.000021506961],"genre_scores_gemma":[0.000034407054,0.99235255,0.0005174571,0.0015750616,0.00005939863,0.0030315912,0.0002705153,0.00007235237,0.0020866743],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99133533,0.0033038233,0.0034191806,0.0010556858,0.00035168644,0.00053429924],"domain_scores_gemma":[0.99124515,0.0010867115,0.0063383444,0.00080784666,0.00032698063,0.00019495882],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0048441524,0.0008622698,0.018975776,0.00041475755,0.00009459445,0.000012324263,0.0002964223,0.000746513,0.0012459652],"category_scores_gemma":[0.00067091105,0.00055067433,0.005178655,0.0017354903,0.00021550042,0.00010987767,0.00008536604,0.00048608947,0.000008036715],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000105736966,0.000033773533,0.00027785244,0.47822398,0.50219655,0.000004339893,0.000015831829,4.123326e-7,0.0000012383975,0.000004009445,0.0009886465,0.018147634],"study_design_scores_gemma":[0.00057400874,0.00023899398,0.0003617539,0.09913835,0.85963774,0.00003712912,0.000010480584,0.000008044396,0.0000027293556,0.00002090236,0.039553747,0.00041612645],"about_ca_topic_score_codex":0.00031805618,"about_ca_topic_score_gemma":0.00025710827,"teacher_disagreement_score":0.37908563,"about_ca_system_score_codex":0.0010901364,"about_ca_system_score_gemma":0.0009288606,"threshold_uncertainty_score":0.99969447},"labels":[],"label_agreement":null},{"id":"W3000398809","doi":"10.1016/j.annonc.2019.10.008","title":"Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials","year":2020,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Randomized controlled trial; Discontinuation; Odds ratio; Meta-analysis; Placebo; Immunotherapy; Oncology; Cancer; Pathology","score_opus":0.3723914785504721,"score_gpt":0.5493400107631066,"score_spread":0.17694853221263446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000398809","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019193163,0.97584945,0.0000858404,0.0016038246,0.000037135203,0.022050818,0.00029371868,0.00001193622,0.000048110167],"genre_scores_gemma":[0.00008369466,0.9922581,0.00043754373,0.0035479364,0.000031704327,0.0031928238,0.0002305794,0.000058651458,0.00015901962],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9832294,0.007274656,0.008330776,0.00056205684,0.00032315528,0.00027994253],"domain_scores_gemma":[0.9829569,0.0076175244,0.0082275085,0.0006485937,0.00042262222,0.00012686668],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.024345305,0.0005680522,0.05818938,0.0005359816,0.000020506703,0.000005512618,0.00028676336,0.00037613112,0.0004460619],"category_scores_gemma":[0.00334476,0.00030452694,0.01104184,0.0011231559,0.0003623572,0.000034628203,0.000029255505,0.00028282675,0.0000016984997],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036234744,0.0005995692,0.0000012291664,0.4449916,0.49608448,0.000014546891,0.00017313527,2.1461352e-7,0.000001910762,0.000005999357,0.0008080217,0.021084568],"study_design_scores_gemma":[0.07318768,0.0024383427,0.0000035488956,0.051335376,0.7842579,0.000029882154,0.00005598195,0.00002600607,0.000009194336,0.000005614325,0.088445745,0.0002047438],"about_ca_topic_score_codex":0.00004349945,"about_ca_topic_score_gemma":0.000019130952,"teacher_disagreement_score":0.3936562,"about_ca_system_score_codex":0.00006822986,"about_ca_system_score_gemma":0.0010575717,"threshold_uncertainty_score":0.9999407},"labels":[],"label_agreement":null},{"id":"W3000415041","doi":"10.1158/1078-0432.ccr-19-2027","title":"Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":247,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Kindai University; AstraZeneca Canada","keywords":"Lung cancer; Medicine; Cancer; Immune system; Cancer research; Mutation; Tumor microenvironment; Immunology; Oncology; Biology; Internal medicine; Gene; Genetics","score_opus":0.12114822744041158,"score_gpt":0.4691180432962325,"score_spread":0.34796981585582093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000415041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759808,0.0069478005,0.0000050207764,0.0138615295,0.0001102122,0.0018436522,0.00015580725,0.000010097451,0.0010850531],"genre_scores_gemma":[0.9893064,0.0075996295,0.000024446988,0.0016793843,0.00031665727,0.00049576786,0.000019161378,0.000038944516,0.0005196217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971783,0.00045968423,0.0007793339,0.00051950733,0.0005434102,0.00051974447],"domain_scores_gemma":[0.99798095,0.0010487356,0.00017726651,0.00043149566,0.00012706744,0.00023449189],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011155258,0.00022442588,0.0005736648,0.0000945285,0.000103051854,0.000022083806,0.00026571273,0.00010479863,0.0016213333],"category_scores_gemma":[0.00012374588,0.00013620021,0.0004719896,0.0005411593,0.0004791407,0.000034662884,0.00008654963,0.0007381081,0.000031593674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07961844,0.005638181,0.516837,0.00060739013,0.0025032524,0.0006521664,0.008424393,0.0008263494,0.26387787,0.000021485574,0.018205307,0.10278815],"study_design_scores_gemma":[0.014144946,0.01120249,0.8633884,0.00085748045,0.00016951948,0.000005099148,0.00075154577,0.00108411,0.10486306,0.000012629021,0.0032358132,0.00028487726],"about_ca_topic_score_codex":0.009786208,"about_ca_topic_score_gemma":0.0003548993,"teacher_disagreement_score":0.34655142,"about_ca_system_score_codex":0.0017525492,"about_ca_system_score_gemma":0.0011808086,"threshold_uncertainty_score":0.9992913},"labels":[],"label_agreement":null},{"id":"W3000469764","doi":"10.1016/j.jgo.2020.01.002","title":"Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: Real-world data from multicentric cohorts in Canada and France","year":2020,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"Institut Du Cancer de Montréal","keywords":"Medicine; Lung cancer; Internal medicine; Proportional hazards model; Hazard ratio; Oncology; Cancer; Multivariate analysis; Univariate analysis; Confidence interval","score_opus":0.009984364627069255,"score_gpt":0.2633424041601597,"score_spread":0.25335803953309044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000469764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99394476,0.00416396,0.000007339905,0.00091525033,0.00038559557,0.0004884415,0.000039710652,0.0000018548943,0.000053072952],"genre_scores_gemma":[0.996129,0.0028529763,0.00051035336,0.0002545488,0.00020162595,0.0000035123157,0.00001883803,0.000016401107,0.000012747277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981272,0.000083365565,0.0010874483,0.0002295476,0.00025078875,0.00022164102],"domain_scores_gemma":[0.9982731,0.00022567982,0.0010518964,0.00020125446,0.00010915339,0.00013896736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028314817,0.00014897958,0.0008146966,0.00022115464,0.000016106507,0.000004849035,0.00019367112,0.000063005275,0.000072537056],"category_scores_gemma":[0.000056316294,0.00011564284,0.000047542366,0.0007540724,0.000053812993,0.00008089779,0.000075336895,0.00036958605,1.808296e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007401755,0.00036858462,0.97905725,0.00012590401,0.000106974374,0.00022046929,0.00060732546,0.00006439592,0.0016218788,2.2371658e-8,0.0006497445,0.009775698],"study_design_scores_gemma":[0.02375871,0.00062887586,0.9728494,0.00024022804,0.00017820814,0.0000045151905,0.0001570001,0.00042112483,0.00076750736,1.8398356e-7,0.0008846892,0.00010950692],"about_ca_topic_score_codex":0.7575773,"about_ca_topic_score_gemma":0.6861537,"teacher_disagreement_score":0.07142359,"about_ca_system_score_codex":0.0008435028,"about_ca_system_score_gemma":0.00284608,"threshold_uncertainty_score":0.5048824},"labels":[],"label_agreement":null},{"id":"W3001041049","doi":"10.3390/ijms21030773","title":"Evaluating the Combination of Radioimmunotherapy and Immunotherapy in a Melanoma Mouse Model","year":2020,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Radioimmunotherapy; Melanoma; Immunotherapy; Cancer research; Medicine; Computational biology; Immunology; Biology; Immune system; Antibody; Monoclonal antibody","score_opus":0.051340314119780406,"score_gpt":0.3647163430887836,"score_spread":0.3133760289690032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001041049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828694,0.0036128752,0.0025750503,0.010620861,0.000085839405,0.00010281653,0.0000016610394,0.0000023686216,0.00012914871],"genre_scores_gemma":[0.99433064,0.0008151549,0.002894632,0.0019151649,0.000024491308,0.0000015398728,4.2500739e-7,0.000004973441,0.000012995188],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99875855,0.000063284446,0.00037908443,0.00008789697,0.00064110564,0.000070097456],"domain_scores_gemma":[0.99936354,0.00005450853,0.00029757555,0.00005387306,0.00020567657,0.00002484943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009135737,0.0000638172,0.00014937768,0.00012969701,0.000029167633,0.000033353335,0.00027174997,0.000024331692,0.00001765082],"category_scores_gemma":[0.00007410557,0.00004099784,0.000086677224,0.00017855642,0.00021350734,0.00012213802,0.00001853966,0.00010591758,1.745356e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001641478,0.00007073278,0.0026748027,0.0000053788003,0.00014019865,0.000011624611,0.0020272946,0.0019281744,0.9488887,0.0005683958,0.000011150945,0.042032074],"study_design_scores_gemma":[0.024545996,0.009555632,0.035464853,0.0005300219,0.00007713896,0.00063076685,0.0022961497,0.35192207,0.5699151,0.004226553,0.00048421946,0.000351477],"about_ca_topic_score_codex":0.000025962558,"about_ca_topic_score_gemma":0.0000012275397,"teacher_disagreement_score":0.37897354,"about_ca_system_score_codex":0.00003745893,"about_ca_system_score_gemma":0.00019221858,"threshold_uncertainty_score":0.16718434},"labels":[],"label_agreement":null},{"id":"W3001622551","doi":"10.1016/j.ejca.2019.12.029","title":"ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Cancer Research UK; CHILDREN with CANCER UK; Action Medical Research","keywords":"Medicine; Clinical trial; Agency (philosophy); Intensive care medicine; Oncology; Internal medicine","score_opus":0.04738878254134485,"score_gpt":0.2875636237656424,"score_spread":0.24017484122429753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001622551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788885,0.016607706,0.00028714258,0.0027299842,0.00042451752,0.00097021984,0.000009745787,0.0000065550116,0.000075628275],"genre_scores_gemma":[0.99416244,0.0036033562,0.0009456479,0.000649196,0.0005461313,0.000012166015,0.000012622796,0.000044301905,0.00002413927],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99788547,0.00019486621,0.0011739554,0.00020955602,0.00031587886,0.0002202537],"domain_scores_gemma":[0.99863213,0.000075482814,0.0006876789,0.0000763682,0.0004057337,0.00012262292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015064817,0.00017814616,0.00039349525,0.00031395297,0.000037753594,0.00001696934,0.000114963965,0.000020996657,0.00001833191],"category_scores_gemma":[0.00023832054,0.00013215307,0.00010248952,0.00042467634,0.000051827414,0.0001875544,0.000023063752,0.0001782618,3.4214682e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053557865,0.00024204592,0.13994609,0.00024932637,0.000094647185,0.000023186949,0.003436086,0.000019784497,0.0071688923,0.0000017704024,0.0023584936,0.8411039],"study_design_scores_gemma":[0.029890843,0.004782517,0.9322384,0.00045026335,0.00007486883,0.0000066698526,0.0004372018,0.00010218528,0.006804494,0.000011118382,0.024987724,0.00021374373],"about_ca_topic_score_codex":0.000011326139,"about_ca_topic_score_gemma":0.00002458458,"teacher_disagreement_score":0.84089017,"about_ca_system_score_codex":0.00010069486,"about_ca_system_score_gemma":0.00028169068,"threshold_uncertainty_score":0.5389046},"labels":[],"label_agreement":null},{"id":"W3002906036","doi":"10.1016/j.intimp.2020.106211","title":"Anti-tumor immune response varies among individuals: A gene expression profiling of mouse melanoma","year":2020,"lang":"en","type":"article","venue":"International Immunopharmacology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Fundamental Research Funds for the Central Universities; National Key Research and Development Program of China; National Natural Science Foundation of China","keywords":"Immune system; Tumor microenvironment; Biology; Melanoma; Cancer research; Gene expression profiling; Chemokine; Gene; Cancer immunology; Immunotherapy; Immunology; Gene expression; Genetics","score_opus":0.02291861050848796,"score_gpt":0.3119098185272505,"score_spread":0.28899120801876255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3002906036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939088,0.0014788759,0.00023686927,0.002856917,0.0006983708,0.0004242984,0.0000982789,0.00007121395,0.00022636926],"genre_scores_gemma":[0.9951806,0.00018455733,0.002373785,0.0015777271,0.00014209384,0.00006126898,0.000084247156,0.000030691073,0.0003650017],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99837786,0.00018053225,0.00061991916,0.00028551382,0.0003217551,0.00021443781],"domain_scores_gemma":[0.99901915,0.00018581415,0.00033457452,0.00016474884,0.00021342548,0.00008229515],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041278335,0.00018171055,0.00040369807,0.00017755415,0.00006394659,0.00001945511,0.00032727138,0.00009796208,0.0014161394],"category_scores_gemma":[0.00020937866,0.00016463776,0.00017258959,0.00018394308,0.00025296933,0.00015821683,0.00016359388,0.00025721535,0.00002981784],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020255152,0.00019903001,0.020685669,0.000038276252,0.0006797606,0.000106334664,0.00064000784,0.000024891882,0.9564514,0.000020721656,0.00058691367,0.00031182973],"study_design_scores_gemma":[0.00478211,0.0004988375,0.07965949,0.00005214262,0.0000767402,0.000067768524,0.00018403059,0.00033397664,0.91075516,0.0000070413835,0.0034474153,0.00013530704],"about_ca_topic_score_codex":0.000051139727,"about_ca_topic_score_gemma":2.702778e-7,"teacher_disagreement_score":0.058973826,"about_ca_system_score_codex":0.00009342874,"about_ca_system_score_gemma":0.000191907,"threshold_uncertainty_score":0.9994967},"labels":[],"label_agreement":null},{"id":"W3003308809","doi":"10.1016/j.jacc.2019.11.049","title":"Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis","year":2020,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":285,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"National Cancer Institute; U.S. Food and Drug Administration; Servier; New York Academy of Medicine; CTI Biopharma; National Institutes of Health; Medtronic; Roche; Novartis; Takeda Pharmaceuticals U.S.A.; Amgen; National Heart, Lung, and Blood Institute; Pfizer; Bristol-Myers Squibb; Merck; GlaxoSmithKline","keywords":"Medicine; Myocarditis; Internal medicine; Cardiogenic shock; Cardiology; Ejection fraction; Mace; Heart failure; Cardiomyopathy; Percutaneous coronary intervention; Myocardial infarction","score_opus":0.007396573460744641,"score_gpt":0.23352965950330362,"score_spread":0.22613308604255897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003308809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951885,0.0009106272,0.000019453037,0.0029920342,0.00027174078,0.00026252578,0.00019174581,0.0000035612354,0.0001598394],"genre_scores_gemma":[0.99936944,0.00018361276,0.00011688669,0.00016998618,0.00013634858,0.0000017217376,0.0000024978597,0.000010803464,0.000008697744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854946,0.00023596144,0.0005892594,0.00014071717,0.00030590864,0.00017868089],"domain_scores_gemma":[0.9988684,0.000041565658,0.00067372195,0.00015829488,0.00016308048,0.00009493712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032045512,0.00014190981,0.0010413588,0.00006130162,0.0000286609,0.0000017457726,0.00013376499,0.00005141083,0.000004706729],"category_scores_gemma":[0.000083668914,0.00008868672,0.0003749085,0.00056723825,0.00043839784,0.000047841924,0.000060048023,0.00022275113,2.8586604e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076283785,0.000033618744,0.9866496,0.000021703185,0.0012333542,0.00007070277,0.00004591032,0.00007535665,0.0014563367,0.000008339906,0.0004335439,0.0023431736],"study_design_scores_gemma":[0.00514698,0.0030939684,0.99005854,0.00012974165,0.00020810851,0.0002362362,0.0002857869,0.0000032405053,0.00012500984,0.000024754021,0.0006013838,0.00008625147],"about_ca_topic_score_codex":0.000033815864,"about_ca_topic_score_gemma":0.0000023273194,"teacher_disagreement_score":0.0041809725,"about_ca_system_score_codex":0.00015578445,"about_ca_system_score_gemma":0.00021414297,"threshold_uncertainty_score":0.36165395},"labels":[],"label_agreement":null},{"id":"W3003499321","doi":"10.1200/jco.19.03022","title":"Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":455,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston General Hospital; Princess Margaret Cancer Centre; Queen's University; University Health Network; Juravinski Cancer Centre","funders":"","keywords":"Carboplatin; Medicine; Atezolizumab; Pembrolizumab; Pemetrexed; Bevacizumab; Oncology; Lung cancer; Internal medicine; Guideline; Crizotinib; Cancer; Chemotherapy; Cisplatin; Immunotherapy; Pathology","score_opus":0.130242166794466,"score_gpt":0.46557585869527746,"score_spread":0.3353336919008114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003499321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8944899,0.0075859786,0.00910368,0.08642975,0.0011355048,0.0008788746,0.000030087755,0.000013285444,0.0003329765],"genre_scores_gemma":[0.7424599,0.055260897,0.04953105,0.1445991,0.0065544504,0.000057649744,0.0000211005,0.00007478531,0.0014411025],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99690217,0.00015896092,0.0023042944,0.00022845341,0.00019997229,0.00020614405],"domain_scores_gemma":[0.99724406,0.00041439044,0.0013766303,0.0001354668,0.0004988919,0.00033056314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019432907,0.00016125504,0.0011485316,0.000050721123,0.00006230574,0.000020488134,0.00011869868,0.00024998284,0.0004756173],"category_scores_gemma":[0.00044210974,0.00010885416,0.00044110883,0.0000941457,0.00014394181,0.00010562862,0.0000315606,0.0005376455,0.0000026055436],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08604185,0.002003193,0.09597692,0.00032665234,0.0032794985,0.00029589148,0.0013455567,0.00013001583,0.07441249,0.000056439247,0.20251305,0.53361845],"study_design_scores_gemma":[0.04482719,0.01441536,0.03238003,0.00014083028,0.00051789527,0.000063894586,0.00018558835,0.0055501126,0.0032783337,0.000044520177,0.89838344,0.0002128181],"about_ca_topic_score_codex":0.000035065324,"about_ca_topic_score_gemma":0.000055024906,"teacher_disagreement_score":0.69587034,"about_ca_system_score_codex":0.00009274861,"about_ca_system_score_gemma":0.0014657396,"threshold_uncertainty_score":0.52076757},"labels":[],"label_agreement":null},{"id":"W3004138890","doi":"10.1038/s41423-020-0361-7","title":"B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling","year":2020,"lang":"en","type":"article","venue":"Cellular and Molecular Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"CD28; T-cell receptor; T cell; Cell biology; Stimulation; Co-stimulation; Transcriptome; Receptor; Signal transduction; Cell growth; Biology; Cytokine; Immunology; Cancer research; Immune system; Gene expression; Neuroscience; Gene; Biochemistry","score_opus":0.011907533796810713,"score_gpt":0.22654503389909728,"score_spread":0.21463750010228655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004138890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98508954,0.010859122,0.0014844192,0.002026249,0.000019096831,0.00035365418,0.0000010138068,0.0000072564007,0.00015965106],"genre_scores_gemma":[0.9982678,0.00074384647,0.00011500253,0.0008108772,0.000016419914,0.000012898437,0.000014386954,0.000008048223,0.00001069014],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99935186,0.000097835866,0.00017740138,0.00018254948,0.00008240682,0.0001079431],"domain_scores_gemma":[0.9997283,0.00005251256,0.00006355668,0.000101290934,0.000029735604,0.000024572955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015810288,0.00009133936,0.00016128302,0.000042077067,0.00003955434,0.000013886172,0.00003983492,0.000089332214,0.0000060135894],"category_scores_gemma":[0.000057723588,0.00007047963,0.00002363658,0.00012282254,0.00014388896,0.00004862815,0.000031380907,0.00013605756,2.9318542e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057438784,0.000034126893,0.0015167245,0.000100978206,0.000032839795,0.000013437926,0.0019706863,0.0000022008478,0.9923943,0.00016708528,0.0000126198265,0.0031805567],"study_design_scores_gemma":[0.001909622,0.0004908307,0.0034694509,0.00005909693,0.00003344078,0.000030123712,0.0006038175,0.00029470038,0.99222326,0.00008723038,0.0007231001,0.000075332646],"about_ca_topic_score_codex":0.000030432273,"about_ca_topic_score_gemma":0.0000014561992,"teacher_disagreement_score":0.013178292,"about_ca_system_score_codex":0.000007019261,"about_ca_system_score_gemma":0.000028533555,"threshold_uncertainty_score":0.2874076},"labels":[],"label_agreement":null},{"id":"W3004517814","doi":"10.1200/jco.2020.38.4_suppl.512","title":"Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Clinical endpoint; Nivolumab; Sorafenib; Oncology; Hepatocellular carcinoma; Clinical trial; Adverse effect; Cancer; Immunotherapy","score_opus":0.1262848890606197,"score_gpt":0.41459406289929873,"score_spread":0.28830917383867904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004517814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99268466,0.0012471501,0.000117952375,0.004692697,0.00052798813,0.0004001929,0.000007972329,0.000015074682,0.00030633176],"genre_scores_gemma":[0.99283284,0.0014419637,0.0010313484,0.0042113303,0.00038408223,0.0000056279473,0.000027852435,0.000030114665,0.000034851222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99618006,0.0004600679,0.0022436462,0.00031242069,0.0005414905,0.00026232703],"domain_scores_gemma":[0.9966799,0.0005995684,0.0017358279,0.00021844429,0.00046050068,0.0003057761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009944194,0.00022111968,0.001593639,0.00014089998,0.000040739655,0.000014363091,0.00023116198,0.00033101172,0.00024451196],"category_scores_gemma":[0.00048393733,0.00015321729,0.00046186746,0.0003931846,0.00019537866,0.00021442078,0.00003086393,0.0008442654,0.000009720328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.093592234,0.0024771409,0.75170946,0.000019424358,0.0005413648,0.00031571568,0.0003741418,0.000012006945,0.0034653929,0.000005154074,0.0004556601,0.14703228],"study_design_scores_gemma":[0.07998718,0.04418354,0.86452657,0.0001122596,0.00018380808,0.000014188062,0.00018769216,0.0007095802,0.0017175766,0.00006213837,0.008146151,0.00016929928],"about_ca_topic_score_codex":0.00020367016,"about_ca_topic_score_gemma":0.000061375176,"teacher_disagreement_score":0.14686298,"about_ca_system_score_codex":0.0002896689,"about_ca_system_score_gemma":0.0008265551,"threshold_uncertainty_score":0.62480193},"labels":[],"label_agreement":null},{"id":"W3004599128","doi":"","title":"The expressions and significance of B7-H3 and CTLA-4 in the clinical stages of non-small-cell lung cancer.","year":2019,"lang":"en","type":"article","venue":"PubMed","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Adenosquamous carcinoma; Adenocarcinoma; Clinical significance; Medicine; Internal medicine; Carcinoma; Lung cancer; Biopsy; Oncology; Metastasis; Cancer; non-small cell lung cancer (NSCLC); Lymph node; Gastroenterology; Pathology; A549 cell","score_opus":0.029135497801037774,"score_gpt":0.3107588778921347,"score_spread":0.2816233800910969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004599128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98772895,0.0078032184,0.0000034283814,0.0013072294,0.00013217058,0.0012194511,0.000012704055,0.0000033459821,0.0017895282],"genre_scores_gemma":[0.992835,0.0060161245,0.00002460545,0.00022639208,0.00003964271,0.00033351508,7.483624e-7,0.0000066869807,0.00051729835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915427,0.0000840534,0.00030214072,0.00014287134,0.00015411501,0.00016256125],"domain_scores_gemma":[0.99897414,0.000572228,0.00013698895,0.00024595653,0.00003167453,0.0000389821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097300636,0.000071484574,0.00021014245,0.000025173884,0.000032293952,0.000008915204,0.00010855992,0.000053404186,0.000009643942],"category_scores_gemma":[0.00006323671,0.00003653427,0.00004572983,0.00011001266,0.00021001343,0.000025132702,0.000031254905,0.00011814409,8.36149e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012826782,0.00012740178,0.8654602,0.00030137147,0.00008398151,0.0000020029802,0.0008816042,0.0000011893043,0.026023604,0.000018786743,0.0012429989,0.10457418],"study_design_scores_gemma":[0.0022075032,0.000074464944,0.9852486,0.0000875579,0.000041933556,0.0000014747056,0.00068501,0.000027555292,0.008395711,0.000009843761,0.003169775,0.00005056475],"about_ca_topic_score_codex":0.00034307913,"about_ca_topic_score_gemma":0.000113067166,"teacher_disagreement_score":0.1197884,"about_ca_system_score_codex":0.000013434799,"about_ca_system_score_gemma":0.00006608551,"threshold_uncertainty_score":0.14898244},"labels":[],"label_agreement":null},{"id":"W3004630265","doi":"10.1016/j.ctrv.2020.101979","title":"Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer","year":2020,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme","keywords":"Medicine; Nivolumab; Pembrolizumab; Atezolizumab; Lung cancer; Chemotherapy; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.05420534162604314,"score_gpt":0.37431323484624324,"score_spread":0.3201078932202001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004630265","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001879622,0.9772495,0.000021555275,0.00063721166,0.00021441576,0.019602858,0.000053487678,0.00011185712,0.00022948535],"genre_scores_gemma":[0.00012910545,0.9741659,0.00080714416,0.0005865383,0.00023942311,0.023010898,0.00026987185,0.0001643023,0.00062677375],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961753,0.00025252378,0.0012110217,0.001280749,0.00039283032,0.00068759377],"domain_scores_gemma":[0.9981099,0.00005242117,0.00081667706,0.0006436944,0.00007086706,0.00030643572],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003408762,0.00126905,0.003979611,0.00026042465,0.000115373645,0.00010140192,0.00020134124,0.0002993951,0.00011324418],"category_scores_gemma":[0.0000052805226,0.0007624097,0.0006624773,0.0008748525,0.00010652562,0.00013213097,0.0000373513,0.0003393777,0.0000052980736],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010833652,0.0007631206,0.0028200122,0.015041539,0.0020098926,0.00009572627,0.00024938578,1.5770227e-7,0.0000074050336,0.000011071324,0.00018572083,0.9777326],"study_design_scores_gemma":[0.013044819,0.0021647627,0.00069937564,0.03689497,0.002157124,0.000033279433,0.00002290959,0.000008085197,0.00010686135,0.0000035324279,0.94416517,0.00069910666],"about_ca_topic_score_codex":0.00046207127,"about_ca_topic_score_gemma":0.0003588651,"teacher_disagreement_score":0.9770335,"about_ca_system_score_codex":0.0029943853,"about_ca_system_score_gemma":0.00055737613,"threshold_uncertainty_score":0.9994827},"labels":[],"label_agreement":null},{"id":"W3004722696","doi":"10.1007/978-3-030-35723-8_3","title":"Janus or Hydra: The Many Faces of T Helper Cells in the Human Tumour Microenvironment","year":2020,"lang":"en","type":"review","venue":"Advances in experimental medicine and biology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Dalhousie University; Occupational Cancer Research Centre; BC Cancer Agency","funders":"","keywords":"Cytotoxic T cell; Homing (biology); Cell biology; Immune system; Effector; CD8; Tumor microenvironment; Biology; Cancer immunotherapy; Lernaean Hydra; Immunotherapy; Immunology; Cancer research; In vitro","score_opus":0.05852364269741321,"score_gpt":0.39873453977258777,"score_spread":0.34021089707517455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004722696","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035505123,0.99351555,0.0000011469199,0.00089754304,0.0002332133,0.0010876791,0.000014375413,0.000004943368,0.0006950075],"genre_scores_gemma":[0.02125449,0.9769397,0.00002625352,0.0012583451,0.00021442867,0.00016876064,0.000044849545,0.000016656539,0.00007654306],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983181,0.00024648407,0.0007087132,0.0003698986,0.000120316894,0.00023653763],"domain_scores_gemma":[0.9992034,0.00025071495,0.00026258052,0.00024168387,0.000004488689,0.000037148668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028600357,0.00032943446,0.0013250518,0.00010956335,0.000051918072,0.0000031783127,0.00028193454,0.00014435888,0.00016293215],"category_scores_gemma":[0.000014398806,0.00012843769,0.00012732329,0.00023484902,0.0010408901,0.000034452747,0.000083561026,0.0003491602,0.000003040979],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071818393,0.00041344058,0.00027575722,0.0034446775,0.00020181428,0.00017836639,0.004885267,1.1016097e-7,0.05515702,0.00013597346,0.000607451,0.93398196],"study_design_scores_gemma":[0.0014872388,0.0019939078,0.000057140907,0.00379298,0.00012544187,0.00016659642,0.005299603,4.3612118e-7,0.002108527,0.000017097125,0.9848082,0.00014279534],"about_ca_topic_score_codex":0.00014636903,"about_ca_topic_score_gemma":0.000049323677,"teacher_disagreement_score":0.9842008,"about_ca_system_score_codex":0.000087258,"about_ca_system_score_gemma":0.000038832375,"threshold_uncertainty_score":0.5237537},"labels":[],"label_agreement":null},{"id":"W3004867668","doi":"10.1136/esmoopen-2019-000573","title":"New pathways in immune stimulation: targeting OX40","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Immune system; Immune checkpoint; Cytotoxic T cell; Immunotherapy; Immunology; Medicine; Antigen; Cancer research; Biology; In vitro","score_opus":0.050628910180302446,"score_gpt":0.30500878946658505,"score_spread":0.2543798792862826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004867668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.826125,0.003942144,0.001769919,0.06728149,0.0007001054,0.0031077096,0.000012437605,0.0001930348,0.096868105],"genre_scores_gemma":[0.99283016,0.000045520857,0.003028411,0.0029875685,0.00020299922,0.000008509221,0.000038616494,0.000014886982,0.0008433266],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99936265,0.00002183587,0.00022210904,0.00016293685,0.00010372549,0.00012672678],"domain_scores_gemma":[0.9997125,0.000021670694,0.00004619066,0.0001234114,0.000015700016,0.00008047964],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001704851,0.00007642704,0.0001854214,0.000023231234,0.000034585217,0.000038555954,0.00016223713,0.000042904627,0.0024824694],"category_scores_gemma":[0.000049066162,0.00006766604,0.00004516254,0.00023055219,0.000011737663,0.00011888008,0.0000914724,0.00011102159,0.00007685359],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017387375,0.0002994525,0.1631276,0.00021228241,0.00038715685,0.0004902046,0.015815133,0.00033412492,0.17890428,0.0010443846,0.14185224,0.48014575],"study_design_scores_gemma":[0.013384996,0.00062787486,0.5781092,0.00026047355,0.000033936638,0.000013079246,0.00067352474,0.0016631477,0.019946264,0.00020210343,0.38475358,0.00033181268],"about_ca_topic_score_codex":0.0022596894,"about_ca_topic_score_gemma":0.0000503785,"teacher_disagreement_score":0.47981393,"about_ca_system_score_codex":0.00004328685,"about_ca_system_score_gemma":0.00015222075,"threshold_uncertainty_score":0.9984294},"labels":[],"label_agreement":null},{"id":"W3004892473","doi":"10.1016/s1470-2045(20)30076-0","title":"Advancing the systemic therapy of lung cancer: quality or quantity?","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Pfizer Canada; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Roche; AstraZeneca","keywords":"Pembrolizumab; Pemetrexed; Medicine; Lung cancer; Oncology; Internal medicine; Chemotherapy; Placebo; Cancer; Immunotherapy; Pathology; Alternative medicine","score_opus":0.09466019374412431,"score_gpt":0.41580427094612077,"score_spread":0.32114407720199645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004892473","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014809137,0.024327967,0.000047999896,0.9563418,0.001650068,0.001411439,0.00014346148,0.00008981041,0.0011782965],"genre_scores_gemma":[0.026217181,0.04184763,0.000075222764,0.9192675,0.010941452,0.0002556554,0.00006373437,0.000068539295,0.0012630987],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99679047,0.0011114891,0.0007714516,0.00037884596,0.00041662456,0.0005311394],"domain_scores_gemma":[0.9966812,0.0012979783,0.0008518781,0.0009955876,0.00013470728,0.000038626476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013818016,0.00033115406,0.0017039843,0.000053982887,0.00015195982,0.000015699712,0.00076608924,0.0005159074,0.0005182573],"category_scores_gemma":[0.0001376516,0.00014766409,0.0003451658,0.00033438695,0.00046462708,0.000032787706,0.000085720094,0.001928024,0.000010343305],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009858187,0.000033765133,0.0018720299,0.0013171673,0.0011494855,0.0001717737,0.0011570109,0.000002090844,0.00479543,0.00003503279,0.96976644,0.00984161],"study_design_scores_gemma":[0.0038572026,0.00070034544,0.0013504109,0.00055347505,0.00022977116,0.00024284092,0.00022420289,0.00003395635,0.00036292087,0.00003276614,0.99221265,0.0001994297],"about_ca_topic_score_codex":0.002125384,"about_ca_topic_score_gemma":0.0005074615,"teacher_disagreement_score":0.037074335,"about_ca_system_score_codex":0.00051666144,"about_ca_system_score_gemma":0.0012874703,"threshold_uncertainty_score":0.8376412},"labels":[],"label_agreement":null},{"id":"W3004966554","doi":"10.1200/jco.2020.38.5_suppl.tps65","title":"SALVO: Single-arm phase II study of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Melanoma; Internal medicine; Mucosal melanoma; Adjuvant therapy; Clinical endpoint; Oncology; Clinical trial; Adjuvant; Phases of clinical research; Surgery; Gastroenterology; Cancer; Immunotherapy; Cancer research","score_opus":0.19823788034640213,"score_gpt":0.4882958499286043,"score_spread":0.2900579695822022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004966554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984426,0.0023029065,0.000053296906,0.011466585,0.0006592729,0.0007363194,0.000009077109,0.000011826481,0.0003347167],"genre_scores_gemma":[0.99375176,0.0011237662,0.00072396355,0.0033121647,0.0009827621,0.000006958451,0.0000030178767,0.000023652989,0.000071971226],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99647003,0.00035992655,0.0023729375,0.00023795436,0.00033743828,0.00022173503],"domain_scores_gemma":[0.99582267,0.0015804322,0.0015948893,0.00016612021,0.00047978395,0.0003560942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020191865,0.00015729842,0.0016521825,0.00009516944,0.000067289926,0.000007409467,0.00016838362,0.00027321884,0.0001889771],"category_scores_gemma":[0.0023200794,0.00010896549,0.00043478198,0.00018025015,0.00023030101,0.00007757842,0.00004920502,0.0005543343,0.0000011106359],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31676298,0.02723922,0.004034492,0.000045119978,0.0016259307,0.00024827142,0.0017217202,7.9196496e-7,0.029201185,0.0000092529035,0.0049557844,0.61415523],"study_design_scores_gemma":[0.17820555,0.7145983,0.02223638,0.000071353235,0.00045577265,0.00021674819,0.0016005945,0.00011651146,0.0017353538,0.00009698722,0.080536254,0.00013018548],"about_ca_topic_score_codex":0.00003900524,"about_ca_topic_score_gemma":0.00004793774,"teacher_disagreement_score":0.6873591,"about_ca_system_score_codex":0.00007898594,"about_ca_system_score_gemma":0.0011127477,"threshold_uncertainty_score":0.4443484},"labels":[],"label_agreement":null},{"id":"W3005292744","doi":"10.1016/s1470-2045(19)30801-0","title":"Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":213,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Hôpital Charles-Le Moyne","funders":"Merck Sharp and Dohme; Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Pembrolizumab; Lung cancer; Carboplatin; Internal medicine; Placebo; Response Evaluation Criteria in Solid Tumors; Oncology; Cancer; Surgery; Progressive disease; Chemotherapy; Cisplatin; Pathology; Immunotherapy","score_opus":0.040831192833675936,"score_gpt":0.33795517121566354,"score_spread":0.2971239783819876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005292744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753358,0.00087474915,0.00013636502,0.0016275138,0.0005272906,0.020693235,0.00005214998,0.00009363948,0.0006592541],"genre_scores_gemma":[0.9939695,0.0002043958,0.00047733376,0.0021038305,0.00023653141,0.002493558,0.000108056505,0.00009262889,0.00031415583],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957497,0.0005034042,0.0014418389,0.0007830829,0.0005537744,0.00096818944],"domain_scores_gemma":[0.9964872,0.0015032109,0.0009949688,0.00054201944,0.00015405161,0.00031855475],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00091464736,0.00067310315,0.003037033,0.0002180132,0.00020078338,0.00006977404,0.00028015423,0.0002383213,0.0002485855],"category_scores_gemma":[0.0003629086,0.0003788592,0.00037275854,0.00059162034,0.00016034838,0.00014478242,0.00011035964,0.00063940964,0.000005925468],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9518723,0.0012865447,0.030622093,0.0002725505,0.0026906526,0.000528646,0.006779513,0.00020582389,0.00023473556,5.33099e-7,0.00047167932,0.00503493],"study_design_scores_gemma":[0.9795827,0.0077885306,0.002004673,0.00017956903,0.0034069002,0.00001999954,0.0008284522,0.004893707,0.0002526384,8.017948e-7,0.00057406054,0.00046793494],"about_ca_topic_score_codex":0.0012686144,"about_ca_topic_score_gemma":0.0017903722,"teacher_disagreement_score":0.028617421,"about_ca_system_score_codex":0.00061857584,"about_ca_system_score_gemma":0.001172344,"threshold_uncertainty_score":0.9998663},"labels":[],"label_agreement":null},{"id":"W3005364954","doi":"10.1200/jco.2020.38.4_suppl.528","title":"RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Nuclear medicine; Discontinuation; Internal medicine; Cancer","score_opus":0.10055749853471928,"score_gpt":0.444024621006399,"score_spread":0.3434671224716797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005364954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97051686,0.0009488068,0.000033637032,0.025005408,0.00026682107,0.00018927138,0.0000031370594,0.000010096898,0.003025937],"genre_scores_gemma":[0.98809296,0.0015061641,0.0022528567,0.007428639,0.00030385194,0.000002920539,0.0000017188769,0.00001741226,0.00039350547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739194,0.00021950301,0.0017565584,0.00020203306,0.0002419397,0.00018800341],"domain_scores_gemma":[0.99730027,0.0011486612,0.0009295659,0.00012148178,0.00016503336,0.0003349669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096847565,0.00014677709,0.0016381027,0.00008889394,0.000023631454,0.0000089474825,0.00010867231,0.00023766537,0.000113928014],"category_scores_gemma":[0.0013995264,0.00008848355,0.00025274837,0.00021187954,0.00024794124,0.00009745163,0.000024076899,0.00074838725,0.0000049871937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13079706,0.00079011556,0.5130747,0.000035603007,0.00044282046,0.0013277882,0.00018320954,0.0000045551947,0.0008007348,0.000012698675,0.0013801554,0.35115054],"study_design_scores_gemma":[0.049041014,0.027393114,0.80994385,0.00014118556,0.00018396051,0.0004861279,0.00018195079,0.000046728892,0.00010481173,0.000027255552,0.11232736,0.00012264772],"about_ca_topic_score_codex":0.00004041956,"about_ca_topic_score_gemma":0.00012431892,"teacher_disagreement_score":0.3510279,"about_ca_system_score_codex":0.00011649673,"about_ca_system_score_gemma":0.0006949241,"threshold_uncertainty_score":0.36082548},"labels":[],"label_agreement":null},{"id":"W3005453403","doi":"10.1200/jco.2020.38.5_suppl.54","title":"Real-world outcomes for metastatic non-small cell lung cancer patients treated with checkpoint inhibitor immunotherapy in Canada.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); University Health Network; Windsor Regional Hospital; Juravinski Cancer Centre; McMaster University; Princess Margaret Cancer Centre; BC Cancer Agency; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Nivolumab; Pembrolizumab; Internal medicine; Lung cancer; Oncology; Immunotherapy; Clinical endpoint; Cancer; Clinical trial","score_opus":0.06196130539225674,"score_gpt":0.3975799223295604,"score_spread":0.33561861693730366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005453403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870119,0.00036875036,0.00004841868,0.010888368,0.0005610877,0.0007155637,0.000025310748,0.0000048064753,0.00037580807],"genre_scores_gemma":[0.9868192,0.0011215576,0.0020992162,0.009291298,0.000335111,0.000033332726,0.0000071066074,0.000035535628,0.00025765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99675316,0.00015971379,0.0023168002,0.00020275111,0.00028882961,0.0002787781],"domain_scores_gemma":[0.99665356,0.0010098917,0.001584527,0.000117401425,0.00034603378,0.00028859932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082661136,0.00019270551,0.0016747952,0.00010286656,0.000026237172,0.000006910379,0.00014680155,0.00010151314,0.000121996934],"category_scores_gemma":[0.00023774325,0.00011905832,0.00037459546,0.0002698944,0.00006760351,0.00005972846,0.000014449308,0.00053756277,5.5048235e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035936967,0.0008467917,0.9380506,0.00011853932,0.0008612235,0.00016181017,0.00019500712,0.000021536764,0.0006802252,7.6375255e-7,0.004481487,0.018645022],"study_design_scores_gemma":[0.047799088,0.010049554,0.9234179,0.00019625685,0.0004027516,0.00000580967,0.00013933357,0.000286824,0.0011818289,0.000002858593,0.016359478,0.00015827332],"about_ca_topic_score_codex":0.20313327,"about_ca_topic_score_gemma":0.5841738,"teacher_disagreement_score":0.38104054,"about_ca_system_score_codex":0.0010426712,"about_ca_system_score_gemma":0.008654753,"threshold_uncertainty_score":0.9969652},"labels":[],"label_agreement":null},{"id":"W3005499534","doi":"10.1007/s10637-020-00904-7","title":"A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; Juravinski Cancer Centre; Queen's University","funders":"Canadian Cancer Society Research Institute","keywords":"Tremelimumab; Durvalumab; Tolerability; Medicine; Adverse effect; Internal medicine; Cohort; Oncology; Cancer; Nivolumab; Immunotherapy; Ipilimumab","score_opus":0.05438185365786288,"score_gpt":0.32869030911327457,"score_spread":0.2743084554554117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005499534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907533,0.000574701,0.000013577644,0.0053689373,0.00028455057,0.0023640827,0.00047312613,0.00004004055,0.00012768916],"genre_scores_gemma":[0.9962847,0.000090063084,0.0004274702,0.002278126,0.00018977278,0.00014001006,0.00035619794,0.000049980023,0.00018365748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996745,0.0002337969,0.0011584794,0.000545993,0.0008628371,0.0004539295],"domain_scores_gemma":[0.99808645,0.00015260467,0.0005843348,0.00025236345,0.00032181563,0.00060242054],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004356688,0.00036202045,0.0010865744,0.00027937163,0.00012224646,0.0000442563,0.00023800721,0.00010758325,0.00049702276],"category_scores_gemma":[0.0003377993,0.00028332873,0.0001296958,0.0008727173,0.00021123247,0.0003135981,0.000030799987,0.00021207059,0.0000069019634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12465047,0.007400609,0.5692454,0.0018776038,0.0062148464,0.00055827666,0.08089046,0.0075628636,0.0884663,0.00073222,0.030130005,0.08227094],"study_design_scores_gemma":[0.4416655,0.017189162,0.47782037,0.0043744384,0.001614067,0.000028117154,0.008161098,0.0016605488,0.020265436,0.0004371601,0.024484454,0.0022996517],"about_ca_topic_score_codex":0.086986996,"about_ca_topic_score_gemma":0.07634543,"teacher_disagreement_score":0.31701505,"about_ca_system_score_codex":0.00070403796,"about_ca_system_score_gemma":0.006765754,"threshold_uncertainty_score":0.9999619},"labels":[],"label_agreement":null},{"id":"W3005534920","doi":"10.1177/1078155220904147","title":"Very high-dose methylprednisolone for treatment of nivolumab-induced limbic encephalitis: A case report","year":2020,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Nivolumab; Limbic encephalitis; Prednisone; Adverse effect; Methylprednisolone; Encephalitis; Weakness; Cancer; Internal medicine; Anesthesia; Surgery; Immunotherapy; Immunology","score_opus":0.1220786963557368,"score_gpt":0.446066123515647,"score_spread":0.3239874271599102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005534920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9524636,0.003988892,0.00032569078,0.040832005,0.001088489,0.0006885144,0.000019991347,0.00001626804,0.000576526],"genre_scores_gemma":[0.9827849,0.0027897917,0.009822077,0.0033771438,0.0009727756,0.000030150106,0.0000066783628,0.000027248267,0.0001891917],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978319,0.00030753715,0.001143338,0.00021413827,0.00027310845,0.00023000795],"domain_scores_gemma":[0.99539965,0.0013898379,0.002092473,0.00018420191,0.0006700541,0.0002637601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010484076,0.00018288205,0.000842273,0.00012507237,0.000074005075,0.000011854599,0.00010000075,0.0001018716,0.00018376019],"category_scores_gemma":[0.0013105745,0.00014797001,0.0003979158,0.00023887082,0.00008961328,0.00043119138,0.000018468154,0.00022068642,0.0000035615305],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12579145,0.003690626,0.00027752027,0.00015295102,0.004557018,0.23027517,0.0031851667,0.0000075325015,0.4473372,0.000012910088,0.0059007546,0.17881167],"study_design_scores_gemma":[0.040593475,0.025893262,0.00017550192,0.000049574133,0.0036536606,0.3555865,0.0018821573,0.00009710121,0.09696059,0.000012931913,0.47495368,0.00014154335],"about_ca_topic_score_codex":0.0004830399,"about_ca_topic_score_gemma":0.0000094674915,"teacher_disagreement_score":0.46905294,"about_ca_system_score_codex":0.000514248,"about_ca_system_score_gemma":0.0016141937,"threshold_uncertainty_score":0.6034042},"labels":[],"label_agreement":null},{"id":"W3005570342","doi":"10.1634/theoncologist.2019-0674","title":"Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"Alberta Cancer Foundation","keywords":"Medicine; Nivolumab; Adverse effect; Pembrolizumab; Pneumonitis; Hazard ratio; Ipilimumab; Internal medicine; Melanoma; Cancer; Immunotherapy; Confidence interval; Lung","score_opus":0.03187919730524732,"score_gpt":0.31172232012643114,"score_spread":0.27984312282118384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005570342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815397,0.0005016867,0.0000029662447,0.014175982,0.00030737792,0.00048802665,0.0000064075493,0.00006081245,0.0029170145],"genre_scores_gemma":[0.99793965,0.0002408549,0.000058039186,0.0012344948,0.000030923373,0.000017246028,0.00000946726,0.000015854956,0.0004534652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989424,0.00010959143,0.00035491263,0.0002208597,0.00015353283,0.00021875119],"domain_scores_gemma":[0.99944806,0.0001242219,0.000119266166,0.0002178104,0.000021588663,0.000069031936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034697886,0.00015336281,0.00044947708,0.000035390334,0.00007772815,0.0000043579853,0.00014126141,0.00010390431,0.00011559132],"category_scores_gemma":[0.00013949825,0.000095873074,0.00010690279,0.00024826065,0.00014285541,0.000054931796,0.00006938997,0.00024257075,0.000027080734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006113067,0.00038032667,0.7659393,0.000075270196,0.00047967027,0.00023301158,0.001977296,0.000018769737,0.18610074,0.00013779828,0.00015437593,0.03839041],"study_design_scores_gemma":[0.0077000163,0.00080662745,0.98660743,0.000045128494,0.000053881457,0.00001767239,0.0007981452,0.00008598569,0.0018555112,0.000039740407,0.0018522108,0.00013762728],"about_ca_topic_score_codex":0.00031136887,"about_ca_topic_score_gemma":0.00009590297,"teacher_disagreement_score":0.22066818,"about_ca_system_score_codex":0.000102963226,"about_ca_system_score_gemma":0.000081319646,"threshold_uncertainty_score":0.39095905},"labels":[],"label_agreement":null},{"id":"W3005626512","doi":"10.1097/pai.0000000000000838","title":"Problems With the Recommendations for PD-L1 Biomarker Testing","year":2020,"lang":"en","type":"letter","venue":"Applied immunohistochemistry & molecular morphology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lions Gate Hospital","funders":"","keywords":"Biomarker; Immunohistochemistry; Internal medicine; Computer science; Medicine; Chemistry; Biochemistry","score_opus":0.03156108046655366,"score_gpt":0.2763760807947559,"score_spread":0.24481500032820225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005626512","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038940446,0.002440779,0.004548316,0.97807413,0.00028754742,0.0032086272,0.00018748321,0.00023675227,0.007122329],"genre_scores_gemma":[0.022503113,0.000054187487,0.009048611,0.9541792,0.0009474899,0.0038805555,0.0059066364,0.00035743363,0.0031227404],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.997303,0.000050839997,0.0006070326,0.0010014218,0.00033384658,0.000703862],"domain_scores_gemma":[0.9976457,0.00028985494,0.00055687444,0.0011965431,0.00023160745,0.00007946219],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019258566,0.0006878199,0.0007935666,0.00008341762,0.00034525828,0.00005530654,0.00056978315,0.00080349133,0.00024608825],"category_scores_gemma":[0.00007081619,0.000517391,0.00035472025,0.0004762608,0.00066963426,0.000020752721,0.00011695561,0.0017983828,0.000028914928],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066401093,0.000027767315,0.000001168335,0.00028420333,0.0005945811,0.00019906134,0.000046128607,7.160709e-7,0.5318624,0.0000036543101,0.464671,0.0016453112],"study_design_scores_gemma":[0.0035554685,0.00042125967,0.00002029946,0.00023196117,0.0009775362,0.0014187676,0.00008420155,0.000018280529,0.06594019,0.00009996709,0.9264969,0.00073518045],"about_ca_topic_score_codex":0.00005684471,"about_ca_topic_score_gemma":1.04728294e-7,"teacher_disagreement_score":0.4659222,"about_ca_system_score_codex":0.000344313,"about_ca_system_score_gemma":0.0004729295,"threshold_uncertainty_score":0.9997278},"labels":[],"label_agreement":null},{"id":"W3006486601","doi":"10.1038/s41379-020-0497-0","title":"PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability","year":2020,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Dipartimento di Scienze Biomediche Avanzate, Università degli Studi di Napoli Federico II; Ministero della Salute; Dipartimenti di Eccellenza; Fondazione IRCCS Policlinico San Matteo; Università degli Studi di Pavia; Ministero dell’Istruzione, dell’Università e della Ricerca; Università degli Studi di Napoli Federico II","keywords":"Microsatellite instability; Etiology; Pathology; Adenocarcinoma; Medicine; Biology; Microsatellite; Internal medicine; Cancer; Genetics; Gene","score_opus":0.02562394659204816,"score_gpt":0.2394008688870945,"score_spread":0.21377692229504633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006486601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952652,0.0010445766,0.00023408173,0.0026824963,0.000032078977,0.0004678292,0.00007301961,0.000037751317,0.00016300977],"genre_scores_gemma":[0.9891429,0.000058430684,0.00063587,0.009957537,0.000031426815,0.000051992993,0.00008462437,0.000020119682,0.000017105116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985558,0.00018315969,0.00035956665,0.0005082094,0.00006667584,0.00032662545],"domain_scores_gemma":[0.99951017,0.0000899311,0.00008938918,0.00016979298,0.000043213142,0.00009751909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003081694,0.00017267269,0.0004111033,0.00011533689,0.00003352047,0.000010051883,0.000065544285,0.00016568805,0.000058597325],"category_scores_gemma":[0.00014685903,0.00015739414,0.000035797366,0.00027830215,0.00014441182,0.000042329895,0.00004119125,0.00022411719,0.000004725615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006002121,0.00014962003,0.8108251,0.00007946822,0.000035448982,0.0009990733,0.010543145,0.000022140553,0.16028367,0.000008947027,0.000073570154,0.010977673],"study_design_scores_gemma":[0.005220641,0.001135576,0.9859244,0.00012086874,0.000019202776,0.00027228106,0.0002615599,0.0014537071,0.0051011196,0.000119940574,0.00017876997,0.00019188692],"about_ca_topic_score_codex":0.00028480505,"about_ca_topic_score_gemma":0.0017493321,"teacher_disagreement_score":0.17509931,"about_ca_system_score_codex":0.00023871574,"about_ca_system_score_gemma":0.00013789866,"threshold_uncertainty_score":0.6418347},"labels":[],"label_agreement":null},{"id":"W3006808367","doi":"10.1016/j.jaci.2019.12.077","title":"Long-term treatment with ligelizumab achieves prolonged symptom control during the post-treatment follow-up","year":2020,"lang":"en","type":"article","venue":"Journal of Allergy and Clinical Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Term (time); Medicine; Pediatrics; Physics","score_opus":0.020436609198201033,"score_gpt":0.2978525089859286,"score_spread":0.2774158997877275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006808367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677907,0.010388853,0.00002356445,0.021094518,0.00030642105,0.0003225851,0.000004276649,0.000015620017,0.00005343916],"genre_scores_gemma":[0.97734183,0.02037399,0.000035283047,0.0014213773,0.0003749892,0.000011521141,0.00000355863,0.000018564206,0.0004189137],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99846125,0.00019995238,0.00074554194,0.000211101,0.00014180057,0.00024038379],"domain_scores_gemma":[0.9987793,0.00028072565,0.00044333783,0.00020359301,0.00014666004,0.00014639966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016710487,0.00022280942,0.0007025726,0.000042932348,0.00014399904,0.000024425459,0.0001280733,0.00017540579,0.00011571463],"category_scores_gemma":[0.00005372297,0.000104483865,0.0003946494,0.00007631551,0.00035095593,0.00007009674,0.000022487653,0.00031825106,0.0000067746464],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.372875,0.0023381955,0.368899,0.00003559796,0.056642585,0.0017378194,0.0022827347,0.0000054931966,0.022376345,0.000027312586,0.000058854424,0.17272106],"study_design_scores_gemma":[0.043769483,0.05405303,0.892732,0.00010125656,0.0007229779,0.001501896,0.0002851368,0.000008880509,0.0008690141,0.0000028768666,0.00582308,0.00013031598],"about_ca_topic_score_codex":0.00003404351,"about_ca_topic_score_gemma":0.00021237602,"teacher_disagreement_score":0.52383304,"about_ca_system_score_codex":0.000108693035,"about_ca_system_score_gemma":0.0002533589,"threshold_uncertainty_score":0.42607284},"labels":[],"label_agreement":null},{"id":"W3006945261","doi":"10.1093/jcag/gwz047.015","title":"A16 ROLE OF MYELOID CELLS IN THE INITIATION OF COLITIS-ASSOCIATED COLON CANCER","year":2020,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Western University","funders":"","keywords":"Colitis; Azoxymethane; Inflammation; Medicine; Cancer research; Colorectal cancer; Carcinogenesis; Immune system; Cancer; Inflammatory bowel disease; Oxazolone; Immunology; Internal medicine; Disease","score_opus":0.011190177398417548,"score_gpt":0.23530457757580825,"score_spread":0.2241144001773907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006945261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715779,0.00007845593,0.0000016929582,0.027665028,0.00020756444,0.00017821751,0.00012960212,9.441087e-7,0.00016061861],"genre_scores_gemma":[0.99547017,0.00010069401,0.000015565474,0.0043054232,0.00006799375,0.0000025199195,0.0000041205444,0.0000064618193,0.00002705933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840015,0.00039594303,0.0006458491,0.000056851793,0.00031605634,0.00018516959],"domain_scores_gemma":[0.99761724,0.00009905362,0.0017527906,0.00008277497,0.00037445553,0.00007370613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089747267,0.000070177804,0.00037815684,0.00013268426,0.000030204805,0.000004012098,0.00020688484,0.00011031063,0.00006522562],"category_scores_gemma":[0.0002839928,0.000049790404,0.00018418489,0.00024073152,0.00006195495,0.000043357424,0.000010266727,0.00024308276,2.663833e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023497872,0.00009152199,0.9480694,0.000033440425,0.00038421602,0.0000041930393,0.0024392754,0.00009088202,0.0410673,0.000017186441,0.0052200356,0.00023274649],"study_design_scores_gemma":[0.003613959,0.0013187242,0.9873709,0.0001300374,0.0001410819,0.000009536995,0.0005634046,0.00006108093,0.0053753136,0.000039169186,0.0013486977,0.000028062697],"about_ca_topic_score_codex":0.014116841,"about_ca_topic_score_gemma":0.3458659,"teacher_disagreement_score":0.33174905,"about_ca_system_score_codex":0.0008833877,"about_ca_system_score_gemma":0.0006364295,"threshold_uncertainty_score":0.9924482},"labels":[],"label_agreement":null},{"id":"W3007159492","doi":"10.1093/jcag/gwz047.232","title":"A233 VEDOLIZUMAB FOR STEROID &amp; INFLIXIMAB-REFRACTORY ICI-COLITIS","year":2020,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Infliximab; Vedolizumab; Colitis; Internal medicine; Gastroenterology; Ipilimumab; Ulcerative colitis; Adverse effect; Discontinuation; Nivolumab; Surgery; Cancer; Tumor necrosis factor alpha; Immunotherapy","score_opus":0.019771667023079344,"score_gpt":0.2553049526102673,"score_spread":0.23553328558718797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007159492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9133098,0.000058446054,0.00010718815,0.0852652,0.00071479153,0.0002611765,0.00010141157,0.0000039190177,0.0001780477],"genre_scores_gemma":[0.98403656,0.000033276956,0.00027542777,0.014824215,0.00037892925,0.0000033792132,0.0000062118556,0.000014174674,0.00042784118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987562,0.00013375933,0.0005153443,0.000081479404,0.00023721576,0.00027603505],"domain_scores_gemma":[0.9982128,0.00006718387,0.0009853087,0.000113553404,0.0003764776,0.0002446662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000471028,0.000091552676,0.0003697348,0.000120667886,0.000068485846,0.000011884264,0.00018447505,0.000115682036,0.00010146021],"category_scores_gemma":[0.00045636317,0.000071840856,0.00033114696,0.00008833739,0.00005059674,0.000061081235,0.000012929375,0.00024063981,0.0000025231946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016935905,0.0001179317,0.7960142,0.00011881118,0.0016228938,0.000013469529,0.0015153417,0.000039060837,0.010972099,0.000039793158,0.17038088,0.0022296072],"study_design_scores_gemma":[0.01174319,0.0035303792,0.6392412,0.000096724056,0.00027149427,0.00013980216,0.00011486375,0.000030715648,0.00036334386,0.000060906757,0.34433445,0.000072907234],"about_ca_topic_score_codex":0.0016319696,"about_ca_topic_score_gemma":0.14486201,"teacher_disagreement_score":0.17395358,"about_ca_system_score_codex":0.001244437,"about_ca_system_score_gemma":0.0006201887,"threshold_uncertainty_score":0.870742},"labels":[],"label_agreement":null},{"id":"W3007192247","doi":"10.1002/eji.201948456","title":"The immune checkpoint receptor associated phosphatases SHP‐1 and SHP‐2 are not required for γδT17 cell development, activation, or skin inflammation","year":2020,"lang":"en","type":"article","venue":"European Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Fondet; Lundbeckfonden; H. Lundbeck A/S; York University","keywords":"Biology; Inflammation; Cell biology; Phosphatase; Immune system; Immunology; Cancer research; Phosphorylation","score_opus":0.03119217862750882,"score_gpt":0.2509776961765237,"score_spread":0.2197855175490149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007192247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755503,0.0049969223,0.0008417473,0.017390292,0.00045140888,0.00046200494,0.000019439665,0.000034004835,0.0002538999],"genre_scores_gemma":[0.9956143,0.0015774352,0.0010888549,0.00078354817,0.00028913555,0.0000064547935,0.000058032743,0.00004587128,0.0005363601],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99825704,0.00028351278,0.0009259319,0.00015015517,0.00015904962,0.00022430805],"domain_scores_gemma":[0.99798054,0.00024910903,0.0012177924,0.00014027541,0.00034342584,0.00006887088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011766754,0.00016518489,0.00033768147,0.000070283524,0.00026769482,0.000050387596,0.00020061115,0.000054220585,0.00007371353],"category_scores_gemma":[0.0011024318,0.000106114814,0.00012226282,0.00018155437,0.00013727164,0.00015842586,0.000054958473,0.00025598644,0.000013481838],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029784452,0.000109911474,0.000323355,0.00007539265,0.0010431657,0.00004454155,0.0032535612,0.0000022618099,0.8474628,0.000019336318,0.0046693487,0.11321188],"study_design_scores_gemma":[0.007827818,0.001624185,0.05764361,0.0002498775,0.000067239256,0.0000620422,0.0015034847,0.000011063917,0.70454323,0.000003337312,0.2263155,0.00014863317],"about_ca_topic_score_codex":0.0000030136018,"about_ca_topic_score_gemma":0.0000021403937,"teacher_disagreement_score":0.22164614,"about_ca_system_score_codex":0.00011876763,"about_ca_system_score_gemma":0.0002193107,"threshold_uncertainty_score":0.43272364},"labels":[],"label_agreement":null},{"id":"W3007666278","doi":"10.1093/eurheartj/ehaa051","title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","year":2020,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":343,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institutes of Health; Kohlberg Foundation; Canadian Institutes of Health Research; Sarnoff Cardiovascular Research Foundation","keywords":"Medicine; Myocarditis; Ejection fraction; Mace; Cardiology; Internal medicine; Cardiogenic shock; Magnetic resonance imaging; Heart failure; Myocardial infarction; Radiology; Percutaneous coronary intervention","score_opus":0.026330558122735957,"score_gpt":0.2467624059852442,"score_spread":0.22043184786250825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007666278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8470182,0.13653153,0.000025219768,0.007254429,0.0005608146,0.00030431894,0.000008650056,0.00008178615,0.008215059],"genre_scores_gemma":[0.9922993,0.0035775015,0.00022555584,0.0025605713,0.0010196639,0.0000019622132,0.0000048615357,0.000059249465,0.00025129016],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99799174,0.00047660808,0.00051380805,0.00023927075,0.00044143986,0.00033714154],"domain_scores_gemma":[0.9993814,0.00002258582,0.00007327082,0.000228909,0.000071644135,0.00022218886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013363097,0.00016579723,0.00045209273,0.00008556793,0.00010189746,0.00005688616,0.00011377519,0.000045210232,0.00031441156],"category_scores_gemma":[0.00020501106,0.00015051785,0.0006518342,0.0004013185,0.000067716894,0.000083839426,0.00004873941,0.0006645807,0.00014873965],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057169884,0.00065734086,0.1880419,0.00021533805,0.0016593839,0.018643618,0.0059629837,0.00009915832,0.22045659,0.000008446868,0.08751843,0.47101983],"study_design_scores_gemma":[0.003994236,0.0005994468,0.6113876,0.00031197298,0.000045661956,0.00088524155,0.000087487075,0.000033323788,0.0015632464,0.000002218688,0.38095364,0.00013587251],"about_ca_topic_score_codex":0.000027409487,"about_ca_topic_score_gemma":0.000001829659,"teacher_disagreement_score":0.47088397,"about_ca_system_score_codex":0.00015681177,"about_ca_system_score_gemma":0.00010605849,"threshold_uncertainty_score":0.613794},"labels":[],"label_agreement":null},{"id":"W3007959681","doi":"10.1016/j.celrep.2020.01.076","title":"Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity","year":2020,"lang":"en","type":"article","venue":"Cell Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Canadian Institutes of Health Research; University of Leeds; University of Cambridge; Cancer Research UK; International Seafood Sustainability Foundation; Wellcome Trust","keywords":"Biology; Cancer immunotherapy; CD8; Immune system; Granzyme B; Cancer research; Granzyme; Cell biology; Cytotoxic T cell; Immune checkpoint; CTL*; T cell; Immunotherapy; Transcription factor; Chemistry; Perforin; Immunology; Biochemistry; Gene","score_opus":0.0297226202093738,"score_gpt":0.2495064445006517,"score_spread":0.2197838242912779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007959681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99299914,0.0006646144,0.001988956,0.00058954756,0.0002565442,0.0011187474,0.0000404038,0.000038932154,0.0023031144],"genre_scores_gemma":[0.9985776,0.00011320445,0.00031756423,0.0004794033,0.00016515596,0.00004061704,0.00014040111,0.000030493515,0.00013554229],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99834013,0.00006208538,0.00085580815,0.00027955775,0.00027456673,0.00018785507],"domain_scores_gemma":[0.9986906,0.000057605743,0.0005820816,0.00033870467,0.00024313765,0.00008784732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043834676,0.00017043449,0.00040569258,0.000056104982,0.00006784524,0.000009033949,0.00006165187,0.00010045452,0.00015337908],"category_scores_gemma":[0.00008748238,0.0001318956,0.00031151008,0.0002299464,0.00020114609,0.000056274428,0.000015112977,0.0001763265,0.0000035795092],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015663203,0.0002599256,0.00020745822,0.000522017,0.000051732764,0.000019984003,0.0010387904,0.0000055761943,0.99360126,0.00000862177,0.001888094,0.00083019404],"study_design_scores_gemma":[0.0016629455,0.0007132797,0.0017362072,0.00020134743,0.00007989224,0.000027426653,0.0004650785,0.000018213508,0.9892935,0.000014969213,0.0056599737,0.00012712825],"about_ca_topic_score_codex":0.0000420023,"about_ca_topic_score_gemma":0.0000057365355,"teacher_disagreement_score":0.005578478,"about_ca_system_score_codex":0.00004733552,"about_ca_system_score_gemma":0.00018692657,"threshold_uncertainty_score":0.5378547},"labels":[],"label_agreement":null},{"id":"W3007994674","doi":"10.1093/jjco/hyaa021","title":"Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data","year":2020,"lang":"en","type":"review","venue":"Japanese Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Immunotherapy; Meta-analysis; Internal medicine; Oncology; Hazard ratio; Subgroup analysis; PD-L1; Clinical trial; Survival analysis; Cancer; Confidence interval","score_opus":0.22924891694507674,"score_gpt":0.4905778551954058,"score_spread":0.2613289382503291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007994674","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009532667,0.98661983,0.000002804084,0.0021977564,0.00011089592,0.0013644577,0.0001538912,0.0000046211585,0.000013071033],"genre_scores_gemma":[0.0020411063,0.996879,0.00031054602,0.00047771577,0.00008969061,0.00002767959,0.000055705343,0.000022870805,0.00009569107],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98421896,0.0055390103,0.008951618,0.00043615152,0.00058645033,0.00026784203],"domain_scores_gemma":[0.97504663,0.013703118,0.00994488,0.0006470173,0.00038204092,0.0002762958],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.026421063,0.00035524994,0.022753187,0.0004194978,0.00002278315,0.000013838389,0.0003447717,0.0005064233,0.00007993653],"category_scores_gemma":[0.022397477,0.00021215012,0.0027974031,0.001017049,0.00013901106,0.00017084106,0.00020744307,0.00095869595,0.0000014480565],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011885905,0.0005534626,0.0010081406,0.4722147,0.48928472,0.0002515245,0.00045192588,4.1609727e-7,0.000044558823,0.000001935385,0.000059350103,0.024243353],"study_design_scores_gemma":[0.0036493712,0.0033040217,0.009408373,0.029899983,0.9045922,0.0001283943,0.00013063647,0.000003973107,6.0910975e-7,0.0000047521016,0.04866185,0.0002157957],"about_ca_topic_score_codex":0.00004761038,"about_ca_topic_score_gemma":0.000038704842,"teacher_disagreement_score":0.4423147,"about_ca_system_score_codex":0.0004196724,"about_ca_system_score_gemma":0.0012796475,"threshold_uncertainty_score":0.99175507},"labels":[],"label_agreement":null},{"id":"W3008280888","doi":"10.1200/jco.2020.38.6_suppl.481","title":"Conditional immune adverse event rate in urothelial and renal cell carcinoma patients treated with immune checkpoint inhibitors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Adverse effect; Renal cell carcinoma; Internal medicine; Incidence (geometry); Cohort; Pneumonitis; Cumulative incidence; Oncology; Gastroenterology; Lung","score_opus":0.03908389342846681,"score_gpt":0.3479053474469485,"score_spread":0.3088214540184817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008280888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931115,0.00049368263,0.000018808722,0.0054410556,0.00025924057,0.00027061944,0.00001254731,0.0000052058913,0.0003873384],"genre_scores_gemma":[0.9970972,0.00026271818,0.00020432666,0.001814612,0.0005075392,0.000004044236,0.00001781133,0.000016210099,0.00007553169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662995,0.00033680862,0.002391031,0.00018992576,0.00026335975,0.00018894474],"domain_scores_gemma":[0.99763113,0.0003712955,0.001385229,0.000091691385,0.00024065343,0.0002799754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001360559,0.00015522244,0.001040885,0.000094036106,0.000030610336,0.00000510872,0.00008403527,0.0002258126,0.00020393402],"category_scores_gemma":[0.00039766525,0.000104058636,0.00035676235,0.00016271997,0.0002615185,0.0000961671,0.000034756515,0.0007375891,0.0000064649034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17521963,0.0039659967,0.7341563,0.00010491545,0.00053798256,0.0018438052,0.00057151035,0.000031174324,0.061974443,0.00000816671,0.0012070804,0.020379024],"study_design_scores_gemma":[0.046851326,0.026182376,0.90948814,0.00010779003,0.00016341687,0.00007764757,0.00010434489,0.000053482454,0.00817887,0.000013379751,0.0086661745,0.00011304299],"about_ca_topic_score_codex":0.00006573345,"about_ca_topic_score_gemma":0.000014733621,"teacher_disagreement_score":0.17533188,"about_ca_system_score_codex":0.00014914069,"about_ca_system_score_gemma":0.0009566779,"threshold_uncertainty_score":0.42433882},"labels":[],"label_agreement":null},{"id":"W3008374819","doi":"10.1016/j.lungcan.2020.02.016","title":"A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; Cancer Care South East; McMaster University; Queen's University; Centre Hospitalier de l’Université de Montréal; University of Calgary; Juravinski Cancer Centre","funders":"Canadian Cancer Society Research Institute","keywords":"Medicine; Internal medicine; Carboplatin; Durvalumab; Tremelimumab; Chemotherapy; Gemcitabine; Pemetrexed; Pneumonitis; Lung cancer; Oxaliplatin; Gastroenterology; Oncology; Surgery; Cancer; Cisplatin; Pembrolizumab; Immunotherapy; Ipilimumab; Colorectal cancer; Lung","score_opus":0.05066850904979687,"score_gpt":0.39482714856463014,"score_spread":0.3441586395148333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008374819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989626,0.002729361,0.000008148533,0.0015950571,0.00015809764,0.0056330147,0.00010559801,0.00004217264,0.000102589365],"genre_scores_gemma":[0.99612767,0.0006396206,0.00008386815,0.0017084854,0.00022884575,0.0009491887,0.000011160428,0.00008133094,0.00016981852],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973355,0.00021533732,0.0008511196,0.00065054203,0.0004744673,0.00047304947],"domain_scores_gemma":[0.99871904,0.00008415563,0.00039491645,0.00033917092,0.00011665836,0.0003460557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006010929,0.00039241047,0.001484672,0.00023866499,0.00009298524,0.000037473244,0.00016638525,0.00009280128,0.0006964994],"category_scores_gemma":[0.000055425087,0.0002741041,0.00007566296,0.0008245649,0.00009304477,0.00016028732,0.00002343902,0.00029333992,5.170745e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1758902,0.003936703,0.6536161,0.00032994678,0.0023102937,0.00025101865,0.060660042,0.000099835204,0.013011096,0.0000013029544,0.00072824355,0.08916522],"study_design_scores_gemma":[0.58003193,0.051344585,0.29879636,0.0020188072,0.0020120097,0.000038579758,0.05223447,0.0027698968,0.0050409557,0.0000025119803,0.0042871786,0.0014227495],"about_ca_topic_score_codex":0.1901607,"about_ca_topic_score_gemma":0.6798894,"teacher_disagreement_score":0.48972866,"about_ca_system_score_codex":0.0005731597,"about_ca_system_score_gemma":0.0013235452,"threshold_uncertainty_score":0.9999711},"labels":[],"label_agreement":null},{"id":"W3008557183","doi":"10.1200/jco.2020.38.6_suppl.725","title":"The impact of surgical resection on circulating tumor-reactive cytotoxic T cells for patients with renal tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cytotoxic T cell; Peripheral blood mononuclear cell; Renal cell carcinoma; Nephrectomy; CD8; Immune system; Granzyme B; Pathology; Internal medicine; Kidney; Immunology","score_opus":0.0802812113267133,"score_gpt":0.43666816177765955,"score_spread":0.35638695045094626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008557183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963125,0.000045876684,0.00004005527,0.0023614643,0.00024776495,0.00034606335,0.000007782161,0.0000036454296,0.00063486176],"genre_scores_gemma":[0.9985124,0.000053243206,0.00020458948,0.00038792897,0.0008078574,0.0000034077882,0.0000019883184,0.00001301623,0.000015555459],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9976414,0.0002617002,0.00147885,0.00013125617,0.0003187073,0.00016809952],"domain_scores_gemma":[0.99376166,0.0034757738,0.00199153,0.00010036593,0.0004704869,0.00020016659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017038727,0.00010464371,0.00083165604,0.00004266796,0.00006128184,0.0000066096295,0.00009960711,0.000121068086,0.000030107565],"category_scores_gemma":[0.0013142026,0.000049656293,0.00069072726,0.00014231414,0.00019150155,0.000053265096,0.000012829815,0.00059415615,0.0000011205474],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77126545,0.003292263,0.114650324,0.000053172796,0.0023406977,0.00039022553,0.0003302351,0.00029372892,0.014956797,0.00003550955,0.005501118,0.08689046],"study_design_scores_gemma":[0.043115675,0.25383887,0.68640697,0.00036773414,0.0002656946,0.00020596883,0.00015324364,0.00041489195,0.0039139325,0.00007560362,0.011100748,0.00014063764],"about_ca_topic_score_codex":0.000019102083,"about_ca_topic_score_gemma":0.000004970522,"teacher_disagreement_score":0.7281498,"about_ca_system_score_codex":0.00019325726,"about_ca_system_score_gemma":0.0009945665,"threshold_uncertainty_score":0.25813457},"labels":[],"label_agreement":null},{"id":"W3008929949","doi":"10.1097/rlu.0000000000002967","title":"FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With Pembrolizumab","year":2020,"lang":"en","type":"article","venue":"Clinical Nuclear Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Cancer Institute","keywords":"Medicine; Nuclear medicine; Pembrolizumab; Response Evaluation Criteria in Solid Tumors; Bone marrow; Standardized uptake value; Melanoma; PET-CT; Progressive disease; Positron emission tomography; Internal medicine; Cancer; Chemotherapy; Immunotherapy","score_opus":0.031715939366375075,"score_gpt":0.3094848928931272,"score_spread":0.2777689535267521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008929949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9704212,0.00035949153,0.000001525393,0.02511512,0.00023419641,0.0008365714,0.000057929992,0.00022950447,0.0027444756],"genre_scores_gemma":[0.98039675,0.00040185993,0.000048597336,0.016833799,0.00033005865,0.000016006654,0.0002784135,0.00011342677,0.0015811154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99615735,0.0005037807,0.0012494244,0.00082409184,0.00074100646,0.0005243706],"domain_scores_gemma":[0.9974131,0.0008246511,0.0003215946,0.00059486576,0.00011318775,0.0007325976],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000883819,0.00040318,0.0011505589,0.00011641814,0.00011888917,0.000011419294,0.00026457597,0.0001868374,0.0024621156],"category_scores_gemma":[0.0013898695,0.0002754364,0.00018648303,0.0004835221,0.0007428054,0.000086635075,0.00014373237,0.0006246852,0.00020433853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26096383,0.00092960877,0.40883896,0.00011349817,0.00036127976,0.0011414888,0.00051018834,4.755062e-7,0.010145874,0.000002008532,0.31305844,0.0039343415],"study_design_scores_gemma":[0.059399486,0.021342134,0.66330886,0.0006355436,0.0002622871,0.0001181956,0.00014565267,0.00038405377,0.00023107204,0.000001373666,0.25385195,0.0003194174],"about_ca_topic_score_codex":0.00016937872,"about_ca_topic_score_gemma":0.00006713447,"teacher_disagreement_score":0.2544699,"about_ca_system_score_codex":0.00041181722,"about_ca_system_score_gemma":0.00012688995,"threshold_uncertainty_score":0.9999698},"labels":[],"label_agreement":null},{"id":"W3009044127","doi":"10.1158/1538-7445.sabcs19-p1-10-08","title":"Abstract P1-10-08: Assessing immune biomarkers of response to anthracyclines in breast cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Oncology; Tumor microenvironment; Immunotherapy; Internal medicine; Chemotherapy; Trastuzumab; Tumor-infiltrating lymphocytes; Immune system; Triple-negative breast cancer; Tissue microarray; Cancer; Immunology","score_opus":0.10412821195878418,"score_gpt":0.45845928599160013,"score_spread":0.35433107403281594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009044127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94214916,0.0052352636,0.000005400525,0.051096395,0.0001622316,0.0006389475,0.00014116698,0.000032612705,0.00053884304],"genre_scores_gemma":[0.9968511,0.0015255591,0.000095803895,0.0006638416,0.0002710812,0.00017265009,0.000008856725,0.000049129376,0.00036201565],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99724096,0.00024163477,0.00059547747,0.00048907695,0.0008102576,0.00062259316],"domain_scores_gemma":[0.9984541,0.00034775084,0.00010612605,0.00038710714,0.00039564443,0.00030929476],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018851816,0.00019305504,0.00048452444,0.00048399516,0.000102436454,0.00005339841,0.00030200576,0.00013138418,0.0041732118],"category_scores_gemma":[0.00031304266,0.0001688897,0.00014180296,0.0020870552,0.00034860586,0.0001805771,0.00011737358,0.00046534097,0.00003323591],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051756512,0.00014639499,0.016792744,0.0003302007,0.0001590857,0.00008366036,0.0007992105,0.000021888654,0.8704169,0.0000014390814,0.0077263247,0.051765632],"study_design_scores_gemma":[0.0041694087,0.00035287076,0.8150082,0.0016988672,0.00002160592,0.000013013684,0.0013692944,0.000070646405,0.15905568,0.000004965701,0.017997056,0.00023836805],"about_ca_topic_score_codex":0.0057142465,"about_ca_topic_score_gemma":0.00024511674,"teacher_disagreement_score":0.7982155,"about_ca_system_score_codex":0.00055077305,"about_ca_system_score_gemma":0.0014056428,"threshold_uncertainty_score":0.9967371},"labels":[],"label_agreement":null},{"id":"W3009056944","doi":"10.3747/co.27.5953","title":"Therapeutic Landscape of Metastatic Non-Small-Cell Lung Cancer in Canada in 2020","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Centre Hospitalier de l’Université de Montréal; Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Lung cancer; Disease; Clinical trial; Precision medicine; Oncology; Cancer; Immunotherapy; Internal medicine; Intensive care medicine; Pathology","score_opus":0.05743105036283791,"score_gpt":0.35623799653935573,"score_spread":0.2988069461765178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009056944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9627347,0.03145146,0.000029247965,0.0040596942,0.0005851219,0.0004696518,0.000025395504,0.0000051996585,0.0006395544],"genre_scores_gemma":[0.99612945,0.0025939697,0.00003146552,0.0010826932,0.000064661675,0.000055320343,0.000011439204,0.000011089373,0.000019913325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905026,0.00006909692,0.00036302418,0.00018764338,0.0001136424,0.00021633119],"domain_scores_gemma":[0.9996054,0.00008225394,0.000107687076,0.000097427655,0.000030305122,0.00007688575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011052944,0.000111665664,0.00042619015,0.00006034915,0.000007929998,0.0000017000602,0.00009437169,0.000036214315,0.00056205783],"category_scores_gemma":[0.000011898755,0.000094744166,0.000050375616,0.00037531846,0.000028156921,0.000016659389,0.000022223643,0.0002294383,0.0000014604988],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020591975,0.0003463087,0.8710318,0.00096100196,0.00012122956,0.00012600685,0.0020810147,0.00010433121,0.008288754,0.0000035329274,0.0063785943,0.10849819],"study_design_scores_gemma":[0.033532448,0.0015567711,0.8073984,0.000758819,0.00045756917,0.000025670342,0.0034521427,0.027785487,0.0065974533,0.000016895916,0.11786127,0.0005571215],"about_ca_topic_score_codex":0.18831347,"about_ca_topic_score_gemma":0.73990774,"teacher_disagreement_score":0.5515943,"about_ca_system_score_codex":0.0005625211,"about_ca_system_score_gemma":0.0030772754,"threshold_uncertainty_score":0.81709164},"labels":[],"label_agreement":null},{"id":"W3009099064","doi":"10.1200/jco.19.03136","title":"Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1154,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Hôpital Charles-Le Moyne","funders":"","keywords":"Pemetrexed; Medicine; Pembrolizumab; Lung cancer; Internal medicine; Hazard ratio; Placebo; Oncology; Progression-free survival; Response Evaluation Criteria in Solid Tumors; Surgery; Cancer; Progressive disease; Chemotherapy; Confidence interval; Pathology; Immunotherapy; Cisplatin","score_opus":0.10207678282217356,"score_gpt":0.43287407696580105,"score_spread":0.33079729414362746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009099064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98164636,0.0033192993,0.004234041,0.00881709,0.00047073155,0.0011374989,0.00012932219,0.000023737739,0.00022190466],"genre_scores_gemma":[0.98039365,0.0023540473,0.008489456,0.007211031,0.00079653895,0.000038859704,0.00007362713,0.000044453554,0.00059834967],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956742,0.00041789643,0.002791268,0.0004176742,0.00032528807,0.00037368966],"domain_scores_gemma":[0.99307877,0.0033714164,0.002235746,0.000216568,0.00046794134,0.0006295579],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014861389,0.00029275595,0.0028943024,0.0002370935,0.00007703072,0.000030093734,0.00022414366,0.0003624385,0.001233588],"category_scores_gemma":[0.001549557,0.00019329318,0.00097598566,0.0007523168,0.00017744029,0.00009568721,0.000055255183,0.00072622194,0.0000035606645],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7553523,0.0017394259,0.053486,0.0004940199,0.035242718,0.0016240121,0.00251663,0.000986931,0.0042379107,0.0000024682702,0.03290837,0.1114092],"study_design_scores_gemma":[0.43068293,0.067333,0.1165393,0.0005425394,0.11056574,0.00035804746,0.002472692,0.18966231,0.0025677218,0.000053256557,0.077967025,0.0012554617],"about_ca_topic_score_codex":0.00075949694,"about_ca_topic_score_gemma":0.0011467347,"teacher_disagreement_score":0.3246694,"about_ca_system_score_codex":0.00029864936,"about_ca_system_score_gemma":0.002985124,"threshold_uncertainty_score":0.99967945},"labels":[],"label_agreement":null},{"id":"W3009460121","doi":"10.1002/cam4.2940","title":"Cancer patients’ experiences with immune checkpoint modulators: A qualitative study","year":2020,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; Princess Margaret Cancer Centre; University of Toronto; University Health Network; TransAlta (Canada); St. Michael's Hospital","funders":"University of Toronto","keywords":"Cognitive reframing; Qualitative research; Feeling; Focus group; Immune checkpoint; Medicine; Quality of life (healthcare); Meaning (existential); Cancer; Psychology; Oncology; Internal medicine; Psychotherapist; Nursing; Social psychology; Immunotherapy","score_opus":0.04070784698618125,"score_gpt":0.36101278959897365,"score_spread":0.3203049426127924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009460121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97630244,0.00850073,0.000051568048,0.012950607,0.00042463947,0.0012351607,0.000015431167,0.00009512506,0.00042429255],"genre_scores_gemma":[0.99376935,0.00035978283,0.000033738215,0.0038447212,0.00071376516,0.0009593291,0.000018986053,0.00004264655,0.0002576775],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9978015,0.00009462199,0.0005566452,0.0005228934,0.0006937565,0.0003305952],"domain_scores_gemma":[0.99887425,0.000049315247,0.0002389287,0.00027389004,0.00027167788,0.00029191392],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002433989,0.00030911877,0.0007007384,0.00007905948,0.00010431349,0.000010747841,0.000162898,0.00005820478,0.0027895186],"category_scores_gemma":[0.00007484463,0.0001886232,0.00008427785,0.0007045085,0.0004476912,0.00011426341,0.00003476871,0.00023445865,0.00000675101],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00781406,0.0004664938,0.029621027,0.00016214447,0.00083304127,0.000035972767,0.94291604,0.000004357922,0.0061415276,0.000004407786,0.0027912755,0.009209684],"study_design_scores_gemma":[0.024420423,0.012695859,0.06449694,0.0010665511,0.00046512994,0.0000048363004,0.88093096,0.00009877474,0.007448993,0.000004658771,0.007884373,0.00048251223],"about_ca_topic_score_codex":0.002740676,"about_ca_topic_score_gemma":0.00012078344,"teacher_disagreement_score":0.06198506,"about_ca_system_score_codex":0.00023848123,"about_ca_system_score_gemma":0.00027743066,"threshold_uncertainty_score":0.9981221},"labels":[],"label_agreement":null},{"id":"W3009834583","doi":"10.1016/s1470-2045(20)30077-2","title":"Anti-PD-1 shows promise against advanced paediatric Hodgkin lymphoma","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Pembrolizumab; Medicine; Refractory (planetary science); Interim; Lymphoma; Clinical trial; Internal medicine; Oncology; Interim analysis; Cancer; Immunotherapy","score_opus":0.03841565935122185,"score_gpt":0.30755215407944975,"score_spread":0.26913649472822787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009834583","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012295121,0.005119967,0.000014561473,0.9604991,0.0020363424,0.0015663622,0.00016711921,0.00028913858,0.018012268],"genre_scores_gemma":[0.007402726,0.005722951,0.0005485036,0.9595336,0.022710748,0.0002531097,0.0005287001,0.00012484295,0.0031748316],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99701023,0.00045814973,0.00059539056,0.00067077344,0.00041457696,0.00085086445],"domain_scores_gemma":[0.9979372,0.00040715755,0.0004785314,0.0009871705,0.00008783874,0.000102105885],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004617094,0.00051593455,0.0017976146,0.00014297166,0.00015311208,0.000031414504,0.00070416374,0.0009574151,0.00039168017],"category_scores_gemma":[0.00013121923,0.00034110347,0.00043495628,0.00046278498,0.00036360562,0.000048132377,0.00015483281,0.0016657157,0.00024009252],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003184556,0.00007280194,0.00017541072,0.00036698283,0.00041136405,0.0021742368,0.00031574373,0.0000011134135,0.0027938108,0.0000032052462,0.8774946,0.113006175],"study_design_scores_gemma":[0.009940499,0.0010226824,0.0012936151,0.000110175446,0.00035068943,0.0002667469,0.000059235394,0.000028880826,0.00030337585,0.00006653758,0.986167,0.0003905352],"about_ca_topic_score_codex":0.000028252054,"about_ca_topic_score_gemma":0.0000138753985,"teacher_disagreement_score":0.11261564,"about_ca_system_score_codex":0.0006308115,"about_ca_system_score_gemma":0.0009908362,"threshold_uncertainty_score":0.9999041},"labels":[],"label_agreement":null},{"id":"W3010087377","doi":"10.1016/j.mayocp.2019.12.009","title":"Immune Checkpoint Inhibitor–Induced Type 1 Diabetes: An Underestimated Risk","year":2020,"lang":"en","type":"letter","venue":"Mayo Clinic Proceedings","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University","keywords":"Medicine; Diabetes mellitus; Type 1 diabetes; Adverse effect; Immune checkpoint; Diabetic ketoacidosis; Type 2 diabetes; Immune system; Internal medicine; Clinical trial; Insulin; Oncology; Immunology; Immunotherapy; Endocrinology","score_opus":0.054600740631088135,"score_gpt":0.316299650619084,"score_spread":0.26169890998799583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010087377","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37950817,0.0017893396,0.0000023239677,0.6086286,0.0027943135,0.0017237571,0.00009286935,0.0010549125,0.0044057206],"genre_scores_gemma":[0.09401226,0.001398044,0.0006518498,0.8854302,0.012147232,0.00013342497,0.0011998266,0.0004912887,0.0045358725],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958128,0.000045118308,0.0013963868,0.0011904355,0.0007078407,0.00084742403],"domain_scores_gemma":[0.9976641,0.00012655188,0.0010042591,0.00050703017,0.00044311213,0.00025492368],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0006587476,0.0007769464,0.0014192385,0.00026149416,0.0001988315,0.00016933179,0.000497823,0.0015082663,0.0012673286],"category_scores_gemma":[0.00072241644,0.0006875579,0.0005742706,0.0007907569,0.00023897462,0.00021587498,0.00015579809,0.0041688774,0.0006067442],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016012922,0.00014204218,0.0013400934,0.001201113,0.00086250727,0.0001418127,0.0004447724,1.8585297e-8,0.03571294,7.2830125e-7,0.95396596,0.0045867166],"study_design_scores_gemma":[0.0056869844,0.0055992636,0.0052268584,0.002010385,0.0013590892,0.000058196125,0.00028784928,0.0002540681,0.0154884,0.00029673212,0.9623588,0.0013733925],"about_ca_topic_score_codex":0.0001381255,"about_ca_topic_score_gemma":0.0000025791487,"teacher_disagreement_score":0.2854959,"about_ca_system_score_codex":0.00033288705,"about_ca_system_score_gemma":0.00048626112,"threshold_uncertainty_score":0.999788},"labels":[],"label_agreement":null},{"id":"W3010122169","doi":"10.1002/path.5406","title":"The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice","year":2020,"lang":"en","type":"review","venue":"The Journal of Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Ontario Institute for Cancer Research; BC Cancer Agency","funders":"Chugai Pharmaceutical; Genentech; National Breast Cancer Foundation; Puma Biotechnology; Novartis Pharma; EMD Serono; Mersana Therapeutics; Incyte; Taiho Pharmaceutical; Genomic Health; Daiichi Sankyo Europe; Breast Cancer Research Foundation; World Health Organization; GlaxoSmithKline; Celgene; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Oncology; Breast cancer; Biomarker; Clinical Practice; Internal medicine; Clinical trial; Clinical Oncology; Cancer; Medical physics; Family medicine","score_opus":0.0819935595309814,"score_gpt":0.5147935023912429,"score_spread":0.43279994286026147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010122169","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025766,0.9746967,0.00287351,0.015845539,0.00039580592,0.0033943006,0.00019667194,0.000002643368,0.000018240871],"genre_scores_gemma":[0.0017249266,0.9947752,0.0021114254,0.00092932006,0.00021403658,0.00021238269,0.0000060578136,0.000024297306,0.0000023954306],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932518,0.003548064,0.002559437,0.00021732326,0.00022269484,0.00020068126],"domain_scores_gemma":[0.9820473,0.012746999,0.004591352,0.00036073377,0.00019034804,0.00006324188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01914884,0.00022806296,0.0017959275,0.00016519177,0.00010040204,0.000014749506,0.00031396994,0.00026052343,0.000015633148],"category_scores_gemma":[0.0010290049,0.00010251163,0.00041532057,0.0003600906,0.00038449184,0.00004474751,0.00011418878,0.00047462643,5.500968e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012356193,0.00007393009,0.00026848004,0.00089810044,0.0029394156,0.000021081929,0.00081650884,8.0494985e-8,0.00010572655,0.00007003819,0.0006814795,0.98176897],"study_design_scores_gemma":[0.0050568567,0.0018748001,0.014871454,0.0026430544,0.01187738,0.0023432074,0.00537571,0.000008740064,0.000009363131,0.00059809606,0.9551837,0.00015763687],"about_ca_topic_score_codex":0.00022278992,"about_ca_topic_score_gemma":0.00006325802,"teacher_disagreement_score":0.9816113,"about_ca_system_score_codex":0.00011910726,"about_ca_system_score_gemma":0.00035155754,"threshold_uncertainty_score":0.6636644},"labels":[],"label_agreement":null},{"id":"W3010538789","doi":"10.3389/fimmu.2020.00369","title":"Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer","year":2020,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":561,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"Northern Ontario Academic Medicine Association","keywords":"Microsatellite instability; Nivolumab; Pembrolizumab; DNA mismatch repair; Immune checkpoint; Immunotherapy; Immune system; Colorectal cancer; Blockade; Medicine; Cancer research; Tumor-infiltrating lymphocytes; Immunology; Cancer; Biology; Internal medicine; Genetics; Microsatellite; Receptor; Gene","score_opus":0.03181026570287831,"score_gpt":0.3119574145819649,"score_spread":0.2801471488790866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010538789","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02206605,0.9742186,0.000060114096,0.00072286476,0.0009523573,0.0017393797,0.000107794316,0.0000525868,0.000080248064],"genre_scores_gemma":[0.0018327686,0.99501336,0.0018900407,0.00008718809,0.0001594811,0.0005243651,0.00012532479,0.000104778526,0.00026269234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99658287,0.0008175035,0.001178224,0.0007132055,0.0001642842,0.0005438914],"domain_scores_gemma":[0.9988168,0.0003456384,0.0003039718,0.00039503715,0.000037369762,0.000101199985],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053706294,0.000546066,0.002798519,0.0012006158,0.000091558315,0.00002915461,0.00033157138,0.0008745168,0.0000735705],"category_scores_gemma":[0.00019447894,0.0004942366,0.00028697262,0.0012353642,0.00021427227,0.00005698945,0.00011219824,0.00136519,0.000018763985],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037419654,0.000051405907,0.06873072,0.0010403115,0.0010908871,0.000112708425,0.00075202127,3.7265394e-7,0.00012233088,0.000005662648,0.0007979323,0.9235537],"study_design_scores_gemma":[0.0022523259,0.0004740671,0.1860443,0.004231532,0.00028160712,0.000095528325,0.00016918984,0.0000027559538,0.000020333076,0.000033589193,0.8059603,0.00043443625],"about_ca_topic_score_codex":0.00056389376,"about_ca_topic_score_gemma":0.00022845918,"teacher_disagreement_score":0.92311925,"about_ca_system_score_codex":0.0007386369,"about_ca_system_score_gemma":0.0008160755,"threshold_uncertainty_score":0.9997509},"labels":[],"label_agreement":null},{"id":"W3010582098","doi":"10.1007/s00262-020-02543-6","title":"Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies","year":2020,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Emberi Eroforrások Minisztériuma","keywords":"Adverse effect; Medicine; Immune system; Immunotherapy; Malignancy; Oncology; Cancer; Internal medicine; Immune checkpoint; Odds ratio; Disease; Immunology","score_opus":0.014139684498317888,"score_gpt":0.25937998291350695,"score_spread":0.24524029841518905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010582098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9496129,0.033722013,0.00005511853,0.0145272985,0.00046394466,0.0010874092,0.000100612655,0.00026771656,0.00016299204],"genre_scores_gemma":[0.9894039,0.007995508,0.00016570189,0.0008526374,0.0004021804,0.0002581747,0.00020402839,0.00011507356,0.00060278334],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9965697,0.00025163012,0.0013634348,0.00069032394,0.00045864726,0.0006662801],"domain_scores_gemma":[0.9981632,0.0001491265,0.0009025066,0.00040224465,0.00025411774,0.00012875503],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005239286,0.00052904966,0.00094406476,0.00022750565,0.00039852157,0.000030705294,0.00021451217,0.0003936942,0.0011973607],"category_scores_gemma":[0.00008887685,0.0005088908,0.00045575175,0.0005653583,0.00031383763,0.00033449032,0.00007917511,0.00074690714,0.000066164284],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052073337,0.000071326285,0.029936695,0.000104191764,0.0044235694,0.00003969423,0.0049437564,0.000017627577,0.94420063,0.000037747355,0.000025070716,0.01099235],"study_design_scores_gemma":[0.018257761,0.000801766,0.772495,0.00035769225,0.00028668743,0.000088582696,0.0013471487,0.000048986447,0.20119339,0.0002164736,0.004258387,0.00064816925],"about_ca_topic_score_codex":0.00047238395,"about_ca_topic_score_gemma":0.0000034348172,"teacher_disagreement_score":0.74300724,"about_ca_system_score_codex":0.0009122028,"about_ca_system_score_gemma":0.00032968982,"threshold_uncertainty_score":0.99973625},"labels":[],"label_agreement":null},{"id":"W3010740851","doi":"10.1177/1758835920909091","title":"Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Mount Sinai Hospital; Dr. H. Bliss Murphy Cancer Centre; BC Cancer Agency","funders":"","keywords":"Atezolizumab; Medicine; Metastatic breast cancer; Pembrolizumab; Oncology; Internal medicine; Hazard ratio; Triple-negative breast cancer; Breast cancer; Population; Chemotherapy; Placebo; Progression-free survival; Clinical trial; Cancer; Immunotherapy; Confidence interval; Pathology","score_opus":0.026929382798199477,"score_gpt":0.4086304143515668,"score_spread":0.3817010315533673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010740851","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010003255,0.9958026,0.000020172683,0.0012542744,0.0005337702,0.0020046167,0.00007969148,0.000020624468,0.00018422588],"genre_scores_gemma":[0.002564153,0.9960965,0.00025277297,0.00020247957,0.00020516143,0.0005865021,0.00003246878,0.00005254876,0.000007436124],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99562716,0.00074389146,0.0019742178,0.0005993851,0.00058390433,0.00047145432],"domain_scores_gemma":[0.9975925,0.0009225386,0.0009650858,0.00021490987,0.00009021763,0.00021476079],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010462955,0.00051520823,0.0036081194,0.00037849526,0.000031050724,0.00000682104,0.00026602007,0.00037538176,0.00038920037],"category_scores_gemma":[0.00021016612,0.00036886777,0.00039262619,0.00093983446,0.0012128715,0.00013226492,0.0001303531,0.0014196484,0.000002683095],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015037603,0.0005208394,0.0002053587,0.0065171015,0.00045096435,0.00014512993,0.0010738518,1.3169404e-7,0.000009561583,0.000039232455,0.0000033360607,0.98953074],"study_design_scores_gemma":[0.008233334,0.0015488622,0.001305107,0.06308019,0.0012730013,0.00061813724,0.0009503334,0.00015776312,0.000040916013,0.00068055885,0.9215772,0.0005345956],"about_ca_topic_score_codex":0.00017213894,"about_ca_topic_score_gemma":0.00021066981,"teacher_disagreement_score":0.98899615,"about_ca_system_score_codex":0.0010301492,"about_ca_system_score_gemma":0.0024281747,"threshold_uncertainty_score":0.9998763},"labels":[],"label_agreement":null},{"id":"W3010808413","doi":"10.1080/2162402x.2020.1736792","title":"LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures","year":2020,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Université de Lausanne; Krebsliga Schweiz; Ludwig Institute for Cancer Research; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Cancer Research Institute","keywords":"Tumor microenvironment; Blockade; Melanoma; Cancer research; Cytotoxic T cell; Immunotherapy; Cancer immunotherapy; CD8; Immune checkpoint; T cell; Cytokine; Immunology; Antibody; Blocking antibody; Medicine; Immune system; Receptor; Biology; Internal medicine; In vitro","score_opus":0.016431249213954606,"score_gpt":0.293452555546814,"score_spread":0.2770213063328594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010808413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98280615,0.0084370095,0.000007911865,0.005512256,0.000117032905,0.00056470797,0.00002440307,0.00013680487,0.0023937027],"genre_scores_gemma":[0.9967556,0.00060598174,0.00016679714,0.0016560949,0.00008016395,0.000040182156,0.00009296897,0.00003415314,0.0005680816],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982839,0.00021726511,0.00051706604,0.00045079528,0.00014077364,0.00039018894],"domain_scores_gemma":[0.9993387,0.000066855486,0.00018688284,0.00028265477,0.000050179733,0.00007476896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027466682,0.0002617342,0.00061988115,0.00017957194,0.00015359763,0.000027127357,0.000115826995,0.00025670658,0.00024941168],"category_scores_gemma":[0.00007871555,0.00022844858,0.00010665575,0.00028343158,0.00041681,0.00009807944,0.00007564952,0.00045273852,0.00003920894],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040715057,0.00021519803,0.0062037935,0.000120431236,0.00008843453,0.000557084,0.0021292958,4.4959384e-7,0.98248374,0.00009009677,0.0006681571,0.003371808],"study_design_scores_gemma":[0.012220708,0.0044736844,0.4573191,0.00024031491,0.000094723386,0.0009027499,0.0012332029,0.000028552868,0.4664209,0.00010638481,0.056475684,0.00048401693],"about_ca_topic_score_codex":0.00037214014,"about_ca_topic_score_gemma":0.000051576848,"teacher_disagreement_score":0.51606286,"about_ca_system_score_codex":0.00012120209,"about_ca_system_score_gemma":0.00013849868,"threshold_uncertainty_score":0.93158627},"labels":[],"label_agreement":null},{"id":"W3010980640","doi":"10.1016/j.cllc.2020.03.006","title":"Immune-related Encephalitis in Two Patients Treated With Immune Checkpoint Inhibitor","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; AstraZeneca France; Roche; Pfizer","keywords":"Medicine; Immune system; Atezolizumab; Immunosuppression; Lung cancer; Immune checkpoint; Ipilimumab; Immunotherapy; Cancer; Nivolumab; Immunology; Cetuximab; Oncology; Cancer research; Internal medicine; Colorectal cancer","score_opus":0.02314803481008118,"score_gpt":0.35463236200858134,"score_spread":0.3314843271985002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010980640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98901105,0.0045226132,0.0000048326565,0.0037239504,0.00041454384,0.0008712948,0.000033695036,0.000097296004,0.0013207342],"genre_scores_gemma":[0.9957467,0.0010888086,0.00006351348,0.002026738,0.0002588635,0.00009825901,0.000078392404,0.00004668801,0.00059204176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974083,0.000120659606,0.0013127816,0.0005112072,0.00028932464,0.00035773747],"domain_scores_gemma":[0.9989487,0.00011336842,0.00027430343,0.0003041683,0.00013206707,0.00022738983],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032905515,0.00024572373,0.000698603,0.000056296016,0.000046322857,0.000018291994,0.00013856859,0.00015516646,0.0011097942],"category_scores_gemma":[0.00014949335,0.000183149,0.00029346542,0.0006088099,0.0002519761,0.00009611205,0.000049484108,0.00054425065,0.00002811962],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010140348,0.0004449872,0.9587919,0.00010635057,0.00043326252,0.00007427522,0.0003729433,0.0000071799277,0.004162245,0.0000068321942,0.00081099215,0.024648681],"study_design_scores_gemma":[0.028191822,0.0016069462,0.9589177,0.0010327675,0.00020940274,0.000004838267,0.00006454805,0.0005243888,0.0046935026,0.000004590848,0.0044166674,0.00033285224],"about_ca_topic_score_codex":0.0010662253,"about_ca_topic_score_gemma":0.00010771503,"teacher_disagreement_score":0.02431583,"about_ca_system_score_codex":0.00024799208,"about_ca_system_score_gemma":0.00026910417,"threshold_uncertainty_score":0.9998033},"labels":[],"label_agreement":null},{"id":"W3010990547","doi":"10.1080/2162402x.2020.1737385","title":"Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation","year":2020,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute; Public Health Ontario; University of Toronto","funders":"Memorial Sloan-Kettering Cancer Center","keywords":"Immunohistochemistry; Osteosarcoma; Sarcoma; Undifferentiated Pleomorphic Sarcoma; PD-L1; Medicine; Immune system; Soft tissue sarcoma; Leiomyosarcoma; Cancer research; Liposarcoma; Immune checkpoint; Pathology; Internal medicine; Oncology; Immunotherapy; Immunology","score_opus":0.050693231766555026,"score_gpt":0.33524057624296144,"score_spread":0.2845473444764064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010990547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98914784,0.0012320324,0.00092871167,0.007501163,0.00013457339,0.0005910333,0.000008214192,0.00010182647,0.0003545782],"genre_scores_gemma":[0.99469817,0.00017692184,0.002145792,0.0025202406,0.00013797398,0.000031261774,0.000057088197,0.000034920566,0.00019765644],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998412,0.00018687961,0.00055860344,0.00044832192,0.00014148906,0.0002526769],"domain_scores_gemma":[0.99909836,0.00015900725,0.0001809653,0.0003315776,0.00007245624,0.00015760411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032193598,0.000214014,0.00051356026,0.00008705291,0.000116569325,0.000034185618,0.00009918449,0.00024654047,0.00009448384],"category_scores_gemma":[0.00012260271,0.00017224139,0.000044653676,0.00020926802,0.0002782293,0.0002411326,0.000076478886,0.00037009802,0.00001710153],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019490732,0.00018921356,0.18320605,0.00007458447,0.0002552488,0.00004811791,0.0025264767,0.0000020712498,0.538442,0.00020608625,0.00007842631,0.25548095],"study_design_scores_gemma":[0.0066396673,0.009026033,0.92836356,0.00010263071,0.00006758377,0.00018117842,0.0009499338,0.00007294553,0.011577232,0.000042486034,0.04268918,0.00028758563],"about_ca_topic_score_codex":0.0001449792,"about_ca_topic_score_gemma":0.000024741641,"teacher_disagreement_score":0.7451575,"about_ca_system_score_codex":0.00004627381,"about_ca_system_score_gemma":0.000091043934,"threshold_uncertainty_score":0.70238},"labels":[],"label_agreement":null},{"id":"W3011361209","doi":"10.1136/jitc-2020-000530","title":"A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Nausea; Adverse effect; Internal medicine; Response Evaluation Criteria in Solid Tumors; Pharmacokinetics; Gastroenterology; Tolerability; Antibody; Lung cancer; Oncology; Population; Monoclonal antibody; Toxicity; Phases of clinical research; Immunology","score_opus":0.021021986374473327,"score_gpt":0.3722325480268819,"score_spread":0.35121056165240855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011361209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99651235,0.0011804987,0.00007924635,0.0002930291,0.00016005889,0.0017161599,0.00003017921,0.000012233846,0.000016243483],"genre_scores_gemma":[0.99890745,0.0004869748,0.00016897732,0.00020036775,0.00008709096,0.00005249611,0.000025955322,0.000054969885,0.000015705693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978291,0.0000611723,0.0010592064,0.0002725607,0.0004787766,0.00029919585],"domain_scores_gemma":[0.99861896,0.000029928658,0.00075186073,0.00024103338,0.00025730516,0.00010092376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027730782,0.00024694548,0.0008157981,0.00027768064,0.0000936764,0.000019933477,0.00018115428,0.00007273884,0.00016712146],"category_scores_gemma":[0.0000150308615,0.00019487496,0.00015455001,0.00048935384,0.00008675415,0.0003500672,0.000010433241,0.00024602696,1.6506154e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15045102,0.008734377,0.63543177,0.00029159378,0.0007297357,0.000025420217,0.009948977,0.0021148014,0.14299528,0.0000046683385,0.000048397702,0.04922396],"study_design_scores_gemma":[0.1167454,0.032971345,0.83898777,0.00089855545,0.0000784596,0.000005784772,0.0010408476,0.0004783582,0.007815571,0.000016646638,0.0006967652,0.00026450204],"about_ca_topic_score_codex":0.00041106564,"about_ca_topic_score_gemma":0.00052232103,"teacher_disagreement_score":0.203556,"about_ca_system_score_codex":0.0001921786,"about_ca_system_score_gemma":0.00018894672,"threshold_uncertainty_score":0.794677},"labels":[],"label_agreement":null},{"id":"W3013528572","doi":"10.1093/jncics/pkaa023","title":"Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer","year":2020,"lang":"en","type":"article","venue":"JNCI Cancer Spectrum","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Sanofi; Pfizer; Institut National de la Santé et de la Recherche Médicale; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Hazard ratio; KRAS; Oncology; Stage (stratigraphy); Proportional hazards model; FOLFOX; Colorectal cancer; Confidence interval; Distributed File System; Cancer; Oxaliplatin","score_opus":0.011658097829961257,"score_gpt":0.28496738216023276,"score_spread":0.2733092843302715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013528572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747269,0.007986475,0.00014495062,0.015556324,0.00040610417,0.0006617378,0.00019531131,0.000035277662,0.00028689383],"genre_scores_gemma":[0.99616283,0.0015354475,0.000022406255,0.0017515016,0.00017464416,0.00008530994,0.000023603188,0.000017674314,0.00022655667],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99896145,0.000031367195,0.0002679372,0.00026941742,0.00024079891,0.00022905265],"domain_scores_gemma":[0.9995856,0.000015007246,0.00009601999,0.00013539186,0.000058660673,0.00010927494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011923504,0.0001404458,0.00035516702,0.00008051764,0.000031253207,0.000011614279,0.00006191857,0.00009181958,0.00029292543],"category_scores_gemma":[0.000028636361,0.00012971704,0.00006270243,0.00040407243,0.000057604208,0.00005476602,0.000032071683,0.00017492948,0.0000010869563],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016634373,0.00008444312,0.12633955,0.0001955926,0.00028251647,0.000049752773,0.001756397,0.00013080303,0.8457669,0.00041361817,0.0026868565,0.005659212],"study_design_scores_gemma":[0.0070753484,0.0011112764,0.6237207,0.00032396193,0.00009133221,0.0000052114206,0.00027060453,0.00020676409,0.35517836,0.00002667648,0.011798534,0.0001912375],"about_ca_topic_score_codex":0.0075998823,"about_ca_topic_score_gemma":0.002623671,"teacher_disagreement_score":0.49738115,"about_ca_system_score_codex":0.00033105686,"about_ca_system_score_gemma":0.00019791786,"threshold_uncertainty_score":0.9990086},"labels":[],"label_agreement":null},{"id":"W3013630572","doi":"10.1158/1538-7445.sabcs19-p4-12-07","title":"Abstract P4-12-07: Single pre-operative radiation therapy (SPORT) trial for low risk breast cancer: A phase 1 study comparing pathological findings in immediate versus delayed surgery","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Breast cancer; Pathological; Radiation therapy; Cancer; Biopsy; Oncology; Internal medicine; Breast-conserving surgery; Tumor-infiltrating lymphocytes; Surgery; Pathology; Immunotherapy; Mastectomy","score_opus":0.19918085724024265,"score_gpt":0.4565327531834848,"score_spread":0.25735189594324215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013630572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99039507,0.0021981793,0.000011766537,0.0017227618,0.00057132595,0.0047061504,0.00031188526,0.000052961044,0.000029891786],"genre_scores_gemma":[0.9922097,0.004097129,0.0000094650695,0.00018548439,0.0010630772,0.0022675025,0.00009864908,0.00004627855,0.00002275574],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970229,0.00023432708,0.0006515672,0.00068083534,0.00071280386,0.0006975617],"domain_scores_gemma":[0.99837846,0.0007098477,0.00016743828,0.00024792925,0.00023910857,0.00025719847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019775103,0.00025775694,0.00071621523,0.00024783824,0.00024341598,0.000094122,0.00019828229,0.00015633626,0.00052563817],"category_scores_gemma":[0.00022972676,0.00021075587,0.00021681824,0.0006628434,0.00018791706,0.00018167037,0.00004391115,0.0007140945,0.000007003207],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8129962,0.002214884,0.07384981,0.000065553,0.00047882955,0.00010539243,0.00540712,0.000073689895,0.025395239,9.1307345e-7,0.0016975849,0.07771479],"study_design_scores_gemma":[0.49464345,0.015546002,0.46899366,0.0002668523,0.00011863205,0.000006221231,0.00249208,0.001270631,0.013546434,0.00000808311,0.0025124715,0.00059546717],"about_ca_topic_score_codex":0.0050505074,"about_ca_topic_score_gemma":0.00096520287,"teacher_disagreement_score":0.39514384,"about_ca_system_score_codex":0.00096438115,"about_ca_system_score_gemma":0.0009698001,"threshold_uncertainty_score":0.85943747},"labels":[],"label_agreement":null},{"id":"W3013777135","doi":"10.1158/1538-7445.sabcs19-pd5-03","title":"Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Taxane; Oncology; Gemcitabine; Vinorelbine; Tumor-infiltrating lymphocytes; Capecitabine; Breast cancer; Triple-negative breast cancer; Anthracycline; Chemotherapy; Eribulin; Metastatic breast cancer; Cancer; Immunotherapy; Colorectal cancer; Cisplatin","score_opus":0.1464990798915513,"score_gpt":0.4320991207423987,"score_spread":0.2856000408508474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013777135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862524,0.001483155,0.0000064179667,0.0075079603,0.000030051026,0.004329527,0.00027592562,0.000026960905,0.00008758673],"genre_scores_gemma":[0.99750483,0.00034796534,0.00005449509,0.000529755,0.00014535885,0.0012423052,0.000017764893,0.000048213322,0.00010931845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972341,0.00037764362,0.0006639471,0.00048288231,0.00072712224,0.0005142939],"domain_scores_gemma":[0.99651706,0.002483359,0.00022207259,0.0003206503,0.00031280724,0.00014404536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014012717,0.00026093857,0.00072942354,0.0002298128,0.00022558955,0.00006790623,0.00028593457,0.00006793061,0.00016220583],"category_scores_gemma":[0.0005270293,0.00017359733,0.0001319155,0.0010514912,0.00027053137,0.00015562683,0.00003415815,0.00046301924,0.0000018231731],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014466753,0.00036388543,0.95118773,0.0006662508,0.00065480225,0.000018157754,0.018030848,0.000014775644,0.0031974772,0.0000117193595,0.000565336,0.010822268],"study_design_scores_gemma":[0.020920437,0.0014538467,0.96611714,0.00032253857,0.00014292523,0.000008540852,0.0073289825,0.00009709433,0.003243189,0.00006448593,0.00012604786,0.00017474031],"about_ca_topic_score_codex":0.008873901,"about_ca_topic_score_gemma":0.001266241,"teacher_disagreement_score":0.014929446,"about_ca_system_score_codex":0.00045938417,"about_ca_system_score_gemma":0.0007384952,"threshold_uncertainty_score":0.9977261},"labels":[],"label_agreement":null},{"id":"W3013855196","doi":"10.1158/1538-7445.sabcs19-pd5-06","title":"Abstract PD5-06: Digital spatial mapping of the immune landscape of triple negative breast cancer reveals novel features of immune-tumor cell interaction","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Triple-negative breast cancer; Breast cancer; Immune system; Tumor-infiltrating lymphocytes; CD8; Stroma; Stromal cell; Medicine; Tumor microenvironment; Cancer research; T cell; Oncology; Pathology; Biology; Cancer; Internal medicine; Immunohistochemistry; Immunology","score_opus":0.04873867938235124,"score_gpt":0.34768320448471385,"score_spread":0.2989445251023626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013855196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98804855,0.0049228515,0.000017110246,0.0031922294,0.00029548974,0.0008255296,0.00085276633,0.000011341773,0.0018341416],"genre_scores_gemma":[0.9983656,0.0005874131,0.000017836985,0.000078847275,0.0002382389,0.00005951112,0.00001793145,0.000027475142,0.0006071665],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99804556,0.0000631401,0.0006294694,0.00026088522,0.0007027188,0.000298222],"domain_scores_gemma":[0.998387,0.0001703576,0.00044487015,0.00033462304,0.0005826889,0.000080497375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041246557,0.00015523308,0.0004861541,0.00014561122,0.000074518946,0.000022188417,0.0003162581,0.000078475176,0.00069480203],"category_scores_gemma":[0.00014741026,0.00010809476,0.00027546487,0.0007891966,0.0003447633,0.00014977173,0.00013315314,0.0005502519,0.0000023117477],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007153872,0.00018593651,0.008378693,0.00093216123,0.00026017096,0.0000026638331,0.002008131,0.000018779598,0.9678398,0.000004756337,0.0020003729,0.011214708],"study_design_scores_gemma":[0.0031017573,0.00019010002,0.4371948,0.0011073782,0.000027228307,0.000008608153,0.0019484619,0.000034156583,0.55547416,0.000007093642,0.0008150978,0.00009117614],"about_ca_topic_score_codex":0.00986733,"about_ca_topic_score_gemma":0.00013435783,"teacher_disagreement_score":0.42881608,"about_ca_system_score_codex":0.00018005796,"about_ca_system_score_gemma":0.0006318932,"threshold_uncertainty_score":0.99672604},"labels":[],"label_agreement":null},{"id":"W3014225460","doi":"10.21037/cco.2020.03.03","title":"Prediction of Immune checkpoint inhibitors benefit from routinely measurable peripheral blood parameters","year":2020,"lang":"en","type":"review","venue":"Chinese Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Sault Area Hospital; Essar Steel Algoma (Canada)","funders":"","keywords":"Medicine; Peripheral blood; Immunotherapy; Immune system; Peripheral; Monoclonal antibody; Biomarker; Cancer immunotherapy; Cancer; Antibody; Oncology; Immunology; Internal medicine","score_opus":0.12781762200122435,"score_gpt":0.4020735567026682,"score_spread":0.2742559347014438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014225460","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017731696,0.97554815,0.000011002211,0.00068775984,0.0033163296,0.001358576,0.00036177287,0.000111985595,0.00087272475],"genre_scores_gemma":[0.0019927653,0.9937533,0.0008707238,0.00034727328,0.0017708179,0.0001221337,0.00078314537,0.000106558175,0.00025324305],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926812,0.00049798976,0.0051068086,0.0009255293,0.0003982956,0.00039018103],"domain_scores_gemma":[0.99503726,0.0014314948,0.00223426,0.000769883,0.00017580623,0.0003513269],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00143779,0.0006916164,0.0066598896,0.00014026562,0.000062260406,0.00001555386,0.0003858663,0.0016461278,0.00042651827],"category_scores_gemma":[0.0017608611,0.0004694553,0.00391109,0.00062546076,0.000510826,0.000068861285,0.0001651135,0.0016462468,0.000040647457],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025289517,0.0012780019,0.0018395649,0.0031463546,0.0041898023,0.00013870257,0.00010089337,6.956003e-7,0.00012687377,0.0000026903433,0.00048504112,0.9861624],"study_design_scores_gemma":[0.0078058993,0.0054862485,0.005620935,0.0069791614,0.005806009,0.00015867743,0.000022337714,0.000033663484,0.000023555813,0.000086428896,0.9675841,0.000392988],"about_ca_topic_score_codex":0.00047852128,"about_ca_topic_score_gemma":0.00003781185,"teacher_disagreement_score":0.98576945,"about_ca_system_score_codex":0.0004045777,"about_ca_system_score_gemma":0.0015559435,"threshold_uncertainty_score":0.9997757},"labels":[],"label_agreement":null},{"id":"W3014484249","doi":"10.1007/s00262-020-02555-2","title":"The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade","year":2020,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Institute of Infection and Immunity; Alberta Cancer Foundation","keywords":"CTLA-4; Immune system; Immune checkpoint; Prednisone; T cell; Dexamethasone; Immunotherapy; Medicine; Jurkat cells; Peripheral blood mononuclear cell; Immunology; Blocking antibody; Internal medicine; Cancer research; Endocrinology; Antibody; Biology; In vitro","score_opus":0.014411720080116605,"score_gpt":0.25882429723489464,"score_spread":0.24441257715477804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014484249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87922335,0.10105776,0.00041856678,0.01731909,0.000532649,0.0012819376,0.000018991275,0.00010974763,0.00003790263],"genre_scores_gemma":[0.9518924,0.04486693,0.00020089718,0.0021437912,0.00011256254,0.00026018266,0.000010976924,0.000098252014,0.0004140532],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99680847,0.00039742587,0.00096627336,0.0008001629,0.00026766455,0.0007600039],"domain_scores_gemma":[0.9984398,0.00027959803,0.0002936288,0.0006938165,0.00011940359,0.0001737924],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00075080665,0.000520045,0.0008984008,0.00022867385,0.00037471473,0.0001180467,0.00030030185,0.00033455782,0.00016777388],"category_scores_gemma":[0.00010652499,0.0004087683,0.00018270181,0.00069159013,0.00064061856,0.00014846248,0.00015980417,0.00064167613,0.000012376466],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053180315,0.00014156803,0.008151631,0.00005304258,0.0006187903,0.000022353948,0.002185226,0.000017279226,0.8783429,0.000008265639,0.00004033971,0.057238244],"study_design_scores_gemma":[0.016262341,0.0021794776,0.7234542,0.00017918805,0.00012108311,0.00007190988,0.00053488585,0.00026715387,0.2394791,0.00004453241,0.016919192,0.00048695374],"about_ca_topic_score_codex":0.00056098326,"about_ca_topic_score_gemma":0.00004032962,"teacher_disagreement_score":0.7153026,"about_ca_system_score_codex":0.00022741956,"about_ca_system_score_gemma":0.00028163096,"threshold_uncertainty_score":0.99983644},"labels":[],"label_agreement":null},{"id":"W3014636761","doi":"10.1158/1940-6207.capr-19-0528","title":"Cancer Immunoprevention: A Case Report Raising the Possibility of “Immuno-interception”","year":2020,"lang":"en","type":"article","venue":"Cancer Prevention Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Cancer; Lynch syndrome; Pembrolizumab; Immune checkpoint; Bladder cancer; Immunotherapy; Blockade; Oncology; Internal medicine; DNA mismatch repair; Colorectal cancer","score_opus":0.20063169781763301,"score_gpt":0.48897991124092693,"score_spread":0.2883482134232939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014636761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97221094,0.011146738,0.0008772314,0.012799577,0.00035847115,0.0013830349,0.000032951088,0.000049133625,0.0011419003],"genre_scores_gemma":[0.991977,0.0014283028,0.00009225757,0.00028969624,0.00036409954,0.00034775192,0.000022116694,0.000026373556,0.0054524275],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99721295,0.0004988324,0.00073531666,0.00045006315,0.0007476148,0.00035524135],"domain_scores_gemma":[0.99809,0.0001060278,0.00024529645,0.0006418847,0.0007900603,0.00012667324],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024882483,0.00015145457,0.00032682295,0.000104852006,0.00032846967,0.000049729962,0.0002224338,0.000107149644,0.0057115406],"category_scores_gemma":[0.00022968477,0.00011047367,0.0003769737,0.0009501287,0.00047704388,0.00015133004,0.00013837262,0.00057271204,0.000014974937],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012519894,0.0008267374,0.027504848,0.001961837,0.0020761495,0.005105324,0.0082449205,0.00004137544,0.3494277,0.00013733265,0.022947704,0.5692062],"study_design_scores_gemma":[0.02974976,0.006109194,0.46548304,0.009242308,0.0014870886,0.034071904,0.01906083,0.0022358482,0.19256029,0.0033240693,0.23483978,0.0018358973],"about_ca_topic_score_codex":0.0034851742,"about_ca_topic_score_gemma":0.00035793177,"teacher_disagreement_score":0.56737024,"about_ca_system_score_codex":0.0003748608,"about_ca_system_score_gemma":0.00085718615,"threshold_uncertainty_score":0.99519736},"labels":[],"label_agreement":null},{"id":"W3015097837","doi":"10.1136/jitc-2019-000371","title":"Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Adverse effect; Internal medicine; Incidence (geometry); Cumulative incidence; Renal cell carcinoma; Cancer; Cohort; Oncology","score_opus":0.014567779285653172,"score_gpt":0.2799380632421677,"score_spread":0.2653702839565145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015097837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858917,0.009072083,0.00026299452,0.0032253324,0.00013485651,0.0011287295,0.00024161425,0.000017751945,0.00002492678],"genre_scores_gemma":[0.99513733,0.0024489101,0.0005173732,0.0012504583,0.00018802895,0.00016811215,0.00004530234,0.00007725312,0.00016721616],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99796784,0.0000766358,0.0008829102,0.00028684502,0.00043471926,0.00035104807],"domain_scores_gemma":[0.9986021,0.00006583827,0.0006751286,0.00015034234,0.00036975057,0.0001368708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003524236,0.00033154635,0.0007893421,0.00017408267,0.00014104781,0.000042586948,0.00011852633,0.00007670338,0.0006051922],"category_scores_gemma":[0.000019045046,0.00021877361,0.00022024344,0.00037814357,0.00027690068,0.00023807636,0.000012582848,0.00034867012,4.391474e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22564061,0.0007690844,0.14122862,0.00036369008,0.004421304,0.000030144141,0.0017347628,0.00037356175,0.5900525,0.000021023418,0.00043961304,0.03492511],"study_design_scores_gemma":[0.07493095,0.008223968,0.6730513,0.0013978268,0.00038680623,0.00003845761,0.00023013141,0.00014646088,0.23395441,0.000059256465,0.0070634154,0.00051699305],"about_ca_topic_score_codex":0.0005347729,"about_ca_topic_score_gemma":0.00009728699,"teacher_disagreement_score":0.5318227,"about_ca_system_score_codex":0.0002326182,"about_ca_system_score_gemma":0.00050093466,"threshold_uncertainty_score":0.8921329},"labels":[],"label_agreement":null},{"id":"W3015154527","doi":"10.1038/s41571-020-0352-8","title":"Moving towards personalized treatments of immune-related adverse events","year":2020,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":345,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University","funders":"","keywords":"Adverse effect; Immune system; Medicine; Intensive care medicine; Cancer; Personalized medicine; Bioinformatics; Immunotherapy; Immunology; Internal medicine; Biology","score_opus":0.1277862675738988,"score_gpt":0.5063780017279471,"score_spread":0.37859173415404834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015154527","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013662999,0.98982006,0.0000029141704,0.00060782285,0.0021203286,0.004050903,0.000074758354,0.00005368711,0.0032558725],"genre_scores_gemma":[0.000007732358,0.99412614,0.0011308298,0.0012213378,0.0004759339,0.00020214864,0.0004169897,0.00009402026,0.0023248417],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9894231,0.0022805277,0.00649325,0.00094656856,0.00043134223,0.00042523732],"domain_scores_gemma":[0.9933542,0.0010168089,0.0043068123,0.0008286277,0.00014982586,0.00034371542],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0032008197,0.0008095575,0.012567509,0.00018842428,0.00005283257,0.0000024536287,0.00051206455,0.004354885,0.0011247533],"category_scores_gemma":[0.002901999,0.0005103045,0.008982067,0.000888634,0.00036062,0.00004906243,0.00016928292,0.0038294536,0.00028036043],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009626293,0.000711358,0.000035125937,0.015452555,0.003809897,0.00017383705,0.000034630375,3.7732932e-9,0.0000021625788,0.000025434265,0.0017862421,0.97700614],"study_design_scores_gemma":[0.005895717,0.0022862402,0.00019183102,0.031037489,0.010753207,0.00023718794,0.000007996827,0.000001060509,4.7577717e-7,0.000010517464,0.94923663,0.00034162082],"about_ca_topic_score_codex":0.000018738709,"about_ca_topic_score_gemma":0.0000028642767,"teacher_disagreement_score":0.9766645,"about_ca_system_score_codex":0.0008499513,"about_ca_system_score_gemma":0.0029632873,"threshold_uncertainty_score":0.99978834},"labels":[],"label_agreement":null},{"id":"W3016210953","doi":"10.1001/jamaoncol.2020.0237","title":"Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":628,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; AstraZeneca","keywords":"Durvalumab; Tremelimumab; Medicine; Internal medicine; Oncology; Lung cancer; Chemotherapy; Cancer; Immunotherapy; Nivolumab; Ipilimumab","score_opus":0.03414082962539107,"score_gpt":0.3314500925352575,"score_spread":0.2973092629098664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016210953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744195,0.0021061804,0.00040029088,0.020396817,0.000101444,0.0015022506,0.00006585765,0.00003492863,0.00097276137],"genre_scores_gemma":[0.9860825,0.0052388464,0.0032426298,0.004136979,0.000179675,0.00024665205,0.000021405163,0.00005449259,0.0007968526],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99853706,0.00007907631,0.00049393356,0.00036255503,0.00021070022,0.00031664516],"domain_scores_gemma":[0.99915165,0.00012792899,0.00024705232,0.00023546252,0.00010379839,0.0001341108],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015070083,0.00026319677,0.0010567284,0.00010545621,0.0000345368,0.000009013141,0.00009870582,0.00012741814,0.0010418498],"category_scores_gemma":[0.000016007249,0.00016589886,0.00012829788,0.00039770504,0.00012728486,0.00004628982,0.000012839403,0.00013786671,0.0000030765425],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5245523,0.0030307143,0.14861462,0.0013998372,0.0018760574,0.0008613258,0.021279743,0.00027869176,0.019946782,0.000004544504,0.0030059603,0.27514946],"study_design_scores_gemma":[0.32727534,0.1354826,0.053165708,0.0008410638,0.001802518,0.00019056712,0.0026115389,0.0104360655,0.09792966,0.00000934141,0.36939946,0.0008561562],"about_ca_topic_score_codex":0.0014528974,"about_ca_topic_score_gemma":0.007146713,"teacher_disagreement_score":0.3663935,"about_ca_system_score_codex":0.0009495113,"about_ca_system_score_gemma":0.0012695658,"threshold_uncertainty_score":0.9998713},"labels":[],"label_agreement":null},{"id":"W3016280944","doi":"10.3747/co.27.5223","title":"A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future","year":2020,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":953,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Immunotherapy; Cancer immunotherapy; Cancer; Radiation therapy; Standard of care; Personalized medicine; Oncology; Intensive care medicine; Internal medicine; Bioinformatics","score_opus":0.1219660166743838,"score_gpt":0.4657855366725746,"score_spread":0.3438195199981908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016280944","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000001813477,0.8403251,0.000017590413,0.1497057,0.0044688866,0.0049188696,0.0003960574,0.000030619307,0.00013533786],"genre_scores_gemma":[4.348333e-7,0.9671548,0.00002078054,0.021556608,0.008954993,0.0019804067,0.00010982528,0.000075164004,0.00014700378],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99698025,0.00083431107,0.000969931,0.0004995335,0.00036571454,0.00035028544],"domain_scores_gemma":[0.99721587,0.0006129166,0.00061036204,0.0012814954,0.00015519478,0.00012416866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007153426,0.00047037535,0.0021355671,0.000049417078,0.00011845734,0.000019263816,0.0012926605,0.00021147769,0.0007252053],"category_scores_gemma":[0.0000818485,0.00017617569,0.0010558531,0.00095436536,0.00014663622,0.000015823422,0.00025659674,0.00095601607,0.0000998537],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017749527,0.000052285846,0.000009267839,0.007936029,0.0005728996,0.0000019823713,0.0003201834,4.1702666e-8,7.8232074e-7,0.0000050560293,0.4044425,0.58648145],"study_design_scores_gemma":[0.00048320612,0.00034904658,0.00009118616,0.063041024,0.001759697,0.000021321397,0.00008102402,4.0676125e-7,5.2986366e-7,0.0000027434328,0.9339917,0.00017816825],"about_ca_topic_score_codex":0.00028623492,"about_ca_topic_score_gemma":0.00038423584,"teacher_disagreement_score":0.5863033,"about_ca_system_score_codex":0.0004111677,"about_ca_system_score_gemma":0.0012866774,"threshold_uncertainty_score":0.79404896},"labels":[],"label_agreement":null},{"id":"W3016541505","doi":"10.1016/j.ejca.2020.02.016","title":"A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":159,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme; European Medicines Agency","keywords":"Dosing; Pembrolizumab; Schedule; Medicine; Cancer; Oncology; Medical physics; Intensive care medicine; Computer science; Internal medicine; Immunotherapy","score_opus":0.0689261964846432,"score_gpt":0.3315198737791199,"score_spread":0.2625936772944767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016541505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97585183,0.0011625142,0.021541443,0.0009001407,0.000097927696,0.0003611823,0.0000073031415,0.0000043130003,0.00007331885],"genre_scores_gemma":[0.996668,0.000035361765,0.0020950078,0.0009258416,0.00023628137,0.0000026382597,0.0000028236936,0.000029613211,0.0000044661965],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9990267,0.00009974565,0.0002906588,0.00012338645,0.0003507466,0.00010873025],"domain_scores_gemma":[0.999231,0.000034949873,0.00026636646,0.000052783278,0.00034503834,0.00006987291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004353496,0.00009626882,0.00017527866,0.00009638058,0.000044340184,0.00002282151,0.00003421711,0.000015382451,0.000041197516],"category_scores_gemma":[0.000035199595,0.000073461364,0.000046952722,0.00014116992,0.000021345613,0.000117414624,0.0000042419333,0.0001184728,1.4649312e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02000173,0.00004593662,0.02262444,0.00005486903,0.000054505523,0.0000038172097,0.00036392198,0.9180665,0.0009043049,3.3036673e-7,0.000018620012,0.037860997],"study_design_scores_gemma":[0.018608319,0.0012215364,0.051422097,0.00095486216,0.00016710113,7.997998e-7,0.00003253664,0.92653036,0.00034844017,0.0000013080241,0.0006207013,0.00009195989],"about_ca_topic_score_codex":0.0000173755,"about_ca_topic_score_gemma":0.000004853327,"teacher_disagreement_score":0.03776904,"about_ca_system_score_codex":0.00022835689,"about_ca_system_score_gemma":0.0002359258,"threshold_uncertainty_score":0.29956675},"labels":[],"label_agreement":null},{"id":"W3016605495","doi":"10.3747/co.27.5095","title":"Cautious Optimism—The Current Role of Immunotherapy in Gastrointestinal Cancers","year":2020,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Sorafenib; Internal medicine; Colorectal cancer; Microsatellite instability; Pembrolizumab; DNA mismatch repair; Clinical trial; Cancer; Hepatocellular carcinoma","score_opus":0.10305701970322123,"score_gpt":0.43355349931344694,"score_spread":0.3304964796102257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016605495","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000034233046,0.99614704,0.000035728866,0.00030336968,0.0012480059,0.0015854193,0.00007436452,0.00003374965,0.00053811533],"genre_scores_gemma":[0.000040810064,0.9988018,0.00012809095,0.0000643355,0.00044623725,0.00031838255,0.00012126834,0.000056076144,0.000022943494],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99721813,0.00033246682,0.0012275199,0.00048742074,0.00027669934,0.00045777275],"domain_scores_gemma":[0.9982808,0.00024610522,0.0007951056,0.00046590227,0.000092777926,0.000119262215],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037885387,0.00048811274,0.0023457587,0.0002460856,0.000048122667,0.000009886322,0.00043132846,0.00015650614,0.00021039514],"category_scores_gemma":[0.000070638824,0.0003301582,0.00081040186,0.0006375546,0.0003783552,0.000026058924,0.0000842821,0.0014531527,0.000025916464],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005971848,0.00029194416,0.0000903588,0.004683558,0.00016245528,0.000028804836,0.0002229709,0.0000012183085,0.000011867428,0.00002300006,0.0015824352,0.9923042],"study_design_scores_gemma":[0.0018979154,0.0009828691,0.00006992084,0.023807537,0.00038353444,0.00049945235,0.00005798104,0.00003940604,0.0000021338087,0.000018813354,0.9720053,0.00023513348],"about_ca_topic_score_codex":0.00012888093,"about_ca_topic_score_gemma":0.000071451934,"teacher_disagreement_score":0.99206907,"about_ca_system_score_codex":0.0021023864,"about_ca_system_score_gemma":0.004347643,"threshold_uncertainty_score":0.99991506},"labels":[],"label_agreement":null},{"id":"W3016631762","doi":"10.1016/j.jtho.2020.03.029","title":"Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Health Authority; Jewish General Hospital; Dalhousie University; University of Ottawa; Ottawa Hospital; University of Manitoba; McGill University; London Health Sciences Centre; Saint John Regional Hospital; University of British Columbia; Sunnybrook Health Science Centre; McMaster University; Manitoba Health; Credit Valley Hospital; Southlake Regional Health Center; Trillium Health Centre; St. Joseph’s Healthcare Hamilton; Institut universitaire de cardiologie et de pneumologie de Québec; McGill University Health Centre; Royal University Hospital; University of Toronto; University of Calgary; Health Sciences Centre; University of Alberta; University Health Network; Health Sciences North; Queen's University; Kingston General Hospital; Centre Hospitalier de l’Université de Montréal; Saskatchewan Health Authority; Université Laval; University of Saskatchewan","funders":"EMD Serono; Pfizer Canada; Merck; Merck Canada; AstraZeneca Canada; AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Standardization; Immunohistochemistry; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.04385648591046105,"score_gpt":0.42259447846627346,"score_spread":0.3787379925558124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016631762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893776,0.001406823,0.0002569151,0.007299092,0.00023776924,0.001004731,0.000054874065,0.000008725467,0.00035346125],"genre_scores_gemma":[0.9953326,0.00036990177,0.0024267617,0.0015786466,0.00017337984,0.00003048759,0.000016513999,0.000024570241,0.000047145564],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998632,0.00009526094,0.0006695266,0.00015003837,0.00021087275,0.00024228917],"domain_scores_gemma":[0.9985435,0.000099442914,0.00051442743,0.0001190071,0.0005720043,0.00015163877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057410443,0.00014554273,0.0005240542,0.00021858029,0.000038860926,0.000011792809,0.00013140118,0.00018783486,0.00002703908],"category_scores_gemma":[0.00028963175,0.000115544986,0.0001400013,0.00031640218,0.00005683628,0.00006480103,0.000007692425,0.00026605235,5.509552e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17239007,0.0007765676,0.0113199,0.00045951674,0.0006151844,0.00027038003,0.0038973792,0.000021293159,0.49195576,0.000007662054,0.004532524,0.31375378],"study_design_scores_gemma":[0.04336703,0.028950239,0.04384318,0.0014264748,0.00033222028,0.00030568568,0.0014395956,0.00025537302,0.45414522,0.000032636715,0.42533493,0.0005674079],"about_ca_topic_score_codex":0.0006431263,"about_ca_topic_score_gemma":0.00094167504,"teacher_disagreement_score":0.4208024,"about_ca_system_score_codex":0.0011288375,"about_ca_system_score_gemma":0.004544438,"threshold_uncertainty_score":0.8061637},"labels":[],"label_agreement":null},{"id":"W3016683260","doi":"10.3747/co.27.5549","title":"Biomarkers of Immune Checkpoint Inhibitor Efficacy in Cancer","year":2020,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Manitoba Beekeepers' Association; CancerCare Manitoba; University of Calgary","funders":"","keywords":"Medicine; Cancer; Immune checkpoint; Immune system; Computational biology; Cancer research; Bioinformatics; Oncology; Internal medicine; Immunology; Immunotherapy; Biology","score_opus":0.17843004294304282,"score_gpt":0.47084652868209265,"score_spread":0.2924164857390498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016683260","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029108988,0.994091,0.0000019194906,0.0004264939,0.0029806101,0.0015958779,0.00007633037,0.000033116386,0.0005035795],"genre_scores_gemma":[0.00007790677,0.99879825,0.00004223852,0.00003396955,0.00051687815,0.00026950092,0.0001567916,0.000056941826,0.000047523972],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996972,0.00023265216,0.0017148376,0.00050682295,0.00021657611,0.00035711308],"domain_scores_gemma":[0.99835855,0.00020548706,0.0008635142,0.00036959947,0.00006971309,0.00013313282],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004040705,0.00043854094,0.0032780601,0.00040730427,0.000020050626,0.000005079741,0.00024326557,0.00047376088,0.0004616493],"category_scores_gemma":[0.00013603557,0.0003435646,0.0011453693,0.00088900677,0.00025878072,0.00002581652,0.00011709665,0.0007558521,0.000034481774],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076710683,0.00090950745,0.000054894997,0.021966727,0.0006134126,0.0000514545,0.00014776809,2.9675784e-8,0.00011166688,0.0000040766804,0.0014148746,0.9739585],"study_design_scores_gemma":[0.003814619,0.0006518676,0.0003341058,0.028732445,0.0009382881,0.000055923774,0.000026567484,0.0000023792645,0.00006477179,0.0000014554089,0.96511203,0.0002655478],"about_ca_topic_score_codex":0.00012795074,"about_ca_topic_score_gemma":0.000038429193,"teacher_disagreement_score":0.97369295,"about_ca_system_score_codex":0.0013049232,"about_ca_system_score_gemma":0.0023715403,"threshold_uncertainty_score":0.99990165},"labels":[],"label_agreement":null},{"id":"W3016779370","doi":"10.3747/co.27.5135","title":"Use of Immuno-Oncology in Melanoma","year":2020,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ipilimumab; Medicine; Melanoma; Immunotherapy; Oncology; Clinical trial; Nivolumab; Metastatic melanoma; Internal medicine; Overall survival; Immune checkpoint; CTLA-4; Food and drug administration; Immune system; Immunology; Cancer; Cancer research; Pharmacology; T cell","score_opus":0.3165619644626238,"score_gpt":0.48523782984783154,"score_spread":0.16867586538520773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016779370","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000085018015,0.9943129,0.0000051108595,0.00023879438,0.0027884026,0.0012180543,0.00006406831,0.00002817526,0.001259499],"genre_scores_gemma":[0.000011399993,0.9988548,0.00012754917,0.0000773007,0.00032279277,0.0001660864,0.00023728979,0.000046026194,0.00015672462],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971618,0.0004623993,0.0014353347,0.00044604694,0.00015825729,0.00033617267],"domain_scores_gemma":[0.9980651,0.00055519777,0.000792126,0.00040130425,0.00007540737,0.0001108294],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031476456,0.00037934407,0.003665916,0.00039120574,0.000017748725,0.000004519473,0.00023480237,0.0006940406,0.0005054943],"category_scores_gemma":[0.00019327155,0.00030066154,0.0007757389,0.00060198974,0.00024991194,0.00004312466,0.00012846608,0.0008067917,0.00005571495],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070923386,0.00059769535,0.00011657444,0.010275048,0.00035091,0.00012246409,0.00015317845,2.0290429e-8,0.000014477598,0.000032196443,0.006319396,0.9813088],"study_design_scores_gemma":[0.0017731467,0.0019340994,0.000079007856,0.007528088,0.0008569148,0.00026287918,0.000023847004,0.0000026651762,0.0000033664382,0.0000049830114,0.9873131,0.00021788602],"about_ca_topic_score_codex":0.000052282947,"about_ca_topic_score_gemma":0.000057475154,"teacher_disagreement_score":0.9810909,"about_ca_system_score_codex":0.001374025,"about_ca_system_score_gemma":0.0027544529,"threshold_uncertainty_score":0.99994457},"labels":[],"label_agreement":null},{"id":"W3016939709","doi":"10.1038/s41523-020-0156-0","title":"Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer","year":2020,"lang":"en","type":"article","venue":"npj Breast Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":206,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of British Columbia; Spinal Cord Injury BC; National Circus School; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"National Center for Research Resources; Daiichi Sankyo Europe; National Cancer Institute; Medical Research Council; Stand Up To Cancer; National Institutes of Health; Rosetrees Trust; CRUK Lung Cancer Centre of Excellence; National Institute for Health and Care Research; University College London; Wellcome Trust; Cancer Research UK; Wallace H. Coulter Foundation; Myriad Genetics; Francis Crick Institute; Georgia Clinical and Translational Science Alliance; Susan G. Komen; Prostate Cancer Foundation; AstraZeneca; U.S. Department of Defense; Eli Lilly and Company; Case Western Reserve University; National Breast Cancer Foundation; U.S. Department of Veterans Affairs; Breast Cancer Alliance; Pfizer; Amgen; European Commission; DOD Peer Reviewed Cancer Research Program; Breast Cancer Research Foundation","keywords":"Breast cancer; Cancer; Medicine; Stromal cell; Breast tumor; Pathology; Stromal tumor; Oncology; Internal medicine","score_opus":0.019980693724880205,"score_gpt":0.30127865816730337,"score_spread":0.28129796444242317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016939709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98052835,0.00259635,0.000015137271,0.014800579,0.0003033063,0.00038203155,0.00023880674,0.00008463246,0.0010507787],"genre_scores_gemma":[0.99167573,0.00035328642,0.00019167975,0.006733452,0.00078629423,0.00014559503,0.000014204727,0.000056524095,0.000043237425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978503,0.00007005092,0.0005677193,0.0005329175,0.00039198334,0.0005870298],"domain_scores_gemma":[0.99925524,0.00005330696,0.000177571,0.00020845809,0.000092491304,0.0002129333],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020048936,0.0003163875,0.00054736,0.00015947691,0.00006439595,0.00008641547,0.0001706511,0.000117692056,0.002001315],"category_scores_gemma":[0.000020325224,0.00029029328,0.00012522943,0.00078982225,0.00011439471,0.00037752936,0.0000513493,0.00037790416,0.000010944357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028252965,0.00013014874,0.82614374,0.00023599296,0.00008862274,0.00018645858,0.00076593,0.00019904305,0.082567595,0.000009245428,0.0006150115,0.08623292],"study_design_scores_gemma":[0.006242288,0.00005682341,0.9856553,0.0014383584,0.000044803473,0.0003442893,0.0006089952,0.0022903169,0.0020622306,0.0000052145588,0.0009021535,0.00034923598],"about_ca_topic_score_codex":0.014642091,"about_ca_topic_score_gemma":0.0017240283,"teacher_disagreement_score":0.15951155,"about_ca_system_score_codex":0.0011660904,"about_ca_system_score_gemma":0.0013017614,"threshold_uncertainty_score":0.99995494},"labels":[],"label_agreement":null},{"id":"W3017287535","doi":"10.1111/his.14115","title":"Programmed cell death‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) expression in PD‐1 inhibitor‐associated colitis and its mimics","year":2020,"lang":"en","type":"article","venue":"Histopathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Colitis; Inflammatory bowel disease; Immune system; Medicine; Immunology; Myocarditis; Immune checkpoint; Inflammation; Programmed cell death; Cancer research; Immunotherapy; Pathology; Biology; Internal medicine; Disease; Apoptosis","score_opus":0.02649742786254835,"score_gpt":0.2586442722200305,"score_spread":0.23214684435748215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017287535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870033,0.008809521,0.00002356251,0.0021032647,0.00022312072,0.0012203469,0.000027124168,0.00013168585,0.00045807174],"genre_scores_gemma":[0.9956031,0.0011175307,0.0007428025,0.0016669417,0.00013006304,0.00018281728,0.0000863424,0.00004939758,0.0004210478],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979328,0.0001799787,0.0004899254,0.0006313235,0.00020387227,0.000562115],"domain_scores_gemma":[0.99915546,0.0000796677,0.00018822397,0.00018681122,0.000089937894,0.00029990522],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032856964,0.00030393718,0.0006141898,0.00014171902,0.00012059294,0.000030078594,0.00009379929,0.0003932137,0.000027037915],"category_scores_gemma":[0.0001845639,0.00028422664,0.000082060295,0.00028652974,0.0001875063,0.00008314452,0.000097292716,0.0003784134,0.000006244347],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075518247,0.0008428489,0.17896654,0.0006827446,0.000024372699,0.0018455388,0.008264975,4.2964675e-7,0.7812819,0.000059283782,0.0019060409,0.018573537],"study_design_scores_gemma":[0.025634436,0.0048484146,0.7796431,0.0006190354,0.00027497511,0.00083191483,0.0008401419,0.000445757,0.08981261,0.00014062562,0.095903985,0.0010049902],"about_ca_topic_score_codex":0.00008758636,"about_ca_topic_score_gemma":0.00011549788,"teacher_disagreement_score":0.69146925,"about_ca_system_score_codex":0.00020743915,"about_ca_system_score_gemma":0.00013840562,"threshold_uncertainty_score":0.999961},"labels":[],"label_agreement":null},{"id":"W3017322331","doi":"10.1016/j.jtho.2020.03.028","title":"Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":607,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"Eli Lilly Japan; Incyte; Yuhan; F. Hoffmann-La Roche; Roche; Chugai Pharmaceutical; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atezolizumab; Medicine; Carboplatin; Hazard ratio; Internal medicine; Oncology; Population; Paclitaxel; Randomized controlled trial; Chemotherapy; Confidence interval; Cancer; Cisplatin; Pembrolizumab; Immunotherapy","score_opus":0.02215734906571848,"score_gpt":0.3832901829427656,"score_spread":0.36113283387704714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017322331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98541594,0.0017477251,0.00013373431,0.010729228,0.00031180785,0.0010860581,0.000015014387,0.000009334781,0.00055115693],"genre_scores_gemma":[0.99742514,0.00033272768,0.0012819837,0.0006891879,0.00018774444,0.000017553546,0.000016617001,0.000015424966,0.00003363478],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99750525,0.000536033,0.001286856,0.00021687163,0.00026050935,0.00019446797],"domain_scores_gemma":[0.9977614,0.0009589323,0.0009177062,0.000110719906,0.00011084785,0.000140358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001461796,0.00016363236,0.0013416413,0.00025557974,0.000024346,0.000014179473,0.000085826105,0.00017645446,0.000030735173],"category_scores_gemma":[0.0010003028,0.00011737384,0.00013418125,0.00033868777,0.00014679333,0.00014846286,0.00001986103,0.0005053696,6.968144e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88341546,0.0007001358,0.000074713775,0.000020415468,0.00012421816,0.0007320888,0.0036357255,0.000013303791,0.0055870917,0.000003947165,0.000107934815,0.10558497],"study_design_scores_gemma":[0.9791423,0.014890978,0.0009992055,0.00027909738,0.00019222761,0.00018001966,0.0010670583,0.0007721705,0.0009527798,0.0001237083,0.0012756214,0.00012485433],"about_ca_topic_score_codex":0.000285171,"about_ca_topic_score_gemma":0.00027432895,"teacher_disagreement_score":0.105460115,"about_ca_system_score_codex":0.00033055732,"about_ca_system_score_gemma":0.0004996843,"threshold_uncertainty_score":0.47863665},"labels":[],"label_agreement":null},{"id":"W3017346043","doi":"10.3747/co.27.5111","title":"Diagnosis, Monitoring, and Management of Adverse Events From Immune Checkpoint Inhibitor Therapy","year":2020,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Adverse effect; Intensive care medicine; Intervention (counseling); Multidisciplinary team; Adjuvant; Multidisciplinary approach; Bioinformatics; Oncology; Internal medicine; Nursing","score_opus":0.13706775065535018,"score_gpt":0.4330643565125157,"score_spread":0.2959966058571655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017346043","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019822866,0.99272007,0.0000029640107,0.00012364237,0.003261239,0.0016793162,0.000090330745,0.000033107044,0.000107061365],"genre_scores_gemma":[0.00011278028,0.9981261,0.00021305494,0.000012782209,0.0007115981,0.0005589013,0.0001736608,0.000047654263,0.000043458313],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793196,0.00015058956,0.0009644031,0.00048683077,0.00023026323,0.00023597862],"domain_scores_gemma":[0.9987218,0.000109522975,0.0006337521,0.00036233215,0.000044337557,0.00012826922],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018573216,0.0004085669,0.0020432507,0.00012353621,0.00003544262,0.0000022808392,0.00018498812,0.00028401375,0.00017995048],"category_scores_gemma":[0.000012273626,0.0003156838,0.0006397341,0.00022257898,0.00012010646,0.000030506051,0.00016048593,0.00041296764,0.000023905179],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046782274,0.0005334916,0.00090469804,0.01212238,0.0015047814,0.000052571188,0.000121371166,5.420849e-9,0.000013339355,0.0000029037446,0.0003100009,0.98396665],"study_design_scores_gemma":[0.0034457196,0.00061067706,0.0031926064,0.0286753,0.0012609006,0.000014830888,0.000064512926,2.425339e-7,0.00010695978,0.000007473958,0.9623945,0.00022631045],"about_ca_topic_score_codex":0.000036342753,"about_ca_topic_score_gemma":9.458514e-7,"teacher_disagreement_score":0.9837403,"about_ca_system_score_codex":0.00038899932,"about_ca_system_score_gemma":0.00022787935,"threshold_uncertainty_score":0.99992955},"labels":[],"label_agreement":null},{"id":"W3017409551","doi":"10.1016/j.clim.2020.108428","title":"Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab","year":2020,"lang":"en","type":"article","venue":"Clinical Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia; Ministero della Salute","keywords":"Ipilimumab; CTLA-4; Melanoma; Immune checkpoint; Immunotherapy; Biomarker; Cancer research; Immune system; Phenotype; Medicine; Immunology; T cell; Biology; Oncology; Gene; Genetics","score_opus":0.0431838913839146,"score_gpt":0.36303087581696963,"score_spread":0.31984698443305504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017409551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916726,0.0016204383,0.000016428265,0.005888335,0.000247146,0.0004651574,0.0000097858565,0.000024719411,0.000055423545],"genre_scores_gemma":[0.9967753,0.0008352118,0.00018393985,0.001942621,0.000103922524,0.000020132531,0.000018358189,0.000017844737,0.00010266361],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99724627,0.0006834338,0.0013467853,0.000410171,0.00009433175,0.00021902655],"domain_scores_gemma":[0.9988134,0.00058502314,0.00021093733,0.00021995971,0.00005823995,0.000112441514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011590963,0.0001340744,0.0007036993,0.0001368156,0.000018630302,0.000006237421,0.00013470024,0.0002634793,0.00014129079],"category_scores_gemma":[0.0017136043,0.00011811223,0.000094186646,0.00033890395,0.0001661232,0.00007416821,0.00012387059,0.00038863783,0.00003321333],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07080399,0.00037064665,0.11399981,0.000027697444,0.000042751577,0.00004182921,0.0005668218,2.461826e-7,0.7863839,0.000007691064,0.00002468225,0.027729925],"study_design_scores_gemma":[0.0069790366,0.0037210807,0.9357355,0.00024430486,0.000018193272,0.0000107228625,0.00014246149,0.0001284678,0.050048,0.000020353416,0.0028385792,0.000113250215],"about_ca_topic_score_codex":0.000017577222,"about_ca_topic_score_gemma":0.000011004772,"teacher_disagreement_score":0.82173574,"about_ca_system_score_codex":0.000030877753,"about_ca_system_score_gemma":0.00014174273,"threshold_uncertainty_score":0.48164767},"labels":[],"label_agreement":null},{"id":"W3018008580","doi":"10.1016/j.jaad.2020.04.069","title":"Machine learning for prediction of cutaneous adverse events in patients receiving anti–PD-1 immunotherapy","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Adverse effect; Scopus; Immunotherapy; Dermatology; MEDLINE; Internal medicine; Oncology; Cancer","score_opus":0.014631323788627252,"score_gpt":0.28029141604083807,"score_spread":0.2656600922522108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3018008580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904206,0.00048681855,0.00012612688,0.008564491,0.00010807375,0.00025391605,0.0000150673,0.0000051474435,0.000019760339],"genre_scores_gemma":[0.9971738,0.0010051458,0.00040015168,0.0013459664,0.000044055807,0.0000017194525,0.0000022659378,0.000016651848,0.000010267146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855435,0.00016274734,0.0008077238,0.00009544026,0.00022592935,0.00015380941],"domain_scores_gemma":[0.99797904,0.00012271934,0.0017205109,0.000062155275,0.00006787604,0.000047717604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014219974,0.000107078675,0.0006465659,0.00013980576,0.000030945786,6.24869e-7,0.00020504388,0.000068309535,0.0000122613465],"category_scores_gemma":[0.00017133473,0.00007605181,0.00026900583,0.0003150146,0.00018311954,0.00006248236,0.000027110766,0.00041304922,3.127096e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009411934,0.00013607192,0.9266632,0.00009921052,0.00031316307,0.0000041051876,0.0005425775,0.00015444252,0.053381424,0.0000021187598,0.00020215106,0.009089582],"study_design_scores_gemma":[0.0075660083,0.0015806638,0.9692518,0.00029990354,0.00011023912,0.0008505173,0.0002312396,0.00093810644,0.014914217,0.000032624095,0.004142117,0.000082527535],"about_ca_topic_score_codex":0.000018254177,"about_ca_topic_score_gemma":4.7843207e-7,"teacher_disagreement_score":0.042588618,"about_ca_system_score_codex":0.000056535537,"about_ca_system_score_gemma":0.00006195834,"threshold_uncertainty_score":0.3101303},"labels":[],"label_agreement":null},{"id":"W3018517995","doi":"10.1136/annrheumdis-2020-217139","title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":276,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Cilag; Pharmacyclics; Chugai Pharmaceutical; LEO Pharma; Regeneron Pharmaceuticals; Gilead Sciences; European League Against Rheumatism; Celgene; Biogen; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Immunotherapy; Cancer immunotherapy; Adverse effect; Cancer; Ipilimumab; Immunology; Intensive care medicine; Oncology; Internal medicine","score_opus":0.04184898885750181,"score_gpt":0.3192135867304184,"score_spread":0.27736459787291656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3018517995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9396714,0.01028695,0.000126812,0.04635802,0.00012753351,0.00327872,0.00010398791,0.000029207591,0.000017366829],"genre_scores_gemma":[0.9883037,0.0068713133,0.00031835452,0.0037286947,0.00000995585,0.0006587031,0.000004174593,0.00004609034,0.0000589768],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984333,0.00006341454,0.00068238913,0.00022632416,0.00036759351,0.00022696517],"domain_scores_gemma":[0.99868506,0.00023226124,0.00033434795,0.0004551664,0.0001392226,0.00015392147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027553132,0.0002171152,0.0005188387,0.00005805009,0.00008935483,0.000008446963,0.00023532711,0.00003309079,0.00013620246],"category_scores_gemma":[0.00013562897,0.00011772063,0.00031441438,0.00038569918,0.00014739094,0.000058755897,0.00010025907,0.000054888056,0.0000028071893],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060359225,0.0039390116,0.100597866,0.02748377,0.053677388,0.00004529924,0.03848535,0.003230158,0.006250898,0.0009196384,0.05275427,0.65225714],"study_design_scores_gemma":[0.012741424,0.0022079765,0.9101811,0.025486099,0.0018981303,0.000017786928,0.0054438175,0.00064402923,0.037023075,0.0007472089,0.002963939,0.0006453776],"about_ca_topic_score_codex":0.00033649194,"about_ca_topic_score_gemma":0.000012568609,"teacher_disagreement_score":0.80958325,"about_ca_system_score_codex":0.000025411056,"about_ca_system_score_gemma":0.000081075355,"threshold_uncertainty_score":0.4800508},"labels":[],"label_agreement":null},{"id":"W3018818368","doi":"10.3390/cancers12051076","title":"Tumor-Infiltrating CD8 T Cells Predict Clinical Breast Cancer Outcomes in Young Women","year":2020,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"","keywords":"Breast cancer; Immune system; Tumor-infiltrating lymphocytes; CD8; Young adult; Medicine; Oncology; Cancer; Transcriptome; Internal medicine; Physiology; Immunology; Biology; Gene; Gene expression","score_opus":0.02856968692251706,"score_gpt":0.3208290709741268,"score_spread":0.2922593840516097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3018818368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99204564,0.00045318078,0.00001276439,0.004021433,0.0009282868,0.00042849366,0.00012801589,0.00009251217,0.0018896903],"genre_scores_gemma":[0.9895454,0.00050844246,0.00008783539,0.008728651,0.0006106556,0.00011955861,0.0000062331374,0.000035238394,0.0003579861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821913,0.00005701317,0.00059649366,0.00040811484,0.0002672761,0.0004519896],"domain_scores_gemma":[0.9992109,0.0000722269,0.00015027304,0.00021517627,0.00004617081,0.00030525407],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003015098,0.00020578918,0.0005529231,0.000055479948,0.000047489877,0.000023355458,0.00014828079,0.00009172215,0.0010709123],"category_scores_gemma":[0.000048795253,0.00017456112,0.00017351398,0.0003516173,0.00015338071,0.0000994516,0.000031698866,0.00036914347,0.000018254937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002714847,0.000035835168,0.96726775,0.00013543965,0.00027073047,0.00007787939,0.0021639643,0.00012553361,0.010071109,0.0000035456087,0.0057451143,0.0113882255],"study_design_scores_gemma":[0.008775931,0.000575301,0.9738956,0.0003297195,0.00007346553,0.000039989776,0.0023622522,0.001747401,0.0018515704,0.0000061136166,0.009929849,0.00041282355],"about_ca_topic_score_codex":0.0020807837,"about_ca_topic_score_gemma":0.00041424215,"teacher_disagreement_score":0.010975402,"about_ca_system_score_codex":0.0017029418,"about_ca_system_score_gemma":0.0012110559,"threshold_uncertainty_score":0.9998422},"labels":[],"label_agreement":null},{"id":"W3018997952","doi":"10.1101/2020.04.25.061200","title":"Elevated expression of <i>ACE2</i> in tumor-adjacent normal tissues of cancer patients","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Azrieli Foundation; Israel Cancer Association","keywords":"Lung cancer; Immune system; Cancer; Receptor; Cancer research; Coronavirus disease 2019 (COVID-19); Messenger RNA; Cancer cell; Medicine; Lung; Internal medicine; Biology; Immunology; Gene; Disease; Genetics","score_opus":0.014002202648951478,"score_gpt":0.24773641687909448,"score_spread":0.233734214230143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3018997952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993656,0.0041015716,0.000021990354,0.00018375422,0.0006079114,0.00097576337,0.0003692425,0.00007642145,0.0000073448664],"genre_scores_gemma":[0.9975098,0.0010623293,0.00087156106,0.00021730608,0.00013370252,0.000119504184,0.0000013838192,0.000081959886,0.0000024458013],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99745697,0.000091374546,0.0009382212,0.000615591,0.00054439716,0.00035346756],"domain_scores_gemma":[0.99785113,0.000030500261,0.000781489,0.0006694227,0.0004985381,0.00016890132],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025057155,0.000408962,0.00093894,0.00025962267,0.00002706105,0.000014620508,0.00030085808,0.0003136925,0.00013961829],"category_scores_gemma":[0.000095249205,0.00039320588,0.00019046191,0.0005885676,0.00013308872,0.00007280852,0.0002840678,0.0005304284,0.000003668027],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001383757,0.000406471,0.18098217,0.0014195862,0.00012487973,0.000021675158,0.000031212734,0.000010543881,0.81528795,0.000006184587,0.00031980727,0.0000057389484],"study_design_scores_gemma":[0.0020781916,0.00017178738,0.30813643,0.0024985296,0.00008108897,2.95956e-9,0.000002395762,0.000038958355,0.6850168,2.222417e-7,0.0017333523,0.00024221725],"about_ca_topic_score_codex":0.0005756488,"about_ca_topic_score_gemma":0.000010572793,"teacher_disagreement_score":0.13027114,"about_ca_system_score_codex":0.0002952713,"about_ca_system_score_gemma":0.00070375064,"threshold_uncertainty_score":0.999852},"labels":[],"label_agreement":null},{"id":"W3019468486","doi":"10.1016/j.lungcan.2020.04.021","title":"Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; MSD Life Science Foundation, Public Interest Incorporated Foundation; Ono Pharmaceutical; Nippon Kayaku; AstraZeneca; Astellas Pharma US; Taiho Pharmaceutical; Novartis; Chugai Pharmaceutical; Pfizer","keywords":"Medicine; Ramucirumab; Docetaxel; Internal medicine; Oncology; Chemotherapy","score_opus":0.01685621219898133,"score_gpt":0.3003720634411888,"score_spread":0.28351585124220746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019468486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99323654,0.0029098622,0.000012269313,0.0016204983,0.0002817802,0.00072599686,0.00013602272,0.0000337981,0.0010432121],"genre_scores_gemma":[0.995817,0.002513022,0.000056036235,0.0009028201,0.00017095738,0.00008306689,0.000116420015,0.000021563565,0.0003191134],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988443,0.000041999792,0.00035272588,0.00030228516,0.00023883197,0.00021980338],"domain_scores_gemma":[0.9994617,0.000036621197,0.0001627045,0.00018319556,0.00007167828,0.00008409831],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000051020248,0.00017571863,0.0004274232,0.000070679365,0.000034693763,0.000009541451,0.00007487096,0.00008247255,0.0011899844],"category_scores_gemma":[0.000026850708,0.00014233288,0.00013598506,0.0003218225,0.00006691816,0.00008474516,0.000013608573,0.00009291615,0.0000072776184],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03173922,0.0032329971,0.40619227,0.0010334397,0.0018639553,0.00003985094,0.011299942,0.0001916682,0.08087416,0.000018325249,0.03836016,0.42515403],"study_design_scores_gemma":[0.017537681,0.001599563,0.87807643,0.00084344967,0.00018537836,8.053647e-7,0.00010950027,0.00039031293,0.07646223,0.0000029395521,0.024556816,0.00023487225],"about_ca_topic_score_codex":0.0006476516,"about_ca_topic_score_gemma":0.0001396413,"teacher_disagreement_score":0.4718842,"about_ca_system_score_codex":0.00038210538,"about_ca_system_score_gemma":0.00015681941,"threshold_uncertainty_score":0.9997231},"labels":[],"label_agreement":null},{"id":"W3019565062","doi":"10.1038/s41416-020-0834-6","title":"Emerging role of PTEN loss in evasion of the immune response to tumours","year":2020,"lang":"en","type":"review","venue":"British Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":202,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Conselho Nacional de Desenvolvimento Científico e Tecnológico; Ministério da Ciência, Tecnologia e Inovação; Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"PTEN; PI3K/AKT/mTOR pathway; Immune system; Immunotherapy; Biology; Cancer research; Carcinogenesis; Tumor microenvironment; Immune checkpoint; Cancer; Immunology; Signal transduction; Genetics","score_opus":0.018383244696894705,"score_gpt":0.3345164446963467,"score_spread":0.316133199999452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019565062","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012153409,0.9861499,0.000001615067,0.0007382868,0.00039651766,0.00042486758,0.000063300504,0.0000022973738,0.00006981148],"genre_scores_gemma":[0.008920431,0.9905429,0.000042176747,0.00010231602,0.00020733831,0.000011934575,0.0000014155975,0.000037011945,0.00013446948],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99751157,0.0002884481,0.0013667415,0.00014273642,0.00051620073,0.000174337],"domain_scores_gemma":[0.9981566,0.00009884115,0.0012480036,0.00019099894,0.00021890634,0.00008666823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096789317,0.00017505305,0.0016660208,0.00021395639,0.000025269792,0.000010745451,0.00035377595,0.00012541754,0.00017364102],"category_scores_gemma":[0.00024179176,0.0001355365,0.0008762681,0.0007094664,0.00008183001,0.00004916427,0.0000680603,0.00054457237,7.769998e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003449698,0.00005129073,0.000164546,0.002288188,0.00027371838,0.00021390646,0.00017886405,0.0000032101202,0.0016795113,5.34896e-7,0.0003538722,0.99134266],"study_design_scores_gemma":[0.0013493851,0.0002239223,0.009711542,0.12275064,0.00051172083,0.0017447848,0.00009788341,6.7160425e-7,0.0006253951,0.0000046248915,0.8628627,0.000116707124],"about_ca_topic_score_codex":0.0007631928,"about_ca_topic_score_gemma":0.00016554438,"teacher_disagreement_score":0.99122596,"about_ca_system_score_codex":0.00033780068,"about_ca_system_score_gemma":0.001454548,"threshold_uncertainty_score":0.5527018},"labels":[],"label_agreement":null},{"id":"W3019679892","doi":"10.1158/1078-0432.ccr-19-3925","title":"Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; Université de Montréal","funders":"Cancer Council Queensland; Amgen Australia; Melanoma Institute Australia; Omeros Corporation; Compass Therapeutics; QIMR Berghofer Medical Research Institute; Bristol-Myers Squibb; Tizona Therapeutics; National Health and Medical Research Council; Amgen","keywords":"Immunotherapy; Melanoma; Metastatic melanoma; Medicine; Cancer research; Nivolumab; Cancer; Immunology; Oncology; Internal medicine","score_opus":0.20826737304915743,"score_gpt":0.48994314227045405,"score_spread":0.2816757692212966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019679892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96237195,0.0038777553,0.000041409017,0.031138651,0.00010793678,0.0012272471,0.00006244418,0.00005524422,0.0011173855],"genre_scores_gemma":[0.98365515,0.0012028039,0.00046337122,0.012296144,0.00020878081,0.00025267553,0.000013344074,0.00006458648,0.0018431138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960319,0.00065267633,0.0008045644,0.0007406994,0.0010922668,0.00067788863],"domain_scores_gemma":[0.99778026,0.0008270161,0.00013183465,0.00048837095,0.00034862585,0.0004239127],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025718766,0.00021200461,0.0007642633,0.00017214249,0.00012446112,0.0000532943,0.00036007524,0.00010972187,0.001434624],"category_scores_gemma":[0.0009510818,0.0001553851,0.0001690386,0.0017378383,0.00034048618,0.00009255274,0.00009129603,0.0010149378,0.00006753934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16627014,0.0023979212,0.37687862,0.00062581233,0.00150605,0.0022600058,0.005406681,0.000018346489,0.18594414,0.00004910994,0.20444718,0.054196004],"study_design_scores_gemma":[0.02808632,0.0063724783,0.6943004,0.0038035365,0.00007046949,0.000009911388,0.00082994526,0.00014098639,0.051527508,0.000119393415,0.21401946,0.0007195775],"about_ca_topic_score_codex":0.0003087744,"about_ca_topic_score_gemma":0.0005066825,"teacher_disagreement_score":0.3174218,"about_ca_system_score_codex":0.00032874392,"about_ca_system_score_gemma":0.0008572536,"threshold_uncertainty_score":0.9994782},"labels":[],"label_agreement":null},{"id":"W3020899675","doi":"10.1016/j.jneuroim.2020.577259","title":"Glial fibrillary acidic protein (GFAP) associated autoimmune meningoencephalitis in a patient receiving nivolumab","year":2020,"lang":"en","type":"article","venue":"Journal of Neuroimmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Children's Hospital Colorado","keywords":"Glial fibrillary acidic protein; Nivolumab; Autoimmune encephalitis; Meningoencephalitis; Medicine; Immunology; Immunotherapy; Autoantibody; Encephalitis; Immune system; Antibody; Immunohistochemistry; Virus","score_opus":0.020779028639864618,"score_gpt":0.25228259445567747,"score_spread":0.23150356581581286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020899675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98356664,0.0037077155,0.000015904106,0.01164366,0.00044512076,0.00032367374,0.000005075708,0.000034688735,0.00025750612],"genre_scores_gemma":[0.9976794,0.0004940835,0.00019904225,0.0013836959,0.000120872246,0.000005956772,0.000004032551,0.00003165391,0.000081251994],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997748,0.00031840563,0.0010217646,0.00021626029,0.00033353386,0.00036199432],"domain_scores_gemma":[0.99874955,0.00008489892,0.0007334529,0.0001782053,0.00016346056,0.0000904169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029615388,0.00019476264,0.00068526214,0.00022317779,0.00006125858,0.000021762691,0.00019461667,0.00017967117,0.00018605583],"category_scores_gemma":[0.00076803175,0.00017600073,0.0002561101,0.00054292375,0.00017624085,0.00015982706,0.00007673649,0.00073925673,0.000008703241],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006537766,0.00019483197,0.0036076377,0.00003612775,0.00028605107,0.001955966,0.0018651475,0.0000075542425,0.9580834,0.000010402256,0.0005385826,0.026876519],"study_design_scores_gemma":[0.019743618,0.020047523,0.8896748,0.001467306,0.00015973872,0.0056656734,0.0012998168,0.0002639748,0.026769672,0.000113799804,0.034275442,0.0005186598],"about_ca_topic_score_codex":0.00011282806,"about_ca_topic_score_gemma":0.000009680694,"teacher_disagreement_score":0.93131375,"about_ca_system_score_codex":0.00025618376,"about_ca_system_score_gemma":0.00032762586,"threshold_uncertainty_score":0.71771014},"labels":[],"label_agreement":null},{"id":"W3021442601","doi":"10.1001/jamaoncol.2020.0910","title":"Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer","year":2020,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":398,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Canadian Red Cross Society; Dalhousie University; Moncton Hospital; Juravinski Cancer Centre; Ottawa Hospital; Saskatchewan Cancer Agency; St. John’s Health Sciences Centre; Université de Sherbrooke; Queen's University; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"Ipsen; Eisai; Celgene; Amgen","keywords":"Medicine; Microsatellite instability; Internal medicine; Colorectal cancer; Oncology; Cetuximab; Regorafenib; Tremelimumab; Irinotecan; Cancer; Ipilimumab; Immunotherapy","score_opus":0.005834023752853325,"score_gpt":0.27359923073120196,"score_spread":0.26776520697834866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021442601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954535,0.00048397025,0.0000026880757,0.0021177176,0.00014072697,0.0012068184,0.000053599662,0.00002195056,0.0005190678],"genre_scores_gemma":[0.9988055,0.00008197123,0.00006415942,0.00058933353,0.000046691606,0.00015907122,0.0002200053,0.000021240463,0.000012013083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883705,0.00013338038,0.00040060282,0.00024238674,0.00017387114,0.0002126759],"domain_scores_gemma":[0.9993144,0.00009583288,0.00024735864,0.00009943737,0.00016605011,0.00007689828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013597148,0.00016124094,0.00063370896,0.00007342676,0.000024097897,0.0000032970756,0.000048617356,0.00016304103,0.00017496668],"category_scores_gemma":[0.00007670848,0.00012272273,0.000092632836,0.0003072475,0.00015271096,0.000074322925,0.000032004813,0.00023503204,0.000005453295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3485377,0.00066222856,0.37223306,0.00066023954,0.00024552902,0.00010662332,0.0047585755,0.000016989929,0.1504605,0.0000023645296,0.00017467559,0.1221415],"study_design_scores_gemma":[0.05409076,0.068993114,0.5277138,0.0003072621,0.00011163126,0.000004110177,0.00046953122,0.000017247623,0.34739587,7.850723e-7,0.0007630623,0.00013288678],"about_ca_topic_score_codex":0.000345431,"about_ca_topic_score_gemma":0.0002855156,"teacher_disagreement_score":0.29444695,"about_ca_system_score_codex":0.0005025812,"about_ca_system_score_gemma":0.0002551678,"threshold_uncertainty_score":0.50044876},"labels":[],"label_agreement":null},{"id":"W3021836902","doi":"10.21037/jtd.2020.04.30","title":"Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Disease","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Princess Margaret Cancer Centre; University Health Network","funders":"MedImmune; Princess Margaret Cancer Foundation; International Association for the Study of Lung Cancer; AstraZeneca; Pfizer","keywords":"Medicine; Immune system; Adverse effect; Lung cancer; Correlation; Oncology; Immunology; Immune checkpoint; Immunotherapy; Internal medicine","score_opus":0.0055659263648431085,"score_gpt":0.2602990633561179,"score_spread":0.2547331369912748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021836902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99286205,0.0057618706,0.00006207463,0.000583832,0.00020976114,0.0004537572,0.000047121248,0.000006083255,0.000013435659],"genre_scores_gemma":[0.9992103,0.0003172159,0.00024967454,0.00009930911,0.00003378945,0.000005352645,0.000019685369,0.000023909563,0.000040768133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983413,0.00011501162,0.00090903736,0.00015914973,0.00033415033,0.00014135323],"domain_scores_gemma":[0.99844784,0.000057663176,0.0009178125,0.00014571883,0.00018153158,0.00024941875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003185167,0.00016221049,0.00040233292,0.00014911169,0.00002802692,0.000004283754,0.00008302709,0.00006383607,0.000079885205],"category_scores_gemma":[0.00011624186,0.00012512055,0.00018827939,0.00030366596,0.000051390878,0.00020571072,0.000030807576,0.00025975527,9.2298455e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20481476,0.00045451417,0.7581694,0.00030765097,0.00022538894,0.00007506349,0.0016031155,0.0008013866,0.027900824,6.5342995e-8,0.000019649095,0.0056281644],"study_design_scores_gemma":[0.01014677,0.00080262724,0.97903997,0.0026235036,0.00039903665,0.0000012870544,0.00033000088,0.00083868724,0.005655274,0.000004114091,0.000024866771,0.00013388952],"about_ca_topic_score_codex":0.00006735414,"about_ca_topic_score_gemma":0.0000027515134,"teacher_disagreement_score":0.22087052,"about_ca_system_score_codex":0.00017011694,"about_ca_system_score_gemma":0.0003834498,"threshold_uncertainty_score":0.5102268},"labels":[],"label_agreement":null},{"id":"W3021996333","doi":"10.3390/cancers12051148","title":"A Novel 4-gene Score to Predict Survival, Distant Metastasis and Response to Neoadjuvant Therapy in Breast Cancer","year":2020,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Susan G. Komen; University of Toronto; Sunnybrook Research Institute; Roswell Park Cancer Institute; Susan G. Komen for the Cure","keywords":"Medicine; Oncology; Internal medicine; Breast cancer; Hazard ratio; Cohort; Proportional hazards model; Biomarker; Chemotherapy; Framingham Risk Score; Hormonal therapy; Pathological; Neoadjuvant therapy; Cancer; Disease; Biology","score_opus":0.04454499954362891,"score_gpt":0.29995526130144906,"score_spread":0.25541026175782017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021996333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95642567,0.002827725,0.00028711083,0.038421214,0.000305476,0.000896833,0.0007332999,0.00005045916,0.00005224358],"genre_scores_gemma":[0.9810612,0.002112935,0.00039207315,0.01586125,0.00020130623,0.00021747891,0.000010875905,0.000047387148,0.00009547763],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984842,0.000057587316,0.0002963339,0.00050367357,0.00029514477,0.00036307756],"domain_scores_gemma":[0.99908024,0.000053603682,0.000053029242,0.00026038053,0.00007163602,0.0004811223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032552192,0.00023276238,0.00043621202,0.00013712564,0.000052459898,0.000030175423,0.00012857627,0.00006058064,0.00022978248],"category_scores_gemma":[0.00004666188,0.00019197221,0.00008346782,0.0008275903,0.00007841268,0.00006174488,0.000047053974,0.00014060806,0.000004925941],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10706193,0.00004136903,0.019523134,0.000056600406,0.00027830785,0.00006250964,0.004294666,0.00029764374,0.79121506,0.0000041471803,0.0046360516,0.07252859],"study_design_scores_gemma":[0.022396415,0.0036894341,0.7407182,0.0010125538,0.00015434263,0.00010746295,0.0025862786,0.00062650885,0.052180845,0.000005206362,0.17551121,0.0010115872],"about_ca_topic_score_codex":0.0044113765,"about_ca_topic_score_gemma":0.0007539565,"teacher_disagreement_score":0.7390342,"about_ca_system_score_codex":0.0012104779,"about_ca_system_score_gemma":0.0009882172,"threshold_uncertainty_score":0.78283995},"labels":[],"label_agreement":null},{"id":"W3022191219","doi":"10.1002/jcp.29769","title":"Immune checkpoints in hematologic malignancies: What made the immune cells and clinicians exhausted!","year":2020,"lang":"en","type":"review","venue":"Journal of Cellular Physiology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Michener Institute; University Health Network","funders":"","keywords":"Immune system; Immunology; Haematopoiesis; Cancer; Hematopoietic stem cell transplantation; Medicine; Immune checkpoint; Myeloid; Stem cell; Leukemia; Cancer research; Immunotherapy; Transplantation; Biology; Internal medicine","score_opus":0.03913473518416273,"score_gpt":0.3150586278762675,"score_spread":0.27592389269210477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022191219","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037622056,0.9934953,0.000010766642,0.00090213347,0.0011071843,0.0006678344,0.000006270017,0.0000091371685,0.00003920838],"genre_scores_gemma":[0.0024362693,0.9963298,0.00007101562,0.00043734256,0.00044790475,0.000015483085,0.00001854257,0.0000559869,0.0001876748],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99618095,0.0005436009,0.0022871988,0.0003433368,0.00024561587,0.0003992812],"domain_scores_gemma":[0.99683964,0.0004023641,0.0020807954,0.0004694673,0.00009952024,0.00010818274],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009819986,0.0004937784,0.0038950318,0.00023817302,0.00006590671,0.000046412035,0.00047850076,0.0005553885,0.00016340434],"category_scores_gemma":[0.000079061494,0.00027699233,0.001305079,0.00042651957,0.00038108442,0.00013754703,0.00013877433,0.0014464087,0.000032307424],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020041459,0.00045237696,0.0000052978644,0.017999928,0.002388266,0.0019159402,0.0008787931,0.0000012002469,0.30833215,0.000037946058,0.00066996994,0.66531396],"study_design_scores_gemma":[0.002288758,0.00113257,0.00016503276,0.022042172,0.0012781629,0.0026227725,0.0009156818,0.000005343059,0.0042089666,0.0001141142,0.9648703,0.00035613478],"about_ca_topic_score_codex":0.00001739882,"about_ca_topic_score_gemma":0.0000015927492,"teacher_disagreement_score":0.9642003,"about_ca_system_score_codex":0.00015536229,"about_ca_system_score_gemma":0.00050259545,"threshold_uncertainty_score":0.99996823},"labels":[],"label_agreement":null},{"id":"W3023607046","doi":"10.12688/f1000research.22715.1","title":"Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry","year":2020,"lang":"en","type":"preprint","venue":"F1000Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Princess Margaret Cancer Centre; Mount Sinai Hospital; University Health Network; University of Toronto","funders":"Genentech; Servier; Regeneron Pharmaceuticals; Mersana Therapeutics; Karyopharm Therapeutics; PTC Therapeutics; Princess Margaret Cancer Foundation; Sanofi; Merck; GlaxoSmithKline; Amgen; Pfizer; MorphoSys; Celgene; Symphogen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Autoantibody; Open peer review; Plant biology; Toxicity; Medicine; Mass spectrometry; Immunology; Pharmacology; Physiology; Biology; Chemistry; Internal medicine; Antibody; Chromatography; Botany","score_opus":0.07401534716565734,"score_gpt":0.37443454786636854,"score_spread":0.3004192007007112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023607046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98547274,0.0026822432,0.0013465439,0.00712463,0.0005050784,0.0015586764,0.0007379857,0.00022995744,0.00034214766],"genre_scores_gemma":[0.9922935,0.0005768241,0.004892903,0.00053928845,0.0006932869,0.00004979165,0.00019928529,0.00009778809,0.00065735215],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9960005,0.00054734375,0.00063588924,0.001040275,0.0011377815,0.0006382033],"domain_scores_gemma":[0.9979773,0.00047679382,0.00016914195,0.0007650786,0.0002458944,0.00036576507],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019411664,0.0003966562,0.0007213972,0.0007085981,0.00029288488,0.00035079214,0.00027597084,0.00041988053,0.00056584977],"category_scores_gemma":[0.0010252434,0.0003961349,0.00022692213,0.0006695512,0.00023933387,0.00012662266,0.0013220393,0.001511458,0.000044324024],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019119278,0.00006452558,0.013226023,0.00042956742,0.00049781316,0.00023727496,0.0013150348,0.00001359354,0.9629448,0.0000038597773,0.00096293056,0.0011852718],"study_design_scores_gemma":[0.0025234562,0.0007035395,0.55118424,0.0026795592,0.00018829604,0.00004560274,0.0009993042,0.0038057377,0.43568382,0.00092721026,0.0007114134,0.00054783537],"about_ca_topic_score_codex":0.0025709597,"about_ca_topic_score_gemma":0.000056034085,"teacher_disagreement_score":0.5379582,"about_ca_system_score_codex":0.0007735817,"about_ca_system_score_gemma":0.00073276326,"threshold_uncertainty_score":0.9998491},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W3024392979","doi":"10.1111/bcp.14355","title":"Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?","year":2020,"lang":"en","type":"review","venue":"British Journal of Clinical Pharmacology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Drug development; Clinical trial; Immune system; Medicine; Biomarker; Milestone; Drug resistance; Drug; Immunotherapy; Immune checkpoint; Bioinformatics; Computational biology; Oncology; Pharmacology; Internal medicine; Immunology; Biology","score_opus":0.11733830561391828,"score_gpt":0.42105946321198956,"score_spread":0.3037211575980713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024392979","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008469564,0.9710053,0.00006407869,0.022929877,0.00422292,0.00077048596,0.00009867603,0.000017752722,0.000043904838],"genre_scores_gemma":[0.0009808262,0.9910407,0.00035784597,0.002598989,0.00481421,0.00003447412,0.00004174199,0.00006890359,0.00006231471],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935567,0.0008937666,0.004215707,0.00045963202,0.00044923282,0.0004249677],"domain_scores_gemma":[0.99420285,0.0019229155,0.0033042666,0.0001809196,0.00009639935,0.00029263453],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0024577728,0.0004567086,0.0043061087,0.00011886484,0.00009845222,0.00014359519,0.00073845516,0.00055454875,0.00043717437],"category_scores_gemma":[0.00033094746,0.00034473755,0.0017541075,0.00038501166,0.00042679466,0.00018079646,0.00015166798,0.0038229646,0.000016833601],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013811584,0.00061524665,0.00003748853,0.0017040472,0.0024880662,0.0036462413,0.00017451838,4.5258267e-7,0.00003113827,0.0000038207027,0.01692791,0.9729899],"study_design_scores_gemma":[0.007613038,0.0002213172,0.0040275725,0.023072513,0.0013324203,0.002280389,0.00018333783,0.0000016439186,0.000015026942,0.00007123442,0.9608643,0.00031722474],"about_ca_topic_score_codex":0.00010718796,"about_ca_topic_score_gemma":0.0001955559,"teacher_disagreement_score":0.9726727,"about_ca_system_score_codex":0.00023230916,"about_ca_system_score_gemma":0.0036853103,"threshold_uncertainty_score":0.99990046},"labels":[],"label_agreement":null},{"id":"W3025373602","doi":"10.1038/s41523-020-0155-1","title":"Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials","year":2020,"lang":"en","type":"review","venue":"npj Breast Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; BC Cancer Agency; Princess Margaret Cancer Centre; University of Ottawa; Ontario Institute for Cancer Research; Centre for Advancing Health Outcomes; Translational Research in Oncology; University of British Columbia","funders":"Medical Research Council; KWF Kankerbestrijding; National Institute for Health and Care Research; Francis Crick Institute; Cancer Research UK; Breast Cancer Research Foundation","keywords":"Clinical trial; Biomarker; Medicine; Immunotherapy; Workflow; Risk stratification; Oncology; Medical physics; Internal medicine; Computer science; Cancer; Database; Biology","score_opus":0.10303037676895636,"score_gpt":0.46580781256314774,"score_spread":0.36277743579419136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025373602","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011189948,0.98249584,0.012234852,0.000092549104,0.0003386337,0.003495631,0.001112368,0.000021251357,0.00009699809],"genre_scores_gemma":[0.0018620449,0.98776656,0.008146328,0.00007159451,0.00071482244,0.0012298793,0.00015863741,0.000043705986,0.000006441428],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961633,0.00039805254,0.0025986657,0.00041706619,0.0002539081,0.00016897448],"domain_scores_gemma":[0.995525,0.0013038131,0.0026492777,0.00033946297,0.000120457575,0.00006199652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022913718,0.00028298804,0.0028601948,0.00016519055,0.000020953026,0.000009316094,0.00016428715,0.00029148557,0.00007436064],"category_scores_gemma":[0.00057554734,0.0002121812,0.0010407037,0.00046031253,0.00008892884,0.000037056896,0.000027454746,0.00032404708,0.0000014025909],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021069038,0.00011768957,0.00059065426,0.011012288,0.0006558476,0.000001379605,0.00005473712,0.000001020681,0.000011634529,0.00046031494,0.0000791694,0.98490834],"study_design_scores_gemma":[0.011454434,0.00086570345,0.0118418,0.12913495,0.009841683,0.00006643066,0.00042227173,0.00085050776,0.00013392516,0.00076140574,0.8338316,0.0007952908],"about_ca_topic_score_codex":0.0005076805,"about_ca_topic_score_gemma":0.00005363739,"teacher_disagreement_score":0.9841131,"about_ca_system_score_codex":0.00038792656,"about_ca_system_score_gemma":0.0006212572,"threshold_uncertainty_score":0.8652498},"labels":[],"label_agreement":null},{"id":"W3025838847","doi":"10.1038/s41593-020-0628-4","title":"RETRACTED ARTICLE: Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma","year":2020,"lang":"en","type":"article","venue":"Nature Neuroscience","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":41,"is_retracted":true,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Canada's Michael Smith Genome Sciences Centre; Hospital for Sick Children","funders":"National Cancer Institute; Canadian Institutes of Health Research; U.S. Department of Health and Human Services; Center for Scientific Review; American Brain Tumor Association; Stand Up To Cancer; California Dental Association Foundation; Brain Tumour Charity; Sparks; National Institute of Allergy and Infectious Diseases; Medical Research Council; CureSearch for Children's Cancer; Cancer Research UK; Accelerate Brain Cancer Cure; Massachusetts Department of Fish and Game; V Foundation for Cancer Research; Deutsche Forschungsgemeinschaft; Government of Canada; Alex's Lemonade Stand Foundation for Childhood Cancer; Division of Cancer Epidemiology and Genetics, National Cancer Institute; St. Baldrick's Foundation; California Institute for Regenerative Medicine; Pediatric Cancer Research Foundation; National Institutes of Health","keywords":"Major histocompatibility complex; Tumor necrosis factor alpha; Cytotoxic T cell; MHC class I; Immune system; Biology; Cancer research; Immunotherapy; Immunology; Immune checkpoint; In vitro","score_opus":0.01648409843585763,"score_gpt":0.2793653606156744,"score_spread":0.2628812621798168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025838847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98919475,0.0005535603,0.000011909764,0.008844328,0.0007008961,0.00036140496,0.000020696147,0.000107940155,0.00020453951],"genre_scores_gemma":[0.9809412,0.00011570714,0.00007992783,0.01869756,0.0000723307,0.000007607369,0.0000023370885,0.000019642503,0.00006370913],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99805653,0.000053371445,0.0003368153,0.0005287613,0.0006450542,0.00037948828],"domain_scores_gemma":[0.99927294,0.000073278476,0.00010776045,0.00028486838,0.00006178753,0.00019936111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001593232,0.00019224147,0.00029426755,0.00011285806,0.000088842826,0.00005653647,0.0002663955,0.0002166888,0.0001340678],"category_scores_gemma":[0.000900648,0.00015132764,0.00011765987,0.0015909723,0.00017438941,0.00023748048,0.00006895837,0.0011749372,0.000013829969],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011928132,0.00009950652,0.011627896,0.00002941187,0.000003089196,0.00016128761,0.00027551802,0.000001690081,0.98365134,0.000011668574,0.00025219945,0.0026936056],"study_design_scores_gemma":[0.0014981512,0.00047194088,0.66599125,0.000082711456,0.000009158668,0.00007946679,0.000035828656,0.0010396492,0.32427904,0.0000075608614,0.006362599,0.00014264057],"about_ca_topic_score_codex":0.00003152253,"about_ca_topic_score_gemma":0.000010429398,"teacher_disagreement_score":0.65937227,"about_ca_system_score_codex":0.00010232639,"about_ca_system_score_gemma":0.00014178878,"threshold_uncertainty_score":0.6170962},"labels":[],"label_agreement":null},{"id":"W3026662395","doi":"10.1186/s13073-020-00743-4","title":"MHC-I genotype and tumor mutational burden predict response to immunotherapy","year":2020,"lang":"en","type":"article","venue":"Genome Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Institute for Advanced Research","funders":"National Center for Advancing Translational Sciences; U.S. National Library of Medicine; Entertainment Industry Foundation; National Cancer Institute; National Institutes of Health; Mark Foundation For Cancer Research; Starr Foundation; Memorial Sloan-Kettering Cancer Center; Geoffrey Beene Cancer Research Center; Cancer Research Institute; Canadian Institute for Advanced Research; Stand Up To Cancer; American Association for Cancer Research","keywords":"Medicine; Immunotherapy; Oncology; Major histocompatibility complex; Immune system; MHC class I; Internal medicine; Immunology; Genotype; Immune checkpoint; Antigen; Biology; Genetics; Gene","score_opus":0.0189961633285255,"score_gpt":0.2735283902991051,"score_spread":0.2545322269705796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026662395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8743077,0.007583814,0.0005806231,0.1156836,0.000174412,0.0007156758,0.000030436104,0.00010314377,0.00082062895],"genre_scores_gemma":[0.96483386,0.0002865199,0.0007208429,0.031608075,0.0013284592,0.00003868322,0.00005308807,0.00004604495,0.0010844542],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985243,0.00007164054,0.0003671697,0.00036540878,0.00040473996,0.0002667392],"domain_scores_gemma":[0.99910074,0.000115831856,0.00007264034,0.00023756856,0.00009964514,0.0003735984],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004976639,0.00020110223,0.00039122242,0.00014503473,0.000088412446,0.000011604502,0.00011977067,0.000053514814,0.0018431597],"category_scores_gemma":[0.00023119182,0.0001552075,0.000056748435,0.00041516015,0.00018796019,0.000040899216,0.000037234542,0.00015816081,0.00006882149],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044016704,0.000029387817,0.00093719835,0.000084331914,0.0002639277,0.00022755937,0.00951937,0.00001182008,0.9231398,0.000019720268,0.0041623805,0.017587801],"study_design_scores_gemma":[0.012655419,0.0068443664,0.30080828,0.00017135555,0.000120839635,0.00043817546,0.0013079023,0.00016147559,0.0015971564,0.00005471058,0.67551494,0.0003253799],"about_ca_topic_score_codex":0.00008340296,"about_ca_topic_score_gemma":0.0000021134726,"teacher_disagreement_score":0.92154264,"about_ca_system_score_codex":0.00008596817,"about_ca_system_score_gemma":0.00017044386,"threshold_uncertainty_score":0.9990693},"labels":[],"label_agreement":null},{"id":"W3026921722","doi":"10.1016/j.ygyno.2020.04.689","title":"The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers","year":2020,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Victoria","funders":"Networks of Centres of Excellence of Canada; Carraresi Foundation; BC Cancer Foundation; Terry Fox Research Institute; Canadian Cancer Society; Canadian HIV Trials Network, Canadian Institutes of Health Research; Michael Smith Health Research BC; VGH and UBC Hospital Foundation; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Immune system; Medicine; Ovarian cancer; Immunology; Immune modulation; Oncology; Cancer research; Internal medicine; Cancer","score_opus":0.022917289350521793,"score_gpt":0.279446881998267,"score_spread":0.2565295926477452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026921722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98480487,0.008687736,0.00002586351,0.0048658424,0.0003093621,0.00060842186,0.000022722546,0.000031899533,0.0006432616],"genre_scores_gemma":[0.9964618,0.0017698806,0.000066719316,0.0014855878,0.000058533198,0.000052942672,0.000008831333,0.000018432467,0.000077252946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998581,0.00019281112,0.00040331413,0.00036549047,0.000090374735,0.00036704316],"domain_scores_gemma":[0.99817365,0.0013297745,0.00021010621,0.00013572002,0.00002849936,0.00012224926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033747358,0.00021499988,0.00051097147,0.000048233687,0.00022488671,0.00003423288,0.00009390876,0.0002678189,0.00021157615],"category_scores_gemma":[0.00039518788,0.00013500759,0.000047471174,0.00010197881,0.00040494112,0.000063342835,0.00012918162,0.0003741926,0.0000010256346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040590246,0.00008075646,0.80378246,0.00009397316,0.00020583742,0.00014835376,0.0063887388,0.000005148046,0.14813443,0.00007388869,0.0002127092,0.03681467],"study_design_scores_gemma":[0.006468253,0.0018664744,0.9694242,0.00011857496,0.00007200789,0.00006165486,0.0064952755,0.00036041086,0.0074096164,0.00007665961,0.0074414564,0.00020540309],"about_ca_topic_score_codex":0.0007037548,"about_ca_topic_score_gemma":0.00052692747,"teacher_disagreement_score":0.16564174,"about_ca_system_score_codex":0.00017066106,"about_ca_system_score_gemma":0.00013070533,"threshold_uncertainty_score":0.550545},"labels":[],"label_agreement":null},{"id":"W3027570141","doi":"10.1016/j.annonc.2020.03.187","title":"53P Role of immune biomarkers in evaluating predictive and prognostic value in advanced stage HER2 positive breast cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; FOXP3; Immune system; CD8; Breast cancer; Internal medicine; Oncology; Tumor microenvironment; Stage (stratigraphy); Tumor-infiltrating lymphocytes; Gastroenterology; Immunology; Cancer; Biology","score_opus":0.041466627787901895,"score_gpt":0.38205366931636053,"score_spread":0.34058704152845864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027570141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831212,0.008944147,0.0000043818227,0.0060748984,0.000043596792,0.0007404799,0.00014517804,0.000008972087,0.00091713795],"genre_scores_gemma":[0.9968205,0.0021244362,0.0001940939,0.00074053573,0.000025145015,0.000058262714,0.000012726782,0.000014037304,0.000010247137],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986288,0.00018716133,0.00054494163,0.00024932518,0.0001628072,0.00022694046],"domain_scores_gemma":[0.9991501,0.00023568425,0.00028422617,0.000097156066,0.00016473504,0.000068112095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051541,0.00012733413,0.00052944594,0.00013449637,0.000014733334,0.0000020138518,0.000069001246,0.000115027135,0.00007210688],"category_scores_gemma":[0.00018921989,0.00011798196,0.000072890805,0.00040072584,0.00021329167,0.0000821345,0.000046635305,0.00015608294,3.8854373e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039241202,0.0006101111,0.2480185,0.0003259955,0.00065324083,0.000056223642,0.0076310365,0.00024260799,0.36655173,0.000037601112,0.000054909884,0.33657685],"study_design_scores_gemma":[0.0067059086,0.0069919466,0.9523087,0.0006805435,0.000057190267,0.000019200863,0.0034837537,0.0027947228,0.02655996,0.000057629804,0.00022413676,0.00011629056],"about_ca_topic_score_codex":0.0026825638,"about_ca_topic_score_gemma":0.00021406224,"teacher_disagreement_score":0.7042902,"about_ca_system_score_codex":0.00008548479,"about_ca_system_score_gemma":0.00041854018,"threshold_uncertainty_score":0.48111644},"labels":[],"label_agreement":null},{"id":"W3028780244","doi":"10.1200/jco.2020.38.15_suppl.e21714","title":"Two-year survival with nivolumab in previously treated, advanced non-small cell lung cancer: A pooled analysis of real-world patients from France, Germany and Canada.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada); McMaster University; Institut universitaire de cardiologie et de pneumologie de Québec; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Hazard ratio; Internal medicine; Proportional hazards model; Oncology; Lung cancer; Cohort; Confidence interval; Cancer; Immunotherapy","score_opus":0.021947352179108648,"score_gpt":0.350484239687062,"score_spread":0.32853688750795335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028780244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99612665,0.00089829887,0.000013644304,0.0012872876,0.00023971335,0.0002852498,0.000047145488,0.0000034745187,0.0010985257],"genre_scores_gemma":[0.9945807,0.0029948812,0.0006644115,0.0014189021,0.00019659402,0.000005127583,0.00001122984,0.000016481947,0.00011168512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997108,0.00023628424,0.0018537965,0.00024855704,0.0003358696,0.00021751672],"domain_scores_gemma":[0.9968782,0.00070322555,0.0016550153,0.00014871791,0.0003059056,0.0003089127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005547814,0.00016025106,0.0020338476,0.00017785776,0.000019319352,0.000004551881,0.00013734937,0.00013231367,0.00011998248],"category_scores_gemma":[0.00011204309,0.00011576166,0.0002698151,0.0006611631,0.00010656561,0.000058132973,0.000027332248,0.00052292284,2.0868276e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02386548,0.0004359211,0.96048456,0.000049972536,0.0030790926,0.00018041834,0.00022708863,0.0001338472,0.00030922878,5.9109476e-7,0.0003587695,0.0108750025],"study_design_scores_gemma":[0.029748693,0.004019516,0.95918906,0.0001838109,0.003941697,0.0000012474148,0.0001535326,0.0005604772,0.00010706324,9.394914e-7,0.0019785552,0.00011542607],"about_ca_topic_score_codex":0.32405207,"about_ca_topic_score_gemma":0.7915125,"teacher_disagreement_score":0.46746042,"about_ca_system_score_codex":0.00027304087,"about_ca_system_score_gemma":0.00266998,"threshold_uncertainty_score":0.6804491},"labels":[],"label_agreement":null},{"id":"W3028860151","doi":"10.1200/jco.2020.38.15_suppl.3063","title":"Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Adverse effect; Response Evaluation Criteria in Solid Tumors; Internal medicine; Monoclonal antibody; Oncology; Immune system; Progressive disease; Antibody; Gastroenterology; Phases of clinical research; Clinical trial; Immunology; Chemotherapy","score_opus":0.047004141341556095,"score_gpt":0.41775422748165525,"score_spread":0.37075008614009913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028860151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951658,0.00013390587,0.00009891261,0.0036071914,0.00029728486,0.00047103365,0.000015079177,0.0000109895,0.00019978543],"genre_scores_gemma":[0.99481505,0.00045460058,0.0025760774,0.0018680783,0.00019755465,0.000002470618,0.000048569847,0.00003180395,0.0000058137093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99537253,0.00053717336,0.0028408195,0.0003455983,0.0005825777,0.00032127905],"domain_scores_gemma":[0.9963589,0.00040274826,0.0021642775,0.00022991996,0.0004924803,0.00035170186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018625398,0.00023431341,0.0020202254,0.00028478695,0.00003398424,0.000009860604,0.00025324957,0.0003030848,0.00012024775],"category_scores_gemma":[0.0004392693,0.00016049494,0.00019065606,0.0006065601,0.00036822917,0.0004562353,0.000035572208,0.0009437485,0.0000015820464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09915411,0.00626145,0.83469456,0.00006314899,0.00020848126,0.0003950234,0.00035647527,0.00022590924,0.0028822355,0.000027436978,0.0000491774,0.055681966],"study_design_scores_gemma":[0.05176545,0.06359151,0.88179845,0.00040885512,0.00009462852,0.000054650176,0.00026962388,0.0005229708,0.00041502382,0.00003397115,0.00087150204,0.00017339834],"about_ca_topic_score_codex":0.00006040089,"about_ca_topic_score_gemma":0.00017080877,"teacher_disagreement_score":0.057330057,"about_ca_system_score_codex":0.00018362651,"about_ca_system_score_gemma":0.0013463392,"threshold_uncertainty_score":0.6544794},"labels":[],"label_agreement":null},{"id":"W3029103020","doi":"10.1200/jco.2020.38.15_suppl.6577","title":"Nivolumab (Nivo) and ipilimumab (Ipi) in combination with radiotherapy (RT) in high-risk patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Mucositis; Internal medicine; Ipilimumab; Oncology; Radiation therapy; Odynophagia; Chemotherapy; Gastroenterology; Cancer; Immunotherapy; Esophagus","score_opus":0.0202377699414593,"score_gpt":0.32398098900909666,"score_spread":0.30374321906763735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029103020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945675,0.0011334193,0.000060475148,0.0035765418,0.00012160815,0.00040258217,0.0000028222512,0.0000027964995,0.00013221495],"genre_scores_gemma":[0.99639577,0.00095993164,0.0012139765,0.0013341578,0.000060492577,0.0000030339538,9.105147e-7,0.000016444079,0.000015272119],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775696,0.00045019062,0.0011749971,0.0001896486,0.00027891406,0.00014926978],"domain_scores_gemma":[0.9976764,0.000751693,0.001141889,0.00012184808,0.0001769104,0.00013129345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000875465,0.00013354098,0.0009086561,0.00008610891,0.00002502328,0.000006162864,0.00010758102,0.00019999062,0.000010333109],"category_scores_gemma":[0.00026670654,0.000076432734,0.000086490974,0.00025388284,0.000375013,0.00009634308,0.000023530845,0.0007079266,1.2253093e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.069810025,0.0013606907,0.81261575,0.000057080208,0.000049812254,0.00006917546,0.0005470875,0.0000443387,0.0001853342,0.0000070620217,0.00006264262,0.115190975],"study_design_scores_gemma":[0.11100111,0.048130125,0.83890337,0.00016828354,0.000069113354,0.0000486562,0.0001627098,0.0002565659,0.00013838305,0.000026492058,0.00101838,0.00007682296],"about_ca_topic_score_codex":0.0001995625,"about_ca_topic_score_gemma":0.0006613524,"teacher_disagreement_score":0.11511415,"about_ca_system_score_codex":0.0001435665,"about_ca_system_score_gemma":0.00071132655,"threshold_uncertainty_score":0.31168365},"labels":[],"label_agreement":null},{"id":"W3029255798","doi":"10.1200/jco.2020.38.15_suppl.3054","title":"An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Cancer; Cohort; Gastroenterology; Oncology; Phases of clinical research; Surgery; Chemotherapy; Clinical trial","score_opus":0.09753620960378719,"score_gpt":0.4727210745813385,"score_spread":0.3751848649775513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029255798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99259794,0.00009210477,0.000035673813,0.0061030155,0.00020465885,0.000702837,0.0000041018625,0.0000030924864,0.0002565694],"genre_scores_gemma":[0.99611396,0.00026483435,0.0017532505,0.0016930365,0.0001386592,0.000006911661,0.0000073749356,0.000014309151,0.0000076887045],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99711275,0.00036202956,0.0018902342,0.00019402381,0.00028770752,0.00015326969],"domain_scores_gemma":[0.9975702,0.00031874163,0.0015381759,0.00011411601,0.00022904806,0.00022967237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015925982,0.00011954809,0.0014094035,0.00014665957,0.000016047085,0.000009661343,0.00016748156,0.00017533988,0.000027493492],"category_scores_gemma":[0.0006133589,0.00007762435,0.00004437114,0.00033229854,0.00022659216,0.00027217882,0.000028930022,0.00058226247,4.1213642e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7045511,0.0142297475,0.036193434,0.000027897828,0.00011267563,0.00025651176,0.00030767533,0.0000045861593,0.0013822356,0.0000055043147,0.00008904362,0.24283959],"study_design_scores_gemma":[0.58395976,0.292116,0.12127094,0.00027819944,0.000078070414,0.000034731995,0.00021871991,0.0001296612,0.000260854,0.00002716939,0.0015390927,0.00008680911],"about_ca_topic_score_codex":0.000043963097,"about_ca_topic_score_gemma":0.00032365875,"teacher_disagreement_score":0.27788624,"about_ca_system_score_codex":0.00009509247,"about_ca_system_score_gemma":0.00090243487,"threshold_uncertainty_score":0.3165429},"labels":[],"label_agreement":null},{"id":"W3029297598","doi":"10.1200/jco.2020.38.15_suppl.tps6591","title":"INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Internal medicine; Clinical endpoint; Population; Antibody; Phases of clinical research; Oncology; Immunotherapy; Immunology; Clinical trial; Adverse effect; Cancer","score_opus":0.2139246181306748,"score_gpt":0.4678649286594228,"score_spread":0.253940310528748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029297598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98856205,0.0037741591,0.00014085667,0.0011507906,0.0011466875,0.004637178,0.00009044185,0.000013758844,0.00048410357],"genre_scores_gemma":[0.9968214,0.0012167478,0.0007104834,0.00029474907,0.0007068076,0.000068536814,0.00005949847,0.000060155475,0.000061638624],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99278855,0.0010732161,0.0044152336,0.0006234772,0.00063564675,0.00046389876],"domain_scores_gemma":[0.98830336,0.0058505945,0.004008634,0.00041306304,0.0007114913,0.0007128783],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026802875,0.0005087209,0.004930325,0.00030947267,0.00013895263,0.00002515714,0.00029599096,0.00046776375,0.000078907025],"category_scores_gemma":[0.0007581343,0.0003780711,0.0011354461,0.00031937088,0.000635543,0.0001803289,0.000067766436,0.00077861216,0.0000025764487],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96489096,0.014782943,0.0034078925,0.00042567306,0.0014840788,0.00036381203,0.004930904,0.00030164747,0.001206568,0.0000066965035,0.00022757259,0.007971248],"study_design_scores_gemma":[0.7674271,0.21718936,0.0041742907,0.00010985813,0.0034024573,0.000093059716,0.0020726856,0.0022068585,0.002116161,0.000009807423,0.00094403385,0.00025434472],"about_ca_topic_score_codex":0.0004756967,"about_ca_topic_score_gemma":0.0003059842,"teacher_disagreement_score":0.2024064,"about_ca_system_score_codex":0.000608807,"about_ca_system_score_gemma":0.0036527351,"threshold_uncertainty_score":0.99986714},"labels":[],"label_agreement":null},{"id":"W3029319309","doi":"10.1200/jco.2020.38.15_suppl.tps9076","title":"Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Stage (stratigraphy); Adjuvant; Randomized controlled trial; Population; Chemotherapy; Cancer; Immunotherapy","score_opus":0.10470251818585603,"score_gpt":0.4519634046092852,"score_spread":0.34726088642342917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029319309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785131,0.0019658452,0.00020055975,0.015173078,0.0012751862,0.0008721529,0.000026895308,0.000020115107,0.0019530616],"genre_scores_gemma":[0.9875681,0.0033061577,0.0008336376,0.0056651477,0.0012699019,0.0000114787,0.000008994333,0.000053451236,0.0012831542],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931449,0.00051899144,0.004731238,0.00039855082,0.0007065435,0.0004997183],"domain_scores_gemma":[0.9947801,0.00094607315,0.0030791764,0.0003425655,0.00031486925,0.0005371958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041414783,0.00030382548,0.003408588,0.00018444179,0.000042571817,0.000016031654,0.00042338367,0.0006847796,0.00084614876],"category_scores_gemma":[0.0016556903,0.00023534545,0.0011965352,0.0005161342,0.00035971802,0.00019171632,0.00006649744,0.0014667279,0.000009412193],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8267404,0.0040660235,0.0013625731,0.00007767372,0.00074455346,0.0007189199,0.0008744829,0.0000051778447,0.049705576,0.0000072297944,0.023990406,0.09170701],"study_design_scores_gemma":[0.74797314,0.06502085,0.0026758807,0.00030027502,0.00027391466,0.000082330866,0.00039688725,0.0005422016,0.008319706,0.000027836093,0.17411967,0.00026734394],"about_ca_topic_score_codex":0.00046304846,"about_ca_topic_score_gemma":0.000088666086,"teacher_disagreement_score":0.15012926,"about_ca_system_score_codex":0.00039386554,"about_ca_system_score_gemma":0.0028839686,"threshold_uncertainty_score":0.9597109},"labels":[],"label_agreement":null},{"id":"W3029353272","doi":"10.1200/jco.2020.38.15_suppl.9623","title":"SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health; Amgen","keywords":"Medicine; Tremelimumab; Durvalumab; Internal medicine; Lung cancer; Clinical endpoint; Oncology; Cohort; Response Evaluation Criteria in Solid Tumors; Interim analysis; Progressive disease; Combination therapy; Cancer; Surgery; Immunotherapy; Gastroenterology; Chemotherapy; Clinical trial; Nivolumab; Ipilimumab","score_opus":0.07130632551805678,"score_gpt":0.4141382348314257,"score_spread":0.34283190931336893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029353272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879753,0.0033188474,0.000052711428,0.0029228074,0.00045970114,0.005145524,0.000059044123,0.000020415644,0.000045634744],"genre_scores_gemma":[0.9963926,0.0005285965,0.00033533288,0.0016570432,0.0005762131,0.00013484883,0.0000067380374,0.000059433696,0.00030920512],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9947553,0.00052597426,0.0031251542,0.0005300424,0.0006633872,0.00040013765],"domain_scores_gemma":[0.99483997,0.000816664,0.0025282963,0.00032237175,0.0009270288,0.0005656503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017619003,0.00036406767,0.0024088246,0.00015007253,0.00013297106,0.000018091598,0.00024876182,0.00025241554,0.00009323435],"category_scores_gemma":[0.0005852103,0.00024265773,0.00040388055,0.00036334177,0.00016905846,0.00013657229,0.00007232743,0.0004254166,5.087557e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7233912,0.034748588,0.1850331,0.00044300122,0.002129937,0.00025774466,0.011535569,0.000030503146,0.004334186,6.4772445e-7,0.0068836026,0.031211948],"study_design_scores_gemma":[0.39614594,0.41820014,0.16441959,0.00034316274,0.0017187946,0.0000061659207,0.0025067744,0.00025331785,0.0019358469,0.0000019301265,0.014069956,0.00039837413],"about_ca_topic_score_codex":0.00012755163,"about_ca_topic_score_gemma":0.00079589325,"teacher_disagreement_score":0.38345155,"about_ca_system_score_codex":0.00044788205,"about_ca_system_score_gemma":0.001648512,"threshold_uncertainty_score":0.9895295},"labels":[],"label_agreement":null},{"id":"W3029465352","doi":"10.1200/jco.2020.38.15_suppl.3036","title":"In vitro and in vivo characterization of MDNA11: A long-acting “beta-only” IL-2 superkine in syngeneic mice tumor models and nonhuman primates.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"In vivo; IL-2 receptor; Medicine; In vitro; CD8; Cancer research; Immune system; Pharmacology; Immunotherapy; Interleukin 2; Immunology; T cell; Chemistry; Biology; Biochemistry","score_opus":0.10027242502314637,"score_gpt":0.4046008536617972,"score_spread":0.30432842863865084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029465352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909913,0.000571917,0.00004625621,0.007962884,0.00014423684,0.00018853084,0.0000058486917,0.0000023424955,0.000086717904],"genre_scores_gemma":[0.9946858,0.0017122804,0.0004292457,0.002943185,0.00020483982,0.0000020073019,0.0000021067988,0.000011376629,0.000009156531],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99741995,0.0002116017,0.0019128523,0.00016526895,0.00013921157,0.0001511232],"domain_scores_gemma":[0.9984631,0.0004663642,0.0008149115,0.000060156162,0.00007257471,0.0001228954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015955725,0.00010374104,0.0011218715,0.0001746386,0.000009379419,0.000006009618,0.00006697246,0.00016590666,0.00003525184],"category_scores_gemma":[0.00040236683,0.00008417336,0.00009690095,0.00019924442,0.00012361853,0.00020766818,0.000036719874,0.0005130259,2.1632695e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030792374,0.0007080476,0.15035936,0.00023045554,0.00009359238,0.00063183194,0.0009657779,0.000008405654,0.7798578,0.000004768622,0.00002052611,0.03632706],"study_design_scores_gemma":[0.024310518,0.0058178017,0.9382053,0.0004956409,0.00012749825,0.00051909086,0.00023437188,0.004983802,0.023078918,0.000051439765,0.0019974422,0.00017817975],"about_ca_topic_score_codex":0.00006624205,"about_ca_topic_score_gemma":0.00018072301,"teacher_disagreement_score":0.7878459,"about_ca_system_score_codex":0.00009163651,"about_ca_system_score_gemma":0.00042776455,"threshold_uncertainty_score":0.34324902},"labels":[],"label_agreement":null},{"id":"W3029817749","doi":"10.1200/jco.2020.38.15_suppl.10019","title":"CheckMate 067: Long-term outcomes in patients with mucosal melanoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Placebo; Melanoma; Population; Adverse effect; Gastroenterology; Malignancy; Oncology; Cancer; Immunotherapy; Pathology","score_opus":0.10396400415171521,"score_gpt":0.4380216071559047,"score_spread":0.3340576030041895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029817749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98292285,0.00015281918,0.00002636202,0.015554119,0.00054686546,0.00017554133,0.0000024421183,0.0000068866348,0.00061211997],"genre_scores_gemma":[0.9897365,0.00014736089,0.00057862856,0.009072885,0.00037213328,0.0000012890441,0.0000029414803,0.000013701174,0.00007455691],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975452,0.00016130376,0.0016764087,0.00013772736,0.0003031862,0.00017616541],"domain_scores_gemma":[0.99803126,0.00043605635,0.0009880491,0.00010490358,0.00016682914,0.00027291337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089703966,0.00011485637,0.0012149122,0.000067077875,0.000013695255,0.0000060089756,0.00013409909,0.0002149251,0.00023690493],"category_scores_gemma":[0.0007029774,0.00006713075,0.00031290873,0.00013018571,0.0001327215,0.000085799176,0.000027282726,0.0006616412,0.000014658391],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032382976,0.0011373289,0.90687555,0.000023295428,0.00037887774,0.00041315274,0.000078152436,7.992799e-7,0.000027378726,0.000002843592,0.00058201386,0.058097646],"study_design_scores_gemma":[0.029066045,0.019842641,0.9461695,0.000065417444,0.00013075442,0.00002798236,0.000017805909,0.000004668131,0.000025398042,0.0000057266775,0.0045705386,0.000073511765],"about_ca_topic_score_codex":0.000007479037,"about_ca_topic_score_gemma":0.000032138778,"teacher_disagreement_score":0.058024134,"about_ca_system_score_codex":0.00009622026,"about_ca_system_score_gemma":0.00066817703,"threshold_uncertainty_score":0.28745386},"labels":[],"label_agreement":null},{"id":"W3029829417","doi":"10.1200/jco.2020.38.15_suppl.e15151","title":"Comparative efficacy, safety, and tolerability of immune checkpoint inhibitors (ICIs) in cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Centre Hospitalier Universitaire de Sherbrooke; University of Toronto; McMaster University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Atezolizumab; Nivolumab; Tolerability; Internal medicine; Avelumab; Oncology; Adverse effect; Lung cancer; Hazard ratio; Head and neck squamous-cell carcinoma; Odds ratio; Cancer; Head and neck cancer; Immunotherapy; Confidence interval","score_opus":0.1782500773696352,"score_gpt":0.4831628988173155,"score_spread":0.3049128214476803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029829417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9660503,0.003576217,0.000020108944,0.028831873,0.00047420707,0.00024211021,0.000004272396,0.0000033613271,0.0007974969],"genre_scores_gemma":[0.9946754,0.0030882794,0.00034250403,0.0014485,0.00042119168,0.000001793798,7.727804e-7,0.0000059368604,0.000015608195],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99528366,0.00033687998,0.0038899991,0.00015165526,0.00020794432,0.00012983977],"domain_scores_gemma":[0.99642825,0.0012468458,0.0018112573,0.000097171316,0.00020790298,0.00020859834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028929831,0.00010486489,0.0019989545,0.00005744214,0.000015117,0.0000026802163,0.000098233446,0.00021619633,0.00015509239],"category_scores_gemma":[0.0012330082,0.000074348,0.0004531759,0.00020334216,0.00042988162,0.00005768192,0.0000485838,0.000757664,0.0000010134921],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2236229,0.0041561574,0.24023819,0.00024778658,0.00113046,0.00023051957,0.0037614822,0.00010716684,0.02217175,0.000032683838,0.0015367888,0.5027641],"study_design_scores_gemma":[0.01832167,0.012287238,0.9384334,0.0002038515,0.00012487086,0.00004808365,0.0004037686,0.000121760524,0.0035919864,0.000034327608,0.026349835,0.000079214326],"about_ca_topic_score_codex":0.00016767961,"about_ca_topic_score_gemma":0.00010884273,"teacher_disagreement_score":0.6981952,"about_ca_system_score_codex":0.0001372251,"about_ca_system_score_gemma":0.000915574,"threshold_uncertainty_score":0.3291715},"labels":[],"label_agreement":null},{"id":"W3029974150","doi":"10.1200/jco.2020.38.15_suppl.4105","title":"Immunoscore as a parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Assistance Publique - Hôpitaux de Paris","keywords":"Medicine; Internal medicine; Colorectal cancer; Oncology; Stage (stratigraphy); Population; Cancer; Adjuvant; Gastroenterology","score_opus":0.09073854372816458,"score_gpt":0.4280500618833683,"score_spread":0.3373115181552037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029974150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9652245,0.0008396317,0.000006505624,0.032501593,0.00070187595,0.0003177714,0.00003518076,0.000007345353,0.00036561792],"genre_scores_gemma":[0.9842612,0.00084136263,0.0004493963,0.013496859,0.0005817279,0.000010576461,0.000003857321,0.000016750906,0.00033828276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973974,0.00029123324,0.0015484513,0.00022046179,0.0003304459,0.00021198965],"domain_scores_gemma":[0.99700767,0.0012094555,0.00078513304,0.00014350499,0.00020299712,0.0006512693],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0014038936,0.00012601247,0.00092685444,0.00007071607,0.000040679854,0.000009895433,0.00019024653,0.00017257215,0.0004959411],"category_scores_gemma":[0.011218486,0.00009508293,0.00021135234,0.00020120708,0.00014348078,0.00009665994,0.00014813723,0.0006953456,0.000010322735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08003995,0.0011908832,0.7445682,0.00007157104,0.00031284374,0.0003457575,0.0007057726,0.000009537658,0.0005772598,0.0000064076808,0.010461159,0.1617106],"study_design_scores_gemma":[0.01568846,0.027922276,0.82583,0.00040162762,0.00017313169,0.000010814492,0.00007398847,0.00022694754,0.000032791366,0.00006043784,0.12944375,0.00013578054],"about_ca_topic_score_codex":0.0001065481,"about_ca_topic_score_gemma":0.000053657364,"teacher_disagreement_score":0.16157483,"about_ca_system_score_codex":0.00014932235,"about_ca_system_score_gemma":0.0013566604,"threshold_uncertainty_score":0.9971104},"labels":[],"label_agreement":null},{"id":"W3030145599","doi":"10.1200/jco.2020.38.15_suppl.e15062","title":"Assessing long-term survival improvement of immune-checkpoint inhibitors (ICI) anticancer agents approved by the Food and Drug Administration: A meta-analysis of randomized controlled trials (RCTs).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Randomized controlled trial; Meta-analysis; Survival rate; Drug; Progression-free survival; Hematology; Overall survival; Pharmacology","score_opus":0.2595562271285577,"score_gpt":0.48441830194270097,"score_spread":0.22486207481414328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030145599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95280886,0.011841582,0.000777472,0.032204907,0.00061423425,0.0015361009,0.000021372853,0.0000040908794,0.00019140728],"genre_scores_gemma":[0.9958568,0.001778541,0.00028513477,0.0016274537,0.00034624088,0.000028892444,0.0000067550595,0.0000122039455,0.000057984867],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98364305,0.003853926,0.011364793,0.0002374445,0.00073061336,0.00017014865],"domain_scores_gemma":[0.9694388,0.015979841,0.013528415,0.0002317246,0.0006171944,0.00020405646],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.044193953,0.0002269468,0.015952429,0.00013731097,0.0000424677,0.000033467604,0.00018854642,0.00021882892,0.00036628387],"category_scores_gemma":[0.015550384,0.000105066094,0.010225389,0.0003411371,0.00060604844,0.00011166288,0.000049458336,0.0005022717,1.6920353e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53970957,0.0011298279,0.0015563434,0.00009106935,0.41990638,0.000020799223,0.00031449515,0.0000050527033,0.02525488,0.000013415807,0.0002868556,0.011711341],"study_design_scores_gemma":[0.5025857,0.0093864715,0.008815511,0.000053642278,0.4628985,0.000013661257,0.0006378447,0.000292668,0.014793965,0.000029724639,0.00035225716,0.000140058],"about_ca_topic_score_codex":0.00003883056,"about_ca_topic_score_gemma":0.00003582273,"teacher_disagreement_score":0.04304796,"about_ca_system_score_codex":0.00005274093,"about_ca_system_score_gemma":0.0011940332,"threshold_uncertainty_score":0.99968696},"labels":[],"label_agreement":null},{"id":"W3030219555","doi":"10.1200/jco.2020.38.15_suppl.510","title":"Role of intratumoral NK cells in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institutes of Health; U.S. Department of Defense","keywords":"Medicine; Triple-negative breast cancer; Breast cancer; Oncology; Cohort; Tumor-infiltrating lymphocytes; Internal medicine; Proportional hazards model; Stromal cell; Gene signature; Adjuvant; Immune system; Pathology; Cancer; Immunology; Immunotherapy; Gene expression; Gene","score_opus":0.07646240536740681,"score_gpt":0.4361222999563779,"score_spread":0.3596598945889711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030219555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97488886,0.0010750314,0.0000017294315,0.022129769,0.00071020896,0.0004946661,0.000020120182,0.0000018020601,0.00067781575],"genre_scores_gemma":[0.9893778,0.004202356,0.00014249816,0.0051394827,0.0010842764,0.000007825327,6.030834e-7,0.000007837861,0.00003731677],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9961229,0.00079532486,0.0025040582,0.00015667819,0.0002567522,0.00016429901],"domain_scores_gemma":[0.9959956,0.002287736,0.0013603447,0.00009804738,0.000121085985,0.00013721465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004157176,0.00010804218,0.0013161245,0.00007993446,0.000012814034,0.000005900146,0.00016851035,0.00026393935,0.00038820956],"category_scores_gemma":[0.001116247,0.00006427935,0.00030636886,0.00028329244,0.00032841408,0.000067697794,0.00002633428,0.0011313561,0.0000020429104],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63816625,0.0016853659,0.1932541,0.00005131485,0.00035559176,0.00030455625,0.0014910765,0.000005327943,0.0021936574,0.00001350856,0.004378746,0.1581005],"study_design_scores_gemma":[0.13412113,0.01606248,0.8415709,0.0001372596,0.00020242893,0.00011411763,0.001245434,0.0001083468,0.00020692608,0.00017642698,0.005970522,0.00008397828],"about_ca_topic_score_codex":0.00026269507,"about_ca_topic_score_gemma":0.00043461687,"teacher_disagreement_score":0.64831686,"about_ca_system_score_codex":0.00008002094,"about_ca_system_score_gemma":0.0013773862,"threshold_uncertainty_score":0.49152422},"labels":[],"label_agreement":null},{"id":"W3030295107","doi":"10.1101/2020.05.29.111542","title":"Tumor-Immune Partitioning and Clustering (TIPC) algorithm reveals distinct signatures of tumor-immune cell interactions within the tumor microenvironment","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Gary Bennett Family Fund; National Institutes of Health; Cancer Research UK; Mitsukoshi Health and Welfare Foundation; Uehara Memorial Foundation; Stand Up To Cancer; Entertainment Industry Foundation; Japan Society for the Promotion of Science; American Association for Cancer Research","keywords":"Immune system; Tumor microenvironment; Stromal cell; Immunotherapy; Biology; Cluster analysis; Subtyping; Cancer; Cancer research; Computational biology; Immunology; Computer science; Genetics; Artificial intelligence","score_opus":0.012162003978994914,"score_gpt":0.2241869714199507,"score_spread":0.21202496744095578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030295107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97981536,0.013726019,0.0017737703,0.0010912513,0.0013124071,0.0016873077,0.00039216204,0.00017768536,0.000024060852],"genre_scores_gemma":[0.99162585,0.0003381725,0.0065465574,0.0006809129,0.0003847465,0.00025243437,0.000002804602,0.00014865493,0.000019860203],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965954,0.00022560009,0.0012815284,0.0009387727,0.00047039363,0.00048830226],"domain_scores_gemma":[0.9969823,0.00015684825,0.001264844,0.0011871251,0.00017749268,0.00023141848],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007810097,0.000685578,0.0010379062,0.00018708772,0.0003254415,0.00015603643,0.00044096613,0.00016594527,0.00012119331],"category_scores_gemma":[0.00014905,0.00058221136,0.00034965156,0.0003722188,0.00044095048,0.00010338413,0.00069634296,0.0014367722,0.00001437649],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005058741,0.00020774343,0.0025688745,0.0011057057,0.00043695277,0.0001661944,0.00009779392,0.00006325217,0.99462575,0.000015417643,0.00019254025,0.000013890008],"study_design_scores_gemma":[0.0021270395,0.00030805494,0.307244,0.0034684076,0.0006606844,0.0000021671465,0.00009794983,0.0023289411,0.6791979,0.000004268304,0.0037132571,0.00084732287],"about_ca_topic_score_codex":0.00028272558,"about_ca_topic_score_gemma":0.0000082947845,"teacher_disagreement_score":0.31542784,"about_ca_system_score_codex":0.00037693305,"about_ca_system_score_gemma":0.00033960494,"threshold_uncertainty_score":0.99966294},"labels":[],"label_agreement":null},{"id":"W3030378344","doi":"10.1200/jco.2020.38.15_suppl.e15227","title":"Efficacy and hepatotoxicity of Infliximab in resolving steroid-refractory immune-related adverse events (irAEs) in a real-world setting.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Infliximab; Adverse effect; Internal medicine; Gastroenterology; Tumor necrosis factor alpha","score_opus":0.08463694468628592,"score_gpt":0.43057567189522455,"score_spread":0.34593872720893865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030378344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923181,0.0009273718,0.0000031836075,0.0054119625,0.0003042019,0.00027766047,0.0000021122164,0.0000063909715,0.00074902177],"genre_scores_gemma":[0.9956118,0.001894428,0.0004609245,0.0018396891,0.00013132115,0.0000016264876,0.000001337927,0.0000145690765,0.00004431082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948528,0.0006333213,0.0038402108,0.000194429,0.0002682765,0.00021098857],"domain_scores_gemma":[0.9957507,0.001711503,0.0020749175,0.00014004852,0.000112149486,0.00021065035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038216142,0.00013690136,0.0014643958,0.0002569449,0.000015542248,0.000001824588,0.00014392607,0.00032116077,0.00008117406],"category_scores_gemma":[0.0028541167,0.000110002606,0.0003242605,0.0004030274,0.00019028182,0.000122052734,0.00007529117,0.0012903613,0.0000020489101],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057509914,0.0018186478,0.85531586,0.00010226396,0.00032982792,0.00067631586,0.0013102401,0.00002696769,0.012495924,0.000006955767,0.00022996191,0.07017713],"study_design_scores_gemma":[0.035148922,0.0066200043,0.9518782,0.0006171965,0.000079096586,0.00004693545,0.00018702114,0.00032612885,0.00023623327,0.00002824192,0.004740547,0.00009147055],"about_ca_topic_score_codex":0.00025951752,"about_ca_topic_score_gemma":0.00035378017,"teacher_disagreement_score":0.096562356,"about_ca_system_score_codex":0.0002110485,"about_ca_system_score_gemma":0.0008294773,"threshold_uncertainty_score":0.56060493},"labels":[],"label_agreement":null},{"id":"W3030666284","doi":"10.1200/jco.19.03158","title":"Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham; Lakeridge Health","funders":"","keywords":"Medicine; Atezolizumab; Bevacizumab; Carboplatin; Lung cancer; Internal medicine; Adverse effect; Oncology; Paclitaxel; Chemotherapy; Population; Clinical endpoint; Cancer; Surgery; Clinical trial; Nivolumab; Cisplatin; Immunotherapy","score_opus":0.06888573817441451,"score_gpt":0.4097461346332562,"score_spread":0.3408603964588417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030666284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97956663,0.0018013318,0.00018336329,0.016189788,0.00069383933,0.0008852474,0.0000107604865,0.000017174865,0.0006518884],"genre_scores_gemma":[0.981686,0.008407788,0.0022923665,0.0070235594,0.0003198951,0.0000140252,0.0000033321448,0.00006350648,0.00018955425],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99483484,0.00022956466,0.0035403904,0.0004274524,0.0005633811,0.0004043536],"domain_scores_gemma":[0.994675,0.0009851546,0.0031684865,0.00030265204,0.0004198594,0.00044884023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009795664,0.00037679332,0.003217876,0.00016900172,0.000048426435,0.000013447232,0.00024497363,0.00051084853,0.0003777537],"category_scores_gemma":[0.00042816185,0.00023477395,0.00047531334,0.00042417547,0.00038702128,0.00013492236,0.0000508763,0.001012277,0.0000010593702],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.644846,0.0009405105,0.1630821,0.00020514056,0.0026568437,0.00064663996,0.0031495746,0.00007187459,0.00079468207,0.000002355358,0.00058383815,0.18302043],"study_design_scores_gemma":[0.45334685,0.06318582,0.44170582,0.0006655134,0.0013972132,0.0004977534,0.0020254203,0.0028474978,0.0018872862,0.0000072949756,0.031811986,0.00062152755],"about_ca_topic_score_codex":0.00036312314,"about_ca_topic_score_gemma":0.0005393766,"teacher_disagreement_score":0.27862376,"about_ca_system_score_codex":0.00070533424,"about_ca_system_score_gemma":0.004559584,"threshold_uncertainty_score":0.95738035},"labels":[],"label_agreement":null},{"id":"W3030945835","doi":"10.1200/jco.2020.38.15_suppl.tps6589","title":"Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Lenvatinib; Pembrolizumab; Medicine; Internal medicine; Oncology; Head and neck squamous-cell carcinoma; Placebo; Clinical trial; Cancer; Head and neck cancer; Immunotherapy; Pathology; Thyroid cancer","score_opus":0.1601881154732406,"score_gpt":0.4592504337238478,"score_spread":0.29906231825060714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030945835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98763996,0.0013359721,0.00007149515,0.009349943,0.00040624785,0.00078994647,0.000006562643,0.000011896036,0.00038796582],"genre_scores_gemma":[0.9936762,0.0005456716,0.0012221582,0.0037104543,0.00064121914,0.0000109970215,0.0000033666577,0.00003267747,0.00015728282],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99569046,0.00045070454,0.002761862,0.00035348293,0.00042336257,0.00032010322],"domain_scores_gemma":[0.9961573,0.0013525473,0.0015502302,0.00020186296,0.00023054972,0.0005074924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017424463,0.00026040702,0.002188782,0.0001503457,0.00005664563,0.00001688577,0.00018161343,0.00019090845,0.00024156547],"category_scores_gemma":[0.0010499685,0.00015939598,0.00024493647,0.000369182,0.00026696434,0.00012719141,0.00005223372,0.0013109307,0.000004983084],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53151155,0.017034777,0.30710593,0.00024542908,0.00031498843,0.004275679,0.0023231492,0.000011407564,0.00019926803,0.0000015509038,0.0020358032,0.13494045],"study_design_scores_gemma":[0.42148173,0.3888385,0.15072818,0.00021174304,0.0008297718,0.001036272,0.0018352207,0.0009095736,0.00009625755,0.000011797082,0.03373885,0.0002820869],"about_ca_topic_score_codex":0.00013804951,"about_ca_topic_score_gemma":0.001464499,"teacher_disagreement_score":0.37180373,"about_ca_system_score_codex":0.00012729134,"about_ca_system_score_gemma":0.0017396647,"threshold_uncertainty_score":0.64999795},"labels":[],"label_agreement":null},{"id":"W3031031270","doi":"10.3747/co.27.5495","title":"Treatment of Non-Small-Cell Lung Cancer after Progression on Nivolumab or Pembrolizumab","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Victoria","funders":"","keywords":"Medicine; Nivolumab; Pembrolizumab; Internal medicine; Erlotinib; Lung cancer; Hazard ratio; Docetaxel; Oncology; Confidence interval; Cancer; Immunotherapy; Epidermal growth factor receptor","score_opus":0.07456514527921008,"score_gpt":0.4123760241915838,"score_spread":0.3378108789123737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031031270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97941744,0.014602304,0.00003883285,0.0027039414,0.00090476096,0.0010154996,0.00003048845,0.000035426816,0.001251284],"genre_scores_gemma":[0.99349844,0.00459509,0.00013490315,0.0004196407,0.0004667406,0.00042457937,0.00002212607,0.000024050969,0.0004144487],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989956,0.00004568456,0.00029250298,0.00029182908,0.00014309754,0.00023125828],"domain_scores_gemma":[0.9994401,0.00004175508,0.00014388771,0.00017819052,0.00006108243,0.00013498837],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000030983174,0.00018043113,0.0004313716,0.000057839683,0.0000301537,0.000004165678,0.000067882575,0.000111998146,0.0009415179],"category_scores_gemma":[0.000008095154,0.00011514283,0.00015953946,0.00015727816,0.00007871671,0.0000190937,0.000022389924,0.00011036162,0.000016253958],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07732345,0.0032108051,0.05027938,0.0008294016,0.00022799576,0.00015331505,0.003242471,0.0000023598147,0.0109037245,0.000002241842,0.0067763603,0.8470485],"study_design_scores_gemma":[0.058087885,0.044205096,0.057603743,0.00095291133,0.00081557623,0.000051118437,0.0002996259,0.0023721757,0.043853365,0.0000018569266,0.7913287,0.00042790713],"about_ca_topic_score_codex":0.00003457701,"about_ca_topic_score_gemma":0.000033879594,"teacher_disagreement_score":0.8466206,"about_ca_system_score_codex":0.00052606215,"about_ca_system_score_gemma":0.00055606914,"threshold_uncertainty_score":0.99997175},"labels":[],"label_agreement":null},{"id":"W3031213565","doi":"10.1002/hep.31396","title":"Severe Refractory Checkpoint Inhibitor‐Related Hepatitis Reversed With Anti‐Thymocyte Globulin and n‐Acetylcysteine","year":2020,"lang":"en","type":"article","venue":"Hepatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Anti-thymocyte globulin; Medicine; Globulin; Internal medicine","score_opus":0.012571523816576597,"score_gpt":0.2318971666539593,"score_spread":0.2193256428373827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031213565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98264563,0.0033627057,0.000033496104,0.01145131,0.00016558154,0.00038295306,0.000018032586,0.00014238566,0.0017979122],"genre_scores_gemma":[0.9920519,0.0022836227,0.0004903803,0.004615404,0.00010822408,0.000012930103,0.000045872643,0.000035285742,0.0003563657],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99866426,0.00008065434,0.00036767722,0.000423587,0.00017280896,0.000290985],"domain_scores_gemma":[0.9992991,0.000044336208,0.00013969436,0.00023600187,0.00007367947,0.00020716297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010809486,0.00022332501,0.0005455252,0.00006201812,0.000071246206,0.00001141155,0.000064337815,0.00023064825,0.00046001465],"category_scores_gemma":[0.000054632925,0.00017852272,0.000080713864,0.00029178834,0.0002445938,0.00007787436,0.000045417186,0.00029769776,0.00005165035],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011298865,0.0002080906,0.83002716,0.00059985014,0.0009028217,0.0021823945,0.0018116238,0.0000017598246,0.12654617,0.00012319961,0.012071043,0.014227003],"study_design_scores_gemma":[0.055797573,0.01143937,0.29110494,0.0009901221,0.00085181685,0.008150674,0.00082607416,0.0031961217,0.04987768,0.00006619335,0.5759183,0.0017811164],"about_ca_topic_score_codex":0.0004982575,"about_ca_topic_score_gemma":0.00013371986,"teacher_disagreement_score":0.56384724,"about_ca_system_score_codex":0.00008596989,"about_ca_system_score_gemma":0.00018375236,"threshold_uncertainty_score":0.72799456},"labels":[],"label_agreement":null},{"id":"W3031455888","doi":"10.1200/jco.2020.38.15_suppl.6517","title":"Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatment-naïve head and neck squamous cell carcinoma (HNSCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Pembrolizumab; Refractory (planetary science); Population; Gastroenterology; Cancer; Head and neck cancer; Combination therapy; Oncology; Immunotherapy","score_opus":0.052614902764829545,"score_gpt":0.3573437048378566,"score_spread":0.30472880207302705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031455888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959921,0.0003471735,0.0000080305335,0.002112813,0.0001747778,0.00049240305,0.000027584903,0.0000072613043,0.0008378472],"genre_scores_gemma":[0.9980263,0.000181733,0.00022181758,0.0013296887,0.00009107749,0.000003989826,0.00003943759,0.00002491965,0.00008099728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966836,0.00050030363,0.0017738492,0.00032908132,0.00046468692,0.00024847148],"domain_scores_gemma":[0.99646556,0.0005217881,0.002068884,0.000277923,0.00039108016,0.00027476542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069639354,0.00024247274,0.0017373093,0.00026193896,0.00006485516,0.000013801951,0.00018220102,0.00032579547,0.00012806208],"category_scores_gemma":[0.00015368692,0.00013696725,0.00040182396,0.0008909175,0.00035286127,0.000115663446,0.00003090677,0.0006174425,0.0000023389678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05361314,0.004902,0.93250895,0.000048848276,0.00086385326,0.00006736977,0.00051889097,0.00016826553,0.0009850689,0.0000023646762,0.0007989723,0.0055222497],"study_design_scores_gemma":[0.07276722,0.049774773,0.86930656,0.00004948725,0.0020424887,0.000013679464,0.00020188004,0.0005066849,0.001780515,0.0000020416876,0.0034145364,0.00014012637],"about_ca_topic_score_codex":0.00021001213,"about_ca_topic_score_gemma":0.0001843547,"teacher_disagreement_score":0.0632024,"about_ca_system_score_codex":0.0003650797,"about_ca_system_score_gemma":0.0014022563,"threshold_uncertainty_score":0.55853623},"labels":[],"label_agreement":null},{"id":"W3031475478","doi":"10.1200/jco.2020.38.15_suppl.6505","title":"KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Population; Proportional hazards model; Progression-free survival; Chemotherapy; Cancer; Immunotherapy","score_opus":0.19787854319714904,"score_gpt":0.44318689677225587,"score_spread":0.24530835357510683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031475478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93454486,0.026451424,0.0003499679,0.035934668,0.0009959197,0.0016069404,0.000012156334,0.000017541199,0.00008653945],"genre_scores_gemma":[0.9655942,0.016083082,0.0026506402,0.013949065,0.0014366262,0.000059427228,0.0000070070532,0.00007058328,0.00014937959],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9951138,0.0004647196,0.0029633688,0.0004256709,0.0005953143,0.00043711285],"domain_scores_gemma":[0.99373,0.0029665672,0.0021378302,0.00034688655,0.00040362764,0.0004150598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022833175,0.00039673285,0.0021756734,0.00011706335,0.00012406966,0.00003540137,0.0003600048,0.00038627294,0.00034890138],"category_scores_gemma":[0.000966728,0.00020847532,0.0013047594,0.00032004758,0.00035172093,0.00017460847,0.00004955043,0.00091126503,0.0000030544034],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55501026,0.0020693983,0.008030216,0.00019582025,0.00051023206,0.00027056382,0.0014454186,0.0000066724924,0.0021248497,0.0000023741384,0.0015312557,0.42880297],"study_design_scores_gemma":[0.27204943,0.32711726,0.06993236,0.00066804595,0.00077039294,0.0006152575,0.0005771176,0.0023545108,0.004733358,0.00025302352,0.32034525,0.00058401225],"about_ca_topic_score_codex":0.000036497517,"about_ca_topic_score_gemma":0.000051997074,"teacher_disagreement_score":0.42821896,"about_ca_system_score_codex":0.00013272186,"about_ca_system_score_gemma":0.0017334406,"threshold_uncertainty_score":0.85013765},"labels":[],"label_agreement":null},{"id":"W3031796418","doi":"10.1200/jco.2020.38.15_suppl.6548","title":"Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Head and neck squamous-cell carcinoma; Internal medicine; Peripheral blood mononuclear cell; Durvalumab; Germline; Gastroenterology; Oncology; Cancer; Immunotherapy; Head and neck cancer; Nivolumab; In vitro; Biology","score_opus":0.10542487010938492,"score_gpt":0.4275511045825271,"score_spread":0.32212623447314215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031796418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723192,0.014796076,0.00002018425,0.010785446,0.0012312339,0.0006268858,0.00010959404,0.00001176222,0.000099624674],"genre_scores_gemma":[0.9875252,0.0029187256,0.0013709834,0.0077873864,0.00030446355,0.0000068662202,0.000028205122,0.00004356787,0.000014560839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99468374,0.00059715705,0.003094977,0.000642408,0.00056001154,0.00042171913],"domain_scores_gemma":[0.9954107,0.0017979909,0.0014193003,0.00027229774,0.0003759798,0.000723726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012611266,0.00037275863,0.0026625362,0.00023826634,0.000066588174,0.000040871164,0.00024379505,0.00032550143,0.000104064566],"category_scores_gemma":[0.0019670848,0.00030355944,0.00043129537,0.00036989813,0.0003441715,0.00016564252,0.00018193178,0.00081869465,0.000010556673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04182181,0.002561528,0.80330795,0.00021582226,0.0015900212,0.0023074541,0.002125746,0.000011263327,0.010765927,0.000002913219,0.006758788,0.12853076],"study_design_scores_gemma":[0.056640733,0.015453886,0.91778636,0.00034260636,0.0007861075,0.00003294726,0.0008902258,0.00015821117,0.0011581357,0.00010878382,0.0063379356,0.0003040982],"about_ca_topic_score_codex":0.0007250186,"about_ca_topic_score_gemma":0.00030256712,"teacher_disagreement_score":0.12822665,"about_ca_system_score_codex":0.0002321515,"about_ca_system_score_gemma":0.0005178831,"threshold_uncertainty_score":0.99994165},"labels":[],"label_agreement":null},{"id":"W3031828754","doi":"10.3747/co.27.5293","title":"Nivolumab in Metastatic Melanoma: Good Efficacy and Tolerability in Elderly Patients","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Nivolumab; Medicine; Tolerability; Melanoma; Oncology; Internal medicine; Immunotherapy; Clinical endpoint; Confidence interval; Response Evaluation Criteria in Solid Tumors; Progressive disease; Chemotherapy; Clinical trial; Adverse effect; Cancer research; Cancer","score_opus":0.08384156640552683,"score_gpt":0.3739866139077672,"score_spread":0.2901450475022404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031828754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941403,0.0024334989,0.0000110166275,0.0021654419,0.00028113966,0.00056312897,0.000007394565,0.000015697777,0.00038234834],"genre_scores_gemma":[0.9992862,0.00018909348,0.000088383254,0.00033089033,0.000037811853,0.000029484687,0.000023507886,0.000007751227,0.000006877188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893224,0.00013096501,0.0003699198,0.000271967,0.000098605546,0.00019630969],"domain_scores_gemma":[0.9995914,0.00011248852,0.00006851616,0.00010645226,0.00002805311,0.00009308026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017955617,0.00010925026,0.00039764112,0.000073420044,0.000015287029,0.0000051751235,0.00005561757,0.000056797304,0.00009811928],"category_scores_gemma":[0.0001404023,0.00009652854,0.00004042706,0.00023735165,0.000086657165,0.000041219533,0.00003388461,0.00023973803,0.000008419829],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026484383,0.0013800368,0.5757096,0.0001483939,0.000024943254,0.000020846754,0.001571871,6.497176e-7,0.00021910979,0.000011762889,0.00035242256,0.41791198],"study_design_scores_gemma":[0.021545699,0.0039599957,0.92957455,0.00007298144,0.00003650718,0.0000060368934,0.00016110684,0.00014690134,0.000065804896,0.000037040776,0.044280756,0.00011260898],"about_ca_topic_score_codex":0.00006797861,"about_ca_topic_score_gemma":0.00022130473,"teacher_disagreement_score":0.41779935,"about_ca_system_score_codex":0.00021242279,"about_ca_system_score_gemma":0.00013781877,"threshold_uncertainty_score":0.39363196},"labels":[],"label_agreement":null},{"id":"W3031847233","doi":"10.1200/jco.2020.38.15_suppl.tps6595","title":"Window-of-opportunity trial of nivolumab with or without the IDO inhibitor BMS-986205 in patients with resectable squamous cell carcinoma of the head and neck (SCCHN).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Lymph node; Internal medicine; Primary tumor; Oncology; Nasal cavity; Stage (stratigraphy); Melanoma; Cancer; Gastroenterology; Surgery; Immunotherapy; Metastasis; Cancer research","score_opus":0.091868815051498,"score_gpt":0.3802406123352916,"score_spread":0.2883717972837936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031847233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949367,0.00019815125,0.0000039573374,0.003363578,0.00030237355,0.0007239989,0.000008471601,0.0000018019192,0.0004609731],"genre_scores_gemma":[0.9983471,0.000060611506,0.00025152802,0.0009431362,0.00030300478,0.0000028881716,7.976165e-7,0.000015075247,0.00007588318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966332,0.00055823603,0.001968117,0.00015250777,0.0005176587,0.00017033539],"domain_scores_gemma":[0.995589,0.001083983,0.002489793,0.0002501087,0.00040287283,0.00018420609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001762836,0.00013591678,0.0013741849,0.000060241513,0.00003331585,0.0000036485965,0.0002215731,0.00021080922,0.00006083983],"category_scores_gemma":[0.0012122933,0.000055974426,0.00021736085,0.00031876686,0.0006721244,0.00007019586,0.00006164635,0.00078223966,1.5499901e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47129497,0.0015145751,0.5215296,0.00008256176,0.0000929885,0.000022343744,0.00037906397,0.0000030948713,0.00027739565,0.0000011919466,0.0004550925,0.0043470934],"study_design_scores_gemma":[0.2080268,0.11723015,0.6703697,0.000209542,0.0002744004,0.000028948709,0.00041781602,0.000020314033,0.0012398867,0.0000066035223,0.0021045553,0.00007130002],"about_ca_topic_score_codex":0.0002590576,"about_ca_topic_score_gemma":0.00052044075,"teacher_disagreement_score":0.2632682,"about_ca_system_score_codex":0.00006122631,"about_ca_system_score_gemma":0.002786029,"threshold_uncertainty_score":0.49422958},"labels":[],"label_agreement":null},{"id":"W3031858365","doi":"10.1200/jco.2020.38.15_suppl.6531","title":"Initial analyses of a phase I/II trial of durvalumab (D) plus tremelimumab (T) and stereotactic body radiotherapy (SBRT) for oligometastatic head and neck carcinoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Cancer Care Ontario; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Adverse effect; Durvalumab; Internal medicine; Head and neck cancer; Head and neck squamous-cell carcinoma; Phases of clinical research; Nuclear medicine; Clinical trial; Radiation therapy; Cancer; Pembrolizumab; Immunotherapy","score_opus":0.28005804536798734,"score_gpt":0.5396743364935574,"score_spread":0.2596162911255701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031858365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902018,0.0037626831,0.0003442697,0.0045685004,0.0004348916,0.000590258,0.000023938042,0.0000037780487,0.00006992387],"genre_scores_gemma":[0.992793,0.0021222048,0.0027593602,0.0014312512,0.0008500601,0.0000053058434,0.000003000077,0.000018077428,0.00001770689],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996145,0.00036496826,0.0028297454,0.00019732921,0.00028718179,0.00017576265],"domain_scores_gemma":[0.99485815,0.002156372,0.0022582943,0.0001330214,0.00029941255,0.0002947818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001668441,0.00016121258,0.0023671726,0.00016800285,0.00003840341,0.000006769377,0.000103631704,0.00020291144,0.00007773842],"category_scores_gemma":[0.0018758983,0.0001151842,0.0005932498,0.00019595114,0.0003828599,0.00010152697,0.000027433465,0.00034668655,1.2245151e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8261946,0.0030569467,0.0016448667,0.00030775726,0.00243008,0.00011602503,0.00075334194,0.0000018766888,0.018290166,0.000011304152,0.00057547,0.14661755],"study_design_scores_gemma":[0.647443,0.32088482,0.017303046,0.0001416344,0.0020884387,0.00029227455,0.0003169032,0.0013208236,0.0015804471,0.00006430217,0.00842647,0.00013784754],"about_ca_topic_score_codex":0.00004421227,"about_ca_topic_score_gemma":0.000010816434,"teacher_disagreement_score":0.31782788,"about_ca_system_score_codex":0.00008048714,"about_ca_system_score_gemma":0.0014787293,"threshold_uncertainty_score":0.46970755},"labels":[],"label_agreement":null},{"id":"W3031893936","doi":"10.1200/jco.2020.38.15_suppl.9576","title":"Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Medicine; Biomarker; Nivolumab; Oncology; Lung cancer; Ipilimumab; Internal medicine; Durvalumab; Clinical trial; Cancer; Immunotherapy","score_opus":0.31570217002083223,"score_gpt":0.5403117599691646,"score_spread":0.22460958994833236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031893936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44508618,0.004827917,0.03192402,0.38886377,0.0020410542,0.12643015,0.00034027634,0.00013352513,0.0003531299],"genre_scores_gemma":[0.9008217,0.0022780441,0.030880462,0.032849103,0.0055138646,0.02663919,0.00009285444,0.00021134151,0.0007134257],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99587405,0.0005919532,0.0024803628,0.00039111474,0.0003017966,0.00036070705],"domain_scores_gemma":[0.99505866,0.0019163566,0.001894827,0.00017399756,0.00046295504,0.00049322844],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016658565,0.00024800785,0.0014039238,0.00009343821,0.00009132709,0.00003486217,0.00019182381,0.00038529647,0.00093496154],"category_scores_gemma":[0.0006344886,0.00017970604,0.00051600544,0.00017293783,0.00020245455,0.00015180466,0.000058488215,0.0005203352,0.0000032119776],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13692772,0.0010175611,0.17226636,0.00054507406,0.0035711143,0.0002718987,0.0010869645,0.000018128441,0.01525233,0.000013236359,0.14049637,0.5285332],"study_design_scores_gemma":[0.11670745,0.028779587,0.16106695,0.00058582297,0.0031431871,0.00010709442,0.0008075282,0.0051472406,0.0028110582,0.00021269557,0.6800864,0.00054500863],"about_ca_topic_score_codex":0.00017313189,"about_ca_topic_score_gemma":0.00015754854,"teacher_disagreement_score":0.53959,"about_ca_system_score_codex":0.0002452844,"about_ca_system_score_gemma":0.0018228749,"threshold_uncertainty_score":0.9999783},"labels":[],"label_agreement":null},{"id":"W3032092952","doi":"10.3389/fimmu.2020.00980","title":"Pro-inflammatory TNF-α and IFN-γ Promote Tumor Growth and Metastasis via Induction of MACC1","year":2020,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chinese Government Scholarship; Partenariat Canadien Contre Le Cancer; Deutschen Konsortium für Translationale Krebsforschung","keywords":"Metastasis; Cancer research; Gene knockdown; Colorectal cancer; Inflammation; Medicine; Cancer; Carcinogenesis; Tumor necrosis factor alpha; Tumor progression; Oncogene; Cytokine; Immunology; Biology; Internal medicine; Cell cycle; Cell culture","score_opus":0.011701155080336782,"score_gpt":0.2291603234960419,"score_spread":0.21745916841570512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032092952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98382854,0.01215836,0.00071835297,0.002265043,0.00040033695,0.00046727457,0.000006393434,0.000029886744,0.000125781],"genre_scores_gemma":[0.9931843,0.0012277439,0.0051175286,0.00033693397,0.000048286176,0.000028033777,0.000008082551,0.000018987515,0.000030047975],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99911815,0.00006948487,0.00030248254,0.0002485781,0.000082415216,0.00017886925],"domain_scores_gemma":[0.999662,0.0000114781105,0.00012259255,0.0001254006,0.000032256798,0.00004627461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014209303,0.00013156327,0.00039154894,0.00016784568,0.00003124829,0.0000055434994,0.000060506867,0.00010477814,0.000022436428],"category_scores_gemma":[0.000057449084,0.00011933673,0.000042954143,0.00021679763,0.00034960173,0.00008932076,0.00004773832,0.00020840127,7.403811e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008984111,0.00013207123,0.11210564,0.00071729993,0.001121944,0.00008478866,0.0036126184,2.5533132e-7,0.59701306,0.00009944286,0.0018169585,0.2743118],"study_design_scores_gemma":[0.01708931,0.003991292,0.5839828,0.0003260812,0.0004466141,0.0006990894,0.003787585,0.0004542748,0.36745793,0.0012368183,0.019875478,0.00065268035],"about_ca_topic_score_codex":0.00007812996,"about_ca_topic_score_gemma":0.0000043468335,"teacher_disagreement_score":0.47187722,"about_ca_system_score_codex":0.000038461974,"about_ca_system_score_gemma":0.00006202621,"threshold_uncertainty_score":0.48664105},"labels":[],"label_agreement":null},{"id":"W3032246744","doi":"10.1200/jco.2020.38.15_suppl.10076","title":"Effect of automated TIL quantification in early-stage melanoma on accuracy of standard T staging using AJCC guidelines.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"National Institutes of Health; Melanoma Research Alliance","keywords":"Medicine; Melanoma; Tumor-infiltrating lymphocytes; Stage (stratigraphy); Cancer staging; Cutoff; Adjuvant therapy; H&E stain; Internal medicine; Cancer; Cohort; Oncology; Nuclear medicine; Surgery; Artificial intelligence; Immunotherapy; Immunohistochemistry; Cancer research","score_opus":0.24113845237824974,"score_gpt":0.5412683804119947,"score_spread":0.30012992803374494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032246744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943012,0.00036168957,0.0002961525,0.004153591,0.000450121,0.00023714965,0.000011054726,0.000013093527,0.00017595985],"genre_scores_gemma":[0.9968044,0.0003942606,0.0016781302,0.0008445985,0.00025058232,7.5283924e-7,0.0000021126707,0.000013999839,0.000011153757],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99536026,0.00063647184,0.0033338957,0.00014657514,0.00038459912,0.00013818635],"domain_scores_gemma":[0.99368167,0.002666357,0.0029027862,0.00015452779,0.0004632236,0.00013143981],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0056673964,0.00011612891,0.0014568615,0.00015463599,0.000013953855,0.000004398223,0.00014076778,0.0002346052,0.000055635715],"category_scores_gemma":[0.008657964,0.000081175196,0.00038680434,0.00029003495,0.0001424418,0.00008510885,0.00002289708,0.00048966566,0.0000015632329],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19662003,0.00076642947,0.2812141,0.00052511937,0.00066433905,0.00038303208,0.00058394787,0.0008175752,0.12835711,0.000027858356,0.0019741107,0.38806635],"study_design_scores_gemma":[0.07042696,0.15129371,0.5263706,0.0027973275,0.00088735943,0.00010484806,0.00037728902,0.03791538,0.16675502,0.00002355314,0.042686325,0.00036161285],"about_ca_topic_score_codex":0.00008764057,"about_ca_topic_score_gemma":0.000007774164,"teacher_disagreement_score":0.38770473,"about_ca_system_score_codex":0.00014421082,"about_ca_system_score_gemma":0.0010668148,"threshold_uncertainty_score":0.99969256},"labels":[],"label_agreement":null},{"id":"W3032247240","doi":"10.1200/jco.2020.38.15_suppl.e21683","title":"Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Internal medicine; Clinical endpoint; Ipilimumab; Taxane; Oncology; Interim analysis; Lung cancer; Progressive disease; Phases of clinical research; Clinical trial; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Cancer; Immunotherapy; Breast cancer","score_opus":0.11981197337168767,"score_gpt":0.4534532654417884,"score_spread":0.33364129207010074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032247240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98974997,0.0003751485,0.000086804626,0.007056521,0.0011439315,0.0014289147,0.000053398486,0.000005206491,0.00010009626],"genre_scores_gemma":[0.9956838,0.00089626975,0.00090052874,0.0017879546,0.000643337,0.000011315438,0.000025829202,0.000018899733,0.000032085976],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99377626,0.0010588376,0.004314523,0.00029593363,0.00036508538,0.00018933201],"domain_scores_gemma":[0.99173087,0.0037821059,0.003649807,0.00019872293,0.00039467734,0.00024384685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037796628,0.00018246437,0.0018418233,0.00007446038,0.000041133153,0.000011508332,0.00020545351,0.00026069584,0.00007545929],"category_scores_gemma":[0.0030136986,0.000104847655,0.00039210627,0.00024319069,0.00036700306,0.000094782044,0.00006841979,0.0009711215,6.047091e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8818654,0.009311935,0.0132033,0.0000218809,0.00079121796,0.000065278015,0.0006619386,0.00000764097,0.000069383066,5.5423993e-7,0.0015224132,0.09247905],"study_design_scores_gemma":[0.76542634,0.17412232,0.056129523,0.0002467438,0.0009283314,0.0000028173652,0.00018454558,0.0008563218,0.000056013898,0.0000037873306,0.0019526891,0.00009059608],"about_ca_topic_score_codex":0.00036408886,"about_ca_topic_score_gemma":0.00016231368,"teacher_disagreement_score":0.16481037,"about_ca_system_score_codex":0.000109124725,"about_ca_system_score_gemma":0.0015312644,"threshold_uncertainty_score":0.42755634},"labels":[],"label_agreement":null},{"id":"W3032485582","doi":"10.1200/jco.2020.38.15_suppl.e19121","title":"Prognostic value of programmed death-ligand 1 in solid tumors: A meta-analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Centre Hospitalier Universitaire de Sherbrooke; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Subgroup analysis; Oncology; Internal medicine; Meta-analysis; Confidence interval; Stage (stratigraphy); Cancer; Disease","score_opus":0.3049344548205364,"score_gpt":0.5032714261614165,"score_spread":0.19833697134088013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032485582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657537,0.0033953944,0.00025760927,0.029497357,0.00017133034,0.00040391117,0.0000038773333,0.0000074512923,0.0005094095],"genre_scores_gemma":[0.9909704,0.0002673417,0.0032602402,0.0051067723,0.00033558265,0.00000813063,0.0000020156028,0.000010853283,0.00003868477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950133,0.0005073592,0.0036885925,0.00018979085,0.00039179038,0.000209143],"domain_scores_gemma":[0.9953787,0.0016074595,0.002224843,0.00015104101,0.00032263313,0.00031537417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039177733,0.00013499486,0.0040524267,0.00019357985,0.000011561276,0.000006159586,0.00018224519,0.00024697869,0.00019830227],"category_scores_gemma":[0.0043916167,0.00008365746,0.0029430715,0.0006920859,0.0001878609,0.000059136113,0.000032220894,0.00070850307,0.0000033822778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05191592,0.006900742,0.5540971,0.0002480735,0.3222491,0.0030576186,0.0011119421,0.00022790158,0.003052156,0.00016934965,0.0017673349,0.055202737],"study_design_scores_gemma":[0.018664619,0.041286472,0.67490906,0.00007331152,0.23934652,0.0002827407,0.00030404187,0.0009376803,0.0013368509,0.00031073627,0.022330517,0.0002174654],"about_ca_topic_score_codex":0.000044909968,"about_ca_topic_score_gemma":0.000048527632,"teacher_disagreement_score":0.12081195,"about_ca_system_score_codex":0.00005683628,"about_ca_system_score_gemma":0.0013696379,"threshold_uncertainty_score":0.52574927},"labels":[],"label_agreement":null},{"id":"W3032800512","doi":"10.1200/jco.2020.38.15_suppl.1000","title":"KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":185,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck","keywords":"Medicine; Gemcitabine; Carboplatin; Internal medicine; Taxane; Pembrolizumab; Oncology; Chemotherapy; Breast cancer; Cancer; Cisplatin; Immunotherapy","score_opus":0.17572670217811448,"score_gpt":0.48563345592442453,"score_spread":0.30990675374631005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032800512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675404,0.0015282696,0.0010708797,0.01955591,0.0017216983,0.008295908,0.00005806982,0.00002989944,0.00019896566],"genre_scores_gemma":[0.9828848,0.00888327,0.0015038161,0.0047479547,0.0012496705,0.00030544333,0.000012674822,0.00008007232,0.0003322719],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99232435,0.0010653858,0.0050077415,0.00048524243,0.0006537389,0.00046355446],"domain_scores_gemma":[0.98841685,0.0052174795,0.004230204,0.000299235,0.0012657276,0.0005705287],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0046258955,0.00044804896,0.005302915,0.0001897234,0.00009052134,0.000024840445,0.00040166295,0.00033973722,0.001113326],"category_scores_gemma":[0.001634668,0.00027650147,0.0013767759,0.0005868929,0.00048762577,0.0001823588,0.000034256638,0.00094079203,0.0000027072533],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8035804,0.0093653165,0.00011205998,0.00014284924,0.008958656,0.00010602628,0.002649546,0.000044299733,0.00022904531,0.0000054523384,0.00305346,0.17175287],"study_design_scores_gemma":[0.88439745,0.1028555,0.00019851803,0.0002532456,0.0028152857,0.00013592832,0.0015361349,0.0011402313,0.0007152423,0.000016280504,0.005692683,0.00024350337],"about_ca_topic_score_codex":0.00031917353,"about_ca_topic_score_gemma":0.00029469124,"teacher_disagreement_score":0.17150936,"about_ca_system_score_codex":0.00041667043,"about_ca_system_score_gemma":0.0044367155,"threshold_uncertainty_score":0.9999687},"labels":[],"label_agreement":null},{"id":"W3033011894","doi":"10.1101/2020.06.07.136366","title":"Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in <i>KRAS/p53</i> mutant lung cancers","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute; U.S. Department of Health and Human Services","keywords":"KRAS; Blockade; MEK inhibitor; Cancer research; Melanoma; Lung cancer; Combination therapy; Medicine; MAPK/ERK pathway; Targeted therapy; Immunotherapy; Immune checkpoint; Downregulation and upregulation; Immune system; Biology; Kinase; Pharmacology; Immunology; Cancer; Oncology; Internal medicine; Receptor; Colorectal cancer; Gene","score_opus":0.011847030163444568,"score_gpt":0.23567283738075262,"score_spread":0.22382580721730805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033011894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753583,0.014501349,0.00025008648,0.0047929627,0.001520996,0.0027882445,0.0005164556,0.00024931904,0.000022281485],"genre_scores_gemma":[0.9881329,0.0071608773,0.00097058737,0.0029016773,0.00037660202,0.00030319628,0.0000020159036,0.00013981787,0.000012318923],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99650264,0.0001634967,0.0008248358,0.0012812882,0.0005767791,0.00065093796],"domain_scores_gemma":[0.9977648,0.00008964813,0.0004329053,0.0008771904,0.00041014265,0.0004252647],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007268786,0.00067457743,0.0010976393,0.00035331055,0.00013724146,0.0001773913,0.00032678657,0.00050759775,0.00003512239],"category_scores_gemma":[0.000112298636,0.0006847347,0.00017783963,0.00093915797,0.00016377862,0.00013847725,0.00020946856,0.00084111106,0.000010918512],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024912567,0.0001493573,0.006556615,0.0006560476,0.0003134084,0.00019191689,0.00011637329,0.000009269513,0.9866317,0.00010254339,0.002769854,0.000011678321],"study_design_scores_gemma":[0.0069460934,0.00022989121,0.18544233,0.0022287339,0.00013003375,5.2107357e-8,0.000013748255,0.00013838412,0.77371436,0.0000033921121,0.030215407,0.0009375505],"about_ca_topic_score_codex":0.00036462554,"about_ca_topic_score_gemma":0.00007322622,"teacher_disagreement_score":0.21291728,"about_ca_system_score_codex":0.0012923074,"about_ca_system_score_gemma":0.0011978977,"threshold_uncertainty_score":0.99956036},"labels":[],"label_agreement":null},{"id":"W3033203711","doi":"10.1016/j.jtho.2020.05.019","title":"The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee","year":2020,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":292,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Merck Sharp and Dohme; EMD Serono; Johnson and Johnson; Illumina; Roche; AstraZeneca; Novartis; Amgen; Pfizer; Merck","keywords":"Medicine; Biomarker; Immunotherapy; Lung cancer; Oncology; Clinical trial; Companion diagnostic; Surrogate endpoint; Cancer; Immune checkpoint; Disease; Internal medicine; Bioinformatics; Biology","score_opus":0.06436462107388363,"score_gpt":0.463307146434376,"score_spread":0.39894252536049235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033203711","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012296694,0.960208,0.000008363053,0.024440506,0.00088929554,0.0020053408,0.00008638112,0.0000042437437,0.00006116739],"genre_scores_gemma":[0.010601015,0.9881298,0.000070316324,0.00016496576,0.0007650147,0.00018898363,0.000006974844,0.000028547858,0.000044368633],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99720967,0.0010278272,0.0010367994,0.00020302962,0.00038499755,0.00013769048],"domain_scores_gemma":[0.99129605,0.004053588,0.0036027513,0.00023882533,0.00077373843,0.000035067813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00239982,0.00021533921,0.0012912864,0.00009951788,0.00015238713,0.000026912934,0.0005137428,0.00019088357,0.000027920334],"category_scores_gemma":[0.0006024929,0.0000981176,0.00040382965,0.00014470183,0.0001848101,0.000069651804,0.00005445922,0.00045260214,1.6658362e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077470145,0.00032099758,0.00012771392,0.0004326166,0.0073575657,0.000031617,0.011079584,5.054663e-7,0.00010923511,0.000032842705,0.00041387262,0.9723464],"study_design_scores_gemma":[0.0039481656,0.0075116926,0.0053230464,0.002355454,0.0064708516,0.000581028,0.043580085,0.00007173889,0.000026172384,0.00033936105,0.92962587,0.00016652135],"about_ca_topic_score_codex":0.00053512835,"about_ca_topic_score_gemma":0.00049846456,"teacher_disagreement_score":0.9721799,"about_ca_system_score_codex":0.0008881908,"about_ca_system_score_gemma":0.0010955104,"threshold_uncertainty_score":0.40011194},"labels":[],"label_agreement":null},{"id":"W3034371375","doi":"10.1016/j.autrev.2020.102595","title":"Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort","year":2020,"lang":"en","type":"review","venue":"Autoimmunity Reviews","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Western University; Université de Montréal; University of Alberta; University of Ottawa; Jewish General Hospital; University of Calgary; McGill University; University of British Columbia; University of Toronto; Dalhousie University","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Prednisone; Cohort; Cancer; Immune system; Exacerbation; Single Center; Immunology","score_opus":0.05960250142615363,"score_gpt":0.3507416728297316,"score_spread":0.291139171403578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034371375","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000116404735,0.9896185,0.000031115887,0.00019633537,0.0006001612,0.008486874,0.00017111957,0.00044169492,0.00033782466],"genre_scores_gemma":[0.00004876181,0.9917364,0.00024492812,0.0005943474,0.00004236809,0.0019003308,0.0019935528,0.00039401068,0.0030453014],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926254,0.0017256606,0.003449421,0.00081556296,0.00068087433,0.00070309365],"domain_scores_gemma":[0.9945813,0.00025463075,0.0031105545,0.0015920015,0.0002573311,0.0002041853],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0020284862,0.0013703571,0.006846499,0.00034855053,0.00029706885,0.000034607318,0.00079408305,0.0007163295,0.0011674635],"category_scores_gemma":[0.0004711714,0.0009393847,0.0026081812,0.0019010061,0.00025399672,0.00022019591,0.00015104671,0.0019427582,0.00037725843],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022850657,0.0010694748,0.00070185016,0.01389299,0.009204429,0.00004056722,0.00041250183,2.6700465e-7,0.000010229738,0.000003031362,0.00057616533,0.97385997],"study_design_scores_gemma":[0.0061363513,0.00024495437,0.0036799794,0.1291615,0.0036422827,0.00015027533,0.00001861447,0.000027094937,7.76034e-7,0.0000016466056,0.8561054,0.0008311054],"about_ca_topic_score_codex":0.0006887931,"about_ca_topic_score_gemma":0.00011315154,"teacher_disagreement_score":0.9730289,"about_ca_system_score_codex":0.0014449242,"about_ca_system_score_gemma":0.001482538,"threshold_uncertainty_score":0.9999047},"labels":[],"label_agreement":null},{"id":"W3034782118","doi":"10.1016/j.semcancer.2020.06.003","title":"The unique immune microenvironment of liver metastases: Challenges and opportunities","year":2020,"lang":"en","type":"review","venue":"Seminars in Cancer Biology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research; Mitacs; Cancer Research UK; National Institute for Health and Care Research; Ministère de l'Économie, de la Science et de l'Innovation - Québec","keywords":"Immune system; Tumor microenvironment; Context (archaeology); Immunology; Liver cancer; Acquired immune system; Medicine; Colorectal cancer; Cancer; Gastrointestinal cancer; Cancer research; Metastasis; Biology; Hepatocellular carcinoma; Internal medicine","score_opus":0.1051626951825617,"score_gpt":0.3534766397183523,"score_spread":0.2483139445357906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034782118","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037596936,0.99735516,8.350984e-7,0.0013761874,0.00017452547,0.0006580376,0.00016658004,0.000008046478,0.00022301731],"genre_scores_gemma":[0.00003911395,0.99908495,0.00005606518,0.00015410548,0.00007259464,0.00024672755,0.000066784545,0.00002968008,0.00024998616],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984925,0.0002969063,0.00058676436,0.00032359635,0.00007055463,0.00022970691],"domain_scores_gemma":[0.99896616,0.00030774836,0.00034507312,0.00031408298,0.000015141323,0.000051792016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042357255,0.00029484555,0.0014257183,0.00009990863,0.00003740834,0.000003853512,0.00018281465,0.00025657803,0.00006696287],"category_scores_gemma":[0.00001793768,0.00017917708,0.00023638718,0.00007386736,0.0007023494,0.000013828082,0.00012942369,0.00030524636,0.0000011661363],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020279302,0.000029505012,0.000003623856,0.0052882303,0.00052505767,0.00004156605,0.0002768189,8.580278e-9,0.0000915732,0.00021023776,0.00022109324,0.99310946],"study_design_scores_gemma":[0.00035482453,0.00044378272,0.000035720634,0.010271366,0.00046641784,0.000109116925,0.00030650507,3.881505e-7,0.00007056081,0.000027164848,0.9877597,0.00015446353],"about_ca_topic_score_codex":0.0002099432,"about_ca_topic_score_gemma":0.00011032808,"teacher_disagreement_score":0.992955,"about_ca_system_score_codex":0.00019905585,"about_ca_system_score_gemma":0.00032902925,"threshold_uncertainty_score":0.73066294},"labels":[],"label_agreement":null},{"id":"W3035136361","doi":"10.3389/fimmu.2020.01152","title":"Immune Signatures and Survival of Patients With Metastatic Melanoma, Renal Cancer, and Breast Cancer","year":2020,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"Eberhard Karls Universität Tübingen; Klaus Tschira Stiftung; Deutsche Forschungsgemeinschaft","keywords":"Medicine; Cancer; Breast cancer; Immune system; Immune checkpoint; Ipilimumab; Kidney cancer; Tumor microenvironment; Melanoma; Oncology; Liquid biopsy; Renal cell carcinoma; Immunotherapy; Circulating tumor cell; Internal medicine; Immunology; Metastasis; Cancer research","score_opus":0.012114140392567157,"score_gpt":0.2726364572041529,"score_spread":0.2605223168115858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035136361","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018701305,0.99544084,0.000028514654,0.00017645671,0.00086981215,0.0009109308,0.00066081004,0.000015165421,0.000027326209],"genre_scores_gemma":[0.00047731012,0.99847186,0.0004883197,0.00004548962,0.000047681868,0.000156164,0.00015500696,0.000058466554,0.000099695884],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99817675,0.00018336454,0.0006634365,0.00047203503,0.00018592813,0.0003184873],"domain_scores_gemma":[0.999027,0.00007333351,0.00049454503,0.0002644147,0.00007805043,0.00006264428],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000139333,0.00044444864,0.0027242834,0.00034152257,0.000041732335,0.000010646169,0.00016114028,0.000289593,0.000075572054],"category_scores_gemma":[0.000017376686,0.00031217656,0.00015931447,0.00041862577,0.00059018313,0.000056797428,0.00008784598,0.00058069767,3.07978e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003630194,0.00009170754,0.007989784,0.0051842877,0.0041096406,0.000032267904,0.00015000394,2.3989426e-7,0.00001590985,0.000008464141,0.00048624168,0.9783013],"study_design_scores_gemma":[0.009481421,0.0010173954,0.06820832,0.015037303,0.0035122945,0.000095509524,0.00017467729,0.0000068752724,0.000011067734,0.00001877739,0.901777,0.0006593446],"about_ca_topic_score_codex":0.00084762217,"about_ca_topic_score_gemma":0.00011097156,"teacher_disagreement_score":0.97764194,"about_ca_system_score_codex":0.00022010197,"about_ca_system_score_gemma":0.00053441024,"threshold_uncertainty_score":0.999933},"labels":[],"label_agreement":null},{"id":"W3035342290","doi":"10.1503/cmaj.191231","title":"Immune checkpoint inhibitors in cancer immunotherapy","year":2020,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cytotoxic T cell; Immune system; Immunotherapy; Immune checkpoint; CTLA-4; Programmed cell death; Cancer immunotherapy; Cancer research; PD-L1; Immunology; Immune receptor; Medicine; T cell; Biology; Apoptosis; Biochemistry","score_opus":0.01202354094226478,"score_gpt":0.2621466733728709,"score_spread":0.25012313243060613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035342290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58977735,0.007470666,0.000021741118,0.3992051,0.001182305,0.00025862214,0.0000142392355,0.000048089692,0.0020218643],"genre_scores_gemma":[0.9301807,0.003536833,0.000058396712,0.06345439,0.00241895,0.000015920601,0.0000066197517,0.000044049175,0.0002841194],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977287,0.00009075107,0.000660236,0.00015335853,0.00092415325,0.00044281795],"domain_scores_gemma":[0.99832726,0.000043296302,0.00020337825,0.000075943615,0.00016123084,0.0011889025],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010614243,0.00012942887,0.00031098502,0.00016103365,0.00008480869,0.000047175847,0.00014135143,0.00031937196,0.0066358964],"category_scores_gemma":[0.000500813,0.00011505516,0.00020264198,0.00047974262,0.00003801093,0.00009102172,0.000008001313,0.0010531149,0.000046081346],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009939461,0.00013490902,0.37273934,0.000051545747,0.00073802593,0.0016036517,0.004063452,0.000008694503,0.015192195,0.00003353908,0.11228277,0.4921579],"study_design_scores_gemma":[0.0061186426,0.00020108257,0.18214425,0.0002586771,0.000019178364,0.00019911944,0.0005463906,0.00020365373,0.0013789486,0.000021050146,0.80870897,0.00020005452],"about_ca_topic_score_codex":0.013438456,"about_ca_topic_score_gemma":0.01806613,"teacher_disagreement_score":0.69642615,"about_ca_system_score_codex":0.0019779827,"about_ca_system_score_gemma":0.004142624,"threshold_uncertainty_score":0.9998516},"labels":[],"label_agreement":null},{"id":"W3036335108","doi":"10.1016/j.lungcan.2020.06.002","title":"Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Ottawa; Princess Margaret Cancer Centre; BC Cancer Agency; Institut Universitaire de Cardiologie et de Pneumologie de Québec","funders":"Bristol-Myers Squibb Canada","keywords":"Concordance; Medicine; Cytology; Lung cancer; Biopsy; Immunohistochemistry; Pathology; Staining; PD-L1; Cancer; Internal medicine; Immunotherapy","score_opus":0.01781178098782026,"score_gpt":0.3258548896462878,"score_spread":0.3080431086584675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036335108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.967167,0.025169514,0.00014976501,0.0033307597,0.00048079513,0.00063742755,0.0002576719,0.000039057508,0.0027680048],"genre_scores_gemma":[0.9911143,0.0036709406,0.0006243505,0.0032532257,0.0004399158,0.00012489753,0.00006601245,0.000042055308,0.00066429964],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99866956,0.000033815475,0.00035432243,0.00045804316,0.0002164029,0.00026787058],"domain_scores_gemma":[0.9991562,0.00008416277,0.0002099982,0.0003023994,0.000105348656,0.00014192502],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00003831624,0.0002563669,0.00057079794,0.00003667792,0.00006083598,0.000011175845,0.00012267924,0.00013620323,0.0014828756],"category_scores_gemma":[0.000004666128,0.00023661631,0.00010350711,0.00014430987,0.00014253148,0.000028489949,0.000058573103,0.0002760575,0.000001926811],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020058174,0.00008601641,0.029135967,0.00077775674,0.0005871528,0.00004988695,0.0010783751,0.000052871153,0.95102435,0.0000045493225,0.013064878,0.0021323483],"study_design_scores_gemma":[0.012601213,0.0009136673,0.31622368,0.0013442033,0.001063817,0.000012811827,0.00069870375,0.0059042093,0.6191509,0.0000068721015,0.041354943,0.0007250101],"about_ca_topic_score_codex":0.0025503938,"about_ca_topic_score_gemma":0.00005356352,"teacher_disagreement_score":0.3318735,"about_ca_system_score_codex":0.00041857097,"about_ca_system_score_gemma":0.0003755939,"threshold_uncertainty_score":0.9994299},"labels":[],"label_agreement":null},{"id":"W3036508677","doi":"10.1136/jitc-2020-000840","title":"Chronic immune checkpoint inhibitor pneumonitis","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Pneumonitis; Immunosuppression; Hypersensitivity pneumonitis; Internal medicine; Bronchoalveolar lavage; Immunology; Gastroenterology; Lung","score_opus":0.024502063692747628,"score_gpt":0.3195411143344083,"score_spread":0.2950390506416607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036508677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6766221,0.2711462,0.0016851373,0.045319576,0.0028439204,0.0015065518,0.000113283946,0.00009242397,0.0006707999],"genre_scores_gemma":[0.9510534,0.038997702,0.0011287641,0.0032122834,0.0038706434,0.00011957217,0.000012443819,0.00012988178,0.001475337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981288,0.000029666575,0.00089735957,0.00021311565,0.00037246675,0.00035859205],"domain_scores_gemma":[0.9987502,0.00004529358,0.00053809537,0.00021346586,0.0002947982,0.00015814019],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030069656,0.00023937541,0.0006207691,0.000103904735,0.00016024827,0.00004058761,0.00020494046,0.00012250156,0.0014406474],"category_scores_gemma":[0.00003120873,0.00019448913,0.000819337,0.00026463057,0.00014034522,0.00015349133,0.0000168994,0.0003491159,0.000005834892],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007181028,0.00005811467,0.0005598075,0.00020605102,0.0008178901,0.000008050524,0.00058684754,0.000012564502,0.7806045,0.000013679897,0.0017717037,0.20817979],"study_design_scores_gemma":[0.013785027,0.0037046194,0.008996957,0.0006163263,0.00013413404,0.00016077473,0.00016595029,0.00011461263,0.50326455,0.00007981706,0.4687035,0.0002737308],"about_ca_topic_score_codex":0.00008457739,"about_ca_topic_score_gemma":0.000008741867,"teacher_disagreement_score":0.4669318,"about_ca_system_score_codex":0.0003774385,"about_ca_system_score_gemma":0.0006791555,"threshold_uncertainty_score":0.99947214},"labels":[],"label_agreement":null},{"id":"W3036992533","doi":"10.1158/2326-6074.tumimm18-pr03","title":"Abstract PR03: Immuno-mass spectrometric identification of serum biomarkers of response and toxicity to pembrolizumab","year":2020,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Autoantibody; Pembrolizumab; Immunotherapy; Immunology; Medicine; Immune system; Antigen; Antibody; Immune checkpoint; Cancer; Cancer immunotherapy; Internal medicine","score_opus":0.07018959431744651,"score_gpt":0.3897958769316217,"score_spread":0.31960628261417523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036992533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97512275,0.014144814,0.000035584948,0.0093503175,0.00013109247,0.00078224443,0.00011340899,0.000026741678,0.00029301885],"genre_scores_gemma":[0.99648446,0.0028915447,0.00009037401,0.00015055752,0.000047486414,0.00006931327,0.0000062625595,0.000027464263,0.00023253704],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99757624,0.00031853945,0.0006826156,0.0004472649,0.0005091272,0.00046621944],"domain_scores_gemma":[0.9981835,0.0004162558,0.00020691837,0.00050885533,0.0005383355,0.00014612832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019463274,0.00016344896,0.0004944548,0.000895212,0.000102102305,0.000018159404,0.00032216217,0.00018994373,0.00052785914],"category_scores_gemma":[0.0009417174,0.00015349477,0.00011853558,0.00254952,0.0007467925,0.00009423396,0.00013259995,0.0004292428,0.000016713813],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049072318,0.00009179689,0.0076532736,0.00026232254,0.00062715734,0.000011290577,0.00079192827,0.0000015324895,0.91907096,0.000019803501,0.0004420233,0.021955593],"study_design_scores_gemma":[0.0019208224,0.0011434141,0.5087238,0.00008443781,0.000022798005,0.000010201481,0.0004048984,0.000014726597,0.4867333,0.000019104216,0.00084335444,0.000079163314],"about_ca_topic_score_codex":0.00032589262,"about_ca_topic_score_gemma":0.0000074685786,"teacher_disagreement_score":0.5010705,"about_ca_system_score_codex":0.00029320776,"about_ca_system_score_gemma":0.0006184015,"threshold_uncertainty_score":0.6259335},"labels":[],"label_agreement":null},{"id":"W3037386451","doi":"10.1016/j.jaip.2020.06.028","title":"Balancing Cancer Immunotherapy Efficacy and Toxicity","year":2020,"lang":"en","type":"review","venue":"The Journal of Allergy and Clinical Immunology In Practice","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; National Institutes of Health; Incyte; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Gilead Sciences; Array BioPharma; Les Laboratories Pierre Fabre; Massachusetts General Hospital; Bristol-Myers Squibb","keywords":"Toxicity; Immunotherapy; Cancer immunotherapy; Medicine; Cancer; Oncology; Internal medicine","score_opus":0.05930494392639328,"score_gpt":0.43298474553577104,"score_spread":0.37367980160937775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037386451","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021586337,0.9902624,0.000010137413,0.006310035,0.00073366327,0.00033011573,0.000002610249,0.0000122378415,0.00018015518],"genre_scores_gemma":[0.00012135267,0.9970794,0.00015082116,0.002143798,0.00039005812,0.0000052351143,0.0000014039643,0.000045321405,0.000062638945],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959716,0.0015497605,0.0018213114,0.00022986539,0.00018631459,0.00024110105],"domain_scores_gemma":[0.99218065,0.005444205,0.0018666036,0.00028517918,0.00013010588,0.00009327363],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0027353743,0.00031823214,0.0020429224,0.00011633176,0.00008129,0.000025682846,0.00028866227,0.00055848615,0.00006012738],"category_scores_gemma":[0.0012493207,0.00018339808,0.00035756498,0.00026001537,0.0005587833,0.00017921581,0.00010880197,0.0026722967,0.0000031733846],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010467522,0.00030166993,0.000023780678,0.00019678613,0.017686268,0.0001844481,0.00027725095,1.5562821e-7,0.00004831266,0.000024754927,0.00023976399,0.9705493],"study_design_scores_gemma":[0.0043072784,0.0019150712,0.0012968853,0.005309852,0.0040811845,0.004152397,0.00024324628,0.000001958812,0.000002779465,0.000016289832,0.97849554,0.00017750221],"about_ca_topic_score_codex":0.000107471365,"about_ca_topic_score_gemma":0.000029095218,"teacher_disagreement_score":0.9782558,"about_ca_system_score_codex":0.000104280494,"about_ca_system_score_gemma":0.00068064255,"threshold_uncertainty_score":0.9996286},"labels":[],"label_agreement":null},{"id":"W3037506839","doi":"10.1016/j.jtho.2020.06.015","title":"A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":645,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Eli Lilly and Company; Ono Pharmaceutical; Bayer; Servier; Astellas Pharma; Les Laboratories Pierre Fabre; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; F. Hoffmann-La Roche; AbbVie; Merck; Spectrum Pharmaceuticals; Celgene; Novartis; Sanofi; PharmaMar; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Pfizer; Roche; Astellas Pharma US","keywords":"Medicine; Pembrolizumab; Oncology; Placebo; Protocol (science); Internal medicine; Chemotherapy; Randomized controlled trial; Immunotherapy; Cancer; Pathology; Alternative medicine","score_opus":0.033090687614001496,"score_gpt":0.3841235725741152,"score_spread":0.35103288496011376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037506839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95689076,0.00010242845,0.0006983184,0.0019424022,0.00011873586,0.039776266,0.000009408229,0.000006474519,0.0004551775],"genre_scores_gemma":[0.9950327,0.000025701891,0.0016336637,0.0005095219,0.00012712211,0.0025802294,0.000005917028,0.000024344972,0.000060797316],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956783,0.00091074413,0.0022747223,0.00021162449,0.00068149186,0.00024309166],"domain_scores_gemma":[0.9952867,0.00090314494,0.0029748674,0.00021331864,0.0004798811,0.00014210181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002059512,0.0002490053,0.0042321356,0.0007899617,0.000023985092,0.000008355512,0.00021496955,0.00014645797,0.00041984237],"category_scores_gemma":[0.00054166507,0.00015449214,0.0011155028,0.0011052486,0.0002745107,0.000090907924,0.000019211748,0.0003953413,6.807962e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97224337,0.0020194242,0.0005346679,0.00017556448,0.0069219037,0.000074067655,0.0011958593,0.00030165532,0.00037073862,0.0000048348716,0.00012094441,0.016036987],"study_design_scores_gemma":[0.968631,0.02010079,0.003651335,0.00012682234,0.0050888667,0.000020844456,0.0001773716,0.0010221826,0.00052109483,0.000014275251,0.00051653857,0.00012883701],"about_ca_topic_score_codex":0.00003148515,"about_ca_topic_score_gemma":0.000027386348,"teacher_disagreement_score":0.03814191,"about_ca_system_score_codex":0.00033578402,"about_ca_system_score_gemma":0.0011292817,"threshold_uncertainty_score":0.63000065},"labels":[],"label_agreement":null},{"id":"W3037575240","doi":"10.1136/jitc-2019-000467","title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"University Health Network","keywords":"Medicine; Acute kidney injury; Internal medicine; Creatinine; Incidence (geometry); Kidney disease; Adverse effect; Cancer; Gastroenterology; Oncology","score_opus":0.017823289581633112,"score_gpt":0.3066846269328215,"score_spread":0.2888613373511884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037575240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832516,0.009484472,0.00016796683,0.005257677,0.00051485404,0.0008211364,0.000416704,0.000049459824,0.00003616909],"genre_scores_gemma":[0.96005595,0.03525358,0.00040916665,0.0035040472,0.00023774632,0.000058190333,0.000025047426,0.00010299882,0.0003532787],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99789226,0.00007512316,0.0008532812,0.000288952,0.0005071212,0.00038328793],"domain_scores_gemma":[0.99800485,0.00011637219,0.001056495,0.00022433796,0.0003151848,0.00028273926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046617413,0.0003987457,0.0009761348,0.00015313193,0.00027172436,0.00006967401,0.00019704712,0.00017604308,0.0003396232],"category_scores_gemma":[0.0001480061,0.00024520763,0.0005404171,0.000358676,0.00024922544,0.0002584256,0.000021735297,0.0005041455,5.352261e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04223474,0.00025395732,0.4402691,0.00006907555,0.009997102,0.000010259121,0.003373517,0.0000026277348,0.4601774,0.0000051785923,0.0027495574,0.04085747],"study_design_scores_gemma":[0.029877784,0.008288154,0.63159406,0.00083314633,0.00063147076,0.000044212073,0.000397201,0.00006659229,0.27909708,0.000093183124,0.04844824,0.00062886014],"about_ca_topic_score_codex":0.0002692829,"about_ca_topic_score_gemma":0.0000109015655,"teacher_disagreement_score":0.19132496,"about_ca_system_score_codex":0.00020311236,"about_ca_system_score_gemma":0.00055917515,"threshold_uncertainty_score":0.99992764},"labels":[],"label_agreement":null},{"id":"W3038119368","doi":"10.1017/cem.2020.409","title":"Just the Facts: Adverse events associated with immune checkpoint inhibitor treatment for cancer","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Emergency Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Schwartz/Reisman Emergency Medicine Institute; University of Toronto","funders":"","keywords":"Lung cancer; Medicine; Oxygen saturation; Adverse effect; Pneumonia; Anesthesia; Cancer treatment; Heart rate; Emergency department; Blood pressure; Cancer; Internal medicine; Oxygen; Nursing; Chemistry","score_opus":0.10361836265831355,"score_gpt":0.3410153313646639,"score_spread":0.23739696870635035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038119368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.836103,0.02293262,0.00014038515,0.13252033,0.0060480265,0.0013631516,0.00014573782,0.000015724876,0.0007309873],"genre_scores_gemma":[0.992863,0.0022360056,0.000027896433,0.001368564,0.0019251157,0.000032936372,0.000028525905,0.000037554935,0.0014803868],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984912,0.00004000423,0.00073032535,0.00014273312,0.00026368618,0.00033203585],"domain_scores_gemma":[0.9982352,0.000042556643,0.00047126526,0.00014876043,0.00040027648,0.0007019347],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003241887,0.00020386575,0.0004710336,0.00010389481,0.00015951335,0.0000016098033,0.00014551441,0.00006738248,0.0029666773],"category_scores_gemma":[0.00035943108,0.000104413186,0.0002506397,0.0003789667,0.00010927801,0.00006490488,0.0000033250644,0.00018070056,0.0000022164352],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03639061,0.0008586277,0.24171548,0.001004143,0.026372887,0.001272803,0.08629594,0.00039210872,0.14051954,0.000095441035,0.40206566,0.06301676],"study_design_scores_gemma":[0.0342999,0.020492995,0.17693953,0.0035334625,0.003351476,0.000078598256,0.010346158,0.00018857133,0.005263812,0.000038133305,0.74490666,0.0005606992],"about_ca_topic_score_codex":0.008648519,"about_ca_topic_score_gemma":0.026676878,"teacher_disagreement_score":0.342841,"about_ca_system_score_codex":0.00059499097,"about_ca_system_score_gemma":0.0017283853,"threshold_uncertainty_score":0.997953},"labels":[],"label_agreement":null},{"id":"W3038346106","doi":"10.1159/000506296","title":"Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Renal Cell Carcinoma: A Systematic Review and Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"Urologia Internationalis","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Hazard ratio; Renal cell carcinoma; Confidence interval; Meta-analysis; Internal medicine; Cochrane Library; Subgroup analysis; Gastroenterology; Carcinoma; Oncology","score_opus":0.06732271529331962,"score_gpt":0.34469069281180637,"score_spread":0.27736797751848674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038346106","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010590134,0.99469423,0.0000142605095,0.0024477309,0.000021494816,0.0022897087,0.00031088613,0.000015127443,0.00010063361],"genre_scores_gemma":[0.007126792,0.99064696,0.00010772664,0.000933517,0.00004485195,0.00047624586,0.00018731313,0.000015793134,0.00046082385],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99691635,0.0010282132,0.0011169183,0.00043226927,0.0003874503,0.00011878517],"domain_scores_gemma":[0.9962066,0.0015239328,0.0018029291,0.0002533047,0.00015827447,0.000054955344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020138402,0.0003204511,0.004883938,0.00017374399,0.00005241476,0.00004040366,0.00018167314,0.00026910112,0.00007484631],"category_scores_gemma":[0.00084066775,0.00015243735,0.0013066826,0.00033122848,0.00015759868,0.000041623513,0.00013845833,0.0003511326,0.0000010378243],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027309995,0.00008106813,0.0026687323,0.81400746,0.17626946,0.0000253714,0.00024052527,6.539156e-8,0.000005468904,0.000052669227,0.00232099,0.0040550656],"study_design_scores_gemma":[0.00078053394,0.00020148426,0.001166827,0.0057389895,0.9783909,0.000047496684,0.000009639957,0.0000023259595,0.000008551011,0.000023419756,0.013464417,0.00016544308],"about_ca_topic_score_codex":0.000048127626,"about_ca_topic_score_gemma":0.000004521798,"teacher_disagreement_score":0.8082685,"about_ca_system_score_codex":0.00006116308,"about_ca_system_score_gemma":0.000051006824,"threshold_uncertainty_score":0.6216215},"labels":[],"label_agreement":null},{"id":"W3038892567","doi":"10.1159/000507816","title":"Rechallenge Strategy in Cancer Therapy","year":2020,"lang":"en","type":"review","venue":"Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Clinical trial; Disease; Immunotherapy; Cancer; Intensive care medicine; Drug; Chemotherapy; Drug resistance; Oncology; Targeted therapy; Limiting; Internal medicine; Pharmacology","score_opus":0.23532073095196746,"score_gpt":0.47827774836007036,"score_spread":0.2429570174081029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038892567","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000053530116,0.9783348,5.8750703e-7,0.0014699658,0.00039284065,0.0009327919,0.000019305025,0.00003596229,0.018808423],"genre_scores_gemma":[0.000005014591,0.9968986,0.0000270711,0.0008748101,0.0004907733,0.0004181123,0.000047422796,0.00005062242,0.0011875548],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985372,0.00020754014,0.00051693723,0.00037730546,0.00010369933,0.00025730568],"domain_scores_gemma":[0.999344,0.00011084412,0.00021228963,0.00022803088,0.00002254898,0.00008228185],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020212503,0.00028318664,0.001977823,0.00014756396,0.000017091641,0.0000057172115,0.00014548855,0.00065420923,0.0015054394],"category_scores_gemma":[0.000011751924,0.00020538643,0.000370778,0.00034953648,0.00006968678,0.000017944341,0.000022795952,0.00064883224,0.00006913943],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037753637,0.0001833335,0.0000026288385,0.0023233087,0.00028958404,0.00040429304,0.00006857426,3.3818978e-8,0.0000041666744,0.000019654775,0.004131861,0.992195],"study_design_scores_gemma":[0.0016975232,0.0017920684,0.000015015117,0.003488538,0.00015900008,0.00015383841,0.000030537383,6.1736944e-7,0.0000010679449,0.000011731253,0.9924718,0.00017826028],"about_ca_topic_score_codex":0.00023586294,"about_ca_topic_score_gemma":0.00042353713,"teacher_disagreement_score":0.9920168,"about_ca_system_score_codex":0.0009389104,"about_ca_system_score_gemma":0.002549708,"threshold_uncertainty_score":0.9994073},"labels":[],"label_agreement":null},{"id":"W3039747873","doi":"10.2217/fon-2020-0248","title":"Real-world effectiveness of nivolumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Nivolumab; Meta-analysis; Lung cancer; Oncology; Internal medicine; Systematic review; MEDLINE; Intensive care medicine; Cancer; Immunotherapy","score_opus":0.022236132718494908,"score_gpt":0.3398117127824406,"score_spread":0.3175755800639457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039747873","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000029928588,0.9909628,0.00000409244,0.00014323836,0.00008695137,0.008181556,0.00012881556,0.000012649291,0.00044994694],"genre_scores_gemma":[0.000057024776,0.997223,0.00010138492,0.00027068553,0.00005250004,0.0018477131,0.00017185269,0.000049504226,0.00022628772],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99649197,0.0012541886,0.0012078513,0.00057618925,0.00023432408,0.0002354743],"domain_scores_gemma":[0.9975032,0.00040035543,0.0013071162,0.0005366925,0.00015137802,0.00010121374],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00081909413,0.00051981665,0.015400716,0.0004641303,0.000024997467,0.000006300362,0.00019304645,0.00031866762,0.00017322465],"category_scores_gemma":[0.000021078127,0.00029491185,0.0015771688,0.0021060153,0.00007129652,0.000024994553,0.00005440998,0.00044146733,0.0000017160006],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041355696,0.00015704177,0.0003268685,0.8643276,0.13098386,0.000033235166,0.00004418462,9.714994e-8,1.5026811e-7,0.0000020679547,0.00012280216,0.0035885083],"study_design_scores_gemma":[0.0020232978,0.00071394164,0.0006072711,0.09817518,0.8443317,0.000007769431,0.000008904536,7.337133e-7,4.0341433e-7,1.604824e-7,0.0538879,0.00024277813],"about_ca_topic_score_codex":0.00062227785,"about_ca_topic_score_gemma":0.001461585,"teacher_disagreement_score":0.76615244,"about_ca_system_score_codex":0.00076313555,"about_ca_system_score_gemma":0.00088042294,"threshold_uncertainty_score":0.9999503},"labels":[],"label_agreement":null},{"id":"W3039842961","doi":"10.1159/000508628","title":"Implementation of PD-L1 22C3 IHC pharmDx&lt;sup&gt;TM&lt;/sup&gt; in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation","year":2020,"lang":"en","type":"article","venue":"Acta Cytologica","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Concordance; Lung cancer; Cytology; Intraclass correlation; Pembrolizumab; Nuclear medicine; Cancer; Pathology; Internal medicine; Immunotherapy","score_opus":0.022021389259381557,"score_gpt":0.3282282079863171,"score_spread":0.3062068187269355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039842961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99544287,0.00072226906,0.00015117129,0.001619542,0.000026714504,0.0010425084,0.00011228961,0.000037213762,0.0008454509],"genre_scores_gemma":[0.99774605,0.0011570518,0.00069198053,0.00006758208,0.000045957364,0.00013991338,0.00010136997,0.000013883591,0.00003618333],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99828535,0.00012651061,0.00073194114,0.00034846907,0.00031687698,0.00019086125],"domain_scores_gemma":[0.99881625,0.00018012516,0.00050403486,0.0002175321,0.00020795682,0.00007412777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025223973,0.00016978956,0.00047722983,0.00013257249,0.00006315331,0.000008876633,0.00010712678,0.0001358917,0.00022878064],"category_scores_gemma":[0.00005481427,0.0001378208,0.00008202421,0.0006633757,0.00022781327,0.00016417747,0.00004255808,0.0001573596,3.6345367e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006319874,0.00035029688,0.15496294,0.00038027225,0.00015356306,0.000010381308,0.0012521534,0.000260451,0.83408535,0.000107368505,0.0012058857,0.0009114961],"study_design_scores_gemma":[0.0110093495,0.0035434011,0.28131366,0.00031508147,0.0004290788,0.000119637065,0.00079323404,0.0017364367,0.697121,0.000029592195,0.0032665161,0.00032297222],"about_ca_topic_score_codex":0.00037221698,"about_ca_topic_score_gemma":0.0004335237,"teacher_disagreement_score":0.13696429,"about_ca_system_score_codex":0.000106105304,"about_ca_system_score_gemma":0.0002436548,"threshold_uncertainty_score":0.5620169},"labels":[],"label_agreement":null},{"id":"W3040650435","doi":"10.1038/s41420-020-0292-1","title":"AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing","year":2020,"lang":"en","type":"article","venue":"Cell Death Discovery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of British Columbia; Brown University","keywords":"Cancer research; Mdm2; Immune system; Cell culture; Ubiquitin ligase; Cancer cell; Immune checkpoint; Biology; Cancer; Immunotherapy; Immunology; Ubiquitin","score_opus":0.01680797577613995,"score_gpt":0.23452830188026977,"score_spread":0.2177203261041298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3040650435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99106467,0.0013308965,0.0012288676,0.0015512023,0.0006249721,0.0005039508,0.00009843787,0.0001621504,0.0034348567],"genre_scores_gemma":[0.9833207,0.0002952107,0.0014049486,0.012676999,0.0006090918,0.00001557843,0.000116074385,0.00007681839,0.00148455],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981047,0.00005430577,0.00041228975,0.00056080864,0.00037022875,0.00049768214],"domain_scores_gemma":[0.9989443,0.00013454599,0.00012843663,0.00036147845,0.000058624646,0.00037261363],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012666828,0.000323517,0.0004786809,0.00009520711,0.00013084915,0.00014995945,0.00015293894,0.000099158104,0.0001832544],"category_scores_gemma":[0.00003338146,0.0002833398,0.00022558238,0.00034389287,0.00006180476,0.00022472945,0.00009020584,0.0002569456,0.00027396058],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015931971,0.00012537783,0.000796543,0.0002621149,0.00005442173,0.00033795618,0.00072966225,0.00011616859,0.9849786,0.0000050479716,0.010517628,0.0004832612],"study_design_scores_gemma":[0.0031642108,0.00045372944,0.0025786357,0.0003105952,0.00014466568,0.000015237798,0.0005995353,0.00056373095,0.96788275,0.000009391104,0.023808831,0.00046867988],"about_ca_topic_score_codex":0.00017411934,"about_ca_topic_score_gemma":0.0000027104545,"teacher_disagreement_score":0.017095864,"about_ca_system_score_codex":0.00011343556,"about_ca_system_score_gemma":0.00019043044,"threshold_uncertainty_score":0.99996185},"labels":[],"label_agreement":null},{"id":"W3040826944","doi":"10.1016/j.annonc.2020.04.070","title":"O-17 A TNM-Immune (TNM-I) classification staging system for predicting survival in colon cancer in a multicenter international SITC study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); TNM staging system; Internal medicine; Oncology; Cancer; Hazard ratio; Cancer staging; Colorectal cancer; Clinical endpoint; Staging system; Clinical trial; Confidence interval","score_opus":0.14403000498712717,"score_gpt":0.4274877786211341,"score_spread":0.2834577736340069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3040826944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832844,0.00032723128,0.000076863,0.013621417,0.00052124535,0.0012792008,0.000044831002,0.000024422989,0.0008203947],"genre_scores_gemma":[0.9986245,0.000114373484,0.000076986595,0.0006855976,0.00015463059,0.00024849002,0.000022881568,0.000014395382,0.000058152007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861944,0.0001262341,0.00063053647,0.00025221496,0.00016909138,0.00020249985],"domain_scores_gemma":[0.99920416,0.00019237582,0.00027704652,0.00011038672,0.00017086981,0.00004513397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007527135,0.000104990526,0.00041409186,0.00015347477,0.000023512232,0.000007288479,0.0001286339,0.0000919376,0.00004899672],"category_scores_gemma":[0.00014735745,0.0001007647,0.000081536935,0.00021482806,0.000041574924,0.00007262798,0.00003825692,0.00015331114,0.0000010190697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023575863,0.0014681345,0.8323108,0.00036071055,0.00044197473,0.000053086,0.014145361,0.00012080586,0.08027254,0.000029237039,0.0004644902,0.04675699],"study_design_scores_gemma":[0.021883598,0.0040480313,0.91539073,0.0005295647,0.00006469324,0.0000041640387,0.0231134,0.021758078,0.0036948917,0.0000027887688,0.009349808,0.00016024044],"about_ca_topic_score_codex":0.0011145916,"about_ca_topic_score_gemma":0.0015158416,"teacher_disagreement_score":0.08307994,"about_ca_system_score_codex":0.00026589615,"about_ca_system_score_gemma":0.0002018342,"threshold_uncertainty_score":0.41090652},"labels":[],"label_agreement":null},{"id":"W3041902060","doi":"10.1016/j.ebiom.2020.102860","title":"Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer","year":2020,"lang":"en","type":"article","venue":"EBioMedicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Japan Society for the Promotion of Science; National Institutes of Health; Faculty of Arts and Sciences; Gary Bennett Family Fund; Bayer Corporation; Research Promotion Foundation; Mitsukoshi Health and Welfare Foundation; Colorectal Cancer Alliance; Conquer Cancer Foundation; George W. Stone Family Foundation; Taiho Pharmaceutical; Entertainment Industry Foundation; Stand Up To Cancer; Uehara Memorial Foundation; National Cancer Institute; Bayer; Gilead Sciences; American Association for Cancer Research; Eli Lilly and Company; Bristol-Myers Squibb; Dana-Farber/Harvard Cancer Center; Merck; Dana-Farber Cancer Institute; Pfizer; Celgene","keywords":"Colorectal cancer; Budding; Biology; Cancer research; Cancer; Medicine; Genetics","score_opus":0.01439458805733817,"score_gpt":0.2684792686064696,"score_spread":0.2540846805491314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041902060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9690644,0.003472659,0.000027818198,0.026496258,0.00020071348,0.00036239065,0.0000199584,0.00006158167,0.00029418324],"genre_scores_gemma":[0.9944636,0.00046930907,0.000054248834,0.004341103,0.00022022428,0.000022229906,0.000030328549,0.000024899971,0.0003740168],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988263,0.00006960848,0.00030380467,0.00030959595,0.00022514194,0.00026554387],"domain_scores_gemma":[0.9995022,0.00007668965,0.00007552388,0.00008691274,0.000033340955,0.0002253428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023890282,0.0001790261,0.0003719821,0.00017756473,0.000038702725,0.0000116200945,0.00007046671,0.00008957298,0.00054507365],"category_scores_gemma":[0.00006708571,0.00013960105,0.00004981653,0.00051114935,0.0001642841,0.000042252243,0.000040208924,0.00020994227,0.0000073326273],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033381235,0.000091336726,0.021219525,0.00010868529,0.0000593457,0.00016772235,0.0020913535,3.927948e-7,0.93352896,8.691512e-7,0.0065062777,0.002844277],"study_design_scores_gemma":[0.02815549,0.004503781,0.8463459,0.0006170861,0.00016287305,0.00008864512,0.0012535013,0.0014879478,0.10249389,0.0000064578676,0.014521777,0.000362635],"about_ca_topic_score_codex":0.00040355674,"about_ca_topic_score_gemma":0.000047878802,"teacher_disagreement_score":0.8310351,"about_ca_system_score_codex":0.00010726174,"about_ca_system_score_gemma":0.00011578207,"threshold_uncertainty_score":0.59681743},"labels":[],"label_agreement":null},{"id":"W3042175304","doi":"10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2733","title":"Real-World Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Treated with Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens","year":2020,"lang":"en","type":"article","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Lung cancer; Lung; Cancer; Oncology; Radiology; Internal medicine","score_opus":0.020416516712100208,"score_gpt":0.26246087551975655,"score_spread":0.24204435880765635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042175304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853742,0.00014392986,0.000006309885,0.0036657234,0.000032117787,0.0011131526,0.00007781684,0.000029782088,0.0095569305],"genre_scores_gemma":[0.99624085,0.0007621357,0.0003288163,0.0016214238,0.00001678798,0.000039934224,0.00003115344,0.000027911574,0.00093098584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984772,0.0000654866,0.0005013285,0.0003697218,0.0003385849,0.00024768437],"domain_scores_gemma":[0.99893284,0.00018508104,0.00031599996,0.0003618431,0.00012966995,0.000074596785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011768639,0.0002624186,0.0006753782,0.00010574132,0.000033438002,0.0000047017315,0.00015346527,0.00006603465,0.0003850752],"category_scores_gemma":[0.000015820167,0.00011941344,0.00010403425,0.0006317363,0.00016373381,0.000037327543,0.000016977978,0.00017534643,0.0000010437255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06873261,0.00064620416,0.9191389,0.00006153831,0.00030135264,0.000014686097,0.0008756019,0.000047993428,0.0074212025,0.000011161575,0.0008535343,0.0018951826],"study_design_scores_gemma":[0.01668048,0.0031223653,0.9165939,0.00019133938,0.00006982567,2.2609606e-7,0.00013559964,0.00006457359,0.062385354,4.7159858e-7,0.0005973583,0.00015847213],"about_ca_topic_score_codex":0.0024663496,"about_ca_topic_score_gemma":0.0014083146,"teacher_disagreement_score":0.05496415,"about_ca_system_score_codex":0.000142197,"about_ca_system_score_gemma":0.00012142415,"threshold_uncertainty_score":0.48695385},"labels":[],"label_agreement":null},{"id":"W3043118722","doi":"10.1016/j.ccell.2020.06.013","title":"Cytotoxic CD4+ T Cells in Bladder Cancer—A New License to Kill","year":2020,"lang":"en","type":"letter","venue":"Cancer Cell","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Cytotoxic T cell; Immune system; Biology; Population; Immunology; Immunity; CD8; T cell; Cancer research; Immunotherapy; Cancer immunotherapy; Medicine; In vitro; Genetics","score_opus":0.024431840420038584,"score_gpt":0.28005128329138856,"score_spread":0.25561944287134997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043118722","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0064965263,0.028060017,0.000027501164,0.9515638,0.004136944,0.0022704348,0.00050318125,0.00017524438,0.006766376],"genre_scores_gemma":[0.0014292701,0.011306438,0.00018713092,0.9164972,0.010636404,0.00015968316,0.0001355152,0.00021822179,0.059430167],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99681854,0.00006789476,0.0006330701,0.0010498106,0.0005582484,0.00087244844],"domain_scores_gemma":[0.9984925,0.000069752714,0.00022817342,0.000725928,0.00008445845,0.00039918287],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007779328,0.00067808636,0.0010281472,0.00021325324,0.000051415824,0.000054329947,0.00041238696,0.00077407155,0.009185507],"category_scores_gemma":[0.000010137566,0.00063885987,0.00037657187,0.00067223917,0.00007882442,0.00007534629,0.000095433395,0.001676463,0.0003706206],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009486669,0.000038188242,0.000090607384,0.0005599928,0.00020473685,0.0008958269,0.0012876474,0.0000147587725,0.06023187,1.447947e-7,0.92885923,0.006868342],"study_design_scores_gemma":[0.0029196977,0.00028208602,0.00019081112,0.0008014776,0.00023555929,0.000009034127,0.000080248916,0.0000120420245,0.04581948,0.0000053217927,0.94895315,0.00069111434],"about_ca_topic_score_codex":0.019593965,"about_ca_topic_score_gemma":0.0028845023,"teacher_disagreement_score":0.052663792,"about_ca_system_score_codex":0.0017093254,"about_ca_system_score_gemma":0.0019767464,"threshold_uncertainty_score":0.99960625},"labels":[],"label_agreement":null},{"id":"W3043154728","doi":"10.1016/j.ctrv.2020.102084","title":"Impact of high tumor mutational burden in solid tumors and challenges for biomarker application","year":2020,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Immunotherapy; Biomarker; Oncology; Cancer; Melanoma; Lung cancer; Clinical trial; Targeted therapy; Circulating tumor cell; Internal medicine; Computational biology; Cancer research; Metastasis","score_opus":0.12482030120339196,"score_gpt":0.42675127690850645,"score_spread":0.3019309757051145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043154728","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009969719,0.9927808,0.000013127829,0.00033796774,0.00005596116,0.006276549,0.00036730853,0.000013740501,0.00005485024],"genre_scores_gemma":[0.00014892925,0.99172693,0.00020655947,0.000028483288,0.00021943849,0.0070759878,0.00049021456,0.00005039865,0.000053051597],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980738,0.0000934128,0.0009866365,0.0005248877,0.00011584446,0.00020540379],"domain_scores_gemma":[0.9986991,0.00011186634,0.00073359336,0.00030440866,0.000047315298,0.000103692146],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018918322,0.00047940243,0.003073281,0.00016790912,0.000024582498,0.00000856303,0.00008565154,0.000116232295,0.00007790166],"category_scores_gemma":[0.000023029032,0.0002923156,0.0009183709,0.00027068367,0.00007083163,0.000037657737,0.0000151102795,0.000075373995,0.0000063532175],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026916224,0.00010193227,0.000035454214,0.02460167,0.00077892997,0.000008669552,0.00009947178,2.1365e-7,0.000010339171,0.000011675605,0.000121408026,0.97396106],"study_design_scores_gemma":[0.0020031824,0.00080189196,0.0009651804,0.017977634,0.0015279629,0.000060883347,0.0000089184605,0.0000119455835,0.0000043011805,0.000015765474,0.9763997,0.00022259861],"about_ca_topic_score_codex":0.0006799557,"about_ca_topic_score_gemma":0.000066446584,"teacher_disagreement_score":0.9762783,"about_ca_system_score_codex":0.0011082496,"about_ca_system_score_gemma":0.00074212486,"threshold_uncertainty_score":0.9999529},"labels":[],"label_agreement":null},{"id":"W3043321283","doi":"10.1038/s41523-020-0171-1","title":"Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer","year":2020,"lang":"en","type":"article","venue":"npj Breast Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cure Brain Cancer Foundation","keywords":"Cyclophosphamide; Medicine; Metastatic breast cancer; Regimen; Breast cancer; Cancer; CD8; Immune system; Primary tumor; Oncology; Combination therapy; Cancer research; Concomitant; Blockade; Immunotherapy; Mammary tumor; Chemotherapy; Internal medicine; Immunology; Metastasis; Receptor","score_opus":0.01242845385308866,"score_gpt":0.26374376268641,"score_spread":0.2513153088333213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043321283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97217166,0.018259937,0.000012539711,0.008133916,0.00019989362,0.0006281873,0.00031551355,0.00006191431,0.00021640435],"genre_scores_gemma":[0.98976976,0.0039872103,0.00017371029,0.005528407,0.00020522032,0.00013322357,0.000022109345,0.00005853544,0.0001218126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825305,0.00006114502,0.00045333535,0.000580478,0.00023661666,0.00041539923],"domain_scores_gemma":[0.9991873,0.0000640025,0.00017317322,0.0002588497,0.00007135269,0.0002453178],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017857298,0.0003378873,0.00071684807,0.00012939051,0.00007588958,0.000041040177,0.000101417805,0.00006936237,0.0008007066],"category_scores_gemma":[0.000009787885,0.00029893903,0.00009365856,0.00035041032,0.0002070477,0.00021559121,0.00008379583,0.00029561136,0.000004338356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005015703,0.00024388195,0.86280537,0.0009226791,0.0007852192,0.0002361986,0.00044743824,0.0000621093,0.06371783,0.00001503695,0.0007320136,0.06501651],"study_design_scores_gemma":[0.007351753,0.0000817441,0.98764735,0.0003823431,0.0002400546,0.0004314886,0.00010435143,0.00032840818,0.00080226053,0.0000054641164,0.0023020639,0.00032270557],"about_ca_topic_score_codex":0.0039989874,"about_ca_topic_score_gemma":0.00019320578,"teacher_disagreement_score":0.12484198,"about_ca_system_score_codex":0.00042774758,"about_ca_system_score_gemma":0.00053092075,"threshold_uncertainty_score":0.9999463},"labels":[],"label_agreement":null},{"id":"W3043447624","doi":"10.1186/s41687-020-00210-z","title":"Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review","year":2020,"lang":"en","type":"review","venue":"Journal of Patient-Reported Outcomes","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute; Trillium Health Centre; McMaster University; Hamilton Health Sciences; Juravinski Hospital","funders":"H2020 Marie Skłodowska-Curie Actions; Université de Lausanne; European Commission","keywords":"Medicine; Clinical trial; PsycINFO; CINAHL; Context (archaeology); MEDLINE; Adverse effect; Internal medicine; Intensive care medicine; Systematic review; Oncology; Psychological intervention; Psychiatry","score_opus":0.20100132948224209,"score_gpt":0.4743632114265452,"score_spread":0.2733618819443031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043447624","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01427706,0.9695479,0.000002910409,0.00096562674,0.0041721985,0.010887812,0.000029195358,0.00004389437,0.00007335512],"genre_scores_gemma":[0.0024345494,0.99483156,0.0002915228,0.00157825,0.00020324322,0.00034574355,0.00008946387,0.00015686426,0.00006878955],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9414598,0.0069836862,0.048005104,0.00086791883,0.0019441639,0.0007393581],"domain_scores_gemma":[0.94928914,0.0033760213,0.0448993,0.0013004604,0.00053797255,0.000597112],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.022689663,0.001346545,0.031744104,0.0017545366,0.000056284636,0.00006540295,0.000535619,0.0012133403,0.0001689052],"category_scores_gemma":[0.044290654,0.0008418117,0.009344312,0.001887366,0.00017279178,0.00029694216,0.00022596607,0.0032968866,0.000028425507],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014889099,0.002338382,0.059858225,0.5237433,0.010256507,0.012907278,0.0004406933,1.8742806e-7,0.000010284276,0.0000010207026,0.0004183063,0.38853693],"study_design_scores_gemma":[0.014079916,0.003441226,0.0024984109,0.78372926,0.019425744,0.005200263,0.0003981401,0.0000020276034,0.000008854567,0.000007969785,0.1703151,0.0008930657],"about_ca_topic_score_codex":0.00009034075,"about_ca_topic_score_gemma":0.000035318462,"teacher_disagreement_score":0.38764387,"about_ca_system_score_codex":0.002651363,"about_ca_system_score_gemma":0.0041647293,"threshold_uncertainty_score":0.99992853},"labels":[],"label_agreement":null},{"id":"W3043703771","doi":"10.1056/nejmoa1910836","title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3708,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Pharmacyclics; Genentech; AstraZeneca; EUSA Pharma; Eisai; National Institute for Health and Care Research; Plexxikon; Array BioPharma; Ipsen; Syndax Pharmaceuticals; Sanofi Genzyme; Pfizer; Incyte; National Cancer Institute; LEO Pharma; Massachusetts Medical Society; Regeneron Pharmaceuticals; Sanofi; GlaxoSmithKline; Amgen; Les Laboratories Pierre Fabre; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Melanoma; Medicine; Oncology; Internal medicine; Metastatic melanoma; Immunotherapy; Cancer research; Cancer","score_opus":0.007370799521923161,"score_gpt":0.24330687348226518,"score_spread":0.23593607396034202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043703771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895928,0.0021438624,0.00002344042,0.0051927078,0.0004508911,0.00020678631,9.439315e-7,0.0000072754356,0.0023813127],"genre_scores_gemma":[0.9964051,0.0008323447,0.00033952543,0.00034414494,0.00055660476,6.325265e-7,0.0000032854061,0.0000167441,0.0015016111],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99885064,0.000055635363,0.00040062095,0.00013278206,0.00038473867,0.00017559652],"domain_scores_gemma":[0.99922353,0.00014673859,0.0002057322,0.00014962222,0.00010305597,0.00017131469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060515926,0.00013963706,0.0005736695,0.00019902199,0.00001741587,0.0000056978533,0.00007437507,0.000054289972,0.00031136366],"category_scores_gemma":[0.000060660066,0.00008273435,0.000039220547,0.00020192355,0.000093983355,0.00009310066,0.000011045589,0.00029958988,0.0000028740915],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1413898,0.00023102738,0.5745825,0.00021308006,0.0004969009,0.0007558076,0.0033963567,0.000020789403,0.03348949,0.00017485069,0.0028583962,0.24239099],"study_design_scores_gemma":[0.5209634,0.02121839,0.4249185,0.002078371,0.00015834325,0.0019213028,0.0018957179,0.000045702578,0.0006937599,0.00016049448,0.025743032,0.00020304136],"about_ca_topic_score_codex":0.00019110802,"about_ca_topic_score_gemma":0.00015812412,"teacher_disagreement_score":0.37957355,"about_ca_system_score_codex":0.000064911124,"about_ca_system_score_gemma":0.00018164316,"threshold_uncertainty_score":0.34092137},"labels":[],"label_agreement":null},{"id":"W3043800934","doi":"10.1016/j.eclinm.2020.100458","title":"Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials","year":2020,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Ramucirumab; Medicine; Meta-analysis; Randomized controlled trial; Oncology; Internal medicine; Overall survival","score_opus":0.08711266742509931,"score_gpt":0.40242075283517,"score_spread":0.31530808541007066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043800934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98056304,0.005629303,0.00057005044,0.0067567513,0.00008171292,0.005873554,0.00006805962,0.000025341953,0.000432183],"genre_scores_gemma":[0.99690616,0.00024556616,0.0008243757,0.0015657769,0.00007772012,0.00024276547,0.000064137195,0.000020819556,0.000052698633],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99223256,0.0016726069,0.0046580113,0.00037860486,0.0008373194,0.0002208828],"domain_scores_gemma":[0.98314023,0.011723212,0.004061048,0.00053530774,0.0004188449,0.00012136369],"candidate_categories":["metaresearch","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.014018848,0.00027687402,0.015796972,0.00027167852,0.000036008896,0.000010998086,0.00018722507,0.000099853016,0.0015731591],"category_scores_gemma":[0.021208335,0.000108981985,0.0040928065,0.0013728329,0.0004954676,0.00008050622,0.000031761138,0.00034173887,0.0000012327741],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7053289,0.00059131545,0.022270383,0.00008341469,0.2675212,0.000005326169,0.0005773866,0.00023215135,0.00036359305,0.0000148232075,0.00008814014,0.0029233892],"study_design_scores_gemma":[0.6014746,0.0015760937,0.06091994,0.00014472127,0.33274797,3.2308586e-7,0.0002969439,0.0023126688,0.000362691,0.000026134576,0.000027405586,0.00011051675],"about_ca_topic_score_codex":0.00011114482,"about_ca_topic_score_gemma":0.000018729772,"teacher_disagreement_score":0.10385429,"about_ca_system_score_codex":0.000026301592,"about_ca_system_score_gemma":0.00018743846,"threshold_uncertainty_score":0.9993395},"labels":[],"label_agreement":null},{"id":"W3045388471","doi":"10.1038/s41598-020-69330-2","title":"A novel predictive model incorporating immune-related gene signatures for overall survival in melanoma patients","year":2020,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Natural Science Foundation of China","keywords":"Nomogram; Melanoma; Concordance; Oncology; Medicine; Internal medicine; Gene signature; Stage (stratigraphy); Survival analysis; Gene; Biology; Cancer research; Gene expression; Genetics","score_opus":0.021254299433134376,"score_gpt":0.2526197214939722,"score_spread":0.23136542206083785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045388471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99179465,0.0003595404,0.0028564525,0.00045331713,0.0024268224,0.0013511467,0.00004422233,0.00007394485,0.0006399161],"genre_scores_gemma":[0.99656695,0.0000027450517,0.0021740673,0.00020571277,0.000054070675,0.000059546463,0.00041100293,0.000028027123,0.0004978535],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9976935,0.000021963955,0.00080881844,0.00070281315,0.00048649148,0.00028642625],"domain_scores_gemma":[0.9988173,0.00003386916,0.00042608642,0.0003552359,0.00024141237,0.00012607515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008271562,0.00017867422,0.00033741922,0.00013330279,0.00014547409,0.00007113286,0.00009201362,0.00013556238,0.000024039982],"category_scores_gemma":[0.0002750962,0.00015539804,0.0001859518,0.00047209073,0.0001468992,0.00015544842,0.00005810421,0.0001847551,0.0000014557864],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027365177,0.0005017694,0.036362216,0.00012171266,0.00020387296,0.00013655939,0.0024457988,0.005418088,0.9473473,0.000058474532,0.0028203232,0.0018473677],"study_design_scores_gemma":[0.026794154,0.0026023397,0.17678338,0.0007507947,0.00033278152,0.00015749286,0.0005404853,0.5938488,0.18452883,0.008252777,0.0039220154,0.0014860994],"about_ca_topic_score_codex":0.000058384776,"about_ca_topic_score_gemma":0.00001608319,"teacher_disagreement_score":0.76281846,"about_ca_system_score_codex":0.00013162827,"about_ca_system_score_gemma":0.0003581132,"threshold_uncertainty_score":0.6336948},"labels":[],"label_agreement":null},{"id":"W3045949208","doi":"10.1016/j.cllc.2020.07.009","title":"Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non–Small-Cell Lung Cancer in the United States","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis; AstraZeneca; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Internal medicine; Lung cancer; Oncology; Confidence interval; Chemotherapy; Retrospective cohort study; Cancer; Performance status; Clinical trial; Immunotherapy","score_opus":0.025052380947219895,"score_gpt":0.3735398882047727,"score_spread":0.3484875072575528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045949208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97699153,0.017655142,0.000045196037,0.0015969819,0.00041522578,0.003047739,0.000065465785,0.00003856739,0.00014415896],"genre_scores_gemma":[0.9446069,0.04969842,0.00004871458,0.0039449697,0.00022681561,0.0012520402,0.00002512713,0.000065066364,0.00013197593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967675,0.0007346717,0.0011507239,0.0006080287,0.00031393525,0.00042513586],"domain_scores_gemma":[0.9978086,0.0011018484,0.0003366836,0.0004799286,0.00014965115,0.00012329203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013000048,0.00033276563,0.0009772982,0.00019224145,0.000037834892,0.000020473051,0.0003384864,0.00019852674,0.00035540404],"category_scores_gemma":[0.000043195076,0.00023041076,0.00030627064,0.0013471397,0.00018410958,0.00007986806,0.00003433311,0.0006288981,0.0000022475572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04830395,0.00043701587,0.9131427,0.0017552442,0.00035830477,0.000055962162,0.00334589,0.001127716,0.008254111,0.000003259219,0.00036481099,0.022851063],"study_design_scores_gemma":[0.025030162,0.0009941165,0.95481884,0.0034758612,0.00015022606,0.0000020829104,0.0005053075,0.0100623565,0.0028820012,0.000008377496,0.0016892987,0.0003813404],"about_ca_topic_score_codex":0.007083137,"about_ca_topic_score_gemma":0.002597879,"teacher_disagreement_score":0.041676197,"about_ca_system_score_codex":0.00047136733,"about_ca_system_score_gemma":0.000553893,"threshold_uncertainty_score":0.99952877},"labels":[],"label_agreement":null},{"id":"W3046570011","doi":"10.1158/1078-0432.ccr-20-0389","title":"Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Canadian Institutes of Health Research; Susan G. Komen; Cancer Research Society; U.S. Department of Defense","keywords":"Medicine; Breast cancer; Stimulation; Cancer research; Cancer; Oncogene; Breast tumor; Immunology; Oncology; Internal medicine; Cell cycle","score_opus":0.15730860877575703,"score_gpt":0.45464304760665103,"score_spread":0.297334438830894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046570011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795565,0.0048333975,0.000026990345,0.013342162,0.00027462747,0.001185928,0.00019997779,0.00006377787,0.00051664957],"genre_scores_gemma":[0.98654914,0.009812649,0.00030465215,0.0018295373,0.00083418225,0.0000886463,0.00003113215,0.000059512015,0.00049052056],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99588037,0.0006192822,0.0012041498,0.0007624657,0.0008807926,0.0006529327],"domain_scores_gemma":[0.9962041,0.0016375581,0.00028829565,0.00046865674,0.0010286488,0.00037274693],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002376689,0.0002582979,0.0008597502,0.00014603754,0.00024187166,0.000086958054,0.00026048016,0.00017064896,0.0010925141],"category_scores_gemma":[0.00075512374,0.0002181831,0.00019918822,0.0012613327,0.00050116953,0.0002595678,0.00016789784,0.0008335652,0.000008235044],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11730168,0.000727006,0.28169578,0.0013455603,0.00049055275,0.00025914717,0.0014197914,0.00015512898,0.5333665,0.00007205671,0.032991756,0.030175025],"study_design_scores_gemma":[0.05577928,0.008884287,0.55482197,0.0026753377,0.0002815752,0.000047984347,0.006763488,0.0052606314,0.28686735,0.00021208252,0.07710496,0.0013010808],"about_ca_topic_score_codex":0.0014531456,"about_ca_topic_score_gemma":0.00014070439,"teacher_disagreement_score":0.27312616,"about_ca_system_score_codex":0.00026940386,"about_ca_system_score_gemma":0.001399039,"threshold_uncertainty_score":0.99982065},"labels":[],"label_agreement":null},{"id":"W3046630186","doi":"10.1007/s40484-020-0212-7","title":"Germline genomes have a dominant‐heritable contribution to cancer immune evasion and immunotherapy response","year":2020,"lang":"en","type":"article","venue":"Quantitative Biology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; University of Calgary","funders":"","keywords":"Immune system; Biology; Germline; Immunotherapy; Cancer immunotherapy; Cancer; Germline mutation; Immunology; Evasion (ethics); Immune checkpoint; Genetics; Cancer research; Mutation; Gene","score_opus":0.041698336884718995,"score_gpt":0.3616408887624188,"score_spread":0.3199425518776998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046630186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92284256,0.05313173,0.0026441962,0.020310672,0.0001627378,0.00072042283,0.00011259771,0.00003987677,0.000035193127],"genre_scores_gemma":[0.9884411,0.004571965,0.0018443452,0.004618312,0.00009587133,0.00010121343,0.00005139353,0.00002581593,0.0002500021],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986381,0.00025783226,0.0003450935,0.00037373687,0.0000823644,0.00030286852],"domain_scores_gemma":[0.9991711,0.00024339368,0.00011556147,0.00015865691,0.00018311299,0.00012817954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048459705,0.00019376737,0.000490389,0.00009700441,0.000115835865,0.000014491848,0.000077471195,0.00013186553,0.00028913608],"category_scores_gemma":[0.00025141734,0.00015220467,0.00009795488,0.00023767778,0.0002047934,0.000056392375,0.000041399522,0.00013253053,0.000024433471],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08061136,0.00004926504,0.0073932195,0.000023953806,0.00022818803,0.000009374841,0.0021295452,0.0000014499869,0.89908296,0.00079630315,0.00028244185,0.009391969],"study_design_scores_gemma":[0.01668515,0.014510574,0.32058975,0.00026123787,0.00009887611,0.00005067333,0.0019187381,0.0004979929,0.20278028,0.00026820388,0.44171688,0.0006216423],"about_ca_topic_score_codex":0.00029789863,"about_ca_topic_score_gemma":0.00003345168,"teacher_disagreement_score":0.69630265,"about_ca_system_score_codex":0.000120168064,"about_ca_system_score_gemma":0.00012767753,"threshold_uncertainty_score":0.6206726},"labels":[],"label_agreement":null},{"id":"W3046772302","doi":"10.1016/j.lungcan.2020.07.013","title":"PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Queen's University; Cystic Fibrosis Canada; University of Toronto","funders":"University Health Network","keywords":"Medicine; Adenocarcinoma; Immunohistochemistry; Pathology; PD-L1; clone (Java method); Flow cytometry; Lung cancer; Carcinoma; Antibody; Antigen; Concordance; Cancer; Immunotherapy; Internal medicine; Immunology; Biology","score_opus":0.026740633659572962,"score_gpt":0.3051447161582569,"score_spread":0.2784040824986839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046772302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9403391,0.051739626,0.0009325876,0.005223861,0.000491256,0.0006848368,0.00015945686,0.00005987,0.0003693998],"genre_scores_gemma":[0.9949316,0.0029492185,0.0002717639,0.0009818923,0.00024462762,0.000062372535,0.00010490508,0.00003252173,0.00042110722],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986029,0.00004532069,0.0004620381,0.00035501123,0.0002846068,0.00025006858],"domain_scores_gemma":[0.99934334,0.000050383413,0.00013884861,0.00028166207,0.00007144326,0.00011431992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014522205,0.0001657776,0.00034897286,0.00012940887,0.000045101802,0.000013881513,0.00013810492,0.00011033919,0.0007751015],"category_scores_gemma":[0.00002523218,0.0001450274,0.00013043998,0.00080078025,0.00007763043,0.00007075753,0.000031912372,0.00020626897,0.000008025456],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035722866,0.0001487382,0.25832367,0.0004573408,0.00016720379,0.000029912808,0.0019050583,0.000052931427,0.6588212,0.000026881567,0.06760689,0.008887895],"study_design_scores_gemma":[0.008103693,0.00040808078,0.6700263,0.0010763982,0.00022862774,0.000018894434,0.000574111,0.04154997,0.23382626,0.0000024141661,0.043637313,0.0005479478],"about_ca_topic_score_codex":0.00040403922,"about_ca_topic_score_gemma":0.00005358884,"teacher_disagreement_score":0.42499495,"about_ca_system_score_codex":0.00023140582,"about_ca_system_score_gemma":0.00013067208,"threshold_uncertainty_score":0.84868175},"labels":[],"label_agreement":null},{"id":"W3046923728","doi":"10.1016/j.jaut.2020.102514","title":"Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development","year":2020,"lang":"en","type":"review","venue":"Journal of Autoimmunity","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Discontinuation; Intensive care medicine; Drug development; Drug; Liver injury; Best practice; Psychological intervention; Adverse effect; Clinical trial; Pharmacology; Internal medicine; Political science","score_opus":0.041030698586307056,"score_gpt":0.3521490677723442,"score_spread":0.3111183691860372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046923728","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.035561766,0.9618925,0.000039988972,0.00017618273,0.0005174568,0.0016889992,0.000041595737,0.000028183502,0.000053348565],"genre_scores_gemma":[0.0058987937,0.99192375,0.001436447,0.000013810516,0.00010400391,0.00007220848,0.000085043146,0.00007600659,0.00038995608],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955774,0.00032466624,0.0029144636,0.00027782287,0.00059570366,0.00030997366],"domain_scores_gemma":[0.9920833,0.00027527858,0.0066432627,0.00037581899,0.0004747293,0.00014757422],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018076487,0.00052944553,0.002370421,0.00043097447,0.00026195685,0.00006129199,0.0003154852,0.00025673685,0.000059502832],"category_scores_gemma":[0.00015696646,0.00042100615,0.0007451539,0.00058581604,0.00014681047,0.00023660854,0.00020287007,0.0011613682,0.0000024849824],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002316088,0.0010650548,0.000031406234,0.05623451,0.009823178,0.00014730176,0.0008777323,1.7875396e-7,0.02491705,0.0000013519414,0.00022538671,0.9043608],"study_design_scores_gemma":[0.004906755,0.0011098632,0.0058448855,0.033097405,0.003926985,0.00031904384,0.0009433673,0.000006824632,0.012163257,0.0000014560342,0.9371658,0.0005143819],"about_ca_topic_score_codex":0.00022110589,"about_ca_topic_score_gemma":0.000010563556,"teacher_disagreement_score":0.9369404,"about_ca_system_score_codex":0.0011649706,"about_ca_system_score_gemma":0.001108076,"threshold_uncertainty_score":0.99982417},"labels":[],"label_agreement":null},{"id":"W3047081808","doi":"10.1016/j.cell.2020.07.005","title":"Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front","year":2020,"lang":"en","type":"article","venue":"Cell","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1045,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; National Human Genome Research Institute; Juno Therapeutics; U.S. Food and Drug Administration; Stanford Bio-X; Defence Science and Technology Laboratory; Hamilton Health Sciences Foundation; National Institutes of Health; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; University of Oxford; Parker Institute for Cancer Immunotherapy; U.S. Department of Defense; Silicon Valley Community Foundation; University of Bern; National Institute of Allergy and Infectious Diseases; Celgene; National Heart, Lung, and Blood Institute; Pfizer; Bill and Melinda Gates Foundation; National Cancer Institute; Kenneth Rainin Foundation; Cancer Research Institute; Cancer Research UK; National Science Foundation","keywords":"Biology; Colorectal cancer; Immunity; Cellular immunity; Cancer; Immunology; Cancer research; Immune system; Genetics","score_opus":0.024544389600224453,"score_gpt":0.2543532474892553,"score_spread":0.22980885788903085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047081808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98339057,0.004584264,0.000026919231,0.004991029,0.00026169565,0.00045333573,0.00004156139,0.00006170192,0.0061889356],"genre_scores_gemma":[0.9943894,0.00054464315,0.000020959347,0.0025977378,0.00018101001,0.000030208073,0.00007025444,0.00002647502,0.0021392717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990461,0.00008744916,0.0002089041,0.00023227186,0.00015957817,0.00026568354],"domain_scores_gemma":[0.9994181,0.00005969671,0.000099978985,0.00021400003,0.00007062818,0.00013760458],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012343825,0.00017717422,0.000254708,0.000019756995,0.00017972187,0.00002547815,0.00017218811,0.00008608197,0.0025037026],"category_scores_gemma":[0.000025439233,0.00011922413,0.00014085848,0.00021410744,0.00021059047,0.000047127058,0.000084687985,0.0002863763,0.0001459278],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024089355,0.00007563983,0.00873098,0.000094809766,0.00012230445,0.0000902294,0.0012818851,0.000011752564,0.97231954,0.0000026955993,0.014317121,0.00054409046],"study_design_scores_gemma":[0.0027153012,0.0004958925,0.022184506,0.00004426485,0.00011705357,0.0000108367785,0.0005190274,0.00023889907,0.9573169,0.000007090583,0.01617021,0.0001800529],"about_ca_topic_score_codex":0.0010324889,"about_ca_topic_score_gemma":0.00021314815,"teacher_disagreement_score":0.015002691,"about_ca_system_score_codex":0.00017478615,"about_ca_system_score_gemma":0.0003188521,"threshold_uncertainty_score":0.99840814},"labels":[],"label_agreement":null},{"id":"W3047448200","doi":"10.1155/2020/7375947","title":"Profound Functional Suppression of Tumor‐Infiltrating T‐Cells in Ovarian Cancer Patients Can Be Reversed Using PD‐1‐Blocking Antibodies or DARPin® Proteins","year":2020,"lang":"en","type":"article","venue":"Journal of Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Vetenskapsrådet; Stockholms Läns Landsting","keywords":"Blockade; Nivolumab; Pembrolizumab; Cancer research; Ovarian cancer; Blocking antibody; Monoclonal antibody; Immunotherapy; Medicine; Antibody; Cancer; Immunology; Immune system; Internal medicine; Receptor","score_opus":0.131626945737836,"score_gpt":0.38881135006815865,"score_spread":0.25718440433032264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047448200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99475175,0.00083663256,0.000024836663,0.0033502318,0.00034094934,0.0005812699,0.000021487509,0.0000049034256,0.00008792829],"genre_scores_gemma":[0.99830544,0.00033161475,0.0007770651,0.00024024659,0.00020981354,0.000009242345,0.0000058593514,0.000022362829,0.00009836507],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973941,0.00038628574,0.0008383377,0.00020360896,0.0007627358,0.00041491733],"domain_scores_gemma":[0.99813175,0.00018141522,0.0005013078,0.00015068146,0.00094536657,0.00008946499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011243301,0.00014602527,0.0005133944,0.00046147476,0.00016783908,0.000021079344,0.00019576355,0.000133824,0.00038859947],"category_scores_gemma":[0.00059603906,0.0001057527,0.000120795055,0.00072341564,0.0003463764,0.00017002423,0.00010221304,0.0010893845,7.3063705e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016864376,0.0002519369,0.07300118,0.000207517,0.00030900454,0.00012010736,0.0016221517,0.000029905123,0.90603906,0.0000039186875,0.00046071367,0.0010901191],"study_design_scores_gemma":[0.013890628,0.004712097,0.20832191,0.0030787524,0.000077709934,0.0002491365,0.0041042166,0.0003449249,0.7633311,0.000020806072,0.0016430545,0.00022564108],"about_ca_topic_score_codex":0.0009375227,"about_ca_topic_score_gemma":0.000107681386,"teacher_disagreement_score":0.14270794,"about_ca_system_score_codex":0.0003799142,"about_ca_system_score_gemma":0.0016862137,"threshold_uncertainty_score":0.47328943},"labels":[],"label_agreement":null},{"id":"W3047452123","doi":"10.1177/1203475420943260","title":"Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management","year":2020,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; McGill University","funders":"","keywords":"Medicine; Toxic epidermal necrolysis; Dermatology; Adverse effect; Vitiligo; Immunology; Internal medicine","score_opus":0.025194253452923816,"score_gpt":0.3133990555904037,"score_spread":0.2882048021374799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047452123","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011639931,0.985836,0.000009823688,0.0073357443,0.0021299012,0.0011580172,0.000010335749,0.000042774976,0.0023133794],"genre_scores_gemma":[0.0040831915,0.99258685,0.000059565482,0.0014189726,0.0010223127,0.000017524022,0.000021322918,0.00011581085,0.0006744363],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99411815,0.00031077283,0.0036303913,0.00048566316,0.00090483576,0.0005501962],"domain_scores_gemma":[0.99570644,0.0007972294,0.0021030884,0.00045943254,0.00037071577,0.0005631215],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006935711,0.00081407634,0.0053711184,0.001531296,0.0001302645,0.000010638603,0.00025087336,0.0004510895,0.00030297012],"category_scores_gemma":[0.0005174501,0.00055219344,0.0019004904,0.00093530933,0.00027969936,0.00005731348,0.000100987185,0.0012919224,0.0000652328],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006595058,0.00035032834,0.00002408243,0.008690737,0.0071591344,0.08331019,0.0022190146,8.009338e-7,0.00013333578,0.000059390175,0.006922492,0.88453543],"study_design_scores_gemma":[0.0013120729,0.0020551672,0.00001091091,0.05429276,0.0031168063,0.20814121,0.0018436183,0.0000016995248,0.000018069735,0.000041457308,0.7287724,0.0003938296],"about_ca_topic_score_codex":0.000080178994,"about_ca_topic_score_gemma":0.0000036421236,"teacher_disagreement_score":0.8841416,"about_ca_system_score_codex":0.0008774452,"about_ca_system_score_gemma":0.00064555224,"threshold_uncertainty_score":0.999693},"labels":[],"label_agreement":null},{"id":"W3047471117","doi":"10.1007/s40264-020-00979-4","title":"Ipilimumab-Induced Enterocolitis: A Systematic Review and Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"Drug Safety","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"George & Fay Yee Centre for Healthcare Innovation; Winnipeg Regional Health Authority; University of Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Meta-analysis; Ipilimumab; Enterocolitis; Intensive care medicine; Internal medicine; Necrotizing enterocolitis; Cancer","score_opus":0.07706174745811163,"score_gpt":0.35928694591775145,"score_spread":0.28222519845963984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047471117","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[4.3288843e-8,0.9909475,0.000010910377,0.0015585424,0.00004396196,0.006610954,0.00026588907,0.000069878035,0.0004923085],"genre_scores_gemma":[0.0000048036077,0.9932761,0.00004249998,0.0032888332,0.000049249767,0.001130081,0.00024170337,0.000058031073,0.0019086789],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9962363,0.0006637773,0.0017797732,0.00066611334,0.00038201513,0.00027201802],"domain_scores_gemma":[0.99773,0.00023946897,0.00081800116,0.0009212737,0.00007467568,0.0002165499],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008831917,0.00064189825,0.015414361,0.0002283406,0.00007189455,0.000035550078,0.00023772934,0.00017366218,0.0010013548],"category_scores_gemma":[0.000118485106,0.0003849782,0.006556005,0.0011955289,0.000046010522,0.00004679732,0.00008683841,0.0003875896,0.00008676284],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021934247,0.000019223273,4.2700336e-8,0.6965317,0.29427144,0.000031409323,0.000046036148,1.543498e-9,5.8467368e-8,0.0000071455916,0.00038182957,0.008689162],"study_design_scores_gemma":[0.00017709489,0.000024052977,3.5340074e-7,0.057060555,0.5530771,0.000093806106,0.00001253398,3.68469e-7,9.743875e-8,5.9757997e-7,0.3893793,0.00017416486],"about_ca_topic_score_codex":0.000061103114,"about_ca_topic_score_gemma":0.000021044249,"teacher_disagreement_score":0.6394712,"about_ca_system_score_codex":0.00021672706,"about_ca_system_score_gemma":0.0002230906,"threshold_uncertainty_score":0.99991184},"labels":[],"label_agreement":null},{"id":"W3047522715","doi":"10.1158/1538-7445.pedca19-a18","title":"Abstract A18: Characterization of checkpoint inhibitors in the tumor microenvironment (TME) and peripheral blood in endemic Burkitt Lymphoma","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"TIGIT; Tumor microenvironment; Immune checkpoint; Immunology; Peripheral blood mononuclear cell; Cytotoxic T cell; Immune system; CD8; Cancer research; T cell; Biology; Medicine; Immunotherapy; In vitro","score_opus":0.041106052142593254,"score_gpt":0.3220867497399568,"score_spread":0.28098069759736355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047522715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917619,0.0022780148,6.1842445e-7,0.005212304,0.000038987433,0.0005871043,0.000012739763,0.0000052628857,0.000103034494],"genre_scores_gemma":[0.9961579,0.0028904942,0.000008093833,0.00066259765,0.0001352578,0.00008273825,0.000014635689,0.000014961015,0.00003334463],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986993,0.00009853073,0.00031689653,0.00024269383,0.0003777348,0.00026484183],"domain_scores_gemma":[0.99965286,0.000040567702,0.00005765971,0.00015207368,0.00003115581,0.000065675886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006444023,0.000098064294,0.0001939042,0.00010217432,0.00003476697,0.000017571425,0.0001171225,0.000052515894,0.00025064065],"category_scores_gemma":[0.000038457878,0.00007295352,0.00003903192,0.0004149256,0.00017695696,0.00006011952,0.00004390965,0.0002531812,0.0000021605804],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015631531,0.00014228915,0.043458063,0.00018185766,0.000024527528,0.000052135638,0.0036239102,0.0000011734343,0.94120336,0.0000035778096,0.000059518687,0.009686447],"study_design_scores_gemma":[0.003478508,0.0003550447,0.7435367,0.00027822322,0.000009005286,0.000016709166,0.0009611616,0.000030387993,0.24700578,0.000005187374,0.004243535,0.0000797186],"about_ca_topic_score_codex":0.0008644373,"about_ca_topic_score_gemma":0.00006732539,"teacher_disagreement_score":0.70007867,"about_ca_system_score_codex":0.00022605364,"about_ca_system_score_gemma":0.00020666464,"threshold_uncertainty_score":0.2974958},"labels":[],"label_agreement":null},{"id":"W3047911379","doi":"10.1111/cas.14605","title":"Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non‐small cell lung cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Science","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Novartis Pharma; Merck Sharp and Dohme; Ono Pharmaceutical; Astellas Pharma; Daiichi Sankyo Company; Clovis Oncology; Astellas Pharma Canada; Taiho Pharmaceutical; Boehringer Ingelheim; Bristol-Myers Squibb; AstraZeneca; Pfizer; Takeda Pharmaceutical Company; AbbVie; Kyowa Hakko Kirin","keywords":"Pembrolizumab; Medicine; Nivolumab; Internal medicine; Oncology; Lung cancer; Retrospective cohort study; Progressive disease; Disease; Cancer; Immunotherapy","score_opus":0.017328337946098962,"score_gpt":0.3128700621882125,"score_spread":0.29554172424211356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047911379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9702227,0.023893645,0.0014035789,0.00158169,0.00025623973,0.0024792352,0.000060316055,0.0000347903,0.000067807494],"genre_scores_gemma":[0.9937252,0.0016956489,0.0012776825,0.0016831199,0.00015218959,0.0013339195,0.0000050582275,0.000030540123,0.000096672906],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979476,0.00001747925,0.0003588429,0.0006804704,0.0003975021,0.00059812446],"domain_scores_gemma":[0.9988184,0.000045715,0.00018265788,0.00031669723,0.00021030533,0.00042621797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018096255,0.00024284114,0.00036764055,0.00011499557,0.00007843822,0.000030144382,0.0003753848,0.00006181796,0.00008546118],"category_scores_gemma":[0.000023490098,0.00019505838,0.0001665196,0.0010252445,0.0005693233,0.00014277357,0.000055672175,0.00015461365,9.590822e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045504518,0.001010691,0.24708265,0.0014099348,0.00008651941,0.00008064376,0.006206232,0.0009810514,0.2530104,0.000005890635,0.0002577133,0.44436374],"study_design_scores_gemma":[0.024224719,0.0012605784,0.30411696,0.00090830424,0.00015363407,0.00000143909,0.00044270567,0.015511464,0.6467798,0.000007710294,0.0059972405,0.00059547415],"about_ca_topic_score_codex":0.00022176182,"about_ca_topic_score_gemma":0.00005275101,"teacher_disagreement_score":0.4437683,"about_ca_system_score_codex":0.00033867738,"about_ca_system_score_gemma":0.0019613358,"threshold_uncertainty_score":0.795425},"labels":[],"label_agreement":null},{"id":"W3048583768","doi":"10.1158/1538-7445.pedca19-a77","title":"Abstract A77: Targeting lymphocyte exclusion in metastatic osteosarcoma","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Osteosarcoma; Cancer; Context (archaeology); Tumor-infiltrating lymphocytes; Immune system; Immune checkpoint; Disease; Extravasation; Cancer research; Immunotherapy; Immunology; Pathology; Oncology; Internal medicine; Biology","score_opus":0.13009418898882158,"score_gpt":0.4229033758782355,"score_spread":0.29280918688941393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048583768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97339946,0.012870689,0.000010969492,0.010870119,0.00010396384,0.0005830112,0.000013025718,0.000040692576,0.0021080447],"genre_scores_gemma":[0.9955752,0.0023423224,0.00017694582,0.0012475506,0.00025537374,0.00009907317,0.00001555177,0.000031777727,0.00025624406],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99804854,0.0001138244,0.0003080223,0.0003453518,0.0006737359,0.0005104922],"domain_scores_gemma":[0.9992889,0.00014081107,0.00003905981,0.00018679704,0.00013214622,0.0002122673],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009873608,0.000120199715,0.00025876146,0.00017567296,0.00011011043,0.00003446964,0.0001734073,0.000054913806,0.0018952667],"category_scores_gemma":[0.0001959922,0.000101299804,0.00008421804,0.00089373614,0.0001353268,0.000093160466,0.00010434913,0.0004502177,0.00009468487],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006101552,0.00009889183,0.004954518,0.0005396876,0.00008454908,0.00045896939,0.0020712076,0.000016599095,0.8368529,0.000015504198,0.009385838,0.13941975],"study_design_scores_gemma":[0.028173799,0.0017864201,0.116747536,0.0020498065,0.000064810585,0.00005683816,0.005759371,0.0020771325,0.45026204,0.00024096586,0.39193037,0.0008508882],"about_ca_topic_score_codex":0.0017960203,"about_ca_topic_score_gemma":0.00011825808,"teacher_disagreement_score":0.3865909,"about_ca_system_score_codex":0.0005844995,"about_ca_system_score_gemma":0.00071815355,"threshold_uncertainty_score":0.9990171},"labels":[],"label_agreement":null},{"id":"W3048679595","doi":"10.14740/wjon1277","title":"Current Status and Future Perspectives of Immunotherapy in Middle-Income Countries: A Single-Center Early Experience","year":2020,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"American University of Beirut","keywords":"Medicine; Pembrolizumab; Nivolumab; Immunotherapy; Internal medicine; Disease; Cancer; Epidemiology; Retrospective cohort study; Oncology; Intensive care medicine","score_opus":0.02696970675105759,"score_gpt":0.31757238875219507,"score_spread":0.2906026820011375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048679595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9377142,0.05426115,0.000013856132,0.007150469,0.00041285262,0.00015900764,0.000005270497,0.000004513704,0.00027868594],"genre_scores_gemma":[0.9804605,0.018053854,0.00033119932,0.00070124,0.00041790414,0.0000033457095,4.1778046e-7,0.000011621296,0.000019873887],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988182,0.000082246355,0.0005676416,0.00013136624,0.00019928295,0.00020125728],"domain_scores_gemma":[0.9991508,0.00007980228,0.00040761847,0.0000838785,0.0001594641,0.00011843517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018225382,0.00011922075,0.0004993612,0.00022754703,0.000023235369,0.000010699927,0.000093144736,0.000054466007,0.00025182674],"category_scores_gemma":[0.000023683044,0.000092696355,0.00011304111,0.00031965133,0.00024660418,0.00011153404,0.000019284438,0.0003220913,7.526036e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048049282,0.0012731611,0.6308318,0.00027735834,0.00042138936,0.000266928,0.17814283,0.0000010615469,0.026377356,0.00022172664,0.0003338058,0.11380332],"study_design_scores_gemma":[0.017894732,0.007929413,0.3448948,0.0008656137,0.000041040406,0.00031704045,0.015438952,0.000005425553,0.00096310803,0.000025239262,0.611459,0.00016563767],"about_ca_topic_score_codex":0.000021295968,"about_ca_topic_score_gemma":0.00005113192,"teacher_disagreement_score":0.6111252,"about_ca_system_score_codex":0.00030990472,"about_ca_system_score_gemma":0.00027631564,"threshold_uncertainty_score":0.37800476},"labels":[],"label_agreement":null},{"id":"W3049052172","doi":"10.1126/science.abc3421","title":"Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy","year":2020,"lang":"en","type":"article","venue":"Science","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1341,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Alberta Children's Hospital; University of Calgary","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Alberta Innovates; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"Inosine; Immunotherapy; Microbiome; Computational biology; Chemistry; Biology; Immunology; Immune system; Bioinformatics; Biochemistry; Adenosine","score_opus":0.019022004749790863,"score_gpt":0.27977309995896754,"score_spread":0.26075109520917666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049052172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9661853,0.00059912604,0.00025016215,0.03213581,0.00024057484,0.00038239325,0.000007652101,0.00009304225,0.00010595095],"genre_scores_gemma":[0.985183,0.0000460362,0.0026314554,0.011736055,0.00011714779,0.000008068254,0.0000018286514,0.000016437538,0.00025999142],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99865395,0.00003062423,0.00023953602,0.00042088324,0.00032290112,0.00033211618],"domain_scores_gemma":[0.9992361,0.000027654425,0.000051623887,0.0003064863,0.00012106401,0.00025705303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062486023,0.00013855299,0.00019467779,0.00016660723,0.00015530987,0.00006500568,0.00027427534,0.00004020422,0.0002225117],"category_scores_gemma":[0.00018245948,0.000112562244,0.00008271273,0.0015814621,0.0004532215,0.00014300388,0.00007792008,0.000098678094,0.00013655519],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008439165,0.00003980843,0.00027418984,0.000011300388,0.0000135069495,0.000010150584,0.002022002,0.0000031827228,0.9791994,0.0000017713478,0.0006145341,0.009371],"study_design_scores_gemma":[0.001661871,0.00085082575,0.042349216,0.000065639506,0.000004941142,0.000023705534,0.00018569302,0.00008965309,0.9055729,0.0000052610217,0.049039282,0.0001510169],"about_ca_topic_score_codex":0.000024194376,"about_ca_topic_score_gemma":0.0000012889144,"teacher_disagreement_score":0.07362649,"about_ca_system_score_codex":0.00015158615,"about_ca_system_score_gemma":0.00037654277,"threshold_uncertainty_score":0.45901552},"labels":[],"label_agreement":null},{"id":"W3049212237","doi":"10.1038/s41467-020-17981-0","title":"Strength of immune selection in tumors varies with sex and age","year":2020,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"National Institute of General Medical Sciences; Entertainment Industry Foundation; Stand Up To Cancer; Mark Foundation For Cancer Research; Broad Institute; Blavatnik Family Foundation; Geoffrey Beene Cancer Research Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute; Melanoma Research Alliance; Leukemia and Lymphoma Society; Howard Hughes Medical Institute; American Association for Cancer Research; National Science Foundation; National Institutes of Health; U.S. Department of Health and Human Services; National Heart, Lung, and Blood Institute; Scheme for Promotion of Academic and Research Collaboration; U.S. National Library of Medicine; Canadian Institute for Advanced Research; Starr Foundation; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Ben and Catherine Ivy Foundation; Cancer Research Institute","keywords":"Immune system; Context (archaeology); Biology; MHC class I; Major histocompatibility complex; Genotype; Immunology; Selection (genetic algorithm); Immune checkpoint; Mutation; Immunity; Genetics; Immunotherapy; Gene","score_opus":0.01595270109892075,"score_gpt":0.28313644212957273,"score_spread":0.26718374103065196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049212237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9584089,0.023928432,0.000024066245,0.014356013,0.000013619362,0.00035817668,0.000012786877,0.00004973857,0.0028482873],"genre_scores_gemma":[0.9954102,0.0013806148,0.0026657616,0.00044315896,0.000010280764,0.000010028775,0.000030980707,0.000007288521,0.00004166786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996004,0.000039789404,0.00015000132,0.00007821782,0.000072024304,0.000059568083],"domain_scores_gemma":[0.9995456,0.000069948095,0.00005873664,0.00026039372,0.0000380866,0.000027285647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000780977,0.00005811389,0.00014872073,0.000040298422,0.00004846737,0.00000671236,0.000121054996,0.00007830515,0.000012797245],"category_scores_gemma":[0.00004472682,0.000046668752,0.000021725025,0.00038351756,0.0001437685,0.00003862606,0.00004318807,0.00042422052,2.935196e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066521796,0.0012390943,0.46739408,0.0005138213,0.00083601795,0.0000256224,0.020427426,0.000018238596,0.44194973,0.012387733,0.00360887,0.044947173],"study_design_scores_gemma":[0.003201882,0.0006326806,0.95100266,0.00023096167,0.0000765302,0.00004212232,0.0013675551,0.00083848793,0.010790059,0.000051625408,0.031611957,0.00015351144],"about_ca_topic_score_codex":0.00013046249,"about_ca_topic_score_gemma":0.0006781573,"teacher_disagreement_score":0.48360854,"about_ca_system_score_codex":0.000021316297,"about_ca_system_score_gemma":0.000062291394,"threshold_uncertainty_score":0.19030966},"labels":[],"label_agreement":null},{"id":"W3049302966","doi":"10.1158/1557-3265.bladder19-ia10","title":"Abstract IA10: Developing rational combination therapy with checkpoint inhibitors","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Dasatinib; Cabozantinib; Medicine; Immunotherapy; Cancer research; In vivo; Druggability; Combination therapy; Cancer; Cancer immunotherapy; Melanoma; Pharmacology; Internal medicine; Imatinib; Biology; Myeloid leukemia","score_opus":0.3418735799590187,"score_gpt":0.5133392790341231,"score_spread":0.17146569907510445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049302966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91357464,0.0012106835,0.000099497935,0.082679644,0.00018027634,0.0006921201,0.000006549689,0.00005364736,0.0015029206],"genre_scores_gemma":[0.9911356,0.002957846,0.000340579,0.004294934,0.0008901107,0.000109353125,0.000028678158,0.000028071163,0.00021484811],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977632,0.0001334803,0.0005348074,0.0003901215,0.00086896506,0.00030942148],"domain_scores_gemma":[0.9986297,0.00036577487,0.000091230715,0.00017578478,0.0005136456,0.00022389521],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017139452,0.00011870718,0.00026795012,0.000074062154,0.00015275394,0.000049369984,0.00013729144,0.00012607998,0.0009921599],"category_scores_gemma":[0.00028813293,0.000084517735,0.00012386376,0.00058659643,0.00038138972,0.0000995254,0.000038920836,0.00074736524,0.00005599969],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06620624,0.0012246604,0.2765354,0.00047972065,0.0010373505,0.00016469616,0.0013950914,0.000015111387,0.05256697,0.0012694778,0.055455714,0.5436496],"study_design_scores_gemma":[0.012043951,0.0027792898,0.8194012,0.00038484053,0.00001305701,0.0000068253926,0.00020683896,0.00012926766,0.026632374,0.00018738446,0.13796355,0.0002514236],"about_ca_topic_score_codex":0.00021050226,"about_ca_topic_score_gemma":0.00004394141,"teacher_disagreement_score":0.54339814,"about_ca_system_score_codex":0.00020972795,"about_ca_system_score_gemma":0.0014806687,"threshold_uncertainty_score":0.9999211},"labels":[],"label_agreement":null},{"id":"W3049330696","doi":"10.1158/1538-7445.am2020-ct302","title":"Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"TIGIT; Atezolizumab; Medicine; Tolerability; Oncology; Pharmacodynamics; Antibody; Internal medicine; Pharmacokinetics; Pharmacology; Cancer; Immunotherapy; Immunology; Adverse effect; Nivolumab","score_opus":0.04779853249571873,"score_gpt":0.4007939234105441,"score_spread":0.35299539091482535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049330696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968371,0.00020664999,0.0000016103322,0.00060610694,0.000025567262,0.0021596476,0.000010461789,0.000010669853,0.00014219419],"genre_scores_gemma":[0.9997031,0.00007233834,0.000006918256,0.00006296263,0.000015383408,0.00007652799,0.000020052188,0.000023256458,0.000019425452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822396,0.00010695059,0.00030903486,0.00032363314,0.00076239475,0.00027404845],"domain_scores_gemma":[0.99932194,0.000043248638,0.000118430326,0.00021606167,0.00022107922,0.00007926721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026406613,0.00012904147,0.0002898881,0.0001808301,0.000073688185,0.000027721135,0.00011441567,0.000042120242,0.00004867797],"category_scores_gemma":[0.000048753816,0.00008472198,0.00002170612,0.0009978373,0.00017635993,0.000129324,0.000046551148,0.0003180166,0.0000011261689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043960504,0.004851563,0.8190553,0.00029557972,0.00011299946,0.00005741587,0.0061944574,0.00022886864,0.07092463,0.0000030429173,0.00003674998,0.05427884],"study_design_scores_gemma":[0.036556173,0.006912069,0.9453232,0.0006995643,0.000013494957,0.0000014526046,0.0012502547,0.00011409111,0.00897637,0.0000051985407,0.000045912144,0.000102182355],"about_ca_topic_score_codex":0.0012130226,"about_ca_topic_score_gemma":0.0006694372,"teacher_disagreement_score":0.1262679,"about_ca_system_score_codex":0.00030721596,"about_ca_system_score_gemma":0.00027982547,"threshold_uncertainty_score":0.34548622},"labels":[],"label_agreement":null},{"id":"W3049587240","doi":"10.1016/j.anndiagpath.2020.151590","title":"Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma","year":2020,"lang":"en","type":"article","venue":"Annals of Diagnostic Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"AstraZeneca Canada","keywords":"Lung cancer; Medicine; Pathology; Companion diagnostic; Internal medicine; Nuclear medicine; Oncology; Cancer","score_opus":0.05772511351640031,"score_gpt":0.3157225826869172,"score_spread":0.2579974691705169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049587240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99222314,0.0027082225,0.000062366664,0.0039919233,0.00008892366,0.00038911623,0.00009022389,0.000009363653,0.0004366944],"genre_scores_gemma":[0.9959896,0.0006710459,0.00027275537,0.002976422,0.00004017467,0.000016925342,0.000017772778,0.000011479139,0.0000037745697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987793,0.00016259216,0.0004905619,0.00024923042,0.00010316507,0.00021515295],"domain_scores_gemma":[0.99841905,0.0009443817,0.00016900596,0.00019618416,0.00016878042,0.00010259278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043826384,0.00013856048,0.00060103915,0.00007773933,0.000018529601,0.0000025420409,0.00009853513,0.0001305198,0.00005388861],"category_scores_gemma":[0.00095687323,0.00013110285,0.000067206085,0.0002750994,0.00026525234,0.000030370482,0.00005886682,0.00016562965,0.0000024683536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00118799,0.00030603568,0.9596469,0.0005081193,0.00002925134,0.00017539844,0.0023073386,0.000002025842,0.03109262,0.000017437616,0.0018700227,0.0028568944],"study_design_scores_gemma":[0.0025053031,0.0007171301,0.9431988,0.00009071378,0.000038824364,0.000008998939,0.0001863654,0.000054667264,0.052731976,0.000024310419,0.0003368174,0.00010610704],"about_ca_topic_score_codex":0.00014448416,"about_ca_topic_score_gemma":0.00006262212,"teacher_disagreement_score":0.021639356,"about_ca_system_score_codex":0.000011576012,"about_ca_system_score_gemma":0.00017061905,"threshold_uncertainty_score":0.53462183},"labels":[],"label_agreement":null},{"id":"W3049758264","doi":"10.1007/s00262-020-02693-7","title":"Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients","year":2020,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Universität Zürich; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Fingolimod; Medicine; Pembrolizumab; Cancer; Multiple sclerosis; Immune system; Tumor-infiltrating lymphocytes; Avelumab; Ipilimumab; Melanoma; Immunotherapy; Oncology; Internal medicine; Immunology; Cancer research","score_opus":0.017191812970620744,"score_gpt":0.2719546069558567,"score_spread":0.254762793985236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049758264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.931582,0.062947355,0.0000076178835,0.0038099538,0.00039557368,0.0007863173,0.00006994288,0.0001491938,0.00025208128],"genre_scores_gemma":[0.97128165,0.019789426,0.00012453628,0.007886512,0.00022046441,0.00040604442,0.000041385436,0.000099126075,0.00015086083],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975964,0.00010998109,0.0007696572,0.0006653426,0.0002134105,0.0006452245],"domain_scores_gemma":[0.9990361,0.00008237338,0.00029134416,0.00032778145,0.00014005233,0.00012237753],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014686897,0.0004619604,0.00079463236,0.00018999749,0.00015191785,0.000046970134,0.00021239223,0.00023927358,0.0007882976],"category_scores_gemma":[0.00005624606,0.00042008533,0.00018090791,0.00062499184,0.00036657255,0.00020287039,0.000055945016,0.0004252762,0.000013830007],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009736346,0.0002215902,0.3468713,0.00010719231,0.0007030104,0.000030296871,0.002510914,0.0000060928546,0.5636017,0.000012037032,0.00040396134,0.07579558],"study_design_scores_gemma":[0.036085907,0.00196044,0.7418564,0.0007672877,0.00010254512,0.000043403146,0.00052748667,0.000328943,0.19121917,0.000021644342,0.026242565,0.0008442241],"about_ca_topic_score_codex":0.002597891,"about_ca_topic_score_gemma":0.0001363659,"teacher_disagreement_score":0.3949851,"about_ca_system_score_codex":0.0005927355,"about_ca_system_score_gemma":0.0004142931,"threshold_uncertainty_score":0.9998251},"labels":[],"label_agreement":null},{"id":"W3064097435","doi":"10.1097/cji.0000000000000337","title":"Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care South East; Queen's University","funders":"","keywords":"Medicine; Immunotherapy; Adverse effect; Cancer; Immune system; Cancer immunotherapy; Oncology; Internal medicine; Immunology","score_opus":0.008550274644871467,"score_gpt":0.25309998093780417,"score_spread":0.2445497062929327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3064097435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96677524,0.029851899,0.000091126094,0.001985494,0.00036618326,0.00076436123,0.000024778903,0.000018800343,0.00012211094],"genre_scores_gemma":[0.97153395,0.02610924,0.00085893547,0.0012179184,0.00007134954,0.000022682972,0.000008439516,0.0000922397,0.00008521971],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966707,0.0001533832,0.0018361673,0.00026794116,0.00070366805,0.0003681266],"domain_scores_gemma":[0.99761903,0.000065944274,0.0013490379,0.00038290353,0.00045882896,0.00012425652],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005096793,0.00037415087,0.0010758791,0.000289956,0.000044375283,0.000004268901,0.00031130793,0.00019729149,0.0011368502],"category_scores_gemma":[0.000027441487,0.00027288377,0.0005194521,0.00068224873,0.00012965806,0.00035452697,0.000021277325,0.00061358267,0.000004499008],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37391344,0.0015647132,0.34795287,0.00016145543,0.003239367,0.00006710928,0.00621467,0.00021423875,0.08108434,0.0000054242914,0.00006017406,0.18552221],"study_design_scores_gemma":[0.064064786,0.0064124716,0.9144221,0.002411365,0.00008567073,0.000025081386,0.0003548726,0.000014328766,0.005552984,0.000021773967,0.0062619857,0.00037261212],"about_ca_topic_score_codex":0.00005448133,"about_ca_topic_score_gemma":0.000011229317,"teacher_disagreement_score":0.5664692,"about_ca_system_score_codex":0.0003512115,"about_ca_system_score_gemma":0.00037807724,"threshold_uncertainty_score":0.99997234},"labels":[],"label_agreement":null},{"id":"W3081206880","doi":"10.3390/cancers12092418","title":"Tumor Infiltrating Lymphocytes Signature as a New Pan-Cancer Predictive Biomarker of Anti PD-1/PD-L1 Efficacy","year":2020,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Immunotherapy; Medicine; Lung cancer; Gene signature; Melanoma; Oncology; Cancer; Tumor-infiltrating lymphocytes; Myeloid; Cancer immunotherapy; Biomarker; Internal medicine; Cancer research; Biology; Gene; Gene expression","score_opus":0.02622262680754774,"score_gpt":0.2952724801144459,"score_spread":0.2690498533068982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081206880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97608644,0.014810099,0.00015124156,0.003977136,0.00059417705,0.00093322597,0.00013931154,0.00016362636,0.0031447434],"genre_scores_gemma":[0.98983794,0.0009012161,0.00026678128,0.007914929,0.0006144254,0.000041462794,0.00002936387,0.0000552389,0.00033862249],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982072,0.000045933004,0.00046654552,0.00048381946,0.00041209647,0.0003844027],"domain_scores_gemma":[0.99878067,0.00012095256,0.0003002789,0.00028260352,0.00013610761,0.00037941773],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010940356,0.00030674093,0.0005770492,0.00009286632,0.000078425444,0.00002383181,0.00020184217,0.00015202689,0.0011373324],"category_scores_gemma":[0.0002733038,0.0002631337,0.00027394082,0.00077190174,0.00023874822,0.00013593824,0.000043127795,0.00025402,0.000015854272],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022437928,0.00007613909,0.010426843,0.0006101875,0.0019148324,0.00011423672,0.004799669,0.00057071797,0.7994429,0.00004045296,0.084306285,0.075259805],"study_design_scores_gemma":[0.034662288,0.003896993,0.17224576,0.0036443814,0.0012096887,0.00012832621,0.0036584595,0.005685234,0.57957226,0.000058223442,0.19379506,0.0014433103],"about_ca_topic_score_codex":0.002523741,"about_ca_topic_score_gemma":0.000028378545,"teacher_disagreement_score":0.21987063,"about_ca_system_score_codex":0.000983374,"about_ca_system_score_gemma":0.0045663947,"threshold_uncertainty_score":0.99998206},"labels":[],"label_agreement":null},{"id":"W3081861280","doi":"10.1158/1538-7445.am2020-ct169","title":"Abstract CT169: A phase Ia study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in patients with locally advanced or metastatic solid tumors","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chills; Immunotherapy; Internal medicine; Adverse effect; Cancer; Immune system; Oncology; Nausea; Gastroenterology; Immunology","score_opus":0.11949571553765717,"score_gpt":0.4719475528965949,"score_spread":0.3524518373589377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081861280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911308,0.0009493834,0.00004106336,0.0012894452,0.00007950189,0.006261659,0.000090995,0.00006689596,0.000090209505],"genre_scores_gemma":[0.9968113,0.0003266084,0.00048501615,0.0010915474,0.00012996572,0.00081178953,0.00006490638,0.00012018792,0.00015869492],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9950203,0.0004361808,0.0007647259,0.0009139039,0.001928035,0.00093689235],"domain_scores_gemma":[0.99795693,0.0001242992,0.00014347627,0.0006130426,0.0006090916,0.000553132],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016455953,0.00038693697,0.0008324168,0.00049560826,0.00018034075,0.00012946189,0.0005212384,0.000052431755,0.00268327],"category_scores_gemma":[0.00011566778,0.00027215792,0.000090422196,0.0022732678,0.00019482842,0.0002883752,0.00008677248,0.00066478585,0.00007576087],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45685247,0.010094373,0.07644871,0.00032294012,0.0012338617,0.00090846966,0.026610723,0.00043158044,0.10929341,0.000002684913,0.0015625935,0.3162382],"study_design_scores_gemma":[0.13479318,0.04358104,0.7949696,0.00093450426,0.0000844429,0.0000075530356,0.0068353224,0.000114154325,0.0090062795,0.000014185907,0.008848874,0.00081087195],"about_ca_topic_score_codex":0.00068552204,"about_ca_topic_score_gemma":0.0007620878,"teacher_disagreement_score":0.7185209,"about_ca_system_score_codex":0.00051549514,"about_ca_system_score_gemma":0.0013419619,"threshold_uncertainty_score":0.99997306},"labels":[],"label_agreement":null},{"id":"W3082399821","doi":"10.1038/s41598-020-71788-z","title":"Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients","year":2020,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; University of Toronto; Sunnybrook Health Science Centre; McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"","keywords":"Nivolumab; Ipilimumab; Pembrolizumab; Discontinuation; Medicine; Internal medicine; Oncology; Population; Cancer; Immunotherapy","score_opus":0.055754327625083235,"score_gpt":0.3356405443520768,"score_spread":0.27988621672699354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082399821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974447,0.00028498608,0.000011790862,0.0002667986,0.00065321825,0.00046079594,0.0000039334445,0.000011321617,0.0008624411],"genre_scores_gemma":[0.99929607,0.000037390866,0.00026053,0.000033249464,0.000019722671,0.000009481699,0.000073326046,0.000009294257,0.00026093697],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99803823,0.00004847184,0.000973911,0.0003318211,0.00048075584,0.00012678198],"domain_scores_gemma":[0.9987734,0.000022563254,0.0006478947,0.00032705598,0.00016798286,0.000061124665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007069059,0.000100046804,0.0003600739,0.00027219413,0.00002514733,0.000016287568,0.000050098133,0.000021683694,0.00013711225],"category_scores_gemma":[0.00011980631,0.000074625,0.0001683087,0.0011829258,0.0001842041,0.00009694796,0.000018657534,0.000055398337,9.565621e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061571825,0.00041130933,0.3655499,0.00008623213,0.00012489989,0.00004414373,0.0017589309,0.000013098481,0.61560404,0.000004305303,0.0011658925,0.0146215735],"study_design_scores_gemma":[0.001268831,0.00030275856,0.28486118,0.00014159449,0.000045673016,0.0000029191713,0.00018899188,0.00007226102,0.7115572,0.00011367623,0.0013633722,0.00008155232],"about_ca_topic_score_codex":0.0006935539,"about_ca_topic_score_gemma":0.00014575743,"teacher_disagreement_score":0.09595318,"about_ca_system_score_codex":0.00004368317,"about_ca_system_score_gemma":0.0001563209,"threshold_uncertainty_score":0.3043119},"labels":[],"label_agreement":null},{"id":"W3082639272","doi":"10.1016/j.ejca.2020.07.028","title":"Increased risk of immune checkpoint inhibitor–induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Medac; Les Laboratories Pierre Fabre; Novartis; Bristol-Myers Squibb; Novartis Pharma; Roche; Amgen","keywords":"Pembrolizumab; Medicine; Type 1 diabetes; Internal medicine; Melanoma; Diabetes mellitus; Adjuvant; Oncology; Gastroenterology; Cancer; Immunotherapy; Endocrinology; Cancer research","score_opus":0.0122356714177343,"score_gpt":0.21873178121989825,"score_spread":0.20649610980216396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082639272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98990786,0.00807011,0.000014251317,0.0012913261,0.00007921289,0.00024652973,0.000008614062,0.0000052473406,0.0003768648],"genre_scores_gemma":[0.99861014,0.0005085638,0.00037055297,0.00025870657,0.00018090689,0.000001000311,0.00000292508,0.0000399932,0.000027221764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983684,0.0002252471,0.0006596803,0.00013273102,0.00044261402,0.00017134035],"domain_scores_gemma":[0.9982186,0.000042131927,0.0010434351,0.00020206739,0.0003654418,0.00012835572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049375946,0.00016781787,0.00047985584,0.00008086716,0.000023603905,0.000009593375,0.00019121982,0.000023304363,0.00010140741],"category_scores_gemma":[0.000081360595,0.00008994272,0.00012464054,0.00042221055,0.00011378631,0.00008239544,0.00002796813,0.00034153386,0.0000013253568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15941447,0.0009469105,0.3922556,0.00044042146,0.0032586649,0.00007994588,0.0057780463,0.00009803532,0.34216917,0.0000048201973,0.0018915362,0.09366239],"study_design_scores_gemma":[0.024387665,0.011342093,0.8674718,0.0010210213,0.00032175574,0.0000043809455,0.000265979,0.000026675432,0.09042882,0.0000010395797,0.0045672003,0.00016154133],"about_ca_topic_score_codex":0.00014540085,"about_ca_topic_score_gemma":0.00002268344,"teacher_disagreement_score":0.4752162,"about_ca_system_score_codex":0.0000667602,"about_ca_system_score_gemma":0.00042390332,"threshold_uncertainty_score":0.36677575},"labels":[],"label_agreement":null},{"id":"W3082705391","doi":"10.1186/s12885-020-07313-2","title":"Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration","year":2020,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto; American Society of Clinical Oncology","keywords":"Medicine; Food and drug administration; Oncology; Internal medicine; Immune checkpoint; Clinical Oncology; Adverse effect; Immunotherapy; Pharmacology; Cancer","score_opus":0.03348437106737064,"score_gpt":0.3142044597034453,"score_spread":0.28072008863607467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082705391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98699385,0.008357324,0.000052885207,0.003638731,0.00021473411,0.0003339766,0.000058918944,0.000025997464,0.00032358037],"genre_scores_gemma":[0.99723625,0.0009777227,0.00028654176,0.00082337053,0.00029289612,0.000030369796,0.00002479006,0.000016174588,0.0003118645],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99892193,0.000021648875,0.00055149937,0.00023466066,0.00015341408,0.00011687058],"domain_scores_gemma":[0.9994727,0.000038871145,0.00018958536,0.00013994733,0.000050817867,0.00010810104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019461475,0.00010923514,0.00029620418,0.000017470566,0.000024974803,0.000009421638,0.00004711505,0.00007914838,0.00013695525],"category_scores_gemma":[0.0000472505,0.00009387617,0.00015410355,0.00011896244,0.00011308385,0.000043637352,0.000023062692,0.00011895071,0.0000015056645],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021038571,0.0005662391,0.32435685,0.0012645564,0.0007383843,0.0000048544025,0.0016205825,0.0000038387257,0.48385784,0.000078171804,0.027094765,0.13937533],"study_design_scores_gemma":[0.01386172,0.00379633,0.27556127,0.00044737197,0.00029972574,0.000013480456,0.00060608675,0.0003956531,0.5890363,0.0000352463,0.115511574,0.00043524764],"about_ca_topic_score_codex":0.00029230968,"about_ca_topic_score_gemma":0.00028372696,"teacher_disagreement_score":0.13894008,"about_ca_system_score_codex":0.000036235837,"about_ca_system_score_gemma":0.00020053834,"threshold_uncertainty_score":0.38281593},"labels":[],"label_agreement":null},{"id":"W3083110487","doi":"10.1158/1538-7445.am2020-917","title":"Abstract 917: Functional blocking of CD5 on T cells to enhance the efficacy of therapeutic PD-1 blockade in treatment of mouse 4T1 breast tumors","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Cytotoxic T cell; CD8; Cancer research; T cell; Blockade; CD5; Ex vivo; In vivo; Biology; Immune system; Immunology; Medicine; Antibody; Receptor; Internal medicine; In vitro","score_opus":0.09600337573824338,"score_gpt":0.40060629083581495,"score_spread":0.30460291509757154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083110487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99267465,0.0014659547,0.000004756007,0.0046998803,0.000052274572,0.000757204,0.00006548225,0.0000071627796,0.0002726612],"genre_scores_gemma":[0.99864537,0.0005411597,0.0000107472,0.00020512717,0.00014024696,0.000079026606,0.0000039338975,0.000020500693,0.00035392147],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983157,0.000086185995,0.0003857314,0.00026365684,0.0006668091,0.0002819328],"domain_scores_gemma":[0.99895364,0.00035910457,0.00010149275,0.0003121499,0.00017700481,0.000096613025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036346182,0.00012709541,0.0003362705,0.00016576519,0.000041328713,0.000005938189,0.00016770366,0.000051754272,0.00055017194],"category_scores_gemma":[0.000029873767,0.000083443985,0.000129125,0.0006961905,0.00022561487,0.000019742716,0.000027004153,0.00020969825,0.000008438167],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013750494,0.0005498302,0.002027228,0.00015615641,0.0001749856,0.0000070554693,0.0018506615,0.00051752495,0.94272506,0.000009765656,0.00025535043,0.03797588],"study_design_scores_gemma":[0.002080061,0.0014597564,0.08811349,0.0003308792,0.000018045195,0.0000023547527,0.000396672,0.000028539207,0.906154,0.000003590938,0.001347141,0.00006549611],"about_ca_topic_score_codex":0.0016817143,"about_ca_topic_score_gemma":0.00010933346,"teacher_disagreement_score":0.08608626,"about_ca_system_score_codex":0.0002842374,"about_ca_system_score_gemma":0.00045397965,"threshold_uncertainty_score":0.6023997},"labels":[],"label_agreement":null},{"id":"W3083222874","doi":"10.3747/co.27.5985","title":"Canadian Cohort Expanded-Access Program of Nivolumab Plus Ipilimumab in Advanced Melanoma","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; Bristol-Myers Squibb (Canada); McMaster University; London Health Sciences Centre","funders":"","keywords":"Ipilimumab; Nivolumab; Medicine; Discontinuation; Internal medicine; Expanded access; Adverse effect; Cohort; Melanoma; Population; Oncology; Hazard ratio; Confidence interval; Surgery; Cancer; Immunotherapy; Cancer research","score_opus":0.08545878039336403,"score_gpt":0.4157891680202777,"score_spread":0.3303303876269137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083222874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871799,0.0035067194,0.000012239569,0.003039501,0.0007408299,0.0013355492,0.000020397265,0.00004953635,0.0041153245],"genre_scores_gemma":[0.9983563,0.00061095855,0.00014056539,0.0004646392,0.00011459735,0.00018481666,0.00006406116,0.00001617054,0.00004791255],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881107,0.00005394356,0.00038673446,0.00028244004,0.00013612366,0.0003297207],"domain_scores_gemma":[0.9993468,0.000031524898,0.00011274342,0.00017487093,0.00007466065,0.00025938652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001226776,0.00013486126,0.00048183277,0.00014324562,0.000026937163,0.000007485192,0.00018052755,0.000117343385,0.0002829361],"category_scores_gemma":[0.00005165898,0.0001266283,0.000093404684,0.00039645858,0.0001083685,0.0000679345,0.000038951548,0.00022911429,0.000009260649],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033793047,0.0003625489,0.33258167,0.00020070125,0.000083292616,0.00006896078,0.00072961237,0.0000050299636,0.000988205,0.000021096752,0.002495542,0.659084],"study_design_scores_gemma":[0.017996732,0.004421082,0.35342288,0.00021894537,0.00009303934,0.000047031797,0.0004567553,0.00073594134,0.0017003851,0.000022543436,0.620608,0.00027669518],"about_ca_topic_score_codex":0.011929047,"about_ca_topic_score_gemma":0.068788946,"teacher_disagreement_score":0.65880734,"about_ca_system_score_codex":0.0010037598,"about_ca_system_score_gemma":0.0016845092,"threshold_uncertainty_score":0.9946506},"labels":[],"label_agreement":null},{"id":"W3083253396","doi":"10.1158/1538-7445.am2020-lb-258","title":"Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score &amp;lt;1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Hazard ratio; Internal medicine; Proportional hazards model; Population; Cetuximab; Oncology; Progression-free survival; Post-hoc analysis; Head and neck cancer; Confidence interval; Subgroup analysis; Urology; Overall survival; Gastroenterology; Nuclear medicine; Cancer; Immunotherapy","score_opus":0.08650490551771019,"score_gpt":0.37831657496832594,"score_spread":0.29181166945061576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083253396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9636846,0.03010942,0.00001905635,0.004429528,0.0000401395,0.001203709,0.00037167064,0.000019679752,0.00012220151],"genre_scores_gemma":[0.9942867,0.004741659,0.00008696903,0.00025984473,0.000055288845,0.00009540212,0.00019850844,0.000042135525,0.00023348877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970906,0.00021502395,0.00062380993,0.00075746846,0.0007076423,0.0006054946],"domain_scores_gemma":[0.99799716,0.00073211076,0.00015794687,0.00035975841,0.00024488568,0.00050810544],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00065968465,0.00031711537,0.0009054442,0.00050230656,0.00016514552,0.0000619431,0.00017500325,0.00012273075,0.0003304756],"category_scores_gemma":[0.00025620358,0.00025964525,0.00014407223,0.001734486,0.0005538968,0.000108527885,0.00014436447,0.0006276289,0.0000025102458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28682724,0.0031418903,0.44196817,0.009281895,0.0024912837,0.0006297133,0.015713004,0.00008764121,0.19465983,0.000025737772,0.012096503,0.03307708],"study_design_scores_gemma":[0.05150313,0.007863675,0.9139217,0.0006996754,0.0010976485,0.000033250966,0.00075367215,0.001686093,0.017596437,0.000032933112,0.00415404,0.0006577356],"about_ca_topic_score_codex":0.006450509,"about_ca_topic_score_gemma":0.006104924,"teacher_disagreement_score":0.4719535,"about_ca_system_score_codex":0.00030025156,"about_ca_system_score_gemma":0.00036470033,"threshold_uncertainty_score":0.9999856},"labels":[],"label_agreement":null},{"id":"W3083266489","doi":"10.1158/1538-7445.am2020-6528","title":"Abstract 6528: Anti-PD-1 induces the endocytosis of the co-receptor from the surface of T-cells: Nivolumab is more effective than Pembrolizumab","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Internalization; Endocytosis; Nivolumab; Pembrolizumab; Cell biology; Receptor; Cancer research; Biology; Chemistry; Molecular biology; Immunotherapy; Immune system; Immunology; Biochemistry","score_opus":0.06894999887386426,"score_gpt":0.38273960844279653,"score_spread":0.31378960956893226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083266489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9690669,0.007201962,0.0000011994703,0.020677421,0.00020082704,0.0014464431,0.0007554627,0.000014801134,0.00063497043],"genre_scores_gemma":[0.9964902,0.0020555863,0.0000068526506,0.0008539062,0.00028606303,0.0000862541,0.000011056736,0.000033910637,0.0001762169],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973857,0.00038829184,0.00033802254,0.0003586494,0.0011373945,0.0003919683],"domain_scores_gemma":[0.9976092,0.0010789223,0.00018686577,0.0007092948,0.00032237222,0.000093354705],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007475314,0.00018514103,0.00039446395,0.00003480667,0.00027091656,0.000034320346,0.00084115815,0.000114944116,0.0013927951],"category_scores_gemma":[0.00015215672,0.00008756627,0.00028474018,0.0007921964,0.0012001308,0.00006354881,0.00016321888,0.0008187305,0.000028868804],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00375627,0.00008634788,0.012213981,0.00015930951,0.00058830495,0.0000022898955,0.009232719,0.00001234501,0.92035306,0.0000044929507,0.047677543,0.0059133274],"study_design_scores_gemma":[0.0023036909,0.0002641326,0.1445977,0.0003274246,0.000057142082,0.0000011292933,0.003532432,0.000020801233,0.8370313,0.000007909535,0.011766778,0.0000895475],"about_ca_topic_score_codex":0.015248394,"about_ca_topic_score_gemma":0.00012987078,"teacher_disagreement_score":0.1323837,"about_ca_system_score_codex":0.00019966839,"about_ca_system_score_gemma":0.000673001,"threshold_uncertainty_score":0.99952006},"labels":[],"label_agreement":null},{"id":"W3083362003","doi":"10.1158/1538-7445.am2020-ct289","title":"Abstract CT289: Pembrolizumab plus lenvatinib vs docetaxel in patients with previously treated metastatic non-small-cell lung cancer (NSCLC) and PD after platinum-doublet chemotherapy and immunotherapy: Phase 3, randomized, open-label LEAP-008 trial","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenvatinib; Medicine; Pembrolizumab; Docetaxel; Internal medicine; Oncology; Chemotherapy; Tolerability; Lung cancer; Cancer; Immunotherapy; Adverse effect; Thyroid cancer","score_opus":0.060631510661958425,"score_gpt":0.38275793540181857,"score_spread":0.32212642473986014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083362003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688058,0.016293997,0.00002346512,0.002159724,0.00008600656,0.012055108,0.00014574567,0.000036506077,0.00039362934],"genre_scores_gemma":[0.980024,0.012937393,0.00023224174,0.001678786,0.00018716857,0.003971965,0.000070636735,0.00015274542,0.0007450974],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99591774,0.00040368355,0.0008957514,0.0010047979,0.0008525448,0.0009255075],"domain_scores_gemma":[0.9981234,0.00038067927,0.00029088336,0.00047228046,0.00034183025,0.0003909026],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015314958,0.00055124174,0.0016434412,0.00030597716,0.00020590627,0.00031706158,0.0003902322,0.00016880147,0.0012147685],"category_scores_gemma":[0.000066771354,0.00040061076,0.000110781926,0.00086184,0.00059094426,0.00037106764,0.00014085532,0.00086152676,0.000004624862],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9556159,0.0010882276,0.006118136,0.00078702014,0.0010180507,0.00007164347,0.0045900103,0.0000048663833,0.0060703787,0.000001489878,0.0009711385,0.023663176],"study_design_scores_gemma":[0.9827843,0.003925844,0.0062349723,0.0010825539,0.00021319624,0.0000047051226,0.00017333675,0.0005951933,0.0031915877,0.0000047694734,0.0012940022,0.0004955624],"about_ca_topic_score_codex":0.0060487953,"about_ca_topic_score_gemma":0.0004707068,"teacher_disagreement_score":0.027168415,"about_ca_system_score_codex":0.0005283102,"about_ca_system_score_gemma":0.0014304587,"threshold_uncertainty_score":0.99984455},"labels":[],"label_agreement":null},{"id":"W3083470695","doi":"10.1158/1538-7445.am2020-4550","title":"Abstract 4550: Increased IL-27 is associated with poor prognosis in renal cell carcinoma and supports use of SRF388, a first-in-class IL-27p28 blocking antibody, to counteract IL-27-mediated immunosuppression in this setting","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Glycoprotein 130; Cancer research; Cytokine; Antibody; Immune system; Biology; Immunology; Medicine; Interleukin 6","score_opus":0.04198249141507971,"score_gpt":0.3361593111368219,"score_spread":0.2941768197217422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083470695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903805,0.0010111112,5.891948e-7,0.006098086,0.000065291315,0.0017576679,0.0005006404,0.00002976189,0.00015630062],"genre_scores_gemma":[0.9979507,0.00068650465,0.000054849872,0.00068574125,0.00006711906,0.0001570377,0.00018201907,0.00007288661,0.00014319642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99591887,0.00030179264,0.00085798744,0.0007962123,0.0011473922,0.0009777739],"domain_scores_gemma":[0.9978588,0.0008549291,0.00025913017,0.0003083859,0.00038965972,0.00032907302],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015649273,0.000347741,0.00076851394,0.00078360725,0.00010542525,0.0000971886,0.0002540546,0.00026017643,0.00063966255],"category_scores_gemma":[0.0006355376,0.00029897355,0.00009412158,0.002107334,0.00019461485,0.0003090461,0.00018174158,0.0011125598,0.0000064589917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007845529,0.00031266696,0.5145766,0.0004398194,0.00007581439,0.00074173725,0.0042913537,0.000018273426,0.46684504,1.1328328e-7,0.0040037874,0.00084924226],"study_design_scores_gemma":[0.009137513,0.0012545238,0.7768126,0.005127238,0.000039570336,0.000015750022,0.0008022823,0.0012394873,0.20071235,0.0000011734924,0.0044577005,0.00039977045],"about_ca_topic_score_codex":0.030928966,"about_ca_topic_score_gemma":0.005283015,"teacher_disagreement_score":0.26613268,"about_ca_system_score_codex":0.0010218187,"about_ca_system_score_gemma":0.0010279266,"threshold_uncertainty_score":0.99994624},"labels":[],"label_agreement":null},{"id":"W3083498943","doi":"10.1158/1538-7445.am2020-ct150","title":"Abstract CT150: A first-in-human phase I study of the OX40 agonist GSK3174998 (GSK998) +/- pembrolizumab in patients (Pts) with selected advanced solid tumors (ENGAGE-1)","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Rash; Cancer; Renal cell carcinoma; Lung cancer; Melanoma; Oncology; Gastroenterology; Immunotherapy; Cancer research","score_opus":0.0506028019822661,"score_gpt":0.3909846976816892,"score_spread":0.3403818956994231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083498943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99513507,0.00030742493,4.8013385e-7,0.0012927458,0.00005429243,0.0027554536,0.000033923116,0.000027896107,0.00039268844],"genre_scores_gemma":[0.9990995,0.000079053934,0.0000070695714,0.00015730981,0.000072366,0.0003911224,0.000018486264,0.000053581796,0.00012149681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99680924,0.00026975758,0.0005861698,0.0005518641,0.0011257688,0.0006571778],"domain_scores_gemma":[0.9986184,0.00011892446,0.00015561336,0.0005156009,0.00041616408,0.00017528253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057027227,0.00023704312,0.0005317881,0.00025170937,0.00026388225,0.000033064152,0.00043496565,0.000078578574,0.00032210542],"category_scores_gemma":[0.0001915914,0.00016426675,0.0000744403,0.0024295982,0.00030514132,0.000112642134,0.00010990112,0.0011732758,0.0000043309597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.114469305,0.012560744,0.65085083,0.0013185289,0.00052409625,0.0003037173,0.02932851,0.0006562257,0.16758645,0.000008714531,0.0018224777,0.02057043],"study_design_scores_gemma":[0.06188169,0.008737002,0.9081069,0.00084319717,0.00002945342,0.0000027368499,0.0033562838,0.00007971215,0.015318777,0.000004089424,0.0013845913,0.00025552162],"about_ca_topic_score_codex":0.003674715,"about_ca_topic_score_gemma":0.00638533,"teacher_disagreement_score":0.25725615,"about_ca_system_score_codex":0.0006884276,"about_ca_system_score_gemma":0.0007780663,"threshold_uncertainty_score":0.66986036},"labels":[],"label_agreement":null},{"id":"W3083711044","doi":"10.1158/1538-7445.am2020-779","title":"Abstract 779: A phase I study of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb: Biomarker analyses from the microsatellite stable metastatic colorectal cancer (MSS mCRC) cohort","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); University of Alberta","funders":"","keywords":"Medicine; Immune checkpoint; Monoclonal antibody; Immune system; Biomarker; Peripheral blood mononuclear cell; CD8; Antibody; Oncology; Tumor microenvironment; Immunotherapy; T cell; Internal medicine; Cancer research; Immunology; Biology; In vitro","score_opus":0.1651016991836861,"score_gpt":0.47874438294533583,"score_spread":0.3136426837616497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083711044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890608,0.0055578975,0.000017835559,0.0013083651,0.00013361729,0.0029648596,0.00083901495,0.00005090009,0.000066668195],"genre_scores_gemma":[0.9962219,0.0022796395,0.000099558165,0.00026090338,0.00013134643,0.0003611984,0.0005256928,0.00008677777,0.000032995278],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99500364,0.0007531197,0.0008334417,0.0010177152,0.0015737921,0.00081829156],"domain_scores_gemma":[0.9976511,0.00035305734,0.0002986626,0.0006602284,0.00068348733,0.00035345438],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016890771,0.00042008678,0.000979373,0.00045890873,0.0003340101,0.0001817515,0.0005834212,0.00012317921,0.0013839912],"category_scores_gemma":[0.000073935524,0.00028933972,0.00013063564,0.0027653878,0.00073631515,0.00051394687,0.0001069617,0.00072216726,0.0000056817653],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014568885,0.0032933427,0.29742396,0.00014833776,0.0013590157,0.00020465089,0.003752976,0.00010378227,0.6702744,0.0000026519963,0.0002817933,0.008586193],"study_design_scores_gemma":[0.018467141,0.0043070223,0.81411636,0.00039061045,0.00037314452,0.000008939097,0.008102791,0.0021648363,0.15122217,0.000014151802,0.00044068502,0.00039215796],"about_ca_topic_score_codex":0.077190615,"about_ca_topic_score_gemma":0.009106574,"teacher_disagreement_score":0.5190522,"about_ca_system_score_codex":0.00044855222,"about_ca_system_score_gemma":0.0012544942,"threshold_uncertainty_score":0.9999559},"labels":[],"label_agreement":null},{"id":"W3083723887","doi":"10.1158/1538-7445.am2020-978","title":"Abstract 978: Monocyte-derived macrophages contribute to the inflammation-induced survival of experimental micrometastases in the lung","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Toronto; University of British Columbia","funders":"","keywords":"Inflammation; Extravasation; Cancer research; Melanoma; Medicine; Lung; Metastasis; CD11c; Monocyte; Immunology; Tumor microenvironment; Pathology; Biology; Cancer; Internal medicine; Tumor cells","score_opus":0.10961423753870707,"score_gpt":0.41656794793144397,"score_spread":0.3069537103927369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083723887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.967234,0.006138142,0.000006532703,0.025114115,0.0000897255,0.0011442918,0.00007326253,0.000010436357,0.00018949255],"genre_scores_gemma":[0.99840915,0.00035964831,0.000012939688,0.0006490371,0.00026077445,0.0002474602,0.000013937642,0.00001504569,0.00003197808],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99833566,0.00022827103,0.00028589892,0.00021474878,0.00061439927,0.00032102782],"domain_scores_gemma":[0.9991226,0.0003018561,0.000053717762,0.0002809464,0.00015318852,0.00008769597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011022391,0.000107912165,0.00022500547,0.00009542962,0.00011688131,0.000046079986,0.00034620918,0.0000432094,0.00047353204],"category_scores_gemma":[0.00015972834,0.00006290056,0.00008196602,0.00071520195,0.00013241649,0.000056117246,0.00007504096,0.0003316135,0.000016720109],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029172238,0.00004760846,0.0009307041,0.000063798274,0.00009558117,0.000029828936,0.004643173,0.000009096746,0.98378116,0.00001810885,0.0041529997,0.0033107416],"study_design_scores_gemma":[0.002102192,0.00029237755,0.05753629,0.00009885917,0.000011084794,0.0000027691613,0.0049890927,0.000023930434,0.9280558,0.0000026441467,0.0068100044,0.00007493278],"about_ca_topic_score_codex":0.0018929563,"about_ca_topic_score_gemma":0.00021054976,"teacher_disagreement_score":0.056605585,"about_ca_system_score_codex":0.00019489053,"about_ca_system_score_gemma":0.000299194,"threshold_uncertainty_score":0.51848435},"labels":[],"label_agreement":null},{"id":"W3083787951","doi":"10.1017/s1460396920000680","title":"A review of radiation induced abscopal effect: combining radiotherapy and immunotherapy to treat the untreated distant metastatic tumours","year":2020,"lang":"en","type":"review","venue":"Journal of Radiotherapy in Practice","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Waterloo; University of Guelph; Grand River Hospital","funders":"","keywords":"Abscopal effect; Radiation therapy; Medicine; Immunotherapy; Oncology; Cancer; Internal medicine; Cancer research","score_opus":0.027951351305468348,"score_gpt":0.3818309865951402,"score_spread":0.35387963528967187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083787951","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004778186,0.9902705,0.00014980708,0.005489947,0.00041930043,0.0030773873,0.000019862233,0.000015821175,0.00007956241],"genre_scores_gemma":[0.00008242308,0.992743,0.001423414,0.005185127,0.0003027463,0.0000773787,0.000013861905,0.0001479338,0.000024102328],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935702,0.0023357903,0.0025590435,0.00041575806,0.00074769894,0.0003715276],"domain_scores_gemma":[0.99184734,0.0033549154,0.0037561667,0.0005771946,0.0002327257,0.00023165865],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0041408436,0.00074031355,0.004584318,0.00061944313,0.00008617826,0.00008454335,0.00045222175,0.00021592989,0.00010561214],"category_scores_gemma":[0.00093500694,0.00043612602,0.0009442997,0.0017398101,0.0001349829,0.0003552468,0.00001955605,0.0012778231,0.0000018019116],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007293072,0.00026276882,0.000026849557,0.023800632,0.0030327283,0.00028551414,0.0013938795,9.4138267e-7,0.001113476,0.000012600554,0.0013317955,0.96144575],"study_design_scores_gemma":[0.007654615,0.006333982,0.000045339686,0.09853502,0.0035875395,0.00490452,0.00014033752,0.00000926214,0.00012425044,0.000002833578,0.8782947,0.00036760725],"about_ca_topic_score_codex":0.00013292226,"about_ca_topic_score_gemma":0.000003529454,"teacher_disagreement_score":0.9610781,"about_ca_system_score_codex":0.0010617588,"about_ca_system_score_gemma":0.0011075082,"threshold_uncertainty_score":0.999809},"labels":[],"label_agreement":null},{"id":"W3083951977","doi":"10.1016/j.ccell.2020.08.007","title":"Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial","year":2020,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":393,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; National Cancer Institute; Genentech; National Institutes of Health; Bristol-Myers Squibb Canada; Ono Pharmaceutical; Parker Institute for Cancer Immunotherapy; Breast Cancer Now; Exelixis; Meso Scale Diagnostics; Sanofi; Merck; Bayer Corporation; Prostate Cancer Foundation; Bristol-Myers Squibb; AstraZeneca; American Anthropological Association; Roche; Astellas Pharma US; Amgen; University of Texas MD Anderson Cancer Center; Pfizer","keywords":"Ipilimumab; Nivolumab; Prostate cancer; Medicine; Oncology; Internal medicine; Clinical trial; Cancer; Immunotherapy","score_opus":0.03752139322097603,"score_gpt":0.3103108764788775,"score_spread":0.2727894832579015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083951977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901249,0.0045904517,0.00004008501,0.0012916916,0.00020881981,0.0027316385,0.0007777437,0.000015026059,0.00021968932],"genre_scores_gemma":[0.99646294,0.0012108618,0.00011066899,0.0008434349,0.00009278503,0.00083165255,0.00020429626,0.000021410044,0.0002219274],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99852455,0.00007014738,0.00055579597,0.00030006847,0.00030901024,0.00024043651],"domain_scores_gemma":[0.99917465,0.00009516415,0.0002928212,0.00023463865,0.00013752552,0.000065186076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021257396,0.00017110285,0.00052833604,0.00008725794,0.000056474513,0.000018174436,0.0001536802,0.000044795706,0.00025579144],"category_scores_gemma":[0.000026146372,0.00012262262,0.00029136814,0.0007886931,0.00007119781,0.0000790858,0.000015224279,0.000097476346,7.4641304e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9219541,0.0009804635,0.006563115,0.0018602266,0.0033531091,0.000019170482,0.020899076,0.002304228,0.017269101,0.000015038355,0.0047672247,0.02001513],"study_design_scores_gemma":[0.6201961,0.026551956,0.20060912,0.00060344004,0.023432255,0.000001421327,0.011690833,0.03720836,0.03987437,0.000044090553,0.038441096,0.0013469454],"about_ca_topic_score_codex":0.003131064,"about_ca_topic_score_gemma":0.0022793277,"teacher_disagreement_score":0.301758,"about_ca_system_score_codex":0.00031161285,"about_ca_system_score_gemma":0.00050490024,"threshold_uncertainty_score":0.5000405},"labels":[],"label_agreement":null},{"id":"W3083966623","doi":"10.1200/jco.19.03205","title":"Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":227,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; Agence Nationale de la Recherche","keywords":"Medicine; Internal medicine; Oncology; Hazard ratio; Colorectal cancer; Stage (stratigraphy); Cohort; Chemotherapy; Proportional hazards model; Cancer; Immunotherapy; Confidence interval","score_opus":0.13079305623513682,"score_gpt":0.4778639689212401,"score_spread":0.3470709126861033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083966623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657359,0.0010695752,0.0001032099,0.030219566,0.0012443956,0.0014726077,0.0001450261,0.0000016049149,0.000008121566],"genre_scores_gemma":[0.9947076,0.0023357538,0.00035352138,0.002169535,0.00025833328,0.000053394368,6.846534e-7,0.000012952583,0.00010826979],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99758667,0.0002122291,0.0017187805,0.00012686518,0.00024958738,0.00010584436],"domain_scores_gemma":[0.9944772,0.0032391204,0.0015688253,0.00012913067,0.0005380259,0.0000476578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027372073,0.00009498674,0.0008296809,0.00003823731,0.000030496327,0.0000029451317,0.0002074693,0.00013683841,0.00004364508],"category_scores_gemma":[0.00074556743,0.000053019652,0.00048624675,0.0001344041,0.00025610407,0.000023740802,0.00003118018,0.0002653595,1.7123114e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58107346,0.0018561155,0.21357504,0.00008268934,0.003155708,0.0000015844925,0.008318295,0.0001462341,0.15435955,0.000004569992,0.0022333043,0.03519344],"study_design_scores_gemma":[0.07249534,0.020174827,0.8595287,0.00019557605,0.00027396216,0.000002754545,0.0067969626,0.0012741805,0.0044234293,0.0000056717863,0.034770433,0.00005815525],"about_ca_topic_score_codex":0.0004375615,"about_ca_topic_score_gemma":0.00048689707,"teacher_disagreement_score":0.64595366,"about_ca_system_score_codex":0.0001433748,"about_ca_system_score_gemma":0.00097034004,"threshold_uncertainty_score":0.21620786},"labels":[],"label_agreement":null},{"id":"W3083986479","doi":"10.1016/s1470-2045(20)30445-9","title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2492,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Cohort; Mesothelioma; Biomarker; Clinical endpoint; Prospective cohort study; Cancer; Progressive disease; Disease; Immunotherapy; Pathology; Clinical trial","score_opus":0.03122114611269687,"score_gpt":0.3549706413578277,"score_spread":0.3237494952451308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083986479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936353,0.000024256593,0.000014341999,0.0033696457,0.000020779702,0.0025098473,0.00011045179,0.000015852042,0.00029954268],"genre_scores_gemma":[0.9990866,0.0000059531276,0.00019580373,0.00039005553,0.000022117654,0.00011902197,0.00005353283,0.000020245809,0.00010664745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982575,0.00032201505,0.0004229108,0.00029665188,0.00046365685,0.0002372351],"domain_scores_gemma":[0.9983468,0.00023017076,0.0007405409,0.00028877557,0.0003498682,0.000043851753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038588681,0.00019406418,0.0011097577,0.000118374366,0.00006192654,0.000011079438,0.00029736522,0.000059854672,0.00004432455],"category_scores_gemma":[0.00010520706,0.00008896064,0.000056929923,0.0013716598,0.00017759894,0.00008706557,0.0000582186,0.00019220414,6.040575e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09481508,0.0025977786,0.8913,0.000017216027,0.0055998745,0.00001360054,0.0029207706,0.00036367145,0.0015153554,0.0000039608294,0.000039211376,0.0008134344],"study_design_scores_gemma":[0.08969664,0.01016329,0.89551497,0.000043644097,0.0023154549,0.000001899529,0.00092821935,0.0006623731,0.0005366306,0.0000028433878,0.000023754925,0.00011028167],"about_ca_topic_score_codex":0.00049740006,"about_ca_topic_score_gemma":0.0017903713,"teacher_disagreement_score":0.0075655114,"about_ca_system_score_codex":0.00038450488,"about_ca_system_score_gemma":0.0002772972,"threshold_uncertainty_score":0.36277094},"labels":[],"label_agreement":null},{"id":"W3084461342","doi":"10.1007/s00384-020-03734-4","title":"Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis","year":2020,"lang":"en","type":"review","venue":"International Journal of Colorectal Disease","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Medicine; Internal medicine; Hazard ratio; Colorectal cancer; Meta-analysis; Oncology; Cochrane Library; Hepatology; Proportional hazards model; Confidence interval; Gastroenterology; Cancer","score_opus":0.0847506050002711,"score_gpt":0.4032869315499616,"score_spread":0.3185363265496905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084461342","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017784849,0.98021764,0.000034620967,0.00042705136,0.0003019135,0.00071143237,0.00047803548,0.0000079817855,0.000036456575],"genre_scores_gemma":[0.11366098,0.8855786,0.00025932342,0.000103776845,0.00017479903,0.0001309558,0.000050546863,0.000022299779,0.000018762941],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9966837,0.00034675264,0.0016518309,0.00035153088,0.00080134044,0.00016480294],"domain_scores_gemma":[0.99694586,0.0005707533,0.001666656,0.00010185742,0.00040699984,0.0003078992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004896549,0.0003398879,0.0032575764,0.00063760026,0.000018214314,0.00003333569,0.0003791358,0.0001726263,0.0004488329],"category_scores_gemma":[0.00063463405,0.00022025486,0.0032075753,0.0006021,0.00021402995,0.000100948055,0.00009673378,0.00049675757,0.0000017261466],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.066001415,0.0031260564,0.026829282,0.0084606325,0.2658527,0.011623652,0.00048183044,0.000060836173,0.0015136569,0.00003417255,0.0006056562,0.6154101],"study_design_scores_gemma":[0.0060261344,0.0031942476,0.091223985,0.011047817,0.69673735,0.00077493984,0.00009311169,0.0001870812,0.0003462931,0.00015314219,0.1892176,0.0009983131],"about_ca_topic_score_codex":0.000016997106,"about_ca_topic_score_gemma":0.000013551181,"teacher_disagreement_score":0.6144118,"about_ca_system_score_codex":0.00022973627,"about_ca_system_score_gemma":0.001167086,"threshold_uncertainty_score":0.8981733},"labels":[],"label_agreement":null},{"id":"W3084510417","doi":"10.3747/co.27.6439","title":"Nivolumab and Ipilimumab Immunotherapy for Hemodialysis Patients with Advanced Renal Cell Carcinoma","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Renal cell carcinoma; Blockade; Adverse effect; Immune checkpoint; Hemodialysis; Oncology; Internal medicine; Immunotherapy; Cancer; Receptor","score_opus":0.03560789113485781,"score_gpt":0.31467102213675757,"score_spread":0.2790631310018998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084510417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914802,0.004778986,0.0008463089,0.001321247,0.00028389707,0.00091837626,0.00004907471,0.00003823777,0.00028368353],"genre_scores_gemma":[0.9971125,0.00035956706,0.0011693353,0.0008451637,0.0001745357,0.000108662774,0.0001517786,0.00003003589,0.000048405247],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989642,0.00003870316,0.0002554975,0.0003504486,0.00013645053,0.00025468814],"domain_scores_gemma":[0.9993605,0.000071520844,0.00013637582,0.00016612654,0.0001327677,0.00013271764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007133678,0.0001771069,0.00041200817,0.000056468125,0.00008430136,0.00000985668,0.00007021336,0.000083018975,0.00009071318],"category_scores_gemma":[0.000017424405,0.00013868425,0.00011335907,0.00015844812,0.00012411665,0.000057142064,0.000022207807,0.00014241057,0.0000037421303],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048549477,0.0008252396,0.07661528,0.00026469814,0.00016931073,0.0000052662103,0.001496829,0.000002407623,0.0126016755,0.000008283179,0.0035636304,0.8558979],"study_design_scores_gemma":[0.1010273,0.02121479,0.18519801,0.00007233351,0.00036168273,0.000010139604,0.00030166635,0.00043667763,0.007349202,0.000024538647,0.68352395,0.00047967592],"about_ca_topic_score_codex":0.0000067265887,"about_ca_topic_score_gemma":0.0000065218896,"teacher_disagreement_score":0.8554182,"about_ca_system_score_codex":0.00015105227,"about_ca_system_score_gemma":0.00017989859,"threshold_uncertainty_score":0.565538},"labels":[],"label_agreement":null},{"id":"W3085025416","doi":"10.21037/tlcr-20-509","title":"Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer","year":2021,"lang":"en","type":"review","venue":"Translational Lung Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Lung cancer; Internal medicine; Chemotherapy; Radiation therapy; Stage (stratigraphy); Neoadjuvant therapy; Adjuvant; Breast cancer; Systemic therapy; Cancer","score_opus":0.05251752598418085,"score_gpt":0.39608506475098987,"score_spread":0.343567538766809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085025416","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006935774,0.98741996,0.00002034098,0.00035634934,0.00034545624,0.0037397414,0.00056665984,0.000027842838,0.0005878714],"genre_scores_gemma":[0.0016788426,0.99019194,0.00010937349,0.00012564556,0.0004085919,0.0038636806,0.0008892251,0.00022031195,0.0025124091],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942858,0.00053720194,0.001085084,0.001051312,0.0018912081,0.0011493464],"domain_scores_gemma":[0.9973875,0.0007268331,0.00021781652,0.0007060998,0.00075332,0.00020837339],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014032028,0.0006424593,0.0021620556,0.0011198778,0.00017818523,0.00011091208,0.00032434383,0.00049161713,0.0043051876],"category_scores_gemma":[0.00001321653,0.0004954167,0.0007010587,0.0023349235,0.00021286358,0.00017000128,0.000043571392,0.0017206147,0.000009287386],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010741547,0.00086174486,0.20400867,0.045490682,0.002275493,0.00022797927,0.00067021686,0.000031089083,0.00001976703,0.000005864062,0.006665599,0.72900134],"study_design_scores_gemma":[0.0064061205,0.00019356747,0.048480567,0.08252054,0.00061512535,0.000008389246,0.000018737586,0.00007032702,0.00002624329,0.0000026147402,0.8607436,0.00091418845],"about_ca_topic_score_codex":0.003799746,"about_ca_topic_score_gemma":0.0014691701,"teacher_disagreement_score":0.854078,"about_ca_system_score_codex":0.0016009202,"about_ca_system_score_gemma":0.009139113,"threshold_uncertainty_score":0.9997497},"labels":[],"label_agreement":null},{"id":"W3085379405","doi":"10.1200/jco.20.00131","title":"Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":240,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Centre intégré de santé et de services sociaux de Chaudière-Appalaches","funders":"","keywords":"Medicine; Nivolumab; Population; Internal medicine; Progression-free survival; Lung cancer; Hazard ratio; Surgery; Continuous variable; Cancer; Oncology; Chemotherapy; Immunotherapy; Confidence interval","score_opus":0.06764736034788141,"score_gpt":0.41848049003450555,"score_spread":0.35083312968662417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085379405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836813,0.0023851178,0.000059389367,0.009519853,0.0013004153,0.0005035969,0.0000044862236,0.000017565519,0.0025282726],"genre_scores_gemma":[0.9876652,0.006654013,0.0011747192,0.0031593775,0.0009728355,0.000013645021,0.000005774303,0.000026047153,0.0003284171],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996617,0.00026037722,0.0023684471,0.00023516752,0.00023749241,0.00028151672],"domain_scores_gemma":[0.9970262,0.0006047553,0.0016418212,0.00014128078,0.00027689795,0.0003090584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012576607,0.0001677685,0.001385542,0.00008506509,0.00002971603,0.000011581527,0.00016963894,0.00036890118,0.00028131434],"category_scores_gemma":[0.0009771626,0.00013249529,0.00044599746,0.0002756169,0.000100554746,0.00011775097,0.000029518054,0.00084217486,0.0000115299845],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29983154,0.0020312485,0.26079008,0.0003330475,0.0011824896,0.0014660883,0.0014072186,0.00013107409,0.024701586,0.000006491439,0.014112803,0.39400634],"study_design_scores_gemma":[0.29760227,0.084923565,0.38212267,0.0011401104,0.0019839073,0.00017120426,0.001576017,0.0035298178,0.008711043,0.0000139038275,0.21754012,0.0006853952],"about_ca_topic_score_codex":0.00014595022,"about_ca_topic_score_gemma":0.0003142115,"teacher_disagreement_score":0.39332095,"about_ca_system_score_codex":0.0003717291,"about_ca_system_score_gemma":0.0016082836,"threshold_uncertainty_score":0.54030013},"labels":[],"label_agreement":null},{"id":"W3086193391","doi":"10.1101/2020.09.15.291765","title":"Antitumor immunity in dMMR colorectal cancers requires interferon-induced CCL5 and CXCL10","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Alexandra Hospital; University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Cancer Research Society","keywords":"CCL5; Cancer research; Immune system; Chemokine; CXCL10; Immune checkpoint; Immunogenicity; Colorectal cancer; Biology; Immunotherapy; Immunology; T cell; Cancer; IL-2 receptor","score_opus":0.024895491543648694,"score_gpt":0.2586879568625896,"score_spread":0.2337924653189409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086193391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929744,0.0023780786,0.000012426965,0.0010592195,0.0019465216,0.0012177277,0.00014858981,0.00023279624,0.00003022818],"genre_scores_gemma":[0.9974519,0.0008524433,0.0004894546,0.00060631573,0.000328471,0.00014125803,6.6069816e-7,0.00012399843,0.0000054945463],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9971827,0.00016439609,0.00070117164,0.0010208578,0.00037368515,0.0005571721],"domain_scores_gemma":[0.9981376,0.000042832333,0.00038006462,0.000923318,0.00019561964,0.0003205533],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004098302,0.00061446807,0.0009864056,0.00031933695,0.00012253337,0.000110589564,0.00041241208,0.00059285975,0.00006764989],"category_scores_gemma":[0.00022121298,0.00064362894,0.00022788481,0.0006901114,0.00024310505,0.00013754939,0.0006780415,0.001437665,0.000010649322],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017401704,0.00011955912,0.05228452,0.0007928702,0.00026558223,0.00015022237,0.00005883684,0.0000016541532,0.94423157,0.000024312356,0.00031978142,0.000010951306],"study_design_scores_gemma":[0.0026771612,0.00033942648,0.56302947,0.0020876718,0.00012177585,1.5928988e-7,0.000012931169,0.00012502192,0.42956203,0.0000010054474,0.0014192994,0.0006240674],"about_ca_topic_score_codex":0.0019752076,"about_ca_topic_score_gemma":0.00015928547,"teacher_disagreement_score":0.5146695,"about_ca_system_score_codex":0.0013663433,"about_ca_system_score_gemma":0.001913938,"threshold_uncertainty_score":0.9996015},"labels":[],"label_agreement":null},{"id":"W3087025265","doi":"10.4049/jimmunol.2000487","title":"Foxp3+ Regulatory T Cell Depletion after Nonablative Oligofractionated Irradiation Boosts the Abscopal Effects in Murine Malignant Mesothelioma","year":2020,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Toronto General Hospital; Toronto Rehabilitation Institute; University of Toronto","funders":"Princess Margaret Cancer Foundation; Uehara Memorial Foundation; Mesothelioma Applied Research Foundation","keywords":"Abscopal effect; FOXP3; Cancer research; CD8; Granzyme B; Cytotoxic T cell; Immune system; Immunology; Medicine; Immunotherapy; Granzyme; Tumor microenvironment; Immune checkpoint; Biology; Perforin","score_opus":0.007790169304986826,"score_gpt":0.23233591274593482,"score_spread":0.224545743440948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087025265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762735,0.010346327,0.00014545942,0.012309522,0.0003345665,0.00033591705,0.0000016798443,0.000010707333,0.00024237325],"genre_scores_gemma":[0.9963663,0.0010415907,0.00005758236,0.0022156574,0.0001999512,0.0000092489445,0.000002367342,0.000018119183,0.00008916328],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986685,0.00038068005,0.00045549465,0.00009521862,0.00021362155,0.00018649513],"domain_scores_gemma":[0.9989751,0.0002809659,0.00040799443,0.00017772282,0.000119668635,0.000038542003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006323377,0.00013469094,0.00027518166,0.0001370796,0.00006698645,0.00000869419,0.00015985771,0.00010230022,0.00013129975],"category_scores_gemma":[0.00008175596,0.00007239665,0.00012035713,0.00026043036,0.00015597374,0.000104624065,0.000030086361,0.00043768316,0.000020833171],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04072897,0.00023188541,0.0069792503,0.000095542055,0.00069298304,0.00024259202,0.0074376734,0.00011833097,0.9284394,0.000051469156,0.0011662471,0.013815648],"study_design_scores_gemma":[0.0061060577,0.0018299097,0.9234547,0.00018670807,0.00018390315,0.00083131803,0.00058196986,0.00021219274,0.060785063,0.00015090648,0.0055570966,0.00012014708],"about_ca_topic_score_codex":0.00009431436,"about_ca_topic_score_gemma":0.000021126069,"teacher_disagreement_score":0.9164755,"about_ca_system_score_codex":0.00017419532,"about_ca_system_score_gemma":0.00013661727,"threshold_uncertainty_score":0.295225},"labels":[],"label_agreement":null},{"id":"W3087401339","doi":"10.1200/jco.20.02110","title":"Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"European Organisation for Research and Treatment of Cancer","keywords":"Medicine; Pembrolizumab; Placebo; Internal medicine; Hazard ratio; Population; Oncology; Melanoma; Lymph node; Cancer; Stage (stratigraphy); Surgery; Gastroenterology; Pathology; Immunotherapy; Confidence interval; Cancer research","score_opus":0.11065833192108306,"score_gpt":0.39444315962501014,"score_spread":0.2837848277039271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087401339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9673995,0.001144064,0.00005589148,0.023743564,0.005606128,0.0006179881,0.00049915095,0.000014510778,0.0009192232],"genre_scores_gemma":[0.9908791,0.0031027119,0.0003770405,0.0023273705,0.0029519538,0.0000049532064,0.00007326034,0.000028761411,0.00025485674],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99145526,0.0012526681,0.0056196824,0.00044248076,0.00083306286,0.00039685823],"domain_scores_gemma":[0.98767143,0.0062605324,0.004553722,0.00064994796,0.00047721688,0.00038713947],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0065674894,0.00029015983,0.0029957076,0.00010583875,0.00005982171,0.000018138093,0.00081857195,0.00069040037,0.000685111],"category_scores_gemma":[0.009787506,0.00017636394,0.000993767,0.0004166983,0.00048115652,0.000127498,0.00016746907,0.002102517,0.000010754443],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88802373,0.001109184,0.016001882,0.000013805645,0.0012414395,0.0004920474,0.00090393424,0.000021044909,0.00029942492,0.00007820051,0.0156096835,0.07620562],"study_design_scores_gemma":[0.60666174,0.031021638,0.2884036,0.00021237269,0.00084822596,0.000027686485,0.00066341506,0.00020258494,0.0002354801,0.00043310394,0.07104573,0.00024443222],"about_ca_topic_score_codex":0.0026322622,"about_ca_topic_score_gemma":0.002712057,"teacher_disagreement_score":0.281362,"about_ca_system_score_codex":0.00017515098,"about_ca_system_score_gemma":0.002066949,"threshold_uncertainty_score":0.99855345},"labels":[],"label_agreement":null},{"id":"W3087457093","doi":"10.1038/s41573-020-0081-9","title":"Targeting co-stimulatory molecules in autoimmune disease","year":2020,"lang":"en","type":"review","venue":"Nature Reviews Drug Discovery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":222,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; Rosetrees Trust","keywords":"Autoimmunity; Immunotherapy; Cancer immunotherapy; Immunology; Blockade; Immune system; Co-stimulation; CD28; Medicine; Cytotoxic T cell; Autoimmune disease; Cancer; Immune checkpoint; Cancer research; Antibody; Receptor; Biology; T cell; Internal medicine","score_opus":0.022882134192211738,"score_gpt":0.35352453227358416,"score_spread":0.3306423980813724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087457093","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005037114,0.99454397,0.000012083523,0.00032047223,0.0006164282,0.003547287,0.00019611724,0.000083136445,0.000675456],"genre_scores_gemma":[0.000021727219,0.99488825,0.00014582973,0.0016150161,0.00057508075,0.00030986627,0.0013472958,0.00015729277,0.0009396192],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995628,0.000567659,0.0017917833,0.000984095,0.00051266205,0.0005158169],"domain_scores_gemma":[0.99780244,0.000189352,0.0008389965,0.00087004364,0.00003416824,0.0002650303],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0008480142,0.00096136105,0.0046880855,0.00032292312,0.000073306954,0.00009468207,0.00046069318,0.0006676262,0.00019874076],"category_scores_gemma":[0.0005738761,0.0006709317,0.0023019065,0.00097421184,0.00012361753,0.0002471025,0.00012250515,0.0028100887,0.00018607156],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002521596,0.00014144405,0.00004027348,0.07217231,0.00027344652,0.0004963908,0.000040599843,8.261255e-7,0.000007136928,0.00003831193,0.020066692,0.9064704],"study_design_scores_gemma":[0.0006991831,0.000022694046,0.000086586646,0.06636866,0.0012533827,0.0000252428,0.000008911493,0.000011038839,9.2672565e-7,0.0000063434804,0.93091744,0.00059958675],"about_ca_topic_score_codex":0.0000136245835,"about_ca_topic_score_gemma":0.000002611665,"teacher_disagreement_score":0.91085076,"about_ca_system_score_codex":0.0006262781,"about_ca_system_score_gemma":0.0013234029,"threshold_uncertainty_score":0.9995742},"labels":[],"label_agreement":null},{"id":"W3087697977","doi":"10.1016/s1470-2045(20)30494-0","title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":525,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Ipilimumab; Medicine; Nivolumab; Clinical endpoint; Internal medicine; Population; Clinical trial; Adjuvant; Stage (stratigraphy); Randomized controlled trial; Surgery; Phases of clinical research; Adverse effect; Melanoma; Cancer; Oncology; Immunotherapy","score_opus":0.11363129802389245,"score_gpt":0.3789429370514308,"score_spread":0.26531163902753835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087697977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97602093,0.00156092,0.000012454365,0.011868735,0.00081271934,0.005239038,0.0005317677,0.00010922596,0.0038442167],"genre_scores_gemma":[0.9934985,0.0016497524,0.0002240888,0.0016156097,0.0014856019,0.0002969654,0.0002453552,0.000044392364,0.00093972613],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967379,0.00074272515,0.0009948567,0.0005995172,0.00032340022,0.000601591],"domain_scores_gemma":[0.9969707,0.0016917564,0.00047464916,0.0005649031,0.00008609117,0.00021186307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014545048,0.0003240505,0.0017572996,0.00010356768,0.000117219235,0.000044298667,0.0003035892,0.00028839862,0.00049045193],"category_scores_gemma":[0.00077844324,0.00021920002,0.00020623306,0.0003289657,0.0002870365,0.000090343245,0.00011064682,0.0006441646,0.0000329226],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9774385,0.0005365125,0.00006915225,0.000042798354,0.0007395439,0.0003379725,0.0033320873,0.000008632028,0.010922051,0.000027490234,0.0025853585,0.00395987],"study_design_scores_gemma":[0.94154215,0.00627738,0.00025623976,0.000054666714,0.0003034809,0.0000049405885,0.0016016356,0.0019342655,0.0011296427,0.0000068009763,0.046663366,0.00022545987],"about_ca_topic_score_codex":0.0018486439,"about_ca_topic_score_gemma":0.0022820178,"teacher_disagreement_score":0.044078007,"about_ca_system_score_codex":0.00028733423,"about_ca_system_score_gemma":0.00043121702,"threshold_uncertainty_score":0.8938717},"labels":[],"label_agreement":null},{"id":"W3087812448","doi":"10.1186/s13073-020-00780-z","title":"Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1","year":2020,"lang":"en","type":"article","venue":"Genome Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Project 211; National Key Research and Development Program of China; Higher Education Discipline Innovation Project; Natural Science Foundation of Hainan Province; National Natural Science Foundation of China; China Postdoctoral Science Foundation; Natural Science Foundation of Shanghai","keywords":"Immune system; Immune checkpoint; Immunotherapy; PD-L1; Cancer research; Tumor microenvironment; Medicine; Cancer immunotherapy; Cancer; Blockade; MMP2; Melanoma; Immunology; Metastasis; Internal medicine; Receptor","score_opus":0.020278783874511562,"score_gpt":0.23887841343820163,"score_spread":0.21859962956369006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087812448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93054974,0.030404417,0.00042581873,0.034065083,0.0004982415,0.00082597777,0.00004641236,0.00026626955,0.0029180332],"genre_scores_gemma":[0.98837674,0.00040481045,0.00034530176,0.007666706,0.0015337724,0.000029656261,0.00030376014,0.000086648484,0.0012526051],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99739045,0.00009072065,0.00082141935,0.000624634,0.0004975119,0.00057529303],"domain_scores_gemma":[0.9986011,0.00009735667,0.0002733171,0.0005203827,0.00013980146,0.00036807233],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005489463,0.000396851,0.00086402276,0.000103730454,0.00015304014,0.000019920979,0.00025048156,0.00011175365,0.0011526897],"category_scores_gemma":[0.00028054233,0.0003163285,0.0001787422,0.0006610649,0.0003084441,0.000058422615,0.0000900306,0.00035344824,0.00006460233],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019475252,0.00006380098,0.0027773227,0.0002560036,0.00023338018,0.00010048587,0.0012349618,0.000007816187,0.9815378,0.0000069860143,0.0076780706,0.004155857],"study_design_scores_gemma":[0.049932964,0.011430416,0.19752033,0.002187381,0.0006278483,0.0007858011,0.00457056,0.0044258493,0.29615653,0.000085688574,0.42941976,0.0028568716],"about_ca_topic_score_codex":0.00030560925,"about_ca_topic_score_gemma":0.000012779815,"teacher_disagreement_score":0.68538123,"about_ca_system_score_codex":0.00014713575,"about_ca_system_score_gemma":0.00011098191,"threshold_uncertainty_score":0.9999289},"labels":[],"label_agreement":null},{"id":"W3087894680","doi":"10.1016/j.ccell.2020.09.005","title":"A Microbiota-Derived Metabolite Augments Cancer Immunotherapy Responses in Mice","year":2020,"lang":"en","type":"letter","venue":"Cancer Cell","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital; University of Guelph","funders":"","keywords":"Blockade; Immune checkpoint; Immune system; Cancer; Immunotherapy; Microbiome; Gut flora; Cancer immunotherapy; T cell; Immunology; Biology; Medicine; Cancer research; Bioinformatics; Internal medicine","score_opus":0.02522146651888246,"score_gpt":0.2910291467256028,"score_spread":0.26580768020672035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087894680","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03881362,0.29656684,0.000008706548,0.6568628,0.0029907783,0.0019832167,0.0012422369,0.00026998218,0.0012618011],"genre_scores_gemma":[0.002945278,0.084084295,0.00020598488,0.88843346,0.0033213203,0.000711269,0.0003597551,0.00036098805,0.019577678],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99667746,0.00023431693,0.0007935129,0.0010124511,0.00045121333,0.00083102385],"domain_scores_gemma":[0.99859864,0.00010523371,0.0004222644,0.00063025614,0.00012446007,0.00011915033],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014943932,0.0007623643,0.0012924362,0.00024745773,0.00007000389,0.00006859181,0.0004498846,0.000763996,0.0025356514],"category_scores_gemma":[0.000011063184,0.00069914747,0.00053554703,0.0005340688,0.00020951682,0.00011299382,0.00007034802,0.0017239066,0.000045927627],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048070587,0.000056350324,0.0003229151,0.0005538141,0.0005325027,0.00045198586,0.00060858985,6.4260064e-7,0.47596923,9.404499e-8,0.5123422,0.0043545733],"study_design_scores_gemma":[0.006368835,0.00014532593,0.0023559576,0.00075068005,0.0002939628,0.000018476465,0.00006496196,0.00000478535,0.08698175,0.0000047160092,0.902345,0.000665573],"about_ca_topic_score_codex":0.008833655,"about_ca_topic_score_gemma":0.00037851353,"teacher_disagreement_score":0.39000273,"about_ca_system_score_codex":0.0015094,"about_ca_system_score_gemma":0.0014007726,"threshold_uncertainty_score":0.999546},"labels":[],"label_agreement":null},{"id":"W3088134494","doi":"10.1016/j.annonc.2020.08.1004","title":"865P A phase II study of sintilimab plus anlotinib for Chinese patients (pts) with persistent, recurrent, or metastatic cervical cancer (CC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; PharmaMar; European Society for Medical Oncology; Eisai; Ipsen; Clovis Oncology; Regeneron Pharmaceuticals; GlaxoSmithKline; Louisiana State University; Spectrum Pharmaceuticals; Takeda Oncology; Amgen; Pfizer; Symphogen; AstraZeneca; Eli Lilly and Company; King Abdullah International Medical Research Center; U.S. Department of Defense","keywords":"Medicine; Internal medicine; Progressive disease; Clinical endpoint; Oncology; Chemotherapy; Cancer; Response Evaluation Criteria in Solid Tumors; Cervical cancer; Adenosquamous carcinoma; Gastroenterology; Progression-free survival; Adenocarcinoma; Clinical trial","score_opus":0.1653421335762386,"score_gpt":0.44790414556087155,"score_spread":0.28256201198463293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088134494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921961,0.00072202634,0.000023633045,0.0047304253,0.00015608511,0.001759354,0.00021779972,0.000016627435,0.00017798187],"genre_scores_gemma":[0.9969605,0.0002001148,0.0002540042,0.0021891282,0.000075580385,0.00016042992,0.000047405472,0.000024397643,0.000088446126],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9985269,0.00009196593,0.00056198635,0.00031300847,0.0002491003,0.0002570389],"domain_scores_gemma":[0.9986583,0.00014849791,0.00039524605,0.00019287462,0.00046273338,0.00014234158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001856395,0.00019391431,0.0008586035,0.000087870125,0.000060035192,0.000003273869,0.00013863074,0.00006260837,0.0002634168],"category_scores_gemma":[0.00015819378,0.0001223589,0.00022396226,0.0003761931,0.00014076187,0.00005835883,0.00005166553,0.00011750325,9.475361e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48933607,0.078513205,0.018941717,0.0015248065,0.0055645723,0.000062684114,0.02415953,0.000021631076,0.0021683022,0.0000061969613,0.012583145,0.36711812],"study_design_scores_gemma":[0.2712831,0.6525399,0.014520511,0.00026017585,0.0015538192,0.000022869892,0.006473841,0.0011575212,0.0010861275,0.000008303638,0.050721824,0.0003720238],"about_ca_topic_score_codex":0.00024105421,"about_ca_topic_score_gemma":0.00057207164,"teacher_disagreement_score":0.5740267,"about_ca_system_score_codex":0.000058263297,"about_ca_system_score_gemma":0.000458964,"threshold_uncertainty_score":0.4989651},"labels":[],"label_agreement":null},{"id":"W3088146375","doi":"10.1016/j.annonc.2020.08.982","title":"843P Association of gene expression signatures and TMB with response to pembrolizumab (pembro) in patients (pts) with recurrent ovarian cancer (ROC) enrolled in KEYNOTE-100","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"Istituto Nazionale Tumori IRCCS \"Fondazione G. Pascale\"; Rockefeller University; Yale University; University College London; Merck","keywords":"Medicine; Pembrolizumab; Ovarian cancer; Oncology; Gynecology; Cancer; Internal medicine; Immunotherapy","score_opus":0.029549381658524606,"score_gpt":0.3316080822242081,"score_spread":0.3020587005656835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088146375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98933256,0.0006772429,0.000011396001,0.009096358,0.000047620804,0.00061101286,0.000028037413,0.000007303042,0.00018847334],"genre_scores_gemma":[0.99708945,0.0003198896,0.0004023062,0.002031218,0.000030026627,0.000052051248,0.000012169059,0.000014266612,0.000048625316],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9986051,0.00027323206,0.00038749783,0.00025551402,0.00026736184,0.00021133928],"domain_scores_gemma":[0.99908864,0.00018746388,0.00030891574,0.00011817066,0.00020307445,0.00009371416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044562735,0.00013389341,0.000522256,0.0002005114,0.00001721902,0.0000033507388,0.00007000413,0.00017179153,0.000052344632],"category_scores_gemma":[0.00020273782,0.00009825317,0.000036997044,0.00040066068,0.0000462616,0.00005101806,0.00002619081,0.00018333372,4.3222894e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59154105,0.000775475,0.21705432,0.00012146835,0.00016282822,0.000028899512,0.0053127543,0.00012177773,0.15393037,0.0000028696268,0.0021468797,0.028801298],"study_design_scores_gemma":[0.033356197,0.020345934,0.89492065,0.00051456067,0.000035368797,0.0000018642766,0.00019721106,0.00003716865,0.044994257,0.000005651197,0.0054406957,0.00015046551],"about_ca_topic_score_codex":0.00033818706,"about_ca_topic_score_gemma":0.0006318634,"teacher_disagreement_score":0.67786634,"about_ca_system_score_codex":0.00019161784,"about_ca_system_score_gemma":0.00037674786,"threshold_uncertainty_score":0.4006648},"labels":[],"label_agreement":null},{"id":"W3088227025","doi":"10.1016/j.annonc.2020.08.2274","title":"LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Population; Clinical endpoint; Oncology; Tolerability; Surgery; Urology; Clinical trial; Adverse effect; Immunotherapy; Cancer","score_opus":0.1887182812101126,"score_gpt":0.4233166752367792,"score_spread":0.23459839402666657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088227025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94918203,0.0012962341,0.000055573822,0.034799352,0.0006146137,0.0023552277,0.000510501,0.00009984802,0.011086592],"genre_scores_gemma":[0.9899713,0.00049894996,0.0009946546,0.0072506443,0.00047990883,0.00017187606,0.00014731027,0.000051186653,0.00043421454],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997535,0.00014460203,0.0009689723,0.0005062438,0.00037238098,0.0004727899],"domain_scores_gemma":[0.9977045,0.00061116315,0.0007711892,0.0003786423,0.00035205542,0.00018243275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004609011,0.00030178827,0.0010980905,0.00015847276,0.00006563615,0.0000078036865,0.00024308242,0.00034438254,0.00016640796],"category_scores_gemma":[0.0006360603,0.00023757707,0.00036288588,0.00031963608,0.000346246,0.000118157484,0.000064809945,0.0002527558,0.00000978127],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6760263,0.0011216915,0.00012064688,0.00085343426,0.00064573286,0.00013163022,0.003328836,0.00001645863,0.058645464,0.00015220157,0.04095632,0.21800128],"study_design_scores_gemma":[0.07146292,0.076801315,0.0018128084,0.00055495306,0.000148671,0.00006302162,0.0009834457,0.00011889337,0.43364716,0.000079611214,0.41397372,0.0003534626],"about_ca_topic_score_codex":0.000058756432,"about_ca_topic_score_gemma":0.00008385848,"teacher_disagreement_score":0.60456336,"about_ca_system_score_codex":0.00009710912,"about_ca_system_score_gemma":0.001124236,"threshold_uncertainty_score":0.96881115},"labels":[],"label_agreement":null},{"id":"W3088474072","doi":"10.1016/j.annonc.2020.08.1200","title":"1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Clinical endpoint; Stage (stratigraphy); Oncology; Adjuvant; Melanoma; Gastroenterology; Cancer; Immunotherapy; Randomized controlled trial; Cancer research","score_opus":0.0914736239595253,"score_gpt":0.34813811171124676,"score_spread":0.25666448775172146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088474072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626277,0.0030114772,0.000006651795,0.023889758,0.00037649673,0.0005066109,0.0006506989,0.000056012836,0.008874613],"genre_scores_gemma":[0.991674,0.0043095048,0.00025846256,0.0026511753,0.000251445,0.000018012817,0.00017523504,0.00003121712,0.0006309705],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99727166,0.0002983283,0.0009647241,0.0006315679,0.000345309,0.00048839743],"domain_scores_gemma":[0.99818236,0.00042628637,0.00040715947,0.00055616925,0.00020081043,0.00022723268],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007588538,0.0002747123,0.0010431936,0.00015941738,0.000053207168,0.000015206932,0.00032029903,0.00033211045,0.00046070185],"category_scores_gemma":[0.00069782,0.0002523269,0.00015027566,0.0003713897,0.00029851118,0.0001325285,0.0002030983,0.00043815724,0.000013631788],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52412647,0.0020245903,0.018390778,0.00056024396,0.0014628236,0.0016286089,0.01636484,0.000018500077,0.118150055,0.00042077593,0.16406979,0.15278253],"study_design_scores_gemma":[0.14613271,0.024817945,0.49152124,0.00080122723,0.00019009916,0.00004421593,0.0019897418,0.0013400518,0.028443718,0.0010350156,0.30267403,0.0010099977],"about_ca_topic_score_codex":0.005414145,"about_ca_topic_score_gemma":0.0029220874,"teacher_disagreement_score":0.47313046,"about_ca_system_score_codex":0.0000990807,"about_ca_system_score_gemma":0.00045910774,"threshold_uncertainty_score":0.9999929},"labels":[],"label_agreement":null},{"id":"W3088612260","doi":"10.1016/j.annonc.2020.08.2300","title":"LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; Juravinski Cancer Centre; Queen Elizabeth II Health Sciences Centre; La Cité Médicale; Moncton Hospital; Jewish General Hospital; Sunnybrook Health Science Centre; Centre Hospitalier Universitaire de Sherbrooke; Centre Hospitalier de l’Université de Montréal; Hôtel-Dieu de Québec; Vancouver General Hospital; Princess Margaret Cancer Centre; CancerCare Manitoba; Ottawa Hospital; London Health Sciences Centre","funders":"","keywords":"Medicine; Gemcitabine; Clinical endpoint; Internal medicine; Hazard ratio; Durvalumab; Randomized controlled trial; Oncology; Nab-paclitaxel; Surrogate endpoint; Urology; Cancer; Gastroenterology; Confidence interval; Immunotherapy; Nivolumab","score_opus":0.17652113345783718,"score_gpt":0.4227879499531035,"score_spread":0.2462668164952663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088612260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93803465,0.026853936,0.000002436893,0.028090106,0.00018454787,0.0063984524,0.0002579995,0.000013257194,0.00016459083],"genre_scores_gemma":[0.979581,0.017589089,0.000066040746,0.001969979,0.00018573704,0.00045092014,0.000042822947,0.000040049563,0.00007439218],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935051,0.0021818762,0.0027957228,0.00056779897,0.00046775013,0.00048171607],"domain_scores_gemma":[0.9945624,0.0028050148,0.0015286226,0.00045745447,0.0003504746,0.000296035],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.007009735,0.0004074293,0.0040489766,0.0004072172,0.00016092391,0.000017174441,0.00024122655,0.00020096284,0.00016485488],"category_scores_gemma":[0.0039426642,0.00026622426,0.00041735152,0.00065571093,0.00076480675,0.0001048688,0.00007421844,0.00030992876,5.404511e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9450999,0.0028278409,0.0010221138,0.00023047197,0.0033638475,0.0001381775,0.016930941,0.000005720238,0.0030812377,0.000032040887,0.0010217127,0.026246019],"study_design_scores_gemma":[0.893371,0.087738715,0.009187746,0.00020921831,0.0013129384,0.00004803042,0.0037818989,0.00020230582,0.000901897,0.00017332961,0.0028295207,0.00024342899],"about_ca_topic_score_codex":0.19288522,"about_ca_topic_score_gemma":0.15470344,"teacher_disagreement_score":0.08491088,"about_ca_system_score_codex":0.000115183124,"about_ca_system_score_gemma":0.0011849151,"threshold_uncertainty_score":0.999979},"labels":[],"label_agreement":null},{"id":"W3088801732","doi":"10.1158/1078-0432.ccr-20-1966","title":"Autoantibody Landscape in Patients with Advanced Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; National Cancer Institute; Vetenskapsrådet","keywords":"Autoantibody; Medicine; Prostate cancer; Cancer; Prostate; Oncology; Internal medicine; Immunology; Antibody","score_opus":0.11474085859844223,"score_gpt":0.4903821128765842,"score_spread":0.37564125427814193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088801732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98017496,0.0024892888,0.0000017771101,0.015049554,0.00016530516,0.0011741645,0.00005123028,0.00004508688,0.0008486443],"genre_scores_gemma":[0.9927298,0.003519954,0.00008009282,0.0025256134,0.0003024937,0.00023665422,0.000030759413,0.000041029332,0.0005335908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99737215,0.00019040193,0.00051541545,0.0005628596,0.00079802395,0.00056116283],"domain_scores_gemma":[0.9987224,0.00020474612,0.000077948906,0.00028205672,0.00038078433,0.00033208667],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008312282,0.00014974154,0.0004405556,0.000103159044,0.00007226038,0.000027795317,0.0001889822,0.00011706602,0.0011827819],"category_scores_gemma":[0.0002396588,0.000104603925,0.00009488028,0.0010062542,0.0003150102,0.000100615594,0.00008206607,0.00095395575,0.000036550315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032995064,0.00028199452,0.8565352,0.00012375813,0.00009099812,0.00002802099,0.00025465005,0.000013746919,0.0002134556,0.000003939393,0.005166457,0.104292706],"study_design_scores_gemma":[0.015465193,0.0027624364,0.934831,0.00038413823,0.000018198902,3.0346118e-7,0.00010316638,0.00012540846,0.00020549563,0.0000069095518,0.04594295,0.00015475904],"about_ca_topic_score_codex":0.0004206472,"about_ca_topic_score_gemma":0.0002984907,"teacher_disagreement_score":0.10413794,"about_ca_system_score_codex":0.00015397344,"about_ca_system_score_gemma":0.0008685526,"threshold_uncertainty_score":0.9997303},"labels":[],"label_agreement":null},{"id":"W3088815348","doi":"10.1016/j.annonc.2020.08.1030","title":"915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme","keywords":"Population; Medicine","score_opus":0.14925297685095465,"score_gpt":0.3705115693477895,"score_spread":0.22125859249683485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088815348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.948009,0.00732694,0.00031549612,0.041418374,0.00022782083,0.002063079,0.00020276377,0.000081300386,0.00035522075],"genre_scores_gemma":[0.9653929,0.0054761088,0.0019809937,0.025764542,0.00029320453,0.0001684791,0.00020378148,0.00012023895,0.000599789],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99687696,0.00016181014,0.0010036918,0.00084537285,0.0004185902,0.00069356343],"domain_scores_gemma":[0.9971785,0.0009219682,0.0006259794,0.0005511233,0.00032834316,0.00039406342],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000314793,0.00061260286,0.0017724282,0.00017419126,0.00014580668,0.000033424276,0.0003150009,0.00028347233,0.00090847193],"category_scores_gemma":[0.00013841742,0.0004004373,0.00038611577,0.00035727088,0.00037058123,0.00014744679,0.00005532257,0.0003251213,0.000013689215],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60674214,0.0039894134,0.103624724,0.0012549149,0.0015223861,0.0004821364,0.004982833,0.0000072681746,0.01391871,0.000014015294,0.011915101,0.25154635],"study_design_scores_gemma":[0.20917094,0.17219186,0.47021794,0.00039262537,0.0006655841,0.00030710752,0.00055343943,0.00040673802,0.056097,0.0001846943,0.08846333,0.0013487374],"about_ca_topic_score_codex":0.0010128558,"about_ca_topic_score_gemma":0.0009310402,"teacher_disagreement_score":0.3975712,"about_ca_system_score_codex":0.000089891204,"about_ca_system_score_gemma":0.00063422194,"threshold_uncertainty_score":0.99984473},"labels":[],"label_agreement":null},{"id":"W3088826944","doi":"10.2196/17898","title":"Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study","year":2020,"lang":"en","type":"article","venue":"JMIR Formative Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Common Terminology Criteria for Adverse Events; Prospective cohort study; Internal medicine; Adverse effect; Nausea; Quality of life (healthcare); Tolerability; Lung cancer; Prostate cancer","score_opus":0.07822043721461464,"score_gpt":0.4312840820252286,"score_spread":0.353063644810614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088826944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918253,0.00021918898,0.000013229759,0.0002085739,0.00014121887,0.00731514,0.000037685728,0.000059590224,0.00018006153],"genre_scores_gemma":[0.99912757,0.0001494019,0.000019678297,0.000121352256,0.00004233798,0.00043472566,0.000032450207,0.000042811444,0.000029664863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99567455,0.00054231327,0.00085461885,0.0005802434,0.00159682,0.00075144233],"domain_scores_gemma":[0.9974253,0.000121334444,0.00036206027,0.0005181816,0.0013871107,0.00018599386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013199428,0.00028554242,0.0007486899,0.00022900838,0.00029200435,0.0000499424,0.00023289587,0.000108159074,0.00022333897],"category_scores_gemma":[0.00022570892,0.00021331421,0.000213704,0.0012411509,0.00023889559,0.00055782474,0.00011932707,0.0006849425,0.0000036898045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00712252,0.0028113828,0.945631,0.00008801103,0.0010893394,0.0000053620256,0.026415596,0.0000025571885,0.0072885696,0.000003261793,0.00010125407,0.009441105],"study_design_scores_gemma":[0.010571611,0.008939265,0.9655913,0.00008878891,0.00004479885,0.0000015757149,0.0041786446,0.00026177714,0.010003456,0.000027803557,0.0000766498,0.00021432246],"about_ca_topic_score_codex":0.0011434093,"about_ca_topic_score_gemma":0.00015871428,"teacher_disagreement_score":0.02223695,"about_ca_system_score_codex":0.0011214563,"about_ca_system_score_gemma":0.00076067186,"threshold_uncertainty_score":0.86987007},"labels":[],"label_agreement":null},{"id":"W3088837832","doi":"10.1016/j.annonc.2020.08.1088","title":"973TiP LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Medicine; Lenvatinib; Internal medicine; Tolerability; Head and neck squamous-cell carcinoma; Oncology; Adverse effect; Placebo; Phases of clinical research; Head and neck cancer; Clinical trial; Immunotherapy; Cancer; Pathology","score_opus":0.09192149957931987,"score_gpt":0.3708962029273843,"score_spread":0.2789747033480644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088837832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616617,0.00052338577,0.0000109957045,0.001140218,0.000045325232,0.0016360723,0.00003700337,0.000015398564,0.00042542926],"genre_scores_gemma":[0.9985788,0.00012558706,0.00021676702,0.0008607522,0.00003489866,0.000054545417,0.00003314464,0.00003405802,0.000061444516],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99807185,0.00014088105,0.0007304841,0.00041239633,0.00032374533,0.0003206698],"domain_scores_gemma":[0.99865484,0.00014901445,0.0004947718,0.0002691747,0.00026988616,0.00016228623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002077311,0.0002700625,0.0010716011,0.00017182494,0.000043920085,0.000005465436,0.00012466963,0.00008172286,0.00010305453],"category_scores_gemma":[0.00006222517,0.00018070152,0.00005535264,0.00049099023,0.00022397659,0.00008499829,0.00004629289,0.00023472829,0.0000012042692],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33233568,0.014357886,0.6058324,0.0007162409,0.00022348003,0.00017635862,0.009323735,0.000016529275,0.0003737378,0.0000013517018,0.0007201711,0.035922408],"study_design_scores_gemma":[0.30175987,0.4511941,0.23625578,0.00026250203,0.0003507652,0.0000477057,0.0037878123,0.00038002417,0.0024390141,0.000003284648,0.0031670493,0.00035208947],"about_ca_topic_score_codex":0.0009847801,"about_ca_topic_score_gemma":0.0035932355,"teacher_disagreement_score":0.4368362,"about_ca_system_score_codex":0.00004374397,"about_ca_system_score_gemma":0.00032376632,"threshold_uncertainty_score":0.7368794},"labels":[],"label_agreement":null},{"id":"W3088871285","doi":"10.1016/j.annonc.2020.08.1147","title":"1027MO ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McGill University Health Centre; Université Laval; University of Alberta; Alberta Health Services; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Adverse effect; Response Evaluation Criteria in Solid Tumors; Pembrolizumab; Pharmacodynamics; Discontinuation; Internal medicine; Pharmacology; Pharmacokinetics; Cancer; Chemotherapy; Phases of clinical research; Immunotherapy","score_opus":0.034447588844563753,"score_gpt":0.32729667239864746,"score_spread":0.2928490835540837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088871285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895456,0.00034440163,0.000014490598,0.008413854,0.000035061636,0.00040291142,0.0000067038072,0.00001390387,0.0012231009],"genre_scores_gemma":[0.9954376,0.00043223597,0.00013141199,0.0038625393,0.000022494201,0.000022827806,0.000020649511,0.000020093732,0.000050155042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989349,0.000087454064,0.00033294447,0.0002480617,0.00017495266,0.00022166764],"domain_scores_gemma":[0.9994188,0.000053853862,0.00019771207,0.00012720874,0.00011620557,0.00008623773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015875406,0.00014242603,0.0004405294,0.00013498156,0.000018815652,0.000005345939,0.00006613565,0.0001238735,0.00004869108],"category_scores_gemma":[0.000025718022,0.000111728776,0.000030464227,0.00026648847,0.00017240846,0.00009652343,0.000014146229,0.00019895997,0.0000015699671],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15474448,0.0025303261,0.7148405,0.00020168319,0.00022285791,0.0001769526,0.004695958,0.000029516861,0.006628117,0.000043371518,0.0021811516,0.11370511],"study_design_scores_gemma":[0.040251676,0.02647236,0.91887176,0.00019185556,0.000022517914,0.00002232425,0.0004093699,0.000114090224,0.004802467,0.000027128603,0.008630543,0.00018390268],"about_ca_topic_score_codex":0.00015862727,"about_ca_topic_score_gemma":0.00034503365,"teacher_disagreement_score":0.20403129,"about_ca_system_score_codex":0.00007444253,"about_ca_system_score_gemma":0.00021164116,"threshold_uncertainty_score":0.4556167},"labels":[],"label_agreement":null},{"id":"W3089064400","doi":"10.3389/fphys.2020.511071","title":"Predicting Relapse in Patients With Triple Negative Breast Cancer (TNBC) Using a Deep-Learning Approach","year":2020,"lang":"en","type":"article","venue":"Frontiers in Physiology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; McGill University Health Centre; McGill University","funders":"University of Toronto; Québec Consortium for Drug Discovery; McGill University Health Centre; V Foundation for Cancer Research; Stand Up To Cancer; Faculty of Medicine, McGill University; McGill University; Breast Cancer Research Foundation; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"Breast cancer; Triple-negative breast cancer; Tumor-infiltrating lymphocytes; Cohort; Medicine; Cancer; Oncology; Internal medicine; CD8; Machine learning; Artificial intelligence; Immunology; Computer science; Immunotherapy; Immune system","score_opus":0.010808016532884629,"score_gpt":0.23229071066543477,"score_spread":0.22148269413255015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089064400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977941,0.00038938498,0.00067387143,0.00019364008,0.00025334352,0.0004975821,0.000012031966,0.000031644908,0.00015441862],"genre_scores_gemma":[0.9945698,0.00006279831,0.004556884,0.0005622192,0.000121481105,0.00004165091,0.000035621888,0.000028782912,0.000020808473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987958,0.00012985696,0.00025908757,0.00037317298,0.00012910218,0.00031299412],"domain_scores_gemma":[0.9996216,0.000018424647,0.00013526062,0.00010826957,0.000045550554,0.00007087935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008310588,0.0001645316,0.0004317638,0.0001230079,0.00005236953,0.000005623921,0.000083928026,0.00011315932,0.000033003013],"category_scores_gemma":[0.000038848048,0.00013518771,0.00005151882,0.0005507755,0.00013133654,0.0000979686,0.00003429261,0.00043115253,5.747766e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015022993,0.00017163549,0.96874565,0.00008839767,0.00015964151,0.000007614658,0.0036814255,0.0023379172,0.0019293365,0.0000010318823,0.00022096599,0.00763341],"study_design_scores_gemma":[0.010121147,0.00046098744,0.9445381,0.00015131646,0.000039476225,0.000003576887,0.0016206998,0.04271045,0.00007559627,0.000015932103,0.00009383876,0.00016887697],"about_ca_topic_score_codex":0.00055151404,"about_ca_topic_score_gemma":0.000024749319,"teacher_disagreement_score":0.04037253,"about_ca_system_score_codex":0.0002645232,"about_ca_system_score_gemma":0.00009664705,"threshold_uncertainty_score":0.5512795},"labels":[],"label_agreement":null},{"id":"W3089711024","doi":"10.1016/j.jamcollsurg.2020.07.094","title":"Identification of Tumor Antigen-Specific T Cells in the Peripheral Blood of Colorectal Cancer Patients","year":2020,"lang":"en","type":"article","venue":"Journal of the American College of Surgeons","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences North","funders":"","keywords":"Medicine; Peripheral blood; Colorectal cancer; Antigen; Identification (biology); Cancer; Immunology; Oncology; Internal medicine; Pathology","score_opus":0.012445070753927739,"score_gpt":0.24797295950817547,"score_spread":0.23552788875424774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089711024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963414,0.00055089215,0.000004175043,0.0023583865,0.00023379027,0.00026193954,0.00020460888,0.000001441541,0.00004335967],"genre_scores_gemma":[0.9985364,0.0010654575,0.0000549979,0.00027347132,0.0000385323,0.0000031563313,7.3063114e-7,0.000010212513,0.000017012635],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983256,0.0001479492,0.00085579336,0.000086514214,0.00046576018,0.00011840238],"domain_scores_gemma":[0.9976227,0.0001164625,0.0017793598,0.00015472701,0.00028416858,0.000042535303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040363107,0.000094881194,0.0005015572,0.00009222869,0.00003228541,0.0000034999944,0.00029073362,0.000015620959,0.000060972696],"category_scores_gemma":[0.00005526173,0.000055553555,0.0003165897,0.00090643676,0.00038662335,0.00004818568,0.000023895202,0.00016096742,1.9376765e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042433986,0.00067052507,0.27034408,0.00005221033,0.00027570827,0.000018125911,0.0013241342,0.000040550985,0.7184304,0.000008757751,0.0038075543,0.0007845261],"study_design_scores_gemma":[0.0020718419,0.0010425688,0.7402124,0.00016511693,0.000092312024,0.000032388663,0.0023181376,0.000036536592,0.2519641,0.000004841394,0.0019933195,0.0000664274],"about_ca_topic_score_codex":0.0002487661,"about_ca_topic_score_gemma":0.000040946237,"teacher_disagreement_score":0.4698683,"about_ca_system_score_codex":0.000050319475,"about_ca_system_score_gemma":0.00026131645,"threshold_uncertainty_score":0.22654083},"labels":[],"label_agreement":null},{"id":"W3090013090","doi":"10.1101/2020.09.29.20193110","title":"Hydroxychloroquine (HCQ) reverses anti-PD-1 immune murine checkpoint blockade: TCF1 as a marker in humans for COVID-19 and HCQ therapy","year":2020,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Hydroxychloroquine; Medicine; CD8; FOXP3; Immune checkpoint; Immunology; Immunotherapy; Cancer research; Blockade; Cancer immunotherapy; Immune system; Cancer; Internal medicine; Disease; Coronavirus disease 2019 (COVID-19); Receptor; Infectious disease (medical specialty)","score_opus":0.0503040995797967,"score_gpt":0.3357604331830571,"score_spread":0.2854563336032604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090013090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9469869,0.019475462,0.00014557448,0.02823639,0.000741509,0.003414179,0.00013170106,0.00020069271,0.00066760695],"genre_scores_gemma":[0.9748219,0.014912666,0.0006436421,0.005865966,0.00059755455,0.00063232915,0.00028771078,0.00016394441,0.0020742791],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99618715,0.00016260211,0.0011699363,0.0013625262,0.00048517925,0.0006325983],"domain_scores_gemma":[0.99766064,0.00023696707,0.00047031595,0.0011005849,0.00010935026,0.00042211733],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013316856,0.0007696068,0.0015346109,0.0004067275,0.00015425832,0.000078382276,0.00043394224,0.00054699654,0.0010942771],"category_scores_gemma":[0.00052803085,0.00067506114,0.0005930515,0.00039646274,0.00035625114,0.00007336921,0.00039948322,0.0009683456,0.000018042696],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051255397,0.0021439863,0.15760912,0.008778316,0.0034564266,0.0014984692,0.0074290144,0.00006092007,0.7492914,0.00015017255,0.007856788,0.010469954],"study_design_scores_gemma":[0.038925376,0.0028229235,0.3698878,0.002075954,0.00046289316,0.00027413352,0.0007171291,0.00065119565,0.06951896,0.0018874764,0.5107771,0.001999034],"about_ca_topic_score_codex":0.0014395989,"about_ca_topic_score_gemma":0.0001403326,"teacher_disagreement_score":0.67977244,"about_ca_system_score_codex":0.00035836798,"about_ca_system_score_gemma":0.0007556315,"threshold_uncertainty_score":0.99981886},"labels":[],"label_agreement":null},{"id":"W3090114622","doi":"10.3390/cancers12102827","title":"Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)","year":2020,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Loxo Oncology; Takeda Oncology; Sierra Oncology; Ipsen; Oryzon Genomics; Eisai; Daiichi-Sankyo; Novartis Pharma; Glenmark Pharmaceuticals; BeiGene; Clovis Oncology; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Pfizer; Incyte; Merck KGaA; Taiho Pharmaceutical; Genentech; Institut Gustave-Roussy; Daiichi Sankyo Europe; Servier; Gilead Sciences; Exelixis; Sanofi; GlaxoSmithKline; Spectrum Pharmaceuticals; Amgen; Celgene; Ignyta; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Internal medicine; Prednisone; Cancer; Gastroenterology; Retrospective cohort study; Oncology","score_opus":0.03137322458875203,"score_gpt":0.3517524092990704,"score_spread":0.3203791847103184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090114622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960485,0.00097054767,0.000048433994,0.0006457606,0.0013301871,0.00077801803,0.00005075044,0.000017581344,0.00011020206],"genre_scores_gemma":[0.9984258,0.00080045837,0.000045741548,0.00032898423,0.00024587073,0.00004099559,0.000032808326,0.000033764823,0.00004560466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781644,0.000067873574,0.0011652275,0.0004073958,0.00027443244,0.00026862978],"domain_scores_gemma":[0.9988339,0.000060506805,0.0005079707,0.0003136324,0.00015016721,0.00013383091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021201721,0.00025593498,0.0007667453,0.00014913137,0.000018348974,0.000005403956,0.00013711075,0.00012386283,0.00017858422],"category_scores_gemma":[0.00007480545,0.00020239638,0.0005584031,0.0003692347,0.00014366597,0.00007978643,0.00004725087,0.00035511452,0.000002054444],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00996779,0.00038111067,0.9222369,0.0003393527,0.00051520375,0.0000016792671,0.0015408737,0.00220805,0.03734762,0.000001080512,0.0012524134,0.02420789],"study_design_scores_gemma":[0.013624005,0.0046504023,0.94387925,0.00065413665,0.0001358682,3.9042735e-7,0.0005976222,0.00047327715,0.0355173,0.0000019255092,0.00021220488,0.00025361966],"about_ca_topic_score_codex":0.0015789919,"about_ca_topic_score_gemma":0.000104005805,"teacher_disagreement_score":0.02395427,"about_ca_system_score_codex":0.0019117745,"about_ca_system_score_gemma":0.0007607324,"threshold_uncertainty_score":0.8253485},"labels":[],"label_agreement":null},{"id":"W3090847458","doi":"10.1213/ane.0000000000005029","title":"Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy","year":2020,"lang":"en","type":"review","venue":"Anesthesia & Analgesia","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Immune system; Medicine; Cancer; Immunotherapy; Immunosuppression; Immunology; Cancer cell; Immune checkpoint; Cancer immunotherapy; T cell; Internal medicine","score_opus":0.023050427090856244,"score_gpt":0.28081975677275767,"score_spread":0.2577693296819014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090847458","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027139294,0.993073,0.0000025964816,0.0009878887,0.000114249706,0.0023987177,0.000012393416,0.00032541997,0.00037182146],"genre_scores_gemma":[0.0017466361,0.9942029,0.00005282888,0.00046753648,0.00019750213,0.00021510042,0.00093533244,0.00031829212,0.0018638722],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950271,0.0004515505,0.001971811,0.0009774761,0.00081851217,0.00075351266],"domain_scores_gemma":[0.9968435,0.00014006557,0.0015254415,0.0010042661,0.00017812167,0.0003085847],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007095316,0.0012398929,0.004050607,0.00037500588,0.00020348326,0.000029144727,0.000510949,0.0009368838,0.0006360641],"category_scores_gemma":[0.000053171985,0.0008635378,0.0024481001,0.0017861183,0.00023055731,0.00013660932,0.000041584393,0.0011506955,0.00028613053],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032185337,0.0010494561,0.0003646817,0.0045992853,0.012617663,0.0055110566,0.0004708964,5.1216085e-7,0.00020431569,0.00003389855,0.00079927663,0.97113043],"study_design_scores_gemma":[0.005170069,0.0015718836,0.00494886,0.027935453,0.0028518345,0.002158694,0.00006487647,0.0000059121826,0.00009039901,0.000008740818,0.95410216,0.0010911064],"about_ca_topic_score_codex":0.00014473106,"about_ca_topic_score_gemma":0.0000062543118,"teacher_disagreement_score":0.9700393,"about_ca_system_score_codex":0.00064392964,"about_ca_system_score_gemma":0.0012581921,"threshold_uncertainty_score":0.99938154},"labels":[],"label_agreement":null},{"id":"W3091570384","doi":"10.1158/1078-0432.ccr-20-1163","title":"Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pancreas Centre (Canada); University of British Columbia; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"Canada Foundation for Innovation","keywords":"Pembrolizumab; Context (archaeology); Medicine; Immune checkpoint; Nivolumab; Oncology; Cancer; Internal medicine; Immunotherapy; Transcriptome; Population; Tumor microenvironment; Lung cancer; Cancer research; Biology; Gene; Gene expression; Genetics","score_opus":0.1321516415974539,"score_gpt":0.4743217142130647,"score_spread":0.3421700726156108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091570384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.963534,0.0056943432,0.00000791568,0.029306415,0.00013369894,0.0010835553,0.00003308179,0.000024589912,0.00018238516],"genre_scores_gemma":[0.99653286,0.001957479,0.00019011612,0.00084827526,0.00015617129,0.00011954395,0.0000045642623,0.00003706181,0.00015391543],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9963723,0.0005660112,0.0013085318,0.00059088354,0.00062590616,0.0005363738],"domain_scores_gemma":[0.99820924,0.00059084554,0.000102687074,0.000347601,0.00022189744,0.00052770396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005126199,0.00016985938,0.0007333111,0.00033564316,0.000056621462,0.00001673799,0.00022850734,0.00015388003,0.00028199083],"category_scores_gemma":[0.0014968117,0.00014896138,0.00022957684,0.0014591293,0.0006598955,0.00007264744,0.00012669525,0.0007193542,0.000013861661],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11348456,0.00015808834,0.013815309,0.00021672765,0.000114410854,0.00006707713,0.0013323007,0.0000052876453,0.84607947,0.0000015920187,0.00012275497,0.02460244],"study_design_scores_gemma":[0.011188149,0.005854154,0.8862417,0.0007554172,0.000023917113,0.0000077441855,0.0014326825,0.00005900103,0.073985696,0.000025035439,0.020167992,0.0002585449],"about_ca_topic_score_codex":0.0004573751,"about_ca_topic_score_gemma":0.00007170694,"teacher_disagreement_score":0.87242633,"about_ca_system_score_codex":0.00020981659,"about_ca_system_score_gemma":0.000696298,"threshold_uncertainty_score":0.60744685},"labels":[],"label_agreement":null},{"id":"W3091948129","doi":"10.1136/jitc-2020-001006","title":"Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Amgen","keywords":"Pembrolizumab; Medicine; Rash; Maculopapular rash; Internal medicine; Adverse effect; Refractory (planetary science); Gastroenterology; Lung cancer; Oncology; Cancer; Immunotherapy","score_opus":0.013646745651569215,"score_gpt":0.32535753150538355,"score_spread":0.31171078585381434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091948129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99503213,0.0023763725,0.00031115857,0.0010355847,0.00009262599,0.0010761931,0.000042443982,0.000012554366,0.000020924821],"genre_scores_gemma":[0.9944054,0.003779417,0.001413551,0.00023271322,0.00005847542,0.00001874599,0.000020344523,0.000050387982,0.000021001384],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983163,0.00005855971,0.00077835325,0.0002536701,0.00032640607,0.00026672502],"domain_scores_gemma":[0.9987758,0.00009907795,0.00065537327,0.00014463231,0.0002354913,0.000089634785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023353565,0.00022593595,0.0007686203,0.00020751674,0.00006799072,0.000016744,0.000115836425,0.00008385227,0.000093858725],"category_scores_gemma":[0.000034061668,0.00015318398,0.00009164485,0.00040831548,0.0001463506,0.0002944711,0.000008403355,0.00028129166,8.633439e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25724012,0.00049808336,0.18400042,0.00044278652,0.00032134808,0.00001084008,0.006748171,0.0015833885,0.41807255,0.000009589001,0.000008904576,0.1310638],"study_design_scores_gemma":[0.092506036,0.013618464,0.8586974,0.0040134015,0.000039984832,0.000046008314,0.0007821272,0.0019605397,0.027165862,0.000008115524,0.0008551357,0.0003068874],"about_ca_topic_score_codex":0.0002636773,"about_ca_topic_score_gemma":0.00016423306,"teacher_disagreement_score":0.67469704,"about_ca_system_score_codex":0.00017948056,"about_ca_system_score_gemma":0.00031510866,"threshold_uncertainty_score":0.62466615},"labels":[],"label_agreement":null},{"id":"W3092016117","doi":"10.1136/jitc-2020-001095","title":"Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences","keywords":"Durvalumab; Medicine; Tolerability; Response Evaluation Criteria in Solid Tumors; Pharmacodynamics; Internal medicine; Clinical endpoint; Oncology; Radiation therapy; Pharmacokinetics; Toxicity; Gastroenterology; Urology; Nivolumab; Adverse effect; Cancer; Phases of clinical research; Clinical trial; Immunotherapy","score_opus":0.020610346657450037,"score_gpt":0.33996781776810464,"score_spread":0.3193574711106546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092016117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99355125,0.0037074143,0.00014124026,0.0015811896,0.00006710068,0.0009203891,0.000022648586,0.0000043147784,0.000004438958],"genre_scores_gemma":[0.9706731,0.028480453,0.00041345495,0.000344026,0.00003333073,0.00001977962,0.000005609066,0.000022515183,0.000007754358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987325,0.00008787707,0.00058315095,0.00019336489,0.00024922274,0.00015385977],"domain_scores_gemma":[0.998971,0.00013742091,0.00057828333,0.0000741478,0.00016834361,0.00007079875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040848862,0.00016123391,0.00064392114,0.00011223464,0.000045413602,0.000012402936,0.000045885023,0.00007272754,0.000018493987],"category_scores_gemma":[0.0000362582,0.00010422617,0.000047089,0.00022928223,0.00022705918,0.00023172384,0.000006700262,0.00024979236,1.1451345e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2359795,0.00029715215,0.44266364,0.00006873543,0.00026046718,0.0000021819972,0.0011912291,0.000012058261,0.0033517007,0.0000029231426,0.000005573562,0.31616485],"study_design_scores_gemma":[0.06624675,0.013177892,0.9159088,0.0004936821,0.000028260434,0.000005202567,0.0001416756,0.0002775034,0.003356561,0.00002041951,0.0002189447,0.00012429598],"about_ca_topic_score_codex":0.00009944392,"about_ca_topic_score_gemma":0.0002103442,"teacher_disagreement_score":0.47324517,"about_ca_system_score_codex":0.00010243432,"about_ca_system_score_gemma":0.00023253204,"threshold_uncertainty_score":0.425022},"labels":[],"label_agreement":null},{"id":"W3092198756","doi":"10.1155/2020/7973568","title":"JAK3 and TYK2 Serve as Prognostic Biomarkers and Are Associated with Immune Infiltration in Stomach Adenocarcinoma","year":2020,"lang":"en","type":"article","venue":"BioMed Research International","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Tianjin Medical University","keywords":"Immune system; Biology; Chemokine; Tyrosine kinase 2; Acquired immune system; Cancer research; Adenocarcinoma; Immunology; Cancer; Receptor","score_opus":0.06572187186669218,"score_gpt":0.34783231469990417,"score_spread":0.28211044283321196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092198756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780758,0.0013730209,0.000014809328,0.019192455,0.00012237979,0.0006017274,0.000037166606,0.000030385203,0.000552244],"genre_scores_gemma":[0.9987918,0.00016318868,0.00016277822,0.00030634532,0.00014479591,0.000058037742,0.0001597751,0.000017854612,0.00019542297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832875,0.00013886456,0.00024334832,0.00032925786,0.0006977822,0.00026202397],"domain_scores_gemma":[0.99918526,0.00019632716,0.00007745707,0.0000948898,0.00027757077,0.00016847698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067872,0.00012107964,0.00017916407,0.0003822874,0.00007628514,0.00008552977,0.000113530696,0.000097564174,0.00012672076],"category_scores_gemma":[0.00071587926,0.00009806181,0.000028914043,0.00067020743,0.00033466355,0.00013819405,0.000076439166,0.00027488885,0.0000069078455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076588425,0.00025003497,0.9218635,0.00012741784,0.000761045,0.00034267138,0.0011523294,7.210869e-7,0.05870956,0.00009658399,0.0018874676,0.00714981],"study_design_scores_gemma":[0.004613718,0.0010193645,0.9875669,0.00036160453,0.00001536779,0.000076686265,0.0007506208,0.002231795,0.0016621229,0.000046770852,0.001535501,0.000119535514],"about_ca_topic_score_codex":0.00036106003,"about_ca_topic_score_gemma":0.0001312628,"teacher_disagreement_score":0.0657034,"about_ca_system_score_codex":0.00019173992,"about_ca_system_score_gemma":0.00019003786,"threshold_uncertainty_score":0.39988446},"labels":[],"label_agreement":null},{"id":"W3092419908","doi":"10.1200/jco.2020.38.29_suppl.201","title":"Characteristics and outcomes of patients (pts) who developed immune-related adverse events (irAEs) with an initial presentation in the emergency department (ED).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Interquartile range; Emergency department; Population; Adverse effect; Internal medicine; Pneumonitis; Pediatrics; Surgery","score_opus":0.07883268291152917,"score_gpt":0.4337724043749996,"score_spread":0.3549397214634704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092419908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960574,0.00008332524,0.000022236227,0.003012234,0.0003920374,0.00030737123,0.000008916252,0.000002303544,0.00011415653],"genre_scores_gemma":[0.99733675,0.0009691454,0.00031948395,0.0012309742,0.00010050215,0.000003447997,0.0000186748,0.000008118446,0.000012918604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969086,0.0004247606,0.0021532495,0.00010761008,0.00029698823,0.000108788925],"domain_scores_gemma":[0.9977682,0.00029853344,0.0015145191,0.00008849456,0.00021874777,0.00011145385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011671514,0.000097609045,0.00074703,0.00004928466,0.000022915965,0.000001633136,0.00011312755,0.00014019966,0.00009614021],"category_scores_gemma":[0.00073255866,0.000054309556,0.00014969405,0.0001268201,0.000094490504,0.00011648365,0.000022258779,0.00036053619,0.0000013090661],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019778922,0.0011340084,0.93956274,0.000024387136,0.00035644555,0.00006765444,0.0009723953,0.0000012287923,0.00003644689,0.0000057923658,0.00012883727,0.03793112],"study_design_scores_gemma":[0.013039401,0.012546316,0.9719175,0.000041987227,0.00019848504,0.000016867414,0.00026765186,0.00003923599,0.000018560897,0.000019656782,0.0018375433,0.0000567958],"about_ca_topic_score_codex":0.00001873237,"about_ca_topic_score_gemma":0.00002972394,"teacher_disagreement_score":0.037874322,"about_ca_system_score_codex":0.000039713108,"about_ca_system_score_gemma":0.0003824799,"threshold_uncertainty_score":0.22146793},"labels":[],"label_agreement":null},{"id":"W3092683220","doi":"10.14740/wjon1302","title":"Overexpression of Programmed Death-Ligand 1 Receptor mRNA as an Independent Negative Prognostic Factor for Triple Negative Breast Cancer","year":2020,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Triple-negative breast cancer; Breast cancer; Internal medicine; Oncology; Cancer; Biopsy; Stage (stratigraphy)","score_opus":0.04321863634476171,"score_gpt":0.3531327389665092,"score_spread":0.3099141026217475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092683220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872753,0.0005752121,0.00010693576,0.009695576,0.00052920054,0.0013627821,0.00017713453,0.000014265084,0.0002636182],"genre_scores_gemma":[0.99494797,0.0002484635,0.0026336508,0.0011638222,0.00065975985,0.000057277517,0.0000069904663,0.000027816064,0.00025422568],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983304,0.00014306669,0.0007210298,0.00020992053,0.00033133567,0.00026424753],"domain_scores_gemma":[0.99766105,0.00033360458,0.0010184607,0.00010137571,0.0005729978,0.00031251032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026111066,0.0001859197,0.0006985915,0.00016317527,0.000062841485,0.000014352027,0.00016328525,0.00012783542,0.00074430025],"category_scores_gemma":[0.0002982887,0.00013341694,0.00025200416,0.0003062057,0.00013174805,0.0001702654,0.000028428807,0.00036653085,0.0000017607439],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13044417,0.0017185083,0.050755996,0.00031789593,0.0016098744,0.00007486775,0.010051585,0.000010066412,0.42308447,0.00005677732,0.0067148358,0.37516096],"study_design_scores_gemma":[0.067892276,0.04682672,0.3791438,0.0023798863,0.0009436206,0.0007788602,0.0038064336,0.0001885592,0.3909283,0.000583565,0.10589515,0.00063283084],"about_ca_topic_score_codex":0.00015193348,"about_ca_topic_score_gemma":0.00017405713,"teacher_disagreement_score":0.3745281,"about_ca_system_score_codex":0.00037250793,"about_ca_system_score_gemma":0.0011470458,"threshold_uncertainty_score":0.8149566},"labels":[],"label_agreement":null},{"id":"W3093424538","doi":"10.3389/fimmu.2020.587014","title":"Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses","year":2020,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"Cancer Council Western Australia; National Health and Medical Research Council; New South Wales Workers' Compensation Dust Disease Board; Raine Medical Research Foundation","keywords":"Repertoire; T-cell receptor; Computational biology; Immune system; Biology; Acquired immune system; Antigen; Immunotherapy; T cell; Immunology","score_opus":0.023784662812466408,"score_gpt":0.28827157171603024,"score_spread":0.26448690890356386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093424538","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028134193,0.99392676,0.000056409193,0.0002712538,0.001226823,0.0012602475,0.00014455768,0.00007463115,0.00022590595],"genre_scores_gemma":[0.0005699165,0.99719554,0.0004274551,0.00009977342,0.00007957152,0.00015317336,0.0004915178,0.00012721954,0.00085580593],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99639803,0.00058774516,0.0016549736,0.00060130854,0.00026432626,0.0004935884],"domain_scores_gemma":[0.9973668,0.00021167306,0.0014055452,0.0008121339,0.00014331914,0.00006056436],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051379105,0.0006375594,0.004590308,0.0006186485,0.00006172368,0.000016526994,0.000468815,0.00087374536,0.00012466614],"category_scores_gemma":[0.00042266946,0.00046878553,0.00071189564,0.001034512,0.00070651225,0.000059986203,0.000084025865,0.001032665,0.0000056094605],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009848524,0.0002995397,0.0013482937,0.0020246156,0.0043237493,0.00032396245,0.000286858,1.0731201e-8,0.00020953939,0.0000036497217,0.00041314773,0.9809181],"study_design_scores_gemma":[0.0038925814,0.0018371047,0.006170965,0.015869249,0.0006639764,0.0002066115,0.00014648169,0.0000020409261,0.0002491622,0.000008279614,0.97045827,0.0004952887],"about_ca_topic_score_codex":0.00010568833,"about_ca_topic_score_gemma":0.0000073246,"teacher_disagreement_score":0.9804228,"about_ca_system_score_codex":0.000630361,"about_ca_system_score_gemma":0.0013024897,"threshold_uncertainty_score":0.99977636},"labels":[],"label_agreement":null},{"id":"W3093627928","doi":"10.1002/eji.202048761","title":"Human CXCR5 <sup>+</sup> PD‐1 <sup>+</sup> CD8 T cells in healthy individuals and patients with hematologic malignancies","year":2020,"lang":"en","type":"article","venue":"European Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"ZonMw","keywords":"Cytotoxic T cell; CD8; CXCR5; Biology; Cancer research; Interleukin 21; Immune system; Immune checkpoint; Immunology; Immunotherapy; In vitro; Biochemistry","score_opus":0.018342036722015318,"score_gpt":0.239246977877785,"score_spread":0.2209049411557697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093627928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99073,0.0037205613,0.00003380401,0.0044719884,0.00007820754,0.00032815675,0.00001681261,0.000029259998,0.00059121003],"genre_scores_gemma":[0.994298,0.0006353878,0.00070071337,0.0040981798,0.00012658295,0.0000023300397,0.000012486253,0.000057269055,0.00006907403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708676,0.00072575756,0.0010665396,0.0003261754,0.00031287526,0.00048191586],"domain_scores_gemma":[0.99864954,0.00008874748,0.00062766165,0.00025730752,0.00018439566,0.00019235909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078017596,0.00031870604,0.00081929116,0.0003115569,0.0001301579,0.00003886418,0.00031878232,0.00009221434,0.00021346135],"category_scores_gemma":[0.00009529999,0.00023321091,0.00013277422,0.0003535793,0.00039228649,0.00016904788,0.000119372744,0.0007211849,0.00003569648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049935687,0.002947326,0.76396644,0.001103786,0.004109581,0.0072652106,0.052139454,0.00085433637,0.06857164,0.0002761277,0.01618874,0.03264165],"study_design_scores_gemma":[0.06286831,0.05167549,0.8051142,0.0018798752,0.00040937169,0.003032521,0.007831865,0.00010561573,0.0051941336,0.00006226484,0.060679454,0.0011468957],"about_ca_topic_score_codex":0.000016003385,"about_ca_topic_score_gemma":0.000001520968,"teacher_disagreement_score":0.06337751,"about_ca_system_score_codex":0.000095116564,"about_ca_system_score_gemma":0.0001442208,"threshold_uncertainty_score":0.9510065},"labels":[],"label_agreement":null},{"id":"W3093653710","doi":"10.1158/1078-0432.ccr-20-2669","title":"Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors","year":2020,"lang":"en","type":"review","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Pembrolizumab; Adverse effect; Internal medicine; Toxicity; Oncology; Renal cell carcinoma; Incidence (geometry); Melanoma; Clinical trial; Lung cancer; Cancer; Immunotherapy; Cancer research","score_opus":0.6305114855276522,"score_gpt":0.6382727501066128,"score_spread":0.007761264578960536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093653710","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00668963,0.9596933,0.0002445197,0.001524141,0.0040411246,0.02750054,0.00016797832,0.00008664865,0.000052133604],"genre_scores_gemma":[0.0004471088,0.98225576,0.00050387974,0.00009591874,0.011865957,0.004165304,0.00016018408,0.0001468995,0.00035899112],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98447895,0.0052317013,0.0062074917,0.0018852269,0.0012516576,0.00094498845],"domain_scores_gemma":[0.981611,0.014756089,0.0010387172,0.0010860736,0.0006419189,0.00086619146],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.036283724,0.0006219337,0.005055153,0.00028192627,0.0002991983,0.00017618937,0.00051162136,0.0017288985,0.00033723103],"category_scores_gemma":[0.012936607,0.00046301205,0.0035581442,0.0009781067,0.0016521822,0.00012662099,0.0002995317,0.0037683477,0.00004053489],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4586735,0.0010577618,0.000009982554,0.00272558,0.0005442383,0.000011904152,0.000020797048,1.3450136e-8,0.0000025266365,0.0000036857869,0.0018015599,0.53514844],"study_design_scores_gemma":[0.3406413,0.030472284,0.00006838964,0.0031779902,0.00089817605,0.0000040864425,0.000010781018,0.000025613606,0.000005464177,0.000063306485,0.6243293,0.00030327364],"about_ca_topic_score_codex":0.00023450864,"about_ca_topic_score_gemma":0.000013553282,"teacher_disagreement_score":0.6225278,"about_ca_system_score_codex":0.0006624081,"about_ca_system_score_gemma":0.0065312604,"threshold_uncertainty_score":0.99978215},"labels":[],"label_agreement":null},{"id":"W3094192068","doi":"10.1016/j.jtho.2020.09.027","title":"Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Janssen Biotech; Fonds de Recherche du Québec - Santé; University of Texas MD Anderson Cancer Center; Bill and Katie Weaver Charitable Trust; EMD Serono; Cancer Prevention and Research Institute of Texas; Genentech; Innovent Biologics; Astellas Pharma; Bayer Fund; Takeda Pharmaceutical Company; Ribon Therapeutics; Merck; Spectrum Pharmaceuticals; North Carolina GlaxoSmithKline Foundation; National Cancer Institute; Bayer; Exelixis; Sanofi; GlaxoSmithKline; Society for Immunotherapy of Cancer; Astellas Pharma US; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim","keywords":"Medicine; Infiltration (HVAC); Cytotoxic T cell; Chemotherapy; Oncology; Cell; Internal medicine; Cancer research; In vitro","score_opus":0.02015960351542771,"score_gpt":0.3554963304333422,"score_spread":0.3353367269179145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094192068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781362,0.008505164,0.000099462486,0.009124821,0.00019965555,0.00035950428,0.0000037707175,0.000013297251,0.003558164],"genre_scores_gemma":[0.989832,0.0039120726,0.0015827365,0.0034887455,0.0005114095,0.0000059978133,0.000003828306,0.00002687914,0.00063636503],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99821895,0.0002641126,0.0007601954,0.00020956047,0.00029121526,0.00025593644],"domain_scores_gemma":[0.9987462,0.00018589935,0.0005624755,0.00015107109,0.00012140596,0.00023295144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007974918,0.00017725586,0.00061386125,0.0002298688,0.000054975604,0.000027395809,0.00013792021,0.0002123246,0.00041815077],"category_scores_gemma":[0.00007231275,0.00014684045,0.00010458738,0.00030407053,0.00009657398,0.00019292234,0.00003297808,0.00049685856,0.000008836207],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019838033,0.00046472056,0.0020136822,0.00027629422,0.000041330382,0.00065239065,0.0019919502,0.000022360318,0.9236465,7.137034e-7,0.0101483,0.040903717],"study_design_scores_gemma":[0.008209654,0.00935331,0.0128143225,0.0002412121,0.00014993842,0.00072192884,0.0023100579,0.00011656503,0.91812897,0.000045673558,0.04767481,0.0002335558],"about_ca_topic_score_codex":0.000248881,"about_ca_topic_score_gemma":0.000074548836,"teacher_disagreement_score":0.040670164,"about_ca_system_score_codex":0.00029474447,"about_ca_system_score_gemma":0.0006569137,"threshold_uncertainty_score":0.598798},"labels":[],"label_agreement":null},{"id":"W3094230929","doi":"10.1016/j.radonc.2020.10.029","title":"Immune cell profiling in Gleason 9 prostate cancer patients treated with brachytherapy versus external beam radiotherapy: An exploratory study","year":2020,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Services and Policy Research; Health Sciences Centre; Sunnybrook Hospital; University of Toronto; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"Prostate Cancer Canada","keywords":"Brachytherapy; Prostate cancer; Medicine; External beam radiotherapy; Radiation therapy; Oncology; Prostate; Radiology; External beam radiation; Urology; Internal medicine; Cancer","score_opus":0.021389539381087813,"score_gpt":0.30120976238789016,"score_spread":0.2798202230068023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094230929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757758,0.02067465,0.000058625996,0.00075418694,0.00021529967,0.0023421007,0.000017513967,0.000101561265,0.000060256774],"genre_scores_gemma":[0.9860943,0.009817957,0.0010072882,0.0021930973,0.0003281946,0.0003471281,0.000031010753,0.000105883395,0.00007513253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99772453,0.0002958223,0.0005300094,0.00069098227,0.00028165444,0.00047698742],"domain_scores_gemma":[0.9990556,0.00007593352,0.000245007,0.00027318503,0.0000897696,0.0002605082],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028184877,0.00040857223,0.00082695857,0.00015706429,0.00012299645,0.00004134175,0.00015079592,0.0001952252,0.00017064186],"category_scores_gemma":[0.0000057764823,0.00031936495,0.00008686491,0.00045713485,0.000184989,0.000265866,0.000013416175,0.00039164457,0.000001236791],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1426809,0.0029467624,0.6172627,0.000077780074,0.0004563841,0.00016918503,0.018803647,0.00004664651,0.13673626,0.000002121742,0.00004760867,0.08077001],"study_design_scores_gemma":[0.3048466,0.18928503,0.42184055,0.00031191448,0.00032613246,0.000055295237,0.007867521,0.0018410131,0.04381308,0.0000039224396,0.028219579,0.0015893548],"about_ca_topic_score_codex":0.00038337524,"about_ca_topic_score_gemma":0.00043180134,"teacher_disagreement_score":0.19542216,"about_ca_system_score_codex":0.0007807607,"about_ca_system_score_gemma":0.0003598501,"threshold_uncertainty_score":0.99992585},"labels":[],"label_agreement":null},{"id":"W3094745505","doi":"10.1158/1078-0432.ccr-20-1830","title":"OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Ottawa Hospital; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre","funders":"Ono Pharmaceutical; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Combination therapy; Internal medicine; Rash; Adverse effect; Pharmacodynamics; Oncology; Clinical endpoint; Pharmacology; Cancer; Pharmacokinetics; Clinical trial; Immunotherapy","score_opus":0.11479046437595773,"score_gpt":0.4554999773211006,"score_spread":0.34070951294514285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094745505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98943764,0.00040284803,0.000006825195,0.00839047,0.000058228175,0.0014439625,0.000016147651,0.000028409044,0.00021544806],"genre_scores_gemma":[0.9968228,0.0009292173,0.00020007443,0.0012958592,0.00009094301,0.00020114527,0.000031545685,0.00004190348,0.0003865633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970307,0.00029569684,0.0006947367,0.00062161544,0.00083389616,0.00052337575],"domain_scores_gemma":[0.99854064,0.00048121644,0.00011524612,0.00028593032,0.00029804863,0.00027891848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010998598,0.00018218628,0.00062499644,0.00017311829,0.000093779985,0.00003929869,0.00017396842,0.00012660888,0.0002773978],"category_scores_gemma":[0.000506395,0.00011298886,0.000044271663,0.0012497968,0.00064821483,0.00014573416,0.00008678449,0.00094496546,0.000008631142],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30553705,0.0013331607,0.59342045,0.00029988523,0.000091259295,0.00022471344,0.0006511422,0.00000960158,0.00014766263,0.000008522201,0.0010228031,0.09725379],"study_design_scores_gemma":[0.06454004,0.021055402,0.90819436,0.0010837952,0.000019708075,0.000004528206,0.00065363746,0.00026919373,0.00034671844,0.000013582392,0.003577817,0.00024121205],"about_ca_topic_score_codex":0.0008170835,"about_ca_topic_score_gemma":0.0040592067,"teacher_disagreement_score":0.31477395,"about_ca_system_score_codex":0.00036078176,"about_ca_system_score_gemma":0.0011253983,"threshold_uncertainty_score":0.46075523},"labels":[],"label_agreement":null},{"id":"W3095305286","doi":"10.1089/gtmb.2020.0063","title":"Clinicopathological and Prognostic Roles of the Expression Levels of the Programmed Cell Death-1 Gene in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"Genetic Testing and Molecular Biomarkers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hazard ratio; Medicine; Confidence interval; Hepatocellular carcinoma; Internal medicine; Meta-analysis; Odds ratio; Oncology; Gastroenterology; Publication bias","score_opus":0.06342801836280511,"score_gpt":0.2894950871233563,"score_spread":0.22606706876055122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095305286","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.080674976,0.9141388,0.000021731348,0.000043854434,0.000008407287,0.0050410647,0.0000595469,0.000007515452,0.0000040892132],"genre_scores_gemma":[0.47570568,0.519286,0.0042601335,0.00018234864,0.0000047322355,0.0004802014,0.00001671566,0.000055697266,0.000008516932],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9969523,0.0008483824,0.0010991957,0.00053704676,0.00035831472,0.00020476994],"domain_scores_gemma":[0.9978907,0.00026853388,0.0010601819,0.00058085925,0.00010949606,0.000090236004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005902025,0.00041369282,0.0033471477,0.00010792384,0.000055153792,0.00001617983,0.00019735376,0.00016467893,0.0000023807488],"category_scores_gemma":[0.00055641274,0.00017908998,0.000734235,0.0009479207,0.00028765228,0.000008691323,0.00019372794,0.00018506752,4.863465e-8],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009624864,0.00022686037,0.15926048,0.8064222,0.016672723,0.000059056885,0.00009757587,3.7557814e-7,0.00052322855,2.835359e-7,0.000002144102,0.016638825],"study_design_scores_gemma":[0.0015489286,0.00074404443,0.081201315,0.063309364,0.8520954,0.00013361531,0.00002599087,0.000032707907,0.00037197018,0.0000036395556,0.00010232249,0.0004306616],"about_ca_topic_score_codex":0.000024063416,"about_ca_topic_score_gemma":0.0000021658927,"teacher_disagreement_score":0.8354227,"about_ca_system_score_codex":0.000020708674,"about_ca_system_score_gemma":0.00016553562,"threshold_uncertainty_score":0.73030776},"labels":[],"label_agreement":null},{"id":"W3095965358","doi":"10.1136/jitc-2020-001389","title":"Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I—conceptual challenges","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Cancer Institute","keywords":"Immunotherapy; Cancer immunotherapy; Medicine; Data science; Volume (thermodynamics); Resource (disambiguation); Cancer; Computer science; Internal medicine","score_opus":0.13094875820765697,"score_gpt":0.413158312917038,"score_spread":0.282209554709381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095965358","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40114397,0.5584721,0.0016999097,0.033448,0.0014315265,0.0024735753,0.0011415496,0.00006130895,0.00012807774],"genre_scores_gemma":[0.17856513,0.7945893,0.012030061,0.009368754,0.0033415887,0.00037383204,0.00013213165,0.0003549045,0.0012443321],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965859,0.0000672352,0.0016526226,0.00070280203,0.00048579558,0.0005056629],"domain_scores_gemma":[0.9971897,0.00029031927,0.0011933019,0.0007389411,0.0003788398,0.00020887355],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001683966,0.00039017765,0.001190171,0.00009679737,0.00023362691,0.000053462438,0.0008547165,0.0002884355,0.00049958756],"category_scores_gemma":[0.00008058336,0.0003269208,0.0011046745,0.00022575587,0.00080775283,0.0003434751,0.00011781236,0.00040439627,3.8123304e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04981976,0.00024354068,0.01258546,0.00083154987,0.012638029,0.0000016500185,0.006110491,0.000014836818,0.076333374,0.00010710181,0.025327308,0.8159869],"study_design_scores_gemma":[0.031735197,0.0032971278,0.018312369,0.0010124432,0.00059166213,0.000024151837,0.002989289,0.0011451697,0.007921718,0.00022191991,0.93222487,0.0005241046],"about_ca_topic_score_codex":0.00026382497,"about_ca_topic_score_gemma":0.000046978355,"teacher_disagreement_score":0.90689754,"about_ca_system_score_codex":0.00013570463,"about_ca_system_score_gemma":0.0005304052,"threshold_uncertainty_score":0.9999183},"labels":[],"label_agreement":null},{"id":"W3095998226","doi":"10.31557/apjcp.2020.21.10.3115","title":"Evaluating the Possible Association between PD-1 (Rs11568821, Rs2227981, Rs2227982) and PD-L1 (Rs4143815, Rs2890658) Polymorphisms and Susceptibility to Breast Cancer in a Sample of Southeast Iranian Women","year":2020,"lang":"en","type":"article","venue":"Asian Pacific Journal of Cancer Prevention","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Genotyping; Genotype; Breast cancer; PD-L1; Allele; Polymerase chain reaction; Oncology; Immune system; Immunology; Medicine; Internal medicine; Estrogen receptor; Biology; Cancer; Genetics; Gene; Immunotherapy","score_opus":0.0314887803579993,"score_gpt":0.3393687596383336,"score_spread":0.3078799792803343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095998226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978622,0.002152525,0.0002960842,0.017782507,0.00015633059,0.00063188304,0.0002379291,0.000010221006,0.00011051265],"genre_scores_gemma":[0.99833435,0.00053290644,0.00033077938,0.00020465012,0.00040536837,0.00003192516,0.0000051422694,0.000024905268,0.00012995364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975222,0.00033165948,0.0009027365,0.0002923165,0.00061028305,0.00034085294],"domain_scores_gemma":[0.99831784,0.00013209232,0.0008603867,0.0001755536,0.00026691487,0.0002472081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002271109,0.00020396382,0.0005910782,0.00017003877,0.00010184579,0.000050776744,0.00012838689,0.00012617974,0.00036230107],"category_scores_gemma":[0.00017157641,0.00015640119,0.00015724503,0.0005448989,0.00009022708,0.00022112802,0.00004344981,0.0003509686,9.84446e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045626103,0.000085276384,0.69904757,0.0002081923,0.00050214643,0.000002782208,0.016814563,0.000018210154,0.032696027,0.0000059056515,0.000097474884,0.24595925],"study_design_scores_gemma":[0.0041261576,0.0013512092,0.9845709,0.0008585067,0.00027972044,0.000032308664,0.00703593,0.00009354194,0.00078883435,0.0003935663,0.000298265,0.00017105759],"about_ca_topic_score_codex":0.00073098956,"about_ca_topic_score_gemma":0.00054523954,"teacher_disagreement_score":0.28552336,"about_ca_system_score_codex":0.00069364544,"about_ca_system_score_gemma":0.00046627133,"threshold_uncertainty_score":0.63778555},"labels":[],"label_agreement":null},{"id":"W3096094105","doi":"10.1158/1078-0432.ccr-20-3299","title":"Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Genomics","funders":"Stiftelsen Jubileumsklinikens Forskningsfond mot Cancer; Cancerfonden","keywords":"Immune system; Breast cancer; Medicine; Radiation therapy; Adjuvant; Oncology; CD8; FOXP3; Immunohistochemistry; Cancer; Primary tumor; Internal medicine; Pathology; Cancer research; Immunology; Metastasis","score_opus":0.1057210141369547,"score_gpt":0.45448103614844715,"score_spread":0.3487600220114925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096094105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91073644,0.01807792,0.0000031405752,0.064414084,0.0004985428,0.0054694545,0.00043483538,0.000020978658,0.00034459913],"genre_scores_gemma":[0.96672577,0.025494011,0.000014630678,0.004604599,0.001898139,0.0011213853,0.00005453288,0.00003858338,0.000048323443],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98855996,0.0067820293,0.00212503,0.00065335864,0.0012915822,0.00058805913],"domain_scores_gemma":[0.98095685,0.017589413,0.0003593243,0.00077521935,0.00015908634,0.00016011267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022214716,0.00026342235,0.0017955562,0.00011335238,0.00009108847,0.000046996804,0.0008517926,0.00019838898,0.00034425902],"category_scores_gemma":[0.002830824,0.00012766667,0.00058978697,0.0012449266,0.0014423629,0.00008161168,0.00010733815,0.0019993647,0.0000052198416],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94353753,0.00027671095,0.015860653,0.00011131293,0.0003503377,0.00006879252,0.0014828589,0.0000143472325,0.0036929569,0.000004335466,0.0047766436,0.02982352],"study_design_scores_gemma":[0.7985456,0.0024761646,0.19284213,0.0008981619,0.00009211548,0.0000056509984,0.00017236249,0.0005334245,0.00076551945,0.0000310764,0.0034938587,0.0001439089],"about_ca_topic_score_codex":0.020581767,"about_ca_topic_score_gemma":0.0007372589,"teacher_disagreement_score":0.17698148,"about_ca_system_score_codex":0.00030269058,"about_ca_system_score_gemma":0.0015357189,"threshold_uncertainty_score":0.9859403},"labels":[],"label_agreement":null},{"id":"W3096173347","doi":"10.1016/j.lungcan.2020.10.023","title":"Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Immunotherapy; Logistic regression; Odds ratio; Cancer; Cohort; PD-L1","score_opus":0.008505465539782077,"score_gpt":0.2914343701218268,"score_spread":0.2829289045820447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096173347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.952895,0.03705026,0.000012230888,0.008475234,0.00034375006,0.00078730955,0.00012031317,0.00004590226,0.00027004373],"genre_scores_gemma":[0.9834477,0.004998225,0.000051081694,0.010539042,0.00021439523,0.00019606952,0.000018707688,0.00004766594,0.0004871486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861884,0.00010703232,0.00031790492,0.000403399,0.00022788317,0.00032494575],"domain_scores_gemma":[0.99940956,0.00007324973,0.000104174316,0.00018430692,0.00009464847,0.00013405859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015735957,0.00023091922,0.0003584046,0.000089231115,0.00007099648,0.000030790492,0.00009649062,0.00012868487,0.000693212],"category_scores_gemma":[0.000030764553,0.0002029784,0.00009254754,0.0003809584,0.0000828247,0.00013263004,0.000035178506,0.00024368745,0.0000021633807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07423256,0.000120840945,0.8390375,0.00013436397,0.0004421159,0.000037900434,0.0069214003,0.000013188361,0.041768,0.000007005205,0.0061507653,0.031134402],"study_design_scores_gemma":[0.009700057,0.0007024789,0.9748072,0.0005894706,0.000084889005,0.0000031587526,0.00017279881,0.0003130349,0.004425848,0.000002472349,0.0089009125,0.00029768908],"about_ca_topic_score_codex":0.0015547662,"about_ca_topic_score_gemma":0.00025207343,"teacher_disagreement_score":0.13576974,"about_ca_system_score_codex":0.00050986,"about_ca_system_score_gemma":0.00027727798,"threshold_uncertainty_score":0.8277219},"labels":[],"label_agreement":null},{"id":"W3096184146","doi":"10.2147/eb.s277760","title":"&lt;p&gt;Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review&lt;/p&gt;","year":2020,"lang":"en","type":"review","venue":"Eye and Brain","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Scarborough Hospital; University of Toronto; Kensington Health; Queen's University","funders":"","keywords":"Medicine; Neuro-ophthalmology; Myositis; Incidence (geometry); Pediatrics; Ptosis; Dermatology; Surgery; Internal medicine; Ophthalmology","score_opus":0.03053503110037413,"score_gpt":0.32015464546006855,"score_spread":0.2896196143596944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096184146","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013791829,0.9914907,0.000010425213,0.0031237712,0.0001640796,0.0039236452,0.00010702601,0.00005449785,0.0011120507],"genre_scores_gemma":[0.00006440523,0.9968301,0.00007560219,0.0011187318,0.00016770119,0.00041480607,0.00024466263,0.00007018564,0.0010138107],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964949,0.0003171426,0.0020986935,0.0005020704,0.0003382248,0.00024898993],"domain_scores_gemma":[0.99743515,0.00033737908,0.0011471318,0.0008416461,0.000092526774,0.00014617977],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007571633,0.0004959487,0.0038557628,0.00017411677,0.00007439986,0.000024016012,0.00025781651,0.00021588452,0.00011014038],"category_scores_gemma":[0.0005431172,0.00035388579,0.0011639347,0.0006539599,0.0001592613,0.00004689581,0.00010188279,0.00032811137,0.00007224307],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029935829,0.00009644898,7.635885e-7,0.94166446,0.00065444305,0.00003752343,0.00008062345,3.03219e-9,0.0025105448,0.000054314954,0.006890409,0.047980558],"study_design_scores_gemma":[0.00038110805,0.00017223023,0.000014495747,0.42744464,0.0017268421,0.00035400892,0.0000061436367,0.0000017576756,0.000023056822,0.000005126965,0.5696657,0.00020491221],"about_ca_topic_score_codex":0.000009461643,"about_ca_topic_score_gemma":0.0000017497379,"teacher_disagreement_score":0.56277525,"about_ca_system_score_codex":0.000104518054,"about_ca_system_score_gemma":0.0002956985,"threshold_uncertainty_score":0.99989134},"labels":[],"label_agreement":null},{"id":"W3096190465","doi":"10.1158/1538-7445.tumhet2020-po-080","title":"Abstract PO-080: Predicting relapse in patients with triple negative breast cancer (TNBC) using a deep-learning approach","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Cohort; Triple-negative breast cancer; Breast cancer; Medicine; Tumor-infiltrating lymphocytes; Oncology; Internal medicine; Cancer; Artificial intelligence; Machine learning; Computer science; Immunotherapy","score_opus":0.0651865803646133,"score_gpt":0.3564657935200026,"score_spread":0.2912792131553893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096190465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99541235,0.00115051,0.000048892092,0.0010968723,0.000079541394,0.001180879,0.000054525626,0.0000548423,0.00092160853],"genre_scores_gemma":[0.99837154,0.00031062405,0.00027338404,0.00027980452,0.00032667548,0.00020636158,0.000025662632,0.000068089736,0.00013786329],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971827,0.00017843666,0.0003530445,0.00058523274,0.0009847889,0.00071577827],"domain_scores_gemma":[0.99887246,0.000097826174,0.00012652589,0.0002108606,0.00041189813,0.00028042519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006277328,0.00021580982,0.00037774967,0.00023621025,0.00024842215,0.00006205816,0.00018880841,0.00012996695,0.00059572415],"category_scores_gemma":[0.00013816866,0.00017318854,0.00007597025,0.0015108567,0.00024172234,0.00022567064,0.00008528822,0.001332795,0.000005710199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02668566,0.00033397306,0.90883875,0.000562637,0.0003579103,0.000061992076,0.007464498,0.0017473093,0.007660287,0.0000028846216,0.00035482907,0.045929253],"study_design_scores_gemma":[0.013101838,0.0006252369,0.97587496,0.0010436982,0.000047503214,0.000009009182,0.002515417,0.0045884303,0.0013337156,0.000004049717,0.0005550534,0.00030109275],"about_ca_topic_score_codex":0.0076516303,"about_ca_topic_score_gemma":0.00030050505,"teacher_disagreement_score":0.06703619,"about_ca_system_score_codex":0.0010385677,"about_ca_system_score_gemma":0.00075111055,"threshold_uncertainty_score":0.9989565},"labels":[],"label_agreement":null},{"id":"W3096233695","doi":"10.1080/2162402x.2020.1836766","title":"Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers","year":2020,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; ACE inhibitor; Lung cancer; Internal medicine; PD-L1; Angiotensin-converting enzyme; Concomitant; Immune system; Captopril; Nivolumab; Cancer; Oncology; Pharmacology; Immunology; Immunotherapy","score_opus":0.011486278366947988,"score_gpt":0.25254715569708575,"score_spread":0.24106087733013776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096233695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9725544,0.006647589,0.0001345141,0.016785378,0.0015890418,0.001762927,0.000028385064,0.00019455627,0.00030321834],"genre_scores_gemma":[0.9915464,0.00034408915,0.0007326191,0.0053613214,0.00038392414,0.00015320926,0.000057609144,0.00010813568,0.001312697],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970463,0.0002921393,0.00075156504,0.00077825726,0.00032257813,0.00080919673],"domain_scores_gemma":[0.99839014,0.00013830324,0.00035595827,0.00059912656,0.00025315915,0.00026330038],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004956958,0.0004784009,0.0007936202,0.00025725376,0.00020069916,0.0000393545,0.00028867676,0.00041409684,0.00034385105],"category_scores_gemma":[0.0002741483,0.00045871251,0.00037629952,0.000642734,0.0001606039,0.00013145038,0.0002418489,0.00057097396,0.00012890981],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043778382,0.00027282932,0.009080021,0.00016358773,0.00042236113,0.00006667104,0.0048916596,0.00001030904,0.924575,9.561152e-7,0.008668144,0.008070088],"study_design_scores_gemma":[0.016659362,0.0043286826,0.26018345,0.0008712339,0.00037145722,0.000034341712,0.00080659403,0.00068319053,0.6640659,0.0000013507675,0.051236838,0.0007576063],"about_ca_topic_score_codex":0.0008771125,"about_ca_topic_score_gemma":0.000044065244,"teacher_disagreement_score":0.2605091,"about_ca_system_score_codex":0.0007632317,"about_ca_system_score_gemma":0.0005156543,"threshold_uncertainty_score":0.99978644},"labels":[],"label_agreement":null},{"id":"W3096421825","doi":"10.3747/co.27.6251","title":"The Risk of Diarrhea and Colitis in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Calgary; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Diarrhea; Lung cancer; Discontinuation; Colitis; Incidence (geometry); Gastroenterology; Relative risk; Colorectal cancer; Cancer; Confidence interval","score_opus":0.05837424893818345,"score_gpt":0.37785499139635403,"score_spread":0.3194807424581706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096421825","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003795452,0.9933618,0.0000018791152,0.00021346725,0.000039900227,0.0057453737,0.00023646967,0.000009157915,0.0000124241715],"genre_scores_gemma":[0.00033199904,0.99766445,0.0000099487315,0.0000345648,0.00001686526,0.0017901896,0.000095127085,0.00002844967,0.000028403338],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9968018,0.00088822545,0.0014290162,0.00041968186,0.00023891624,0.00022238804],"domain_scores_gemma":[0.9972677,0.00037489104,0.0016971278,0.00040063914,0.00016321396,0.00009640348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071490643,0.00043019015,0.008221082,0.00018153636,0.0000568625,0.000013819166,0.00011043933,0.00013775907,0.000044093384],"category_scores_gemma":[0.00010690615,0.00018055955,0.00080612884,0.0010649257,0.00027074615,0.000028763377,0.000051587776,0.000404806,3.8016682e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056928146,0.00018167937,0.0031800927,0.7722007,0.18114054,0.000009215365,0.000114118135,4.8350874e-8,1.6647427e-8,0.0000015092315,0.000064327534,0.04253847],"study_design_scores_gemma":[0.001668093,0.00075204944,0.0016340329,0.08571006,0.8525119,0.0000151838385,0.000015486712,0.000003693211,3.0921356e-7,2.5336314e-7,0.05749116,0.00019780779],"about_ca_topic_score_codex":0.00034402506,"about_ca_topic_score_gemma":0.0004567194,"teacher_disagreement_score":0.68649065,"about_ca_system_score_codex":0.00036062745,"about_ca_system_score_gemma":0.00039310238,"threshold_uncertainty_score":0.7363005},"labels":[],"label_agreement":null},{"id":"W3096533280","doi":"10.1182/blood-2020-141462","title":"Identification of LAG3+ T Cell Populations in the Tumor Microenvironment of Classical Hodgkin Lymphoma and B-Cell Non-Hodgkin Lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; BC Cancer Agency; University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Cancer research; Lymphoma; Tumor microenvironment; Mantle cell lymphoma; T cell; T-cell lymphoma; CD8; Immune system; Medicine; Biology; Immunology","score_opus":0.017817434885302245,"score_gpt":0.24428899797571577,"score_spread":0.22647156309041352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096533280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99686605,0.0009447576,0.00006268594,0.0014238574,0.000033854896,0.0003706457,0.000026801714,0.0000066234566,0.0002647258],"genre_scores_gemma":[0.9989734,0.00013705864,0.00028877993,0.00044074008,0.000043824453,0.000017926463,0.00001866785,0.000012552881,0.00006701532],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990055,0.000059103848,0.00042370558,0.00019110001,0.00020337965,0.000117195654],"domain_scores_gemma":[0.999487,0.000041313877,0.00018536337,0.00022725752,0.000014987603,0.000044087592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018390878,0.000102636666,0.00021182933,0.000052811527,0.000029120058,0.000008897375,0.00010642499,0.000049533308,0.000024806646],"category_scores_gemma":[0.000014235656,0.00007915621,0.0000788102,0.00019863284,0.00011301257,0.000033455563,0.000027082928,0.000040430157,0.0000045971783],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042665578,0.001687075,0.028722826,0.00018375799,0.000030732495,0.000013427061,0.0015006975,0.0000022673405,0.963736,0.000018400126,0.0003836012,0.003294545],"study_design_scores_gemma":[0.008189077,0.00036660154,0.5463376,0.000044649852,0.00015017121,0.00002108566,0.00057488197,0.0001867062,0.44303918,0.000016498316,0.0009925669,0.00008094825],"about_ca_topic_score_codex":0.000084194406,"about_ca_topic_score_gemma":0.00001782486,"teacher_disagreement_score":0.5206968,"about_ca_system_score_codex":0.000026289137,"about_ca_system_score_gemma":0.000049306826,"threshold_uncertainty_score":0.32278967},"labels":[],"label_agreement":null},{"id":"W3096769611","doi":"10.3389/fonc.2020.570080","title":"Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Meta-analysis; Medicine; Systematic review; Internal medicine; Oncology; Intensive care medicine; MEDLINE; Chemistry","score_opus":0.028047711616409912,"score_gpt":0.35333794561240234,"score_spread":0.32529023399599244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096769611","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000062357016,0.9906818,0.00008473031,0.000045751214,0.000086683984,0.008800613,0.00017916654,0.0000100354055,0.000048842176],"genre_scores_gemma":[0.00060651056,0.9960232,0.0015052285,0.00017778296,0.0000094693005,0.0014821681,0.00011373544,0.000044994762,0.00003695445],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9928171,0.0022277292,0.003702765,0.0005497919,0.00043930556,0.0002633077],"domain_scores_gemma":[0.9945345,0.00041292343,0.0041448376,0.0006364663,0.00017358664,0.000097682576],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0016278471,0.0005694925,0.023474243,0.0010368134,0.000017313438,0.0000068085865,0.00023109296,0.00029682793,0.00004211146],"category_scores_gemma":[0.00040725968,0.00032673287,0.0017870087,0.0021594681,0.00018396974,0.00004682057,0.000060082722,0.00044419293,8.475214e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011396777,0.00032864168,0.0011983654,0.85323656,0.14429805,0.000064299595,0.00013054181,9.534482e-7,6.486109e-8,8.9629145e-7,0.00017260591,0.00045505774],"study_design_scores_gemma":[0.0015011815,0.00073092146,0.00012656869,0.35877386,0.63781077,0.00002548901,0.00011257189,0.000014212989,3.8496424e-7,0.0000017588414,0.0007036327,0.00019862088],"about_ca_topic_score_codex":0.00025182273,"about_ca_topic_score_gemma":0.00011088742,"teacher_disagreement_score":0.4944627,"about_ca_system_score_codex":0.0013175183,"about_ca_system_score_gemma":0.00084807974,"threshold_uncertainty_score":0.99991846},"labels":[],"label_agreement":null},{"id":"W3096950825","doi":"10.1007/s00259-020-05081-6","title":"Physiologic colonic uptake of 18F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors","year":2020,"lang":"en","type":"article","venue":"European Journal of Nuclear Medicine and Molecular Imaging","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Centre hospitalier universitaire de Québec; University of Ottawa; Montreal Heart Institute; Centre Hospitalier de l’Université de Montréal","funders":"Agence Nationale de la Recherche","keywords":"Medicine; Microbiome; Internal medicine; Gastroenterology; Colorectal cancer; Lung cancer; Dysbiosis; Immune system; Gut flora; Oncology; Cancer; Immunology; Bioinformatics; Biology","score_opus":0.009790092667316234,"score_gpt":0.2504472963221077,"score_spread":0.24065720365479149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096950825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946672,0.0010375957,0.0000095655,0.0038722127,0.000026130787,0.0002966235,0.000006092034,0.000009369246,0.00007525704],"genre_scores_gemma":[0.9953691,0.00033514583,0.00027514232,0.0039289156,0.000028170864,6.365893e-7,0.000009926697,0.000049763024,0.0000032387345],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984446,0.00030087182,0.00063061516,0.00023344395,0.00021720963,0.0001732664],"domain_scores_gemma":[0.998888,0.000048396334,0.0006248292,0.00011340847,0.00018694822,0.00013840222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006005996,0.00020352479,0.000559081,0.00014562995,0.000044197997,0.000010491353,0.00007087972,0.000008148851,0.00001418692],"category_scores_gemma":[0.000043273907,0.0001243915,0.00006523628,0.00026717616,0.00026535796,0.000058349586,0.000025016514,0.0003480961,3.0409817e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07690428,0.0003998742,0.066077,0.00013267809,0.0004563336,0.004876888,0.0015322103,0.000022020147,0.8468219,1.338321e-7,0.00043323115,0.0023434465],"study_design_scores_gemma":[0.039651785,0.018432373,0.92465883,0.0056094546,0.00046262727,0.00028478072,0.0007608509,0.00019372882,0.009165527,1.19040315e-7,0.00055953016,0.00022036306],"about_ca_topic_score_codex":0.000014947798,"about_ca_topic_score_gemma":6.650786e-7,"teacher_disagreement_score":0.85858184,"about_ca_system_score_codex":0.00006325763,"about_ca_system_score_gemma":0.000073242,"threshold_uncertainty_score":0.5072538},"labels":[],"label_agreement":null},{"id":"W3097135495","doi":"10.1016/s0959-8049(20)31240-5","title":"CD8+ T tumour-infiltrating lymphocytes lacking CD5 cell surface expression exhibited increased levels of activation and exhaustion","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"CD5; CD8; T cell; Cytotoxic T cell; Cancer research; Cell; Biology; Receptor; Molecular biology; Flow cytometry; Immunology; Immune system; In vitro; Biochemistry","score_opus":0.03549726996102447,"score_gpt":0.2753930583163978,"score_spread":0.23989578835537334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097135495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936089,0.002462387,0.0016990218,0.001024528,0.00007533683,0.00009908461,0.000010120426,0.000012562854,0.0010080903],"genre_scores_gemma":[0.9971998,0.0005044934,0.0014230709,0.0004786712,0.00031986937,2.6938537e-7,0.0000022540596,0.000025880037,0.000045719436],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988504,0.00017395304,0.0004724434,0.0001165307,0.0002787265,0.000107924156],"domain_scores_gemma":[0.9989022,0.00007459148,0.0006327264,0.00006792068,0.000207787,0.000114777366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046556257,0.00011419741,0.0002414626,0.000056211178,0.000056483357,0.000020855967,0.00006538877,0.00002302737,0.00017745199],"category_scores_gemma":[0.00011375466,0.00009101851,0.000077613106,0.00016893947,0.000044983368,0.00018510366,0.000020422738,0.00014999362,0.0000011700652],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00228738,0.000024384726,0.006930029,0.00014674696,0.00004178731,0.000026017316,0.0010551852,0.00023831865,0.9788567,4.741558e-7,0.0005582396,0.009834748],"study_design_scores_gemma":[0.004304385,0.0003876794,0.06632558,0.0013575808,0.00006269033,0.000027990956,0.00042706472,0.00028487874,0.9253182,9.248692e-7,0.001410064,0.00009298837],"about_ca_topic_score_codex":0.000023872053,"about_ca_topic_score_gemma":8.733868e-7,"teacher_disagreement_score":0.059395555,"about_ca_system_score_codex":0.000077714154,"about_ca_system_score_gemma":0.00014662853,"threshold_uncertainty_score":0.3711627},"labels":[],"label_agreement":null},{"id":"W3097212981","doi":"10.1038/s41467-020-19408-2","title":"Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer","year":2020,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec","funders":"Genentech; University of Leeds","keywords":"Cytotoxic T cell; Ovarian cancer; Cancer research; Immunotherapy; Biology; Cancer immunotherapy; Tumor microenvironment; Stroma; Transcriptome; T cell; Cell; Immune system; Cancer; Immunology; In vitro; Immunohistochemistry; Gene expression","score_opus":0.013883743510148708,"score_gpt":0.2916653426299481,"score_spread":0.2777815991197994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097212981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95338404,0.035849493,0.00018016805,0.009823263,0.00004320763,0.0001966539,0.000106192856,0.000019830735,0.0003971565],"genre_scores_gemma":[0.99203986,0.00640969,0.00047946488,0.00083274464,0.000006802961,0.000016711421,0.00019079741,0.000008427383,0.000015513722],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99936384,0.00006266221,0.00024386741,0.00013958281,0.00010727788,0.00008278708],"domain_scores_gemma":[0.99928874,0.000057181365,0.00007264385,0.00044451145,0.00008321011,0.000053703137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008875501,0.00008476729,0.0002528959,0.00016785473,0.000036349153,0.000012538381,0.00022593979,0.00017446959,0.000054477932],"category_scores_gemma":[0.000057718677,0.000073292475,0.000102742044,0.0011938781,0.00016360535,0.0000635339,0.000071139024,0.0004250584,6.8852364e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038776538,0.00016908179,0.046813723,0.00005252776,0.0004083092,0.000016998594,0.0030842042,0.0000048167212,0.9456775,0.00013851606,0.00026546777,0.0029810793],"study_design_scores_gemma":[0.015506736,0.00069868664,0.69950914,0.00051423564,0.0042396006,0.000046302575,0.007059752,0.0063330987,0.20956554,0.0003400096,0.055174083,0.0010128332],"about_ca_topic_score_codex":0.00014683111,"about_ca_topic_score_gemma":0.00054968585,"teacher_disagreement_score":0.736112,"about_ca_system_score_codex":0.000032307802,"about_ca_system_score_gemma":0.0000687701,"threshold_uncertainty_score":0.29887804},"labels":[],"label_agreement":null},{"id":"W3097344277","doi":"10.1177/1533033820969446","title":"High Expression of Pd-1 in Circulating Cells of Patients With Advanced Colorectal Cancer Receiving Adjuvant Therapy","year":2020,"lang":"en","type":"article","venue":"Technology in Cancer Research & Treatment","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"King Abdulaziz City for Science and Technology","keywords":"Colorectal cancer; Immune system; Medicine; Mouse model of colorectal and intestinal cancer; Cancer; Adjuvant therapy; Adjuvant; Cancer research; Immunology; Tumor microenvironment; Oncology; Internal medicine","score_opus":0.043509523704362216,"score_gpt":0.36243533304750863,"score_spread":0.3189258093431464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097344277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99123985,0.005172243,0.0000023881007,0.0019992935,0.00004265196,0.0014300821,0.00004843646,0.00003514787,0.000029925197],"genre_scores_gemma":[0.99146545,0.007371961,0.0004242068,0.000034248307,0.000016434753,0.0006379488,0.00001110035,0.000027784896,0.000010871934],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982531,0.00008612243,0.00041800726,0.0003983823,0.00043302454,0.00041137842],"domain_scores_gemma":[0.9992466,0.00009540308,0.00016638654,0.00024531322,0.00018720949,0.00005907684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017892622,0.00018045017,0.00055610685,0.00046246327,0.000039120336,0.0000030019041,0.0001549921,0.00016479053,0.00017486405],"category_scores_gemma":[0.00003128884,0.00012716909,0.000052521118,0.001354523,0.00034097128,0.00005593288,0.000053828586,0.00032134337,6.8996053e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008784183,0.0005135478,0.40093306,0.00006990892,0.000081518585,0.000023553479,0.0008894761,0.00017180423,0.47560298,0.000005578661,0.000010761577,0.1129136],"study_design_scores_gemma":[0.010893033,0.0041113645,0.24638899,0.00084240467,0.000009808982,5.401036e-7,0.00043550602,0.000032485004,0.73703015,0.000026667894,0.00013542916,0.00009362822],"about_ca_topic_score_codex":0.0048431237,"about_ca_topic_score_gemma":0.0012671786,"teacher_disagreement_score":0.26142716,"about_ca_system_score_codex":0.0010302205,"about_ca_system_score_gemma":0.00050345826,"threshold_uncertainty_score":0.7321387},"labels":[],"label_agreement":null},{"id":"W3097717312","doi":"10.1111/apt.16142","title":"The significance of histological activity measurements in immune checkpoint inhibitor colitis","year":2020,"lang":"en","type":"article","venue":"Alimentary Pharmacology & Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Colitis; Microscopic colitis; Medicine; Internal medicine; Gastroenterology; Odds ratio; Colectomy; Adverse effect; Ulcerative colitis; Biopsy; Ischemic colitis; Collagenous colitis; Colorectal cancer; Inflammatory bowel disease; Cancer; Disease","score_opus":0.08620234354203679,"score_gpt":0.3363254510010588,"score_spread":0.250123107459022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097717312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96225345,0.005128487,0.000014889864,0.030813659,0.0005761045,0.00091554626,0.000014567413,0.000030916894,0.00025236575],"genre_scores_gemma":[0.9823544,0.0014882651,0.000076782686,0.015801096,0.00012820814,0.00007700813,0.00000751708,0.000017580895,0.000049122722],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984378,0.0002617674,0.00046137054,0.00025871032,0.0002603152,0.0003200363],"domain_scores_gemma":[0.9993544,0.00014530862,0.00019756827,0.00016196963,0.000056830788,0.000083928346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040043786,0.00017988225,0.00035685758,0.000035409234,0.000097682045,0.0000058745727,0.00019624646,0.00009591359,0.00029766804],"category_scores_gemma":[9.410093e-7,0.0001328478,0.0001509879,0.00024554427,0.0004281857,0.000050786184,0.000054094387,0.00031366578,0.00000766153],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013114881,0.00043625393,0.010296366,0.00003695304,0.0028393911,0.000018973455,0.00044016546,0.0000033949793,0.9658812,0.0000033872916,0.00027163263,0.006657372],"study_design_scores_gemma":[0.0058872662,0.0011477515,0.062961355,0.00002275379,0.0012520466,0.000012917895,0.00018175451,0.00014946821,0.91049576,0.0000161492,0.017727122,0.0001456309],"about_ca_topic_score_codex":0.00015909945,"about_ca_topic_score_gemma":0.000024700594,"teacher_disagreement_score":0.055385448,"about_ca_system_score_codex":0.0002604734,"about_ca_system_score_gemma":0.00015553588,"threshold_uncertainty_score":0.5417376},"labels":[],"label_agreement":null},{"id":"W3098433453","doi":"10.1136/bcr-2020-235886","title":"Durvalumab-associated vasculitis presenting as ‘the blue toe syndrome’","year":2020,"lang":"en","type":"article","venue":"BMJ Case Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bentley (Canada)","funders":"","keywords":"Durvalumab; Medicine; Vasculitis; Pneumonitis; Nivolumab; Dermatology; Pathology; Cancer; Internal medicine; Lung; Immunotherapy; Disease","score_opus":0.030690871550534835,"score_gpt":0.30817786901098304,"score_spread":0.2774869974604482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3098433453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869564,0.0006168776,0.000010409907,0.0076445634,0.00032814546,0.00093919627,0.000004321313,0.00014775124,0.0033523003],"genre_scores_gemma":[0.99515474,0.00004738154,0.000035716603,0.0023690332,0.00021959968,0.00006313154,0.000027352136,0.000032195625,0.0020508415],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9982575,0.00008781509,0.00057335565,0.0003548468,0.0004348028,0.00029167754],"domain_scores_gemma":[0.9988727,0.00007691564,0.00031637453,0.0004602229,0.00009999584,0.00017381768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006311443,0.00016005315,0.0003194679,0.000030741845,0.00018464401,0.00004583596,0.00003986971,0.000098789234,0.0007326632],"category_scores_gemma":[0.0008132174,0.00011843186,0.00028630797,0.00034066365,0.00007536457,0.000067439694,0.000058185404,0.00019866342,0.000046708905],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016758018,0.00007316131,0.004132685,0.000085698164,0.00059874204,0.9766715,0.0012776215,0.0000044548,0.0014416439,0.0000044709795,0.010119572,0.0054228567],"study_design_scores_gemma":[0.0011307258,0.00022713542,0.012353779,0.00013747884,0.0002443784,0.932718,0.00058812276,0.00012872633,0.0015873916,0.000023871718,0.050666593,0.00019379066],"about_ca_topic_score_codex":0.0012936377,"about_ca_topic_score_gemma":0.000058725484,"teacher_disagreement_score":0.043953504,"about_ca_system_score_codex":0.000096180636,"about_ca_system_score_gemma":0.00024703584,"threshold_uncertainty_score":0.8022148},"labels":[],"label_agreement":null},{"id":"W3100080748","doi":"10.1158/1078-0432.ccr-20-3305","title":"Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Bristol-Myers Squibb; AstraZeneca; York University; Syndax Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Genentech; Parker Institute for Cancer Immunotherapy; Damon Runyon Cancer Research Foundation; Roswell Park Cancer Institute","keywords":"Pembrolizumab; Medicine; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.18471186659029343,"score_gpt":0.4600124273515743,"score_spread":0.2753005607612809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3100080748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908598,0.002082131,0.000012647372,0.0039320583,0.00004616072,0.0023946445,0.000028644996,0.00005297596,0.00059090566],"genre_scores_gemma":[0.9940203,0.0030690543,0.000111213376,0.0020382912,0.00013981498,0.00021810703,0.000054069944,0.00006563696,0.00028355658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99620265,0.00053900084,0.00066326436,0.00071441557,0.0011402224,0.0007404676],"domain_scores_gemma":[0.99809885,0.00042611128,0.0001270251,0.0004430478,0.0004891442,0.0004157921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010383175,0.00024976896,0.0007571877,0.00016092008,0.00009764968,0.000056151566,0.0002646439,0.000104594095,0.00074247713],"category_scores_gemma":[0.00019232719,0.00015215688,0.00013494858,0.0013381597,0.0006004386,0.00012080848,0.000059079022,0.00095621403,0.00003274246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13904816,0.00074494735,0.8017967,0.00015240285,0.00049000693,0.00014848738,0.00054533477,0.000008987016,0.0001222495,0.0000043378795,0.0022849126,0.054653484],"study_design_scores_gemma":[0.06528573,0.012701097,0.9057915,0.00055980944,0.0000706888,0.0000041162198,0.00017253442,0.0001041215,0.0005225693,0.000005111255,0.0145103885,0.0002723007],"about_ca_topic_score_codex":0.0010547055,"about_ca_topic_score_gemma":0.0002403482,"teacher_disagreement_score":0.10399484,"about_ca_system_score_codex":0.00029286384,"about_ca_system_score_gemma":0.0012206185,"threshold_uncertainty_score":0.8129604},"labels":[],"label_agreement":null},{"id":"W3101543312","doi":"10.1136/jitc-2020-sitc2020.0727","title":"727 Increased serum levels of EBI3 are associated with poor outcome in hepatocellular carcinoma patients and SRF388, a first-in-class IL-27 blocking antibody, inhibits the growth of murine liver tumors","year":2020,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"TIGIT; Cancer research; Antibody; Cytokine; Hepatocellular carcinoma; Proinflammatory cytokine; Tumor microenvironment; Immune system; Biology; Medicine; Molecular biology; Immunology; T cell; Inflammation","score_opus":0.022493175923070513,"score_gpt":0.2240064407249474,"score_spread":0.2015132648018769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101543312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99629503,0.0006061092,8.759733e-7,0.0021789493,0.000042089447,0.0006675317,0.00015698379,0.000020397247,0.000032037082],"genre_scores_gemma":[0.99907756,0.00005413226,0.0000428385,0.0007052981,0.000026353986,0.0000074976674,0.000029384684,0.00003607431,0.00002087118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980083,0.000105310326,0.0007361396,0.00037727298,0.00044559705,0.00032735764],"domain_scores_gemma":[0.99876684,0.00010392648,0.0004898884,0.00018916595,0.00015749456,0.000292661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044900278,0.0002957058,0.0007089576,0.00015348916,0.0000619027,0.000020773026,0.00011687446,0.00015235404,0.000008611059],"category_scores_gemma":[0.00053659506,0.00021490465,0.0000880442,0.0004963267,0.000389228,0.00012539599,0.000069573674,0.00029087428,4.4078882e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005361879,0.00015187252,0.9765156,0.0006507864,0.00011677099,0.00018406229,0.001219132,0.0000048633865,0.020513847,0.000009457616,0.00003624752,0.00006118421],"study_design_scores_gemma":[0.0053931456,0.0004242416,0.92970914,0.0012444862,0.000106276726,0.000027994905,0.00024819453,0.0006548507,0.06192373,0.000015019199,0.00003358583,0.0002193599],"about_ca_topic_score_codex":0.0018474652,"about_ca_topic_score_gemma":0.00045156924,"teacher_disagreement_score":0.046806473,"about_ca_system_score_codex":0.000098051576,"about_ca_system_score_gemma":0.00019904009,"threshold_uncertainty_score":0.87635577},"labels":[],"label_agreement":null},{"id":"W3101654075","doi":"10.1136/jitc-2020-001583","title":"Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee","year":2020,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Society for Immunotherapy of Cancer","keywords":"Medicine; Immunotherapy; Subspecialty; Clinical trial; Medical physics; Cancer immunotherapy; Cancer; Oncology; Intensive care medicine; Internal medicine; Pathology","score_opus":0.37732158310077407,"score_gpt":0.5774039456333534,"score_spread":0.20008236253257933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101654075","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000424419,0.9716055,0.0006135591,0.0076766587,0.0047118478,0.011326326,0.0036073176,0.000019444893,0.000014939775],"genre_scores_gemma":[0.000029649415,0.9847746,0.0055607385,0.0014921533,0.001849465,0.005445841,0.00024317623,0.00026264615,0.00034171177],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9876241,0.0014777177,0.008608534,0.00074872246,0.00073702104,0.0008039089],"domain_scores_gemma":[0.95462924,0.025574872,0.017900597,0.00070317637,0.0010532648,0.00013882208],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.018480966,0.0009414126,0.008359731,0.00023585004,0.000354622,0.000098580174,0.0007861464,0.0009172813,0.00036739325],"category_scores_gemma":[0.0018241759,0.0006116711,0.00844515,0.00048499167,0.00052236393,0.00013488572,0.000050740637,0.0012112476,8.6896074e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03468467,0.0007405344,0.00023872765,0.0065129385,0.024503604,0.000003650029,0.0011116226,0.0000040580035,0.001171232,0.000015363321,0.04050584,0.89050776],"study_design_scores_gemma":[0.018672394,0.003041146,0.0000463321,0.019227985,0.005062455,0.000028956993,0.0010018573,0.00002616828,0.0004995551,0.00009891233,0.9517248,0.00056939875],"about_ca_topic_score_codex":0.0033342005,"about_ca_topic_score_gemma":0.0009841769,"teacher_disagreement_score":0.911219,"about_ca_system_score_codex":0.001584474,"about_ca_system_score_gemma":0.010092995,"threshold_uncertainty_score":0.9996335},"labels":[],"label_agreement":null},{"id":"W3102097728","doi":"10.1186/s13046-020-01818-1","title":"PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells","year":2021,"lang":"en","type":"article","venue":"Journal of Experimental & Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cancer research; Protein tyrosine phosphatase; Cell growth; MAPK/ERK pathway; Cancer cell; Western blot; Apoptosis; Chemistry; Cancer; Biology; Molecular biology; Medicine; Cell biology; Signal transduction; Internal medicine; Biochemistry","score_opus":0.12417913315407668,"score_gpt":0.4907928248261419,"score_spread":0.3666136916720652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3102097728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.946144,0.05026355,0.000009338515,0.0021816082,0.00069659087,0.00032909363,0.000028804097,0.000013052608,0.00033394762],"genre_scores_gemma":[0.98659164,0.009263095,0.00037695328,0.0016155407,0.0017660919,0.00005336003,0.000008314816,0.00006346843,0.00026152763],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9944329,0.0008056294,0.0018952911,0.0005610102,0.0015061925,0.00079892215],"domain_scores_gemma":[0.99714035,0.00071492075,0.00045887154,0.00025321913,0.0008350931,0.0005975426],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003906982,0.0002695841,0.0008772567,0.00031487836,0.00017807064,0.00011613294,0.0003705362,0.00020595695,0.0016476905],"category_scores_gemma":[0.00033367134,0.00022988702,0.00043002787,0.00091522554,0.00040998645,0.00034154122,0.00017848145,0.0022476306,0.000009358272],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007101161,0.0016310066,0.015474661,0.000065311004,0.00022200818,0.0010979393,0.0005951666,0.000011849692,0.9624169,0.000008307476,0.00556157,0.005814119],"study_design_scores_gemma":[0.00799582,0.0027367282,0.0031045126,0.0011858942,0.00003691953,0.0001548272,0.0031804736,0.00008049062,0.9787442,0.000036929287,0.002489753,0.00025346427],"about_ca_topic_score_codex":0.0018202696,"about_ca_topic_score_gemma":0.0003224347,"teacher_disagreement_score":0.041000456,"about_ca_system_score_codex":0.0012258161,"about_ca_system_score_gemma":0.0020562417,"threshold_uncertainty_score":0.99926496},"labels":[],"label_agreement":null},{"id":"W3102332210","doi":"10.3389/fimmu.2020.584423","title":"Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy","year":2020,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Cancer Council Western Australia; National Health and Medical Research Council; Raine Medical Research Foundation; Department of Health, Government of Western Australia; University of Western Australia; New South Wales Workers' Compensation Dust Disease Board; Medical Research Council","keywords":"Cytotoxic T cell; CTL*; Antigen; Immunology; Immune system; Tumor antigen; Biology; Granzyme B; CD8; Interleukin-7 receptor; Cancer research; Immunotherapy; IL-2 receptor; T cell; In vitro","score_opus":0.014183038890549478,"score_gpt":0.24110065563878763,"score_spread":0.22691761674823815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3102332210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9618719,0.027053429,0.0014779199,0.004986201,0.0026627602,0.0014192677,0.000024193936,0.0001721915,0.00033213527],"genre_scores_gemma":[0.9836171,0.0044053895,0.007534293,0.0035036374,0.00035091562,0.00015972593,0.000034185712,0.000100501995,0.00029422416],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972346,0.00045935175,0.000803332,0.0006111224,0.0002480629,0.00064354314],"domain_scores_gemma":[0.9988333,0.00014844723,0.00018816962,0.0006007735,0.00006840289,0.00016091441],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008280163,0.0003684264,0.0008415907,0.0003744827,0.00010951048,0.000031717074,0.00037240228,0.00021768548,0.00035827857],"category_scores_gemma":[0.00018322816,0.00034087992,0.00026749095,0.0008167809,0.000280839,0.000100376026,0.00009109885,0.0005905911,0.00008873378],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060294993,0.00013188033,0.0046219365,0.000029791141,0.00032296122,0.00017734035,0.0026929383,0.000011955224,0.89830047,0.0000014411464,0.008937573,0.024476709],"study_design_scores_gemma":[0.010434125,0.00371724,0.16861482,0.00019710943,0.000013686973,0.00007558451,0.0016759393,0.000114213355,0.60525185,0.000009858814,0.20944947,0.000446137],"about_ca_topic_score_codex":0.00008612028,"about_ca_topic_score_gemma":0.000002434596,"teacher_disagreement_score":0.29304865,"about_ca_system_score_codex":0.00029589154,"about_ca_system_score_gemma":0.00023843943,"threshold_uncertainty_score":0.99990433},"labels":[],"label_agreement":null},{"id":"W3103244011","doi":"10.1136/jitc-2020-sitc2020.0351","title":"351 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009","year":2020,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Lenvatinib; Pembrolizumab; Medicine; Oncology; Immunotherapy; Head and neck squamous-cell carcinoma; Chemotherapy; Internal medicine; Head and neck cancer; Head and neck; Radiation therapy; Surgery; Cancer","score_opus":0.04785480680630224,"score_gpt":0.2749732537829019,"score_spread":0.22711844697659964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103244011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9650548,0.02307801,0.000033119682,0.008710152,0.00017637732,0.0025837068,0.000094045456,0.00013760194,0.00013215822],"genre_scores_gemma":[0.9835534,0.005736013,0.002357332,0.0074879387,0.00024487122,0.00017648509,0.00008322606,0.0001688876,0.00019186408],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99700844,0.000112516835,0.00071547227,0.0010408906,0.00046447944,0.0006581715],"domain_scores_gemma":[0.998082,0.00023221054,0.0004285347,0.00042341516,0.0000914569,0.0007424142],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040814708,0.0007644002,0.0010332785,0.0001602929,0.00035936054,0.00025567983,0.00015009876,0.00027563405,0.000026602045],"category_scores_gemma":[0.00008447516,0.0006462506,0.0001752442,0.0002236778,0.00068954786,0.00026652563,0.000033196524,0.0004218906,0.0000016597029],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15464878,0.0014390302,0.12687863,0.0053668944,0.0015793189,0.00021869189,0.036529865,0.000022145081,0.3291618,0.00046752716,0.009133747,0.33455357],"study_design_scores_gemma":[0.13827372,0.026969176,0.5641825,0.0010319623,0.0003397747,0.00066279044,0.0017778515,0.0031386751,0.18517195,0.0008580867,0.0750327,0.0025608107],"about_ca_topic_score_codex":0.00013502852,"about_ca_topic_score_gemma":0.000017337221,"teacher_disagreement_score":0.43730387,"about_ca_system_score_codex":0.000081053506,"about_ca_system_score_gemma":0.00034438042,"threshold_uncertainty_score":0.99959886},"labels":[],"label_agreement":null},{"id":"W3103439105","doi":"10.1016/j.cjco.2020.11.004","title":"Plasma Exchange for Immune Checkpoint Inhibitor–Induced Myocarditis","year":2020,"lang":"en","type":"article","venue":"CJC Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Pembrolizumab; Fulminant; Cardiogenic shock; Myocarditis; Medicine; Therapeutic plasma exchange; Immunosuppression; Adverse effect; Refractory (planetary science); Nivolumab; Internal medicine; Immune system; Immunology; Immunotherapy; Myocardial infarction","score_opus":0.05570859914673051,"score_gpt":0.3122756255199002,"score_spread":0.2565670263731697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103439105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9181093,0.0020100183,0.00021205639,0.039359983,0.0013191397,0.0050033107,0.00013248301,0.00015577525,0.033697914],"genre_scores_gemma":[0.9910521,0.00016183182,0.00085097924,0.004874882,0.0009241204,0.00031070434,0.00009748698,0.000048524278,0.0016794029],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990794,0.00001990658,0.00026794526,0.00027724242,0.00013403932,0.00022143892],"domain_scores_gemma":[0.9994506,0.000033022676,0.00007848216,0.00024605243,0.000056080386,0.00013572609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002141456,0.0001378059,0.00041110968,0.000027529619,0.000083274834,0.00006801757,0.00023807773,0.0000869642,0.0006795858],"category_scores_gemma":[0.00007217793,0.00012028299,0.00019092616,0.00015975398,0.000033543714,0.00012087729,0.0001506549,0.00010630745,0.00008354303],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008479678,0.00011123315,0.00019493388,0.00031744875,0.00051033887,0.0000555906,0.0019975344,3.058936e-7,0.7159021,0.00005555853,0.0700522,0.20232306],"study_design_scores_gemma":[0.014225983,0.0016203241,0.006546817,0.0001932734,0.000098870354,0.000043432075,0.0004205008,0.00015762991,0.36093983,0.000028359698,0.6154527,0.00027228476],"about_ca_topic_score_codex":0.00016707908,"about_ca_topic_score_gemma":0.0000109484945,"teacher_disagreement_score":0.5454005,"about_ca_system_score_codex":0.00007075374,"about_ca_system_score_gemma":0.00011649788,"threshold_uncertainty_score":0.7440988},"labels":[],"label_agreement":null},{"id":"W3104385858","doi":"10.1186/s12967-020-02612-5","title":"Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors","year":2020,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; York University","keywords":"Medicine; Adverse effect; Confounding; Internal medicine; Oncology; Cancer; Ipilimumab; Proportional hazards model; Melanoma; Immune system; Immune checkpoint; Toxicity; Immunotherapy; Immunology; Cancer research","score_opus":0.014190689389148158,"score_gpt":0.27326873858166834,"score_spread":0.2590780491925202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3104385858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8813252,0.0015305032,0.000043917644,0.116815366,0.000038502367,0.00020010478,0.0000087806475,0.0000041400144,0.00003348667],"genre_scores_gemma":[0.9976292,0.00020409244,0.00014903503,0.0012800086,0.000697422,0.000003468855,0.000010029533,0.000011209816,0.000015496926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998436,0.00013218915,0.0006774171,0.000103634215,0.00053196313,0.00011880518],"domain_scores_gemma":[0.9988075,0.00038122945,0.00048092313,0.00004677546,0.00020427516,0.00007928213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009588021,0.0001116526,0.00036293754,0.00009660986,0.000046746787,0.0000065612176,0.000048700535,0.00005697955,0.0000507139],"category_scores_gemma":[0.00023684719,0.00006145723,0.00006822029,0.0003211976,0.00006194017,0.00011628241,0.0000040857326,0.0003066146,2.9126986e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019452997,0.000031020627,0.9200338,0.000048051228,0.00025775903,0.000013796113,0.0018433217,0.00001745171,0.026422113,6.419135e-7,0.000054732747,0.03182432],"study_design_scores_gemma":[0.011376102,0.0012727021,0.9809115,0.0010010485,0.00018276366,0.000010866692,0.00010736971,0.000042762236,0.0036438764,0.000007259783,0.0013775533,0.000066221466],"about_ca_topic_score_codex":0.00003627528,"about_ca_topic_score_gemma":0.0000062239287,"teacher_disagreement_score":0.11630404,"about_ca_system_score_codex":0.00015309089,"about_ca_system_score_gemma":0.000091446615,"threshold_uncertainty_score":0.2506153},"labels":[],"label_agreement":null},{"id":"W3104499934","doi":"10.1136/jitc-2020-sitc2020.0498","title":"498 Downregulation of CD5 in CD8+ T tumour-infiltrating lymphocytes associates with increased level of activation and exhaustion","year":2020,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"CD5; CD8; T cell; Molecular biology; T-cell receptor; CD28; Biology; Cytotoxic T cell; Cancer research; Flow cytometry; Chemistry; Immunology; Antigen; Immune system; In vitro; Biochemistry","score_opus":0.04433985947392986,"score_gpt":0.2528445104636845,"score_spread":0.20850465098975463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3104499934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998241,0.00027333613,0.000060943115,0.0010197955,0.000012609362,0.00025640184,0.000019690575,0.000019030216,0.000097192235],"genre_scores_gemma":[0.9983969,0.00006168819,0.0012326471,0.00018063601,0.000043332257,0.0000056827193,0.000051430558,0.000014670273,0.000013068972],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989964,0.000039765164,0.00039075656,0.00020096064,0.00024342291,0.00012871948],"domain_scores_gemma":[0.99929273,0.00006431941,0.00031367055,0.00008502967,0.00008973805,0.00015450858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000282181,0.00013887632,0.0003145728,0.00008760088,0.000038020473,0.000015956199,0.000030262558,0.00010612028,0.000005194827],"category_scores_gemma":[0.000296178,0.00011810594,0.00003511037,0.00023198267,0.00019492955,0.00018952221,0.0000112006,0.00008948093,2.0053311e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075443235,0.000035836318,0.17585179,0.00034110085,0.0000663261,0.000003957398,0.0008620227,0.000062216466,0.8209138,0.000047780875,0.00005579758,0.0010049685],"study_design_scores_gemma":[0.0018363324,0.00017999139,0.59258413,0.00044085542,0.000042940686,0.0000162083,0.00028829442,0.0004933266,0.40397638,0.00004076552,0.00002171649,0.00007903606],"about_ca_topic_score_codex":0.00081824383,"about_ca_topic_score_gemma":0.00004356601,"teacher_disagreement_score":0.41693738,"about_ca_system_score_codex":0.00006576618,"about_ca_system_score_gemma":0.0002463338,"threshold_uncertainty_score":0.48162204},"labels":[],"label_agreement":null},{"id":"W3105826467","doi":"10.1136/jitc-2020-sitc2020.0075","title":"75 Generalizability of potential biomarkers of response to CTLA-4 and PD-1 blockade therapy in cancer","year":2020,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Generalizability theory; Blockade; CTLA-4; Cancer; Cancer therapy; Medicine; Oncology; Internal medicine; Immunology; Immune system; Mathematics; T cell; Receptor; Statistics","score_opus":0.02573454979681641,"score_gpt":0.2777691241262219,"score_spread":0.2520345743294055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3105826467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985819,0.0038948723,0.0000072317557,0.009625307,0.00010161364,0.00045678936,0.00004618939,0.000018347422,0.000030695424],"genre_scores_gemma":[0.99700516,0.0009549151,0.0005616233,0.0013447852,0.000060494167,0.000015219768,0.0000057821508,0.00002073901,0.00003128562],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99854994,0.00012088731,0.00050887774,0.00034254225,0.00026436584,0.00021337571],"domain_scores_gemma":[0.9990795,0.000040254377,0.00014612656,0.00021463321,0.0000763081,0.00044315212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005740383,0.00018439634,0.00043863372,0.00012017149,0.000031257117,0.000012568913,0.00007758241,0.00013064242,0.000028571698],"category_scores_gemma":[0.00022457103,0.00015974161,0.000090161884,0.00032971427,0.0004009737,0.00006409256,0.000033838107,0.00011027398,4.2252438e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009455079,0.000072165436,0.07719027,0.00019637014,0.00016504111,0.000023951876,0.0013799904,0.000038015736,0.9075911,0.000003882917,0.0006655342,0.003218595],"study_design_scores_gemma":[0.0027424642,0.0005779046,0.60280365,0.0001516138,0.00003925309,0.000023096136,0.00013044634,0.00008593677,0.39133698,0.000031477317,0.0019414086,0.00013573669],"about_ca_topic_score_codex":0.001561173,"about_ca_topic_score_gemma":0.00003095337,"teacher_disagreement_score":0.5256134,"about_ca_system_score_codex":0.000046128655,"about_ca_system_score_gemma":0.00028782964,"threshold_uncertainty_score":0.6514074},"labels":[],"label_agreement":null},{"id":"W3106755160","doi":"10.3390/cancers12123529","title":"Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer","year":2020,"lang":"en","type":"review","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity; University of Ottawa","funders":"Canadian Institutes of Health Research; Cancer Research Society; University of Ottawa","keywords":"Triple-negative breast cancer; Immunotherapy; Medicine; Immunogenicity; Breast cancer; Cancer immunotherapy; Cancer; Oncology; Targeted therapy; Immune system; Immunology; Cancer research; Internal medicine","score_opus":0.07208635046271518,"score_gpt":0.37602494184632934,"score_spread":0.3039385913836142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106755160","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000040102612,0.9969146,6.8894354e-7,0.0005566782,0.00047388353,0.0015552022,0.00030854432,0.000024886785,0.00012538084],"genre_scores_gemma":[0.00008982897,0.9989285,0.000029152096,0.00005178799,0.00023682225,0.0005655613,0.000016137217,0.000061010032,0.000021219537],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99834436,0.00009599599,0.00061210035,0.00046857054,0.00021993424,0.0002590349],"domain_scores_gemma":[0.99905026,0.00008990588,0.00044418103,0.0002494017,0.0000689448,0.0000973311],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001358842,0.00041086515,0.0020044588,0.00022750511,0.000023292416,0.000010178178,0.000145606,0.00018290617,0.00014552142],"category_scores_gemma":[0.000017030636,0.00031058915,0.00032674434,0.0005021496,0.0002768085,0.000052722673,0.00003143907,0.0003908802,0.0000015904078],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078805955,0.000027904014,0.00005468313,0.029790392,0.00058409973,0.000012292895,0.0005019681,8.000939e-8,0.0000036552472,0.000014463629,0.00017285038,0.9680495],"study_design_scores_gemma":[0.0022758248,0.00019647714,0.0007017399,0.059669856,0.00034441534,0.000053694548,0.00012678556,0.000001963245,0.000015728696,0.000007999381,0.9363211,0.0002844468],"about_ca_topic_score_codex":0.0007526243,"about_ca_topic_score_gemma":0.0002508316,"teacher_disagreement_score":0.9677651,"about_ca_system_score_codex":0.0014958739,"about_ca_system_score_gemma":0.0028625464,"threshold_uncertainty_score":0.9999346},"labels":[],"label_agreement":null},{"id":"W3107430348","doi":"10.2147/ott.s281397","title":"&lt;p&gt;The Immunostimulative Effect and Mechanisms of a Novel Mouse Anti-Human PD-1 Monoclonal Antibody on Jurkat Lymphocytic Cells Cocultured with Hepatoma Cells&lt;/p&gt;","year":2020,"lang":"en","type":"article","venue":"OncoTargets and Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kane Biotech (Canada)","funders":"","keywords":"Jurkat cells; Monoclonal antibody; Cancer research; Molecular biology; Cell culture; Antibody; Chemistry; Immunology; Cell biology; Medicine; Biology; T cell; Immune system; Genetics","score_opus":0.012559176557217866,"score_gpt":0.2609022516389771,"score_spread":0.24834307508175926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107430348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928577,0.004505827,0.00038518975,0.0006473548,0.00010848621,0.0010990398,0.000088623434,0.000055744124,0.000252046],"genre_scores_gemma":[0.9946885,0.0029389653,0.0004209629,0.0015242848,0.00009617706,0.000022646169,0.000047499037,0.000061964325,0.0001989619],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983068,0.00009811781,0.00035956,0.0004987024,0.0003997684,0.00033705184],"domain_scores_gemma":[0.99902713,0.00016068073,0.00023337925,0.00030851387,0.0000965223,0.00017377503],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025382865,0.00044234982,0.0007487608,0.00007052728,0.000259075,0.000053796135,0.00014527363,0.00014850797,0.00007204935],"category_scores_gemma":[0.0000070772207,0.00025000953,0.00016089469,0.00024011696,0.000315128,0.00008378183,0.00003819512,0.00018615832,0.000003423039],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010449513,0.00028206376,0.000417493,0.00010019502,0.00069549837,0.000034232653,0.0016017946,0.000027062038,0.98397493,0.00045826496,0.00020307442,0.0017558696],"study_design_scores_gemma":[0.027321517,0.012186404,0.008947911,0.0002735124,0.00017158246,0.000052630523,0.00010431422,0.0026247439,0.93920094,0.000048695376,0.008597613,0.00047013795],"about_ca_topic_score_codex":0.00008961707,"about_ca_topic_score_gemma":0.000009878243,"teacher_disagreement_score":0.044774,"about_ca_system_score_codex":0.00008321062,"about_ca_system_score_gemma":0.00011712801,"threshold_uncertainty_score":0.99999523},"labels":[],"label_agreement":null},{"id":"W3107595197","doi":"10.1016/j.jdin.2020.10.005","title":"Cutaneous immune-related adverse events in patients with metastatic melanoma on antiprogrammed cell death protein 1 and anticytotoxic T-lymphocyte–associated protein 4 therapy: A retrospective cohort study","year":2020,"lang":"en","type":"article","venue":"JAAD International","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"University of Toronto","keywords":"Medicine; Adverse effect; Pembrolizumab; Melanoma; Internal medicine; Immune system; Oncology; Immunotherapy; Retrospective cohort study; Immunology; Cancer; Cancer research","score_opus":0.009651668965631136,"score_gpt":0.237846891017656,"score_spread":0.22819522205202486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107595197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99309474,0.000058300076,0.000005330999,0.00028634825,0.00007236751,0.0059671425,0.0000421802,0.00006639782,0.0004072034],"genre_scores_gemma":[0.99878615,0.00001638614,0.000112356516,0.00020533419,0.000019142819,0.00031872402,0.00013668954,0.000043303084,0.0003619144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789304,0.0001397037,0.00049604743,0.00044588596,0.00076686864,0.00025845302],"domain_scores_gemma":[0.9992204,0.000024217967,0.00029737118,0.00017421714,0.00018596377,0.000097878365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023999531,0.00027810765,0.00045303302,0.00016540434,0.000060561066,0.00001661271,0.00014566134,0.00007493606,0.00016438159],"category_scores_gemma":[0.000098939854,0.00021564064,0.00009379631,0.0003607498,0.000056332163,0.0001063859,0.000038673537,0.0002648092,0.000012971831],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015688706,0.0028859463,0.9742096,0.000016732856,0.0012295695,0.00013163574,0.00095053803,0.0000038801986,0.003959307,0.000010073019,0.0000047290196,0.0009092826],"study_design_scores_gemma":[0.029356666,0.0073357346,0.95928895,0.00022570098,0.00006448398,0.000010321481,0.00023204462,0.0004003949,0.0028021766,0.000021380132,0.000031867305,0.0002302467],"about_ca_topic_score_codex":0.00027071257,"about_ca_topic_score_gemma":0.000022760878,"teacher_disagreement_score":0.014920617,"about_ca_system_score_codex":0.0006382822,"about_ca_system_score_gemma":0.000131296,"threshold_uncertainty_score":0.87935704},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W3107686376","doi":"10.1038/s41379-020-00710-9","title":"Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer","year":2020,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Rosetrees Trust; National Institute for Health and Care Research; Cancer Research UK; Merck","keywords":"Pembrolizumab; Head and neck squamous-cell carcinoma; Medicine; Oncology; Internal medicine; Receiver operating characteristic; Head and neck cancer; Clinical trial; Immunotherapy; Cancer","score_opus":0.06803595048684008,"score_gpt":0.32906841315846747,"score_spread":0.2610324626716274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107686376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924585,0.0036572318,0.0007409701,0.0020432037,0.00005687969,0.0008038008,0.0000099342515,0.00006105387,0.00016840597],"genre_scores_gemma":[0.9976381,0.00017621646,0.00072149956,0.001092413,0.00014411974,0.00016221397,0.000016932961,0.000023061813,0.000025454618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903274,0.000024114508,0.00023603106,0.00033439987,0.00007532629,0.0002973985],"domain_scores_gemma":[0.99965775,0.000051726165,0.000059838778,0.0001095954,0.000028388024,0.000092705195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010668829,0.0001309982,0.00035441952,0.000053229556,0.00005480152,0.00001552573,0.000055240693,0.00009529665,0.000006387501],"category_scores_gemma":[0.00006140406,0.00011593026,0.00005545511,0.0000882056,0.000071506605,0.00002933159,0.00003719611,0.00014510288,5.583355e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006910921,0.00011248764,0.910768,0.0002073544,0.0000581475,0.00008192399,0.0028547123,0.00006140598,0.029908648,0.000024840223,0.000059929156,0.048951652],"study_design_scores_gemma":[0.020679591,0.0012301719,0.93454283,0.00028361028,0.0000805687,0.0001433518,0.00011578812,0.038109433,0.0038361705,0.0000774421,0.00070665375,0.00019439294],"about_ca_topic_score_codex":0.0001902476,"about_ca_topic_score_gemma":0.00036645992,"teacher_disagreement_score":0.04875726,"about_ca_system_score_codex":0.00004941988,"about_ca_system_score_gemma":0.00007092083,"threshold_uncertainty_score":0.4727499},"labels":[],"label_agreement":null},{"id":"W3107733830","doi":"10.1016/j.ejca.2020.10.008","title":"Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; Jewish General Hospital; McGill University Health Centre; Hôpital du Sacré-Cœur de Montréal; Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; Hôtel-Dieu de Québec; McGill University; Centre Hospitalier de l’Université de Montréal; Hôpital Charles-Le Moyne; University Health Network","funders":"AstraZeneca Canada","keywords":"Durvalumab; Medicine; Hazard ratio; Pneumonitis; Internal medicine; Cohort; Proportional hazards model; Lung cancer; Univariate analysis; Stage (stratigraphy); Retrospective cohort study; Confidence interval; Oncology; Incidence (geometry); Survival analysis; Multivariate analysis; Cancer; Lung; Immunotherapy","score_opus":0.01454905598128353,"score_gpt":0.2502036527384733,"score_spread":0.23565459675718975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107733830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959045,0.0013011816,0.00006470392,0.00059373054,0.00010911486,0.0014814496,0.000009060632,0.00002708248,0.000509173],"genre_scores_gemma":[0.9980963,0.0004146375,0.00023749791,0.0003963189,0.00022925697,0.000025398818,0.000017973167,0.000088488756,0.0004941628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782145,0.0002072391,0.0006415578,0.00033170613,0.0007138889,0.00028418005],"domain_scores_gemma":[0.9984344,0.000025226767,0.00079500885,0.00019268977,0.0003210761,0.00023159113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003588257,0.00030828026,0.0007291552,0.00018934457,0.00008800861,0.00004088525,0.00014867469,0.000023717479,0.00007407631],"category_scores_gemma":[0.0000069402486,0.00020374199,0.00009997184,0.00077688246,0.00003392381,0.00018928562,0.000011618788,0.0003469651,9.339786e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054857057,0.0008192598,0.9305287,0.000054869488,0.00095076783,0.00042799528,0.005955822,0.0010986404,0.0007961673,2.2547948e-8,0.00045082503,0.0040598875],"study_design_scores_gemma":[0.0851849,0.0038607675,0.906346,0.00041975928,0.0005562026,0.0000025558038,0.0004958036,0.0007381946,0.00070523325,8.067258e-9,0.0014246256,0.00026591858],"about_ca_topic_score_codex":0.0023585574,"about_ca_topic_score_gemma":0.0015306141,"teacher_disagreement_score":0.030327845,"about_ca_system_score_codex":0.0017316864,"about_ca_system_score_gemma":0.00043630443,"threshold_uncertainty_score":0.83083576},"labels":[],"label_agreement":null},{"id":"W3107738233","doi":"10.1016/j.ctrv.2020.102134","title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":375,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Medicine; Meta-analysis; Immune system; Oncology; Bioinformatics; Immunology; Internal medicine","score_opus":0.05682420004956792,"score_gpt":0.3523567482553131,"score_spread":0.2955325482057452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107738233","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000034460805,0.98641926,9.901047e-7,0.0005348553,0.00004319999,0.012733331,0.00015891362,0.000028144521,0.000046850368],"genre_scores_gemma":[0.000034327033,0.9957755,0.000046519603,0.00011240935,0.00003977864,0.002722976,0.0002525842,0.000060031387,0.00095588196],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9944724,0.0005973565,0.0035899794,0.00076588296,0.00029411848,0.00028026468],"domain_scores_gemma":[0.9944415,0.0006182839,0.003969232,0.00069656776,0.00008028635,0.00019410609],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0012569525,0.0009544763,0.021523405,0.00025121402,0.00007764575,0.000037708014,0.00010788288,0.0003296427,0.000075844044],"category_scores_gemma":[0.0002214731,0.00053460285,0.0044280277,0.0011524244,0.0000828157,0.00006627569,0.00007076346,0.00025296403,0.000007166352],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010765964,0.000040507155,0.000027264414,0.5809199,0.2585909,0.0000052578202,0.00006789526,9.72899e-9,0.0000043562527,0.0000010540508,0.000013814682,0.16031824],"study_design_scores_gemma":[0.0010049837,0.0003437199,0.00011915097,0.1465048,0.72657454,0.00001592959,0.0000023932523,2.5587008e-7,0.00001585988,0.0000016839588,0.12513354,0.00028312104],"about_ca_topic_score_codex":0.0003464723,"about_ca_topic_score_gemma":0.000020007328,"teacher_disagreement_score":0.46798366,"about_ca_system_score_codex":0.00084700616,"about_ca_system_score_gemma":0.00012887265,"threshold_uncertainty_score":0.99971056},"labels":[],"label_agreement":null},{"id":"W3108129662","doi":"10.3390/curroncol28010007","title":"Emergency Department Utilization for Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis of Identification and Outcomes for Those Presenting for Immune-Related Adverse Events","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Emergency department; Adverse effect; Retrospective cohort study; Presentation (obstetrics); Single Center; Pediatrics; Emergency medicine; Internal medicine; Surgery","score_opus":0.07512524394048144,"score_gpt":0.3970057462585445,"score_spread":0.3218805023180631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108129662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852386,0.0014966996,0.007354614,0.00058973517,0.0012370565,0.0038179539,0.00022308054,0.00002952508,0.000012695992],"genre_scores_gemma":[0.9967325,0.00065400725,0.00046610562,0.00001475925,0.000059646438,0.0006909986,0.0013111028,0.000020716854,0.00005019711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981218,0.00005385106,0.0011201971,0.0003583786,0.00014211588,0.00020363746],"domain_scores_gemma":[0.998342,0.00012891686,0.0008487837,0.0001566946,0.00046441433,0.000059207025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048607108,0.00015472822,0.00058667385,0.0001842226,0.000109051594,0.0000033961476,0.00006873278,0.00010973013,0.000024128778],"category_scores_gemma":[0.00090535847,0.00014155316,0.00055283296,0.00045368445,0.000041284304,0.00009393191,0.00003899046,0.000067030785,3.2880354e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033949893,0.0011663567,0.9241732,0.00077853637,0.0032539351,1.241626e-7,0.0030545027,0.000014519594,0.01795935,0.000049257087,0.00035239206,0.04580288],"study_design_scores_gemma":[0.007883756,0.0012433792,0.969926,0.00008992366,0.0025623862,2.239097e-7,0.00033859734,0.009247144,0.005421687,0.00014518581,0.002993371,0.00014833699],"about_ca_topic_score_codex":0.000008234808,"about_ca_topic_score_gemma":0.000013617706,"teacher_disagreement_score":0.045752853,"about_ca_system_score_codex":0.00024305674,"about_ca_system_score_gemma":0.000062255705,"threshold_uncertainty_score":0.57723707},"labels":[],"label_agreement":null},{"id":"W3108138683","doi":"10.1016/j.jaad.2020.06.256","title":"15578 Cutaneous immune-related adverse events to immune checkpoint inhibitors: A dermatology perspective","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Atezolizumab; Toxic epidermal necrolysis; Durvalumab; Nivolumab; Avelumab; Pembrolizumab; Ipilimumab; Adverse effect; Immunology; Dermatology; Erythema multiforme; Immune system; Immunotherapy; Internal medicine","score_opus":0.012328381913671659,"score_gpt":0.29464151945984407,"score_spread":0.28231313754617243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108138683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78659105,0.0020886885,0.000041872547,0.21049128,0.0002436418,0.00033415994,0.000006918915,0.000019868847,0.00018253637],"genre_scores_gemma":[0.9917758,0.00045423157,0.00052620197,0.0070558367,0.00010929726,0.000004520547,6.9383543e-7,0.00003541996,0.00003797434],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99680084,0.00034019983,0.0018137032,0.00024103018,0.00040506758,0.00039913523],"domain_scores_gemma":[0.99670523,0.00014119591,0.002506441,0.00020360033,0.00018361157,0.00025992387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016231723,0.00027397674,0.0014535377,0.00026466156,0.000082122155,0.0000029901164,0.0005919517,0.00018122424,0.000082914084],"category_scores_gemma":[0.0003969901,0.00019317311,0.0009259422,0.00091060053,0.00068955554,0.000092410264,0.00018408931,0.0010254598,0.000030760246],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01526973,0.00034753978,0.017743656,0.00014911841,0.0026716075,0.0008398746,0.006357359,0.00006412537,0.95095503,0.00015528455,0.0033011567,0.0021454878],"study_design_scores_gemma":[0.012433805,0.0027296166,0.083498105,0.0010048825,0.0013098718,0.25597256,0.014823021,0.00023849648,0.602449,0.00078779436,0.023989266,0.0007635372],"about_ca_topic_score_codex":0.000090807254,"about_ca_topic_score_gemma":0.0000010274395,"teacher_disagreement_score":0.34850603,"about_ca_system_score_codex":0.00023233483,"about_ca_system_score_gemma":0.0002743349,"threshold_uncertainty_score":0.7877371},"labels":[],"label_agreement":null},{"id":"W3109003874","doi":"10.1016/j.annonc.2020.10.063","title":"43O Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme","keywords":"Medicine; Gemcitabine; Internal medicine; Carboplatin; Oncology; Taxane; Triple-negative breast cancer; Progression-free survival; Breast cancer; Population; Pembrolizumab; Metastatic breast cancer; Chemotherapy; Cancer; Cisplatin; Immunotherapy","score_opus":0.07946991080433974,"score_gpt":0.405684776383466,"score_spread":0.32621486557912627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109003874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795774,0.00046671566,0.000109766464,0.006994779,0.00020939765,0.011308147,0.0010757763,0.000033954737,0.00022402471],"genre_scores_gemma":[0.993815,0.0011097047,0.0005245595,0.0024282476,0.00009192495,0.0014254221,0.00018990548,0.000060956256,0.0003542517],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963324,0.00032280543,0.0017364209,0.0006740621,0.0003482062,0.0005861079],"domain_scores_gemma":[0.9966112,0.00081364013,0.0010163898,0.00034061001,0.0010146897,0.00020349225],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008075179,0.00042186424,0.0019011933,0.00025207465,0.000075269,0.000010703918,0.00027368523,0.00019900654,0.00019328392],"category_scores_gemma":[0.0006689777,0.00032380864,0.00031291068,0.0007197545,0.00017010077,0.00012513809,0.000042534288,0.00022530575,0.0000013370645],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8216475,0.012544218,0.00059382454,0.00058514054,0.0017898503,0.000020325155,0.011010524,0.00004149378,0.0023082397,0.000003376139,0.0122858565,0.13716961],"study_design_scores_gemma":[0.79071105,0.16263074,0.00743735,0.0006387115,0.00069366005,0.00001780429,0.0032325527,0.0028113935,0.018661268,0.000033798264,0.012584058,0.0005475914],"about_ca_topic_score_codex":0.0011959531,"about_ca_topic_score_gemma":0.0013550658,"teacher_disagreement_score":0.15008652,"about_ca_system_score_codex":0.00028176466,"about_ca_system_score_gemma":0.0012281527,"threshold_uncertainty_score":0.9999214},"labels":[],"label_agreement":null},{"id":"W3109702162","doi":"10.1038/s42003-020-01441-y","title":"Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy","year":2020,"lang":"en","type":"article","venue":"Communications Biology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Cancer Center, University of Colorado; Canadian Institutes of Health Research; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; Boettcher Foundation","keywords":"CCR2; Blockade; Combination therapy; Cancer research; Immunotherapy; CD8; Medicine; Immune checkpoint; CCL2; T cell; Cancer; PD-L1; Immune system; Immunology; Receptor; Pharmacology; Chemokine; Internal medicine; Chemokine receptor","score_opus":0.049575937489123506,"score_gpt":0.32726551382197305,"score_spread":0.2776895763328495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109702162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.893809,0.0045174886,0.00008664417,0.099941246,0.00010465344,0.00053084886,0.0000278824,0.00003896094,0.00094326213],"genre_scores_gemma":[0.9918649,0.0017904569,0.0014413162,0.004632369,0.00003776969,0.00008048203,0.000037597958,0.000011110034,0.00010395337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988463,0.00043921394,0.00037920175,0.00014799528,0.000064015774,0.0001232744],"domain_scores_gemma":[0.99826854,0.00019785423,0.00016047474,0.0012097325,0.00011112098,0.000052260864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042739508,0.000098110475,0.00022231315,0.000051486186,0.00013533908,0.0000052158703,0.0004892554,0.000064572094,0.00020405538],"category_scores_gemma":[0.00028465854,0.00006538047,0.00014581777,0.00047052372,0.00039853848,0.000024793779,0.00022226613,0.00017584542,0.00003741476],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040773563,0.00011019611,0.00076097035,0.0000073240058,0.000053041924,1.1820157e-7,0.00131287,2.1113215e-7,0.9852106,0.00012278362,0.000438027,0.007906518],"study_design_scores_gemma":[0.0015627766,0.0009128086,0.02158835,0.00008241731,0.0000139816075,0.000007022542,0.00047190159,0.000017521423,0.73332477,0.00010319759,0.24181825,0.000096974516],"about_ca_topic_score_codex":0.00006461516,"about_ca_topic_score_gemma":0.000014278678,"teacher_disagreement_score":0.2518858,"about_ca_system_score_codex":0.000048762,"about_ca_system_score_gemma":0.00013203468,"threshold_uncertainty_score":0.2666138},"labels":[],"label_agreement":null},{"id":"W3109853980","doi":"10.1016/s0140-6736(20)32531-9","title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","year":2020,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1800,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Gemcitabine; Internal medicine; Pembrolizumab; Triple-negative breast cancer; Breast cancer; Oncology; Chemotherapy; Docetaxel; Metastatic breast cancer; Placebo; Taxane; Cancer; Pathology; Cisplatin; Immunotherapy","score_opus":0.13783723338943807,"score_gpt":0.4138224453152746,"score_spread":0.2759852119258366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109853980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82412857,0.006039119,0.0034281565,0.0861468,0.0039658616,0.07316691,0.001234799,0.0006683425,0.001221439],"genre_scores_gemma":[0.88701504,0.027173856,0.0022058224,0.037073743,0.01784672,0.021063572,0.0005872868,0.00062534964,0.006408625],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946421,0.0006980759,0.0018223865,0.0010260532,0.0007048402,0.001106564],"domain_scores_gemma":[0.9950906,0.0022722466,0.000878583,0.00092655886,0.00036076098,0.00047123065],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023860282,0.00084007415,0.003758484,0.000116185576,0.00033613315,0.00018347493,0.0007585448,0.0002955937,0.0020162456],"category_scores_gemma":[0.0005664412,0.0004903047,0.0011489305,0.0007175306,0.00044247834,0.00018558347,0.000054528235,0.0008269573,0.000034793993],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91885954,0.00081011927,0.000008858286,0.00025788127,0.005583826,0.000030132984,0.002832423,0.000101269114,0.0002703697,0.000016623257,0.025890507,0.045338467],"study_design_scores_gemma":[0.95519966,0.010922357,0.000017568802,0.000313245,0.001771073,0.000051506053,0.00044286842,0.012545797,0.0008277407,0.000018536171,0.01729247,0.0005971879],"about_ca_topic_score_codex":0.00046774634,"about_ca_topic_score_gemma":0.00033637506,"teacher_disagreement_score":0.06288645,"about_ca_system_score_codex":0.00071917643,"about_ca_system_score_gemma":0.0025459586,"threshold_uncertainty_score":0.99975485},"labels":[],"label_agreement":null},{"id":"W3110058912","doi":"10.1002/advs.202001596","title":"The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD‐L1","year":2020,"lang":"en","type":"article","venue":"Advanced Science","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China; Overseas Expertise Introduction Project for Discipline Innovation; China Postdoctoral Science Foundation; Natural Science Foundation of Shanghai","keywords":"Sunitinib; Immune system; Cancer research; Immune checkpoint; Medicine; In vivo; Cancer; Antibody; Immunotherapy; Monoclonal antibody; Cytotoxic T cell; Immunology; In vitro; Biology; Internal medicine","score_opus":0.00954921457374333,"score_gpt":0.26369632444912233,"score_spread":0.25414710987537903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110058912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939816,0.0029926288,0.000026940943,0.0014754814,0.00010872638,0.00025975084,0.000012939427,0.000027501681,0.001114433],"genre_scores_gemma":[0.99876124,0.00009060334,0.00049951917,0.00054606044,0.00003960092,0.000008512218,0.0000030377653,0.000010291031,0.000041166142],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985401,0.000031041887,0.00038526466,0.00029291725,0.00040497156,0.0003456855],"domain_scores_gemma":[0.9992054,0.0001520659,0.00018791942,0.00026497533,0.00010798802,0.0000816317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006588554,0.00011112046,0.00023138797,0.00004454983,0.00021209565,0.000022261585,0.00033823555,0.000015786518,0.00002134726],"category_scores_gemma":[0.00049408723,0.000081764774,0.000056251047,0.0011725711,0.000620075,0.00016454264,0.00006535418,0.0001422566,0.0000027161484],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010175374,0.000024949668,0.0043166303,0.000016346437,0.0000042328647,0.000003912058,0.0004935701,0.00008011057,0.95922154,0.00010977407,0.000021991193,0.03468939],"study_design_scores_gemma":[0.0036688903,0.0007232655,0.14281705,0.0002258573,0.0000075417397,0.000032723572,0.004398952,0.004885698,0.8233832,0.00020433625,0.019320885,0.0003315722],"about_ca_topic_score_codex":0.00011794296,"about_ca_topic_score_gemma":0.000053295975,"teacher_disagreement_score":0.13850042,"about_ca_system_score_codex":0.00006697167,"about_ca_system_score_gemma":0.00020724616,"threshold_uncertainty_score":0.33342707},"labels":[],"label_agreement":null},{"id":"W3110945690","doi":"10.1136/ijgc-2020-esgo.147","title":"518 Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers","year":2020,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Ignyta; Clovis Oncology; Amgen; Pfizer; PharmaMar; Mersana Therapeutics; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Endometrial cancer; Oncology; Internal medicine; Cervical cancer; Durvalumab; Ovarian cancer; Tolerability; Cancer; Adverse effect; Clinical endpoint; Immunotherapy; Nivolumab; Clinical trial","score_opus":0.029914152296946425,"score_gpt":0.31827349044143205,"score_spread":0.2883593381444856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110945690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943289,0.0018937456,0.0000868674,0.0023442295,0.00056979334,0.0005682093,0.00013108988,0.0000058868513,0.00007128474],"genre_scores_gemma":[0.99616206,0.002031635,0.00048690315,0.0009245823,0.00033280565,0.0000101201895,0.000015818647,0.000013969426,0.000022094559],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978563,0.000110460445,0.00091680145,0.00023629876,0.00068763737,0.00019251046],"domain_scores_gemma":[0.9981402,0.000591082,0.00057646015,0.000068713365,0.00043134717,0.00019215509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038338956,0.00018280471,0.0006839504,0.0001917967,0.000032857904,0.000037518883,0.00015917013,0.00008548215,0.00075877085],"category_scores_gemma":[0.00065847713,0.00012431988,0.00012526599,0.00029531468,0.00022439683,0.0001583772,0.0000574855,0.00030000723,4.963874e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90751755,0.00186053,0.018448802,0.0000714094,0.0011569206,0.00017751854,0.00061507715,0.00020360325,0.0012888671,0.000033683773,0.00016285756,0.06846318],"study_design_scores_gemma":[0.80736655,0.01835875,0.15489267,0.0003416224,0.00033885348,0.000045530025,0.0001726628,0.00025247023,0.0013683789,0.000033040065,0.016554905,0.00027454575],"about_ca_topic_score_codex":0.00022302826,"about_ca_topic_score_gemma":0.000047720194,"teacher_disagreement_score":0.13644387,"about_ca_system_score_codex":0.0006425216,"about_ca_system_score_gemma":0.0005653057,"threshold_uncertainty_score":0.8308009},"labels":[],"label_agreement":null},{"id":"W3111827772","doi":"10.3389/fimmu.2020.595655","title":"Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Science and Technology Major Project; Shandong First Medical University; Natural Science Foundation of Shandong Province","keywords":"Medicine; Internal medicine; Dysgeusia; Meta-analysis; Peripheral neuropathy; Clinical trial; Immunotherapy; Cancer; Oncology; Adverse effect; Gastroenterology","score_opus":0.03185907139907623,"score_gpt":0.3033441843967727,"score_spread":0.27148511299769645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111827772","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009747027,0.9949434,0.000005943809,0.00048259186,0.00044813033,0.003814699,0.00012551963,0.000028184024,0.000054106145],"genre_scores_gemma":[0.00021608366,0.99759245,0.000099752855,0.0005750753,0.000010151953,0.0011071339,0.00014547471,0.000050396688,0.0002034764],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9938711,0.0013446393,0.0033777088,0.0007175993,0.0002625688,0.00042638314],"domain_scores_gemma":[0.99742657,0.00020351882,0.0015579902,0.000658764,0.00009366726,0.000059517686],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0006919971,0.00068818213,0.015728924,0.0012177192,0.000031804386,0.000011504771,0.00038736346,0.00074017403,0.00027872124],"category_scores_gemma":[0.0003654229,0.00046433834,0.0027719636,0.0025338351,0.00048375854,0.00006863986,0.00016557744,0.0009885301,0.0000033825222],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042416708,0.00035382353,0.0005050651,0.66870046,0.30764598,0.000089273555,0.0003316098,6.4716903e-7,0.0000019339382,0.000014377575,0.00074077793,0.021191875],"study_design_scores_gemma":[0.0018766739,0.0009605623,0.00038825703,0.058842495,0.868239,0.000050546165,0.00012913717,0.000008967068,0.000002481234,0.000023908682,0.068809226,0.00066877203],"about_ca_topic_score_codex":0.00028046584,"about_ca_topic_score_gemma":0.00003422295,"teacher_disagreement_score":0.609858,"about_ca_system_score_codex":0.00030489144,"about_ca_system_score_gemma":0.00024634108,"threshold_uncertainty_score":0.99978083},"labels":[],"label_agreement":null},{"id":"W3112132685","doi":"10.1136/ijgc-2020-esgo.180","title":"256 Differences in immune-related adverse events between vulvovaginal vs. cutaneous melanoma: a retrospective cohort study","year":2020,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Adverse effect; Melanoma; Dermatology; Internal medicine; Retrospective cohort study; Cohort","score_opus":0.024203209545164577,"score_gpt":0.3092863526856376,"score_spread":0.285083143140473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112132685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99174964,0.0004223857,0.000019908563,0.0060484596,0.0008081188,0.00044492,0.000026196181,0.000016431808,0.00046390676],"genre_scores_gemma":[0.9983507,0.00037529637,0.000051618557,0.0007027556,0.00036810918,0.000020488398,0.0000057912207,0.000011818332,0.000113435075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976407,0.00012072198,0.0009167582,0.00025244782,0.0008684537,0.00020086674],"domain_scores_gemma":[0.99867374,0.00016903541,0.0005230745,0.00008050333,0.00041001692,0.00014363372],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000371682,0.00018158357,0.00067609036,0.0001524302,0.000035064513,0.000013015512,0.0003799555,0.000120082295,0.0025615525],"category_scores_gemma":[0.00036226117,0.00012875951,0.00024129965,0.00025498995,0.00009049069,0.00011903847,0.00007219986,0.0005996094,0.000011965561],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047720405,0.00046388476,0.9878457,0.000005116688,0.0014905287,0.0014090441,0.00052638457,0.000014416303,0.00048438486,0.00000946381,0.000107200685,0.002871831],"study_design_scores_gemma":[0.0056794235,0.0037048266,0.9890985,0.00009686093,0.00016587698,0.00017785949,0.00028460144,0.000045366454,0.00010232258,0.00012472305,0.0003886256,0.00013100923],"about_ca_topic_score_codex":0.00020072787,"about_ca_topic_score_gemma":0.000061716615,"teacher_disagreement_score":0.0066010146,"about_ca_system_score_codex":0.0009143637,"about_ca_system_score_gemma":0.00022732481,"threshold_uncertainty_score":0.99835026},"labels":[],"label_agreement":null},{"id":"W3112811149","doi":"10.1038/s41467-020-19810-w","title":"PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma","year":2020,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Parker Institute for Cancer Immunotherapy; AstraZeneca; National Institutes of Health; Cancer Research Institute","keywords":"Blockade; Melanoma; MAPK/ERK pathway; Cancer research; Medicine; Signal transduction; Biology; Bioinformatics; Pharmacology; Cell biology; Internal medicine; Receptor","score_opus":0.011359017731123286,"score_gpt":0.26057252176004686,"score_spread":0.24921350402892356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112811149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927453,0.0021766063,0.000020556925,0.0041005705,0.000012857481,0.00057857775,0.00001359985,0.000021049818,0.00033092173],"genre_scores_gemma":[0.9958622,0.00018864592,0.003056081,0.0005482589,0.000006526035,0.00003594968,0.0002824905,0.000014842467,0.0000049910864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992426,0.00006738241,0.00025746948,0.00013610782,0.0001955295,0.00010087767],"domain_scores_gemma":[0.9991577,0.0000733015,0.00014010261,0.00044527106,0.00014714719,0.000036462287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000097123935,0.00009622822,0.00019435768,0.000111234425,0.00003888336,0.0000051890643,0.00015745213,0.00012408197,0.000013088111],"category_scores_gemma":[0.00003877094,0.00007833596,0.000030506693,0.00075949996,0.00008362386,0.000095494324,0.00003909954,0.000528612,9.919894e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015078064,0.0024126458,0.8653974,0.00017604572,0.00018958324,0.0000074967024,0.0034158824,0.00014593528,0.09798383,0.00068638526,0.00017623181,0.014330504],"study_design_scores_gemma":[0.018047856,0.0018563401,0.95440096,0.0007547414,0.00006138333,0.0000026612393,0.00044019773,0.00030128736,0.021947296,0.000035498204,0.001955811,0.00019597168],"about_ca_topic_score_codex":0.00003706024,"about_ca_topic_score_gemma":0.00042413847,"teacher_disagreement_score":0.089003555,"about_ca_system_score_codex":0.00011454488,"about_ca_system_score_gemma":0.000090914866,"threshold_uncertainty_score":0.31944478},"labels":[],"label_agreement":null},{"id":"W3113031448","doi":"10.1016/j.annonc.2020.10.555","title":"67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BeiGene; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Oncology; Clinical endpoint; Randomized controlled trial; Cancer; Immunotherapy","score_opus":0.15544898252665074,"score_gpt":0.42046484643018,"score_spread":0.26501586390352927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113031448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93848217,0.00096574845,0.00006828221,0.056269586,0.00027479383,0.0011721416,0.000093561655,0.000025516996,0.0026482048],"genre_scores_gemma":[0.9921424,0.0018175582,0.0004893851,0.004444303,0.00013633053,0.00013146726,0.000046490197,0.000029071754,0.000762995],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984662,0.00007684137,0.00063284463,0.00032379958,0.00016478168,0.00033553905],"domain_scores_gemma":[0.9989172,0.00027988703,0.00022160976,0.0002521936,0.00017780284,0.0001512608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036374232,0.00018270615,0.00080602925,0.00014040218,0.000029082461,0.000002468819,0.00012403422,0.00015039832,0.00023034924],"category_scores_gemma":[0.0002577733,0.00016174241,0.00024452232,0.00034089584,0.000107896645,0.000046895195,0.000031526022,0.00007502161,0.000011276913],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36593553,0.002696749,0.002139376,0.0005225132,0.0010133552,0.00010896543,0.0070023714,0.0003147266,0.10492632,0.0002453721,0.015420272,0.49967444],"study_design_scores_gemma":[0.036708947,0.067867644,0.0062358673,0.00026721237,0.00010694892,0.000013352408,0.001370279,0.00014001169,0.1326521,0.00016809965,0.75419134,0.00027816833],"about_ca_topic_score_codex":0.00029345832,"about_ca_topic_score_gemma":0.00084169535,"teacher_disagreement_score":0.7387711,"about_ca_system_score_codex":0.00014868226,"about_ca_system_score_gemma":0.00043270786,"threshold_uncertainty_score":0.6595664},"labels":[],"label_agreement":null},{"id":"W3113081454","doi":"10.1136/jitc-2020-sitc2020.0265","title":"265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort","year":2020,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Interim analysis; Interim; Avelumab; Cohort; Urothelial carcinoma; Oncology; Medicine; Internal medicine; Political science; Bladder cancer; Immunotherapy; Cancer; Clinical trial","score_opus":0.01670594694064256,"score_gpt":0.26632339166413244,"score_spread":0.24961744472348987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113081454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99774086,0.00015546032,0.000012834041,0.00037765916,0.000094105846,0.0012613869,0.00025005103,0.000046869347,0.000060742794],"genre_scores_gemma":[0.9987627,0.000025747775,0.0003264971,0.0003689391,0.000082948565,0.00003122158,0.0003383622,0.000042275096,0.000021264581],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99710554,0.00010897045,0.0010332627,0.0007649749,0.0006354692,0.00035181176],"domain_scores_gemma":[0.9983116,0.000050036382,0.00045373867,0.0005149146,0.00015714052,0.00051256357],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031366144,0.00036035303,0.0009902021,0.00024603674,0.00007656832,0.00003887249,0.00015362156,0.00012594654,0.000018705276],"category_scores_gemma":[0.00025004917,0.00029225726,0.00015380049,0.00075040804,0.00023738606,0.00019398498,0.000060866354,0.0002802466,0.0000023003468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03773657,0.0035056677,0.9098084,0.00012377505,0.0018940622,0.00024748567,0.00988936,0.0002405701,0.03396284,0.0000010905238,0.00018258131,0.00240762],"study_design_scores_gemma":[0.044526692,0.005237709,0.93079704,0.0003007904,0.00090256624,0.0000042700467,0.0014385632,0.0003957526,0.015979094,0.0000053291155,0.00009615445,0.00031603387],"about_ca_topic_score_codex":0.0024393261,"about_ca_topic_score_gemma":0.0003500867,"teacher_disagreement_score":0.020988664,"about_ca_system_score_codex":0.000106568594,"about_ca_system_score_gemma":0.00030853637,"threshold_uncertainty_score":0.999953},"labels":[],"label_agreement":null},{"id":"W3113156128","doi":"10.3390/cancers12123828","title":"Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer","year":2020,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Danmarks Frie Forskningsfond; Michael Smith Health Research BC; Ovacure Foundation; Anticancer Fund; Kræftens Bekæmpelse","keywords":"Ovarian cancer; Tumor microenvironment; Immune system; Medicine; Disease; Tumor progression; Cancer research; Cancer; Oncology; Internal medicine; Immunology","score_opus":0.009473603628021944,"score_gpt":0.2382939434860005,"score_spread":0.22882033985797856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113156128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893222,0.0020431015,7.007197e-7,0.007705116,0.0000606648,0.00079417886,0.000017824479,0.000011501839,0.000044749075],"genre_scores_gemma":[0.9965141,0.0003329093,0.000020273796,0.002753476,0.00007375021,0.00025057828,0.000016080261,0.000016515196,0.000022340873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992002,0.00003077194,0.0001337084,0.00021357561,0.0002114784,0.0002102423],"domain_scores_gemma":[0.99968773,0.000006358018,0.000061025712,0.00015704829,0.000007841523,0.00007998677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000056757435,0.00011726934,0.00014991121,0.0000407183,0.00003832939,0.0000099893405,0.000092151626,0.000018564042,0.00013884708],"category_scores_gemma":[0.0000058810383,0.00007206446,0.000029221681,0.00023118172,0.000070406495,0.00003785974,0.000019020392,0.00013130519,0.0000018168853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015710024,0.00008190996,0.9657097,0.00020558349,0.000043871918,0.0001049731,0.0026291432,0.00010859292,0.005750823,0.0000010070017,0.00012767171,0.009526742],"study_design_scores_gemma":[0.0060467334,0.00023976111,0.9883926,0.00054663426,0.000024071363,6.5225225e-7,0.00031177007,0.00003489936,0.0017343776,4.9456764e-7,0.002565227,0.000102771686],"about_ca_topic_score_codex":0.00040900934,"about_ca_topic_score_gemma":0.00037891316,"teacher_disagreement_score":0.02268295,"about_ca_system_score_codex":0.00088626443,"about_ca_system_score_gemma":0.00018030747,"threshold_uncertainty_score":0.29387033},"labels":[],"label_agreement":null},{"id":"W3114127133","doi":"10.1016/j.cjca.2020.12.022","title":"Immune Checkpoint Inhibitor Myocarditis With Normal Cardiac Magnetic Resonance Imaging: Importance of Cardiac Biopsy and Early Diagnosis","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myocarditis; Cardiology; Magnetic resonance imaging; Internal medicine; Cardiac magnetic resonance imaging; Troponin; Biopsy; Radiology; Myocardial infarction","score_opus":0.008229109168691129,"score_gpt":0.2062829648955765,"score_spread":0.19805385572688536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114127133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8476593,0.14663619,0.00002505071,0.0035938912,0.00053401454,0.00024309407,0.00013782844,0.0000070966207,0.0011635751],"genre_scores_gemma":[0.9954774,0.0027728383,0.00027237576,0.00029727747,0.0011035728,0.00001391619,0.000005364768,0.000034230656,0.000023074426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983408,0.000126207,0.00066926354,0.00024315174,0.00021228004,0.0004082846],"domain_scores_gemma":[0.998369,0.00006651948,0.00031486741,0.00024768573,0.00032344158,0.0006785148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003985206,0.00022095694,0.0011466497,0.00018608283,0.00006814974,0.000020399102,0.00014021691,0.00011421815,0.000030497293],"category_scores_gemma":[0.00011728565,0.00018643602,0.00046591804,0.0003057192,0.00060069544,0.000115364455,0.000018300867,0.00034241256,0.000001418405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008357463,0.0000021360008,0.96359676,0.000056721125,0.00035492217,0.0004740539,0.0004299004,0.0000038561384,0.0072486037,0.000008974741,0.0034372797,0.023551019],"study_design_scores_gemma":[0.001482833,0.0013426954,0.8360414,0.0001787948,0.0002983025,0.0007297961,0.00032347755,0.0000017574365,0.0034759156,0.0000065315508,0.15593505,0.00018347127],"about_ca_topic_score_codex":0.001786976,"about_ca_topic_score_gemma":0.00009794567,"teacher_disagreement_score":0.15249777,"about_ca_system_score_codex":0.00012761109,"about_ca_system_score_gemma":0.00095118233,"threshold_uncertainty_score":0.76026404},"labels":[],"label_agreement":null},{"id":"W3114638465","doi":"10.1016/j.ejca.2020.11.010","title":"Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Merck Sharp and Dohme; National Institutes of Health","keywords":"Pembrolizumab; Medicine; Adverse effect; Pneumonitis; Melanoma; Internal medicine; Discontinuation; Progression-free survival; Surgery; Survival analysis; Gastroenterology; Overall survival; Cancer; Immunotherapy","score_opus":0.02761193364044567,"score_gpt":0.3175923673352526,"score_spread":0.2899804336948069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114638465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961662,0.0016748826,0.0005014366,0.0011467246,0.00003675539,0.00015861716,0.000009735089,0.0000046343475,0.0003010146],"genre_scores_gemma":[0.99806595,0.00064724236,0.00054715475,0.00059275166,0.00007241421,7.7101265e-7,0.000004363773,0.000023133078,0.00004621788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848545,0.00021121808,0.0007716909,0.00014639148,0.00027640257,0.00010884379],"domain_scores_gemma":[0.99891406,0.000072787945,0.0005878472,0.00012661585,0.00017168421,0.00012697694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043542258,0.000120362194,0.0005224652,0.00014306208,0.000022234497,0.000009094193,0.00008250475,0.000021926558,0.0000875531],"category_scores_gemma":[0.00004064341,0.00007421643,0.00013145772,0.00047665584,0.00009626615,0.000093188,0.000010262949,0.00025261223,4.8796966e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05986135,0.00008664939,0.9027446,0.00003212866,0.0010202436,0.000067740024,0.00035165242,0.00009893207,0.000021105701,0.0000012253507,0.000022569926,0.035691794],"study_design_scores_gemma":[0.023243425,0.0029128382,0.9723687,0.000210808,0.00051550183,0.0000074921504,0.00002917782,0.000013657415,0.000016000262,3.088421e-7,0.0005922552,0.00008979257],"about_ca_topic_score_codex":0.0000057744014,"about_ca_topic_score_gemma":0.000046012556,"teacher_disagreement_score":0.06962413,"about_ca_system_score_codex":0.00004873382,"about_ca_system_score_gemma":0.00009285506,"threshold_uncertainty_score":0.3026458},"labels":[],"label_agreement":null},{"id":"W3115335364","doi":"10.1016/j.kint.2020.12.015","title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","year":2020,"lang":"en","type":"article","venue":"Kidney International","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Medicine; Kidney cancer; Kidney transplant; Immune checkpoint; Cancer; Oncology; Kidney transplantation; Internal medicine; Kidney; Immunotherapy","score_opus":0.01658243946828755,"score_gpt":0.2760918878169197,"score_spread":0.25950944834863215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115335364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98995596,0.000034377957,0.000023369896,0.008414028,0.00024256205,0.00061814114,0.00038387638,0.000014151069,0.00031352034],"genre_scores_gemma":[0.99719846,0.00006229567,0.00010963738,0.0023237113,0.000063871106,0.000019797128,0.00015622651,0.0000149598145,0.000051012063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989276,0.000024175168,0.00039960135,0.00022684986,0.00031375038,0.000108024025],"domain_scores_gemma":[0.99954253,0.000018837556,0.000107482796,0.000083496576,0.000067985646,0.00017966909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000085898864,0.00013007736,0.0002192564,0.00009162597,0.00001706597,0.000007771319,0.00008070334,0.000035746638,0.00019259797],"category_scores_gemma":[0.0000832589,0.00009616648,0.00006145208,0.00011617849,0.00005292837,0.000049208447,0.000019253213,0.00013862376,0.0000023197658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023978097,0.004384422,0.9527518,0.00005910589,0.000535777,0.00001710821,0.0055113104,0.000004013386,0.01012878,0.0000033677527,0.00046084236,0.0021653376],"study_design_scores_gemma":[0.048930924,0.0012605252,0.9397672,0.0006791598,0.00004011338,0.000002067037,0.00013783263,0.00017359862,0.0034849325,2.1116706e-7,0.005412114,0.00011136314],"about_ca_topic_score_codex":0.0003153085,"about_ca_topic_score_gemma":0.0000257546,"teacher_disagreement_score":0.024952825,"about_ca_system_score_codex":0.0000999298,"about_ca_system_score_gemma":0.00012794284,"threshold_uncertainty_score":0.3921555},"labels":[],"label_agreement":null},{"id":"W3115800286","doi":"10.4049/immunohorizons.2000089","title":"Enhanced Immunotherapeutic Efficacy of Anti–PD-L1 Antibody in Combination with an EP4 Antagonist","year":2020,"lang":"en","type":"article","venue":"ImmunoHorizons","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bio-oriented Technology Research Advancement Institution; Japan Society for the Promotion of Science; National Agriculture and Food Research Organization; Ministry of Agriculture - Saskatchewan","keywords":"Blockade; Downregulation and upregulation; Immunotherapy; PD-L1; Cancer research; Cancer immunotherapy; Tumor necrosis factor alpha; T cell; Immune system; Pharmacology; Chemistry; Cytokine; Medicine; Receptor; Immunology; Biochemistry","score_opus":0.018217170986839722,"score_gpt":0.3055320010749877,"score_spread":0.28731483008814795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115800286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99447626,0.0012536471,0.00084385346,0.0013173246,0.00014772997,0.0007264318,0.000016444652,0.00008878587,0.0011295391],"genre_scores_gemma":[0.998255,0.0005126078,0.00039460586,0.00050269824,0.000055056764,0.00001766268,0.00015227494,0.00005139758,0.000058692112],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983814,0.000097836135,0.0005259244,0.00036563296,0.0003129837,0.00031624638],"domain_scores_gemma":[0.99905604,0.00006719134,0.00020180368,0.0004720001,0.000113958435,0.00008901833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002178105,0.00024674376,0.0005430127,0.00015526208,0.000084380124,0.000030569652,0.00021608904,0.00011573594,0.00015068319],"category_scores_gemma":[0.00002832616,0.00020975899,0.00012527457,0.0008054144,0.000247397,0.0002007323,0.000026346665,0.0002715961,0.000014953081],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010846179,0.00086842064,0.0053836615,0.000090426845,0.0002439887,0.000022477028,0.0014208695,0.0000058475725,0.963143,0.00022078135,0.00001196591,0.017742394],"study_design_scores_gemma":[0.023522394,0.009940344,0.5132938,0.00048017388,0.0001678392,0.00004885494,0.0009416548,0.00025159816,0.44812974,0.000028024122,0.002730389,0.00046516093],"about_ca_topic_score_codex":0.0003924199,"about_ca_topic_score_gemma":0.000018290239,"teacher_disagreement_score":0.5150133,"about_ca_system_score_codex":0.000089871166,"about_ca_system_score_gemma":0.00022128658,"threshold_uncertainty_score":0.85537237},"labels":[],"label_agreement":null},{"id":"W3116093824","doi":"10.1016/j.lungcan.2020.12.026","title":"Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; AstraZeneca France; Pfizer; British Microcirculation Society; Boehringer Ingelheim; AbbVie; Roche","keywords":"Medicine; Lung cancer; Incidence (geometry); Internal medicine; Cancer; Response Evaluation Criteria in Solid Tumors; Medical record; Oncology; Retrospective cohort study; Disease; Progressive disease","score_opus":0.010774719639024865,"score_gpt":0.25192111033758624,"score_spread":0.24114639069856136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3116093824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98902804,0.008258328,0.000013673604,0.000910818,0.000057913934,0.0011671224,0.000037221358,0.00002637399,0.0005005339],"genre_scores_gemma":[0.993877,0.004758012,0.00047358088,0.00039897277,0.000024425106,0.00028678516,0.000041426993,0.000036817833,0.00010298999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988883,0.000017364066,0.0003340645,0.0002989318,0.0002449325,0.00021640255],"domain_scores_gemma":[0.9994904,0.000010027994,0.00017047703,0.00017292866,0.00006732784,0.00008883646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000054633376,0.00020953108,0.00037846089,0.00007562299,0.000041961284,0.000010663854,0.000058082584,0.000059676597,0.00010039368],"category_scores_gemma":[0.0000012699674,0.0001365671,0.000053396845,0.00038570393,0.0000720439,0.000060343886,0.00003585314,0.00012961333,4.331017e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004776345,0.000207796,0.9867896,0.0013657504,0.00043759332,0.000021662552,0.00047544797,0.000017898734,0.001143642,0.000002857486,0.00019365984,0.004567739],"study_design_scores_gemma":[0.015472959,0.0004887024,0.97247726,0.0031769557,0.00045243482,8.284753e-7,0.00017339553,0.00018693318,0.0071298,3.86046e-7,0.0002279131,0.0002124534],"about_ca_topic_score_codex":0.0013834923,"about_ca_topic_score_gemma":0.00016587976,"teacher_disagreement_score":0.014312369,"about_ca_system_score_codex":0.00020909651,"about_ca_system_score_gemma":0.000094265735,"threshold_uncertainty_score":0.5569045},"labels":[],"label_agreement":null},{"id":"W3116800504","doi":"10.1016/j.jaccao.2020.10.013","title":"Immune Checkpoint Inhibitor-Associated Myocarditis With Persistent Troponin Elevation Despite Abatacept and Prolonged Immunosuppression","year":2020,"lang":"en","type":"review","venue":"JACC CardioOncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network; Toronto General Hospital; University of Toronto","funders":"","keywords":"Abatacept; Immunosuppression; Medicine; Myocarditis; Troponin I; Troponin; Immune system; Internal medicine; Immunology; Cardiology; Antibody; Myocardial infarction","score_opus":0.024769544413214217,"score_gpt":0.2901575457178197,"score_spread":0.2653880013046055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3116800504","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021785202,0.9923366,0.000019052639,0.0007851744,0.0006710631,0.00296687,0.0001196955,0.0001567073,0.0007663333],"genre_scores_gemma":[0.0031674914,0.9937551,0.0001725902,0.00017344396,0.0006143593,0.00062245957,0.0009772307,0.0001464217,0.00037090114],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996429,0.0006515306,0.0009967983,0.0008979756,0.00047112638,0.0005535549],"domain_scores_gemma":[0.9979572,0.00019780887,0.00087012455,0.0005738195,0.00020094513,0.00020008246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006311606,0.000744048,0.0039502056,0.00027884115,0.00020358617,0.000060270442,0.00018299116,0.0009670284,0.00007821679],"category_scores_gemma":[0.00017035217,0.0005469061,0.001650904,0.00060271536,0.00031422864,0.000108232765,0.00016713906,0.0010083532,0.000025461028],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023594203,0.0001474881,0.00011261729,0.0047837733,0.0073019653,0.00048935093,0.00046747347,4.7389548e-7,0.0009288813,0.000003258669,0.0016318709,0.98177344],"study_design_scores_gemma":[0.0053577563,0.0038244398,0.0018745876,0.008786782,0.005980954,0.002039625,0.00023308035,0.0000082133365,0.000092785776,0.0000010715004,0.9712083,0.0005924377],"about_ca_topic_score_codex":0.000060626335,"about_ca_topic_score_gemma":0.000011122026,"teacher_disagreement_score":0.98118097,"about_ca_system_score_codex":0.0014993557,"about_ca_system_score_gemma":0.0010025246,"threshold_uncertainty_score":0.9996982},"labels":[],"label_agreement":null},{"id":"W3117475035","doi":"10.1093/jncics/pkaa115","title":"Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis","year":2020,"lang":"en","type":"article","venue":"JNCI Cancer Spectrum","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; Memorial University of Newfoundland; University Health Network","funders":"Terry Fox Research Institute; Ontario Institute for Cancer Research; Princess Margaret Cancer Foundation","keywords":"Pembrolizumab; Germline; Medicine; Human leukocyte antigen; Computational biology; Genetics; Immunology; Immune system; Immunotherapy; Biology; Gene; Antigen","score_opus":0.022318453447249562,"score_gpt":0.2988618526463341,"score_spread":0.2765433991990845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3117475035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9447278,0.00218049,0.000471598,0.051108286,0.00016997535,0.00040423265,0.00009180641,0.00012227421,0.00072355405],"genre_scores_gemma":[0.9857195,0.0005902722,0.00035045916,0.012022812,0.0007009731,0.000042149037,0.000011741975,0.000035035606,0.0005270259],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99832076,0.000073385,0.0003751967,0.00054509274,0.00029259076,0.00039300535],"domain_scores_gemma":[0.99917126,0.00006914794,0.00011744325,0.00032539517,0.00003822115,0.00027852127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002352511,0.00022962337,0.00053301326,0.00013957606,0.00012412535,0.000044307297,0.0001271232,0.00009897761,0.0006744446],"category_scores_gemma":[0.00007393022,0.00020661825,0.0002257598,0.0011061762,0.00007628692,0.00008963729,0.000086455926,0.00023200086,0.00001570372],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13253136,0.00023453275,0.25800478,0.00024860087,0.005688857,0.00022670055,0.013347864,0.00044532176,0.5714076,0.00009369462,0.008397974,0.009372716],"study_design_scores_gemma":[0.008365222,0.0019821653,0.8671213,0.000106707856,0.0018084854,0.00005604745,0.0005674282,0.0049587437,0.03751697,0.000048556776,0.07687983,0.0005885471],"about_ca_topic_score_codex":0.001490914,"about_ca_topic_score_gemma":0.0008487667,"teacher_disagreement_score":0.6091165,"about_ca_system_score_codex":0.00048464458,"about_ca_system_score_gemma":0.00025972576,"threshold_uncertainty_score":0.84256476},"labels":[],"label_agreement":null},{"id":"W3118386410","doi":"10.1016/j.clinre.2020.101604","title":"Vedolizumab for steroid &amp; infliximab refractory immune checkpoint inhibitor associated colitis","year":2021,"lang":"en","type":"letter","venue":"Clinics and Research in Hepatology and Gastroenterology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Vedolizumab; Medicine; Infliximab; Colitis; Refractory (planetary science); Internal medicine; Pharmacology; Gastroenterology; Ulcerative colitis; Tumor necrosis factor alpha; Disease","score_opus":0.09002683150155434,"score_gpt":0.38906760129281837,"score_spread":0.29904076979126404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118386410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6907063,0.007205065,0.00000978229,0.30002767,0.0008708298,0.000923618,0.0001832639,0.000019636464,0.00005379856],"genre_scores_gemma":[0.49663702,0.057384264,0.0005603443,0.431424,0.0034992993,0.0012583615,0.004764714,0.00024186418,0.0042301393],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950861,0.0012503868,0.0011557499,0.00093427097,0.00029605764,0.0012774784],"domain_scores_gemma":[0.9972471,0.0013704298,0.00030383328,0.00050512556,0.0004209318,0.00015258393],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0024615957,0.00037081077,0.001469493,0.00058124284,0.00020400617,0.000045619712,0.00017980869,0.0021781495,0.00007557175],"category_scores_gemma":[0.0006662567,0.0003407978,0.00027548856,0.00018925012,0.0014733017,0.00004765552,0.00030479798,0.004109403,0.0000035626617],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051590256,0.0014408323,0.39277706,0.003654433,0.002534579,0.0047813477,0.00076935714,1.5349706e-7,0.0012856766,0.00002858244,0.5254917,0.015646],"study_design_scores_gemma":[0.017184502,0.0069374596,0.059749406,0.00089771376,0.000130802,0.001154571,0.00011424715,0.00006879498,0.000052949315,0.00063035724,0.9127975,0.00028171475],"about_ca_topic_score_codex":0.00020734017,"about_ca_topic_score_gemma":0.0009078767,"teacher_disagreement_score":0.38730577,"about_ca_system_score_codex":0.0002425428,"about_ca_system_score_gemma":0.00044094585,"threshold_uncertainty_score":0.9999044},"labels":[],"label_agreement":null},{"id":"W3118593288","doi":"10.5005/jp-journals-10018-1321","title":"A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma","year":2021,"lang":"en","type":"review","venue":"Euroasian Journal of Hepato-Gastroenterology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sault Area Hospital; NOSM University","funders":"","keywords":"Gastroesophageal Junction; Medicine; Internal medicine; Gastric adenocarcinoma; Meta-analysis; Adenocarcinoma; Oncology; Gastroenterology; Cancer","score_opus":0.04711467605891032,"score_gpt":0.32247059784932386,"score_spread":0.2753559217904135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118593288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006127035,0.99188054,0.00013919672,0.0004203066,0.00009283974,0.0012792347,0.000051690564,0.000005445853,0.000003723214],"genre_scores_gemma":[0.0055013625,0.99304235,0.0005594631,0.00067717454,0.000040193663,0.000052852225,0.000026742639,0.000057303223,0.00004257189],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9932163,0.0021366142,0.0033117346,0.00052888226,0.0003933019,0.00041319514],"domain_scores_gemma":[0.99591655,0.00021351594,0.0029965646,0.00043352784,0.0001806036,0.00025923512],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018929256,0.0006598876,0.012272757,0.0023385347,0.000040603893,0.000035800895,0.00017304963,0.00014897328,0.00011409559],"category_scores_gemma":[0.00014506502,0.0004499906,0.0022408543,0.0011780938,0.0002532829,0.00012920753,0.00007265761,0.0007007069,4.0181305e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016941327,0.0003897021,0.01356348,0.60096925,0.37075418,0.0020123743,0.0003481669,0.0000011310974,0.00000842885,0.0000046897626,0.000193319,0.010061149],"study_design_scores_gemma":[0.0026923441,0.003522077,0.003662014,0.037911527,0.93326485,0.017736915,0.00012899454,0.000012024459,0.0000010363731,0.000002214507,0.0008666744,0.0001993369],"about_ca_topic_score_codex":0.000019328412,"about_ca_topic_score_gemma":0.00003753733,"teacher_disagreement_score":0.5630577,"about_ca_system_score_codex":0.000108172935,"about_ca_system_score_gemma":0.00017189451,"threshold_uncertainty_score":0.9997952},"labels":[],"label_agreement":null},{"id":"W3118849389","doi":"10.3389/fimmu.2020.615317","title":"LAG3’s Enigmatic Mechanism of Action","year":2021,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research; Research Manitoba","keywords":"Mechanism (biology); Action (physics); Medicine; Philosophy; Epistemology; Physics","score_opus":0.03889115676556501,"score_gpt":0.3297627945960524,"score_spread":0.2908716378304874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118849389","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026460044,0.99402934,0.0011158207,0.000040503684,0.0037328054,0.0005919302,0.000012453894,0.000023526665,0.00042717173],"genre_scores_gemma":[0.000014558277,0.9959288,0.0024045191,0.00005371533,0.000056244728,0.00009201201,0.00015119766,0.00004325721,0.0012556502],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99826044,0.00025466466,0.00078772503,0.00030802013,0.00012956839,0.00025959997],"domain_scores_gemma":[0.9989486,0.00005585397,0.00040668505,0.0005178126,0.000047251346,0.000023831497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024937524,0.00027879403,0.0024902592,0.00056871836,0.000022294042,0.0000052992928,0.00017423269,0.00055983517,0.00022477185],"category_scores_gemma":[0.000065791144,0.00024257766,0.0005767817,0.0005100998,0.00014104244,0.00003354453,0.000053140076,0.00050941395,0.000008836467],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013307351,0.00009951165,0.000009248635,0.0078042047,0.0013336388,0.00004601631,0.000080556216,2.7647802e-8,0.000069649665,0.00021763766,0.0026389784,0.9875675],"study_design_scores_gemma":[0.0009874688,0.00020005502,0.000015033215,0.011898295,0.00061492115,0.00027778352,0.00026788047,0.000002934025,0.00008962879,0.00016558355,0.9852858,0.00019458537],"about_ca_topic_score_codex":0.000048753274,"about_ca_topic_score_gemma":0.000008927073,"teacher_disagreement_score":0.9873729,"about_ca_system_score_codex":0.000412961,"about_ca_system_score_gemma":0.0005745816,"threshold_uncertainty_score":0.989203},"labels":[],"label_agreement":null},{"id":"W3119551045","doi":"10.1016/j.ejca.2020.12.006","title":"Corrigendum to “A six-weekly (Q6W) dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation” [Eur J Canc 131 (2020) 68–75]","year":2021,"lang":"en","type":"erratum","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Dosing; Regret; Schedule; Medicine; Cancer; Medical physics; Family medicine; Internal medicine; Computer science; Statistics; Mathematics","score_opus":0.05203422038001544,"score_gpt":0.3276092768531242,"score_spread":0.27557505647310876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119551045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87207067,0.0488998,0.028296823,0.0022267376,0.04100616,0.004414661,0.00044770067,0.000040802082,0.0025966375],"genre_scores_gemma":[0.97794574,0.0011802518,0.004598112,0.0026766537,0.0049805013,0.00004441301,0.00021492281,0.0003752232,0.007984195],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99683857,0.00030362094,0.0008808981,0.0004672404,0.0011270626,0.00038263417],"domain_scores_gemma":[0.9968654,0.000054792356,0.0009328828,0.0002760132,0.0016567917,0.00021414743],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010298061,0.00041307058,0.0007330863,0.00044939088,0.00014427876,0.00010138777,0.00014473472,0.00011898728,0.00029655138],"category_scores_gemma":[0.00010495457,0.00034178427,0.00018493854,0.0004372744,0.00004850643,0.00015445029,0.000025199697,0.0007232657,7.8319033e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018509235,0.00017431877,0.005425117,0.00037912914,0.00040722045,0.000073813935,0.00051686517,0.91193515,0.00016739308,3.2233342e-7,0.026678171,0.03573325],"study_design_scores_gemma":[0.031534128,0.002909867,0.049524307,0.018421596,0.0015181863,0.000016158807,0.00014903434,0.754409,0.0001529669,0.0000025425074,0.14049888,0.000863301],"about_ca_topic_score_codex":0.00024882748,"about_ca_topic_score_gemma":0.00019488727,"teacher_disagreement_score":0.15752612,"about_ca_system_score_codex":0.0015803125,"about_ca_system_score_gemma":0.0025316544,"threshold_uncertainty_score":0.99990344},"labels":[],"label_agreement":null},{"id":"W3119577993","doi":"10.1016/j.cllc.2020.12.015","title":"Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Bristol-Myers Squibb Canada; Bayer; AstraZeneca; Amgen; Pfizer; Merck","keywords":"Medicine; Hazard ratio; Lung cancer; Internal medicine; Oncology; Exon; Confidence interval; Response Evaluation Criteria in Solid Tumors; Cancer research; Mutation; Population; Progressive disease; Chemotherapy; Biology; Genetics; Gene","score_opus":0.025623159091516502,"score_gpt":0.38673176705541334,"score_spread":0.3611086079638968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119577993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97880024,0.0132265445,0.000022575743,0.00695555,0.0004545238,0.00036239467,0.000028811695,0.000023810782,0.00012557438],"genre_scores_gemma":[0.9941038,0.002212232,0.0006210767,0.002015052,0.000118961776,0.000041687985,0.0000041136236,0.000023689074,0.0008593953],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99797726,0.00022001873,0.00095666293,0.00037514287,0.0002469452,0.0002239567],"domain_scores_gemma":[0.9984061,0.0005719824,0.00018471782,0.00040251514,0.00024219207,0.00019248301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013020498,0.0001533381,0.00057371886,0.000063261214,0.000041359996,0.000015620477,0.00008082822,0.00009385656,0.00033553506],"category_scores_gemma":[0.0012126495,0.00012545416,0.00022986968,0.00039211535,0.0002487563,0.000054731932,0.00008558321,0.00022937189,0.0000064467235],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033584442,0.0003573903,0.100221165,0.00041489702,0.00078920776,0.0001737914,0.0006226467,0.000015140862,0.8225474,0.00001917195,0.0010419621,0.040212825],"study_design_scores_gemma":[0.005115726,0.0009860775,0.79646164,0.0016360194,0.00039874436,0.000053786203,0.0002768217,0.0000636107,0.17150491,0.000036506714,0.023196135,0.0002700464],"about_ca_topic_score_codex":0.0002456891,"about_ca_topic_score_gemma":0.00008618279,"teacher_disagreement_score":0.6962404,"about_ca_system_score_codex":0.00011657998,"about_ca_system_score_gemma":0.0006793964,"threshold_uncertainty_score":0.5115872},"labels":[],"label_agreement":null},{"id":"W3119730599","doi":"10.1158/1078-0432.ccr-20-3241","title":"Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Cancer Institute; Dana-Farber Cancer Institute; University of Texas MD Anderson Cancer Center; Stanford University; Language Literacy and Culture, University of Maryland, Baltimore County","keywords":"Cancer; Biomarker; Clinical trial; Medicine; Harmonization; Cancer immunotherapy; Cancer biomarkers; Immunotherapy; Oncology; Computational biology; Internal medicine; Biology","score_opus":0.36760951917107715,"score_gpt":0.5418912594727787,"score_spread":0.17428174030170157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119730599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.53410405,0.44743702,0.00031443872,0.012239147,0.0018700615,0.0020635668,0.0018449522,0.00009940439,0.00002735897],"genre_scores_gemma":[0.50040793,0.48629478,0.0022698678,0.000998571,0.0021452825,0.005109997,0.00054805516,0.00024688157,0.0019786302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939747,0.00054142583,0.0015130384,0.0017528934,0.00067460677,0.0015433693],"domain_scores_gemma":[0.99382687,0.0024666796,0.0003902015,0.0017452367,0.0012465781,0.00032444735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004765711,0.00050508924,0.0016462875,0.00033449492,0.00088834175,0.00026478854,0.0007579893,0.00049087196,0.00039629254],"category_scores_gemma":[0.0004643034,0.00044732762,0.000590805,0.0019690562,0.0011844566,0.00028291365,0.00077380816,0.0010960666,8.9419297e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019356158,0.00032271622,0.48410195,0.0006027044,0.012933602,0.00002077367,0.00022269986,0.000060859005,0.05368742,0.000024637431,0.004477756,0.4241887],"study_design_scores_gemma":[0.020077812,0.000964268,0.73417294,0.0023455697,0.0035598557,0.00001737539,0.0010714165,0.0069742044,0.0073385015,0.00032333256,0.2219822,0.001172532],"about_ca_topic_score_codex":0.015739508,"about_ca_topic_score_gemma":0.0033240924,"teacher_disagreement_score":0.4230162,"about_ca_system_score_codex":0.0006264261,"about_ca_system_score_gemma":0.0016603626,"threshold_uncertainty_score":0.9997978},"labels":[],"label_agreement":null},{"id":"W3120020820","doi":"10.1093/jnci/djaa216","title":"Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges","year":2020,"lang":"en","type":"review","venue":"JNCI Journal of the National Cancer Institute","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Medicine; Immunotherapy; Neoadjuvant therapy; Oncology; Melanoma; Adjuvant; Immune checkpoint; Immune system; Clinical trial; Cancer; Internal medicine; Immunology; Cancer research; Breast cancer","score_opus":0.18904853290741855,"score_gpt":0.42885690711422336,"score_spread":0.23980837420680481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120020820","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019634672,0.9868064,0.000056857185,0.004189328,0.006737792,0.0012361426,0.0006862719,0.000008930114,0.00008195781],"genre_scores_gemma":[0.000082911174,0.99380577,0.00076895463,0.0005592211,0.0035783723,0.00009682453,0.000041457966,0.000039986957,0.0010265004],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99674624,0.00018809435,0.0014510355,0.00036291574,0.0010380329,0.00021369699],"domain_scores_gemma":[0.9961662,0.00046787725,0.0019035899,0.00020901754,0.0011300613,0.00012321859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022813573,0.00030887255,0.0014060566,0.00023233196,0.0004005241,0.000107980515,0.00045080003,0.00025827312,0.00006983504],"category_scores_gemma":[0.0007928284,0.00018323927,0.0011001086,0.00040008902,0.00048436242,0.00025186015,0.00006433715,0.0007362041,0.0000030044482],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013168349,0.00011862405,0.00003410926,0.0027953736,0.002222916,0.000008411721,0.00011841896,0.000007318556,0.000033513537,0.00077620876,0.025618965,0.9669493],"study_design_scores_gemma":[0.002950937,0.000357253,0.0003097667,0.007557161,0.000929435,0.00028870776,0.000015538732,0.000012614651,0.000016000256,0.0005213081,0.98685306,0.00018821267],"about_ca_topic_score_codex":0.00004417917,"about_ca_topic_score_gemma":0.000111542104,"teacher_disagreement_score":0.9667611,"about_ca_system_score_codex":0.0006796429,"about_ca_system_score_gemma":0.0057135886,"threshold_uncertainty_score":0.9999231},"labels":[],"label_agreement":null},{"id":"W3120146143","doi":"10.3390/curroncol28010028","title":"Tuberculous Lymphadenitis in a Patient Receiving PD-1 Inhibitor for Melanoma: A Case Report and Brief Literature Review","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Nivolumab; Medicine; Melanoma; Immunotherapy; Oncolytic virus; Metastatic melanoma; Oncology; Internal medicine; Ipilimumab; Pembrolizumab; Cancer; Combination therapy; Immunology; Cancer research","score_opus":0.040142697618898375,"score_gpt":0.3674361394173771,"score_spread":0.3272934417984787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120146143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.53974956,0.454485,0.000014534677,0.0036115332,0.0010634573,0.00074633147,0.000033282908,0.00001873894,0.00027755563],"genre_scores_gemma":[0.70074886,0.28858167,0.0016558267,0.005607362,0.0010415486,0.0010380605,0.00071301893,0.000070919006,0.00054270675],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99865335,0.00011051209,0.0005315078,0.00037618566,0.0000984516,0.00022997276],"domain_scores_gemma":[0.99921507,0.00013111008,0.00014326852,0.00022385604,0.00019342203,0.00009325644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029009173,0.00014634208,0.00047518336,0.00007654211,0.000050645944,0.000017148777,0.000025584466,0.00013230812,0.00006473235],"category_scores_gemma":[0.00043392065,0.00012901316,0.00012554774,0.00030096233,0.000056000437,0.000051187526,0.000043891996,0.00017552912,9.4788e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006749851,0.00054439035,0.0040256353,0.0039792643,0.00007858317,0.23538858,0.0013182658,3.096697e-8,0.0010874015,0.000013746285,0.018495545,0.7343936],"study_design_scores_gemma":[0.0035887118,0.0006049689,0.0012429171,0.00678759,0.00011868476,0.43427166,0.00013717926,0.000010884618,0.00043766593,0.00001893418,0.5526428,0.00013794388],"about_ca_topic_score_codex":0.000022635453,"about_ca_topic_score_gemma":0.00018071776,"teacher_disagreement_score":0.7342556,"about_ca_system_score_codex":0.00031004468,"about_ca_system_score_gemma":0.00038171138,"threshold_uncertainty_score":0.5261004},"labels":[],"label_agreement":null},{"id":"W3120579476","doi":"10.1007/s00262-020-02823-1","title":"Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"CD8; Immunosenescence; Lung cancer; Immunology; Immune system; Medicine; Cytotoxic T cell; Cancer; Internal medicine; Oncology; Biology","score_opus":0.00831132474066344,"score_gpt":0.2774168532262508,"score_spread":0.2691055284855874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120579476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8988683,0.09839613,0.00003214746,0.0010652626,0.00051598856,0.00074844854,0.00014019015,0.000081302715,0.00015223633],"genre_scores_gemma":[0.93336964,0.063139066,0.0002480655,0.0014003597,0.00006610238,0.00071679585,0.00029365814,0.00008759988,0.0006787295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979094,0.00013316935,0.00057977764,0.00057261554,0.0002536462,0.00055135123],"domain_scores_gemma":[0.99862176,0.00011848419,0.00030189546,0.00052148016,0.00036668795,0.000069706875],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013656545,0.00036257878,0.0006811517,0.00023889262,0.00024000696,0.00004567541,0.0001377525,0.0002709992,0.00053702766],"category_scores_gemma":[0.000042620974,0.00033031663,0.00012469171,0.0008664939,0.0003291387,0.00028401578,0.00004051512,0.000346924,0.0000020068676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003183265,0.0003322839,0.90234244,0.000029128996,0.001152271,0.00003671438,0.0009975948,0.000056108616,0.017656147,0.000031796662,0.00013802321,0.07404424],"study_design_scores_gemma":[0.02308186,0.00028331406,0.9666406,0.00040053923,0.000115901814,0.000012837192,0.00018229644,0.000057021094,0.00379092,0.000015170502,0.0050389566,0.00038059644],"about_ca_topic_score_codex":0.0035638274,"about_ca_topic_score_gemma":0.0038328785,"teacher_disagreement_score":0.07366365,"about_ca_system_score_codex":0.0012592749,"about_ca_system_score_gemma":0.0007777967,"threshold_uncertainty_score":0.9999149},"labels":[],"label_agreement":null},{"id":"W3122051635","doi":"10.1007/s00262-021-02851-5","title":"Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology","year":2021,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; University of Ottawa; Western University; University of Alberta; University of Toronto; Dalhousie University; University of British Columbia; University of Calgary; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Immunosuppression; Internal medicine; Psoriatic arthritis; Discontinuation; Context (archaeology); Rheumatology; Adverse effect; Cancer; Rheumatoid arthritis; Psoriasis; Polyarthritis; Arthritis; Oncology; Immunology","score_opus":0.03504324545533205,"score_gpt":0.3368035687868914,"score_spread":0.30176032333155933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122051635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.815529,0.17426826,0.0000036798392,0.007300841,0.00086502987,0.0011923584,0.0004145892,0.00009748549,0.00032877206],"genre_scores_gemma":[0.9628211,0.034198646,0.00012911911,0.0008407009,0.00004204249,0.0008602791,0.00035273362,0.00018642166,0.0005689145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99353623,0.0016965745,0.00170454,0.001010467,0.0007171259,0.0013350571],"domain_scores_gemma":[0.9953902,0.0012462587,0.0007875515,0.0011056062,0.0012837226,0.00018666839],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002195222,0.00066526124,0.0015204609,0.0006331174,0.00093772716,0.0000460419,0.00058000005,0.00077313214,0.0012587693],"category_scores_gemma":[0.00040634302,0.0005425346,0.00032974622,0.0019930769,0.0025827698,0.00036527822,0.0001732268,0.0016085436,0.0000044945864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030594498,0.0016021718,0.56842536,0.0001851729,0.017853286,0.004560099,0.012055053,0.00014097148,0.32674932,0.0022592589,0.00031372008,0.035261095],"study_design_scores_gemma":[0.022398023,0.00091206573,0.95351267,0.002242272,0.00022998071,0.0032189724,0.0028398724,0.00010970593,0.0023879234,0.0014021134,0.009969146,0.0007772562],"about_ca_topic_score_codex":0.3103614,"about_ca_topic_score_gemma":0.300926,"teacher_disagreement_score":0.3850873,"about_ca_system_score_codex":0.002983382,"about_ca_system_score_gemma":0.008259981,"threshold_uncertainty_score":0.99970263},"labels":[],"label_agreement":null},{"id":"W3122855631","doi":"10.3390/curroncol28010059","title":"Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Institute for Research in Immunology and Cancer; Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Immunotherapy; Brain metastasis; Metastasis; Cancer","score_opus":0.09877714152805095,"score_gpt":0.4456508150187392,"score_spread":0.34687367349068826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122855631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783622,0.020310778,0.000019107101,0.00017940752,0.00041642642,0.0001904982,0.00002182332,0.0000065966474,0.00049318443],"genre_scores_gemma":[0.9932137,0.0064240815,0.00013301475,0.000017299242,0.000055695513,0.00002370437,0.000043762102,0.000008065154,0.00008064222],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991979,0.00013279337,0.00024717653,0.0001829359,0.00007748377,0.00016170097],"domain_scores_gemma":[0.9993906,0.00014029224,0.00019765826,0.00014621178,0.000057201767,0.00006803112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010637994,0.000111349735,0.00040970114,0.00010049868,0.00001639348,0.0000033564152,0.000026526977,0.000059810274,0.0002629755],"category_scores_gemma":[0.00008495472,0.000077283155,0.0001182899,0.00016884581,0.00009092921,0.00002527347,0.000025681244,0.000082851315,0.0000021044868],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005157575,0.0022360885,0.22354768,0.00016250752,0.00027507526,0.00027659492,0.00204143,0.000003499424,0.15940039,0.000013538076,0.0005589246,0.6063267],"study_design_scores_gemma":[0.022099605,0.0054907803,0.91688824,0.001014175,0.00018667345,0.0002940916,0.00093953434,0.000083427745,0.03786415,0.00010047441,0.014833442,0.00020542146],"about_ca_topic_score_codex":0.000070745744,"about_ca_topic_score_gemma":0.000078321376,"teacher_disagreement_score":0.69334054,"about_ca_system_score_codex":0.00036657817,"about_ca_system_score_gemma":0.00044388365,"threshold_uncertainty_score":0.31515157},"labels":[],"label_agreement":null},{"id":"W3122927199","doi":"10.3390/biomedicines9020101","title":"Checkpoint Inhibitors and Hepatotoxicity","year":2021,"lang":"en","type":"review","venue":"Biomedicines","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Immune system; Cancer research; Immune checkpoint; Immunology; Mechanism (biology); Immunotherapy; Biology; Tumor microenvironment; Immune tolerance; Medicine","score_opus":0.05049969239815653,"score_gpt":0.35160065384467226,"score_spread":0.3011009614465157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122927199","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011618894,0.997281,0.000003827856,0.00037226573,0.000842457,0.00069465325,0.00002734441,0.00007153452,0.0005907117],"genre_scores_gemma":[0.000013571541,0.9967186,0.00011150059,0.0003112151,0.0012176936,0.00006363622,0.00021942703,0.000054721844,0.0012896615],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99820334,0.00006506168,0.00070342625,0.00048051644,0.0002877407,0.00025993792],"domain_scores_gemma":[0.9990142,0.000083513034,0.00023720966,0.00040216203,0.00006883692,0.00019410795],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030417542,0.00042152638,0.0020728037,0.0003130048,0.00005943515,0.000022705177,0.000078372475,0.0003760654,0.00022583995],"category_scores_gemma":[0.00008326482,0.00027360642,0.00053108245,0.0006359217,0.00031567225,0.000028981052,0.00007561428,0.00027349815,0.000016430098],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025152198,0.000057385616,0.000035539702,0.01614063,0.0004174791,0.00014304538,0.000038912116,1.2220179e-10,0.000072077455,0.0000058874816,0.008075139,0.97498876],"study_design_scores_gemma":[0.00069904927,0.00018774546,0.000041882795,0.038417798,0.0010913064,0.0010011672,0.000044311022,3.07271e-7,0.000042591357,0.0000023007285,0.9582224,0.0002491515],"about_ca_topic_score_codex":0.000100658515,"about_ca_topic_score_gemma":0.0000064905807,"teacher_disagreement_score":0.9747396,"about_ca_system_score_codex":0.00012810942,"about_ca_system_score_gemma":0.00043936193,"threshold_uncertainty_score":0.9999716},"labels":[],"label_agreement":null},{"id":"W3123363775","doi":"10.1016/j.jtho.2020.11.018","title":"Meeting Immunotherapy Resistance in Lung Cancer","year":2021,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Takeda Canada; Pfizer Canada; Amgen Canada; Princess Margaret Cancer Foundation; Merck Sharp and Dohme; Open Society Institute; Roche; Boehringer Ingelheim; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Immunotherapy; Oncology; Cancer; Internal medicine","score_opus":0.024147572562883156,"score_gpt":0.40616278526307026,"score_spread":0.3820152127001871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123363775","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019576455,0.16522571,0.00002670068,0.80601054,0.0032654342,0.00028880328,0.0000146202065,0.000011735771,0.00557997],"genre_scores_gemma":[0.003223231,0.036083587,0.0054117134,0.92346424,0.01247583,0.00004368731,0.00003889567,0.00015349855,0.0191053],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968533,0.00050607393,0.0013730024,0.0002864549,0.00052952697,0.00045162896],"domain_scores_gemma":[0.9972302,0.00033390432,0.0016122401,0.00033956915,0.000422623,0.000061464845],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012890719,0.00031164844,0.0014840384,0.00052394206,0.000050407194,0.000029717976,0.0002987427,0.0011222987,0.0008804878],"category_scores_gemma":[0.00010389823,0.00025822065,0.00057390076,0.00045330834,0.00012611058,0.00008915274,0.000033781198,0.0034140188,0.0000018978865],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007659668,0.000156892,0.0011077517,0.000857339,0.0010173421,0.01328237,0.00055243407,0.000002593872,0.0052465717,7.103312e-7,0.92882556,0.041290756],"study_design_scores_gemma":[0.0019293447,0.00038287646,0.0020097452,0.004430696,0.0003203094,0.0010729731,0.00010893678,0.000004462882,0.0007931795,0.00003601878,0.9886775,0.00023396726],"about_ca_topic_score_codex":0.00011228373,"about_ca_topic_score_gemma":0.00038381811,"teacher_disagreement_score":0.12914214,"about_ca_system_score_codex":0.002213787,"about_ca_system_score_gemma":0.002609537,"threshold_uncertainty_score":0.999987},"labels":[],"label_agreement":null},{"id":"W3123536427","doi":"10.2139/ssrn.3720296","title":"Checkpoint Inhibitor Induced Colitis is Dependent on the Microbiota and Activation of Cytotoxic Innate and Adaptive Lymphocytes","year":2020,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Cytotoxic T cell; Colitis; Innate immune system; Innate lymphoid cell; Chemistry; Immunology; Biology; Biochemistry; Immune system; In vitro","score_opus":0.018068204761195757,"score_gpt":0.24000606295871826,"score_spread":0.22193785819752251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123536427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98898935,0.0014373751,0.000051542545,0.009146263,0.000029117868,0.0002443853,0.000005236625,0.0000068281115,0.00008988449],"genre_scores_gemma":[0.99434394,0.003680016,0.000012774849,0.0017589787,0.00012332456,0.0000040017826,0.0000011369793,0.000012906112,0.000062896324],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99898344,0.00005293519,0.00021690226,0.0001453388,0.0001570096,0.00044437396],"domain_scores_gemma":[0.9995991,0.000047511407,0.0001604105,0.000073488794,0.000058597798,0.00006090487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041793595,0.00011426958,0.0001741257,0.000051423347,0.00009567596,0.000020472125,0.00005364491,0.00006484581,0.000028402146],"category_scores_gemma":[0.00004229057,0.000075987205,0.00005485254,0.00012539454,0.00006750806,0.000059078204,0.00002307459,0.00058397383,0.0000011473953],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048594363,0.000041785588,0.0003431912,0.000020388336,0.00036736965,0.0000023355026,0.001199913,1.9142392e-7,0.97344804,0.001119732,0.000091651804,0.018505987],"study_design_scores_gemma":[0.004626948,0.0033765002,0.012490935,0.00021681775,0.00006611648,0.00046648146,0.0035451963,0.00005858202,0.9732847,0.0014635002,0.0002708195,0.00013339646],"about_ca_topic_score_codex":0.00009944119,"about_ca_topic_score_gemma":0.00004589975,"teacher_disagreement_score":0.018372592,"about_ca_system_score_codex":0.00048092354,"about_ca_system_score_gemma":0.00085978745,"threshold_uncertainty_score":0.30986685},"labels":[],"label_agreement":null},{"id":"W3123927868","doi":"10.1177/1078155220984252","title":"Safety and efficacy analysis of pembrolizumab dosing patterns in patients with advanced melanoma and non-small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Adverse effect; Lung cancer; Oncology; Melanoma; Dosing; Cancer; Clinical endpoint; Ipilimumab; Area under the curve; Retrospective cohort study; Immunotherapy; Clinical trial","score_opus":0.013520859069533205,"score_gpt":0.34912054884712973,"score_spread":0.3355996897775965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123927868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99293107,0.0044295774,0.000118652555,0.0017802392,0.00013225539,0.00018268246,0.00001266383,0.000001951097,0.00041092557],"genre_scores_gemma":[0.98768467,0.009998858,0.0012545396,0.00097277266,0.00004281028,0.0000020979203,0.0000056639838,0.000011937193,0.000026665346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987139,0.0002006723,0.00056415633,0.0001647905,0.00020039256,0.00015605256],"domain_scores_gemma":[0.99787223,0.0005887684,0.0009213722,0.00010093082,0.00041642218,0.000100244964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045615938,0.00012325919,0.0006114154,0.00027515317,0.000038874106,0.0000116861365,0.00005079381,0.000050837807,0.000107251064],"category_scores_gemma":[0.000101250385,0.00009620432,0.00008374583,0.0004717525,0.0000551947,0.00030255987,0.000031544056,0.00036870915,6.8334934e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06164818,0.0011007357,0.85767627,0.00013198718,0.0030771731,0.00040311896,0.0011716203,0.00016480859,0.009246784,3.942999e-7,0.000031666255,0.06534727],"study_design_scores_gemma":[0.051794823,0.0011932872,0.92705184,0.00021485618,0.006365562,0.00021957268,0.0004764553,0.00036362075,0.003539326,1.6586665e-7,0.008672576,0.00010793665],"about_ca_topic_score_codex":0.000132641,"about_ca_topic_score_gemma":0.00010199368,"teacher_disagreement_score":0.06937556,"about_ca_system_score_codex":0.00024846548,"about_ca_system_score_gemma":0.0005369154,"threshold_uncertainty_score":0.39230984},"labels":[],"label_agreement":null},{"id":"W3124047768","doi":"10.1002/eji.202048747","title":"Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action","year":2021,"lang":"en","type":"review","venue":"European Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"Cancer Research UK; Medical Research Council; National Institute for Health and Care Research; Breast Cancer Now","keywords":"Ipilimumab; Nivolumab; Pembrolizumab; Immune checkpoint; Blockade; Immune system; CTLA-4; Melanoma; Immunotherapy; Immunology; Cytotoxic T cell; Biology; Cancer research; T cell; Medicine; Internal medicine; Receptor","score_opus":0.04351420935544933,"score_gpt":0.30832786575545507,"score_spread":0.26481365640000576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124047768","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04090694,0.95779705,0.000057562484,0.0001304336,0.000542874,0.00031807978,0.00001749974,0.00000710104,0.00022244378],"genre_scores_gemma":[0.022701513,0.9765275,0.00040013733,0.0000101070755,0.00008854815,0.0000016512265,0.000025960342,0.00005985125,0.0001847144],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969047,0.0007670436,0.0017090396,0.00023938305,0.00017321388,0.00020665099],"domain_scores_gemma":[0.99704176,0.000115133735,0.0021968137,0.0003623246,0.00021665034,0.000067311244],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068426866,0.0003827524,0.0030237534,0.0004136974,0.000047520785,0.00001313195,0.00014714853,0.00015642913,0.00009803988],"category_scores_gemma":[0.0000514113,0.00026778277,0.0006745103,0.00022602532,0.00029644225,0.00005235079,0.000077020566,0.00032983368,0.0000018832612],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009026574,0.00042307228,0.000019216359,0.0023831495,0.0048572775,0.00055575895,0.00021351059,6.208659e-8,0.11348987,0.000041226027,0.000016375025,0.87709785],"study_design_scores_gemma":[0.027040962,0.03550186,0.010809781,0.04474842,0.011020147,0.03501602,0.0010045957,0.000002007265,0.11324802,0.000040825304,0.72064614,0.00092123373],"about_ca_topic_score_codex":0.000017750752,"about_ca_topic_score_gemma":4.6426914e-7,"teacher_disagreement_score":0.8761766,"about_ca_system_score_codex":0.00010588607,"about_ca_system_score_gemma":0.00027320898,"threshold_uncertainty_score":0.9999774},"labels":[],"label_agreement":null},{"id":"W3124154134","doi":"10.21203/rs.3.rs-152467/v1","title":"Functional and Molecular Characterization of PD1+&amp;nbsp;Tumor-Infiltrating Lymphocytes From Lung Cancer Patients","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Innovative Medicines Initiative; European Commission; European Federation of Pharmaceutical Industries and Associations","keywords":"Lung cancer; Cancer research; Characterization (materials science); Cancer; Tumor-infiltrating lymphocytes; Chemistry; Medicine; Pathology; Internal medicine; Materials science; Nanotechnology; Immunotherapy","score_opus":0.038886791344254205,"score_gpt":0.35911610956796824,"score_spread":0.32022931822371403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124154134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99182296,0.0058027995,0.00020527504,0.00029887434,0.000308881,0.0008280474,0.000556501,0.000024135443,0.00015254333],"genre_scores_gemma":[0.9921774,0.00208947,0.00021299726,0.0001410469,0.0002470498,0.00019841247,0.004705119,0.00004172661,0.0001867603],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974545,0.000228908,0.0004071863,0.0005302117,0.0010739818,0.000305164],"domain_scores_gemma":[0.9981452,0.00012955003,0.00019221449,0.00039826997,0.0010129542,0.000121761674],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037956348,0.00020815391,0.00041304462,0.00022392265,0.00011040026,0.00009267824,0.00010158358,0.00021119871,0.0010853679],"category_scores_gemma":[0.00020255028,0.00019723554,0.00014785117,0.00030056087,0.00015241961,0.00007631778,0.00030444257,0.0005318101,0.0000018324549],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015385485,0.00025637276,0.2580339,0.0025268707,0.0006347356,0.000027275417,0.00084986555,0.000010962674,0.7246068,0.000007727081,0.0003382351,0.011168677],"study_design_scores_gemma":[0.002762011,0.00016295118,0.9005576,0.005424683,0.0001025079,0.000004074234,0.0002608081,0.00062906643,0.08891648,0.000025880485,0.0008909163,0.00026303233],"about_ca_topic_score_codex":0.0023370336,"about_ca_topic_score_gemma":0.00007202413,"teacher_disagreement_score":0.6425237,"about_ca_system_score_codex":0.00046963236,"about_ca_system_score_gemma":0.0011429448,"threshold_uncertainty_score":0.9998278},"labels":[],"label_agreement":null},{"id":"W3124587416","doi":"10.1200/jco.20.03579","title":"Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; St Mary's Hospital Centre","funders":"","keywords":"Pembrolizumab; Ipilimumab; Medicine; Internal medicine; Placebo; Lung cancer; Hazard ratio; Population; Oncology; Adverse effect; Cancer; Surgery; Immunotherapy; Confidence interval; Pathology","score_opus":0.15214844631860835,"score_gpt":0.48328001778486057,"score_spread":0.3311315714662522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124587416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819226,0.0029016733,0.0042964946,0.0027795085,0.0017840151,0.005840981,0.000015420914,0.00001839543,0.00044090682],"genre_scores_gemma":[0.9867811,0.0014282205,0.0041373153,0.0020857658,0.0014705398,0.0005364182,0.000019423436,0.00007018265,0.003471003],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99326617,0.0007897009,0.0042763064,0.0004989075,0.0006899432,0.000478979],"domain_scores_gemma":[0.9909409,0.0030586908,0.0037935255,0.00037126805,0.0013942958,0.00044129306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006839171,0.000373422,0.004099119,0.00021588276,0.00013994944,0.00004510379,0.00023750169,0.00024747464,0.00077646127],"category_scores_gemma":[0.0011216006,0.0002140886,0.0011287192,0.0003634198,0.0003629474,0.00017921535,0.000054952074,0.0010840216,0.0000028676843],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96211195,0.009080695,0.0010780864,0.00035302056,0.0046310634,0.0028660323,0.0006052472,0.000107887914,0.00047724595,0.000004636318,0.0013915651,0.017292565],"study_design_scores_gemma":[0.94591606,0.033387527,0.00074319215,0.000468176,0.00810885,0.0014551391,0.0015834813,0.0013843486,0.0008365635,0.000015719543,0.005832949,0.00026801182],"about_ca_topic_score_codex":0.00015110547,"about_ca_topic_score_gemma":0.0010052067,"teacher_disagreement_score":0.024306834,"about_ca_system_score_codex":0.0006003005,"about_ca_system_score_gemma":0.01445833,"threshold_uncertainty_score":0.9911288},"labels":[],"label_agreement":null},{"id":"W3124917933","doi":"10.1016/j.jtho.2020.11.029","title":"Shifting From a “One Size Fits All” to a Tailored Approach for Immune-Related Adverse Events","year":2021,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; Merck Sharp and Dohme; Roche Italia; Daiichi Sankyo Company; Clovis Oncology; Merck KGaA; United Therapeutics Corporation; Celgene; Bayer; Novartis; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Nivolumab; Adverse effect; Lung cancer; Internal medicine; Oncology; Scopus; Clinical trial; Docetaxel; Cancer; MEDLINE; Immunotherapy","score_opus":0.04296113153062505,"score_gpt":0.37961464062165257,"score_spread":0.33665350909102754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124917933","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10098176,0.0081614945,0.0020843807,0.88043475,0.004760777,0.002180002,0.0001910765,0.00005019298,0.0011555416],"genre_scores_gemma":[0.028162032,0.00084299385,0.14703946,0.7979899,0.013350224,0.00018919972,0.0012580935,0.00032909858,0.010838999],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960001,0.00044309697,0.0019029861,0.00046632712,0.00059987814,0.0005876262],"domain_scores_gemma":[0.99586624,0.0009181396,0.0020029305,0.0004615239,0.000556924,0.00019425213],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0013008445,0.00043236496,0.0019823976,0.0002914613,0.000085429565,0.00001650172,0.00044082047,0.0016335744,0.0005380411],"category_scores_gemma":[0.00078587455,0.00037297877,0.0012824321,0.00037154494,0.00007539789,0.000097964796,0.00011065255,0.0024824007,0.000012550497],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045308046,0.001299645,0.00022163599,0.001171796,0.014376518,0.0043957066,0.002550868,0.000042245116,0.05004281,0.000001094281,0.80150205,0.07908758],"study_design_scores_gemma":[0.0076071178,0.0044504805,0.0025716177,0.0022209724,0.0037770802,0.0017531426,0.00064540695,0.000081235004,0.0014827306,0.00012790719,0.9747069,0.00057542877],"about_ca_topic_score_codex":0.00006340592,"about_ca_topic_score_gemma":0.0000066791636,"teacher_disagreement_score":0.17320482,"about_ca_system_score_codex":0.0010760264,"about_ca_system_score_gemma":0.0012598607,"threshold_uncertainty_score":0.9998722},"labels":[],"label_agreement":null},{"id":"W3125964008","doi":"10.1136/jitc-2020-001642","title":"Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"University of Toronto","keywords":"Medicine; Neuroblastoma RAS viral oncogene homolog; Oncology; Internal medicine; Melanoma; Cohort; Proportional hazards model; Nivolumab; Immune checkpoint; Progression-free survival; Retrospective cohort study; Cancer; Immunotherapy; Cancer research; Overall survival; KRAS","score_opus":0.025299693950167255,"score_gpt":0.3139723413321364,"score_spread":0.2886726473819692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125964008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9372703,0.0567195,0.00022811405,0.0010093366,0.0036290796,0.00065721886,0.00018171473,0.000028198368,0.0002765346],"genre_scores_gemma":[0.947132,0.0511978,0.0005766956,0.000097793105,0.0003334439,0.000034316836,0.000061538165,0.00008525091,0.00048117604],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964136,0.00012690682,0.0019328587,0.00037529404,0.0006829535,0.0004683966],"domain_scores_gemma":[0.9960448,0.00025150954,0.001857317,0.0005420596,0.0012098943,0.00009440629],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001088692,0.00041939295,0.0015385199,0.00035814726,0.00016539927,0.000032222106,0.00033789696,0.00032405992,0.00072204246],"category_scores_gemma":[0.00007817578,0.00034652956,0.0011885327,0.0006479716,0.0003772139,0.0002214761,0.0000348956,0.00035479484,8.856976e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016315836,0.00083378184,0.044793952,0.00031467972,0.003182535,0.000009130191,0.00048513108,0.000074081,0.8885269,0.0001522035,0.00019352906,0.045118246],"study_design_scores_gemma":[0.02450763,0.0030076741,0.23914815,0.000815375,0.00023574442,0.00005470643,0.00041292087,0.00007528881,0.7229314,0.00022830616,0.008271294,0.00031151786],"about_ca_topic_score_codex":0.0005116377,"about_ca_topic_score_gemma":0.00004918821,"teacher_disagreement_score":0.1943542,"about_ca_system_score_codex":0.0002651003,"about_ca_system_score_gemma":0.0007119322,"threshold_uncertainty_score":0.9998987},"labels":[],"label_agreement":null},{"id":"W3126798229","doi":"10.1016/j.ctarc.2021.100330","title":"A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors","year":2021,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"KRAS; Medicine; Internal medicine; Oncology; Lung cancer; Cancer; Adverse effect; Colorectal cancer","score_opus":0.0786849360391814,"score_gpt":0.40058061211302104,"score_spread":0.3218956760738396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126798229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752997,0.020092642,0.00000721588,0.0017239521,0.00007252848,0.0023077908,0.00009656409,0.000030140749,0.00036943663],"genre_scores_gemma":[0.97118044,0.025982117,0.0005056231,0.000021684511,0.000031479914,0.0014595935,0.00019189833,0.000032725853,0.0005944161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979891,0.0002574115,0.0005589944,0.00038688508,0.0004527377,0.0003548757],"domain_scores_gemma":[0.99710625,0.00028709366,0.00021799284,0.0011809609,0.0010775649,0.00013010396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003742371,0.00025698793,0.0005191158,0.00017933497,0.00065374054,0.00004365161,0.00021334377,0.00007984507,0.00007615206],"category_scores_gemma":[0.00007457829,0.00017771265,0.00012126596,0.00085076224,0.00037356664,0.000114029426,0.00020876894,0.00025976685,0.0000010729399],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025159214,0.008546894,0.8638816,0.00024551677,0.0014780875,0.000012523981,0.0050791637,0.000081024016,0.076166056,0.0000056314952,0.000025744139,0.04196182],"study_design_scores_gemma":[0.030419119,0.007867158,0.7965129,0.0019852163,0.0009198526,0.000003916833,0.003399466,0.0005774524,0.157068,0.0000053295926,0.00089271757,0.00034888863],"about_ca_topic_score_codex":0.011492285,"about_ca_topic_score_gemma":0.010945633,"teacher_disagreement_score":0.080901936,"about_ca_system_score_codex":0.0012076104,"about_ca_system_score_gemma":0.001125526,"threshold_uncertainty_score":0.99509025},"labels":[],"label_agreement":null},{"id":"W3127357052","doi":"10.1016/j.cllc.2021.01.014","title":"Outcomes of Patients With Interstitial Lung Disease Receiving Programmed Cell Death 1 Inhibitors: A Retrospective Case Series","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; National Cancer Institute; Scleroderma Foundation; National Heart, Lung, and Blood Institute; Francis Family Foundation","keywords":"Medicine; Pembrolizumab; Interstitial lung disease; Pneumonitis; Nivolumab; Lung cancer; Internal medicine; Respiratory failure; Retrospective cohort study; Cancer; Lung; Immunotherapy","score_opus":0.017857843154615218,"score_gpt":0.3471131015781794,"score_spread":0.3292552584235642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127357052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99555886,0.001515245,0.000044481953,0.00083231984,0.00090023706,0.0006853249,0.00014635366,0.000047453665,0.00026972155],"genre_scores_gemma":[0.99747443,0.00026458307,0.00041670553,0.0005141842,0.0002832224,0.00009522317,0.00005171355,0.000034581706,0.0008653791],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982891,0.0000935193,0.0006171209,0.00043597395,0.00030281697,0.00026146744],"domain_scores_gemma":[0.998603,0.0001397316,0.00024537105,0.00035705068,0.0004143075,0.0002405686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020131987,0.0001983247,0.0005552529,0.00004243404,0.00006897022,0.00002381693,0.00006305853,0.000103630904,0.00034196544],"category_scores_gemma":[0.00029164384,0.00014458569,0.00028878736,0.00024156387,0.0002409255,0.00012385602,0.00006377964,0.00027813044,8.656692e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008032505,0.0007056012,0.98319376,0.00031122108,0.0005276128,0.0008315381,0.00020224327,9.885619e-7,0.00003221331,0.0000061408864,0.0013190504,0.0048371404],"study_design_scores_gemma":[0.006646573,0.0006337935,0.9894745,0.00071154634,0.00064800965,0.00002771671,0.00014984612,0.000052930256,0.00043980186,0.000009409105,0.0009940102,0.00021190534],"about_ca_topic_score_codex":0.00013442498,"about_ca_topic_score_gemma":0.0003020096,"teacher_disagreement_score":0.0062807137,"about_ca_system_score_codex":0.00029929544,"about_ca_system_score_gemma":0.00055922515,"threshold_uncertainty_score":0.5896033},"labels":[],"label_agreement":null},{"id":"W3127379102","doi":"10.1097/cji.0000000000000360","title":"Impact of Baseline Corticosteroids on Immunotherapy Efficacy in Patients With Advanced Melanoma","year":2021,"lang":"en","type":"article","venue":"Journal of Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Western University","funders":"","keywords":"Medicine; Prednisone; Hazard ratio; Internal medicine; Confidence interval; Corticosteroid; Oncology; Immunotherapy; Retrospective cohort study; Cancer; Surgery","score_opus":0.00865073645500127,"score_gpt":0.2852234393671364,"score_spread":0.27657270291213515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127379102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932231,0.0056717433,0.00011249897,0.0002673796,0.00022769459,0.00033621938,0.000015866812,0.000009194314,0.00013632444],"genre_scores_gemma":[0.9952123,0.0028995306,0.0010602574,0.0005643133,0.00007417205,0.0000034785628,0.000017637254,0.00006283254,0.00010545406],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99755853,0.00016254358,0.0011518472,0.0002073094,0.0006146357,0.00030514228],"domain_scores_gemma":[0.9976966,0.00019226078,0.00084435235,0.00050881016,0.000669512,0.0000884733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046657122,0.0002966153,0.0008847839,0.00036556198,0.00003541834,0.00002190958,0.00018076305,0.00011160191,0.000659281],"category_scores_gemma":[0.0000697618,0.00019536822,0.0005479665,0.00060328015,0.00009715446,0.00017449592,0.000009950148,0.00039681312,0.0000027464612],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13059689,0.0054624146,0.30799365,0.000028778668,0.0018283837,0.00013961505,0.00057542237,0.00017357834,0.23819406,0.0000038576436,0.00016792225,0.31483543],"study_design_scores_gemma":[0.05252791,0.016349075,0.9086862,0.0009565346,0.0000375418,0.00012024439,0.000057478042,0.000007533185,0.01995991,0.0000065212703,0.0010944149,0.00019664784],"about_ca_topic_score_codex":0.0000311699,"about_ca_topic_score_gemma":0.0000056442045,"teacher_disagreement_score":0.6006926,"about_ca_system_score_codex":0.00037469104,"about_ca_system_score_gemma":0.00059229287,"threshold_uncertainty_score":0.7966885},"labels":[],"label_agreement":null},{"id":"W3127961017","doi":"10.1016/j.immuni.2021.01.011","title":"Germline genetic contribution to the immune landscape of cancer","year":2021,"lang":"en","type":"article","venue":"Immunity","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Calgary","funders":"Qatar National Research Fund; National Cancer Institute; National Institutes of Health; Janssen Biotech; MedImmune; Cancer Research Institute; AbbVie; Sanofi; Institut National de la Santé et de la Recherche Médicale; Associazione Italiana per la Ricerca sul Cancro; AstraZeneca","keywords":"Biology; Germline; Cancer; Immune system; Genetics; Evolutionary biology; Computational biology; Gene","score_opus":0.013371158133236955,"score_gpt":0.29803047707301145,"score_spread":0.2846593189397745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127961017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9550779,0.039236665,0.0001340671,0.0046687927,0.00026453089,0.00020756426,0.000038474,0.000016151707,0.0003558517],"genre_scores_gemma":[0.9971094,0.0011240147,0.00010755394,0.0007962114,0.00009657539,0.000025588675,0.00004122987,0.000008419668,0.0006910104],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9993174,0.00007890173,0.00023319758,0.00009090683,0.00014034918,0.00013921388],"domain_scores_gemma":[0.99913883,0.000049796847,0.00006456936,0.00044600834,0.00026403062,0.00003677868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002166499,0.00007618146,0.00019534232,0.000029928988,0.00008419242,0.000008450318,0.0000946417,0.000046153433,0.0008789726],"category_scores_gemma":[0.00009179721,0.000051621068,0.00010824686,0.00033389262,0.00004695421,0.000016306618,0.00005030245,0.00013488556,0.000012574274],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023277958,0.00030447383,0.047251966,0.00007476926,0.0005108316,0.000023394476,0.0006459052,0.000029518033,0.8608876,0.000080795115,0.0017341339,0.08612882],"study_design_scores_gemma":[0.0014898117,0.00011077865,0.7657989,0.000095676696,0.00007742666,0.00002835508,0.00013498822,0.000037289017,0.19275375,0.000012606141,0.03939824,0.000062155086],"about_ca_topic_score_codex":0.001254806,"about_ca_topic_score_gemma":0.00042118746,"teacher_disagreement_score":0.718547,"about_ca_system_score_codex":0.000046434172,"about_ca_system_score_gemma":0.00017737747,"threshold_uncertainty_score":0.9624134},"labels":[],"label_agreement":null},{"id":"W3128131226","doi":"10.1038/s41571-021-00473-5","title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","year":2021,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1560,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Biomarker; Concordance; Biomarker discovery; Oncology; Companion diagnostic; Immune checkpoint; Clinical trial; PD-L1; Cancer; Disease; Internal medicine; Immunotherapy; Bioinformatics; Biology; Proteomics","score_opus":0.1525086424784524,"score_gpt":0.5349054464247085,"score_spread":0.3823968039462561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128131226","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000064849046,0.9856509,0.000004238408,0.0029613574,0.0038299218,0.004520376,0.000047765632,0.000045850473,0.0028747371],"genre_scores_gemma":[0.000011001503,0.98927414,0.001752813,0.004350343,0.00091556896,0.00037797607,0.00017427535,0.000121542755,0.0030223578],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9825356,0.006602943,0.008367545,0.0013324285,0.0005515879,0.0006098984],"domain_scores_gemma":[0.98803693,0.005672629,0.003345355,0.0019434643,0.00043410916,0.00056748244],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.01688328,0.00090959144,0.013737183,0.0005224074,0.00005970756,0.00001672436,0.0006276474,0.005632502,0.0015354543],"category_scores_gemma":[0.022433473,0.0006032166,0.008643927,0.0019804828,0.0004422641,0.000042077365,0.00039917263,0.004371546,0.00056403317],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067165494,0.00079532,0.0000061013025,0.01255589,0.0012553202,0.00035106734,0.00002621952,2.7508984e-9,0.00012595058,0.00001230668,0.032560438,0.94559485],"study_design_scores_gemma":[0.0021596455,0.0035064504,0.00013835184,0.066103354,0.0032169328,0.00070341845,0.000013062686,9.893824e-8,0.000017810295,0.0000055247137,0.9236523,0.00048307635],"about_ca_topic_score_codex":0.000028234961,"about_ca_topic_score_gemma":0.000015639973,"teacher_disagreement_score":0.94511175,"about_ca_system_score_codex":0.0008330241,"about_ca_system_score_gemma":0.005869745,"threshold_uncertainty_score":0.99976605},"labels":[],"label_agreement":null},{"id":"W3128231733","doi":"10.3389/fimmu.2020.584937","title":"Reduced CD5 on CD8+ T Cells in Tumors but Not Lymphoid Organs Is Associated With Increased Activation and Effector Function","year":2021,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"Canadian Institutes of Health Research","keywords":"CD5; CD8; Cytotoxic T cell; T cell; Biology; Cancer research; Interleukin 21; IL-2 receptor; Flow cytometry; Molecular biology; Immunology; Immune system","score_opus":0.006458522124591778,"score_gpt":0.21009107119601975,"score_spread":0.20363254907142797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128231733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974004,0.0005532049,0.00018421069,0.00061770924,0.00063454953,0.0003412358,0.0000165231,0.000036855465,0.00021530692],"genre_scores_gemma":[0.9975207,0.0002450558,0.0002350139,0.0012962769,0.00003113853,0.000038084738,0.00012280009,0.00002814202,0.0004828121],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987502,0.00021438846,0.0002646476,0.0003571515,0.00013861118,0.00027497252],"domain_scores_gemma":[0.99944305,0.000107698994,0.00011932819,0.00023290291,0.00006316949,0.000033870685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021819545,0.00018127203,0.0004244641,0.00031386333,0.000050812672,0.000013398044,0.00005148506,0.00023531403,0.00009058086],"category_scores_gemma":[0.00014546963,0.00016532672,0.000043200314,0.0005732325,0.00013343578,0.00007529208,0.000018818591,0.00026886933,0.000004158377],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013098896,0.00026264414,0.046404615,0.000025408517,0.0003447322,0.00006963031,0.00045669396,0.0000021709832,0.93167096,0.0000039136157,0.0012967401,0.0063636145],"study_design_scores_gemma":[0.008982656,0.0008612318,0.43170437,0.00033629866,0.000042616408,0.000036576097,0.00064893597,0.000052709194,0.5564555,0.000018369308,0.00070527423,0.00015548883],"about_ca_topic_score_codex":0.00058096263,"about_ca_topic_score_gemma":0.00008107319,"teacher_disagreement_score":0.38529974,"about_ca_system_score_codex":0.0006732021,"about_ca_system_score_gemma":0.00027475035,"threshold_uncertainty_score":0.67418283},"labels":[],"label_agreement":null},{"id":"W3128527220","doi":"10.1038/s41598-021-83317-7","title":"Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial","year":2021,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Texas MD Anderson Cancer Center; National Institutes of Health; National Cancer Institute; Fondation du cancer des Cèdres; U.S. Department of Health and Human Services","keywords":"Pembrolizumab; Medicine; Response Evaluation Criteria in Solid Tumors; Discontinuation; Vulvar Carcinoma; Vulva; Internal medicine; Oncology; Population; Vaginal disease; Vulvar neoplasm; Chemotherapy; Vagina; Surgery; Dermatology; Progressive disease; Cancer; Immunotherapy","score_opus":0.017601567461385324,"score_gpt":0.2775365031636543,"score_spread":0.259934935702269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128527220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915363,0.0028536478,0.0000062140793,0.0003400178,0.0038259367,0.00044188017,0.000028404393,0.000029779078,0.00093777716],"genre_scores_gemma":[0.9929368,0.000010399177,0.00021594336,0.000073758994,0.00015881527,0.000030275234,0.00014463953,0.000015645126,0.006413755],"study_design_codex":"case_report","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979816,0.000068526715,0.00053458987,0.00077846705,0.00034777008,0.00028905476],"domain_scores_gemma":[0.99886405,0.00003425619,0.0001606104,0.0006783818,0.00011300658,0.00014972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006492591,0.00016471451,0.00032624183,0.00015316263,0.00027049115,0.00014624176,0.000036728612,0.00008542961,0.0007039875],"category_scores_gemma":[0.00010136201,0.0001483654,0.00010017958,0.0004896414,0.00026013993,0.00015520463,0.00007336512,0.00015407887,0.000002306499],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06456422,0.002818356,0.013402761,0.00017948398,0.000051898423,0.57823163,0.0057622646,0.0000011857571,0.31155586,0.0000065774702,0.013931799,0.009493978],"study_design_scores_gemma":[0.3022489,0.004391509,0.0062655723,0.00019044583,0.0004543189,0.24915628,0.003993054,0.00018819196,0.28229743,0.0012820711,0.14857028,0.0009619458],"about_ca_topic_score_codex":0.0010033424,"about_ca_topic_score_gemma":0.00071498955,"teacher_disagreement_score":0.32907534,"about_ca_system_score_codex":0.00009333166,"about_ca_system_score_gemma":0.0007157677,"threshold_uncertainty_score":0.7708169},"labels":[],"label_agreement":null},{"id":"W3129279218","doi":"10.1038/s41467-021-21410-1","title":"Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arbutus Biopharma (Canada)","funders":"University of Pennsylvania","keywords":"Internalization; Programmed cell death; Ligand (biochemistry); Small molecule; Cell biology; Cancer research; Antigen; Chemistry; Biology; Apoptosis; Immunology; Cell; Receptor; Biochemistry","score_opus":0.05259540967132212,"score_gpt":0.34485585981108147,"score_spread":0.2922604501397593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129279218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9504065,0.026922531,0.0025660251,0.0102419695,0.00020103532,0.00063621096,0.000019656369,0.00010359507,0.008902477],"genre_scores_gemma":[0.9877297,0.0024342316,0.008125315,0.0010382303,0.00003326622,0.00004489552,0.00045349557,0.00001722214,0.00012363795],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999192,0.00008521923,0.0003148626,0.00014882704,0.00014753878,0.00011157637],"domain_scores_gemma":[0.9982641,0.00005563589,0.00014951009,0.0010640102,0.0004309715,0.000035773555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013555006,0.00010002031,0.00018008825,0.000042709118,0.000081933766,0.000017961125,0.00017502799,0.00022658282,0.000028962011],"category_scores_gemma":[0.00015211744,0.000093588125,0.00013596198,0.00043321567,0.00007688391,0.000060037124,0.0001150432,0.0004454894,0.0000028807121],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003025618,0.0007349082,0.005592766,0.000098195174,0.00026240482,0.000010190424,0.0009938492,4.269235e-7,0.9771634,0.008012211,0.00064502517,0.0061840615],"study_design_scores_gemma":[0.002112548,0.00015647354,0.011819686,0.00045867325,0.00014091426,0.00010544371,0.00027574805,0.0001162174,0.9551221,0.00052915455,0.029021028,0.0001420257],"about_ca_topic_score_codex":0.00010708069,"about_ca_topic_score_gemma":0.0005106092,"teacher_disagreement_score":0.037323207,"about_ca_system_score_codex":0.00008632211,"about_ca_system_score_gemma":0.00017026502,"threshold_uncertainty_score":0.3816413},"labels":[],"label_agreement":null},{"id":"W3129319671","doi":"10.15557/cgo.2020.0009","title":"Examining the impact of body mass index on overall survival in vulvar, vaginal and other mucosal melanomas: a retrospective cohort study","year":2020,"lang":"en","type":"article","venue":"Ginekologia Onkologiczna/Current Gynecologic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"University of Toronto","keywords":"Medicine; Mucosal melanoma; Melanoma; Retrospective cohort study; Body mass index; Vulvar cancer; Internal medicine; Vulva; Oncology; Dermatology; Cancer research","score_opus":0.04873170746496784,"score_gpt":0.345321906944135,"score_spread":0.29659019947916715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129319671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887367,0.00052830315,0.000052663454,0.0042764787,0.00057305355,0.0028130389,0.000043286964,0.00013589225,0.0028405727],"genre_scores_gemma":[0.9954423,0.00019560695,0.000090254674,0.0036736175,0.0002468102,0.00027128335,0.000021183103,0.000034179175,0.00002481768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99537855,0.0012156264,0.0009936723,0.0011047822,0.00046717667,0.000840172],"domain_scores_gemma":[0.9970242,0.0014900242,0.0006298823,0.00052710995,0.00015059697,0.00017819938],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019288422,0.0006135847,0.001706782,0.00026612662,0.00013524223,0.000025667636,0.0004770327,0.00054645515,0.00069368357],"category_scores_gemma":[0.0012934612,0.00036452676,0.00025722446,0.0006579612,0.00075547275,0.00008033377,0.00022933072,0.0016074263,0.000016389518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055943453,0.0016724643,0.9848383,0.000034737917,0.00060499256,0.0003819543,0.0005278982,0.000086893335,0.001873395,0.00016205132,0.0013356864,0.0028872886],"study_design_scores_gemma":[0.008588042,0.03914738,0.94913584,0.000026401873,0.00016385449,0.000060692833,0.0008267706,0.0005079139,0.000039783496,0.00025587954,0.0008980195,0.00034942295],"about_ca_topic_score_codex":0.0004490414,"about_ca_topic_score_gemma":0.00011874903,"teacher_disagreement_score":0.03747492,"about_ca_system_score_codex":0.0010547796,"about_ca_system_score_gemma":0.0004669556,"threshold_uncertainty_score":0.9998807},"labels":[],"label_agreement":null},{"id":"W3129923342","doi":"10.1158/1538-7445.sabcs20-pd14-07","title":"Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Cohort; Triple-negative breast cancer; Breast cancer; Biomarker; Cancer; Immunotherapy; Biology","score_opus":0.04501016533167566,"score_gpt":0.3672172241175309,"score_spread":0.3222070587858552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129923342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99161243,0.0012830687,0.000013468119,0.0043703257,0.000085431704,0.00083245116,0.0017235498,0.000022827557,0.00005646618],"genre_scores_gemma":[0.9979689,0.0004762791,0.00011903792,0.00031245136,0.00010315165,0.00037745346,0.00016200489,0.000043217166,0.00043746884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99605656,0.0007785447,0.0004572535,0.0007232698,0.0013435283,0.0006408553],"domain_scores_gemma":[0.99711144,0.000998745,0.00016324129,0.00043324317,0.0009638171,0.00032954302],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016991491,0.00024709743,0.0006781629,0.0008969222,0.00016299431,0.000104429564,0.00014726202,0.00013005723,0.0014272237],"category_scores_gemma":[0.00042711024,0.00021148044,0.00012703473,0.0036122466,0.00014906436,0.00022986475,0.00008512306,0.0005089403,0.00001827965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07189955,0.00022093565,0.89014477,0.000074592266,0.0065487456,0.000073225776,0.0026130574,0.0000226959,0.007540643,4.0568162e-7,0.0016914534,0.019169925],"study_design_scores_gemma":[0.0115481885,0.00025308479,0.9800428,0.00036859667,0.00057588174,5.2886605e-7,0.001616452,0.000011441286,0.004721027,0.000014866946,0.00060767314,0.00023941703],"about_ca_topic_score_codex":0.016057497,"about_ca_topic_score_gemma":0.008096356,"teacher_disagreement_score":0.089898065,"about_ca_system_score_codex":0.0032096123,"about_ca_system_score_gemma":0.001694189,"threshold_uncertainty_score":0.9994856},"labels":[],"label_agreement":null},{"id":"W3130243787","doi":"10.3390/curroncol28010088","title":"Very Delayed Acute Hepatitis after Pembrolizumab Therapy for Advanced Malignancy: How Long Should We Watch?","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pembrolizumab; Malignancy; Natural history; Adverse effect; Hepatitis; Immune system; Hepatitis C; Immunology; Internal medicine; Immunotherapy","score_opus":0.07249969318809091,"score_gpt":0.3856125077407154,"score_spread":0.3131128145526245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130243787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86110085,0.09218808,0.0029487936,0.037366726,0.0046155793,0.0012320891,0.00018441502,0.00011189463,0.00025158905],"genre_scores_gemma":[0.87732905,0.112096585,0.00083279697,0.0033899862,0.00079730904,0.0011712793,0.0005147607,0.00008295528,0.0037852505],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984242,0.00009146825,0.00031672153,0.0004810025,0.00020288795,0.00048373447],"domain_scores_gemma":[0.99897414,0.00012536332,0.0001272201,0.00038792187,0.00025673694,0.00012860195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013317313,0.00026648532,0.0005645215,0.00006788243,0.00008253788,0.000027571006,0.0001141582,0.00022447985,0.0005310101],"category_scores_gemma":[0.000026989701,0.00022560444,0.0003733971,0.00018954754,0.00011761944,0.000113956936,0.000045803034,0.0002469053,0.000013390181],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02923411,0.00089195307,0.013567656,0.00021201384,0.0009391457,0.00052937836,0.000667003,7.3541196e-7,0.022464493,0.00005059726,0.032885257,0.89855766],"study_design_scores_gemma":[0.018266065,0.0025604723,0.016736545,0.0002556257,0.00025617945,0.0003030535,0.00006762137,0.00005187106,0.021904022,0.00013784037,0.9391403,0.00032038742],"about_ca_topic_score_codex":0.000009155776,"about_ca_topic_score_gemma":0.00015343803,"teacher_disagreement_score":0.90625507,"about_ca_system_score_codex":0.00038289212,"about_ca_system_score_gemma":0.00057337567,"threshold_uncertainty_score":0.9199882},"labels":[],"label_agreement":null},{"id":"W3130253087","doi":"10.1158/1078-0432.ccr-20-4338","title":"FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non–small Cell Lung Cancer, A Collaborative Project Orbis Review","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"U.S. Food and Drug Administration; National Institutes of Health","keywords":"Nivolumab; Ipilimumab; Medicine; Oncology; Chemotherapy; Cancer; Lung cancer; Internal medicine; Immunotherapy; Intensive care medicine","score_opus":0.14277968763737794,"score_gpt":0.5034665726369157,"score_spread":0.3606868849995378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130253087","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34801948,0.60352623,0.00029850058,0.030455949,0.0004955545,0.014004759,0.00057486823,0.00008537498,0.0025393043],"genre_scores_gemma":[0.03319548,0.92260766,0.007059762,0.009449191,0.0007908839,0.007724126,0.00015266113,0.00020001017,0.018820211],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962588,0.00055486214,0.00076498627,0.0009809615,0.00071340526,0.0007269999],"domain_scores_gemma":[0.99609447,0.001060881,0.00019976601,0.0006032634,0.0017748328,0.00026677625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030020245,0.0003003256,0.0011089639,0.00012144566,0.00024352084,0.00008225176,0.0002160019,0.00014503756,0.0004956704],"category_scores_gemma":[0.00037745154,0.0002198559,0.000240654,0.0016383207,0.00063232525,0.000093885654,0.00009369054,0.00078450004,0.0000023484404],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06830473,0.0023656746,0.02840776,0.038001206,0.004024669,0.00035647865,0.0016389199,0.0000021969902,0.004780983,0.000042311814,0.470227,0.38184807],"study_design_scores_gemma":[0.07012782,0.009706341,0.008915745,0.021653142,0.0018052593,0.00009010796,0.0025111053,0.0013084705,0.011073893,0.000081149265,0.8715393,0.0011876733],"about_ca_topic_score_codex":0.0016109751,"about_ca_topic_score_gemma":0.002380299,"teacher_disagreement_score":0.4013123,"about_ca_system_score_codex":0.00040462046,"about_ca_system_score_gemma":0.0083870515,"threshold_uncertainty_score":0.99723446},"labels":[],"label_agreement":null},{"id":"W3130387627","doi":"10.1158/1538-7445.sabcs20-pd14-03","title":"Abstract PD14-03: Molecular mechanism of ipatasertib (IPAT) and its combination with atezolizumab (atezo) in patients (pts) with locally advanced/metastatic triple-negative breast cancer (aTNBC)","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Paclitaxel; Breast cancer; Oncology; Cohort; Internal medicine; Immunohistochemistry; Cancer; Cyclin D1; Chemotherapy; Immune checkpoint; Triple-negative breast cancer; Cyclophosphamide; Cancer research; Cell cycle; Immunotherapy; Nivolumab","score_opus":0.028021584279272475,"score_gpt":0.346558188338385,"score_spread":0.3185366040591125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130387627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939471,0.0030398099,0.00004241159,0.0008927292,0.00006207526,0.0013640012,0.00038738828,0.000015796679,0.00024871159],"genre_scores_gemma":[0.9968448,0.0020592608,0.00013581754,0.00015223857,0.000015866983,0.00039926192,0.00009168997,0.00005259745,0.000248425],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972502,0.0001739445,0.00039680462,0.0005532695,0.0010892573,0.0005364961],"domain_scores_gemma":[0.9978593,0.00010157265,0.0001591511,0.0003218282,0.001378681,0.00017944135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004227912,0.00024734263,0.00048389312,0.00030663205,0.00009563959,0.000033316275,0.00013720966,0.00008298145,0.00045651986],"category_scores_gemma":[0.00006193906,0.0001902532,0.000048956714,0.0011910293,0.0002423758,0.00020605871,0.00006373842,0.0004604855,0.0000040457157],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17454073,0.0051346724,0.048551492,0.0064458936,0.002970521,0.002196291,0.004909697,0.0007198493,0.3811108,0.0021812427,0.00078423903,0.37045458],"study_design_scores_gemma":[0.059037287,0.0036553475,0.4020622,0.0064433054,0.00015725521,0.00006452404,0.0014585688,0.00039725853,0.5253048,0.0006450595,0.00015801753,0.0006163682],"about_ca_topic_score_codex":0.0018876607,"about_ca_topic_score_gemma":0.0012815895,"teacher_disagreement_score":0.36983824,"about_ca_system_score_codex":0.0006533757,"about_ca_system_score_gemma":0.0013916256,"threshold_uncertainty_score":0.77583},"labels":[],"label_agreement":null},{"id":"W3130576199","doi":"10.1158/1538-7445.sabcs20-gs3-01","title":"Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Taxane; Carboplatin; Pembrolizumab; Chemotherapy; Internal medicine; Oncology; Interim analysis; Clinical endpoint; Chemotherapy regimen; Paclitaxel; Premedication; Progression-free survival; Triple-negative breast cancer; Metastatic breast cancer; Phases of clinical research; Clinical trial; Breast cancer; Cancer; Surgery; Cisplatin","score_opus":0.10626608274781106,"score_gpt":0.4343006938422686,"score_spread":0.32803461109445753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130576199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9640752,0.006622677,0.000090188376,0.011784318,0.00050078053,0.0076470473,0.009060797,0.00006111463,0.00015784508],"genre_scores_gemma":[0.96445966,0.021436842,0.00022720553,0.002996022,0.0012449375,0.0055598756,0.0009011841,0.0001977135,0.002976555],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946754,0.00045439007,0.0010093757,0.0010962691,0.0017930606,0.0009714859],"domain_scores_gemma":[0.9936756,0.0031330257,0.00036522912,0.0009917421,0.001528525,0.00030586458],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012426282,0.0005738971,0.001176685,0.00022914619,0.00059801195,0.0001405063,0.0006496959,0.00017956232,0.06247949],"category_scores_gemma":[0.0003858952,0.0003785188,0.0004102079,0.0012893035,0.0005666702,0.00020307876,0.00008408192,0.0009665572,0.000021639715],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6374625,0.0078093586,0.00014426628,0.00031181276,0.005007999,0.00014154534,0.010943737,0.000293347,0.016746886,0.000010862582,0.07927403,0.24185365],"study_design_scores_gemma":[0.6410541,0.018100394,0.043135073,0.003693096,0.0004363559,0.00016602356,0.012592104,0.0019863658,0.12957117,0.00038073247,0.14731269,0.0015718837],"about_ca_topic_score_codex":0.006688496,"about_ca_topic_score_gemma":0.0049616466,"teacher_disagreement_score":0.24028176,"about_ca_system_score_codex":0.0017148997,"about_ca_system_score_gemma":0.0069361734,"threshold_uncertainty_score":0.99992603},"labels":[],"label_agreement":null},{"id":"W3130910054","doi":"10.1016/j.semcancer.2021.02.002","title":"Tackling cancer cell dormancy: Insights from immune models, and transplantation","year":2021,"lang":"en","type":"review","venue":"Seminars in Cancer Biology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Norges Forskningsråd; Kreftforeningen","keywords":"Immune system; Biology; Cancer; Transplantation; Cancer cell; Dormancy; Immunology; Medicine; Genetics; Internal medicine","score_opus":0.04053441548466186,"score_gpt":0.3552858411115648,"score_spread":0.31475142562690295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130910054","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020950811,0.99517226,0.000027693579,0.00006593932,0.0010466626,0.0006178354,0.0004471455,0.000027255806,0.0005001371],"genre_scores_gemma":[0.00056086644,0.9966182,0.0001986112,0.00020132423,0.00033244144,0.00042957667,0.0013533008,0.000060335304,0.00024530725],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979791,0.00015897266,0.00073740876,0.0006933903,0.00010658607,0.00032451242],"domain_scores_gemma":[0.9991066,0.00014978944,0.00030065665,0.00032205312,0.000048829977,0.000072064824],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010949617,0.0004482264,0.0018318968,0.00017591054,0.000056088138,0.000013956027,0.00014438554,0.00070875266,0.00030119362],"category_scores_gemma":[0.0000037181878,0.0003599494,0.00027571424,0.00033092624,0.00014043812,0.00008062611,0.000043868025,0.00047672732,0.0000019701833],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022436754,0.00005566961,0.000053582717,0.005973054,0.0003282644,0.00007257372,0.00080541894,0.00000410872,0.0006741103,0.000017738497,0.00012250482,0.9916686],"study_design_scores_gemma":[0.0018751648,0.00015297324,0.000055820066,0.053847194,0.0013355933,0.00005912669,0.00013687613,0.00006629015,0.00045128114,0.000118107215,0.94134516,0.00055640173],"about_ca_topic_score_codex":0.012786329,"about_ca_topic_score_gemma":0.0026889,"teacher_disagreement_score":0.99111223,"about_ca_system_score_codex":0.0005784433,"about_ca_system_score_gemma":0.0007984333,"threshold_uncertainty_score":0.99988526},"labels":[],"label_agreement":null},{"id":"W3130979972","doi":"10.3390/cancers13040781","title":"Prognostic Significance of CD4+ and CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Cancer Research UK","keywords":"Head and neck squamous-cell carcinoma; Head and neck; Basal cell; Medicine; Tumor-infiltrating lymphocytes; CD8; Pathology; Meta-analysis; Oncology; Internal medicine; Cancer research; Head and neck cancer; Immunology; Immune system; Cancer; Surgery","score_opus":0.07082424784178697,"score_gpt":0.3268750311253219,"score_spread":0.2560507832835349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130979972","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0120205665,0.9862568,0.000005287548,0.000023821425,0.00006331653,0.0011516494,0.00012725068,0.000014560235,0.00033678926],"genre_scores_gemma":[0.0929129,0.9058703,0.0003403017,0.000120576195,0.000053940847,0.0003533143,0.00007924441,0.00004843795,0.00022094774],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99750936,0.00019437169,0.00095356215,0.00072558766,0.000273066,0.00034403132],"domain_scores_gemma":[0.9982717,0.0004600358,0.00059072336,0.00044927947,0.00009118082,0.00013707628],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003502956,0.00049338915,0.0045171133,0.0004024377,0.000048575534,0.00003557887,0.00011710831,0.0001783649,0.00015667462],"category_scores_gemma":[0.000099548655,0.00038591493,0.0012470736,0.0014625902,0.00023727267,0.00005173639,0.000045871824,0.00027106045,5.784495e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011207826,0.00035143315,0.023136081,0.23535395,0.14334421,0.0017718845,0.0027743569,0.00013949332,0.000582956,0.000036351543,0.0008886127,0.5904999],"study_design_scores_gemma":[0.0059161815,0.0010446655,0.0020841304,0.0065389676,0.72603536,0.00036376194,0.0009884895,0.00020844681,0.0004993956,0.000005613217,0.25469747,0.001617535],"about_ca_topic_score_codex":0.003673633,"about_ca_topic_score_gemma":0.0007410588,"teacher_disagreement_score":0.5888824,"about_ca_system_score_codex":0.0010147473,"about_ca_system_score_gemma":0.0028549985,"threshold_uncertainty_score":0.9998593},"labels":[],"label_agreement":null},{"id":"W3131164337","doi":"10.3390/cancers13040806","title":"Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy","year":2021,"lang":"en","type":"review","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Immunotherapy; Tumor microenvironment; Medicine; Cancer; Tumor heterogeneity; Immunosuppression; Cancer immunotherapy; Oncology; Bioinformatics; Immunology; Internal medicine; Biology","score_opus":0.05482578134967032,"score_gpt":0.37024798674742754,"score_spread":0.3154222053977572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131164337","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00076221913,0.99683017,0.000002103862,0.000068830406,0.00054723356,0.0011828662,0.00013381086,0.000025215908,0.00044755256],"genre_scores_gemma":[0.0000905531,0.99665433,0.000025966425,0.0016868794,0.00024977178,0.00070508,0.000097335804,0.000105658066,0.0003844475],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997836,0.00023772866,0.00075392786,0.00044320937,0.00036899175,0.0003601614],"domain_scores_gemma":[0.9986054,0.00011283121,0.00034012354,0.00082741416,0.00006205158,0.00005221004],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003696086,0.00043655763,0.002089615,0.00019952108,0.00003788386,0.000026721116,0.0003724302,0.00021072423,0.0005453568],"category_scores_gemma":[0.000021369176,0.00027273304,0.0010928434,0.00083872286,0.00024086922,0.00003436964,0.000030013258,0.0004625744,0.000002633098],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021278168,0.000021366632,0.00011378016,0.006724075,0.0010928866,0.0003366863,0.00038404446,0.0000013842667,0.00008080627,0.0000072745825,0.0017802332,0.9892447],"study_design_scores_gemma":[0.0011516252,0.000109547844,0.00012264423,0.020006822,0.00061275024,0.00012123906,0.00010466515,8.3077737e-7,0.000064509484,0.000001528025,0.97744536,0.0002584479],"about_ca_topic_score_codex":0.0032536974,"about_ca_topic_score_gemma":0.001457588,"teacher_disagreement_score":0.98898625,"about_ca_system_score_codex":0.0020533276,"about_ca_system_score_gemma":0.0037903506,"threshold_uncertainty_score":0.99997246},"labels":[],"label_agreement":null},{"id":"W3131242205","doi":"10.1016/j.cllc.2021.02.010","title":"Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC)","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme; Bayer Fund; Ipsen Biopharmaceuticals; Merck KGaA; Prince of Songkla University; F. Hoffmann-La Roche; AbbVie; Meso Scale Diagnostics; Sanofi; Roche; EMD Serono; Novartis; MedImmune; GlaxoSmithKline; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Durvalumab; Tremelimumab; Medicine; Hazard ratio; Internal medicine; Chemotherapy; Oncology; Lung cancer; Confidence interval; Cancer; Immunotherapy","score_opus":0.05276557928474587,"score_gpt":0.3996062283725302,"score_spread":0.34684064908778434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131242205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98568696,0.007974422,0.00028425257,0.0022647423,0.0008546327,0.002083284,0.00017615713,0.00007805157,0.0005974791],"genre_scores_gemma":[0.97395134,0.014604227,0.0028086565,0.0014829198,0.00026175837,0.00070222904,0.00007713637,0.00016177191,0.005949968],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963876,0.00011716679,0.0013507176,0.0008664551,0.0007440321,0.00053400436],"domain_scores_gemma":[0.99678606,0.00057375286,0.00078472425,0.000887191,0.00065412297,0.00031416808],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024329733,0.00056939054,0.0018336963,0.00009005579,0.00012415378,0.000035079796,0.0001239104,0.00016775017,0.0024843898],"category_scores_gemma":[0.000095706084,0.0003277826,0.00044056866,0.00055959256,0.00033460298,0.000080881204,0.000028285289,0.00024843676,0.0000024911703],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.291817,0.0027528156,0.62128335,0.00083792565,0.013403982,0.0007855288,0.0013121016,0.00025087158,0.00043184933,0.00000223799,0.0010312495,0.066091046],"study_design_scores_gemma":[0.54599625,0.09862597,0.19003306,0.006980303,0.03157206,0.0003008816,0.0025447735,0.005264488,0.055162583,0.00001038129,0.060592175,0.0029170453],"about_ca_topic_score_codex":0.0016001461,"about_ca_topic_score_gemma":0.008021668,"teacher_disagreement_score":0.4312503,"about_ca_system_score_codex":0.00093587657,"about_ca_system_score_gemma":0.0038011796,"threshold_uncertainty_score":0.99991745},"labels":[],"label_agreement":null},{"id":"W3131436232","doi":"10.3390/ijms22041827","title":"In Vitro Suppression of T Cell Proliferation Is a Conserved Function of Primary and Immortalized Human Cancer-Associated Fibroblasts","year":2021,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Saudi Arabian Cultural Mission; Faculty of Medicine, Nursing and Health Sciences, Monash University","keywords":"Cancer-Associated Fibroblasts; Cancer research; Tumor microenvironment; Immunotherapy; Stromal cell; Cancer; Biology; Pancreatic cancer; Immune system; Immunology; Medicine; Internal medicine","score_opus":0.016287246357777674,"score_gpt":0.300570950643376,"score_spread":0.28428370428559835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131436232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968983,0.0016438228,0.000097778575,0.0009136585,0.0002137066,0.000059253216,0.000009472391,0.0000011745931,0.0001628637],"genre_scores_gemma":[0.99891496,0.00022643816,0.00037647728,0.00039878348,0.00002034519,0.0000013125533,0.000005825853,0.0000028063137,0.000053052438],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99887556,0.000058720376,0.0003956079,0.00009104118,0.0005198188,0.000059241258],"domain_scores_gemma":[0.9990217,0.000025710538,0.00042656847,0.000039629038,0.00046201865,0.000024387997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000337388,0.00005274271,0.00018271025,0.00017268439,0.000019500398,0.000014849218,0.00008368453,0.00003680151,0.00006812036],"category_scores_gemma":[0.00003914342,0.00004287493,0.00007901358,0.00018533018,0.000118022974,0.00013664969,0.00002216035,0.0000639871,4.3365993e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012095098,0.00016154548,0.0073821056,0.000029576806,0.00009438031,0.0000417392,0.00024467104,0.000013830663,0.9895859,0.000010619515,0.00007742807,0.0011486936],"study_design_scores_gemma":[0.0026434388,0.00031211396,0.043705836,0.000363801,0.000031086573,0.000042755615,0.00010506825,0.00011989168,0.9524677,0.00011898265,0.000053282783,0.000036071575],"about_ca_topic_score_codex":0.00013503624,"about_ca_topic_score_gemma":0.000024915975,"teacher_disagreement_score":0.03711823,"about_ca_system_score_codex":0.000063456595,"about_ca_system_score_gemma":0.00036793965,"threshold_uncertainty_score":0.1748389},"labels":[],"label_agreement":null},{"id":"W3132005627","doi":"10.26650/iuitfd.2020.0094","title":"KRONİK HEPATİT B HASTALARINDA SERUM IL-17 DÜZEYLERİNİN DEĞERLENDİRİLMESİ","year":2021,"lang":"tr","type":"article","venue":"Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stantec (Canada)","funders":"","keywords":"Medicine; Gynecology; Gastroenterology","score_opus":0.028426574654491034,"score_gpt":0.312838628496604,"score_spread":0.28441205384211293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132005627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7916495,0.1081968,0.0023108742,0.06701858,0.0097772665,0.0017677576,0.0023021877,0.00016581465,0.016811185],"genre_scores_gemma":[0.92414516,0.026245013,0.005388154,0.00495037,0.0057264906,0.000021059965,0.0004440181,0.00044321944,0.032636486],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9825301,0.00078669866,0.007319513,0.0015255457,0.0055653066,0.002272813],"domain_scores_gemma":[0.98329633,0.0011556139,0.006058686,0.001895106,0.0058469484,0.0017472935],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.004630846,0.002038801,0.005523814,0.0013228054,0.00061168557,0.00021803334,0.0017058351,0.0012663826,0.0120580215],"category_scores_gemma":[0.002816291,0.0016879593,0.0021896537,0.0027421438,0.00257674,0.000983666,0.00043492933,0.003334766,0.000076671204],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027488258,0.0048562395,0.026816972,0.0053661163,0.014639206,0.013788564,0.028338874,0.00014646242,0.13980617,0.0012231352,0.65467954,0.08285044],"study_design_scores_gemma":[0.05589743,0.014455222,0.06727898,0.018429754,0.005896822,0.010046979,0.06769443,0.0003116557,0.031267516,0.0008242989,0.7253571,0.0025397728],"about_ca_topic_score_codex":0.00067758583,"about_ca_topic_score_gemma":0.0005676981,"teacher_disagreement_score":0.13249566,"about_ca_system_score_codex":0.0019018264,"about_ca_system_score_gemma":0.004571532,"threshold_uncertainty_score":0.9992354},"labels":[],"label_agreement":null},{"id":"W3132116659","doi":"10.1038/s41392-021-00463-0","title":"PD-L1 regulates genomic stability via interaction with cohesin-SA1 in the nucleus","year":2021,"lang":"en","type":"letter","venue":"Signal Transduction and Targeted Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cohesin; Nucleus; Biology; Cell biology; Genetics; DNA","score_opus":0.028120718709838396,"score_gpt":0.24591813592213688,"score_spread":0.21779741721229848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132116659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7381625,0.007383519,0.0002525686,0.2518746,0.0005768459,0.001319369,0.00005061189,0.00008394972,0.00029599166],"genre_scores_gemma":[0.8037411,0.0052366788,0.0002072457,0.1876038,0.0018320889,0.00011334184,0.0008140479,0.00010152574,0.00035016934],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979901,0.00037199832,0.0004143363,0.000553707,0.00035949875,0.00031037824],"domain_scores_gemma":[0.9992418,0.000105735984,0.00014561799,0.0003657884,0.0001000506,0.000040949817],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003729776,0.00038106562,0.0004912585,0.0001742438,0.00013467624,0.0000823458,0.000110791596,0.00042668532,0.0022649472],"category_scores_gemma":[0.0000023344153,0.0002446897,0.00020836493,0.00036061325,0.00025051605,0.00012235776,0.0000039115994,0.0013302508,0.0000035609235],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0297072,0.0007330413,0.0015820785,0.0006012142,0.002017571,0.0006139246,0.008784731,0.00001320808,0.83181614,0.00000644985,0.034696244,0.08942818],"study_design_scores_gemma":[0.007179088,0.0016805246,0.0250647,0.0003687741,0.00020337255,0.001110013,0.0015426656,0.00005358325,0.066331394,0.00016941987,0.89565635,0.00064010837],"about_ca_topic_score_codex":0.00032246375,"about_ca_topic_score_gemma":0.00007077228,"teacher_disagreement_score":0.8609601,"about_ca_system_score_codex":0.0001622188,"about_ca_system_score_gemma":0.00014291766,"threshold_uncertainty_score":0.9986471},"labels":[],"label_agreement":null},{"id":"W3132138449","doi":"10.33380/2305-2066-2021-10-1-31-36","title":"PD-L1 as a Potential Target in Cancer Therapy (Review)","year":2021,"lang":"en","type":"article","venue":"Drug development & registration","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Public Health Association","funders":"","keywords":"Durvalumab; Avelumab; Immunotherapy; Immune system; Cancer; Medicine; Clinical trial; Cancer immunotherapy; Mechanism (biology); Immunology; Cancer research; Internal medicine; Nivolumab","score_opus":0.019832939404268567,"score_gpt":0.3036877309930628,"score_spread":0.28385479158879423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132138449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7816477,0.18208948,0.00025995143,0.024324944,0.00072887604,0.0010972931,0.000006160654,0.000084171064,0.0097614685],"genre_scores_gemma":[0.73557276,0.20771876,0.0053675547,0.016097493,0.00033417338,0.00045924782,0.0008263163,0.00005083395,0.03357284],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987768,0.00004938645,0.00039049427,0.00027388183,0.00032152946,0.00018788682],"domain_scores_gemma":[0.999536,0.0000075598514,0.00010766199,0.00018494674,0.00011175584,0.000052092328],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029726405,0.00014127338,0.00022602222,0.00005629263,0.000056852234,0.000019422087,0.0000562629,0.000055613404,0.0014365544],"category_scores_gemma":[0.000021260304,0.00012590375,0.00007363578,0.00030493503,0.000029122555,0.00008511135,0.000011057588,0.00011545435,0.000029245062],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032889997,0.0012167778,0.017552035,0.0013463089,0.0004629778,0.00079064624,0.0034640324,0.00002430593,0.17282186,0.00017590878,0.12627515,0.67258096],"study_design_scores_gemma":[0.003581141,0.00005538833,0.13441132,0.0016924441,0.000025558104,0.00010424338,0.00024213361,0.000031264677,0.09127207,0.00006492469,0.76820487,0.0003146373],"about_ca_topic_score_codex":0.00021960039,"about_ca_topic_score_gemma":0.00036896605,"teacher_disagreement_score":0.67226636,"about_ca_system_score_codex":0.00023327286,"about_ca_system_score_gemma":0.0013728495,"threshold_uncertainty_score":0.99947625},"labels":[],"label_agreement":null},{"id":"W3132303491","doi":"10.1158/1538-7445.sabcs20-ps6-02","title":"Abstract PS6-02: Spatially defined immune-related proteins and outcome in triple negative breast cancer in the FinXX trial and Mayo Clinic cohort","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Triple-negative breast cancer; Breast cancer; Oncology; Cohort; Tumor-infiltrating lymphocytes; Immune system; Internal medicine; CD8; Proportional hazards model; Cancer; Immunology","score_opus":0.08142677421550706,"score_gpt":0.4232534601446759,"score_spread":0.34182668592916887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132303491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97630614,0.008794278,5.297099e-7,0.010854606,0.00024236231,0.0028456082,0.000110867455,0.000012904715,0.0008327294],"genre_scores_gemma":[0.98931974,0.0077466373,0.00001968848,0.0002834346,0.00015041606,0.0010555387,0.00001764593,0.000027757125,0.0013791415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723023,0.00043498963,0.0007128132,0.0004942596,0.0006141512,0.00051353435],"domain_scores_gemma":[0.9987339,0.00047965793,0.000107740874,0.00036779567,0.00021466598,0.00009625012],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002889921,0.00018690541,0.00049952755,0.00023451951,0.00013620623,0.00008141197,0.00016380603,0.00019261034,0.0018669016],"category_scores_gemma":[0.00036474154,0.00013338708,0.00009208896,0.0010128147,0.00040932492,0.000103757084,0.00008753688,0.0010787273,0.0000070913275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16785419,0.00088826584,0.6552087,0.00063454383,0.00058590283,0.0007546695,0.0048124488,0.000007903724,0.051792122,0.000061814004,0.0011356691,0.11626377],"study_design_scores_gemma":[0.049835134,0.0003332607,0.9461822,0.00044182778,0.000031965752,0.00004122418,0.00064082054,0.000028093746,0.0016202789,0.0001125502,0.0005733465,0.0001593014],"about_ca_topic_score_codex":0.026076376,"about_ca_topic_score_gemma":0.016446033,"teacher_disagreement_score":0.29097348,"about_ca_system_score_codex":0.00040516554,"about_ca_system_score_gemma":0.0013694736,"threshold_uncertainty_score":0.99904555},"labels":[],"label_agreement":null},{"id":"W3133776625","doi":"10.1093/jcag/gwab002.000","title":"A1 F4/80+LY6CHI MACROPHAGES ARE KEY TO CANCER INITIATION IN COLITIS","year":2021,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; SickKids Foundation; Western University","funders":"","keywords":"Colitis; Azoxymethane; Inflammatory bowel disease; Inflammation; Medicine; Immune system; Carcinogenesis; Colorectal cancer; Cancer research; Myeloperoxidase; Cancer; Immunology; Citrobacter rodentium; Internal medicine; Disease","score_opus":0.011040747081548239,"score_gpt":0.25927038780460765,"score_spread":0.24822964072305942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133776625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92278194,0.00011221167,0.0000066908856,0.07604388,0.0007246483,0.00010129762,0.00007109717,0.0000013892595,0.00015684844],"genre_scores_gemma":[0.9881925,0.00013526386,0.00008675988,0.010735001,0.0001625738,0.0000039167535,0.0000033643084,0.00000858534,0.0006720332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987522,0.00023604638,0.00044783755,0.00008083174,0.00023800733,0.00024512134],"domain_scores_gemma":[0.998567,0.00003881096,0.0006803674,0.00010525141,0.0004597077,0.00014885729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005146082,0.000073182804,0.0003109846,0.00023085471,0.000045876135,0.000012790742,0.00010552302,0.00009368462,0.00022362715],"category_scores_gemma":[0.00033638827,0.00006233679,0.00014771188,0.00022861021,0.000022948914,0.000049514645,0.000014503401,0.00022340125,0.0000015776941],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087880687,0.00003786881,0.98217195,0.000016096279,0.00018746994,0.00006478371,0.00035692722,0.00006045568,0.002471143,0.0000067907226,0.013370493,0.000377238],"study_design_scores_gemma":[0.0024571405,0.0002916535,0.9893817,0.00018857411,0.00005526345,0.00010595536,0.00019013834,0.0000060959305,0.00089372025,0.000025677838,0.0063735195,0.000030602987],"about_ca_topic_score_codex":0.010003725,"about_ca_topic_score_gemma":0.83539057,"teacher_disagreement_score":0.8253869,"about_ca_system_score_codex":0.0024007026,"about_ca_system_score_gemma":0.00085971877,"threshold_uncertainty_score":0.99658877},"labels":[],"label_agreement":null},{"id":"W3134221665","doi":"10.1136/jitc-2020-001901","title":"Considerations for treatment duration in responders to immune checkpoint inhibitors","year":2021,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Cancer Institute; Society for Immunotherapy of Cancer","keywords":"Medicine; Immunotherapy; Clinical trial; Limiting; Oncology; Cancer; Internal medicine; Intensive care medicine","score_opus":0.08771796083704402,"score_gpt":0.4250182670291007,"score_spread":0.3373003061920567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134221665","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003894802,0.99117994,0.00026700873,0.0018394444,0.0017015028,0.0043337396,0.00024728465,0.000012877823,0.000028712762],"genre_scores_gemma":[0.000052344883,0.9925337,0.0025743076,0.00026906296,0.00058388105,0.0018937279,0.00009351979,0.00011757462,0.0018818931],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966056,0.000120582205,0.0022655851,0.00035595117,0.00027498437,0.00037733157],"domain_scores_gemma":[0.9974738,0.0004951104,0.0011173652,0.00037435573,0.00043716352,0.00010224133],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00082814856,0.00047268835,0.0024861074,0.0006864109,0.00018308709,0.00007846495,0.000109464156,0.00032321466,0.00036589178],"category_scores_gemma":[0.000172692,0.0003603957,0.0022665623,0.00043522593,0.00006316089,0.00010058254,0.000010198075,0.0002111876,0.0000010830119],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036892886,0.00028112205,0.0000050677622,0.0024513388,0.0023714101,0.000010515026,0.00074155483,0.000010067961,0.006335633,0.00003375335,0.0020442926,0.982026],"study_design_scores_gemma":[0.0072327727,0.0018626334,0.000027299762,0.017865889,0.00072239735,0.00019432609,0.00016555985,0.000003674984,0.0033144993,0.00008378379,0.96819425,0.00033293027],"about_ca_topic_score_codex":0.00017510027,"about_ca_topic_score_gemma":0.00024380672,"teacher_disagreement_score":0.981693,"about_ca_system_score_codex":0.0020669785,"about_ca_system_score_gemma":0.0032421395,"threshold_uncertainty_score":0.9998848},"labels":[],"label_agreement":null},{"id":"W3134394982","doi":"10.1016/j.chest.2021.02.053","title":"Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens","year":2021,"lang":"en","type":"article","venue":"CHEST Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Lung cancer; Oncology; PD-L1; Internal medicine; Radiology; Immunotherapy; Cancer","score_opus":0.020022151978895404,"score_gpt":0.2696073538476109,"score_spread":0.24958520186871552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134394982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99472296,0.00062241405,0.0000055746364,0.0016275703,0.00008776563,0.00034777197,0.000039150185,0.000007633404,0.002539132],"genre_scores_gemma":[0.9954635,0.0028807528,0.0004318221,0.00035085253,0.000042714728,0.000012147042,0.000015925341,0.000024988787,0.00077732146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850976,0.00009432432,0.000536575,0.00023753637,0.0003650903,0.00025671461],"domain_scores_gemma":[0.99865884,0.00017570014,0.0004994201,0.00031498063,0.00027199212,0.0000790643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024171326,0.00021910513,0.000589697,0.00013727676,0.00006618644,0.000011617957,0.00013327927,0.00006703281,0.00026611486],"category_scores_gemma":[0.000027049542,0.00010699879,0.0001312296,0.00050254003,0.00015350955,0.0000469255,0.000013392056,0.0003573345,4.6010697e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025832774,0.0008841995,0.9560343,0.00006021733,0.0003589763,0.00012035049,0.0007148206,0.00004750693,0.012680068,0.0000027422411,0.00037831772,0.0028857226],"study_design_scores_gemma":[0.014016862,0.0012187469,0.893436,0.00054044876,0.00008454046,0.0000103502425,0.00016132706,0.000010425628,0.08965695,0.0000014653828,0.0007384163,0.00012443602],"about_ca_topic_score_codex":0.00026789965,"about_ca_topic_score_gemma":0.00052564265,"teacher_disagreement_score":0.07697688,"about_ca_system_score_codex":0.00026683882,"about_ca_system_score_gemma":0.0003245644,"threshold_uncertainty_score":0.4363284},"labels":[],"label_agreement":null},{"id":"W3134569327","doi":"10.1016/j.jtho.2020.12.026","title":"The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"National Cancer Institute; EMD Serono; Regeneron Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Foghorn Therapeutics; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Spectrum Pharmaceuticals; Amgen; Pfizer; Genentech","keywords":"Medicine; Lung cancer; Pembrolizumab; Turnaround time; Internal medicine; Oncology; Medical physics; Cancer; Family medicine","score_opus":0.07540617302975257,"score_gpt":0.47785478885301935,"score_spread":0.4024486158232668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134569327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827158,0.0017294355,0.00025447115,0.011497643,0.0024300234,0.0011045642,0.000056113375,0.000004314912,0.00020764706],"genre_scores_gemma":[0.99765056,0.00013894305,0.00053465023,0.00046444562,0.0005744748,0.000109167166,0.000005827354,0.0000084335115,0.0005134829],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99883944,0.00016518186,0.00047010946,0.00008858598,0.0002896094,0.00014709024],"domain_scores_gemma":[0.9941934,0.0034434444,0.0008416237,0.00009501752,0.0013968849,0.00002967341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030441277,0.000071270886,0.00025837874,0.000025197436,0.00013849018,0.000029202387,0.00015534964,0.000072360766,0.0000054872016],"category_scores_gemma":[0.0027335086,0.000038572653,0.00014261046,0.00016854265,0.000023338845,0.000029882296,0.000020035506,0.00013884163,7.471737e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020514734,0.0008542236,0.45684683,0.00002918554,0.002201372,0.000010820563,0.0002771329,0.000032504446,0.0019116339,0.000011546479,0.009618084,0.5076919],"study_design_scores_gemma":[0.005896127,0.0059208716,0.9417707,0.00016814908,0.00079892087,0.00008377945,0.0012759143,0.0006664802,0.0019053736,0.00008890777,0.041351944,0.00007286525],"about_ca_topic_score_codex":0.00018014571,"about_ca_topic_score_gemma":0.0018369149,"teacher_disagreement_score":0.5076191,"about_ca_system_score_codex":0.00095395587,"about_ca_system_score_gemma":0.0009395649,"threshold_uncertainty_score":0.32724628},"labels":[],"label_agreement":null},{"id":"W3134795762","doi":"10.3390/ijms22052608","title":"Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors","year":2021,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Cancer Society Research Institute; Canadian Cancer Society","keywords":"Tumor microenvironment; Cancer research; Immune system; Cancer; Kinase; Immunogenicity; Immunotherapy; Immune checkpoint; Medicine; Melanoma; Cancer immunotherapy; Immunology; Biology; Internal medicine","score_opus":0.038694628403802715,"score_gpt":0.3886751044547189,"score_spread":0.3499804760509162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134795762","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031324662,0.9659352,0.0004856176,0.0004753591,0.0012134579,0.0005254641,0.000021326012,0.0000015487528,0.000017374405],"genre_scores_gemma":[0.06779156,0.931208,0.000708878,0.000023135195,0.00020807987,0.000016076277,0.000012882923,0.000012922308,0.000018436062],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99687415,0.00013759056,0.0018159476,0.00018405398,0.0008685012,0.000119735814],"domain_scores_gemma":[0.99696004,0.00024179116,0.001995466,0.00013437196,0.000626643,0.00004170393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013836508,0.00018031459,0.001100271,0.00041153491,0.000029798866,0.000023338196,0.00037586814,0.00009507225,0.0000142443905],"category_scores_gemma":[0.00012453341,0.00009540387,0.0011950443,0.00036948282,0.000502103,0.00007117028,0.00002724376,0.0001534976,1.4602635e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006257395,0.0011620345,0.00013867859,0.00036989688,0.0012645697,0.00024180103,0.00013293886,0.00005550635,0.0011597011,0.00005019913,0.000018398177,0.99478054],"study_design_scores_gemma":[0.042846825,0.057630368,0.0039692307,0.17363867,0.007625472,0.005810507,0.0034956248,0.00061274925,0.10557943,0.00036199598,0.59705913,0.0013700031],"about_ca_topic_score_codex":0.000060540802,"about_ca_topic_score_gemma":0.000008410939,"teacher_disagreement_score":0.9934105,"about_ca_system_score_codex":0.00019106813,"about_ca_system_score_gemma":0.0013210136,"threshold_uncertainty_score":0.3890457},"labels":[],"label_agreement":null},{"id":"W3134802082","doi":"10.1200/po.20.00370","title":"Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment","year":2021,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University Health Network; Toronto General Hospital; University of Toronto; McMaster University; Juravinski Hospital","funders":"Canadian Institutes of Health Research","keywords":"Myocarditis; Immune checkpoint; Medicine; Immune system; Immunology; Inflammation; Cancer research; Immunotherapy; Internal medicine","score_opus":0.02483418104461527,"score_gpt":0.30841904254623725,"score_spread":0.283584861501622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134802082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9598349,0.029568741,0.00001852472,0.0037975502,0.0020544748,0.0015724694,0.00031426377,0.00011491194,0.0027242128],"genre_scores_gemma":[0.9654994,0.02288104,0.00046334602,0.0015460321,0.00040728596,0.00091921526,0.0011176227,0.00012848288,0.0070375996],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99603885,0.00050132175,0.001234649,0.0010057329,0.00053423137,0.00068522827],"domain_scores_gemma":[0.99745566,0.0003942216,0.00049938785,0.0010082243,0.00029677324,0.00034575997],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034143246,0.0006438226,0.0012710183,0.00018325512,0.0002638802,0.000073303665,0.00020466032,0.0005698551,0.0020981813],"category_scores_gemma":[0.000095325704,0.00051641115,0.0012763067,0.0003114688,0.00017524199,0.00014511793,0.00015134606,0.0003208866,0.00013812483],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008950615,0.0020111136,0.00043102753,0.00002800745,0.0021596563,0.00020424165,0.0023515043,8.589588e-7,0.52503496,0.0000015310359,0.04417647,0.41465],"study_design_scores_gemma":[0.016789282,0.011609829,0.0060891914,0.00030998565,0.0005483373,0.00029652222,0.0014704921,0.000050967534,0.3804539,0.000012486043,0.5819117,0.00045727813],"about_ca_topic_score_codex":0.00034945188,"about_ca_topic_score_gemma":0.00004552353,"teacher_disagreement_score":0.5377352,"about_ca_system_score_codex":0.005205568,"about_ca_system_score_gemma":0.0011482754,"threshold_uncertainty_score":0.99972874},"labels":[],"label_agreement":null},{"id":"W3134803739","doi":"10.1200/jco.2021.39.6_suppl.327","title":"Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Axitinib; Pembrolizumab; Sunitinib; Renal cell carcinoma; Internal medicine; Clinical endpoint; Population; Oncology; Surgery; Clinical trial; Cancer; Immunotherapy","score_opus":0.10072991463613369,"score_gpt":0.46138044553359125,"score_spread":0.3606505308974576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134803739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958769,0.00021430923,0.000014105775,0.0023039952,0.00024301949,0.00095750316,0.00001711734,0.0000016417206,0.0003713953],"genre_scores_gemma":[0.997455,0.00015528116,0.00032470003,0.0018106794,0.00014026726,0.000033218792,0.000011699461,0.000011473319,0.00005768447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99663544,0.00078883115,0.0018464522,0.00017589361,0.00034306577,0.00021029798],"domain_scores_gemma":[0.99486065,0.0034443857,0.0011105052,0.00026625054,0.0002521023,0.00006612533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001845595,0.0001418304,0.0012662931,0.000095091615,0.000031077427,0.000007282109,0.0002134283,0.00009900792,0.000037112284],"category_scores_gemma":[0.0004378347,0.000068922964,0.00040312085,0.0002333708,0.00015530428,0.000043543565,0.000017814536,0.00042348308,4.3214396e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13107054,0.03433164,0.61296624,0.000024770767,0.00047010023,0.0010700603,0.004735815,0.000028967055,0.00019768965,0.00001353131,0.00046844702,0.21462223],"study_design_scores_gemma":[0.16941895,0.08061647,0.7377317,0.00005042004,0.00024308843,0.00005663533,0.0027530794,0.000027127428,0.00005847768,0.00002442536,0.008956767,0.00006286385],"about_ca_topic_score_codex":0.00019045401,"about_ca_topic_score_gemma":0.0012194884,"teacher_disagreement_score":0.21455936,"about_ca_system_score_codex":0.00019441059,"about_ca_system_score_gemma":0.0010701347,"threshold_uncertainty_score":0.2810597},"labels":[],"label_agreement":null},{"id":"W3134997655","doi":"10.3389/fonc.2021.628138","title":"Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis","year":2021,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Alberta Cancer Foundation; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Tumor microenvironment; Breast cancer; Immune system; Context (archaeology); Medicine; Cancer; Immunogenicity; Cancer research; Immunotherapy; Immune checkpoint; Clinical trial; Immunology; Bioinformatics; Biology; Internal medicine","score_opus":0.025493520704663344,"score_gpt":0.3666543517185278,"score_spread":0.34116083101386446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134997655","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005723789,0.9840245,0.0007848925,0.0011939354,0.009834644,0.0021845656,0.00069997937,0.000048888807,0.0012228512],"genre_scores_gemma":[0.0000036300826,0.98482054,0.008120854,0.0007064564,0.0011394664,0.0012240768,0.0007189545,0.00013189114,0.0031341221],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966047,0.00025458395,0.0013210226,0.0008255013,0.0002198877,0.000774312],"domain_scores_gemma":[0.99823684,0.00023369696,0.0006248741,0.00059348653,0.00016283132,0.00014830571],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00072645233,0.00060423743,0.0044436264,0.0005215245,0.00011495254,0.000022773433,0.00036291403,0.0011700089,0.00062298594],"category_scores_gemma":[0.00008931011,0.00053089915,0.0012919555,0.0006616547,0.000246997,0.000063206644,0.000103369886,0.00081625866,0.000007569362],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010225079,0.00020061582,0.000086216445,0.0073159738,0.0013746152,0.0001582938,0.00012443714,6.1587986e-7,0.0000073449487,0.000012605089,0.08861002,0.90108675],"study_design_scores_gemma":[0.0033939986,0.0004133312,0.00008815323,0.010065429,0.0013907212,0.000458633,0.00019288644,0.000017907334,0.0000066305174,0.000038757633,0.9834524,0.0004811515],"about_ca_topic_score_codex":0.00024193733,"about_ca_topic_score_gemma":0.000106333195,"teacher_disagreement_score":0.9006056,"about_ca_system_score_codex":0.0032013813,"about_ca_system_score_gemma":0.0035068493,"threshold_uncertainty_score":0.99971426},"labels":[],"label_agreement":null},{"id":"W3135213711","doi":"10.1016/j.ccell.2021.02.013","title":"Progressive immune dysfunction with advancing disease stage in renal cell carcinoma","year":2021,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":517,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Human Genome Research Institute; Genentech; EMD Serono; Fondation de France; Eisai; Parker Institute for Cancer Immunotherapy; Danmarks Frie Forskningsfond; Kay Kendall Leukaemia Fund; Celldex Therapeutics; National Institutes of Health; BioMarin Pharmaceutical; Harvard Medical School; National Cancer Institute; Chinook Therapeutics; Gilead Sciences; G. Harold and Leila Y. Mathers Foundation; Dermatology Foundation; Leukemia and Lymphoma Society; Novartis; Bristol-Myers Squibb; Dana-Farber/Harvard Cancer Center; Merck; GlaxoSmithKline; Dana-Farber Cancer Institute; Roche; Astellas Pharma US; Pfizer; U.S. Department of Defense; Eli Lilly and Company; AstraZeneca; American Association for Cancer Research; Conquer Cancer Foundation; Exelixis","keywords":"Immune system; Immunotherapy; Cancer research; Tumor microenvironment; Clear cell renal cell carcinoma; CD8; Renal cell carcinoma; Biology; T cell; Myeloid; Cytotoxic T cell; Cell; Immunology; Cancer; Medicine; Internal medicine","score_opus":0.008063668867447894,"score_gpt":0.24567068903670503,"score_spread":0.23760702016925714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135213711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94053215,0.054428842,0.000100323035,0.0003922876,0.00025690102,0.00036510915,0.000027237165,0.000030826955,0.0038663389],"genre_scores_gemma":[0.9891098,0.00053042494,0.00024219364,0.000391143,0.0001538316,0.00012604464,0.000062954285,0.00003334845,0.009350242],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889314,0.00003619119,0.00021582414,0.00034106258,0.00020974208,0.0003040352],"domain_scores_gemma":[0.9993149,0.00001754898,0.00010405689,0.00031274947,0.00010628186,0.00014446629],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007711653,0.00016262497,0.00022418496,0.000046141646,0.000053480224,0.0000185809,0.000050892522,0.000048846323,0.0014931076],"category_scores_gemma":[0.0000059784725,0.00013394246,0.00008052985,0.00028684185,0.000058185953,0.00011517685,0.000023722938,0.00016567874,0.0000056401914],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018384852,0.0007919682,0.18849653,0.0015495971,0.00009116845,0.00488704,0.001228382,0.00029420402,0.7638619,0.000008262984,0.001406981,0.018999128],"study_design_scores_gemma":[0.012348861,0.00055453705,0.2623368,0.0006929126,0.00017758041,0.000030500176,0.0015896189,0.0002123544,0.6931054,0.0000056523304,0.028540036,0.0004057402],"about_ca_topic_score_codex":0.0005664444,"about_ca_topic_score_gemma":0.00034029735,"teacher_disagreement_score":0.07384027,"about_ca_system_score_codex":0.00051321194,"about_ca_system_score_gemma":0.0008779306,"threshold_uncertainty_score":0.9994197},"labels":[],"label_agreement":null},{"id":"W3135662544","doi":"10.1016/s1470-2045(21)00019-x","title":"Pembrolizumab monotherapy in metastatic triple-negative breast cancer","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Triple-negative breast cancer; Metastatic breast cancer; Oncology; Breast cancer; Internal medicine; Cancer; Immunotherapy","score_opus":0.05430835432453917,"score_gpt":0.3755661800372451,"score_spread":0.32125782571270595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135662544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.876593,0.00607771,0.00006004344,0.10529799,0.000703416,0.00062938867,0.000098909404,0.000059852104,0.010479717],"genre_scores_gemma":[0.97018534,0.0071242047,0.00062322355,0.01823889,0.000627617,0.00021942952,0.000015112155,0.000029782308,0.0029364086],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986964,0.0003326599,0.000271979,0.00022747098,0.00013715352,0.00033435092],"domain_scores_gemma":[0.99920213,0.00023376098,0.00010068502,0.00033784768,0.00008024283,0.00004534686],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043289305,0.00013591175,0.000588925,0.000058276546,0.000053944797,0.000011248243,0.00013287342,0.00007225252,0.0017815512],"category_scores_gemma":[0.00003860442,0.000088000554,0.000107140564,0.00041746718,0.00016234083,0.00004158451,0.00002654784,0.0002941614,0.000021051297],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12687878,0.0019765492,0.04445989,0.00034026845,0.0029452676,0.0020602855,0.013371906,0.000091595604,0.093615025,0.0024664856,0.052567035,0.6592269],"study_design_scores_gemma":[0.07750298,0.0009395862,0.66996056,0.0002612393,0.00028717436,0.0026499927,0.0021447549,0.00047823827,0.010887011,0.0025555275,0.23191,0.00042294062],"about_ca_topic_score_codex":0.0009871186,"about_ca_topic_score_gemma":0.002582968,"teacher_disagreement_score":0.65880394,"about_ca_system_score_codex":0.00041601044,"about_ca_system_score_gemma":0.00073529856,"threshold_uncertainty_score":0.99913096},"labels":[],"label_agreement":null},{"id":"W3135766757","doi":"10.1016/j.immuni.2021.02.012","title":"Cancer immunotherapy: Macs in the middle","year":2021,"lang":"en","type":"letter","venue":"Immunity","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Institute of Infection and Immunity; Université de Montréal; Canadian Liver Foundation","keywords":"Biology; Cancer; Cancer immunotherapy; Immunotherapy; Immunology; Cancer research; Computational biology; Genetics","score_opus":0.0606630888192051,"score_gpt":0.3040101587957556,"score_spread":0.2433470699765505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135766757","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05663042,0.05832169,0.000004353316,0.87646633,0.001508469,0.000912663,0.000089799425,0.00011163623,0.0059546386],"genre_scores_gemma":[0.007397047,0.0080006225,0.000046192406,0.9750583,0.001959161,0.00025510712,0.0005417273,0.0001287025,0.0066131465],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977607,0.0005124543,0.00044849192,0.0003115863,0.0004973565,0.00046941443],"domain_scores_gemma":[0.99812096,0.00022717049,0.00016776651,0.001359597,0.00010317249,0.000021351772],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00056798785,0.0003696366,0.00059402856,0.0001603049,0.000117182535,0.00007982195,0.00055453525,0.00069898955,0.001541605],"category_scores_gemma":[0.000030653253,0.00025385694,0.00039533555,0.00056294224,0.000197809,0.00005170833,0.000058389196,0.003588296,0.000016193055],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005362791,0.00016050515,0.0010083624,0.00030222727,0.00052086555,0.0009150946,0.002250648,2.2983865e-7,0.0028489416,0.0000022229644,0.9750068,0.016447809],"study_design_scores_gemma":[0.0019129938,0.000102853344,0.010267632,0.00075811043,0.00009221505,0.000182646,0.00052538083,0.0000025399231,0.0004507251,0.000036005575,0.9853771,0.000291835],"about_ca_topic_score_codex":0.009880916,"about_ca_topic_score_gemma":0.00062230683,"teacher_disagreement_score":0.09859197,"about_ca_system_score_codex":0.0003527943,"about_ca_system_score_gemma":0.00055015675,"threshold_uncertainty_score":0.99999136},"labels":[],"label_agreement":null},{"id":"W3135804634","doi":"10.1136/jitc-2020-002007","title":"Electrocardiographic features of immune checkpoint inhibitor associated myocarditis","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Myocarditis; Medicine; Mace; Internal medicine; QRS complex; Cardiology; PR interval; QT interval; Viral Myocarditis; Electrocardiography; Odds ratio; Heart rate; Blood pressure; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.011009566007240729,"score_gpt":0.298156691801623,"score_spread":0.2871471257943823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135804634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7332996,0.2607484,0.0002768964,0.0020037864,0.0020056623,0.00052683306,0.00013134722,0.00003041354,0.0009770646],"genre_scores_gemma":[0.9339312,0.06207409,0.0007093252,0.0005489055,0.00050600833,0.000058416674,0.000034347806,0.0000674314,0.0020702772],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99775636,0.000085275795,0.0010415706,0.00021024099,0.0005362552,0.00037032395],"domain_scores_gemma":[0.99760795,0.000096103424,0.00084971293,0.00032321716,0.0010470663,0.00007596587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007072312,0.00023852647,0.0009498354,0.00025527112,0.00013769118,0.000029030307,0.00015119428,0.00019584937,0.0003563478],"category_scores_gemma":[0.00009493657,0.00020262293,0.0019125146,0.00065334537,0.00016133154,0.000106968684,0.000014675496,0.00037371082,3.2621244e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062020235,0.00025667003,0.0034651586,0.00013802883,0.0053991214,0.000014279012,0.00028229036,0.0000065702156,0.91120124,0.000034280114,0.003642941,0.06935742],"study_design_scores_gemma":[0.010408807,0.0012511814,0.17050457,0.0009190518,0.00033015493,0.0003063597,0.00018961608,0.000003889817,0.76797485,0.0002931922,0.047604002,0.00021432008],"about_ca_topic_score_codex":0.00015839815,"about_ca_topic_score_gemma":0.00003672135,"teacher_disagreement_score":0.20063159,"about_ca_system_score_codex":0.00023220347,"about_ca_system_score_gemma":0.0007639372,"threshold_uncertainty_score":0.8262723},"labels":[],"label_agreement":null},{"id":"W3135861526","doi":"10.1080/2162402x.2021.1893466","title":"Tumor-intrinsic determinants of immunogenic cell death modalities","year":2021,"lang":"en","type":"review","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Agence Nationale de la Recherche","keywords":"Immunosurveillance; Immunogenic cell death; Cytotoxic T cell; Immune system; Acquired immune system; Immunology; Antigen presentation; T cell; Antigen; Antigen-presenting cell; Inflammation; Major histocompatibility complex; Secretion; Biology; Immunotherapy; Cancer research; In vitro","score_opus":0.05194550613869627,"score_gpt":0.3467005463507449,"score_spread":0.2947550402120486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135861526","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041634007,0.9917048,0.000002076156,0.000010985544,0.00085059204,0.0006925032,0.00008285174,0.000052269366,0.0024404998],"genre_scores_gemma":[0.0004885589,0.99425757,0.0001980058,0.00008345622,0.0001231936,0.0001168168,0.00017257377,0.000105354724,0.00445449],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99697113,0.00031466837,0.0013946998,0.0005538043,0.00023211274,0.00053360575],"domain_scores_gemma":[0.9974864,0.00022907423,0.0008724714,0.001193669,0.00016006244,0.000058296428],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029316207,0.000596716,0.004232357,0.0003727722,0.000071913804,0.00001415471,0.0004075278,0.0006104708,0.00063528697],"category_scores_gemma":[0.00005590125,0.0004914708,0.0015512514,0.00043659896,0.000329916,0.000046268848,0.00020828098,0.00062146207,0.00006809769],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024805136,0.00024596837,0.00008055869,0.013661165,0.00102212,0.0003781017,0.00009283833,1.3339862e-8,0.00018801137,0.00005708267,0.0001777516,0.98384833],"study_design_scores_gemma":[0.0015701411,0.00068130594,0.0002665788,0.015499735,0.0019059369,0.002527082,0.00013417014,3.850967e-7,0.0005404979,0.000012187458,0.97643876,0.00042323157],"about_ca_topic_score_codex":0.00050043286,"about_ca_topic_score_gemma":0.000020031208,"teacher_disagreement_score":0.9834251,"about_ca_system_score_codex":0.0004003396,"about_ca_system_score_gemma":0.0021473088,"threshold_uncertainty_score":0.9997537},"labels":[],"label_agreement":null},{"id":"W3135880610","doi":"10.1101/2021.03.09.21253153","title":"The Prognostic Value of PD-1/PD-L1 Expression on Tumor Cells and Tumor-Infiltrating Immune Cells in Patients with Colorectal Cancer: a Systematic Review and Meta-Analysis Protocol","year":2021,"lang":"en","type":"review","venue":"medRxiv","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Iran University of Medical Sciences","keywords":"Funnel plot; Medicine; Colorectal cancer; Meta-analysis; Oncology; Publication bias; PD-L1; Internal medicine; Cancer; Bioinformatics; Immunotherapy; Biology","score_opus":0.028577942758063163,"score_gpt":0.3196912487080797,"score_spread":0.2911133059500165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135880610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028112577,0.8882154,7.0359107e-7,0.000031134325,0.000029251414,0.10877663,0.00010320468,0.000011840294,0.000020561582],"genre_scores_gemma":[0.0010440424,0.8555878,0.000084957705,0.0001279336,0.000015488902,0.14294094,0.000036637157,0.000067770445,0.0000944323],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99547285,0.0011415584,0.0018340392,0.0006207407,0.0006195245,0.0003113094],"domain_scores_gemma":[0.9964245,0.0008016788,0.0018397107,0.00065863837,0.00017838475,0.00009711175],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014516135,0.0006027959,0.0070103533,0.00021750171,0.00011413044,0.000058108053,0.00021722158,0.000099517565,0.000075348],"category_scores_gemma":[0.00021418689,0.00027821353,0.0009813966,0.0011623043,0.00016528828,0.000050998147,0.000078229845,0.00040167355,0.0000010248161],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033181562,0.0002486537,0.0008496252,0.9630334,0.033821873,0.000039841772,0.000106265026,9.028088e-7,0.0001354323,0.0000019162446,0.000026240152,0.0014040468],"study_design_scores_gemma":[0.0017052073,0.001083234,0.00087985495,0.45071387,0.5387722,0.000029578727,0.00006665058,0.000008383545,0.0011726234,5.5261785e-7,0.0050310874,0.000536727],"about_ca_topic_score_codex":0.00007985332,"about_ca_topic_score_gemma":0.000032327287,"teacher_disagreement_score":0.5123195,"about_ca_system_score_codex":0.00011934632,"about_ca_system_score_gemma":0.00033770307,"threshold_uncertainty_score":0.999967},"labels":[],"label_agreement":null},{"id":"W3135934225","doi":"10.1016/j.jtho.2021.01.549","title":"P16.03 Early Mortality Associated Factors With Immune Checkpoint Inhibition in Real-World Canadian NSCLC Patients","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Internal medicine; Lung cancer; Randomized controlled trial; Overall survival; Immune system; Immunology","score_opus":0.028695556838341678,"score_gpt":0.3669351624204483,"score_spread":0.33823960558210664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135934225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993538,0.00022033135,0.0000025520326,0.0016925305,0.00046019818,0.00016717866,0.00002111545,0.0000075264697,0.0038905316],"genre_scores_gemma":[0.9987297,0.00014362493,0.00010494601,0.00038503582,0.000079293604,0.0000027858798,0.00004798558,0.000017894534,0.0004887322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981977,0.00026302921,0.0007746969,0.00015179171,0.00030512552,0.0003076552],"domain_scores_gemma":[0.99843603,0.000069255104,0.00062722055,0.00016055083,0.00048322335,0.00022371672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075811817,0.00014524058,0.00056780817,0.00039273684,0.000056869656,0.000018237755,0.00005603836,0.00018101514,0.00029965807],"category_scores_gemma":[0.00015529491,0.00011199253,0.00017829257,0.00061177276,0.00007693207,0.0001407841,0.000015053979,0.0005214683,0.0000035884066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033116066,0.00071532256,0.9778187,0.00004553732,0.0005095847,0.0017853645,0.00088017713,0.0000036194604,0.0066251555,0.000003986048,0.00029424208,0.008006659],"study_design_scores_gemma":[0.0027083594,0.0015719618,0.98395187,0.00043874912,0.00020750103,0.000093666844,0.00030919243,0.0000026053337,0.009096323,0.00002980593,0.0014754379,0.0001145534],"about_ca_topic_score_codex":0.058724023,"about_ca_topic_score_gemma":0.40654317,"teacher_disagreement_score":0.34781912,"about_ca_system_score_codex":0.0023326215,"about_ca_system_score_gemma":0.0022123943,"threshold_uncertainty_score":0.94754404},"labels":[],"label_agreement":null},{"id":"W3136062456","doi":"10.1017/cjn.2021.46","title":"Multiple Immune-Related Adverse Event Overlap in Two Patients Treated with Pembrolizumab","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"Alberta Precision Laboratories","keywords":"Pembrolizumab; Content (measure theory); Adverse effect; Medicine; Immune system; Internal medicine; Immunology; Immunotherapy; Mathematics","score_opus":0.017567427632097656,"score_gpt":0.26491572061231466,"score_spread":0.24734829298021702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136062456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99412185,0.0014370114,0.000003056722,0.0020018064,0.00046170637,0.00020712287,0.00001058365,0.000013652992,0.0017432057],"genre_scores_gemma":[0.9970807,0.00034494718,0.00037354117,0.0020509257,0.00007312312,0.000002764691,0.0000016338068,0.000013841196,0.00005851899],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955664,0.00071784446,0.0011714365,0.0005305553,0.0008223798,0.001191358],"domain_scores_gemma":[0.9968325,0.00031605683,0.0007268698,0.0001754316,0.0006301892,0.0013189722],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0020551896,0.00033166932,0.00062672974,0.0008854894,0.0010997956,0.00022461919,0.0007752241,0.00014295764,0.0003084514],"category_scores_gemma":[0.0012641301,0.00021045336,0.00033356794,0.0021850786,0.0037066154,0.000671248,0.000041408857,0.0011412882,0.000002659936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009979489,0.00010907003,0.9815277,0.0000064242254,0.00003380345,0.013136839,0.00020933503,0.001341966,0.00018317689,0.000049813712,0.00006532746,0.0023386304],"study_design_scores_gemma":[0.0040933397,0.04120164,0.9271109,0.00013705227,0.000054859276,0.024554105,0.00026357127,0.0006506271,0.00036126212,0.00045624396,0.0008514977,0.0002648664],"about_ca_topic_score_codex":0.003864606,"about_ca_topic_score_gemma":0.13281955,"teacher_disagreement_score":0.12895495,"about_ca_system_score_codex":0.00052468263,"about_ca_system_score_gemma":0.005277756,"threshold_uncertainty_score":0.9990047},"labels":[],"label_agreement":null},{"id":"W3136180086","doi":"10.21926/obm.genet.2101127","title":"Current Progress in Cancer Immunotherapies Using Small Molecules Targeting PD-L1 Stability","year":2021,"lang":"en","type":"article","venue":"OBM Genetics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research; Cure Brain Cancer Foundation","keywords":"PD-L1; Immune system; Immune checkpoint; Cancer research; Tumor microenvironment; Immunotherapy; Context (archaeology); Monoclonal antibody; Cancer immunotherapy; Small molecule; Nivolumab; Biology; Antibody; Immunology; Biochemistry","score_opus":0.055901903990209945,"score_gpt":0.3370238142511775,"score_spread":0.28112191026096756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136180086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76182145,0.23699711,0.00018255619,0.00035949756,0.00035226854,0.00021009186,0.00001351341,0.000021150692,0.00004235399],"genre_scores_gemma":[0.9770883,0.012167617,0.010171913,0.0002373822,0.00018706649,0.0000418625,0.000028484317,0.00004299824,0.000034405555],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99875075,0.000082312,0.00035102217,0.000310975,0.00019232953,0.0003126374],"domain_scores_gemma":[0.9993761,0.000024013005,0.000087423956,0.0003011957,0.00015609537,0.00005517072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020114498,0.0001679978,0.0002546485,0.00005570552,0.00006022761,0.00003421318,0.00008229281,0.00007587085,0.00027917005],"category_scores_gemma":[0.000020041565,0.00015785327,0.00010699309,0.00030859394,0.0001312471,0.000021671678,0.000053467415,0.00017995253,0.000001605162],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006112966,0.0004583956,0.48820132,0.00037019327,0.00015127273,0.00004602979,0.0018857504,0.00009732935,0.2906165,0.00000895798,0.000052974705,0.21749997],"study_design_scores_gemma":[0.0050215586,0.0002308031,0.42999437,0.0011043138,0.00015663785,0.000038364007,0.0016278095,0.0053053377,0.51779413,0.00010788139,0.037948012,0.00067077554],"about_ca_topic_score_codex":0.00011861666,"about_ca_topic_score_gemma":0.00022982911,"teacher_disagreement_score":0.22717763,"about_ca_system_score_codex":0.00023105134,"about_ca_system_score_gemma":0.00043472255,"threshold_uncertainty_score":0.643707},"labels":[],"label_agreement":null},{"id":"W3136973847","doi":"10.1007/s00432-021-03591-w","title":"Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"Journal of Cancer Research and Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Odds ratio; Oncology; Triple-negative breast cancer; Breast cancer; Adverse effect; Chemotherapy; Meta-analysis; Confidence interval; Cancer; Gastroenterology","score_opus":0.22545379788599076,"score_gpt":0.5483017007115142,"score_spread":0.32284790282552345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136973847","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000747443,0.9920167,0.0000013792986,0.0042233285,0.000112633315,0.0026467238,0.00021229756,0.0000023734422,0.000037143083],"genre_scores_gemma":[0.00051355537,0.9983328,0.000053794174,0.00020600489,0.00014963465,0.00019280279,0.0000064733135,0.000029403076,0.000515556],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98848563,0.0036273557,0.0061281985,0.0005225623,0.00080020225,0.00043604602],"domain_scores_gemma":[0.989878,0.004672612,0.0035659745,0.00041259208,0.0010217308,0.0004491054],"candidate_categories":["metaepi_broad","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.013807176,0.00040638616,0.01746749,0.000768796,0.00007075489,0.000033871802,0.00024793588,0.00052882225,0.0004607292],"category_scores_gemma":[0.0017326447,0.00023279007,0.0029146564,0.0017258801,0.0009888379,0.000095661206,0.00021060591,0.0023785068,4.6830863e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060010194,0.0008742526,0.00029229373,0.4887936,0.2801254,0.000501137,0.0001881881,2.4480235e-7,0.00000395806,0.000010770145,0.00021616256,0.22299294],"study_design_scores_gemma":[0.010112812,0.0055192225,0.0033192604,0.2140643,0.6978005,0.00066900434,0.0002450006,0.0000020667103,0.0000044506455,0.000011917762,0.06788863,0.00036282738],"about_ca_topic_score_codex":0.0021531326,"about_ca_topic_score_gemma":0.0012303598,"teacher_disagreement_score":0.4176751,"about_ca_system_score_codex":0.0006205982,"about_ca_system_score_gemma":0.0036067392,"threshold_uncertainty_score":0.99992305},"labels":[],"label_agreement":null},{"id":"W3137239260","doi":"10.1016/j.jtho.2021.01.530","title":"P14.24 Evolution of TCR Clonality during Chemoradiation and Durvalumab as Predictors of Survival in Stage 3 NSCLC","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; T-cell receptor; Immune system; Stage (stratigraphy); Medicine; Repertoire; Immunology; Oncology; Immunotherapy; T cell; Biology","score_opus":0.019441310107998565,"score_gpt":0.3695756449481801,"score_spread":0.3501343348401816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137239260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948741,0.0026857418,0.000041592357,0.00105434,0.0006335459,0.00009618749,0.000010625757,0.0000030499268,0.00060077186],"genre_scores_gemma":[0.9985258,0.0005983098,0.00036545887,0.000032230215,0.000165481,0.0000010537204,0.000003453264,0.000007595194,0.00030059277],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99847496,0.0002595937,0.0007463255,0.00010864935,0.00028789713,0.00012254949],"domain_scores_gemma":[0.9986911,0.00011931849,0.0007144043,0.00011808322,0.0002936895,0.00006340345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011785926,0.00008218079,0.0005374478,0.00018687328,0.000019451714,0.000003278095,0.00005385961,0.00014484575,0.00011380995],"category_scores_gemma":[0.00030642925,0.00007329075,0.0001223724,0.0002697412,0.00011485061,0.00009977654,0.000026630545,0.00023610977,3.3628007e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023888096,0.0008018627,0.45448902,0.00079999253,0.00042986238,0.00031179033,0.0011839713,0.000039776416,0.49417922,0.00006222456,0.000091046146,0.023723155],"study_design_scores_gemma":[0.0035270422,0.0011323751,0.9223218,0.0002681308,0.00013727117,0.00052281533,0.0011409409,0.000038789905,0.06973187,0.00009898322,0.0010189811,0.00006103242],"about_ca_topic_score_codex":0.0001370846,"about_ca_topic_score_gemma":0.00012885462,"teacher_disagreement_score":0.46783277,"about_ca_system_score_codex":0.0005613853,"about_ca_system_score_gemma":0.00091792125,"threshold_uncertainty_score":0.298871},"labels":[],"label_agreement":null},{"id":"W3137491601","doi":"10.1016/j.ctarc.2021.100353","title":"Discordance in PD-L1 scores on repeat testing of non-small cell lung carcinomas","year":2021,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Oncology; Pleural effusion; Carcinoma; Biopsy; Retrospective cohort study; Malignant pleural effusion; Pathology","score_opus":0.14059017514654282,"score_gpt":0.4125888941020173,"score_spread":0.2719987189554745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137491601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92983806,0.0591078,0.0000029486696,0.002758024,0.000028274097,0.00046415348,0.000025386555,0.000009674123,0.0077656563],"genre_scores_gemma":[0.9520269,0.04441165,0.0011856329,0.000046164398,0.000029369072,0.0002846927,0.000037478487,0.000013742972,0.0019643519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989857,0.00016664356,0.0002258345,0.00022587643,0.0001619011,0.00023402082],"domain_scores_gemma":[0.9980672,0.0005261295,0.000050645303,0.0010561374,0.00022474637,0.00007516807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026005058,0.000105286905,0.00022106357,0.00012970313,0.00020886333,0.000021205995,0.00017347855,0.000044040517,0.000027401074],"category_scores_gemma":[0.00006775718,0.000081308266,0.00005838347,0.00062556175,0.0003098985,0.000035822137,0.00013620158,0.000223074,0.0000014172592],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007708563,0.0012563489,0.8247556,0.00027393107,0.00015264058,0.000048243928,0.0023253676,0.0000123925,0.115916625,0.00012046565,0.000502275,0.053865265],"study_design_scores_gemma":[0.0060653575,0.0011857282,0.8746487,0.0021038074,0.00009537596,0.000020609581,0.0019345795,0.0013614233,0.10584072,0.000077592325,0.0064719836,0.00019412371],"about_ca_topic_score_codex":0.0037116045,"about_ca_topic_score_gemma":0.0025354424,"teacher_disagreement_score":0.05367114,"about_ca_system_score_codex":0.00039329563,"about_ca_system_score_gemma":0.0006338378,"threshold_uncertainty_score":0.56108606},"labels":[],"label_agreement":null},{"id":"W3137736070","doi":"10.1016/j.jtho.2021.01.1184","title":"P79.05 Phase II Randomized Trial of Neoadjuvant Pembrolizumab +/- Chemotherapy for Operable Stage IA3-IIA Non-Small Cell Lung Cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Oncology; Lung cancer; Pembrolizumab; Stage (stratigraphy); Internal medicine; Chemotherapy; Immunotherapy; Randomized controlled trial; Neoadjuvant therapy; Cancer","score_opus":0.023053894360969898,"score_gpt":0.4153785200569625,"score_spread":0.39232462569599263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137736070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752725,0.009639202,0.0025560893,0.006433508,0.0028162827,0.001836813,0.00005255052,0.000010247867,0.0013828389],"genre_scores_gemma":[0.94317746,0.013972372,0.013901711,0.004230107,0.0027389294,0.0002308901,0.00003227561,0.00011230122,0.021603927],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99722433,0.00034141995,0.0014920292,0.00024785707,0.0003171359,0.00037724563],"domain_scores_gemma":[0.99686867,0.0004903236,0.0014049766,0.00029574064,0.0007639719,0.00017631621],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022037257,0.00025280568,0.0021160124,0.000211101,0.00011686761,0.000018928571,0.00021638525,0.00028320463,0.0012355751],"category_scores_gemma":[0.00018533593,0.0001864843,0.001065709,0.0002461505,0.00015928347,0.000105779916,0.000040924973,0.00040195888,6.7740126e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7536717,0.002202931,0.00001413446,0.00033661988,0.001018989,0.00017662905,0.000936609,0.000026572023,0.16011642,0.0000046188125,0.0058639017,0.07563087],"study_design_scores_gemma":[0.7752221,0.010178743,0.00001671111,0.00029587143,0.0010752958,0.00026538724,0.00033278068,0.00072975014,0.12839697,0.00002541125,0.083302304,0.00015866877],"about_ca_topic_score_codex":0.000094283416,"about_ca_topic_score_gemma":0.00004403906,"teacher_disagreement_score":0.07743841,"about_ca_system_score_codex":0.0004820192,"about_ca_system_score_gemma":0.0032199838,"threshold_uncertainty_score":0.9996774},"labels":[],"label_agreement":null},{"id":"W3137963785","doi":"10.1136/jitc-2020-001831","title":"Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Dermatology; Immunosuppression; Adverse effect; Refractory (planetary science); Immune system; Ultraviolet b; Immunology; Internal medicine","score_opus":0.024746355654553263,"score_gpt":0.3409145376868956,"score_spread":0.31616818203234237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137963785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8374453,0.1518867,0.0004258233,0.005470237,0.0024368134,0.0017256687,0.00019144327,0.00005748417,0.00036052047],"genre_scores_gemma":[0.8393802,0.13943382,0.0018212663,0.008537756,0.0010480287,0.000729389,0.00015328133,0.00031016488,0.0085860845],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99669147,0.000121117344,0.0016452157,0.00046208742,0.00051326933,0.0005668154],"domain_scores_gemma":[0.9964841,0.0003300498,0.0012237666,0.00072017417,0.0010870412,0.00015486941],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010351083,0.0004712022,0.0010121667,0.0002559676,0.00048199066,0.00009290104,0.000212981,0.0003371814,0.001197422],"category_scores_gemma":[0.00009363791,0.00037483592,0.0013891486,0.0003687917,0.00019104224,0.00020760861,0.000009229332,0.0005256226,0.0000017104704],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027091984,0.0011030858,0.0006830003,0.00014669678,0.0044256398,0.0033240928,0.0020783274,0.0000230096,0.6288748,0.0000386236,0.01153001,0.32068077],"study_design_scores_gemma":[0.035898745,0.004174112,0.0051386342,0.0008004617,0.00014042814,0.04783794,0.0005353755,0.000030391391,0.35153535,0.0004323015,0.55293363,0.00054262095],"about_ca_topic_score_codex":0.00020249632,"about_ca_topic_score_gemma":0.000031674266,"teacher_disagreement_score":0.54140365,"about_ca_system_score_codex":0.00037591427,"about_ca_system_score_gemma":0.0011888073,"threshold_uncertainty_score":0.99987036},"labels":[],"label_agreement":null},{"id":"W3138047597","doi":"10.1200/op.20.00949","title":"Challenges of Immunotherapy in Stage IV Non–Small-Cell Lung Cancer","year":2021,"lang":"en","type":"review","venue":"JCO Oncology Practice","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Hôpital du Sacré-Cœur de Montréal; University of Ottawa","funders":"","keywords":"Immunotherapy; Medicine; Lung cancer; Oncology; Adverse effect; Chemotherapy; Internal medicine; Immune system; Immune checkpoint; Targeted therapy; Cancer; Immunology","score_opus":0.09085460350274119,"score_gpt":0.44692957633112995,"score_spread":0.35607497282838874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138047597","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000058086636,0.9625455,0.000007901223,0.0022264726,0.00088303274,0.0016553842,0.000033254168,0.000024539238,0.032565836],"genre_scores_gemma":[0.000011125205,0.99366707,0.0008955278,0.0010138707,0.00027818448,0.00050278835,0.000045600384,0.000099796234,0.0034860617],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964902,0.0009563034,0.0011919623,0.00065295177,0.00027652257,0.0004321027],"domain_scores_gemma":[0.99533206,0.0019647258,0.001584741,0.000801101,0.0002334874,0.0000838607],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015794205,0.00049406756,0.003197643,0.0003581493,0.000043541215,0.0000134452675,0.00030913003,0.0010245665,0.0009523012],"category_scores_gemma":[0.00023186715,0.00041894105,0.0006286783,0.0005612092,0.00013130509,0.00014496139,0.0000958269,0.0013191036,0.000016716183],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010783491,0.0012236993,0.000027191785,0.01960166,0.001756454,0.0006218273,0.0007525021,4.5710678e-7,0.0000951647,0.000047774673,0.001236399,0.97355855],"study_design_scores_gemma":[0.0037097074,0.00063611317,0.000069236536,0.014726223,0.0019716197,0.00029439954,0.0008623297,0.0000033489466,0.000025281002,6.2052425e-7,0.9773625,0.00033862202],"about_ca_topic_score_codex":0.00093060423,"about_ca_topic_score_gemma":0.00058531197,"teacher_disagreement_score":0.9761261,"about_ca_system_score_codex":0.0012605694,"about_ca_system_score_gemma":0.00470911,"threshold_uncertainty_score":0.99996096},"labels":[],"label_agreement":null},{"id":"W3138063070","doi":"10.1016/j.jacc.2021.01.050","title":"Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis","year":2021,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":188,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; McGill University; Toronto General Hospital; Jewish General Hospital; University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institutes of Health; Kohlberg Foundation; CSL Behring; Canadian Institutes of Health Research; Harvard University Center for AIDS Research; Canada Research Chairs; New York Academy of Medicine; AstraZeneca","keywords":"Medicine; Myocarditis; Cardiogenic shock; Internal medicine; Ejection fraction; Cardiology; Mace; Magnetic resonance imaging; Cardiac magnetic resonance; Pericardial effusion; Heart failure; Myocardial infarction; Percutaneous coronary intervention; Radiology","score_opus":0.004977394613136391,"score_gpt":0.20894176948309165,"score_spread":0.20396437486995525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138063070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891389,0.0083643645,0.000010922553,0.0015417656,0.00030760732,0.0001746369,0.000097615346,0.0000031462282,0.00036104358],"genre_scores_gemma":[0.9975984,0.0016253381,0.00016803487,0.0003626461,0.00012417648,0.0000032555113,0.0000036690856,0.000016196856,0.000098254626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983987,0.00034104104,0.0005880974,0.00014921083,0.00031037373,0.00021253523],"domain_scores_gemma":[0.9986935,0.00010550713,0.00061958976,0.00022215191,0.00030439644,0.00005483688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042982723,0.00013693277,0.0010265614,0.0001108795,0.000041629526,0.000004438353,0.000108646134,0.000060144957,0.000006678094],"category_scores_gemma":[0.00018641473,0.00009326516,0.0002998331,0.0006378887,0.0004978866,0.00004125692,0.00006294348,0.00028371584,1.8561003e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064129555,0.00012593753,0.9451239,0.00003098914,0.0009521326,0.0003248953,0.00012548397,0.000015847805,0.02671469,0.0000033479448,0.007256978,0.012912832],"study_design_scores_gemma":[0.006434266,0.0017569207,0.9732072,0.00030579529,0.00012227533,0.00047969646,0.0004166656,0.000002774835,0.0015156161,0.0000116421925,0.015645035,0.000102114784],"about_ca_topic_score_codex":0.000039134142,"about_ca_topic_score_gemma":0.0000069951197,"teacher_disagreement_score":0.028083289,"about_ca_system_score_codex":0.00017897636,"about_ca_system_score_gemma":0.00029107596,"threshold_uncertainty_score":0.3803243},"labels":[],"label_agreement":null},{"id":"W3138705137","doi":"10.1038/s41590-021-00916-2","title":"Publisher Correction: Gut CD4+ T cell phenotypes are a continuum molded by microbes, not by TH archetypes","year":2021,"lang":"en","type":"erratum","venue":"Nature Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Canadian Institute for Advanced Research; University of British Columbia","funders":"Boehringer Ingelheim Fonds; National Institute of General Medical Sciences; Harvard Stem Cell Institute; Harvard University; Division of Intramural Research, National Institute of Allergy and Infectious Diseases; U.S. Department of Health and Human Services","keywords":"Phenotype; Archetype; Biology; Cell biology; Computational biology; Genetics; Philosophy; Theology; Gene","score_opus":0.005073793926852137,"score_gpt":0.23446879910260546,"score_spread":0.2293950051757533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138705137","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020698505,0.69569606,0.000022932592,0.012569818,0.20688635,0.0010465981,0.00046954872,0.00035863742,0.080880225],"genre_scores_gemma":[0.0051610484,0.015630085,0.00011842859,0.009323131,0.001986936,0.00010057616,0.010387686,0.00021311104,0.957079],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99637467,0.00028871853,0.000738241,0.0012212212,0.00048461097,0.0008925199],"domain_scores_gemma":[0.99718195,0.00017824947,0.00071816554,0.0011635488,0.0006317305,0.00012634319],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00029532495,0.0008699925,0.0015930079,0.0003129345,0.00020102994,0.00017033533,0.00061870815,0.0057803937,0.0020797176],"category_scores_gemma":[0.00028338569,0.00078229676,0.00059243775,0.0006444044,0.00046067726,0.00014592793,0.0001980205,0.0075487997,0.00006994889],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022939555,0.00039154777,0.000109033535,0.00021833465,0.0013943528,0.000076195465,0.00013660238,2.0589537e-8,0.13769068,0.0000030443628,0.852932,0.004754272],"study_design_scores_gemma":[0.0037961183,0.00042912495,0.0011540486,0.0005979554,0.00037841345,0.00034041138,0.000327535,0.0000014210135,0.016501235,0.000016707172,0.97574073,0.0007162846],"about_ca_topic_score_codex":0.0005286868,"about_ca_topic_score_gemma":0.00043669745,"teacher_disagreement_score":0.87619877,"about_ca_system_score_codex":0.0005180281,"about_ca_system_score_gemma":0.00091237004,"threshold_uncertainty_score":0.9994628},"labels":[],"label_agreement":null},{"id":"W3144883130","doi":"10.21037/pcm-20-58","title":"The role of immunotherapy in metastatic triple negative breast cancer: a narrative review of the current clinical trials","year":2021,"lang":"en","type":"review","venue":"Precision Cancer Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Triple-negative breast cancer; Immunotherapy; Metastatic breast cancer; Oncology; Medicine; Clinical trial; Breast cancer; Narrative; Narrative review; Internal medicine; Cancer; Cancer immunotherapy; Intensive care medicine; Art","score_opus":0.16181610135790667,"score_gpt":0.5293993507710599,"score_spread":0.36758324941315323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3144883130","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010331212,0.986587,0.000007427176,0.0039860355,0.0030840815,0.0056954273,0.00047633413,0.0000089493815,0.0001444333],"genre_scores_gemma":[0.00002077634,0.9971451,0.00002532785,0.00051123905,0.00059820624,0.0013595793,0.000042549236,0.000057810357,0.00023937803],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9854385,0.006063112,0.006225307,0.00064889726,0.0012648562,0.00035927814],"domain_scores_gemma":[0.9862116,0.006554417,0.0050399615,0.0012704348,0.0007980879,0.00012551989],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.014288231,0.0006192463,0.00845133,0.0002031202,0.00011211629,0.000009240358,0.00075406884,0.00018840678,0.0015330663],"category_scores_gemma":[0.004832205,0.00025436652,0.002304221,0.0021419036,0.00091138313,0.000052947344,0.00013656374,0.0012948118,0.0000011439415],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014022009,0.00019247417,0.0000483423,0.02042844,0.0017485548,0.0000020449659,0.00064920494,1.363344e-7,0.0000113278375,0.000012294712,0.007266917,0.96823806],"study_design_scores_gemma":[0.0029780965,0.00018291158,0.00015533902,0.40259463,0.0020123613,0.000021483194,0.0002684649,0.0000034927618,0.000016655895,0.000057459183,0.5915742,0.00013490676],"about_ca_topic_score_codex":0.0010232239,"about_ca_topic_score_gemma":0.00031359677,"teacher_disagreement_score":0.9681032,"about_ca_system_score_codex":0.0005169491,"about_ca_system_score_gemma":0.004738052,"threshold_uncertainty_score":0.9999909},"labels":[],"label_agreement":null},{"id":"W3145138207","doi":"10.21037/pcm-20-64","title":"A narrative review of immune checkpoint inhibitors in early stage triple negative breast cancer","year":2021,"lang":"en","type":"review","venue":"Precision Cancer Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Taxane; Triple-negative breast cancer; Pembrolizumab; Breast cancer; Atezolizumab; Internal medicine; Chemotherapy; Immune checkpoint; Population; Cancer","score_opus":0.04721812796156658,"score_gpt":0.3967856712577745,"score_spread":0.34956754329620787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3145138207","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001351911,0.9902944,0.0000056802946,0.002752858,0.0017730256,0.0039216946,0.00049196143,0.000033596498,0.0005915718],"genre_scores_gemma":[0.00004698099,0.9940571,0.00005809833,0.0006739269,0.0008019767,0.0014428576,0.00019964614,0.000112578375,0.0026067942],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9929901,0.0005679412,0.003672177,0.0010029527,0.0012428341,0.00052399747],"domain_scores_gemma":[0.9954047,0.00048116082,0.0021502564,0.00095542806,0.0007585077,0.00024991095],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019221288,0.00088453694,0.006778401,0.0006588142,0.000066165805,0.000011178975,0.0003859579,0.000448366,0.009069373],"category_scores_gemma":[0.00064955413,0.000583403,0.0012525064,0.0029381667,0.00045160463,0.00013764737,0.00016302353,0.0011668357,0.0000067176084],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007159758,0.00015323625,0.000046359517,0.10077674,0.0008161435,0.00006988321,0.0029088515,1.8503361e-7,0.00006623967,0.0000026103453,0.0071475115,0.88729626],"study_design_scores_gemma":[0.0028412745,0.00026709927,0.00037160958,0.5162455,0.00101808,0.000058294896,0.00042227763,0.0000010249117,0.00009814886,0.000002714467,0.47837132,0.00030266558],"about_ca_topic_score_codex":0.013080537,"about_ca_topic_score_gemma":0.0005812829,"teacher_disagreement_score":0.8869936,"about_ca_system_score_codex":0.0015421307,"about_ca_system_score_gemma":0.0030495324,"threshold_uncertainty_score":0.99966174},"labels":[],"label_agreement":null},{"id":"W3145804410","doi":"10.3390/cancers13071705","title":"IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; Université Laval; Centre hospitalier universitaire de Québec","funders":"Canadian Institutes of Health Research","keywords":"FOLFIRI; Irinotecan; Colorectal cancer; Oncology; Medicine; Internal medicine; Fluorouracil; Chemotherapy; Cetuximab; Immune system; Cancer; Immunology","score_opus":0.018865154629874897,"score_gpt":0.2587461337020068,"score_spread":0.23988097907213188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3145804410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901928,0.008181506,0.000022507409,0.00032839703,0.0002350564,0.0005846928,0.000067359346,0.000032845957,0.00035484118],"genre_scores_gemma":[0.9936109,0.004709646,0.00019379998,0.0007082232,0.00008409195,0.00009901164,0.000056284433,0.000042602205,0.00049541984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860317,0.00007715524,0.00026788542,0.00042622426,0.00027695822,0.00034862803],"domain_scores_gemma":[0.9994175,0.000051735387,0.000093741495,0.00018662799,0.00006505948,0.0001853397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007127152,0.00023905883,0.00042997493,0.00008471574,0.00004793841,0.000039091687,0.000063656094,0.00006654034,0.0003771238],"category_scores_gemma":[0.000015498177,0.00018711801,0.00006395176,0.00040419505,0.00010630335,0.000082195926,0.0000161687,0.00013963997,0.0000014376243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014170793,0.00021328601,0.91804993,0.0001002928,0.0013458466,0.0003565558,0.0014632347,0.00019126199,0.0064011062,0.000014852609,0.0016493386,0.056043524],"study_design_scores_gemma":[0.021697057,0.0015510599,0.9691189,0.00030323636,0.0001643403,0.000037136484,0.0000950903,0.00038909342,0.002380898,0.00003375374,0.0039480026,0.00028146207],"about_ca_topic_score_codex":0.008791946,"about_ca_topic_score_gemma":0.003605744,"teacher_disagreement_score":0.055762064,"about_ca_system_score_codex":0.0008890664,"about_ca_system_score_gemma":0.0020843374,"threshold_uncertainty_score":0.9978086},"labels":[],"label_agreement":null},{"id":"W3147445522","doi":"10.1016/s1556-0864(21)01939-0","title":"97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Ono Pharmaceutical; Astellas Pharma; F. Hoffmann-La Roche; Sanofi; Servier; Amgen; Pfizer; Les Laboratories Pierre Fabre; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Chemotherapy; Immunotherapy; Cancer","score_opus":0.015216673979625726,"score_gpt":0.3473521490314572,"score_spread":0.3321354750518315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3147445522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866292,0.0018575883,0.0021842602,0.0067123,0.0016053464,0.000508105,0.00005798429,0.00002160338,0.00042362194],"genre_scores_gemma":[0.9818277,0.00068599894,0.012696054,0.0027847902,0.00074742595,0.000020632518,0.00007544426,0.000065420965,0.0010965734],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814296,0.000092288465,0.0007309932,0.00028208178,0.00039989766,0.00035176653],"domain_scores_gemma":[0.9975057,0.00039453595,0.00073150074,0.0003168176,0.0008634971,0.00018791408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002890339,0.0002463561,0.00090895745,0.00013856236,0.00010714965,0.000022101582,0.00017857988,0.00024973502,0.00045387776],"category_scores_gemma":[0.00022643979,0.00018241552,0.0003991559,0.00025150648,0.0000981797,0.00014576047,0.000026914426,0.00036358106,0.000006060049],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44361135,0.0017394988,0.0075524636,0.00016846984,0.0013564371,0.00039364296,0.0012389327,0.00006667939,0.0057102544,0.0000075445364,0.0072794734,0.53087527],"study_design_scores_gemma":[0.24924646,0.051374152,0.0897646,0.0014119248,0.0020377464,0.0010294565,0.0020876816,0.00026163398,0.03166948,0.00066526525,0.5694451,0.0010065106],"about_ca_topic_score_codex":0.000032153082,"about_ca_topic_score_gemma":0.00016120492,"teacher_disagreement_score":0.5621656,"about_ca_system_score_codex":0.0007117093,"about_ca_system_score_gemma":0.0010940522,"threshold_uncertainty_score":0.7438689},"labels":[],"label_agreement":null},{"id":"W3149101508","doi":"10.1186/s13223-021-00616-4","title":"Aplastic anemia secondary to dual cancer immunotherapies a physician nightmare: case report and literature review","year":2021,"lang":"en","type":"article","venue":"Allergy Asthma and Clinical Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Adverse effect; Cancer; Immunotherapy; Aplastic anemia; Immune system; Internal medicine; Oncology; Intensive care medicine; Immunology; Bone marrow","score_opus":0.014931705773064657,"score_gpt":0.3278872093350559,"score_spread":0.3129555035619912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3149101508","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4425085,0.5425822,0.000027359136,0.013194391,0.00076320494,0.00029426167,0.000032854732,0.000047314894,0.0005499018],"genre_scores_gemma":[0.18325716,0.7559046,0.0006220397,0.050368182,0.0007605956,0.00014599237,0.000279793,0.0000870597,0.00857458],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977991,0.00021599568,0.00083225354,0.0006720394,0.00012633525,0.00035424987],"domain_scores_gemma":[0.99858886,0.0003093888,0.0001868693,0.00052096316,0.00023050416,0.00016342186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034833528,0.00028999802,0.0008223385,0.0000631451,0.00015976613,0.000045061377,0.00006432776,0.0003198094,0.0007270076],"category_scores_gemma":[0.00020356309,0.00023886007,0.00021866178,0.00032866196,0.00036001744,0.00009410997,0.000137395,0.0006359459,0.000010727635],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005230965,0.0006811455,0.00085061474,0.0010461176,0.005728028,0.2972264,0.0009563023,2.936877e-7,0.0134003535,0.00036783383,0.01791654,0.6565954],"study_design_scores_gemma":[0.0057449187,0.0018716704,0.039419666,0.0047935387,0.00023741742,0.26634774,0.0004983954,0.000006955601,0.0005926171,0.00008691571,0.6797998,0.0006003814],"about_ca_topic_score_codex":0.00013219987,"about_ca_topic_score_gemma":0.000437259,"teacher_disagreement_score":0.66188323,"about_ca_system_score_codex":0.000038437,"about_ca_system_score_gemma":0.00031581792,"threshold_uncertainty_score":0.97404313},"labels":[],"label_agreement":null},{"id":"W3150218649","doi":"10.1200/op.20.00845","title":"Evaluation of a Multidisciplinary Immunotherapy Toxicity Monitoring Program for Patients Receiving Ipilimumab for Metastatic Melanoma","year":2021,"lang":"en","type":"article","venue":"JCO Oncology Practice","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Ipilimumab; Medicine; Toxicity; Adverse effect; Internal medicine; Retrospective cohort study; Melanoma; Expanded access; Checklist; Cancer; Immunotherapy","score_opus":0.0787262558232179,"score_gpt":0.44806685726415457,"score_spread":0.36934060144093667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3150218649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98741406,0.0022616,0.0010567041,0.0024921445,0.0011198262,0.0045544454,0.000037129088,0.000048964033,0.0010151159],"genre_scores_gemma":[0.8628201,0.0004250464,0.13402005,0.00020268782,0.00019172064,0.0020100423,0.00010093671,0.000040093284,0.00018936359],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99796396,0.0004943896,0.0005172382,0.0003195001,0.0004498504,0.00025503556],"domain_scores_gemma":[0.99453604,0.0022509978,0.00054047036,0.00029291518,0.0023297395,0.000049827944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033470837,0.00015160831,0.00042403967,0.00007939947,0.00015162422,0.000016055712,0.00007956516,0.00013290634,0.000043688047],"category_scores_gemma":[0.0038955295,0.00014090782,0.00021465086,0.00022318393,0.00006580844,0.00027037223,0.000031886964,0.00014255445,0.0000013366446],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01659324,0.0055980757,0.0048654824,0.0002225538,0.0015083571,0.000006010431,0.0014719227,0.000013098969,0.06233782,0.000013462839,0.00026426296,0.9071057],"study_design_scores_gemma":[0.1602339,0.04988947,0.28590232,0.0008944284,0.011664625,0.00035074368,0.014081548,0.013015865,0.21970348,0.0010389478,0.24219835,0.0010263149],"about_ca_topic_score_codex":0.000027141803,"about_ca_topic_score_gemma":0.000028969429,"teacher_disagreement_score":0.9060794,"about_ca_system_score_codex":0.0006683914,"about_ca_system_score_gemma":0.0010916264,"threshold_uncertainty_score":0.5746054},"labels":[],"label_agreement":null},{"id":"W3151335080","doi":"10.3389/pore.2021.609717","title":"Automated PD-L1 Scoring for Non-Small Cell Lung Carcinoma Using Open-Source Software","year":2021,"lang":"en","type":"article","venue":"Pathology & Oncology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"Mitacs","keywords":"Concordance; Medicine; Gold standard (test); Scoring system; Lung cancer; Correlation; Radiology; Internal medicine","score_opus":0.12340286802928656,"score_gpt":0.43885926914444945,"score_spread":0.3154564011151629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3151335080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98801684,0.002729267,0.002377955,0.0014750928,0.0005515722,0.0017605948,0.000027304422,0.00018613506,0.0028752368],"genre_scores_gemma":[0.9542578,0.00024061058,0.035911616,0.0014269111,0.0004188903,0.0005005629,0.00012789424,0.00012189599,0.0069938563],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99642134,0.0007658888,0.000498813,0.00086346397,0.00028226458,0.0011682408],"domain_scores_gemma":[0.99702036,0.0010365066,0.00012651512,0.0007109393,0.0008790617,0.00022660271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029912307,0.00024009649,0.0007429577,0.0003570931,0.0006134461,0.00006858121,0.00049997325,0.00058732496,0.00027855835],"category_scores_gemma":[0.0005530691,0.0002342429,0.00019317404,0.000762483,0.000520056,0.00008978152,0.0007389315,0.00086949224,0.00003680828],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056674303,0.0009325981,0.17030351,0.00068212533,0.00023403455,0.0055480353,0.0021456962,0.000025242469,0.78037596,0.000016426342,0.00941193,0.024657026],"study_design_scores_gemma":[0.056308787,0.010964437,0.3331344,0.0010755783,0.0008628632,0.014713911,0.009061894,0.032806233,0.39829347,0.00025699168,0.14090551,0.0016159201],"about_ca_topic_score_codex":0.00027899383,"about_ca_topic_score_gemma":0.0001542048,"teacher_disagreement_score":0.3820825,"about_ca_system_score_codex":0.00085629604,"about_ca_system_score_gemma":0.0031176722,"threshold_uncertainty_score":0.9552148},"labels":[],"label_agreement":null},{"id":"W3152514714","doi":"10.1177/17588359211010156","title":"Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single-agent pembrolizumab","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Jubilee Hospital; Spinal Cord Injury BC","funders":"","keywords":"Pembrolizumab; Medicine; Adenocarcinoma; Pancreas; Lung cancer; Tumor microenvironment; Lung; Gemcitabine; Pathology; Pancreatic cancer; Chemotherapy; Immune system; Oncology; Immunotherapy; Cancer research; Internal medicine; Cancer; Immunology","score_opus":0.01879562548514577,"score_gpt":0.29419115280817876,"score_spread":0.27539552732303296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152514714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856213,0.010640838,0.0006519458,0.002238259,0.000056126555,0.00063994265,0.000008447473,0.000004427077,0.00013875648],"genre_scores_gemma":[0.9949389,0.0040634647,0.00017394518,0.00068337435,0.000016871842,0.000060502865,0.0000210758,0.000016358243,0.000025525993],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978336,0.0004543529,0.0007180816,0.00022032193,0.00056149816,0.00021211918],"domain_scores_gemma":[0.9986651,0.0003782901,0.00049569085,0.00036066087,0.00006357418,0.000036670186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048320595,0.00016793433,0.00065986,0.00008114916,0.0000297362,0.000002190235,0.0002388884,0.00007278916,0.000174908],"category_scores_gemma":[0.000051564988,0.00008225629,0.00008195619,0.00057156064,0.0007205565,0.00006117327,0.000038002043,0.00023574839,2.04575e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050316095,0.0066921767,0.36567497,0.0018497037,0.0007718084,0.000758706,0.005732259,0.00015909305,0.43453625,0.00022334131,0.0000031288832,0.13328247],"study_design_scores_gemma":[0.018612422,0.0057742177,0.8487427,0.0023398092,0.00052612164,0.00086755626,0.001522513,0.0004317449,0.11817517,0.00006606024,0.0027548154,0.00018682577],"about_ca_topic_score_codex":0.00011401646,"about_ca_topic_score_gemma":0.00063616177,"teacher_disagreement_score":0.48306775,"about_ca_system_score_codex":0.00019842271,"about_ca_system_score_gemma":0.00051538204,"threshold_uncertainty_score":0.3354314},"labels":[],"label_agreement":null},{"id":"W3152567134","doi":"10.1172/jci.insight.131458","title":"PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer","year":2021,"lang":"en","type":"article","venue":"JCI Insight","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; École Polytechnique Fédérale de Lausanne; California Institute for Quantitative Biosciences; Cancer Research Institute; York University; Mayo Clinic","keywords":"Triple-negative breast cancer; Cancer research; PD-L1; Phosphorylation; GSK-3; Immunotherapy; Breast cancer; Signal transduction; Metastasis; Tumor progression; Chemistry; Biology; Cancer; Immune system; Medicine; Cell biology; Immunology; Internal medicine","score_opus":0.022586297835191057,"score_gpt":0.29202248799309233,"score_spread":0.26943619015790127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152567134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97665226,0.017741693,0.000012391043,0.0037647241,0.00018152979,0.00039036802,0.000025071398,0.000034292538,0.0011976776],"genre_scores_gemma":[0.99556005,0.0015930362,0.000034108787,0.0020959028,0.00015604545,0.000070928814,0.000012868212,0.00002005874,0.00045699888],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990361,0.000059649352,0.0002551072,0.0002958914,0.00015558345,0.00019771166],"domain_scores_gemma":[0.9994771,0.000070536495,0.0000811828,0.00016918343,0.0001358802,0.00006610295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000108160115,0.00014039695,0.00025190783,0.00010356196,0.000060743005,0.00002679348,0.000044982116,0.00006726925,0.00056898466],"category_scores_gemma":[0.000020246944,0.00011791777,0.000061387,0.0004803717,0.00004236871,0.000108162814,0.000022449627,0.0001712029,0.00000889777],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030946971,0.00025932855,0.01895794,0.0001814761,0.0003135946,0.00016218201,0.0033780436,0.0000027552894,0.871392,0.00046926222,0.00031924126,0.10146944],"study_design_scores_gemma":[0.0058764145,0.00012767031,0.766142,0.00040207678,0.00009283387,0.00034662732,0.0004704155,0.00019670252,0.21694559,0.00026440923,0.00887085,0.0002644186],"about_ca_topic_score_codex":0.00026072102,"about_ca_topic_score_gemma":0.00020206578,"teacher_disagreement_score":0.74718404,"about_ca_system_score_codex":0.00019007092,"about_ca_system_score_gemma":0.00025360528,"threshold_uncertainty_score":0.6229983},"labels":[],"label_agreement":null},{"id":"W3152750473","doi":"10.1016/s1470-2045(21)00081-4","title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pharmacyclics; Novartis Pharma; EMD Serono; Meso Scale Diagnostics; Les Laboratories Pierre Fabre; Johnson and Johnson; Genentech; Eisai; SkylineDx; Array BioPharma; Ipsen; Syndax Pharmaceuticals; Pfizer; Incyte; Sun Pharma; Regeneron Pharmaceuticals; Sanofi; AstraZeneca; EUSA Pharma; Roche; Novartis; GlaxoSmithKline; Amgen; Qbiotics; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Clinical endpoint; Hazard ratio; Placebo; Internal medicine; Quality of life (healthcare); Population; Clinical trial; Adverse effect; Oncology; Melanoma; Randomized controlled trial; Surgery; Cancer; Confidence interval; Pathology; Immunotherapy; Alternative medicine","score_opus":0.16983074091665748,"score_gpt":0.43179126405716817,"score_spread":0.26196052314051066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152750473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95775074,0.0064033624,0.000030690055,0.021184573,0.002084604,0.005310963,0.00045063026,0.0001007153,0.006683711],"genre_scores_gemma":[0.99186605,0.002041897,0.00015598201,0.0019707372,0.0011412433,0.0004714007,0.0008804277,0.00004852422,0.0014237355],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99146503,0.0034937195,0.0029590586,0.0006932384,0.0005620073,0.0008269158],"domain_scores_gemma":[0.9910677,0.0057375086,0.0015240639,0.0011919452,0.00023739514,0.00024137324],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0065113306,0.0003884819,0.0040038796,0.00021125289,0.00016036844,0.000027503515,0.0004135651,0.0004986662,0.0008347452],"category_scores_gemma":[0.002413165,0.00027493088,0.00050327997,0.0007206122,0.00036365268,0.00007582658,0.00011458295,0.0010007828,0.000021225767],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9789946,0.0013631769,0.00003293906,0.00007483942,0.0017002155,0.00028945334,0.002843254,0.0000317415,0.006147485,0.00024078444,0.003523436,0.0047580935],"study_design_scores_gemma":[0.9756864,0.0052947868,0.00049007457,0.00015333042,0.00023689985,0.000024279507,0.0011003684,0.00031924224,0.0008864387,0.00006260873,0.0154812,0.00026439814],"about_ca_topic_score_codex":0.010067097,"about_ca_topic_score_gemma":0.009628176,"teacher_disagreement_score":0.0341153,"about_ca_system_score_codex":0.000713361,"about_ca_system_score_gemma":0.0036595992,"threshold_uncertainty_score":0.9999703},"labels":[],"label_agreement":null},{"id":"W3152795894","doi":"10.1007/s00428-021-03093-7","title":"Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path)","year":2021,"lang":"en","type":"article","venue":"Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Royal University Hospital; Saskatchewan Health Authority","funders":"Foundation Medicine; Illumina; Roche; Merck KGaA; Genentech; AstraZeneca; Bristol-Myers Squibb","keywords":"Indel; Medicine; Genetic testing; Medical physics; Pathology; Oncology; Computational biology; Internal medicine; Biology; Genotype; Genetics; Gene; Single-nucleotide polymorphism","score_opus":0.09006913746391482,"score_gpt":0.4001454080725867,"score_spread":0.3100762706086719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152795894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98346734,0.0035148067,0.0025380237,0.004486223,0.0016678675,0.0011568872,0.00048242853,0.00012561504,0.002560823],"genre_scores_gemma":[0.9810843,0.000345258,0.012463322,0.0038585945,0.00072017644,0.00011922024,0.00095180346,0.000051791016,0.00040557553],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99541634,0.0012497264,0.0012563128,0.00087318145,0.0005330446,0.00067138014],"domain_scores_gemma":[0.993055,0.00415988,0.0008344457,0.0010520197,0.000753522,0.00014517219],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035573035,0.00042140175,0.0010065921,0.00010496005,0.00025507965,0.000027153337,0.0007052301,0.00026325317,0.00008199591],"category_scores_gemma":[0.010279922,0.00028305262,0.00046197276,0.00080282055,0.0011091902,0.0000783074,0.00038010444,0.0006832658,0.0000071712907],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011945124,0.0014501372,0.20395187,0.0006981075,0.0025664766,0.00086096325,0.0021952658,0.0008516582,0.65545017,0.0035793288,0.016479429,0.09997145],"study_design_scores_gemma":[0.007127682,0.0014407042,0.950337,0.00046577543,0.00048907154,0.00022999344,0.0008788307,0.0023599039,0.01931407,0.00833743,0.008480724,0.0005388219],"about_ca_topic_score_codex":0.0008789704,"about_ca_topic_score_gemma":0.00025116184,"teacher_disagreement_score":0.7463851,"about_ca_system_score_codex":0.000088368346,"about_ca_system_score_gemma":0.0011149121,"threshold_uncertainty_score":0.99996215},"labels":[],"label_agreement":null},{"id":"W3152878368","doi":"10.1016/j.annonc.2021.04.008","title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":418,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Hôpital Charles-Le Moyne","funders":"Foundation Medicine; Samsung; Genentech; EMD Serono; Otsuka Pharmaceutical; Chugai Pharmaceutical; Seagen; Incyte; Mirati Therapeutics; Novocure; Jazz Pharmaceuticals; Amgen; Ariad Pharmaceuticals; Merck KGaA; Sanofi; GlaxoSmithKline; Spectrum Pharmaceuticals; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pemetrexed; Pembrolizumab; Medicine; Carboplatin; Internal medicine; Oncology; Lung cancer; Hazard ratio; Placebo; Chemotherapy; Progression-free survival; Cisplatin; Confidence interval; Cancer; Pathology; Immunotherapy","score_opus":0.07969916344976641,"score_gpt":0.37129884328562884,"score_spread":0.29159967983586244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152878368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822804,0.000117154195,0.00017208385,0.00067308353,0.000028653621,0.015057757,0.00008727033,0.00003597393,0.0015476506],"genre_scores_gemma":[0.9895866,0.000030659266,0.0029867117,0.0008755791,0.000035276254,0.0052514975,0.00037233657,0.00004298456,0.00081834296],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99736035,0.00031027012,0.00078390026,0.00057411456,0.0004946546,0.00047670954],"domain_scores_gemma":[0.9978784,0.00026354525,0.0005316703,0.000554777,0.0006252994,0.00014631901],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002691567,0.0003374005,0.0015232036,0.00045473943,0.00005466673,0.000019604402,0.00015153569,0.00015527903,0.0014266204],"category_scores_gemma":[0.00010493673,0.00021712655,0.00019877708,0.002016737,0.00022664311,0.0001034932,0.000042774645,0.00026535318,0.0000067043766],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53380305,0.004076429,0.39390486,0.00025140154,0.0081753675,0.0011426613,0.002183574,0.00019493685,0.000514758,0.000008456129,0.0010112827,0.05473321],"study_design_scores_gemma":[0.122778215,0.031411465,0.82594746,0.0006090401,0.0028379688,0.000068889334,0.00096294406,0.0005635494,0.005757387,0.000022381522,0.008437739,0.00060295814],"about_ca_topic_score_codex":0.0022736506,"about_ca_topic_score_gemma":0.010998184,"teacher_disagreement_score":0.4320426,"about_ca_system_score_codex":0.00022687993,"about_ca_system_score_gemma":0.0016824653,"threshold_uncertainty_score":0.9994862},"labels":[],"label_agreement":null},{"id":"W3153913656","doi":"10.1097/md.0000000000025488","title":"A systematic review and meta-analysis on the regulation of programmed cell death-1 on T-cells in type 2 diabetes","year":2021,"lang":"en","type":"review","venue":"Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Fogarty International Center","keywords":"Medicine; Meta-analysis; Type 2 diabetes; Confidence interval; Downregulation and upregulation; Immune system; Internal medicine; Diabetes mellitus; Disease; Oncology; Immunology; Endocrinology","score_opus":0.09288362657926924,"score_gpt":0.3504921059000348,"score_spread":0.2576084793207656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3153913656","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014002212,0.9941118,7.2315606e-7,0.0017668995,0.00004711941,0.0037366513,0.0000105575655,0.000009107709,0.0003031523],"genre_scores_gemma":[0.00016696668,0.99661916,0.000017579043,0.0014514282,0.00003153698,0.00037141575,0.0001334212,0.000026237456,0.0011822361],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.997146,0.0006532654,0.0012319352,0.00035136822,0.0004491451,0.00016828794],"domain_scores_gemma":[0.9974373,0.000823137,0.0007484222,0.00082538475,0.00011187516,0.000053858515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019540011,0.00035290286,0.0077076037,0.00036164914,0.000021573022,0.0000061894293,0.00012518684,0.00013693004,0.00066233386],"category_scores_gemma":[0.000359192,0.00014753755,0.0010745025,0.0017979506,0.00009478946,0.000009881894,0.000018415845,0.00026054357,0.000005858122],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020753949,0.00011531947,0.0000016140289,0.92908657,0.061629854,0.0000073610445,0.00005362838,1.04625485e-7,0.000012990626,0.000028609345,0.00094877445,0.008094437],"study_design_scores_gemma":[0.0002917469,0.00046253906,0.0000062671465,0.22850344,0.7187352,0.0000038515527,0.00001839921,0.0000028507727,0.000020824355,0.0000022391228,0.051838577,0.00011404698],"about_ca_topic_score_codex":0.0000327924,"about_ca_topic_score_gemma":0.0000085816,"teacher_disagreement_score":0.7005831,"about_ca_system_score_codex":0.00008394112,"about_ca_system_score_gemma":0.00009196087,"threshold_uncertainty_score":0.7252091},"labels":[],"label_agreement":null},{"id":"W3154186241","doi":"10.1158/1557-3265.radsci21-ia-014","title":"Abstract IA-014: Strategies to enhance the immunogenicity of radiation therapy","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunogenicity; Immune system; Cancer research; Cancer; Immunology; Medicine; CD8; Immune checkpoint; Immunotherapy; Oncolytic virus; Cancer immunotherapy; Internal medicine","score_opus":0.1999027175686072,"score_gpt":0.5693669929650879,"score_spread":0.36946427539648063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154186241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626944,0.021177571,0.000030073297,0.012514898,0.0003637273,0.000538024,0.000020002366,0.000017414945,0.002643877],"genre_scores_gemma":[0.96973044,0.027515898,0.000047563724,0.0011893963,0.00047213925,0.00010022331,0.000009223466,0.000018094423,0.00091701513],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975601,0.00035762537,0.0006408825,0.00036211326,0.0007245657,0.00035471708],"domain_scores_gemma":[0.99744666,0.001015824,0.00010102207,0.00067351625,0.00064026564,0.00012270291],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033137389,0.00010853286,0.00033135936,0.00006369221,0.00014323869,0.00005558547,0.00027488853,0.00013377891,0.0019473163],"category_scores_gemma":[0.00048197145,0.00007140855,0.00025912217,0.0007270424,0.00043771084,0.00007770826,0.00007385249,0.0006840073,0.00004243021],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008915168,0.00043880037,0.009664833,0.00008096324,0.0004116668,0.000022178761,0.0005458636,0.000008683183,0.230529,0.00013195297,0.011294346,0.7379565],"study_design_scores_gemma":[0.0016520689,0.0006847401,0.62177515,0.00014929837,0.000014944263,0.0000043200976,0.0006943062,0.0000073241595,0.27318838,0.00024421987,0.10147938,0.00010589951],"about_ca_topic_score_codex":0.0016363862,"about_ca_topic_score_gemma":0.00039723443,"teacher_disagreement_score":0.73785067,"about_ca_system_score_codex":0.00012836287,"about_ca_system_score_gemma":0.0018741194,"threshold_uncertainty_score":0.998965},"labels":[],"label_agreement":null},{"id":"W3154244221","doi":"10.1080/13696998.2021.1917139","title":"Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"","keywords":"Medicine; Nivolumab; Docetaxel; Population; Clinical trial; Cost effectiveness; Quality-adjusted life year; Internal medicine; Oncology; Randomized controlled trial; Cost–benefit analysis; Demography; Cancer; Environmental health; Immunotherapy","score_opus":0.02007993074301333,"score_gpt":0.2834601182077676,"score_spread":0.2633801874647543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154244221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99591225,0.0027532002,0.00005443905,0.0007821049,0.00019239441,0.00020679564,0.000050319195,8.686876e-7,0.00004762107],"genre_scores_gemma":[0.99350214,0.0058145877,0.00018189623,0.00037740052,0.00008387722,0.000003805765,0.0000133912135,0.000015721316,0.00000715232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881357,0.000077975026,0.00051807874,0.00021448353,0.00019256215,0.0001833127],"domain_scores_gemma":[0.99901235,0.00020093069,0.00024049156,0.00023489847,0.00006407964,0.0002472252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00107865,0.00011941904,0.00054871093,0.00009251044,0.00001566903,0.000015256212,0.00018984004,0.00010047181,0.00009904187],"category_scores_gemma":[0.00006052859,0.00009875062,0.000023237062,0.0001022963,0.0000864865,0.00013901659,0.000081684106,0.00037552477,6.2936245e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007148932,0.0003487447,0.9543939,0.0010345805,0.00018633956,0.001482366,0.00046677064,0.0003654203,0.0010149973,0.000004545125,0.00034638835,0.033206977],"study_design_scores_gemma":[0.03468464,0.00083082326,0.93473417,0.0017710201,0.00018191282,0.0010097921,0.0022069511,0.019574258,0.003453656,0.0000128570255,0.0012262944,0.0003136033],"about_ca_topic_score_codex":0.29063806,"about_ca_topic_score_gemma":0.88699496,"teacher_disagreement_score":0.5963569,"about_ca_system_score_codex":0.00053220656,"about_ca_system_score_gemma":0.0057702996,"threshold_uncertainty_score":0.99986607},"labels":[],"label_agreement":null},{"id":"W3154709616","doi":"10.1016/j.annonc.2021.03.208","title":"How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy","year":2021,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Immunotherapy; Biomarker; Cancer; Oncology; Cancer immunotherapy; Internal medicine; Cancer research","score_opus":0.0840677914914246,"score_gpt":0.437595009934382,"score_spread":0.3535272184429574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154709616","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.082460694,0.12699892,0.000007854778,0.021166747,0.76327777,0.0021667627,0.001582815,0.000067443456,0.0022709798],"genre_scores_gemma":[0.053782173,0.37282023,0.00046838002,0.003640108,0.5476417,0.0010125679,0.0022483286,0.00052542053,0.017861107],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951276,0.000979423,0.0018799944,0.00064720254,0.00083055877,0.00053522614],"domain_scores_gemma":[0.9942777,0.0017374998,0.0021599468,0.0007576392,0.0009445186,0.00012266493],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003002751,0.0004988384,0.0035418249,0.0005914568,0.000030943625,0.000022002856,0.00036887493,0.0020780137,0.00093472016],"category_scores_gemma":[0.0023064648,0.00040615172,0.001014181,0.00056211726,0.00038082124,0.00007301196,0.00008761265,0.00073083583,0.0000014974041],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023516428,0.0006083128,0.000103927814,0.00048313086,0.0010734057,0.00011041273,0.0004273626,3.4592895e-7,0.21188186,0.000001636981,0.65297455,0.10881863],"study_design_scores_gemma":[0.010795941,0.0026915935,0.00080863386,0.0027559965,0.00014987301,0.000007526691,0.00025829114,0.000001416829,0.098607086,0.000043608918,0.8835769,0.0003030833],"about_ca_topic_score_codex":0.006190907,"about_ca_topic_score_gemma":0.0017924105,"teacher_disagreement_score":0.24582131,"about_ca_system_score_codex":0.00031972863,"about_ca_system_score_gemma":0.0052854195,"threshold_uncertainty_score":0.99997854},"labels":[],"label_agreement":null},{"id":"W3154805493","doi":"10.1200/jco.21.00174","title":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Chemotherapy; Lung cancer; Hazard ratio; Oncology; Clinical endpoint; Cancer; Surgery; Randomized controlled trial; Immunotherapy; Confidence interval","score_opus":0.08258638092140791,"score_gpt":0.4375760962292222,"score_spread":0.3549897153078143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154805493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856274,0.0013241404,0.0010451286,0.009631712,0.0010202894,0.00068177504,0.000010871007,0.000011161419,0.00064748735],"genre_scores_gemma":[0.9612191,0.0020132214,0.025478972,0.007031133,0.0010670109,0.00007821779,0.000013834134,0.00007940272,0.003019142],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9974313,0.00014168578,0.0014675072,0.00026946992,0.00039388478,0.00029617886],"domain_scores_gemma":[0.99613076,0.0008953079,0.0016961752,0.00022368984,0.0008205129,0.00023353825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011545545,0.0002110467,0.001496945,0.000086232896,0.000060093298,0.000017984821,0.00012944223,0.0001491685,0.00035458844],"category_scores_gemma":[0.00031251728,0.00012134755,0.0005190231,0.00018291944,0.00020094296,0.000099304445,0.000015457093,0.00056624203,0.0000018502562],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61257714,0.004374218,0.29761884,0.0007353609,0.007841227,0.0020581097,0.00047552848,0.000087594584,0.0021662703,0.000031747506,0.0078185145,0.06421545],"study_design_scores_gemma":[0.27890897,0.06574297,0.5732024,0.00090541865,0.0048455657,0.0010456642,0.0014347654,0.00035287003,0.0039879954,0.000042827243,0.069036335,0.00049426674],"about_ca_topic_score_codex":0.000050492625,"about_ca_topic_score_gemma":0.00035294134,"teacher_disagreement_score":0.3336682,"about_ca_system_score_codex":0.00028464026,"about_ca_system_score_gemma":0.0055023986,"threshold_uncertainty_score":0.9761019},"labels":[],"label_agreement":null},{"id":"W3154837170","doi":"10.1186/s12894-021-00829-0","title":"Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma","year":2021,"lang":"en","type":"article","venue":"BMC Urology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Urothelium; Medicine; Urothelial Cell; Immunohistochemistry; Bladder cancer; Flow cytometry; Pathology; Immune checkpoint; Urothelial carcinoma; Immune system; Cancer; Urinary bladder; Urology; Internal medicine; Immunotherapy; Immunology","score_opus":0.01781896564841612,"score_gpt":0.2564762268131028,"score_spread":0.23865726116468666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154837170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955679,0.0020371673,0.00007123142,0.001315799,0.00034145816,0.0001590504,0.000007638992,0.0000073715432,0.00049237045],"genre_scores_gemma":[0.9987547,0.00003175372,0.000060650345,0.0005073612,0.0000779914,0.00001287111,0.0000054202956,0.0000108707545,0.0005384113],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992027,0.00010481177,0.00027455637,0.0001641647,0.00010046879,0.00015325424],"domain_scores_gemma":[0.9994631,0.000049140614,0.00007906435,0.00035292952,0.00003394202,0.000021870866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014326842,0.00008065603,0.00020694974,0.000040359337,0.000021731837,0.0000026199727,0.000088373694,0.00010257236,0.00025982744],"category_scores_gemma":[0.000056360575,0.00005412434,0.00013099935,0.00011353673,0.00006426068,0.000014494033,0.00007258388,0.00014036967,0.0000034832035],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010107564,0.00008096024,0.36060587,0.000044873657,0.0000066008197,0.000021517722,0.0002489112,0.000001923745,0.6375847,0.000014232581,0.000025492509,0.00035417607],"study_design_scores_gemma":[0.0018859039,0.0000964163,0.53856987,0.000015841551,0.00001443814,0.00006669466,0.00007407918,0.000015982481,0.4576157,0.000019704195,0.0015927254,0.00003266985],"about_ca_topic_score_codex":0.00024164116,"about_ca_topic_score_gemma":0.00031413088,"teacher_disagreement_score":0.179969,"about_ca_system_score_codex":0.000025267616,"about_ca_system_score_gemma":0.00018493965,"threshold_uncertainty_score":0.28449282},"labels":[],"label_agreement":null},{"id":"W3156212653","doi":"10.3390/ijms22094843","title":"Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer","year":2021,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Canadian Cancer Society Research Institute; Max-Planck-Institut für Chemie; McMaster University","keywords":"Triple-negative breast cancer; Medicine; Breast cancer; Immunotherapy; Radiation therapy; Immune checkpoint; Oncology; Radionuclide therapy; Immune system; Cancer; Clinical trial; Internal medicine; Cancer research; Immunology","score_opus":0.026615058097374373,"score_gpt":0.3336987862568684,"score_spread":0.30708372815949403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156212653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788182,0.012087575,0.0005974157,0.0076501276,0.0005911856,0.00013796514,0.00003196642,0.0000022711977,0.00008333662],"genre_scores_gemma":[0.98061067,0.0155545585,0.0029596284,0.0006420443,0.00009709395,0.0000073413903,0.0000019078775,0.0000061052738,0.00012063912],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991802,0.000030903604,0.00027469805,0.00010076679,0.00033643135,0.00007700157],"domain_scores_gemma":[0.9990538,0.000061947554,0.00024640522,0.000052843036,0.00054928835,0.000035757195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018417595,0.0000740752,0.00020971085,0.000109937915,0.000036838104,0.00003043502,0.00011132685,0.000023894763,0.000094513125],"category_scores_gemma":[0.000017858662,0.000050203897,0.00017823544,0.00012633401,0.00018719077,0.00008354263,0.0000061614387,0.000021770222,7.684429e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070748217,0.00043706884,0.0062822406,0.0000061800606,0.0012998604,0.00007895187,0.00084396044,0.000019549117,0.68236077,0.0003183242,0.00011750316,0.30116075],"study_design_scores_gemma":[0.024355568,0.0040013134,0.08253425,0.00024844726,0.00006733516,0.001212095,0.0007403335,0.00023195315,0.87883157,0.0012054797,0.006432681,0.00013898945],"about_ca_topic_score_codex":0.000079112484,"about_ca_topic_score_gemma":0.000005659006,"teacher_disagreement_score":0.30102175,"about_ca_system_score_codex":0.0000807153,"about_ca_system_score_gemma":0.00039034302,"threshold_uncertainty_score":0.20472555},"labels":[],"label_agreement":null},{"id":"W3156427152","doi":"10.1186/s12957-021-02254-x","title":"Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis","year":2021,"lang":"en","type":"review","venue":"World Journal of Surgical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"West China Hospital, Sichuan University; Sichuan University; National Natural Science Foundation of China","keywords":"Medicine; Hazard ratio; Internal medicine; Oncology; Lung cancer; Immunohistochemistry; Cochrane Library; Meta-analysis; Confidence interval; Subgroup analysis; Epidermal growth factor receptor; Biomarker; Surgical oncology; Predictive marker; Cancer; Biology","score_opus":0.058166544449569126,"score_gpt":0.3836644596843958,"score_spread":0.32549791523482663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156427152","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024492922,0.99540657,0.000060266655,0.00043124615,0.0003855545,0.00088828953,0.000096547345,0.000005065589,0.0024815593],"genre_scores_gemma":[0.0008368171,0.9965152,0.0007352506,0.00007744452,0.0002611332,0.00013098565,0.00003590031,0.00004124921,0.0013660034],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.99439144,0.0011624212,0.002936795,0.0004792821,0.0006238663,0.0004062144],"domain_scores_gemma":[0.9946764,0.0011760858,0.0031146372,0.00041904542,0.00034486275,0.00026895117],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015029742,0.0005526891,0.010547993,0.0014838475,0.000037754842,0.0000126288505,0.00031170543,0.00048616919,0.0025431383],"category_scores_gemma":[0.00002239434,0.0003275786,0.0077526392,0.002233516,0.00015156172,0.000056195182,0.00010852706,0.001163686,0.0000012354283],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009037206,0.0049681575,0.0007586374,0.0115910135,0.48877096,0.01674282,0.0007577163,0.00040720482,0.00015497056,0.000017606897,0.0021864062,0.4646073],"study_design_scores_gemma":[0.003018291,0.000994425,0.000049615614,0.00458335,0.30045894,0.00045712732,0.000044869135,0.000024010937,0.00013720553,0.0000018424826,0.69004536,0.000184957],"about_ca_topic_score_codex":0.0001687612,"about_ca_topic_score_gemma":0.0002176255,"teacher_disagreement_score":0.68785894,"about_ca_system_score_codex":0.0021092095,"about_ca_system_score_gemma":0.0029995893,"threshold_uncertainty_score":0.9999176},"labels":[],"label_agreement":null},{"id":"W3156756924","doi":"10.1101/2021.04.22.440902","title":"Immune cell networks uncover candidate biomarkers of cancer immunotherapy response","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Directorate for Biological Sciences; Queen's University; Queen's University Belfast","keywords":"Nivolumab; Immune system; Immunotherapy; Context (archaeology); Immunology; Biology; Melanoma; Tumor microenvironment; T cell; Cancer; Cancer immunotherapy; Computational biology; Oncology; Medicine; Cancer research; Internal medicine","score_opus":0.009361070698207009,"score_gpt":0.24218292888264845,"score_spread":0.23282185818444143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156756924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91276705,0.08207153,0.00054489647,0.00046927773,0.0024468116,0.0011300122,0.00026113237,0.0002994003,0.000009896305],"genre_scores_gemma":[0.9778318,0.019136958,0.0013507087,0.00065152114,0.00035128434,0.00027217492,0.0000025235577,0.0003579578,0.00004512048],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9956585,0.00041512164,0.0012759852,0.0011802264,0.0006594596,0.0008106955],"domain_scores_gemma":[0.9953431,0.00016324669,0.0010379365,0.002370647,0.00080311595,0.00028194612],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014163699,0.00087641826,0.0014816313,0.0004525587,0.0001233544,0.00014107372,0.00055986305,0.0009757258,0.0004798629],"category_scores_gemma":[0.0000709889,0.00087749603,0.0007824774,0.0010970032,0.00035196505,0.00013334614,0.0003508929,0.0010355936,0.000005358738],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01399922,0.00036900802,0.015709622,0.00071833876,0.002381388,0.00017340678,0.00003535778,0.0001706006,0.9657555,0.0000031476645,0.0006554086,0.000028981247],"study_design_scores_gemma":[0.004561265,0.00023600909,0.2936253,0.0020651934,0.0004625271,9.159016e-8,0.000014748934,0.00032170842,0.687596,1.5858002e-7,0.010221163,0.0008958445],"about_ca_topic_score_codex":0.0022196309,"about_ca_topic_score_gemma":0.000025531259,"teacher_disagreement_score":0.27815953,"about_ca_system_score_codex":0.00090467907,"about_ca_system_score_gemma":0.0031878655,"threshold_uncertainty_score":0.9993676},"labels":[],"label_agreement":null},{"id":"W3157516959","doi":"10.1016/j.lungcan.2021.04.022","title":"Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada); McMaster University; Institut universitaire de cardiologie et de pneumologie de Québec; Juravinski Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Lung cancer; Pooled analysis; Oncology; Internal medicine; Cancer; Demography; Intensive care medicine; Immunotherapy; Meta-analysis","score_opus":0.004109893966680977,"score_gpt":0.2502025030859512,"score_spread":0.24609260911927022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157516959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884713,0.008316259,0.0000074581276,0.00014639631,0.00022067688,0.0006450438,0.0005090442,0.000019650744,0.0016641166],"genre_scores_gemma":[0.99220365,0.004277118,0.00014698668,0.00033541804,0.000061987885,0.0001599822,0.00025679008,0.00004354354,0.0025144988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981003,0.00007322777,0.00047955607,0.0005533093,0.00040246703,0.00039115016],"domain_scores_gemma":[0.99884033,0.00007046602,0.00026288713,0.00042682418,0.00025971184,0.00013978984],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000080290585,0.00028109842,0.0009065498,0.00023032655,0.000053253363,0.000016776994,0.000105736326,0.00007063415,0.0005928391],"category_scores_gemma":[0.0000050723957,0.0002476393,0.00011627185,0.0016101998,0.00006111136,0.00007329998,0.000037857037,0.00019133372,1.5661516e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025411458,0.00013445491,0.9867733,0.00023965177,0.003595307,0.000062703395,0.0004483482,0.0003791028,0.0034059796,0.0000013012601,0.00034604792,0.0020726253],"study_design_scores_gemma":[0.012663965,0.00008957078,0.9747495,0.0006800956,0.0045218472,3.499011e-7,0.00019632898,0.002009957,0.004060362,3.7853314e-7,0.00072032714,0.00030732818],"about_ca_topic_score_codex":0.9298399,"about_ca_topic_score_gemma":0.9886659,"teacher_disagreement_score":0.058826007,"about_ca_system_score_codex":0.00090673467,"about_ca_system_score_gemma":0.0015850574,"threshold_uncertainty_score":0.99999756},"labels":[],"label_agreement":null},{"id":"W3157675313","doi":"10.1136/jitc-2021-002535","title":"Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Canadian Cancer Society; ECOG-ACRIN Cancer Research Group; National Cancer Institute; National Institutes of Health; American College of Radiology Imaging Network; Bristol-Myers Squibb","keywords":"Ipilimumab; Medicine; Rash; Internal medicine; Adverse effect; Adjuvant; Melanoma; Oncology; Multivariate analysis; Proportional hazards model; Immunotherapy; Cancer","score_opus":0.024259388212844894,"score_gpt":0.3273518728818649,"score_spread":0.30309248466902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157675313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884503,0.009991237,0.00012292244,0.0002951139,0.0002200524,0.00080874655,0.00008641843,0.000011606641,0.000013609402],"genre_scores_gemma":[0.9928402,0.0050252806,0.0009456712,0.000121694546,0.000037758553,0.00007034118,0.000015667792,0.000059469985,0.0008839467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973347,0.00015602159,0.0011829933,0.00030295365,0.00067878974,0.0003444966],"domain_scores_gemma":[0.99751616,0.00017508268,0.0011966154,0.00040457165,0.00064173096,0.00006582036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078806514,0.0002896872,0.0012638273,0.00044999213,0.000106350984,0.000023783989,0.0001319643,0.00011776938,0.00017592008],"category_scores_gemma":[0.000045198154,0.00020690248,0.00038752463,0.0009105054,0.00007444124,0.0003259851,0.000023548668,0.00031191934,2.097976e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028307602,0.0009516537,0.9178069,0.00009059403,0.0114783915,0.000037939826,0.0015092423,0.0002879367,0.030505797,0.0000011470752,0.000030791107,0.008991976],"study_design_scores_gemma":[0.028407602,0.002625652,0.9507692,0.00044695887,0.0017460173,0.00005035563,0.0017930974,0.000060033748,0.012787913,0.000007153015,0.0010611445,0.0002448801],"about_ca_topic_score_codex":0.0017055757,"about_ca_topic_score_gemma":0.0025086002,"teacher_disagreement_score":0.032962263,"about_ca_system_score_codex":0.0004762414,"about_ca_system_score_gemma":0.00040037037,"threshold_uncertainty_score":0.8437238},"labels":[],"label_agreement":null},{"id":"W3157689170","doi":"10.3390/ijms22094843","title":"Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer","year":2021,"lang":"en","type":"article","venue":"MDPI (MDPI AG)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"Canadian Cancer Society Research Institute","keywords":"Medicine; Triple-negative breast cancer; Immunotherapy; Breast cancer; Radiation therapy; Immune checkpoint; Cancer; Radionuclide therapy; Immune system; Oncology; Cancer research; Clinical trial; Targeted therapy; Internal medicine; Immunology","score_opus":0.02768484157534559,"score_gpt":0.300098017914056,"score_spread":0.2724131763387104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157689170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96863824,0.023025306,0.000074225296,0.005705484,0.0004940469,0.0012646023,0.00035039155,0.000046344627,0.00040137462],"genre_scores_gemma":[0.9329836,0.053850148,0.0014257686,0.0018444759,0.0003433597,0.0004927766,0.000118775606,0.000085378044,0.008855768],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889094,0.000053162465,0.0003371899,0.00031275288,0.00015890643,0.00024704987],"domain_scores_gemma":[0.99914324,0.0001234087,0.00014099476,0.00031946803,0.00019410068,0.00007875563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010370557,0.0002271405,0.0005675232,0.000072677074,0.000101308724,0.00002176386,0.00005636208,0.00009566018,0.00069835794],"category_scores_gemma":[0.000010242098,0.00017081022,0.00026004095,0.00021658032,0.00014862465,0.000062142586,0.000008369072,0.000042097658,0.0000013427261],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033220973,0.0014424906,0.011686376,0.00011464463,0.0024061964,0.000028634118,0.0038920206,0.0000015538651,0.318644,0.00019000146,0.0034447054,0.6249284],"study_design_scores_gemma":[0.091708,0.0054862252,0.3170942,0.00033880817,0.0002653648,0.00018753245,0.0010993677,0.00018596959,0.44434476,0.00056270225,0.13817087,0.0005562141],"about_ca_topic_score_codex":0.0008254339,"about_ca_topic_score_gemma":0.00010020691,"teacher_disagreement_score":0.6243722,"about_ca_system_score_codex":0.00019091723,"about_ca_system_score_gemma":0.00027621805,"threshold_uncertainty_score":0.76465297},"labels":[],"label_agreement":null},{"id":"W3158426271","doi":"10.1016/s0735-1097(21)04410-7","title":"MYOCARDIAL T1 AND T2 MAPPING BY CARDIOVASCULAR MAGNETIC RESONANCE IN IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED MYOCARDITIS","year":2021,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Medicine; Myocarditis; Cardiology; Magnetic resonance imaging; Internal medicine; Cardiac magnetic resonance; Radiology","score_opus":0.007884855610402522,"score_gpt":0.22258981289563462,"score_spread":0.2147049572852321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158426271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8772063,0.11931445,0.00003126883,0.0020153136,0.00057907193,0.0001852868,0.00008715155,0.0000050756457,0.0005760497],"genre_scores_gemma":[0.9846745,0.014263786,0.0002040422,0.00036649482,0.0003035651,0.000005768794,0.000002427079,0.000022206325,0.00015718043],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99756175,0.0006823129,0.0008341125,0.0002137796,0.00042220837,0.00028583888],"domain_scores_gemma":[0.9985504,0.0001550111,0.00051992486,0.0004050199,0.0002954729,0.00007416207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011888838,0.00017859411,0.0017043586,0.00014320346,0.000055794084,0.0000063352995,0.0001650393,0.00009961486,0.000007900773],"category_scores_gemma":[0.00038759474,0.00013778052,0.0012649202,0.00081315584,0.00060911244,0.00004663779,0.000107487154,0.00040689227,3.8992025e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007279188,0.00027176135,0.2884873,0.00019845269,0.0115772365,0.0051432084,0.0005147451,0.00022338804,0.53985435,0.000027289665,0.0357012,0.11072192],"study_design_scores_gemma":[0.0067386553,0.001134061,0.80941415,0.00049072644,0.00049769395,0.0059540994,0.0013328104,0.000014539968,0.009554474,0.00005894907,0.16459398,0.00021586027],"about_ca_topic_score_codex":0.00009092643,"about_ca_topic_score_gemma":0.0000065172476,"teacher_disagreement_score":0.53029984,"about_ca_system_score_codex":0.00025220864,"about_ca_system_score_gemma":0.00042049732,"threshold_uncertainty_score":0.56185263},"labels":[],"label_agreement":null},{"id":"W3158474445","doi":"10.3390/curroncol28030152","title":"Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pembrolizumab; Medicine; Melanoma; Positron emission tomography; Oncology; Internal medicine; Adverse effect; Nuclear medicine; Immunotherapy; Cancer; Cancer research","score_opus":0.03436873811414008,"score_gpt":0.35286309051781367,"score_spread":0.3184943524036736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158474445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99613035,0.001494168,0.0000041046533,0.00012066842,0.0006867879,0.0006807125,0.00007705767,0.00003502566,0.00077109836],"genre_scores_gemma":[0.99885076,0.00019393419,0.000057871403,0.000090671965,0.000057732414,0.00011050195,0.00029617205,0.000029500916,0.00031287764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809426,0.00015690821,0.00061164325,0.00042888316,0.0003417092,0.00036658722],"domain_scores_gemma":[0.99898785,0.000059437592,0.00027905282,0.00037136735,0.00017527578,0.0001270245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011630235,0.00025511926,0.0007943656,0.00019097043,0.000031659914,0.000008474294,0.000092237016,0.00002844888,0.00025951106],"category_scores_gemma":[0.000044832097,0.0001993672,0.00012261469,0.00036189216,0.0001216727,0.00007884073,0.000045904915,0.00028391264,0.000012303219],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0078217955,0.0027562473,0.912782,0.00013650846,0.00018996085,0.0010491473,0.000087028886,0.0000026330574,0.0006302135,0.000016648475,0.00007075181,0.07445706],"study_design_scores_gemma":[0.021647662,0.0051155975,0.96805465,0.00030680862,0.00018293674,0.0003943261,0.00003804905,0.000018531466,0.0015994107,0.0000013667093,0.002461421,0.00017920767],"about_ca_topic_score_codex":0.00007770011,"about_ca_topic_score_gemma":0.00010899281,"teacher_disagreement_score":0.07427785,"about_ca_system_score_codex":0.00043898454,"about_ca_system_score_gemma":0.0004334482,"threshold_uncertainty_score":0.81299585},"labels":[],"label_agreement":null},{"id":"W3158697155","doi":"10.1016/j.jtho.2021.03.028","title":"Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Saskatchewan Health Authority; Queen's University; Princess Margaret Cancer Centre; Saskatchewan Health; University Health Network; University of Toronto; Saskatchewan Cancer Agency; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Boehringer Ingelheim; Roche; Merck; AstraZeneca; Pfizer; Takeda Pharmaceutical Company; Bristol-Myers Squibb","keywords":"Medicine; Concordance; Biopsy; Lung cancer; Adenocarcinoma; Population; Internal medicine; Biomarker; Oncology; Cancer; Immunohistochemistry; Pathology; Gastroenterology","score_opus":0.057276530612910034,"score_gpt":0.4899315111543924,"score_spread":0.4326549805414823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158697155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876788,0.010592246,0.000054695305,0.0013438911,0.00016915848,0.00010960413,0.000007296785,0.0000021715505,0.000042096795],"genre_scores_gemma":[0.9953148,0.0010992077,0.0031232126,0.00034051263,0.00007998452,0.000003038163,0.0000024263034,0.000006678946,0.000030139936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982583,0.0005035584,0.0008239925,0.00015227553,0.00014211844,0.00011974716],"domain_scores_gemma":[0.9984401,0.0006808371,0.0005747013,0.00008830509,0.00014649515,0.00006959693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018071873,0.00008135087,0.0004667083,0.00010098982,0.000019546149,0.000005030274,0.000043339707,0.0001525232,0.000032774893],"category_scores_gemma":[0.0006955738,0.000065242166,0.0000552785,0.00018064301,0.00007375417,0.00006747025,0.000028370463,0.0003184432,3.258755e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004133098,0.00021333895,0.8946308,0.0002608231,0.000028753933,0.000095780655,0.00007426163,0.000021854717,0.048521467,2.1976165e-7,0.000084009735,0.051935628],"study_design_scores_gemma":[0.0023503304,0.0006898791,0.9806909,0.0015923054,0.00007733841,0.0001425643,0.000052496827,0.00089560857,0.013302335,0.000013785577,0.00013197403,0.000060481954],"about_ca_topic_score_codex":0.0001545025,"about_ca_topic_score_gemma":0.00023697398,"teacher_disagreement_score":0.08606014,"about_ca_system_score_codex":0.00021107691,"about_ca_system_score_gemma":0.00039034974,"threshold_uncertainty_score":0.26604983},"labels":[],"label_agreement":null},{"id":"W3158839617","doi":"10.3390/ijms22094893","title":"Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells","year":2021,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; McMaster University","funders":"","keywords":"PD-L1; Cancer; Tumor microenvironment; Immunotherapy; Immunogenicity; Immune system; Cancer research; Cancer cell; Cancer immunotherapy; Cytotoxic T cell; Medicine; Immunology; Inflammation; Immune checkpoint; Biology; Internal medicine","score_opus":0.02925994645953198,"score_gpt":0.34279490573881505,"score_spread":0.31353495927928304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158839617","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033946245,0.9940597,0.0014939932,0.00014328616,0.00061081373,0.00013483688,0.00000770013,0.000001908081,0.00015318157],"genre_scores_gemma":[0.008999229,0.98909044,0.0017371967,0.00008083143,0.000042650463,0.0000017730754,0.0000061126316,0.000008053166,0.000033731245],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99820584,0.000107278196,0.0007163948,0.00015647332,0.0007239253,0.00009006213],"domain_scores_gemma":[0.9987696,0.00006523457,0.0007568872,0.00007662567,0.00029059048,0.000041094936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007688374,0.0001265038,0.0006368175,0.0005504342,0.000015172533,0.00003952362,0.00024402147,0.00009255781,0.00008478565],"category_scores_gemma":[0.000059959802,0.00008971893,0.00029913,0.00035623563,0.00013927546,0.00008530833,0.000045466142,0.00014395219,5.882484e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001499746,0.00016917314,0.000019398833,0.00069993467,0.0006362225,0.00071914133,0.000105060746,0.000015357517,0.1067827,0.0013062012,0.00006694944,0.8893299],"study_design_scores_gemma":[0.006472652,0.0030350874,0.0014970775,0.16625205,0.0019832838,0.011671024,0.000418871,0.00022538428,0.19788833,0.0040669683,0.6053818,0.0011074774],"about_ca_topic_score_codex":0.000032924687,"about_ca_topic_score_gemma":0.000007419752,"teacher_disagreement_score":0.8882224,"about_ca_system_score_codex":0.00009806373,"about_ca_system_score_gemma":0.00060634804,"threshold_uncertainty_score":0.36586317},"labels":[],"label_agreement":null},{"id":"W3158888399","doi":"10.1097/cmr.0000000000000736","title":"Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors","year":2021,"lang":"en","type":"article","venue":"Melanoma Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Metastatic melanoma; Adverse effect; Melanoma; Immune system; Medicine; Oncology; Cancer research; Immunology; Internal medicine","score_opus":0.04263292290255613,"score_gpt":0.3553960744760919,"score_spread":0.31276315157353574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158888399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99732816,0.000765051,0.000001933124,0.00015218665,0.00003758172,0.0005741899,0.0000094955985,0.000007614409,0.0011237672],"genre_scores_gemma":[0.99798506,0.000038108315,0.00032818053,0.0000036766558,0.000007425106,0.000032054642,0.000029805187,0.000023028833,0.0015526296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99743825,0.00042811086,0.00072186434,0.00024323679,0.0007999295,0.00036859972],"domain_scores_gemma":[0.99878395,0.00014783649,0.00015702334,0.0004794829,0.0003598895,0.000071809285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013275096,0.00014940092,0.00042317467,0.000310856,0.000072938,0.0000026045086,0.00017225834,0.000076952376,0.0004244753],"category_scores_gemma":[0.00014193679,0.00008563024,0.00020909258,0.0019551793,0.00020453417,0.000051462266,0.00010022333,0.00035080977,0.000008435085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045567374,0.0006542097,0.7768714,0.00015355453,0.00092397997,0.000104319864,0.0019114054,0.000011365525,0.21047764,0.0000067664223,0.000043168486,0.0042854883],"study_design_scores_gemma":[0.00432246,0.000582756,0.7842463,0.00056366355,0.000029723855,0.00005211294,0.00071560143,0.000022726099,0.2093099,0.000010393326,0.0000707326,0.000073599476],"about_ca_topic_score_codex":0.00088442094,"about_ca_topic_score_gemma":0.00036866416,"teacher_disagreement_score":0.007374956,"about_ca_system_score_codex":0.00044502347,"about_ca_system_score_gemma":0.001775357,"threshold_uncertainty_score":0.46477067},"labels":[],"label_agreement":null},{"id":"W3159083673","doi":"10.1210/jendso/bvab048.1204","title":"Isolated Central Adrenal Insufficiency Due to Nivolumab: A Case Report","year":2021,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Nivolumab; Medicine; Hyponatremia; Ipilimumab; Renal cell carcinoma; Adrenal insufficiency; Internal medicine; Adverse effect; Context (archaeology); Gastroenterology; Cancer; Immunotherapy","score_opus":0.011727067736234699,"score_gpt":0.2790470999450547,"score_spread":0.26732003220882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159083673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837307,0.0011407535,0.0006175489,0.01287076,0.0011401825,0.00013294499,0.0000065507434,0.000013266304,0.00034734842],"genre_scores_gemma":[0.99139863,0.00013233112,0.0018637334,0.0029773365,0.0005691684,0.0000013855145,0.0000017067745,0.000017100801,0.0030385787],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9985655,0.00005358212,0.0005597194,0.00014087436,0.00038003922,0.00030031602],"domain_scores_gemma":[0.9988148,0.000034007197,0.00030534988,0.00031753184,0.0003556368,0.00017267659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028710306,0.000121359444,0.0003002551,0.000025922976,0.00014384878,0.000027572934,0.00012872655,0.00003931744,0.00028366523],"category_scores_gemma":[0.00018529523,0.00007752902,0.00085757516,0.0004989832,0.00005875651,0.00006810225,0.000080347265,0.00041154312,0.000002263768],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025105043,0.0019320828,0.009512491,0.0001479323,0.0021220886,0.5630944,0.0054938747,0.00007819481,0.120983966,0.000038919115,0.27605602,0.018029558],"study_design_scores_gemma":[0.0027610876,0.00047580374,0.0134392595,0.00017145374,0.00018319464,0.91336805,0.0014434939,0.00012083959,0.012695686,0.000018518802,0.055209026,0.00011359139],"about_ca_topic_score_codex":0.000085022795,"about_ca_topic_score_gemma":0.000026116375,"teacher_disagreement_score":0.35027367,"about_ca_system_score_codex":0.00024816173,"about_ca_system_score_gemma":0.00064985367,"threshold_uncertainty_score":0.31615415},"labels":[],"label_agreement":null},{"id":"W3160437920","doi":"10.1080/2162402x.2021.1924492","title":"The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine","year":2021,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Centre for Advancing Health Outcomes; University of British Columbia","funders":"Canadian Institutes of Health Research; Else og Mogens Wedell Wedellsborgs Fond; Købmand M. Kristjan Kjær og Hustru Margrethe Kjær, Født la Cour-Holmes Fond; Canadian Cancer Society","keywords":"Docetaxel; Medicine; Gemcitabine; Breast cancer; Oncology; Internal medicine; Clinical endpoint; Biomarker; FOXP3; Cancer; Immune system; Clinical trial; Immunology","score_opus":0.0067823068047744425,"score_gpt":0.24567822307952522,"score_spread":0.2388959162747508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160437920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927231,0.0023114593,0.000023111783,0.0039869067,0.000044695964,0.0007330227,0.000020002202,0.000024240977,0.00013342676],"genre_scores_gemma":[0.995915,0.0007396817,0.00063159835,0.00035759233,0.000012064991,0.00014951693,0.000041083233,0.00003852797,0.0021149297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987804,0.000060982864,0.0003015896,0.0003577388,0.00017724508,0.00032202445],"domain_scores_gemma":[0.99928075,0.00004556837,0.00013344486,0.0003971333,0.00009198312,0.00005113819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000078621546,0.000228217,0.00042190615,0.00007308561,0.00012691742,0.00001913759,0.00007098726,0.00007898456,0.0000975568],"category_scores_gemma":[0.0000085359225,0.00011114199,0.00002370845,0.00036556207,0.00024304651,0.00008633676,0.00003952219,0.00020794144,0.0000041471],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05802868,0.00023342694,0.89994115,0.000019621433,0.00033030353,0.00004870804,0.00026608442,0.000016849142,0.008392968,0.0000070217106,0.0000062776644,0.032708917],"study_design_scores_gemma":[0.01850862,0.0026008405,0.973808,0.00025464036,0.00010495502,0.00026312494,0.000370575,0.0000062947965,0.0009195965,7.6517335e-7,0.0029774006,0.00018521222],"about_ca_topic_score_codex":0.00044658594,"about_ca_topic_score_gemma":0.0013686398,"teacher_disagreement_score":0.07386683,"about_ca_system_score_codex":0.00032245283,"about_ca_system_score_gemma":0.0001436243,"threshold_uncertainty_score":0.45322388},"labels":[],"label_agreement":null},{"id":"W3161716130","doi":"10.1007/s43678-021-00145-4","title":"New DKA in a geriatric patient on immune checkpoint inhibitor therapy: a case report","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Emergency Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Nivolumab; Intensive care medicine; Immune system; Immunotherapy; Immunology","score_opus":0.04924814227135344,"score_gpt":0.31467486739793427,"score_spread":0.26542672512658083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161716130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9331923,0.04234714,0.000026703485,0.012669014,0.008684598,0.00025803136,0.000004707644,0.000005702126,0.0028117925],"genre_scores_gemma":[0.99111027,0.0029407027,0.00017721455,0.0007553372,0.0022005304,0.000004902715,0.000013913282,0.000038844733,0.0027583013],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974347,0.00007442923,0.0015581875,0.00021742813,0.00035330595,0.0003619826],"domain_scores_gemma":[0.9978569,0.000028638902,0.0005006465,0.00036330963,0.0003726957,0.0008777758],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00063517026,0.00020679472,0.0005556908,0.0005923843,0.00006883591,0.0000049869946,0.00008486892,0.00010490518,0.010123791],"category_scores_gemma":[0.00054336357,0.00015605259,0.00026593497,0.0010060583,0.00004865466,0.00006502916,0.000006502279,0.0004193184,0.0000053437625],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023069321,0.00022048703,0.012149058,0.00009419246,0.00053373334,0.73661155,0.0057523767,0.000010253312,0.05430387,0.000023600582,0.10695506,0.08103891],"study_design_scores_gemma":[0.02020795,0.008704899,0.055593923,0.0029326393,0.00029889197,0.22497547,0.005114466,0.0000122145975,0.025127271,0.00023401935,0.65612155,0.00067671575],"about_ca_topic_score_codex":0.03293936,"about_ca_topic_score_gemma":0.03248963,"teacher_disagreement_score":0.5491665,"about_ca_system_score_codex":0.0004274963,"about_ca_system_score_gemma":0.0040701465,"threshold_uncertainty_score":0.99078107},"labels":[],"label_agreement":null},{"id":"W3162226089","doi":"10.1038/s41467-021-22875-w","title":"Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Cancer Prevention and Research Institute of Texas; University of Texas MD Anderson Cancer Center; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; LUNGevity Foundation","keywords":"KRAS; MEK inhibitor; Blockade; Cancer research; Melanoma; Medicine; Lung cancer; Combination therapy; MAPK/ERK pathway; Targeted therapy; Selumetinib; Immunotherapy; Immune checkpoint; Downregulation and upregulation; PD-L1; Immune system; Biology; Kinase; Pharmacology; Immunology; Cancer; Oncology; Internal medicine; Receptor; Colorectal cancer","score_opus":0.013240834388321096,"score_gpt":0.30614055441789517,"score_spread":0.2928997200295741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162226089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70527136,0.2314343,0.00005025541,0.058501873,0.0005242499,0.0012100168,0.00016611468,0.00008165486,0.0027601724],"genre_scores_gemma":[0.9609586,0.033091508,0.0016267837,0.0036824937,0.000040288578,0.00007690276,0.00014670061,0.000020989419,0.0003557336],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881977,0.00016237982,0.00031482193,0.0002677735,0.00021917875,0.00021607723],"domain_scores_gemma":[0.9981272,0.00023767597,0.00009872272,0.0011383112,0.0003044487,0.00009360456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033549048,0.00015285746,0.00029079034,0.00011430183,0.00019877334,0.000047647685,0.00027887753,0.00022891347,0.00003346942],"category_scores_gemma":[0.00011459321,0.00014517913,0.00006888582,0.0007798441,0.00012388371,0.00009367264,0.00010572988,0.00066073856,0.0000027205117],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002047563,0.000747575,0.016296098,0.00011649549,0.00038473023,0.000053747455,0.0036488003,0.0000068168592,0.9197846,0.005756292,0.04164223,0.009515024],"study_design_scores_gemma":[0.009634678,0.00014510498,0.24218953,0.00084388664,0.00008298451,0.00002769695,0.0008423361,0.00025054786,0.1532577,0.00024681533,0.5920105,0.00046820834],"about_ca_topic_score_codex":0.00015330437,"about_ca_topic_score_gemma":0.0052026184,"teacher_disagreement_score":0.76652694,"about_ca_system_score_codex":0.00041203632,"about_ca_system_score_gemma":0.00034203284,"threshold_uncertainty_score":0.5920233},"labels":[],"label_agreement":null},{"id":"W3163003678","doi":"10.1038/s41571-021-00508-x","title":"Beneficial autoimmunity improves cancer prognosis","year":2021,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"National Cancer Institute; Canadian Institutes of Health Research; Agence Nationale de la Recherche","keywords":"Medicine; Autoimmunity; Oncology; Cancer; Internal medicine; Disease","score_opus":0.20716222520985014,"score_gpt":0.5541318934361366,"score_spread":0.3469696682262864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163003678","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000063496996,0.9865846,0.0000014425789,0.0014912154,0.005636055,0.004069158,0.000078254336,0.00008896467,0.0020439757],"genre_scores_gemma":[9.377968e-7,0.9863334,0.000937436,0.0056052087,0.0037206996,0.00126716,0.0004625574,0.00011043514,0.0015622167],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99055964,0.0026537091,0.00462388,0.0011687127,0.00037197868,0.0006220795],"domain_scores_gemma":[0.9937536,0.0019100427,0.0025103313,0.0011733541,0.0003212642,0.0003313737],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0045654015,0.0008705152,0.012430123,0.00018397506,0.0001352514,0.000033091288,0.00058885955,0.006614865,0.0012629051],"category_scores_gemma":[0.0030239264,0.000558026,0.0063502737,0.0010519715,0.00041747486,0.000055080967,0.00026610686,0.008026454,0.00013648925],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018295486,0.00087497116,0.000027837295,0.021558901,0.0014116496,0.00010068735,0.000008289665,1.9807267e-9,0.0000012270918,0.000039009865,0.028386502,0.94740796],"study_design_scores_gemma":[0.0012662774,0.0011424745,0.00015090943,0.042814765,0.0075671077,0.0001911836,0.000004010586,3.8453155e-7,5.0764174e-7,0.0000049979435,0.9463658,0.00049158285],"about_ca_topic_score_codex":0.00006900549,"about_ca_topic_score_gemma":0.00013225406,"teacher_disagreement_score":0.9469164,"about_ca_system_score_codex":0.0009277944,"about_ca_system_score_gemma":0.006575699,"threshold_uncertainty_score":0.99968714},"labels":[],"label_agreement":null},{"id":"W3163018211","doi":"10.3892/ol.2021.12804","title":"Immune-related gene expression signatures in colorectal cancer.","year":2021,"lang":"en","type":"article","venue":"PubMed","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Immune system; Biology; Gene expression profiling; Clusterin; Gene expression; Gene signature; Microarray analysis techniques; Carcinogenesis; Cancer research; Immunology; Cancer; Gene; Genetics","score_opus":0.012254613925746262,"score_gpt":0.24395446923656613,"score_spread":0.23169985531081988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163018211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96948516,0.02472123,0.0000020658317,0.0012122726,0.00051380356,0.00046081562,0.000008654896,0.000046354053,0.003549658],"genre_scores_gemma":[0.99608976,0.0011392733,0.00006281194,0.0003485024,0.00007397143,0.0007961053,0.000026311991,0.000016549999,0.0014467309],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990555,0.00004622848,0.00024277608,0.00021617327,0.00015956404,0.0002797738],"domain_scores_gemma":[0.9996768,0.00003233111,0.000054237942,0.00013517286,0.000032951426,0.00006846661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014199616,0.000101415375,0.00020642143,0.00006965046,0.000034308774,0.000013045006,0.000056143304,0.00013310142,0.00036560328],"category_scores_gemma":[0.00005609855,0.000085883155,0.00009902514,0.00035315493,0.000043500095,0.00004613583,0.00003054897,0.00019624924,0.0000019424049],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001368692,0.00012684496,0.011654383,0.0000293082,0.00008835587,0.00018317216,0.00018122724,0.000016681908,0.90541244,0.000005688195,0.0008246297,0.08010857],"study_design_scores_gemma":[0.0018505388,0.000012254424,0.4597674,0.000040446652,0.000013187412,0.000014688499,0.000034870543,0.000009326227,0.536681,0.00001046668,0.001499968,0.000065883956],"about_ca_topic_score_codex":0.00015134562,"about_ca_topic_score_gemma":0.00006495628,"teacher_disagreement_score":0.448113,"about_ca_system_score_codex":0.00012701728,"about_ca_system_score_gemma":0.00011051955,"threshold_uncertainty_score":0.40030995},"labels":[],"label_agreement":null},{"id":"W3163069657","doi":"10.1016/j.ygyno.2020.05.233","title":"GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-programmed death (PD)-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer","year":2020,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bevacizumab; Taxane; Chemotherapy; Oncology; Internal medicine; Phases of clinical research; Cancer","score_opus":0.2867256213653118,"score_gpt":0.4777661927906862,"score_spread":0.1910405714253744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163069657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97659236,0.0010434933,0.00015017243,0.013191578,0.0013434816,0.007167232,0.0001128679,0.000114270275,0.00028452885],"genre_scores_gemma":[0.9678333,0.002855952,0.011865097,0.0136311315,0.00070550194,0.0024873647,0.0004437769,0.000080070015,0.00009785214],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950015,0.0013407869,0.0015940216,0.00092717295,0.00048402828,0.00065247045],"domain_scores_gemma":[0.99562126,0.0021842879,0.0007945729,0.00040566575,0.0003412327,0.00065294997],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023973382,0.00048523786,0.0024889414,0.00021151025,0.00011781245,0.000046644072,0.0006916661,0.00042856843,0.0018022088],"category_scores_gemma":[0.0037661102,0.00035327123,0.00018368491,0.0008501285,0.0006211904,0.0002853495,0.00015274568,0.0005972973,0.000008463839],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8913433,0.014670745,0.00023172681,0.00011193227,0.00069109834,0.000095520765,0.0010108496,0.000019762198,0.008154764,0.00007485162,0.0007674629,0.08282801],"study_design_scores_gemma":[0.9246192,0.045026477,0.0006799,0.000053450727,0.00047978666,0.000011568773,0.0003604438,0.0075059445,0.0011566296,0.000057445228,0.019660313,0.0003888338],"about_ca_topic_score_codex":0.0012854226,"about_ca_topic_score_gemma":0.0034991957,"teacher_disagreement_score":0.08243918,"about_ca_system_score_codex":0.0008554489,"about_ca_system_score_gemma":0.0033352613,"threshold_uncertainty_score":0.99989194},"labels":[],"label_agreement":null},{"id":"W3163100624","doi":"10.1093/ckj/sfab090","title":"Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review","year":2021,"lang":"en","type":"review","venue":"Clinical Kidney Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Fondation contre le Cancer; Fonds Wetenschappelijk Onderzoek","keywords":"Medicine; Adverse effect; Dialysis; Population; Cancer; Kidney disease; Disease; Malignancy; Internal medicine; Incidence (geometry); Kidney cancer; Intensive care medicine; Oncology","score_opus":0.06897490264049363,"score_gpt":0.40014183453057306,"score_spread":0.3311669318900794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163100624","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037966904,0.99336565,0.0000021234714,0.00029360197,0.00034564576,0.0008927268,0.0012850484,0.000012017671,0.000006517608],"genre_scores_gemma":[0.0000872497,0.99195206,0.00020374461,0.0017794787,0.00024862663,0.000019887952,0.005343673,0.000059980706,0.00030529368],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927949,0.0010369373,0.004448406,0.0007227599,0.00066360435,0.00033345097],"domain_scores_gemma":[0.99297786,0.00049948436,0.0028675322,0.0010683569,0.0006435975,0.0019431595],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023805008,0.0005578565,0.005284882,0.0006128392,0.000071184164,0.00013187289,0.00019144472,0.00041392184,0.00081385893],"category_scores_gemma":[0.010391601,0.0003490419,0.0022907276,0.0021395434,0.00027834967,0.00027119147,0.00008831063,0.0017109296,6.7793974e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045050513,0.003935248,0.2278129,0.0907097,0.022432258,0.014387376,0.000076848635,1.2130243e-7,0.0000018717762,0.000003282853,0.007246668,0.62888867],"study_design_scores_gemma":[0.0027760155,0.00072206336,0.05421034,0.32960445,0.022602316,0.0004870088,0.0000069765797,0.0000016318628,3.5614357e-7,2.893248e-7,0.5892634,0.0003251957],"about_ca_topic_score_codex":0.000022891913,"about_ca_topic_score_gemma":0.000008726799,"teacher_disagreement_score":0.62856346,"about_ca_system_score_codex":0.00017266333,"about_ca_system_score_gemma":0.003199095,"threshold_uncertainty_score":0.99989617},"labels":[],"label_agreement":null},{"id":"W3163193104","doi":"10.1016/j.ijrobp.2020.10.013","title":"Too Big to Fail: Miracle Drugs or False Hope?","year":2021,"lang":"en","type":"letter","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Scopus; Radiation therapy; Miracle; Medicine; Lung cancer; Oncology; Chemotherapy; Internal medicine; MEDLINE; Political science","score_opus":0.032378041636430155,"score_gpt":0.3394881883386931,"score_spread":0.30711014670226294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163193104","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.069956854,0.0025266383,0.0032260416,0.9039934,0.01792891,0.0006873186,0.00040142695,0.00008083684,0.0011985656],"genre_scores_gemma":[0.039335568,0.00312988,0.002864474,0.90115654,0.04710423,0.000047545862,0.0011128365,0.00015005753,0.0050988644],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967992,0.0003477253,0.0013118266,0.00045996654,0.0006622855,0.00041904554],"domain_scores_gemma":[0.9957996,0.0006163496,0.0015726702,0.00035199276,0.0014884204,0.00017095436],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063419895,0.00043538227,0.0010870887,0.00043034228,0.00008276451,0.00008678102,0.0007175605,0.0010732785,0.0005545041],"category_scores_gemma":[0.00041606647,0.00035129744,0.0007111137,0.0003810101,0.0001991467,0.00018350454,0.00012329579,0.00191391,0.00010695282],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002459332,0.00021115976,0.0028510145,0.000034850582,0.002232717,0.0010286362,0.00077691214,0.000020919586,0.0029392135,0.00012972254,0.7297648,0.2575507],"study_design_scores_gemma":[0.0058109327,0.0016344846,0.0011524496,0.00025834126,0.00027891432,0.000868509,0.00015770072,0.000032470143,0.0016179007,0.00051964296,0.98731685,0.00035178068],"about_ca_topic_score_codex":0.00006176146,"about_ca_topic_score_gemma":0.000013054478,"teacher_disagreement_score":0.25755203,"about_ca_system_score_codex":0.0017538884,"about_ca_system_score_gemma":0.0024408267,"threshold_uncertainty_score":0.9998939},"labels":[],"label_agreement":null},{"id":"W3164286345","doi":"10.1016/j.euros.2021.05.001","title":"Analysis of Prostate Cancer Tumor Microenvironment Identifies Reduced Stromal CD4 Effector T-cell Infiltration in Tumors with Pelvic Nodal Metastasis","year":2021,"lang":"en","type":"article","venue":"European Urology Open Science","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Beatson Institute for Cancer Research; Medical Research Council; Cancer Research UK","keywords":"Prostate cancer; Stromal cell; NODAL; Metastasis; Medicine; Infiltration (HVAC); Tumor microenvironment; Oncology; Prostate; Effector; Cancer research; Pathology; Internal medicine; Cancer; Immunology","score_opus":0.012924173144947773,"score_gpt":0.276208845040397,"score_spread":0.26328467189544924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164286345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969789,0.0004426697,0.00001646265,0.00052911375,0.00007998731,0.00043916394,0.000035994693,0.000008077297,0.0014696635],"genre_scores_gemma":[0.99844044,0.00006589943,0.00039790056,0.0005262559,0.000012366421,0.000016326967,0.00002972551,0.000014402497,0.0004966738],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980665,0.00032173513,0.00038118407,0.0005964774,0.00033421844,0.0002999068],"domain_scores_gemma":[0.99912465,0.000041695086,0.00022643294,0.0004393157,0.00008656961,0.00008133112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012800043,0.00014700429,0.00040325912,0.00035232666,0.00010035374,0.00007937078,0.0004588778,0.000013563749,0.0003401213],"category_scores_gemma":[0.00005076168,0.000116948984,0.000076002936,0.001966692,0.0007654594,0.00024201495,0.00023526503,0.00013491862,0.00001172471],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013395941,0.00017133392,0.13793288,0.000023584162,0.00020889721,0.00029554253,0.000843335,0.00044909003,0.8573367,0.0000021715755,0.000037664886,0.0013591885],"study_design_scores_gemma":[0.0017438224,0.0005053848,0.7696792,0.000034522083,0.00045083463,0.000046338835,0.0003182778,0.0001616107,0.22664705,4.666054e-7,0.00029778492,0.00011469601],"about_ca_topic_score_codex":0.00038342463,"about_ca_topic_score_gemma":0.00047618573,"teacher_disagreement_score":0.63174635,"about_ca_system_score_codex":0.000102347345,"about_ca_system_score_gemma":0.0004284136,"threshold_uncertainty_score":0.47690412},"labels":[],"label_agreement":null},{"id":"W3164890381","doi":"10.1016/j.ygyno.2021.05.010","title":"Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary","year":2021,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Kingston Health Sciences Centre; Hospital for Sick Children; SickKids Foundation; Queen's University","funders":"Canadian Institutes of Health Research; Ontario Ministry of Research and Innovation; Ontario Ministry of Research, Innovation and Science","keywords":"FOXP3; Immune system; Immune checkpoint; Tissue microarray; Cytotoxic T cell; CD20; CD8; Medicine; Cancer research; CD68; T cell; Immunotherapy; Immunohistochemistry; Pathology; Immunology; Biology","score_opus":0.014276331882922799,"score_gpt":0.2546512290902594,"score_spread":0.2403748972073366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164890381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912978,0.004426738,0.0000016404746,0.0010526956,0.0003269326,0.0005743593,0.000020275551,0.000012192511,0.0022874007],"genre_scores_gemma":[0.99828416,0.0004619168,0.00027511583,0.00031609923,0.000018809473,0.000034746914,0.000008688636,0.000013174311,0.0005872741],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998336,0.0003744469,0.00060028,0.0002726349,0.0001397125,0.00027691812],"domain_scores_gemma":[0.9985819,0.0005964596,0.00039793985,0.00025007981,0.0001330143,0.000040611383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057079503,0.00014481903,0.00060444785,0.000063751664,0.000043108026,0.000003509445,0.00013699126,0.00024605566,0.00031435973],"category_scores_gemma":[0.00043369882,0.00010522809,0.00014825755,0.00041388464,0.00035946054,0.000021385657,0.00012551258,0.00028864454,0.0000024856129],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089498906,0.0010027492,0.13461326,0.00019724377,0.00005941548,0.00022319541,0.00039778624,0.0000060174757,0.8601941,0.000008515077,0.00018134541,0.0022213883],"study_design_scores_gemma":[0.0025188178,0.0013585932,0.6430524,0.00003949754,0.00006502577,0.000025045307,0.0005242653,0.000024524616,0.35187483,0.00004583073,0.00040379204,0.00006741137],"about_ca_topic_score_codex":0.00026649114,"about_ca_topic_score_gemma":0.00024450768,"teacher_disagreement_score":0.5084391,"about_ca_system_score_codex":0.000253944,"about_ca_system_score_gemma":0.0006333981,"threshold_uncertainty_score":0.4291077},"labels":[],"label_agreement":null},{"id":"W3165037032","doi":"10.14740/jocmr4511","title":"Clinical and Hematological Predictors of High-Grade Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Lung cancer; Nivolumab; Adverse effect; Cancer; Ipilimumab; Melanoma; Cohort; Hazard ratio; Incidence (geometry); Stage (stratigraphy); Proportional hazards model; Oncology; Gastroenterology; Immunotherapy; Confidence interval","score_opus":0.10938954691795358,"score_gpt":0.4611716085873394,"score_spread":0.35178206166938586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165037032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789928,0.0066197813,0.000013825946,0.012455673,0.0011904937,0.00037045305,0.0000052807923,0.00001627277,0.0003353737],"genre_scores_gemma":[0.9893992,0.008840507,0.00028840883,0.0001427805,0.0007545504,0.000003986298,0.000015798645,0.00003376702,0.00052099716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98840135,0.002230722,0.006152189,0.0004224158,0.0022734886,0.00051980885],"domain_scores_gemma":[0.9894627,0.005379715,0.0018741683,0.0004884213,0.002131479,0.0006635587],"candidate_categories":["metaresearch","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.023186548,0.00025364026,0.0025564523,0.00035487703,0.00010304083,0.0000057426646,0.0002816767,0.00063163723,0.000465355],"category_scores_gemma":[0.023656487,0.00014769772,0.0007767477,0.0011692042,0.0028566043,0.00011652646,0.00017520926,0.0032726459,0.0000037224806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016377548,0.0036020682,0.9532616,0.0002506649,0.004188146,0.002162812,0.00030161394,0.0000017145419,0.0072862487,0.000077862496,0.0019177438,0.010571937],"study_design_scores_gemma":[0.031263296,0.013175911,0.9412354,0.0058067297,0.0004858905,0.001021026,0.0011577563,0.00003011344,0.0040455386,0.00042282807,0.0012036851,0.00015181706],"about_ca_topic_score_codex":0.0000755691,"about_ca_topic_score_gemma":0.000011233609,"teacher_disagreement_score":0.014885746,"about_ca_system_score_codex":0.00009867204,"about_ca_system_score_gemma":0.0013704412,"threshold_uncertainty_score":0.99985707},"labels":[],"label_agreement":null},{"id":"W3165664607","doi":"10.3389/fonc.2021.662392","title":"Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Shandong First Medical University; Natural Science Foundation of Shandong Province","keywords":"Medicine; Meta-analysis; Clinical trial; Cancer; Safety profile; Oncology; Systematic review; Internal medicine; MEDLINE; Adverse effect","score_opus":0.11752264063271432,"score_gpt":0.4744646237762179,"score_spread":0.35694198314350356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165664607","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009577801,0.99045414,0.00004967004,0.00012211717,0.0005710836,0.008082441,0.00051021297,0.000006581944,0.000107979395],"genre_scores_gemma":[0.000087209206,0.9962751,0.0016488539,0.00026170487,0.000033136967,0.00082376425,0.0005918079,0.000033227036,0.00024519485],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98455054,0.009105127,0.005091237,0.00058022066,0.0004502066,0.00022264401],"domain_scores_gemma":[0.99250364,0.0006040961,0.0054866546,0.0009835562,0.00032208886,0.00009995792],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0086594345,0.00042900132,0.022642696,0.00032643537,0.000037048063,0.000007143433,0.00031057833,0.00053409464,0.00046347166],"category_scores_gemma":[0.0005261586,0.00020419824,0.0032311594,0.0015990402,0.00046157342,0.000051041658,0.00009538685,0.0005596244,1.12433014e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040378817,0.0009866328,0.018395988,0.51685643,0.40718156,0.000010601118,0.00005112675,9.301897e-7,1.0710221e-7,0.0000042391207,0.008029246,0.04807938],"study_design_scores_gemma":[0.002027287,0.0007399399,0.0033505699,0.044992622,0.89263713,0.000003789473,0.0000697245,0.0000060971665,5.4200643e-7,7.779817e-7,0.05595945,0.00021203971],"about_ca_topic_score_codex":0.00020371983,"about_ca_topic_score_gemma":0.00025419536,"teacher_disagreement_score":0.4854556,"about_ca_system_score_codex":0.00057799916,"about_ca_system_score_gemma":0.0019874207,"threshold_uncertainty_score":0.9918672},"labels":[],"label_agreement":null},{"id":"W3166324988","doi":"10.1016/j.cllc.2021.05.009","title":"Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non–Small–Cell Lung Cancer (PACIFIC)","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"Genentech; Daiichi-Sankyo; Merck KGaA; Moffitt Cancer Center; Takeda Pharmaceuticals U.S.A.; Spectrum Pharmaceuticals; Sanofi; Novartis; Merck; GlaxoSmithKline; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Roche; Astellas Pharma US; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Durvalumab; Medicine; Chemoradiotherapy; Stage (stratigraphy); Lung cancer; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.018877387211315665,"score_gpt":0.3471904455025281,"score_spread":0.32831305829121243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166324988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9672751,0.026592389,0.00011877284,0.00104744,0.0016943461,0.0013781163,0.00017206567,0.000050016115,0.0016717827],"genre_scores_gemma":[0.9726806,0.008925749,0.00019802716,0.0026744294,0.0005894432,0.0007327486,0.00008162842,0.000102151986,0.014015169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99679846,0.00014358667,0.0009645513,0.00089113635,0.00052907504,0.00067322294],"domain_scores_gemma":[0.9982782,0.00018104124,0.00027175175,0.0006329213,0.00035160506,0.00028446683],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044921468,0.00039469043,0.0009814274,0.00009517416,0.00007594133,0.000067932895,0.000197141,0.00029065326,0.005227425],"category_scores_gemma":[0.00003388811,0.00031576617,0.00030280827,0.00059922744,0.00022097473,0.00013074777,0.000059480528,0.0007062276,0.000005948883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00938936,0.0010410822,0.9519863,0.0005732392,0.00050939625,0.00013869582,0.0004249018,0.00002458332,0.00046067167,0.000002240373,0.0076685594,0.027780948],"study_design_scores_gemma":[0.052474413,0.0011754233,0.86959964,0.0022995912,0.0004634723,0.0000040954333,0.00023456835,0.0013863432,0.0027939244,0.0000019647023,0.068721004,0.0008455887],"about_ca_topic_score_codex":0.0009950176,"about_ca_topic_score_gemma":0.0024248166,"teacher_disagreement_score":0.08238671,"about_ca_system_score_codex":0.0007874605,"about_ca_system_score_gemma":0.0015862923,"threshold_uncertainty_score":0.9999294},"labels":[],"label_agreement":null},{"id":"W3166578944","doi":"10.1200/jco.2021.39.15_suppl.9506","title":"CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Placebo; Oncology; Immunotherapy; Cancer; Pathology","score_opus":0.05612230571088557,"score_gpt":0.43305479178709033,"score_spread":0.3769324860762048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166578944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905738,0.00029095952,0.00001170164,0.0052442113,0.0008788786,0.000106888394,0.0000021649003,0.0000047627923,0.0028866169],"genre_scores_gemma":[0.9922613,0.0006231242,0.0028423204,0.0034792395,0.0001844127,0.0000018806393,0.000003114369,0.000013768153,0.00059086684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975966,0.0002045625,0.00158307,0.00014374545,0.0002921686,0.0001798293],"domain_scores_gemma":[0.99789226,0.0005487846,0.00087692344,0.00016311483,0.00036092347,0.0001580143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011472384,0.000103503975,0.0011721436,0.000078905265,0.000015608732,0.000005398013,0.0000903277,0.00020799792,0.00025104042],"category_scores_gemma":[0.0011047451,0.00006412593,0.00031328626,0.00016594454,0.00010667578,0.000085539374,0.00002542824,0.0005807907,0.000011092343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018019145,0.0019530278,0.848212,0.000015124154,0.00035887212,0.00059320615,0.000050041413,0.000002962822,0.00014711909,0.000013776789,0.0005394078,0.13009533],"study_design_scores_gemma":[0.033196658,0.011706448,0.9082076,0.00011517417,0.00009404073,0.000066176,0.00012306539,0.0000023224995,0.00021819002,0.00003682356,0.046161573,0.00007194],"about_ca_topic_score_codex":0.000007264855,"about_ca_topic_score_gemma":0.00007675297,"teacher_disagreement_score":0.13002339,"about_ca_system_score_codex":0.0001571743,"about_ca_system_score_gemma":0.0012052371,"threshold_uncertainty_score":0.27487165},"labels":[],"label_agreement":null},{"id":"W3167094271","doi":"10.1200/jco.2021.39.15_suppl.3559","title":"Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + Imprime PGG (Imprime) + bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Regorafenib; TIGIT; Colorectal cancer; Oncology; Clinical endpoint; Bevacizumab; Internal medicine; Immune checkpoint; Cancer research; Cancer; Clinical trial; Immunotherapy; Nivolumab; Chemotherapy","score_opus":0.18330794189422442,"score_gpt":0.5130975292467511,"score_spread":0.3297895873525267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167094271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691339,0.020286942,0.000085385785,0.0055821217,0.002033174,0.0016994188,0.0000528965,0.000011890445,0.0011142499],"genre_scores_gemma":[0.9784832,0.013508645,0.005115125,0.0015463511,0.00042251055,0.0001005239,0.0000541968,0.00005786766,0.000711599],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9870793,0.0040445486,0.0065296446,0.0005650803,0.0012009686,0.00058043684],"domain_scores_gemma":[0.98824674,0.0035869547,0.004667187,0.00046575975,0.0026425964,0.00039077015],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.022237824,0.0003996798,0.005230676,0.00034172848,0.00011013163,0.000046930916,0.0005492095,0.0005631651,0.0025129984],"category_scores_gemma":[0.0076635107,0.00030537395,0.0009341763,0.0008012995,0.0006942253,0.0004303687,0.00025322643,0.001275193,0.00001129556],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6315868,0.012381565,0.0005819912,0.000118651384,0.0028984314,0.00062810536,0.0005546043,0.00006343538,0.11301452,0.00004667695,0.0019756753,0.23614955],"study_design_scores_gemma":[0.89482176,0.017513525,0.0016427165,0.000666925,0.003985633,0.0008030334,0.00039881712,0.0032310784,0.058225695,0.0007209884,0.017622495,0.00036730492],"about_ca_topic_score_codex":0.00080987107,"about_ca_topic_score_gemma":0.00064038346,"teacher_disagreement_score":0.263235,"about_ca_system_score_codex":0.001230854,"about_ca_system_score_gemma":0.014089893,"threshold_uncertainty_score":0.99993986},"labels":[],"label_agreement":null},{"id":"W3167387657","doi":"10.1200/jco.2021.39.15_suppl.11522","title":"A phase II, open-label, randomized trial of durvalumab (D) with olaparib (O) or cediranib (C) in patients (pts) with leiomyosarcoma (LMS).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Urology; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Hazard ratio; Immunohistochemistry; Oncology; Gastroenterology; Randomized controlled trial; Progressive disease; Chemotherapy; Confidence interval","score_opus":0.13899322669740014,"score_gpt":0.4789900451769662,"score_spread":0.3399968184795661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167387657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99196297,0.00032615874,0.00007270301,0.0036568192,0.000889157,0.0013398881,0.0000080343025,0.000004626729,0.0017396585],"genre_scores_gemma":[0.9907949,0.0006976593,0.005250483,0.0020926986,0.00043933038,0.000024661973,0.000010578608,0.00002809159,0.00066161447],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937716,0.00130596,0.0037549068,0.00027439036,0.00062147656,0.00027165897],"domain_scores_gemma":[0.99286157,0.0027541008,0.0029331155,0.00030596825,0.000892829,0.00025242518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006195168,0.00020765649,0.0039244406,0.00016469836,0.000047298803,0.00001701411,0.00029821126,0.0003315806,0.0005291115],"category_scores_gemma":[0.003728282,0.0001087409,0.00035451064,0.00046556132,0.00052430533,0.00019230461,0.00009523556,0.00084694166,0.0000014963194],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8539688,0.0401809,0.0019397398,0.00003317645,0.001404136,0.0010711601,0.00014422084,7.990282e-7,0.00020101448,0.000016224905,0.0009877695,0.10005204],"study_design_scores_gemma":[0.7897825,0.19478038,0.0020289957,0.00042587967,0.0006504748,0.00025166053,0.00008799189,0.000022569644,0.00018948487,0.000032117,0.011633435,0.000114483635],"about_ca_topic_score_codex":0.00007490554,"about_ca_topic_score_gemma":0.000356968,"teacher_disagreement_score":0.15459947,"about_ca_system_score_codex":0.00017063656,"about_ca_system_score_gemma":0.005861959,"threshold_uncertainty_score":0.99977386},"labels":[],"label_agreement":null},{"id":"W3167422454","doi":"10.1200/jco.2021.39.15_suppl.tps2681","title":"Phase I study investigating the safety of stereotactic body radiotherapy (SBRT) with anti-PD-1 and anti-IL-8 for the treatment of multiple metastases in advanced solid tumors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Immunotherapy; Melanoma; Response Evaluation Criteria in Solid Tumors; Ipilimumab; Oncology; Internal medicine; Cabozantinib; Clinical trial; Cancer research; Phases of clinical research; Cancer","score_opus":0.09879509858647831,"score_gpt":0.4692649152665609,"score_spread":0.3704698166800826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167422454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905338,0.005181124,0.00015106767,0.0030852214,0.00020746514,0.00080727827,0.000020380687,0.0000020367002,0.000011614326],"genre_scores_gemma":[0.9909952,0.006215054,0.0020806515,0.00050583907,0.00015545922,0.0000137402585,0.0000019153306,0.000013543795,0.000018591532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969555,0.0005536759,0.0019669,0.00015761085,0.00021208583,0.00015419417],"domain_scores_gemma":[0.99077076,0.006852106,0.0017994996,0.00022878168,0.00026557513,0.00008326078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022673951,0.00013645375,0.0015567755,0.00006169911,0.000057285448,0.000006473196,0.00009996596,0.00006950941,0.000019949379],"category_scores_gemma":[0.0011315079,0.000060752955,0.00028956047,0.00020638971,0.0003921868,0.00006622277,0.0000125445495,0.00023790526,4.278143e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07356052,0.02539595,0.49425483,0.00010461985,0.005462096,0.0004290329,0.0031672122,0.0001397315,0.04226251,0.000010499291,0.00007298253,0.35514],"study_design_scores_gemma":[0.15200052,0.13058862,0.6845638,0.0003334281,0.0013691193,0.00048788884,0.006600583,0.0007537862,0.011926552,0.000020568343,0.0112279765,0.00012715797],"about_ca_topic_score_codex":0.000050547107,"about_ca_topic_score_gemma":0.00016812919,"teacher_disagreement_score":0.35501286,"about_ca_system_score_codex":0.000099138946,"about_ca_system_score_gemma":0.0010155931,"threshold_uncertainty_score":0.24774335},"labels":[],"label_agreement":null},{"id":"W3168540735","doi":"10.1200/jco.2021.39.15_suppl.9502","title":"Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Internal medicine; Ipilimumab; Oncology; Regimen; Response Evaluation Criteria in Solid Tumors; Progressive disease; Stage (stratigraphy); Melanoma; Surgery; Gastroenterology; Chemotherapy; Cancer; Immunotherapy; Cancer research","score_opus":0.06720521001582311,"score_gpt":0.4402667250112583,"score_spread":0.37306151499543516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168540735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98933524,0.0024025207,0.0005477229,0.003841173,0.0012144586,0.0005720624,0.000023848423,0.000017678629,0.0020453054],"genre_scores_gemma":[0.9745252,0.0064294874,0.012916801,0.002561498,0.0009241602,0.00000866319,0.000035868055,0.00006557195,0.0025327487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945871,0.00055174105,0.0032355154,0.0005307931,0.0006045885,0.00049022824],"domain_scores_gemma":[0.99248177,0.0028283694,0.0023681477,0.0004210131,0.0013749903,0.00052568794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004078418,0.0002887918,0.0026382394,0.00013104407,0.00013679688,0.00003308526,0.0001900464,0.0006317503,0.0001885918],"category_scores_gemma":[0.0017330539,0.00017921865,0.0005797235,0.00027896286,0.00063420506,0.00023189637,0.00008343929,0.0013996544,0.0000036806236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14959447,0.0064159506,0.6988151,0.00013662195,0.0025565806,0.0026020943,0.00014050896,0.000005534274,0.00058789854,0.000085428255,0.0068824403,0.13217734],"study_design_scores_gemma":[0.10780467,0.09232767,0.5792056,0.0006885059,0.0010553702,0.0011122791,0.00044670218,0.00012221174,0.0001619549,0.000041246236,0.21673413,0.00029970356],"about_ca_topic_score_codex":0.00004565503,"about_ca_topic_score_gemma":0.0001940941,"teacher_disagreement_score":0.20985168,"about_ca_system_score_codex":0.00016453442,"about_ca_system_score_gemma":0.0034273162,"threshold_uncertainty_score":0.73083246},"labels":[],"label_agreement":null},{"id":"W3168647721","doi":"10.1200/jco.2021.39.15_suppl.9504","title":"Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Clinical endpoint; Oncology; Tolerability; Adjuvant; Phases of clinical research; Lenvatinib; Clinical trial; Adverse effect; Melanoma; Immunotherapy; Cancer; Cancer research","score_opus":0.06523484828108818,"score_gpt":0.43359733112642074,"score_spread":0.3683624828453326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168647721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944761,0.00045272737,0.000038155733,0.0029706855,0.00079591444,0.0006228737,0.000022619226,0.000010258434,0.0006106929],"genre_scores_gemma":[0.99248,0.0006662437,0.0040423977,0.0018664562,0.00033276906,0.000015075182,0.000033847533,0.00003124921,0.00053196255],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966115,0.00025909673,0.0021103441,0.0002994317,0.00044468264,0.00027499255],"domain_scores_gemma":[0.9947914,0.0019985412,0.0018695063,0.00019939212,0.0008940179,0.0002471489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011693164,0.0002087719,0.0015805931,0.00012654575,0.000060146827,0.000011078859,0.00011534909,0.0004062434,0.00021799089],"category_scores_gemma":[0.0023356874,0.00012450614,0.00032185783,0.00020741028,0.00032795483,0.0001214959,0.00004156551,0.0005775226,0.0000016137835],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63067496,0.0041599227,0.037828915,0.0002840783,0.0010032458,0.00038060584,0.00030803794,0.0000036981116,0.004416312,0.00004368755,0.007178074,0.31371847],"study_design_scores_gemma":[0.23323295,0.2084197,0.29798296,0.0024557495,0.00076084066,0.000675613,0.00045223653,0.00009395185,0.014157947,0.000063766805,0.2413436,0.00036068447],"about_ca_topic_score_codex":0.0000048231163,"about_ca_topic_score_gemma":0.000039643077,"teacher_disagreement_score":0.39744198,"about_ca_system_score_codex":0.00018848751,"about_ca_system_score_gemma":0.0024383597,"threshold_uncertainty_score":0.50772136},"labels":[],"label_agreement":null},{"id":"W3169007939","doi":"10.1200/jco.2021.39.15_suppl.2575","title":"CheckMate 8KX: Phase 1/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab (± rHuPH20).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Immunogenicity; Internal medicine; Cancer; Oncology; Immunotherapy; Antibody; Immunology","score_opus":0.21387878469376403,"score_gpt":0.5434117586399005,"score_spread":0.3295329739461365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169007939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943677,0.0024440305,0.00032018046,0.0012973695,0.0006200397,0.00012313414,0.00000952682,0.0000046023074,0.00081341877],"genre_scores_gemma":[0.9932517,0.0013412866,0.0044096904,0.00039447937,0.00031586405,0.0000010414697,0.0000072848807,0.000011617048,0.00026704857],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961126,0.00027066164,0.0030059456,0.00013424968,0.00033092377,0.00014565165],"domain_scores_gemma":[0.9948406,0.0012155279,0.002719916,0.00021199184,0.0008708639,0.00014106573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015294738,0.00010727052,0.0014753477,0.00013228062,0.000020272,0.0000028778368,0.00010567847,0.00025690824,0.00035709538],"category_scores_gemma":[0.0020235938,0.000079982,0.00084478944,0.00023407825,0.00017977403,0.00008496499,0.00003201131,0.00038093157,0.000001860486],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16386566,0.009634165,0.008880612,0.00034262752,0.00242883,0.0040173205,0.00032726603,0.00007288352,0.37886477,0.000032324417,0.0018141943,0.42971933],"study_design_scores_gemma":[0.13768677,0.19952722,0.28563398,0.0016582436,0.0053888126,0.016381111,0.0013583993,0.0054238564,0.3056292,0.0005301694,0.0403069,0.0004753407],"about_ca_topic_score_codex":0.000042610216,"about_ca_topic_score_gemma":0.000021812859,"teacher_disagreement_score":0.429244,"about_ca_system_score_codex":0.00009185699,"about_ca_system_score_gemma":0.0017169826,"threshold_uncertainty_score":0.39099443},"labels":[],"label_agreement":null},{"id":"W3169354761","doi":"10.3390/curroncol28030201","title":"Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"EMD Serono; Array BioPharma; Sanofi; Symphogen; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Infliximab; Medicine; Adverse effect; Internal medicine; Gastroenterology; Refractory (planetary science); Toxicity; Hepatitis; Tumor necrosis factor alpha","score_opus":0.06359563949543295,"score_gpt":0.3909024922535652,"score_spread":0.32730685275813226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169354761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99299234,0.005099433,8.5006917e-7,0.00044687465,0.00041902246,0.00034713338,0.0000151991935,0.000006225376,0.0006729248],"genre_scores_gemma":[0.9935778,0.006069128,0.000026921998,0.000050348164,0.000014111614,0.000026797552,0.000027501374,0.0000063578595,0.0002010372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888533,0.0001907242,0.00050927076,0.00015186786,0.0001276664,0.00013511171],"domain_scores_gemma":[0.99928546,0.00018628659,0.00020873829,0.00023833179,0.000052561445,0.000028639597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001973988,0.00011501462,0.0004782244,0.00010945385,0.000018320245,7.9051347e-7,0.00005666331,0.000072131355,0.00010038687],"category_scores_gemma":[0.000023279552,0.00007405625,0.00015411954,0.00022501346,0.00013673087,0.000027671294,0.000020277794,0.00010898856,0.0000011718096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015127762,0.0040927385,0.89881945,0.000087037944,0.0002533859,0.000035934285,0.0035192373,6.659236e-7,0.01132823,0.000035236983,0.000043264467,0.08027207],"study_design_scores_gemma":[0.01036854,0.0014164303,0.9616275,0.00011039272,0.00010830036,0.000016641054,0.00061510305,0.000019861605,0.004113626,0.000031765114,0.021505946,0.000065921035],"about_ca_topic_score_codex":0.00022176228,"about_ca_topic_score_gemma":0.00053219247,"teacher_disagreement_score":0.080206156,"about_ca_system_score_codex":0.0002492945,"about_ca_system_score_gemma":0.00020622254,"threshold_uncertainty_score":0.30199262},"labels":[],"label_agreement":null},{"id":"W3169509716","doi":"10.1200/jco.2021.39.15_suppl.9038","title":"Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; St Mary's Hospital Centre","funders":"","keywords":"Medicine; Discontinuation; Placebo; Lung cancer; Internal medicine; Quality of life (healthcare); Oncology; Pathology; Alternative medicine","score_opus":0.14657495138159443,"score_gpt":0.44327872357133413,"score_spread":0.2967037721897397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169509716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910806,0.0013437695,0.00044800216,0.004307859,0.0011292362,0.0013977092,0.000032762495,0.000015513686,0.0002445479],"genre_scores_gemma":[0.9937128,0.00020880744,0.004156747,0.0014072648,0.00022021044,0.000029053617,0.000057476904,0.000048054208,0.00015960833],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9914831,0.0012127178,0.005425267,0.00043914551,0.0009409845,0.0004987851],"domain_scores_gemma":[0.98884743,0.003151453,0.0058420985,0.00039257458,0.0012789912,0.00048743185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004806674,0.00031449881,0.00339565,0.00023640798,0.00007906947,0.000013804663,0.0002018702,0.00029874386,0.00014424301],"category_scores_gemma":[0.00466633,0.00021067537,0.00059473864,0.0004925913,0.00044942324,0.00019603567,0.000044640918,0.0011267703,0.0000022234174],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9119538,0.0034179222,0.059971757,0.0006659009,0.0018660667,0.00018117025,0.00035808384,0.00027364015,0.000060579478,0.000043867614,0.0006336383,0.020573562],"study_design_scores_gemma":[0.2965145,0.05311432,0.6461345,0.00082617113,0.0005195662,0.00012722565,0.00053054205,0.00019904564,0.000052018782,0.000047179194,0.0017032811,0.00023167119],"about_ca_topic_score_codex":0.0003952342,"about_ca_topic_score_gemma":0.0015032872,"teacher_disagreement_score":0.6154393,"about_ca_system_score_codex":0.0011587954,"about_ca_system_score_gemma":0.016562728,"threshold_uncertainty_score":0.9890124},"labels":[],"label_agreement":null},{"id":"W3169652452","doi":"10.1200/jco.2021.39.15_suppl.4552","title":"The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Renal cell carcinoma; Oncology; Proportional hazards model; Gastroenterology","score_opus":0.06997620596433854,"score_gpt":0.40645599253833703,"score_spread":0.33647978657399846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169652452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99645793,0.0011884784,0.0000045743586,0.0011686374,0.00046519528,0.0005094822,0.00001326312,0.0000073829374,0.00018506768],"genre_scores_gemma":[0.99738866,0.0011776491,0.00051921495,0.00044819192,0.000194886,0.0000030211274,0.000012941078,0.000042514934,0.0002129152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9926461,0.0014314901,0.0045209965,0.0003353194,0.0006525488,0.00041356817],"domain_scores_gemma":[0.9914808,0.0036272753,0.0033355863,0.0004843688,0.0007916382,0.00028032615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036953466,0.00034843266,0.0027028352,0.00017586973,0.00006841996,0.00001896891,0.000245649,0.00034430952,0.00013459621],"category_scores_gemma":[0.0012711261,0.0001425189,0.0013002785,0.0005374883,0.00057376473,0.000098112796,0.000035273602,0.0013689081,0.0000026402406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15875816,0.007365903,0.8037669,0.000021345952,0.0019977954,0.0007910894,0.00011096794,0.000018479761,0.0009203889,7.6392706e-7,0.00024549014,0.02600273],"study_design_scores_gemma":[0.05502865,0.12816052,0.81194955,0.0002420735,0.00030988143,0.000077434444,0.000228611,0.000009597082,0.0035070933,0.0000050675008,0.0003348456,0.0001466975],"about_ca_topic_score_codex":0.00019185488,"about_ca_topic_score_gemma":0.00015699319,"teacher_disagreement_score":0.12079462,"about_ca_system_score_codex":0.00027672775,"about_ca_system_score_gemma":0.0035312308,"threshold_uncertainty_score":0.62642515},"labels":[],"label_agreement":null},{"id":"W3169994009","doi":"10.1200/jco.2021.39.15_suppl.9574","title":"Association of health-related quality of life (HRQoL) and treatment safety with nivolumab (NIVO) in patients (pts) with resected stage IIIB/C or IV melanoma: Analysis of CheckMate 238 four-year follow-up (FU) data.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Discontinuation; Internal medicine; Randomization; Quality of life (healthcare); Population; Ipilimumab; Adverse effect; Oncology; Randomized controlled trial; Cancer; Immunotherapy; Nursing","score_opus":0.15403626871309478,"score_gpt":0.4370518829146876,"score_spread":0.2830156142015928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169994009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99685323,0.00054694497,0.00003846593,0.0018718836,0.00013574596,0.00026974003,0.00017341664,0.0000032691655,0.000107279506],"genre_scores_gemma":[0.99572176,0.0023035987,0.00117242,0.00016499283,0.000031273976,0.0000015494721,0.00011237199,0.000012578084,0.0004794462],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99307096,0.0016209326,0.0042608413,0.00025748846,0.0005917103,0.00019805392],"domain_scores_gemma":[0.98993653,0.0018926319,0.006722788,0.00039213125,0.00089364377,0.00016226762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060600243,0.00014578777,0.0030595497,0.00025244485,0.000028041439,0.0000036937072,0.00012678574,0.00029930883,0.00018889153],"category_scores_gemma":[0.0028568974,0.00008901338,0.0002912065,0.00095384923,0.00016505212,0.000108086584,0.000047675236,0.00035670502,1.926832e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15438768,0.002688278,0.81212896,0.00010977051,0.010309739,0.00005185513,0.00036656935,0.00002032335,0.00012076112,0.0000055227492,0.00015382878,0.019656716],"study_design_scores_gemma":[0.06468013,0.023718257,0.9081321,0.00020312355,0.0017266121,0.0000055801065,0.00044433266,0.00013450216,0.000067997506,0.0000029991058,0.0008083631,0.00007599725],"about_ca_topic_score_codex":0.0020764181,"about_ca_topic_score_gemma":0.020213768,"teacher_disagreement_score":0.09600315,"about_ca_system_score_codex":0.0006028071,"about_ca_system_score_gemma":0.0035139427,"threshold_uncertainty_score":0.99766475},"labels":[],"label_agreement":null},{"id":"W3170062184","doi":"10.1053/j.gastro.2021.06.025","title":"Interferon-Gamma–Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor–Colitis","year":2021,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":204,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Pfizer Canada; National Institutes of Health; Norman Collisson Foundation; National Institute of Allergy and Infectious Diseases; British Microcirculation Society; National Institute for Health and Care Research; NIHR Bristol Biomedical Research Centre; Juvenile Diabetes Research Foundation United States of America; Wellcome Trust; Juvenile Diabetes Research Foundation United Kingdom","keywords":"Colitis; CD8; Immune system; Interferon gamma; Cancer research; Cytotoxic T cell; Medicine; Immunology; Chemistry","score_opus":0.010809398569717799,"score_gpt":0.243256506481326,"score_spread":0.2324471079116082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170062184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905508,0.0033715551,0.0003043448,0.003481654,0.0013209275,0.00036707032,0.000032782114,0.000048559577,0.0005222722],"genre_scores_gemma":[0.9933794,0.00044733234,0.00115273,0.0009723099,0.00035951866,0.00003954047,0.00005297623,0.000044114415,0.0035520927],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99748415,0.00020060982,0.0008888256,0.00056706514,0.00025341543,0.0006059485],"domain_scores_gemma":[0.9985006,0.000033775887,0.00037021027,0.00073230575,0.0002322781,0.00013082786],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048385086,0.00026185668,0.0007801038,0.00015801274,0.00006063356,0.000016476644,0.00016208613,0.0001419628,0.0014473853],"category_scores_gemma":[0.00007270646,0.0002567921,0.0002780663,0.0001727264,0.00020881709,0.00008073608,0.00018884943,0.0003090952,0.000029988969],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008218998,0.00030646782,0.016038744,0.00039286772,0.00041324887,0.00041227858,0.00087107054,0.000019035586,0.96765095,0.0000027846902,0.0041112183,0.0015623289],"study_design_scores_gemma":[0.004330053,0.0018069331,0.11515773,0.0005264152,0.0001222575,0.00063560036,0.000943799,0.0000148055615,0.87194675,0.000019297475,0.0043673664,0.00012899384],"about_ca_topic_score_codex":0.0007068265,"about_ca_topic_score_gemma":0.000711699,"teacher_disagreement_score":0.099118985,"about_ca_system_score_codex":0.00018783017,"about_ca_system_score_gemma":0.00014160408,"threshold_uncertainty_score":0.99998844},"labels":[],"label_agreement":null},{"id":"W3170157402","doi":"10.1016/j.ctarc.2021.100421","title":"A phase I/II study of pembrolizumab in combination with nab-paclitaxel in patients with unresectable stage III or stage IV non small-cell lung carcinoma (NSCLC)","year":2021,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Centre Hospitalier de l’Université de Montréal","funders":"Merck","keywords":"Stage (stratigraphy); Pembrolizumab; Medicine; Oncology; Internal medicine; Paclitaxel; Nab-paclitaxel; Carcinoma; Chemotherapy; Cancer; Immunotherapy; Biology","score_opus":0.07057552295191545,"score_gpt":0.3883166627883285,"score_spread":0.31774113983641306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170157402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908946,0.0051108887,0.0000034023485,0.0005165147,0.000013371562,0.002482564,0.00007183624,0.000009118071,0.00089769147],"genre_scores_gemma":[0.9906484,0.0035320641,0.00011488342,0.000017023418,0.000005882765,0.00087923004,0.00016737463,0.000023336044,0.004611809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983419,0.0003413373,0.00031156436,0.00030509543,0.00037968333,0.00032042913],"domain_scores_gemma":[0.9981173,0.00019248755,0.00009527556,0.0010453432,0.00045442514,0.00009511986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003455606,0.00016724806,0.000356165,0.00031493334,0.00029809214,0.000033223387,0.00021301236,0.000056191104,0.00009758812],"category_scores_gemma":[0.000016744012,0.00011060743,0.000028750788,0.0011497263,0.00022322909,0.00011472782,0.0001733967,0.0002828112,2.724889e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031941414,0.04516632,0.8955336,0.00026345075,0.00038155116,0.00006531223,0.015850523,0.000014341009,0.0015908389,0.000029279496,0.00008349022,0.009079833],"study_design_scores_gemma":[0.27494848,0.045470316,0.6475347,0.00086818426,0.00016806484,0.0000027656681,0.025142385,0.0010969543,0.0027955018,0.0000035168023,0.0016939281,0.0002751477],"about_ca_topic_score_codex":0.013792756,"about_ca_topic_score_gemma":0.043701854,"teacher_disagreement_score":0.2479989,"about_ca_system_score_codex":0.0008333504,"about_ca_system_score_gemma":0.0011759439,"threshold_uncertainty_score":0.9927745},"labels":[],"label_agreement":null},{"id":"W3170286532","doi":"10.1007/978-3-030-71155-9_10","title":"Immune Checkpoint Inhibitor Cardiovascular Toxicities","year":2021,"lang":"en","type":"book-chapter","venue":"Clinical cases in cardiology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University","funders":"","keywords":"Immune system; Medicine; Immunology","score_opus":0.07902930368810186,"score_gpt":0.34774006602393076,"score_spread":0.2687107623358289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170286532","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029559141,0.38433582,0.000053947802,0.0008705126,0.008946168,0.001305139,0.00021300025,0.00015552259,0.57456076],"genre_scores_gemma":[0.30122975,0.15284047,0.00048175795,0.0039309175,0.016941812,0.00018045287,0.0011500035,0.00043875296,0.52280605],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961332,0.0002565122,0.0018840343,0.000949315,0.00035010217,0.00042682845],"domain_scores_gemma":[0.996998,0.000967928,0.000254803,0.0014325319,0.00019321908,0.00015353333],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0017450076,0.0005028887,0.0034554326,0.000194624,0.00004820191,0.000015067852,0.00017846693,0.0016910805,0.00079902314],"category_scores_gemma":[0.00078015623,0.00045721175,0.00506522,0.0000652831,0.0010379506,0.000028031698,0.00022836399,0.0015152956,0.00008233676],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024778109,0.0006239339,0.014659085,0.00324163,0.06484864,0.2513721,0.00027372866,0.00009309403,0.0016529626,0.01100156,0.04143878,0.58601636],"study_design_scores_gemma":[0.004208913,0.0013409603,0.0049271374,0.001111553,0.0011457636,0.0059298896,0.00008761158,0.0000017397019,0.0002067634,0.0005183111,0.9799173,0.00060405774],"about_ca_topic_score_codex":0.00006825982,"about_ca_topic_score_gemma":0.000027371172,"teacher_disagreement_score":0.9384785,"about_ca_system_score_codex":0.0003043732,"about_ca_system_score_gemma":0.0005744715,"threshold_uncertainty_score":0.999788},"labels":[],"label_agreement":null},{"id":"W3170341220","doi":"10.1200/jco.2021.39.15_suppl.9000","title":"First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Pemetrexed; Internal medicine; Nivolumab; Ipilimumab; Clinical endpoint; Lung cancer; Oncology; Chemotherapy; Cancer; Randomized controlled trial; Cisplatin; Immunotherapy","score_opus":0.030966787785416724,"score_gpt":0.37581410776589413,"score_spread":0.3448473199804774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170341220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99085385,0.0028421264,0.00014324917,0.0026479936,0.0019361419,0.000566131,0.00006258453,0.000018738803,0.00092917023],"genre_scores_gemma":[0.9818263,0.008032996,0.0071177385,0.0018138551,0.00087545556,0.000016900114,0.000051749925,0.00008855234,0.00017644365],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99478644,0.00025366084,0.003116811,0.00058085856,0.0006897278,0.0005725014],"domain_scores_gemma":[0.9944597,0.0010341932,0.0027343815,0.0005700098,0.0008373988,0.00036430522],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011620256,0.00043540105,0.0028190613,0.00018636849,0.00006441832,0.000018726972,0.00040796597,0.0004769419,0.0007736182],"category_scores_gemma":[0.0003149536,0.00034861758,0.0006812285,0.0004842266,0.00034771377,0.00020578213,0.00011321509,0.0012654867,0.000008242767],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5469348,0.0069457223,0.29632312,0.0003918517,0.0034584505,0.00082046306,0.0011138387,0.0025081546,0.0063308417,0.000008108922,0.0013397457,0.13382494],"study_design_scores_gemma":[0.4518663,0.008846334,0.5124533,0.0016231518,0.0009658107,0.00002879441,0.00051880995,0.0016087171,0.015586385,0.000049720526,0.005854095,0.00059855083],"about_ca_topic_score_codex":0.000782397,"about_ca_topic_score_gemma":0.0026631695,"teacher_disagreement_score":0.21613023,"about_ca_system_score_codex":0.0012199591,"about_ca_system_score_gemma":0.0038148863,"threshold_uncertainty_score":0.9998966},"labels":[],"label_agreement":null},{"id":"W3170362163","doi":"10.1200/jco.2021.39.15_suppl.e21010","title":"The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and the influence of the NLR in NSCLC patients treated with immunotherapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"KRAS; STK11; Medicine; Internal medicine; Oncology; Cancer; Overall survival; Mutation; Gene; Colorectal cancer; Biology; Genetics","score_opus":0.02976515583640647,"score_gpt":0.403708412751568,"score_spread":0.3739432569151615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170362163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940805,0.0023877544,0.0000016226134,0.0030424073,0.00007181462,0.0002906681,0.0000043950467,0.0000010689416,0.00011977063],"genre_scores_gemma":[0.9971382,0.0023536347,0.000054584518,0.00037343122,0.000031040847,0.0000038206786,6.6103945e-7,0.0000065097593,0.000038101498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977777,0.0005998945,0.0012237024,0.00008314883,0.0002065732,0.00010898201],"domain_scores_gemma":[0.99410623,0.004010819,0.001211693,0.00017115542,0.0004508099,0.00004928348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016631476,0.000084496896,0.0006222159,0.000035604757,0.000055622502,0.0000079817655,0.00011171504,0.00010344201,0.000011939259],"category_scores_gemma":[0.0019600876,0.000030089057,0.00021578044,0.00024696763,0.0011421591,0.00005076534,0.00002652611,0.00039523735,9.161441e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019519955,0.00058508397,0.93572783,0.000012666907,0.0005574593,0.000016921107,0.00047742476,0.000025905987,0.0006865198,0.00002292355,0.000035958805,0.04233132],"study_design_scores_gemma":[0.01847653,0.0052551953,0.9748794,0.00018359232,0.00019155147,0.00011665312,0.00020365574,0.000019950805,0.000091820926,0.00011288839,0.0004360528,0.000032747146],"about_ca_topic_score_codex":0.00018654302,"about_ca_topic_score_gemma":0.00024633412,"teacher_disagreement_score":0.042298574,"about_ca_system_score_codex":0.000049467188,"about_ca_system_score_gemma":0.0010952807,"threshold_uncertainty_score":0.4208333},"labels":[],"label_agreement":null},{"id":"W3170413052","doi":"10.7150/jca.57413","title":"Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers","year":2021,"lang":"en","type":"article","venue":"Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca; Pfizer","keywords":"Tolerability; Medicine; PD-L1; Antibody; Meta-analysis; Oncology; Solid tumor; Internal medicine; Pharmacology; Immunotherapy; Immunology; Adverse effect; Cancer","score_opus":0.07284538578062501,"score_gpt":0.36594692534192497,"score_spread":0.2931015395613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170413052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9150226,0.08216271,0.00013493461,0.0019534645,0.00024459176,0.000108516615,0.00001589998,0.000003957972,0.00035333203],"genre_scores_gemma":[0.98962724,0.009169214,0.00043375773,0.00047296472,0.00017731056,0.0000020344726,0.000003048926,0.000010531104,0.0001038759],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980118,0.00012885431,0.001067453,0.00019434394,0.00036647645,0.00023103076],"domain_scores_gemma":[0.99851716,0.00017379073,0.0006340255,0.00023233464,0.00034944777,0.000093236624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086778746,0.0001609756,0.002085118,0.0001698604,0.000049256916,0.000018808014,0.00008822395,0.00007095496,0.00056175195],"category_scores_gemma":[0.00006883097,0.00011885206,0.00086347986,0.0008227364,0.00014957043,0.00009780424,0.000037097292,0.0002744675,1.4454753e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068179485,0.00021786347,0.83207196,0.00020901964,0.10696033,0.00011881332,0.00092884316,0.039009973,0.008348514,0.000016666654,0.00076776056,0.004532307],"study_design_scores_gemma":[0.002969579,0.00013514832,0.9454519,0.00019228569,0.04267925,0.000048853173,0.00023307928,0.00049370853,0.004698946,0.000027781676,0.0029235391,0.0001459032],"about_ca_topic_score_codex":0.00090078864,"about_ca_topic_score_gemma":0.0030820789,"teacher_disagreement_score":0.11337996,"about_ca_system_score_codex":0.00029103234,"about_ca_system_score_gemma":0.00055014866,"threshold_uncertainty_score":0.615079},"labels":[],"label_agreement":null},{"id":"W3170799867","doi":"10.1371/journal.pone.0253070","title":"Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy","year":2021,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto Liver Centre; University Health Network","funders":"Genentech; Servier; Astellas Pharma; Intercept Pharmaceuticals; EMD Serono; Mersana Therapeutics; Regeneron Pharmaceuticals; Array BioPharma; Gilead Sciences; PTC Therapeutics; Sanofi; GlaxoSmithKline; Amgen; Pfizer; MorphoSys; Celgene; Symphogen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Cancer; Gastroenterology; Liver enzyme; Adverse effect","score_opus":0.04534679011720157,"score_gpt":0.255201225553827,"score_spread":0.20985443543662544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170799867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979789,0.0011556338,0.000003859401,0.0001256488,0.000006372443,0.0005263442,0.000011731756,0.000011497618,0.00018001214],"genre_scores_gemma":[0.99895495,0.0003832319,0.00035578027,0.00010161393,0.000017061797,0.00004211897,0.000050944207,0.00001172622,0.00008259929],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989412,0.000084577034,0.0002156671,0.00014843646,0.0005193015,0.000090842266],"domain_scores_gemma":[0.99916136,0.000022067516,0.00007817737,0.00015970589,0.0005527155,0.000025969435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003144618,0.00008055656,0.00020504268,0.00007684926,0.000022303568,0.0000061297574,0.00001835193,0.00004981983,0.0002293001],"category_scores_gemma":[0.00006273406,0.00006735949,0.000026022257,0.000272553,0.000048210422,0.000059333146,0.000008042981,0.000068890426,0.0000013024886],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001578732,0.0034308834,0.46301058,0.00007896433,0.00049334654,0.0000028354757,0.0004706276,6.256247e-7,0.52475214,0.0000036040922,0.000011197721,0.006166487],"study_design_scores_gemma":[0.0057827854,0.0004012255,0.5725462,0.00032893242,0.00015368144,9.568181e-7,0.000025758121,0.00037048155,0.4203269,0.0000063978596,0.000005106676,0.000051619114],"about_ca_topic_score_codex":0.00018915701,"about_ca_topic_score_gemma":0.00016011814,"teacher_disagreement_score":0.10953559,"about_ca_system_score_codex":0.00014022391,"about_ca_system_score_gemma":0.00015656283,"threshold_uncertainty_score":0.274684},"labels":[],"label_agreement":null},{"id":"W3171392184","doi":"10.1200/jco.2021.39.15_suppl.e21531","title":"Prognostic pathological and clinical factors associated with overall survival in metastatic melanoma undergoing anti PD-1 treatment.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); University of Calgary; Abbotsford Veterinary Clinic","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Pembrolizumab; Internal medicine; Oncology; Melanoma; Immunotherapy; Cohort; Proportional hazards model; Gastroenterology; Cancer","score_opus":0.21448340736016416,"score_gpt":0.45974703263170025,"score_spread":0.24526362527153608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171392184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951618,0.00092371996,0.000040483996,0.002559942,0.0006674155,0.0001851457,0.0000059119307,0.0000096076865,0.00044599175],"genre_scores_gemma":[0.9949983,0.0030044313,0.00081371213,0.0008067168,0.00020594615,0.0000017851572,0.000011080828,0.000015952019,0.0001421035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951399,0.0016179566,0.0023909416,0.0002822366,0.0002952203,0.00027373442],"domain_scores_gemma":[0.9862134,0.011867712,0.0012603372,0.00013769227,0.00023989838,0.00028094684],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003347209,0.0001883354,0.0020861528,0.00008829065,0.000036351197,0.000018003628,0.00007289265,0.00036423188,0.00011732731],"category_scores_gemma":[0.009070379,0.00010839121,0.00049431995,0.00019555377,0.00033575433,0.000088674686,0.00003231466,0.00076980126,0.0000013315873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052079824,0.003731733,0.96419126,0.000013074066,0.0014322511,0.0061804717,0.00006935946,0.000002378125,0.00010294208,0.000022949933,0.00006252476,0.018983064],"study_design_scores_gemma":[0.024878414,0.028271027,0.9434304,0.00021866822,0.0007806937,0.00046071457,0.00030558716,0.00003191527,0.000025283523,0.00011623432,0.0013682375,0.000112783404],"about_ca_topic_score_codex":0.000019599629,"about_ca_topic_score_gemma":0.00070696144,"teacher_disagreement_score":0.024539296,"about_ca_system_score_codex":0.00023823848,"about_ca_system_score_gemma":0.002540727,"threshold_uncertainty_score":0.99927664},"labels":[],"label_agreement":null},{"id":"W3171495697","doi":"10.1200/jco.2021.39.15_suppl.2592","title":"A phase 1/2 study of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab [KEYNOTE-A10] in adult subjects with locally advanced, unresectable and metastatic solid tumors refractory to therapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Response Evaluation Criteria in Solid Tumors; Internal medicine; Cancer; Oncology; Tolerability; Phases of clinical research; Gastroenterology; Chemotherapy; Immunotherapy; Adverse effect","score_opus":0.06703042630878267,"score_gpt":0.4407346407945011,"score_spread":0.37370421448571844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171495697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584347,0.00053690746,0.00009879299,0.0025163407,0.00015852992,0.00073113415,0.000002302856,0.0000045038396,0.00010798904],"genre_scores_gemma":[0.9951556,0.00094960205,0.0019058993,0.0018027882,0.00006402317,0.000022376467,0.0000029166993,0.000023788267,0.000073061026],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99604714,0.00072110695,0.0021918651,0.00029312735,0.00047182344,0.00027496525],"domain_scores_gemma":[0.99644816,0.0012581985,0.0011768347,0.00021294282,0.0006780529,0.0002258206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001999058,0.00019869737,0.0018273789,0.00033400787,0.000024563415,0.0000129008,0.0001227307,0.00012311601,0.0000639994],"category_scores_gemma":[0.0014434194,0.00012116475,0.00009020076,0.0007913591,0.00017583983,0.00020642315,0.0000326107,0.00087580696,4.7272334e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7219125,0.039048173,0.042699814,0.00012369038,0.00072267436,0.010320727,0.0028495782,0.00014914744,0.0048240838,0.000009978957,0.00014670486,0.17719294],"study_design_scores_gemma":[0.36294022,0.40478185,0.2155403,0.0014657517,0.00022875024,0.0017714491,0.009914125,0.00017667832,0.0020290373,0.000056596546,0.0008424725,0.000252781],"about_ca_topic_score_codex":0.00024591415,"about_ca_topic_score_gemma":0.010644714,"teacher_disagreement_score":0.36573365,"about_ca_system_score_codex":0.00023496206,"about_ca_system_score_gemma":0.0032938442,"threshold_uncertainty_score":0.59400004},"labels":[],"label_agreement":null},{"id":"W3171509414","doi":"10.1200/jco.2021.39.15_suppl.9501","title":"Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institutes of Health","keywords":"Medicine; Ipilimumab; Pembrolizumab; Internal medicine; Melanoma; Adjuvant; Randomized controlled trial; Surgery; Lymph node; Oncology; Gastroenterology; Immunotherapy; Cancer","score_opus":0.07201326935886022,"score_gpt":0.40374774333367636,"score_spread":0.33173447397481615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171509414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99575585,0.00018638652,0.00014413874,0.0016925787,0.001163924,0.00085548084,0.00001812921,0.0000055163487,0.00017800568],"genre_scores_gemma":[0.9981418,0.00040241942,0.00049760146,0.00049111806,0.00031710922,0.000018275532,0.000024034853,0.000021542279,0.00008608432],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9905942,0.003976496,0.004006257,0.00037834558,0.0007235918,0.00032112648],"domain_scores_gemma":[0.9902632,0.0064491946,0.0021537938,0.00049072376,0.00044576608,0.00019728279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008608944,0.00026601716,0.0044666394,0.0005933733,0.00003995914,0.000025732368,0.00038484315,0.0003220354,0.00030845831],"category_scores_gemma":[0.005223353,0.00014547269,0.0006787547,0.0010029378,0.0003350863,0.0001257186,0.00014783598,0.0012838473,7.700096e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91760534,0.005115928,0.059957314,0.000020835994,0.00417987,0.00034974795,0.0007984579,0.00006518973,0.00006610864,0.000039027716,0.00020018156,0.011601991],"study_design_scores_gemma":[0.6531644,0.02670172,0.31712133,0.00018890262,0.0019314961,0.000012330468,0.00028503343,0.00021392827,0.00001799755,0.000047019068,0.00020362284,0.000112218324],"about_ca_topic_score_codex":0.0011948367,"about_ca_topic_score_gemma":0.011303499,"teacher_disagreement_score":0.26444092,"about_ca_system_score_codex":0.00027355488,"about_ca_system_score_gemma":0.00085774506,"threshold_uncertainty_score":0.6307618},"labels":[],"label_agreement":null},{"id":"W3171517418","doi":"10.1016/s0140-6736(21)00797-2","title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2927,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Medicine; Gastric adenocarcinoma; Gastro-; Chemotherapy; Nivolumab; Internal medicine; Gastroenterology; Open label; Adenocarcinoma; Gastroesophageal Junction; Oncology; Clinical trial; Cancer; Reflux; Immunotherapy; Disease","score_opus":0.05805096571869594,"score_gpt":0.3440784328444417,"score_spread":0.2860274671257457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171517418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9516562,0.014854949,0.003517448,0.02054486,0.001793948,0.0067728455,0.00023110883,0.00019925622,0.00042936753],"genre_scores_gemma":[0.9529112,0.010912734,0.011645582,0.00972098,0.006826744,0.001587116,0.0005393801,0.00025389402,0.005602385],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972915,0.00014174855,0.00069256005,0.0007345965,0.0003819254,0.00075768516],"domain_scores_gemma":[0.9978869,0.00037174986,0.00032944552,0.0009854612,0.00022391324,0.0002025375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008949838,0.0004805067,0.0014794864,0.00008385034,0.00044671967,0.0002011933,0.0004768749,0.0001753961,0.00051858416],"category_scores_gemma":[0.0001576095,0.0003618452,0.00023187259,0.0004487972,0.0002506199,0.00022307792,0.00009902024,0.00034315544,0.000010616817],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9346992,0.0008444701,0.000120239005,0.0001473941,0.0008456249,0.00006921827,0.00045289315,0.000009416771,0.010106956,0.000028499064,0.013511795,0.03916432],"study_design_scores_gemma":[0.95305896,0.005943913,0.0008547041,0.0001223332,0.00032573257,0.00020432753,0.00017623315,0.0011041771,0.008972924,0.00012276744,0.028776325,0.00033761485],"about_ca_topic_score_codex":0.00007788491,"about_ca_topic_score_gemma":0.000070740476,"teacher_disagreement_score":0.038826708,"about_ca_system_score_codex":0.00025626668,"about_ca_system_score_gemma":0.00040687175,"threshold_uncertainty_score":0.99988335},"labels":[],"label_agreement":null},{"id":"W3171912160","doi":"10.1200/jco.2021.39.15_suppl.9516","title":"Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Discontinuation; Ipilimumab; Internal medicine; Clinical endpoint; Incidence (geometry); Adverse effect; Safety profile; Oncology; Gastroenterology; Randomized controlled trial; Cancer; Immunotherapy","score_opus":0.10085294632141979,"score_gpt":0.4533463520984132,"score_spread":0.3524934057769934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171912160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98346895,0.0028722421,0.0005116828,0.00584876,0.002070425,0.00035506807,0.00004184846,0.0000102296635,0.0048207715],"genre_scores_gemma":[0.973555,0.0016172628,0.022478951,0.00065219303,0.0008545135,0.000004090144,0.000010520848,0.000030648258,0.0007968092],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950897,0.00024963287,0.0037211063,0.00026153363,0.00039334426,0.0002846726],"domain_scores_gemma":[0.99251455,0.0022302181,0.0035251507,0.00038366418,0.0011568707,0.00018953333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034518642,0.0001671935,0.0020802107,0.00012354774,0.000041270727,0.0000051765637,0.0001977422,0.00034760093,0.000098559154],"category_scores_gemma":[0.0030771561,0.0001311612,0.0010551341,0.00024131883,0.00034322726,0.000107161686,0.000059802638,0.00056059676,0.0000020682382],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59145707,0.0038104465,0.004404247,0.00052187376,0.0031133073,0.0006368513,0.00061888795,0.00013916256,0.10660402,0.00048761783,0.007572278,0.28063422],"study_design_scores_gemma":[0.4976778,0.089520045,0.07243883,0.002740163,0.0025736257,0.0016316312,0.0022031064,0.0007791233,0.09655507,0.0023382055,0.23092115,0.0006212627],"about_ca_topic_score_codex":0.00003906776,"about_ca_topic_score_gemma":0.00021787598,"teacher_disagreement_score":0.28001297,"about_ca_system_score_codex":0.00024796685,"about_ca_system_score_gemma":0.0030014785,"threshold_uncertainty_score":0.53485984},"labels":[],"label_agreement":null},{"id":"W3172200015","doi":"10.1200/jco.2021.39.15_suppl.6529","title":"Uptake of immunotherapy in patients with advanced cancer: A population-based study using health administrative data from Ontario, Canada.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre; University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Medicine; Pembrolizumab; Nivolumab; Cancer; Internal medicine; Hazard ratio; Cohort; Bladder cancer; Population; Ipilimumab; Proportional hazards model; Melanoma; Lung cancer; Retrospective cohort study; Oncology; Cancer registry; Immunotherapy; Confidence interval; Cancer research; Environmental health","score_opus":0.17895957994067835,"score_gpt":0.48796057311026697,"score_spread":0.3090009931695886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172200015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996344,0.0009811799,0.000025662559,0.0015730507,0.00061975897,0.00033441998,0.000100568715,0.0000014421925,0.000019932011],"genre_scores_gemma":[0.99340504,0.000103733895,0.0041841227,0.0021026316,0.0000960739,0.0000018894452,0.00007861948,0.000011973406,0.000015935988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964437,0.00037364656,0.0023573234,0.00022268853,0.00044529897,0.00015735571],"domain_scores_gemma":[0.99626684,0.0005993197,0.0022293788,0.00035940192,0.00041097502,0.00013409989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010551148,0.00011825199,0.0013471865,0.000056719535,0.000030126264,0.00000416835,0.00017287927,0.00009607796,0.00035334847],"category_scores_gemma":[0.00028572703,0.00008645801,0.00009637318,0.00020044892,0.000043646214,0.00008744426,0.00002193206,0.0005026567,5.036404e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033282332,0.0030187827,0.8940255,0.000008614541,0.00059503043,0.00012027324,0.00021343342,0.0000920039,0.000028661638,2.4591597e-7,0.00013603264,0.06847907],"study_design_scores_gemma":[0.029450782,0.010759933,0.9547637,0.0003303998,0.00009755602,0.000003615031,0.00048362056,0.00004832418,0.000014490888,0.0000037256013,0.0039724996,0.00007136239],"about_ca_topic_score_codex":0.82824916,"about_ca_topic_score_gemma":0.99094486,"teacher_disagreement_score":0.1626957,"about_ca_system_score_codex":0.0014427847,"about_ca_system_score_gemma":0.048856303,"threshold_uncertainty_score":0.9565358},"labels":[],"label_agreement":null},{"id":"W3172376856","doi":"10.1200/jco.2021.39.15_suppl.2513","title":"ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Royal Victoria Hospital; McGill University Health Centre; University of Alberta; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Chills; Internal medicine; Melanoma; Renal cell carcinoma; Adverse effect; Response Evaluation Criteria in Solid Tumors; Tolerability; Gastroenterology; Aldesleukin; Toxicity; Oncology; Phases of clinical research; Surgery; Interleukin 2; Cytokine; Immunotherapy; Cancer; Cancer research","score_opus":0.03361205118455683,"score_gpt":0.3936374816355411,"score_spread":0.36002543045098423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172376856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955938,0.0004963348,0.000053232936,0.0030556894,0.00016973024,0.00017604836,0.0000013976136,0.0000032030073,0.00045057756],"genre_scores_gemma":[0.9955316,0.0011046781,0.0015391957,0.0016388021,0.000082885286,0.0000043396667,0.000004864873,0.000013963997,0.000079655765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781764,0.00023311675,0.001346987,0.00017593816,0.0002549486,0.00017139812],"domain_scores_gemma":[0.9982949,0.00036397233,0.00082839065,0.00012236282,0.000270925,0.00011945914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085733144,0.00011266536,0.00096471887,0.000118892865,0.00001649322,0.000008612559,0.000058788508,0.00016205826,0.00005521957],"category_scores_gemma":[0.00029056869,0.00007557552,0.00008177567,0.0002347655,0.00015668874,0.0001290752,0.000013178368,0.0005772497,7.1789617e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09758047,0.0029313508,0.6376279,0.000026859556,0.00013390495,0.0009969645,0.00013925474,0.000030027039,0.0003775356,0.000012567148,0.00012195823,0.2600212],"study_design_scores_gemma":[0.07644003,0.021165343,0.89717513,0.00035912608,0.000037796286,0.00031139044,0.00012984904,0.000060619517,0.0002876316,0.000083538675,0.003862736,0.00008680085],"about_ca_topic_score_codex":0.000020721573,"about_ca_topic_score_gemma":0.00043798794,"teacher_disagreement_score":0.25993443,"about_ca_system_score_codex":0.00020716157,"about_ca_system_score_gemma":0.0011254695,"threshold_uncertainty_score":0.30818802},"labels":[],"label_agreement":null},{"id":"W3172587474","doi":"10.1097/cji.0000000000000377","title":"Safety and Clinical Outcomes of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Diseases","year":2021,"lang":"en","type":"article","venue":"Journal of Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre","funders":"","keywords":"Medicine; Cancer; Immunology; Internal medicine","score_opus":0.012997031282716304,"score_gpt":0.3046834379528645,"score_spread":0.2916864066701482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172587474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9601906,0.038515963,0.000016956623,0.0007826231,0.0002523694,0.00018651958,0.000014918057,0.0000051736724,0.000034861212],"genre_scores_gemma":[0.97929263,0.019637525,0.00063064945,0.00022189542,0.000059228532,0.0000021095984,0.0000048167676,0.000027019629,0.00012410618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782586,0.00009048175,0.001455064,0.00015637165,0.0003072056,0.0001650029],"domain_scores_gemma":[0.9984276,0.00018165378,0.000828448,0.00019828044,0.00029482105,0.00006917235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055821764,0.00017070195,0.0008423603,0.00012818539,0.00004412755,0.000018764627,0.00006710963,0.00008239637,0.00007817301],"category_scores_gemma":[0.00012402593,0.0001146761,0.0002324324,0.00021031333,0.00022119784,0.00014019769,0.000030098348,0.00028003682,9.150338e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012285099,0.0005354331,0.87001806,0.000056833098,0.0009186261,0.00002425112,0.00028989682,0.0000018955682,0.0042423722,0.0000029029998,0.000009789066,0.11161481],"study_design_scores_gemma":[0.020635469,0.0012030305,0.9744102,0.0011336526,0.00011619731,0.00003770971,0.00017613453,0.000005884418,0.0012352777,0.00001135941,0.00091265887,0.00012247909],"about_ca_topic_score_codex":0.000174347,"about_ca_topic_score_gemma":0.000027637976,"teacher_disagreement_score":0.111492336,"about_ca_system_score_codex":0.000091444155,"about_ca_system_score_gemma":0.0003091837,"threshold_uncertainty_score":0.46763554},"labels":[],"label_agreement":null},{"id":"W3172704995","doi":"10.1200/jco.2021.39.15_suppl.e18008","title":"Cytokines performance during nivolumab treatment: A subgroup analysis of NIVACTOR study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Subgroup analysis; Population; Gastroenterology; Immunotherapy; Confidence interval; Cancer","score_opus":0.10989313684410822,"score_gpt":0.4529072815231682,"score_spread":0.34301414467906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172704995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99704224,0.00094726816,0.0000076988945,0.0008081571,0.00051833445,0.000105049396,0.000003997759,0.00000478043,0.0005624775],"genre_scores_gemma":[0.9955617,0.0027579067,0.00029257053,0.000188897,0.00044609292,0.0000020612092,0.0000026115079,0.000009099861,0.0007390342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99701446,0.00026809156,0.0021191256,0.00016060693,0.00028397265,0.00015376783],"domain_scores_gemma":[0.997137,0.00061973114,0.0014093823,0.00024785413,0.00044230596,0.000143739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010964434,0.00011410719,0.0018632256,0.00025610143,0.000035561065,0.0000052240293,0.000098338445,0.0001690695,0.00043835488],"category_scores_gemma":[0.0005071315,0.00007701241,0.0011477445,0.0006831147,0.00010892817,0.000079249345,0.00002591098,0.00027633933,0.0000020229645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019588202,0.0057560485,0.86974806,0.000033113116,0.013030844,0.00084524835,0.00037140324,0.000016969603,0.0055083814,0.0000015505258,0.00006651967,0.085033655],"study_design_scores_gemma":[0.01572526,0.017765174,0.9528425,0.000047496247,0.0051042554,0.00019484133,0.0005253169,0.000079218094,0.0019540694,0.0000017689857,0.0056953263,0.000064782405],"about_ca_topic_score_codex":0.000054310214,"about_ca_topic_score_gemma":0.00024656492,"teacher_disagreement_score":0.08496887,"about_ca_system_score_codex":0.00022704028,"about_ca_system_score_gemma":0.00106296,"threshold_uncertainty_score":0.47996786},"labels":[],"label_agreement":null},{"id":"W3172791693","doi":"10.1200/jco.2021.39.15_suppl.9569","title":"Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Clinical endpoint; Oncology; Population; Adjuvant; Clinical trial; Cancer; Immunotherapy","score_opus":0.07024500424129045,"score_gpt":0.4155460451486779,"score_spread":0.34530104090738745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172791693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99782497,0.0005401661,0.00004120079,0.00092089106,0.00009772266,0.00014664062,0.000019015812,0.0000037933887,0.00040561453],"genre_scores_gemma":[0.9970607,0.0009342006,0.001068337,0.0006721049,0.00005329667,0.0000029324526,0.000020679456,0.00001477213,0.00017294096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99631083,0.00048874354,0.0023424516,0.00022758734,0.0004067857,0.00022358689],"domain_scores_gemma":[0.99684876,0.00088140083,0.0013261609,0.00022572544,0.00056911,0.00014881413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00151226,0.00015941955,0.0023372748,0.0005000395,0.00001662479,0.000006015799,0.000113910566,0.00021980499,0.00056616333],"category_scores_gemma":[0.00047019715,0.00008969589,0.00045875937,0.001743076,0.00022634518,0.00010396687,0.000015781363,0.0005334317,9.4415464e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14564706,0.0047371197,0.7861404,0.000046368186,0.005357826,0.002262364,0.00020273452,0.00012392462,0.00024431507,0.0000018921344,0.00008552967,0.055150498],"study_design_scores_gemma":[0.045869198,0.019335693,0.9268193,0.00027802333,0.0034742472,0.00009124221,0.0004041363,0.000110954694,0.0006497403,0.000003236045,0.0028529647,0.00011126991],"about_ca_topic_score_codex":0.00022370096,"about_ca_topic_score_gemma":0.0076358225,"teacher_disagreement_score":0.14067893,"about_ca_system_score_codex":0.00022287027,"about_ca_system_score_gemma":0.0018615994,"threshold_uncertainty_score":0.6199091},"labels":[],"label_agreement":null},{"id":"W3173030298","doi":"10.1200/jco.2021.39.15_suppl.2546","title":"A 4-chemokine signature to predict intermediate immunogenicity in homologous recombination repair deficient tumors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; McGill University Health Centre","funders":"","keywords":"Chemokine; Medicine; Immune checkpoint; Cancer research; Immunology; Immunotherapy; Gene signature; Immune system; Cancer; Biology; Internal medicine; Gene expression; Gene","score_opus":0.053055332531290286,"score_gpt":0.41124278167931455,"score_spread":0.35818744914802425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173030298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98572725,0.0017445689,0.00006912756,0.008938078,0.002108125,0.00019828204,0.0000040957,0.000015590238,0.0011948547],"genre_scores_gemma":[0.99058485,0.0008938533,0.0016416137,0.005965453,0.00044852204,0.0000054453726,0.000006791919,0.000012698286,0.00044079326],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9961594,0.00047309534,0.002566167,0.00023819324,0.00032613814,0.00023704385],"domain_scores_gemma":[0.99713165,0.00087328424,0.0009665005,0.00024007872,0.0005670511,0.00022145173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038876229,0.00012835512,0.0011920991,0.00020123132,0.000024116605,0.0000073608007,0.0001489505,0.0004218244,0.00028044384],"category_scores_gemma":[0.005620515,0.00009930118,0.0007067075,0.00043771297,0.00011537214,0.00006519743,0.0000774564,0.0012131409,0.00001033615],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06889544,0.011203452,0.3139142,0.00014866766,0.0013973862,0.01568931,0.0011317651,0.0000734637,0.029630287,0.00006924383,0.026908796,0.53093797],"study_design_scores_gemma":[0.01315967,0.011611096,0.9281237,0.0003844006,0.0001486013,0.0014716953,0.00020748955,0.000082973624,0.0027683198,0.00020367856,0.041726217,0.000112147616],"about_ca_topic_score_codex":0.00002761642,"about_ca_topic_score_gemma":0.00011816934,"teacher_disagreement_score":0.6142095,"about_ca_system_score_codex":0.00047457858,"about_ca_system_score_gemma":0.0017774851,"threshold_uncertainty_score":0.6728687},"labels":[],"label_agreement":null},{"id":"W3173110589","doi":"10.1200/jco.2021.39.15_suppl.2509","title":"Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis","keywords":"Medicine; Tolerability; Lung cancer; Internal medicine; Cancer; Monoclonal antibody; Oncology; Pharmacology; Antibody; Adverse effect; Immunology","score_opus":0.04631767264630706,"score_gpt":0.4352997352500569,"score_spread":0.38898206260374985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173110589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965908,0.00019855327,0.000009259042,0.0014829674,0.00077875686,0.0006481032,0.000007509705,0.000005952626,0.00027811603],"genre_scores_gemma":[0.9982653,0.00014907095,0.00037744935,0.00089084794,0.0002143436,0.0000070071897,0.0000074573773,0.00002610044,0.000062383835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99535984,0.0006095405,0.0027036432,0.00029438408,0.0007368011,0.00029578136],"domain_scores_gemma":[0.9957361,0.00054991647,0.0023757266,0.0003816973,0.000760284,0.00019626242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013170339,0.00022698173,0.0020061412,0.0001256512,0.000058682188,0.000010896879,0.00023121168,0.00019679686,0.00011111063],"category_scores_gemma":[0.00059327506,0.00012300233,0.00032648983,0.00053974177,0.00036805173,0.00013609324,0.000074476215,0.0009688218,0.000001298658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16369255,0.05406021,0.747776,0.00005036546,0.0010573524,0.001562128,0.00056864275,0.000061048755,0.00249252,0.000007605979,0.0003858876,0.028285751],"study_design_scores_gemma":[0.16100648,0.1395308,0.69402707,0.0005558727,0.00032214422,0.00024028504,0.00090149004,0.0000325513,0.001616766,0.000015040331,0.0016131711,0.00013833534],"about_ca_topic_score_codex":0.000046301593,"about_ca_topic_score_gemma":0.0004107428,"teacher_disagreement_score":0.08547058,"about_ca_system_score_codex":0.00016720718,"about_ca_system_score_gemma":0.0027734027,"threshold_uncertainty_score":0.50158894},"labels":[],"label_agreement":null},{"id":"W3173127935","doi":"10.1136/jitc-2020-002157","title":"Follicular helper-T cells restore CD8<sup>+</sup>-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Ligue Contre le Cancer; Agence Nationale de la Recherche; Université de Franche-Comté; Fondation de France; Université Laval; Université de Bourgogne; Association pour la Recherche sur le Cancer","keywords":"Germinal center; Cytotoxic T cell; Immune system; CD8; Chemokine; Immunology; Cancer research; Biology; T cell; Adoptive cell transfer; Antibody; Flow cytometry; Cytokine; B cell; In vitro","score_opus":0.02059658743093797,"score_gpt":0.3176562006179244,"score_spread":0.2970596131869864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173127935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9002659,0.095366895,0.00029710127,0.0020426763,0.0010485942,0.0006678201,0.000098803386,0.00003443018,0.00017779753],"genre_scores_gemma":[0.90168685,0.0891996,0.0019170125,0.0018702227,0.0007679886,0.000059488288,0.000029851277,0.0001440766,0.004324885],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99725634,0.00015312064,0.00096248963,0.00040772965,0.00065742456,0.0005628753],"domain_scores_gemma":[0.99786305,0.00016495219,0.0005238455,0.00063168234,0.0006171595,0.00019929156],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00082147995,0.00040971866,0.00097382313,0.00022224014,0.0004515073,0.00012548243,0.00027727237,0.00022601969,0.00094316964],"category_scores_gemma":[0.000058641934,0.00034317622,0.0007384352,0.0003658817,0.00026058799,0.00023100243,0.00005121713,0.0005953106,0.0000034205873],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009754391,0.00063109695,0.003916485,0.0003177851,0.0022008119,0.00014089012,0.0014678459,0.0001623528,0.92276543,0.000032590866,0.0043179463,0.054292385],"study_design_scores_gemma":[0.030009419,0.0015702535,0.044982124,0.0017466482,0.0005401311,0.0014498828,0.0015186494,0.00021476705,0.5771221,0.00012611956,0.3399548,0.00076510716],"about_ca_topic_score_codex":0.00033722393,"about_ca_topic_score_gemma":0.000026552492,"teacher_disagreement_score":0.3456433,"about_ca_system_score_codex":0.00032051138,"about_ca_system_score_gemma":0.0008257376,"threshold_uncertainty_score":0.9999701},"labels":[],"label_agreement":null},{"id":"W3173596797","doi":"10.1371/journal.pone.0251731","title":"Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy","year":2021,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Canadian Institutes of Health Research","keywords":"Hydroxychloroquine; Medicine; Immunotherapy; Blockade; Immune checkpoint; FOXP3; Immunology; Cancer immunotherapy; Cancer research; CD8; Cancer; Tumor microenvironment; Immune system; Internal medicine; Receptor","score_opus":0.026583192369984045,"score_gpt":0.24624580311649943,"score_spread":0.21966261074651539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173596797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97374254,0.020940954,0.0000039213646,0.0039213807,0.00006152234,0.00045935877,0.000020654692,0.000040948828,0.00080869714],"genre_scores_gemma":[0.9931832,0.0041665654,0.0005643417,0.00075912295,0.00012233036,0.00005512645,0.00004298444,0.000045362536,0.001060998],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998147,0.00005807132,0.00069592305,0.0003007073,0.00046633906,0.00033195585],"domain_scores_gemma":[0.99868214,0.00012697154,0.00020227008,0.0007609474,0.00016284504,0.00006485344],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035937972,0.00021936536,0.0006731524,0.00011836172,0.000066773544,0.000018965864,0.00020136773,0.0000789285,0.0012671662],"category_scores_gemma":[0.0001185867,0.00016275774,0.0002519415,0.0006070913,0.00017658967,0.00006269191,0.00005924306,0.00025344949,0.0000158555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016932528,0.003273734,0.013651899,0.00017060601,0.000870941,0.00008907561,0.00039931768,0.0000026000912,0.97767323,0.000031795767,0.000023496967,0.0021200604],"study_design_scores_gemma":[0.0042532263,0.00030853966,0.16755839,0.00096051284,0.00014822338,0.00006582179,0.000273899,0.00008319712,0.82556355,0.00009586314,0.000527958,0.00016083001],"about_ca_topic_score_codex":0.0007283589,"about_ca_topic_score_gemma":0.00012677746,"teacher_disagreement_score":0.15390648,"about_ca_system_score_codex":0.00010222724,"about_ca_system_score_gemma":0.00021315072,"threshold_uncertainty_score":0.9996458},"labels":[],"label_agreement":null},{"id":"W3174387710","doi":"10.1038/s41698-021-00200-4","title":"The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response","year":2021,"lang":"en","type":"article","venue":"npj Precision Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"National Natural Science Foundation of China","keywords":"Immune system; Crosstalk; Immunotherapy; Evasion (ethics); Biology; Cancer immunotherapy; Epithelial–mesenchymal transition; Immunology; Tumor microenvironment; Cancer; Cancer research; Metastasis; Genetics","score_opus":0.021587363755261175,"score_gpt":0.33808371811417914,"score_spread":0.316496354358918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174387710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96449643,0.017878272,0.00018674602,0.01633799,0.00023727893,0.00065756525,0.000060011847,0.000021724147,0.00012394771],"genre_scores_gemma":[0.98127294,0.016642535,0.00090998766,0.00048240216,0.00010893657,0.00009488685,0.000014229047,0.00002475433,0.00044935953],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981015,0.00044479128,0.00056782353,0.00035934386,0.00027359117,0.00025294768],"domain_scores_gemma":[0.9978434,0.0013524478,0.0001581401,0.00031838636,0.00023484045,0.000092775954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001509853,0.00016862543,0.0004932712,0.00010777113,0.00022555934,0.00003474141,0.00008727879,0.00022340215,0.00015058137],"category_scores_gemma":[0.00024331982,0.0001126713,0.00011956932,0.00031140732,0.00023021112,0.00006576052,0.00006535509,0.00019407595,0.0000032014075],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02707905,0.00008567312,0.0028446196,0.000021893953,0.00011868497,0.000015385227,0.0013164124,7.193781e-7,0.5075716,0.000005401289,0.00021401214,0.4607266],"study_design_scores_gemma":[0.0074301222,0.004048371,0.6501582,0.00038809728,0.00012527959,0.00016199687,0.00088528404,0.00004332561,0.23094475,0.00019593045,0.1054321,0.00018651313],"about_ca_topic_score_codex":0.00008622096,"about_ca_topic_score_gemma":0.000060963946,"teacher_disagreement_score":0.6473136,"about_ca_system_score_codex":0.00009686372,"about_ca_system_score_gemma":0.00036141288,"threshold_uncertainty_score":0.45946026},"labels":[],"label_agreement":null},{"id":"W3175514092","doi":"10.1016/j.jtocrr.2021.100205","title":"Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042","year":2021,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"Janssen Pharmaceuticals; Loxo Oncology; Chugai Pharmaceutical; Genentech; Free Market Institute, Texas Tech University; National Institutes of Health; Shire; Bayer Fund; Mirati Therapeutics; Clovis Oncology; National Center for Advancing Translational Sciences; Teva Pharmaceutical Industries; Verily Life Sciences; Les Laboratories Pierre Fabre; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; AbbVie; ACEA Biosciences; Novartis; Celgene; Merck; Spectrum Pharmaceuticals; Sanofi; EMD Serono; Mesothelioma Applied Research Foundation; Heron Therapeutics; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; AstraZeneca; Pfizer; Boehringer Ingelheim; Amgen; Roche","keywords":"Pembrolizumab; Medicine; Brain metastasis; Internal medicine; Chemotherapy; Lung cancer; Oncology; Confidence interval; Metastasis; Adverse effect; Cancer; Immunotherapy","score_opus":0.042763170746134116,"score_gpt":0.40124649074367263,"score_spread":0.3584833199975385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175514092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99580085,0.0008509588,0.00003146217,0.0020624772,0.00001984898,0.0010095979,0.000027496139,0.000016166061,0.00018116363],"genre_scores_gemma":[0.9977393,0.0003807587,0.0006620489,0.00036493287,0.000019781959,0.000063230524,0.00012651809,0.000028330736,0.0006151093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963225,0.00042271972,0.00088407745,0.00073678355,0.0011951979,0.00043873413],"domain_scores_gemma":[0.9972173,0.0007883341,0.00028116867,0.0005100145,0.00091077056,0.00029240243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024721469,0.00023724424,0.0011483404,0.0003963906,0.00010150087,0.00006716058,0.000055978144,0.00014483756,0.000046661928],"category_scores_gemma":[0.0004376344,0.00012531152,0.00014822673,0.0014134457,0.0008425505,0.00010186693,0.000060046874,0.0004716675,2.2416557e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030869788,0.0016085157,0.93569744,0.00008571864,0.0058465283,0.0017440864,0.00024135178,0.000001986853,0.00010203125,0.000009075253,0.00007167624,0.0237218],"study_design_scores_gemma":[0.016547302,0.0049267714,0.9755144,0.00032497648,0.0009413733,0.000093740244,0.00025512392,0.000032496035,0.00048884656,0.000028199986,0.0006617074,0.00018502431],"about_ca_topic_score_codex":0.00097307283,"about_ca_topic_score_gemma":0.0015599431,"teacher_disagreement_score":0.039816994,"about_ca_system_score_codex":0.000053569973,"about_ca_system_score_gemma":0.000550615,"threshold_uncertainty_score":0.5110055},"labels":[],"label_agreement":null},{"id":"W3175903440","doi":"10.1002/cam4.4086","title":"Quality of patient‐reported outcomes in oncology clinical trials using immune checkpoint inhibitors: A systematic review","year":2021,"lang":"en","type":"review","venue":"Cancer Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Clinical trial; Internal medicine; Nivolumab; Regimen; Oncology; Clinical endpoint; Lung cancer; Cancer; Immunotherapy","score_opus":0.43931025888098385,"score_gpt":0.5912794023294586,"score_spread":0.15196914344847479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175903440","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022761156,0.988426,0.0000071718555,0.0008702732,0.0026349905,0.007645527,0.000041653115,0.000028215683,0.00011854044],"genre_scores_gemma":[0.00003773261,0.9969882,0.00007236093,0.0011930092,0.0005299047,0.0007956865,0.00016538874,0.00007458185,0.00014317188],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9709337,0.0074042543,0.019620692,0.0007721234,0.000865051,0.0004042286],"domain_scores_gemma":[0.98282784,0.0034379961,0.011612074,0.0014145289,0.00047719388,0.00023035804],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.02766219,0.00072356465,0.03165568,0.0004191591,0.000030024163,0.0000050803433,0.00025217363,0.000785015,0.00077349547],"category_scores_gemma":[0.026552906,0.00042165926,0.0034659551,0.0013036798,0.00044915467,0.00004517485,0.000106462205,0.0010493206,0.0000025296265],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017966669,0.0002939323,0.00012898963,0.71258926,0.0031728295,0.0001520121,0.00012151234,2.8582665e-8,0.000031976153,0.0000020536224,0.0002979684,0.2830298],"study_design_scores_gemma":[0.0041247318,0.0005187032,0.000056004537,0.84702724,0.014277621,0.00018757644,0.00021356114,7.3279466e-7,0.000007609978,0.0000019721294,0.13327956,0.0003046662],"about_ca_topic_score_codex":0.0018952064,"about_ca_topic_score_gemma":0.00006875225,"teacher_disagreement_score":0.28272513,"about_ca_system_score_codex":0.0014983527,"about_ca_system_score_gemma":0.0042513143,"threshold_uncertainty_score":0.9998235},"labels":[],"label_agreement":null},{"id":"W3175939027","doi":"10.1016/s1368-8375(21)00375-4","title":"P-88 First-Line Pembrolizumab With or Without Lenvatinib in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Phase 3 LEAP-010 Study","year":2021,"lang":"en","type":"article","venue":"Oral Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Pembrolizumab; Lenvatinib; Head and neck squamous-cell carcinoma; Medicine; Oncology; Internal medicine; Head and neck cancer; Basal cell; Head and neck; Phases of clinical research; Cancer research; Cancer; Immunotherapy; Chemotherapy; Surgery","score_opus":0.05775824172927307,"score_gpt":0.37283060855002553,"score_spread":0.31507236682075246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175939027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99367577,0.0020929023,0.000020834623,0.00153565,0.00024486572,0.0011083541,0.000022302704,0.000035693756,0.0012636178],"genre_scores_gemma":[0.99609286,0.00016656316,0.0010704125,0.0007289814,0.00009307226,0.00010998507,0.000048648126,0.000036692243,0.0016528176],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980072,0.00023487222,0.00053914654,0.00054951303,0.00023322167,0.00043604436],"domain_scores_gemma":[0.99899995,0.00018184245,0.00017770208,0.0003623748,0.00011944658,0.00015869032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002949653,0.00029664993,0.00089043344,0.00016209706,0.00009156122,0.000023029865,0.00009240435,0.000116375246,0.00053738366],"category_scores_gemma":[0.000072524235,0.00021398377,0.00006782186,0.00053489214,0.00017388051,0.00008692584,0.000048284168,0.00039167237,0.000010571494],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1784619,0.022541359,0.5578456,0.00068839215,0.00025375522,0.011018325,0.006423477,0.000009228194,0.00527462,0.000009622537,0.0022774767,0.21519628],"study_design_scores_gemma":[0.39978498,0.16448459,0.33207327,0.00032052756,0.000966928,0.0034558245,0.007870548,0.001047595,0.0042260806,0.00002790001,0.08471681,0.0010249369],"about_ca_topic_score_codex":0.0009130628,"about_ca_topic_score_gemma":0.02457252,"teacher_disagreement_score":0.22577229,"about_ca_system_score_codex":0.0002875047,"about_ca_system_score_gemma":0.0009128087,"threshold_uncertainty_score":0.99322647},"labels":[],"label_agreement":null},{"id":"W3176276868","doi":"10.1016/j.thromres.2021.06.018","title":"Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study","year":2021,"lang":"en","type":"article","venue":"Thrombosis Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut Universitaire de Cardiologie et de Pneumologie de Québec; Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Cumulative incidence; Retrospective cohort study; Incidence (geometry); Cohort; Lung cancer; Venous thrombosis; Univariate analysis; Thrombosis; Cancer; Cohort study; Oncology; Gastroenterology; Surgery; Multivariate analysis","score_opus":0.03053277433096401,"score_gpt":0.3465519319417737,"score_spread":0.3160191576108097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176276868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99100035,0.000933141,0.000006783817,0.00020001612,0.0001471972,0.0073308107,0.00003491996,0.000035494955,0.00031126314],"genre_scores_gemma":[0.99722993,0.00077943713,0.000100729194,0.000027365797,0.00008282904,0.0011664268,0.00008631254,0.00008119761,0.00044575494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99632597,0.0003059714,0.0005949807,0.000798864,0.0010855698,0.0008886595],"domain_scores_gemma":[0.9977772,0.00016507508,0.00013926254,0.00063110923,0.0011265418,0.00016079762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012913218,0.00029590933,0.00084623066,0.000409921,0.00025020516,0.000035703953,0.00019936127,0.00014078591,0.00019383998],"category_scores_gemma":[0.0001405551,0.00024313419,0.00017332821,0.0020543,0.00016554112,0.000093363255,0.0001264852,0.0005809207,0.000009477887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003039153,0.008406464,0.97127426,0.00030513902,0.0008376195,0.000032901957,0.0022000247,0.0000069280295,0.013322598,4.21917e-7,0.00013081443,0.000443659],"study_design_scores_gemma":[0.018631913,0.0043738983,0.9429897,0.00058659515,0.00025191758,0.0000016578879,0.001709599,0.00026632258,0.030924428,0.0000025996287,0.000015518359,0.00024583223],"about_ca_topic_score_codex":0.007859517,"about_ca_topic_score_gemma":0.0014755699,"teacher_disagreement_score":0.028284557,"about_ca_system_score_codex":0.0023546296,"about_ca_system_score_gemma":0.000734855,"threshold_uncertainty_score":0.9987472},"labels":[],"label_agreement":null},{"id":"W3176859254","doi":"10.1158/1538-7445.am2021-lb040","title":"Abstract LB040: Targeting CD38 and PD-1 with isatuximab (Isa) plus cemiplimab (Cemi) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label, multicenter study","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Tolerability; Oncology; Internal medicine; Immune checkpoint; Interim analysis; Adverse effect; Immunotherapy; Cancer; Clinical trial","score_opus":0.08120297173712268,"score_gpt":0.41291577264296403,"score_spread":0.3317128009058413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176859254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929626,0.0025555945,0.00000489276,0.0006153721,0.00009878609,0.0026018785,0.00040363593,0.000028431059,0.0007287947],"genre_scores_gemma":[0.9970493,0.0006386713,0.00064754166,0.0002936557,0.000087281034,0.00042901107,0.00024189975,0.00007114087,0.00054151955],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962843,0.00020376561,0.0005603461,0.0010726517,0.0010755352,0.0008034155],"domain_scores_gemma":[0.9978983,0.00031106788,0.00015841024,0.0006656392,0.00072223425,0.0002443925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009453287,0.0003098929,0.000599645,0.00019065698,0.00024326629,0.00020260602,0.00031269746,0.00010363599,0.00030641307],"category_scores_gemma":[0.00025398342,0.00023074589,0.000027619142,0.0009153664,0.00028068558,0.0003721861,0.00029530912,0.00075461325,0.000008131939],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5545125,0.018286278,0.17156953,0.0005309279,0.0012359162,0.0025199181,0.019222217,0.000053551463,0.1493818,0.000002853955,0.004611489,0.078073025],"study_design_scores_gemma":[0.6163391,0.012876183,0.29843858,0.005228966,0.00014980155,0.000011222936,0.025081469,0.00022535247,0.03077105,0.000008244495,0.009912087,0.0009579799],"about_ca_topic_score_codex":0.0049654823,"about_ca_topic_score_gemma":0.002893065,"teacher_disagreement_score":0.12686904,"about_ca_system_score_codex":0.0008938852,"about_ca_system_score_gemma":0.0011785876,"threshold_uncertainty_score":0.94095445},"labels":[],"label_agreement":null},{"id":"W3176956457","doi":"10.1158/1078-0432.ccr-21-0793","title":"Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme","keywords":"Ipilimumab; Pembrolizumab; Medicine; Cohort; Regimen; Internal medicine; Adverse effect; Dosing; Melanoma; Incidence (geometry); Gastroenterology; Oncology; Cancer; Immunotherapy","score_opus":0.13851459770828084,"score_gpt":0.5370049475480762,"score_spread":0.3984903498397953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176956457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98410195,0.009804783,0.00003834669,0.00089322665,0.0006530744,0.003717332,0.00007440849,0.000048774844,0.0006681141],"genre_scores_gemma":[0.9902312,0.0075738216,0.00033282264,0.00019327135,0.00035350092,0.0006955503,0.000032607706,0.0000745653,0.00051262835],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.991369,0.0024526634,0.0022268773,0.0011407303,0.0019072664,0.0009034808],"domain_scores_gemma":[0.99439615,0.0025637806,0.00034181698,0.0011512998,0.0011732357,0.00037371612],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009666056,0.00035310202,0.0024313454,0.00043201356,0.0001773556,0.000075622534,0.0004242089,0.0002180675,0.0009423708],"category_scores_gemma":[0.0026670045,0.0002919344,0.0005695787,0.0013517503,0.0010455651,0.0001684927,0.0003229406,0.0016258382,0.000012394876],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8799222,0.004602927,0.038600005,0.00023605017,0.0011799731,0.00091181626,0.0007334172,0.000047660684,0.010835889,0.00006536082,0.00018467974,0.062680006],"study_design_scores_gemma":[0.9643909,0.005056378,0.012508957,0.0010459065,0.0003015014,0.000029737712,0.0017362374,0.0009295655,0.012178508,0.0003423729,0.0011111076,0.0003688801],"about_ca_topic_score_codex":0.0035723501,"about_ca_topic_score_gemma":0.0026102425,"teacher_disagreement_score":0.08446863,"about_ca_system_score_codex":0.0010456366,"about_ca_system_score_gemma":0.0034886494,"threshold_uncertainty_score":0.9999709},"labels":[],"label_agreement":null},{"id":"W3178128501","doi":"10.1158/1538-7445.am2021-ct003","title":"Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Oncology; Internal medicine; Nivolumab; Lung cancer; Clinical endpoint; non-small cell lung cancer (NSCLC); Neoadjuvant therapy; Chemotherapy; Clinical trial; Cancer; Immunotherapy; Breast cancer","score_opus":0.0873477316640326,"score_gpt":0.43491273243975653,"score_spread":0.34756500077572394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178128501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96484417,0.013979528,0.000021650645,0.007396125,0.00061618094,0.0061721057,0.00023475377,0.000053417927,0.0066820863],"genre_scores_gemma":[0.9481524,0.017860651,0.00020492071,0.0017412378,0.002144495,0.0072497656,0.00024173592,0.00020494414,0.022199815],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9950836,0.00021668366,0.00082333904,0.0011205843,0.0011637874,0.0015920409],"domain_scores_gemma":[0.9971753,0.00051820726,0.00021720094,0.0011778619,0.00063186634,0.00027961165],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002110049,0.0005321576,0.0009244921,0.0003058574,0.0004595397,0.0002567969,0.0005933995,0.0003507082,0.0038018988],"category_scores_gemma":[0.00010771227,0.00039618948,0.00047562367,0.0012774451,0.00027141318,0.00017531046,0.00008646454,0.00089514663,0.00003072837],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3309132,0.003338118,0.00091965374,0.0010542156,0.0007692404,0.00043531312,0.006155229,0.000030164827,0.5315332,0.000018283721,0.039594963,0.08523844],"study_design_scores_gemma":[0.26804474,0.0029871627,0.0012607556,0.00096211996,0.00012789125,0.0000333665,0.0014793938,0.0004193219,0.60900176,0.000052171366,0.115115896,0.0005154278],"about_ca_topic_score_codex":0.013916891,"about_ca_topic_score_gemma":0.0031207108,"teacher_disagreement_score":0.08472301,"about_ca_system_score_codex":0.002741146,"about_ca_system_score_gemma":0.0051769237,"threshold_uncertainty_score":0.999849},"labels":[],"label_agreement":null},{"id":"W3179376270","doi":"10.3389/fonc.2021.667650","title":"The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Science and Technology Major Project; Shandong First Medical University; Natural Science Foundation of Shandong Province; National Natural Science Foundation of China","keywords":"Medicine; Internal medicine; Thyroid cancer; Incidence (geometry); Meta-analysis; Thyroiditis; Clinical trial; Oncology; Placebo; Thyroid; Thyroid dysfunction; Pathology","score_opus":0.028290565783227077,"score_gpt":0.33898826627649786,"score_spread":0.3106977004932708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179376270","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003091257,0.99445194,0.000007968538,0.00020131226,0.00076960307,0.00400652,0.00017632039,0.000015396756,0.00006182356],"genre_scores_gemma":[0.00017653524,0.9970154,0.000052374016,0.00024025743,0.00001562422,0.0010769826,0.0010202164,0.00004752956,0.0003550566],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99197966,0.0034467278,0.0032712542,0.0006340389,0.00031806264,0.00035028663],"domain_scores_gemma":[0.9959714,0.00025708054,0.0026804423,0.00079696847,0.00021001168,0.00008412637],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026935693,0.00053314416,0.01030378,0.00065092585,0.000083731546,0.000018313383,0.00028042274,0.0007706815,0.000171764],"category_scores_gemma":[0.00032926726,0.0003127169,0.0018610593,0.0027965247,0.00020113676,0.00008992082,0.00007287364,0.00091425347,0.0000011866113],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055897725,0.0012418687,0.0010530942,0.32814354,0.5073209,0.000029066954,0.00049947266,0.0000021028784,0.000011729053,0.000004437476,0.026043355,0.13509148],"study_design_scores_gemma":[0.0019092932,0.00081190985,0.00011338932,0.021705529,0.82963526,0.000010231859,0.0002898094,0.0000133814765,0.0000036855304,0.000005802858,0.14511083,0.0003908504],"about_ca_topic_score_codex":0.0013462391,"about_ca_topic_score_gemma":0.00067189266,"teacher_disagreement_score":0.3223144,"about_ca_system_score_codex":0.0012966075,"about_ca_system_score_gemma":0.0006003265,"threshold_uncertainty_score":0.99993247},"labels":[],"label_agreement":null},{"id":"W3179925795","doi":"10.1080/14737140.2021.1953987","title":"Tumor infiltrating lymphocytes: current pathways to a standard biomarker in breast cancer","year":2021,"lang":"en","type":"editorial","venue":"Expert Review of Anticancer Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Taiwan Forestry Research Institute","keywords":"Medicine; Breast cancer; Biomarker; Tumor-infiltrating lymphocytes; Oncology; Cancer; Internal medicine; Pathology; Immunotherapy","score_opus":0.02767202126527464,"score_gpt":0.37237589696896484,"score_spread":0.3447038757036902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179925795","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00084881106,0.7445858,0.000019490031,0.0022388601,0.2496866,0.0015209329,0.00093030045,0.00004071464,0.00012849963],"genre_scores_gemma":[0.00022049923,0.8407042,0.00033820802,0.004584338,0.15310673,0.00067107106,0.00022152656,0.00011835971,0.000035069144],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99491686,0.00023539273,0.0016119537,0.00095370377,0.0016397932,0.00064229197],"domain_scores_gemma":[0.99698436,0.00029056473,0.00063399546,0.00097002106,0.000885171,0.00023587148],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009630225,0.0007551559,0.0025739023,0.00028866448,0.00006389562,0.000047300673,0.00041567135,0.0002975988,0.002297623],"category_scores_gemma":[0.00023952714,0.0005882482,0.00073564,0.001237121,0.00017414478,0.00010288943,0.00008178192,0.0005955424,0.0000069067623],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033932687,0.00021638427,0.00016188785,0.0066519957,0.00032811286,0.00004752429,0.0004328653,1.0586237e-7,0.0067826724,0.0000016833726,0.6474841,0.33449936],"study_design_scores_gemma":[0.0039328127,0.0003029754,0.00060252525,0.1334535,0.00006600822,0.000020392336,0.0000816759,0.0000027949209,0.001828618,0.0000020951284,0.85915977,0.0005468464],"about_ca_topic_score_codex":0.0010798736,"about_ca_topic_score_gemma":0.00008778323,"teacher_disagreement_score":0.33395252,"about_ca_system_score_codex":0.0013788164,"about_ca_system_score_gemma":0.005584375,"threshold_uncertainty_score":0.9996569},"labels":[],"label_agreement":null},{"id":"W3180418576","doi":"10.1158/1538-7445.am2021-lb034","title":"Abstract LB034: Analysis of PD-L1 IHC tests using NIST SRM 1934-traceable reference materials: A new paradigm for development of predictive IHC biomarkers","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Saskatchewan Health Authority","funders":"","keywords":"Immunohistochemistry; Gold standard (test); Detection limit; NIST; Chemistry; Medicine; Pathology; Internal medicine; Computer science; Chromatography","score_opus":0.21920378215054082,"score_gpt":0.46282798124992763,"score_spread":0.24362419909938682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180418576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99269545,0.004564278,0.0003851373,0.00035890634,0.00015220509,0.0007507941,0.00040133396,0.00001776513,0.00067413884],"genre_scores_gemma":[0.9941363,0.00083243684,0.0035046316,0.00003783739,0.00010367448,0.00013547414,0.00018828799,0.00003466382,0.001026715],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99727505,0.000100925296,0.0007551588,0.0005117253,0.0008062434,0.00055087416],"domain_scores_gemma":[0.9979923,0.00030426594,0.00025213868,0.00050588965,0.0007505142,0.00019488759],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013689722,0.00019435825,0.000718588,0.0005730485,0.00016829524,0.0000438221,0.0002242731,0.00015833059,0.0014997447],"category_scores_gemma":[0.00020215285,0.00017521673,0.00019237488,0.0020602203,0.00029876342,0.000102767124,0.0000827804,0.00018813583,0.0000027711508],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007784599,0.00021948884,0.0036727532,0.0007535503,0.0048184874,0.000016961954,0.0009130076,0.00005092603,0.96922946,0.000023824738,0.001368776,0.011148159],"study_design_scores_gemma":[0.0024128666,0.00024426397,0.16104789,0.0009250938,0.0006129857,0.0000060698344,0.0007310708,0.00015423242,0.8200299,0.00005551678,0.013580426,0.00019965578],"about_ca_topic_score_codex":0.0040402254,"about_ca_topic_score_gemma":0.0010935769,"teacher_disagreement_score":0.15737514,"about_ca_system_score_codex":0.0007286102,"about_ca_system_score_gemma":0.0049304105,"threshold_uncertainty_score":0.999413},"labels":[],"label_agreement":null},{"id":"W3180793944","doi":"10.1097/md.0000000000026649","title":"The incidence of pseudoprogressive disease associated with programmed cell death 1/programmed cell death ligand 1 inhibitors","year":2021,"lang":"en","type":"review","venue":"Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Particle Physics","funders":"National Natural Science Foundation of China","keywords":"Medicine; Incidence (geometry); Cochrane Library; Internal medicine; Meta-analysis; Confidence interval; Population; Disease; Lung cancer; Subgroup analysis; Programmed cell death 1; Cancer; Oncology; PD-L1; Immunotherapy","score_opus":0.03239005858367159,"score_gpt":0.3209884547655422,"score_spread":0.2885983961818706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180793944","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036992081,0.99052745,0.00001000061,0.00074427226,0.00050014094,0.0038689987,0.000048078073,0.000113435766,0.0004884311],"genre_scores_gemma":[0.0067205294,0.9885317,0.00014059327,0.00019262517,0.00059741153,0.00075887446,0.00085439224,0.00016212024,0.0020417566],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947921,0.00038564394,0.0015459376,0.00089968403,0.0014758918,0.0009007105],"domain_scores_gemma":[0.9948773,0.00087969896,0.00177087,0.0012006145,0.00064273307,0.0006287938],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012812153,0.00095433043,0.003197868,0.0002539254,0.00026881084,0.000056665805,0.0005240485,0.00043126818,0.00007411248],"category_scores_gemma":[0.00070312165,0.0004796129,0.0007548904,0.0015841444,0.00089796766,0.00006205166,0.00013406138,0.00094373146,0.000005901613],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011691059,0.0010299822,0.0041948687,0.01637869,0.0015424693,0.0014269344,0.00039790693,1.4606732e-7,0.00003713777,0.00001181422,0.0037343313,0.9700766],"study_design_scores_gemma":[0.0063023544,0.0026684182,0.00080371293,0.10692404,0.009061476,0.00013065054,0.00038251095,0.000006571006,0.0002822903,0.000011353662,0.8727265,0.00070014095],"about_ca_topic_score_codex":0.00020035503,"about_ca_topic_score_gemma":0.00006483095,"teacher_disagreement_score":0.96937644,"about_ca_system_score_codex":0.00045153132,"about_ca_system_score_gemma":0.0022650326,"threshold_uncertainty_score":0.9997656},"labels":[],"label_agreement":null},{"id":"W3181270705","doi":"10.1038/s41379-021-00865-z","title":"Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study","year":2021,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Cliniques Universitaires Saint-Luc; U.S. Department of Health and Human Services; National Cancer Institute; Fondation contre le Cancer; Stichting Tegen Kanker; Fondation Saint Luc","keywords":"Medicine; Biopsy; Pathological; Breast cancer; Pathology; Intraclass correlation; Renal cell carcinoma; Cancer; Internal medicine","score_opus":0.03240910133872378,"score_gpt":0.3029422878647602,"score_spread":0.2705331865260364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181270705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956468,0.0000891755,0.00015027772,0.0028158957,0.00006372193,0.001050907,0.000060546055,0.000009857119,0.00011285661],"genre_scores_gemma":[0.99858403,0.0000059974673,0.00022095142,0.0009360119,0.000024771225,0.00019335489,0.000011221483,0.000009249786,0.000014438299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9920287,0.006303609,0.0005605157,0.0004081944,0.00041060118,0.0002883657],"domain_scores_gemma":[0.9946588,0.0042472742,0.00034418647,0.00053523964,0.00019387128,0.000020581521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063518044,0.00018959031,0.00046068573,0.00005957626,0.00012731568,0.000034736215,0.00029607306,0.00009219166,0.000024548253],"category_scores_gemma":[0.0013046446,0.00008852611,0.000088313434,0.0004693356,0.0003361773,0.00007644702,0.000106133186,0.0004725209,4.3211887e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00308551,0.00055889244,0.9512435,0.000016970138,0.00006981292,0.0005778496,0.0139085,0.000090406844,0.02984599,0.000038015296,0.0000060415828,0.0005584675],"study_design_scores_gemma":[0.004073544,0.0012467594,0.976938,0.00006263464,0.00006510765,0.00060896925,0.01518846,0.00093836116,0.0005285517,0.0002548829,0.000002621815,0.000092098446],"about_ca_topic_score_codex":0.00045069304,"about_ca_topic_score_gemma":0.002931434,"teacher_disagreement_score":0.029317439,"about_ca_system_score_codex":0.00044966408,"about_ca_system_score_gemma":0.00061424996,"threshold_uncertainty_score":0.36099902},"labels":[],"label_agreement":null},{"id":"W3181289099","doi":"10.1158/1538-7445.am2021-1647","title":"Abstract 1647: CAPTIV-8: A prospective trial of atezolizumab using a multivariate model incorporating whole genome and transcriptome analysis","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Pancreas Centre (Canada); Spinal Cord Injury BC; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Medicine; Atezolizumab; Oncology; Cohort; Context (archaeology); Internal medicine; Disease; Cancer; Clinical trial; Immunotherapy; Pembrolizumab; Biology","score_opus":0.127506638324887,"score_gpt":0.4230340859456433,"score_spread":0.2955274476207563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181289099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944703,0.0030927772,0.00065038254,0.0003568666,0.000050468145,0.00076848315,0.00015151934,0.000016138738,0.00044309197],"genre_scores_gemma":[0.9979406,0.00031894151,0.0010246241,0.00003191397,0.000124614,0.00010180169,0.000027220201,0.000026745838,0.000403531],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99803203,0.00011557358,0.00040909174,0.00045546427,0.0006204605,0.00036738848],"domain_scores_gemma":[0.9987311,0.00007201604,0.00011675811,0.00032084732,0.00062788965,0.0001313888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008722007,0.00014685065,0.0005278365,0.00041570843,0.00016114833,0.000047355028,0.00008889533,0.0001125612,0.00014462246],"category_scores_gemma":[0.00007655853,0.00013144921,0.000208215,0.0017090548,0.00029382313,0.0001202988,0.00005315486,0.0003972672,0.0000010266509],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03605999,0.0002067925,0.0010533849,0.00018687647,0.001468845,0.00005512782,0.0020021359,0.0011365635,0.9559576,0.000036372083,0.00000765795,0.0018286478],"study_design_scores_gemma":[0.31683698,0.0032028346,0.15024394,0.0016418784,0.0036611692,0.0000944881,0.00792619,0.16345401,0.34848687,0.0021222548,0.00082340674,0.0015059776],"about_ca_topic_score_codex":0.0034846328,"about_ca_topic_score_gemma":0.0004433059,"teacher_disagreement_score":0.60747075,"about_ca_system_score_codex":0.00049891364,"about_ca_system_score_gemma":0.0013535608,"threshold_uncertainty_score":0.53603435},"labels":[],"label_agreement":null},{"id":"W3181675264","doi":"10.1158/1538-7445.am2021-ct004","title":"Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Ipilimumab; Oncology; Stage (stratigraphy); Adjuvant; Gastroenterology; Cancer; Immunotherapy","score_opus":0.03971357376249071,"score_gpt":0.33448434079264733,"score_spread":0.2947707670301566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181675264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991075,0.0027064034,0.000006822087,0.0017035275,0.0001061466,0.002031209,0.00012750905,0.000103530736,0.0021398438],"genre_scores_gemma":[0.9910362,0.0022213655,0.00017327577,0.00036348548,0.000101570164,0.000484608,0.00023862059,0.00016736817,0.0052135033],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99453294,0.00032649448,0.000567969,0.0011037523,0.0021138028,0.001355018],"domain_scores_gemma":[0.99658465,0.00017638535,0.00019303692,0.0012211488,0.0014575134,0.00036723723],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00087749085,0.0005066632,0.00091285736,0.00050866354,0.0003061638,0.00014595037,0.00040546898,0.0002248926,0.0022366717],"category_scores_gemma":[0.000048545982,0.00034151305,0.00010180971,0.0023570901,0.0006763293,0.00029564457,0.000100351084,0.0012922413,0.000028939938],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5334687,0.0036946598,0.34208584,0.00087601907,0.0018351559,0.0028475209,0.0027356953,0.000072544186,0.07192889,0.000031628242,0.0036715209,0.036751803],"study_design_scores_gemma":[0.09814668,0.0152991535,0.8108694,0.0024135143,0.000052231197,0.0000486613,0.0012698532,0.000049860017,0.061296895,0.000012881036,0.009816079,0.0007247878],"about_ca_topic_score_codex":0.006672069,"about_ca_topic_score_gemma":0.014770716,"teacher_disagreement_score":0.46878356,"about_ca_system_score_codex":0.0012819677,"about_ca_system_score_gemma":0.0027531944,"threshold_uncertainty_score":0.9999426},"labels":[],"label_agreement":null},{"id":"W3181766350","doi":"10.1097/med.0000000000000664","title":"Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancers","year":2021,"lang":"en","type":"review","venue":"Current Opinion in Endocrinology Diabetes and Obesity","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes","funders":"","keywords":"Medicine; Thyroid cancer; Endocrine system; Adverse effect; Context (archaeology); Cancer; Autoimmunity; Thyroid; Oncology; Immune system; Immunology; Internal medicine; Bioinformatics; Hormone; Biology","score_opus":0.05180924695399076,"score_gpt":0.35302169124492117,"score_spread":0.3012124442909304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181766350","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020980604,0.9658095,0.000013044219,0.000049949187,0.011632138,0.001323658,0.000136921,0.000031880434,0.000022285689],"genre_scores_gemma":[0.0017495967,0.9964219,0.00006240389,0.0000067104543,0.0004930402,0.00034738096,0.00082821865,0.00004640979,0.000044390996],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99709827,0.000113583315,0.0012610613,0.0006733417,0.00020477518,0.0006489558],"domain_scores_gemma":[0.99862736,0.00028197857,0.0005114376,0.00037802465,0.00010351867,0.00009766288],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003007444,0.0005056482,0.0026799012,0.000382101,0.00009472389,0.000016470844,0.00013834416,0.00023466708,0.000032734384],"category_scores_gemma":[0.00010231764,0.00044942793,0.0012285151,0.00037625327,0.000168294,0.00007334757,0.0001522438,0.00051699183,0.0000011679359],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010509404,0.0002758449,0.013836794,0.028805804,0.0007199679,0.0000037806967,0.000047097867,7.796386e-7,0.00007327155,0.00013336728,0.0001819891,0.9558162],"study_design_scores_gemma":[0.004852278,0.0005740337,0.005814047,0.03011421,0.00084999984,0.00002665882,0.00009875317,0.000013328084,0.00043850992,0.000032886903,0.9566409,0.0005444181],"about_ca_topic_score_codex":0.00015618108,"about_ca_topic_score_gemma":0.000030559215,"teacher_disagreement_score":0.95645887,"about_ca_system_score_codex":0.00042344394,"about_ca_system_score_gemma":0.00038168408,"threshold_uncertainty_score":0.99979573},"labels":[],"label_agreement":null},{"id":"W3182473146","doi":"10.1016/j.clon.2021.06.009","title":"Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma in a Population-based Cohort","year":2021,"lang":"en","type":"article","venue":"Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia","funders":"Merck; AstraZeneca Canada; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Nivolumab; Discontinuation; Hazard ratio; Internal medicine; Cohort; Adverse effect; Population; Survival analysis; Proportional hazards model; Confidence interval; Oncology; Immunotherapy; Cancer","score_opus":0.05244218482308755,"score_gpt":0.4277913085962518,"score_spread":0.37534912377316426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182473146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956562,0.00031772905,0.00025275483,0.0023733845,0.00068356027,0.00045136796,0.00000733822,0.000010678038,0.0002470041],"genre_scores_gemma":[0.9967541,0.000037199043,0.0023036327,0.00050327205,0.000042676795,0.00004457938,0.00009146325,0.0000099025265,0.00021316025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986527,0.00013947955,0.0007435821,0.0002339643,0.000094113806,0.00013613596],"domain_scores_gemma":[0.9977939,0.001764322,0.00017517648,0.00015153,0.000066857676,0.000048216218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009280771,0.000077344186,0.0007008335,0.0000460672,0.000022208977,0.0000031011264,0.000031849573,0.00016268641,0.000028687842],"category_scores_gemma":[0.0014173596,0.00006699139,0.00024609646,0.00010730729,0.000058936737,0.000035175522,0.000014179104,0.00009899619,4.1295755e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021410182,0.00038176368,0.92010623,0.000024744235,0.00012296802,0.000013639097,0.000022960214,0.000002564377,0.00065415987,0.000047481233,0.00001468917,0.0764678],"study_design_scores_gemma":[0.01717304,0.0012362099,0.979761,0.000059069043,0.0001085111,0.0000013470744,0.00008437006,0.00025599453,0.00017278778,0.000100677935,0.0009798082,0.00006720071],"about_ca_topic_score_codex":0.00011601598,"about_ca_topic_score_gemma":0.001460139,"teacher_disagreement_score":0.0764006,"about_ca_system_score_codex":0.0001079792,"about_ca_system_score_gemma":0.00037529372,"threshold_uncertainty_score":0.27318296},"labels":[],"label_agreement":null},{"id":"W3182497052","doi":"10.1097/ju.0000000000002056.06","title":"PD42-06 BOOSTING THE COMBINATION OF RADIATION AND ANTI-PD-L1 WITH STING AGONIST IN A PRECLINICAL MUSCLE INVASIVE BLADDER CANCER MURINE MODEL","year":2021,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Agonist; Bladder cancer; Sting; Cancer; Radiation therapy; Boosting (machine learning); Urology; Internal medicine; Receptor","score_opus":0.033083540683932364,"score_gpt":0.3129833481896025,"score_spread":0.2798998075056701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182497052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98405176,0.0039705704,0.00024027328,0.011451357,0.000056295812,0.000111617956,0.0000019781698,0.0000019741353,0.00011414022],"genre_scores_gemma":[0.99672383,0.0020596152,0.00010101158,0.0009952093,0.00006835386,0.0000018856982,0.0000016617569,0.000007264158,0.000041153853],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991524,0.0001869061,0.0003614915,0.000067254354,0.00013145326,0.00010049767],"domain_scores_gemma":[0.99881643,0.0005184061,0.0003946549,0.00009758059,0.00015092548,0.000021978578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085852854,0.000062113046,0.00021418811,0.00004819806,0.00005592141,0.000006042541,0.000060919596,0.00004883398,0.000017119875],"category_scores_gemma":[0.00023357257,0.000033402062,0.00003628229,0.00013603775,0.00016100462,0.000051838102,0.000023396527,0.00026684473,1.2639326e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020922804,0.0011050809,0.38445488,0.00029401158,0.001760316,0.00023282872,0.019038565,0.03456124,0.40880024,0.00021077093,0.00108425,0.12753505],"study_design_scores_gemma":[0.010518624,0.0015196908,0.95056415,0.0002563392,0.0005371838,0.0010909485,0.0011894492,0.023256987,0.01012344,0.00042880408,0.00040626744,0.000108119486],"about_ca_topic_score_codex":0.00008696826,"about_ca_topic_score_gemma":0.0003158995,"teacher_disagreement_score":0.5661093,"about_ca_system_score_codex":0.000031450345,"about_ca_system_score_gemma":0.00030977785,"threshold_uncertainty_score":0.13620967},"labels":[],"label_agreement":null},{"id":"W3182552500","doi":"10.1038/s42003-021-02361-1","title":"Multiplexed imaging analysis of the tumor-immune microenvironment reveals predictors of outcome in triple-negative breast cancer","year":2021,"lang":"en","type":"article","venue":"Communications Biology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"School of Medicine, Stanford University","keywords":"Tumor microenvironment; Breast cancer; Immune system; Context (archaeology); Triple-negative breast cancer; Medicine; Cancer research; Oncology; Cancer; Computational biology; Biology; Internal medicine; Immunology","score_opus":0.026857119368514988,"score_gpt":0.3235070892312375,"score_spread":0.2966499698627225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182552500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831553,0.009554842,0.000010776998,0.006209933,0.000099823796,0.00032645682,0.0004107067,0.000007415177,0.00022476148],"genre_scores_gemma":[0.9967765,0.0020100698,0.0005951285,0.0003226562,0.0000068633967,0.000054147808,0.00009239006,0.00000727412,0.0001349635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986288,0.00036685678,0.0006585058,0.00015122072,0.00006613204,0.00012847499],"domain_scores_gemma":[0.9977833,0.0002416701,0.00034231597,0.001516529,0.000094941955,0.000021226962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028545785,0.00009571092,0.00048455136,0.00018518763,0.000056553497,0.0000019927625,0.00041665358,0.000044646273,0.00019888837],"category_scores_gemma":[0.00011383772,0.00006949274,0.00026347578,0.001073058,0.00062632456,0.000020851965,0.00027644445,0.00016360254,5.2463326e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000114780276,0.0001567001,0.6851872,0.000012609245,0.00062722026,3.393012e-7,0.00032634012,0.000009108946,0.3123277,0.00003213476,0.000016982052,0.0011888514],"study_design_scores_gemma":[0.0013567358,0.000015046269,0.98261726,0.000086190135,0.00049960986,0.0000084953945,0.00048383296,0.00028314363,0.014137498,0.000022317312,0.00043202908,0.00005782323],"about_ca_topic_score_codex":0.001773539,"about_ca_topic_score_gemma":0.0012731962,"teacher_disagreement_score":0.2981902,"about_ca_system_score_codex":0.00015816123,"about_ca_system_score_gemma":0.00009190655,"threshold_uncertainty_score":0.28338316},"labels":[],"label_agreement":null},{"id":"W3182666754","doi":"10.1158/1538-7445.am2021-ct006","title":"Abstract CT006: Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Cohort; Tolerability; Discontinuation; Pembrolizumab; Internal medicine; Clinical endpoint; Oncology; Clinical trial; Adverse effect; Surgery; Cancer; Immunotherapy","score_opus":0.09035054185042334,"score_gpt":0.4364000889593772,"score_spread":0.34604954710895386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182666754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863185,0.0081605315,0.00008659669,0.0003684827,0.0003680605,0.0029880651,0.00024179168,0.000043476248,0.001424487],"genre_scores_gemma":[0.99375147,0.00076608604,0.00028297983,0.00011073382,0.00018589736,0.00081331935,0.000068594236,0.00009839514,0.0039225137],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959891,0.00032469837,0.0007826101,0.00081237574,0.0012009622,0.0008902625],"domain_scores_gemma":[0.9962017,0.0011584132,0.00020015627,0.0008672907,0.0012662847,0.00030617],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00084970606,0.00033235765,0.00076221593,0.0003351628,0.0002297769,0.00006203401,0.0003551438,0.00012943476,0.0017578397],"category_scores_gemma":[0.00044941896,0.0002765791,0.00025550986,0.0010452308,0.00029433603,0.00010647791,0.00011211525,0.00068262895,0.000012898916],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17642374,0.010611606,0.00068190874,0.0040507037,0.00039902198,0.0031582215,0.00287295,0.00006764078,0.4799593,0.000012050831,0.007368584,0.31439427],"study_design_scores_gemma":[0.23674887,0.05012764,0.007927537,0.0014077005,0.00075496733,0.00096056494,0.020678217,0.00076752476,0.6054769,0.00011544442,0.07367701,0.00135762],"about_ca_topic_score_codex":0.0005769238,"about_ca_topic_score_gemma":0.0006870866,"teacher_disagreement_score":0.31303665,"about_ca_system_score_codex":0.0006039213,"about_ca_system_score_gemma":0.0032533468,"threshold_uncertainty_score":0.99996865},"labels":[],"label_agreement":null},{"id":"W3182868687","doi":"10.1158/1538-7445.am2021-1485","title":"Abstract 1485: Tumors with homologous recombination repair deficiency signatures associate with an RNAseq profile profile suggestive of T cell-inflammation","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; McGill University; Concordia University; McGill University Health Centre","funders":"","keywords":"Immune system; Immune checkpoint; Biology; Inflammation; Cancer research; Cancer; Ovarian cancer; Pancreatic cancer; Carcinogenesis; Transcriptome; Immunology; Chemokine; Immunotherapy; Gene; Genetics; Gene expression","score_opus":0.029867818748172723,"score_gpt":0.3420742597793572,"score_spread":0.31220644103118445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182868687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99111474,0.0014577295,0.000011321746,0.0005491524,0.00006207184,0.0009721566,0.00006470844,0.00007733229,0.005690776],"genre_scores_gemma":[0.9957059,0.00021862358,0.00078442146,0.000031400155,0.00009484656,0.00031935688,0.00018308533,0.000038254624,0.0026240803],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976411,0.0002116899,0.00029739304,0.00045972658,0.00095268514,0.00043740362],"domain_scores_gemma":[0.997621,0.00014466436,0.00019840138,0.00037823876,0.0015429421,0.00011477971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010409091,0.00016108387,0.00029377037,0.00021501485,0.00019335453,0.000035208195,0.00012603725,0.0001350359,0.00080982153],"category_scores_gemma":[0.00011876434,0.00011865973,0.00007070927,0.0009999153,0.000293777,0.00020127383,0.000029987872,0.0005453929,0.000007421952],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011691738,0.000959212,0.010848879,0.0012755184,0.00025906778,0.00061202724,0.002088524,0.000081805774,0.9395873,0.00013236993,0.0026638308,0.029799737],"study_design_scores_gemma":[0.0027415568,0.0027467022,0.1577143,0.00069783535,0.00004311039,0.000034867502,0.0014961216,0.0000976712,0.8339377,0.000055731598,0.0002444516,0.0001899546],"about_ca_topic_score_codex":0.0008812172,"about_ca_topic_score_gemma":0.00051777647,"teacher_disagreement_score":0.14686543,"about_ca_system_score_codex":0.00056011707,"about_ca_system_score_gemma":0.0020663724,"threshold_uncertainty_score":0.88669777},"labels":[],"label_agreement":null},{"id":"W3182946075","doi":"10.1158/1538-7445.am2021-441","title":"Abstract 441: Potential implications of population kinetic characteristics of PD-1/PDL-1 monoclonals combined with chemotherapy in lung cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Chemotherapy; Lung cancer; Medicine; Internal medicine; Oncology; Population; Cancer","score_opus":0.04466715355760361,"score_gpt":0.4010688425013572,"score_spread":0.3564016889437536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182946075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931244,0.0025125626,0.000024830946,0.0033874337,0.00007110763,0.0005485377,0.000116312054,0.000009027219,0.000205768],"genre_scores_gemma":[0.9954329,0.0036248674,0.00010387084,0.00011672654,0.0000929725,0.0001767976,0.000113075,0.000027536224,0.00031125286],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985073,0.000059706235,0.00042862524,0.00025684453,0.000467691,0.00027979593],"domain_scores_gemma":[0.99870986,0.000069910544,0.00014933854,0.000353914,0.0006461732,0.000070832684],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034064258,0.00011057419,0.00035900887,0.00020631829,0.000045175373,0.0000127183785,0.00011298605,0.000089067034,0.0012799116],"category_scores_gemma":[0.000029944784,0.00009575015,0.00007230969,0.0008008432,0.00015825969,0.000053684384,0.0000244937,0.00025565748,6.449189e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006163899,0.0003569955,0.27682695,0.00069228833,0.00022392576,0.000016264457,0.0002754054,0.000048042566,0.68482965,0.0000832548,0.00049675925,0.02998655],"study_design_scores_gemma":[0.0029476439,0.00018194367,0.9296412,0.0006217513,0.000028896176,0.000005654185,0.000066184126,0.0000997895,0.06595726,0.00004349689,0.00031948718,0.000086677435],"about_ca_topic_score_codex":0.005333021,"about_ca_topic_score_gemma":0.0009374214,"teacher_disagreement_score":0.65281427,"about_ca_system_score_codex":0.00031114757,"about_ca_system_score_gemma":0.00067274924,"threshold_uncertainty_score":0.9996331},"labels":[],"label_agreement":null},{"id":"W3183254943","doi":"10.1038/s41586-021-03752-4","title":"Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers","year":2021,"lang":"en","type":"article","venue":"Nature","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":547,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Ontario Institute for Cancer Research","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Human Genome Research Institute; Ludwig Center at Harvard; Sidney Kimmel Comprehensive Cancer Center; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; National Institutes of Health; Promotion and Mutual Aid Corporation for Private Schools of Japan; Swim Across America; Mark Foundation For Cancer Research; Parker Institute for Cancer Immunotherapy; Johns Hopkins University; Memorial Sloan-Kettering Cancer Center; Stand Up To Cancer; LUNGevity Foundation; Entertainment Industry Foundation; Commonwealth Foundation; Lustgarten Foundation; International Association for the Study of Lung Cancer; American Society of Clinical Oncology; American Association for Cancer Research; Bristol-Myers Squibb; Allegheny Health Network; Virginia and D.K. Ludwig Fund for Cancer Research; Damon Runyon Cancer Research Foundation; Bloomberg Philanthropies; Conquer Cancer Foundation; Cancer Research Institute; V Foundation for Cancer Research","keywords":"Cancer research; Lung; PD-L1; Biology; Medicine; Genetics; Internal medicine; Cancer; Immunotherapy","score_opus":0.013413874488688417,"score_gpt":0.27670937668946355,"score_spread":0.26329550220077513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183254943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9421573,0.05376436,0.000007675977,0.0014125687,0.00034369048,0.00024379349,0.000026479493,0.000028279579,0.0020158016],"genre_scores_gemma":[0.9955936,0.0025760757,0.00023328915,0.0005149188,0.0000921056,0.000010722576,0.00017705082,0.0000149008865,0.0007873413],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99912894,0.000025269215,0.00020638564,0.00021243627,0.0002505285,0.00017641699],"domain_scores_gemma":[0.99960685,0.00001131564,0.000043890886,0.00017240322,0.00012395285,0.000041570816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000086923326,0.00010797019,0.00023575732,0.00008081989,0.000022121445,0.000009147551,0.000056805617,0.000513339,0.00046541844],"category_scores_gemma":[0.0000063662965,0.00009333678,0.00012966017,0.0006037642,0.00006564591,0.000045561123,0.0000055552,0.00074462814,0.0000022397228],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022366121,0.00041408598,0.18230504,0.0002528768,0.00026488423,0.00036280786,0.00076701684,0.0000077377545,0.7249066,0.0004030894,0.007569504,0.08050971],"study_design_scores_gemma":[0.0050185192,0.00013226348,0.6443267,0.000610591,0.000045054858,0.000097523225,0.0003181817,0.00006456193,0.0799497,0.000020369149,0.26923257,0.00018398814],"about_ca_topic_score_codex":0.000085564454,"about_ca_topic_score_gemma":0.00015720869,"teacher_disagreement_score":0.64495695,"about_ca_system_score_codex":0.00017105567,"about_ca_system_score_gemma":0.00026609594,"threshold_uncertainty_score":0.5096006},"labels":[],"label_agreement":null},{"id":"W3183392064","doi":"10.1101/2021.06.10.447835","title":"Cellular-level phenotyping of tumor-immune microenvironment (TiME) in patients in vivo reveals distinct inflammation and endothelial anergy signatures","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Institute of Biomedical Imaging and Bioengineering; National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Marie-Josée and Henry R. Kravis Center for Molecular Oncology; Cycle for Survival; Melanoma Research Alliance","keywords":"Immunotherapy; Immune system; In vivo; Tumor microenvironment; Medicine; Angiogenesis; Inflammation; Immunology; Phenotype; Cancer research; Pathology; Biology; Gene","score_opus":0.007877421921341183,"score_gpt":0.1957084864669768,"score_spread":0.1878310645456356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183392064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99509317,0.0033694042,0.00007134915,0.00006529791,0.0002752925,0.000888966,0.00019819826,0.000031962343,0.000006349349],"genre_scores_gemma":[0.99829394,0.00046284506,0.00090264593,0.00006265016,0.00011627752,0.00007538309,0.0000039920956,0.000073008334,0.000009253976],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974409,0.00017682255,0.0009733409,0.00068196916,0.00035948705,0.0003675066],"domain_scores_gemma":[0.9985009,0.000058301022,0.0005624137,0.00065151736,0.00013054164,0.00009635195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005485437,0.00043001783,0.00084376615,0.00036020274,0.000041293042,0.00004683361,0.00018298623,0.000338172,0.00011171368],"category_scores_gemma":[0.00013728318,0.00045732994,0.00013193325,0.00031241492,0.00013443377,0.00009364975,0.0002690626,0.00053816417,0.0000020712064],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073532807,0.000258932,0.091643825,0.0007727146,0.00011299758,0.000060901115,0.00004860976,0.000026718755,0.9062927,0.000006881108,0.000012206048,0.000028207702],"study_design_scores_gemma":[0.0021081208,0.000051229,0.52534497,0.0016183626,0.000044508997,1.4327071e-8,0.000004157675,0.00010632478,0.4703349,3.837802e-7,0.00013370434,0.0002533224],"about_ca_topic_score_codex":0.00039835705,"about_ca_topic_score_gemma":0.0000238434,"teacher_disagreement_score":0.4359578,"about_ca_system_score_codex":0.00049070816,"about_ca_system_score_gemma":0.0002626868,"threshold_uncertainty_score":0.99978787},"labels":[],"label_agreement":null},{"id":"W3184147678","doi":"10.3390/jpm11080749","title":"LAG-3 Expression Predicts Outcome in Stage II Colon Cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Personalized Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Colorectal cancer; Immunosurveillance; Medicine; Tumor-infiltrating lymphocytes; Cancer; Oncology; Internal medicine; Tumor microenvironment; Stage (stratigraphy); Tissue microarray; Biomarker; Immunohistochemistry; Pathology; Immunotherapy; Biology","score_opus":0.04795250333516122,"score_gpt":0.36893805524706663,"score_spread":0.3209855519119054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184147678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94193155,0.033002004,0.00006537239,0.022346692,0.0011088153,0.00018062168,0.00001274287,0.000012711962,0.0013395136],"genre_scores_gemma":[0.95635676,0.010027722,0.0007950671,0.0065950514,0.0015692895,0.000012824427,0.000016288563,0.000039316026,0.024587689],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978236,0.00009711849,0.0008709103,0.00017883067,0.00077498105,0.00025456966],"domain_scores_gemma":[0.998726,0.00009806243,0.0004376915,0.00017881171,0.00034256757,0.00021685085],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008575793,0.00017251141,0.00076269737,0.00024471278,0.00006319395,0.000006246938,0.00010351225,0.0001237763,0.005297596],"category_scores_gemma":[0.00037475282,0.00011484734,0.00019654643,0.00041183914,0.00016824371,0.00010848582,0.00003390352,0.00046606187,0.0000015176536],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009634747,0.00046861477,0.08871207,0.000378857,0.00028310798,0.002947753,0.005385526,0.000007761127,0.85788316,0.000036467743,0.026882181,0.0073797344],"study_design_scores_gemma":[0.068448894,0.0033892917,0.12753516,0.009084659,0.00052210735,0.001850991,0.006653071,0.00008620534,0.051188625,0.000053111522,0.730841,0.00034688943],"about_ca_topic_score_codex":0.000120706274,"about_ca_topic_score_gemma":0.00006684025,"teacher_disagreement_score":0.80669457,"about_ca_system_score_codex":0.0003445366,"about_ca_system_score_gemma":0.00058504037,"threshold_uncertainty_score":0.99561167},"labels":[],"label_agreement":null},{"id":"W3184251505","doi":"10.1016/j.cllc.2021.07.002","title":"Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non–Small Cell Lung Cancer: Results From a Phase 1b Trial","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche; Roche","keywords":"Atezolizumab; Medicine; Ipilimumab; Internal medicine; Tolerability; Lung cancer; Adverse effect; Oncology; Population; Common Terminology Criteria for Adverse Events; Cancer; Nivolumab; Immunotherapy","score_opus":0.05774961993168776,"score_gpt":0.4387506707119048,"score_spread":0.38100105078021707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184251505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98120165,0.0106182,0.00046647925,0.001534528,0.0022995966,0.0021454687,0.0012973632,0.00004065434,0.00039604362],"genre_scores_gemma":[0.9452883,0.048986245,0.0013615274,0.0012583046,0.0009029971,0.00018051495,0.00013631622,0.00007107502,0.0018147079],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943099,0.00064832426,0.0028802895,0.0012052563,0.00042734505,0.0005288921],"domain_scores_gemma":[0.9943683,0.0032934987,0.0008770983,0.0008132337,0.0002706991,0.00037717246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017157076,0.00040302527,0.002074182,0.000089252535,0.00007449672,0.00002686781,0.00022001873,0.0003945803,0.0005020007],"category_scores_gemma":[0.001241159,0.00032309012,0.00059406256,0.0005518882,0.0004538926,0.00013658765,0.00015808838,0.0009762831,0.0000020457999],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75424093,0.0034312776,0.0053568357,0.00036052504,0.0010305045,0.0003120193,0.00025574898,0.000043607215,0.0014633249,0.0000017579787,0.0009888354,0.23251462],"study_design_scores_gemma":[0.92360294,0.0050730756,0.03476788,0.0026128974,0.0022167347,0.000010999413,0.00020431068,0.017883534,0.0041194335,0.000017241533,0.008835979,0.00065496267],"about_ca_topic_score_codex":0.0027069561,"about_ca_topic_score_gemma":0.008422268,"teacher_disagreement_score":0.23185965,"about_ca_system_score_codex":0.0006121422,"about_ca_system_score_gemma":0.004781746,"threshold_uncertainty_score":0.9999221},"labels":[],"label_agreement":null},{"id":"W3185001536","doi":"10.3390/cancers13143596","title":"The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy","year":2021,"lang":"en","type":"review","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; Ted Rogers Centre for Heart Research; Queen's University","funders":"Natural Sciences and Engineering Research Council of Canada; Mitacs; Queen's University","keywords":"Immunotherapy; Immune system; Antigen; Cancer immunotherapy; Tumor microenvironment; Immunology; Cancer; Biology; Cancer research; Medicine; Internal medicine","score_opus":0.09459434894739228,"score_gpt":0.3696072190731526,"score_spread":0.2750128701257603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185001536","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020105639,0.99142677,0.0003540321,0.00040889857,0.0026995814,0.0027808265,0.00008796071,0.000102209124,0.00012918259],"genre_scores_gemma":[0.003227431,0.9926512,0.00021578291,0.00037589585,0.0004769551,0.00148031,0.0002498015,0.00032017732,0.0010024357],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952575,0.00038893826,0.002026887,0.00086608075,0.0007015273,0.0007590693],"domain_scores_gemma":[0.9967525,0.00026607723,0.0010558021,0.0013760848,0.0003969647,0.00015255554],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009211929,0.0008790267,0.0028481106,0.00034333282,0.00038520907,0.00015371336,0.0006634887,0.00054560427,0.00029601785],"category_scores_gemma":[0.000048931535,0.00066175626,0.0016631582,0.0015541087,0.00034916372,0.00014634355,0.00003973321,0.00071281765,0.0000070060278],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039126805,0.000043074724,0.000002364988,0.0014423378,0.0022784981,0.0000054288525,0.0014046634,0.000034007222,0.019344894,0.00007146713,0.00039067352,0.9745913],"study_design_scores_gemma":[0.0013230373,0.000520767,0.00005591133,0.013420262,0.00066212844,0.00003434685,0.00035453954,0.000038623453,0.0046216156,0.0000073331535,0.9782685,0.00069295836],"about_ca_topic_score_codex":0.0011989612,"about_ca_topic_score_gemma":0.00018939139,"teacher_disagreement_score":0.9778778,"about_ca_system_score_codex":0.0035239467,"about_ca_system_score_gemma":0.005961191,"threshold_uncertainty_score":0.9996741},"labels":[],"label_agreement":null},{"id":"W3186130481","doi":"10.1080/2162402x.2021.1952539","title":"Alternol triggers immunogenic cell death <i>via</i> reactive oxygen species generation","year":2021,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Immunogenic cell death; Calreticulin; Cancer research; Immune system; HMGB1; Cytokine; Prostate cancer; Immunology; Inflammation; T cell; Medicine; Cancer; Biology; Immunotherapy; Endoplasmic reticulum; Cell biology; Internal medicine","score_opus":0.030107106238168986,"score_gpt":0.26766494366361293,"score_spread":0.23755783742544395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186130481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9455748,0.02055221,0.0005641678,0.0020673366,0.0012242307,0.00035574497,0.00001957692,0.00011254203,0.029529346],"genre_scores_gemma":[0.9695583,0.004930233,0.0010736246,0.0018748763,0.0004386722,0.000053176114,0.0004048971,0.000050420862,0.021615798],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998422,0.00013947408,0.0004088596,0.0004397351,0.0001956329,0.00039428132],"domain_scores_gemma":[0.99891686,0.00006158912,0.00015902317,0.0006155482,0.00019112692,0.00005584159],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001750173,0.00023883668,0.00044948547,0.00011671673,0.00016481175,0.0000290519,0.00013503828,0.00024229898,0.0010809725],"category_scores_gemma":[0.00003257348,0.00022451076,0.00027833262,0.00029528042,0.00014289981,0.000108803564,0.0000660341,0.0003069529,0.00015879323],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011055438,0.0002663856,0.0006586384,0.000019434723,0.000434963,0.00017683365,0.00040045744,0.0000012668669,0.9754579,0.000091718066,0.0018479066,0.019538919],"study_design_scores_gemma":[0.0047569475,0.0006054537,0.023649935,0.000034989123,0.00017053843,0.00075079786,0.0004617692,0.000044375396,0.7621999,0.000057906534,0.2069939,0.00027352865],"about_ca_topic_score_codex":0.00018996182,"about_ca_topic_score_gemma":0.000045279106,"teacher_disagreement_score":0.21325807,"about_ca_system_score_codex":0.00041286892,"about_ca_system_score_gemma":0.00045797945,"threshold_uncertainty_score":0.99983215},"labels":[],"label_agreement":null},{"id":"W3186399754","doi":"10.1093/jcag/gwab019","title":"Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort","year":2021,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Calgary; University of Alberta","funders":"","keywords":"Cohort; Medicine; Oncology; Short course; Internal medicine; Pediatrics","score_opus":0.011302464517008769,"score_gpt":0.2766215427087699,"score_spread":0.2653190781917611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186399754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97277176,0.00020186928,0.00000673496,0.026354142,0.00036764183,0.00017981422,0.00006615499,0.000001629632,0.000050242408],"genre_scores_gemma":[0.9981774,0.0008617569,0.0001303527,0.0005812573,0.000058481568,0.000002791713,0.000020992113,0.0000064552905,0.00016051006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998543,0.00025896286,0.00080722565,0.00008020526,0.00016455218,0.00014600418],"domain_scores_gemma":[0.9976546,0.000113141374,0.0012741357,0.0001413487,0.0006865582,0.00013018075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069553417,0.000072785566,0.0004041526,0.00008598063,0.00005030572,0.000006039213,0.00006169515,0.000109079694,0.000041132567],"category_scores_gemma":[0.00037868065,0.000056370744,0.00024273522,0.00010543215,0.00008865059,0.000036418623,0.000011855607,0.00014455029,4.1773455e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004474656,0.0002752164,0.99286574,0.000009217127,0.0008435448,0.0000056698873,0.00012170579,0.0000014084796,0.0039379736,0.000008470914,0.0006784587,0.000805128],"study_design_scores_gemma":[0.00581391,0.0010099608,0.9908882,0.000076962184,0.00033172045,0.00009270623,0.00008067573,0.000029539327,0.0007350182,0.00001563719,0.0009017233,0.000023950974],"about_ca_topic_score_codex":0.004620724,"about_ca_topic_score_gemma":0.21310507,"teacher_disagreement_score":0.20848434,"about_ca_system_score_codex":0.00095300534,"about_ca_system_score_gemma":0.0008315683,"threshold_uncertainty_score":0.80125374},"labels":[],"label_agreement":null},{"id":"W3187242233","doi":"","title":"Genetic Mechanisms of Immune Evasion in Colorectal Cancer","year":2018,"lang":"en","type":"other","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Biology; Wnt signaling pathway; Loss of heterozygosity; Microsatellite instability; Cancer research; Immune system; Colorectal cancer; AXIN2; Genetics; Immunoediting; Gene; Cancer; Allele; Immunotherapy; Microsatellite","score_opus":0.011312036128388804,"score_gpt":0.2749449060744986,"score_spread":0.2636328699461098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187242233","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024735535,0.009520043,0.00035866836,0.00018186684,0.0012438142,0.0012740584,0.000037821555,0.000110971196,0.9625372],"genre_scores_gemma":[0.04861156,0.004417761,0.0027668786,0.00027072645,0.00032131444,0.000080652106,0.000023494893,0.00036066645,0.94314694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999175,0.000018827659,0.0002739735,0.00019960101,0.00018297922,0.00014963567],"domain_scores_gemma":[0.9996028,0.00000840094,0.00014775002,0.00018525544,0.000026144227,0.000029646728],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008615485,0.00016085249,0.0004026894,0.00024168394,0.000006614745,0.0000022680997,0.00008151369,0.0002700084,0.044576637],"category_scores_gemma":[0.000005319026,0.00012207858,0.000116469135,0.00017252553,0.00008439992,0.000005679792,0.000023626184,0.00007346341,0.00005612244],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025088198,0.00025148306,0.0013292566,0.0005592975,0.0005411217,0.000028776509,0.0001344944,1.78586e-7,0.65901476,0.000087226275,0.3090111,0.026533503],"study_design_scores_gemma":[0.012794453,0.002662801,0.067632824,0.0067030545,0.0003711425,0.00006323113,0.0002098709,0.00007837639,0.4595729,0.0002696225,0.44877595,0.00086575863],"about_ca_topic_score_codex":0.0072987163,"about_ca_topic_score_gemma":0.0030048029,"teacher_disagreement_score":0.19944182,"about_ca_system_score_codex":0.00009231567,"about_ca_system_score_gemma":0.00016173862,"threshold_uncertainty_score":0.99931175},"labels":[],"label_agreement":null},{"id":"W3189341011","doi":"10.1080/2162402x.2021.1956173","title":"Association of <i>PIK3CA</i> mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma","year":2021,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; Uehara Memorial Foundation; Stand Up To Cancer; National Institutes of Health; American Association for Cancer Research; Yasuda Memorial Medical Foundation; George W. Stone Family Foundation; Mitsukoshi Health and Welfare Foundation; Japan Society for the Promotion of Science; Dana-Farber/Harvard Cancer Center; Gary Bennett Family Fund; Dana-Farber Cancer Institute","keywords":"PTEN; Microsatellite instability; Cancer research; Medicine; Colorectal cancer; Oncology; Cancer; Immune checkpoint; KRAS; Internal medicine; Odds ratio; Immunotherapy; Biology; PI3K/AKT/mTOR pathway; Genetics; Signal transduction; Allele","score_opus":0.00587155657809464,"score_gpt":0.23575548685067801,"score_spread":0.2298839302725834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3189341011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961209,0.002108532,0.000016984946,0.0005963198,0.00007629487,0.00013648324,0.000008465294,0.000007662484,0.0009283095],"genre_scores_gemma":[0.99899817,0.0003061274,0.00027334693,0.000064581924,0.00001312856,0.000010912048,0.00003660611,0.000008717746,0.00028843744],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992687,0.00008649799,0.0002565591,0.00014580936,0.00012150482,0.00012091472],"domain_scores_gemma":[0.9994231,0.00010265007,0.0002101464,0.00011174935,0.00013831486,0.00001403147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016215997,0.00007642836,0.00029965225,0.0000830131,0.000016878395,0.000002419536,0.00003096703,0.00014306798,0.000060176466],"category_scores_gemma":[0.000059460162,0.00006458906,0.00003555163,0.00021399547,0.00010241312,0.000047979298,0.000023011571,0.00010799727,6.779529e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035681312,0.00013356072,0.30567232,0.00006328924,0.00007619315,0.000066050845,0.0009480896,0.000001237382,0.6846058,0.00001763594,0.000054912787,0.004792806],"study_design_scores_gemma":[0.004015433,0.0005761265,0.5951134,0.00012705555,0.000036048314,0.0001286125,0.0005392172,0.000011334356,0.39906725,0.000020497855,0.0003166983,0.00004835195],"about_ca_topic_score_codex":0.00029331146,"about_ca_topic_score_gemma":0.00026424616,"teacher_disagreement_score":0.28944105,"about_ca_system_score_codex":0.00012789831,"about_ca_system_score_gemma":0.00017251323,"threshold_uncertainty_score":0.26338655},"labels":[],"label_agreement":null},{"id":"W3189971813","doi":"10.1016/j.ejca.2021.05.040","title":"Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Foundation Medicine; Pharmacyclics; Chugai Pharmaceutical; Genentech; Sociedad Española de Oncología Médica; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Eisai; Cancer Research UK; Seagen; Cilag; Puma Biotechnology; Arog Pharmaceuticals; Eisai Canada; BeiGene; Clovis Oncology; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Ipsen; Array BioPharma; Mersana Therapeutics; Exelixis; Karyopharm Therapeutics; Symphogen; Pfizer; Incyte; Grifols; F. Hoffmann-La Roche; Amgen; Deciphera Pharmaceuticals; Takeda Oncology; Halozyme; Sanofi; GlaxoSmithKline; Celgene; Daiichi Sankyo Europe; Servier; Bayer; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Medicine; Cohort; Clinical endpoint; Oncology; Internal medicine; Confidence interval; Clinical trial; Surrogate endpoint","score_opus":0.10619197210280618,"score_gpt":0.4763975619444084,"score_spread":0.37020558984160223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3189971813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98608583,0.002976145,0.0021139223,0.0051001552,0.0025214574,0.00082774594,0.00015170082,0.000015879123,0.00020713553],"genre_scores_gemma":[0.9810453,0.0012377208,0.0056906,0.005740191,0.0052317306,0.000031534943,0.000020012394,0.00006768255,0.00093519344],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964481,0.0010228608,0.0017854816,0.00023233848,0.0002728286,0.0002383638],"domain_scores_gemma":[0.9973264,0.00042191258,0.00091871095,0.00014387298,0.0009429084,0.00024624408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038595165,0.00015407614,0.0007510419,0.00011571293,0.00005624579,0.000034997778,0.00008895859,0.00005192171,0.00034099],"category_scores_gemma":[0.0027580685,0.0001155409,0.00054508337,0.00024266954,0.000043466705,0.00007781513,0.000022581047,0.0003420887,0.0000068453232],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032051675,0.0026362017,0.00038108794,0.000029683128,0.0005836455,0.00026143022,0.00024658648,0.0000034869095,0.18020204,0.0000014941439,0.013803045,0.76979965],"study_design_scores_gemma":[0.06840702,0.051883712,0.0021625424,0.00040049542,0.0008105639,0.00029636078,0.00013814624,0.0001617992,0.017162465,0.0000046403065,0.8583926,0.00017963441],"about_ca_topic_score_codex":0.000006005892,"about_ca_topic_score_gemma":0.000026489717,"teacher_disagreement_score":0.8445896,"about_ca_system_score_codex":0.00023990647,"about_ca_system_score_gemma":0.0015171941,"threshold_uncertainty_score":0.4711621},"labels":[],"label_agreement":null},{"id":"W3190341154","doi":"10.1186/s40425-015-0078-9","title":"Pembrolizumab","year":2015,"lang":"id","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":222,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Pembrolizumab; Ipilimumab; Medicine; Melanoma; Oncology; Internal medicine; Lung cancer; Nivolumab; Cancer; Immunotherapy; Cancer research","score_opus":0.06837773108908334,"score_gpt":0.4185399310356333,"score_spread":0.35016219994654996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190341154","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025175625,0.9819048,0.00020078248,0.0006267632,0.012239202,0.002833716,0.0004822625,0.000030885098,0.0014298555],"genre_scores_gemma":[0.0000670943,0.9631194,0.000337382,0.00061048474,0.0041317614,0.00036422478,0.00007079106,0.00036137216,0.030937532],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99316406,0.00031512612,0.0033932189,0.00062066177,0.0013993917,0.0011075353],"domain_scores_gemma":[0.99221957,0.00030832321,0.0041760406,0.0009433979,0.0019184018,0.0004342696],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027139075,0.0012031596,0.0049776738,0.0007121284,0.00037382418,0.00015245509,0.0010355593,0.00096739625,0.0041538193],"category_scores_gemma":[0.00009385208,0.00090507296,0.00436433,0.0007122168,0.00046897834,0.00026207743,0.00004952221,0.0014394667,0.000041468124],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017773023,0.00035651907,0.000036546142,0.009335047,0.009563198,0.000018392624,0.0005486885,0.000003839438,0.0009640816,0.000029741952,0.052544426,0.9088265],"study_design_scores_gemma":[0.01926395,0.003299314,0.000069344205,0.029110536,0.0031593335,0.0007541437,0.00014315474,0.000008605199,0.00028787742,0.0001494502,0.94289696,0.00085733645],"about_ca_topic_score_codex":0.00020460617,"about_ca_topic_score_gemma":0.000024916937,"teacher_disagreement_score":0.9079692,"about_ca_system_score_codex":0.002357351,"about_ca_system_score_gemma":0.008113945,"threshold_uncertainty_score":0.99934},"labels":[],"label_agreement":null},{"id":"W3191482422","doi":"10.1038/s41467-021-25285-0","title":"Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Blockade; Melanoma; Cancer research; MAPK/ERK pathway; Medicine; Pharmacology; Signal transduction; Chemistry; Biology; Receptor; Cell biology; Internal medicine","score_opus":0.010558770397326004,"score_gpt":0.275234799033892,"score_spread":0.264676028636566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3191482422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99345964,0.0031979592,0.000034493565,0.0021941161,0.00010425111,0.0004388267,0.000010634136,0.000022389,0.0005377118],"genre_scores_gemma":[0.99579895,0.00017166624,0.0032027662,0.00017387817,0.000008447192,0.000050457096,0.0004531179,0.000015545747,0.00012516994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999098,0.000113557835,0.0002907344,0.00016273958,0.00022168242,0.00011329332],"domain_scores_gemma":[0.99870557,0.00011633745,0.00015355856,0.00065352104,0.0003415338,0.000029459039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015416017,0.000104135164,0.00020815845,0.00016169912,0.000066432105,0.000008454521,0.0001121959,0.0001656416,0.000027730532],"category_scores_gemma":[0.000060380575,0.00008976459,0.000038864397,0.0010381286,0.00008517345,0.0001056455,0.00003988024,0.00060835155,8.591292e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009938233,0.00514896,0.86836827,0.00014249237,0.00027489994,0.000022839,0.0022299157,0.00021132147,0.07962208,0.0006608734,0.0006549951,0.032725148],"study_design_scores_gemma":[0.01110431,0.0008347225,0.9413135,0.0011092563,0.000067523215,0.000018971941,0.0006741538,0.00023661427,0.04118733,0.000039344533,0.0032351143,0.0001791293],"about_ca_topic_score_codex":0.000049234124,"about_ca_topic_score_gemma":0.0018066834,"teacher_disagreement_score":0.07294529,"about_ca_system_score_codex":0.00022017465,"about_ca_system_score_gemma":0.00020097234,"threshold_uncertainty_score":0.36604935},"labels":[],"label_agreement":null},{"id":"W3193706729","doi":"10.21203/rs.2.12808/v1","title":"Association between PD-L1 expression and head and neck cancer prognosis: a meta-analysis","year":2019,"lang":"en","type":"preprint","venue":"Research Square (Research Square)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Natural Science Foundation of Zhejiang Province; Medical and Health Research Project of Zhejiang Province; Natural Science Foundation of Ningbo","keywords":"Medicine; Head and neck cancer; Internal medicine; Oncology; Cochrane Library; Meta-analysis; Hazard ratio; Cancer; Head and neck; Squamous cell cancer; Surgery; Confidence interval","score_opus":0.22824644807702435,"score_gpt":0.4821789945558114,"score_spread":0.25393254647878705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193706729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87537843,0.091729075,0.000073390285,0.021357508,0.00017006038,0.008673117,0.0013453717,0.00016880452,0.0011042383],"genre_scores_gemma":[0.9606983,0.024529602,0.00036708434,0.00012111725,0.0007473707,0.00354161,0.00063683104,0.00015032422,0.009207725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98248154,0.004264142,0.0011495232,0.0024136207,0.007342569,0.0023485993],"domain_scores_gemma":[0.98966545,0.0034198237,0.00042405218,0.0017988308,0.003723748,0.0009681018],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.017800435,0.00077483244,0.0030620752,0.0035343794,0.0008406344,0.0008826635,0.00072059385,0.0014453414,0.0019262001],"category_scores_gemma":[0.0016552925,0.0006048305,0.0016229025,0.003360466,0.00068905647,0.00030740656,0.002405083,0.0058195693,0.00006598487],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040713046,0.0007516981,0.7385949,0.008120988,0.19502027,0.000094380026,0.0028488596,0.000052908646,0.004645979,0.000023798413,0.033354066,0.012420824],"study_design_scores_gemma":[0.0067483084,0.0033537562,0.85665137,0.0033070294,0.06802808,0.000009458529,0.0019161764,0.0011513858,0.006921512,0.0009245121,0.049466953,0.0015214426],"about_ca_topic_score_codex":0.012946086,"about_ca_topic_score_gemma":0.0013690178,"teacher_disagreement_score":0.1269922,"about_ca_system_score_codex":0.0022201086,"about_ca_system_score_gemma":0.0020095226,"threshold_uncertainty_score":0.999851},"labels":[],"label_agreement":null},{"id":"W3194210289","doi":"10.1136/jitc-2021-003188","title":"Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EUSA Pharma; Ipsen; Pharmacyclics; Eisai; Incyte; Genentech; Les Laboratories Pierre Fabre; AstraZeneca; Pfizer; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Discontinuation; Adjuvant; Ipilimumab; Adverse effect; Oncology; Internal medicine; Proportional hazards model; Melanoma; Cancer; Immunotherapy","score_opus":0.03369585980913195,"score_gpt":0.35122985655377575,"score_spread":0.3175339967446438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194210289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9560984,0.0358874,0.0018865515,0.002906984,0.0012928635,0.0012291708,0.00042000652,0.000009999052,0.00026861535],"genre_scores_gemma":[0.9558552,0.028012164,0.005034252,0.00055292196,0.00047394718,0.00029308847,0.000083634804,0.00010741728,0.009587362],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99800205,0.000098471224,0.00066675077,0.00018349044,0.0008275417,0.00022172122],"domain_scores_gemma":[0.99669033,0.00028190258,0.0009227663,0.0002529088,0.0018044645,0.000047649006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022490316,0.00016699675,0.00064715877,0.00009820655,0.00013533127,0.000024475185,0.000103866245,0.00011321243,0.0003496663],"category_scores_gemma":[0.00020414354,0.00012484149,0.00028518523,0.00016511756,0.00006514484,0.0001417383,0.000011106742,0.00014345799,5.7360747e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06903238,0.0005327454,0.19367895,0.00057057774,0.007442035,0.000002895819,0.0022386054,0.00010451287,0.1136142,0.00021339483,0.00344473,0.60912496],"study_design_scores_gemma":[0.17164087,0.0051765516,0.62132436,0.0016168627,0.002152529,0.000071155315,0.0023167105,0.001252809,0.09345902,0.001198719,0.099150725,0.0006396712],"about_ca_topic_score_codex":0.00017425702,"about_ca_topic_score_gemma":0.00046985815,"teacher_disagreement_score":0.6084853,"about_ca_system_score_codex":0.0005698089,"about_ca_system_score_gemma":0.0010933978,"threshold_uncertainty_score":0.5090888},"labels":[],"label_agreement":null},{"id":"W3194415632","doi":"10.1136/gutjnl-2021-324420","title":"Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition","year":2021,"lang":"en","type":"article","venue":"Gut","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); University Health Network","funders":"National Medical Research Council; Associazione Italiana per la Ricerca sul Cancro; National Research Foundation Singapore; Duke-NUS Medical School","keywords":"Immune system; Immunotherapy; Cancer research; Tumor microenvironment; Immune checkpoint; Biology; Cancer; Epigenetics; Cancer immunotherapy; Immunology; Medicine; Gene; Genetics","score_opus":0.01435740946988463,"score_gpt":0.26664356598308303,"score_spread":0.2522861565131984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194415632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841674,0.0041391803,0.00023907195,0.009088908,0.0001342312,0.0003037239,0.0000075040857,0.000022079223,0.0018978748],"genre_scores_gemma":[0.99528325,0.00014387608,0.0019428509,0.00048000558,0.00012676,0.00004732921,0.00003686542,0.000014003312,0.0019250363],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99913377,0.000038645576,0.00033047926,0.00021208779,0.000113974005,0.00017102617],"domain_scores_gemma":[0.9996397,0.000017850343,0.000048739243,0.00018089914,0.00006473744,0.0000480603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021789852,0.000091397305,0.00016998853,0.000074803924,0.00006643709,0.00003354004,0.000023209228,0.000043880253,0.00012585231],"category_scores_gemma":[0.000079558726,0.000089826186,0.000050360515,0.00024378655,0.000030053176,0.000055736782,0.00003093247,0.000109974404,0.000014316662],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023026003,0.000056635166,0.00069705094,0.000072855975,0.000017094244,0.00007931578,0.001001383,0.0000012758321,0.99467313,0.000039643262,0.000106245476,0.0030251208],"study_design_scores_gemma":[0.0021941925,0.00012219601,0.36579514,0.0010595053,0.00002218734,0.00008642413,0.0005159377,0.000032694476,0.62509036,0.0002704904,0.0046479404,0.00016292268],"about_ca_topic_score_codex":0.0000818499,"about_ca_topic_score_gemma":0.00046952115,"teacher_disagreement_score":0.36958274,"about_ca_system_score_codex":0.00008613702,"about_ca_system_score_gemma":0.00007960249,"threshold_uncertainty_score":0.36630055},"labels":[],"label_agreement":null},{"id":"W3194598620","doi":"10.3390/curroncol28050280","title":"Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Fonds Wetenschappelijk Onderzoek; Ipsen; Kom op tegen Kanker; Pfizer","keywords":"Germline; CHEK2; Medicine; Germline mutation; Immune checkpoint; Somatic cell; Cancer research; DNA damage; Disease; Immune system; Mutation; Gene; Immunotherapy; Bioinformatics; Immunology; Genetics; Biology; DNA; Internal medicine","score_opus":0.05014658346155843,"score_gpt":0.35989197163927106,"score_spread":0.30974538817771263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194598620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993062,0.0038952217,0.0000058072137,0.0008048196,0.0014292382,0.0003541588,0.000050380968,0.00003521583,0.00036315527],"genre_scores_gemma":[0.9982654,0.0007755056,0.00015788198,0.00010185978,0.00013068569,0.000021944452,0.00013464785,0.000022766839,0.0003892958],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984526,0.0001433162,0.00064208824,0.00033411843,0.00017262957,0.00025523902],"domain_scores_gemma":[0.99899185,0.00011305817,0.00026657776,0.00025581097,0.0002664365,0.00010624522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032245484,0.0001924863,0.00051684113,0.00021634604,0.00008704002,0.000010204572,0.000046617824,0.00012588223,0.00015271321],"category_scores_gemma":[0.00029212702,0.00016878435,0.00013809856,0.00039654443,0.0002370302,0.00007234279,0.00007728771,0.00027111062,0.00000570207],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024638444,0.0052167256,0.08219419,0.0012514128,0.00062017445,0.0055867913,0.0047659664,0.0000046060704,0.48694515,0.00013206722,0.0018207799,0.3868237],"study_design_scores_gemma":[0.038187712,0.008422502,0.14948988,0.0017939903,0.00041122752,0.0081263175,0.002810896,0.00016172344,0.6114524,0.000053957545,0.1783728,0.0007166122],"about_ca_topic_score_codex":0.000039560236,"about_ca_topic_score_gemma":0.00004065704,"teacher_disagreement_score":0.3861071,"about_ca_system_score_codex":0.00025984648,"about_ca_system_score_gemma":0.0002655665,"threshold_uncertainty_score":0.6882826},"labels":[],"label_agreement":null},{"id":"W3194633883","doi":"10.1016/j.annonc.2021.06.012","title":"LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Medicine; TIGIT; Oncology; Esophageal cancer; Immunotherapy; Internal medicine; Cancer; Lung cancer; Pembrolizumab","score_opus":0.04275491701376318,"score_gpt":0.39406399826764876,"score_spread":0.3513090812538856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194633883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99760884,0.0004452782,0.000002632546,0.00085445546,0.000074128046,0.00075113797,0.000019905874,0.0000041285402,0.00023948192],"genre_scores_gemma":[0.99936336,0.00012925865,0.00003075266,0.00034026767,0.000006636006,0.000029023562,0.00002741836,0.0000123319605,0.000060963375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987404,0.00019952902,0.00040701625,0.0001970285,0.0002754184,0.00018062687],"domain_scores_gemma":[0.9991036,0.00005995681,0.00027264212,0.00023837319,0.00029846185,0.00002698899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021396129,0.0001148769,0.00051214104,0.00013751605,0.000021943044,0.000003618932,0.00008916306,0.000046572088,0.00007437579],"category_scores_gemma":[0.000027573378,0.00007290869,0.00004321725,0.00065779523,0.00013192273,0.000058565856,0.000027927395,0.00013469992,3.662563e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012521063,0.015539533,0.91977423,0.00011115815,0.00044522007,0.00016339101,0.002372699,0.000051671428,0.0014138215,0.000019118832,0.000119616474,0.04746845],"study_design_scores_gemma":[0.05133692,0.014154115,0.92803407,0.00022936979,0.000087795146,0.000008417771,0.00076587044,0.000029542216,0.0050431723,0.00001425937,0.00022015322,0.000076290395],"about_ca_topic_score_codex":0.0011213184,"about_ca_topic_score_gemma":0.0025952503,"teacher_disagreement_score":0.04739216,"about_ca_system_score_codex":0.00007847723,"about_ca_system_score_gemma":0.0005305675,"threshold_uncertainty_score":0.29731303},"labels":[],"label_agreement":null},{"id":"W3194791464","doi":"10.1097/der.0000000000000776","title":"Systemic Treatment of Cutaneous Adverse Events after Immune Checkpoint Inhibitor Therapy: A Review","year":2021,"lang":"en","type":"review","venue":"Dermatitis","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Adverse effect; Dermatology; Intensive care medicine; Internal medicine","score_opus":0.027250660614570626,"score_gpt":0.3105022867244809,"score_spread":0.2832516261099103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194791464","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010944917,0.9958146,0.0000024392546,0.00018451182,0.00048196185,0.002925583,0.0002253609,0.000038509752,0.0002175876],"genre_scores_gemma":[0.000112306945,0.9965388,0.00007012263,0.0005679892,0.00017756186,0.00090838876,0.000507989,0.000081975464,0.0010348415],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99715215,0.00024813725,0.0016004466,0.00037732115,0.00035327958,0.00026866226],"domain_scores_gemma":[0.99812835,0.000064238375,0.0007417032,0.00084997725,0.000119809854,0.00009593525],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012036447,0.0005565128,0.0036308554,0.00014290826,0.000031189047,0.0000054952175,0.00012011153,0.0002592179,0.0012574653],"category_scores_gemma":[0.000019000545,0.0003849092,0.0021966482,0.0003726171,0.000056002344,0.000041400723,0.0000303978,0.00014581573,0.00009867614],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039152343,0.00024973907,0.0000114968125,0.12647022,0.0016075248,0.00084586267,0.00012543745,9.072235e-9,0.000010885831,4.369371e-7,0.0009669996,0.86967224],"study_design_scores_gemma":[0.00093510305,0.00027444406,0.000021612934,0.30286235,0.0014497723,0.0069019715,0.000012453318,1.641718e-7,0.00005529974,2.8861547e-7,0.68727124,0.00021533135],"about_ca_topic_score_codex":0.000108198365,"about_ca_topic_score_gemma":0.000005847824,"teacher_disagreement_score":0.8694569,"about_ca_system_score_codex":0.00061771635,"about_ca_system_score_gemma":0.0006184366,"threshold_uncertainty_score":0.9998603},"labels":[],"label_agreement":null},{"id":"W3194855235","doi":"10.3390/curroncol28050283","title":"Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Observational study; Immune system; Intensive care medicine; Bioinformatics; Internal medicine; Oncology; Immunology; Biology","score_opus":0.15159972648987305,"score_gpt":0.4132243789306086,"score_spread":0.2616246524407355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194855235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958249,0.0016547247,0.000009506911,0.00048808075,0.0011552155,0.00044663547,0.000012414153,0.0000115901275,0.00039694775],"genre_scores_gemma":[0.99925214,0.00018038398,0.00010212028,0.00007004878,0.00010088364,0.000032147167,0.00020610703,0.0000091126685,0.00004704476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858415,0.00015225018,0.00070919935,0.00021544116,0.00018991403,0.00014905112],"domain_scores_gemma":[0.9992652,0.000057443267,0.0001650516,0.00021778351,0.0002478802,0.00004664915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036926992,0.00009819115,0.00034292205,0.00008655021,0.000025274863,0.0000032096482,0.00006296777,0.000072315124,0.00029965024],"category_scores_gemma":[0.00011476112,0.000089506495,0.00009915538,0.00031476837,0.000065799424,0.00006716961,0.00004030438,0.00018270602,0.0000031718457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00211532,0.008807205,0.75831544,0.000053963566,0.000069773116,0.000016245016,0.0016263074,0.0000016930992,0.006314955,0.000029078095,0.00015902692,0.22249103],"study_design_scores_gemma":[0.010201468,0.003208531,0.95219564,0.00009887049,0.000034499102,0.000005041836,0.001417508,0.000017516279,0.0021013075,0.000028193246,0.030607847,0.00008355555],"about_ca_topic_score_codex":0.000079075035,"about_ca_topic_score_gemma":0.0002948183,"teacher_disagreement_score":0.22240746,"about_ca_system_score_codex":0.00029773792,"about_ca_system_score_gemma":0.000466362,"threshold_uncertainty_score":0.3649969},"labels":[],"label_agreement":null},{"id":"W3195094572","doi":"10.1016/j.celrep.2021.109599","title":"Evaluating the impact of age on immune checkpoint therapy biomarkers","year":2021,"lang":"en","type":"article","venue":"Cell Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institute on Aging; National Institutes of Health; Calgary Laboratory Services; Lustgarten Foundation","keywords":"Immune checkpoint; Immune system; Blockade; Immunotherapy; Medicine; Methylation; Oncology; DNA methylation; Bioinformatics; Cancer; Immunology; Cancer research; Biology; Internal medicine; Receptor; Gene; Gene expression; Genetics","score_opus":0.054923912368986035,"score_gpt":0.36773447685415406,"score_spread":0.31281056448516803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195094572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749172,0.0060464293,0.0000054281672,0.00028695638,0.00028047775,0.00035022007,0.000001730525,0.000023684464,0.018087922],"genre_scores_gemma":[0.99674845,0.0005853645,0.00014248338,0.00013408584,0.000071312126,0.000015540245,0.000027462223,0.000024478903,0.002250816],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985344,0.0000855218,0.00056543486,0.00026206506,0.00035151743,0.00020107297],"domain_scores_gemma":[0.99853987,0.000087742796,0.00037219175,0.0008133656,0.00013316782,0.000053678086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009936122,0.000154927,0.00029298145,0.000049512615,0.000072058,0.000018107143,0.0000559247,0.00006887414,0.0009015491],"category_scores_gemma":[0.00012717056,0.00008825259,0.00055370666,0.00029651236,0.000105576386,0.000023823479,0.000023839943,0.00013776917,0.00000390695],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012953669,0.00024864814,0.0024648774,0.000026915091,0.00038773817,0.0009845713,0.00039710783,0.000021810127,0.9576824,8.0587165e-7,0.0006308688,0.035858918],"study_design_scores_gemma":[0.0016198703,0.001338224,0.14201526,0.00015654342,0.000049800215,0.00071466283,0.00022234,0.00006703435,0.8521088,0.00007585447,0.0015083605,0.00012327278],"about_ca_topic_score_codex":0.00037918752,"about_ca_topic_score_gemma":0.0000024754877,"teacher_disagreement_score":0.13955039,"about_ca_system_score_codex":0.000121710684,"about_ca_system_score_gemma":0.00047045897,"threshold_uncertainty_score":0.987133},"labels":[],"label_agreement":null},{"id":"W3195489010","doi":"10.1055/s-0041-1723292","title":"CheckMate 77 T: A phase 3 trial of neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) followed by adjuvant NIVO in resectable early-stage non-small cell lung cancer (NSCLC)","year":2021,"lang":"en","type":"article","venue":"Pneumologie","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Nivolumab; Oncology; Internal medicine; Adjuvant; Stage (stratigraphy); Chemotherapy; Lung cancer; Randomized controlled trial; Neoadjuvant therapy; Cancer; Immunotherapy; Breast cancer","score_opus":0.022374330748294077,"score_gpt":0.31817262308544947,"score_spread":0.2957982923371554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195489010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98354274,0.009710527,0.00010090602,0.0014108638,0.00078288105,0.0015311203,0.00017657853,0.00008999217,0.0026543825],"genre_scores_gemma":[0.98139256,0.0058969297,0.00035998443,0.000813194,0.00018588353,0.0002646855,0.00009658153,0.00009615164,0.01089401],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967946,0.00014812428,0.0009382939,0.0007988045,0.00045798882,0.00086218497],"domain_scores_gemma":[0.9982652,0.00014893856,0.00038359987,0.00084149936,0.00018822719,0.00017251747],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00061487645,0.00045334097,0.0011661506,0.00019961144,0.000083332176,0.000039904204,0.00033865048,0.0003583016,0.0010765628],"category_scores_gemma":[0.00010888378,0.00041361203,0.0004307028,0.0007839808,0.00016298814,0.00012605499,0.0001085665,0.00049674115,0.000009265124],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08286582,0.002064928,0.008968213,0.00040454642,0.0002586142,0.0004941485,0.00085456436,0.000007462714,0.8890697,0.0000020979305,0.0048986054,0.010111333],"study_design_scores_gemma":[0.22282337,0.0020415194,0.0039132563,0.0005053858,0.00015401801,0.000023683491,0.00038860136,0.00049295515,0.7607773,0.000012946043,0.008346101,0.0005208618],"about_ca_topic_score_codex":0.0041079163,"about_ca_topic_score_gemma":0.00048661514,"teacher_disagreement_score":0.13995755,"about_ca_system_score_codex":0.0005040794,"about_ca_system_score_gemma":0.0011359153,"threshold_uncertainty_score":0.99983656},"labels":[],"label_agreement":null},{"id":"W3195636258","doi":"10.1111/bjh.17789","title":"Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target","year":2021,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"Snowdome Foundation; Peter MacCallum Cancer Centre","keywords":"Lymphoma; Immune checkpoint; Immune system; Cancer research; Follicular lymphoma; Context (archaeology); T cell; Immunohistochemistry; Immunology; Biology; Medicine; Immunotherapy","score_opus":0.00913646912819125,"score_gpt":0.25974973975312615,"score_spread":0.2506132706249349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195636258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757072,0.022152549,0.000115684525,0.0012536689,0.0005683266,0.00009551043,0.000005409014,0.0000048260317,0.000096837204],"genre_scores_gemma":[0.9973851,0.0017926978,0.00022926717,0.00031222883,0.000042455817,0.000002750122,0.000013211755,0.000014364767,0.00020793827],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.99842846,0.00014791227,0.0009019085,0.00012111765,0.00022506894,0.00017555579],"domain_scores_gemma":[0.9990777,0.00003305319,0.00047893185,0.000117662494,0.00025004568,0.00004261359],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043217637,0.000088301975,0.00066808483,0.00017119401,0.00002745615,0.000023979786,0.000092603485,0.00012078366,0.00093525345],"category_scores_gemma":[0.00008946162,0.000097811586,0.00024392053,0.00019630948,0.000110951376,0.00014913444,0.000025291498,0.00024437785,0.000008255622],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032237407,0.0010357072,0.012787296,0.00046920462,0.001205189,0.22036994,0.0008469954,0.0000034415875,0.7273219,0.000050221654,0.00039810917,0.032288242],"study_design_scores_gemma":[0.0031863516,0.00024494002,0.40015835,0.0007151732,0.000083575724,0.5524667,0.0003265362,0.000007738815,0.041854106,0.0005655638,0.0003108817,0.000080110534],"about_ca_topic_score_codex":0.00013416502,"about_ca_topic_score_gemma":0.00004096652,"teacher_disagreement_score":0.68546784,"about_ca_system_score_codex":0.00004456274,"about_ca_system_score_gemma":0.00022016029,"threshold_uncertainty_score":0.999978},"labels":[],"label_agreement":null},{"id":"W3195751328","doi":"10.1136/jitc-2021-002973","title":"Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health; National Center for Advancing Translational Sciences; AstraZeneca; National Cancer Institute; Foundation for the National Institutes of Health","keywords":"Durvalumab; Tremelimumab; Medicine; Lung cancer; PD-L1; Internal medicine; Oncology; Squamous cell cancer; Cancer; Immunotherapy; Nivolumab","score_opus":0.016859926611319694,"score_gpt":0.3365914877365322,"score_spread":0.3197315611252125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195751328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9142769,0.076970674,0.00011518814,0.0003454409,0.0009489424,0.0066454853,0.0005954667,0.000045496694,0.000056381745],"genre_scores_gemma":[0.97876096,0.014178917,0.000239404,0.00040287973,0.00027021227,0.0009655195,0.00009364951,0.0002458221,0.0048426283],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950354,0.0002266205,0.0018725483,0.00074961846,0.0012386434,0.00087713054],"domain_scores_gemma":[0.99454635,0.0002403029,0.0018657267,0.0008848711,0.002243899,0.00021887365],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00074981333,0.0007603263,0.0018789887,0.00037705497,0.0006617508,0.000085480446,0.00044570287,0.00023074518,0.0011506474],"category_scores_gemma":[0.00003825071,0.00056464056,0.0008466098,0.0007054278,0.00018944565,0.0002994328,0.00003653026,0.00042816324,3.5203456e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5794823,0.03741722,0.080912754,0.0017593218,0.011776492,0.00008401699,0.018468097,0.00031963072,0.21419667,0.0000075373614,0.004895318,0.050680645],"study_design_scores_gemma":[0.61313194,0.12513939,0.06576171,0.0021318793,0.0030215846,0.00003498203,0.005752743,0.0005245071,0.13083808,0.000019852918,0.052021507,0.0016218312],"about_ca_topic_score_codex":0.0018087917,"about_ca_topic_score_gemma":0.00081368245,"teacher_disagreement_score":0.08772217,"about_ca_system_score_codex":0.0011481426,"about_ca_system_score_gemma":0.0023248317,"threshold_uncertainty_score":0.9997624},"labels":[],"label_agreement":null},{"id":"W3196898938","doi":"10.1016/j.annonc.2021.08.2151","title":"Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute, Cairo University; Fiona and Stanley Druckenmiller Center for Lung Cancer Research; Parker Institute for Cancer Immunotherapy; National Cancer Institute; Damon Runyon Cancer Research Foundation","keywords":"Medicine; Blockade; Immunotherapy; Clinical trial; Lung cancer; Oncology; Cancer; Disease; Internal medicine; Receptor","score_opus":0.07092507640607015,"score_gpt":0.3939201297053346,"score_spread":0.3229950532992644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196898938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918396,0.0028120088,0.00007969408,0.0021127209,0.00014129697,0.00041238952,0.000034108696,0.000004894204,0.0025632752],"genre_scores_gemma":[0.9880902,0.0023958343,0.005163957,0.003990315,0.000025281759,0.000049399285,0.00003028578,0.000018096936,0.00023659617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986112,0.0001494693,0.00065998983,0.00022026032,0.0001631252,0.00019592754],"domain_scores_gemma":[0.99879736,0.00017865913,0.00028713368,0.00025482802,0.000426075,0.000055928802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004358231,0.000107926615,0.0005942288,0.00010460175,0.000015011076,0.0000022938118,0.00007759835,0.0000886095,0.00018547528],"category_scores_gemma":[0.000047997055,0.00009044359,0.00011980954,0.00037537378,0.00010190727,0.00003458717,0.00001863317,0.00006701776,0.0000014659964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06399897,0.0051958347,0.8172999,0.00068024226,0.0010954762,0.000094685114,0.0015507673,0.00001232883,0.029267346,0.000080794845,0.006629997,0.074093655],"study_design_scores_gemma":[0.016121913,0.0046305275,0.9454108,0.0005924973,0.00009807263,0.0000018288297,0.00017144125,0.000004653836,0.023938034,0.000066347566,0.008820596,0.00014327891],"about_ca_topic_score_codex":0.00014115557,"about_ca_topic_score_gemma":0.0007950891,"teacher_disagreement_score":0.12811092,"about_ca_system_score_codex":0.000057676647,"about_ca_system_score_gemma":0.00065698544,"threshold_uncertainty_score":0.36881825},"labels":[],"label_agreement":null},{"id":"W3197128913","doi":"10.1159/000518313","title":"Skin Deep: A Fascinating Case Report of Immunotherapy-Triggered, Treatment-Refractory Autoimmune Lichen Planus and Keratoacanthoma","year":2021,"lang":"en","type":"article","venue":"Case Reports in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre; London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Dermatology; Pembrolizumab; Refractory (planetary science); Keratoacanthoma; Prednisone; Immunotherapy; Surgery; Internal medicine; Cancer","score_opus":0.020044679355887086,"score_gpt":0.32523013922087035,"score_spread":0.30518545986498324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197128913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97202015,0.023713285,0.00002681764,0.00031056086,0.00049307506,0.0004927306,0.000010266243,0.000041972107,0.0028911713],"genre_scores_gemma":[0.9954894,0.0017211129,0.0013618981,0.00018520381,0.00010153466,0.000082850034,0.000053200936,0.000041131425,0.0009636615],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99725354,0.00021193564,0.001420392,0.00058441743,0.00017166078,0.00035806594],"domain_scores_gemma":[0.997818,0.00035033267,0.0007938673,0.00073880266,0.0001871483,0.00011183423],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008785257,0.00027818262,0.00095513026,0.00023337727,0.00011426547,0.000015961814,0.00002590817,0.00034384287,0.0002742003],"category_scores_gemma":[0.00030091117,0.0002463291,0.00019827529,0.00037953397,0.0002489521,0.000079278805,0.000050453855,0.00026358233,6.517775e-7],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069096236,0.0006015266,0.0047949404,0.00006653743,0.00034050897,0.7556586,0.001736221,0.0000015336116,0.02278171,0.000005105271,0.00004906618,0.21327327],"study_design_scores_gemma":[0.0045304894,0.0011187777,0.004367066,0.0001388851,0.00013358705,0.9382605,0.0027161012,0.000054736392,0.014432381,0.000023331433,0.03401964,0.00020453657],"about_ca_topic_score_codex":0.0031815972,"about_ca_topic_score_gemma":0.0019364427,"teacher_disagreement_score":0.21306872,"about_ca_system_score_codex":0.00090265594,"about_ca_system_score_gemma":0.0012986182,"threshold_uncertainty_score":0.99999887},"labels":[],"label_agreement":null},{"id":"W3197498721","doi":"10.1158/1078-0432.ccr-21-0261","title":"Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company","keywords":"Antibody; Cancer; Combination therapy; Microsatellite; Immunotherapy; Clinical trial","score_opus":0.05442876539091771,"score_gpt":0.44188418583987726,"score_spread":0.38745542044895953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197498721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965103,0.0008432282,0.000020052748,0.00097369635,0.000079225494,0.0013575116,0.00004809286,0.000024093206,0.00014378168],"genre_scores_gemma":[0.99572265,0.0035026048,0.00020850718,0.00017998129,0.000027327056,0.000035300538,0.000094077346,0.00003800133,0.00019152461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961414,0.0007147439,0.0008884938,0.0008183777,0.0009151222,0.0005218854],"domain_scores_gemma":[0.99773073,0.0006005766,0.00019673302,0.00061405386,0.0006985078,0.00015939628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028882362,0.00022447265,0.00086405076,0.00029476872,0.00009386234,0.000034875764,0.00014112663,0.00017028493,0.00019611215],"category_scores_gemma":[0.00031203887,0.00015525639,0.00009818825,0.0017399102,0.00096154644,0.00016514218,0.00009748605,0.0008284141,0.0000021442006],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.109439075,0.0032885144,0.86147994,0.00036277558,0.00011058915,0.00013554902,0.00035819298,0.000007749352,0.010356427,0.00003006306,0.000010415239,0.014420721],"study_design_scores_gemma":[0.021469865,0.0047164815,0.96311647,0.0015994108,0.000018696779,0.000008885331,0.0002461072,0.00009517681,0.007890589,0.000023139848,0.000620967,0.00019421618],"about_ca_topic_score_codex":0.0041910363,"about_ca_topic_score_gemma":0.0021791705,"teacher_disagreement_score":0.10163654,"about_ca_system_score_codex":0.0003595045,"about_ca_system_score_gemma":0.0015541697,"threshold_uncertainty_score":0.6335621},"labels":[],"label_agreement":null},{"id":"W3198525580","doi":"10.1136/jitc-2021-002876","title":"Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Associazione Italiana per la Ricerca sul Cancro; Ministero della Salute","keywords":"Tumor microenvironment; Cancer research; Immune system; Pancreatic cancer; Medicine; Cancer; Immunotherapy; TLR9; Immunology; Internal medicine; Biology","score_opus":0.014385650407572545,"score_gpt":0.3010974693788345,"score_spread":0.28671181897126197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198525580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98558813,0.012417121,0.00018854403,0.0008695541,0.00015230088,0.00071550015,0.00005560552,0.00000481481,0.000008397979],"genre_scores_gemma":[0.98138523,0.017961139,0.00028148518,0.00012384255,0.000040425763,0.00009018827,0.000016696942,0.00002821241,0.00007277009],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987719,0.00012340603,0.00047639417,0.00021855383,0.00021117528,0.00019856954],"domain_scores_gemma":[0.99921274,0.000039004164,0.00035447662,0.00013313348,0.00021974415,0.00004088612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027634177,0.00018982358,0.00056460855,0.0001831186,0.00009250905,0.00003295744,0.00005076692,0.000078295714,0.00008290227],"category_scores_gemma":[0.000009886398,0.00015388046,0.000082081,0.00030502485,0.00020326262,0.00035097892,0.0000052592036,0.0002331179,3.5261767e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013148651,0.0008538845,0.040030707,0.0002442123,0.00039430233,0.000020997802,0.003217109,0.00024967344,0.9194234,0.0000072837015,0.000008532342,0.022401238],"study_design_scores_gemma":[0.011180942,0.0025251335,0.43690553,0.0014131129,0.00009467987,0.00020358167,0.0008740141,0.00025464693,0.54624814,0.000028049948,0.00011540547,0.00015673295],"about_ca_topic_score_codex":0.0022174348,"about_ca_topic_score_gemma":0.0022381903,"teacher_disagreement_score":0.39687485,"about_ca_system_score_codex":0.00038797728,"about_ca_system_score_gemma":0.0005475415,"threshold_uncertainty_score":0.6275063},"labels":[],"label_agreement":null},{"id":"W3198818236","doi":"10.3390/ijms22179550","title":"The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer","year":2021,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"Prostate cancer; Immunotherapy; Immune system; Tumor microenvironment; Somatic cell; Cancer; PTEN; Cancer research; Biology; Cancer immunotherapy; Immunology; Medicine; Gene; Genetics; PI3K/AKT/mTOR pathway; Signal transduction","score_opus":0.01772058643760874,"score_gpt":0.33088773094572865,"score_spread":0.3131671445081199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198818236","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.080061756,0.9162541,0.0000019556162,0.0029991167,0.00032927038,0.00028023822,0.000016756156,4.989794e-7,0.00005632085],"genre_scores_gemma":[0.09379643,0.9058961,0.000047989965,0.00014089752,0.000025758678,0.000021587603,8.936781e-7,0.000007567129,0.00006276473],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977458,0.00041654398,0.0007701946,0.00009643355,0.000876627,0.00009439475],"domain_scores_gemma":[0.9980394,0.00048392316,0.0011549105,0.00017825501,0.0001269892,0.0000164787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016407623,0.000108456574,0.00037611782,0.00013924965,0.00006814588,0.000032526,0.00077104225,0.000022951592,0.000046637553],"category_scores_gemma":[0.0002372041,0.00004394335,0.00045772427,0.00028328696,0.00053694216,0.000030115478,0.00006735749,0.0002146073,5.6694694e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014873355,0.00044400734,0.00036990302,0.00045239835,0.0019747957,0.00019866433,0.0015374549,0.0003182849,0.054871902,0.00073405873,0.00006742603,0.93754375],"study_design_scores_gemma":[0.0025456778,0.0012413918,0.009725489,0.101407945,0.001114515,0.0021066002,0.005368166,0.00010316459,0.1182629,0.00091136596,0.7568154,0.0003974178],"about_ca_topic_score_codex":0.000042770847,"about_ca_topic_score_gemma":0.000007091723,"teacher_disagreement_score":0.93714637,"about_ca_system_score_codex":0.00017753003,"about_ca_system_score_gemma":0.001122496,"threshold_uncertainty_score":0.19912596},"labels":[],"label_agreement":null},{"id":"W3199134341","doi":"10.1200/jco.2020.39.28_suppl.303","title":"Impact of antibiotic (ATB) exposure prior to immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre","funders":"Conquer Cancer Foundation","keywords":"Medicine; Pembrolizumab; Internal medicine; Ipilimumab; Cohort; Proportional hazards model; Hazard ratio; Population; Cancer; Nivolumab; Retrospective cohort study; Oncology; Immunotherapy; Confidence interval","score_opus":0.09860802118991938,"score_gpt":0.4615979562461227,"score_spread":0.36298993505620336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199134341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942908,0.0003802187,0.000013448298,0.0032332754,0.001400218,0.0004595611,0.000011246578,0.00000734988,0.00020382598],"genre_scores_gemma":[0.9977082,0.000114505005,0.0006177885,0.00053529005,0.0007740772,0.000002070345,0.000009126816,0.000021427451,0.00021748511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955753,0.00061255344,0.0028869803,0.00023855554,0.0004607177,0.000225875],"domain_scores_gemma":[0.99611443,0.0012743408,0.0014995877,0.00034778987,0.0004731342,0.00029070445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002041198,0.00020420474,0.0019035627,0.00016455707,0.000037904123,0.000009932159,0.00010639021,0.0002591499,0.00035601566],"category_scores_gemma":[0.0015110702,0.0001304416,0.0014926104,0.00023052032,0.00005924891,0.00004527308,0.000024655808,0.000411756,0.0000073644196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06995694,0.01952595,0.8029307,0.00003487881,0.002307497,0.0009576679,0.00029717723,0.00020526738,0.024940152,0.0000036148808,0.00021977803,0.07862036],"study_design_scores_gemma":[0.025906095,0.1103113,0.85966986,0.00022705761,0.00034333926,0.000054564644,0.00017129275,0.00001396572,0.002493473,0.000006422406,0.00070379284,0.00009886071],"about_ca_topic_score_codex":0.0003744012,"about_ca_topic_score_gemma":0.00020086349,"teacher_disagreement_score":0.09078535,"about_ca_system_score_codex":0.0008106908,"about_ca_system_score_gemma":0.0028636388,"threshold_uncertainty_score":0.5319254},"labels":[],"label_agreement":null},{"id":"W3199590448","doi":"10.1200/jco.2020.39.28_suppl.296","title":"Real-world trends in EU4 and the UK in frontline (1L) maintenance (MT) for nonsquamous (NSQ) advanced non-small cell lung cancer (aNSCLC) without actionable mutations after introduction of immune checkpoint inhibitors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Pemetrexed; Lung cancer; Medicine; Internal medicine; Oncology; Pembrolizumab; Tumor microenvironment; Cancer; Chemotherapy; Immunotherapy; Cisplatin","score_opus":0.025836235520329928,"score_gpt":0.3920085313243367,"score_spread":0.3661722958040068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199590448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9712362,0.0035958136,0.000297177,0.022505527,0.0014626379,0.00039608256,0.000012349029,0.0000034564937,0.0004907225],"genre_scores_gemma":[0.9855301,0.004976702,0.004996859,0.0004806923,0.0011186965,0.00009084865,0.000011237201,0.000019222556,0.002775638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99653983,0.00024837593,0.0025830113,0.00023616332,0.00016732489,0.00022528793],"domain_scores_gemma":[0.99707115,0.00080030476,0.0014186208,0.0001890119,0.00043856696,0.0000823447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028438508,0.0001418041,0.0012046928,0.00025664305,0.000033179673,0.0000074294758,0.00007933025,0.0001906738,0.00018327877],"category_scores_gemma":[0.0006256095,0.00009539025,0.00042858714,0.0004376415,0.00029708314,0.000100806654,0.000030188476,0.0006889839,2.665458e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30157873,0.004461191,0.36091205,0.00058938726,0.001059491,0.00033848226,0.0029261904,0.0014118361,0.08248691,0.00008220459,0.006218988,0.23793456],"study_design_scores_gemma":[0.07188872,0.0026273027,0.8896117,0.00055149535,0.00049820467,0.0001325767,0.0009877189,0.0014984446,0.009041206,0.00018914598,0.022783754,0.00018970847],"about_ca_topic_score_codex":0.00081019534,"about_ca_topic_score_gemma":0.012281294,"teacher_disagreement_score":0.5286997,"about_ca_system_score_codex":0.00041559094,"about_ca_system_score_gemma":0.0011369808,"threshold_uncertainty_score":0.685325},"labels":[],"label_agreement":null},{"id":"W3199883623","doi":"10.21203/rs.3.rs-847464/v1","title":"Tumor-Immune Partitioning and Clustering (TIPC): an algorithm for identifying tumor-immune cell spatial interaction signatures within the tumor microenvironment","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Gary Bennett Family Fund; National Institutes of Health; Cancer Research UK; Mitsukoshi Health and Welfare Foundation; Uehara Memorial Foundation; Stand Up To Cancer; Entertainment Industry Foundation; Japan Society for the Promotion of Science; American Association for Cancer Research","keywords":"Immune system; Cluster analysis; Tumor microenvironment; Computer science; Computational biology; Biology; Algorithm; Immunology; Artificial intelligence","score_opus":0.05054255496665394,"score_gpt":0.36712965920853674,"score_spread":0.3165871042418828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199883623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9569359,0.02200388,0.013843622,0.00094782276,0.0015144788,0.004361165,0.00016261473,0.000106694824,0.00012381161],"genre_scores_gemma":[0.9922542,0.0006892343,0.004039758,0.0002043292,0.0007281767,0.0008993679,0.00071870914,0.000119643184,0.00034656536],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995754,0.0006501576,0.00084698125,0.0009919743,0.0010138395,0.0007430692],"domain_scores_gemma":[0.9977448,0.00036727398,0.00041016986,0.00096500845,0.0003180199,0.00019472234],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002745461,0.00045220405,0.0006555368,0.00033032615,0.00085233705,0.0007472182,0.00038466882,0.00018994402,0.00026576524],"category_scores_gemma":[0.00016193371,0.0003705891,0.00036806092,0.00022775195,0.00037296364,0.00023697609,0.0010030696,0.0023461233,0.0000063642033],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065041073,0.0012007545,0.0011521201,0.008926444,0.0010482887,0.00095591997,0.0102297,0.0016803892,0.8815423,0.000011178504,0.00051819766,0.08623058],"study_design_scores_gemma":[0.010816171,0.0035634367,0.07703505,0.020817438,0.00056924846,0.0009807124,0.058322538,0.1653621,0.6544914,0.0003035508,0.005903195,0.0018351387],"about_ca_topic_score_codex":0.0034227245,"about_ca_topic_score_gemma":0.0006116856,"teacher_disagreement_score":0.2270509,"about_ca_system_score_codex":0.0007303502,"about_ca_system_score_gemma":0.00040401146,"threshold_uncertainty_score":0.9999555},"labels":[],"label_agreement":null},{"id":"W3200214671","doi":"10.1016/j.annonc.2021.09.021","title":"Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; Fonds de Recherche du Québec - Santé; University of Texas MD Anderson Cancer Center; EMD Serono; Genentech; Astellas Pharma; Ribon Therapeutics; National Institutes of Health; Innovent Biologics; Sanofi; Exelixis; GlaxoSmithKline; Society for Immunotherapy of Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Tumor-infiltrating lymphocytes; Medicine; Flow cytometry; CD8; Cancer research; CD3; Pathology; Lung cancer; T cell; Immune system; Immunology","score_opus":0.05903546487884821,"score_gpt":0.39262687515047506,"score_spread":0.33359141027162686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200214671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99140763,0.002376054,0.00001850687,0.0027807502,0.00020026979,0.00024248028,0.0000323977,0.000021846143,0.0029200534],"genre_scores_gemma":[0.9941288,0.001023985,0.00017638867,0.003949107,0.00007589459,0.000039905186,0.00003452944,0.000021236763,0.0005501383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830043,0.00021616243,0.0007027841,0.0002933297,0.00016637254,0.00032091208],"domain_scores_gemma":[0.9983252,0.0006343699,0.00047503863,0.00020675165,0.00026969367,0.000088893605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065755314,0.00016730455,0.0009543993,0.00007086381,0.000037088943,0.000008126803,0.0000905619,0.00017735195,0.00022195389],"category_scores_gemma":[0.00035044955,0.00012620151,0.00020987245,0.00030863206,0.000108254935,0.00003423076,0.00003619397,0.00021828568,0.000001716754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025807132,0.0008202334,0.9825077,0.00010072655,0.00051680946,0.0005851178,0.00019177863,0.000011202898,0.0008848589,0.0000016983956,0.0012627053,0.01053647],"study_design_scores_gemma":[0.014728447,0.0011755863,0.9729438,0.0005701095,0.0001440719,0.000029940305,0.0004463978,0.00044934364,0.004540428,0.0000053374765,0.004791262,0.0001752758],"about_ca_topic_score_codex":0.0006202799,"about_ca_topic_score_gemma":0.008509509,"teacher_disagreement_score":0.012147735,"about_ca_system_score_codex":0.00013251408,"about_ca_system_score_gemma":0.0013302454,"threshold_uncertainty_score":0.51463485},"labels":[],"label_agreement":null},{"id":"W3200804649","doi":"10.1097/coc.0000000000000866","title":"Trends in Diagnosis and Treatment of Metastatic Cancer in the United States","year":2021,"lang":"en","type":"article","venue":"American Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Centre for Family Medicine","funders":"National Cancer Institute","keywords":"Medicine; Epidemiology; Internal medicine; Cancer; Incidence (geometry); Colorectal cancer; Oncology; Cancer registry; Surveillance, Epidemiology, and End Results; Metastatic breast cancer; Prostate; Metastasis; Prostate cancer; Kidney cancer; Breast cancer","score_opus":0.1264741920221116,"score_gpt":0.4957059781453322,"score_spread":0.3692317861232206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200804649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97353375,0.0028436126,0.000003272647,0.023355186,0.000108033324,0.00004878678,0.0000071104873,7.571139e-7,0.0000995086],"genre_scores_gemma":[0.9426429,0.05420273,0.00043756416,0.002600887,0.000063808475,0.000010487914,0.0000040351583,0.000004696309,0.00003284008],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979839,0.0006765061,0.0010225744,0.00008922173,0.000117128526,0.00011070467],"domain_scores_gemma":[0.9967207,0.0024436673,0.00059747224,0.00009195407,0.00008642986,0.000059820715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008606585,0.00007051638,0.0008690172,0.00021272768,0.000007605761,0.0000026996768,0.000050939027,0.00003084225,0.00016665453],"category_scores_gemma":[0.00019443517,0.000039119976,0.00017378156,0.0007371623,0.00041662165,0.00001972262,0.0000068290824,0.00017229057,1.4028682e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002680338,0.0011550331,0.30482972,0.0000035325586,0.00024900897,0.00044661897,0.000979509,0.000017145456,0.000032506337,0.0000036566644,0.00014773298,0.6894552],"study_design_scores_gemma":[0.008671824,0.018454166,0.8971537,0.00009376088,0.00025173425,0.00020517703,0.0047312933,0.000050768784,0.00011437981,0.000035051355,0.070190646,0.000047512793],"about_ca_topic_score_codex":0.0018297436,"about_ca_topic_score_gemma":0.0021528925,"teacher_disagreement_score":0.6894077,"about_ca_system_score_codex":0.000104579,"about_ca_system_score_gemma":0.00040066545,"threshold_uncertainty_score":0.2766037},"labels":[],"label_agreement":null},{"id":"W3201382752","doi":"10.2139/ssrn.3875767","title":"Leveraging Big Data of Immune Checkpoint Blockade Response Identifies Novel Potential Targets","year":2021,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network; Université de Montréal","funders":"","keywords":"Blockade; Immune checkpoint; Big data; Immune system; Computer science; Medicine; Immunology; Biology; Immunotherapy; Data mining; Genetics; Receptor","score_opus":0.03195141627540803,"score_gpt":0.28324860556694587,"score_spread":0.2512971892915378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201382752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9389313,0.043446798,0.0114740785,0.004935578,0.0009583269,0.0001191194,0.000021640064,0.000023288452,0.00008988255],"genre_scores_gemma":[0.987407,0.007942878,0.00026247607,0.00010664096,0.0005274651,0.0000015707725,0.000054047527,0.000031666183,0.0036662468],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972241,0.0001212443,0.0006695811,0.00030443983,0.00044543744,0.0012352135],"domain_scores_gemma":[0.9986765,0.000049571667,0.00029997816,0.000687875,0.00021169701,0.00007440837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034522368,0.00017237142,0.00036021232,0.00016389035,0.00016254548,0.00004666279,0.000354474,0.00008710247,0.00013083773],"category_scores_gemma":[0.00026646742,0.00015396014,0.00026372648,0.00030772356,0.00009828027,0.00014700792,0.00017044334,0.0012010479,0.0000056221365],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066070864,0.00021937645,0.00016805831,0.000028686858,0.0009806532,0.00008142544,0.00022341966,0.0000064506985,0.97452044,0.00005036018,0.00007946435,0.017034572],"study_design_scores_gemma":[0.0146058155,0.0009396295,0.029474892,0.000525112,0.0006646017,0.021224773,0.008399766,0.00032459112,0.90642744,0.0040215384,0.012870411,0.0005214381],"about_ca_topic_score_codex":0.0001538782,"about_ca_topic_score_gemma":0.00013515957,"teacher_disagreement_score":0.06809302,"about_ca_system_score_codex":0.0005239551,"about_ca_system_score_gemma":0.0055736816,"threshold_uncertainty_score":0.98874724},"labels":[],"label_agreement":null},{"id":"W3201657560","doi":"10.1177/12034754211041610","title":"Reader Comment Regarding “Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management”","year":2021,"lang":"en","type":"letter","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Dermatology; Perspective (graphical); Adverse effect; Immune system; Immunology; Internal medicine","score_opus":0.019811270873037027,"score_gpt":0.2740235104904651,"score_spread":0.25421223961742806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201657560","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041919775,0.014022775,0.000021356062,0.93416846,0.0042069745,0.0008117314,0.000011612718,0.000048759186,0.004788531],"genre_scores_gemma":[0.16174795,0.019542659,0.0002374013,0.80350333,0.0071194335,0.00002771048,0.00016463906,0.00027232227,0.007384548],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941932,0.00036741022,0.0028212362,0.00060315715,0.0012709356,0.00074406137],"domain_scores_gemma":[0.99574125,0.00094598223,0.0016548836,0.00063363556,0.0007231035,0.0003011572],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0008419601,0.00074138684,0.0027936634,0.0015944511,0.00019337013,0.000019178944,0.00022518987,0.00077804376,0.00050586363],"category_scores_gemma":[0.0004475042,0.0005615169,0.0011518678,0.00061446644,0.00032604946,0.0000745891,0.00011136332,0.0026484234,0.00001899021],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006885096,0.00022643586,0.0002472336,0.0008034158,0.0054312726,0.22481637,0.0024783465,0.000003124954,0.003569431,0.0000140685715,0.74976635,0.005758886],"study_design_scores_gemma":[0.003923408,0.002119639,0.00015496324,0.018512495,0.001845851,0.26342785,0.007323541,0.0000066299035,0.0011957686,0.000099884615,0.7007214,0.0006685953],"about_ca_topic_score_codex":0.000218143,"about_ca_topic_score_gemma":0.000006378211,"teacher_disagreement_score":0.13066515,"about_ca_system_score_codex":0.0010237074,"about_ca_system_score_gemma":0.00034664405,"threshold_uncertainty_score":0.9996836},"labels":[],"label_agreement":null},{"id":"W3201697427","doi":"10.1016/j.annonc.2021.08.1225","title":"783P Impact of cemiplimab on quality of life (QoL), functioning and symptoms in patients (pts) with recurrent/metastatic (R/M) cervical carcinoma: Results from EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Daiichi-Sankyo; Novartis; Regeneron Pharmaceuticals; Eisai; Sanofi; Bayer","keywords":"Medicine; Quality of life (healthcare); Cervical carcinoma; Oncology; Internal medicine; Cervical cancer; Nursing; Cancer","score_opus":0.07336111082192427,"score_gpt":0.38140641411518517,"score_spread":0.3080453032932609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201697427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962381,0.00085268717,0.000007089707,0.0011074506,0.00013475413,0.00027685126,0.00035242914,0.000008331539,0.0010223052],"genre_scores_gemma":[0.998907,0.00018323884,0.00014405789,0.0004453527,0.000042704047,0.000009010161,0.00022309416,0.000017073156,0.00002844923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739677,0.00042844005,0.0011205464,0.00040500032,0.00036930823,0.0002799668],"domain_scores_gemma":[0.9976134,0.00078550697,0.00061100855,0.00039174652,0.00044518037,0.00015317799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063513295,0.00020637043,0.0010457877,0.00016660092,0.000027882228,0.000004803001,0.00008999553,0.00017558872,0.00019325629],"category_scores_gemma":[0.00053774676,0.00014753081,0.00020336983,0.00040053873,0.00024679714,0.00006195,0.00006035383,0.00027646092,0.0000017408246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12429953,0.0044587813,0.80569583,0.0003074933,0.0010242178,0.00003052279,0.0020694647,0.000021687933,0.003216925,0.00002620909,0.000917142,0.057932205],"study_design_scores_gemma":[0.021944875,0.017754244,0.95749754,0.00029101412,0.00008581556,0.000005293182,0.0004102008,0.0000394307,0.0013754168,0.000041255455,0.00041793543,0.00013697278],"about_ca_topic_score_codex":0.0032764296,"about_ca_topic_score_gemma":0.00055784825,"teacher_disagreement_score":0.15180174,"about_ca_system_score_codex":0.00011941682,"about_ca_system_score_gemma":0.0007213706,"threshold_uncertainty_score":0.6016132},"labels":[],"label_agreement":null},{"id":"W3201711247","doi":"10.1016/j.annonc.2021.08.263","title":"1809P Evaluation of KRAS mutation subtype on survival in patients with metastatic non-small cell lung cancer receiving immunotherapy","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"KRAS; Medicine; Lung cancer; Immunotherapy; Oncology; Mutation; Cancer research; Cancer; Internal medicine; Colorectal cancer; Biology; Genetics; Gene","score_opus":0.06389037474187814,"score_gpt":0.3823474344286752,"score_spread":0.31845705968679705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201711247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99498826,0.0015813467,0.000035506633,0.00063952233,0.00022641616,0.00052100344,0.00001470784,0.0000045489696,0.0019886922],"genre_scores_gemma":[0.9983283,0.0006536102,0.00029453353,0.0005008434,0.000021788957,0.000041681298,0.00006145442,0.000017543172,0.000080228725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985507,0.000298496,0.0004128249,0.00019364717,0.00037772112,0.0001666215],"domain_scores_gemma":[0.99836165,0.00017226108,0.00034597752,0.00019145192,0.0009010322,0.00002760464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010075977,0.00011251974,0.00041263454,0.00014803302,0.000019304513,0.0000031798784,0.000053126583,0.00007350187,0.00034394144],"category_scores_gemma":[0.00007434084,0.000094956755,0.00007236636,0.00034761484,0.000055974175,0.00004786153,0.000008801659,0.00010818049,0.0000011099957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021971593,0.0033573427,0.55250686,0.00046906134,0.0010234384,0.000031644056,0.003825929,0.001154336,0.041712992,0.000020122114,0.00052552245,0.37340114],"study_design_scores_gemma":[0.013881578,0.0036882642,0.9258518,0.0003347858,0.00017153105,0.0000019069394,0.0003047019,0.00044929096,0.054790396,0.000031214753,0.00038224796,0.0001122591],"about_ca_topic_score_codex":0.0006247957,"about_ca_topic_score_gemma":0.00092779484,"teacher_disagreement_score":0.37334496,"about_ca_system_score_codex":0.00015286979,"about_ca_system_score_gemma":0.0009955358,"threshold_uncertainty_score":0.3872224},"labels":[],"label_agreement":null},{"id":"W3202197007","doi":"10.3389/fonc.2021.714550","title":"Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer","year":2021,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Head and neck squamous-cell carcinoma; Medicine; Immune system; Oncology; Cancer; Effector; Lung cancer; Immunotherapy; Cancer research; Transcriptome; Tumor-infiltrating lymphocytes; Internal medicine; Head and neck cancer; Immunology; Gene; Gene expression; Biology","score_opus":0.015738510859394934,"score_gpt":0.2982460248582651,"score_spread":0.2825075139988702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202197007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97814864,0.018350283,0.00006267412,0.002504044,0.00042568037,0.00014230306,0.0000027070796,0.0000057567495,0.00035789088],"genre_scores_gemma":[0.99365205,0.004576312,0.001182386,0.0004295799,0.000015863017,0.000018937717,0.000006192607,0.0000057759894,0.00011291245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999401,0.00006265733,0.00021398404,0.0001567864,0.000042515414,0.00012305591],"domain_scores_gemma":[0.9998004,0.000041630996,0.00004642492,0.00006909907,0.000021622613,0.000020843543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001025508,0.000068341935,0.00031275768,0.00011142839,0.0000122100955,0.0000023231794,0.000024376097,0.00017602822,0.000059890812],"category_scores_gemma":[0.000025682155,0.00006279138,0.000024307923,0.00018114432,0.00015087955,0.000037806327,0.000012009244,0.0001698262,1.2164018e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037207713,0.00016773446,0.83801204,0.000080157726,0.00006202663,0.000027598866,0.0012199407,0.000003592439,0.04743733,0.00002493387,0.0005940833,0.108649775],"study_design_scores_gemma":[0.0066539925,0.0004799312,0.98034126,0.00015149462,0.000023652374,0.000032042113,0.0010656207,0.00028358796,0.005602299,0.0002882224,0.005007737,0.000070161026],"about_ca_topic_score_codex":0.00045048379,"about_ca_topic_score_gemma":0.0006374894,"teacher_disagreement_score":0.1423292,"about_ca_system_score_codex":0.00021252986,"about_ca_system_score_gemma":0.00017385649,"threshold_uncertainty_score":0.2560558},"labels":[],"label_agreement":null},{"id":"W3202631206","doi":"10.1038/s41586-021-03893-6","title":"Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers","year":2021,"lang":"en","type":"erratum","venue":"Nature","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Ontario Institute for Cancer Research","funders":"National Institute of General Medical Sciences; National Human Genome Research Institute","keywords":"Lung; Medicine; Cancer research; Biology; Computational biology; Internal medicine","score_opus":0.01651183717779025,"score_gpt":0.28985464739713607,"score_spread":0.2733428102193458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202631206","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04232021,0.7112015,0.000030231427,0.006215738,0.1933255,0.0029109938,0.00049372675,0.0002879117,0.043214172],"genre_scores_gemma":[0.18534882,0.034954846,0.00029488615,0.0013398044,0.0054073734,0.00018191627,0.012747277,0.00023408288,0.75949097],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977468,0.00007389596,0.00054185494,0.0005897463,0.00068259815,0.00036509446],"domain_scores_gemma":[0.99891293,0.000022155593,0.00023163496,0.0004093212,0.00033143398,0.00009252825],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0001988225,0.00039531128,0.00084762246,0.00034170906,0.000060824586,0.00003234439,0.00016820768,0.0040697474,0.0011547309],"category_scores_gemma":[0.000019496789,0.0003566279,0.0004476085,0.0012383434,0.00015316387,0.000064898115,0.000014500041,0.005549685,0.0000036355407],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001480935,0.00022044955,0.003781457,0.000523635,0.00040252483,0.00022512958,0.00035078035,0.0000024424205,0.00500425,0.000017219263,0.9560492,0.03194199],"study_design_scores_gemma":[0.0020020602,0.00018528105,0.05286622,0.0031894152,0.00012995877,0.00013095605,0.00022441367,0.000085852815,0.0009232072,0.0000024913363,0.93995297,0.00030714605],"about_ca_topic_score_codex":0.00035873416,"about_ca_topic_score_gemma":0.0006284277,"teacher_disagreement_score":0.7162768,"about_ca_system_score_codex":0.0008015072,"about_ca_system_score_gemma":0.0013905673,"threshold_uncertainty_score":0.9998886},"labels":[],"label_agreement":null},{"id":"W3202679461","doi":"10.1016/j.ejca.2021.08.045","title":"Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Asymptomatic; Medicine; Immunotherapy; Adverse effect; Internal medicine; Immune system; Creatine kinase; Cancer; Biomarker; Gastroenterology; Oncology; Immunology; Biology","score_opus":0.02848893888801255,"score_gpt":0.28379796881887803,"score_spread":0.25530902993086546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202679461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909309,0.005385259,0.0001497234,0.00034365623,0.00018574961,0.0028793756,0.000040955707,0.000019897014,0.00006448187],"genre_scores_gemma":[0.99826986,0.00029643936,0.00082548003,0.00008236651,0.00009713135,0.00009879378,0.000014834267,0.00008244489,0.00023262456],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9948387,0.0005658227,0.0029380084,0.00033094938,0.00095427816,0.00037224052],"domain_scores_gemma":[0.9960587,0.00010493534,0.001484849,0.00044380774,0.0016907194,0.00021696184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032239838,0.00034812474,0.0016081389,0.0001985855,0.0000592009,0.000044092365,0.00021205303,0.000057481204,0.000042633437],"category_scores_gemma":[0.0008168632,0.00022252569,0.000576464,0.00062836317,0.00009790739,0.00009540704,0.000049441674,0.00028291126,0.0000016709162],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05005917,0.003722646,0.1739697,0.016170617,0.0069962814,0.0013560761,0.0024926802,0.0002799573,0.72468334,0.0000143829875,0.00008888601,0.020166248],"study_design_scores_gemma":[0.022386728,0.009318912,0.5532656,0.06538639,0.00093165506,0.00005525736,0.0005846345,0.000080554404,0.34747845,0.0000023514767,0.000103653576,0.00040581851],"about_ca_topic_score_codex":0.00017102051,"about_ca_topic_score_gemma":0.000029073128,"teacher_disagreement_score":0.3792959,"about_ca_system_score_codex":0.000312787,"about_ca_system_score_gemma":0.0005118327,"threshold_uncertainty_score":0.90743345},"labels":[],"label_agreement":null},{"id":"W3202734983","doi":"10.1007/s10549-021-06405-2","title":"Novel classes of immunotherapy for breast cancer","year":2021,"lang":"en","type":"review","venue":"Breast Cancer Research and Treatment","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Breast cancer; Immunotherapy; Tumor microenvironment; Medicine; Immune checkpoint; Cancer; Oncology; Immune system; Disease; Cancer immunotherapy; Immunology; Cancer research; Internal medicine","score_opus":0.1567430733818638,"score_gpt":0.46845098389637924,"score_spread":0.3117079105145154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202734983","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013548462,0.98387027,0.000011577862,0.001148836,0.00019316858,0.0027541735,0.011763044,0.000021953721,0.00010151681],"genre_scores_gemma":[0.00012668347,0.9918082,0.0001387445,0.000044872377,0.0005672707,0.0043069264,0.00026118194,0.00011214342,0.0026339744],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972903,0.00010377703,0.0006251628,0.00073272444,0.00055054383,0.00069750816],"domain_scores_gemma":[0.99800164,0.00029607542,0.00024049432,0.00057550304,0.0006468536,0.00023941172],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032531325,0.0005355843,0.0021917014,0.00035851772,0.0001863391,0.00006377291,0.00016599474,0.00029275945,0.00089949806],"category_scores_gemma":[0.0000065825343,0.00035152398,0.0007944862,0.00063536526,0.00038960512,0.00005974653,0.000058150243,0.00027290094,0.0000023576727],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029215997,0.0010163557,0.00012041409,0.0076398514,0.0048899767,0.000020050833,0.000060283634,7.6258075e-8,0.00021509935,0.000054030606,0.0008682235,0.98219407],"study_design_scores_gemma":[0.006253392,0.0009517823,0.001386731,0.028929815,0.0009084475,0.0010993949,0.000071534974,0.0000014087324,0.00009174524,0.000007030905,0.95998347,0.00031523287],"about_ca_topic_score_codex":0.007618297,"about_ca_topic_score_gemma":0.00065633113,"teacher_disagreement_score":0.9818788,"about_ca_system_score_codex":0.0015302988,"about_ca_system_score_gemma":0.004117055,"threshold_uncertainty_score":0.99989367},"labels":[],"label_agreement":null},{"id":"W3202784931","doi":"10.1158/1055-9965.epi-21-0686","title":"Disease-Associated Risk Variants in <i>ANRIL</i> Are Associated with Tumor-Infiltrating Lymphocyte Presence in Primary Melanomas in the Population-Based GEM Study","year":2021,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"Cancer Council NSW; National Health and Medical Research Council; University of California, Irvine; University of North Carolina at Chapel Hill; Moffitt Cancer Center; Menzies Institute for Medical Research; University of Sydney; University of Tasmania; University of Oxford; University of North Carolina; Memorial Sloan-Kettering Cancer Center; Cancer Care Ontario; National Cancer Institute; Emory University; City of Hope; University of Pennsylvania","keywords":"Neuroblastoma RAS viral oncogene homolog; Medicine; CDKN2A; Oncology; Melanoma; CDKN2B; Tumor-infiltrating lymphocytes; Internal medicine; Odds ratio; Cancer; Cancer research; Immunotherapy; KRAS","score_opus":0.03398690408153011,"score_gpt":0.31879328238182075,"score_spread":0.28480637830029065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202784931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888022,0.0068954243,0.00006722101,0.0020052833,0.00024926383,0.0017857411,0.000065255874,0.00004901932,0.000080571306],"genre_scores_gemma":[0.9964197,0.00036998605,0.00015193429,0.0017025573,0.00004368783,0.00062728924,0.0005719967,0.00003421083,0.00007860346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99162185,0.0053604627,0.0012307283,0.0008176951,0.00033332364,0.00063592935],"domain_scores_gemma":[0.9961607,0.0020961561,0.0010045855,0.0005201247,0.00011759779,0.00010083762],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0058844364,0.00034599082,0.0009140461,0.00028201603,0.00013795518,0.00002064188,0.0002185271,0.00021262589,0.0000671795],"category_scores_gemma":[0.0030595327,0.00027240184,0.00019260414,0.0015805264,0.00012825377,0.0001770932,0.000039723098,0.00045558173,0.0000014206212],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039469255,0.0012604152,0.9899247,0.000064518485,0.0004181997,0.0004070737,0.0002954916,0.0007055773,0.00016358112,0.00000442414,0.00018402348,0.0026250132],"study_design_scores_gemma":[0.011117845,0.0002835315,0.9824042,0.002140091,0.00024306121,0.000008339384,0.00073233695,0.0024970516,0.00001854737,0.00024571334,0.000024947147,0.00028434105],"about_ca_topic_score_codex":0.005767578,"about_ca_topic_score_gemma":0.052022494,"teacher_disagreement_score":0.046254918,"about_ca_system_score_codex":0.002063143,"about_ca_system_score_gemma":0.0012565117,"threshold_uncertainty_score":0.9999728},"labels":[],"label_agreement":null},{"id":"W3202872245","doi":"10.1136/jitc-2021-003467","title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":225,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Thomas Hospital; University Health Network","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Acute kidney injury; Renal function; Internal medicine; Creatinine; Odds ratio; Proportional hazards model; Biopsy; Urology; Gastroenterology","score_opus":0.008752036805244228,"score_gpt":0.2927027088432207,"score_spread":0.28395067203797647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202872245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99184155,0.004872741,0.00003424947,0.00169748,0.0006644105,0.00054410414,0.00012745328,0.000016545675,0.00020147074],"genre_scores_gemma":[0.9797334,0.013234575,0.0010271595,0.0019963966,0.00030584924,0.00012213108,0.00009639234,0.00012313109,0.0033609765],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99813217,0.00004422669,0.00086530624,0.00022425561,0.0003873276,0.00034668724],"domain_scores_gemma":[0.99854076,0.000019633726,0.00047749403,0.00028235494,0.0005593964,0.00012036346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027921965,0.00024561418,0.0006195684,0.00022899786,0.00009700307,0.00003391327,0.00011776532,0.00012869436,0.0005789162],"category_scores_gemma":[0.000025542808,0.00018064764,0.0004122997,0.0005049664,0.000106389496,0.00016741462,0.000013052433,0.00030720865,9.617399e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.070373304,0.0009173158,0.19003473,0.0001297705,0.002849006,0.000039154827,0.00058322167,0.0000032727937,0.623093,0.0000062447225,0.0034653794,0.108505584],"study_design_scores_gemma":[0.03318033,0.0031179502,0.27045336,0.0014427861,0.00020644865,0.000084436506,0.000076071985,0.000008673601,0.6188357,0.000034195866,0.072251655,0.000308436],"about_ca_topic_score_codex":0.00017966068,"about_ca_topic_score_gemma":0.000015433396,"teacher_disagreement_score":0.108197145,"about_ca_system_score_codex":0.0004319788,"about_ca_system_score_gemma":0.0008593223,"threshold_uncertainty_score":0.7366597},"labels":[],"label_agreement":null},{"id":"W3202898318","doi":"10.30683/1927-7229.2019.08.10","title":"Ra-SBRT is Potential Immune Adjuvant for Innate Immune Cell Populations in Advance Stage NSCLC Patients","year":2019,"lang":"en","type":"article","venue":"Journal of Analytical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Stage (stratigraphy); Adjuvant; Context (archaeology); Oncology; Immune system; Lung cancer; Bystander effect; Radiation therapy; Internal medicine; Immunotherapy; Lung; Cancer; Immunology","score_opus":0.021503165227745577,"score_gpt":0.34115319151071416,"score_spread":0.31965002628296857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202898318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896258,0.001684647,0.0007329775,0.0046853106,0.0011847737,0.0005346149,0.000026462143,0.0000060963885,0.0015193319],"genre_scores_gemma":[0.9935024,0.00038047292,0.0020874364,0.0009590713,0.0001395719,0.0000041875915,0.000018304649,0.000020913945,0.0028876793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979727,0.00006841008,0.0011810093,0.00017430034,0.00028649578,0.0003170365],"domain_scores_gemma":[0.99857354,0.000113430724,0.0005882194,0.0002545577,0.0003531608,0.000117112904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005680714,0.0001508486,0.00077828957,0.00030467618,0.000037287627,0.00001098221,0.00018791738,0.00018373536,0.0005975329],"category_scores_gemma":[0.00009535145,0.00011872931,0.00044458444,0.00026870717,0.00009571953,0.00015137646,0.00004595947,0.000392309,0.000023822413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15493494,0.014801371,0.33624315,0.00096038927,0.0021768352,0.0008717011,0.0018769259,0.00068994873,0.26849613,0.0015298643,0.011676238,0.20574248],"study_design_scores_gemma":[0.067231886,0.01952431,0.6978714,0.0004702654,0.0007071936,0.000170701,0.00058442843,0.009757944,0.0052582067,0.00053185207,0.19736971,0.00052213884],"about_ca_topic_score_codex":0.000037207974,"about_ca_topic_score_gemma":0.000013806751,"teacher_disagreement_score":0.3616282,"about_ca_system_score_codex":0.0005164603,"about_ca_system_score_gemma":0.00034943083,"threshold_uncertainty_score":0.65425664},"labels":[],"label_agreement":null},{"id":"W3202959831","doi":"10.14740/jmc3783","title":"Nivolumab, a Double-Edged Sword: A Case Report of Nivolumab-Induced Myasthenia Gravis","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; SWORD; Nivolumab; Myasthenia gravis; Dermatology; Internal medicine; Gastroenterology; Immunotherapy; World Wide Web; Cancer","score_opus":0.04661397894388697,"score_gpt":0.34589613106312167,"score_spread":0.2992821521192347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202959831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873212,0.0043048854,0.000099092256,0.00678776,0.0008919054,0.0001299869,0.000006305514,0.000014687242,0.00044420408],"genre_scores_gemma":[0.99676466,0.0004856102,0.00050667697,0.0006649855,0.00073050195,0.0000032526273,0.0000070018964,0.00002660725,0.0008107332],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9962799,0.00011823073,0.001398529,0.00021344905,0.0017131068,0.00027679635],"domain_scores_gemma":[0.9972194,0.00026398298,0.0007964732,0.00039652103,0.00080786203,0.0005157475],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015426744,0.00018868336,0.0008044417,0.00019792787,0.000075868076,0.000024764076,0.00016366193,0.00025158408,0.0023776975],"category_scores_gemma":[0.001595534,0.00014314085,0.00055612077,0.0004767466,0.0001900058,0.000105871826,0.000060047318,0.00063698186,0.0000039160586],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005836405,0.0006969704,0.0012829456,0.00019552653,0.0005763727,0.9152179,0.0003365153,2.3874355e-7,0.0163224,0.00002245365,0.012509378,0.047002893],"study_design_scores_gemma":[0.01200387,0.0014640307,0.0011751241,0.0010420197,0.00036811305,0.9350496,0.0012922784,0.000018875646,0.0267662,0.000028037826,0.020646289,0.00014554431],"about_ca_topic_score_codex":0.00068953715,"about_ca_topic_score_gemma":0.00033863934,"teacher_disagreement_score":0.04685735,"about_ca_system_score_codex":0.0001383117,"about_ca_system_score_gemma":0.0024141562,"threshold_uncertainty_score":0.99853426},"labels":[],"label_agreement":null},{"id":"W3202997693","doi":"10.1016/j.ejca.2021.08.013","title":"Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Pembrolizumab; Medicine; Internal medicine; Post-hoc analysis; Melanoma; Gastroenterology; Surgery; Cancer; Immunotherapy","score_opus":0.010574117557572711,"score_gpt":0.26825047468346064,"score_spread":0.25767635712588793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202997693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935371,0.004550844,0.000028290122,0.00074756955,0.0001514009,0.00020676834,0.000027323695,0.0000070781603,0.00074361323],"genre_scores_gemma":[0.9975908,0.0007531983,0.00013822818,0.00073851744,0.00009632441,0.0000038388343,0.0000128160345,0.00005084031,0.0006154562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838,0.00017803686,0.00049040106,0.00022946768,0.00043998536,0.00028210584],"domain_scores_gemma":[0.9990241,0.00003422714,0.00028343347,0.0002018199,0.00024771006,0.00020874054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021776385,0.00021432756,0.00048159168,0.0001809801,0.000038456452,0.00004211928,0.00009819756,0.000021416916,0.0002251293],"category_scores_gemma":[0.000036461064,0.00014488587,0.000062776024,0.00026025312,0.00010265173,0.00026802026,0.00003443218,0.0003150249,0.000001566458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036219336,0.00038561935,0.9173668,0.00008204118,0.00017440069,0.0032584504,0.00026829474,0.000055995886,0.00011051775,0.000001483444,0.00007758959,0.041999474],"study_design_scores_gemma":[0.03762655,0.001355502,0.95747876,0.0013896758,0.00009669236,0.000050690334,0.00004584237,0.000003948855,0.00022332669,0.0000016962875,0.0015366416,0.00019067911],"about_ca_topic_score_codex":0.000040341423,"about_ca_topic_score_gemma":0.00034163758,"teacher_disagreement_score":0.04180879,"about_ca_system_score_codex":0.00019684063,"about_ca_system_score_gemma":0.00041323958,"threshold_uncertainty_score":0.5908274},"labels":[],"label_agreement":null},{"id":"W3203232737","doi":"10.1016/j.annonc.2021.08.1900","title":"1298P PD-1 inhibitors combined with chemotherapy may preferentially improve survival in metastatic NSCLC with myeloid-mediated primary resistance to immunotherapy","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"BeiGene","keywords":"Medicine; Immunotherapy; Myeloid; Immunosuppression; Debulking; Chemotherapy; Oncology; Cancer research; Internal medicine; Immunology; Immune system; Cancer; Ovarian cancer","score_opus":0.029457590352189863,"score_gpt":0.31698012425351346,"score_spread":0.2875225339013236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203232737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9700012,0.0014301245,0.00015239442,0.020456739,0.00029617446,0.0010973306,0.00004625017,0.00004894288,0.006470794],"genre_scores_gemma":[0.9810577,0.0015948195,0.003453755,0.010508393,0.000095300056,0.00014451423,0.00015170767,0.00009057863,0.0029032568],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976297,0.00022013673,0.00069619896,0.00051192107,0.0004424186,0.00049963896],"domain_scores_gemma":[0.99826795,0.00025947284,0.00032831362,0.00051410514,0.00048418881,0.00014597252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000625316,0.00032387787,0.0010597449,0.00023393812,0.000045228666,0.000017687114,0.00017630986,0.00015687809,0.00025850954],"category_scores_gemma":[0.000049148694,0.00024464144,0.00013662865,0.0009077218,0.00024439252,0.00010187909,0.000032455657,0.00027970332,0.000006701685],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24751525,0.0031690365,0.010787153,0.0004646242,0.002038124,0.0004917838,0.0021137532,0.000011324722,0.6534271,0.00012195382,0.004869091,0.074990764],"study_design_scores_gemma":[0.0640083,0.034500726,0.26806155,0.0010762729,0.00018058732,0.00006594135,0.0013251362,0.0000062347913,0.4282476,0.00013720841,0.20142058,0.0009698566],"about_ca_topic_score_codex":0.0001799083,"about_ca_topic_score_gemma":0.0025515785,"teacher_disagreement_score":0.2572744,"about_ca_system_score_codex":0.00016945384,"about_ca_system_score_gemma":0.0016649984,"threshold_uncertainty_score":0.99761885},"labels":[],"label_agreement":null},{"id":"W3203425821","doi":"10.51731/cjht.2021.168","title":"Nivolumab (Opdivo) in combination with Ipilimumab (Yervoy)","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ipilimumab; Nivolumab; Reimbursement; Medicine; Drug; Internal medicine; Oncology; Pharmacology; Immunotherapy; Cancer","score_opus":0.020374842019405787,"score_gpt":0.27163697770100426,"score_spread":0.2512621356815985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203425821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8158344,0.08293431,0.00014374891,0.100031026,0.00027463696,0.00022762775,0.000005851451,0.00005299964,0.0004953778],"genre_scores_gemma":[0.99731046,0.0010248708,0.0006521217,0.0008686843,0.0000044808835,0.000003150844,0.00000343739,0.000010444072,0.00012234408],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989985,0.00003978107,0.00041135927,0.00010590087,0.00014233179,0.00030213394],"domain_scores_gemma":[0.9992991,0.000024078437,0.00021933187,0.00018841683,0.00020787954,0.00006119618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039239178,0.000087640095,0.00031747675,0.0005387459,0.00008941129,0.000019416104,0.00011050681,0.00010542954,0.000051299678],"category_scores_gemma":[0.00016142405,0.0000708558,0.00005086232,0.00060512824,0.00014777065,0.0000833371,0.0000066299967,0.00036351028,0.0000017764195],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045352778,0.000088597604,0.036066245,0.00018423914,0.00008648649,0.0015693584,0.00044188628,0.0000053104,0.00041765845,0.0005065676,0.0029212977,0.9572588],"study_design_scores_gemma":[0.023443813,0.006356794,0.53325075,0.0039307824,0.00005855537,0.007971612,0.025001196,0.000039932238,0.008678913,0.0034159112,0.38737425,0.00047748326],"about_ca_topic_score_codex":0.004362132,"about_ca_topic_score_gemma":0.030361967,"teacher_disagreement_score":0.9567813,"about_ca_system_score_codex":0.0007744959,"about_ca_system_score_gemma":0.0058829375,"threshold_uncertainty_score":0.99975276},"labels":[],"label_agreement":null},{"id":"W3203532227","doi":"10.1016/s2666-7568(21)00179-3","title":"Is cancer biology different in older patients?","year":2021,"lang":"en","type":"review","venue":"The Lancet Healthy Longevity","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Vlaamse regering; Fonds Wetenschappelijk Onderzoek; ASCRS Research Foundation","keywords":"Cancer; Prostate cancer; Malignancy; Breast cancer; Immunosenescence; Narrative review; Affect (linguistics); Colorectal cancer; Medicine; Lung cancer; Oncology; Immune system; Gerontology; Internal medicine; Immunology; Psychology; Intensive care medicine","score_opus":0.123293351263279,"score_gpt":0.4373445681115688,"score_spread":0.3140512168482898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203532227","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003302031,0.9886541,0.0000024359915,0.0049295984,0.0009179392,0.0016718874,0.000273074,0.000032439675,0.0002164951],"genre_scores_gemma":[0.00034045376,0.9903221,0.000010087941,0.0074941404,0.00090625265,0.00037264632,0.00027814793,0.00004614885,0.00022998],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973357,0.0005840132,0.0007239156,0.00053491123,0.0002038493,0.00061765197],"domain_scores_gemma":[0.9983206,0.00021958255,0.0003604116,0.00092614384,0.00006450166,0.00010878659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049994554,0.0004220451,0.0031251314,0.000109339366,0.00008508228,0.000017519382,0.00029637793,0.00038385775,0.00084258575],"category_scores_gemma":[0.000041660816,0.00022880749,0.0005057466,0.00043606054,0.00012992596,0.00002209759,0.000106150175,0.00095272745,0.000023658888],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024577067,0.00024636218,0.009317414,0.012529456,0.00022894221,0.0000054297684,0.00015913029,7.717784e-9,2.4149102e-7,0.000020423173,0.0072755986,0.96997124],"study_design_scores_gemma":[0.0019148203,0.0001536145,0.023084715,0.011945726,0.00031039596,0.000010020018,0.000007425571,6.6259355e-7,7.9250555e-7,0.000010933509,0.9623389,0.00022195402],"about_ca_topic_score_codex":0.00088641845,"about_ca_topic_score_gemma":0.00066201924,"teacher_disagreement_score":0.9697493,"about_ca_system_score_codex":0.00070252334,"about_ca_system_score_gemma":0.0006330058,"threshold_uncertainty_score":0.93304986},"labels":[],"label_agreement":null},{"id":"W3203563479","doi":"10.14740/cr1319","title":"Clinical Characteristics and Outcomes in Immune Checkpoint Inhibitor Therapy-Associated Myocarditis","year":2021,"lang":"en","type":"review","venue":"Cardiology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myocarditis; Nivolumab; Internal medicine; Heart failure; Population; Adverse effect; Malignancy; Cancer; Oncology; Cardiology; Intensive care medicine; Immunotherapy","score_opus":0.19565975713122968,"score_gpt":0.49023373633494544,"score_spread":0.29457397920371575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203563479","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009045357,0.9876775,7.1983686e-7,0.00026328792,0.00091307383,0.0013684566,0.00012842056,0.000031551484,0.0005716064],"genre_scores_gemma":[0.0012852838,0.9960319,0.000014187041,0.00009000598,0.00072890334,0.00028929985,0.0005708044,0.000077771445,0.00091189065],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99279976,0.0035839875,0.0015969708,0.0008205013,0.00044430673,0.000754456],"domain_scores_gemma":[0.9965368,0.0019048142,0.00024594096,0.0007883931,0.00034800655,0.00017605256],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0073909825,0.00041735082,0.006752202,0.00048112756,0.000109292,0.000044602464,0.00023437929,0.0014167451,0.00007855073],"category_scores_gemma":[0.0020554503,0.0003093513,0.0015976907,0.00069208874,0.0009222361,0.000029772911,0.00029517163,0.002750882,0.000031673615],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018128085,0.00012429834,0.03184533,0.0014510129,0.0029624396,0.0010986754,0.000033590375,2.3739855e-9,0.000013870304,0.0000044675276,0.0009908974,0.9612941],"study_design_scores_gemma":[0.0021936444,0.0005115565,0.12997636,0.0067223613,0.00022575936,0.00034925848,0.0000505518,3.2572623e-7,0.0000017964769,0.0000055103833,0.8596992,0.00026366068],"about_ca_topic_score_codex":0.00005833967,"about_ca_topic_score_gemma":0.000005380236,"teacher_disagreement_score":0.9610305,"about_ca_system_score_codex":0.00042496895,"about_ca_system_score_gemma":0.0013227708,"threshold_uncertainty_score":0.99993587},"labels":[],"label_agreement":null},{"id":"W3203668858","doi":"10.30683/1927-7229.2020.09.04","title":"Molecular Pathology of Immune Checkpoint Inhibitor-Induced Myocarditis","year":2020,"lang":"en","type":"article","venue":"Journal of Analytical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Myocarditis; Adverse effect; Autoimmunity; Medicine; Immune system; Clinical trial; Immunology; Repertoire; Immune checkpoint; Melanoma; Mechanism (biology); Immunotherapy; Pathological; Pathology; Internal medicine; Cancer research","score_opus":0.02870322882195739,"score_gpt":0.3194139655113435,"score_spread":0.2907107366893861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203668858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96727926,0.0011388152,0.0005270221,0.027292728,0.0003049968,0.000100584984,0.0000027827002,0.000006932536,0.0033468571],"genre_scores_gemma":[0.9956589,0.0002651731,0.00068234274,0.0029630398,0.00039552103,8.2198693e-7,0.0000015472597,0.00001392455,0.00001875321],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981151,0.000131121,0.0011430274,0.00013198626,0.00028188239,0.00019686145],"domain_scores_gemma":[0.99865943,0.00010783892,0.0005629041,0.00013598893,0.00030126274,0.00023259381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005440955,0.00012080091,0.00094422244,0.00012842834,0.000015978772,0.000004001172,0.00012488043,0.00021812628,0.0002839739],"category_scores_gemma":[0.00044567784,0.00009289635,0.0006950273,0.00028311968,0.00018720381,0.000043228712,0.000040886862,0.00045876708,0.00000870135],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005508091,0.00031222746,0.00063839846,0.000063636064,0.00080471585,0.0036185815,0.0002552558,0.000007999832,0.96678513,0.0002071286,0.0012668953,0.020531917],"study_design_scores_gemma":[0.026903937,0.060490914,0.09119257,0.0003777241,0.0023267858,0.0104244845,0.0011414987,0.0010852485,0.72206575,0.00039049238,0.08312963,0.0004709872],"about_ca_topic_score_codex":0.000008886846,"about_ca_topic_score_gemma":6.7936793e-7,"teacher_disagreement_score":0.24471943,"about_ca_system_score_codex":0.00015400517,"about_ca_system_score_gemma":0.0005056723,"threshold_uncertainty_score":0.3788203},"labels":[],"label_agreement":null},{"id":"W3203678481","doi":"10.1002/cjp2.241","title":"Characterizing the tumor microenvironment in rare renal cancer histological types","year":2021,"lang":"en","type":"article","venue":"The Journal of Pathology Clinical Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"CD68; CD20; Pathology; Immunohistochemistry; Tumor microenvironment; Medicine; Stromal cell; Immune system; Cancer; Biology; Internal medicine; Immunology","score_opus":0.18939847183095146,"score_gpt":0.4769299608256652,"score_spread":0.2875314889947137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203678481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93240935,0.01321597,0.000008232422,0.05370712,0.00029213782,0.00012840814,0.0000041167946,0.0000020133134,0.00023267078],"genre_scores_gemma":[0.97821677,0.016477842,0.00007960807,0.004093157,0.00041350132,0.000007067144,0.000001503498,0.000008030734,0.00070252066],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9960553,0.0023213872,0.0007436877,0.00014189642,0.00042415533,0.00031354857],"domain_scores_gemma":[0.99723643,0.001999587,0.00020889763,0.00029355337,0.00017849437,0.00008305449],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010062812,0.00007760287,0.0003619757,0.000068907764,0.00011753603,0.000010632941,0.00029482073,0.000107373824,0.00093944883],"category_scores_gemma":[0.0016118938,0.00003543787,0.00018374232,0.00023070756,0.0009542706,0.000027026368,0.0001375179,0.0018828248,0.000022897046],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020452969,0.0011057894,0.11138483,0.000043776323,0.00038560282,0.016146634,0.0012645395,0.0000066479365,0.760843,0.00003660679,0.012378094,0.07595155],"study_design_scores_gemma":[0.003735632,0.0016636534,0.9008757,0.00033282003,0.000112460206,0.006939075,0.0009927595,0.000014893181,0.010144537,0.00019420242,0.07490417,0.000090131805],"about_ca_topic_score_codex":0.000016361188,"about_ca_topic_score_gemma":0.00004494636,"teacher_disagreement_score":0.7894908,"about_ca_system_score_codex":0.00016382046,"about_ca_system_score_gemma":0.00051208853,"threshold_uncertainty_score":0.99997383},"labels":[],"label_agreement":null},{"id":"W3204150676","doi":"10.2139/ssrn.3782440","title":"Smoking as a Predictor of Cell Surface Receptor Anti PD-1/PD-L1, MUC1, and CTLA-4 as the First Line or Monotherapy and Multiple Therapy Among Them in NSCLC Patients","year":2021,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Medicine; Oncology; PD-L1; Internal medicine; CTLA-4; Immunotherapy; Immunology; T cell; Immune system; Cancer","score_opus":0.010978381088880135,"score_gpt":0.23884742108337298,"score_spread":0.22786903999449284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204150676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98246807,0.015337226,0.000040382467,0.0013571572,0.00014900834,0.00046092944,0.000009594378,0.000015841873,0.00016180726],"genre_scores_gemma":[0.89674175,0.101892844,0.000048242327,0.00047827512,0.000113743656,0.000005427625,0.00000881202,0.000042797434,0.0006680845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773407,0.00015560004,0.0004955208,0.00030578792,0.00036170048,0.0009473383],"domain_scores_gemma":[0.99899095,0.00023575197,0.0002873136,0.000244698,0.00015126704,0.00009000207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010946052,0.0002536603,0.00041110883,0.00007699206,0.00019996331,0.000054328855,0.0001493467,0.0001446273,0.00020203991],"category_scores_gemma":[0.00009159664,0.00015895921,0.00012381098,0.00035143827,0.00017925292,0.00014248145,0.000035333178,0.000998277,0.000001533038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013318727,0.0007649436,0.893516,0.00005981729,0.0007821595,0.000021745669,0.0037606093,0.000014027929,0.048298147,0.000055326545,0.000114753355,0.03929373],"study_design_scores_gemma":[0.085745856,0.009086112,0.68070406,0.0014683511,0.000250987,0.0011376966,0.009158644,0.0007554305,0.19056912,0.003006637,0.017045643,0.0010714389],"about_ca_topic_score_codex":0.00051604275,"about_ca_topic_score_gemma":0.00097486464,"teacher_disagreement_score":0.21281193,"about_ca_system_score_codex":0.00032597632,"about_ca_system_score_gemma":0.0012174633,"threshold_uncertainty_score":0.64821684},"labels":[],"label_agreement":null},{"id":"W3204256814","doi":"10.1016/j.annonc.2021.08.1132","title":"619P Immune profiling of advanced prostate cancer harbouring homologous recombination deficiency","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Immune system; Homologous recombination; Prostate; Homologous chromosome; Cancer research; Oncology; Tumor microenvironment; Cancer; Immunology; Internal medicine; Gene; Biology; Genetics","score_opus":0.046136250413522234,"score_gpt":0.37789281509396716,"score_spread":0.3317565646804449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204256814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97517467,0.015133723,0.00001694716,0.0042942846,0.00036360513,0.0002703706,0.000012616826,0.000017054386,0.0047167344],"genre_scores_gemma":[0.99165803,0.0059539685,0.0012205533,0.00048025316,0.000027201331,0.000040907235,0.00001985831,0.000012459588,0.00058674853],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99894506,0.00006564728,0.00046472752,0.0001862807,0.00012920996,0.00020908222],"domain_scores_gemma":[0.99890095,0.00006785873,0.00031742192,0.00019005494,0.00049087696,0.00003282721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035735342,0.000089442416,0.00039018164,0.00009450993,0.00003562694,0.0000023533107,0.00006494778,0.00009820856,0.00014398071],"category_scores_gemma":[0.00012775122,0.00008339711,0.00012560637,0.00028737017,0.00012042743,0.000060281276,0.000033017193,0.00011524468,0.0000013655825],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017624104,0.00049238844,0.0038401547,0.0002674872,0.0001093542,0.000045618646,0.0004926076,0.000029507204,0.6815779,0.00021331177,0.00014066357,0.31102857],"study_design_scores_gemma":[0.002717328,0.0019871374,0.039307155,0.00022199364,0.00004090032,0.000057725716,0.00041041098,0.0000272558,0.94987696,0.00030200722,0.004960295,0.00009084954],"about_ca_topic_score_codex":0.0001347507,"about_ca_topic_score_gemma":0.00003508468,"teacher_disagreement_score":0.31093773,"about_ca_system_score_codex":0.000060622668,"about_ca_system_score_gemma":0.0005982985,"threshold_uncertainty_score":0.34008354},"labels":[],"label_agreement":null},{"id":"W3204288709","doi":"10.1016/j.annonc.2021.08.1435","title":"1050P Outcome and impact of immune related adverse events in patients with advanced melanoma treated with checkpoint inhibitors","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Francis Xavier University; BC Cancer Agency","funders":"","keywords":"Medicine; Adverse effect; Melanoma; Oncology; Immune checkpoint; Internal medicine; Immune system; Immunotherapy; Immunology; Cancer research","score_opus":0.02104005985972968,"score_gpt":0.3314567446937864,"score_spread":0.3104166848340567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204288709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99811995,0.00046627858,4.7374976e-7,0.0003497154,0.000032211738,0.00032828015,0.000015761469,0.00000871863,0.0006786309],"genre_scores_gemma":[0.99939615,0.00018170556,0.0001313233,0.00008115072,0.00000466446,0.000008046545,0.000058081816,0.000016296663,0.00012256946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876004,0.00007564076,0.0006201839,0.00019705783,0.00014833892,0.00019871851],"domain_scores_gemma":[0.9990508,0.000047452108,0.0003730785,0.00020610601,0.00025896684,0.00006361657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019388528,0.00014873756,0.0006214238,0.00014449582,0.000014529073,5.5079227e-7,0.000039423725,0.00012568914,0.00009509843],"category_scores_gemma":[0.00005063372,0.00009847926,0.00012939573,0.00039356397,0.00013859877,0.000073418945,0.00002367845,0.00012748524,8.111271e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020239947,0.00086237834,0.95817274,0.000055540033,0.0005365076,0.000060954735,0.00025990294,0.000014769659,0.009128725,0.0000022791771,0.000014494252,0.01065176],"study_design_scores_gemma":[0.018143382,0.014387309,0.95180756,0.00027003416,0.000060496124,0.000029397273,0.00018189689,0.0000037166774,0.014913578,0.0000057303037,0.00009681611,0.000100079895],"about_ca_topic_score_codex":0.00034132937,"about_ca_topic_score_gemma":0.00009973381,"teacher_disagreement_score":0.013524931,"about_ca_system_score_codex":0.00009146181,"about_ca_system_score_gemma":0.00025369835,"threshold_uncertainty_score":0.40158677},"labels":[],"label_agreement":null},{"id":"W3204365794","doi":"10.1016/j.annonc.2021.08.1373","title":"989P Autoimmune panels as predictors of immune-related adverse events (irAEs) in patients (pts) treated with immune checkpoint inhibitors (ALERT)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Iterion Therapeutics; Sanofi; Symphogen; GlaxoSmithKline; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Autoantibody; Adverse effect; Immune system; Immune checkpoint; Immunology; Microarray; Internal medicine; Antibody; Immunotherapy; Gene; Genetics; Gene expression","score_opus":0.021662015225602044,"score_gpt":0.2982200241457827,"score_spread":0.2765580089201807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204365794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932996,0.0016457973,8.602687e-7,0.0009692476,0.00036045298,0.00065593264,0.000032168966,0.00003827102,0.0029976733],"genre_scores_gemma":[0.99727774,0.0010966655,0.000051643776,0.00022104185,0.000025085732,0.00003247742,0.00022472345,0.000043121654,0.0010275305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996659,0.0002521898,0.0018294642,0.00039440772,0.0004135963,0.00045134776],"domain_scores_gemma":[0.9977606,0.00011005117,0.00090530224,0.0005529256,0.0005688176,0.00010231405],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006129018,0.00030744684,0.0011602711,0.00033237616,0.000042275926,0.0000020150794,0.00017216147,0.00039320168,0.0005470217],"category_scores_gemma":[0.00020319354,0.00025646904,0.00044128922,0.00093206187,0.00032023975,0.00013100312,0.00009333473,0.00033568364,0.000016412985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029027257,0.007689637,0.65835977,0.00036634997,0.003043468,0.00039611143,0.0030050878,0.00006650794,0.2571053,0.00002474821,0.00034140502,0.040574368],"study_design_scores_gemma":[0.016167121,0.0077448767,0.77649957,0.00075221865,0.00013642012,0.00004645622,0.0004806915,0.000013637825,0.19548732,0.000022592232,0.0024505293,0.00019858209],"about_ca_topic_score_codex":0.0014593949,"about_ca_topic_score_gemma":0.00005129746,"teacher_disagreement_score":0.11813978,"about_ca_system_score_codex":0.0001882621,"about_ca_system_score_gemma":0.0007480299,"threshold_uncertainty_score":0.99998873},"labels":[],"label_agreement":null},{"id":"W3204465208","doi":"10.3390/cancers13194910","title":"Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Center for Advancing Translational Sciences; Roche Diagnostics","keywords":"Triple-negative breast cancer; Concordance; Medicine; Immunohistochemistry; Atezolizumab; Pathology; Cancer; Breast cancer; Oncology; Internal medicine; Immunotherapy","score_opus":0.027457023729488463,"score_gpt":0.31998431057205917,"score_spread":0.29252728684257073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204465208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930694,0.0048933397,0.000011550312,0.00017510964,0.00055645074,0.0006604631,0.00018406923,0.0000045074253,0.0004450858],"genre_scores_gemma":[0.99938613,0.00013555391,0.00014193343,0.00006075947,0.00002849112,0.00011662905,0.000026289154,0.00001592838,0.000088282504],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99783313,0.00012101088,0.0010991564,0.0003564398,0.00040875011,0.00018151235],"domain_scores_gemma":[0.997945,0.0001618078,0.0011584173,0.00042160015,0.00027738218,0.000035804667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004981784,0.00020626443,0.0006793338,0.00010066673,0.00003565143,0.0000069398093,0.00021555607,0.000060441853,0.00019116826],"category_scores_gemma":[0.00016579435,0.00015907294,0.0002131521,0.0004519338,0.00052624865,0.000057395817,0.00012949877,0.00014165838,2.1031603e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014096516,0.0008534461,0.11627896,0.00047278835,0.0024699925,0.00017756158,0.006161671,0.00009821349,0.8154562,0.000019185287,0.00017569005,0.043739732],"study_design_scores_gemma":[0.00882745,0.0008253083,0.116856806,0.0037712718,0.00028596746,0.00024652528,0.014324935,0.00011959773,0.85431635,0.000014497663,0.00022159588,0.00018969821],"about_ca_topic_score_codex":0.0063537904,"about_ca_topic_score_gemma":0.0011887671,"teacher_disagreement_score":0.043550033,"about_ca_system_score_codex":0.0021207118,"about_ca_system_score_gemma":0.001617536,"threshold_uncertainty_score":0.9605073},"labels":[],"label_agreement":null},{"id":"W3204548506","doi":"10.1016/j.annonc.2021.08.2089","title":"LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Carboplatin; Pembrolizumab; Clinical endpoint; Internal medicine; Oncology; Chemotherapy; Taxane; Clinical trial; Cancer; Cisplatin; Breast cancer","score_opus":0.14542339366557264,"score_gpt":0.42940929772729547,"score_spread":0.28398590406172286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204548506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97502965,0.0021337473,0.0008346476,0.016121766,0.0003312646,0.004354078,0.00032256934,0.00003549237,0.00083677797],"genre_scores_gemma":[0.9890017,0.003764186,0.0015437959,0.0032826539,0.0002972232,0.00043760682,0.0003638375,0.00006568639,0.0012432995],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962912,0.00032529872,0.0018391643,0.0006525238,0.00042894608,0.00046285227],"domain_scores_gemma":[0.9951587,0.0020863758,0.0010759147,0.0007293687,0.0008021481,0.00014753852],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017844379,0.00039445146,0.0026967723,0.00023847693,0.0000951301,0.0000152576395,0.0002512036,0.00023961272,0.00068573473],"category_scores_gemma":[0.0003494117,0.00032579107,0.00074853585,0.00043685222,0.000347151,0.000089302506,0.000041438296,0.0002390224,0.0000030232766],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9246075,0.010875621,0.000031939668,0.0001307417,0.004497397,0.000108739136,0.0046946565,0.000024138937,0.0060463557,0.000021094067,0.005479183,0.04348263],"study_design_scores_gemma":[0.88706344,0.017096488,0.00012803283,0.00015297066,0.0006692102,0.000048641203,0.0010563567,0.00046957523,0.061182126,0.000277295,0.03160187,0.00025396026],"about_ca_topic_score_codex":0.0011077237,"about_ca_topic_score_gemma":0.00073655875,"teacher_disagreement_score":0.05513577,"about_ca_system_score_codex":0.000079150916,"about_ca_system_score_gemma":0.0007467996,"threshold_uncertainty_score":0.9999194},"labels":[],"label_agreement":null},{"id":"W3204661301","doi":"10.1158/1078-0432.ccr-21-2160","title":"First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"Merck","keywords":"Pembrolizumab; Immunotherapy; Antibody; Mechanism (biology); Cancer; Mechanism of action; Inflammation; Tumor cells","score_opus":0.058578049202519425,"score_gpt":0.41581195227931544,"score_spread":0.35723390307679603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204661301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98140913,0.011483571,0.00003581178,0.004207513,0.00066019065,0.0014061425,0.00012276725,0.000056465506,0.00061840616],"genre_scores_gemma":[0.9785079,0.017880518,0.0004965853,0.000718562,0.00018648256,0.00023643715,0.00010707363,0.000092208764,0.0017742559],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938823,0.0005759504,0.0014613243,0.0013033209,0.0014915306,0.0012855759],"domain_scores_gemma":[0.99697465,0.0006570377,0.00017921907,0.0010358095,0.00083434157,0.0003189274],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023210766,0.00038289564,0.0011750759,0.00037474954,0.0002237091,0.00007238849,0.0004743231,0.00032617807,0.0008416321],"category_scores_gemma":[0.00029169949,0.0003270262,0.00028543506,0.0022744164,0.0007044917,0.0002230535,0.00012085207,0.001783122,0.000043486343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.116329044,0.0069708438,0.79365844,0.0015316358,0.00070031977,0.0029031604,0.0017054506,0.0000956583,0.041274853,0.00052505324,0.005529503,0.02877604],"study_design_scores_gemma":[0.026144313,0.0016835502,0.89050835,0.0035615258,0.000028669287,0.000006676451,0.0006381433,0.000043639524,0.006557407,0.00031061273,0.070006035,0.00051105436],"about_ca_topic_score_codex":0.00034372264,"about_ca_topic_score_gemma":0.0047794576,"teacher_disagreement_score":0.09684993,"about_ca_system_score_codex":0.00078608585,"about_ca_system_score_gemma":0.0013179018,"threshold_uncertainty_score":0.99991816},"labels":[],"label_agreement":null},{"id":"W3205381631","doi":"10.1080/2162402x.2021.1984677","title":"Trial watch: intratumoral immunotherapy","year":2021,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Labex Immuno-Oncology; High-end Foreign Experts Recruitment Plan of China; Stand Up To Cancer; Weill Cornell Medical College; European Research Area Network on Cardiovascular Diseases; Institut Universitaire de France; Centre National de la Recherche Scientifique; Ligue Contre le Cancer; Fondation pour la Recherche Médicale; Institut National Du Cancer; Institut National de la Santé et de la Recherche Médicale; Association pour la Recherche sur le Cancer; Seerave Foundation; Institut Gustave-Roussy; Fondation Leducq; European Commission; Agence Nationale de la Recherche; E-Rare; Leukemia and Lymphoma Society","keywords":"Oncolytic virus; Immunotherapy; Immune system; Chemotherapy; Context (archaeology); Radiation therapy; T cell; Cancer immunotherapy; Myeloid","score_opus":0.022843804974087212,"score_gpt":0.3018789860251105,"score_spread":0.27903518105102326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205381631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9567018,0.010791923,0.00007980916,0.011069863,0.0022990755,0.00039773056,0.000006399263,0.00014736259,0.018506005],"genre_scores_gemma":[0.9681282,0.0034305193,0.0011744678,0.0050265086,0.00059800426,0.000082833605,0.00011616905,0.000057809546,0.02138551],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986664,0.00011381685,0.00037731434,0.000318574,0.00015815019,0.0003657109],"domain_scores_gemma":[0.99911183,0.000058616286,0.00008739859,0.00057030644,0.0001231785,0.000048644797],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019010664,0.00018070507,0.00045346268,0.00005616305,0.00009068122,0.000025399315,0.000118505435,0.00021927891,0.0030252328],"category_scores_gemma":[0.00005135313,0.00015886199,0.00025558233,0.00031635497,0.00020561428,0.00006187192,0.00004176258,0.0003277101,0.00015387623],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18156585,0.0008623378,0.0009019213,0.000024462985,0.00085712917,0.00064227544,0.0004982805,2.1649606e-7,0.6401304,0.0011418075,0.008585354,0.16478997],"study_design_scores_gemma":[0.15525779,0.0028121194,0.013333073,0.00006374115,0.00007417635,0.0015748554,0.00044860278,0.0000049573996,0.07005774,0.00040895352,0.755648,0.0003159835],"about_ca_topic_score_codex":0.000082870385,"about_ca_topic_score_gemma":0.000022887698,"teacher_disagreement_score":0.7470626,"about_ca_system_score_codex":0.00014857433,"about_ca_system_score_gemma":0.00053379947,"threshold_uncertainty_score":0.9978861},"labels":[],"label_agreement":null},{"id":"W3205424152","doi":"10.1016/j.jgo.2021.10.002","title":"Immune related adverse events and treatment discontinuation in patients older and younger than 75 years with advanced melanoma receiving nivolumab or pembrolizumab","year":2021,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia","funders":"AstraZeneca","keywords":"Medicine; Discontinuation; Internal medicine; Nivolumab; Adverse effect; Hazard ratio; Incidence (geometry); Pembrolizumab; Cohort; Proportional hazards model; Logistic regression; Retrospective cohort study; Cancer; Immunotherapy; Confidence interval","score_opus":0.006622549659378028,"score_gpt":0.25996559357946797,"score_spread":0.25334304392008994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205424152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99663603,0.0023330397,0.0000061145697,0.0003641219,0.00029232135,0.00025799396,0.0000022838979,0.0000041767694,0.00010391139],"genre_scores_gemma":[0.9961935,0.0023966015,0.0007588588,0.000037416354,0.000051347593,0.0000056037034,0.0000079413885,0.00001475416,0.00053396646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893606,0.00009942337,0.0005092695,0.00015338072,0.00014777594,0.00015407232],"domain_scores_gemma":[0.9992254,0.00006761757,0.00043127878,0.00009664867,0.00011208732,0.00006699731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019433201,0.000118144664,0.00043966263,0.0001788681,0.00003193932,0.0000053452814,0.00002936629,0.00010724053,0.00009076412],"category_scores_gemma":[0.00004955569,0.0000804889,0.00006525355,0.00025810322,0.000037601687,0.00017563562,0.000017836388,0.00013764664,7.109788e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040966894,0.0011173439,0.5731904,0.000024768897,0.0005511891,0.00078493427,0.0019776209,0.0000068025747,0.0026641327,0.0000019056648,0.000034138982,0.37867984],"study_design_scores_gemma":[0.037663974,0.0075739664,0.952254,0.00016984754,0.00020176281,0.0007233366,0.00037323983,0.000013247741,0.00010539391,0.000006347927,0.0008273404,0.00008752134],"about_ca_topic_score_codex":0.00006613455,"about_ca_topic_score_gemma":0.00024348345,"teacher_disagreement_score":0.3790636,"about_ca_system_score_codex":0.00055003667,"about_ca_system_score_gemma":0.0003497127,"threshold_uncertainty_score":0.32822418},"labels":[],"label_agreement":null},{"id":"W3206277101","doi":"10.15557/cgo.2020.0008","title":"Immunotherapy toxicities in metastatic vulvar and vaginal melanomas: a retrospective cohort study","year":2020,"lang":"en","type":"article","venue":"Ginekologia Onkologiczna/Current Gynecologic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"University of Toronto","keywords":"Medicine; Melanoma; Retrospective cohort study; Adverse effect; Internal medicine; Oncology; Dermatology; Cancer research","score_opus":0.035976053881701914,"score_gpt":0.3292158606143972,"score_spread":0.29323980673269534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206277101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96799546,0.00452029,0.00012823517,0.020947268,0.00068710226,0.003785199,0.000028101229,0.00033403383,0.0015742943],"genre_scores_gemma":[0.979196,0.0019034605,0.0010203514,0.016803252,0.00020705267,0.0007144293,0.00004908967,0.000039976716,0.00006637352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950919,0.00095483626,0.0011611687,0.0013514986,0.0004430583,0.000997508],"domain_scores_gemma":[0.9978349,0.000813828,0.00047169146,0.00047066074,0.00017705247,0.00023186182],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014920151,0.0006788201,0.0020402186,0.00035267547,0.00018815989,0.00004430454,0.00041202386,0.00042564698,0.0011300765],"category_scores_gemma":[0.00094894477,0.0005203797,0.0002278168,0.00087042595,0.0008107991,0.00016472071,0.00023646951,0.0014725304,0.000050935112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031847558,0.0019351098,0.968316,0.00007937111,0.00056977925,0.001380966,0.0014816617,0.000008205479,0.0018226182,0.00023035976,0.0023240885,0.018667039],"study_design_scores_gemma":[0.01065717,0.024036478,0.9485254,0.000024866678,0.00025306357,0.00026779133,0.0022995253,0.00015210973,0.000094994044,0.00060629286,0.012548195,0.00053405704],"about_ca_topic_score_codex":0.00014181406,"about_ca_topic_score_gemma":0.00016112195,"teacher_disagreement_score":0.022101369,"about_ca_system_score_codex":0.0010049298,"about_ca_system_score_gemma":0.00044368464,"threshold_uncertainty_score":0.99978304},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W3206448916","doi":"10.1136/ijgc-2021-esgo.156","title":"482 Tertiary lymphoid structures as markers of anti-tumor immunity with independent prognostic value in the PORTEC-3 trial of high-risk endometrial cancer","year":2021,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Germinal center; Immunohistochemistry; Endometrial cancer; Medicine; Oncology; Cancer; Internal medicine; Pathology; Cancer research; Biology; Antibody; B cell; Immunology","score_opus":0.01618138655093317,"score_gpt":0.3054717830177106,"score_spread":0.28929039646677746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206448916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938964,0.0022020463,0.000035978926,0.0014336775,0.0017395575,0.00045000404,0.000086938846,0.000003966775,0.00015138632],"genre_scores_gemma":[0.99599963,0.0025426839,0.00019630433,0.00071239803,0.00046714194,0.000035890065,0.000008977042,0.000011634354,0.000025321717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704176,0.00037710494,0.0009836731,0.00017990504,0.0012295044,0.00018806197],"domain_scores_gemma":[0.9967873,0.0009863613,0.0011896769,0.00017120599,0.0008012607,0.00006419415],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001012763,0.00017472544,0.00059407623,0.0002596716,0.00003573704,0.00002511667,0.00044449492,0.00011301337,0.0018198849],"category_scores_gemma":[0.0013236625,0.0000967898,0.000291624,0.00038954636,0.00023123677,0.000103262435,0.000063220454,0.00048710778,3.329992e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3103224,0.002071252,0.61975116,0.00007194187,0.0036435954,0.0018966768,0.0004398777,0.0010816068,0.021633917,0.00023756402,0.00033681397,0.038513202],"study_design_scores_gemma":[0.06824198,0.0034212964,0.9091936,0.00032125815,0.00034874355,0.0007730667,0.00047153997,0.000018558892,0.016071176,0.0005194791,0.0004923339,0.00012701054],"about_ca_topic_score_codex":0.0037138732,"about_ca_topic_score_gemma":0.00044877315,"teacher_disagreement_score":0.28944242,"about_ca_system_score_codex":0.00041681126,"about_ca_system_score_gemma":0.0015168284,"threshold_uncertainty_score":0.9990926},"labels":[],"label_agreement":null},{"id":"W3206449862","doi":"10.3390/curroncol28050357","title":"Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Pembrolizumab; Medicine; Immunotherapy; Retrospective cohort study; Lung cancer; Cohort; Database; Oncology; Internal medicine; PD-L1; Cancer","score_opus":0.011465198026363517,"score_gpt":0.3127079149895267,"score_spread":0.3012427169631632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206449862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881168,0.007678919,0.00005665174,0.00015854635,0.00041037065,0.0031879302,0.00010637357,0.000005352412,0.0002790835],"genre_scores_gemma":[0.99561477,0.003905493,0.000017855522,0.000035053126,0.00003997327,0.00027819275,0.000040308223,0.000024582296,0.000043753742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982795,0.00033407865,0.0004459294,0.00048176205,0.00022472798,0.00023400928],"domain_scores_gemma":[0.99848443,0.00035866533,0.00031291338,0.00045812596,0.00033773176,0.000048102618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034355614,0.00022953181,0.0008085413,0.00008988542,0.000069209134,0.0000042242796,0.00012766346,0.00009660902,0.00008414159],"category_scores_gemma":[0.000036421356,0.0001569718,0.00009319438,0.0004956052,0.00020803853,0.000046902955,0.00010141746,0.00033230748,1.6068545e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041650206,0.0041372254,0.9373151,0.00077933003,0.0005358504,0.000028744866,0.007038618,0.000011363851,0.003159265,0.000004431759,0.000026755983,0.005313102],"study_design_scores_gemma":[0.04049098,0.0025138964,0.94385105,0.0022787387,0.00029991195,0.000038429946,0.0011825172,0.00016453143,0.008892219,0.0000014526261,0.00013422893,0.00015203099],"about_ca_topic_score_codex":0.0059285816,"about_ca_topic_score_gemma":0.019875785,"teacher_disagreement_score":0.013947203,"about_ca_system_score_codex":0.0006070505,"about_ca_system_score_gemma":0.0005079695,"threshold_uncertainty_score":0.9980089},"labels":[],"label_agreement":null},{"id":"W3206671425","doi":"10.1002/wsbm.1539","title":"The tumor immune microenvironments of <scp>HPV</scp><sup>+</sup> and <scp>HPV</scp><sup>−</sup> head and neck cancers","year":2021,"lang":"en","type":"review","venue":"WIREs Mechanisms of Disease","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"Canadian Institutes of Health Research","keywords":"Immune system; Head and neck squamous-cell carcinoma; Antigen; Immunology; Medicine; Etiology; Tumor microenvironment; Cancer; HPV infection; Disease; Head and neck cancer; Cancer research; Internal medicine; Cervical cancer","score_opus":0.01604479339526291,"score_gpt":0.27083759560676174,"score_spread":0.2547928022114988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206671425","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031927947,0.9633427,0.000044594788,0.00012623356,0.0003024954,0.00249352,0.0014144048,0.00005948831,0.0002886133],"genre_scores_gemma":[0.0051636985,0.9899437,0.00039052777,0.0004136078,0.00023281304,0.00035216848,0.0005035407,0.00024433777,0.0027555937],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943207,0.0004501259,0.0018112346,0.0013021337,0.0010664581,0.0010493849],"domain_scores_gemma":[0.9952099,0.0009018203,0.001237962,0.0016740148,0.00014255894,0.0008337536],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007062703,0.0012530505,0.0032473614,0.00032799042,0.0003812749,0.00012096579,0.0006966593,0.00040391443,0.00014040193],"category_scores_gemma":[0.00052302534,0.0009520796,0.001284838,0.00049579283,0.0008993041,0.00018131414,0.00053048605,0.0006606884,0.000015741816],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011230612,0.001457624,0.00033572517,0.057689633,0.008668038,0.0007498996,0.0024731262,0.000053065112,0.0025005946,0.0006729569,0.013053581,0.9112227],"study_design_scores_gemma":[0.0067984345,0.0013477926,0.0010428681,0.025696186,0.0070983795,0.00019155271,0.003320562,0.00023493991,0.0020138964,0.00042505286,0.95132744,0.000502865],"about_ca_topic_score_codex":0.00037203106,"about_ca_topic_score_gemma":0.000021043188,"teacher_disagreement_score":0.9382739,"about_ca_system_score_codex":0.00043869525,"about_ca_system_score_gemma":0.0014102139,"threshold_uncertainty_score":0.99929297},"labels":[],"label_agreement":null},{"id":"W3207550038","doi":"10.1136/ijgc-2021-esgo.484","title":"846 Cancer-induced accelerated immunoaging in women suffering from ovarian cancer","year":2021,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Socioeconomic status; Medicine; Ovarian cancer; Cancer; Oncology; Internal medicine; Population; Environmental health","score_opus":0.050946680115362776,"score_gpt":0.3572223587196444,"score_spread":0.3062756786042816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207550038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786868,0.006013204,0.00002854864,0.011298497,0.0034231616,0.00011250404,0.00005552982,0.000016728778,0.00036502926],"genre_scores_gemma":[0.9875922,0.0064347265,0.00017394913,0.004499246,0.0009569233,0.000080166836,0.00000905699,0.000020417692,0.00023331119],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99797773,0.00009119796,0.0007490459,0.0002648708,0.00057709345,0.00034005364],"domain_scores_gemma":[0.9983625,0.0001986795,0.00038992643,0.00012483,0.00078232534,0.00014173577],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031832332,0.00019225913,0.00050995784,0.00018501868,0.00004618267,0.00008577284,0.00032647295,0.00015826958,0.01582821],"category_scores_gemma":[0.00019754123,0.00015385218,0.00018952275,0.0003347905,0.000050543455,0.00021597993,0.000088329216,0.00057168014,0.000004061373],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007652288,0.0004959605,0.19134231,0.000021974945,0.0021198494,0.002408841,0.0011439602,0.00037446208,0.5439261,0.000028366958,0.0007462226,0.24973968],"study_design_scores_gemma":[0.008144159,0.00023305544,0.9266432,0.0007614108,0.00006887961,0.000099402554,0.0005035276,0.00020282531,0.043181863,0.0002079945,0.019702163,0.00025154708],"about_ca_topic_score_codex":0.0038797178,"about_ca_topic_score_gemma":0.001398851,"teacher_disagreement_score":0.7353009,"about_ca_system_score_codex":0.0028067369,"about_ca_system_score_gemma":0.0012374901,"threshold_uncertainty_score":0.9850715},"labels":[],"label_agreement":null},{"id":"W3207786785","doi":"10.1016/j.jtho.2021.09.010","title":"First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":322,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Cilag; Janssen Pharmaceuticals; Sandoz; Chugai Pharmaceutical; Merck Sharp and Dohme; Genentech; Ipsen; Teijin Pharma; Astellas Pharma; Eisai; Daiichi-Sankyo; Clovis Oncology; AstraZeneca; Novocure; Merck KGaA; Taiho Pharmaceutical; Takeda Pharmaceutical Company; AbbVie; Merck; Spectrum Pharmaceuticals; Johnson and Johnson; Teva Pharmaceutical Industries; Servier; Bayer; Gilead Sciences; Sanofi; University of Pennsylvania; Celgene; Novartis; GlaxoSmithKline; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb; Roche; Astellas Pharma US; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Nivolumab; Ipilimumab; Medicine; Internal medicine; Oncology; Chemotherapy; Hazard ratio; Adverse effect; Confidence interval; Cancer; Immunotherapy","score_opus":0.06623119738577873,"score_gpt":0.44944619521606427,"score_spread":0.38321499783028556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207786785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9517897,0.0064511728,0.00018609654,0.034395017,0.0040231682,0.0014285804,0.000039013008,0.000014548357,0.001672737],"genre_scores_gemma":[0.97419584,0.007934226,0.0051948153,0.006582939,0.001990994,0.00012537764,0.00005297332,0.00006904254,0.0038537742],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964158,0.00094121514,0.0016164137,0.00028119105,0.00039785245,0.00034751775],"domain_scores_gemma":[0.9962736,0.0017762787,0.0010663721,0.000446923,0.00029478056,0.0001420695],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031131872,0.0002498945,0.0020532433,0.00011993783,0.00011827186,0.000065350505,0.0004743521,0.0002360919,0.0013115532],"category_scores_gemma":[0.0013901572,0.00015249902,0.00041776986,0.00035587084,0.00022492063,0.00023315812,0.000153503,0.00072366156,0.000018857476],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8788446,0.0019307729,0.000111881716,0.00002141471,0.0008093906,0.0008252375,0.0004894265,0.000016436881,0.0014778132,0.000011326828,0.003279408,0.112182274],"study_design_scores_gemma":[0.8965654,0.0034021342,0.00031859716,0.00040611494,0.0005983154,0.0002815522,0.00072346296,0.00014584014,0.0013104628,0.00032122975,0.0957609,0.00016602509],"about_ca_topic_score_codex":0.00012867774,"about_ca_topic_score_gemma":0.00056295464,"teacher_disagreement_score":0.112016246,"about_ca_system_score_codex":0.0006582469,"about_ca_system_score_gemma":0.001614178,"threshold_uncertainty_score":0.99960136},"labels":[],"label_agreement":null},{"id":"W3208513157","doi":"10.1016/j.jtocrr.2021.100251","title":"Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy","year":2021,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Takeda Canada; Bristol-Myers Squibb Canada; EMD Serono; Amgen; Boehringer Ingelheim; Meso Scale Diagnostics; Sanofi; Roche; GlaxoSmithKline; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Internal medicine; Hazard ratio; Stage (stratigraphy); Adverse effect; Incidence (geometry); Chemotherapy; Oncology; Cancer; Confidence interval; Immunotherapy","score_opus":0.0722457016137158,"score_gpt":0.42115690683150875,"score_spread":0.34891120521779295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208513157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996147,0.0007948557,0.000018465205,0.00093738927,0.000091406466,0.00085174857,0.0000059188046,0.000017426251,0.0011358288],"genre_scores_gemma":[0.9928088,0.0014033666,0.00010364587,0.00011748668,0.000083007,0.000024099796,0.0000481139,0.000019167717,0.00539227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715275,0.00024363254,0.0006860493,0.0005765918,0.00097519107,0.00036579254],"domain_scores_gemma":[0.9982521,0.00044273926,0.00014991747,0.0003333836,0.00055076723,0.00027111493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027086816,0.00014181026,0.0005029877,0.00009458458,0.00013722619,0.00006884186,0.00003764871,0.00012929937,0.00017104365],"category_scores_gemma":[0.0008534254,0.00007929781,0.00004231643,0.00047291024,0.00051884627,0.00010260628,0.000073210285,0.0005723323,9.20918e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019972235,0.00088634755,0.83100665,0.0001533959,0.00013328549,0.0013370095,0.00018755291,8.85912e-7,0.000076885575,0.0000061275746,0.00027561068,0.14596401],"study_design_scores_gemma":[0.02304659,0.0044114743,0.9397065,0.0006366442,0.00003464828,0.00018790641,0.0002595759,0.000078052275,0.0002256545,0.000006549565,0.031239402,0.0001669898],"about_ca_topic_score_codex":0.00050248706,"about_ca_topic_score_gemma":0.0010864864,"teacher_disagreement_score":0.14579701,"about_ca_system_score_codex":0.00008094485,"about_ca_system_score_gemma":0.0009963036,"threshold_uncertainty_score":0.3233671},"labels":[],"label_agreement":null},{"id":"W3209426760","doi":"10.1016/j.purol.2021.08.120","title":"Impact de l’expression de Pd-l1 au sein du microenvironnement tumoral sur les résultats oncologiques de la thérapie trimodale pour cancer de vessie infiltrant le muscle","year":2021,"lang":"fr","type":"article","venue":"Progrès en Urologie","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Molecular biology; Gynecology; Biology; Medicine","score_opus":0.02808065130909129,"score_gpt":0.3340565614450863,"score_spread":0.305975910135995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209426760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90538454,0.07631161,0.0013228697,0.015115292,0.00042152684,0.00059761736,0.00013300925,0.00016837794,0.0005451426],"genre_scores_gemma":[0.9649298,0.024320444,0.006856529,0.0016580045,0.0011208357,0.0003393613,0.00005305085,0.000085215346,0.00063671684],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99479336,0.0019158337,0.0005691273,0.0006527268,0.0002786257,0.0017903143],"domain_scores_gemma":[0.9977435,0.0009851485,0.00026859745,0.0004492235,0.000136389,0.0004171658],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024741066,0.00052148965,0.00064915436,0.000107800544,0.00032020797,0.00012617583,0.00039526343,0.00071908056,0.0007681661],"category_scores_gemma":[0.00090757484,0.00045936243,0.0004395374,0.00027835567,0.00064114534,0.00018916398,0.00018761681,0.00091386196,0.000012105934],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0032783474,0.002026565,0.21473734,0.0002760441,0.00040903033,0.0013896109,0.0033689495,0.0009153803,0.5681833,0.0000189167,0.0034930955,0.20190345],"study_design_scores_gemma":[0.007993452,0.0017509579,0.65273166,0.0006582403,0.00037979675,0.00042887867,0.0013704449,0.0020501763,0.2676158,0.00033978667,0.06417399,0.00050681445],"about_ca_topic_score_codex":0.019385485,"about_ca_topic_score_gemma":0.0009990173,"teacher_disagreement_score":0.43799433,"about_ca_system_score_codex":0.0042924806,"about_ca_system_score_gemma":0.01154941,"threshold_uncertainty_score":0.9997858},"labels":[],"label_agreement":null},{"id":"W3209675408","doi":"10.3390/curroncol28060378","title":"Immunotherapy in the First-Line Setting in Wild-Type NSCLC","year":2021,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Immunotherapy; Medicine; Chemotherapy; Lung cancer; Oncology; Internal medicine; Cancer; Cancer research","score_opus":0.16219940296336,"score_gpt":0.4688364623873406,"score_spread":0.3066370594239806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209675408","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017631291,0.99396384,0.0000046040036,0.0014033676,0.0022430902,0.0013463292,0.000010318938,0.00002097225,0.0008311792],"genre_scores_gemma":[0.00005788432,0.99802864,0.000036007696,0.00065139704,0.0005620755,0.00023874523,0.0002966629,0.000047258218,0.000081356826],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972271,0.0005664711,0.0010645315,0.00047653832,0.00022556428,0.00043981167],"domain_scores_gemma":[0.9983783,0.00058395223,0.00036288777,0.00057509076,0.00006246581,0.00003730659],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012296344,0.00040333014,0.0020385885,0.00034610034,0.000054173426,0.000021444672,0.00036645593,0.00046108343,0.00028816468],"category_scores_gemma":[0.000101560545,0.0002615357,0.00052860123,0.0012058871,0.00011833622,0.0000322286,0.00006240979,0.0013263769,0.000031851367],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002186119,0.0005833767,0.00024990764,0.0033903539,0.00013172808,0.00017124416,0.000537542,1.885089e-7,8.4732613e-7,0.000018764573,0.0031329712,0.99156445],"study_design_scores_gemma":[0.0025361066,0.00041650495,0.00020504622,0.019014984,0.0002021232,0.00042395727,0.00011133289,0.000003913239,3.3599252e-7,0.000011379543,0.9768393,0.00023503552],"about_ca_topic_score_codex":0.00005687664,"about_ca_topic_score_gemma":0.00032357225,"teacher_disagreement_score":0.99132943,"about_ca_system_score_codex":0.00087839674,"about_ca_system_score_gemma":0.0013510075,"threshold_uncertainty_score":0.99998367},"labels":[],"label_agreement":null},{"id":"W3210090444","doi":"10.3390/curroncol28060373","title":"The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer","year":2021,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Immune system; Immunotherapy; Adverse effect; Cancer; Cancer immunotherapy; Lung cancer; Immunology; Immune checkpoint; Oncology; Bioinformatics; Internal medicine; Biology","score_opus":0.0767422857098301,"score_gpt":0.4517579582288347,"score_spread":0.3750156725190046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210090444","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013827507,0.99145895,0.000004627713,0.00017664609,0.004963633,0.0015248092,0.00011438032,0.000021693135,0.00035250888],"genre_scores_gemma":[0.00010809143,0.99841356,0.000017039341,0.000034111006,0.00018514605,0.00046356,0.0003735649,0.000060025985,0.00034490155],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963581,0.00064063945,0.0018023939,0.000484256,0.00028950078,0.000425129],"domain_scores_gemma":[0.9972002,0.00066996505,0.0012222789,0.00069791346,0.00014629285,0.0000633362],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00066754,0.00044095796,0.0025671232,0.00020312202,0.0000814075,0.0000056254535,0.00047542356,0.00055174215,0.0009891336],"category_scores_gemma":[0.00007802362,0.0002897618,0.0010663162,0.000811606,0.00021702259,0.000047403202,0.000113797,0.0009942976,0.0000096900385],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046855072,0.00047580365,0.001316744,0.00358033,0.0017341427,0.00002694214,0.0002725614,3.8422775e-7,0.00002253177,0.000017138307,0.0006554997,0.9914294],"study_design_scores_gemma":[0.0036515882,0.00013298116,0.0018340248,0.028282288,0.0008743467,0.000023213284,0.00006919409,0.000010466209,0.0000062707736,0.000008765984,0.9648587,0.0002481416],"about_ca_topic_score_codex":0.0006748368,"about_ca_topic_score_gemma":0.00018239785,"teacher_disagreement_score":0.99118125,"about_ca_system_score_codex":0.0014637425,"about_ca_system_score_gemma":0.0026739673,"threshold_uncertainty_score":0.9999555},"labels":[],"label_agreement":null},{"id":"W3210639163","doi":"10.1136/ijgc-2021-esgo.641","title":"58 KEYNOTE-826: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer","year":2021,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Pembrolizumab; Medicine; Bevacizumab; Chemotherapy; Carboplatin; Internal medicine; Placebo; Oncology; Cervical cancer; Clinical endpoint; Surgery; Cancer; Randomized controlled trial; Cisplatin; Immunotherapy; Pathology","score_opus":0.073051747860394,"score_gpt":0.3840308324736213,"score_spread":0.3109790846132273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210639163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88976306,0.02033373,0.002274475,0.06967904,0.014256888,0.001503961,0.00040799842,0.00007886227,0.0017020201],"genre_scores_gemma":[0.9431252,0.02573657,0.004032227,0.016404731,0.003408719,0.0003619553,0.000074005606,0.00010594398,0.0067506577],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99714357,0.00010642106,0.00092042895,0.0004239506,0.0009511862,0.0004544195],"domain_scores_gemma":[0.9965678,0.000789667,0.0006436463,0.00020472717,0.0015300342,0.00026413202],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040403684,0.00034979064,0.0008465811,0.00017337393,0.00010547775,0.00010118324,0.000483304,0.00020171455,0.017528158],"category_scores_gemma":[0.00045977396,0.00024355575,0.0010094426,0.0002760523,0.00018041805,0.00018164581,0.00005681274,0.0004791258,0.0000073945107],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63829494,0.0015328979,0.0019574976,0.000257644,0.01270394,0.0010506576,0.0011961306,0.0008193261,0.00904879,0.00021780591,0.038406853,0.2945135],"study_design_scores_gemma":[0.25895086,0.009573622,0.02533214,0.0010609931,0.0015803553,0.0016154448,0.0015794609,0.00466615,0.012006219,0.0003365869,0.68218833,0.0011098757],"about_ca_topic_score_codex":0.00009282938,"about_ca_topic_score_gemma":0.00040311198,"teacher_disagreement_score":0.6437815,"about_ca_system_score_codex":0.002864881,"about_ca_system_score_gemma":0.0025530837,"threshold_uncertainty_score":0.99319154},"labels":[],"label_agreement":null},{"id":"W3210654350","doi":"10.3389/fimmu.2021.768957","title":"Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis","year":2021,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","keywords":"Immune system; Colitis; Immunology; Medicine; Colorectal cancer; Immune checkpoint; Adverse effect; Cancer; Biology; Bioinformatics; Cancer research; Immunotherapy; Internal medicine","score_opus":0.01849236876837089,"score_gpt":0.28212799272713784,"score_spread":0.26363562395876694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210654350","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004313123,0.9927272,0.00060152676,0.000080506936,0.00474105,0.0010940062,0.000102856524,0.000048078313,0.00056163187],"genre_scores_gemma":[0.00003981463,0.99453217,0.0031810375,0.000061852916,0.00007385344,0.00020073153,0.00086589804,0.00009644653,0.0009482108],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99630225,0.0003794902,0.0019385667,0.0005757059,0.000240754,0.00056321884],"domain_scores_gemma":[0.99802214,0.0001114802,0.0008042212,0.00087337487,0.00012702092,0.00006173594],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005450857,0.00053854275,0.0045222016,0.00065281923,0.00003790678,0.000010619221,0.00034071284,0.0011728978,0.00040251733],"category_scores_gemma":[0.0002130175,0.00048846105,0.0012486376,0.0010717965,0.00041176876,0.000045819088,0.00016589584,0.0009199542,0.000019840394],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069802185,0.00032332423,0.00001631514,0.009326677,0.0031106821,0.00031034317,0.00012487345,3.7185043e-8,0.00091015524,0.00022469947,0.0030063842,0.9819485],"study_design_scores_gemma":[0.0026690164,0.00047100848,0.00016801295,0.023038935,0.00066083856,0.00040269105,0.00031384654,0.0000015161764,0.00068053487,0.00014156214,0.97103995,0.0004120789],"about_ca_topic_score_codex":0.00019694709,"about_ca_topic_score_gemma":0.000011815059,"teacher_disagreement_score":0.9815364,"about_ca_system_score_codex":0.0007039714,"about_ca_system_score_gemma":0.0012656195,"threshold_uncertainty_score":0.9997567},"labels":[],"label_agreement":null},{"id":"W3210722715","doi":"10.1007/s10549-021-06431-0","title":"Breast cancer immune microenvironment: from pre-clinical models to clinical therapies","year":2021,"lang":"en","type":"review","venue":"Breast Cancer Research and Treatment","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Tumor microenvironment; Immune system; Breast cancer; Cancer research; Cancer; Immunology; Medicine; Biology; Internal medicine","score_opus":0.22796645007064711,"score_gpt":0.4921559509684505,"score_spread":0.26418950089780335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210722715","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004262292,0.98232555,0.0000059476642,0.0029768902,0.0005321368,0.0029665446,0.0067949025,0.000043544816,0.00009216518],"genre_scores_gemma":[0.0007078356,0.98937184,0.00013169629,0.0002202191,0.0020604134,0.002697716,0.00051359617,0.00015359516,0.0041430807],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99377656,0.00096416863,0.0016363839,0.0017198077,0.0008711805,0.0010318905],"domain_scores_gemma":[0.9967073,0.00061761646,0.0002912825,0.001245835,0.0002184795,0.00091944647],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009937485,0.0008353527,0.003545497,0.00025613123,0.00027596916,0.00016415813,0.00034750038,0.00060296315,0.0027558382],"category_scores_gemma":[0.0000086440705,0.00055385527,0.0013599587,0.00051426346,0.00071178086,0.000103987906,0.00032425605,0.0009780864,0.000075064105],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042733406,0.0017903295,0.0017448,0.000823593,0.007982025,0.00019612735,0.00019254086,4.95138e-7,0.000005420153,0.0000066080215,0.0019859779,0.98099875],"study_design_scores_gemma":[0.0055900984,0.0013002421,0.027325395,0.021409769,0.0018060212,0.0005422579,0.00010681546,0.000005954612,0.000005349634,0.000029151388,0.9412989,0.00058005453],"about_ca_topic_score_codex":0.023380933,"about_ca_topic_score_gemma":0.0012911463,"teacher_disagreement_score":0.9804187,"about_ca_system_score_codex":0.0017321183,"about_ca_system_score_gemma":0.0025163412,"threshold_uncertainty_score":0.9996913},"labels":[],"label_agreement":null},{"id":"W3210787730","doi":"10.2217/imt-2021-0068","title":"Association Between PD-L1 Inhibitor, Tumor Site and Adverse Events of Potential Immune Etiology Within the US FDA Adverse Event Reporting System","year":2021,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Adverse effect; Adverse Event Reporting System; Common Terminology Criteria for Adverse Events; Internal medicine; Ipilimumab; Oncology; Cancer; Immunotherapy; Nivolumab; Etiology; MedDRA; Kidney cancer; Pharmacovigilance","score_opus":0.010245077100603362,"score_gpt":0.2668065637972968,"score_spread":0.25656148669669343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210787730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944671,0.0028671299,0.00015029007,0.0008315501,0.00093046785,0.00054010085,0.000028052897,0.00005869372,0.00012660603],"genre_scores_gemma":[0.997578,0.0003627406,0.0002584687,0.00034076232,0.0002847028,0.00003160108,0.00007699194,0.00004119635,0.0010255404],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99679273,0.00039183602,0.0017016942,0.00035631208,0.00044898834,0.00030844848],"domain_scores_gemma":[0.996523,0.00014891892,0.0024627163,0.0005276486,0.0002839127,0.000053804957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021994067,0.00024138564,0.0006670259,0.00008674728,0.00022673498,0.000010100975,0.00010918596,0.00018517596,0.000085408],"category_scores_gemma":[0.0002417615,0.00018297143,0.0003753924,0.0002965616,0.000099564306,0.00010137167,0.000056166868,0.00035994683,0.000011170867],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003048438,0.00016516134,0.31128067,0.00023183585,0.0024293845,0.00015081433,0.0016606027,0.000055730652,0.67631704,0.000036278194,0.00009578478,0.0045282827],"study_design_scores_gemma":[0.0077857315,0.00044517757,0.91735643,0.0007464971,0.00039380923,0.0004658354,0.0019182877,0.00018378318,0.06729725,0.000025366364,0.0031020269,0.00027977934],"about_ca_topic_score_codex":0.000647896,"about_ca_topic_score_gemma":0.000034840366,"teacher_disagreement_score":0.60901976,"about_ca_system_score_codex":0.00040895186,"about_ca_system_score_gemma":0.00028537324,"threshold_uncertainty_score":0.74613583},"labels":[],"label_agreement":null},{"id":"W3210792018","doi":"10.1126/sciadv.abh2148","title":"PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NFκB pathway","year":2021,"lang":"en","type":"article","venue":"Science Advances","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; Hotchkiss Brain Institute; University of Calgary","funders":"Canadian Institutes of Health Research; Cumming School of Medicine, University of Calgary; Merck KGaA; International Microbiome Centre, University of Calgary; Pfizer","keywords":"Glioblastoma; Ligation; Cancer research; NF-κB; NFKB1; Signal transduction; Chemistry; Medicine; Cell biology; Biology; Internal medicine; Biochemistry; Transcription factor; Gene","score_opus":0.01291755375410582,"score_gpt":0.28752770422858315,"score_spread":0.27461015047447734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210792018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98562163,0.005752369,0.00030958757,0.0033537392,0.00049752305,0.00028218445,0.0000072854714,0.000033396358,0.0041422565],"genre_scores_gemma":[0.9977449,0.00033337274,0.0009017918,0.000480925,0.00007572881,0.000015361597,0.0000020295238,0.0000060585376,0.00043979165],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985552,0.000028914672,0.00023109055,0.00029739374,0.00066066603,0.00022675649],"domain_scores_gemma":[0.9991597,0.00006055566,0.0001395189,0.00029502547,0.00030373738,0.000041477255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043237844,0.00009805278,0.00015501287,0.00005072818,0.00021400652,0.000036094825,0.00022913972,0.000031542997,0.00008511833],"category_scores_gemma":[0.00020706402,0.00006006626,0.00007326872,0.001150562,0.0008943565,0.0005867873,0.00005722713,0.00009911579,0.000007271981],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038353857,0.00012626857,0.0030090758,0.00008252243,0.000023361692,0.000016768416,0.002123571,0.000007968086,0.94138604,0.0011523595,0.000058752674,0.051629744],"study_design_scores_gemma":[0.0005301375,0.00036240666,0.01375152,0.0001553129,0.000013143176,0.00006032172,0.00181113,0.000017574886,0.97414505,0.0024472934,0.0066232323,0.000082893595],"about_ca_topic_score_codex":0.0000437442,"about_ca_topic_score_gemma":0.00007559126,"teacher_disagreement_score":0.05154685,"about_ca_system_score_codex":0.00006421523,"about_ca_system_score_gemma":0.0005203505,"threshold_uncertainty_score":0.32952937},"labels":[],"label_agreement":null},{"id":"W3211366294","doi":"10.1101/2021.11.07.21266031","title":"Analysis of Corticosteroids in Immune Checkpoint Inhibitors (ICE) Induced Myocarditis – A Systematic Review of 352 Screened Articles","year":2021,"lang":"en","type":"review","venue":"medRxiv","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myocarditis; Guideline; Adverse effect; Internal medicine; Regimen; Lymphoma; Oncology; Pathology","score_opus":0.04614259786075261,"score_gpt":0.32969665844337154,"score_spread":0.28355406058261895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211366294","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012392764,0.98514557,0.0000049254218,0.0000554164,0.00013148651,0.002140142,0.000044616645,0.000015443029,0.00006962185],"genre_scores_gemma":[0.006248242,0.993112,0.000032699503,0.00009597932,0.000030054987,0.00022134646,0.00016890919,0.000045885365,0.000044853256],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9938146,0.0007432951,0.0041055637,0.0004322725,0.00063795695,0.0002663388],"domain_scores_gemma":[0.9961658,0.00026728003,0.0020040427,0.0012239706,0.0002485592,0.00009036109],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021090799,0.00042502253,0.009148859,0.00096551597,0.000016596354,0.0000107540145,0.0002464463,0.0002542728,0.0001956877],"category_scores_gemma":[0.0008275819,0.00031218742,0.0031779453,0.004728921,0.00009869761,0.000045155834,0.0000868807,0.0003067512,0.0000045143706],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031348005,0.00015827686,0.0004497899,0.939518,0.008940019,0.00006273827,0.000076055454,5.839939e-8,0.0009112549,0.0000019852282,0.000008292241,0.049842186],"study_design_scores_gemma":[0.00060120085,0.00016555615,0.0016919327,0.95035434,0.04343923,0.00004830625,0.00007860425,0.000005837455,0.00075797405,3.3935896e-7,0.0026060115,0.00025066108],"about_ca_topic_score_codex":0.00021678812,"about_ca_topic_score_gemma":0.000043504857,"teacher_disagreement_score":0.049591526,"about_ca_system_score_codex":0.00021211592,"about_ca_system_score_gemma":0.00041334977,"threshold_uncertainty_score":0.999933},"labels":[],"label_agreement":null},{"id":"W3211713559","doi":"10.1136/jitc-2021-sitc2021.459","title":"459 Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1–positive metastatic NSCLC","year":2021,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Pembrolizumab; TIGIT; Medicine; Internal medicine; Oncology; Lung cancer; Antibody; Phases of clinical research; Chemotherapy; Immunotherapy; Cancer; Immunology","score_opus":0.013459531560581944,"score_gpt":0.2621275120378249,"score_spread":0.24866798047724298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211713559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99773914,0.0007375735,0.000011226836,0.00030047394,0.000049612998,0.0009396833,0.00004770703,0.000024744822,0.00014986178],"genre_scores_gemma":[0.99896324,0.00011441889,0.00050125574,0.00018133667,0.000022627404,0.000027796717,0.00007849979,0.000043393517,0.00006741625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813557,0.00008051176,0.00048761256,0.00049617706,0.00049161015,0.00030852208],"domain_scores_gemma":[0.99879694,0.00004372636,0.00023938733,0.00034432826,0.00024478912,0.0003308015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001984266,0.00032305872,0.00070474745,0.00016846108,0.00009687251,0.000048588547,0.0000593693,0.000072242474,0.000011237984],"category_scores_gemma":[0.0000829746,0.0002361718,0.000046677535,0.00038950954,0.00038536725,0.00020102157,0.000035216948,0.00021452982,6.3404576e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011735657,0.0034651894,0.9752382,0.0004199701,0.00097836,0.00039903514,0.0028761963,0.000034442535,0.0026682345,0.0000100277775,0.000044884786,0.0021298057],"study_design_scores_gemma":[0.04754683,0.00494136,0.9320618,0.0009848981,0.0005746031,0.00027047153,0.0011561686,0.000059002305,0.011897276,0.000015398542,0.00017720352,0.00031501142],"about_ca_topic_score_codex":0.0004712099,"about_ca_topic_score_gemma":0.00059261476,"teacher_disagreement_score":0.04317642,"about_ca_system_score_codex":0.0000665637,"about_ca_system_score_gemma":0.00034897562,"threshold_uncertainty_score":0.9630807},"labels":[],"label_agreement":null},{"id":"W3212274217","doi":"10.1136/jitc-2021-sitc2021.374","title":"374 A phase IB trial of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors","year":2021,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Sanofi","keywords":"Pembrolizumab; Aflibercept; Medicine; Oncology; Internal medicine; Cancer; Bevacizumab; Immunotherapy; Chemotherapy","score_opus":0.010628406773812712,"score_gpt":0.26602352087909115,"score_spread":0.25539511410527843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212274217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975437,0.0005818963,0.000004401092,0.00036303294,0.00023581428,0.00066892017,0.00003090154,0.00003263995,0.0005386813],"genre_scores_gemma":[0.99853164,0.00010472244,0.00046767978,0.00032378657,0.00007825277,0.000026883665,0.00010790542,0.00003739672,0.0003217266],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981542,0.000059154965,0.000605423,0.00039742608,0.00045270406,0.00033108788],"domain_scores_gemma":[0.9988559,0.000030595493,0.00023824528,0.0003729157,0.00015558256,0.0003468001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020052938,0.00025008785,0.0006296302,0.00012770275,0.000055507375,0.000026378963,0.000073772244,0.00013228606,0.00004086946],"category_scores_gemma":[0.00018318032,0.00020877893,0.00011658176,0.00032480253,0.0003141531,0.00016418699,0.000028533017,0.00021907197,0.0000022834058],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6637543,0.0073625525,0.07087082,0.0019692993,0.0014037755,0.0015918297,0.0064983927,0.00027835026,0.19186299,0.00021384074,0.0024917824,0.05170208],"study_design_scores_gemma":[0.47360414,0.0054068337,0.41526788,0.0015912408,0.0002519339,0.00017051645,0.00052471913,0.00007502394,0.098217286,0.00013087774,0.00414113,0.0006184206],"about_ca_topic_score_codex":0.000092250775,"about_ca_topic_score_gemma":0.00005431468,"teacher_disagreement_score":0.34439707,"about_ca_system_score_codex":0.00013511366,"about_ca_system_score_gemma":0.0009582291,"threshold_uncertainty_score":0.8513758},"labels":[],"label_agreement":null},{"id":"W3212489268","doi":"10.1097/cji.0000000000000400","title":"Racial Differences in Survival Among Advanced-stage Non–small-Cell Lung Cancer Patients Who Received Immunotherapy: An Analysis of the US National Cancer Database (NCDB)","year":2021,"lang":"en","type":"article","venue":"Journal of Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Population and Public Health","funders":"","keywords":"Quartile; Lung cancer; Comorbidity; Hazard ratio; Proportional hazards model; Confidence interval; Psychological intervention; Cancer; National Death Index","score_opus":0.0169396481623604,"score_gpt":0.3064357109546174,"score_spread":0.28949606279225704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212489268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843419,0.013108447,0.00010175494,0.0003522285,0.001214158,0.00042015145,0.0003088555,0.000007700883,0.0001447758],"genre_scores_gemma":[0.9743367,0.02332762,0.00024038393,0.00081152393,0.00021682555,0.000038258564,0.0000504128,0.0000523996,0.00092589104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99639875,0.00038113297,0.001362035,0.00035608816,0.0011273659,0.00037461118],"domain_scores_gemma":[0.99653673,0.00016608722,0.0014607141,0.00051151396,0.0012266329,0.00009831309],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008472723,0.00035111947,0.0011557364,0.0005538556,0.00014708754,0.00005968612,0.0005234892,0.0001658576,0.0013779746],"category_scores_gemma":[0.00006129574,0.0002480264,0.00074086775,0.0017536926,0.00020880507,0.00042128228,0.000045246208,0.00055940624,2.735698e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057589943,0.0010333228,0.8307415,0.00006555997,0.0032830816,0.000016563365,0.0024176475,0.0008199406,0.14500691,0.0000031865534,0.00007667786,0.010776567],"study_design_scores_gemma":[0.0111711575,0.0003835185,0.9624891,0.00074258744,0.00047339345,0.000003142328,0.00046572238,0.0012694682,0.02153752,0.000004844165,0.0011820814,0.0002774133],"about_ca_topic_score_codex":0.0023073312,"about_ca_topic_score_gemma":0.005248353,"teacher_disagreement_score":0.1317476,"about_ca_system_score_codex":0.0006488984,"about_ca_system_score_gemma":0.0014776398,"threshold_uncertainty_score":0.9999972},"labels":[],"label_agreement":null},{"id":"W3212495819","doi":"10.1136/jitc-2021-sitc2021.302","title":"302 Characterization of TIGIT and PVR expression in colorectal liver metastases","year":2021,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Institute of Cancer Research; Institut Du Cancer de Montréal; Bristol-Myers Squibb","keywords":"TIGIT; Immune system; Cancer research; Immune checkpoint; Immunotherapy; Medicine; Metastasis; Cancer; Immunology; Internal medicine","score_opus":0.014115980077505693,"score_gpt":0.2360600032502943,"score_spread":0.2219440231727886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212495819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722177,0.0019970012,0.000007326503,0.00033998373,0.00009277491,0.00015420938,0.000028299572,0.000015344742,0.00014329361],"genre_scores_gemma":[0.9979127,0.0011482139,0.0004082854,0.00020206504,0.000040823572,0.000006979673,0.00010322076,0.000012796157,0.00016490222],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991745,0.00004608419,0.00027102273,0.0002157811,0.00016058517,0.00013204885],"domain_scores_gemma":[0.999542,0.000024556257,0.00010198049,0.00011391096,0.00005821092,0.00015931453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016766253,0.0001171879,0.000255025,0.00007368369,0.0000348873,0.000023757124,0.00002447578,0.00009251262,0.00003152664],"category_scores_gemma":[0.000111830115,0.000103075385,0.000043655717,0.00014225655,0.0001781339,0.0001373592,0.000026702726,0.000090132424,9.321939e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023862996,0.00006545229,0.03303371,0.00018855502,0.000038641145,0.00010446032,0.00033601015,4.6622148e-7,0.96362984,0.000024703328,0.000103129896,0.0022364012],"study_design_scores_gemma":[0.00075651694,0.000060598526,0.45743793,0.00026785245,0.000030258732,0.0001371741,0.00006131159,0.000021131085,0.53959525,0.000021420028,0.0015437283,0.00006682939],"about_ca_topic_score_codex":0.000054532593,"about_ca_topic_score_gemma":0.000022026534,"teacher_disagreement_score":0.42440423,"about_ca_system_score_codex":0.000024199664,"about_ca_system_score_gemma":0.00016610498,"threshold_uncertainty_score":0.4203292},"labels":[],"label_agreement":null},{"id":"W3212553475","doi":"10.1136/jitc-2021-sitc2021.466","title":"466 Use of a 27-gene immuno-oncology (IO) assay to associate response to single-agent immune checkpoint inhibitor (ICI) therapy in advanced-stage NSCLC patients from a large Canadian cohort","year":2021,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Oncology; Medicine; Internal medicine; Lung cancer; Cancer; Targeted therapy; Biomarker; Breast cancer; Immunotherapy; Immunohistochemistry; Biology","score_opus":0.02346754772782018,"score_gpt":0.2608376512464363,"score_spread":0.23737010351861615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212553475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920183,0.0018881302,0.0000076204556,0.0032181707,0.0008448641,0.0012470508,0.0006360851,0.000037297552,0.000102480175],"genre_scores_gemma":[0.9932568,0.00033546606,0.0015251549,0.0034255402,0.000082115555,0.0000744579,0.0003112829,0.00007276627,0.00091642264],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99650484,0.00043580605,0.0010850097,0.0006869292,0.00052481063,0.0007625885],"domain_scores_gemma":[0.99735063,0.00020471014,0.0003144469,0.0006658893,0.00036475924,0.0010995374],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014865178,0.00039862565,0.00088989007,0.0003790064,0.00012210988,0.00007288613,0.00015418943,0.0003567428,0.000080109916],"category_scores_gemma":[0.0017547604,0.00039468278,0.00022682546,0.0006351198,0.00015477662,0.00018755127,0.00009242788,0.00031664496,0.0000133077065],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006072059,0.000558321,0.1199599,0.000033465218,0.00038252937,0.00037143368,0.0026664014,0.000031213836,0.865175,0.000003278976,0.00078558375,0.0039608213],"study_design_scores_gemma":[0.004434815,0.00080018,0.5732615,0.0004299225,0.00004619399,0.000014663596,0.000326556,0.0000074469076,0.3513645,0.000010027853,0.06900817,0.00029606014],"about_ca_topic_score_codex":0.04383892,"about_ca_topic_score_gemma":0.039051667,"teacher_disagreement_score":0.5138105,"about_ca_system_score_codex":0.0015079587,"about_ca_system_score_gemma":0.002149456,"threshold_uncertainty_score":0.9998505},"labels":[],"label_agreement":null},{"id":"W3212914573","doi":"10.1136/jitc-2021-sitc2021.509","title":"509 A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer","year":2021,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; CD8; Immunotherapy; Refractory (planetary science); Cytotoxic T cell; Cancer; Internal medicine; Oncology; Cancer immunotherapy; Dosing; Immune system; Cancer research; Immunology; Chemistry; Biology; In vitro","score_opus":0.018619486975963523,"score_gpt":0.28676740589623634,"score_spread":0.2681479189202728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212914573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997993,0.0007708432,2.9064128e-7,0.00031846168,0.00013542698,0.00061876705,0.000018593786,0.000019204144,0.0001253991],"genre_scores_gemma":[0.9990206,0.00012693196,0.000070141825,0.00021220758,0.00004087336,0.000043438937,0.0000345659,0.000031168118,0.00042009182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835545,0.00006480832,0.0005357814,0.00039133945,0.00038384716,0.00026878098],"domain_scores_gemma":[0.9990619,0.00003477028,0.00019343625,0.00035966432,0.00011803661,0.00023219868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023668923,0.00021468278,0.00048251232,0.0001612407,0.0000618055,0.000020227937,0.00006929004,0.00011936637,0.000078261364],"category_scores_gemma":[0.00010876457,0.0001623107,0.0000475906,0.00039083618,0.0001696157,0.00013623174,0.000025551997,0.00024822645,7.1118546e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005320512,0.004547309,0.9707889,0.00035591694,0.00025542922,0.00053959544,0.0031532396,0.000022735825,0.01245791,0.0000053213857,0.0006067403,0.0019463875],"study_design_scores_gemma":[0.029228857,0.0024941072,0.95691144,0.000938269,0.000105254236,0.000016826743,0.00090167904,0.000008541108,0.0069770077,0.000012122705,0.0021831193,0.0002227725],"about_ca_topic_score_codex":0.0019285082,"about_ca_topic_score_gemma":0.006107031,"teacher_disagreement_score":0.023908345,"about_ca_system_score_codex":0.00016442852,"about_ca_system_score_gemma":0.00051335676,"threshold_uncertainty_score":0.66188383},"labels":[],"label_agreement":null},{"id":"W3213598721","doi":"10.1182/blood-2021-148528","title":"Characterizing Safety in Patients with Hematologic Malignancies Receiving Allogeneic Stem Cell Transplant (Allo-SCT) Following Pembrolizumab Therapy","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cumulative incidence; Pembrolizumab; Internal medicine; Incidence (geometry); Transplantation; Oncology; Lymphoma; Graft-versus-host disease; Gastroenterology; Surgery; Cancer; Immunotherapy","score_opus":0.010974602034954747,"score_gpt":0.21045519621638298,"score_spread":0.19948059418142822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213598721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949111,0.0037529713,0.000018294022,0.00025215087,0.00014176543,0.00039655648,0.000017203796,0.000060781662,0.00044919126],"genre_scores_gemma":[0.9973777,0.0013863879,0.00018340547,0.0006928214,0.000030629802,0.000029819055,0.00008118236,0.000038024416,0.00018006255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845713,0.00008813515,0.00038677733,0.00038492223,0.00029492847,0.00038810226],"domain_scores_gemma":[0.99942005,0.00004908537,0.000105349885,0.00029980912,0.000056540488,0.00006915939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018112765,0.00023996283,0.00046910226,0.00008652553,0.00009113838,0.000028552604,0.000099427365,0.000115824325,0.00006927392],"category_scores_gemma":[0.0000034545542,0.00018314831,0.00017777231,0.00026789683,0.000029826042,0.000103311155,0.000016535363,0.00016560235,0.0000041722983],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035100745,0.0012203793,0.65592784,0.00016143368,0.00035705706,0.0006455056,0.0018417693,9.564429e-7,0.33268532,0.0000052753803,0.000004615292,0.003639747],"study_design_scores_gemma":[0.025370274,0.0005181313,0.7766988,0.0008461136,0.00012981672,0.00010697608,0.00024221712,0.000001946797,0.1950968,0.0000019695779,0.0006889913,0.0002979164],"about_ca_topic_score_codex":0.000025406542,"about_ca_topic_score_gemma":0.000029975025,"teacher_disagreement_score":0.13758852,"about_ca_system_score_codex":0.000071247436,"about_ca_system_score_gemma":0.00016662978,"threshold_uncertainty_score":0.74685717},"labels":[],"label_agreement":null},{"id":"W3214653934","doi":"10.1158/2159-8290.cd-21-1141","title":"Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma","year":2021,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Sanofi Genzyme; Takeda Oncology; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Natera; Chugai Pharmaceutical; Seagen; Array BioPharma; OncoSec Medical; Pfizer; Incyte; AstraZeneca; Amarin Corporation; Castle Biosciences; National Cancer Institute; Foghorn Therapeutics; Gilead Sciences; Eisai; National Comprehensive Cancer Network; Sanofi; Jounce Therapeutics; Celgene; Bristol-Myers Squibb; Amgen; GlaxoSmithKline","keywords":"Ipilimumab; Pembrolizumab; Adjuvant; Melanoma; Blockade; Immunotherapy; Adjuvant therapy","score_opus":0.026013566291155563,"score_gpt":0.3044026289868365,"score_spread":0.2783890626956809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214653934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824929,0.011990354,0.000024478793,0.0010618236,0.0018950431,0.00030545113,0.00019960738,0.00006039064,0.0019699116],"genre_scores_gemma":[0.98250103,0.009326064,0.0000694619,0.0005296164,0.00045175198,0.000115229355,0.00011757777,0.000048286332,0.0068409564],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99816394,0.000106192936,0.00039781796,0.0005300103,0.0003494313,0.00045261832],"domain_scores_gemma":[0.9989394,0.00015373612,0.000121392055,0.00057653716,0.00009888578,0.00011007907],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013173695,0.00024712278,0.0004964283,0.0001345911,0.00007886041,0.00006504438,0.00013323556,0.00015053197,0.0015030621],"category_scores_gemma":[0.00013164525,0.00019431373,0.00017740409,0.00074063917,0.000115921845,0.00027377444,0.00007255167,0.00034624105,0.000023671168],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45027432,0.0015750362,0.14701648,0.0009241356,0.0029763132,0.0055926032,0.0023405277,0.00019478213,0.11377716,0.00041770053,0.04163101,0.23327994],"study_design_scores_gemma":[0.11356703,0.002807999,0.7039916,0.0017590773,0.0006947867,0.00020211782,0.002152616,0.00022288071,0.12134479,0.0001880027,0.051912513,0.0011565977],"about_ca_topic_score_codex":0.003577292,"about_ca_topic_score_gemma":0.011255845,"teacher_disagreement_score":0.5569751,"about_ca_system_score_codex":0.0007975558,"about_ca_system_score_gemma":0.0015861419,"threshold_uncertainty_score":0.9994097},"labels":[],"label_agreement":null},{"id":"W3214742056","doi":"10.1016/j.ctarc.2021.100496","title":"Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study","year":2021,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Hospital; Queen's University","funders":"","keywords":"Durvalumab; Medicine; Pneumonitis; Internal medicine; Discontinuation; Lung cancer; Stage (stratigraphy); Clinical endpoint; Hazard ratio; Cancer; Oncology; Radiation therapy; Retrospective cohort study; Gastroenterology; Lung; Immunotherapy; Nivolumab; Clinical trial; Confidence interval","score_opus":0.13774220181707245,"score_gpt":0.464566545389948,"score_spread":0.3268243435728756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214742056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9472225,0.044232085,0.000002697324,0.005410674,0.000046141737,0.001982868,0.00011984051,0.0000141233395,0.00096906995],"genre_scores_gemma":[0.91335505,0.07403894,0.00019891451,0.00007180632,0.000011612967,0.001341319,0.000044397788,0.000018881281,0.010919093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824756,0.00049908605,0.00032185973,0.00034264446,0.00020720108,0.0003816663],"domain_scores_gemma":[0.9982302,0.00036621772,0.000054906082,0.0009841488,0.0002504866,0.00011402052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041497068,0.0001739627,0.00040236325,0.00021486799,0.00024694094,0.000047091857,0.00022136098,0.0000701808,0.00033363892],"category_scores_gemma":[0.000032403004,0.00013622291,0.00007162202,0.0006453337,0.00025419466,0.00006618658,0.0002351672,0.0003784321,0.0000030104088],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004203383,0.005110944,0.96668005,0.000061459665,0.00037977388,0.0000699079,0.018006673,0.000008730033,0.0022569234,0.000011580977,0.000120272336,0.006873317],"study_design_scores_gemma":[0.036886398,0.0003698554,0.9086703,0.0005321451,0.00013652022,0.0000024324572,0.043235175,0.0017498124,0.0027322767,0.0000043091422,0.005428518,0.00025223245],"about_ca_topic_score_codex":0.026040306,"about_ca_topic_score_gemma":0.13379285,"teacher_disagreement_score":0.10775255,"about_ca_system_score_codex":0.0012544383,"about_ca_system_score_gemma":0.0012467541,"threshold_uncertainty_score":0.9804454},"labels":[],"label_agreement":null},{"id":"W3214810715","doi":"10.1155/2021/5440572","title":"Prognostic Role of TIGIT Expression in Patients with Solid Tumors: A Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"Journal of Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"China Scholarship Council; National Natural Science Foundation of China","keywords":"TIGIT; Meta-analysis; Cancer research; Oncology; Internal medicine; Expression (computer science); Medicine; Computer science; Immunotherapy; Cancer; Programming language","score_opus":0.1278867278787847,"score_gpt":0.43447790803885544,"score_spread":0.30659118016007075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214810715","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0067274077,0.99239326,0.0000031049155,0.00005874518,0.000033554927,0.00067115953,0.00001819562,0.000002471441,0.000092116694],"genre_scores_gemma":[0.003838362,0.99549764,0.0002218726,0.000008507562,0.000041285293,0.000053312328,0.000051298786,0.00003689097,0.0002508057],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.99515885,0.0013468695,0.0016775021,0.000290237,0.0010967841,0.0004297764],"domain_scores_gemma":[0.9958785,0.0006529893,0.0012564254,0.0005765144,0.0015540345,0.00008150758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023290874,0.00028443066,0.005685134,0.0026721838,0.000047508725,0.000023962339,0.00043650207,0.00034695645,0.0006756657],"category_scores_gemma":[0.00049492554,0.00015580843,0.0023451867,0.0027032224,0.00034173054,0.00009151529,0.00014410596,0.0018107432,0.0000046106416],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062225447,0.003033842,0.011679491,0.00575566,0.6000758,0.0006930961,0.000398707,0.0000025949619,0.00039860944,0.0000052033433,0.00035931682,0.37137514],"study_design_scores_gemma":[0.009139826,0.013188665,0.025810482,0.042755835,0.44090903,0.00090084504,0.0008999048,0.000002050217,0.0007166983,0.000032458913,0.4649025,0.0007417319],"about_ca_topic_score_codex":0.00003384661,"about_ca_topic_score_gemma":0.000010290304,"teacher_disagreement_score":0.46454316,"about_ca_system_score_codex":0.0002610337,"about_ca_system_score_gemma":0.0017832665,"threshold_uncertainty_score":0.7866879},"labels":[],"label_agreement":null},{"id":"W3214836900","doi":"10.1111/ajco.13700","title":"Poster Abstracts","year":2021,"lang":"en","type":"article","venue":"Asia-Pacific Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Medical Research Council; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; National Health and Medical Research Council; Peter MacCallum Cancer Centre; University of Melbourne","keywords":"Citation; Library science; Computer science; Information retrieval; World Wide Web","score_opus":0.09283884681477143,"score_gpt":0.4456423787686756,"score_spread":0.3528035319539041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214836900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7837322,0.0027783837,0.00004023366,0.04957735,0.0044814334,0.000110384266,0.0000036457843,0.000013185558,0.15926322],"genre_scores_gemma":[0.9876325,0.0017083312,0.0017100093,0.003510075,0.0014798302,8.2183044e-7,0.0000041348626,0.00001641152,0.0039378908],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99682623,0.00027740424,0.002186604,0.00017665995,0.0003002686,0.00023284317],"domain_scores_gemma":[0.9969648,0.00092839065,0.0010036984,0.0002475956,0.00055746804,0.0002980595],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002373114,0.00011797593,0.0009568814,0.00008130254,0.000032787404,0.000014649626,0.000116911935,0.00036213145,0.0010702678],"category_scores_gemma":[0.0012781775,0.00008656629,0.0007257368,0.00017015102,0.00020799032,0.00009015243,0.000028113385,0.000863143,0.000077149896],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019401034,0.0030780847,0.060238734,0.00005244916,0.0016849543,0.011667878,0.00029262708,0.0000014283098,0.013672664,0.00008898116,0.08345722,0.80636394],"study_design_scores_gemma":[0.0068136915,0.0038860687,0.2621549,0.00009806278,0.0001930154,0.0065217786,0.000617271,9.738964e-7,0.0027438358,0.00016440683,0.7167207,0.00008529162],"about_ca_topic_score_codex":0.000004102893,"about_ca_topic_score_gemma":0.000012447284,"teacher_disagreement_score":0.80627865,"about_ca_system_score_codex":0.00010059673,"about_ca_system_score_gemma":0.0022781163,"threshold_uncertainty_score":0.9998429},"labels":[],"label_agreement":null},{"id":"W3214960410","doi":"10.1038/s41523-021-00346-1","title":"The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group","year":2021,"lang":"en","type":"review","venue":"npj Breast Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; University of British Columbia; Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; Ontario Institute for Cancer Research","funders":"Medical Research Council; National Cancer Institute; Cancer Research UK; National Institutes of Health; National Breast Cancer Foundation; National Center for Advancing Translational Sciences; Royal Australasian College of Physicians; National Health and Medical Research Council; Breast Cancer Research Foundation","keywords":"Oncology; Immunotherapy; Breast cancer; Medicine; Tumor-infiltrating lymphocytes; Biomarker; Internal medicine; Immune checkpoint; Cancer; Clinical Oncology; Triple-negative breast cancer; Biology","score_opus":0.0420120292087145,"score_gpt":0.3629201689834325,"score_spread":0.320908139774718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214960410","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024713392,0.9855031,0.0000035623355,0.0070651053,0.0036886132,0.0008395672,0.0011534379,0.000024583276,0.0014749457],"genre_scores_gemma":[0.0010096721,0.99493915,0.000025754465,0.00060280313,0.0013810046,0.000868212,0.00040433652,0.00008106471,0.0006879854],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99656177,0.0002817235,0.0014059797,0.0006670422,0.000628764,0.00045471662],"domain_scores_gemma":[0.9969824,0.00059154636,0.0011718295,0.0009446556,0.00023424122,0.00007532675],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009708207,0.00048434242,0.0016840657,0.00013120976,0.00013988104,0.00007568312,0.0007596745,0.00043098777,0.0024906357],"category_scores_gemma":[0.000036122663,0.00027157707,0.0008686139,0.00072391354,0.00041301374,0.00006848116,0.00024647848,0.00066721055,0.000005406652],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093490665,0.00012651477,0.0043784883,0.00043097025,0.0024806159,0.00025790645,0.00011122405,2.3857635e-7,0.00010985026,0.000009550591,0.010180517,0.9809792],"study_design_scores_gemma":[0.0012696711,0.000015570587,0.024623044,0.024153752,0.0007678755,0.003475751,0.0001428819,0.0000060413836,0.000003549756,0.0000065978143,0.94527453,0.00026075545],"about_ca_topic_score_codex":0.019995965,"about_ca_topic_score_gemma":0.005664071,"teacher_disagreement_score":0.98071843,"about_ca_system_score_codex":0.0019925372,"about_ca_system_score_gemma":0.0028571426,"threshold_uncertainty_score":0.99997365},"labels":[],"label_agreement":null},{"id":"W3215173967","doi":"10.7759/cureus.19835","title":"Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice","year":2021,"lang":"en","type":"article","venue":"Cureus","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Nivolumab; Pembrolizumab; Interquartile range; Hazard ratio; Proportional hazards model; Internal medicine; Oncology; Melanoma; Survival analysis; Cohort; Cancer; Surgery; Confidence interval; Immunotherapy","score_opus":0.010031572416345393,"score_gpt":0.2743858091931806,"score_spread":0.2643542367768352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215173967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923919,0.0009791483,0.000082632614,0.0017625932,0.00008413705,0.0015876007,0.000049826187,0.000039172217,0.0030230032],"genre_scores_gemma":[0.941161,0.00032548147,0.01937918,0.0028330954,0.00014658985,0.00079085934,0.00030309058,0.00011231227,0.034948424],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99912375,0.000026092885,0.00015412441,0.00029152294,0.00017644912,0.00022805357],"domain_scores_gemma":[0.9992449,0.000109847526,0.00006476585,0.00029365058,0.0002014894,0.00008532932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000045330387,0.0001560012,0.0002568705,0.000039375904,0.000040715855,0.000014441391,0.000044778462,0.00004637892,0.0004413297],"category_scores_gemma":[0.000072724135,0.00009497543,0.00004125233,0.00024977553,0.000026001968,0.00013325144,0.000010766007,0.000044153636,0.000028576136],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55232704,0.008076762,0.01674004,0.00018413053,0.0024183902,0.00093047484,0.0040048403,0.000051867497,0.005659551,0.000020239908,0.0059762932,0.40361038],"study_design_scores_gemma":[0.07815376,0.04569321,0.04635707,0.00048896845,0.00045533953,0.00023560647,0.00085736514,0.00005757128,0.005446206,0.000003860163,0.8217496,0.0005014448],"about_ca_topic_score_codex":0.00007728327,"about_ca_topic_score_gemma":0.00046059783,"teacher_disagreement_score":0.8157733,"about_ca_system_score_codex":0.00049222977,"about_ca_system_score_gemma":0.00041496012,"threshold_uncertainty_score":0.48322508},"labels":[],"label_agreement":null},{"id":"W3215621197","doi":"10.1111/apt.16718","title":"Systematic review: disease activity indices for immune checkpoint inhibitor‐associated enterocolitis","year":2021,"lang":"en","type":"review","venue":"Alimentary Pharmacology & Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Robarts Clinical Trials; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Disease; Enterocolitis; Adverse effect; Cochrane Library; Severity of illness; Inflammatory bowel disease; Ulcerative colitis; MEDLINE; Intensive care medicine; Gastroenterology; Meta-analysis","score_opus":0.054567318656296646,"score_gpt":0.3961754524137198,"score_spread":0.34160813375742316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215621197","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012356172,0.9827098,0.0000064725514,0.0014499165,0.0018327406,0.013017335,0.0007375805,0.00010483551,0.000017707805],"genre_scores_gemma":[0.000046051562,0.97403735,0.000026512454,0.017747007,0.00038507115,0.004755665,0.0021659904,0.00015352668,0.0006828288],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9952986,0.0011034765,0.0017452394,0.00075792574,0.00041080033,0.0006839457],"domain_scores_gemma":[0.9968259,0.000568406,0.0015323998,0.00063503534,0.00017550866,0.0002627555],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093871023,0.0008746486,0.004815309,0.00020492352,0.00021035303,0.000037444424,0.00039234466,0.0003901357,0.0005899495],"category_scores_gemma":[0.0000041954713,0.0007108447,0.0025084724,0.00044546474,0.00019799618,0.00010937338,0.00014007733,0.00064476504,0.00002491056],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073338515,0.0013092301,0.0000049793744,0.8765656,0.09856341,0.00014510006,0.00006636393,2.4029013e-8,0.0006609736,9.709073e-7,0.0015691067,0.02038087],"study_design_scores_gemma":[0.0026270584,0.00043388957,0.000006330862,0.39459413,0.24879572,0.00008573106,0.00002063348,0.0000042622005,0.00052332715,0.0000020224547,0.35241073,0.0004961627],"about_ca_topic_score_codex":0.000028338634,"about_ca_topic_score_gemma":0.000004313692,"teacher_disagreement_score":0.48197144,"about_ca_system_score_codex":0.0011401548,"about_ca_system_score_gemma":0.0009060578,"threshold_uncertainty_score":0.99953425},"labels":[],"label_agreement":null},{"id":"W3215925274","doi":"10.1080/2162402x.2021.2006893","title":"Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival","year":2021,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Novartis Foundation; Sanofi; Bristol-Myers Squibb; Krebsliga Schweiz; National Science Foundation","keywords":"Epitope; Antigen; Immunology; Lung cancer; Human leukocyte antigen; Immune system; Immunotherapy; CD8; Medicine; Cancer research; Biology; Oncology","score_opus":0.012535353175104302,"score_gpt":0.22722299800351764,"score_spread":0.21468764482841335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215925274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949627,0.0027015656,0.000029586909,0.00031356845,0.0007448353,0.00048184633,0.000038214064,0.00008723274,0.0006404789],"genre_scores_gemma":[0.9965918,0.0015273492,0.0000739645,0.00010830746,0.000057278397,0.000039397313,0.0008350564,0.00005013379,0.00071672624],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978902,0.00025869478,0.0006555825,0.000492476,0.00023579015,0.0004672994],"domain_scores_gemma":[0.9986572,0.00008086455,0.00038208233,0.0004637819,0.000365372,0.000050681832],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002009439,0.00030809586,0.00069999776,0.00017555145,0.00010746757,0.00003849984,0.00010505384,0.0003259795,0.00030771503],"category_scores_gemma":[0.00006287902,0.00026331007,0.00015591408,0.000629975,0.0001438853,0.00009753745,0.00006529256,0.00041442108,0.000022778073],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033289487,0.0011777035,0.20077723,0.00001740792,0.00043749512,0.00010240154,0.0003089443,0.0000010010142,0.7870754,0.0000062354047,0.000057722194,0.0067095174],"study_design_scores_gemma":[0.011604503,0.000577477,0.7373059,0.00030604456,0.000027106757,0.000009050521,0.00028778866,0.0000315498,0.24857308,0.000003855999,0.0010521912,0.00022149539],"about_ca_topic_score_codex":0.00027759344,"about_ca_topic_score_gemma":0.00072195125,"teacher_disagreement_score":0.5385023,"about_ca_system_score_codex":0.0005635962,"about_ca_system_score_gemma":0.00019097485,"threshold_uncertainty_score":0.99998194},"labels":[],"label_agreement":null},{"id":"W3216845069","doi":"10.1177/10781552211061133","title":"Evaluation and clinical impact of a pharmacist-led, interdisciplinary service focusing on education, monitoring and toxicity management of immune checkpoint inhibitors","year":2021,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Saint John Regional Hospital; Horizon Health Network; Moncton Hospital","funders":"Association Canadienne de Pharmacie en Oncologie","keywords":"Medicine; Ipilimumab; Discontinuation; Pharmacist; Adverse effect; Cohort; Hazard ratio; Immune checkpoint; Internal medicine; Retrospective cohort study; Oncology; Emergency medicine; Pharmacy; Cancer; Confidence interval; Immunotherapy; Family medicine","score_opus":0.09540476578122901,"score_gpt":0.5345291494025659,"score_spread":0.4391243836213369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216845069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98473835,0.0067127696,0.00002449029,0.0057690376,0.0011683323,0.00026872978,0.0000019370045,0.000002871567,0.0013135042],"genre_scores_gemma":[0.9878003,0.008854428,0.0027013791,0.00020480646,0.00040100393,0.0000039530623,0.000001672987,0.0000111664285,0.000021318489],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997455,0.00068440294,0.0011948162,0.00015388416,0.00039971407,0.000112185466],"domain_scores_gemma":[0.99599725,0.0005647938,0.001659158,0.00012853324,0.0015391209,0.00011115004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005711993,0.00012160342,0.00044472842,0.0001415256,0.000055892502,0.0000122360225,0.000061880826,0.000058194004,0.000066182445],"category_scores_gemma":[0.0003965118,0.00010021688,0.00020580098,0.0002485185,0.00008681827,0.00038733415,0.00011910036,0.00041176233,5.18994e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02183922,0.0035224382,0.016935563,0.00035396477,0.0037153945,0.00015298884,0.0014144543,0.000020469464,0.35351002,0.0000017095421,0.00026324842,0.59827054],"study_design_scores_gemma":[0.05514882,0.008120974,0.33387655,0.0034839842,0.011899987,0.010139696,0.013898666,0.0010140219,0.5534479,0.00014168351,0.008490429,0.00033727274],"about_ca_topic_score_codex":0.000044402583,"about_ca_topic_score_gemma":0.0000013888287,"teacher_disagreement_score":0.59793323,"about_ca_system_score_codex":0.0004742596,"about_ca_system_score_gemma":0.0013425723,"threshold_uncertainty_score":0.40867257},"labels":[],"label_agreement":null},{"id":"W3216903068","doi":"10.26502/jsr.10020186","title":"Analysis of Corticosteroids in Immune Checkpoint Inhibitors (ICI) Induced Myocarditis- A Systematic Review of 352 Screened Articles","year":2021,"lang":"en","type":"review","venue":"Journal of Surgery and Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Medicine; Myocarditis; Adverse effect; Lymphoma; Guideline; Nivolumab; Melanoma; Oncology; Internal medicine; Renal cell carcinoma; Ipilimumab; Lung cancer; Cancer; Immunology; Immunotherapy; Cancer research; Pathology","score_opus":0.19138188175784585,"score_gpt":0.42747217798711484,"score_spread":0.236090296229269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216903068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024608409,0.9743688,0.0000011614935,0.00014797825,0.00012284213,0.00071316457,0.000011596194,0.0000015274755,0.000024495415],"genre_scores_gemma":[0.009580865,0.9902168,0.000010872803,0.00002549352,0.00006412037,0.000022138393,0.00001758901,0.000020974614,0.000041132484],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99180114,0.0018568421,0.004551312,0.0002025683,0.0012964034,0.0002917129],"domain_scores_gemma":[0.9942741,0.0019572326,0.0021615704,0.00044460254,0.0010195759,0.00014296363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015001077,0.00022749802,0.007758943,0.0028578432,0.000033917535,0.000022783343,0.00015383413,0.0002334103,0.0000872279],"category_scores_gemma":[0.0022669383,0.00014423471,0.0027314164,0.0047002756,0.00020132515,0.000084504856,0.000085076616,0.0008829194,5.1021493e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019885346,0.0002280722,0.0004839216,0.8823675,0.008185474,0.00034001365,0.00007427074,7.110291e-8,0.00065047195,0.000001110673,0.00009163139,0.107378595],"study_design_scores_gemma":[0.00038601403,0.00023864763,0.0014067821,0.98569196,0.009009024,0.00041366785,0.00028345638,0.0000023075725,0.0004249091,0.0000012424242,0.0020197274,0.00012226265],"about_ca_topic_score_codex":0.00009054671,"about_ca_topic_score_gemma":0.0000057772363,"teacher_disagreement_score":0.10725633,"about_ca_system_score_codex":0.00018210096,"about_ca_system_score_gemma":0.0012605058,"threshold_uncertainty_score":0.5881721},"labels":[],"label_agreement":null},{"id":"W3217126890","doi":"10.1200/jco.21.02229","title":"Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Alberta Cancer Foundation","funders":"National Cancer Institute; EMD Serono; Genentech; National Institute for Health and Care Research; Regeneron Pharmaceuticals; Amgen; Celldex Therapeutics; Array BioPharma; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Melanoma; Metastatic melanoma; Clinical trial; Immunotherapy","score_opus":0.07445865462662754,"score_gpt":0.41722741619718856,"score_spread":0.342768761570561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217126890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99356127,0.00072835723,0.00005375833,0.0025919904,0.001717326,0.0004093765,0.000007883538,0.000018597493,0.000911462],"genre_scores_gemma":[0.9933701,0.00066605175,0.002983546,0.0014751999,0.00032036053,0.000009570471,0.000019325644,0.0000512925,0.0011045564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954136,0.00038841422,0.0024901486,0.000433071,0.0007879325,0.00048683106],"domain_scores_gemma":[0.99497026,0.0016582061,0.0016943399,0.0004778527,0.00082745776,0.00037187114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010556577,0.00032774007,0.0025069078,0.00020276813,0.00006481287,0.000021491815,0.00025852467,0.00043083003,0.0005245098],"category_scores_gemma":[0.0010772252,0.00019354273,0.00046357542,0.0004831111,0.00037869543,0.00027335357,0.00007042516,0.0011874202,0.000012671675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34801444,0.0027425897,0.5247004,0.000044753564,0.0011601452,0.0030793871,0.00009290258,0.000012298404,0.000022610206,0.0000031682875,0.0002534264,0.119873844],"study_design_scores_gemma":[0.20517702,0.05007746,0.73991066,0.00036205928,0.00040498908,0.00031120633,0.0001778579,0.0000072004814,0.00007107936,0.0000042067336,0.0032852492,0.00021103233],"about_ca_topic_score_codex":0.00003377469,"about_ca_topic_score_gemma":0.0023042732,"teacher_disagreement_score":0.21521021,"about_ca_system_score_codex":0.00089621823,"about_ca_system_score_gemma":0.005240915,"threshold_uncertainty_score":0.9297158},"labels":[],"label_agreement":null},{"id":"W3217539862","doi":"10.1016/j.fander.2021.09.567","title":"Étude CheckMate 067 : résultats à 6,5 ans chez des patients atteints d’un mélanome avancé","year":2021,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gynecology; Ipilimumab; Internal medicine; Cancer; Immunotherapy","score_opus":0.041021231396387504,"score_gpt":0.3220029691389286,"score_spread":0.2809817377425411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217539862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.914392,0.061012197,0.0008796452,0.015940482,0.0022105335,0.0006157474,0.00032299303,0.00043065354,0.0041957647],"genre_scores_gemma":[0.91761416,0.057101935,0.0040938617,0.016131919,0.0003465892,0.00012429395,0.0004941297,0.00013961809,0.0039534657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99291307,0.001284925,0.001275093,0.0011758026,0.0005827607,0.0027683515],"domain_scores_gemma":[0.9961759,0.0009681348,0.0004921586,0.0011295184,0.00062075345,0.0006135329],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012256758,0.00094723405,0.0013321077,0.00027663502,0.0004139156,0.00020745108,0.0008020718,0.0011762215,0.0017900603],"category_scores_gemma":[0.002209474,0.0009492079,0.0007008622,0.0010002849,0.0014946652,0.00048673892,0.00048876175,0.0011672457,0.0007348437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016251045,0.002212904,0.8121311,0.0016010744,0.0018865541,0.009643726,0.0054303184,0.000082497005,0.018282834,0.00036093593,0.030706946,0.11603601],"study_design_scores_gemma":[0.006141943,0.0006150138,0.79348624,0.0013370939,0.0005200835,0.0030871385,0.0023871846,0.00025821038,0.10665035,0.0018516937,0.08248784,0.0011771984],"about_ca_topic_score_codex":0.00041238713,"about_ca_topic_score_gemma":0.00062398665,"teacher_disagreement_score":0.11485882,"about_ca_system_score_codex":0.0013345724,"about_ca_system_score_gemma":0.002460723,"threshold_uncertainty_score":0.99929583},"labels":[],"label_agreement":null},{"id":"W3217613933","doi":"10.52586/5030","title":"4th Summer School in Immuno-Oncology, July 1st–3rd, 2021, Athens, Greece","year":2021,"lang":"en","type":"article","venue":"Frontiers in Bioscience-Landmark","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"","keywords":"Medicine; Immunotherapy; Cancer immunotherapy; Cancer; Modalities; Therapeutic modalities; Oncology; Tumor immunology; Internal medicine; Immunology","score_opus":0.017944382800979996,"score_gpt":0.2904771532319554,"score_spread":0.2725327704309754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217613933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92162246,0.029015386,0.00079965097,0.008027751,0.00915925,0.0011390368,0.00007252346,0.00008340802,0.030080551],"genre_scores_gemma":[0.9227883,0.019490521,0.026055284,0.008832091,0.00077512587,0.00017616013,0.00015403263,0.00009707981,0.021631377],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.997197,0.0001988281,0.00062089897,0.0007492879,0.00047058813,0.00076341635],"domain_scores_gemma":[0.9988476,0.00007037535,0.00014059023,0.00062177115,0.00010119278,0.00021848212],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001086492,0.00028948314,0.00062841224,0.00049093785,0.00013018824,0.00007438603,0.00037535297,0.00029248072,0.0005666899],"category_scores_gemma":[0.00033046567,0.00025178128,0.00018459505,0.001991846,0.00052719354,0.00023447012,0.000120660916,0.0005000823,0.000055690754],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025044908,0.0006409728,0.70342624,0.000070451344,0.0001037916,0.00082064606,0.0010781912,0.0000044917238,0.041746248,0.000020728141,0.16405903,0.08552472],"study_design_scores_gemma":[0.008307453,0.0004737211,0.25302613,0.00047426895,0.000048864906,0.0001860856,0.0024215067,0.0003906822,0.003946135,0.0002476014,0.7299407,0.0005368715],"about_ca_topic_score_codex":0.00046337093,"about_ca_topic_score_gemma":0.0004520255,"teacher_disagreement_score":0.56588167,"about_ca_system_score_codex":0.0008822537,"about_ca_system_score_gemma":0.0011798694,"threshold_uncertainty_score":0.99999344},"labels":[],"label_agreement":null},{"id":"W4200021190","doi":"10.12932/ap-240721-1196","title":"Nivolumab-induced diffuse type 2 rhinosinusitis: A case report","year":2022,"lang":"en","type":"article","venue":"Asian Pacific Journal of Allergy and Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Nivolumab; Medicine; Anosmia; Nasal congestion; Histopathology; Dermatology; Internal medicine; Gastroenterology; Surgery; Pathology; Nose; Cancer; Immunotherapy; Disease; Coronavirus disease 2019 (COVID-19)","score_opus":0.012941562513226883,"score_gpt":0.24942553924603725,"score_spread":0.23648397673281035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200021190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98302037,0.008272067,0.000015000488,0.002684609,0.0013640027,0.00010222042,0.0000036166473,0.000015488544,0.004522608],"genre_scores_gemma":[0.99696285,0.0009657625,0.000117464704,0.0002521995,0.00011705089,0.000003726809,0.000007682056,0.000019554178,0.0015537279],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9987501,0.00013585114,0.0005362588,0.00016916876,0.00017913617,0.0002294939],"domain_scores_gemma":[0.99909383,0.00002833479,0.00040370328,0.00025971996,0.00013136445,0.000083039115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034697357,0.00013880314,0.00036735594,0.00022961917,0.00027417624,0.000015789892,0.0000956493,0.000090454356,0.0006985923],"category_scores_gemma":[0.00003859952,0.0001228591,0.00014175518,0.00023155264,0.00012456902,0.00008707864,0.00006622106,0.0005431234,0.0000029911675],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024315458,0.0014700815,0.0013778985,0.00003443027,0.007891175,0.6435587,0.008787968,0.0000016010598,0.16686411,0.00051553553,0.014469079,0.13071398],"study_design_scores_gemma":[0.004487541,0.0039603426,0.007124351,0.000031506992,0.000067528,0.8589299,0.01203231,0.000003805964,0.00064822275,0.000086387925,0.11248866,0.00013946297],"about_ca_topic_score_codex":0.00008971406,"about_ca_topic_score_gemma":0.000016210013,"teacher_disagreement_score":0.2153712,"about_ca_system_score_codex":0.00011834719,"about_ca_system_score_gemma":0.00026731045,"threshold_uncertainty_score":0.76490957},"labels":[],"label_agreement":null},{"id":"W4200061060","doi":"10.3390/cancers14010089","title":"CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; University of Calgary; University of Manitoba; Ottawa Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto; University of British Columbia","funders":"","keywords":"Medicine; Diabetic ketoacidosis; Internal medicine; Adverse effect; Diabetes mellitus; Insulin; Cohort; Ketoacidosis; Retrospective cohort study; Immune system; Gastroenterology; Melanoma; Endocrinology; Immunology; Type 1 diabetes; Cancer research","score_opus":0.014326860967628566,"score_gpt":0.24977704374102191,"score_spread":0.23545018277339336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200061060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719797,0.020789225,0.0000023649657,0.00078359013,0.0009074443,0.00039793094,0.00006353621,0.000029373965,0.0050468286],"genre_scores_gemma":[0.9954233,0.0027338814,0.00006423939,0.00078330893,0.00020196494,0.00006152259,0.00006201592,0.00003399971,0.000635727],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983226,0.00004174947,0.00051923504,0.0003475869,0.0003150111,0.00045380878],"domain_scores_gemma":[0.9988504,0.00003151039,0.00014918603,0.00048171266,0.0002132882,0.00027392321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002849346,0.00020085115,0.0004968175,0.00014582458,0.00007885153,0.000018987685,0.00010777528,0.00015119999,0.0006876195],"category_scores_gemma":[0.00007309563,0.00019242665,0.0002467562,0.00040795904,0.00011383279,0.000056641977,0.000028902012,0.00022036486,0.000015392792],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005980675,0.000051409992,0.03760128,0.0002704671,0.0010994955,0.00015803459,0.00077447935,0.000009946344,0.8993728,0.00003283041,0.00087110745,0.05916009],"study_design_scores_gemma":[0.003161137,0.0002683184,0.14349064,0.00042281408,0.0001774976,0.000022420798,0.00067647436,0.000037759597,0.83631784,0.00002179371,0.015132176,0.0002711243],"about_ca_topic_score_codex":0.13331254,"about_ca_topic_score_gemma":0.060087208,"teacher_disagreement_score":0.105889365,"about_ca_system_score_codex":0.0028523733,"about_ca_system_score_gemma":0.005187605,"threshold_uncertainty_score":0.95706373},"labels":[],"label_agreement":null},{"id":"W4200129566","doi":"10.21203/rs.3.rs-986514/v1","title":"Tumor microenvironment before and after chemoradiation in locally advanced rectal cancer: Beyond PD-L1","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northeast Cancer Centre","funders":"","keywords":"Medicine; Colorectal cancer; Neoadjuvant therapy; Tumor microenvironment; Oncology; CD8; Internal medicine; Downregulation and upregulation; Cancer; Immune system; Immunology; Biology","score_opus":0.015388499692615036,"score_gpt":0.3366050206031959,"score_spread":0.3212165209105809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200129566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96779466,0.027039226,0.000008292966,0.0030393214,0.00018137335,0.0015737081,0.00011411792,0.000021404434,0.00022790486],"genre_scores_gemma":[0.98472226,0.012193225,0.00039357174,0.00031750146,0.0002264405,0.0010493702,0.00028139626,0.000054706445,0.0007615182],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99729806,0.00018149329,0.00038351127,0.00077070185,0.0007996123,0.00056661846],"domain_scores_gemma":[0.9989908,0.000056948167,0.000084995256,0.0005331641,0.00014708229,0.00018700834],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00070338143,0.0002698802,0.00048588138,0.00033033226,0.000070615344,0.00008735438,0.00013254723,0.00025084647,0.000646811],"category_scores_gemma":[0.00007537622,0.0002538925,0.00014220223,0.0003225025,0.00024759208,0.00007824414,0.0004422479,0.0012692498,0.000007036195],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023145016,0.0008853251,0.33510065,0.0087999925,0.0005063968,0.0022876305,0.006066186,0.00012947155,0.054580595,0.000005841979,0.0010988539,0.567394],"study_design_scores_gemma":[0.0041629723,0.00063232746,0.9729871,0.0054223007,0.000035664714,0.000047929523,0.0012760628,0.00030119586,0.009556277,0.000079628386,0.005174338,0.00032417357],"about_ca_topic_score_codex":0.0010252431,"about_ca_topic_score_gemma":0.0033842605,"teacher_disagreement_score":0.63788646,"about_ca_system_score_codex":0.0015580459,"about_ca_system_score_gemma":0.0008378283,"threshold_uncertainty_score":0.99999136},"labels":[],"label_agreement":null},{"id":"W4200142029","doi":"10.1016/j.annonc.2021.10.139","title":"120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Merck Sharp and Dohme; Eisai","keywords":"Medicine; Pembrolizumab; Internal medicine; First line treatment; Oncology; First line; Population; Placebo; Tolerability; Stock options; Phases of clinical research; Metastatic melanoma; Clinical trial; Adverse effect; Cancer; Chemotherapy; Immunotherapy; Pathology","score_opus":0.1440297160081384,"score_gpt":0.4343394679977686,"score_spread":0.2903097519896302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200142029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830241,0.0020970355,0.00040939476,0.005715019,0.00015063006,0.0042678793,0.000023557135,0.000051263007,0.004261128],"genre_scores_gemma":[0.99185985,0.0015176102,0.0013308221,0.0021120135,0.00012075061,0.0007159429,0.000076551034,0.00007168711,0.0021947792],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99606407,0.0005637027,0.0013775117,0.00073428237,0.0006140471,0.000646367],"domain_scores_gemma":[0.9968702,0.00089127605,0.0007102322,0.000686066,0.0006326563,0.00020957258],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018965711,0.0004961467,0.0029003038,0.00042270677,0.000106866995,0.00002789676,0.00023062926,0.00017894525,0.0010541065],"category_scores_gemma":[0.0002012386,0.00030998362,0.00027082334,0.0011345808,0.00060481776,0.00018613179,0.000073934556,0.00047887483,0.000008611017],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96250343,0.0093197,0.0017041992,0.00021821789,0.0029528465,0.0020403436,0.0033409933,0.000045170433,0.0007806416,0.00003713302,0.00064610504,0.016411187],"study_design_scores_gemma":[0.95060974,0.02930927,0.00075054745,0.0005601228,0.0010909113,0.0009793767,0.0033845936,0.00020911825,0.0054284604,0.000033367487,0.007234869,0.00040962204],"about_ca_topic_score_codex":0.0013452955,"about_ca_topic_score_gemma":0.011188768,"teacher_disagreement_score":0.01998957,"about_ca_system_score_codex":0.00011272928,"about_ca_system_score_gemma":0.0019823972,"threshold_uncertainty_score":0.9999352},"labels":[],"label_agreement":null},{"id":"W4200147408","doi":"10.1016/j.annonc.2021.10.018","title":"2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Atezolizumab; Oncology; Internal medicine; Adjuvant; Adjuvant chemotherapy; Chemotherapy; Stage (stratigraphy); Distributed File System; Cancer; Immunotherapy; Breast cancer","score_opus":0.04314062178960634,"score_gpt":0.3874494096085126,"score_spread":0.3443087878189063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200147408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909294,0.004694805,0.0000026477207,0.0015468346,0.00028179685,0.0011056376,0.0004238223,0.0000111687605,0.0010038639],"genre_scores_gemma":[0.99755174,0.0015334561,0.00004082521,0.00045367482,0.000044635537,0.00009130852,0.0000907034,0.000039846876,0.00015380414],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9968006,0.0003742842,0.0013796539,0.0005150295,0.00044710241,0.00048332068],"domain_scores_gemma":[0.99780524,0.00018894552,0.00055481534,0.0007801404,0.00050277304,0.00016809198],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006440547,0.00030719946,0.0014575323,0.00045767106,0.000020730673,0.000004707718,0.00026554873,0.00020909372,0.0007113037],"category_scores_gemma":[0.00014177615,0.00028523616,0.00030918705,0.0007792923,0.0003695352,0.000097982964,0.00013706187,0.00022507747,0.0000015923192],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4155019,0.03038416,0.3494054,0.0011906453,0.0022731156,0.00416395,0.034748837,0.0000062552194,0.055049784,0.000024781804,0.0011932752,0.106057905],"study_design_scores_gemma":[0.1426182,0.033937696,0.710883,0.0008530169,0.0002669464,0.000022965281,0.062304333,0.000022836964,0.043444674,0.0000695162,0.005056535,0.0005202727],"about_ca_topic_score_codex":0.0034385377,"about_ca_topic_score_gemma":0.008176238,"teacher_disagreement_score":0.3614776,"about_ca_system_score_codex":0.00017888464,"about_ca_system_score_gemma":0.0012843623,"threshold_uncertainty_score":0.99996},"labels":[],"label_agreement":null},{"id":"W4200168537","doi":"10.1093/bioinformatics/btab836","title":"TMBleR: a bioinformatic tool to optimize TMB estimation and predictive power","year":2021,"lang":"en","type":"article","venue":"Bioinformatics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"Ministero della Salute","keywords":"MIT License; Computer science; License; Container (type theory); Exome; Open source; Interface (matter); Heuristic; Predictive power; Data mining; Computational biology; Exome sequencing; Software; Gene; Operating system; Artificial intelligence; Mutation; Biology","score_opus":0.01103806359430913,"score_gpt":0.2568978572876185,"score_spread":0.24585979369330935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200168537","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65791935,0.0014838156,0.2716625,0.006842303,0.0011547247,0.0031460566,0.00029063076,0.00047301085,0.057027638],"genre_scores_gemma":[0.34758425,0.00055052614,0.6377139,0.01181295,0.000096370306,0.00010108263,0.00032390296,0.00004778025,0.0017692152],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99885815,0.000010108994,0.0005096465,0.000107752516,0.00028059396,0.00023373673],"domain_scores_gemma":[0.99924415,0.000043572705,0.00010716107,0.00031391942,0.00014581773,0.0001453504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001952151,0.00016373997,0.00025960646,0.00012492463,0.00008868981,0.00008719577,0.000055680433,0.000095197225,0.00021274836],"category_scores_gemma":[0.00016595975,0.00013719339,0.00007970571,0.0003381978,0.000054496155,0.00037340441,0.00006788888,0.00010350422,0.000106220716],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061407266,0.000579165,0.0022814337,0.003204554,0.001498765,0.00011089497,0.044030227,0.0012868774,0.0050598425,0.0009551383,0.074781545,0.8600708],"study_design_scores_gemma":[0.014105473,0.0028918285,0.041591685,0.0018133948,0.0005175698,0.0019381497,0.010667255,0.82008576,0.014669498,0.00026423053,0.09015322,0.0013019383],"about_ca_topic_score_codex":0.0000041228514,"about_ca_topic_score_gemma":0.0000012169124,"teacher_disagreement_score":0.8587689,"about_ca_system_score_codex":0.00009887698,"about_ca_system_score_gemma":0.00019898896,"threshold_uncertainty_score":0.55945843},"labels":[],"label_agreement":null},{"id":"W4200186763","doi":"10.1158/1078-0432.ccr-21-3329","title":"Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Merck","keywords":"Pembrolizumab; Biology; Cancer research; Oncology; Angiogenesis; Internal medicine; Cancer; Medicine; Immunotherapy; Genetics","score_opus":0.2046272144022776,"score_gpt":0.5705772446636609,"score_spread":0.3659500302613833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200186763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911678,0.0035807493,0.000013183259,0.004009355,0.00042957845,0.00049373694,0.00008549199,0.00002540808,0.0001947212],"genre_scores_gemma":[0.99176246,0.002255149,0.00014500714,0.0014934698,0.00030096993,0.00011177522,0.0000032213109,0.00004527983,0.0038826477],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99654454,0.00073997525,0.0008388556,0.00054131536,0.0006927658,0.00064254267],"domain_scores_gemma":[0.9973509,0.000859788,0.00008135725,0.00068617245,0.00070221105,0.00031960855],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0039585074,0.00015014768,0.00065608614,0.00011845311,0.00012544663,0.00003314955,0.0002750625,0.00015244416,0.0011594165],"category_scores_gemma":[0.00093653373,0.0001273407,0.0003378305,0.0007770016,0.0004984604,0.000051190767,0.00008155576,0.0005656156,0.000059228732],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26915067,0.00078624656,0.107024066,0.00025527444,0.00031679097,0.00037667304,0.0014967395,0.0000039167167,0.4712641,0.0000056345575,0.00532274,0.14399713],"study_design_scores_gemma":[0.013013328,0.0032706705,0.5284836,0.0007171267,0.00003802354,0.0000742333,0.00057474425,0.000084065374,0.38143098,0.000065374465,0.07199391,0.00025393415],"about_ca_topic_score_codex":0.00036329537,"about_ca_topic_score_gemma":0.0008933676,"teacher_disagreement_score":0.42145956,"about_ca_system_score_codex":0.00020820647,"about_ca_system_score_gemma":0.001881987,"threshold_uncertainty_score":0.99975365},"labels":[],"label_agreement":null},{"id":"W4200189057","doi":"10.3390/curroncol29010004","title":"New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer","year":2021,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Immunotherapy; Medicine; Lung cancer; Immune system; Tumor microenvironment; Cancer immunotherapy; Immune checkpoint; T cell; Clinical trial; Cancer; Immunology; Cancer research; Oncology; Internal medicine","score_opus":0.10806560009674963,"score_gpt":0.46427656267390216,"score_spread":0.3562109625771525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200189057","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015192658,0.9935944,0.00014838878,0.00048331617,0.0016164341,0.0023127208,0.0000461421,0.000014618068,0.00026468333],"genre_scores_gemma":[0.00008906023,0.99768114,0.0003951727,0.000158053,0.00007257291,0.00080781936,0.00008430672,0.00004447789,0.00066739955],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99794334,0.00020557994,0.0008611676,0.0004928739,0.0001315522,0.00036547103],"domain_scores_gemma":[0.99896973,0.00028788776,0.00026102582,0.00030424845,0.000059261718,0.000117838244],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030567893,0.00040729955,0.0024068414,0.0005459583,0.000029617828,0.000050410657,0.00016406918,0.00021561202,0.00021028033],"category_scores_gemma":[0.000025680132,0.00032884255,0.0002882748,0.0005961198,0.000051532756,0.00007079286,0.00007054859,0.0006036897,0.00000437197],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000074900905,0.00060866,0.0009388732,0.006798187,0.00030159592,0.00004321913,0.0006486261,5.141108e-7,0.000025352407,0.00007158753,0.0006242321,0.98986423],"study_design_scores_gemma":[0.0073377416,0.00046075336,0.0015503376,0.009474329,0.0006383941,0.000024185447,0.0005021279,0.000011879346,0.0000039535093,0.000031195053,0.97958654,0.0003785787],"about_ca_topic_score_codex":0.0009782047,"about_ca_topic_score_gemma":0.0021842513,"teacher_disagreement_score":0.9894857,"about_ca_system_score_codex":0.0009916994,"about_ca_system_score_gemma":0.0044982787,"threshold_uncertainty_score":0.9999164},"labels":[],"label_agreement":null},{"id":"W4200216655","doi":"10.1016/j.annonc.2021.10.168","title":"149P KEYNOTE-629: Efficacy of pembrolizumab (Pembro) per immune-related RECIST (irRECIST) in locally advanced (LA) and recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Basal cell; Response Evaluation Criteria in Solid Tumors; Immunotherapy; Internal medicine; Dermatology; Cancer research; Cancer; Chemotherapy; Phases of clinical research","score_opus":0.040726694827437536,"score_gpt":0.34813504704351783,"score_spread":0.3074083522160803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200216655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9703707,0.020276666,0.000021712489,0.0015896399,0.00033344934,0.0005866895,0.000035199522,0.000020805512,0.0067651533],"genre_scores_gemma":[0.9932229,0.0038682134,0.0008462963,0.00046209202,0.000023480528,0.00002645858,0.000050837752,0.000041248015,0.0014584677],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99699795,0.0004580751,0.001311101,0.00049537135,0.00029701163,0.00044051625],"domain_scores_gemma":[0.9972018,0.0012497853,0.00051531906,0.00048998976,0.00040194587,0.00014117327],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054735434,0.00030012414,0.0012219212,0.00025660568,0.00004537539,0.000008939696,0.0001693562,0.00025910055,0.0005549428],"category_scores_gemma":[0.00053670054,0.00025599985,0.00028996204,0.00050966215,0.0004293241,0.00006275951,0.00009441041,0.00041107327,0.0000074416953],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.100610204,0.004660707,0.0015096251,0.0011593637,0.0003908679,0.0036075222,0.002714547,0.00006954448,0.18760863,0.00007740465,0.001333681,0.6962579],"study_design_scores_gemma":[0.17211993,0.0669753,0.18544978,0.0019592273,0.0013726255,0.014851137,0.0046415003,0.0010407186,0.37143874,0.00056858506,0.17767517,0.0019072979],"about_ca_topic_score_codex":0.00023968042,"about_ca_topic_score_gemma":0.00026457992,"teacher_disagreement_score":0.6943506,"about_ca_system_score_codex":0.00013790707,"about_ca_system_score_gemma":0.0012221131,"threshold_uncertainty_score":0.9999892},"labels":[],"label_agreement":null},{"id":"W4200237636","doi":"10.21203/rs.3.rs-1088499/v1","title":"Novel Immune Subtypes Identification of HER2 Positive Breast Cancer Based On Immunogenomic Landscape","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Natural Science Foundation of Jiangsu Province; Government of Jiangsu Province; China Postdoctoral Science Foundation","keywords":"Immune system; Identification (biology); Breast cancer; Cancer; Immunology; Medicine; Cancer research; Oncology; Virology; Biology; Internal medicine; Ecology","score_opus":0.03385086352278686,"score_gpt":0.3690104911683471,"score_spread":0.33515962764556023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200237636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753613,0.014372253,0.00022589393,0.0041911355,0.0005381585,0.0018703247,0.002411753,0.000050604925,0.0009786012],"genre_scores_gemma":[0.9950221,0.002336756,0.00007876251,0.00007581298,0.00021584403,0.00023603476,0.001301273,0.00006130222,0.00067210174],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9969639,0.0002626447,0.0006102484,0.0006334694,0.0011004868,0.00042921683],"domain_scores_gemma":[0.996928,0.00022147373,0.00026766304,0.0010998055,0.0013826598,0.00010044631],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014174873,0.00026504186,0.0005696745,0.00051940617,0.00013550404,0.00010125688,0.00031944306,0.00034388123,0.001156447],"category_scores_gemma":[0.00009057605,0.0002391104,0.00041085636,0.0005637792,0.00022589207,0.00004678989,0.00023635408,0.0010609734,0.000016181093],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01141528,0.0012656148,0.00933065,0.0026380836,0.00088036485,0.00004459087,0.0007296333,0.00048012348,0.9571385,0.00001989468,0.00044344144,0.015613865],"study_design_scores_gemma":[0.0027554655,0.00035822956,0.8553483,0.005885389,0.000100919315,0.00002888888,0.00095087086,0.0020308045,0.13207205,0.00000958013,0.00018791422,0.0002715865],"about_ca_topic_score_codex":0.0057795024,"about_ca_topic_score_gemma":0.0001498931,"teacher_disagreement_score":0.84601766,"about_ca_system_score_codex":0.00069465593,"about_ca_system_score_gemma":0.0019635537,"threshold_uncertainty_score":0.99975663},"labels":[],"label_agreement":null},{"id":"W4200249070","doi":"10.51731/cjht.2021.225","title":"Pembrolizumab (Keytruda)","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Pembrolizumab; Medicine; Refractory (planetary science); Drug; Family medicine; Intensive care medicine; Internal medicine; Pharmacology; Political science; Cancer; Health care; Immunotherapy","score_opus":0.027838581508828623,"score_gpt":0.294519728736736,"score_spread":0.26668114722790737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200249070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40087813,0.39076093,0.00019043316,0.20491078,0.00096929236,0.00017557178,0.000014392491,0.0001100517,0.0019903902],"genre_scores_gemma":[0.9945876,0.0023513595,0.00068327965,0.002069912,0.000017121358,0.000001371801,0.0000020840812,0.0000105422005,0.00027674774],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990122,0.000028613847,0.0004124132,0.00009182173,0.00012859015,0.00032637507],"domain_scores_gemma":[0.99923766,0.000020660784,0.00020873158,0.00022633902,0.00021529525,0.00009130602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003008644,0.000082085826,0.0003133032,0.00033227846,0.00013274707,0.000020247278,0.00012681776,0.00011293413,0.00014971511],"category_scores_gemma":[0.0002891387,0.00006862413,0.00011572762,0.00036649738,0.000156993,0.0000509387,0.000008400169,0.00033250413,0.0000053408853],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013206704,0.00002058338,0.0062753307,0.00012317426,0.00010989291,0.0013021112,0.00019827465,7.5631726e-7,0.0008673556,0.00052125007,0.017265823,0.9731834],"study_design_scores_gemma":[0.0020053254,0.0006855013,0.03365567,0.00049432716,0.000023183582,0.006869439,0.0044568977,0.0000023528075,0.007095849,0.0011735138,0.9434216,0.00011635546],"about_ca_topic_score_codex":0.0015570681,"about_ca_topic_score_gemma":0.0029747803,"teacher_disagreement_score":0.97306705,"about_ca_system_score_codex":0.00044095502,"about_ca_system_score_gemma":0.00808721,"threshold_uncertainty_score":0.997536},"labels":[],"label_agreement":null},{"id":"W4200320597","doi":"10.1158/1535-7163.targ-21-p239","title":"Abstract P239: Safety and efficacy of copanlisib in combination with nivolumab: A phase Ib study in patients with advanced solid tumors","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Nivolumab; Internal medicine; Pharmacodynamics; Cancer; Pharmacokinetics; Gastroenterology; Oncology; Adverse effect; Pharmacology; Immunotherapy","score_opus":0.01232018435498204,"score_gpt":0.3024308497985526,"score_spread":0.29011066544357056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200320597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968781,0.0017257113,0.000097738346,0.00017112373,0.00003184873,0.0009900111,0.00001676133,0.000012067982,0.00007666133],"genre_scores_gemma":[0.9991128,0.0002522533,0.00013946963,0.0003721991,0.000005086131,0.00003305058,0.00003564478,0.000034377103,0.000015159778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987298,0.000059200993,0.00036814058,0.00029833743,0.0003385178,0.00020600721],"domain_scores_gemma":[0.9993358,0.000029274608,0.00015327235,0.0002693622,0.0001671933,0.00004506571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012410838,0.00018296098,0.00040699696,0.00012138147,0.00002731163,0.0000123435775,0.000058137448,0.000050776995,0.000028359133],"category_scores_gemma":[0.0000064465066,0.00014981965,0.000034160767,0.00050325046,0.0000931921,0.00006333239,0.000016711487,0.00017731838,1.8328616e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.071546465,0.011932146,0.60032094,0.00022219206,0.00084522,0.00042867853,0.003988986,0.00050579204,0.07035483,0.000017116687,0.00000167541,0.23983598],"study_design_scores_gemma":[0.07673793,0.0036694019,0.90129083,0.0005081207,0.000114048984,0.0000042213633,0.000560608,0.000080748134,0.016688053,0.000005377483,0.00014964183,0.00019098891],"about_ca_topic_score_codex":0.00021099413,"about_ca_topic_score_gemma":0.00064970116,"teacher_disagreement_score":0.30096993,"about_ca_system_score_codex":0.00019187851,"about_ca_system_score_gemma":0.00027577937,"threshold_uncertainty_score":0.6109468},"labels":[],"label_agreement":null},{"id":"W4200325010","doi":"10.1136/jitc-2021-003439","title":"Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"Medizinischen Fakultät, Eberhard Karls Universität Tübingen; Klaus Tschira Stiftung; Eberhard Karls Universität Tübingen; Merck Sharp and Dohme; Bristol-Myers Squibb","keywords":"Medicine; Peripheral blood; Melanoma; Antigen; Peripheral; Metastatic melanoma; Immunology; Oncology; Internal medicine; Cancer research","score_opus":0.02305420118363625,"score_gpt":0.33290988309969516,"score_spread":0.3098556819160589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200325010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96202564,0.035257116,0.00015805254,0.00073748385,0.0010288825,0.0005865183,0.000148013,0.000013559045,0.000044745146],"genre_scores_gemma":[0.9725142,0.024746321,0.0011916774,0.0008425134,0.0002008539,0.000039089435,0.0000093389035,0.00008157499,0.00037444234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734324,0.00014229283,0.0012690941,0.00037778245,0.00046827344,0.00039928767],"domain_scores_gemma":[0.99801695,0.0003017418,0.00075200986,0.0004015576,0.0004286932,0.00009906527],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043140716,0.00034963488,0.0013794106,0.00013491047,0.00009628305,0.000044799315,0.00022858812,0.00017546095,0.000758199],"category_scores_gemma":[0.00001982085,0.00024698544,0.00076066144,0.00032186203,0.00036766467,0.00022262224,0.000014819756,0.0004996821,7.7837433e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022286113,0.0009993768,0.598716,0.000028674798,0.0033174779,0.00005408924,0.0010741266,0.00003283101,0.3610592,0.000009798589,0.000040776686,0.01238154],"study_design_scores_gemma":[0.02464601,0.0021595317,0.7596884,0.0006624263,0.00012797867,0.00007342067,0.0006379785,0.000017428778,0.20942634,0.000090389534,0.002202237,0.0002678928],"about_ca_topic_score_codex":0.0011303975,"about_ca_topic_score_gemma":0.00024655016,"teacher_disagreement_score":0.16097236,"about_ca_system_score_codex":0.00012184243,"about_ca_system_score_gemma":0.0008632545,"threshold_uncertainty_score":0.9999982},"labels":[],"label_agreement":null},{"id":"W4200428978","doi":"10.1016/j.annonc.2021.10.181","title":"162P Population pharmacokinetic modeling of tremelimumab in patients (pts) with advanced solid tumors","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tremelimumab; Pharmacokinetics; Population; Internal medicine; Oncology; Durvalumab; Pharmacology; Immunology; Cancer; Immunotherapy; Nivolumab","score_opus":0.04898740511987927,"score_gpt":0.3773817252703681,"score_spread":0.32839432015048886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200428978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972898,0.0005524621,0.000040506886,0.0006680751,0.00007053047,0.0001760769,0.0000056806302,0.000006467146,0.0011904301],"genre_scores_gemma":[0.99853265,0.0003830831,0.0003819774,0.00058095355,0.000018943017,0.000007642146,0.000047741036,0.000010703911,0.000036277987],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99910444,0.00005017974,0.00040706026,0.00014500735,0.00014600849,0.00014731564],"domain_scores_gemma":[0.99938416,0.000026861793,0.00017072451,0.00012498889,0.00026100056,0.00003224542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012431694,0.00007990461,0.00037163973,0.000107626336,0.000010898016,0.0000010099379,0.000039110233,0.00005573909,0.00008294363],"category_scores_gemma":[0.000034239707,0.00006875079,0.000060814033,0.00023174979,0.00003628479,0.00004884564,0.000013664607,0.00007713156,6.3708353e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03101181,0.002903611,0.13451982,0.0003548372,0.0003281563,0.00008217512,0.0009963395,0.015236297,0.0676314,0.00003092218,0.0002305978,0.74667406],"study_design_scores_gemma":[0.05452567,0.020182129,0.7512148,0.0013687906,0.00019519606,0.00005049628,0.0007935556,0.023347326,0.14483212,0.0002826708,0.0027640732,0.0004431977],"about_ca_topic_score_codex":0.0001420288,"about_ca_topic_score_gemma":0.00009695885,"teacher_disagreement_score":0.74623084,"about_ca_system_score_codex":0.000045167337,"about_ca_system_score_gemma":0.0001479711,"threshold_uncertainty_score":0.2803576},"labels":[],"label_agreement":null},{"id":"W4200464648","doi":"10.1080/2162402x.2021.2010905","title":"CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development","year":2021,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; University of British Columbia","funders":"Canadian Institutes of Health Research; BC Cancer Foundation; Terry Fox Research Institute","keywords":"CCL5; Tumor microenvironment; Immune system; Cancer research; Chemokine; KRAS; Lung cancer; Immunotherapy; Cytokine; Immunology; Medicine; T cell; CD8; Cancer; Biology; IL-2 receptor; Oncology; Internal medicine","score_opus":0.012650492094816673,"score_gpt":0.27437048894631544,"score_spread":0.26171999685149877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200464648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98288804,0.01257209,0.000010306321,0.0033812698,0.0005391362,0.0005176365,0.0000031412821,0.000025214109,0.00006319101],"genre_scores_gemma":[0.99343336,0.0013435575,0.0024052288,0.0007392223,0.00009515826,0.00018144805,0.00003286846,0.000027801829,0.0017413521],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99875224,0.00007581477,0.0003399173,0.0004344724,0.00009919636,0.0002983482],"domain_scores_gemma":[0.9995287,0.000010950036,0.0000684378,0.00030383313,0.000035180026,0.000052884774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019031725,0.00016064355,0.00031480627,0.0001135512,0.00006730607,0.000013495381,0.00006481709,0.00007508688,0.00025733325],"category_scores_gemma":[0.000016214535,0.00015357624,0.0000315882,0.00018954152,0.00009023281,0.00006513034,0.00007338233,0.00016693091,0.000011200235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008403811,0.0003182898,0.0132372,0.00008048647,0.0000956059,0.000051349114,0.001993691,0.0000040263103,0.93629706,0.0000016960727,0.00012927216,0.046950962],"study_design_scores_gemma":[0.0013528032,0.00023111777,0.32923368,0.00018091354,0.000022340522,0.00014132807,0.00028643207,0.000006212847,0.6568439,0.0000020264117,0.011562738,0.00013652313],"about_ca_topic_score_codex":0.00026521937,"about_ca_topic_score_gemma":0.0005370377,"teacher_disagreement_score":0.31599647,"about_ca_system_score_codex":0.0004577108,"about_ca_system_score_gemma":0.00028066523,"threshold_uncertainty_score":0.62626576},"labels":[],"label_agreement":null},{"id":"W4200604006","doi":"10.3390/curroncol28060437","title":"The Challenge to the Pathologist of PD-L1 Expression in Tumor Cells of Non-Small-Cell Lung Cancer—An Overview","year":2021,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Concordance; Context (archaeology); Lung cancer; Immunotherapy; Oncology; Cancer; Biomarker; Cancer immunotherapy; Companion diagnostic; PD-L1; Internal medicine; Pathology; Biology","score_opus":0.20137463183731424,"score_gpt":0.4754145955967117,"score_spread":0.27403996375939743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200604006","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00068191194,0.9940113,0.000009860074,0.0003683178,0.0023796242,0.0020938672,0.00011795317,0.000007959675,0.0003292479],"genre_scores_gemma":[0.00012791686,0.99856526,0.000049372356,0.000096410506,0.00028991417,0.00067765237,0.00006137929,0.000036174974,0.000095951415],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99703306,0.0007492281,0.001150915,0.00047383417,0.000236312,0.00035665926],"domain_scores_gemma":[0.9975275,0.00046525378,0.00087606447,0.0009027385,0.0001400744,0.000088413144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011188977,0.00035785168,0.0020966448,0.00012808113,0.0000674451,0.000008145505,0.00059245183,0.0002630503,0.0001749875],"category_scores_gemma":[0.000055062308,0.00018343813,0.00055821275,0.00044822856,0.0002034896,0.00001858896,0.00024063473,0.0006576571,0.0000044428907],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020881067,0.00069603306,0.00003560091,0.022035541,0.000079680794,0.00003367609,0.0006293655,9.86685e-7,0.00029915056,0.000009788454,0.004058615,0.97191274],"study_design_scores_gemma":[0.00092271913,0.00063343707,0.00010020497,0.031442825,0.0005136771,0.00001952393,0.00024379653,0.0000072208445,0.00028745117,0.0000017474746,0.9656591,0.00016831594],"about_ca_topic_score_codex":0.00011442518,"about_ca_topic_score_gemma":0.00053010724,"teacher_disagreement_score":0.9717444,"about_ca_system_score_codex":0.00044631524,"about_ca_system_score_gemma":0.001523552,"threshold_uncertainty_score":0.74803895},"labels":[],"label_agreement":null},{"id":"W4200623684","doi":"10.1136/jim-2021-002099","title":"Immune Checkpoint Inhibitor-Induced Hypophysitis: Lessons Learnt from a Large Cancer Cohort","year":2021,"lang":"en","type":"article","venue":"Journal of Investigative Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes","funders":"National Center for Advancing Translational Sciences","keywords":"Ipilimumab; Hypophysitis; Nivolumab; Medicine; Pembrolizumab; Internal medicine; Cohort; Retrospective cohort study; Oncology; Cancer; Immunotherapy; Pituitary gland; Hormone","score_opus":0.053996172580428714,"score_gpt":0.325127185711637,"score_spread":0.2711310131312083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200623684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91895586,0.016955102,0.000070600974,0.061947085,0.0011521829,0.00019944532,0.00003280843,0.000019361269,0.00066756003],"genre_scores_gemma":[0.9894644,0.0024925591,0.00063614076,0.0041682,0.0024296963,0.000013747399,0.000038352144,0.000040150953,0.00071676675],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972112,0.00019985207,0.0011301717,0.0002848666,0.0008426208,0.0003312424],"domain_scores_gemma":[0.9973397,0.00014329395,0.00084628543,0.00031897303,0.000966222,0.0003854996],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000830738,0.0002823131,0.001079568,0.00017353859,0.00011243825,0.000016957712,0.00014345786,0.00013414136,0.0015041498],"category_scores_gemma":[0.00084044423,0.00019918334,0.00032823862,0.00058221794,0.0005680462,0.00015756494,0.000054575885,0.00082022406,0.000010160371],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070860016,0.00019550644,0.010838067,0.000056019988,0.00136152,0.0007998733,0.002126081,0.0000012576048,0.97306764,0.00006653804,0.005048299,0.005730576],"study_design_scores_gemma":[0.008159931,0.0011014919,0.34826493,0.003539302,0.0005694129,0.00033293813,0.0025943513,0.000019658248,0.6278424,0.00077334384,0.006616399,0.00018582732],"about_ca_topic_score_codex":0.0009726319,"about_ca_topic_score_gemma":0.00010737843,"teacher_disagreement_score":0.34522524,"about_ca_system_score_codex":0.00040395278,"about_ca_system_score_gemma":0.001206296,"threshold_uncertainty_score":0.9994086},"labels":[],"label_agreement":null},{"id":"W4205108774","doi":"10.1097/cji.0000000000000409","title":"Rapid Unmasking of Immune-related Adverse Events After Discontinuation of Chemotherapy in Chemo-immunotherapy Regimens","year":2022,"lang":"en","type":"article","venue":"Journal of Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Pembrolizumab; Discontinuation; Adverse effect; Chemotherapy; Incidence (geometry); Cancer","score_opus":0.008424769347801111,"score_gpt":0.25487114318210635,"score_spread":0.24644637383430523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205108774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96971786,0.027556416,0.00010347458,0.0010061057,0.00064329937,0.00065527076,0.000017237304,0.000014167428,0.0002861947],"genre_scores_gemma":[0.9883466,0.009606719,0.00083485944,0.0004959756,0.00006962832,0.000036376594,0.000012676778,0.00009073665,0.0005064763],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9953582,0.00032355302,0.002747086,0.00025217124,0.0009487357,0.0003701959],"domain_scores_gemma":[0.99620986,0.0001226505,0.0027248408,0.00059498136,0.00029020422,0.00005747811],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023573954,0.00034607612,0.0011950607,0.000862106,0.00008426298,0.0000060839343,0.00043135835,0.00014850429,0.0028280336],"category_scores_gemma":[0.000032608852,0.0003057618,0.0010524025,0.0010334817,0.00018394722,0.00027964023,0.000043290765,0.00067598996,0.0000013621079],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054520275,0.0022810686,0.024799779,0.000085050284,0.0019815587,0.00006015049,0.00902901,0.0001562848,0.8046117,0.000026144682,0.00013707645,0.10231191],"study_design_scores_gemma":[0.08691979,0.010058473,0.63266546,0.0022497962,0.0002100975,0.00090642564,0.0046088668,0.00018604453,0.23315024,0.0005196174,0.027648464,0.00087673526],"about_ca_topic_score_codex":0.00012291403,"about_ca_topic_score_gemma":0.0000042887045,"teacher_disagreement_score":0.6078657,"about_ca_system_score_codex":0.0005127566,"about_ca_system_score_gemma":0.00041552432,"threshold_uncertainty_score":0.99993944},"labels":[],"label_agreement":null},{"id":"W4205274612","doi":"10.1016/j.xcrm.2021.100506","title":"MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression","year":2022,"lang":"en","type":"letter","venue":"Cell Reports Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute, Cairo University; Takeda Pharmaceuticals U.S.A.; Sanofi; Astellas Pharma US; Janssen Pharmaceuticals; AstraZeneca; Eli Lilly and Company","keywords":"Cancer research; Chemoimmunotherapy; Medicine; Cancer; MEK inhibitor; MAPK/ERK pathway; Internal medicine; Immunotherapy; Biology; Kinase; Cell biology","score_opus":0.01590015017601759,"score_gpt":0.25525136529952597,"score_spread":0.23935121512350838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205274612","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18088852,0.05545428,0.00005237207,0.7267879,0.010181677,0.004389234,0.00009529224,0.0007726227,0.021378076],"genre_scores_gemma":[0.032054037,0.0026165163,0.00012810675,0.89905465,0.008335551,0.00058528996,0.010203168,0.00045966738,0.046563037],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99421734,0.00018681602,0.0017424768,0.0013160465,0.0017786946,0.000758642],"domain_scores_gemma":[0.9961562,0.00017123308,0.0016881427,0.0015768234,0.0002121923,0.00019541063],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00088869676,0.00090565736,0.0015610917,0.0004704138,0.00030371107,0.000036616057,0.00021034124,0.0007851883,0.014635382],"category_scores_gemma":[0.000120316756,0.00070980715,0.00042338742,0.0006045463,0.00033116597,0.00012192014,0.00010120473,0.0029281862,0.000019293828],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000533546,0.00010005694,0.00005897992,0.00035917122,0.00009747859,0.008675974,0.00023914024,7.562103e-8,0.44618836,4.1251457e-8,0.5427786,0.0009685706],"study_design_scores_gemma":[0.0029603615,0.0011562754,0.0000505467,0.0009612979,0.0001923461,0.0020610553,0.0002014376,0.0000016203003,0.3052958,0.000032499494,0.6866063,0.00048049158],"about_ca_topic_score_codex":0.00044690055,"about_ca_topic_score_gemma":0.000001567125,"teacher_disagreement_score":0.17226669,"about_ca_system_score_codex":0.0006528035,"about_ca_system_score_gemma":0.0004736859,"threshold_uncertainty_score":0.9995353},"labels":[],"label_agreement":null},{"id":"W4205289006","doi":"10.1016/j.jval.2021.11.103","title":"POSA30 Canadian Real-World Experience with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Systemic Anticancer Therapy","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Nivolumab; Medicine; Lung cancer; Regimen; Internal medicine; Stage (stratigraphy); Oncology; Population; Cancer; Database; Immunotherapy","score_opus":0.012919443884347018,"score_gpt":0.26732898897647517,"score_spread":0.25440954509212815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205289006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912847,0.004006004,0.000004810898,0.00043984814,0.000101418875,0.0037087745,0.000056408782,0.00003988648,0.00035814356],"genre_scores_gemma":[0.9951438,0.0018445025,0.00021079057,0.0011831057,0.000026761209,0.0011014845,0.000047794947,0.00007800761,0.0003637766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973415,0.00020452327,0.00051062735,0.00060488156,0.00048823238,0.0008502256],"domain_scores_gemma":[0.9988008,0.000039944378,0.00027971086,0.0004796476,0.00009196155,0.00030791375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031209292,0.00031522382,0.0005973989,0.00048774222,0.0002148771,0.000018141118,0.0001910107,0.00004433761,0.0001395365],"category_scores_gemma":[0.0000023395223,0.00022995617,0.000035319707,0.001612747,0.0000870495,0.00009837771,0.000016639608,0.00039088287,5.571157e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01082009,0.00025906935,0.97433233,0.00037031787,0.000053146883,0.00007686402,0.0066072843,0.0042311884,0.000079918536,0.0000027184037,0.00006380182,0.003103285],"study_design_scores_gemma":[0.022135686,0.0055423197,0.9653641,0.002828822,0.000023563663,0.000024660338,0.0016842228,0.00093146885,0.00018483726,4.4718456e-7,0.0008412649,0.00043859376],"about_ca_topic_score_codex":0.8255104,"about_ca_topic_score_gemma":0.4934447,"teacher_disagreement_score":0.3320657,"about_ca_system_score_codex":0.0047700796,"about_ca_system_score_gemma":0.004384643,"threshold_uncertainty_score":0.99905044},"labels":[],"label_agreement":null},{"id":"W4205349336","doi":"10.1136/jitc-2021-003779","title":"Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Cancer Prevention and Research Institute of Texas","keywords":"Medicine; Lung cancer; Internal medicine; Adverse effect; Cancer; Retrospective cohort study; Adverse Event Reporting System; Antibiotics; Pharmacovigilance; Logistic regression; Oncology","score_opus":0.008027828496329797,"score_gpt":0.2762625650620914,"score_spread":0.2682347365657616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205349336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98550814,0.011477524,0.000022985438,0.0006657346,0.00069254974,0.0014239429,0.00013605105,0.000014776546,0.00005831756],"genre_scores_gemma":[0.9876534,0.009152978,0.00027069132,0.00017001602,0.000048099908,0.00018487776,0.000031532585,0.00009372537,0.0023947202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738723,0.0001384438,0.0010209006,0.00025552075,0.00078869803,0.00040920635],"domain_scores_gemma":[0.9974495,0.00009399276,0.0017248827,0.0002907238,0.00039089067,0.00005001422],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00065787195,0.00030756555,0.000832186,0.0003776132,0.0002344852,0.0000060442453,0.00019069777,0.0000976273,0.0010765463],"category_scores_gemma":[0.000007997855,0.00022120142,0.00038551714,0.0006352392,0.000069669644,0.00017718374,0.0000133056465,0.00032674012,2.463586e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06311891,0.0013446804,0.8346685,0.000074796386,0.0047507323,0.0000028768843,0.0017856639,0.0010660833,0.03147571,0.000002435576,0.00008099417,0.061628576],"study_design_scores_gemma":[0.06325807,0.01067425,0.906132,0.00090789853,0.0002916498,0.000015992866,0.00042526316,0.000046274516,0.009276228,0.00001898,0.0086282855,0.00032510102],"about_ca_topic_score_codex":0.0015043374,"about_ca_topic_score_gemma":0.0002367707,"teacher_disagreement_score":0.07146347,"about_ca_system_score_codex":0.002931121,"about_ca_system_score_gemma":0.00074139546,"threshold_uncertainty_score":0.9998366},"labels":[],"label_agreement":null},{"id":"W4205361646","doi":"10.2217/fon-2021-1348","title":"Optimal first-line immune checkpoint inhibitor treatment in lung cancer: how to choose?","year":2022,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Pembrolizumab; Medicine; Oncology; Lung cancer; Internal medicine; Chemotherapy; MEDLINE; Cancer; Immunotherapy","score_opus":0.009674789902303988,"score_gpt":0.3116780937574068,"score_spread":0.3020033038551028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205361646","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008813682,0.02793482,0.0000043764835,0.041592337,0.91749084,0.0024916674,0.0007789192,0.00010258206,0.0007907559],"genre_scores_gemma":[0.0006158165,0.02334072,0.00046985972,0.000540476,0.95518976,0.002968889,0.0019342786,0.00014917979,0.014791008],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967974,0.0001674357,0.00075522036,0.0009273154,0.0006297117,0.0007229094],"domain_scores_gemma":[0.99826634,0.000294271,0.00039299627,0.0006690278,0.00014498236,0.00023235724],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047147178,0.0006654633,0.0016742668,0.00046591143,0.00016215029,0.000031896558,0.00032310153,0.0014839487,0.0031983058],"category_scores_gemma":[0.0001362219,0.00056186115,0.0005218985,0.0005868645,0.000081539765,0.000050418206,0.00019225212,0.0014724635,0.000013707473],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01650974,0.00076516514,0.00009951593,0.00031367491,0.0007055889,0.0006487923,0.001471473,0.000051420586,0.0010112649,0.0000013294724,0.9431281,0.03529394],"study_design_scores_gemma":[0.013631714,0.0065003484,0.0007028141,0.00033941533,0.0003644777,0.00003309251,0.0004970717,0.000018666698,0.0005612903,7.420376e-7,0.9768678,0.00048256098],"about_ca_topic_score_codex":0.004190784,"about_ca_topic_score_gemma":0.0077120354,"teacher_disagreement_score":0.04105186,"about_ca_system_score_codex":0.011320458,"about_ca_system_score_gemma":0.003397074,"threshold_uncertainty_score":0.9998123},"labels":[],"label_agreement":null},{"id":"W4205491929","doi":"10.1016/j.ccell.2021.12.009","title":"MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells","year":2022,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":217,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec; Université de Montréal","funders":"Ipsen; Conseil régional de Bourgogne-Franche-Comté; Ligue Contre le Cancer; Division of Agriculture and Natural Resources, University of California; Servier; Institut National Du Cancer; Institut National de la Santé et de la Recherche Médicale; Sanofi; Fondation ARC pour la Recherche sur le Cancer; Agence Nationale de la Recherche; Roche; Novartis; Association pour la Recherche sur le Cancer; Amgen; Pfizer; Université de Bourgogne; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Chemoimmunotherapy; Cancer research; Mitophagy; CXCL10; Autophagy; Medicine; Nivolumab; Immunotherapy; Immunology; Immune system; Chemistry; Chemokine; Apoptosis","score_opus":0.013573416290190671,"score_gpt":0.27010334842856126,"score_spread":0.2565299321383706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205491929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9142961,0.076878585,0.000012702649,0.001987393,0.0008431111,0.00057357893,0.00021365579,0.0000635095,0.0051313546],"genre_scores_gemma":[0.96334666,0.01372294,0.00008186143,0.0053966762,0.00016184687,0.00075639633,0.00006686493,0.00007220434,0.01639456],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982946,0.00007380032,0.00038519298,0.00044680468,0.00039931774,0.00040027592],"domain_scores_gemma":[0.9993389,0.000037581445,0.00017436007,0.00033720702,0.000042021264,0.00006991565],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027662082,0.00022780424,0.0003533506,0.0001011209,0.00017908656,0.00002280883,0.0001332981,0.00008226022,0.0067537813],"category_scores_gemma":[0.0000025292015,0.0002367621,0.00012949738,0.00052878325,0.000072070994,0.00013372114,0.00004972638,0.00040102442,0.0000049120295],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002278747,0.0002469307,0.002151318,0.00014343065,0.00005921963,0.000023678702,0.0015643497,0.00006284673,0.92387456,0.000006252299,0.062226772,0.0073618907],"study_design_scores_gemma":[0.0060267285,0.00015229377,0.0029326167,0.0002007001,0.00003417526,0.0000037391737,0.0008864057,0.000029786426,0.5757174,0.000029154364,0.41364276,0.00034424965],"about_ca_topic_score_codex":0.006065031,"about_ca_topic_score_gemma":0.0014344293,"teacher_disagreement_score":0.351416,"about_ca_system_score_codex":0.0021928996,"about_ca_system_score_gemma":0.00037478897,"threshold_uncertainty_score":0.99415416},"labels":[],"label_agreement":null},{"id":"W4205514480","doi":"10.1016/j.jval.2021.11.751","title":"POSA236 Real-World Treatment (Tx) Characteristics for Advanced Non-Small Cell Lung Cancer (aNSCLC) Without Actionable Mutations After Introduction of Immune Checkpoint Inhibitors (ICIs) in EU4 and UK","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Pemetrexed; Pembrolizumab; Carboplatin; Lung cancer; Nivolumab; Oncology; Medicine; Internal medicine; Atezolizumab; Cancer; Chemotherapy; Immunotherapy; Cisplatin","score_opus":0.017029739607347674,"score_gpt":0.3016004906995064,"score_spread":0.28457075109215874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205514480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99123937,0.0025817214,0.000039286835,0.0032559542,0.00055743405,0.00211546,0.00015003818,0.000014365927,0.00004637525],"genre_scores_gemma":[0.9930816,0.0028875773,0.00084594195,0.00013054111,0.00021089739,0.001772238,0.00015089473,0.000029842258,0.00089044485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984077,0.00008435534,0.0007842666,0.00030601656,0.00014685423,0.00027080456],"domain_scores_gemma":[0.99929655,0.00005970007,0.00033346895,0.00019674654,0.000052059295,0.00006148466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050822494,0.0001539442,0.00040138583,0.0003265555,0.00010550747,0.0000067257,0.00003603263,0.000036526373,0.00010678401],"category_scores_gemma":[0.000013541589,0.00015045355,0.00008687092,0.000403338,0.000041161486,0.00005420072,0.00002072621,0.00016118691,1.8656914e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030926455,0.002415196,0.78397214,0.0047994186,0.00027751943,0.000021842596,0.017930482,0.010381273,0.091408625,0.00007271829,0.0004004321,0.057393916],"study_design_scores_gemma":[0.012781949,0.002335656,0.9466521,0.0005276522,0.00010606204,0.000018654348,0.001878177,0.0059897113,0.021695575,0.00005220914,0.0076474138,0.0003148121],"about_ca_topic_score_codex":0.031217761,"about_ca_topic_score_gemma":0.0021011431,"teacher_disagreement_score":0.16268,"about_ca_system_score_codex":0.0018763562,"about_ca_system_score_gemma":0.00053969666,"threshold_uncertainty_score":0.97523344},"labels":[],"label_agreement":null},{"id":"W4205565447","doi":"10.1200/jco.2022.40.4_suppl.379","title":"Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":400,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Hazard ratio; Regimen; Confidence interval; Internal medicine; Clinical endpoint; Gastroenterology; Phases of clinical research; Randomized controlled trial; Surgery; Toxicity","score_opus":0.10917407562743807,"score_gpt":0.43190488269526556,"score_spread":0.3227308070678275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205565447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941605,0.0013342438,0.000006483774,0.0013751981,0.00047448426,0.0024010828,0.000008212901,0.000003901838,0.00023591601],"genre_scores_gemma":[0.9971689,0.0011189054,0.00020339171,0.0011405685,0.00011776119,0.00006654422,0.00000630522,0.000028848106,0.00014879601],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941031,0.0017138354,0.0029229147,0.00030457182,0.0006961649,0.00025944365],"domain_scores_gemma":[0.9953126,0.0017006038,0.0021060435,0.00028652587,0.0003966029,0.00019763045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067779194,0.00021040201,0.0026106015,0.00024309583,0.00010423036,0.00001693485,0.00037903182,0.00013343668,0.00054630986],"category_scores_gemma":[0.00078801444,0.00013726123,0.00021426502,0.00030876388,0.00027135824,0.00015394363,0.00020377226,0.00088836387,9.63464e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60234565,0.048391573,0.3114041,0.00001742889,0.00074566255,0.0004007767,0.00068225665,0.000008123126,0.00009048205,0.0000016367042,0.00019803034,0.035714265],"study_design_scores_gemma":[0.73649436,0.20326802,0.053927723,0.000059292975,0.0002946373,0.000061896535,0.0007492317,0.000602131,0.00006362613,0.000016535452,0.0043501165,0.00011243659],"about_ca_topic_score_codex":0.000780736,"about_ca_topic_score_gemma":0.00019538257,"teacher_disagreement_score":0.2574764,"about_ca_system_score_codex":0.00025962983,"about_ca_system_score_gemma":0.0009055207,"threshold_uncertainty_score":0.598171},"labels":[],"label_agreement":null},{"id":"W4205571568","doi":"10.15430/jcp.2021.26.4.309","title":"Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report","year":2021,"lang":"en","type":"article","venue":"Journal of Cancer Prevention","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Cancer prevention; Medicine; Library science; Cancer; Environmental ethics; Philosophy; Internal medicine; Computer science","score_opus":0.034192395549886255,"score_gpt":0.36845774952262234,"score_spread":0.3342653539727361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205571568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9472518,0.04595674,0.0025205244,0.0014312395,0.0019778397,0.00035306218,0.000004813154,0.000012927528,0.00049104536],"genre_scores_gemma":[0.96533805,0.024861682,0.0012796351,0.00040489557,0.00060085877,0.00009121019,0.000054460448,0.00003502043,0.007334174],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974453,0.00012931337,0.0011911023,0.00026240997,0.00075187127,0.00022000472],"domain_scores_gemma":[0.99859273,0.00003534742,0.00077373936,0.00017811159,0.0003316379,0.0000884283],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00075247406,0.0001893327,0.00040142142,0.00024403489,0.00007353255,0.000026419397,0.000087994325,0.000116084986,0.0013279087],"category_scores_gemma":[0.000041120096,0.0001720441,0.00034209306,0.0003699188,0.00003677381,0.0004399624,0.00001454328,0.00033275405,0.0000029277744],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043999893,0.0011366911,0.017595166,0.00014904316,0.0007357354,0.000488571,0.00083780533,0.002543348,0.012706644,0.000036878388,0.00066927396,0.95870084],"study_design_scores_gemma":[0.011260776,0.00074740686,0.6310345,0.008218498,0.00033750688,0.00064195547,0.0006253551,0.00010281923,0.028059801,0.00036698126,0.3181587,0.00044571652],"about_ca_topic_score_codex":0.000017342245,"about_ca_topic_score_gemma":0.00046483258,"teacher_disagreement_score":0.9582551,"about_ca_system_score_codex":0.0008814522,"about_ca_system_score_gemma":0.0018105098,"threshold_uncertainty_score":0.99958503},"labels":[],"label_agreement":null},{"id":"W4205576580","doi":"10.1200/jco.2022.40.4_suppl.659","title":"Nemvaleukin alfa combination therapy for gastrointestinal (GI) cancers: Preclinical evidence and clinical data from the ARTISTRY-1 trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Alberta; Université Laval; Princess Margaret Cancer Centre; McMaster University; Alberta Health Services; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Cancer; Colorectal cancer; Pancreatic cancer; Adenocarcinoma; Clinical trial; Gastroenterology; Immunotherapy","score_opus":0.46681925037491434,"score_gpt":0.5574949983397592,"score_spread":0.0906757479648449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205576580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93349475,0.0060698283,0.00084619864,0.05389809,0.004163868,0.0012936352,0.00014247093,0.000013400208,0.00007776213],"genre_scores_gemma":[0.9504324,0.015390216,0.008672034,0.018209219,0.0067846985,0.00006693666,0.00009430769,0.0000392656,0.00031092338],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99276626,0.00203847,0.0039165583,0.0004546323,0.0005724274,0.00025165832],"domain_scores_gemma":[0.9586376,0.036653366,0.0032748554,0.00077311584,0.00037347773,0.0002875711],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021809736,0.00016510225,0.001344225,0.00004252604,0.0002056914,0.00003205229,0.0008158779,0.00018764067,0.00048137445],"category_scores_gemma":[0.019125612,0.00010512843,0.0006229174,0.00014370338,0.0006369892,0.00020248216,0.00029739577,0.0017325808,0.0000021554765],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49450994,0.0027542028,0.10408618,0.000009587666,0.00065584225,0.00009404414,0.000041919662,0.0000030972915,0.00008508648,0.000026984448,0.07471946,0.32301366],"study_design_scores_gemma":[0.16945226,0.097798124,0.39208898,0.00025367213,0.0006460502,0.0006696453,0.0002996194,0.0015295432,0.0000060738244,0.0007378346,0.33636928,0.00014890761],"about_ca_topic_score_codex":0.00018422028,"about_ca_topic_score_gemma":0.00012309321,"teacher_disagreement_score":0.32505766,"about_ca_system_score_codex":0.00024231894,"about_ca_system_score_gemma":0.0042347843,"threshold_uncertainty_score":0.9891367},"labels":[],"label_agreement":null},{"id":"W4205700458","doi":"10.21203/rs.3.rs-1155834/v1","title":"A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nicolet Chartrand Knoll (Canada)","funders":"","keywords":"Immune system; Immune checkpoint; Cancer research; T cell; Cytotoxic T cell; Immunology; Breast cancer; Tumor microenvironment; Cell; Biology; Mass cytometry; Immunotherapy; Cancer; Medicine; Phenotype; Internal medicine","score_opus":0.0610371263340373,"score_gpt":0.37005171985493757,"score_spread":0.30901459352090027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205700458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849534,0.009553261,0.0000022549762,0.00083438534,0.00025587087,0.0019567925,0.0010155995,0.000027987922,0.0014004167],"genre_scores_gemma":[0.9894192,0.0017823623,0.000025201454,0.000046571506,0.00008734169,0.00045803512,0.0009821592,0.00007522958,0.0071238484],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.995809,0.0006066334,0.0006984468,0.00065492024,0.0015639202,0.0006670341],"domain_scores_gemma":[0.99837023,0.00016988919,0.0003235976,0.0007909048,0.00021415838,0.00013119045],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008677391,0.0003153746,0.00073863583,0.00066800346,0.00018943765,0.000030019624,0.00040878903,0.00035602885,0.0066929697],"category_scores_gemma":[0.000016005628,0.00032356972,0.00032327705,0.00046175913,0.00032540466,0.000038866798,0.0009804134,0.002087357,0.000018095756],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031004853,0.00420676,0.040764444,0.004628239,0.00035993796,0.00017729218,0.0016232703,0.00035039234,0.94083744,0.0000031872214,0.0025576013,0.0013909766],"study_design_scores_gemma":[0.014513638,0.0019410079,0.8713649,0.005205734,0.00014725588,0.000011099155,0.0054289023,0.00016462487,0.078060195,0.00011501057,0.022235656,0.0008119775],"about_ca_topic_score_codex":0.009837591,"about_ca_topic_score_gemma":0.00016402105,"teacher_disagreement_score":0.86277723,"about_ca_system_score_codex":0.0028326951,"about_ca_system_score_gemma":0.0005243427,"threshold_uncertainty_score":0.9999216},"labels":[],"label_agreement":null},{"id":"W4205824700","doi":"10.1200/jco.2021.39.15_suppl.2582","title":"Platform trial of ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients (pts) with previously treated advanced solid tumors: Combination with BI 836880, a VEGF/Ang2-blocking nanobody.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Medicine; Cohort; Oncology; Bevacizumab; Internal medicine; Cancer; Chemotherapy; Cancer research","score_opus":0.05288422157225228,"score_gpt":0.4208904504800132,"score_spread":0.3680062289077609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205824700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973265,0.00026862707,0.000039453033,0.00075561996,0.0005282745,0.0006854568,0.000005681669,0.000013886291,0.0003765256],"genre_scores_gemma":[0.997137,0.000672449,0.0012749737,0.00050748495,0.00025989316,0.0000074463023,0.00005326127,0.000035820365,0.000051674324],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9954214,0.0003958274,0.002855686,0.00032634544,0.0006457095,0.0003550322],"domain_scores_gemma":[0.99500066,0.0006060189,0.0028664807,0.0002921222,0.001007659,0.00022706446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019642143,0.00024559165,0.0021720827,0.000278662,0.00004966985,0.000016149777,0.00018196506,0.00034898345,0.000055534605],"category_scores_gemma":[0.00078256323,0.00016215158,0.00033524632,0.00059142447,0.0002764607,0.00036830376,0.000035266494,0.0007422483,0.0000011827974],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60464215,0.016036047,0.24845167,0.00012838983,0.0008945454,0.0010903608,0.00042050122,0.000040468407,0.0052192444,0.00001800222,0.0000767813,0.12298181],"study_design_scores_gemma":[0.40226895,0.16412137,0.42488253,0.001818696,0.00048184325,0.0003344921,0.00046531676,0.00013489212,0.0037818095,0.000044481432,0.0014160632,0.00024956046],"about_ca_topic_score_codex":0.000059833066,"about_ca_topic_score_gemma":0.0002619023,"teacher_disagreement_score":0.20237325,"about_ca_system_score_codex":0.0002946346,"about_ca_system_score_gemma":0.002312353,"threshold_uncertainty_score":0.661235},"labels":[],"label_agreement":null},{"id":"W4205984778","doi":"10.3390/curroncol29010025","title":"Immune-Related Pneumonitis Was Decreased by Addition of Chemotherapy with PD-1/L1 Inhibitors: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTs)","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"West China Hospital, Sichuan University; Sichuan University; National Natural Science Foundation of China","keywords":"Chemotherapy; Randomized controlled trial; Pneumonitis; Lower risk; Observational study; Radiation therapy","score_opus":0.061820965335758093,"score_gpt":0.3636418611585258,"score_spread":0.3018208958227677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205984778","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021694435,0.96380085,0.00010913117,0.001967874,0.00028341808,0.011681049,0.00028497464,0.000030130448,0.00014815667],"genre_scores_gemma":[0.8579249,0.12981273,0.00012316098,0.0012259871,0.00007578694,0.008975754,0.0014555868,0.000058416274,0.0003476838],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9893665,0.0059977844,0.0036910335,0.00029735905,0.00044041438,0.00020693011],"domain_scores_gemma":[0.9909556,0.0042011905,0.0041401247,0.00037458367,0.00025173518,0.00007678423],"candidate_categories":["metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.012713776,0.00028827644,0.019811805,0.0003024017,0.000082766936,0.0000065197146,0.00011484655,0.000090947775,0.0035836864],"category_scores_gemma":[0.0011986952,0.00016359735,0.004027867,0.0010247538,0.0002720758,0.000034360404,0.000028317763,0.0002192397,5.20868e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30678126,0.001106916,0.000039614715,0.026677439,0.6568883,0.0000070341885,0.00031579504,0.000026033922,0.0023274997,0.00005223963,0.0050457385,0.00073211],"study_design_scores_gemma":[0.27481285,0.0010137608,0.000021144604,0.0028048488,0.71977574,0.000032626685,0.00010919914,0.00022720359,0.00020352076,0.00002555558,0.0008211006,0.00015246768],"about_ca_topic_score_codex":0.000057243935,"about_ca_topic_score_gemma":0.0000057715542,"teacher_disagreement_score":0.83623046,"about_ca_system_score_codex":0.0001536295,"about_ca_system_score_gemma":0.00021459472,"threshold_uncertainty_score":0.99732715},"labels":[],"label_agreement":null},{"id":"W4206023678","doi":"10.1158/2767-9764.crc-21-0032","title":"Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation","year":2022,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Durvalumab; Head and neck squamous-cell carcinoma; PD-L1; Medicine; Oncology; Immune system; Biomarker; Immune checkpoint; Cancer research; Internal medicine; Immunotherapy; Head and neck cancer; Cancer; Immunology; Biology; Nivolumab","score_opus":0.094955199636439,"score_gpt":0.39300963255965166,"score_spread":0.29805443292321265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206023678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838008,0.012224963,0.0000042507263,0.0026238775,0.00003904833,0.0008152597,0.00009325281,0.000008791396,0.00038972468],"genre_scores_gemma":[0.99463975,0.0040190932,0.00037023268,0.00004206524,0.0000093252975,0.00041848188,0.000054390406,0.000017185148,0.00042948834],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99770397,0.0010582944,0.00028282963,0.0002157559,0.00052850804,0.00021065235],"domain_scores_gemma":[0.99804455,0.0009826676,0.0001583061,0.0005752513,0.00016738415,0.00007183945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002011281,0.00010107862,0.00024451775,0.00021542955,0.000348695,0.000028623535,0.00017669196,0.00002581633,0.00009652098],"category_scores_gemma":[0.000121739875,0.00008170832,0.000021945765,0.0005016601,0.00018324837,0.00007761274,0.00027941196,0.00051189034,3.0834437e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03384059,0.0034997421,0.227485,0.0016123166,0.00025988085,0.00003364357,0.012548151,0.00012379141,0.68241847,0.00023568395,0.00416191,0.033780854],"study_design_scores_gemma":[0.029405328,0.010705825,0.7749901,0.0012652545,0.00030072473,0.000042510022,0.01287746,0.0032559156,0.14017671,0.00022908326,0.026093522,0.00065759313],"about_ca_topic_score_codex":0.0019891593,"about_ca_topic_score_gemma":0.0010020919,"teacher_disagreement_score":0.5475051,"about_ca_system_score_codex":0.0004531253,"about_ca_system_score_gemma":0.00030436376,"threshold_uncertainty_score":0.33319688},"labels":[],"label_agreement":null},{"id":"W4206202786","doi":"10.1158/2326-6074.tumimm21-p013","title":"Abstract P013: Germinal center hypoxia in tumor-draining lymph nodes negatively regulates humoral immune responses and affects the activation of tumor-infiltrating T cells","year":2022,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Germinal center; Immune system; Tumor hypoxia; Cancer research; Lymph; Immunology; Antibody; Immunoglobulin class switching; Biology; Hypoxia (environmental); Lymph node; Medicine; B cell; Pathology; Chemistry; Internal medicine; Radiation therapy","score_opus":0.05903517423731405,"score_gpt":0.3599433665381531,"score_spread":0.3009081923008391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206202786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99016106,0.006304384,8.767861e-7,0.0021669974,0.00017646317,0.0006350202,0.000035397778,0.000023172515,0.0004966443],"genre_scores_gemma":[0.9985815,0.0003436234,0.00005468802,0.00019809036,0.000067416455,0.0003262107,0.000014228023,0.000034458375,0.00037974791],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99715084,0.0008324068,0.00047712727,0.00040574453,0.0005096495,0.0006242295],"domain_scores_gemma":[0.9979051,0.0012351848,0.00025380924,0.00039362052,0.00016873336,0.000043553347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025185924,0.00020254066,0.00043165352,0.00049502245,0.0005771478,0.000037161044,0.0003116531,0.00007094429,0.0004602315],"category_scores_gemma":[0.00025639017,0.00016336578,0.0000957205,0.00084295485,0.0011583301,0.00015123968,0.00028485747,0.0009960732,0.0000017642411],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011595733,0.00013805972,0.031225612,0.00011588051,0.00017259666,0.000074635296,0.0028977056,0.000023876582,0.9414499,0.000042645235,0.00013080686,0.012132555],"study_design_scores_gemma":[0.0030024045,0.0003882302,0.66117877,0.0003244459,0.000011088337,0.00014576923,0.006648185,0.000085120046,0.32740104,0.00006123196,0.0006230516,0.00013069292],"about_ca_topic_score_codex":0.001913731,"about_ca_topic_score_gemma":0.000024461748,"teacher_disagreement_score":0.62995315,"about_ca_system_score_codex":0.00054608774,"about_ca_system_score_gemma":0.00073738315,"threshold_uncertainty_score":0.66618633},"labels":[],"label_agreement":null},{"id":"W4206274135","doi":"10.1016/j.ctro.2021.12.008","title":"Stereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC)","year":2022,"lang":"en","type":"article","venue":"Clinical and Translational Radiation Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Varian Medical Systems; AstraZeneca","keywords":"Medicine; SABR volatility model; Oncology; Randomized controlled trial; Internal medicine; Lung cancer; Radiation therapy; Systemic therapy; Clinical endpoint; Context (archaeology); Quality of life (healthcare); Cancer","score_opus":0.03669078119217174,"score_gpt":0.4070221651495956,"score_spread":0.3703313839574239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206274135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624374,0.014953333,0.0025622628,0.009928766,0.00095738895,0.008624897,0.0004272921,0.00003102294,0.000077633056],"genre_scores_gemma":[0.98804116,0.0016735431,0.000634655,0.0036498022,0.0005295571,0.004955281,0.00030526455,0.000031953277,0.0001787745],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970642,0.00078667066,0.0011187603,0.00051696814,0.0002587381,0.00025468043],"domain_scores_gemma":[0.99611944,0.002841751,0.00048709667,0.00019616666,0.0001100511,0.00024550388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00153858,0.00022065979,0.00093360315,0.00021061423,0.00025615975,0.000016647833,0.00011566573,0.00015667101,0.0003899156],"category_scores_gemma":[0.0001606682,0.00019171818,0.00042654274,0.00024286652,0.00020482606,0.000068124136,0.000010759872,0.000339208,3.9824522e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9357104,0.002472324,0.003832039,0.00008595881,0.00046507549,0.000022655071,0.0011650161,0.00056077715,0.00047923098,0.00003876325,0.00043254514,0.05473524],"study_design_scores_gemma":[0.94166446,0.008063883,0.006399279,0.00008294997,0.00026310628,0.0000060364837,0.000068255715,0.022894677,0.00003445467,0.0000799457,0.020210568,0.00023239489],"about_ca_topic_score_codex":0.000054305547,"about_ca_topic_score_gemma":0.000012775905,"teacher_disagreement_score":0.054502845,"about_ca_system_score_codex":0.00024270553,"about_ca_system_score_gemma":0.0015863361,"threshold_uncertainty_score":0.7818041},"labels":[],"label_agreement":null},{"id":"W4206312263","doi":"10.1038/s41416-021-01692-4","title":"Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy","year":2022,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"Natural Science Foundation of Zhejiang Province","keywords":"Evasion (ethics); Ovarian cancer; Immune system; Serous ovarian cancer; Serous fluid; Immunotherapy; Selection (genetic algorithm); Cancer","score_opus":0.01715629107594695,"score_gpt":0.26333862470955716,"score_spread":0.2461823336336102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206312263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93038595,0.06787757,0.00004868856,0.00078241865,0.00029807838,0.00053019065,0.000059517643,0.000014410995,0.0000031611046],"genre_scores_gemma":[0.97326124,0.025867442,0.0003303552,0.00021048042,0.000080206286,0.000088592715,0.00001466051,0.00003454946,0.00011244943],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983793,0.00017858806,0.0006181088,0.00024149808,0.0003455566,0.0002369752],"domain_scores_gemma":[0.99875367,0.00004080109,0.0007584585,0.00014920895,0.00022082608,0.00007702738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000586663,0.00017481025,0.0005847715,0.00012964482,0.0002687141,0.000087679764,0.000143683,0.00007964293,0.00035074298],"category_scores_gemma":[0.000013960209,0.00015485425,0.000096396245,0.00021653714,0.00014843758,0.00025958507,0.000059220183,0.00038665964,9.450567e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073446278,0.0002504744,0.0030820614,0.00008206423,0.0006416931,0.000055362772,0.00050825876,0.000009366529,0.8003099,0.00001185184,0.0000092335495,0.18769509],"study_design_scores_gemma":[0.009280504,0.0032885992,0.9424097,0.0008017,0.00048619293,0.0031178,0.00078399904,0.0000413325,0.038932238,0.00020680239,0.00041080816,0.00024031303],"about_ca_topic_score_codex":0.0054754955,"about_ca_topic_score_gemma":0.00027816425,"teacher_disagreement_score":0.93932766,"about_ca_system_score_codex":0.00022731523,"about_ca_system_score_gemma":0.00027107802,"threshold_uncertainty_score":0.8277348},"labels":[],"label_agreement":null},{"id":"W4206341203","doi":"10.1200/jco.2022.40.4_suppl.tps216","title":"GOBLET: A phase 1/2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic gastrointestinal cancers exploring treatment combinations with pelareorep and atezolizumab.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"Oncolytics Biotech","keywords":"Atezolizumab; Medicine; Blockade; Immune checkpoint; Oncology; Cancer; Pembrolizumab; Colorectal cancer; Internal medicine; Cancer research; Immunotherapy; Melanoma; Receptor","score_opus":0.21386098103290557,"score_gpt":0.48079493828909386,"score_spread":0.2669339572561883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206341203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995889,0.00052398077,0.00012841719,0.0024042362,0.00016670124,0.00082991086,0.000010109809,0.000010762275,0.000036866324],"genre_scores_gemma":[0.996363,0.0011265366,0.0021779384,0.00016025393,0.00003905241,0.000067911555,0.000005639314,0.00001928089,0.000040384606],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973631,0.00052716833,0.0014227189,0.00023009592,0.00027413378,0.00018280184],"domain_scores_gemma":[0.9965264,0.0020385135,0.0010184195,0.00012733221,0.000103081176,0.0001862144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017370947,0.00014624505,0.0008998819,0.00025270897,0.00011262735,0.000009318821,0.0000715487,0.000025833644,0.00006112118],"category_scores_gemma":[0.0007284126,0.000095979376,0.00010030117,0.0003017443,0.00018727864,0.000121373785,0.000041386364,0.00039522757,1.9252936e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2046616,0.011812052,0.13395461,0.000023268058,0.00067233003,0.0018022784,0.0016049335,0.00012691751,0.00031154117,0.000007832872,0.000023285134,0.6449993],"study_design_scores_gemma":[0.17578898,0.24428685,0.5616916,0.00016258647,0.0005257448,0.0035479076,0.008239333,0.00083064055,0.000013674555,0.0000126802615,0.0047762413,0.0001237943],"about_ca_topic_score_codex":0.0002002928,"about_ca_topic_score_gemma":0.00094829773,"teacher_disagreement_score":0.6448755,"about_ca_system_score_codex":0.0008562509,"about_ca_system_score_gemma":0.0013792025,"threshold_uncertainty_score":0.39139253},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W4206483067","doi":"10.1016/j.jval.2021.11.759","title":"POSA244 First-Line Maintenance (1L MT) Treatment of Stage IV Non-Small Cell Lung Cancer (NSCLC) in Western Europe (WE): Results of the CancerMPact® Survey 2020","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Pembrolizumab; Pemetrexed; Carboplatin; Internal medicine; Oncology; Medicine; Lung cancer; Chemotherapy; Cancer; Immunotherapy; Cisplatin","score_opus":0.04938723913475337,"score_gpt":0.3179807771920575,"score_spread":0.2685935380573041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206483067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9703531,0.014331384,0.0000077438235,0.011450037,0.00052006723,0.0016080553,0.0015721878,0.000010257281,0.00014712321],"genre_scores_gemma":[0.9745126,0.021324888,0.00003285726,0.00054201327,0.00006126174,0.000101565165,0.000043012482,0.000037354606,0.0033444737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973225,0.00061130256,0.00086757104,0.00038573204,0.00036301283,0.00044987988],"domain_scores_gemma":[0.9983902,0.0002480945,0.0006081898,0.0005789282,0.00008011638,0.00009449385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001308397,0.00021869515,0.00062400405,0.00013168885,0.00008327911,0.0000056761946,0.0002365068,0.00004847851,0.000063075466],"category_scores_gemma":[0.000053971344,0.0001578989,0.00011520156,0.001034434,0.00008316472,0.000032169286,0.00007581889,0.00025714294,4.186486e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013876403,0.0011761162,0.9466524,0.0014028692,0.00009765864,0.00005907687,0.011183588,0.016589154,0.001679202,0.0000029363173,0.001937079,0.005343529],"study_design_scores_gemma":[0.015607377,0.0025974952,0.9542953,0.0013989152,0.000024032805,0.00000899726,0.0004445816,0.003934864,0.0017841029,0.0000019087654,0.019709144,0.00019331952],"about_ca_topic_score_codex":0.33551368,"about_ca_topic_score_gemma":0.08784105,"teacher_disagreement_score":0.24767263,"about_ca_system_score_codex":0.0018062547,"about_ca_system_score_gemma":0.0019838996,"threshold_uncertainty_score":0.92880344},"labels":[],"label_agreement":null},{"id":"W4206499749","doi":"10.1158/1078-0432.ccr-21-0664","title":"Single-Cell Immune Mapping of Melanoma Sentinel Lymph Nodes Reveals an Actionable Immunotolerant Microenvironment","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Center for Research Resources; National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health","keywords":"Melanoma; Lymph; Immune system; Immunity; Antibody; Immunotherapy; Stage (stratigraphy); Clinical trial","score_opus":0.16042761551657023,"score_gpt":0.4227069855418419,"score_spread":0.2622793700252717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206499749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98619,0.008997316,0.000017929378,0.002296936,0.0003745478,0.00058928464,0.000065270346,0.00002830753,0.0014403659],"genre_scores_gemma":[0.98879296,0.0018818835,0.00024187726,0.0004942643,0.00026301618,0.0002946198,0.00006783726,0.00004912882,0.0079143895],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99586093,0.0008038731,0.00110137,0.0005566143,0.001090686,0.000586539],"domain_scores_gemma":[0.9982065,0.0004167046,0.00025562246,0.0007799656,0.00016731265,0.00017391049],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0044800853,0.00016992143,0.0005723494,0.00023075847,0.00043090933,0.000026595113,0.00039636815,0.00010578209,0.004560753],"category_scores_gemma":[0.00008359653,0.00015920855,0.0003406763,0.0005736449,0.0005141655,0.00008533083,0.00038525477,0.00081578986,0.000020299662],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064911097,0.0021773751,0.07743539,0.00021662717,0.00022502233,0.00005098478,0.000284828,0.000024506075,0.89292043,0.000008404428,0.0012170125,0.018948285],"study_design_scores_gemma":[0.014325793,0.0018977465,0.76782477,0.00038495188,0.00008123954,0.0001047483,0.0039474885,0.00031930231,0.0764682,0.00011937748,0.13406791,0.00045850576],"about_ca_topic_score_codex":0.0013239946,"about_ca_topic_score_gemma":0.0000037267394,"teacher_disagreement_score":0.81645226,"about_ca_system_score_codex":0.000764277,"about_ca_system_score_gemma":0.00047133968,"threshold_uncertainty_score":0.9963492},"labels":[],"label_agreement":null},{"id":"W4206500679","doi":"10.1158/2326-6066.cir-21-1083","title":"Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma","year":2022,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; University of Texas MD Anderson Cancer Center; American Association for Cancer Research","keywords":"Melanoma; Immunotherapy; Stromal cell; Cancer; MHC class I; Tumor-infiltrating lymphocytes; Antigen; Cytotoxic T cell; Major histocompatibility complex","score_opus":0.047796247781921916,"score_gpt":0.37120881998169686,"score_spread":0.32341257219977493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206500679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978965,0.010592364,0.0000014580635,0.009001437,0.00023546378,0.00057702133,0.00004693789,0.0000421989,0.0005381192],"genre_scores_gemma":[0.9935886,0.0004227248,0.000050224233,0.0005235069,0.000076512835,0.001136461,0.000030486564,0.00003905216,0.0041323933],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9962664,0.0014291799,0.00030980486,0.00046625096,0.0007704792,0.0007578339],"domain_scores_gemma":[0.9985994,0.0006230671,0.00008506603,0.00042875748,0.00018601242,0.000077661825],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002699307,0.00016438533,0.0003557613,0.0005966899,0.00045998843,0.000020032408,0.00034858717,0.0001065825,0.0033386634],"category_scores_gemma":[0.00018130413,0.00013387688,0.000075964475,0.0008852563,0.0005764958,0.000077315504,0.00031070173,0.0015307481,0.000020718218],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20247383,0.00044016363,0.08427101,0.00003595555,0.0002579727,0.0007424573,0.0015020015,0.000023383496,0.69543314,0.00004621661,0.008836495,0.005937349],"study_design_scores_gemma":[0.0115710925,0.006130169,0.7889246,0.00034658296,0.00002097462,0.00042494995,0.00441924,0.0000548541,0.06474862,0.00012355435,0.122903556,0.00033180072],"about_ca_topic_score_codex":0.0005773249,"about_ca_topic_score_gemma":0.0001669244,"teacher_disagreement_score":0.7046536,"about_ca_system_score_codex":0.0018359359,"about_ca_system_score_gemma":0.0016543446,"threshold_uncertainty_score":0.9975724},"labels":[],"label_agreement":null},{"id":"W4206512154","doi":"10.1002/cti2.1363","title":"Comparison of the tumor microenvironments of squamous cell carcinoma at different anatomical locations within the upper aerodigestive tract in relation to response to ICI therapy","year":2022,"lang":"en","type":"review","venue":"Clinical & Translational Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Immunotherapy; Tumor microenvironment; Head and neck squamous-cell carcinoma; Medicine; Cancer; Immune system; Esophagus; Basal cell; Carcinoma; Lung cancer; Head and neck cancer; Cancer research; Pathology; Oncology; Internal medicine; Immunology","score_opus":0.09219054147919568,"score_gpt":0.4001961568070064,"score_spread":0.3080056153278107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206512154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5892966,0.40704042,0.000012724913,0.0014086145,0.00030452275,0.0017899531,0.00011850266,0.0000052104206,0.000023461393],"genre_scores_gemma":[0.87383026,0.12506829,0.00006835197,0.00043222515,0.000034251883,0.00019949015,0.0001573486,0.000042373762,0.00016743362],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9946624,0.0019950045,0.0022586118,0.0004789558,0.00037834665,0.00022668955],"domain_scores_gemma":[0.99453586,0.003890335,0.00077712885,0.00067924435,0.00004283598,0.00007460919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009888132,0.00032848865,0.0015326145,0.00022370828,0.00013416841,0.0000044268654,0.00047746478,0.00030157296,0.00045159302],"category_scores_gemma":[0.00029703745,0.00019668703,0.00081147044,0.00049032114,0.00049928325,0.00002265198,0.000094447154,0.0009897032,0.000013326384],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09283682,0.011957002,0.4256035,0.0014655457,0.0014304951,0.000018525949,0.008294733,0.00047292063,0.012810771,0.00020463204,0.00054571714,0.44435933],"study_design_scores_gemma":[0.002382833,0.0013260435,0.8168227,0.00041676252,0.00029763614,0.000020690806,0.00011455303,0.000012833408,0.00030258065,0.000012634251,0.17811793,0.0001727679],"about_ca_topic_score_codex":0.000059100177,"about_ca_topic_score_gemma":0.000040675524,"teacher_disagreement_score":0.44418657,"about_ca_system_score_codex":0.0003847244,"about_ca_system_score_gemma":0.0005095134,"threshold_uncertainty_score":0.80206645},"labels":[],"label_agreement":null},{"id":"W4206520893","doi":"10.3390/curroncol29010021","title":"Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional Experience","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"William Osler Health System; McMaster University; Sunnybrook Hospital","funders":"Eisai; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Pneumonitis; Internal medicine; Lung cancer; Nausea; Oncology; Radiation therapy; Confidence interval; Cancer; Lung","score_opus":0.02103299377897553,"score_gpt":0.3150540406115163,"score_spread":0.29402104683254077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206520893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884312,0.008957638,0.00007430903,0.0006385409,0.00076013594,0.000916069,0.000017593899,0.000009475249,0.00019500242],"genre_scores_gemma":[0.99889004,0.00042051496,0.00024481493,0.00013167929,0.00002353566,0.00022770028,0.000022246812,0.000011164501,0.000028294293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989695,0.0000662185,0.00038673985,0.00022180848,0.00017376844,0.00018196688],"domain_scores_gemma":[0.9995451,0.00004046612,0.00016818361,0.00014975182,0.000051277646,0.000045197932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002122074,0.00011414309,0.0002635699,0.00010637358,0.00013761282,0.000003192347,0.00009729142,0.000035509496,0.00013424545],"category_scores_gemma":[0.000011543406,0.00008261669,0.00004537392,0.0003809873,0.00014246866,0.000038284663,0.00007133721,0.00023596174,1.7901705e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020007754,0.002444839,0.51237774,0.00018482887,0.00012838784,0.000012362299,0.03636189,0.0021413274,0.056885414,0.000018271987,0.00020187483,0.36923528],"study_design_scores_gemma":[0.032209236,0.006543853,0.82221293,0.00061827945,0.00007308421,0.000028412498,0.0029224737,0.0014623734,0.010295281,0.000003990634,0.12324907,0.0003810046],"about_ca_topic_score_codex":0.00010959503,"about_ca_topic_score_gemma":0.00005142146,"teacher_disagreement_score":0.36885428,"about_ca_system_score_codex":0.0009622264,"about_ca_system_score_gemma":0.0003078731,"threshold_uncertainty_score":0.33690107},"labels":[],"label_agreement":null},{"id":"W4206697524","doi":"10.1038/s41591-021-01623-z","title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":325,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Center for Advancing Translational Sciences; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of General Medical Sciences; V Foundation for Cancer Research; National Heart, Lung, and Blood Institute; Yale Cancer Center; Cancer Research Foundation; Donald E. and Delia B. Baxter Foundation; Natural Sciences and Engineering Research Council of Canada; Virginia and D.K. Ludwig Fund for Cancer Research; National Cancer Institute; Government of Canada; U.S. Department of Health and Human Services","keywords":"Blockade; Melanoma; Immune checkpoint; Toxicity; Medicine; Immune system; Cancer research; Immunology; Immunotherapy; Internal medicine; Receptor","score_opus":0.004085841480793367,"score_gpt":0.21822925996041007,"score_spread":0.2141434184796167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206697524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99256706,0.00068185956,0.000008138686,0.0044523748,0.0002949587,0.000848621,0.000056381436,0.00005059927,0.0010399958],"genre_scores_gemma":[0.9952001,0.000011791606,0.0000810609,0.0030988965,0.00012177778,0.00006035617,0.000394963,0.000041135518,0.0009899447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979748,0.000073946045,0.00039498426,0.0003433525,0.00086627126,0.00034665925],"domain_scores_gemma":[0.99910456,0.0000626606,0.00020279501,0.00034419203,0.0001460157,0.00013977868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047718736,0.00024364116,0.0005615317,0.00025564054,0.00011160221,0.00000551649,0.00015982446,0.00014399299,0.0007256636],"category_scores_gemma":[0.00012930832,0.00015805554,0.000046166842,0.0009834634,0.000087853245,0.000029902072,0.000061802246,0.0011400768,0.0000025772158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04197117,0.002760934,0.8670343,0.00014076834,0.0005014427,0.00044507915,0.0032627927,0.000010432274,0.0756195,0.000007992392,0.0029214069,0.005324156],"study_design_scores_gemma":[0.015861724,0.0073455656,0.96167976,0.00035565667,0.00011405081,0.000015783406,0.0002512735,0.000012105373,0.0056946226,0.000002261147,0.008442351,0.00022485184],"about_ca_topic_score_codex":0.00010833419,"about_ca_topic_score_gemma":0.000056875484,"teacher_disagreement_score":0.094645426,"about_ca_system_score_codex":0.0005519622,"about_ca_system_score_gemma":0.00013484881,"threshold_uncertainty_score":0.7945508},"labels":[],"label_agreement":null},{"id":"W4206943819","doi":"10.1093/oncolo/oyac031","title":"Optimism Bias in the Design of Phase III Randomized Control Trials Evaluating PD-1/PD-L1 Targeting Monoclonal Antibodies","year":2022,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Hazard ratio; Monoclonal antibody; Confidence interval; Internal medicine; Optimism; Randomized controlled trial; Clinical endpoint; Oncology; Antibody; Immunology","score_opus":0.45022287493741125,"score_gpt":0.5122209442929506,"score_spread":0.061998069355539365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206943819","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000116952324,0.98552364,0.00069762627,0.0007083729,0.0006166543,0.011023913,0.00008759916,0.000034685978,0.0011905382],"genre_scores_gemma":[0.00045621107,0.9948089,0.0010597312,0.0005668266,0.0004256946,0.0020144738,0.00014267483,0.000046798785,0.0004786707],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9761591,0.019174146,0.0030883544,0.0004133935,0.00074665155,0.00041837143],"domain_scores_gemma":[0.95462954,0.04136397,0.0032436557,0.0006341208,0.0000864835,0.000042220887],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0784402,0.0005275398,0.007119113,0.00020997474,0.00027221712,0.000047181824,0.000728822,0.0002555348,0.0009831549],"category_scores_gemma":[0.011586368,0.00022935307,0.0019402852,0.00051662506,0.0008478978,0.000037108388,0.00009276616,0.00090971787,0.000004282281],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21888244,0.0004937508,7.83798e-7,0.0018797808,0.0022858873,0.00006673655,0.001113796,0.00013684394,0.00011146788,0.000032888416,0.003512896,0.7714827],"study_design_scores_gemma":[0.42913112,0.0016186049,0.0000010132472,0.0038682753,0.008956073,0.00013055251,0.00094689976,0.0016017773,0.000008636347,0.00008357445,0.55329156,0.00036188564],"about_ca_topic_score_codex":0.00035496685,"about_ca_topic_score_gemma":0.0000049488035,"teacher_disagreement_score":0.77112085,"about_ca_system_score_codex":0.0005202105,"about_ca_system_score_gemma":0.0018543531,"threshold_uncertainty_score":0.9999301},"labels":[],"label_agreement":null},{"id":"W4206945433","doi":"10.1016/j.anndiagpath.2022.151901","title":"Histological subtype is associated with PD-L1 expression and CD8+ T-cell infiltrates in triple-negative breast carcinoma","year":2022,"lang":"en","type":"article","venue":"Annals of Diagnostic Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Jubilee Hospital; University of British Columbia","funders":"","keywords":"CD8; Immunohistochemistry; Tissue microarray; Tumor-infiltrating lymphocytes; Pathology; Tumor microenvironment; PD-L1; Medicine; Biology; Cancer research; Immune system; Immunotherapy; Immunology","score_opus":0.03310557393561932,"score_gpt":0.2826278799710998,"score_spread":0.24952230603548048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206945433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382,0.0030403,0.0000033290348,0.0020346574,0.00007368389,0.00033031366,0.00015578297,0.00001639374,0.00052552205],"genre_scores_gemma":[0.9972973,0.0004629843,0.000046097757,0.0018984186,0.000014182878,0.0000773243,0.000050367635,0.00001274482,0.00014058418],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987168,0.0002728684,0.0002919858,0.0002862015,0.0001752165,0.00025696572],"domain_scores_gemma":[0.9981405,0.0013291548,0.00021578344,0.00016434904,0.00008621816,0.0000639707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003541668,0.0001459002,0.00043022158,0.00014866226,0.0000743921,0.000003549978,0.00008235273,0.00010192846,0.0004515696],"category_scores_gemma":[0.0007791111,0.00011510669,0.00005743442,0.0002827017,0.00027324978,0.00003892836,0.000066434426,0.0002510645,0.0000013683871],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006709031,0.0011545145,0.91121054,0.000052930962,0.000068171685,0.0017558171,0.002504567,0.0000051191123,0.0688256,0.0000206351,0.005152652,0.0025403989],"study_design_scores_gemma":[0.0046917624,0.0030411007,0.9631313,0.00010647485,0.000043978373,0.00064395403,0.0006450537,0.000014208628,0.027168885,0.0002033812,0.00015835701,0.00015156122],"about_ca_topic_score_codex":0.00021297463,"about_ca_topic_score_gemma":0.00003591558,"teacher_disagreement_score":0.051920727,"about_ca_system_score_codex":0.00004313314,"about_ca_system_score_gemma":0.0001215023,"threshold_uncertainty_score":0.494437},"labels":[],"label_agreement":null},{"id":"W4206946700","doi":"10.3410/f.739532974.793585242","title":"Faculty Opinions recommendation of BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8+ T cells.","year":2021,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Stem cell; Epigenetics; CD8; Biology; Cancer research; Cell biology; Genetics; Gene; Immune system","score_opus":0.03788492707966276,"score_gpt":0.3346098623441685,"score_spread":0.2967249352645057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206946700","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008401479,0.012019006,0.00001849922,0.10729796,0.0007920406,0.00170543,0.87811387,0.000015051472,0.000029751747],"genre_scores_gemma":[0.000043938566,0.0046483777,0.0003739396,0.0031291172,0.0001755744,0.00021116783,0.99025124,0.000022302378,0.0011443382],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958208,0.00040335875,0.0016362355,0.0005225297,0.0013437818,0.0002733004],"domain_scores_gemma":[0.99378526,0.00013600626,0.0012617713,0.0011288567,0.0034980073,0.0001900815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012496717,0.00043339017,0.0009903648,0.00021146372,0.00017941743,0.000079848076,0.0007656185,0.00053013617,0.00044998748],"category_scores_gemma":[0.0004091743,0.00023760597,0.0007533453,0.001553692,0.00077715144,0.00014776958,0.00017928125,0.000732402,0.000004140086],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008795284,0.0004363939,0.000012799196,0.011710609,0.0004223221,2.486909e-7,0.00022808816,3.9521773e-8,0.000081419,0.00006583243,0.973104,0.013850317],"study_design_scores_gemma":[0.0011843258,0.00030947462,0.002607921,0.013329696,0.00046204668,0.000067103974,0.00013772119,0.0000046728546,0.00015297704,0.000006025017,0.9815274,0.0002106302],"about_ca_topic_score_codex":0.000083621206,"about_ca_topic_score_gemma":0.000011577136,"teacher_disagreement_score":0.11213738,"about_ca_system_score_codex":0.000075359596,"about_ca_system_score_gemma":0.00070346316,"threshold_uncertainty_score":0.968929},"labels":[],"label_agreement":null},{"id":"W4210297506","doi":"10.3390/curroncol29020070","title":"Immunotherapy in Thoracic Malignancies: New Treatment and New Hope","year":2022,"lang":"en","type":"editorial","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Immunotherapy; Intensive care medicine; Bioinformatics; Cancer research; Cancer; Internal medicine; Biology","score_opus":0.0836465497451243,"score_gpt":0.4223432449485328,"score_spread":0.3386966952034085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210297506","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050142976,0.17395115,0.000017819873,0.0014760037,0.8172555,0.0011246636,0.00010596338,0.00006850872,0.0009860996],"genre_scores_gemma":[0.00013660245,0.22671437,0.00022635875,0.00028620785,0.751918,0.00030242928,0.0013166259,0.00013875842,0.01896063],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99770564,0.00018701918,0.00060542364,0.00066862185,0.0003671511,0.0004661514],"domain_scores_gemma":[0.9985744,0.00041034105,0.00029201098,0.00046166763,0.000049904564,0.00021169313],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033336383,0.00047153988,0.0011291443,0.00035011943,0.00008093756,0.000028746637,0.00019705632,0.000629131,0.002344413],"category_scores_gemma":[0.00009372148,0.00040018867,0.00025197532,0.00032120702,0.00011835597,0.000049445804,0.000084182175,0.0008733435,0.00001792765],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043292795,0.00032347723,0.0002887128,0.000074735486,0.00015551857,0.000048043377,0.0007363818,1.9269483e-7,0.00019495859,0.0000029397495,0.57341367,0.42043212],"study_design_scores_gemma":[0.011359513,0.0047148676,0.00048766893,0.0002935695,0.00016629409,0.00003634243,0.00015744512,0.000002039318,0.000042773885,0.000060314793,0.9823479,0.00033126725],"about_ca_topic_score_codex":0.0017618899,"about_ca_topic_score_gemma":0.00057435594,"teacher_disagreement_score":0.42010084,"about_ca_system_score_codex":0.0028583778,"about_ca_system_score_gemma":0.006030684,"threshold_uncertainty_score":0.999845},"labels":[],"label_agreement":null},{"id":"W4210565879","doi":"10.3390/curroncol29020074","title":"A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Western University; University of Toronto; William Osler Health System","funders":"","keywords":"Medicine; Multidisciplinary approach; Patient education; Comprehension; Presentation (obstetrics); Multidisciplinary team; Best practice; Medical education; Health care; Medical emergency; Nursing; Computer science","score_opus":0.07563328030385497,"score_gpt":0.43025976573269614,"score_spread":0.3546264854288412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210565879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880553,0.0029697665,0.000009539559,0.0038622562,0.0023510973,0.0013186433,0.0003713126,0.00008685857,0.0009752376],"genre_scores_gemma":[0.99554455,0.00007127963,0.00046119245,0.0015431165,0.00025138268,0.0013668399,0.0003396064,0.000030384193,0.00039167356],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977151,0.00035095811,0.0006306578,0.00030237617,0.00026106456,0.0007398481],"domain_scores_gemma":[0.99886906,0.00005274932,0.00020326104,0.00042369336,0.00009719757,0.0003540279],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008816626,0.00019503791,0.00037834505,0.00018152483,0.000823843,0.000022715401,0.0002937944,0.000058917445,0.0033102043],"category_scores_gemma":[0.00007674196,0.00019265112,0.00015600919,0.00049066695,0.00007657625,0.000043989523,0.0003875842,0.00075379136,0.000010362437],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024661857,0.0029519943,0.22631975,0.00011245832,0.0004184682,0.00013637582,0.123151295,0.000008127862,0.032448754,0.0000559876,0.046881,0.5650496],"study_design_scores_gemma":[0.0032107842,0.0006544369,0.014950644,0.00009927757,0.000053566506,0.000019712732,0.028437091,0.00009882225,0.002183723,0.000009506491,0.9500777,0.00020473724],"about_ca_topic_score_codex":0.53448015,"about_ca_topic_score_gemma":0.5983718,"teacher_disagreement_score":0.9031967,"about_ca_system_score_codex":0.0027700143,"about_ca_system_score_gemma":0.0014774685,"threshold_uncertainty_score":0.9976009},"labels":[],"label_agreement":null},{"id":"W4210573911","doi":"10.1016/j.eururo.2022.01.028","title":"Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis","year":2022,"lang":"en","type":"review","venue":"European Urology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Incidence (geometry); Pneumonitis; Hazard ratio; Meta-analysis; Clinical trial; Confidence interval; Oncology; Lung","score_opus":0.2107031185622853,"score_gpt":0.4523014668649802,"score_spread":0.2415983483026949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210573911","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008473997,0.9875118,0.0000035789824,0.00025006084,0.00023331364,0.011271071,0.0005503806,0.000015952584,0.00007906222],"genre_scores_gemma":[0.00014288862,0.99563265,0.000032132448,0.0015836325,0.00004764734,0.001994598,0.00031709476,0.000072226685,0.00017715326],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9755738,0.016968153,0.0061776363,0.0007366513,0.00026303466,0.0002807609],"domain_scores_gemma":[0.991546,0.0025295187,0.004994863,0.00067455415,0.0001701001,0.00008496533],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.018535977,0.0005498221,0.016098285,0.0005169047,0.000051513685,0.0000036051667,0.00030910186,0.00019881615,0.0009057566],"category_scores_gemma":[0.003292575,0.0003297409,0.006368205,0.0013759644,0.00016448862,0.000030678766,0.0001322444,0.0005302686,0.000004544951],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025163994,0.0010930722,0.0001818277,0.5199816,0.4445981,0.000038822713,0.00021053119,0.0000013456668,6.5272803e-7,0.0000042016427,0.00035669457,0.03101671],"study_design_scores_gemma":[0.0031101936,0.0021684668,0.00020370458,0.0038398246,0.6875584,0.0000070167093,0.000016650087,0.0000012235307,2.2304178e-7,0.0000018912821,0.3028406,0.00025182363],"about_ca_topic_score_codex":0.000039376944,"about_ca_topic_score_gemma":0.000017642966,"teacher_disagreement_score":0.5161418,"about_ca_system_score_codex":0.00010864871,"about_ca_system_score_gemma":0.0003156504,"threshold_uncertainty_score":0.9999155},"labels":[],"label_agreement":null},{"id":"W4210620015","doi":"10.1200/jco.21.02377","title":"Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":317,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Adverse effect; Chemotherapy; Pharmacogenomics; Clinical trial; Drug; Cancer; Modalities; Cancer treatment","score_opus":0.19273730881806414,"score_gpt":0.4954685399841905,"score_spread":0.3027312311661263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210620015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99338275,0.0018296954,0.00000429448,0.0016889278,0.0021106375,0.00085685536,0.0000261148,0.000005412897,0.000095308664],"genre_scores_gemma":[0.9617618,0.03519906,0.00030848966,0.0021432538,0.0003157847,0.000040655108,0.0000038169937,0.000030396326,0.00019678324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98148364,0.008798336,0.008336589,0.0003481553,0.0006735037,0.00035976677],"domain_scores_gemma":[0.98579234,0.007654679,0.00592723,0.0002845462,0.00018623819,0.00015494914],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.033793543,0.00025000438,0.0039820964,0.00051025586,0.000042326705,0.00000240709,0.00042475254,0.000474612,0.0019721484],"category_scores_gemma":[0.0049737003,0.00016715832,0.0010363908,0.00073065504,0.0002009475,0.00012414559,0.00006901456,0.0023553781,8.3051333e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12186218,0.0050968346,0.59927064,0.000011333754,0.0005122286,0.00004395328,0.000525229,0.00003693095,0.00008898583,3.2923109e-7,0.00020885553,0.2723425],"study_design_scores_gemma":[0.08947843,0.017589035,0.88692516,0.00022826817,0.00005495784,0.000013625498,0.0005990828,0.000066144225,0.000027204134,0.000096903896,0.004764061,0.00015712251],"about_ca_topic_score_codex":0.000990268,"about_ca_topic_score_gemma":0.0011072964,"teacher_disagreement_score":0.28765452,"about_ca_system_score_codex":0.0006348871,"about_ca_system_score_gemma":0.0026406774,"threshold_uncertainty_score":0.99994624},"labels":[],"label_agreement":null},{"id":"W4210645321","doi":"10.3390/curroncol29020043","title":"Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Immunotherapy; STK11; Lung cancer; Oncology; Cancer; Internal medicine; Immunology; KRAS; Colorectal cancer","score_opus":0.14181339242520116,"score_gpt":0.46630053274697175,"score_spread":0.3244871403217706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210645321","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001884102,0.9885885,0.000055370954,0.00063489075,0.0018733328,0.008404207,0.00015946108,0.00002744167,0.00023791671],"genre_scores_gemma":[4.2889644e-7,0.99021804,0.0002657667,0.00032943604,0.00023356054,0.008307878,0.00036817585,0.0000972281,0.0001794605],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99680626,0.00042250968,0.00128288,0.00072875735,0.00020943611,0.0005501792],"domain_scores_gemma":[0.9980289,0.00059103285,0.00076139893,0.00044870502,0.00004995637,0.00012001811],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012043952,0.0005633936,0.0031240252,0.00045195722,0.00010472386,0.000014285666,0.0002787006,0.00015978809,0.0008557216],"category_scores_gemma":[0.000036318495,0.0004612706,0.000834002,0.0006429461,0.0001079982,0.000037160597,0.00012141463,0.0006220094,0.0000018438947],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030470398,0.0003114982,0.000033610482,0.18209557,0.00089169136,0.000021711414,0.00013321775,8.62931e-8,0.0000032548323,0.0000012066537,0.013951665,0.80225176],"study_design_scores_gemma":[0.0040119346,0.000514662,0.000008703496,0.046704747,0.0031580462,0.00008850314,0.000051412233,0.00005574289,9.0002203e-7,0.000003093692,0.94500977,0.00039250925],"about_ca_topic_score_codex":0.00013963407,"about_ca_topic_score_gemma":0.000035630488,"teacher_disagreement_score":0.9310581,"about_ca_system_score_codex":0.0013830941,"about_ca_system_score_gemma":0.0017756117,"threshold_uncertainty_score":0.9997839},"labels":[],"label_agreement":null},{"id":"W4210675547","doi":"10.1093/ehjcr/ytab478","title":"Immune checkpoint inhibitor-related myocarditis: an illustrative case series of applying the updated Cardiovascular Magnetic Resonance Lake Louise Criteria","year":2022,"lang":"en","type":"article","venue":"European Heart Journal - Case Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Myocarditis; Troponin; Internal medicine; Cardiology; Magnetic resonance imaging; Troponin I; Cardiac magnetic resonance; Radiology; Myocardial infarction","score_opus":0.025468868113037026,"score_gpt":0.26972611623784654,"score_spread":0.2442572481248095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210675547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94858086,0.047722448,0.000008384309,0.00034491447,0.0010881632,0.0009157944,0.000058243993,0.00006419211,0.0012169741],"genre_scores_gemma":[0.99801743,0.00055225356,0.0001827105,0.00018783342,0.00038161673,0.000046814857,0.000041085565,0.00008391027,0.000506348],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99544865,0.0016004875,0.0014618965,0.0004137413,0.00070046366,0.00037474147],"domain_scores_gemma":[0.99802196,0.000035585028,0.0004959013,0.0009510413,0.0002862123,0.0002092711],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004684829,0.00029044406,0.000627227,0.00014896157,0.0010202193,0.00009134205,0.00008198099,0.000045718236,0.0012891525],"category_scores_gemma":[0.00010344991,0.0002242569,0.0007983268,0.00052338094,0.00031124376,0.00023889054,0.00014928357,0.0009286284,0.0000038844405],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008805138,0.00014738564,0.00042618052,0.00004085194,0.0005950533,0.9609977,0.0022658997,0.00010830246,0.015263918,0.0000016902699,0.001923061,0.017349454],"study_design_scores_gemma":[0.001062688,0.00093155034,0.004273464,0.00012639923,0.00026997944,0.73565334,0.0034684676,0.000025566469,0.0014114159,0.00000891747,0.25258192,0.00018631281],"about_ca_topic_score_codex":0.00021063544,"about_ca_topic_score_gemma":0.000028037859,"teacher_disagreement_score":0.25065887,"about_ca_system_score_codex":0.00014085845,"about_ca_system_score_gemma":0.0002438703,"threshold_uncertainty_score":0.9996238},"labels":[],"label_agreement":null},{"id":"W4210679360","doi":"10.1080/2162402x.2022.2033433","title":"CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2","year":2022,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC","funders":"Rijksuniversiteit Groningen; Canadian Cancer Society Research Institute; Universitair Medisch Centrum Groningen; Genome British Columbia; Genome Canada","keywords":"Immune system; Antigen; Biology; Population; T cell; Cancer research; Lymphoma; Immunology; Molecular biology; Medicine","score_opus":0.018380466357034587,"score_gpt":0.2532166011963488,"score_spread":0.23483613483931423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210679360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961179,0.0012635321,0.000033049117,0.00092945795,0.0006321106,0.00028973914,0.000031273776,0.00006204776,0.0006409117],"genre_scores_gemma":[0.9978612,0.00029602845,0.00003848155,0.0003295446,0.000026653865,0.0000668374,0.000105957326,0.000020477399,0.0012547923],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987257,0.00022578449,0.00029386126,0.0002861308,0.00018337066,0.0002851318],"domain_scores_gemma":[0.9995919,0.00007444195,0.00009057839,0.00018448393,0.000021327012,0.000037293215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027143545,0.00015150353,0.0003286174,0.00020005048,0.0001325529,0.000011604889,0.00008833505,0.00017420258,0.00056609],"category_scores_gemma":[0.00002313336,0.00014794631,0.00008676884,0.00027901976,0.0001337707,0.000068797905,0.000048501453,0.00026459649,0.0000032434166],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030024345,0.00064211665,0.013185497,0.000017263073,0.00011448899,0.000060451785,0.0022427777,0.000011909893,0.9498716,0.000048729875,0.00079784816,0.030004907],"study_design_scores_gemma":[0.013483419,0.0025276938,0.88260156,0.00006619689,0.00009492275,0.00012894592,0.0038680553,0.000491991,0.017223785,0.00008926915,0.0790703,0.00035387886],"about_ca_topic_score_codex":0.00054839934,"about_ca_topic_score_gemma":0.00009654555,"teacher_disagreement_score":0.93264776,"about_ca_system_score_codex":0.00064872025,"about_ca_system_score_gemma":0.000099815225,"threshold_uncertainty_score":0.6198289},"labels":[],"label_agreement":null},{"id":"W4210690867","doi":"10.1136/jitc-2021-003551","title":"Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition","year":2022,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Canadian Cancer Society; McGill University Health Centre; McGill University","keywords":"Janus kinase; Immune system; Monoclonal antibody; Medicine; Kinase; Cancer research; STAT protein; Immunology; Proinflammatory cytokine; Antibody; Tyrosine kinase; Signal transduction; Inflammation; Biology; STAT3; Cytokine; Cell biology; Receptor; Internal medicine","score_opus":0.03088694924051371,"score_gpt":0.3364963500272145,"score_spread":0.3056094007867008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210690867","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027020015,0.9624004,0.00043242107,0.00059200596,0.0022121472,0.004699033,0.002552351,0.00006582978,0.000025835176],"genre_scores_gemma":[0.0014498949,0.99147296,0.0009905028,0.0002796214,0.0005427653,0.0016927221,0.0019101705,0.00031178692,0.0013495521],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99468607,0.0002511263,0.0028098486,0.00063757197,0.0009220863,0.0006932819],"domain_scores_gemma":[0.9952115,0.00028011686,0.0032321662,0.0005348491,0.0005817596,0.0001596452],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012764388,0.00093787315,0.0031949996,0.0006911682,0.00070339424,0.000051113064,0.00031909958,0.0005003617,0.002467151],"category_scores_gemma":[0.00008007875,0.00071951735,0.0035813674,0.0006981711,0.00019650233,0.00026733548,0.00006147279,0.00092270237,0.0000028317431],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03151489,0.0010829527,0.000044684628,0.0033397714,0.024451733,0.00006435719,0.0014155458,0.000063123116,0.024784528,0.000014443903,0.0009463151,0.91227764],"study_design_scores_gemma":[0.022464292,0.0043399762,0.0010262821,0.034383092,0.0039654244,0.0002591202,0.00044488904,0.000015160804,0.0026886882,0.00032128158,0.9289377,0.0011541058],"about_ca_topic_score_codex":0.00031154204,"about_ca_topic_score_gemma":0.000036213394,"teacher_disagreement_score":0.9279914,"about_ca_system_score_codex":0.0016441661,"about_ca_system_score_gemma":0.0014746065,"threshold_uncertainty_score":0.9995256},"labels":[],"label_agreement":null},{"id":"W4210910593","doi":"10.1136/jitc-2021-003534","title":"Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novelis (Canada)","funders":"High-level Hospital Construction Project of Guangdong Provincial People's Hospital; National Natural Science Foundation of China","keywords":"Immunotherapy; Cancer research; Epidermal growth factor receptor; Tumor microenvironment; CD8; Adenocarcinoma; Immune system; Lung cancer; Biology; Cell; Cytotoxic T cell; Immune checkpoint; Medicine; Cancer; Immunology; Pathology; Internal medicine","score_opus":0.01319586278171577,"score_gpt":0.27630196322931394,"score_spread":0.2631061004475982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210910593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8757089,0.120656446,0.0002636269,0.0014525166,0.0006356816,0.0009786271,0.00020745919,0.000013193083,0.00008355091],"genre_scores_gemma":[0.9921131,0.0043822606,0.00045212012,0.0010062383,0.000119354154,0.00034739665,0.000031289732,0.00007583702,0.0014723842],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99707633,0.00016401695,0.0012443458,0.00035451932,0.0006358681,0.000524919],"domain_scores_gemma":[0.998512,0.00008222175,0.0008039322,0.00041189196,0.00009256498,0.000097370415],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00075884763,0.00031618716,0.0010152039,0.0007815657,0.00029108,0.000033203258,0.00035756797,0.000067242196,0.0045257453],"category_scores_gemma":[0.0000073083265,0.00028678676,0.0012425544,0.00091880176,0.00012922577,0.00012276905,0.0000320668,0.00054635474,5.200551e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021899309,0.0009058975,0.026143935,0.00013717225,0.00314689,0.000082150626,0.0024940523,0.0005351159,0.9376552,0.000002109018,0.00055595976,0.006442191],"study_design_scores_gemma":[0.059635554,0.006075537,0.28532904,0.0005364327,0.0036537927,0.00078840094,0.0041688336,0.0010376596,0.5328885,0.00008013952,0.10472414,0.0010819898],"about_ca_topic_score_codex":0.0003975378,"about_ca_topic_score_gemma":0.000040688188,"teacher_disagreement_score":0.40476674,"about_ca_system_score_codex":0.0016459017,"about_ca_system_score_gemma":0.00030041876,"threshold_uncertainty_score":0.99995846},"labels":[],"label_agreement":null},{"id":"W4212829041","doi":"10.1158/1078-0432.ccr-16-0732","title":"CD103 and Intratumoral Immune Response in Breast Cancer","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia; BC Cancer Agency","funders":"Canadian Cancer Society Research Institute","keywords":"Medicine; Breast cancer; Tumor-infiltrating lymphocytes; Internal medicine; CD8; Cancer; Context (archaeology); Immune system; Oncology; Basal (medicine); Confidence interval; Gastroenterology; Immunotherapy; Immunology; Biology","score_opus":0.15605407737987972,"score_gpt":0.5203377031857345,"score_spread":0.3642836258058547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212829041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91986644,0.0055300673,0.0000018274342,0.073588215,0.00030603269,0.00039964326,0.00006106246,0.000023862636,0.00022284928],"genre_scores_gemma":[0.975889,0.019432876,0.000023135835,0.00075784075,0.00044969236,0.00019581133,0.0000012015095,0.000028051154,0.0032223403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970666,0.00072779687,0.00062025886,0.0004949135,0.00050002575,0.0005903857],"domain_scores_gemma":[0.9978974,0.0011276252,0.0000605738,0.00041084565,0.0002422796,0.00026127303],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005728413,0.00013669505,0.0004187247,0.00022119247,0.00008217259,0.000029019302,0.00017328079,0.0001855063,0.0019322123],"category_scores_gemma":[0.00047721312,0.00008393573,0.00011407496,0.0005535786,0.0010783335,0.00010190351,0.00012882637,0.0006685374,0.00003307473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14270346,0.00025925835,0.4245318,0.00006598163,0.00010242919,0.0001451239,0.00011226866,9.8814496e-8,0.08437802,0.00003907121,0.0073947012,0.3402678],"study_design_scores_gemma":[0.0071755685,0.0006653841,0.9672217,0.000830381,0.000011454822,0.000039376562,0.000060496026,0.000007868451,0.0012828083,0.00011280996,0.02246169,0.00013047764],"about_ca_topic_score_codex":0.002476382,"about_ca_topic_score_gemma":0.00031236262,"teacher_disagreement_score":0.5426899,"about_ca_system_score_codex":0.00043762222,"about_ca_system_score_gemma":0.0011306335,"threshold_uncertainty_score":0.99898016},"labels":[],"label_agreement":null},{"id":"W4212992860","doi":"10.1200/jco.2022.40.6_suppl.163","title":"Immune profiling of advanced prostate cancer harboring homologous recombination deficiency.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Immune system; Prostate; Stromal cell; CD8; Internal medicine; Oncology; Cancer research; Cancer; Pathology; Immunology","score_opus":0.06820284130697328,"score_gpt":0.4411733774309218,"score_spread":0.3729705361239485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212992860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98581123,0.0061094216,0.00002873557,0.0039906343,0.0028364589,0.00026605054,0.000005620608,0.000007738503,0.0009440766],"genre_scores_gemma":[0.9938801,0.0026467163,0.0024180943,0.0005014142,0.00016851844,0.000022628075,0.0000022911358,0.000012787938,0.00034747657],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968604,0.0003112621,0.00216912,0.00013722313,0.00034839966,0.00017362526],"domain_scores_gemma":[0.996526,0.000520626,0.0023929325,0.00013183657,0.00034950615,0.00007909903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041179173,0.000084726096,0.00087554095,0.00014193801,0.00007876546,0.000002684172,0.00015511537,0.00009999578,0.00027772682],"category_scores_gemma":[0.00078315195,0.00006725446,0.0003916894,0.00026368193,0.00013941781,0.00008084889,0.00006107436,0.0008105884,6.5051034e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0334088,0.0023509732,0.04778374,0.00010034042,0.00035989558,0.00026789503,0.00044774267,0.0006459697,0.07912534,0.00011824346,0.00034822308,0.83504283],"study_design_scores_gemma":[0.058050293,0.08985065,0.6971292,0.00047046642,0.00088107167,0.0016828859,0.0034573127,0.00048497293,0.040262714,0.001183125,0.10609926,0.00044807245],"about_ca_topic_score_codex":0.00004664931,"about_ca_topic_score_gemma":0.0000063260936,"teacher_disagreement_score":0.8345948,"about_ca_system_score_codex":0.00035543126,"about_ca_system_score_gemma":0.0018467621,"threshold_uncertainty_score":0.35216483},"labels":[],"label_agreement":null},{"id":"W4213214577","doi":"10.1200/jco.2022.40.6_suppl.332","title":"Survival outcomes of metastatic renal cell carcinoma (mRCC) with sarcomatoid differentiation (SD): A single-institutional experience and literature meta-analysis.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"William Osler Health System; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Oncology; Proportional hazards model; Renal cell carcinoma; Chemotherapy; Survival analysis; Cancer; Meta-analysis; Progression-free survival; Targeted therapy; Confidence interval","score_opus":0.16146357670425726,"score_gpt":0.4184731399109814,"score_spread":0.25700956320672413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213214577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929944,0.0035585752,0.00071303494,0.0020627538,0.00030536423,0.00013710845,0.000030628064,0.000003610031,0.00019448182],"genre_scores_gemma":[0.9961195,0.000086454515,0.0027610497,0.00075157726,0.00006944545,0.000009543363,0.000014787228,0.0000075518906,0.0001800892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99652934,0.00070094457,0.0017690563,0.00019501442,0.0006633892,0.00014227616],"domain_scores_gemma":[0.9966164,0.00095021114,0.0018267652,0.00017711996,0.00028257666,0.00014688262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019354995,0.00014788963,0.0023766898,0.00026337834,0.00009207557,0.000013124601,0.00013747164,0.00008049056,0.0004727889],"category_scores_gemma":[0.00024425177,0.000085772874,0.0013334611,0.000458157,0.0002951173,0.000110150795,0.00005632039,0.0005592676,1.9383312e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0421815,0.00847286,0.7602829,0.00016077596,0.16496651,0.0022011972,0.0032081197,0.0003981192,0.010758401,0.00045042514,0.00035912785,0.0065600956],"study_design_scores_gemma":[0.012078544,0.014634286,0.8840212,0.000011301376,0.08087059,0.0008654867,0.0006916818,0.00016589943,0.00077488355,0.00008776939,0.005626928,0.00017143278],"about_ca_topic_score_codex":0.000025590898,"about_ca_topic_score_gemma":0.000030875417,"teacher_disagreement_score":0.123738326,"about_ca_system_score_codex":0.000101618134,"about_ca_system_score_gemma":0.0006244128,"threshold_uncertainty_score":0.5176707},"labels":[],"label_agreement":null},{"id":"W4213219040","doi":"10.1158/2326-6066.cir-20-0973","title":"Overproduction of IFNγ by Cbl-b–Deficient CD8+ T Cells Provides Resistance against Regulatory T Cells and Induces Potent Antitumor Immunity","year":2022,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Immune system; Ubiquitin ligase; Cytotoxic T cell; Cytokine; IL-2 receptor; Function (biology); T cell; Immunotherapy; Interleukin 21; Acquired immune system","score_opus":0.03512501272261518,"score_gpt":0.32311491335468334,"score_spread":0.28798990063206814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213219040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92763406,0.06762587,0.0000022230038,0.002032093,0.0007211119,0.0008894721,0.00016060528,0.000037395937,0.00089714275],"genre_scores_gemma":[0.9826818,0.01027794,0.00004878634,0.00020491995,0.0000734297,0.00029806094,0.00004288535,0.00003785577,0.006334314],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99685585,0.00065324234,0.0004927749,0.0006043601,0.00077900355,0.00061477907],"domain_scores_gemma":[0.99840003,0.000134514,0.00022009239,0.0008048351,0.00035987207,0.00008066409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020107422,0.00021039248,0.00045697216,0.0004027444,0.00073064386,0.000025956757,0.00034793958,0.00012842569,0.00034304682],"category_scores_gemma":[0.00005858678,0.0002021081,0.00010752446,0.0008648548,0.0014472404,0.000110030494,0.0003954609,0.0011078679,0.0000034850577],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051785884,0.00036473974,0.0007174151,0.0002420959,0.00026858973,0.000016116073,0.0008478667,0.000015637746,0.96267897,0.000042815635,0.015826497,0.0138006415],"study_design_scores_gemma":[0.0024212035,0.000986776,0.015982788,0.00017953909,0.00004015033,0.000022374115,0.0033951122,0.000013518244,0.8582879,0.000045593693,0.11838458,0.00024047724],"about_ca_topic_score_codex":0.0010973297,"about_ca_topic_score_gemma":0.000039841852,"teacher_disagreement_score":0.104391105,"about_ca_system_score_codex":0.00081435643,"about_ca_system_score_gemma":0.00080565555,"threshold_uncertainty_score":0.8241729},"labels":[],"label_agreement":null},{"id":"W4213248339","doi":"10.1016/j.bbi.2021.08.022","title":"Converging evidence for immune dysregulation in frontal cortex in schizophrenia","year":2021,"lang":"en","type":"article","venue":"Brain Behavior and Immunity","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Soft tissue; Adenocarcinoma; Biopsy; Pathology; Nuclear medicine; Cancer; Internal medicine","score_opus":0.045880922531898356,"score_gpt":0.338726111349615,"score_spread":0.29284518881771665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213248339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99332154,0.0052890456,0.00004346123,0.0006310603,0.0001527909,0.00049060816,0.000009703982,0.000016292352,0.00004550821],"genre_scores_gemma":[0.9985554,0.00027662655,0.00042333303,0.00020066484,0.000024756142,0.00008053512,0.000084789244,0.000012864574,0.00034098624],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99913365,0.00008532538,0.00031069724,0.00019031379,0.00009918882,0.00018084752],"domain_scores_gemma":[0.99944025,0.0001831258,0.000054523487,0.00023256207,0.00005260382,0.00003692739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004357457,0.00011231367,0.00024831283,0.000109962195,0.00007370948,0.000024142986,0.000052088344,0.00009029554,0.00011627573],"category_scores_gemma":[0.00016384562,0.00011519341,0.000074549105,0.00022933524,0.00007619109,0.00016339222,0.00003803543,0.00019064175,0.0000010596038],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034056648,0.00025508308,0.16710898,0.00007472132,0.000014514557,0.000045685185,0.0006481406,3.7812566e-7,0.7497907,0.000032903397,0.000056886605,0.07856631],"study_design_scores_gemma":[0.0063712983,0.00014501506,0.9756893,0.0004642838,0.000033600198,0.000065888904,0.00064132997,0.000112878835,0.016047662,0.00002600815,0.00027731937,0.00012541389],"about_ca_topic_score_codex":0.0011385322,"about_ca_topic_score_gemma":0.00066485937,"teacher_disagreement_score":0.80858034,"about_ca_system_score_codex":0.00012825202,"about_ca_system_score_gemma":0.00014944063,"threshold_uncertainty_score":0.4697451},"labels":[],"label_agreement":null},{"id":"W4213272981","doi":"10.1007/s40291-022-00576-4","title":"Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis","year":2022,"lang":"en","type":"review","venue":"Molecular Diagnosis & Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McGill University","funders":"","keywords":"Hazard ratio; Oncology; Meta-analysis; Medicine; Subgroup analysis; Internal medicine; Confidence interval; Survival analysis; Cancer","score_opus":0.061930059052580234,"score_gpt":0.35678002923783675,"score_spread":0.2948499701852565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213272981","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00076041627,0.98553497,0.000036861402,0.00011825279,0.000029139945,0.013371935,0.00010065009,0.000033794884,0.000013985218],"genre_scores_gemma":[0.0019642946,0.98024106,0.0002489016,0.0005304542,0.000008635722,0.01671381,0.00013180973,0.00013659771,0.00002443132],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9931105,0.0018706336,0.0027861784,0.0008861073,0.00091729435,0.00042932483],"domain_scores_gemma":[0.99525726,0.00083027553,0.0022715935,0.0013714107,0.00015565334,0.00011381117],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001823876,0.0009046653,0.013228098,0.0010341606,0.000062977655,0.000029154106,0.0004958798,0.00026645671,0.0004240517],"category_scores_gemma":[0.0002465265,0.0006025849,0.0053161466,0.002726849,0.00016026176,0.000059115227,0.00009210781,0.00048499234,8.482004e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004015546,0.0019829527,0.00024981587,0.6580925,0.2978076,0.00017392795,0.00068661873,0.000002567659,0.00032922876,0.000022218801,0.000024441299,0.040226568],"study_design_scores_gemma":[0.0026570025,0.0024456736,0.00022632886,0.16648942,0.80712575,0.00010141882,0.00009604175,0.0000019721626,0.0024604495,0.0000396653,0.017395003,0.00096125586],"about_ca_topic_score_codex":0.0001578344,"about_ca_topic_score_gemma":0.000007426025,"teacher_disagreement_score":0.5093182,"about_ca_system_score_codex":0.00023063061,"about_ca_system_score_gemma":0.00036992657,"threshold_uncertainty_score":0.99964255},"labels":[],"label_agreement":null},{"id":"W4213280237","doi":"10.1200/jco.2022.40.6_suppl.512","title":"Post hoc analysis of the efficacy of pembrolizumab retreatment after progression of advanced urothelial carcinoma (UC) in KEYNOTE-045 and KEYNOTE-052.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Pembrolizumab; Discontinuation; Oncology; Internal medicine; Clinical trial; Cancer; Immunotherapy","score_opus":0.03649077028794652,"score_gpt":0.41552770364427966,"score_spread":0.37903693335633315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213280237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939079,0.0026444974,0.0000029973678,0.0025194322,0.00040499846,0.00034179605,0.000037484093,0.0000016838728,0.00013916602],"genre_scores_gemma":[0.9984563,0.0005419548,0.0003997451,0.00042877556,0.00008700606,0.000008507089,0.0000028787977,0.000010945692,0.00006387265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960869,0.000670097,0.0023789497,0.00017942804,0.00051521196,0.00016944401],"domain_scores_gemma":[0.99579287,0.0011690722,0.002396304,0.00029069622,0.00025637524,0.000094659445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019807967,0.00012727524,0.0016035712,0.00033306403,0.000033719916,0.0000017414648,0.00018919545,0.0001613433,0.00022301901],"category_scores_gemma":[0.0007075711,0.000076130025,0.0009049764,0.0006303266,0.0003834641,0.00004099494,0.00013709615,0.00054534466,1.1787615e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29098347,0.0035546573,0.4993748,0.000070001755,0.0018436312,0.00017158006,0.0008060091,0.0001005954,0.010979933,0.0000088763945,0.000069963,0.19203648],"study_design_scores_gemma":[0.024602614,0.02739371,0.9421854,0.00012389077,0.001541652,0.000070954775,0.00026920118,0.00007014293,0.0013850281,0.000016404025,0.0022786974,0.0000622772],"about_ca_topic_score_codex":0.000075262855,"about_ca_topic_score_gemma":0.00008246221,"teacher_disagreement_score":0.44281062,"about_ca_system_score_codex":0.00021258574,"about_ca_system_score_gemma":0.0009997921,"threshold_uncertainty_score":0.31044924},"labels":[],"label_agreement":null},{"id":"W4213454747","doi":"10.1016/j.athoracsur.2022.01.063","title":"Radical Resection in an Era of Immune Therapy for Primary Esophageal Melanoma","year":2022,"lang":"en","type":"article","venue":"The Annals of Thoracic Surgery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"Royal College of Surgeons in Ireland","keywords":"Medicine; Melanoma; Perioperative; Immunotherapy; Esophagus; Overall survival; Resection; Oncology; Internal medicine; Surgery; Cancer research; Cancer","score_opus":0.08845846479625798,"score_gpt":0.38290424269933604,"score_spread":0.2944457779030781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213454747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831536,0.012123943,0.000013237645,0.0038394246,0.00025397446,0.00047074334,0.000032279186,0.000015491612,0.00009731288],"genre_scores_gemma":[0.9971112,0.0014143629,0.000055748103,0.0009900758,0.000101024976,0.0001066836,0.000075408614,0.000021454,0.0001240614],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984083,0.00036322232,0.0005408653,0.00015954481,0.00032416932,0.00020390327],"domain_scores_gemma":[0.9986549,0.0005860851,0.00025129342,0.0003913059,0.000081803184,0.000034620705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036335872,0.00010325937,0.00043824338,0.0001820433,0.000095529365,0.0000048476754,0.00015251712,0.000047820504,0.00027054627],"category_scores_gemma":[0.00006529621,0.00007616024,0.00034051173,0.0004254028,0.00014097596,0.000077060424,0.00003675269,0.0002259544,3.286784e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12806241,0.0011969762,0.02144108,0.00027451658,0.0003308034,0.000024048799,0.0010943719,0.00002932749,0.14341702,0.000036493326,0.0036794841,0.70041347],"study_design_scores_gemma":[0.0018381401,0.0035905456,0.49046952,0.0002789082,0.000051827996,0.00010840206,0.0008592059,0.00019010303,0.4899197,0.0008362887,0.01158293,0.00027444345],"about_ca_topic_score_codex":0.0002248041,"about_ca_topic_score_gemma":0.000009645321,"teacher_disagreement_score":0.70013905,"about_ca_system_score_codex":0.00003556427,"about_ca_system_score_gemma":0.00021070977,"threshold_uncertainty_score":0.31057248},"labels":[],"label_agreement":null},{"id":"W4214496408","doi":"10.1007/s00262-022-03169-6","title":"Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors","year":2022,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; National Center for Advancing Translational Sciences; Institute for Clinical and Translational Research, University of Wisconsin, Madison; National Cancer Institute; National Institutes of Health; ECOG-ACRIN Cancer Research Group; LUNGevity Foundation; Bristol-Myers Squibb; International Association for the Study of Lung Cancer","keywords":"Biology; Microbiome; Human microbiome; Immune system; Humanized mouse; Feces; Human Microbiome Project; Immunology; Microbiology; Bioinformatics","score_opus":0.020243961806006173,"score_gpt":0.2630004640901598,"score_spread":0.24275650228415363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214496408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9706569,0.019918386,0.00016598283,0.006328471,0.00036382943,0.0020942467,0.00022776614,0.00019744622,0.000047020585],"genre_scores_gemma":[0.99227923,0.00081034674,0.000255248,0.002594185,0.00006746089,0.0014579479,0.00017669835,0.00014612734,0.002212759],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9966739,0.0005458343,0.0007384181,0.00084361836,0.0003760915,0.0008221469],"domain_scores_gemma":[0.9989509,0.000089709865,0.00015124129,0.00044182566,0.00023578043,0.00013055651],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009069261,0.0005545807,0.0008453614,0.000388158,0.0008574087,0.000058717276,0.00030850153,0.00020892674,0.00059111963],"category_scores_gemma":[0.000011523522,0.00050616794,0.00027963516,0.00087783457,0.0006478655,0.00016366696,0.00006537673,0.0008822164,0.0000025877935],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.083080634,0.00083632366,0.0018122698,0.000023886298,0.0021392673,0.000054459113,0.0044813105,0.00005328296,0.89736235,0.00004437404,0.00046196103,0.009649852],"study_design_scores_gemma":[0.08425021,0.033165082,0.456057,0.001176389,0.0006303801,0.0022153275,0.002615504,0.0000778326,0.29135826,0.0002366199,0.12549967,0.0027177227],"about_ca_topic_score_codex":0.0008901033,"about_ca_topic_score_gemma":0.00024248919,"teacher_disagreement_score":0.6060041,"about_ca_system_score_codex":0.001451447,"about_ca_system_score_gemma":0.00067266606,"threshold_uncertainty_score":0.999739},"labels":[],"label_agreement":null},{"id":"W4214604063","doi":"10.1101/2022.02.25.481189","title":"The ITPRIPL1- CD3ε axis: a novel immune checkpoint controlling T cells activation","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Immune system; T-cell receptor; T cell; Antigen; Major histocompatibility complex; CD8; Immune checkpoint; Biology; Immunology; Cancer research; Monoclonal antibody; Cytotoxic T cell; CD3; Cell biology; Immunotherapy; Antibody; Genetics","score_opus":0.016125878303875196,"score_gpt":0.2354286080607858,"score_spread":0.21930272975691062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214604063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9707435,0.011473019,0.0035548303,0.0040267208,0.0052618827,0.0038235104,0.0002921946,0.0007265214,0.000097867836],"genre_scores_gemma":[0.9939131,0.0021170983,0.0014375797,0.0007219686,0.00075833447,0.00076564087,0.0000015843125,0.00019676886,0.000087915105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99630785,0.00014556479,0.0010666321,0.00096988,0.00079216046,0.000717909],"domain_scores_gemma":[0.99633974,0.00021950893,0.00091226894,0.0018856939,0.00043982296,0.0002029899],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017676373,0.00065950333,0.0008355795,0.00024666006,0.00070442865,0.00027108006,0.00065100746,0.0004473135,0.00025751485],"category_scores_gemma":[0.00022853803,0.0005525948,0.0005927667,0.0006220251,0.0002093694,0.00011491108,0.00051656325,0.0016190527,0.000025676662],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016521154,0.00025564354,0.00033327288,0.00026855938,0.0008379263,0.000021131018,0.000027493952,0.00007223559,0.9961221,0.00013736176,0.0002548402,0.000017289212],"study_design_scores_gemma":[0.0045657535,0.00020814603,0.039059337,0.0007012567,0.0003231996,7.6715786e-8,0.00003430599,0.00076509983,0.8335162,0.00000152178,0.12003549,0.00078964664],"about_ca_topic_score_codex":0.00028388537,"about_ca_topic_score_gemma":0.0000024291605,"teacher_disagreement_score":0.16260597,"about_ca_system_score_codex":0.001147855,"about_ca_system_score_gemma":0.0012397668,"threshold_uncertainty_score":0.99969256},"labels":[],"label_agreement":null},{"id":"W4214685750","doi":"10.1136/jitc-2021-003776","title":"Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation; American Society of Clinical Oncology; Novartis","keywords":"Medicine; Adverse effect; Dosing; Internal medicine; Oncology; Cancer; Gastroenterology","score_opus":0.011892139948701776,"score_gpt":0.30239322763100274,"score_spread":0.290501087682301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214685750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98965967,0.0066455295,0.000008952424,0.00043354524,0.0010754352,0.002009497,0.00012982248,0.000010061316,0.000027481137],"genre_scores_gemma":[0.9981884,0.00057571445,0.00008424517,0.00033820354,0.00007594601,0.00024177047,0.0000074582217,0.000056628454,0.00043164744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975748,0.00011563532,0.00087611214,0.00023866969,0.0008544578,0.00034029403],"domain_scores_gemma":[0.9983341,0.00004606361,0.0008452661,0.00042246413,0.0003062267,0.000045890123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000456055,0.00024915134,0.0006628272,0.00022706436,0.00044273754,0.000014785337,0.00033043325,0.000048706323,0.00036846453],"category_scores_gemma":[0.000016001613,0.0001625462,0.00029077497,0.0006054202,0.00014374964,0.00015562058,0.000060222526,0.00036939143,8.4361616e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23353723,0.03178137,0.28625506,0.0002692523,0.0029038643,0.000017515207,0.016697401,0.0013339032,0.19222936,0.000015535341,0.002115649,0.23284385],"study_design_scores_gemma":[0.29953027,0.08939952,0.49278253,0.0009764119,0.00035749128,0.000050895684,0.0077197547,0.00004265583,0.050218925,0.000053199416,0.058239575,0.0006287693],"about_ca_topic_score_codex":0.00019035442,"about_ca_topic_score_gemma":0.0001268162,"teacher_disagreement_score":0.23221508,"about_ca_system_score_codex":0.00040681902,"about_ca_system_score_gemma":0.00043373372,"threshold_uncertainty_score":0.6628442},"labels":[],"label_agreement":null},{"id":"W4214729308","doi":"10.1038/s41598-022-07228-x","title":"PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma","year":2022,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Irish Research Council","keywords":"Downregulation and upregulation; Blockade; Cancer research; Chemotherapy; Immune checkpoint; Immune system; Apoptosis; Biology; Medicine; Pharmacology; Immunology; Receptor; Internal medicine","score_opus":0.013181769459512795,"score_gpt":0.2645328590053448,"score_spread":0.251351089545832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214729308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99003416,0.002465706,0.000009081331,0.0010362234,0.004191426,0.00046368295,0.000003420043,0.00006139668,0.0017348723],"genre_scores_gemma":[0.990195,0.000021987384,0.00012990992,0.000502546,0.000102591825,0.000080459555,0.000036694026,0.00001770692,0.008913151],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99767643,0.0000603761,0.0005055885,0.0006924095,0.0007189531,0.00034624012],"domain_scores_gemma":[0.9989729,0.000018983894,0.00019831628,0.0006770477,0.00004236518,0.000090369846],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015445285,0.00014080113,0.00025754768,0.00026889765,0.00034838752,0.000068118105,0.00012816527,0.000043093387,0.0031398563],"category_scores_gemma":[0.000027821425,0.00013000371,0.0001484946,0.0009366693,0.00021560387,0.000080204474,0.000073208204,0.00023271002,0.000007779086],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010459244,0.0006766452,0.20153598,0.000054439406,0.00007922366,0.0037433566,0.002256163,0.000025998024,0.7548966,0.000010637344,0.022465982,0.013209035],"study_design_scores_gemma":[0.0023083745,0.00042080626,0.3083459,0.000053663807,0.00003206553,0.0028210164,0.0007255585,0.00012274225,0.5377589,0.0012240832,0.14581576,0.0003711323],"about_ca_topic_score_codex":0.00018692084,"about_ca_topic_score_gemma":0.000064232154,"teacher_disagreement_score":0.21713772,"about_ca_system_score_codex":0.00027569392,"about_ca_system_score_gemma":0.00033841157,"threshold_uncertainty_score":0.9977714},"labels":[],"label_agreement":null},{"id":"W4214757946","doi":"10.1136/bcr-2021-246722","title":"Isolated metastatic melanoma to the pancreas in the context of myeloproliferative neoplasm: a rare occurrence","year":2022,"lang":"en","type":"article","venue":"BMJ Case Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Melanoma; Pancreas; Neoplasm; Myeloproliferative neoplasm; Context (archaeology); Metastasis; Biopsy; Metastatic melanoma; Mucosal melanoma; Radiology; Internal medicine; Pathology; Cancer; Cancer research","score_opus":0.030049728421937767,"score_gpt":0.31622105260763866,"score_spread":0.2861713241857009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214757946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922096,0.00093170785,0.000037281752,0.004036325,0.00021669759,0.0020253332,0.000069186266,0.000013978964,0.00045987326],"genre_scores_gemma":[0.996633,0.000014161906,0.00003890702,0.0025244318,0.000027240849,0.00055372773,0.000034672168,0.000008014468,0.00016585445],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9983438,0.00030930588,0.0005651713,0.00022591808,0.0003783671,0.00017741801],"domain_scores_gemma":[0.9988708,0.00020299625,0.0002807919,0.0005207974,0.00007968334,0.000044916847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014135845,0.00012531277,0.00029687525,0.000084796215,0.00015885434,0.000013714141,0.00007000079,0.000018746121,0.0002949806],"category_scores_gemma":[0.0002097925,0.000070040325,0.000109122644,0.00062070927,0.000059374666,0.000026847354,0.000057298883,0.00021214625,0.0000027788344],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070030303,0.00047628072,0.0148711875,0.00014808009,0.0006698557,0.8191785,0.049180225,0.000055071796,0.0022775566,0.00007091168,0.030335696,0.075733595],"study_design_scores_gemma":[0.0015089354,0.0010215617,0.0061303168,0.000105140294,0.00017611872,0.91751844,0.027936153,0.00024764612,0.000813975,0.00004041893,0.04431528,0.00018601386],"about_ca_topic_score_codex":0.001221816,"about_ca_topic_score_gemma":0.0005591835,"teacher_disagreement_score":0.09833994,"about_ca_system_score_codex":0.000083573264,"about_ca_system_score_gemma":0.00035240693,"threshold_uncertainty_score":0.3229831},"labels":[],"label_agreement":null},{"id":"W4220658353","doi":"10.1016/j.jmoldx.2022.02.004","title":"The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space","year":2022,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Pancreas Centre (Canada); Canada's Michael Smith Genome Sciences Centre","funders":"Canadian Institutes of Health Research; BC Cancer Foundation; Natural Sciences and Engineering Research Council of Canada; Servier; Genome British Columbia; AstraZeneca; Bayer; Celgene; Roche","keywords":"Immunotherapy; Transcriptome; Biology; Genome; Computational biology; Medicine; Cancer; Genetics; Gene; Gene expression","score_opus":0.008891616212109373,"score_gpt":0.25251724377675483,"score_spread":0.24362562756464545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220658353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9455222,0.046044134,0.00021487413,0.0073070647,0.0004972858,0.00014964552,0.000011402904,0.0000021727178,0.00025124897],"genre_scores_gemma":[0.9836744,0.01542137,0.00009656945,0.00061843015,0.00009406152,0.0000037617995,4.4302857e-7,0.000011663293,0.000079282516],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991526,0.00007016843,0.00025582776,0.000056591853,0.00034971,0.00011507381],"domain_scores_gemma":[0.9991519,0.00025212744,0.00032274923,0.00013899295,0.00009332667,0.000040925006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004525668,0.0000668809,0.00016003964,0.00004226011,0.00021194469,0.000016507585,0.00015151837,0.000019866708,0.000052783846],"category_scores_gemma":[0.0002041272,0.000038004,0.00012805873,0.00016988107,0.00007406854,0.00001707201,0.00009077376,0.00024273638,1.1999752e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002071366,0.00022354518,0.21392412,0.00015930756,0.0015377597,0.0005662298,0.0024890872,0.001738199,0.7438901,0.0007851638,0.009998169,0.022616947],"study_design_scores_gemma":[0.009552397,0.0021409441,0.45786348,0.0008939662,0.0015493084,0.0027661878,0.0043147295,0.0006023017,0.11905291,0.00043593757,0.40038127,0.00044658128],"about_ca_topic_score_codex":0.00001797239,"about_ca_topic_score_gemma":0.0000056598956,"teacher_disagreement_score":0.6248372,"about_ca_system_score_codex":0.00006396821,"about_ca_system_score_gemma":0.00017811936,"threshold_uncertainty_score":0.16301286},"labels":[],"label_agreement":null},{"id":"W4220684825","doi":"10.1016/j.jtocrr.2022.100316","title":"Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Durvalumab; Medicine; Toxicity; Internal medicine; Regimen; Cohort; Chemoradiotherapy; Log-rank test; Cisplatin; Proportional hazards model; Overall survival; Surgery; Chemotherapy; Cancer","score_opus":0.145011355453734,"score_gpt":0.48796667512408687,"score_spread":0.34295531967035287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220684825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913979,0.0011886046,0.00016653133,0.0030794223,0.00028539944,0.0018481502,0.00001773433,0.00005006572,0.0019661752],"genre_scores_gemma":[0.99472475,0.0002445553,0.00085867505,0.00013033581,0.00014379331,0.0002926149,0.00013237566,0.00003616537,0.0034367198],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960921,0.00025937514,0.0013799827,0.00064517057,0.0012408112,0.0003825935],"domain_scores_gemma":[0.9969691,0.0008319061,0.0005634406,0.00059148355,0.0008265718,0.00021750176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005197947,0.00016368908,0.0008136299,0.00015270479,0.00032193822,0.000026289676,0.00008858171,0.00012232752,0.00018678866],"category_scores_gemma":[0.0011478706,0.00012277006,0.00021048119,0.0005019185,0.00079004216,0.00006710205,0.00007614129,0.00054871273,3.9075496e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28190672,0.0043683127,0.40693983,0.0004888891,0.0016483862,0.004001714,0.00046951862,0.000037494112,0.019246923,0.00006683735,0.025296493,0.25552887],"study_design_scores_gemma":[0.067334,0.069513276,0.24572481,0.00058907404,0.00041741494,0.005163119,0.0033355895,0.0014787065,0.017577384,0.00024138026,0.58782613,0.0007991136],"about_ca_topic_score_codex":0.0002736394,"about_ca_topic_score_gemma":0.000042529606,"teacher_disagreement_score":0.5625296,"about_ca_system_score_codex":0.00015468248,"about_ca_system_score_gemma":0.0010530079,"threshold_uncertainty_score":0.50064176},"labels":[],"label_agreement":null},{"id":"W4220691742","doi":"10.1002/cncr.34190","title":"Association of B7‐H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer","year":2022,"lang":"en","type":"article","venue":"Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Prostate cancer; Androgen receptor; Medicine; Immune system; Cancer; Enzalutamide; Transcriptome; Immunotherapy; Cancer research; Androgen; Immunology; Oncology; Internal medicine; Biology; Gene expression; Hormone; Genetics; Gene","score_opus":0.012735043155099162,"score_gpt":0.27103028674125546,"score_spread":0.2582952435861563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220691742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956349,0.0025650533,0.00000472321,0.0010081109,0.00018079691,0.00041781086,0.000034445507,0.000012404382,0.00014171992],"genre_scores_gemma":[0.99649805,0.0014882045,0.000054068187,0.00019925387,0.000074778916,0.00023829399,0.000030208343,0.000015185458,0.0014019548],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99916905,0.000050597442,0.00018743773,0.00018326633,0.00026625057,0.00014340015],"domain_scores_gemma":[0.9995387,0.000022209977,0.00024411638,0.000096838274,0.00006996598,0.000028121094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001848143,0.00009148337,0.00020043307,0.000070194816,0.00008182151,0.000007311411,0.000038640228,0.00004028473,0.00041634665],"category_scores_gemma":[0.000007754092,0.00007857545,0.000028102424,0.00026118456,0.000032080985,0.000088910085,0.000035831064,0.00013790416,2.1481046e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046238527,0.00007211329,0.3751904,0.00008937173,0.00004337765,0.0000013211497,0.001261982,0.00004759192,0.6089682,6.619199e-7,0.0012645304,0.00843659],"study_design_scores_gemma":[0.0058369534,0.00034684685,0.1369076,0.0003045942,0.00004959816,0.0000018792439,0.0007320995,0.000031155556,0.8387532,0.000009395894,0.016870076,0.00015655851],"about_ca_topic_score_codex":0.0013991232,"about_ca_topic_score_gemma":0.00033307847,"teacher_disagreement_score":0.2382828,"about_ca_system_score_codex":0.0006150564,"about_ca_system_score_gemma":0.00021109833,"threshold_uncertainty_score":0.45587036},"labels":[],"label_agreement":null},{"id":"W4220702214","doi":"10.1136/jitc-2021-003569","title":"Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"Research and Development; National Cancer Institute; Sanofi; Merck","keywords":"Medicine; Pembrolizumab; Renal cell carcinoma; Internal medicine; Oncology; Aflibercept; Melanoma; Adverse effect; Population; Cancer; Gastroenterology; Bevacizumab; Immunotherapy; Cancer research; Chemotherapy","score_opus":0.013439187549297058,"score_gpt":0.339573802387077,"score_spread":0.32613461483777995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220702214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99360263,0.0038101713,0.000033930177,0.00014523164,0.00050864974,0.0017375828,0.000086307875,0.000011232006,0.00006423794],"genre_scores_gemma":[0.99827856,0.0004668615,0.00015088485,0.00027211016,0.000060823153,0.00027615222,0.000012828946,0.000066696964,0.00041509612],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976606,0.00008842608,0.00094337517,0.00022959962,0.00074940076,0.0003286468],"domain_scores_gemma":[0.99845177,0.000048051716,0.00083968707,0.00031123057,0.00028508613,0.00006420283],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003951978,0.00023229512,0.00080035185,0.00037202696,0.00019478901,0.0000115447665,0.00024857692,0.00003946442,0.00091947307],"category_scores_gemma":[0.000009416158,0.00018400357,0.00023750232,0.00046908177,0.00008982604,0.00014686839,0.000026804524,0.00037379633,1.5857653e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.550506,0.016016802,0.05947073,0.00018358282,0.0023073175,0.000026385964,0.016118754,0.0030517012,0.045333594,0.0000059939985,0.00079042674,0.30618867],"study_design_scores_gemma":[0.5367376,0.111699075,0.31027082,0.00066624675,0.00030071207,0.00007617026,0.009320028,0.00018058537,0.0076815886,0.000053524047,0.022362698,0.0006509265],"about_ca_topic_score_codex":0.0002624963,"about_ca_topic_score_gemma":0.00008402885,"teacher_disagreement_score":0.30553776,"about_ca_system_score_codex":0.00070617354,"about_ca_system_score_gemma":0.00056346506,"threshold_uncertainty_score":0.9999938},"labels":[],"label_agreement":null},{"id":"W4220708647","doi":"10.1016/j.clon.2022.03.006","title":"Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses","year":2022,"lang":"en","type":"letter","venue":"Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Programmed cell death 1; Medicine; PD-L1; Programmed cell death; Propensity score matching; Adverse effect; Immune system; Oncology; Apoptosis; Internal medicine; Immunology; Immunotherapy; Biochemistry; Biology","score_opus":0.07959562166458727,"score_gpt":0.3647466321096888,"score_spread":0.2851510104451015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220708647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979855,0.0033516318,0.0000062273725,0.005660871,0.0008395373,0.009736339,0.00002938558,0.00018080065,0.0003402149],"genre_scores_gemma":[0.9746657,0.0016227525,0.0014730756,0.018513456,0.001093699,0.0009075179,0.0004811795,0.00022305378,0.0010195831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9908624,0.002812269,0.0029267108,0.0015952968,0.0008288296,0.0009744779],"domain_scores_gemma":[0.9915421,0.0034568596,0.003221837,0.0010661749,0.00039793775,0.00031506087],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0030827983,0.00093517714,0.003994558,0.00035797615,0.00030152922,0.000041393003,0.00045308567,0.0017398685,0.00012834836],"category_scores_gemma":[0.0005814736,0.0006745403,0.00095107075,0.00073711714,0.0010608298,0.000084013685,0.0005353688,0.005355933,0.000010857462],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050113693,0.017445615,0.85347915,0.0051001753,0.006517997,0.015897987,0.003070763,0.000004267498,0.0028051103,3.4613285e-7,0.013128263,0.032436613],"study_design_scores_gemma":[0.09341015,0.17784455,0.5650035,0.002441213,0.021279305,0.00049972004,0.0024127972,0.0001219154,0.004921988,0.000013761927,0.12982488,0.00222619],"about_ca_topic_score_codex":0.0020794945,"about_ca_topic_score_gemma":0.00019021814,"teacher_disagreement_score":0.28847563,"about_ca_system_score_codex":0.00045021897,"about_ca_system_score_gemma":0.0013616612,"threshold_uncertainty_score":0.9995706},"labels":[],"label_agreement":null},{"id":"W4220720369","doi":"10.3389/fimmu.2022.840198","title":"Desmoplastic Reaction, Immune Cell Response, and Prognosis in Colorectal Cancer","year":2022,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Gary Bennett Family Fund; National Institutes of Health; Huazhong University of Science and Technology; National Cancer Institute; Entertainment Industry Foundation; Mitsukoshi Health and Welfare Foundation; American Association for Cancer Research; American Society of Clinical Oncology; Massachusetts General Hospital; Conquer Cancer Foundation; Japan Society for the Promotion of Science; American Cancer Society; Research Promotion Foundation; Stand Up To Cancer; Uehara Memorial Foundation","keywords":"Immune system; Colorectal cancer; Medicine; Immune reaction; Cancer research; Oncology; Immunology; Cancer; Internal medicine","score_opus":0.0070486825147939355,"score_gpt":0.23590297899236368,"score_spread":0.22885429647756975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220720369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726587,0.023953427,0.000019168254,0.0011598134,0.0015709776,0.00042178156,0.000013530352,0.000028203367,0.00017441479],"genre_scores_gemma":[0.99645466,0.0017824601,0.0004172677,0.0001453808,0.000017287037,0.00055597257,0.00001574164,0.000021856247,0.00058940117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986969,0.0002736637,0.00032500087,0.0002832526,0.00011189077,0.00030925486],"domain_scores_gemma":[0.9996552,0.00008561306,0.000092098206,0.000121628465,0.000020503916,0.000024952791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045376952,0.00013430948,0.00034006927,0.0004974604,0.000108130575,0.0000061521064,0.0000986012,0.000102657374,0.0001554629],"category_scores_gemma":[0.000047941237,0.00014230653,0.000050369483,0.0005583361,0.00020175938,0.000052414365,0.0000869024,0.00046512214,0.000001307808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044872116,0.0002770827,0.570296,0.000025564159,0.00012069139,0.00011133656,0.0010702567,0.000009054502,0.37352905,0.000004457952,0.0015980224,0.008086397],"study_design_scores_gemma":[0.0056468155,0.0008282052,0.9641496,0.000038147457,0.000029148692,0.00016573546,0.0021852679,0.00009032276,0.013165976,0.000041546722,0.01350384,0.00015540265],"about_ca_topic_score_codex":0.00078956585,"about_ca_topic_score_gemma":0.000074109914,"teacher_disagreement_score":0.3938536,"about_ca_system_score_codex":0.0007133166,"about_ca_system_score_gemma":0.0002445846,"threshold_uncertainty_score":0.58030915},"labels":[],"label_agreement":null},{"id":"W4220767373","doi":"10.1158/1538-7445.sabcs21-pd10-09","title":"Abstract PD10-09: Comparison of early modulation of biological pathways and immune microenvironment by anthracyclines- or taxane-based treatment","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Taxane; Medicine; Immune system; Oncology; Breast cancer; Paclitaxel; Internal medicine; Doxorubicin; Cyclophosphamide; Chemotherapy; Carboplatin; Cancer; Immune checkpoint; Cancer research; Immunotherapy; Immunology; Cisplatin","score_opus":0.16828568174729894,"score_gpt":0.42076595494338925,"score_spread":0.25248027319609034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220767373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896733,0.008733882,0.000011599701,0.0005611427,0.000048785318,0.0006432646,0.00027343773,0.000008474976,0.000046086552],"genre_scores_gemma":[0.99784267,0.0015753405,0.00006956377,0.000021009468,0.000026894628,0.0002016053,0.000092181486,0.000013529045,0.0001572199],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99854577,0.00012959153,0.00039196873,0.0002494257,0.0004497312,0.00023352267],"domain_scores_gemma":[0.9993379,0.00015362231,0.00015014879,0.00024437442,0.000050677747,0.00006328423],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004682107,0.00011087027,0.00035628976,0.000117255724,0.00013824382,0.0000062865693,0.00009301955,0.000053293574,0.0011688276],"category_scores_gemma":[0.000017877155,0.000078003846,0.00008202463,0.00022619503,0.00035178152,0.000022719163,0.000053072734,0.00018881971,0.0000010244548],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010706932,0.0008234253,0.04747424,0.00007907874,0.000095654315,0.0000071620816,0.0003497541,0.00007808012,0.8824904,0.0000025978438,0.00030611746,0.057586573],"study_design_scores_gemma":[0.004883651,0.0061303885,0.4079646,0.00008716965,0.000021526856,0.000003123254,0.00072895904,0.00025113326,0.57420266,0.0000075401936,0.00561607,0.000103188344],"about_ca_topic_score_codex":0.0025215282,"about_ca_topic_score_gemma":0.000022699604,"teacher_disagreement_score":0.36049035,"about_ca_system_score_codex":0.0004359342,"about_ca_system_score_gemma":0.00020810934,"threshold_uncertainty_score":0.99974424},"labels":[],"label_agreement":null},{"id":"W4220823484","doi":"10.3390/jcm11061605","title":"High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Essar Steel Algoma (Canada); Sault Area Hospital","funders":"","keywords":"Medicine; Breast cancer; Mutation; CDH1; Immunotherapy; Cancer research; Cancer; Oncology; Germline mutation; Internal medicine; Gene; Cell; Genetics; Biology","score_opus":0.034733195201279383,"score_gpt":0.38867285930519563,"score_spread":0.35393966410391625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220823484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95459545,0.0009719911,0.000067879526,0.039852202,0.0028066128,0.00027369754,0.000018676903,0.0000095928835,0.0014038867],"genre_scores_gemma":[0.99259764,0.00045059496,0.00029113732,0.0027707603,0.0034662734,0.000008568829,0.000010704218,0.000018855835,0.0003854842],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964839,0.00039495243,0.0018314912,0.00019439777,0.0008798846,0.00021537293],"domain_scores_gemma":[0.9975042,0.0008876956,0.0009857651,0.00015657085,0.0002529801,0.00021281418],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003241061,0.00014800874,0.0008891541,0.00028048092,0.00007673832,0.0000051586007,0.00017089615,0.00007921542,0.0022053234],"category_scores_gemma":[0.00074522576,0.00010815624,0.00024528595,0.00049425045,0.00034132987,0.00009407994,0.000029075694,0.0010912629,0.0000029384294],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10939537,0.0013939313,0.11111467,0.0001967016,0.0017231631,0.0073470487,0.0061217127,0.00076331117,0.0066457903,0.00014611168,0.04136617,0.713786],"study_design_scores_gemma":[0.03542725,0.012942529,0.92027444,0.0012296226,0.00039481706,0.005441937,0.0055078594,0.00018278774,0.00025816137,0.00036989647,0.017758692,0.00021199563],"about_ca_topic_score_codex":0.00198478,"about_ca_topic_score_gemma":0.00008795926,"teacher_disagreement_score":0.80915976,"about_ca_system_score_codex":0.00050944294,"about_ca_system_score_gemma":0.000678065,"threshold_uncertainty_score":0.9987068},"labels":[],"label_agreement":null},{"id":"W4220827996","doi":"10.2174/1568009622666220317091723","title":"Current Treatment and Future Trends of Immunotherapy in BreastCancer","year":2022,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Immunotherapy; Medicine; Breast cancer; Clinical trial; Metastatic breast cancer; Oncology; Cancer; Immune checkpoint; Disease; Cancer immunotherapy; Blockade; Internal medicine","score_opus":0.04692936036399204,"score_gpt":0.3792937953587975,"score_spread":0.33236443499480545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220827996","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012245966,0.9929475,6.345275e-7,0.00021361948,0.004613942,0.0010974698,0.0007638476,0.00003853425,0.00020196495],"genre_scores_gemma":[0.000022085029,0.9961995,0.000012797882,0.000026210995,0.0012136525,0.0015870902,0.0005642402,0.0001045556,0.0002698708],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99694103,0.0002036079,0.0010831147,0.00080637657,0.00040068958,0.000565184],"domain_scores_gemma":[0.99845606,0.00007340273,0.0006654023,0.000601541,0.00004285938,0.00016074005],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002671858,0.0008114536,0.0026920624,0.00079615007,0.000087060944,0.000017957327,0.00023769362,0.00014875719,0.003986042],"category_scores_gemma":[0.000003137934,0.00060731976,0.00093783473,0.0010287379,0.00015167221,0.00007227362,0.00007792885,0.0006733426,0.0000025922732],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054418773,0.000608685,0.00029619617,0.009514443,0.00057523244,0.0000070681413,0.0006527573,2.5737518e-7,0.0000017397307,0.000011840647,0.0021600153,0.9856276],"study_design_scores_gemma":[0.003566162,0.00021868914,0.0005500664,0.011065129,0.00073757174,0.000033564946,0.0000472106,0.0000021650926,0.000004966016,0.0000046642385,0.9832665,0.0005033271],"about_ca_topic_score_codex":0.00047265098,"about_ca_topic_score_gemma":0.00017954146,"teacher_disagreement_score":0.98512423,"about_ca_system_score_codex":0.002129476,"about_ca_system_score_gemma":0.0013198279,"threshold_uncertainty_score":0.99963784},"labels":[],"label_agreement":null},{"id":"W4220894291","doi":"10.1016/j.it.2022.03.003","title":"All is not lost: learning from 9p21 loss in cancer","year":2022,"lang":"en","type":"review","venue":"Trends in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"Genentech; Canada Research Chairs; Astellas Pharma Canada; Princess Margaret Cancer Foundation; Merck; University Health Network; Ontario Institute for Cancer Research; Roche; Novartis; University of Toronto; AbbVie; Terry Fox Research Institute; Celgene; Bayer; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Pembrolizumab; Genotype; Information and Communications Technology; Cancer; Evasion (ethics); Antibody; Immune system; Immunology; Medicine; Oncology; Immunotherapy; Internal medicine; Biology; Gene; Genetics; Political science","score_opus":0.11191423088062265,"score_gpt":0.395589634095474,"score_spread":0.28367540321485135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220894291","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008302907,0.9944788,3.9568818e-7,0.0007229919,0.0010814045,0.0002582068,0.00011603131,0.000041567495,0.0024702935],"genre_scores_gemma":[0.00019122708,0.98913485,0.000025298355,0.00079278625,0.00015440736,0.0003241488,0.00080529734,0.000092558985,0.008479404],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99708164,0.0004379507,0.0009613413,0.0007197862,0.00021790602,0.0005813592],"domain_scores_gemma":[0.9986726,0.00029682723,0.000384989,0.0005929826,0.000013580902,0.00003900849],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030235684,0.0005015703,0.0022931418,0.0012131418,0.00004642809,0.000011774347,0.00039918083,0.00062735914,0.040474396],"category_scores_gemma":[0.000036429632,0.00045483417,0.0005370239,0.0011414001,0.00019309444,0.00004276891,0.00021044885,0.0022322284,0.00010815981],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075841555,0.0001433882,0.00046687113,0.00060795306,0.0009455558,0.00035553507,0.0006770685,8.594624e-7,0.000018612614,0.00000707085,0.0009526845,0.995066],"study_design_scores_gemma":[0.0025550064,0.00025810153,0.0019448646,0.003402534,0.000388933,0.00009815862,0.000072462826,0.000003229656,0.000008670904,0.000007409121,0.9908707,0.00038990227],"about_ca_topic_score_codex":0.010117774,"about_ca_topic_score_gemma":0.0012068182,"teacher_disagreement_score":0.99467605,"about_ca_system_score_codex":0.001363396,"about_ca_system_score_gemma":0.0003990409,"threshold_uncertainty_score":0.9997903},"labels":[],"label_agreement":null},{"id":"W4220909053","doi":"10.1038/s41586-022-04508-4","title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","year":2022,"lang":"en","type":"article","venue":"Nature","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":442,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Ipilimumab; Hazard ratio; Internal medicine; Chemotherapy; Oncology; Cancer; Gastroenterology; Randomized controlled trial; Immunotherapy; Confidence interval","score_opus":0.010581438853851407,"score_gpt":0.3003839206273684,"score_spread":0.289802481773517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220909053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686766,0.017466871,0.0000043574605,0.010320994,0.0010609125,0.0006353707,0.00008374712,0.000092271424,0.0016588377],"genre_scores_gemma":[0.97663224,0.00046477094,0.0001545238,0.012917904,0.0002865963,0.00013867702,0.00003370937,0.000035091263,0.009336514],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99882275,0.00004222666,0.00018612648,0.00027885314,0.00038186522,0.0002881565],"domain_scores_gemma":[0.99958175,0.000024500561,0.000058876216,0.000249397,0.00002946726,0.00005599926],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017719371,0.00014755128,0.00025960125,0.00013362369,0.00010747528,0.000010925773,0.00015515542,0.0003217045,0.0063828644],"category_scores_gemma":[0.000010767208,0.00011852248,0.000106492815,0.00053675944,0.00004130057,0.000043854794,0.000041899817,0.0021000905,0.000004327736],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1483857,0.0013995116,0.08815256,0.00036825577,0.0008311741,0.0019798467,0.006522814,0.00021295257,0.057997327,0.0001340884,0.40924543,0.2847703],"study_design_scores_gemma":[0.04545497,0.001622496,0.17257293,0.00014939067,0.000063720116,0.00041415874,0.0014254043,0.00056344515,0.005565998,0.000053966516,0.7716558,0.00045770704],"about_ca_topic_score_codex":0.0003404733,"about_ca_topic_score_gemma":0.00034347858,"teacher_disagreement_score":0.3624104,"about_ca_system_score_codex":0.0008840174,"about_ca_system_score_gemma":0.0004761517,"threshold_uncertainty_score":0.99452543},"labels":[],"label_agreement":null},{"id":"W4220969080","doi":"10.3390/cancers14061580","title":"Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy","year":2022,"lang":"en","type":"review","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"Canadian Institutes of Health Research","keywords":"CTLA-4; Priming (agriculture); Immunology; Cytotoxic T cell; CD80; Immunotherapy; Effector; Medicine; Immune system; Cancer immunotherapy; T cell; Tumor microenvironment; Cancer research; Biology; CD40; In vitro","score_opus":0.1050909900318455,"score_gpt":0.35481633374665034,"score_spread":0.24972534371480484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220969080","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005912539,0.98918813,0.00000682194,0.000074394986,0.001400535,0.0027053605,0.00009671495,0.00003427723,0.00058123056],"genre_scores_gemma":[0.0019580799,0.99616367,0.00001671472,0.0005507035,0.000240781,0.0005784707,0.0001560913,0.00012565486,0.000209847],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965262,0.0008409545,0.00087504694,0.0005365138,0.0007370062,0.00048426777],"domain_scores_gemma":[0.99709255,0.0008843782,0.00085579994,0.0010783416,0.00003971831,0.000049239363],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015430069,0.00056718785,0.0014960082,0.00021239612,0.00025249328,0.00005072723,0.0007542447,0.00026944675,0.0005518165],"category_scores_gemma":[0.000023588009,0.00032389784,0.0008617015,0.00088256376,0.0002649592,0.00007012688,0.000044072043,0.00088226295,0.0000046773675],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020672388,0.00010230512,0.000010252072,0.004117155,0.000626971,0.000016181464,0.0009484789,0.00001087582,0.012184832,0.0000020656253,0.009646393,0.97026724],"study_design_scores_gemma":[0.0046029855,0.00055856776,0.000030483643,0.0036184343,0.00028371805,0.000020711788,0.00032848382,0.0000075750904,0.0018692884,7.705391e-7,0.9883362,0.00034278407],"about_ca_topic_score_codex":0.0006519471,"about_ca_topic_score_gemma":0.000015146172,"teacher_disagreement_score":0.9786898,"about_ca_system_score_codex":0.0024976793,"about_ca_system_score_gemma":0.001871362,"threshold_uncertainty_score":0.9999213},"labels":[],"label_agreement":null},{"id":"W4220991301","doi":"10.1158/1538-7445.sabcs21-gs1-01","title":"Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Carboplatin; Placebo; Internal medicine; Oncology; Pembrolizumab; Epirubicin; Stage (stratigraphy); Chemotherapy; Cyclophosphamide; Cisplatin; Cancer; Pathology; Immunotherapy","score_opus":0.07198443318772366,"score_gpt":0.4048215236955636,"score_spread":0.33283709050783994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220991301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864732,0.0034671917,0.00008559595,0.0024197958,0.00040948397,0.0055901404,0.0011642273,0.000105888634,0.00028448124],"genre_scores_gemma":[0.99248916,0.0016070846,0.000052755877,0.0003698986,0.00028540965,0.0014355548,0.00013177306,0.00020763672,0.0034207457],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9926275,0.00095927954,0.0010306386,0.0013696392,0.002600159,0.0014128009],"domain_scores_gemma":[0.995938,0.0011387574,0.00043818893,0.0015634692,0.00050163065,0.00041992252],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00445983,0.00066265155,0.001580483,0.00063646043,0.0008920843,0.0001262795,0.0007093015,0.00022549693,0.001645322],"category_scores_gemma":[0.0002084786,0.0006174691,0.0004942601,0.0011759376,0.0005337767,0.00022703139,0.00042407008,0.0011410277,0.0000028803197],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40835702,0.0032940605,0.023269318,0.0007196835,0.0024304937,0.0002547602,0.0054377527,0.00015206123,0.5149112,0.00001396285,0.02888037,0.012279337],"study_design_scores_gemma":[0.32084897,0.02834861,0.44178903,0.0005468267,0.0006674665,0.00013834791,0.01840625,0.0019337749,0.13075341,0.00010059955,0.054090176,0.0023765403],"about_ca_topic_score_codex":0.013903177,"about_ca_topic_score_gemma":0.00327965,"teacher_disagreement_score":0.4185197,"about_ca_system_score_codex":0.0012233306,"about_ca_system_score_gemma":0.0010230996,"threshold_uncertainty_score":0.99962765},"labels":[],"label_agreement":null},{"id":"W4221048747","doi":"10.1177/23814683221089659","title":"Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma","year":2022,"lang":"en","type":"article","venue":"MDM Policy & Practice","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"EMD Serono; Sanofi; Amgen; Pfizer; NeraCare; Bristol-Myers Squibb; Sun Pharma; GlaxoSmithKline","keywords":"Ipilimumab; Survival analysis; Nivolumab; Proportional hazards model; Medicine; Hazard ratio; Piecewise; Parametric statistics; Semiparametric model; Statistics; Oncology; Internal medicine; Mathematics; Cancer; Immunotherapy; Confidence interval","score_opus":0.04668034980675517,"score_gpt":0.38332610536716266,"score_spread":0.3366457555604075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221048747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868067,0.0012334932,0.000035073364,0.009203552,0.00008861066,0.002224966,0.000066157554,0.000029515675,0.0003119425],"genre_scores_gemma":[0.99796146,0.0000921595,0.0003531784,0.0003173647,0.00007968254,0.0010748026,0.000022078002,0.00003264573,0.0000666137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982864,0.00036725015,0.0004922109,0.00036975855,0.00019175226,0.00029261393],"domain_scores_gemma":[0.99866176,0.00061757053,0.00022732372,0.0003271354,0.00009020203,0.000075999174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013956154,0.00017416256,0.00031044873,0.00033695868,0.00025970142,0.000027062037,0.000078365345,0.000039920695,0.000015842696],"category_scores_gemma":[0.0004924777,0.00016689341,0.0000604934,0.00090705126,0.000045600504,0.000308695,0.00007856246,0.00028898334,5.889311e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056836803,0.012098063,0.73125607,0.0002905996,0.0012725902,0.002244025,0.025471646,0.00039804826,0.121980816,0.0023257947,0.00004598651,0.04577957],"study_design_scores_gemma":[0.028386312,0.0051227524,0.8984888,0.000061786166,0.0002726359,0.0073727625,0.04479543,0.00028480554,0.0021118862,0.00011163351,0.012389555,0.0006016273],"about_ca_topic_score_codex":0.016366744,"about_ca_topic_score_gemma":0.010742903,"teacher_disagreement_score":0.16723275,"about_ca_system_score_codex":0.0004613416,"about_ca_system_score_gemma":0.0004539057,"threshold_uncertainty_score":0.99018335},"labels":[],"label_agreement":null},{"id":"W4221090420","doi":"10.1158/1538-7445.sabcs21-p5-16-13","title":"Abstract P5-16-13: Safety and efficacy of INT230-6, a potential first-in-class intratumoral therapy, in monotherapy and in combination with pembrolizumab: Results from the IT-01 study [KEYNOTE-A10] in subjects with locally advanced, unresectable and metastatic breast cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Dosing; Breast cancer; Response Evaluation Criteria in Solid Tumors; Internal medicine; Tolerability; Oncology; Cancer; Phases of clinical research; Adverse effect; Clinical trial; Immunotherapy","score_opus":0.027447146859004182,"score_gpt":0.33030144978083276,"score_spread":0.3028543029218286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221090420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867387,0.0061226576,0.0000038446774,0.004161469,0.000038099424,0.0027176435,0.0001628025,0.000007853323,0.00004695977],"genre_scores_gemma":[0.99155444,0.0076016965,0.000017522301,0.00014239557,0.000023378881,0.00055581494,0.000023703054,0.000039414706,0.00004162096],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99703026,0.0004985157,0.00055433303,0.00063034805,0.00077854417,0.00050798047],"domain_scores_gemma":[0.9987282,0.00059677806,0.00014515457,0.00032345526,0.00012128984,0.00008509708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017830576,0.00024322636,0.0005445969,0.0004706791,0.00015793207,0.000056181936,0.00019310288,0.000051730243,0.00012665897],"category_scores_gemma":[0.000040996918,0.00016777084,0.000022782766,0.0014477661,0.00043940503,0.00019274846,0.00009931562,0.00094491296,9.48128e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5588911,0.0020207062,0.3403313,0.00015148656,0.00026318012,0.00038520145,0.014042341,0.004127465,0.0066631227,0.00000821216,0.0000698217,0.073046096],"study_design_scores_gemma":[0.08484596,0.0027518296,0.9026381,0.00070904114,0.000014806215,0.000030971292,0.007619373,0.0006438701,0.00038357457,0.000038545117,0.00013473164,0.00018922686],"about_ca_topic_score_codex":0.12044922,"about_ca_topic_score_gemma":0.31574827,"teacher_disagreement_score":0.5623068,"about_ca_system_score_codex":0.00083178916,"about_ca_system_score_gemma":0.00076982036,"threshold_uncertainty_score":0.8854078},"labels":[],"label_agreement":null},{"id":"W4221104422","doi":"10.6004/jnccn.2021.7268","title":"CLO22-052: A Tale of Two Schedules: A Study of the Efficacy and Toxicity Outcomes of Extended Durvalumab Dosing in Patients with Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)","year":2022,"lang":"en","type":"article","venue":"Journal of the National Comprehensive Cancer Network","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Durvalumab; Dosing; Toxicity; Oncology; Stage (stratigraphy); Internal medicine; Lung cancer; non-small cell lung cancer (NSCLC); Cancer; Immunotherapy","score_opus":0.020011767071446553,"score_gpt":0.30492830326985554,"score_spread":0.284916536198409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221104422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99449277,0.0037113335,0.000011371127,0.00020246884,0.000444932,0.0010228184,0.00006261777,0.0000018459415,0.000049825943],"genre_scores_gemma":[0.99923456,0.00009648675,0.000107365995,0.0003482479,0.00009583944,0.000023418086,0.0000012030358,0.000017691456,0.00007519587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757385,0.0002638289,0.00072455505,0.00015964183,0.0010936382,0.00018449318],"domain_scores_gemma":[0.99712193,0.00029953642,0.0013748093,0.00018270926,0.0009804079,0.00004061176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037852355,0.00016528108,0.0005945318,0.00012866686,0.00016716674,0.000007830258,0.0002959118,0.000031214026,0.00007612461],"category_scores_gemma":[0.000033206492,0.00009787321,0.00016195378,0.0007093427,0.00014190887,0.00006681289,0.00019081532,0.00041685347,1.2635458e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011197106,0.0012766733,0.87807935,0.00014030184,0.0008949386,0.0000018326695,0.001667296,0.101515144,0.004683919,0.000009200111,0.0002890569,0.0002452059],"study_design_scores_gemma":[0.025566688,0.00097604195,0.96912,0.0006923039,0.00022576848,0.0000038168264,0.0009869093,0.0006685312,0.0015560996,0.000021326545,0.0000800834,0.00010240251],"about_ca_topic_score_codex":0.00058187725,"about_ca_topic_score_gemma":0.00026037518,"teacher_disagreement_score":0.10084661,"about_ca_system_score_codex":0.0004629088,"about_ca_system_score_gemma":0.00067829585,"threshold_uncertainty_score":0.39911538},"labels":[],"label_agreement":null},{"id":"W4221119237","doi":"10.1136/jitc-2022-004560","title":"Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Western University; Mount Sinai Hospital; Vancouver General Hospital; University of Calgary","funders":"National Cancer Institute","keywords":"Medicine; H&E stain; Pathology; Biopsy; Internal medicine; Immunohistochemistry","score_opus":0.03298784563646882,"score_gpt":0.36664944114517334,"score_spread":0.3336615955087045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221119237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9576839,0.024825545,0.00440457,0.008543568,0.0017110325,0.0014447534,0.0012537435,0.000023048533,0.00010981839],"genre_scores_gemma":[0.9872275,0.0054126177,0.005780509,0.000424849,0.00013952992,0.0004264794,0.00009326956,0.000039281316,0.00045596325],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99835795,0.00008253056,0.0008729005,0.00015495632,0.00031382585,0.00021782161],"domain_scores_gemma":[0.99838436,0.00014506883,0.0009246936,0.00012763278,0.00037247702,0.000045790955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013165931,0.00013833567,0.0005190039,0.0001692309,0.00043619671,0.000018100809,0.00009178702,0.000068337955,0.0007536627],"category_scores_gemma":[0.000030039122,0.00012380711,0.00043607166,0.00017800779,0.000112328846,0.0000817699,0.000023946217,0.00021198433,1.7855879e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019353174,0.00063968863,0.0034664539,0.00020831077,0.0020010953,0.0000026118892,0.00091193407,0.000033082106,0.8698322,0.00030624383,0.004115947,0.09912926],"study_design_scores_gemma":[0.072790846,0.018753922,0.25299034,0.0015643095,0.0008766738,0.00060801744,0.004342996,0.00091781415,0.11055015,0.0029416054,0.5328274,0.00083593384],"about_ca_topic_score_codex":0.00012340202,"about_ca_topic_score_gemma":0.000008256036,"teacher_disagreement_score":0.75928205,"about_ca_system_score_codex":0.0009744797,"about_ca_system_score_gemma":0.00043542785,"threshold_uncertainty_score":0.8252078},"labels":[],"label_agreement":null},{"id":"W4221123017","doi":"10.1016/j.critrevonc.2022.103660","title":"Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis","year":2022,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Canadian Centre for Applied Research in Cancer Control; Sunnybrook Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; University Health Network; University of Toronto","funders":"","keywords":"Pembrolizumab; Medicine; Oncology; Lung cancer; Internal medicine; Adverse effect; Meta-analysis; Hazard ratio; Chemotherapy; Randomized controlled trial; Cancer; Immunotherapy; Confidence interval","score_opus":0.13754416683348544,"score_gpt":0.4488775729735346,"score_spread":0.3113334061400491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221123017","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.034768e-7,0.9732391,0.0009092142,0.002676802,0.00016462409,0.022657666,0.000114838855,0.000039520386,0.00019793097],"genre_scores_gemma":[0.0000011381686,0.9328341,0.005723767,0.010412741,0.00006921044,0.04996701,0.0001706414,0.00014871635,0.00067269016],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9893395,0.003086011,0.004603441,0.0014948014,0.0003482195,0.0011280377],"domain_scores_gemma":[0.9879335,0.008424202,0.0017404133,0.0014012487,0.00017049986,0.00033012158],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0051271454,0.0012981937,0.03990662,0.0005386826,0.00019548587,0.000032801086,0.0006059747,0.00054445793,0.0036910698],"category_scores_gemma":[0.0017412236,0.00072121236,0.004656217,0.0026384806,0.0004927338,0.000060201262,0.00015094416,0.0011183782,0.000010578983],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004846135,0.00039645482,0.0000028667887,0.8917565,0.08275133,0.0003313206,0.00004674659,2.1284089e-7,4.6936297e-8,0.0002639682,0.004500274,0.01946568],"study_design_scores_gemma":[0.0014466814,0.00070286973,1.1060323e-7,0.097208284,0.4763707,0.001717238,0.000016382199,0.00001852575,1.328392e-7,0.0000142342415,0.42209986,0.0004050153],"about_ca_topic_score_codex":0.00003984507,"about_ca_topic_score_gemma":0.00031135324,"teacher_disagreement_score":0.7945482,"about_ca_system_score_codex":0.000862745,"about_ca_system_score_gemma":0.0018329484,"threshold_uncertainty_score":0.999977},"labels":[],"label_agreement":null},{"id":"W4223553787","doi":"10.3389/fimmu.2022.875093","title":"Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features","year":2022,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Tianjin Municipal Science and Technology Bureau","keywords":"Medicine; Internal medicine; Lung cancer; Oncology; Hazard ratio; Cochrane Library; Confidence interval; Meta-analysis; Clinical trial; Randomized controlled trial; Chemotherapy; Immunotherapy; Cancer","score_opus":0.046343003006802025,"score_gpt":0.3628849536562788,"score_spread":0.31654195064947677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223553787","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025878525,0.9950759,0.0000357242,0.00006154273,0.00091624574,0.0009860795,0.00012370257,0.0000062535555,0.00020669113],"genre_scores_gemma":[0.0004321407,0.9978037,0.0009617846,0.00008394941,0.000020230731,0.00029509922,0.00011556171,0.000040522496,0.00024702755],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960656,0.00074269786,0.0020918462,0.0005913818,0.00020410553,0.00030436943],"domain_scores_gemma":[0.99792457,0.00024555787,0.0011041161,0.00064631616,0.000039063176,0.0000404037],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001142969,0.00039630535,0.008341641,0.00200324,0.000018662056,0.0000039420634,0.00032101548,0.0006601437,0.0003025947],"category_scores_gemma":[0.000081986065,0.00032046315,0.0030969598,0.0019561714,0.00045183674,0.000021513468,0.00017321456,0.0010438601,1.1531839e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015025822,0.00052621274,0.012454139,0.011296822,0.3822156,0.00017129551,0.00051339116,0.000011937074,0.000059764257,0.000008874039,0.0029261084,0.5883133],"study_design_scores_gemma":[0.0029611283,0.00046731654,0.0029263152,0.0010114474,0.38398007,0.000016871827,0.00034597854,0.00002751286,0.000076950484,0.000009205266,0.60774225,0.00043495288],"about_ca_topic_score_codex":0.0017495183,"about_ca_topic_score_gemma":0.00021117875,"teacher_disagreement_score":0.60481614,"about_ca_system_score_codex":0.00018683991,"about_ca_system_score_gemma":0.0006013289,"threshold_uncertainty_score":0.9999247},"labels":[],"label_agreement":null},{"id":"W4223580441","doi":"10.1007/s40265-022-01707-1","title":"Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews","year":2022,"lang":"en","type":"review","venue":"Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Waterloo; Montfort Hospital; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Medicine; Systematic review; Common Terminology Criteria for Adverse Events; Interquartile range; Adverse effect; Incidence (geometry); Data extraction; MEDLINE; Internal medicine; Oncology; Intensive care medicine","score_opus":0.1008775101479818,"score_gpt":0.3539215827697252,"score_spread":0.2530440726217434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223580441","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023023855,0.9921495,5.499065e-7,0.00001667447,0.00034494876,0.00600804,0.00006459359,0.00003979936,0.001352872],"genre_scores_gemma":[0.00001740639,0.9959492,0.000024191575,0.00006122106,0.00006746951,0.001086925,0.0004530829,0.0000887985,0.0022516937],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953959,0.0008483456,0.0024212862,0.00038230166,0.00067299337,0.0002791628],"domain_scores_gemma":[0.99582046,0.00028924266,0.0028341387,0.00090950466,0.000066379835,0.00008025607],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024828452,0.0005316019,0.0054642074,0.0002247725,0.00006499917,0.000004263272,0.00028411695,0.00020359358,0.0010500832],"category_scores_gemma":[0.00039151643,0.00032954096,0.0019710213,0.0009986159,0.00006127106,0.0000509339,0.0000964099,0.00046550683,0.000048027763],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094279174,0.00025569843,0.000003046977,0.87702113,0.0019767315,0.000031427877,0.00030566493,3.0496928e-8,0.000003078463,0.000004785483,0.000396962,0.119907185],"study_design_scores_gemma":[0.0007713664,0.00017485664,0.0000052310556,0.4373972,0.0031877842,0.00007228033,0.00007843395,2.3639927e-7,0.000002804814,0.0000011427715,0.5581019,0.00020677222],"about_ca_topic_score_codex":0.00007838769,"about_ca_topic_score_gemma":0.0000030668675,"teacher_disagreement_score":0.5577049,"about_ca_system_score_codex":0.0008069808,"about_ca_system_score_gemma":0.0005105863,"threshold_uncertainty_score":0.99991566},"labels":[],"label_agreement":null},{"id":"W4224264528","doi":"10.3390/curroncol29040234","title":"Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Kaohsiung Medical University Chung-Ho Memorial Hospital; Ministry of Science and Technology, Taiwan","keywords":"Medicine; Maculopapular rash; Adverse effect; Rash; Immunology; Immune system; Immunotherapy; Cancer; Monoclonal antibody; Dermatology; Antibody; Internal medicine","score_opus":0.11194545814217353,"score_gpt":0.41425607513979407,"score_spread":0.3023106169976205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224264528","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001123822,0.9945638,0.0000014078539,0.00023205076,0.0016042333,0.0025758934,0.00006118643,0.00009775063,0.00075127895],"genre_scores_gemma":[0.000013444128,0.99743736,0.000013936202,0.00023009857,0.00022876097,0.00073216634,0.0007581357,0.00007795525,0.00050813664],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99678403,0.0005575533,0.0012884308,0.00046288545,0.00043286738,0.0004742337],"domain_scores_gemma":[0.9978691,0.0002515982,0.0010920276,0.0005495224,0.00008328896,0.00015446973],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007445781,0.00048977934,0.0027961915,0.0001597925,0.000112697424,0.0000033101046,0.00023482302,0.00025528372,0.003305604],"category_scores_gemma":[0.00032130902,0.0003506761,0.0010723848,0.0007851174,0.00012606186,0.00003630172,0.00014366435,0.0011032262,0.00010703623],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002949602,0.0010167965,0.00002869358,0.026707053,0.00086301577,0.0002561352,0.00006052893,3.5275125e-8,0.0000022349059,0.0000012681004,0.0032791754,0.9674901],"study_design_scores_gemma":[0.0017687894,0.001426301,0.000015467374,0.093562275,0.003564162,0.0016519893,0.000028977114,9.2734007e-7,0.0000012907094,0.0000022428517,0.89765084,0.00032673377],"about_ca_topic_score_codex":0.000015078685,"about_ca_topic_score_gemma":0.000012012021,"teacher_disagreement_score":0.9671634,"about_ca_system_score_codex":0.0025432108,"about_ca_system_score_gemma":0.0016230854,"threshold_uncertainty_score":0.9998945},"labels":[],"label_agreement":null},{"id":"W4224288069","doi":"10.3390/curroncol29050238","title":"Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Medicine; Chemoradiotherapy; Oncology; Esophageal squamous cell carcinoma; Chemotherapy; Internal medicine; Basal cell; Squamous carcinoma; Carcinoma; Cancer research","score_opus":0.026669330000658454,"score_gpt":0.3189625403734915,"score_spread":0.292293210372833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224288069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99714196,0.00061121216,0.000003001972,0.00021400492,0.00029307863,0.0016144349,0.0000058765163,0.000014890566,0.000101529105],"genre_scores_gemma":[0.99951935,0.000014218957,0.000027185086,0.00011821112,0.000028546683,0.00020409671,0.00004046751,0.000025812536,0.000022135122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985739,0.00018136934,0.00038052685,0.00028629552,0.00036304916,0.00021483877],"domain_scores_gemma":[0.999438,0.00004966127,0.00020250329,0.00020385862,0.000066738714,0.000039275004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002672982,0.00015886268,0.0004718633,0.00035915416,0.000044588705,0.000003323889,0.00009554966,0.00004527421,0.0001236483],"category_scores_gemma":[0.0000057215916,0.00012770697,0.000034497356,0.0006845796,0.00008697117,0.000045692366,0.000025941792,0.000322002,3.414875e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019542323,0.014641376,0.9201069,0.000040837793,0.00003912405,0.000042878495,0.005705689,0.000024872077,0.000082270766,0.0000045344077,0.00012947382,0.039639708],"study_design_scores_gemma":[0.072125286,0.027045906,0.89693654,0.000027814147,0.000022220907,0.000010410673,0.0019283722,0.0000357323,0.00017398817,0.0000036939748,0.0015670728,0.00012295453],"about_ca_topic_score_codex":0.00021366797,"about_ca_topic_score_gemma":0.00030195373,"teacher_disagreement_score":0.05258296,"about_ca_system_score_codex":0.00088712195,"about_ca_system_score_gemma":0.00024216402,"threshold_uncertainty_score":0.52077395},"labels":[],"label_agreement":null},{"id":"W4224325677","doi":"10.1186/s12916-022-02332-1","title":"Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR","year":2022,"lang":"en","type":"article","venue":"BMC Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; Eisai","keywords":"Medicine; Breast cancer; Triple-negative breast cancer; Carboplatin; Anthracycline; Immune system; Cancer; Cancer research; Internal medicine; Oncology; Chemotherapy; Immunology; Cisplatin","score_opus":0.030118922561589476,"score_gpt":0.32990065954161607,"score_spread":0.2997817369800266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224325677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9385368,0.013570055,0.000026141754,0.044987716,0.000490501,0.0020252177,0.00018302072,0.000046866848,0.00013363583],"genre_scores_gemma":[0.9882126,0.0050717206,0.00008150574,0.0030361696,0.00018529246,0.0010832291,0.000033431057,0.0000711568,0.0022248877],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99570465,0.0010644654,0.0007055946,0.00081249484,0.0009731583,0.0007396551],"domain_scores_gemma":[0.998381,0.0005235301,0.00019650266,0.0005642896,0.00010781063,0.00022682617],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004198692,0.00034877937,0.00069946377,0.00085758686,0.00043873463,0.000019156154,0.00031981905,0.00010923535,0.0040798443],"category_scores_gemma":[0.000082868115,0.00028769558,0.00009714907,0.0015986592,0.00060583284,0.00007312789,0.00015196152,0.00073151896,0.000006187379],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11262727,0.0010823507,0.05221246,0.00015857175,0.00018160636,0.00007114031,0.010599052,0.000032464224,0.5799446,0.000038989292,0.002979285,0.24007224],"study_design_scores_gemma":[0.021523982,0.0029785475,0.9615617,0.00048898737,0.00007151954,0.0009133704,0.0061607566,0.00015740536,0.0014958817,0.00012320334,0.0041945097,0.00033015606],"about_ca_topic_score_codex":0.012244866,"about_ca_topic_score_gemma":0.0010434698,"teacher_disagreement_score":0.9093492,"about_ca_system_score_codex":0.0020198103,"about_ca_system_score_gemma":0.00044071223,"threshold_uncertainty_score":0.9999575},"labels":[],"label_agreement":null},{"id":"W4224881443","doi":"10.14740/gr1491","title":"Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival","year":2022,"lang":"en","type":"article","venue":"Gastroenterology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Cleveland Clinic","keywords":"Medicine; Internal medicine; Adverse effect; Gastroenterology; Cancer; Oncology","score_opus":0.029753418953959904,"score_gpt":0.3041349263974436,"score_spread":0.2743815074434837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224881443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99780035,0.00021604798,0.000047152505,0.0011805173,0.00008615131,0.0004990548,0.000060319322,0.000028324592,0.00008208931],"genre_scores_gemma":[0.9991106,0.000016479562,0.00012565832,0.000112657406,0.0000369206,0.00015258155,0.000029750763,0.000028055892,0.00038733406],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99713546,0.00085815147,0.00044125863,0.00035684975,0.0005698981,0.0006383811],"domain_scores_gemma":[0.99871606,0.0002573984,0.00024113727,0.00028383164,0.00039791208,0.00010367565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002442916,0.00016295713,0.00048523486,0.000350053,0.00026642787,0.000012596321,0.00016440397,0.00002650522,0.00019428198],"category_scores_gemma":[0.0003766649,0.00014064868,0.000100774516,0.00036631155,0.0009076138,0.00004399661,0.00029390736,0.0007275339,6.021804e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060422126,0.00030492837,0.2920812,0.000059124177,0.00017897344,0.00015594868,0.00025452985,0.0000042858537,0.6463251,0.0000035742016,0.00006247243,0.0001476872],"study_design_scores_gemma":[0.008151505,0.014387959,0.91353285,0.00031678285,0.000028446033,0.0010380073,0.0066612773,0.00007257732,0.05564847,0.000016958837,0.000048314247,0.00009683459],"about_ca_topic_score_codex":0.0001926003,"about_ca_topic_score_gemma":0.0002064717,"teacher_disagreement_score":0.6214517,"about_ca_system_score_codex":0.00023774743,"about_ca_system_score_gemma":0.00023774561,"threshold_uncertainty_score":0.5735487},"labels":[],"label_agreement":null},{"id":"W4225003814","doi":"10.1136/gutjnl-2021-326183","title":"Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer","year":2022,"lang":"en","type":"article","venue":"Gut","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Biotechnology and Biological Sciences Research Council; Medical Research Council; Public Health Agency; Associazione Italiana per la Ricerca sul Cancro; Queen's University Belfast; Queen's University; Cancer Research UK; Wellcome Trust","keywords":"Stroma; Stromal cell; In vivo; Biology; Cancer research; Immune system; Cancer; Immunology; Immunohistochemistry","score_opus":0.021085054251705506,"score_gpt":0.2988662013190695,"score_spread":0.277781147067364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225003814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926999,0.003819414,0.000056620283,0.0021280805,0.00017210953,0.000798618,0.00008812711,0.000022981727,0.00021415703],"genre_scores_gemma":[0.99776936,0.00009813182,0.00006507222,0.00076515425,0.000022971872,0.00041253673,0.00003827475,0.000018879346,0.0008096276],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99869967,0.00019210913,0.00036843115,0.00025075075,0.00029563674,0.00019339992],"domain_scores_gemma":[0.9994347,0.000072484436,0.0001401296,0.00026620735,0.000046692883,0.00003980589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004124015,0.00013172788,0.00028426762,0.00013709164,0.00008546872,0.0000049018636,0.000111375404,0.000046734716,0.00055878476],"category_scores_gemma":[0.000028419616,0.0001194085,0.00007313522,0.00056115823,0.000044167882,0.00005850104,0.00006952636,0.00025908518,0.0000012231392],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009091139,0.0009706401,0.012066172,0.000048284095,0.00017593817,0.0000038026776,0.002735053,0.00009764399,0.92570126,0.000030349307,0.0009770246,0.048102666],"study_design_scores_gemma":[0.0070708203,0.0050397296,0.53680366,0.00026397547,0.00011427641,0.000016453554,0.0030311109,0.00034311524,0.43312672,0.00020702166,0.013506244,0.00047687945],"about_ca_topic_score_codex":0.0054212,"about_ca_topic_score_gemma":0.00019555283,"teacher_disagreement_score":0.5247375,"about_ca_system_score_codex":0.0006589653,"about_ca_system_score_gemma":0.0001922839,"threshold_uncertainty_score":0.81952685},"labels":[],"label_agreement":null},{"id":"W4225272679","doi":"10.21203/rs.3.rs-1598645/v1","title":"Thirteen tumor necrosis factor receptor superfamily gene expression in malignancies and their clinical relevance to immunotherapy: a pan-cancer analysis","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Southern Methodist University","keywords":"Biology; Carcinogenesis; Cancer research; Cancer; Tumor necrosis factor alpha; Cancer immunotherapy; Immune system; Neuroblastoma RAS viral oncogene homolog; Oncogene; Melanoma; Immunology; Cancer cell; Immunotherapy; Genetics; KRAS; Cell cycle; Colorectal cancer","score_opus":0.09369958369694975,"score_gpt":0.4275444720156388,"score_spread":0.333844888318689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225272679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96499604,0.02727998,0.00007031905,0.0030577122,0.00040648252,0.0026049055,0.0013823783,0.00008278961,0.00011937339],"genre_scores_gemma":[0.9196179,0.07274794,0.0012759079,0.0010679711,0.00039242255,0.00235318,0.00029796048,0.00013509755,0.002111605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935608,0.0014030762,0.0011401331,0.0015883709,0.0013400555,0.0009675985],"domain_scores_gemma":[0.9964086,0.0010248016,0.00022174956,0.0015580761,0.0004495567,0.0003372256],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034066453,0.00054208026,0.001559067,0.0013867075,0.00032036,0.00017471526,0.00067316677,0.0004227968,0.0030538542],"category_scores_gemma":[0.0005227616,0.00042026507,0.00077287026,0.0023482307,0.00036515348,0.0001009935,0.0013943872,0.0026205045,0.000016096066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017283797,0.00080185995,0.4826522,0.001068445,0.002380975,0.00008635852,0.0069955736,0.00007853481,0.42510033,0.000003307873,0.0065746373,0.056973998],"study_design_scores_gemma":[0.0034678436,0.0015193644,0.900103,0.00263463,0.00012178275,0.0000060734706,0.0028712892,0.00021735739,0.026597051,0.000077221186,0.061613098,0.00077134336],"about_ca_topic_score_codex":0.0028770375,"about_ca_topic_score_gemma":0.0004901941,"teacher_disagreement_score":0.41745076,"about_ca_system_score_codex":0.0010105586,"about_ca_system_score_gemma":0.0010618938,"threshold_uncertainty_score":0.99982494},"labels":[],"label_agreement":null},{"id":"W4225684867","doi":"10.1097/01.ogx.0000805152.09501.f1","title":"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer","year":2022,"lang":"en","type":"article","venue":"Obstetrical & Gynecological Survey","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Pembrolizumab; Bevacizumab; Oncology; Chemotherapy; Cervical cancer; Internal medicine; Paclitaxel; Cancer; Immunotherapy","score_opus":0.1206040151824032,"score_gpt":0.35710787764108065,"score_spread":0.23650386245867744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225684867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9608803,0.019731713,0.00038062717,0.0050902073,0.0046226284,0.004489756,0.0024153995,0.0003600807,0.002029282],"genre_scores_gemma":[0.98932225,0.00033923218,0.00055911834,0.0029173014,0.000100379715,0.00127095,0.00035681477,0.000039627634,0.0050943047],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99686193,0.00065070536,0.000565122,0.0006410692,0.0006049974,0.00067615934],"domain_scores_gemma":[0.99381846,0.005216099,0.00015891013,0.00031138345,0.00017661238,0.00031854128],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008164791,0.00028182086,0.00071208953,0.00015495418,0.00045643072,0.00003730261,0.00031675806,0.00011270306,0.018553669],"category_scores_gemma":[0.0038644683,0.00018976752,0.0006173753,0.0013849008,0.00014116634,0.000046980025,0.00020267566,0.00049932185,0.000023065522],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14454007,0.0108723845,0.22349322,0.0006208687,0.0032066146,0.000631208,0.000457079,0.0001689926,0.0015196385,0.00039766208,0.12230508,0.4917872],"study_design_scores_gemma":[0.012510081,0.0114399195,0.66246647,0.000017411921,0.00037357927,0.00010771524,0.00032714434,0.0013262244,0.00004002078,0.00006905763,0.31080353,0.00051884324],"about_ca_topic_score_codex":0.00033322856,"about_ca_topic_score_gemma":0.00021804273,"teacher_disagreement_score":0.49126834,"about_ca_system_score_codex":0.000981177,"about_ca_system_score_gemma":0.00034664635,"threshold_uncertainty_score":0.9823435},"labels":[],"label_agreement":null},{"id":"W4225763352","doi":"10.30683/1927-7229.2021.10.06","title":"Application of the Plan-Do-Check-Act Cycle for Managing Immune-Related Adverse Events","year":2021,"lang":"en","type":"article","venue":"Journal of Analytical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"PDCA; Medicine; Adverse effect; Medical record; Flow chart; Chart; Medical emergency; Emergency medicine; Diarrhea; Emergency department; Quality management; Operations management; Internal medicine; Management system; Nursing","score_opus":0.016578583285723675,"score_gpt":0.3296343820960424,"score_spread":0.31305579881031875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225763352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968113,0.0015163417,0.0036025066,0.019382926,0.00074357423,0.00038768115,0.000008550472,0.000007632603,0.006237805],"genre_scores_gemma":[0.9981329,0.00019804311,0.00061843556,0.0004637712,0.00009759958,0.0000027053698,0.0000035446255,0.00000904744,0.00047395873],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99883044,0.00006548694,0.00069211575,0.00009248258,0.00018569788,0.0001337525],"domain_scores_gemma":[0.99885845,0.00017543774,0.00049334863,0.00017450846,0.0002378741,0.000060366685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005235245,0.00007278862,0.00038456905,0.0000709358,0.000039356855,0.0000018198758,0.00011532815,0.00011499765,0.00013240021],"category_scores_gemma":[0.00015485377,0.00004756956,0.0004847259,0.00024846298,0.000086268315,0.00003919119,0.00002731046,0.00021468509,0.000002461418],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04433633,0.005608884,0.14511636,0.0008148148,0.011568896,0.0005644645,0.0018333646,0.0014238823,0.3896681,0.010013944,0.008488047,0.3805629],"study_design_scores_gemma":[0.042178284,0.0068609607,0.6215231,0.0010709681,0.0046556704,0.004652796,0.003263485,0.03242728,0.035757408,0.0127580175,0.234349,0.00050304417],"about_ca_topic_score_codex":0.000011397877,"about_ca_topic_score_gemma":0.0000057537454,"teacher_disagreement_score":0.47640672,"about_ca_system_score_codex":0.00020457244,"about_ca_system_score_gemma":0.00038866454,"threshold_uncertainty_score":0.19398305},"labels":[],"label_agreement":null},{"id":"W4225892150","doi":"10.1016/j.annonc.2022.02.054","title":"45P Pembrolizumab versus best supportive care survival outcomes in ECOG performance status 2 NSCLC patients","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Multivariate analysis; Cancer; Immunotherapy","score_opus":0.06702358270823291,"score_gpt":0.37947969330167036,"score_spread":0.3124561105934375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225892150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98129153,0.0005498599,1.9047391e-7,0.0007937106,0.0010836247,0.00032743922,0.00014923503,0.0000122278925,0.015792187],"genre_scores_gemma":[0.9981128,0.0005575791,0.000018639377,0.00069843023,0.000029886845,0.00005982445,0.0001643265,0.000015989148,0.00034250293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858147,0.00012008618,0.00040711233,0.00021466825,0.00029135856,0.00038533425],"domain_scores_gemma":[0.9992183,0.00013071642,0.00019851232,0.00020264881,0.0001767946,0.00007306339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019845608,0.00013279567,0.00048011626,0.00018170703,0.00007682135,0.0000025802103,0.000117515716,0.00007289813,0.00071737554],"category_scores_gemma":[0.00005952529,0.00012451623,0.00013456303,0.00021945928,0.00010586363,0.00006481787,0.00009810003,0.00023351655,0.000009951879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036131073,0.0011997323,0.7736512,0.000082201404,0.00022698283,0.00004980456,0.0031491548,0.000019430441,0.0001258838,0.00001593091,0.0012722308,0.18407638],"study_design_scores_gemma":[0.021511097,0.022254605,0.8471578,0.00002049466,0.000041357416,0.0000048311394,0.0051043364,0.000010403161,0.0006648437,0.000004303606,0.10307022,0.00015575388],"about_ca_topic_score_codex":0.0006367146,"about_ca_topic_score_gemma":0.00043255667,"teacher_disagreement_score":0.18392062,"about_ca_system_score_codex":0.00032277172,"about_ca_system_score_gemma":0.0005338465,"threshold_uncertainty_score":0.7854759},"labels":[],"label_agreement":null},{"id":"W4226005246","doi":"10.2139/ssrn.4066218","title":"Real-World Outcomes with Ipilimumab and Nivolumab in Advanced Melanoma: A Multicentre Retrospective Study","year":2022,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Ipilimumab; Nivolumab; Medicine; Retrospective cohort study; Melanoma; Real world evidence; Oncology; Internal medicine; Cancer; Immunotherapy; Cancer research","score_opus":0.006660069429091562,"score_gpt":0.26789854256218887,"score_spread":0.2612384731330973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226005246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959938,0.0017344524,0.0000105404315,0.00092485093,0.00009363323,0.0006930342,0.0000035112323,0.000026980835,0.00051918195],"genre_scores_gemma":[0.99532825,0.0011986119,0.000049825147,0.00010415154,0.000033815908,0.000046888643,0.0000028420545,0.000031051135,0.0032045804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976025,0.00013298745,0.00029831214,0.00029286902,0.00041811488,0.001255171],"domain_scores_gemma":[0.9994982,0.000031834115,0.00015921507,0.00019066063,0.000047579662,0.00007252618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001004595,0.0001838022,0.00039033178,0.0002713532,0.00027877983,0.000020854985,0.00011121654,0.000021419137,0.000104188686],"category_scores_gemma":[0.000019217194,0.00014149492,0.00007333921,0.00048222922,0.000046955018,0.000104818406,0.000050407685,0.0017262814,9.662185e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011052813,0.0007754047,0.9748605,0.000006022136,0.00061361043,0.00012865114,0.0017052185,0.000012711892,0.00040468638,0.0003970927,0.000014276769,0.010029008],"study_design_scores_gemma":[0.027720245,0.0069742566,0.92985666,0.000026697817,0.00012454986,0.0007547969,0.033077996,0.00003286645,0.000017370483,0.0009197745,0.00029737575,0.0001973935],"about_ca_topic_score_codex":0.0011350939,"about_ca_topic_score_gemma":0.041873563,"teacher_disagreement_score":0.045003824,"about_ca_system_score_codex":0.004292868,"about_ca_system_score_gemma":0.0013727976,"threshold_uncertainty_score":0.9995295},"labels":[],"label_agreement":null},{"id":"W4226113086","doi":"10.1016/j.annonc.2022.02.015","title":"6MO Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; St Mary's Hospital Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Cancer; Immunotherapy","score_opus":0.07065250765017408,"score_gpt":0.349824965715346,"score_spread":0.2791724580651719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226113086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909546,0.0012439993,0.000024430487,0.0024630076,0.0002447238,0.0019740423,0.00004445834,0.00006403571,0.0029867245],"genre_scores_gemma":[0.9940906,0.0003516914,0.0002906781,0.0017873393,0.000050880033,0.0004130665,0.00011796437,0.00005083609,0.0028469274],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99742264,0.00035627472,0.00074796774,0.00045104258,0.0004895658,0.0005325127],"domain_scores_gemma":[0.99862915,0.0001591524,0.0004906808,0.00039832864,0.00020116905,0.00012150338],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008483172,0.00027147465,0.0009068223,0.00037021993,0.000119101125,0.000009913052,0.00019995493,0.00008270686,0.0017282559],"category_scores_gemma":[0.0001364244,0.00020173588,0.00017743018,0.00074570597,0.00023113139,0.00010466209,0.00008380353,0.00038144516,0.0000124042035],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88851696,0.0022738718,0.008827645,0.0006809016,0.0014124007,0.0026466113,0.0041514775,0.00030224098,0.006054861,0.00013078505,0.009615347,0.075386904],"study_design_scores_gemma":[0.36109546,0.20283419,0.11256559,0.0018024168,0.0019796179,0.0073328167,0.013660582,0.0013399945,0.017942851,0.0004571402,0.27696827,0.0020210724],"about_ca_topic_score_codex":0.0010857327,"about_ca_topic_score_gemma":0.0013925711,"teacher_disagreement_score":0.5274215,"about_ca_system_score_codex":0.00048425276,"about_ca_system_score_gemma":0.0022070238,"threshold_uncertainty_score":0.9991843},"labels":[],"label_agreement":null},{"id":"W4226120074","doi":"10.1038/s41467-022-29611-y","title":"Targeting TCTP sensitizes tumor to T cell-mediated therapy by reversing immune-refractory phenotypes","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"Korea Drug Development Fund; Korean Foundation for Cancer Research; National Research Foundation of Korea; National Research Foundation","keywords":"Immune system; Immunotherapy; Combination therapy; Cancer research; Targeted therapy; Immunology; Medicine; Cytotoxic T cell; T cell; Cancer; Biology; Pharmacology; Internal medicine","score_opus":0.012902178929644705,"score_gpt":0.2782830516813301,"score_spread":0.2653808727516854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226120074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5413544,0.4033377,0.000052688363,0.042935554,0.0010621857,0.0018716716,0.00042932047,0.00048278426,0.008473676],"genre_scores_gemma":[0.98360485,0.003542663,0.0023905495,0.009016016,0.0000616551,0.000083537816,0.0007643441,0.000042038762,0.0004943513],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99865603,0.00025837353,0.00030684774,0.00022635954,0.0003073386,0.00024505527],"domain_scores_gemma":[0.9980455,0.00033289383,0.00014672003,0.0012561978,0.00012828622,0.00009040321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000456086,0.00016389259,0.00023963123,0.00011371698,0.0010206342,0.000025527856,0.00057985785,0.00009883676,0.00035564322],"category_scores_gemma":[0.00010814272,0.00016029703,0.00012681627,0.00062119425,0.00009102258,0.000064674605,0.0002969099,0.0013099907,0.000021369717],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008523464,0.00041443037,0.00054545153,0.000011597779,0.000114852686,0.000005411868,0.0011761026,0.000010110333,0.8323349,0.000028399354,0.16110203,0.0034044092],"study_design_scores_gemma":[0.001583624,0.00023637505,0.0017566312,0.00002954543,0.000032581018,0.000019919085,0.0015873837,0.00015808422,0.009278258,0.0000063941993,0.9850924,0.00021880164],"about_ca_topic_score_codex":0.00017433125,"about_ca_topic_score_gemma":0.000016295171,"teacher_disagreement_score":0.82399035,"about_ca_system_score_codex":0.00028520433,"about_ca_system_score_gemma":0.00013450251,"threshold_uncertainty_score":0.7849996},"labels":[],"label_agreement":null},{"id":"W4226192985","doi":"","title":"Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors","year":2021,"lang":"en","type":"article","venue":"Seoul National University Open Repository (Seoul National University)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company","keywords":"Microsatellite instability; Antibody; Medicine; Microsatellite; Cancer research; Oncology; Immunology; Biology; Genetics; Gene","score_opus":0.008646846262266696,"score_gpt":0.24571613632241512,"score_spread":0.23706929006014843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226192985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896165,0.000034645967,0.00012602836,0.0003880652,0.00005542846,0.0009624212,0.00013413785,0.00003229602,0.00865047],"genre_scores_gemma":[0.99543047,0.00010523695,0.00095950125,0.00010419685,0.000011250552,4.4274145e-7,0.00053541566,0.00001870742,0.0028347662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747115,0.0002855034,0.0003326736,0.0006891482,0.0009770064,0.00024450567],"domain_scores_gemma":[0.99761456,0.00020127457,0.0003379729,0.00023192246,0.0015047801,0.00010946619],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045084368,0.00026328795,0.0005045677,0.00085443136,0.00030317914,0.000048661772,0.00026429744,0.00015225756,0.00006079919],"category_scores_gemma":[0.000046440684,0.00025977346,0.00009195846,0.0019350628,0.00035045587,0.0009149552,0.00016527931,0.00028722672,0.0000014850883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08873795,0.00456965,0.8653668,0.00021615275,0.0005465507,0.0013110535,0.00068653596,0.00056499854,0.023080884,0.014536861,0.000023963315,0.00035855523],"study_design_scores_gemma":[0.021213224,0.00096204336,0.9684358,0.0005008241,0.000062359744,0.00009182764,0.00093687355,0.00026938965,0.0044213766,0.00005091174,0.0026975612,0.00035777554],"about_ca_topic_score_codex":0.0013978136,"about_ca_topic_score_gemma":0.0004710176,"teacher_disagreement_score":0.103068985,"about_ca_system_score_codex":0.0015502836,"about_ca_system_score_gemma":0.0023182034,"threshold_uncertainty_score":0.99998546},"labels":[],"label_agreement":null},{"id":"W4226198844","doi":"10.21203/rs.3.rs-1450580/v1","title":"A combined spatial score of granzyme B and CD68 surpasses CD8 as an independent prognostic factor in TNM stage II colorectal cancer","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"University of Bern","keywords":"Medicine; Granzyme B; CD8; Internal medicine; CD68; Oncology; Tissue microarray; Cohort; Colorectal cancer; Pathology; Immunohistochemistry; Cancer; Gastroenterology; Immunology; Immune system","score_opus":0.07101933932116547,"score_gpt":0.4087045238641658,"score_spread":0.33768518454300034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226198844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99125487,0.002647023,0.0000026857895,0.00054772553,0.0002804767,0.0038616022,0.0011174758,0.00004346071,0.00024470966],"genre_scores_gemma":[0.9955964,0.001950092,0.000017602862,0.000030244273,0.00011337542,0.0011020977,0.0004747387,0.000060355138,0.0006550714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955736,0.00065804314,0.0005433393,0.0007860516,0.0018109813,0.00062799576],"domain_scores_gemma":[0.998306,0.00032619206,0.0001860814,0.00051050435,0.00041749032,0.00025375406],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012896039,0.00032436647,0.00075801683,0.0007619717,0.00021442473,0.000067247376,0.00034944425,0.00033256633,0.0037158127],"category_scores_gemma":[0.00037052936,0.00029100972,0.00015728897,0.0005553201,0.00038129528,0.00007829959,0.0011278751,0.0019538472,0.0000014810954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016960273,0.0014109943,0.94647026,0.003939721,0.0003659997,0.0004363077,0.004301658,0.000023149041,0.01711297,0.000059035072,0.00019328385,0.008726324],"study_design_scores_gemma":[0.005500543,0.00688521,0.976213,0.0018002241,0.000040056682,0.00001170539,0.0018402725,0.00021654033,0.006026529,0.00014820555,0.0009872754,0.0003304827],"about_ca_topic_score_codex":0.054248907,"about_ca_topic_score_gemma":0.018315734,"teacher_disagreement_score":0.03593317,"about_ca_system_score_codex":0.00079310796,"about_ca_system_score_gemma":0.0026376154,"threshold_uncertainty_score":0.9999542},"labels":[],"label_agreement":null},{"id":"W4226254150","doi":"10.1177/10781552221090199","title":"International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions","year":2022,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Cancer Care Ontario; CancerCare Manitoba","funders":"","keywords":"Medicine; Pharmacy; Oncology nursing; Pharmacy practice; Oncology; Clinical pharmacy; Internal medicine; Immunotherapy; Position statement; Immune checkpoint; Cancer; Family medicine; Nursing; Nurse education","score_opus":0.03706517425586087,"score_gpt":0.4121058449302516,"score_spread":0.37504067067439073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226254150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71034044,0.00696444,0.00065602275,0.26108998,0.0036155013,0.004878112,0.00067784364,0.000043873708,0.011733769],"genre_scores_gemma":[0.95968884,0.02764481,0.0061135716,0.004746802,0.0005203707,0.00072108454,0.00029268916,0.00006483899,0.00020696089],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948737,0.001384122,0.0022619742,0.00033615137,0.00072974386,0.000414318],"domain_scores_gemma":[0.99013865,0.0023973102,0.0060037985,0.00024005999,0.0010893663,0.0001308381],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004307176,0.00034321952,0.00093327335,0.0004636072,0.00039696967,0.000022540351,0.0003487774,0.00008871391,0.0016143991],"category_scores_gemma":[0.00014201064,0.00026032494,0.00065193744,0.00055511115,0.00047249076,0.0011886733,0.00008034509,0.0011786841,0.0000023490284],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11723346,0.013074168,0.0010866314,0.00006805757,0.0070447545,0.00025738424,0.008352769,0.0007583267,0.7675775,0.00011956233,0.0072323494,0.07719503],"study_design_scores_gemma":[0.051386733,0.012073034,0.00019392227,0.00007141772,0.0012793252,0.005153183,0.021355841,0.0006374371,0.12359947,0.00008081364,0.7839786,0.00019023911],"about_ca_topic_score_codex":0.0010993686,"about_ca_topic_score_gemma":0.000029519653,"teacher_disagreement_score":0.7767462,"about_ca_system_score_codex":0.005854603,"about_ca_system_score_gemma":0.005360247,"threshold_uncertainty_score":0.9999849},"labels":[],"label_agreement":null},{"id":"W4226258201","doi":"10.5167/uzh-213514","title":"Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma","year":2022,"lang":"en","type":"article","venue":"Zurich Open Repository and Archive (University of Zurich)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":557,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Alberta Cancer Foundation","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Melanoma; Internal medicine; Oncology; Cancer; Immunotherapy; Cancer research","score_opus":0.012386245694846164,"score_gpt":0.2277708140967711,"score_spread":0.21538456840192494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226258201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947838,0.00020834703,0.00012976125,0.00017539148,0.00016429843,0.0013528815,0.00007319836,0.00004064966,0.0030716257],"genre_scores_gemma":[0.99329734,0.00006733489,0.0021259456,0.0000752492,0.000015484038,0.000009606692,0.00012065461,0.00003672067,0.004251638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786663,0.00032354353,0.00026441063,0.0006385907,0.0005312772,0.00037555795],"domain_scores_gemma":[0.9986409,0.0002592447,0.00031730277,0.0005246631,0.000090340654,0.00016755241],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002601456,0.00030474816,0.0007170762,0.00028345038,0.0007312427,0.000038421844,0.00052779785,0.000056361492,0.00022739531],"category_scores_gemma":[0.000010080412,0.00026279766,0.00010007266,0.0005133288,0.00036005155,0.00043892767,0.0005906813,0.0003570613,0.0000022157103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26509213,0.0013151333,0.7195119,0.00016625182,0.0008944269,0.0011709094,0.003265348,0.000064009975,0.0005874216,0.000027455371,0.0005592844,0.00734569],"study_design_scores_gemma":[0.07029337,0.009847537,0.91436744,0.00018683085,0.0002610975,0.00010143993,0.0031910578,0.000044599525,0.00009935192,0.0000061380965,0.001190125,0.00041100127],"about_ca_topic_score_codex":0.001124454,"about_ca_topic_score_gemma":0.001352763,"teacher_disagreement_score":0.19485551,"about_ca_system_score_codex":0.00037519372,"about_ca_system_score_gemma":0.00041816433,"threshold_uncertainty_score":0.9999824},"labels":[],"label_agreement":null},{"id":"W4226329559","doi":"10.3390/curroncol29050247","title":"Immune Checkpoint Inhibitors in Cancer Therapy","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1280,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Nivolumab; Durvalumab; Medicine; Ipilimumab; Avelumab; Pembrolizumab; Atezolizumab; Immunotherapy; CTLA-4; Immune checkpoint; Cancer; Cancer immunotherapy; Lung cancer; Oncology; Immunology; Immune system; Cancer research; Internal medicine; T cell","score_opus":0.2411030219700868,"score_gpt":0.48359365454263703,"score_spread":0.24249063257255024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226329559","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000120578254,0.9898076,4.6174196e-7,0.00026258623,0.0065291245,0.0016978071,0.00004033564,0.000047917292,0.0014935746],"genre_scores_gemma":[0.0000063551824,0.99653184,0.000008583744,0.00010484212,0.00072122813,0.001888094,0.0002644949,0.00007152409,0.00040301902],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99724483,0.00034631055,0.0012036928,0.0005227057,0.00025293083,0.00042951055],"domain_scores_gemma":[0.9987418,0.00016617491,0.00054712855,0.00042978735,0.000027995098,0.00008713399],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006497913,0.0004409261,0.0023469508,0.00046513847,0.00006377135,0.000009111559,0.00025579476,0.0003495729,0.0060042166],"category_scores_gemma":[0.000036167326,0.0003394297,0.0010114297,0.0007412038,0.00013660772,0.000029445635,0.00012024044,0.0013559791,0.00003172931],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038133483,0.0007268069,0.000062874846,0.0043905885,0.00023881045,0.00005190719,0.00017749563,5.6231958e-8,0.000008230472,0.0000041742164,0.0025843792,0.99137336],"study_design_scores_gemma":[0.0028120994,0.000678694,0.00008028169,0.006042549,0.00024937524,0.00010463207,0.000044331475,7.856754e-7,0.0000063583043,0.000005422437,0.98966587,0.00030958105],"about_ca_topic_score_codex":0.00024822706,"about_ca_topic_score_gemma":0.00006511252,"teacher_disagreement_score":0.9910638,"about_ca_system_score_codex":0.0029702275,"about_ca_system_score_gemma":0.00232687,"threshold_uncertainty_score":0.99990577},"labels":[],"label_agreement":null},{"id":"W4226395090","doi":"","title":"Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by Programmed Death Ligand-1 combined positive score","year":2022,"lang":"en","type":"article","venue":"Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Cetuximab; Internal medicine; Hazard ratio; Head and neck squamous-cell carcinoma; Oncology; Chemotherapy; Subgroup analysis; Population; Head and neck cancer; Post-hoc analysis; Cancer; Confidence interval; Immunotherapy; Colorectal cancer","score_opus":0.009436508755720111,"score_gpt":0.2338819730931807,"score_spread":0.2244454643374606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226395090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904358,0.0010493422,0.001474303,0.0013290887,0.000036916583,0.0018195699,0.0011757365,0.00013083432,0.0025484336],"genre_scores_gemma":[0.99290437,0.00011740069,0.0016939138,0.0007663509,0.000017131839,0.000070146234,0.0017077533,0.00011335924,0.0026095556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99636334,0.00034720413,0.00037266742,0.0009946439,0.0007098686,0.0012122727],"domain_scores_gemma":[0.9977537,0.0007808159,0.00027735994,0.0004519342,0.00015486502,0.0005813261],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004981524,0.00063503446,0.0009928755,0.0012023788,0.0007917736,0.00019301068,0.0005168992,0.0001571756,0.00034589123],"category_scores_gemma":[0.00003502197,0.0006774277,0.00048202704,0.002371743,0.0004998213,0.0006282573,0.0002664427,0.00065148546,0.0000017229019],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29486698,0.005266015,0.63945377,0.0008027753,0.0038901481,0.010267663,0.020446189,0.0005408553,0.0055500017,0.0009985165,0.0053223497,0.012594722],"study_design_scores_gemma":[0.15820158,0.036703166,0.7090627,0.00023351093,0.0058018873,0.0022624377,0.05549719,0.010037097,0.0018968921,0.00073660596,0.016327156,0.0032398123],"about_ca_topic_score_codex":0.00085418136,"about_ca_topic_score_gemma":0.0002768287,"teacher_disagreement_score":0.13666542,"about_ca_system_score_codex":0.0029382086,"about_ca_system_score_gemma":0.00090744824,"threshold_uncertainty_score":0.9995677},"labels":[],"label_agreement":null},{"id":"W4229041964","doi":"10.1007/s10620-021-06948-w","title":"Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review","year":2021,"lang":"en","type":"review","venue":"Digestive Diseases and Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Robarts Clinical Trials; University of Calgary","funders":"","keywords":"Medicine; Enterocolitis; Internal medicine; Randomized controlled trial; Infliximab; Hepatology; Retrospective cohort study; Intensive care medicine; Disease","score_opus":0.10311613918946562,"score_gpt":0.4260605160642643,"score_spread":0.3229443768747987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229041964","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00050775154,0.99399775,0.000009592414,0.00013684745,0.00009200754,0.0050222436,0.00021667383,0.0000085257025,0.000008578546],"genre_scores_gemma":[0.001014871,0.99677485,0.000009054436,0.00003196776,0.00002759855,0.0018814004,0.00008145133,0.000005973213,0.00017282969],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9985588,0.00019896752,0.0006915395,0.00026710058,0.0001507394,0.0001328586],"domain_scores_gemma":[0.9987735,0.0004607284,0.0005198135,0.000097208016,0.00008840449,0.000060301096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038630524,0.00019213598,0.0015401008,0.0000525756,0.00017784987,0.000041275594,0.00007274081,0.00004740593,0.000026440253],"category_scores_gemma":[0.000266408,0.00009093017,0.0011945696,0.00022835295,0.00037911153,0.00004067832,0.000031944826,0.000037018326,1.9363372e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055256514,0.00085102033,0.00020232859,0.8226542,0.0022065463,0.0000063822936,0.000071982744,1.9179677e-8,0.0000042983193,0.00004352815,0.00004634738,0.1738581],"study_design_scores_gemma":[0.00080103206,0.0018869874,0.002319602,0.9662745,0.021731067,0.000034311484,0.00026238186,0.000007418013,0.000003828643,0.000010613759,0.0065385615,0.00012969149],"about_ca_topic_score_codex":0.000017823042,"about_ca_topic_score_gemma":0.0000018191165,"teacher_disagreement_score":0.17372842,"about_ca_system_score_codex":0.00008809368,"about_ca_system_score_gemma":0.00020893273,"threshold_uncertainty_score":0.37080246},"labels":[],"label_agreement":null},{"id":"W4229068667","doi":"10.1016/j.annonc.2022.03.183","title":"164O Health-related quality of life (HRQoL) with pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Gemcitabine; Pembrolizumab; Internal medicine; Breast cancer; Oncology; Cancer; Nursing","score_opus":0.07916337031695886,"score_gpt":0.40314876597677396,"score_spread":0.3239853956598151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229068667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93291545,0.0027616753,0.000024042512,0.05574961,0.00033287186,0.0027629887,0.003973415,0.00006502611,0.001414943],"genre_scores_gemma":[0.98428535,0.0029322247,0.0008078991,0.008663471,0.00013829255,0.0007958833,0.0005275,0.00007782297,0.0017715506],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959284,0.0004785636,0.0017135581,0.00075240864,0.00051033316,0.00061672373],"domain_scores_gemma":[0.9955816,0.0010390147,0.0020056493,0.00064414885,0.00046509647,0.00026448045],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010669157,0.00043983903,0.0019874808,0.00019212697,0.0002178687,0.0000060953034,0.000261658,0.00023643076,0.0011234286],"category_scores_gemma":[0.0002100325,0.00036305576,0.00046303408,0.0005306022,0.00038435165,0.000093914,0.000054129905,0.00030984456,0.0000026831465],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8262804,0.0027393952,0.00065641495,0.00018459959,0.0029734494,0.000017077877,0.0067904973,0.0001486733,0.015054746,0.000048268048,0.009613148,0.13549334],"study_design_scores_gemma":[0.54671264,0.093883514,0.093920216,0.0006204913,0.00048643613,0.00021171758,0.009922973,0.0003683797,0.14314574,0.00084416795,0.108526476,0.0013572221],"about_ca_topic_score_codex":0.039546944,"about_ca_topic_score_gemma":0.002033651,"teacher_disagreement_score":0.27956775,"about_ca_system_score_codex":0.0010639505,"about_ca_system_score_gemma":0.0034053195,"threshold_uncertainty_score":0.99988216},"labels":[],"label_agreement":null},{"id":"W4229441815","doi":"10.20944/preprints202205.0120.v1","title":"Mathematical Modeling of the Growth Suppression of HER2+ Breast Cancer Colonies Under the Effect of Trastuzumab and PD-1/PD-L1 Inhibitor","year":2022,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Qatar National Library; Qatar University","keywords":"Trastuzumab; Breast cancer; PI3K/AKT/mTOR pathway; Medicine; Growth inhibition; Cancer research; Neratinib; Pharmacology; Immune system; Cancer; Cell growth; Oncology; Internal medicine; Signal transduction; Biology; Immunology","score_opus":0.04907973605708391,"score_gpt":0.3388066776985429,"score_spread":0.28972694164145896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229441815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99512917,0.0010094367,0.00003859879,0.001292554,0.0003016144,0.0013575649,0.00015150219,0.000020910295,0.0006986594],"genre_scores_gemma":[0.99889326,0.00045382782,0.000021391766,0.00004726636,0.00007085327,0.00022205681,0.000008629324,0.00003824292,0.00024444502],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976505,0.00035556598,0.0007282697,0.00044732128,0.0006133683,0.00020498053],"domain_scores_gemma":[0.9980523,0.00030587247,0.0005158379,0.00094007375,0.00013471815,0.000051227624],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010568396,0.00029701478,0.0008091874,0.000081430284,0.00010413109,0.000005816709,0.00043319544,0.00021407784,0.0017368002],"category_scores_gemma":[0.00009350645,0.00016520041,0.0003927838,0.00017245466,0.00046843773,0.000033557066,0.001328882,0.00069779606,0.0000019220065],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025153946,0.0008865726,0.6726539,0.015216884,0.0031743567,0.000005496371,0.008120238,0.0066212676,0.26587397,0.0002918321,0.00016860028,0.0018329235],"study_design_scores_gemma":[0.004179706,0.00048716087,0.49067762,0.0052133254,0.0012377839,0.000091437105,0.0013203579,0.0043501756,0.49069047,0.0012833746,0.000083516854,0.0003850523],"about_ca_topic_score_codex":0.0010711959,"about_ca_topic_score_gemma":0.00001884275,"teacher_disagreement_score":0.22481652,"about_ca_system_score_codex":0.00018041838,"about_ca_system_score_gemma":0.00027017342,"threshold_uncertainty_score":0.9991757},"labels":[],"label_agreement":null},{"id":"W4230839613","doi":"10.1158/1538-7445.am2019-4550","title":"Abstract 4550: Correlations between tumor mutation burden, inflammatory profile and histological characteristics of tumor microenvironment in early-stage squamous cell lung carcinoma","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Tumor microenvironment; Immunotherapy; CD8; Lung cancer; Immune system; Cancer; Tumor-infiltrating lymphocytes; Immunohistochemistry; Medicine; Cancer research; Pathology; Biology; Immunology; Internal medicine","score_opus":0.02931991368300928,"score_gpt":0.31356870054116265,"score_spread":0.28424878685815336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230839613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99649924,0.0014601017,0.0000033365948,0.00020150763,0.00007895008,0.0011734248,0.00011010324,0.000011236627,0.00046209124],"genre_scores_gemma":[0.9983344,0.00008806663,0.000036210284,0.000026742146,0.00009537237,0.000119312615,0.00005147566,0.000022194508,0.0012261906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984734,0.00008477379,0.00040836004,0.00029850815,0.0004046971,0.00033024515],"domain_scores_gemma":[0.99923766,0.00018930342,0.0001427705,0.00024326725,0.0000851625,0.000101828235],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005092673,0.00012449814,0.00029940958,0.00022251571,0.000060281294,0.000015650958,0.0000990772,0.00008059877,0.0009931988],"category_scores_gemma":[0.000042179414,0.00011339523,0.000049967002,0.00018528428,0.0002487364,0.00007117439,0.00005730275,0.00046573454,0.000028947334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008115882,0.00006263313,0.819255,0.0006147348,0.000015145329,0.00009731018,0.0008782428,0.000005025013,0.17672059,0.000004602557,0.00015503439,0.0013801155],"study_design_scores_gemma":[0.002040463,0.00031268486,0.9784691,0.00013786589,0.000018292492,0.0000069942002,0.00034006446,0.000110739325,0.017213343,0.0000030120113,0.0012391851,0.000108258224],"about_ca_topic_score_codex":0.0013592511,"about_ca_topic_score_gemma":0.00002524764,"teacher_disagreement_score":0.15950724,"about_ca_system_score_codex":0.0006062834,"about_ca_system_score_gemma":0.00030412906,"threshold_uncertainty_score":0.99992},"labels":[],"label_agreement":null},{"id":"W4232022766","doi":"10.1016/j.annonc.2021.08.1154","title":"641TiP Phase Ib/II trial of pembrolizumab (pembro) + vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Foundation Medicine; Pharmacyclics; Genentech; Astellas Pharma; Merck Sharp and Dohme; Eisai; Invitae; Advanced Accelerator Applications; Menarini Silicon Biosystems; Clovis Oncology; Sanofi Genzyme; Sierra Oncology; Taiho Pharmaceutical; Vertex Pharmaceuticals; Boston Scientific Corporation; Daiichi Sankyo Europe; Sanofi; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Docetaxel; Prostate cancer; Pembrolizumab; Oncology; Olaparib; Internal medicine; Enzalutamide; Cancer; Immunotherapy; Androgen receptor","score_opus":0.07525017458406637,"score_gpt":0.385290777884475,"score_spread":0.31004060330040867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232022766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992277,0.0020992283,0.0000022493232,0.0030805701,0.00022661895,0.0019583565,0.00016633794,0.000013566102,0.0001760291],"genre_scores_gemma":[0.98825544,0.010320634,0.000100070894,0.0005014896,0.00003335993,0.00024962908,0.00018425322,0.000032855867,0.0003222519],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977214,0.000278932,0.0008755038,0.00042229038,0.00034756295,0.00035432808],"domain_scores_gemma":[0.998441,0.00013523725,0.00053529826,0.00029808568,0.0004777054,0.0001126755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017078959,0.00028622666,0.00094630796,0.00024776955,0.00007494843,0.000009463153,0.00006845547,0.000058441066,0.00020517656],"category_scores_gemma":[0.000062529194,0.00020653747,0.0001279032,0.00046527258,0.00020214762,0.00012278523,0.000027555734,0.00011757358,3.5743508e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70381874,0.014997484,0.014874527,0.00019856448,0.0010754301,0.00062472513,0.0013484806,0.000011893994,0.017609624,0.000032053642,0.0003357526,0.24507272],"study_design_scores_gemma":[0.5836476,0.18780337,0.14800517,0.00022438995,0.00043288263,0.00015916121,0.0004919524,0.00010652783,0.06894396,0.00003654944,0.0098256245,0.00032280915],"about_ca_topic_score_codex":0.0012819493,"about_ca_topic_score_gemma":0.0018719864,"teacher_disagreement_score":0.24474992,"about_ca_system_score_codex":0.00017085347,"about_ca_system_score_gemma":0.001118088,"threshold_uncertainty_score":0.8422353},"labels":[],"label_agreement":null},{"id":"W4232258040","doi":"10.21203/rs.3.rs-18123/v2","title":"Immune Characterization Of Metastatic Colorectal Cancer Patients Post Reovirus Administration","year":2020,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Cancer Institute","keywords":"Colorectal cancer; Immune system; Medicine; Virology; Oncology; Immunology; Cancer; Internal medicine","score_opus":0.06175960867406749,"score_gpt":0.40052736937348493,"score_spread":0.33876776069941744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232258040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923877,0.0006466375,0.000021661406,0.002761374,0.00030695318,0.0021697024,0.0014282069,0.00003666875,0.00024106246],"genre_scores_gemma":[0.9927978,0.001480466,0.00006213673,0.00010415737,0.00015620179,0.00031692948,0.004860967,0.000043168355,0.00017816397],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972594,0.0003022904,0.0005817453,0.00042734898,0.0011201723,0.00030905064],"domain_scores_gemma":[0.99740005,0.00008752806,0.00029671326,0.00031568515,0.0017625253,0.00013748024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005417329,0.00020685515,0.00050767435,0.00028161457,0.000088120316,0.000047725098,0.00018765783,0.0001868908,0.00059615646],"category_scores_gemma":[0.00038824553,0.00018612918,0.00022567686,0.0004628888,0.00017467707,0.000071356146,0.00022449515,0.0007660825,0.000018264744],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014494381,0.0007472411,0.012000791,0.004628005,0.00059903006,0.00003418794,0.0011551919,0.0000013083963,0.9495813,0.000021349098,0.00025266895,0.016484495],"study_design_scores_gemma":[0.0022831818,0.0032446762,0.7426275,0.0019173732,0.00011994766,0.0000033440479,0.00020244562,0.0001435769,0.24772598,0.000037358277,0.0014752337,0.00021937441],"about_ca_topic_score_codex":0.0008732183,"about_ca_topic_score_gemma":0.00007305551,"teacher_disagreement_score":0.7306267,"about_ca_system_score_codex":0.00037810154,"about_ca_system_score_gemma":0.0016558302,"threshold_uncertainty_score":0.7590128},"labels":[],"label_agreement":null},{"id":"W4232382020","doi":"10.1007/978-3-319-48066-4_13","title":"Pembrolizumab","year":2016,"lang":"id","type":"book-chapter","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Pembrolizumab; Nivolumab; Medicine; Ipilimumab; Monoclonal antibody; Melanoma; Oncology; Metastatic melanoma; Adverse effect; Clinical trial; Drug; Monoclonal; Internal medicine; Antibody; Immunotherapy; Pharmacology; Cancer research; Immunology; Cancer","score_opus":0.021946187028585196,"score_gpt":0.2614806494050266,"score_spread":0.23953446237644138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232382020","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009203695,0.008308058,0.000118038246,0.003086045,0.0018437703,0.0005710735,0.000057153873,0.00011842327,0.9858054],"genre_scores_gemma":[0.013454635,0.013030972,0.000045566187,0.0025388242,0.0016790248,0.000010746438,0.000026139156,0.00013150621,0.9690826],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99777734,0.000015978805,0.00062251947,0.000605092,0.0004930201,0.0004860176],"domain_scores_gemma":[0.9984584,0.00010111629,0.00024269035,0.0008316011,0.00013633523,0.00022985024],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00018768842,0.00060349,0.0007550972,0.00020225406,0.00010549876,0.000029327453,0.00022701043,0.00068415154,0.14730227],"category_scores_gemma":[0.000014794365,0.00038696674,0.00064798596,0.000027464961,0.00038931597,0.00006093967,0.00007195646,0.00034833996,0.010127606],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015235618,0.00011182485,0.00014720432,0.00047453737,0.0035750468,0.00039631786,0.00014546602,9.994486e-9,0.015199477,0.3613461,0.05059132,0.5527771],"study_design_scores_gemma":[0.0066481065,0.00073665974,0.00038259558,0.0017788758,0.00034470652,0.0001661579,0.000015528545,9.463759e-7,0.001087614,0.0011020047,0.987153,0.0005837967],"about_ca_topic_score_codex":0.000047693837,"about_ca_topic_score_gemma":0.000026176473,"teacher_disagreement_score":0.9365617,"about_ca_system_score_codex":0.00032078155,"about_ca_system_score_gemma":0.00032975955,"threshold_uncertainty_score":0.9998582},"labels":[],"label_agreement":null},{"id":"W4233687895","doi":"10.1200/jco.2006.09.4813","title":"In Reply","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine","score_opus":0.1388950118554293,"score_gpt":0.5277704356645774,"score_spread":0.3888754238091481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233687895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9567932,0.0007252295,0.00013291228,0.023754954,0.0020173923,0.00006293524,1.5562901e-7,0.000002803521,0.016510412],"genre_scores_gemma":[0.9636023,0.00067873875,0.002585713,0.030715184,0.0015472414,2.173057e-7,1.534282e-7,0.0000059992144,0.00086442765],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99751705,0.00009109222,0.0020273756,0.00006893602,0.00016221788,0.00013331028],"domain_scores_gemma":[0.99768764,0.0011695363,0.000783263,0.00009339281,0.00012445675,0.00014169843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008918492,0.00004574017,0.0006399189,0.000117553645,0.0000073332753,0.0000015768279,0.000067244284,0.00018303828,0.00026554012],"category_scores_gemma":[0.001796685,0.000030809166,0.00030925754,0.00013162564,0.000103617785,0.000053668176,0.000009700094,0.00059386186,0.000010278208],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05805624,0.0016824505,0.1741443,0.000013934112,0.00022670838,0.0046235826,0.00012536653,5.8361286e-7,0.0023902818,0.00009341916,0.039044224,0.7195989],"study_design_scores_gemma":[0.006836199,0.005324885,0.45140544,0.000033730787,0.000026458021,0.0005586882,0.000056552173,0.0000015556087,0.00021566756,0.00015202964,0.5353645,0.000024278295],"about_ca_topic_score_codex":0.000027130101,"about_ca_topic_score_gemma":0.000065730805,"teacher_disagreement_score":0.71957463,"about_ca_system_score_codex":0.00012216417,"about_ca_system_score_gemma":0.00072563393,"threshold_uncertainty_score":0.3090989},"labels":[],"label_agreement":null},{"id":"W4233827183","doi":"10.1515/iupac.84.0857","title":"Lymphoid Stem Cell","year":2016,"lang":"en","type":"dataset","venue":"IUPAC Standards Online","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"","keywords":"Glossary; Immunotoxicology; Immunology; Medicine; Immune system; Philosophy; Linguistics","score_opus":0.014014691123070331,"score_gpt":0.3752170028126131,"score_spread":0.36120231168954275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233827183","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006349568,0.0062388675,0.000022236585,0.00091546,0.0011794543,0.00048587192,0.9901818,0.00008529495,0.00025605294],"genre_scores_gemma":[0.000045715053,0.0070798243,0.000019310299,0.0014241977,0.0013028698,0.000018345265,0.9841511,0.000063232255,0.0058953525],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972348,0.000057284004,0.00055931957,0.00054622116,0.0011274606,0.00047490498],"domain_scores_gemma":[0.9980101,0.00006583289,0.00028727006,0.0010924352,0.0003201926,0.00022415552],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004393676,0.0004930817,0.00083062163,0.00023761406,0.00008624641,0.00003605871,0.00028590648,0.00049594307,0.006415609],"category_scores_gemma":[0.000028605067,0.0003360418,0.00038830936,0.00020692652,0.00017692309,0.00005183796,0.00008735242,0.00034165315,0.000008667261],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003529625,0.000322405,0.00003384765,0.00045210766,0.0002629723,0.00018115813,0.000010685681,3.3375617e-8,0.00031571637,3.040828e-7,0.9731464,0.021744741],"study_design_scores_gemma":[0.0058722887,0.00071325066,0.000054842785,0.00096584484,0.00031398732,0.00015602025,0.00003457482,6.876732e-7,0.00074730744,0.0000056950885,0.9907219,0.00041360516],"about_ca_topic_score_codex":0.00015247558,"about_ca_topic_score_gemma":0.00015327915,"teacher_disagreement_score":0.021331135,"about_ca_system_score_codex":0.0010758025,"about_ca_system_score_gemma":0.0019690115,"threshold_uncertainty_score":0.99990916},"labels":[],"label_agreement":null},{"id":"W4233885426","doi":"10.1001/jamaoncol.2019.6921","title":"Error in Table 2","year":2020,"lang":"en","type":"erratum","venue":"JAMA Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Oncology; MEDLINE; Internal medicine","score_opus":0.031382739229008964,"score_gpt":0.3340743508320977,"score_spread":0.3026916116030887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233885426","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003914452,0.009763068,0.00000390086,0.061220065,0.038516697,0.00068754115,0.000054693293,0.00009125417,0.8892713],"genre_scores_gemma":[0.0013107593,0.0056949356,0.00043600035,0.04729475,0.009150896,0.00015924954,0.0015260761,0.00011140031,0.9343159],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986209,0.000092610746,0.00040271046,0.0003746746,0.00017684323,0.00033221042],"domain_scores_gemma":[0.9993396,0.0000716436,0.00017000675,0.00026855015,0.000045030367,0.00010521766],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023282526,0.00021710311,0.0008144235,0.00017435507,0.00002390605,0.000013004546,0.00015832095,0.0015655833,0.0022259383],"category_scores_gemma":[0.00014594069,0.00019278639,0.00013735826,0.00035588726,0.00010149055,0.00003627169,0.00005976475,0.001869569,0.00019717216],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026644403,0.0001384306,0.00015770059,0.00020749068,0.00012433567,0.00093767996,0.00022407401,1.4635066e-7,0.0004342793,0.000018518784,0.9543231,0.04076981],"study_design_scores_gemma":[0.00429933,0.0013573978,0.0025262847,0.00022244333,0.000075216165,0.00013555834,0.0001357034,0.000047409325,0.00003407884,0.000038916547,0.9909524,0.00017528988],"about_ca_topic_score_codex":0.0006132523,"about_ca_topic_score_gemma":0.00085322396,"teacher_disagreement_score":0.045044594,"about_ca_system_score_codex":0.0007624381,"about_ca_system_score_gemma":0.0020741436,"threshold_uncertainty_score":0.9997306},"labels":[],"label_agreement":null},{"id":"W4234138863","doi":"10.1186/s40425-017-0297-3","title":"32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Late-Breaking Abstracts","year":2017,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cancer immunotherapy; Immunotherapy; Cancer; Medicine; Internal medicine","score_opus":0.03271945670655681,"score_gpt":0.35928972632851763,"score_spread":0.32657026962196084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234138863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94891703,0.045801673,0.00020109939,0.0019093935,0.0010966674,0.0016574106,0.000237264,0.000011936574,0.00016754253],"genre_scores_gemma":[0.96779597,0.027928343,0.0020305628,0.0002891648,0.0003614332,0.00018923351,0.0000042583297,0.000075391436,0.0013256146],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99767625,0.000034283228,0.0011027418,0.00027694818,0.00047004767,0.000439743],"domain_scores_gemma":[0.99539405,0.00013543028,0.0028651436,0.00060704234,0.0009286392,0.00006969522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011188599,0.00031743787,0.0008232576,0.000070915805,0.00061863585,0.00009268355,0.00058487826,0.0002210027,0.00008261336],"category_scores_gemma":[0.00004764681,0.00021604294,0.0012104412,0.00009779071,0.00068044255,0.00031710352,0.000044554316,0.0003110174,5.242787e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014118845,0.00024425937,0.025685789,0.0006990186,0.0037781463,5.65977e-7,0.0058068456,0.000054732227,0.5097948,0.000036333568,0.00089736807,0.4388833],"study_design_scores_gemma":[0.030434411,0.0028066714,0.53269666,0.00738701,0.0008106897,0.00006806348,0.0013772637,0.0003600296,0.31575426,0.00078411493,0.106820956,0.0006998785],"about_ca_topic_score_codex":0.0028150955,"about_ca_topic_score_gemma":0.00047916398,"teacher_disagreement_score":0.5070109,"about_ca_system_score_codex":0.00014917432,"about_ca_system_score_gemma":0.00077631715,"threshold_uncertainty_score":0.8809976},"labels":[],"label_agreement":null},{"id":"W4234685159","doi":"10.1158/1538-7445.am2019-579","title":"Abstract 579: Immune features and neoantigen recognition in mismatch repair-proficient colorectal cancer liver metastases","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; Institute for Research in Immunology and Cancer; Université de Montréal; Jewish General Hospital","funders":"","keywords":"Immune system; Immunotherapy; CD8; Colorectal cancer; Cancer research; Antigen; Tumor-infiltrating lymphocytes; Biology; Cancer; Immunology; Medicine; Internal medicine","score_opus":0.0614319214106752,"score_gpt":0.38043770882940686,"score_spread":0.31900578741873165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234685159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9488361,0.04723996,2.9948333e-7,0.0011029319,0.00027018046,0.0011975198,0.0001036546,0.000045772398,0.0012035889],"genre_scores_gemma":[0.9806347,0.016755974,0.00006232164,0.00018877316,0.00014064906,0.00034344033,0.000049136786,0.00003316086,0.0017918602],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979598,0.0001292384,0.00029468906,0.00048217928,0.00059101864,0.00054306275],"domain_scores_gemma":[0.99915344,0.00015736498,0.00006315728,0.00025604144,0.00024956156,0.000120462435],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011936758,0.00016910583,0.00033759678,0.0003251151,0.000107906555,0.000048139816,0.000112267146,0.00013567685,0.003545146],"category_scores_gemma":[0.00005645326,0.00013982832,0.00011941095,0.0005893551,0.00022889413,0.00012482035,0.00007340845,0.00058109727,0.00007583292],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009365221,0.00022461927,0.043342695,0.00079230726,0.00032418533,0.00014937359,0.0014909937,0.00000717454,0.8352442,0.0000120844825,0.009410736,0.09963644],"study_design_scores_gemma":[0.0037010552,0.0004806409,0.761696,0.0010867947,0.000041098574,0.000050656887,0.0011069194,0.000052408013,0.22135803,0.000030307716,0.010137913,0.0002582102],"about_ca_topic_score_codex":0.01686775,"about_ca_topic_score_gemma":0.0016886293,"teacher_disagreement_score":0.7183533,"about_ca_system_score_codex":0.00046583332,"about_ca_system_score_gemma":0.00047846042,"threshold_uncertainty_score":0.9973658},"labels":[],"label_agreement":null},{"id":"W4235321914","doi":"10.21203/rs.2.21605/v1","title":"Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada","year":2020,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; Health Sciences Centre; Canadian Partnership Against Cancer; Canadian Agency for Drugs and Technologies in Health; Sunnybrook Health Science Centre; Queen's University; Cancer Care Ontario","funders":"Canadian Institutes of Health Research; Government of Ontario; Canadian Centre for Applied Research in Cancer Control; Ontario Ministry of Health and Long-Term Care; Ontario Institute for Cancer Research; Cancer Care Ontario","keywords":"Ipilimumab; Metastatic melanoma; Medicine; Oncology; Cohort; Melanoma; Comparative effectiveness research; Real world evidence; Internal medicine; Cohort study; Demography; Cancer; Immunotherapy; Alternative medicine; Cancer research; Pathology; Sociology","score_opus":0.10579252947285712,"score_gpt":0.4238886071689379,"score_spread":0.3180960776960808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235321914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98488426,0.00019815429,0.000037983657,0.00019823835,0.00016579134,0.0134353265,0.0005190284,0.00001839492,0.0005428287],"genre_scores_gemma":[0.9951631,0.0000067306105,0.00018992453,0.000024737874,0.000039749953,0.0022229396,0.0019030182,0.000039444454,0.00041034204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956252,0.0012582017,0.0007387488,0.0007377897,0.0011990762,0.00044100033],"domain_scores_gemma":[0.99599504,0.0023226775,0.00021518698,0.0006120833,0.0006896981,0.0001652941],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029070303,0.00031739348,0.0014830852,0.0005547347,0.000089316185,0.000026930415,0.00024876423,0.00009582469,0.0004999816],"category_scores_gemma":[0.00019181591,0.00028483305,0.00021283895,0.0006797761,0.00008404061,0.0000303833,0.00014518315,0.0011545283,0.0000010565109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.022020401,0.0009001962,0.9676644,0.005628419,0.0011688647,0.000102387785,0.0007577142,0.00067629304,0.00048466388,0.000021570622,0.00046702227,0.00010806239],"study_design_scores_gemma":[0.0082015,0.0020210634,0.98449093,0.0016656325,0.00014745147,8.429482e-7,0.0006384758,0.0010225028,0.0012161833,0.00013759547,0.00023689448,0.00022094129],"about_ca_topic_score_codex":0.99375457,"about_ca_topic_score_gemma":0.9995108,"teacher_disagreement_score":0.016826512,"about_ca_system_score_codex":0.00525091,"about_ca_system_score_gemma":0.011549747,"threshold_uncertainty_score":0.99996036},"labels":[],"label_agreement":null},{"id":"W4235783426","doi":"10.21203/rs.2.15875/v1","title":"Risk of ophthalmic adverse events in patients treated with immune checkpoint inhibitor regimens: A systematic review and meta-analysis","year":2019,"lang":"en","type":"review","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal","funders":"","keywords":"Medicine; Adverse effect; Meta-analysis; Internal medicine; Inclusion and exclusion criteria; Odds ratio; Randomized controlled trial; Chemotherapy; Oncology; Gastroenterology; Pathology","score_opus":0.098180933432261,"score_gpt":0.4069661323993088,"score_spread":0.3087851989670478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235783426","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00090190617,0.98586076,2.7361418e-7,0.000025953601,0.000009069951,0.0128337275,0.000284881,0.000011386636,0.00007203477],"genre_scores_gemma":[0.00193758,0.9950138,0.000019624818,0.000010468028,0.000007665205,0.0011223891,0.00035828428,0.000064516156,0.0014657105],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9931925,0.0024584464,0.0018634292,0.00068292883,0.0013373911,0.00046529874],"domain_scores_gemma":[0.9961697,0.00043031623,0.0011851585,0.0014731417,0.00060549565,0.00013623045],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0038207625,0.00052605907,0.010119418,0.001415936,0.00005290744,0.0000072881257,0.0002597053,0.00026143863,0.00027750642],"category_scores_gemma":[0.00047217077,0.00028249397,0.002704966,0.0036087623,0.00014286031,0.000077231954,0.00012242886,0.00077140087,0.000032965792],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003177543,0.0002816725,0.000869443,0.8590779,0.13884258,0.000019825722,0.00003803197,1.083767e-7,3.67093e-7,3.5449386e-7,0.000014824167,0.0005371617],"study_design_scores_gemma":[0.0016931199,0.0011890269,0.0011900546,0.34867856,0.6458398,0.00002148022,0.000050291957,0.0000013738916,0.0000027114127,4.8231396e-7,0.0010753697,0.00025772073],"about_ca_topic_score_codex":0.0007157869,"about_ca_topic_score_gemma":0.00002714392,"teacher_disagreement_score":0.5103993,"about_ca_system_score_codex":0.0005026341,"about_ca_system_score_gemma":0.00039363716,"threshold_uncertainty_score":0.99996275},"labels":[],"label_agreement":null},{"id":"W4235986531","doi":"10.3410/f.725726463.793509473","title":"Faculty Opinions recommendation of Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells.","year":2015,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Stimulation; Glucocorticoid receptor; Tumor necrosis factor alpha; Glucocorticoid; Tumor cells; Regression; Cancer research; Receptor; Chemistry; Endocrinology; Internal medicine; Cell biology; Psychology; Biology; Medicine","score_opus":0.040653267279869724,"score_gpt":0.35432647108681575,"score_spread":0.313673203806946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235986531","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00062865287,0.0014314728,0.000008092571,0.062045254,0.001274438,0.0048784553,0.9296258,0.00008741009,0.000020439864],"genre_scores_gemma":[0.00038936414,0.00018203366,0.00042257964,0.0021878327,0.00019912569,0.00039111468,0.9946405,0.00006798814,0.0015194059],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99243546,0.0007144382,0.0028348719,0.0012239765,0.0022369127,0.0005543544],"domain_scores_gemma":[0.98844737,0.00016632648,0.0029979185,0.001887734,0.006051696,0.00044894553],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020242608,0.0008902384,0.0016916075,0.0005520144,0.00029337557,0.00015042438,0.00097001944,0.0008782565,0.0010459031],"category_scores_gemma":[0.0062842453,0.0005747343,0.00083174487,0.002536505,0.0003364446,0.0005308113,0.00028561617,0.0016239653,0.00009073735],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027327146,0.0005899272,0.000020928403,0.009095868,0.00031773074,4.901398e-7,0.00044473965,2.1497839e-7,0.008789365,0.0000026870102,0.9771863,0.003278437],"study_design_scores_gemma":[0.0025832176,0.00058958476,0.000995365,0.029864512,0.00024681425,0.000032872285,0.000101276564,0.000028317989,0.0076847156,0.0000045970623,0.9573186,0.0005501116],"about_ca_topic_score_codex":0.00034293748,"about_ca_topic_score_gemma":0.0000037146685,"teacher_disagreement_score":0.06501477,"about_ca_system_score_codex":0.0006035572,"about_ca_system_score_gemma":0.0012958742,"threshold_uncertainty_score":0.99986726},"labels":[],"label_agreement":null},{"id":"W4236441826","doi":"10.37247/pacr.1.2021.42","title":"Tackling Immune Targets for Breast Cancer Beyond PD-1PD-L1 Axis","year":2021,"lang":"en","type":"book-chapter","venue":"Vide Leaf, Hyderabad eBooks","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Alberta Cancer Foundation; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Breast cancer; Immune system; Medicine; Cancer research; Oncology; Internal medicine; Cancer; Immunology","score_opus":0.017469934128705258,"score_gpt":0.26829446881301183,"score_spread":0.2508245346843066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236441826","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014629739,0.100803666,0.0005639385,0.008393081,0.004795177,0.004749171,0.0029498541,0.0005484939,0.8757336],"genre_scores_gemma":[0.013115467,0.002560756,0.0007999498,0.0058224616,0.0029377765,0.00039963983,0.00053783634,0.0004968614,0.97332925],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961428,0.00003151864,0.0011416633,0.0011784922,0.00064516265,0.0008603625],"domain_scores_gemma":[0.9973542,0.00017549447,0.0005644803,0.0011090912,0.00051146245,0.0002852679],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037006085,0.0009969741,0.0015757603,0.00035143117,0.0003869207,0.00012456247,0.000316371,0.00094357977,0.003949707],"category_scores_gemma":[0.000029646344,0.0009510678,0.0013709485,0.000048815866,0.00031821322,0.00008479786,0.00013760717,0.0010155628,0.0000559211],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012111615,0.0001752451,0.00007341747,0.003111717,0.007887931,0.00079472404,0.001494048,0.000009634084,0.07859273,0.009122616,0.036850672,0.8497757],"study_design_scores_gemma":[0.00635869,0.00042223776,0.00048669614,0.003910585,0.0011572837,0.00060611486,0.00011742557,0.00004601315,0.013290773,0.002366586,0.96979487,0.0014427017],"about_ca_topic_score_codex":0.0005029792,"about_ca_topic_score_gemma":0.00034552597,"teacher_disagreement_score":0.93294424,"about_ca_system_score_codex":0.0006542347,"about_ca_system_score_gemma":0.0010588529,"threshold_uncertainty_score":0.999294},"labels":[],"label_agreement":null},{"id":"W4236850195","doi":"10.1017/cjn.2019.120","title":"P.020 Avelumab in newly diagnosed glioblastoma multiforme-the SEJ study","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Avelumab; Temozolomide; Medicine; Radiation therapy; Internal medicine; Adverse effect; Interim analysis; Oncology; Incidence (geometry); Clinical trial; Immunotherapy; Nivolumab; Cancer","score_opus":0.024254249053722126,"score_gpt":0.27824070227114034,"score_spread":0.2539864532174182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236850195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896377,0.00096077565,0.000002670549,0.006349384,0.0010434318,0.0005771344,0.000004573756,0.0000136470235,0.0014106876],"genre_scores_gemma":[0.99390125,0.00022868923,0.00023157959,0.005349865,0.00020633085,0.0000051776847,1.2468966e-7,0.000012954985,0.00006399551],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952041,0.00088638824,0.0010731677,0.00053532055,0.0009803181,0.0013207295],"domain_scores_gemma":[0.9969213,0.0006885047,0.00065617077,0.00023433275,0.0003081082,0.0011915946],"candidate_categories":["sts"],"consensus_categories":["sts"],"category_scores_codex":[0.0055041094,0.0003373746,0.00062844576,0.0010840194,0.0013713504,0.000517419,0.0017539685,0.00016493992,0.0006867742],"category_scores_gemma":[0.0012437254,0.00018733111,0.00030219482,0.0021533666,0.0038790605,0.0006805909,0.00006242809,0.001512803,0.000014268244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007684623,0.00010610351,0.9837394,0.0000058438973,0.00002428343,0.007145149,0.00106374,0.0008371468,0.00009927668,0.000042960106,0.0004070816,0.0057605677],"study_design_scores_gemma":[0.0024019054,0.13634738,0.833174,0.00007003113,0.000041592863,0.020058181,0.0020382083,0.00096167886,0.00006553126,0.000747208,0.0038216293,0.000272688],"about_ca_topic_score_codex":0.005250989,"about_ca_topic_score_gemma":0.24870498,"teacher_disagreement_score":0.243454,"about_ca_system_score_codex":0.00039097253,"about_ca_system_score_gemma":0.0039433604,"threshold_uncertainty_score":0.9999287},"labels":[],"label_agreement":null},{"id":"W4237259863","doi":"10.5489/cuaj.124","title":"Early immune outcome of retroperitoneal laparoscopic radical nephrectomy for localized renal cell carcinoma: a prospective, randomized study","year":2012,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Nephrectomy; Laparoscopy; Urology; CD8; Gastroenterology; Renal cell carcinoma; Cytokine; Group B; Kidney; Internal medicine; Surgery; Immune system; Immunology","score_opus":0.01470085917495577,"score_gpt":0.2581111045046096,"score_spread":0.24341024532965383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237259863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937154,0.0012684694,0.00014230279,0.0020958595,0.0005587472,0.0016720829,0.000030613402,0.000017930388,0.0004986142],"genre_scores_gemma":[0.99747723,0.000018495246,0.0006082162,0.000643858,0.0005446824,0.00009936137,0.00001086954,0.000020572117,0.0005766947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728394,0.0004921734,0.0009369661,0.00018911719,0.0004354051,0.0006624061],"domain_scores_gemma":[0.9980911,0.00033105127,0.00054803485,0.00014556451,0.00028028255,0.0006039622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027802517,0.00019949442,0.0010513825,0.00020208729,0.00023082372,0.00004559525,0.00014168912,0.0002643664,0.0004001495],"category_scores_gemma":[0.0008505044,0.00014284742,0.00051734183,0.00025722283,0.00012836019,0.000115753,0.000013917584,0.0005464048,0.000006808404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043865133,0.00037668706,0.9525901,0.0000130756935,0.00032571657,0.00001310196,0.00052056566,8.157544e-7,0.0011905293,0.000033936474,0.00086680433,0.00020353033],"study_design_scores_gemma":[0.19691366,0.0015384788,0.79053396,0.000010034097,0.00038122406,0.000048985927,0.00014489007,0.000027611348,0.00062332937,0.000054464126,0.009565355,0.00015803418],"about_ca_topic_score_codex":0.0032468764,"about_ca_topic_score_gemma":0.00017664277,"teacher_disagreement_score":0.16205616,"about_ca_system_score_codex":0.0011705024,"about_ca_system_score_gemma":0.0004174001,"threshold_uncertainty_score":0.5825149},"labels":[],"label_agreement":null},{"id":"W4238575387","doi":"10.1093/annonc/mdy425.042","title":"KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Santé Montérégie","funders":"","keywords":"Medicine; Placebo; Carboplatin; Nausea; Internal medicine; Lung cancer; Pembrolizumab; Oncology; Cisplatin; Chemotherapy; Cancer; Pathology","score_opus":0.07705669747757675,"score_gpt":0.3994233666933724,"score_spread":0.32236666921579565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238575387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926052,0.0008726927,0.00013854828,0.000951817,0.00035301567,0.0033602396,0.00027409257,0.000045667803,0.0013987328],"genre_scores_gemma":[0.99673164,0.0001855375,0.0015419606,0.0004801005,0.0001417739,0.00014813065,0.000041178693,0.00006717937,0.00066251884],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99644506,0.00035993886,0.0014196931,0.0006754766,0.00047526692,0.00062456704],"domain_scores_gemma":[0.99421567,0.0031081582,0.0012282156,0.00060303515,0.00064037676,0.00020453744],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011768247,0.0005284068,0.0023321146,0.0005133405,0.00015779054,0.00001724891,0.00024327035,0.00031046028,0.00018363791],"category_scores_gemma":[0.0008723158,0.00038596193,0.00028186338,0.00042313104,0.0008507568,0.00015464569,0.00015994611,0.00025793296,0.0000022034308],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48344314,0.008026351,0.19865635,0.005546135,0.013563362,0.00019991833,0.037026722,0.00007111298,0.087522194,0.00033145968,0.010472696,0.15514055],"study_design_scores_gemma":[0.29957408,0.15590298,0.437843,0.0009657993,0.003683088,0.00035288782,0.014176855,0.0030466702,0.07140449,0.000374074,0.011130695,0.0015454135],"about_ca_topic_score_codex":0.0021393618,"about_ca_topic_score_gemma":0.0032731362,"teacher_disagreement_score":0.23918663,"about_ca_system_score_codex":0.000120025274,"about_ca_system_score_gemma":0.0004999797,"threshold_uncertainty_score":0.9998592},"labels":[],"label_agreement":null},{"id":"W4238658989","doi":"10.3410/f.725408916.793526424","title":"Faculty Opinions recommendation of IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.","year":2016,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Breast cancer metastasis; Breast cancer; Metastasis; Medicine; Cancer; Immunology; Cancer research; Oncology; Internal medicine; Cancer metastasis","score_opus":0.03021643119664933,"score_gpt":0.3530930049500216,"score_spread":0.32287657375337225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238658989","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005447939,0.001878396,0.00000767296,0.34682444,0.0006787207,0.0018141684,0.64875203,0.000025238563,0.000013876746],"genre_scores_gemma":[0.0000114388,0.0023857022,0.00050934416,0.01147224,0.00049449067,0.00034887998,0.98355377,0.00003940043,0.0011847632],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955149,0.00029468606,0.0016222642,0.0009359022,0.0011980393,0.0004342035],"domain_scores_gemma":[0.992103,0.00008803189,0.0013370245,0.0015458221,0.004468764,0.00045738491],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013921254,0.0006152966,0.0013373266,0.00043817319,0.00021796764,0.00009801973,0.0007897226,0.00053980615,0.000883498],"category_scores_gemma":[0.0012096959,0.00035170605,0.0005925317,0.0017377189,0.00044348583,0.00026846366,0.0003752089,0.00072698726,0.000018032211],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017551566,0.0002770877,0.0000072275748,0.00816473,0.00047687802,5.487467e-7,0.00012600237,2.9315515e-8,0.00022193645,0.000016083633,0.9682831,0.022250835],"study_design_scores_gemma":[0.0014509937,0.0002358328,0.0032247878,0.027385069,0.00052446616,0.00013195412,0.00001740911,9.575809e-7,0.0002919878,0.000004764052,0.9663727,0.00035904595],"about_ca_topic_score_codex":0.00020835787,"about_ca_topic_score_gemma":0.0000143264,"teacher_disagreement_score":0.33535218,"about_ca_system_score_codex":0.00021942695,"about_ca_system_score_gemma":0.00079755334,"threshold_uncertainty_score":0.9998935},"labels":[],"label_agreement":null},{"id":"W4238776496","doi":"10.1007/978-3-319-48066-4_12","title":"Nivolumab","year":2016,"lang":"fr","type":"book-chapter","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Receptor; Melanoma; Cancer research; Pharmacology; Monoclonal antibody; Antibody; Adverse effect; Oncology; Immunotherapy; Chemistry; Internal medicine; Cancer; Immunology","score_opus":0.02430039613199481,"score_gpt":0.2620649599978691,"score_spread":0.2377645638658743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238776496","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007897231,0.017617324,0.000424779,0.0046871346,0.0037866794,0.0003886371,0.000063986176,0.00008330518,0.97286916],"genre_scores_gemma":[0.009033858,0.0103404755,0.00023464051,0.002158903,0.002688849,0.000006892274,0.000015574895,0.00009086581,0.97542995],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99835753,0.000014477344,0.00045000287,0.00042331137,0.0003164266,0.00043826483],"domain_scores_gemma":[0.9988886,0.00011048486,0.00014505522,0.0005764311,0.00009126965,0.00018812684],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00019491884,0.00041579967,0.0005215316,0.000120374396,0.000083749226,0.000016354421,0.00015472584,0.0005584683,0.19269784],"category_scores_gemma":[0.000014043365,0.0002835339,0.00046016075,0.000022135697,0.0005581079,0.00005598445,0.000049273112,0.00024977096,0.011064809],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009936643,0.000025729983,0.00009731572,0.00011665747,0.0006916131,0.00009548401,0.000020956877,8.956476e-9,0.0035696027,0.3986437,0.011111018,0.58463424],"study_design_scores_gemma":[0.0032053927,0.0005350982,0.00041579467,0.0024142824,0.00024133566,0.00013807179,0.000014410324,0.000003039536,0.0008838284,0.0020745802,0.9896526,0.0004215932],"about_ca_topic_score_codex":0.00013477112,"about_ca_topic_score_gemma":0.000065094326,"teacher_disagreement_score":0.97854155,"about_ca_system_score_codex":0.0004366133,"about_ca_system_score_gemma":0.00026072856,"threshold_uncertainty_score":0.9999617},"labels":[],"label_agreement":null},{"id":"W4239003806","doi":"10.1515/iupac.84.0479","title":"Cytotoxic T Lymphocyte Antigen 4 (CTLA-4)","year":2016,"lang":"en","type":"dataset","venue":"IUPAC Standards Online","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"","keywords":"Glossary; Immunotoxicology; Immunology; Medicine; Immune system; Philosophy; Linguistics","score_opus":0.015970725637785815,"score_gpt":0.395187002438716,"score_spread":0.3792162768009302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239003806","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009809907,0.0068441876,0.00003313594,0.0015282185,0.0012244747,0.0006861904,0.9884582,0.00012209897,0.00012248242],"genre_scores_gemma":[0.00006257906,0.021407157,0.00004654819,0.0017956685,0.001811655,0.000025404426,0.9731325,0.00008285978,0.0016356203],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99654734,0.00007275697,0.0006961573,0.00069831713,0.0013523304,0.0006331157],"domain_scores_gemma":[0.9975594,0.000069163085,0.00034041193,0.0013409825,0.00040852785,0.00028147842],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00049501745,0.00062448275,0.0010756279,0.00034830783,0.00013283879,0.00005296155,0.00037550862,0.0006295303,0.01014847],"category_scores_gemma":[0.00019737527,0.00043756134,0.00049823767,0.0003059292,0.00029578857,0.00007868855,0.00012058454,0.00039811037,0.000011961166],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053510293,0.000269375,0.000029664508,0.00028462562,0.0006585846,0.0003268741,0.000008878673,4.9814314e-8,0.0016374215,8.7788334e-7,0.9748204,0.016612262],"study_design_scores_gemma":[0.0070023728,0.0007775473,0.00022630765,0.0015668194,0.00027212175,0.00023800878,0.000010784528,0.0000012496382,0.0011613903,0.000020280335,0.98818123,0.0005418599],"about_ca_topic_score_codex":0.00039970726,"about_ca_topic_score_gemma":0.0003071107,"teacher_disagreement_score":0.016070403,"about_ca_system_score_codex":0.0015808508,"about_ca_system_score_gemma":0.0029400922,"threshold_uncertainty_score":0.9998076},"labels":[],"label_agreement":null},{"id":"W4239347184","doi":"10.33590/emj/20-00039","title":"Metastasis: A Bane of Breast Cancer Therapy","year":2020,"lang":"en","type":"article","venue":"European Medical Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Research Institute in Oncology and Hematology; University of Manitoba","funders":"CancerCare Manitoba Foundation","keywords":"Breast cancer; Medicine; Metastasis; Cancer; Metastatic breast cancer; CA15-3; Oncology; Internal medicine; Immunotherapy","score_opus":0.0351480343098273,"score_gpt":0.29761696293084056,"score_spread":0.26246892862101323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239347184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76491463,0.02629687,0.0012154096,0.1894461,0.0009106758,0.00030679232,0.000063291394,0.000098969096,0.016747275],"genre_scores_gemma":[0.96409726,0.011814169,0.0002350221,0.021816734,0.001866839,0.0000010604995,0.000002641041,0.00003736417,0.00012892585],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998253,0.000226623,0.00043513812,0.00013330145,0.00076349423,0.0001884385],"domain_scores_gemma":[0.99901956,0.00002700155,0.00015746857,0.00010763785,0.00010189152,0.00058643584],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007551079,0.00011626989,0.00028604968,0.00004629995,0.000048772912,0.000015648535,0.00020593642,0.000033560682,0.011538134],"category_scores_gemma":[0.0000958975,0.00007494568,0.0002131279,0.00020875342,0.00014551991,0.000047217884,0.000029140294,0.00046936408,0.000035349603],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005287479,0.00020268076,0.0038681903,0.00005237383,0.0008231788,0.0013149416,0.00092783634,9.314362e-7,0.0342226,0.000009977522,0.04817611,0.9051137],"study_design_scores_gemma":[0.023311015,0.0021434634,0.36322227,0.0014168973,0.00029576986,0.011409868,0.0006008186,0.0001629074,0.007455931,0.000014788129,0.58955586,0.0004103998],"about_ca_topic_score_codex":0.000012603521,"about_ca_topic_score_gemma":7.518875e-7,"teacher_disagreement_score":0.9047033,"about_ca_system_score_codex":0.000025674948,"about_ca_system_score_gemma":0.0003036515,"threshold_uncertainty_score":0.98936546},"labels":[],"label_agreement":null},{"id":"W4239600564","doi":"10.14740/jmc3131w","title":"Pembrolizumab-Induced Hepatitis and Pancreatitis in a Patient With Stage IV Non-Small Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Nausea; Pembrolizumab; Acute pancreatitis; Vomiting; Internal medicine; Toxic hepatitis; Pancreatitis; Gastroenterology; Cancer; Hepatitis; Immunotherapy","score_opus":0.014850809918831994,"score_gpt":0.28535214945055326,"score_spread":0.2705013395317213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239600564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944657,0.00316644,0.000047566817,0.0014699472,0.00022871754,0.00018329325,0.000010848808,0.000005135957,0.00042236142],"genre_scores_gemma":[0.9932663,0.004710791,0.00019068268,0.0012698977,0.00042078007,0.000009097496,0.000001199702,0.000016024174,0.000115220675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984673,0.000049721635,0.000428887,0.0001303344,0.0007121486,0.00021157623],"domain_scores_gemma":[0.99908406,0.00012136326,0.0002389459,0.000104882136,0.00016063539,0.00029012832],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030496047,0.00013021452,0.00037407994,0.00014234018,0.000042853793,0.000018614328,0.000077410165,0.00011043519,0.0009898049],"category_scores_gemma":[0.00011404377,0.00008363834,0.00006238076,0.00016806908,0.00014893139,0.00007052287,0.000024304716,0.00030706363,9.932312e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012747101,0.00059746206,0.8191175,0.00059198105,0.00037267635,0.03400753,0.0037695824,8.9452965e-7,0.006755888,0.0000054897755,0.007938381,0.11409555],"study_design_scores_gemma":[0.043105204,0.027556464,0.8318636,0.009683021,0.00060478505,0.031006934,0.0022065812,0.0011863792,0.029499948,0.000008323868,0.022622146,0.0006566408],"about_ca_topic_score_codex":0.004765904,"about_ca_topic_score_gemma":0.0040860856,"teacher_disagreement_score":0.113438904,"about_ca_system_score_codex":0.00014942656,"about_ca_system_score_gemma":0.0006950184,"threshold_uncertainty_score":0.9999234},"labels":[],"label_agreement":null},{"id":"W4240295576","doi":"10.1158/1538-7445.sabcs16-p4-03-08","title":"Abstract P4-03-08: Mechanisms of CD8+ T cell immunosuppression in triple negative breast cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; University Health Network","funders":"","keywords":"Triple-negative breast cancer; Stromal cell; Cytotoxic T cell; CD8; Cancer research; Estrogen receptor; Stroma; Breast cancer; T cell; Immune system; Tumor microenvironment; Medicine; Cancer; Biology; Pathology; Immunology; Internal medicine; Immunohistochemistry","score_opus":0.06673681666675702,"score_gpt":0.4107836348163933,"score_spread":0.3440468181496363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240295576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98593396,0.0031814894,0.000008667814,0.0028444934,0.00051077455,0.0009543521,0.0002457446,0.00001797064,0.0063025462],"genre_scores_gemma":[0.9928611,0.0039178375,0.000064278276,0.00008266825,0.00017588011,0.000277143,0.000007987347,0.00003790637,0.0025752313],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977313,0.00009800571,0.00038675175,0.00040595906,0.0007929773,0.000584966],"domain_scores_gemma":[0.99829775,0.000108501285,0.00021880843,0.00084954774,0.00038580684,0.00013956707],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010518583,0.00017923169,0.00041303967,0.00028506655,0.00031711627,0.00006432376,0.00051943364,0.00017369779,0.004527134],"category_scores_gemma":[0.000079842815,0.00014418659,0.00013624252,0.0002854113,0.0004438871,0.0002220343,0.00016800479,0.0006639382,0.000029083021],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007253273,0.00022672296,0.0049177976,0.0003257588,0.00008299056,0.00004107177,0.00058182667,0.0000045019765,0.95210844,0.000034973902,0.0034762977,0.030946353],"study_design_scores_gemma":[0.005822875,0.00017555509,0.32062456,0.0012024238,0.000015644338,0.0000063591187,0.0003971612,0.000026652195,0.6701329,0.00043463212,0.001013598,0.00014765667],"about_ca_topic_score_codex":0.03949201,"about_ca_topic_score_gemma":0.0020513753,"teacher_disagreement_score":0.31570676,"about_ca_system_score_codex":0.00056651776,"about_ca_system_score_gemma":0.00091468316,"threshold_uncertainty_score":0.9963829},"labels":[],"label_agreement":null},{"id":"W4241004585","doi":"10.1016/j.annder.2019.09.092","title":"Étude de phase II de l’administration de pembrolizumab (MK-3475) en monothérapie et en première ligne chez des patients présentant un carcinome épidermoïde cutané non opérable","year":2019,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Gynecology","score_opus":0.02006660599185038,"score_gpt":0.32212000092951365,"score_spread":0.30205339493766326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241004585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665168,0.015150848,0.0026169436,0.010148314,0.00089683605,0.0017329438,0.00028065682,0.0003616057,0.002295064],"genre_scores_gemma":[0.96479493,0.020834992,0.0059128855,0.006407567,0.00030090145,0.00026546835,0.00040139697,0.00015771465,0.00092416495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919305,0.0020313142,0.0013184801,0.0010980772,0.0005510905,0.0030705319],"domain_scores_gemma":[0.9958576,0.001496075,0.00062710466,0.0010479495,0.00026400655,0.00070726214],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0027676148,0.0010169742,0.0012889439,0.00038482493,0.00041170404,0.00020625933,0.0010023456,0.001521894,0.0004322004],"category_scores_gemma":[0.0012600351,0.0010295642,0.00059784093,0.00058707537,0.0006579426,0.0006939078,0.0003769111,0.0013772122,0.00012570653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010348781,0.005162647,0.7956564,0.0021009108,0.0016307608,0.0035225681,0.021030745,0.00063819415,0.12231614,0.0005707041,0.0100039765,0.02701821],"study_design_scores_gemma":[0.026245384,0.009018341,0.5611406,0.00212533,0.0012648845,0.00863563,0.0072450726,0.009811053,0.35598058,0.0031109583,0.01328467,0.0021375164],"about_ca_topic_score_codex":0.0010541592,"about_ca_topic_score_gemma":0.0003346666,"teacher_disagreement_score":0.23451579,"about_ca_system_score_codex":0.003776856,"about_ca_system_score_gemma":0.005633203,"threshold_uncertainty_score":0.99977434},"labels":[],"label_agreement":null},{"id":"W4241519036","doi":"10.1016/j.annonc.2020.01.049","title":"1O Inducible T cell co-stimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and combination with pembrolizumab: Preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Head and neck squamous-cell carcinoma; Internal medicine; Population; Tolerability; Agonist; Oncology; Head and neck cancer; Gastroenterology; Cancer; Receptor; Adverse effect; Immunotherapy","score_opus":0.05711588904831182,"score_gpt":0.3158570011451614,"score_spread":0.2587411120968496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241519036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872644,0.0037240994,0.0000027396884,0.0055821054,0.00010164331,0.0007795957,0.00010188533,0.000031915435,0.0024116149],"genre_scores_gemma":[0.99617136,0.0008885411,0.00024133433,0.0021941562,0.00008621309,0.000024737585,0.0002602179,0.000035972775,0.00009745702],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99799216,0.00018692091,0.00063408696,0.00060604163,0.0002598189,0.0003209703],"domain_scores_gemma":[0.99866694,0.00029351594,0.00036659217,0.00029217178,0.0001487209,0.00023206323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003443151,0.00026277572,0.0007244339,0.0001747865,0.00007582673,0.0000142314475,0.00009698923,0.00036422597,0.000044159813],"category_scores_gemma":[0.000070336275,0.00023869099,0.000058371657,0.00025733717,0.0002705048,0.000141552,0.00006510721,0.0003662809,0.0000047561393],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3077824,0.0043803523,0.18010584,0.0008880041,0.00015758812,0.0007064392,0.017037444,0.00005838141,0.40926248,0.000011541667,0.03550191,0.044107627],"study_design_scores_gemma":[0.055144344,0.050241273,0.6692207,0.00022800795,0.000121357865,0.00005524743,0.0010372732,0.00051004527,0.21182762,0.00003400544,0.011147031,0.0004331127],"about_ca_topic_score_codex":0.00207564,"about_ca_topic_score_gemma":0.00014706378,"teacher_disagreement_score":0.48911485,"about_ca_system_score_codex":0.000080668964,"about_ca_system_score_gemma":0.00044483025,"threshold_uncertainty_score":0.9733536},"labels":[],"label_agreement":null},{"id":"W4243956777","doi":"10.1136/jitc-2020-0485-9corr","title":"Correction: <i>Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy</i>","year":2020,"lang":"en","type":"erratum","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Tumor microenvironment; Chemoradiotherapy; Medicine; Cancer research; Oncology; Tumor cells; Overall survival","score_opus":0.014953348568983692,"score_gpt":0.2911113908260646,"score_spread":0.2761580422570809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243956777","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06397599,0.7509421,0.0021288518,0.006806362,0.16764764,0.004294294,0.00061333633,0.00011860572,0.0034728358],"genre_scores_gemma":[0.03481848,0.6687502,0.0033861392,0.0050314907,0.010009389,0.00050298136,0.0003766202,0.0005860214,0.27653867],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967107,0.000051143146,0.0016335287,0.000456092,0.00071924314,0.00042927422],"domain_scores_gemma":[0.99616104,0.00009108532,0.0027587248,0.0004887507,0.00039759974,0.000102803984],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003745694,0.00059545285,0.0018483712,0.00030010272,0.0001859373,0.00004035607,0.0004202598,0.00051177654,0.001507286],"category_scores_gemma":[0.000028593107,0.00049972517,0.0013898251,0.00034123397,0.00033043046,0.00014755526,0.000024236935,0.0010585748,0.0000021295207],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016821109,0.00029296483,0.00023435347,0.0006681845,0.0032145712,0.0000058620717,0.0004541357,0.00006715869,0.44422024,0.0000031928487,0.4054186,0.12859963],"study_design_scores_gemma":[0.006962391,0.003245523,0.004522739,0.0023596208,0.00038979884,0.00018591824,0.000120774435,0.00024559782,0.10637091,0.000096465796,0.8750292,0.00047104625],"about_ca_topic_score_codex":0.0002305046,"about_ca_topic_score_gemma":0.000027357,"teacher_disagreement_score":0.46961063,"about_ca_system_score_codex":0.0007269883,"about_ca_system_score_gemma":0.00079290464,"threshold_uncertainty_score":0.9997454},"labels":[],"label_agreement":null},{"id":"W4244794707","doi":"10.1007/978-3-319-48066-4_11","title":"Ipilimumab","year":2016,"lang":"en","type":"book-chapter","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Ipilimumab; Medicine; CTLA-4; Melanoma; Monoclonal antibody; Adverse effect; Blockade; Oncology; Internal medicine; Clinical trial; Drug; Immune system; Metastatic melanoma; Receptor; Immunotherapy; Antibody; Cancer research; Pharmacology; Immunology; Cancer; T cell","score_opus":0.02122487094835646,"score_gpt":0.25937179865738597,"score_spread":0.2381469277090295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244794707","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008766611,0.0016365001,0.000036902737,0.0016077855,0.0002754652,0.000186471,0.0000136565295,0.00008100254,0.9961535],"genre_scores_gemma":[0.00052335847,0.001301494,0.000073258794,0.0017566829,0.00041877438,0.0000028573593,0.000011462971,0.000042367585,0.99586976],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993915,0.0000013487029,0.00016003507,0.00018249846,0.0001567679,0.000107839536],"domain_scores_gemma":[0.9995339,0.000018010429,0.000051119463,0.00030366462,0.000038219347,0.000055091947],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00004508934,0.00015956443,0.00024209548,0.00006836123,0.000017892999,0.00000483127,0.000046865793,0.0002177105,0.036304716],"category_scores_gemma":[0.0000024129913,0.00009385184,0.00020680772,0.000005566374,0.000073795716,0.000013894868,0.00001560542,0.00010237604,0.0012097154],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027435033,0.000021198266,0.000015756323,0.00010913702,0.00084734097,0.00010055344,0.000022647231,1.2773147e-9,0.0031606832,0.16623352,0.19099103,0.63575464],"study_design_scores_gemma":[0.0014401384,0.0001658322,0.000042192598,0.0003686759,0.00006765031,0.000054803397,0.0000011588456,1.05635394e-7,0.00028447635,0.0027210237,0.99471164,0.00014231216],"about_ca_topic_score_codex":0.000004145847,"about_ca_topic_score_gemma":0.0000054914703,"teacher_disagreement_score":0.8037206,"about_ca_system_score_codex":0.00009417016,"about_ca_system_score_gemma":0.00010114828,"threshold_uncertainty_score":0.999568},"labels":[],"label_agreement":null},{"id":"W4244827489","doi":"10.1158/1538-7445.am2019-463","title":"Abstract 463: Integrated digital pathology and transcriptome analysis identifies molecular mediators of T cell exclusion in ovarian cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quebec - Clinical Research Organization in Cancer","funders":"","keywords":"Ovarian cancer; Transcriptome; CD8; Cytotoxic T cell; Immunotherapy; Biology; Cancer research; Phenotype; Cancer immunotherapy; Cancer; Immune system; Pathology; Medicine; Immunology; Gene expression; In vitro; Gene; Genetics","score_opus":0.024170201862757118,"score_gpt":0.35169495756540664,"score_spread":0.3275247557026495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244827489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99185485,0.006408417,0.000016599417,0.00041309505,0.00014311523,0.00043337612,0.00010310776,0.000010085243,0.0006173279],"genre_scores_gemma":[0.9959658,0.0032341406,0.000011917802,0.00006112735,0.000025220765,0.000064451895,0.000039990617,0.000019767504,0.0005775751],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998365,0.00007677304,0.00034007375,0.00036564286,0.0004991844,0.0003533514],"domain_scores_gemma":[0.9992657,0.00007936924,0.000064584274,0.00027833148,0.00021115132,0.000100897545],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00061472686,0.00013100654,0.00042366458,0.00085706415,0.000033261054,0.000034473767,0.00013750937,0.00014221354,0.0021002044],"category_scores_gemma":[0.000028266173,0.00010737704,0.00013395792,0.0016290696,0.00026303946,0.00012491873,0.00004656021,0.0003774422,0.000008195519],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014782666,0.00008713565,0.079102375,0.00025061998,0.00026981957,0.00010153656,0.0010815978,0.00001623814,0.9123476,0.000005817737,0.00009989762,0.005159052],"study_design_scores_gemma":[0.0052040773,0.00031497914,0.45224768,0.000472727,0.0001833585,0.000007720864,0.0018463503,0.000099744284,0.53765064,0.0000815609,0.0016449003,0.00024626206],"about_ca_topic_score_codex":0.00486425,"about_ca_topic_score_gemma":0.0010771194,"teacher_disagreement_score":0.374697,"about_ca_system_score_codex":0.0002311632,"about_ca_system_score_gemma":0.00036329913,"threshold_uncertainty_score":0.998812},"labels":[],"label_agreement":null},{"id":"W4246608042","doi":"10.14740/cr838","title":"A Case of Acute Heart Failure due to Immune Checkpoint Blocker Nivolumab","year":2019,"lang":"en","type":"article","venue":"Cardiology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Nivolumab; Fulminant; Cardiology; Internal medicine; Heart failure; Cardiomyopathy; Immune checkpoint; Myocarditis; Disease; Blockade; Immunotherapy; Cancer","score_opus":0.035610865736528295,"score_gpt":0.36419316433871946,"score_spread":0.3285822986021912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246608042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99111515,0.0009296259,0.000021947892,0.004754937,0.00024510527,0.0008600256,0.000028356844,0.000024112216,0.0020207153],"genre_scores_gemma":[0.9963027,0.000045046927,0.0004169364,0.00015023231,0.00017167929,0.00006320853,0.0000145857975,0.000024591567,0.002810986],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982386,0.00027790296,0.00031426645,0.00036370728,0.00027920812,0.00052631873],"domain_scores_gemma":[0.99844706,0.00017519979,0.000031796902,0.0007932311,0.00040418864,0.00014853623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016119037,0.00012525014,0.0007635716,0.00030349058,0.00007464692,0.00000844075,0.00014798509,0.00021196385,0.00049249025],"category_scores_gemma":[0.00011126242,0.00010278454,0.00031002075,0.0005409534,0.00030058177,0.000029918572,0.0001635923,0.0005034884,0.00038611013],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004185191,0.000049187733,0.015150622,0.00011638572,0.0012966255,0.004464863,0.0004114639,0.0000024875494,0.9511237,0.000029005098,0.021185616,0.001984837],"study_design_scores_gemma":[0.016440194,0.010438576,0.16117683,0.0004963426,0.00038509167,0.1905441,0.004037983,0.00009783435,0.3185292,0.00012921334,0.29696897,0.00075568934],"about_ca_topic_score_codex":0.0003578702,"about_ca_topic_score_gemma":0.000015395583,"teacher_disagreement_score":0.6325945,"about_ca_system_score_codex":0.00013279903,"about_ca_system_score_gemma":0.00026656326,"threshold_uncertainty_score":0.53924227},"labels":[],"label_agreement":null},{"id":"W4247213363","doi":"10.36879/gsl.jcst.2019.000112","title":"Checking in with immune checkpoint inhibitors: Results of a needs assessmentsurvey of Canadian rheumatologists","year":2019,"lang":"en","type":"article","venue":"Journal of Cancer Science and Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rheumatology; Medicine; Internal medicine; Adverse effect; Descriptive statistics; Family medicine; Immune system; Oncology; Immunology","score_opus":0.028661516775151965,"score_gpt":0.3151605251380268,"score_spread":0.28649900836287484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247213363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99324703,0.0045299046,0.0000052923415,0.00095418334,0.00020233598,0.00013694397,0.000005523221,0.0000012956218,0.00091748574],"genre_scores_gemma":[0.99603754,0.0035365652,0.00020541753,0.00016245458,0.000015694197,9.489706e-7,3.023732e-7,0.000005968365,0.00003510305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985288,0.000025112235,0.00063602073,0.00009692642,0.0005119057,0.00020127662],"domain_scores_gemma":[0.99858236,0.000037915903,0.0006125713,0.00015477923,0.00052577176,0.00008661196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018337033,0.000089862275,0.0003704829,0.0009953253,0.000027660948,0.00001692309,0.00015870217,0.000049927527,0.000009639711],"category_scores_gemma":[0.000024815423,0.00005950486,0.00005254828,0.0017485468,0.00039551413,0.00019094594,0.00001469646,0.00016740628,1.01846844e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004369793,0.000113646136,0.61482006,0.0001325124,0.00021428177,0.000012551118,0.0034304436,0.000035315945,0.33866507,0.000062717416,0.000011306313,0.03813233],"study_design_scores_gemma":[0.007263689,0.001736697,0.7940231,0.0018889188,0.000057700214,0.00012654728,0.0019702911,0.00013624986,0.18790591,0.000024943054,0.0047339983,0.00013194568],"about_ca_topic_score_codex":0.0367416,"about_ca_topic_score_gemma":0.013723144,"teacher_disagreement_score":0.17920306,"about_ca_system_score_codex":0.00021867143,"about_ca_system_score_gemma":0.002665653,"threshold_uncertainty_score":0.9696728},"labels":[],"label_agreement":null},{"id":"W4248873911","doi":"10.26226/morressier.59a3e8b6d462b8028d89554d","title":"Real-World Evidence of Patients Treated With Alemtuzumab in Canada","year":2017,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Real world evidence; Alemtuzumab; Medicine; Business; Internal medicine","score_opus":0.03259034343149515,"score_gpt":0.29807208592993995,"score_spread":0.2654817424984448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248873911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855061,0.00034442992,0.0000013375526,0.00032273948,0.00013603737,0.00064651546,0.00003444611,0.000011986801,0.012996406],"genre_scores_gemma":[0.99455684,0.00092544215,0.000109847504,0.000106535146,0.000020793388,0.000030497995,0.00006149024,0.000017753238,0.0041707926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877954,0.000026849097,0.00035608234,0.0003033736,0.00035681395,0.00017732357],"domain_scores_gemma":[0.99864197,0.00004889005,0.00032542035,0.00077285565,0.00014887289,0.00006200368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000102153776,0.00019451615,0.0005084484,0.0001283536,0.000021457265,0.000009720839,0.00020111489,0.000075382726,0.00031987423],"category_scores_gemma":[0.000027225224,0.0001339516,0.000058899994,0.0000930731,0.00006830488,0.000035397017,0.00008999575,0.00023996025,7.299153e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052712155,0.00006117143,0.9847793,0.00044255113,0.0001672461,0.0000433495,0.00004878469,0.0000064212886,0.000087286215,0.0000020883435,0.001997297,0.007093282],"study_design_scores_gemma":[0.0021450508,0.00023043052,0.99031574,0.0043213624,0.000073216856,0.0000011364782,0.00002245541,0.000034262008,0.0021101157,0.000003979825,0.00058028783,0.00016198141],"about_ca_topic_score_codex":0.9975905,"about_ca_topic_score_gemma":0.9978188,"teacher_disagreement_score":0.009050747,"about_ca_system_score_codex":0.0015970721,"about_ca_system_score_gemma":0.0049330746,"threshold_uncertainty_score":0.8751062},"labels":[],"label_agreement":null},{"id":"W4249335081","doi":"10.1200/jco.2017.35.15_suppl.tps4132","title":"CheckMate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (nivo) + ipilimumab (ipi) or nivo + chemotherapy (CTX) vs CTX alone in pts with previously untreated advanced (adv) gastric (G) or gastroesophageal junction (GEJ) cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Cancer; Refractory (planetary science); Oncology; Phases of clinical research; Chemotherapy; Gastroenterology; Immunotherapy","score_opus":0.11682681699129105,"score_gpt":0.4915325814690506,"score_spread":0.37470576447775955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249335081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99140304,0.00089745445,0.00013619495,0.0021574632,0.0013956418,0.003808059,0.00001286731,0.000020822094,0.00016845351],"genre_scores_gemma":[0.9862016,0.007730392,0.0030563616,0.0009701336,0.0005462977,0.00013312187,0.0000062736935,0.00007155877,0.0012843014],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9924105,0.0011883877,0.004495398,0.0005923964,0.0006882939,0.00062501436],"domain_scores_gemma":[0.98960316,0.0014610671,0.0069402773,0.0007860469,0.0007893487,0.00042009933],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005369289,0.00048687612,0.0050632423,0.00033177226,0.00019518775,0.00007191013,0.00086079165,0.00039473118,0.0005996993],"category_scores_gemma":[0.0023609365,0.00028228745,0.0004083474,0.00039926823,0.00069814065,0.00060135167,0.00013740861,0.0011407728,0.0000041777353],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7826111,0.02391773,0.013193787,0.000100153935,0.0020951477,0.00149221,0.0006271762,0.000022219914,0.0011811344,4.451557e-7,0.000504763,0.17425415],"study_design_scores_gemma":[0.8459784,0.11822851,0.029774174,0.0011515382,0.0012521637,0.0005302586,0.0006272062,0.00050898467,0.00044821147,0.000005012507,0.0012668776,0.00022867102],"about_ca_topic_score_codex":0.001817597,"about_ca_topic_score_gemma":0.005411487,"teacher_disagreement_score":0.17402548,"about_ca_system_score_codex":0.0007370327,"about_ca_system_score_gemma":0.0032189111,"threshold_uncertainty_score":0.9999629},"labels":[],"label_agreement":null},{"id":"W4249524913","doi":"10.21037/tcr.2017.05.06","title":"Commentary on “The MLL1-H3K4me3 axis-mediated PD-L1 expression and pancreatic cancer immune evasion”","year":2017,"lang":"en","type":"article","venue":"Translational Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Immune system; Pancreatic cancer; Evasion (ethics); Immunology; Cancer research; H3K4me3; Biology; Medicine; Cancer; Gene expression; Gene; Genetics","score_opus":0.11837160995472107,"score_gpt":0.42529369466826655,"score_spread":0.3069220847135455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249524913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7716413,0.012722204,0.000014062509,0.2118066,0.00024952486,0.0011487948,0.0002160111,0.000030999414,0.0021704778],"genre_scores_gemma":[0.98709726,0.0074442606,0.000063251624,0.002964287,0.00046296002,0.00050311175,0.00008759833,0.000033586053,0.0013436967],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976872,0.00018944361,0.00028127717,0.00034860426,0.0010905793,0.00040286407],"domain_scores_gemma":[0.99842805,0.00056000473,0.00008980441,0.00058293634,0.0002002938,0.00013893757],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00087964075,0.00017581624,0.00025586912,0.00013602768,0.0012549069,0.00010551327,0.0002970682,0.00010401643,0.0032148766],"category_scores_gemma":[0.0000754199,0.00011553847,0.000097490156,0.00015457618,0.0006143641,0.00015220864,0.00005153045,0.0005655481,0.000023166684],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036413673,0.0005625716,0.09997326,0.0005593751,0.00096021214,0.00006232732,0.0031098195,0.000039374117,0.57246476,0.00038994863,0.12812322,0.15734145],"study_design_scores_gemma":[0.008374423,0.00052145316,0.79248613,0.0020511118,0.00009185043,0.000010344688,0.00022302713,0.0007724067,0.033065457,0.00061363995,0.16145658,0.0003335784],"about_ca_topic_score_codex":0.006110742,"about_ca_topic_score_gemma":0.00054446055,"teacher_disagreement_score":0.69251287,"about_ca_system_score_codex":0.0001814902,"about_ca_system_score_gemma":0.00031576454,"threshold_uncertainty_score":0.99769634},"labels":[],"label_agreement":null},{"id":"W4249577962","doi":"10.1158/1538-7445.sabcs19-ot2-04-04","title":"Abstract OT2-04-04: Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase 2 trial","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Trastuzumab; Pertuzumab; Internal medicine; Breast cancer; Oncology; Neoadjuvant therapy; Clinical endpoint; Randomized controlled trial; Cancer; Metastatic breast cancer; Gastroenterology; Immunotherapy","score_opus":0.16369235837609136,"score_gpt":0.46420772914625336,"score_spread":0.300515370770162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249577962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9596623,0.014355497,0.000052223324,0.01318906,0.00032248892,0.009608578,0.00011429219,0.0001685347,0.0025270265],"genre_scores_gemma":[0.974449,0.014803054,0.00033942887,0.004684283,0.0013761979,0.0025850807,0.00018540048,0.0002187015,0.0013589044],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994553,0.0009128242,0.00085196225,0.0010467871,0.0015442279,0.0010911742],"domain_scores_gemma":[0.99704224,0.00042670057,0.00025328758,0.0009929254,0.0006321613,0.0006526887],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003108543,0.00050468335,0.0015482958,0.00025536364,0.00044778126,0.00043581118,0.0011871535,0.00025402277,0.008378677],"category_scores_gemma":[0.00014946837,0.0003430605,0.0002375865,0.001171009,0.0008692621,0.00048250007,0.000127156,0.0011973893,0.000057789024],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6939656,0.0013015908,0.000019299925,0.000056604753,0.00091315754,0.00012798168,0.0016201871,0.000003520884,0.20414975,0.000028885224,0.0037978946,0.09401551],"study_design_scores_gemma":[0.8926003,0.012752639,0.00025142022,0.00022668528,0.000052149768,0.000015993379,0.00039157365,0.00020644866,0.03221002,0.000056500296,0.060788557,0.00044770268],"about_ca_topic_score_codex":0.0061118607,"about_ca_topic_score_gemma":0.00021587852,"teacher_disagreement_score":0.1986347,"about_ca_system_score_codex":0.0004162005,"about_ca_system_score_gemma":0.002342827,"threshold_uncertainty_score":0.9999021},"labels":[],"label_agreement":null},{"id":"W4250261805","doi":"10.1515/iupac.84.0373","title":"CD5+ B Lymphocyte","year":2016,"lang":"en","type":"dataset","venue":"IUPAC Standards Online","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"","keywords":"Glossary; Immunotoxicology; Immunology; Medicine; Immune system; Philosophy; Linguistics","score_opus":0.015037865769434394,"score_gpt":0.40340505250108805,"score_spread":0.38836718673165366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250261805","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014372861,0.006501443,0.000029947534,0.0016891678,0.0012462478,0.00043364,0.98968965,0.00009103678,0.00017516396],"genre_scores_gemma":[0.0000104264645,0.011373833,0.000035851626,0.0020791509,0.0017334963,0.000018757713,0.9819278,0.000057068257,0.0027635826],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972895,0.000049068327,0.00053602766,0.0005252123,0.0011319406,0.00046825036],"domain_scores_gemma":[0.9980183,0.000061703366,0.0002484595,0.0010849453,0.00036874754,0.00021780549],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044679214,0.00047258558,0.00083367707,0.00025274904,0.00008749948,0.000034763347,0.00026676068,0.0004947986,0.010698243],"category_scores_gemma":[0.00018521493,0.00031863645,0.0003948097,0.0002192407,0.0002286158,0.000053677693,0.00008754045,0.00033485246,0.000008272066],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005204465,0.00020600537,0.000008125047,0.00025293874,0.0004691098,0.00022292878,0.0000064647293,2.568233e-8,0.000159094,9.638889e-7,0.95623314,0.03723672],"study_design_scores_gemma":[0.0067000333,0.00063901284,0.00009278603,0.0013274829,0.00032699425,0.00018769683,0.00001272803,6.994729e-7,0.00017610025,0.000017182965,0.99012226,0.00039700928],"about_ca_topic_score_codex":0.00027965728,"about_ca_topic_score_gemma":0.00033019827,"teacher_disagreement_score":0.036839712,"about_ca_system_score_codex":0.0014590893,"about_ca_system_score_gemma":0.002514739,"threshold_uncertainty_score":0.99992657},"labels":[],"label_agreement":null},{"id":"W4250326583","doi":"10.31525/cmr-1d27113","title":"Simultaneous review decisions for pembrolizumab plus lenvatinib in Australia, Canada and US","year":2019,"lang":"en","type":"article","venue":"Case Medical Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lenvatinib; Pembrolizumab; Medicine; Internal medicine; Immunotherapy; Cancer","score_opus":0.11355470158987467,"score_gpt":0.45229043272735037,"score_spread":0.3387357311374757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250326583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97948533,0.013716281,0.000009767488,0.0048002414,0.00012992714,0.0014605138,0.000030190084,0.000007090344,0.00036066532],"genre_scores_gemma":[0.98160166,0.009875819,0.00006841091,0.002104666,0.00008979658,0.00010107432,0.000024574294,0.000017129532,0.0061168945],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99751776,0.00013055603,0.00035820893,0.0003138792,0.0011803309,0.00049924874],"domain_scores_gemma":[0.99500406,0.0039587803,0.000027046814,0.00032429295,0.00021111508,0.00047470813],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002053979,0.00010536965,0.0003683332,0.00010921483,0.00006754821,0.000012151524,0.00012205163,0.00012638369,0.0022871208],"category_scores_gemma":[0.009031935,0.00007902785,0.000053064803,0.00039667555,0.00018102756,0.00002322937,0.0000639837,0.0005572068,0.000017952858],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066530607,0.00017689996,0.0032007473,0.004522676,0.00011473694,0.04781604,0.00021461319,0.0000035303872,0.0005471666,0.000078715224,0.09833833,0.8383335],"study_design_scores_gemma":[0.012201388,0.0010323932,0.0019039533,0.008169946,0.00003136024,0.009701557,0.00023232754,0.002839043,0.00013766959,0.00006635032,0.9634592,0.0002247997],"about_ca_topic_score_codex":0.5622807,"about_ca_topic_score_gemma":0.6748637,"teacher_disagreement_score":0.8651209,"about_ca_system_score_codex":0.00046237124,"about_ca_system_score_gemma":0.0030271132,"threshold_uncertainty_score":0.9993154},"labels":[],"label_agreement":null},{"id":"W4250523013","doi":"10.1016/j.annonc.2020.08.1139","title":"1019O Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacodynamics; Immunogenicity; Tolerability; Adverse effect; Pharmacology; Pharmacokinetics; Oncology; Internal medicine; Antibody; Immunology","score_opus":0.14229690519594798,"score_gpt":0.45291356441973685,"score_spread":0.3106166592237889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250523013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826853,0.0030302855,0.000034695935,0.013188017,0.00010446685,0.0005676815,0.000028640603,0.000030220961,0.00033063986],"genre_scores_gemma":[0.9897058,0.007971925,0.00028801142,0.0018217624,0.0000580022,0.00001445525,0.00006269613,0.000026340067,0.000051027313],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982356,0.000167295,0.00066923094,0.00037449555,0.00025281153,0.00030055866],"domain_scores_gemma":[0.9987088,0.00019580362,0.0004002069,0.00023797258,0.0003319293,0.0001253195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055377686,0.00022426056,0.0012017256,0.0002377226,0.00005049042,0.000006902329,0.00012939754,0.000162218,0.00008257504],"category_scores_gemma":[0.00015883401,0.0001669766,0.000080504644,0.00056389824,0.00058274507,0.00018650417,0.000063143874,0.00018095932,0.0000020532862],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04474755,0.007245228,0.1041392,0.0021385266,0.0022683812,0.0009360677,0.007902158,0.000034962908,0.743052,0.00025668883,0.0041708043,0.08310841],"study_design_scores_gemma":[0.08972214,0.13219549,0.44154435,0.0018763418,0.0007580532,0.00056178146,0.010975547,0.0016719118,0.29968023,0.00016254779,0.01983139,0.0010202295],"about_ca_topic_score_codex":0.00017297668,"about_ca_topic_score_gemma":0.000112908645,"teacher_disagreement_score":0.4433718,"about_ca_system_score_codex":0.00003138691,"about_ca_system_score_gemma":0.0002784297,"threshold_uncertainty_score":0.6809108},"labels":[],"label_agreement":null},{"id":"W4250857274","doi":"10.1158/1538-7445.am2019-4051","title":"Abstract 4051: First step for development of checkpoint inhibitors immune monitoring panels in human whole blood and peripheral mononuclear cells","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada)","funders":"","keywords":"Peripheral blood mononuclear cell; Immune system; Monoclonal antibody; Flow cytometry; Antibody; Immunotherapy; CD8; clone (Java method); Immunology; Medicine; Cancer immunotherapy; Cancer research; Biology; In vitro","score_opus":0.06484803613932401,"score_gpt":0.3703665553649097,"score_spread":0.3055185192255857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250857274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959323,0.0023709037,0.0000029275095,0.00022727104,0.00018682043,0.0010455835,0.000010173778,0.000011963229,0.00021206227],"genre_scores_gemma":[0.9978025,0.00039265412,0.00044638017,0.000007849796,0.00014761713,0.00017012848,0.0000050951103,0.000036329962,0.0009914611],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984146,0.000024214563,0.00045248552,0.00030467295,0.00038056224,0.00042349647],"domain_scores_gemma":[0.9993847,0.00006834261,0.00007705882,0.00023938078,0.00014316615,0.00008733214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009241812,0.00013296928,0.0003112866,0.00018958328,0.00012838731,0.000030125972,0.00012370425,0.000102677295,0.00023418646],"category_scores_gemma":[0.000013318971,0.0001207502,0.00007493714,0.00021070433,0.00012290436,0.000079066136,0.00007482914,0.0003020732,0.0000047323633],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011571605,0.00014658239,0.01655784,0.0008089454,0.00010127113,0.0000051112647,0.0028369091,0.000011342582,0.96781135,0.0000024547812,0.000048968555,0.010512059],"study_design_scores_gemma":[0.004411926,0.0003434425,0.17765604,0.0010188245,0.000009308446,0.0000015849582,0.0014001202,0.000010033855,0.80638176,0.000006025351,0.008630609,0.00013033018],"about_ca_topic_score_codex":0.0010676171,"about_ca_topic_score_gemma":0.000102335754,"teacher_disagreement_score":0.1614296,"about_ca_system_score_codex":0.00027974823,"about_ca_system_score_gemma":0.00028426087,"threshold_uncertainty_score":0.49240503},"labels":[],"label_agreement":null},{"id":"W4251148738","doi":"10.1016/j.jtho.2018.08.607","title":"P1.01-51 Real world Experience of Pembrolizumab in Patients with Metastatic Nonsmall Cell Lung Cancer (mNSCLC)","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Lung cancer; Adverse effect; Gastroenterology; Cohort; Pneumonitis; Cancer; Oncology; Lung; Immunotherapy","score_opus":0.01938270157736518,"score_gpt":0.3958075948341308,"score_spread":0.37642489325676565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251148738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99501956,0.00067595526,0.000059682778,0.0004722692,0.00051430066,0.0002651862,0.0000069911553,0.0000048667275,0.0029811864],"genre_scores_gemma":[0.9960138,0.00023856311,0.0026401414,0.00037927108,0.0001792124,0.000010560929,0.0000017753399,0.000019402203,0.0005172411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983269,0.00015057958,0.000743503,0.0001556967,0.0003553119,0.00026799203],"domain_scores_gemma":[0.9983931,0.000099238096,0.0008593468,0.00019050184,0.00034328917,0.0001145031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042938045,0.00015105728,0.00064094143,0.0003904177,0.000035419125,0.0000066277,0.00017591362,0.00006963173,0.0005591527],"category_scores_gemma":[0.000025800558,0.00010341489,0.00011452686,0.00047289848,0.00029250432,0.00013651358,0.000028238737,0.0002844816,0.0000017286626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14592882,0.0025377497,0.71715736,0.0004439609,0.00063695246,0.00032902273,0.008445811,0.000017510421,0.015206841,0.000009564796,0.003100281,0.10618615],"study_design_scores_gemma":[0.015048476,0.010087178,0.9435649,0.0010339023,0.00063744717,0.00013736448,0.0010878543,0.00010482985,0.016280191,0.000016968736,0.011738669,0.00026221375],"about_ca_topic_score_codex":0.00037299583,"about_ca_topic_score_gemma":0.0012878717,"teacher_disagreement_score":0.22640757,"about_ca_system_score_codex":0.00056649884,"about_ca_system_score_gemma":0.00082011527,"threshold_uncertainty_score":0.612233},"labels":[],"label_agreement":null},{"id":"W4251412578","doi":"10.1038/s41416-019-0512-8","title":"Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy","year":2019,"lang":"en","type":"erratum","venue":"British Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; PD-L1; Internal medicine; Oncology; Immunotherapy; Pathology; Cancer","score_opus":0.006148988101065753,"score_gpt":0.26583518499217446,"score_spread":0.2596861968911087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251412578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.839063,0.1526418,0.000022585346,0.00006363252,0.0067034066,0.00071674003,0.00016700776,0.0000036722026,0.00061814307],"genre_scores_gemma":[0.92282987,0.073758796,0.00003165622,0.00010816658,0.00049548765,0.000015500034,0.00004219566,0.00003842182,0.0026799215],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99853045,0.00006747464,0.0006543986,0.00018216282,0.0004187956,0.00014674845],"domain_scores_gemma":[0.99830544,0.000059438782,0.0009692989,0.000083566185,0.00052343524,0.00005883231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021201196,0.00016729686,0.00068217446,0.00023451715,0.00002671147,0.000023334811,0.000072343915,0.00019681282,0.00010129304],"category_scores_gemma":[0.00006400341,0.00016744494,0.00008739989,0.00016785611,0.00014676571,0.00015510668,0.00001862711,0.00047746577,7.6280365e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063002594,0.0005147525,0.27147138,0.001289399,0.0007332329,0.00010410327,0.0008466146,0.0000135315495,0.0025901918,4.24237e-7,0.053711116,0.662425],"study_design_scores_gemma":[0.0052017136,0.0014972318,0.96725184,0.009066446,0.00020653066,0.0005126404,0.0002017588,0.00019367244,0.0012982195,0.000015233474,0.014401723,0.00015297695],"about_ca_topic_score_codex":0.00067428505,"about_ca_topic_score_gemma":0.00031191084,"teacher_disagreement_score":0.69578046,"about_ca_system_score_codex":0.00017411106,"about_ca_system_score_gemma":0.00047494087,"threshold_uncertainty_score":0.6828207},"labels":[],"label_agreement":null},{"id":"W4252437847","doi":"10.21203/rs.3.rs-18123/v3","title":"Immune Characterization of Metastatic Colorectal Cancer Patients Post Reovirus Administration","year":2020,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Cancer Institute","keywords":"Immune system; Colorectal cancer; Medicine; Oncology; Cancer; Internal medicine; Cancer research; Immunology","score_opus":0.06175960867406749,"score_gpt":0.40052736937348493,"score_spread":0.33876776069941744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252437847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923877,0.0006466375,0.000021661406,0.002761374,0.00030695318,0.0021697024,0.0014282069,0.00003666875,0.00024106246],"genre_scores_gemma":[0.9927978,0.001480466,0.00006213673,0.00010415737,0.00015620179,0.00031692948,0.004860967,0.000043168355,0.00017816397],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972594,0.0003022904,0.0005817453,0.00042734898,0.0011201723,0.00030905064],"domain_scores_gemma":[0.99740005,0.00008752806,0.00029671326,0.00031568515,0.0017625253,0.00013748024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005417329,0.00020685515,0.00050767435,0.00028161457,0.000088120316,0.000047725098,0.00018765783,0.0001868908,0.00059615646],"category_scores_gemma":[0.00038824553,0.00018612918,0.00022567686,0.0004628888,0.00017467707,0.000071356146,0.00022449515,0.0007660825,0.000018264744],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014494381,0.0007472411,0.012000791,0.004628005,0.00059903006,0.00003418794,0.0011551919,0.0000013083963,0.9495813,0.000021349098,0.00025266895,0.016484495],"study_design_scores_gemma":[0.0022831818,0.0032446762,0.7426275,0.0019173732,0.00011994766,0.0000033440479,0.00020244562,0.0001435769,0.24772598,0.000037358277,0.0014752337,0.00021937441],"about_ca_topic_score_codex":0.0008732183,"about_ca_topic_score_gemma":0.00007305551,"teacher_disagreement_score":0.7306267,"about_ca_system_score_codex":0.00037810154,"about_ca_system_score_gemma":0.0016558302,"threshold_uncertainty_score":0.7590128},"labels":[],"label_agreement":null},{"id":"W4253096809","doi":"10.1016/j.jtho.2021.01.723","title":"P35.22 WITHDRAWN","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine","score_opus":0.023723224505432867,"score_gpt":0.41673963735636693,"score_spread":0.3930164128509341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253096809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94499874,0.0070842495,0.00036071282,0.022113364,0.0018399407,0.00007730391,0.0000021182757,0.000012052014,0.023511514],"genre_scores_gemma":[0.97820115,0.0009372956,0.00769298,0.0049381317,0.0009937217,0.0000015332638,0.0000028942177,0.000017582917,0.007214681],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99902606,0.000112561254,0.000425585,0.000087517285,0.00020019274,0.00014807718],"domain_scores_gemma":[0.9990206,0.00008123179,0.00031568616,0.00014593916,0.00032795416,0.000108590306],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00050994125,0.000077489734,0.00038974689,0.00009802871,0.00003789916,0.000011233913,0.00007417138,0.00012013492,0.0014579005],"category_scores_gemma":[0.000114072325,0.00005805308,0.00022066048,0.00020503448,0.00007947798,0.00006468267,0.000021160618,0.0003087544,0.00001782989],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013377521,0.00070691964,0.0045276633,0.00009688919,0.0007180372,0.0064860415,0.00046650015,0.0000032965436,0.1748886,0.000049834183,0.052172974,0.74650574],"study_design_scores_gemma":[0.002061058,0.0025489673,0.022167502,0.0001810734,0.00031112236,0.022011438,0.0006613742,0.000008603464,0.04401113,0.00022837987,0.9057143,0.00009509773],"about_ca_topic_score_codex":0.000004493661,"about_ca_topic_score_gemma":0.0000112309945,"teacher_disagreement_score":0.85354125,"about_ca_system_score_codex":0.00024182713,"about_ca_system_score_gemma":0.001147892,"threshold_uncertainty_score":0.9994549},"labels":[],"label_agreement":null},{"id":"W4253325695","doi":"10.1515/iupac.84.1109","title":"Regulatory T Cell (TREG)","year":2016,"lang":"en","type":"dataset","venue":"IUPAC Standards Online","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"","keywords":"Glossary; Immunotoxicology; Immunology; Disease; Medicine; Immune system; Pathology; Philosophy","score_opus":0.011932292841371334,"score_gpt":0.376379987614961,"score_spread":0.3644476947735897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253325695","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00050268846,0.0063291877,0.000014942413,0.0012695612,0.0010897077,0.00045256963,0.98992515,0.000088009096,0.00032817113],"genre_scores_gemma":[0.00004715982,0.004363706,0.000037309503,0.0013971651,0.0015788573,0.00001530184,0.9863029,0.000065381166,0.00619219],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99718463,0.000056430326,0.00054585317,0.0005601808,0.0011927299,0.0004601824],"domain_scores_gemma":[0.99775404,0.00005757695,0.00029266224,0.00132308,0.0003445938,0.00022803686],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004829863,0.0004860601,0.00080580724,0.0002610436,0.00008756177,0.000028153336,0.00027076667,0.0005534951,0.009821821],"category_scores_gemma":[0.0000885155,0.00033828345,0.00040710968,0.00019239417,0.00025685786,0.00005348702,0.00008479928,0.00047244955,0.0000070386495],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029926107,0.00032220123,0.000014640356,0.00043133277,0.00025139007,0.00016205106,0.000008103493,3.4573976e-8,0.000549247,7.975108e-7,0.9852285,0.010039123],"study_design_scores_gemma":[0.004808328,0.0006303232,0.00021199907,0.0010478713,0.00032709778,0.000069531685,0.000017665147,3.705049e-7,0.00060516834,0.000016053466,0.99184793,0.00041768668],"about_ca_topic_score_codex":0.00012411043,"about_ca_topic_score_gemma":0.00018506555,"teacher_disagreement_score":0.009814782,"about_ca_system_score_codex":0.0008075766,"about_ca_system_score_gemma":0.0016967984,"threshold_uncertainty_score":0.9999069},"labels":[],"label_agreement":null},{"id":"W4253605264","doi":"10.4021/jmc886w","title":"Ipilimumab Associated Autoimmune Alveolitis Responding to Corticosteroids","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Ipilimumab; Melanoma; Incidence (geometry); Metastatic melanoma; Immunotherapy; Drug; Nivolumab; Immunology; Dermatology; Immune system; Internal medicine; Oncology; Cancer research; Pharmacology","score_opus":0.03574798075258941,"score_gpt":0.34339942928615436,"score_spread":0.30765144853356496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253605264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822427,0.0053901933,0.00010021543,0.010393003,0.0012941597,0.00010414528,0.000005426252,0.000019291765,0.00045083946],"genre_scores_gemma":[0.9936741,0.00039148342,0.00014694883,0.0040574796,0.0008064088,0.0000022368718,0.0000030935666,0.000017888087,0.0009003482],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973631,0.00011742805,0.0006890738,0.000078373225,0.0013787723,0.00037327947],"domain_scores_gemma":[0.99833924,0.00039889078,0.00026964984,0.00014270369,0.00015828073,0.0006912197],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020868678,0.00011843669,0.00042113243,0.0003953494,0.000060229373,0.00001968698,0.00015207184,0.00016117815,0.0021723139],"category_scores_gemma":[0.0040009874,0.000085290005,0.0002326401,0.00048712213,0.00007458967,0.00014311889,0.000044491168,0.0003940601,0.000023442104],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033974912,0.003931831,0.17234844,0.00023539414,0.0028356127,0.011481706,0.005712992,0.000001707467,0.09210873,0.00039833577,0.19575778,0.48121256],"study_design_scores_gemma":[0.012137119,0.0049472935,0.6628363,0.0027689685,0.00045223077,0.023846354,0.0013546266,0.000026755888,0.0056358506,0.000020730917,0.2856553,0.00031847254],"about_ca_topic_score_codex":0.000041430252,"about_ca_topic_score_gemma":0.0000055912087,"teacher_disagreement_score":0.49048787,"about_ca_system_score_codex":0.00029852576,"about_ca_system_score_gemma":0.0003291471,"threshold_uncertainty_score":0.99873984},"labels":[],"label_agreement":null},{"id":"W4253690459","doi":"10.1200/edbk_158713","title":"Treatment of Lung Cancer in Medically Compromised Patients","year":2016,"lang":"en","type":"article","venue":"American Society of Clinical Oncology Educational Book","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Lung cancer; Clinical trial; Intensive care medicine; Cancer; Population; Performance status; Disease; Radiation therapy; Internal medicine","score_opus":0.0453200208877816,"score_gpt":0.46002147750916433,"score_spread":0.41470145662138275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253690459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9139674,0.00071433315,0.000019839432,0.082646936,0.0003038637,0.00040691593,0.0000352281,0.000006006598,0.001899532],"genre_scores_gemma":[0.9783722,0.007889807,0.0024216645,0.00610687,0.0002841525,0.000114703675,0.000018575896,0.000012006606,0.0047800313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840456,0.000100834324,0.00093276147,0.0002070416,0.00021347872,0.00014129802],"domain_scores_gemma":[0.997095,0.0018506992,0.00059282774,0.00015615758,0.00019345172,0.00011190445],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024613467,0.00009528598,0.00071610266,0.000025703337,0.000015368472,5.377464e-7,0.00007628519,0.00010455641,0.0015655344],"category_scores_gemma":[0.00014914937,0.00005919289,0.00040244908,0.00012294234,0.0015661031,0.000029386596,0.00001192818,0.00006970498,0.0000026252294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014480299,0.002702973,0.6165694,0.000015769103,0.0002979943,2.2914948e-7,0.0003126328,1.4496322e-7,0.00067090464,0.000026135,0.009055749,0.36890006],"study_design_scores_gemma":[0.009110061,0.0030174884,0.88771147,0.000088459055,0.000075622454,7.3797196e-7,0.000091517395,0.00001820428,0.00014949431,0.000026979957,0.09964941,0.00006056716],"about_ca_topic_score_codex":0.00045601875,"about_ca_topic_score_gemma":0.00002512869,"teacher_disagreement_score":0.3688395,"about_ca_system_score_codex":0.00048535375,"about_ca_system_score_gemma":0.002970772,"threshold_uncertainty_score":0.99934715},"labels":[],"label_agreement":null},{"id":"W4254735370","doi":"10.1002/cncy.21893","title":"Issue Information","year":2017,"lang":"en","type":"paratext","venue":"Cancer Cytopathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Citation; Medicine; Information retrieval; World Wide Web; Library science; Internet privacy; Computer science","score_opus":0.02066571226052487,"score_gpt":0.33585360065224534,"score_spread":0.31518788839172046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254735370","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004484276,0.044927396,0.00027518082,0.008240917,0.04138471,0.0013099301,0.0009833435,0.00010276329,0.89829147],"genre_scores_gemma":[0.00804901,0.03438911,0.00017829596,0.011986893,0.005296778,0.00049360463,0.0018208276,0.00007548255,0.93771],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988296,0.00003656361,0.00037164017,0.00026425245,0.00017038158,0.00032753596],"domain_scores_gemma":[0.99853396,0.000014632422,0.00044057198,0.000759359,0.0001631232,0.0000883501],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014653204,0.00028512147,0.00065350346,0.00019818536,0.00014913433,0.00005176133,0.0002451031,0.0006467455,0.01886966],"category_scores_gemma":[0.000035023484,0.00024890358,0.00020061113,0.00006444128,0.00025620314,0.00018099957,0.00006108756,0.00045936354,0.014855377],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008669002,0.000016257474,0.0001578191,0.00036143357,0.000093287694,0.000035252804,0.00022627394,0.0000012207427,0.0010125014,0.0000056094673,0.8801315,0.117091976],"study_design_scores_gemma":[0.0016851745,0.00022732715,0.00271246,0.0003514244,0.00012662611,0.00023222812,0.000027268099,0.0000030087424,0.001291654,0.000006516629,0.9930892,0.00024712633],"about_ca_topic_score_codex":0.00028923407,"about_ca_topic_score_gemma":0.000023661785,"teacher_disagreement_score":0.11684485,"about_ca_system_score_codex":0.00029897748,"about_ca_system_score_gemma":0.0007550635,"threshold_uncertainty_score":0.9999963},"labels":[],"label_agreement":null},{"id":"W4254889096","doi":"10.1093/annonc/mdw594.001","title":"437O KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Oncology; Internal medicine; Chemotherapy; Cancer; Immunotherapy","score_opus":0.04872773898541408,"score_gpt":0.35374730336662435,"score_spread":0.30501956438121025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254889096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96034414,0.0013206473,0.0037315576,0.030308086,0.00020812433,0.0026215815,0.00006346974,0.00012339646,0.001278983],"genre_scores_gemma":[0.9821324,0.0018283055,0.0024353478,0.011572393,0.00028768455,0.00047921584,0.000063235864,0.00010206403,0.001099388],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975145,0.00007132073,0.0007790111,0.0006086004,0.00040225426,0.0006243252],"domain_scores_gemma":[0.99753433,0.00036117062,0.00073249516,0.00058435404,0.0006158694,0.00017175889],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052842573,0.00041719363,0.0009666395,0.00022191997,0.00012472784,0.000011473578,0.0002284255,0.0002752347,0.0006013115],"category_scores_gemma":[0.0001361968,0.0002583334,0.00036602493,0.0002932641,0.00044119827,0.0001569094,0.000017143184,0.00016731163,0.000016114485],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43531093,0.0014182482,0.0027399866,0.00022909392,0.00048680662,0.000043864897,0.00025748953,0.000015248794,0.14664207,0.000076290286,0.002987445,0.4097925],"study_design_scores_gemma":[0.10519678,0.061569985,0.03641991,0.0010610401,0.0000970246,0.00022813497,0.00009262948,0.00013105132,0.49356022,0.0008028192,0.30020675,0.00063367526],"about_ca_topic_score_codex":0.00009884181,"about_ca_topic_score_gemma":0.00009586002,"teacher_disagreement_score":0.40915886,"about_ca_system_score_codex":0.00018408736,"about_ca_system_score_gemma":0.0011166363,"threshold_uncertainty_score":0.9999869},"labels":[],"label_agreement":null},{"id":"W4256572840","doi":"10.21203/rs.3.rs-18123/v1","title":"Immune Characterization Of Metastatic Colorectal Cancer Patients Post Reovirus Administration","year":2020,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Immune system; Colorectal cancer; Medicine; Oncology; Cancer; Cancer research; Internal medicine; Immunology","score_opus":0.06175960867406749,"score_gpt":0.40052736937348493,"score_spread":0.33876776069941744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256572840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923877,0.0006466375,0.000021661406,0.002761374,0.00030695318,0.0021697024,0.0014282069,0.00003666875,0.00024106246],"genre_scores_gemma":[0.9927978,0.001480466,0.00006213673,0.00010415737,0.00015620179,0.00031692948,0.004860967,0.000043168355,0.00017816397],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972594,0.0003022904,0.0005817453,0.00042734898,0.0011201723,0.00030905064],"domain_scores_gemma":[0.99740005,0.00008752806,0.00029671326,0.00031568515,0.0017625253,0.00013748024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005417329,0.00020685515,0.00050767435,0.00028161457,0.000088120316,0.000047725098,0.00018765783,0.0001868908,0.00059615646],"category_scores_gemma":[0.00038824553,0.00018612918,0.00022567686,0.0004628888,0.00017467707,0.000071356146,0.00022449515,0.0007660825,0.000018264744],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014494381,0.0007472411,0.012000791,0.004628005,0.00059903006,0.00003418794,0.0011551919,0.0000013083963,0.9495813,0.000021349098,0.00025266895,0.016484495],"study_design_scores_gemma":[0.0022831818,0.0032446762,0.7426275,0.0019173732,0.00011994766,0.0000033440479,0.00020244562,0.0001435769,0.24772598,0.000037358277,0.0014752337,0.00021937441],"about_ca_topic_score_codex":0.0008732183,"about_ca_topic_score_gemma":0.00007305551,"teacher_disagreement_score":0.7306267,"about_ca_system_score_codex":0.00037810154,"about_ca_system_score_gemma":0.0016558302,"threshold_uncertainty_score":0.7590128},"labels":[],"label_agreement":null},{"id":"W4280529326","doi":"10.1200/edbk_349799","title":"Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again","year":2022,"lang":"en","type":"article","venue":"American Society of Clinical Oncology Educational Book","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Immunogenicity; Cancer; Immunotherapy; Pediatric oncology; Clinical trial; Lymphoma; Pediatric cancer; Oncology; Immune system; Internal medicine; Immunology; Pediatrics","score_opus":0.046503994747724646,"score_gpt":0.41669958455230804,"score_spread":0.3701955898045834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280529326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88546395,0.006252916,0.000019194267,0.0966621,0.000426961,0.00048689375,0.000021866646,0.000013314026,0.010652784],"genre_scores_gemma":[0.7796221,0.026492633,0.023653021,0.13392985,0.0011562521,0.000316798,0.00012546235,0.000060976465,0.03464291],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980153,0.0002570258,0.0009752893,0.00031215328,0.0002444644,0.00019579547],"domain_scores_gemma":[0.9974617,0.0015928089,0.0005591052,0.00020775158,0.00007752524,0.000101115555],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014475138,0.00012060667,0.0006613457,0.00005005841,0.00007954939,0.0000032327569,0.00012535411,0.00008394387,0.0033883036],"category_scores_gemma":[0.00011027258,0.000117631454,0.000400393,0.0003372999,0.0010993864,0.00004329121,0.000069413916,0.0005211023,0.000012211519],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004310872,0.0036244055,0.52405864,0.00006618595,0.0004022322,0.0000033646836,0.0022427219,0.000010077314,0.0013812901,0.00022268979,0.10929683,0.3543807],"study_design_scores_gemma":[0.003228693,0.001951013,0.48439422,0.000008104203,0.000027088168,0.000021300284,0.0028970037,0.000030390642,0.000014233605,0.00018498348,0.5071371,0.00010585953],"about_ca_topic_score_codex":0.00048119726,"about_ca_topic_score_gemma":0.000009251618,"teacher_disagreement_score":0.39784026,"about_ca_system_score_codex":0.0003357133,"about_ca_system_score_gemma":0.0023346688,"threshold_uncertainty_score":0.9975227},"labels":[],"label_agreement":null},{"id":"W4280541127","doi":"10.1136/jitc-2021-004076","title":"Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Foundation Medicine; Takeda Oncology; Chugai Pharmaceutical; Novartis Pharma; Genentech; Daiichi Sankyo Europe; National Cancer Institute; Servier; Eisai; Basilea Pharmaceutica; AstraZeneca; Institut National Du Cancer; Seagen; Agios Pharmaceuticals; Eisai Canada; BeiGene; Clovis Oncology; Loxo Oncology; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Boston Pharmaceuticals; Taiho Pharmaceutical; F. Hoffmann-La Roche; Yale University; Bayer HealthCare; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atezolizumab; Blockade; Solid tumor; Medicine; Immune checkpoint; Immune system; Oncology; Cancer research; Internal medicine; Immunology; Immunotherapy; Pembrolizumab; Cancer; Receptor","score_opus":0.014477426203594235,"score_gpt":0.32528427437223195,"score_spread":0.31080684816863774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280541127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99010825,0.0048000095,0.00027425864,0.00092445844,0.000990004,0.0027507434,0.0001038205,0.000021669293,0.000026813941],"genre_scores_gemma":[0.99460816,0.0020871374,0.0010270552,0.00044403638,0.00007301005,0.0013826087,0.000045271252,0.00010150665,0.00023123574],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969502,0.000074621435,0.00133763,0.00038246796,0.0006521847,0.00060289813],"domain_scores_gemma":[0.9981076,0.00010138537,0.0010191548,0.00031450816,0.0003818225,0.000075496886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006289083,0.00035950076,0.0010029393,0.0005488593,0.00032744167,0.000041526306,0.00032992876,0.00008301668,0.00045833059],"category_scores_gemma":[0.000054750366,0.00028070758,0.00037485114,0.000692623,0.00014186613,0.0003227,0.000035473127,0.000454386,2.5535968e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23319407,0.0033755575,0.01682321,0.00044990407,0.0008348254,0.000053591764,0.010228373,0.00308418,0.6592176,0.000029427552,0.000115776245,0.07259351],"study_design_scores_gemma":[0.22667712,0.022972047,0.25135398,0.0022615525,0.00013370924,0.00034068077,0.0068158917,0.00089195045,0.46870372,0.00047220816,0.018295437,0.00108172],"about_ca_topic_score_codex":0.0003946761,"about_ca_topic_score_gemma":0.000121790465,"teacher_disagreement_score":0.23453076,"about_ca_system_score_codex":0.0018777178,"about_ca_system_score_gemma":0.0011244374,"threshold_uncertainty_score":0.99996454},"labels":[],"label_agreement":null},{"id":"W4280640049","doi":"10.3390/cells11091550","title":"Framework of Intrinsic Immune Landscape of Dormant Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"Cells","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Mitacs; Terry Fox Research Institute; Prostate Cancer Foundation","keywords":"Prostate cancer; Immune system; Dormancy; Disease; Medicine; Immune checkpoint; Immunotherapy; Androgen deprivation therapy; Cancer; Prostate; Oncology; Bioinformatics; Biology; Immunology; Internal medicine","score_opus":0.0092299240239519,"score_gpt":0.2599557965958189,"score_spread":0.250725872571867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280640049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880976,0.009639754,0.000008193573,0.00037786973,0.00044931995,0.00025822542,0.000053699874,0.000011932865,0.0011033963],"genre_scores_gemma":[0.99705637,0.0012364659,0.00014776227,0.00019716083,0.00004069404,0.000031135864,0.000010396408,0.000011272537,0.001268752],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993576,0.000021199747,0.0002385671,0.00009348776,0.000178636,0.00011052188],"domain_scores_gemma":[0.9995692,0.000029630954,0.00013457477,0.00020607297,0.00003740367,0.000023118664],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001468603,0.000063003026,0.00021299203,0.00006357559,0.000031821328,0.0000016743558,0.000074334144,0.000026522777,0.0027083613],"category_scores_gemma":[0.0000045418005,0.000052810352,0.000087109336,0.00024314145,0.000053634754,0.000014398484,0.000051707822,0.00014113131,0.0000026667562],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005682956,0.0003597834,0.016018195,0.0004774102,0.00033857653,0.000020564965,0.0038408048,0.000085501255,0.9048772,0.00009737101,0.0062107937,0.061990865],"study_design_scores_gemma":[0.003449406,0.001003815,0.04615674,0.00028280384,0.000119229895,0.000015676727,0.0012225155,0.00004885206,0.856128,0.0001259201,0.091278985,0.00016806452],"about_ca_topic_score_codex":0.00021737827,"about_ca_topic_score_gemma":0.0000026777132,"teacher_disagreement_score":0.085068196,"about_ca_system_score_codex":0.000038372138,"about_ca_system_score_gemma":0.00010836796,"threshold_uncertainty_score":0.9982033},"labels":[],"label_agreement":null},{"id":"W4280654651","doi":"10.1101/2022.05.06.490968","title":"Single-Cell RNAseq Analysis Reveals Robust, Anti-PD-1-Mediated Increase of Immune Infiltrate in Metastatic Castration-Sensitive Prostate Cancer","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Institutes of Health; Conquer Cancer Foundation; Regeneron Pharmaceuticals; Prostate Cancer Foundation","keywords":"Prostate cancer; Immune system; Androgen deprivation therapy; Immunotherapy; Tumor microenvironment; Medicine; Druggability; Context (archaeology); Oncology; Castration; Cancer; Prostate; Metastasis; Cancer research; Hormonal therapy; Internal medicine; Immunology; Biology; Hormone","score_opus":0.020198211639372347,"score_gpt":0.24698949051033184,"score_spread":0.22679127887095948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280654651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891571,0.005650021,0.00009443447,0.00023680858,0.00040544115,0.0018375395,0.0024721406,0.00012526619,0.000021294343],"genre_scores_gemma":[0.99495804,0.0023584405,0.0017180659,0.00025696144,0.0000876449,0.00043131632,0.000029669338,0.00013045217,0.000029384657],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9953034,0.0005345872,0.001708904,0.0010854623,0.0007262729,0.00064138114],"domain_scores_gemma":[0.9960511,0.00017550473,0.0015367691,0.0012576269,0.0007209227,0.00025810418],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014892382,0.0007098871,0.0018983152,0.0014348052,0.000119227734,0.0000812728,0.0003191881,0.00029226037,0.00048814894],"category_scores_gemma":[0.00022442786,0.00074446143,0.0005732,0.0035754298,0.00023916156,0.00016337732,0.0002469014,0.0010327956,0.000005486452],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014332461,0.00078732125,0.076093726,0.0010932412,0.0030305746,0.00048187166,0.00010173128,0.0028589438,0.9140409,0.000006700278,0.00006807365,0.0000036480353],"study_design_scores_gemma":[0.0040384457,0.00028953585,0.64248735,0.0009987265,0.0033760986,1.342422e-7,0.000074457166,0.001118524,0.346382,4.573072e-7,0.0003400324,0.00089429057],"about_ca_topic_score_codex":0.0052867834,"about_ca_topic_score_gemma":0.00013884694,"teacher_disagreement_score":0.56765896,"about_ca_system_score_codex":0.0009739193,"about_ca_system_score_gemma":0.0020039233,"threshold_uncertainty_score":0.99950063},"labels":[],"label_agreement":null},{"id":"W4281256287","doi":"10.1183/13993003.02512-2021","title":"The paradox of immune checkpoint inhibition re-activating tuberculosis","year":2022,"lang":"en","type":"review","venue":"European Respiratory Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Wellcome Trust","keywords":"Immune system; Immunology; Medicine; Immunity; Tuberculosis; T cell; Mycobacterium tuberculosis; Programmed cell death; Disease; Effector; Biology; Pathology; Apoptosis","score_opus":0.0849140871084715,"score_gpt":0.3353430036444945,"score_spread":0.250428916536023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281256287","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004097456,0.98845816,0.000007386864,0.00008301986,0.0005897739,0.00043304046,0.000013407954,0.000026529739,0.009978926],"genre_scores_gemma":[0.000106694395,0.9984889,0.000036421134,0.00020455077,0.0007343912,0.000016082342,0.000014466719,0.00012450997,0.00027396556],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950211,0.0018077989,0.0019815392,0.00026757736,0.000610099,0.0003118871],"domain_scores_gemma":[0.99694484,0.00028356139,0.0019833867,0.00058151374,0.000088286186,0.00011842411],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0049462956,0.00035674582,0.0010576351,0.00023581545,0.0007094117,0.000089596884,0.0003056468,0.00007810811,0.0009886012],"category_scores_gemma":[0.00031836788,0.0002208586,0.0014625854,0.00046880892,0.0001686465,0.00007946689,0.00015044193,0.0016650355,0.000026140786],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023815177,0.000057608355,0.000003907477,0.0016798661,0.0005580171,0.00025064943,0.00009399268,2.7224377e-7,0.0005090095,0.000004045394,0.0012739496,0.9953305],"study_design_scores_gemma":[0.0007946812,0.0004935268,0.00013630245,0.008823988,0.0003874918,0.0010083414,0.00018699818,2.1132448e-7,0.00021140442,0.000002760566,0.9877447,0.0002095879],"about_ca_topic_score_codex":0.0000040920663,"about_ca_topic_score_gemma":6.0595033e-7,"teacher_disagreement_score":0.99512094,"about_ca_system_score_codex":0.0004322825,"about_ca_system_score_gemma":0.0005249638,"threshold_uncertainty_score":0.99992466},"labels":[],"label_agreement":null},{"id":"W4281257339","doi":"10.3390/tomography8030110","title":"Analysis of Spatial Heterogeneity of Responses in Metastatic Sites in Renal Cell Carcinoma Patients Treated with Nivolumab","year":2022,"lang":"en","type":"article","venue":"Tomography","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Juravinski Hospital","funders":"","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Lymph node; Lung; Exact test; Metastasis; Lymph; Internal medicine; Carcinoma; Oncology; Urology; Pathology; Cancer; Immunotherapy","score_opus":0.01375454939818146,"score_gpt":0.2476362080692834,"score_spread":0.23388165867110194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281257339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990092,0.0004571744,0.000004344209,0.000011820255,0.000008799817,0.0002556397,0.0001834869,0.0000059067556,0.00006362738],"genre_scores_gemma":[0.9996825,0.000009332933,0.000082992636,0.000029082737,0.0000018592046,0.000029437422,0.00013965866,0.000008672993,0.000016502054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988308,0.00019914297,0.00035827298,0.0001837579,0.00029160024,0.00013644563],"domain_scores_gemma":[0.9994724,0.00006085796,0.00017026153,0.00021985325,0.00004852133,0.00002813181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002124978,0.000102465594,0.0004301284,0.0017007521,0.000021441632,0.0000019768531,0.000071312905,0.000018063518,0.00018776086],"category_scores_gemma":[0.0000069188495,0.00008644254,0.00021488793,0.0031082598,0.000087348155,0.000023958532,0.000023372379,0.00008502926,7.2705674e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015962726,0.0008298016,0.9633975,0.00004246311,0.0005422251,0.000025041398,0.0004459537,0.000082959064,0.017810494,2.0954273e-7,0.000008080092,0.00085255556],"study_design_scores_gemma":[0.0049856226,0.0020165085,0.9566185,0.000015681688,0.0005916851,0.0000011326074,0.00014907768,0.00020256643,0.035323393,8.310296e-7,0.000017836506,0.000077161945],"about_ca_topic_score_codex":0.007442849,"about_ca_topic_score_gemma":0.00409878,"teacher_disagreement_score":0.017512899,"about_ca_system_score_codex":0.0000520777,"about_ca_system_score_gemma":0.000053626874,"threshold_uncertainty_score":0.99916667},"labels":[],"label_agreement":null},{"id":"W4281263793","doi":"10.1055/s-0042-1745814","title":"Pembrolizumab Weight-Based Dosing: Conviction and Lacunae in Adopting a Cost-Saving Approach—A Survey Report","year":2022,"lang":"en","type":"article","venue":"Indian Journal of Medical and Paediatric Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dosing; Medicine; Pembrolizumab; Family medicine; Intensive care medicine; Cancer; Immunotherapy; Internal medicine","score_opus":0.026382732241818363,"score_gpt":0.3082807832665081,"score_spread":0.28189805102468973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281263793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880633,0.0056374487,0.00017381305,0.004775001,0.0008474915,0.00021230214,0.000007145924,0.0000069451835,0.00027654803],"genre_scores_gemma":[0.9966633,0.0012143839,0.00044023863,0.001115124,0.0004789617,0.000013206003,0.000019387997,0.0000117198715,0.000043725468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763316,0.0005464557,0.0007723883,0.00018734652,0.0006180697,0.00024258292],"domain_scores_gemma":[0.9984207,0.0005962926,0.0005186804,0.0000817362,0.00006214615,0.00032043122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004851188,0.00011811977,0.0004778238,0.0004438673,0.0001337958,0.000013556572,0.000101376565,0.00019269068,0.00029065984],"category_scores_gemma":[0.00055288547,0.0000958549,0.00007420224,0.0005237676,0.0001494838,0.000051647497,0.000055775905,0.00096375035,2.0407154e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007240437,0.00057840743,0.669938,0.00015153854,0.00012414045,0.015948376,0.0011479573,0.000015997945,0.00008028203,0.000007972287,0.0012719433,0.30349493],"study_design_scores_gemma":[0.026706383,0.004235856,0.8065619,0.00012566881,0.00017026842,0.07989172,0.0017042835,0.0009259935,0.000016573194,0.000022285662,0.07939366,0.00024543548],"about_ca_topic_score_codex":0.00020899906,"about_ca_topic_score_gemma":0.00007015489,"teacher_disagreement_score":0.3032495,"about_ca_system_score_codex":0.0002143106,"about_ca_system_score_gemma":0.0012648649,"threshold_uncertainty_score":0.41870692},"labels":[],"label_agreement":null},{"id":"W4281491769","doi":"10.1016/j.jtho.2022.03.003","title":"Hyper–Sensitive? Targeted Therapy With a Primed Immune System","year":2022,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Roche; Takeda Pharmaceutical Company; Pfizer","keywords":"Medicine; Immunotherapy; Oncology; Lung cancer; Cohort; Internal medicine; Targeted therapy; Cancer; Immune system; Immunology","score_opus":0.020798191963922696,"score_gpt":0.3448333240027889,"score_spread":0.3240351320388662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281491769","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09481063,0.029381858,0.00011572845,0.8622917,0.0055200118,0.0015468193,0.00007047612,0.00010719324,0.0061555654],"genre_scores_gemma":[0.13133419,0.0041774376,0.005573258,0.8276964,0.017132381,0.00011894351,0.00035679576,0.0004678004,0.013142809],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996293,0.00085962785,0.0011785486,0.00031904376,0.00087702123,0.00047276533],"domain_scores_gemma":[0.99637365,0.0003185705,0.0022130786,0.00046599045,0.0005210851,0.00010762483],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001288397,0.00043564077,0.0019078036,0.00060618465,0.00014676816,0.00002556175,0.00034222644,0.00080738106,0.00084600446],"category_scores_gemma":[0.000035067238,0.0002890595,0.00068155,0.00041365175,0.00022290529,0.0000806604,0.000052102936,0.0038639938,0.000010761336],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11893466,0.0004938984,0.0001251944,0.00075438217,0.0058963816,0.0395354,0.0007961006,0.000004028613,0.024054507,0.0000020670757,0.7017654,0.10763798],"study_design_scores_gemma":[0.0038201683,0.013752605,0.000898335,0.0006322257,0.00074817584,0.038565867,0.0007235652,0.0000048683796,0.004894242,0.0000022603278,0.9356645,0.0002931941],"about_ca_topic_score_codex":0.000057545814,"about_ca_topic_score_gemma":0.0000029285054,"teacher_disagreement_score":0.2338991,"about_ca_system_score_codex":0.0020722602,"about_ca_system_score_gemma":0.002257122,"threshold_uncertainty_score":0.99995613},"labels":[],"label_agreement":null},{"id":"W4281620370","doi":"10.1200/jco.2022.40.16_suppl.9053","title":"Impact of performance status on survival outcomes and health care utilization in patients with advanced non–small cell lung cancer treated with immune checkpoint inhibitors.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Lung cancer; Internal medicine; Performance status; Nivolumab; Cancer; Cohort; Log-rank test; Medical record; Oncology; Retrospective cohort study; Survival analysis; Immunotherapy","score_opus":0.049555050929143744,"score_gpt":0.4229738043697134,"score_spread":0.37341875344056963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281620370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975505,0.0012340582,0.00000491099,0.00036580887,0.0002519754,0.00044592275,0.000020812888,0.0000033220697,0.00012268807],"genre_scores_gemma":[0.9981172,0.0013857182,0.0001626459,0.00022511295,0.00004103119,0.000009636889,0.000017121063,0.000017414986,0.000024094697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763805,0.00020920957,0.0014521747,0.00015292427,0.00032669998,0.0002209231],"domain_scores_gemma":[0.99752516,0.00018066517,0.0017664686,0.000121529585,0.00026285075,0.00014333152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093034125,0.00014156374,0.0011515556,0.00015874917,0.000051177434,0.0000029040257,0.00006166191,0.000077504745,0.000054430384],"category_scores_gemma":[0.00004660306,0.00008290349,0.00017136653,0.00024201372,0.00008931415,0.00006506258,0.00002563524,0.00056420773,5.9588285e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056176107,0.0012057727,0.87309885,0.000088248504,0.00022711573,0.000013136935,0.00055753684,0.00055204245,0.000048067242,1.6992048e-7,0.000020590416,0.06801237],"study_design_scores_gemma":[0.033071537,0.072608545,0.8930816,0.0002004966,0.00007960821,0.0000048295265,0.000412918,0.000060677172,0.000112528614,1.2934083e-7,0.0002909297,0.00007618643],"about_ca_topic_score_codex":0.0006394828,"about_ca_topic_score_gemma":0.00030970146,"teacher_disagreement_score":0.071402766,"about_ca_system_score_codex":0.0010060583,"about_ca_system_score_gemma":0.0025223047,"threshold_uncertainty_score":0.44744602},"labels":[],"label_agreement":null},{"id":"W4281620645","doi":"10.1101/2022.05.28.22275728","title":"Membrane-Localized Mutations Predict the Efficacy of Cancer Immunotherapy","year":2022,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institutes of Health; University of Chicago","keywords":"Immune system; Immunotherapy; Cancer; Melanoma; Biology; Cancer research; Mutation; Cancer cell; Microsatellite instability; Cancer immunotherapy; Gene; Medicine; Immunology; Genetics; Allele","score_opus":0.024704415076196428,"score_gpt":0.32381724684610164,"score_spread":0.2991128317699052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281620645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747742,0.015279805,0.00008610614,0.004617147,0.0017714946,0.0016745627,0.00021129234,0.00018760102,0.0013977903],"genre_scores_gemma":[0.9860223,0.009026719,0.00017986538,0.0011367315,0.00034077207,0.0009167651,0.00019365524,0.00013171138,0.0020514606],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977913,0.00022105555,0.0006674021,0.00042461167,0.0006326336,0.00026298608],"domain_scores_gemma":[0.9979819,0.0003036279,0.00042422293,0.0011138731,0.00011468222,0.00006168734],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006453193,0.0003053157,0.00062426296,0.0001576619,0.00014487113,0.0000221811,0.00051845465,0.00017836719,0.0048415926],"category_scores_gemma":[0.00007572149,0.00020588652,0.00059178355,0.00038078404,0.00035436504,0.000021372567,0.00021293557,0.00080840074,0.000003232733],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046613768,0.0033316512,0.34402344,0.0036245363,0.021989433,0.00017825134,0.02093096,0.0069941767,0.37518618,0.000466344,0.012175166,0.1644861],"study_design_scores_gemma":[0.015038288,0.00054034963,0.47093737,0.0009238702,0.0012790731,0.000037091806,0.0006885883,0.00083280506,0.03268061,0.00019893427,0.47616762,0.0006753986],"about_ca_topic_score_codex":0.0018227533,"about_ca_topic_score_gemma":0.000073673844,"teacher_disagreement_score":0.46399245,"about_ca_system_score_codex":0.00019961051,"about_ca_system_score_gemma":0.0007349131,"threshold_uncertainty_score":0.9960681},"labels":[],"label_agreement":null},{"id":"W4281638593","doi":"10.1200/jco.2022.40.16_suppl.tps3166","title":"Rationale and design of phase 1 FTIH study of FOXP3 antisense oligonucleotide AZD8701 in patients with selected advanced solid tumors.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"FOXP3; Medicine; Cancer research; Immune system; Immunosuppression; Context (archaeology); Gene knockdown; Immunology; Oncology; Biology; Cell culture","score_opus":0.06591170919294542,"score_gpt":0.424148845111125,"score_spread":0.3582371359181796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281638593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99862546,0.0001589525,0.00006517782,0.00028518657,0.00016544874,0.00066124805,0.0000082207325,0.0000023826926,0.00002792926],"genre_scores_gemma":[0.99799466,0.00009205505,0.0015596508,0.00026731368,0.000044680048,0.0000070477104,0.0000033583206,0.0000104953315,0.00002071297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968195,0.0006197159,0.0019424534,0.00012858576,0.00037100352,0.00011871847],"domain_scores_gemma":[0.99665457,0.0009238142,0.0017995363,0.00010569253,0.00043017344,0.0000862043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018251829,0.0000877424,0.0011100523,0.00017133245,0.000032369684,0.0000016056107,0.00008078665,0.000055029574,0.00009184116],"category_scores_gemma":[0.00071927963,0.00006481201,0.000084684114,0.00032679763,0.00013469647,0.00006489385,0.000032555115,0.00042456377,1.1435746e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30230996,0.04255873,0.57214606,0.000044508815,0.00088705897,0.00037441732,0.0011012121,0.0006314758,0.009649796,0.0000034719228,0.00065128837,0.06964201],"study_design_scores_gemma":[0.09764251,0.13295673,0.7673333,0.00006235943,0.00016021138,0.00006974474,0.0007008084,0.00014560706,0.0003742066,0.000014573094,0.00047495187,0.000064937645],"about_ca_topic_score_codex":0.000018893015,"about_ca_topic_score_gemma":0.000025603249,"teacher_disagreement_score":0.20466746,"about_ca_system_score_codex":0.000086930384,"about_ca_system_score_gemma":0.0009489789,"threshold_uncertainty_score":0.2642957},"labels":[],"label_agreement":null},{"id":"W4281654209","doi":"10.1200/jco.2022.40.16_suppl.2508","title":"Major adverse cardiac events (MACE) with immune checkpoint inhibitor (ICI)-based therapies for cancer: A pooled analysis of investigational clinical trials sponsored by the National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP) in the United States and Canada.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Mace; Medicine; Internal medicine; Myocarditis; Adverse effect; Oncology; Clinical trial; Cancer; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.18865839977323307,"score_gpt":0.5038805220845376,"score_spread":0.31522212231130453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281654209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93964255,0.007169852,0.000016289774,0.04942283,0.0009562522,0.0021266304,0.0006552089,0.0000046595505,0.000005732296],"genre_scores_gemma":[0.9820986,0.006295198,0.00034780434,0.008893891,0.0005994062,0.0014090489,0.0002957741,0.0000195864,0.0000407085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9895096,0.004994271,0.0035608248,0.00027042322,0.001436056,0.00022882194],"domain_scores_gemma":[0.9879962,0.006624839,0.0037267199,0.00016760972,0.001360586,0.00012402351],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.033859517,0.00020803692,0.0018137334,0.00030729416,0.00019015987,0.00001161049,0.0002706542,0.00016194384,0.00020976813],"category_scores_gemma":[0.0026777147,0.00010916032,0.00076801935,0.0010939403,0.00065526785,0.00008558569,0.000025578553,0.00077060563,2.7007262e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17801522,0.004121037,0.4873772,0.00007846124,0.04100107,0.000017590426,0.0023410995,0.020335967,0.0033136657,0.000030339896,0.014845645,0.24852273],"study_design_scores_gemma":[0.03502738,0.005808579,0.7809939,0.00013164105,0.0062256926,0.000007940727,0.0015664345,0.008411508,0.00027865698,0.000085898224,0.16127251,0.00018990503],"about_ca_topic_score_codex":0.14875673,"about_ca_topic_score_gemma":0.2025632,"teacher_disagreement_score":0.29361665,"about_ca_system_score_codex":0.0009727267,"about_ca_system_score_gemma":0.017942289,"threshold_uncertainty_score":0.9948449},"labels":[],"label_agreement":null},{"id":"W4281671660","doi":"10.3389/fimmu.2022.939789","title":"Editorial: Cancer Immunotherapies: From Efficacy to Resistance Mechanisms","year":2022,"lang":"en","type":"editorial","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Diamantina Institute, University of Queensland; Agence Nationale de la Recherche; Australia and New Zealand Sarcoma Association; Cancer Australia; Cancer Council NSW; U.S. Department of Defense","keywords":"Immunotherapy; Medicine; Cancer immunotherapy; Cancer; Immunology; Immunity; Oncology; Immune system; Internal medicine","score_opus":0.00676104315231786,"score_gpt":0.26614970453322173,"score_spread":0.2593886613809039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281671660","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027856225,0.06436286,0.0006353089,0.00113735,0.9305108,0.0012817977,0.0012420389,0.00017726197,0.00037398565],"genre_scores_gemma":[0.000028474366,0.01814216,0.0054526576,0.00061499054,0.96229035,0.0012209807,0.0014621924,0.00027713366,0.01051109],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99499017,0.00035888667,0.0010879892,0.0013615321,0.0012298076,0.00097161584],"domain_scores_gemma":[0.99710196,0.0005435686,0.00047263622,0.0015198356,0.00023760828,0.00012441215],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0006641409,0.0007821038,0.0018896741,0.00089268875,0.00022919866,0.00006079573,0.0011127739,0.001940767,0.0026022715],"category_scores_gemma":[0.00057536096,0.0008223797,0.00045452794,0.00093777536,0.00025663787,0.0000931469,0.00031583488,0.0027833823,0.00003663226],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027128626,0.0002475381,0.000038478815,0.0000641239,0.0020667047,0.00005512116,0.0011141908,0.000004272641,0.0054314816,0.000013084911,0.95739484,0.006441563],"study_design_scores_gemma":[0.008667632,0.0006430472,0.00025148463,0.0005812052,0.00021466427,0.0000011355465,0.0006352108,0.0000010440713,0.0003915319,0.0006276886,0.98722124,0.00076408766],"about_ca_topic_score_codex":0.0051192897,"about_ca_topic_score_gemma":0.0006795529,"teacher_disagreement_score":0.046220697,"about_ca_system_score_codex":0.0032150578,"about_ca_system_score_gemma":0.0018011075,"threshold_uncertainty_score":0.99951726},"labels":[],"label_agreement":null},{"id":"W4281673499","doi":"10.1200/jco.2022.40.16_suppl.e21506","title":"Literature on target therapy of malignant melanoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fraser Health; Providence Health Care","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Dacarbazine; Oncology; Internal medicine; Combination therapy; Melanoma; Carboplatin; Bevacizumab; Dysgeusia; Mucosal melanoma; Immunotherapy; Surgery; Chemotherapy; Cancer; Adverse effect; Cancer research; Cisplatin","score_opus":0.0987984687595069,"score_gpt":0.4408057179688073,"score_spread":0.34200724920930037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281673499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710603,0.007528213,0.000014163938,0.014757296,0.0024276474,0.00016114817,0.00001604339,0.0000050747935,0.00403011],"genre_scores_gemma":[0.98260057,0.0046858047,0.0010984807,0.010063725,0.0008154171,0.0000039706947,0.0000047049903,0.000013475202,0.0007138442],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971956,0.0004993437,0.0016584172,0.00011561537,0.00039852923,0.00013247019],"domain_scores_gemma":[0.997239,0.0008111788,0.0014627267,0.00017319746,0.000193906,0.000120007164],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00329552,0.00009128035,0.00097161176,0.00013364146,0.00004238042,0.000003433141,0.0001722796,0.000163355,0.001329776],"category_scores_gemma":[0.00035169607,0.000057519796,0.00068746816,0.0002060169,0.0001104968,0.000033586395,0.000030399378,0.0009742606,0.0000022217976],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21586242,0.007791506,0.040040094,0.000042091615,0.0020677382,0.0024871563,0.0008980751,0.000047470407,0.015588191,0.00047751944,0.067125514,0.6475722],"study_design_scores_gemma":[0.012863944,0.060390227,0.08033848,0.00008609171,0.000048389084,0.00072987925,0.00015479828,0.000011340404,0.0012776959,0.0004689821,0.84356004,0.00007012647],"about_ca_topic_score_codex":0.0000051532297,"about_ca_topic_score_gemma":8.5211553e-7,"teacher_disagreement_score":0.77643454,"about_ca_system_score_codex":0.00010670771,"about_ca_system_score_gemma":0.00096059294,"threshold_uncertainty_score":0.9995831},"labels":[],"label_agreement":null},{"id":"W4281704010","doi":"10.3389/fonc.2022.877014","title":"Cutaneous Breast Cancer Metastasis Is Effectively Treated With Intralesional Interleukin-2 and Imiquimod: A Case Report and Brief Literature Review","year":2022,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of Toronto","funders":"","keywords":"Medicine; Imiquimod; Breast cancer; Metastasis; Cancer; Dermatology; Oncology; Disease; Internal medicine; Immunotherapy","score_opus":0.008243246394448704,"score_gpt":0.286923045192951,"score_spread":0.2786797987985023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281704010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8387388,0.1508773,0.000047873287,0.0083246995,0.00033297125,0.0010352378,0.00036531527,0.000030173725,0.00024764752],"genre_scores_gemma":[0.89452696,0.08619125,0.0030863245,0.01393364,0.0001284277,0.00076250534,0.0001323333,0.000060563034,0.0011780213],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9987264,0.00021821387,0.0003026992,0.0003859128,0.00014363612,0.00022311143],"domain_scores_gemma":[0.999449,0.000057218054,0.00015477331,0.00017722335,0.00006434683,0.00009741902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003254695,0.00019216265,0.0006238354,0.00017986074,0.000108619126,0.000012479867,0.00004993308,0.00008595967,0.00025451524],"category_scores_gemma":[0.000019210254,0.00014723388,0.0000618367,0.00035036064,0.00021446141,0.000055811728,0.0000678978,0.0003886336,1.0981621e-7],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019850435,0.00032221113,0.11637555,0.001193814,0.0010751376,0.40771016,0.0020418693,0.000001273773,0.00040719812,0.000004305661,0.07456893,0.3764491],"study_design_scores_gemma":[0.003913305,0.0020470324,0.010406642,0.0013437865,0.00043069085,0.9088885,0.00040620362,0.00005035628,0.00008606619,0.000016108981,0.07221162,0.00019964179],"about_ca_topic_score_codex":0.00055679365,"about_ca_topic_score_gemma":0.00017687786,"teacher_disagreement_score":0.5011784,"about_ca_system_score_codex":0.0006472212,"about_ca_system_score_gemma":0.0002526397,"threshold_uncertainty_score":0.60040236},"labels":[],"label_agreement":null},{"id":"W4281708993","doi":"10.1200/jco.2022.40.16_suppl.605","title":"Intratumoral (IT) INT230-6 can cause tumor necrosis in vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group; University of Ottawa; Canadian Electricity Association; Ontario Institute for Cancer Research; Ottawa Hospital","funders":"","keywords":"Medicine; Breast cancer; Clinical endpoint; Cancer; In vivo; Phases of clinical research; Oncology; Clinical trial; Internal medicine; Pathology; Surgery","score_opus":0.10876867856335491,"score_gpt":0.44258848703200215,"score_spread":0.33381980846864723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281708993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99078745,0.00017044411,9.219362e-7,0.005609885,0.00077524123,0.0023812351,0.000082212195,0.0000052003284,0.0001873914],"genre_scores_gemma":[0.9984608,0.00015784879,0.00004427144,0.0008789726,0.00019022063,0.00012219376,0.0000032801822,0.000020147358,0.00012225211],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98668617,0.0053603584,0.006388175,0.00033860368,0.0008782813,0.00034841202],"domain_scores_gemma":[0.99053425,0.0045281365,0.003863716,0.00044196998,0.00033037152,0.00030157214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023000807,0.00023923769,0.0033764425,0.0004512677,0.000103075545,0.000007808196,0.00049468974,0.00014423546,0.000266112],"category_scores_gemma":[0.003845211,0.0001591579,0.0006751718,0.0008713214,0.00072309765,0.00010542094,0.00030547963,0.002108506,1.7413971e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85202533,0.03186735,0.09364238,0.0000240727,0.0010712591,0.0027498095,0.00821705,0.00009032082,0.0003658442,0.0000019295796,0.0014429776,0.008501665],"study_design_scores_gemma":[0.6045098,0.13225569,0.25210378,0.00013961931,0.0007098918,0.0004904481,0.008553062,0.00012388584,0.00007882657,0.000027978971,0.0008701698,0.0001369047],"about_ca_topic_score_codex":0.014335378,"about_ca_topic_score_gemma":0.009168946,"teacher_disagreement_score":0.2475156,"about_ca_system_score_codex":0.00076451775,"about_ca_system_score_gemma":0.0064879567,"threshold_uncertainty_score":0.9991443},"labels":[],"label_agreement":null},{"id":"W4281709253","doi":"10.1200/jco.2022.40.16_suppl.tps3154","title":"Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody–drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Tolerability; Cancer research; Brentuximab vedotin; Antibody-drug conjugate; Pharmacology; Oncology; Internal medicine; Antibody; Immunology; Adverse effect; Monoclonal antibody; Immunohistochemistry","score_opus":0.06244149653943871,"score_gpt":0.46314520347122873,"score_spread":0.40070370693179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281709253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951405,0.00010689726,0.000002594652,0.0019999682,0.0008532521,0.0018045611,0.00002683891,0.000009806294,0.000055563858],"genre_scores_gemma":[0.9973391,0.000016884966,0.0011030257,0.0011728348,0.00021686974,0.00006268111,0.000023606075,0.000022849248,0.00004209612],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9941315,0.0008220112,0.0036021639,0.0003023359,0.0008522538,0.00028973777],"domain_scores_gemma":[0.99587214,0.0008907153,0.0023598876,0.00019649307,0.00041868302,0.00026208884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003758961,0.00019059966,0.001773963,0.00046702137,0.00005145769,0.0000068120844,0.00024637635,0.000096292504,0.000200836],"category_scores_gemma":[0.0014804819,0.00014448157,0.00019208727,0.0007915469,0.0002445595,0.00011838024,0.000094754236,0.0010584509,9.692883e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6274416,0.058800478,0.29233775,0.000020278554,0.00032694123,0.00028008636,0.00075629656,0.0002161311,0.0006993861,0.0000031160055,0.00043507552,0.01868289],"study_design_scores_gemma":[0.4028376,0.12439208,0.4689035,0.00016341425,0.00009409542,0.000024364652,0.0004883093,0.00007675625,0.000056063902,0.000012062398,0.0028317124,0.000120027726],"about_ca_topic_score_codex":0.00008296835,"about_ca_topic_score_gemma":0.0002321238,"teacher_disagreement_score":0.22460398,"about_ca_system_score_codex":0.00033694232,"about_ca_system_score_gemma":0.0021609268,"threshold_uncertainty_score":0.58917874},"labels":[],"label_agreement":null},{"id":"W4281710573","doi":"10.1200/jco.2022.40.16_suppl.3107","title":"First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer: Safety, activity, pharmacokinetic (PK), and pharmacodynamic (PD) results.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adverse effect; Pharmacodynamics; Pharmacokinetics; Melanoma; Immune system; Discontinuation; Cancer; Pharmacology; Oncology; Toxicity; Internal medicine; Immunology; Cancer research","score_opus":0.03137461808433421,"score_gpt":0.40204014508579133,"score_spread":0.3706655270014571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281710573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937939,0.0005670941,0.0000018165046,0.0027262205,0.001192308,0.001482748,0.00011164243,0.0000076069723,0.00011663184],"genre_scores_gemma":[0.99828476,0.0005801541,0.000050758863,0.0006951056,0.00025552104,0.000057619625,0.000006046862,0.00003280846,0.000037229685],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9949493,0.0010208002,0.0025209081,0.00041051462,0.0007495508,0.00034891933],"domain_scores_gemma":[0.9958295,0.0010260957,0.002401897,0.00024045349,0.00030869636,0.00019334779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023058786,0.00026746112,0.0014493796,0.00028668277,0.00018544678,0.0000075468297,0.00029277048,0.00012789013,0.00006786162],"category_scores_gemma":[0.0002985902,0.00018447528,0.00024064674,0.0007646817,0.0002936547,0.00016885664,0.00022289372,0.0017948188,1.7392593e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43654138,0.033802524,0.3716244,0.00008307661,0.0008933564,0.00049075077,0.0016584458,0.0011593251,0.008070757,0.000002030354,0.0009256347,0.14474832],"study_design_scores_gemma":[0.21493642,0.06501133,0.71195537,0.00029623738,0.00047983925,0.00004540622,0.000540047,0.00025496128,0.0023121685,0.000016081973,0.0039311233,0.00022103483],"about_ca_topic_score_codex":0.0009405427,"about_ca_topic_score_gemma":0.0023441778,"teacher_disagreement_score":0.34033093,"about_ca_system_score_codex":0.0010953987,"about_ca_system_score_gemma":0.0011144583,"threshold_uncertainty_score":0.7797694},"labels":[],"label_agreement":null},{"id":"W4281722284","doi":"10.1200/jco.2022.40.16_suppl.2522","title":"The association of pre-existing autoimmune disease and immune-related adverse events secondary to immune checkpoint inhibition therapy in a UK multicenter cohort.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cohort; Internal medicine; Adverse effect; Retrospective cohort study; Cohort study; Cancer; Oncology; Disease; Propensity score matching","score_opus":0.03444418082719999,"score_gpt":0.38759659642076455,"score_spread":0.3531524155935646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281722284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876135,0.002729508,0.0000066138305,0.007734745,0.001015408,0.0005767683,0.000008549289,0.0000052447404,0.00030964104],"genre_scores_gemma":[0.99676734,0.0018267647,0.000113667134,0.0007439544,0.00008769728,0.000024461742,0.000008595199,0.0000131446,0.00041438843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952616,0.0008637853,0.0031261141,0.00014715536,0.0004067887,0.00019452884],"domain_scores_gemma":[0.9954712,0.0013191556,0.0027454498,0.00016707966,0.00017489576,0.00012224108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009505636,0.00011073128,0.00078947295,0.00012751715,0.000126819,0.000003958045,0.00011455909,0.00013282432,0.00019997382],"category_scores_gemma":[0.0021549396,0.00007833589,0.00046729465,0.00022102204,0.00009190534,0.00007035084,0.00010075934,0.0010158869,0.0000011145111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12990005,0.0026902345,0.6848706,0.00004260374,0.0018677777,0.00020034201,0.0015158539,0.0001265366,0.035777375,0.000017030863,0.00023851854,0.14275305],"study_design_scores_gemma":[0.018405516,0.0046511274,0.9682113,0.00015381137,0.00013253326,0.000034709974,0.00035426905,0.00016879357,0.00023110282,0.00014164804,0.007442411,0.00007281305],"about_ca_topic_score_codex":0.00011086592,"about_ca_topic_score_gemma":0.000028128434,"teacher_disagreement_score":0.28334063,"about_ca_system_score_codex":0.000606136,"about_ca_system_score_gemma":0.00083144987,"threshold_uncertainty_score":0.44135794},"labels":[],"label_agreement":null},{"id":"W4281752808","doi":"10.3390/jpm12060958","title":"Immune Cell Networks Uncover Candidate Biomarkers of Melanoma Immunotherapy Response","year":2022,"lang":"en","type":"article","venue":"Journal of Personalized Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Directorate for Biological Sciences; Queen's University; Queen's University Belfast","keywords":"Nivolumab; Immune system; Immunotherapy; Context (archaeology); Immunology; Melanoma; Medicine; Tumor microenvironment; Immune checkpoint; Oncology; Biology; Bioinformatics; Cancer research","score_opus":0.011655197165084464,"score_gpt":0.272814315552969,"score_spread":0.2611591183878845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281752808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9128722,0.07602173,0.0005207789,0.0076067285,0.00155044,0.00039661647,0.000027975097,0.000017204577,0.0009863566],"genre_scores_gemma":[0.98957986,0.0041697533,0.00041096748,0.0020247046,0.00041397114,0.000011668965,0.000021812448,0.000057558125,0.0033097158],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99646205,0.0005047726,0.0013303183,0.0002053616,0.0011500448,0.0003474558],"domain_scores_gemma":[0.9974059,0.00038118832,0.0013473781,0.00037907693,0.00029735445,0.00018909709],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003944887,0.00027184756,0.0010694877,0.00056993566,0.00016875814,0.000006866349,0.0003218323,0.00009036908,0.0068136794],"category_scores_gemma":[0.00011945967,0.00019919225,0.00056053925,0.00077462115,0.00044044215,0.000089446316,0.00005400371,0.0005999806,0.0000012411776],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24093196,0.00044767334,0.003132603,0.000097347496,0.0017413837,0.00055102765,0.0031356837,0.00008381,0.72008836,0.000015829572,0.0220256,0.007748739],"study_design_scores_gemma":[0.119467616,0.02984737,0.054941878,0.0012941597,0.0014797633,0.0071999347,0.014381548,0.00056635524,0.023328925,0.00008426805,0.74667025,0.0007379237],"about_ca_topic_score_codex":0.0002916942,"about_ca_topic_score_gemma":0.0000028200539,"teacher_disagreement_score":0.72464466,"about_ca_system_score_codex":0.0004871502,"about_ca_system_score_gemma":0.00067427533,"threshold_uncertainty_score":0.99409425},"labels":[],"label_agreement":null},{"id":"W4281769949","doi":"10.1200/jco.2022.40.16_suppl.2500","title":"Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Université Laval; Princess Margaret Cancer Centre; Royal Victoria Hospital; University of Toronto; University Health Network","funders":"","keywords":"Pembrolizumab; Medicine; Melanoma; Toxicity; Internal medicine; Combination therapy; Renal cell carcinoma; Interleukin 2; Nivolumab; Oncology; CD8; Pharmacology; Cytokine; Immunotherapy; Cancer research; Cancer; Immunology; Immune system","score_opus":0.032399570157146854,"score_gpt":0.38733640719850715,"score_spread":0.3549368370413603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281769949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962082,0.00028304354,0.000025066778,0.002720353,0.00018439238,0.0002863199,0.0000026897983,0.000003776223,0.00028614895],"genre_scores_gemma":[0.99713343,0.00034315154,0.0006582753,0.0017046586,0.00006548591,0.000014989397,0.0000049286214,0.000015024176,0.000060062892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771917,0.00031832996,0.0012879798,0.00016461822,0.00033706962,0.00017286194],"domain_scores_gemma":[0.9983345,0.0003442102,0.0009926915,0.00011128821,0.00011660801,0.00010069536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013363451,0.00010801977,0.0008371818,0.00018538105,0.000035536,0.0000058780615,0.000090799884,0.00008757711,0.000101726415],"category_scores_gemma":[0.0001392703,0.00007497365,0.00007619644,0.00024576017,0.00014488371,0.0001139648,0.000024142371,0.0007838976,3.88978e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1885832,0.0034446642,0.6013199,0.000017417744,0.00011591591,0.0004613269,0.00024408459,0.00016550234,0.00014925783,0.000011300807,0.00021126497,0.20527616],"study_design_scores_gemma":[0.081621125,0.05248317,0.8571415,0.00012413865,0.000031072017,0.0002565305,0.00026035792,0.00011626812,0.000036866415,0.00008226011,0.0077579794,0.00008871392],"about_ca_topic_score_codex":0.00003867355,"about_ca_topic_score_gemma":0.00018525282,"teacher_disagreement_score":0.25582162,"about_ca_system_score_codex":0.00036888942,"about_ca_system_score_gemma":0.0007795475,"threshold_uncertainty_score":0.34056884},"labels":[],"label_agreement":null},{"id":"W4281772053","doi":"10.1053/j.semnuclmed.2022.04.010","title":"FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients","year":2022,"lang":"en","type":"review","venue":"Seminars in Nuclear Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Lung cancer; Pneumonitis; Immunotherapy; Response Evaluation Criteria in Solid Tumors; Immune system; Biomarker; Cancer; Radiation therapy; Oncology; Internal medicine; Chemotherapy; Progressive disease; Lung; Immunology","score_opus":0.046140019474901144,"score_gpt":0.40229785046732375,"score_spread":0.3561578309924226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281772053","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019693373,0.97461903,2.186277e-7,0.00032621657,0.0008074822,0.0041281064,0.00008831478,0.000017704328,0.00031952802],"genre_scores_gemma":[0.0008116503,0.99728113,0.000052154144,0.00030866213,0.00010756443,0.000802036,0.00026047588,0.00013642429,0.00023989334],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961422,0.00070817687,0.0013016745,0.0004899893,0.001018313,0.00033963023],"domain_scores_gemma":[0.9979404,0.0006825256,0.0006504813,0.0005267936,0.000141318,0.000058436075],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005298915,0.0003944963,0.001979334,0.0009321211,0.000052662195,0.000003874492,0.00027682155,0.000067816894,0.004324083],"category_scores_gemma":[0.0007424025,0.0003174861,0.0003556056,0.0009872846,0.0001786485,0.000046187088,0.00005013697,0.0005077543,0.0000014187286],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010670696,0.00032063952,0.0002491372,0.008295856,0.0002818322,0.000050519408,0.00085116713,0.0000020429209,0.00003721592,0.0000029631788,0.0058224457,0.9734155],"study_design_scores_gemma":[0.012474666,0.0016689061,0.00068105414,0.060691107,0.0009435391,0.000065537264,0.00030133023,0.00017747449,0.0000017722219,0.000008378836,0.9227321,0.00025413095],"about_ca_topic_score_codex":0.00036024055,"about_ca_topic_score_gemma":0.000029397383,"teacher_disagreement_score":0.97316134,"about_ca_system_score_codex":0.00227138,"about_ca_system_score_gemma":0.0008350315,"threshold_uncertainty_score":0.9999277},"labels":[],"label_agreement":null},{"id":"W4281773798","doi":"10.1200/jco.2022.40.16_suppl.2528","title":"Customized autoantibodies (autoAbs) profiling to predict and monitor immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICI).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Rash; Gastroenterology; Adverse effect; Myositis; Pneumonitis; Autoantibody; Optic neuritis; Colitis; Immunology; Antibody","score_opus":0.03472342453510978,"score_gpt":0.3754870551264373,"score_spread":0.3407636305913275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281773798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908259,0.001142119,0.000004957647,0.0026220852,0.004276748,0.00077054376,0.000008520128,0.00002199001,0.00032712118],"genre_scores_gemma":[0.99712026,0.00057619304,0.001126943,0.00052098685,0.0003013446,0.000023615466,0.000009259895,0.00003271024,0.00028867275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99289435,0.00088380993,0.0049386625,0.00030285647,0.00061141275,0.0003689187],"domain_scores_gemma":[0.99609685,0.00080048834,0.002360518,0.00022578679,0.00025257564,0.00026377596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007885218,0.00022424647,0.0017282433,0.00043439242,0.00014168028,0.0000058086553,0.00022400147,0.00029390867,0.00015980474],"category_scores_gemma":[0.0028312735,0.00018236939,0.0007021126,0.00042068257,0.00014719053,0.00015736985,0.00027216514,0.001689815,0.0000058548426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06895663,0.0027688702,0.8294852,0.000070635484,0.000915354,0.00025236953,0.001042023,0.00019273747,0.009872629,0.0000040707355,0.0003861901,0.08605332],"study_design_scores_gemma":[0.04119051,0.011685669,0.9394366,0.0004113039,0.00021613672,0.00010263168,0.00087415776,0.0002243478,0.00075728475,0.00004086662,0.0048740706,0.00018640424],"about_ca_topic_score_codex":0.000106726606,"about_ca_topic_score_gemma":0.000009290124,"teacher_disagreement_score":0.10995145,"about_ca_system_score_codex":0.0006944151,"about_ca_system_score_gemma":0.0008486634,"threshold_uncertainty_score":0.7436808},"labels":[],"label_agreement":null},{"id":"W4281782152","doi":"10.1200/jco.2022.40.16_suppl.2558","title":"Assessment of a 4-chemokine signature in prediction of T-cell inflammation and response to immune checkpoint inhibition across tumor types.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Canada's Michael Smith Genome Sciences Centre; McGill University Health Centre","funders":"Terry Fox Research Institute","keywords":"CCL5; CXCL9; Chemokine; Medicine; TIGIT; Immune checkpoint; Immunology; Cancer research; T cell; CXCL10; Immune system; Biology; Immunotherapy; IL-2 receptor","score_opus":0.041281778992316984,"score_gpt":0.4216655925978812,"score_spread":0.3803838136055642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281782152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99551946,0.00028947004,0.00005019968,0.0033889292,0.0003608544,0.00023415942,0.000018360884,0.000002450819,0.00013613494],"genre_scores_gemma":[0.99851954,0.00015070087,0.0008816663,0.0002546094,0.00012414754,0.000006898413,0.0000050797835,0.0000067201654,0.0000506135],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9969764,0.00046135634,0.0020695666,0.00009865576,0.00030012924,0.00009388771],"domain_scores_gemma":[0.9975065,0.00057856727,0.0015379484,0.00009910339,0.00021047272,0.00006739975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007112699,0.00006520056,0.0006727946,0.0001565873,0.000022842456,0.0000020440239,0.000050611143,0.000118767646,0.00009546793],"category_scores_gemma":[0.0008123487,0.000053706608,0.00017861434,0.00024035343,0.00008490198,0.000055116434,0.000061533705,0.0006350142,1.4835732e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059325427,0.0008523939,0.023353066,0.00006288589,0.00007896247,0.000080953025,0.00056224084,0.00010968662,0.9019037,0.000003499794,0.000094199175,0.013572996],"study_design_scores_gemma":[0.014022483,0.018463098,0.9102717,0.00014394677,0.00006708542,0.00016853478,0.0006396487,0.00015891812,0.050985646,0.00004434667,0.004990254,0.00004431759],"about_ca_topic_score_codex":0.000024307385,"about_ca_topic_score_gemma":0.000013149822,"teacher_disagreement_score":0.88691866,"about_ca_system_score_codex":0.0002896558,"about_ca_system_score_gemma":0.0007637951,"threshold_uncertainty_score":0.2758856},"labels":[],"label_agreement":null},{"id":"W4281787542","doi":"10.1200/jco.2022.40.16_suppl.9573","title":"SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Adjuvant; Melanoma; Internal medicine; Clinical endpoint; Adjuvant therapy; Concomitant; Oncology; Radiation therapy; Clinical trial; Surgery; Cancer; Gastroenterology; Immunotherapy; Cancer research","score_opus":0.14525947719671414,"score_gpt":0.460658767907029,"score_spread":0.3153992907103148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281787542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851792,0.0030147408,0.000031447107,0.007390954,0.0026663386,0.0006852988,0.000017003325,0.00000853722,0.0010064915],"genre_scores_gemma":[0.99356484,0.0017872098,0.0009990578,0.0020015182,0.0012321825,0.000021646765,0.000006443331,0.000023693949,0.00036338152],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962027,0.00059975724,0.0023377778,0.00019417293,0.0004352237,0.00023037898],"domain_scores_gemma":[0.9945608,0.0028249228,0.0019044775,0.00018937784,0.00032865518,0.00019179516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004848061,0.00012794611,0.0014535644,0.00015681701,0.00008844398,0.0000063388175,0.00017975889,0.00022568824,0.0005375535],"category_scores_gemma":[0.001992893,0.000094468865,0.0006867518,0.0001660422,0.00027676672,0.00005475384,0.000058489823,0.0007018497,6.8708795e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6494374,0.0048299814,0.0007668402,0.00001826317,0.0006582504,0.00008776177,0.00013488565,0.0000010804783,0.007189239,0.00003702517,0.004983394,0.33185586],"study_design_scores_gemma":[0.3547659,0.32582995,0.012495019,0.00003726185,0.00025449082,0.00059580384,0.00036881233,0.000039879378,0.0008492836,0.00061898236,0.30403492,0.00010969637],"about_ca_topic_score_codex":0.00004757253,"about_ca_topic_score_gemma":0.00002592689,"teacher_disagreement_score":0.33174616,"about_ca_system_score_codex":0.00020640033,"about_ca_system_score_gemma":0.0021480354,"threshold_uncertainty_score":0.58858335},"labels":[],"label_agreement":null},{"id":"W4281829220","doi":"10.1093/neuonc/noac079.301","title":"IMMU-08. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: efficacy, safety, biomarker, and pharmacokinetic results from Checkmate 908","year":2022,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Oncology; Cancer; Immunotherapy","score_opus":0.01715287258485537,"score_gpt":0.27390931060693846,"score_spread":0.2567564380220831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281829220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942411,0.0006646889,0.000007034757,0.0020239532,0.00056720636,0.0016072838,0.00038718636,0.000112594156,0.0003889114],"genre_scores_gemma":[0.9958575,0.0011302729,0.0004302714,0.0016970992,0.00014653984,0.0001751886,0.0003044022,0.00009321297,0.00016554941],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99669874,0.00041875837,0.00076533295,0.00091714785,0.000571376,0.00062865735],"domain_scores_gemma":[0.998199,0.0005867134,0.000433783,0.00050223904,0.00008394596,0.00019430596],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003573737,0.0004245378,0.00083035795,0.00038524385,0.00024124258,0.000023368595,0.00026711408,0.00013839475,0.0003464646],"category_scores_gemma":[0.00007193552,0.00031043767,0.00007273186,0.0010353648,0.00029240586,0.00009932495,0.000220695,0.00059829827,0.00000881997],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59846896,0.004771798,0.23224972,0.00019680827,0.0005913442,0.0020961878,0.003874646,0.00011604236,0.098503664,0.0000043553428,0.006883099,0.052243363],"study_design_scores_gemma":[0.18853426,0.018202689,0.71719337,0.00009556464,0.0006756726,0.0003409809,0.00052329997,0.00029658843,0.0024177863,0.0000071154464,0.071010605,0.00070207677],"about_ca_topic_score_codex":0.0009579636,"about_ca_topic_score_gemma":0.00049552135,"teacher_disagreement_score":0.48494366,"about_ca_system_score_codex":0.000556895,"about_ca_system_score_gemma":0.00069605623,"threshold_uncertainty_score":0.9999348},"labels":[],"label_agreement":null},{"id":"W4281835697","doi":"10.1200/jco.2022.40.16_suppl.tps6603","title":"A randomized study to measure and enhance the health-related quality of life in patients with cancer receiving immune checkpoint modulators (ME-Q).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Psychological intervention; Quality of life (healthcare); Usability; Randomized controlled trial; Adverse effect; Telemedicine; Regret; Clinical trial; Health care; Internal medicine; Nursing","score_opus":0.08657224252246375,"score_gpt":0.44483245686024236,"score_spread":0.3582602143377786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281835697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981402,0.0031479567,0.000017410095,0.013526737,0.00061440276,0.001241763,0.000003490139,0.000003075072,0.00004317307],"genre_scores_gemma":[0.9973675,0.00034430632,0.00014203745,0.0019982026,0.000060587114,0.00003552831,5.797896e-7,0.000011111891,0.000040167182],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9910567,0.0037763037,0.004250955,0.00017143055,0.00057575514,0.00016889835],"domain_scores_gemma":[0.9940636,0.001973678,0.0033527361,0.00019222176,0.0002711718,0.00014657943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0238493,0.000111084126,0.0024504396,0.00009086666,0.0000760144,0.00000348997,0.0001461496,0.00007060245,0.00012592395],"category_scores_gemma":[0.0036633394,0.000060761788,0.00029120778,0.00034150126,0.0001925984,0.00004508084,0.00007480913,0.0009449976,1.6919086e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6009515,0.0025034752,0.37243113,0.000021544953,0.00083257805,0.000005631485,0.0032727954,0.000073280724,0.000048320588,0.0000023066236,0.00007926066,0.01977816],"study_design_scores_gemma":[0.24559589,0.012629983,0.73992246,0.0001093991,0.00008978352,0.0000047615467,0.0013140744,0.000013181259,0.000008125764,0.00002097428,0.00023742065,0.000053971708],"about_ca_topic_score_codex":0.0023694043,"about_ca_topic_score_gemma":0.0007411508,"teacher_disagreement_score":0.3674913,"about_ca_system_score_codex":0.00029425483,"about_ca_system_score_gemma":0.0016414843,"threshold_uncertainty_score":0.8265739},"labels":[],"label_agreement":null},{"id":"W4281868030","doi":"10.1200/jco.2022.40.16_suppl.9067","title":"Effect of bone metastasis on outcomes in the CCTG BR.34 phase II randomized trial of dual immune checkpoint inhibitor (ICI) treatment with or without chemotherapy in high-risk, stage IVA/B NSCLC.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Durvalumab; Nivolumab; Oncology; Chemotherapy; Lung cancer; Population; Bone metastasis; Gastroenterology; Metastasis; Cancer; Immunotherapy","score_opus":0.06106345008876598,"score_gpt":0.44348192977934575,"score_spread":0.3824184796905798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281868030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908288,0.0005954132,0.000010458386,0.0051401304,0.00074477063,0.0025486564,0.000037647314,0.0000047503113,0.00008935232],"genre_scores_gemma":[0.99692917,0.0014850918,0.00030949689,0.00055261864,0.0002840147,0.00012993724,0.0000060714265,0.00002692804,0.000276701],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98826545,0.0057826797,0.0046713944,0.00024205682,0.00077862677,0.00025981254],"domain_scores_gemma":[0.98470783,0.010243916,0.004489899,0.00036558797,0.00009769055,0.00009509081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023719164,0.0002949665,0.0057030297,0.0003697976,0.00006440323,0.0000049221035,0.00019376542,0.00018641012,0.000391008],"category_scores_gemma":[0.0019374773,0.00012787407,0.0014560833,0.00040036073,0.0005185127,0.00005496128,0.000042449283,0.0010663114,4.0036443e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8788184,0.018420568,0.0030176449,0.000036805886,0.0022536237,0.00039471406,0.0010217484,0.000018347338,0.001650112,0.0000063550287,0.000050710816,0.094311],"study_design_scores_gemma":[0.67791885,0.3119946,0.0022990855,0.00010092527,0.0008085836,0.00007996931,0.00049027026,0.00002593792,0.0044006445,0.0000075663565,0.0017888552,0.00008470119],"about_ca_topic_score_codex":0.0009317266,"about_ca_topic_score_gemma":0.00026060053,"teacher_disagreement_score":0.29357404,"about_ca_system_score_codex":0.00045462867,"about_ca_system_score_gemma":0.001198725,"threshold_uncertainty_score":0.82206357},"labels":[],"label_agreement":null},{"id":"W4281922328","doi":"10.3390/curroncol29060334","title":"Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Head and neck squamous-cell carcinoma; Immunotherapy; Medicine; Biomarker; Immune checkpoint; Immune system; Cancer research; Head and neck cancer; Epigenomics; Cancer immunotherapy; Mass cytometry; Cancer; Computational biology; Bioinformatics; Oncology; Immunology; Internal medicine; Biology; DNA methylation; Gene expression","score_opus":0.08616609426532607,"score_gpt":0.3938095978415013,"score_spread":0.30764350357617526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281922328","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006666437,0.9830935,0.0000017973645,0.00032026297,0.0061633764,0.0033569662,0.00015390126,0.00003359532,0.00021017947],"genre_scores_gemma":[0.0004262702,0.99658287,0.00006146861,0.00003278968,0.0011071507,0.0010554648,0.00061681605,0.00008044069,0.000036731977],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968684,0.00026725585,0.001254786,0.0008401951,0.00020660149,0.00056281604],"domain_scores_gemma":[0.998463,0.00033033467,0.00058036606,0.00038702725,0.00004188249,0.00019741959],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00069208856,0.0006265012,0.0022963875,0.0005657168,0.00013750172,0.000022744003,0.0001595509,0.0004300211,0.00017142479],"category_scores_gemma":[0.000047492915,0.0005231774,0.0006402904,0.0004684367,0.00023257162,0.000046743593,0.00021965592,0.0010022906,0.0000025804413],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091889355,0.00062446564,0.0005253922,0.030786619,0.000073374285,0.000027562723,0.0002911279,8.012832e-9,0.000008560582,0.0000071607833,0.0021625145,0.96457434],"study_design_scores_gemma":[0.0076468666,0.0018488269,0.001057891,0.0022973905,0.00078350137,0.00025187255,0.00022344143,0.000006440479,0.000005726874,0.000009075584,0.98539764,0.00047131508],"about_ca_topic_score_codex":0.000060752598,"about_ca_topic_score_gemma":0.000047080306,"teacher_disagreement_score":0.9832351,"about_ca_system_score_codex":0.0011293245,"about_ca_system_score_gemma":0.001007366,"threshold_uncertainty_score":0.999722},"labels":[],"label_agreement":null},{"id":"W4281981040","doi":"10.1200/jco.2022.40.16_suppl.9542","title":"The prognostic impact of immune-related adverse events in real-world patients with metastatic melanoma treated with single-agent and combination immune checkpoint blockade.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Pembrolizumab; Adverse effect; Internal medicine; Oncology; Immune checkpoint; Blockade; Clinical endpoint; Proportional hazards model; Melanoma; Metastatic melanoma; Immunotherapy; Cancer; Clinical trial; Cancer research","score_opus":0.04547724419523528,"score_gpt":0.37675807960631336,"score_spread":0.33128083541107806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281981040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976799,0.0004969782,0.0000025143238,0.00078859925,0.00017545963,0.00065119384,0.000005858289,0.000004823647,0.00019468117],"genre_scores_gemma":[0.9993817,0.0002541404,0.00012385486,0.000039101713,0.000014752633,0.000014902218,0.0000149679045,0.000017765955,0.00013881212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995971,0.0007830663,0.0024634167,0.00014323667,0.0004402346,0.00019901062],"domain_scores_gemma":[0.9953185,0.0012857538,0.0028341794,0.00016773875,0.00028647282,0.0001074073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002967581,0.0001515564,0.0010097108,0.00021285558,0.00008781668,0.0000027579524,0.0001261496,0.00006555492,0.00008399564],"category_scores_gemma":[0.00047124628,0.00007742273,0.00033604118,0.00047688533,0.00025705932,0.00007341358,0.00004674936,0.00066830294,4.0103768e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060931124,0.0047717765,0.9160466,0.000021318401,0.001881744,0.00014598125,0.00022551157,0.0000991993,0.0007280399,0.0000052414284,0.000013654215,0.015129796],"study_design_scores_gemma":[0.03353511,0.05731311,0.9075719,0.00017267694,0.0005337829,0.00013727207,0.0002310307,0.00011209649,0.000098100645,0.00003793037,0.00017838187,0.000078615056],"about_ca_topic_score_codex":0.00041638818,"about_ca_topic_score_gemma":0.00018325225,"teacher_disagreement_score":0.052541334,"about_ca_system_score_codex":0.00056587736,"about_ca_system_score_gemma":0.00083240675,"threshold_uncertainty_score":0.31572074},"labels":[],"label_agreement":null},{"id":"W4282021936","doi":"10.1200/jco.2022.40.16_suppl.e12614","title":"A novel immune cell signature predicts pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer patients in the Q-CROC3 trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Chemotherapy; Oncology; Tumor-infiltrating lymphocytes; Breast cancer; Internal medicine; Stromal cell; FOXP3; Immune system; Cancer; Pathology; Immunology; Immunotherapy","score_opus":0.07438614511012666,"score_gpt":0.409740350759453,"score_spread":0.33535420564932633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282021936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9590714,0.00046590777,0.000012177151,0.037453357,0.0014842466,0.001265019,0.00010945236,0.0000051478,0.00013327808],"genre_scores_gemma":[0.97717106,0.0004171365,0.0003957403,0.021357603,0.00042196963,0.00009227583,0.0000052242535,0.000017545362,0.00012144062],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9939059,0.0023165436,0.0025410878,0.0002690597,0.0006398597,0.00032753794],"domain_scores_gemma":[0.99490184,0.0031556056,0.0013553044,0.00022273751,0.00020828773,0.00015620474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009696444,0.00018376736,0.0013667468,0.00024738454,0.00007965243,0.000010682407,0.00044928447,0.00028035796,0.00053703325],"category_scores_gemma":[0.0014018586,0.00011068255,0.0004969494,0.00066894054,0.00016581602,0.000060224524,0.00009409795,0.0021894611,0.0000019107376],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9131324,0.0098157935,0.011103299,0.000008345571,0.00010184059,0.0004710218,0.0019339739,0.000060929164,0.009200727,0.0000015995687,0.004126073,0.05004395],"study_design_scores_gemma":[0.21443772,0.032527268,0.7207914,0.0000631679,0.000045257122,0.00018154815,0.0007175024,0.00005467503,0.000041922165,0.0000251294,0.031011153,0.00010327771],"about_ca_topic_score_codex":0.00020221996,"about_ca_topic_score_gemma":0.000110917674,"teacher_disagreement_score":0.70968807,"about_ca_system_score_codex":0.0006099048,"about_ca_system_score_gemma":0.0014732464,"threshold_uncertainty_score":0.951224},"labels":[],"label_agreement":null},{"id":"W4282831736","doi":"10.2217/imt-2021-0250","title":"No Association Between BMI and Immunotoxicity or Clinical Outcomes for Immune Checkpoint Inhibitors","year":2022,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Oncology; Immune system; Immune checkpoint; Immunotherapy; Retrospective cohort study; Cancer; Population; Immunology","score_opus":0.037653132573444666,"score_gpt":0.35211722116296235,"score_spread":0.3144640885895177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282831736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990419,0.0023801613,0.00014556546,0.0030859895,0.0015635611,0.0017713837,0.00015987169,0.00015217908,0.00032229075],"genre_scores_gemma":[0.966998,0.0025029068,0.0016769689,0.0039089266,0.00086737674,0.0007689402,0.00020703363,0.00015108209,0.02291881],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971675,0.00022025182,0.0012343636,0.00044349933,0.0004875391,0.0004468135],"domain_scores_gemma":[0.99783486,0.00086388993,0.0005763704,0.00049127446,0.00015176144,0.000081825296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028030649,0.00029929256,0.0008560474,0.00013572512,0.0005120058,0.000057129328,0.00020711271,0.00019537653,0.0006946473],"category_scores_gemma":[0.00031277467,0.00023830826,0.0007026693,0.00026299042,0.000111366426,0.00011799006,0.000098454,0.000509004,0.000015064527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024827214,0.0009136664,0.7610055,0.0000993918,0.004612154,0.000010854364,0.0006951974,0.0000010435467,0.09096732,0.000050586914,0.0041024727,0.11271457],"study_design_scores_gemma":[0.017032968,0.002872381,0.6098418,0.000039584666,0.0001447084,0.000019401537,0.00019967499,0.000033915683,0.003813365,0.00007625421,0.36556858,0.00035730857],"about_ca_topic_score_codex":0.00032568048,"about_ca_topic_score_gemma":0.000009765259,"teacher_disagreement_score":0.3614661,"about_ca_system_score_codex":0.00062132784,"about_ca_system_score_gemma":0.00025503428,"threshold_uncertainty_score":0.9717929},"labels":[],"label_agreement":null},{"id":"W4282915892","doi":"10.1158/1538-7445.am2022-ct250","title":"Abstract CT250: A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; CD8; Melanoma; Immunotherapy; Cancer; Refractory (planetary science); Cytotoxic T cell; Cancer immunotherapy; Dosing; Oncology; Internal medicine; Immune system; Cancer research; Immunology; Biology; In vitro","score_opus":0.08198810902565855,"score_gpt":0.4348763330431794,"score_spread":0.35288822401752085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282915892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962431,0.0009772669,8.104608e-8,0.00030448477,0.00012482045,0.0019453712,0.00007977316,0.00001354678,0.0003115305],"genre_scores_gemma":[0.99705946,0.0001967415,0.0000031652671,0.00007758289,0.000055694807,0.0014695198,0.000022063752,0.00004131954,0.0010744247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99717754,0.00018626699,0.00044295003,0.00043086795,0.0012684086,0.00049394945],"domain_scores_gemma":[0.9989856,0.0001222355,0.000120575,0.0004724129,0.00019940714,0.00009975208],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010173162,0.00015218323,0.0003830729,0.00060320296,0.00020136249,0.000012412208,0.0002616428,0.00005167588,0.0070950813],"category_scores_gemma":[0.000038423954,0.000115748575,0.000043887616,0.0013178388,0.00015254336,0.00009125391,0.00010955586,0.00091773004,0.000001785033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11232865,0.014880062,0.82266206,0.0003926892,0.00029763862,0.00032709748,0.00872362,0.00014280347,0.010686701,0.0000020878813,0.0058699627,0.02368662],"study_design_scores_gemma":[0.059421673,0.012824817,0.9081195,0.00045497433,0.000023817433,0.000001206654,0.004175626,0.000009231234,0.00081367587,0.000003919166,0.0139484005,0.0002031388],"about_ca_topic_score_codex":0.028433114,"about_ca_topic_score_gemma":0.02904028,"teacher_disagreement_score":0.08545745,"about_ca_system_score_codex":0.0017685625,"about_ca_system_score_gemma":0.00089520775,"threshold_uncertainty_score":0.99381256},"labels":[],"label_agreement":null},{"id":"W4282922206","doi":"10.1016/j.annonc.2022.05.517","title":"Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","year":2022,"lang":"en","type":"erratum","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Open label; Oncology; Phases of clinical research; Metastatic melanoma; Basal cell; Expanded access; Internal medicine; Clinical trial; Dermatology; Surgery; Immunotherapy; Cancer","score_opus":0.12182562326581722,"score_gpt":0.4326201249267309,"score_spread":0.3107945016609137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282922206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87752557,0.010727586,0.00011803495,0.0016972515,0.06493386,0.037424006,0.0025813056,0.000083761865,0.0049086194],"genre_scores_gemma":[0.8960558,0.002844341,0.002275233,0.0067853,0.0018204817,0.0058658067,0.0036211114,0.00039885475,0.080333024],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948923,0.000785166,0.0017060024,0.0012289613,0.0005569585,0.0008306384],"domain_scores_gemma":[0.9963222,0.0005507198,0.0012017968,0.00091077416,0.0005454209,0.00046908122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012782308,0.0007286471,0.003066485,0.00048816935,0.00037216133,0.000050815914,0.0008455064,0.0004074728,0.0006639463],"category_scores_gemma":[0.0005510558,0.00067747734,0.00029836982,0.00034288006,0.00019606894,0.00013476124,0.0005494038,0.0008772227,0.0000035441035],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.559448,0.025971092,0.000001701211,0.00032635205,0.00033841428,0.0004185521,0.0011592834,9.333766e-7,0.001021519,0.00000114642,0.22996208,0.18135092],"study_design_scores_gemma":[0.374851,0.29398176,0.000006560262,0.00006260478,0.00059321447,0.000102820886,0.0006021056,0.00012627068,0.00013540973,0.000006518183,0.32922077,0.00031096916],"about_ca_topic_score_codex":0.00073200243,"about_ca_topic_score_gemma":0.00071949,"teacher_disagreement_score":0.26801068,"about_ca_system_score_codex":0.00032824496,"about_ca_system_score_gemma":0.0020672309,"threshold_uncertainty_score":0.9995676},"labels":[],"label_agreement":null},{"id":"W4282933772","doi":"10.1001/jama.2022.7596","title":"Collaborator Name Misspelled","year":2022,"lang":"en","type":"erratum","venue":"JAMA","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Swedish Orphan Biovitrum; Queen's University; Queen's University Belfast; Intensive Care Society; National Institute for Health and Care Research; Wellcome Trust; GlaxoSmithKline; Eli Lilly and Company","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Correct name; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Virology; Internal medicine; Infectious disease (medical specialty)","score_opus":0.012621585408478313,"score_gpt":0.2713189136757397,"score_spread":0.2586973282672614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282933772","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018445324,0.066344164,0.0000024314365,0.021818558,0.08858358,0.0012926,0.0006758179,0.00027645877,0.81916183],"genre_scores_gemma":[0.00024480015,0.0037547078,0.00008217393,0.006568346,0.004402589,0.0000634336,0.0012354237,0.00009068439,0.9835578],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850404,0.000060890245,0.00029991864,0.00035897727,0.00050978793,0.0002663848],"domain_scores_gemma":[0.99899226,0.000035746285,0.00017114569,0.0005504673,0.00013827762,0.00011209637],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021332222,0.00025585023,0.0005244349,0.00014309355,0.00010298553,0.00005260844,0.00018934936,0.00043898023,0.039320428],"category_scores_gemma":[0.00010529397,0.00022982119,0.000242018,0.00046200998,0.00006309523,0.000032357533,0.00006724472,0.0010256914,0.00020916032],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019034517,0.00008306658,0.000035636072,0.00020123777,0.0003628038,0.00024397015,0.00014762829,5.0902486e-8,0.00042527015,0.000010311696,0.97689855,0.01968802],"study_design_scores_gemma":[0.0036461488,0.00037370063,0.0010959132,0.00019231901,0.00014930157,0.0000618893,0.00014083194,0.000009582323,0.00010171986,0.0000075501202,0.99397576,0.00024530757],"about_ca_topic_score_codex":0.00010274656,"about_ca_topic_score_gemma":0.00001671317,"teacher_disagreement_score":0.16439599,"about_ca_system_score_codex":0.0004274956,"about_ca_system_score_gemma":0.001346811,"threshold_uncertainty_score":0.96155775},"labels":[],"label_agreement":null},{"id":"W4282934712","doi":"10.1158/1538-7445.am2022-1361","title":"Abstract 1361: Crosstalk between peripherally expanded T cells and Tfh-like cells in shaping effector functions of CD8 T cells in ovarian cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Cytotoxic T cell; Ovarian cancer; Cancer research; CD8; Immune checkpoint; Immune system; Tumor microenvironment; Granzyme; Biology; Perforin; Immunology; T cell; Cancer; Immunotherapy","score_opus":0.07595620165777602,"score_gpt":0.38082194835241356,"score_spread":0.30486574669463756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282934712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990998,0.005356718,0.0000066415973,0.00052379275,0.0005116505,0.0011911992,0.0008574491,0.000019434041,0.0005350789],"genre_scores_gemma":[0.9951499,0.0013640788,0.000030268688,0.00015588722,0.00021286936,0.00071844447,0.000038662944,0.000052848,0.0022770157],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970751,0.00026990072,0.0005368145,0.0005697828,0.00081883086,0.0007296121],"domain_scores_gemma":[0.9988908,0.00031139186,0.000109693756,0.00038082318,0.00013248625,0.00017480874],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015918536,0.00021938271,0.00052066887,0.0005772686,0.00025864143,0.000054038188,0.00024448213,0.00012520033,0.0041810875],"category_scores_gemma":[0.000015637019,0.00021673381,0.00011499609,0.001199698,0.00032828722,0.00011995317,0.00019379401,0.001069376,0.000006798524],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002512386,0.00017997879,0.05518584,0.0005120051,0.000117649724,0.00006349279,0.002147249,0.0002340647,0.9255147,0.0000011909192,0.0025757202,0.010955722],"study_design_scores_gemma":[0.011183415,0.00083177496,0.45168886,0.0009294917,0.000048855687,0.000005841921,0.0027786635,0.000092291266,0.4936672,0.000019715582,0.0382715,0.00048240024],"about_ca_topic_score_codex":0.030385064,"about_ca_topic_score_gemma":0.0055778758,"teacher_disagreement_score":0.4318475,"about_ca_system_score_codex":0.0013061982,"about_ca_system_score_gemma":0.0010964024,"threshold_uncertainty_score":0.99672925},"labels":[],"label_agreement":null},{"id":"W4282935821","doi":"10.1158/1078-0432.ccr-21-4020","title":"First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Genentech","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Adverse effect; Pharmacokinetics; Cancer; Nausea; Agonist; Oncology; Gastroenterology; Receptor","score_opus":0.11390939730489072,"score_gpt":0.5092122895520722,"score_spread":0.3953028922471815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282935821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99606186,0.00023712995,1.3366703e-7,0.001100923,0.00016825707,0.00207729,0.0000306047,0.000008338787,0.00031545127],"genre_scores_gemma":[0.9987268,0.000056352408,0.000004538237,0.00019461596,0.000052413703,0.00056897476,0.000007821744,0.000025481684,0.0003629976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996557,0.00061758363,0.0007787962,0.00042833362,0.0012005259,0.00041778217],"domain_scores_gemma":[0.99866635,0.00030406183,0.0001447334,0.0006235627,0.00016995159,0.00009135447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002301362,0.00011874686,0.00045363395,0.0001852914,0.00029031045,0.000010873201,0.00041833657,0.00004160403,0.00063617475],"category_scores_gemma":[0.00017663221,0.000078692974,0.00009933233,0.0012299254,0.00043420042,0.000042690543,0.00029449537,0.0012070327,0.0000011481793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027541308,0.0100447405,0.949754,0.00005919481,0.00007483109,0.00003896402,0.0008995294,0.0001661751,0.00015294501,0.0000073866763,0.00044671312,0.010814191],"study_design_scores_gemma":[0.04085121,0.013695395,0.9397453,0.00018968566,0.000014391892,6.4323706e-7,0.0021693662,0.000038515813,0.00013048641,0.00001998012,0.0030432937,0.00010172983],"about_ca_topic_score_codex":0.0022945367,"about_ca_topic_score_gemma":0.00541274,"teacher_disagreement_score":0.013309901,"about_ca_system_score_codex":0.0005309102,"about_ca_system_score_gemma":0.00050873467,"threshold_uncertainty_score":0.69656676},"labels":[],"label_agreement":null},{"id":"W4282945728","doi":"10.1158/1078-0432.ccr-22-0541","title":"PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy","year":2022,"lang":"en","type":"letter","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"NYU Grossman School of Medicine; York University; U.S. Department of Veterans Affairs","keywords":"Immunotherapy; Agonism; Cancer immunotherapy; Tumor microenvironment; Immune system; Cancer research; Medicine; Immunology; Political science","score_opus":0.3209360935131581,"score_gpt":0.5552180262642052,"score_spread":0.23428193275104714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282945728","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.043083083,0.053193815,0.000012499386,0.8836982,0.0033066794,0.0028232858,0.00030342554,0.00014051373,0.013438487],"genre_scores_gemma":[0.008358395,0.058644045,0.0001838447,0.74262196,0.021649437,0.00067091297,0.0006434643,0.00046756913,0.1667604],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914151,0.0011719309,0.001959029,0.0012341075,0.0029289972,0.0012908672],"domain_scores_gemma":[0.9948268,0.0019632806,0.0005602646,0.0016753632,0.0006114957,0.0003628015],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0049497657,0.0004931762,0.0016198765,0.00053596625,0.00037238962,0.00013382132,0.0011866904,0.0015404546,0.0385412],"category_scores_gemma":[0.0006044136,0.00043381873,0.0012556341,0.0011346891,0.0014974703,0.00008543195,0.00036700763,0.011212972,0.0001075354],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013034952,0.0001956169,0.0006140188,0.00043178035,0.0010923116,0.0006466089,0.00019872612,0.000002002122,0.0014564095,0.000015803344,0.8474661,0.13484564],"study_design_scores_gemma":[0.0062319604,0.0037101517,0.002589101,0.0006574402,0.000095124626,0.00005352543,0.00011163514,0.0000054984307,0.0005409688,0.00089818635,0.98470587,0.0004005249],"about_ca_topic_score_codex":0.012755331,"about_ca_topic_score_gemma":0.00011061499,"teacher_disagreement_score":0.1533219,"about_ca_system_score_codex":0.000842826,"about_ca_system_score_gemma":0.012247872,"threshold_uncertainty_score":0.99981135},"labels":[],"label_agreement":null},{"id":"W4282961029","doi":"10.1158/1538-7445.am2022-ct236","title":"Abstract CT236: INTERLINK-1: A phase 3, randomized, double-blind, placebo-controlled, multicenter, global study of monalizumab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma previously treated with an immune checkpoint inhibitor","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cetuximab; Medicine; Pembrolizumab; Head and neck squamous-cell carcinoma; Internal medicine; Nivolumab; Oncology; Cancer; Discontinuation; Head and neck cancer; Phases of clinical research; Chemotherapy; Immunotherapy; Colorectal cancer","score_opus":0.04767354555543456,"score_gpt":0.3697721642947267,"score_spread":0.32209861873929213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282961029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818868,0.0021305294,0.0000024582093,0.00010513287,0.000042399824,0.015710283,0.000066170156,0.000016717951,0.00003947816],"genre_scores_gemma":[0.9950532,0.000062164705,0.000046728812,0.000014435804,0.000013894854,0.0045842966,0.00011840174,0.000045366312,0.000061509396],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957784,0.0008471996,0.0009323057,0.0006287946,0.0012642515,0.0005490796],"domain_scores_gemma":[0.9984131,0.00021828308,0.00036382957,0.00040976985,0.00043167206,0.0001633408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018222935,0.0003403015,0.0012866051,0.00053906965,0.00013552465,0.000053327516,0.00020251707,0.000046297322,0.00014210022],"category_scores_gemma":[0.00003794303,0.0002090022,0.00007614418,0.0011755686,0.00028089675,0.00019687985,0.00009068207,0.0006535279,3.7760944e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8977248,0.023917247,0.06831844,0.00041823633,0.00030949916,0.00020416372,0.0044209585,0.00008476929,0.00025652075,7.283813e-7,0.000005173236,0.0043394873],"study_design_scores_gemma":[0.9026416,0.048581682,0.041830912,0.00047623072,0.0002261897,0.000013444789,0.004827176,0.0005529273,0.00061789475,0.0000014837044,0.0000063968982,0.0002240809],"about_ca_topic_score_codex":0.0152142,"about_ca_topic_score_gemma":0.014143206,"teacher_disagreement_score":0.026487527,"about_ca_system_score_codex":0.0014641416,"about_ca_system_score_gemma":0.00075149006,"threshold_uncertainty_score":0.99134356},"labels":[],"label_agreement":null},{"id":"W4282965232","doi":"10.1158/1538-7445.am2022-ct011","title":"Abstract CT011: NeoCOAST: open-label, randomized, phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC)","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University","funders":"","keywords":"Medicine; Durvalumab; Tolerability; Clinical endpoint; Neoadjuvant therapy; Internal medicine; Lung cancer; Gastroenterology; Oncology; Cancer; Lymph node; Surgery; Randomized controlled trial; Immunotherapy; Breast cancer; Adverse effect; Pembrolizumab","score_opus":0.10182909005067348,"score_gpt":0.4069291801461712,"score_spread":0.3051000900954977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282965232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818086,0.0006382866,0.000011957357,0.00019681329,0.00019616749,0.015929215,0.0005332231,0.000027963497,0.0006577658],"genre_scores_gemma":[0.98873574,0.0004456871,0.00010990105,0.00015146137,0.000056281788,0.0057585556,0.00010640005,0.00014417135,0.004491832],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939291,0.00037476918,0.0010692595,0.000997597,0.0024875156,0.0011417958],"domain_scores_gemma":[0.9970886,0.00044926064,0.00049572304,0.0009587349,0.000694215,0.0003134689],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033595501,0.00048425197,0.0015513371,0.0007222631,0.0005357441,0.00012304814,0.0010011316,0.000101872676,0.0023586552],"category_scores_gemma":[0.00007682244,0.00033148788,0.00008554931,0.0021134636,0.00038973195,0.0003725864,0.00070841296,0.0014396529,0.0000026345651],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9040952,0.022116886,0.049005326,0.00058910536,0.0012278812,0.00040209424,0.008119263,0.00044227944,0.008996426,0.0000016625755,0.0012577544,0.0037461552],"study_design_scores_gemma":[0.9301939,0.018743329,0.0370147,0.0011300385,0.00021082125,0.0000061823107,0.00529306,0.0013782973,0.00499034,8.162284e-7,0.0005281864,0.0005103526],"about_ca_topic_score_codex":0.12398864,"about_ca_topic_score_gemma":0.022320604,"teacher_disagreement_score":0.10166804,"about_ca_system_score_codex":0.0016691865,"about_ca_system_score_gemma":0.0025293415,"threshold_uncertainty_score":0.9999137},"labels":[],"label_agreement":null},{"id":"W4282972075","doi":"10.1158/1538-7445.am2022-3881","title":"Abstract 3881: Immune profiling of advanced prostate cancer harboring homologous recombination deficiency","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Immune system; Cancer; Immune checkpoint; Cancer research; Tumor microenvironment; Prostate; Internal medicine; CD8; Oncology; Stromal cell; Immunotherapy; Immunology","score_opus":0.05647749439758661,"score_gpt":0.3997149279789818,"score_spread":0.3432374335813952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282972075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97095615,0.024249448,0.0000029266946,0.0014579833,0.0005346828,0.001151664,0.000072037685,0.000043946788,0.0015311891],"genre_scores_gemma":[0.9920771,0.0043541077,0.00011984114,0.000051315757,0.000066411834,0.001628711,0.000026907079,0.000038042854,0.0016375768],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99761784,0.00011814241,0.0004209016,0.0003871715,0.00091794686,0.0005380183],"domain_scores_gemma":[0.99890906,0.00009287745,0.00015779611,0.00035532322,0.0004097791,0.00007514538],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016003085,0.00012992663,0.00028126934,0.00035461716,0.00041590005,0.000017979335,0.00024787732,0.00004824759,0.0015851895],"category_scores_gemma":[0.00007726329,0.00012428591,0.000107979766,0.0011067506,0.00020228664,0.000113220995,0.00015002044,0.0007223121,0.0000036436395],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032971487,0.00023070062,0.005582104,0.0003993231,0.00006546973,0.000027928729,0.0008569728,0.0004019334,0.8645477,0.00008894978,0.00024755963,0.1242542],"study_design_scores_gemma":[0.0058777668,0.0014160948,0.11125088,0.0005250284,0.000039543353,0.000027553482,0.0032666863,0.00011518207,0.86710817,0.00027158097,0.009769274,0.00033223335],"about_ca_topic_score_codex":0.0023669398,"about_ca_topic_score_gemma":0.000043633052,"teacher_disagreement_score":0.12392196,"about_ca_system_score_codex":0.0011771788,"about_ca_system_score_gemma":0.0010819566,"threshold_uncertainty_score":0.9993275},"labels":[],"label_agreement":null},{"id":"W4282972120","doi":"10.3390/curroncol29060342","title":"Prognostic and Predictive Relevance of Tumor-Infiltrating Lymphocytes in Squamous Cell Head–Neck Cancer Patients Treated with Radical Radiotherapy/Chemo-Radiotherapy","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Squamous cell cancer; Radiation therapy; Head and neck; Head and neck cancer; Oncology; Tumor-infiltrating lymphocytes; Cancer research; Internal medicine; Pathology; Cancer; Surgery; Immunotherapy","score_opus":0.023441174585150264,"score_gpt":0.32192834953505167,"score_spread":0.2984871749499014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282972120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688782,0.029127134,0.000031636337,0.00021574134,0.00028558585,0.0011925803,0.00010707964,0.000035682126,0.00012637986],"genre_scores_gemma":[0.99663085,0.0020180992,0.0003519872,0.0002734026,0.00009399134,0.00047806595,0.00007485461,0.00004093631,0.000037834303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981982,0.00020797305,0.000487482,0.00043206703,0.00031684965,0.0003574363],"domain_scores_gemma":[0.9990301,0.00028740655,0.00031461183,0.00018103686,0.00008338271,0.00010342185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019625796,0.0002422814,0.0006113164,0.0001811824,0.000103970204,0.000006649362,0.000114221686,0.00006984368,0.00022840463],"category_scores_gemma":[0.000044966713,0.00020205205,0.00007131363,0.0004650996,0.00033424966,0.00005829739,0.000029584142,0.00034761152,2.0165764e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015830765,0.0023153718,0.92477596,0.0002774704,0.00010189299,0.000042356973,0.0019378583,0.00010205286,0.008953006,0.0000028060708,0.0005025604,0.045157917],"study_design_scores_gemma":[0.079855956,0.037274808,0.7879554,0.00068447477,0.00028137641,0.00029680107,0.00081341807,0.008585883,0.0070525166,0.000011292333,0.07647609,0.0007120002],"about_ca_topic_score_codex":0.0002510175,"about_ca_topic_score_gemma":0.00006791159,"teacher_disagreement_score":0.13682055,"about_ca_system_score_codex":0.0015803287,"about_ca_system_score_gemma":0.00062790955,"threshold_uncertainty_score":0.8239444},"labels":[],"label_agreement":null},{"id":"W4282972367","doi":"10.1158/1538-7445.am2022-ct022","title":"Abstract CT022: CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Oncology; Cohort; Cancer; Immunotherapy","score_opus":0.058200113624989905,"score_gpt":0.4146993516726031,"score_spread":0.3564992380476132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282972367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909467,0.00030701113,0.000007957834,0.00022240385,0.000051659554,0.008271976,0.00014434409,0.000012562671,0.000035372315],"genre_scores_gemma":[0.99533135,0.00008795472,0.000253307,0.000048126192,0.000010879446,0.0037877276,0.00009556066,0.00006367825,0.0003214159],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99567086,0.00065777823,0.0009826686,0.0005282405,0.0016948847,0.0004655718],"domain_scores_gemma":[0.9980199,0.00039903348,0.00048818009,0.00041351723,0.0005917363,0.00008765703],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021707756,0.00025030636,0.0012272787,0.00079316297,0.00015068435,0.000033013413,0.00044858851,0.000027461003,0.0019023757],"category_scores_gemma":[0.00012558834,0.00016988786,0.000042455806,0.0018629367,0.0003576909,0.00028479515,0.0001247168,0.00052543066,0.0000010804553],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95719355,0.013386254,0.003199583,0.0003199547,0.0005784942,0.00022526098,0.0056296224,0.001343692,0.002960649,0.000009794946,0.000048192265,0.015104977],"study_design_scores_gemma":[0.92443377,0.028761692,0.033180412,0.00070257514,0.00007214608,0.000012999123,0.010226414,0.00057885674,0.0016859855,0.00005648164,0.000033050754,0.00025562666],"about_ca_topic_score_codex":0.014003823,"about_ca_topic_score_gemma":0.003318842,"teacher_disagreement_score":0.032759763,"about_ca_system_score_codex":0.0009920707,"about_ca_system_score_gemma":0.001992466,"threshold_uncertainty_score":0.99901},"labels":[],"label_agreement":null},{"id":"W4282977144","doi":"10.1007/s00262-022-03228-y","title":"Acidosis significantly alters immune checkpoint expression profiles of T cells from oesophageal adenocarcinoma patients","year":2022,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Irish Research Council; Irish Research Council for Science, Engineering and Technology; Irish Research eLibrary","keywords":"Immune checkpoint; Immune system; Cancer research; Acidosis; Adenocarcinoma; Medicine; Internal medicine; Immunology; Cancer; Immunotherapy","score_opus":0.014016184611313641,"score_gpt":0.2539326952524399,"score_spread":0.23991651064112623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282977144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9058968,0.08933996,0.000069589,0.000507043,0.00206539,0.0012784096,0.00060093927,0.00011808543,0.00012382913],"genre_scores_gemma":[0.98965037,0.0069304863,0.0004519733,0.0008399526,0.000119844466,0.00094468973,0.0004010003,0.00013401806,0.0005276607],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962444,0.00038340414,0.0012803341,0.0007817491,0.00062532804,0.00068482925],"domain_scores_gemma":[0.9975231,0.00013781546,0.00086753635,0.0011784416,0.00020674847,0.00008632023],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003671451,0.0005293385,0.0010581902,0.00036060374,0.0004485389,0.000022216967,0.000721557,0.00023633389,0.007911747],"category_scores_gemma":[0.000015877586,0.00049656164,0.00061748695,0.00057503546,0.0005400367,0.00016353487,0.000249164,0.0007469953,0.000019254036],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016928805,0.00081286946,0.027571676,0.000044312135,0.0014121558,0.000018530442,0.0022200935,0.000020059486,0.91899604,0.0000066363405,0.0007171659,0.031251673],"study_design_scores_gemma":[0.011191194,0.0017488721,0.21937156,0.000107721105,0.00011288682,0.000010507525,0.00096255925,0.000015447611,0.75810486,0.00004878695,0.007934101,0.00039151058],"about_ca_topic_score_codex":0.00187188,"about_ca_topic_score_gemma":0.0000059472172,"teacher_disagreement_score":0.19179988,"about_ca_system_score_codex":0.00072389684,"about_ca_system_score_gemma":0.00044854727,"threshold_uncertainty_score":0.9997486},"labels":[],"label_agreement":null},{"id":"W4282979181","doi":"10.1158/1538-7445.am2022-388","title":"Abstract 388: AI/ML-driven discovery of a novel proteoglycan for precision targeting of ADCs for disruption of stromal barriers and direct anti-tumor activity","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"","keywords":"Stromal cell; Cancer-Associated Fibroblasts; Cancer research; Cancer; Medicine; Triple-negative breast cancer; Cancer cell; Fibroblast activation protein, alpha; Breast cancer; Tumor microenvironment; Tumor cells; Internal medicine","score_opus":0.06428709810769946,"score_gpt":0.41034370056206676,"score_spread":0.3460566024543673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282979181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939907,0.0006451224,0.00071173307,0.0003151266,0.000093614726,0.002577259,0.0016267156,0.000006552018,0.000033157266],"genre_scores_gemma":[0.9982222,0.00012209863,0.0004624583,0.00001190692,0.000071513234,0.00095028366,0.00003142067,0.000025623238,0.00010252144],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998462,0.00006565336,0.0003255543,0.00029182853,0.00056601496,0.00028894976],"domain_scores_gemma":[0.9988729,0.00033728496,0.00022419215,0.00020081656,0.00029389616,0.00007091467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014171735,0.00010384496,0.00038260667,0.00018635285,0.00017021227,0.000011245288,0.0001256156,0.000041518848,0.00006413689],"category_scores_gemma":[0.00032521778,0.000090447844,0.00014975069,0.00029469118,0.0002587759,0.00014894955,0.00009543914,0.00021946678,1.8220753e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020551063,0.0002235491,0.0072008804,0.0014126286,0.00013565306,8.639341e-7,0.00043301992,0.00009538199,0.95945156,0.000015904581,0.00031144544,0.010168077],"study_design_scores_gemma":[0.0075414134,0.0032164361,0.07202686,0.0005710959,0.000058660913,0.0000038450207,0.0014209602,0.0017129767,0.9110497,0.000025757694,0.0022226514,0.00014959848],"about_ca_topic_score_codex":0.0010272469,"about_ca_topic_score_gemma":0.00004980514,"teacher_disagreement_score":0.06482598,"about_ca_system_score_codex":0.00023105943,"about_ca_system_score_gemma":0.0006705005,"threshold_uncertainty_score":0.36883563},"labels":[],"label_agreement":null},{"id":"W4283022888","doi":"10.1136/jitc-2022-004849","title":"iRECIST and atypical patterns of response to immuno-oncology drugs","year":2022,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Canadian Partnership Against Cancer","funders":"","keywords":"Medicine; Oncology; Precision oncology; Internal medicine; Bioinformatics; Cancer; Biology","score_opus":0.0556000296636933,"score_gpt":0.43022200263523774,"score_spread":0.3746219729715444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283022888","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0052461657,0.99028796,0.00006762914,0.00063361315,0.0016566275,0.0016136564,0.00043189264,0.000011634534,0.00005080351],"genre_scores_gemma":[0.000105562765,0.99634576,0.00042001533,0.00048757278,0.00031047262,0.00039634263,0.00002260103,0.00012536571,0.0017863008],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99664026,0.00039739208,0.0017351928,0.00034165537,0.0005017335,0.0003837611],"domain_scores_gemma":[0.9967687,0.0009484616,0.0014657094,0.00046937837,0.00019909622,0.00014866985],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019313653,0.000446815,0.0028988854,0.0006009659,0.00018064621,0.000023977793,0.0003924482,0.00032756175,0.0022701062],"category_scores_gemma":[0.00009282244,0.00034394336,0.0014546132,0.00035675042,0.00015781385,0.0000585983,0.0000738378,0.00062769384,8.205018e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08088003,0.00017873185,0.000029606701,0.0038710106,0.0023019293,0.00001077508,0.0007809831,3.4844226e-7,0.0015465948,0.0000064065753,0.0015037323,0.90888983],"study_design_scores_gemma":[0.005166192,0.0042076437,0.00033784323,0.008067806,0.0008315763,0.0005373188,0.00022883803,4.647882e-7,0.00012814476,0.000015009031,0.9801723,0.0003068592],"about_ca_topic_score_codex":0.00010237926,"about_ca_topic_score_gemma":0.000012617842,"teacher_disagreement_score":0.9786686,"about_ca_system_score_codex":0.0010388492,"about_ca_system_score_gemma":0.0019722409,"threshold_uncertainty_score":0.99990124},"labels":[],"label_agreement":null},{"id":"W4283024933","doi":"10.3390/curroncol29060347","title":"An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Adverse effect; Demographics; Internal medicine; Odds ratio; Descriptive statistics; Cancer; Health care; Cancer treatment; Emergency medicine; Family medicine","score_opus":0.08670605085434345,"score_gpt":0.42581451161498646,"score_spread":0.339108460760643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283024933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9422699,0.039494295,0.0015729535,0.0022277283,0.0072112796,0.004756554,0.0003194066,0.00008398364,0.0020638737],"genre_scores_gemma":[0.9956512,0.0019491983,0.00034892044,0.00018713073,0.000055777495,0.0010257285,0.00037905172,0.000019305011,0.00038368852],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980597,0.00031255893,0.0007787539,0.0003416894,0.000225424,0.00028189068],"domain_scores_gemma":[0.9986407,0.00016563738,0.00046597826,0.00048313156,0.00015702765,0.000087526314],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008859659,0.00015705333,0.00058160245,0.00023929724,0.00024110322,0.0000013786713,0.00029021522,0.00008495946,0.0023732497],"category_scores_gemma":[0.000016176184,0.00011884657,0.00076696003,0.0007605955,0.00015392795,0.00003091134,0.00013334985,0.00029112716,0.000005303038],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030324461,0.0072387815,0.02183593,0.0006288225,0.03082511,0.00008101933,0.02451785,0.0008891529,0.001719522,0.00046472135,0.0036765742,0.8777981],"study_design_scores_gemma":[0.014670544,0.0099895345,0.07048174,0.000056750425,0.012276642,0.00002846665,0.088354066,0.0014819595,0.00013662876,0.00007496314,0.80219996,0.00024871537],"about_ca_topic_score_codex":0.00005746646,"about_ca_topic_score_gemma":0.00004091998,"teacher_disagreement_score":0.87754935,"about_ca_system_score_codex":0.0013586596,"about_ca_system_score_gemma":0.00039480758,"threshold_uncertainty_score":0.99853873},"labels":[],"label_agreement":null},{"id":"W4283364422","doi":"10.1158/1538-7445.am2022-ct561","title":"Abstract CT561: KeyVibe-003: Randomized, double-blind, phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; TIGIT; Internal medicine; Oncology; Atezolizumab; Lung cancer; Phases of clinical research; Gastroenterology; Chemotherapy; Cancer; Immunotherapy","score_opus":0.06263140322258151,"score_gpt":0.39675302328117185,"score_spread":0.33412162005859036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283364422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905401,0.0013632374,0.000011883522,0.00035409458,0.000058859936,0.0070903376,0.00013932095,0.000021292582,0.00042091202],"genre_scores_gemma":[0.99713564,0.0003415333,0.000033849596,0.000064729604,0.00003622287,0.0020811716,0.00008276296,0.000068669455,0.00015541328],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959764,0.00040873158,0.00062320876,0.00064287713,0.0017387304,0.0006100778],"domain_scores_gemma":[0.99827075,0.0003124239,0.00024932082,0.0004925791,0.00049218425,0.00018274429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016873735,0.0003133823,0.0011285213,0.00075300504,0.00032737115,0.000049896393,0.00023389341,0.00004469405,0.00048723957],"category_scores_gemma":[0.000042414253,0.00021689404,0.000086145534,0.0013629548,0.0006174368,0.00017547392,0.00014920655,0.00083827385,0.0000015439333],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8937223,0.0051135174,0.09176669,0.00023830193,0.001212256,0.000107503336,0.0035303736,0.00014424765,0.00031204606,0.000004887411,0.000058300153,0.0037895734],"study_design_scores_gemma":[0.91076744,0.010272691,0.07366735,0.00043600085,0.00031284086,0.00002662146,0.0028050656,0.000078023,0.0011469888,0.000005975187,0.0002016063,0.00027938813],"about_ca_topic_score_codex":0.007244248,"about_ca_topic_score_gemma":0.0019570354,"teacher_disagreement_score":0.018099345,"about_ca_system_score_codex":0.0005203535,"about_ca_system_score_gemma":0.0006583458,"threshold_uncertainty_score":0.9993666},"labels":[],"label_agreement":null},{"id":"W4283370638","doi":"10.14740/wjon1481","title":"Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma","year":2022,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Surrogate endpoint; Clinical endpoint; Internal medicine; Randomized controlled trial; Oncology; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Clinical trial; Carcinoma; Overall survival; Phases of clinical research","score_opus":0.048048024624307795,"score_gpt":0.36644039151380337,"score_spread":0.31839236688949557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283370638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98623085,0.004473458,0.00005969495,0.0038419524,0.0029109172,0.00070700934,0.00006246779,0.0000063076322,0.0017073154],"genre_scores_gemma":[0.995621,0.00024063485,0.002190311,0.000536651,0.00032175024,0.0000490902,0.000015504094,0.000025012705,0.0009999915],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99588794,0.0010603184,0.0021843833,0.00018002445,0.0003174877,0.00036983116],"domain_scores_gemma":[0.9960569,0.0015017433,0.0019587725,0.00018316247,0.00019812574,0.00010131003],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0069687488,0.00016868327,0.0018492397,0.0006888183,0.00007177684,0.0000037394443,0.0002433126,0.00008212961,0.0010621451],"category_scores_gemma":[0.0004162949,0.00014778123,0.00065515237,0.0003478761,0.0001300645,0.00007442479,0.00007805636,0.0005644582,7.312431e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26997524,0.0027001228,0.041967876,0.00018165048,0.001060245,0.001845969,0.0019840829,0.0004969595,0.4220458,0.00057403534,0.004739892,0.25242814],"study_design_scores_gemma":[0.12093186,0.038643975,0.18037915,0.00014517867,0.0004872672,0.0024832992,0.0025305022,0.000066576096,0.01553819,0.0006478268,0.6378455,0.00030063532],"about_ca_topic_score_codex":0.00007527483,"about_ca_topic_score_gemma":0.00024925946,"teacher_disagreement_score":0.63310564,"about_ca_system_score_codex":0.0012361637,"about_ca_system_score_gemma":0.0014495546,"threshold_uncertainty_score":0.99985105},"labels":[],"label_agreement":null},{"id":"W4283512735","doi":"10.1016/j.annonc.2022.06.008","title":"Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Genentech; Sirtex Medical; Eli Lilly and Company; Ono Pharmaceutical; Daiichi Sankyo Europe; Servier; Alberta Health Services; Alberta Cancer Foundation; Seagen; Pfizer; Incyte; Canadian Institutes of Health Research; Ipsen; BeiGene; Astellas Pharma; Mylan; Les Laboratories Pierre Fabre; Helsinn; Merck KGaA; Halozyme; Sanofi; GlaxoSmithKline; Bristol-Myers Squibb; AstraZeneca; Amgen; Celgene","keywords":"Ipilimumab; Nivolumab; Medicine; Microsatellite instability; Colorectal cancer; Internal medicine; Oncology; Cancer; Gastroenterology; Immunotherapy","score_opus":0.028486911596228674,"score_gpt":0.3066975440504603,"score_spread":0.2782106324542316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283512735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993826,0.0023861716,0.0000014264482,0.0006660736,0.00040610827,0.0017203296,0.00064456725,0.00008024584,0.0002691024],"genre_scores_gemma":[0.9970066,0.0006763498,0.0002303706,0.0008379312,0.000025010318,0.000380269,0.00058322086,0.0000507815,0.00020950023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969522,0.00043940754,0.00090208877,0.00063425826,0.000485207,0.00058684143],"domain_scores_gemma":[0.99849117,0.00016526149,0.00047030204,0.00045896947,0.0002811553,0.00013316018],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006672568,0.00031592973,0.0010847619,0.00024729423,0.00013577317,0.000010817949,0.00022215921,0.00011610625,0.0007406028],"category_scores_gemma":[0.000053624844,0.00027422296,0.00027815913,0.00075611146,0.00028532482,0.000092712056,0.00013762496,0.00036799008,0.000007658464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3205017,0.011507995,0.51984346,0.00076399714,0.0034915698,0.00049131585,0.019285884,0.00048796635,0.034204863,0.000035929726,0.005039389,0.08434594],"study_design_scores_gemma":[0.13487647,0.04240935,0.74229753,0.0007821022,0.00085844245,0.000049559974,0.0039553577,0.0004208886,0.034835946,0.00013710112,0.03825561,0.0011216657],"about_ca_topic_score_codex":0.014118855,"about_ca_topic_score_gemma":0.0041120197,"teacher_disagreement_score":0.22245403,"about_ca_system_score_codex":0.0009301303,"about_ca_system_score_gemma":0.001046781,"threshold_uncertainty_score":0.999971},"labels":[],"label_agreement":null},{"id":"W4283694544","doi":"10.1186/s13065-022-00842-w","title":"Leveraging structural and 2D-QSAR to investigate the role of functional group substitutions, conserved surface residues and desolvation in triggering the small molecule-induced dimerization of hPD-L1","year":2022,"lang":"en","type":"article","venue":"BMC Chemistry","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Small molecule; Chemistry; Moiety; Molecule; Ligand (biochemistry); Quantitative structure–activity relationship; Molecular dynamics; Monomer; Stereochemistry; Computational chemistry; Receptor; Biochemistry","score_opus":0.02822935709471149,"score_gpt":0.23320648697837865,"score_spread":0.20497712988366715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283694544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980916,0.0012602952,0.000050827697,0.0003082025,0.000025137952,0.00019383161,0.000007743022,0.000007802486,0.000054583536],"genre_scores_gemma":[0.9996563,0.000022127222,0.0001478482,0.000082241604,0.000014895506,0.00001536126,0.000028564684,0.0000059494037,0.000026709715],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99942786,0.000043774897,0.00019793515,0.00012611177,0.0001286733,0.00007564082],"domain_scores_gemma":[0.9996553,0.000078336525,0.00009340763,0.000119787335,0.000029974823,0.00002320096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000244573,0.00007052844,0.00010758316,0.000018778946,0.00012149706,0.000008443876,0.00004892296,0.000025527106,0.000022772147],"category_scores_gemma":[0.00006153305,0.000051916737,0.000023282744,0.00019853633,0.000103417944,0.000024990257,0.000048529488,0.00010263053,2.4850227e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005562785,0.000008725138,0.06485503,0.00007310789,0.000021259215,4.086093e-7,0.0005563505,0.0002553208,0.93345326,0.000033098862,0.000003804785,0.00018333507],"study_design_scores_gemma":[0.0009685678,0.000031458974,0.3088331,0.00005566517,0.0000254763,0.000026422344,0.0017308678,0.0014750907,0.6866732,0.000060315702,0.000058768266,0.00006104797],"about_ca_topic_score_codex":0.00040466673,"about_ca_topic_score_gemma":0.000047167636,"teacher_disagreement_score":0.24678005,"about_ca_system_score_codex":0.000048237256,"about_ca_system_score_gemma":0.000097369,"threshold_uncertainty_score":0.2117103},"labels":[],"label_agreement":null},{"id":"W4283708528","doi":"10.1038/s41590-022-01239-6","title":"Overcoming the LAG3 phase problem","year":2022,"lang":"en","type":"letter","venue":"Nature Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Swiss National Centre of Competence in Research Kidney Control of Homeostasis; Australian Research Council; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Chemistry; Cancer research; Cell biology; Computational biology; Biology","score_opus":0.01127974782105173,"score_gpt":0.2948007885940209,"score_spread":0.2835210407729692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283708528","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018989871,0.058143098,0.000003901055,0.927291,0.0031193453,0.0009484274,0.00010021143,0.0001350901,0.008359989],"genre_scores_gemma":[0.002405781,0.001305858,0.00011787927,0.97376484,0.0030194488,0.0002167591,0.0010605373,0.000102251885,0.018006653],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99799496,0.00023150037,0.00037640275,0.0004765377,0.0003935716,0.0005270082],"domain_scores_gemma":[0.9984586,0.00026116928,0.0002611186,0.0009281183,0.00007297626,0.000018009283],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00031904888,0.00036954036,0.0005712309,0.00021061342,0.00029186648,0.00002858852,0.00054279563,0.0023108195,0.00509048],"category_scores_gemma":[0.000053577754,0.00024275284,0.0003955725,0.00034097186,0.0002899205,0.00003684924,0.00017914856,0.012398687,0.000039035716],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002255135,0.000081529164,0.0000116344,0.000085338776,0.001177892,0.00072551897,0.0001688234,6.815788e-8,0.005833402,0.00005310239,0.9746732,0.014934325],"study_design_scores_gemma":[0.004208027,0.0008505164,0.0000861265,0.00007822999,0.00023712906,0.0012855685,0.000058895843,0.0000014689513,0.00044603925,0.00013191144,0.99236506,0.00025102415],"about_ca_topic_score_codex":0.00009324011,"about_ca_topic_score_gemma":0.0000066402445,"teacher_disagreement_score":0.05683724,"about_ca_system_score_codex":0.00037804205,"about_ca_system_score_gemma":0.0003224414,"threshold_uncertainty_score":0.9989844},"labels":[],"label_agreement":null},{"id":"W4283717199","doi":"10.3389/fimmu.2022.907591","title":"Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology","year":2022,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Canadian Liver Foundation; American Association for the Study of Liver Diseases","keywords":"Immunotherapy; Autoimmune hepatitis; Immune system; Medicine; Immunology; Cancer immunotherapy; Cancer; Hepatitis; Immune checkpoint; Internal medicine","score_opus":0.01923303325363372,"score_gpt":0.28005207400058924,"score_spread":0.2608190407469555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283717199","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01764573,0.96825653,0.000048501646,0.000507998,0.0090527,0.0028546844,0.0010103753,0.00049813616,0.00012535191],"genre_scores_gemma":[0.0006773836,0.9906634,0.00091212994,0.00017584278,0.0003497127,0.0027400053,0.0023665465,0.00064326735,0.0014716869],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9904876,0.0013656928,0.003681586,0.0020534014,0.0005903785,0.001821386],"domain_scores_gemma":[0.9950694,0.0005160363,0.0019331726,0.002195198,0.00012508228,0.00016110635],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0008065917,0.001889446,0.0072277263,0.0021133365,0.0005668395,0.00010926708,0.0012232832,0.0020586643,0.0036224863],"category_scores_gemma":[0.0002198526,0.0018862353,0.0017372657,0.001725273,0.0015389426,0.0003289768,0.0010735658,0.0039176615,0.000047601658],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033051244,0.00059669046,0.0023849052,0.0034746444,0.011286784,0.0012881212,0.0014084775,6.8141725e-7,0.0056739817,0.000025107385,0.0005680545,0.96998745],"study_design_scores_gemma":[0.008825459,0.000709222,0.050595254,0.009121705,0.0013084732,0.00095297716,0.0003832497,0.00003360213,0.0003529778,0.00004943462,0.9258535,0.0018141641],"about_ca_topic_score_codex":0.044049527,"about_ca_topic_score_gemma":0.00077122415,"teacher_disagreement_score":0.96817327,"about_ca_system_score_codex":0.003822337,"about_ca_system_score_gemma":0.0016352824,"threshold_uncertainty_score":0.9995278},"labels":[],"label_agreement":null},{"id":"W4283749380","doi":"10.3390/curroncol29070366","title":"Can Radiotherapy Empower the Host Immune System to Counterattack Neoplastic Cells? A Systematic Review on Tumor Microenvironment Radiomodulation","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Ministero della Salute","keywords":"Tumor microenvironment; Immune system; Immunotherapy; Radiation therapy; Medicine; Cancer research; Immunology; Internal medicine","score_opus":0.061226946821643195,"score_gpt":0.3810342079183749,"score_spread":0.3198072610967317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283749380","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024331492,0.980462,0.000034945806,0.0007107154,0.00526747,0.013170038,0.00017295104,0.000064996435,0.00009256407],"genre_scores_gemma":[0.000042794036,0.9930186,0.000016732502,0.0016169766,0.0003749594,0.004186887,0.00030288973,0.00012395931,0.00031618087],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946656,0.0015014599,0.0019508007,0.0007581238,0.000616517,0.0005074533],"domain_scores_gemma":[0.9964652,0.00069605286,0.0012983917,0.001321375,0.00004140007,0.00017755275],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013065416,0.00077869825,0.0045217797,0.00028079734,0.00024940018,0.000042220727,0.0005668398,0.00015999157,0.0007581532],"category_scores_gemma":[0.00007622005,0.00047035777,0.0011334246,0.0005811442,0.00011111681,0.000023073508,0.00009748199,0.00084223185,0.00017028251],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031283428,0.00042009848,7.1754835e-7,0.9089003,0.0009852445,0.00009851659,0.00028252698,0.0000022839934,0.00003160193,0.000013192869,0.0068344064,0.08211826],"study_design_scores_gemma":[0.00071606383,0.0009947786,0.0000030942215,0.3439673,0.002885567,0.00079331547,0.00006787692,0.000013430448,0.0000015056503,5.022361e-8,0.65028614,0.00027091254],"about_ca_topic_score_codex":0.000018040624,"about_ca_topic_score_gemma":0.0000063239463,"teacher_disagreement_score":0.6434517,"about_ca_system_score_codex":0.0073645874,"about_ca_system_score_gemma":0.0006913265,"threshold_uncertainty_score":0.9997748},"labels":[],"label_agreement":null},{"id":"W4283776238","doi":"10.1016/j.annonc.2022.04.252","title":"P-162 Atezolizumab and bevacizumab pre-liver transplantation for patients with hepatocellular carcinoma beyond Milan criteria","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Atezolizumab; Bevacizumab; Liver transplantation; Hepatocellular carcinoma; Transplantation; Oncology; Cirrhosis; Internal medicine; Cancer research; Cancer; Immunotherapy; Chemotherapy; Nivolumab","score_opus":0.03240277524290608,"score_gpt":0.3159590780138492,"score_spread":0.2835563027709431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283776238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99642235,0.00094604,0.00005149413,0.0009410877,0.00011400209,0.0007738061,0.00028200552,0.0000113664655,0.00045782232],"genre_scores_gemma":[0.9976289,0.00039531657,0.0003145753,0.0010252952,0.000030740823,0.00012948304,0.0003313088,0.000016674334,0.00012770506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991738,0.000065257984,0.00023014331,0.00019765038,0.00015253718,0.00018060434],"domain_scores_gemma":[0.99950796,0.00006440379,0.00012650348,0.00012341257,0.00012666629,0.000051078136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016210641,0.00010515685,0.00027421088,0.00008999647,0.00010661802,0.0000037723555,0.00005735047,0.000057173325,0.00019761635],"category_scores_gemma":[0.000006522801,0.00009122053,0.00006750705,0.000086163534,0.000094766685,0.000049378217,0.000017425671,0.00007493104,3.528658e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26636067,0.0029514523,0.4435874,0.001933107,0.0009836188,0.00041398904,0.013401461,0.0000061053415,0.016742304,0.0003086174,0.014204175,0.2391071],"study_design_scores_gemma":[0.027653882,0.046415072,0.8135474,0.000048251077,0.00035692923,0.00028374742,0.00035947203,0.00045739606,0.010509275,0.00018353359,0.09988931,0.0002957382],"about_ca_topic_score_codex":0.00018690513,"about_ca_topic_score_gemma":0.000029025254,"teacher_disagreement_score":0.36996,"about_ca_system_score_codex":0.000048508424,"about_ca_system_score_gemma":0.00012920928,"threshold_uncertainty_score":0.3719865},"labels":[],"label_agreement":null},{"id":"W4284674170","doi":"10.1080/2162402x.2022.2096535","title":"<i>Helicobacter pylori</i> serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors","year":2022,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Jewish General Hospital; McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"Institute of Cancer Research; Canadian Institutes of Health Research; Institut Du Cancer de Montréal; Fonds de Recherche du Québec - Santé; Fondation pour la Recherche Nuovo-Soldati","keywords":"Helicobacter pylori; Medicine; Serology; Melanoma; Pembrolizumab; Immune system; Nivolumab; Immunology; Immune checkpoint; Oncology; Cancer research; Immunotherapy; Internal medicine; Antibody","score_opus":0.008021120937645447,"score_gpt":0.21284744110005052,"score_spread":0.20482632016240507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284674170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99578685,0.00037556278,0.0000022049185,0.0013751813,0.00023310148,0.00082248,0.000065920314,0.000108954126,0.0012297666],"genre_scores_gemma":[0.9964859,0.000038951915,0.000042806136,0.0012421026,0.000031833762,0.00020274073,0.0004951329,0.00008943169,0.0013711326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973552,0.0003186431,0.0005732332,0.0005955323,0.00045333113,0.00070402445],"domain_scores_gemma":[0.99870807,0.00008793369,0.00039750006,0.00057121547,0.0001646505,0.00007060446],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003454604,0.000428293,0.000897155,0.00032097657,0.00019477535,0.00001633626,0.00021485535,0.00021387386,0.0009881231],"category_scores_gemma":[0.000017357943,0.00030362397,0.00010929452,0.0008305841,0.0003468244,0.000116191884,0.0001218677,0.00079644803,0.000011603583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0624514,0.0015043572,0.9266497,0.000013291346,0.0015887765,0.00028082944,0.0009617348,0.000013786953,0.00468368,0.000011843407,0.00017412094,0.0016665112],"study_design_scores_gemma":[0.03508413,0.013303496,0.94310784,0.00011037086,0.00016357414,0.00010996915,0.00037367534,0.0000065715067,0.0015666201,0.0000050800195,0.0057613594,0.00040733663],"about_ca_topic_score_codex":0.0021377604,"about_ca_topic_score_gemma":0.00086587266,"teacher_disagreement_score":0.02736727,"about_ca_system_score_codex":0.0008905554,"about_ca_system_score_gemma":0.0003354607,"threshold_uncertainty_score":0.9999416},"labels":[],"label_agreement":null},{"id":"W4284703131","doi":"10.3389/fimmu.2022.906352","title":"Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade","year":2022,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"Medizinischen Fakultät, Eberhard Karls Universität Tübingen; Klaus Tschira Stiftung; European Research Council; H. Lundbeck A/S; Lundbeckfonden; Bristol-Myers Squibb; Carlsbergfondet; Eberhard Karls Universität Tübingen","keywords":"CD8; Blockade; Epitope; Melanoma; Flow cytometry; Cytotoxic T cell; Immunotherapy; Cancer research; T cell; Immune checkpoint; Biology; Immune system; Antigen; Immunology; Medicine; Internal medicine; Receptor; Biochemistry","score_opus":0.0190596029892993,"score_gpt":0.268901374262976,"score_spread":0.2498417712736767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284703131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885513,0.005035995,0.00028398033,0.002728187,0.0022981982,0.0005704505,0.000046166584,0.000024010807,0.00046170037],"genre_scores_gemma":[0.9962988,0.0013990568,0.0005795213,0.00064158515,0.000027335858,0.00006142995,0.00007958254,0.000031524047,0.0008811949],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974133,0.00066484686,0.0009178572,0.00033713173,0.00026809017,0.0003987952],"domain_scores_gemma":[0.9988506,0.00022644024,0.00033569272,0.0005264522,0.000035717436,0.000025093908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012848069,0.00019540297,0.0007274167,0.00030163568,0.00009206084,0.0000072066355,0.00042760093,0.00022170928,0.0001690694],"category_scores_gemma":[0.000032770575,0.00014617121,0.00017613429,0.00074955163,0.00048801771,0.000032474978,0.00010049783,0.0011381191,0.0000027291821],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011393826,0.0025871329,0.9672574,0.000025470323,0.0016929825,0.00041545375,0.0018760273,0.00025764422,0.003220274,0.00049009564,0.003600703,0.0071830144],"study_design_scores_gemma":[0.024558116,0.004031557,0.9432095,0.00008196996,0.0003069007,0.00023984481,0.012701691,0.00072613696,0.00032194363,0.000612591,0.012792409,0.00041729867],"about_ca_topic_score_codex":0.0002745889,"about_ca_topic_score_gemma":0.00025574415,"teacher_disagreement_score":0.024047835,"about_ca_system_score_codex":0.00040504022,"about_ca_system_score_gemma":0.00016206715,"threshold_uncertainty_score":0.5960689},"labels":[],"label_agreement":null},{"id":"W4284964011","doi":"10.1002/cam4.4796","title":"Tertiary lymphoid structures in lung adenocarcinoma: characteristics and related factors","year":2022,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Education; National Natural Science Foundation of China; Natural Science Foundation of Beijing Municipality; Innovationsfonden; Capital Health","keywords":"Adenocarcinoma; Lung; Internal medicine; Oncology; Medicine; Cancer","score_opus":0.012631621660541971,"score_gpt":0.2716730135195787,"score_spread":0.2590413918590367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284964011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96159357,0.032867268,0.0000022300787,0.0037371903,0.0010063385,0.00033453983,0.00003904613,0.000041107778,0.00037868775],"genre_scores_gemma":[0.99568707,0.0013350513,0.000007228455,0.001910904,0.000182492,0.00006291759,0.00010470277,0.000027902763,0.00068172294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987407,0.00005573019,0.00037362514,0.00029390055,0.00029051866,0.00024554983],"domain_scores_gemma":[0.9994881,0.000052405856,0.00011307533,0.00021035144,0.000024993451,0.000111076624],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019507024,0.00017852217,0.0003869527,0.00021464632,0.000117618816,0.0000046767873,0.00008833664,0.00006023933,0.0035309717],"category_scores_gemma":[0.000037246766,0.00013772998,0.000042299387,0.00034660465,0.00019246888,0.000040746025,0.000062253435,0.00031285876,4.0257552e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089359604,0.00003270761,0.9681057,0.000135298,0.00012389908,0.00017301674,0.0032138375,0.0000018165746,0.0145502165,0.000036389953,0.0033601606,0.009373381],"study_design_scores_gemma":[0.0050175567,0.00026430684,0.9853944,0.0001431749,0.000115756884,0.00027524884,0.0011865647,0.00014807127,0.0003751848,0.00006023474,0.006870232,0.00014926857],"about_ca_topic_score_codex":0.0009092585,"about_ca_topic_score_gemma":0.000019301693,"teacher_disagreement_score":0.034093488,"about_ca_system_score_codex":0.00048339556,"about_ca_system_score_gemma":0.00016242609,"threshold_uncertainty_score":0.99737996},"labels":[],"label_agreement":null},{"id":"W4285043434","doi":"10.1200/jco.22.00825","title":"Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston General Hospital; Princess Margaret Cancer Centre; Queen's University; University Health Network; Juravinski Cancer Centre","funders":"","keywords":"Nivolumab; Medicine; Ipilimumab; Atezolizumab; Oncology; Internal medicine; Guideline; Lung cancer; Chemotherapy; Cancer; Clinical trial; Randomized controlled trial; Immunotherapy; Pathology","score_opus":0.10364059094424469,"score_gpt":0.4805426847156378,"score_spread":0.37690209377139317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285043434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96700585,0.0066900216,0.005263888,0.015276479,0.0038138235,0.00093979074,0.000034943103,0.000014536952,0.0009606726],"genre_scores_gemma":[0.911392,0.010308644,0.019621,0.04241209,0.0048774183,0.00018966262,0.000014904703,0.00007075587,0.011113526],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964247,0.00035670627,0.0024371597,0.000207921,0.00032998272,0.00024354384],"domain_scores_gemma":[0.9958417,0.0015197489,0.001777002,0.00020013942,0.0004822322,0.00017918293],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005126186,0.000144298,0.0010040147,0.00012719868,0.00017613696,0.000014566231,0.00022208992,0.00016056414,0.0023899851],"category_scores_gemma":[0.0005272438,0.00010789902,0.00068646873,0.00014403989,0.00009196483,0.000087626715,0.000060476646,0.00079844025,0.0000013134126],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053914994,0.005606599,0.26319858,0.00013568779,0.0028824783,0.00025589098,0.0015465523,0.0011553754,0.017849332,0.0000386765,0.24488828,0.40852752],"study_design_scores_gemma":[0.021864086,0.014935403,0.04044252,0.000106451625,0.00035761023,0.00010473818,0.00046917968,0.004558553,0.0002843806,0.000025752615,0.91667956,0.00017176729],"about_ca_topic_score_codex":0.00008501461,"about_ca_topic_score_gemma":0.00008537981,"teacher_disagreement_score":0.67179126,"about_ca_system_score_codex":0.00036781156,"about_ca_system_score_gemma":0.0030732981,"threshold_uncertainty_score":0.998522},"labels":[],"label_agreement":null},{"id":"W4285390563","doi":"10.1007/s00432-022-04181-0","title":"Safety and efficacy of pembrolizumab for advanced nonsmall cell lung cancer: before and during the COVID-19 pandemic","year":2022,"lang":"en","type":"article","venue":"Journal of Cancer Research and Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Surrey Memorial Hospital; University of Victoria; University of British Columbia","funders":"BC Cancer Foundation","keywords":"Pembrolizumab; Medicine; Cohort; Internal medicine; Lung cancer; Pandemic; Population; Adverse effect; Cohort study; Odds ratio; Retrospective cohort study; Cancer; Oncology; Coronavirus disease 2019 (COVID-19); Immunotherapy; Disease","score_opus":0.09538815471989688,"score_gpt":0.5145710105056397,"score_spread":0.4191828557857428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285390563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9491094,0.032249276,0.000019039024,0.017563123,0.00023694124,0.00066982105,0.000062288855,0.0000038147264,0.00008632774],"genre_scores_gemma":[0.9096721,0.08816468,0.00007853173,0.0011796711,0.00033419242,0.000064869244,0.0000015793883,0.0000144168,0.0004899868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977805,0.00040847118,0.00087785197,0.00021866093,0.0003943558,0.00032016437],"domain_scores_gemma":[0.9959956,0.0027768926,0.0004855739,0.00013613777,0.0002544369,0.0003513653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003973247,0.00010223925,0.00062206725,0.0001294166,0.00040230053,0.000010953593,0.00016227088,0.00010661955,0.00019081224],"category_scores_gemma":[0.0005214039,0.00006545843,0.00015658027,0.00018862438,0.0007667813,0.000049616527,0.00016919138,0.0010072474,3.424179e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2706666,0.0006241117,0.49954915,0.0008204424,0.0008652067,0.00008242378,0.0010496473,0.000050951436,0.007653807,0.000052495892,0.0025606845,0.21602449],"study_design_scores_gemma":[0.08358852,0.027483726,0.45429796,0.00017092079,0.00040203638,0.0008573911,0.0019356253,0.00019810535,0.00020294178,0.00025762618,0.43044108,0.00016406558],"about_ca_topic_score_codex":0.00031492065,"about_ca_topic_score_gemma":0.0009229295,"teacher_disagreement_score":0.4278804,"about_ca_system_score_codex":0.00064855494,"about_ca_system_score_gemma":0.0023822829,"threshold_uncertainty_score":0.43760446},"labels":[],"label_agreement":null},{"id":"W4285419401","doi":"10.46747/cfp.6707e174","title":"L’immunothérapie","year":2021,"lang":"en","type":"article","venue":"Canadian Family Physician","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières","funders":"","keywords":"Medicine; Gynecology; Humanities; Philosophy","score_opus":0.016933253897547663,"score_gpt":0.24054859774792367,"score_spread":0.223615343850376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285419401","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1736185,0.01012035,0.000012643768,0.0038623596,0.0006220127,0.00018664099,0.000058327772,0.000064223655,0.81145495],"genre_scores_gemma":[0.6509807,0.00023182742,0.00017895109,0.34386897,0.00038553544,0.000014194535,0.000121153134,0.000041440333,0.004177227],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991376,0.00001818177,0.00013835581,0.00022002032,0.00012994334,0.0003558934],"domain_scores_gemma":[0.9991695,0.000012070032,0.000025198375,0.0003897009,0.00010126852,0.00030223452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000048495556,0.00012210128,0.00019124596,0.00009439065,0.000111546964,0.00003168591,0.00007098323,0.000069089605,0.000054902317],"category_scores_gemma":[0.0000057920442,0.00012749086,0.00015455786,0.00039901736,0.000066361,0.000054809803,0.0000063550733,0.00013474011,0.0002080056],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017919799,0.00011691967,0.00040398576,0.000053857028,0.00046520185,0.0012042942,0.0001517162,0.0000013585482,0.43985325,0.0014278089,0.16177572,0.39436668],"study_design_scores_gemma":[0.0011509965,0.00006167804,0.04096993,0.00008166503,0.000046818353,0.000014914878,0.00047886054,0.000010361067,0.013140567,0.0001442185,0.94371307,0.00018693152],"about_ca_topic_score_codex":0.006806743,"about_ca_topic_score_gemma":0.0063996436,"teacher_disagreement_score":0.80727774,"about_ca_system_score_codex":0.00029971183,"about_ca_system_score_gemma":0.001531613,"threshold_uncertainty_score":0.999807},"labels":[],"label_agreement":null},{"id":"W4285420323","doi":"10.46747/cfp.6707512","title":"Immunotherapy","year":2021,"lang":"en","type":"article","venue":"Canadian Family Physician","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"College of Family Physicians of Canada","funders":"","keywords":"Immunotherapy; Medicine; Kidney cancer; Metastatic melanoma; Nivolumab; Melanoma; Oncology; Ipilimumab; Cancer; Internal medicine; Renal cell carcinoma; Cancer research","score_opus":0.01676566096912104,"score_gpt":0.24730932893474594,"score_spread":0.2305436679656249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285420323","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25887558,0.013632225,0.000031850872,0.0047125476,0.0007245213,0.0002554684,0.000063515945,0.00008021783,0.7216241],"genre_scores_gemma":[0.46128887,0.0004418071,0.00029182486,0.5315518,0.0004684326,0.000018804902,0.00012248008,0.000055926805,0.0057600928],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991532,0.000020240786,0.00013838925,0.00021690874,0.00012887602,0.0003424111],"domain_scores_gemma":[0.9992152,0.000010783644,0.000025795214,0.0003840682,0.00009665158,0.00026752576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004922924,0.00012450633,0.00019800148,0.00009039209,0.00010587198,0.000031566877,0.00007059868,0.00006682108,0.00006640762],"category_scores_gemma":[0.0000031682466,0.00012712252,0.00016213056,0.00037491828,0.000060937993,0.000052041833,0.0000055934543,0.0001217309,0.00015964618],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019189609,0.00008237818,0.00041548698,0.000026529233,0.00034428271,0.00052700803,0.00012867384,8.969591e-7,0.4511391,0.0008120234,0.08454819,0.46178353],"study_design_scores_gemma":[0.0012930952,0.00006822334,0.042812932,0.000060975315,0.000022250146,0.000011019647,0.00039509675,0.000009700209,0.012000797,0.00015389523,0.94299537,0.00017662012],"about_ca_topic_score_codex":0.007061053,"about_ca_topic_score_gemma":0.0056458595,"teacher_disagreement_score":0.8584472,"about_ca_system_score_codex":0.00030271718,"about_ca_system_score_gemma":0.0014495036,"threshold_uncertainty_score":0.999551},"labels":[],"label_agreement":null},{"id":"W4285492295","doi":"10.1038/s43018-022-00420-y","title":"Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy","year":2022,"lang":"en","type":"erratum","venue":"Nature Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Immunotherapy; Vaccination; Coronavirus disease 2019 (COVID-19); Immunology; Cancer immunotherapy; Cancer; Cytokine release syndrome; Internal medicine; Immune system; Disease","score_opus":0.02461077739243508,"score_gpt":0.36356205484647663,"score_spread":0.3389512774540416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285492295","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.042209163,0.6359069,0.000104918254,0.096075214,0.21475369,0.004213327,0.0048964755,0.00088099693,0.0009593082],"genre_scores_gemma":[0.18797855,0.15845524,0.00008500159,0.10071381,0.0046300716,0.004546197,0.0012569319,0.0005894796,0.5417447],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99512446,0.00044495685,0.0010916545,0.001441258,0.0012352617,0.0006624035],"domain_scores_gemma":[0.9967538,0.0003015496,0.0010237795,0.0010044449,0.000424057,0.00049234217],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0008338602,0.0008846911,0.0013062862,0.00060136477,0.00039225863,0.00011549067,0.00034610982,0.002188195,0.016100353],"category_scores_gemma":[0.00030253766,0.0007844456,0.00052655686,0.0009124484,0.00018710518,0.0001562845,0.000157939,0.005181785,0.0000048929787],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031324293,0.00024883778,0.008518457,0.0008759219,0.0014511984,0.00068674877,0.000344506,0.000031324675,0.00013077876,0.0000057484795,0.93756425,0.018817909],"study_design_scores_gemma":[0.0042442987,0.0007275655,0.18876971,0.0010166031,0.00048769257,0.00041531905,0.0002962431,0.000036705736,0.000026845375,0.000039309307,0.803219,0.00072067307],"about_ca_topic_score_codex":0.0014605123,"about_ca_topic_score_gemma":0.002748889,"teacher_disagreement_score":0.5407854,"about_ca_system_score_codex":0.005578986,"about_ca_system_score_gemma":0.0048598032,"threshold_uncertainty_score":0.99946064},"labels":[],"label_agreement":null},{"id":"W4285493158","doi":"10.1126/sciimmunol.abn8097","title":"Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic T <sub>reg</sub> reduction and effector T cell activation","year":2022,"lang":"en","type":"article","venue":"Science Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Melanoma; Immunology; Blockade; Lymphatic system; T cell; Sentinel lymph node; CTLA-4; Immune system; Cancer research; Internal medicine; Cancer; Receptor","score_opus":0.007034484885960348,"score_gpt":0.23223688957578872,"score_spread":0.22520240468982838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285493158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99522126,0.0009780071,0.00029754706,0.0017591835,0.00088234403,0.00077153667,0.0000059906192,0.000025003726,0.000059111306],"genre_scores_gemma":[0.99921805,0.00007849887,0.000039292285,0.00045324396,0.00003543116,0.000088471956,0.0000047643593,0.000011043782,0.00007120197],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985769,0.00016793607,0.00026296524,0.00036048927,0.00033504385,0.0002966708],"domain_scores_gemma":[0.99926347,0.00007849639,0.000121893165,0.00037329155,0.00010455016,0.00005827387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093050004,0.00012346025,0.00024258536,0.00035160582,0.00036833904,0.000018554587,0.00026593494,0.000046320387,0.000026620337],"category_scores_gemma":[0.000064890104,0.00009554198,0.000050623472,0.0012610717,0.00058887055,0.00012841835,0.00017131904,0.00011835642,0.00001758186],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013045333,0.00006703893,0.00057263597,0.000045967237,0.00002094921,0.0000025850784,0.0010122258,0.00011882918,0.96853197,0.000012659255,0.00024082515,0.028069815],"study_design_scores_gemma":[0.0010927075,0.0014364744,0.044143483,0.00009608654,0.000024147625,0.00031087865,0.001744235,0.00017197916,0.95055056,0.000004662112,0.0003163627,0.00010843693],"about_ca_topic_score_codex":0.00026633134,"about_ca_topic_score_gemma":0.000004063948,"teacher_disagreement_score":0.043570846,"about_ca_system_score_codex":0.00048121338,"about_ca_system_score_gemma":0.00040469793,"threshold_uncertainty_score":0.3896089},"labels":[],"label_agreement":null},{"id":"W4285742106","doi":"10.5114/wo.2022.118004","title":"Nivolumab and ipilimumab therapy in a patient with non-small cell lung cancer with chronic kidney disease","year":2022,"lang":"pl","type":"article","venue":"Współczesna Onkologia","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ipilimumab; Nivolumab; Medicine; Kidney disease; Internal medicine; Kidney cancer; Lung cancer; Cancer; Oncology; Immunotherapy","score_opus":0.00781366102461687,"score_gpt":0.22953950371631576,"score_spread":0.2217258426916989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285742106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92565674,0.06793387,0.000025210564,0.0021991413,0.00054805493,0.0026775312,0.00034551162,0.00007000937,0.00054393604],"genre_scores_gemma":[0.9839817,0.008816944,0.000100832,0.0036900032,0.00019148969,0.0012925288,0.0001206029,0.0001226045,0.0016832533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962671,0.00028400085,0.00058057794,0.0011495308,0.00066456076,0.0010542292],"domain_scores_gemma":[0.9980798,0.00009073214,0.00038255067,0.0007996472,0.00009590158,0.0005513902],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033897813,0.00069411506,0.0007822206,0.0003237956,0.00045005736,0.000069956695,0.00034263282,0.00014783112,0.0028096838],"category_scores_gemma":[0.000013029691,0.0005234768,0.0001330013,0.0009190999,0.000450731,0.00012149337,0.00021061586,0.00095955736,0.0000057779025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14792684,0.0038275535,0.7241834,0.0021239496,0.0016708198,0.0049771573,0.011671573,0.0014325572,0.009199072,0.000025777834,0.012687066,0.080274254],"study_design_scores_gemma":[0.1713753,0.06730637,0.6422844,0.004921171,0.0018517784,0.0005183456,0.0070699877,0.012258907,0.0036055453,0.000029135825,0.084304534,0.0044745025],"about_ca_topic_score_codex":0.005118737,"about_ca_topic_score_gemma":0.0015054466,"teacher_disagreement_score":0.08189897,"about_ca_system_score_codex":0.0018964501,"about_ca_system_score_gemma":0.0040320028,"threshold_uncertainty_score":0.9997217},"labels":[],"label_agreement":null},{"id":"W4285992810","doi":"10.1056/nejmoa2202809","title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","year":2022,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1096,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck","keywords":"Pembrolizumab; Triple-negative breast cancer; Medicine; Chemotherapy; Breast cancer; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.01369630633823049,"score_gpt":0.2953716532372217,"score_spread":0.2816753468989912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285992810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93023866,0.008312799,0.000067589375,0.058241636,0.0015515944,0.0003704772,0.000018756358,0.000014394877,0.0011840613],"genre_scores_gemma":[0.9887834,0.0031523567,0.00014590425,0.003813027,0.0022673185,0.000012360504,0.000004495072,0.000026867618,0.0017942744],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982145,0.00011845172,0.0006204891,0.00015297592,0.00065562,0.00023796062],"domain_scores_gemma":[0.9990204,0.00012542473,0.0003933515,0.00015027706,0.00012061528,0.00018995059],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00080091605,0.00016878334,0.0006310365,0.0003455083,0.00007178788,0.0000043491123,0.00015904293,0.000038056547,0.0044727265],"category_scores_gemma":[0.000068139016,0.000116772644,0.00011602519,0.00052394724,0.00009572727,0.000086845495,0.000020207686,0.000615827,6.910743e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12936223,0.00021340534,0.0105729215,0.000051350075,0.0003850333,0.0006237005,0.0072540115,0.0003546674,0.019253809,0.000025885225,0.019107163,0.8127958],"study_design_scores_gemma":[0.6348619,0.005601054,0.1755899,0.0008417667,0.00018154756,0.010014135,0.0027817748,0.00018496238,0.0009405376,0.00040126112,0.16833599,0.00026518464],"about_ca_topic_score_codex":0.0009850165,"about_ca_topic_score_gemma":0.00014815941,"teacher_disagreement_score":0.81253064,"about_ca_system_score_codex":0.00067175704,"about_ca_system_score_gemma":0.0007831718,"threshold_uncertainty_score":0.9964373},"labels":[],"label_agreement":null},{"id":"W4286293841","doi":"10.1200/jco.2022.40.16_suppl.2545","title":"Baseline peripheral T-cell composition in relation to radiographic phenotypes of immune-related pneumonitis.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health","keywords":"Medicine; Pneumonitis; Immune system; CD8; T cell; CXCR3; Immunology; Internal medicine; Gastroenterology; Chemokine; Lung; Chemokine receptor","score_opus":0.04137695127662742,"score_gpt":0.38370161056652324,"score_spread":0.3423246592898958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890167,0.0019252088,0.00011076516,0.0065354635,0.0010845357,0.000210948,0.000004948343,0.000005612038,0.0011058344],"genre_scores_gemma":[0.99685365,0.00057545607,0.0010602404,0.0012216099,0.00015093271,0.000004903695,0.000011271831,0.000011892767,0.000110053974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99590695,0.0007888575,0.0027439352,0.00012068637,0.0003066968,0.00013287165],"domain_scores_gemma":[0.997592,0.00065192796,0.0013624101,0.00012109851,0.0001649555,0.000107655025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046269945,0.00008550596,0.000866091,0.00034330023,0.000044894696,0.0000025826841,0.00011594791,0.0001523603,0.0006329996],"category_scores_gemma":[0.00024472864,0.00007413516,0.00051962637,0.00052032585,0.00009837339,0.000059603546,0.00003432112,0.0008687791,0.0000018008077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11246082,0.009923691,0.30804673,0.000104398576,0.00092774484,0.0009388743,0.0015999218,0.0045255665,0.28907114,0.0001381724,0.002771019,0.2694919],"study_design_scores_gemma":[0.019685995,0.02315529,0.93426406,0.00012438478,0.00021369733,0.00046134996,0.00035121088,0.0007114021,0.0006673192,0.00018366345,0.020058135,0.0001234794],"about_ca_topic_score_codex":0.000068772,"about_ca_topic_score_gemma":0.0000132381165,"teacher_disagreement_score":0.6262173,"about_ca_system_score_codex":0.0002313595,"about_ca_system_score_gemma":0.00053812674,"threshold_uncertainty_score":0.69309014},"labels":[],"label_agreement":null},{"id":"W4286294474","doi":"10.1200/jco.2022.40.16_suppl.e21549","title":"Long-term toxicities with immune checkpoint inhibitor (ICI) in melanoma patients.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Adverse effect; Melanoma; Regimen; Population; Adjuvant; Internal medicine; Ipilimumab; Surgery; Retrospective cohort study; Immunotherapy; Cancer","score_opus":0.06041713287285471,"score_gpt":0.3908551932033071,"score_spread":0.33043806033045237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919746,0.0010376591,0.000008832831,0.003930168,0.0013936887,0.00021011232,0.000004238108,0.0000060600373,0.0014346237],"genre_scores_gemma":[0.9964424,0.0003199891,0.0002545388,0.0019997512,0.00049425516,0.000010133771,0.000005936492,0.000016878306,0.0004561349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99652046,0.00036581722,0.0023160388,0.00014491349,0.00044196346,0.00021077799],"domain_scores_gemma":[0.99761033,0.0005124272,0.0014213339,0.00015805717,0.00016508783,0.00013278119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025837822,0.00011970913,0.0010778598,0.00018101133,0.000053962623,0.000005742964,0.00016250725,0.00013869687,0.00087801774],"category_scores_gemma":[0.00033561073,0.00008167242,0.00040505594,0.00020298598,0.00025431174,0.000079749516,0.00007941803,0.0011202869,0.0000032021198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06471877,0.003914673,0.813715,0.000037697457,0.00043390997,0.0012435813,0.0004900139,0.0000093749395,0.00097594684,0.000011766044,0.0008987234,0.11355058],"study_design_scores_gemma":[0.022847356,0.04197097,0.9161143,0.000114881535,0.000100263765,0.00042885874,0.00051838264,0.000004506543,0.0004652124,0.000025182513,0.017309258,0.00010085248],"about_ca_topic_score_codex":0.00004191909,"about_ca_topic_score_gemma":0.000088947476,"teacher_disagreement_score":0.11344973,"about_ca_system_score_codex":0.0004416551,"about_ca_system_score_gemma":0.001172583,"threshold_uncertainty_score":0.96136785},"labels":[],"label_agreement":null},{"id":"W4286294580","doi":"10.1200/jco.2022.40.16_suppl.tps9146","title":"EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non–small cell lung cancer (NSCLC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Gilead Sciences","keywords":"Medicine; Carboplatin; Lung cancer; Internal medicine; Chemotherapy; Oncology; Pembrolizumab; Cisplatin; Cancer; Phases of clinical research; Paclitaxel; Immunotherapy","score_opus":0.0822613191702985,"score_gpt":0.44876321393303004,"score_spread":0.36650189476273154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99371725,0.0012933704,0.00032174223,0.0019204635,0.0006919316,0.0015929792,0.000029697123,0.000012401955,0.00042018192],"genre_scores_gemma":[0.99463105,0.0008108688,0.0013154326,0.0018572317,0.00037489692,0.000119026336,0.00000455866,0.000064142456,0.00082281453],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99396306,0.00071929785,0.0036395474,0.0004122037,0.0008268702,0.00043899767],"domain_scores_gemma":[0.99418104,0.0014233015,0.003380188,0.00038723458,0.00033288545,0.0002953379],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003345583,0.0003453552,0.0030159024,0.00039911893,0.00011074942,0.00001182494,0.00041397865,0.00017137169,0.0015631344],"category_scores_gemma":[0.00025608955,0.00022753088,0.00046627523,0.00071647146,0.00022337247,0.00010666537,0.00008913212,0.0016399227,8.5325996e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75310904,0.032177504,0.09467998,0.00042483452,0.0034016802,0.0027733662,0.008142796,0.0022375588,0.0022389116,0.0000021860342,0.0016910689,0.099121064],"study_design_scores_gemma":[0.6188801,0.28302145,0.05733882,0.00065549323,0.0027448377,0.0014546376,0.0093513625,0.009131739,0.00067673385,0.000019335765,0.016122693,0.0006028013],"about_ca_topic_score_codex":0.0011124031,"about_ca_topic_score_gemma":0.0040870337,"teacher_disagreement_score":0.25084394,"about_ca_system_score_codex":0.0011688937,"about_ca_system_score_gemma":0.006447024,"threshold_uncertainty_score":0.9993496},"labels":[],"label_agreement":null},{"id":"W4286295232","doi":"10.1200/jco.2022.40.16_suppl.2589","title":"The effect of circadian rhythm on clinical outcome in patients receiving pembrolizumab in the INSPIRE pan-cancer trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Pembrolizumab; Medicine; Cohort; Internal medicine; Oncology; Melanoma; Adverse effect; Cancer; Immunotherapy; Breast cancer; Immune system; Immunology; Cancer research","score_opus":0.1164887187995321,"score_gpt":0.489061600304296,"score_spread":0.3725728815047639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98146844,0.00065942353,4.1950116e-7,0.011711685,0.0043846085,0.00077248435,0.000003838196,0.0000026658452,0.0009964213],"genre_scores_gemma":[0.9934385,0.0012304503,0.000010885824,0.0044040494,0.00077488687,0.000047463625,0.0000012769275,0.000014545779,0.000077965866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98919845,0.0051111095,0.004565156,0.00019515639,0.0006594823,0.00027066979],"domain_scores_gemma":[0.9820027,0.015030758,0.0024573593,0.00032125806,0.00009189808,0.000096060554],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.02473898,0.0001414705,0.0015539431,0.00015836088,0.00009898103,0.000008350051,0.00041697366,0.00025429612,0.000107704596],"category_scores_gemma":[0.0075268145,0.00007033252,0.0008789941,0.0003759326,0.0002852312,0.0000478501,0.00006993578,0.0026111354,0.0000023793061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22473061,0.0009542736,0.46557122,0.000009669122,0.00011648922,0.00007552082,0.000098599296,0.00000950861,0.0000016390303,0.0000065985087,0.0009367374,0.30748913],"study_design_scores_gemma":[0.12959978,0.07147972,0.7489308,0.00007967964,0.00008866272,0.000027807604,0.00010416324,0.000012533508,0.000002520103,0.000022989887,0.049596116,0.000055215507],"about_ca_topic_score_codex":0.00009599818,"about_ca_topic_score_gemma":0.00025945256,"teacher_disagreement_score":0.3074339,"about_ca_system_score_codex":0.00040712158,"about_ca_system_score_gemma":0.0009005006,"threshold_uncertainty_score":0.9996899},"labels":[],"label_agreement":null},{"id":"W4286295746","doi":"10.1200/jco.2022.40.16_suppl.2584","title":"Factors associated with acute kidney injury among patients with cancer treated with immune checkpoint inhibitor therapy: A population-based study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Acute kidney injury; Internal medicine; Interquartile range; Kidney disease; Nephrology; Cancer; Renal replacement therapy; Dialysis; Population; Adverse effect; Creatinine; Oncology","score_opus":0.05894117129586121,"score_gpt":0.3887593888572356,"score_spread":0.3298182175613744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972679,0.000066223525,0.0000049773093,0.0011905977,0.00042388384,0.00088372827,0.00009263267,0.000024907127,0.00004514656],"genre_scores_gemma":[0.99795556,0.000029308027,0.00004818444,0.0014691163,0.00014883842,0.000055049648,0.000097928074,0.00004978945,0.00014622505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961188,0.00068632385,0.0017612099,0.00027125512,0.0008828062,0.0002796454],"domain_scores_gemma":[0.99544126,0.00043392967,0.0029995088,0.00022936314,0.00057438825,0.0003215355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014214983,0.00027289122,0.001518556,0.00020248399,0.00018315435,0.000015456586,0.00017301046,0.00016971798,0.0006197122],"category_scores_gemma":[0.00027682562,0.00014069099,0.00032570376,0.0005694787,0.00016723412,0.00012409738,0.00002830953,0.0010974465,2.457867e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10535745,0.0057103354,0.87878007,0.000004577714,0.0045038993,0.00015229176,0.00018759284,0.000032119053,0.000102606355,1.1761583e-7,0.0003141587,0.004854777],"study_design_scores_gemma":[0.04494175,0.08905416,0.8633776,0.00015171454,0.00083097466,0.0000047504864,0.00018594865,0.000015688458,0.00014503858,9.70831e-7,0.0011162396,0.00017520074],"about_ca_topic_score_codex":0.00079259963,"about_ca_topic_score_gemma":0.00030253382,"teacher_disagreement_score":0.083343826,"about_ca_system_score_codex":0.0008919785,"about_ca_system_score_gemma":0.002881615,"threshold_uncertainty_score":0.6785414},"labels":[],"label_agreement":null},{"id":"W4286296240","doi":"10.1200/jco.2022.40.16_suppl.2505","title":"Phase 1 first-in-human study of anti–ILT3 mAb MK-0482 as monotherapy and in combination with pembrolizumab in advanced solid tumors: Dose escalation results.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of British Columbia; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Pharmacokinetics; Internal medicine; Pharmacology; Oncology; Adverse effect; Cancer; Immunotherapy","score_opus":0.05910397734427379,"score_gpt":0.457865669327313,"score_spread":0.3987616919830392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962918,0.00024378762,0.0000049761643,0.0024150023,0.00017505696,0.0006349558,0.0000032776488,0.0000037829648,0.0002273694],"genre_scores_gemma":[0.99903834,0.00037847873,0.00011896409,0.00033563052,0.000059599453,0.000018740247,0.0000055387463,0.000013810103,0.000030914092],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9960965,0.0005823509,0.0025770946,0.00021473654,0.00036471014,0.00016463958],"domain_scores_gemma":[0.99735326,0.00069435034,0.0016085894,0.0001537411,0.000114185656,0.000075885284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033930328,0.00012002454,0.0011485124,0.00044467676,0.000043744367,0.0000051357883,0.00011342231,0.000110838584,0.00006432939],"category_scores_gemma":[0.00036208538,0.00009575299,0.00009741874,0.0004087396,0.0001129261,0.00013508699,0.000031568994,0.00079362944,1.8787765e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.499809,0.052090976,0.32042968,0.000050007537,0.00024040438,0.0016034864,0.00440378,0.001424752,0.0043438324,0.00003251178,0.0001018668,0.11546968],"study_design_scores_gemma":[0.23288378,0.102149926,0.66100305,0.00014855977,0.00003832104,0.0001407392,0.0019913716,0.00043843494,0.000111692134,0.00019804311,0.0008118919,0.00008417871],"about_ca_topic_score_codex":0.00027678514,"about_ca_topic_score_gemma":0.001361689,"teacher_disagreement_score":0.34057337,"about_ca_system_score_codex":0.00034348076,"about_ca_system_score_gemma":0.0005127526,"threshold_uncertainty_score":0.39046937},"labels":[],"label_agreement":null},{"id":"W4286296256","doi":"10.1200/jco.2022.40.16_suppl.5506","title":"Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Carboplatin; Pembrolizumab; Adenosquamous carcinoma; Oncology; Internal medicine; Cervical cancer; Population; Chemotherapy; Adenocarcinoma; Hazard ratio; Cisplatin; Cancer; Confidence interval; Immunotherapy","score_opus":0.08432459763388121,"score_gpt":0.4298550331995215,"score_spread":0.3455304355656403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99450964,0.0008937972,0.000022349604,0.003533534,0.00055437005,0.00027053518,0.000037504782,0.000004141367,0.00017415948],"genre_scores_gemma":[0.99597245,0.0009591734,0.00051649945,0.002236582,0.00011175147,0.000013951979,0.000015597847,0.000018443945,0.00015556012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957555,0.00063552725,0.0024274455,0.00022751895,0.00071058015,0.00024346022],"domain_scores_gemma":[0.99619174,0.0008828697,0.0022062627,0.00022220219,0.00030916507,0.00018773433],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022046925,0.00015723704,0.0021455018,0.00054900924,0.000045944525,0.0000046751243,0.00024409719,0.000110156194,0.0029416198],"category_scores_gemma":[0.00027537526,0.00009930582,0.0011210637,0.001255243,0.00020293477,0.00006836003,0.00004648475,0.00087860774,5.479121e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25171766,0.0053622182,0.6283721,0.000043759956,0.008499597,0.00011945015,0.00032102177,0.00020812199,0.00002278762,0.0000052174005,0.0007524794,0.10457565],"study_design_scores_gemma":[0.043312572,0.041689206,0.8898517,0.000060217855,0.0039073634,0.00003836435,0.00037741396,0.00039436552,0.0000077123,0.000007776751,0.020237112,0.000116217234],"about_ca_topic_score_codex":0.00020701904,"about_ca_topic_score_gemma":0.000563537,"teacher_disagreement_score":0.26147965,"about_ca_system_score_codex":0.0005705979,"about_ca_system_score_gemma":0.0016748552,"threshold_uncertainty_score":0.9979698},"labels":[],"label_agreement":null},{"id":"W4286299150","doi":"10.1200/jco.2022.40.16_suppl.e18780","title":"COVID-19 vaccine humoral response and treatment effect in patients with hematologic malignancy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Internal medicine; Titer; Vaccination; Gastroenterology; Immunology; Hematologic malignancy; Serology; Antibody titer; Antibody","score_opus":0.06993593062474698,"score_gpt":0.4419147618172505,"score_spread":0.3719788311925035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286299150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98829377,0.0006495973,0.0000033604174,0.01032246,0.00030959494,0.00034644082,0.000004525677,0.000005342561,0.00006489867],"genre_scores_gemma":[0.99376,0.00017449998,0.0002284851,0.005625314,0.00006991973,0.000015634241,0.0000029297137,0.000008857099,0.00011437561],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969349,0.0013809232,0.0011387485,0.00015389732,0.00023409697,0.00015747064],"domain_scores_gemma":[0.99622154,0.002514625,0.0008049507,0.00012106157,0.000051444073,0.000286353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003864711,0.00011639191,0.0011351018,0.00015584475,0.000059712045,0.000003419218,0.00007200885,0.0001034333,0.00037575117],"category_scores_gemma":[0.0015205889,0.000064501684,0.00019080123,0.00016218446,0.00008288514,0.00003399126,0.000037078247,0.00040723247,8.965609e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3251581,0.0014378323,0.65107495,0.000012629074,0.00018113093,0.0013410577,0.00009422109,0.000006882707,0.000037458634,0.000002917543,0.0008629902,0.019789826],"study_design_scores_gemma":[0.056281887,0.14140192,0.76345265,0.000023595632,0.00012266627,0.00044744668,0.00006888061,0.0000037765749,0.000015997244,0.000025404726,0.038098846,0.000056908495],"about_ca_topic_score_codex":0.000042533902,"about_ca_topic_score_gemma":0.000051302068,"teacher_disagreement_score":0.2688762,"about_ca_system_score_codex":0.0007926284,"about_ca_system_score_gemma":0.0016355001,"threshold_uncertainty_score":0.41142118},"labels":[],"label_agreement":null},{"id":"W4286299175","doi":"10.1200/jco.2022.40.16_suppl.e24043","title":"Patients' perspectives and safety of COVID-19 vaccination among cancer patients: A prospective single-center study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Université de Sherbrooke","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Vaccination; Tolerability; Lung cancer; Cancer; Common Terminology Criteria for Adverse Events; Population; Malignancy; Confidence interval; Immunology","score_opus":0.06046458249867042,"score_gpt":0.43211973444953944,"score_spread":0.371655151950869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286299175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99534506,0.00043888646,0.000019286013,0.0020691457,0.00078040373,0.00080029585,0.00002795773,0.0000050066424,0.0005139502],"genre_scores_gemma":[0.9982883,0.00033338863,0.000070051414,0.0010105089,0.00017673692,0.000024282308,0.0000033678825,0.000011005698,0.0000823893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970704,0.0006054534,0.0015635053,0.00019385375,0.0004424954,0.0001243388],"domain_scores_gemma":[0.9964301,0.0006891245,0.0019224328,0.00009733942,0.00068006915,0.00018093236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018495793,0.000102092774,0.00080846885,0.00015005974,0.00010359383,0.0000047477415,0.00009691816,0.00008967408,0.0006707442],"category_scores_gemma":[0.0019717584,0.00007727926,0.000250409,0.0001960014,0.00015331052,0.00011000055,0.00008728037,0.00053874135,1.8541378e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03815703,0.015144511,0.9031433,0.00002312093,0.00063086825,0.000019780593,0.004553884,0.000006111643,0.000019054758,0.000010054263,0.0011069045,0.037185412],"study_design_scores_gemma":[0.036822546,0.0432084,0.90117985,0.00002076649,0.00020254283,0.000012951552,0.006014809,0.000006262308,0.0000059482254,0.00003961971,0.012420194,0.000066109686],"about_ca_topic_score_codex":0.000112866845,"about_ca_topic_score_gemma":0.00015361526,"teacher_disagreement_score":0.037119303,"about_ca_system_score_codex":0.0012645781,"about_ca_system_score_gemma":0.0009224401,"threshold_uncertainty_score":0.7344179},"labels":[],"label_agreement":null},{"id":"W4286299180","doi":"10.1200/jco.2022.40.16_suppl.2520","title":"Effect of intratumoral INT230-6 on tumor necrosis and promotion of a systemic immune response: Results from a multicenter phase 1/2 study of solid tumors with and without pembrolizumab (PEM) [Intensity IT-01; Merck KEYNOTE-A10].","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Nausea; Cancer; Vomiting; Internal medicine; Pembrolizumab; Gastroenterology; Adverse effect; Immunotherapy","score_opus":0.053420525828164714,"score_gpt":0.42683596112054406,"score_spread":0.37341543529237936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286299180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970955,0.0002924262,0.000008255935,0.0010550186,0.00037388524,0.001068427,0.00008755341,0.0000057223733,0.000013168435],"genre_scores_gemma":[0.9994215,0.00009179714,0.0001604693,0.00016751135,0.000091523325,0.000015177319,0.0000054898182,0.000021441385,0.000025105805],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99263513,0.0028702992,0.0034134034,0.00031992566,0.0005689958,0.00019222472],"domain_scores_gemma":[0.9919778,0.0028969147,0.004237947,0.00031820472,0.00040229986,0.0001668494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008359463,0.0002240135,0.0027111,0.00024535955,0.00006308228,0.0000054118113,0.00015878597,0.000121074554,0.0000256814],"category_scores_gemma":[0.002915451,0.00014677116,0.0002708707,0.0002197048,0.00047575365,0.000075111675,0.000110048255,0.000931616,1.6915716e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8611103,0.0067213443,0.035563696,0.00018420178,0.0010760421,0.00034594382,0.0022933022,0.00001156254,0.08241996,3.4676518e-7,0.000114255134,0.010159037],"study_design_scores_gemma":[0.17271557,0.4867341,0.32237038,0.0015232424,0.0011889539,0.0012049611,0.0027649303,0.00033970186,0.01096897,0.0000042286133,0.000052181473,0.0001327836],"about_ca_topic_score_codex":0.00047722727,"about_ca_topic_score_gemma":0.000045412235,"teacher_disagreement_score":0.6883947,"about_ca_system_score_codex":0.00017761596,"about_ca_system_score_gemma":0.00065446197,"threshold_uncertainty_score":0.5985154},"labels":[],"label_agreement":null},{"id":"W4286491030","doi":"10.3390/ijms23148053","title":"Tumor-Stroma Ratio and Programmed Cell Death Ligand 1 Expression in Preoperative Biopsy and Matched Laryngeal Carcinoma Surgical Specimen","year":2022,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Università degli Studi di Padova","keywords":"Stroma; Pathological; Medicine; Pathology; Immunohistochemistry; Biopsy; Carcinoma; Surgical pathology; Oncology","score_opus":0.015377649980696878,"score_gpt":0.2837070014399951,"score_spread":0.26832935145929826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286491030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99581474,0.002286812,0.000051501385,0.001258559,0.00015614959,0.00013250989,0.000004798965,0.0000028136021,0.00029209538],"genre_scores_gemma":[0.9981763,0.00007785132,0.0014782234,0.00015649741,0.0000524564,0.0000069491075,0.0000021714823,0.0000041168782,0.00004543475],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99879324,0.00008140956,0.00026246376,0.00015212674,0.000600592,0.000110144436],"domain_scores_gemma":[0.9996265,0.000035011122,0.00015023733,0.000040811654,0.00008168592,0.00006575106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052340375,0.00007825806,0.00015180702,0.00019019595,0.00007966194,0.000075279895,0.00015838484,0.00001651904,0.00005106673],"category_scores_gemma":[0.0000134329375,0.000058770664,0.000046786925,0.00011838809,0.00014700883,0.00012847324,0.00009091773,0.00015163749,1.4483217e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022132972,0.00029373003,0.2552698,0.00001250535,0.00006370562,0.004475368,0.0018149064,0.000045630026,0.73277485,0.00013527562,0.000049449114,0.0028514722],"study_design_scores_gemma":[0.012025186,0.0037117545,0.5170576,0.00020684494,0.000047247497,0.01504748,0.0044338913,0.0012003217,0.44400612,0.00040422502,0.0015762993,0.00028302876],"about_ca_topic_score_codex":0.000041445976,"about_ca_topic_score_gemma":0.0000025053969,"teacher_disagreement_score":0.28876874,"about_ca_system_score_codex":0.00007370586,"about_ca_system_score_gemma":0.00017692042,"threshold_uncertainty_score":0.2396598},"labels":[],"label_agreement":null},{"id":"W4286511961","doi":"10.1016/j.annonc.2022.05.065","title":"PS2-2 KEYNOTE-355 Asian subset: Pembrolizumab + chemotherapy vs placebo + chemotherapy for triple-negative breast cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Chemotherapy; Oncology; Triple-negative breast cancer; Breast cancer; Internal medicine; Placebo; Cancer; Pathology; Immunotherapy; Alternative medicine","score_opus":0.04495780894443804,"score_gpt":0.3732214279464666,"score_spread":0.3282636190020286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286511961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73825264,0.0026987917,0.00020652403,0.24093091,0.0015510604,0.0042449054,0.0017138335,0.00015570351,0.0102456175],"genre_scores_gemma":[0.95689666,0.0029248206,0.00051691814,0.033529025,0.0005629359,0.0011692557,0.000103055565,0.00011250722,0.004184804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99772495,0.00018001934,0.0006293428,0.00049374276,0.00037500987,0.00059691694],"domain_scores_gemma":[0.99840456,0.00023844159,0.0004884932,0.0004159064,0.00030236176,0.00015023378],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000719285,0.00031646056,0.00092543574,0.00024767168,0.0002445067,0.000010547252,0.00030998842,0.00020360219,0.0050537735],"category_scores_gemma":[0.000037939575,0.00029649917,0.00050455227,0.00046971205,0.0002917827,0.00008356762,0.00004715845,0.00033708895,0.0000047500303],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28768906,0.0017339292,0.0022698357,0.00017867617,0.0017515562,0.00003070516,0.0043600644,0.00001889741,0.020833837,0.00020287011,0.15310447,0.5278261],"study_design_scores_gemma":[0.072134726,0.014299141,0.056569483,0.00008188106,0.00014635573,0.00044929018,0.0016013553,0.00022152481,0.035797365,0.0007375855,0.8173975,0.0005638033],"about_ca_topic_score_codex":0.0007176117,"about_ca_topic_score_gemma":0.0001811683,"teacher_disagreement_score":0.66429305,"about_ca_system_score_codex":0.00039185057,"about_ca_system_score_gemma":0.0010800288,"threshold_uncertainty_score":0.99994874},"labels":[],"label_agreement":null},{"id":"W4286602972","doi":"10.1200/jco.22.00221","title":"Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Royal Victoria Hospital; University of Toronto; University Health Network; McGill University; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Population; Gastroenterology; Lenvatinib; Phases of clinical research; Oncology; Immunotherapy; Toxicity; Cancer","score_opus":0.12266143385166989,"score_gpt":0.46588470242273133,"score_spread":0.34322326857106145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286602972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987153,0.00018164724,0.000045174304,0.0031567558,0.00034885682,0.008955527,0.000010133847,0.000023023424,0.0001258584],"genre_scores_gemma":[0.99462825,0.00006112114,0.0024427949,0.0005272862,0.0002600561,0.0013580584,0.000017043247,0.000053885695,0.0006515229],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9947486,0.00080824236,0.0027919703,0.00040142497,0.0008413247,0.00040842473],"domain_scores_gemma":[0.99470955,0.0010980851,0.0032031797,0.000266056,0.00048320214,0.00023993617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003608563,0.0002953129,0.0018463327,0.00034387,0.00018517926,0.000018396933,0.00027259637,0.00027343584,0.000103781735],"category_scores_gemma":[0.0007367804,0.00017203792,0.00033436142,0.00045233616,0.0001705039,0.00010119235,0.000062852545,0.0009993267,5.0936706e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6223753,0.07721262,0.005404952,0.00013665119,0.00053206744,0.0006825212,0.0019664995,0.000008688543,0.0026739165,0.000016836459,0.00023381603,0.28875613],"study_design_scores_gemma":[0.29951826,0.66335773,0.004993401,0.00035816804,0.00025472054,0.0002501477,0.002268022,0.00016561439,0.0045748423,0.00006053908,0.024011066,0.00018750834],"about_ca_topic_score_codex":0.0001118653,"about_ca_topic_score_gemma":0.00021045598,"teacher_disagreement_score":0.5861451,"about_ca_system_score_codex":0.00056587363,"about_ca_system_score_gemma":0.005092242,"threshold_uncertainty_score":0.9033418},"labels":[],"label_agreement":null},{"id":"W4287448591","doi":"10.1016/j.lungcan.2022.07.018","title":"PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC","year":2022,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; University Health Network; University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Cytology; Medicine; Histology; Internal medicine; Lung cancer; PD-L1; Biomarker; Oncology; Cancer; Pathology; Gastroenterology; Immunotherapy; Biology","score_opus":0.05902054763603569,"score_gpt":0.4145764070750323,"score_spread":0.3555558594389966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4287448591","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032213184,0.99000865,0.000003546806,0.0012059415,0.0011662641,0.0034370655,0.00023741096,0.00004742345,0.0006723987],"genre_scores_gemma":[0.00036981993,0.99156344,0.00013396422,0.0004546495,0.00027836635,0.0054787565,0.00018029849,0.00008760263,0.0014530831],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99664474,0.00059285376,0.0010637086,0.00076702045,0.0003784405,0.00055322715],"domain_scores_gemma":[0.99858767,0.00038372926,0.00027134304,0.0005829003,0.000020601898,0.00015375725],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008385322,0.00053786236,0.0020224813,0.0008453213,0.000054888693,0.000018897614,0.00019651855,0.00030135424,0.0019612925],"category_scores_gemma":[0.00007305023,0.0004280033,0.00049730175,0.0010328545,0.000059769518,0.000037503585,0.000112479844,0.0005929915,0.0000067485794],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058586327,0.00035572168,0.0017555153,0.0038111839,0.00053547916,0.00038032254,0.00077032566,0.000008578735,0.000059624454,0.000006346434,0.0021868711,0.9842714],"study_design_scores_gemma":[0.0030884135,0.0009171822,0.005351533,0.01231027,0.00047026423,0.00005843697,0.00010443372,0.000006175551,0.000013275075,0.000001835956,0.9773208,0.00035736107],"about_ca_topic_score_codex":0.004614522,"about_ca_topic_score_gemma":0.0034348825,"teacher_disagreement_score":0.983914,"about_ca_system_score_codex":0.012139352,"about_ca_system_score_gemma":0.0037553788,"threshold_uncertainty_score":0.9998172},"labels":[],"label_agreement":null},{"id":"W4288084598","doi":"10.3389/fimmu.2022.938063","title":"The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment","year":2022,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Immunoediting; Tumor microenvironment; Immune system; Radiation therapy; Immunotherapy; Medicine; Cancer; Immunology; Cancer immunology; Disease; Immune checkpoint; Cancer research; Immunity; Internal medicine","score_opus":0.0141655170892208,"score_gpt":0.26987916142185103,"score_spread":0.2557136443326302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288084598","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013802868,0.99499905,0.000047859932,0.00032228648,0.0015363895,0.0015846087,0.0000264603,0.000009200488,0.000093875395],"genre_scores_gemma":[0.00028786797,0.99744326,0.00021373143,0.00031822294,0.00006730275,0.0011980586,0.00006820098,0.0000660198,0.0003373352],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967958,0.0007652829,0.0012409586,0.00043123477,0.000284327,0.0004824502],"domain_scores_gemma":[0.99802923,0.00020216107,0.00058441237,0.0011577593,0.0000074520044,0.000018974057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001047781,0.00042852445,0.0016504495,0.00031384552,0.00009555887,0.000014261757,0.00084427925,0.00025718825,0.0005653524],"category_scores_gemma":[0.00002756083,0.00024122195,0.00065138587,0.00041034687,0.00053671096,0.00003286813,0.00016104133,0.001114321,0.000004287939],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014484779,0.00026518953,0.0004925297,0.0012779183,0.00047570234,0.000098409415,0.00097613176,1.109388e-7,0.00038348205,5.7718404e-7,0.002062346,0.99251914],"study_design_scores_gemma":[0.001875494,0.00029161855,0.002327633,0.002936759,0.00013335877,0.00019507339,0.0008714794,0.0000013061841,0.0001125625,0.000009678279,0.9910256,0.00021943059],"about_ca_topic_score_codex":0.0001584772,"about_ca_topic_score_gemma":0.000015244574,"teacher_disagreement_score":0.9922997,"about_ca_system_score_codex":0.00083198096,"about_ca_system_score_gemma":0.00018759568,"threshold_uncertainty_score":0.9836745},"labels":[],"label_agreement":null},{"id":"W4288725086","doi":"10.3390/vaccines10081195","title":"Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis","year":2022,"lang":"en","type":"review","venue":"Vaccines","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"National Cancer Institute","keywords":"Medicine; Vaccination; Meta-analysis; Adverse effect; Internal medicine; Immunogenicity; Influenza vaccine; Observational study; Immune system; Immunology","score_opus":0.04856518752876719,"score_gpt":0.3283916035510482,"score_spread":0.279826416022281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288725086","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011786778,0.99535733,0.0000022371096,0.00005147958,0.000049765644,0.0043007373,0.00002769191,0.000020537322,0.00007233091],"genre_scores_gemma":[0.0001737188,0.9989044,0.00003924236,0.000094336174,0.000016849359,0.00037512343,0.00023392282,0.000048104215,0.00011429776],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9955793,0.000520553,0.0027820615,0.00046382096,0.00046443538,0.00018981472],"domain_scores_gemma":[0.99658066,0.00040742842,0.0020690027,0.000753427,0.00013818796,0.000051299536],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017243522,0.00048166508,0.008356539,0.0008311632,0.000054471173,0.000015311183,0.00017382433,0.00012893969,0.0007377653],"category_scores_gemma":[0.00047464002,0.00028170357,0.0020429245,0.0027248973,0.000011701314,0.000086847125,0.00009311681,0.00030371675,0.0000016518165],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003609419,0.00018686145,0.00018694896,0.8714096,0.08097071,0.000003474624,0.00007270149,9.575419e-7,2.1190897e-7,0.0000011619446,0.000016432135,0.04679],"study_design_scores_gemma":[0.002578635,0.0003817012,0.0047082244,0.19111504,0.74304265,0.000019705707,0.000018492143,0.0000017384011,0.000002111069,4.53172e-7,0.05774101,0.00039023373],"about_ca_topic_score_codex":0.00012885814,"about_ca_topic_score_gemma":0.000042620846,"teacher_disagreement_score":0.6802946,"about_ca_system_score_codex":0.0002658975,"about_ca_system_score_gemma":0.00013561099,"threshold_uncertainty_score":0.9999635},"labels":[],"label_agreement":null},{"id":"W4289517208","doi":"10.3389/fonc.2022.843707","title":"Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis","year":2022,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Chinese Society of Clinical Oncology","keywords":"Medicine; Incidence (geometry); Internal medicine; Cochrane Library; Meta-analysis; Oncology; Odds ratio; Hazard ratio; Disease; Cancer; Gastroenterology; Confidence interval","score_opus":0.033071071848177105,"score_gpt":0.32809520556474653,"score_spread":0.29502413371656944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289517208","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014412431,0.9936317,0.0000049161667,0.00014731828,0.0002546292,0.0051805107,0.0005833086,0.00002582591,0.000027638407],"genre_scores_gemma":[0.000084468,0.99329126,0.00015552988,0.00034697956,0.000018777213,0.003993686,0.0017912094,0.000059682166,0.00025840136],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9947424,0.001292088,0.0024326243,0.00078457006,0.00033524437,0.00041306092],"domain_scores_gemma":[0.99753785,0.00022212596,0.0013461716,0.0006909452,0.00004747725,0.00015540169],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00084574637,0.00064326165,0.0130504705,0.0007832379,0.000059014677,0.000020846353,0.0002736853,0.00030509158,0.00048117392],"category_scores_gemma":[0.00031048703,0.0004565571,0.0024032344,0.0014517177,0.00016193192,0.00006571807,0.00016604162,0.00055082695,0.0000025890824],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006838799,0.001039609,0.0026203024,0.7503743,0.21304764,0.00044247461,0.00029795736,3.7068685e-7,8.4598815e-7,2.9622436e-7,0.0029868595,0.02850542],"study_design_scores_gemma":[0.0016636321,0.00039894696,0.0001933678,0.04316988,0.80224913,0.000006911931,0.000089118905,0.0000063478797,8.3034655e-7,0.0000041144226,0.15171981,0.000497923],"about_ca_topic_score_codex":0.000494443,"about_ca_topic_score_gemma":0.000034902387,"teacher_disagreement_score":0.70720446,"about_ca_system_score_codex":0.0017315528,"about_ca_system_score_gemma":0.00035797575,"threshold_uncertainty_score":0.99978864},"labels":[],"label_agreement":null},{"id":"W4289755198","doi":"10.1002/cam4.5070","title":"Comparing the associations between host and tumor factors with survival outcomes with <scp>anti‐PD</scp>‐1 immunotherapy in metastatic melanoma","year":2022,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of Calgary","funders":"","keywords":"Medicine; Melanoma; Immunotherapy; Internal medicine; Neutrophilia; Lactate dehydrogenase; Gastroenterology; Lymphocytopenia; Neutrophil to lymphocyte ratio; Nivolumab; Metastasis; Anemia; Oncology; Cancer; Immunology; Lymphocyte; Cancer research","score_opus":0.04446327441637379,"score_gpt":0.30342953619613394,"score_spread":0.2589662617797602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289755198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98887575,0.005120833,0.000056587865,0.004407703,0.00021719719,0.00069779815,0.00008491431,0.00004453947,0.00049470074],"genre_scores_gemma":[0.9976998,0.00023887571,0.000035953646,0.0012154321,0.00010490647,0.0001578351,0.000075443306,0.000045981804,0.00042578182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811006,0.00016372542,0.00039448682,0.0003168444,0.0006511953,0.00036370207],"domain_scores_gemma":[0.9985038,0.00075981265,0.00027117395,0.000308789,0.00006243607,0.00009397981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067394297,0.00027355278,0.00087834767,0.00017980818,0.00033189138,0.000019187479,0.00018239768,0.00002344036,0.00015418924],"category_scores_gemma":[0.000062658844,0.00014267735,0.000053861146,0.00070157327,0.00033973355,0.00007284752,0.000044333538,0.00045241028,5.28525e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024895486,0.00005207033,0.9923126,0.000029965604,0.00083807186,0.00003270557,0.004922942,0.0000205726,0.00074780587,0.00003577745,0.0003264328,0.0004320681],"study_design_scores_gemma":[0.008334198,0.0008779264,0.9754533,0.00014782322,0.0003089595,0.00002106313,0.007347795,0.00002189146,0.00021360173,0.000009824697,0.0071648112,0.000098776916],"about_ca_topic_score_codex":0.0055374764,"about_ca_topic_score_gemma":0.0015055679,"teacher_disagreement_score":0.016859304,"about_ca_system_score_codex":0.00038703723,"about_ca_system_score_gemma":0.00026130205,"threshold_uncertainty_score":0.8371045},"labels":[],"label_agreement":null},{"id":"W4289820683","doi":"10.1200/jco.2022.40.17_suppl.lba8511","title":"Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Pathological; Clinical endpoint; Internal medicine; Oncology; Nivolumab; Lung cancer; Neoadjuvant therapy; Receiver operating characteristic; Post-hoc analysis; Stage (stratigraphy); Chemotherapy; non-small cell lung cancer (NSCLC); Surrogate endpoint; Cancer; Clinical trial; Immunotherapy; Breast cancer","score_opus":0.06948997712028145,"score_gpt":0.4151919174606839,"score_spread":0.34570194034040247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289820683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987472,0.0012198974,0.0002081115,0.0068838354,0.0021159349,0.00084037706,0.000047819645,0.000012878948,0.0011991424],"genre_scores_gemma":[0.9908065,0.002065479,0.0030735563,0.0011506818,0.00089678273,0.00009945105,0.000022733393,0.000058032663,0.0018267663],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99518126,0.00057176535,0.0025386112,0.00038429498,0.00082267966,0.0005013851],"domain_scores_gemma":[0.9929471,0.002148407,0.0038438386,0.0003746475,0.00049976434,0.00018624635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007813046,0.00026276647,0.001980906,0.00018356416,0.00011790588,0.000012274581,0.00046779195,0.0005111937,0.00053481385],"category_scores_gemma":[0.0011464701,0.00018949904,0.00063664507,0.00041183885,0.00012801096,0.00011151334,0.00014417528,0.0014466521,5.326268e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55872357,0.005681894,0.31105554,0.00038417845,0.0013355128,0.0005021235,0.0010524016,0.0005323229,0.034211613,0.000015253566,0.030087607,0.056417983],"study_design_scores_gemma":[0.46719494,0.075314924,0.3663355,0.0013529751,0.0012586945,0.00022428867,0.0021084545,0.004704134,0.018746775,0.00021994529,0.061633047,0.0009063213],"about_ca_topic_score_codex":0.00023144642,"about_ca_topic_score_gemma":0.00046770438,"teacher_disagreement_score":0.09152862,"about_ca_system_score_codex":0.0016301994,"about_ca_system_score_gemma":0.0026070725,"threshold_uncertainty_score":0.7727546},"labels":[],"label_agreement":null},{"id":"W4290065735","doi":"10.1002/ijc.34218","title":"A multi‐omic single cell sequencing approach to develop a <scp>CD8</scp> T cell specific gene signature for <scp>anti‐PD1</scp> response in solid tumors","year":2022,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Transcriptome; CD8; T-cell receptor; Nivolumab; Biology; Immune checkpoint; Gene signature; Immune system; T cell; Cancer research; Cytotoxic T cell; Cell; Immunotherapy; Immunology; Gene; Computational biology; Gene expression; Genetics; In vitro","score_opus":0.03204679548992201,"score_gpt":0.29758501904518186,"score_spread":0.26553822355525986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290065735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842021,0.00836198,0.0035907538,0.0007835784,0.0016624731,0.0005971036,0.00020060317,0.000017957102,0.00058347866],"genre_scores_gemma":[0.9832192,0.0003363145,0.009584536,0.0025247568,0.0007392381,0.00013539074,0.000036402293,0.00007261134,0.0033515536],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971355,0.00015902992,0.00092031754,0.00036963302,0.000990282,0.00042520065],"domain_scores_gemma":[0.9976376,0.0004837122,0.0006603538,0.00018074572,0.00085737795,0.00018020018],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013396231,0.0002696536,0.0004942065,0.0008000744,0.00011208628,0.00007704318,0.0005628465,0.000103855586,0.00008248537],"category_scores_gemma":[0.00034695753,0.0002524406,0.00028118346,0.0006380781,0.000052888645,0.00015905702,0.00012269936,0.0006452687,0.0000044886547],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00379016,0.00056985073,0.001252696,0.000050096558,0.00030162276,0.0002769922,0.0044244477,0.011680429,0.9531445,0.0000033267606,0.022785313,0.0017205916],"study_design_scores_gemma":[0.015254956,0.001332359,0.017804649,0.00044776464,0.00011412345,0.00092002796,0.0057428917,0.001479141,0.639805,0.00004142234,0.31688473,0.00017294766],"about_ca_topic_score_codex":0.000102153885,"about_ca_topic_score_gemma":0.000026612845,"teacher_disagreement_score":0.31333947,"about_ca_system_score_codex":0.0034849362,"about_ca_system_score_gemma":0.0017788246,"threshold_uncertainty_score":0.9999928},"labels":[],"label_agreement":null},{"id":"W4290466119","doi":"10.3390/curroncol29080441","title":"Immune Biomarkers in Blood from Sarcoma Patients: A Pilot Study","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Universiti Malaya","keywords":"Medicine; Immune system; Sarcoma; Immunology; Tumor necrosis factor alpha; Cancer research; Cytokine; Biology; Pathology","score_opus":0.0725129018308545,"score_gpt":0.36165803247732575,"score_spread":0.28914513064647124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290466119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894061,0.0060564047,0.000002165936,0.0004516723,0.002227385,0.001167089,0.000063056505,0.000045017798,0.00058108335],"genre_scores_gemma":[0.9988681,0.00016295587,0.00003247056,0.00022461996,0.00008784609,0.00036563637,0.00019719944,0.000021344686,0.000039834853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981655,0.00036499722,0.0005084091,0.0003732265,0.00029171826,0.0002961875],"domain_scores_gemma":[0.9992843,0.000119724325,0.00015110968,0.00033425965,0.000042540767,0.0000680264],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004024102,0.00016441666,0.00041616074,0.00024469759,0.00011719995,0.000006909778,0.00019524427,0.000029351282,0.0016127557],"category_scores_gemma":[0.000045130873,0.00015693104,0.000087801505,0.0004637749,0.00007975927,0.00003714194,0.00020557252,0.00039586704,0.000014655178],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012597634,0.03543815,0.837074,0.000017452672,0.00057842414,0.00011314259,0.0015623111,6.471514e-7,0.004746551,0.0000046034065,0.0019519941,0.10591514],"study_design_scores_gemma":[0.034000553,0.026566576,0.8562877,0.000029786417,0.00019267062,0.000014188805,0.0021494315,0.000016480506,0.0001140031,0.000035603247,0.08040726,0.0001857422],"about_ca_topic_score_codex":0.0012106339,"about_ca_topic_score_gemma":0.000293931,"teacher_disagreement_score":0.10572939,"about_ca_system_score_codex":0.000591997,"about_ca_system_score_gemma":0.00021853746,"threshold_uncertainty_score":0.9992999},"labels":[],"label_agreement":null},{"id":"W4290467448","doi":"10.3390/cancers14153808","title":"Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Region Hovedstaden; Canadian Cancer Society","keywords":"Medicine; Oncology; Cyclophosphamide; Breast cancer; Chemotherapy; Immune system; Tissue microarray; Hazard ratio; Internal medicine; Cytotoxic T cell; FOXP3; CD8; Tumor-infiltrating lymphocytes; Biomarker; Cancer; Immunology; Biology; Confidence interval","score_opus":0.03410743516031906,"score_gpt":0.3392639275326478,"score_spread":0.3051564923723287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290467448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99344045,0.0011498751,0.000045336637,0.0005623909,0.0015176276,0.0016995431,0.00017866127,0.00006367808,0.0013424098],"genre_scores_gemma":[0.98766565,0.00041157665,0.00012905546,0.009400784,0.0012942231,0.0005938569,0.00007023512,0.000050208706,0.00038442612],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974909,0.00020503467,0.0008340539,0.00052771706,0.00052734494,0.00041499475],"domain_scores_gemma":[0.99857575,0.00040557137,0.00032042264,0.00056614913,0.000031668274,0.00010044174],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00096664374,0.00026515604,0.0005578403,0.00008633027,0.00022634851,0.000040757302,0.000393342,0.00008576858,0.0029680864],"category_scores_gemma":[0.00003982603,0.00020390359,0.00034295453,0.0004726231,0.00017689246,0.00007584546,0.0000405134,0.0004791742,0.000008256517],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5473715,0.0009851839,0.0019213848,0.00003599472,0.00074368546,0.00014490471,0.0068641617,0.00054241624,0.30943996,0.00001769845,0.010435329,0.12149777],"study_design_scores_gemma":[0.75463426,0.009694568,0.005614737,0.00026206506,0.00026689074,0.00003728287,0.007943985,0.002586413,0.12271095,0.000090393936,0.095294304,0.00086414587],"about_ca_topic_score_codex":0.0022122767,"about_ca_topic_score_gemma":0.00024788646,"teacher_disagreement_score":0.20726275,"about_ca_system_score_codex":0.0016958951,"about_ca_system_score_gemma":0.0013013211,"threshold_uncertainty_score":0.99794334},"labels":[],"label_agreement":null},{"id":"W4290793760","doi":"10.1097/der.0000000000000928","title":"Nivolumab-Induced Disseminated Morphea","year":2022,"lang":"en","type":"article","venue":"Dermatitis","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Morphea; Presentation (obstetrics); Nivolumab; Dermatology; Surgery; Immunology; Immunotherapy; Immune system","score_opus":0.013883184580721103,"score_gpt":0.26097288617009695,"score_spread":0.24708970158937585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290793760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981103,0.00053979974,0.000027104374,0.0068919663,0.0003673234,0.00023953458,0.000034018853,0.0001075206,0.0106897075],"genre_scores_gemma":[0.99072903,0.00003774832,0.000080225385,0.006014523,0.0000437704,0.0000722316,0.00008713018,0.000016194255,0.0029191154],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993141,0.00003577601,0.00015607371,0.000119855074,0.00022179016,0.00015238911],"domain_scores_gemma":[0.99966776,0.000017597413,0.0000434745,0.00019817367,0.00002146282,0.00005152676],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000080527294,0.0000760912,0.00013287908,0.000066193585,0.00017925791,0.000011467096,0.00007190459,0.000023031136,0.0055427705],"category_scores_gemma":[0.000009863127,0.00007612715,0.00007846104,0.00024461502,0.000021289405,0.000041445233,0.000040511302,0.00013590138,0.000042381183],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003058455,0.0003474571,0.009964117,0.00011858709,0.00027779935,0.0006766816,0.002398621,0.0000039685083,0.18245593,0.0001897865,0.66694844,0.13631274],"study_design_scores_gemma":[0.0037978906,0.000551,0.24798368,0.00005717267,0.00006428996,0.0015081285,0.0011998729,0.0004915931,0.040085107,0.00007249192,0.7039106,0.00027816094],"about_ca_topic_score_codex":0.00026957854,"about_ca_topic_score_gemma":0.000012651754,"teacher_disagreement_score":0.23801956,"about_ca_system_score_codex":0.00013377362,"about_ca_system_score_gemma":0.000055320044,"threshold_uncertainty_score":0.9953663},"labels":[],"label_agreement":null},{"id":"W4291012346","doi":"10.1016/j.ejca.2022.06.041","title":"Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sandoz; Merck Sharp and Dohme; EMD Serono; Genentech; Qbiotics; Sun Pharma; Astellas Pharma; Eisai; Daiichi-Sankyo; BeiGene; Regeneron Pharmaceuticals; Mylan; AstraZeneca; Amarin Corporation; Ono Pharmaceutical; Eli Lilly and Company; National Comprehensive Cancer Network; Les Laboratories Pierre Fabre; Array BioPharma; AbbVie; Daiichi Sankyo Europe; Bayer; Gilead Sciences; Sanofi; Celgene; Novartis; Merck; GlaxoSmithKline; American Society of Clinical Oncology; Bristol-Myers Squibb; Amgen; Hexal AG; Incyte; Pfizer; Gilead UK and Ireland Corporate Contributions; Castle Biosciences; Roche; Astellas Pharma US","keywords":"Medicine; Ipilimumab; Nivolumab; Melanoma; Cancer; Internal medicine; Hazard ratio; Oncology; Stage (stratigraphy); Adjuvant; Immunotherapy; Confidence interval","score_opus":0.02135862200431434,"score_gpt":0.31096001516852717,"score_spread":0.28960139316421285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291012346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99545956,0.0007648071,0.000014972036,0.00037252175,0.0011478945,0.00044813787,0.00006316566,0.000009077666,0.001719854],"genre_scores_gemma":[0.99822795,0.00015159191,0.00022845308,0.00013509378,0.00011866547,0.0000071044005,0.000008295817,0.000055940705,0.0010668881],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9974603,0.00042261824,0.0008537561,0.00019681935,0.00080862024,0.00025789926],"domain_scores_gemma":[0.9986111,0.000056162902,0.00075512007,0.00027862875,0.00019601447,0.000102961916],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009964657,0.00019788014,0.00060518284,0.00024873167,0.00008171949,0.00002306997,0.00022892596,0.000014746279,0.0024270366],"category_scores_gemma":[0.000023864464,0.00014757439,0.0001935639,0.00021504347,0.00006992125,0.00012633721,0.00008527513,0.00036630113,0.000002437652],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78519297,0.0016420525,0.14931433,0.000097177246,0.0013181239,0.00029536622,0.0027973272,0.0001452245,0.0016242217,0.000008011484,0.0012481472,0.05631703],"study_design_scores_gemma":[0.2973337,0.008689255,0.67685246,0.00025499862,0.0001865517,0.0000065361614,0.0011952826,0.0000070479296,0.00022224085,4.1183316e-7,0.015059865,0.00019167311],"about_ca_topic_score_codex":0.00010752767,"about_ca_topic_score_gemma":0.000017681063,"teacher_disagreement_score":0.5275381,"about_ca_system_score_codex":0.0005627233,"about_ca_system_score_gemma":0.0003470104,"threshold_uncertainty_score":0.9984849},"labels":[],"label_agreement":null},{"id":"W4291129604","doi":"10.1016/j.jval.2022.07.009","title":"A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer Immunotherapies","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Institute for Health and Care Research; Bristol-Myers Squibb","keywords":"Medicine","score_opus":0.08805298515709291,"score_gpt":0.40495892514454024,"score_spread":0.3169059399874473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291129604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742306,0.0046936786,0.00052248716,0.015506164,0.000754893,0.0016966071,0.00010927469,0.000056826113,0.0024295],"genre_scores_gemma":[0.98879033,0.0004689364,0.0027472582,0.005006926,0.00010364745,0.00054565846,0.000014834717,0.000039159448,0.0022832432],"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","domain_scores_codex":[0.99846965,0.00010934483,0.00064605137,0.0001988845,0.00027324632,0.00030285175],"domain_scores_gemma":[0.99937016,0.00009012044,0.0001425326,0.00025020313,0.000052798794,0.00009418279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016956141,0.0001043815,0.0003185097,0.0003485208,0.00018757413,0.000008351916,0.00012515497,0.000023138455,0.00054157875],"category_scores_gemma":[0.000022189268,0.0001098958,0.0000694999,0.0006413196,0.000015221017,0.000060376577,0.000060037975,0.00014281372,0.0000058136325],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025140808,0.00013152292,0.0062467325,0.0001998172,0.0001609574,9.3140824e-7,0.019220669,0.8695098,0.005660649,0.0012169392,0.0032192403,0.09191866],"study_design_scores_gemma":[0.01895334,0.009974916,0.07288029,0.0019085546,0.00009853924,0.00006476162,0.0217482,0.20162849,0.012184908,0.0023160758,0.6568316,0.0014103218],"about_ca_topic_score_codex":0.13877681,"about_ca_topic_score_gemma":0.0024864408,"teacher_disagreement_score":0.6678813,"about_ca_system_score_codex":0.001999844,"about_ca_system_score_gemma":0.0020086414,"threshold_uncertainty_score":0.86695814},"labels":[],"label_agreement":null},{"id":"W4291743883","doi":"10.3390/curroncol29080451","title":"Detection of Potential Mutated Genes Associated with Common Immunotherapy Biomarkers in Non-Small-Cell Lung Cancer Patients","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immunotherapy; Microsatellite instability; Wnt signaling pathway; Medicine; Cancer research; Lung cancer; AXIN2; Gene; Cancer; Mutation; Biology; Oncology; Genetics; Internal medicine; Microsatellite","score_opus":0.021859724258497776,"score_gpt":0.3188580003761313,"score_spread":0.2969982761176335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291743883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989662,0.00774902,0.000057470497,0.000100990124,0.0013449101,0.00089495484,0.000059713737,0.000028017606,0.00010293761],"genre_scores_gemma":[0.998279,0.0010789444,0.000012769513,0.00008667842,0.000031589123,0.00027501932,0.000175439,0.000029112001,0.00003144763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853706,0.00023796356,0.00043835692,0.00025804498,0.00024907413,0.00027949596],"domain_scores_gemma":[0.99925303,0.000051845596,0.0003738324,0.00015721685,0.00011951032,0.00004455797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029171267,0.00016960305,0.0004159865,0.0002749848,0.00011156349,0.0000046213495,0.00011985185,0.00009200388,0.00022234934],"category_scores_gemma":[0.0000070514648,0.00015285696,0.00011094498,0.00061273645,0.000101476646,0.000034034754,0.000048679558,0.0002999804,4.88741e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01569526,0.0036879336,0.54045564,0.00012548917,0.000776302,0.000028183302,0.0010585159,0.00016044328,0.17108206,2.3301354e-7,0.00026394607,0.266666],"study_design_scores_gemma":[0.041361347,0.006307815,0.9071885,0.0002249338,0.00033400854,0.000014595728,0.0006897972,0.0040881205,0.031974994,0.000004459192,0.0074180486,0.00039338315],"about_ca_topic_score_codex":0.0008674683,"about_ca_topic_score_gemma":0.00076363236,"teacher_disagreement_score":0.36673287,"about_ca_system_score_codex":0.001200326,"about_ca_system_score_gemma":0.00029325046,"threshold_uncertainty_score":0.62333256},"labels":[],"label_agreement":null},{"id":"W4292641407","doi":"10.1038/s41591-022-01933-w","title":"Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"Sanofi Genzyme; EMD Serono; AstraZeneca; Genentech; Amgen; Tizona Therapeutics; Chinese Society of Clinical Oncology; Astellas Pharma; Y-mAbs Therapeutics; Eisai; G1 Therapeutics; Lunit; Puma Biotechnology; Relay Therapeutics; Yuhan; Loxo Oncology; Ribon Therapeutics; Syndax Pharmaceuticals; BeiGene; Hong Kong Cancer Fund; Jounce Therapeutics; Regeneron Pharmaceuticals; Helsinn; Mirati Therapeutics; Mylan; Daiichi Sankyo Europe; Takeda Oncology; Foundation Medicine; GlaxoSmithKline; Vertex Pharmaceuticals; Array BioPharma; Gilead Sciences; Taiho Pharmaceutical; Merck KGaA; LEO Pharma; Eli Lilly and Company; Calithera Biosciences; AbbVie; Revolution Medicines; Exelixis; Sanofi; National Cancer Institute; Grifols; F. Hoffmann-La Roche; Roche; PharmaMar; OncoMed Pharmaceutical; Incyte; Pfizer; Bristol-Myers Squibb","keywords":"Atezolizumab; Medicine; Oncology; Internal medicine; Hazard ratio; Lung cancer; Clinical endpoint; Population; Cohort; Biomarker; Randomized controlled trial; Confidence interval; Cancer; Pembrolizumab; Immunotherapy","score_opus":0.010304609580355515,"score_gpt":0.3133534069105685,"score_spread":0.303048797330213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292641407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98846906,0.0028878562,0.00015454808,0.004410202,0.00054908905,0.003069326,0.00011920265,0.000043789554,0.00029692292],"genre_scores_gemma":[0.99298173,0.00010341398,0.001283056,0.003010628,0.00021016871,0.0005720021,0.0015295048,0.000041483774,0.00026802675],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965953,0.00033587267,0.00090727385,0.00047368734,0.0014018781,0.00028598515],"domain_scores_gemma":[0.99756527,0.0011972529,0.0005370946,0.0004043776,0.00019067185,0.00010532574],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015267553,0.00032023684,0.0021460298,0.0010586759,0.000084232655,0.0000050229714,0.00018240823,0.00008325292,0.0038700378],"category_scores_gemma":[0.00037760814,0.00019866537,0.0003313874,0.0030610892,0.00040454816,0.000051933606,0.000017858538,0.00069683645,3.6773457e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9777732,0.0011497111,0.000093137074,0.00009921505,0.008269662,0.00047308777,0.00037779557,0.00064881466,0.007054079,0.00003091428,0.00018759984,0.0038428097],"study_design_scores_gemma":[0.97482896,0.009136858,0.00141321,0.00015870434,0.0094563775,0.000047126887,0.00041480045,0.001318465,0.0018743491,0.000008533623,0.0011270047,0.0002155972],"about_ca_topic_score_codex":0.00034921814,"about_ca_topic_score_gemma":0.00007663367,"teacher_disagreement_score":0.007987147,"about_ca_system_score_codex":0.00032035183,"about_ca_system_score_gemma":0.000807155,"threshold_uncertainty_score":0.99704057},"labels":[],"label_agreement":null},{"id":"W4293009542","doi":"10.3390/cancers14174092","title":"MHC Class II Expression Influences the Composition and Distribution of Immune Cells in the Metastatic Colorectal Cancer Microenvironment","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; American Cancer Society","keywords":"Cytotoxic T cell; Stromal cell; Immune system; Tumor microenvironment; MHC class I; Colorectal cancer; Immunology; Medicine; Cancer research; Population; CD8; Granzyme B; Immune checkpoint; Major histocompatibility complex; CTL*; Biology; Cancer; Immunotherapy; Internal medicine","score_opus":0.010495086414263988,"score_gpt":0.25503566087929713,"score_spread":0.24454057446503313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293009542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99135137,0.006332835,0.000009778476,0.001514211,0.00014691871,0.00045717228,0.00015158122,0.000004104521,0.000032061045],"genre_scores_gemma":[0.9979385,0.0012274549,0.0000099608105,0.0004774697,0.000016853644,0.00024644457,0.000054385575,0.000004907549,0.000023992927],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992142,0.00012826835,0.00020244296,0.00012138797,0.00021759424,0.000116135176],"domain_scores_gemma":[0.99968237,0.000055642082,0.00012158057,0.00011577696,0.000009233703,0.000015404372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029685078,0.00007779534,0.00013620208,0.000022736074,0.00024629867,0.000006529485,0.000097500524,0.000014465382,0.000120323944],"category_scores_gemma":[0.0000024578342,0.00004595738,0.000050541817,0.00016405,0.00021924656,0.00003346949,0.000052055708,0.00014471952,1.7882788e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013750866,0.000043378972,0.0017261609,0.00003559707,0.000052097275,0.0000035712144,0.0028472946,0.0014353683,0.9888069,0.000010786723,0.001037194,0.002626541],"study_design_scores_gemma":[0.0044804267,0.0012374762,0.27783912,0.00026751857,0.00023782662,0.000053304935,0.013108468,0.00086097536,0.66141313,0.00003759013,0.040247288,0.0002169029],"about_ca_topic_score_codex":0.0013693626,"about_ca_topic_score_gemma":0.000055873497,"teacher_disagreement_score":0.3273938,"about_ca_system_score_codex":0.00078516226,"about_ca_system_score_gemma":0.00012431867,"threshold_uncertainty_score":0.20700757},"labels":[],"label_agreement":null},{"id":"W4293103691","doi":"10.3390/curroncol29090483","title":"Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Oncology; Metastatic breast cancer; Proportional hazards model; Gastroenterology; Neutrophil to lymphocyte ratio; Lymphocyte; Estrogen receptor; Breast cancer; Progression-free survival; Cancer; Overall survival","score_opus":0.051890225511975606,"score_gpt":0.38466148428155456,"score_spread":0.33277125876957897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293103691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867409,0.0070090247,0.000063591615,0.0029139174,0.0010823396,0.0016209267,0.00031557534,0.000019435522,0.00023432232],"genre_scores_gemma":[0.9976583,0.00052262103,0.00012612667,0.00041457993,0.000070167545,0.0010313812,0.00006566675,0.000018182562,0.00009295435],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99861,0.00025391683,0.00037536232,0.0002788399,0.00022974599,0.00025210524],"domain_scores_gemma":[0.99943364,0.0000936278,0.00014604919,0.00017161726,0.00007093329,0.00008411555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021510561,0.000148848,0.00042706562,0.00020192936,0.00006012079,0.0000036381234,0.0000960938,0.000026972939,0.00060793984],"category_scores_gemma":[0.000017183549,0.0001312773,0.00010577115,0.00047145874,0.000080449165,0.00002798754,0.000079896396,0.0001730044,0.000005220962],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027822431,0.011710502,0.2930882,0.000567668,0.0013010631,0.00041997063,0.008671585,0.0025646999,0.021699574,0.0006160034,0.0031865055,0.6283518],"study_design_scores_gemma":[0.016798323,0.007968005,0.92994744,0.00040163955,0.0006497334,0.000542178,0.0010261327,0.0015444037,0.0023069268,0.00007235123,0.038411193,0.0003316942],"about_ca_topic_score_codex":0.0006580777,"about_ca_topic_score_gemma":0.00012897301,"teacher_disagreement_score":0.63685924,"about_ca_system_score_codex":0.0020336087,"about_ca_system_score_gemma":0.0009038303,"threshold_uncertainty_score":0.6656515},"labels":[],"label_agreement":null},{"id":"W4293113555","doi":"10.14740/wjon1512","title":"Expression of Programmed Death Ligand 1 in Breast Cancer in Mexican Women","year":2022,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Quadrantectomy; Breast cancer; Immunohistochemistry; Cancer; Oncology; Modified Radical Mastectomy; Mastectomy; Lymph node; Stage (stratigraphy); Internal medicine; Axillary lymph nodes; Pathology","score_opus":0.01864395678300937,"score_gpt":0.326502661923463,"score_spread":0.30785870514045366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293113555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99195826,0.0015420803,0.0000011150656,0.005466143,0.00026154832,0.00015028655,0.000007573426,0.0000022652691,0.0006107462],"genre_scores_gemma":[0.9985175,0.0003989683,0.00012357437,0.0005262695,0.000083313025,0.000041981028,7.1302884e-7,0.00000815866,0.00029953418],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888474,0.00012765251,0.0005101758,0.00008088634,0.0001992049,0.00019731882],"domain_scores_gemma":[0.9994036,0.00005622101,0.00035285697,0.00007476035,0.00004664924,0.00006589568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007809019,0.00006739822,0.0004019052,0.00046482746,0.000022201186,0.0000020363618,0.00010253023,0.000031100655,0.00078362337],"category_scores_gemma":[0.000009551496,0.000053386495,0.00006922097,0.0004743539,0.000050484123,0.000028222628,0.0000384719,0.0003716389,1.2247901e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030461371,0.0014829598,0.464475,0.000054783774,0.000098809694,0.0006044485,0.0048548947,0.000091931615,0.17808966,0.000012566939,0.0011958805,0.31857768],"study_design_scores_gemma":[0.017926574,0.0034200463,0.83386976,0.00040539866,0.00003469921,0.0012394824,0.0033550006,0.000017251372,0.008015319,0.00012805525,0.13146372,0.00012468813],"about_ca_topic_score_codex":0.00032229864,"about_ca_topic_score_gemma":0.000797875,"teacher_disagreement_score":0.36939475,"about_ca_system_score_codex":0.0011758481,"about_ca_system_score_gemma":0.00062398444,"threshold_uncertainty_score":0.8580127},"labels":[],"label_agreement":null},{"id":"W4293181453","doi":"10.1093/rheumatology/keac133.046","title":"P047 The triple M threat of check-point inhibitors - an emerging overlap syndrome","year":2022,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Myasthenia gravis; Rituximab; Myositis; Internal medicine; Cyclophosphamide; Prednisolone; Myocarditis; Immunosuppression; myalgia; Chlorambucil; Gastroenterology; Surgery; Lymphoma; Chemotherapy","score_opus":0.020185111040649666,"score_gpt":0.2769904143092401,"score_spread":0.2568053032685904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293181453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99246293,0.0017996698,0.000009765121,0.0028783416,0.0005815526,0.00041614386,0.00003450341,0.000052285803,0.0017648219],"genre_scores_gemma":[0.99695474,0.00008383069,0.00005580919,0.0010880221,0.00011589219,0.00005916246,0.00004128649,0.000027261904,0.0015740221],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987716,0.000084869265,0.0002962611,0.00021462413,0.00040979014,0.00022286967],"domain_scores_gemma":[0.9992674,0.000032233052,0.000119888995,0.00048605507,0.00003680779,0.00005759969],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000528661,0.00012796397,0.00026365984,0.00008237731,0.00021049222,0.000012379584,0.00018876887,0.0000407574,0.0011988087],"category_scores_gemma":[0.000020906587,0.0000932176,0.00018003551,0.0003739472,0.000085976455,0.000084781816,0.0000986201,0.00023603693,0.0000055077394],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016972093,0.003328314,0.15341388,0.000558952,0.00278769,0.0010736404,0.028005805,0.00024688258,0.6002904,0.0019548007,0.078043304,0.113324195],"study_design_scores_gemma":[0.02108642,0.008704348,0.38176787,0.00038943932,0.0007412243,0.0027563001,0.029960038,0.0010936299,0.05011638,0.0010748234,0.5010525,0.0012570085],"about_ca_topic_score_codex":0.000545877,"about_ca_topic_score_gemma":0.000027412236,"teacher_disagreement_score":0.55017406,"about_ca_system_score_codex":0.00012615169,"about_ca_system_score_gemma":0.00009327013,"threshold_uncertainty_score":0.99971426},"labels":[],"label_agreement":null},{"id":"W4293243564","doi":"10.1016/j.kint.2022.07.019","title":"Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer","year":2022,"lang":"en","type":"article","venue":"Kidney International","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; School of Medicine, Stanford University; National Institute of General Medical Sciences; Universitätsklinikum Heidelberg; Sorbonne Université; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Genentech; Vlaamse regering; Otsuka Pharmaceutical; Universitair Medisch Centrum Groningen; University of Texas MD Anderson Cancer Center; Union Chimique Belge; International Society of Nephrology; University of Washington; Memorial Sloan-Kettering Cancer Center; Ohio State University; University of California, Los Angeles; Medac; Fonds Wetenschappelijk Onderzoek; University of Pennsylvania; Universität Heidelberg; Gilead Sciences; Leonard M. Miller School of Medicine; University of Toronto; Natera; Brigham and Women's Hospital; Assistance publique-Hôpitaux de Paris; Massachusetts General Hospital; GlaxoSmithKline; Mayo Clinic; University of Miami; Northwestern University; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Astex Pharmaceuticals; American Society of Nephrology","keywords":"Pembrolizumab; Medicine; Lung cancer; Internal medicine; Oncology; Kidney cancer; Acute kidney injury; Combination therapy; Cancer; Urology; Immunotherapy","score_opus":0.012829943455684462,"score_gpt":0.31773863125377394,"score_spread":0.3049086877980895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293243564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97342604,0.00023838892,0.00013929377,0.0136097,0.006591037,0.0018836601,0.001694479,0.00010427082,0.0023131273],"genre_scores_gemma":[0.9845576,0.0010347884,0.00034281085,0.007893159,0.00023111145,0.0016438542,0.002036304,0.00007478729,0.0021855342],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979933,0.000069682035,0.00047249589,0.00045172413,0.0006696886,0.0003431031],"domain_scores_gemma":[0.9990212,0.00005561648,0.00024347816,0.000250878,0.00023999998,0.00018884621],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022547513,0.00025061236,0.00029898458,0.0003947163,0.00020742996,0.000041237003,0.00032964072,0.000080133526,0.0021699339],"category_scores_gemma":[0.00013098998,0.00026071732,0.00021515047,0.00032628156,0.000047177502,0.0002556205,0.00006666454,0.0002873473,0.0000025085699],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42655975,0.0029735363,0.16607635,0.00010629193,0.0035532536,0.00001506802,0.0025099006,0.00009784854,0.03627139,0.0009692476,0.17751354,0.18335384],"study_design_scores_gemma":[0.27997163,0.004020622,0.1837631,0.00031658597,0.00015400695,0.000014052912,0.00011615448,0.0075898683,0.008967415,0.0002367966,0.51392835,0.0009213905],"about_ca_topic_score_codex":0.00013524726,"about_ca_topic_score_gemma":0.000006218194,"teacher_disagreement_score":0.33641484,"about_ca_system_score_codex":0.0017925007,"about_ca_system_score_gemma":0.0006670321,"threshold_uncertainty_score":0.9999845},"labels":[],"label_agreement":null},{"id":"W4293249108","doi":"10.21203/rs.3.rs-1613398/v1","title":"Early clonal expansion of tumor-infiltrating lymphocytes predicts response to immune checkpoint therapy","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"Cancer Council Western Australia; Australian Cancer Research Foundation; Simon Lee Foundation; National Health and Medical Research Council; Lee Foundation","keywords":"Immune system; Immune checkpoint; Cancer research; Tumor-infiltrating lymphocytes; Immunology; Biology; Medicine; Immunotherapy","score_opus":0.06153605369707184,"score_gpt":0.3864141602766142,"score_spread":0.32487810657954236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293249108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844755,0.008973668,0.000020837055,0.001878217,0.00036198998,0.003001331,0.00028394276,0.00014277117,0.00086174184],"genre_scores_gemma":[0.9951001,0.001575008,0.000700621,0.00015188537,0.00030209273,0.00082395406,0.0001807259,0.00010628286,0.0010593318],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9929847,0.0014579579,0.001015819,0.00086331135,0.0028535817,0.00082459213],"domain_scores_gemma":[0.99622494,0.00087717065,0.00028554304,0.0014895574,0.00079931493,0.00032346594],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0072847446,0.0003993376,0.00083673355,0.0010160683,0.0003356547,0.00008719087,0.0006481519,0.00026314062,0.0018106],"category_scores_gemma":[0.0010759386,0.00035338046,0.0005842677,0.0010328374,0.0002976165,0.00006759214,0.0011775051,0.001735607,0.000022339944],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.115361705,0.00041193893,0.0061344528,0.0011498736,0.00040989253,0.00026249074,0.0050517283,0.00009004973,0.8554518,0.000011815852,0.0010368492,0.014627367],"study_design_scores_gemma":[0.008688812,0.010818179,0.6321524,0.0054049473,0.00003634711,0.00009438923,0.0039252196,0.00026839308,0.3191623,0.00013063203,0.018688556,0.0006298327],"about_ca_topic_score_codex":0.0027541146,"about_ca_topic_score_gemma":0.000010151129,"teacher_disagreement_score":0.6260179,"about_ca_system_score_codex":0.0013414635,"about_ca_system_score_gemma":0.0039694593,"threshold_uncertainty_score":0.9998918},"labels":[],"label_agreement":null},{"id":"W4293581698","doi":"10.1016/j.annonc.2022.08.084","title":"Leveraging big data of immune checkpoint blockade response identifies novel potential targets","year":2022,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Public Health Ontario; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; Université de Montréal; University of Toronto; University Health Network; Artificial Intelligence in Medicine (Canada); Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Immune checkpoint; Medicine; Blockade; Oncology; Biomarker; Transcriptome; Immune system; Gene expression profiling; Immunotherapy; Gene signature; Cancer research; Computational biology; Gene; Bioinformatics; Internal medicine; Gene expression; Immunology; Biology; Genetics; Receptor","score_opus":0.3409202798145177,"score_gpt":0.4489994096355463,"score_spread":0.10807912982102857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293581698","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00069524616,0.99461496,0.00004419612,0.0012915122,0.0016980362,0.0006718031,0.0005555764,0.000021827547,0.00040686261],"genre_scores_gemma":[0.0005762638,0.99669284,0.00017970179,0.00020142211,0.0003176398,0.00004545298,0.00087958924,0.000058150068,0.0010489229],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962598,0.0005029088,0.0018767267,0.000564573,0.0004234552,0.00037254312],"domain_scores_gemma":[0.9961169,0.00052787474,0.0016391602,0.0014970687,0.00014413084,0.00007486661],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036186473,0.0003555191,0.0027845837,0.0005429888,0.00008150965,0.000008189949,0.0008854373,0.00035751043,0.00094751245],"category_scores_gemma":[0.0005690414,0.00030876117,0.00097641296,0.00046536,0.00033611958,0.000060700873,0.00082797214,0.00056071836,0.0000065061495],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006156549,0.0006599023,8.504012e-7,0.00726913,0.0020894392,0.0001477812,0.00021129493,5.380704e-7,0.011659535,0.0000015325185,0.0032426696,0.96856076],"study_design_scores_gemma":[0.001660771,0.0015185402,0.000101441234,0.0028505733,0.001055412,0.00052680884,0.00015955382,0.0000036047538,0.001376818,0.000008309096,0.99050593,0.00023221805],"about_ca_topic_score_codex":0.00037789866,"about_ca_topic_score_gemma":0.000009874633,"teacher_disagreement_score":0.98726326,"about_ca_system_score_codex":0.00012807263,"about_ca_system_score_gemma":0.0022540234,"threshold_uncertainty_score":0.9999657},"labels":[],"label_agreement":null},{"id":"W4293776153","doi":"10.3390/curroncol29090492","title":"Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Immune system; Cancer research; Immune checkpoint; Cancer; Immunology; Oncology; Bioinformatics; Immunotherapy; Internal medicine; Biology","score_opus":0.14249894894921702,"score_gpt":0.4288219183545983,"score_spread":0.28632296940538127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293776153","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09421355,0.8995406,0.00000215317,0.00030572902,0.002714138,0.0030445014,0.00008352873,0.000028931194,0.000066875626],"genre_scores_gemma":[0.000114726055,0.996601,0.000060113645,0.00024396634,0.0003668391,0.0019411804,0.00009317234,0.00008321471,0.0004957871],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969728,0.00064601057,0.0010234338,0.0006913691,0.00017821652,0.0004881907],"domain_scores_gemma":[0.99825835,0.00059703295,0.00039303364,0.0005163966,0.00005418541,0.0001810017],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001147878,0.00051012135,0.0020700993,0.0005959943,0.00007963177,0.00003230853,0.00023311835,0.0003528764,0.00083722494],"category_scores_gemma":[0.00010736638,0.00041598722,0.00047085577,0.0006643173,0.000089458896,0.000051574032,0.00023253057,0.0010248226,0.000010287576],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065035718,0.0005442924,0.00086028525,0.0037818707,0.00015715855,0.000086874345,0.0008322793,1.8174336e-7,0.0004373547,3.8663435e-7,0.0017001118,0.9850956],"study_design_scores_gemma":[0.0042848648,0.0014416582,0.0026031733,0.006291706,0.0002912158,0.00006106708,0.000084028565,0.0000022286886,0.0000362315,4.3662294e-7,0.9845027,0.00040072994],"about_ca_topic_score_codex":0.00036468275,"about_ca_topic_score_gemma":0.00016934704,"teacher_disagreement_score":0.9846949,"about_ca_system_score_codex":0.002512296,"about_ca_system_score_gemma":0.0020095606,"threshold_uncertainty_score":0.9998292},"labels":[],"label_agreement":null},{"id":"W4294051614","doi":"10.1038/s41388-022-02443-2","title":"GPNMB: a potent inducer of immunosuppression in cancer","year":2022,"lang":"en","type":"review","venue":"Oncogene","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"Biology; Immunosuppression; Immune system; Context (archaeology); Tumor microenvironment; Immunology; Cancer research; Cancer; Tumor progression; Acquired immune system; Innate immune system; Metastasis","score_opus":0.12521407266969967,"score_gpt":0.4189559654040242,"score_spread":0.2937418927343245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294051614","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036898867,0.99625486,4.909223e-7,0.000056179357,0.0005675139,0.00079696666,0.00010517046,0.0000140072325,0.0018358345],"genre_scores_gemma":[0.0000726911,0.99766564,0.000043933414,0.0000943422,0.0001311572,0.00039382488,0.00016295485,0.000057454516,0.0013779713],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982998,0.00012531185,0.0007016015,0.00031374788,0.00033943492,0.00022014129],"domain_scores_gemma":[0.9990881,0.00005674458,0.00037098138,0.00041083802,0.000023230567,0.000050099112],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002811105,0.00027184677,0.0014825623,0.00030428736,0.000031707994,0.000004561537,0.0001882249,0.00022997166,0.004500304],"category_scores_gemma":[0.000018166937,0.00020316632,0.0005581083,0.0005804923,0.000046657893,0.00002302269,0.00011340934,0.0004325688,0.0000072472876],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025308228,0.00019725124,0.000014685549,0.006226613,0.00030247305,0.000050594685,0.00007756129,2.605122e-7,0.00089956145,0.0000011486717,0.0007705584,0.9912062],"study_design_scores_gemma":[0.0010553896,0.00019990171,0.00003877025,0.014476754,0.0005044189,0.00006996277,0.000027273847,4.9371744e-7,0.00026447416,0.0000015102387,0.983174,0.00018704902],"about_ca_topic_score_codex":0.0010180566,"about_ca_topic_score_gemma":0.000038299713,"teacher_disagreement_score":0.9910192,"about_ca_system_score_codex":0.00072329585,"about_ca_system_score_gemma":0.0010455863,"threshold_uncertainty_score":0.9964097},"labels":[],"label_agreement":null},{"id":"W4294214767","doi":"10.1007/s00432-022-04283-9","title":"FLOT and CROSS chemotherapy regimens alter the frequency of CD27+ and CD69+ T cells in oesophagogastric adenocarcinomas: implications for combination with immunotherapy","year":2022,"lang":"en","type":"article","venue":"Journal of Cancer Research and Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Irish Research Council; Science Foundation Ireland; Irish Research Council for Science, Engineering and Technology; Irish Research eLibrary","keywords":"Ex vivo; Immunotherapy; In vivo; Chemotherapy; Cancer research; Cytotoxic T cell; Immunology; Biology; In vitro; Pharmacology; Medicine; Internal medicine; Immune system; Biochemistry","score_opus":0.09685836843418835,"score_gpt":0.48796427215686355,"score_spread":0.3911059037226752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294214767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9567111,0.017503683,0.000033767446,0.024955705,0.000093282775,0.000620556,0.00002340766,0.0000017419013,0.000056751254],"genre_scores_gemma":[0.97583705,0.022699276,0.00031086922,0.0007660237,0.000118590586,0.00009608124,0.0000015017117,0.000013552439,0.0001570701],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983869,0.0003023756,0.0006712903,0.00017160461,0.00025140686,0.00021641007],"domain_scores_gemma":[0.99778306,0.0012378605,0.0003749366,0.00014499947,0.00036369645,0.00009546275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032125486,0.00008197302,0.00041103654,0.00017656147,0.000180543,0.000018261253,0.0001316195,0.000076418575,0.00005818158],"category_scores_gemma":[0.00005816187,0.00005097236,0.00007440393,0.00029435602,0.00077408133,0.00006529942,0.00003888678,0.00060652115,4.1809887e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043484755,0.0015813082,0.72933114,0.00009697366,0.000674787,0.000023201786,0.0010258546,0.0000047209555,0.030719647,0.00060672406,0.0017098107,0.19074109],"study_design_scores_gemma":[0.0218528,0.024089089,0.9378633,0.00005195528,0.000042748954,0.00018408014,0.00054086995,0.000025361996,0.00085078966,0.0023502018,0.012084203,0.000064588414],"about_ca_topic_score_codex":0.00023842654,"about_ca_topic_score_gemma":0.00015715459,"teacher_disagreement_score":0.20853218,"about_ca_system_score_codex":0.00020055668,"about_ca_system_score_gemma":0.00076393306,"threshold_uncertainty_score":0.28521347},"labels":[],"label_agreement":null},{"id":"W4294233822","doi":"10.1038/s41423-022-00911-z","title":"Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis","year":2022,"lang":"en","type":"article","venue":"Cellular and Molecular Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"China Postdoctoral Science Foundation; Central South University; National Natural Science Foundation of China; National Key Research and Development Program of China; Gastroenterological Society of Australia","keywords":"Sphingosine kinase 1; Cancer research; Sphingosine; Melanoma; Immunotherapy; Immune system; Biology; Monoclonal antibody; Tumor microenvironment; Immune checkpoint; Immunology; Antibody; Sphingosine-1-phosphate; Receptor","score_opus":0.007167238602927729,"score_gpt":0.22112935661713357,"score_spread":0.21396211801420584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294233822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9187257,0.075602554,0.00034541846,0.003993354,0.00029433574,0.0006052567,0.0000146586635,0.0000653085,0.0003533831],"genre_scores_gemma":[0.99693674,0.00025573338,0.00015123894,0.001354109,0.00003552601,0.000109010885,0.00017371462,0.000047987276,0.0009359396],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99835455,0.00024949491,0.00036777335,0.00039854215,0.00024564294,0.0003839981],"domain_scores_gemma":[0.999095,0.000047742556,0.0001568082,0.00059971056,0.00004910615,0.00005158359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000503463,0.00023450087,0.00033961257,0.00009496024,0.000604995,0.000030200488,0.00021599553,0.00006544957,0.00041129833],"category_scores_gemma":[0.000059448736,0.00018262815,0.00018839719,0.00029042395,0.00030758488,0.000039860213,0.00029905938,0.00045746623,0.0000053583535],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011306243,0.0001416091,0.00011946047,0.000034669654,0.00024510178,0.00019061113,0.0003305738,0.000002272086,0.98743755,0.00015077068,0.00062594,0.009590796],"study_design_scores_gemma":[0.0036666077,0.0013215205,0.001450856,0.000055880373,0.00016753722,0.0011221669,0.00085930584,0.00023985826,0.8822586,0.00019078639,0.10836287,0.00030403977],"about_ca_topic_score_codex":0.0003271984,"about_ca_topic_score_gemma":0.0000020252241,"teacher_disagreement_score":0.10773693,"about_ca_system_score_codex":0.00009863897,"about_ca_system_score_gemma":0.00008207303,"threshold_uncertainty_score":0.74473596},"labels":[],"label_agreement":null},{"id":"W4294243626","doi":"10.1038/s41598-022-19256-8","title":"ICOS is upregulated on T cells following radiation and agonism combined with radiation results in enhanced tumor control","year":2022,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; Medical Research Council; National Institutes of Health; Jounce Therapeutics","keywords":"CD8; Radiation therapy; Cancer research; Downregulation and upregulation; Agonist; Immune checkpoint; Immune system; Antibody; Medicine; T cell; Regimen; Blockade; Immunology; Immunotherapy; Biology; Receptor; Internal medicine","score_opus":0.006020562826586259,"score_gpt":0.22889778485375475,"score_spread":0.2228772220271685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294243626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995057,0.00018294365,0.000023509978,0.001032738,0.0021761134,0.000970369,0.000011025212,0.00004193355,0.0005043943],"genre_scores_gemma":[0.9975146,0.0000057270845,0.00003311971,0.0004902949,0.000022274982,0.000071624454,0.00015127468,0.000014462003,0.0016966284],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99814343,0.00007532322,0.00046137572,0.0005696331,0.0005400072,0.00021021081],"domain_scores_gemma":[0.99912626,0.000040081995,0.00031356927,0.0004158821,0.0000374275,0.00006675431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013359365,0.000121787474,0.0002283568,0.00024924622,0.00029301117,0.00008617736,0.000039827788,0.000030434354,0.000088655266],"category_scores_gemma":[0.000041588683,0.00010525818,0.00006728482,0.00059694867,0.00006951597,0.00009806802,0.00001469214,0.00013726114,0.0000016690144],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0084248325,0.00024611625,0.0022482816,0.000022527343,0.00011208056,0.000744989,0.0022959723,0.0004583937,0.9596547,0.0000030590145,0.007979562,0.017809518],"study_design_scores_gemma":[0.030767009,0.002623765,0.08866517,0.00021337111,0.00015441825,0.00029628916,0.00050655106,0.004358008,0.83327335,0.00025520203,0.038375743,0.0005111398],"about_ca_topic_score_codex":0.000085817956,"about_ca_topic_score_gemma":0.000011580254,"teacher_disagreement_score":0.12638134,"about_ca_system_score_codex":0.00023045873,"about_ca_system_score_gemma":0.00020212142,"threshold_uncertainty_score":0.4292304},"labels":[],"label_agreement":null},{"id":"W4294295963","doi":"10.1126/sciimmunol.abn9644","title":"Autoreactive napsin A–specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade","year":2022,"lang":"en","type":"article","venue":"Science Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Antigen; Lung cancer; Cytotoxic T cell; Lung; CD8; Immune system; Biology; T cell; Immunology; Cancer research; Proinflammatory cytokine; Medicine; Pathology; Inflammation; Internal medicine; In vitro","score_opus":0.008766906726652505,"score_gpt":0.2471710137176991,"score_spread":0.23840410699104658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294295963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880107,0.009584939,0.0000038070286,0.0008224012,0.0005784589,0.00054057717,0.000005840728,0.000062969004,0.0003903012],"genre_scores_gemma":[0.9986731,0.00058239285,0.000094283925,0.00007958323,0.0000355643,0.00010315175,0.0000047770945,0.000020277408,0.00040688275],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978643,0.000103413906,0.00046961426,0.0005879793,0.0003672584,0.000607436],"domain_scores_gemma":[0.99908066,0.000057799854,0.00021889975,0.00048760086,0.00006679813,0.00008823134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008722608,0.00020405752,0.00039524506,0.00071501365,0.00065036985,0.000033527183,0.00035081187,0.00007827022,0.00026635686],"category_scores_gemma":[0.00005876994,0.00019831189,0.00009929303,0.0012229782,0.0011867154,0.00018843304,0.0004927064,0.0006505637,0.000005462446],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010736701,0.00013461697,0.01824198,0.000038431193,0.000048827933,0.00019741995,0.0016831133,0.000016595863,0.97759223,0.00004821199,0.000013258144,0.00091165793],"study_design_scores_gemma":[0.0023170444,0.00016549496,0.7770716,0.00008151415,0.00001643858,0.0004461029,0.004262494,0.00022700407,0.21466203,0.000021333755,0.000543487,0.00018545827],"about_ca_topic_score_codex":0.00019302455,"about_ca_topic_score_gemma":0.000009604693,"teacher_disagreement_score":0.7629302,"about_ca_system_score_codex":0.0012641025,"about_ca_system_score_gemma":0.00061746134,"threshold_uncertainty_score":0.8086924},"labels":[],"label_agreement":null},{"id":"W4294760508","doi":"10.1016/j.ejca.2022.08.003","title":"A risk stratification model for toxicities in phase 1 immunotherapy trials","year":2022,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"CRIS Cancer Foundation; Sociedad Española de Oncología Médica","keywords":"Medicine; Clinical trial; Adverse effect; Toxicity; Internal medicine; Oncology; Risk stratification; Immunotherapy; Pharmacology; Intensive care medicine; Cancer","score_opus":0.2056162104715523,"score_gpt":0.4513113053180979,"score_spread":0.2456950948465456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294760508","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006868531,0.99504346,0.0021968023,0.000119241675,0.00060453836,0.0011243089,0.00035477616,0.00000865479,0.00047950694],"genre_scores_gemma":[0.00007156987,0.99694884,0.00055486313,0.0001570775,0.000723331,0.000100294885,0.000039400373,0.00010247519,0.0013021395],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956239,0.0013277233,0.0023152374,0.0001971902,0.00034498048,0.00019098102],"domain_scores_gemma":[0.9960939,0.00036553762,0.0031008006,0.00026249458,0.0001125645,0.00006465166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006683629,0.00028941588,0.0021708906,0.0004119953,0.00007370798,0.000041488525,0.0002672164,0.000052890326,0.00082827156],"category_scores_gemma":[0.00025164493,0.00020473964,0.001378985,0.00024437672,0.00004942315,0.0000838448,0.000012951464,0.00059205934,0.0000014168971],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036793563,0.00016596011,7.8720694e-7,0.0014035704,0.00091514864,0.000030214058,0.0005178175,0.000054132164,0.000077113575,0.0000068663344,0.0027421308,0.99040693],"study_design_scores_gemma":[0.008265973,0.00097123376,0.0000039355878,0.0050031506,0.0011882174,0.00006648069,0.00008721487,0.0001863307,0.000010195546,0.000021740234,0.9840032,0.00019232724],"about_ca_topic_score_codex":0.000011819119,"about_ca_topic_score_gemma":0.000007790937,"teacher_disagreement_score":0.9902146,"about_ca_system_score_codex":0.00050437887,"about_ca_system_score_gemma":0.0012439362,"threshold_uncertainty_score":0.9068993},"labels":[],"label_agreement":null},{"id":"W4294875893","doi":"10.1186/s12920-022-01348-z","title":"TMBur: a distributable tumor mutation burden approach for whole genome sequencing","year":2022,"lang":"en","type":"article","venue":"BMC Medical Genomics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; SickKids Foundation; Hospital for Sick Children; Canada's Michael Smith Genome Sciences Centre","funders":"Genome British Columbia; Canada Foundation for Innovation; Genome Canada","keywords":"Computer science; Computational biology; Context (archaeology); Whole genome sequencing; Workflow; Genome; Biology; Replicate; Data mining; Genetics; Statistics; Mathematics; Database","score_opus":0.03173677153330106,"score_gpt":0.2717395468601512,"score_spread":0.24000277532685016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294875893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7835302,0.0027930238,0.2070367,0.0014240798,0.0005182738,0.0022108094,0.0006830328,0.00015521822,0.0016487128],"genre_scores_gemma":[0.94472283,0.0000865407,0.039088733,0.003952533,0.0017082297,0.001298903,0.004743928,0.00011533777,0.004282935],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983371,0.00006499719,0.00037961957,0.0003334847,0.0005309518,0.00035382854],"domain_scores_gemma":[0.99919206,0.0001327345,0.00015268414,0.0002582117,0.000046141748,0.00021817627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010011441,0.000142022,0.00029531095,0.00007019148,0.0002790166,0.000022119322,0.00020479488,0.000065727225,0.0007043124],"category_scores_gemma":[0.0002567247,0.00013460655,0.00017790054,0.00021111142,0.000086200074,0.000035116565,0.00010070197,0.00024459983,0.000007195595],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0335451,0.0021364817,0.0048499727,0.0057680565,0.002115867,0.000888044,0.015197591,0.027342018,0.77122647,0.0017595784,0.031245932,0.103924885],"study_design_scores_gemma":[0.015880875,0.0017134048,0.0015136619,0.000066805995,0.0003381849,0.0020676488,0.010921419,0.1754355,0.001763947,0.0003896623,0.78915757,0.000751353],"about_ca_topic_score_codex":0.00013495712,"about_ca_topic_score_gemma":0.000009446179,"teacher_disagreement_score":0.7694625,"about_ca_system_score_codex":0.0011065898,"about_ca_system_score_gemma":0.0017738413,"threshold_uncertainty_score":0.7711727},"labels":[],"label_agreement":null},{"id":"W4294940204","doi":"10.1016/j.jtho.2022.07.663","title":"EP08.01-091 Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Lung cancer; Chemotherapy; Internal medicine; Oncology; Immunotherapy; Cancer","score_opus":0.010292224125193981,"score_gpt":0.33288584980094604,"score_spread":0.32259362567575206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294940204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920113,0.0006280753,0.0001249492,0.006172454,0.0003293458,0.00047915545,0.000012785574,0.000009858298,0.00023208495],"genre_scores_gemma":[0.99473673,0.0002059286,0.0020914262,0.0023273353,0.00005436525,0.000018726938,0.000012278195,0.00003966049,0.0005135445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977415,0.00026939422,0.000802943,0.00016902435,0.00074478594,0.00027231523],"domain_scores_gemma":[0.99759734,0.00017010329,0.0016654318,0.0002162632,0.0002881372,0.00006271449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010238681,0.00019352845,0.00094224705,0.00032798774,0.00007214923,0.000007080851,0.00017971957,0.000108217464,0.00046226082],"category_scores_gemma":[0.000027096994,0.00013146353,0.00016764627,0.00040431932,0.00007929942,0.00014633388,0.000022225004,0.00052224344,7.419666e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14586043,0.0027003174,0.72688663,0.000039276412,0.0014629898,0.00006372572,0.0012565708,0.00033473727,0.0055898763,0.0000048650654,0.0007078214,0.11509275],"study_design_scores_gemma":[0.025719265,0.01811551,0.9454902,0.00014546754,0.0001445539,0.00009064734,0.001235039,0.0000070474675,0.0013254087,0.000044502445,0.0075011784,0.00018118459],"about_ca_topic_score_codex":0.00005612966,"about_ca_topic_score_gemma":0.000096905685,"teacher_disagreement_score":0.21860357,"about_ca_system_score_codex":0.002010378,"about_ca_system_score_gemma":0.00060264004,"threshold_uncertainty_score":0.53609276},"labels":[],"label_agreement":null},{"id":"W4294940241","doi":"10.1016/j.jtho.2022.07.592","title":"EP08.01-020 Phase 2 Platform Trial of Anti-TIGIT GSK’859A/EOS-448 + Anti-PD-1 Dostarlimab in Non-small Cell Lung Cancer (NSCLC)","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"TIGIT; Medicine; Lung cancer; Oncology; non-small cell lung cancer (NSCLC); Internal medicine; Cancer research; Lung; Cancer; A549 cell; Immunotherapy","score_opus":0.029756570005303486,"score_gpt":0.40368168482379607,"score_spread":0.3739251148184926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294940241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98738855,0.0042388877,0.00006718605,0.0026343018,0.0028444545,0.000899217,0.00008159308,0.000013125303,0.0018326718],"genre_scores_gemma":[0.99525714,0.0019133072,0.0006093445,0.0009262981,0.00077217096,0.000040735802,0.00001642809,0.000046707915,0.00041787548],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966375,0.0002437783,0.0016500412,0.00029265822,0.00060772867,0.0005682663],"domain_scores_gemma":[0.9973484,0.0002507087,0.0016684736,0.00032127355,0.00019629224,0.00021484247],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022152548,0.0002857056,0.0014209104,0.000694484,0.00012666704,0.00001763561,0.00041384413,0.00023282664,0.0022822125],"category_scores_gemma":[0.00006761969,0.00024471758,0.00053414213,0.0006595171,0.00015397492,0.00018184642,0.00013409027,0.0011465233,0.000003125997],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5798568,0.008001749,0.011390154,0.0006152627,0.0010055938,0.0030727808,0.003445499,0.00035983452,0.18690377,0.000004809934,0.012111225,0.19323249],"study_design_scores_gemma":[0.53427327,0.059691012,0.021197788,0.001257988,0.0026650745,0.0039842855,0.007054245,0.0016736275,0.08780952,0.00009297674,0.27906942,0.0012307814],"about_ca_topic_score_codex":0.0003698536,"about_ca_topic_score_gemma":0.00013256882,"teacher_disagreement_score":0.26695818,"about_ca_system_score_codex":0.0014224134,"about_ca_system_score_gemma":0.0024282336,"threshold_uncertainty_score":0.9986298},"labels":[],"label_agreement":null},{"id":"W4294942468","doi":"10.1016/j.jtho.2022.07.662","title":"EP08.01-090 Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Oncology; Chemotherapy; Immunotherapy; Internal medicine; Association (psychology); Cancer; Psychotherapist","score_opus":0.01063937803010871,"score_gpt":0.3284517726679701,"score_spread":0.3178123946378614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294942468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973687,0.00032355217,0.000045527886,0.0015422206,0.000060936556,0.00053540646,0.000006682283,0.000005798661,0.00011119692],"genre_scores_gemma":[0.9974551,0.00020375906,0.0015145178,0.0005539392,0.00001023603,0.000022287515,0.000011604798,0.000025085716,0.00020346713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840987,0.00024291589,0.000565403,0.00014255721,0.00045669655,0.00018255359],"domain_scores_gemma":[0.99845463,0.00013993328,0.0010540534,0.00011531264,0.0001971006,0.00003899265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073712616,0.00015197882,0.0007185491,0.00036359404,0.000042431904,0.000006097104,0.00007727929,0.000080420556,0.00012360603],"category_scores_gemma":[0.000020719088,0.000090429676,0.00004535647,0.0004235415,0.000059310158,0.0001415683,0.000010750211,0.00032256552,9.7800026e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17236066,0.0020863935,0.76457214,0.000027091337,0.0005039212,0.00006442107,0.0013937379,0.000060119317,0.0011775205,0.0000017016876,0.000041128467,0.05771114],"study_design_scores_gemma":[0.040239893,0.022293894,0.9344412,0.00010664718,0.000080997954,0.00009499358,0.001197738,0.00002059753,0.0005754657,0.000010958122,0.00082273415,0.00011488165],"about_ca_topic_score_codex":0.00008131507,"about_ca_topic_score_gemma":0.00021703543,"teacher_disagreement_score":0.16986904,"about_ca_system_score_codex":0.0012846021,"about_ca_system_score_gemma":0.00033811873,"threshold_uncertainty_score":0.3687615},"labels":[],"label_agreement":null},{"id":"W4294944568","doi":"10.1016/j.jtho.2022.07.206","title":"P1.15-10 Chronic Obstructive Pulmonary Disease Patients Receiving Immunotherapy for Lung Cancer: A Population-Based Study in Canada","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Pulmonary disease; Immunotherapy; Internal medicine; Oncology; Population; Intensive care medicine; Disease; Lung; Cancer; Environmental health","score_opus":0.013554324106417243,"score_gpt":0.362537698635397,"score_spread":0.34898337452897976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294944568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918552,0.0039839437,0.000025012961,0.0014949801,0.0014455426,0.0010866128,0.00007171334,0.000005212457,0.000031760646],"genre_scores_gemma":[0.99858236,0.000049295664,0.00014962403,0.0006092906,0.00020525104,0.00020704605,0.000032165164,0.000028291703,0.00013667344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980674,0.00032003087,0.0007272667,0.00019075189,0.00042405666,0.0002705443],"domain_scores_gemma":[0.9985717,0.00024458303,0.00072358246,0.00017068947,0.00017401113,0.000115449744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055206596,0.00015181625,0.0005014379,0.00025350167,0.00017382066,0.000007493223,0.00018258524,0.00003751955,0.0007360194],"category_scores_gemma":[0.00006004069,0.00013784986,0.00016555327,0.00031916326,0.000018438912,0.00008167666,0.000028899454,0.0003606533,7.492036e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.034405448,0.0008109526,0.7743969,0.000080319034,0.0002234907,0.00019528327,0.00021645939,0.0017666684,0.00022974605,2.807526e-7,0.0005019086,0.18717255],"study_design_scores_gemma":[0.004889188,0.0023410954,0.9841899,0.00009591143,0.00018815484,0.000023442866,0.00080060307,0.0019851027,0.000024015633,0.000016704005,0.0053051324,0.0001407101],"about_ca_topic_score_codex":0.136319,"about_ca_topic_score_gemma":0.32023582,"teacher_disagreement_score":0.20979305,"about_ca_system_score_codex":0.015022735,"about_ca_system_score_gemma":0.0090029845,"threshold_uncertainty_score":0.99661505},"labels":[],"label_agreement":null},{"id":"W4295027129","doi":"10.1016/j.crimmu.2022.08.009","title":"New insights into the tumour immune microenvironment of nasopharyngeal carcinoma","year":2022,"lang":"en","type":"review","venue":"Current Research in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Nasopharyngeal carcinoma; Mass cytometry; Immune system; Immunotherapy; Tumor microenvironment; Biomarker; Immunology; Disease; Biology; Head and neck squamous-cell carcinoma; Medicine; Cancer research; Radiation therapy; Head and neck cancer; Pathology; Internal medicine; Gene; Phenotype; Genetics","score_opus":0.1303249421775259,"score_gpt":0.4121292213518502,"score_spread":0.28180427917432427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295027129","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018501608,0.9940155,0.0000019717947,0.00036632112,0.0012332066,0.0021788732,0.000009781264,0.000014097722,0.00033005196],"genre_scores_gemma":[0.001048706,0.99733347,0.000024372546,0.000012222553,0.000218605,0.0005409251,0.0002564795,0.00006626843,0.0004989686],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946704,0.0017520793,0.0012942792,0.0006696702,0.0008178381,0.00079575955],"domain_scores_gemma":[0.99743867,0.0007635449,0.0003703734,0.0012730479,0.000051318773,0.00010305057],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015787691,0.00044956052,0.0019245576,0.0011802946,0.00023447895,0.00001900525,0.0012325093,0.0002781781,0.0017216756],"category_scores_gemma":[0.00010035874,0.000296424,0.0007248549,0.0014617539,0.0009188375,0.000047735688,0.0010924118,0.0035027852,0.00007300162],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006308548,0.00032162174,0.000028228873,0.0055153673,0.000395966,0.00007992672,0.0009752358,6.350228e-8,0.00062004704,0.00013000694,0.0013609084,0.9899418],"study_design_scores_gemma":[0.0016537957,0.0008143456,0.00080536323,0.004704437,0.0001589733,0.00012883586,0.00025963906,7.727393e-7,0.00015789272,0.00010314841,0.99099845,0.00021436959],"about_ca_topic_score_codex":0.0016862304,"about_ca_topic_score_gemma":0.000045063025,"teacher_disagreement_score":0.9897274,"about_ca_system_score_codex":0.0016996373,"about_ca_system_score_gemma":0.002566764,"threshold_uncertainty_score":0.9999488},"labels":[],"label_agreement":null},{"id":"W4295063545","doi":"10.3390/cancers14184346","title":"Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; Labex Immuno-Oncology; Ligue Contre le Cancer; Institut National de la Santé et de la Recherche Médicale; Assistance publique-Hôpitaux de Paris; Ministry of Education, Culture, Sports, Science and Technology; Society for Immunotherapy of Cancer; Neuroendocrine Tumor Research Foundation; Japan Agency for Medical Research and Development","keywords":"Medicine; Internal medicine; Stage (stratigraphy); Oncology; Colorectal cancer; Population; Proportional hazards model; Gastroenterology; Cancer","score_opus":0.03344347572143396,"score_gpt":0.3535300641163454,"score_spread":0.32008658839491144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295063545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992414,0.000547789,1.1943573e-7,0.0043545645,0.0014738364,0.00089316844,0.000070546936,0.0000044315034,0.00024151728],"genre_scores_gemma":[0.997756,0.0001480982,0.000004065931,0.0016933196,0.000108338456,0.00016675383,0.000016425633,0.000008075757,0.00009889279],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867123,0.0003142134,0.00040006544,0.00016352622,0.00033426963,0.00011668561],"domain_scores_gemma":[0.9993184,0.00016992635,0.00017294034,0.00030011003,0.000027743885,0.000010887569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006818376,0.00008160114,0.00015833593,0.00003405572,0.000107078034,0.000008272594,0.0003431723,0.000028170682,0.00043301075],"category_scores_gemma":[0.000042031566,0.000043839893,0.00008391788,0.00027609288,0.00012012738,0.000022894013,0.00007277669,0.0003893659,6.2002016e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036339173,0.000114087976,0.97879994,0.0000043738205,0.00009246238,0.000004560155,0.0050434526,0.00072038727,0.00038967305,0.0000020935463,0.00064840703,0.010546619],"study_design_scores_gemma":[0.0038455417,0.00021504717,0.9801027,0.00007452994,0.000034264183,0.0000022195404,0.010109491,0.002077441,0.000033352113,0.0000031651132,0.0034526063,0.00004961379],"about_ca_topic_score_codex":0.020326609,"about_ca_topic_score_gemma":0.014525251,"teacher_disagreement_score":0.010497005,"about_ca_system_score_codex":0.0010251888,"about_ca_system_score_gemma":0.00028746977,"threshold_uncertainty_score":0.9861971},"labels":[],"label_agreement":null},{"id":"W4295423187","doi":"10.1172/jci159579","title":"Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Huntsman Cancer Foundation; Genentech; National Institutes of Health; Technische Universität Dresden; Fonds National de la Recherche Luxembourg; Johns Hopkins University; American Society for Transplantation and Cellular Therapy; Qatar National Research Fund; American Society of Clinical Oncology; Huntsman Cancer Institute; National Heart, Lung, and Blood Institute; John and Lucille Van Geest Foundation; Gabrielle's Angel Foundation for Cancer Research; American Association for Cancer Research; St. Baldrick's Foundation; Trent University; Ladies Leukemia League; Leukemia and Lymphoma Society; Stand Up To Cancer; Entertainment Industry Foundation; U.S. Department of Defense; Rally Foundation; Children's Hospital of Philadelphia; Nottingham Trent University; Conquer Cancer Foundation","keywords":"Myeloid leukemia; Medicine; Immune checkpoint; Blockade; Immunotherapy; Oncology; CD8; Immune system; Leukemia; Effector; Internal medicine; Immunology; Cancer research; Receptor","score_opus":0.030171004445256167,"score_gpt":0.3197234006004307,"score_spread":0.28955239615517453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295423187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920165,0.001493478,0.000028784732,0.0055407826,0.00064515305,0.00022878646,0.000009932838,0.000008260593,0.000028318764],"genre_scores_gemma":[0.99581164,0.0009201238,0.0009204864,0.0017655578,0.00015632622,0.000009977613,0.000021854978,0.000015922156,0.00037812674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973664,0.00033647523,0.0015251492,0.00017782707,0.00045058187,0.00014353178],"domain_scores_gemma":[0.9983861,0.0003523864,0.0009201987,0.00014367893,0.000057923105,0.00013974754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022383304,0.00013530615,0.0005323471,0.00020935382,0.000088961024,0.000015051809,0.000077029,0.00011943665,0.00014776616],"category_scores_gemma":[0.0005935045,0.000108227076,0.00024408066,0.00019504318,0.00021048721,0.00013789232,0.00006752384,0.0008748621,0.0000015528212],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016173229,0.00028656365,0.5885846,0.000037739388,0.00078195013,0.00027003846,0.0004581181,0.0002806698,0.3796631,0.000011220828,0.0011845051,0.012268256],"study_design_scores_gemma":[0.008073449,0.0017831987,0.9798788,0.0000960967,0.00022373784,0.00042140248,0.00019865573,0.00021075996,0.006319815,0.00040509558,0.0022899092,0.0000991224],"about_ca_topic_score_codex":0.00003804641,"about_ca_topic_score_gemma":0.0000036749025,"teacher_disagreement_score":0.39129415,"about_ca_system_score_codex":0.0003325676,"about_ca_system_score_gemma":0.00034078085,"threshold_uncertainty_score":0.4413372},"labels":[],"label_agreement":null},{"id":"W4295817391","doi":"10.1016/j.annonc.2022.07.782","title":"658MO Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; Merck","keywords":"Medicine; Docetaxel; Cetuximab; Pembrolizumab; Head and neck squamous-cell carcinoma; Internal medicine; Oncology; Head and neck cancer; Radiation therapy; Cancer; Immunotherapy","score_opus":0.04529320590359399,"score_gpt":0.34223123775879116,"score_spread":0.2969380318551972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801026,0.015634932,0.0000024737026,0.0007448588,0.0002216243,0.0008874581,0.00028465307,0.000016038573,0.0021053893],"genre_scores_gemma":[0.9978314,0.0012225925,0.00020876809,0.00028151067,0.00002379569,0.00006497178,0.0000910353,0.000033951936,0.00024194288],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9975565,0.00040001934,0.00089951535,0.0003639301,0.00038108625,0.00039894637],"domain_scores_gemma":[0.9984699,0.00024049338,0.00052649673,0.00037669626,0.00028063462,0.000105769934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005402602,0.00023651731,0.0011968695,0.00037446548,0.00006232202,0.0000038169305,0.0001823818,0.00011840594,0.00040452013],"category_scores_gemma":[0.00009723655,0.00022682008,0.00027338928,0.0005166623,0.00024614757,0.000052450803,0.00011534855,0.0002915421,0.0000011269532],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49497998,0.0039875004,0.2293313,0.006281492,0.0006102943,0.00047566486,0.025450263,0.000050749837,0.030346576,0.00014689825,0.01656831,0.19177099],"study_design_scores_gemma":[0.20629704,0.28826505,0.26319495,0.00083786104,0.0010636112,0.00035338278,0.014298904,0.0001467926,0.12123186,0.00033199982,0.102894545,0.0010840095],"about_ca_topic_score_codex":0.0011484738,"about_ca_topic_score_gemma":0.0006314498,"teacher_disagreement_score":0.28868294,"about_ca_system_score_codex":0.00021601922,"about_ca_system_score_gemma":0.0007383017,"threshold_uncertainty_score":0.9249454},"labels":[],"label_agreement":null},{"id":"W4295817491","doi":"10.1016/j.annonc.2022.07.1086","title":"960P Beyond PACIFIC: Real-world outcomes of adjuvant durvalumab according to treatment received and PD-L1 expression","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"China Scholarship Council","keywords":"Durvalumab; Medicine; Internal medicine; Chemoradiotherapy; Multivariate analysis; Proportional hazards model; Oncology; Cancer; Adjuvant; Hazard ratio; Stage (stratigraphy); Lung cancer; Immunotherapy; Confidence interval","score_opus":0.08226763748118476,"score_gpt":0.40132208972991773,"score_spread":0.31905445224873297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783687,0.0007650245,0.0000026817972,0.0086488165,0.00026065647,0.00045329743,0.00005862419,0.000017204447,0.0114249885],"genre_scores_gemma":[0.99439794,0.0017167267,0.0003846428,0.0010404753,0.00003536455,0.00008351959,0.000023114035,0.000015639676,0.0023025689],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99878895,0.00014148898,0.00042889788,0.00023804158,0.00019321442,0.00020942136],"domain_scores_gemma":[0.9991284,0.0002021109,0.00023750153,0.00026368228,0.000077340446,0.00009094014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039088662,0.00013544786,0.00066374097,0.00023751023,0.00008968267,0.0000026964883,0.00008123233,0.00005219199,0.00035468617],"category_scores_gemma":[0.000039125185,0.00010489657,0.00014670765,0.00022152497,0.00008454481,0.000034791832,0.00009475561,0.00008565603,0.0000014381267],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018522494,0.00128697,0.16877507,0.00007637223,0.00060771493,0.00007495498,0.0038669512,0.000014199622,0.32317564,0.00006891615,0.010360571,0.47317016],"study_design_scores_gemma":[0.009224158,0.02260083,0.5236741,0.00011117496,0.00016864871,0.000054848344,0.008302247,0.000015460944,0.13435903,0.00020501718,0.3010258,0.00025868055],"about_ca_topic_score_codex":0.00074528466,"about_ca_topic_score_gemma":0.0001329215,"teacher_disagreement_score":0.47291148,"about_ca_system_score_codex":0.00014461801,"about_ca_system_score_gemma":0.00016539393,"threshold_uncertainty_score":0.4277558},"labels":[],"label_agreement":null},{"id":"W4295817549","doi":"10.1016/j.annonc.2022.07.647","title":"519MO Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Adenocarcinoma; Cervical cancer; Population; Clinical endpoint; Oncology; Cancer; Randomized controlled trial","score_opus":0.1354505986576437,"score_gpt":0.4640827921681646,"score_spread":0.3286321935105209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988875,0.0025293096,0.000047243066,0.005788596,0.00089625485,0.0009847628,0.00025706686,0.00003031324,0.0005915093],"genre_scores_gemma":[0.99580204,0.002296045,0.000071940034,0.000984991,0.00016020273,0.00028851017,0.00016331546,0.000033734446,0.00019923715],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960591,0.0007671195,0.0014936187,0.000501515,0.0006740111,0.0005045924],"domain_scores_gemma":[0.9978785,0.0005709426,0.0006630456,0.00050590525,0.00020877803,0.00017282536],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017532137,0.0002715131,0.0018802726,0.0007173473,0.00006854787,0.000006159758,0.0003469122,0.0001432949,0.0061463756],"category_scores_gemma":[0.00012213738,0.00022667168,0.00071619486,0.0019224739,0.0002548667,0.000058731173,0.00018575504,0.00049043086,0.0000021005187],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7476295,0.014014639,0.010667243,0.00029458228,0.0055741174,0.0004354678,0.0015251534,0.00006253585,0.0027780612,0.00005045624,0.0018310273,0.21513718],"study_design_scores_gemma":[0.692633,0.1127739,0.09731158,0.00024210762,0.0068177613,0.00014658338,0.0026029225,0.00097508304,0.006398432,0.00012555857,0.07890181,0.0010712662],"about_ca_topic_score_codex":0.0016560669,"about_ca_topic_score_gemma":0.003921532,"teacher_disagreement_score":0.21406592,"about_ca_system_score_codex":0.0003021124,"about_ca_system_score_gemma":0.0011896278,"threshold_uncertainty_score":0.9947621},"labels":[],"label_agreement":null},{"id":"W4295818061","doi":"10.1016/j.annonc.2022.07.1102","title":"974MO 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Medicine; Placebo; Internal medicine; Population; Pembrolizumab; Oncology; Lung cancer; Cancer; Alternative medicine","score_opus":0.030858326892885635,"score_gpt":0.33781582150594486,"score_spread":0.3069574946130592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295818061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731185,0.006748836,0.000025286496,0.011553326,0.000637915,0.0006277221,0.0001425032,0.00003223282,0.0071137217],"genre_scores_gemma":[0.97987455,0.0036778394,0.0002050858,0.014768473,0.0002212517,0.00017992317,0.00007566194,0.00004974807,0.00094744697],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998148,0.00015398503,0.0005532756,0.00041146862,0.00027061356,0.000462606],"domain_scores_gemma":[0.9989624,0.00015339698,0.00029151115,0.0003997942,0.000091509406,0.000101390775],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041160165,0.00022142695,0.00069893076,0.00022835653,0.00008327116,0.0000070184205,0.00029017523,0.00017482643,0.004339566],"category_scores_gemma":[0.000016632159,0.00022070363,0.00022971114,0.00037593892,0.00011569164,0.000046734174,0.00010880968,0.000438225,0.000011834789],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17940491,0.0053104353,0.06953608,0.0005918413,0.001478669,0.0010526155,0.017746605,0.0011080421,0.17855623,0.000103171245,0.2952871,0.24982427],"study_design_scores_gemma":[0.08171314,0.008711485,0.10073837,0.00019668572,0.00023476785,0.00006701236,0.0033774092,0.0020923095,0.06969087,0.00026529352,0.7320137,0.00089895865],"about_ca_topic_score_codex":0.008712432,"about_ca_topic_score_gemma":0.0007933062,"teacher_disagreement_score":0.43672657,"about_ca_system_score_codex":0.00043311922,"about_ca_system_score_gemma":0.0011268158,"threshold_uncertainty_score":0.9978886},"labels":[],"label_agreement":null},{"id":"W4295819112","doi":"10.1016/j.annonc.2022.07.783","title":"659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; Eisai; Merck KGaA; Sanofi; AstraZeneca; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Internal medicine; Head and neck squamous-cell carcinoma; Oncology; Chemotherapy; Population; Head and neck cancer; Immunotherapy; Cancer","score_opus":0.08290346032636627,"score_gpt":0.3642580752485326,"score_spread":0.28135461492216635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295819112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895809,0.0027045205,0.00002696394,0.0048683095,0.00013426188,0.0012449812,0.00090173865,0.000017192713,0.0005210731],"genre_scores_gemma":[0.9949805,0.0013343949,0.0016151344,0.00082503184,0.00008681448,0.00016946832,0.0002288754,0.000038877137,0.00072086713],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99841076,0.000099955185,0.00058687583,0.00038962162,0.00021890005,0.00029386164],"domain_scores_gemma":[0.99849546,0.0004414398,0.0004558767,0.00035979706,0.00014807578,0.000099349774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022596454,0.00023217667,0.00086878455,0.00013556336,0.00010021138,0.0000044753338,0.00010360818,0.00007265016,0.00023787496],"category_scores_gemma":[0.000034156797,0.00016560085,0.00016299088,0.00019891563,0.0001824272,0.000033419892,0.000026517204,0.00009540465,7.6479387e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8226843,0.006467447,0.013940599,0.00040181517,0.00070846785,0.00009918579,0.007853905,0.00003535054,0.0050417394,0.000012995684,0.0073859147,0.13536829],"study_design_scores_gemma":[0.2508012,0.35510853,0.032926537,0.00013272055,0.00064706313,0.00018818729,0.002757031,0.00074471283,0.04999079,0.00015547182,0.30604133,0.00050639827],"about_ca_topic_score_codex":0.0020703957,"about_ca_topic_score_gemma":0.0008343429,"teacher_disagreement_score":0.5718831,"about_ca_system_score_codex":0.00013517402,"about_ca_system_score_gemma":0.00045890396,"threshold_uncertainty_score":0.67530066},"labels":[],"label_agreement":null},{"id":"W4295820897","doi":"10.1016/j.annonc.2022.07.1184","title":"1058P Non-smokers with squamous lung cancers have a high incidence of HHV infections, DDR gene alterations and good prognosis","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Incidence (geometry); Oncology; Internal medicine","score_opus":0.028747422765389247,"score_gpt":0.33891746401659306,"score_spread":0.31017004125120384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295820897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99268514,0.0013531803,0.00006722891,0.0042353678,0.00013543012,0.00054026337,0.00005995606,0.00001428724,0.0009091616],"genre_scores_gemma":[0.99704593,0.0007162673,0.00042368128,0.0013142059,0.00004606003,0.00025457758,0.000026461175,0.0000132088635,0.00015963089],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902475,0.00008212187,0.00032099994,0.00019965206,0.00019155728,0.00018093486],"domain_scores_gemma":[0.99921554,0.00012352735,0.0002552603,0.0001684819,0.00017549988,0.000061660496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002928697,0.00010734393,0.0003444104,0.00017039494,0.00014074429,0.0000043521895,0.00006848294,0.00005813431,0.00019591923],"category_scores_gemma":[0.000029605762,0.00009573841,0.00006698298,0.00028293623,0.0002346077,0.00006219096,0.00005126229,0.00015388851,2.8055524e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011943052,0.002322872,0.7801418,0.000523178,0.0020246722,0.00016272931,0.0068213516,0.0013712444,0.08927327,0.00031172717,0.024188919,0.080915235],"study_design_scores_gemma":[0.01898927,0.07730783,0.6970757,0.00032549677,0.0009627047,0.0013466887,0.0045703365,0.0016661113,0.12806424,0.00015939081,0.06878236,0.0007498304],"about_ca_topic_score_codex":0.006733588,"about_ca_topic_score_gemma":0.0016225877,"teacher_disagreement_score":0.08306602,"about_ca_system_score_codex":0.00016867992,"about_ca_system_score_gemma":0.0007639237,"threshold_uncertainty_score":0.9998807},"labels":[],"label_agreement":null},{"id":"W4295827764","doi":"10.1016/j.annonc.2022.07.1312","title":"1189TiP Phase II study of anti-TIGIT GSK4428859A (GSK’859A)/EOS-448 + anti-CD96 GSK6097608 (GSK’608) + anti-PD-1 dostarlimab in non-small cell lung cancer (NSCLC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Brampton Civic Hospital","funders":"","keywords":"TIGIT; Medicine; Lung cancer; non-small cell lung cancer (NSCLC); Cancer research; Atezolizumab; Internal medicine; Oncology; Cancer; Immunotherapy; A549 cell; Pembrolizumab","score_opus":0.05462985005233335,"score_gpt":0.3872184693149579,"score_spread":0.33258861926262456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295827764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98348004,0.005833233,0.000010387457,0.0033213496,0.0010039209,0.0022767573,0.00029030183,0.000054804594,0.003729236],"genre_scores_gemma":[0.9931229,0.003066538,0.00008558165,0.002502642,0.00019403889,0.00027785305,0.000076534285,0.00008944062,0.00058447546],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99514854,0.00046810723,0.0016803201,0.000887816,0.0007315399,0.00108368],"domain_scores_gemma":[0.9971891,0.00026253893,0.0010160608,0.00091148046,0.00038669902,0.000234142],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016849171,0.00053063006,0.0019791475,0.000824997,0.00029937553,0.000015356733,0.0006558523,0.0002813248,0.001640051],"category_scores_gemma":[0.00006763946,0.0005226757,0.0004425186,0.0013488968,0.00032894604,0.0001722712,0.00049473706,0.00079651974,0.0000055175115],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022526035,0.059906557,0.37318417,0.001210129,0.0023993424,0.0016924869,0.022501355,0.0008104699,0.39298683,0.000022525384,0.03922819,0.083531916],"study_design_scores_gemma":[0.14661738,0.105763525,0.41596457,0.0007809589,0.0013310431,0.00027270746,0.022778887,0.0012142634,0.120722465,0.00004206048,0.18249138,0.0020207355],"about_ca_topic_score_codex":0.005940573,"about_ca_topic_score_gemma":0.0010105688,"teacher_disagreement_score":0.27226436,"about_ca_system_score_codex":0.00035365514,"about_ca_system_score_gemma":0.0014832292,"threshold_uncertainty_score":0.9997225},"labels":[],"label_agreement":null},{"id":"W4295828361","doi":"10.1016/j.annonc.2022.07.1441","title":"1309P CD8+ T cell infiltration is associated with improved survival in advanced pancreatic cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Nova Scotia Cancer Centre; Princess Margaret Cancer Centre; McGill University; Centre Hospitalier de l’Université de Montréal; University of Toronto; University Health Network","funders":"","keywords":"Medicine; CD8; Pancreatic cancer; Internal medicine; Immunohistochemistry; Pathology; Adenocarcinoma; Gastroenterology; Exact test; Immune system; Oncology; Cancer; Immunology","score_opus":0.04264593338123257,"score_gpt":0.3493253143852004,"score_spread":0.30667938100396785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98990947,0.000948702,0.0000049554924,0.0042110095,0.00017670455,0.00037364315,0.000051209856,0.000016558113,0.004307773],"genre_scores_gemma":[0.99473524,0.00060778414,0.00005342968,0.00342934,0.000026236821,0.00014831644,0.000047072524,0.0000148930685,0.0009376685],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989717,0.00014061456,0.00030585963,0.00018084973,0.00017966487,0.00022131557],"domain_scores_gemma":[0.9993255,0.00012444773,0.00025279575,0.0001453463,0.00011352066,0.000038348247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042280264,0.00010155261,0.00039094055,0.00010900635,0.000050182105,0.0000024754079,0.000072819545,0.00006975193,0.0007588513],"category_scores_gemma":[0.000036675774,0.00008951902,0.00006642934,0.00038211842,0.0000649527,0.000049571274,0.000023763732,0.0001905776,8.1497404e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034471903,0.002538009,0.14603196,0.0001484231,0.00081010116,0.00012222475,0.0046614823,0.00025872578,0.6792182,0.000032882646,0.006780877,0.12492526],"study_design_scores_gemma":[0.043571647,0.043836538,0.56726927,0.0002803167,0.00032776193,0.00005080966,0.004777921,0.0011006456,0.19601575,0.00019471679,0.14182271,0.0007519048],"about_ca_topic_score_codex":0.0012279551,"about_ca_topic_score_gemma":0.0013738347,"teacher_disagreement_score":0.4832024,"about_ca_system_score_codex":0.00020365932,"about_ca_system_score_gemma":0.0005497775,"threshold_uncertainty_score":0.830889},"labels":[],"label_agreement":null},{"id":"W4295828450","doi":"10.1016/j.annonc.2022.07.1262","title":"1138P Alternate pembrolizumab dosing interval in advanced NSCLC with PD-L1 &gt;/= 50%: 3 weekly compared to 6 weekly dosing","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"","keywords":"Dosing; Medicine; Pembrolizumab; Internal medicine; Oncology; Immunotherapy; Cancer","score_opus":0.05550377184018356,"score_gpt":0.36892179412118337,"score_spread":0.3134180222809998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719341,0.0011232353,0.00008516525,0.018755756,0.000480389,0.00058007654,0.000027352118,0.000044784443,0.006969164],"genre_scores_gemma":[0.99180216,0.000109741166,0.0009508066,0.0062056016,0.00009241445,0.00008938232,0.00002829903,0.00003913739,0.0006824678],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978806,0.00020314545,0.0006327405,0.00041598472,0.00035704722,0.0005104819],"domain_scores_gemma":[0.9989687,0.00012348084,0.00029311382,0.000350215,0.00012715482,0.0001373008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056281866,0.0002262441,0.00075653667,0.0003933194,0.000117512885,0.000013098902,0.0002730518,0.000074805714,0.0003387272],"category_scores_gemma":[0.00003214088,0.00020903598,0.0001567164,0.0005136098,0.00014279205,0.000109191,0.00017051048,0.000370467,0.000008375504],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26652136,0.002411964,0.012171377,0.00022375361,0.0007788393,0.00091027527,0.0060344846,0.0017707467,0.32361886,0.00016837758,0.014853593,0.37053636],"study_design_scores_gemma":[0.04761833,0.04431426,0.13950212,0.0012212438,0.00017258777,0.0014882341,0.004995416,0.0007822522,0.047582213,0.00026333093,0.7110595,0.001000512],"about_ca_topic_score_codex":0.00081676355,"about_ca_topic_score_gemma":0.00045657973,"teacher_disagreement_score":0.6962059,"about_ca_system_score_codex":0.00034616882,"about_ca_system_score_gemma":0.00036626888,"threshold_uncertainty_score":0.85242397},"labels":[],"label_agreement":null},{"id":"W4295837182","doi":"10.1016/j.annonc.2022.07.1744","title":"1664MO Tumor-naïve methylomes and fragmentomes during pembrolizumab (P) in metastatic cancer patients","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"Genentech; Servier; Eisai; Seagen; Daiichi Sankyo Europe; Princess Margaret Cancer Foundation; Sanofi; Iterion Therapeutics; Karyopharm Therapeutics; Gilead Sciences; GlaxoSmithKline; Amgen; Pfizer; Symphogen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.05125988401333968,"score_gpt":0.3830134366659977,"score_spread":0.331753552652658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99079967,0.0055041723,3.1106242e-7,0.002281648,0.00017072645,0.00029958037,0.000042710235,0.000009891836,0.0008912651],"genre_scores_gemma":[0.9965268,0.0012479695,0.000056060482,0.0017073437,0.000019562243,0.00014015476,0.00001125769,0.000012995247,0.00027785773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888116,0.00013914242,0.00034045763,0.00019344316,0.00020998769,0.00023579178],"domain_scores_gemma":[0.99951005,0.00008752933,0.00017135926,0.000115084134,0.000061772305,0.00005422942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000303066,0.000104593426,0.00041502222,0.00026363917,0.000062270105,0.000003160521,0.000073071606,0.000025337276,0.00074001035],"category_scores_gemma":[0.000036532667,0.000095863266,0.00007446978,0.00026860883,0.000093945986,0.000048473365,0.00009309058,0.00015878466,8.5686895e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032576445,0.00411089,0.65221846,0.0009345176,0.0017478189,0.00052014494,0.009257802,0.00009602214,0.046593957,0.00020087432,0.005551547,0.24619153],"study_design_scores_gemma":[0.014372307,0.004946198,0.9269673,0.00007119605,0.00008788175,0.000064610045,0.0012727007,0.000028391405,0.012993112,0.0002157267,0.038795304,0.00018522657],"about_ca_topic_score_codex":0.00078255875,"about_ca_topic_score_gemma":0.00013353849,"teacher_disagreement_score":0.2747489,"about_ca_system_score_codex":0.00015152457,"about_ca_system_score_gemma":0.00019705266,"threshold_uncertainty_score":0.81025946},"labels":[],"label_agreement":null},{"id":"W4295837323","doi":"10.1016/j.annonc.2022.07.1827","title":"1749P Association between immune-mediated adverse events (imAEs) and outcomes in metastatic urothelial cancer (mUC) treated with durvalumab (D) alone or in combination with tremelimumab (T) in the DANUBE study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb Canada; Astellas Pharma Canada; Roche; Sanofi; Merck; Janssen Pharmaceuticals; Bayer; AstraZeneca; Pfizer","keywords":"Medicine; Durvalumab; Internal medicine; Hazard ratio; Cancer; Adverse effect; Oncology; Proportional hazards model; Immune system; Immunotherapy; Immunology; Confidence interval; Pembrolizumab","score_opus":0.057251954807823795,"score_gpt":0.3696447928145789,"score_spread":0.3123928380067551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99329257,0.00015949101,7.6274864e-7,0.00475865,0.000033069722,0.0015997838,0.000067771274,0.0000094178395,0.000078506026],"genre_scores_gemma":[0.9984159,0.00017293336,0.000017640454,0.0005909304,0.000008318552,0.000577324,0.00006245228,0.00001653333,0.00013796691],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975072,0.0009859354,0.0005755605,0.00023143625,0.0004490132,0.0002508489],"domain_scores_gemma":[0.998667,0.00066990097,0.00039387573,0.00015956209,0.000083863226,0.000025805173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019178862,0.0001577497,0.00070442626,0.00036690978,0.000057018537,0.0000031744885,0.00011646711,0.00005474677,0.00008936078],"category_scores_gemma":[0.00014154277,0.00009653021,0.00003938394,0.00083725725,0.000058800477,0.000088062334,0.00003194464,0.000283202,5.233965e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018256892,0.0028028716,0.96718216,0.000023957,0.0005427294,0.00014168078,0.005144292,0.000043650292,0.00026833793,0.0000015316529,0.000041820484,0.0055500595],"study_design_scores_gemma":[0.036645576,0.011637244,0.9440871,0.00005310283,0.00016622376,0.00001022883,0.0068487194,0.000046537556,0.00012751693,0.0000101751075,0.0002606974,0.000106893305],"about_ca_topic_score_codex":0.009431079,"about_ca_topic_score_gemma":0.020836372,"teacher_disagreement_score":0.023095096,"about_ca_system_score_codex":0.000505041,"about_ca_system_score_gemma":0.00042141782,"threshold_uncertainty_score":0.9971652},"labels":[],"label_agreement":null},{"id":"W4295904913","doi":"10.1177/17588359221122714","title":"The role of gut microbiome in immune modulation in metastatic renal cell carcinoma","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Medicine; Microbiome; Immunotherapy; Renal cell carcinoma; Gut microbiome; Immune system; Intensive care medicine; Gut flora; Immunology; Oncology; Bioinformatics; Biology","score_opus":0.032753435061530105,"score_gpt":0.37980260325678,"score_spread":0.3470491681952499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295904913","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00085671083,0.9959833,0.00002002294,0.0002544518,0.00041828788,0.0011590532,0.000010430919,0.000008793861,0.0012889422],"genre_scores_gemma":[0.010866681,0.98816115,0.00013230916,0.0002096134,0.00005886114,0.00035985283,0.00008081868,0.000039970586,0.00009073697],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99559945,0.001212133,0.0018239145,0.0003982013,0.00049929036,0.0004670073],"domain_scores_gemma":[0.9970455,0.0018015708,0.00064512086,0.00041928492,0.000020257397,0.00006823592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024811015,0.0003305115,0.0021160285,0.0005003195,0.000046653913,0.0000038861594,0.0005112962,0.0003360216,0.00081696926],"category_scores_gemma":[0.00010288448,0.00021955236,0.00031977813,0.0011048014,0.0005283276,0.00005785109,0.000112943526,0.0012555821,0.000004235585],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093376107,0.00043821975,0.00008879154,0.0016757046,0.00006731976,0.000141303,0.00026818668,0.000005220268,0.00015928294,0.00007326937,0.0000027622555,0.9961462],"study_design_scores_gemma":[0.0032955492,0.0007693792,0.0003263335,0.0017734641,0.00016690223,0.00015216519,0.00036220302,0.0001335894,0.0000185712,0.00065100944,0.9921643,0.00018649592],"about_ca_topic_score_codex":0.00020717763,"about_ca_topic_score_gemma":0.00053042296,"teacher_disagreement_score":0.9959597,"about_ca_system_score_codex":0.001170439,"about_ca_system_score_gemma":0.0016256425,"threshold_uncertainty_score":0.89530855},"labels":[],"label_agreement":null},{"id":"W4296007697","doi":"10.1016/j.annonc.2022.07.775","title":"651O Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dr. H. Bliss Murphy Cancer Centre; Kingston General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Pembrolizumab; Carboplatin; Internal medicine; Clinical trial; Oncology; Head and neck squamous-cell carcinoma; Phases of clinical research; Surgery; Head and neck cancer; Radiation therapy; Cancer; Chemotherapy; Cisplatin; Adverse effect; Immunotherapy","score_opus":0.08756686997280383,"score_gpt":0.3949093965393589,"score_spread":0.3073425265665551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296007697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795117,0.011874669,0.0000031910938,0.0031742298,0.0004693328,0.0020758852,0.00014082037,0.000041873296,0.0027082947],"genre_scores_gemma":[0.99521834,0.001557805,0.00008307788,0.0022271848,0.00010717958,0.00030449827,0.00008666263,0.00006354068,0.00035172206],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9962245,0.0007020574,0.001140358,0.00070194,0.00055662077,0.00067451893],"domain_scores_gemma":[0.9979291,0.00055818993,0.0005119875,0.0006147289,0.00016823648,0.00021774623],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001208149,0.00043432557,0.00122379,0.0005230498,0.000207931,0.000016649998,0.0002758789,0.00014347935,0.0007222228],"category_scores_gemma":[0.00014109832,0.00040867802,0.00025865782,0.0007426814,0.00023569631,0.000093792136,0.00016957655,0.0006872037,0.000006298641],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2826896,0.06477817,0.10870454,0.0008338865,0.0009755962,0.0036905603,0.032049797,0.00017866516,0.02756795,0.00008016097,0.00966805,0.46878305],"study_design_scores_gemma":[0.29555926,0.39426452,0.19345908,0.00013821213,0.00044493235,0.0007719895,0.011363091,0.0013732451,0.008638634,0.0006322695,0.091995165,0.0013596406],"about_ca_topic_score_codex":0.005098838,"about_ca_topic_score_gemma":0.0015388734,"teacher_disagreement_score":0.4674234,"about_ca_system_score_codex":0.00025303493,"about_ca_system_score_gemma":0.0006193761,"threshold_uncertainty_score":0.9998365},"labels":[],"label_agreement":null},{"id":"W4296008883","doi":"10.1016/j.annonc.2022.07.158","title":"126P The HLA I composite score and VHIO immune gene-expression signature (VIGex) as selection tools to explore the tumor microenvironment (TME) in patients (pts) treated with immunotherapy (IT)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hazard ratio; Immunotherapy; Proportional hazards model; Oncology; Human leukocyte antigen; Tumor microenvironment; Internal medicine; Gene signature; Log-rank test; Immune system; Cancer; Progression-free survival; Gene expression; Immunology; Antigen; Overall survival; Gene; Confidence interval; Biology","score_opus":0.03864686665267729,"score_gpt":0.3063800342567599,"score_spread":0.2677331676040826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296008883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872814,0.002099649,0.000004488043,0.009050863,0.0000734105,0.001274811,0.000019436568,0.000013196337,0.0001827741],"genre_scores_gemma":[0.98933256,0.0007807602,0.00008126184,0.009205056,0.000031704178,0.00025571842,0.00006118186,0.000026979422,0.00022477291],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99848795,0.00030924144,0.00037428233,0.0002801537,0.000281262,0.00026712468],"domain_scores_gemma":[0.99924994,0.00012029987,0.0002292292,0.00029477256,0.00006065389,0.000045124845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004058133,0.0001904868,0.00036048243,0.00010945407,0.00029798396,0.000014321919,0.00018999325,0.000071748174,0.00021187509],"category_scores_gemma":[0.0000114759005,0.00010751679,0.0000856888,0.0003263422,0.00015809329,0.00005912924,0.00009663065,0.00035767735,0.0000025523711],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03757449,0.0013788121,0.075251974,0.000021543367,0.00031421284,0.000033599885,0.0060375324,0.00019818827,0.8284779,0.00000406906,0.0047230516,0.045984607],"study_design_scores_gemma":[0.0079758195,0.017159628,0.64014363,0.00013310493,0.00004991813,0.0001234307,0.0018214659,0.0000149118305,0.25196296,0.000016422746,0.08039697,0.00020172402],"about_ca_topic_score_codex":0.00026191722,"about_ca_topic_score_gemma":0.000037857153,"teacher_disagreement_score":0.57651496,"about_ca_system_score_codex":0.00018279947,"about_ca_system_score_gemma":0.00009654774,"threshold_uncertainty_score":0.43844074},"labels":[],"label_agreement":null},{"id":"W4296012582","doi":"10.1016/j.annonc.2022.07.148","title":"116P Any regression of tumor (ART) as an intermediate endpoint in patients (pts) treated with immune checkpoint inhibitors (ICI): A pan-cancer analysis","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University Medical Centre","funders":"","keywords":"Medicine; Oncology; Cancer; Internal medicine; Regression; Statistics","score_opus":0.028948718374145324,"score_gpt":0.344051997848164,"score_spread":0.31510327947401867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296012582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972584,0.0006116772,0.0000012889792,0.00095796,0.00011724285,0.0004433558,0.00006543912,0.000024342466,0.0005202452],"genre_scores_gemma":[0.9983772,0.00036790824,0.000037807455,0.0006764276,0.000031440224,0.00012382066,0.00016355186,0.000028972645,0.00019285886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977827,0.00028980497,0.00090864697,0.00034115167,0.00037291748,0.00030478463],"domain_scores_gemma":[0.9984834,0.000060278926,0.00077951065,0.00037550976,0.00021224485,0.00008904975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065509323,0.0002053571,0.0009619026,0.00068748504,0.000042854314,0.0000033859524,0.00016216829,0.00008203962,0.0009002875],"category_scores_gemma":[0.00004652238,0.00014935636,0.0003019602,0.0012168074,0.00022439021,0.00008673577,0.000100258454,0.0002617337,0.0000017494481],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09085454,0.0066760397,0.7288805,0.00016589569,0.0029325255,0.00023173798,0.0037718771,0.000095024,0.06483557,0.0000097607135,0.001453742,0.100092776],"study_design_scores_gemma":[0.009565234,0.023980856,0.86140627,0.00020914467,0.00044284126,0.000011488178,0.0011147525,0.00010727408,0.09598679,0.000019171785,0.006956154,0.00020005049],"about_ca_topic_score_codex":0.0025710906,"about_ca_topic_score_gemma":0.0006106646,"teacher_disagreement_score":0.13252574,"about_ca_system_score_codex":0.00023748264,"about_ca_system_score_gemma":0.00032532567,"threshold_uncertainty_score":0.9857516},"labels":[],"label_agreement":null},{"id":"W4296012608","doi":"10.1016/j.annonc.2022.07.324","title":"CN12 Impact of diet on immune checkpoint blockade: Nurse-directed dietary intervention","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Dietary fiber; Immune checkpoint; Oncology; Cancer; Immunotherapy; Food science","score_opus":0.0638778829407786,"score_gpt":0.4078346802023032,"score_spread":0.34395679726152456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296012608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891082,0.002237086,0.0000015149026,0.0033677162,0.0003473501,0.00029175176,0.00006595024,0.000036971192,0.0045434325],"genre_scores_gemma":[0.998639,0.00030350356,0.000041786578,0.0003005025,0.00005554366,0.000036184825,0.00008461754,0.000016577675,0.00052232505],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986384,0.00019237239,0.0005829812,0.00017231469,0.00020641038,0.00020750986],"domain_scores_gemma":[0.9990598,0.00008726251,0.00040519866,0.0002761881,0.000121421,0.000050151728],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00060244027,0.00012461367,0.0005108521,0.00019303239,0.00005010427,0.0000014926236,0.00012380554,0.000079257276,0.0023999708],"category_scores_gemma":[0.00006486373,0.00010587504,0.00069971976,0.0002854692,0.00013195995,0.000028370436,0.00004861931,0.00023307432,0.0000042561337],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1084683,0.0067591253,0.0057053063,0.00018915505,0.0025363902,0.0000847046,0.0015226476,0.00008383106,0.5946361,0.000023599094,0.01861924,0.2613716],"study_design_scores_gemma":[0.010184053,0.14307375,0.65911674,0.0002519819,0.00019229183,0.00013579446,0.0009974522,0.0002233655,0.15165168,0.00020123106,0.033721704,0.00024996564],"about_ca_topic_score_codex":0.0010719572,"about_ca_topic_score_gemma":0.00002037989,"teacher_disagreement_score":0.65341145,"about_ca_system_score_codex":0.00015765154,"about_ca_system_score_gemma":0.00017410002,"threshold_uncertainty_score":0.99851197},"labels":[],"label_agreement":null},{"id":"W4296130885","doi":"10.1101/2022.09.10.507426","title":"Discovery of a novel monoclonal PD-L1 antibody H1A that promotes T-cell mediated tumor killing activity in renal cell carcinoma","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fonds de Recherche du Québec - Santé; National Institutes of Health","keywords":"Cytotoxic T cell; CD8; Immunotherapy; Cancer research; Immune system; Medicine; Nivolumab; T cell; Monoclonal antibody; Immune checkpoint; Immunology; Antibody; Biology; In vitro","score_opus":0.020960123528143495,"score_gpt":0.24570492157156,"score_spread":0.2247447980434165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296130885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933276,0.0025648326,0.0004226874,0.00017089769,0.0008359305,0.00153496,0.0009834126,0.00012987955,0.000029784504],"genre_scores_gemma":[0.9971796,0.00037606162,0.0016570245,0.00014064883,0.0002252978,0.00022035248,0.000007969085,0.00017132558,0.000021707436],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961178,0.0001858785,0.0008346069,0.0012689503,0.00086933654,0.00072345056],"domain_scores_gemma":[0.9971634,0.00018175798,0.0009681143,0.0012717893,0.00021562997,0.00019929216],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010043441,0.0007558656,0.0012420677,0.0006539553,0.00012348476,0.00009207188,0.0005485173,0.00041956964,0.000120577955],"category_scores_gemma":[0.000085322245,0.00076746655,0.00043534738,0.00091161206,0.00022030695,0.0002502883,0.0005976411,0.0015207755,0.00000378902],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002093639,0.0015867769,0.10201919,0.0015579007,0.0001519888,0.0002246107,0.000042385247,0.000030557014,0.8922482,0.0000047788035,0.00003852331,0.0000014130602],"study_design_scores_gemma":[0.0032967005,0.00023985999,0.34850228,0.00054326764,0.00013925871,1.1208266e-7,0.0000126755385,0.0007462339,0.6456608,1.8051709e-7,0.00031434535,0.00054425944],"about_ca_topic_score_codex":0.0010907892,"about_ca_topic_score_gemma":0.000012796859,"teacher_disagreement_score":0.2465874,"about_ca_system_score_codex":0.0007730624,"about_ca_system_score_gemma":0.00212974,"threshold_uncertainty_score":0.9994776},"labels":[],"label_agreement":null},{"id":"W4296163140","doi":"10.1186/s12885-022-10048-x","title":"A combined spatial score of granzyme B and CD68 surpasses CD8 as an independent prognostic factor in TNM stage II colorectal cancer","year":2022,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"University of Bern","keywords":"Medicine; Granzyme B; CD8; Oncology; Internal medicine; Tissue microarray; Surgical oncology; CD68; Colorectal cancer; Cohort; Pathology; Immunohistochemistry; Cancer; Immunology; Immune system","score_opus":0.029254253333186566,"score_gpt":0.3046140398298634,"score_spread":0.27535978649667686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296163140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951306,0.002435432,0.0000070119195,0.00023104172,0.0004780621,0.0011098009,0.00047093566,0.000033343033,0.00010374708],"genre_scores_gemma":[0.9978322,0.0003450442,0.000022288146,0.0002367993,0.000092086484,0.00070819934,0.000047277408,0.00003267062,0.00068346947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984207,0.00010455506,0.00034804564,0.00036532283,0.00047471793,0.0002866719],"domain_scores_gemma":[0.9994082,0.00006672142,0.0001703855,0.0001778928,0.00007002578,0.00010677322],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001920121,0.00019360888,0.00041034157,0.00016874752,0.00013788104,0.00001517406,0.000118862365,0.00007015042,0.003592611],"category_scores_gemma":[0.0000337315,0.00017697584,0.00008069711,0.00032944547,0.00012562402,0.00008630321,0.00011897235,0.00024995362,4.94998e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010295127,0.00045317598,0.939866,0.00022121238,0.00011706313,0.000034854962,0.0018883811,0.00004575155,0.0410907,0.000030143292,0.0001945053,0.005763084],"study_design_scores_gemma":[0.008020576,0.0026276312,0.9741182,0.00016877604,0.000069627415,0.000016733378,0.00067293324,0.00024307954,0.011463798,0.000021630789,0.0023347153,0.00024230014],"about_ca_topic_score_codex":0.045490295,"about_ca_topic_score_gemma":0.062177222,"teacher_disagreement_score":0.0342522,"about_ca_system_score_codex":0.0004310978,"about_ca_system_score_gemma":0.001045578,"threshold_uncertainty_score":0.99731827},"labels":[],"label_agreement":null},{"id":"W4296167489","doi":"10.3389/fphar.2022.960323","title":"Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer","year":2022,"lang":"en","type":"review","venue":"Frontiers in Pharmacology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"NYU Grossman School of Medicine; Peking Union Medical College; Chinese Academy of Medical Sciences; National Natural Science Foundation of China; York University; Cancer Foundation of China; Beijing Xisike Clinical Oncology Research Foundation; China International Medical Foundation; Massachusetts General Hospital","keywords":"Medicine; Triple-negative breast cancer; Breast cancer; Oncology; Chemotherapy; Internal medicine; Clinical trial; Cancer; Triple negative; Randomized controlled trial; Pharmacology","score_opus":0.04995882683707331,"score_gpt":0.4186236046634209,"score_spread":0.3686647778263476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296167489","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0071091806,0.979811,0.000025211602,0.00067168905,0.0028247978,0.00923885,0.00020206269,0.000021462369,0.00009570607],"genre_scores_gemma":[0.00067370344,0.9969056,0.00025791943,0.0004713003,0.0002665046,0.0010871331,0.00007410596,0.000070248396,0.00019344258],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.989617,0.0061375964,0.0029167847,0.0007058864,0.0002443325,0.00037839205],"domain_scores_gemma":[0.9933777,0.004559331,0.0016597115,0.00020497399,0.000043815915,0.00015448325],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009289356,0.0005507976,0.009372414,0.00071157754,0.00005538827,0.000009536509,0.00017430923,0.00048183516,0.00077243743],"category_scores_gemma":[0.00039486712,0.00038287928,0.00062631996,0.0007493526,0.0015463016,0.00006414857,0.000076777185,0.001150158,1.6875346e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45904285,0.00033393415,0.0019341991,0.0017915856,0.0029107668,0.000039740164,0.00025622692,4.9185485e-7,0.0000031243933,0.0000011979171,0.005191725,0.5284942],"study_design_scores_gemma":[0.6940912,0.00090238097,0.0032230318,0.0046334476,0.0039994703,0.000066489374,0.00016540205,0.00006407104,0.000016054662,0.000017416342,0.29235837,0.00046268365],"about_ca_topic_score_codex":0.00034691775,"about_ca_topic_score_gemma":0.00004884227,"teacher_disagreement_score":0.52803147,"about_ca_system_score_codex":0.00043054597,"about_ca_system_score_gemma":0.00082507974,"threshold_uncertainty_score":0.9998623},"labels":[],"label_agreement":null},{"id":"W4296629891","doi":"10.1111/trf.17114","title":"Therapeutic plasma exchange in the management of immune checkpoint <scp>inhibitor‐associated</scp> immune‐related adverse effects: A review","year":2022,"lang":"en","type":"review","venue":"Transfusion","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"American Society of Hematology","keywords":"Immune system; Adverse effect; Medicine; Immunology; Pharmacology","score_opus":0.027766999595827346,"score_gpt":0.2955141814990001,"score_spread":0.26774718190317276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296629891","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007777601,0.9878629,0.000003296137,0.00018817146,0.0006472234,0.0071971877,0.00003328111,0.000069654394,0.0032205614],"genre_scores_gemma":[0.000182947,0.9971317,0.000011633893,0.0002393704,0.000043109074,0.0011596406,0.00041334762,0.00010343043,0.0007148408],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951702,0.0010296078,0.0019635332,0.00054900936,0.00081642787,0.0004712303],"domain_scores_gemma":[0.9976969,0.00057244074,0.00075795955,0.000884218,0.00003510618,0.000053428394],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031220778,0.00065366115,0.0025354603,0.0003051905,0.00014769522,0.000009729921,0.0005435026,0.0003551678,0.0006271463],"category_scores_gemma":[0.000039835435,0.00042700543,0.0021967483,0.001720714,0.00011075145,0.000055066153,0.00008459165,0.0010426727,0.000027487697],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001073084,0.0006552023,0.000004001752,0.17534454,0.0017703833,0.00021071729,0.0011961999,1.2919274e-7,0.00008507843,0.000016573773,0.00019381299,0.82041603],"study_design_scores_gemma":[0.003880777,0.0006087928,0.00033012126,0.16107795,0.005409849,0.000117183066,0.00032170114,0.0000027438487,0.000033358923,0.0000063698285,0.8280398,0.00017131878],"about_ca_topic_score_codex":0.00022885061,"about_ca_topic_score_gemma":0.000020123287,"teacher_disagreement_score":0.82784605,"about_ca_system_score_codex":0.00056369556,"about_ca_system_score_gemma":0.00015304479,"threshold_uncertainty_score":0.99981815},"labels":[],"label_agreement":null},{"id":"W4296661760","doi":"10.1136/jitc-2022-005646","title":"Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"School of Medicine, Stanford University; Universitätsklinikum Heidelberg; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; University of Washington; University of Miami; Universitair Medisch Centrum Groningen; University of Texas MD Anderson Cancer Center; Northwestern University; National Cancer Institute; University of Toronto; National Institute of General Medical Sciences; Massachusetts General Hospital; University of California, Los Angeles; Memorial Sloan-Kettering Cancer Center; Ohio State University; Leonard M. Miller School of Medicine; University of Pennsylvania","keywords":"Medicine; Corticosteroid; Creatinine; Internal medicine; Cohort; Acute kidney injury; Adverse effect; Confounding; Duration (music)","score_opus":0.02640980364461186,"score_gpt":0.32402318233306016,"score_spread":0.2976133786884483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296661760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94852614,0.04445251,0.000079715304,0.0023587313,0.0037136886,0.00068746135,0.00007287161,0.000021622709,0.000087227134],"genre_scores_gemma":[0.9891114,0.00878835,0.0001136682,0.00044401994,0.00029649006,0.00019715891,0.000035531742,0.000056463843,0.0009569084],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99797994,0.0000761096,0.0009752511,0.00020409904,0.0004742965,0.0002903159],"domain_scores_gemma":[0.9987054,0.00007447762,0.0007582819,0.00019470965,0.00019416674,0.000072975],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007803213,0.0002014649,0.0004518587,0.0001718773,0.0003831831,0.00004467472,0.000114363254,0.00007358376,0.0010952384],"category_scores_gemma":[0.000033245902,0.0001761999,0.00037318678,0.00020991395,0.00009708412,0.0001386966,0.000033588494,0.00038592922,4.5107984e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.082839526,0.0005656996,0.003073294,0.000085202875,0.0022260805,0.000010329202,0.0021768296,0.000022435497,0.70312357,0.000011838562,0.0023392397,0.20352595],"study_design_scores_gemma":[0.123421565,0.02859857,0.21722394,0.0011475284,0.0011048468,0.0006876669,0.0029393996,0.0007912775,0.20735589,0.00034812928,0.4150037,0.0013774912],"about_ca_topic_score_codex":0.000089841364,"about_ca_topic_score_gemma":0.0000431217,"teacher_disagreement_score":0.49576768,"about_ca_system_score_codex":0.0006860534,"about_ca_system_score_gemma":0.00026514573,"threshold_uncertainty_score":0.9998179},"labels":[],"label_agreement":null},{"id":"W4296709146","doi":"10.1158/1078-0432.ccr-22-0979","title":"CD8+ Tumor-Infiltrating Lymphocyte Abundance Is a Positive Prognostic Indicator in Nasopharyngeal Cancer","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Public Health Ontario; University of Toronto; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research; Princess Margaret Cancer Foundation; Ministry of Health, Ontario","keywords":"Tumor-infiltrating lymphocytes; Immune system; CD8; Cohort; Oncology; Medicine; T-cell receptor; Internal medicine; T cell; Biology; Immunology","score_opus":0.13594631134784171,"score_gpt":0.4920593935842087,"score_spread":0.35611308223636695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296709146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9706406,0.017137043,0.0000020949133,0.008261802,0.00060570106,0.0015826738,0.00027791955,0.00005302505,0.0014391263],"genre_scores_gemma":[0.985746,0.003966548,0.000070949,0.0059133116,0.00069775153,0.002389524,0.000026361075,0.00006136966,0.0011281325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947886,0.0008643026,0.0009716491,0.00090149767,0.001509918,0.000964058],"domain_scores_gemma":[0.99740505,0.0013439343,0.00020600187,0.00048254724,0.0002279837,0.00033450907],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003958364,0.0002292243,0.00062373426,0.0003575851,0.0005803426,0.00005468976,0.0004763619,0.0001159589,0.006043793],"category_scores_gemma":[0.0005421887,0.00021599364,0.00026218846,0.0016119692,0.0006916729,0.00011064877,0.00036867533,0.0020250226,0.000041726154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019411886,0.0010716125,0.8436421,0.0003012248,0.00038435016,0.00080452184,0.0018092351,0.000020477626,0.0052684327,0.000052633775,0.014757531,0.11247598],"study_design_scores_gemma":[0.015319993,0.00354333,0.90105253,0.0010815315,0.00008383336,0.00010236745,0.0011729782,0.00073682104,0.004892481,0.00013898568,0.07131001,0.0005651513],"about_ca_topic_score_codex":0.0067670443,"about_ca_topic_score_gemma":0.0008862691,"teacher_disagreement_score":0.11191083,"about_ca_system_score_codex":0.0021843866,"about_ca_system_score_gemma":0.004538974,"threshold_uncertainty_score":0.999847},"labels":[],"label_agreement":null},{"id":"W4296768785","doi":"10.1016/j.ebiom.2022.104254","title":"Immune checkpoint expression on HIV-specific CD4+ T cells and response to their blockade are dependent on lineage and function","year":2022,"lang":"en","type":"article","venue":"EBioMedicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"National Institute of Allergy and Infectious Diseases; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; National Institutes of Health; Université de Montréal; Canada Foundation for Innovation; National Heart, Lung, and Blood Institute; McGill University","keywords":"TIGIT; Blockade; Immune checkpoint; Immune system; Biology; Immunology; Effector; T cell; Chemokine; Cancer research; Immunotherapy; Receptor; Genetics","score_opus":0.01532761375872171,"score_gpt":0.24152742971170243,"score_spread":0.22619981595298072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296768785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845368,0.0035041347,0.000081830796,0.01009886,0.00074553885,0.00066308974,0.000076212564,0.000069214606,0.00022430054],"genre_scores_gemma":[0.99291277,0.0005093682,0.00006417086,0.0025797698,0.00036192502,0.00007622593,0.000052517382,0.000037486312,0.0034057503],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99828196,0.00015463424,0.00036113636,0.00047894637,0.00046819285,0.0002551446],"domain_scores_gemma":[0.99903095,0.00017120744,0.00013046294,0.00043969238,0.000032249216,0.0001954246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091991515,0.00024144014,0.00036282482,0.0003865196,0.00026694973,0.00001655105,0.00008157367,0.000069264104,0.00062086317],"category_scores_gemma":[0.000033582965,0.00017513777,0.00006598,0.0003137284,0.00009953957,0.000026703734,0.000115862655,0.0003536128,0.000018344525],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060612213,0.00023772054,0.00016290453,0.000034697718,0.000048657086,0.00008867441,0.0011605235,0.000006697296,0.9145467,0.000001718689,0.0066709123,0.016428534],"study_design_scores_gemma":[0.009142665,0.008155171,0.058130927,0.0005332963,0.000044331093,0.00012717534,0.003721818,0.00003773308,0.57935375,0.000007961452,0.34050044,0.0002447441],"about_ca_topic_score_codex":0.000020796984,"about_ca_topic_score_gemma":0.0000016420198,"teacher_disagreement_score":0.335193,"about_ca_system_score_codex":0.00022056141,"about_ca_system_score_gemma":0.000037193164,"threshold_uncertainty_score":0.7141911},"labels":[],"label_agreement":null},{"id":"W4296769722","doi":"10.1016/j.mbs.2022.108911","title":"Mathematical modeling for the combination treatment of IFN-<mml:math xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" display=\"inline\" id=\"d1e4854\" altimg=\"si118.svg\"><mml:mi>γ</mml:mi></mml:math> and anti-PD-1 in cancer immunotherapy","year":2022,"lang":"en","type":"article","venue":"Mathematical Biosciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Immune system; CD8; Cytotoxic T cell; Apoptosis; Cancer research; Programmed cell death; T cell; PD-L1; Cytokine; Biology; Immune checkpoint; Immunotherapy; Immunology; Biochemistry; In vitro","score_opus":0.032018191930432933,"score_gpt":0.29428033977982415,"score_spread":0.2622621478493912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296769722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99451977,0.0012075488,0.0017318338,0.0016755377,0.0001888286,0.00027046513,0.00005730491,0.000044510303,0.00030417397],"genre_scores_gemma":[0.9965689,0.0006839035,0.0016121711,0.0002994474,0.00006582045,0.0006287717,0.000019807825,0.00004126933,0.000079869475],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9980178,0.00004794748,0.0005854219,0.00036166658,0.0006188862,0.00036828782],"domain_scores_gemma":[0.99873817,0.0005336994,0.00024453938,0.00036819334,0.000036006077,0.00007942001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085999887,0.00020718193,0.00029031988,0.000103225866,0.00037948156,0.00008957225,0.00028039273,0.00011790871,0.00012190855],"category_scores_gemma":[0.000113900016,0.00015601187,0.0002280079,0.0003227459,0.00049234217,0.00013923396,0.000107855434,0.00014486241,0.000013863236],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005906396,0.00076305645,0.000023487246,0.0003436478,0.00015612603,0.000011364878,0.0023831062,0.00020083041,0.007858583,0.9811164,0.000027845703,0.0065248916],"study_design_scores_gemma":[0.0016945467,0.0013223665,0.000106318184,0.00024832066,0.00013534108,0.00008686066,0.0020303815,0.98518753,0.0046802736,0.003765147,0.00057317957,0.00016976113],"about_ca_topic_score_codex":0.00019896828,"about_ca_topic_score_gemma":0.00003480044,"teacher_disagreement_score":0.98498666,"about_ca_system_score_codex":0.000046848654,"about_ca_system_score_gemma":0.00020730111,"threshold_uncertainty_score":0.6361979},"labels":[],"label_agreement":null},{"id":"W4296769725","doi":"10.1016/j.jtho.2022.07.075","title":"OA15.06 Pooled Analysis of Outcomes with Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Lung cancer; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.02972234667860972,"score_gpt":0.46124054949718124,"score_spread":0.4315182028185715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296769725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845871,0.012690736,0.00007408096,0.0015987173,0.0004351765,0.00025611202,0.00014112685,0.0000053545277,0.00021160505],"genre_scores_gemma":[0.99646324,0.0007553056,0.0005393518,0.00056181976,0.00008962302,0.000025079866,0.0000080109985,0.00002119931,0.0015363808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977713,0.0002158762,0.0010802733,0.00018344396,0.00046391157,0.00028520037],"domain_scores_gemma":[0.99678504,0.00026314467,0.0020012585,0.00027628188,0.0005760474,0.00009820803],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001204543,0.0001991724,0.0017903507,0.00045173286,0.00011814805,0.0000053040944,0.00024873822,0.00008478525,0.001083668],"category_scores_gemma":[0.000031494837,0.00013797279,0.00063900417,0.0009691054,0.00024535172,0.00007314436,0.00009203299,0.0004433028,2.821274e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12556069,0.008479797,0.43067992,0.0016696505,0.12578988,0.0014088664,0.024708204,0.0032017084,0.17392644,0.0000033814952,0.007956633,0.09661484],"study_design_scores_gemma":[0.074090816,0.040951595,0.58915216,0.0007280893,0.11413486,0.0015970785,0.07586609,0.0021843063,0.0794407,0.000023523902,0.020851888,0.0009788646],"about_ca_topic_score_codex":0.00011125768,"about_ca_topic_score_gemma":0.0005031296,"teacher_disagreement_score":0.15847227,"about_ca_system_score_codex":0.0006004954,"about_ca_system_score_gemma":0.0010828297,"threshold_uncertainty_score":0.9998295},"labels":[],"label_agreement":null},{"id":"W4296771720","doi":"10.1016/j.jtho.2022.07.647","title":"EP08.01-075 Combination of Baseline Disease and Smoking Pack-Years Can Guide The 1st-line Treatment Decision in Advanced NSCLC with High PD-L1 Expression","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital","funders":"","keywords":"Medicine; Oncology; Baseline (sea); Internal medicine; Line (geometry); Expression (computer science)","score_opus":0.016534481846255555,"score_gpt":0.369993945903954,"score_spread":0.35345946405769846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296771720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99157214,0.0022091784,0.00022084641,0.0053339945,0.0002706132,0.00032054426,0.000027279239,0.0000045814477,0.000040791947],"genre_scores_gemma":[0.9968803,0.0008489844,0.0015781489,0.00043517316,0.00007411143,0.000019773204,0.000020719204,0.000014594433,0.00012818615],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99843794,0.00033236018,0.00058122416,0.00014000249,0.00036722794,0.00014125727],"domain_scores_gemma":[0.9986249,0.00037564954,0.0006033165,0.00018362845,0.00011812664,0.00009438514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010950998,0.00011690573,0.00039957045,0.00022303451,0.00009033778,0.000006026946,0.000100153884,0.000044278913,0.00012720963],"category_scores_gemma":[0.00011429618,0.000069355985,0.00007885375,0.00026588695,0.00008764036,0.00006603671,0.0000484342,0.00023612144,9.046082e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.116199225,0.0014344541,0.013821501,0.000039441093,0.0001817371,0.00086675823,0.0009166896,0.0010391795,0.02789827,0.000015239117,0.0009175643,0.8366699],"study_design_scores_gemma":[0.052554194,0.04964163,0.7348069,0.0022585536,0.0015035017,0.0024204091,0.0069630533,0.0013560461,0.021867113,0.0011567317,0.12496932,0.0005025444],"about_ca_topic_score_codex":0.00012162992,"about_ca_topic_score_gemma":0.00013820123,"teacher_disagreement_score":0.8361674,"about_ca_system_score_codex":0.0007126719,"about_ca_system_score_gemma":0.0004733245,"threshold_uncertainty_score":0.2828255},"labels":[],"label_agreement":null},{"id":"W4297094017","doi":"10.1200/jco.22.00533","title":"Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sanofi Pasteur; Pharmacyclics; EMD Serono; Genentech; Aptitude Health; Qbiotics; Italfarmaco; Eli Lilly and Company; Ono Pharmaceutical; Eisai; Astellas Pharma; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Calithera Biosciences; Pfizer; Incyte; Array BioPharma; Five Prime Therapeutics; Ipsen; Clovis Oncology; Les Laboratories Pierre Fabre; Sun Pharma; Advanced Accelerator Applications; Regeneron Pharmaceuticals; Endocyte; Sanofi; GlaxoSmithKline; Amgen; Celgene; EUSA Pharma; AstraZeneca; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Ipilimumab; Hazard ratio; Internal medicine; Adjuvant; Population; Melanoma; Adjuvant therapy; Adverse effect; Randomized controlled trial; Stage (stratigraphy); Gastroenterology; Oncology; Surgery; Cancer; Immunotherapy; Confidence interval; Cancer research","score_opus":0.08196171607296819,"score_gpt":0.3946335868003538,"score_spread":0.3126718707273856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297094017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959553,0.0004707821,0.000011890009,0.0011123136,0.0010792505,0.00075026584,0.000059945487,0.000016457234,0.000543779],"genre_scores_gemma":[0.9965641,0.0006498019,0.0007258782,0.0006579944,0.00011849653,0.000020216507,0.000027495435,0.000051343166,0.0011846769],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99454474,0.00094108836,0.0026896314,0.0003403056,0.00106292,0.0004213261],"domain_scores_gemma":[0.99456275,0.0013018962,0.0028745192,0.00044720882,0.0005668976,0.00024673017],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027903419,0.0002723797,0.0021767332,0.00033181484,0.00010039192,0.00000951573,0.00037694027,0.00023886161,0.0019112821],"category_scores_gemma":[0.00045906694,0.00016709357,0.00032776265,0.0006770403,0.0004297446,0.00015088561,0.00009731777,0.0014410651,0.0000019835898],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79757345,0.0062008123,0.16036421,0.00004243068,0.001348068,0.00088052306,0.0003333401,0.000054787743,0.00034286338,0.000008815844,0.0009012944,0.031949434],"study_design_scores_gemma":[0.23003778,0.23046045,0.5136012,0.00011666815,0.00012260517,0.000045031742,0.000723558,0.000059637383,0.00014638883,0.0000046561427,0.024503913,0.00017810527],"about_ca_topic_score_codex":0.0003125585,"about_ca_topic_score_gemma":0.0010325406,"teacher_disagreement_score":0.56753564,"about_ca_system_score_codex":0.00064343034,"about_ca_system_score_gemma":0.00317068,"threshold_uncertainty_score":0.9990011},"labels":[],"label_agreement":null},{"id":"W4297151133","doi":"10.3390/biomedicines10102391","title":"Telomere-Associated Changes in Nuclear Architecture of Cancer-Associated Macrophage-like Cells in Liquid Biopsies from Melanoma Patients","year":2022,"lang":"en","type":"article","venue":"Biomedicines","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Telomere; Melanoma; Cancer; Macrophage; Biology; Cancer research; Cancer cell; Telomerase; Pathology; Immunology; Medicine; Genetics; DNA; In vitro; Gene","score_opus":0.008427075666828205,"score_gpt":0.2383197069788452,"score_spread":0.22989263131201698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297151133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99262035,0.0029567226,1.9011087e-7,0.0020090225,0.00088822946,0.0005260921,0.00082260545,0.000050498074,0.00012632014],"genre_scores_gemma":[0.99745184,0.00061842165,0.00002907409,0.0011497178,0.000078099525,0.00007483504,0.00033225564,0.000044991702,0.00022075512],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980624,0.00016242621,0.00050790876,0.00035412092,0.00052739884,0.00038578294],"domain_scores_gemma":[0.99919933,0.000109033914,0.0003093248,0.00023135825,0.00007269793,0.00007826451],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002922293,0.00024033911,0.0006378578,0.0006704387,0.00007524882,0.000005751889,0.00020787209,0.0001413329,0.0010455339],"category_scores_gemma":[0.00006634837,0.00020708283,0.00009552935,0.0015100234,0.00018770524,0.000026861742,0.00011482185,0.0003116439,0.0000023895336],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010415995,0.0023264592,0.30855176,0.00016476422,0.0006351917,0.00017828528,0.010728544,0.000020731433,0.6389729,0.0000018777123,0.0039412244,0.024062274],"study_design_scores_gemma":[0.017553931,0.004680558,0.9309809,0.0008651013,0.00014986505,0.00000310717,0.00299534,0.00010439694,0.021253023,0.000025533995,0.020946525,0.00044170293],"about_ca_topic_score_codex":0.014746638,"about_ca_topic_score_gemma":0.0072867093,"teacher_disagreement_score":0.62242913,"about_ca_system_score_codex":0.0005436946,"about_ca_system_score_gemma":0.00011320551,"threshold_uncertainty_score":0.9998676},"labels":[],"label_agreement":null},{"id":"W4297225789","doi":"10.14218/jctp.2022.00017","title":"Immune Checkpoint Inhibitor-Induced Hepatic Injury: A Clinicopathologic Review","year":2022,"lang":"en","type":"review","venue":"Journal of Clinical and Translational Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Differential diagnosis; Immune system; Autoantibody; Liver injury; Medical diagnosis; Gastrointestinal tract; Pathology; Immunology; Internal medicine; Antibody","score_opus":0.16868376024743229,"score_gpt":0.45933509979225634,"score_spread":0.29065133954482403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297225789","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012125962,0.9945157,0.00001800043,0.0017342983,0.0014580453,0.00074413774,0.00005319333,0.000013014021,0.0002509802],"genre_scores_gemma":[0.00031408534,0.9965861,0.0005634305,0.0014218382,0.0009029517,0.000033819077,0.00007470671,0.000040867828,0.000062215884],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99145603,0.0014037297,0.005989017,0.00040589905,0.0005031066,0.00024223785],"domain_scores_gemma":[0.9948698,0.0015355006,0.002924931,0.00030703587,0.0001585253,0.00020420465],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0070771105,0.00039973704,0.0050442414,0.00025272605,0.00009407195,0.00001131857,0.00022233711,0.00055442087,0.0010552667],"category_scores_gemma":[0.0009729263,0.0002649803,0.0031245586,0.00034969367,0.00031388944,0.000075464064,0.00005382857,0.0022748003,0.000012226292],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096131937,0.0003801135,0.00027448082,0.01357546,0.0004278664,0.00070743944,0.000014951972,1.3852279e-8,0.0000076260435,0.000021707092,0.00016744944,0.98346156],"study_design_scores_gemma":[0.0024936188,0.0033860605,0.0029161323,0.023683598,0.0034733047,0.00840193,0.0000048886322,8.135876e-7,8.1909246e-7,0.0003425089,0.95504,0.00025635917],"about_ca_topic_score_codex":0.0000016622878,"about_ca_topic_score_gemma":7.7523424e-7,"teacher_disagreement_score":0.9832052,"about_ca_system_score_codex":0.00002836884,"about_ca_system_score_gemma":0.0012940731,"threshold_uncertainty_score":0.9999802},"labels":[],"label_agreement":null},{"id":"W4297878103","doi":"10.1016/j.tcm.2022.09.004","title":"Immune checkpoint inhibitors – the revolutionary cancer immunotherapy comes with a cardiotoxic price","year":2022,"lang":"en","type":"review","venue":"Trends in Cardiovascular Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Immunotherapy; Intensive care medicine; Pembrolizumab; Cancer; Adverse effect; Cancer immunotherapy; Myocarditis; Internal medicine; Oncology","score_opus":0.043268049823876414,"score_gpt":0.3281700794074981,"score_spread":0.28490202958362165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297878103","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001451704,0.99229217,0.000018483555,0.001201326,0.0012954543,0.0019128107,0.000049188664,0.00019021846,0.0030258186],"genre_scores_gemma":[0.0000860546,0.9930151,0.000046751524,0.00035205117,0.0013721293,0.0024347496,0.0004071856,0.00032686722,0.0019590813],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933501,0.00094394456,0.001712078,0.0010965279,0.0020780768,0.000819259],"domain_scores_gemma":[0.9961211,0.00030929537,0.00059865724,0.0027308343,0.00008936788,0.0001507086],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036334854,0.0010840851,0.005895189,0.0012101408,0.00025822027,0.0000142329245,0.0006850689,0.0003847214,0.0023651584],"category_scores_gemma":[0.000060238053,0.00058443274,0.004798553,0.004167265,0.000811833,0.000078426776,0.00017072316,0.0019354476,0.0000057386997],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005979694,0.00010149203,0.00004293858,0.0043155793,0.016225535,0.000461231,0.00039008737,0.000017401808,0.0000074936834,0.000004292348,0.0031992616,0.97463673],"study_design_scores_gemma":[0.0056744963,0.0006000041,0.0014230498,0.017777896,0.006176547,0.0022618703,0.00033096783,0.0000027825276,0.0000034895063,0.000002096425,0.96511215,0.00063464063],"about_ca_topic_score_codex":0.0023996413,"about_ca_topic_score_gemma":0.00005186246,"teacher_disagreement_score":0.97400206,"about_ca_system_score_codex":0.0022501617,"about_ca_system_score_gemma":0.0009136885,"threshold_uncertainty_score":0.99966073},"labels":[],"label_agreement":null},{"id":"W4297973509","doi":"10.21037/tlcr-22-617","title":"International expert consensus on immunotherapy for early-stage non-small cell lung cancer","year":2022,"lang":"en","type":"review","venue":"Translational Lung Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre","funders":"David Geffen School of Medicine, University of California, Los Angeles","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Immunotherapy; Cancer immunotherapy; Consensus conference; Oncology; Intensive care medicine; Cancer; Internal medicine","score_opus":0.1465575694928405,"score_gpt":0.4803857198026822,"score_spread":0.3338281503098417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297973509","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020723026,0.98049706,0.00011145946,0.0022455486,0.0015132076,0.0060403957,0.0030976657,0.00006133523,0.0062260954],"genre_scores_gemma":[0.0000928119,0.969651,0.00034771865,0.00038734547,0.001415568,0.009773956,0.0010057675,0.00023238102,0.017093461],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950742,0.00031861066,0.0009327806,0.0010067069,0.0018303633,0.0008373045],"domain_scores_gemma":[0.99717337,0.0013866327,0.00027492235,0.0005810182,0.00039579792,0.00018824835],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013371495,0.000594717,0.0012646789,0.00086536305,0.0005034974,0.0001076979,0.00070025364,0.00037668273,0.015307092],"category_scores_gemma":[0.000022401984,0.0005237403,0.0011196049,0.0007453025,0.00023172579,0.00005924686,0.00005214352,0.0015075216,0.000011256139],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009141956,0.00044480877,0.0002642434,0.01520072,0.0036227559,0.000050095972,0.001258571,0.000061769344,0.00029923627,0.00014609763,0.031343073,0.9381667],"study_design_scores_gemma":[0.004606566,0.00031617322,0.0001186549,0.005640569,0.0002765857,0.000010660916,0.00004229413,0.00044949626,0.00006702426,0.000007159153,0.98796076,0.00050408853],"about_ca_topic_score_codex":0.0026055414,"about_ca_topic_score_gemma":0.00013648545,"teacher_disagreement_score":0.95661765,"about_ca_system_score_codex":0.0021362107,"about_ca_system_score_gemma":0.004378243,"threshold_uncertainty_score":0.9997214},"labels":[],"label_agreement":null},{"id":"W4297976362","doi":"10.3389/fimmu.2022.1000681","title":"Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy","year":2022,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Chinese Society of Clinical Oncology; Medical Science and Technology Project of Zhejiang Province; Science and Technology Program of Zhejiang Province; Health Commission of Zhejiang Province; Natural Science Foundation of Zhejiang Province; National Natural Science Foundation of China","keywords":"Medicine; Vaccination; Immunogenicity; Adjuvant; ELISPOT; Cancer; Immunotherapy; Cohort; Immune system; Internal medicine; Oncology; Immunology; Peptide vaccine; Antigen; T cell; Epitope","score_opus":0.0133601970066196,"score_gpt":0.27863034921984914,"score_spread":0.2652701522132295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297976362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9284729,0.06321144,0.0019869772,0.003184441,0.0015810063,0.0014107737,0.000041458374,0.000036347858,0.00007469053],"genre_scores_gemma":[0.9814004,0.013235736,0.0038639817,0.00011612977,0.00009734107,0.0006903794,0.00013335064,0.00003502081,0.00042769383],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990549,0.0001040809,0.000336009,0.0002242553,0.000105711595,0.0001750518],"domain_scores_gemma":[0.99951196,0.000027067317,0.00019311772,0.00018669426,0.0000663074,0.0000148369945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021577594,0.00012851214,0.00035497738,0.00023814866,0.00013037662,0.0000062482727,0.00006428114,0.00008309773,0.00008777941],"category_scores_gemma":[0.0000070910223,0.00012517627,0.000089163696,0.0002392747,0.000061343744,0.00008005869,0.000012175584,0.00008641689,5.0010517e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010667651,0.000657241,0.13760567,0.00009977381,0.0008133331,0.0000046149585,0.0054321894,0.000054079464,0.048357993,0.0005539274,0.0008249122,0.7949286],"study_design_scores_gemma":[0.030232014,0.0047281394,0.85430676,0.000049721108,0.00013079772,0.00007024454,0.004206093,0.0021031743,0.012179269,0.0039562522,0.08771024,0.00032730406],"about_ca_topic_score_codex":0.00036843677,"about_ca_topic_score_gemma":0.000015735106,"teacher_disagreement_score":0.7946013,"about_ca_system_score_codex":0.00083026686,"about_ca_system_score_gemma":0.0001633861,"threshold_uncertainty_score":0.510454},"labels":[],"label_agreement":null},{"id":"W4297981956","doi":"10.1016/j.annonc.2022.08.050","title":"LBA50 Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Genentech; Novartis Pharmaceuticals Corporation; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Lung cancer; Lymph node; Nivolumab; Chemotherapy; non-small cell lung cancer (NSCLC); Oncology; Gastroenterology; Cancer; Immunotherapy","score_opus":0.04156605645833943,"score_gpt":0.3631809270560452,"score_spread":0.32161487059770577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297981956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902864,0.0035953086,0.0000460396,0.004055274,0.00006793285,0.0009511901,0.00012702437,0.000013438855,0.00085739023],"genre_scores_gemma":[0.9947562,0.0013082738,0.0006758297,0.0020269654,0.000025464242,0.0002465287,0.00005055624,0.000024004314,0.000886174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845546,0.000101089274,0.0005011455,0.00037650255,0.00020777155,0.00035805377],"domain_scores_gemma":[0.99884933,0.00030699268,0.00037855105,0.00027088245,0.00012941915,0.00006481573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007016179,0.00019498366,0.0011725121,0.00038908742,0.000078269986,0.0000062010768,0.00016035716,0.00013979625,0.00029291064],"category_scores_gemma":[0.000028573852,0.00014450337,0.00023919865,0.0007038905,0.00016598128,0.0000353267,0.00007000356,0.0002419181,9.016437e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15030691,0.003364957,0.6417473,0.00083564525,0.0069832215,0.00023532323,0.0108310655,0.0034656243,0.0924723,0.000059236798,0.011545024,0.07815343],"study_design_scores_gemma":[0.03884302,0.01082501,0.920856,0.000110732566,0.0009645131,0.000038572092,0.0011440864,0.0016042951,0.016986277,0.000018629653,0.00827747,0.00033138585],"about_ca_topic_score_codex":0.0015751162,"about_ca_topic_score_gemma":0.001166495,"teacher_disagreement_score":0.27910873,"about_ca_system_score_codex":0.00013602176,"about_ca_system_score_gemma":0.00041328016,"threshold_uncertainty_score":0.5892676},"labels":[],"label_agreement":null},{"id":"W4297981965","doi":"10.1016/j.annonc.2022.08.052","title":"LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sanofi Genzyme; European Society for Medical Oncology; F. Hoffmann-La Roche; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Atezolizumab; Internal medicine; Regimen; Gemcitabine; Taxane; Oncology; Clinical endpoint; Vinorelbine; Chemotherapy regimen; Phases of clinical research; Chemotherapy; Cancer; Clinical trial; Cisplatin; Breast cancer; Immunotherapy; Pembrolizumab","score_opus":0.08437136665025254,"score_gpt":0.36605979612960593,"score_spread":0.2816884294793534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297981965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939342,0.00022851075,0.000024540794,0.0025461835,0.00014356378,0.002284553,0.000348128,0.000026643711,0.00046365417],"genre_scores_gemma":[0.99735945,0.00008734147,0.0002906088,0.0013542295,0.000054576903,0.0002952412,0.00034306885,0.00004492032,0.00017058455],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974614,0.0001319419,0.0011187678,0.0005081596,0.00038180797,0.0003979569],"domain_scores_gemma":[0.99798125,0.00036981076,0.0008624271,0.00046429085,0.000252121,0.00007011354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007274387,0.0002564722,0.0010119262,0.000274971,0.000112124275,0.0000061234177,0.0002232656,0.00011581603,0.00014219785],"category_scores_gemma":[0.00010153989,0.00022626357,0.00014650969,0.00041941955,0.000101916776,0.00007106291,0.00008365181,0.0002195125,6.881254e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7790445,0.026457962,0.011284903,0.00007396211,0.0013304536,0.000059541806,0.025283657,0.000173158,0.010179613,0.0000033436095,0.003717897,0.14239101],"study_design_scores_gemma":[0.5335095,0.3193872,0.016982485,0.00038657195,0.00025554173,0.000015813992,0.010481126,0.0004950199,0.065182514,0.000052320032,0.05272265,0.0005292735],"about_ca_topic_score_codex":0.003492354,"about_ca_topic_score_gemma":0.0010192532,"teacher_disagreement_score":0.29292923,"about_ca_system_score_codex":0.0003155259,"about_ca_system_score_gemma":0.00025348633,"threshold_uncertainty_score":0.922676},"labels":[],"label_agreement":null},{"id":"W4297986257","doi":"10.1016/j.annonc.2022.07.1943","title":"1202TiP Evolution of the tumor immune microenvironment in hepatocellular carcinoma (HCC) and non-squamous non-small cell lung cancer (NSCLC) with liver metastases treated with atezolizumab and bevacizumab (INTEGRATE)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MaRS; Princess Margaret Cancer Centre; University Health Network","funders":"EMD Serono; AstraZeneca; Amgen","keywords":"Medicine; Atezolizumab; Bevacizumab; Hepatocellular carcinoma; Oncology; Lung cancer; Tumor microenvironment; Immune system; Internal medicine; Cancer research; Cancer; Immunotherapy; Nivolumab; Immunology; Chemotherapy","score_opus":0.016327319268081907,"score_gpt":0.2506900521574491,"score_spread":0.2343627328893672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297986257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97444516,0.023633499,0.000014503884,0.00062531995,0.00003284544,0.0009651887,0.00008944408,0.000005183205,0.00018884096],"genre_scores_gemma":[0.99797046,0.0013296984,0.00008481498,0.00021015493,0.000012082334,0.00015047897,0.00001576461,0.000025062049,0.00020149801],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986642,0.00017169114,0.0003825683,0.00031212298,0.00019549229,0.0002739172],"domain_scores_gemma":[0.99920976,0.00006382282,0.0003321542,0.0002728873,0.00006557826,0.00005580229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027169372,0.00021464084,0.0005873682,0.00014663476,0.00010046738,0.000004210669,0.00011586211,0.00005579158,0.00012353313],"category_scores_gemma":[0.000004439709,0.00013841964,0.00008122601,0.00028321313,0.0003702775,0.000034466997,0.000105177205,0.00022347242,1.9748843e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030675793,0.0010568949,0.73709536,0.0005464202,0.00045134334,0.00043080348,0.0024025277,0.00011269515,0.21968274,0.0000065199506,0.00045777072,0.007081144],"study_design_scores_gemma":[0.014269078,0.010165018,0.77437615,0.000277827,0.00048707452,0.000395623,0.0021586693,0.0013244909,0.19511685,0.000003609135,0.0011797283,0.0002459028],"about_ca_topic_score_codex":0.012458884,"about_ca_topic_score_gemma":0.0008553646,"teacher_disagreement_score":0.03728078,"about_ca_system_score_codex":0.00032372662,"about_ca_system_score_gemma":0.0004367668,"threshold_uncertainty_score":0.99411726},"labels":[],"label_agreement":null},{"id":"W4297986259","doi":"10.1016/j.annonc.2022.08.029","title":"LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Head and neck squamous-cell carcinoma; Placebo; Oncology; Head and neck; Head and neck cancer; Phases of clinical research; Basal cell; Internal medicine; Radiation therapy; Clinical trial; Surgery; Cancer; Immunotherapy; Pathology","score_opus":0.037661649349017924,"score_gpt":0.3400283840036157,"score_spread":0.30236673465459774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297986259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98882306,0.0022241224,0.00003411927,0.0033250314,0.00015516594,0.0028595005,0.00012530596,0.000021547421,0.0024321554],"genre_scores_gemma":[0.9964051,0.00026083528,0.00018667677,0.002118729,0.00006616078,0.0003221791,0.00006245683,0.000037594436,0.0005402571],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980097,0.00027916988,0.0006346397,0.00039779412,0.00036305943,0.00031563983],"domain_scores_gemma":[0.9981593,0.0004513849,0.0006097335,0.00046721098,0.00023422303,0.00007813985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007862427,0.00022961778,0.00073898135,0.00012684299,0.00018540052,0.000006899439,0.00022318066,0.0001097172,0.000033640634],"category_scores_gemma":[0.000053741704,0.00016692879,0.00016009425,0.0003013616,0.00026135438,0.000071289876,0.000082997125,0.0002470559,2.1214909e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.844639,0.0045082755,0.0025506099,0.00022597666,0.00024064143,0.00004382643,0.005148777,0.00029976896,0.03704038,0.000012976732,0.0049640574,0.10032569],"study_design_scores_gemma":[0.6014718,0.15438451,0.09701002,0.00006769221,0.00024326838,0.00020180768,0.0027712248,0.0005964002,0.0510033,0.000051796225,0.091765545,0.00043266412],"about_ca_topic_score_codex":0.00035963015,"about_ca_topic_score_gemma":0.00014319856,"teacher_disagreement_score":0.24316725,"about_ca_system_score_codex":0.00020187919,"about_ca_system_score_gemma":0.001231017,"threshold_uncertainty_score":0.6807158},"labels":[],"label_agreement":null},{"id":"W4298008223","doi":"10.1016/j.jtho.2022.09.109","title":"Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee","year":2022,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Pharmaceuticals; Johnson and Johnson; Ribon Therapeutics; Boehringer Ingelheim; International Association for the Study of Lung Cancer; Novartis; Daiichi Sankyo Europe; Sanofi; Merck; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Immunotherapy; Biomarker; Lung cancer; Oncology; Companion diagnostic; Cancer; Tumor microenvironment; Cancer immunotherapy; Adjuvant; Biomarker discovery; Internal medicine; Immunohistochemistry; Immunology; Proteomics","score_opus":0.04654945551221298,"score_gpt":0.47204737299830063,"score_spread":0.4254979174860877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298008223","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023079813,0.9799171,0.00012416091,0.0066277236,0.0049351486,0.0049565644,0.0010245477,0.0000064109277,0.00010033731],"genre_scores_gemma":[0.0014017702,0.99426526,0.00011662378,0.000500917,0.0011921099,0.0022325714,0.00004273288,0.00005644923,0.00019153877],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99643207,0.0009747778,0.0014866412,0.00031329895,0.0005109994,0.00028219604],"domain_scores_gemma":[0.9882317,0.006815742,0.003977058,0.00030135308,0.0006380189,0.000036085054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036849172,0.00031434238,0.0019514156,0.00032679908,0.00018903486,0.000021452048,0.0008138094,0.00034828525,0.00041543072],"category_scores_gemma":[0.0005067338,0.00018009782,0.0010185104,0.00040492727,0.00011634197,0.000076950106,0.000090338464,0.00097422383,8.189687e-8],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022298919,0.001051009,0.0049921437,0.0007221031,0.023610042,0.000030097386,0.007500928,0.000024338211,0.000032909997,0.000007433256,0.015466271,0.9242638],"study_design_scores_gemma":[0.006242168,0.0033701153,0.00493492,0.002251059,0.00828775,0.00008378089,0.011366943,0.00024885577,0.000005161876,0.000053811393,0.96295977,0.0001956453],"about_ca_topic_score_codex":0.001980516,"about_ca_topic_score_gemma":0.0017921982,"teacher_disagreement_score":0.9474935,"about_ca_system_score_codex":0.009460801,"about_ca_system_score_gemma":0.0025890602,"threshold_uncertainty_score":0.99434173},"labels":[],"label_agreement":null},{"id":"W4298111170","doi":"10.1016/j.pathol.2022.07.016","title":"The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer","year":2022,"lang":"en","type":"article","venue":"Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AstraZeneca; Bristol-Myers Squibb; University of British Columbia; Roche; Amgen","keywords":"Medicine; Concordance; Lung cancer; Internal medicine; Oncology; Cancer; Head and neck cancer; Immunohistochemistry; PD-L1; Head and neck squamous-cell carcinoma; Pembrolizumab; Pathology; Immunotherapy","score_opus":0.016108319288662475,"score_gpt":0.3174821127759352,"score_spread":0.3013737934872727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298111170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98207307,0.01593834,0.00004125125,0.00047883426,0.00056029786,0.00066365773,0.00008667346,0.00000963734,0.00014823764],"genre_scores_gemma":[0.9962189,0.0028783868,0.000025330492,0.0002516436,0.00007312756,0.00046549347,0.000008619828,0.000017760694,0.00006069953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989729,0.00015394467,0.00029630135,0.00028929673,0.00011042068,0.00017715058],"domain_scores_gemma":[0.99929935,0.00032680036,0.00015616466,0.00013339357,0.000040795658,0.00004351868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033707675,0.00013742936,0.000282561,0.0000975601,0.00013999236,0.000018618739,0.00010330527,0.00004474019,0.00004934984],"category_scores_gemma":[0.000029144347,0.00010586604,0.000024760582,0.00009510898,0.0001232539,0.000050626626,0.000119087286,0.0002428718,6.890893e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017625462,0.0002941273,0.92412055,0.000080942234,0.00003775692,0.00001907769,0.020066248,0.0002368111,0.018338284,0.0000030034628,0.000036448528,0.035004232],"study_design_scores_gemma":[0.005876089,0.0011398803,0.96784925,0.00007452161,0.00008315004,0.00002536039,0.005802819,0.016094899,0.002392519,0.000015170314,0.0005001184,0.00014622157],"about_ca_topic_score_codex":0.0057837064,"about_ca_topic_score_gemma":0.011890225,"teacher_disagreement_score":0.04372873,"about_ca_system_score_codex":0.00014607701,"about_ca_system_score_gemma":0.00009336882,"threshold_uncertainty_score":0.87432724},"labels":[],"label_agreement":null},{"id":"W4298139160","doi":"10.1200/jco.2022.40.28_suppl.126","title":"Uptake of second-line anticancer therapy after first-line pembrolizumab in patients with stage IV non–small cell lung cancer with PD-L1 &gt; 50%: Comparison between clinical trials and the real world.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Internal medicine; Stage (stratigraphy); Progression-free survival; Cancer; Oncology; Retrospective cohort study; Univariate analysis; Chemotherapy; Multivariate analysis; Surgery; Immunotherapy","score_opus":0.12152832720090546,"score_gpt":0.46121229726665824,"score_spread":0.3396839700657528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906547,0.0031799423,0.00004994732,0.0036355213,0.00071361015,0.0013011942,0.000102687285,0.0000059454046,0.00035643397],"genre_scores_gemma":[0.99029416,0.00549285,0.0005223765,0.002109188,0.0009433042,0.00006525252,0.000011459068,0.000040892995,0.0005205331],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9903778,0.0022493468,0.005939016,0.00037708334,0.00069449184,0.00036229537],"domain_scores_gemma":[0.9876966,0.006373911,0.0049313344,0.00036287704,0.0003745805,0.0002607032],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.015282282,0.00029228503,0.004182402,0.00022353501,0.00009069997,0.00001472893,0.00030620297,0.00024991087,0.0011821936],"category_scores_gemma":[0.00039255124,0.00015070206,0.0006138081,0.00039345585,0.0008044675,0.0000858308,0.00010060361,0.0019583711,4.601764e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3301611,0.0016905919,0.63075316,0.00005352273,0.0009079419,0.00004615375,0.00026458275,0.00006747943,0.0000078729245,0.0000019381014,0.00047019141,0.03557547],"study_design_scores_gemma":[0.12840903,0.023234615,0.80719733,0.00017201135,0.00070673705,0.0000060279185,0.00011497794,0.00016393981,0.000020706242,0.000008523317,0.039817844,0.00014827696],"about_ca_topic_score_codex":0.00027762583,"about_ca_topic_score_gemma":0.004074489,"teacher_disagreement_score":0.20175207,"about_ca_system_score_codex":0.0002562049,"about_ca_system_score_gemma":0.0020698293,"threshold_uncertainty_score":0.9997309},"labels":[],"label_agreement":null},{"id":"W4298394429","doi":"10.1016/j.jtho.2022.07.1150","title":"There Is an Unmet Need for Another Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Inhibitor","year":2022,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Programmed cell death 1; Programmed cell death; Ligand (biochemistry); Programmed instruction; Apoptosis; Cancer research; Receptor; Internal medicine; Biochemistry; PD-L1; Cancer; Immunotherapy; Biology","score_opus":0.03218937784012032,"score_gpt":0.39145727128409524,"score_spread":0.3592678934439749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298394429","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19697206,0.010954505,0.00037514014,0.006988378,0.77371716,0.008850058,0.0006682343,0.00015922118,0.0013152661],"genre_scores_gemma":[0.013295139,0.0010741294,0.023575854,0.0016990973,0.94220954,0.0012991966,0.00064640434,0.000555939,0.015644714],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949618,0.0005456595,0.0016785208,0.0006357939,0.0013290017,0.0008492335],"domain_scores_gemma":[0.9947931,0.000548686,0.0026393367,0.0006374266,0.0010034717,0.0003779518],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.002999374,0.00067956606,0.0020202524,0.00056747237,0.00024954817,0.00011741029,0.0006975895,0.0017410392,0.0007831953],"category_scores_gemma":[0.00038200087,0.00052858697,0.0011357325,0.00041250608,0.00016806189,0.00019090963,0.00010789571,0.0023082588,0.0000053361446],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06462437,0.0024999352,0.00013835152,0.00092417427,0.0012527768,0.0005110498,0.0008189741,5.9148033e-7,0.01477658,0.0000023940302,0.7476118,0.16683897],"study_design_scores_gemma":[0.008339242,0.02801237,0.00004554418,0.00041097868,0.0014014107,0.00025021716,0.0008661027,0.000010149639,0.012353365,0.0001365034,0.94766587,0.00050825614],"about_ca_topic_score_codex":0.00014074772,"about_ca_topic_score_gemma":0.000060204013,"teacher_disagreement_score":0.20005403,"about_ca_system_score_codex":0.0017259634,"about_ca_system_score_gemma":0.004505511,"threshold_uncertainty_score":0.99999344},"labels":[],"label_agreement":null},{"id":"W4302362490","doi":"10.1038/s41591-022-02029-1","title":"Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access","year":2022,"lang":"en","type":"letter","venue":"Nature Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Medical Research Council; Jon Moulton Charity Trust","keywords":"Schedule; Cancer; Immune system; Immune checkpoint; Cancer immunotherapy; Cancer research; Medicine; Immunotherapy; Computer science; Immunology; Internal medicine","score_opus":0.018467266168814202,"score_gpt":0.33639778529071207,"score_spread":0.31793051912189785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4302362490","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06835851,0.093086734,0.0000029561975,0.8338475,0.0020960798,0.0011453562,0.00006983512,0.000027887776,0.00136511],"genre_scores_gemma":[0.11806478,0.004161274,0.00023353398,0.8701614,0.005524684,0.0002997899,0.00027999716,0.000088514666,0.0011860313],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972693,0.00010845896,0.0007832836,0.00051671953,0.00091450376,0.00040776184],"domain_scores_gemma":[0.9987494,0.00013176147,0.00034308014,0.0005801268,0.00011486462,0.0000808172],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00084132294,0.00039815277,0.00096221187,0.00029268893,0.0000817471,0.000016699967,0.0004786937,0.00083124096,0.001189225],"category_scores_gemma":[0.00020738835,0.00024202364,0.00017897558,0.0011508856,0.00031902592,0.00005922744,0.00029262566,0.0038993477,6.958846e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045249825,0.00010815394,0.0037827543,0.0012906855,0.00073083286,0.000649205,0.0017712611,0.000021699518,0.014256101,0.000013084873,0.9568014,0.01604981],"study_design_scores_gemma":[0.005497881,0.0007871541,0.021054769,0.0028386444,0.0003054925,0.00010970987,0.00033047106,0.000016211996,0.0023124777,0.000023344219,0.9664175,0.0003063612],"about_ca_topic_score_codex":0.0033079328,"about_ca_topic_score_gemma":0.00035395043,"teacher_disagreement_score":0.088925466,"about_ca_system_score_codex":0.000616823,"about_ca_system_score_gemma":0.00032400395,"threshold_uncertainty_score":0.99972385},"labels":[],"label_agreement":null},{"id":"W4303470795","doi":"10.1159/000526899","title":"PD-1/CTLA-4 Blockade Leads to Expansion of CD8+PD-1int TILs and Results in Tumor Remission in Experimental Liver Cancer","year":2022,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medizinischen Hochschule Hannover; Deutsche Forschungsgemeinschaft; Government of Canada; Wilhelm Sander-Stiftung","keywords":"Blockade; CD8; Cytotoxic T cell; Medicine; Cancer research; Priming (agriculture); Tumor-infiltrating lymphocytes; Tumor microenvironment; Immunology; Nivolumab; Immunotherapy; Immune system; Biology; Internal medicine; Receptor","score_opus":0.02389854169721906,"score_gpt":0.3067304720411475,"score_spread":0.28283193034392845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303470795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97759265,0.01976631,0.000001276046,0.0010533974,0.00032693686,0.00064130174,0.00008545373,0.00001920315,0.0005134509],"genre_scores_gemma":[0.99462897,0.0019633,0.00012428645,0.0013209017,0.0001122347,0.0003198311,0.00001232761,0.000027891187,0.0014902388],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99824756,0.00008691143,0.0004924155,0.0004633188,0.00040206293,0.00030774917],"domain_scores_gemma":[0.9994091,0.000040728835,0.0001349734,0.00026007902,0.000036884903,0.00011823051],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029757744,0.0001934678,0.00036895732,0.0002590363,0.0000699347,0.000008135866,0.00011787189,0.00005824786,0.0015233268],"category_scores_gemma":[0.000018702614,0.00017894252,0.00006976684,0.00048582556,0.00007638489,0.000076770135,0.0001653087,0.00026261315,0.0000023381012],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017336143,0.00027581313,0.016999172,0.00012263574,0.000037638147,0.00021827771,0.010174834,0.00017286248,0.9287466,0.0000036011716,0.0051039453,0.02080851],"study_design_scores_gemma":[0.011076553,0.0012110795,0.15672684,0.0012786093,0.00004559633,0.00005065475,0.0024092149,0.0006341613,0.78470856,0.000004003918,0.041425515,0.00042920647],"about_ca_topic_score_codex":0.017745309,"about_ca_topic_score_gemma":0.0012350244,"teacher_disagreement_score":0.14403799,"about_ca_system_score_codex":0.0010081918,"about_ca_system_score_gemma":0.0002957127,"threshold_uncertainty_score":0.9993894},"labels":[],"label_agreement":null},{"id":"W4303628882","doi":"10.3390/curroncol29100580","title":"Immunotherapy and Radiotherapy as an Antitumoral Long-Range Weapon—A Partnership with Unsolved Challenges: Dose, Fractionation, Volumes, Therapeutic Sequence","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Sequence (biology); Radiation therapy; General partnership; Immunotherapy; Range (aeronautics); Medical physics; Dose fractionation; Fractionation; Therapeutic index; Computational biology; Pharmacology; Internal medicine; Cancer; Biology; Chemistry; Drug","score_opus":0.2946913072446637,"score_gpt":0.4677289673702094,"score_spread":0.17303766012554572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303628882","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047233605,0.99449277,0.000049558806,0.00053193915,0.0011614945,0.0022094043,0.00003600936,0.00016249905,0.0008839647],"genre_scores_gemma":[0.0002844126,0.9963774,0.00012148593,0.00047807247,0.00063382497,0.00087352353,0.00054027064,0.00016530309,0.0005257071],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960335,0.0009322098,0.0008356119,0.0010495554,0.0005629897,0.00058614294],"domain_scores_gemma":[0.99770755,0.00036039014,0.00076900964,0.0008066704,0.00012939346,0.00022699252],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008623539,0.0007832914,0.002227469,0.00045730072,0.0003140022,0.00006369716,0.0003872166,0.00045995336,0.0017142497],"category_scores_gemma":[0.000021133359,0.0006034627,0.00041444227,0.00045831915,0.00055209186,0.0002008688,0.000040415573,0.0012078913,0.000014390278],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00218624,0.0007615112,0.00028436744,0.0037463459,0.001099159,0.00011378196,0.0007493605,1.2412887e-7,0.0000068580885,0.000264273,0.00021328837,0.9905747],"study_design_scores_gemma":[0.004830192,0.0049434635,0.00074514735,0.0021045317,0.000747122,0.001918487,0.00024034265,0.000014688434,6.7045994e-7,0.00005278302,0.9837461,0.0006564809],"about_ca_topic_score_codex":0.00006801401,"about_ca_topic_score_gemma":0.00011710674,"teacher_disagreement_score":0.98991823,"about_ca_system_score_codex":0.0013874227,"about_ca_system_score_gemma":0.0022821114,"threshold_uncertainty_score":0.99964166},"labels":[],"label_agreement":null},{"id":"W4304783156","doi":"10.54097/hset.v14i.1840","title":"Immune Checkpoint inhibitor Therapy in Various Cancers","year":2022,"lang":"en","type":"article","venue":"Highlights in Science Engineering and Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Immune system; Immunotherapy; Immune checkpoint; CTLA-4; Cancer immunotherapy; Tumor microenvironment; Ipilimumab; Monoclonal antibody; Cancer; Immunology; Medicine; Cancer research; T cell; Antibody; Internal medicine","score_opus":0.007117906881766555,"score_gpt":0.22982610168909087,"score_spread":0.22270819480732432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304783156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923461,0.0031845542,0.00001821401,0.0035469278,0.00042984216,0.0002046465,0.0000017928384,0.00011364502,0.00015424965],"genre_scores_gemma":[0.9983336,0.00093721977,0.0004835684,0.00005386697,0.000020613943,0.00010190215,8.00614e-7,0.000009968397,0.000058473328],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989468,0.000006801134,0.00022687581,0.00030060724,0.00019740257,0.00032153074],"domain_scores_gemma":[0.9996752,0.000015040695,0.00003378273,0.00022319137,0.000018341207,0.00003444882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046051294,0.00010734928,0.00019960201,0.0011648452,0.000107934866,0.000011243059,0.00018479407,0.00006011966,0.000024041245],"category_scores_gemma":[0.000026839538,0.000093929026,0.000021811682,0.0024340716,0.00028538864,0.00005986698,0.00010064799,0.00031000018,0.0000020011091],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024698823,0.00010587996,0.0038985196,0.000017799217,0.000014415602,0.00015479802,0.00082863396,0.00070910977,0.96955806,0.0068836873,0.000026713902,0.017555367],"study_design_scores_gemma":[0.013396184,0.0031511427,0.10020876,0.00033720318,0.000012732791,0.0010107473,0.0016609865,0.0136837615,0.6525176,0.0009278285,0.21208848,0.0010045697],"about_ca_topic_score_codex":0.00033909688,"about_ca_topic_score_gemma":0.000030701616,"teacher_disagreement_score":0.3170405,"about_ca_system_score_codex":0.0005385142,"about_ca_system_score_gemma":0.00020600799,"threshold_uncertainty_score":0.38303146},"labels":[],"label_agreement":null},{"id":"W4306376957","doi":"10.3390/curroncol29100608","title":"Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Ipilimumab; Internal medicine; Logistic regression; Proportional hazards model; Oncology; Survival analysis; Cohort; Melanoma; Stage (stratigraphy); Breslow Thickness; Multivariate analysis; Cancer; Immunotherapy; Breast cancer","score_opus":0.14555908121126337,"score_gpt":0.4141718936419667,"score_spread":0.26861281243070334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306376957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99785846,0.0003531329,0.000030084879,0.00032096074,0.0003131186,0.0009481749,0.000033620472,0.000045734498,0.00009671663],"genre_scores_gemma":[0.99890244,0.00010876531,0.000024264331,0.000074593554,0.000016021319,0.00012976301,0.00057860115,0.0000323283,0.00013324512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974699,0.0007967275,0.0005869469,0.00041153407,0.00037831566,0.00035657483],"domain_scores_gemma":[0.9987596,0.0005329202,0.0003335383,0.00020480291,0.00008445462,0.00008463789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008249587,0.00023613073,0.00088729605,0.00029276707,0.00007412692,0.00000994651,0.00011977248,0.00007722849,0.00034481182],"category_scores_gemma":[0.000076003394,0.00014565827,0.000059668517,0.0009796947,0.00022725223,0.00007113727,0.000038648974,0.00058281433,0.0000013019645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022237577,0.005199835,0.9576409,0.00004252697,0.000419919,0.0005776995,0.0004775323,0.000012355766,0.00006408281,0.0000044931835,0.00004861625,0.013274492],"study_design_scores_gemma":[0.043784432,0.01634723,0.93799645,0.00020401896,0.00023522784,0.000064867796,0.00057795463,0.000093051174,0.000044057764,0.000002391452,0.000444203,0.00020610105],"about_ca_topic_score_codex":0.00018994698,"about_ca_topic_score_gemma":0.006983322,"teacher_disagreement_score":0.021546856,"about_ca_system_score_codex":0.0009954211,"about_ca_system_score_gemma":0.00070137123,"threshold_uncertainty_score":0.5939772},"labels":[],"label_agreement":null},{"id":"W4306685697","doi":"10.3389/fonc.2022.978069","title":"Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis","year":2022,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Natural Science Foundation of Shandong Province; National Natural Science Foundation of China","keywords":"Medicine; Lung cancer; Meta-analysis; Oncology; Cancer; Immune system; Nivolumab; Internal medicine; Immunotherapy; Cancer research; Immunology","score_opus":0.03969313056451478,"score_gpt":0.3651086068643795,"score_spread":0.3254154762998647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306685697","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000976065,0.9930666,0.00001263127,0.00041430185,0.00020724289,0.0061393124,0.00008338413,0.0000075339717,0.000059247344],"genre_scores_gemma":[0.000020756268,0.9958871,0.00044033382,0.00033857673,0.000012810522,0.003020504,0.000052585514,0.000028690702,0.00019862564],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9947004,0.002053403,0.0022909846,0.0004749667,0.0002328844,0.0002473873],"domain_scores_gemma":[0.99680084,0.0010351815,0.0015250312,0.000556712,0.00003279785,0.00004946481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034067847,0.000412423,0.013922805,0.0007208944,0.000045284174,0.000007209664,0.00022763656,0.00018125585,0.00036202927],"category_scores_gemma":[0.0004707878,0.00022825359,0.002290884,0.0016355297,0.0004119979,0.00003960723,0.0001542735,0.00054548297,1.7130309e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006212532,0.00014573433,0.000021311393,0.7439288,0.16591412,0.00006346138,0.0003769371,0.0000018510818,2.465852e-7,0.000007672217,0.0005313907,0.0883872],"study_design_scores_gemma":[0.0029839408,0.00015636283,0.000013331538,0.023334019,0.787017,0.00006478316,0.0001982426,0.000017775594,5.089872e-7,0.0000028485176,0.18601072,0.00020046755],"about_ca_topic_score_codex":0.00071241567,"about_ca_topic_score_gemma":0.00019807753,"teacher_disagreement_score":0.7205948,"about_ca_system_score_codex":0.0007224422,"about_ca_system_score_gemma":0.00041863348,"threshold_uncertainty_score":0.9517351},"labels":[],"label_agreement":null},{"id":"W4306916507","doi":"10.3390/curroncol29100629","title":"Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; Queen's University","funders":"","keywords":"Medicine; Adverse effect; Surgery; Population; Melanoma; Ipilimumab; Adrenal insufficiency; Regimen; Nausea; Internal medicine; Pediatrics; Immunotherapy; Cancer","score_opus":0.053441722095590866,"score_gpt":0.3507051192079411,"score_spread":0.2972633971123503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306916507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98998785,0.0063547753,0.000003745806,0.0003074079,0.0020429215,0.00042258043,0.000030534095,0.000016566977,0.0008336175],"genre_scores_gemma":[0.9990696,0.00035572686,0.000015017131,0.00008621381,0.000094245064,0.000105956744,0.00011096424,0.000013353871,0.00014892237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870014,0.00011155629,0.0005717576,0.0001845873,0.00021577638,0.00021617909],"domain_scores_gemma":[0.9994603,0.000047832367,0.00021085651,0.00018965882,0.00005126504,0.000040092193],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028294747,0.00011490193,0.00038242716,0.00019920547,0.00004885545,0.0000022456056,0.000113392634,0.00005379173,0.0010839751],"category_scores_gemma":[0.000029274464,0.00010790006,0.00014908472,0.00022543516,0.00015490841,0.00003089493,0.00013733536,0.00027684643,0.0000046890686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005110547,0.003286441,0.77650815,0.00024259179,0.00008868719,0.000034326495,0.002717233,0.0000019284828,0.020220919,0.000031887685,0.00082372915,0.19093356],"study_design_scores_gemma":[0.010074478,0.0040105707,0.9416155,0.0001349055,0.000033438195,0.000028256005,0.0007712763,0.000013889689,0.0121623045,0.000026395604,0.03097684,0.00015215053],"about_ca_topic_score_codex":0.000055126246,"about_ca_topic_score_gemma":0.0000444103,"teacher_disagreement_score":0.19078141,"about_ca_system_score_codex":0.0006085881,"about_ca_system_score_gemma":0.00020290392,"threshold_uncertainty_score":0.9998292},"labels":[],"label_agreement":null},{"id":"W4307144265","doi":"10.1016/j.ijrobp.2022.07.2079","title":"Immune Cell Stimulation Primes Tumor Cells for Radiation Effect","year":2022,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; McMaster University; Movember Foundation; Astellas Pharma; Patient-Centered Outcomes Research Institute","keywords":"Medicine; Immune system; Cancer research; Immunotherapy; Renal cell carcinoma; Flow cytometry; Immune checkpoint; Cell culture; Immunology; Oncology; Biology","score_opus":0.012288828793983209,"score_gpt":0.3165754862883881,"score_spread":0.3042866574944049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307144265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722851,0.0024811411,0.013470483,0.0024197127,0.0075217504,0.0010620434,0.00022452857,0.000056945784,0.00047829933],"genre_scores_gemma":[0.9942939,0.0002521302,0.001717943,0.0011566693,0.001938753,0.00006900588,0.00036905272,0.00003674412,0.00016575144],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981056,0.0003037191,0.000813891,0.00021857875,0.00034515932,0.0002130525],"domain_scores_gemma":[0.99731284,0.0006599157,0.001378579,0.00014581636,0.00042668043,0.00007616017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011515373,0.00019053428,0.00046443788,0.00022898853,0.00017874844,0.000024519055,0.00030467607,0.00010957455,0.00021852902],"category_scores_gemma":[0.00012929735,0.00017673982,0.00043300245,0.00019113818,0.00008454549,0.00020363236,0.000052885087,0.00039203197,0.000009323471],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014309691,0.0012086057,0.07712853,0.000055217166,0.0013316442,0.000037426486,0.0008332154,0.00815423,0.44788975,0.0011450422,0.0074419305,0.4404647],"study_design_scores_gemma":[0.05365901,0.01847146,0.050326098,0.00007153157,0.0007194291,0.00047392078,0.00024323113,0.018868718,0.34049144,0.0038876545,0.5121611,0.0006264306],"about_ca_topic_score_codex":0.00001947312,"about_ca_topic_score_gemma":5.170527e-7,"teacher_disagreement_score":0.50471914,"about_ca_system_score_codex":0.0013814581,"about_ca_system_score_gemma":0.0006214454,"threshold_uncertainty_score":0.72072405},"labels":[],"label_agreement":null},{"id":"W4307336810","doi":"10.1515/cclm-2022-0471","title":"Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study","year":2022,"lang":"en","type":"article","venue":"Clinical Chemistry and Laboratory Medicine (CCLM)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Medicine; Troponin I; Cardiotoxicity; Internal medicine; Thyroid cancer; Adverse effect; Cancer; Troponin; Thyroglobulin; Gastroenterology; Toxicity; Myocardial infarction; Cardiology; Thyroid","score_opus":0.02140431135112974,"score_gpt":0.3314146911413603,"score_spread":0.31001037979023055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307336810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941593,0.0042146426,7.7624645e-7,0.00041160177,0.00017097488,0.0007484946,0.0001687391,0.00002317115,0.00010229427],"genre_scores_gemma":[0.99903345,0.0002308225,0.00000920392,0.00018568478,0.00021213267,0.00016969182,0.000044556928,0.000023486607,0.00009094708],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976843,0.00028160654,0.001078208,0.00039608628,0.00036511564,0.00019465416],"domain_scores_gemma":[0.99871427,0.00026228259,0.00038226985,0.00028178643,0.00022640976,0.00013297319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001385871,0.00020705377,0.0008181593,0.000051557898,0.000093415096,0.0000041465173,0.00006879992,0.00009727805,0.00041425545],"category_scores_gemma":[0.00027743835,0.00015476346,0.000091108275,0.00060960697,0.00034951893,0.00004805454,0.000032781943,0.0005016403,2.762365e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010339274,0.0019807555,0.9412102,0.0002375489,0.0004980366,0.00033994508,0.0010036002,0.0000050012686,0.040649764,6.0897406e-7,0.00032491304,0.0034103338],"study_design_scores_gemma":[0.04317085,0.010303877,0.9173508,0.00054166664,0.0009083186,0.00004952193,0.012588086,0.000068919675,0.012385952,0.0000022541553,0.0022639527,0.00036579842],"about_ca_topic_score_codex":0.0006587698,"about_ca_topic_score_gemma":0.0000336292,"teacher_disagreement_score":0.032831576,"about_ca_system_score_codex":0.00014120554,"about_ca_system_score_gemma":0.000257453,"threshold_uncertainty_score":0.6311071},"labels":[],"label_agreement":null},{"id":"W4307645421","doi":"10.1016/j.semarthrit.2022.152110","title":"Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group","year":2022,"lang":"en","type":"review","venue":"Seminars in Arthritis and Rheumatism","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health; University of British Columbia; McGill University; Jewish General Hospital; University of Ottawa","funders":"National Cancer Institute; National Center for Advancing Translational Sciences; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Rheumatology Research Foundation; Bristol-Myers Squibb","keywords":"Medicine; Polymyalgia rheumatica; Rheumatoid arthritis; Adverse effect; Arthritis; Internal medicine; Inflammatory arthritis; Disease; Vasculitis; Giant cell arteritis","score_opus":0.027820493470371296,"score_gpt":0.31397394975773274,"score_spread":0.28615345628736144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307645421","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022230504,0.9734588,0.000002792199,0.00017390249,0.00036176623,0.0036427474,0.000040412506,0.000025481035,0.00006355938],"genre_scores_gemma":[0.009323265,0.98940736,0.000054836095,0.00007454402,0.000022152954,0.0008778514,0.0001292065,0.00007576323,0.00003503383],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9940594,0.00055203424,0.003828786,0.0006260847,0.00050366635,0.00043006282],"domain_scores_gemma":[0.99706715,0.0005853055,0.0015908142,0.0006404843,0.000023060411,0.000093210925],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035332,0.00055191264,0.0028603678,0.00040743267,0.00021337556,0.000075163065,0.00023358279,0.00028598067,0.00017190602],"category_scores_gemma":[0.00030641368,0.0004476852,0.00039572964,0.0007308543,0.0002877805,0.00016779001,0.00022555135,0.00092768454,0.0000024476465],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042050848,0.00007704832,0.00030150518,0.046351094,0.00009180809,0.000038462935,0.0005484232,1.7874543e-8,0.00022573408,0.000031456722,0.00006578916,0.95222664],"study_design_scores_gemma":[0.0027562042,0.00016180017,0.0016640405,0.9839318,0.00011225597,0.0008169675,0.0002574374,0.0000039480287,0.000024644627,0.000023189861,0.009805621,0.0004421195],"about_ca_topic_score_codex":0.00032037386,"about_ca_topic_score_gemma":0.0002658359,"teacher_disagreement_score":0.9517845,"about_ca_system_score_codex":0.00024405002,"about_ca_system_score_gemma":0.00018497158,"threshold_uncertainty_score":0.99979746},"labels":[],"label_agreement":null},{"id":"W4307667995","doi":"10.1101/2022.10.27.513993","title":"Proliferative Exhausted CD8 T Cells Exacerbate Long-lasting Anti-tumor Effects in Human Papillomavirus Positive Head and Neck Squamous Cell Carcinoma","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"West China Hospital, Sichuan University; Health Department of Sichuan Province; Sichuan University; Department of Science and Technology of Sichuan Province; China Postdoctoral Science Foundation","keywords":"Head and neck squamous-cell carcinoma; Cancer research; CD8; Cell; Cancer; Antigen; Biology; Head and neck cancer; Medicine; Internal medicine; Immunology","score_opus":0.01245379582239153,"score_gpt":0.24165863529475587,"score_spread":0.22920483947236434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307667995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875513,0.0073224194,0.00004592345,0.00008779945,0.0008797115,0.0035920127,0.00022088166,0.00025470686,0.000045292294],"genre_scores_gemma":[0.9975085,0.00015965739,0.0005676285,0.0005218597,0.00034524815,0.000622141,0.000003715743,0.00024000595,0.000031194773],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99542,0.0004471344,0.00092449534,0.0016627394,0.00060067076,0.00094497233],"domain_scores_gemma":[0.99740726,0.00020893752,0.0006719528,0.0010469324,0.00029103656,0.00037387328],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068826164,0.00099766,0.0013937543,0.0006093754,0.0004097474,0.00018673785,0.0003530581,0.000453489,0.00011839149],"category_scores_gemma":[0.00007621501,0.00105426,0.00024691373,0.0008136011,0.00024842995,0.00015689156,0.00065127,0.0017177075,0.000009962617],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009673987,0.0005407316,0.16096556,0.0021885643,0.00014229826,0.002107561,0.00015943762,0.000038401544,0.8327881,0.000013882054,0.00008335572,0.0000047166964],"study_design_scores_gemma":[0.0050558792,0.00071435573,0.5424576,0.0008155702,0.00018819839,3.4958526e-7,0.000016124113,0.00014880531,0.44970992,3.8739282e-7,0.0001672234,0.0007256263],"about_ca_topic_score_codex":0.00073818216,"about_ca_topic_score_gemma":0.000024045556,"teacher_disagreement_score":0.38307816,"about_ca_system_score_codex":0.0011024813,"about_ca_system_score_gemma":0.000797847,"threshold_uncertainty_score":0.99919075},"labels":[],"label_agreement":null},{"id":"W4307804562","doi":"10.1200/jco.22.01928","title":"Reply to S. Rossi et al and P. Palassin et al","year":2022,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; Conquer Cancer Foundation","keywords":"Medicine","score_opus":0.11288508398988809,"score_gpt":0.4824033575385294,"score_spread":0.3695182735486413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307804562","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02697035,0.009989829,0.00008509636,0.9370693,0.021939581,0.00037720494,0.00006320438,0.00001126878,0.0034941481],"genre_scores_gemma":[0.0014420366,0.02255808,0.0022424178,0.9613902,0.0056361603,0.00001383567,0.000028796892,0.00007397417,0.006614506],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9884819,0.0037410632,0.00539058,0.0006437445,0.0010566284,0.000686122],"domain_scores_gemma":[0.9857896,0.008657167,0.0040006177,0.0004770338,0.00035823038,0.000717341],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0187311,0.00046045,0.003434377,0.00031704106,0.00013457339,0.00006513232,0.00048540984,0.0010394007,0.0056098914],"category_scores_gemma":[0.0053870226,0.0003607411,0.0014126201,0.00028707265,0.0008038975,0.0001612533,0.00031061994,0.009871043,0.000049044003],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02444671,0.0007962306,0.005476465,0.00004387282,0.0013409334,0.0064600026,0.00022854346,0.0000049930704,0.0002004939,0.00002531611,0.7920576,0.16891883],"study_design_scores_gemma":[0.012122679,0.03867673,0.061802108,0.00053101196,0.0005210006,0.0035038071,0.00013712622,0.000013173856,0.000006267517,0.00006146259,0.8823154,0.00030922037],"about_ca_topic_score_codex":0.00026272293,"about_ca_topic_score_gemma":0.00009337768,"teacher_disagreement_score":0.16860962,"about_ca_system_score_codex":0.00078601495,"about_ca_system_score_gemma":0.006393028,"threshold_uncertainty_score":0.9998844},"labels":[],"label_agreement":null},{"id":"W4307832570","doi":"10.1371/journal.pone.0272022","title":"Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy","year":2022,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Defense Health Agency; Astellas Pharma; Intuitive Surgical; World Health Organization","keywords":"Medicine; Combination therapy; Odds ratio; Internal medicine; Pharmacovigilance; Heart failure; Oncology; Cardiology; Adverse effect","score_opus":0.037954940035772,"score_gpt":0.2396001411271443,"score_spread":0.2016452010913723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307832570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923976,0.0022799612,0.00000765905,0.0033821973,0.00011302264,0.0009766768,0.000078228455,0.0001383995,0.00062622834],"genre_scores_gemma":[0.9945917,0.00090088777,0.00007409596,0.0013574404,0.000097029195,0.00026985473,0.00014630177,0.000058026042,0.0025046454],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99817246,0.00015244672,0.00030900695,0.00030154915,0.00079244905,0.000272109],"domain_scores_gemma":[0.9991809,0.000051160845,0.00020184909,0.00036474087,0.00013606474,0.000065274995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004878785,0.00020242439,0.00049849384,0.00011303418,0.00027672685,0.000027320873,0.00012507966,0.00007410186,0.0006569707],"category_scores_gemma":[0.000015647502,0.0001743148,0.0001842597,0.0004601178,0.000078257195,0.00007887957,0.000034807803,0.00031863595,0.0000051690854],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007360916,0.0070479214,0.027404904,0.00003700809,0.0036041362,0.000013490942,0.002474345,0.0000011557522,0.9462115,0.000022643166,0.0004158803,0.0054061017],"study_design_scores_gemma":[0.011829516,0.0036509414,0.12425565,0.0002320755,0.0001769497,0.0000044560215,0.0006822354,0.00013131539,0.85743874,0.00005487986,0.0011905574,0.00035267786],"about_ca_topic_score_codex":0.00028360574,"about_ca_topic_score_gemma":0.00001326782,"teacher_disagreement_score":0.096850745,"about_ca_system_score_codex":0.00048458343,"about_ca_system_score_gemma":0.00013424506,"threshold_uncertainty_score":0.71933687},"labels":[],"label_agreement":null},{"id":"W4308187251","doi":"10.1002/cac2.12383","title":"Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy","year":2022,"lang":"en","type":"article","venue":"Cancer Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"Science and Technology Commission of Shanghai Municipality; Shanghai Pulmonary Hospital; National Natural Science Foundation of China","keywords":"Chemotherapy; Oncology; Lung cancer; Medicine; Immune system; Immunotherapy; Internal medicine; CD68; Predictive marker; PD-L1; CD8; Blockade; Immune checkpoint; Cancer research; Cancer; Immunology; Immunohistochemistry; Receptor","score_opus":0.014554368802750031,"score_gpt":0.2962930912548511,"score_spread":0.2817387224521011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308187251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95617265,0.028891912,0.000026247393,0.012225431,0.00013201234,0.0020589244,0.00040100885,0.000019598507,0.00007224858],"genre_scores_gemma":[0.9854173,0.0063497177,0.0031830869,0.0020315694,0.000015044418,0.0019874363,0.00004992183,0.00005526919,0.0009106345],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981175,0.00038189476,0.0006638998,0.00027071312,0.00026776223,0.00029820055],"domain_scores_gemma":[0.99755937,0.00040234177,0.0004185732,0.0014902577,0.000061431,0.000067999405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006066286,0.00023225204,0.0005078071,0.0001808131,0.00025658344,0.000012089284,0.0009706606,0.000022425449,0.0006919777],"category_scores_gemma":[0.00003799414,0.00018525567,0.00018196466,0.0006748911,0.00035936563,0.00006374046,0.00038847563,0.0004012643,6.5878356e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03554754,0.00034535993,0.0051792795,0.00012095854,0.00024021936,0.000005969703,0.0048184856,0.00051725394,0.94109094,0.000001122457,0.00038656054,0.0117463125],"study_design_scores_gemma":[0.022287022,0.0006458776,0.659757,0.0010256275,0.00039871078,0.00006461614,0.016043322,0.0031479893,0.2660957,0.0000034046855,0.029956067,0.0005746665],"about_ca_topic_score_codex":0.0029239275,"about_ca_topic_score_gemma":0.00078726717,"teacher_disagreement_score":0.67499524,"about_ca_system_score_codex":0.0009005233,"about_ca_system_score_gemma":0.0007210925,"threshold_uncertainty_score":0.75766706},"labels":[],"label_agreement":null},{"id":"W4308372329","doi":"10.1002/cam4.5429","title":"T cell‐inflamed gene expression profile is associated with favorable disease‐specific survival in non‐hypermutated microsatellite‐stable colorectal cancer patients","year":2022,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Office of Research Infrastructure Programs, National Institutes of Health; Juno Therapeutics; National Institutes of Health; National Cancer Institute; University of Washington; Fred Hutchinson Cancer Research Center","keywords":"Microsatellite instability; Somatic hypermutation; Colorectal cancer; Cancer research; Biology; Biomarker; Cancer; Germline mutation; Oncology; Medicine; Gene; Mutation; Immunology; Genetics; Microsatellite; B cell; Allele","score_opus":0.013884683528446662,"score_gpt":0.25091229811671456,"score_spread":0.2370276145882679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308372329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811396,0.013383943,0.0000070010633,0.0012878905,0.0010520993,0.0015901687,0.00070910336,0.00008105755,0.0007491119],"genre_scores_gemma":[0.9890547,0.0025972882,0.000030245701,0.0013180545,0.00023758262,0.0012813434,0.0011813797,0.000095667405,0.004203782],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.996862,0.00014693415,0.0005819193,0.00071557047,0.0009978445,0.00069570955],"domain_scores_gemma":[0.998676,0.00008267231,0.00032266224,0.00034456924,0.00026423042,0.00030986508],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003995459,0.00039284307,0.00075731275,0.00025873608,0.0003011383,0.000017169048,0.00022889899,0.00009692427,0.0075454833],"category_scores_gemma":[0.000027104412,0.0003034116,0.00009208187,0.0013191064,0.00025267183,0.00011435035,0.000093019284,0.0005131642,0.0000058840315],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017033193,0.0009242746,0.4631094,0.00018643941,0.00021260403,0.00021666825,0.00332255,0.00015310287,0.4708734,5.662885e-7,0.041324634,0.0026431996],"study_design_scores_gemma":[0.042199243,0.002375742,0.6842348,0.001938247,0.0003272654,0.00000764091,0.0015141587,0.0004770975,0.2198913,0.000008610596,0.046132587,0.0008933185],"about_ca_topic_score_codex":0.0015101667,"about_ca_topic_score_gemma":0.00014534604,"teacher_disagreement_score":0.25098208,"about_ca_system_score_codex":0.0017264909,"about_ca_system_score_gemma":0.0007133495,"threshold_uncertainty_score":0.9999418},"labels":[],"label_agreement":null},{"id":"W4308375764","doi":"10.1136/jitc-2022-sitc2022.0059","title":"59 DetermaIO (IO score) is associated with efficacy of ICI monotherapy in advanced NSCLC patients: a retrospective BC Cancer study","year":2022,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Internal medicine; Medicine; Cohort; Oncology; Retrospective cohort study; Chemotherapy; Cancer; Combination therapy; PD-L1; Immunotherapy","score_opus":0.013312479880391408,"score_gpt":0.25634213303346753,"score_spread":0.24302965315307612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308375764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99703926,0.0008200326,0.0000010133772,0.00032405937,0.00018112431,0.0013635962,0.00007665447,0.000042922027,0.00015135598],"genre_scores_gemma":[0.99865514,0.0001193554,0.00004662074,0.0006789641,0.000030164067,0.00016593585,0.000033648532,0.00005012689,0.00022003324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978923,0.00011861127,0.00052537705,0.00048435168,0.0006442779,0.0003350373],"domain_scores_gemma":[0.9988994,0.000048215024,0.000376072,0.00033205334,0.0001404819,0.00020376797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003756883,0.00027660624,0.00058645685,0.00018894445,0.00015536505,0.000021907917,0.00012461132,0.00007742841,0.000082781604],"category_scores_gemma":[0.0001138139,0.00023858051,0.00010095933,0.00056752446,0.00022956102,0.00013181899,0.000043958284,0.00035315682,5.4625394e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004621529,0.0013332106,0.9755773,0.00003832305,0.0005268051,0.00006507057,0.0056006624,0.0000797685,0.00917009,0.000004583622,0.00029620007,0.0026864528],"study_design_scores_gemma":[0.017308602,0.00252748,0.9713516,0.00034310707,0.0001264156,0.000011073052,0.0008234283,0.000030425725,0.0067435694,0.000030684998,0.00043166394,0.00027194287],"about_ca_topic_score_codex":0.001820858,"about_ca_topic_score_gemma":0.00056193426,"teacher_disagreement_score":0.012687072,"about_ca_system_score_codex":0.00057740515,"about_ca_system_score_gemma":0.00041582828,"threshold_uncertainty_score":0.9729031},"labels":[],"label_agreement":null},{"id":"W4308396193","doi":"10.1136/jitc-2022-sitc2022.0936","title":"936 Assessing educational needs for immune-related adverse events curriculum in clinical practice","year":2022,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; MEDLINE; Curriculum; Family medicine; Oncology; Psychology","score_opus":0.021263464959580085,"score_gpt":0.338515185282241,"score_spread":0.3172517203226609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308396193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984947,0.0019372393,0.000008746914,0.010069613,0.0014460628,0.0006617407,0.000017401346,0.00003634758,0.0008758138],"genre_scores_gemma":[0.99460083,0.00012696294,0.002263823,0.0015004463,0.00018885867,0.00012299475,0.00016002484,0.000034244094,0.0010018355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781936,0.00022470632,0.0009296336,0.00033123215,0.00038953655,0.00030555532],"domain_scores_gemma":[0.998679,0.0002924789,0.00038351974,0.00025399047,0.00010689569,0.0002841333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023782558,0.00018582129,0.00034175944,0.00019988224,0.00031418333,0.000023472347,0.00010944626,0.00013068331,0.00007828642],"category_scores_gemma":[0.001543987,0.0001843326,0.0002216407,0.00041864024,0.00017199705,0.00033207418,0.00005976789,0.0005692403,0.0000045091006],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036246,0.0052918307,0.90147287,0.0007535683,0.0017244755,0.00025516786,0.0042719985,0.00049463136,0.035239894,0.0032791705,0.024041265,0.019550538],"study_design_scores_gemma":[0.0064272247,0.00043509295,0.8922101,0.00026686865,0.00026350867,0.00085726695,0.004479511,0.0004901031,0.0005240092,0.0009355277,0.09274167,0.00036910834],"about_ca_topic_score_codex":0.0002608446,"about_ca_topic_score_gemma":0.000006196256,"teacher_disagreement_score":0.0687004,"about_ca_system_score_codex":0.00023658537,"about_ca_system_score_gemma":0.0011230578,"threshold_uncertainty_score":0.7516865},"labels":[],"label_agreement":null},{"id":"W4308400766","doi":"10.1136/jitc-2022-sitc2022.0913","title":"913 Translational analysis of advanced metastatic bladder cancer patients treated with IO combination maveropepimut-S, cyclophosphamide, and pembrolizumab","year":2022,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"ELISPOT; Immune system; Medicine; Immunotherapy; Immunology; Antigen; T cell; Cancer research; Pembrolizumab","score_opus":0.009540570406654516,"score_gpt":0.23996536801863053,"score_spread":0.230424797611976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308400766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967455,0.0019500616,0.0000066957928,0.00045121112,0.00005844179,0.00041858503,0.00019884472,0.00002477571,0.00014588106],"genre_scores_gemma":[0.9984182,0.00030062775,0.00023531189,0.00024852314,0.000008342851,0.00006423456,0.0003908206,0.00002288673,0.00031102126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858224,0.000062886356,0.00037741705,0.0003074876,0.00048799985,0.00018198047],"domain_scores_gemma":[0.9992506,0.000037614653,0.00023314962,0.00015688023,0.00012888783,0.00019287404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016922293,0.0001885286,0.00043302038,0.00025353028,0.00016517816,0.000018457997,0.000049936625,0.00003792536,0.000119523414],"category_scores_gemma":[0.000022575106,0.0001588474,0.00009524687,0.0006756874,0.0002384255,0.0001284738,0.000017403872,0.00013180434,2.1302189e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048108827,0.000652913,0.957495,0.00027383605,0.0069384947,0.00004232787,0.0015747856,0.00274777,0.01682841,0.00017531747,0.00045558834,0.008004683],"study_design_scores_gemma":[0.0064135515,0.0005951576,0.98402333,0.00005839419,0.002329521,0.000022619155,0.00016725565,0.0006817311,0.0044558584,0.00006158724,0.0009945997,0.00019638521],"about_ca_topic_score_codex":0.0005189214,"about_ca_topic_score_gemma":0.00008926364,"teacher_disagreement_score":0.02652835,"about_ca_system_score_codex":0.000083345934,"about_ca_system_score_gemma":0.00020249093,"threshold_uncertainty_score":0.64776087},"labels":[],"label_agreement":null},{"id":"W4308522396","doi":"10.1016/j.jtocrr.2022.100431","title":"Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Merck Sharp and Dohme; EMD Serono; Astellas Pharma; Chugai Pharmaceutical; Seagen; Mirati Therapeutics; National Cancer Institute; Genomic Health; Genentech; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Celgene; Pfizer","keywords":"Pembrolizumab; Medicine; Internal medicine; KRAS; Oncology; Hazard ratio; Chemotherapy; Confidence interval; Cancer; Immunotherapy; Colorectal cancer","score_opus":0.14070093782473087,"score_gpt":0.48564353220969525,"score_spread":0.3449425943849644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308522396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98977655,0.00046092112,0.00015053485,0.007275486,0.00018534258,0.0016582432,0.00016337816,0.000025474652,0.0003040611],"genre_scores_gemma":[0.992723,0.0002677148,0.004355004,0.00056310464,0.00023784288,0.0003046508,0.00020466716,0.000044517412,0.0012995226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99611413,0.00032800363,0.0011393807,0.0005532144,0.0014698486,0.00039543497],"domain_scores_gemma":[0.99483275,0.0034256738,0.00048978155,0.00027320674,0.0007144323,0.00026417326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046304544,0.00017715582,0.0007427492,0.00015504859,0.00036111436,0.0000381142,0.00007228113,0.000069503956,0.0002835081],"category_scores_gemma":[0.0010772011,0.000118663025,0.0001687686,0.0003332235,0.00094982464,0.00007742822,0.000053244137,0.00052959257,4.6268843e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15843213,0.002289125,0.69051373,0.00036189592,0.0068932283,0.0015777911,0.0019743622,0.000091220056,0.0002831131,0.0005465269,0.005527134,0.13150975],"study_design_scores_gemma":[0.043947194,0.011610263,0.9107717,0.000059557035,0.00021426588,0.00061770354,0.0012107306,0.00035621965,0.000083331586,0.00078618206,0.030086532,0.00025626886],"about_ca_topic_score_codex":0.00039202732,"about_ca_topic_score_gemma":0.000095253126,"teacher_disagreement_score":0.22025803,"about_ca_system_score_codex":0.00014715045,"about_ca_system_score_gemma":0.0019417242,"threshold_uncertainty_score":0.48389378},"labels":[],"label_agreement":null},{"id":"W4308544300","doi":"10.1016/j.ygyno.2022.10.022","title":"Profiling the immune landscape in mucinous ovarian carcinoma","year":2022,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia; Vancouver General Hospital; Canada's Michael Smith Genome Sciences Centre; Foothills Medical Centre; BC Cancer Agency","funders":"National Cancer Institute; Cancer Council Tasmania; National Health and Medical Research Council; Medical Research Council; Horizon 2020 Framework Programme; Oak Foundation; BC Cancer Foundation; Canada Research Chairs; Cancer Research Society; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Cancer Council Victoria; University of New South Wales; Canadian Institutes of Health Research; Cancer Institute NSW; European Commission; Calgary Laboratory Services; University of Cambridge; University College London; Cancer Research UK; Michael Smith Health Research BC; Faculty of Medicine and Health, University of Sydney; Translational Cancer Research Network; European Regional Development Fund; Bundesministerium für Bildung und Forschung; National Institute for Health and Care Research; Cancer Council NSW; Ovarian Cancer Australia; Peter MacCallum Foundation; Medical Research and Materiel Command; NSW Ministry of Health; Cancer Council South Australia; Deutsches Krebsforschungszentrum; Ovarian Cancer Research Fund; Cancer Australia; National Institutes of Health","keywords":"CD20; FOXP3; CD68; Stromal cell; Immune system; CD8; Medicine; Cancer research; Tissue microarray; CD3; Tumor microenvironment; Pathology; Immunohistochemistry; Oncology; Immunology","score_opus":0.021461663216129596,"score_gpt":0.2847816725541987,"score_spread":0.2633200093380691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308544300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.961761,0.0026687451,0.000004146695,0.009818392,0.0009463933,0.00083569495,0.000007711991,0.000055207507,0.023902688],"genre_scores_gemma":[0.9945167,0.00006493059,0.00028204775,0.0035130586,0.000097694756,0.00044646798,0.000034192544,0.000013889915,0.0010310627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845326,0.00034696536,0.00037468367,0.00027746518,0.00015989349,0.00038774958],"domain_scores_gemma":[0.9990833,0.00038952677,0.00013080963,0.00032977696,0.000026836316,0.00003978641],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011559937,0.0001295773,0.0003587081,0.00013185466,0.00028882344,0.0000073705824,0.00023482597,0.00011353579,0.003517952],"category_scores_gemma":[0.00011558627,0.000088168825,0.00012029353,0.00043977873,0.000111969806,0.000022478966,0.0001809413,0.00056599046,0.000019787994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009580609,0.0021305382,0.80986,0.00007018086,0.00026888406,0.0028292998,0.0030930843,0.00023056433,0.029607777,0.0025218066,0.0052777487,0.13452949],"study_design_scores_gemma":[0.0073304754,0.0046027717,0.8371256,0.000004396717,0.00005799427,0.00086659694,0.0047708126,0.000481851,0.00062685786,0.00021926188,0.14373566,0.00017773184],"about_ca_topic_score_codex":0.00023771453,"about_ca_topic_score_gemma":0.00018677126,"teacher_disagreement_score":0.13845791,"about_ca_system_score_codex":0.0006381346,"about_ca_system_score_gemma":0.0005327478,"threshold_uncertainty_score":0.99739295},"labels":[],"label_agreement":null},{"id":"W4308545065","doi":"10.1136/jitc-2022-sitc2022.1472","title":"1472 Assessing the correlation between CD8 cell PET Imaging with 89-Zr-Crefmirlimab Berdoxam and CD8 cell immunohistochemistry in patients with advanced cancer receiving immunotherapy","year":2022,"lang":"en","type":"article","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Biopsy; Immunotherapy; Clinical endpoint; CD8; Immunohistochemistry; Lung cancer; Cancer; Renal cell carcinoma; Melanoma; Pathology; Nuclear medicine; Oncology; Internal medicine; Clinical trial; Immune system; Cancer research; Immunology","score_opus":0.005141705943094756,"score_gpt":0.2539279403923161,"score_spread":0.24878623444922132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308545065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904813,0.0038935377,0.00025733298,0.000553592,0.00012260315,0.00083114364,0.000022762379,0.00006357982,0.0037741435],"genre_scores_gemma":[0.99675363,0.0002332877,0.0008698254,0.00051383424,0.00004445848,0.0001683267,0.000120668614,0.000075550844,0.0012204052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805576,0.00010415059,0.00041796858,0.00048534584,0.0005312223,0.00040553737],"domain_scores_gemma":[0.9989197,0.00013779847,0.00033457088,0.00044721222,0.00010022136,0.000060450344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038462033,0.00031994062,0.0003778773,0.0001182708,0.0005211217,0.000084011794,0.00015471167,0.000040947038,0.0004613249],"category_scores_gemma":[0.000005848226,0.0002183072,0.000061664614,0.00048902695,0.00017420016,0.00030142348,0.00007683623,0.00059946656,8.5799064e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033869126,0.0002364954,0.8761012,0.00009683295,0.00010538067,0.000017044997,0.001344516,0.00020803235,0.0843852,7.4405693e-7,0.00012881488,0.03398884],"study_design_scores_gemma":[0.02385659,0.0008349979,0.9540566,0.00045370185,0.00018351868,0.000048204332,0.0047148573,0.0005139608,0.011476617,0.000008440825,0.003130284,0.0007221821],"about_ca_topic_score_codex":0.00077341544,"about_ca_topic_score_gemma":0.000023990153,"teacher_disagreement_score":0.07795546,"about_ca_system_score_codex":0.00069082476,"about_ca_system_score_gemma":0.00026843866,"threshold_uncertainty_score":0.89023095},"labels":[],"label_agreement":null},{"id":"W4308770416","doi":"10.3390/cancers14215406","title":"Implications and Emerging Therapeutic Avenues of Inflammatory Response in HPV+ Head and Neck Squamous Cell Carcinoma","year":2022,"lang":"en","type":"review","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior","keywords":"Head and neck; Medicine; Head and neck squamous-cell carcinoma; Basal cell; Inflammatory response; Cancer research; Oncology; Pathology; Inflammation; Head and neck cancer; Internal medicine; Cancer; Surgery","score_opus":0.04506405721083127,"score_gpt":0.3353010725138588,"score_spread":0.29023701530302753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308770416","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07541586,0.92340505,5.457889e-7,0.00007143653,0.000100308986,0.0006377382,0.000057625046,0.000011883126,0.0002995417],"genre_scores_gemma":[0.05014735,0.94926745,0.000012303552,0.0001094885,0.00003846766,0.00021503767,0.000024223396,0.00003901609,0.00014667088],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99883705,0.0001598724,0.0004183653,0.00029052125,0.00011093793,0.00018323837],"domain_scores_gemma":[0.99914587,0.00021930231,0.00023580967,0.00031945272,0.000016337099,0.00006321959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030270696,0.00021041624,0.00074037217,0.00027176712,0.00006414959,0.000008064242,0.00009012775,0.00010899868,0.00013016761],"category_scores_gemma":[0.000020302268,0.00019449132,0.00013630577,0.000310477,0.00014253636,0.000029430112,0.00004553558,0.0002681186,5.026728e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012769056,0.000014518139,0.0017374401,0.009517123,0.000060947757,0.000017699818,0.000953285,0.0000011579453,0.00014624461,0.0000071760114,0.00013746099,0.98613006],"study_design_scores_gemma":[0.0012839624,0.00031061014,0.019787611,0.0011644744,0.00024165171,0.00005723457,0.00020844043,0.0000036468314,0.00001246561,0.0000084064195,0.9767354,0.00018609146],"about_ca_topic_score_codex":0.0003034826,"about_ca_topic_score_gemma":0.000051712497,"teacher_disagreement_score":0.985944,"about_ca_system_score_codex":0.0010330058,"about_ca_system_score_gemma":0.0013764941,"threshold_uncertainty_score":0.7931126},"labels":[],"label_agreement":null},{"id":"W4308925590","doi":"10.1016/j.freeradbiomed.2022.10.163","title":"Mitochondrial DNA-Dependent Changes in Lipid Flux and Oxidative Stress in Skeletal Muscle","year":2022,"lang":"en","type":"article","venue":"Free Radical Biology and Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Nivolumab; Medicine; Immunotherapy; Oncology; Internal medicine; Lung cancer; Response Evaluation Criteria in Solid Tumors; Biomarker; Immunology; Chemotherapy; Cancer; Progressive disease; Biology","score_opus":0.014617186117788873,"score_gpt":0.2823176472606543,"score_spread":0.2677004611428654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308925590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97186595,0.0074529895,0.000010453595,0.019066388,0.0006722704,0.00040338107,0.00006401588,0.000017873257,0.0004466529],"genre_scores_gemma":[0.9953032,0.0014176677,0.000061669096,0.0019690366,0.00062503084,0.000093029776,0.00014368599,0.000010119893,0.00037655066],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99883485,0.0001780598,0.0002474545,0.00033546952,0.00014093943,0.00026324514],"domain_scores_gemma":[0.99947804,0.0001742449,0.0000546964,0.00016748358,0.000010150118,0.00011541102],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037176057,0.00014026527,0.0004012384,0.00022538679,0.00007948003,0.0000020688474,0.0000969217,0.00012553613,0.0010545518],"category_scores_gemma":[0.00017177108,0.00010488945,0.000023333232,0.0002034906,0.00067686656,0.000020751666,0.00012439417,0.00041527257,7.309524e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050332756,0.0007176899,0.08821582,0.00015474993,0.00019846532,0.00048589107,0.0040709926,6.7454454e-7,0.6978009,0.00101294,0.0070539042,0.19525471],"study_design_scores_gemma":[0.0713254,0.015535743,0.47840652,0.000601565,0.00017709378,0.0006254024,0.006168006,0.00012843404,0.012113173,0.0018966434,0.4123475,0.00067450525],"about_ca_topic_score_codex":0.0006008496,"about_ca_topic_score_gemma":0.0015319542,"teacher_disagreement_score":0.6856877,"about_ca_system_score_codex":0.000076116994,"about_ca_system_score_gemma":0.00005242285,"threshold_uncertainty_score":0.9998586},"labels":[],"label_agreement":null},{"id":"W4309098807","doi":"10.1093/oncolo/oyac235","title":"Comparison of Four Clinical Prognostic Scores in Patients with Advanced Gastric and Esophageal Cancer","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University Health Network; University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; Public Health Ontario","funders":"University Health Network","keywords":"Medicine; Internal medicine; Cancer; Proportional hazards model; Esophageal cancer; Oncology; Clinical trial; Survival analysis","score_opus":0.05138439056493653,"score_gpt":0.3854788857640811,"score_spread":0.3340944951991446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309098807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973369,0.0012731684,0.00000429363,0.0005270036,0.000110551104,0.00059333025,0.000014921355,0.0000100576835,0.00012975578],"genre_scores_gemma":[0.99930817,0.0000830214,0.00015121457,0.00025135197,0.000024305655,0.00009332559,0.000007887315,0.000007149903,0.00007359586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999166,0.000117998934,0.00027594165,0.00013309772,0.00018360688,0.0001233565],"domain_scores_gemma":[0.9994538,0.00019870064,0.0001614218,0.00012907058,0.000030417516,0.0000266112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003283984,0.00006943226,0.00027168563,0.00003961466,0.0000707735,0.00000314467,0.00008345492,0.000022641781,0.00008664111],"category_scores_gemma":[0.00005624816,0.000040824758,0.000030396968,0.000223884,0.00028424544,0.000016674958,0.00005921306,0.00021372968,3.1684462e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008590492,0.0005005554,0.9254152,0.000018941912,0.00003942252,0.000006455863,0.00013637784,0.00007044733,0.00003416354,0.0000047499034,0.0002883043,0.06489485],"study_design_scores_gemma":[0.0061779553,0.0051420406,0.9875518,0.000038638147,0.000050744693,0.0000036449392,0.00021021739,0.00008136099,0.000026499152,0.0000067036094,0.0006652272,0.000045181736],"about_ca_topic_score_codex":0.00019861992,"about_ca_topic_score_gemma":0.00020782075,"teacher_disagreement_score":0.06484967,"about_ca_system_score_codex":0.00011001605,"about_ca_system_score_gemma":0.00013888424,"threshold_uncertainty_score":0.16647853},"labels":[],"label_agreement":null},{"id":"W4309161022","doi":"10.1097/cmr.0000000000000858","title":"Survivals following discontinuation of PD-1 inhibitor treatment in advanced melanoma patients","year":2022,"lang":"en","type":"article","venue":"Melanoma Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Queen's University","funders":"","keywords":"Discontinuation; Medicine; Toxicity; Internal medicine; Retrospective cohort study; Surgery; Oncology; Gastroenterology","score_opus":0.04796817465584214,"score_gpt":0.3649881183745609,"score_spread":0.3170199437187188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309161022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99564886,0.0006597372,0.0000019967092,0.0003985701,0.00028031846,0.0010894218,0.00003410125,0.000013590034,0.0018734186],"genre_scores_gemma":[0.99754095,0.00004317743,0.00007288197,0.000019053374,0.000047521975,0.00035499592,0.00012002177,0.000022290838,0.0017791009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761194,0.0004279242,0.00038183256,0.0002890144,0.00092506426,0.00036420682],"domain_scores_gemma":[0.9992677,0.00019707215,0.00007165234,0.00030915762,0.00009112738,0.00006330442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001229978,0.000115465846,0.00031872228,0.00042460588,0.00015108357,0.00001184193,0.00012435194,0.00004133751,0.00036133738],"category_scores_gemma":[0.00009910047,0.00009861952,0.00015325485,0.00074067945,0.000055721233,0.00007881597,0.000102856204,0.00021003306,0.000007709485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006502995,0.0018467592,0.81737006,0.000041325966,0.00015987153,0.00008171607,0.0018094013,0.000010735672,0.054741334,0.00004177627,0.00030870512,0.11708534],"study_design_scores_gemma":[0.01656001,0.008521443,0.91221744,0.00014152777,0.000024923906,0.0000043108435,0.0021877459,0.0000854526,0.043298505,0.000054620203,0.016711785,0.00019222058],"about_ca_topic_score_codex":0.0014307188,"about_ca_topic_score_gemma":0.00026844273,"teacher_disagreement_score":0.11689312,"about_ca_system_score_codex":0.0008697228,"about_ca_system_score_gemma":0.00022411882,"threshold_uncertainty_score":0.40215877},"labels":[],"label_agreement":null},{"id":"W4309264028","doi":"10.1126/science.adf8359","title":"Tumors can teem with microbes. But what are they doing there?","year":2022,"lang":"en","type":"article","venue":"Science","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Federation of Science Journalists","funders":"","keywords":"Biology","score_opus":0.010598923714916261,"score_gpt":0.24119160952604068,"score_spread":0.2305926858111244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309264028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939376,0.0012456946,0.000010054329,0.0026168742,0.00024791635,0.00018514098,0.0000070279357,0.00003729926,0.0017123639],"genre_scores_gemma":[0.99649346,0.00009752938,0.0002461128,0.0018518454,0.0000330466,0.000013547791,0.0000014475156,0.000009286819,0.001253713],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99890745,0.000018471914,0.0000937865,0.00026888162,0.0004455013,0.00026589638],"domain_scores_gemma":[0.9995319,0.000014267942,0.000068103254,0.00027268668,0.00004336601,0.00006965365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004387057,0.000082172155,0.00010985581,0.00009293778,0.00048329183,0.000089701905,0.00025983504,0.00000913444,0.00024914413],"category_scores_gemma":[0.000007824015,0.00005649616,0.000033521013,0.00054176553,0.00037189323,0.0001768193,0.00008352008,0.00013508373,0.0000046686823],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012431386,0.0001774073,0.040226415,0.00005197199,0.000048506747,0.00029751653,0.0072693154,0.00009303683,0.84345835,0.000078012046,0.00064803346,0.1064083],"study_design_scores_gemma":[0.0066420725,0.0026018631,0.33657122,0.0013056567,0.000091635105,0.00269636,0.14341635,0.00021206253,0.2612822,0.00014592151,0.2439766,0.0010580543],"about_ca_topic_score_codex":0.00045903487,"about_ca_topic_score_gemma":0.00026032416,"teacher_disagreement_score":0.58217615,"about_ca_system_score_codex":0.00023347705,"about_ca_system_score_gemma":0.00046003473,"threshold_uncertainty_score":0.3717139},"labels":[],"label_agreement":null},{"id":"W4309309141","doi":"10.3390/curroncol29110685","title":"Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Dosing; Pembrolizumab; Medicine; Lung cancer; Pharmacokinetics; Internal medicine; Hazard ratio; Demographics; Cancer; Confidence interval; Demography; Immunotherapy","score_opus":0.06388930667282215,"score_gpt":0.38120082469492417,"score_spread":0.317311518022102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309309141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859031,0.0030198374,0.00038109394,0.004821611,0.0027809737,0.00087444606,0.000026132706,0.00009065964,0.002102142],"genre_scores_gemma":[0.9973952,0.000089121364,0.0005862895,0.0010331521,0.00021185391,0.00022471593,0.00006618413,0.000044437023,0.00034903115],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997756,0.00022353204,0.0005515528,0.00053942954,0.00036234994,0.00056711765],"domain_scores_gemma":[0.99911267,0.00009541343,0.00020617814,0.00034763428,0.00006723468,0.0001708969],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000377159,0.0002711648,0.0006463123,0.00037934695,0.00018292852,0.000024733386,0.00027554485,0.000059555576,0.0004111679],"category_scores_gemma":[0.000025713747,0.00024766097,0.00013309342,0.0005313782,0.00011892,0.00009763976,0.0002185493,0.000651542,0.000020339681],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19055763,0.0030563087,0.04617275,0.00027900274,0.00035055436,0.0005422627,0.006435946,0.00077352824,0.06278786,0.0001004958,0.008182627,0.68076104],"study_design_scores_gemma":[0.03976754,0.009037904,0.10695656,0.0010145803,0.0001589887,0.0010051905,0.0031284895,0.0011721898,0.0022130453,0.000067403605,0.8347575,0.0007205794],"about_ca_topic_score_codex":0.00022359115,"about_ca_topic_score_gemma":0.0002744047,"teacher_disagreement_score":0.8265749,"about_ca_system_score_codex":0.001718586,"about_ca_system_score_gemma":0.0003930176,"threshold_uncertainty_score":0.99999756},"labels":[],"label_agreement":null},{"id":"W4309827972","doi":"10.1001/jamaoncol.2022.5486","title":"Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma","year":2022,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Medicine; Ipilimumab; Pembrolizumab; Internal medicine; Quality of life (healthcare); Clinical endpoint; Oncology; Randomized controlled trial; Randomization; Clinical trial; Adjuvant therapy; Cancer; Immunotherapy","score_opus":0.02678739375407324,"score_gpt":0.33753905426309,"score_spread":0.31075166050901676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309827972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971039,0.00010512924,0.00003419381,0.00051060144,0.00036610907,0.0015937624,0.0001685571,0.000018213357,0.00009947971],"genre_scores_gemma":[0.99882126,0.000008475603,0.00018876427,0.00028035292,0.000019259865,0.0004022778,0.0001403545,0.000026476939,0.00011275981],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9977738,0.0007829145,0.0006419367,0.00027750636,0.00028214508,0.00024167255],"domain_scores_gemma":[0.99766356,0.0014338858,0.00037365963,0.00029778862,0.0001773948,0.00005373392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009796151,0.00015785011,0.0010327224,0.00025065464,0.000048448263,0.0000027250237,0.00016059361,0.000118394215,0.0002475966],"category_scores_gemma":[0.00038896757,0.00011019471,0.00012487019,0.00031668702,0.0001343668,0.000049822367,0.00009710444,0.00022725547,5.785569e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6178963,0.001864783,0.3641977,0.00069782534,0.0003920752,0.000010666505,0.0004862874,0.000011939715,0.0046561314,0.000087291985,0.00013872891,0.009560276],"study_design_scores_gemma":[0.08601483,0.037958965,0.872549,0.000118372074,0.000058529757,0.000004684658,0.00030863646,0.000013687991,0.0017595587,0.00003007495,0.0010672547,0.00011639931],"about_ca_topic_score_codex":0.0010749161,"about_ca_topic_score_gemma":0.0004685927,"teacher_disagreement_score":0.53188145,"about_ca_system_score_codex":0.0006720874,"about_ca_system_score_gemma":0.00062942033,"threshold_uncertainty_score":0.449361},"labels":[],"label_agreement":null},{"id":"W4309998959","doi":"10.14740/jmc4008","title":"Pembrolizumab-Induced Myasthenia Gravis and Myositis: Literature Review on Neurological Toxicities of Programmed Death Protein 1 Inhibitors","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myasthenia gravis; Pembrolizumab; Myositis; Rituximab; Plasmapheresis; Adverse effect; Weakness; Immunotherapy; Internal medicine; Surgery; Cancer; Antibody; Immunology; Lymphoma","score_opus":0.027071078379143843,"score_gpt":0.30457225478791483,"score_spread":0.277501176408771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309998959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90263015,0.080729105,0.000001422495,0.015976423,0.00017425964,0.00042609227,0.000012881089,0.000011074041,0.000038564056],"genre_scores_gemma":[0.9796103,0.014890588,0.00007161731,0.0050273486,0.0002914295,0.00003481038,0.0000063508314,0.0000142243725,0.000053321808],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99719566,0.00029557265,0.0006728975,0.00014949369,0.0014961062,0.00019026324],"domain_scores_gemma":[0.99892324,0.00016100268,0.0003951871,0.00013381448,0.00013415374,0.00025258862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010744731,0.00015609375,0.00057168794,0.00014897733,0.000086294735,0.000018682234,0.00015414969,0.00010575386,0.0004405316],"category_scores_gemma":[0.0007975454,0.00009903322,0.00024190696,0.00027729437,0.00012660831,0.000052646614,0.00006745646,0.000876911,2.6055068e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04313737,0.0032957864,0.0046475674,0.0069751753,0.00079267554,0.045632813,0.0014182284,7.391818e-7,0.023737049,0.0005110407,0.025973687,0.84387785],"study_design_scores_gemma":[0.041027196,0.19260143,0.044133794,0.10192961,0.0013950078,0.286239,0.0019364154,0.00007056794,0.022548096,0.00061247445,0.30619597,0.0013104319],"about_ca_topic_score_codex":0.000015597701,"about_ca_topic_score_gemma":0.0000020300306,"teacher_disagreement_score":0.84256744,"about_ca_system_score_codex":0.000049279526,"about_ca_system_score_gemma":0.00029029828,"threshold_uncertainty_score":0.48235124},"labels":[],"label_agreement":null},{"id":"W4310042477","doi":"10.3390/curroncol29120718","title":"Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-Analysis","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Oncology; Hazard ratio; Meta-analysis; Regimen; Adverse effect; Cochrane Library; Clinical endpoint; Triple-negative breast cancer; Confidence interval; Randomized controlled trial; Breast cancer; Chemotherapy; Cancer","score_opus":0.19751704308041718,"score_gpt":0.45000632377535277,"score_spread":0.2524892806949356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310042477","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022269802,0.9896405,0.000271322,0.0005696554,0.0013176448,0.0058755083,0.002132683,0.000054955843,0.000115464914],"genre_scores_gemma":[0.00002035001,0.98667425,0.00037164096,0.0003603891,0.00095222006,0.008402245,0.0026318198,0.00011011733,0.00047698148],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99620825,0.00049069826,0.0011180473,0.0010112748,0.00049241504,0.00067929825],"domain_scores_gemma":[0.9961744,0.0013160118,0.0013707989,0.00065218325,0.0002704823,0.00021609916],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005474689,0.00082810724,0.0065046516,0.00042487372,0.000324826,0.000027476488,0.0004066272,0.0003342706,0.0095676035],"category_scores_gemma":[0.000061704646,0.0005178114,0.00462348,0.0019717151,0.00019148659,0.000061508734,0.00008400989,0.00076492847,0.0000057341535],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047414163,0.0012003011,0.00031160432,0.0017229733,0.20524423,0.000005897066,0.000081928265,0.00004047754,3.0533016e-9,0.0000039307865,0.0046347375,0.7820125],"study_design_scores_gemma":[0.0053844857,0.0029699302,0.00019340125,0.0002844096,0.26394507,0.000020084735,0.000008873241,0.000029846062,3.2195178e-8,0.00000388387,0.7267777,0.00038232078],"about_ca_topic_score_codex":0.00028931606,"about_ca_topic_score_gemma":0.00046425805,"teacher_disagreement_score":0.78163016,"about_ca_system_score_codex":0.0013355631,"about_ca_system_score_gemma":0.001666539,"threshold_uncertainty_score":0.99972737},"labels":[],"label_agreement":null},{"id":"W4310108176","doi":"10.1182/blood-2022-162789","title":"High-Plex Imaging and Cellular Neighborhood Spatial Analysis Reveals Multiple Immune Escape and Suppression Patterns in DLBCL","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Tumor microenvironment; Immune system; Cohort; Context (archaeology); Oncology; Diffuse large B-cell lymphoma; Medicine; Biology; Internal medicine; Cancer research; Immunology; Lymphoma","score_opus":0.006078191677673482,"score_gpt":0.22029740884258056,"score_spread":0.21421921716490708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310108176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934708,0.005303733,0.00015197416,0.00057554763,0.00009826001,0.0002664568,0.00006717774,0.000026095497,0.000039942606],"genre_scores_gemma":[0.999084,0.00023726928,0.000120272976,0.00020579669,0.00006466565,0.00003804508,0.00015157694,0.000019592884,0.000078762416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882805,0.00010358685,0.0003049779,0.00032563118,0.00021761438,0.00022012743],"domain_scores_gemma":[0.9995001,0.000058489873,0.000096843985,0.00026180007,0.000017067594,0.00006568887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028250157,0.000143796,0.00035924325,0.00026477457,0.00013256437,0.00002547381,0.00006891517,0.000034674886,0.0005442489],"category_scores_gemma":[0.0000196611,0.00013285055,0.00009299895,0.00035564468,0.00003723939,0.000056640703,0.0001424071,0.000184645,5.391605e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041401578,0.00037927754,0.71961224,0.00004193969,0.00031089748,0.000100426274,0.0003719231,0.0000039288598,0.2723386,0.0000023281998,0.000025933225,0.006398472],"study_design_scores_gemma":[0.013334321,0.00017927532,0.95556307,0.000057674035,0.00080992904,0.000045834775,0.0005141794,0.0016390145,0.02742061,0.000024654484,0.00021950848,0.00019194187],"about_ca_topic_score_codex":0.003095844,"about_ca_topic_score_gemma":0.00013429171,"teacher_disagreement_score":0.24491797,"about_ca_system_score_codex":0.000033158198,"about_ca_system_score_gemma":0.000023172635,"threshold_uncertainty_score":0.5959144},"labels":[],"label_agreement":null},{"id":"W4310459994","doi":"10.1007/s00432-022-04440-0","title":"Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy","year":2022,"lang":"en","type":"article","venue":"Journal of Cancer Research and Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Irish Research Council; Irish Research Council for Science, Engineering and Technology","keywords":"Immune system; Immune checkpoint; Nivolumab; Cancer research; Downregulation and upregulation; Tumor microenvironment; Immunotherapy; Cytotoxic T cell; TIGIT; T cell; Stromal cell; Immunology; Biology; Medicine; In vitro","score_opus":0.08980063267757109,"score_gpt":0.4944848289899192,"score_spread":0.4046841963123481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310459994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96497077,0.023189498,0.00031783307,0.010332301,0.0005383902,0.00053219433,0.000018453264,0.0000040082646,0.00009654261],"genre_scores_gemma":[0.96421295,0.03339392,0.00063448725,0.0005501817,0.000719325,0.00007749968,0.0000051642946,0.000019345825,0.0003871511],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975218,0.00039484634,0.0010308956,0.00020834216,0.00051686907,0.00032724513],"domain_scores_gemma":[0.9980253,0.0006741346,0.0004978256,0.000156877,0.00041060537,0.00023527989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004682209,0.000108756234,0.0005574691,0.00019014509,0.00028158852,0.000026437565,0.0001441776,0.00012335276,0.0006450697],"category_scores_gemma":[0.00013206353,0.00007576076,0.0003510492,0.00017043052,0.00031577988,0.00008259337,0.000119542776,0.0009536237,3.926421e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15636599,0.0019413882,0.008299876,0.00008194691,0.0006588176,0.000117715914,0.00035834132,0.000013403004,0.5978579,0.00001797603,0.0076734894,0.22661313],"study_design_scores_gemma":[0.08838427,0.1300534,0.286824,0.0002583938,0.0002106455,0.0011622186,0.002235251,0.0003495853,0.05982997,0.004476666,0.42582557,0.00039003225],"about_ca_topic_score_codex":0.00011227103,"about_ca_topic_score_gemma":0.000008090117,"teacher_disagreement_score":0.53802794,"about_ca_system_score_codex":0.0004505963,"about_ca_system_score_gemma":0.0011352564,"threshold_uncertainty_score":0.7063061},"labels":[],"label_agreement":null},{"id":"W4310497577","doi":"10.1111/bcp.15622","title":"Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time‐varying clearance","year":2022,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Pharmacokinetics; Medicine; Tremelimumab; NONMEM; Dosing; Population; Durvalumab; Internal medicine; Volume of distribution; Pharmacology; Oncology; Cancer; Immunotherapy; Nivolumab","score_opus":0.025836765211469145,"score_gpt":0.37138964677570957,"score_spread":0.3455528815642404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310497577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99715745,0.001938078,0.000024765744,0.00021728211,0.00022108953,0.00037207978,0.0000406637,0.0000027115123,0.000025897076],"genre_scores_gemma":[0.997413,0.0020019978,0.00007090314,0.00039517824,0.00008273296,0.0000052581795,0.000008476016,0.000014736902,0.000007752915],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99787074,0.00046693796,0.0010476415,0.00013031316,0.00031144818,0.00017293105],"domain_scores_gemma":[0.99842006,0.00039068164,0.0008695146,0.00006047315,0.00013727516,0.00012197953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009299417,0.000091014306,0.00062115205,0.00009976118,0.00005253242,0.0000040729824,0.00009094656,0.000025166852,0.00021850152],"category_scores_gemma":[0.00007997465,0.00006915912,0.00022281356,0.00016590793,0.00020004841,0.00007390929,0.000027028133,0.0005070066,1.2541983e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43009153,0.0018486532,0.17221567,0.00005540492,0.00045804115,0.00010955447,0.00010100964,0.29572162,0.0006090008,8.073211e-7,0.00030938385,0.098479316],"study_design_scores_gemma":[0.06584392,0.0044388534,0.90628976,0.00025475275,0.00025021372,0.000045662495,0.000016075863,0.022644082,0.000068475034,0.000041055013,0.000028963253,0.000078204204],"about_ca_topic_score_codex":0.00014057847,"about_ca_topic_score_gemma":0.0000011630091,"teacher_disagreement_score":0.73407406,"about_ca_system_score_codex":0.000078603014,"about_ca_system_score_gemma":0.00017094512,"threshold_uncertainty_score":0.28202268},"labels":[],"label_agreement":null},{"id":"W4310597798","doi":"10.14309/ajg.0000000000001983","title":"Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management","year":2022,"lang":"en","type":"review","venue":"The American Journal of Gastroenterology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Western University","funders":"","keywords":"Medicine; Immune system; Immunotherapy; Gastrointestinal cancer; Adverse effect; Cancer; Pancreatic cancer; Gastrointestinal tract; Pancreas; Immunology; Oncology; Cancer research; Internal medicine; Colorectal cancer","score_opus":0.022655652459345116,"score_gpt":0.3088287657398733,"score_spread":0.2861731132805282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310597798","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03349887,0.9645737,0.00029842992,0.00043892334,0.00015355366,0.00098562,0.000032737054,0.000008829473,0.000009343299],"genre_scores_gemma":[0.0011097337,0.996393,0.0008033046,0.0012469481,0.00018774801,0.00016178079,0.000008781925,0.000054892007,0.00003376915],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811935,0.0005184708,0.0006506353,0.0002240052,0.000134172,0.00035334288],"domain_scores_gemma":[0.9973913,0.0007065464,0.0014847051,0.00028488965,0.00003587201,0.000096725096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005437398,0.00037033658,0.0024512974,0.0002248537,0.00013278097,0.000019858353,0.00027838472,0.000021328555,0.000016270447],"category_scores_gemma":[0.000014603444,0.00020863672,0.00048019327,0.00014419945,0.000614745,0.000027780896,0.000102144935,0.00046915427,1.9215982e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014532167,0.000073816525,0.000828482,0.0036326854,0.0021985252,0.000096543554,0.00011435369,3.6033117e-7,0.00001075086,0.0000019101747,0.00022937242,0.978281],"study_design_scores_gemma":[0.0045977375,0.05425502,0.0059048985,0.009534388,0.0039284467,0.03347647,0.000493376,0.000012838483,0.0000011765828,0.000030564686,0.8875547,0.00021035905],"about_ca_topic_score_codex":0.00006312944,"about_ca_topic_score_gemma":0.000023053917,"teacher_disagreement_score":0.9780707,"about_ca_system_score_codex":0.00016596097,"about_ca_system_score_gemma":0.00007258995,"threshold_uncertainty_score":0.8507958},"labels":[],"label_agreement":null},{"id":"W4310692028","doi":"10.3390/curroncol29120741","title":"Nivolumab Hypersensitivity Reactions a Myth or Reality in Solid Tumors—A Systematic Review of the Literature","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Nivolumab; Medicine; Desensitization (medicine); Hypersensitivity reaction; Skin reaction; Intensive care medicine; Dermatology; Immunotherapy; Cancer; Internal medicine","score_opus":0.18047338159929913,"score_gpt":0.4654871803132237,"score_spread":0.2850137987139246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310692028","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005598777,0.9925166,7.965689e-7,0.00045335985,0.001506294,0.004472026,0.0002033687,0.000022320812,0.0008196436],"genre_scores_gemma":[0.000012729259,0.99803376,0.0000052288638,0.00035851446,0.00013320199,0.0007669553,0.00021983332,0.00003045209,0.00043930893],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99494123,0.0023422465,0.0017107809,0.00040720482,0.0003361291,0.00026238352],"domain_scores_gemma":[0.9967542,0.000641514,0.0014729229,0.0009768662,0.0000925526,0.00006193585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018003872,0.00035585355,0.004361405,0.000203189,0.0000830153,0.0000074188724,0.00026801432,0.00024375354,0.00024338668],"category_scores_gemma":[0.0011748918,0.00019172768,0.0011391877,0.0014023412,0.00015126051,0.000032855172,0.00014277981,0.0013380295,0.000005198784],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011201777,0.00038506102,0.0000010257168,0.8042587,0.00016706546,0.000059960606,0.00011785428,1.0310346e-8,7.264735e-7,0.000010022552,0.0023023263,0.19258524],"study_design_scores_gemma":[0.0003116294,0.00014642991,0.000005175934,0.47921476,0.0013917948,0.001128886,0.00003747457,6.488382e-7,1.5679007e-7,0.0000017408581,0.5176711,0.000090201815],"about_ca_topic_score_codex":0.000042844913,"about_ca_topic_score_gemma":0.00006664166,"teacher_disagreement_score":0.51536876,"about_ca_system_score_codex":0.0016553464,"about_ca_system_score_gemma":0.0022019204,"threshold_uncertainty_score":0.78184277},"labels":[],"label_agreement":null},{"id":"W4310720896","doi":"10.1016/j.ekir.2022.11.020","title":"Cytokines and Immune Cell Phenotype in Acute Kidney Injury Associated With Immune Checkpoint Inhibitors","year":2022,"lang":"en","type":"article","venue":"Kidney International Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Center for Advancing Translational Sciences; Maritime and Port Authority of Singapore; Norges Idrettshøgskole; National Institute of Diabetes and Digestive and Kidney Diseases; Center for Clinical and Translational Science, Mayo Clinic; National Institutes of Health","keywords":"Acute kidney injury; Medicine; Immune system; Kidney; Immunology; Tumor necrosis factor alpha; Cytokine; Internal medicine","score_opus":0.0065886011394775575,"score_gpt":0.2447163762568471,"score_spread":0.23812777511736954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310720896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802679,0.00032743395,0.000007082362,0.0077639567,0.0014746864,0.00044512626,0.00017746395,0.000072173694,0.009464175],"genre_scores_gemma":[0.99155456,0.00010811968,0.00010441941,0.0020164105,0.0000940292,0.00010054455,0.0008447732,0.000038245373,0.0051389216],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979416,0.000048425307,0.0007387885,0.0003824409,0.0006530934,0.00023562447],"domain_scores_gemma":[0.9988842,0.000024687666,0.0004865312,0.00026959844,0.00013642905,0.00019857094],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00062690367,0.00020450674,0.00032231264,0.00027817595,0.00011531466,0.000034402547,0.00010669237,0.00006627509,0.001057051],"category_scores_gemma":[0.00037825998,0.00018108806,0.00012095006,0.00036039384,0.00008944898,0.00012462673,0.00016407129,0.00034820678,0.0000022059955],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061275405,0.0012649338,0.21744841,0.00006658425,0.0015856207,0.0041234526,0.0012838845,0.000008514244,0.7393513,0.000053980562,0.025896786,0.0027890366],"study_design_scores_gemma":[0.011093309,0.0016214867,0.5829091,0.00083352247,0.00034383681,0.0029359048,0.00045747383,0.0002511746,0.18638976,0.00046570646,0.21178876,0.0009099364],"about_ca_topic_score_codex":0.0006135524,"about_ca_topic_score_gemma":0.000006918878,"teacher_disagreement_score":0.55296147,"about_ca_system_score_codex":0.000534616,"about_ca_system_score_gemma":0.00061360764,"threshold_uncertainty_score":0.9998561},"labels":[],"label_agreement":null},{"id":"W4310725957","doi":"10.1016/j.cllc.2022.11.009","title":"27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Cancer; Pembrolizumab; Cohort; Immunotherapy; Nivolumab; Retrospective cohort study; Progression-free survival; PD-L1; Overall survival","score_opus":0.03495201550638214,"score_gpt":0.4031342660278066,"score_spread":0.36818225052142445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310725957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805698,0.012635017,0.000006384944,0.0017827158,0.0013585964,0.0028146645,0.00018059257,0.000066578315,0.00058565073],"genre_scores_gemma":[0.9920201,0.003025562,0.0000646849,0.0020223982,0.00018357528,0.0011480906,0.000035729867,0.00009068842,0.0014091848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958085,0.0005256772,0.0015350208,0.0008643641,0.0007093321,0.00055710657],"domain_scores_gemma":[0.99751997,0.00042641058,0.0008956856,0.0007306484,0.00030599552,0.00012130072],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001699545,0.0003760485,0.0015432033,0.00020130815,0.0001694189,0.000012179265,0.00037027575,0.00020646877,0.0034024888],"category_scores_gemma":[0.00020286691,0.00031526643,0.0004383667,0.0012847491,0.0003839935,0.00008399561,0.00015227727,0.0010831396,0.0000018141768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059063144,0.0055858735,0.87558913,0.00003670019,0.003244885,0.00011927644,0.0039731576,0.000119026794,0.01270403,0.0000041143953,0.0015568727,0.038003787],"study_design_scores_gemma":[0.047692288,0.009270397,0.9346491,0.00046807315,0.00038555288,0.000011013137,0.0012854835,0.00011190729,0.001571898,0.0000141086875,0.0041325404,0.0004076246],"about_ca_topic_score_codex":0.0026432471,"about_ca_topic_score_gemma":0.0020061508,"teacher_disagreement_score":0.059059985,"about_ca_system_score_codex":0.0033142944,"about_ca_system_score_gemma":0.0017733438,"threshold_uncertainty_score":0.99992996},"labels":[],"label_agreement":null},{"id":"W4310753211","doi":"10.1016/j.annonc.2022.10.469","title":"438P Estimating scenarios for survival time in patients with metastatic melanoma receiving immunotherapy or targeted therapy","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Metastatic melanoma; Melanoma; Internal medicine; Targeted therapy; Cancer; Cancer research","score_opus":0.059194602733875244,"score_gpt":0.3526533677524453,"score_spread":0.2934587650185701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310753211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99542713,0.0006438592,0.00018922075,0.0018847098,0.00023906973,0.0013090655,0.0000613144,0.000026879328,0.00021877204],"genre_scores_gemma":[0.98458976,0.00010094561,0.011787315,0.0025158657,0.000055833076,0.00034336073,0.00016251982,0.00006445025,0.00037992792],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99843436,0.00020046801,0.00050694065,0.00025132927,0.00026950045,0.00033742105],"domain_scores_gemma":[0.99879235,0.0004310068,0.00033951394,0.00022723647,0.00016616797,0.000043708944],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00097543345,0.00017127804,0.00062781165,0.0002040779,0.00012020436,0.000006453887,0.00015148357,0.000051531835,0.0011511077],"category_scores_gemma":[0.00008602101,0.000126402,0.00012227507,0.00038293286,0.00008774761,0.000066763714,0.00002977094,0.00017480172,0.0000017987611],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19768308,0.0038357438,0.099867515,0.0001407225,0.0018342605,0.00005472192,0.0028586856,0.0007006219,0.013708337,0.000017508484,0.0031925489,0.6761063],"study_design_scores_gemma":[0.11075365,0.13008931,0.64790857,0.00031086185,0.00013868028,0.000073057934,0.0010341799,0.0077141235,0.004355176,0.00033602593,0.09632778,0.0009585816],"about_ca_topic_score_codex":0.00021406333,"about_ca_topic_score_gemma":0.00008530422,"teacher_disagreement_score":0.67514765,"about_ca_system_score_codex":0.00012489867,"about_ca_system_score_gemma":0.00043204514,"threshold_uncertainty_score":0.999762},"labels":[],"label_agreement":null},{"id":"W4310859181","doi":"10.1016/j.jtocrr.2022.100444","title":"First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Sharp and Dohme; Ministère de la Santé et des Services sociaux; Merck","keywords":"Pembrolizumab; Medicine; Carboplatin; Internal medicine; Chemotherapy; Oncology; Confidence interval; Retrospective cohort study; Cancer; Immunotherapy; Cisplatin","score_opus":0.17584824350593595,"score_gpt":0.5244882499617058,"score_spread":0.34864000645576987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310859181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9285067,0.0019685652,0.000011418931,0.05861572,0.0010079839,0.0023880082,0.000023061519,0.0000886047,0.007389953],"genre_scores_gemma":[0.9397422,0.0060914247,0.00052297395,0.002447022,0.00049845024,0.00080402184,0.00005741763,0.000054188447,0.049782295],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99582106,0.000395826,0.0012343527,0.0008062474,0.0011213905,0.00062112295],"domain_scores_gemma":[0.9938453,0.003994919,0.0007705407,0.00065396057,0.00039831165,0.00033696738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007913405,0.0002011496,0.0008178765,0.0002202562,0.00086027704,0.000032241678,0.00014682187,0.00016155036,0.00083509344],"category_scores_gemma":[0.0035750263,0.00014624921,0.00038243417,0.00041558495,0.00058028946,0.00008823513,0.00032711294,0.00090982154,0.0000041717535],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16085342,0.0039712633,0.3868617,0.00064015953,0.0010737629,0.0047789337,0.00080252904,0.000041118616,0.0018896457,0.000164007,0.09791201,0.34101146],"study_design_scores_gemma":[0.012915039,0.0058136918,0.0985128,0.000034514625,0.00005713428,0.00062365667,0.00020917438,0.00017887849,0.00016418961,0.0005407605,0.88076335,0.00018682948],"about_ca_topic_score_codex":0.00095796277,"about_ca_topic_score_gemma":0.0019097571,"teacher_disagreement_score":0.78285134,"about_ca_system_score_codex":0.00074851175,"about_ca_system_score_gemma":0.0011369738,"threshold_uncertainty_score":0.91436875},"labels":[],"label_agreement":null},{"id":"W4310923624","doi":"10.1016/j.iotech.2022.100230","title":"241P Treatment and outcomes of patients with gastrointestinal toxicity following immunotherapy: A large multi-center retrospective study in the United Kingdom by the National Oncology Trainees Collaborative for Healthcare Research (NOTCH)","year":2022,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Center (category theory); Retrospective cohort study; Health care; Immunotherapy; Toxicity; Internal medicine; Family medicine; Oncology; Cancer; Political science","score_opus":0.059524769806824473,"score_gpt":0.4100764466070851,"score_spread":0.3505516768002606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310923624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97745794,0.0005127418,0.000050132636,0.01653739,0.0001005449,0.004785206,0.0004837496,0.000040577434,0.000031690382],"genre_scores_gemma":[0.9956472,0.00003170942,0.000522679,0.00095883274,0.000012514066,0.0026161452,0.00013933865,0.000029622079,0.000041950672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690294,0.0011132029,0.0005441201,0.0004439576,0.00045122887,0.0005445197],"domain_scores_gemma":[0.99783516,0.0009162865,0.00030205384,0.0003361015,0.0005841107,0.000026267575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023047007,0.00025528178,0.00071103085,0.0006750862,0.000734471,0.000012469387,0.00038663286,0.00015371088,0.00002332439],"category_scores_gemma":[0.00029290043,0.00014911685,0.000107868094,0.0016632746,0.00070527307,0.00004545688,0.00014316376,0.0007383948,2.3652817e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013705742,0.012585397,0.95196277,0.000011813362,0.0010382478,0.000031752523,0.01209001,0.0000021428573,0.004977296,0.00038831585,0.00033652366,0.0028699993],"study_design_scores_gemma":[0.083937384,0.08567607,0.712142,0.00004722605,0.00011122094,0.00018765718,0.08705856,0.00006083765,0.00032208912,0.00024164244,0.02997163,0.00024368253],"about_ca_topic_score_codex":0.0007352727,"about_ca_topic_score_gemma":0.0018862323,"teacher_disagreement_score":0.23982075,"about_ca_system_score_codex":0.0025083704,"about_ca_system_score_gemma":0.0007807809,"threshold_uncertainty_score":0.65593016},"labels":[],"label_agreement":null},{"id":"W4311008623","doi":"10.5206/mase/15100","title":"Combination therapy for cancer with IL-27 and anti-PD-1: A simplified mathematical model","year":2022,"lang":"en","type":"article","venue":"Mathematics in Applied Sciences and Engineering","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"CD8; Immune system; Combination therapy; Cancer cell; Cancer; Interleukin 2; Cancer therapy; PD-L1; Cancer research; Immunotherapy; Medicine; Pharmacology; Immunology; Internal medicine","score_opus":0.028850878906840915,"score_gpt":0.2749573970323212,"score_spread":0.2461065181254803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311008623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968408,0.00032776213,0.029342102,0.0004193087,0.000027495824,0.0006791707,0.000009009747,0.00003202277,0.00075514073],"genre_scores_gemma":[0.97651416,0.00015947413,0.022852512,0.00010591032,0.000009346429,0.00028546512,0.000001650983,0.000013534141,0.00005796636],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9993317,0.0000022263657,0.0001551693,0.00016609028,0.00018239119,0.00016238449],"domain_scores_gemma":[0.99977094,0.00007468618,0.000038046062,0.00007391006,0.000008729828,0.000033666987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042060227,0.00009818978,0.00019436164,0.00009914425,0.00012578127,0.000032283548,0.000057589863,0.000021634076,0.000015255771],"category_scores_gemma":[0.000005548081,0.000073345196,0.000016792133,0.00020670521,0.00007639275,0.000027702323,0.000028130069,0.000079239646,8.239491e-8],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012843254,0.0012494333,0.001243737,0.0032205211,0.00025171647,0.000008781964,0.01992034,0.14190514,0.30826035,0.49096787,0.00024919887,0.03143857],"study_design_scores_gemma":[0.002241163,0.0002155198,0.00028514207,0.00007771871,0.00001556269,0.000027460419,0.0009994293,0.98802304,0.0013483401,0.0062894966,0.00032152445,0.00015560364],"about_ca_topic_score_codex":0.0000034725858,"about_ca_topic_score_gemma":0.00000159476,"teacher_disagreement_score":0.8461179,"about_ca_system_score_codex":0.000037322363,"about_ca_system_score_gemma":0.000035119156,"threshold_uncertainty_score":0.29909304},"labels":[],"label_agreement":null},{"id":"W4311053290","doi":"10.3390/biomedicines10123092","title":"Identification of DDX60 as a Regulator of MHC-I Class Molecules in Colorectal Cancer","year":2022,"lang":"en","type":"article","venue":"Biomedicines","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Collège Jean-de-Brébeuf","funders":"Fred and Pamela Buffett Cancer Center","keywords":"MHC class I; Colorectal cancer; Microsatellite instability; Immune checkpoint; Gene knockdown; Immunotherapy; Major histocompatibility complex; Cancer research; Cancer; Biology; Cancer immunotherapy; Immune system; Downregulation and upregulation; Immunology; Gene; Genetics","score_opus":0.010737727971578827,"score_gpt":0.2921678345433522,"score_spread":0.28143010657177336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311053290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932583,0.0036557477,0.000008106789,0.0020927752,0.0003670915,0.00030810767,0.000047946163,0.000013105451,0.00024884],"genre_scores_gemma":[0.9989374,0.00021601313,0.000021925247,0.00018347797,0.0000628685,0.00009224063,0.000027729557,0.000011535783,0.00044679397],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989056,0.00004028199,0.00044525476,0.00015606899,0.00034179116,0.00011100465],"domain_scores_gemma":[0.9994958,0.000030994313,0.00022251403,0.00014887095,0.000070075,0.0000317232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028869088,0.00008079611,0.0002641806,0.00029644265,0.000027966984,0.0000014908895,0.00009146572,0.00003734887,0.0004965808],"category_scores_gemma":[0.00003727742,0.00006891883,0.00006971297,0.0007060268,0.00020468193,0.000022463442,0.000032099913,0.00006770057,8.794387e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020015184,0.00017112905,0.018887853,0.00013788232,0.00008052441,0.000009386077,0.00078430236,0.0000047768685,0.96654797,0.000069342874,0.0014699998,0.009835319],"study_design_scores_gemma":[0.004083332,0.0010318025,0.41993755,0.00016469667,0.0000918826,0.00004933481,0.0020879898,0.00035636866,0.55887496,0.00009570284,0.013108297,0.00011811643],"about_ca_topic_score_codex":0.0012589846,"about_ca_topic_score_gemma":0.00006387984,"teacher_disagreement_score":0.40767303,"about_ca_system_score_codex":0.00012262448,"about_ca_system_score_gemma":0.00019802825,"threshold_uncertainty_score":0.54372114},"labels":[],"label_agreement":null},{"id":"W4311098518","doi":"10.1158/2326-6074.tumimm22-a09","title":"Abstract A09: Immune checkpoint inhibitor-induced polyarthritis: a case series","year":2022,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Nivolumab; Polyarthritis; Prednisone; Ipilimumab; Arthritis; Internal medicine; Cancer; Rash; Synovitis; Dermatology; Surgery; Oncology; Immunotherapy","score_opus":0.06990754541223117,"score_gpt":0.37819605054656996,"score_spread":0.3082885051343388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311098518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9308275,0.05637498,5.9759935e-7,0.007920539,0.0011355644,0.00087008596,0.00008574879,0.00012524973,0.0026597593],"genre_scores_gemma":[0.9906498,0.0030293614,0.000029356514,0.0002886806,0.0003348433,0.0015067807,0.000043206714,0.000070227055,0.00404775],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966107,0.00038716797,0.0006211642,0.0006098341,0.0007123494,0.0010587567],"domain_scores_gemma":[0.99841464,0.00013719503,0.00012544221,0.00085323665,0.00032970813,0.00013977358],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018541653,0.00026132638,0.0005120116,0.00054505613,0.0013293036,0.00005416444,0.00034988575,0.00019344199,0.009225079],"category_scores_gemma":[0.00011267529,0.00026134888,0.0002642391,0.0011184952,0.00074368436,0.00017974207,0.00052520866,0.0021708286,0.000075128766],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009948448,0.0003327928,0.0010113446,0.0000953492,0.00063404546,0.008430006,0.0012690343,0.0000016081395,0.89067113,0.00008480828,0.002378329,0.085143104],"study_design_scores_gemma":[0.019318752,0.007884994,0.07522157,0.0005001213,0.00010645682,0.090046234,0.02629238,0.000016366625,0.51300836,0.00030506702,0.26620054,0.001099141],"about_ca_topic_score_codex":0.0056206337,"about_ca_topic_score_gemma":0.00036252267,"teacher_disagreement_score":0.37766275,"about_ca_system_score_codex":0.0011719071,"about_ca_system_score_gemma":0.0013517777,"threshold_uncertainty_score":0.99998385},"labels":[],"label_agreement":null},{"id":"W4311247417","doi":"10.1001/jamanetworkopen.2022.45596","title":"Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy","year":2022,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Adverse effect; Proportional hazards model; Internal medicine; Oncology; Melanoma; Retrospective cohort study; Immune checkpoint; Cohort; Survival analysis; Cancer; Metastatic melanoma; Immunotherapy","score_opus":0.013679963665347815,"score_gpt":0.24154326137218676,"score_spread":0.22786329770683894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311247417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958488,0.0006984564,0.00019673373,0.0005089738,0.00024145508,0.0022322158,0.000021961636,0.000031964948,0.00021945495],"genre_scores_gemma":[0.9970245,0.0005658071,0.00046987704,0.00015170821,0.000023404156,0.00016365272,0.00051608967,0.000052800387,0.0010321618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977999,0.00044879643,0.0005890366,0.0002945413,0.0006273569,0.00024041897],"domain_scores_gemma":[0.9982967,0.000143211,0.0009868206,0.0002730061,0.00025527048,0.000044993358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015400912,0.00020064221,0.00041815278,0.00009634981,0.00032513824,0.00004382306,0.00018106838,0.00006420046,0.0004887512],"category_scores_gemma":[0.00003463253,0.0001467359,0.00006344541,0.0007190836,0.00005486249,0.00041088028,0.00008078511,0.00018606118,6.588423e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02372822,0.0006902745,0.95644915,0.000026897846,0.0015187137,0.0000044477406,0.0008782326,0.00070199353,0.0002215362,0.000025856334,0.00026067736,0.015494004],"study_design_scores_gemma":[0.02292072,0.0039797453,0.970317,0.0002925305,0.00013874467,0.0000046512823,0.00029285756,0.0004071094,0.00008315579,0.00005798338,0.001295191,0.00021029543],"about_ca_topic_score_codex":0.00048127715,"about_ca_topic_score_gemma":0.00020079895,"teacher_disagreement_score":0.015283708,"about_ca_system_score_codex":0.00043536111,"about_ca_system_score_gemma":0.00010659777,"threshold_uncertainty_score":0.5983716},"labels":[],"label_agreement":null},{"id":"W4311569750","doi":"10.4143/crt.2022.1460","title":"Top Ten Lessons Learned from Trials in Oligometastatic Cancers","year":2022,"lang":"en","type":"review","venue":"Cancer Research and Treatment","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Clinical trial; Medical physics; Oncology; Clinical Practice; Intensive care medicine; Accrual; Disease; Systemic therapy; Internal medicine; Cancer; Family medicine; Breast cancer","score_opus":0.6142362181636167,"score_gpt":0.5678875440363716,"score_spread":0.04634867412724508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311569750","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007533127,0.99325687,3.4951145e-7,0.0013356912,0.00020673579,0.0026104813,0.001195054,0.000020972318,0.0006205459],"genre_scores_gemma":[0.00008433001,0.98980457,0.000029168716,0.000051311254,0.00024558688,0.0057043387,0.0005477638,0.000061757666,0.003471206],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99589735,0.0012720575,0.000820352,0.00078396685,0.00059137394,0.0006348995],"domain_scores_gemma":[0.99705493,0.0019079475,0.0002193516,0.0005202435,0.000040813422,0.0002566981],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001965017,0.00040664754,0.003086437,0.00070779555,0.00018672332,0.00006997421,0.0001638298,0.00015586105,0.003643049],"category_scores_gemma":[0.00021481948,0.0002657703,0.00052817725,0.0009457957,0.00021160766,0.000039203762,0.000091951646,0.0006083059,0.000014721748],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012280393,0.00019668762,0.0000608452,0.0015709667,0.0020133317,0.0002832594,0.00028372032,3.181565e-7,0.000004990072,0.000014703319,0.0007900172,0.9935531],"study_design_scores_gemma":[0.004157207,0.0012463579,0.00006691684,0.0048831115,0.0008140395,0.000013675502,0.00027862206,0.0000012619688,0.000014392438,0.00011193503,0.9882035,0.00020897528],"about_ca_topic_score_codex":0.039591424,"about_ca_topic_score_gemma":0.0033651104,"teacher_disagreement_score":0.9933441,"about_ca_system_score_codex":0.0064942795,"about_ca_system_score_gemma":0.0042763306,"threshold_uncertainty_score":0.99997944},"labels":[],"label_agreement":null},{"id":"W4311654287","doi":"10.1101/2022.12.05.22283131","title":"Efficacy of PD-(L)1 blockade monotherapy compared to PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study","year":2022,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Legend Biotech; EMD Serono; Genentech; National Institutes of Health; Daiichi Sankyo Europe; Sanofi; Kowa Company; Ipsen; Regeneron Pharmaceuticals; Natera; Memorial Sloan-Kettering Cancer Center; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Chemotherapy; Medicine; Internal medicine; Oncology; Blockade; Cohort; Retrospective cohort study; PD-L1; Propensity score matching; Proportional hazards model; Gastroenterology; Cancer; Immunotherapy","score_opus":0.019592443046157263,"score_gpt":0.31097712337767563,"score_spread":0.2913846803315184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311654287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97608584,0.0058388147,0.0002053618,0.002787512,0.0010081925,0.013171532,0.00023026322,0.00023236591,0.0004400905],"genre_scores_gemma":[0.99215156,0.0017203287,0.00070662034,0.0011067622,0.00041337026,0.0022205333,0.0003045359,0.00029638142,0.0010799321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99250317,0.00050443184,0.0022155193,0.0021778254,0.0015338021,0.0010652296],"domain_scores_gemma":[0.99543875,0.00047740104,0.0009461472,0.002422401,0.0002995422,0.0004157426],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0014669257,0.001292323,0.003138475,0.0011503558,0.00022744517,0.00006072786,0.0012524854,0.0004852881,0.0014665014],"category_scores_gemma":[0.00014235126,0.00127885,0.00082844286,0.0015593504,0.000254026,0.000083283034,0.00067414565,0.0018505463,0.000012536729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07918196,0.0055498076,0.8580546,0.00065344316,0.0039675473,0.0004632293,0.020559682,0.008958389,0.017545665,0.0000033515385,0.0004442028,0.0046181562],"study_design_scores_gemma":[0.036872007,0.0024430647,0.94058233,0.0011831091,0.000556107,0.000038415983,0.0015687667,0.0016259062,0.010428688,0.000020360863,0.0034982373,0.0011830046],"about_ca_topic_score_codex":0.0023412525,"about_ca_topic_score_gemma":0.0007553659,"teacher_disagreement_score":0.082527764,"about_ca_system_score_codex":0.0020352798,"about_ca_system_score_gemma":0.00081314065,"threshold_uncertainty_score":0.99998283},"labels":[],"label_agreement":null},{"id":"W4311820175","doi":"10.1101/2022.12.13.520329","title":"Lung tumor-infiltrating T <sub>reg</sub> have divergent transcriptional profiles and function linked to checkpoint blockade response","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; Sidney Kimmel Comprehensive Cancer Center; Swim Across America; Mark Foundation For Cancer Research; Johns Hopkins University; LUNGevity Foundation; U.S. Department of Defense; National Institutes of Health; National Science Foundation","keywords":"FOXP3; Cancer research; T cell; Immune checkpoint; Biology; Tumor-infiltrating lymphocytes; Blockade; Immune system; Tumor microenvironment; Immunotherapy; Immunology; Receptor; Genetics","score_opus":0.01605078553224359,"score_gpt":0.23596853809309823,"score_spread":0.21991775256085463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311820175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98880357,0.004252411,0.0005927401,0.0016871137,0.0016685063,0.0021788802,0.00044663108,0.00036337855,0.0000067530505],"genre_scores_gemma":[0.99547493,0.000391892,0.0013395277,0.0010018746,0.0006520766,0.00095209194,0.000004196209,0.00015510338,0.000028316907],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9961224,0.00032795817,0.0008521043,0.0012799337,0.00079841795,0.0006191431],"domain_scores_gemma":[0.997814,0.00009414195,0.00039640337,0.0009021932,0.0003364989,0.00045677094],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015584616,0.000681346,0.00073063036,0.00051304535,0.0004399393,0.00015704439,0.0002582564,0.00035459409,0.00029898642],"category_scores_gemma":[0.00020984521,0.00072790054,0.0003349502,0.0004931513,0.00014453233,0.00012000817,0.0003420051,0.0011492148,0.000013108648],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009271628,0.00020133237,0.010220019,0.00053262233,0.00052293716,0.00011686071,0.00009193977,0.000045893335,0.9782748,0.000030094914,0.0006763754,0.000015469148],"study_design_scores_gemma":[0.0019007138,0.0004558461,0.5094902,0.0005552869,0.00036192336,4.2934388e-7,0.00003565,0.00035462674,0.4754258,9.5026877e-7,0.010732897,0.0006856874],"about_ca_topic_score_codex":0.00007384004,"about_ca_topic_score_gemma":0.000004424168,"teacher_disagreement_score":0.502849,"about_ca_system_score_codex":0.00094386144,"about_ca_system_score_gemma":0.0011477914,"threshold_uncertainty_score":0.9995172},"labels":[],"label_agreement":null},{"id":"W4311867136","doi":"10.3892/ol.2022.13625","title":"Prognostic value of CD8<sup>+</sup> tumor‑infiltrating T cells in patients with breast cancer: A systematic review and meta‑analysis","year":2022,"lang":"en","type":"review","venue":"Oncology Letters","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Medicine; Hazard ratio; Internal medicine; Estrogen receptor; Oncology; Tumor-infiltrating lymphocytes; CD8; Cochrane Library; Cancer; Odds ratio; Meta-analysis; Confidence interval; Immunology; Immune system; Immunotherapy","score_opus":0.0225795988487535,"score_gpt":0.3004059435035421,"score_spread":0.2778263446547886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311867136","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040390764,0.992819,0.0000031428372,0.0008360534,0.000036492722,0.0055275015,0.00031572263,0.000017966724,0.00004020183],"genre_scores_gemma":[0.00014568625,0.99189466,0.00017363146,0.00524979,0.000019765745,0.0022717053,0.00015504958,0.00005546339,0.000034217745],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9962328,0.0010131447,0.0014417619,0.0005631359,0.00040452302,0.00034464855],"domain_scores_gemma":[0.9973414,0.0005972702,0.0014068027,0.0005093311,0.000057897894,0.000087328575],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00086073513,0.0005164629,0.008512175,0.00052318664,0.00006015447,0.000010736036,0.00022282072,0.00012935835,0.00060708885],"category_scores_gemma":[0.00005218037,0.00032971252,0.001085016,0.0015185178,0.00018238618,0.000050977793,0.00006447801,0.0005359886,0.0000017941345],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016360031,0.00020795221,0.00074663374,0.8982724,0.094629,0.00009923515,0.00012938821,0.000019833109,0.0000010798633,0.0000011339857,0.00025012644,0.005479649],"study_design_scores_gemma":[0.0012438231,0.000601722,0.00020071375,0.08636676,0.8887184,0.00017514362,0.00003805989,0.000008870792,2.2140422e-7,1.4583397e-7,0.022254108,0.0003920122],"about_ca_topic_score_codex":0.00035925,"about_ca_topic_score_gemma":0.00003837869,"teacher_disagreement_score":0.8119056,"about_ca_system_score_codex":0.0006790426,"about_ca_system_score_gemma":0.0005146589,"threshold_uncertainty_score":0.9999155},"labels":[],"label_agreement":null},{"id":"W4312073676","doi":"10.3390/cancers15010048","title":"Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Centre for Interdisciplinary Research in Rehabilitation; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Metastasis; Breast cancer; Cancer research; Medicine; Cancer; Combination therapy; Bone metastasis; Primary tumor; In vivo; Immune system; Immunotherapy; Mammary tumor; Oncology; Internal medicine; Immunology; Biology","score_opus":0.00806834896806137,"score_gpt":0.26652502285450347,"score_spread":0.2584566738864421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312073676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94321203,0.050256602,0.0000030067692,0.0054748654,0.00012941919,0.00063947757,0.00013358724,0.00003686151,0.00011416506],"genre_scores_gemma":[0.99454415,0.0026094492,0.001013665,0.0011184928,0.00020564643,0.00030614497,0.000025601108,0.000041140607,0.00013569815],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99848205,0.000062707855,0.000305328,0.00051273167,0.00032557859,0.00031161946],"domain_scores_gemma":[0.9993546,0.000038024395,0.00016732274,0.0001235877,0.00006707478,0.00024939302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042657112,0.0002473112,0.00045089712,0.00014702546,0.00041007617,0.00005508945,0.000049058493,0.00003581176,0.00010469421],"category_scores_gemma":[0.000019148987,0.00019431741,0.00003331988,0.00030612858,0.00039892588,0.00013053867,0.00011274115,0.00026533508,1.2298825e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017386371,0.00006574967,0.035358343,0.0011153395,0.0005757725,0.00018386988,0.004576486,0.0000041386224,0.86441314,0.000012653639,0.003221352,0.07308679],"study_design_scores_gemma":[0.020926166,0.005509521,0.59103817,0.00273469,0.0012792248,0.0077078072,0.01417895,0.000105555824,0.33167207,0.000028818436,0.023108542,0.0017104772],"about_ca_topic_score_codex":0.0011358008,"about_ca_topic_score_gemma":0.000029833884,"teacher_disagreement_score":0.5556798,"about_ca_system_score_codex":0.00046782696,"about_ca_system_score_gemma":0.0004564071,"threshold_uncertainty_score":0.79240346},"labels":[],"label_agreement":null},{"id":"W4312084145","doi":"10.1016/j.jaccao.2022.11.010","title":"A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?","year":2022,"lang":"en","type":"editorial","venue":"JACC CardioOncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Risk factor; Immune checkpoint; Immune system; Oncology; Internal medicine; Immunotherapy; Immunology","score_opus":0.013837324271414549,"score_gpt":0.2709715094436619,"score_spread":0.25713418517224734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312084145","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027023623,0.024658555,0.00013746247,0.00017367002,0.9406556,0.005259565,0.0015332405,0.00012432253,0.00043395243],"genre_scores_gemma":[0.01961153,0.017540602,0.0008587071,0.00016500129,0.9535626,0.0020720076,0.0023766009,0.00048472654,0.0033282337],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99481833,0.0006649541,0.0011405249,0.0011757367,0.0013576117,0.0008428658],"domain_scores_gemma":[0.996729,0.00086169376,0.000654452,0.0012314676,0.00032796545,0.00019543158],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0017916653,0.0007133704,0.0027789534,0.00051865884,0.00019452971,0.00002154259,0.00043741346,0.0016028307,0.0006010907],"category_scores_gemma":[0.0012733806,0.0006799383,0.004377191,0.00048578496,0.0000647831,0.00009531963,0.00024080646,0.0018790027,0.000012280823],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019680236,0.00035889915,0.0081400005,0.00027380523,0.009567507,0.000038963146,0.0007783523,0.000020867132,0.00020529071,2.6895736e-7,0.6434683,0.3174675],"study_design_scores_gemma":[0.03178186,0.00291757,0.05674698,0.00017642141,0.0007176088,0.0000065291933,0.00008713183,0.0000018861956,0.00013986845,0.000015774185,0.90682817,0.00058018876],"about_ca_topic_score_codex":0.0017854599,"about_ca_topic_score_gemma":0.00013124589,"teacher_disagreement_score":0.31688732,"about_ca_system_score_codex":0.0031706316,"about_ca_system_score_gemma":0.0022317944,"threshold_uncertainty_score":0.9996933},"labels":[],"label_agreement":null},{"id":"W4312139568","doi":"10.1136/ijgc-2022-igcs.50","title":"6/#455 Management of immune-related adverse events in patients with solid tumors treated with dostarlimab in the garnet study","year":2022,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Discontinuation; Medicine; Adverse effect; Internal medicine; Interim analysis; Lung cancer; Thyroid cancer; Interim; Cancer; Oncology; Surgery; Clinical trial","score_opus":0.010203547223004383,"score_gpt":0.2824847885999458,"score_spread":0.27228124137694143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312139568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99824077,0.0001556589,0.0000014750998,0.00050095597,0.00014929942,0.0006218666,0.000016495844,0.0000031525174,0.0003103153],"genre_scores_gemma":[0.9994691,0.000058921523,0.000028315766,0.0002623854,0.000012276418,0.00006698987,0.000013119943,0.000008262083,0.00008060962],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979771,0.00015729979,0.00067363464,0.00013090743,0.00092009705,0.00014096386],"domain_scores_gemma":[0.9991097,0.0000701279,0.00050676527,0.000099011915,0.00018833014,0.000026092226],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00056342967,0.000116458956,0.00029689164,0.0002112243,0.00003101055,0.000003335755,0.00033196466,0.00002390368,0.0010679407],"category_scores_gemma":[0.000013155611,0.000061708284,0.00008800887,0.00035754553,0.00005499724,0.000069636284,0.000060240283,0.00033455717,4.901129e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024993883,0.0035387166,0.9642539,0.000007263787,0.00090958254,0.0008234545,0.0006982135,0.0019057507,0.000034742985,0.000009258674,0.000027123153,0.0027980884],"study_design_scores_gemma":[0.020487236,0.005990238,0.9702137,0.00015691975,0.000086592576,0.000038978924,0.0027345896,0.000020720388,0.000021169757,0.000014836667,0.00016133192,0.00007368856],"about_ca_topic_score_codex":0.00022708949,"about_ca_topic_score_gemma":0.00012882841,"teacher_disagreement_score":0.005959777,"about_ca_system_score_codex":0.0006450865,"about_ca_system_score_gemma":0.00009877615,"threshold_uncertainty_score":0.9998452},"labels":[],"label_agreement":null},{"id":"W4312192878","doi":"10.1038/s44161-022-00184-9","title":"Unchecked autoreactive CD8+ T cells wreak havoc in cancer immunotherapy","year":2022,"lang":"en","type":"article","venue":"Nature Cardiovascular Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Ted Rogers Centre for Heart Research; University Health Network","funders":"National Heart, Lung, and Blood Institute","keywords":"Immunotherapy; Cancer immunotherapy; Cytotoxic T cell; Cancer; CD8; Biology; Immunology; Immune system; Genetics","score_opus":0.04342626523323898,"score_gpt":0.3771129204614374,"score_spread":0.3336866552281984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312192878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6972302,0.28592962,0.000030489724,0.003246465,0.0016028492,0.0030505133,0.00012210627,0.00022488685,0.008562863],"genre_scores_gemma":[0.9903919,0.005266433,0.00008233542,0.00073294155,0.0003706101,0.00088801654,0.000053439286,0.00012244406,0.0020918932],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944248,0.0010127963,0.00031251533,0.0007199232,0.0027358907,0.0007940528],"domain_scores_gemma":[0.99816567,0.00015478431,0.000046213594,0.0011506914,0.00035262923,0.00013001006],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005182966,0.00024331344,0.00065860327,0.00072652753,0.00031419258,0.000043525182,0.000431363,0.00033733368,0.00092815753],"category_scores_gemma":[0.000079612175,0.00022147858,0.001077462,0.0021756631,0.00018850644,0.00008928453,0.0002176244,0.0042330604,0.00001289077],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022994569,0.0017348687,0.0075826966,0.0003915998,0.015246258,0.0030136842,0.0054085813,0.0013629685,0.53768855,0.0003344377,0.065927915,0.3383139],"study_design_scores_gemma":[0.00704196,0.00041648914,0.020408737,0.000077744924,0.00007803662,0.00011533637,0.0011971671,0.00010144257,0.031198116,0.00006845262,0.9389995,0.00029703684],"about_ca_topic_score_codex":0.0033013339,"about_ca_topic_score_gemma":0.000090463196,"teacher_disagreement_score":0.87307155,"about_ca_system_score_codex":0.0023207134,"about_ca_system_score_gemma":0.00093533297,"threshold_uncertainty_score":0.99998516},"labels":[],"label_agreement":null},{"id":"W4312441204","doi":"10.1136/ijgc-2022-esgo.437","title":"2022-RA-1144-ESGO Management of immune-related adverse events in patients with solid tumours treated with dostarlimab in the GARNET study","year":2022,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Discontinuation; Adverse effect; Internal medicine; Interim analysis; Thyroid cancer; Surgery; Cancer; Oncology; Clinical trial","score_opus":0.009573825460149116,"score_gpt":0.2815752089474993,"score_spread":0.2720013834873502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312441204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99770766,0.00025028456,0.0000019786476,0.00071646523,0.0002550024,0.0006983314,0.000025546398,0.0000037858929,0.00034096514],"genre_scores_gemma":[0.99927694,0.00012054085,0.000029197137,0.00029822873,0.000016931353,0.000080076854,0.000020903864,0.00001041488,0.00014674259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768007,0.00019898749,0.0007066047,0.00016078947,0.0010831686,0.00017038114],"domain_scores_gemma":[0.99899197,0.00007708444,0.00055718847,0.00012042045,0.00022048793,0.000032851378],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006780009,0.00013867595,0.00032512896,0.0002445356,0.000039163428,0.0000044310095,0.00039953695,0.00003112189,0.0014640996],"category_scores_gemma":[0.0000164402,0.00007591051,0.00010317552,0.0004224032,0.00006411405,0.00008413423,0.000075477845,0.00041504417,6.452474e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02551404,0.003918191,0.9637702,0.000008459121,0.0010089756,0.00079056073,0.0006456414,0.0015280722,0.000057150035,0.00001011398,0.00007285654,0.0026757084],"study_design_scores_gemma":[0.021818403,0.0058988663,0.9682587,0.00014915016,0.0001194463,0.000040972358,0.0033065744,0.000024832922,0.000027190681,0.000016817181,0.00024917192,0.0000898835],"about_ca_topic_score_codex":0.00024850614,"about_ca_topic_score_gemma":0.00021619715,"teacher_disagreement_score":0.0044884584,"about_ca_system_score_codex":0.0007539717,"about_ca_system_score_gemma":0.00011655984,"threshold_uncertainty_score":0.9994487},"labels":[],"label_agreement":null},{"id":"W4312817941","doi":"10.1177/10732748221140694","title":"Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis","year":2022,"lang":"en","type":"review","venue":"Cancer Control","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Meta-analysis; Internal medicine; Combination therapy; Cochrane Library; PD-L1; Randomized controlled trial; Clinical trial; Cancer; Pharmacology; Immunotherapy","score_opus":0.044619619522156886,"score_gpt":0.3540165647860065,"score_spread":0.30939694526384964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312817941","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027072642,0.9911871,0.000020421872,0.00041865197,0.00005296458,0.0076065664,0.00033755918,0.000026279133,0.00007972946],"genre_scores_gemma":[0.016632792,0.97914714,0.000015686348,0.0012174172,0.000026105085,0.0026578163,0.00005827495,0.00008974181,0.00015500515],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9949915,0.0008259192,0.0022837704,0.00079648267,0.0006568049,0.0004455146],"domain_scores_gemma":[0.9965015,0.0005578439,0.0018720627,0.0008378112,0.00014071657,0.00009004472],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016380189,0.00073777774,0.015605216,0.0010712476,0.00005743371,0.0000341794,0.00030367894,0.000129139,0.0010624009],"category_scores_gemma":[0.00013735353,0.00047236308,0.0017980458,0.002517392,0.00024041397,0.000110311834,0.00004843867,0.0004988654,0.0000020119637],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037502628,0.0004014098,0.0005165947,0.86748934,0.126837,0.00006551424,0.0002862079,0.0000100073175,0.000008190354,0.000026163456,0.000044254175,0.0039402912],"study_design_scores_gemma":[0.0066953003,0.0003289798,0.0007320504,0.15416355,0.8228104,0.000060235943,0.00011486478,0.000051049046,0.0000036367412,0.000003360551,0.014324967,0.0007116047],"about_ca_topic_score_codex":0.00092566526,"about_ca_topic_score_gemma":0.00024116188,"teacher_disagreement_score":0.7133258,"about_ca_system_score_codex":0.00048221956,"about_ca_system_score_gemma":0.0006838589,"threshold_uncertainty_score":0.99985075},"labels":[],"label_agreement":null},{"id":"W4312858914","doi":"10.1007/978-3-031-11363-5_13","title":"Immune Checkpoint Inhibitors","year":2022,"lang":"en","type":"book-chapter","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; University of Alberta","funders":"","keywords":"Immunology; Immune system; Cytopenia; Medicine; Immune checkpoint; Immunotherapy","score_opus":0.018049252675756227,"score_gpt":0.24859829253925775,"score_spread":0.23054903986350153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312858914","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008985722,0.0065520857,0.0000033600236,0.0017562173,0.0008093672,0.00040861077,0.000019338067,0.00012517248,0.990236],"genre_scores_gemma":[0.0015549222,0.0020288012,0.000091370144,0.001039763,0.0003755176,0.000019109757,0.00016731984,0.000084622574,0.99463856],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99871606,0.000005191532,0.00045678695,0.00029319793,0.00036191248,0.00016688446],"domain_scores_gemma":[0.9992733,0.00001754094,0.00015263529,0.00045243377,0.000035376994,0.00006873017],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017765148,0.00026446456,0.00043056894,0.00015434576,0.00007343494,0.000010406481,0.000091563445,0.00019871276,0.12137825],"category_scores_gemma":[0.000005315247,0.00022088244,0.0005617538,0.000029835757,0.00008781031,0.000025917558,0.000091360824,0.0004781163,0.0002122693],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012734149,0.00041738094,0.00009814128,0.0010406675,0.006529137,0.0014726947,0.00079793227,0.0000013489396,0.059737697,0.1679205,0.3189051,0.43034527],"study_design_scores_gemma":[0.0012023532,0.00035882078,0.00008477609,0.00014737115,0.00012002432,0.000118848744,0.000022298416,8.6785883e-7,0.00224595,0.00045487878,0.9949899,0.000253955],"about_ca_topic_score_codex":0.00017070027,"about_ca_topic_score_gemma":0.000010572193,"teacher_disagreement_score":0.67608476,"about_ca_system_score_codex":0.00030810572,"about_ca_system_score_gemma":0.00018281986,"threshold_uncertainty_score":0.90073246},"labels":[],"label_agreement":null},{"id":"W4313037203","doi":"10.18103/mra.v10i10.3190","title":"Emerging Evidence from Landmark Clinical Trials on Perioperative Immunotherapy in Resectable Non-Small Cell Lung Cancer","year":2022,"lang":"en","type":"article","venue":"Medical Research Archives","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Vancouver Coastal Health Research Institute; University of British Columbia","funders":"","keywords":"Medicine; Clinical trial; Lung cancer; Perioperative; Immunotherapy; Oncology; Internal medicine; Clinical endpoint; Cancer; Disease; Stage (stratigraphy); Adjuvant; Intensive care medicine; Surgery","score_opus":0.1725829873187692,"score_gpt":0.5128888028569806,"score_spread":0.3403058155382114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313037203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9506639,0.028336499,0.0001844732,0.01294592,0.0005366497,0.0016417024,0.00007119436,0.000031585612,0.005588037],"genre_scores_gemma":[0.9274863,0.061847948,0.0003885707,0.0020427778,0.0010616764,0.0015322348,0.000054114433,0.000066152184,0.0055202395],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98709184,0.007716516,0.0011811533,0.0007779532,0.002360284,0.00087225443],"domain_scores_gemma":[0.9808739,0.017761897,0.0001574461,0.0006290166,0.00007240025,0.0005053484],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.02156208,0.00022825415,0.00093188253,0.00050354033,0.00050152437,0.000057638954,0.00069270225,0.000117310185,0.014027666],"category_scores_gemma":[0.00720094,0.00017054866,0.00034915342,0.00075846096,0.0005708282,0.000074547555,0.00039113182,0.0031348274,0.000015585814],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07227847,0.0015876802,0.20459305,0.00019091673,0.000535641,0.00090802385,0.014796535,0.00005059479,0.09034989,0.000028449564,0.013164237,0.6015165],"study_design_scores_gemma":[0.051819358,0.011253935,0.5071573,0.009136298,0.00010786003,0.000030412702,0.011284615,0.039568562,0.01916183,0.000459058,0.3488476,0.0011731702],"about_ca_topic_score_codex":0.0068774414,"about_ca_topic_score_gemma":0.0008177073,"teacher_disagreement_score":0.60034335,"about_ca_system_score_codex":0.00032276323,"about_ca_system_score_gemma":0.0026986557,"threshold_uncertainty_score":0.99973583},"labels":[],"label_agreement":null},{"id":"W4313054915","doi":"10.1016/j.hpb.2022.05.465","title":"Eliciting a Systemic Immune Response against Liver Tumors Utilizing Locoregional Therapies - A Systematic Review of Prospective Studies","year":2022,"lang":"en","type":"review","venue":"HPB","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Immune system; Immunotherapy; Prospective cohort study; Hepatocellular carcinoma; Melanoma; Oncology; Colorectal cancer; Abscopal effect; Cancer; Internal medicine; Immunology; Cancer research","score_opus":0.08820152609403702,"score_gpt":0.36129823895227764,"score_spread":0.2730967128582406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313054915","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013227995,0.9919585,0.000003576502,0.000023808572,0.00018666209,0.007442467,0.000049777263,0.00007386595,0.00012905693],"genre_scores_gemma":[0.0000727832,0.99626786,0.00007423408,0.00032543295,0.00008395103,0.002639585,0.000056247412,0.00009753022,0.00038238082],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9948257,0.0014679305,0.0021783467,0.000502688,0.0007032436,0.00032209154],"domain_scores_gemma":[0.99544305,0.0014164203,0.0020720297,0.00078170456,0.00023255861,0.00005423863],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003254646,0.00059564,0.0059034624,0.00035041076,0.00017585799,0.000014494869,0.00031095522,0.00012277972,0.0001462823],"category_scores_gemma":[0.0012006332,0.00040286212,0.001553505,0.0008233333,0.00022212182,0.00005250785,0.00015555373,0.0004932018,0.000014246144],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005569393,0.000059648402,0.0000013628422,0.91476643,0.003706149,0.00016585617,0.0011414182,1.8286444e-8,0.000022555128,0.000013122624,0.00014404434,0.07942246],"study_design_scores_gemma":[0.0005454165,0.00027752668,0.0000053818185,0.92937446,0.0037976599,0.0014937295,0.0031164163,0.0000030571364,0.0000014315592,0.0000010986455,0.061062563,0.00032128414],"about_ca_topic_score_codex":0.000018540533,"about_ca_topic_score_gemma":7.1833574e-7,"teacher_disagreement_score":0.079101175,"about_ca_system_score_codex":0.0011381324,"about_ca_system_score_gemma":0.00082090654,"threshold_uncertainty_score":0.99984235},"labels":[],"label_agreement":null},{"id":"W4313140213","doi":"10.1136/ijgc-2022-esgo.518","title":"2022-RA-588-ESGO Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients with advanced solid tumours: ARTISTRY-1","year":2022,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of Alberta; Alberta Health Services; Université Laval; Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Melanoma; Response Evaluation Criteria in Solid Tumors; Internal medicine; Combination therapy; CD8; Renal cell carcinoma; Cytokine; Immunotherapy; Gastroenterology; Nivolumab; Oncology; Pharmacology; Phases of clinical research; Cancer research; Immunology; Chemotherapy; Cancer; Immune system","score_opus":0.007700267472341213,"score_gpt":0.2772337533473079,"score_spread":0.26953348587496667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313140213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956915,0.0007694836,0.000040131756,0.0027178542,0.00031912312,0.00028689462,0.000026720776,0.0000061037053,0.00014222738],"genre_scores_gemma":[0.99784297,0.00048742283,0.00021072394,0.0012177499,0.000058400306,0.000062551524,0.00001881621,0.000014196482,0.00008717855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984315,0.000080567486,0.00043121705,0.00018819253,0.00069044525,0.00017807544],"domain_scores_gemma":[0.99915767,0.00009584562,0.00035893664,0.00007428424,0.0002494692,0.000063820895],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000260757,0.00013659382,0.0003051558,0.0002612197,0.000044327317,0.00002387984,0.00018035386,0.000044606157,0.0011276643],"category_scores_gemma":[0.000041010047,0.00009585246,0.000048971448,0.0002292348,0.00008776348,0.00018053854,0.000041215946,0.00040616823,3.6882102e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05767189,0.0012594415,0.89259315,0.000009391047,0.0001979969,0.0003529951,0.00023581726,0.0014607051,0.0011341998,0.000034083805,0.00023863529,0.044811677],"study_design_scores_gemma":[0.027375728,0.0043479954,0.9648982,0.00012059954,0.000019309562,0.000113040776,0.00017586644,0.0001327331,0.00024080655,0.000113926944,0.002332166,0.00012962817],"about_ca_topic_score_codex":0.00006765335,"about_ca_topic_score_gemma":0.00029990668,"teacher_disagreement_score":0.07230503,"about_ca_system_score_codex":0.0010021742,"about_ca_system_score_gemma":0.00023772728,"threshold_uncertainty_score":0.9997854},"labels":[],"label_agreement":null},{"id":"W4313251443","doi":"10.1038/s41598-022-26650-9","title":"Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer","year":2022,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of British Columbia","funders":"NHLBI Division of Intramural Research; National Heart, Lung, and Blood Institute","keywords":"COPD; Lung cancer; Bronchoalveolar lavage; Medicine; Downregulation and upregulation; Pathology; Lung; Parenchyma; Immunohistochemistry; Immunology; Internal medicine; Gene; Biology","score_opus":0.010930470186087303,"score_gpt":0.263466338509435,"score_spread":0.25253586832334773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313251443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948261,0.0017870613,0.0000025003749,0.00022386876,0.0014085966,0.0014477272,0.000011912113,0.00003676092,0.00025551548],"genre_scores_gemma":[0.9964661,0.000013269336,0.00023162627,0.0001219197,0.00002391879,0.00041217904,0.00013866283,0.00001965816,0.0025726785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980934,0.000036481022,0.0003248778,0.00060045236,0.0006573958,0.00028734887],"domain_scores_gemma":[0.9991937,0.00001034086,0.0001959828,0.0004134837,0.0000870793,0.00009938111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006333375,0.00013290187,0.00020581989,0.00016051238,0.00033426605,0.00007283375,0.00005319449,0.00003563766,0.00034381053],"category_scores_gemma":[0.000018494808,0.000098080585,0.000039886298,0.00050844625,0.00013409178,0.000094663126,0.000082086335,0.00015602265,3.0584874e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015323345,0.0003347577,0.9630632,0.00009830039,0.0000388504,0.00020884575,0.0007825397,0.000009334445,0.012726996,5.375482e-7,0.016149452,0.0050548953],"study_design_scores_gemma":[0.006329577,0.00068131834,0.8413782,0.00064215204,0.00010857378,0.00012618156,0.00039932682,0.0001973715,0.05010718,0.00004938098,0.0995455,0.00043524313],"about_ca_topic_score_codex":0.0001491306,"about_ca_topic_score_gemma":0.0000456832,"teacher_disagreement_score":0.12168496,"about_ca_system_score_codex":0.00018748925,"about_ca_system_score_gemma":0.00026742386,"threshold_uncertainty_score":0.39996102},"labels":[],"label_agreement":null},{"id":"W4313351584","doi":"10.4049/jimmunol.190.supp.170.36","title":"Colorectal tumor-specific regulatory and effector CD4+ T cell responses: translating laboratory results to the clinic (P2159)","year":2013,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"ELISPOT; FOXP3; T cell; Immune system; Regulatory T cell; Immunology; Immunotherapy; Tumor microenvironment; Cancer research; Epitope; Colorectal cancer; Tumor-infiltrating lymphocytes; Biology; Population; Cytotoxic T cell; Antigen; Regulatory B cells; Cancer immunotherapy; Medicine; Cancer; IL-2 receptor; Interleukin 10; Internal medicine; In vitro","score_opus":0.013442176985402517,"score_gpt":0.26026104850507037,"score_spread":0.24681887151966786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313351584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9707054,0.018477982,0.000015115896,0.009344706,0.0005972186,0.0005046175,0.000012899619,0.000014000379,0.0003280658],"genre_scores_gemma":[0.99673927,0.0011760478,0.00018261344,0.0011732318,0.00026219443,0.000008907647,0.0000010232371,0.000023437804,0.0004332907],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978579,0.00081015594,0.00072565075,0.0001311724,0.00020707115,0.00026800865],"domain_scores_gemma":[0.9978198,0.0010930747,0.0004341893,0.00035299343,0.00022608043,0.000073870455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027588173,0.00016262017,0.0003737411,0.00013435954,0.00018938846,0.000025894537,0.0002815607,0.000099929006,0.00018013568],"category_scores_gemma":[0.00020010618,0.00008363998,0.0001228667,0.00026837195,0.0003730389,0.00008799321,0.000039620314,0.00058979954,0.000083284096],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034479264,0.000071122624,0.00043559066,0.000018289127,0.000261014,0.000028567198,0.0037387747,0.0000018064046,0.9324543,0.000003332929,0.01475127,0.013756653],"study_design_scores_gemma":[0.01852818,0.01259596,0.66820174,0.00055233674,0.00034662246,0.0030270938,0.009150075,0.000020250101,0.14738101,0.000064735534,0.139709,0.00042298826],"about_ca_topic_score_codex":0.00004291612,"about_ca_topic_score_gemma":0.0000121542125,"teacher_disagreement_score":0.78507334,"about_ca_system_score_codex":0.00008492846,"about_ca_system_score_gemma":0.00021640428,"threshold_uncertainty_score":0.34107393},"labels":[],"label_agreement":null},{"id":"W4313359080","doi":"10.4049/jimmunol.200.supp.109.19","title":"Structural, functional, and evolutionary differences between PD-L1 and PD-L2","year":2018,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Surface plasmon resonance; PD-L1; Immune system; Ligand (biochemistry); Cell biology; Cancer immunotherapy; Receptor; T cell; Chemistry; Biology; Monoclonal antibody; Immunotherapy; Biophysics; Molecular biology; Antibody; Biochemistry; Immunology; Materials science; Nanotechnology","score_opus":0.030284380135460694,"score_gpt":0.2701722409953366,"score_spread":0.2398878608598759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313359080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733963,0.020994112,0.000038387905,0.0049948744,0.00036438758,0.00006360113,0.0000034284674,0.0000058424066,0.00013909437],"genre_scores_gemma":[0.9956733,0.0031283956,0.00010734241,0.00033266546,0.0004966047,4.990031e-7,0.0000014407891,0.000005969648,0.00025380563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993293,0.00009396791,0.000260599,0.000068139445,0.000119756136,0.00012822033],"domain_scores_gemma":[0.9993494,0.00017703309,0.00019262983,0.00011042232,0.00013546197,0.000035066565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026524032,0.000090773014,0.0002323244,0.00008836976,0.00017732292,0.000009126422,0.00008222641,0.00007481726,0.000263641],"category_scores_gemma":[0.000038548395,0.000049321057,0.000042843254,0.00007816466,0.0008706682,0.00007864797,0.000042049316,0.00021707594,0.000003396696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036003552,0.000104857405,0.45154592,0.000079352925,0.005239746,0.000033040662,0.00368594,5.9503424e-7,0.32876793,0.00040606537,0.020540513,0.15359248],"study_design_scores_gemma":[0.0015752595,0.0016995986,0.9875251,0.000054304375,0.00015192809,0.0021753113,0.00042649562,0.000006304239,0.00074088585,0.0011668028,0.0044210595,0.000056961748],"about_ca_topic_score_codex":0.000057022567,"about_ca_topic_score_gemma":0.0000062685563,"teacher_disagreement_score":0.53597915,"about_ca_system_score_codex":0.00003289131,"about_ca_system_score_gemma":0.00007345542,"threshold_uncertainty_score":0.32080135},"labels":[],"label_agreement":null},{"id":"W4313366294","doi":"10.4049/jimmunol.202.supp.71.5","title":"A powerful ICOS agonist that enhances anti-tumor immune responses restored by immune checkpoint inhibitors","year":2019,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"CD28; Cancer research; Immune system; CD8; T cell; Cytotoxic T cell; Chemistry; Avidity; Molecular biology; Cell biology; Biology; Antibody; Immunology; Biochemistry; In vitro","score_opus":0.01156100531116554,"score_gpt":0.2624896223480312,"score_spread":0.25092861703686564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313366294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92449915,0.06628641,0.00002137624,0.006222043,0.0020115953,0.00039282217,0.000011945531,0.000027200937,0.0005274488],"genre_scores_gemma":[0.9900171,0.0063665626,0.000070255235,0.0004814222,0.00016006042,0.0000034817233,0.000007747098,0.000044473818,0.00284887],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972556,0.00048641718,0.0011719081,0.00019117491,0.00042185737,0.00047299583],"domain_scores_gemma":[0.9973244,0.0003710305,0.0012987654,0.00071024575,0.00022850596,0.000067074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021073387,0.00030615134,0.0008924159,0.00026440428,0.00015946089,0.00003656588,0.0005702622,0.00017084352,0.00067302986],"category_scores_gemma":[0.00018859477,0.00018872952,0.00048268528,0.0003126447,0.00061591127,0.00020017641,0.00010936872,0.00082159595,0.0001168736],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024843942,0.00021761554,0.0013726878,0.00003052426,0.0008508936,0.00006001252,0.00083354797,7.4976884e-7,0.96785605,0.000009199949,0.001985654,0.0019391122],"study_design_scores_gemma":[0.005779862,0.0034104723,0.065683074,0.0004537191,0.00019503855,0.0038737212,0.0025612658,0.0000030331564,0.86932254,0.00003884055,0.04844503,0.00023342004],"about_ca_topic_score_codex":0.00027313916,"about_ca_topic_score_gemma":0.000005016721,"teacher_disagreement_score":0.09853353,"about_ca_system_score_codex":0.00023337227,"about_ca_system_score_gemma":0.0004076309,"threshold_uncertainty_score":0.76961666},"labels":[],"label_agreement":null},{"id":"W4313373133","doi":"10.4049/jimmunol.204.supp.164.22","title":"Altering the dendritic cell signature in the lung: a new adjuvant to immune checkpoint inhibitor therapies?","year":2020,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Immune system; Cancer research; Immunotherapy; Lung cancer; Dendritic cell; Immune checkpoint; Tumor microenvironment; Population; Immunology; Antigen; T cell; Antigen presentation; CD8; FOXP3; Medicine; Biology; Oncology","score_opus":0.015717687470427094,"score_gpt":0.2586034995301426,"score_spread":0.24288581205971552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313373133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7888569,0.07776555,0.00024112323,0.13199443,0.00044192147,0.00045196337,0.0000015092106,0.0000098279,0.0002367273],"genre_scores_gemma":[0.9864279,0.0023436814,0.000094316114,0.010411697,0.00054846174,0.00000502351,7.361758e-7,0.000021961469,0.00014620561],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983161,0.0003747849,0.00063876965,0.00010599507,0.00026365372,0.00030069097],"domain_scores_gemma":[0.9989152,0.0002893169,0.0002980269,0.00035772863,0.00007836607,0.000061367515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011029439,0.00017965397,0.00038855785,0.00008268007,0.00011398804,0.000028797762,0.00071755727,0.000100274454,0.0001715646],"category_scores_gemma":[0.00011192297,0.000075726384,0.00022641571,0.0004126266,0.00014226795,0.00006459529,0.00008710428,0.0010810895,0.000015461374],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006595997,0.000077642624,0.00009404849,0.000025537382,0.0003029701,0.00008199851,0.02639927,0.000027225624,0.9560344,0.000019708392,0.0039173984,0.006423759],"study_design_scores_gemma":[0.03182655,0.015717328,0.12785533,0.0018570481,0.0012867252,0.010403382,0.07743015,0.00025080369,0.5031285,0.00075883686,0.22850543,0.0009799015],"about_ca_topic_score_codex":0.00010299968,"about_ca_topic_score_gemma":0.000012228531,"teacher_disagreement_score":0.45290592,"about_ca_system_score_codex":0.000092240894,"about_ca_system_score_gemma":0.00022016233,"threshold_uncertainty_score":0.46968558},"labels":[],"label_agreement":null},{"id":"W4313373184","doi":"10.4049/jimmunol.204.supp.242.16","title":"Tumor intrinsic mechanisms of immunosuppression in CD8 T cell function and response to lung cancer","year":2020,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; University of British Columbia","funders":"","keywords":"Tumor microenvironment; Chemokine; CD8; Cancer research; Immune system; Lung cancer; Immunotherapy; T cell; Cytokine; Immunology; Immunosuppression; Downregulation and upregulation; Cytotoxic T cell; Biology; Medicine; In vitro; Oncology","score_opus":0.010711137682155659,"score_gpt":0.26002092529900234,"score_spread":0.2493097876168467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313373184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778035,0.012432632,0.0005557333,0.008704345,0.00028887086,0.00018503194,0.0000023556615,0.000004229566,0.00002328566],"genre_scores_gemma":[0.9971019,0.0012070695,0.000126205,0.0014659343,0.000046061763,0.0000027828448,3.0532925e-7,0.000010523732,0.00003920327],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99900407,0.00025382242,0.0004185964,0.00007186219,0.00012363419,0.00012804667],"domain_scores_gemma":[0.9993247,0.00013982563,0.00027973298,0.00012352537,0.00009039049,0.000041838724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006825009,0.00008881726,0.0002995065,0.0001500006,0.000031012296,0.0000036138274,0.0001186517,0.000054858123,0.00013668733],"category_scores_gemma":[0.00008937797,0.000055617696,0.00005748004,0.00023858402,0.00007005376,0.000052728203,0.000056157653,0.00028380033,0.0000013712187],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.108600855,0.00004325809,0.0005642011,0.000031271815,0.000113181326,0.000015185813,0.0015326915,0.000012563966,0.88323003,0.0000094749275,0.00027996858,0.0055672964],"study_design_scores_gemma":[0.010857238,0.0077389046,0.2589321,0.00058400823,0.00028468505,0.00046119135,0.0029139323,0.00007356011,0.71571326,0.00019467561,0.002102395,0.00014404164],"about_ca_topic_score_codex":0.0000999281,"about_ca_topic_score_gemma":0.0000063337825,"teacher_disagreement_score":0.25836793,"about_ca_system_score_codex":0.00008359572,"about_ca_system_score_gemma":0.00015743815,"threshold_uncertainty_score":0.22680238},"labels":[],"label_agreement":null},{"id":"W4313380390","doi":"10.4049/jimmunol.198.supp.56.11","title":"Small molecule drug inhibition of PD-1 transcription is as effective as anti-PD-1 biologic blockade in cancer therapy","year":2017,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Cancer research; CD8; Cytotoxic T cell; Adoptive cell transfer; GSK-3; Kinase; Chemistry; Biology; T cell; Cell biology; Immune system; Immunology; Biochemistry; In vitro","score_opus":0.025301251321000195,"score_gpt":0.3026982235633807,"score_spread":0.2773969722423805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313380390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97401017,0.017416786,0.000015995636,0.007380926,0.00040434647,0.0003802551,0.0000056740614,0.000005977053,0.00037985385],"genre_scores_gemma":[0.9746627,0.024259098,0.000016000775,0.00080522156,0.00009021189,0.000010041485,0.0000015962966,0.000013403934,0.00014171659],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99881256,0.00028229604,0.00046236193,0.0001102817,0.00013031295,0.00020217516],"domain_scores_gemma":[0.99867743,0.000090422815,0.0007235163,0.00031810216,0.0001650025,0.000025494995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008025898,0.00015102018,0.00045215304,0.00018085215,0.00012417609,0.000011439233,0.0002519657,0.00014776342,0.00022079943],"category_scores_gemma":[0.00006061508,0.00009116595,0.00019866382,0.00010218826,0.0004241387,0.00009345267,0.00002221258,0.00041843933,0.000006148558],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011895702,0.00020611536,0.0027391142,0.000017876211,0.00048113984,0.000029039304,0.002615726,0.000005594452,0.9646148,0.0000131697225,0.00009886306,0.017282832],"study_design_scores_gemma":[0.0063438797,0.0021475852,0.21702902,0.0003226767,0.0000858503,0.00035776687,0.0005091933,0.000004445513,0.7721366,0.0003867663,0.00059066113,0.00008554752],"about_ca_topic_score_codex":0.0023404344,"about_ca_topic_score_gemma":0.00010191408,"teacher_disagreement_score":0.21428992,"about_ca_system_score_codex":0.00012679746,"about_ca_system_score_gemma":0.00015916987,"threshold_uncertainty_score":0.37176397},"labels":[],"label_agreement":null},{"id":"W4313381160","doi":"10.4049/jimmunol.202.supp.194.41","title":"TNF superfamily cytokines overcome immune evasion in medulloblastoma","year":2019,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; BC Cancer Agency; Canada's Michael Smith Genome Sciences Centre; Hospital for Sick Children","funders":"","keywords":"Cytotoxic T cell; Tumor necrosis factor alpha; Major histocompatibility complex; Biology; Immune system; Cancer research; MHC class I; CD8; Immunotherapy; Lymphotoxin; Immunology; In vitro","score_opus":0.010936645788102394,"score_gpt":0.25418837817547063,"score_spread":0.24325173238736825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313381160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97976714,0.015476478,0.00000954204,0.002796279,0.00096399646,0.00021647276,0.0000010599654,0.000008644854,0.00076035876],"genre_scores_gemma":[0.99498045,0.003669011,0.000056355355,0.0005850898,0.00009464237,0.0000013172205,0.0000011855924,0.000017581371,0.0005943345],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99864566,0.00018667536,0.00061976776,0.00008331926,0.00021915602,0.00024544465],"domain_scores_gemma":[0.9990301,0.00019238473,0.00028473104,0.0003401112,0.00012549339,0.000027144864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010022124,0.00013780083,0.0004660919,0.00025285268,0.00003593542,0.000006704196,0.00028532612,0.00012475843,0.0004960703],"category_scores_gemma":[0.00006192229,0.00007935716,0.000176421,0.00027230804,0.0001455417,0.000112873335,0.000055265857,0.0004966596,0.000070753595],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012818911,0.00012959757,0.010980332,0.000020507716,0.00028104574,0.000039163817,0.0005882662,0.00001048096,0.9645274,0.000034816625,0.00020126194,0.010368201],"study_design_scores_gemma":[0.010831325,0.0037130318,0.8845191,0.0004999077,0.00011081291,0.004737541,0.0016680588,0.00002342557,0.077794515,0.00016685844,0.015773343,0.00016207244],"about_ca_topic_score_codex":0.00016182441,"about_ca_topic_score_gemma":0.000017091066,"teacher_disagreement_score":0.8867329,"about_ca_system_score_codex":0.0001577592,"about_ca_system_score_gemma":0.0001585706,"threshold_uncertainty_score":0.54316217},"labels":[],"label_agreement":null},{"id":"W4313381379","doi":"10.4049/jimmunol.202.supp.194.5","title":"T-Cell Intrinsic Mechanisms of Resistance to PD-1 Checkpoint Blockade","year":2019,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Blockade; Immune checkpoint; T-cell receptor; T cell; Signal transduction; Biology; Cancer immunotherapy; Immunotherapy; CD28; Immune system; CD8; Cell biology; Antigen; Cancer research; Receptor; Immunology; Computational biology; Genetics","score_opus":0.008722862220280849,"score_gpt":0.23846772786038173,"score_spread":0.22974486564010088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313381379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860678,0.0059229424,0.0005015207,0.0050683036,0.00057226134,0.00022236723,0.0000018635477,0.000005844782,0.0016370992],"genre_scores_gemma":[0.99485564,0.00075866847,0.0007738711,0.00061384734,0.000060778093,0.0000010036612,3.770969e-7,0.00001376382,0.002922033],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989359,0.000098758996,0.00052577513,0.00007180495,0.00018963545,0.0001781411],"domain_scores_gemma":[0.99889106,0.000102122474,0.00043651598,0.00035000918,0.00018286146,0.00003743048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007680819,0.00010171074,0.00038466864,0.0001498276,0.000026719224,0.0000031964937,0.00027196988,0.00007918213,0.00035634643],"category_scores_gemma":[0.000044107248,0.00006192964,0.00015070035,0.00021176529,0.00008569866,0.00003348706,0.000048146132,0.00028664767,0.000047394897],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01143723,0.000090766465,0.000091432106,0.000034992278,0.0002592519,0.000009636701,0.000627414,0.0000036760846,0.9848824,0.00014040199,0.0007915632,0.0016312097],"study_design_scores_gemma":[0.0039750654,0.002569191,0.011232739,0.00023806136,0.00012663956,0.0004687588,0.0010925283,0.0000011914475,0.9661016,0.00078627776,0.013319411,0.00008855059],"about_ca_topic_score_codex":0.000024596306,"about_ca_topic_score_gemma":0.000006885512,"teacher_disagreement_score":0.01878084,"about_ca_system_score_codex":0.00008774172,"about_ca_system_score_gemma":0.00014973573,"threshold_uncertainty_score":0.39017436},"labels":[],"label_agreement":null},{"id":"W4313383854","doi":"10.4049/jimmunol.200.supp.112.6","title":"Global phosphoproteomic analysis of PD-1 signaling reveals T cell subset specific PD-1 functions","year":2018,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"T-cell receptor; Jurkat cells; Cell biology; Phosphorylation; Dephosphorylation; T cell; Signal transduction; Immunological synapse; Biology; Tyrosine phosphorylation; Immune system; Cancer research; Immunology; Phosphatase","score_opus":0.016296334571865665,"score_gpt":0.2664401757200053,"score_spread":0.2501438411481396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313383854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857629,0.010227069,0.0015351798,0.00070235867,0.00061078405,0.0001374656,0.000029981114,0.000008457872,0.0009857884],"genre_scores_gemma":[0.99706453,0.0015765311,0.00035785456,0.0002450957,0.00023685583,0.0000011659571,0.000004673616,0.000010310555,0.00050298154],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99848694,0.00018495484,0.0007647732,0.00010587137,0.0002237303,0.00023373745],"domain_scores_gemma":[0.99822533,0.00012439277,0.00078620523,0.0004056728,0.00041425962,0.000044113163],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010534803,0.00013895026,0.00059644476,0.00028535037,0.00011752723,0.000008483424,0.00028192758,0.00011557485,0.002001323],"category_scores_gemma":[0.0000357168,0.00008856066,0.0004348892,0.0011922086,0.00050000753,0.000058139296,0.000035701803,0.00022911234,0.000022844859],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011809263,0.00017155192,0.008661615,0.000011828041,0.005110735,0.000012140654,0.00051132083,0.000044451463,0.96624684,0.000021777327,0.005125254,0.0022732283],"study_design_scores_gemma":[0.009177186,0.0073559266,0.4421441,0.00027527873,0.009992936,0.0015276389,0.0038566918,0.00007750665,0.49828178,0.00043522377,0.026491797,0.00038392184],"about_ca_topic_score_codex":0.0001636499,"about_ca_topic_score_gemma":0.000029629407,"teacher_disagreement_score":0.46796504,"about_ca_system_score_codex":0.00018717578,"about_ca_system_score_gemma":0.000149682,"threshold_uncertainty_score":0.99891096},"labels":[],"label_agreement":null},{"id":"W4313386023","doi":"10.4049/jimmunol.194.supp.69.30","title":"Longitudinal analyses of CD3ζ-chain expression in the correlation of the disease status in a cohort of head and neck cancer patients (TUM2P.1033)","year":2015,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Biomarker; Medicine; Internal medicine; Peripheral blood mononuclear cell; Oncology; Head and neck cancer; Cohort; Cancer; CD3; Stage (stratigraphy); Flow cytometry; Disease; Longitudinal study; Prospective cohort study; Pathology; Immunology; Biology; Antigen; CD8","score_opus":0.036433119989432994,"score_gpt":0.33321363461369496,"score_spread":0.29678051462426197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313386023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98634416,0.012698202,0.000016020516,0.00050491013,0.00015885972,0.0002342127,0.00000964233,6.7416715e-7,0.00003334292],"genre_scores_gemma":[0.9980278,0.0018628128,0.000015726475,0.000054854972,0.000016194499,0.0000029040184,0.000001747854,0.0000048167103,0.000013163834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986263,0.00037740293,0.0005634628,0.00005598955,0.00026156157,0.00011528007],"domain_scores_gemma":[0.9987424,0.00015633536,0.00068392936,0.00019981584,0.00019187032,0.000025634994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077517,0.00007897963,0.00031070277,0.00013363702,0.000020580197,0.0000017933885,0.00015365418,0.000047878042,0.00001657159],"category_scores_gemma":[0.00018996396,0.00003514186,0.0000746335,0.0002672484,0.00029223572,0.00005782342,0.00004009583,0.0002150724,7.3432886e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012289019,0.0002834676,0.9493945,0.000026884012,0.0001517507,0.000002570419,0.0029639665,0.00019649591,0.03289979,0.000004764286,0.000099114724,0.0016876439],"study_design_scores_gemma":[0.0042167953,0.00070706796,0.9878522,0.0005351292,0.00014628212,0.000013597487,0.0010786577,0.0000661247,0.0052229613,0.0000832731,0.000046307487,0.000031565065],"about_ca_topic_score_codex":0.0015514574,"about_ca_topic_score_gemma":0.00024558368,"teacher_disagreement_score":0.038457703,"about_ca_system_score_codex":0.00008078995,"about_ca_system_score_gemma":0.00022907763,"threshold_uncertainty_score":0.234535},"labels":[],"label_agreement":null},{"id":"W4313389229","doi":"10.3390/cancers15010276","title":"Tumor Microenvironment before and after Chemoradiation in Locally Advanced Rectal Cancer: Beyond PD-L1","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northeast Cancer Centre","funders":"","keywords":"Colorectal cancer; Tumor microenvironment; Medicine; Cancer research; Cancer; Oncology; Internal medicine","score_opus":0.003951185176001459,"score_gpt":0.22379044838712528,"score_spread":0.21983926321112382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313389229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895797,0.0081149,0.0000044175545,0.0011410572,0.00032946852,0.00046951577,0.00006792159,0.000019210729,0.00027383],"genre_scores_gemma":[0.9942053,0.0008618839,0.00012270136,0.0033515561,0.000081548016,0.00065740285,0.000029234743,0.000025186271,0.00066518487],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99904317,0.000024006484,0.00020065512,0.0002961552,0.00019817798,0.00023786686],"domain_scores_gemma":[0.9996782,0.00000875002,0.00007328424,0.00015573544,0.000009244705,0.00007478618],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000111864174,0.00013389224,0.00020419947,0.00008755898,0.000075215015,0.000008140194,0.000055740125,0.00002696649,0.001063956],"category_scores_gemma":[0.000004410178,0.00013626638,0.00005345772,0.00020014442,0.00009468724,0.00006344003,0.000045435245,0.00018635295,0.0000018490492],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03314377,0.00013589535,0.2424781,0.0003358451,0.00026999874,0.00040763215,0.005736339,0.0026088953,0.098457664,0.00001340006,0.0048314314,0.611581],"study_design_scores_gemma":[0.013718863,0.0015145583,0.8264185,0.00024702263,0.00009911689,0.0001433228,0.0020352963,0.0011103563,0.010648537,0.00006484473,0.14349751,0.0005020269],"about_ca_topic_score_codex":0.00065450853,"about_ca_topic_score_gemma":0.0013056004,"teacher_disagreement_score":0.611079,"about_ca_system_score_codex":0.0041898624,"about_ca_system_score_gemma":0.00040976622,"threshold_uncertainty_score":0.9998492},"labels":[],"label_agreement":null},{"id":"W4313405911","doi":"10.4049/jimmunol.208.supp.121.03","title":"Metabolic reprogramming of antitumor CD8+ T cells by modulation of GSH-Gpx4 axis","year":2022,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Cytotoxic T cell; CD8; Tumor microenvironment; Cell biology; Glutathione; T cell; Biology; Effector; Immune system; Cancer research; Chemistry; Immunology; Biochemistry; In vitro","score_opus":0.012994518932548191,"score_gpt":0.26033586992210694,"score_spread":0.24734135098955876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313405911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734268,0.024921358,0.00023970567,0.00074915716,0.0004112044,0.00013688367,0.000010359367,0.000004474822,0.000100044505],"genre_scores_gemma":[0.997232,0.002119474,0.00025147124,0.000095649586,0.000038874325,0.0000020104737,0.0000030203166,0.000011049711,0.00024641483],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987107,0.00023315042,0.0006202098,0.00006434027,0.00023821989,0.00013338894],"domain_scores_gemma":[0.99860936,0.00009028281,0.0008752554,0.00026717986,0.0001412415,0.000016687944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011373427,0.00007950705,0.00039907257,0.00014997675,0.00007308379,0.0000020653895,0.00021241736,0.00003643365,0.00033675396],"category_scores_gemma":[0.000038335074,0.00005427679,0.00017585559,0.00027747787,0.0001856746,0.00004668502,0.000058667778,0.00027926444,7.615828e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038191606,0.0001790915,0.0005552445,0.000017545399,0.0005770193,0.0000053332797,0.00079731725,0.000060460035,0.96641415,0.000042707983,0.00052480213,0.027007157],"study_design_scores_gemma":[0.0046015554,0.0033841513,0.028383635,0.00006948757,0.00042683343,0.0012803791,0.0025460597,0.00008366336,0.91512656,0.00017551646,0.043812275,0.000109863526],"about_ca_topic_score_codex":0.00020495337,"about_ca_topic_score_gemma":0.0000016798049,"teacher_disagreement_score":0.051287584,"about_ca_system_score_codex":0.000045704845,"about_ca_system_score_gemma":0.0001015136,"threshold_uncertainty_score":0.36872196},"labels":[],"label_agreement":null},{"id":"W4313406001","doi":"10.4049/jimmunol.208.supp.110.20","title":"Modulating levels of cell surface CD6 is a novel mechanism for regulating T cell activity.","year":2022,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"T cell; IL-2 receptor; Cell biology; Chemistry; Cytotoxic T cell; Cell; Cytokine; Cell growth; Receptor; Immune system; Biology; Immunology; Biochemistry","score_opus":0.035580642667901605,"score_gpt":0.27751142202001167,"score_spread":0.24193077935211005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313406001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98907036,0.0011492758,0.0072171865,0.0016803463,0.0003893797,0.0002633007,0.00003443185,0.000006437238,0.00018926081],"genre_scores_gemma":[0.9937757,0.00007329307,0.0048599984,0.000343625,0.00005895923,0.00000283867,7.331579e-7,0.000024445304,0.0008603998],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998822,0.00013360941,0.00049684907,0.00009150479,0.0002368351,0.00021925656],"domain_scores_gemma":[0.99820876,0.00033437292,0.0009860742,0.00024914677,0.00019932854,0.000022302645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011931858,0.00011937434,0.00039004468,0.00009437532,0.00021542663,0.0000043998994,0.00024703355,0.00006151396,0.00019701998],"category_scores_gemma":[0.000040535808,0.000087210086,0.00022907912,0.00017911759,0.00007762594,0.00005801321,0.000102200036,0.00039071098,4.367421e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004213096,0.00018580141,0.000031844967,0.000050319144,0.00024607824,0.0000016994669,0.0020587894,0.00026862597,0.9899222,0.00005398887,0.000106652034,0.002860859],"study_design_scores_gemma":[0.0056214,0.0024866192,0.0021381716,0.000053365522,0.00018044631,0.0004836247,0.0025570309,0.0015837917,0.98390985,0.00044689904,0.00043896562,0.00009983376],"about_ca_topic_score_codex":0.000083621795,"about_ca_topic_score_gemma":0.0000015401233,"teacher_disagreement_score":0.006012394,"about_ca_system_score_codex":0.00014061986,"about_ca_system_score_gemma":0.00019341393,"threshold_uncertainty_score":0.35563242},"labels":[],"label_agreement":null},{"id":"W4313408129","doi":"10.4049/jimmunol.208.supp.180.03","title":"Peripheral CD4 T cell resistance to type I interferon defines outcome of PD1 blockade therapy in human cancer","year":2022,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Immune system; Blockade; Immune checkpoint; Immunology; Medicine; Immunotherapy; Myeloid; Interferon; Cancer; Inflammation; Melanoma; Mass cytometry; Effector; Cancer research; Cell; T cell; Biology; Receptor; Internal medicine; Phenotype","score_opus":0.029970071676826818,"score_gpt":0.3147562028167405,"score_spread":0.2847861311399137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313408129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9712777,0.022249257,0.000005237138,0.005301969,0.00055915804,0.00016355573,0.0000069683297,0.0000045518955,0.00043157008],"genre_scores_gemma":[0.99482137,0.0016709536,0.00006206454,0.00089990976,0.000069022506,0.000007184041,0.0000012406757,0.000016492222,0.002451772],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986674,0.00021535715,0.0006651618,0.00008394033,0.00018245161,0.00018569968],"domain_scores_gemma":[0.99915606,0.000066984605,0.0003951896,0.00024580205,0.000112567184,0.00002339631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006850532,0.00011195878,0.00038717006,0.00018161611,0.000084296,0.0000035537564,0.00033394792,0.000042289616,0.0006483513],"category_scores_gemma":[0.000020850719,0.00007407428,0.00010873184,0.00033069696,0.00010934688,0.000027288279,0.00006832236,0.00043831966,9.876237e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045805693,0.00022857786,0.012797011,0.000018454988,0.00025673193,0.000021940374,0.0031705983,0.00011996661,0.93317497,0.000017253433,0.0015255667,0.0028632192],"study_design_scores_gemma":[0.028747244,0.027967995,0.43477395,0.00040153743,0.0002745835,0.00063935353,0.0081541175,0.000009103097,0.3097067,0.00029129762,0.18849409,0.00054003537],"about_ca_topic_score_codex":0.00045971654,"about_ca_topic_score_gemma":0.00029227004,"teacher_disagreement_score":0.6234683,"about_ca_system_score_codex":0.00024249328,"about_ca_system_score_gemma":0.00012645646,"threshold_uncertainty_score":0.70989925},"labels":[],"label_agreement":null},{"id":"W4313427034","doi":"10.4049/jimmunol.208.supp.176.07","title":"Glycogen synthase kinase (GSK-3) synergizes with PD-1/PDL1 blockade to generate super-armed CD8 killers against tumors","year":2022,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"GSK-3; Cancer research; Granzyme B; Immune checkpoint; Granzyme; CD8; Blockade; GSK3B; Biology; Kinase; Chemistry; Immune system; Cell biology; Immunology; Perforin; Immunotherapy; Receptor; Biochemistry","score_opus":0.011593160722235932,"score_gpt":0.23984902336254924,"score_spread":0.2282558626403133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313427034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97985137,0.0076430948,0.000045858087,0.011060716,0.0006783667,0.00036005295,0.000020671981,0.0000273626,0.00031252654],"genre_scores_gemma":[0.99361247,0.0012719593,0.00028451538,0.0036356745,0.00022579795,0.000026602329,0.0000087849385,0.000051346207,0.0008828281],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977474,0.00046620614,0.00065275567,0.0001910131,0.0004616907,0.00048091833],"domain_scores_gemma":[0.99858403,0.00018180681,0.00040715927,0.0004964734,0.00018505879,0.0001454827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010628754,0.00026704915,0.00058691273,0.00035716625,0.00042176587,0.000018972409,0.00054297043,0.00006684682,0.0007626643],"category_scores_gemma":[0.00008788311,0.00016415174,0.00021497837,0.00055794977,0.00030596036,0.00007321578,0.00016171642,0.00073135353,0.00001504167],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06014018,0.0003405981,0.00038545125,0.00001802373,0.0017855478,0.0012099106,0.0017899543,0.0012369975,0.91608226,0.00001530086,0.0040369635,0.01295878],"study_design_scores_gemma":[0.036968026,0.04218124,0.01858648,0.0007276679,0.0019652625,0.04053597,0.03134957,0.00020159535,0.5500824,0.0000717717,0.27582243,0.0015075837],"about_ca_topic_score_codex":0.00014439522,"about_ca_topic_score_gemma":0.000021807948,"teacher_disagreement_score":0.3659999,"about_ca_system_score_codex":0.00038526536,"about_ca_system_score_gemma":0.00055547815,"threshold_uncertainty_score":0.83506393},"labels":[],"label_agreement":null},{"id":"W4313445763","doi":"10.1007/978-1-0716-2914-7_11","title":"Assessing the Efficacy of Immune Checkpoint Inhibitors in Preclinical Tumor Models","year":2023,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Immunotherapy; Immune system; Context (archaeology); Breast cancer; Metastasis; Cancer research; Lung cancer; Cancer; Oncology; Immunology; Internal medicine; Biology","score_opus":0.09342074133338052,"score_gpt":0.4920234129747234,"score_spread":0.3986026716413429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313445763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9020224,0.0023304247,0.092453964,0.0016013399,0.0003907104,0.00051081734,0.0000018581212,0.00003681015,0.00065162574],"genre_scores_gemma":[0.81255406,0.00016293571,0.1866114,0.00047047078,0.00005454111,0.000060385177,0.000018411807,0.000028969731,0.000038800048],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99726987,0.0012861671,0.0008059298,0.00028062717,0.000087094566,0.00027030872],"domain_scores_gemma":[0.9985233,0.000877399,0.0001563427,0.00038717221,0.000029117742,0.000026668222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005203279,0.00012546126,0.00045033218,0.00023891099,0.00002068161,0.0000070618985,0.00016304322,0.00015376386,0.000018664583],"category_scores_gemma":[0.0011122294,0.00008503678,0.00022458225,0.0008538407,0.0002798686,0.000026508778,0.00010644785,0.00034280476,0.0000019381134],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037425564,0.000107276,0.004188148,0.00003182147,0.000052859647,0.00004463574,0.00025723435,0.00019296988,0.93150634,0.00021229826,0.0000070918195,0.063025065],"study_design_scores_gemma":[0.006215606,0.0005042715,0.12555361,0.00041132097,0.000054484764,0.000046911275,0.00054965867,0.010421588,0.84546465,0.009496979,0.0010277029,0.0002532419],"about_ca_topic_score_codex":0.00021296868,"about_ca_topic_score_gemma":0.0000079411475,"teacher_disagreement_score":0.12136546,"about_ca_system_score_codex":0.000056147474,"about_ca_system_score_gemma":0.00011594658,"threshold_uncertainty_score":0.34676993},"labels":[],"label_agreement":null},{"id":"W4313451929","doi":"10.7326/aimcc.2022.0815","title":"Immune Checkpoint Inhibitor-Induced Polyarthritis: A Case Series","year":2023,"lang":"en","type":"article","venue":"Annals of Internal Medicine Clinical Cases","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Nivolumab; Polyarthritis; Ipilimumab; Medicine; Adverse effect; Cancer; Arthritis; Internal medicine; Autoantibody; Immunology; Pembrolizumab; Oncology; Dermatology; Immunotherapy; Antibody","score_opus":0.17279574155638605,"score_gpt":0.44663903390793624,"score_spread":0.2738432923515502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313451929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726483,0.0040899934,0.000004359049,0.019980758,0.0014581747,0.00029479412,0.000030235162,0.00013918878,0.001354167],"genre_scores_gemma":[0.9886594,0.004210539,0.000035974143,0.004037112,0.0015633905,0.000020687012,0.000021628337,0.0000358381,0.001415442],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996692,0.00013986221,0.001953132,0.00037583377,0.00045211817,0.00038705854],"domain_scores_gemma":[0.997442,0.0009633106,0.00042850373,0.00048072793,0.0003859869,0.0002994522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018601916,0.00025468203,0.0010085028,0.00027174182,0.000067728004,0.000010195485,0.00014855628,0.00017902878,0.00073364767],"category_scores_gemma":[0.004084007,0.000185554,0.00057168165,0.0005244059,0.0006671832,0.00012525047,0.00010508307,0.00042468673,0.00006497915],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039921407,0.0012088674,0.03858344,0.00090328336,0.0021048055,0.17007102,0.0013452974,4.6135628e-7,0.10301222,0.00018469588,0.109600656,0.5330638],"study_design_scores_gemma":[0.026915375,0.07530129,0.1827991,0.019169413,0.0006282121,0.21959732,0.01204381,0.00008375657,0.38386557,0.0007591899,0.07762167,0.0012153045],"about_ca_topic_score_codex":0.002119554,"about_ca_topic_score_gemma":0.00016910897,"teacher_disagreement_score":0.53184855,"about_ca_system_score_codex":0.000016472772,"about_ca_system_score_gemma":0.00012820333,"threshold_uncertainty_score":0.80329275},"labels":[],"label_agreement":null},{"id":"W4313453191","doi":"10.1158/1078-0432.ccr-22-2323","title":"Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"National Cancer Institute; Genentech; National Institutes of Health; Institut National de la Santé et de la Recherche Médicale; Regeneron Pharmaceuticals; BeiGene; Daiichi Sankyo Europe; Sanofi; Université de Paris; G1 Therapeutics; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Resampling; Phase (matter); Decision support system; Computer science; Artificial intelligence; Chemistry","score_opus":0.2819218439402065,"score_gpt":0.627311248327568,"score_spread":0.34538940438736154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313453191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987425,0.00013795195,0.0031103522,0.0030532167,0.00066856586,0.0051987483,0.00024746422,0.00006275538,0.00009594128],"genre_scores_gemma":[0.9969908,0.00016539007,0.0003428201,0.0005555723,0.00009930027,0.0013121109,0.000055789715,0.000050725877,0.0004274618],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99535644,0.0004363368,0.0011662068,0.0007560271,0.001742968,0.0005420002],"domain_scores_gemma":[0.99377483,0.0034244738,0.00030119673,0.00093883334,0.0014049177,0.00015575881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011057015,0.00021509983,0.0007559963,0.0003918975,0.00057659054,0.000027008655,0.00038845415,0.00011519927,0.00011477634],"category_scores_gemma":[0.0025204,0.00014605353,0.0004502412,0.0015195287,0.00054216426,0.000054654993,0.00017276518,0.00081779587,0.0000027954131],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5262448,0.07652066,0.054705866,0.0013951011,0.002982493,0.00018012442,0.0033083276,0.007651735,0.02540604,0.00027548126,0.047996238,0.2533331],"study_design_scores_gemma":[0.14365256,0.046571143,0.03801555,0.0010488923,0.00021690666,7.1521725e-7,0.0018432008,0.7652455,0.0012706432,0.00095337443,0.00092426717,0.00025725394],"about_ca_topic_score_codex":0.00009546328,"about_ca_topic_score_gemma":0.00018406258,"teacher_disagreement_score":0.75759375,"about_ca_system_score_codex":0.0014280736,"about_ca_system_score_gemma":0.002420395,"threshold_uncertainty_score":0.59558904},"labels":[],"label_agreement":null},{"id":"W4313469586","doi":"10.3390/curroncol30010006","title":"Solid Organ Transplantation Is Associated with an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; National Center for Advancing Translational Sciences; Swim Across America; Johns Hopkins University","keywords":"Medicine; Immunosuppression; Colorectal cancer; Cohort; Internal medicine; Transplantation; Organ transplantation; Oncology; Population; Cancer; Gastroenterology","score_opus":0.042379572203640845,"score_gpt":0.3755820197621719,"score_spread":0.33320244755853107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313469586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980233,0.00084945635,0.000012053235,0.00032448673,0.000158387,0.00034975877,0.00014444227,0.000029845707,0.00010827856],"genre_scores_gemma":[0.99902046,0.0003935995,0.000034872355,0.00016792172,0.000013259212,0.00012716009,0.0002208997,0.000009668195,0.00001216984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999113,0.00020608454,0.00023887142,0.00018261258,0.00010641147,0.0001530131],"domain_scores_gemma":[0.999601,0.000093027375,0.00013469503,0.000060599905,0.000066597284,0.0000440626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003510931,0.00008158731,0.00023380101,0.00012367671,0.00009421294,0.0000025673912,0.000039668932,0.00004207675,0.00028107635],"category_scores_gemma":[0.00002089335,0.00007316931,0.000032381766,0.00037654446,0.00011168893,0.000041281797,0.000009927489,0.00015493757,2.1659044e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02444373,0.004456079,0.7417191,0.00037957812,0.0003115561,0.00016208513,0.032741085,0.00009476708,0.17114747,0.0000688241,0.0007765287,0.023699189],"study_design_scores_gemma":[0.012847546,0.0052851927,0.9664999,0.00013043659,0.0002954094,0.00012234598,0.0024592164,0.0018287391,0.009223581,0.000053529624,0.001075158,0.00017894193],"about_ca_topic_score_codex":0.00072559505,"about_ca_topic_score_gemma":0.0015950716,"teacher_disagreement_score":0.22478078,"about_ca_system_score_codex":0.0003207966,"about_ca_system_score_gemma":0.00050328625,"threshold_uncertainty_score":0.3077589},"labels":[],"label_agreement":null},{"id":"W4313889865","doi":"10.3390/ijms24021294","title":"Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers","year":2023,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Melanoma; Immunotherapy; Medicine; Cancer immunotherapy; Cancer; Skin cancer; Disease; Oncology; Metastatic melanoma; Ipilimumab; Immunology; Internal medicine; Cancer research","score_opus":0.027342505544428478,"score_gpt":0.33908086782460145,"score_spread":0.311738362280173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313889865","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018290307,0.97959197,0.000023247692,0.00084731134,0.0008709983,0.00025375516,0.000015022713,0.0000032786402,0.00010411044],"genre_scores_gemma":[0.009491554,0.9898422,0.0002711422,0.00018107638,0.00017229553,0.0000056338986,0.000002664265,0.000017443057,0.000016039003],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981473,0.000088645196,0.0007322467,0.00020818341,0.000664755,0.00015887491],"domain_scores_gemma":[0.9987777,0.00016257106,0.000761191,0.0001066494,0.00014099026,0.00005089048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000868754,0.00020101033,0.0006971995,0.0005817513,0.000051711722,0.00006718032,0.0005069511,0.00011333643,0.000018755556],"category_scores_gemma":[0.00003511594,0.00011834375,0.00027579043,0.00042766225,0.00048577628,0.00008253381,0.00006381312,0.0002532872,5.177263e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002854102,0.000020713933,0.0002965136,0.0005264168,0.0015801508,0.0006951481,0.0003484474,0.0000040251125,0.000667101,0.00003456919,0.00007456471,0.99546695],"study_design_scores_gemma":[0.0056447517,0.002862201,0.003248101,0.069238715,0.00097317505,0.02574582,0.0030053325,0.00028231187,0.0005691938,0.00064388866,0.88682437,0.0009621316],"about_ca_topic_score_codex":0.0001754856,"about_ca_topic_score_gemma":0.000053093023,"teacher_disagreement_score":0.9945048,"about_ca_system_score_codex":0.00017060374,"about_ca_system_score_gemma":0.00073945837,"threshold_uncertainty_score":0.4825918},"labels":[],"label_agreement":null},{"id":"W4313890401","doi":"10.3390/cancers15020418","title":"Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer","year":2023,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; Ministry of Education, Culture, Sports, Science and Technology; Society for Immunotherapy of Cancer; Neuroendocrine Tumor Research Foundation","keywords":"Medicine; Internal medicine; Stage (stratigraphy); Microsatellite instability; Oncology; Colorectal cancer; Clinical endpoint; Cohort; Proportional hazards model; Cancer; Randomized controlled trial","score_opus":0.03738400144067851,"score_gpt":0.31949659745710135,"score_spread":0.28211259601642286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313890401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99644935,0.00035427883,0.000001854044,0.0006383192,0.0013237617,0.00097101176,0.00018813869,0.000008739355,0.00006454585],"genre_scores_gemma":[0.9984876,0.00054497796,0.0000032881148,0.000053969437,0.000043547567,0.00013294737,0.000004547488,0.000008666564,0.0007204741],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994063,0.000029936826,0.00021049802,0.00010888646,0.00015599141,0.00008842616],"domain_scores_gemma":[0.99949914,0.00015513998,0.00011105591,0.0001498882,0.00007274384,0.000012031128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021520598,0.00005988818,0.00012729481,0.00005018644,0.000038974587,0.0000038528356,0.000084083396,0.000031446987,0.000024234087],"category_scores_gemma":[0.000049992806,0.000036075387,0.000046963836,0.00019577249,0.00014445225,0.0000161191,0.000029227744,0.00007763187,1.2242745e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008216926,0.000069384994,0.9525091,0.00009367714,0.0005048711,0.0000022672868,0.0075089075,0.00063104596,0.026714467,0.000011256747,0.0013767878,0.002361281],"study_design_scores_gemma":[0.0069876877,0.00032352784,0.9775776,0.00015047134,0.00006817673,6.3880736e-7,0.007109888,0.0029701341,0.0017435241,0.000002475041,0.003031108,0.00003472422],"about_ca_topic_score_codex":0.007113003,"about_ca_topic_score_gemma":0.0034147887,"teacher_disagreement_score":0.025068518,"about_ca_system_score_codex":0.0002694481,"about_ca_system_score_gemma":0.00016249693,"threshold_uncertainty_score":0.9994987},"labels":[],"label_agreement":null},{"id":"W4313893683","doi":"10.3390/curroncol30010060","title":"Impact of Patient Characteristics on the Outcomes of Patients with Gastrointestinal Cancers Treated with Immune Checkpoint Inhibitors","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Gastrointestinal cancer; Colorectal cancer; Esophageal cancer; Gastrointestinal tract; Oncology; Pancreatic cancer; Cancer; Disease; Incidence (geometry); Clinical trial","score_opus":0.0805548172219734,"score_gpt":0.39242524094784,"score_spread":0.3118704237258666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313893683","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6069463,0.3878455,0.000002550761,0.000048432295,0.00056878245,0.0034921186,0.000946452,0.000050078124,0.00009981469],"genre_scores_gemma":[0.025743859,0.97248614,0.000035341018,0.000015091439,0.000109764704,0.00032781714,0.0010936094,0.00013602358,0.000052337895],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976158,0.00016678838,0.0011866105,0.00032098478,0.0003798483,0.00032996325],"domain_scores_gemma":[0.9968381,0.00035449408,0.0019361397,0.0004788133,0.00030540035,0.00008704725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018919379,0.0005052219,0.0024444335,0.00025014207,0.00004002054,0.000005034866,0.00017013273,0.00011993793,0.00009469091],"category_scores_gemma":[0.00011326845,0.00021758222,0.00071243494,0.00051344297,0.00039915516,0.000017593391,0.000047667956,0.00049975415,0.0000060943025],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059277555,0.0015168526,0.15074871,0.005785104,0.0026589895,0.000024369785,0.00017269915,9.1106784e-7,0.000004535907,0.000003351212,0.00028576466,0.83287096],"study_design_scores_gemma":[0.008931187,0.0665997,0.63551426,0.09311551,0.005361968,0.00011666184,0.00015133733,0.000004743363,0.0000314976,0.0000012425896,0.18938985,0.00078200403],"about_ca_topic_score_codex":0.00023467577,"about_ca_topic_score_gemma":0.000019674255,"teacher_disagreement_score":0.83208895,"about_ca_system_score_codex":0.0014297512,"about_ca_system_score_gemma":0.0016641279,"threshold_uncertainty_score":0.8872745},"labels":[],"label_agreement":null},{"id":"W4315630495","doi":"10.1016/j.modpat.2022.100057","title":"In Reply: Programmed Death-Ligand 1 (PD-L1) Immunohistochemistry Calibration","year":2023,"lang":"en","type":"letter","venue":"Modern Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Saskatchewan Health Authority","funders":"National Cancer Institute; National Institutes of Health","keywords":"Immunohistochemistry; Pathology; Medicine","score_opus":0.02819661316858195,"score_gpt":0.30054350351278414,"score_spread":0.2723468903442022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315630495","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14348722,0.0039391313,0.00056652713,0.8464201,0.0018280048,0.0016635732,0.00011068772,0.00046382938,0.0015209143],"genre_scores_gemma":[0.023374058,0.0005496877,0.00045429933,0.9249737,0.003377375,0.0008923119,0.003451478,0.00029120946,0.042635877],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99766034,0.0001040582,0.00059834507,0.0007758733,0.0002840399,0.0005773269],"domain_scores_gemma":[0.9987743,0.00007549506,0.00021865513,0.00082960655,0.000056611356,0.000045358138],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00030648874,0.00037737496,0.0007019973,0.00025352152,0.000055235447,0.000026821928,0.00019193832,0.0013652713,0.000092191316],"category_scores_gemma":[0.000073697636,0.00036054128,0.00023651752,0.0002363296,0.0001731959,0.000056322453,0.00006640364,0.0015587953,0.00004346393],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012980168,0.00009765284,0.00082933425,0.00058616203,0.00015977513,0.015267776,0.00068688375,0.000001677517,0.13825832,0.0000019002479,0.8371456,0.005666858],"study_design_scores_gemma":[0.0064475243,0.0007028382,0.0031699678,0.0006648587,0.00028313862,0.003338619,0.00004494849,0.00072775857,0.016202856,0.0015998981,0.9657528,0.0010647955],"about_ca_topic_score_codex":0.00023961581,"about_ca_topic_score_gemma":0.00001715022,"teacher_disagreement_score":0.12860715,"about_ca_system_score_codex":0.00035560215,"about_ca_system_score_gemma":0.00028200255,"threshold_uncertainty_score":0.99993116},"labels":[],"label_agreement":null},{"id":"W4315650998","doi":"10.1016/j.lungcan.2023.01.006","title":"Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis","year":2023,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; Prevention of Organ Failure","funders":"Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Ipilimumab; Pembrolizumab; Internal medicine; Oncology; Population; Lung cancer; Hazard ratio; Atezolizumab; Docetaxel; Cancer; Confidence interval; Immunotherapy","score_opus":0.07048827422576923,"score_gpt":0.39530272533794564,"score_spread":0.32481445111217644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315650998","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045828903,0.97945905,0.0007732292,0.00039404008,0.00021592752,0.01772302,0.00129214,0.000052729592,0.000044006847],"genre_scores_gemma":[0.00007023825,0.9857399,0.00039038018,0.000578719,0.00021086053,0.0076194815,0.00020655518,0.00014404136,0.0050398638],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9959074,0.00034642228,0.0018293296,0.0010431107,0.00035427872,0.000519451],"domain_scores_gemma":[0.99585676,0.0011328526,0.0015803823,0.0008412773,0.00039540988,0.00019329163],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006992984,0.0009943541,0.011432534,0.00035795386,0.00019686868,0.00006142533,0.0002769402,0.0003537143,0.00018927675],"category_scores_gemma":[0.000042031417,0.0006465807,0.0022496227,0.002406717,0.00012943853,0.000109599365,0.00010437036,0.00044937758,0.0000013799738],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011899151,0.000049555252,0.000046817477,0.756201,0.23265398,0.000008014299,0.0021297708,0.00015290092,0.0000015298448,0.000008653949,0.0008305613,0.0067272694],"study_design_scores_gemma":[0.0033396615,0.00026753402,0.000088042914,0.40141267,0.56480354,0.0000112005255,0.000029129817,0.00016720171,0.0000016436737,0.0000015787489,0.029263131,0.0006146551],"about_ca_topic_score_codex":0.00013895995,"about_ca_topic_score_gemma":0.0013939688,"teacher_disagreement_score":0.35478836,"about_ca_system_score_codex":0.0006599808,"about_ca_system_score_gemma":0.00044368595,"threshold_uncertainty_score":0.99959856},"labels":[],"label_agreement":null},{"id":"W4315754001","doi":"10.1097/hep.0000000000000045","title":"Checkpoint inhibitor hepatotoxicity: pathogenesis and management","year":2023,"lang":"en","type":"review","venue":"Hepatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto Liver Centre; University Health Network","funders":"","keywords":"Pathogenesis; Medicine; Intensive care medicine; Internal medicine","score_opus":0.07329655356148833,"score_gpt":0.3506948007920936,"score_spread":0.27739824723060524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315754001","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003398971,0.9965941,0.000009928828,0.00016513647,0.00054944726,0.0013832519,0.000046546942,0.00017509036,0.000736636],"genre_scores_gemma":[0.00001403924,0.9966527,0.0002142993,0.0003443368,0.00019144968,0.00043169025,0.00011003032,0.00010003322,0.0019414136],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99806535,0.00012230541,0.0006755904,0.0005872426,0.00017138163,0.0003781297],"domain_scores_gemma":[0.99908245,0.000080631486,0.00021766877,0.00046885287,0.00002542846,0.00012498481],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002790728,0.0004096182,0.0019268667,0.0003814769,0.00006748219,0.00001591714,0.000107360465,0.0004699564,0.00010433893],"category_scores_gemma":[0.000018224924,0.0003215768,0.00049729727,0.0004263961,0.00019935609,0.000018104558,0.0001703917,0.00023695569,0.00023815742],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008955885,0.00005111978,0.00024542146,0.046461266,0.0009844896,0.0009732011,0.00001829453,7.2745954e-10,0.0000071148947,0.00013504925,0.0022632868,0.9487712],"study_design_scores_gemma":[0.00064254,0.00013141708,0.000065493485,0.0079242075,0.0014734648,0.0010375093,0.000013193843,0.0000049828827,0.000008031743,0.000024006535,0.9883902,0.0002849275],"about_ca_topic_score_codex":0.0000455443,"about_ca_topic_score_gemma":0.000036504884,"teacher_disagreement_score":0.98612696,"about_ca_system_score_codex":0.00016941434,"about_ca_system_score_gemma":0.00015567067,"threshold_uncertainty_score":0.99992365},"labels":[],"label_agreement":null},{"id":"W4317103528","doi":"10.3390/curroncol30010098","title":"Immune Checkpoint Glycoproteins Have Polymorphism: Are Monoclonal Antibodies Too Specific?","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Monoclonal antibody; Antibody; Immunotherapy; Epitope; Immune system; Immunology; Cancer immunotherapy; Polyclonal antibodies; Monoclonal; clone (Java method); Biology; Immune checkpoint; Medicine; Cancer research; Genetics; Gene","score_opus":0.11665343835683786,"score_gpt":0.3825374220982916,"score_spread":0.2658839837414537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317103528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95603216,0.0229136,0.000077863886,0.011275598,0.004026556,0.00076409336,0.000065571774,0.00031764613,0.0045268917],"genre_scores_gemma":[0.97333384,0.01642106,0.00045027293,0.0005668805,0.0020216636,0.00020938371,0.00038464266,0.00008338757,0.0065288926],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99823856,0.000065965316,0.0005248004,0.00040211383,0.00026690194,0.0005016598],"domain_scores_gemma":[0.9990785,0.00007031394,0.00021979328,0.00039910857,0.00010493607,0.0001273367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035569476,0.00024231993,0.0005622623,0.00025727757,0.0001377663,0.000018930863,0.00016310714,0.0001713724,0.00083805143],"category_scores_gemma":[0.000050808092,0.00020829812,0.00031522138,0.00036457574,0.0002901928,0.000059056612,0.00011490458,0.00036302063,0.0005088681],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008371713,0.0014545073,0.056432728,0.0003723626,0.0005575186,0.0008211859,0.0019971395,0.0000028313414,0.22437163,0.00031657927,0.13382809,0.5714737],"study_design_scores_gemma":[0.004130109,0.0006821265,0.23639041,0.0001889828,0.000051755516,0.0001669473,0.0007761568,0.00007737627,0.017888464,0.0001297891,0.7392782,0.00023967441],"about_ca_topic_score_codex":0.00006994167,"about_ca_topic_score_gemma":0.000027054142,"teacher_disagreement_score":0.6054501,"about_ca_system_score_codex":0.00038364824,"about_ca_system_score_gemma":0.0002167443,"threshold_uncertainty_score":0.91760755},"labels":[],"label_agreement":null},{"id":"W4317548432","doi":"10.1016/j.cllc.2022.12.014","title":"Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade","year":2023,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Foothills Medical Centre; Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Cohort; Oncology; Proportional hazards model; Lung cancer; Framingham Risk Score; non-small cell lung cancer (NSCLC); Atezolizumab; Cancer; Nivolumab; Immunotherapy; Disease","score_opus":0.035899805712855636,"score_gpt":0.36607902581447854,"score_spread":0.33017922010162293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317548432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742953,0.011380514,0.0031838266,0.0006017645,0.00057659094,0.009236044,0.00038487665,0.00022309207,0.00011797288],"genre_scores_gemma":[0.98045987,0.007969065,0.0016413558,0.00032682525,0.00036559734,0.006693626,0.00054954813,0.00021501852,0.0017790926],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.995834,0.00012448044,0.0013570593,0.0010662077,0.00078374654,0.00083452824],"domain_scores_gemma":[0.99647784,0.0005245022,0.00088190427,0.0007892205,0.0010804607,0.00024608008],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013791845,0.00059886836,0.0010712589,0.00018101513,0.0002822197,0.000051298797,0.0002748487,0.00032624157,0.00016818139],"category_scores_gemma":[0.00018126608,0.00041274293,0.0004751695,0.00093715836,0.00022775243,0.00016560465,0.00005445196,0.0005998026,0.0000035379705],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049747985,0.0018942594,0.85593456,0.0007679906,0.0027420102,0.0000057683114,0.001044743,0.010366907,0.01022459,0.0000012554378,0.0006310581,0.066638865],"study_design_scores_gemma":[0.0457264,0.0017164499,0.4613525,0.0014551511,0.0018563474,9.048111e-7,0.000067451394,0.48468864,0.0021928416,0.000004246959,0.00039455164,0.00054451876],"about_ca_topic_score_codex":0.0006674652,"about_ca_topic_score_gemma":0.00026458548,"teacher_disagreement_score":0.47432175,"about_ca_system_score_codex":0.00073836447,"about_ca_system_score_gemma":0.0014528418,"threshold_uncertainty_score":0.99983245},"labels":[],"label_agreement":null},{"id":"W4317746132","doi":"10.3390/curroncol30020111","title":"CD8+ T Cells and PD-L1 Expression as Prognostic Indicators in a Low Prevalence of HPV-Associated Oropharyngeal Squamous Cell Carcinoma","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Health Systems Research Institute","keywords":"Medicine; Basal cell; Oncology; Internal medicine; CD8; Cancer research; Cell; Pathology; Bioinformatics; Immunology; Immune system; Biology; Genetics","score_opus":0.03278939230734031,"score_gpt":0.3354561230288049,"score_spread":0.3026667307214646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317746132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99358153,0.004208154,0.000001350279,0.00011360458,0.0006518777,0.0007146715,0.000034520006,0.000047974972,0.00064633595],"genre_scores_gemma":[0.9981107,0.0013696352,0.000013212349,0.00004426166,0.00005128819,0.0000729311,0.000035670637,0.000018375777,0.00028390886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985687,0.0001630149,0.00040428466,0.00032364897,0.00021161026,0.0003287111],"domain_scores_gemma":[0.99910724,0.00033825624,0.00022443525,0.00017312869,0.00004561237,0.00011132485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003317477,0.00015709033,0.00039399657,0.00044299397,0.00004351373,0.000004558263,0.00010346513,0.00018175936,0.0002539316],"category_scores_gemma":[0.00016058634,0.00013609607,0.00007257865,0.00073999393,0.00018430209,0.000041142142,0.00008625539,0.0002550866,0.00002340072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026878768,0.0019132975,0.8046259,0.0033314999,0.000021905737,0.00019449546,0.0030953235,0.0000027868796,0.13881704,0.000003504955,0.0028780373,0.042428315],"study_design_scores_gemma":[0.007281252,0.002459242,0.92838836,0.00038314212,0.00009721847,0.000014833989,0.00026100944,0.00015897007,0.058154903,0.000016771835,0.0026128956,0.00017142708],"about_ca_topic_score_codex":0.00004864474,"about_ca_topic_score_gemma":0.000021910944,"teacher_disagreement_score":0.123762414,"about_ca_system_score_codex":0.00021131472,"about_ca_system_score_gemma":0.00035026166,"threshold_uncertainty_score":0.5549837},"labels":[],"label_agreement":null},{"id":"W4318025266","doi":"10.1097/spc.0000000000000637","title":"Immunotherapy for older patients with cancer","year":2023,"lang":"en","type":"review","venue":"Current Opinion in Supportive and Palliative Care","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Tolerability; Clinical trial; Immunotherapy; Geriatric oncology; Intensive care medicine; MEDLINE; Cancer; Internal medicine; Adverse effect","score_opus":0.1440418552162001,"score_gpt":0.45456062181625995,"score_spread":0.31051876660005984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318025266","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014367238,0.9916026,0.000036941212,0.000024297375,0.0020963724,0.004060175,0.0019850498,0.000032816635,0.000018103236],"genre_scores_gemma":[0.000017851495,0.99261874,0.000023666991,0.000032044383,0.0003047773,0.0022345008,0.004555912,0.00009210097,0.00012039957],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981791,0.00006339088,0.0006039346,0.00057595863,0.00024121918,0.00033639112],"domain_scores_gemma":[0.9987637,0.0001471595,0.0004277325,0.00021045284,0.00036591155,0.00008503485],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000094584175,0.00047374208,0.0013600391,0.00025919735,0.000071605544,0.000024101559,0.00009301274,0.00019863012,0.000115400435],"category_scores_gemma":[0.000020614845,0.00031899277,0.00035306698,0.0004267627,0.000115221264,0.000054842647,0.000028799828,0.00031430428,0.000005683743],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005576308,0.00009547006,0.025319083,0.052157596,0.0004916821,5.8330585e-7,0.0013386506,3.846267e-8,3.83263e-8,0.00001563686,0.0019046183,0.91811895],"study_design_scores_gemma":[0.004154469,0.0004141852,0.032566953,0.07098837,0.00022871252,3.5137995e-7,0.00026935025,3.9625374e-7,5.05595e-7,0.000005231455,0.89099944,0.00037202376],"about_ca_topic_score_codex":0.000019748002,"about_ca_topic_score_gemma":0.000010466021,"teacher_disagreement_score":0.91774696,"about_ca_system_score_codex":0.0003393961,"about_ca_system_score_gemma":0.0005364772,"threshold_uncertainty_score":0.9999262},"labels":[],"label_agreement":null},{"id":"W4318027372","doi":"10.1016/j.medj.2022.12.007","title":"Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors","year":2023,"lang":"en","type":"article","venue":"Med","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Horizon 2020 Framework Programme; Deutsche Forschungsgemeinschaft; European Commission; Novartis Foundation; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; European Research Council; Krebsliga Schweiz; National Science Foundation","keywords":"Medicine; Immune system; Adverse effect; CXCL10; CXCL9; Immunology; Peripheral blood mononuclear cell; Oncology; Biomarker; Bioinformatics; Internal medicine; Chemokine; Biology","score_opus":0.008574387757537444,"score_gpt":0.23405424898138108,"score_spread":0.22547986122384364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318027372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754274,0.0009544939,0.0000053774984,0.0002324274,0.000108724125,0.00084815704,0.000018039067,0.00011552837,0.00017453817],"genre_scores_gemma":[0.9986265,0.000073386596,0.00021455204,0.000037939364,0.00001976378,0.00014595542,0.0001850311,0.000040061266,0.00065685244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821246,0.000039444447,0.00063073356,0.00027644317,0.00049503846,0.00034589297],"domain_scores_gemma":[0.99925435,0.000028938515,0.00022558974,0.0003003246,0.00013358798,0.00005723084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031265122,0.00024134757,0.00052030734,0.0002824619,0.00006402541,0.000007880847,0.00009557044,0.00011414057,0.00015813383],"category_scores_gemma":[0.000021873828,0.00015590269,0.00007348316,0.0011127729,0.00013553472,0.00006586357,0.00004128409,0.00020989934,0.0000041252856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02722682,0.001000281,0.57364094,0.0003579023,0.0011385634,0.000055787696,0.004036752,0.000101044636,0.35920098,0.0000014926972,0.00023012633,0.033009287],"study_design_scores_gemma":[0.008287361,0.00054144685,0.7312332,0.0008252006,0.000040681723,9.625802e-7,0.00013362113,0.000028708893,0.25824,6.019098e-7,0.00051661604,0.00015158644],"about_ca_topic_score_codex":0.00088818185,"about_ca_topic_score_gemma":0.00029851514,"teacher_disagreement_score":0.15759224,"about_ca_system_score_codex":0.00028827056,"about_ca_system_score_gemma":0.00035629745,"threshold_uncertainty_score":0.6357527},"labels":[],"label_agreement":null},{"id":"W4318169575","doi":"10.1002/advs.202206756","title":"An Ionic Liquid Ablation Agent for Local Ablation and Immune Activation in Pancreatic Cancer","year":2023,"lang":"en","type":"article","venue":"Advanced Science","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"National Key Research and Development Program of China; Natural Science Foundation of Zhejiang Province; National Natural Science Foundation of China","keywords":"Immunotherapy; Immune system; Cancer research; Medicine; Immunogenicity; Immunology; Pancreatic cancer; Cytotoxic T cell; Cancer; Biology; Internal medicine","score_opus":0.02124045493162778,"score_gpt":0.3383301570409507,"score_spread":0.3170897021093229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318169575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841909,0.00024923045,0.014185416,0.0006146216,0.00013188159,0.00052305043,0.0000023352936,0.0000506524,0.000051920877],"genre_scores_gemma":[0.99860585,0.00037111732,0.000596766,0.00017744997,0.000029554903,0.00009388193,0.000022499831,0.000008078223,0.0000947961],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99914616,0.000012203852,0.00017677332,0.00026086814,0.00019479652,0.00020921552],"domain_scores_gemma":[0.99961406,0.00005348834,0.00006637185,0.00014919037,0.00007443189,0.000042430536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047270858,0.000072665774,0.00011238834,0.00020268465,0.0001459699,0.000018805276,0.00005883058,0.000031714106,0.000012572687],"category_scores_gemma":[0.0000628234,0.000065238004,0.000020060663,0.0009864881,0.0001829586,0.00054835965,0.000011099962,0.000048468806,0.000001799134],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013326656,0.000024112302,0.0012571601,0.000036763257,0.000004717704,5.3749653e-7,0.0005102905,0.005138695,0.8565943,0.00011123371,0.000005932295,0.13498357],"study_design_scores_gemma":[0.0038728816,0.0012431082,0.6200426,0.0004621805,0.000023219722,0.0000043785226,0.00107156,0.15494652,0.2166937,0.0005341761,0.00086707843,0.00023855134],"about_ca_topic_score_codex":0.00016236768,"about_ca_topic_score_gemma":0.000071853065,"teacher_disagreement_score":0.6399006,"about_ca_system_score_codex":0.0002685374,"about_ca_system_score_gemma":0.00016584805,"threshold_uncertainty_score":0.26603287},"labels":[],"label_agreement":null},{"id":"W4318478559","doi":"10.1093/ckj/sfad014","title":"Immunotherapy in oncology and the kidneys: a clinical review of the evaluation and management of kidney immune-related adverse events","year":2023,"lang":"en","type":"review","venue":"Clinical Kidney Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital du Sacré-Cœur de Montréal; Université Laval; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Immunotherapy; Adverse effect; Kidney cancer; Intensive care medicine; Immune system; Oncology; Internal medicine; Immunology; Renal cell carcinoma","score_opus":0.14517849381463163,"score_gpt":0.5022353193505009,"score_spread":0.35705682553586926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318478559","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014653258,0.9853215,0.0000026417463,0.007903007,0.002028537,0.004066661,0.000039031038,0.000009369497,0.00048267754],"genre_scores_gemma":[0.000017973374,0.9941019,0.00011323243,0.005034124,0.00016812074,0.00010139192,0.00003699953,0.000055341978,0.00037090722],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9856837,0.005583146,0.007186743,0.00046181885,0.00077944703,0.0003051453],"domain_scores_gemma":[0.9912621,0.0020407662,0.004845147,0.00095684646,0.0003239895,0.00057116663],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.035110187,0.00041053118,0.0040563205,0.00018593798,0.000108510096,0.0000078931025,0.00056043244,0.0006518933,0.000270323],"category_scores_gemma":[0.00889218,0.00020256627,0.0024843903,0.00083102396,0.0013560855,0.000057959416,0.00028296435,0.0020744044,0.00000824303],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001596384,0.0003910246,0.0007039782,0.041598275,0.004200281,0.000024171262,0.000055459714,3.6256047e-8,4.8472174e-7,0.000052204818,0.0093384255,0.94203925],"study_design_scores_gemma":[0.017289355,0.00047086552,0.004975691,0.30750597,0.005030591,0.0003534023,0.000044569144,0.000015200503,1.5440051e-7,0.0002172176,0.66393936,0.00015762754],"about_ca_topic_score_codex":0.000020529631,"about_ca_topic_score_gemma":0.0000014042303,"teacher_disagreement_score":0.94188166,"about_ca_system_score_codex":0.00020889289,"about_ca_system_score_gemma":0.0040469575,"threshold_uncertainty_score":0.99945635},"labels":[],"label_agreement":null},{"id":"W4318708176","doi":"10.21203/rs.3.rs-2417294/v1","title":"Chemokine expression predicts T cell-inflammation and improved survival with checkpoint inhibition across solid cancers","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; BC Cancer Agency; Princess Margaret Cancer Centre; Canada's Michael Smith Genome Sciences Centre; Ontario Genomics; McGill University Health Centre","funders":"Terry Fox Research Institute","keywords":"Inflammation; Chemokine; Cancer research; Expression (computer science); Immunology; Biology; Medicine; Computer science","score_opus":0.054426814057229086,"score_gpt":0.38602264576553247,"score_spread":0.33159583170830337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318708176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930088,0.00072730746,0.00021723006,0.0019847478,0.0003213482,0.0025823563,0.00026556596,0.00023191392,0.0006607236],"genre_scores_gemma":[0.99245393,0.002867979,0.00021186132,0.000016697262,0.0008149782,0.00063411857,0.000970254,0.000109400135,0.0019207563],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963506,0.00019848828,0.00047273395,0.00085679675,0.0013421808,0.0007792178],"domain_scores_gemma":[0.9979773,0.0001446097,0.00021433536,0.00070271303,0.00068352674,0.00027747682],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002096856,0.0003520717,0.0005229027,0.00028378275,0.00031662258,0.00017813736,0.00013848125,0.0004921867,0.00008297836],"category_scores_gemma":[0.00015230828,0.00027568507,0.00013402766,0.00045126004,0.00037633628,0.00012212349,0.0006201778,0.0014622158,0.00001298379],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011308587,0.0001195796,0.0035807986,0.008235717,0.00022573926,0.00012462273,0.0036424464,0.00012060032,0.9623982,0.0000026757427,0.0015661038,0.008674982],"study_design_scores_gemma":[0.008675859,0.0017636722,0.06042857,0.009798309,0.00006296665,0.000027092108,0.0038067503,0.0030757522,0.91015494,0.00014207838,0.0015133576,0.00055063306],"about_ca_topic_score_codex":0.0020128149,"about_ca_topic_score_gemma":0.00087308296,"teacher_disagreement_score":0.056847773,"about_ca_system_score_codex":0.0010165093,"about_ca_system_score_gemma":0.0010010235,"threshold_uncertainty_score":0.99996954},"labels":[],"label_agreement":null},{"id":"W4318773806","doi":"10.1136/jitc-2022-006127","title":"First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Hôpital du Sacré-Cœur de Montréal","funders":"EMD Serono; Ipsen; Universiteit Gent; Astellas Pharma; Eisai; G1 Therapeutics; Sanofi; Apollomics; Agios Pharmaceuticals; University of Texas Southwestern Medical Center; BeiGene; GlaxoSmithKline; Tizona Therapeutics; Les Laboratories Pierre Fabre; Daiichi Sankyo Europe; National Cancer Institute; Servier; Calithera Biosciences; AstraZeneca; Novocure; MacroGenics; Celldex Therapeutics; Cilag; Puma Biotechnology; Regeneron Pharmaceuticals; Pfizer; Incyte; Grifols; F. Hoffmann-La Roche; Celgene; PTC Therapeutics; Genentech; Aeglea BioTherapeutics; Amgen; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Oncology; Internal medicine; Lung cancer; Metastatic melanoma; First line; Cancer; Immunotherapy","score_opus":0.041473298833537224,"score_gpt":0.33657208283311646,"score_spread":0.29509878399957923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318773806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838194,0.010585225,0.0009719791,0.0003979054,0.0015536811,0.0021513323,0.000421287,0.000035481542,0.0000636534],"genre_scores_gemma":[0.94322246,0.042916834,0.005400174,0.0009551566,0.0020335151,0.0010970993,0.00010143753,0.000311169,0.0039621266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789006,0.000023339993,0.0007757352,0.0003057832,0.00038862176,0.00061648194],"domain_scores_gemma":[0.9983826,0.00011534369,0.00071886665,0.0002323147,0.00042553415,0.00012532712],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042480507,0.0003401087,0.0006842556,0.00034086552,0.0005313795,0.000067340596,0.00015552256,0.000092294154,0.0002841538],"category_scores_gemma":[0.000018599536,0.00026308434,0.0002598192,0.00040614186,0.00011214414,0.00024062897,0.000024239378,0.00021553031,8.797103e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13579561,0.00084846106,0.52626354,0.005836526,0.005279087,0.000006705133,0.009907742,0.0096271075,0.010111478,0.00003380215,0.009888788,0.28640118],"study_design_scores_gemma":[0.19022073,0.008783668,0.51473624,0.0059095486,0.0019163351,0.000036795864,0.00102733,0.04016334,0.012335754,0.0003435608,0.22280636,0.0017203573],"about_ca_topic_score_codex":0.0005272491,"about_ca_topic_score_gemma":0.0006290249,"teacher_disagreement_score":0.28468084,"about_ca_system_score_codex":0.00064121775,"about_ca_system_score_gemma":0.0005659518,"threshold_uncertainty_score":0.9999821},"labels":[],"label_agreement":null},{"id":"W4318826747","doi":"10.1136/jitc-2022-005545","title":"Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec; University of Toronto; McGill University","funders":"Canadian Institutes of Health Research; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Canada Foundation for Innovation; Fonds de Recherche du Québec - Santé; Brain Tumor Funders' Collaborative","keywords":"Immunotherapy; Immune system; Tumor microenvironment; Mass cytometry; Immune checkpoint; Immunology; Cancer research; Medicine; Cancer immunotherapy; T cell; Cancer; Biology; Internal medicine; Phenotype","score_opus":0.02469995268454188,"score_gpt":0.31953550746252946,"score_spread":0.29483555477798756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318826747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777859,0.013289684,0.0054362565,0.0006497346,0.0013790515,0.000993508,0.00021251377,0.00004946905,0.00020390034],"genre_scores_gemma":[0.9810425,0.014416532,0.0016998022,0.00028054442,0.0001780643,0.000069435824,0.000022245993,0.000116728595,0.0021741474],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965603,0.00024870285,0.001675944,0.000275557,0.00072782417,0.0005117167],"domain_scores_gemma":[0.9961984,0.00046987092,0.0017608558,0.0006531488,0.00082269456,0.000094986004],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023523353,0.00036952028,0.0012662908,0.00068877434,0.00017644688,0.000023624152,0.0004491875,0.00023036989,0.0010142042],"category_scores_gemma":[0.000102676706,0.00030967884,0.0009775021,0.000848173,0.00026160106,0.00016615713,0.000032885877,0.0003466759,0.0000028447664],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09150323,0.0004769707,0.0005333484,0.00031709464,0.00097384705,0.000005079503,0.0011703934,0.000031552918,0.8571971,0.000022001523,0.0009732386,0.046796143],"study_design_scores_gemma":[0.016386444,0.0052102655,0.01830235,0.0011350156,0.00012397049,0.000043024786,0.0006115566,0.00005182652,0.9504879,0.0007774436,0.0065693213,0.0003008718],"about_ca_topic_score_codex":0.00034735317,"about_ca_topic_score_gemma":0.000023430306,"teacher_disagreement_score":0.09329081,"about_ca_system_score_codex":0.0001799945,"about_ca_system_score_gemma":0.00064135593,"threshold_uncertainty_score":0.9999355},"labels":[],"label_agreement":null},{"id":"W4318934067","doi":"10.1007/s00198-023-06690-1","title":"Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse event","year":2023,"lang":"en","type":"article","venue":"Osteoporosis International","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Manitoba; University of Alberta","funders":"","keywords":"Medicine; Osteoporosis; Adverse effect; Internal medicine; Incidence (geometry); Rate ratio; Population; Cohort; Cancer; Surgery; Confidence interval","score_opus":0.008060758742134815,"score_gpt":0.2606665753485625,"score_spread":0.2526058166064277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318934067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98778474,0.0016138449,0.000023492776,0.0070815096,0.0016037473,0.00049925194,0.00010725019,0.00022822873,0.0010579552],"genre_scores_gemma":[0.9685392,0.00114097,0.000111699934,0.0005412262,0.0005543746,0.00010119008,0.0010466573,0.000048970996,0.02791573],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981166,0.00005292566,0.00072108244,0.00038753345,0.00041972153,0.00030209852],"domain_scores_gemma":[0.99910337,0.000045458095,0.00024340708,0.0003408213,0.00011537999,0.00015158336],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024999052,0.00028959694,0.00033651717,0.00028348478,0.00008666944,0.000041208914,0.00015237779,0.0001764665,0.0069930768],"category_scores_gemma":[0.00007180228,0.00023710766,0.00062379986,0.000335538,0.00007908238,0.00018344629,0.00008085536,0.00017854579,0.0005847798],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031648196,0.0020669915,0.014263535,0.0001035393,0.0051379483,0.0015757415,0.004024683,0.0003133567,0.8664079,0.00004648773,0.01698788,0.057423793],"study_design_scores_gemma":[0.022959499,0.001261869,0.697933,0.0009147261,0.00048714504,0.000349265,0.00078511355,0.00063071377,0.15066405,0.00022817528,0.12314037,0.0006460481],"about_ca_topic_score_codex":0.0014934472,"about_ca_topic_score_gemma":0.000046751127,"teacher_disagreement_score":0.7157438,"about_ca_system_score_codex":0.00050576,"about_ca_system_score_gemma":0.00026358425,"threshold_uncertainty_score":0.99391466},"labels":[],"label_agreement":null},{"id":"W4319068412","doi":"10.1200/jco.22.01990","title":"Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":512,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Clinical endpoint; Carboplatin; Internal medicine; Hazard ratio; Lung cancer; Placebo; Chemotherapy; Oncology; Population; Clinical trial; Phases of clinical research; Cancer; Surgery; Confidence interval; Pathology; Immunotherapy; Cisplatin","score_opus":0.06809060181907818,"score_gpt":0.45897296203500015,"score_spread":0.390882360215922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319068412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98842347,0.0007865348,0.000017045511,0.007465809,0.0017910074,0.00076906907,0.000006747158,0.0000116765195,0.0007286336],"genre_scores_gemma":[0.9927728,0.0033273553,0.000083271014,0.0024063585,0.00068324397,0.000014380007,0.0000013109643,0.000029190307,0.00068209384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958783,0.0004388987,0.0026977414,0.00022545457,0.0004422045,0.0003173961],"domain_scores_gemma":[0.9965092,0.0009112374,0.0018152032,0.00035774335,0.00024136866,0.00016526449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00384867,0.00017815453,0.0015952969,0.0002134469,0.000046489273,0.000007423046,0.00041229418,0.00031144003,0.000326031],"category_scores_gemma":[0.00038635265,0.00011045406,0.0006688491,0.0006602047,0.00021501751,0.000056328,0.00007812581,0.0010467803,0.000006510775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29794303,0.017449277,0.40707475,0.00026502032,0.0020401347,0.0014709358,0.004679912,0.00033485075,0.0088086175,0.0000129338405,0.03226704,0.22765353],"study_design_scores_gemma":[0.3414296,0.023713598,0.5937942,0.0003069689,0.0007979144,0.00011475443,0.0021880735,0.0015546619,0.0015790446,0.000051488285,0.03421496,0.0002547035],"about_ca_topic_score_codex":0.00033780193,"about_ca_topic_score_gemma":0.00045099357,"teacher_disagreement_score":0.22739883,"about_ca_system_score_codex":0.00036114603,"about_ca_system_score_gemma":0.002912971,"threshold_uncertainty_score":0.51674855},"labels":[],"label_agreement":null},{"id":"W4319297059","doi":"10.3390/curroncol30020155","title":"Immunotherapy and Chemotherapy Versus Sleep Disturbances for NSCLC Patients","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chemotherapy; Immunotherapy; Lung cancer; Internal medicine; Oncology; Sleep (system call); Sleep disorder; Adverse effect; Cancer; Polysomnography; Insomnia; Pharmacology","score_opus":0.07984728438969074,"score_gpt":0.40189880189220867,"score_spread":0.3220515175025179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319297059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98497033,0.0059203203,0.000104290346,0.0026967754,0.0043591117,0.0010127914,0.000039919683,0.00013895701,0.00075751374],"genre_scores_gemma":[0.9813065,0.014667951,0.0003375611,0.001150124,0.000830761,0.00053625734,0.00042218828,0.00007425943,0.00067442446],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990545,0.000027700049,0.00023444372,0.00027018433,0.00012362124,0.00028956108],"domain_scores_gemma":[0.9993921,0.00019698271,0.000093683135,0.00017010747,0.00008107503,0.00006605737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018274505,0.00015002524,0.00030405083,0.0001022691,0.00009991681,0.0000123964555,0.00007839902,0.00009907987,0.00007883913],"category_scores_gemma":[0.00003861679,0.00012289628,0.00012504857,0.00022231067,0.00015152358,0.000045128225,0.000018626706,0.00010276529,0.00001664876],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016344445,0.00031908182,0.029601268,0.00007718922,0.00018906577,0.0000013453158,0.00052270823,1.817913e-7,0.0007528955,0.00006398572,0.02114271,0.93098515],"study_design_scores_gemma":[0.025541654,0.0023952238,0.17832054,0.000039493552,0.00003640526,0.000002046939,0.000104874656,0.00011724499,0.00022788848,0.00009360788,0.79298294,0.00013808352],"about_ca_topic_score_codex":0.000007156092,"about_ca_topic_score_gemma":0.00000871418,"teacher_disagreement_score":0.93084705,"about_ca_system_score_codex":0.0001450661,"about_ca_system_score_gemma":0.00006928186,"threshold_uncertainty_score":0.50115645},"labels":[],"label_agreement":null},{"id":"W4319320751","doi":"10.1038/s41419-023-05567-9","title":"Regulation of immunological tolerance by the p53-inhibitor iASPP","year":2023,"lang":"en","type":"article","venue":"Cell Death and Disease","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute of Allergy and Infectious Diseases; Rhodes Scholarships; Ludwig Institute for Cancer Research; Wellcome Trust; National Institute of General Medical Sciences; Wellcome; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Biology; Autoimmunity; Immune tolerance; Cancer research; Immune system; Immunology; Regulator; Peripheral tolerance; Apoptosis; Gene","score_opus":0.014108909651528391,"score_gpt":0.24683372990694816,"score_spread":0.23272482025541977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319320751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881317,0.009269771,0.000016046164,0.0012166717,0.000085588836,0.00017900403,0.000026573634,0.00003671666,0.0010378968],"genre_scores_gemma":[0.9956848,0.00074589875,0.000011830875,0.00041855534,0.0000554863,0.000012978078,0.000049927774,0.000005271268,0.0030152786],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9995572,0.000018712472,0.00010886676,0.00011327622,0.00009948371,0.00010244318],"domain_scores_gemma":[0.99965954,0.000034826004,0.000032865486,0.00015562859,0.000020454878,0.000096667616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007547954,0.00006116161,0.00008895728,0.000020366026,0.000057286223,0.0000075327066,0.00003447392,0.00003007941,0.000092240785],"category_scores_gemma":[0.000027319045,0.000036833724,0.000059254373,0.00011818893,0.00008027233,0.000022529613,0.000015164703,0.00003971876,0.000011506551],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013050405,0.0004334619,0.06348151,0.00044492033,0.00008762795,0.00004506493,0.00045980536,0.000010687864,0.7408038,0.00034566692,0.111071624,0.06976547],"study_design_scores_gemma":[0.0027985226,0.00020475332,0.94555837,0.00007677956,0.00009024455,0.000003584898,0.00014471485,0.00065162935,0.018661268,0.00048533024,0.031210966,0.00011383407],"about_ca_topic_score_codex":0.000014639867,"about_ca_topic_score_gemma":2.4360358e-7,"teacher_disagreement_score":0.88207686,"about_ca_system_score_codex":0.000009399672,"about_ca_system_score_gemma":0.000041487667,"threshold_uncertainty_score":0.15020357},"labels":[],"label_agreement":null},{"id":"W4319432278","doi":"10.4049/jimmunol.206.supp.57.22","title":"The Role of CD4+ Tissue Resident Memory Cells in Oncogene Driven Lung Adenocarcinoma","year":2021,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; University of British Columbia","funders":"","keywords":"Biology; CD8; Immunology; Cancer research; CD69; Lung; Antigen; IL-2 receptor; Immune system; T cell; Medicine","score_opus":0.00797997739453165,"score_gpt":0.2574811075287284,"score_spread":0.24950113013419672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319432278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8436762,0.15210626,0.000011443752,0.0030858302,0.00040559078,0.00010756554,0.0000016802221,0.0000024640985,0.0006029574],"genre_scores_gemma":[0.9850737,0.013614913,0.00007769444,0.00017842322,0.00011702241,0.0000015165947,7.833479e-7,0.000012426851,0.00092353404],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985899,0.00035933955,0.000587308,0.00007041747,0.00019583486,0.00019720028],"domain_scores_gemma":[0.99872667,0.00031315562,0.0003902632,0.00035149994,0.00019256782,0.000025862942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008074649,0.0000945526,0.0003275269,0.00008808031,0.000071375616,0.00000682027,0.00028066168,0.00008551811,0.00018025286],"category_scores_gemma":[0.00006786274,0.000052395597,0.00012077057,0.00020522795,0.00023399972,0.000036922534,0.000071235525,0.00037225924,0.000005096393],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034006238,0.00006658329,0.0022663132,0.000011622196,0.00044297506,0.00013531503,0.0017759445,0.000019678453,0.9739078,0.000029287776,0.0005828641,0.017360937],"study_design_scores_gemma":[0.0023721303,0.0006505732,0.07058698,0.00016001803,0.0001505897,0.0018445504,0.0060384376,0.000017807706,0.9074715,0.00018747321,0.010458627,0.00006134585],"about_ca_topic_score_codex":0.00019665375,"about_ca_topic_score_gemma":0.00014510487,"teacher_disagreement_score":0.14139748,"about_ca_system_score_codex":0.00013525106,"about_ca_system_score_gemma":0.00038610824,"threshold_uncertainty_score":0.21366304},"labels":[],"label_agreement":null},{"id":"W4319432474","doi":"10.4049/jimmunol.206.supp.21.21","title":"BTLA signaling is needed in newly generated T cells to block autoimmunity","year":2021,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"BTLA; Autoimmunity; Immunology; CD8; Adoptive cell transfer; Medicine; T cell; Biology; Immune system","score_opus":0.020569360388698412,"score_gpt":0.27138819907525213,"score_spread":0.25081883868655375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319432474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796285,0.007996561,0.000076523,0.011372286,0.0005520434,0.00010959337,0.0000022164118,0.00000856451,0.00025371538],"genre_scores_gemma":[0.9906021,0.0014359041,0.00067999784,0.0061556757,0.00011996798,0.0000012976965,0.0000016906733,0.00001814981,0.000985248],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99858737,0.0003201724,0.00059133884,0.000085323634,0.00016229188,0.0002535169],"domain_scores_gemma":[0.9989736,0.00013307987,0.00022779482,0.0003160654,0.0003000921,0.000049349175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008335943,0.0001284896,0.0004011029,0.00019205884,0.00008025803,0.000015569685,0.00023086143,0.00011646596,0.0004965216],"category_scores_gemma":[0.000076715995,0.0000877346,0.00013813509,0.000590179,0.00008987786,0.000046723228,0.00006475676,0.00056846725,0.000022612801],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034572748,0.0001320685,0.00013992148,0.0000078821495,0.00038630713,0.00014668849,0.0027446616,0.00017724052,0.98578817,0.0000039991273,0.0022963665,0.004719415],"study_design_scores_gemma":[0.0043950407,0.0008089266,0.008853834,0.00019453328,0.00011623577,0.0022400129,0.003540908,0.00004661438,0.9642997,0.000044175707,0.01534033,0.00011968106],"about_ca_topic_score_codex":0.0004377146,"about_ca_topic_score_gemma":0.00003776033,"teacher_disagreement_score":0.021488467,"about_ca_system_score_codex":0.00015047441,"about_ca_system_score_gemma":0.00043261013,"threshold_uncertainty_score":0.54365635},"labels":[],"label_agreement":null},{"id":"W4319455137","doi":"10.1007/16833_2022_121","title":"Immunogenic Cell Death in Cancer","year":2023,"lang":"en","type":"book-chapter","venue":"Interdisciplinary cancer research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Immunosurveillance; Immunogenic cell death; Cytotoxic T cell; Programmed cell death; Priming (agriculture); Cancer; Immunology; T cell; Medicine; Cancer research; Immunotherapy; Biology; Apoptosis; Immune system; Internal medicine; In vitro","score_opus":0.13789376894575645,"score_gpt":0.4536212972036922,"score_spread":0.31572752825793576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319455137","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.037696175,0.045799546,0.0000018470159,0.00923813,0.0022278067,0.0026961816,0.0005617778,0.00022833624,0.9015502],"genre_scores_gemma":[0.046226237,0.031134166,0.0000137733705,0.0001651856,0.00094654236,0.000892609,0.00011304301,0.00030587602,0.92020255],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956152,0.000079888814,0.00081378064,0.0010633218,0.0013629821,0.00106483],"domain_scores_gemma":[0.99802095,0.00021442832,0.00016665575,0.0009966282,0.00037001504,0.0002312964],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001107414,0.00055205764,0.0009055757,0.0014958567,0.00024721742,0.00006801743,0.0006260682,0.00066630077,0.013780577],"category_scores_gemma":[0.000010879123,0.00049744436,0.0005432784,0.0004327868,0.00045037206,0.000075868076,0.0014328003,0.0026075323,0.00078430003],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06335227,0.0012782953,0.007712895,0.008086729,0.0051539694,0.011585617,0.009864989,0.000079493795,0.06855926,0.0031696255,0.4722185,0.34893835],"study_design_scores_gemma":[0.018594433,0.0059990627,0.045937393,0.039305173,0.0006920671,0.00027158053,0.0017572289,0.00022491306,0.013058097,0.022868449,0.847313,0.003978594],"about_ca_topic_score_codex":0.002775412,"about_ca_topic_score_gemma":0.006100474,"teacher_disagreement_score":0.3750945,"about_ca_system_score_codex":0.0027241355,"about_ca_system_score_gemma":0.0019852708,"threshold_uncertainty_score":0.9999937},"labels":[],"label_agreement":null},{"id":"W4319460787","doi":"10.1631/jzus.b2200292","title":"USH2A mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Zhejiang University SCIENCE B","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"Fundamental Research Funds for the Central Universities; Chinese Academy of Medical Sciences; Natural Science Foundation of Zhejiang Province; National Natural Science Foundation of China","keywords":"Hazard ratio; Internal medicine; Confidence interval; Medicine; Oncology; Odds ratio; Missense mutation; Lung cancer; Mutation; Cancer; Epidermal growth factor receptor; Progression-free survival; Cancer research; Overall survival; Biology; Gene; Genetics","score_opus":0.022642023366932034,"score_gpt":0.29858564519561176,"score_spread":0.2759436218286797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319460787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986513,0.00026396965,0.00002522113,0.0007142694,0.00017088694,0.00011037389,0.0000030222436,0.0000074103204,0.000053491254],"genre_scores_gemma":[0.9992381,0.0004734386,0.00010449768,0.000016761958,0.000032323784,3.8286565e-8,0.0000016606257,0.0000036464887,0.00012954563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990385,0.000049591144,0.00031242496,0.000121196186,0.00035369396,0.00012459712],"domain_scores_gemma":[0.9989409,0.000110629655,0.00053363503,0.00006467967,0.000284049,0.00006611349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012200284,0.000060480164,0.00021564224,0.0004741973,0.000075326265,0.000012615699,0.00009056631,0.0000469192,0.000015021667],"category_scores_gemma":[0.00014640982,0.000049627586,0.000076469834,0.0014227157,0.00043439164,0.00032420663,0.00002117301,0.00015788001,5.4054874e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036589017,0.00024163329,0.9394508,0.00004883853,0.00016740127,0.0009700715,0.0038371983,0.0003704998,0.038353324,0.000016465032,0.0003347053,0.012550186],"study_design_scores_gemma":[0.0036863193,0.0002757126,0.98877907,0.0006063296,0.000051466282,0.000031402717,0.0031401012,0.00042540394,0.0028350507,0.0000033094263,0.000109735534,0.000056101206],"about_ca_topic_score_codex":0.00010557576,"about_ca_topic_score_gemma":0.00010050788,"teacher_disagreement_score":0.04932829,"about_ca_system_score_codex":0.00030974322,"about_ca_system_score_gemma":0.00036236923,"threshold_uncertainty_score":0.20237543},"labels":[],"label_agreement":null},{"id":"W4319939127","doi":"10.1016/j.jtho.2023.01.091","title":"Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Cancer Institute; National Human Genome Research Institute; NIHR Imperial Biomedical Research Centre; Genentech; G1 Therapeutics; Bayer HealthCare; Jazz Pharmaceuticals; Royal College of Physicians and Surgeons of Canada; Canadian Institutes of Health Research; Associazione Italiana per la Ricerca sul Cancro; GlaxoSmithKline; Northwell Health; Imperial College London; Pfizer; Moderna; Boston Pharmaceuticals; Imperial Experimental Cancer Medicine Centre; Eisai; Wellcome Trust; Relay Therapeutics; Amgen; ViiV Healthcare; Bristol-Myers Squibb; AstraZeneca; National Institute for Health and Care Research; Falk Foundation","keywords":"Chemoimmunotherapy; Medicine; Internal medicine; Oncology; Blockade; Progression-free survival; Chemotherapy; Gastroenterology; Cancer; Immunotherapy; Receptor","score_opus":0.047569612600812425,"score_gpt":0.43930395670906125,"score_spread":0.3917343441082488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319939127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947232,0.002580966,0.000021980113,0.0017167563,0.0005711536,0.00021031576,0.000003453383,0.000015815325,0.00015637375],"genre_scores_gemma":[0.9940868,0.0047669555,0.0007123109,0.00017886139,0.00014545232,0.000001922318,0.0000031774164,0.00001989613,0.000084615596],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984006,0.00011878218,0.0009500521,0.00014352455,0.00014610947,0.00024088676],"domain_scores_gemma":[0.99815655,0.0006689284,0.00084870646,0.00015808195,0.000093335235,0.00007438341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001502125,0.00014302971,0.0007664549,0.00042262062,0.000038625367,0.0000057834413,0.00011938235,0.00018175459,0.00006911652],"category_scores_gemma":[0.0003668428,0.0001049549,0.00020943905,0.00042906145,0.00013119828,0.00008125441,0.00003438615,0.00039429293,0.0000022142701],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029513655,0.0004507925,0.16476142,0.00012623494,0.00018882786,0.00031221635,0.002116013,0.00008825978,0.25807,0.0000010974697,0.000120508805,0.54425097],"study_design_scores_gemma":[0.0073776827,0.0053611915,0.96994215,0.0003816831,0.00009389966,0.0005810144,0.0013913327,0.00007363555,0.009684932,0.00007014552,0.0049157715,0.000126566],"about_ca_topic_score_codex":0.000019123505,"about_ca_topic_score_gemma":0.00002258895,"teacher_disagreement_score":0.8051807,"about_ca_system_score_codex":0.00024729507,"about_ca_system_score_gemma":0.00022251262,"threshold_uncertainty_score":0.42799366},"labels":[],"label_agreement":null},{"id":"W4320061587","doi":"10.4049/jimmunol.206.supp.98.43","title":"Blockade of the CD6-ALCAM pathway modulates effector T cell function","year":2021,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"ALCAM; Effector; T cell; Cell biology; IL-2 receptor; Chemistry; Cytotoxic T cell; Biology; Immune system; Immunology; Cell adhesion molecule; Biochemistry; In vitro","score_opus":0.008112609268584677,"score_gpt":0.22011957783317285,"score_spread":0.21200696856458817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320061587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760578,0.019322844,0.00007370398,0.002897462,0.0011191972,0.000096618,0.0000026925738,0.0000046594187,0.00042501118],"genre_scores_gemma":[0.99724686,0.0012902761,0.000033908153,0.0003383243,0.00014879645,8.538915e-7,0.0000010294559,0.000010725184,0.00092922436],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990023,0.00028030976,0.00036599653,0.00005694469,0.00015999346,0.00013449759],"domain_scores_gemma":[0.9988933,0.00018146796,0.00038584808,0.0003155835,0.00020567061,0.000018094444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046842688,0.00009007009,0.00026430344,0.000048866743,0.000069480106,0.00000504658,0.00017081489,0.00008817345,0.00024750168],"category_scores_gemma":[0.00006937076,0.000043394193,0.00023909796,0.0002010961,0.00017508723,0.000030954838,0.000046506797,0.0003328579,0.0000064656474],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003017603,0.00012108534,0.0008396851,0.000028753815,0.00047021,0.000010027552,0.00030262794,0.000015767171,0.98575807,0.000012631052,0.0004498893,0.008973681],"study_design_scores_gemma":[0.0028785062,0.001136806,0.083214074,0.00012480603,0.00029657545,0.00121806,0.00046390202,0.000013072345,0.89869094,0.00015050876,0.011757679,0.000055073117],"about_ca_topic_score_codex":0.000025268973,"about_ca_topic_score_gemma":0.0000048105276,"teacher_disagreement_score":0.087067105,"about_ca_system_score_codex":0.000050832543,"about_ca_system_score_gemma":0.0002135464,"threshold_uncertainty_score":0.270997},"labels":[],"label_agreement":null},{"id":"W4320068904","doi":"10.33590/emjhepatol/10082046","title":"Management of Severe, Steroid-Resistant and Steroid-Refractory Hepatotoxicity in Patients Treated with Checkpoint Inhibitor Immunotherapy","year":2022,"lang":"en","type":"article","venue":"EMJ Hepatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Toronto Liver Centre","funders":"","keywords":"Steroid; Refractory (planetary science); Medicine; Immunotherapy; Steroid use; Pharmacology; Internal medicine; Biology; Cancer; Hormone","score_opus":0.008923985138340317,"score_gpt":0.23364553427232645,"score_spread":0.22472154913398615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320068904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972168,0.0010577082,0.0000046142827,0.00018528396,0.000110480796,0.00084883044,0.000042766427,0.00003093541,0.0005025585],"genre_scores_gemma":[0.9986845,0.00022635519,0.0001403095,0.00039919905,0.000010212437,0.00012870607,0.000049632203,0.00003298994,0.00032808463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983509,0.00017187528,0.00050184445,0.00037124756,0.00030629835,0.00029783114],"domain_scores_gemma":[0.9993013,0.000031795513,0.00021406788,0.00034823213,0.00004536188,0.00005923053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023433527,0.00021935233,0.0005148581,0.00022626788,0.00008499677,0.00000621865,0.00010752259,0.00007432155,0.00032596258],"category_scores_gemma":[0.0000026369216,0.00018492235,0.00007353904,0.00032019938,0.00016056883,0.00005483353,0.00010388171,0.00022919808,0.0000014322833],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032786574,0.0012485549,0.9452383,0.00019500026,0.0005106383,0.00034310416,0.0005649742,0.0000017472572,0.0074917953,0.000026200512,0.00015746478,0.011435645],"study_design_scores_gemma":[0.019347513,0.004905231,0.96490276,0.00013510321,0.000063378866,0.00010132195,0.00042563988,0.00003062499,0.004482056,0.000017499651,0.005320882,0.00026801784],"about_ca_topic_score_codex":0.0005830411,"about_ca_topic_score_gemma":0.00013873947,"teacher_disagreement_score":0.019664431,"about_ca_system_score_codex":0.0003204308,"about_ca_system_score_gemma":0.00006239348,"threshold_uncertainty_score":0.75409144},"labels":[],"label_agreement":null},{"id":"W4321091949","doi":"10.3390/curroncol30020182","title":"Tumors of the Digestive System: Comprehensive Review of Ancillary Testing and Biomarkers in the Era of Precision Medicine","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Medicine; Precision medicine; Immunotherapy; Extant taxon; Acquired resistance; Cancer; Oncology; Internal medicine; Intensive care medicine; Medical physics; Pathology","score_opus":0.2397052221007557,"score_gpt":0.45262586880235683,"score_spread":0.21292064670160113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321091949","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00060945575,0.99497104,9.29944e-7,0.00029742197,0.0007329893,0.0029947062,0.00006459257,0.000010088583,0.00031879693],"genre_scores_gemma":[0.00025343246,0.9994021,0.00003059249,0.0000653181,0.00008964264,0.00009889264,0.00003374164,0.000022519911,0.0000037628113],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99636596,0.0010020336,0.001739128,0.00029643768,0.00041090004,0.00018553191],"domain_scores_gemma":[0.9933603,0.0038883914,0.0018759576,0.00050130865,0.00033725292,0.00003682938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017445409,0.0002918727,0.0029673185,0.00018295765,0.000033294407,0.0000011717739,0.00033556102,0.00017595709,0.000009099474],"category_scores_gemma":[0.0015118781,0.00013458895,0.0003366932,0.0014586312,0.0008040338,0.000015877913,0.00014231574,0.0005252014,7.3264806e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000098038014,0.00006808572,0.00032853044,0.3159478,0.00022972013,0.00000991001,0.00018595102,3.6372374e-8,0.000014003174,0.000007926124,0.0010835761,0.68202645],"study_design_scores_gemma":[0.0008711595,0.0007055801,0.003983858,0.65090275,0.0013764696,0.0002794148,0.00037516007,0.000004662636,0.00000196634,0.0000044925055,0.3414052,0.00008928165],"about_ca_topic_score_codex":0.00013052468,"about_ca_topic_score_gemma":0.000008123106,"teacher_disagreement_score":0.68193716,"about_ca_system_score_codex":0.00024174896,"about_ca_system_score_gemma":0.000801751,"threshold_uncertainty_score":0.5488378},"labels":[],"label_agreement":null},{"id":"W4321105976","doi":"10.3390/curroncol30020181","title":"Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Immunotherapy; Disease; Lung cancer; Biomarker; Cancer; Clinical trial; Oncology; Intensive care medicine; Bioinformatics; Internal medicine","score_opus":0.16002782196937468,"score_gpt":0.47286407281289966,"score_spread":0.31283625084352495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321105976","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045891997,0.990051,0.00040765162,0.00015709823,0.0036423805,0.005152272,0.00028025452,0.00010526037,0.0001582439],"genre_scores_gemma":[0.0000027773483,0.9946127,0.00039707922,0.00016101678,0.00040565818,0.0033879557,0.00027855457,0.00017387231,0.0005804114],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99721056,0.00020060697,0.0010083596,0.00076546666,0.00018214302,0.0006328444],"domain_scores_gemma":[0.99770427,0.0008680715,0.0007334596,0.0004332973,0.000110916044,0.0001499896],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062576454,0.0006825794,0.0027885253,0.00043444394,0.00014623722,0.00003390173,0.00027698503,0.00032867017,0.00010339465],"category_scores_gemma":[0.000022101935,0.0005090276,0.00091551023,0.00053105596,0.00025666278,0.000059025064,0.000059081292,0.0004466122,0.000013602901],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006370225,0.00021761487,0.000047194728,0.07674634,0.002137295,0.000010921937,0.00015008544,8.532154e-8,0.000015059536,0.000005195499,0.002340571,0.9176926],"study_design_scores_gemma":[0.0045792423,0.0008241395,0.00002184317,0.010601047,0.004455305,0.00005547968,0.00008982726,0.000050823408,0.000006911246,0.000036194368,0.978791,0.00048816265],"about_ca_topic_score_codex":0.0000373795,"about_ca_topic_score_gemma":0.00005463274,"teacher_disagreement_score":0.97645044,"about_ca_system_score_codex":0.00066668703,"about_ca_system_score_gemma":0.0015657098,"threshold_uncertainty_score":0.99973613},"labels":[],"label_agreement":null},{"id":"W4321208155","doi":"10.2139/ssrn.4336842","title":"A Pan-Cancer Clinical Platform to Predict Immunotherapy Outcomes and Prioritize Immuno-Oncology Combinations in Early-Phase Trials","year":2023,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Université de Montréal","funders":"","keywords":"Oncology; Clinical trial; Immunotherapy; Medicine; Internal medicine; Cancer; Cancer immunotherapy; Clinical Oncology; Medical physics","score_opus":0.09511143527396658,"score_gpt":0.4553834664015806,"score_spread":0.360272031127614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321208155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95949745,0.021924479,0.0006631548,0.012294642,0.0028614565,0.0024402486,0.000105994164,0.000110812725,0.000101769525],"genre_scores_gemma":[0.75732625,0.23724324,0.00021412756,0.0010298436,0.0008167158,0.00043905742,0.00005596431,0.00013609375,0.0027386944],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9931513,0.0006265165,0.0027950362,0.00068696163,0.00055908767,0.0021811174],"domain_scores_gemma":[0.99683005,0.0011261101,0.0010345363,0.0005666508,0.00021554244,0.0002271403],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.015400536,0.0005446269,0.0024505933,0.0008040192,0.00019682723,0.00013941151,0.000466479,0.00085749436,0.00008746141],"category_scores_gemma":[0.0008860759,0.00044212263,0.00092690927,0.0004174949,0.0002048048,0.0001299312,0.0002563873,0.0059954436,0.000016456248],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028029088,0.0025317888,0.14807957,0.00012748186,0.0094258245,0.0001270729,0.0020515257,0.000009045286,0.0019937349,0.0017403509,0.0011093736,0.8047751],"study_design_scores_gemma":[0.14925295,0.016714785,0.69600886,0.0024329515,0.0014730033,0.0010277935,0.0035617298,0.0001300302,0.00017389886,0.10382386,0.023780078,0.0016200559],"about_ca_topic_score_codex":0.0013190366,"about_ca_topic_score_gemma":0.0029502588,"teacher_disagreement_score":0.80315506,"about_ca_system_score_codex":0.003633854,"about_ca_system_score_gemma":0.01111404,"threshold_uncertainty_score":0.99980307},"labels":[],"label_agreement":null},{"id":"W4321372107","doi":"10.3389/fphar.2023.1161811","title":"Editorial: New immunotherapeutic and pharmacological targets and strategies in haematological malignancies","year":2023,"lang":"en","type":"editorial","venue":"Frontiers in Pharmacology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer research; Immunology; Computational biology; Biology","score_opus":0.015936270116375023,"score_gpt":0.3246705143698103,"score_spread":0.3087342442534353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321372107","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006700328,0.033265237,0.000047049278,0.0012504403,0.95754516,0.00091371854,0.000050721548,0.000136691,0.000090654],"genre_scores_gemma":[0.0013589541,0.06371663,0.00070872495,0.0006016672,0.9322141,0.00024408259,0.00012513454,0.00009880803,0.00093194464],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99677145,0.00030559686,0.00078107003,0.00086886797,0.00046220026,0.0008107998],"domain_scores_gemma":[0.9985653,0.0007769319,0.00022090484,0.00015546627,0.000079153084,0.00020221235],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00076488144,0.00057058665,0.0015130885,0.0006138513,0.0000736559,0.00006674687,0.0002515598,0.001821093,0.00016117144],"category_scores_gemma":[0.0001683699,0.0004953177,0.0001255054,0.0004616254,0.0006859419,0.00014889437,0.00016561564,0.0018119344,0.00000667351],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070984922,0.00015270463,0.0010165476,0.00028278056,0.0004915834,0.0005464498,0.00035918618,0.0000026432292,0.0065589086,0.000008411999,0.98004293,0.003439344],"study_design_scores_gemma":[0.012182447,0.0006591941,0.0013432108,0.00019541,0.00034147978,0.000026591804,0.00044407317,0.000067625566,0.00031837018,0.0008438463,0.98309445,0.00048327318],"about_ca_topic_score_codex":0.00032912317,"about_ca_topic_score_gemma":0.000059325812,"teacher_disagreement_score":0.030451385,"about_ca_system_score_codex":0.0003491502,"about_ca_system_score_gemma":0.0010175275,"threshold_uncertainty_score":0.99974984},"labels":[],"label_agreement":null},{"id":"W4321375958","doi":"10.3389/fimmu.2023.1086102","title":"VISTA expression and patient selection for immune-based anticancer therapy","year":2023,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Heart, Lung, and Blood Institute; EMD Serono; Genentech; Astellas Pharma; Eisai; EQRx; Y-mAbs Therapeutics; Daiichi Sankyo Europe; Calithera Biosciences; Pfizer; Incyte; G1 Therapeutics; Jounce Therapeutics; Syndax Pharmaceuticals; BeiGene; Mirati Therapeutics; GlaxoSmithKline; Tizona Therapeutics; National Institutes of Health; Regeneron Pharmaceuticals; National Center for Advancing Translational Sciences; Helsinn; Loxo Oncology; Ribon Therapeutics; Array BioPharma; Exelixis; Sanofi; OncoMed Pharmaceutical; Relay Therapeutics; Amgen; AstraZeneca; Eli Lilly and Company","keywords":"Immunotherapy; Tumor microenvironment; Cytotoxic T cell; Cancer research; Immune system; T cell; Antigen; Myeloid-derived Suppressor Cell; Immune checkpoint; Myeloid; Cancer immunotherapy; Biology; Immunology; Suppressor; Cancer; In vitro; Genetics","score_opus":0.032567560517229865,"score_gpt":0.3256557732942972,"score_spread":0.2930882127770673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321375958","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028648286,0.9939417,0.0010253524,0.00010409949,0.0021095641,0.002374882,0.000040916828,0.00009095969,0.00002602277],"genre_scores_gemma":[0.00003718431,0.9958694,0.0023283504,0.00013182867,0.000077011005,0.0009994283,0.00018453416,0.00010378184,0.00026850693],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980663,0.00016213757,0.00072048476,0.00051712623,0.00012350948,0.00041041258],"domain_scores_gemma":[0.999084,0.0001424489,0.00033990302,0.0003405385,0.00005734835,0.00003576911],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022513098,0.00038755086,0.0016738918,0.0006357039,0.00009747952,0.000020489755,0.00013219386,0.0005840013,0.000030066063],"category_scores_gemma":[0.00005436933,0.00030625294,0.00039982688,0.0004959421,0.00021182852,0.00003915406,0.000035115074,0.00039972115,0.000003495745],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024510599,0.00009755295,0.000089242785,0.0030134118,0.00056410395,0.000005377251,0.00008009749,2.5663718e-7,0.0004756937,0.0000047014887,0.005476894,0.9877416],"study_design_scores_gemma":[0.0033631148,0.0010067937,0.00012577507,0.007970805,0.00018256105,0.000025918003,0.00008022043,0.00003847312,0.00031850662,0.000039138584,0.9865498,0.00029892323],"about_ca_topic_score_codex":0.00006957395,"about_ca_topic_score_gemma":0.000005519634,"teacher_disagreement_score":0.9874427,"about_ca_system_score_codex":0.00040742024,"about_ca_system_score_gemma":0.00045843225,"threshold_uncertainty_score":0.99993896},"labels":[],"label_agreement":null},{"id":"W4321436832","doi":"10.1200/jco.22.01989","title":"Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":643,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"Chugai Pharmaceutical; EMD Serono; Genentech; Ipsen; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Eisai; Regeneron Pharmaceuticals; Natera; Grifols; Y-mAbs Therapeutics; Shionogi; Actuate Therapeutics; Daiichi Sankyo Europe; Gilead Sciences; Calithera Biosciences; Pfizer; Incyte; Mirati Therapeutics; Les Laboratories Pierre Fabre; Helsinn; Merck KGaA; Sanofi; GlaxoSmithKline; Helsinn Therapeutics; Amgen; Celgene; AstraZeneca; Samsung; Bristol-Myers Squibb","keywords":"Pemetrexed; Medicine; Pembrolizumab; Carboplatin; Internal medicine; Lung cancer; Oncology; Clinical endpoint; Hazard ratio; Phases of clinical research; Clinical trial; Surgery; Cisplatin; Chemotherapy; Cancer; Confidence interval; Immunotherapy","score_opus":0.11470995085224713,"score_gpt":0.4737687742129537,"score_spread":0.3590588233607066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321436832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870902,0.0013047737,0.000014394876,0.008936661,0.001498601,0.0006797449,0.000021059199,0.00001548937,0.000439105],"genre_scores_gemma":[0.9944464,0.002043131,0.00016564355,0.0020756754,0.00075659057,0.000019046938,0.0000039796923,0.000024422105,0.00046512348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964613,0.00049099885,0.0021136361,0.00025739486,0.00037599177,0.00030068675],"domain_scores_gemma":[0.99367285,0.004652299,0.0010607371,0.0002658516,0.00014480154,0.0002034516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003434363,0.0001894673,0.0015293881,0.0001805908,0.000071781265,0.000020104402,0.00025522054,0.0002755033,0.0002743461],"category_scores_gemma":[0.0011481735,0.00011141347,0.00038192613,0.0003992664,0.00017418519,0.00006509524,0.000097558455,0.0011139022,0.000010035911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032896627,0.0023273965,0.8705879,0.000025692902,0.0008116397,0.0011915575,0.0019768383,0.000022476226,0.00040680607,0.0000012226573,0.007744926,0.08200692],"study_design_scores_gemma":[0.10098632,0.008653657,0.880575,0.00009088382,0.00055445125,0.000028924333,0.002725719,0.00084606424,0.000031012936,0.00002211147,0.005364005,0.000121875266],"about_ca_topic_score_codex":0.0011767944,"about_ca_topic_score_gemma":0.0020410724,"teacher_disagreement_score":0.08188504,"about_ca_system_score_codex":0.00025953766,"about_ca_system_score_gemma":0.0015929029,"threshold_uncertainty_score":0.48394126},"labels":[],"label_agreement":null},{"id":"W4321491185","doi":"10.7554/elife.82705.sa2","title":"Author response: Proliferative exhausted CD8+ T cells exacerbate long-lasting anti-tumor effects in human papillomavirus-positive head and neck squamous cell carcinoma","year":2023,"lang":"en","type":"peer-review","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Head and neck squamous-cell carcinoma; Tumor microenvironment; Cancer research; Cancer; CD8; Cell; Medicine; Head and neck cancer; Oncology; Antigen; Internal medicine; Biology; Immunology","score_opus":0.0342362463090908,"score_gpt":0.33181672207769425,"score_spread":0.29758047576860347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321491185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89747435,0.07805839,0.000023488941,0.010555229,0.0020125785,0.009026365,0.0004263542,0.00038095604,0.0020422766],"genre_scores_gemma":[0.53159004,0.0015592993,0.00023209595,0.0048403526,0.0006480471,0.00075454643,0.00087823113,0.000404623,0.45909277],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9942419,0.0010102689,0.0013443653,0.0015245102,0.00082634826,0.0010526016],"domain_scores_gemma":[0.9965792,0.0012965768,0.00063199864,0.000784866,0.000349604,0.00035776797],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001736264,0.0011599625,0.00244949,0.00074037455,0.00029823786,0.00011164356,0.00027800072,0.0005845726,0.0003328423],"category_scores_gemma":[0.00031579667,0.0009701855,0.0004050823,0.0011595841,0.0002980297,0.0001263345,0.00024126089,0.0013728559,0.00008082011],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01836216,0.0009983332,0.008309154,0.05139948,0.00052961824,0.010459344,0.0023396092,0.000005327105,0.1986745,0.000006671506,0.70289725,0.0060185804],"study_design_scores_gemma":[0.042067874,0.015094679,0.4930889,0.095610425,0.0027571276,0.0007403173,0.00056106376,0.0002919675,0.20163397,0.00002044297,0.14338368,0.004749547],"about_ca_topic_score_codex":0.0018963662,"about_ca_topic_score_gemma":0.0008706634,"teacher_disagreement_score":0.55951357,"about_ca_system_score_codex":0.0006736166,"about_ca_system_score_gemma":0.0007348175,"threshold_uncertainty_score":0.99927485},"labels":[],"label_agreement":null},{"id":"W4321495507","doi":"10.3390/curroncol30030196","title":"Mapping Immune Correlates and Surfaceome Genes in BRAF Mutated Colorectal Cancers","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Instituto de Salud Carlos III; CRIS Cancer Foundation; Nemzeti Kutatási Fejlesztési és Innovációs Hivatal; Ministerio de Ciencia e Innovación; European Commission","keywords":"Human leukocyte antigen; Antigen processing; Downregulation and upregulation; Colorectal cancer; Immunotherapy; Major histocompatibility complex; MHC class I; Cancer research; Gene; Cancer; Medicine; Antigen; Immunology; Immune system; Biology; Genetics; Internal medicine","score_opus":0.06341145849639453,"score_gpt":0.36729899611641326,"score_spread":0.30388753762001874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321495507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796115,0.016903874,0.0000069895204,0.0009550866,0.0017426616,0.00036074084,0.000010310143,0.000101387675,0.00030745022],"genre_scores_gemma":[0.99041593,0.009067591,0.000019594881,0.00006660442,0.00007082685,0.000050537627,0.00007873887,0.000016563245,0.00021361384],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989824,0.00006333637,0.00030696226,0.00024061039,0.00009321531,0.00031344988],"domain_scores_gemma":[0.99958444,0.00013732175,0.000079526,0.000096803364,0.000036726877,0.00006520344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030006593,0.00012903722,0.00034792992,0.00025730373,0.00005341136,0.000008045994,0.000056827193,0.00011928881,0.000116024676],"category_scores_gemma":[0.00003684696,0.0001174022,0.000057837467,0.0006680893,0.00018143599,0.00003861865,0.000050541836,0.00022063134,0.000033433535],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033564535,0.00019592927,0.39910072,0.00024673206,0.00020822836,0.00029048324,0.004407765,0.00006117314,0.1043646,0.000017049842,0.0027740097,0.48497686],"study_design_scores_gemma":[0.009444964,0.001146872,0.8599158,0.00035775063,0.000043912223,0.00022347069,0.0023683568,0.0056697954,0.002350525,0.00006644874,0.118112646,0.00029948787],"about_ca_topic_score_codex":0.00027871958,"about_ca_topic_score_gemma":0.00027533778,"teacher_disagreement_score":0.48467737,"about_ca_system_score_codex":0.0004457254,"about_ca_system_score_gemma":0.00027439257,"threshold_uncertainty_score":0.4787523},"labels":[],"label_agreement":null},{"id":"W4321499107","doi":"10.3389/fcell.2023.1111796","title":"Tailoring therapies to counter the divergent immune landscapes of breast cancer","year":2023,"lang":"en","type":"review","venue":"Frontiers in Cell and Developmental Biology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; McGill University","keywords":"Breast cancer; Immunotherapy; Medicine; Immune system; Cancer; Oncology; Tumor microenvironment; Cancer immunotherapy; Clinical trial; Immunology; Internal medicine","score_opus":0.027741359007993526,"score_gpt":0.2948672359934257,"score_spread":0.26712587698543216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321499107","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022006014,0.9954133,0.00001191328,0.00016563329,0.0012077917,0.0005964144,0.00015422069,0.000014465825,0.00023567506],"genre_scores_gemma":[0.0005094474,0.9978238,0.0003390334,0.0001339694,0.00006945525,0.00016564103,0.000070782175,0.000024413683,0.00086348405],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99887395,0.000056525212,0.0004757761,0.0002741306,0.000081382546,0.0002382533],"domain_scores_gemma":[0.9996343,0.000051914918,0.00013381946,0.0001167728,0.000021025366,0.0000421203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022587988,0.00024665552,0.000983532,0.0002116466,0.000056286164,0.000007774418,0.0001540447,0.00017113544,0.0001138699],"category_scores_gemma":[0.000004115143,0.00013766065,0.00014932307,0.00030794265,0.00011576616,0.000015458503,0.00013103569,0.00016663538,0.000010571367],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041073392,0.00003940664,0.011315097,0.0035522075,0.00076058717,0.000007578273,0.0010493834,7.7420076e-8,0.00015796523,0.000002539796,0.0066260784,0.97607833],"study_design_scores_gemma":[0.00060819584,0.0000698862,0.0040142303,0.0035297265,0.00013410368,0.00003503221,0.0009305008,6.0938027e-7,0.000047546004,0.000011048699,0.9904124,0.00020669797],"about_ca_topic_score_codex":0.00026783368,"about_ca_topic_score_gemma":0.00005297973,"teacher_disagreement_score":0.98378634,"about_ca_system_score_codex":0.0001666708,"about_ca_system_score_gemma":0.00020388942,"threshold_uncertainty_score":0.5613638},"labels":[],"label_agreement":null},{"id":"W4321500387","doi":"10.7554/elife.82705","title":"Proliferative exhausted CD8+ T cells exacerbate long-lasting anti-tumor effects in human papillomavirus-positive head and neck squamous cell carcinoma","year":2023,"lang":"en","type":"article","venue":"eLife","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Health Department of Sichuan Province; Sichuan University; West China Hospital, Sichuan University; Department of Science and Technology of Sichuan Province; Sichuan Province Science and Technology Support Program; National Youth Foundation of China; China Postdoctoral Science Foundation","keywords":"Head and neck squamous-cell carcinoma; Cancer research; CD8; Cell; Cancer; Biology; Antigen; Medicine; Immunology; Head and neck cancer; Internal medicine","score_opus":0.016142069786391704,"score_gpt":0.2762301884715075,"score_spread":0.2600881186851158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321500387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956863,0.0015104695,0.00001237064,0.00016030425,0.0002403733,0.0012844127,0.000018991213,0.0001507549,0.0009360065],"genre_scores_gemma":[0.99768394,0.00006597358,0.00007013061,0.00076139934,0.00021293334,0.00008548397,0.0000481768,0.000058750582,0.0010132097],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980761,0.00013894848,0.00040462616,0.0005115345,0.00033278205,0.00053604005],"domain_scores_gemma":[0.9991437,0.00021844689,0.00013613387,0.00025143314,0.00008358836,0.00016668462],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000326054,0.00031302456,0.00051938696,0.0002679925,0.00019247549,0.000048072234,0.00008614448,0.00011232075,0.00003857265],"category_scores_gemma":[0.0000445527,0.0002797414,0.00009375471,0.00064988143,0.00013122262,0.00010897114,0.00007966006,0.00031048805,0.000054101198],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012980705,0.00024356478,0.2590053,0.0006208695,0.000052328505,0.0016883888,0.0032776103,0.000022371094,0.7309798,0.000007927346,0.0013861774,0.0014175599],"study_design_scores_gemma":[0.006823077,0.0009816277,0.6145389,0.00032819694,0.00004287797,0.000031420168,0.00025042318,0.00035659934,0.37622243,0.0000038236362,0.00017474039,0.00024587213],"about_ca_topic_score_codex":0.000434112,"about_ca_topic_score_gemma":0.00013615194,"teacher_disagreement_score":0.35553363,"about_ca_system_score_codex":0.0001510444,"about_ca_system_score_gemma":0.00010636073,"threshold_uncertainty_score":0.9999655},"labels":[],"label_agreement":null},{"id":"W4321597883","doi":"10.2217/fon-2023-0007","title":"Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"","keywords":"Nivolumab; Medicine; Chemotherapy; Lung cancer; Cancer; Internal medicine; Oncology; Immunotherapy; Surgery","score_opus":0.015032802171098278,"score_gpt":0.3127348910883733,"score_spread":0.29770208891727507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321597883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792602,0.0018063943,0.000009291574,0.012695128,0.0020390155,0.0025315273,0.00033920194,0.00009154376,0.0012277103],"genre_scores_gemma":[0.970556,0.0014422077,0.00015623015,0.0030220281,0.002833578,0.0008219101,0.0002746679,0.00012025155,0.020773081],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839646,0.0001351455,0.00051349524,0.00035177197,0.0002034603,0.0003996539],"domain_scores_gemma":[0.9987007,0.0003185596,0.00032239308,0.0004981317,0.000098246666,0.00006197129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010181059,0.00021680168,0.00064837624,0.00014346796,0.00012251895,0.000007672611,0.00023486155,0.0002615752,0.000102008475],"category_scores_gemma":[0.000050718172,0.00014468089,0.00033109725,0.00056008867,0.0001030604,0.000030071487,0.00006302282,0.00023346429,0.0000035321345],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044806592,0.0012577566,0.051974677,0.0014491578,0.0018034815,0.0001991868,0.04914337,0.000019407804,0.037857547,0.0000073029937,0.6968015,0.11468006],"study_design_scores_gemma":[0.056819726,0.0036318067,0.33912078,0.00073068286,0.00078542146,0.00004902804,0.0342297,0.00093215285,0.01590551,0.000016712465,0.54716253,0.00061597355],"about_ca_topic_score_codex":0.0007531041,"about_ca_topic_score_gemma":0.0032908022,"teacher_disagreement_score":0.2871461,"about_ca_system_score_codex":0.00045402235,"about_ca_system_score_gemma":0.0008409022,"threshold_uncertainty_score":0.58999157},"labels":[],"label_agreement":null},{"id":"W4321609350","doi":"10.21037/tcr-22-2843","title":"The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management","year":2023,"lang":"en","type":"letter","venue":"Translational Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut Universitaire de Cardiologie et de Pneumologie de Québec","funders":"","keywords":"Stage (stratigraphy); Oncology; Medicine; Internal medicine; Intensive care medicine; Biology","score_opus":0.10142360732872932,"score_gpt":0.4052467398309005,"score_spread":0.3038231325021712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321609350","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016039334,0.015675388,0.000009123253,0.93962306,0.00090635766,0.0038949116,0.0010172813,0.00004520601,0.02278931],"genre_scores_gemma":[0.14192626,0.05987107,0.000115520204,0.104054436,0.0054676365,0.004465984,0.0013495262,0.00053445145,0.6822151],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99519813,0.00022443806,0.00054897834,0.00043669544,0.0026939525,0.00089781533],"domain_scores_gemma":[0.99814403,0.00072410266,0.000107503925,0.0006898865,0.0002821218,0.000052354397],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016595881,0.0002269886,0.00034035224,0.00040073795,0.000329369,0.000056471894,0.0005736468,0.00029355224,0.0011083692],"category_scores_gemma":[0.00001675259,0.00013706318,0.00025151036,0.001591327,0.00050297566,0.000052516258,0.00008948383,0.002145232,0.000018149107],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0121394405,0.00010096954,0.004815871,0.0022092438,0.0013426697,0.00018803387,0.0011824337,0.0004080291,0.00083961483,0.0012684868,0.93847156,0.037033666],"study_design_scores_gemma":[0.003489669,0.000088870314,0.05646853,0.0009202802,0.000044414162,0.0000018830149,0.00016362879,0.000061669125,0.0003078235,0.00075658667,0.9375419,0.00015471906],"about_ca_topic_score_codex":0.011279461,"about_ca_topic_score_gemma":0.008566899,"teacher_disagreement_score":0.83556867,"about_ca_system_score_codex":0.00053942605,"about_ca_system_score_gemma":0.0009505991,"threshold_uncertainty_score":0.99980474},"labels":[],"label_agreement":null},{"id":"W4321612204","doi":"10.1001/jamanetworkopen.2023.0490","title":"Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors","year":2023,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Dosing; Medicine; Intensive care medicine; Emergency medicine; Internal medicine","score_opus":0.028295213363531184,"score_gpt":0.3643391361360067,"score_spread":0.3360439227724755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321612204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924472,0.0008241558,0.00006415517,0.0040993504,0.00025714093,0.0009669453,0.00007389835,0.00006341418,0.001203731],"genre_scores_gemma":[0.9962821,0.000076022305,0.002053125,0.00056167116,0.00005491227,0.000025914947,0.0006098744,0.000021203236,0.00031514853],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982685,0.00011915862,0.0007709,0.00026450987,0.00031314415,0.00026378338],"domain_scores_gemma":[0.9988481,0.000121064564,0.00036141137,0.00028737748,0.00026955025,0.0001125344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010588062,0.00013020604,0.0006228423,0.00034502774,0.00007774143,0.000030895208,0.00020582607,0.00009280167,0.00020214856],"category_scores_gemma":[0.00010040376,0.00011678232,0.00023655822,0.003502635,0.00005188262,0.00008758919,0.00019128714,0.00012789959,0.000007896966],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020026457,0.0005447758,0.36691338,0.0006160674,0.011873083,0.000065886365,0.018487893,0.041976705,0.017089712,0.00029656495,0.08020928,0.44190022],"study_design_scores_gemma":[0.0033439014,0.00050178374,0.96791524,0.0015385372,0.00034621943,0.000003983694,0.0010347732,0.021638358,0.0022728913,0.000010506702,0.0012504605,0.00014336861],"about_ca_topic_score_codex":0.0017928968,"about_ca_topic_score_gemma":0.0003245406,"teacher_disagreement_score":0.60100186,"about_ca_system_score_codex":0.00030694346,"about_ca_system_score_gemma":0.00021514446,"threshold_uncertainty_score":0.47622448},"labels":[],"label_agreement":null},{"id":"W4321769995","doi":"10.1016/j.esmoop.2023.100787","title":"Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies","year":2023,"lang":"en","type":"review","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Hazard ratio; Randomized controlled trial; Confidence interval; Meta-analysis; Placebo; Odds ratio; Oncology; Pathology","score_opus":0.09677872305832615,"score_gpt":0.40661535831806084,"score_spread":0.3098366352597347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321769995","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000046847148,0.98308784,6.1685e-7,0.00020481917,0.0001528508,0.01626732,0.000109937915,0.000028692984,0.000101057354],"genre_scores_gemma":[0.00028612808,0.9938407,0.000035118494,0.000037917955,0.00000961248,0.0013647927,0.00033344782,0.00007473068,0.0040175724],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98988014,0.0020318462,0.0066591096,0.0005749048,0.00059124664,0.0002627709],"domain_scores_gemma":[0.9918637,0.0012006972,0.0053219143,0.0011593404,0.00037477355,0.00007956159],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.009674848,0.0007094877,0.036217123,0.0006862566,0.000071916234,0.00001411922,0.0006034514,0.000274778,0.0006655329],"category_scores_gemma":[0.00213537,0.0004039958,0.013651152,0.0021731805,0.0003510334,0.000093907634,0.0005917647,0.00031369875,0.000035933423],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018172127,0.00009485661,1.4824363e-7,0.46418482,0.53340834,0.000013162824,0.00015674335,3.9652565e-7,0.0000027703034,0.000006260276,0.000020862277,0.0002943972],"study_design_scores_gemma":[0.020148009,0.000091906055,0.0000058385467,0.19859676,0.7801633,0.00003286905,0.000116943615,0.0000018386296,0.000018877656,0.000009792481,0.00056191004,0.00025199953],"about_ca_topic_score_codex":0.0016260529,"about_ca_topic_score_gemma":0.00003187991,"teacher_disagreement_score":0.26558807,"about_ca_system_score_codex":0.0001124447,"about_ca_system_score_gemma":0.0002958527,"threshold_uncertainty_score":0.9998412},"labels":[],"label_agreement":null},{"id":"W4321793664","doi":"10.1016/j.jtocrr.2023.100482","title":"Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Performance status; Pembrolizumab; Internal medicine; Nivolumab; Emergency department; Oncology; Immunotherapy; Cancer; Nursing","score_opus":0.10305086351462374,"score_gpt":0.46670079103210477,"score_spread":0.36364992751748104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321793664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99838865,0.00034823894,3.099327e-7,0.00026809057,0.00004560785,0.0007516809,0.00000820539,0.00002117561,0.00016801737],"genre_scores_gemma":[0.9978762,0.0018535003,0.000016781876,0.000015701165,0.000015339385,0.000016443128,0.00008757498,0.000016221502,0.00010221897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782836,0.000122593,0.0007000918,0.00032204142,0.0006792292,0.00034769217],"domain_scores_gemma":[0.99890727,0.0001375008,0.00019564437,0.000244478,0.00033654977,0.00017855626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018009522,0.00012252112,0.00047202597,0.00021929576,0.00007900366,0.000011264747,0.00002174059,0.00007339064,0.000008248023],"category_scores_gemma":[0.00022229031,0.000064119486,0.00006293181,0.000619415,0.0003169252,0.0000643398,0.000034509852,0.0002933677,3.931385e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009633495,0.0002513454,0.90500104,0.0001438946,0.00007807264,0.0000449945,0.00024656762,0.0000050278863,0.000026318367,4.0915134e-7,0.000023857026,0.08454498],"study_design_scores_gemma":[0.0058168056,0.01227145,0.98071384,0.00054904143,0.0000066085013,0.0000040247696,0.000277713,0.000016906133,0.00013229436,0.0000014090276,0.00013618387,0.00007372022],"about_ca_topic_score_codex":0.0010602609,"about_ca_topic_score_gemma":0.00017968215,"teacher_disagreement_score":0.084471256,"about_ca_system_score_codex":0.00013553762,"about_ca_system_score_gemma":0.00048160017,"threshold_uncertainty_score":0.2614717},"labels":[],"label_agreement":null},{"id":"W4322208210","doi":"10.1016/j.transci.2023.103685","title":"Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient’s safety and survival outcome:A systematic narrative appraisal of where we are now!","year":2023,"lang":"en","type":"review","venue":"Transfusion and Apheresis Science","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Saskatchewan Cancer Agency","funders":"","keywords":"Medicine; Adverse effect; Intensive care medicine; Immune system; Immunotherapy; Narrative review; Immunology; Cancer; Oncology; Internal medicine","score_opus":0.05563457838782358,"score_gpt":0.35856968191949684,"score_spread":0.30293510353167324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322208210","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42223442,0.5760421,0.0000030510803,0.00018676504,0.00006813855,0.0013756177,0.000058352085,0.00001104288,0.000020519912],"genre_scores_gemma":[0.25725657,0.74264616,0.000010239982,0.000004969838,0.000008688635,0.000013813409,0.0000022360325,0.00001763094,0.00003970821],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9969272,0.00038847176,0.0014259146,0.00055659184,0.00044336813,0.00025844653],"domain_scores_gemma":[0.9975875,0.0012743317,0.00064184517,0.00026723812,0.00010531207,0.00012378287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019502728,0.00045417927,0.002781709,0.00028403208,0.00024654233,0.000036885467,0.0001665655,0.00022994813,0.000027404118],"category_scores_gemma":[0.00010545679,0.00022511609,0.00035903836,0.00077138527,0.0024403636,0.000081679595,0.00006615986,0.00026853415,1.8114535e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016997376,0.0012962287,0.0016065999,0.6233914,0.0035042188,0.00003031564,0.04032273,0.0000013605647,0.2005094,0.00059662695,0.000011095314,0.111732654],"study_design_scores_gemma":[0.05485669,0.011411825,0.03344095,0.8053422,0.01165335,0.0019025648,0.055979613,0.0002386192,0.02142778,0.000081652615,0.0010792764,0.0025854711],"about_ca_topic_score_codex":0.00022193963,"about_ca_topic_score_gemma":0.000117762065,"teacher_disagreement_score":0.18195081,"about_ca_system_score_codex":0.000030227455,"about_ca_system_score_gemma":0.00013611543,"threshold_uncertainty_score":0.91799676},"labels":[],"label_agreement":null},{"id":"W4322422761","doi":"10.1016/s1470-2045(22)00742-2","title":"Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop","year":2023,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institutes of Health; National Cancer Institute; Canadian Institute of Steel Construction","keywords":"Medical physics; Medicine; Clinical trial; Magnetic resonance imaging; Cancer; Immunotherapy; Steering committee; Radiology; Pathology; Internal medicine; Engineering","score_opus":0.3285918679246932,"score_gpt":0.5010001650143106,"score_spread":0.17240829708961736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322422761","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000034677687,0.94496715,0.0002099854,0.044381082,0.005726459,0.0023065743,0.00072674314,0.00023372188,0.0014136013],"genre_scores_gemma":[0.000009558599,0.95828176,0.00044467463,0.024733575,0.01207981,0.0020793686,0.00027355875,0.00017629443,0.0019214266],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99457663,0.0014052195,0.0017886492,0.0007428314,0.00064389076,0.00084275403],"domain_scores_gemma":[0.99230295,0.00535834,0.0010971593,0.00090206135,0.00023318679,0.00010628415],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0063871117,0.0007105436,0.003974652,0.00022308463,0.00054718467,0.00028063447,0.0013228572,0.0002786725,0.00046464027],"category_scores_gemma":[0.0008727356,0.00039532266,0.00092127663,0.000994205,0.00041318557,0.0002244803,0.00034121829,0.0013482288,0.000067439105],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077737804,0.000028378772,0.000104377796,0.00060619257,0.001622422,0.00004009824,0.00061646814,0.00002185972,0.000118039716,0.000029500558,0.17156135,0.8244739],"study_design_scores_gemma":[0.0026071214,0.000022504351,0.0003617681,0.023809193,0.000918647,0.000049050668,0.0001752734,0.000046191883,0.000004525268,0.000066876724,0.97148854,0.0004503122],"about_ca_topic_score_codex":0.007829903,"about_ca_topic_score_gemma":0.003028478,"teacher_disagreement_score":0.8240236,"about_ca_system_score_codex":0.0029635762,"about_ca_system_score_gemma":0.0034563087,"threshold_uncertainty_score":0.99984986},"labels":[],"label_agreement":null},{"id":"W4322617905","doi":"10.2217/imt-2022-0210","title":"Antithymocyte Globulin for Aplastic Anemia Secondary to Pembrolizumab: A Case Report and Review of Literature","year":2023,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Aplastic anemia; Medicine; Pembrolizumab; Anemia; Immunology; Globulin; Immunotherapy; Internal medicine; Immune system; Gastroenterology; Bone marrow","score_opus":0.03739182895557941,"score_gpt":0.37282529568210915,"score_spread":0.33543346672652974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322617905","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006409674,0.99335873,0.000081884486,0.00022534783,0.0005524901,0.0047482094,0.00073434884,0.00010003487,0.00013487601],"genre_scores_gemma":[0.0000018029775,0.9935279,0.0007762878,0.0011384011,0.00029349967,0.0005868529,0.0006053332,0.00019862922,0.0028713106],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968284,0.000103867445,0.0016528448,0.00072843855,0.00028800408,0.0003984905],"domain_scores_gemma":[0.9974239,0.00037285037,0.00076236174,0.0010264745,0.00026826476,0.00014615353],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000859635,0.00065416034,0.0031583505,0.0003895793,0.00009566807,0.00005136182,0.00020000238,0.00044519413,0.00014029977],"category_scores_gemma":[0.0002170182,0.00048945745,0.0010617308,0.0010282695,0.000112062386,0.000067481014,0.000051448682,0.0004516676,0.000016369753],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009995212,0.00004530466,5.927865e-7,0.30291677,0.0008893071,0.012431139,0.000098071185,1.1252134e-8,0.000032999586,0.000015760108,0.0064070984,0.67616343],"study_design_scores_gemma":[0.0014899449,0.0005292821,0.000004597139,0.24529323,0.00068302895,0.104962595,0.0000064673054,5.061201e-7,0.0000067994915,0.000006728309,0.64671975,0.00029705957],"about_ca_topic_score_codex":0.00006682931,"about_ca_topic_score_gemma":0.000010841343,"teacher_disagreement_score":0.67586637,"about_ca_system_score_codex":0.00019171489,"about_ca_system_score_gemma":0.0009992389,"threshold_uncertainty_score":0.9997557},"labels":[],"label_agreement":null},{"id":"W4322761884","doi":"10.1016/j.jtcvs.2023.01.034","title":"Turning the tides on the perioperative care of resectable lung cancer","year":2023,"lang":"en","type":"editorial","venue":"Journal of Thoracic and Cardiovascular Surgery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Perioperative; Lung cancer; Oncology; Stage (stratigraphy); Disease; Adverse effect; Chemotherapy; Internal medicine; Immune system; Clinical trial; Immune checkpoint; Cancer; Immunotherapy; Intensive care medicine; Surgery; Immunology","score_opus":0.019273430034202055,"score_gpt":0.3203678076819673,"score_spread":0.30109437764776525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322761884","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.045875207,0.44652295,0.000018707235,0.00066245726,0.50622153,0.00034507574,0.00006605102,0.000012314163,0.00027571036],"genre_scores_gemma":[0.10077559,0.19186004,0.000019692976,0.00022331146,0.70530957,0.00007727767,0.000039534294,0.00016870108,0.0015263064],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968825,0.00051884557,0.00062850467,0.00021647448,0.0015128754,0.00024081318],"domain_scores_gemma":[0.99510664,0.002931255,0.0005085508,0.00051395904,0.0008722074,0.00006739891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043896637,0.00026551637,0.0012785604,0.00019831624,0.0002314716,0.00007029476,0.00016725012,0.00030530224,0.00004870387],"category_scores_gemma":[0.0015016794,0.0001254159,0.002382544,0.0003550304,0.00019410439,0.00006974875,0.000052727348,0.0011660521,6.90767e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021485002,0.000014676829,0.00038828191,0.0008769618,0.0118266335,0.000269038,0.0020969778,0.00015029297,0.00021310737,8.216104e-7,0.950106,0.031908657],"study_design_scores_gemma":[0.00033087516,0.00015617118,0.0007476654,0.004776369,0.0029459065,0.00010775378,0.004364895,0.000008550666,0.0015049811,0.0000028479442,0.9848519,0.00020209809],"about_ca_topic_score_codex":0.00031515933,"about_ca_topic_score_gemma":0.000019875706,"teacher_disagreement_score":0.25466293,"about_ca_system_score_codex":0.00016499663,"about_ca_system_score_gemma":0.0010994812,"threshold_uncertainty_score":0.51143116},"labels":[],"label_agreement":null},{"id":"W4322769285","doi":"10.1158/1538-7445.sabcs22-pd9-06","title":"Abstract PD9-06: Histopathological and molecular immune landscape and DNA damage response signatures to predict response to carboplatin and docetaxel in TNT trial TNBC cohort","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Shared Health","funders":"","keywords":"Immune system; Docetaxel; Oncology; Carboplatin; Medicine; Triple-negative breast cancer; Internal medicine; Breast cancer; Cancer; Cohort; Cancer research; Immunology; Chemotherapy; Cisplatin","score_opus":0.04054599805270391,"score_gpt":0.38241318281013653,"score_spread":0.3418671847574326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322769285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98428994,0.0049174395,0.0000014651881,0.008441868,0.00010203191,0.0019847099,0.00006750407,0.00005431889,0.00014070369],"genre_scores_gemma":[0.9970812,0.00086394703,0.000041867275,0.0003953516,0.00009545965,0.0004690828,0.000014053705,0.000033454926,0.0010055699],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9970778,0.0006824831,0.00036484667,0.0006455769,0.0006503862,0.0005788802],"domain_scores_gemma":[0.9982346,0.0008757869,0.00003762044,0.00038586435,0.0001102246,0.0003559037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067476556,0.00020176914,0.00043548085,0.00079965015,0.00013856184,0.00007861448,0.00014016604,0.00020749983,0.00010120816],"category_scores_gemma":[0.0016143018,0.00016693628,0.000048541446,0.0010100397,0.00027429947,0.000055869117,0.00023406917,0.0006114522,0.000007721723],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34995604,0.000042326585,0.005774659,0.00005452499,0.00003392801,0.0011034547,0.00080737536,0.0000068442973,0.63784385,0.0000036567194,0.0023455792,0.0020277987],"study_design_scores_gemma":[0.019260963,0.002206312,0.9577213,0.00029707156,0.0000190466,0.000027812368,0.00039801796,0.000037951704,0.01155197,0.000023227893,0.008254515,0.00020182072],"about_ca_topic_score_codex":0.0003913808,"about_ca_topic_score_gemma":0.00007969354,"teacher_disagreement_score":0.9519466,"about_ca_system_score_codex":0.00024061574,"about_ca_system_score_gemma":0.00036479058,"threshold_uncertainty_score":0.68074644},"labels":[],"label_agreement":null},{"id":"W4322774054","doi":"10.1158/1538-7445.sabcs22-p2-23-17","title":"Abstract P2-23-17: Programmed death ligand-1 expression in triple-negative breast cancer from Nigeria","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Triple-negative breast cancer; Medicine; Breast cancer; Incidence (geometry); Immunohistochemistry; Cancer; Oncology; Estrogen receptor; Internal medicine; Pathology","score_opus":0.09576948097587393,"score_gpt":0.42849388761945884,"score_spread":0.33272440664358494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322774054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98900104,0.0028938488,0.0000016253958,0.004857244,0.00042312779,0.0014368852,0.00040930594,0.0001132093,0.00086368946],"genre_scores_gemma":[0.9866743,0.005989961,0.000047502886,0.0002381867,0.00070242205,0.0017483416,0.000109419176,0.000063841515,0.004425993],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99689984,0.00014233428,0.00040551147,0.00063494063,0.00097545073,0.00094189116],"domain_scores_gemma":[0.9986072,0.00031007646,0.00008197495,0.0004533302,0.0002827842,0.00026459547],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010268192,0.0002320728,0.00042258578,0.00048388462,0.00018553321,0.00008325402,0.0002794372,0.0002128757,0.0022289618],"category_scores_gemma":[0.00010547352,0.0001848835,0.0001333595,0.001755496,0.00023963152,0.00012462444,0.0001145013,0.0007936895,0.00011763484],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011891958,0.00023725325,0.08236878,0.00017075492,0.00019644944,0.00025120733,0.0026762555,0.000010731838,0.7743956,0.0000027301223,0.044710048,0.083088234],"study_design_scores_gemma":[0.006955318,0.00015365913,0.79922205,0.0018336994,0.000014237819,0.0000056387457,0.0012571306,0.000041115673,0.17638588,0.00018816577,0.01367754,0.00026554658],"about_ca_topic_score_codex":0.020401401,"about_ca_topic_score_gemma":0.004630083,"teacher_disagreement_score":0.71685326,"about_ca_system_score_codex":0.0009492846,"about_ca_system_score_gemma":0.001100937,"threshold_uncertainty_score":0.99868315},"labels":[],"label_agreement":null},{"id":"W4322775509","doi":"10.1158/1538-7445.sabcs22-pd9-05","title":"Abstract PD9-05: Stromal tumor-infiltrating lymphocytes identify early-stage triple-negative breast cancer patients with favorable outcomes at 10-year follow-up in the absence of systemic therapy: a pooled analysis of 1835 patients","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Alberta","funders":"","keywords":"Medicine; Oncology; Triple-negative breast cancer; Internal medicine; Systemic therapy; Breast cancer; Stage (stratigraphy); Adjuvant therapy; Biomarker; Cancer","score_opus":0.04254153472431679,"score_gpt":0.36010775946637796,"score_spread":0.3175662247420612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322775509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996339,0.00044844954,5.110888e-7,0.00011669134,0.00013163772,0.0015601835,0.0012514472,0.00002575991,0.00012629834],"genre_scores_gemma":[0.9977787,0.00051074894,0.000006186464,0.000051381307,0.000029690314,0.00040128874,0.00009524315,0.000041690426,0.0010850392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99578774,0.00032286925,0.00077214814,0.0005129479,0.0019262526,0.00067804876],"domain_scores_gemma":[0.9972504,0.00060638256,0.0004625155,0.0005789252,0.0009977887,0.00010399056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014030081,0.00027571982,0.0008461875,0.00091748027,0.00019408255,0.00005466635,0.00046956132,0.00009465331,0.0009040901],"category_scores_gemma":[0.0001591734,0.00017452458,0.00029574946,0.004488075,0.0003716882,0.00020789079,0.00009046846,0.0003244339,0.000009767388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0104740495,0.0002320028,0.96496904,0.00029161197,0.0022238381,0.000015808082,0.0038363538,0.00011870147,0.01615719,0.000002787441,0.0003544243,0.0013241721],"study_design_scores_gemma":[0.012165402,0.00049486523,0.9777946,0.00087820046,0.00017889452,8.2231406e-7,0.0029648065,0.00007755191,0.005255677,0.0000026647745,0.00001614327,0.00017039306],"about_ca_topic_score_codex":0.031316277,"about_ca_topic_score_gemma":0.0042098463,"teacher_disagreement_score":0.02710643,"about_ca_system_score_codex":0.00096834934,"about_ca_system_score_gemma":0.0007719921,"threshold_uncertainty_score":0.98991525},"labels":[],"label_agreement":null},{"id":"W4322775526","doi":"10.1158/1538-7445.sabcs22-pd11-02","title":"Abstract PD11-02: PD11-02 A Phase II Randomized Window of Opportunity Trial Evaluating Cytotoxic and Immunomodulatory effects of Intratumoral INT230-6 in Early Stage Breast Cancer: the INVINCIBLE Trial","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Canada; McMaster University; Ontario Institute for Cancer Research; Institute of Cancer Research; Ottawa Hospital","funders":"","keywords":"Medicine; Breast cancer; Tumor microenvironment; Cancer; Cytotoxic T cell; Immune system; Immunotherapy; Oncology; Clinical trial; Internal medicine; Immunology; Cancer research; Biology; In vitro","score_opus":0.11706761168293735,"score_gpt":0.45392317659157977,"score_spread":0.33685556490864244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322775526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98779696,0.003106354,0.0000011344432,0.0010378213,0.00061417924,0.007144544,0.00018047325,0.000034645895,0.00008390392],"genre_scores_gemma":[0.99350524,0.0036480874,0.000008314932,0.000065136715,0.00047999778,0.0018172781,0.00002382899,0.000049084792,0.0004030082],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948848,0.0013639703,0.0011459726,0.00049742055,0.0013825531,0.0007253159],"domain_scores_gemma":[0.99627787,0.0020053308,0.00043520425,0.0006393014,0.00041743123,0.00022486616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011698462,0.00028714622,0.0012794997,0.0006873876,0.00026321702,0.000048310336,0.00036454876,0.00019651634,0.0004844753],"category_scores_gemma":[0.0014995235,0.00020331096,0.0003137736,0.001560949,0.0012565907,0.00018945218,0.00022827771,0.0010579585,0.0000024394415],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7134745,0.00045315732,0.00027743628,0.0006058581,0.0003661481,0.000042693875,0.0017158609,0.000009884453,0.25912693,0.000009107814,0.0002968561,0.02362154],"study_design_scores_gemma":[0.9225731,0.0055031367,0.016350446,0.0012254337,0.000121210716,0.000006384798,0.00048609325,0.00032022365,0.053050555,0.0000604362,0.0001005978,0.00020236889],"about_ca_topic_score_codex":0.016567705,"about_ca_topic_score_gemma":0.00068399066,"teacher_disagreement_score":0.20909859,"about_ca_system_score_codex":0.00051902235,"about_ca_system_score_gemma":0.0034589153,"threshold_uncertainty_score":0.98998106},"labels":[],"label_agreement":null},{"id":"W4323058948","doi":"10.1211/pj.2023.1.176484","title":"Recent antibiotic reduces cancer survival after immune checkpoint inhibitors by 12%, study results show","year":2023,"lang":"en","type":"article","venue":"Pharmaceutical journal/˜The œpharmaceutical journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Antibiotics; Cancer; Oncology; Cohort; Immune checkpoint; Cancer therapy; Internal medicine; Cohort study; Immunotherapy; Biology; Microbiology","score_opus":0.09340975753077818,"score_gpt":0.4088140495391065,"score_spread":0.3154042920083283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323058948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85889,0.037148993,0.000049591006,0.09171255,0.009159193,0.0017105807,0.000121961566,0.0002865735,0.0009205731],"genre_scores_gemma":[0.8859952,0.1041409,0.000054875596,0.00390995,0.0040421593,0.00004850293,0.000017786026,0.00017853502,0.0016120753],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9892929,0.0016219015,0.00307039,0.00087652594,0.0028991892,0.0022390732],"domain_scores_gemma":[0.99499357,0.00068713963,0.00079315505,0.000609999,0.0007111741,0.0022049677],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009068152,0.00093879545,0.0012592742,0.00057818566,0.0013028422,0.00080113474,0.0010033449,0.00032497256,0.0029881867],"category_scores_gemma":[0.00051395304,0.0006094619,0.0011116497,0.0018395756,0.00085625565,0.0005019713,0.00038805243,0.005880513,0.00030290952],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061961185,0.004800426,0.017406011,0.00016947305,0.006241148,0.0067522307,0.0029964806,0.000071344504,0.30533284,0.000005008531,0.09991832,0.49434555],"study_design_scores_gemma":[0.03666609,0.0018120237,0.029438706,0.0009608523,0.0031196612,0.008698071,0.004158769,0.0016897531,0.11202172,0.00008581084,0.7999391,0.0014094684],"about_ca_topic_score_codex":0.000029092018,"about_ca_topic_score_gemma":0.00001341299,"teacher_disagreement_score":0.70002073,"about_ca_system_score_codex":0.0010213793,"about_ca_system_score_gemma":0.00080569315,"threshold_uncertainty_score":0.9999973},"labels":[],"label_agreement":null},{"id":"W4323353417","doi":"10.1093/jcag/gwac036.242","title":"A242 DELAYED STEROID TAPER MAY REDUCE RISK OF RELAPSE IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR ASSOCIATED HEPATOTOXICIT","year":2023,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Methylprednisolone; Hepatitis; Prednisolone; Steroid use; Gastroenterology; Cancer","score_opus":0.006071217340296956,"score_gpt":0.21655890744050457,"score_spread":0.21048769010020763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323353417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943677,0.000021197498,0.0000012892787,0.004735762,0.0004458234,0.00026062157,0.00012355502,0.000004385018,0.000039618193],"genre_scores_gemma":[0.99914736,0.00005311356,0.000038804486,0.00035093472,0.000043233795,0.0000029671899,0.000018342651,0.000019308163,0.0003259576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771214,0.00041305387,0.00095297914,0.000107521475,0.0004636076,0.00035069656],"domain_scores_gemma":[0.9967531,0.00007400575,0.0023444747,0.00018455992,0.0005170794,0.00012681332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016559346,0.00012789345,0.0005426935,0.00047021362,0.000056917503,0.0000070629626,0.00018169351,0.00017063029,0.00004191611],"category_scores_gemma":[0.0005644428,0.000092202565,0.00025908,0.00045728695,0.0000758008,0.00007456043,0.000023313865,0.000437967,0.0000017443951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005445172,0.00014039512,0.98784506,0.000012346975,0.0008190305,0.000008183734,0.00031700596,0.000052797335,0.0033211918,6.982954e-7,0.0019328311,0.00010525887],"study_design_scores_gemma":[0.010038826,0.002442672,0.9857668,0.00022339523,0.00015879408,0.000009056681,0.00009157639,0.000025325968,0.0010123025,0.000010118312,0.0001734709,0.000047629717],"about_ca_topic_score_codex":0.008659833,"about_ca_topic_score_gemma":0.16487733,"teacher_disagreement_score":0.15621749,"about_ca_system_score_codex":0.001959293,"about_ca_system_score_gemma":0.00045541936,"threshold_uncertainty_score":0.9979416},"labels":[],"label_agreement":null},{"id":"W4323354020","doi":"10.4049/jimmunol.2200646","title":"cIAP1/2 Antagonism Induces Antigen-Specific T Cell–Dependent Immunity","year":2023,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Moonshot; National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Institutes of Health; Moderna; National Institute of Diabetes and Digestive and Kidney Diseases; Novartis Institutes for BioMedical Research; Tillotts Pharma; Moonshot Research and Development Program; Bristol-Myers Squibb; Eli Lilly and Company; Foghorn Therapeutics; Society for Immunotherapy of Cancer; Mallinckrodt Pharmaceuticals; Novartis; National Cancer Institute; Melanoma Research Alliance; Ludwig Center at Harvard; Deutsche Forschungsgemeinschaft","keywords":"Biology; Cancer research; Cytotoxic T cell; T cell; CD28; Cell biology; Immune system; Immunology; In vitro","score_opus":0.0315629959148587,"score_gpt":0.2834355051629644,"score_spread":0.25187250924810567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323354020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754667,0.018121274,0.00003307506,0.0034017055,0.0015264583,0.00013753863,0.000004223255,0.000034231947,0.0012747715],"genre_scores_gemma":[0.93594164,0.06257293,0.00003476741,0.0003261713,0.00024609195,0.0000014389226,0.0000051185343,0.000020748872,0.0008510982],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985073,0.0002681654,0.0005520139,0.00008631895,0.00027255528,0.00031360035],"domain_scores_gemma":[0.9987773,0.0001963074,0.00041381386,0.0004017305,0.00016575471,0.000045118606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014849612,0.00014785497,0.00036894676,0.00028596228,0.0002117963,0.000017386075,0.00041886556,0.00013583804,0.0003029963],"category_scores_gemma":[0.000029742929,0.00009033257,0.00018861597,0.00044801994,0.00027943886,0.00008514122,0.00009122718,0.00070459174,0.00012815106],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029709411,0.000115244875,0.000447249,0.00000880238,0.00039590697,0.000112966256,0.0013656263,0.0000033298948,0.972018,0.000024676216,0.004111289,0.01842596],"study_design_scores_gemma":[0.0054182145,0.0019292177,0.22398533,0.00010895312,0.00009612644,0.0033627308,0.006170224,0.0000039092197,0.6523477,0.00030534304,0.10606784,0.00020444804],"about_ca_topic_score_codex":0.00007926739,"about_ca_topic_score_gemma":0.000003120538,"teacher_disagreement_score":0.31967032,"about_ca_system_score_codex":0.00009630081,"about_ca_system_score_gemma":0.00018351652,"threshold_uncertainty_score":0.36836553},"labels":[],"label_agreement":null},{"id":"W4324046120","doi":"10.1016/j.ccell.2023.02.017","title":"B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity","year":2023,"lang":"en","type":"review","venue":"Cancer Cell","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":227,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia","funders":"BC Cancer Agency; BC Cancer Foundation; Michael Smith Health Research BC","keywords":"Effector; Tumor microenvironment; Immunity; Cancer research; Tumor cells; Biology; Cell biology; Immunology; Immune system","score_opus":0.03040074006533063,"score_gpt":0.2997326561663102,"score_spread":0.26933191610097956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324046120","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026193755,0.9711931,0.000001497959,0.00002228269,0.0003662946,0.001920808,0.0002322029,0.00002985549,0.00004022524],"genre_scores_gemma":[0.0017177367,0.9971786,0.000050350867,0.0001479731,0.00008528324,0.00013345758,0.00008220295,0.000111777874,0.0004926124],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978754,0.0003875219,0.0007015207,0.00043546894,0.00024813323,0.00035197195],"domain_scores_gemma":[0.9984597,0.00025479269,0.00048306104,0.0007056927,0.000020923973,0.00007585689],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006620736,0.00047057017,0.0016425656,0.00014692236,0.000067411725,0.000018783081,0.00032887212,0.00017595175,0.00022975804],"category_scores_gemma":[0.000019043877,0.00030870078,0.00034527906,0.0006148548,0.0002733446,0.000036719342,0.000099381294,0.0004907805,0.000017770253],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001041457,0.0019015874,0.0034524256,0.33101273,0.0030552023,0.0007229515,0.0044674524,0.0000050502695,0.13631184,0.0000042402235,0.013372847,0.5046522],"study_design_scores_gemma":[0.0037375651,0.00025237558,0.0030493005,0.021671236,0.0018000551,0.000071703966,0.00048269902,0.000008172623,0.011214691,6.7998974e-7,0.95709455,0.00061697856],"about_ca_topic_score_codex":0.0014693581,"about_ca_topic_score_gemma":0.00011713123,"teacher_disagreement_score":0.9437217,"about_ca_system_score_codex":0.0004185164,"about_ca_system_score_gemma":0.00029886558,"threshold_uncertainty_score":0.9999365},"labels":[],"label_agreement":null},{"id":"W4324056400","doi":"10.3390/curroncol30030247","title":"Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study)","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université Laval; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; McGill University Health Centre; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Oncology; Internal medicine; First line treatment; Family medicine; Cancer; Immunotherapy; Chemotherapy","score_opus":0.03587474657463547,"score_gpt":0.32278180727893385,"score_spread":0.2869070607042984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324056400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973411,0.00066496764,0.000010140771,0.00009217193,0.00015022758,0.0015038392,0.00004444386,0.000027312122,0.0001657755],"genre_scores_gemma":[0.9988489,0.00066638924,0.000017015873,0.0000063130324,0.00001832026,0.000082715065,0.0001163407,0.00001988828,0.0002241314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981758,0.00024112593,0.00051777286,0.00048631898,0.00018214835,0.00039681687],"domain_scores_gemma":[0.99919224,0.00013471901,0.0002857773,0.00024342892,0.000066760775,0.00007706159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002550914,0.00027060736,0.00097052916,0.0014910398,0.000072789146,0.000008540361,0.00012789069,0.00010684202,0.000041607815],"category_scores_gemma":[0.00001619588,0.0002276336,0.00014181812,0.0017771651,0.00009142114,0.00010152575,0.00005979735,0.00026170004,8.145638e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074789734,0.0043746666,0.9520158,0.0001415664,0.0004855024,0.00016860027,0.022191463,0.0010107834,0.000094431954,2.5185201e-7,0.000037733244,0.012000188],"study_design_scores_gemma":[0.024597997,0.003053508,0.9598464,0.0010674905,0.00079091865,3.78285e-7,0.0070768697,0.0029365292,0.00015632028,2.0972914e-7,0.00027157005,0.00020184105],"about_ca_topic_score_codex":0.107797146,"about_ca_topic_score_gemma":0.4870892,"teacher_disagreement_score":0.37929207,"about_ca_system_score_codex":0.004300855,"about_ca_system_score_gemma":0.00034427198,"threshold_uncertainty_score":0.99952143},"labels":[],"label_agreement":null},{"id":"W4324129452","doi":"10.1007/s40487-023-00224-9","title":"Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review","year":2023,"lang":"en","type":"review","venue":"Oncology and Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Breast cancer; Malignancy; Adverse effect; Cancer; Oncology; Narrative review; Adjuvant; Internal medicine; Metastatic breast cancer; Immune system; Intensive care medicine; Immunology","score_opus":0.054315171648327346,"score_gpt":0.4046859411102719,"score_spread":0.35037076946194456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324129452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000071667266,0.9923359,9.2175014e-8,0.004442444,0.00051617756,0.0019440993,0.000049979422,0.000055089957,0.0005845239],"genre_scores_gemma":[0.0000043369314,0.9963166,0.000008885898,0.001385426,0.00028520598,0.00091708876,0.00007507325,0.00006065114,0.0009467118],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978399,0.00031339342,0.0009516603,0.00044988535,0.00013172036,0.00031339427],"domain_scores_gemma":[0.9989923,0.00015182406,0.000436786,0.00028555383,0.00004929453,0.00008420055],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008467906,0.0004182768,0.0027822074,0.00023408902,0.000074929456,0.000008380481,0.00011986234,0.00052541663,0.0004712477],"category_scores_gemma":[0.000014415133,0.00028396887,0.0005385563,0.0007198178,0.0002226761,0.000039615887,0.00003848706,0.00067346863,0.000028959294],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047856919,0.0001299759,0.000026088195,0.017131798,0.0006846821,0.00011111215,0.00037473798,3.2241623e-9,0.00001315978,0.000008086133,0.001958934,0.9790829],"study_design_scores_gemma":[0.0019137701,0.0003699225,0.0002377591,0.103891276,0.0002787264,0.0005283861,0.00007421268,1.6949747e-7,0.0000021757778,0.000016859824,0.892444,0.00024274107],"about_ca_topic_score_codex":0.00038123713,"about_ca_topic_score_gemma":0.00012403943,"teacher_disagreement_score":0.9788401,"about_ca_system_score_codex":0.00043089283,"about_ca_system_score_gemma":0.0011456934,"threshold_uncertainty_score":0.99996126},"labels":[],"label_agreement":null},{"id":"W4324149309","doi":"10.51731/cjht.2022.596","title":"Pembrolizumab (Keytruda)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pembrolizumab; Reimbursement; Medicine; Bevacizumab; Test (biology); Family medicine; Intensive care medicine; Chemotherapy; Cancer; Internal medicine; Health care; Immunotherapy; Political science","score_opus":0.038417204387254815,"score_gpt":0.3117376367690041,"score_spread":0.2733204323817493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324149309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7166063,0.08047093,0.000054745855,0.19996922,0.0010615438,0.00030841847,0.000017413622,0.00041128136,0.0011001534],"genre_scores_gemma":[0.99646455,0.0021123716,0.00013623963,0.0009581945,0.00001713191,0.0000027312444,0.0000024630215,0.0000128994125,0.00029339292],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989492,0.000019841222,0.00040119622,0.00008311081,0.000140389,0.0004062119],"domain_scores_gemma":[0.99938554,0.000026318006,0.00020637254,0.00019686723,0.00009649765,0.00008842427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005281416,0.00008349108,0.00028743068,0.0009062113,0.00015521508,0.000015796273,0.00017525417,0.00011018229,0.000057708497],"category_scores_gemma":[0.0002266633,0.000066642104,0.00010258137,0.000729328,0.0001786456,0.000051129413,0.0000087703565,0.00029864532,0.000027883409],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014941081,0.0000074337304,0.0065322123,0.00011173048,0.000076394834,0.00047123551,0.0002618195,0.0000019262056,0.00030590527,0.00029773952,0.059211314,0.9325729],"study_design_scores_gemma":[0.0018702062,0.0010870118,0.08801529,0.00043220748,0.00001630513,0.0014903153,0.004551306,0.0000112185635,0.000990849,0.0015524658,0.8998606,0.0001222089],"about_ca_topic_score_codex":0.0024403597,"about_ca_topic_score_gemma":0.0015300225,"teacher_disagreement_score":0.93245065,"about_ca_system_score_codex":0.00037038923,"about_ca_system_score_gemma":0.0033715025,"threshold_uncertainty_score":0.59809005},"labels":[],"label_agreement":null},{"id":"W4353015145","doi":"10.1038/s41588-023-01316-y","title":"Author Correction: The landscape of viral associations in human cancers","year":2023,"lang":"en","type":"erratum","venue":"Nature Genetics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; BC Cancer Agency; University of British Columbia; Prostate Cancer Canada; Simon Fraser University; University of Ottawa; McGill University; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Calgary; Vector Institute; University of Toronto; McGill University and Génome Québec Innovation Centre; Toronto General Hospital; University Health Network; Genome Canada; Canada's Michael Smith Genome Sciences Centre; Hospital for Sick Children; Université de Montréal; Institute of Cancer Research; Ontario Institute for Cancer Research","funders":"Medical Research Council; Cancer Research UK","keywords":"Biology; Computational biology; Evolutionary biology; Virology; Genetics","score_opus":0.01618637235036813,"score_gpt":0.31752070353098266,"score_spread":0.30133433118061453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353015145","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.104304284,0.1701617,0.000016153184,0.021917364,0.50307095,0.004368757,0.0018825522,0.0004659576,0.1938123],"genre_scores_gemma":[0.13319302,0.004503771,0.000048306512,0.0011931233,0.0052921493,0.00006190801,0.0016888077,0.000112058646,0.85390687],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987488,0.00005073663,0.00034568645,0.00022389805,0.00042306364,0.00020785941],"domain_scores_gemma":[0.99915385,0.00006052293,0.00025382702,0.00036189886,0.00013752823,0.00003237909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002792737,0.00017998867,0.00036528445,0.00019564896,0.00008975111,0.000014727513,0.00018223526,0.0012230878,0.000101856065],"category_scores_gemma":[0.000090013724,0.00013336186,0.00018658009,0.000619082,0.000074815405,0.000008882916,0.000033882257,0.0020369827,0.000003936603],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083560255,0.000022792929,0.004622562,0.00006027698,0.00019720162,0.0000066335797,0.00032359114,0.000018202654,0.00019459981,0.0000048380825,0.99198866,0.0024770864],"study_design_scores_gemma":[0.000947302,0.00028326962,0.22379595,0.00037058248,0.00021559381,0.0000071200006,0.00024514197,0.00024183087,0.00031698926,0.000051574963,0.773343,0.00018164057],"about_ca_topic_score_codex":0.00034113237,"about_ca_topic_score_gemma":0.0038520528,"teacher_disagreement_score":0.66009456,"about_ca_system_score_codex":0.0003878653,"about_ca_system_score_gemma":0.0007045391,"threshold_uncertainty_score":0.9433573},"labels":[],"label_agreement":null},{"id":"W4353076861","doi":"10.51731/cjht.2023.603","title":"Pembrolizumab (Keytruda)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pembrolizumab; Reimbursement; Medicine; Chemotherapy; Oncology; Disease; Internal medicine; Breast cancer; Test (biology); Family medicine; Cancer; Health care; Immunotherapy; Political science","score_opus":0.038417204387254815,"score_gpt":0.3117376367690041,"score_spread":0.2733204323817493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353076861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7166063,0.08047093,0.000054745855,0.19996922,0.0010615438,0.00030841847,0.000017413622,0.00041128136,0.0011001534],"genre_scores_gemma":[0.99646455,0.0021123716,0.00013623963,0.0009581945,0.00001713191,0.0000027312444,0.0000024630215,0.0000128994125,0.00029339292],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989492,0.000019841222,0.00040119622,0.00008311081,0.000140389,0.0004062119],"domain_scores_gemma":[0.99938554,0.000026318006,0.00020637254,0.00019686723,0.00009649765,0.00008842427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005281416,0.00008349108,0.00028743068,0.0009062113,0.00015521508,0.000015796273,0.00017525417,0.00011018229,0.000057708497],"category_scores_gemma":[0.0002266633,0.000066642104,0.00010258137,0.000729328,0.0001786456,0.000051129413,0.0000087703565,0.00029864532,0.000027883409],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014941081,0.0000074337304,0.0065322123,0.00011173048,0.000076394834,0.00047123551,0.0002618195,0.0000019262056,0.00030590527,0.00029773952,0.059211314,0.9325729],"study_design_scores_gemma":[0.0018702062,0.0010870118,0.08801529,0.00043220748,0.00001630513,0.0014903153,0.004551306,0.0000112185635,0.000990849,0.0015524658,0.8998606,0.0001222089],"about_ca_topic_score_codex":0.0024403597,"about_ca_topic_score_gemma":0.0015300225,"teacher_disagreement_score":0.93245065,"about_ca_system_score_codex":0.00037038923,"about_ca_system_score_gemma":0.0033715025,"threshold_uncertainty_score":0.59809005},"labels":[],"label_agreement":null},{"id":"W4353086296","doi":"10.54097/hset.v36i.5579","title":"Battling Non-Small Cell Lung Carcinoma: Applying Biomarkers Testing to Pick the Best Immune Checkpoint Inhibitors Therapy","year":2023,"lang":"en","type":"article","venue":"Highlights in Science Engineering and Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Oncology; Biomarker; Lung cancer; Internal medicine; Intensive care medicine; Biology","score_opus":0.015421954833141923,"score_gpt":0.23968566274664183,"score_spread":0.2242637079134999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353086296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99354815,0.0014658263,0.0001508482,0.0031417748,0.000518502,0.0006509817,0.0000012611943,0.00032210807,0.00020055001],"genre_scores_gemma":[0.9972186,0.00030080145,0.0021002851,0.00004268604,0.000077620585,0.0001664118,0.0000010694707,0.000027017053,0.00006552242],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99829364,0.000007670345,0.00036867568,0.0004832154,0.00022956406,0.0006172545],"domain_scores_gemma":[0.99922806,0.00012959634,0.00006372764,0.0004152061,0.00007426625,0.00008914561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000963086,0.00021709684,0.00026217848,0.0013739502,0.00029367456,0.00005663004,0.00035437514,0.00013645945,0.000001740621],"category_scores_gemma":[0.00015731892,0.00015188423,0.00004591622,0.0057881265,0.00035467523,0.000076827,0.00017533745,0.00028361214,0.000024634752],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037422942,0.000028986276,0.01603127,0.000050399372,0.0000153026,0.000046791483,0.0005620862,0.00031850778,0.97264063,0.00012171515,0.000029253322,0.010117611],"study_design_scores_gemma":[0.0024533195,0.00050929264,0.063442454,0.0006715504,0.00002569564,0.00013916357,0.002359028,0.030130958,0.8923539,0.00003612565,0.0073257936,0.0005527118],"about_ca_topic_score_codex":0.00020383547,"about_ca_topic_score_gemma":0.000007630559,"teacher_disagreement_score":0.08028674,"about_ca_system_score_codex":0.00015174234,"about_ca_system_score_gemma":0.00013308015,"threshold_uncertainty_score":0.61936593},"labels":[],"label_agreement":null},{"id":"W4360614721","doi":"10.1136/ejhpharm-2023-eahp.6","title":"NP-006 Immunotherapy in second-line treatment of non-small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health","keywords":"Nivolumab; Medicine; Atezolizumab; Pembrolizumab; Internal medicine; Immunotherapy; Oncology; Lung cancer; Progression-free survival; Retrospective cohort study; Cancer; Chemotherapy","score_opus":0.019500303498280386,"score_gpt":0.30471975076215335,"score_spread":0.28521944726387294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360614721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855811,0.004867549,0.000028444261,0.0008458298,0.00023360575,0.00060725794,0.000029101811,0.000060541435,0.0077465903],"genre_scores_gemma":[0.9422,0.010005994,0.00023334226,0.0006869714,0.0001159974,0.0001573561,0.00004387947,0.000039621507,0.046516836],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990479,0.000017887985,0.00034448347,0.00021263894,0.000120388555,0.00025674107],"domain_scores_gemma":[0.99952304,0.000046410696,0.00007314334,0.00027819723,0.00003538747,0.000043788066],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012011039,0.00016296991,0.000358385,0.0002117282,0.000021350765,0.000005913744,0.000065931345,0.00008347157,0.0032975513],"category_scores_gemma":[0.0000013627433,0.000119527474,0.00015794016,0.00050295476,0.000039111063,0.000028619495,0.000009694235,0.0000547699,0.00001992176],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035001778,0.00081096083,0.11283033,0.00029167515,0.00043217206,0.000061891595,0.0025187903,0.00004412063,0.7964045,0.000008425075,0.007538902,0.075558044],"study_design_scores_gemma":[0.02678964,0.0021737437,0.2891618,0.00022806588,0.000090574606,0.000011071477,0.00059904164,0.0020324374,0.6032566,0.000014233609,0.07527882,0.0003639799],"about_ca_topic_score_codex":0.0035248774,"about_ca_topic_score_gemma":0.0019255393,"teacher_disagreement_score":0.19314791,"about_ca_system_score_codex":0.00023362793,"about_ca_system_score_gemma":0.00017610034,"threshold_uncertainty_score":0.99761355},"labels":[],"label_agreement":null},{"id":"W4360828746","doi":"10.21203/rs.3.rs-2708875/v1","title":"Targeting Liver Metastases to Potentiate Immunotherapy In MS-stable colorectal cancer- A Scoping Review of Literature","year":2023,"lang":"en","type":"review","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Israel Cancer Research Fund","keywords":"Medicine; Immunotherapy; Colorectal cancer; Clinical trial; Cancer; Oncology; Melanoma; Disease; Internal medicine; Cancer research; Immunology","score_opus":0.11036983260760476,"score_gpt":0.47477586526464083,"score_spread":0.3644060326570361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360828746","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005219411,0.9909322,0.00000351724,0.00016669607,0.0001629515,0.007882094,0.00062827085,0.000054345597,0.00011768127],"genre_scores_gemma":[0.0000053351973,0.99629396,0.00016779368,0.00013723725,0.00020776763,0.0018014539,0.0005957767,0.00014319338,0.00064745505],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9945654,0.0011639226,0.0013504686,0.00072881853,0.0012426325,0.0009487307],"domain_scores_gemma":[0.99759007,0.00064485037,0.00033473276,0.0005608603,0.00068060256,0.00018886651],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004569316,0.00047345736,0.0028959927,0.0013806334,0.00012714799,0.00007935181,0.00043381457,0.00030627652,0.00093252124],"category_scores_gemma":[0.0007459313,0.00035814845,0.0008279955,0.005849261,0.00012294373,0.00011558944,0.00022200045,0.0011979894,0.00006585823],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003957562,0.000094446776,0.000014428986,0.6443978,0.00045102983,0.0002502392,0.0001732847,6.655272e-7,0.00015410807,0.0000039003203,0.0035647047,0.35049963],"study_design_scores_gemma":[0.00048350697,0.00031568267,0.000025703064,0.7062069,0.00012909045,0.000022372296,0.00003507694,0.0000020502564,0.00005089715,0.0000014742783,0.29250664,0.00022061648],"about_ca_topic_score_codex":0.0014668193,"about_ca_topic_score_gemma":0.00022469825,"teacher_disagreement_score":0.350279,"about_ca_system_score_codex":0.0007422783,"about_ca_system_score_gemma":0.0023988648,"threshold_uncertainty_score":0.99998075},"labels":[],"label_agreement":null},{"id":"W4360991431","doi":"10.1016/s2665-9913(23)00059-0","title":"Reconciling immunotherapy and autoimmunity: not for the faint of heart","year":2023,"lang":"en","type":"article","venue":"The Lancet Rheumatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Rheumatoid arthritis; Immune system; Immunotherapy; Cancer; Adverse effect; Immune checkpoint; Cancer immunotherapy; Immunology; Adjuvant; Oncology; Internal medicine","score_opus":0.06685285596376572,"score_gpt":0.3337102290731903,"score_spread":0.2668573731094246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360991431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9391162,0.004121721,0.00010980361,0.05559827,0.00032433963,0.00051500706,0.000016532702,0.0000815,0.00011666537],"genre_scores_gemma":[0.98985034,0.007186868,0.00021868035,0.0022722445,0.00004126737,0.000083244704,0.000009132848,0.000018564406,0.000319669],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992113,0.00007912939,0.00026234708,0.00011796318,0.00008263612,0.00024662554],"domain_scores_gemma":[0.99822646,0.001159596,0.00009516811,0.00045577934,0.000047658563,0.000015346564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012207868,0.0000951384,0.00044531288,0.000047080986,0.00017603014,0.000009434223,0.00016568539,0.00006801953,0.0000541022],"category_scores_gemma":[0.00011248059,0.000050144627,0.00010138849,0.0001752656,0.000356809,0.00001837657,0.000038842132,0.00015293344,0.0000075619346],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035240177,0.00013516989,0.094155334,0.0013337061,0.0036278735,0.0000092791615,0.018277211,0.000044392218,0.42601946,0.014944286,0.09329681,0.31291628],"study_design_scores_gemma":[0.015744628,0.0010217424,0.44714025,0.00048270478,0.00015462823,0.0011458818,0.003984659,0.004874168,0.020021493,0.0029354226,0.50213224,0.0003621971],"about_ca_topic_score_codex":0.00035961153,"about_ca_topic_score_gemma":0.000035588662,"teacher_disagreement_score":0.4088354,"about_ca_system_score_codex":0.00001715042,"about_ca_system_score_gemma":0.00006414875,"threshold_uncertainty_score":0.20448385},"labels":[],"label_agreement":null},{"id":"W4361202523","doi":"10.3389/fgene.2023.1086163","title":"Exploring immune interactions in triple negative breast cancer: IL-1β inhibition and its therapeutic potential","year":2023,"lang":"en","type":"review","venue":"Frontiers in Genetics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network; Queen's University","funders":"Canadian Cancer Society","keywords":"Immunotherapy; Triple-negative breast cancer; Breast cancer; Medicine; Immune system; Tumor microenvironment; Clinical trial; Oncology; Cancer; Cancer immunotherapy; Cancer research; Immunology; Internal medicine","score_opus":0.11608177061674285,"score_gpt":0.34651927104075897,"score_spread":0.23043750042401612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361202523","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023134076,0.99276626,0.000086264285,0.00016321076,0.0030767217,0.0012860307,0.00023897014,0.000038100326,0.000031060612],"genre_scores_gemma":[0.0012085461,0.9971406,0.00020903233,0.000040739134,0.00028049556,0.00055696786,0.00009651703,0.00008481732,0.0003823125],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982088,0.00013725912,0.00072724477,0.0004097469,0.00019264864,0.00032428853],"domain_scores_gemma":[0.9993876,0.000039910825,0.00023808684,0.00022021653,0.00004878068,0.0000653999],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020517765,0.00034430492,0.0011293844,0.0007337128,0.000058145775,0.000031555344,0.000093414616,0.00015897435,0.00003306097],"category_scores_gemma":[0.000013381198,0.00031916393,0.00024016168,0.0008697096,0.00007523592,0.00010840576,0.000061537394,0.00056328793,0.000005872544],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003221879,0.000058337188,0.00011665875,0.0034368834,0.00041415132,0.00004854832,0.0004934387,0.0000081403805,0.00006641072,0.0000014381338,0.0004065824,0.99462724],"study_design_scores_gemma":[0.00938955,0.00038367507,0.0128010195,0.08539079,0.0027111508,0.0005357212,0.0031732777,0.001464858,0.00033876338,0.00016131463,0.881984,0.0016659099],"about_ca_topic_score_codex":0.00025568646,"about_ca_topic_score_gemma":0.00017849504,"teacher_disagreement_score":0.9929613,"about_ca_system_score_codex":0.0006461516,"about_ca_system_score_gemma":0.00028962147,"threshold_uncertainty_score":0.99992603},"labels":[],"label_agreement":null},{"id":"W4361816696","doi":"10.1158/1078-0432.c.6528354","title":"Data from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; National Center for Advancing Translational Sciences; Swim Across America","keywords":"Medicine; Internal medicine; Proportional hazards model; Oncology; Melanoma; Receiver operating characteristic; Survival analysis; Population; Area under the curve; Stage (stratigraphy); Cohort; Adjuvant; Gastroenterology; Immune system; Immunology; Cancer research; Biology","score_opus":0.08799104364349762,"score_gpt":0.3181423265658654,"score_spread":0.23015128292236775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361816696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9465426,0.0046689473,0.0070710443,0.00079108257,0.0023739906,0.007971408,0.029614864,0.00049488497,0.00047116634],"genre_scores_gemma":[0.7916413,0.0015624738,0.010410619,0.00007167677,0.00090927526,0.001657871,0.17664029,0.00022825517,0.016878255],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960864,0.000088271656,0.0015789306,0.0012066526,0.00061451964,0.0004252049],"domain_scores_gemma":[0.9956464,0.0002624247,0.0009378736,0.0026989018,0.00035119988,0.00010321137],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010178279,0.0005280314,0.0011489708,0.00032279405,0.00016863657,0.00005808763,0.00079454517,0.0006053416,0.0014095579],"category_scores_gemma":[0.00027532372,0.0004614025,0.0004026699,0.0003138567,0.00014817496,0.00018573082,0.0013997444,0.0004653188,0.000020427491],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027778588,0.0021734806,0.03403841,0.006516934,0.01153505,0.000071208466,0.002001402,0.00012475594,0.8727521,0.00008738664,0.020919304,0.022001417],"study_design_scores_gemma":[0.019536873,0.0037014717,0.20287995,0.0055746296,0.0035978248,0.000034563804,0.0008933984,0.018638015,0.7332851,0.0005606059,0.009990278,0.0013072633],"about_ca_topic_score_codex":0.003891102,"about_ca_topic_score_gemma":0.00015507184,"teacher_disagreement_score":0.16884154,"about_ca_system_score_codex":0.00022664065,"about_ca_system_score_gemma":0.00076140754,"threshold_uncertainty_score":0.99978375},"labels":[],"label_agreement":null},{"id":"W4361884352","doi":"10.1158/1078-0432.22456220","title":"Supplementary Figure 3 from Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"FOXP3; Chemokine; Medicine; Breast carcinoma; Cancer research; Breast cancer; Molecular biology; Cancer; Internal medicine; Biology; Immunology; Immune system; Receptor","score_opus":0.01945552799183042,"score_gpt":0.26188249067007807,"score_spread":0.24242696267824765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361884352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777426,0.00061111385,0.000005389754,0.008731866,0.0010889806,0.0009080917,0.010764134,0.00002663248,0.00012119966],"genre_scores_gemma":[0.9932454,0.0009592441,0.00009520473,0.0012901083,0.00059721706,0.00015592008,0.0025667422,0.000040753894,0.0010494086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979615,0.00008603489,0.00060399686,0.0005884239,0.0004990773,0.00026094425],"domain_scores_gemma":[0.9985379,0.00011185823,0.00037324344,0.0008407795,0.00006973048,0.00006647251],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018250257,0.00036279266,0.0005396583,0.000055112403,0.000086646265,0.000041025058,0.0003672826,0.00029034057,0.0043296344],"category_scores_gemma":[0.000009247573,0.00021069468,0.00019259483,0.0001741438,0.0002487006,0.000054419343,0.0004011385,0.0006708173,0.000001087259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067297122,0.00006920135,0.88894963,0.00016960858,0.0004297575,0.000019280651,0.0040049236,0.00021480459,0.06295726,0.0000016097102,0.033105496,0.003348712],"study_design_scores_gemma":[0.0045417906,0.000025611303,0.97694033,0.0027507718,0.00022399734,0.000021206446,0.0012210212,0.00023090768,0.012291775,0.000120002,0.0013866923,0.00024589305],"about_ca_topic_score_codex":0.9617903,"about_ca_topic_score_gemma":0.7798399,"teacher_disagreement_score":0.18195045,"about_ca_system_score_codex":0.0030506,"about_ca_system_score_gemma":0.002965262,"threshold_uncertainty_score":0.99658054},"labels":[],"label_agreement":null},{"id":"W4361911342","doi":"10.1158/1078-0432.22456223.v1","title":"Supplementary Figure 2 from Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CD8; Cancer research; Medicine; Breast carcinoma; CXCL10; Tumor-infiltrating lymphocytes; Breast cancer; Chemokine; Internal medicine; Molecular biology; Cancer; Biology; Immunology; Immune system; Receptor","score_opus":0.01913521880064305,"score_gpt":0.2617334239540961,"score_spread":0.24259820515345304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361911342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778103,0.0006177008,0.0000052456,0.008729603,0.0010850594,0.00090664305,0.010695534,0.000026664353,0.00012323125],"genre_scores_gemma":[0.9931781,0.00097265147,0.00009444791,0.0012941079,0.0006004445,0.00015621545,0.002628293,0.000040792296,0.0010349184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796194,0.00008608906,0.00060399645,0.00058824295,0.00049885147,0.00026086884],"domain_scores_gemma":[0.99853915,0.000111274334,0.0003737036,0.00084043946,0.00006896607,0.00006646852],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018159457,0.00036272922,0.0005397344,0.000055094977,0.00008666005,0.000041029034,0.00036731112,0.000290367,0.0043559344],"category_scores_gemma":[0.000009139049,0.00021068005,0.00019257012,0.000174074,0.00024867945,0.000054414417,0.00040137337,0.0006708012,0.0000010640518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067746374,0.0000704727,0.8883807,0.00017132152,0.0004379538,0.000019924935,0.0040810737,0.00021969221,0.061813533,0.000001678236,0.034575604,0.0034533748],"study_design_scores_gemma":[0.0045242407,0.000025731815,0.9772436,0.002731392,0.00022592608,0.000021521237,0.0012182128,0.00022972308,0.011996224,0.000120975325,0.0014163398,0.00024612024],"about_ca_topic_score_codex":0.96174055,"about_ca_topic_score_gemma":0.7796807,"teacher_disagreement_score":0.18205982,"about_ca_system_score_codex":0.0030394057,"about_ca_system_score_gemma":0.0029505473,"threshold_uncertainty_score":0.9965542},"labels":[],"label_agreement":null},{"id":"W4361911394","doi":"10.1158/1078-0432.22456220.v1","title":"Supplementary Figure 3 from Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"FOXP3; Chemokine; Medicine; Cancer research; Breast carcinoma; Breast cancer; Molecular biology; Cancer; Internal medicine; Biology; Immunology; Immune system; Receptor","score_opus":0.01945552799183042,"score_gpt":0.26188249067007807,"score_spread":0.24242696267824765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361911394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777426,0.00061111385,0.000005389754,0.008731866,0.0010889806,0.0009080917,0.010764134,0.00002663248,0.00012119966],"genre_scores_gemma":[0.9932454,0.0009592441,0.00009520473,0.0012901083,0.00059721706,0.00015592008,0.0025667422,0.000040753894,0.0010494086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979615,0.00008603489,0.00060399686,0.0005884239,0.0004990773,0.00026094425],"domain_scores_gemma":[0.9985379,0.00011185823,0.00037324344,0.0008407795,0.00006973048,0.00006647251],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018250257,0.00036279266,0.0005396583,0.000055112403,0.000086646265,0.000041025058,0.0003672826,0.00029034057,0.0043296344],"category_scores_gemma":[0.000009247573,0.00021069468,0.00019259483,0.0001741438,0.0002487006,0.000054419343,0.0004011385,0.0006708173,0.000001087259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067297122,0.00006920135,0.88894963,0.00016960858,0.0004297575,0.000019280651,0.0040049236,0.00021480459,0.06295726,0.0000016097102,0.033105496,0.003348712],"study_design_scores_gemma":[0.0045417906,0.000025611303,0.97694033,0.0027507718,0.00022399734,0.000021206446,0.0012210212,0.00023090768,0.012291775,0.000120002,0.0013866923,0.00024589305],"about_ca_topic_score_codex":0.9617903,"about_ca_topic_score_gemma":0.7798399,"teacher_disagreement_score":0.18195045,"about_ca_system_score_codex":0.0030506,"about_ca_system_score_gemma":0.002965262,"threshold_uncertainty_score":0.99658054},"labels":[],"label_agreement":null},{"id":"W4361937856","doi":"10.1158/1078-0432.22477923.v1","title":"Supplementary Data from NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Complete response; Gene; Randomized controlled trial; Oncology; Medicine; Internal medicine; Biology; Genetics; Chemotherapy","score_opus":0.1089265121860138,"score_gpt":0.3383071415660233,"score_spread":0.22938062938000953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361937856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9504673,0.0074911094,0.00029358835,0.009519248,0.0010093941,0.006269706,0.024523055,0.00036496655,0.00006164856],"genre_scores_gemma":[0.8210792,0.013322731,0.008940335,0.00796612,0.0009770665,0.0012158052,0.14073676,0.00034272167,0.005419295],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955071,0.0014973142,0.0008496876,0.0012028199,0.00055579207,0.00038726968],"domain_scores_gemma":[0.99438316,0.0033241273,0.00048783177,0.0015762728,0.00009799892,0.00013060604],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0040637883,0.0005444449,0.0020043196,0.00022510438,0.00011572761,0.00011309039,0.00051212555,0.00047333265,0.0017613434],"category_scores_gemma":[0.0007983367,0.00034028865,0.0002623629,0.00017638058,0.00042677595,0.00004570024,0.001169362,0.00069181144,0.000006274129],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9637914,0.00016748352,0.00023991856,0.000048184687,0.003289697,0.00060401513,0.00021896795,0.0000047655817,0.0070639723,0.000002013632,0.023318132,0.0012514782],"study_design_scores_gemma":[0.9768455,0.0011175269,0.007834912,0.0009191546,0.0021645986,0.000022038566,0.00041613876,0.0012695568,0.00035024798,0.0004632508,0.0079553425,0.00064172444],"about_ca_topic_score_codex":0.006157168,"about_ca_topic_score_gemma":0.0025235282,"teacher_disagreement_score":0.12938811,"about_ca_system_score_codex":0.00013342385,"about_ca_system_score_gemma":0.00041122347,"threshold_uncertainty_score":0.99990493},"labels":[],"label_agreement":null},{"id":"W4361942613","doi":"10.1158/1078-0432.c.6516816","title":"Data from Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Gary Bennett Family Fund","keywords":"Microsatellite instability; Colorectal cancer; KRAS; MLH1; Internal medicine; Hazard ratio; Cancer research; Medicine; Tumor-infiltrating lymphocytes; Lymph node; Cancer; Oncology; Biology; Immunotherapy; DNA mismatch repair; Genetics; Allele; Gene","score_opus":0.059198310689803774,"score_gpt":0.3200398842973101,"score_spread":0.26084157360750637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361942613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834118,0.002040646,0.00015608985,0.00049103255,0.00095248624,0.0010826981,0.011439683,0.00010947351,0.00031610753],"genre_scores_gemma":[0.9912314,0.0032906467,0.00025540398,0.00063349964,0.000162312,0.00011524802,0.0032287303,0.000107999454,0.00097475643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969568,0.00012477356,0.0006642123,0.0011843345,0.0007275888,0.0003422875],"domain_scores_gemma":[0.99756956,0.00031521282,0.000424394,0.0011636654,0.0003601487,0.00016699282],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008637331,0.00045204125,0.0010469113,0.00019078562,0.00006448249,0.00007507059,0.000365538,0.000519382,0.00059407554],"category_scores_gemma":[0.00013071609,0.00035769158,0.00009916422,0.00038279276,0.00018815133,0.00010463101,0.0008025169,0.00033185046,0.00001507902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039873824,0.0007863665,0.60353017,0.0014083568,0.013252411,0.00008838146,0.0044569196,0.000058426536,0.32129705,0.0000049728897,0.007926187,0.007316939],"study_design_scores_gemma":[0.008408812,0.00027221028,0.9603448,0.0018047848,0.0013645121,0.000008793752,0.0005209633,0.0009143129,0.023290228,0.000100066834,0.0021972514,0.00077329995],"about_ca_topic_score_codex":0.083439834,"about_ca_topic_score_gemma":0.04017018,"teacher_disagreement_score":0.35681462,"about_ca_system_score_codex":0.0018045325,"about_ca_system_score_gemma":0.0018512483,"threshold_uncertainty_score":0.9998875},"labels":[],"label_agreement":null},{"id":"W4361944915","doi":"10.1158/1078-0432.c.6523244","title":"Data from Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CXCL10; CXCR3; CD8; Chemokine; Cancer research; Tumor microenvironment; Medicine; Lymphocytic infiltration; Lymphocyte; CXCL13; Pathology; Biology; Immunology; Cancer; Chemokine receptor; Internal medicine; Immune system","score_opus":0.05018237673053554,"score_gpt":0.2935535698220781,"score_spread":0.24337119309154254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361944915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818637,0.0010329123,0.000015057906,0.0048072822,0.001204032,0.0007278094,0.010115986,0.000038186667,0.00019504924],"genre_scores_gemma":[0.9937336,0.0014221704,0.00010510612,0.0007662559,0.00062995096,0.00007395209,0.0022832495,0.000040907686,0.0009448317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789584,0.000085171676,0.0005721396,0.00073804887,0.00048108734,0.00022770007],"domain_scores_gemma":[0.9974116,0.00013458576,0.00040088367,0.0019223241,0.00006880982,0.00006180856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026246882,0.0003265037,0.00053613324,0.000047173427,0.00007512933,0.000051647217,0.00077332713,0.0002984996,0.0007425443],"category_scores_gemma":[0.000024570974,0.00018497849,0.00011249291,0.00018297398,0.00029925673,0.00009831934,0.0010631514,0.0006542207,0.0000017017809],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010107472,0.00010343988,0.85603875,0.00023397422,0.00060629065,0.000024416755,0.0033415055,0.00025902007,0.085748345,0.0000024124517,0.03590395,0.0076304437],"study_design_scores_gemma":[0.0033949597,0.000013721181,0.9868785,0.0029500953,0.00020705748,0.00002761542,0.0006173708,0.0010463491,0.0036247673,0.000097367054,0.0009206245,0.00022154769],"about_ca_topic_score_codex":0.94018036,"about_ca_topic_score_gemma":0.7903465,"teacher_disagreement_score":0.14983383,"about_ca_system_score_codex":0.0021135875,"about_ca_system_score_gemma":0.0039269635,"threshold_uncertainty_score":0.81303394},"labels":[],"label_agreement":null},{"id":"W4361947113","doi":"10.1158/1078-0432.c.6530079","title":"Data from Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"Cancerfonden","keywords":"Immune system; Breast cancer; Medicine; Radiation therapy; CD8; FOXP3; Adjuvant; Tumor-infiltrating lymphocytes; Immunohistochemistry; Oncology; Cancer research; Cancer; Internal medicine; Pathology; Immunology","score_opus":0.03997447953258912,"score_gpt":0.32004920838188033,"score_spread":0.2800747288492912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361947113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9288459,0.01837534,0.000046958634,0.013833972,0.0028948952,0.011946449,0.023503868,0.00011493805,0.00043768724],"genre_scores_gemma":[0.9182214,0.050135713,0.00028009276,0.00335698,0.0032824257,0.002403935,0.02170091,0.00020792677,0.0004106039],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9919159,0.0029953457,0.0024714705,0.0011958247,0.00095507386,0.0004663918],"domain_scores_gemma":[0.9854289,0.0096273245,0.0010411988,0.0037766702,0.00006240604,0.00006349685],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010170883,0.0006751752,0.0031967412,0.00022814157,0.000057627058,0.000088946435,0.0022131747,0.00040264544,0.0003260159],"category_scores_gemma":[0.0006828584,0.00032131348,0.0006243919,0.0005739779,0.0005017161,0.00010795084,0.0006450773,0.0015485568,0.00000592001],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97589076,0.00024603592,0.0019422214,0.00015680223,0.001844807,0.00008830661,0.0015461956,0.00006064672,0.0044433675,0.0000014983167,0.0076582963,0.0061210725],"study_design_scores_gemma":[0.8490496,0.0003385157,0.14216381,0.0035236506,0.00064768404,0.000011695225,0.00019443607,0.0022850963,0.0005908886,0.00012526609,0.00072007824,0.00034925362],"about_ca_topic_score_codex":0.19959295,"about_ca_topic_score_gemma":0.007273977,"teacher_disagreement_score":0.19231896,"about_ca_system_score_codex":0.00035942503,"about_ca_system_score_gemma":0.0012144508,"threshold_uncertainty_score":0.9999239},"labels":[],"label_agreement":null},{"id":"W4361947353","doi":"10.1158/1078-0432.c.6530529","title":"Data from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; Spinal Cord Injury BC; University of British Columbia","funders":"BC Cancer Foundation; Terry Fox Research Institute; Michael Smith Health Research BC; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Tumor-infiltrating lymphocytes; CD8; Biology; TIGIT; Cancer research; T cell; Ovarian cancer; Immune system; Immunology; Molecular biology; Cancer","score_opus":0.09444355469029884,"score_gpt":0.3454900004132791,"score_spread":0.25104644572298024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361947353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98700947,0.009147612,0.00007543435,0.00020013924,0.00019917496,0.0010523611,0.001754304,0.00007423536,0.0004872632],"genre_scores_gemma":[0.9936665,0.0011655134,0.0037014943,0.000080230784,0.00017697438,0.0000645846,0.0009102182,0.000064850356,0.00016963122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788797,0.000079880236,0.0006473609,0.00081606186,0.00025420025,0.0003145296],"domain_scores_gemma":[0.998292,0.00039587746,0.00038235978,0.0007538652,0.00006645931,0.00010940904],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038269124,0.0003735161,0.00076013355,0.00020626269,0.000052002473,0.00011827529,0.00023831816,0.00021733732,0.00020670367],"category_scores_gemma":[0.0001956835,0.0002932268,0.000083231185,0.00018405466,0.00020900903,0.00012976628,0.0007318729,0.00033859804,0.0000010362107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014723656,0.00019209951,0.55113083,0.0015162273,0.00048296168,0.00007487655,0.000834878,0.000033909117,0.43625876,0.0000010756164,0.0009733108,0.007028732],"study_design_scores_gemma":[0.0072420584,0.00043160195,0.90751517,0.011996363,0.00047918683,0.000044318156,0.0009334846,0.013652606,0.05674267,0.00014992568,0.000090036614,0.00072259316],"about_ca_topic_score_codex":0.048082102,"about_ca_topic_score_gemma":0.0012941462,"teacher_disagreement_score":0.3795161,"about_ca_system_score_codex":0.00024781283,"about_ca_system_score_gemma":0.0009581004,"threshold_uncertainty_score":0.99995196},"labels":[],"label_agreement":null},{"id":"W4361947405","doi":"10.1158/1078-0432.c.6530597","title":"Data from Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; Eli Lilly and Company; University of Toronto Scarborough; National Institutes of Health; Astellas Pharma; Genomic Health; Kowa Company; Society for Immunotherapy of Cancer; Cancer Prevention and Research Institute of Texas; Genentech; Amgen; Nancy Owens Memorial Foundation; Array BioPharma; Conquer Cancer Foundation; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; EMD Serono; Novartis; Ludwig Center at Harvard; GlaxoSmithKline; University of Texas MD Anderson Cancer Center; Astellas Pharma Global Development; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Breast cancer; Triple-negative breast cancer; Immune system; Tumor-infiltrating lymphocytes; Medicine; Tumor microenvironment; Cancer; Neoadjuvant therapy; T cell; CD3; Internal medicine; Gastroenterology; Immunology; CD8","score_opus":0.08224299910603904,"score_gpt":0.36065479689985286,"score_spread":0.2784117977938138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361947405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9537552,0.0078079137,0.00007326064,0.027454538,0.001279933,0.0020234915,0.0072365636,0.00015743078,0.00021168265],"genre_scores_gemma":[0.941652,0.03356765,0.0023043177,0.0056454544,0.00083992246,0.0005421625,0.002011874,0.00023189545,0.013204695],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9975814,0.0002064628,0.000554604,0.0010180942,0.0003144782,0.00032491042],"domain_scores_gemma":[0.9976155,0.00038573504,0.00014492743,0.0016221819,0.000090432564,0.00014119198],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009161295,0.00037802683,0.0007673773,0.00030939397,0.000046012643,0.00006225878,0.00049531297,0.00029070204,0.0014584428],"category_scores_gemma":[0.00013167995,0.00029435748,0.00008922512,0.00038030813,0.00010321336,0.00007324251,0.0009839133,0.00057845603,0.000047455364],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4383363,0.00048344082,0.015557548,0.00015878973,0.0025778476,0.00028393118,0.0073323227,0.00003207453,0.12620439,0.000006849783,0.03058905,0.37843743],"study_design_scores_gemma":[0.009059453,0.0002708505,0.9791751,0.0012923606,0.000071378556,0.000009329514,0.0007161483,0.00042129756,0.0014607465,0.00026917172,0.0067973775,0.00045678968],"about_ca_topic_score_codex":0.08655368,"about_ca_topic_score_gemma":0.0099048745,"teacher_disagreement_score":0.96361756,"about_ca_system_score_codex":0.0003166524,"about_ca_system_score_gemma":0.00076444517,"threshold_uncertainty_score":0.9999508},"labels":[],"label_agreement":null},{"id":"W4361947545","doi":"10.1158/1078-0432.c.6530069","title":"Data from Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Prostate cancer; Transcriptome; Immune system; Proinflammatory cytokine; Cancer research; Prostate; Tumor microenvironment; Cancer; Biology; Medicine; Immunology; Gene; Internal medicine; Inflammation; Gene expression; Genetics","score_opus":0.1344578805448216,"score_gpt":0.359653716261516,"score_spread":0.22519583571669438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361947545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753545,0.0020250601,0.00009563571,0.002747567,0.00028827123,0.0028462862,0.008796309,0.00024599113,0.00760039],"genre_scores_gemma":[0.98443747,0.0033892116,0.0022185189,0.00036594455,0.00021487374,0.00063697656,0.005954058,0.00008305073,0.0026999195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99696434,0.00016878275,0.00078881666,0.0012307599,0.000357966,0.0004893112],"domain_scores_gemma":[0.9970461,0.00024571433,0.00068510836,0.0017909837,0.000101568905,0.00013051127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004602896,0.00051730464,0.0015089604,0.00018003039,0.00006817516,0.00006926392,0.0007941394,0.00015914802,0.00032235114],"category_scores_gemma":[0.000030509656,0.00036172816,0.000107838525,0.00050694484,0.0005033545,0.00006424383,0.0011998531,0.00081196625,0.000032243282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13694942,0.0027380856,0.51182735,0.001585421,0.01441224,0.002085927,0.05348817,0.0011126485,0.09260124,0.00004745849,0.113425806,0.069726236],"study_design_scores_gemma":[0.005322454,0.0010282078,0.95717365,0.0014191539,0.00047020096,0.000009507119,0.013438556,0.0028839759,0.0010888168,0.0004248659,0.01565951,0.0010811164],"about_ca_topic_score_codex":0.076590724,"about_ca_topic_score_gemma":0.03401312,"teacher_disagreement_score":0.4453463,"about_ca_system_score_codex":0.0011331383,"about_ca_system_score_gemma":0.0012492462,"threshold_uncertainty_score":0.9998835},"labels":[],"label_agreement":null},{"id":"W4361947597","doi":"10.1158/1078-0432.c.6530916","title":"Data from Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Fundamental Research Funds for the Central Universities; East China Normal University; China Postdoctoral Science Foundation; Chinese Academy of Sciences; Government of Jiangxi Province; Shanghai Municipal Education Commission; National Natural Science Foundation of China","keywords":"Cancer research; Immune system; Prostate cancer; Immunotherapy; Tumor microenvironment; CD8; T cell; Cancer immunotherapy; Chemokine; Cytotoxic T cell; Medicine; Immunology; Chemistry; Cancer; In vitro; Internal medicine","score_opus":0.09603129604657247,"score_gpt":0.35190248301058374,"score_spread":0.2558711869640113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361947597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96544284,0.00830895,0.011183201,0.004351661,0.0011245137,0.0038663559,0.0044828667,0.00031700396,0.00092258235],"genre_scores_gemma":[0.81331325,0.01177917,0.09908081,0.0049179443,0.0018961461,0.0010722626,0.018395528,0.00042765646,0.049117234],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971295,0.00007948707,0.0007459304,0.0012654032,0.00037638802,0.0004032709],"domain_scores_gemma":[0.997372,0.00027973377,0.00036937775,0.0016105647,0.00020945491,0.00015892241],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008376495,0.00042930138,0.0009114742,0.00047728576,0.00013692191,0.0002022515,0.00028578003,0.00030010473,0.00018231376],"category_scores_gemma":[0.000080717604,0.0003963802,0.00024902401,0.00057034026,0.00004519938,0.00012420949,0.0003998152,0.00033129778,0.000012364375],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064437124,0.00018173212,0.010346549,0.0007363115,0.004125525,0.00003437393,0.003217789,0.0006337345,0.9499843,0.000002103982,0.012121042,0.01217279],"study_design_scores_gemma":[0.031054683,0.004010672,0.058853865,0.006629317,0.015973698,0.000029511,0.0057796636,0.033233564,0.5065903,0.0027085315,0.32882005,0.006316129],"about_ca_topic_score_codex":0.01675076,"about_ca_topic_score_gemma":0.0022016042,"teacher_disagreement_score":0.44339404,"about_ca_system_score_codex":0.00041357393,"about_ca_system_score_gemma":0.00047072,"threshold_uncertainty_score":0.9998488},"labels":[],"label_agreement":null},{"id":"W4361948562","doi":"10.1158/1078-0432.c.6516816.v1","title":"Data from Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Gary Bennett Family Fund","keywords":"Microsatellite instability; MLH1; KRAS; Colorectal cancer; Internal medicine; Hazard ratio; Lymph node; Cancer research; CDKN2A; Medicine; Cancer; Oncology; Biology; DNA mismatch repair; Allele; Genetics","score_opus":0.059198310689803774,"score_gpt":0.3200398842973101,"score_spread":0.26084157360750637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361948562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834118,0.002040646,0.00015608985,0.00049103255,0.00095248624,0.0010826981,0.011439683,0.00010947351,0.00031610753],"genre_scores_gemma":[0.9912314,0.0032906467,0.00025540398,0.00063349964,0.000162312,0.00011524802,0.0032287303,0.000107999454,0.00097475643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969568,0.00012477356,0.0006642123,0.0011843345,0.0007275888,0.0003422875],"domain_scores_gemma":[0.99756956,0.00031521282,0.000424394,0.0011636654,0.0003601487,0.00016699282],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008637331,0.00045204125,0.0010469113,0.00019078562,0.00006448249,0.00007507059,0.000365538,0.000519382,0.00059407554],"category_scores_gemma":[0.00013071609,0.00035769158,0.00009916422,0.00038279276,0.00018815133,0.00010463101,0.0008025169,0.00033185046,0.00001507902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039873824,0.0007863665,0.60353017,0.0014083568,0.013252411,0.00008838146,0.0044569196,0.000058426536,0.32129705,0.0000049728897,0.007926187,0.007316939],"study_design_scores_gemma":[0.008408812,0.00027221028,0.9603448,0.0018047848,0.0013645121,0.000008793752,0.0005209633,0.0009143129,0.023290228,0.000100066834,0.0021972514,0.00077329995],"about_ca_topic_score_codex":0.083439834,"about_ca_topic_score_gemma":0.04017018,"teacher_disagreement_score":0.35681462,"about_ca_system_score_codex":0.0018045325,"about_ca_system_score_gemma":0.0018512483,"threshold_uncertainty_score":0.9998875},"labels":[],"label_agreement":null},{"id":"W4361951919","doi":"10.1158/1078-0432.c.6523244.v1","title":"Data from Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CXCL10; CXCR3; CD8; Chemokine; Cancer research; Tumor microenvironment; Medicine; Breast cancer; Lymphocytic infiltration; CXCL13; Lymphocyte; Pathology; Biology; Immunology; Cancer; Internal medicine; Chemokine receptor; Immune system","score_opus":0.05018237673053554,"score_gpt":0.2935535698220781,"score_spread":0.24337119309154254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361951919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818637,0.0010329123,0.000015057906,0.0048072822,0.001204032,0.0007278094,0.010115986,0.000038186667,0.00019504924],"genre_scores_gemma":[0.9937336,0.0014221704,0.00010510612,0.0007662559,0.00062995096,0.00007395209,0.0022832495,0.000040907686,0.0009448317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789584,0.000085171676,0.0005721396,0.00073804887,0.00048108734,0.00022770007],"domain_scores_gemma":[0.9974116,0.00013458576,0.00040088367,0.0019223241,0.00006880982,0.00006180856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026246882,0.0003265037,0.00053613324,0.000047173427,0.00007512933,0.000051647217,0.00077332713,0.0002984996,0.0007425443],"category_scores_gemma":[0.000024570974,0.00018497849,0.00011249291,0.00018297398,0.00029925673,0.00009831934,0.0010631514,0.0006542207,0.0000017017809],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010107472,0.00010343988,0.85603875,0.00023397422,0.00060629065,0.000024416755,0.0033415055,0.00025902007,0.085748345,0.0000024124517,0.03590395,0.0076304437],"study_design_scores_gemma":[0.0033949597,0.000013721181,0.9868785,0.0029500953,0.00020705748,0.00002761542,0.0006173708,0.0010463491,0.0036247673,0.000097367054,0.0009206245,0.00022154769],"about_ca_topic_score_codex":0.94018036,"about_ca_topic_score_gemma":0.7903465,"teacher_disagreement_score":0.14983383,"about_ca_system_score_codex":0.0021135875,"about_ca_system_score_gemma":0.0039269635,"threshold_uncertainty_score":0.81303394},"labels":[],"label_agreement":null},{"id":"W4361953361","doi":"10.1158/1078-0432.c.6528486.v1","title":"Data from A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Melanoma; Medicine; Gene signature; Oncology; Immunotherapy; Lymph node; Lung cancer; Internal medicine; Cancer; Immune system; Immunology; Cancer research; Gene expression; Gene; Biology","score_opus":0.03796119972705284,"score_gpt":0.30100234095064093,"score_spread":0.26304114122358807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361953361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97287756,0.013117247,0.00011641528,0.0031729513,0.0006608017,0.002816791,0.006839914,0.00005722381,0.00034109535],"genre_scores_gemma":[0.9864486,0.006018062,0.0018140521,0.0010949292,0.0004096033,0.0003990871,0.002344625,0.00009110505,0.0013799361],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965089,0.00026262488,0.00093497126,0.0011498395,0.00060455414,0.0005391318],"domain_scores_gemma":[0.99640924,0.0007825822,0.000517025,0.0021191307,0.00010696646,0.000065050706],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015399687,0.00046096434,0.00096551946,0.00031285602,0.00005623237,0.000056364595,0.0013156793,0.00062205887,0.00052997563],"category_scores_gemma":[0.00018079799,0.00031144323,0.00016090198,0.00060974865,0.00006996472,0.000066599176,0.0012018417,0.0018674065,0.000008595964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007611661,0.0008542784,0.7780527,0.0041452027,0.001813498,0.00069192343,0.013890314,0.00089556916,0.13245775,0.0000031954091,0.048435792,0.011148155],"study_design_scores_gemma":[0.0078456085,0.00025935913,0.89356595,0.0057143997,0.001056011,0.000008091356,0.0026251355,0.026486829,0.060862064,0.00014700321,0.0006351302,0.00079442275],"about_ca_topic_score_codex":0.25228098,"about_ca_topic_score_gemma":0.07922824,"teacher_disagreement_score":0.17305276,"about_ca_system_score_codex":0.00026309755,"about_ca_system_score_gemma":0.00084151,"threshold_uncertainty_score":0.9999338},"labels":[],"label_agreement":null},{"id":"W4361953961","doi":"10.1158/1078-0432.c.6530597.v1","title":"Data from Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; Eli Lilly and Company; University of Toronto Scarborough; National Institutes of Health; Astellas Pharma; Genomic Health; Kowa Company; Society for Immunotherapy of Cancer; Cancer Prevention and Research Institute of Texas; Genentech; Amgen; Nancy Owens Memorial Foundation; Array BioPharma; Conquer Cancer Foundation; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; EMD Serono; Novartis; Ludwig Center at Harvard; GlaxoSmithKline; University of Texas MD Anderson Cancer Center; Astellas Pharma Global Development; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Breast cancer; Triple-negative breast cancer; Immune system; Tumor-infiltrating lymphocytes; Medicine; Tumor microenvironment; Cancer; Neoadjuvant therapy; T cell; CD3; Internal medicine; Immunology; CD8","score_opus":0.08224299910603904,"score_gpt":0.36065479689985286,"score_spread":0.2784117977938138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361953961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9537552,0.0078079137,0.00007326064,0.027454538,0.001279933,0.0020234915,0.0072365636,0.00015743078,0.00021168265],"genre_scores_gemma":[0.941652,0.03356765,0.0023043177,0.0056454544,0.00083992246,0.0005421625,0.002011874,0.00023189545,0.013204695],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9975814,0.0002064628,0.000554604,0.0010180942,0.0003144782,0.00032491042],"domain_scores_gemma":[0.9976155,0.00038573504,0.00014492743,0.0016221819,0.000090432564,0.00014119198],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009161295,0.00037802683,0.0007673773,0.00030939397,0.000046012643,0.00006225878,0.00049531297,0.00029070204,0.0014584428],"category_scores_gemma":[0.00013167995,0.00029435748,0.00008922512,0.00038030813,0.00010321336,0.00007324251,0.0009839133,0.00057845603,0.000047455364],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4383363,0.00048344082,0.015557548,0.00015878973,0.0025778476,0.00028393118,0.0073323227,0.00003207453,0.12620439,0.000006849783,0.03058905,0.37843743],"study_design_scores_gemma":[0.009059453,0.0002708505,0.9791751,0.0012923606,0.000071378556,0.000009329514,0.0007161483,0.00042129756,0.0014607465,0.00026917172,0.0067973775,0.00045678968],"about_ca_topic_score_codex":0.08655368,"about_ca_topic_score_gemma":0.0099048745,"teacher_disagreement_score":0.96361756,"about_ca_system_score_codex":0.0003166524,"about_ca_system_score_gemma":0.00076444517,"threshold_uncertainty_score":0.9999508},"labels":[],"label_agreement":null},{"id":"W4361954349","doi":"10.1158/1078-0432.c.6532568.v1","title":"Data from Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Institute of Cancer Research","funders":"Ono Pharmaceutical; Hirosaki University","keywords":"Nivolumab; Microsatellite instability; Medicine; Colorectal cancer; Chemoradiotherapy; Internal medicine; Confidence interval; Gastroenterology; Oncology; Cancer; Microsatellite; Immunotherapy; Biology","score_opus":0.02948951516768081,"score_gpt":0.28177942871377465,"score_spread":0.2522899135460938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361954349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805772,0.008462662,0.000102320206,0.0005239743,0.0006769031,0.0027916534,0.0066537485,0.00017232391,0.000039228264],"genre_scores_gemma":[0.9404499,0.017809205,0.005922328,0.0012813637,0.00030730778,0.0004254216,0.030347202,0.00037401193,0.0030832777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99565935,0.00013868626,0.0009956318,0.002008002,0.00052164134,0.0006766787],"domain_scores_gemma":[0.997038,0.00020132784,0.00036884376,0.0019034126,0.00029524698,0.00019317241],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005110362,0.0007802521,0.0017123014,0.00028117117,0.00010425345,0.00017457367,0.00046355324,0.00050630403,0.00049644185],"category_scores_gemma":[0.000045673398,0.00061436405,0.00013048503,0.00051457324,0.00043931624,0.00035703173,0.00064146495,0.0008724779,0.0000073371684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03749816,0.00052528904,0.88180304,0.000966433,0.0014156849,0.00005608638,0.0024607156,0.00009847202,0.002491885,0.0000010883911,0.0006096819,0.07207346],"study_design_scores_gemma":[0.014119893,0.00048401122,0.9694046,0.005034787,0.00017643986,0.000003834195,0.00030152843,0.00043488378,0.005437324,0.00006212678,0.003511001,0.0010296084],"about_ca_topic_score_codex":0.028415592,"about_ca_topic_score_gemma":0.033817563,"teacher_disagreement_score":0.08760152,"about_ca_system_score_codex":0.0011018788,"about_ca_system_score_gemma":0.001717899,"threshold_uncertainty_score":0.99963075},"labels":[],"label_agreement":null},{"id":"W4361955244","doi":"10.1158/1078-0432.c.6526599.v1","title":"Data from Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; Université de Moncton; University Health Network; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Tumor-infiltrating lymphocytes; Immune system; Chemotherapy; CD8; Medicine; Cancer research; Internal medicine; Immunology","score_opus":0.08533555148204584,"score_gpt":0.3544894738158662,"score_spread":0.26915392233382035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361955244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9324549,0.0015216628,0.013635696,0.007785936,0.00026092766,0.0031355564,0.040988922,0.000113684066,0.00010271908],"genre_scores_gemma":[0.9818685,0.0020232566,0.009113406,0.00048113396,0.00022344316,0.0007052383,0.0049607684,0.00018107961,0.00044317578],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99673665,0.00010183358,0.0014817794,0.0010084654,0.00031347934,0.0003577998],"domain_scores_gemma":[0.99470526,0.00094212464,0.0011049754,0.002928955,0.000248753,0.00006993433],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012826254,0.00043815922,0.0011105003,0.00027691753,0.000053927066,0.000028549985,0.0008593186,0.00023837706,0.0001416615],"category_scores_gemma":[0.00015523448,0.0003413116,0.0002099973,0.00034892003,0.00015341726,0.000074139745,0.00024670374,0.00029942385,7.7325797e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47160584,0.0006985577,0.2205566,0.0010112764,0.003195984,0.000019038773,0.0016732769,0.00017432566,0.21469834,0.000057711706,0.001202336,0.085106716],"study_design_scores_gemma":[0.020885317,0.00054375036,0.9579106,0.0032696014,0.0001414443,0.0000075979415,0.0002322341,0.0015333002,0.013384355,0.00045542585,0.0012381435,0.0003982164],"about_ca_topic_score_codex":0.044842303,"about_ca_topic_score_gemma":0.027945956,"teacher_disagreement_score":0.737354,"about_ca_system_score_codex":0.00035459403,"about_ca_system_score_gemma":0.0017778621,"threshold_uncertainty_score":0.9999039},"labels":[],"label_agreement":null},{"id":"W4361958092","doi":"10.1158/1078-0432.c.6530916.v1","title":"Data from Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Fundamental Research Funds for the Central Universities; East China Normal University; China Postdoctoral Science Foundation; Chinese Academy of Sciences; Government of Jiangxi Province; Shanghai Municipal Education Commission; National Natural Science Foundation of China","keywords":"Cancer research; Immune system; Prostate cancer; Immunotherapy; Tumor microenvironment; CD8; T cell; Cancer immunotherapy; Chemokine; Cytotoxic T cell; In vivo; Medicine; Chemistry; Immunology; Cancer; Biology; In vitro; Internal medicine","score_opus":0.09603129604657247,"score_gpt":0.35190248301058374,"score_spread":0.2558711869640113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361958092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96544284,0.00830895,0.011183201,0.004351661,0.0011245137,0.0038663559,0.0044828667,0.00031700396,0.00092258235],"genre_scores_gemma":[0.81331325,0.01177917,0.09908081,0.0049179443,0.0018961461,0.0010722626,0.018395528,0.00042765646,0.049117234],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971295,0.00007948707,0.0007459304,0.0012654032,0.00037638802,0.0004032709],"domain_scores_gemma":[0.997372,0.00027973377,0.00036937775,0.0016105647,0.00020945491,0.00015892241],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008376495,0.00042930138,0.0009114742,0.00047728576,0.00013692191,0.0002022515,0.00028578003,0.00030010473,0.00018231376],"category_scores_gemma":[0.000080717604,0.0003963802,0.00024902401,0.00057034026,0.00004519938,0.00012420949,0.0003998152,0.00033129778,0.000012364375],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064437124,0.00018173212,0.010346549,0.0007363115,0.004125525,0.00003437393,0.003217789,0.0006337345,0.9499843,0.000002103982,0.012121042,0.01217279],"study_design_scores_gemma":[0.031054683,0.004010672,0.058853865,0.006629317,0.015973698,0.000029511,0.0057796636,0.033233564,0.5065903,0.0027085315,0.32882005,0.006316129],"about_ca_topic_score_codex":0.01675076,"about_ca_topic_score_gemma":0.0022016042,"teacher_disagreement_score":0.44339404,"about_ca_system_score_codex":0.00041357393,"about_ca_system_score_gemma":0.00047072,"threshold_uncertainty_score":0.9998488},"labels":[],"label_agreement":null},{"id":"W4361958404","doi":"10.1158/1078-0432.c.6530069.v1","title":"Data from Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Prostate cancer; Transcriptome; Immune system; Proinflammatory cytokine; Cancer research; Prostate; Tumor microenvironment; Cancer; Biology; Medicine; Immunology; Gene; Internal medicine; Inflammation; Gene expression; Genetics","score_opus":0.1344578805448216,"score_gpt":0.359653716261516,"score_spread":0.22519583571669438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361958404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753545,0.0020250601,0.00009563571,0.002747567,0.00028827123,0.0028462862,0.008796309,0.00024599113,0.00760039],"genre_scores_gemma":[0.98443747,0.0033892116,0.0022185189,0.00036594455,0.00021487374,0.00063697656,0.005954058,0.00008305073,0.0026999195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99696434,0.00016878275,0.00078881666,0.0012307599,0.000357966,0.0004893112],"domain_scores_gemma":[0.9970461,0.00024571433,0.00068510836,0.0017909837,0.000101568905,0.00013051127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004602896,0.00051730464,0.0015089604,0.00018003039,0.00006817516,0.00006926392,0.0007941394,0.00015914802,0.00032235114],"category_scores_gemma":[0.000030509656,0.00036172816,0.000107838525,0.00050694484,0.0005033545,0.00006424383,0.0011998531,0.00081196625,0.000032243282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13694942,0.0027380856,0.51182735,0.001585421,0.01441224,0.002085927,0.05348817,0.0011126485,0.09260124,0.00004745849,0.113425806,0.069726236],"study_design_scores_gemma":[0.005322454,0.0010282078,0.95717365,0.0014191539,0.00047020096,0.000009507119,0.013438556,0.0028839759,0.0010888168,0.0004248659,0.01565951,0.0010811164],"about_ca_topic_score_codex":0.076590724,"about_ca_topic_score_gemma":0.03401312,"teacher_disagreement_score":0.4453463,"about_ca_system_score_codex":0.0011331383,"about_ca_system_score_gemma":0.0012492462,"threshold_uncertainty_score":0.9998835},"labels":[],"label_agreement":null},{"id":"W4361959639","doi":"10.1158/1078-0432.c.6526599","title":"Data from Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; Université de Moncton; University Health Network; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Tumor-infiltrating lymphocytes; Immune system; CD8; Chemotherapy; Medicine; Cancer research; Internal medicine; Immunology","score_opus":0.08533555148204584,"score_gpt":0.3544894738158662,"score_spread":0.26915392233382035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361959639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9324549,0.0015216628,0.013635696,0.007785936,0.00026092766,0.0031355564,0.040988922,0.000113684066,0.00010271908],"genre_scores_gemma":[0.9818685,0.0020232566,0.009113406,0.00048113396,0.00022344316,0.0007052383,0.0049607684,0.00018107961,0.00044317578],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99673665,0.00010183358,0.0014817794,0.0010084654,0.00031347934,0.0003577998],"domain_scores_gemma":[0.99470526,0.00094212464,0.0011049754,0.002928955,0.000248753,0.00006993433],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012826254,0.00043815922,0.0011105003,0.00027691753,0.000053927066,0.000028549985,0.0008593186,0.00023837706,0.0001416615],"category_scores_gemma":[0.00015523448,0.0003413116,0.0002099973,0.00034892003,0.00015341726,0.000074139745,0.00024670374,0.00029942385,7.7325797e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47160584,0.0006985577,0.2205566,0.0010112764,0.003195984,0.000019038773,0.0016732769,0.00017432566,0.21469834,0.000057711706,0.001202336,0.085106716],"study_design_scores_gemma":[0.020885317,0.00054375036,0.9579106,0.0032696014,0.0001414443,0.0000075979415,0.0002322341,0.0015333002,0.013384355,0.00045542585,0.0012381435,0.0003982164],"about_ca_topic_score_codex":0.044842303,"about_ca_topic_score_gemma":0.027945956,"teacher_disagreement_score":0.737354,"about_ca_system_score_codex":0.00035459403,"about_ca_system_score_gemma":0.0017778621,"threshold_uncertainty_score":0.9999039},"labels":[],"label_agreement":null},{"id":"W4361970967","doi":"10.1158/1078-0432.22456223","title":"Supplementary Figure 2 from Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CD8; Medicine; CXCL10; Breast carcinoma; Cancer research; Chemokine; Breast cancer; Internal medicine; Cancer; Molecular biology; Pathology; Biology; Immunology; Immune system; Receptor","score_opus":0.01913521880064305,"score_gpt":0.2617334239540961,"score_spread":0.24259820515345304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361970967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778103,0.0006177008,0.0000052456,0.008729603,0.0010850594,0.00090664305,0.010695534,0.000026664353,0.00012323125],"genre_scores_gemma":[0.9931781,0.00097265147,0.00009444791,0.0012941079,0.0006004445,0.00015621545,0.002628293,0.000040792296,0.0010349184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796194,0.00008608906,0.00060399645,0.00058824295,0.00049885147,0.00026086884],"domain_scores_gemma":[0.99853915,0.000111274334,0.0003737036,0.00084043946,0.00006896607,0.00006646852],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018159457,0.00036272922,0.0005397344,0.000055094977,0.00008666005,0.000041029034,0.00036731112,0.000290367,0.0043559344],"category_scores_gemma":[0.000009139049,0.00021068005,0.00019257012,0.000174074,0.00024867945,0.000054414417,0.00040137337,0.0006708012,0.0000010640518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067746374,0.0000704727,0.8883807,0.00017132152,0.0004379538,0.000019924935,0.0040810737,0.00021969221,0.061813533,0.000001678236,0.034575604,0.0034533748],"study_design_scores_gemma":[0.0045242407,0.000025731815,0.9772436,0.002731392,0.00022592608,0.000021521237,0.0012182128,0.00022972308,0.011996224,0.000120975325,0.0014163398,0.00024612024],"about_ca_topic_score_codex":0.96174055,"about_ca_topic_score_gemma":0.7796807,"teacher_disagreement_score":0.18205982,"about_ca_system_score_codex":0.0030394057,"about_ca_system_score_gemma":0.0029505473,"threshold_uncertainty_score":0.9965542},"labels":[],"label_agreement":null},{"id":"W4361988864","doi":"10.1177/17588359231156382","title":"A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"FP7 Health; Pharmacyclics; Sanofi Genzyme; Genentech; Daiichi Sankyo Europe; National Cancer Institute; Servier; AstraZeneca; Institut National Du Cancer; Canadian Cancer Society; Foundation Medicine; Fondation ARC pour la Recherche sur le Cancer; Seagen; Puma Biotechnology; Actuate Therapeutics; Symphogen; Pfizer; Incyte; Grifols; EQRx; BeiGene; European Commission; Sanofi; Halozyme; Chugai Pharmaceutical; Israel Science Foundation; Ipsen; Array BioPharma; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Instituto de Salud Carlos III; Amgen; Novartis Pharmaceuticals Corporation; Les Laboratories Pierre Fabre","keywords":"Medicine; Oncology; Clinical trial; Internal medicine; Immunotherapy; Metastasis; Cancer","score_opus":0.17780642204238725,"score_gpt":0.5108081939300281,"score_spread":0.3330017718876408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361988864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67341995,0.11535531,0.05079271,0.11629634,0.0064572147,0.009559622,0.0000492289,0.0006750655,0.027394565],"genre_scores_gemma":[0.7610797,0.18810475,0.010345946,0.037889857,0.0007554988,0.0011083465,0.00005569245,0.000093842,0.0005663504],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934338,0.0026772781,0.0020936327,0.00067026186,0.00044910156,0.0006759679],"domain_scores_gemma":[0.9938875,0.0050728656,0.00023773927,0.0003326684,0.000044962362,0.0004242814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01600995,0.0002900724,0.0020684612,0.00054110977,0.0000627172,0.000011862054,0.00029171124,0.0007814393,0.00026922193],"category_scores_gemma":[0.0011526732,0.00022351876,0.0002620879,0.0011358501,0.0008023204,0.000111660614,0.000066789005,0.0010289504,0.000026124895],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0103993,0.0012925107,0.0027877232,0.00007028287,0.0001783879,0.00018192828,0.0018216744,0.000084516556,0.0007656322,0.0011680798,0.00019043498,0.98105955],"study_design_scores_gemma":[0.038829226,0.0060831937,0.03002806,0.00031168462,0.00025997142,0.00051620987,0.0044213636,0.008778416,0.000065909415,0.0053754547,0.904776,0.00055451924],"about_ca_topic_score_codex":0.000034767992,"about_ca_topic_score_gemma":0.00020781012,"teacher_disagreement_score":0.980505,"about_ca_system_score_codex":0.00040445462,"about_ca_system_score_gemma":0.00093739067,"threshold_uncertainty_score":0.91148305},"labels":[],"label_agreement":null},{"id":"W4362410609","doi":"10.1158/1078-0432.22477923","title":"Supplementary Data from NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Complete response; Randomized controlled trial; Gene; Oncology; Internal medicine; Medicine; Biology; Genetics; Chemotherapy","score_opus":0.1089265121860138,"score_gpt":0.3383071415660233,"score_spread":0.22938062938000953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362410609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9504673,0.0074911094,0.00029358835,0.009519248,0.0010093941,0.006269706,0.024523055,0.00036496655,0.00006164856],"genre_scores_gemma":[0.8210792,0.013322731,0.008940335,0.00796612,0.0009770665,0.0012158052,0.14073676,0.00034272167,0.005419295],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955071,0.0014973142,0.0008496876,0.0012028199,0.00055579207,0.00038726968],"domain_scores_gemma":[0.99438316,0.0033241273,0.00048783177,0.0015762728,0.00009799892,0.00013060604],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0040637883,0.0005444449,0.0020043196,0.00022510438,0.00011572761,0.00011309039,0.00051212555,0.00047333265,0.0017613434],"category_scores_gemma":[0.0007983367,0.00034028865,0.0002623629,0.00017638058,0.00042677595,0.00004570024,0.001169362,0.00069181144,0.000006274129],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9637914,0.00016748352,0.00023991856,0.000048184687,0.003289697,0.00060401513,0.00021896795,0.0000047655817,0.0070639723,0.000002013632,0.023318132,0.0012514782],"study_design_scores_gemma":[0.9768455,0.0011175269,0.007834912,0.0009191546,0.0021645986,0.000022038566,0.00041613876,0.0012695568,0.00035024798,0.0004632508,0.0079553425,0.00064172444],"about_ca_topic_score_codex":0.006157168,"about_ca_topic_score_gemma":0.0025235282,"teacher_disagreement_score":0.12938811,"about_ca_system_score_codex":0.00013342385,"about_ca_system_score_gemma":0.00041122347,"threshold_uncertainty_score":0.99990493},"labels":[],"label_agreement":null},{"id":"W4362456155","doi":"10.3899/jrheum.221182","title":"Successful Management of Checkpoint Inhibitor-Induced Arthritis With Disease-Modifying Antirheumatic Drugs During Active Immune Checkpoint Inhibition Treatment","year":2023,"lang":"en","type":"letter","venue":"The Journal of Rheumatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Socialstyrelsen; Stiftelsen Jubileumsklinikens Forskningsfond mot Cancer","keywords":"Medicine; Antirheumatic drugs; Arthritis; Antirheumatic Agents; Immune system; Disease; Internal medicine; Pharmacology; Immunology; Oncology","score_opus":0.016632960070544517,"score_gpt":0.26000913632925265,"score_spread":0.24337617625870814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362456155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9154985,0.0028767157,0.000028082655,0.080000356,0.0005863367,0.0008607113,0.000030206578,0.00004173983,0.000077367884],"genre_scores_gemma":[0.9667566,0.030748075,0.000112734895,0.0017363498,0.00014099454,0.000049325256,0.000072583745,0.00012969768,0.00025365516],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99624157,0.0003210985,0.0018145611,0.0003087405,0.0007780566,0.0005359605],"domain_scores_gemma":[0.9962078,0.00023345767,0.0025639473,0.0006237979,0.00025941615,0.00011161438],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006296469,0.00055479154,0.0016996069,0.0005639159,0.00017951104,0.000026623251,0.000259055,0.00033680274,0.00008846803],"category_scores_gemma":[0.000024055134,0.0003414965,0.0006357556,0.0004189114,0.0003275743,0.00014878376,0.00009664136,0.0011355424,0.0000144099995],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2786288,0.005378469,0.02801271,0.080209345,0.11453773,0.04166171,0.04833961,0.0002722815,0.17032212,0.00008920335,0.0536858,0.17886221],"study_design_scores_gemma":[0.1420054,0.018468862,0.12570596,0.26589808,0.014250845,0.083185785,0.030966816,0.00018162832,0.30599782,0.0009019783,0.0083239265,0.004112892],"about_ca_topic_score_codex":0.0006256327,"about_ca_topic_score_gemma":0.000029437142,"teacher_disagreement_score":0.18568875,"about_ca_system_score_codex":0.00065623096,"about_ca_system_score_gemma":0.0003410443,"threshold_uncertainty_score":0.9999037},"labels":[],"label_agreement":null},{"id":"W4362506944","doi":"10.1007/s10549-023-06921-3","title":"Tumour Infiltrating Lymphocytes (TILs) and immune composition in breast cancer patients from Kenya: Spatial distributions and associations with risk factors and tumour characteristics","year":2023,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Division of Cancer Epidemiology and Genetics, National Cancer Institute; National Cancer Institute; Medical Research Council; UK Research and Innovation; University of Cape Town; Irving Medical Center, Columbia University; National Commission for Science, Technology and Innovation","keywords":"Tumor-infiltrating lymphocytes; Breast cancer; Oncology; FOXP3; Immunohistochemistry; CD68; CD3; Medicine; Stroma; Internal medicine; CD20; CD8; Pathology; Cancer; Immune system; Immunology","score_opus":0.02312506720409118,"score_gpt":0.3095471636068535,"score_spread":0.28642209640276234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362506944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98381567,0.00102898,0.0000036080648,0.0011803751,0.00003681953,0.0005440495,0.013353312,0.000027488764,0.000009683388],"genre_scores_gemma":[0.9891947,0.009375889,0.000012706208,0.000011628155,0.000084251966,0.00019898909,0.0010880346,0.000018367267,0.000015431553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986873,0.000093034294,0.00023319772,0.00034260625,0.00028261836,0.0003612332],"domain_scores_gemma":[0.9992855,0.0001776115,0.00010359244,0.00009345587,0.00015709376,0.00018272326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013815827,0.00020172063,0.0003225179,0.00015675965,0.0004170413,0.00010916722,0.000028443694,0.00006555138,0.00003363239],"category_scores_gemma":[0.000012442716,0.00014382445,0.000026001213,0.0003065919,0.00022928421,0.00011602458,0.000048114154,0.00015512828,7.468116e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017389634,0.0002596406,0.9633056,0.000025882537,0.0002871306,0.000017113996,0.00062066584,5.075101e-7,0.0041274866,0.0000049426308,0.000018136017,0.029593952],"study_design_scores_gemma":[0.0061818985,0.0004449648,0.99097633,0.0003379272,0.00010322263,0.000025947023,0.00034565298,0.00022120311,0.0011859093,0.00002183377,0.00001830881,0.00013679061],"about_ca_topic_score_codex":0.115047075,"about_ca_topic_score_gemma":0.0064308974,"teacher_disagreement_score":0.10861617,"about_ca_system_score_codex":0.00074133987,"about_ca_system_score_gemma":0.00022707345,"threshold_uncertainty_score":0.8908459},"labels":[],"label_agreement":null},{"id":"W4362523523","doi":"10.1093/oncolo/oyad073","title":"Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Lactate dehydrogenase; Proportional hazards model; Oncology; Melanoma; Cohort; Retrospective cohort study; White blood cell; Cancer research","score_opus":0.020070594544156505,"score_gpt":0.2679739571272112,"score_spread":0.24790336258305473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362523523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99802876,0.00006410371,0.00027860762,0.00017409745,0.00001751637,0.0012964456,0.000017431135,0.000046163714,0.00007685942],"genre_scores_gemma":[0.9958975,0.000048513517,0.003472079,0.000016747339,0.000008470215,0.00023405656,0.00010119947,0.000014604148,0.00020687655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99937254,0.000018582627,0.00021649305,0.00013380541,0.0001291747,0.000129384],"domain_scores_gemma":[0.9994791,0.00008421991,0.00019211041,0.0001252451,0.00009546406,0.000023817842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024471543,0.00009988043,0.00018491998,0.000045868353,0.00009417093,0.0000059308627,0.000040642713,0.00003606567,0.0000023972755],"category_scores_gemma":[0.00004874297,0.00004970158,0.000026045269,0.00020623831,0.00014643342,0.0000306854,0.000016432658,0.000049088536,8.5712077e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06908932,0.0012095306,0.6661908,0.00047498682,0.0012121904,0.0000096733565,0.008096661,0.0016528782,0.021323986,0.00003020721,0.00020584966,0.23050392],"study_design_scores_gemma":[0.01747287,0.00654893,0.8834203,0.00039425105,0.00035290507,0.00000571268,0.0007887369,0.0052663675,0.08481374,0.000035726214,0.00067272474,0.00022772451],"about_ca_topic_score_codex":0.000049329134,"about_ca_topic_score_gemma":0.00004334765,"teacher_disagreement_score":0.2302762,"about_ca_system_score_codex":0.000086295324,"about_ca_system_score_gemma":0.00012553549,"threshold_uncertainty_score":0.20267716},"labels":[],"label_agreement":null},{"id":"W4362539804","doi":"10.1158/1538-7445.am2023-3651","title":"Abstract 3651: The role of caspase-1 in basal-like breast cancer and the tumor microenvironment","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Tumor microenvironment; Cancer research; Breast cancer; Gene knockdown; Medicine; Cancer; Caspase 3; Estrogen receptor; Immune system; Apoptosis; Biology; Immunology; Internal medicine; Programmed cell death","score_opus":0.034471047079649444,"score_gpt":0.3531149410124961,"score_spread":0.31864389393284664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362539804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96343523,0.014987649,7.93916e-8,0.020090135,0.00009137613,0.00070042757,0.00012326491,0.000010723846,0.000561139],"genre_scores_gemma":[0.9846579,0.013129045,0.0000017151636,0.0005167255,0.00013193564,0.00044619187,0.0000047166645,0.000021856838,0.0010899148],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99852395,0.00010793164,0.00022361841,0.00023055036,0.000513693,0.00040026865],"domain_scores_gemma":[0.9992156,0.0002647031,0.000049000406,0.00035114834,0.000056139972,0.000063420026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015600533,0.00010253112,0.000207671,0.00013291795,0.00012932035,0.000021688678,0.00019415248,0.00004004759,0.00083740376],"category_scores_gemma":[0.000020102989,0.00005423864,0.00006700949,0.0005886423,0.00091300695,0.000034808727,0.00010869355,0.00040351742,0.000021942864],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020920452,0.00020475297,0.12287522,0.0004466827,0.0004592431,0.00013081498,0.0049670637,0.00006810247,0.6850738,0.00013486076,0.03061956,0.13409947],"study_design_scores_gemma":[0.00463969,0.000060521972,0.9257668,0.00036861532,0.000022847398,0.000024897163,0.0027809755,0.00012714599,0.019969262,0.00018435967,0.045957543,0.00009732938],"about_ca_topic_score_codex":0.02300023,"about_ca_topic_score_gemma":0.002583636,"teacher_disagreement_score":0.8028916,"about_ca_system_score_codex":0.0002600175,"about_ca_system_score_gemma":0.00027646325,"threshold_uncertainty_score":0.9835057},"labels":[],"label_agreement":null},{"id":"W4362546031","doi":"10.1158/2326-6066.c.6548740.v1","title":"Data from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"York University; University of Pennsylvania","keywords":"Pancreatic cancer; Medicine; Cancer research; T cell; Immune checkpoint; Tumor microenvironment; Immune system; Antibody; CTLA-4; Immunology; Cancer; Immunotherapy; Internal medicine","score_opus":0.08951590363320547,"score_gpt":0.30707576592223335,"score_spread":0.21755986228902788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362546031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99286145,0.0032841512,0.000038821654,0.0009336994,0.00034092422,0.00071494345,0.0012627178,0.00003931969,0.00052394945],"genre_scores_gemma":[0.9940416,0.0018984341,0.001572005,0.00009136257,0.0000926368,0.000021917567,0.0008232724,0.000032789983,0.0014259722],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99831766,0.00012185362,0.00050543604,0.0006237214,0.00023608038,0.00019524732],"domain_scores_gemma":[0.99819624,0.00026689033,0.00017415437,0.0012231497,0.000053057607,0.00008651148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005130294,0.00025568003,0.0007328778,0.00021022206,0.00004197788,0.00003289109,0.0002632168,0.00020844983,0.000041699335],"category_scores_gemma":[0.000088551125,0.0002282854,0.000045452252,0.00019980497,0.0001447135,0.0000624184,0.0009969485,0.00041984112,0.000001804217],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004841965,0.00016512656,0.17983285,0.0017804268,0.00037528537,0.000021527463,0.001178609,0.0000011704201,0.8087104,0.000010039545,0.0013253513,0.0017572636],"study_design_scores_gemma":[0.002316876,0.00011872438,0.9854547,0.00067065505,0.00015292439,0.0000024398319,0.001000408,0.00015118704,0.00886213,0.00028204705,0.00074282783,0.00024510574],"about_ca_topic_score_codex":0.04008772,"about_ca_topic_score_gemma":0.01169333,"teacher_disagreement_score":0.8056218,"about_ca_system_score_codex":0.00008954242,"about_ca_system_score_gemma":0.00015505885,"threshold_uncertainty_score":0.9663044},"labels":[],"label_agreement":null},{"id":"W4362546308","doi":"10.1158/2159-8290.c.6549583.v1","title":"Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Sanofi Genzyme; Takeda Oncology; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Natera; Chugai Pharmaceutical; Seagen; Array BioPharma; OncoSec Medical; Pfizer; Incyte; AstraZeneca; Amarin Corporation; Castle Biosciences; National Cancer Institute; Foghorn Therapeutics; Gilead Sciences; Eisai; National Comprehensive Cancer Network; Sanofi; Jounce Therapeutics; Celgene; Bristol-Myers Squibb; Amgen; GlaxoSmithKline","keywords":"Pembrolizumab; Medicine; Ipilimumab; Adjuvant; Internal medicine; Melanoma; Adverse effect; Confidence interval; Adjuvant therapy; Oncology; Gastroenterology; Cancer; Immunotherapy; Cancer research","score_opus":0.14333108001793435,"score_gpt":0.36250416838652466,"score_spread":0.2191730883685903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362546308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97798276,0.0024680689,0.00007959059,0.0019928988,0.0054988046,0.001535903,0.007454072,0.0006387856,0.0023491005],"genre_scores_gemma":[0.950791,0.011026662,0.0021015976,0.0003145309,0.0012773832,0.00017199304,0.02262406,0.00022699895,0.011465798],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99597687,0.00022208707,0.0009292473,0.0016106216,0.00068487896,0.00057628157],"domain_scores_gemma":[0.9947682,0.000710877,0.0003257873,0.003917981,0.00010178265,0.00017539176],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00057498016,0.00055950525,0.0011381789,0.00044360635,0.00007300799,0.00008210722,0.0012234164,0.00074157823,0.004316365],"category_scores_gemma":[0.0005406538,0.00041770271,0.00019404851,0.00054246053,0.00013744154,0.000102965365,0.0022213669,0.0014679412,0.00039314196],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5568696,0.0011708307,0.017134558,0.00088716944,0.0076104407,0.0035362958,0.0011753178,0.000054998112,0.003985858,0.00004237531,0.31240812,0.09512441],"study_design_scores_gemma":[0.15625541,0.0037671959,0.7582017,0.004166385,0.002362595,0.00004973577,0.0019368705,0.01068243,0.0034562764,0.0012550864,0.055247948,0.0026183273],"about_ca_topic_score_codex":0.093118355,"about_ca_topic_score_gemma":0.09425605,"teacher_disagreement_score":0.7410672,"about_ca_system_score_codex":0.00059253094,"about_ca_system_score_gemma":0.0012517958,"threshold_uncertainty_score":0.9998275},"labels":[],"label_agreement":null},{"id":"W4362571174","doi":"10.1007/978-3-030-80962-1_316-1","title":"Advancing Cancer Immunotherapy Through Integrating Molecular and Computational Approaches","year":2023,"lang":"en","type":"book-chapter","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Cancer immunotherapy; Immunotherapy; Computational biology; Cancer; Computer science; Medicine; Biology; Internal medicine","score_opus":0.042002862767060736,"score_gpt":0.29423540267299875,"score_spread":0.252232539905938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362571174","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023513795,0.044367254,0.02044416,0.0068922127,0.00088497234,0.001980088,0.000107305656,0.0011233016,0.9218493],"genre_scores_gemma":[0.01278397,0.016873702,0.042569187,0.008083012,0.0007207034,0.00018683088,0.0005349212,0.00089664006,0.917351],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987155,0.000009604618,0.00036030918,0.00040390925,0.00029969026,0.00021098397],"domain_scores_gemma":[0.99944276,0.000083587634,0.00015394315,0.0001983947,0.000071482114,0.00004984858],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014170846,0.00033637616,0.00047069837,0.00010516485,0.00006844576,0.000034033073,0.00006676787,0.00023334211,0.00044475752],"category_scores_gemma":[0.000007790632,0.00027290356,0.00019088772,0.000050087805,0.0001560054,0.00006301758,0.000037052116,0.00033664718,0.000010417338],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024148899,0.00007925233,0.00028465115,0.001033334,0.005623698,0.00024965507,0.0026338436,0.00035409964,0.012821259,0.3424292,0.007825207,0.6242509],"study_design_scores_gemma":[0.015279801,0.0012746941,0.0013162836,0.009759751,0.0010828264,0.00060453184,0.0018975787,0.0062050917,0.0047508082,0.16221297,0.7918877,0.0037279378],"about_ca_topic_score_codex":0.00025895046,"about_ca_topic_score_gemma":0.00008111332,"teacher_disagreement_score":0.7840625,"about_ca_system_score_codex":0.00015249476,"about_ca_system_score_gemma":0.00020510773,"threshold_uncertainty_score":0.99997234},"labels":[],"label_agreement":null},{"id":"W4362586968","doi":"10.1016/s1556-0864(23)00338-6","title":"84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Regeneron Pharmaceuticals; Genentech; F-star Therapeutics; Daiichi Sankyo Europe; Sanofi; Bristol-Myers Squibb; AstraZeneca; Daiichi-Sankyo; G1 Therapeutics; Amgen; LUNGevity Foundation; Mesothelioma Applied Research Foundation","keywords":"Medicine; Internal medicine; Oncology; Complete response; Neoadjuvant therapy; Nivolumab; Gastroenterology; Chemotherapy; Surgery; Cancer; Breast cancer; Immunotherapy","score_opus":0.034453478235764695,"score_gpt":0.4077052869778547,"score_spread":0.37325180874208996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362586968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96763396,0.0021256965,0.00082607794,0.024421254,0.0023958518,0.00061840087,0.00007771473,0.00008310091,0.0018179439],"genre_scores_gemma":[0.9466248,0.0064681363,0.019953834,0.009704233,0.0043958146,0.000085170825,0.00019882392,0.00021780246,0.012351365],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978496,0.00011888152,0.00092758005,0.00025877613,0.00035216878,0.00049301964],"domain_scores_gemma":[0.9980196,0.00036144545,0.0007896236,0.0003185306,0.0003259027,0.00018491833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015079689,0.00022440967,0.0008939385,0.00033395295,0.00012696326,0.000037368995,0.0002871141,0.00028844483,0.00090876286],"category_scores_gemma":[0.00014519779,0.00017545669,0.00042747604,0.0004747625,0.00011297134,0.00018251434,0.000044765948,0.00042445553,0.00007868449],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07888693,0.00035215085,0.00085058087,0.0001244747,0.0011609048,0.00044794075,0.0008770187,0.000022696635,0.16391425,0.000019861678,0.18470739,0.5686358],"study_design_scores_gemma":[0.016905028,0.0053346767,0.012136522,0.0005792655,0.0004001572,0.0007653116,0.0007578203,0.00073438976,0.04829816,0.0013824011,0.91236836,0.00033792542],"about_ca_topic_score_codex":0.000106306084,"about_ca_topic_score_gemma":0.00005805761,"teacher_disagreement_score":0.72766095,"about_ca_system_score_codex":0.00044814017,"about_ca_system_score_gemma":0.00069763325,"threshold_uncertainty_score":0.99503165},"labels":[],"label_agreement":null},{"id":"W4362592768","doi":"10.1158/1538-7445.am2023-3281","title":"Abstract 3281: GEN1042 (DuoBody-CD40x4-1BB)®in combination with PD-1 blockade reverses T-cell exhaustion <i>in vitro</i>","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Optech (Canada)","funders":"","keywords":"CD28; T cell; CD40; Priming (agriculture); Immune system; IL-2 receptor; Mixed lymphocyte reaction; Cytokine; Immunology; Biology; Chemistry; Cancer research; In vitro; Cytotoxic T cell; Biochemistry","score_opus":0.06643323065617299,"score_gpt":0.38639158776393967,"score_spread":0.31995835710776666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362592768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990363,0.0013425192,0.0000039692864,0.0036890835,0.00016899384,0.0009315527,0.000021822727,0.000075646894,0.0034033968],"genre_scores_gemma":[0.990999,0.002988438,0.000050089213,0.00016696393,0.00014982691,0.0003287518,0.00008322077,0.00004360172,0.0051901],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99761623,0.00009797699,0.00031367308,0.0004430819,0.0008620165,0.0006670157],"domain_scores_gemma":[0.99914736,0.00014881979,0.000059644688,0.0003409888,0.00018882177,0.00011435438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014307649,0.0001614664,0.00027190702,0.00077328016,0.00010371917,0.000037326103,0.00016672467,0.0001385134,0.00039912446],"category_scores_gemma":[0.000048114387,0.00013993696,0.00006313664,0.0022208195,0.00018660961,0.00013885972,0.000044375756,0.00066248036,0.0001211978],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008090849,0.0002772818,0.005878765,0.0003575267,0.00003449282,0.00029711865,0.00044865784,0.00007159044,0.96312463,0.000008941352,0.008648852,0.012761263],"study_design_scores_gemma":[0.013880117,0.0006249478,0.18947698,0.0010532404,0.000023054532,0.00001844678,0.0014411402,0.00022126321,0.7615805,0.00011294502,0.0312147,0.00035266695],"about_ca_topic_score_codex":0.0035593999,"about_ca_topic_score_gemma":0.0007276458,"teacher_disagreement_score":0.20154415,"about_ca_system_score_codex":0.0008308536,"about_ca_system_score_gemma":0.0005394089,"threshold_uncertainty_score":0.5706464},"labels":[],"label_agreement":null},{"id":"W4362593635","doi":"10.1158/1538-7445.am2023-3014","title":"Abstract 3014: Association between HLA-KIR allele interaction combinations and density of T-cell subsets in colorectal cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Odds ratio; Colorectal cancer; Human leukocyte antigen; Genome-wide association study; CD8; T cell; Biology; Immunology; Immune system; Quartile; Confidence interval; Medicine; Oncology; Cancer; Internal medicine; Genotype; Genetics; Antigen; Single-nucleotide polymorphism; Gene","score_opus":0.07854447037274405,"score_gpt":0.42259466917876437,"score_spread":0.34405019880602034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362593635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99623156,0.0004508295,7.6669625e-7,0.0018877821,0.00013226089,0.00041950785,0.0000569591,0.00002577661,0.0007945373],"genre_scores_gemma":[0.99607956,0.0027393247,0.000005416882,0.000027561031,0.000090934846,0.000121674726,0.00006552626,0.000014718941,0.00085529755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986838,0.00009296268,0.00023901807,0.00020758454,0.00047923546,0.00029737232],"domain_scores_gemma":[0.9990902,0.0003476755,0.00009201716,0.000096075106,0.00030630446,0.00006772755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011497777,0.0000781766,0.00021621528,0.00035650624,0.00008884685,0.000019692223,0.00006675492,0.000117707226,0.0002791674],"category_scores_gemma":[0.00011254827,0.00007673367,0.000045853278,0.0008220854,0.00008504122,0.000098901255,0.000043567168,0.0004012613,0.000016413982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006389012,0.000099643185,0.6080687,0.0001663646,0.00010502201,0.0000074304244,0.00075742626,0.0000054177285,0.37273058,0.000006049621,0.008556631,0.008857812],"study_design_scores_gemma":[0.0019520789,0.00010279191,0.8644848,0.00013144789,0.000016123378,5.904217e-7,0.00035139098,0.000052647687,0.13130379,0.000048820228,0.0014929071,0.00006264444],"about_ca_topic_score_codex":0.009350794,"about_ca_topic_score_gemma":0.0058682715,"teacher_disagreement_score":0.25641605,"about_ca_system_score_codex":0.0010376605,"about_ca_system_score_gemma":0.00031937848,"threshold_uncertainty_score":0.997246},"labels":[],"label_agreement":null},{"id":"W4362594122","doi":"10.1158/1538-7445.am2023-6667","title":"Abstract 6667: Pan-cancer assessment of tumour and peripheral T-cell receptor repertoire dynamics in patients treated with immune checkpoint inhibitors","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"T-cell receptor; Biology; Immune system; Pembrolizumab; T cell; Immune checkpoint; Immunology; Cancer research; Immunotherapy","score_opus":0.030198213604252788,"score_gpt":0.35987041134560416,"score_spread":0.32967219774135137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362594122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99569374,0.0012126345,5.507928e-7,0.0010533935,0.00011570764,0.0008736131,0.00008436771,0.000037015703,0.00092900323],"genre_scores_gemma":[0.9938344,0.0039295238,0.000036605114,0.000024901225,0.00007278946,0.00031559062,0.00010115139,0.000050657174,0.0016343845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776244,0.000087863846,0.0004705774,0.00041818127,0.0007485972,0.000512318],"domain_scores_gemma":[0.99905926,0.00006656774,0.00012825108,0.00029801927,0.00033380341,0.000114102346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076811423,0.0001893642,0.00039822276,0.0003450055,0.00010032278,0.00002930041,0.000121415476,0.00011782526,0.00046581935],"category_scores_gemma":[0.000028118266,0.0001440837,0.000078257435,0.0011091838,0.00031538605,0.00009793837,0.000074009164,0.00051015726,0.0000032876148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004122582,0.00033622523,0.6395603,0.0005234535,0.000119370285,0.000024551227,0.00040503877,0.000016033342,0.33201456,0.0000036032068,0.0007012615,0.022173028],"study_design_scores_gemma":[0.0064664283,0.00094559294,0.9338548,0.0011234634,0.000016645168,0.0000011004748,0.0010010098,0.00041323245,0.055414762,0.000002990088,0.00058013486,0.00017982739],"about_ca_topic_score_codex":0.008863847,"about_ca_topic_score_gemma":0.001061191,"teacher_disagreement_score":0.29429454,"about_ca_system_score_codex":0.001759546,"about_ca_system_score_gemma":0.000679351,"threshold_uncertainty_score":0.9977362},"labels":[],"label_agreement":null},{"id":"W4362594156","doi":"10.1158/1538-7445.am2023-5760","title":"Abstract 5760: Molecular, immune, and microbial profiles of early-onset, intermediate-onset, and later-onset CRCs","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"KRAS; Microsatellite instability; Colorectal cancer; Age of onset; Medicine; Internal medicine; Cancer; Oncology; Gastroenterology; Biology; Genetics; Disease; Gene; Microsatellite; Allele","score_opus":0.04423971322434717,"score_gpt":0.3780475635882365,"score_spread":0.3338078503638893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362594156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99207586,0.00548302,9.998495e-7,0.0011420179,0.00016641125,0.0006418677,0.00022634966,0.00004915111,0.00021430555],"genre_scores_gemma":[0.99295604,0.0055508153,0.000028589757,0.00010082089,0.00007284366,0.00012257368,0.000052218038,0.000042071726,0.0010740373],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99818796,0.00011187023,0.00035298103,0.0003820017,0.0004293923,0.0005357986],"domain_scores_gemma":[0.99902576,0.00020439106,0.00007248406,0.00034281667,0.00019208508,0.0001624332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096277863,0.00017339847,0.0003465217,0.0004170368,0.0001237141,0.00005654586,0.00015884283,0.00014860959,0.00026346886],"category_scores_gemma":[0.00010440935,0.00014907861,0.00008578829,0.00061134575,0.00086170784,0.00007945876,0.00018666517,0.00045773818,0.000022036664],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005159952,0.000078019446,0.13629355,0.00082213205,0.00027769196,0.00019072862,0.0012207774,4.134701e-7,0.829681,0.0000042294364,0.009482583,0.016788924],"study_design_scores_gemma":[0.0022492576,0.00042944745,0.75385344,0.0006161355,0.000026012483,0.00005986515,0.000313521,0.000011963223,0.24007665,0.00006869116,0.002136595,0.00015841748],"about_ca_topic_score_codex":0.0016349981,"about_ca_topic_score_gemma":0.000103831684,"teacher_disagreement_score":0.6175599,"about_ca_system_score_codex":0.000098033415,"about_ca_system_score_gemma":0.00038394376,"threshold_uncertainty_score":0.60792494},"labels":[],"label_agreement":null},{"id":"W4362594548","doi":"10.1158/1538-7445.am2023-3019","title":"Abstract 3019: Density of T cell subsets in colorectal cancer in relation to disease-specific survival","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Colorectal cancer; Hazard ratio; KRAS; CD8; Stromal cell; Microsatellite instability; Proportional hazards model; Oncology; T cell; Internal medicine; Medicine; Cancer; Cytotoxic T cell; Cancer research; Confidence interval; Biology; Immunology; Immune system; Genetics; Allele","score_opus":0.10334140350255044,"score_gpt":0.4007434649016552,"score_spread":0.29740206139910474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362594548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951252,0.0014852834,9.236799e-7,0.0016426104,0.0002822689,0.0007370698,0.00007338779,0.000023186865,0.00063006877],"genre_scores_gemma":[0.9956085,0.0035294336,0.000005886982,0.000031369305,0.00011230133,0.00020436574,0.000024524725,0.00002377824,0.00045985015],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99812204,0.00010871547,0.0003049207,0.0003347918,0.0006693898,0.0004601449],"domain_scores_gemma":[0.9992267,0.00018465664,0.00003914834,0.00020704135,0.00017272914,0.00016971849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001262181,0.00010246423,0.00024714723,0.00061975815,0.00004599257,0.000012859481,0.00012872386,0.00008471974,0.00065416633],"category_scores_gemma":[0.00006676297,0.00009821981,0.000062340834,0.002165103,0.00011566737,0.00006328291,0.000057931164,0.0003914884,0.000058664646],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076342127,0.000114147355,0.4675776,0.00017935003,0.0000149097095,0.00011296127,0.0006797423,0.00016411392,0.5151817,0.000012958857,0.0023805206,0.005947748],"study_design_scores_gemma":[0.001640721,0.00007276475,0.949625,0.0003466816,0.000003210926,3.1769335e-7,0.00022495897,0.000054065436,0.0464672,0.000027808266,0.0014458783,0.00009135437],"about_ca_topic_score_codex":0.0053305025,"about_ca_topic_score_gemma":0.008503651,"teacher_disagreement_score":0.48204744,"about_ca_system_score_codex":0.0008777685,"about_ca_system_score_gemma":0.0006596973,"threshold_uncertainty_score":0.8058161},"labels":[],"label_agreement":null},{"id":"W4362633521","doi":"10.1136/gutjnl-2022-328364","title":"Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma","year":2023,"lang":"en","type":"article","venue":"Gut","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health and Medical Research Fund; Chinese University of Hong Kong; Merck Sharp and Dohme; Terry Fox Foundation; Li Ka Shing Foundation","keywords":"Cancer research; Tumor microenvironment; Immune checkpoint; Immunotherapy; Immune system; Cytotoxic T cell; Medicine; Pembrolizumab; CD8; Hepatocellular carcinoma; Cancer; Biology; Immunology; Internal medicine","score_opus":0.0275483769946172,"score_gpt":0.27037518312255004,"score_spread":0.24282680612793284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362633521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99562794,0.00072668097,0.00007747706,0.0020947596,0.00033411066,0.00049427943,0.0000071511513,0.00010625368,0.0005313502],"genre_scores_gemma":[0.9977962,0.000082428625,0.0002560975,0.00035775176,0.00017369274,0.000057843466,0.00008921498,0.000031178693,0.0011556355],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99867886,0.000037595433,0.00041744942,0.00026110926,0.00025950372,0.0003454686],"domain_scores_gemma":[0.9995216,0.000045958514,0.00007713953,0.0002070017,0.000059322694,0.00008898689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048023934,0.00014565188,0.00024027863,0.00024021589,0.00005563522,0.000023981393,0.00008962952,0.00006918347,0.00012990256],"category_scores_gemma":[0.000106954074,0.00013964006,0.0000965799,0.0005931695,0.000020676085,0.00006703637,0.000040464336,0.0001575399,0.0003530038],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009246534,0.000047734186,0.032342896,0.00006820763,0.000030126128,0.00029826513,0.0032803959,0.00017208004,0.95927286,0.0000042437828,0.0008568689,0.0027016683],"study_design_scores_gemma":[0.005629127,0.0005291573,0.6744076,0.0006064247,0.00005522194,0.000076532226,0.0052466844,0.046352264,0.22747748,0.000056239824,0.03903016,0.0005331192],"about_ca_topic_score_codex":0.0017135169,"about_ca_topic_score_gemma":0.00007429184,"teacher_disagreement_score":0.7317954,"about_ca_system_score_codex":0.00019291502,"about_ca_system_score_gemma":0.0001149076,"threshold_uncertainty_score":0.56943566},"labels":[],"label_agreement":null},{"id":"W4363674327","doi":"10.1038/s43018-023-00534-x","title":"Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab","year":2023,"lang":"en","type":"article","venue":"Nature Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Public Health Ontario; University Health Network; University of Toronto; Western University; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ontario Institute for Cancer Research; Princess Margaret Cancer Foundation; Ontario Ministry of Research and Innovation; Genentech; F. Hoffmann-La Roche","keywords":"Atezolizumab; Biomarker; Immune system; Oncology; Medicine; Immunotherapy; CD8; Internal medicine; Immunology; Cancer research; Biology; Pembrolizumab","score_opus":0.02100281669015009,"score_gpt":0.3297458533754007,"score_spread":0.3087430366852506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4363674327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99488544,0.0026348503,0.0000040947994,0.00008764962,0.00053092657,0.001101264,0.00066759874,0.000046194764,0.00004195942],"genre_scores_gemma":[0.9990243,0.00016287906,0.000045619334,0.0001741789,0.00010603116,0.00009411206,0.0002488565,0.000034509387,0.000109526925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979805,0.000071379516,0.000669848,0.00043905067,0.00055953366,0.00027968962],"domain_scores_gemma":[0.9986755,0.00009375756,0.00032758532,0.00050127227,0.00028948384,0.00011239372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001766369,0.00023854345,0.00082964555,0.0011473049,0.00004680359,0.000008461018,0.0001977314,0.00019483882,0.000491681],"category_scores_gemma":[0.00007370338,0.00019686854,0.00038289657,0.004084075,0.0000354991,0.000039497027,0.00007359795,0.00020894279,0.00000763774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033263672,0.0056130136,0.5978009,0.0001096807,0.012068075,0.000042430664,0.0058577117,0.00029044683,0.30524445,3.9970627e-7,0.002336622,0.037372615],"study_design_scores_gemma":[0.021978313,0.0016035334,0.9635405,0.000056824916,0.0034826025,2.0924848e-7,0.000577972,0.00041740073,0.007682373,0.0000011400616,0.00044042506,0.00021869522],"about_ca_topic_score_codex":0.0020172615,"about_ca_topic_score_gemma":0.00033994848,"teacher_disagreement_score":0.3657396,"about_ca_system_score_codex":0.00033707585,"about_ca_system_score_gemma":0.000150815,"threshold_uncertainty_score":0.8028066},"labels":[],"label_agreement":null},{"id":"W4365512024","doi":"10.1158/1538-7445.am2023-ct266","title":"Abstract CT266: Chinese race and origin have no clinically meaningful effect on tiragolumab and atezolizumab pharmacokinetics and safety in patients with advanced solid tumors","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Atezolizumab; Medicine; Dosing; Adverse effect; Internal medicine; Pharmacokinetics; Oncology; Cancer; Immunotherapy","score_opus":0.02831565334505279,"score_gpt":0.4150989559091454,"score_spread":0.3867833025640926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365512024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967469,0.00072971184,4.3600528e-7,0.00054160797,0.00010096675,0.0011625402,0.000038291026,0.00004063963,0.00063893315],"genre_scores_gemma":[0.99421126,0.0047871983,0.000022280848,0.00014152113,0.00010513798,0.00008889915,0.000027668159,0.0000469625,0.00056910067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784,0.00013386879,0.00036021936,0.00053778786,0.0006057342,0.00052241096],"domain_scores_gemma":[0.9987305,0.0005471997,0.00007634619,0.00024480905,0.00018499036,0.00021616001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011848263,0.00022626687,0.0004612399,0.00027506144,0.00014106669,0.00004686553,0.00009245154,0.000091010996,0.00008595024],"category_scores_gemma":[0.00023687413,0.00015958928,0.000032609816,0.00050792744,0.0003538188,0.00009262749,0.00009477313,0.00065069174,0.0000124018225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09088662,0.0001707856,0.71508235,0.0006662501,0.00014928625,0.00015686559,0.0010040276,0.00003436277,0.010338322,0.000002839258,0.0007578958,0.1807504],"study_design_scores_gemma":[0.020959508,0.00440734,0.9700679,0.00088048406,0.000018125178,0.000005579993,0.000078337536,0.00021550896,0.00089117745,0.000009980807,0.0022648855,0.00020112957],"about_ca_topic_score_codex":0.0002435602,"about_ca_topic_score_gemma":0.00013407801,"teacher_disagreement_score":0.2549856,"about_ca_system_score_codex":0.00020557416,"about_ca_system_score_gemma":0.00017271005,"threshold_uncertainty_score":0.6507862},"labels":[],"label_agreement":null},{"id":"W4365512242","doi":"10.1158/1538-7445.am2023-ct174","title":"Abstract CT174: First-in-class anti-CD200R1 antibody 23ME-00610 in patients with advanced solid malignancies: Phase 1 results","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Discontinuation; Pharmacodynamics; Cancer; Oncology; Internal medicine; Pharmacokinetics; Immunotherapy; Antibody; Adverse effect; Pharmacology; Immunology","score_opus":0.04987680613467357,"score_gpt":0.4245616367554918,"score_spread":0.37468483062081825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365512242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99370116,0.0006804884,0.0000011344848,0.0021820972,0.00022668754,0.0014371707,0.00022940431,0.00007992129,0.0014619429],"genre_scores_gemma":[0.9952882,0.002702479,0.000021671372,0.00015221065,0.00011630258,0.00025132933,0.0002812665,0.00006293058,0.0011235895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962977,0.00008332118,0.0005919566,0.00070079195,0.0011580312,0.001168156],"domain_scores_gemma":[0.99847376,0.00023788922,0.00010583931,0.00062460074,0.00036527056,0.00019262251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013642007,0.00025077173,0.0004967342,0.00090248254,0.00015424052,0.00004952609,0.00028689316,0.00015323324,0.00028646743],"category_scores_gemma":[0.00022128111,0.000202894,0.00008184456,0.0029022424,0.00031449128,0.0002211082,0.00008287211,0.00070126104,0.0001053473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14055851,0.0040706038,0.49736127,0.0016317698,0.00039777535,0.0019903095,0.0042981836,0.0008404765,0.23598881,0.000025124553,0.032635055,0.0802021],"study_design_scores_gemma":[0.04357061,0.0014112128,0.9068122,0.0022009157,0.000009815185,0.0000024088945,0.0005322303,0.0001036685,0.011637263,0.000013586552,0.033388242,0.00031784468],"about_ca_topic_score_codex":0.001530606,"about_ca_topic_score_gemma":0.0016346923,"teacher_disagreement_score":0.40945095,"about_ca_system_score_codex":0.00074161845,"about_ca_system_score_gemma":0.0006846462,"threshold_uncertainty_score":0.82737774},"labels":[],"label_agreement":null},{"id":"W4365512265","doi":"10.1158/1538-7445.am2023-ct110","title":"Abstract CT110: Safety and anti-tumor activity of a novel Treg depleter RG6292, as a single agent and in combination with atezolizumab in patients with solid tumors","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Rash; Adverse effect; Atezolizumab; Internal medicine; Gastroenterology; Surgery; Cancer; Nivolumab; Immunotherapy","score_opus":0.053231216726673435,"score_gpt":0.35702177253605033,"score_spread":0.3037905558093769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365512265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99840873,0.00014071625,0.0000045326196,0.00047029543,0.000016436035,0.00076423795,0.00002702384,0.00001178182,0.00015621806],"genre_scores_gemma":[0.9995624,0.00021480244,0.000013720289,0.00003477306,0.000009616994,0.00005853098,0.000013237309,0.0000213364,0.000071605005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867964,0.000046443565,0.00019226779,0.00027958222,0.00048119022,0.00032090797],"domain_scores_gemma":[0.9994989,0.000086437765,0.00006793068,0.00015257599,0.00012153101,0.00007263143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045963548,0.000110797526,0.00028302948,0.00040448352,0.000050012262,0.000019243425,0.000051705545,0.000042535994,0.00002645003],"category_scores_gemma":[0.000037510974,0.00008211747,0.00001616612,0.0008066184,0.000251978,0.00009588191,0.000042944383,0.00024028315,9.319368e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.065806076,0.001814156,0.73125917,0.00078913494,0.00014439499,0.00016215727,0.0022119354,0.000037767095,0.13665281,0.000012584279,0.000089557696,0.061020248],"study_design_scores_gemma":[0.015104986,0.0011649663,0.9712393,0.0009547686,0.000006531172,0.0000060495518,0.00018288288,0.00010422473,0.011063469,0.0000063957673,0.00007026846,0.00009612705],"about_ca_topic_score_codex":0.0028872977,"about_ca_topic_score_gemma":0.0015371012,"teacher_disagreement_score":0.23998015,"about_ca_system_score_codex":0.00032646162,"about_ca_system_score_gemma":0.00025786663,"threshold_uncertainty_score":0.43647495},"labels":[],"label_agreement":null},{"id":"W4365512331","doi":"10.1158/1538-7445.am2023-ct265","title":"Abstract CT265: Phase 1 dose-escalation study of SGN-TGT monotherapy in patients with advanced malignancies","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"TIGIT; Medicine; Tolerability; Internal medicine; Antibody; Immune system; Oncology; Immunology; T cell; Adverse effect","score_opus":0.0774468423390009,"score_gpt":0.4359110392759378,"score_spread":0.3584641969369369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365512331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974024,0.00037565778,0.0000011997637,0.0002691375,0.000075165204,0.0016668425,0.00002434957,0.000038743638,0.00014645743],"genre_scores_gemma":[0.9987377,0.00049333344,0.0000148397185,0.000035141227,0.000042284624,0.00031345253,0.000025246973,0.000032799155,0.00030523763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980747,0.00007401629,0.00031595654,0.0003052665,0.00084660633,0.0003834193],"domain_scores_gemma":[0.99911004,0.00009241571,0.000076532684,0.00033161335,0.0003189205,0.00007045297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006298483,0.00012355005,0.0002702833,0.00047415175,0.00007294413,0.000015336986,0.00012531389,0.000057418718,0.00026105344],"category_scores_gemma":[0.000031294745,0.00009426704,0.000039548286,0.0015710687,0.00012666256,0.00012355756,0.00002541713,0.00025215355,0.000011194581],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05415553,0.0038496004,0.58106077,0.0002419342,0.0002467337,0.00004527968,0.005085508,0.00022528593,0.13542716,0.0000051087695,0.0009974533,0.21865967],"study_design_scores_gemma":[0.029096095,0.0039276807,0.9568122,0.00032025774,0.000008381739,2.2889755e-7,0.0015515295,0.000027469283,0.0072812852,0.000009716852,0.00085909746,0.00010605538],"about_ca_topic_score_codex":0.00095333596,"about_ca_topic_score_gemma":0.00046907255,"teacher_disagreement_score":0.37575147,"about_ca_system_score_codex":0.00026548916,"about_ca_system_score_gemma":0.00024294324,"threshold_uncertainty_score":0.38440984},"labels":[],"label_agreement":null},{"id":"W4365513292","doi":"10.3390/curroncol30040317","title":"Understanding Real-World Treatment Patterns and Clinical Outcomes among Metastatic Melanoma Patients in Alberta, Canada","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Calgary; Queen's University; Alberta Health Services","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Melanoma; Internal medicine; Population; Metastatic melanoma; Targeted therapy; Systemic therapy; Retrospective cohort study; Oncology; Cohort; Clinical trial; Medical record; Immunotherapy; Cancer","score_opus":0.22625916034867027,"score_gpt":0.4345839446841984,"score_spread":0.20832478433552815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365513292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965111,0.00003733353,0.0000052889295,0.0010459307,0.0013609366,0.00042475376,0.000026503707,0.000017736116,0.00057043793],"genre_scores_gemma":[0.9975959,0.0015164178,0.00000729381,0.00013974939,0.000039410315,0.00003772416,0.00012209309,0.000013576735,0.0005278547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987417,0.00012727281,0.00046000042,0.00025702704,0.00013771951,0.00027631415],"domain_scores_gemma":[0.9989522,0.0006566867,0.000112023234,0.00014225874,0.000017051081,0.00011975521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019358753,0.00014617074,0.00047769217,0.00017035949,0.000042910073,0.0000066880434,0.000044044937,0.000044379573,0.000069412294],"category_scores_gemma":[0.000052186937,0.000109648354,0.00008635392,0.00022284834,0.00008237681,0.000029294522,0.000029697256,0.00012608749,0.0000041065364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002821598,0.00030094286,0.9716115,0.000033084478,0.000198768,0.00006171256,0.00019987137,3.850105e-7,2.5186392e-7,0.000028955117,0.0016655795,0.025616795],"study_design_scores_gemma":[0.0065735434,0.0007371946,0.97969157,0.000068636844,0.0001179738,0.0000018875928,0.00031538538,0.000109058616,0.0000025159447,0.000029906005,0.012251869,0.00010046041],"about_ca_topic_score_codex":0.7665102,"about_ca_topic_score_gemma":0.99389523,"teacher_disagreement_score":0.22738498,"about_ca_system_score_codex":0.001905829,"about_ca_system_score_gemma":0.0004420222,"threshold_uncertainty_score":0.49836764},"labels":[],"label_agreement":null},{"id":"W4365513372","doi":"10.1158/1538-7445.am2023-ct037","title":"Abstract CT037: Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Nivolumab; Medicine; Internal medicine; Oncology; Cancer; Ipilimumab; Pemetrexed; Biomarker; Chemotherapy; Immunotherapy; Biology","score_opus":0.1584976595064492,"score_gpt":0.46073225989458755,"score_spread":0.3022346003881383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365513372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9550968,0.031320382,0.00008777553,0.006953514,0.0013906616,0.0037947933,0.00065072445,0.00041647276,0.00028890042],"genre_scores_gemma":[0.9287592,0.047559872,0.00013070658,0.00040246767,0.0015074561,0.0066630053,0.0003990645,0.00022884148,0.014349368],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99406487,0.00013744064,0.0009044868,0.0014585879,0.0014043914,0.0020302548],"domain_scores_gemma":[0.9970255,0.0003497406,0.00030794315,0.0009449629,0.0008062191,0.00056562957],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00095202937,0.000738906,0.0011507159,0.0012137868,0.0010126248,0.00015118907,0.00047471464,0.00033993315,0.002790613],"category_scores_gemma":[0.00008512106,0.00062833884,0.00068140216,0.0032714582,0.0005264949,0.00031496325,0.00010039466,0.0005829329,0.00011827847],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12450723,0.0009978788,0.016805802,0.001555413,0.00426583,0.00052835944,0.0013496712,0.004236955,0.26614264,0.000016304435,0.028366964,0.551227],"study_design_scores_gemma":[0.10415568,0.010659563,0.5836006,0.0020226003,0.0010485658,0.00013367944,0.0014511491,0.0080992095,0.23302406,0.00018685122,0.053960744,0.0016572835],"about_ca_topic_score_codex":0.020205075,"about_ca_topic_score_gemma":0.003048951,"teacher_disagreement_score":0.5667948,"about_ca_system_score_codex":0.0062141884,"about_ca_system_score_gemma":0.0027529232,"threshold_uncertainty_score":0.9996168},"labels":[],"label_agreement":null},{"id":"W4365515216","doi":"10.1080/2162402x.2023.2201147","title":"Neoadjuvant immune checkpoint blockade triggers persistent and systemic T <sub>reg</sub> activation which blunts therapeutic efficacy against metastatic spread of breast tumors","year":2023,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia; Ministerie van Volksgezondheid, Welzijn en Sport; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; F. Hoffmann-La Roche; Oncode Institute; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Medicine; Immune checkpoint; Breast cancer; Immune system; Cancer research; Metastatic breast cancer; Metastasis; Primary tumor; Cancer; Immunotherapy; Blockade; Oncology; CD8; Internal medicine; Immunology; Receptor","score_opus":0.02013765047830695,"score_gpt":0.2661501953040062,"score_spread":0.24601254482569923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365515216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891769,0.007185785,0.000022688884,0.0019088073,0.00034466994,0.0009146265,0.000028429178,0.00015583697,0.00026223075],"genre_scores_gemma":[0.9961804,0.0031421406,0.000026433936,0.00012804523,0.000048142876,0.00007207392,0.0001282792,0.000060720417,0.00021375521],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975622,0.00022760562,0.000878944,0.00047972353,0.00032142128,0.00053009496],"domain_scores_gemma":[0.9984309,0.00023084204,0.00047824063,0.00058023445,0.00019464434,0.00008511307],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00064542686,0.00035812886,0.00094040483,0.0004897968,0.0001388966,0.00002017904,0.00019109185,0.00019500084,0.000030658168],"category_scores_gemma":[0.00009390046,0.00030396236,0.000339093,0.0010024159,0.00034183293,0.000102205,0.00008634012,0.0003574033,0.00004390863],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003248546,0.0002595123,0.00050235115,0.00025680315,0.0014655981,0.000030120435,0.0014633464,0.000043017626,0.91959184,0.000015120052,0.000031752126,0.073092],"study_design_scores_gemma":[0.019145088,0.0023958352,0.32190484,0.0022450539,0.00093510497,0.0024062085,0.0076822108,0.0012765015,0.640695,0.000034741657,0.0006007339,0.000678702],"about_ca_topic_score_codex":0.00023050356,"about_ca_topic_score_gemma":0.000013216959,"teacher_disagreement_score":0.3214025,"about_ca_system_score_codex":0.00031024875,"about_ca_system_score_gemma":0.0003216944,"threshold_uncertainty_score":0.99994123},"labels":[],"label_agreement":null},{"id":"W4365812973","doi":"10.1016/j.euo.2023.03.002","title":"Adaptive Immunity in Genitourinary Cancers","year":2023,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of British Columbia; Queen's University","funders":"Cancer Research Institute","keywords":"Immune system; Medicine; Prostate cancer; Cancer; Tumor microenvironment; Immunotherapy; Acquired immune system; Immune checkpoint; Genitourinary system; Immunology; Cancer research; Immunity; Oncology; Internal medicine","score_opus":0.12046106995638806,"score_gpt":0.3908199258552533,"score_spread":0.27035885589886527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365812973","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011096371,0.9491794,0.0000036053245,0.00024392501,0.0012633627,0.0010137942,0.000039575647,0.00017128413,0.04797407],"genre_scores_gemma":[0.000095213865,0.99486566,0.000076771896,0.0010530328,0.00063706364,0.000111204165,0.00016168298,0.0001890724,0.0028103024],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947162,0.002836072,0.0010315186,0.0006490734,0.00013092585,0.00063617754],"domain_scores_gemma":[0.9981256,0.00057597837,0.000470018,0.00064942834,0.00004609448,0.00013286629],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013793467,0.00050397706,0.0023928117,0.0007280672,0.00008301107,0.0000060867737,0.00043888355,0.000570214,0.0003152867],"category_scores_gemma":[0.000118158096,0.00043310627,0.0005989506,0.00075996906,0.00049471733,0.000028843097,0.0002891041,0.0018011604,0.0015123265],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013869896,0.00015333245,0.000018755249,0.0016378427,0.00075617334,0.007862902,0.00019357924,0.0000013870706,0.0000022028019,0.000015448035,0.00390694,0.98406446],"study_design_scores_gemma":[0.0019809005,0.0031530024,0.0008568377,0.00138029,0.00080174906,0.0016952094,0.00006656478,0.0000029910825,9.047687e-8,0.000008399611,0.98973846,0.0003155191],"about_ca_topic_score_codex":0.00032876496,"about_ca_topic_score_gemma":0.00030931726,"teacher_disagreement_score":0.9858315,"about_ca_system_score_codex":0.0014314229,"about_ca_system_score_gemma":0.0019145126,"threshold_uncertainty_score":0.99981207},"labels":[],"label_agreement":null},{"id":"W4366004431","doi":"","title":"Spotlight on pembrolizumab in the treatment of advanced melanoma","year":2015,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pembrolizumab; Medicine; Melanoma; Internal medicine; Cancer research; Immunotherapy; Cancer","score_opus":0.2558356997043778,"score_gpt":0.5488155397325114,"score_spread":0.2929798400281336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366004431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95708907,0.028872123,0.000004629086,0.0008149694,0.0003533775,0.0007838162,0.00002055093,0.000012251388,0.012049204],"genre_scores_gemma":[0.98192924,0.016756441,0.00005954754,0.00054519,0.00012705996,0.00005780526,0.000010414951,0.000030326057,0.00048399428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979295,0.00020436295,0.000681567,0.00026472376,0.0006594579,0.0002603638],"domain_scores_gemma":[0.99844784,0.00021004806,0.00048383584,0.00055227807,0.00016101978,0.00014500535],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007525861,0.00024795375,0.0007364189,0.0005021344,0.00005862601,0.0001273111,0.000922211,0.00008094591,0.0016534199],"category_scores_gemma":[0.00007761314,0.00015002534,0.00022721937,0.0007317316,0.000118349824,0.00042304554,0.000063537314,0.00016227202,0.00000879491],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049031798,0.005549693,0.45852563,0.00015441675,0.001026427,0.00045757726,0.0051060896,0.00014486337,0.1436959,0.00015934336,0.034978397,0.30116984],"study_design_scores_gemma":[0.010078147,0.0006796086,0.8201675,0.0005855213,0.00013076393,0.00006832703,0.0005898356,0.000013471194,0.07277777,0.0007376261,0.09392626,0.00024518973],"about_ca_topic_score_codex":0.00094711006,"about_ca_topic_score_gemma":0.000106112704,"teacher_disagreement_score":0.36164182,"about_ca_system_score_codex":0.00030845564,"about_ca_system_score_gemma":0.0002406083,"threshold_uncertainty_score":0.99925923},"labels":[],"label_agreement":null},{"id":"W4366263395","doi":"10.1016/j.matbio.2023.04.002","title":"Tumor-associated fibrosis impairs the response to immunotherapy","year":2023,"lang":"en","type":"review","venue":"Matrix Biology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Canadian Institutes of Health Research","keywords":"Immunotherapy; Tumor microenvironment; Immunogenicity; Immune system; Stroma; Cancer; Cancer immunotherapy; Cancer research; Medicine; Fibrosis; Stromal cell; Immunology; Biology; Pathology; Internal medicine","score_opus":0.046488409812932015,"score_gpt":0.38911964016660305,"score_spread":0.34263123035367105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366263395","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00081518665,0.9942726,0.0000054411366,0.0015176934,0.00078812137,0.0019167349,0.0003265638,0.00027403072,0.000083667175],"genre_scores_gemma":[0.000038027574,0.9906246,0.00004532591,0.0010584394,0.0002512041,0.00041736895,0.00023341774,0.00013575394,0.00719588],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969104,0.0009849471,0.0008334935,0.00052321824,0.00015865853,0.0005893068],"domain_scores_gemma":[0.9973505,0.0012461519,0.00037319708,0.00085884804,0.00006771276,0.000103555474],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018218372,0.00050000934,0.0019148795,0.00039876244,0.00016635204,0.000034316483,0.0004916147,0.0005216206,0.00039266792],"category_scores_gemma":[0.0003949044,0.00027970245,0.0011092608,0.0013282541,0.00017538393,0.000013938471,0.00012215467,0.00048555812,0.0009771762],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069573233,0.00010196949,0.000034666125,0.0022521194,0.0026877697,0.00006673132,0.00023351812,1.04019605e-7,0.00095225155,0.00003066633,0.031092068,0.9555908],"study_design_scores_gemma":[0.0008992929,0.0010463661,0.00033216985,0.0037024675,0.00040618994,0.00011896179,0.000039139348,4.9335443e-7,0.000006919065,0.000022846978,0.99311596,0.00030916967],"about_ca_topic_score_codex":0.00028207904,"about_ca_topic_score_gemma":0.00002982716,"teacher_disagreement_score":0.9620239,"about_ca_system_score_codex":0.0005020118,"about_ca_system_score_gemma":0.0006385612,"threshold_uncertainty_score":0.9999655},"labels":[],"label_agreement":null},{"id":"W4366274280","doi":"10.3390/curroncol30040321","title":"Impact of Race on Outcomes of Advanced Stage Non-Small Cell Lung Cancer Patients Receiving Immunotherapy","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Stage (stratigraphy); Race (biology); Immunotherapy; Lung cancer; Oncology; Cancer; Internal medicine; Biology","score_opus":0.04441037869164884,"score_gpt":0.4137926302784709,"score_spread":0.3693822515868221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366274280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948896,0.001994959,0.000015710573,0.00012450929,0.0014724066,0.0007075028,0.00010074719,0.00003649694,0.0006580363],"genre_scores_gemma":[0.99361545,0.005293323,0.000054485776,0.000059532238,0.000047520425,0.000069827765,0.000053999385,0.00003285215,0.00077302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866676,0.0000684336,0.0005048919,0.00024333366,0.00020548292,0.0003110977],"domain_scores_gemma":[0.9988193,0.00021872226,0.0004299814,0.00030242765,0.00016627189,0.000063286185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022836817,0.00019764656,0.00065615174,0.00023854684,0.000034738045,0.000002775524,0.00014200092,0.00010859753,0.00031823205],"category_scores_gemma":[0.00004585678,0.00014942173,0.00033540893,0.00040331,0.000086629974,0.00003991859,0.00003612182,0.0001990775,0.0000068534478],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003501784,0.0010291692,0.7875424,0.00027390884,0.0002982384,0.0000023728694,0.0012639961,0.0000900263,0.042054594,0.0000014125536,0.0018428218,0.16209926],"study_design_scores_gemma":[0.010085628,0.002860925,0.9726184,0.00028728883,0.00005570165,3.2834137e-7,0.00012444273,0.0001318992,0.0072964877,0.0000022878319,0.006398639,0.00013799072],"about_ca_topic_score_codex":0.00017310212,"about_ca_topic_score_gemma":0.00003541904,"teacher_disagreement_score":0.18507597,"about_ca_system_score_codex":0.00050576235,"about_ca_system_score_gemma":0.00038204767,"threshold_uncertainty_score":0.6093241},"labels":[],"label_agreement":null},{"id":"W4366335781","doi":"10.1038/s41467-023-37806-0","title":"Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer","year":2023,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Susan G. Komen; National Center for Advancing Translational Sciences; Florida Department of Health; Mayo Clinic; Breast Cancer Research Foundation; Georgia Clinical and Translational Science Alliance; Susan G. Komen for the Cure; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Triple-negative breast cancer; Stromal cell; Immune system; Tumor microenvironment; Breast cancer; Biomarker; Context (archaeology); Medicine; Cancer research; Immunology; Biology; Oncology; Cancer; Internal medicine","score_opus":0.016433087007985347,"score_gpt":0.30953812519570856,"score_spread":0.2931050381877232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366335781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.962568,0.005998252,0.0000038178273,0.028186295,0.00025892007,0.0009150164,0.0008984079,0.00024010343,0.00093121047],"genre_scores_gemma":[0.996663,0.0013250207,0.00006148114,0.00043554202,0.000030056592,0.00017407366,0.00044858898,0.000029884039,0.000832353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988383,0.00013641619,0.00030478078,0.0002060279,0.00026508048,0.00024937626],"domain_scores_gemma":[0.99825937,0.00038623775,0.0002181074,0.0008916406,0.00019041638,0.000054246433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028113823,0.00018288504,0.00038225346,0.00020058146,0.00019782619,0.000028270137,0.00045517058,0.00027425398,0.000094354466],"category_scores_gemma":[0.00020389014,0.00013593413,0.00011250702,0.0011009765,0.00015243482,0.0000793358,0.00013729851,0.0010359212,0.000011519419],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097135163,0.0003480153,0.99181783,0.000013383998,0.0004915454,0.000014033822,0.0005277048,0.0000021756641,0.001255428,0.00002249283,0.0017510145,0.002785019],"study_design_scores_gemma":[0.004733806,0.000052787116,0.9926569,0.00031862714,0.00008337963,0.0000142036715,0.00040119322,0.00020326982,0.00017756959,0.000018931518,0.0011745136,0.00016480815],"about_ca_topic_score_codex":0.002083401,"about_ca_topic_score_gemma":0.06713403,"teacher_disagreement_score":0.06505063,"about_ca_system_score_codex":0.00026660148,"about_ca_system_score_gemma":0.0001850357,"threshold_uncertainty_score":0.94988835},"labels":[],"label_agreement":null},{"id":"W4366590730","doi":"10.1038/s43018-023-00547-6","title":"CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma","year":2023,"lang":"en","type":"article","venue":"Nature Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"McGill University; KWF Kankerbestrijding; Brain Tumor Funders' Collaborative","keywords":"Immunotherapy; Glioblastoma; Cytotoxic T cell; CD8; Cancer research; T cell; Immunology; Biology; Neuroscience; Cell biology; Medicine; Antigen; Immune system; Genetics; In vitro","score_opus":0.0075560715485842095,"score_gpt":0.27406594608740625,"score_spread":0.266509874538822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366590730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98499554,0.007522813,0.000014634927,0.00549146,0.00054028234,0.00062314764,0.00001835516,0.00013687246,0.0006569191],"genre_scores_gemma":[0.98624986,0.0020431287,0.00014684485,0.004309402,0.00023606815,0.00009113095,0.000008276602,0.000051531853,0.00686373],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986634,0.0000405832,0.0002444929,0.0004026866,0.00031114093,0.0003376478],"domain_scores_gemma":[0.9993422,0.000067891604,0.00008113971,0.00034015477,0.00006762436,0.000100970086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002674048,0.00020569329,0.00028489603,0.000338307,0.000072416056,0.000024421226,0.0001028106,0.00034356187,0.00014501686],"category_scores_gemma":[0.000014471144,0.0001862565,0.00007749195,0.0011299066,0.00006433511,0.000102443635,0.000022309328,0.00047142027,0.000014264109],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065648574,0.000053868145,0.0021738238,0.00018276484,0.00007040656,0.000020763799,0.0009008129,0.000033574877,0.9130927,0.000045556255,0.06449492,0.012365966],"study_design_scores_gemma":[0.005416946,0.0003051468,0.18525827,0.00064350315,0.000021789947,0.000004187497,0.0002514433,0.00003647008,0.5704669,0.00013460086,0.23707955,0.000381247],"about_ca_topic_score_codex":0.00006535867,"about_ca_topic_score_gemma":0.00035390368,"teacher_disagreement_score":0.34262583,"about_ca_system_score_codex":0.00053923065,"about_ca_system_score_gemma":0.00020055001,"threshold_uncertainty_score":0.7595319},"labels":[],"label_agreement":null},{"id":"W4366599450","doi":"10.3390/curroncol30040323","title":"Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Pembrolizumab; Immunotherapy; Immune checkpoint; Cancer; PARP inhibitor; Oncology; Ipilimumab; Cancer research; Internal medicine; Poly ADP ribose polymerase; Biology","score_opus":0.15331718860362473,"score_gpt":0.45004403519098374,"score_spread":0.29672684658735904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366599450","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016917512,0.99363536,0.0000014872871,0.00044346382,0.0030234687,0.0021389928,0.00030199767,0.00008628598,0.0001997982],"genre_scores_gemma":[0.000011651898,0.99701154,0.000074722746,0.000036331985,0.0004423436,0.00090189005,0.00057546736,0.00008165559,0.00086440344],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997249,0.00020561855,0.0013260673,0.0005550415,0.00024503472,0.00041923116],"domain_scores_gemma":[0.9984893,0.00020373893,0.00071121514,0.00033130054,0.00010402601,0.00016037372],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060119765,0.00047898275,0.0022141095,0.0003073397,0.000106608735,0.00003370043,0.0001166538,0.0002258109,0.00014335164],"category_scores_gemma":[0.00007372314,0.00035905433,0.00051684387,0.00050808693,0.00026445463,0.000050170078,0.00009171354,0.00062296406,0.000046314923],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030320973,0.0001814587,0.0000061106025,0.029174633,0.00073195796,0.00009072549,0.00022563258,3.8262698e-8,0.00008839326,0.000023286386,0.0028964377,0.96627814],"study_design_scores_gemma":[0.0018580118,0.00065886223,0.000051151263,0.012898961,0.0023591486,0.00018232713,0.0001094031,0.0000028411876,0.000014148598,0.000034176737,0.98151714,0.0003138139],"about_ca_topic_score_codex":0.00015270307,"about_ca_topic_score_gemma":0.00019609914,"teacher_disagreement_score":0.9786207,"about_ca_system_score_codex":0.00077319896,"about_ca_system_score_gemma":0.0020809202,"threshold_uncertainty_score":0.99988616},"labels":[],"label_agreement":null},{"id":"W4366982970","doi":"10.1002/advs.202204378","title":"Intracellular Adhesion Molecule‐1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8<sup>+</sup> T Cells","year":2023,"lang":"en","type":"article","venue":"Advanced Science","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"Samsung Medical Center, Sungkyunkwan University; Samsung; Korea Health Industry Development Institute; National Research Foundation of Korea; Ministry of Science and ICT, South Korea; National Research Foundation","keywords":"Cancer research; Cytotoxic T cell; Intracellular; Immune system; CD8; Chemokine; Lung cancer; ICAM-1; Intercellular adhesion molecule; Chemistry; Immunotherapy; Medicine; Immunology; Cell biology; Biology; Cell adhesion; Cell; Internal medicine; Biochemistry; In vitro","score_opus":0.010601691719386233,"score_gpt":0.27831158842344955,"score_spread":0.2677098967040633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366982970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959421,0.00051572855,0.0006725418,0.0014854467,0.0003323746,0.00065606926,0.000010584567,0.00018898294,0.00019612799],"genre_scores_gemma":[0.9947283,0.00015270263,0.0028088656,0.0005623755,0.00007533538,0.000051402032,0.000011713577,0.000034778943,0.0015745035],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99749,0.000045527973,0.00042051033,0.0006980299,0.0006773617,0.00066859426],"domain_scores_gemma":[0.9987254,0.00012881511,0.00013243992,0.0005674895,0.00020002954,0.00024580842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010909237,0.00022893578,0.0002921927,0.00032970723,0.0003853555,0.000064659806,0.000358364,0.00007284435,0.000035673467],"category_scores_gemma":[0.00053604826,0.0002010527,0.00010847264,0.0027844948,0.00036282997,0.00041485444,0.00019252705,0.00021843213,0.000100248115],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012558883,0.000043960365,0.000018175968,0.00003847094,0.000009777371,0.000020426736,0.00086386397,0.0002659695,0.93816966,0.000005394952,0.0001916503,0.059116747],"study_design_scores_gemma":[0.0011451263,0.00054248876,0.0009426523,0.0002895187,0.000008008374,0.000009993796,0.0014429973,0.0015155573,0.9836036,0.000021529988,0.010228074,0.00025045173],"about_ca_topic_score_codex":0.000049917333,"about_ca_topic_score_gemma":8.0822707e-7,"teacher_disagreement_score":0.058866296,"about_ca_system_score_codex":0.00030541074,"about_ca_system_score_gemma":0.00034811234,"threshold_uncertainty_score":0.8198691},"labels":[],"label_agreement":null},{"id":"W4366984184","doi":"10.1158/1078-0432.c.6615932","title":"Data from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group","funders":"Pharmacyclics; Genentech; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Medicine; Adjuvant therapy; Adjuvant; Melanoma; Mucosal melanoma; Oncology; Internal medicine; Surgery; Immunotherapy; Cancer","score_opus":0.15853264823888616,"score_gpt":0.3672105630276414,"score_spread":0.20867791478875522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366984184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780518,0.0057376255,0.00036715728,0.0024071091,0.0026225557,0.0045987414,0.0048419475,0.00027289853,0.001100162],"genre_scores_gemma":[0.9541917,0.010986284,0.0052231676,0.0007290429,0.0025491267,0.00041583984,0.019261774,0.00030124458,0.006341851],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99704623,0.0001088358,0.0008688345,0.0011091701,0.0004900846,0.00037685488],"domain_scores_gemma":[0.9965799,0.00063484296,0.0003995457,0.0020627496,0.0001895688,0.00013343082],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007171995,0.00041985663,0.0011318731,0.00021967519,0.000067688576,0.00006275143,0.0006095256,0.00055235886,0.0007032062],"category_scores_gemma":[0.00034215226,0.0003340008,0.00028127173,0.00016953827,0.00021088029,0.000069768044,0.0007214112,0.00040850244,0.000010603774],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76996696,0.0018546139,0.00025724102,0.00043115948,0.0035097164,0.00003293591,0.0004261064,6.3401507e-7,0.058681622,0.000029481367,0.03991979,0.12488974],"study_design_scores_gemma":[0.779654,0.035866994,0.017055828,0.0024922672,0.0016341736,0.000044125096,0.0011902234,0.0030548638,0.048793416,0.006764473,0.1015917,0.001857928],"about_ca_topic_score_codex":0.00708135,"about_ca_topic_score_gemma":0.0016257934,"teacher_disagreement_score":0.12303181,"about_ca_system_score_codex":0.00013078685,"about_ca_system_score_gemma":0.0007875095,"threshold_uncertainty_score":0.9999112},"labels":[],"label_agreement":null},{"id":"W4367042670","doi":"10.1200/po.22.00317","title":"Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis","year":2023,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Breast cancer; Cohort; Triple-negative breast cancer; Metastatic breast cancer; Tumor-infiltrating lymphocytes; Progression-free survival; Cancer; Immunotherapy; Chemotherapy","score_opus":0.034109530947823555,"score_gpt":0.37195274827056923,"score_spread":0.3378432173227457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367042670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99686205,0.00010696441,0.00007142434,0.0016834838,0.00018645647,0.0007632951,0.00023422229,0.000038834285,0.000053280724],"genre_scores_gemma":[0.99767804,0.0011946218,0.00040542652,0.00029438164,0.00003467579,0.0000747273,0.00008869601,0.00002484371,0.00020461265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973236,0.00054966204,0.0009618013,0.00041760388,0.0004684368,0.0002789427],"domain_scores_gemma":[0.99671865,0.0019824079,0.00067878555,0.00026405702,0.00024533906,0.00011076304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014874474,0.00020260285,0.0012486601,0.00082890585,0.000048559705,0.000010345933,0.00010542949,0.00022307342,0.00015725468],"category_scores_gemma":[0.00027080276,0.00014647156,0.00026224263,0.0018575222,0.00014820465,0.00012734058,0.00004277786,0.0002170453,0.000005450225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015302066,0.00030772685,0.8553271,0.000014518824,0.007511912,0.0000057116195,0.00042667516,0.000008459446,0.000022215138,6.0748977e-7,0.00063880376,0.120434165],"study_design_scores_gemma":[0.026316885,0.0016000995,0.96936554,0.0000521447,0.0015756147,5.9712016e-7,0.00026526817,0.00013841364,0.00004399017,0.000040096907,0.00045916438,0.0001422112],"about_ca_topic_score_codex":0.00060033624,"about_ca_topic_score_gemma":0.001002328,"teacher_disagreement_score":0.12029195,"about_ca_system_score_codex":0.0006474811,"about_ca_system_score_gemma":0.0003112383,"threshold_uncertainty_score":0.5972937},"labels":[],"label_agreement":null},{"id":"W4367183940","doi":"10.3389/fonc.2023.1160269","title":"Abscopal responses in patients with metastatic melanoma involving skin and subcutaneous tissues treated with intralesional IL2 plus BCG","year":2023,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Melanoma; Cohort; Immunotherapy; Internal medicine; Adverse effect; Disease; Surgery; Adjuvant; Oncology; Systemic therapy; Dermatology; Cancer","score_opus":0.012438492668879761,"score_gpt":0.27327641065839564,"score_spread":0.2608379179895159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367183940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976591,0.0009289113,0.0000249287,0.00047072195,0.00015648943,0.00052789546,0.00001780935,0.000042375224,0.00017178625],"genre_scores_gemma":[0.99363273,0.00040930213,0.0047878334,0.00022994024,0.00002471331,0.00005391645,0.000088397435,0.000028886374,0.0007442899],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987358,0.00017545,0.00027780692,0.00029551893,0.00018916563,0.0003262733],"domain_scores_gemma":[0.9994948,0.00017394048,0.00008476088,0.00013700011,0.00003909804,0.00007038003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002599103,0.00017072073,0.00049554394,0.00051778223,0.00004177643,0.000010486553,0.000068173045,0.00009916039,0.000041812782],"category_scores_gemma":[0.00004879567,0.00012369746,0.000022641188,0.00048948586,0.00026383813,0.00006246805,0.000026559122,0.00018147769,0.0000035891692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07029249,0.00019388982,0.89523643,0.0000616528,0.00019417785,0.0022581026,0.001901831,0.000016055092,0.00014640248,0.000006313627,0.0028683115,0.02682434],"study_design_scores_gemma":[0.01704699,0.008170903,0.9670512,0.00028768278,0.000083700266,0.00019391254,0.0017075002,0.0003544666,0.00016589707,0.00004704636,0.004665657,0.00022506014],"about_ca_topic_score_codex":0.0004175365,"about_ca_topic_score_gemma":0.0016182727,"teacher_disagreement_score":0.07181475,"about_ca_system_score_codex":0.00051225285,"about_ca_system_score_gemma":0.0003088277,"threshold_uncertainty_score":0.5044236},"labels":[],"label_agreement":null},{"id":"W4367184214","doi":"10.1080/2162402x.2023.2204745","title":"Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes","year":2023,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Bristol-Myers Squibb","keywords":"Medicine; Blockade; CD8; Lymph; Positron emission tomography; Pathological; Oncology; Imaging biomarker; Pathology; Internal medicine; Cancer research; Immune system; Nuclear medicine; Receptor; Immunology; Radiology; Magnetic resonance imaging","score_opus":0.03555770407278394,"score_gpt":0.3185617188335017,"score_spread":0.2830040147607178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367184214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996747,0.0015035137,0.0000027313913,0.00019291026,0.00016862259,0.00041858913,0.000012609178,0.000027602575,0.0009264024],"genre_scores_gemma":[0.9992529,0.00017591089,0.0003241278,0.000056022865,0.000012439184,0.000036110687,0.000026872816,0.000019702535,0.00009589782],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984347,0.00034441976,0.0004746208,0.00022941316,0.00028621938,0.00023063278],"domain_scores_gemma":[0.9990632,0.00025737268,0.00023869266,0.0002504312,0.00017364194,0.000016679673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013941005,0.00012592312,0.00036888625,0.00027006652,0.00003591083,0.000003859334,0.00008279738,0.00003844729,0.0000400195],"category_scores_gemma":[0.0003240488,0.00011752833,0.00006072106,0.00050045317,0.00021885215,0.000072091076,0.000055069995,0.00011921086,0.0000060305983],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014174269,0.00026688376,0.19902815,0.00014226405,0.00013471741,0.000050728548,0.003601551,0.0000224984,0.76686805,0.000016944672,0.000019246494,0.015674688],"study_design_scores_gemma":[0.011495461,0.00076488004,0.8625375,0.000318842,0.00008260691,0.000041245537,0.0015719982,0.00035227658,0.12249367,0.000108154396,0.00011957693,0.00011377882],"about_ca_topic_score_codex":0.0005152295,"about_ca_topic_score_gemma":0.000008092737,"teacher_disagreement_score":0.66350937,"about_ca_system_score_codex":0.00014428906,"about_ca_system_score_gemma":0.0003311799,"threshold_uncertainty_score":0.4792666},"labels":[],"label_agreement":null},{"id":"W4367294640","doi":"10.3390/curroncol30050342","title":"Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Hamilton Health Sciences","keywords":"Medicine; Toxicity; Dermatology; Basal cell; Pathology; Internal medicine","score_opus":0.07063833753870484,"score_gpt":0.35609835245642824,"score_spread":0.2854600149177234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367294640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950039,0.00026459352,0.000024689629,0.0011902567,0.00068371295,0.0008107075,0.00002519272,0.00012854196,0.0018684182],"genre_scores_gemma":[0.9991778,0.00004084584,0.00006493797,0.00023286784,0.000100412864,0.00008455822,0.00017104099,0.000027208762,0.00010031479],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99769586,0.0001995841,0.0008313093,0.00050894916,0.0003270264,0.00043728514],"domain_scores_gemma":[0.99853325,0.00020363055,0.000478725,0.0004659796,0.00015735437,0.00016106706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054797326,0.0002842677,0.0006899463,0.00026987388,0.00011235975,0.000007997644,0.00008731981,0.00031779398,0.000169568],"category_scores_gemma":[0.00015713641,0.00021969414,0.00025145645,0.00056894385,0.00027677973,0.000050892853,0.00007621541,0.00049773755,0.000049089278],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029556446,0.007788951,0.046524197,0.0013055394,0.00022251373,0.17925781,0.0035630248,0.00001861331,0.7049265,0.0001068352,0.006561401,0.020168172],"study_design_scores_gemma":[0.01228519,0.0073818117,0.074486695,0.00015389817,0.00020823236,0.056525785,0.0018538322,0.000120796685,0.8432361,0.00006410755,0.0032682568,0.00041531003],"about_ca_topic_score_codex":0.00026417273,"about_ca_topic_score_gemma":0.00009395769,"teacher_disagreement_score":0.13830958,"about_ca_system_score_codex":0.0004930361,"about_ca_system_score_gemma":0.0004842269,"threshold_uncertainty_score":0.89588666},"labels":[],"label_agreement":null},{"id":"W4367315655","doi":"10.1007/s00432-023-04803-1","title":"Off-label use of immune checkpoint inhibitors for the treatment of solid tumors: analysis of a nationwide patient sample","year":2023,"lang":"en","type":"article","venue":"Journal of Cancer Research and Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University","keywords":"Atezolizumab; Medicine; Pembrolizumab; Nivolumab; Internal medicine; Lung cancer; Melanoma; Oncology; Kidney cancer; Guideline; Cancer; Renal cell carcinoma; Immunotherapy; Pathology","score_opus":0.25279609753568166,"score_gpt":0.5423579591887919,"score_spread":0.28956186165311026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367315655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888755,0.0055085965,0.000036339046,0.004804715,0.00018750783,0.00043158344,0.00014528098,0.0000018863575,0.000008560674],"genre_scores_gemma":[0.9336811,0.06558613,0.0003217941,0.000069919675,0.00017388003,0.000037564776,0.000008484735,0.0000090541425,0.0001121312],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99704516,0.00021748606,0.0019188349,0.00012112871,0.00048956444,0.00020785401],"domain_scores_gemma":[0.990535,0.006865348,0.0010859156,0.00018245161,0.0012231772,0.00010810137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027538948,0.0000792435,0.0009985383,0.00047819392,0.000050565603,0.000004699717,0.000096999815,0.00010463172,0.00006794695],"category_scores_gemma":[0.0015008687,0.000044063287,0.00064682163,0.0009937098,0.00059992116,0.00004512034,0.00003142933,0.0001987011,1.5827719e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05625068,0.004440686,0.08525443,0.00015476017,0.015610505,0.000024936597,0.0013913051,0.000117726966,0.031211615,0.000032534273,0.0020983021,0.8034125],"study_design_scores_gemma":[0.023790339,0.12915331,0.6727497,0.0005485659,0.0036460545,0.000014321639,0.0026104862,0.003004649,0.054685034,0.00037392808,0.10928466,0.00013892022],"about_ca_topic_score_codex":0.0016551637,"about_ca_topic_score_gemma":0.0010451091,"teacher_disagreement_score":0.8032736,"about_ca_system_score_codex":0.00020488299,"about_ca_system_score_gemma":0.0010576163,"threshold_uncertainty_score":0.25021234},"labels":[],"label_agreement":null},{"id":"W4367320137","doi":"10.3390/ijms24097946","title":"The Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma","year":2023,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Immune system; Cytotoxic T cell; Tumor microenvironment; Cancer research; Biology; T cell; Clear cell renal cell carcinoma; Cell biology; Immunology; Medicine; Renal cell carcinoma; Internal medicine","score_opus":0.02775565838779592,"score_gpt":0.3164979955874431,"score_spread":0.2887423371996472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367320137","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0076682805,0.9900818,0.000016786382,0.00049662084,0.00094630703,0.00020781887,0.0000070464985,0.0000034470768,0.00057188014],"genre_scores_gemma":[0.0064810854,0.99260736,0.00018063589,0.00014562748,0.00016477439,0.000006668804,0.0000034366767,0.000020839057,0.0003895712],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974884,0.00012981052,0.0009382613,0.00020121939,0.0010269808,0.00021537521],"domain_scores_gemma":[0.99871695,0.00013635041,0.0008521464,0.00015498439,0.00007912556,0.000060447244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013287095,0.00018915038,0.00053084525,0.00038824754,0.00007562844,0.000107733904,0.0010228292,0.0000629492,0.00004581572],"category_scores_gemma":[0.000034961122,0.00011018047,0.0006295755,0.0003202926,0.0003055938,0.000060318613,0.00011443624,0.00039633072,0.000029893625],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000851874,0.00044218445,0.00010938711,0.0015145058,0.00065468356,0.007310093,0.00027874968,0.00004267898,0.015225586,0.000045860852,0.0015346358,0.97198975],"study_design_scores_gemma":[0.0011824813,0.00066677516,0.0003524328,0.005574562,0.00021007929,0.0012633009,0.00019912273,0.00001308586,0.003012461,0.000041097683,0.9872863,0.00019826542],"about_ca_topic_score_codex":0.000040466497,"about_ca_topic_score_gemma":0.0000043208674,"teacher_disagreement_score":0.9857517,"about_ca_system_score_codex":0.00031841817,"about_ca_system_score_gemma":0.00067990384,"threshold_uncertainty_score":0.4493029},"labels":[],"label_agreement":null},{"id":"W4367670225","doi":"10.1016/s1470-2045(23)00026-8","title":"The rise of immuno-oncology in China: a challenge to western dominance?","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute for Health and Care Research","keywords":"China; Population; Government (linguistics); Political science; Christian ministry; Library science; Scopus; Action plan; Economic growth; Geography; Medicine; Traditional medicine; Demography; Public administration; Management; MEDLINE; Sociology; Environmental health; Law","score_opus":0.04492027790961976,"score_gpt":0.3693331403452687,"score_spread":0.32441286243564893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367670225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8783153,0.003111086,0.000005534812,0.10504105,0.00079601083,0.0006575581,0.0000088070265,0.0000510968,0.012013511],"genre_scores_gemma":[0.9844003,0.0108560575,0.000055985336,0.0012325218,0.000517212,0.00024345056,0.0000038627877,0.000022001745,0.0026686147],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985271,0.00029843042,0.00041037815,0.00018699084,0.00013216732,0.00044494847],"domain_scores_gemma":[0.9987021,0.0005114313,0.00015692336,0.0005517502,0.000038283986,0.00003949592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020056337,0.00012246969,0.0006014257,0.0000963785,0.000094892144,0.0000045132188,0.00037940432,0.00014124933,0.000054661028],"category_scores_gemma":[0.000113940296,0.000066563,0.00009817643,0.00053764903,0.00030738438,0.00002148324,0.00013362717,0.00026927303,0.000086014894],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067960724,0.000919161,0.027935375,0.00026551864,0.0006602407,0.0004079997,0.035142697,0.000047846283,0.061787695,0.002075336,0.083763,0.71903443],"study_design_scores_gemma":[0.0051864074,0.001990486,0.22332305,0.00006715254,0.000026378942,0.000051935902,0.0007732472,0.00003412515,0.00047327805,0.00035276098,0.767644,0.00007719688],"about_ca_topic_score_codex":0.000342525,"about_ca_topic_score_gemma":0.0027417473,"teacher_disagreement_score":0.7189572,"about_ca_system_score_codex":0.00025896178,"about_ca_system_score_gemma":0.00024613627,"threshold_uncertainty_score":0.27143604},"labels":[],"label_agreement":null},{"id":"W4367853294","doi":"10.3389/fimmu.2023.1145028","title":"Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint","year":2023,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Ministry of Science and ICT, South Korea; National Research Foundation of Korea; National Natural Science Foundation of China; National Research Foundation","keywords":"Perforin; Immunotherapy; Cancer research; Immune system; Cancer immunotherapy; Medicine; Immune checkpoint; Immunology; Pentamidine; Granzyme B; T cell; CD8; Internal medicine","score_opus":0.013412175018339842,"score_gpt":0.2801775124559177,"score_spread":0.26676533743757785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367853294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6885126,0.27916622,0.0030660243,0.016353242,0.009016727,0.002862266,0.00008487553,0.00057991326,0.00035812214],"genre_scores_gemma":[0.73103416,0.21270004,0.012065558,0.006642877,0.0014421024,0.005223066,0.0013395528,0.0008424565,0.028710192],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975807,0.00013247995,0.0008021573,0.00048103934,0.00019363403,0.0008100095],"domain_scores_gemma":[0.99888057,0.00013916685,0.00027314207,0.0005788106,0.000090174224,0.00003816519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001098625,0.0003127637,0.0006538514,0.00029951308,0.00026956457,0.000036617654,0.0003833747,0.00025525098,0.00013079966],"category_scores_gemma":[0.000117929085,0.0002397012,0.0003450486,0.00086683204,0.00040150757,0.000105448235,0.000080728925,0.00045077453,0.000009837078],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0081489375,0.00013452803,0.008174386,0.000080015176,0.0011432869,0.000017086215,0.0015865342,0.000016374459,0.726616,0.000035751258,0.12905943,0.124987654],"study_design_scores_gemma":[0.00905671,0.0005771078,0.018825606,0.0002506815,0.00009273766,0.000043007858,0.0034655053,0.00087374175,0.118293606,0.00044934414,0.84761864,0.00045328203],"about_ca_topic_score_codex":0.00084692996,"about_ca_topic_score_gemma":0.000024032312,"teacher_disagreement_score":0.71855927,"about_ca_system_score_codex":0.0004902918,"about_ca_system_score_gemma":0.00017374395,"threshold_uncertainty_score":0.97747314},"labels":[],"label_agreement":null},{"id":"W4368367270","doi":"10.3390/diagnostics13091617","title":"Impact of [18F]FDG PET/CT in the Assessment of Immunotherapy-Induced Arterial Wall Inflammation in Melanoma Patients Receiving Immune Checkpoint Inhibitors","year":2023,"lang":"en","type":"article","venue":"Diagnostics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Positron emission tomography; Melanoma; Standardized uptake value; Radiology; Population; Coronary artery disease; Vasculitis; Internal medicine; Disease","score_opus":0.016480513482223496,"score_gpt":0.30952092208282594,"score_spread":0.29304040860060243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4368367270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99825394,0.00010399624,0.0000022181366,0.00028184656,0.00033825167,0.00078136724,0.000020679,0.00001774958,0.00019995162],"genre_scores_gemma":[0.99862707,0.0009853137,0.000056167108,0.000027494829,0.00006728447,0.00005641297,0.00014996725,0.000023927001,0.0000063925313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981314,0.00015305022,0.0009176338,0.00016658653,0.00038197252,0.000249391],"domain_scores_gemma":[0.9986266,0.00054319703,0.00035957477,0.00034654562,0.000098537035,0.000025530791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008883429,0.00017506068,0.00040353424,0.00033270003,0.00002637955,0.000014901192,0.00015232657,0.000030334919,0.00005176717],"category_scores_gemma":[0.00040395377,0.00012707547,0.00020775438,0.0007579668,0.000053689124,0.000083718165,0.00003196325,0.00020295862,0.0000031560087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071994535,0.0005509549,0.81021047,0.000097152275,0.00013712543,0.00008726915,0.0019403246,0.0000589542,0.16858453,0.000010677696,0.00012369538,0.017478907],"study_design_scores_gemma":[0.005111467,0.0009336381,0.97269636,0.0006087138,0.000021528225,0.000010117506,0.0002910847,0.0003127666,0.01980395,0.00003201218,0.00006092543,0.00011741851],"about_ca_topic_score_codex":0.0014857638,"about_ca_topic_score_gemma":0.00018345237,"teacher_disagreement_score":0.1624859,"about_ca_system_score_codex":0.0002763246,"about_ca_system_score_gemma":0.00020003249,"threshold_uncertainty_score":0.5181987},"labels":[],"label_agreement":null},{"id":"W4368618118","doi":"10.14740/jh1090","title":"Incidence and Risk of Hematological Adverse Events Associated With Immune Checkpoint Inhibitors: A Systematic Literature Review and Meta-Analysis","year":2023,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Anemia; Incidence (geometry); Odds ratio; Adverse effect; Cochrane Library; Meta-analysis; Confidence interval; Gastroenterology; Chemotherapy","score_opus":0.023091124896414687,"score_gpt":0.2984345578798623,"score_spread":0.2753434329834476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4368618118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6504188,0.34761184,0.00002562728,0.0015027028,0.000023524208,0.0003873532,0.000011485751,0.000010663423,0.000007961591],"genre_scores_gemma":[0.9455545,0.053878028,0.00025814245,0.00019165664,0.0000068317563,0.00001524495,0.00000529352,0.000009706697,0.000080585254],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9977574,0.00038857743,0.0012508462,0.00015263337,0.0002967466,0.00015385057],"domain_scores_gemma":[0.9972356,0.00036780158,0.0017918231,0.0001965037,0.0003248834,0.00008336306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019400566,0.00017010373,0.0031389177,0.0003448539,0.000038599595,0.0000046286036,0.00007863308,0.00013401754,0.000050002767],"category_scores_gemma":[0.00089559064,0.00008765208,0.0007344447,0.0011370367,0.00012527988,0.00008677983,0.000039332248,0.00028227354,9.645377e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024507598,0.0005576231,0.15046303,0.14953157,0.6886377,0.0034867418,0.0019242814,0.000007820618,0.002036871,0.00012227742,0.0007489905,0.000032327876],"study_design_scores_gemma":[0.0039138054,0.0016046761,0.062038675,0.03155194,0.8761543,0.021787023,0.00060401723,0.00007116801,0.0017762386,0.00019498722,0.000018654811,0.00028451523],"about_ca_topic_score_codex":0.000008009193,"about_ca_topic_score_gemma":0.000013595071,"teacher_disagreement_score":0.29513568,"about_ca_system_score_codex":0.000027202033,"about_ca_system_score_gemma":0.00005300101,"threshold_uncertainty_score":0.3574348},"labels":[],"label_agreement":null},{"id":"W4375862356","doi":"10.3390/curroncol30050362","title":"Active Immune Phenotype in Head and Neck Cancer: Reevaluating the Iso-Effect Fractionation Based on the Linear Quadratic (LQ) Model—A Narrative Review","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Narrative; Phenotype; Head and neck; Head and neck cancer; Quadratic equation; Narrative review; Immune system; Computational biology; Cancer; Genetics; Internal medicine; Biology; Immunology; Gene; Intensive care medicine; Mathematics; Surgery","score_opus":0.2582315673338312,"score_gpt":0.5238258071094181,"score_spread":0.2655942397755869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375862356","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030022423,0.9878546,0.000019486828,0.005447711,0.0009436064,0.0050665555,0.00003868794,0.00003527228,0.00029386656],"genre_scores_gemma":[0.000097708966,0.9959054,0.000021065493,0.0007014874,0.00029112466,0.0026563194,0.00018762184,0.000048296126,0.00009099239],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963805,0.0016683225,0.00084285665,0.00046597765,0.00036703685,0.000275284],"domain_scores_gemma":[0.99584496,0.0027552536,0.0007752136,0.0004437467,0.00013618058,0.00004462779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002281095,0.00041651388,0.0016947455,0.00016898247,0.00022911967,0.000014079915,0.00019745388,0.00024840477,0.00013263006],"category_scores_gemma":[0.00096539396,0.00021162444,0.00037039936,0.00077809265,0.00017418849,0.000048330294,0.000051742278,0.0013095838,0.000024844498],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004342589,0.00012561613,0.000007135129,0.016418288,0.00021932602,0.0000031235477,0.00055357337,0.000040680326,0.00000242876,0.00002046239,0.0015596182,0.9806155],"study_design_scores_gemma":[0.0018892427,0.0011439117,0.00011935116,0.13436899,0.0015099692,0.000009561233,0.00014565328,0.02194892,0.0000023647647,0.000037038964,0.83854795,0.00027706157],"about_ca_topic_score_codex":0.00011818883,"about_ca_topic_score_gemma":0.00018388683,"teacher_disagreement_score":0.98033845,"about_ca_system_score_codex":0.0012666782,"about_ca_system_score_gemma":0.0016553997,"threshold_uncertainty_score":0.8629795},"labels":[],"label_agreement":null},{"id":"W4376118539","doi":"10.4049/jimmunol.2200933","title":"A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma","year":2023,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Fonds de Recherche du Québec - Santé; National Institutes of Health","keywords":"Cytotoxic T cell; Renal cell carcinoma; Nephrectomy; Medicine; Antibody; Cancer research; Peripheral; Urology; Immunology; Internal medicine; Chemistry; Kidney; In vitro; Biochemistry","score_opus":0.007713169436304123,"score_gpt":0.23004359754595086,"score_spread":0.22233042810964673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376118539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975164,0.0015490717,0.00009083939,0.000294962,0.00022285522,0.00026964274,0.000006295434,0.000010351834,0.000039599185],"genre_scores_gemma":[0.99936396,0.00016549445,0.00017157466,0.0001179239,0.0000702773,0.0000046171303,0.0000090820995,0.000020216557,0.00007685063],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987703,0.000116029594,0.00049935654,0.00010392147,0.00025465497,0.00025576417],"domain_scores_gemma":[0.99919796,0.000073676776,0.00035014618,0.00019857993,0.00014581055,0.000033853536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043804312,0.00014791614,0.00040077796,0.00029851173,0.000041976793,0.0000067266,0.00014751873,0.00009242837,0.00012525126],"category_scores_gemma":[0.000026145412,0.00008466323,0.00011363782,0.00048053643,0.0003004357,0.00009935418,0.00003563765,0.00028157755,0.0000041827866],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07087889,0.00046355595,0.22307825,0.000051473977,0.00026013097,0.00005128003,0.0007068248,0.000007911961,0.70292187,0.0000018360572,0.0000645619,0.0015134306],"study_design_scores_gemma":[0.014018642,0.0050764973,0.9443284,0.00020108974,0.00011715501,0.000280668,0.00021082108,0.000026809459,0.035272904,0.00000681986,0.0003702982,0.000089884066],"about_ca_topic_score_codex":0.00009267831,"about_ca_topic_score_gemma":0.000012828415,"teacher_disagreement_score":0.7212502,"about_ca_system_score_codex":0.00014597834,"about_ca_system_score_gemma":0.0002790472,"threshold_uncertainty_score":0.34524664},"labels":[],"label_agreement":null},{"id":"W4376127536","doi":"10.1016/j.radonc.2023.109712","title":"Can radiation restore immunotherapy response in metastatic melanoma refractory to checkpoint inhibitors: An institutional experience in salvaging immunotherapy resistant disease","year":2023,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Alberta","funders":"","keywords":"Medicine; Immunotherapy; Melanoma; Refractory (planetary science); Cancer research; Tumor microenvironment; Radiation therapy; Infiltration (HVAC); Disease; Oncology; Metastatic melanoma; Immunology; Internal medicine; Immune system; Biology; Tumor cells","score_opus":0.028869436239595897,"score_gpt":0.34405754043586384,"score_spread":0.31518810419626797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376127536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808183,0.008169842,0.00007039689,0.009366313,0.00038120284,0.0010121515,0.000028603094,0.00010974778,0.000043459786],"genre_scores_gemma":[0.9879651,0.006533722,0.0008692329,0.003784075,0.0001791146,0.00037040273,0.000062018924,0.000060739352,0.0001755879],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9969844,0.0006846653,0.00080914627,0.0006403162,0.00033176507,0.00054971],"domain_scores_gemma":[0.9987317,0.00030013153,0.00016428289,0.0004825135,0.000045116078,0.000276309],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018048187,0.00032259393,0.00061255146,0.0011096905,0.00017115843,0.000043147513,0.00017896565,0.00016434766,0.000121848185],"category_scores_gemma":[0.00012626291,0.000302564,0.00011796937,0.0012271885,0.0002863434,0.00025793692,0.000021387115,0.00032707833,0.0000046960017],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18123971,0.00076138927,0.053019296,0.00006385453,0.00015112788,0.001171193,0.03164633,0.00019493951,0.5693793,0.00017705224,0.00020596165,0.16198981],"study_design_scores_gemma":[0.01192192,0.003706581,0.877434,0.00024387028,0.000011212547,0.00007240845,0.0016145791,0.0006133838,0.0013795742,0.0001498152,0.10244556,0.00040707397],"about_ca_topic_score_codex":0.0010848432,"about_ca_topic_score_gemma":0.0009745884,"teacher_disagreement_score":0.82441473,"about_ca_system_score_codex":0.0025919501,"about_ca_system_score_gemma":0.001070732,"threshold_uncertainty_score":0.99994266},"labels":[],"label_agreement":null},{"id":"W4376131131","doi":"10.1002/bies.202200204","title":"Tumor‐infiltrating lymphocyte therapy: Clinical aspects and future developments in this breakthrough cancer treatment","year":2023,"lang":"en","type":"article","venue":"BioEssays","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"","keywords":"Tumor-infiltrating lymphocytes; Medicine; Clinical trial; Cancer; Cancer therapy; Oncology; Intensive care medicine; Immunotherapy; Internal medicine","score_opus":0.05895020568034321,"score_gpt":0.3621460947795305,"score_spread":0.3031958890991873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376131131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789223,0.009053804,6.907903e-7,0.0027372336,0.00077937974,0.00048144243,0.000020207255,0.00013336402,0.007871567],"genre_scores_gemma":[0.9179624,0.07642302,0.00034533604,0.0023382062,0.001062896,0.0001570104,0.000046643243,0.00004692975,0.0016175997],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987044,0.000059379672,0.0003851402,0.00035837907,0.00018626245,0.00030643668],"domain_scores_gemma":[0.9995252,0.0000720862,0.00008921458,0.00019285965,0.000030316729,0.000090343296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031622348,0.00020001607,0.00035173012,0.00010828017,0.00008718924,0.000025449694,0.00006031697,0.0001192136,0.00027647603],"category_scores_gemma":[0.000011443538,0.00014333978,0.00009054378,0.0004682267,0.000093208786,0.00006255363,0.00002353324,0.000098617136,0.000029462706],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015487573,0.00018693798,0.22140105,0.0000376459,0.0002804844,0.00021237847,0.0014568743,2.9334925e-7,0.0040002065,0.00007202075,0.0021221526,0.76868117],"study_design_scores_gemma":[0.010671779,0.00051896676,0.71267277,0.00018320545,0.000028583496,0.000056014826,0.000519904,0.000043802174,0.0047164205,0.000034961096,0.27031082,0.00024278814],"about_ca_topic_score_codex":0.0013819367,"about_ca_topic_score_gemma":0.00043980012,"teacher_disagreement_score":0.7684384,"about_ca_system_score_codex":0.0003385911,"about_ca_system_score_gemma":0.0005208147,"threshold_uncertainty_score":0.58452266},"labels":[],"label_agreement":null},{"id":"W4376470433","doi":"10.14283/jpad.2023.58","title":"Clinical Efficacy in Individual Patients Treated with Lecanemab","year":2023,"lang":"en","type":"letter","venue":"The Journal of Prevention of Alzheimer s Disease","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; McGill University; Douglas Mental Health University Institute; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean","funders":"","keywords":"Clinical efficacy; Psychology; Self-efficacy; Medicine; Internal medicine; Psychotherapist","score_opus":0.06712598945434768,"score_gpt":0.3577029479376759,"score_spread":0.2905769584833282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376470433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9043555,0.0055570696,0.0000067204746,0.08804861,0.0005735553,0.0012027678,0.00013781282,0.000021775892,0.00009615107],"genre_scores_gemma":[0.89879197,0.0026330934,0.00013999108,0.09263877,0.0031688896,0.000016851844,0.0007231139,0.00022035568,0.0016669877],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9969752,0.0005696393,0.001261909,0.00015242981,0.0008362337,0.00020462244],"domain_scores_gemma":[0.9976622,0.00023737544,0.0013785851,0.00034150766,0.0002610869,0.00011927068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011481087,0.0002232619,0.0006643679,0.0003356221,0.000030580653,0.000011434218,0.00027251188,0.00021557332,0.00018728468],"category_scores_gemma":[0.00009580527,0.00012868896,0.0005543213,0.0003440432,0.00020954874,0.000075238844,0.000037018068,0.0010765983,0.000009144258],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032713346,0.0030243155,0.1027486,0.0002868336,0.011001115,0.00083943695,0.00026882318,0.000012002034,0.000016339263,6.378837e-7,0.8030437,0.046044838],"study_design_scores_gemma":[0.011887273,0.0025875345,0.958835,0.0023373691,0.0092361905,0.00002622171,0.000025900166,0.000002245956,0.00004392618,0.000024699837,0.014824495,0.00016910904],"about_ca_topic_score_codex":0.000027311826,"about_ca_topic_score_gemma":0.0000057678294,"teacher_disagreement_score":0.85608643,"about_ca_system_score_codex":0.000041166455,"about_ca_system_score_gemma":0.0005518799,"threshold_uncertainty_score":0.52477837},"labels":[],"label_agreement":null},{"id":"W4376604489","doi":"10.1101/cshperspect.a041324","title":"Breast Cancer Immunity: It is TIME for the Next Chapter","year":2023,"lang":"en","type":"article","venue":"Cold Spring Harbor Perspectives in Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Immune system; Breast cancer; Disease; Tumor microenvironment; Cancer; Metastasis; Immunology; Proteomics; Biology; Computational biology; Bioinformatics; Medicine; Internal medicine; Genetics","score_opus":0.04505078346901818,"score_gpt":0.32688348440214665,"score_spread":0.28183270093312845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376604489","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40405387,0.04331175,0.00020868174,0.5431334,0.0014766002,0.0034115082,0.00010437317,0.00044267316,0.003857183],"genre_scores_gemma":[0.9798188,0.010540523,0.00006266374,0.0052890093,0.0009671819,0.00028732198,0.0000016436323,0.000060733437,0.0029720908],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987252,0.000023163637,0.00027340217,0.00033179641,0.00028851253,0.0003579471],"domain_scores_gemma":[0.9989197,0.00030175672,0.00007687679,0.00047954437,0.00014688514,0.00007522967],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006886514,0.00019666919,0.0003645544,0.00024138598,0.00017150072,0.000017169683,0.00021467169,0.00007745874,0.0018655423],"category_scores_gemma":[0.00009544299,0.00013034859,0.00012543699,0.0005787261,0.00039023993,0.000077536395,0.000054490556,0.0002779198,0.00004772464],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011244765,0.00047997167,0.014161665,0.0005894626,0.0026014186,0.00016234774,0.047772918,0.000030913743,0.7828868,0.013161534,0.09694566,0.029962549],"study_design_scores_gemma":[0.014900385,0.0007705047,0.6887733,0.0028384994,0.00049303216,0.000031704334,0.02075525,0.0069809677,0.0041813254,0.00009929218,0.2595413,0.0006344738],"about_ca_topic_score_codex":0.00087982276,"about_ca_topic_score_gemma":0.000046929043,"teacher_disagreement_score":0.7787055,"about_ca_system_score_codex":0.00028014556,"about_ca_system_score_gemma":0.00008649418,"threshold_uncertainty_score":0.99904686},"labels":[],"label_agreement":null},{"id":"W4376613717","doi":"10.1016/j.esmoop.2023.101290","title":"66P Digital profiling of immune biomarkers: Relation to anthracycline benefit","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Queen's University; University of British Columbia","funders":"","keywords":"Cyclophosphamide; Breast cancer; Oncology; Immune system; Anthracycline; Medicine; Epirubicin; Internal medicine; Chemotherapy; Immunology; Cancer","score_opus":0.03478004766884513,"score_gpt":0.3375019741374314,"score_spread":0.30272192646858626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376613717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848229,0.00012822455,0.00006871858,0.0029040403,0.00023542815,0.0010207511,0.000044120545,0.00007369369,0.0107021155],"genre_scores_gemma":[0.99524754,0.00007277462,0.0010196484,0.00016767159,0.00006152693,0.000035725345,0.00028520156,0.000024694133,0.0030852372],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990316,0.000009919804,0.0003877568,0.00021050598,0.0001839048,0.00017631506],"domain_scores_gemma":[0.99939454,0.000054166463,0.000103549406,0.00031809995,0.00006715061,0.00006252399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038711223,0.000101664766,0.00024729068,0.00015539695,0.000057524005,0.00005448659,0.00019715208,0.000062965126,0.0002475818],"category_scores_gemma":[0.00010537385,0.00008773986,0.0000947457,0.00073379773,0.000042469124,0.00026048732,0.0001724761,0.00006645531,0.00014407355],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016500682,0.00063825294,0.13220866,0.00030230495,0.001372174,0.000097765886,0.0020343391,0.00006947088,0.3939817,0.00068523054,0.009681953,0.4424275],"study_design_scores_gemma":[0.003990126,0.0006752897,0.85414666,0.0005774588,0.000056150973,0.0000215551,0.0007396974,0.0003225453,0.119016856,0.0002887026,0.019925093,0.00023984147],"about_ca_topic_score_codex":0.0005706743,"about_ca_topic_score_gemma":0.000024953086,"teacher_disagreement_score":0.721938,"about_ca_system_score_codex":0.00004727242,"about_ca_system_score_gemma":0.000063142805,"threshold_uncertainty_score":0.35779276},"labels":[],"label_agreement":null},{"id":"W4376637980","doi":"10.1101/2023.05.15.23289680","title":"Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis","year":2023,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Georgia Clinical and Translational Science Alliance; Vanderbilt University Medical Center; Princess Margaret Cancer Foundation; Vanderbilt Institute for Clinical and Translational Research; Memorial Sloan-Kettering Cancer Center; Vanderbilt University; American Diabetes Association","keywords":"Medicine; Internal medicine; Cohort; Ulcerative colitis; Cancer; Adverse effect; Gastroenterology; Disease; Colorectal cancer; Inflammatory bowel disease; Oncology; Colitis; Cohort study","score_opus":0.03372612012797142,"score_gpt":0.2868247189048499,"score_spread":0.25309859877687846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376637980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97864306,0.003045021,0.00032090332,0.002359674,0.00466777,0.00516276,0.004604778,0.00068270107,0.00051330327],"genre_scores_gemma":[0.9787909,0.0060832594,0.00047567277,0.00041559254,0.001999885,0.0023399128,0.0029148434,0.00028552595,0.006694449],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956461,0.00024323633,0.0013447743,0.0011740555,0.00068997586,0.0009018291],"domain_scores_gemma":[0.9967389,0.00046173373,0.000782174,0.0011827698,0.00047478784,0.00035965172],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014038774,0.00072863826,0.0013384437,0.00032001472,0.0002624962,0.00010040144,0.00040686553,0.0008511683,0.00031507824],"category_scores_gemma":[0.0010123181,0.00067830726,0.0010450954,0.0004922563,0.00038771375,0.0000708618,0.00042746062,0.0012264912,0.00013411282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16854405,0.0033065847,0.4487263,0.021701925,0.032228544,0.0020046986,0.021023419,0.000118192795,0.122690946,0.00043986685,0.12010289,0.059112582],"study_design_scores_gemma":[0.00904215,0.0010911132,0.9495122,0.0027530293,0.0006923929,0.00005189441,0.00032416,0.0006193017,0.018959045,0.000776141,0.015386702,0.00079189637],"about_ca_topic_score_codex":0.001973645,"about_ca_topic_score_gemma":0.0010042686,"teacher_disagreement_score":0.5007859,"about_ca_system_score_codex":0.00066454255,"about_ca_system_score_gemma":0.0012051475,"threshold_uncertainty_score":0.9995668},"labels":[],"label_agreement":null},{"id":"W4376640915","doi":"10.2217/imt-2022-0139","title":"Association of Circadian Timing of Initial Infusions of Immune Checkpoint Inhibitors with Survival in Advanced Melanoma","year":2023,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre","funders":"","keywords":"Circadian rhythm; Medicine; Melanoma; Immune system; Immune checkpoint; Association (psychology); Oncology; Internal medicine; Immunotherapy; Immunology; Cancer research; Psychology","score_opus":0.017196116946273547,"score_gpt":0.3009920710369966,"score_spread":0.28379595409072306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376640915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997315,0.00070768443,0.000014680735,0.0004583708,0.00022830017,0.00039226428,0.000024938296,0.00003014426,0.00082864746],"genre_scores_gemma":[0.9984029,0.0009231979,0.00025123617,0.00003285469,0.00003473656,0.000021345013,0.000036675843,0.00003256162,0.00026449273],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99831164,0.00007236546,0.0008573108,0.00015705072,0.0003744781,0.00022716202],"domain_scores_gemma":[0.9987602,0.000170405,0.00059284386,0.0002913367,0.0001582739,0.000026909924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007534877,0.00014490975,0.0005516661,0.00039307325,0.000027589607,0.0000034699347,0.000105144296,0.00012976542,0.00013184808],"category_scores_gemma":[0.00007309035,0.00012497552,0.00018804435,0.0010083992,0.00010625372,0.00008368855,0.000018578956,0.00015151342,0.0000024890064],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049247383,0.00018764955,0.06987806,0.000107656466,0.0003673227,0.0000066012276,0.0028577067,0.00003433167,0.8967872,0.000029343186,0.000023014163,0.024796365],"study_design_scores_gemma":[0.009202248,0.0010404584,0.60344607,0.0006757471,0.000030300358,0.0000040061027,0.0010313039,0.00007983029,0.38360247,0.000025823942,0.00072428555,0.00013745036],"about_ca_topic_score_codex":0.0011824284,"about_ca_topic_score_gemma":0.00023848243,"teacher_disagreement_score":0.533568,"about_ca_system_score_codex":0.00015087936,"about_ca_system_score_gemma":0.00020888737,"threshold_uncertainty_score":0.5096353},"labels":[],"label_agreement":null},{"id":"W4376862935","doi":"10.1158/1078-0432.c.6637744.v1","title":"Data from Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Medicine; Internal medicine; Adjuvant; Clinical endpoint; Melanoma; Oncology; Stage (stratigraphy); Gastroenterology; Cancer; Immunotherapy; Clinical trial; Cancer research","score_opus":0.14283289971332294,"score_gpt":0.35440725093080433,"score_spread":0.2115743512174814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376862935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9634157,0.0036387597,0.000028536162,0.0016839303,0.0024399164,0.0016799059,0.023126995,0.00049717654,0.003489115],"genre_scores_gemma":[0.9287737,0.006788774,0.0018516731,0.0001918463,0.00063715153,0.0000760454,0.051204722,0.0002430683,0.010233009],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.994492,0.0002473245,0.0014087382,0.0024269759,0.0007455436,0.0006794148],"domain_scores_gemma":[0.9940552,0.0010908397,0.00045069607,0.004026153,0.0001129123,0.00026420047],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001028309,0.00072810636,0.0013496687,0.0004743278,0.000098283024,0.00016656674,0.0010086591,0.000875134,0.0012813896],"category_scores_gemma":[0.00063871,0.000642738,0.0001712363,0.0005250817,0.00027825907,0.00015964119,0.002832975,0.0011631452,0.00015948349],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70376545,0.0014806446,0.0048104823,0.0006127093,0.008753376,0.0022965283,0.0033247112,0.000017842827,0.05378333,0.000016991155,0.18395968,0.037178237],"study_design_scores_gemma":[0.23061603,0.0008329428,0.7098339,0.0035563682,0.0009858308,0.0000060173556,0.0023628266,0.008499811,0.0031700623,0.0001696394,0.038068604,0.0018979551],"about_ca_topic_score_codex":0.096350215,"about_ca_topic_score_gemma":0.027548183,"teacher_disagreement_score":0.7050234,"about_ca_system_score_codex":0.00042643372,"about_ca_system_score_gemma":0.0006039758,"threshold_uncertainty_score":0.9996316},"labels":[],"label_agreement":null},{"id":"W4376871320","doi":"10.1093/jnci/djad090","title":"Early mortality in patients with cancer treated with immune checkpoint inhibitors in routine practice","year":2023,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Western University","funders":"Schulich School of Medicine and Dentistry, Western University; Western University; Ontario Ministry of Health and Long-Term Care; Schulich School of Medicine and Dentistry; Academic Medical Organization of Southwestern Ontario; Lawson Health Research Institute","keywords":"Medicine; Internal medicine; Cancer; Lung cancer; Bladder cancer; Retrospective cohort study; Cohort; Melanoma; Chemotherapy; Head and neck cancer; Pembrolizumab; Kidney cancer; Surgery; Oncology; Immunotherapy","score_opus":0.031245971666579008,"score_gpt":0.3281210213840586,"score_spread":0.2968750497174796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376871320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940077,0.00037673127,0.0000017472291,0.004165039,0.00057176093,0.00037521316,0.000038129296,0.0000102670265,0.00045338683],"genre_scores_gemma":[0.9985675,0.0002648061,0.000055969802,0.0005627662,0.00027547823,0.000034270714,0.000009569206,0.000016697331,0.00021293099],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787635,0.00006099729,0.0006114311,0.0001472393,0.001106512,0.00019749046],"domain_scores_gemma":[0.99842435,0.000044930475,0.000598897,0.00011168092,0.000765494,0.0000546511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000726356,0.00015101796,0.0002987168,0.00029566002,0.000060398732,0.000021524746,0.00014943302,0.00006348245,0.00003991631],"category_scores_gemma":[0.00016242785,0.00008454002,0.00009754559,0.0014847734,0.00013019361,0.00051301136,0.000025836085,0.0004171973,0.0000015072347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010706291,0.0002638889,0.9827528,0.000031422707,0.00039737826,0.00004444603,0.00038629168,0.0027756991,0.0008178587,0.000014268321,0.00034616014,0.0014634669],"study_design_scores_gemma":[0.010139836,0.00032426676,0.9826223,0.00095116155,0.000098983975,0.000024183271,0.000051305233,0.000029492205,0.001961561,0.0000130364315,0.0036705998,0.000113258444],"about_ca_topic_score_codex":0.006135306,"about_ca_topic_score_gemma":0.0028509097,"teacher_disagreement_score":0.004559786,"about_ca_system_score_codex":0.0013407655,"about_ca_system_score_gemma":0.001180656,"threshold_uncertainty_score":0.9274788},"labels":[],"label_agreement":null},{"id":"W4377094752","doi":"10.1111/ijd.16714","title":"Detection of novel therapies using a <scp>multi‐national</scp>, <scp>multi‐institutional</scp> registry of cutaneous <scp>immune‐related</scp> adverse events and management","year":2023,"lang":"en","type":"article","venue":"International Journal of Dermatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Psoriasis Foundation; Genentech; Amryt Pharma; Incyte; National Cancer Institute; Pelotonia; National Comprehensive Cancer Network; InflaRx; Biogen; National Center for Advancing Translational Sciences; LUNGevity Foundation; Eli Lilly and Company; Pfizer","keywords":"Medicine; Adverse effect; Rituximab; Dermatology; Dupilumab; Psoriasis; Immune dysregulation; Disease; Internal medicine; Atopic dermatitis","score_opus":0.027816746289593953,"score_gpt":0.3049459355497978,"score_spread":0.27712918926020386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377094752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98871,0.0023380534,0.005961793,0.00046058165,0.0015238633,0.0003308085,0.000072342096,0.00003760233,0.00056496187],"genre_scores_gemma":[0.9923473,0.0029467104,0.0033841901,0.00015621533,0.000106927946,0.000010069748,0.00004146312,0.000033539804,0.00097359717],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9969659,0.00009742409,0.001371611,0.00027365552,0.0009876067,0.00030380243],"domain_scores_gemma":[0.99647623,0.000717246,0.0014832113,0.00019273176,0.0010246203,0.0001059599],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032850014,0.0002854439,0.0005989768,0.0010281552,0.000112720496,0.000015840289,0.0003884794,0.00025766346,0.000008295605],"category_scores_gemma":[0.00084672414,0.00025575704,0.00038148096,0.00043192387,0.0003791894,0.00026130606,0.0001250336,0.00035925876,0.000008084318],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086765306,0.0032936519,0.091261044,0.0012415951,0.019160375,0.0056063756,0.007368438,0.0068067303,0.85111725,0.0032430785,0.0021057066,0.007928119],"study_design_scores_gemma":[0.057015155,0.0010593424,0.37535217,0.00505653,0.0017047272,0.24175805,0.01799389,0.05527223,0.16625161,0.0019733587,0.07624435,0.00031859777],"about_ca_topic_score_codex":0.000053259588,"about_ca_topic_score_gemma":0.000017320894,"teacher_disagreement_score":0.6848656,"about_ca_system_score_codex":0.00029586934,"about_ca_system_score_gemma":0.00027681747,"threshold_uncertainty_score":0.99998945},"labels":[],"label_agreement":null},{"id":"W4377107205","doi":"10.3390/curroncol30050387","title":"The Effect of Lung Resection for NSCLC on Circulating Immune Cells: A Pilot Study","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Dartmouth College; Dartmouth Cancer Center; American Cancer Society; American Association for Thoracic Surgery; Hitchcock Foundation","keywords":"Medicine; Immune system; FOXP3; CD8; Flow cytometry; Lymph node; Lung; Lymph; Cluster of differentiation; Lymphocyte; Cell; T cell; Immunology; Pathology; Internal medicine; Biology","score_opus":0.1049605805134727,"score_gpt":0.4383873489675179,"score_spread":0.3334267684540452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377107205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99320775,0.0012918516,0.000026964753,0.00031621792,0.002829097,0.001946622,0.000004144055,0.00005105766,0.00032627175],"genre_scores_gemma":[0.9991216,0.00015401797,0.0000030020235,0.000011002038,0.00021739858,0.00033857505,0.00001302843,0.000014588403,0.0001267532],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9989974,0.00020372673,0.00029204844,0.00016817544,0.00013900136,0.00019965624],"domain_scores_gemma":[0.9984114,0.0011619091,0.000136679,0.00021431492,0.00005129814,0.00002440982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013399841,0.00009479543,0.0002613098,0.000095524214,0.0001656764,0.0000060560074,0.0000760605,0.00003390839,0.000011107785],"category_scores_gemma":[0.00018795796,0.000059261372,0.00010649402,0.0002858055,0.00006347294,0.000013331483,0.000026088846,0.00014794352,0.0000073236397],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08145657,0.0015066934,0.02560204,0.00072383677,0.0006615392,0.000012791022,0.0013747754,0.000025656282,0.21952191,0.000034267632,0.009505352,0.65957457],"study_design_scores_gemma":[0.06090277,0.46555078,0.27669838,0.0010489271,0.00094127475,0.000035063593,0.0025448403,0.0066293334,0.080914356,0.00007363482,0.1042183,0.0004423319],"about_ca_topic_score_codex":0.000027912902,"about_ca_topic_score_gemma":0.000033169683,"teacher_disagreement_score":0.65913224,"about_ca_system_score_codex":0.00018994058,"about_ca_system_score_gemma":0.000059939804,"threshold_uncertainty_score":0.24166086},"labels":[],"label_agreement":null},{"id":"W4377982028","doi":"10.1038/s41467-023-38837-3","title":"Towards evidence-based response criteria for cancer immunotherapy","year":2023,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Ottawa Hospital","funders":"","keywords":"Immunotherapy; Guideline; Medicine; Response Evaluation Criteria in Solid Tumors; Cancer immunotherapy; Cancer; Oncology; Medical physics; Clinical trial; Internal medicine; Pathology","score_opus":0.10750571868092333,"score_gpt":0.4416217652019882,"score_spread":0.33411604652106486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377982028","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2275961,0.2551218,0.00050610176,0.5096469,0.0015098462,0.0031218592,0.00038516682,0.0016001858,0.0005120523],"genre_scores_gemma":[0.9557967,0.025479354,0.0071307085,0.009180454,0.0001361086,0.0011486941,0.00016222833,0.00007142149,0.00089433097],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989312,0.00019438712,0.0002536708,0.0001970882,0.00019388471,0.00022976258],"domain_scores_gemma":[0.9967533,0.0010270532,0.00008465199,0.0017727797,0.00030247198,0.0000597497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010540975,0.00013992401,0.00021526752,0.00017655204,0.00024263961,0.000038649006,0.0006063268,0.00026116378,0.00013051447],"category_scores_gemma":[0.0005109343,0.000121388664,0.0002230948,0.000838784,0.00016545529,0.000100093945,0.000064998196,0.00041963937,0.000013494542],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034038704,0.00027035543,0.0030316412,0.00013062735,0.0004374322,0.000004001293,0.00077979214,0.0000066189154,0.59974587,0.0007968922,0.25891182,0.10184626],"study_design_scores_gemma":[0.0021513968,0.00024687726,0.10859287,0.00043256948,0.000058872054,0.000004090749,0.00008900557,0.0014724628,0.008229969,0.00009164217,0.8784693,0.00016093043],"about_ca_topic_score_codex":0.0001070034,"about_ca_topic_score_gemma":0.00013395166,"teacher_disagreement_score":0.7282006,"about_ca_system_score_codex":0.00019856011,"about_ca_system_score_gemma":0.0006280817,"threshold_uncertainty_score":0.4950086},"labels":[],"label_agreement":null},{"id":"W4378349559","doi":"10.3390/curroncol30050355","title":"Adverse Effects of Immune-Checkpoint Inhibitors: A Comprehensive Imaging-Oriented Review","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Adverse effect; Ipilimumab; Immune system; Melanoma; Lymphoma; Cancer; Oncology; Immunotherapy; Intensive care medicine; Immunology; Internal medicine; Cancer research","score_opus":0.10489465729861512,"score_gpt":0.446197915956205,"score_spread":0.34130325865758987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378349559","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017187605,0.9892769,0.000008440499,0.00016989675,0.0060416455,0.0040998855,0.00004761871,0.00012714403,0.00021129003],"genre_scores_gemma":[0.0000012371834,0.99801344,0.000037718848,0.00016240786,0.0004374615,0.0005599969,0.0005279177,0.000094922485,0.00016489867],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99600065,0.00048411146,0.0021425732,0.0005916579,0.00033699285,0.00044404622],"domain_scores_gemma":[0.9965372,0.0006882801,0.0015706753,0.0007332771,0.00032011344,0.00015045947],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047247522,0.00060424936,0.004561369,0.00039759505,0.00004582065,0.0000030797082,0.00024001939,0.00029653058,0.00012031136],"category_scores_gemma":[0.0004064386,0.00046261007,0.002295041,0.0009924246,0.0003500763,0.0000378975,0.0002114326,0.00082743797,0.00022269633],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009958612,0.0002886035,0.0000059273866,0.32974857,0.0005252913,0.00010966365,0.000042587966,3.4074878e-9,0.00002262683,0.000005514777,0.01096196,0.65818965],"study_design_scores_gemma":[0.0016681161,0.00040674047,0.00002405626,0.30545655,0.0031395818,0.00017123348,0.000018061544,6.872378e-7,0.000016032058,0.0000025527902,0.6888611,0.00023530865],"about_ca_topic_score_codex":0.00003210113,"about_ca_topic_score_gemma":0.0000024193134,"teacher_disagreement_score":0.6778991,"about_ca_system_score_codex":0.00075308763,"about_ca_system_score_gemma":0.001226802,"threshold_uncertainty_score":0.99978256},"labels":[],"label_agreement":null},{"id":"W4378471985","doi":"10.3390/curroncol30060402","title":"Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Alberta; CancerCare Manitoba","funders":"BC Cancer Foundation","keywords":"Pembrolizumab; Medicine; Internal medicine; Systemic therapy; Lung cancer; Stage (stratigraphy); Cohort; Retrospective cohort study; Oncology; Progression-free survival; Cancer; Chemotherapy; Surgery; Immunotherapy; Breast cancer","score_opus":0.08688624052559522,"score_gpt":0.3781644631220842,"score_spread":0.29127822259648894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378471985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934969,0.002521456,0.000029237373,0.00047513677,0.00038010275,0.001238655,0.0001714607,0.00014364206,0.0015434329],"genre_scores_gemma":[0.9889878,0.0060310154,0.00007097513,0.00007313505,0.00011057057,0.00013150499,0.00021558731,0.00005902656,0.004320389],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792093,0.000099120036,0.0008431693,0.00039734322,0.00033734812,0.0004020923],"domain_scores_gemma":[0.99822474,0.00028283685,0.0005798951,0.00054670934,0.0002507745,0.00011504245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035932267,0.0003321813,0.0012327406,0.00043671107,0.00005679608,0.0000054981933,0.00018191176,0.00013564734,0.0006946851],"category_scores_gemma":[0.000021905831,0.00020678269,0.00018590245,0.0008764915,0.00032468516,0.00005493138,0.000032029617,0.00023922874,0.000011732768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11805029,0.0028164755,0.75360197,0.005026778,0.003139197,0.00021132635,0.0020980139,0.00013014792,0.026116615,0.00016983168,0.0034160523,0.085223295],"study_design_scores_gemma":[0.04873837,0.014895919,0.8652132,0.0037546267,0.00042010096,0.00013658656,0.00073968014,0.0002228658,0.007585358,0.000008959465,0.057798896,0.00048542334],"about_ca_topic_score_codex":0.0003538476,"about_ca_topic_score_gemma":0.003604096,"teacher_disagreement_score":0.11161124,"about_ca_system_score_codex":0.0002499678,"about_ca_system_score_gemma":0.0006233366,"threshold_uncertainty_score":0.8432353},"labels":[],"label_agreement":null},{"id":"W4378528212","doi":"10.1016/j.jtho.2023.05.019","title":"Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Human Genome Research Institute; Canadian Institutes of Health Research; Genentech; Bristol-Myers Squibb; AstraZeneca; Foghorn Therapeutics; Revolution Medicines; National Cancer Institute; Royal College of Physicians and Surgeons of Canada; Gilead Sciences; GlaxoSmithKline; G1 Therapeutics; V Foundation for Cancer Research; Pfizer; Amgen","keywords":"Medicine; Aneuploidy; Oncology; Immunotherapy; Internal medicine; Biomarker; Lung cancer; Cancer; Chromosome; Cancer research; Gene; Genetics; Biology","score_opus":0.016763935468031836,"score_gpt":0.36924656841797476,"score_spread":0.3524826329499429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378528212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929268,0.004196194,0.0000011072044,0.0022672596,0.00025161754,0.0002702573,0.000008788621,0.000007814353,0.000070178015],"genre_scores_gemma":[0.9966142,0.0028844555,0.00012540811,0.00009275819,0.00016087359,0.0000035707765,0.000003863528,0.000022016942,0.00009284272],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983033,0.00013493397,0.0009200104,0.00016930971,0.0002088679,0.00026357747],"domain_scores_gemma":[0.9988498,0.00018748819,0.00062002183,0.00018173449,0.000041360032,0.00011961083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010426032,0.00017922295,0.0007970652,0.00042627077,0.000033920714,0.00000841408,0.000089873254,0.00012086615,0.0000882503],"category_scores_gemma":[0.00008779703,0.00013048569,0.00024011955,0.00028236676,0.00026666958,0.00007222648,0.0000669767,0.00040743785,0.0000057909238],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019782634,0.00096938014,0.010873319,0.00014677987,0.00030928547,0.0010858647,0.0007705508,0.000016099028,0.9045266,0.0000010312323,0.00014113505,0.06137732],"study_design_scores_gemma":[0.0057918383,0.010312857,0.9085272,0.00067319366,0.00010481141,0.0026348978,0.00025745927,0.000020534886,0.07076609,0.000020395883,0.0007723246,0.000118430034],"about_ca_topic_score_codex":0.00006702482,"about_ca_topic_score_gemma":0.000005748779,"teacher_disagreement_score":0.8976539,"about_ca_system_score_codex":0.0004774798,"about_ca_system_score_gemma":0.00021313743,"threshold_uncertainty_score":0.53210515},"labels":[],"label_agreement":null},{"id":"W4378715513","doi":"10.31557/apjcp.2023.24.5.1453","title":"Analysis of PD-L1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis in Asian Population","year":2023,"lang":"en","type":"review","venue":"Asian Pacific Journal of Cancer Prevention","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Meta-analysis; Hazard ratio; Confidence interval; Internal medicine; Odds ratio; Medicine; Oncology; Breast cancer; Population; Cancer; Gastroenterology","score_opus":0.05656956388188109,"score_gpt":0.39474848246635,"score_spread":0.3381789185844689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378715513","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000038844195,0.99732435,0.000042346775,0.0005317084,0.00008075754,0.0017242511,0.0001986424,0.0000069988,0.000052123694],"genre_scores_gemma":[0.004413135,0.99464333,0.000043840675,0.00002457532,0.00003745626,0.00029273046,0.0001168389,0.000038094116,0.00038998475],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9940758,0.0010044748,0.0036346137,0.00038458884,0.00066674536,0.0002338306],"domain_scores_gemma":[0.9946315,0.00007654687,0.0045263986,0.0004609355,0.00019948177,0.00010511315],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025276293,0.0004146314,0.010434341,0.0037599844,0.00002788166,0.000026938866,0.0001897352,0.0002578726,0.00046821294],"category_scores_gemma":[0.000047915106,0.00027907337,0.0047858753,0.0067283106,0.00004019688,0.00020199307,0.000027724944,0.00043628158,7.591637e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018039736,0.00014183212,0.0012413714,0.6241297,0.3106429,0.000034044424,0.00022497338,0.000016982918,0.0000042420024,0.000001930987,0.00006205074,0.06331958],"study_design_scores_gemma":[0.00044774162,0.00005311123,0.0077074314,0.20041081,0.79042333,0.000054089454,0.0001753647,0.000009619759,5.6944583e-7,0.000012087153,0.00051741867,0.00018842568],"about_ca_topic_score_codex":0.0005639102,"about_ca_topic_score_gemma":0.0020729515,"teacher_disagreement_score":0.4797804,"about_ca_system_score_codex":0.00066674245,"about_ca_system_score_gemma":0.00034805638,"threshold_uncertainty_score":0.99996614},"labels":[],"label_agreement":null},{"id":"W4379230501","doi":"10.3390/curroncol30060410","title":"Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Japan Society for the Promotion of Science","keywords":"Medicine; Internal medicine; Oncology; Head and neck cancer; Head and neck squamous-cell carcinoma; Biomarker; Antibody; Cancer; Multivariate analysis; Performance status; Immunology","score_opus":0.09162956156182502,"score_gpt":0.4393964561776715,"score_spread":0.3477668946158465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379230501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98482174,0.010713566,0.000040668343,0.00092956214,0.0013034671,0.0018629268,0.00003486998,0.00011454845,0.0001786424],"genre_scores_gemma":[0.98751235,0.01042573,0.00031622034,0.00010905905,0.00028743246,0.00088804506,0.00029646227,0.000035887897,0.00012878819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865997,0.00006669883,0.0002988527,0.0003873171,0.00009889529,0.0004882943],"domain_scores_gemma":[0.9993341,0.0002553994,0.00009944333,0.00015451883,0.000037965474,0.0001185655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024664562,0.00020400206,0.00046825694,0.00023324613,0.000080147634,0.000013356586,0.00005462791,0.00014003133,0.00001564541],"category_scores_gemma":[0.000041521387,0.00016554086,0.00012441688,0.000378439,0.000090515794,0.000037858987,0.000030436979,0.00010460448,0.000004680972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015777448,0.0005257263,0.57172513,0.0005312368,0.00014372657,0.00004296024,0.00047767392,0.000001496707,0.017352572,0.000005116149,0.0009079383,0.4067087],"study_design_scores_gemma":[0.025866028,0.0046205935,0.7686713,0.00042984655,0.00024068981,0.000024087845,0.0002449587,0.0025985758,0.0037926792,0.000028379234,0.19325031,0.00023257018],"about_ca_topic_score_codex":0.00041024986,"about_ca_topic_score_gemma":0.00029492032,"teacher_disagreement_score":0.4064761,"about_ca_system_score_codex":0.00048764734,"about_ca_system_score_gemma":0.00023245755,"threshold_uncertainty_score":0.67505604},"labels":[],"label_agreement":null},{"id":"W4379280628","doi":"10.1200/jco.2023.41.16_suppl.e18840","title":"Is aggregate use of published case reports as a viable option for augmenting pharmacovigilance? An applied example of pembrolizumab-related adverse events in patients with non-small cell lung cancer receiving first-line treatment.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Pembrolizumab; Medicine; Pharmacovigilance; Adverse effect; Internal medicine; Lung cancer; Oncology; Cohort; Population; Clinical trial; Adverse Event Reporting System; Intensive care medicine; Cancer; Immunotherapy","score_opus":0.07976227313535207,"score_gpt":0.40686519276608746,"score_spread":0.3271029196307354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99780005,0.00008881665,0.000058163325,0.00025609374,0.00062360946,0.0010665503,0.00002130944,0.000010593593,0.000074788746],"genre_scores_gemma":[0.9973468,0.00077014405,0.0011228457,0.00021757386,0.00012435066,0.000047849397,0.000043025488,0.00003177214,0.0002956274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99612963,0.00012659687,0.0028578772,0.000312671,0.0002773272,0.00029589923],"domain_scores_gemma":[0.9940871,0.00077918207,0.0042199353,0.00024356133,0.0004869013,0.00018334652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002104731,0.00018447898,0.0012598064,0.00029601852,0.000050413182,0.000004923866,0.00007194613,0.000254227,0.00012653379],"category_scores_gemma":[0.00034118665,0.00013468276,0.00033880907,0.00045663468,0.0000742788,0.000302616,0.000028337581,0.00030248938,4.3273067e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062367428,0.0037631246,0.9009248,0.00035009373,0.0012403892,0.0014669787,0.0008580498,0.0021147989,0.0020048912,7.691604e-7,0.0004199219,0.02448877],"study_design_scores_gemma":[0.1608186,0.031849664,0.77916104,0.0018422684,0.0024374041,0.0007719032,0.0002986973,0.008267398,0.0064402274,0.00006603564,0.0076287836,0.0004179876],"about_ca_topic_score_codex":0.0016330502,"about_ca_topic_score_gemma":0.00049528544,"teacher_disagreement_score":0.12176376,"about_ca_system_score_codex":0.0003866604,"about_ca_system_score_gemma":0.0010376743,"threshold_uncertainty_score":0.5492204},"labels":[],"label_agreement":null},{"id":"W4379281044","doi":"10.1200/jco.2023.41.16_suppl.9053","title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease: A systematic review and meta-analysis in non-small cell lung cancer.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Meta-analysis; Oncology; Cancer; Adverse effect; Population","score_opus":0.10919054630018293,"score_gpt":0.4567624176956659,"score_spread":0.34757187139548296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281044","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0070239445,0.9893498,0.000002610105,0.00047986035,0.0001298499,0.0029340747,0.00006078871,0.0000039283855,0.000015131808],"genre_scores_gemma":[0.0015413476,0.99779654,0.000102439284,0.00015906242,0.00005467785,0.00012146002,0.000013943798,0.000040091658,0.00017044449],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.989422,0.0010312534,0.00851773,0.00040916263,0.00036390938,0.00025589258],"domain_scores_gemma":[0.9881604,0.0026885394,0.008326087,0.00032941657,0.00025885072,0.00023672586],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0068737245,0.00042264108,0.017155489,0.0005162179,0.000029576206,0.0000116287765,0.0001696729,0.00037057762,0.000041512292],"category_scores_gemma":[0.0014787443,0.0002366451,0.0019626147,0.001031747,0.00024436112,0.000062448955,0.00012078974,0.0011088055,1.5744621e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038800053,0.00075637765,0.012241459,0.8492984,0.08820334,0.000122033176,0.0001284054,0.000006858402,2.8487264e-7,4.9950773e-7,0.000017290477,0.04534503],"study_design_scores_gemma":[0.007431554,0.0013630206,0.15541677,0.22213832,0.6109479,0.000013724695,0.000015825846,0.00002059449,1.0542077e-7,6.225142e-7,0.0024181204,0.00023343615],"about_ca_topic_score_codex":0.000512475,"about_ca_topic_score_gemma":0.00041324316,"teacher_disagreement_score":0.6271601,"about_ca_system_score_codex":0.0003669242,"about_ca_system_score_gemma":0.0017193464,"threshold_uncertainty_score":0.99743587},"labels":[],"label_agreement":null},{"id":"W4379282018","doi":"10.1200/jco.2023.41.16_suppl.6606","title":"The safety of seasonal influenza vaccination among patients prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Université de Sherbrooke; McGill University; Western University; Public Health Ontario; Dalhousie University; University of Toronto","funders":"Canadian Immunization Research Network","keywords":"Medicine; Vaccination; Poisson regression; Adverse effect; Incidence (geometry); Rate ratio; Influenza vaccine; Seasonal influenza; Population; Internal medicine; Immunology; Confidence interval; Environmental health; Disease; Coronavirus disease 2019 (COVID-19)","score_opus":0.14974235888975182,"score_gpt":0.47345569402657084,"score_spread":0.323713335136819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962617,0.00031783665,0.000008730827,0.0010116268,0.0011776334,0.0010642116,0.000025266878,0.000015269445,0.00011773713],"genre_scores_gemma":[0.99864036,0.00029467136,0.0003473174,0.00011885317,0.0005057604,0.000009004424,0.000009478579,0.00001523791,0.00005929163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939468,0.0010780172,0.0040494977,0.00020025927,0.0005131452,0.00021231585],"domain_scores_gemma":[0.9923184,0.002661847,0.0035881244,0.00037155743,0.000913327,0.00014674602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009334828,0.0001571613,0.0013646819,0.000110585934,0.00016478171,0.000020718226,0.0002543579,0.00021470265,0.00003837929],"category_scores_gemma":[0.0053105415,0.0000920452,0.00046789303,0.00034765044,0.00018449745,0.000341251,0.00015865224,0.00062756473,0.0000014377208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30015042,0.007703556,0.6094116,0.00007709279,0.006944234,0.0027035351,0.0029408718,0.000024601168,0.0005713654,0.000011198192,0.0011170136,0.06834454],"study_design_scores_gemma":[0.06600912,0.020632744,0.90172714,0.00013100171,0.0010010026,0.0006287885,0.0045932326,0.0007742401,0.00015649019,0.00003509867,0.0042000655,0.00011109569],"about_ca_topic_score_codex":0.00007966042,"about_ca_topic_score_gemma":0.00026268236,"teacher_disagreement_score":0.29231554,"about_ca_system_score_codex":0.00020406392,"about_ca_system_score_gemma":0.0017754085,"threshold_uncertainty_score":0.6357598},"labels":[],"label_agreement":null},{"id":"W4379282039","doi":"10.1200/jco.2023.41.16_suppl.6050","title":"Phase I/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma: Final results.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Western University; Jewish General Hospital; London Health Sciences Centre; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Durvalumab; Tremelimumab; Clinical endpoint; Head and neck squamous-cell carcinoma; Internal medicine; Oncology; Phases of clinical research; Head and neck cancer; Adverse effect; Radiation therapy; Nivolumab; Clinical trial; Immunotherapy; Cancer; Ipilimumab","score_opus":0.23514552807841463,"score_gpt":0.5088777108746165,"score_spread":0.27373218279620193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876744,0.00201303,0.00006548383,0.008286347,0.0011310839,0.00067838124,0.000036231355,0.000008759493,0.000106267085],"genre_scores_gemma":[0.99199045,0.0038062378,0.0020131094,0.00077576993,0.000905247,0.00001112041,0.00000810426,0.000021482387,0.00046847307],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99629664,0.0003421037,0.0026311984,0.00021779163,0.00027999823,0.00023226927],"domain_scores_gemma":[0.99452895,0.0031829635,0.0016599126,0.00017519762,0.00022958353,0.00022341432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046244906,0.00015226331,0.0017322839,0.0002093344,0.00006999266,0.000009675191,0.00009302551,0.0001941342,0.000026165968],"category_scores_gemma":[0.002200938,0.00010776311,0.0004678059,0.00018771732,0.00031470117,0.000093980605,0.000027150112,0.00039207956,4.846327e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78466517,0.0026332615,0.0004120758,0.00010668425,0.0010021836,0.00021230767,0.00035997242,9.4778187e-7,0.0014241197,0.000015956844,0.004088131,0.2050792],"study_design_scores_gemma":[0.68773186,0.22707929,0.026178764,0.0001109744,0.00073682,0.00047955217,0.00015441852,0.0008015584,0.000100691934,0.00014373024,0.05637915,0.00010318172],"about_ca_topic_score_codex":0.00003947543,"about_ca_topic_score_gemma":0.000025712223,"teacher_disagreement_score":0.22444603,"about_ca_system_score_codex":0.000116225565,"about_ca_system_score_gemma":0.0013851288,"threshold_uncertainty_score":0.4394452},"labels":[],"label_agreement":null},{"id":"W4379282347","doi":"10.1200/jco.2023.41.16_suppl.3545","title":"Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Bausch Health (Canada); Hôpital du Sacré-Cœur de Montréal; Jewish General Hospital; Juravinski Cancer Centre; Hôpital Charles-Le Moyne; St. John’s Health Sciences Centre; BC Cancer Agency; Hôtel-Dieu de Québec; Saskatchewan Cancer Agency; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; Queen's University; Dalhousie University; Moncton Hospital","funders":"","keywords":"Medicine; Oncology; Internal medicine; Hazard ratio; Biomarker; Immune system; Colorectal cancer; Post-hoc analysis; Proportional hazards model; Cancer; Gastroenterology; Cancer research; Immunology; Confidence interval; Biology","score_opus":0.10498592062238005,"score_gpt":0.47535596303189404,"score_spread":0.370370042409514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805147,0.00018428531,0.000052703523,0.016555805,0.0012061811,0.0012499355,0.00013097528,0.000012099239,0.0000933385],"genre_scores_gemma":[0.99796504,0.0004821087,0.00019520405,0.0006913541,0.00019364615,0.00012502827,0.000012910379,0.000023366585,0.00031135464],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99451715,0.0011366273,0.0033730438,0.00023714534,0.00044885595,0.00028716185],"domain_scores_gemma":[0.9920141,0.005006269,0.0021615103,0.00020902306,0.00042665828,0.00018244227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011982158,0.00016604505,0.00196994,0.0008741702,0.000049215843,0.000007868795,0.00017097284,0.00023832973,0.00019536975],"category_scores_gemma":[0.007618218,0.00010344303,0.0013894545,0.0021919124,0.00028212456,0.000069078844,0.00005250136,0.00047135566,0.000004746796],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89279974,0.0010587631,0.0064359903,0.00003042371,0.006157075,0.00012832879,0.0006871297,0.00028614,0.07851603,0.0000036028437,0.0016093164,0.012287451],"study_design_scores_gemma":[0.14265807,0.03128079,0.7909899,0.00034611745,0.004213668,0.000058825815,0.00082001387,0.0027607314,0.014265842,0.00009058256,0.012364663,0.00015081394],"about_ca_topic_score_codex":0.00038460412,"about_ca_topic_score_gemma":0.0011922038,"teacher_disagreement_score":0.7845539,"about_ca_system_score_codex":0.00047191896,"about_ca_system_score_gemma":0.0027901945,"threshold_uncertainty_score":0.9120269},"labels":[],"label_agreement":null},{"id":"W4379282862","doi":"10.1200/jco.2023.41.16_suppl.4004","title":"Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Hazard ratio; Discontinuation; Internal medicine; Adverse effect; Proportional hazards model; Tremelimumab; Oncology; Confidence interval; Gastroenterology; Cancer; Immunotherapy; Ipilimumab","score_opus":0.11499127931369861,"score_gpt":0.4508944703931721,"score_spread":0.3359031910794735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99566644,0.0006320322,0.0000061623955,0.0022056333,0.0004961448,0.0008291451,0.00002725849,0.000008945847,0.00012823583],"genre_scores_gemma":[0.99876094,0.00046759748,0.000039180504,0.0005144289,0.00006284527,0.0000222354,0.000019016412,0.000015243232,0.00009849187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99421024,0.0011521648,0.0032560872,0.0002522815,0.00075449987,0.00037474005],"domain_scores_gemma":[0.99512386,0.0025134832,0.0016458367,0.00036103366,0.00022324549,0.00013256643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007985446,0.00021091288,0.0018253825,0.00037061883,0.000035748304,0.0000036181075,0.0004458926,0.00023157592,0.000103385304],"category_scores_gemma":[0.001642009,0.000120855075,0.00041647494,0.0010578128,0.0002333717,0.00013062266,0.000058576992,0.0010718968,0.000010136253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041947413,0.006863757,0.9395368,0.00003778633,0.00034882702,0.0019656797,0.0011485283,0.000020361804,0.00078228716,9.1406184e-7,0.0011234701,0.0062241647],"study_design_scores_gemma":[0.099355906,0.025726287,0.86711603,0.00015135971,0.00019232323,0.00009076233,0.004093585,0.0006053999,0.0000890983,0.000010582257,0.0024425995,0.00012606222],"about_ca_topic_score_codex":0.0008211858,"about_ca_topic_score_gemma":0.00044758653,"teacher_disagreement_score":0.07242078,"about_ca_system_score_codex":0.00029985877,"about_ca_system_score_gemma":0.001893615,"threshold_uncertainty_score":0.4928327},"labels":[],"label_agreement":null},{"id":"W4379282944","doi":"10.1200/jco.2023.41.16_suppl.2635","title":"Multisystem immune-related adverse events from dual agent immunotherapy use.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Adverse effect; Internal medicine; Cancer; Cohort; Immunotherapy","score_opus":0.1364889781021885,"score_gpt":0.45279909526999446,"score_spread":0.316310117167806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868569,0.0014741697,0.00005258154,0.0038640413,0.0070301006,0.00029475792,0.000018055765,0.00005061938,0.00035878885],"genre_scores_gemma":[0.9891331,0.004703745,0.0007557388,0.0017129504,0.0009148904,0.0000053788463,0.000023893073,0.00004058035,0.0027097322],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99423,0.00065751787,0.004059088,0.00022945367,0.00051108014,0.00031286146],"domain_scores_gemma":[0.9945876,0.00219318,0.002332635,0.00033301962,0.00029327406,0.0002603062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004037821,0.00019270377,0.0015942534,0.00020939634,0.000063898005,0.0000065143295,0.00020008904,0.00059118925,0.00070518104],"category_scores_gemma":[0.0012032508,0.00013834662,0.0014341684,0.0003645765,0.00016542044,0.00017298503,0.000053244912,0.0009600499,0.00026068097],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08261456,0.0035982071,0.2727962,0.000058587993,0.011302804,0.006387003,0.0011889494,0.00009583428,0.04336584,0.000052054103,0.027278079,0.5512619],"study_design_scores_gemma":[0.023519248,0.0048487815,0.8006773,0.00025660644,0.0002423425,0.00028050435,0.00029764243,0.00016309324,0.00019447684,0.000110599,0.16927543,0.00013398284],"about_ca_topic_score_codex":0.00022845095,"about_ca_topic_score_gemma":0.000023638466,"teacher_disagreement_score":0.5511279,"about_ca_system_score_codex":0.00028157767,"about_ca_system_score_gemma":0.0009839032,"threshold_uncertainty_score":0.7721238},"labels":[],"label_agreement":null},{"id":"W4379283073","doi":"10.1200/jco.2023.41.16_suppl.2514","title":"Association of common inherited <i>NOD2</i> mutations with exceptional response to immune checkpoint inhibitors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; NOD2; Lung cancer; Oncology; Internal medicine; Immune system; Melanoma; Colorectal cancer; Cohort; Immunology; Cancer; Cancer research; Innate immune system","score_opus":0.07366329743773874,"score_gpt":0.4402658457155609,"score_spread":0.3666025482778221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9534261,0.00008220973,0.00004586009,0.045183625,0.0006951013,0.00017514758,0.000009706665,0.000015262449,0.0003669543],"genre_scores_gemma":[0.995427,0.00017508883,0.0013412206,0.0013967701,0.00049850455,0.000005839119,0.000011202572,0.000014514717,0.0011298544],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9964345,0.0005524652,0.002272394,0.00010618339,0.00047736042,0.00015709411],"domain_scores_gemma":[0.9945576,0.0026532991,0.0018916641,0.000127044,0.0006101586,0.00016019058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007714718,0.00008744562,0.0008638421,0.00024436796,0.000037758993,0.0000056006193,0.000090139874,0.0002581378,0.00015209359],"category_scores_gemma":[0.0031651268,0.00006319112,0.00039595607,0.0006189114,0.00011636921,0.00006869341,0.000027391576,0.000496974,0.000025913963],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28571454,0.0034203466,0.213369,0.00006719552,0.0023826323,0.0004622223,0.0012737411,0.00018407723,0.3546532,0.000013592306,0.04260063,0.09585882],"study_design_scores_gemma":[0.009769508,0.01353901,0.8797575,0.00017828557,0.00018027704,0.00010153352,0.00028205285,0.000021435988,0.0019601863,0.000065664586,0.09407602,0.000068485504],"about_ca_topic_score_codex":0.000034127308,"about_ca_topic_score_gemma":0.000059655693,"teacher_disagreement_score":0.6663885,"about_ca_system_score_codex":0.0003252859,"about_ca_system_score_gemma":0.0012372144,"threshold_uncertainty_score":0.3789181},"labels":[],"label_agreement":null},{"id":"W4379283245","doi":"10.1200/jco.2023.41.16_suppl.2515","title":"Intestinal microbiome characterization in immune checkpoint inhibition (ICI) resistant disease.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Microbiome; Gastroenterology; Melanoma; Progressive disease; Adjuvant; Colorectal cancer; Immune system; Oncology; Disease; Cancer; Immunology; Cancer research; Bioinformatics; Biology","score_opus":0.09736325671866872,"score_gpt":0.4256533730893036,"score_spread":0.3282901163706349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806319,0.0002228818,0.000068280344,0.017657964,0.0009979694,0.0001602032,0.000009863451,0.000017783119,0.00023318188],"genre_scores_gemma":[0.99604475,0.0012274629,0.00027798326,0.0012736138,0.00066388224,0.000004221211,0.00006955518,0.000014879853,0.00042362243],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99672997,0.00024717444,0.0024951412,0.00013946043,0.00020236237,0.00018586632],"domain_scores_gemma":[0.9978455,0.00042356865,0.0012207226,0.0001270248,0.00020775045,0.00017547287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003688222,0.000097291406,0.0007376387,0.00031921826,0.000025240506,0.000008761705,0.00007337773,0.00017726031,0.00013816213],"category_scores_gemma":[0.0016897244,0.00007418069,0.0004034918,0.0005008129,0.00015231135,0.000103485785,0.00003346761,0.00052816357,0.00003250322],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04805512,0.0010813418,0.03159469,0.000085042295,0.00012631017,0.0018817298,0.00010238488,0.0000021232752,0.84837776,0.000026609643,0.0008323892,0.06783448],"study_design_scores_gemma":[0.0072947517,0.00368129,0.9535844,0.0005646264,0.00007691797,0.00015640674,0.00006191923,0.00006925491,0.0020781131,0.00013584005,0.032220937,0.000075562755],"about_ca_topic_score_codex":0.00001305223,"about_ca_topic_score_gemma":0.000012658677,"teacher_disagreement_score":0.9219897,"about_ca_system_score_codex":0.0002357006,"about_ca_system_score_gemma":0.0010070283,"threshold_uncertainty_score":0.30250007},"labels":[],"label_agreement":null},{"id":"W4379283389","doi":"10.1200/jco.2023.41.16_suppl.3110","title":"First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Melanoma; Internal medicine; Cancer; Hematology; Cohort; Dosing; Response Evaluation Criteria in Solid Tumors; Oncology; Gastroenterology; Pharmacology; Phases of clinical research; Toxicity; Cancer research","score_opus":0.05513052242782712,"score_gpt":0.3994851417478971,"score_spread":0.34435461932007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99728745,0.00024339919,0.0000011226688,0.00097022933,0.00055154,0.00089628133,0.000021738688,0.0000045201937,0.00002369223],"genre_scores_gemma":[0.9992943,0.00026534093,0.00005126183,0.00022630485,0.00010531905,0.000022173304,0.0000096394815,0.0000143066045,0.000011374167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965272,0.00025233702,0.0024169357,0.0002014341,0.00039621798,0.00020588537],"domain_scores_gemma":[0.9974428,0.0004305065,0.0016189198,0.00019097605,0.00022360748,0.00009318573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016230552,0.00015467302,0.0010709679,0.0002515263,0.00003698828,0.0000058378882,0.0001265476,0.00018165741,0.00003439673],"category_scores_gemma":[0.00029364548,0.00010249509,0.00013856111,0.0005472865,0.00020302403,0.00018774066,0.00005505838,0.00043229258,3.757219e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03400003,0.004416613,0.9279417,0.00007705157,0.00013674377,0.00006929026,0.000765371,0.0004842581,0.00026844168,0.0000025231607,0.00017522318,0.031662747],"study_design_scores_gemma":[0.062675714,0.015375098,0.91888654,0.00068697473,0.00010115994,0.0000052658766,0.00026614117,0.0004894137,0.00031353865,0.000011459945,0.0010975108,0.00009116073],"about_ca_topic_score_codex":0.0005819595,"about_ca_topic_score_gemma":0.0089354515,"teacher_disagreement_score":0.031571586,"about_ca_system_score_codex":0.0002665068,"about_ca_system_score_gemma":0.0003838749,"threshold_uncertainty_score":0.49861914},"labels":[],"label_agreement":null},{"id":"W4379283505","doi":"10.1200/jco.2023.41.16_suppl.tps2673","title":"A phase II study of durvalumab re-treatment +/- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Queen's University; McMaster University; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network; Juravinski Cancer Centre","funders":"AstraZeneca Canada","keywords":"Durvalumab; Medicine; Tolerability; Discontinuation; Adverse effect; Internal medicine; Oncology; Tremelimumab; Prednisone; Leukocytopenia; Toxicity; Cancer; Surgery; Nivolumab; Immunotherapy; Ipilimumab","score_opus":0.10086411216741632,"score_gpt":0.46395260846125325,"score_spread":0.36308849629383694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932607,0.00029234323,0.0000027896394,0.0037540938,0.0009075113,0.0015831498,0.000010909885,0.00001738085,0.00017111156],"genre_scores_gemma":[0.99795705,0.00085747807,0.00012696731,0.00033969144,0.00018177753,0.000028826958,0.000007597942,0.000027879614,0.00047271463],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.993574,0.0007613286,0.004513711,0.0003056759,0.0005147764,0.0003304782],"domain_scores_gemma":[0.99614453,0.0007091062,0.0021727358,0.00038620082,0.00033703778,0.00025038104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004036248,0.00023316959,0.0024051454,0.00037180952,0.000065475324,0.0000075313033,0.00022950124,0.00035498163,0.00015125982],"category_scores_gemma":[0.0013864221,0.00015604439,0.0006238407,0.000732135,0.00013492735,0.00010051617,0.00009700395,0.00062497036,0.000008374988],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18038777,0.09460063,0.1190967,0.000022502649,0.0023240156,0.0007576881,0.008422041,0.000014171535,0.00948431,0.0000017949562,0.00073763286,0.58415073],"study_design_scores_gemma":[0.1241095,0.22525945,0.6456199,0.00018255696,0.00013594475,0.000017454084,0.00079095404,0.000022681903,0.0012673474,0.00002497771,0.002466809,0.00010236709],"about_ca_topic_score_codex":0.0001903541,"about_ca_topic_score_gemma":0.0002565778,"teacher_disagreement_score":0.5840484,"about_ca_system_score_codex":0.0004698683,"about_ca_system_score_gemma":0.00083965674,"threshold_uncertainty_score":0.63633054},"labels":[],"label_agreement":null},{"id":"W4379283528","doi":"10.1200/jco.2023.41.16_suppl.2602","title":"Deciphering primary and acquired immunotherapy resistance with whole genome and transcriptome analysis (WGTA).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"University of Toronto","keywords":"Medicine; Internal medicine; Oncology; Melanoma; Immunotherapy; Cancer; Primary tumor; Cancer research; Metastasis","score_opus":0.06197621445913011,"score_gpt":0.3991467992697854,"score_spread":0.3371705848106553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98381674,0.0075709727,0.000396564,0.00715559,0.00018985152,0.00012968962,0.000005929555,0.0000187082,0.00071593054],"genre_scores_gemma":[0.9763365,0.015340427,0.0034466882,0.0029062044,0.00033623236,0.000004343821,0.0000065281083,0.000024988118,0.0015981233],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978463,0.00017032638,0.0013027173,0.00020265671,0.00026936358,0.00020865412],"domain_scores_gemma":[0.9981447,0.0006672354,0.00067771145,0.00016938579,0.00014281338,0.00019818236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002499628,0.00013017764,0.0013141934,0.00025190113,0.000060715545,0.000018501154,0.00009558282,0.00020156146,0.000058718248],"category_scores_gemma":[0.00010671635,0.00008733552,0.0003316375,0.00065851054,0.00035695973,0.00011555466,0.000017417467,0.00029003038,0.0000018697023],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15699638,0.0009983041,0.1835796,0.00027071906,0.019772286,0.0022152371,0.0021276185,0.00003949974,0.2698053,0.00003632423,0.0017735166,0.36238518],"study_design_scores_gemma":[0.009830301,0.0038371189,0.83103883,0.00007061518,0.00082776777,0.00013908744,0.00019065429,0.00002535828,0.000033909593,0.00004441262,0.15386283,0.000099087694],"about_ca_topic_score_codex":0.000009745826,"about_ca_topic_score_gemma":0.000076786666,"teacher_disagreement_score":0.64745927,"about_ca_system_score_codex":0.00008643607,"about_ca_system_score_gemma":0.0004299075,"threshold_uncertainty_score":0.3561439},"labels":[],"label_agreement":null},{"id":"W4379283554","doi":"10.1200/jco.2023.41.16_suppl.2502","title":"Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Pharmacodynamics; Cancer; Response Evaluation Criteria in Solid Tumors; Lung cancer; Oncology; Nausea; Pancreatic cancer; Toxicity; Chills; Tolerability; Phases of clinical research; Gastroenterology; Pharmacokinetics","score_opus":0.055033909224283875,"score_gpt":0.43084518347711925,"score_spread":0.3758112742528354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99733925,0.000116368676,8.39059e-7,0.00057287083,0.0011261374,0.00064218946,0.000030992684,0.00001270747,0.00015864926],"genre_scores_gemma":[0.99887323,0.00013265565,0.000118542775,0.00025802903,0.0005214463,0.000010850185,0.00003473724,0.000028428862,0.00002209469],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9940492,0.00033573268,0.0044384166,0.00032384324,0.0005564657,0.00029634644],"domain_scores_gemma":[0.9954806,0.0013406571,0.0024313272,0.0003139819,0.00025988472,0.00017354624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026845776,0.00020362678,0.0019228723,0.00042925338,0.00003433679,0.000005351493,0.00020827063,0.00028202558,0.000058902973],"category_scores_gemma":[0.001363244,0.00015092344,0.00026116127,0.0005325356,0.00019812034,0.00014885551,0.000060943054,0.001002387,0.000005114373],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45964962,0.029926505,0.42556834,0.000039263163,0.0007954883,0.0012096288,0.0025072843,0.00014668547,0.0037849084,8.300839e-7,0.0009964773,0.075374976],"study_design_scores_gemma":[0.16797744,0.07849565,0.7501918,0.0006108461,0.000092710856,0.000004918042,0.0007258704,0.00004862259,0.00042492736,0.000024088362,0.0012681743,0.0001349098],"about_ca_topic_score_codex":0.00028630058,"about_ca_topic_score_gemma":0.0006068199,"teacher_disagreement_score":0.3246235,"about_ca_system_score_codex":0.00029726914,"about_ca_system_score_gemma":0.0007913395,"threshold_uncertainty_score":0.61544794},"labels":[],"label_agreement":null},{"id":"W4379283603","doi":"10.1200/jco.2023.41.16_suppl.tps2680","title":"Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): Phase 3, investigator-initiated, randomized, placebo-controlled study to evaluate the efficacy and safety of abatacept compared to placebo in hospitalized patients with immune checkpoint inhibitor associated myocarditis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Abatacept; Placebo; Internal medicine; Mace; Myocarditis; Adverse effect; Population; Myocardial infarction; Rituximab; Pathology; Percutaneous coronary intervention","score_opus":0.049994155593255936,"score_gpt":0.392043112508057,"score_spread":0.3420489569148011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760055,0.0006232777,0.000057781057,0.0059920875,0.002194429,0.014738893,0.00024027728,0.00006190102,0.00008587898],"genre_scores_gemma":[0.99678093,0.00041634386,0.00028909472,0.0010845296,0.0005317825,0.0005551036,0.00015623626,0.00010323987,0.0000827301],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98323625,0.005056558,0.008716357,0.0006870128,0.0014681183,0.0008356931],"domain_scores_gemma":[0.97770333,0.014275198,0.004645226,0.00058185775,0.0019704245,0.00082393223],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03450967,0.00066907174,0.008107866,0.0006865791,0.0002195366,0.00006297948,0.0004764762,0.0005516525,0.00006670173],"category_scores_gemma":[0.05321697,0.00042620485,0.0018713295,0.0014507754,0.000689767,0.00021907734,0.00025028564,0.0013404051,0.000011217999],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95475066,0.008302046,0.014837197,0.00006063612,0.0094645405,0.00015724103,0.002754903,0.0001672424,0.0020325244,0.000001934233,0.0031789567,0.0042921253],"study_design_scores_gemma":[0.65054464,0.027364232,0.3163195,0.00093944295,0.0020628478,0.000014481708,0.0011840448,0.00025947497,0.00046206507,0.000021786951,0.0004871005,0.00034041214],"about_ca_topic_score_codex":0.00024534596,"about_ca_topic_score_gemma":0.00017067276,"teacher_disagreement_score":0.30420604,"about_ca_system_score_codex":0.00088790315,"about_ca_system_score_gemma":0.0022203575,"threshold_uncertainty_score":0.999819},"labels":[],"label_agreement":null},{"id":"W4379283755","doi":"10.1200/jco.2023.41.16_suppl.e13593","title":"A bibliometric analysis of immuno-oncology research: Is a new global leader emerging?","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; China; Cancer; Oncology; Library science; Internal medicine; Political science","score_opus":0.47145745755442675,"score_gpt":0.6163869865647756,"score_spread":0.1449295290103489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9436153,0.005686116,0.000104525745,0.04350228,0.0016112833,0.00018505412,0.000015284402,0.000019408535,0.005260751],"genre_scores_gemma":[0.96928275,0.020596676,0.0015280121,0.004725533,0.0014240602,0.0000037212808,0.000007986298,0.000021941009,0.0024093504],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9936361,0.000945721,0.0035531898,0.00026540615,0.0011059598,0.0004936575],"domain_scores_gemma":[0.9913511,0.0045370203,0.0019421754,0.00038063305,0.0013164934,0.0004725646],"candidate_categories":["bibliometrics","insufficient_payload"],"consensus_categories":["bibliometrics"],"category_scores_codex":[0.01511479,0.00014381361,0.0024942744,0.046733707,0.000056363006,0.000011831136,0.00041414952,0.000658422,0.0015049333],"category_scores_gemma":[0.0071134386,0.00010474267,0.0018615662,0.19315,0.00057803106,0.00010225265,0.00012709986,0.00105656,0.00005720283],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015805893,0.0010509632,0.10148842,0.000028473394,0.009813891,0.00053320854,0.00034867116,0.0000122714455,0.0010675873,0.000032812663,0.17480677,0.695011],"study_design_scores_gemma":[0.0071498854,0.012571309,0.54663604,0.000048569254,0.0017822767,0.0001210071,0.00058399054,0.00014217682,0.000069550166,0.0002587097,0.43056527,0.00007124373],"about_ca_topic_score_codex":0.0004459424,"about_ca_topic_score_gemma":0.00015331927,"teacher_disagreement_score":0.6949398,"about_ca_system_score_codex":0.0004973088,"about_ca_system_score_gemma":0.0056732027,"threshold_uncertainty_score":0.9999637},"labels":[],"label_agreement":null},{"id":"W4379284260","doi":"10.1200/jco.2023.41.16_suppl.581","title":"Characteristics associated with spatially resolved immune landscapes in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Breast Cancer Research Foundation","keywords":"Triple-negative breast cancer; Medicine; Immune system; Breast cancer; Tumor-infiltrating lymphocytes; CD8; Cohort; Oncology; Stromal cell; Internal medicine; Cancer research; Immunology; Cancer","score_opus":0.06959085374094032,"score_gpt":0.4230436699381012,"score_spread":0.3534528161971609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379284260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841052,0.00023879018,0.000002131842,0.013903221,0.000918307,0.0005404757,0.000033940774,0.0000071816826,0.00025074094],"genre_scores_gemma":[0.99171335,0.005996792,0.000035043762,0.0012688092,0.0006969893,0.000021933034,0.000009579839,0.000013815279,0.00024367543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959497,0.00096954114,0.0023419617,0.0001680272,0.00033446573,0.00023628959],"domain_scores_gemma":[0.9927019,0.005217208,0.0016659711,0.00013100945,0.00019698401,0.00008691627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009097066,0.00013263476,0.0013818524,0.00017939128,0.000034441407,0.000014633119,0.0001521611,0.00033642363,0.00018954187],"category_scores_gemma":[0.0035674635,0.000072967974,0.00021879436,0.0004999619,0.00021305581,0.00006462457,0.00002600666,0.001105823,0.0000030839387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36261168,0.0009840118,0.56971174,0.000014367505,0.0005158559,0.0007832108,0.00046598134,0.0000020850682,0.000058509402,0.0000021403237,0.00087903824,0.0639714],"study_design_scores_gemma":[0.11342845,0.007186155,0.87710977,0.00026860033,0.00020219419,0.0000803417,0.00022414804,0.00011115911,0.000002954309,0.00003146721,0.0012780399,0.00007674051],"about_ca_topic_score_codex":0.0002987475,"about_ca_topic_score_gemma":0.002856862,"teacher_disagreement_score":0.30739802,"about_ca_system_score_codex":0.00014894389,"about_ca_system_score_gemma":0.0014296606,"threshold_uncertainty_score":0.4804312},"labels":[],"label_agreement":null},{"id":"W4379328412","doi":"10.1200/jco.2023.41.16_suppl.573","title":"Phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Ottawa Hospital; University of Ottawa; McMaster University; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Oncology; Biopsy; Internal medicine; Cancer; Pathology","score_opus":0.14429373958511077,"score_gpt":0.49485442827497106,"score_spread":0.3505606886898603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379328412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99299437,0.0009224651,0.000006233698,0.0021006386,0.0020232226,0.0018760982,0.000014255833,0.0000066579446,0.00005604038],"genre_scores_gemma":[0.996082,0.002550545,0.000083205276,0.00040788436,0.0007247849,0.000043494838,0.0000020940463,0.000015405994,0.00009059849],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9924345,0.0027252226,0.003943699,0.0001733431,0.0004905764,0.00023267428],"domain_scores_gemma":[0.98743373,0.008243702,0.0035831034,0.00023954202,0.00031219985,0.00018774057],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02456397,0.00016122757,0.002826284,0.00028147158,0.000056612927,0.000007133484,0.00019938206,0.0002947699,0.00008308647],"category_scores_gemma":[0.009545914,0.00009580577,0.0007337797,0.00043857243,0.00080780766,0.00011471655,0.00008860171,0.00097152765,3.9363678e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8728966,0.002435732,0.0013071286,0.00010750677,0.00073703827,0.00010924635,0.00045478262,0.000003499234,0.014557902,0.0000104655965,0.00015107032,0.10722904],"study_design_scores_gemma":[0.89515656,0.064507134,0.037481736,0.00038748616,0.00049304665,0.000044986966,0.00015134923,0.00018698192,0.0012154253,0.0001205921,0.00017787762,0.000076841854],"about_ca_topic_score_codex":0.0005616821,"about_ca_topic_score_gemma":0.00008208232,"teacher_disagreement_score":0.1071522,"about_ca_system_score_codex":0.00014389,"about_ca_system_score_gemma":0.003993896,"threshold_uncertainty_score":0.9987971},"labels":[],"label_agreement":null},{"id":"W4379332762","doi":"10.1200/jco.2023.41.16_suppl.4073","title":"Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; STRIDE; Regimen; Adverse effect; Internal medicine; Oncology; Surgery; Gastroenterology; Physical medicine and rehabilitation","score_opus":0.11774840846087462,"score_gpt":0.43704786002037305,"score_spread":0.31929945155949846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379332762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965181,0.00032554558,0.000009731381,0.0016042385,0.00047048146,0.0009183178,0.000012305837,0.000009403282,0.00013188916],"genre_scores_gemma":[0.9988642,0.00033854827,0.000048011952,0.00037220863,0.00019616622,0.000022612634,0.000017443044,0.000025370848,0.000115486146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939002,0.0013231551,0.0033994608,0.00025083948,0.0007457679,0.00038061675],"domain_scores_gemma":[0.9960158,0.0015512318,0.0016922384,0.00037454325,0.00022864623,0.00013754219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008750144,0.00020734654,0.0017105503,0.00047093496,0.000034491244,0.0000037840036,0.00039939763,0.00025698135,0.0001387217],"category_scores_gemma":[0.0008757529,0.00012280693,0.0004445731,0.0009246837,0.00015026281,0.0001281367,0.000062123436,0.0011169098,0.000009101119],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060885042,0.006477391,0.91940486,0.000054957858,0.0003432339,0.0054396037,0.0015092564,0.0000321038,0.0006277733,0.0000011206713,0.00015316428,0.0050714836],"study_design_scores_gemma":[0.10046895,0.032904442,0.8575121,0.0002332045,0.00018499805,0.00017435862,0.0062903943,0.00086047914,0.00007813247,0.000011320434,0.001166975,0.00011464161],"about_ca_topic_score_codex":0.0021248802,"about_ca_topic_score_gemma":0.0016854191,"teacher_disagreement_score":0.061892767,"about_ca_system_score_codex":0.00034234623,"about_ca_system_score_gemma":0.002108907,"threshold_uncertainty_score":0.5007921},"labels":[],"label_agreement":null},{"id":"W4379335619","doi":"10.1200/jco.2023.41.16_suppl.5500","title":"KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Carboplatin; Chemotherapy; Cervical cancer; Placebo; Internal medicine; Oncology; Interim analysis; Gemcitabine; Cancer; Cisplatin; Surgery; Randomized controlled trial; Immunotherapy; Pathology","score_opus":0.30500281861651696,"score_gpt":0.5088345386815675,"score_spread":0.20383172006505051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379335619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98025715,0.0011889689,0.00013029444,0.0127182435,0.0018218608,0.0034581595,0.00032125448,0.00002141575,0.00008266663],"genre_scores_gemma":[0.9755306,0.020230602,0.00088327035,0.0006694833,0.0014732522,0.00019704804,0.0000897788,0.00006612803,0.0008598241],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9919514,0.000809223,0.0055750655,0.0004963426,0.0007402735,0.00042771557],"domain_scores_gemma":[0.9837626,0.010319041,0.0044194045,0.00045073908,0.00071828143,0.00032991156],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004745277,0.00041840892,0.005440368,0.00032161883,0.000075989505,0.000013712854,0.00032704422,0.00035413765,0.0004901985],"category_scores_gemma":[0.001244558,0.00025748237,0.0030133354,0.000443589,0.00039891448,0.00009302659,0.000030272206,0.0004427287,0.000002580033],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8664819,0.021669706,0.00064117444,0.00011274264,0.01158191,0.00013192036,0.0020608176,0.00014938791,0.0001471928,0.0000036526078,0.0017193469,0.09530027],"study_design_scores_gemma":[0.8455556,0.13014264,0.0020110242,0.00024855096,0.0031725203,0.000042290452,0.00071493105,0.0020340101,0.00032599823,0.000059394366,0.015497522,0.00019551996],"about_ca_topic_score_codex":0.00091352855,"about_ca_topic_score_gemma":0.0010727941,"teacher_disagreement_score":0.10847294,"about_ca_system_score_codex":0.00041801378,"about_ca_system_score_gemma":0.0020620578,"threshold_uncertainty_score":0.9999877},"labels":[],"label_agreement":null},{"id":"W4379336689","doi":"10.1200/jco.2023.41.16_suppl.tps5612","title":"ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; London Health Sciences Centre; Hamilton Health Sciences","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Internal medicine; Ovarian cancer; Oncology; Chemotherapy; Fallopian tube; Phases of clinical research; Cancer; Fallopian tube cancer; Carboplatin; Serous carcinoma; Response Evaluation Criteria in Solid Tumors; Endometrial cancer; Immunotherapy; Gynecology; Adverse effect; Cisplatin","score_opus":0.065304763447694,"score_gpt":0.42476654696221133,"score_spread":0.35946178351451735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379336689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968599,0.000046027308,0.000010576221,0.0013543852,0.00061880786,0.00095267553,0.000027150256,0.000010960792,0.00011952041],"genre_scores_gemma":[0.9984808,0.00024790966,0.00039799197,0.00048530515,0.00022174612,0.000031426247,0.000018108314,0.000033594544,0.00008312145],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9960533,0.00041130322,0.0022490774,0.00029151596,0.00067662704,0.00031820845],"domain_scores_gemma":[0.99703157,0.00085648143,0.0013859585,0.00022527379,0.00034074925,0.00015993886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014622279,0.00022245674,0.0014208438,0.00032768547,0.00003455851,0.00001114218,0.00018260018,0.00025138943,0.0001513164],"category_scores_gemma":[0.00031355958,0.000140428,0.00013595066,0.000592374,0.00020600187,0.00014851184,0.000031389292,0.0007604885,0.0000013595842],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57033795,0.01385718,0.3556135,0.0000604712,0.000589965,0.00058194,0.0011548898,0.000047829482,0.0005116871,0.0000022923866,0.00014270733,0.05709955],"study_design_scores_gemma":[0.2756224,0.06635255,0.6551873,0.00027044068,0.00013165844,0.000008865737,0.00058064493,0.00015989781,0.000055354347,0.0000020560428,0.0015175948,0.000111241985],"about_ca_topic_score_codex":0.00065687596,"about_ca_topic_score_gemma":0.004756926,"teacher_disagreement_score":0.29957378,"about_ca_system_score_codex":0.0005574967,"about_ca_system_score_gemma":0.0017633487,"threshold_uncertainty_score":0.57264876},"labels":[],"label_agreement":null},{"id":"W4379338513","doi":"10.1200/jco.2023.41.16_suppl.e21524","title":"Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: A retrospective observational cohort study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Pembrolizumab; Progressive disease; Oncology; Response Evaluation Criteria in Solid Tumors; Context (archaeology); Retrospective cohort study; Cohort; Cancer; Immunotherapy; Disease","score_opus":0.05065080828758043,"score_gpt":0.41441770345213397,"score_spread":0.3637668951645535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379338513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98998404,0.00006074227,0.0000071264058,0.008137797,0.00085995597,0.00075094623,0.000003207093,0.000014467864,0.00018175054],"genre_scores_gemma":[0.9980455,0.000032275104,0.0006487168,0.0008531454,0.00022814113,0.000018975476,0.000004223275,0.000018371496,0.00015062401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963147,0.0004511119,0.0022108094,0.00022721256,0.0005739605,0.00022222174],"domain_scores_gemma":[0.99705285,0.0009994068,0.001013438,0.00018293936,0.00058193563,0.00016944545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007829184,0.00012737261,0.0010751974,0.0003217055,0.000036501642,0.000007445423,0.00012002352,0.000106152664,0.000053377833],"category_scores_gemma":[0.004041582,0.00008852601,0.00024567606,0.0007526054,0.00010029065,0.00012824699,0.000053497028,0.0006276185,0.000012208503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14310193,0.0015285711,0.8370129,0.0000035601454,0.00024816132,0.00032344594,0.00025923684,0.000015076819,0.0006560352,8.2863943e-7,0.0003890001,0.016461251],"study_design_scores_gemma":[0.025191722,0.023548227,0.9473033,0.00013306108,0.00007470802,0.00001802795,0.00041114318,0.000010677681,0.00004887441,0.00002249066,0.0031452987,0.000092492446],"about_ca_topic_score_codex":0.000036570687,"about_ca_topic_score_gemma":0.000053201846,"teacher_disagreement_score":0.117910214,"about_ca_system_score_codex":0.0006502677,"about_ca_system_score_gemma":0.0010886752,"threshold_uncertainty_score":0.4838443},"labels":[],"label_agreement":null},{"id":"W4379345743","doi":"10.1200/jco.2023.41.16_suppl.e18030","title":"Combinatorial immune biomarkers of efficacy on buparlisib and paclitaxel in patients with SCCHN: BERIL-1 sub-analysis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Immune system; Oncology; Internal medicine; Paclitaxel; CDKN2A; Chemotherapy; Cancer; Immunology","score_opus":0.05026273937400142,"score_gpt":0.40831075219027435,"score_spread":0.3580480128162729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379345743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965441,0.00022857712,0.000003505479,0.0016213651,0.0009629191,0.00022409872,0.000006974826,0.000007144769,0.00040131956],"genre_scores_gemma":[0.9988601,0.00050926005,0.000105158964,0.00030644846,0.00017319852,0.0000017376356,0.000010356329,0.000013392219,0.000020329155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99646515,0.00035199238,0.0023152926,0.00019123046,0.00046506137,0.00021128991],"domain_scores_gemma":[0.99569994,0.002069375,0.001558272,0.00021599275,0.00028254458,0.00017389354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037308245,0.00013872131,0.0017946431,0.0005618235,0.000024519812,0.000006011766,0.00012301133,0.00028984636,0.000042130625],"category_scores_gemma":[0.0014301146,0.0000905142,0.00052180485,0.001060171,0.00036329162,0.00006339044,0.000035161236,0.0005186246,0.00000342134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12190674,0.0033369532,0.81076837,0.000034699562,0.0055049714,0.00015162112,0.00011206729,0.000014976821,0.00044790827,0.00007462489,0.0009792519,0.0566678],"study_design_scores_gemma":[0.03796463,0.020713583,0.937532,0.00012503455,0.0009214323,0.000006551511,0.000068829715,0.000019144385,0.00013190402,0.00007591192,0.0023570326,0.00008396271],"about_ca_topic_score_codex":0.000055511216,"about_ca_topic_score_gemma":0.000029667772,"teacher_disagreement_score":0.1267636,"about_ca_system_score_codex":0.00010614724,"about_ca_system_score_gemma":0.00048566706,"threshold_uncertainty_score":0.3691062},"labels":[],"label_agreement":null},{"id":"W4379345905","doi":"10.1200/jco.2023.41.16_suppl.8561","title":"Incidence, outcomes, and risk factors of acute immune checkpoint inhibitor (ICI) pneumonitis post-chemoradiation with durvalumab for patients with locally advanced non-small cell lung cancer (LA-NSCLC): A population-based multicenter study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Durvalumab; Medicine; Pneumonitis; Internal medicine; Lung cancer; Radiation therapy; Oncology; Cancer; Lung; Pembrolizumab; Immunotherapy","score_opus":0.021213238515244634,"score_gpt":0.36598598011295885,"score_spread":0.3447727415977142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379345905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99716914,0.00010069811,0.00020314683,0.0005087447,0.00045386865,0.0014656677,0.00007704701,0.0000122157935,0.000009475654],"genre_scores_gemma":[0.997508,0.00033207345,0.0017189828,0.00019541885,0.000089613975,0.000041955118,0.000040152052,0.000035164834,0.000038639795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969419,0.0002264519,0.0019480482,0.00024411167,0.0004122525,0.00022722912],"domain_scores_gemma":[0.9943018,0.0016716828,0.0027968336,0.00017582158,0.0008838486,0.00017003888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013398485,0.00021594348,0.0012885568,0.0002155378,0.00006879859,0.000011522851,0.0001089977,0.00020683638,0.000013716933],"category_scores_gemma":[0.0005334499,0.00013243686,0.0003131301,0.00025107455,0.00013999599,0.0001398978,0.000026506557,0.00044447384,3.3805162e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04424923,0.0017968405,0.9381836,0.00010317475,0.0012314413,0.00004123567,0.00048665956,0.00015860732,0.00045961046,1.0222885e-7,0.000017068725,0.013272449],"study_design_scores_gemma":[0.054415707,0.024047347,0.9179469,0.00036476305,0.0014098557,0.0000033106658,0.00045118344,0.0008484861,0.00032200234,0.0000013153112,0.000048947004,0.00014022116],"about_ca_topic_score_codex":0.0007018835,"about_ca_topic_score_gemma":0.00052730076,"teacher_disagreement_score":0.022250507,"about_ca_system_score_codex":0.00022906574,"about_ca_system_score_gemma":0.0011293816,"threshold_uncertainty_score":0.54006183},"labels":[],"label_agreement":null},{"id":"W4379507891","doi":"10.1002/cac2.12447","title":"Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer","year":2023,"lang":"en","type":"letter","venue":"Cancer Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"Ligue Contre le Cancer","keywords":"Oncology; Medicine; Internal medicine; Breast cancer; Pembrolizumab; Cancer; Predictive marker; Immunotherapy; Gene signature; Biology; Gene expression","score_opus":0.015106574438103298,"score_gpt":0.30304266497191407,"score_spread":0.28793609053381075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379507891","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06467249,0.06679438,0.000030135127,0.8416619,0.00063160836,0.0038484975,0.022156905,0.00013508034,0.00006900874],"genre_scores_gemma":[0.21349436,0.18037498,0.001802196,0.5862154,0.0015393941,0.006246928,0.0029654943,0.00082864315,0.0065326295],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99760085,0.00023015785,0.0007470516,0.0006078154,0.00034399444,0.00047012937],"domain_scores_gemma":[0.9961127,0.0008347515,0.00055588054,0.001971722,0.00045471668,0.000070251066],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031723082,0.00054986204,0.00096690847,0.0003860776,0.00018392205,0.000034030367,0.0007647692,0.0010186646,0.0004855844],"category_scores_gemma":[0.000039094073,0.0004896055,0.0003138608,0.0006705408,0.0007405426,0.0001261597,0.00014438959,0.0014376866,9.966967e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05359428,0.0003719262,0.013565227,0.0010521827,0.0052097067,0.000034056586,0.012938023,0.00007696559,0.05098967,0.000017945435,0.7856518,0.076498196],"study_design_scores_gemma":[0.018457573,0.00078339747,0.42242298,0.005819391,0.000491975,0.00013525429,0.0010726779,0.00044992872,0.0037692843,0.00092070835,0.5444308,0.0012460047],"about_ca_topic_score_codex":0.0038698195,"about_ca_topic_score_gemma":0.0017193559,"teacher_disagreement_score":0.40885776,"about_ca_system_score_codex":0.00094805734,"about_ca_system_score_gemma":0.0010347294,"threshold_uncertainty_score":0.99975556},"labels":[],"label_agreement":null},{"id":"W4379653153","doi":"10.1136/annrheumdis-2023-eular.6448","title":"AB1768-HPR SAFETY AND EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH RHEUMATIC AUTOIMMUNE DISEASE: EXPERIENCE FROM THE CANADIAN RESEARCH GROUP OF RHEUMATOLOGY IN IMMUNO-ONCOLOGY (CANRIO)","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Western University; Dalhousie University; McGill University; University of Calgary; Université de Montréal; University of Alberta; University of British Columbia","funders":"Bristol-Myers Squibb","keywords":"Medicine; Psoriatic arthritis; Immunosuppression; Internal medicine; Ankylosing spondylitis; Rheumatology; Polymyalgia rheumatica; Rheumatoid arthritis; Cohort; Prospective cohort study; Retrospective cohort study; Oncology; Disease","score_opus":0.03664909965736421,"score_gpt":0.3305346509348274,"score_spread":0.2938855512774632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379653153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98815835,0.007157044,7.068852e-7,0.0030609209,0.00014081268,0.0012545036,0.00016912339,0.000013513568,0.000045054978],"genre_scores_gemma":[0.99653864,0.0031626648,0.00001887291,0.000062782885,0.0000032233881,0.000082508464,0.00008382354,0.000027177384,0.000020297868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99643743,0.000594045,0.00145903,0.0003053098,0.00067711127,0.00052705273],"domain_scores_gemma":[0.9966391,0.001505608,0.00054388365,0.00092097983,0.00021962037,0.00017081782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013351325,0.00022906864,0.00090618385,0.00043524202,0.00016275438,0.000014613473,0.0005331944,0.00010226959,0.000100486664],"category_scores_gemma":[0.0015965434,0.00013796131,0.0002006807,0.0014284139,0.0015288723,0.000108402724,0.0002197115,0.00025032167,0.0000024763096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011129825,0.0011016119,0.94260925,0.0008220738,0.00043835177,0.000008897916,0.010369976,0.00005843603,0.00035271893,0.00021635563,0.00026468106,0.03262782],"study_design_scores_gemma":[0.0051305327,0.00039215237,0.9853384,0.005712417,0.00004465111,0.0000017581203,0.0024025121,0.00017296727,0.00021841895,0.00036181597,0.0000917221,0.0001326733],"about_ca_topic_score_codex":0.2360183,"about_ca_topic_score_gemma":0.042536113,"teacher_disagreement_score":0.19348219,"about_ca_system_score_codex":0.00017557196,"about_ca_system_score_gemma":0.0010386234,"threshold_uncertainty_score":0.9749351},"labels":[],"label_agreement":null},{"id":"W4379662223","doi":"10.1200/jco.2023.41.17_suppl.lba100","title":"KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Placebo; Randomization; Tolerability; Lung cancer; Population; Internal medicine; Stage (stratigraphy); Oncology; Surgery; Clinical trial; Cancer; Adverse effect; Pathology; Immunotherapy","score_opus":0.1590405190309529,"score_gpt":0.48809078074049345,"score_spread":0.32905026170954055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379662223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98915726,0.00028718243,0.0011474127,0.0027392872,0.0013445569,0.0049591493,0.000047759422,0.000048693877,0.00026867195],"genre_scores_gemma":[0.99184406,0.0010016445,0.00047410306,0.0009378056,0.00078376627,0.00022012745,0.000023177201,0.00008024834,0.0046350732],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99305636,0.0010137461,0.0041820253,0.00047873062,0.0007756307,0.0004935158],"domain_scores_gemma":[0.9844734,0.010957647,0.00322397,0.00037679757,0.00057325285,0.0003949104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009193695,0.00038537133,0.0037262214,0.00050536625,0.00014991146,0.000039042236,0.00028292573,0.00068466243,0.00041445182],"category_scores_gemma":[0.0030493715,0.00024055634,0.0009958755,0.0005977463,0.0004670811,0.00018429157,0.000043701948,0.0009297668,0.000003914456],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95581114,0.004272858,0.0007157712,0.00017420965,0.0023356008,0.00028320524,0.0008754626,0.000056601555,0.0013200875,0.0000036364675,0.011156799,0.022994598],"study_design_scores_gemma":[0.8892904,0.09058868,0.00078945915,0.00019712852,0.0009229418,0.00012215995,0.0011078726,0.0018374118,0.00084549625,0.00001562163,0.014049272,0.00023356371],"about_ca_topic_score_codex":0.00020675204,"about_ca_topic_score_gemma":0.00035915422,"teacher_disagreement_score":0.086315826,"about_ca_system_score_codex":0.00032683706,"about_ca_system_score_gemma":0.0031268843,"threshold_uncertainty_score":0.9809603},"labels":[],"label_agreement":null},{"id":"W4379768913","doi":"10.1001/jamaoncol.2023.1374","title":"Changes to Primary End Points in Randomized Clinical Trials on Immune Checkpoint Inhibitors in Urothelial, Renal Cell, and Lung Cancers","year":2023,"lang":"en","type":"review","venue":"JAMA Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Oncology; Clinical trial; Nivolumab; Immune checkpoint; Internal medicine; Endpoint Determination; Urothelial cancer; Immunotherapy; Cancer; Bladder cancer","score_opus":0.1272674042778694,"score_gpt":0.4600022332855313,"score_spread":0.33273482900766194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379768913","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018211415,0.9792099,0.0000021077437,0.00657101,0.0022926186,0.008354119,0.00008170958,0.000051276573,0.0016161151],"genre_scores_gemma":[0.000034616,0.99243164,0.00013380594,0.0031529553,0.0013819456,0.001758736,0.00012390649,0.000103049446,0.0008793186],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9868091,0.007066942,0.0043153563,0.00089393265,0.00033784716,0.00057687645],"domain_scores_gemma":[0.98676604,0.011094897,0.0014209363,0.00045412875,0.000045864206,0.0002181077],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.03366315,0.00058646034,0.010632473,0.001239319,0.000036906862,0.000029314051,0.00022242275,0.0013861159,0.00018875941],"category_scores_gemma":[0.00536221,0.00041990148,0.0013218791,0.0007992153,0.00033724125,0.00003643736,0.00016665505,0.0014371043,0.00004531511],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12602058,0.00021541514,0.000007972708,0.0054020504,0.0005218238,0.000351373,0.0002868039,2.687292e-7,0.00015895546,0.0000042939823,0.0042431797,0.8627873],"study_design_scores_gemma":[0.16772933,0.0014724288,0.00013405358,0.022959456,0.000838579,0.000047480462,0.000053939166,0.0000044006442,0.000050371746,0.000012128929,0.8063414,0.00035644262],"about_ca_topic_score_codex":0.0016425638,"about_ca_topic_score_gemma":0.0019865495,"teacher_disagreement_score":0.8624309,"about_ca_system_score_codex":0.002731046,"about_ca_system_score_gemma":0.0028477765,"threshold_uncertainty_score":0.9999103},"labels":[],"label_agreement":null},{"id":"W4379780265","doi":"10.1126/science.abo2296","title":"A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers","year":2023,"lang":"en","type":"article","venue":"Science","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Agence Nationale de la Recherche","keywords":"Addressin; Immunology; Immunosuppression; Biology; Immune system; ABX test; Immunosurveillance; Cancer research; Immune checkpoint; Integrin; Receptor; Immunotherapy","score_opus":0.013252377214394755,"score_gpt":0.28858018924480633,"score_spread":0.27532781203041157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379780265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961246,0.0004225031,0.000021616996,0.0011317332,0.00085013994,0.00027330173,0.0000050672293,0.00019231546,0.0009786707],"genre_scores_gemma":[0.9967287,0.00014543187,0.0007672295,0.00042603494,0.00005906777,0.000012850514,0.0000073832884,0.000013937271,0.001839374],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985851,0.000016636375,0.00021149628,0.00041219025,0.0003385043,0.00043605815],"domain_scores_gemma":[0.9992483,0.000035945366,0.00008056201,0.0003506669,0.00015482347,0.00012969298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005023194,0.00013690055,0.00017996036,0.00026254417,0.00023232626,0.000054959106,0.00029134913,0.000042982843,0.00016222535],"category_scores_gemma":[0.0001171967,0.00011104377,0.000083883504,0.002327617,0.0009173303,0.000138869,0.00011392782,0.00014232338,0.00018342446],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023810849,0.000017242191,0.0002905752,0.000027891458,0.000018647266,0.00004697368,0.0015513048,0.000017266431,0.9839201,0.0000025075542,0.0013863709,0.012482997],"study_design_scores_gemma":[0.00094224233,0.00020696624,0.03674805,0.00027894627,0.000017957125,0.00007424452,0.00035634974,0.0011773844,0.9501028,0.000040154133,0.009883576,0.00017133972],"about_ca_topic_score_codex":0.00065519684,"about_ca_topic_score_gemma":0.000031841686,"teacher_disagreement_score":0.03645748,"about_ca_system_score_codex":0.00048290714,"about_ca_system_score_gemma":0.00083298725,"threshold_uncertainty_score":0.45282337},"labels":[],"label_agreement":null},{"id":"W4379797966","doi":"10.1136/annrheumdis-2023-eular.1018","title":"POS1567 OUTCOMES AND PREDICTORS OF CHRONIC IMMUNE CHECKPOINT INHIBITOR INDUCED INFLAMMATORY ARTHRITIS: DATA FROM THE CANADIAN RESEARCH GROUP OF RHEUMATOLOGY IN IMMUNO-ONCOLOGY (CANRIO) RETROSPECTIVE COHORT","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; University of Alberta; Université de Montréal; Western University; University of British Columbia; McGill University","funders":"National Institutes of Health","keywords":"Medicine; Rheumatology; Internal medicine; Retrospective cohort study; Oncology; Inflammatory arthritis; Arthritis; Cohort; Ipilimumab; Immunology; Immunotherapy; Cancer","score_opus":0.0665424352592655,"score_gpt":0.35586201548970237,"score_spread":0.28931958023043686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379797966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813905,0.012401718,1.5609629e-7,0.0039818464,0.00033767754,0.001037587,0.0007536135,0.000017168772,0.00007975816],"genre_scores_gemma":[0.9898045,0.0098365415,0.000005147987,0.00006548164,0.000018990497,0.00006683747,0.00015926814,0.000024105062,0.000019125155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970333,0.0005197225,0.0011060211,0.00032350133,0.00058818655,0.00042929465],"domain_scores_gemma":[0.996804,0.0009986322,0.00047067154,0.0013618984,0.00023899815,0.00012581875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022324605,0.00018617888,0.0009214759,0.0003271459,0.00014470397,0.0000142295585,0.0007276392,0.00015775887,0.00009823007],"category_scores_gemma":[0.0020279747,0.00011971283,0.00017274606,0.000726457,0.0011864397,0.0001258813,0.00047166616,0.0003050086,0.0000032644843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007484495,0.0002112864,0.9830285,0.00032579128,0.0011795238,0.000008696005,0.0013578006,0.0000013296369,0.003565741,0.00011571449,0.0022203783,0.007236795],"study_design_scores_gemma":[0.0020886844,0.0004076136,0.99107975,0.0025067104,0.000071259106,0.000008549283,0.0013440382,0.000089253794,0.0015632631,0.00062211964,0.000120194156,0.00009857262],"about_ca_topic_score_codex":0.27308565,"about_ca_topic_score_gemma":0.24030104,"teacher_disagreement_score":0.032784615,"about_ca_system_score_codex":0.00024144795,"about_ca_system_score_gemma":0.0018745926,"threshold_uncertainty_score":0.7735615},"labels":[],"label_agreement":null},{"id":"W4380029463","doi":"10.1158/1538-7445.am2023-6362","title":"Abstract 6362: Overcoming resistance to immunotherapy due to loss of antigen presentation","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cytotoxic T cell; Cancer research; Immune system; CD8; Immunotherapy; Melanoma; CD40; Immunology; Tumor microenvironment; Antigen presentation; Biology; T cell; Cancer immunotherapy; In vitro","score_opus":0.086722358174086,"score_gpt":0.4450993976130972,"score_spread":0.3583770394390112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380029463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98795563,0.0014782924,0.00004597128,0.007314644,0.00020844536,0.0010100467,0.000051984694,0.0000561102,0.0018788734],"genre_scores_gemma":[0.9901732,0.001808499,0.00019020181,0.00041340376,0.00023044067,0.00024945347,0.0000151942595,0.00004381635,0.006875764],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99791026,0.00006838718,0.0003197888,0.00034094747,0.00085129746,0.0005092914],"domain_scores_gemma":[0.99877447,0.0001840816,0.00004847346,0.00047134826,0.00035760054,0.00016401122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011976183,0.000116212184,0.00026883412,0.00052182394,0.00013123975,0.000033249915,0.00024030317,0.000072410396,0.00065133086],"category_scores_gemma":[0.00011889869,0.00010766629,0.000092693226,0.002013262,0.00011197794,0.00008236124,0.00006697253,0.00022256757,0.0001436132],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071826666,0.0000509808,0.0059727365,0.00020401237,0.00014557247,0.00007476143,0.0020398663,0.0000309229,0.9161784,0.00004436342,0.042582303,0.025493419],"study_design_scores_gemma":[0.0016031913,0.00022339937,0.5398652,0.0006200018,0.000005098696,0.0000035248522,0.00052727864,0.0000052005344,0.3427476,0.00010394669,0.11414897,0.00014655951],"about_ca_topic_score_codex":0.001598044,"about_ca_topic_score_gemma":0.00048112718,"teacher_disagreement_score":0.5734308,"about_ca_system_score_codex":0.00032754184,"about_ca_system_score_gemma":0.00036115636,"threshold_uncertainty_score":0.7131616},"labels":[],"label_agreement":null},{"id":"W4380053151","doi":"10.1016/j.celrep.2023.112630","title":"Extrafollicular IgD−CD27−CXCR5−CD11c− DN3 B cells infiltrate inflamed tissues in autoimmune fibrosis and in severe COVID-19","year":2023,"lang":"en","type":"article","venue":"Cell Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Massachusetts Consortium on Pathogen Readiness; Howard Hughes Medical Institute","keywords":"Immunoglobulin D; CD11c; Immunology; Antibody; CXCR5; Fibrosis; Inflammation; Biology; B cell; Pathology; Medicine; Germinal center; Phenotype; Genetics","score_opus":0.01733964104502,"score_gpt":0.27824782309289214,"score_spread":0.26090818204787214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380053151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99186194,0.0036737022,0.000005064191,0.0011640334,0.00031891908,0.000733843,0.0000063502716,0.00016902151,0.0020671429],"genre_scores_gemma":[0.9889701,0.002201755,0.0001281772,0.00079898076,0.00005231433,0.00007488357,0.00008327101,0.000044733635,0.0076457714],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99780726,0.00007655908,0.0008113501,0.0005360961,0.0003144565,0.000454255],"domain_scores_gemma":[0.9988708,0.000120715784,0.00023365367,0.0005390545,0.000032373977,0.00020343385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081181544,0.00026103805,0.00050881755,0.00041144245,0.000065019354,0.00004439775,0.000074493146,0.0002223068,0.0003201436],"category_scores_gemma":[0.00011919929,0.00024503045,0.0001105481,0.0009690398,0.00012991183,0.00011986659,0.00005495304,0.00025565553,0.000024592428],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011982801,0.00020820633,0.17581837,0.0009540319,0.000084175466,0.017508423,0.003819862,0.0003899018,0.78201705,0.0000031342136,0.010877869,0.007120704],"study_design_scores_gemma":[0.0065572825,0.0003852632,0.4638746,0.0007539626,0.00009196439,0.0015970608,0.0013131192,0.00033813863,0.1650047,0.00027399734,0.3589303,0.00087960396],"about_ca_topic_score_codex":0.0016469476,"about_ca_topic_score_gemma":0.00034951966,"teacher_disagreement_score":0.6170123,"about_ca_system_score_codex":0.00023265436,"about_ca_system_score_gemma":0.00038490523,"threshold_uncertainty_score":0.9992051},"labels":[],"label_agreement":null},{"id":"W4380077943","doi":"10.1136/jitc-2022-006624","title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Society for Immunotherapy of Cancer","keywords":"Medicine; Guideline; Immunotherapy; Cancer; Cervical cancer; Endometrial cancer; Clinical Practice; Ovarian cancer; Intensive care medicine; Oncology; Multidisciplinary approach; Clinical trial; Quality of life (healthcare); Internal medicine; Biomarker; Disease; Gynecology; Family medicine; Nursing; Pathology","score_opus":0.07599925134873417,"score_gpt":0.46799917507606126,"score_spread":0.39199992372732706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380077943","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4304497,0.48321685,0.0085285455,0.0474985,0.012435916,0.014303193,0.0032818187,0.00014848968,0.00013698297],"genre_scores_gemma":[0.027705105,0.93780184,0.011533839,0.009325568,0.0027771532,0.005120858,0.0000826494,0.00034611364,0.0053068916],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945695,0.0001384434,0.003137178,0.0005634669,0.00077249133,0.00081895874],"domain_scores_gemma":[0.9893841,0.0042582857,0.0031860208,0.00086505234,0.0021960882,0.000110415145],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003120759,0.0006408197,0.0018857978,0.00025792836,0.00050909224,0.000044146916,0.00062040676,0.00044627528,0.00073966244],"category_scores_gemma":[0.00019508184,0.00040588024,0.00426603,0.00069820136,0.0005617337,0.00020123365,0.000016812392,0.0003450679,0.0000010414554],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.097348236,0.0017912702,0.0019150482,0.00027352935,0.017392691,0.0000013305754,0.002065206,0.0007629977,0.14486893,0.00008831831,0.052172635,0.68131983],"study_design_scores_gemma":[0.039884046,0.014645718,0.007956631,0.00052074983,0.0010070407,0.000012559318,0.0010873841,0.0010803898,0.0488682,0.0002966058,0.88421804,0.00042261335],"about_ca_topic_score_codex":0.0015043081,"about_ca_topic_score_gemma":0.00022332754,"teacher_disagreement_score":0.83204544,"about_ca_system_score_codex":0.00087732746,"about_ca_system_score_gemma":0.0017249963,"threshold_uncertainty_score":0.9998393},"labels":[],"label_agreement":null},{"id":"W4380084535","doi":"10.1002/hon.3163_109","title":"FAVEZELIMAB PLUS PEMBROLIZUMAB IN ANTI–PD‐1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL): ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Refractory (planetary science); Medicine; Internal medicine; Oncology; Clinical trial; Gastroenterology; Immunotherapy; Cancer","score_opus":0.04668407612535397,"score_gpt":0.349987444580797,"score_spread":0.30330336845544303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380084535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98474383,0.0007526767,0.00034571678,0.006298843,0.00044155237,0.0008263071,0.000010670107,0.00019900173,0.0063814213],"genre_scores_gemma":[0.99681866,0.00021536475,0.0016284973,0.0008040383,0.00011984327,0.000098657096,0.00003459325,0.00003258492,0.00024778605],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996842,0.0004736309,0.0010474657,0.0005488593,0.00041373554,0.00067425845],"domain_scores_gemma":[0.9959811,0.0029213745,0.00040314946,0.00046903078,0.000099800505,0.00012554866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008677872,0.00031857475,0.0012753012,0.00026096872,0.00014448285,0.000012856769,0.00031192217,0.0005996311,0.0002535199],"category_scores_gemma":[0.00124288,0.00019747461,0.00037384746,0.0010838133,0.0009153944,0.00008665017,0.00020514271,0.0005713583,0.0001520015],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10450408,0.01547001,0.07448643,0.0018753161,0.0026948736,0.015111705,0.01736836,0.00095519447,0.07371121,0.044096842,0.027684525,0.62204146],"study_design_scores_gemma":[0.055824913,0.0064758104,0.8685041,0.0007610132,0.00031977825,0.0031561453,0.0016708839,0.024364475,0.0028856292,0.0028626497,0.032393664,0.0007809465],"about_ca_topic_score_codex":0.000070505695,"about_ca_topic_score_gemma":0.000029933452,"teacher_disagreement_score":0.7940177,"about_ca_system_score_codex":0.00059366674,"about_ca_system_score_gemma":0.00058666634,"threshold_uncertainty_score":0.8052781},"labels":[],"label_agreement":null},{"id":"W4380149798","doi":"10.1016/j.jval.2023.03.1433","title":"HTA4 Pembrolizumab Vs. Standard of Care Chemotherapy As First-Line Treatment for Advanced Non-Small Cell Lung Cancer with High Pd-L1 Expression Levels: A Cost-Utility Analysis from the Ontario, Canada Public Payer Perspective","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Sunnybrook Health Science Centre; York University; University of Toronto","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Chemotherapy; Oncology; Internal medicine; Cancer; Intensive care medicine; Immunotherapy","score_opus":0.0349656346771366,"score_gpt":0.3159447320730994,"score_spread":0.28097909739596283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380149798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799268,0.004749693,0.00021162447,0.010196994,0.00016116387,0.0030063833,0.0016590952,0.000030221801,0.000057985344],"genre_scores_gemma":[0.9959635,0.0015828696,0.00043077095,0.0007905602,0.00007243499,0.0005929205,0.00024802596,0.000037884445,0.00028099702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979013,0.00011551583,0.0004999881,0.0005482707,0.00044347064,0.00049144746],"domain_scores_gemma":[0.9982798,0.00034256498,0.00031453354,0.0005598725,0.00033997715,0.0001632461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002906015,0.00028589243,0.0008334322,0.00015316044,0.0002094712,0.000017009654,0.0001544255,0.00008592894,0.00034131596],"category_scores_gemma":[0.000025285624,0.00017871651,0.00019695681,0.00092200434,0.00006205297,0.00005139058,0.00002012742,0.00017988958,1.9140806e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.14781009,0.0008208732,0.6677866,0.0015423477,0.0044234684,0.000052538526,0.12179687,0.025406675,0.0010432719,0.000025816207,0.0035620383,0.025729418],"study_design_scores_gemma":[0.044529986,0.00622257,0.8750171,0.0014372331,0.0007757915,0.0000024893072,0.021716537,0.0047945385,0.019565232,0.000061018232,0.025334956,0.0005425385],"about_ca_topic_score_codex":0.9931314,"about_ca_topic_score_gemma":0.9932381,"teacher_disagreement_score":0.20723051,"about_ca_system_score_codex":0.008848595,"about_ca_system_score_gemma":0.008769466,"threshold_uncertainty_score":0.9968499},"labels":[],"label_agreement":null},{"id":"W4380757939","doi":"10.1016/j.cjca.2023.06.007","title":"Immune Checkpoint Inhibitor-Induced Myocarditis With Concurrent Myasthenia Gravis","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Nivolumab; Myocarditis; Chest radiograph; Prednisone; Infliximab; Myasthenia gravis; Ptosis; Internal medicine; Pericardial effusion; Surgery; Gastroenterology; Cancer; Immunotherapy","score_opus":0.02063141440677274,"score_gpt":0.25427714555493364,"score_spread":0.2336457311481609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380757939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898887,0.0018380996,0.0001457144,0.0031337067,0.0020562124,0.00019733021,0.00003103087,0.000020878208,0.0026882836],"genre_scores_gemma":[0.9981604,0.00023507753,0.000028094682,0.00022345131,0.0011329347,0.0000060545617,0.00001832879,0.000027853323,0.00016780269],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986763,0.000094441784,0.0004647427,0.00014941531,0.00018154169,0.00043354448],"domain_scores_gemma":[0.99877733,0.000041720305,0.00019717276,0.00021558987,0.00025989066,0.0005082897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005278415,0.00016227698,0.0006590425,0.00045104508,0.00009248844,0.000019157595,0.00013074322,0.00013186326,0.000054210203],"category_scores_gemma":[0.000063657375,0.00012313551,0.0003826908,0.00040996703,0.0002133721,0.00005234518,0.000008875686,0.00035818457,0.000033028486],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004506691,0.000019466614,0.14301497,0.00025747667,0.009175277,0.017254684,0.0028603768,0.00033951318,0.2626616,0.00029079098,0.13493475,0.42468438],"study_design_scores_gemma":[0.006227323,0.0027160142,0.5020261,0.0003826107,0.000296685,0.008512369,0.0007263105,0.00000715798,0.007719252,0.00005576538,0.4710348,0.00029560257],"about_ca_topic_score_codex":0.0012189213,"about_ca_topic_score_gemma":0.0007491887,"teacher_disagreement_score":0.4243888,"about_ca_system_score_codex":0.00028219368,"about_ca_system_score_gemma":0.0018745193,"threshold_uncertainty_score":0.50213206},"labels":[],"label_agreement":null},{"id":"W4380987679","doi":"10.3390/cancers15123220","title":"Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery","year":2023,"lang":"en","type":"review","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Ovarian cancer; Immunotherapy; Context (archaeology); Medicine; Immune checkpoint; Tumor microenvironment; Biomarker discovery; Immune system; Biomarker; Cancer; Cancer immunotherapy; Cancer research; Oncology; Immunology; Internal medicine; Biology; Proteomics","score_opus":0.0719278631585186,"score_gpt":0.3567076550093486,"score_spread":0.28477979185083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380987679","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028234825,0.99552435,0.000022894757,0.00042091453,0.0015427212,0.0014274354,0.0002350745,0.00007344547,0.00047080443],"genre_scores_gemma":[0.00039110263,0.99674666,0.000037203623,0.0001021462,0.00022660535,0.0005355232,0.00020469817,0.00013199156,0.001624041],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759024,0.00005447862,0.0010167719,0.0006128789,0.00026755425,0.00045809825],"domain_scores_gemma":[0.9988721,0.000121686586,0.00042384112,0.00041656286,0.000044973585,0.000120812474],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004572483,0.0004936379,0.0016467165,0.00066072174,0.00011312037,0.00008505207,0.00015146866,0.0003606351,0.000045505356],"category_scores_gemma":[0.00006152189,0.00042339184,0.00050714234,0.0014075355,0.00026186783,0.0001699913,0.00009595626,0.0004938217,0.000008272691],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019446883,0.000075672346,0.000047025052,0.015460744,0.00097429444,0.000051459992,0.00027438835,0.00000200084,0.00044909198,0.00008306346,0.00057576614,0.981812],"study_design_scores_gemma":[0.004826833,0.00008848838,0.0008859024,0.06788128,0.00084175647,0.00008450896,0.00021710052,0.00004654224,0.000045874094,0.00001687993,0.92442554,0.0006393121],"about_ca_topic_score_codex":0.007486976,"about_ca_topic_score_gemma":0.00077898987,"teacher_disagreement_score":0.98117274,"about_ca_system_score_codex":0.0046360623,"about_ca_system_score_gemma":0.0029662359,"threshold_uncertainty_score":0.9998218},"labels":[],"label_agreement":null},{"id":"W4381250197","doi":"10.3390/curroncol30060439","title":"Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Sorafenib; Hepatocellular carcinoma; Atezolizumab; Bevacizumab; Liver transplantation; Immune system; Tumor microenvironment; Cancer research; Liver disease; Immunotherapy; Immune checkpoint; Colorectal cancer; Immunology; Inflammation; Cancer; Oncology; Transplantation; Internal medicine; Chemotherapy; Nivolumab","score_opus":0.2003887597590895,"score_gpt":0.43649177626153896,"score_spread":0.23610301650244944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381250197","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013773314,0.98730654,0.000036247286,0.000087392094,0.006594979,0.004168172,0.00026821348,0.000088284156,0.00007286271],"genre_scores_gemma":[0.00014911202,0.9955576,0.00004050371,0.000011609671,0.0014566963,0.0012925888,0.0012187343,0.0001315048,0.00014162737],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965499,0.00018486813,0.0018411577,0.00062353024,0.00028344025,0.00051709526],"domain_scores_gemma":[0.9975293,0.0003502754,0.0011080169,0.000643442,0.00022860637,0.00014035843],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00083821354,0.0005862889,0.0034010499,0.00047336277,0.00006651802,0.000010820321,0.0002897314,0.00049683393,0.00016266343],"category_scores_gemma":[0.00009357494,0.00043250856,0.0022788616,0.000559374,0.00018841507,0.000028063021,0.000101916376,0.000631459,0.00005192652],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090194517,0.0007568554,0.00035380578,0.04291875,0.00052565744,0.000011349206,0.000113755705,1.2463813e-8,0.00005376722,0.00001882168,0.0046270685,0.94971824],"study_design_scores_gemma":[0.00480422,0.0017646756,0.00014365035,0.014335467,0.0010090388,0.00005306225,0.000029932506,0.000024375004,0.000120770805,0.000021647093,0.9773275,0.00036563058],"about_ca_topic_score_codex":0.000014920136,"about_ca_topic_score_gemma":0.0000032047783,"teacher_disagreement_score":0.9727005,"about_ca_system_score_codex":0.0004364939,"about_ca_system_score_gemma":0.0017897972,"threshold_uncertainty_score":0.99981266},"labels":[],"label_agreement":null},{"id":"W4381434619","doi":"10.1158/1078-0432.ccr-22-3815","title":"The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Occupational Cancer Research Centre; Vancouver General Hospital; University of British Columbia","funders":"U.S. Army Medical Research and Development Command; National Cancer Institute; AstraZeneca; Novocure; National Health and Medical Research Council; Canadian Institutes of Health Research; National Institutes of Health; Janet D. Cottrelle Foundation; Medical Research Council; PharmaMar; Medical Research and Materiel Command; Eisai; European Commission; BC Cancer Foundation; Seagen; Deutsche Forschungsgemeinschaft; VGH and UBC Hospital Foundation; Marshfield Clinic Research Foundation; Amgen; Mersana Therapeutics; Stryker; Victorian Cancer Agency; Michael Smith Health Research BC; Memorial Sloan-Kettering Cancer Center","keywords":"Immune system; Serous fluid; Biology; Serous carcinoma; Clear cell; Carcinoma; Clear cell carcinoma; Ovarian carcinoma; Pathology; Cancer research; Immunohistochemistry; Ovarian cancer; Immunology; Medicine; Cancer","score_opus":0.10071752740082382,"score_gpt":0.4737054319116363,"score_spread":0.37298790451081243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381434619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99101627,0.0037555692,0.0000024803853,0.0017473707,0.00031866308,0.0011711925,0.000007730312,0.000026565862,0.0019541513],"genre_scores_gemma":[0.9959012,0.002978711,0.00000622212,0.000066361485,0.00012780065,0.0002695658,0.000019328023,0.000025811036,0.0006049516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99667287,0.0009968863,0.0007055794,0.0003294552,0.0008192979,0.00047589585],"domain_scores_gemma":[0.99278516,0.0063094404,0.000103105776,0.00051421934,0.00018536269,0.00010274405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008911067,0.000121424026,0.00037583118,0.00040379952,0.000111981,0.000027376444,0.00025323985,0.00015849565,0.00009622548],"category_scores_gemma":[0.003392447,0.00007755837,0.00021920244,0.0024846662,0.00037059988,0.000029446092,0.00007798142,0.0008629229,0.000055298864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034426346,0.0003547995,0.6502146,0.0004746641,0.00019223739,0.00025121297,0.00016045611,0.000027803697,0.17926033,0.00013525874,0.0012825375,0.13321972],"study_design_scores_gemma":[0.0071021225,0.0059280363,0.84513974,0.00025786372,0.00003180145,0.000002761073,0.00006002737,0.00013191589,0.1372023,0.00006163595,0.003981125,0.00010065122],"about_ca_topic_score_codex":0.0011495432,"about_ca_topic_score_gemma":0.00019979484,"teacher_disagreement_score":0.19492513,"about_ca_system_score_codex":0.00016433687,"about_ca_system_score_gemma":0.00052060385,"threshold_uncertainty_score":0.4061321},"labels":[],"label_agreement":null},{"id":"W4381598443","doi":"10.1038/s41598-023-36468-8","title":"The effect of blocking immune checkpoints LAG-3 and PD-1 on human invariant Natural Killer T cell function","year":2023,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research; National Institutes of Health","keywords":"Immune system; Invariant (physics); Lag; Blocking (statistics); Function (biology); Biology; Immunology; Computer science; Mathematics; Cell biology; Computer network","score_opus":0.012603275470389695,"score_gpt":0.27125837963127186,"score_spread":0.25865510416088217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381598443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98911023,0.00081421214,9.165151e-7,0.00026384945,0.007936643,0.00038090156,3.6182053e-7,0.000050820534,0.001442051],"genre_scores_gemma":[0.9836208,0.000019408211,0.0000033980543,0.000021071934,0.000057045494,0.000013534918,0.000030604144,0.000011825805,0.016222265],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986382,0.000053891847,0.00036891983,0.00034630796,0.00039005268,0.00020259195],"domain_scores_gemma":[0.99906486,0.00009009141,0.00022862067,0.00052930345,0.000046434245,0.000040659575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002592228,0.00010897062,0.00018292974,0.00013711903,0.00046122787,0.00008251892,0.000049707953,0.000049113398,0.00004705435],"category_scores_gemma":[0.00008684461,0.00006319466,0.00011092636,0.00048324125,0.00025806975,0.0000427917,0.000045498007,0.00012947511,0.000010405668],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007495853,0.000025367806,0.0056736064,0.000108049826,0.00007775658,0.00015216926,0.0002499504,0.0000030557408,0.9726146,0.00001213833,0.011955623,0.008378092],"study_design_scores_gemma":[0.0021038733,0.0010201386,0.18316352,0.00038943862,0.00012644487,0.00024071947,0.00016004671,0.00013332226,0.76356936,0.00035396335,0.048544873,0.00019430082],"about_ca_topic_score_codex":0.00005991031,"about_ca_topic_score_gemma":0.000014398332,"teacher_disagreement_score":0.20904525,"about_ca_system_score_codex":0.000036475292,"about_ca_system_score_gemma":0.0000389689,"threshold_uncertainty_score":0.35474384},"labels":[],"label_agreement":null},{"id":"W4381598533","doi":"10.1021/acs.jpcb.3c00911","title":"Predicting a Stable Dimeric Form of the PD1-PDL1 Complex: Implications for Understanding the PD1 Activation Mechanism","year":2023,"lang":"en","type":"article","venue":"The Journal of Physical Chemistry B","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Calgary","funders":"","keywords":"Effector; Chemistry; Extracellular; Intracellular; Cell biology; Biophysics; Biology; Biochemistry","score_opus":0.06986617830090217,"score_gpt":0.3178593418019621,"score_spread":0.24799316350105996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381598533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808472,0.00003189464,0.007852737,0.010149307,0.000064821776,0.0003405592,0.000021657417,0.000017098786,0.0006747241],"genre_scores_gemma":[0.99925256,0.000020093572,0.000024409575,0.0001236862,0.00030823893,0.000008734083,0.00000446845,0.000011891958,0.00024594116],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99933034,0.00002140602,0.00023652973,0.000057043693,0.00021416962,0.00014051714],"domain_scores_gemma":[0.9988138,0.00046644337,0.00037469817,0.00021683221,0.00009905253,0.000029162295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041094076,0.00007888157,0.00016262462,0.0000122155025,0.0002514419,0.000011107717,0.00022209744,0.000028117096,0.000014595915],"category_scores_gemma":[0.00008790816,0.000036317266,0.00020246787,0.00033612276,0.00010499155,0.000055153956,0.000037524755,0.00019170667,3.2421735e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039806266,0.00005138689,0.000082219194,0.000072706694,0.00016162888,6.589004e-8,0.0009097656,0.00004339912,0.99644727,0.00052672677,0.00086170615,0.00044507236],"study_design_scores_gemma":[0.002187558,0.00027459435,0.010958204,0.00035536007,0.00044865545,0.000061776926,0.0056096553,0.0063387565,0.91508967,0.057763826,0.00079993077,0.000112006805],"about_ca_topic_score_codex":0.000011013277,"about_ca_topic_score_gemma":7.8825667e-7,"teacher_disagreement_score":0.08135758,"about_ca_system_score_codex":0.00015269242,"about_ca_system_score_gemma":0.00009745834,"threshold_uncertainty_score":0.19339132},"labels":[],"label_agreement":null},{"id":"W4381612727","doi":"10.1200/jco.22.01599","title":"Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Ipilimumab; Medicine; Clinical endpoint; Internal medicine; Hazard ratio; Melanoma; Oncology; Clinical trial; Confidence interval; Cancer; Immunotherapy; Cancer research","score_opus":0.10690249198560138,"score_gpt":0.47226073629170395,"score_spread":0.3653582443061026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381612727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98933595,0.0002553355,0.0000037350735,0.0035338711,0.004898727,0.00043681197,0.0000054648826,0.000011944699,0.0015181493],"genre_scores_gemma":[0.99785066,0.0004963338,0.00009386005,0.00041562223,0.00045458417,0.000006822812,0.0000017166839,0.00001928117,0.00066113996],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99596137,0.00055251265,0.002526491,0.00019591123,0.00049465493,0.0002690847],"domain_scores_gemma":[0.99583393,0.001965284,0.0014875876,0.0003426989,0.00022783052,0.00014269419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035155842,0.00014555232,0.0014116623,0.00019400376,0.00004276351,0.0000044986505,0.0003263045,0.00027405765,0.0001489273],"category_scores_gemma":[0.0020596888,0.000090896916,0.00074147753,0.00062942813,0.0002216479,0.000081074875,0.000089524074,0.0008765715,0.000012809942],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6464722,0.005901374,0.04787516,0.000040270756,0.0013803354,0.0007409999,0.001343541,0.000031974345,0.002608959,0.000032391454,0.0067359596,0.2868368],"study_design_scores_gemma":[0.49832147,0.05706531,0.3956355,0.00019987318,0.0004829921,0.00009296902,0.0035122817,0.00007090131,0.00043340196,0.00013446776,0.043900244,0.00015058904],"about_ca_topic_score_codex":0.00005645562,"about_ca_topic_score_gemma":0.00037477823,"teacher_disagreement_score":0.34776035,"about_ca_system_score_codex":0.00022619797,"about_ca_system_score_gemma":0.0015682239,"threshold_uncertainty_score":0.3808316},"labels":[],"label_agreement":null},{"id":"W4381715763","doi":"10.1001/jamanetworkopen.2023.19607","title":"Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma","year":2023,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Pembrolizumab; Internal medicine; Oncology; Melanoma; Clinical endpoint; Clinical trial; Censoring (clinical trials); Immunotherapy; Cancer; Pathology","score_opus":0.024281604452299557,"score_gpt":0.3016705749623989,"score_spread":0.27738897051009936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381715763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9636996,0.0026322138,0.0001268241,0.011027998,0.0023142288,0.005358995,0.0003137859,0.00045342863,0.014072918],"genre_scores_gemma":[0.93367505,0.0017819391,0.0019821632,0.0017749509,0.0023463136,0.0024582564,0.0006305504,0.00021087406,0.055139896],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970022,0.00014152723,0.00060444186,0.0008043038,0.0003995225,0.0010480174],"domain_scores_gemma":[0.99761134,0.00035378066,0.00020314794,0.0014431749,0.00014785178,0.0002407233],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006063218,0.00047212536,0.00094466616,0.00013238189,0.0003270199,0.00025813276,0.00083064556,0.0002780016,0.000808557],"category_scores_gemma":[0.00009982411,0.0004044405,0.00045750255,0.0008131267,0.00012473781,0.00039712974,0.00042250485,0.00019648595,0.00022160573],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42421886,0.00058706355,0.042357,0.0002657827,0.002244561,0.00047698102,0.00096012914,0.0001984554,0.0007501069,0.0003677751,0.24023074,0.28734255],"study_design_scores_gemma":[0.09791402,0.007408902,0.25727537,0.00058266195,0.00045494616,0.000109862565,0.00036562426,0.0018585856,0.00048793256,0.00093113235,0.6317263,0.0008846381],"about_ca_topic_score_codex":0.000706892,"about_ca_topic_score_gemma":0.0011502017,"teacher_disagreement_score":0.3914956,"about_ca_system_score_codex":0.0005345415,"about_ca_system_score_gemma":0.0003547397,"threshold_uncertainty_score":0.99984074},"labels":[],"label_agreement":null},{"id":"W4381952533","doi":"10.31219/osf.io/u2v8h","title":"Pembrolizumab and its effectiveness in treating non-small cell lung cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Pembrolizumab; Immunotherapy; Lung cancer; Immune system; Cancer; Cancer immunotherapy; Medicine; Monoclonal antibody; Cancer research; Immunology; Antibody; Oncology; Internal medicine","score_opus":0.024193463171365837,"score_gpt":0.3137495484523325,"score_spread":0.28955608528096666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381952533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854272,0.007634928,0.00008979707,0.00023327336,0.0005192013,0.0014125098,0.000025229294,0.00009606461,0.004561816],"genre_scores_gemma":[0.99020374,0.0038352297,0.000100025834,0.00012001738,0.00016012683,0.00049310003,0.00003361316,0.00006205397,0.0049921214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986899,0.000068183304,0.00028452344,0.00053864985,0.00014224024,0.00027649602],"domain_scores_gemma":[0.99937177,0.00016298323,0.00009872707,0.00024181485,0.000053814652,0.00007088282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033892045,0.0002810424,0.00054580945,0.0002232579,0.000037570248,0.000030004654,0.00008924013,0.00029068213,0.00012900431],"category_scores_gemma":[0.000018068573,0.00023525073,0.00012343429,0.00018502343,0.000024484518,0.000022975786,0.00021083452,0.0004475276,0.0000054717825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010819185,0.00038061242,0.80826837,0.032275844,0.001160375,0.0004508552,0.0037133626,0.0006576379,0.097443774,0.00002495849,0.0009843325,0.043820698],"study_design_scores_gemma":[0.011095092,0.00018892433,0.93520707,0.007069703,0.00029973383,0.000016928561,0.0002115341,0.009449939,0.03566397,0.000032563737,0.00020916486,0.0005553986],"about_ca_topic_score_codex":0.0078082234,"about_ca_topic_score_gemma":0.0013385902,"teacher_disagreement_score":0.12693869,"about_ca_system_score_codex":0.00038257302,"about_ca_system_score_gemma":0.00034450705,"threshold_uncertainty_score":0.99879885},"labels":[],"label_agreement":null},{"id":"W4382020994","doi":"10.1038/s41571-023-00785-8","title":"Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy","year":2023,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Canadian Institutes of Health Research; Fondation pour la Recherche Médicale; Horizon 2020 Framework Programme; Institut Universitaire de France; Stand Up To Cancer; Genentech; Labex Immuno-Oncology; National Institutes of Health; PharmaMar; University of Texas MD Anderson Cancer Center; Ligue Contre le Cancer; AstraZeneca; Institut National Du Cancer; Fonds de Recherche du Québec - Santé; Institut National de la Santé et de la Recherche Médicale; Exelixis; Sanofi; European Commission; Daiichi Sankyo Europe; National Cancer Institute; HORIZON EUROPE Framework Programme; Gilead Sciences; Melanoma Research Alliance; GlaxoSmithKline; Fondation ARC pour la Recherche sur le Cancer; Agence Nationale de la Recherche; Bristol-Myers Squibb; American Association for Cancer Research; Seerave Foundation","keywords":"Dysbiosis; Medicine; Gut flora; Clinical trial; Cancer; Biomarker; Metagenomics; Bioinformatics; Oncology; Computational biology; Immunology; Internal medicine; Biology","score_opus":0.3343139125727195,"score_gpt":0.5517493436111188,"score_spread":0.21743543103839935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382020994","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001030342,0.97596675,0.00002144018,0.002523079,0.009851483,0.01067423,0.00024874392,0.00031447713,0.00038950652],"genre_scores_gemma":[0.000001289729,0.9723742,0.0015096073,0.010982922,0.0064138235,0.0032121225,0.0015904108,0.00043823785,0.003477375],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9898286,0.0017967011,0.0053530703,0.0017221074,0.00040455276,0.0008949585],"domain_scores_gemma":[0.99117285,0.0035390025,0.0032471195,0.0013277457,0.0003484614,0.00036484216],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0065846746,0.0012507904,0.009873694,0.00057872996,0.0001876686,0.00008234564,0.0008406623,0.007869433,0.00048953807],"category_scores_gemma":[0.0021762538,0.0008422002,0.0068510706,0.0014208636,0.00047668905,0.00012248188,0.00012495618,0.003965267,0.00033567395],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011636986,0.00033189234,0.0000017082378,0.0131217,0.0034385673,0.00003775466,0.000012950235,4.623721e-8,0.00040467049,0.00005471548,0.17592287,0.80550945],"study_design_scores_gemma":[0.004057735,0.0022012433,0.000012352618,0.0195727,0.004171091,0.00011628948,0.0000060187353,0.0000076191636,0.000004301308,0.0000348534,0.9690072,0.00080858695],"about_ca_topic_score_codex":0.000053104974,"about_ca_topic_score_gemma":0.00017874804,"teacher_disagreement_score":0.80470085,"about_ca_system_score_codex":0.0015531568,"about_ca_system_score_gemma":0.004583801,"threshold_uncertainty_score":0.9994029},"labels":[],"label_agreement":null},{"id":"W4382046230","doi":"10.1093/oncolo/oyad182","title":"Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Université Laval","keywords":"Medicine; Pembrolizumab; Lung cancer; Regimen; Internal medicine; Adverse effect; Dosing; Cancer; Surgery; Immunotherapy","score_opus":0.029539634537534293,"score_gpt":0.3284088507184091,"score_spread":0.2988692161808748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382046230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96351254,0.0029663672,0.000010794576,0.0039118743,0.0020208969,0.0008725064,0.000026126889,0.00017669302,0.026502186],"genre_scores_gemma":[0.9809042,0.003317538,0.00007144033,0.0010914637,0.00035963737,0.0002970693,0.000032108157,0.000039438077,0.013887083],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9983319,0.00009241954,0.00036574493,0.0003751358,0.00026440015,0.0005704166],"domain_scores_gemma":[0.9988107,0.00037826237,0.0001453348,0.00052648684,0.000055208515,0.00008401088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005302342,0.00024647114,0.00041362434,0.00015454485,0.00014791368,0.000023740093,0.00032355025,0.00019050355,0.00035135954],"category_scores_gemma":[0.00006199375,0.00017455815,0.0001807915,0.000785095,0.00023068258,0.00007497915,0.000117936615,0.0004312258,0.0001218256],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16131337,0.0016999226,0.10828273,0.0014334685,0.0013429965,0.0019031725,0.008662671,0.0031923768,0.19521935,0.00011884474,0.2896812,0.2271499],"study_design_scores_gemma":[0.058544006,0.0032287063,0.7633959,0.0007914823,0.0004957939,0.00004320619,0.0041098148,0.0026675705,0.01161342,0.00009034527,0.15399408,0.0010256371],"about_ca_topic_score_codex":0.002331792,"about_ca_topic_score_gemma":0.0023773734,"teacher_disagreement_score":0.6551132,"about_ca_system_score_codex":0.00093639,"about_ca_system_score_gemma":0.0006316539,"threshold_uncertainty_score":0.71182746},"labels":[],"label_agreement":null},{"id":"W4382340742","doi":"10.2139/ssrn.4489785","title":"Early Clonal Expansion of Tumour-Infiltrating Lymphocytes Predicts Response to Immune Checkpoint Therapy","year":2023,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Immune system; Immune checkpoint; Immunology; Biology; Cancer research; Medicine; Immunotherapy","score_opus":0.021949355228379933,"score_gpt":0.28679093015024665,"score_spread":0.2648415749218667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382340742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97824955,0.015836902,0.0008619933,0.003039507,0.0008835188,0.00086063123,0.000031643187,0.0001600935,0.000076143144],"genre_scores_gemma":[0.9744133,0.02256803,0.00038606458,0.0001665159,0.0007337301,0.000056280085,0.000034228382,0.00013407688,0.0015078048],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9946472,0.0003474566,0.0013627518,0.00054609735,0.0009687313,0.0021277643],"domain_scores_gemma":[0.99777555,0.00021935374,0.00082495675,0.0006142212,0.00035013875,0.00021580326],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0063771345,0.0005060189,0.0009231833,0.00060309854,0.00019073488,0.00007630289,0.0005050538,0.0003995227,0.000060431386],"category_scores_gemma":[0.00032999075,0.00042499046,0.0008135869,0.0004419741,0.00011603389,0.0000873173,0.0002172543,0.0033365455,0.00002518498],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05988905,0.00015831181,0.0012868444,0.00010225097,0.0016034871,0.000053188905,0.0016450159,0.000110840934,0.9098287,0.000089223875,0.00013200431,0.025101056],"study_design_scores_gemma":[0.029680915,0.021855565,0.43229717,0.008579299,0.0006042503,0.004379591,0.00595068,0.0004362448,0.47124237,0.020943632,0.0020116565,0.0020186396],"about_ca_topic_score_codex":0.0009058073,"about_ca_topic_score_gemma":0.00009141362,"teacher_disagreement_score":0.43858638,"about_ca_system_score_codex":0.002810459,"about_ca_system_score_gemma":0.015211688,"threshold_uncertainty_score":0.9998202},"labels":[],"label_agreement":null},{"id":"W4382361694","doi":"10.1016/j.gore.2023.101235","title":"Esophagitis as a complication of the combination of lenvatinib and pembrolizumab for advanced endometrial cancer: A case report","year":2023,"lang":"en","type":"article","venue":"Gynecologic Oncology Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Université de Montréal","funders":"","keywords":"Medicine; Lenvatinib; Pembrolizumab; Internal medicine; Oncology; Cancer; Gastroenterology; Immunotherapy; Thyroid cancer","score_opus":0.03266670006542467,"score_gpt":0.36287053016776877,"score_spread":0.3302038301023441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382361694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936708,0.0005481507,0.000019255174,0.0020168328,0.00085716875,0.0018735226,0.000025702071,0.000044600223,0.00094397424],"genre_scores_gemma":[0.9981856,0.00025882706,0.00026726,0.00016971055,0.000039830535,0.0005371868,0.00005707148,0.00001099867,0.00047351298],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99851424,0.00007008347,0.0007988145,0.00029043236,0.00015814509,0.00016826626],"domain_scores_gemma":[0.9973299,0.00077986484,0.001208896,0.00034494713,0.00029731484,0.000039092163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008914833,0.00010786828,0.00048390141,0.00015244973,0.00010518588,0.0000030159192,0.00004777547,0.00016967571,0.0000621776],"category_scores_gemma":[0.0021070638,0.000078587786,0.00014317896,0.0005616185,0.00027829557,0.000039139904,0.000050724655,0.00008915929,3.132882e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00983154,0.0016550787,0.2534158,0.0010324407,0.0011488821,0.041795474,0.0013835143,0.00005855671,0.1395726,0.0009920568,0.0070522777,0.5420618],"study_design_scores_gemma":[0.023302255,0.008364988,0.69513965,0.00016529234,0.0006187639,0.19588165,0.0006430712,0.000193437,0.044149745,0.0043932404,0.026901035,0.00024687793],"about_ca_topic_score_codex":0.00031730247,"about_ca_topic_score_gemma":0.00015948144,"teacher_disagreement_score":0.5418149,"about_ca_system_score_codex":0.00018539967,"about_ca_system_score_gemma":0.0005442014,"threshold_uncertainty_score":0.3204717},"labels":[],"label_agreement":null},{"id":"W4382794593","doi":"10.1016/j.breast.2023.06.010","title":"Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers","year":2023,"lang":"en","type":"review","venue":"The Breast","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre","funders":"AstraZeneca; Breast Cancer Research Foundation","keywords":"Medicine; Breast cancer; Oncology; Radiation therapy; Internal medicine; Cancer","score_opus":0.04843570531051944,"score_gpt":0.3313331753465822,"score_spread":0.28289747003606275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382794593","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02331247,0.97268414,0.0000016095146,0.0005947343,0.00033767484,0.0018020289,0.0010835556,0.00007835154,0.00010540811],"genre_scores_gemma":[0.008537058,0.9900693,0.000016747073,0.00048198397,0.00022484911,0.00019291877,0.0003450043,0.000109135464,0.000022978475],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977991,0.0002867254,0.0007047775,0.00045319877,0.00039239548,0.00036383167],"domain_scores_gemma":[0.9983079,0.0007293366,0.00043533297,0.0003797448,0.000050957697,0.000096727825],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00070573646,0.00045504954,0.00095627666,0.00051041244,0.00019581297,0.00009334247,0.00022683726,0.00021965822,0.00006303369],"category_scores_gemma":[0.00004391606,0.0002826752,0.00028465892,0.0009019593,0.00012401537,0.00006667554,0.000046349112,0.000297011,0.000018171939],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067480054,0.00009684488,0.004050199,0.0005390651,0.00031271583,0.000006551027,0.00014369939,0.000003831463,0.000020654888,0.000001447008,0.00028784413,0.99386233],"study_design_scores_gemma":[0.015440955,0.0003744724,0.7529523,0.08297899,0.0012164689,0.0006743149,0.00019091064,0.00055400276,0.000013466155,0.000023269016,0.14421856,0.0013622943],"about_ca_topic_score_codex":0.0010715158,"about_ca_topic_score_gemma":0.00006112372,"teacher_disagreement_score":0.99250007,"about_ca_system_score_codex":0.0007445499,"about_ca_system_score_gemma":0.00077837484,"threshold_uncertainty_score":0.99996257},"labels":[],"label_agreement":null},{"id":"W4382862333","doi":"10.3892/ol.2023.13937","title":"Efficacy and safety of envafolimab in the treatment of advanced dMMR/MSI‑H solid tumors: A single‑arm meta‑analysis","year":2023,"lang":"en","type":"article","venue":"Oncology Letters","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Hebei Medical University","keywords":"Medicine; Meta-analysis; Internal medicine; Oncology; Microsatellite instability; Cochrane Library; Adverse effect; Incidence (geometry); Cancer","score_opus":0.03919895181763679,"score_gpt":0.334431862189964,"score_spread":0.29523291037232724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382862333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97987115,0.0014516669,0.00001568332,0.01775534,0.000045137658,0.00045884858,0.000016140688,0.000016763242,0.0003692697],"genre_scores_gemma":[0.996468,0.0010087737,0.00026416543,0.0020593992,0.000027494154,0.00006217906,0.000024740424,0.0000097221555,0.00007553837],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998926,0.00014541564,0.00038899726,0.00020225861,0.00013997153,0.00019737803],"domain_scores_gemma":[0.99904484,0.0004677405,0.00017117015,0.0002696188,0.000018636885,0.000027995544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002964765,0.00013215622,0.00086822174,0.00029750995,0.000029201514,0.000002689117,0.000078541074,0.000060510625,0.00008224738],"category_scores_gemma":[0.000019872146,0.0000816524,0.00036838575,0.00084116095,0.00024415224,0.000023403518,0.0000119809565,0.00006421206,0.0000018703611],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0279415,0.0053489893,0.005397092,0.0001588379,0.081959456,0.0006132035,0.020013923,0.0008849644,0.7572333,0.00003990456,0.0010369625,0.09937185],"study_design_scores_gemma":[0.07314676,0.044299416,0.5306587,0.00016391481,0.14512281,0.00021765109,0.0075373384,0.00032548295,0.085939445,0.00007880796,0.11168085,0.0008288143],"about_ca_topic_score_codex":0.0001881337,"about_ca_topic_score_gemma":0.00018575112,"teacher_disagreement_score":0.67129385,"about_ca_system_score_codex":0.00015232658,"about_ca_system_score_gemma":0.000045843106,"threshold_uncertainty_score":0.33296883},"labels":[],"label_agreement":null},{"id":"W4383224422","doi":"10.22541/au.168855488.83152562/v1","title":"Hypoglycemia as First Presentation of Immune Checkpoint Inhibitor-induced Type 1 Diabetes","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Lawson Health Research Institute; Western University","funders":"","keywords":"Hypoglycemia; Medicine; Type 2 Diabetes Mellitus; Presentation (obstetrics); Diabetes mellitus; Adverse effect; Immunotherapy; Immune system; Type 2 diabetes; Renal cell carcinoma; Internal medicine; Endocrinology; Immunology; Surgery","score_opus":0.04082762223104424,"score_gpt":0.3089637816280756,"score_spread":0.26813615939703134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383224422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899486,0.0011248864,0.0000073569768,0.0021588213,0.0020331903,0.0009072399,0.000016021786,0.00019221366,0.0036116757],"genre_scores_gemma":[0.9920269,0.0009829109,0.00028656464,0.00012717056,0.00034990575,0.00007523027,0.00031344875,0.000068112146,0.005769711],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981362,0.000033968427,0.0007604379,0.00041634237,0.00040054574,0.00025246476],"domain_scores_gemma":[0.99856544,0.00010483109,0.0003532638,0.0006705286,0.00023156937,0.000074353746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003275944,0.0002753227,0.00059130474,0.00021903568,0.00004379254,0.000025287009,0.00017029802,0.00039877542,0.000789345],"category_scores_gemma":[0.00019325988,0.00023500803,0.0003701095,0.00031065717,0.00008120775,0.000041133142,0.00029644443,0.00041776977,0.00014104739],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044356715,0.00031798013,0.009200403,0.0030226668,0.0017103506,0.000022672808,0.0009382354,0.000054329914,0.9612712,0.000036530408,0.007572413,0.011417547],"study_design_scores_gemma":[0.0028134412,0.00085837225,0.10325437,0.0017706632,0.0002548329,0.000005241336,0.00030269127,0.0003141817,0.8874625,0.0004273797,0.002166891,0.0003694522],"about_ca_topic_score_codex":0.0023809741,"about_ca_topic_score_gemma":0.0000919442,"teacher_disagreement_score":0.09405397,"about_ca_system_score_codex":0.00017011011,"about_ca_system_score_gemma":0.00036215372,"threshold_uncertainty_score":0.9583349},"labels":[],"label_agreement":null},{"id":"W4383314786","doi":"10.1016/s0140-6736(23)00774-2","title":"First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study","year":2023,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Atezolizumab; Medicine; Internal medicine; Regimen; Population; Chemotherapy regimen; Oncology; Chemotherapy; Vinorelbine; Clinical endpoint; Performance status; Lung cancer; Gemcitabine; Phases of clinical research; Cancer; Surgery; Clinical trial; Pembrolizumab; Immunotherapy; Cisplatin","score_opus":0.05724716795188822,"score_gpt":0.3473963572473626,"score_spread":0.2901491892954744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383314786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97718763,0.000743467,0.00013357268,0.0017562947,0.0001536918,0.019548967,0.00011067943,0.000104956656,0.00026073816],"genre_scores_gemma":[0.9920684,0.0009440539,0.0005176975,0.0007827287,0.00022704228,0.0048359027,0.00010316639,0.00008522569,0.0004357661],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978392,0.00010201253,0.00052870315,0.0005425663,0.00031764645,0.0006698789],"domain_scores_gemma":[0.9983945,0.00034228488,0.00035873152,0.0006660369,0.00013440513,0.00010406784],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004544441,0.00046770327,0.0014901813,0.000098743454,0.00020882126,0.00011453254,0.0003626878,0.00007566732,0.000047956506],"category_scores_gemma":[0.000018681912,0.00025430706,0.0000981666,0.000642618,0.00006282168,0.00009857622,0.000037733076,0.00010005892,0.0000029799824],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93288946,0.0063801804,0.04044182,0.00007604739,0.0027336658,0.00003280631,0.0048595807,0.00040385794,0.00038728045,0.0000010255419,0.00087306974,0.010921191],"study_design_scores_gemma":[0.9548538,0.025329042,0.005618946,0.00038204624,0.0006193597,0.0000012267114,0.00089586654,0.0103022875,0.00050707394,0.0000029279577,0.0011448129,0.00034266617],"about_ca_topic_score_codex":0.001511889,"about_ca_topic_score_gemma":0.0029504339,"teacher_disagreement_score":0.034822874,"about_ca_system_score_codex":0.0008962681,"about_ca_system_score_gemma":0.00027121726,"threshold_uncertainty_score":0.99999094},"labels":[],"label_agreement":null},{"id":"W4383370361","doi":"10.21203/rs.3.rs-3088575/v1","title":"Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"Cancer Prevention and Research Institute of Texas; Pfizer; University of Texas MD Anderson Cancer Center; Bristol-Myers Squibb","keywords":"Immune checkpoint; Transcriptome; Immune system; Cancer research; Cytotoxic T cell; Immunotherapy; PD-L1; Renal cell carcinoma; Clear cell renal cell carcinoma; T cell; Medicine; Immunology; Biology; Oncology; Gene; Gene expression; Genetics","score_opus":0.08026354292313152,"score_gpt":0.3924754073943119,"score_spread":0.3122118644711804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383370361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99457115,0.0015891697,0.000012098124,0.0010867418,0.00022318643,0.0020121336,0.0003008604,0.000039035425,0.00016561894],"genre_scores_gemma":[0.9961708,0.00041459527,0.00020040329,0.000022345646,0.00016788082,0.00040921607,0.00023764667,0.000080176214,0.0022969353],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99560064,0.0007588779,0.0010441705,0.00069516845,0.0012118318,0.00068930816],"domain_scores_gemma":[0.997782,0.00037813603,0.00019414193,0.0009723114,0.00049748045,0.00017596691],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005620662,0.00028948547,0.00067754934,0.0018227171,0.00009447026,0.000038957365,0.0002488266,0.00042155574,0.00038404428],"category_scores_gemma":[0.00042127178,0.0002851408,0.00039770923,0.0009011268,0.00023403362,0.000044549404,0.0009141311,0.0012851099,0.00018182983],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04140563,0.00031470842,0.012260906,0.0016646762,0.00003705468,0.0004669526,0.0014410741,0.000057336543,0.9396851,0.0000011096027,0.0003789322,0.0022865345],"study_design_scores_gemma":[0.002643189,0.001187162,0.6940535,0.0030407703,0.000012349224,0.000027806014,0.0005537778,0.00007526491,0.29767984,0.00011716191,0.00040084668,0.0002083493],"about_ca_topic_score_codex":0.0033142692,"about_ca_topic_score_gemma":0.00031875545,"teacher_disagreement_score":0.68179256,"about_ca_system_score_codex":0.001443883,"about_ca_system_score_gemma":0.0017634835,"threshold_uncertainty_score":0.99996006},"labels":[],"label_agreement":null},{"id":"W4383555722","doi":"10.30683/1929-2279.2023.12.6","title":"Tumor Infiltrating Lymphocytes as Immunebiomarkers in Oral Cancer: An Update","year":2023,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immune system; Tumor microenvironment; Immunotherapy; Cancer; Medicine; Disease; Carcinogenesis; Immunology; Tumor-infiltrating lymphocytes; Tumor progression; Cancer research; Pathology; Internal medicine","score_opus":0.06719422615367782,"score_gpt":0.4536658836662083,"score_spread":0.3864716575125305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383555722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784009,0.012735923,0.0000011879064,0.0076492573,0.00044521096,0.00032997987,0.000026144993,0.00004035671,0.00037103792],"genre_scores_gemma":[0.97538596,0.022652255,0.00018222541,0.00076616905,0.00047463595,0.00006947742,0.000018983772,0.00005523981,0.0003950671],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9963545,0.0003487032,0.0008871227,0.00028593736,0.0012956135,0.0008281201],"domain_scores_gemma":[0.9981554,0.00021748873,0.00032437808,0.00032159511,0.00067359034,0.00030752274],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003997083,0.00021472169,0.0005701235,0.0012835112,0.00017941768,0.00013795188,0.0004544092,0.00009708398,0.0013008842],"category_scores_gemma":[0.00030090217,0.0001686388,0.00019822085,0.0023850312,0.00031663087,0.0005984514,0.00009457977,0.000738064,0.000042777814],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027962953,0.0004081792,0.25999957,0.00039336496,0.0011687574,0.002455117,0.001694418,0.0002852651,0.38971755,0.000099713674,0.037884522,0.2779306],"study_design_scores_gemma":[0.02421397,0.004495632,0.48628923,0.0047539263,0.00018553947,0.0010051312,0.009210612,0.0021122096,0.2958329,0.0015138831,0.16946706,0.0009198926],"about_ca_topic_score_codex":0.008097171,"about_ca_topic_score_gemma":0.0016573706,"teacher_disagreement_score":0.2770107,"about_ca_system_score_codex":0.0010302474,"about_ca_system_score_gemma":0.0027178496,"threshold_uncertainty_score":0.99961203},"labels":[],"label_agreement":null},{"id":"W4383647203","doi":"10.1177/17588359231183668","title":"Radiation and immune checkpoint inhibitors in the treatment of oligometastatic non-small-cell lung cancer: a practical review of rationale, recent data, and research questions","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; London Health Sciences Centre","funders":"","keywords":"SABR volatility model; Medicine; Lung cancer; Oncology; Clinical trial; Radiation therapy; Narrative review; Internal medicine; Medical physics; Intensive care medicine","score_opus":0.14720216806980715,"score_gpt":0.5244359166054591,"score_spread":0.37723374853565195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383647203","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000105971456,0.99028736,0.000040219722,0.005888887,0.00019076501,0.0032829957,0.000047696816,0.00000559609,0.000150519],"genre_scores_gemma":[0.000030755586,0.99806273,0.00034083409,0.0002887726,0.0001159402,0.0009161289,0.00019239626,0.00002359627,0.000028850181],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954771,0.001592452,0.0015982469,0.00041280087,0.00064198306,0.00027744786],"domain_scores_gemma":[0.9942387,0.004490885,0.00058410555,0.00047994682,0.00012161422,0.000084770996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005669975,0.00023630212,0.0018285724,0.00035689413,0.00004095773,0.0000046428186,0.00023547294,0.00026714403,0.00009222154],"category_scores_gemma":[0.00075913814,0.00014130956,0.00009970129,0.0012416493,0.0006987919,0.000074114854,0.00007607191,0.00062438945,0.0000011013523],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022923459,0.00073265436,0.0000456148,0.045875087,0.00019744692,0.000048388418,0.0005462608,1.5085753e-7,0.0000036059544,0.00005616391,0.00006512815,0.9522003],"study_design_scores_gemma":[0.0023254906,0.0013814629,0.00013804792,0.05861427,0.0008508029,0.00013203819,0.000284135,0.00011917036,0.00000605728,0.00009943357,0.9359373,0.000111791815],"about_ca_topic_score_codex":0.00026272587,"about_ca_topic_score_gemma":0.00038818285,"teacher_disagreement_score":0.9520885,"about_ca_system_score_codex":0.00055602717,"about_ca_system_score_gemma":0.0031380367,"threshold_uncertainty_score":0.57624364},"labels":[],"label_agreement":null},{"id":"W4383683290","doi":"10.58931/cdet.2023.1210","title":"Endocrinopathies Associated with Immune Checkpoint Inhibitors","year":2023,"lang":"en","type":"article","venue":"Canadian Diabetes & Endocrinology Today","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Immune system; Medicine; Adverse effect; Immune checkpoint; Immunology; Immunotherapy; Ipilimumab; Autoimmunity; CTLA-4; Oncology; Internal medicine; T cell","score_opus":0.012285071572449251,"score_gpt":0.22962886244100975,"score_spread":0.21734379086856048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383683290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983052,0.0019263517,4.3825438e-7,0.007608217,0.00060904556,0.000471753,0.000077291246,0.00042812765,0.005826742],"genre_scores_gemma":[0.9930656,0.00025958178,0.000026035079,0.0016941929,0.00014961461,0.00014811727,0.00026581547,0.00007151453,0.004319519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704796,0.00008522389,0.00043634904,0.0004643465,0.00022315653,0.0017429686],"domain_scores_gemma":[0.9986421,0.00014077038,0.00012185668,0.0005006831,0.00012684723,0.00046774317],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022489505,0.00033001116,0.0005473266,0.00081330515,0.00025017356,0.00003341242,0.00019898101,0.00015825761,0.0005083292],"category_scores_gemma":[0.0002399107,0.00028562295,0.00020229213,0.0011087614,0.0004473355,0.00009376138,0.000044706518,0.0004148228,0.000290434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049615133,0.00017362228,0.7899829,0.00015935577,0.0026039942,0.0044335076,0.0011326575,0.000014246471,0.11067713,0.00060634624,0.033300716,0.05641936],"study_design_scores_gemma":[0.0045976588,0.0010199577,0.77991855,0.0003734007,0.00020653667,0.00014551773,0.00054461096,0.000043799017,0.10251611,0.00013449042,0.109881274,0.0006181098],"about_ca_topic_score_codex":0.013541514,"about_ca_topic_score_gemma":0.037966926,"teacher_disagreement_score":0.07658056,"about_ca_system_score_codex":0.0005844314,"about_ca_system_score_gemma":0.00077477883,"threshold_uncertainty_score":0.9999596},"labels":[],"label_agreement":null},{"id":"W4383872841","doi":"10.2217/imt-2022-0257","title":"An Assessment of Extended Pembrolizumab Dosing in Advanced Non-Small-Cell Lung Cancer in the Covid-19 Pandemic","year":2023,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Pembrolizumab; Medicine; Dosing; Lung cancer; Adverse effect; Internal medicine; Cancer; Retrospective cohort study; Toxicity; Gastroenterology; Immunotherapy","score_opus":0.03164804547800199,"score_gpt":0.40218010515864516,"score_spread":0.3705320596806432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383872841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921099,0.004655593,0.00033185305,0.0010433669,0.0002204722,0.0011481536,0.000019765856,0.00007480153,0.0003960878],"genre_scores_gemma":[0.98718554,0.009228584,0.00025750202,0.0027253286,0.000053913038,0.00031069847,0.00002909961,0.00004538123,0.00016393277],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99812096,0.00020865946,0.0005651593,0.0003525857,0.00033706918,0.0004155627],"domain_scores_gemma":[0.99888885,0.0002017195,0.00018938139,0.00061763934,0.000040847568,0.000061564446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011723731,0.0002294195,0.00043104074,0.00036819198,0.000077469704,0.000026351296,0.00033844693,0.00012739773,0.00017493925],"category_scores_gemma":[0.000013964018,0.00016933861,0.00013963213,0.0011115127,0.00009807705,0.00011478879,0.0000170857,0.00033290184,0.0000016511782],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039093047,0.00044426872,0.31357294,0.00022281414,0.00010032984,0.000058182442,0.007432963,0.0009770127,0.62614906,0.000031429827,0.00012393479,0.046977755],"study_design_scores_gemma":[0.025152365,0.00064652506,0.9567444,0.00032224727,0.000033472486,0.000038728478,0.002547935,0.0075548077,0.002845919,0.000081204074,0.003719788,0.0003126346],"about_ca_topic_score_codex":0.0025655502,"about_ca_topic_score_gemma":0.0010336738,"teacher_disagreement_score":0.6431714,"about_ca_system_score_codex":0.0006190879,"about_ca_system_score_gemma":0.0007984939,"threshold_uncertainty_score":0.6905428},"labels":[],"label_agreement":null},{"id":"W4383982502","doi":"10.1038/s41586-023-06383-z","title":"Author Correction: GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19","year":2023,"lang":"en","type":"erratum","venue":"Nature","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University and Génome Québec Innovation Centre; University of Toronto; Kingston Health Sciences Centre; Queen's University","funders":"Medical Research Council","keywords":"Genome-wide association study; Coronavirus disease 2019 (COVID-19); Meta-analysis; Computational biology; Biology; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Genetics; Virology; Medicine; Single-nucleotide polymorphism; Internal medicine; Genotype; Gene; Outbreak; Disease","score_opus":0.09956064858439032,"score_gpt":0.4093574029237633,"score_spread":0.30979675433937304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383982502","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030843876,0.5502867,0.0041094604,0.20494007,0.21899533,0.002597106,0.0016778809,0.0013870308,0.01569796],"genre_scores_gemma":[0.02073594,0.0020339682,0.0002701088,0.013100669,0.0014227355,0.00009206652,0.0008093474,0.00011283834,0.9614223],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974216,0.00016577361,0.00046330996,0.0008130913,0.00077369926,0.00036251763],"domain_scores_gemma":[0.99826777,0.00045334117,0.00015853647,0.0006158791,0.00019857273,0.00030589607],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00046285513,0.000426839,0.0015552056,0.0006926309,0.0003123864,0.00018716953,0.00018019178,0.0038976064,0.0024177714],"category_scores_gemma":[0.0012652879,0.00033559313,0.0013111441,0.0014348885,0.00022842348,0.00006229754,0.000076228636,0.0044865706,0.000037206075],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023347924,0.000040089242,0.000030699426,0.00049451634,0.09509399,0.0003282304,0.00019263831,0.000004141786,0.000055022196,0.000017937047,0.90331036,0.000198889],"study_design_scores_gemma":[0.00054339145,0.00014409292,0.007842126,0.000036109886,0.39621115,0.00024766134,0.00032689003,0.00022796435,0.000011155338,0.0003748785,0.593617,0.00041753464],"about_ca_topic_score_codex":0.00037977725,"about_ca_topic_score_gemma":0.0008409667,"teacher_disagreement_score":0.94572437,"about_ca_system_score_codex":0.00023905683,"about_ca_system_score_gemma":0.00063491473,"threshold_uncertainty_score":0.99990964},"labels":[],"label_agreement":null},{"id":"W4384155464","doi":"10.1038/s41416-023-02344-5","title":"Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC)","year":2023,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Cancer Institute; Oncolytics Biotech; Merck","keywords":"Pembrolizumab; Medicine; Internal medicine; Chemotherapy; Oncology; CD8; Immunotherapy; Immune system; Gastroenterology; Regimen; Chemotherapy regimen; Immunology; Cancer","score_opus":0.012853819566891618,"score_gpt":0.2831648186824827,"score_spread":0.2703109991155911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384155464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9637641,0.03517466,0.0000052146265,0.00051916885,0.00015780053,0.0002193464,0.000015952994,0.000011157065,0.0001326073],"genre_scores_gemma":[0.9820843,0.017564457,0.00008207777,0.00006593918,0.00005321338,0.000009294123,0.000007682056,0.000017126269,0.000115946685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988422,0.00007235142,0.0005200733,0.00010674647,0.00028368388,0.0001749866],"domain_scores_gemma":[0.99922,0.000058419802,0.00033341677,0.00008820909,0.00023812131,0.000061802646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045019464,0.00009364266,0.00042286067,0.00022361423,0.000045218476,0.000020919508,0.00008267849,0.000059788545,0.00008118097],"category_scores_gemma":[0.000119722274,0.00009805724,0.00009750151,0.00044085592,0.00010265995,0.00017196263,0.000023378669,0.00024622565,5.2517674e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040053143,0.00035990772,0.50399894,0.0007858569,0.0003511497,0.0010110387,0.0010165416,0.000028227158,0.12448922,0.00002382656,0.0006380611,0.3632919],"study_design_scores_gemma":[0.007711505,0.00055800984,0.9786598,0.0022557795,0.00008073483,0.0014726694,0.00041934507,0.000087882414,0.008156576,0.00016947082,0.00033463156,0.00009361256],"about_ca_topic_score_codex":0.00083012943,"about_ca_topic_score_gemma":0.00028071972,"teacher_disagreement_score":0.4746608,"about_ca_system_score_codex":0.00011449336,"about_ca_system_score_gemma":0.00021432994,"threshold_uncertainty_score":0.3998658},"labels":[],"label_agreement":null},{"id":"W4384300579","doi":"10.3390/curroncol30070491","title":"Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Tolerability; Medicine; Discontinuation; Immunotherapy; Desensitization (medicine); Hypersensitivity reaction; Oncology; Merkel cell carcinoma; Internal medicine; Intensive care medicine; Carcinoma; Adverse effect; Cancer","score_opus":0.12313124674910454,"score_gpt":0.4562449799487703,"score_spread":0.33311373319966575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384300579","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008144017,0.8371885,0.000003850412,0.000078431876,0.00055292126,0.1618452,0.0000387002,0.00006461256,0.0001463556],"genre_scores_gemma":[0.000010899196,0.8614783,0.00003482511,0.000040716433,0.00017783443,0.1366393,0.0012156965,0.00006463062,0.00033774055],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99728423,0.00026252048,0.0013756383,0.0006321008,0.00014660953,0.00029891197],"domain_scores_gemma":[0.9980703,0.00031874448,0.00093058666,0.00036640375,0.00021439807,0.00009957287],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006562676,0.00040636005,0.0017369722,0.0003969562,0.000076357275,0.000016933858,0.000054391996,0.0006901215,0.000015047387],"category_scores_gemma":[0.00031926425,0.0003173742,0.00034936125,0.0008571135,0.00006313273,0.000047635414,0.000055076172,0.00071318436,0.0000073535384],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003938073,0.00023920843,0.000010140317,0.239597,0.000024077875,0.05952712,0.00010433321,2.4778616e-8,0.0000101051755,0.0000014226055,0.003457869,0.6966349],"study_design_scores_gemma":[0.0021549573,0.0006012906,0.0000041367634,0.0672595,0.0006231571,0.2602245,0.000010132361,0.000014241444,0.0000012028902,0.000005058187,0.6689146,0.00018724732],"about_ca_topic_score_codex":0.000026154774,"about_ca_topic_score_gemma":0.000050015737,"teacher_disagreement_score":0.6964477,"about_ca_system_score_codex":0.0008687249,"about_ca_system_score_gemma":0.00077842444,"threshold_uncertainty_score":0.9999278},"labels":[],"label_agreement":null},{"id":"W4384343202","doi":"10.1038/s41417-023-00644-9","title":"Influence of ADT on B7-H3 expression during CRPC progression from hormone-naïve prostate cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Gene Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; Spinal Cord Injury BC; University of British Columbia; Prevention of Organ Failure; BC Cancer Agency","funders":"Terry Fox Research Institute; Canadian Institutes of Health Research; Mitacs; Cancer Research Society; Prostate Cancer Foundation; Government of Canada; U.S. Department of Defense","keywords":"Prostate cancer; Androgen deprivation therapy; Medicine; Immunotherapy; Biomarker; Oncology; Cancer; Androgen receptor; Internal medicine; Cancer research; Biology","score_opus":0.02174220333819844,"score_gpt":0.3279413548074306,"score_spread":0.30619915146923216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384343202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719237,0.025652397,0.0000015246211,0.0008109651,0.00029185694,0.00089778745,0.00018072287,0.0001819135,0.000059098667],"genre_scores_gemma":[0.9251756,0.072488874,0.000061493425,0.0005328089,0.00034956253,0.00059204863,0.00005394119,0.0000673738,0.0006782621],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811566,0.000058887636,0.00040987413,0.0004964655,0.0005067676,0.00041235547],"domain_scores_gemma":[0.9989026,0.000044980374,0.00025812676,0.00052382826,0.00014247154,0.00012796024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015243483,0.0002893766,0.0004281323,0.0001728774,0.00013506351,0.000017929668,0.00019247593,0.00014116381,0.00025898468],"category_scores_gemma":[0.000010660949,0.00021453986,0.00014733445,0.000591994,0.00013815123,0.000119301825,0.00004542147,0.00018400313,0.00001529745],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018502986,0.00009264974,0.019277962,0.000060002894,0.00018310259,0.000022816077,0.0016435734,0.00070957566,0.8962866,6.386396e-7,0.0014791543,0.061740953],"study_design_scores_gemma":[0.0046176724,0.00042841057,0.3090655,0.00089716155,0.000019327967,0.0000015657516,0.00007688118,0.000030624364,0.6804038,0.000025738624,0.004246653,0.00018668167],"about_ca_topic_score_codex":0.0009072357,"about_ca_topic_score_gemma":0.000031095038,"teacher_disagreement_score":0.28978753,"about_ca_system_score_codex":0.0002266639,"about_ca_system_score_gemma":0.00023475049,"threshold_uncertainty_score":0.87486815},"labels":[],"label_agreement":null},{"id":"W4384931169","doi":"10.3390/curroncol30070498","title":"Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Kaohsiung Medical University Chung-Ho Memorial Hospital; National Science and Technology Council; Kaohsiung Medical University","keywords":"Medicine; Immune system; Adverse effect; Immunology; Immune checkpoint; Cancer; Immunotherapy; Bioinformatics; Internal medicine; Biology","score_opus":0.07580870574116809,"score_gpt":0.39428400357830795,"score_spread":0.31847529783713985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384931169","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028599605,0.9881063,0.000032075593,0.00008804339,0.0057735574,0.0025553687,0.00013986755,0.00016303665,0.00028178052],"genre_scores_gemma":[0.0010720515,0.9968441,0.000033288936,0.000023996332,0.000101101046,0.00027365063,0.0011221812,0.00018566809,0.00034395262],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946794,0.00044124707,0.0029890982,0.00074357574,0.0005148408,0.00063184754],"domain_scores_gemma":[0.99668944,0.00016822522,0.0019632888,0.00083105476,0.0001607401,0.00018725228],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007522985,0.00077570055,0.0037514535,0.00055114616,0.000070383125,0.000004011304,0.00045489977,0.0012154417,0.0002919939],"category_scores_gemma":[0.00017558923,0.0006588857,0.0023016739,0.0010393583,0.00017120391,0.000038943028,0.00026110586,0.0012880657,0.00023551658],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004519009,0.0011598602,0.0000016207164,0.016169958,0.0025117719,0.00027331733,0.00014191263,3.4688682e-7,0.016648008,0.00007215001,0.0004989635,0.96207017],"study_design_scores_gemma":[0.0042898864,0.002219673,0.0000067679844,0.029093834,0.0035126903,0.0007196475,0.00010826674,0.00000838631,0.0033736266,0.0001907554,0.9557167,0.00075971696],"about_ca_topic_score_codex":0.000103595106,"about_ca_topic_score_gemma":0.00000392273,"teacher_disagreement_score":0.96131045,"about_ca_system_score_codex":0.0011768716,"about_ca_system_score_gemma":0.001279002,"threshold_uncertainty_score":0.9995862},"labels":[],"label_agreement":null},{"id":"W4384934514","doi":"10.3390/curroncol30070502","title":"Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical trial; Adverse effect; Intensive care medicine; Drug; Oncology; Pharmacology; Bioinformatics; Internal medicine","score_opus":0.45490736784772945,"score_gpt":0.5984346654688568,"score_spread":0.14352729762112737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384934514","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024796429,0.9783597,0.000012966462,0.0002237776,0.0071846168,0.01146997,0.00006900605,0.0000610705,0.00013922903],"genre_scores_gemma":[0.0002459494,0.9961099,0.000023866472,0.000044596727,0.0016985537,0.0015055166,0.000026848968,0.00005644104,0.00028833066],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914666,0.0028836946,0.0042908215,0.00067010714,0.00035656407,0.00033226056],"domain_scores_gemma":[0.9939225,0.0029547026,0.0019280519,0.00084577047,0.00021755142,0.00013143652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010922034,0.0004178685,0.005795978,0.00020417066,0.00007610393,0.000009826412,0.00040036193,0.00037235685,0.00009075748],"category_scores_gemma":[0.0044958103,0.00022834326,0.001748675,0.0008594752,0.00023564884,0.000022377608,0.00027182806,0.0011016717,0.00009691846],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018556482,0.003178095,0.00017224936,0.0044875424,0.0012694233,0.00001485833,0.000495707,6.114991e-8,0.000011255899,0.0000078339845,0.0020323223,0.986475],"study_design_scores_gemma":[0.0044649527,0.007342075,0.0011440298,0.008629324,0.0022112245,0.000022647278,0.00050841464,4.720687e-7,0.000014692124,0.000014813891,0.97543985,0.00020747804],"about_ca_topic_score_codex":0.000024748542,"about_ca_topic_score_gemma":0.0000764703,"teacher_disagreement_score":0.9862675,"about_ca_system_score_codex":0.0006380351,"about_ca_system_score_gemma":0.00118733,"threshold_uncertainty_score":0.93115675},"labels":[],"label_agreement":null},{"id":"W4385067316","doi":"10.21203/rs.3.rs-3153100/v1","title":"External validation of the VIGex gene-expression signature as a novel predictive biomarker for immune checkpoint treatment","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"Merck Canada; CRIS Cancer Foundation; Sociedad Española de Oncología Médica; Banco Bilbao Vizcaya Argentaria; Natera; Fundación BBVA","keywords":"Biomarker; Signature (topology); Immune checkpoint; Gene; Computational biology; Immune system; Gene signature; Gene expression; Biology; Computer science; Immunotherapy; Immunology; Genetics; Mathematics","score_opus":0.10372211186423176,"score_gpt":0.4184358807438433,"score_spread":0.31471376887961156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385067316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730199,0.0051700226,0.0036851158,0.0033059975,0.0011897915,0.011077794,0.0019972594,0.00013043842,0.0004236963],"genre_scores_gemma":[0.99028003,0.0012321768,0.00090005546,0.000024387238,0.0004290377,0.0018700284,0.000639134,0.00010389224,0.0045212274],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965874,0.000261955,0.00060714124,0.00068282144,0.0013564493,0.0005042576],"domain_scores_gemma":[0.9971526,0.0003988507,0.00032355273,0.001133209,0.000871059,0.0001206765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015569243,0.00033290518,0.00053228985,0.00037126962,0.000241863,0.000056766236,0.00041404754,0.0005711062,0.00015466829],"category_scores_gemma":[0.00042595388,0.00020345871,0.0008633967,0.00046738863,0.00027108696,0.00004754413,0.000563416,0.0007653154,0.00001176549],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011033138,0.00061870494,0.0015102194,0.0012477711,0.00069261185,0.00001013041,0.0010205448,0.00010264041,0.97947466,0.000013008891,0.0007073582,0.0035691937],"study_design_scores_gemma":[0.0044537615,0.001574232,0.08139226,0.0054855677,0.00013350658,0.000015431247,0.0004130209,0.0007401922,0.9031635,0.0006430149,0.0017994161,0.00018610142],"about_ca_topic_score_codex":0.0010704244,"about_ca_topic_score_gemma":0.000016178172,"teacher_disagreement_score":0.07988204,"about_ca_system_score_codex":0.0010132085,"about_ca_system_score_gemma":0.0012040396,"threshold_uncertainty_score":0.82968056},"labels":[],"label_agreement":null},{"id":"W4385161939","doi":"10.3390/cancers15143708","title":"Analysis of the Circulating Metabolome of Patients with Cutaneous, Mucosal and Uveal Melanoma Reveals Distinct Metabolic Profiles with Implications for Response to Immunotherapy","year":2023,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Princess Margaret Cancer Centre; Jewish General Hospital; University Health Network; University of Toronto; McGill University","funders":"","keywords":"Metabolome; Metabolomics; Melanoma; Kynurenine; Kynurenic acid; Cancer research; Kynurenine pathway; Biology; Sphingolipid; Medicine; Internal medicine; Immunology; Tryptophan; Bioinformatics; Biochemistry; Amino acid","score_opus":0.013801625766829041,"score_gpt":0.2783660863600531,"score_spread":0.2645644605932241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385161939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996917,0.00047747025,0.00013811869,0.00058369513,0.000031663447,0.001145546,0.0006610938,0.00002214815,0.00002323773],"genre_scores_gemma":[0.9988643,0.000051235682,0.0005044001,0.00013336669,0.0000144315545,0.00021697054,0.000061742554,0.00002474268,0.00012881489],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904263,0.000060381582,0.000294,0.00023172956,0.00018580155,0.0001854848],"domain_scores_gemma":[0.99890524,0.00020181599,0.00024367208,0.00038957168,0.00020622544,0.0000534962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025535724,0.00013197318,0.00046928477,0.00024711582,0.00009650896,0.0000074766967,0.000107075386,0.000036384714,0.000014948897],"category_scores_gemma":[0.00006801438,0.00007714619,0.0001318065,0.0018474149,0.00016617023,0.00003102182,0.000018266976,0.0000468512,1.3866679e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019556534,0.00002617316,0.8710004,0.000079729965,0.0035694262,6.4202e-7,0.0010677654,0.00028808566,0.09538306,0.000053866737,0.00007653558,0.008897765],"study_design_scores_gemma":[0.0018993374,0.00050807634,0.99214166,0.00006806932,0.0011884224,0.0000033890017,0.00018421285,0.00008686015,0.002664424,0.000009203096,0.0011437042,0.00010265309],"about_ca_topic_score_codex":0.0002359217,"about_ca_topic_score_gemma":0.00013197625,"teacher_disagreement_score":0.12114123,"about_ca_system_score_codex":0.00013334672,"about_ca_system_score_gemma":0.00032362595,"threshold_uncertainty_score":0.31459305},"labels":[],"label_agreement":null},{"id":"W4385215055","doi":"10.1136/jitc-2023-006994","title":"Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Royal College of Physicians and Surgeons of Canada; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Canadian Institutes of Health Research; V Foundation for Cancer Research","keywords":"Blockade; Medicine; PD-L1; Chemotherapy; Oncology; Cohort; Internal medicine; First line; Lung; Pharmacology; Immunotherapy; Cancer; Receptor","score_opus":0.01725263915675259,"score_gpt":0.3307501556499867,"score_spread":0.31349751649323415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385215055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742334,0.01658337,0.0003954474,0.002108959,0.0006203112,0.0057569616,0.000117377145,0.000098785444,0.000085407],"genre_scores_gemma":[0.9790704,0.017156715,0.00068674417,0.0005122405,0.00040537692,0.00066846696,0.000042517077,0.00024578127,0.001211762],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99506646,0.00016231298,0.0019626392,0.0007348641,0.0011326021,0.00094114087],"domain_scores_gemma":[0.99645877,0.00046438904,0.0013982073,0.00081544125,0.0006596536,0.00020356133],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012023473,0.0007583399,0.0021478857,0.0009813736,0.00029162088,0.000056597684,0.00059120177,0.0002592397,0.00040434216],"category_scores_gemma":[0.000037796104,0.0006062912,0.00074204186,0.0017891931,0.0003676668,0.00026033647,0.00003428733,0.0006919684,0.0000021870003],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38974598,0.0036761474,0.3690831,0.0004942713,0.010729513,0.00013166547,0.017364124,0.008114342,0.15003355,0.000007759334,0.001165652,0.04945389],"study_design_scores_gemma":[0.12147393,0.007669477,0.8118827,0.0020119643,0.00046578606,0.00013064366,0.00205688,0.001918308,0.04575085,0.00004748585,0.0058118366,0.00078013685],"about_ca_topic_score_codex":0.0010048957,"about_ca_topic_score_gemma":0.00056738564,"teacher_disagreement_score":0.4427996,"about_ca_system_score_codex":0.0010475,"about_ca_system_score_gemma":0.00088468415,"threshold_uncertainty_score":0.99963886},"labels":[],"label_agreement":null},{"id":"W4385500231","doi":"10.1002/cti2.1453","title":"Inverse relationship between <i>Fusobacterium nucleatum</i> amount and tumor <scp>CD274</scp> (<scp>PD‐L1</scp>) expression in colorectal carcinoma","year":2023,"lang":"en","type":"article","venue":"Clinical & Translational Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Uehara Memorial Foundation; Stand Up To Cancer; Gary Bennett Family Fund; National Institutes of Health; Japan Society for the Promotion of Science; Prevent Cancer Foundation; Mochida Memorial Foundation for Medical and Pharmaceutical Research; American Cancer Society; Cancer Research UK; Mitsukoshi Health and Welfare Foundation; Harvard T.H. Chan School of Public Health; American Association for Cancer Research","keywords":"Fusobacterium nucleatum; Colorectal cancer; Microsatellite instability; Cancer research; Immune checkpoint; Tissue microarray; KRAS; Medicine; Cancer; Biology; Oncology; Immunology; Internal medicine; Immunotherapy; Genetics","score_opus":0.057771398455958405,"score_gpt":0.3338328309657226,"score_spread":0.27606143250976417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385500231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946353,0.0010666229,0.000032578577,0.0015256038,0.00070087664,0.0006274107,0.00011216389,0.00017684278,0.0011226308],"genre_scores_gemma":[0.996914,0.00029286818,0.00040143615,0.00068804575,0.0003293064,0.00005944907,0.0005593289,0.000058341568,0.0006972018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966552,0.0004592012,0.00127991,0.00069428596,0.0003235961,0.000587783],"domain_scores_gemma":[0.99198973,0.0071198298,0.00025744073,0.0003255624,0.000116238945,0.00019117926],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011316963,0.0003332215,0.0007579065,0.00039319415,0.00019876256,0.00003448126,0.00021183731,0.0005974134,0.00004487397],"category_scores_gemma":[0.0015349918,0.00031672564,0.00031513386,0.0007772244,0.00079005334,0.00022996763,0.00007974174,0.0010213995,0.00017035032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055095286,0.00019440206,0.9592006,0.00005673653,0.00015721202,0.00007556992,0.0009786522,0.000004016498,0.034021728,0.00014685505,0.00355248,0.001060773],"study_design_scores_gemma":[0.006650653,0.00067206734,0.96974313,0.00013599203,0.00011083209,0.00006024375,0.00057762,0.00012726939,0.0017645617,0.0008715988,0.01920072,0.00008532303],"about_ca_topic_score_codex":0.00006980329,"about_ca_topic_score_gemma":0.00008128768,"teacher_disagreement_score":0.032257166,"about_ca_system_score_codex":0.00011197236,"about_ca_system_score_gemma":0.00035007327,"threshold_uncertainty_score":0.9999285},"labels":[],"label_agreement":null},{"id":"W4385532450","doi":"10.1136/jitc-2022-006500","title":"Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review","year":2023,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; McMaster University; University of Toronto","funders":"McMaster University","keywords":"Medicine; Adverse effect; Pembrolizumab; Nivolumab; Internal medicine; Endocrine system; Cancer; Immunotherapy","score_opus":0.023318942090214626,"score_gpt":0.34530797997758805,"score_spread":0.32198903788737343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385532450","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005233836,0.98543227,0.0000051445413,0.00022565282,0.002226095,0.011350867,0.00016288484,0.000056929475,0.000016784918],"genre_scores_gemma":[0.00005272234,0.9937165,0.000043326912,0.00011053553,0.00033914193,0.0030236454,0.0001222798,0.00040305915,0.0021888057],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9910677,0.00038560256,0.006013996,0.00060409924,0.0010826773,0.0008458908],"domain_scores_gemma":[0.99174887,0.00024807762,0.0062924125,0.00093354133,0.00063460146,0.00014249426],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002538908,0.001070482,0.007227145,0.0008812201,0.00018988439,0.00001995811,0.0006476959,0.0005534446,0.0005484314],"category_scores_gemma":[0.00015101398,0.00070619077,0.0033326203,0.0017077301,0.00014694949,0.00026854337,0.000057027544,0.0013378125,0.000013225096],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017035431,0.00024118251,0.00022583996,0.8135688,0.009405874,0.000010457061,0.00018452604,0.0000063431107,0.00005632281,8.6843124e-7,0.00016295316,0.17443334],"study_design_scores_gemma":[0.010769306,0.0011057368,0.00095360324,0.90162665,0.005221219,0.000062959705,0.000027976555,0.0000027110725,0.000025673835,0.0000070852834,0.07948599,0.00071110384],"about_ca_topic_score_codex":0.00053076586,"about_ca_topic_score_gemma":0.00011902416,"teacher_disagreement_score":0.17372222,"about_ca_system_score_codex":0.004300883,"about_ca_system_score_gemma":0.0030674075,"threshold_uncertainty_score":0.9995389},"labels":[],"label_agreement":null},{"id":"W4385554303","doi":"10.1200/go.2023.9.supplement_1.59","title":"Identification of intratumoral and peripheral T-cell receptor (TCR) repertoire features associated with acquired (Ar) and primary (Pr) resistance to immune checkpoint inhibitors (ICI).","year":2023,"lang":"en","type":"article","venue":"JCO Global Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"Conquer Cancer Foundation","keywords":"T-cell receptor; Antigen; T cell; Immune checkpoint; Immune system; Immunology; Antibody; Biology; Cancer research; Medicine; Immunotherapy","score_opus":0.008387846670398321,"score_gpt":0.26315401097914193,"score_spread":0.2547661643087436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385554303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891185,0.0023929153,0.0000054230945,0.0054179225,0.00034002058,0.00056188804,0.00006447407,0.00008918265,0.0020096407],"genre_scores_gemma":[0.9947237,0.00040874063,0.00026962676,0.0005387466,0.00008919938,0.00004410211,0.000107319516,0.000019065434,0.003799508],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984482,0.00010480053,0.0005419,0.00038236572,0.00023559929,0.00028712416],"domain_scores_gemma":[0.99913746,0.000056586818,0.00030910183,0.00023313865,0.00014742398,0.000116298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000505655,0.00018527574,0.0005050362,0.000075973534,0.00009680913,0.000023750426,0.00008201994,0.00021743034,0.000025575868],"category_scores_gemma":[0.00012778753,0.00015262052,0.000069625494,0.00061747787,0.0003032528,0.0000789959,0.00006405165,0.00011000112,0.000003247982],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011976428,0.00024846508,0.011766181,0.00018172583,0.00019799087,0.000064527776,0.0010017073,0.0000018103119,0.94789076,0.00004031262,0.016698586,0.0099315075],"study_design_scores_gemma":[0.0072997385,0.0028727092,0.89988,0.0004156615,0.00015194378,0.00007923084,0.0011862306,0.000014204778,0.072951525,0.000080004764,0.014736424,0.0003323453],"about_ca_topic_score_codex":0.0001177841,"about_ca_topic_score_gemma":0.0003361497,"teacher_disagreement_score":0.8881138,"about_ca_system_score_codex":0.0007103567,"about_ca_system_score_gemma":0.00027235178,"threshold_uncertainty_score":0.6223684},"labels":[],"label_agreement":null},{"id":"W4385580814","doi":"10.14740/wjon1620","title":"The Effect of mRNA-Based COVID-19 Vaccination on Anti-Programmed Cell Death Protein 1 Blockade for Nasopharyngeal Cancer May Differ From a Virus-Inactivated Vaccine","year":2023,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Blockade; Vaccination; Virology; Coronavirus disease 2019 (COVID-19); Virus; Messenger RNA; Immunology; Internal medicine; Disease; Gene; Receptor; Biology","score_opus":0.027407491166814735,"score_gpt":0.3582986719524328,"score_spread":0.3308911807856181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385580814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978225,0.0010357221,0.00012233848,0.018287813,0.00060949154,0.001552765,0.000054083604,0.000033461052,0.00007933931],"genre_scores_gemma":[0.99743736,0.00028039442,0.00018081338,0.00087661436,0.0004117828,0.00019988764,0.000032861284,0.000034942314,0.00054535846],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981628,0.00033356994,0.0006612508,0.00019640061,0.00031608448,0.00032989282],"domain_scores_gemma":[0.9968231,0.0018033104,0.0008260862,0.00020246701,0.00017362488,0.00017142587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011734873,0.0002092121,0.0006981733,0.00038886367,0.00016001535,0.0000151086115,0.00020156882,0.0001304643,0.00021461336],"category_scores_gemma":[0.000286051,0.00012446895,0.00032997396,0.0005960056,0.000042329226,0.000040250423,0.000019184661,0.0003603126,0.0000025452716],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.117823035,0.00053856487,0.030925894,0.00032083027,0.0008462802,0.00018859832,0.00016347102,0.00015871433,0.72077227,0.000010948337,0.013098647,0.115152776],"study_design_scores_gemma":[0.042462844,0.015296122,0.12023007,0.0002684176,0.00048641438,0.00002199687,0.000040357918,0.0005825562,0.68995667,0.00007072545,0.13041262,0.00017122009],"about_ca_topic_score_codex":0.000398098,"about_ca_topic_score_gemma":0.00050931267,"teacher_disagreement_score":0.11731397,"about_ca_system_score_codex":0.00081761216,"about_ca_system_score_gemma":0.0006951558,"threshold_uncertainty_score":0.5075696},"labels":[],"label_agreement":null},{"id":"W4385583941","doi":"10.14740/wjon1625","title":"Impact of Liver Metastasis on First-Line Immunotherapy in Stage IV Non-Small Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Immunotherapy; Internal medicine; Lung cancer; Oncology; Hazard ratio; Propensity score matching; Stage (stratigraphy); Metastasis; Cancer; Gastroenterology; Confidence interval","score_opus":0.03402591601547943,"score_gpt":0.3625864137141212,"score_spread":0.32856049769864176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385583941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903713,0.0056863707,0.000032209366,0.001517397,0.00044153395,0.00029065125,0.000030540188,0.000008892442,0.0016211359],"genre_scores_gemma":[0.979935,0.016510446,0.0002517467,0.0004411438,0.00021272826,0.000010983474,0.00000391045,0.0000316632,0.0026024105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984336,0.00010511598,0.0007718352,0.00014387236,0.00023170061,0.0003138663],"domain_scores_gemma":[0.9986321,0.00028509906,0.0006388838,0.0001995735,0.00015076362,0.00009361011],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008552421,0.00018062012,0.00075511314,0.0009610579,0.00003851019,0.000006232326,0.000173881,0.00009624257,0.0017406299],"category_scores_gemma":[0.000021762185,0.0001303032,0.00047287391,0.00093520223,0.00008149286,0.00005791392,0.000022828026,0.0004358833,0.0000075504877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06991025,0.003160636,0.42651096,0.00054222386,0.003916504,0.002884676,0.0046977266,0.0060070967,0.14574891,0.000017417724,0.032276146,0.30432746],"study_design_scores_gemma":[0.02081782,0.008973016,0.88388443,0.00063076435,0.00022355819,0.00009569184,0.0001531251,0.0006267582,0.00780123,0.000009745181,0.07656503,0.00021884794],"about_ca_topic_score_codex":0.0013484479,"about_ca_topic_score_gemma":0.0031454435,"teacher_disagreement_score":0.45737347,"about_ca_system_score_codex":0.0008895677,"about_ca_system_score_gemma":0.0006613139,"threshold_uncertainty_score":0.9991719},"labels":[],"label_agreement":null},{"id":"W4385584071","doi":"10.14740/wjon1617","title":"<i>Hemophilus influenzae</i> Infection’s Association With Decreased Risk of Breast Cancer","year":2023,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Nova Southeastern University","keywords":"Medicine; Incidence (geometry); Internal medicine; Odds ratio; Confidence interval; Cohort; Relative risk; Statistical significance; Breast cancer; Haemophilus influenzae; Cancer; Antibiotics; Microbiology","score_opus":0.012643691237215829,"score_gpt":0.30308484627954546,"score_spread":0.29044115504232965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385584071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912171,0.00042903886,0.000018920318,0.006099999,0.0005168879,0.00011996206,0.000024626697,0.000018376815,0.0015550879],"genre_scores_gemma":[0.99508476,0.00236056,0.00015600632,0.0010341385,0.00040810904,0.0000066883313,0.0000027477918,0.000015466778,0.00093154475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989065,0.00010790053,0.00045285287,0.00007884038,0.0002879644,0.00016592472],"domain_scores_gemma":[0.9981134,0.00021418219,0.0010602414,0.00009098036,0.0004335646,0.00008764306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078966125,0.00008885659,0.00039426715,0.00037774353,0.00004691461,0.0000051653983,0.000052439213,0.000082593164,0.00024759735],"category_scores_gemma":[0.00008486885,0.00006352299,0.00015252456,0.0008332663,0.000056742123,0.00007325435,0.000010747015,0.00029582914,0.0000063735283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007938681,0.00017887552,0.91296834,0.00003210236,0.0010082745,0.00006520653,0.00017633986,0.00012672009,0.005695399,0.0000062579697,0.022967711,0.04883608],"study_design_scores_gemma":[0.006524155,0.0010738939,0.8813839,0.00017241652,0.00040199477,0.00042591733,0.000036999056,0.000016416989,0.001240744,0.000039169412,0.10862049,0.00006393257],"about_ca_topic_score_codex":0.00076764973,"about_ca_topic_score_gemma":0.0015765519,"teacher_disagreement_score":0.085652776,"about_ca_system_score_codex":0.0008405327,"about_ca_system_score_gemma":0.0007408412,"threshold_uncertainty_score":0.2711017},"labels":[],"label_agreement":null},{"id":"W4385637524","doi":"10.1016/j.xcrm.2023.101145","title":"Membrane-localized neoantigens predict the efficacy of cancer immunotherapy","year":2023,"lang":"en","type":"article","venue":"Cell Reports Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of General Medical Sciences; National Institutes of Health; National Cancer Institute; National Institute of Allergy and Infectious Diseases; National Nuclear Security Administration; University of Chicago; Sandia National Laboratories; U.S. Department of Energy","keywords":"Immunotherapy; Cancer; Medicine; Immune system; Melanoma; Cancer immunotherapy; Antigen; Oncology; Internal medicine; Immunology; Cancer research","score_opus":0.019856875022349656,"score_gpt":0.30525915079181654,"score_spread":0.28540227576946686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385637524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9646612,0.014693129,0.000052669835,0.008478172,0.0022289648,0.0012471039,0.000006111028,0.00042314982,0.008209509],"genre_scores_gemma":[0.9724969,0.015048462,0.000029031,0.0014921365,0.00066779484,0.00007449928,0.000059241815,0.00008902939,0.0100428965],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975249,0.000060311766,0.0009482507,0.00037034048,0.0007178372,0.00037836022],"domain_scores_gemma":[0.99802107,0.00027166685,0.00047907938,0.00095066265,0.00015600274,0.000121494755],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011020801,0.00024551168,0.0006380098,0.00019605481,0.000100068086,0.0000062889085,0.00015450879,0.000118001095,0.0013756569],"category_scores_gemma":[0.0001629725,0.00013569121,0.00024719004,0.0010244672,0.0005995696,0.000032508477,0.000033573026,0.0002299064,0.000008619056],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033946694,0.0002101045,0.025499765,0.00037984602,0.0007331312,0.00097062933,0.0029661001,0.000046615467,0.8552357,0.000011415166,0.065855905,0.04469614],"study_design_scores_gemma":[0.011180342,0.00085511757,0.14103448,0.0010361404,0.0005033404,0.00043960646,0.00095949817,0.00020955827,0.17575344,0.000045878474,0.667696,0.0002865925],"about_ca_topic_score_codex":0.0012863909,"about_ca_topic_score_gemma":0.000023915749,"teacher_disagreement_score":0.6794822,"about_ca_system_score_codex":0.000066476896,"about_ca_system_score_gemma":0.00030221912,"threshold_uncertainty_score":0.9995372},"labels":[],"label_agreement":null},{"id":"W4385641417","doi":"10.7150/jca.85966","title":"Combined Use of Immune Checkpoint Inhibitors and Phytochemicals as a Novel Therapeutic Strategy against Cancer","year":2023,"lang":"en","type":"review","venue":"Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"China Postdoctoral Science Foundation; National Natural Science Foundation of China; Harbin Medical University","keywords":"Medicine; Adverse effect; Rash; Immune system; Cancer; Oncology; Immune checkpoint; Combination therapy; Immunology; Pharmacology; Immunotherapy; Internal medicine","score_opus":0.10690653366029228,"score_gpt":0.3969457465237053,"score_spread":0.290039212863413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385641417","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009667357,0.9884262,0.0000037160062,0.0002591841,0.00076714804,0.000702437,0.00010264351,0.00001477553,0.000056503428],"genre_scores_gemma":[0.0011398572,0.99700975,0.00003927787,0.00023681685,0.00061367766,0.00006837252,0.000011461147,0.00010282303,0.00077793206],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99673873,0.00006178484,0.0020976644,0.00025273752,0.00054964994,0.00029940775],"domain_scores_gemma":[0.99643254,0.0001985141,0.0025305783,0.00028978477,0.00038294864,0.0001656149],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047144014,0.0004507551,0.0027087957,0.00035323531,0.000037251506,0.00004304765,0.00018334104,0.00035563632,0.00016379311],"category_scores_gemma":[0.00006659279,0.00030446335,0.0011933879,0.0005771233,0.00021202503,0.0001321928,0.000049799703,0.00073629426,0.0000020910659],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001696095,0.00022133038,0.00007436286,0.016139535,0.0055276398,0.000048687023,0.00013134113,0.0000050517756,0.02179326,0.0000067104634,0.00081377145,0.95354223],"study_design_scores_gemma":[0.0049592257,0.0009192381,0.0005396982,0.09833855,0.0040268074,0.0001778314,0.00008297157,0.0000074940353,0.0040348154,0.000021922171,0.88641864,0.00047278422],"about_ca_topic_score_codex":0.0005078185,"about_ca_topic_score_gemma":0.000034242228,"teacher_disagreement_score":0.95306945,"about_ca_system_score_codex":0.0004724654,"about_ca_system_score_gemma":0.002151859,"threshold_uncertainty_score":0.99994075},"labels":[],"label_agreement":null},{"id":"W4385686732","doi":"10.4049/jimmunol.210.supp.84.06","title":"Topology of cell-free DNA from tumour cells influences its immunogenicity in macrophages and dendritic cells <i>in vitro</i>","year":2023,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Social Innovation; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Immunogenicity; Biology; Immune system; In vitro; Cancer research; Cell biology; Cell; DNA; Molecular biology; Chemistry; Immunology; Genetics","score_opus":0.01123699557424958,"score_gpt":0.251306987697126,"score_spread":0.2400699921228764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385686732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97555083,0.021888893,0.0000032421754,0.0017619561,0.00051732187,0.00016037074,0.000029279605,0.000007861269,0.000080223166],"genre_scores_gemma":[0.983585,0.01582625,0.00009939814,0.00028921443,0.000060342885,0.0000023394107,0.000001950579,0.000014679216,0.000120827775],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982242,0.00035831812,0.0008002171,0.00012723177,0.00016842097,0.0003215874],"domain_scores_gemma":[0.99860305,0.0005834364,0.00040717638,0.0002868462,0.000086024156,0.000033481123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000858348,0.00015879824,0.0006020552,0.0003576998,0.000041664836,0.0000068028203,0.00043444824,0.0001554131,0.00008616375],"category_scores_gemma":[0.00005370152,0.00011154106,0.00011492371,0.00042473752,0.00040739292,0.00008082446,0.00014003935,0.00047718798,0.000009620592],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055407374,0.00010590309,0.0007497089,0.000036095495,0.00016213514,0.00017948667,0.0012512231,0.000013968988,0.9908325,0.0000038666735,0.0001881198,0.00093626336],"study_design_scores_gemma":[0.0048974003,0.0005830693,0.066635914,0.00012166221,0.00008303747,0.00023388553,0.0017510388,0.000014809971,0.9250807,0.00029356265,0.00021620384,0.00008869835],"about_ca_topic_score_codex":0.0008904227,"about_ca_topic_score_gemma":0.00007891476,"teacher_disagreement_score":0.06588621,"about_ca_system_score_codex":0.000069529684,"about_ca_system_score_gemma":0.00013901133,"threshold_uncertainty_score":0.45485127},"labels":[],"label_agreement":null},{"id":"W4385687828","doi":"10.4049/jimmunol.210.supp.68.03","title":"Examining methotrexate’s safety and efficacy in combination with immune checkpoint inhibitors to control immune related inflammatory arthritis in cancer","year":2023,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Arthritis; Immune system; Rheumatoid arthritis; Immunology; CD8; Cytotoxic T cell; Cancer research; Cancer; Hydroxychloroquine; Inflammatory arthritis; Inflammation; Internal medicine; In vitro; Biology; Disease","score_opus":0.013329256759602,"score_gpt":0.2639616700765685,"score_spread":0.2506324133169665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385687828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97784436,0.015791086,0.000021816919,0.0055044177,0.00030221426,0.000450367,0.0000018142134,0.000019642028,0.00006430886],"genre_scores_gemma":[0.98796415,0.011702244,0.000039790375,0.00012530916,0.000028892337,0.000011717719,0.0000026947337,0.00002441355,0.00010079138],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978404,0.00041182913,0.0011536177,0.00012363467,0.00018156573,0.0002889507],"domain_scores_gemma":[0.9987575,0.0003996956,0.000490378,0.00019725936,0.00011380726,0.000041360432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030617001,0.00016138118,0.00061299285,0.00062840583,0.00006413723,0.000009924026,0.00013322273,0.00012878909,0.00004534113],"category_scores_gemma":[0.00020437811,0.000108096356,0.00006404977,0.0008408092,0.00019944069,0.000109249915,0.000045925484,0.00062093226,0.000004935335],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034061983,0.00020678692,0.016892608,0.00003359479,0.0007018193,0.00029944477,0.008358436,0.000595076,0.8163577,0.000038832226,0.000025605621,0.122428134],"study_design_scores_gemma":[0.027208595,0.0019590973,0.9502409,0.0014446088,0.00006017459,0.0006333513,0.0020000422,0.000068254645,0.015726563,0.00003694804,0.0004879118,0.0001335618],"about_ca_topic_score_codex":0.00050047506,"about_ca_topic_score_gemma":0.00021770486,"teacher_disagreement_score":0.9333483,"about_ca_system_score_codex":0.0002592266,"about_ca_system_score_gemma":0.0001820598,"threshold_uncertainty_score":0.44080415},"labels":[],"label_agreement":null},{"id":"W4385700132","doi":"10.1038/s41698-023-00428-2","title":"Chemokine expression predicts T cell-inflammation and improved survival with checkpoint inhibition across solid cancers","year":2023,"lang":"en","type":"article","venue":"npj Precision Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Ontario Institute for Cancer Research; University of British Columbia; McGill University and Génome Québec Innovation Centre; McGill University Health Centre; Canada's Michael Smith Genome Sciences Centre; McGill University","funders":"Fonds de Recherche du Québec - Santé; Canadian Cancer Society Research Institute; Terry Fox Research Institute; Hebrew University of Jerusalem; Genome British Columbia; Pancreatic Cancer Canada Foundation; Government of Ontario; BC Cancer Foundation; Ontario Institute for Cancer Research; Ministère de la Santé; Ministère de la Santé et des Services sociaux; Princess Margaret Cancer Foundation; McGill University","keywords":"Medicine; Oncology; Internal medicine; Cancer; CXCL9; Immune checkpoint; Chemokine; CCL5; Biomarker; CXCL10; Immunotherapy; Immune system; Inflammation; T cell; Immunology; Biology","score_opus":0.019881229712794813,"score_gpt":0.3255169520978146,"score_spread":0.3056357223850198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385700132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944249,0.00013531167,0.00047488327,0.0014831667,0.00048318578,0.0007356127,0.000024695664,0.00018607058,0.0020521898],"genre_scores_gemma":[0.9966611,0.00083767925,0.0006417433,0.00013559387,0.00033058878,0.00012391184,0.00014964036,0.000034703,0.0010850414],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99839675,0.00008034228,0.00041908573,0.00042293637,0.0003139466,0.00036695626],"domain_scores_gemma":[0.9990557,0.00016097604,0.00022430853,0.00027016705,0.00014690254,0.00014198222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076783774,0.00019490231,0.00038357257,0.00012291518,0.00016354033,0.00002654166,0.00005968291,0.000280793,0.0001430553],"category_scores_gemma":[0.00007894827,0.00014479583,0.000066388966,0.00037590915,0.00015916477,0.00014895143,0.0000957719,0.00023103635,0.000020403146],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008504273,0.000056355766,0.0008645542,0.00008527419,0.000035383982,0.000034594847,0.0012881522,0.000029326884,0.89767253,0.0000014316556,0.0014420038,0.08998609],"study_design_scores_gemma":[0.014317841,0.0033282014,0.04558504,0.00038092854,0.000056289988,0.00010465467,0.0011700239,0.0027673894,0.9100052,0.00006321415,0.021965792,0.00025543902],"about_ca_topic_score_codex":0.0001179055,"about_ca_topic_score_gemma":0.00024288995,"teacher_disagreement_score":0.08973065,"about_ca_system_score_codex":0.00044839433,"about_ca_system_score_gemma":0.0002952032,"threshold_uncertainty_score":0.5904603},"labels":[],"label_agreement":null},{"id":"W4385702448","doi":"10.1097/01.hs9.0000971168.59900.67","title":"P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Refractory (planetary science); Cohort; Salvage therapy; Chemotherapy; Gastroenterology; Cancer; Immunotherapy","score_opus":0.03137807776785468,"score_gpt":0.3217374355978094,"score_spread":0.2903593578299547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385702448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971301,0.000044069166,0.0000015214868,0.00018060347,0.00005633754,0.002177906,0.00016211245,0.000057430305,0.00018993439],"genre_scores_gemma":[0.99786377,0.0000308351,0.00014489547,0.00008509125,0.000015238773,0.00018817351,0.0010742523,0.000053377375,0.0005443718],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9978977,0.0001848425,0.0005924325,0.00057918654,0.00045284774,0.00029302994],"domain_scores_gemma":[0.99890333,0.000078044795,0.00022304813,0.000590257,0.00010993063,0.00009536066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017262938,0.00028352163,0.0006081075,0.00016627656,0.000040457224,0.00003193749,0.00015558391,0.00013138604,0.00016249971],"category_scores_gemma":[0.000022105316,0.00018061911,0.0000210575,0.0009959014,0.00007668209,0.00027089473,0.000048536916,0.000117143616,0.000008797276],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6482593,0.07478619,0.2086949,0.000039872917,0.0004337167,0.0010261447,0.0060579455,0.000007856434,0.0012393617,0.000002087062,0.00047671088,0.05897591],"study_design_scores_gemma":[0.3253472,0.039052904,0.6321606,0.00033612462,0.000079932805,0.0000025988586,0.0017603429,0.00024620863,0.00046217273,0.0000027127692,0.000360418,0.00018881739],"about_ca_topic_score_codex":0.0026265497,"about_ca_topic_score_gemma":0.0069669206,"teacher_disagreement_score":0.42346567,"about_ca_system_score_codex":0.00049495214,"about_ca_system_score_gemma":0.0003000231,"threshold_uncertainty_score":0.73654336},"labels":[],"label_agreement":null},{"id":"W4385704562","doi":"10.1097/01.hs9.0000976692.37823.82","title":"PB2497: HEMATOLOGIC TOXICITIES WITH IMMUNOTHERAPY IN CANCER PATIENTS AT THE ALLAN BLAIR CANCER CENTRE: RETROSPECTIVE DATA COLLECTION STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Health Authority; Saskatchewan Health; University of Saskatchewan","funders":"","keywords":"Medicine; Cancer; Immunotherapy; Internal medicine; Oncology; Context (archaeology); Incidence (geometry); Neutropenia; Chemotherapy","score_opus":0.03287270210165945,"score_gpt":0.31162655776670695,"score_spread":0.2787538556650475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385704562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922052,0.0025752138,0.0000013219454,0.00212477,0.00032687304,0.0016635485,0.000112993395,0.00012839731,0.0008616835],"genre_scores_gemma":[0.9864344,0.002242419,0.000013671601,0.0005333362,0.00008271484,0.00030942485,0.00012508388,0.000047853955,0.0102110775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982294,0.000100499645,0.0003068179,0.0005225406,0.0004548838,0.0003858664],"domain_scores_gemma":[0.9989107,0.00006822831,0.00014670182,0.0007227978,0.000106328625,0.000045239543],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024666826,0.00024439953,0.00039327613,0.00006555941,0.00024753375,0.000030102416,0.00024830925,0.000087019274,0.0021001701],"category_scores_gemma":[0.000020399219,0.00014711113,0.00005438365,0.0011115348,0.00014034956,0.00009885609,0.00012416767,0.00020988155,0.000024485564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003629161,0.0005439661,0.9556688,0.00004918786,0.00046812766,0.000038852868,0.0044161766,0.000015872387,0.0006380976,0.0000052260393,0.032282155,0.0022443586],"study_design_scores_gemma":[0.008211148,0.00087149383,0.97293365,0.00027074706,0.00007815398,0.000010609432,0.008005475,0.00014855995,0.0012832026,0.000018303279,0.00790809,0.00026057984],"about_ca_topic_score_codex":0.0085141435,"about_ca_topic_score_gemma":0.085974954,"teacher_disagreement_score":0.07746081,"about_ca_system_score_codex":0.00090422796,"about_ca_system_score_gemma":0.00020876917,"threshold_uncertainty_score":0.998812},"labels":[],"label_agreement":null},{"id":"W4385705955","doi":"10.1097/01.hs9.0000971156.02746.02","title":"P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Refractory (planetary science); Oncology; Lymphoma; Cohort; Phases of clinical research; Cancer; Chemotherapy; Gastroenterology; Immunotherapy","score_opus":0.033128835339500215,"score_gpt":0.32422289692761935,"score_spread":0.2910940615881191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385705955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99702036,0.000031477986,0.0000033997826,0.00020947447,0.00007603896,0.002068717,0.00014556048,0.00007399082,0.00037097538],"genre_scores_gemma":[0.9978681,0.000022642054,0.00017622748,0.00011833892,0.000017490614,0.00007385454,0.0012567097,0.000059268044,0.00040734108],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9975358,0.00022907331,0.0006892326,0.0006267405,0.00059199095,0.0003271154],"domain_scores_gemma":[0.9986461,0.00012342946,0.00032239238,0.0006177736,0.00018542772,0.00010487936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003058072,0.00027882028,0.00065496156,0.00020083979,0.000058458052,0.000035581852,0.00025609738,0.00016048868,0.00013125394],"category_scores_gemma":[0.00006870618,0.00019359542,0.000019561954,0.0014909772,0.00010701169,0.00035685563,0.000080277016,0.00021731615,0.0000092853525],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66584986,0.070449345,0.19181101,0.00008809666,0.00050251564,0.00096237974,0.008608941,0.000019104733,0.003896383,0.000011614611,0.0024367922,0.055363964],"study_design_scores_gemma":[0.33144104,0.026265567,0.63633597,0.0005040986,0.000065898654,0.00000330012,0.0037535764,0.000528492,0.0005554691,0.000007322978,0.00030077633,0.00023845039],"about_ca_topic_score_codex":0.0024963443,"about_ca_topic_score_gemma":0.0041085933,"teacher_disagreement_score":0.44452497,"about_ca_system_score_codex":0.00031432966,"about_ca_system_score_gemma":0.00036789654,"threshold_uncertainty_score":0.78945917},"labels":[],"label_agreement":null},{"id":"W4385712768","doi":"10.4251/wjgo.v15.i8.1349","title":"Potential of damage associated molecular patterns in synergising radiation and the immune response in oesophageal cancer","year":2023,"lang":"en","type":"article","venue":"World Journal of Gastrointestinal Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Damp; Immunogenic cell death; Immune system; Medicine; Radioresistance; Cancer; Cancer research; Calreticulin; Ex vivo; Immunology; Cancer cell; Programmed cell death; Immunotherapy; Radiation therapy; In vivo; Apoptosis; Internal medicine; Biology","score_opus":0.01020253119645747,"score_gpt":0.3005735884040015,"score_spread":0.290371057207544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385712768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99056405,0.0011196294,0.00008284895,0.007864425,0.0001810554,0.00014737448,0.0000045247225,0.0000049771706,0.000031103238],"genre_scores_gemma":[0.99918115,0.00026958677,0.00017275762,0.00019284569,0.000051179864,0.0000040645423,0.0000027122617,0.000011146375,0.00011455214],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99818903,0.00059690507,0.0007206427,0.0000922498,0.00019781952,0.00020332707],"domain_scores_gemma":[0.99870276,0.00050305045,0.0005694718,0.00007998,0.00010175009,0.000042969525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027356567,0.00009492666,0.0004554141,0.0006094189,0.000023325569,0.000007541353,0.00008841857,0.000034229255,0.000039217095],"category_scores_gemma":[0.0004893299,0.00006899781,0.000115726674,0.0006245978,0.00016919433,0.00005250016,0.00003146757,0.0003940072,3.8005058e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13884608,0.00032601398,0.36753476,0.000057743957,0.00018253244,0.0073489216,0.0009099792,0.0022138194,0.46851844,0.000032305627,0.00015063341,0.0138787795],"study_design_scores_gemma":[0.014393742,0.0014389674,0.97912437,0.00092073967,0.00006571593,0.00107922,0.0003062847,0.0012251106,0.0013236818,0.000037123962,0.000038360464,0.000046689187],"about_ca_topic_score_codex":0.00040639154,"about_ca_topic_score_gemma":0.0004656429,"teacher_disagreement_score":0.6115896,"about_ca_system_score_codex":0.0003592805,"about_ca_system_score_gemma":0.0003342339,"threshold_uncertainty_score":0.28136492},"labels":[],"label_agreement":null},{"id":"W4385741022","doi":"10.1172/jci169823","title":"Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Dental and Craniofacial Research; National Cancer Institute; Pfizer Canada; Allos Therapeutics; Genentech; National Institutes of Health; Celldex Therapeutics; Astellas Pharma; Eisai; Memorial Sloan-Kettering Cancer Center; Geoffrey Beene Cancer Research Center; Fundación Alfonso Martín Escudero; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Daiichi Sankyo Europe; U.S. Department of Defense","keywords":"Head and neck squamous-cell carcinoma; Medicine; Blockade; Immune checkpoint; Oncology; Internal medicine; Adverse effect; Head and neck cancer; Head and neck; Disease; Cancer; Surgery; Receptor","score_opus":0.09400576823591318,"score_gpt":0.39880115054653764,"score_spread":0.3047953823106245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385741022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99653333,0.00089326204,0.0000024676694,0.0017875906,0.0005302461,0.00020528123,0.0000038427384,0.000009075097,0.000034876935],"genre_scores_gemma":[0.9978117,0.0006830637,0.0007369379,0.00030990178,0.00026654167,0.0000019068817,0.000002697349,0.000018302953,0.00016898365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950016,0.00056726066,0.0037904475,0.00018772724,0.00027263185,0.00018032728],"domain_scores_gemma":[0.996283,0.0015048148,0.0015980575,0.00023129827,0.00015874195,0.00022411463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008621067,0.00012660521,0.00084751105,0.00027168044,0.000027827873,0.000010548258,0.0001157403,0.00024263939,0.000024923833],"category_scores_gemma":[0.0029730054,0.000102532154,0.00039414922,0.00037058126,0.00038417047,0.00009747327,0.000043537544,0.00053393445,0.0000071753575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018706247,0.00020002807,0.86958486,0.000111929796,0.000023515253,0.00012498623,0.00027758107,0.00000677683,0.0997107,5.701936e-7,0.000120890225,0.011131924],"study_design_scores_gemma":[0.009960712,0.0039649284,0.960442,0.0003428192,0.00007658605,0.000080566926,0.0001238335,0.0006584076,0.023722785,0.00018475305,0.0003519749,0.00009061319],"about_ca_topic_score_codex":0.00008534777,"about_ca_topic_score_gemma":0.000023947448,"teacher_disagreement_score":0.09085717,"about_ca_system_score_codex":0.000051531177,"about_ca_system_score_gemma":0.0005868876,"threshold_uncertainty_score":0.41811398},"labels":[],"label_agreement":null},{"id":"W4385758521","doi":"10.3389/fimmu.2023.1229575","title":"Considerations for the clinical development of immuno-oncology agents in cancer","year":2023,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"CRIS Cancer Foundation; Instituto de Salud Carlos III; Centro de Investigación Biomédica en Red de Cáncer","keywords":"Drug development; Medicine; Clinical trial; Cancer; Intensive care medicine; Clinical Oncology; Oncology; Bioinformatics; Medical physics; Drug; Internal medicine; Pharmacology; Biology","score_opus":0.24952598196219067,"score_gpt":0.476657713599544,"score_spread":0.22713173163735334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385758521","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010856419,0.9902585,0.00024712775,0.00040663622,0.0062063094,0.0026305409,0.00005163323,0.000020768162,0.00006989554],"genre_scores_gemma":[0.000015546024,0.991508,0.0054331063,0.0001761967,0.00009938751,0.0020351026,0.000081382095,0.000054238215,0.0005970182],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965558,0.00035893638,0.002179562,0.00039471962,0.000109105844,0.00040187605],"domain_scores_gemma":[0.9972945,0.0015201293,0.0006205312,0.00046352466,0.000076030614,0.000025291129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014530582,0.00029458283,0.0024966928,0.00055100356,0.00010284757,0.0000084292315,0.00027902017,0.0007841651,0.00010101012],"category_scores_gemma":[0.0004473329,0.00020723451,0.00051409705,0.0005096566,0.0006146608,0.000023051338,0.000102385806,0.0006279729,0.000007251545],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054591673,0.00019305892,0.00043843169,0.0020643265,0.0025901992,0.000018106748,0.0005183538,6.685375e-7,0.0000027296232,0.000025041216,0.017259406,0.97634375],"study_design_scores_gemma":[0.0028617515,0.0002197051,0.0017563995,0.0045742546,0.00046080016,0.000025711193,0.00032898335,0.000010141537,0.000004153882,0.000109545814,0.9894694,0.00017916318],"about_ca_topic_score_codex":0.00018678061,"about_ca_topic_score_gemma":0.0009755816,"teacher_disagreement_score":0.9761646,"about_ca_system_score_codex":0.0009117031,"about_ca_system_score_gemma":0.005115177,"threshold_uncertainty_score":0.90741044},"labels":[],"label_agreement":null},{"id":"W4385760516","doi":"10.1016/j.medj.2023.07.006","title":"A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials","year":2023,"lang":"en","type":"article","venue":"Med","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Ontario Institute for Cancer Research; Université de Montréal; University of Toronto; University Health Network; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"Sociedad Española de Oncología Médica; Generalitat de Catalunya; Fundación Fero; Princess Margaret Cancer Foundation; Agencia Estatal de Investigación; Fundación Cellex; Fundación BBVA","keywords":"Immunotherapy; Medicine; Oncology; Clinical trial; Tumor microenvironment; Internal medicine; Cancer; Biomarker; Cohort; Cancer immunotherapy; Biology","score_opus":0.12871038245660793,"score_gpt":0.47959208807349857,"score_spread":0.35088170561689064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385760516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856101,0.0013078556,0.000023564658,0.009964528,0.001007811,0.001575218,0.00006045093,0.00013327648,0.00031714825],"genre_scores_gemma":[0.9890596,0.0054259137,0.00019502359,0.0023197962,0.0001596899,0.00055573107,0.000042158823,0.000038576894,0.0022034973],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997731,0.00022081194,0.0011199676,0.000320179,0.00025422618,0.00035385223],"domain_scores_gemma":[0.9980822,0.0012338606,0.00017425805,0.00031856267,0.00006678826,0.00012430448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032737742,0.00018618979,0.0010336153,0.00034195272,0.00008005256,0.000030330797,0.00012751886,0.00021560304,0.00021982842],"category_scores_gemma":[0.0007765646,0.00014448309,0.00023016208,0.0006285981,0.00014324057,0.00008653646,0.00005078799,0.00024176798,0.000033890672],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014328824,0.0011636182,0.29383355,0.00004645762,0.00086443464,0.00009375398,0.003154559,4.4841434e-7,0.022011291,0.0000888271,0.006152322,0.6582619],"study_design_scores_gemma":[0.049557053,0.0018634276,0.88628876,0.00013785099,0.000077885205,0.000010297291,0.00037740302,0.000048224858,0.00060357485,0.00018482696,0.060672134,0.00017854443],"about_ca_topic_score_codex":0.0004622355,"about_ca_topic_score_gemma":0.00022318677,"teacher_disagreement_score":0.6580834,"about_ca_system_score_codex":0.00019041928,"about_ca_system_score_gemma":0.00030079432,"threshold_uncertainty_score":0.58918494},"labels":[],"label_agreement":null},{"id":"W4385791542","doi":"10.1158/1078-0432.ccr-23-0370","title":"Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Shared Health","funders":"National Institute of Environmental Health Sciences; Cancer Research UK; National Cancer Institute; National Institute for Health and Care Research; Myriad Genetics","keywords":"Carboplatin; Docetaxel; Immune system; Oncology; Medicine; Internal medicine; Breast cancer; Triple-negative breast cancer; Cancer; Chemotherapy; Immunology; Cancer research; Cisplatin","score_opus":0.21338475753544037,"score_gpt":0.5400903936612291,"score_spread":0.32670563612578873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385791542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98968863,0.0011959337,0.0000011531665,0.006129471,0.00027531837,0.0021426838,0.00048843544,0.000018448363,0.000059894217],"genre_scores_gemma":[0.9956726,0.0030444236,0.000031800453,0.00011435893,0.000086348744,0.0004798658,0.000016029464,0.000031922722,0.00052267505],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9869589,0.009000946,0.0017524117,0.000560153,0.001153701,0.00057385437],"domain_scores_gemma":[0.9838715,0.0146224415,0.00030060372,0.0006190108,0.00043667032,0.00014975322],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.029895283,0.00023166431,0.0010333058,0.0011411305,0.00007534841,0.000024592811,0.0004186254,0.00019147685,0.000549328],"category_scores_gemma":[0.010306526,0.000149543,0.00029877032,0.0042852834,0.0018214661,0.00010619332,0.00014784641,0.0011813059,0.0000040350124],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9167264,0.00057249435,0.024565127,0.00013055181,0.00053036475,0.00013969399,0.0020728607,0.000024697763,0.04593255,0.0000028942695,0.00076389324,0.008538462],"study_design_scores_gemma":[0.06642567,0.004209254,0.91618747,0.0008220216,0.0001071108,0.000006842736,0.00625457,0.0008024384,0.00475643,0.000057871774,0.00023358979,0.00013672841],"about_ca_topic_score_codex":0.024707215,"about_ca_topic_score_gemma":0.002467333,"teacher_disagreement_score":0.89162236,"about_ca_system_score_codex":0.00036329057,"about_ca_system_score_gemma":0.0028071278,"threshold_uncertainty_score":0.99892694},"labels":[],"label_agreement":null},{"id":"W4385897815","doi":"10.1093/oncolo/oyad197","title":"Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; Legend Biotech; EMD Serono; Genentech; Revolution Medicines; Flatiron Health; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Sanofi; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Pfizer; National Center for Advancing Translational Sciences; LUNGevity Foundation","keywords":"Medicine; Immunotherapy; Internal medicine; Oncology; Pembrolizumab; Lung cancer; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Cancer; Progressive disease","score_opus":0.022751087646396148,"score_gpt":0.31742688171044264,"score_spread":0.2946757940640465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385897815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888659,0.0005859778,0.000009587389,0.007912502,0.00020111952,0.0006936842,0.000017066986,0.00004527356,0.001668861],"genre_scores_gemma":[0.99541825,0.0022635607,0.000055243123,0.0007340692,0.00004084124,0.000058705988,0.000012900909,0.000019594692,0.0013968606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990724,0.00004380105,0.00031287599,0.000187999,0.00015922917,0.00022371636],"domain_scores_gemma":[0.99936706,0.000176065,0.00015967725,0.0002254693,0.000038661372,0.000033056356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052616774,0.00014164796,0.0003817966,0.00011405413,0.000062458086,0.000012497903,0.00012925315,0.00010075842,0.00009429965],"category_scores_gemma":[0.000019694327,0.00009068381,0.00006653666,0.00042915758,0.00020747224,0.00003099958,0.00004182346,0.00015796527,0.0000039896418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011463929,0.00030680385,0.79578704,0.00021609175,0.00016456297,0.000030018724,0.002290266,0.000032678876,0.18883625,0.000038187714,0.0019852067,0.009166539],"study_design_scores_gemma":[0.008217159,0.00027144988,0.948275,0.00011326594,0.000062098334,0.000006421794,0.00058087823,0.0011965715,0.039539427,0.000040032664,0.0015708315,0.00012685794],"about_ca_topic_score_codex":0.0015835192,"about_ca_topic_score_gemma":0.000454084,"teacher_disagreement_score":0.152488,"about_ca_system_score_codex":0.0001478854,"about_ca_system_score_gemma":0.00013583453,"threshold_uncertainty_score":0.36979786},"labels":[],"label_agreement":null},{"id":"W4385948906","doi":"10.3410/f.742667056.793600420","title":"Faculty Opinions recommendation of KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.","year":2023,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Pembrolizumab; Placebo; Chemotherapy; Medicine; Double blind; Stage (stratigraphy); Internal medicine; Resection; Oncology; Surgery; Cancer; Immunotherapy; Alternative medicine; Pathology","score_opus":0.06448465581763016,"score_gpt":0.40973428266509865,"score_spread":0.3452496268474685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385948906","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002676748,0.00079117535,0.00021474107,0.042588864,0.00085784774,0.016916264,0.9382671,0.00008181589,0.000014498902],"genre_scores_gemma":[0.00026788673,0.0008706449,0.00026195464,0.0014472698,0.00024664585,0.0029072142,0.98962533,0.000097362186,0.0042756908],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99260366,0.000827681,0.003072617,0.0010766155,0.0018987253,0.000520718],"domain_scores_gemma":[0.98987645,0.00116153,0.0030750802,0.0015623495,0.0039751623,0.00034944384],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003409383,0.00088982156,0.0028483472,0.000834882,0.00033863616,0.00015162246,0.0009468275,0.0009829515,0.0003954868],"category_scores_gemma":[0.004653971,0.0005235366,0.0010594919,0.00266819,0.0005921896,0.00031750137,0.00019181422,0.0009858822,0.000007286185],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37048516,0.0014269076,0.0000019741274,0.008226933,0.0009277429,7.5732277e-7,0.00036142525,3.6012898e-7,0.000014060517,0.000005093534,0.617408,0.0011416166],"study_design_scores_gemma":[0.37714326,0.0027542622,0.000052852323,0.0067879483,0.00070860377,0.000021314421,0.00017718386,0.00008269232,0.0000879547,0.0000014950015,0.61185294,0.0003294682],"about_ca_topic_score_codex":0.00062186585,"about_ca_topic_score_gemma":0.00010668851,"teacher_disagreement_score":0.05135821,"about_ca_system_score_codex":0.00033016584,"about_ca_system_score_gemma":0.0016523487,"threshold_uncertainty_score":0.99972165},"labels":[],"label_agreement":null},{"id":"W4385978221","doi":"10.3390/curroncol30080559","title":"Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; London Health Sciences Centre; University of British Columbia; Western University","funders":"","keywords":"Durvalumab; Medicine; Lung cancer; Internal medicine; Pneumonitis; Chemoradiotherapy; Rash; Oncology; Stage (stratigraphy); Cancer; Adverse effect; Lung; Nivolumab; Immunotherapy","score_opus":0.05736792587421749,"score_gpt":0.40484672323015586,"score_spread":0.34747879735593834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385978221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952094,0.0015930408,0.00002085631,0.00042894672,0.0006721745,0.00037679548,0.000046151774,0.000029552375,0.0016230874],"genre_scores_gemma":[0.9928175,0.004483853,0.000027123551,0.000090991634,0.00011000801,0.00020490879,0.00014962544,0.000013879277,0.0021021152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988924,0.000055773526,0.0004195197,0.00024574492,0.00014472993,0.00024179021],"domain_scores_gemma":[0.9994013,0.00007358238,0.00017993865,0.00022269352,0.000067701025,0.00005480859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003495472,0.00011692843,0.0005171529,0.0009190444,0.000017884637,0.000003853414,0.00007310793,0.00008613774,0.00086062826],"category_scores_gemma":[0.000010502794,0.00010805311,0.00018604721,0.0024496813,0.00005660919,0.0000312143,0.000033066128,0.00015566467,0.000007540862],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025087849,0.00043109836,0.94841146,0.0003921539,0.0006564348,0.000035435754,0.0019336381,0.00018200796,0.0070950403,0.00000643571,0.0028790769,0.035468407],"study_design_scores_gemma":[0.005067773,0.00013408334,0.9628154,0.000092889815,0.00091539224,3.110813e-7,0.00017855222,0.012321192,0.0015762852,0.0000018410658,0.016779782,0.00011648652],"about_ca_topic_score_codex":0.0017954712,"about_ca_topic_score_gemma":0.00937269,"teacher_disagreement_score":0.03535192,"about_ca_system_score_codex":0.00064658164,"about_ca_system_score_gemma":0.00034436045,"threshold_uncertainty_score":0.94232756},"labels":[],"label_agreement":null},{"id":"W4386011732","doi":"10.15252/rc.2023531651","title":"Author Reply to Peer Reviews of Predicting developmental relationships of tumor resident and circulating T cells in ovarian cancer","year":2023,"lang":"en","type":"peer-review","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Ovarian cancer; Oncology; Cancer; Psychology; Biology; Internal medicine; Cancer research; Medicine","score_opus":0.11442181589751582,"score_gpt":0.36720126263116093,"score_spread":0.2527794467336451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386011732","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06980414,0.4726056,0.0002513052,0.38734514,0.007911801,0.025860375,0.0017640796,0.00030074647,0.03415685],"genre_scores_gemma":[0.0074692094,0.059231486,0.01674387,0.0100752255,0.0006061836,0.000976658,0.000682761,0.00023252802,0.9039821],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99664766,0.00018883706,0.0018464691,0.00046626746,0.0006121695,0.00023859063],"domain_scores_gemma":[0.9983126,0.00023901339,0.00072616787,0.0003330595,0.0002846629,0.000104474115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003961433,0.00026883924,0.0012433709,0.00035561607,0.000053201704,0.000008750553,0.00011602796,0.0001380516,0.00070028775],"category_scores_gemma":[0.0017653898,0.00022453058,0.00016883238,0.00082653144,0.0000503676,0.000042465133,0.00010295111,0.0004513408,0.0000077176155],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020232543,0.000030499861,0.014916032,0.0170764,0.00018387093,0.000018904248,0.0013303268,0.000002669541,0.006730041,0.0000061221026,0.9524815,0.007021318],"study_design_scores_gemma":[0.0009609882,0.00009974484,0.049736563,0.07153316,0.00031554178,0.000039786806,0.00044396037,0.000015779739,0.0018544204,0.000007999596,0.8746968,0.00029526727],"about_ca_topic_score_codex":0.008097426,"about_ca_topic_score_gemma":0.002722614,"teacher_disagreement_score":0.86982524,"about_ca_system_score_codex":0.00035484883,"about_ca_system_score_gemma":0.0006693641,"threshold_uncertainty_score":0.99850774},"labels":[],"label_agreement":null},{"id":"W4386084933","doi":"10.1002/path.6165","title":"Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer","year":2023,"lang":"en","type":"review","venue":"The Journal of Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre; University of Guelph; University of British Columbia; Trillium Health Centre; BC Cancer Agency","funders":"DOD Prostate Cancer Research Program; National Institute of Biomedical Imaging and Bioengineering; National Institute of Diabetes and Digestive and Kidney Diseases; Japan Society for the Promotion of Science; Medical Research Council; National Institutes of Health; KU Leuven; Ministerie van Volksgezondheid, Welzijn en Sport; Fondation ARC pour la Recherche sur le Cancer; Agence Nationale de la Recherche; Higher Education Authority; Susan G. Komen; National Health and Medical Research Council; AstraZeneca; Cancer Research Institute; Breast Cancer Now; Science Foundation Ireland; Prostate Cancer Foundation; European Commission; Svenska Sällskapet för Medicinsk Forskning; Cancer Research UK; National Heart, Lung, and Blood Institute; Peter MacCallum Cancer Centre; National Breast Cancer Foundation; U.S. Department of Veterans Affairs; U.S. Department of Defense; DOD Peer Reviewed Cancer Research Program; Breast Cancer Research Foundation; Engineering and Physical Sciences Research Council; Irish Cancer Society; National Cancer Institute; Gilead Sciences","keywords":"Breast cancer; Oncology; Biomarker; Medicine; Infiltration (HVAC); Immune system; Internal medicine; Cancer; Immunology; Biology; Geography","score_opus":0.1223017105000335,"score_gpt":0.48130078641076735,"score_spread":0.3589990759107339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386084933","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0053483504,0.9883685,0.000061586754,0.0010073434,0.0046721674,0.00041343752,0.000049780112,0.0000044004264,0.00007442886],"genre_scores_gemma":[0.0020544473,0.99695003,0.00015865336,0.00003475927,0.000691602,0.00003663757,0.000012155913,0.000025420688,0.000036301393],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996362,0.0012306521,0.0018033424,0.00017098513,0.0002807976,0.00015227875],"domain_scores_gemma":[0.9953672,0.00049278873,0.0035965086,0.000314151,0.00020256579,0.00002676785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031267595,0.00023448089,0.0014518568,0.000527372,0.000053221316,0.0000063811476,0.0003163459,0.00024817354,0.00007345846],"category_scores_gemma":[0.00008590156,0.00011992202,0.0005532196,0.000671572,0.00026009243,0.00003573507,0.00009043184,0.0007033667,1.748965e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010562823,0.00017027877,0.00045663616,0.0010085364,0.000770036,0.00009432594,0.00037198229,0.0000024012552,0.007798928,0.0000030682406,0.00008869905,0.98817885],"study_design_scores_gemma":[0.0023064518,0.0005335702,0.045425594,0.02039082,0.004026112,0.016455267,0.00038098308,0.00001896118,0.00066291506,0.00004436822,0.909521,0.00023397876],"about_ca_topic_score_codex":0.0011213372,"about_ca_topic_score_gemma":0.0005459535,"teacher_disagreement_score":0.98794484,"about_ca_system_score_codex":0.00040573167,"about_ca_system_score_gemma":0.0007427615,"threshold_uncertainty_score":0.4890278},"labels":[],"label_agreement":null},{"id":"W4386091349","doi":"10.1186/s40364-023-00513-5","title":"Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?","year":2023,"lang":"en","type":"review","venue":"Biomarker Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Medical Research Council; Medical Research Council; Terry Fox Foundation; Duke-NUS Medical School","keywords":"Medicine; Immunotherapy; Biomarker; Immune system; Cancer; Oncology; Cancer research; Immune checkpoint; Cancer immunotherapy; Immunology; Internal medicine; Biology","score_opus":0.48580214013810247,"score_gpt":0.5969145511737669,"score_spread":0.11111241103566444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386091349","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005960339,0.9804138,0.00002312288,0.004481977,0.0008072898,0.012616093,0.00065684615,0.00014405177,0.00026082047],"genre_scores_gemma":[0.00008773691,0.9911065,0.0003952193,0.0001072275,0.000548904,0.0041759536,0.0013518144,0.0002619802,0.001964665],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9912621,0.00140319,0.003160521,0.0014776902,0.0012572672,0.0014392253],"domain_scores_gemma":[0.9955758,0.0017501008,0.0005249276,0.0012103848,0.0004677173,0.00047109523],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.014010942,0.00065448653,0.0025626628,0.0030330282,0.00024558068,0.0001433514,0.00040136467,0.0008054038,0.00047949652],"category_scores_gemma":[0.0007757471,0.000550076,0.0018156946,0.0044874684,0.0003656857,0.00010695134,0.0004525242,0.0009590293,0.0004376505],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030959416,0.0003907041,0.00023454081,0.019726729,0.0013166671,0.00024805334,0.00008882038,8.358035e-9,0.000162137,0.000021435339,0.05092177,0.9237932],"study_design_scores_gemma":[0.0047928733,0.000839464,0.0037585471,0.027906824,0.00028222846,0.000070720045,0.0006581738,0.000005067569,0.00007425666,0.000099192905,0.9609719,0.0005407423],"about_ca_topic_score_codex":0.0006237194,"about_ca_topic_score_gemma":0.00070922397,"teacher_disagreement_score":0.92325246,"about_ca_system_score_codex":0.0014379063,"about_ca_system_score_gemma":0.001730505,"threshold_uncertainty_score":0.99969506},"labels":[],"label_agreement":null},{"id":"W4386121561","doi":"10.3892/ol.2023.14028","title":"Prognostic relevance of tumor‑infiltrating lymphocytes in residual tumor tissue from patients with triple‑negative breast cancer following neoadjuvant chemotherapy: A systematic review and meta‑analysis","year":2023,"lang":"en","type":"review","venue":"Oncology Letters","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Triple-negative breast cancer; Hazard ratio; Breast cancer; Oncology; Internal medicine; Tumor-infiltrating lymphocytes; Chemotherapy; Meta-analysis; Regimen; Confidence interval; Cochrane Library; Adjuvant therapy; Neoadjuvant therapy; Cancer; Immunotherapy","score_opus":0.027338480542564096,"score_gpt":0.33010644642690734,"score_spread":0.30276796588434324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386121561","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025964358,0.98913777,0.0000052413493,0.0012396313,0.00008742438,0.006341986,0.0005354596,0.000045216093,0.000010841265],"genre_scores_gemma":[0.00029840125,0.99198747,0.00072026445,0.0041280906,0.00005220087,0.0024402994,0.00019555965,0.000114802904,0.00006289662],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99584025,0.000719258,0.0017764055,0.00078689284,0.00045012304,0.00042706655],"domain_scores_gemma":[0.99580246,0.0016198615,0.0018674041,0.00051288854,0.00010076586,0.00009664281],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00071074336,0.00068132987,0.009751669,0.0004903074,0.00006280271,0.000019987616,0.00023832708,0.00016775246,0.00011524713],"category_scores_gemma":[0.00029415905,0.0004382428,0.0009633902,0.0018129788,0.00021052784,0.00009155512,0.00004762655,0.00039263978,0.000003859143],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007482387,0.00021044692,0.0011342192,0.7667342,0.21194704,0.0006145847,0.0005349109,0.0000024713593,0.000026550066,5.90923e-7,0.0003148903,0.0177319],"study_design_scores_gemma":[0.004073756,0.00049374247,0.0014331443,0.29323795,0.6984631,0.00008610922,0.000077081284,0.0000038623193,0.0000114504055,0.0000020409439,0.0015060535,0.0006117284],"about_ca_topic_score_codex":0.0018730297,"about_ca_topic_score_gemma":0.0008205093,"teacher_disagreement_score":0.48651603,"about_ca_system_score_codex":0.0008439489,"about_ca_system_score_gemma":0.0006967884,"threshold_uncertainty_score":0.99980694},"labels":[],"label_agreement":null},{"id":"W4386160179","doi":"10.21203/rs.3.rs-3277787/v1","title":"Ribosomal Protein S6 Kinase 2 (RPS6KB2) is a Potential immunotherapeutic target for cancer with up-regulating pro-inflammatory cytokines","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Wu Jieping Medical Foundation; University of Calgary","keywords":"Cancer research; Cancer; Immune system; Biology; Gene; Drug resistance; Apoptosis; Medicine; Immunology; Genetics","score_opus":0.07486066856212055,"score_gpt":0.3951454512714455,"score_spread":0.320284782709325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386160179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9503233,0.011266877,0.001198374,0.012559315,0.000995272,0.021298174,0.001532797,0.00064935914,0.0001765219],"genre_scores_gemma":[0.9356845,0.0011530779,0.004048909,0.0003957454,0.0032505242,0.02386841,0.001022589,0.00074756047,0.029828707],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99424183,0.0003199956,0.0007483063,0.0012911749,0.0019734744,0.0014252167],"domain_scores_gemma":[0.99653214,0.00015945073,0.00032678884,0.0012510342,0.0014686203,0.00026194268],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017791183,0.00064730714,0.00088721886,0.0007408882,0.0005738818,0.00021492015,0.000502371,0.0006290141,0.0007501313],"category_scores_gemma":[0.00013246093,0.00051378325,0.00056982524,0.0007265711,0.0005162689,0.00014805177,0.0004942874,0.0016582421,0.00003195546],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.120540716,0.0010820125,0.018514995,0.056434456,0.009212017,0.000718876,0.0068779,0.00089319935,0.65125155,0.00030303432,0.015629293,0.11854195],"study_design_scores_gemma":[0.055168368,0.013781836,0.077608384,0.07561974,0.0012359851,0.0002355538,0.0063195154,0.021824887,0.44817924,0.0039862273,0.29042757,0.0056126886],"about_ca_topic_score_codex":0.0017189217,"about_ca_topic_score_gemma":0.00022477885,"teacher_disagreement_score":0.27479827,"about_ca_system_score_codex":0.0009087421,"about_ca_system_score_gemma":0.0031103333,"threshold_uncertainty_score":0.99973136},"labels":[],"label_agreement":null},{"id":"W4386184698","doi":"10.1177/2050313x231195462","title":"Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: A case series and review of the literature","year":2023,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adverse effect; Immune system; Dupilumab; Immunotherapy; Dermatology; Avelumab; Immunology; Cancer; Pembrolizumab; Internal medicine; Atopic dermatitis","score_opus":0.014877140705149226,"score_gpt":0.31328278695709594,"score_spread":0.2984056462519467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386184698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9326936,0.057456437,5.187286e-7,0.005047387,0.0004929451,0.0039076754,0.0000841145,0.00004387263,0.0002734506],"genre_scores_gemma":[0.96222234,0.031622875,0.00003938362,0.00059795304,0.00006634397,0.00043879906,0.00024070844,0.000050199902,0.0047214176],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9972185,0.0001451315,0.0013789573,0.00044350862,0.0005120374,0.00030185023],"domain_scores_gemma":[0.9982114,0.00010942049,0.0005866541,0.0007285961,0.000120698096,0.00024327161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014382959,0.0002862321,0.0007623804,0.000064352425,0.00021049437,0.000020600137,0.000093112074,0.00026321862,0.0005284002],"category_scores_gemma":[0.0011327827,0.00017188728,0.000418989,0.0006561188,0.00015995678,0.00012477524,0.00022015089,0.00026965723,0.0000029137377],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024103916,0.00044354197,0.00011858412,0.0040277275,0.0009682646,0.881766,0.0020272932,5.9280783e-8,0.018506344,0.0000029998134,0.0017941679,0.08793458],"study_design_scores_gemma":[0.0038183487,0.001376346,0.000075011034,0.025841694,0.00042058717,0.9389078,0.0006757987,0.000007905754,0.011153359,0.000059585484,0.0174524,0.00021117773],"about_ca_topic_score_codex":0.0017765103,"about_ca_topic_score_gemma":0.00009612612,"teacher_disagreement_score":0.087723404,"about_ca_system_score_codex":0.0001823526,"about_ca_system_score_gemma":0.0006532512,"threshold_uncertainty_score":0.70093596},"labels":[],"label_agreement":null},{"id":"W4386219585","doi":"10.3390/curroncol30090570","title":"Two Cases of Durable and Deep Responses to Immune Checkpoint Inhibition-Refractory Metastatic Melanoma after Addition of Camu Camu Prebiotic","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Nivolumab; Medicine; Melanoma; Immune checkpoint; Immune system; Adverse effect; Internal medicine; Cancer research; Oncology; Immunology; Immunotherapy","score_opus":0.06647806795255667,"score_gpt":0.38013670680228806,"score_spread":0.3136586388497314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386219585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99178207,0.0063850326,0.000025774923,0.0005425545,0.00043664753,0.0005106361,0.00017915355,0.000030318697,0.000107802975],"genre_scores_gemma":[0.9982694,0.0010055338,0.00020009532,0.00006603064,0.000057501504,0.00010896308,0.000118243246,0.00001611881,0.00015814397],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99871844,0.00015965944,0.00053527823,0.000215303,0.00016067918,0.00021062941],"domain_scores_gemma":[0.998941,0.00042379185,0.00020665051,0.00021022913,0.00013345125,0.000084860076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003950812,0.00013738927,0.00045709452,0.0003257878,0.000034905846,0.0000041848334,0.000040893556,0.00005665385,0.000513669],"category_scores_gemma":[0.00028571745,0.00011841223,0.0001112424,0.0003582668,0.00020333887,0.000059971706,0.000050211765,0.000118009906,0.000019978175],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038525235,0.0019775303,0.02112155,0.0024667117,0.00072859885,0.00056395604,0.0055106515,0.00000939357,0.7824837,0.0000666122,0.0029773738,0.14356868],"study_design_scores_gemma":[0.01579554,0.013533833,0.7289212,0.0020109029,0.00093218946,0.0008917502,0.0038702246,0.00017091064,0.17930895,0.00022467683,0.0537963,0.0005435254],"about_ca_topic_score_codex":0.00017608191,"about_ca_topic_score_gemma":0.00019332959,"teacher_disagreement_score":0.7077997,"about_ca_system_score_codex":0.00015342726,"about_ca_system_score_gemma":0.00021391582,"threshold_uncertainty_score":0.5624315},"labels":[],"label_agreement":null},{"id":"W4386346756","doi":"10.1177/10781552231199048","title":"Utilization and toxicity patterns of 2-weekly (Q2W) versus 4-weekly (Q4W) nivolumab for treatment of adjuvant and metastatic melanoma at BC cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Dosing; Medicine; Incidence (geometry); Nivolumab; Adverse effect; Cancer; Internal medicine; Immunotherapy","score_opus":0.16286691192930697,"score_gpt":0.46567016003911027,"score_spread":0.3028032481098033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386346756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843185,0.0068295477,0.00009845473,0.007478296,0.0005759621,0.0004512462,0.00007969329,0.000006920596,0.00016141428],"genre_scores_gemma":[0.9487074,0.04951691,0.0008440882,0.00029628194,0.00014147868,0.000023778532,0.000011712529,0.000018908837,0.0004394647],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99869555,0.00017685675,0.0006097793,0.00014256894,0.00021029753,0.00016493059],"domain_scores_gemma":[0.9969143,0.001417158,0.0011390555,0.000092625516,0.00033505715,0.000101792284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006397212,0.0001354109,0.00059339835,0.00017222001,0.000060283484,0.0000060648304,0.000051444047,0.00004847719,0.00013632755],"category_scores_gemma":[0.00025528602,0.00010487304,0.00012317522,0.00015907286,0.00009773192,0.0002488361,0.000024482079,0.00008122729,6.8475356e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17692369,0.0021909724,0.02948644,0.0006754681,0.0054788115,0.0003375566,0.003582089,0.000023302593,0.21041617,0.000016853564,0.005197063,0.56567156],"study_design_scores_gemma":[0.12854986,0.038604878,0.054737084,0.00031601498,0.008808143,0.0019618087,0.004515697,0.0017084075,0.22493027,0.00002705788,0.53554803,0.0002927307],"about_ca_topic_score_codex":0.00043821035,"about_ca_topic_score_gemma":0.0001350047,"teacher_disagreement_score":0.56537884,"about_ca_system_score_codex":0.00039974166,"about_ca_system_score_gemma":0.00041691907,"threshold_uncertainty_score":0.42765987},"labels":[],"label_agreement":null},{"id":"W4386350530","doi":"10.1109/isbi53787.2023.10230665","title":"Ensemble Tabnet Predicting a T-Cell/MHC-I-Based Immune Profile Biomarker for Colorectal Liver Metastases from CT Images","year":2023,"lang":"en","type":"article","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Polytechnique Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Colorectal cancer; Immune system; Major histocompatibility complex; Artificial intelligence; Confidence interval; Test set; T cell; Computer science; Medicine; Machine learning; Oncology; Internal medicine; Immunology; Cancer","score_opus":0.026176991466381427,"score_gpt":0.28010613048988015,"score_spread":0.25392913902349873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386350530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880486,0.0022794716,0.0013559248,0.00081627094,0.00046377096,0.0020266362,0.0012095189,0.0006468323,0.0031529553],"genre_scores_gemma":[0.98603284,0.00012561402,0.0054741288,0.00046252838,0.00015802639,0.0004826665,0.0017121639,0.00007110307,0.0054809293],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99829584,0.00006427108,0.00042121846,0.00045256419,0.00028811026,0.00047797713],"domain_scores_gemma":[0.9987449,0.0005751757,0.00013436406,0.00032712804,0.000109415945,0.0001090101],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048457552,0.0002655466,0.00042569957,0.00020186104,0.00017462693,0.000052405292,0.00013054564,0.00007260304,0.0019791317],"category_scores_gemma":[0.00011548197,0.00020963044,0.00034858088,0.00052289024,0.000116728865,0.00010565269,0.00004879807,0.00011069415,0.00012468366],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005536844,0.00026987592,0.0047415313,0.00019734075,0.0005034259,0.000112607806,0.000117125084,0.000003946959,0.89585894,0.0000037207844,0.07165358,0.021001043],"study_design_scores_gemma":[0.008557908,0.00080849737,0.039492037,0.00015278123,0.00034079232,0.000019164043,0.0005412455,0.01236772,0.91876173,0.000018519358,0.018610412,0.0003291882],"about_ca_topic_score_codex":0.0017994923,"about_ca_topic_score_gemma":0.00007300942,"teacher_disagreement_score":0.053043168,"about_ca_system_score_codex":0.00008167818,"about_ca_system_score_gemma":0.00021908706,"threshold_uncertainty_score":0.9989332},"labels":[],"label_agreement":null},{"id":"W4386369507","doi":"10.3390/curroncol30090589","title":"Effects of Acetaminophen Exposure on Outcomes of Patients Receiving Immune Checkpoint Inhibitors for Advanced Non-Small-Cell Lung Cancer: A Propensity Score-Matched Analysis","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Atezolizumab; Pembrolizumab; Nivolumab; Internal medicine; Oncology; Propensity score matching; Lung cancer; Concomitant; Blockade; Cancer; Immunotherapy","score_opus":0.04018058443792568,"score_gpt":0.34164755354218507,"score_spread":0.3014669691042594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386369507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99400383,0.0017576359,0.00008332894,0.00017768543,0.0014884173,0.0023622625,0.000042738673,0.000040361392,0.000043738837],"genre_scores_gemma":[0.9981304,0.00081872643,0.00012634517,0.000034223718,0.00005637236,0.000559798,0.00011561184,0.000026295984,0.00013226314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818707,0.0000923763,0.00078308076,0.00036557397,0.00024115549,0.00033075057],"domain_scores_gemma":[0.9982462,0.00037894121,0.00068008585,0.00032449496,0.0002953297,0.000074970536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041666834,0.00023771767,0.0012673641,0.00039027177,0.000055487373,0.000003847674,0.00014888046,0.00015104917,0.000020931237],"category_scores_gemma":[0.00019737148,0.00018699252,0.00058942003,0.0009250414,0.000098932804,0.000041320665,0.00008307364,0.00018041607,0.000001698219],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003992889,0.0012696115,0.8312415,0.0028163348,0.0014345804,0.0000030595452,0.0014895363,0.00006345167,0.094252005,8.2958985e-7,0.00024033799,0.06319589],"study_design_scores_gemma":[0.010563578,0.0018776791,0.81367314,0.00047421438,0.001418467,1.5800762e-7,0.00009806577,0.00022932563,0.17113547,0.0000029258326,0.0003763195,0.00015067305],"about_ca_topic_score_codex":0.00009557618,"about_ca_topic_score_gemma":0.00007954752,"teacher_disagreement_score":0.07688346,"about_ca_system_score_codex":0.00035508955,"about_ca_system_score_gemma":0.00024032898,"threshold_uncertainty_score":0.76253337},"labels":[],"label_agreement":null},{"id":"W4386521145","doi":"10.5505/ktd.2023.91298","title":"Tumor-infiltrating lymphocytes may predict prognosis in breast cancer patients receiving neoadjuvant chemotherapy","year":2023,"lang":"en","type":"article","venue":"Kocaeli Medical Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stantec (Canada)","funders":"","keywords":"Breast cancer; Medicine; Chemotherapy; Oncology; Internal medicine; Neoadjuvant therapy; Cancer","score_opus":0.01233100911286323,"score_gpt":0.28630937104365217,"score_spread":0.27397836193078895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386521145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769455,0.00069588097,0.000016603308,0.02020512,0.0010126631,0.00035759594,0.00002118215,0.00013225115,0.000613189],"genre_scores_gemma":[0.98912984,0.0051920973,0.00012636145,0.004074658,0.0011526075,0.000059829803,0.000020069356,0.00005664267,0.00018790412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99657214,0.00012029029,0.0008446675,0.0003194083,0.0014549425,0.0006885274],"domain_scores_gemma":[0.9987742,0.00015046199,0.00024681745,0.00015112374,0.00016103814,0.0005164015],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013213245,0.00025806014,0.00047158301,0.00032994652,0.00017286901,0.00007108571,0.00025056355,0.00017951551,0.0021077825],"category_scores_gemma":[0.0002820269,0.00019283169,0.0002063298,0.0009197044,0.00016286231,0.00016683442,0.000047230016,0.0007185092,0.000032096566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001098755,0.00025181816,0.6323131,0.00006949308,0.000141828,0.0004319379,0.00046226464,0.0000038956573,0.0009313375,0.000002083985,0.012947413,0.35134608],"study_design_scores_gemma":[0.010681807,0.00032546176,0.97690797,0.0031146589,0.000039649585,0.0016143048,0.0003263265,0.001367069,0.001091035,0.000023739993,0.004270065,0.00023789264],"about_ca_topic_score_codex":0.00024133622,"about_ca_topic_score_gemma":0.000046683606,"teacher_disagreement_score":0.3511082,"about_ca_system_score_codex":0.00055304274,"about_ca_system_score_gemma":0.0010616946,"threshold_uncertainty_score":0.99880445},"labels":[],"label_agreement":null},{"id":"W4386545786","doi":"10.1002/ccr3.7897","title":"Hypoglycemia as first presentation of presumed immune checkpoint inhibitor‐induced type 1 diabetes","year":2023,"lang":"en","type":"article","venue":"Clinical Case Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Lawson Health Research Institute; Western University","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Hypoglycemia; Renal cell carcinoma; Immunotherapy; Presentation (obstetrics); Diabetes mellitus; Type 2 Diabetes Mellitus; Type 2 diabetes; Type 1 diabetes; Internal medicine; Immune system; Oncology; Immunology; Surgery; Endocrinology","score_opus":0.06864069643421976,"score_gpt":0.38629771931395895,"score_spread":0.3176570228797392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386545786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995637,0.00050140085,7.026004e-7,0.0007359655,0.0015662757,0.00054762984,0.0000033556641,0.00012275156,0.0008849079],"genre_scores_gemma":[0.9980958,0.00033822327,0.00005030695,0.00011057159,0.0003425985,0.000029683652,0.00007732657,0.000029139266,0.0009263335],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99747145,0.00007096235,0.001534523,0.00036891963,0.00031215933,0.00024197409],"domain_scores_gemma":[0.99803513,0.0004493836,0.00055316585,0.0006125761,0.00020165098,0.0001481147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013410186,0.00014506374,0.00048689626,0.00009962191,0.00006518058,0.000012430618,0.000034772693,0.0002176095,0.0002460453],"category_scores_gemma":[0.0023161503,0.000121881974,0.00034504168,0.0005236229,0.0001466195,0.00006707853,0.00006702387,0.00022970782,0.000044880213],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012410269,0.0018787043,0.32590708,0.0016542574,0.002116455,0.15726645,0.0010450245,0.000022555625,0.38498065,0.000012668023,0.024288913,0.08841696],"study_design_scores_gemma":[0.006853123,0.0044037206,0.57235646,0.0010156075,0.0006068084,0.015793178,0.00044616373,0.00042226748,0.37239626,0.00028878188,0.02485312,0.00056449376],"about_ca_topic_score_codex":0.0002699213,"about_ca_topic_score_gemma":0.00002013013,"teacher_disagreement_score":0.24644938,"about_ca_system_score_codex":0.00004688818,"about_ca_system_score_gemma":0.00024137093,"threshold_uncertainty_score":0.49702027},"labels":[],"label_agreement":null},{"id":"W4386579317","doi":"10.1097/01.eem.0000654992.36759.67","title":"Special Report","year":2020,"lang":"en","type":"article","venue":"Emergency Medicine News","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chemistry","score_opus":0.05997303991813887,"score_gpt":0.3378937444819039,"score_spread":0.27792070456376505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386579317","genre_codex":"other","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09343304,0.0028758834,0.00039290686,0.18203402,0.012454207,0.0006771672,0.000004159221,0.00022954374,0.7078991],"genre_scores_gemma":[0.3332476,0.013782874,0.0011904085,0.048332624,0.43400964,0.000108873115,0.0004416978,0.0002632221,0.16862305],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99844927,0.000020772353,0.0006221188,0.00031079593,0.00038435136,0.0002127199],"domain_scores_gemma":[0.9992304,0.000010191999,0.0001311578,0.00028193652,0.000073367424,0.00027294422],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015745728,0.00015551725,0.0003401728,0.00005002609,0.00004915013,0.0000012135176,0.0000917115,0.000063506726,0.05870939],"category_scores_gemma":[0.000324591,0.000113496266,0.000141779,0.00043285906,0.00007874742,0.000043163836,0.000020446461,0.00016740337,0.00017218325],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007558387,0.00003210928,0.013003661,0.000048446575,0.00008193738,0.00028341182,0.000939254,1.5146922e-7,0.013931662,0.00003713375,0.9582714,0.0126149915],"study_design_scores_gemma":[0.0018575711,0.00068934174,0.016346129,0.000043328713,0.00008517315,0.00015883455,0.00036333487,0.000012382118,0.0005003591,0.00003101264,0.97979486,0.000117694486],"about_ca_topic_score_codex":0.00023834314,"about_ca_topic_score_gemma":0.000034732893,"teacher_disagreement_score":0.539276,"about_ca_system_score_codex":0.00003236868,"about_ca_system_score_gemma":0.00008684009,"threshold_uncertainty_score":0.94215107},"labels":[],"label_agreement":null},{"id":"W4386608057","doi":"10.1016/j.immuni.2023.08.009","title":"Tertiary lymphoid structures and B cells: An intratumoral immunity cycle","year":2023,"lang":"en","type":"review","venue":"Immunity","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":284,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sorbonne Université; Institute of Cancer Research; Institut National Du Cancer; Ligue Contre le Cancer; Institut National de la Santé et de la Recherche Médicale; Fondation ARC pour la Recherche sur le Cancer; Agence Nationale de la Recherche; Université de Paris; Association pour la Recherche sur le Cancer","keywords":"Biology; Follicular dendritic cells; Immunity; Antibody; Immunology; Context (archaeology); Immune system; Antigen; Affinity maturation; Antigen presentation; Lymphatic system; Cancer research; Antigen-presenting cell; T cell","score_opus":0.049468271695075096,"score_gpt":0.35239872088754676,"score_spread":0.30293044919247164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386608057","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01428135,0.9834465,0.000001518827,0.000024722422,0.0006321764,0.00084153883,0.00015632596,0.00024598106,0.00036988457],"genre_scores_gemma":[0.0011350327,0.99710053,0.00010542341,0.00018541189,0.0002506305,0.000057830406,0.00062820123,0.00012500396,0.00041192726],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99762523,0.00059331604,0.0007000114,0.00039734683,0.00025440552,0.00042967979],"domain_scores_gemma":[0.99801296,0.0001826422,0.00029216238,0.0012459279,0.00006223778,0.00020408834],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006316347,0.00057611766,0.0016024323,0.00027514977,0.00032255775,0.00010280778,0.00042552355,0.00047124096,0.00020693392],"category_scores_gemma":[0.000053242038,0.00044663934,0.00043320592,0.00047102213,0.00036069038,0.00014970645,0.0002449648,0.0010730783,0.00004350632],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021229136,0.00013167641,0.000034927798,0.010598542,0.0007132977,0.0000714981,0.00025811567,6.922928e-8,0.00029007925,0.000013638628,0.0005016768,0.9871742],"study_design_scores_gemma":[0.0020029834,0.00059205823,0.0038796437,0.011614031,0.002232395,0.0012866438,0.00038907514,0.0000110898445,0.00025724235,0.0003346378,0.97635466,0.0010455693],"about_ca_topic_score_codex":0.0032183211,"about_ca_topic_score_gemma":0.00012394672,"teacher_disagreement_score":0.9861286,"about_ca_system_score_codex":0.00023654383,"about_ca_system_score_gemma":0.00056799024,"threshold_uncertainty_score":0.99979854},"labels":[],"label_agreement":null},{"id":"W4386608462","doi":"10.1016/j.ccell.2023.08.003","title":"Peeling the I-Onion to Demystify Pseudoprogression","year":2023,"lang":"en","type":"letter","venue":"Cancer Cell","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Cancer; Oncology; Immunotherapy","score_opus":0.039094765389411826,"score_gpt":0.32689217241695673,"score_spread":0.2877974070275449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386608462","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027100386,0.014120938,0.00003039464,0.97427845,0.004088858,0.0010609651,0.00006491815,0.00021174605,0.0034337007],"genre_scores_gemma":[0.0013023473,0.0039629634,0.00010632753,0.9245711,0.012134937,0.000422309,0.00018688846,0.00016933885,0.0571438],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981912,0.000054139917,0.0003062304,0.00048128588,0.000501407,0.00046575864],"domain_scores_gemma":[0.998963,0.000101370366,0.00014042029,0.00059929455,0.00009461586,0.000101320096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024743343,0.00030584115,0.00036112856,0.00008704664,0.0001627594,0.000050224313,0.000277177,0.00052233104,0.0008109534],"category_scores_gemma":[0.000024437635,0.00019080311,0.00024857934,0.00034805614,0.000068747766,0.000029187311,0.00007946971,0.0010963568,0.00032542075],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002868702,0.00000920679,0.00009942932,0.00034026927,0.00008333749,0.00013216342,0.00025502185,0.000003984515,0.003926105,2.553334e-7,0.97341263,0.02145074],"study_design_scores_gemma":[0.00064392854,0.00012688155,0.0003223319,0.001063857,0.00016669645,0.000016807939,0.00007991093,0.000021632759,0.0039126324,0.0000071693094,0.99339014,0.00024802852],"about_ca_topic_score_codex":0.000842244,"about_ca_topic_score_gemma":0.000067883586,"teacher_disagreement_score":0.0537101,"about_ca_system_score_codex":0.0005002905,"about_ca_system_score_gemma":0.00039021924,"threshold_uncertainty_score":0.8879371},"labels":[],"label_agreement":null},{"id":"W4386691447","doi":"10.1158/1078-0432.ccr-23-1953","title":"Rerouting the GPS Directing Immunotherapy in Endometrial Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Endometrial cancer; Immunotherapy; Global Positioning System; Cancer; Medicine; Cancer immunotherapy; Cancer research; Oncology; Internal medicine; Computer science; Telecommunications","score_opus":0.3971738174280782,"score_gpt":0.5891527291047443,"score_spread":0.19197891167666603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386691447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96654314,0.010274339,0.0000028129707,0.01813997,0.001711125,0.0010290144,0.000015054062,0.00012107296,0.002163474],"genre_scores_gemma":[0.95608795,0.035243634,0.0000266396,0.0011243377,0.0024337047,0.0006117087,0.0000056787685,0.00005824126,0.0044081067],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995757,0.0008874432,0.0009115405,0.0005503405,0.0009847442,0.00090897054],"domain_scores_gemma":[0.9941632,0.004759631,0.00012101277,0.00058101997,0.00024425908,0.00013086777],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.014299382,0.00016119932,0.0004927934,0.00046976955,0.00034879387,0.00007455208,0.00041046334,0.00020250898,0.0011246639],"category_scores_gemma":[0.0026172458,0.0001055254,0.0003060087,0.004441846,0.0005686087,0.000069172194,0.00016723826,0.0017205593,0.00009484379],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010367891,0.00014840168,0.29747635,0.0000639241,0.00027809408,0.00007199874,0.0008888101,0.000018483252,0.009039347,0.000035967867,0.014219365,0.66739136],"study_design_scores_gemma":[0.015583191,0.00077114213,0.70152324,0.0009084405,0.000031131825,0.000008895144,0.0015008175,0.0006061392,0.0029087784,0.0002628814,0.27558225,0.00031308597],"about_ca_topic_score_codex":0.008990774,"about_ca_topic_score_gemma":0.0016317762,"teacher_disagreement_score":0.66707826,"about_ca_system_score_codex":0.00052741665,"about_ca_system_score_gemma":0.0008736626,"threshold_uncertainty_score":0.99978846},"labels":[],"label_agreement":null},{"id":"W4386725951","doi":"10.1158/2159-8290.cd-23-0436","title":"Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial","year":2023,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Pharmacyclics; Genentech; Novocure; Amgen; Aeglea BioTherapeutics; Regeneron Pharmaceuticals; Pfizer; Agios Pharmaceuticals; Society for Immunotherapy of Cancer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Oncology; Immune system; Internal medicine; Lung cancer; Clinical endpoint; Surgical oncology; Cancer; Immunotherapy; Clinical trial; Cancer research; Immunology; Nivolumab","score_opus":0.061998186632568335,"score_gpt":0.3770023694520501,"score_spread":0.3150041828194818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386725951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865675,0.0029576332,0.00003261086,0.0048142984,0.0019168763,0.0026582172,0.00037388716,0.00009709172,0.0005819016],"genre_scores_gemma":[0.97812927,0.005437302,0.000018853392,0.0019484285,0.00071216776,0.0015536768,0.00019332606,0.00008487708,0.011922077],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975278,0.000060534752,0.00063367054,0.00051246904,0.00051540864,0.00075011206],"domain_scores_gemma":[0.99875456,0.00020181258,0.00027088844,0.000588305,0.00007636597,0.000108072716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006109047,0.0003462732,0.00076377497,0.00022490034,0.00040410456,0.00009697889,0.0003193113,0.00016795503,0.000654357],"category_scores_gemma":[0.000050841107,0.0002001786,0.0001705155,0.0013908382,0.00032379982,0.00043409714,0.00016281169,0.00041155904,0.0000050354033],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88634616,0.0016123166,0.0021800883,0.00021821313,0.0012029719,0.0003460371,0.0037451435,0.0003794625,0.027974036,0.000034833625,0.044507135,0.0314536],"study_design_scores_gemma":[0.79201627,0.020417018,0.0134962825,0.0023078893,0.00072757126,0.00012838871,0.004225931,0.0042472417,0.010876032,0.000028662553,0.15055759,0.0009711401],"about_ca_topic_score_codex":0.0095526,"about_ca_topic_score_gemma":0.01842864,"teacher_disagreement_score":0.10605046,"about_ca_system_score_codex":0.0013820716,"about_ca_system_score_gemma":0.002877271,"threshold_uncertainty_score":0.99948245},"labels":[],"label_agreement":null},{"id":"W4386742019","doi":"10.1080/2162402x.2023.2253642","title":"Homogeneity in immune features between colorectal liver metastases better identifies patients with good prognosis compared to pathological response to preoperative chemotherapy","year":2023,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé; Institute of Cancer Research; Institut Du Cancer de Montréal; International Hepato-Pancreato-Biliary Association; Ethicon; Université de Montréal","keywords":"Medicine; Chemotherapy; Colorectal cancer; Pathological; Immune system; Grading (engineering); Oncology; Internal medicine; Pathology; Gastroenterology; Cancer; Immunology; Biology","score_opus":0.01867915437774884,"score_gpt":0.2863768383331473,"score_spread":0.26769768395539845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386742019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99308836,0.00040950783,0.000013238741,0.0040255357,0.00014034285,0.0019222101,0.0001776501,0.00015077542,0.000072371295],"genre_scores_gemma":[0.9966962,0.00005963193,0.0007435935,0.0011845884,0.00004554102,0.00048126758,0.00024427142,0.000040853472,0.0005040927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976563,0.00049564784,0.00043958132,0.0005713695,0.00029007002,0.000547058],"domain_scores_gemma":[0.998947,0.00031947502,0.00009765025,0.00037132256,0.00016515923,0.00009939167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060013356,0.0003225263,0.00077141146,0.0004863153,0.00013372794,0.000041113948,0.00024870128,0.00020276291,0.00017169511],"category_scores_gemma":[0.000148214,0.00023702774,0.00012893774,0.0011990586,0.0002421404,0.00009246875,0.00015344277,0.0003037537,0.00012651233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0631884,0.0006702171,0.79260147,0.000025990455,0.0006905006,0.00020090342,0.0046372814,0.0000064389274,0.12039538,0.000003969018,0.0014703071,0.016109142],"study_design_scores_gemma":[0.0056273253,0.004328321,0.9446874,0.000121024976,0.00006933721,0.000018266459,0.00044959597,0.0000010282131,0.04162133,0.0000050727886,0.0027930783,0.00027818323],"about_ca_topic_score_codex":0.00033377545,"about_ca_topic_score_gemma":0.00031522906,"teacher_disagreement_score":0.15208596,"about_ca_system_score_codex":0.00023882242,"about_ca_system_score_gemma":0.000116494804,"threshold_uncertainty_score":0.96657103},"labels":[],"label_agreement":null},{"id":"W4386742277","doi":"10.3390/curroncol30090611","title":"Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"AstraZeneca; U.S. Department of Veterans Affairs","keywords":"Durvalumab; Medicine; Discontinuation; Interquartile range; Stage (stratigraphy); Internal medicine; Population; Hazard ratio; Cancer; Chemoradiotherapy; Confidence interval","score_opus":0.0811667729709135,"score_gpt":0.43075441941727105,"score_spread":0.34958764644635754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386742277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99181116,0.0002255196,0.000089626024,0.0013686301,0.000640633,0.005379758,0.000243135,0.00003539457,0.00020612458],"genre_scores_gemma":[0.99515396,0.00086598675,0.00001826965,0.00018124182,0.00013176522,0.002410048,0.0004564546,0.000022398364,0.000759874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984853,0.00018328454,0.00040308444,0.00032932972,0.00023772425,0.0003612496],"domain_scores_gemma":[0.9991873,0.00020720118,0.00020314913,0.0002423494,0.00009795181,0.000062073064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049610285,0.00018189686,0.0003549177,0.00021623824,0.00014436114,0.0000226112,0.00011166854,0.000043509834,0.00006221026],"category_scores_gemma":[0.000007424899,0.00011700343,0.000072024966,0.00047877355,0.000028787843,0.000048114518,0.00001426173,0.00012841391,0.000001829887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006019947,0.0046642544,0.9293306,0.00030716698,0.00012887329,0.000014973844,0.011812505,0.000024295703,0.000021655982,0.000004775136,0.0013417536,0.046329223],"study_design_scores_gemma":[0.02921516,0.015404543,0.9314668,0.00016797052,0.000114680784,9.287455e-7,0.002974893,0.00068080693,0.000050659513,0.0000015131744,0.019780722,0.00014132928],"about_ca_topic_score_codex":0.004373619,"about_ca_topic_score_gemma":0.099247076,"teacher_disagreement_score":0.09487346,"about_ca_system_score_codex":0.0010872092,"about_ca_system_score_gemma":0.001005883,"threshold_uncertainty_score":0.9171893},"labels":[],"label_agreement":null},{"id":"W4386764738","doi":"10.1200/jco.23.00170","title":"Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Internal medicine; Chemotherapy; Cancer; Oncology; Population; Esophageal cancer; Quality of life (healthcare); Adenocarcinoma; Gastroenterology; Immunotherapy; Nursing","score_opus":0.08815538424877481,"score_gpt":0.4211214824627632,"score_spread":0.33296609821398837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386764738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916762,0.0011648939,0.000073819385,0.0051592584,0.0012011382,0.0006195127,0.00003058869,0.00003311038,0.000041477113],"genre_scores_gemma":[0.9936672,0.0019394385,0.0018896359,0.0018476392,0.0003925313,0.000015633632,0.000034498433,0.0000555424,0.00015789579],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99426216,0.0005432632,0.0035646504,0.00038858963,0.00076962734,0.00047169562],"domain_scores_gemma":[0.9939074,0.0009800053,0.0039496995,0.00030889254,0.0004578523,0.00039614638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022872526,0.00029715855,0.0026433584,0.00028028892,0.00005460705,0.000008761404,0.00021687368,0.00037660787,0.00040025564],"category_scores_gemma":[0.0003727554,0.0001884375,0.0003504122,0.0009263275,0.00033825944,0.00018471174,0.000023448352,0.0009678563,0.0000046718055],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4424859,0.0010248813,0.4359347,0.000047861948,0.0010111512,0.00008447466,0.0003092318,0.00015202892,0.00005940631,0.0000011980661,0.00059968827,0.11828946],"study_design_scores_gemma":[0.15582494,0.03805108,0.8048807,0.00025267203,0.00009066072,0.0000115201,0.00020882837,0.000093208255,0.00005016787,0.0000074413647,0.00040542323,0.00012336602],"about_ca_topic_score_codex":0.0014158067,"about_ca_topic_score_gemma":0.0009842338,"teacher_disagreement_score":0.368946,"about_ca_system_score_codex":0.0008406764,"about_ca_system_score_gemma":0.004584932,"threshold_uncertainty_score":0.8133472},"labels":[],"label_agreement":null},{"id":"W4386766337","doi":"10.1126/sciimmunol.adg1487","title":"Lung tumor–infiltrating T<sub>reg</sub>have divergent transcriptional profiles and function linked to checkpoint blockade response","year":2023,"lang":"en","type":"article","venue":"Science Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; National Institute of Biomedical Imaging and Bioengineering; Sidney Kimmel Comprehensive Cancer Center; Genentech; National Institutes of Health; National Institute of General Medical Sciences; Swim Across America; Revolution Medicines; Regeneron Pharmaceuticals; Achievement Rewards for College Scientists Foundation; U.S. Department of Defense; Sanofi; GlaxoSmithKline; Celgene; Bristol-Myers Squibb; AstraZeneca; Eli Lilly and Company; National Human Genome Research Institute; LUNGevity Foundation; Johns Hopkins University; Amgen; National Science Foundation","keywords":"Biology; T cell; Cancer research; FOXP3; Immune checkpoint; Tumor-infiltrating lymphocytes; Immune system; Immunology; Immunotherapy","score_opus":0.020322094062458083,"score_gpt":0.2812712641501099,"score_spread":0.2609491700876518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386766337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917707,0.0008708621,0.00012678043,0.0055095,0.00093875505,0.0005179648,0.000010779746,0.0001467308,0.00010795706],"genre_scores_gemma":[0.9985211,0.00015318232,0.00016977693,0.00057899236,0.000090887006,0.00008676857,0.000011814776,0.0000139334925,0.0003735802],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99823,0.000088918365,0.00032129412,0.00049416855,0.00035998938,0.0005056749],"domain_scores_gemma":[0.9993246,0.00008064866,0.000078642865,0.000262785,0.00013164683,0.000121679266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014617525,0.00016314856,0.00021574525,0.00050546974,0.00044399247,0.000045860794,0.00016087333,0.00008067859,0.00007462518],"category_scores_gemma":[0.00029685415,0.00014304419,0.00007918985,0.0010965833,0.0007908851,0.00016815285,0.00008538037,0.0002114021,0.000058898673],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056876563,0.0000352628,0.0026517834,0.000015852267,0.00005046866,0.000020653644,0.0011161508,0.000007516758,0.9825784,0.000060713828,0.00023595295,0.007539582],"study_design_scores_gemma":[0.0011655847,0.00078864145,0.6097535,0.00006737067,0.000027924818,0.00013755997,0.0010786108,0.00046355123,0.38390014,0.000062290834,0.0024074651,0.0001474074],"about_ca_topic_score_codex":0.000060312363,"about_ca_topic_score_gemma":0.0000130838625,"teacher_disagreement_score":0.6071017,"about_ca_system_score_codex":0.00020403485,"about_ca_system_score_gemma":0.00044049593,"threshold_uncertainty_score":0.5833173},"labels":[],"label_agreement":null},{"id":"W4386784022","doi":"10.1158/1557-3265.aacrahns23-pr11","title":"Abstract PR11: Allogeneic memory-like natural killer (NK) cell therapy with IL-15 superagonist with or without ipilimumab for advanced, incurable head and neck cancer: A phase 1 trial","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Ipilimumab; Internal medicine; Oncology; Regimen; Cohort; Immunotherapy; Cyclophosphamide; Cancer; Chemotherapy; Gastroenterology","score_opus":0.19200859287251712,"score_gpt":0.5151618163253213,"score_spread":0.3231532234528042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386784022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97991747,0.009347669,0.0000051078887,0.0037423333,0.0009897737,0.0054561705,0.00016165285,0.0001440531,0.00023579905],"genre_scores_gemma":[0.9486013,0.0299154,0.00035727338,0.0012147631,0.0012436236,0.003361755,0.000115117,0.00016414792,0.01502663],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953621,0.00022145701,0.0008475624,0.0012061809,0.0011295557,0.0012331625],"domain_scores_gemma":[0.996724,0.0012101176,0.00019082753,0.0007300276,0.00064972707,0.0004952981],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022908302,0.00044750923,0.0010631284,0.00025114344,0.0005415239,0.00014376274,0.0003573884,0.0002816943,0.00069524726],"category_scores_gemma":[0.00015262538,0.0002636218,0.0002089032,0.0010596286,0.0011654566,0.00022447127,0.00008472662,0.0012411427,0.000014822282],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8202909,0.0010941946,0.005873309,0.0004645777,0.0005680465,0.00011333975,0.00033569458,0.000017682552,0.011009421,0.0000015189012,0.013788664,0.14644265],"study_design_scores_gemma":[0.6235305,0.04903773,0.009447827,0.0011907064,0.00017238046,0.000046085064,0.001267841,0.0005174092,0.007831359,0.000021070462,0.3060412,0.00089589163],"about_ca_topic_score_codex":0.002390269,"about_ca_topic_score_gemma":0.0067182435,"teacher_disagreement_score":0.29225254,"about_ca_system_score_codex":0.00034077867,"about_ca_system_score_gemma":0.0031387794,"threshold_uncertainty_score":0.9999816},"labels":[],"label_agreement":null},{"id":"W4386784024","doi":"10.1158/1557-3265.aacrahns23-pr12","title":"Abstract PR12: High-dimensional spatial analysis of the tumor-microenvironment to determine metastatic disease progression and response and resistance to therapy in head and neck cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immune system; Tumor microenvironment; Medicine; CD8; Head and neck squamous-cell carcinoma; Cancer; Primary tumor; Head and neck cancer; Tumor progression; Mass cytometry; Cytotoxic T cell; T cell; Cancer research; Pathology; Oncology; Internal medicine; Immunology; Metastasis; Biology; Phenotype","score_opus":0.1293566082335363,"score_gpt":0.4868440163052318,"score_spread":0.35748740807169543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386784024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768088,0.0044668876,8.298155e-7,0.01734013,0.00006886918,0.0011613441,0.0001408912,0.000008508271,0.0000037714262],"genre_scores_gemma":[0.9945136,0.0037383107,0.00012985004,0.000934589,0.000049252656,0.00031531736,0.0000059453923,0.000018447301,0.00029469634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744743,0.0004421281,0.0005378988,0.000547237,0.00067462976,0.0003506845],"domain_scores_gemma":[0.99819905,0.0008834879,0.00008578684,0.00037799324,0.00008391468,0.00036978893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027303954,0.00014220185,0.00046953905,0.00036780463,0.000112939764,0.00002492767,0.00011692643,0.00003859027,0.00012939534],"category_scores_gemma":[0.0004737401,0.00009128109,0.00009073473,0.00130355,0.00048257367,0.000035610003,0.00021023785,0.00029405512,0.0000015911861],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14043896,0.0003415488,0.6785192,0.00019177671,0.0005227672,0.00015313324,0.00044404564,0.00006536879,0.03845275,0.000003193194,0.0013028722,0.13956438],"study_design_scores_gemma":[0.002856658,0.00062160695,0.992167,0.0006730451,0.000097383396,7.996847e-7,0.000037448648,0.00016593002,0.0011138478,0.00002786971,0.0021396035,0.000098828175],"about_ca_topic_score_codex":0.0016634009,"about_ca_topic_score_gemma":0.005486252,"teacher_disagreement_score":0.31364778,"about_ca_system_score_codex":0.0001581885,"about_ca_system_score_gemma":0.00036319473,"threshold_uncertainty_score":0.37223345},"labels":[],"label_agreement":null},{"id":"W4386784341","doi":"10.1158/1557-3265.aacrahns23-po-048","title":"Abstract PO-048: Baseline blood DNA methylation-based immune profiles are associated with survival outcomes in head and neck cancer patients on immune checkpoint therapy","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Internal medicine; Head and neck squamous-cell carcinoma; Immunotherapy; Immune system; Hazard ratio; Biomarker; Ipilimumab; DNA methylation; Pembrolizumab; Proportional hazards model; Cancer; Head and neck cancer; Immunology; Confidence interval; Biology","score_opus":0.16669272135349594,"score_gpt":0.47080515836399994,"score_spread":0.304112437010504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386784341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98673105,0.0023755974,5.271308e-7,0.008518496,0.00033941446,0.0015476105,0.0002441989,0.000096604104,0.000146487],"genre_scores_gemma":[0.99296194,0.0048484597,0.000015769896,0.00046489926,0.00016946426,0.0005624082,0.00023887522,0.00007849638,0.0006596552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99530107,0.00067172037,0.0011977012,0.0007359691,0.0013162106,0.0007773546],"domain_scores_gemma":[0.99543864,0.002850737,0.00032998328,0.0005155479,0.0006440832,0.00022101213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005691783,0.00032321946,0.0009988659,0.0004252661,0.0002010884,0.000057910143,0.00023531022,0.00029808393,0.0006070034],"category_scores_gemma":[0.0017193162,0.0002255821,0.00024949518,0.0014646011,0.0004753068,0.00008668078,0.00006690596,0.001240416,0.00001786512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015481348,0.0021085376,0.95065355,0.00010859134,0.00060216954,0.000052233772,0.000115466966,0.000026357884,0.0038375608,0.0000020862265,0.00023633435,0.026775772],"study_design_scores_gemma":[0.024332453,0.002147603,0.96290827,0.0013271002,0.000035817,1.7643619e-7,0.000117761265,0.0001436448,0.008186351,0.000016703043,0.0005270638,0.00025706142],"about_ca_topic_score_codex":0.0057583516,"about_ca_topic_score_gemma":0.0037907602,"teacher_disagreement_score":0.02651871,"about_ca_system_score_codex":0.00035914293,"about_ca_system_score_gemma":0.0008993813,"threshold_uncertainty_score":0.91989714},"labels":[],"label_agreement":null},{"id":"W4386784394","doi":"10.1158/1557-3265.aacrahns23-po-035","title":"Abstract PO-035: Immune profiles of long-term survivors of patients with head and neck squamous carcinoma on immune checkpoint inhibitor therapy","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunotherapy; Head and neck squamous-cell carcinoma; Medicine; Immune system; Cancer; Oncology; Head and neck cancer; Pembrolizumab; CD8; Internal medicine; Immune checkpoint; Immunology; Cancer research","score_opus":0.11894448955992439,"score_gpt":0.4381471259585031,"score_spread":0.3192026363985787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386784394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936259,0.0036435246,2.4525804e-7,0.0007665413,0.0002566429,0.0013848623,0.00010173929,0.000033390166,0.00018717437],"genre_scores_gemma":[0.99550545,0.003724685,0.000011293159,0.00004967383,0.00017974054,0.00007992478,0.000078984114,0.000054483033,0.00031576265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99657065,0.00022128724,0.0011308027,0.000496344,0.0010618789,0.0005190636],"domain_scores_gemma":[0.9974544,0.0008105409,0.00029136814,0.0006416682,0.00062589307,0.00017613318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022727589,0.00022010974,0.00076024485,0.00029622452,0.00009959983,0.000017873565,0.00023032949,0.00020657465,0.0003498457],"category_scores_gemma":[0.00026361004,0.00015129289,0.00023944536,0.0008329381,0.0010473502,0.00006844321,0.000112050846,0.00071598584,0.00001147167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039402075,0.0010363685,0.8945817,0.0005704352,0.000203308,0.000030149657,0.00025308543,0.0000011058263,0.012946462,0.0000028694737,0.00016884335,0.050803628],"study_design_scores_gemma":[0.010905942,0.0061784987,0.9292024,0.0007947113,0.000016676797,0.0000010868597,0.00010173374,0.000004931534,0.052491847,0.000007533796,0.00015123702,0.00014342666],"about_ca_topic_score_codex":0.0037430346,"about_ca_topic_score_gemma":0.00030373616,"teacher_disagreement_score":0.0506602,"about_ca_system_score_codex":0.00011136845,"about_ca_system_score_gemma":0.00050371734,"threshold_uncertainty_score":0.61695445},"labels":[],"label_agreement":null},{"id":"W4386784562","doi":"10.1158/1557-3265.aacrahns23-pr01","title":"Abstract PR01: Lymph node colonization promotes distant tumor metastasis through the induction of tumor-specific immune tolerance","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metastasis; Immune system; Cancer research; Tumor progression; Immunotherapy; Lymphatic system; Biology; Immunology; Adoptive cell transfer; Cancer; FOXP3; Primary tumor; Medicine; T cell; Internal medicine","score_opus":0.2273694373695485,"score_gpt":0.4783466230660269,"score_spread":0.25097718569647837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386784562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98206836,0.0060827713,0.00003300299,0.009106688,0.00083811337,0.0011153187,0.00006877412,0.00007824802,0.0006087101],"genre_scores_gemma":[0.9920115,0.0062567093,0.0001006882,0.0002401389,0.0005687381,0.00027311035,0.000046806956,0.000042080766,0.0004602665],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9966198,0.0003650093,0.0010151578,0.0004892295,0.0010100128,0.0005007639],"domain_scores_gemma":[0.9975079,0.0008488538,0.00026244682,0.0006859266,0.0006046243,0.00009023745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040360596,0.00016249961,0.00049244915,0.00012233797,0.0002882717,0.000049619,0.00033111562,0.00010131773,0.00067307905],"category_scores_gemma":[0.00061448984,0.000107029045,0.00025900162,0.001993416,0.0010330892,0.0001401753,0.000110989386,0.0006728379,0.00006878829],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05395304,0.003472906,0.09834905,0.0028322437,0.0021159563,0.0004210611,0.00466292,0.00030512403,0.4158401,0.0014279116,0.07098316,0.34563655],"study_design_scores_gemma":[0.0044140755,0.00065702264,0.8579882,0.0008531217,0.00006896762,0.000021874619,0.0012943762,0.00022714055,0.04836345,0.0006438084,0.08522915,0.00023886116],"about_ca_topic_score_codex":0.0011433942,"about_ca_topic_score_gemma":0.00005471946,"teacher_disagreement_score":0.7596391,"about_ca_system_score_codex":0.00026883517,"about_ca_system_score_gemma":0.0006638443,"threshold_uncertainty_score":0.73697436},"labels":[],"label_agreement":null},{"id":"W4386784577","doi":"10.1158/1557-3265.aacrahns23-pr02","title":"Abstract PR02: Tumor sequestered, neoantigen specific T cells are dynamically increased in circulation following neoadjuvant immunotherapy","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; CD8; Tumor microenvironment; Immune checkpoint; T cell; T-cell receptor; Immunotherapy; Cancer research; Transcriptome; Antigen; Memory T cell; Cytotoxic T cell; Immunology; Immune system; Gene; Genetics","score_opus":0.18612098032476052,"score_gpt":0.48044560482625437,"score_spread":0.2943246245014939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386784577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921628,0.002459671,0.000010517538,0.002300846,0.00084245106,0.0012763607,0.000038325124,0.00014868156,0.00076035253],"genre_scores_gemma":[0.99305224,0.0049475734,0.00007602292,0.00060516543,0.00055492984,0.0001790432,0.000066539345,0.00008318617,0.00043529016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99544305,0.00048258202,0.0012213078,0.000791483,0.0011459655,0.00091562205],"domain_scores_gemma":[0.9975456,0.0010210193,0.00018962575,0.00073754846,0.00023269982,0.000273489],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005773168,0.00024969017,0.0007067558,0.0005437494,0.00017477256,0.0001055677,0.00036613567,0.00026298882,0.0011183146],"category_scores_gemma":[0.00026156538,0.00022007393,0.00049026404,0.0017425445,0.00032121592,0.00015076634,0.00010017124,0.0012740805,0.00038666063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011557127,0.00066552946,0.52948767,0.0002738449,0.00038517994,0.0021434133,0.00033297786,0.00006335271,0.3424693,0.00001989148,0.005908294,0.1066934],"study_design_scores_gemma":[0.0067045214,0.00029636177,0.974633,0.0009978514,0.000012795525,0.000007498822,0.00028552365,0.00077777036,0.0019091015,0.00018433099,0.013927579,0.0002637114],"about_ca_topic_score_codex":0.0017573108,"about_ca_topic_score_gemma":0.0003689544,"teacher_disagreement_score":0.44514525,"about_ca_system_score_codex":0.00070101273,"about_ca_system_score_gemma":0.0007937335,"threshold_uncertainty_score":0.9997948},"labels":[],"label_agreement":null},{"id":"W4386785090","doi":"10.1158/1557-3265.aacrahns23-ia05","title":"Abstract IA05: Nodal and systemic Immune effects of radiation in HNSCC","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immune system; Immunotherapy; Metastasis; Medicine; Lymph; Cancer; Lymph node; Cancer research; Radiation therapy; Antigen; Immunology; Pathology; Internal medicine","score_opus":0.1254624242287148,"score_gpt":0.5101282871669741,"score_spread":0.38466586293825933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386785090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860235,0.011500347,8.7491094e-7,0.0011798869,0.00033925037,0.00063270325,0.0000062147647,0.000024924808,0.00029232583],"genre_scores_gemma":[0.98021567,0.018980427,0.0000047064514,0.000059246257,0.00020377057,0.00009553065,0.000008978667,0.000015799369,0.00041587968],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99822,0.0002057675,0.0005819356,0.00025934257,0.00042872995,0.00030418538],"domain_scores_gemma":[0.9978589,0.0016254303,0.000076256685,0.00024436592,0.00009912746,0.000095922886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034999503,0.00007613759,0.00036106262,0.00027183405,0.000039656275,0.000011258087,0.00009637088,0.00015135731,0.00008543565],"category_scores_gemma":[0.0007778057,0.0000629493,0.00009781611,0.00079540716,0.00031264412,0.000044633176,0.000056805544,0.0005068211,0.000029718869],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006654485,0.0002223108,0.28240886,0.002857746,0.00016196482,0.00013462619,0.00040314544,0.0000040284394,0.13496907,0.000032116885,0.0030547346,0.5690969],"study_design_scores_gemma":[0.0050539686,0.00049301126,0.9832217,0.0011457357,0.000011697935,0.0000049736645,0.000113935326,0.00008797189,0.008419297,0.00004647497,0.0013375357,0.0000637182],"about_ca_topic_score_codex":0.0014136272,"about_ca_topic_score_gemma":0.00007715611,"teacher_disagreement_score":0.7008128,"about_ca_system_score_codex":0.00013607119,"about_ca_system_score_gemma":0.00032403332,"threshold_uncertainty_score":0.2566998},"labels":[],"label_agreement":null},{"id":"W4386848448","doi":"10.34133/research.0247","title":"Remodeling Tumor Immune Microenvironment by Using Polymer-Lipid-Manganese Dioxide Nanoparticles with Radiation Therapy to Boost Immune Response of Castration-Resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Tumor microenvironment; Immunogenic cell death; Cancer research; Immune system; Radioresistance; Prostate cancer; Medicine; Programmed cell death; Immunotherapy; Radiation therapy; Cancer; Chemistry; Apoptosis; Immunology; Internal medicine","score_opus":0.04893507293984671,"score_gpt":0.35667312623215186,"score_spread":0.30773805329230514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386848448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98505294,0.010497085,0.00000688581,0.0031931344,0.000044645058,0.0010907969,0.00007040533,0.000035382793,0.000008711628],"genre_scores_gemma":[0.99641186,0.0021170953,0.00013424973,0.00009098732,0.00005096039,0.00012493618,0.000030980347,0.000051109666,0.000987829],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975101,0.00032154642,0.00046034018,0.00033762312,0.00081903825,0.00055140577],"domain_scores_gemma":[0.9990179,0.00017487665,0.000107161504,0.00042468568,0.00014439912,0.00013097865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020683852,0.00016192463,0.00028465773,0.000333645,0.00023186143,0.000037729154,0.00013196177,0.00004499199,0.000082245],"category_scores_gemma":[0.00006222541,0.00012842035,0.000072786854,0.0010636037,0.00018979712,0.000099429104,0.000048862505,0.00018476519,0.000013381913],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048862442,0.00011537833,0.0011057311,0.00006702459,0.000115863215,0.000032556265,0.0017765939,0.00023149452,0.9377298,0.0000010709399,0.00016648616,0.00979556],"study_design_scores_gemma":[0.0028170147,0.0010377434,0.044950604,0.00035245996,0.000018134384,0.000014635903,0.001073396,0.0005385435,0.9468657,0.0000015354691,0.0021902963,0.00013994641],"about_ca_topic_score_codex":0.004230184,"about_ca_topic_score_gemma":0.00005600302,"teacher_disagreement_score":0.046045426,"about_ca_system_score_codex":0.00043884918,"about_ca_system_score_gemma":0.0004470583,"threshold_uncertainty_score":0.6394801},"labels":[],"label_agreement":null},{"id":"W4386851430","doi":"10.1016/j.gastha.2023.09.007","title":"Colorectal Cancer Immunotherapy: State of the Art and Future Directions","year":2023,"lang":"en","type":"article","venue":"Gastro Hep Advances","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health","keywords":"Immunotherapy; Medicine; Colorectal cancer; Clinical trial; Cancer immunotherapy; Cancer; Oncology; Internal medicine; Disease","score_opus":0.00708362243154964,"score_gpt":0.27085509031548116,"score_spread":0.2637714678839315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386851430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97857594,0.016192226,0.0000148450235,0.0035943803,0.00083343923,0.00026838228,0.00005562702,0.000108491695,0.00035664198],"genre_scores_gemma":[0.85216844,0.14116819,0.0005730686,0.0007104619,0.00053641107,0.00017610262,0.000016018952,0.00006380441,0.0045875106],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99936527,0.000024196908,0.00015212076,0.00013825785,0.00014784903,0.00017228675],"domain_scores_gemma":[0.99969476,0.000028647417,0.00007701769,0.00013215367,0.000036528727,0.000030894058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000091971204,0.000095949275,0.00016492953,0.000052876927,0.000086518754,0.000007707172,0.000057820034,0.000023013226,0.00006420157],"category_scores_gemma":[0.000005544531,0.000060671955,0.00008314323,0.0004147186,0.00017089068,0.00007104447,0.000019480793,0.000095098425,0.0000029149064],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001602177,0.00004009875,0.060830195,0.00006384224,0.00018944891,0.0000030270787,0.0007355892,0.000028541757,0.07382907,0.000011118313,0.0019227753,0.8607441],"study_design_scores_gemma":[0.00095541903,0.00015088214,0.37615123,0.000070790105,0.000021237911,0.000019364148,0.00026445911,0.000043862998,0.010211888,0.00006933709,0.6119793,0.00006224069],"about_ca_topic_score_codex":0.000053823343,"about_ca_topic_score_gemma":0.00025428087,"teacher_disagreement_score":0.8606819,"about_ca_system_score_codex":0.000033586442,"about_ca_system_score_gemma":0.000057639474,"threshold_uncertainty_score":0.24741305},"labels":[],"label_agreement":null},{"id":"W4386877869","doi":"10.1139/cjpp-2023-0083","title":"Tumour adaptation to immune factors: old and new ideas for cancer immunotherapy","year":2023,"lang":"en","type":"review","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immunoediting; Immune system; Immunotherapy; Adaptation (eye); Cancer immunotherapy; Cancer; Acquired immune system; Cancer research; Biology; Cancer cell; Adaptability; Immunology; Neuroscience","score_opus":0.09076184386235048,"score_gpt":0.3891977744532894,"score_spread":0.2984359305909389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386877869","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009448997,0.9866695,0.000016721217,0.0010733372,0.0018354316,0.0008167885,0.00012434032,0.000010947974,0.0000039766537],"genre_scores_gemma":[0.0008501098,0.9959881,0.000115444884,0.0013658305,0.0010299019,0.00005269536,0.000036781916,0.000073389725,0.0004878033],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99857855,0.00011127768,0.00064580276,0.00024019263,0.000052895914,0.00037129744],"domain_scores_gemma":[0.9984909,0.00026144975,0.00045908362,0.00008675659,0.00011760537,0.000584163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025972349,0.00030292763,0.0015097252,0.0005122965,0.000112101916,0.000013279112,0.0001401687,0.0003139805,0.00040720124],"category_scores_gemma":[0.000028202836,0.00023370264,0.00033367894,0.0002177289,0.00013998525,0.00005060332,0.000011414343,0.00039825353,0.0000024875308],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017212131,0.000026433576,0.000017412263,0.0081286775,0.004572114,0.00007648495,0.0018563312,0.000005400134,0.096400745,0.000068520814,0.017806772,0.8693199],"study_design_scores_gemma":[0.001983445,0.00076568517,0.00046666223,0.0020263647,0.0011556875,0.00018510132,0.00009362812,0.0000032093335,0.00044279394,0.00019444319,0.99245745,0.00022553134],"about_ca_topic_score_codex":0.0057342565,"about_ca_topic_score_gemma":0.0026772746,"teacher_disagreement_score":0.9746507,"about_ca_system_score_codex":0.00019826813,"about_ca_system_score_gemma":0.0032443365,"threshold_uncertainty_score":0.9530117},"labels":[],"label_agreement":null},{"id":"W4386895156","doi":"10.3390/cancers15184639","title":"Association between AHR Expression and Immune Dysregulation in Pancreatic Ductal Adenocarcinoma: Insights from Comprehensive Immune Profiling of Peripheral Blood Mononuclear Cells","year":2023,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Immune dysregulation; Peripheral blood mononuclear cell; Immune system; Pancreatic ductal adenocarcinoma; Medicine; Gene expression profiling; Peripheral blood; Immunology; Pathology; Biology; Pancreatic cancer; Internal medicine; Gene expression; Gene; Cancer","score_opus":0.015904752668905002,"score_gpt":0.24595925348827308,"score_spread":0.23005450081936807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386895156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922078,0.006852351,0.000007976805,0.00009988597,0.00019028095,0.0004684372,0.000035555753,0.00004990438,0.000087801214],"genre_scores_gemma":[0.99839264,0.0007531548,0.0003021203,0.00002575064,0.00013727865,0.00002357066,0.0001759978,0.00002808956,0.0001614119],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99876404,0.00007786918,0.00043878125,0.00026775498,0.0002459733,0.00020558824],"domain_scores_gemma":[0.99930143,0.00012016759,0.0002589297,0.00019352227,0.00007596563,0.0000499707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008754805,0.0001560338,0.00044994755,0.00015538113,0.00006556996,0.00001451714,0.00006145194,0.00015001222,0.000041812018],"category_scores_gemma":[0.000020397552,0.00014787953,0.000084843865,0.00038238213,0.00006993306,0.0001220821,0.00003886736,0.0001607866,0.0000031153097],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059900584,0.000012786147,0.13968329,0.0000934567,0.00026605048,0.000011140325,0.0019658064,0.00013467626,0.85677093,0.0000024824676,0.000045932906,0.00041446328],"study_design_scores_gemma":[0.003393811,0.00014828438,0.7155588,0.00035260056,0.00017056012,0.0000011250686,0.0012341868,0.00075371965,0.27817765,0.000055568584,0.000035853907,0.000117815674],"about_ca_topic_score_codex":0.0020800987,"about_ca_topic_score_gemma":0.000025495694,"teacher_disagreement_score":0.57859325,"about_ca_system_score_codex":0.0007407946,"about_ca_system_score_gemma":0.00015614231,"threshold_uncertainty_score":0.6030352},"labels":[],"label_agreement":null},{"id":"W4386898610","doi":"10.1016/j.chest.2023.09.013","title":"Accuracy of Cytologic vs Histologic Specimens for Assessment of Programmed Cell Death Ligand-1 Expression in Non-Small Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"CHEST Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Lung Cancer Canada; McGill University","keywords":"Cytology; Cell; Pathology; Lung cancer; Programmed cell death; Lung; Cancer; Apoptosis; Expression (computer science); Medicine; Ligand (biochemistry); Biology; Internal medicine; Receptor; Computer science; Genetics","score_opus":0.05144225715426308,"score_gpt":0.3526134451415043,"score_spread":0.3011711879872412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386898610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942692,0.002955452,0.0006545419,0.00048734687,0.0003304797,0.0007708613,0.000012889844,0.000017743323,0.000501474],"genre_scores_gemma":[0.98855793,0.0036677662,0.007005781,0.00007912694,0.00013622898,0.00009063649,0.000013706901,0.000020018555,0.00042877483],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99865305,0.000039377945,0.0005760977,0.00018687212,0.00021184303,0.00033277573],"domain_scores_gemma":[0.9988687,0.00018150196,0.0005533688,0.00017491286,0.00013018891,0.00009130655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005811078,0.00015673284,0.00046511204,0.00022433283,0.000058555943,0.000012213803,0.00016020633,0.0001281916,0.00008900237],"category_scores_gemma":[0.000040952258,0.000113149916,0.00025051998,0.00029685613,0.000059580616,0.000051392046,0.000036117417,0.0002787988,7.229678e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013325438,0.00044885534,0.17885897,0.0012027037,0.00005721957,0.00006459598,0.0005808257,0.000041224055,0.81153417,0.0000021251237,0.0021968007,0.0036799512],"study_design_scores_gemma":[0.008530581,0.0011509998,0.37133336,0.0009284967,0.00015234092,0.00004320745,0.00056585035,0.0008022904,0.61236036,0.000051210616,0.0039009626,0.00018034174],"about_ca_topic_score_codex":0.000044374945,"about_ca_topic_score_gemma":0.000017485598,"teacher_disagreement_score":0.19917382,"about_ca_system_score_codex":0.00030072144,"about_ca_system_score_gemma":0.00044660605,"threshold_uncertainty_score":0.46141195},"labels":[],"label_agreement":null},{"id":"W4386933010","doi":"10.34172/jnp.2023.21520","title":"Immune checkpoint inhibitor-associated sarcoidosis reaction","year":2023,"lang":"en","type":"article","venue":"Journal of Nephropathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Sarcoidosis; Medicine; Immune system; Immunology; Inflammation; Adverse effect; Kidney; Disease; Pathology; Internal medicine","score_opus":0.021187514841387756,"score_gpt":0.28903887411131085,"score_spread":0.2678513592699231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386933010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929134,0.0009859684,0.00002101325,0.0041665244,0.0011359011,0.00009323746,0.0000028351496,0.000050062416,0.00063105597],"genre_scores_gemma":[0.99659604,0.0015517132,0.0001311224,0.0004991219,0.00045331122,0.0000027122449,0.000009144525,0.000021605447,0.00073524687],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99868506,0.0001054641,0.00064138544,0.00010508101,0.00023933234,0.00022367285],"domain_scores_gemma":[0.9990118,0.000060863567,0.00049849495,0.0001476142,0.00020990495,0.00007129672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010509404,0.00010756584,0.0003875587,0.00035520428,0.000059985054,0.000009188973,0.000073623174,0.00015090467,0.00007547019],"category_scores_gemma":[0.0002322991,0.0000852268,0.0003077349,0.0005276571,0.00009457325,0.00009240108,0.000024044672,0.00033603364,0.000058695437],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016593146,0.00014022522,0.002060613,0.00001721259,0.0001498183,0.00083922193,0.00026647668,0.0000010580012,0.9783981,0.000007635098,0.0060917116,0.010368611],"study_design_scores_gemma":[0.005385457,0.0022598282,0.904487,0.00023330607,0.00018298365,0.0050218054,0.0004575686,0.000025472333,0.052210912,0.00015769238,0.029441359,0.00013659016],"about_ca_topic_score_codex":0.000021451635,"about_ca_topic_score_gemma":0.0000030224796,"teacher_disagreement_score":0.9261872,"about_ca_system_score_codex":0.00020932547,"about_ca_system_score_gemma":0.00013365482,"threshold_uncertainty_score":0.34754482},"labels":[],"label_agreement":null},{"id":"W4387060891","doi":"10.21203/rs.3.rs-3318337/v1","title":"Whole-genome sequencing uncovers the genomic determinants of therapeutic resistance to immune checkpoint blockade","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Royal Ottawa Mental Health Centre","funders":"Medical Research Council; National Institute for Health and Care Research; Department of Health and Social Care; Cancer Research UK; Wellcome Trust","keywords":"Blockade; Immune checkpoint; Genome; Biology; Genetics; Whole genome sequencing; Computational biology; DNA sequencing; Resistance (ecology); Genomic sequencing; Gene; Receptor","score_opus":0.11064371621983413,"score_gpt":0.39689633799398816,"score_spread":0.286252621774154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387060891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9758469,0.012256021,0.000043077547,0.0066656647,0.0004502105,0.0035033391,0.00045000965,0.00010405864,0.0006807213],"genre_scores_gemma":[0.98612076,0.0021605783,0.000156066,0.00013019136,0.00031038525,0.00038181676,0.00008761364,0.0001319071,0.010520667],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.995392,0.00046013188,0.00091394834,0.00079296983,0.0015076384,0.000933287],"domain_scores_gemma":[0.9965265,0.00046071582,0.00027297912,0.0019792807,0.0005615991,0.00019897087],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0041680397,0.00037630962,0.00080738176,0.00059606903,0.00029519497,0.00009363601,0.000955144,0.00033899728,0.00012559595],"category_scores_gemma":[0.00032184087,0.0002714072,0.00053866423,0.0010141268,0.00045600662,0.000036610054,0.0010321164,0.0015835637,0.00015286924],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004115064,0.00008038375,0.0034775066,0.0032888232,0.00057347893,0.00016546508,0.0040128753,0.00023206654,0.9798474,0.000010186322,0.00028506774,0.003911701],"study_design_scores_gemma":[0.0049700406,0.0020264245,0.6585938,0.01648844,0.00035766844,0.00006897881,0.012492291,0.00034722657,0.21349546,0.0024334914,0.08733129,0.001394929],"about_ca_topic_score_codex":0.0018502997,"about_ca_topic_score_gemma":0.0009447709,"teacher_disagreement_score":0.76635194,"about_ca_system_score_codex":0.0018865054,"about_ca_system_score_gemma":0.0020686276,"threshold_uncertainty_score":0.99997383},"labels":[],"label_agreement":null},{"id":"W4387115048","doi":"10.1001/jamaoncol.2023.3867","title":"Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors","year":2023,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; National Center for Advancing Translational Sciences; National Cancer Institute; EMD Serono; Genentech; European Society for Medical Oncology; Servier; Yonsei University; MacroGenics; LG Chem; Regeneron Pharmaceuticals; BeiGene; F. Hoffmann-La Roche; Handok; Gilead Sciences; Yuhan; Eli Lilly and Company; AstraZeneca; Celgene; TG Therapeutics; Pfizer","keywords":"Medicine; Atezolizumab; Internal medicine; TIGIT; Tolerability; Oncology; Clinical endpoint; Clinical trial; Phases of clinical research; Antibody; Adverse effect; Immunology; Pembrolizumab; Immunotherapy; Cancer","score_opus":0.012491511114451901,"score_gpt":0.3158602043763073,"score_spread":0.3033686932618554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387115048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99480766,0.00007203139,0.000009523125,0.0019669202,0.00016386474,0.00077547284,0.000019404102,0.00014319757,0.0020419413],"genre_scores_gemma":[0.9966364,0.00018087133,0.0003734508,0.0013268795,0.00007712127,0.00006114857,0.0002185538,0.000050587085,0.0010750177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983132,0.000068237605,0.00039378073,0.00039847707,0.00030474438,0.0005215986],"domain_scores_gemma":[0.9991677,0.00010060268,0.00018088389,0.0003258088,0.0001219534,0.00010307786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019342735,0.00022209217,0.0006918777,0.0002947637,0.000065741464,0.000017034869,0.00012392811,0.00016633353,0.00021129414],"category_scores_gemma":[0.000052822797,0.00014219916,0.000052435407,0.0010451877,0.0002018372,0.00012105269,0.000043343036,0.00026605927,0.00008092604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12099182,0.0012506762,0.6189919,0.00019739353,0.00042061918,0.0029147046,0.0010237612,0.00008438841,0.005397582,0.000017012242,0.005413306,0.24329682],"study_design_scores_gemma":[0.037362926,0.010448626,0.92832434,0.00039518988,0.000046875903,0.00011403042,0.0003038547,0.00006495638,0.0009197655,0.000007403431,0.021769471,0.00024253853],"about_ca_topic_score_codex":0.00014229276,"about_ca_topic_score_gemma":0.00036154763,"teacher_disagreement_score":0.30933243,"about_ca_system_score_codex":0.00035399615,"about_ca_system_score_gemma":0.00055526476,"threshold_uncertainty_score":0.57987136},"labels":[],"label_agreement":null},{"id":"W4387135688","doi":"10.1136/ijgc-2023-esgo.1","title":"#67 Pembrolizumab + chemotherapy for first-line treatment of patients with persistent, recurrent, or metastatic cervical cancer: bevacizumab subgroup analysis based on protocol-specified final overall survival results of KEYNOTE-826","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Carboplatin; Bevacizumab; Internal medicine; Oncology; Cervical cancer; Hazard ratio; Cancer; Gemcitabine; Progression-free survival; Chemotherapy; Cisplatin; Immunotherapy; Confidence interval","score_opus":0.08366524295195818,"score_gpt":0.3744814509143597,"score_spread":0.2908162079624015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387135688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98389244,0.00009064293,0.0003373717,0.0049717217,0.00051120046,0.008519015,0.0015510631,0.000020159547,0.00010638497],"genre_scores_gemma":[0.99462825,0.00058423483,0.0004167484,0.00031809873,0.00023612576,0.0033129528,0.00015909676,0.000026046459,0.00031845656],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99708724,0.00009905996,0.0011210149,0.00033318048,0.0010859518,0.0002735528],"domain_scores_gemma":[0.9964515,0.0008933885,0.0011977659,0.00019606255,0.0011328153,0.00012847042],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031232846,0.00028327448,0.00093771744,0.0005019453,0.000053018026,0.00002012807,0.0002861998,0.000102958,0.0015287763],"category_scores_gemma":[0.00021718057,0.00016250071,0.0009069493,0.0005864105,0.00013696439,0.00007516304,0.000018634375,0.00014372137,8.4672223e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8551702,0.0060719075,0.059661835,0.00022673956,0.009611673,0.000100816505,0.0003027678,0.010142999,0.00030671115,0.000031007025,0.00096592854,0.057407416],"study_design_scores_gemma":[0.15917113,0.049498223,0.75529116,0.00055413175,0.0019914326,0.000009531055,0.00007585469,0.008390871,0.0036530779,0.000058121295,0.020932738,0.00037369248],"about_ca_topic_score_codex":0.00015623446,"about_ca_topic_score_gemma":0.00065124186,"teacher_disagreement_score":0.6959991,"about_ca_system_score_codex":0.0010970547,"about_ca_system_score_gemma":0.00051137846,"threshold_uncertainty_score":0.999384},"labels":[],"label_agreement":null},{"id":"W4387135840","doi":"10.1136/ijgc-2023-esgo.886","title":"#1121 KEYNOTE-826: final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Pembrolizumab; Medicine; Carboplatin; Chemotherapy; Cervical cancer; Placebo; Internal medicine; Oncology; Interim analysis; Gemcitabine; Cancer; Cisplatin; Randomized controlled trial; Immunotherapy","score_opus":0.14921725532726443,"score_gpt":0.42177302605141054,"score_spread":0.2725557707241461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387135840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842828,0.0015161893,0.00017330261,0.008866597,0.0017426631,0.0023533849,0.0009890421,0.000023038741,0.000052962747],"genre_scores_gemma":[0.9845917,0.012569301,0.0002533538,0.00047638573,0.0007773296,0.00042867372,0.0001227365,0.00003953702,0.0007409484],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961708,0.00018917712,0.0018620578,0.00041726144,0.0010290263,0.00033166888],"domain_scores_gemma":[0.9946751,0.002296945,0.0015394547,0.00023135648,0.0010917642,0.00016540287],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00087403733,0.0003790225,0.0017981083,0.0003392506,0.00006508811,0.000033043085,0.00041662174,0.00014567513,0.0024968274],"category_scores_gemma":[0.0003406777,0.0002316671,0.0013706463,0.00031481683,0.00020995078,0.000115843075,0.00003618187,0.00021388558,0.0000018582475],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94287676,0.0071550105,0.0012043271,0.000055540302,0.010452519,0.00011036495,0.0018623839,0.0008922483,0.0006882177,0.000009297316,0.0010268759,0.03366647],"study_design_scores_gemma":[0.9595467,0.021036433,0.004643279,0.00032790916,0.0012749379,0.000034014567,0.00057946204,0.002977244,0.0019223962,0.00009590856,0.007312203,0.0002495351],"about_ca_topic_score_codex":0.0012794968,"about_ca_topic_score_gemma":0.001165617,"teacher_disagreement_score":0.033416934,"about_ca_system_score_codex":0.00084662676,"about_ca_system_score_gemma":0.0005985423,"threshold_uncertainty_score":0.99841505},"labels":[],"label_agreement":null},{"id":"W4387160327","doi":"10.1016/j.ijrobp.2023.06.1945","title":"Characterization of Antibody Repertoires in Patients with HPV-Related HNSCC Undergoing Definitive Radiation with Immunotherapy","year":2023,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fondation du cancer des Cèdres","keywords":"Medicine; Antibody; Antigen; Immunotherapy; Head and neck squamous-cell carcinoma; Immune system; Cancer research; Cancer; Radiation therapy; Flow cytometry; Head and neck cancer; Oncology; Immunology; Internal medicine","score_opus":0.01106452478171623,"score_gpt":0.2967584499077569,"score_spread":0.2856939251260407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387160327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99632174,0.00012890241,0.0012676567,0.0010261649,0.0006293811,0.00031375542,0.000048288708,0.0000290712,0.0002350179],"genre_scores_gemma":[0.9963877,0.0016481568,0.0002961659,0.0003515764,0.00022420159,0.000008330699,0.001027425,0.00003149267,0.000024937006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983683,0.00016300117,0.0007691411,0.00019039954,0.0003281752,0.00018096012],"domain_scores_gemma":[0.99755424,0.00026087576,0.0013498871,0.00012089142,0.00066914014,0.00004494463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040859214,0.00017328683,0.0004314404,0.0004194064,0.000047413552,0.0000154536,0.00016289338,0.00017393289,0.00006235275],"category_scores_gemma":[0.00009623802,0.00013294492,0.00011354303,0.0005758523,0.00016767843,0.00033890348,0.000016047134,0.00026375268,0.000005175075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069707823,0.0004990488,0.8488249,0.000012952436,0.00094242155,0.000019827237,0.0009251574,0.00023418415,0.03988377,0.0007008523,0.000028589764,0.1009575],"study_design_scores_gemma":[0.019570025,0.003200465,0.9690353,0.00023685033,0.00006485628,0.000034345445,0.000105050414,0.0004148086,0.0056299847,0.00044474134,0.0011114259,0.00015213182],"about_ca_topic_score_codex":0.00003051363,"about_ca_topic_score_gemma":0.000009576582,"teacher_disagreement_score":0.1202104,"about_ca_system_score_codex":0.00053937343,"about_ca_system_score_gemma":0.0006082027,"threshold_uncertainty_score":0.5421336},"labels":[],"label_agreement":null},{"id":"W4387169014","doi":"10.3390/curroncol30100645","title":"Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Nivolumab; Medicine; Adverse effect; Internal medicine; Head and neck squamous-cell carcinoma; Pneumonitis; Oncology; Ipilimumab; Head and neck cancer; Cancer; Retrospective cohort study; Surgery; Immunotherapy; Lung","score_opus":0.08728943819800758,"score_gpt":0.3986667302705207,"score_spread":0.3113772920725131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387169014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908816,0.0033364631,0.00004286637,0.0013510489,0.002088111,0.001427567,0.00008138507,0.00012733565,0.0006635782],"genre_scores_gemma":[0.99563766,0.0010018212,0.00032919992,0.0001876895,0.00024069223,0.00035449534,0.000102018,0.000034277444,0.0021121625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982347,0.00009080657,0.00042510786,0.0005377832,0.00018963462,0.00052198075],"domain_scores_gemma":[0.99900746,0.00025516792,0.00016276522,0.00028080892,0.00011498046,0.00017880904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002347608,0.00023768372,0.0005239576,0.00023607195,0.0001396836,0.000017516584,0.0001087044,0.00006945886,0.00018789277],"category_scores_gemma":[0.00010663791,0.00018717266,0.00014903351,0.00052109006,0.00020513232,0.00006852253,0.00007450783,0.00021468116,0.000020447771],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035906825,0.0032680135,0.46361363,0.0021456438,0.00018578045,0.00040372796,0.020806035,0.0000010344273,0.0051662717,0.00023767976,0.13700055,0.33126482],"study_design_scores_gemma":[0.026418122,0.008222347,0.6313309,0.00023845672,0.00038335883,0.00010553397,0.0030663512,0.0014131264,0.0024651003,0.00020552475,0.32560262,0.0005485299],"about_ca_topic_score_codex":0.00017322782,"about_ca_topic_score_gemma":0.0012989478,"teacher_disagreement_score":0.33071628,"about_ca_system_score_codex":0.0006543444,"about_ca_system_score_gemma":0.0003381138,"threshold_uncertainty_score":0.76326793},"labels":[],"label_agreement":null},{"id":"W4387264700","doi":"10.3390/curroncol30100646","title":"Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Pembrolizumab; Cohort; Melanoma; Internal medicine; Retrospective cohort study; Vemurafenib; Pediatrics; Oncology; Metastatic melanoma; Immunotherapy; Cancer","score_opus":0.02770860161339756,"score_gpt":0.3447322580984122,"score_spread":0.3170236564850146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387264700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962525,0.0011878932,0.00004127677,0.00020194017,0.00047143307,0.0016841613,0.0000069895864,0.00005051055,0.00010332416],"genre_scores_gemma":[0.9986519,0.00071973907,0.000108132444,0.000012276989,0.000023279457,0.00034411615,0.00008315387,0.00003816367,0.000019189907],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99847883,0.00017736117,0.0004095614,0.0003796351,0.0002389675,0.0003156529],"domain_scores_gemma":[0.99907815,0.00027217393,0.00021857323,0.00024806618,0.00013633266,0.00004670649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045878754,0.00023158317,0.0006495751,0.00038767338,0.000026524905,0.000005140462,0.00008854192,0.00011769539,0.00003457534],"category_scores_gemma":[0.00002370938,0.0001453487,0.000052067062,0.001130485,0.00020344427,0.0001304078,0.000019738596,0.0002582465,0.0000037284149],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73253155,0.0035803383,0.10125534,0.0017143826,0.00034314915,0.0002788632,0.003449445,0.0000868017,0.034491066,0.00003923087,0.000020614123,0.12220924],"study_design_scores_gemma":[0.14088869,0.017902654,0.80967134,0.0041570487,0.000049013957,0.00003673872,0.001272514,0.00013997788,0.025229393,0.0000050673616,0.00041563308,0.00023194424],"about_ca_topic_score_codex":0.00012678994,"about_ca_topic_score_gemma":0.00047568663,"teacher_disagreement_score":0.708416,"about_ca_system_score_codex":0.0005045788,"about_ca_system_score_gemma":0.00040305103,"threshold_uncertainty_score":0.5927148},"labels":[],"label_agreement":null},{"id":"W4387341321","doi":"10.1016/j.jaad.2023.09.070","title":"Onset of psoriasis with immune checkpoint inhibitor therapy: A systematic review","year":2023,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Western University","funders":"","keywords":"Psoriasis; Medicine; Adverse effect; Dermatology; Immune system; Immune checkpoint; Intensive care medicine; Oncology; Internal medicine; Immunology; Immunotherapy","score_opus":0.0448462268079264,"score_gpt":0.36322248899155074,"score_spread":0.31837626218362436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387341321","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006194502,0.99272585,0.0000029863504,0.0047581806,0.00016235074,0.0016747895,0.000028995393,0.000010974394,0.000016414495],"genre_scores_gemma":[0.0003944353,0.99826074,0.00013278602,0.00092830905,0.000084579195,0.000046951023,0.0000025269746,0.00007319891,0.00007646176],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9940752,0.0010073102,0.003816698,0.00019186753,0.0006321659,0.00027675738],"domain_scores_gemma":[0.98491484,0.00056206423,0.013821007,0.0004573683,0.00015509754,0.000089632944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009793154,0.0004364102,0.009171081,0.00043853687,0.000036262452,0.0000046657306,0.00082129904,0.000211164,0.000021791311],"category_scores_gemma":[0.00031747686,0.00020318085,0.0023616694,0.0014239561,0.0008749153,0.00004553151,0.00008757721,0.0010444728,0.0000062811296],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090121734,0.00013722859,0.000025196714,0.95475066,0.0073990882,0.00007573056,0.0000787035,6.2170706e-8,0.000088920286,0.0000051823313,0.0023414784,0.03419656],"study_design_scores_gemma":[0.0012437791,0.0005836576,0.000076922086,0.86769617,0.009299031,0.038047925,0.00010183779,2.986758e-7,0.00038979042,0.000010934754,0.08233288,0.00021680676],"about_ca_topic_score_codex":0.000020669735,"about_ca_topic_score_gemma":5.272365e-7,"teacher_disagreement_score":0.0870545,"about_ca_system_score_codex":0.00013246022,"about_ca_system_score_gemma":0.0007110211,"threshold_uncertainty_score":0.8285475},"labels":[],"label_agreement":null},{"id":"W4387341552","doi":"10.1186/s13058-023-01721-5","title":"The loss of B7-H4 expression in breast cancer cells escaping from T cell cytotoxicity contributes to epithelial-to-mesenchymal transition","year":2023,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fujian Medical University; University of Toronto; Natural Science Foundation of Fujian Province; National Natural Science Foundation of China","keywords":"Breast cancer; Cancer research; Metastasis; Cancer cell; Cancer stem cell; Epithelial–mesenchymal transition; Tumor microenvironment; Cancer; Biology; Reprogramming; Medicine; Internal medicine; Cell","score_opus":0.03068281468081368,"score_gpt":0.35113639555208187,"score_spread":0.3204535808712682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387341552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96725684,0.0011823651,0.00009652319,0.026928268,0.0002976642,0.0014109458,0.0026780458,0.000049032224,0.00010031061],"genre_scores_gemma":[0.9952146,0.002797359,0.00003171103,0.0004784195,0.0003984153,0.00061166123,0.000030333467,0.00004566553,0.00039187184],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966957,0.00034193936,0.00049946393,0.00054500694,0.0010315366,0.00088634825],"domain_scores_gemma":[0.9982661,0.00044121314,0.00007613741,0.0004988544,0.00046742594,0.00025024125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016310323,0.00021960368,0.0004296591,0.00050357694,0.00027762397,0.00006340256,0.00037543694,0.00015478193,0.0004971277],"category_scores_gemma":[0.00002672596,0.0001600525,0.00014925664,0.002253494,0.00025099333,0.00009857142,0.00014006831,0.00048294576,0.00006441621],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013414371,0.00014008828,0.009114212,0.00012994368,0.00007319715,0.000032313248,0.0015487107,0.00025422507,0.951778,0.000004195245,0.0060649905,0.017445782],"study_design_scores_gemma":[0.0031572785,0.00010373986,0.37931663,0.0016654758,0.000018308214,0.000008714514,0.0011598541,0.00024532978,0.61218107,0.00005453272,0.0019111807,0.00017790886],"about_ca_topic_score_codex":0.031880666,"about_ca_topic_score_gemma":0.002625907,"teacher_disagreement_score":0.3702024,"about_ca_system_score_codex":0.0006757716,"about_ca_system_score_gemma":0.0005958562,"threshold_uncertainty_score":0.9745661},"labels":[],"label_agreement":null},{"id":"W4387393214","doi":"10.1007/s11864-023-01132-w","title":"Optimal Therapeutic Strategy for PD-L1 Negative Metastatic Non-Small Cell Lung Cancer: A Decision-Making Guide Based on Clinicopathological and Molecular Features","year":2023,"lang":"en","type":"review","venue":"Current Treatment Options in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Durvalumab; Medicine; Atezolizumab; Pembrolizumab; Tremelimumab; Nivolumab; Ipilimumab; Oncology; Lung cancer; PD-L1; Internal medicine; Immunotherapy; Avelumab; Immune checkpoint; Blockade; Cancer; Chemotherapy; Receptor","score_opus":0.14797085779575342,"score_gpt":0.5008112849415937,"score_spread":0.35284042714584024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387393214","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010096774,0.99037224,0.0015927241,0.00012105757,0.0005953896,0.0057613547,0.0002841495,0.00005974117,0.0002036941],"genre_scores_gemma":[0.00046253434,0.9856017,0.006949009,0.00016020604,0.00011899926,0.0061777825,0.00030894327,0.00008206913,0.00013870462],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99696463,0.00040776908,0.001041068,0.0009086162,0.00018031782,0.00049758225],"domain_scores_gemma":[0.99548,0.0034253488,0.00046929336,0.00042584623,0.000087225795,0.00011230185],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049132283,0.00067547814,0.0021940893,0.00060090714,0.00013712162,0.000040673858,0.00017695571,0.00039986565,0.00005670927],"category_scores_gemma":[0.000107466054,0.00045973266,0.00081895746,0.00051748584,0.00018538929,0.000026590393,0.00004639796,0.0004845673,0.0000074437444],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013426968,0.0015800673,0.000034134064,0.0031281898,0.00048490972,0.00023237441,0.00009330335,0.0007779477,0.0000019251313,0.00003676402,0.0005267342,0.99176097],"study_design_scores_gemma":[0.01739315,0.015316755,0.00063162635,0.03784275,0.011767788,0.00016284427,0.00027114872,0.0062904404,0.000008049599,0.00019703337,0.9090858,0.0010326102],"about_ca_topic_score_codex":0.00002921702,"about_ca_topic_score_gemma":0.00008401492,"teacher_disagreement_score":0.9907283,"about_ca_system_score_codex":0.0020632795,"about_ca_system_score_gemma":0.0017891832,"threshold_uncertainty_score":0.9997854},"labels":[],"label_agreement":null},{"id":"W4387393296","doi":"10.1097/md.0000000000034990","title":"Predictive value of tumor mutational burden for PD-1/PD-L1 inhibitors in NSCLC: A meta-analysis","year":2023,"lang":"en","type":"review","venue":"Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Oncology; Cochrane Library; Internal medicine; Lung cancer; Biomarker; Predictive value; Randomized controlled trial; Publication bias; Bioinformatics","score_opus":0.13277906196014114,"score_gpt":0.40764719228496943,"score_spread":0.27486813032482826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387393296","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000034335608,0.99395293,0.00024189109,0.0014711089,0.00034679638,0.0029864572,0.0005438873,0.00005369122,0.00036888052],"genre_scores_gemma":[0.00034221102,0.9919107,0.00024352079,0.00030309768,0.0011889182,0.0015344429,0.0018103938,0.00011718389,0.0025495444],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959291,0.0002106426,0.0019523172,0.0006655827,0.0008841091,0.00035823943],"domain_scores_gemma":[0.9969236,0.0012199067,0.0009317512,0.0005406229,0.00024730383,0.00013678151],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018330057,0.00054628315,0.006641764,0.0019069174,0.000041611907,0.000005753255,0.00024192661,0.00026469972,0.00075043814],"category_scores_gemma":[0.00065896544,0.00034161497,0.003394094,0.003268927,0.00032444412,0.00004247991,0.000046100195,0.0003801549,0.0000117551],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028480564,0.0003451677,0.000044156084,0.055825207,0.68764687,0.00033725094,0.0022060648,0.00005918934,0.000037362955,0.00020944444,0.015707966,0.23473324],"study_design_scores_gemma":[0.0028184154,0.0008799142,0.00012318086,0.007010859,0.4861837,0.00004733214,0.00030343255,0.0001594878,0.000009043565,0.00007802834,0.50210696,0.00027964625],"about_ca_topic_score_codex":0.00094115344,"about_ca_topic_score_gemma":0.000091424925,"teacher_disagreement_score":0.486399,"about_ca_system_score_codex":0.0003162832,"about_ca_system_score_gemma":0.0007042801,"threshold_uncertainty_score":0.99990356},"labels":[],"label_agreement":null},{"id":"W4387402628","doi":"10.1016/j.esmoop.2023.101891","title":"81P Single-cell spatial landscape of NSCLC reveals subtype specific immune features","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McGill University","funders":"","keywords":"Mass cytometry; Immune system; Adenocarcinoma; Biology; Tumor microenvironment; Lung cancer; Cell; Cancer research; Context (archaeology); Flow cytometry; Cell type; Pathology; Immunology; Cancer; Medicine; Phenotype; Gene; Genetics","score_opus":0.03213982978182304,"score_gpt":0.2851381018444327,"score_spread":0.25299827206260966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387402628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.881504,0.0024925848,0.000014970627,0.0024938416,0.0008656016,0.0010519943,0.00003905684,0.00009737998,0.11144057],"genre_scores_gemma":[0.97499776,0.00047449907,0.00018522533,0.00022215743,0.00020580002,0.000015437841,0.00014382674,0.00003075366,0.023724522],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99899566,0.0000445311,0.0002941824,0.00022788011,0.00021536724,0.00022236988],"domain_scores_gemma":[0.9992581,0.00006553657,0.00012907188,0.00043355246,0.00005883366,0.00005487898],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003995654,0.00013011074,0.00035168443,0.00011116943,0.000058815433,0.000043351323,0.0003029124,0.00009508667,0.0019439459],"category_scores_gemma":[0.000026222579,0.00010593083,0.00011876239,0.0004286438,0.00006262659,0.000069925234,0.0001397554,0.00012904007,0.00018485167],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009316532,0.00045498772,0.021274779,0.00019517953,0.00027279262,0.0001431799,0.0011166686,0.0000029052162,0.58852273,0.00009096758,0.31835312,0.060256153],"study_design_scores_gemma":[0.0059490046,0.000810259,0.68016696,0.0003465323,0.00005745339,0.000033379,0.00036326205,0.0000080861,0.15649687,0.00009309244,0.15543091,0.00024417893],"about_ca_topic_score_codex":0.001673717,"about_ca_topic_score_gemma":0.00014624323,"teacher_disagreement_score":0.6588922,"about_ca_system_score_codex":0.00003291113,"about_ca_system_score_gemma":0.000077103265,"threshold_uncertainty_score":0.9989684},"labels":[],"label_agreement":null},{"id":"W4387402830","doi":"10.33590/emjgastroenterol/10303980.","title":"Challenges in Management of Immune Checkpoint Inhibitor-Associated Hepatitis","year":2023,"lang":"en","type":"article","venue":"EMJ Gastroenterology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Liver Centre; University Health Network","funders":"","keywords":"Medicine; Virology","score_opus":0.03191322957300105,"score_gpt":0.27954489891570156,"score_spread":0.2476316693427005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387402830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99304634,0.0007697103,0.000004913918,0.0044503175,0.00028237142,0.00024165216,0.0000068464988,0.00006150938,0.0011363217],"genre_scores_gemma":[0.9930633,0.0062975683,0.00006861708,0.000119669865,0.000025382738,0.000043951637,0.00003910014,0.000015948905,0.00032647094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988467,0.00006418865,0.00042539992,0.00020889388,0.00013647293,0.0003183192],"domain_scores_gemma":[0.9995933,0.000014988279,0.000114291324,0.00021740526,0.000026729234,0.00003325489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040700726,0.000108516855,0.0003228114,0.00021748463,0.000014154403,0.000002043536,0.00007820199,0.000071409195,0.0001013857],"category_scores_gemma":[0.000010446053,0.00010378317,0.00012501996,0.00021751793,0.000075724165,0.000023673949,0.00006897762,0.00011058925,0.000027477055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010937805,0.001335736,0.8898116,0.0011895404,0.0018531989,0.0019068299,0.0021505472,0.000018992436,0.04004193,0.00017938043,0.0021775772,0.048396908],"study_design_scores_gemma":[0.0044947118,0.0011698944,0.9913382,0.00035542808,0.000028378849,0.000039598133,0.00035478972,0.00003682663,0.0016775014,0.000047890135,0.00041223463,0.00004455855],"about_ca_topic_score_codex":0.00015972686,"about_ca_topic_score_gemma":0.0004897145,"teacher_disagreement_score":0.10152663,"about_ca_system_score_codex":0.00009309101,"about_ca_system_score_gemma":0.000009942053,"threshold_uncertainty_score":0.42321548},"labels":[],"label_agreement":null},{"id":"W4387491491","doi":"10.1016/j.ctarc.2023.100767","title":"The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy","year":2023,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Université de Montréal","keywords":"STK11; KRAS; Immunotherapy; Oncology; Medicine; Internal medicine; Cancer","score_opus":0.07313046330335114,"score_gpt":0.40848728692078057,"score_spread":0.3353568236174294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387491491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98115087,0.012624355,1.5698696e-7,0.0047416086,0.00000448782,0.0011936667,0.000059841146,0.000015493695,0.00020955279],"genre_scores_gemma":[0.9255014,0.07358802,0.000006692541,0.00002468755,0.000004713142,0.0006542871,0.0000403642,0.000012279687,0.00016754521],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990877,0.00024973505,0.00016354684,0.00014320694,0.00014236923,0.00021344282],"domain_scores_gemma":[0.99749744,0.0015934223,0.00005280122,0.00062599935,0.00017756091,0.000052789466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037220202,0.00012085152,0.00015222614,0.00012938268,0.000614949,0.000049991308,0.00015815893,0.000035211713,0.0000073731812],"category_scores_gemma":[0.00005957345,0.00004967597,0.000035231405,0.00070325204,0.0010742124,0.0000514721,0.000058980557,0.00017023523,8.9440135e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001543323,0.0004111681,0.90630853,0.000017016104,0.00050200766,0.0000011670643,0.005101783,0.0000075458456,0.0020732393,0.0002033303,0.00012322309,0.08370766],"study_design_scores_gemma":[0.0026416827,0.0017436536,0.992476,0.00021305124,0.00002420355,0.0000022132544,0.0011973688,0.00022510307,0.00025386538,0.000101091384,0.0010640565,0.00005772933],"about_ca_topic_score_codex":0.003592825,"about_ca_topic_score_gemma":0.001457049,"teacher_disagreement_score":0.08616744,"about_ca_system_score_codex":0.00017951711,"about_ca_system_score_gemma":0.00021481211,"threshold_uncertainty_score":0.54313004},"labels":[],"label_agreement":null},{"id":"W4387533911","doi":"10.1186/s12957-023-03215-2","title":"Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"World Journal of Surgical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Meta-analysis; Lung cancer; Oncology; Cochrane Library; Subgroup analysis; Confidence interval; PD-L1; Publication bias; Surgical oncology; Immunotherapy; Cancer","score_opus":0.045013791212096865,"score_gpt":0.3354845096966751,"score_spread":0.2904707184845782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387533911","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007707772,0.99499977,0.000019364603,0.00036799157,0.000058907543,0.0036739148,0.000048719216,0.000009149508,0.000051382962],"genre_scores_gemma":[0.003488515,0.99523073,0.0002173205,0.00015478,0.000043845514,0.0004190767,0.00003546776,0.00006135315,0.00034890504],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9927951,0.0012168386,0.004432485,0.0004917059,0.0006628528,0.00040099592],"domain_scores_gemma":[0.9905776,0.0023203273,0.005894844,0.00048792752,0.00051919,0.0002001549],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0029084315,0.0006344386,0.016995199,0.0024217062,0.0000443481,0.000022417775,0.0003104728,0.00025682448,0.00036665972],"category_scores_gemma":[0.00008083692,0.00034818993,0.005418765,0.0071342783,0.0001861629,0.00005486304,0.000046835736,0.00083060545,0.000001040452],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011257448,0.0009562911,0.002433108,0.55510646,0.43813276,0.00045760657,0.000043479955,0.00005311388,0.0000021970206,5.8812134e-7,0.000016466875,0.0016721637],"study_design_scores_gemma":[0.0044389837,0.001173662,0.00062704505,0.08306056,0.905266,0.00002660824,0.0000108803415,0.000011841757,0.0000056993404,4.630644e-7,0.0050600474,0.00031820463],"about_ca_topic_score_codex":0.00013626493,"about_ca_topic_score_gemma":0.00064863334,"teacher_disagreement_score":0.47204593,"about_ca_system_score_codex":0.00047762782,"about_ca_system_score_gemma":0.0017640184,"threshold_uncertainty_score":0.999897},"labels":[],"label_agreement":null},{"id":"W4387543797","doi":"10.1159/000532004","title":"Remitting Seronegative Symmetrical Synovitis with Pitting Edema: A Case Report of an Immune-Related Adverse Event following Surgery","year":2023,"lang":"en","type":"article","venue":"Case Reports in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; Princess Margaret Cancer Centre; Hamilton Health Sciences; University of Toronto; University Health Network; Trillium Health Centre","funders":"","keywords":"Medicine; Adverse effect; Immune system; Context (archaeology); Synovitis; Adjuvant; Edema; Peripheral edema; Cancer; Surgery; Dermatology; Immunology; Internal medicine; Rheumatoid arthritis","score_opus":0.023728514680015043,"score_gpt":0.33347594915213835,"score_spread":0.30974743447212333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387543797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99657905,0.0005131797,0.000023659162,0.0002691121,0.00081405515,0.0006468662,0.0000031223192,0.00014222684,0.0010087183],"genre_scores_gemma":[0.99866134,0.000043804754,0.00067373784,0.0000692658,0.00007691777,0.000077074576,0.00006125399,0.00005172466,0.00028486038],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9958471,0.0002864775,0.0023813294,0.00064036716,0.00033849612,0.00050620496],"domain_scores_gemma":[0.9962745,0.0012954923,0.0014614176,0.00063142733,0.00016684692,0.00017033072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052924287,0.00025073008,0.001092436,0.00079596427,0.0001439335,0.000006438984,0.000032753716,0.00033395542,0.000044564655],"category_scores_gemma":[0.0027405277,0.00021956833,0.00039460527,0.0022445251,0.00019148657,0.00015069076,0.00007217674,0.0004415402,0.0000016147281],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006609754,0.0002939746,0.030512841,0.00011124342,0.00042560417,0.9394554,0.0011939788,0.000056369205,0.0021382207,0.0000024166447,0.000102513084,0.0250465],"study_design_scores_gemma":[0.0018343313,0.0007482696,0.009399884,0.0006615211,0.0002408606,0.97741777,0.0062118927,0.00036368667,0.0023712977,0.000018463828,0.000500497,0.00023153315],"about_ca_topic_score_codex":0.002612404,"about_ca_topic_score_gemma":0.0003943076,"teacher_disagreement_score":0.0379624,"about_ca_system_score_codex":0.0007487973,"about_ca_system_score_gemma":0.0011590786,"threshold_uncertainty_score":0.8953737},"labels":[],"label_agreement":null},{"id":"W4387579013","doi":"10.1016/j.ccell.2023.09.011","title":"Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma","year":2023,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"CD8; Cancer research; Cytotoxic T cell; Immunotherapy; Immune checkpoint; Blockade; Medicine; T cell; Progenitor cell; Cell; Immune system; Immunology; Biology; Internal medicine; Stem cell; Cell biology; Receptor; In vitro","score_opus":0.017532066080426487,"score_gpt":0.27323026596238403,"score_spread":0.2556981998819575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387579013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98799086,0.006477196,0.0000100945745,0.00064818695,0.001965648,0.0014865724,0.00009882329,0.00018937989,0.001133238],"genre_scores_gemma":[0.98269427,0.00038568332,0.000108520544,0.001128977,0.00045394193,0.00032384225,0.000055273813,0.000109926914,0.014739544],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99712604,0.00012055348,0.00058245606,0.0007711108,0.0004886428,0.00091116835],"domain_scores_gemma":[0.9985971,0.00008722535,0.00014329684,0.00066385634,0.00014927458,0.00035926778],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003665404,0.00041115968,0.0005741209,0.00039184274,0.00011860782,0.000043712032,0.00030423814,0.00023646199,0.0006547494],"category_scores_gemma":[0.0000119676115,0.00039471022,0.00024032556,0.0013904499,0.000083090075,0.000094516,0.00012744278,0.00031861648,0.00034431866],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006694781,0.00027280863,0.01308973,0.00048557884,0.000036105437,0.0016155407,0.0015199446,0.0003651266,0.9611343,8.268188e-7,0.010299204,0.0044860607],"study_design_scores_gemma":[0.0075619505,0.00062782544,0.118192695,0.00013685913,0.00012652345,0.000023026176,0.0008095581,0.0002596381,0.83953285,0.0000047343738,0.03220723,0.00051712024],"about_ca_topic_score_codex":0.0035690998,"about_ca_topic_score_gemma":0.00048922864,"teacher_disagreement_score":0.12160145,"about_ca_system_score_codex":0.0007790924,"about_ca_system_score_gemma":0.0006556672,"threshold_uncertainty_score":0.99985045},"labels":[],"label_agreement":null},{"id":"W4387597413","doi":"10.1007/s00262-023-03520-5","title":"PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies","year":2023,"lang":"en","type":"review","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; University of Toronto; Western University","funders":"Canadian Institutes of Health Research","keywords":"Colorectal cancer; Medicine; Immunotherapy; Oncology; Cancer; Internal medicine; Cancer research","score_opus":0.06282607383926041,"score_gpt":0.3628216248640533,"score_spread":0.29999555102479286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387597413","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009066676,0.98547137,5.6985004e-7,0.0008071782,0.0016348711,0.0023249446,0.00014745884,0.00023618498,0.00031072646],"genre_scores_gemma":[0.00039346132,0.9952515,0.000022012495,0.00022272459,0.00033183544,0.0026860635,0.00005312314,0.00028281898,0.00075650704],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958894,0.0003403198,0.00134248,0.0012050036,0.00027725621,0.0009455052],"domain_scores_gemma":[0.9981302,0.00038763133,0.0006411308,0.00062512426,0.00010261469,0.00011328681],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00056314556,0.0011080677,0.0035307365,0.00089646596,0.00018385587,0.00009923936,0.0003643092,0.0013393426,0.0001867756],"category_scores_gemma":[0.000024554758,0.00094672426,0.00045809208,0.00074398646,0.0011800177,0.00022982927,0.00015438728,0.0013155143,0.00001812304],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018041845,0.000103069215,0.00008824962,0.0072267517,0.0033854684,0.00009229016,0.0013498325,2.513001e-7,0.0019292805,0.00025875156,0.00029661958,0.98346525],"study_design_scores_gemma":[0.005158722,0.00082846766,0.0035982702,0.022780523,0.00054842024,0.00025578777,0.0010132117,0.0000016374013,0.00017144105,0.00008647787,0.9645759,0.0009811274],"about_ca_topic_score_codex":0.0019452837,"about_ca_topic_score_gemma":0.0014355194,"teacher_disagreement_score":0.9824841,"about_ca_system_score_codex":0.00086306874,"about_ca_system_score_gemma":0.001771213,"threshold_uncertainty_score":0.99995714},"labels":[],"label_agreement":null},{"id":"W4387706982","doi":"10.1099/acmi.0.000671.v2","title":"Radioimmunotherapy as a pathogen-agnostic treatment method for  opportunistic fungal infections","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Radioimmunotherapy; Immune system; Mucormycosis; Antigen; Immunosuppression; Immunology; Pathogen; Immunotherapy; Pandemic; Biology; Medicine; Antibody; Coronavirus disease 2019 (COVID-19); Monoclonal antibody; Internal medicine; Disease; Infectious disease (medical specialty); Pathology","score_opus":0.0894054042527378,"score_gpt":0.3926570116144848,"score_spread":0.303251607361747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387706982","genre_codex":"methods","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.049781512,0.012882789,0.81810665,0.027606793,0.02018924,0.034193724,0.0069771325,0.005345724,0.024916423],"genre_scores_gemma":[0.10565209,0.074926086,0.17197631,0.013011577,0.006193471,0.03097361,0.01453758,0.0017894061,0.5809399],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99776363,0.000109010354,0.0006393965,0.0007759634,0.00025882668,0.00045319804],"domain_scores_gemma":[0.99768436,0.00079593534,0.00022999174,0.0009378756,0.00016157198,0.00019024484],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00051566795,0.00054743915,0.0009150499,0.000353252,0.0001936973,0.00007573219,0.0001374074,0.0004661067,0.0011114747],"category_scores_gemma":[0.00017589536,0.00043398803,0.001005715,0.00022117706,0.00007978548,0.000025520174,0.000079045036,0.00030641258,0.000099751924],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018614609,0.0053627403,0.0035838017,0.0024702284,0.02330069,0.0009720965,0.002908135,0.00030691034,0.11001577,0.0049514724,0.05073544,0.7767781],"study_design_scores_gemma":[0.033461187,0.019784808,0.013606484,0.0021079155,0.0065316837,0.0017514802,0.0006975173,0.009756534,0.0070781386,0.0106533,0.8918177,0.0027532699],"about_ca_topic_score_codex":0.002922989,"about_ca_topic_score_gemma":0.000200358,"teacher_disagreement_score":0.8410822,"about_ca_system_score_codex":0.00078617735,"about_ca_system_score_gemma":0.0014243061,"threshold_uncertainty_score":0.9998112},"labels":[],"label_agreement":null},{"id":"W4387763222","doi":"10.1016/j.ygyno.2023.09.012","title":"Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100","year":2023,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Oncology; Internal medicine; Proportional hazards model; Ovarian cancer; Pembrolizumab; Progression-free survival; Immunohistochemistry; Cancer research; Cancer; Immunotherapy; Overall survival","score_opus":0.08579269681327752,"score_gpt":0.43773957484359644,"score_spread":0.35194687803031893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387763222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975236,0.0005424876,0.0000073897795,0.00047468912,0.00061898335,0.0003644524,0.000053919215,0.000022760029,0.0003917329],"genre_scores_gemma":[0.9976383,0.0017486094,0.00014839275,0.00028906658,0.00001650211,0.00007496622,0.000021820697,0.00001112727,0.00005125642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971477,0.0003913391,0.0016207551,0.0003256447,0.00022540013,0.00028917345],"domain_scores_gemma":[0.9975754,0.0009928454,0.0008136283,0.00039954763,0.0001481384,0.00007041465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014279779,0.00015700552,0.0019606384,0.0007825989,0.000015014048,0.0000010589941,0.00020155525,0.0003579801,0.00040016396],"category_scores_gemma":[0.0007571169,0.00012560075,0.00059835427,0.0018086657,0.00034838184,0.000028471111,0.00009078244,0.00020258865,0.0000035044545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030329116,0.0007889274,0.88404876,0.00010201423,0.0015048495,0.00015512432,0.000311512,0.00008294644,0.0029738378,0.000028484483,0.00017395159,0.10679668],"study_design_scores_gemma":[0.0055541205,0.0028046407,0.9861079,0.000043925567,0.0009839034,0.0000019619813,0.00034394866,0.00057394383,0.0023619588,0.000054665972,0.0010661309,0.000102931335],"about_ca_topic_score_codex":0.00043035616,"about_ca_topic_score_gemma":0.0023234845,"teacher_disagreement_score":0.106693745,"about_ca_system_score_codex":0.00018852316,"about_ca_system_score_gemma":0.0007417728,"threshold_uncertainty_score":0.512185},"labels":[],"label_agreement":null},{"id":"W4387782335","doi":"10.1038/s41591-023-02593-0","title":"The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"MacroGenics; NRG Oncology","keywords":"Medicine; Internal medicine; Refractory (planetary science); Adverse effect; Clinical endpoint; Cancer; Clinical trial; Oncology; Cohort; Gastroenterology","score_opus":0.018204015918651298,"score_gpt":0.3508122363939516,"score_spread":0.3326082204753003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387782335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93868446,0.04383503,0.000004310853,0.015308597,0.0005938439,0.0007678158,0.00000571517,0.00008551353,0.0007146971],"genre_scores_gemma":[0.9907062,0.0069001713,0.00003410398,0.0013744117,0.00054203684,0.000054017222,0.000031830245,0.000022346623,0.00033485686],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985028,0.00006880321,0.00040306675,0.00033612814,0.00032815934,0.00036106465],"domain_scores_gemma":[0.9991981,0.0003211028,0.00011084985,0.00021269034,0.000052040647,0.000105236046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010502622,0.00019272677,0.00046434253,0.00020921134,0.00016053166,0.000018949799,0.00008979069,0.00021045905,0.000047092297],"category_scores_gemma":[0.0006324561,0.00010832818,0.000044085984,0.0007414938,0.0003874393,0.000037216945,0.00004159823,0.0006619942,0.000002806091],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34059775,0.0005033214,0.004208955,0.0009850379,0.00067401427,0.0038228796,0.009723984,0.000004166434,0.30999976,0.00093315117,0.15963419,0.1689128],"study_design_scores_gemma":[0.70619947,0.012047062,0.018403186,0.0042637065,0.00042081106,0.0012547034,0.018841982,0.0037358736,0.024071483,0.0014407025,0.20814972,0.0011712927],"about_ca_topic_score_codex":0.00014201636,"about_ca_topic_score_gemma":0.00011608608,"teacher_disagreement_score":0.36560172,"about_ca_system_score_codex":0.000104762104,"about_ca_system_score_gemma":0.00010980437,"threshold_uncertainty_score":0.4417495},"labels":[],"label_agreement":null},{"id":"W4387809560","doi":"10.1016/j.annonc.2023.10.066","title":"LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Daiichi Sankyo Europe; MSD Italia; EMD Serono; Sociedad Española de Oncología Médica; European Society for Medical Oncology; Astellas Pharma; MacroGenics; Pfizer; Incyte; BeiGene; Mirati Therapeutics; Spectrum Pharmaceuticals; Yuhan; Mersana Therapeutics; Les Laboratories Pierre Fabre; Ipsen; Array BioPharma; Jazz Pharmaceuticals; Merck KGaA; Regeneron Pharmaceuticals; AstraZeneca; Associazione Italiana di Oncologia Medica; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; American Society of Clinical Oncology; Exelixis; Sanofi; Amgen; LAM Therapeutics; Celgene","keywords":"Medicine; Discontinuation; Pembrolizumab; Adverse effect; Internal medicine; Lung cancer; Nausea; Oncology; Cancer; Immunotherapy","score_opus":0.02248700678897033,"score_gpt":0.3272610444920983,"score_spread":0.304774037703128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969091,0.00069599116,0.00001580031,0.00039896823,0.000059247403,0.00094110565,0.000035397232,0.000020474297,0.0009239491],"genre_scores_gemma":[0.9976793,0.0016423526,0.00021968303,0.00011257445,0.000019462635,0.00007762983,0.00005161734,0.000025400854,0.00017195834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998908,0.000043903106,0.00035996144,0.00025944793,0.00015614218,0.0002725337],"domain_scores_gemma":[0.9991955,0.0001244379,0.00027243208,0.00017176323,0.00016972517,0.00006615443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012081614,0.00017298569,0.00050586654,0.00022921365,0.000032590764,0.000003108517,0.000051535957,0.00009246917,0.000024939029],"category_scores_gemma":[0.000011707932,0.0001252564,0.000048107522,0.00045705188,0.000116013915,0.00007216883,0.000017114473,0.00008282089,5.695107e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10807779,0.0017244988,0.6427086,0.0006096885,0.00071745744,0.00011344234,0.0041869655,0.00058210676,0.013674386,0.000008189231,0.00017686689,0.22742002],"study_design_scores_gemma":[0.040887978,0.013215442,0.9311339,0.0005500938,0.00012926561,0.000004921241,0.00030671744,0.00011139752,0.012478638,0.000002220396,0.0010355872,0.00014382601],"about_ca_topic_score_codex":0.0007045263,"about_ca_topic_score_gemma":0.00075838895,"teacher_disagreement_score":0.28842533,"about_ca_system_score_codex":0.00013165188,"about_ca_system_score_gemma":0.00040606648,"threshold_uncertainty_score":0.5107808},"labels":[],"label_agreement":null},{"id":"W4387809597","doi":"10.1016/j.annonc.2023.10.052","title":"LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"Daiichi Sankyo Company; MSD Italia; Eli Lilly Japan; Sanofi Genzyme; Chugai Pharmaceutical; Ipsen; AstraZeneca Pharma Poland; Eli Lilly and Company; Ono Pharmaceutical; Otsuka Pharmaceutical; Seagen; Lunit; BeiGene; Mirati Therapeutics; Pfizer; Incyte; Merck KGaA; Taiho Pharmaceutical; Regeneron Pharmaceuticals; AstraZeneca España; Helsinn; Daiichi Sankyo Europe; Gilead Sciences; Bayer HealthCare; Exelixis; Sanofi; Spectrum Pharmaceuticals; Medtronic Japan; Amgen; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Placebo; Lung cancer; Interim; Interim analysis; Randomization; Stage (stratigraphy); Internal medicine; Pembrolizumab; Perioperative; Oncology; Tolerability; Cancer; Clinical trial; Surgery; Adverse effect; Pathology","score_opus":0.09338101173832299,"score_gpt":0.41300561536293673,"score_spread":0.31962460362461376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99010855,0.0005545052,0.000012363729,0.0027218757,0.00028443715,0.0018612944,0.00006493979,0.000014151272,0.004377882],"genre_scores_gemma":[0.99562556,0.0008917159,0.00002391453,0.000960014,0.00011214535,0.00032213004,0.000014345102,0.000022806573,0.0020273677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848145,0.00020291028,0.000496758,0.00025856454,0.00022272574,0.00033761343],"domain_scores_gemma":[0.99880683,0.00041177144,0.00021556261,0.00029782188,0.00022758018,0.000040426366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009282418,0.00016341014,0.00059717643,0.0001756205,0.00005950818,0.00000771382,0.00022510898,0.00013169274,0.0001113233],"category_scores_gemma":[0.000051406114,0.00011597148,0.00017558517,0.00038014012,0.000112645226,0.00004833843,0.000048912832,0.00018225722,0.0000023040186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09972903,0.011786577,0.45425627,0.0018856362,0.0030740178,0.00042695788,0.24700533,0.0006686545,0.115702845,0.00044083892,0.021500044,0.0435238],"study_design_scores_gemma":[0.036984168,0.023926558,0.87969124,0.00018165982,0.00020414632,0.0000060775196,0.021204036,0.0007884092,0.0096863685,0.000019883533,0.027007991,0.0002994566],"about_ca_topic_score_codex":0.0051010353,"about_ca_topic_score_gemma":0.003480849,"teacher_disagreement_score":0.42543498,"about_ca_system_score_codex":0.00006284881,"about_ca_system_score_gemma":0.00047512059,"threshold_uncertainty_score":0.77112734},"labels":[],"label_agreement":null},{"id":"W4387809604","doi":"10.1016/j.annonc.2023.10.053","title":"LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Institutes of Health; European Society for Medical Oncology; BeiGene; AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Chemotherapy; Complete response; Pathological; Clinical endpoint; Phases of clinical research; Neoadjuvant therapy; Immunotherapy; Clinical trial; Cancer","score_opus":0.07998844053475229,"score_gpt":0.4265823777995135,"score_spread":0.34659393726476123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97583663,0.0007324728,0.0000030454287,0.01895797,0.0002130693,0.0009998844,0.00005437083,0.000060881317,0.0031416768],"genre_scores_gemma":[0.9909233,0.0014413125,0.000019973055,0.0061642774,0.00012057392,0.00010272272,0.00007130253,0.000025723088,0.001130824],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979472,0.00025717623,0.0007149186,0.00034596107,0.00032583566,0.00040887666],"domain_scores_gemma":[0.99880606,0.00023253201,0.0003026349,0.00049456785,0.00009728047,0.000066908906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018142629,0.00018901868,0.0005770187,0.00018812108,0.00007652856,0.000009704002,0.00028242203,0.00012450684,0.00013640673],"category_scores_gemma":[0.000100183875,0.00012643424,0.00014896983,0.0006315312,0.00015935002,0.00006792369,0.00004586294,0.00024133922,0.00002659051],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072810054,0.0054589547,0.0008307639,0.00005311436,0.0002120163,0.0004704958,0.0110579925,0.0000024472079,0.30614528,0.000005817094,0.42301166,0.1799414],"study_design_scores_gemma":[0.10993904,0.025625695,0.037639864,0.0003026361,0.000059377897,0.00009362222,0.009581725,0.00012998894,0.12958527,0.00011559899,0.68657815,0.000349039],"about_ca_topic_score_codex":0.00052582787,"about_ca_topic_score_gemma":0.000098437355,"teacher_disagreement_score":0.26356646,"about_ca_system_score_codex":0.00005316339,"about_ca_system_score_gemma":0.00018781408,"threshold_uncertainty_score":0.5155839},"labels":[],"label_agreement":null},{"id":"W4387809745","doi":"10.1016/j.annonc.2023.09.2951","title":"228P Biomarker discovery via meta-analysis of immunotherapy clinical trials in cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Immunotherapy; Medicine; Cancer immunotherapy; Oncology; Clinical trial; Biomarker; Gene signature; Cancer; Gene expression profiling; Internal medicine; Computational biology; Bioinformatics; Gene; Gene expression; Biology; Genetics","score_opus":0.6018903158374248,"score_gpt":0.588874700187685,"score_spread":0.013015615649739853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.959939,0.01872316,0.00012436812,0.018775577,0.0005036085,0.00065625156,0.00022226336,0.000030074429,0.0010256827],"genre_scores_gemma":[0.9674103,0.027318528,0.00009951493,0.0037273893,0.00007484232,0.0001115264,0.00006657759,0.000023208884,0.0011681019],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.99502707,0.0015158823,0.002561082,0.0003283157,0.00027314122,0.00029454214],"domain_scores_gemma":[0.99544585,0.0027804654,0.0010580283,0.0004722556,0.00018279695,0.000060600094],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0133847045,0.00017671341,0.004247312,0.0010010395,0.000017814675,0.000005220901,0.00017432105,0.00029137658,0.001749334],"category_scores_gemma":[0.0006092295,0.00012272513,0.003942751,0.0023885944,0.00031459786,0.00008568062,0.000039544404,0.00016436497,0.000007130714],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023274947,0.0016009726,0.039496683,0.00008818048,0.49623683,0.00006700502,0.000466569,0.00006963467,0.08038191,0.000063832376,0.017572014,0.34068143],"study_design_scores_gemma":[0.010182663,0.0043634586,0.7614319,0.000050322764,0.10206859,0.0000065096856,0.00026824838,0.0005847697,0.015084211,0.0003804577,0.1052273,0.0003515692],"about_ca_topic_score_codex":0.0020969713,"about_ca_topic_score_gemma":0.0008701384,"teacher_disagreement_score":0.7219352,"about_ca_system_score_codex":0.00004031674,"about_ca_system_score_gemma":0.00039265867,"threshold_uncertainty_score":0.9991632},"labels":[],"label_agreement":null},{"id":"W4387811078","doi":"10.1016/j.annonc.2023.09.2223","title":"1089P Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Oncology; Adjuvant; Melanoma; Stage (stratigraphy); Adjuvant therapy; Immunotherapy; Cancer; Cancer research","score_opus":0.0882871583234907,"score_gpt":0.3801278779248938,"score_spread":0.29184071960140306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729794,0.0013591779,0.0000025003587,0.010734373,0.00051549525,0.0005076035,0.000395475,0.00013963213,0.013366312],"genre_scores_gemma":[0.98792034,0.002976412,0.00010840537,0.0014456538,0.00020415575,0.000039952683,0.00037689743,0.000040952986,0.006887227],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99726045,0.0002303219,0.0010215503,0.0005295207,0.00034259312,0.00061555195],"domain_scores_gemma":[0.9981813,0.00046828573,0.0003752121,0.0006288371,0.00021181644,0.00013456405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011515196,0.00024197195,0.00091910316,0.00045897753,0.0000599062,0.000009851717,0.00026072346,0.0003764404,0.00068438845],"category_scores_gemma":[0.00034262953,0.00022018315,0.00021359815,0.00096126564,0.00023997734,0.0000972293,0.00011960234,0.0003574697,0.00014024726],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28201815,0.0021188438,0.007634564,0.00030024681,0.001442836,0.0031716009,0.009728946,0.000054513064,0.2354137,0.00016751989,0.2651968,0.19275227],"study_design_scores_gemma":[0.06531264,0.010567253,0.47771358,0.00056368543,0.00010374645,0.000036681282,0.0021859654,0.00085825473,0.055246666,0.0005109846,0.3863291,0.0005714472],"about_ca_topic_score_codex":0.0069614532,"about_ca_topic_score_gemma":0.0035204098,"teacher_disagreement_score":0.470079,"about_ca_system_score_codex":0.00016364871,"about_ca_system_score_gemma":0.0005390997,"threshold_uncertainty_score":0.99965125},"labels":[],"label_agreement":null},{"id":"W4387811453","doi":"10.1016/j.annonc.2023.09.1883","title":"697P Open-label, phase I, dose escalation/expansion trial of the anti-SIRPα monoclonal antibody BI 770371 in patients with advanced solid tumours, alone or in combination with the anti-PD-1 monoclonal antibody ezabenlimab","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Hackensack Meridian Health; National Cancer Center Japan; Sanofi; Boehringer Ingelheim","keywords":"Medicine; Internal medicine; Adverse effect; Clinical endpoint; Discontinuation; Gastroenterology; Peripheral edema; Clinical trial","score_opus":0.06275232884655985,"score_gpt":0.42106978766187136,"score_spread":0.3583174588153115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884918,0.00012717604,0.0000188694,0.008027868,0.0002646588,0.0028122338,0.00008959642,0.000022352158,0.00014546231],"genre_scores_gemma":[0.9978463,0.0005844537,0.00019143816,0.00071291236,0.0000472817,0.000066313245,0.00043863812,0.000036685935,0.000075964126],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99723643,0.00037128705,0.0009017748,0.0004318076,0.00060672755,0.00045199005],"domain_scores_gemma":[0.9979338,0.00033708542,0.0007865147,0.0004803299,0.0003955755,0.00006669114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011940236,0.00028381532,0.00095256144,0.0003706914,0.00013630326,0.000020749245,0.00044599388,0.00018690695,0.00004168759],"category_scores_gemma":[0.0001306353,0.00015431836,0.00008488454,0.0017180985,0.00044980203,0.00031173724,0.00015526099,0.00033034646,0.0000027699255],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61146694,0.021660333,0.1847561,0.00014698319,0.0004931388,0.00012497944,0.001412589,0.00033770048,0.11949278,0.000089513574,0.0016904824,0.05832849],"study_design_scores_gemma":[0.24979137,0.024156509,0.71494514,0.0004319802,0.00007204045,0.000012048113,0.0002762558,0.000634447,0.008770526,0.00004193393,0.00066749746,0.00020027919],"about_ca_topic_score_codex":0.00030424425,"about_ca_topic_score_gemma":0.00029783428,"teacher_disagreement_score":0.53018904,"about_ca_system_score_codex":0.000088960114,"about_ca_system_score_gemma":0.0008197647,"threshold_uncertainty_score":0.629292},"labels":[],"label_agreement":null},{"id":"W4387812500","doi":"10.1016/j.annonc.2023.09.1267","title":"2239P Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; Foundation Medicine; Takeda Pharmaceuticals International; Sierra Oncology; INCLIVA Instituto de Investigación Sanitaria; Sociedad Española de Oncología Médica; PharmaMar; Novartis Farmacéutica; European Society for Medical Oncology; Fundación Científica Asociación Española Contra el Cáncer; Cancer Research UK; Seagen; F-star Therapeutics; Genentech; Veracyte; BeiGene; Mirati Therapeutics; Les Laboratories Pierre Fabre; Natera; Regeneron Pharmaceuticals; Ribon Therapeutics; Ipsen; Array BioPharma; Pfizer; Incyte; Grifols; F. Hoffmann-La Roche; Merck KGaA; Daiichi Sankyo Europe; Servier; Gilead Sciences; Astellas Pharma; FibroGen; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Exelixis; Sanofi; Amgen; Celgene","keywords":"Medicine; CD19; Cancer; Tumor-infiltrating lymphocytes; Tumor microenvironment; Gene expression profiling; Gene signature; Pancreatic cancer; Colorectal cancer; Cancer research; Gene expression; Gene; Oncology; Internal medicine; Immunotherapy; Pathology; Immunology; Flow cytometry; Biology; Genetics","score_opus":0.051258496362040856,"score_gpt":0.39954416982533575,"score_spread":0.34828567346329486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387812500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574035,0.0020490678,0.0000029248736,0.001632753,0.00008364868,0.00024464246,0.000018906107,0.000031085023,0.00019661446],"genre_scores_gemma":[0.99680686,0.0016334344,0.00036422125,0.00092702237,0.00006867283,0.000039207003,0.000015423891,0.000015620133,0.00012952842],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991489,0.000043198062,0.00022946991,0.00020568598,0.00011586118,0.00025685393],"domain_scores_gemma":[0.99960667,0.000042561664,0.00011177312,0.00012874238,0.000058136295,0.000052141673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000246738,0.00010726414,0.0003183751,0.000099107165,0.00004214819,0.0000048104102,0.000057221492,0.000099403645,0.00003052474],"category_scores_gemma":[0.000021863654,0.0000747383,0.000032236712,0.00021902738,0.00017978497,0.000049908354,0.00003275373,0.00008872746,0.0000010053453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043785535,0.000045944216,0.46360072,0.00010518545,0.000065356384,0.00005569402,0.0008482302,0.00002781162,0.48809248,0.0000036594934,0.00040338546,0.042372975],"study_design_scores_gemma":[0.0027155513,0.00083871436,0.41524643,0.00020499344,0.00001130311,0.00009085301,0.00043464956,0.00003540137,0.5789196,0.000067149,0.0013518889,0.00008345467],"about_ca_topic_score_codex":0.00048313566,"about_ca_topic_score_gemma":0.00026301877,"teacher_disagreement_score":0.09082714,"about_ca_system_score_codex":0.000033255703,"about_ca_system_score_gemma":0.00021870923,"threshold_uncertainty_score":0.30477396},"labels":[],"label_agreement":null},{"id":"W4387825362","doi":"10.1016/j.annonc.2023.09.2066","title":"922P Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Plexxikon; Eisai; EMD Serono; Rakuten Medical; MacroGenics; Genentech; Coherus Biosciences; Actuate Therapeutics; Regeneron Pharmaceuticals; Sanofi; Exelixis; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Conquer Cancer Foundation; Gilead Sciences; Astellas Pharma; Celldex Therapeutics; Gateway for Cancer Research; HCA Healthcare; Pfizer","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Head and neck squamous-cell carcinoma; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Cohort; Expanded access; Progression-free survival; Progressive disease; Head and neck cancer; Gastroenterology; Surgery; Cancer; Chemotherapy; Immunotherapy; Clinical trial","score_opus":0.04322910080545783,"score_gpt":0.3161477198912267,"score_spread":0.27291861908576887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963743,0.00034900178,8.3164093e-7,0.0017936373,0.0001625992,0.0005071539,0.0000674257,0.00001082621,0.0007341914],"genre_scores_gemma":[0.9991853,0.00008276428,0.00008229023,0.00033903302,0.000029128856,0.000021027983,0.000055221368,0.000015155667,0.00019005175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998713,0.0001235682,0.0004099102,0.00023823562,0.00029407124,0.00022118902],"domain_scores_gemma":[0.99904966,0.0001708488,0.00028493235,0.00023589225,0.00020270556,0.000055982422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028904428,0.00013733548,0.0003714215,0.0001909417,0.000040203973,0.000003039773,0.00007029705,0.00007191142,0.00001776245],"category_scores_gemma":[0.000058690734,0.00007989263,0.000059647064,0.00055260904,0.0002319936,0.000057303623,0.00004170464,0.00014916334,0.0000018622783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32598796,0.003796698,0.58262604,0.0007787324,0.00022678023,0.00008757393,0.0037121633,0.00009488514,0.006332308,0.000023411558,0.019870216,0.05646321],"study_design_scores_gemma":[0.03194684,0.01836787,0.9416516,0.00018172305,0.000058156835,0.000014610016,0.00028286487,0.000031972922,0.003517262,0.000017291493,0.0038343072,0.000095539755],"about_ca_topic_score_codex":0.0004210515,"about_ca_topic_score_gemma":0.00045550303,"teacher_disagreement_score":0.35902548,"about_ca_system_score_codex":0.00004731281,"about_ca_system_score_gemma":0.0003480007,"threshold_uncertainty_score":0.3257927},"labels":[],"label_agreement":null},{"id":"W4387825574","doi":"10.1016/j.annonc.2023.09.2000","title":"854O INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Hazard ratio; Internal medicine; Head and neck squamous-cell carcinoma; Cetuximab; Clinical endpoint; Oncology; Interim analysis; Cancer; Progression-free survival; Head and neck cancer; Confidence interval; Phases of clinical research; Urology; Gastroenterology; Chemotherapy; Clinical trial","score_opus":0.06185240039931168,"score_gpt":0.3751156339257055,"score_spread":0.31326323352639385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950181,0.0019891795,0.0000013966868,0.00048169255,0.000023669441,0.0023716276,0.000035145054,0.000037263297,0.000041915795],"genre_scores_gemma":[0.9989851,0.00023460829,0.000094626885,0.00015667285,0.000024266508,0.00033328286,0.000054270553,0.00005597758,0.00006119421],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99763215,0.00022524163,0.000759036,0.0005517198,0.00034189477,0.0004899327],"domain_scores_gemma":[0.9986116,0.00010517476,0.0004577735,0.00040441763,0.00015988584,0.0002611454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041016584,0.00036487044,0.0009979658,0.00031928488,0.000050600913,0.000013540126,0.00009264632,0.00005477807,0.000035885954],"category_scores_gemma":[0.0000185336,0.00023055366,0.000057221798,0.0005268657,0.00041519926,0.00012525126,0.0000386088,0.00022089183,7.180189e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5919159,0.024800884,0.2483713,0.00094701763,0.00042493263,0.0023150458,0.013140104,0.000017488415,0.006142197,0.0000012459442,0.000060324575,0.11186352],"study_design_scores_gemma":[0.17087422,0.28614214,0.5187127,0.0016734521,0.000424471,0.00012519232,0.0046813786,0.0006673074,0.016136033,0.00001013462,0.00012681984,0.00042617452],"about_ca_topic_score_codex":0.00051466044,"about_ca_topic_score_gemma":0.0008737096,"teacher_disagreement_score":0.4210417,"about_ca_system_score_codex":0.00006568965,"about_ca_system_score_gemma":0.00028638667,"threshold_uncertainty_score":0.9401705},"labels":[],"label_agreement":null},{"id":"W4387826320","doi":"10.1016/j.annonc.2023.09.739","title":"1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Chemotherapy; Internal medicine; Oncology; Phases of clinical research; Immunotherapy; Cancer","score_opus":0.11002207350618665,"score_gpt":0.4371958706070614,"score_spread":0.32717379710087474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387826320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9614082,0.00056399574,0.000006045659,0.030690324,0.0005085637,0.0009838486,0.000015314175,0.000059309565,0.005764428],"genre_scores_gemma":[0.98415387,0.0035324222,0.000027185006,0.010495318,0.00037940094,0.00010826011,0.000043026717,0.000025833739,0.001234676],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99824625,0.00017906915,0.0006220628,0.00026044546,0.00027052712,0.00042163985],"domain_scores_gemma":[0.99898356,0.00023810973,0.00022307012,0.00041049274,0.00008642134,0.00005831828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015705061,0.00016916574,0.0006259229,0.00023054588,0.000057901223,0.000009418057,0.00025202526,0.00020247315,0.00044133322],"category_scores_gemma":[0.00007191028,0.00011718178,0.00026209783,0.00068413303,0.00021783303,0.000058451864,0.000028817598,0.00023352946,0.00004898046],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50906855,0.0019139323,0.000080499856,0.000052458592,0.000253842,0.00020135495,0.0034085198,0.0000021163655,0.0150311,0.00011842603,0.061543576,0.4083256],"study_design_scores_gemma":[0.39355746,0.026552537,0.004708897,0.000100474026,0.000052048956,0.00008018162,0.0012059397,0.0001864305,0.008244423,0.00044633725,0.56465614,0.00020915108],"about_ca_topic_score_codex":0.00032316847,"about_ca_topic_score_gemma":0.00009421877,"teacher_disagreement_score":0.50311255,"about_ca_system_score_codex":0.000058696824,"about_ca_system_score_gemma":0.00034758647,"threshold_uncertainty_score":0.48322892},"labels":[],"label_agreement":null},{"id":"W4387826437","doi":"10.1016/j.annonc.2023.09.766","title":"1288P Neoadjuvant therapy with anti-PD-1/PD-L1 plus platinum-base chemotherapy for resectable stage II-III non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials","year":2023,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Pfizer; Eli Lilly and Company","keywords":"Medicine; Lung cancer; Internal medicine; Chemotherapy; Randomized controlled trial; Oncology; Meta-analysis; Stage (stratigraphy); Neoadjuvant therapy; Cancer; Surgery; Breast cancer","score_opus":0.3831206968258392,"score_gpt":0.5308186288225758,"score_spread":0.1476979319967366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387826437","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016573572,0.9688953,0.00019690774,0.001465855,0.0001405416,0.027829211,0.0011225641,0.000035484944,0.00014841261],"genre_scores_gemma":[0.000033426917,0.9864335,0.00044707587,0.002816374,0.00011115549,0.0061920434,0.00027479822,0.00013843848,0.0035532066],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98379016,0.0054953774,0.008587174,0.0010040691,0.0005232738,0.00059994246],"domain_scores_gemma":[0.9705171,0.01665194,0.010474634,0.0012691679,0.00086442253,0.00022271945],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.04081346,0.0009526495,0.061421722,0.0008677833,0.000107749394,0.00002136557,0.0004849781,0.0008334927,0.0006700795],"category_scores_gemma":[0.0018291197,0.0005073207,0.012953551,0.0017485835,0.00050283375,0.000056401164,0.00006440443,0.0005202481,9.797858e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054448508,0.0004130723,0.0000015554859,0.5097162,0.4199813,0.00002133706,0.0002113874,0.000003981643,0.000008790232,0.000006120911,0.0029408392,0.012246914],"study_design_scores_gemma":[0.110605404,0.0036433672,9.0351284e-7,0.054225083,0.77485025,0.000013735566,0.00006346589,0.00012964121,0.000056225334,0.0000038643802,0.055946346,0.00046171955],"about_ca_topic_score_codex":0.0008297948,"about_ca_topic_score_gemma":0.00021358929,"teacher_disagreement_score":0.4554911,"about_ca_system_score_codex":0.00013058567,"about_ca_system_score_gemma":0.0028437476,"threshold_uncertainty_score":0.99973786},"labels":[],"label_agreement":null},{"id":"W4387843842","doi":"10.1186/s13046-023-02851-6","title":"Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2023,"lang":"en","type":"article","venue":"Journal of Experimental & Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Autoantibody; Immune system; Immune checkpoint; Toxicity; Internal medicine; Etiology; Prospective cohort study; Adverse effect; Immunology; Immunotherapy; Antibody","score_opus":0.10091094301967657,"score_gpt":0.4607383611919131,"score_spread":0.3598274181722365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387843842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571,0.0022788695,2.205039e-7,0.00057665654,0.00041784768,0.00059190916,0.0000130941025,0.000017661172,0.00039371336],"genre_scores_gemma":[0.99752265,0.0015964444,0.000021170477,0.00006567415,0.0002574574,0.000033850796,0.000010421998,0.000037815604,0.0004545395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952857,0.000388769,0.00199252,0.0002820029,0.0015620214,0.0004889955],"domain_scores_gemma":[0.99799937,0.00034413266,0.00055544253,0.00031411042,0.000544606,0.00024234632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033247585,0.0001938912,0.000848847,0.0005610964,0.00007125936,0.00002011323,0.00027947436,0.00018734443,0.0005178108],"category_scores_gemma":[0.00034054127,0.00013310244,0.0004054962,0.0013951353,0.00063256884,0.00017234687,0.00012944276,0.0009982977,0.000012943207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0378076,0.0024500669,0.6498674,0.000058393813,0.00048548187,0.0001453859,0.00078942644,0.000005702465,0.30313212,0.0000020614407,0.00080700335,0.0044493717],"study_design_scores_gemma":[0.010699899,0.009891029,0.6446783,0.0008627786,0.000023165667,0.0000121794765,0.0008663265,0.0000099707795,0.3322173,0.000004289078,0.0006385494,0.00009619346],"about_ca_topic_score_codex":0.0013359691,"about_ca_topic_score_gemma":0.000019742907,"teacher_disagreement_score":0.029085182,"about_ca_system_score_codex":0.0006539485,"about_ca_system_score_gemma":0.0007510994,"threshold_uncertainty_score":0.56696653},"labels":[],"label_agreement":null},{"id":"W4387936522","doi":"10.1016/j.ebiom.2023.104841","title":"The prognostic impact of SIGLEC5-induced impairment of CD8+ T cell activation in sepsis","year":2023,"lang":"en","type":"article","venue":"EBioMedicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Horizon 2020; Instituto de Salud Carlos III; European Regional Development Fund; Federación Española de Enfermedades Raras; Horizon 2020 Framework Programme; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; European Commission; Catherine Donnelly Foundation","keywords":"Sepsis; Medicine; Biomarker; CD8; Internal medicine; Prospective cohort study; In vivo; Ex vivo; Gastroenterology; Immune system; T cell; Log-rank test; Systemic inflammatory response syndrome; Immunology; Survival analysis; Biology","score_opus":0.020910060694164317,"score_gpt":0.3188954003827217,"score_spread":0.29798533968855734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387936522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968662,0.00021886338,0.000008906908,0.0017590901,0.00012687407,0.0005935649,0.000005451741,0.000027079934,0.00039391455],"genre_scores_gemma":[0.99933827,0.00018175111,0.000016012395,0.00005906726,0.00006856456,0.000024520059,0.000037686532,0.000014098813,0.00026003388],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99887246,0.000039578346,0.00041812085,0.0001323911,0.000316806,0.00022067068],"domain_scores_gemma":[0.9991752,0.0002644088,0.00017796675,0.0002527613,0.000077590295,0.000052065392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053400814,0.00011283074,0.00028154964,0.00030155605,0.000030183604,0.0000026978416,0.000084065614,0.00006082162,0.00008017089],"category_scores_gemma":[0.00011056818,0.000064027925,0.00012785413,0.0013297687,0.00011559623,0.000030390795,0.00002142748,0.00010122151,0.0000055481405],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014775416,0.00020424736,0.056780577,0.00014842363,0.000122007106,0.000006069311,0.0008627853,0.0000036135054,0.9249328,0.0000020663435,0.0027768528,0.01268306],"study_design_scores_gemma":[0.0041314415,0.0029996443,0.8595993,0.00044623698,0.000045695542,0.0000035951784,0.0006526439,0.00018598094,0.13155772,0.00003489524,0.00027530926,0.00006753523],"about_ca_topic_score_codex":0.000690842,"about_ca_topic_score_gemma":0.000016370319,"teacher_disagreement_score":0.8028187,"about_ca_system_score_codex":0.00015367319,"about_ca_system_score_gemma":0.00018845715,"threshold_uncertainty_score":0.2610983},"labels":[],"label_agreement":null},{"id":"W4388001316","doi":"10.1186/s13223-023-00849-5","title":"Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab","year":2023,"lang":"en","type":"article","venue":"Allergy Asthma and Clinical Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Osimertinib; Medicine; Pembrolizumab; Lung cancer; Toxic epidermal necrolysis; Adverse effect; Context (archaeology); Oncology; Internal medicine; Dermatology; Epidermal growth factor receptor; Cancer; Immunotherapy; Erlotinib","score_opus":0.016581954051785468,"score_gpt":0.28421130504186626,"score_spread":0.2676293509900808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388001316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918469,0.0058755325,0.0000031354778,0.0012844054,0.0001535682,0.0005566108,0.000006408327,0.00010120033,0.00017223148],"genre_scores_gemma":[0.9807155,0.017609177,0.00006098887,0.00053118315,0.00004219164,0.0002757801,0.000020838957,0.000048590704,0.0006957099],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99781185,0.00016895865,0.0006734651,0.00061422656,0.00017852378,0.0005529525],"domain_scores_gemma":[0.9990737,0.00016596307,0.00016319043,0.00043631782,0.000051132953,0.00010971042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014465109,0.00033407417,0.00071715825,0.00017244343,0.00008896651,0.000017367589,0.00008053887,0.00023756406,0.00022934098],"category_scores_gemma":[0.000010543574,0.00021409435,0.00014819628,0.0004256739,0.00038993126,0.0000782201,0.00004303194,0.00030484478,0.000035762612],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3801656,0.0040339604,0.18773195,0.0000703987,0.007896087,0.013396105,0.0032692535,0.000055086104,0.006955288,0.000024863844,0.00009827704,0.3963031],"study_design_scores_gemma":[0.024824327,0.02120809,0.9304815,0.00030230067,0.000029292238,0.0015395196,0.00030533122,0.000065503664,0.0006528237,0.00000656177,0.020278014,0.00030671826],"about_ca_topic_score_codex":0.00036008764,"about_ca_topic_score_gemma":0.00051696284,"teacher_disagreement_score":0.7427496,"about_ca_system_score_codex":0.000085239735,"about_ca_system_score_gemma":0.00013207094,"threshold_uncertainty_score":0.87305146},"labels":[],"label_agreement":null},{"id":"W4388013818","doi":"10.1158/2326-6066.cir-23-0321","title":"Determinants for Antitumor and Protumor Effects of Programmed Cell Death","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Canadian Institutes of Health Research; Hospital for Sick Children; Cancer Research Society","keywords":"Immunosurveillance; Tumor microenvironment; Programmed cell death; Biology; Immune system; Epigenetics; Immunology; Cancer; Context (archaeology); Immunotherapy; Chemokine; Immunogenic cell death; Cancer research; Apoptosis; Genetics; Gene","score_opus":0.07155914524658015,"score_gpt":0.4224807868041451,"score_spread":0.35092164155756495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388013818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98645514,0.009628594,0.0000068024588,0.0004828003,0.0002071492,0.0030287125,0.000016002872,0.000057738533,0.000117060066],"genre_scores_gemma":[0.98966974,0.00433884,0.00017904236,0.00004596841,0.00007766316,0.0027227192,0.000012245928,0.000034768993,0.0029189927],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985032,0.000100139165,0.00023646303,0.00032012578,0.00021817765,0.0006218904],"domain_scores_gemma":[0.9989106,0.000385836,0.00006478683,0.00029725183,0.00027476822,0.000066766435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074542715,0.00012310833,0.00035810255,0.0003446073,0.00014690889,0.0000136082745,0.00014693964,0.00012502287,0.000023852317],"category_scores_gemma":[0.00019298278,0.0001002468,0.00008237008,0.0006010447,0.0005522592,0.000042410997,0.00009770551,0.0002445976,0.000009140587],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005645142,0.00017339498,0.08070798,0.0030106113,0.00019675183,0.000087826855,0.00038425642,7.5043374e-8,0.78838646,0.00003689628,0.0014010885,0.119969524],"study_design_scores_gemma":[0.007046272,0.0029813352,0.29062822,0.0005091929,0.0000486158,0.000041156152,0.00022256609,0.000098496836,0.68779767,0.00013477687,0.010354862,0.0001368151],"about_ca_topic_score_codex":0.0002188558,"about_ca_topic_score_gemma":0.000017727465,"teacher_disagreement_score":0.20992024,"about_ca_system_score_codex":0.000086837004,"about_ca_system_score_gemma":0.00039093778,"threshold_uncertainty_score":0.40879455},"labels":[],"label_agreement":null},{"id":"W4388017657","doi":"10.3390/cancers15215210","title":"Targeting Liver Metastases to Potentiate Immunotherapy in MS-Stable Colorectal Cancer—A Review of the Literature","year":2023,"lang":"en","type":"review","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Israel Cancer Research Fund","keywords":"Medicine; Immunotherapy; Colorectal cancer; Clinical trial; Melanoma; Cancer; Cancer immunotherapy; Oncology; Limiting; Tumor microenvironment; Microsatellite instability; Immune system; Disease; Internal medicine; Cancer research; Immunology","score_opus":0.03454948886595714,"score_gpt":0.33943436181119463,"score_spread":0.3048848729452375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388017657","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000633843,0.9946507,0.0000015402045,0.0001894252,0.0010568171,0.0030487357,0.00080198335,0.00004204687,0.00014537435],"genre_scores_gemma":[0.0000057783245,0.9958322,0.0000591194,0.0015560915,0.00020963489,0.0008015908,0.00018405994,0.00011526774,0.0012362713],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99725467,0.00027547684,0.0010497159,0.0005191039,0.00042475056,0.00047627738],"domain_scores_gemma":[0.99849105,0.0001169375,0.000610262,0.0005282108,0.00016078119,0.00009273133],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000748757,0.0005022751,0.0022997803,0.0002797145,0.00007540342,0.000027635291,0.00045939494,0.00022989196,0.00051414827],"category_scores_gemma":[0.00012710007,0.00031400527,0.0010377131,0.003027439,0.00010830493,0.00006650416,0.00010013668,0.00057675724,0.000016074597],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036984554,0.000023203787,0.000017277052,0.24444653,0.0013420824,0.00006165619,0.00032890265,0.000017425744,0.00019778845,0.000005265522,0.035036385,0.71815366],"study_design_scores_gemma":[0.0003795489,0.000062451676,0.000026443151,0.3487312,0.00052114547,0.000017087248,0.000018246787,0.0000018205137,0.000053774034,9.60323e-7,0.64997613,0.00021119582],"about_ca_topic_score_codex":0.0023848666,"about_ca_topic_score_gemma":0.00021946205,"teacher_disagreement_score":0.7179424,"about_ca_system_score_codex":0.0025322875,"about_ca_system_score_gemma":0.0029390852,"threshold_uncertainty_score":0.9999312},"labels":[],"label_agreement":null},{"id":"W4388019704","doi":"10.1136/jitc-2023-007047","title":"Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Concordance; Internal medicine; Lung cancer; Adjuvant; Immunohistochemistry; Oncology; PD-L1; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.05075007968482245,"score_gpt":0.45012553697261176,"score_spread":0.39937545728778934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388019704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9236028,0.068698026,0.0003562055,0.00089974614,0.0018572276,0.0037601215,0.0007550351,0.000013727767,0.000057064222],"genre_scores_gemma":[0.9368282,0.060986206,0.00045438646,0.00013804548,0.0006656367,0.00032988377,0.00009586848,0.00006994825,0.00043182957],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99511206,0.0001975359,0.003484271,0.00036721752,0.00042921756,0.00040967096],"domain_scores_gemma":[0.99269086,0.0036231817,0.0027054593,0.00049361,0.00039673393,0.0000901444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003892299,0.00033960192,0.0024933543,0.00017476869,0.00014193488,0.000024221923,0.00039051467,0.0002975878,0.00009727552],"category_scores_gemma":[0.00037096566,0.00023178302,0.0013392417,0.00033847714,0.0004998316,0.00007052506,0.000035939964,0.00053328363,1.4037998e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74944437,0.0007592718,0.0009981244,0.00018900674,0.0015676584,0.0000017571481,0.0023365763,0.000035485304,0.19997251,0.0000018046177,0.004374261,0.040319156],"study_design_scores_gemma":[0.90734214,0.0020872308,0.004311617,0.0013820312,0.0007185215,0.0000041741373,0.000566922,0.0020513071,0.07642165,0.000055085613,0.004815993,0.0002433382],"about_ca_topic_score_codex":0.002139684,"about_ca_topic_score_gemma":0.000087470326,"teacher_disagreement_score":0.15789776,"about_ca_system_score_codex":0.00022014703,"about_ca_system_score_gemma":0.00089471915,"threshold_uncertainty_score":0.94518375},"labels":[],"label_agreement":null},{"id":"W4388040550","doi":"10.3390/curroncol30110699","title":"The Predictive Value of CD3+/CD8+ Lymphocyte Infiltration and PD-L1 Expression in Colorectal Cancer","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Colorectal cancer; Medicine; CD8; Tumor-infiltrating lymphocytes; Immunohistochemistry; Stage (stratigraphy); CD3; Oncology; Chemotherapy; Internal medicine; Adenocarcinoma; Infiltration (HVAC); Univariate analysis; Immune system; Cancer research; Cancer; Immunology; Multivariate analysis; Biology","score_opus":0.05453906014425876,"score_gpt":0.39283492937101916,"score_spread":0.3382958692267604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388040550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908565,0.006519592,0.000017243501,0.0006692703,0.0010565965,0.00039898124,0.000017362481,0.000025766196,0.00043865765],"genre_scores_gemma":[0.9862337,0.013344011,0.000013436339,0.000041725078,0.00012756155,0.00015404624,0.00002247392,0.000007721427,0.000055291253],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99922407,0.00009887253,0.00024211894,0.00015058229,0.00012336118,0.00016100389],"domain_scores_gemma":[0.9995054,0.00022084432,0.00010652693,0.000080999234,0.00005027689,0.00003594724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031194746,0.00007914816,0.0001881498,0.00008835548,0.000062280684,0.0000046075043,0.000051539264,0.0000871098,0.000023811454],"category_scores_gemma":[0.000067526445,0.000053022737,0.000040229603,0.00026908796,0.00019834569,0.00003955725,0.000037119673,0.00011731525,0.00000230418],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015340963,0.00027874674,0.15468408,0.00016876278,0.00010371025,0.000012329222,0.004209848,0.000050628194,0.32968494,0.00011734027,0.0068342467,0.48851442],"study_design_scores_gemma":[0.0063833087,0.0012148559,0.86241114,0.00037620385,0.000048480102,0.00001865623,0.00089245173,0.0031879873,0.055881843,0.00014907712,0.06933741,0.00009859943],"about_ca_topic_score_codex":0.00008884012,"about_ca_topic_score_gemma":0.00017306936,"teacher_disagreement_score":0.7077271,"about_ca_system_score_codex":0.00029589352,"about_ca_system_score_gemma":0.00034487582,"threshold_uncertainty_score":0.21622044},"labels":[],"label_agreement":null},{"id":"W4388041288","doi":"10.1158/2326-6066.cir-23-0522","title":"Lessons for the Next Generation of Scientists from the Second Annual Arthur and Sandra Irving Cancer Immunology Symposium","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"National Cancer Institute","keywords":"Publishing; Scientific publishing; Engineering ethics; Political science; Engineering","score_opus":0.1869273419889362,"score_gpt":0.4251396820144746,"score_spread":0.2382123400255384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388041288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8649015,0.08823294,0.000026299509,0.043824933,0.0013523444,0.00094944565,0.0005845321,0.000032623644,0.00009542038],"genre_scores_gemma":[0.955883,0.036494534,0.000021572712,0.0005063008,0.00059694756,0.001063637,0.000083986044,0.000035885605,0.0053141154],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99804425,0.00026721018,0.0003344797,0.0004377584,0.00029655593,0.00061973685],"domain_scores_gemma":[0.99743223,0.0013065153,0.00011330349,0.0005998709,0.0005084471,0.00003960186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014398572,0.0001598451,0.0003223547,0.00020390532,0.0008460949,0.000066155764,0.00041238833,0.0002023994,0.0006691285],"category_scores_gemma":[0.00014901656,0.00009924347,0.000107910455,0.00081135595,0.0019636808,0.00013008033,0.00025112476,0.000524004,0.00001018696],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018404516,0.000031117244,0.0031590643,0.00005489986,0.001037664,0.000004349124,0.0033261448,0.000007610968,0.9089961,0.00036592974,0.028100438,0.05307625],"study_design_scores_gemma":[0.0081090825,0.0010195879,0.44798937,0.00042278308,0.00022844135,0.00005807338,0.010291523,0.0020296546,0.18027735,0.00050978444,0.348685,0.00037934075],"about_ca_topic_score_codex":0.0027694593,"about_ca_topic_score_gemma":0.004030677,"teacher_disagreement_score":0.72871876,"about_ca_system_score_codex":0.00018556905,"about_ca_system_score_gemma":0.00070524076,"threshold_uncertainty_score":0.73264873},"labels":[],"label_agreement":null},{"id":"W4388042564","doi":"10.1136/jitc-2023-sitc2023.0695","title":"695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy (HUDSON)","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Durvalumab; Medicine; Internal medicine; Clinical endpoint; Oncology; Tremelimumab; Lung cancer; Trastuzumab; non-small cell lung cancer (NSCLC); Adverse effect; Cancer; Immunotherapy; Clinical trial; Nivolumab; Ipilimumab; Breast cancer","score_opus":0.010455952032273884,"score_gpt":0.2406354814381965,"score_spread":0.2301795294059226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388042564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959452,0.0012452885,0.0000044894646,0.00053244014,0.00012423232,0.0017902323,0.000052767547,0.00007650938,0.00022882981],"genre_scores_gemma":[0.99780107,0.0011603448,0.00025886545,0.00027665612,0.00007528964,0.00007573388,0.000076642515,0.00008804608,0.00018732877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766976,0.00007751281,0.00054566213,0.00063025893,0.0005376075,0.0005392319],"domain_scores_gemma":[0.99868715,0.00006792337,0.0003086149,0.00041504475,0.00012972385,0.0003915743],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003597268,0.00044692418,0.00072018435,0.00025130232,0.00013465647,0.000055561643,0.00012805012,0.00018552695,0.000014858864],"category_scores_gemma":[0.000026882446,0.00032085576,0.00007515775,0.0005971455,0.00046950535,0.00013471162,0.000026351754,0.00031170325,0.0000013889588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018047603,0.0008760779,0.93970394,0.0009931795,0.00067180366,0.00009704966,0.0030196423,0.00017426923,0.015348398,0.00000893973,0.00060975185,0.020449348],"study_design_scores_gemma":[0.02229468,0.002102692,0.94707394,0.0022457484,0.00012907873,0.000013768648,0.0001628904,0.00011927232,0.024856202,0.0000065251998,0.0006016375,0.00039358696],"about_ca_topic_score_codex":0.00072103966,"about_ca_topic_score_gemma":0.00022256294,"teacher_disagreement_score":0.020055762,"about_ca_system_score_codex":0.00013337382,"about_ca_system_score_gemma":0.00056866306,"threshold_uncertainty_score":0.99992436},"labels":[],"label_agreement":null},{"id":"W4388044214","doi":"10.1016/j.jtho.2023.09.563","title":"P2.07-05 Immune Checkpoint Blockers in Lung Cancer after Solid Organ Transplantation: INNOVATED Registry","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Organ transplantation; Lung cancer; Transplantation; Oncology; Solid organ; Lung transplantation; Cancer; PD-L1; Immune system; Clinical trial; Internal medicine; Intensive care medicine; Immunology; Immunotherapy","score_opus":0.018188234456912557,"score_gpt":0.40165788514028,"score_spread":0.38346965068336747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388044214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97125643,0.0026837527,0.000033095253,0.024237331,0.0012778194,0.0002022243,0.000012394011,0.000028686261,0.00026823932],"genre_scores_gemma":[0.9928818,0.0040049353,0.00047205927,0.000992559,0.00043301846,0.000023362645,0.000015831582,0.000029748478,0.0011466856],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99807405,0.00011752761,0.0010288989,0.00016294084,0.0002700824,0.00034648867],"domain_scores_gemma":[0.99887365,0.000071606984,0.0005480164,0.00018052214,0.00023386446,0.00009234197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011386644,0.00016184966,0.0005855603,0.0004941344,0.00004409888,0.000013740026,0.00014838556,0.0002426077,0.0008055993],"category_scores_gemma":[0.000049403992,0.00013198149,0.00018972527,0.0010885112,0.00011703199,0.00011253546,0.00002143733,0.0005870064,0.000015915612],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10974649,0.00077386596,0.06359845,0.001626664,0.0018707478,0.022179184,0.009030134,0.00011803516,0.616485,0.000005517369,0.025496919,0.14906897],"study_design_scores_gemma":[0.013371443,0.0029724746,0.76186806,0.0033198555,0.0010386223,0.009633644,0.0025800327,0.00045306273,0.13908297,0.00009361233,0.0650042,0.0005820075],"about_ca_topic_score_codex":0.00012875911,"about_ca_topic_score_gemma":0.00016561957,"teacher_disagreement_score":0.6982696,"about_ca_system_score_codex":0.00066534284,"about_ca_system_score_gemma":0.0009073055,"threshold_uncertainty_score":0.8820748},"labels":[],"label_agreement":null},{"id":"W4388045239","doi":"10.1016/j.jtho.2023.09.110","title":"OA22.05 TTFields and Immune-Checkpoint Inhibitor in Metastatic Non-Small Cell Lung Cancer: PD-L1 Subgroups in the Phase 3 LUNAR Study","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Docetaxel; Oncology; Internal medicine; Nivolumab; Lung cancer; Cancer; Immune checkpoint; Immune system; Immunotherapy; Immunology","score_opus":0.031110110736264452,"score_gpt":0.4162212888867883,"score_spread":0.3851111781505238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388045239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855414,0.0050749127,0.000021850938,0.0075208633,0.00076531543,0.0008115945,0.000005668775,0.0000089562955,0.0002494538],"genre_scores_gemma":[0.9968072,0.001669987,0.000247932,0.000760426,0.00021992094,0.000052162453,0.0000026790858,0.000020663534,0.00021900686],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976299,0.00048814763,0.0010615911,0.00019745702,0.00028615515,0.00033679462],"domain_scores_gemma":[0.9986939,0.00040313043,0.0005064226,0.00022117412,0.00009035018,0.00008501683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032720896,0.00018950361,0.0007335671,0.00054523133,0.000059220067,0.000026037476,0.0002240874,0.00012509835,0.00007962375],"category_scores_gemma":[0.00008223439,0.00012458205,0.00016964026,0.0007745849,0.00008733421,0.00010465928,0.000059866885,0.00080989767,0.0000031249338],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07271644,0.013321803,0.17811163,0.0014123762,0.0014387398,0.021508306,0.078899585,0.00013369675,0.19997478,0.0000054544735,0.012585706,0.4198915],"study_design_scores_gemma":[0.077977635,0.043435503,0.649929,0.0020274343,0.0025020458,0.00397008,0.1708037,0.003491262,0.025380963,0.0002928105,0.019245163,0.00094442215],"about_ca_topic_score_codex":0.0006809953,"about_ca_topic_score_gemma":0.0014921238,"teacher_disagreement_score":0.47181734,"about_ca_system_score_codex":0.00036328277,"about_ca_system_score_gemma":0.0005852472,"threshold_uncertainty_score":0.50803083},"labels":[],"label_agreement":null},{"id":"W4388045246","doi":"10.1016/j.jtho.2023.09.1110","title":"EP08.04-01 Predictors and Outcomes of Pneumonitis in Non-Small Cell Lung Cancer Patients treated with Consolidative Durvalumab","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Durvalumab; Pneumonitis; Lung cancer; Radiation therapy; Intensive care medicine; Cancer; Oncology; Internal medicine; Lung; Immunotherapy; Pembrolizumab","score_opus":0.01501962528952766,"score_gpt":0.3577376444077282,"score_spread":0.34271801911820055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388045246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997685,0.00043432004,0.00000416783,0.00076519535,0.00024143199,0.00034761245,0.00003703506,0.000008967095,0.00047628474],"genre_scores_gemma":[0.99784845,0.0013723446,0.0001351089,0.0001452635,0.000042252013,0.000013562225,0.000007735162,0.000018815275,0.00041644863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870855,0.00013360975,0.00059387495,0.00013548763,0.00021363226,0.00021483484],"domain_scores_gemma":[0.99872845,0.0002167578,0.00063338573,0.00009635194,0.00022739898,0.000097623466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038062688,0.00014632022,0.0007056606,0.0003939615,0.000029035005,0.000005849178,0.00008159172,0.00012992077,0.00007002244],"category_scores_gemma":[0.000036428544,0.00009862205,0.000091430076,0.00040771195,0.00016026633,0.00007665524,0.000022252108,0.0002561963,9.000767e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067821634,0.00034934093,0.9710846,0.00016095718,0.00043828125,0.00029232557,0.0018506334,0.000009651113,0.0033467729,2.437574e-7,0.00047476348,0.015210246],"study_design_scores_gemma":[0.0059776516,0.0038776172,0.98248273,0.00042306646,0.00035240877,0.00008901198,0.0006717708,0.000071743816,0.005481734,0.0000033705937,0.0004741151,0.000094789924],"about_ca_topic_score_codex":0.00024100133,"about_ca_topic_score_gemma":0.00028568262,"teacher_disagreement_score":0.015115457,"about_ca_system_score_codex":0.00030984718,"about_ca_system_score_gemma":0.00036835286,"threshold_uncertainty_score":0.40216905},"labels":[],"label_agreement":null},{"id":"W4388045325","doi":"10.1016/j.jtho.2023.09.530","title":"P2.05-03 Association Between Immune-Related Adverse Events and Survival in a Contemporary Metastatic Non-Small Cell Lung Cancer Cohort","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Cohort; Lung cancer; Oncology; Immune system; Cancer; Internal medicine; Immunology","score_opus":0.03197573877820174,"score_gpt":0.3882890751755947,"score_spread":0.35631333639739293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388045325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922353,0.00241872,0.000017820352,0.0027095072,0.0011153957,0.0004575686,0.000020473834,0.000015513742,0.0010096804],"genre_scores_gemma":[0.9960479,0.0015083232,0.00017114998,0.0001766327,0.00013959322,0.000015485773,0.000021912767,0.000023537494,0.001895428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978163,0.00039412425,0.0010385865,0.00016305975,0.0003143329,0.00027356224],"domain_scores_gemma":[0.9980923,0.00042031577,0.0010913945,0.00011180516,0.00017006647,0.00011409784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003397137,0.00015513583,0.00083892606,0.00040831196,0.00004850424,0.000005563801,0.000104671664,0.00020960986,0.00006708933],"category_scores_gemma":[0.00011919941,0.00013068301,0.00020412693,0.0005303935,0.000039990446,0.00012855495,0.00003997224,0.00052813836,0.000008587861],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026695433,0.0001527945,0.9783288,0.0001806274,0.0014027333,0.0004682912,0.0008686497,0.000020802976,0.0059270496,4.9807295e-7,0.0018303915,0.008149774],"study_design_scores_gemma":[0.005264881,0.00082819065,0.98816544,0.00039083036,0.00079549866,0.000067603454,0.0006902228,0.00023166696,0.0007823515,0.00003844206,0.0026136802,0.00013122367],"about_ca_topic_score_codex":0.00037629667,"about_ca_topic_score_gemma":0.000100586825,"teacher_disagreement_score":0.009836565,"about_ca_system_score_codex":0.0010447252,"about_ca_system_score_gemma":0.0009035477,"threshold_uncertainty_score":0.5329098},"labels":[],"label_agreement":null},{"id":"W4388047700","doi":"10.1136/jitc-2023-sitc2023.0609","title":"609 Phase 1/2a dose selection of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced solid malignancies","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Antibody; Pharmacokinetics; In vitro; Monoclonal antibody; Pharmacology; Receptor; Cancer research; Cell cycle; Medicine; Chemistry; Internal medicine; Immunology; Cancer; Biochemistry","score_opus":0.010168535610960905,"score_gpt":0.27046151261438733,"score_spread":0.2602929770034264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388047700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981677,0.00028556437,0.0000033905935,0.00050663616,0.00017423366,0.000627418,0.000028174618,0.00007280106,0.00013409997],"genre_scores_gemma":[0.99891853,0.0003692206,0.00018658928,0.0001473065,0.000037734782,0.000023918814,0.0001208833,0.00003678243,0.00015902803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822766,0.000037898124,0.0005402478,0.00038634965,0.0003840174,0.00042380719],"domain_scores_gemma":[0.9991868,0.0000440414,0.00021309289,0.00023100254,0.00011183632,0.00021323378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033721104,0.00025318467,0.0005097082,0.00038181563,0.00007217557,0.00002437755,0.00007563802,0.00014875997,0.000013401855],"category_scores_gemma":[0.00015145405,0.00021407293,0.00007443111,0.00092612486,0.00027129118,0.00023212528,0.000023999442,0.00019401369,0.0000048331044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034488996,0.0007530731,0.77933705,0.0006532394,0.00015189865,0.00013679168,0.0008728281,0.0003482468,0.2102766,0.000027817774,0.00062760344,0.0033659432],"study_design_scores_gemma":[0.012731005,0.0009513926,0.93152326,0.001061657,0.000047675625,0.00002120028,0.0001498223,0.00027123853,0.051353827,0.00003883393,0.0016013418,0.0002487519],"about_ca_topic_score_codex":0.00029537722,"about_ca_topic_score_gemma":0.00028301938,"teacher_disagreement_score":0.15892278,"about_ca_system_score_codex":0.000107502245,"about_ca_system_score_gemma":0.00027024306,"threshold_uncertainty_score":0.87296414},"labels":[],"label_agreement":null},{"id":"W4388047770","doi":"10.1136/jitc-2023-sitc2023.0607","title":"607 TTFields therapy with an immune checkpoint inhibitor in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based therapy: histology subgroups in the pivotal LUNAR study","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Novocure","keywords":"Medicine; Docetaxel; Internal medicine; Oncology; Lung cancer; Cancer","score_opus":0.019905545277624854,"score_gpt":0.27974167768409136,"score_spread":0.2598361324064665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388047770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929608,0.0024574902,0.000004008845,0.0018007596,0.00014131104,0.0024872338,0.000010228622,0.000069194146,0.000068979156],"genre_scores_gemma":[0.9974833,0.0002793928,0.00024128171,0.0009373961,0.00008711503,0.00078651536,0.000041866133,0.00007183861,0.00007129267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750525,0.00025923483,0.0005726803,0.000610992,0.0005231903,0.00052867894],"domain_scores_gemma":[0.99885136,0.000100696976,0.00023131513,0.00054217,0.00006333719,0.00021109373],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010209536,0.00044548075,0.00057973573,0.0003224633,0.0001249934,0.00007286219,0.00018475183,0.00015769363,0.000023042929],"category_scores_gemma":[0.000018213186,0.00025234564,0.000087265806,0.000695047,0.000329475,0.00013989322,0.000018053504,0.0005667839,0.000002051171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033077992,0.0036374673,0.83881855,0.00047733827,0.00043733,0.0030142718,0.02530628,0.00043925352,0.087724745,0.0000055971163,0.00021662696,0.0068445625],"study_design_scores_gemma":[0.01694918,0.006299171,0.94096315,0.0008737342,0.000090774745,0.00007411444,0.0028718626,0.0005737855,0.030546889,0.000012691602,0.00030723665,0.00043742053],"about_ca_topic_score_codex":0.0016494609,"about_ca_topic_score_gemma":0.0024088204,"teacher_disagreement_score":0.10214461,"about_ca_system_score_codex":0.00014455664,"about_ca_system_score_gemma":0.00068065786,"threshold_uncertainty_score":0.9999929},"labels":[],"label_agreement":null},{"id":"W4388047842","doi":"10.1136/jitc-2023-sitc2023.0544","title":"544 Coordinated blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector memory responses","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research; EMD Serono","keywords":"Ovarian cancer; Cancer research; Immune system; Immunotherapy; Tumor microenvironment; Cytotoxic T cell; Cancer; Medicine; Immunology; Cytokine; Biology; Internal medicine","score_opus":0.03204473608297409,"score_gpt":0.30242633622972054,"score_spread":0.27038160014674645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388047842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99028504,0.0042798044,0.0000040281625,0.0038882087,0.0002454672,0.0008996901,0.00020302052,0.00012222213,0.000072507166],"genre_scores_gemma":[0.9979788,0.00079176447,0.00010317036,0.00013271946,0.00008401551,0.00007342497,0.00010081531,0.000055573804,0.00067970646],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99747896,0.00031338888,0.00076853146,0.0005828326,0.00037751417,0.00047874235],"domain_scores_gemma":[0.9985363,0.00037893435,0.00025289503,0.00028936105,0.00008216357,0.0004603388],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019863732,0.00031078744,0.00068779493,0.00018886961,0.000098556804,0.000049183065,0.00011278094,0.0003156693,0.0000152103985],"category_scores_gemma":[0.0008508081,0.0002798152,0.000100252444,0.0004943354,0.00056267483,0.00017113502,0.00006134126,0.00036701225,0.0000018586073],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023647274,0.00021209255,0.035156693,0.00092156493,0.00033511498,0.00009563248,0.0012551823,0.000022659116,0.9479404,0.0000110158135,0.004627244,0.007057646],"study_design_scores_gemma":[0.0099341655,0.0010561951,0.31556407,0.002595241,0.0003209619,0.00016472692,0.000382172,0.006811852,0.6600025,0.00042895827,0.0019410083,0.0007981412],"about_ca_topic_score_codex":0.0018490434,"about_ca_topic_score_gemma":0.00010971792,"teacher_disagreement_score":0.28793794,"about_ca_system_score_codex":0.00007643345,"about_ca_system_score_gemma":0.0003948285,"threshold_uncertainty_score":0.9999654},"labels":[],"label_agreement":null},{"id":"W4388072441","doi":"10.1136/jitc-2023-sitc2023.0866","title":"866 The effect of butyrophilin 1A1 blockade in combination with radiation treatment in colon and Lewis lung carcinoma","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Radioresistance; Cancer research; Lung cancer; Lewis lung carcinoma; Apoptosis; Medicine; CD44; Radiation therapy; Flow cytometry; Pathology; Cell; Biology; Cancer; Internal medicine; Immunology; Metastasis","score_opus":0.008263332487901847,"score_gpt":0.24190241718371935,"score_spread":0.2336390846958175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388072441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956271,0.0015850072,4.4545428e-7,0.0019173658,0.0000592325,0.0007363587,0.0000063339567,0.00001978969,0.00004836879],"genre_scores_gemma":[0.99932134,0.0003803563,0.000012319483,0.000043070813,0.000025482515,0.00005119009,0.00003389978,0.0000134685515,0.000118899945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991619,0.00008814318,0.0002359772,0.00018897341,0.00016401675,0.00016101604],"domain_scores_gemma":[0.99956095,0.00010617427,0.00008998511,0.00014008964,0.000016158334,0.00008663426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043488084,0.00013708792,0.0002585005,0.00016497492,0.00004536464,0.00001628914,0.000030721494,0.000084538915,0.0000017970009],"category_scores_gemma":[0.00006398922,0.00008633416,0.000031748776,0.00033503084,0.00018573196,0.000060484894,0.000009543215,0.0000909994,5.86158e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011557187,0.000057461457,0.9269652,0.00025492834,0.00007733093,0.00008771526,0.0015414985,0.000069917965,0.059407752,0.000022747026,0.00010853193,0.010251205],"study_design_scores_gemma":[0.005609411,0.0012332457,0.8881684,0.00018452153,0.000068997106,0.000048621114,0.00011427247,0.00076850154,0.10341834,0.00003138663,0.0002721644,0.00008211735],"about_ca_topic_score_codex":0.001372532,"about_ca_topic_score_gemma":0.00032300394,"teacher_disagreement_score":0.044010594,"about_ca_system_score_codex":0.00013785932,"about_ca_system_score_gemma":0.00011054584,"threshold_uncertainty_score":0.3520605},"labels":[],"label_agreement":null},{"id":"W4388076128","doi":"10.1136/jitc-2023-sitc2023.1250","title":"1250 Molecular predictors and mechanisms of immune checkpoint inhibitor-induced myocarditis: a case-control study with translational correlates","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Christie (Canada); McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"Jewish General Hospital","keywords":"Myocarditis; Immune system; Peripheral blood mononuclear cell; Medicine; Immune checkpoint; Immunology; Internal medicine; Biology; Immunotherapy; Genetics","score_opus":0.010502649626950758,"score_gpt":0.2293011904421242,"score_spread":0.21879854081517341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388076128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970646,0.0007777826,0.00012984664,0.0006057066,0.0001802912,0.0010103098,0.00006333088,0.0001092539,0.000058858594],"genre_scores_gemma":[0.9994484,0.000049164963,0.00019157784,0.00009650133,0.00005325818,0.000049375267,0.000025816033,0.000043930806,0.000041969623],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99827504,0.000074171025,0.000551328,0.00037907995,0.00044635887,0.00027399178],"domain_scores_gemma":[0.9990909,0.000061198,0.0001843908,0.00025597215,0.00009539298,0.00031215337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063300505,0.0002667991,0.0004928676,0.00018050877,0.00011887102,0.00003601734,0.000050247152,0.0001532422,0.00001046927],"category_scores_gemma":[0.0000669322,0.00021632701,0.0001229389,0.00031466343,0.0002467718,0.00012033823,0.000015037585,0.0002127135,0.0000017294932],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018203806,0.00025382556,0.046696056,0.00036437146,0.002239296,0.004238652,0.0032365688,0.00009173293,0.9388164,0.00022378546,0.00008325376,0.0019356495],"study_design_scores_gemma":[0.011159636,0.0026254929,0.7833858,0.00056215003,0.0009291029,0.0044683465,0.0028399143,0.0005129297,0.1923894,0.00068144104,0.00004031664,0.00040545777],"about_ca_topic_score_codex":0.00024240208,"about_ca_topic_score_gemma":0.00003182592,"teacher_disagreement_score":0.746427,"about_ca_system_score_codex":0.000028401773,"about_ca_system_score_gemma":0.00020969182,"threshold_uncertainty_score":0.88215595},"labels":[],"label_agreement":null},{"id":"W4388077811","doi":"10.1136/jitc-2023-sitc2023.0760","title":"760 Interim PK/PD, safety and efficacy data of monotherapy dose escalation of a phase 1/2 study with MDNA11 in patients with advanced solid tumors","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacodynamics; Adverse effect; Pharmacokinetics; Internal medicine; Dosing; Toxicity; Response Evaluation Criteria in Solid Tumors; Melanoma; Gastroenterology; Oncology; Pharmacology; Phases of clinical research; Urology; Cancer research","score_opus":0.025246474224272793,"score_gpt":0.30882989092477237,"score_spread":0.2835834167004996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388077811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99839646,0.00023492645,0.000010429146,0.0001649233,0.00004082813,0.0010211003,0.00006822914,0.00003884238,0.000024273215],"genre_scores_gemma":[0.9992679,0.00014616358,0.00028202686,0.000040669074,0.000012723782,0.0000097841685,0.00018678865,0.00003081741,0.000023161876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985165,0.000050750998,0.0005256804,0.00038282378,0.00032819365,0.00019607163],"domain_scores_gemma":[0.99895674,0.000046218647,0.00027953778,0.0004913211,0.00007935438,0.00014684493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039633046,0.00020176466,0.000493026,0.00018967639,0.000041349533,0.000014589108,0.00010731852,0.000059316204,0.0000037274444],"category_scores_gemma":[0.00007594092,0.00014684268,0.000024655097,0.00041099722,0.00032122215,0.00021828858,0.000047420297,0.00012270748,3.648991e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061943978,0.0030267122,0.83080596,0.00053783704,0.00072179135,0.000081373815,0.005801695,0.0001477047,0.04135465,0.000010254194,0.0001154898,0.055452537],"study_design_scores_gemma":[0.02890602,0.004384837,0.9582225,0.00078113086,0.00009228617,0.000010249841,0.00089345523,0.00025322466,0.006108471,0.000009259245,0.00016559596,0.00017296882],"about_ca_topic_score_codex":0.00016565358,"about_ca_topic_score_gemma":0.00007568384,"teacher_disagreement_score":0.12741652,"about_ca_system_score_codex":0.000031881158,"about_ca_system_score_gemma":0.00016254204,"threshold_uncertainty_score":0.59880704},"labels":[],"label_agreement":null},{"id":"W4388084134","doi":"10.1136/jitc-2023-sitc2023.0741","title":"741 TWT-101: a first-in-clinic study of CFI-402411, a hematopoietic progenitor Kinase-1 (HPK1) inhibitor, as single agent or combined with pembrolizumab in subjects with advanced solid malignancies","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta; University Health Network; Ottawa Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Adverse effect; Gastroenterology; Oncology; Toxicity; Cancer; Immunotherapy","score_opus":0.022824699747663726,"score_gpt":0.2716791618740001,"score_spread":0.24885446212633638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388084134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959788,0.0006132535,5.38552e-7,0.00062244915,0.00019179046,0.0022803121,0.000009278482,0.0001293077,0.0001742928],"genre_scores_gemma":[0.9983832,0.00015708045,0.00016117703,0.00015100956,0.000059909707,0.00021768795,0.000025053805,0.00008547368,0.0007594102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969741,0.00009552891,0.0008907755,0.0006816132,0.0007198765,0.0006381055],"domain_scores_gemma":[0.99845916,0.00012370621,0.00034917775,0.0005358507,0.0001358193,0.00039627092],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048397447,0.0004659804,0.0009473981,0.00043485104,0.000110005836,0.000056036908,0.00015278219,0.00017409168,0.000024189902],"category_scores_gemma":[0.0002201505,0.00033239354,0.00009558148,0.0012574731,0.0004273125,0.0001948259,0.00006052286,0.00029384554,0.000013130557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.104189485,0.0107798325,0.523491,0.006363291,0.0015861394,0.014315191,0.03509759,0.00040325377,0.29998076,0.00004212102,0.0018625151,0.0018888031],"study_design_scores_gemma":[0.05087716,0.030436378,0.67162013,0.0073645236,0.00040673252,0.0010608146,0.015870495,0.00008961055,0.21999495,0.00012579128,0.0010275402,0.0011258868],"about_ca_topic_score_codex":0.00056185044,"about_ca_topic_score_gemma":0.00411617,"teacher_disagreement_score":0.14812909,"about_ca_system_score_codex":0.00020215187,"about_ca_system_score_gemma":0.0008141621,"threshold_uncertainty_score":0.9999128},"labels":[],"label_agreement":null},{"id":"W4388124188","doi":"10.1200/jco.23.00914","title":"First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":236,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Hazard ratio; Clinical endpoint; Chemotherapy; Placebo; Internal medicine; Cervical cancer; Clinical trial; Surgery; Oncology; Confidence interval; Cancer; Immunotherapy; Pathology","score_opus":0.2622251498244805,"score_gpt":0.4862756760409937,"score_spread":0.22405052621651322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388124188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91811264,0.0015998246,0.0003179958,0.07006754,0.0075489213,0.0012645889,0.00024007677,0.000053489086,0.0007949474],"genre_scores_gemma":[0.91641,0.058288507,0.0066586738,0.0058430713,0.0060137613,0.00010002363,0.0001027602,0.0001818812,0.0064012916],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99437517,0.0003603611,0.0036484296,0.0004072091,0.0006833413,0.0005254742],"domain_scores_gemma":[0.98913324,0.0067121093,0.0027147965,0.0003597794,0.00070734514,0.0003727593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004631672,0.00032426786,0.0024446754,0.00026554486,0.00008758566,0.000014629138,0.0003853398,0.0004324699,0.00056562835],"category_scores_gemma":[0.0028819446,0.00022349178,0.0019490537,0.00048440555,0.0003646408,0.000110320136,0.00004271696,0.00079304876,0.0000083893165],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7909551,0.0017628095,0.0008561086,0.00027098536,0.003132611,0.000120876466,0.00032155088,0.00012682105,0.00027504924,0.00002294141,0.029815786,0.17233932],"study_design_scores_gemma":[0.37648365,0.08311993,0.03336552,0.00054471084,0.0012796427,0.00017564863,0.0003444088,0.0030793173,0.00039979903,0.00018372663,0.5006567,0.00036693196],"about_ca_topic_score_codex":0.00012449147,"about_ca_topic_score_gemma":0.00050758774,"teacher_disagreement_score":0.47084093,"about_ca_system_score_codex":0.00039845912,"about_ca_system_score_gemma":0.002711614,"threshold_uncertainty_score":0.911373},"labels":[],"label_agreement":null},{"id":"W4388203347","doi":"10.1200/op.2023.19.11_suppl.538","title":"Real-world comparative effectiveness and safety of pembrolizumab vs chemotherapy for previously untreated PD-L1≥50% metastatic non-small cell lung cancer.","year":2023,"lang":"en","type":"article","venue":"JCO Oncology Practice","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Hazard ratio; Lung cancer; Cohort; Oncology; Retrospective cohort study; Chemotherapy; Confidence interval; Population; Proportional hazards model; Propensity score matching; Surgery; Cancer; Immunotherapy","score_opus":0.03380880804976588,"score_gpt":0.39326229766768467,"score_spread":0.3594534896179188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388203347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783283,0.0021794694,0.00040982442,0.00429911,0.00039166427,0.0055852146,0.000088787325,0.00011888572,0.00859877],"genre_scores_gemma":[0.9722938,0.017557826,0.0039632707,0.0016326205,0.00016680258,0.0012617676,0.00012426887,0.00008685456,0.0029127926],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99793285,0.0005302309,0.00052106316,0.0004453486,0.00017142546,0.00039910438],"domain_scores_gemma":[0.9935724,0.005117518,0.00060326885,0.00029323314,0.00029934986,0.00011418901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013879092,0.00027528495,0.0010603676,0.00022011324,0.0001479715,0.00001503139,0.00011599741,0.00013875843,0.00010851769],"category_scores_gemma":[0.00014219763,0.00023589953,0.00015279067,0.0006617918,0.00021313778,0.00017152588,0.000040325944,0.00025576903,0.000007023815],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7365647,0.0031773562,0.0257538,0.010944177,0.008797984,0.00025871396,0.015808776,0.0002787946,0.13595222,0.00026448796,0.021482388,0.040716596],"study_design_scores_gemma":[0.12832156,0.01480363,0.53624237,0.0028647534,0.007237554,0.00031055466,0.004470866,0.0063749314,0.08427923,0.000085756445,0.21389489,0.001113933],"about_ca_topic_score_codex":0.0021000074,"about_ca_topic_score_gemma":0.00088038645,"teacher_disagreement_score":0.60824317,"about_ca_system_score_codex":0.000549717,"about_ca_system_score_gemma":0.0009246247,"threshold_uncertainty_score":0.9619704},"labels":[],"label_agreement":null},{"id":"W4388233301","doi":"10.1038/s41467-023-42744-y","title":"Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial","year":2023,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"KU Leuven; AstraZeneca","keywords":"Medicine; Clinical endpoint; Durvalumab; Triple-negative breast cancer; Carboplatin; Internal medicine; Oncology; Breast cancer; Atezolizumab; Metastatic breast cancer; Phases of clinical research; Randomized controlled trial; Clinical trial; Response Evaluation Criteria in Solid Tumors; Immunotherapy; Cancer; Chemotherapy; Nivolumab; Cisplatin","score_opus":0.024731334565646423,"score_gpt":0.35183229657228415,"score_spread":0.32710096200663774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388233301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91626585,0.017688077,0.0005820539,0.032403626,0.00029874983,0.030172033,0.0014518623,0.0005914198,0.00054633466],"genre_scores_gemma":[0.97599113,0.006960693,0.0031219616,0.00073761714,0.000061686434,0.009132002,0.00023153257,0.00007738809,0.0036859699],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977602,0.0005209037,0.00054252526,0.00038348546,0.00035368602,0.00043925186],"domain_scores_gemma":[0.99523413,0.0024121704,0.00041181484,0.0013519964,0.00044041767,0.00014946156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010066957,0.00036339898,0.001111295,0.0001458641,0.0007570366,0.000060791237,0.00047133846,0.00015789298,0.00006895043],"category_scores_gemma":[0.00055512047,0.00016673654,0.00011717197,0.0013254035,0.0008537671,0.00013522261,0.000114034374,0.000624246,8.5990393e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9663259,0.00039021813,0.000015341479,0.00009281757,0.002206414,0.000008028471,0.0044476227,0.000026670778,0.00023118086,0.00011434996,0.00071161246,0.02542986],"study_design_scores_gemma":[0.9730402,0.007000724,0.00019761932,0.0006295749,0.0012778984,0.00016811154,0.00402682,0.007392256,0.00011270032,0.00006329439,0.005750145,0.00034063996],"about_ca_topic_score_codex":0.00056427706,"about_ca_topic_score_gemma":0.010241748,"teacher_disagreement_score":0.059725303,"about_ca_system_score_codex":0.00037342307,"about_ca_system_score_gemma":0.0015276691,"threshold_uncertainty_score":0.6799319},"labels":[],"label_agreement":null},{"id":"W4388302491","doi":"10.2174/0109298673263784230922060257","title":"Association of PD-L1 Expression with Clinicopathologic Charactersin Gastric Cancer: A Comprehensive Meta-analysis","year":2023,"lang":"en","type":"article","venue":"Current Medicinal Chemistry","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Meta-analysis; Cancer; Expression (computer science); Medicine; Oncology; Cancer research; Internal medicine; Computational biology; Biology; Computer science","score_opus":0.0975351583934424,"score_gpt":0.3668537736574302,"score_spread":0.2693186152639878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388302491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854274,0.011797526,0.00009470718,0.0018561481,0.00019160012,0.00025023124,0.00010451315,0.00008445921,0.0001934168],"genre_scores_gemma":[0.99420404,0.0033772448,0.0000711616,0.000178943,0.00026089294,0.00009766201,0.0004132549,0.000017754353,0.001379037],"study_design_codex":"bench_or_experimental","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9981838,0.00005594391,0.00046756247,0.0003467461,0.0006759325,0.000270011],"domain_scores_gemma":[0.99857855,0.000169876,0.0005619191,0.00030535628,0.00026441793,0.00011988567],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039476212,0.00020468979,0.0010156608,0.00015004307,0.00005134535,0.0000065703853,0.00011226675,0.00011623839,0.001043263],"category_scores_gemma":[0.00007294563,0.0001344395,0.0006449776,0.0013891503,0.00010108382,0.00003846093,0.000031644384,0.00030988173,0.000007555789],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044431826,0.00047411263,0.13819978,0.0016595754,0.061200626,0.000094894014,0.00052861543,0.00004290023,0.76877487,3.393948e-7,0.014060128,0.010520954],"study_design_scores_gemma":[0.00989007,0.00087967137,0.291822,0.0008655782,0.38932493,0.00009193714,0.0018149227,0.0002687129,0.27987796,0.0000135186665,0.024425449,0.00072523387],"about_ca_topic_score_codex":0.000028924273,"about_ca_topic_score_gemma":0.0000024479623,"teacher_disagreement_score":0.48889694,"about_ca_system_score_codex":0.00018036988,"about_ca_system_score_gemma":0.00015452634,"threshold_uncertainty_score":0.99986994},"labels":[],"label_agreement":null},{"id":"W4388440789","doi":"10.1101/2023.11.01.565223","title":"The circulating immune cell landscape stratifies metastatic burden in breast cancer patients","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Metastatic breast cancer; Immune system; Breast cancer; Peripheral blood mononuclear cell; Circulating tumor cell; Cancer; Disease; Transcriptome; Metastasis; Medicine; CA15-3; Cell; Cancer research; Immunology; Oncology; Biology; Internal medicine; Gene; Gene expression","score_opus":0.01645802093616165,"score_gpt":0.2444105304417792,"score_spread":0.22795250950561757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388440789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893678,0.005884075,0.000013559252,0.0013822217,0.00149397,0.0012024044,0.00041727748,0.00022433807,0.000014383878],"genre_scores_gemma":[0.9961948,0.0025666482,0.00016950622,0.000114813214,0.00034431036,0.00042247467,0.0000020404357,0.00014920259,0.000036213292],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99709654,0.00014430853,0.00086211035,0.00072425284,0.0005457206,0.00062709436],"domain_scores_gemma":[0.99784094,0.000156159,0.0005069364,0.0009822374,0.00037508184,0.00013862582],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077903277,0.0005057934,0.0006673626,0.00025488652,0.0002325999,0.00021330094,0.00040236107,0.0002652453,0.00008088264],"category_scores_gemma":[0.00007445438,0.00040043014,0.00024258302,0.00069034845,0.00013368117,0.00009110253,0.00025816946,0.0008279889,0.000032608255],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012293538,0.00049508055,0.3551361,0.0024874746,0.0013659939,0.00022359156,0.00018838822,0.0003722861,0.63692904,0.00003745182,0.0014453145,0.000089957655],"study_design_scores_gemma":[0.0025346817,0.00005963315,0.978042,0.0014435134,0.00023806581,4.074144e-8,0.000045456036,0.00068787136,0.015532089,0.0000017596208,0.000855086,0.0005598163],"about_ca_topic_score_codex":0.0013766609,"about_ca_topic_score_gemma":0.000051953793,"teacher_disagreement_score":0.6229059,"about_ca_system_score_codex":0.00039596538,"about_ca_system_score_gemma":0.0008523045,"threshold_uncertainty_score":0.99984473},"labels":[],"label_agreement":null},{"id":"W4388461185","doi":"10.1016/j.cllc.2023.11.003","title":"Lack of Association Between Immunotherapy and Improvement of Survival for Non-small Cell Lung Cancer Patients With Hemodialysis: A Nationwide Retrospective Cohort Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Novo Nordisk Pharma; Bayer Yakuhin; Eli Lilly Japan; Novartis Pharma; Daiichi Sankyo Company; Shionogi; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Eisai; Novo Nordisk; Daiichi-Sankyo; JCR Pharmaceuticals; Nipro; Chugai Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Mallinckrodt Pharmaceuticals; Kissei; Asahi Kasei Pharma Corporation; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Kyorin Pharmaceutical; Pfizer; Nippon Shinyaku; Bristol-Myers Squibb; AstraZeneca; Torii Pharmaceutical","keywords":"Medicine; Lung cancer; Retrospective cohort study; Internal medicine; Oncology; Hemodialysis; Immunotherapy; Cohort; Proportional hazards model; Cohort study; Cancer; Intensive care medicine","score_opus":0.02647111851505887,"score_gpt":0.36919193737432016,"score_spread":0.3427208188592613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388461185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99490196,0.00039341408,0.000088136505,0.00024429135,0.00041896105,0.0034734257,0.00037174896,0.000024808858,0.000083278996],"genre_scores_gemma":[0.9970066,0.0011379084,0.00005951191,0.0001326742,0.0002321789,0.0005937752,0.00007420174,0.000036534657,0.0007266006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979309,0.00006864382,0.00086575904,0.000405474,0.00049455994,0.00023468249],"domain_scores_gemma":[0.99769413,0.0004989792,0.0007773719,0.00024112951,0.0007247409,0.000063622196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014925573,0.00017389002,0.00087615364,0.0001077876,0.000060821018,0.000010775475,0.00009275633,0.00014017009,0.000045641544],"category_scores_gemma":[0.00010817766,0.00013813666,0.0001963532,0.00045937154,0.00007358256,0.000051579063,0.000032113232,0.00015988754,2.6501624e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026424935,0.0005635459,0.9874682,0.0002458998,0.003598259,2.696955e-7,0.00048060855,0.0000069867615,0.0007314645,6.352885e-7,0.0007215118,0.003540145],"study_design_scores_gemma":[0.014119905,0.0018548465,0.9806448,0.00018328734,0.0013033377,1.022854e-8,0.00012578827,0.0002499491,0.0012702079,0.00000662258,0.00009322781,0.000147992],"about_ca_topic_score_codex":0.000986503,"about_ca_topic_score_gemma":0.0005124107,"teacher_disagreement_score":0.011477413,"about_ca_system_score_codex":0.00050855736,"about_ca_system_score_gemma":0.0002973981,"threshold_uncertainty_score":0.5633049},"labels":[],"label_agreement":null},{"id":"W4388493259","doi":"10.1097/cji.0000000000000492","title":"Effectiveness and Safety of Immune Checkpoint Inhibitors in Cancer Patients With Autoimmune Disease: A Retrospective Cohort Study","year":2023,"lang":"en","type":"article","venue":"Journal of Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; CancerCare Manitoba; Manitoba Health; University of Manitoba","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Retrospective cohort study; Odds ratio; Adverse effect; Proportional hazards model; Cancer; Cohort; Logistic regression; Confidence interval; Oncology; Surgery","score_opus":0.006176008549061644,"score_gpt":0.2705369440056471,"score_spread":0.26436093545658546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388493259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906409,0.0073217615,0.000009454344,0.00019781159,0.00030441422,0.0014680385,0.000017754062,0.000017775668,0.000022112254],"genre_scores_gemma":[0.99511373,0.004650599,0.000023289635,0.000024260227,0.000043602195,0.000047457626,0.0000050953317,0.000043790864,0.000048149093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770427,0.00018265874,0.0010316862,0.00021702998,0.0006294435,0.00023492619],"domain_scores_gemma":[0.9984333,0.0001057303,0.0007241758,0.00026852172,0.00039667368,0.00007162581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016452168,0.00023012675,0.00089638255,0.00044945485,0.00006279776,0.000016060156,0.000121221456,0.000063509826,0.00007042757],"category_scores_gemma":[0.00005772162,0.0001594636,0.0002098741,0.00092730706,0.00016131856,0.00016682236,0.000028860415,0.00031679706,6.6252534e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04742861,0.0011961515,0.90603906,0.000107034706,0.0013160873,0.000051000356,0.0011243157,0.000021368536,0.03330505,0.0000016636899,0.000013577982,0.009396069],"study_design_scores_gemma":[0.024141215,0.0035001044,0.96691287,0.0017887272,0.00011784736,0.000009907437,0.00030237666,0.0000086487025,0.0029199596,0.000018007366,0.00011812308,0.00016220524],"about_ca_topic_score_codex":0.00048344114,"about_ca_topic_score_gemma":0.000021071532,"teacher_disagreement_score":0.060873806,"about_ca_system_score_codex":0.0004938607,"about_ca_system_score_gemma":0.000281616,"threshold_uncertainty_score":0.6502737},"labels":[],"label_agreement":null},{"id":"W4388494161","doi":"10.3390/curroncol30110711","title":"Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Immunotherapy; Hepatocellular carcinoma; Tumor microenvironment; Clinical trial; Cancer; Targeted therapy; Oncology; Cancer research; Bioinformatics; Internal medicine; Biology","score_opus":0.2276041787232559,"score_gpt":0.48157078629868,"score_spread":0.2539666075754241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388494161","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000053495074,0.992319,0.00006734536,0.00010780515,0.0035244918,0.0033476178,0.000085721906,0.00008461991,0.00040993976],"genre_scores_gemma":[0.000008355662,0.996154,0.00007846133,0.0000555837,0.00064953684,0.0019494666,0.0005084256,0.00011577597,0.00048038675],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975727,0.00016172751,0.0010191252,0.00057052216,0.00016480255,0.00051112194],"domain_scores_gemma":[0.9985565,0.00043646988,0.00042219082,0.00043320734,0.000069626396,0.00008200552],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005421242,0.00045400657,0.0026793038,0.0004945345,0.000053051284,0.000010953252,0.00025955494,0.0004815349,0.000103209095],"category_scores_gemma":[0.000060373863,0.000360093,0.00097146584,0.00058429333,0.00013621697,0.000053094605,0.000043448614,0.00052146363,0.000075070144],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005609263,0.00025439044,0.0002973999,0.026652358,0.00012498812,0.00004559219,0.0000713513,2.6449147e-8,0.0000023136886,0.00004492879,0.0017883278,0.9701574],"study_design_scores_gemma":[0.003343965,0.00084293965,0.000034841687,0.010995403,0.00035649718,0.00007321342,0.00002866337,0.000020128142,0.0000017557985,0.00008081446,0.98389626,0.0003255517],"about_ca_topic_score_codex":0.000015099571,"about_ca_topic_score_gemma":0.00003723381,"teacher_disagreement_score":0.9821079,"about_ca_system_score_codex":0.00095905625,"about_ca_system_score_gemma":0.0011773648,"threshold_uncertainty_score":0.9998851},"labels":[],"label_agreement":null},{"id":"W4388494972","doi":"10.1136/ijgc-2023-igcs.80","title":"PR038/#248  Management of immune-related adverse events in patients with primary advanced or recurrent endometrial cancer: dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Carboplatin; Medicine; Paclitaxel; Placebo; Internal medicine; Chemotherapy; Adverse effect; Endometrial cancer; Oncology; Urology; Surgery; Cancer; Cisplatin; Pathology","score_opus":0.022118742384950128,"score_gpt":0.31551453856649325,"score_spread":0.2933957961815431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388494972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930894,0.00074553693,0.0000145056365,0.0025617527,0.001266554,0.0020975263,0.0000556069,0.000018827714,0.00015032261],"genre_scores_gemma":[0.99228483,0.0060386853,0.00027581403,0.0007627075,0.00016941866,0.00023356154,0.000060463874,0.000031249983,0.00014329073],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99628913,0.00017952063,0.0013678847,0.00031932167,0.0014758776,0.00036824268],"domain_scores_gemma":[0.9977646,0.00038244645,0.001133945,0.00021225012,0.000430066,0.000076683886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009536147,0.00030767004,0.0008593413,0.0005299433,0.000042956995,0.000012529865,0.0005946643,0.00013004855,0.0008791675],"category_scores_gemma":[0.000070494614,0.00016524503,0.0002596252,0.0012150713,0.00015521905,0.00019416849,0.000051442155,0.00051394646,0.0000020979378],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80962783,0.0023915032,0.10125649,0.00008343394,0.002241264,0.00029808847,0.0011370229,0.0011404688,0.00033816183,0.000010863506,0.00024739822,0.08122748],"study_design_scores_gemma":[0.2851219,0.0050369655,0.7059153,0.00093590684,0.00009528941,0.000014577736,0.00039492248,0.000056670317,0.00018457978,0.000025738467,0.0020227393,0.00019546546],"about_ca_topic_score_codex":0.0001826648,"about_ca_topic_score_gemma":0.00026255535,"teacher_disagreement_score":0.6046588,"about_ca_system_score_codex":0.0016382077,"about_ca_system_score_gemma":0.0004972509,"threshold_uncertainty_score":0.9626268},"labels":[],"label_agreement":null},{"id":"W4388495440","doi":"10.1136/ijgc-2023-igcs.2","title":"PO002/#156  Efficacy and safety results from skyscraper-04: an open-label randomized phase 2 trial of tiragolumab plus atezolizumab for PD-L1-positive recurrent cervical cancer","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Atezolizumab; Medicine; Oncology; Internal medicine; Clinical endpoint; TIGIT; Randomized controlled trial; Regimen; Progression-free survival; Cancer; Chemotherapy; Immunotherapy; Pembrolizumab","score_opus":0.08152142274293853,"score_gpt":0.4260592654103299,"score_spread":0.3445378426673914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388495440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980174,0.0017591408,0.00018530474,0.010188715,0.0032744843,0.0020528184,0.0020295815,0.000024039746,0.00031192458],"genre_scores_gemma":[0.9890064,0.007106608,0.00059870444,0.0010815884,0.0013593619,0.00020625546,0.00027950495,0.000027924165,0.00033363764],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99677986,0.000284477,0.0015289625,0.0003979746,0.0007238392,0.00028489172],"domain_scores_gemma":[0.9951166,0.0024770303,0.0010370308,0.0001668061,0.000978491,0.00022403055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001422668,0.00025157485,0.0012181707,0.00020540963,0.00009405122,0.00008260708,0.0005575067,0.00020994313,0.00088458596],"category_scores_gemma":[0.001396948,0.00017350964,0.0002883407,0.00022035603,0.00030457322,0.00023881182,0.00015983194,0.0003438594,0.000002368652],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8412591,0.0015058867,0.000032210042,0.000013540698,0.0016257575,0.00007800988,0.00044115377,0.000036452344,0.0025467225,0.00007767018,0.0017172868,0.15066619],"study_design_scores_gemma":[0.9695373,0.008525235,0.008921268,0.00047653113,0.00049012207,0.000031079056,0.00011871257,0.0020605484,0.0008966985,0.00044185275,0.008279353,0.00022125723],"about_ca_topic_score_codex":0.000899107,"about_ca_topic_score_gemma":0.00034379907,"teacher_disagreement_score":0.15044492,"about_ca_system_score_codex":0.0007225041,"about_ca_system_score_gemma":0.000734614,"threshold_uncertainty_score":0.96855956},"labels":[],"label_agreement":null},{"id":"W4388653325","doi":"10.3390/curroncol30110721","title":"Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chemotherapy; Bevacizumab; Lung cancer; Internal medicine; Oncology; Immunotherapy; Cancer","score_opus":0.034644932567519354,"score_gpt":0.3610786376047578,"score_spread":0.32643370503723845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388653325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932443,0.0027378765,0.000008207138,0.0015675055,0.0012690985,0.0009210572,0.000014917514,0.00006063621,0.00017638494],"genre_scores_gemma":[0.99760014,0.0016604926,0.00002335715,0.00012842918,0.00016719013,0.00012681406,0.00015471212,0.000031818967,0.00010705386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984787,0.00006419246,0.00060106535,0.00028729468,0.0002519419,0.00031678667],"domain_scores_gemma":[0.9992743,0.0000638364,0.00027686465,0.0001999565,0.000119354576,0.00006568959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027433404,0.00018552029,0.0004885048,0.00029753326,0.000034796452,0.000004567883,0.00009530702,0.00013880238,0.00022217799],"category_scores_gemma":[0.000034047735,0.00014532781,0.00013150941,0.00076882716,0.00013548757,0.000061125305,0.000033323005,0.00024504514,0.000008673065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031110834,0.002967836,0.54457474,0.00075848657,0.0003574712,0.000018623858,0.0036757,0.00006355359,0.058618788,0.000007971114,0.005221316,0.35262468],"study_design_scores_gemma":[0.030556759,0.0014122126,0.9276824,0.0008016898,0.000069516595,0.0000025271395,0.00014453281,0.00046412033,0.013999067,0.0000042868687,0.024668079,0.00019482627],"about_ca_topic_score_codex":0.00031246385,"about_ca_topic_score_gemma":0.00019271873,"teacher_disagreement_score":0.38310766,"about_ca_system_score_codex":0.0009373062,"about_ca_system_score_gemma":0.00041675376,"threshold_uncertainty_score":0.5926296},"labels":[],"label_agreement":null},{"id":"W4388666126","doi":"10.1016/j.jtocrr.2023.100601","title":"Real-World Immunotherapy Use and Effectiveness in Advanced NSCLC With Programmed Death-Ligand 1 Greater Than or Equal to 50% and Greater Than or Equal to 90%","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Sanofi; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Internal medicine; Cohort; Oncology; PD-L1; Immunotherapy; Clinical endpoint; Chemotherapy; Population; Cancer; Clinical trial","score_opus":0.20496001696559404,"score_gpt":0.47969571614272694,"score_spread":0.2747356991771329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388666126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99460703,0.00016032711,0.000039543225,0.0019373065,0.00015159583,0.0029038403,0.0000113296965,0.00008659408,0.00010241624],"genre_scores_gemma":[0.9923015,0.0012559654,0.0003410174,0.00032641986,0.00016195455,0.0005128831,0.000016400409,0.00006525266,0.005018603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99581206,0.0005301851,0.0008680453,0.0010834038,0.00083424797,0.00087205844],"domain_scores_gemma":[0.996982,0.0014240467,0.00010882459,0.0005701805,0.00028126675,0.00063373137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005896901,0.0003245481,0.00084616017,0.0005367524,0.00020191442,0.00020635557,0.00009294976,0.00020958393,0.00003713235],"category_scores_gemma":[0.0008550206,0.00017342721,0.000091685586,0.0011526039,0.00051150564,0.00018508913,0.0002223721,0.00053865643,0.000005366856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10213824,0.00021664912,0.815416,0.0002233197,0.00024015966,0.004934121,0.0007157847,7.0145444e-7,0.0045088343,0.000009335141,0.00028642503,0.07131042],"study_design_scores_gemma":[0.0066578537,0.0083187325,0.96982396,0.0011496763,0.000030257552,0.00041618987,0.00022487005,0.0000097938755,0.0023762367,0.000116292715,0.010567018,0.0003091088],"about_ca_topic_score_codex":0.00234504,"about_ca_topic_score_gemma":0.0042738663,"teacher_disagreement_score":0.15440796,"about_ca_system_score_codex":0.000095773226,"about_ca_system_score_gemma":0.0003486816,"threshold_uncertainty_score":0.7072156},"labels":[],"label_agreement":null},{"id":"W4388688898","doi":"10.7759/cureus.48859","title":"Stage 4 Non-small Cell Lung Cancer With Human Epidermal Growth Factor Receptor 2 Alterations and Myocarditis Induced by Immune Checkpoint Inhibitors: A Case Report","year":2023,"lang":"en","type":"article","venue":"Cureus","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Jewish General Hospital; McGill University","keywords":"Medicine; Pembrolizumab; Myocarditis; Oncology; Internal medicine; Lung cancer; Epidermal growth factor receptor; Cancer; Immunotherapy; Palpitations; Metastatic breast cancer; Breast cancer","score_opus":0.021610048031598595,"score_gpt":0.2908663795518844,"score_spread":0.2692563315202858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388688898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99509335,0.0017928369,0.00004587573,0.0009107289,0.00039063676,0.0007812739,0.0002561913,0.00013209833,0.00059702166],"genre_scores_gemma":[0.99545753,0.00045190574,0.00011950793,0.00018326107,0.00037173208,0.0002259263,0.00031000265,0.000058633763,0.0028215155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984972,0.000040293235,0.00048572037,0.00042334435,0.00020897949,0.00034449433],"domain_scores_gemma":[0.9990878,0.000038060825,0.00021448551,0.00036762247,0.00012347268,0.00016853576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022410096,0.0002504562,0.00036413054,0.00007805155,0.00026000704,0.00006080278,0.00006016308,0.00012977145,0.0004430236],"category_scores_gemma":[0.000028192326,0.0002069232,0.000114079965,0.0003218303,0.000085129745,0.00014830583,0.00004961511,0.0002473703,0.0000059518857],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027540122,0.00013154784,0.01436004,0.00032562035,0.00048008937,0.0077714706,0.0027601682,0.000001039543,0.9545583,0.0000037100103,0.018361758,0.0009708449],"study_design_scores_gemma":[0.010566708,0.001575406,0.08254938,0.00071930286,0.00045580277,0.0065871747,0.0025684065,0.00018149923,0.8772792,0.0000058302776,0.016353829,0.0011574298],"about_ca_topic_score_codex":0.0074826204,"about_ca_topic_score_gemma":0.0005992809,"teacher_disagreement_score":0.077279076,"about_ca_system_score_codex":0.00021064778,"about_ca_system_score_gemma":0.00020915955,"threshold_uncertainty_score":0.9991266},"labels":[],"label_agreement":null},{"id":"W4388694835","doi":"10.1016/j.jhep.2023.10.040","title":"Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours","year":2023,"lang":"en","type":"article","venue":"Journal of Hepatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"National Institute on Minority Health and Health Disparities; Genentech; Bayer HealthCare; G1 Therapeutics; MacroGenics; Tarveda Therapeutics; Pfizer; Incyte; Mersana Therapeutics; Les Laboratories Pierre Fabre; Ipsen; Jazz Pharmaceuticals; ViiV Healthcare; Agios Pharmaceuticals; Sirtex Medical; Cancer Research UK; Wellcome Trust; Exelixis; Revolution Medicines; Regeneron Pharmaceuticals; Astellas Pharma; Eisai; FibroGen; Servier; Gilead Sciences; Sanofi; GlaxoSmithKline; OncoMed Pharmaceutical; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Falk Foundation","keywords":"Medicine; Internal medicine; Hepatocellular carcinoma; Gastroenterology; Incidence (geometry); Bevacizumab; Atezolizumab; Cohort; Cumulative incidence; Liver cancer; Cancer; Immunotherapy; Oncology; Nivolumab; Chemotherapy","score_opus":0.011220291192931043,"score_gpt":0.2627151369099966,"score_spread":0.25149484571706554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388694835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984202,0.0006602345,0.0000032830426,0.00027261014,0.0003879934,0.00019772674,0.000013494568,0.000009816135,0.000034646913],"genre_scores_gemma":[0.9990352,0.0006078494,0.00010413093,0.00015521151,0.000015727222,0.0000025958216,0.000006690652,0.000027362355,0.000045238598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987506,0.00006924992,0.0006336987,0.00012215583,0.0002097044,0.00021458633],"domain_scores_gemma":[0.99903405,0.00008604338,0.00051208376,0.0001519054,0.00015889951,0.000057001285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023368886,0.00015185513,0.000676052,0.00036264854,0.000023631124,0.000004266954,0.0000850609,0.00011542951,0.00007044589],"category_scores_gemma":[0.000041268166,0.00010849677,0.000102135185,0.00027521583,0.00015467158,0.00007685703,0.000025284138,0.00021882477,0.0000028385082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02018633,0.00016694401,0.967015,0.00003557915,0.00030844274,0.00011843182,0.0003816681,5.778016e-7,0.00295064,0.0000062565896,0.000049499704,0.008780622],"study_design_scores_gemma":[0.014245274,0.002702418,0.9805577,0.00011358758,0.000076385826,0.000042995598,0.000065194625,0.000084860374,0.0016702331,0.000012841049,0.00032029147,0.00010820902],"about_ca_topic_score_codex":0.000056043245,"about_ca_topic_score_gemma":0.000008945915,"teacher_disagreement_score":0.013542701,"about_ca_system_score_codex":0.00007501187,"about_ca_system_score_gemma":0.00012311591,"threshold_uncertainty_score":0.442437},"labels":[],"label_agreement":null},{"id":"W4388781963","doi":"10.1016/j.fander.2023.09.584","title":"Nivolumab (NIVO) versus ipilimumab (IPI) dans le traitement adjuvant du mélanome opéré de stade III/IV : résultats à 7 ans de l’étude CheckMate 238","year":2023,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Gynecology","score_opus":0.052538473746187905,"score_gpt":0.3323278608727383,"score_spread":0.2797893871265504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388781963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92341375,0.022631686,0.0031345552,0.041108865,0.0028293226,0.0013139202,0.00052388967,0.0014393609,0.0036046363],"genre_scores_gemma":[0.92831135,0.059545316,0.0021367087,0.0057771113,0.00059285073,0.0004196658,0.0004999923,0.00021718432,0.002499818],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99013746,0.0015704996,0.001614885,0.0013964991,0.0007611975,0.0045194854],"domain_scores_gemma":[0.9951085,0.0018335748,0.00061090937,0.0013292552,0.00024179592,0.00087596336],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0033582537,0.0012269693,0.0016729793,0.0006511119,0.00069346325,0.00025017568,0.0015297842,0.0013746355,0.00042119372],"category_scores_gemma":[0.0012370738,0.0012727466,0.0009072691,0.0015520541,0.0014580982,0.00052739365,0.00055236433,0.0014757618,0.0004396058],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04127687,0.005078204,0.20828688,0.0052723554,0.009443916,0.055390604,0.07305197,0.009093674,0.18220077,0.0059798886,0.3102981,0.09462679],"study_design_scores_gemma":[0.05127678,0.0040366645,0.60009634,0.0024984097,0.0018734533,0.007901638,0.05595845,0.02638484,0.066189684,0.002814092,0.17719331,0.0037763466],"about_ca_topic_score_codex":0.0038937563,"about_ca_topic_score_gemma":0.003398869,"teacher_disagreement_score":0.39180943,"about_ca_system_score_codex":0.0033432096,"about_ca_system_score_gemma":0.005681514,"threshold_uncertainty_score":0.99995536},"labels":[],"label_agreement":null},{"id":"W4388826596","doi":"10.4049/jimmunol.2200775","title":"Establishment of CD8+ T Cell Thymic Central Tolerance to Tissue-Restricted Antigen Requires PD-1","year":2023,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"Cytotoxic T cell; Antigen; Immunology; T cell; Central tolerance; CD8; Immune tolerance; Cell biology; Biology; Immune system; Genetics","score_opus":0.01624249763014938,"score_gpt":0.2789225657113414,"score_spread":0.262680068081192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388826596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880548,0.0058675096,0.00008010536,0.004538373,0.0008390748,0.00023005529,0.000007411591,0.00001935448,0.00036332736],"genre_scores_gemma":[0.9912068,0.007303688,0.00015321752,0.0003812706,0.0001491896,0.0000018471928,0.000003372605,0.00001618536,0.00078440225],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986067,0.00013065625,0.0005883463,0.00008777635,0.00024569745,0.00034084785],"domain_scores_gemma":[0.9989543,0.00013741275,0.0003791899,0.00030382542,0.00016453133,0.00006075419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044381397,0.00012192779,0.00038231802,0.00025556184,0.00006035982,0.000007996727,0.00033319675,0.000080904916,0.00016781224],"category_scores_gemma":[0.00007040056,0.00007756078,0.0001147777,0.00065231876,0.00014496336,0.00006903155,0.00006070232,0.00024265434,0.00002798984],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005723032,0.00009896174,0.001413611,0.00002644098,0.00024663645,0.000052629835,0.0015764677,0.00008438426,0.97050965,0.00000896465,0.008880607,0.01137862],"study_design_scores_gemma":[0.0038243916,0.0031786766,0.3703009,0.0002753885,0.00013162804,0.0004655593,0.0012661614,0.000019108711,0.5744906,0.00006570918,0.045845784,0.00013608333],"about_ca_topic_score_codex":0.0001733266,"about_ca_topic_score_gemma":0.0000096902595,"teacher_disagreement_score":0.39601904,"about_ca_system_score_codex":0.00009133159,"about_ca_system_score_gemma":0.0001995733,"threshold_uncertainty_score":0.31628367},"labels":[],"label_agreement":null},{"id":"W4389048097","doi":"10.1038/s41591-023-02690-0","title":"Author Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis","year":2023,"lang":"en","type":"erratum","venue":"Nature Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute; Sunnybrook Hospital; McMaster University; University of Toronto","funders":"","keywords":"Myocarditis; Immune system; Immunology; Medicine; Immune checkpoint; Cancer research; Internal medicine; Immunotherapy","score_opus":0.01490765162882758,"score_gpt":0.31239049540461616,"score_spread":0.2974828437757886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389048097","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009385378,0.12818925,0.00021346488,0.22701807,0.58337694,0.0053885826,0.0004862503,0.0013302495,0.044611786],"genre_scores_gemma":[0.03345725,0.0062831384,0.00022568693,0.0065487195,0.038423114,0.00027128588,0.0038962606,0.00025954336,0.910635],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99654025,0.0001088037,0.0009183972,0.000975716,0.00096890394,0.00048795616],"domain_scores_gemma":[0.9977035,0.00018937018,0.00026115557,0.0009736188,0.00046520217,0.00040713657],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0011020076,0.0006025067,0.0013327493,0.0005938203,0.00025952756,0.00004152517,0.00017845063,0.0017421617,0.0008409679],"category_scores_gemma":[0.0015590219,0.00045867488,0.00031219865,0.001166436,0.00036487592,0.00006519067,0.000119760014,0.0037245075,0.00006514496],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008297153,0.000058290698,0.00012818046,0.00042310558,0.00038540724,0.000115260016,0.0007363692,2.0235467e-7,0.0072557935,0.0000072841567,0.9667228,0.023337584],"study_design_scores_gemma":[0.0024554834,0.0017042452,0.03261327,0.0037821599,0.00048563763,0.00033318633,0.0005659269,0.000050315466,0.0009921978,0.000038596398,0.9565557,0.0004232307],"about_ca_topic_score_codex":0.00062219816,"about_ca_topic_score_gemma":0.0008640722,"teacher_disagreement_score":0.86602324,"about_ca_system_score_codex":0.00049744063,"about_ca_system_score_gemma":0.00048436562,"threshold_uncertainty_score":0.9997865},"labels":[],"label_agreement":null},{"id":"W4389091353","doi":"10.33590/emjgastroenterol/10303980","title":"Challenges in Management of Immune Checkpoint Inhibitor-Associated Hepatitis","year":2023,"lang":"en","type":"article","venue":"EMJ Gastroenterology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Liver Centre; University Health Network","funders":"","keywords":"Medicine; Colorectal cancer; Cancer; Pembrolizumab; Internal medicine; Oncology; Immunology; Gastroenterology; Immunotherapy","score_opus":0.03191322957300105,"score_gpt":0.27954489891570156,"score_spread":0.2476316693427005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389091353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99304634,0.0007697103,0.000004913918,0.0044503175,0.00028237142,0.00024165216,0.0000068464988,0.00006150938,0.0011363217],"genre_scores_gemma":[0.9930633,0.0062975683,0.00006861708,0.000119669865,0.000025382738,0.000043951637,0.00003910014,0.000015948905,0.00032647094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988467,0.00006418865,0.00042539992,0.00020889388,0.00013647293,0.0003183192],"domain_scores_gemma":[0.9995933,0.000014988279,0.000114291324,0.00021740526,0.000026729234,0.00003325489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040700726,0.000108516855,0.0003228114,0.00021748463,0.000014154403,0.000002043536,0.00007820199,0.000071409195,0.0001013857],"category_scores_gemma":[0.000010446053,0.00010378317,0.00012501996,0.00021751793,0.000075724165,0.000023673949,0.00006897762,0.00011058925,0.000027477055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010937805,0.001335736,0.8898116,0.0011895404,0.0018531989,0.0019068299,0.0021505472,0.000018992436,0.04004193,0.00017938043,0.0021775772,0.048396908],"study_design_scores_gemma":[0.0044947118,0.0011698944,0.9913382,0.00035542808,0.000028378849,0.000039598133,0.00035478972,0.00003682663,0.0016775014,0.000047890135,0.00041223463,0.00004455855],"about_ca_topic_score_codex":0.00015972686,"about_ca_topic_score_gemma":0.0004897145,"teacher_disagreement_score":0.10152663,"about_ca_system_score_codex":0.00009309101,"about_ca_system_score_gemma":0.000009942053,"threshold_uncertainty_score":0.42321548},"labels":[],"label_agreement":null},{"id":"W4389130677","doi":"10.1136/jitc-2023-007479","title":"TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China","keywords":"Chromatin immunoprecipitation; mTORC1; Cancer research; Immunotherapy; Hepatocellular carcinoma; PI3K/AKT/mTOR pathway; PD-L1; Biology; Transcription factor; Immune system; Flow cytometry; Small hairpin RNA; Immunology; Signal transduction; Gene knockdown; Cell culture; Promoter; Cell biology; Gene expression; Gene","score_opus":0.02587258318433669,"score_gpt":0.30907782748007884,"score_spread":0.2832052442957421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389130677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786442,0.018796692,0.00013412404,0.0006757337,0.0009946126,0.0006072747,0.00004592647,0.000032436164,0.00006899405],"genre_scores_gemma":[0.9894069,0.0087589165,0.000246534,0.000092889706,0.0002237175,0.00006289472,0.00005987161,0.000054741708,0.0010935591],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99791247,0.00006141273,0.0010092547,0.00019972259,0.00048793436,0.00032922378],"domain_scores_gemma":[0.9985772,0.00014317447,0.0005987365,0.00024210468,0.00037999553,0.000058811216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009213055,0.00020035954,0.00057380623,0.0006499441,0.00010294806,0.000013449073,0.00013971822,0.00016908621,0.0004740079],"category_scores_gemma":[0.000051562198,0.00017124752,0.00045295715,0.00086749386,0.00011598197,0.00014681273,0.000013342397,0.00021536427,0.0000027637338],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011026931,0.00012882864,0.08540897,0.00014478932,0.00035491693,0.0000046105415,0.00047789773,0.00025308988,0.8828248,0.000013600813,0.0007883154,0.018573303],"study_design_scores_gemma":[0.009056379,0.0007099363,0.63753164,0.0006190406,0.000056743975,0.000035206303,0.00015104386,0.0045987684,0.33539099,0.00037928091,0.011288266,0.00018270763],"about_ca_topic_score_codex":0.0006943379,"about_ca_topic_score_gemma":0.00003100493,"teacher_disagreement_score":0.55212265,"about_ca_system_score_codex":0.00035197407,"about_ca_system_score_gemma":0.00038745024,"threshold_uncertainty_score":0.6983271},"labels":[],"label_agreement":null},{"id":"W4389132867","doi":"10.1136/rmdopen-2023-003795","title":"Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study","year":2023,"lang":"en","type":"article","venue":"RMD Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Adverse effect; Observational study; Prednisone; Immune system; Cancer; Oncology; Immunology","score_opus":0.053054158321621726,"score_gpt":0.323287625399988,"score_spread":0.27023346707836626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389132867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924014,0.0016856148,3.1080182e-7,0.00051878893,0.00038743322,0.0044377013,0.000008562752,0.00010314839,0.00045704015],"genre_scores_gemma":[0.9971501,0.00084610964,0.000052315314,0.000117405194,0.00004565789,0.0006434709,0.00014076603,0.00004332013,0.00096082536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975076,0.0001584381,0.0010474866,0.00044431112,0.00043887206,0.00040334323],"domain_scores_gemma":[0.9989957,0.000059657334,0.00022909434,0.0004984081,0.00012323058,0.000093895644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009427994,0.00023345233,0.00051188684,0.00018118262,0.00012302189,0.00007367747,0.00036273236,0.00012225806,0.00039267098],"category_scores_gemma":[0.00018822994,0.00021840382,0.00013024575,0.00070586096,0.000066494,0.00038645518,0.00034060678,0.00026321335,0.00012695066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009331292,0.0031338795,0.85510033,0.00018696331,0.0005140562,0.00024768914,0.06516251,0.000020570546,0.022235584,0.000022427897,0.0007346909,0.04331],"study_design_scores_gemma":[0.024931142,0.00067222497,0.9634048,0.0010827298,0.000018794464,0.000002838251,0.0066970224,0.00012470548,0.0016113248,0.0000125481,0.0011846678,0.00025723214],"about_ca_topic_score_codex":0.0005788173,"about_ca_topic_score_gemma":0.0003943359,"teacher_disagreement_score":0.10830443,"about_ca_system_score_codex":0.0002727994,"about_ca_system_score_gemma":0.00020535216,"threshold_uncertainty_score":0.89062494},"labels":[],"label_agreement":null},{"id":"W4389227574","doi":"10.1158/2326-6074.tumimm23-pr04","title":"Abstract PR04: Temporal single cell profiling identifies B-cell specific checkpoint molecules that regulate anti-tumor immunity","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Acquired immune system; Cancer immunotherapy; TIGIT; Immune checkpoint; Immunotherapy; Antigen presentation; T cell; Cancer research; B cell; Immunology; Immunity; Antigen; Immune system; Antibody","score_opus":0.11737914931982456,"score_gpt":0.3683198197744457,"score_spread":0.25094067045462115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9601594,0.03133569,0.00000802273,0.0016100247,0.0009212576,0.0010931928,0.000048164613,0.00028571652,0.0045385086],"genre_scores_gemma":[0.9819424,0.008097947,0.00011920629,0.0000901696,0.00022898453,0.00026066694,0.00017520113,0.00010426656,0.0089811245],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99611974,0.0003346579,0.00063138426,0.00076612114,0.0007947809,0.0013532917],"domain_scores_gemma":[0.99777114,0.00024352135,0.00021741465,0.0011544174,0.00046866224,0.00014481886],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022125475,0.0003624359,0.00061764073,0.00081932725,0.00060079386,0.0001506609,0.00061136484,0.0002995519,0.0009713663],"category_scores_gemma":[0.00007271698,0.00032881164,0.00029709103,0.0015266796,0.0012945253,0.0002160855,0.00038222162,0.001472768,0.00053681195],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021901785,0.0003855886,0.0076810787,0.00042646835,0.00022262303,0.00034713067,0.00059098785,0.0000081507615,0.9771444,0.00001029456,0.007981026,0.0030120478],"study_design_scores_gemma":[0.0029772879,0.0003889093,0.1287921,0.00030836157,0.000024467618,0.00004691258,0.002836939,0.00003280516,0.8475725,0.00012554479,0.016583484,0.00031068752],"about_ca_topic_score_codex":0.0011889172,"about_ca_topic_score_gemma":0.000045055498,"teacher_disagreement_score":0.12957193,"about_ca_system_score_codex":0.0005904094,"about_ca_system_score_gemma":0.00066838315,"threshold_uncertainty_score":0.9999419},"labels":[],"label_agreement":null},{"id":"W4389227651","doi":"10.1158/2326-6074.tumimm23-b047","title":"Abstract B047: Tertiary lymphoid structures and B cells signatures determine clinically relevant T cell phenotype in ovarian cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Germinal center; CD8; Immunotherapy; Biology; Follicular dendritic cells; Immunosurveillance; Cancer research; Immunology; T cell; Immune system; B cell; Antigen-presenting cell; Antibody","score_opus":0.050372601418938595,"score_gpt":0.38741373420365127,"score_spread":0.3370411327847127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9579483,0.036072694,0.0000013733178,0.003534437,0.00082371494,0.0007420578,0.00006403486,0.00008365344,0.0007296897],"genre_scores_gemma":[0.95548666,0.04119821,0.000079382,0.0007452391,0.00030391855,0.00027146237,0.00003188748,0.00006447887,0.001818744],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9968529,0.00025141795,0.0006653656,0.0007372987,0.00046417603,0.00102885],"domain_scores_gemma":[0.9982667,0.00065149297,0.0001239042,0.0005829358,0.00022340401,0.00015158487],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013760763,0.0002860728,0.00053960783,0.00068608084,0.00020572371,0.00004981777,0.00037059205,0.00051614543,0.0011508978],"category_scores_gemma":[0.00013618633,0.0002376229,0.00011634817,0.0010218159,0.0008660101,0.00010465103,0.00024281842,0.0013195882,0.000052045154],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053467522,0.00010380445,0.043496937,0.0002495496,0.00023500672,0.00032804208,0.00063616654,0.000021662338,0.86006945,0.000013791976,0.0052647595,0.08423406],"study_design_scores_gemma":[0.0063353484,0.0004498798,0.87964934,0.00035519208,0.00003835455,0.000026045682,0.0004022294,0.000116518175,0.100665025,0.0004194968,0.011217876,0.0003247108],"about_ca_topic_score_codex":0.0040825945,"about_ca_topic_score_gemma":0.00057924713,"teacher_disagreement_score":0.8361524,"about_ca_system_score_codex":0.00040454595,"about_ca_system_score_gemma":0.0010610862,"threshold_uncertainty_score":0.9997622},"labels":[],"label_agreement":null},{"id":"W4389227671","doi":"10.1158/2326-6074.tumimm23-b046","title":"Abstract B046: Analyzing heterogeneity of tumor microenvironment of TNBC patients by meta-analysis of 7 breast cancer scRNAseq studies","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tumor microenvironment; Stromal cell; Breast cancer; Triple-negative breast cancer; Cancer research; Immunotherapy; Immune system; CD8; Medicine; Estrogen receptor; Immune checkpoint; Cancer; T cell; Oncology; Biology; Internal medicine; Immunology","score_opus":0.16784164586879086,"score_gpt":0.43705841957133656,"score_spread":0.2692167737025457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89684373,0.100138076,9.61672e-7,0.00084815745,0.00009331854,0.00039442957,0.0016472851,0.000011957903,0.00002207756],"genre_scores_gemma":[0.9724951,0.026810775,0.000013715582,0.00005601333,0.000016698912,0.00021348226,0.00008897567,0.000025068417,0.00028021482],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9971792,0.00025254374,0.00088886346,0.00045054618,0.0006977745,0.00053104863],"domain_scores_gemma":[0.9978295,0.00027958292,0.00045804292,0.0006631135,0.00070507167,0.00006470738],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012549155,0.00021782125,0.001706908,0.0009930378,0.000098973775,0.0000046494424,0.00032239995,0.00011033322,0.0012295146],"category_scores_gemma":[0.0000676467,0.00016834652,0.0009275506,0.0023874766,0.0014095006,0.000062533996,0.00021724861,0.00032545082,0.0000054330117],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024212447,0.00036588756,0.1848705,0.0003572513,0.24836269,0.000008117559,0.00038400566,0.00006430766,0.5574535,0.0000013502715,0.0022263026,0.0034848491],"study_design_scores_gemma":[0.0014704446,0.00028219805,0.7544804,0.000082955965,0.019235289,0.0000013938833,0.0005392255,0.000012166018,0.22328746,0.0000038341595,0.0004862796,0.00011834757],"about_ca_topic_score_codex":0.0044003935,"about_ca_topic_score_gemma":0.00045304562,"teacher_disagreement_score":0.5696099,"about_ca_system_score_codex":0.00038405752,"about_ca_system_score_gemma":0.00022504324,"threshold_uncertainty_score":0.9996835},"labels":[],"label_agreement":null},{"id":"W4389227786","doi":"10.1158/2326-6074.tumimm23-b021","title":"Abstract B021: In vivo gain-of-function screen identifies CREB5, a novel ECM modulator that promotes immunotherapy resistance via the Collagen-Lair1 axis","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunotherapy; Immune system; Cancer immunotherapy; Cancer research; In vivo; Biology; Immune checkpoint; Stromal cell; Cancer cell; Downregulation and upregulation; Cell biology; Cancer; Immunology; Medicine; Gene; Genetics","score_opus":0.08539948952769882,"score_gpt":0.3718062214813789,"score_spread":0.28640673195368005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96135104,0.028536085,0.00006913975,0.0060504046,0.0006832914,0.0018043967,0.000099934434,0.0001213235,0.0012843603],"genre_scores_gemma":[0.9797689,0.00812488,0.00004125032,0.00018921313,0.0001600065,0.00066299725,0.000032201053,0.00007705046,0.010943532],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.996589,0.0002889514,0.0006584814,0.00064030377,0.0008616397,0.0009616143],"domain_scores_gemma":[0.997463,0.0006282651,0.00021405914,0.0011443668,0.0004850481,0.00006527157],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00292666,0.00029918546,0.0005869582,0.0008113841,0.00043009582,0.00006522361,0.0006464594,0.00034886404,0.0011515025],"category_scores_gemma":[0.00017143367,0.00022794408,0.00022204524,0.00259173,0.001422367,0.00019920015,0.00017153424,0.00074044225,0.000060720806],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012642882,0.00021799142,0.006083949,0.00020328563,0.0008585957,0.00003368977,0.0016814724,0.000015234035,0.9579178,0.00007325917,0.006266084,0.014005748],"study_design_scores_gemma":[0.007436125,0.0006704649,0.6592401,0.00095109263,0.000044881963,0.000026947899,0.0026837746,0.00021287231,0.2830782,0.0006510181,0.044609435,0.00039509797],"about_ca_topic_score_codex":0.004034609,"about_ca_topic_score_gemma":0.0026033414,"teacher_disagreement_score":0.6748396,"about_ca_system_score_codex":0.00054792105,"about_ca_system_score_gemma":0.0007901013,"threshold_uncertainty_score":0.9997616},"labels":[],"label_agreement":null},{"id":"W4389227799","doi":"10.1158/2326-6074.tumimm23-b039","title":"Abstract B039: T cell recruitment dynamics at different stages of primary and metastatic colorectal cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Colorectal cancer; Medicine; Metastasis; Tumor microenvironment; KRAS; FOXP3; Cancer research; Oncology; Immunotherapy; Cancer; Pathology; Internal medicine; Immune system; Immunology","score_opus":0.129604609222508,"score_gpt":0.410922813002028,"score_spread":0.28131820377952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96238536,0.03288868,0.0000013367081,0.002072834,0.0003456787,0.001170599,0.00024406367,0.000053262163,0.0008382033],"genre_scores_gemma":[0.9308465,0.062449086,0.000018749395,0.00007798367,0.000046922763,0.00093979755,0.0001265044,0.000041052623,0.0054533994],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99787325,0.00017061067,0.00039307584,0.00042086127,0.00048258103,0.0006595991],"domain_scores_gemma":[0.9988109,0.00041183367,0.00012161084,0.0003301525,0.00022352932,0.00010195744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006434119,0.00020534897,0.00055324147,0.00040819478,0.00018892587,0.000015399168,0.00018815309,0.00014293268,0.00086155924],"category_scores_gemma":[0.000035424688,0.00016340149,0.00010952762,0.0005988798,0.0009340787,0.000051351508,0.000284592,0.0005046971,0.00002218292],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068045817,0.00023393269,0.0662418,0.0009152928,0.00100787,0.000075932854,0.0008122322,0.0000051970455,0.83865744,0.000036024292,0.0033492565,0.08186043],"study_design_scores_gemma":[0.004142287,0.00092133984,0.8241728,0.00029272708,0.00009203808,0.000020098698,0.00075900904,0.000099911216,0.16420354,0.000060549188,0.0050403103,0.00019538653],"about_ca_topic_score_codex":0.0013924502,"about_ca_topic_score_gemma":0.0009188579,"teacher_disagreement_score":0.757931,"about_ca_system_score_codex":0.0016098791,"about_ca_system_score_gemma":0.00043757676,"threshold_uncertainty_score":0.943347},"labels":[],"label_agreement":null},{"id":"W4389240145","doi":"10.1158/2326-6074.tumimm23-a035","title":"Abstract A035: Comparing the clinical and genomic landscapes of acral, mucosal, and cutaneous metastatic melanomas treated with immune checkpoint inhibitors","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Melanoma; Mucosal melanoma; Oncology; Malignancy; Internal medicine; Metastatic melanoma; Cancer; Immunotherapy; Immune checkpoint; Cohort; Pembrolizumab; Cancer research","score_opus":0.10236977837228804,"score_gpt":0.402273994166284,"score_spread":0.29990421579399595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389240145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9586196,0.03798426,4.6151348e-7,0.002461016,0.00011848439,0.00060823525,0.000010869202,0.000045124467,0.00015197918],"genre_scores_gemma":[0.95739424,0.042062026,0.000023876102,0.000034738292,0.00006484463,0.00008845038,0.000018990997,0.00003119821,0.0002816437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998076,0.0002412405,0.0005741746,0.00036477984,0.00026360594,0.00048018698],"domain_scores_gemma":[0.9985589,0.00066100346,0.00013952905,0.00039307863,0.00017181988,0.00007570915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015226854,0.00017819469,0.0005866405,0.0002596397,0.00022554834,0.000053402007,0.00017571644,0.000120384604,0.00009503471],"category_scores_gemma":[0.00008235703,0.00010791274,0.000088511966,0.0005773607,0.0018162413,0.0000866501,0.00017339147,0.0006861832,0.000011845702],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019437667,0.00023422335,0.45793843,0.00049540173,0.00392276,0.00039675483,0.0019123978,0.000011505888,0.4444116,0.000037012407,0.0008149606,0.07038727],"study_design_scores_gemma":[0.0057343156,0.0014991779,0.96663505,0.00047566745,0.00015907697,0.0005169165,0.0039724642,0.00019501126,0.017972538,0.00004827517,0.0026101153,0.00018137194],"about_ca_topic_score_codex":0.0014970072,"about_ca_topic_score_gemma":0.0003215324,"teacher_disagreement_score":0.5086966,"about_ca_system_score_codex":0.00006812493,"about_ca_system_score_gemma":0.0002922627,"threshold_uncertainty_score":0.6692017},"labels":[],"label_agreement":null},{"id":"W4389240415","doi":"10.1158/2326-6074.tumimm23-b041","title":"Abstract B041: Defining the Determinants of Immune Response in DNA Homologous Recombination Deficient Tumors","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immune checkpoint; CXCL10; Tumor microenvironment; Immune system; Immunotherapy; Cancer research; Chemokine; CXCR3; Cancer immunotherapy; Biology; Cancer; Immunology; Chemokine receptor; Medicine; Genetics","score_opus":0.06969010939385277,"score_gpt":0.40386602749732037,"score_spread":0.3341759181034676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389240415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98359287,0.011998191,3.500493e-7,0.0028877633,0.00037236526,0.00058832165,0.000016160044,0.000045464207,0.0004985196],"genre_scores_gemma":[0.9957044,0.002917983,0.0000085021875,0.000056174966,0.000018781062,0.0002483681,0.000014156986,0.000029256324,0.0010023889],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972743,0.00058304396,0.0006457495,0.0003476701,0.0004340813,0.00071517046],"domain_scores_gemma":[0.99768925,0.0012347616,0.00015926293,0.000605671,0.0002737723,0.000037271366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062528765,0.00014796117,0.0003946493,0.0008937199,0.00021029069,0.000016807895,0.0003929469,0.00019456126,0.00025460037],"category_scores_gemma":[0.0008928369,0.000110753615,0.00012843382,0.002047592,0.00090668007,0.00006270298,0.00017119966,0.00077184284,0.00010954407],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043990303,0.00035540227,0.079889484,0.00020664577,0.00022677622,0.0003913367,0.0038655417,0.000034527853,0.74356216,0.00016832624,0.0011098734,0.12619965],"study_design_scores_gemma":[0.0023716874,0.0007902401,0.9281762,0.00044943066,0.0000096156855,0.000075935284,0.0019756602,0.000103013735,0.0649058,0.00015140041,0.00088673696,0.00010423644],"about_ca_topic_score_codex":0.0014170258,"about_ca_topic_score_gemma":0.0001830779,"teacher_disagreement_score":0.84828675,"about_ca_system_score_codex":0.0004906945,"about_ca_system_score_gemma":0.0008383644,"threshold_uncertainty_score":0.45164013},"labels":[],"label_agreement":null},{"id":"W4389241582","doi":"10.1158/2326-6074.tumimm23-b048","title":"Abstract B048: Multiplex analysis of pancreatic, oesophageal and rectal adenocarcinoma: A cross-cancer approach on the impact of neoadjuvant therapy on the tumour microenvironment","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tumor microenvironment; Medicine; FOXP3; Stromal cell; Pancreatic cancer; Immune system; Cancer research; CD8; Immunotherapy; Tumor-infiltrating lymphocytes; Colorectal cancer; Pathology; Cancer; Immunology; Internal medicine","score_opus":0.11217253789018335,"score_gpt":0.4123460487443221,"score_spread":0.3001735108541388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724509,0.023790462,8.7291977e-7,0.0019968264,0.00006487387,0.0011005653,0.00021437102,0.000020766453,0.00036036308],"genre_scores_gemma":[0.97613215,0.022588024,0.000005518254,0.00012169872,0.0000741897,0.0005151414,0.000035073877,0.000037035614,0.00049116486],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99732363,0.00041804457,0.0004954962,0.0005050527,0.0006079125,0.0006498838],"domain_scores_gemma":[0.99745065,0.0012513179,0.00022120257,0.000837933,0.00017130187,0.00006761373],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001864954,0.00027577905,0.0007031755,0.0006019274,0.00030607087,0.000032220643,0.0004399649,0.0001810372,0.0012383838],"category_scores_gemma":[0.00012484788,0.00013863733,0.00046795816,0.0017371601,0.0020577505,0.000041582123,0.00012304458,0.0008308426,0.000012858175],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017769985,0.0005169085,0.26381642,0.00006004516,0.01153653,0.0000237263,0.002693676,0.0004320088,0.68583834,0.000052250572,0.0016768255,0.015583301],"study_design_scores_gemma":[0.002273293,0.0012118208,0.9500772,0.000106529216,0.00015771059,0.0000061439596,0.0007694248,0.0006882302,0.04448483,0.000018447476,0.000096894175,0.00010950927],"about_ca_topic_score_codex":0.0057123536,"about_ca_topic_score_gemma":0.000041664753,"teacher_disagreement_score":0.68626076,"about_ca_system_score_codex":0.00040216398,"about_ca_system_score_gemma":0.00032365776,"threshold_uncertainty_score":0.9996746},"labels":[],"label_agreement":null},{"id":"W4389241602","doi":"10.1158/2326-6074.tumimm23-pr06","title":"Abstract PR06: Hallmarks of CD8 T cell dysfunction are established within hours of tumor antigen encounter prior to cell division","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tumor microenvironment; Immunology; T cell; CD8; Cytotoxic T cell; Epigenetics; Immunotherapy; Cancer; Biology; Cancer research; Cancer immunotherapy; Antigen; Context (archaeology); Medicine; Immune system; Genetics; In vitro","score_opus":0.04536079984949287,"score_gpt":0.35569516336923906,"score_spread":0.3103343635197462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917278,0.0037334585,0.000015783711,0.0008846011,0.00076163874,0.0009867019,0.00007078368,0.000059432674,0.001759769],"genre_scores_gemma":[0.9950685,0.0018039005,0.000071068025,0.00011234671,0.000090554306,0.00014773596,0.000038692007,0.00005178537,0.0026154472],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99723494,0.00017560608,0.0006590304,0.00051127194,0.000747057,0.0006720688],"domain_scores_gemma":[0.99781036,0.00025634904,0.00030636965,0.000710889,0.00080065464,0.00011536886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018856492,0.0002132547,0.00057686074,0.00093548064,0.00014106641,0.000022883652,0.00039276763,0.0002326907,0.00084227],"category_scores_gemma":[0.00018646268,0.00018187883,0.00016633079,0.0016315788,0.0004997553,0.0001365824,0.00020819606,0.0006778697,0.00008277427],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067831315,0.00029236937,0.05347638,0.0005241912,0.00017531737,0.000047886904,0.0014249732,0.00004036167,0.9186228,0.0000018766217,0.009808988,0.008801741],"study_design_scores_gemma":[0.002477811,0.0009843288,0.4840657,0.0006028419,0.000020390087,0.0000050033077,0.0021834776,0.000022477867,0.506865,0.000012296344,0.0026270999,0.00013352963],"about_ca_topic_score_codex":0.0016942697,"about_ca_topic_score_gemma":0.00020215173,"teacher_disagreement_score":0.43058935,"about_ca_system_score_codex":0.00030983106,"about_ca_system_score_gemma":0.00075332745,"threshold_uncertainty_score":0.92222655},"labels":[],"label_agreement":null},{"id":"W4389241634","doi":"10.1158/2326-6074.tumimm23-b032","title":"Abstract B032: CD161+ TRM cells counteract HPV-associated clinical benefits in oropharyngeal cancer immunotherapy","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunotherapy; Cancer; Medicine; Cancer immunotherapy; CD8; Immunology; Cancer research; Context (archaeology); Immune system; Oncology; Biology; Internal medicine","score_opus":0.14820406812954517,"score_gpt":0.46991587073285385,"score_spread":0.32171180260330867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9538357,0.035214707,4.275876e-7,0.0055911853,0.002531069,0.0011762502,0.00019285607,0.00029125178,0.0011665127],"genre_scores_gemma":[0.8524166,0.1411352,0.000008353711,0.0009608799,0.00046391794,0.0007464696,0.000106877465,0.00016308742,0.003998669],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9943506,0.00060937565,0.0012905111,0.0010006344,0.00093484996,0.0018140074],"domain_scores_gemma":[0.9969159,0.0011304333,0.00025678286,0.00089089957,0.0006395095,0.00016648017],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004186705,0.00043001608,0.0011628304,0.0010311684,0.00027948347,0.000077166165,0.000703023,0.00078737224,0.004061939],"category_scores_gemma":[0.00023208615,0.0003906134,0.0004063414,0.002794345,0.0010235889,0.00022404258,0.00019570034,0.002563953,0.00041318985],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023710314,0.0013723497,0.13398859,0.00018466683,0.0026988958,0.0006388166,0.0014726778,0.000060425085,0.41738257,0.000046356356,0.049320593,0.36912376],"study_design_scores_gemma":[0.011512845,0.00087230507,0.9364033,0.0006171616,0.00003457414,0.000014592162,0.0005327279,0.00012253497,0.011344588,0.000055528428,0.038085617,0.0004042494],"about_ca_topic_score_codex":0.009810294,"about_ca_topic_score_gemma":0.002743901,"teacher_disagreement_score":0.8024147,"about_ca_system_score_codex":0.0016497948,"about_ca_system_score_gemma":0.0019845553,"threshold_uncertainty_score":0.99985456},"labels":[],"label_agreement":null},{"id":"W4389241744","doi":"10.1158/2326-6074.tumimm23-a043","title":"Abstract A043: Identifying critical vulnerabilities that sensitise <i>Lkb1</i>-mutant lung adenocarcinoma to T cell mediated killing","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"KRAS; Cancer research; Immune checkpoint; STK11; Biology; Adenocarcinoma; CD8; CRISPR; Immunotherapy; Cancer; Memory T cell; T cell; Immune system; Immunology; Gene; Genetics; Colorectal cancer","score_opus":0.11875345147917762,"score_gpt":0.4189211730398104,"score_spread":0.30016772156063276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95955646,0.021540817,0.000039811992,0.014916957,0.0014277356,0.0009081798,0.00009012282,0.00032009583,0.0011998443],"genre_scores_gemma":[0.9904317,0.0056195664,0.00006610603,0.0008979169,0.00033795706,0.00039633378,0.000075603304,0.000094521085,0.0020802687],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99559134,0.00035266418,0.00056360464,0.0008473556,0.0009808468,0.0016641739],"domain_scores_gemma":[0.9958539,0.0023350285,0.00006242535,0.0007957938,0.0006284451,0.00032442767],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022641332,0.00032302536,0.0006079673,0.0009821188,0.0006251013,0.00012553121,0.00040100105,0.00037889302,0.0015337346],"category_scores_gemma":[0.00086051313,0.00030067103,0.00021779186,0.0017586114,0.000982014,0.00019688616,0.0003278661,0.0014610777,0.0006501245],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004083404,0.00014717873,0.04159532,0.0008227362,0.0004541595,0.0013344856,0.0037354338,0.000015535654,0.92145383,0.000059720118,0.020029776,0.0062684366],"study_design_scores_gemma":[0.005198436,0.0008714032,0.57786465,0.0015716448,0.00013535621,0.00023397406,0.014897617,0.00057751534,0.37348446,0.00027668336,0.024001142,0.00088712334],"about_ca_topic_score_codex":0.0015768647,"about_ca_topic_score_gemma":0.00013493375,"teacher_disagreement_score":0.54796934,"about_ca_system_score_codex":0.0008486795,"about_ca_system_score_gemma":0.0007886723,"threshold_uncertainty_score":0.99994457},"labels":[],"label_agreement":null},{"id":"W4389241775","doi":"10.1158/2326-6074.tumimm23-a054","title":"Abstract A054: Anti-CTLA-4 generates memory T-cell with greater expansion and functionality than anti-PD-1","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytotoxic T cell; Memory T cell; Immunotherapy; Cancer immunotherapy; CD8; Immunology; Immune system; T cell; CTLA-4; Cancer research; Cancer; Antigen; Medicine; Biology; In vitro; Internal medicine; Biochemistry","score_opus":0.08523785618377776,"score_gpt":0.36477024238039285,"score_spread":0.2795323861966151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852055,0.008880933,0.0000025877473,0.0033550162,0.00036123232,0.0005026986,0.00003464565,0.00012609894,0.0015313053],"genre_scores_gemma":[0.98534477,0.008467152,0.000024115343,0.00022461255,0.00023329495,0.00018014516,0.000083825755,0.00004660008,0.0053954786],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99774975,0.00016438295,0.00027262574,0.00059881713,0.0004837728,0.0007306352],"domain_scores_gemma":[0.9988075,0.0001509756,0.00006379954,0.00051069283,0.0003550596,0.000111986905],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010363837,0.00022421755,0.00039008816,0.00042416403,0.00039699368,0.000052951134,0.00016588738,0.00023635142,0.0010207654],"category_scores_gemma":[0.000028701606,0.00016339727,0.00007617538,0.00088145206,0.0009943868,0.00013083649,0.00012762303,0.0006493868,0.00013220677],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038966867,0.0001076356,0.1441273,0.0002033687,0.00044104547,0.00017879443,0.00042852532,0.000009291232,0.83270395,0.0000066792472,0.007643252,0.010253498],"study_design_scores_gemma":[0.0033727929,0.00048611182,0.81052166,0.00015436576,0.000031664033,0.000081869475,0.0006828809,0.000023015851,0.18032815,0.000023129003,0.004109741,0.00018464515],"about_ca_topic_score_codex":0.0013504347,"about_ca_topic_score_gemma":0.00006865144,"teacher_disagreement_score":0.66639435,"about_ca_system_score_codex":0.0001793078,"about_ca_system_score_gemma":0.000534759,"threshold_uncertainty_score":0.9998924},"labels":[],"label_agreement":null},{"id":"W4389242999","doi":"10.1182/blood-2023-182536","title":"Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba; BC Cancer Agency; Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Cohort; Refractory (planetary science); Lymphoma; Diffuse large B-cell lymphoma; Gastroenterology; Neutropenia; Febrile neutropenia; Oncology; Phases of clinical research; Cancer; Chemotherapy; Immunotherapy","score_opus":0.02301311069555842,"score_gpt":0.3045561159586645,"score_spread":0.28154300526310605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389242999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99517494,0.0001629375,0.000002878802,0.000041619132,0.00012279527,0.0038902047,0.00010713722,0.00010938783,0.00038809952],"genre_scores_gemma":[0.9977819,0.00014416607,0.00011326092,0.00017487501,0.00003373705,0.00024198012,0.00020683199,0.00009244921,0.0012108046],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971864,0.0001300117,0.0007502927,0.00063502946,0.0007238918,0.0005743639],"domain_scores_gemma":[0.99841166,0.00010641248,0.00029279923,0.0008528531,0.00017836786,0.00015790717],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005325674,0.00036123738,0.00089842983,0.00036905773,0.00010408371,0.00003905458,0.00038426605,0.00015195111,0.000089408284],"category_scores_gemma":[0.00008039049,0.00026356394,0.000075489355,0.0010912548,0.0000961874,0.00018930972,0.0001846121,0.00019233374,0.000031883577],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06121693,0.30003244,0.62674904,0.00022020191,0.0011041419,0.0009836743,0.0020114554,4.0630465e-7,0.0042860545,0.0000014593179,0.0005255243,0.002868701],"study_design_scores_gemma":[0.5115266,0.007317689,0.4777856,0.00019189659,0.00045864104,0.000013830476,0.000673789,0.0000930344,0.001290038,4.772138e-7,0.00039417096,0.00025427926],"about_ca_topic_score_codex":0.0004642779,"about_ca_topic_score_gemma":0.00016542582,"teacher_disagreement_score":0.45030963,"about_ca_system_score_codex":0.00019206159,"about_ca_system_score_gemma":0.00052459084,"threshold_uncertainty_score":0.99998164},"labels":[],"label_agreement":null},{"id":"W4389279939","doi":"10.1016/j.annonc.2023.10.132","title":"LBA3 Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Triple-negative breast cancer; Placebo; Oncology; Internal medicine; Breast cancer; Subgroup analysis; Adjuvant; Chemotherapy; Adjuvant chemotherapy; Stage (stratigraphy); Cancer; Meta-analysis; Immunotherapy; Pathology","score_opus":0.06947741953422655,"score_gpt":0.4134884706244978,"score_spread":0.34401105109027125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389279939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98746675,0.00055061345,0.0002673661,0.003229027,0.00043129805,0.005280134,0.0022552372,0.00020333179,0.0003162452],"genre_scores_gemma":[0.98559004,0.0024573035,0.00009154365,0.0011170676,0.00020892468,0.0010743777,0.00028651932,0.00015606199,0.009018149],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948662,0.00041158134,0.0018238138,0.001023138,0.0007879834,0.0010873083],"domain_scores_gemma":[0.9954424,0.00119383,0.0013821924,0.0009044751,0.0007253968,0.00035169604],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001334095,0.0007015424,0.003126039,0.0010626003,0.00019565404,0.000026906093,0.00054606143,0.00045955315,0.001578334],"category_scores_gemma":[0.0002121211,0.0005178467,0.0010051347,0.0028378787,0.00045569477,0.00020222532,0.000109771594,0.00037967568,0.0000061564547],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84681493,0.005888479,0.002619238,0.00031985153,0.014088994,0.0003585229,0.011762368,0.00017090655,0.016101222,0.00000818156,0.044248264,0.05761904],"study_design_scores_gemma":[0.75662696,0.09715769,0.04911158,0.00042293008,0.0064163734,0.00015011898,0.01890495,0.007059922,0.03147079,0.000036225534,0.03098866,0.0016537936],"about_ca_topic_score_codex":0.0095848115,"about_ca_topic_score_gemma":0.00795158,"teacher_disagreement_score":0.09126921,"about_ca_system_score_codex":0.0004642082,"about_ca_system_score_gemma":0.0016634237,"threshold_uncertainty_score":0.9997273},"labels":[],"label_agreement":null},{"id":"W4389286306","doi":"10.1016/j.annonc.2023.10.349","title":"213P Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; BC Cancer Agency","funders":"Cilag; Daiichi Sankyo Europe; Astellas Pharma; Genentech; AstraZeneca; LEO Pharma; Seagen; Pfizer","keywords":"Medicine; Renal cell carcinoma; Lymphocyte; Oncology; Internal medicine; First line; Immunotherapy; Cancer","score_opus":0.04678872414601174,"score_gpt":0.29577311872238576,"score_spread":0.24898439457637403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389286306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935276,0.0006806407,0.00006306744,0.0021554972,0.00011026125,0.0013341728,0.0017731574,0.00002558943,0.00033004727],"genre_scores_gemma":[0.995873,0.0004048119,0.0004895578,0.0005590756,0.000028295175,0.00012916476,0.00226503,0.000039971594,0.00021113406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972044,0.00025959744,0.001040767,0.0004868907,0.0006319631,0.0003763662],"domain_scores_gemma":[0.99634564,0.0014192885,0.0009688379,0.00055084494,0.00064022717,0.00007514453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008671863,0.0002999102,0.00070519676,0.00028742172,0.00007277308,0.000015473546,0.00032894468,0.00007281534,0.00009183147],"category_scores_gemma":[0.00015551226,0.00019700754,0.000110318644,0.0007318868,0.0004508359,0.0001435699,0.000056719666,0.00019368863,0.0000072236735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37903357,0.0127615705,0.4776154,0.00116947,0.004016265,0.0011294262,0.01182897,0.0018971934,0.079320304,0.000054101347,0.017358381,0.013815364],"study_design_scores_gemma":[0.056483924,0.013339573,0.8602261,0.00046305775,0.00047172516,0.000012597524,0.00074203196,0.0011428483,0.06324663,0.00003449494,0.0035159346,0.00032110215],"about_ca_topic_score_codex":0.0056003304,"about_ca_topic_score_gemma":0.0015388045,"teacher_disagreement_score":0.38261068,"about_ca_system_score_codex":0.0002123749,"about_ca_system_score_gemma":0.00090992195,"threshold_uncertainty_score":0.8466062},"labels":[],"label_agreement":null},{"id":"W4389326973","doi":"10.1001/jamanetworkopen.2023.46094","title":"Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer","year":2023,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Ottawa; Hôpital du Sacré-Cœur de Montréal; Queen Elizabeth II Health Sciences Centre; Moncton Hospital; Juravinski Cancer Centre; Hôpital Charles-Le Moyne; St. John’s Health Sciences Centre; BC Cancer Agency; Hôtel-Dieu de Québec; Queen's University; Princess Margaret Cancer Centre; Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Tremelimumab; Durvalumab; Colorectal cancer; Internal medicine; Hazard ratio; Oncology; Microsatellite instability; Clinical endpoint; Cancer; Proportional hazards model; Randomized controlled trial; Immunotherapy; Confidence interval; Nivolumab; Ipilimumab","score_opus":0.020015842583654245,"score_gpt":0.2862240956349806,"score_spread":0.26620825305132634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389326973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99439275,0.002988659,0.0000012416497,0.0006099181,0.00017705798,0.0014178014,0.000036556827,0.00004048495,0.00033554572],"genre_scores_gemma":[0.99734825,0.0010163605,0.00033603265,0.00039964533,0.00014976657,0.00016906887,0.00014802029,0.000038606002,0.00039424465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986259,0.00012745168,0.00034401382,0.00031402928,0.00024030276,0.00034833746],"domain_scores_gemma":[0.9993393,0.00016287946,0.0001429324,0.0002002179,0.00006306632,0.00009162839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006735833,0.0001875551,0.0004442394,0.00009799822,0.00008435332,0.0000921659,0.0001448539,0.00005623969,0.00030724413],"category_scores_gemma":[0.000045922145,0.00013493809,0.000056376906,0.0007288771,0.00010463749,0.00024232741,0.00018594542,0.0002140923,0.000018999493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.082872644,0.0017632698,0.58898145,0.0003469272,0.0024004527,0.0004352553,0.0024707958,0.00034379607,0.0028049485,0.00003748105,0.025540024,0.29200298],"study_design_scores_gemma":[0.013308745,0.0008971882,0.9757301,0.00071768905,0.0001291467,0.0000046413393,0.000106882886,0.00012182916,0.00068314234,0.000007299108,0.008101587,0.00019173215],"about_ca_topic_score_codex":0.0013668624,"about_ca_topic_score_gemma":0.0005011443,"teacher_disagreement_score":0.3867487,"about_ca_system_score_codex":0.0001281812,"about_ca_system_score_gemma":0.0001388229,"threshold_uncertainty_score":0.55026156},"labels":[],"label_agreement":null},{"id":"W4389442794","doi":"10.1212/wnl.86.16_supplement.p3.026","title":"Patients Who Discontinued SC IFNB-1a and Switched to Alemtuzumab in the CARE-MS I Extension Study Show Durable Reduction in New Lesion Activity (P3.026)","year":2016,"lang":"en","type":"article","venue":"Neurology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"","keywords":"Alemtuzumab; Medicine; Lesion; Reduction (mathematics); Internal medicine; Surgery; Mathematics","score_opus":0.02176676223858798,"score_gpt":0.2829093017392405,"score_spread":0.2611425395006525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389442794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98962456,0.000105868596,0.000010541225,0.008783449,0.0002991552,0.0010903833,0.0000020931175,0.000015099424,0.00006885375],"genre_scores_gemma":[0.998797,0.00008512025,0.000007546217,0.000820167,0.000077611316,0.000029518724,0.0000024338483,0.000014429397,0.00016619773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874103,0.00025435453,0.00020229745,0.00039791194,0.00016755339,0.0002368518],"domain_scores_gemma":[0.99945474,0.000079335645,0.00006474101,0.0003127337,0.00003468152,0.000053799027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023843175,0.00013545182,0.00025971443,0.00014907382,0.000049410068,0.000011249138,0.00008238526,0.0000968727,0.000022015874],"category_scores_gemma":[0.00006791212,0.000078096156,0.000033021002,0.00021811131,0.00004900757,0.00010063123,0.00004674322,0.00017847562,0.0000040824743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034280248,0.0006439469,0.43325794,0.000014699856,0.000019677096,0.00005726285,0.006158535,0.0000016327784,0.26800922,0.000002276077,0.0010190669,0.2565355],"study_design_scores_gemma":[0.0073542623,0.006090549,0.9827464,0.00004758035,0.000018143925,0.00002701748,0.00021780007,0.0000065627014,0.0019796307,0.000015790172,0.0014092867,0.00008696834],"about_ca_topic_score_codex":0.0023543292,"about_ca_topic_score_gemma":0.0037967686,"teacher_disagreement_score":0.5494885,"about_ca_system_score_codex":0.00006438107,"about_ca_system_score_gemma":0.000060924598,"threshold_uncertainty_score":0.35590574},"labels":[],"label_agreement":null},{"id":"W4389445517","doi":"10.1212/wnl.96.15_supplement.4927","title":"Antigen-presenting cells from PD patients exhibit an autoinflammatory cytokine profile (4927)","year":2021,"lang":"en","type":"article","venue":"Neurology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Cytokine; Antigen; Medicine; Immunology","score_opus":0.012497655126201799,"score_gpt":0.24833566919703076,"score_spread":0.23583801407082897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389445517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99594307,0.00025272535,0.000015517486,0.0005981855,0.0009632439,0.00023014894,0.000048161568,0.000098121374,0.0018508228],"genre_scores_gemma":[0.99465126,0.00012382714,0.00033081628,0.0038532412,0.00036930732,0.000014899567,0.00026436758,0.000039198665,0.00035310426],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985795,0.00014582738,0.0002978077,0.00045437398,0.00020004554,0.0003224204],"domain_scores_gemma":[0.99915296,0.00006171796,0.00010446403,0.00047067826,0.00010723898,0.00010295112],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008495602,0.00015430425,0.0002794536,0.00006355154,0.00008041856,0.00001799803,0.00010507421,0.00016378482,0.0016306943],"category_scores_gemma":[0.000034197255,0.00014828982,0.00010228519,0.00014629817,0.0000804896,0.00008087731,0.00007974921,0.00025506414,0.00009840769],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019171971,0.00035219552,0.21330336,0.000023162078,0.000097601864,0.00062776095,0.00022244277,0.0000022401346,0.76984364,0.000006545456,0.0025698284,0.011034013],"study_design_scores_gemma":[0.003094348,0.00067167287,0.68378395,0.0000130356175,0.000028910305,0.0000353714,0.000013178306,0.00018988222,0.23987086,0.000024563033,0.07212847,0.0001457293],"about_ca_topic_score_codex":0.00017178571,"about_ca_topic_score_gemma":0.00008153605,"teacher_disagreement_score":0.5299728,"about_ca_system_score_codex":0.00001720109,"about_ca_system_score_gemma":0.00012177374,"threshold_uncertainty_score":0.99928194},"labels":[],"label_agreement":null},{"id":"W4389460714","doi":"10.1212/wnl.94.15_supplement.2723","title":"Blood pressure changes during Alemtuzumab infusion for persons with MS (2723)","year":2020,"lang":"en","type":"article","venue":"Neurology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Alemtuzumab; Medicine; Blood pressure; Internal medicine","score_opus":0.016643259793583665,"score_gpt":0.23976135999821063,"score_spread":0.22311810020462697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389460714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.958122,0.0009137645,0.000022780287,0.03996479,0.00009147572,0.00045771393,0.000021084137,0.000078036974,0.00032833318],"genre_scores_gemma":[0.9874677,0.00011425227,0.00010661406,0.011630133,0.00034718626,0.000060408285,0.000011716719,0.000025777896,0.00023621715],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.999366,0.000020578183,0.00008070335,0.00024795817,0.00008336801,0.00020143458],"domain_scores_gemma":[0.9996895,0.00003479187,0.000044805503,0.0001318945,0.000026334126,0.00007268257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000029352093,0.00010317438,0.00018133219,0.00003559064,0.00006740454,0.0000055824858,0.00006109685,0.000089960864,0.00016562418],"category_scores_gemma":[0.000019073716,0.000078737816,0.00004829823,0.00008671981,0.000059852176,0.000019645053,0.000022792252,0.00013821169,0.0000029590517],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08617326,0.00023051133,0.019654753,0.00086964434,0.0010447548,0.00031931655,0.0032225782,0.000020748663,0.8775032,0.00003759639,0.003866095,0.0070575355],"study_design_scores_gemma":[0.029482504,0.040216528,0.17406826,0.00006695957,0.0016771263,0.0011862746,0.00006632313,0.0006417454,0.08113112,0.0000086632035,0.6710427,0.0004117962],"about_ca_topic_score_codex":0.00006396545,"about_ca_topic_score_gemma":0.0001127871,"teacher_disagreement_score":0.79637206,"about_ca_system_score_codex":0.000002516567,"about_ca_system_score_gemma":0.0000355097,"threshold_uncertainty_score":0.3210835},"labels":[],"label_agreement":null},{"id":"W4389480683","doi":"10.1016/j.iotech.2023.100693","title":"LBA3 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic NSCLC (mNSCLC): 5-year (y) overall survival (OS) update from the POSEIDON study","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Internal medicine; Durvalumab; Regimen; Chemotherapy; Gastroenterology; Progression-free survival; Nuclear medicine; Confidence interval; Oncology; Immunotherapy; Pembrolizumab; Cancer","score_opus":0.025379405179619445,"score_gpt":0.3139009496148696,"score_spread":0.28852154443525013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389480683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95097107,0.0036162017,0.00004327789,0.0403178,0.0013715292,0.002250215,0.000069446956,0.0008400572,0.0005204048],"genre_scores_gemma":[0.9919168,0.0046182442,0.00030337812,0.0016923987,0.00017737281,0.00044778624,0.00018843738,0.0001338703,0.00052174466],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995767,0.000464225,0.0012077213,0.0009952752,0.0004938462,0.0010719132],"domain_scores_gemma":[0.99683475,0.00082676933,0.00039172056,0.0017228685,0.00014201872,0.00008184253],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016124569,0.0006060202,0.0014191103,0.00089810725,0.0003158675,0.000039410523,0.0010493473,0.0004411705,0.001198363],"category_scores_gemma":[0.00033185625,0.00046450866,0.00031526963,0.0024387885,0.00076021964,0.00013100024,0.00034831985,0.0011556677,0.00045661503],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053025354,0.011500419,0.2505793,0.00014103147,0.010332306,0.006113156,0.006473698,0.00013667702,0.12208988,0.0018678268,0.022494433,0.5152459],"study_design_scores_gemma":[0.14325523,0.012354636,0.4292913,0.00045860646,0.001171693,0.0006990294,0.018726792,0.00084399333,0.008427606,0.009391535,0.3734807,0.0018988689],"about_ca_topic_score_codex":0.0025711185,"about_ca_topic_score_gemma":0.0060787974,"teacher_disagreement_score":0.513347,"about_ca_system_score_codex":0.0008040701,"about_ca_system_score_gemma":0.00048521018,"threshold_uncertainty_score":0.99978065},"labels":[],"label_agreement":null},{"id":"W4389484114","doi":"10.1186/s12885-023-11672-x","title":"Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study","year":2023,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics","keywords":"Medicine; Immunotherapy; Head and neck squamous-cell carcinoma; Tumor microenvironment; Surgical oncology; Immune system; Oncology; Cancer research; Immune checkpoint; Immunology; Internal medicine; Radiation therapy; Head and neck cancer","score_opus":0.01764889940321762,"score_gpt":0.2861607559540882,"score_spread":0.26851185655087056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389484114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812294,0.015858235,0.000038103706,0.0002744725,0.00024041736,0.002233482,0.00004866544,0.00004103724,0.000036145568],"genre_scores_gemma":[0.9968149,0.0012234088,0.00024606855,0.00008000014,0.000059360405,0.00040924392,0.000013409811,0.000051373892,0.0011022026],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99871904,0.000039914907,0.00040465491,0.0003172295,0.00020246362,0.00031672916],"domain_scores_gemma":[0.99925894,0.00009040494,0.00017043014,0.00041173032,0.000032374704,0.000036101777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003042252,0.00019403451,0.00034847346,0.00009217704,0.00018165882,0.000016071454,0.00012965214,0.000054938595,0.00004524055],"category_scores_gemma":[0.000007824935,0.00014003669,0.00016002553,0.00026167298,0.00010721168,0.000041323936,0.00005594887,0.00011334204,0.000002789947],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003408806,0.00030044434,0.20995224,0.0005848028,0.000110663204,0.000005513899,0.0019185991,0.000079435034,0.7817943,0.0000010849525,0.000059667233,0.0017844556],"study_design_scores_gemma":[0.010403726,0.0005769457,0.89704466,0.000066416986,0.000103269354,0.000009389744,0.0022557562,0.00043336223,0.088487476,0.0000031761354,0.00045936808,0.00015647711],"about_ca_topic_score_codex":0.000852039,"about_ca_topic_score_gemma":0.00017572376,"teacher_disagreement_score":0.6933068,"about_ca_system_score_codex":0.00018676669,"about_ca_system_score_gemma":0.00009580527,"threshold_uncertainty_score":0.571053},"labels":[],"label_agreement":null},{"id":"W4389488043","doi":"10.1016/j.iotech.2023.100537","title":"65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Docetaxel; Medicine; Lenvatinib; Oncology; Chemotherapy; Internal medicine; Lung cancer; Phases of clinical research; Cancer; Immunotherapy","score_opus":0.04270142033337985,"score_gpt":0.3679328438520774,"score_spread":0.32523142351869755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389488043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879132,0.003296883,0.00011381265,0.0019404311,0.0008355594,0.0051785605,0.000054660006,0.00038982567,0.00027704876],"genre_scores_gemma":[0.9949264,0.0008602545,0.0007256438,0.00030615815,0.00010308166,0.0026226921,0.00005046135,0.00010675107,0.00029854843],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997198,0.00010022684,0.0008653952,0.00077437074,0.00026531637,0.0007967271],"domain_scores_gemma":[0.99771285,0.0006392341,0.0006901867,0.0006811291,0.0001951902,0.00008140013],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063056324,0.0005054331,0.0014258315,0.0009695114,0.00025716,0.00002048339,0.0003580751,0.00052834325,0.00007846915],"category_scores_gemma":[0.00010439849,0.00045208153,0.00019225711,0.0010040961,0.00056432217,0.00008458404,0.00014022486,0.0005437829,0.0000038249814],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29053792,0.0056739547,0.0076256795,0.00092052587,0.005150198,0.00035773104,0.017990284,0.000029996289,0.38541147,0.000111273774,0.0026675921,0.28352338],"study_design_scores_gemma":[0.6193648,0.09214257,0.00325797,0.000783885,0.0018045312,0.00016766788,0.04153956,0.0029831969,0.22473189,0.000112528236,0.0119778365,0.0011335675],"about_ca_topic_score_codex":0.00024783477,"about_ca_topic_score_gemma":0.00026383318,"teacher_disagreement_score":0.32882687,"about_ca_system_score_codex":0.000536883,"about_ca_system_score_gemma":0.0007845883,"threshold_uncertainty_score":0.9997931},"labels":[],"label_agreement":null},{"id":"W4389504875","doi":"10.1093/jnci/djad240","title":"Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355","year":2023,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Merck","keywords":"Medicine; Pembrolizumab; Carboplatin; Internal medicine; Breast cancer; Chemotherapy; Quality of life (healthcare); Gemcitabine; Placebo; Oncology; Cancer; Clinical endpoint; Clinical trial; Immunotherapy; Pathology","score_opus":0.051891146061795866,"score_gpt":0.36837930499250593,"score_spread":0.3164881589307101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389504875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89789814,0.0029057087,0.00042815157,0.09192289,0.0029941765,0.0023524782,0.0011424982,0.000065998094,0.00028995634],"genre_scores_gemma":[0.9841756,0.0045119654,0.0006876359,0.0076122982,0.0010228155,0.00017946505,0.000028764003,0.00007105389,0.001710399],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99630475,0.0001253302,0.0014239518,0.00030045424,0.0014460202,0.00039949224],"domain_scores_gemma":[0.9955153,0.00026594542,0.0022143286,0.000229261,0.0015686636,0.00020651359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013411487,0.00032649926,0.0011132933,0.00030626514,0.0002766952,0.000024773002,0.00041401648,0.00015392234,0.00017514486],"category_scores_gemma":[0.0002443097,0.00021351567,0.0005229433,0.0012012665,0.0003902571,0.0003500245,0.000026869342,0.00045039767,0.0000015080709],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7748876,0.0005881989,0.0067097167,0.0015625543,0.0077846367,0.000011788595,0.0064340583,0.04657476,0.01800604,0.00087595586,0.06371053,0.072854124],"study_design_scores_gemma":[0.34982452,0.0032815947,0.5579271,0.004882918,0.00042968552,0.0007122176,0.00086332974,0.0041789543,0.0179711,0.0016812541,0.056977652,0.0012696873],"about_ca_topic_score_codex":0.0016870762,"about_ca_topic_score_gemma":0.0009564493,"teacher_disagreement_score":0.5512174,"about_ca_system_score_codex":0.0027749215,"about_ca_system_score_gemma":0.009171784,"threshold_uncertainty_score":0.9964453},"labels":[],"label_agreement":null},{"id":"W4389599797","doi":"10.3390/curroncol30120757","title":"Durvalumab-Associated Pneumonitis in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Real-World Population Study","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Durvalumab; Medicine; Pneumonitis; Lung cancer; Population; Internal medicine; Atezolizumab; Radiation Pneumonitis; Oncology; Cancer; Lung; Pembrolizumab; Immunotherapy; Environmental health","score_opus":0.03257175949043568,"score_gpt":0.364190985565024,"score_spread":0.3316192260745883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389599797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958529,0.00024205433,0.0000038853,0.00018653051,0.0010130147,0.0020974402,0.000027931883,0.000109175584,0.00046708668],"genre_scores_gemma":[0.99826527,0.00050855987,0.000016681764,0.00006431134,0.00006151421,0.00036509827,0.0003320036,0.00003551612,0.0003510238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983478,0.00014131317,0.00044783743,0.0003845186,0.00027161976,0.00040687827],"domain_scores_gemma":[0.99923664,0.000075858305,0.00023773643,0.00021317745,0.000151613,0.00008494245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027761943,0.00020083741,0.00048058422,0.00035970888,0.00007460417,0.000009743985,0.000098399214,0.0000874681,0.000058900183],"category_scores_gemma":[0.000023263763,0.00017406276,0.0000643033,0.0011510551,0.00003835444,0.00006168456,0.000043525208,0.00027966622,0.0000102628765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026716208,0.0019453886,0.92237246,0.00008506559,0.00008403106,0.000033517306,0.0009143351,0.00006543442,0.00009114815,7.230191e-7,0.00044659982,0.07128966],"study_design_scores_gemma":[0.020767026,0.0024566108,0.9742996,0.00035089275,0.00012096413,4.2731963e-7,0.00028796197,0.0005261628,0.000019480609,0.0000031161373,0.0009824885,0.00018527568],"about_ca_topic_score_codex":0.0023022988,"about_ca_topic_score_gemma":0.021004599,"teacher_disagreement_score":0.071104385,"about_ca_system_score_codex":0.0014465719,"about_ca_system_score_gemma":0.0003122412,"threshold_uncertainty_score":0.9968595},"labels":[],"label_agreement":null},{"id":"W4389609207","doi":"10.1038/s41540-023-00322-4","title":"Mesenchymal ovarian cancer cells promote CD8+ T cell exhaustion through the LGALS3-LAG3 axis","year":2023,"lang":"en","type":"article","venue":"npj Systems Biology and Applications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Institute of Infection and Immunity; University of Ottawa","funders":"Natural Sciences and Engineering Research Council of Canada; Government of Canada","keywords":"Mesenchymal stem cell; Cancer research; CD8; Cytotoxic T cell; Tumor microenvironment; Ovarian cancer; Immune system; Biology; Cancer cell; Epithelial–mesenchymal transition; Immunology; Cancer; Medicine; Cell biology; In vitro; Internal medicine; Metastasis","score_opus":0.02402473781975536,"score_gpt":0.3145100096311011,"score_spread":0.29048527181134576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389609207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8277717,0.040528137,0.02125988,0.052734446,0.004458662,0.016841354,0.0009368194,0.0014860067,0.033982966],"genre_scores_gemma":[0.9904536,0.0018640485,0.00006744876,0.00034034927,0.0005427741,0.0016176235,0.00010378204,0.000015438616,0.004994926],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990682,0.00006794215,0.00025748453,0.00030199563,0.0000757779,0.00022862696],"domain_scores_gemma":[0.9993805,0.00006697789,0.00010873829,0.00033662515,0.00006008416,0.00004705818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027772854,0.00013083425,0.00020357163,0.000046870187,0.00032757147,0.00002067302,0.0001051251,0.00018654128,0.00006972901],"category_scores_gemma":[0.000004182191,0.000083344494,0.000062264175,0.00041623227,0.0002473468,0.00003468475,0.000031135412,0.00014708455,0.0000965026],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002697755,0.00014670969,0.0042843223,0.0003826854,0.00030335117,0.0000037739387,0.0012517632,0.000029246381,0.93628216,0.012878443,0.023656292,0.02051147],"study_design_scores_gemma":[0.0012359143,0.00015841812,0.009022704,0.000078266006,0.00013534776,0.00004245038,0.0007904722,0.00036362323,0.017295431,0.0007152756,0.96995926,0.00020285284],"about_ca_topic_score_codex":0.0011135103,"about_ca_topic_score_gemma":0.000036353875,"teacher_disagreement_score":0.94630295,"about_ca_system_score_codex":0.000039470535,"about_ca_system_score_gemma":0.00007278046,"threshold_uncertainty_score":0.33986896},"labels":[],"label_agreement":null},{"id":"W4389776065","doi":"10.1016/j.jtbi.2023.111704","title":"IL-27 in combination with anti-PD-1 can be anti-cancer or pro-cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Theoretical Biology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Division of Mathematical Sciences; Natural Sciences and Engineering Research Council of Canada; National Cancer Institute; University of Manitoba; Ohio State University","keywords":"Cancer; Cancer immunotherapy; Melanoma; Immunotherapy; Function (biology); Immune system; Cancer research; Cancer therapy; Cancer cell; Medicine; Immunology; Internal medicine; Biology; Cell biology","score_opus":0.024630732008078773,"score_gpt":0.3368610572972207,"score_spread":0.31223032528914196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389776065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96224374,0.0004191208,0.00005045207,0.03624745,0.0004965026,0.00022248019,0.00003060384,0.000018014958,0.0002716329],"genre_scores_gemma":[0.9946057,0.0032376116,0.00010797207,0.0015660054,0.00019023857,0.000012303811,0.000009544833,0.000017532851,0.00025305132],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988431,0.00011887174,0.00042081822,0.00015452444,0.00017467867,0.0002880201],"domain_scores_gemma":[0.9992638,0.00016203514,0.00020800086,0.000118943106,0.00015675096,0.00009046228],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005894202,0.00013238577,0.00046210032,0.00026164536,0.000032192347,0.0000106263515,0.00012946795,0.00014808719,0.0009916376],"category_scores_gemma":[0.00012032134,0.00007199254,0.00009687585,0.00052641047,0.0006199891,0.000041761094,0.000025441645,0.0003141709,0.000004345412],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04091921,0.00112938,0.35568875,0.0003019956,0.001360851,0.0007020866,0.0011449264,0.00003658419,0.449175,0.076446146,0.008993342,0.064101726],"study_design_scores_gemma":[0.066368505,0.026401909,0.551502,0.0035556888,0.0009272892,0.0018621224,0.0019949614,0.0011145779,0.22720529,0.030358182,0.08728642,0.0014230649],"about_ca_topic_score_codex":0.000040211096,"about_ca_topic_score_gemma":0.000044514207,"teacher_disagreement_score":0.2219697,"about_ca_system_score_codex":0.00013408472,"about_ca_system_score_gemma":0.00030082875,"threshold_uncertainty_score":0.9999216},"labels":[],"label_agreement":null},{"id":"W4389794710","doi":"10.21203/rs.3.rs-3701293/v1","title":"A phase 2 trial of peri-operative avelumab and chemotherapy for locally advanced gastro-esophageal adenocarcinoma: Association of AGR2/AP-1 complex CD8 T-cells and M2-Tumour Associated Macrophages with treatment response","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Fondation de l'Hôpital Général de Montréal; U.S. Army Medical Research Acquisition Activity; EMD Serono; McGill University Health Centre; Merck KGaA","keywords":"Avelumab; Medicine; Neoadjuvant therapy; Docetaxel; Oncology; Adenocarcinoma; Immunotherapy; CD8; Internal medicine; Chemotherapy; Nivolumab; Cancer research; Immune system; Immunology; Cancer","score_opus":0.060378650443087406,"score_gpt":0.404917345697739,"score_spread":0.34453869525465164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389794710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879001,0.0013595648,0.00010776255,0.0014612883,0.000084132196,0.006745823,0.0022775119,0.00004368565,0.000020128438],"genre_scores_gemma":[0.9930131,0.0021057168,0.00078306685,0.000029898514,0.00011629709,0.0007132684,0.00049171795,0.00009261894,0.0026543175],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960145,0.00091840053,0.00069246424,0.00073203695,0.0010491171,0.0005935245],"domain_scores_gemma":[0.99633634,0.001398154,0.0005599304,0.00040302225,0.0011179716,0.00018455411],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026425791,0.00041630925,0.0012510684,0.000437092,0.00018505938,0.00006709597,0.00014653555,0.00036554757,0.000051761468],"category_scores_gemma":[0.0004927104,0.00032849383,0.00024951703,0.00038364195,0.0003962102,0.000058737856,0.00012330164,0.0004888416,9.376147e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.716317,0.002924691,0.0027861327,0.0011421681,0.002154097,0.00007977102,0.0044530206,0.00001685898,0.2626277,0.000004677627,0.0006821372,0.0068117785],"study_design_scores_gemma":[0.6195862,0.1134123,0.1491186,0.0029359187,0.00050188723,0.00001621855,0.0043626623,0.0015034816,0.10740888,0.000066095505,0.00050138676,0.0005863124],"about_ca_topic_score_codex":0.0003873506,"about_ca_topic_score_gemma":0.00013971339,"teacher_disagreement_score":0.1552188,"about_ca_system_score_codex":0.0013517241,"about_ca_system_score_gemma":0.0012974931,"threshold_uncertainty_score":0.99991673},"labels":[],"label_agreement":null},{"id":"W4389888978","doi":"10.3390/curroncol30120766","title":"Exploring a Rarity: Incidence of and Therapeutic Approaches for Neurological Complications and Hypophysitis in Cancer Patients on Immune Checkpoint Inhibitors—A Single-Center Study","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Hypophysitis; Adverse effect; Incidence (geometry); Internal medicine; Regimen; Oncology; Cancer; Immunotherapy; Hormone","score_opus":0.44489199227128917,"score_gpt":0.4050773246467166,"score_spread":0.039814667624572586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389888978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996687,0.0007337599,0.000005198022,0.0010143468,0.000262028,0.001239009,0.000016647613,0.000020328089,0.000021707383],"genre_scores_gemma":[0.9985768,0.00042932894,0.000014931827,0.000079958234,0.00003775786,0.00083217,0.000017521115,0.000009244791,0.0000022606841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991192,0.000072847826,0.0003085031,0.0002532287,0.00009090948,0.00015527212],"domain_scores_gemma":[0.99956095,0.00014901384,0.00010328215,0.00011114983,0.00004084135,0.000034748584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018603036,0.00010181859,0.00027726442,0.00013028867,0.000049411028,0.000005570598,0.000045871904,0.00004034635,0.0000020781877],"category_scores_gemma":[0.000036718913,0.00008397903,0.00004414987,0.00019899973,0.00012405193,0.000037219543,0.00006024092,0.00012981512,5.111609e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016189227,0.003729478,0.5425925,0.00010851961,0.00004937793,0.000001975095,0.0025762792,0.0000028314614,0.0033323236,0.000019066993,0.000016097816,0.44595256],"study_design_scores_gemma":[0.0055601657,0.0045239483,0.98724014,0.000109916604,0.00003310565,0.0000030256197,0.00050181686,0.00053712685,0.00027973548,0.000058624562,0.001077163,0.00007523765],"about_ca_topic_score_codex":0.00004258241,"about_ca_topic_score_gemma":0.000060611947,"teacher_disagreement_score":0.44587734,"about_ca_system_score_codex":0.00007814237,"about_ca_system_score_gemma":0.000032416843,"threshold_uncertainty_score":0.34245655},"labels":[],"label_agreement":null},{"id":"W4389892676","doi":"10.1158/2326-6066.cir-23-0498","title":"Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research; Legend Biotech; Juno Therapeutics; Genentech; National Institutes of Health; National Cancer Institute; Natera; Regeneron Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Amgen; Society of Memorial Sloan Kettering; Seres Therapeutics; Da Volterra; BeiGene; Cycle for Survival; Daiichi Sankyo Europe; Sanofi; Eli Lilly and Company; AstraZeneca; National Institute on Aging; Parker Institute for Cancer Immunotherapy","keywords":"Dysbiosis; Fecal bacteriotherapy; Microbiome; Medicine; Feces; Gut flora; Context (archaeology); Colitis; Transplantation; Immunology; Internal medicine; Inflammatory bowel disease; Gastroenterology; Antibiotics; Clostridium difficile; Disease; Biology; Microbiology; Bioinformatics","score_opus":0.03188858580801742,"score_gpt":0.3309719139326852,"score_spread":0.2990833281246678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389892676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97387826,0.006195221,0.0000012047851,0.017222844,0.00023702248,0.00086826616,0.0011676194,0.00017947718,0.00025007004],"genre_scores_gemma":[0.9785977,0.01214756,0.0000091971615,0.000740262,0.000037427842,0.00020097349,0.001485463,0.00007507454,0.00670634],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99704343,0.00041863142,0.0004703349,0.00063585164,0.0003812058,0.0010505558],"domain_scores_gemma":[0.99873316,0.00027833358,0.000107504864,0.00034250706,0.00039291376,0.00014559079],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008447147,0.00029188648,0.0005436067,0.00045469607,0.0004821759,0.00006522509,0.00021895253,0.00055291306,0.0006967626],"category_scores_gemma":[0.000065425615,0.00025986534,0.00011761852,0.0018121599,0.0016355449,0.00008208972,0.0000699822,0.00096787594,0.000029462062],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064815357,0.00012182679,0.0057923137,0.00010299489,0.0017699191,0.00018655184,0.0020107934,3.1396766e-7,0.9494367,0.000010370038,0.030194113,0.003892551],"study_design_scores_gemma":[0.023382748,0.0022889022,0.34469315,0.0012666732,0.00034959966,0.00065750704,0.0011817536,0.00006991643,0.60958856,0.000031083666,0.01580206,0.0006880681],"about_ca_topic_score_codex":0.004160872,"about_ca_topic_score_gemma":0.0008277658,"teacher_disagreement_score":0.33984816,"about_ca_system_score_codex":0.00060879823,"about_ca_system_score_gemma":0.00063829665,"threshold_uncertainty_score":0.99998534},"labels":[],"label_agreement":null},{"id":"W4390004386","doi":"10.1080/2162402x.2023.2290787","title":"A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies","year":2023,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Society for Immunotherapy of Cancer; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Rash; Internal medicine; Renal cell carcinoma; Oncology; Melanoma; Nausea; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Adverse effect; Cancer; Phases of clinical research; Nivolumab; Immunotherapy; Clinical trial; Cancer research","score_opus":0.026400031308302294,"score_gpt":0.3339655591300359,"score_spread":0.3075655278217336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390004386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99701554,0.00022177862,0.000004788697,0.00017260421,0.00014382982,0.0022555098,0.000017595998,0.000043583375,0.00012475018],"genre_scores_gemma":[0.9991635,0.00020207338,0.00012553656,0.000090076486,0.000004027186,0.00015040296,0.00012956122,0.000034683417,0.00010010735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833107,0.00012800739,0.00052020326,0.00038932322,0.00024716463,0.00038420403],"domain_scores_gemma":[0.9990967,0.00005564822,0.00024697985,0.0004154146,0.00015687509,0.00002840451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023664934,0.00022330348,0.00071483426,0.00046762335,0.000052426585,0.000015380381,0.00023179679,0.00009804901,0.00002300198],"category_scores_gemma":[0.000034532673,0.00017459324,0.000021208589,0.0010966468,0.00017981022,0.00022098687,0.00010398266,0.00019745436,0.000006925121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07100174,0.07569356,0.76251525,0.00015571131,0.0004970232,0.00033361078,0.0067287465,0.000043223346,0.046871196,0.000021798129,0.00005934128,0.03607878],"study_design_scores_gemma":[0.24966434,0.02199722,0.72253674,0.0004286047,0.00004240246,0.0000072938074,0.003096535,0.00014865039,0.0017661012,0.000003820307,0.00013374341,0.00017457388],"about_ca_topic_score_codex":0.0007923762,"about_ca_topic_score_gemma":0.0009356296,"teacher_disagreement_score":0.1786626,"about_ca_system_score_codex":0.00017331797,"about_ca_system_score_gemma":0.00014767653,"threshold_uncertainty_score":0.71197057},"labels":[],"label_agreement":null},{"id":"W4390005679","doi":"10.3390/curroncol31010001","title":"Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune Response","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Immune system; Immune checkpoint; Immunotherapy; Tumor microenvironment; Medicine; Oncolytic virus; Immunology; Cancer; Cancer immunotherapy; Antigen; Cancer research; Internal medicine","score_opus":0.1429423087106384,"score_gpt":0.42384739786566034,"score_spread":0.28090508915502194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390005679","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00054134364,0.9869791,0.0001926227,0.0021867657,0.0067851967,0.0028464089,0.00005965146,0.00021490638,0.00019399141],"genre_scores_gemma":[0.0001530674,0.9955363,0.00022043793,0.00023807537,0.0008352493,0.00073240924,0.000093028066,0.00018188545,0.0020094982],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947411,0.0010507576,0.0020272394,0.0008715522,0.0004913227,0.00081804546],"domain_scores_gemma":[0.9962789,0.001164318,0.0009774737,0.0012520185,0.00014324134,0.00018405307],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004241122,0.0007316074,0.0029979125,0.00055150635,0.00033427536,0.00006314476,0.00066383596,0.000367283,0.00014972482],"category_scores_gemma":[0.00077243836,0.0004989787,0.0014352608,0.0013123594,0.00019883722,0.000060102095,0.00044581623,0.0013688449,0.0003681558],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044972273,0.0003228642,0.0000015442056,0.01403262,0.00085207674,0.00035584028,0.0008588207,3.333599e-7,0.0044240532,0.000103706814,0.006403802,0.9681471],"study_design_scores_gemma":[0.0014773981,0.0004114438,0.000120025885,0.037501186,0.0008435118,0.00024328909,0.00023081191,0.0000021041546,0.00022206249,0.000060795817,0.95839626,0.0004911226],"about_ca_topic_score_codex":0.000043054253,"about_ca_topic_score_gemma":0.000019852967,"teacher_disagreement_score":0.967656,"about_ca_system_score_codex":0.0020516263,"about_ca_system_score_gemma":0.0017864555,"threshold_uncertainty_score":0.9997462},"labels":[],"label_agreement":null},{"id":"W4390129317","doi":"10.1016/j.ejca.2023.113505","title":"The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Immunotherapy; Medicine; Adverse effect; Side effect (computer science); Internal medicine; Oncology; Immune system; Immunology","score_opus":0.01502355529334317,"score_gpt":0.3225996918108311,"score_spread":0.30757613651748794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390129317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97489816,0.019857526,0.00030497953,0.0013558366,0.0012739169,0.0013263645,0.000013224476,0.000035887922,0.0009340998],"genre_scores_gemma":[0.99518657,0.0028132955,0.000078387304,0.00036353155,0.00032298462,0.00006593911,0.000004674808,0.000065323526,0.001099312],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99684227,0.0010269197,0.0012043031,0.00017052256,0.00043562122,0.000320381],"domain_scores_gemma":[0.99550474,0.0021045164,0.0014412407,0.00052259135,0.00035621264,0.00007072915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00474479,0.00022487395,0.0011790917,0.00037752482,0.00015379314,0.00004244009,0.0003806383,0.00005473674,0.000018986415],"category_scores_gemma":[0.0007164396,0.00013010214,0.0010942097,0.0010944668,0.00011515172,0.00006788369,0.000032325515,0.0002329775,0.0000058987985],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014751469,0.00007443071,0.0010914339,0.004689445,0.021237578,0.00033615314,0.00110371,0.00011154227,0.7849292,0.0000109329985,0.0023410872,0.16932303],"study_design_scores_gemma":[0.05669533,0.029907418,0.43128672,0.04966207,0.032139514,0.0008547275,0.0021064854,0.001403743,0.31234476,0.00004713307,0.08217061,0.0013814694],"about_ca_topic_score_codex":0.000032147454,"about_ca_topic_score_gemma":0.00003409889,"teacher_disagreement_score":0.47258443,"about_ca_system_score_codex":0.0002753487,"about_ca_system_score_gemma":0.00029661047,"threshold_uncertainty_score":0.5305411},"labels":[],"label_agreement":null},{"id":"W4390372702","doi":"10.1016/j.jtho.2023.12.023","title":"Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Eisai","keywords":"Pembrolizumab; Medicine; Lenvatinib; Internal medicine; Placebo; Adverse effect; Oncology; Randomized controlled trial; Nivolumab; Gastroenterology; Immunotherapy; Cancer; Pathology","score_opus":0.09940783536830322,"score_gpt":0.4412411812161992,"score_spread":0.341833345847896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390372702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98736197,0.00038028613,0.00245589,0.0019313127,0.0003865913,0.0072920634,0.000025049163,0.000040274826,0.00012655686],"genre_scores_gemma":[0.99003655,0.00020283426,0.0067249876,0.00014831583,0.00048679762,0.0006250451,0.000065393346,0.000075244985,0.0016348269],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966384,0.00023275753,0.0016586753,0.00031969443,0.0006788002,0.00047164602],"domain_scores_gemma":[0.99537617,0.00055344,0.0027717105,0.00026139358,0.00081005396,0.00022720477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028481458,0.0003540041,0.0022300777,0.0005083963,0.00014434294,0.000026590225,0.00018204108,0.00013881388,0.00009892907],"category_scores_gemma":[0.00021157657,0.00018634654,0.00047717214,0.0007007689,0.00042862844,0.00016885975,0.000031350504,0.0003594536,0.000003498507],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9630945,0.0023484514,0.00040462738,0.000994362,0.0014739922,0.00060240226,0.0006512986,0.000041545543,0.0037026843,0.0000044906637,0.00038165273,0.026300024],"study_design_scores_gemma":[0.90559393,0.061641354,0.000051427713,0.00081775215,0.0034723186,0.0034070348,0.00052728225,0.0005129936,0.020845702,0.000026280624,0.0028780021,0.00022589219],"about_ca_topic_score_codex":0.000039841598,"about_ca_topic_score_gemma":0.00035528681,"teacher_disagreement_score":0.059292905,"about_ca_system_score_codex":0.00034642348,"about_ca_system_score_gemma":0.001963886,"threshold_uncertainty_score":0.75989914},"labels":[],"label_agreement":null},{"id":"W4390503058","doi":"10.1016/j.radonc.2023.110077","title":"Brachytherapy for high grade prostate cancer induces distinct changes in circulating CD4 and CD8 T cells – Implications for systemic control","year":2024,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Services and Policy Research; Health Sciences Centre; Sunnybrook Hospital; University of Toronto; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"Sunnybrook Foundation; Government of Ontario; Movember Foundation","keywords":"Prostate cancer; Brachytherapy; Medicine; Oncology; CD8; Internal medicine; Cancer; Cancer research; Immunology; Immune system; Radiation therapy","score_opus":0.024882195514985713,"score_gpt":0.338575947549831,"score_spread":0.3136937520348453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390503058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9056939,0.06373474,0.0017891838,0.025611345,0.00035588763,0.0025648342,0.00018400962,0.00005790335,0.000008233178],"genre_scores_gemma":[0.98173845,0.013139023,0.00061669364,0.0019331014,0.00043872907,0.0019021829,0.000027921747,0.000041358475,0.00016254242],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989853,0.000051826733,0.00027706326,0.0003624196,0.00004586082,0.0002775583],"domain_scores_gemma":[0.9991688,0.00053064193,0.0000888948,0.00011071382,0.00003826353,0.00006269166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035128585,0.00016930218,0.0004421144,0.0001404471,0.00011128906,0.000039902578,0.00004408427,0.00016415583,0.000016241584],"category_scores_gemma":[0.0000084689755,0.0001363159,0.0000632729,0.0001458044,0.000119176504,0.0000538769,0.0000035157143,0.00010708982,1.03774305e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00252474,0.00007963894,0.0066324295,0.00080840726,0.00038175605,0.000009077761,0.0022890153,0.000007194803,0.6721849,0.000718469,0.00043987043,0.3139245],"study_design_scores_gemma":[0.10816216,0.01751825,0.27664652,0.0037567418,0.0011018254,0.002949242,0.001787559,0.014492647,0.02756852,0.0058091693,0.538077,0.0021303622],"about_ca_topic_score_codex":0.00020368588,"about_ca_topic_score_gemma":0.00056617276,"teacher_disagreement_score":0.64461637,"about_ca_system_score_codex":0.00036531407,"about_ca_system_score_gemma":0.00018040653,"threshold_uncertainty_score":0.5558801},"labels":[],"label_agreement":null},{"id":"W4390542043","doi":"10.3389/fimmu.2023.1295208","title":"NLRC5 overexpression in ovarian tumors remodels the tumor microenvironment and increases T-cell reactivity toward autologous tumor-associated antigens","year":2024,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Canadian Institutes of Health Research; University of Ottawa","keywords":"Tumor microenvironment; Immune system; Antigen presentation; Antigen; CD8; Cancer research; Ovarian cancer; Biology; T cell; Immunology; Major histocompatibility complex; Medicine; Cancer; Internal medicine","score_opus":0.009119978673420879,"score_gpt":0.22907231211766121,"score_spread":0.21995233344424034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390542043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756316,0.020781226,0.00015086864,0.0017442501,0.0006078017,0.0004634321,0.000030325853,0.00006783683,0.000522663],"genre_scores_gemma":[0.9965367,0.0017190615,0.0005583954,0.0006159627,0.000038042246,0.00004705664,0.00003263556,0.00003746062,0.00041474198],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99805105,0.00032288543,0.00044339,0.00052235165,0.00016140066,0.0004989389],"domain_scores_gemma":[0.99931556,0.00012264619,0.000119917626,0.00037874974,0.00001538574,0.000047762314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005507701,0.00027131065,0.000541374,0.00039663306,0.000087884706,0.000033668377,0.00017506335,0.00017384395,0.00006407331],"category_scores_gemma":[0.000090871996,0.0002048559,0.000104614024,0.00040896755,0.00044782794,0.00012029502,0.00013006522,0.00063544384,0.000005301717],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054315836,0.0009675658,0.08825617,0.00020829664,0.00041004983,0.0017121953,0.002528869,0.000013331403,0.8622983,0.0000516801,0.012530295,0.025591647],"study_design_scores_gemma":[0.0059742527,0.00076927873,0.9231187,0.0019316762,0.0001077718,0.0008456385,0.002267625,0.0018926546,0.050706413,0.0009152368,0.010928726,0.0005420248],"about_ca_topic_score_codex":0.00249586,"about_ca_topic_score_gemma":0.00007147387,"teacher_disagreement_score":0.83486253,"about_ca_system_score_codex":0.00063980505,"about_ca_system_score_gemma":0.00017144563,"threshold_uncertainty_score":0.8353781},"labels":[],"label_agreement":null},{"id":"W4390571070","doi":"10.1038/s41591-023-02771-0","title":"Publisher Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis","year":2024,"lang":"en","type":"erratum","venue":"Nature Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute; Sunnybrook Hospital; McMaster University; University of Toronto","funders":"","keywords":"Myocarditis; Immune system; Immune checkpoint; Immunology; Medicine; Immunotherapy; Internal medicine","score_opus":0.00888520115008737,"score_gpt":0.2859144609578685,"score_spread":0.2770292598077811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390571070","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014846377,0.24603043,0.000056449542,0.10706592,0.49899274,0.002249855,0.00009327739,0.0004606793,0.143566],"genre_scores_gemma":[0.03068916,0.007925111,0.00018315756,0.010245106,0.04049344,0.00022251948,0.0031385033,0.0002219532,0.90688103],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99658555,0.00008241318,0.0008705432,0.0010618662,0.00095157686,0.00044803327],"domain_scores_gemma":[0.997904,0.000108040455,0.00017622986,0.0009359797,0.0004911752,0.0003845699],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0009240553,0.0006244855,0.0012223396,0.0006271972,0.00016810674,0.00012988668,0.00018288552,0.0017513179,0.0013605503],"category_scores_gemma":[0.0009242494,0.00044987132,0.00033476474,0.0010811609,0.0003642978,0.0001358156,0.00013370714,0.0048726364,0.000048753293],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005791896,0.00006234627,0.000084421896,0.00068061135,0.00049754407,0.00012256995,0.0006354464,7.43467e-8,0.0026289877,0.000013347386,0.9705367,0.024158763],"study_design_scores_gemma":[0.0018028824,0.001319566,0.0073398445,0.004472159,0.00064754934,0.0005482241,0.0003914715,0.000022790275,0.00023579222,0.00011730855,0.98270094,0.0004014803],"about_ca_topic_score_codex":0.0005184309,"about_ca_topic_score_gemma":0.0006466701,"teacher_disagreement_score":0.7633151,"about_ca_system_score_codex":0.00057415763,"about_ca_system_score_gemma":0.0005865213,"threshold_uncertainty_score":0.9997953},"labels":[],"label_agreement":null},{"id":"W4390609252","doi":"10.1016/j.ijrobp.2023.12.046","title":"The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives","year":2024,"lang":"en","type":"review","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Immunotherapy; Medicine; Radiation therapy; Cancer therapy; Cancer immunotherapy; Cancer; Medical physics; Internal medicine","score_opus":0.052958237128851365,"score_gpt":0.3863024915041709,"score_spread":0.33334425437531956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390609252","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017486659,0.9899435,0.00012606896,0.0035243097,0.003722506,0.000660617,0.00004662397,0.000026065878,0.000201623],"genre_scores_gemma":[0.006255073,0.9908114,0.00007545205,0.00027640493,0.0022580256,0.00007137291,0.00006811908,0.000064848755,0.00011926719],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99762297,0.00031608198,0.0011843997,0.00034080294,0.00030692032,0.00022882785],"domain_scores_gemma":[0.9973575,0.00052815635,0.0014254538,0.00019241124,0.00043189194,0.00006457716],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009320951,0.00037968982,0.0010629862,0.00040823754,0.00010987773,0.00013463423,0.0003858584,0.00042183703,0.00006736801],"category_scores_gemma":[0.000056275574,0.00024695584,0.00056094205,0.0003045554,0.00033047987,0.00026407588,0.000039831506,0.0009215153,0.00001341673],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006571333,0.00017585134,0.00045962425,0.00008983612,0.0015672909,0.000018415143,0.00094696984,0.0000017621577,0.00009401237,0.010326313,0.00049179676,0.985171],"study_design_scores_gemma":[0.00399511,0.0007468942,0.00077945256,0.0014088934,0.0002143334,0.00021388495,0.0001949097,0.00007399327,0.000017533313,0.0024133986,0.98972255,0.00021903604],"about_ca_topic_score_codex":0.000038571117,"about_ca_topic_score_gemma":0.0000087879,"teacher_disagreement_score":0.98923075,"about_ca_system_score_codex":0.0018195244,"about_ca_system_score_gemma":0.0008019532,"threshold_uncertainty_score":0.9999983},"labels":[],"label_agreement":null},{"id":"W4390616641","doi":"10.1038/s41571-023-00857-9","title":"‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent","year":2024,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Pembrolizumab; Perioperative; Medicine; Adjuvant; Oncology; Stage (stratigraphy); Lung cancer; Internal medicine; Population; Neoadjuvant therapy; Immunotherapy; Intensive care medicine; Surgery; Cancer; Biology","score_opus":0.08469361818736132,"score_gpt":0.4895845095704079,"score_spread":0.40489089138304657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390616641","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015722499,0.9879288,0.0000041197563,0.0032383515,0.002631835,0.005296514,0.000038438488,0.000023900357,0.0008223239],"genre_scores_gemma":[0.00004932653,0.99654466,0.00016160232,0.000990815,0.0010704427,0.00038490878,0.0001565861,0.00003998355,0.0006016694],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918375,0.0027215348,0.0042994157,0.000630622,0.00025088913,0.00026005445],"domain_scores_gemma":[0.995234,0.0020775925,0.0017374596,0.0006080879,0.00021669155,0.00012615256],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.007987066,0.000517587,0.007897921,0.00011188375,0.00006816693,0.000021969468,0.00024994952,0.0022892246,0.00010336255],"category_scores_gemma":[0.0028621492,0.00022525626,0.0034565562,0.00039385055,0.0011497485,0.00003140388,0.00021519916,0.0040977877,0.000072974646],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001413047,0.00022024596,0.0000022321585,0.015260815,0.001228962,0.000019377207,0.000057976285,1.8059921e-9,0.000006898552,0.00066392525,0.0035132302,0.9776133],"study_design_scores_gemma":[0.003989459,0.0011129716,0.000029307968,0.031707145,0.0074891043,0.0002908604,0.00000950709,0.0000018721562,0.0000033216531,0.000024781213,0.95514953,0.0001921514],"about_ca_topic_score_codex":0.000014117026,"about_ca_topic_score_gemma":0.000019234676,"teacher_disagreement_score":0.97742116,"about_ca_system_score_codex":0.00037431333,"about_ca_system_score_gemma":0.0009240698,"threshold_uncertainty_score":0.99900603},"labels":[],"label_agreement":null},{"id":"W4390650725","doi":"10.1016/j.ijrobp.2024.01.001","title":"Immunotherapy and Radiation Therapy Sequencing in Breast Cancer: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Oncology; Internal medicine; Concomitant; Discontinuation; Breast cancer; Radiation therapy; Pembrolizumab; Population; Immunotherapy; Cancer; Intensive care medicine","score_opus":0.036973440738430195,"score_gpt":0.3856367264602048,"score_spread":0.34866328572177463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390650725","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000204503,0.99367857,0.000076830736,0.0020002162,0.0023219585,0.0014817996,0.00014619237,0.000032729975,0.000057197376],"genre_scores_gemma":[0.00038654983,0.9953369,0.00010134398,0.0020906061,0.0016786833,0.00017400435,0.0001080979,0.00007819059,0.000045660006],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962118,0.00060483394,0.0022166355,0.00036139673,0.00035424362,0.00025106085],"domain_scores_gemma":[0.996305,0.00038272992,0.0025666596,0.00023881209,0.00041213963,0.000094667455],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014766526,0.0004807468,0.0030289001,0.0005037958,0.00004224847,0.00005777367,0.0004127361,0.00047012878,0.000072878116],"category_scores_gemma":[0.00009894376,0.00033548026,0.00085535174,0.000493646,0.000118852804,0.00022833954,0.000038634844,0.00093231443,0.000016399894],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026038985,0.00009761983,0.00037016685,0.07051527,0.0033937702,0.00007224914,0.00022260132,0.0000017852599,0.000062657695,0.00024489866,0.00072635856,0.9240322],"study_design_scores_gemma":[0.0053120796,0.0007091824,0.00015171056,0.46410564,0.0034380734,0.0043863077,0.000043201686,0.00012731712,0.000010841847,0.0006118208,0.52056795,0.0005358937],"about_ca_topic_score_codex":0.00007602462,"about_ca_topic_score_gemma":0.0000043532677,"teacher_disagreement_score":0.92349637,"about_ca_system_score_codex":0.0043139635,"about_ca_system_score_gemma":0.0028530497,"threshold_uncertainty_score":0.9999097},"labels":[],"label_agreement":null},{"id":"W4390658508","doi":"10.1117/12.3012850","title":"The PD-1 and PD-L1 checkpoint and the application of their inhibitors","year":2024,"lang":"en","type":"article","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Immunotherapy; Cancer immunotherapy; PD-L1; Medicine; Immune system; Immune checkpoint; Cancer research; Bioinformatics; Immunology; Computational biology; Biology","score_opus":0.007446572856937546,"score_gpt":0.25316502583892525,"score_spread":0.24571845298198772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390658508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89813656,0.04726332,0.0006356828,0.03968794,0.00022290772,0.0009261351,0.0000051618613,0.00006757221,0.013054742],"genre_scores_gemma":[0.9958757,0.002575219,0.000025163989,0.0003162169,0.00007646783,0.000026070673,0.0000013541398,0.0000058692353,0.001097899],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996346,0.000016293332,0.00012907597,0.00009250283,0.000068406036,0.00005909928],"domain_scores_gemma":[0.9996544,0.00015219483,0.000021874539,0.00013876878,0.000016039105,0.000016686494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039711152,0.000053427488,0.00008306319,0.000016441252,0.000058926664,0.000025273863,0.000029509878,0.00002646917,0.000015305099],"category_scores_gemma":[0.000009037527,0.000019846508,0.00004150691,0.000090463065,0.00030283286,0.000019739293,0.000019939836,0.00005972846,0.0000015227126],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030725738,0.000030902214,0.0010853701,0.00021393003,0.00036066055,0.0000011147147,0.0030772015,1.651748e-7,0.09861509,0.019917293,0.005469377,0.8681563],"study_design_scores_gemma":[0.0058406694,0.00035902328,0.0399726,0.00030438992,0.00019629726,0.00014422249,0.0049458314,0.005143535,0.16153261,0.0061408794,0.77521604,0.00020391552],"about_ca_topic_score_codex":0.0001778624,"about_ca_topic_score_gemma":0.00004130548,"teacher_disagreement_score":0.8679524,"about_ca_system_score_codex":0.000010859412,"about_ca_system_score_gemma":0.00002264206,"threshold_uncertainty_score":0.11158004},"labels":[],"label_agreement":null},{"id":"W4390752627","doi":"10.3390/curroncol31010028","title":"Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; McMaster University","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Adverse effect; Cancer; Internal medicine; Cohort; Incidence (geometry); Oncology; Immunotherapy","score_opus":0.07574059233300882,"score_gpt":0.3838031312046092,"score_spread":0.30806253887160034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390752627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9074014,0.074657,0.00030698272,0.0009734748,0.014743259,0.00094166334,0.00012205312,0.0003613091,0.0004928808],"genre_scores_gemma":[0.99068123,0.005673886,0.000193156,0.00021650032,0.00039624475,0.00011473149,0.00035152564,0.00007082252,0.0023018806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978537,0.00019655461,0.00079165073,0.0005020852,0.00027074025,0.00038529607],"domain_scores_gemma":[0.998947,0.00023614864,0.00014527081,0.00046969342,0.00007733291,0.00012454712],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034472995,0.00029059537,0.00054337655,0.00020458463,0.00008482203,0.000019368557,0.00012627766,0.00026567612,0.0016078044],"category_scores_gemma":[0.000037133694,0.00023901655,0.00047667857,0.0003297328,0.00011622403,0.00016163534,0.000055461056,0.00047791546,0.0006125841],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063398015,0.0018421068,0.027576594,0.00043720315,0.0035230834,0.00085686834,0.004583985,0.000010250327,0.13750707,0.0003128698,0.015538709,0.8014715],"study_design_scores_gemma":[0.0072172345,0.00066509587,0.098260686,0.0010118715,0.00024820026,0.0001781317,0.0002565138,0.0010107083,0.0012435314,0.0000879507,0.88950336,0.00031672913],"about_ca_topic_score_codex":0.00033711016,"about_ca_topic_score_gemma":0.000025705163,"teacher_disagreement_score":0.87396467,"about_ca_system_score_codex":0.0008655753,"about_ca_system_score_gemma":0.00034282194,"threshold_uncertainty_score":0.9993049},"labels":[],"label_agreement":null},{"id":"W4390754195","doi":"10.1016/j.ejca.2024.113530","title":"Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Pembrolizumab; Discontinuation; Medicine; Adverse effect; Internal medicine; Clinical trial; Immune system; Cancer; Oncology; Immunotherapy; Immunology","score_opus":0.024230192302989534,"score_gpt":0.32023523195457865,"score_spread":0.2960050396515891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390754195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779889,0.008652884,0.00037792395,0.000906727,0.0010023458,0.0004775872,0.00010327628,0.0000168034,0.01047355],"genre_scores_gemma":[0.9975299,0.001383686,0.00021784619,0.00032866784,0.00026092635,0.0000022177805,0.00001478995,0.000045344965,0.0002166263],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975654,0.0004930785,0.0007579338,0.0001458912,0.0009118102,0.00012590396],"domain_scores_gemma":[0.9984018,0.000050288734,0.00050737563,0.00022153037,0.0007389088,0.000080076876],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020405839,0.00013722561,0.00030774786,0.0002146574,0.00002901555,0.000011855687,0.00012512726,0.000026238244,0.0011858125],"category_scores_gemma":[0.000054998207,0.00009914389,0.00022003376,0.00024178303,0.000072743824,0.00012189658,0.0000070137107,0.00018310272,0.0000042360057],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03030584,0.00031854675,0.0022098727,0.00014858277,0.0004074753,0.000022214825,0.0007226958,0.0012425688,0.01742485,0.000010859563,0.0014945801,0.9456919],"study_design_scores_gemma":[0.053455,0.014898635,0.64095247,0.008752449,0.0012732788,0.000036867794,0.00017922919,0.024038574,0.074531294,0.00003371473,0.18137342,0.0004750709],"about_ca_topic_score_codex":0.000016829656,"about_ca_topic_score_gemma":0.0000043747273,"teacher_disagreement_score":0.94521683,"about_ca_system_score_codex":0.0002723335,"about_ca_system_score_gemma":0.0005697799,"threshold_uncertainty_score":0.99972725},"labels":[],"label_agreement":null},{"id":"W4390776260","doi":"10.1016/j.oor.2024.100160","title":"Inhibition of anti-tumour reactivity of immune cells in the salivary gland cancer: A proteomic approach","year":2024,"lang":"en","type":"article","venue":"Oral Oncology Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Australian and New Zealand Head and Neck Cancer Society; Fraser Institute; University of Chicago; University of Queensland; Macquarie University; University of Michigan","keywords":"Immune system; Salivary gland; Cancer; Salivary gland cancer; Cancer research; Adenoid cystic carcinoma; Head and neck squamous-cell carcinoma; Biology; Cancer cell; Immunotherapy; Immune checkpoint; Immunology; Head and neck cancer; Carcinoma; Medicine; Internal medicine","score_opus":0.022566390573616108,"score_gpt":0.31165259046829175,"score_spread":0.28908619989467566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390776260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933611,0.0018178512,0.00001703372,0.00079668657,0.00029919975,0.0007494043,0.000009484384,0.000017538,0.0029316777],"genre_scores_gemma":[0.99906296,0.00034094672,0.00022566198,0.000080720434,0.00006165689,0.000090542155,0.00002209024,0.000011224679,0.00010417887],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988275,0.000120153854,0.0005471755,0.00020999927,0.00016082222,0.0001343599],"domain_scores_gemma":[0.99938744,0.000049825154,0.00028465278,0.00022243428,0.000037740796,0.000017924229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011638026,0.000098673605,0.00041816258,0.00011217951,0.000017116496,0.00000473586,0.000036811518,0.00013351289,0.00003938989],"category_scores_gemma":[0.000017744667,0.00006380833,0.00012673147,0.00031824992,0.00015951261,0.00006281958,0.000019357542,0.00022438708,5.2548006e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065869663,0.00045405806,0.018197708,0.00036431762,0.000088342604,0.0013136644,0.00083177176,0.0000048824872,0.9680914,0.000008151618,0.0006948398,0.0092921145],"study_design_scores_gemma":[0.0015976407,0.0011330657,0.2912426,0.0006393152,0.00020836877,0.0036825421,0.00035586668,0.00010798671,0.6938339,0.00015699075,0.0069147735,0.00012697918],"about_ca_topic_score_codex":0.002885336,"about_ca_topic_score_gemma":0.00008512453,"teacher_disagreement_score":0.27425757,"about_ca_system_score_codex":0.00015209276,"about_ca_system_score_gemma":0.0005234278,"threshold_uncertainty_score":0.43617842},"labels":[],"label_agreement":null},{"id":"W4390789159","doi":"10.1038/s41598-024-51704-5","title":"Advancing cancer immunotherapy: from innovative preclinical models to clinical insights","year":2024,"lang":"en","type":"editorial","venue":"Scientific Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Immunotherapy; Cancer immunotherapy; Cancer; Chimeric antigen receptor; Medicine; Tumor microenvironment; Immune system; Tumor immunology; Immune checkpoint; Immunology; Computational biology; Biology; Internal medicine","score_opus":0.043183562312875366,"score_gpt":0.39266545803426306,"score_spread":0.3494818957213877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390789159","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01874591,0.015933849,0.00021647147,0.00067650917,0.9615081,0.0014220098,0.00016792801,0.0004077722,0.0009214538],"genre_scores_gemma":[0.0061638225,0.0024266164,0.0016534773,0.0009190473,0.95763177,0.00044941876,0.0019383705,0.00041397393,0.028403485],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99072146,0.00017076626,0.0030982513,0.0030424611,0.0022805,0.0006865703],"domain_scores_gemma":[0.9938366,0.0008352111,0.0009907662,0.0023542608,0.001575239,0.0004079121],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0038631384,0.0006589803,0.0016003601,0.00058573287,0.00020838401,0.00052006915,0.00037433414,0.0014162192,0.00041375853],"category_scores_gemma":[0.001074714,0.00051977905,0.00073511904,0.0018691651,0.00058563385,0.00025514668,0.0002735589,0.0020663354,0.00008424448],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015986661,0.00021184246,0.00013691423,0.00011539148,0.0010510366,0.0009771712,0.001046892,0.000016273547,0.0028103213,0.000003085011,0.9663821,0.025650302],"study_design_scores_gemma":[0.00094535295,0.00032338905,0.00009368837,0.0025579361,0.00024346376,0.000017222581,0.00007417483,0.00008913531,0.00089638284,0.004402309,0.9897751,0.000581851],"about_ca_topic_score_codex":0.0013532882,"about_ca_topic_score_gemma":0.0006433111,"teacher_disagreement_score":0.02748203,"about_ca_system_score_codex":0.0007278812,"about_ca_system_score_gemma":0.0063901325,"threshold_uncertainty_score":0.99988014},"labels":[],"label_agreement":null},{"id":"W4390828140","doi":"10.1016/j.adro.2023.101380","title":"In Regard to Smart et al","year":2024,"lang":"en","type":"article","venue":"Advances in Radiation Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Melanoma; Immunotherapy; Radiation therapy; Oncology; Ipilimumab; Internal medicine; Immune checkpoint; Immune system; Cancer research; Immunology","score_opus":0.013394307890729366,"score_gpt":0.39169919056485,"score_spread":0.3783048826741206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390828140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5528234,0.05826067,0.00094360206,0.32436237,0.0064761834,0.0011510728,0.000014233018,0.000146423,0.05582202],"genre_scores_gemma":[0.9028496,0.013992088,0.0014359297,0.07995417,0.00014897695,0.00014890458,0.000022661081,0.000019309706,0.0014283776],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993507,0.000053665393,0.00020694759,0.00018119546,0.00007536932,0.00013211525],"domain_scores_gemma":[0.9997017,0.00014811277,0.00002028673,0.00008676118,0.000010217346,0.000032958094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003299175,0.000060164075,0.00014695743,0.00024883912,0.000007976598,0.0000063058233,0.000036844995,0.000053550586,0.00018777754],"category_scores_gemma":[0.00006133463,0.00005531071,0.000030114616,0.00040152026,0.000026194497,0.0001882038,0.000008936864,0.00013833435,0.00005394022],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023555967,0.00015952454,0.028245134,0.00006229805,0.000028688917,0.00037218066,0.0015924057,0.00034664397,0.0049162144,0.0027398265,0.05814861,0.90103287],"study_design_scores_gemma":[0.0012103366,0.00045288657,0.018165177,0.00006740417,0.0000033900012,0.000034436063,0.00006885915,0.00024114926,0.00036422777,0.00030175137,0.9790321,0.00005826443],"about_ca_topic_score_codex":0.000085860156,"about_ca_topic_score_gemma":0.0012814124,"teacher_disagreement_score":0.9208835,"about_ca_system_score_codex":0.000475901,"about_ca_system_score_gemma":0.00017719342,"threshold_uncertainty_score":0.22555053},"labels":[],"label_agreement":null},{"id":"W4390903209","doi":"10.1186/s12865-024-00597-0","title":"Negative prognostic behaviour of PD-L1 expression in tongue and larynx squamous cell carcinoma and its significant predictive power in combination with PD-1 expression on TILs","year":2024,"lang":"en","type":"article","venue":"BMC Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences; Shiraz University; Shiraz University of Medical Sciences","keywords":"Medicine; Larynx; Univariate analysis; Tongue; Internal medicine; Proportional hazards model; Multivariate analysis; Oncology; PD-L1; Univariate; Immunohistochemistry; Basal cell; Immunotherapy; Pathology; Cancer; Multivariate statistics; Surgery","score_opus":0.011528065335969012,"score_gpt":0.24843259785622376,"score_spread":0.23690453252025476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390903209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922614,0.006108016,0.00003842803,0.00009731857,0.00012138662,0.001037694,0.000021611122,0.00002654932,0.00028759308],"genre_scores_gemma":[0.9994508,0.00012218593,0.00009524976,0.000024768528,0.00000929777,0.00011459711,0.000022240292,0.000022765174,0.00013812231],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988039,0.0001655429,0.0002999096,0.0003730586,0.00014695166,0.00021064772],"domain_scores_gemma":[0.99933904,0.00032347447,0.00009172186,0.00015417146,0.0000571112,0.0000344959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000186225,0.0001818718,0.00030900555,0.0003408217,0.000031016854,0.000011581602,0.000055111886,0.00018191342,0.000036873793],"category_scores_gemma":[0.00006480107,0.00013522862,0.000029011404,0.00023278953,0.00015821819,0.000109584,0.000047234633,0.00028704747,0.0000014260634],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01442344,0.0006946057,0.22205633,0.00031863217,0.000020144253,0.00015286006,0.0055778367,0.000005263026,0.7559983,0.000045969584,0.00004461769,0.0006619719],"study_design_scores_gemma":[0.004810635,0.0036799328,0.6770836,0.0008460737,0.000027914693,0.00003061763,0.0012418177,0.0001914928,0.31193757,0.000030467838,0.000013460577,0.00010638316],"about_ca_topic_score_codex":0.00015920497,"about_ca_topic_score_gemma":0.000045332163,"teacher_disagreement_score":0.4550273,"about_ca_system_score_codex":0.00010449248,"about_ca_system_score_gemma":0.0001321224,"threshold_uncertainty_score":0.5514463},"labels":[],"label_agreement":null},{"id":"W4390903581","doi":"10.21203/rs.3.rs-3809489/v1","title":"Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Arthritis; Inflammatory arthritis; Rheumatology; Surgery; Cancer; Dermatology; Immunotherapy","score_opus":0.03186515174350881,"score_gpt":0.34533707192681257,"score_spread":0.3134719201833038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390903581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91466814,0.07380852,0.0000035444198,0.0051434156,0.00095982687,0.0032731495,0.00020614167,0.0002461687,0.0016910909],"genre_scores_gemma":[0.96152204,0.032599684,0.00016024831,0.00030559636,0.0024548683,0.001008586,0.00009982635,0.00020881937,0.001640314],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99514455,0.000263028,0.00085231644,0.0013000082,0.0014500351,0.0009900482],"domain_scores_gemma":[0.99735993,0.00024488627,0.00011757393,0.0012061847,0.00053579675,0.000535598],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002163862,0.0005607123,0.0008398042,0.0016375277,0.00033701962,0.00039738382,0.00035510497,0.0007919099,0.0009087511],"category_scores_gemma":[0.00021999862,0.0005307295,0.0004295103,0.0009782882,0.00023077302,0.00008110548,0.0016444667,0.0040533883,0.0003133256],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026684944,0.001270461,0.015759062,0.05658817,0.0026790756,0.003360315,0.022334268,0.000010627597,0.10925926,0.00017628902,0.109458774,0.65241873],"study_design_scores_gemma":[0.039706256,0.015168658,0.40406317,0.0528689,0.00041288653,0.0009889663,0.0064254585,0.00027251922,0.042927455,0.0061508426,0.4256534,0.0053615225],"about_ca_topic_score_codex":0.0009586372,"about_ca_topic_score_gemma":0.00069970783,"teacher_disagreement_score":0.64705724,"about_ca_system_score_codex":0.0009723904,"about_ca_system_score_gemma":0.0026054878,"threshold_uncertainty_score":0.99971443},"labels":[],"label_agreement":null},{"id":"W4390917779","doi":"10.1158/1538-7445.panca2023-b025","title":"Abstract B025: IL-1 blockade prevents cardiac toxicity and improves immunotherapy efficacy in mouse models of pancreatic cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Cardiotoxicity; FOLFIRINOX; Myocarditis; Cancer; Pancreatic cancer; Internal medicine; Blockade; Oncology; Chemotherapy","score_opus":0.05690371483072138,"score_gpt":0.39486169239733965,"score_spread":0.3379579775666183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390917779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9125876,0.08492066,0.0000043239966,0.0006522077,0.00018477373,0.001009002,0.00017534928,0.000038513263,0.00042760468],"genre_scores_gemma":[0.94444454,0.05246693,0.00003033512,0.00005731834,0.00017787528,0.0003778241,0.000007742405,0.000052223826,0.0023851935],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99787605,0.00011522091,0.00041050193,0.0004660239,0.0006111197,0.00052107003],"domain_scores_gemma":[0.9990835,0.00024424336,0.000046688452,0.00038279514,0.00012019573,0.00012258782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010055079,0.00019659122,0.00048364265,0.00037600443,0.000067227214,0.0000557566,0.00016758073,0.00014731011,0.00028591143],"category_scores_gemma":[0.000029587305,0.00016123118,0.00015239292,0.0006361398,0.00031533538,0.00016402506,0.000061031114,0.0005751233,0.0000031698073],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022326305,0.0002223128,0.0013508186,0.0009282243,0.00047440655,0.000017102437,0.001385811,0.00002936232,0.88788676,0.00002752117,0.0006607413,0.1047843],"study_design_scores_gemma":[0.005882562,0.0006442347,0.07443808,0.0037210216,0.00008844166,0.0000069072075,0.00049871916,0.0009823872,0.9050907,0.00039196975,0.007830618,0.00042436956],"about_ca_topic_score_codex":0.009597665,"about_ca_topic_score_gemma":0.0002949048,"teacher_disagreement_score":0.10435993,"about_ca_system_score_codex":0.00052080996,"about_ca_system_score_gemma":0.0007863573,"threshold_uncertainty_score":0.99699754},"labels":[],"label_agreement":null},{"id":"W4390950175","doi":"10.1002/path.6238","title":"Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer","year":2024,"lang":"en","type":"review","venue":"The Journal of Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia; University of Guelph; Sunnybrook Health Science Centre; Health Sciences Centre; BC Cancer Agency","funders":"National Institute of Biomedical Imaging and Bioengineering; National Cancer Institute; Servier; Incyte; Medical Research Council; Chugai Pharmaceutical; National Institutes of Health; Peter MacCallum Cancer Centre; Ligue Contre le Cancer; KU Leuven; DOD Prostate Cancer Research Program; Japan Society for the Promotion of Science; Astellas Pharma; Eisai; Fondation ARC pour la Recherche sur le Cancer; DOD Peer Reviewed Cancer Research Program; Ministerie van Volksgezondheid, Welzijn en Sport; Daiichi-Sankyo; Agence Nationale de la Recherche; Amgen; Science Foundation Ireland; AstraZeneca; Genentech; European Commission; Engineering and Physical Sciences Research Council; Yuhan; Irish Cancer Society; National Breast Cancer Foundation; Svenska Sällskapet för Medicinsk Forskning; KWF Kankerbestrijding; U.S. Department of Defense; Cancer Research UK; Seagen; Puma Biotechnology; Daiichi Sankyo Europe; Veracyte; Pfizer; Susan G. Komen; National Institute of Diabetes and Digestive and Kidney Diseases; Carrick Therapeutics; Gilead Sciences; GlaxoSmithKline; Sanofi; California Breast Cancer Research Program; National Health and Medical Research Council; Cancer Research Institute; Eli Lilly and Company; Bristol-Myers Squibb; Breast Cancer Research Foundation; Higher Education Authority; Silverback Therapeutics; U.S. Department of Veterans Affairs; Irish Research eLibrary","keywords":"Multiplex; Breast cancer; Biomarker; Oncology; Medicine; Profiling (computer programming); Internal medicine; Immune system; Cancer; Pathology; Bioinformatics; Immunology; Biology; Genetics; Computer science","score_opus":0.07682459191772924,"score_gpt":0.41873753895062743,"score_spread":0.3419129470328982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390950175","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017420553,0.9885804,0.00015264204,0.0059579685,0.0021794182,0.0008220331,0.0003161578,0.000009477353,0.00023981497],"genre_scores_gemma":[0.010299248,0.9877431,0.00093595445,0.00018567493,0.000490945,0.00010198723,0.000055322856,0.00006210749,0.00012570989],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965469,0.00043505782,0.0021276532,0.00023475102,0.00044237732,0.00021321989],"domain_scores_gemma":[0.9954731,0.00043546074,0.0030838423,0.00052397524,0.0004448989,0.000038734925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019668834,0.00032099194,0.0014557344,0.0003905785,0.00007530747,0.000010405229,0.00066579634,0.0003060791,0.00027101432],"category_scores_gemma":[0.00007518552,0.00016188904,0.0010871433,0.00052808685,0.0005125864,0.00004191154,0.000071064176,0.00076433644,0.0000016009972],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029448515,0.0003610355,0.00064027886,0.0030523227,0.0031734928,0.0002693066,0.0003939818,0.000011283438,0.05450664,0.00004887863,0.000644009,0.93395394],"study_design_scores_gemma":[0.0050959024,0.0007274979,0.020881759,0.058229696,0.012574785,0.046136376,0.00023301218,0.00013835517,0.0016181407,0.00015645318,0.8536616,0.00054641394],"about_ca_topic_score_codex":0.00017420761,"about_ca_topic_score_gemma":0.00006760316,"teacher_disagreement_score":0.9334075,"about_ca_system_score_codex":0.0004259758,"about_ca_system_score_gemma":0.0018316619,"threshold_uncertainty_score":0.66016436},"labels":[],"label_agreement":null},{"id":"W4390963940","doi":"10.1007/s00262-023-03593-2","title":"Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment","year":2024,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"National Cancer Institute; Sanofi","keywords":"Pembrolizumab; Medicine; Melanoma; Aflibercept; Oncology; Internal medicine; Adverse effect; Immune system; Combination therapy; Immunology; Gastroenterology; Immunotherapy; Cancer research; Bevacizumab; Chemotherapy","score_opus":0.009877809274415455,"score_gpt":0.2785006858800478,"score_spread":0.26862287660563233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390963940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9301785,0.06344885,0.000052388223,0.0023247192,0.0010952399,0.0017951608,0.000097405755,0.00026019852,0.0007474994],"genre_scores_gemma":[0.9829974,0.01134422,0.00036021412,0.001418007,0.00010098588,0.0008573698,0.00010502556,0.00017703652,0.0026397416],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971783,0.00010648738,0.00067201816,0.0008860564,0.00032574372,0.0008314066],"domain_scores_gemma":[0.9986651,0.00008082672,0.00011195662,0.0008997829,0.00013114767,0.00011121364],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014692114,0.00060132967,0.0009323184,0.00062724075,0.00013849672,0.00007404389,0.0002851817,0.0002707544,0.0011041955],"category_scores_gemma":[0.000008433239,0.000446843,0.00024821734,0.0010512301,0.00027113047,0.00021250772,0.00003710698,0.0003655146,0.00009791193],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15606342,0.0010311486,0.032108735,0.00015658376,0.004326374,0.00030220722,0.0065561654,0.000118980446,0.17256227,0.00016911457,0.0010660405,0.62553895],"study_design_scores_gemma":[0.036176622,0.010009189,0.70098877,0.0011407692,0.0001308093,0.0000425154,0.00029058976,0.00002342094,0.009181685,0.000023463472,0.24123773,0.0007544625],"about_ca_topic_score_codex":0.0009530619,"about_ca_topic_score_gemma":0.0002907978,"teacher_disagreement_score":0.66888,"about_ca_system_score_codex":0.0029341467,"about_ca_system_score_gemma":0.00089830684,"threshold_uncertainty_score":0.9998089},"labels":[],"label_agreement":null},{"id":"W4390972675","doi":"10.1001/jamanetworkopen.2023.52302","title":"Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors","year":2024,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Alberta Cancer Foundation; University of Calgary","funders":"EMD Serono; Ipsen; Eisai; Sanofi; F. Hoffmann-La Roche; Roche; Janssen Pharmaceuticals; AstraZeneca; Pfizer","keywords":"Medicine; Discontinuation; Internal medicine; Adverse effect; Proportional hazards model; Cohort; Oncology; Cohort study; Retrospective cohort study; Lung cancer; Observational study; Immunotherapy; Cancer","score_opus":0.009040085013555433,"score_gpt":0.24360594914331904,"score_spread":0.2345658641297636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390972675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99194026,0.0026898244,0.000020252683,0.00043978798,0.00032138792,0.0018998905,0.000018797728,0.00010401667,0.002565789],"genre_scores_gemma":[0.9963993,0.00020625234,0.00031453278,0.00008626817,0.000088710854,0.000093357434,0.0002707143,0.000085797205,0.002455097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979543,0.0001556482,0.00060888124,0.0004813352,0.00037366623,0.00042618337],"domain_scores_gemma":[0.9990799,0.000089669775,0.00019547349,0.00038720388,0.00010098233,0.00014677564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077099085,0.00034418254,0.00058508484,0.000099810124,0.0001517794,0.00011702053,0.00018993749,0.00010924621,0.00029892175],"category_scores_gemma":[0.000015598986,0.00021798324,0.00012430064,0.000851248,0.00018528296,0.00047725558,0.00014697015,0.0003551561,0.00002022581],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028777355,0.00046669453,0.9298626,0.00027864572,0.0059211594,0.00039443123,0.001109159,0.00018105854,0.00049039995,0.000043725067,0.0010538582,0.03142088],"study_design_scores_gemma":[0.01520431,0.0014366285,0.9752969,0.004026717,0.00064034655,0.000035797224,0.00026008376,0.0005291511,0.00033547913,0.000022819826,0.0018340312,0.00037772246],"about_ca_topic_score_codex":0.0015505552,"about_ca_topic_score_gemma":0.00014109032,"teacher_disagreement_score":0.045434278,"about_ca_system_score_codex":0.00014325288,"about_ca_system_score_gemma":0.00014501793,"threshold_uncertainty_score":0.8889099},"labels":[],"label_agreement":null},{"id":"W4391034036","doi":"10.1111/1759-7714.15205","title":"Real‐world survival outcomes of immunotherapy for advanced non‐small cell lung cancer: A single‐center retrospective review","year":2024,"lang":"en","type":"article","venue":"Thoracic Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; University of Windsor; Western University","funders":"","keywords":"Medicine; Chemoimmunotherapy; Lung cancer; Immunotherapy; Internal medicine; Oncology; Chemotherapy; Clinical trial; Survival analysis; Stage (stratigraphy); Survival rate; Cancer; Surgery","score_opus":0.025915107201589065,"score_gpt":0.3758785449583016,"score_spread":0.3499634377567125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391034036","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31808856,0.6529532,0.0008008658,0.0071487552,0.004648875,0.005307053,0.0011675378,0.00032255333,0.009562601],"genre_scores_gemma":[0.4287418,0.53283805,0.001611985,0.0031325563,0.00076441345,0.0022089388,0.00011004545,0.00028003752,0.030312194],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99790984,0.000051343293,0.0006737602,0.00056293013,0.00035240754,0.00044968698],"domain_scores_gemma":[0.9987517,0.00012882166,0.0002451633,0.00052026036,0.00026176698,0.000092274386],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004489021,0.00037261998,0.0010881202,0.00019464525,0.00007025534,0.000029758578,0.00018859371,0.000095712705,0.0010164551],"category_scores_gemma":[0.000016742835,0.000295516,0.0006104398,0.0007252194,0.00011046038,0.00011924354,0.000032332766,0.00024735084,0.000004185976],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0107637495,0.0007005621,0.12671696,0.031535145,0.0034109524,0.00003669695,0.0017051741,0.000010882542,0.31687093,0.00011335941,0.021312911,0.4868227],"study_design_scores_gemma":[0.017676635,0.0024218748,0.12330072,0.098007046,0.0042228377,0.000035317295,0.00040335255,0.00074893615,0.22537959,0.00021216461,0.5249933,0.0025982046],"about_ca_topic_score_codex":0.0016409728,"about_ca_topic_score_gemma":0.0014667774,"teacher_disagreement_score":0.5036804,"about_ca_system_score_codex":0.0010406188,"about_ca_system_score_gemma":0.0005137146,"threshold_uncertainty_score":0.9999497},"labels":[],"label_agreement":null},{"id":"W4391043513","doi":"10.14740/wjon1701","title":"The Addition of Atezolizumab to Chemotherapy in Non-Small Cell Lung Cancer: A Trial-Based Review and Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"World Journal of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Atezolizumab; Medicine; Hazard ratio; Oncology; Lung cancer; Internal medicine; Population; Meta-analysis; Confidence interval; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.0699429456618741,"score_gpt":0.41616525152776673,"score_spread":0.34622230586589264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391043513","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012644636,0.989295,0.000012769728,0.0080304835,0.0002591208,0.0019267006,0.00006374866,0.0000032629582,0.00039628576],"genre_scores_gemma":[0.000034668647,0.9955691,0.00022356854,0.0022012452,0.00016796234,0.00025188856,0.000011970381,0.00003400168,0.0015055739],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968108,0.00045126653,0.0020218878,0.00024747636,0.00024861537,0.00021996809],"domain_scores_gemma":[0.9970802,0.00054198015,0.0017744419,0.00031285788,0.00018116593,0.00010934057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021484918,0.00033317006,0.0062699257,0.0010570765,0.00003336063,0.00001698584,0.0002439232,0.00016644054,0.0008089153],"category_scores_gemma":[0.000040012255,0.00016980062,0.003328579,0.002087335,0.000084588195,0.000021186172,0.000024793033,0.00064217765,0.0000019738468],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010279665,0.00025603911,0.0000020170392,0.03669732,0.124586284,0.000130064,0.000077275276,0.000002522495,0.000004252945,0.0000043914356,0.033930793,0.79402936],"study_design_scores_gemma":[0.0049069617,0.00074527116,0.000003425851,0.0038075997,0.37761134,0.000039641913,0.000004950216,0.0000018119364,0.0000024745523,0.0000018553436,0.61278826,0.000086378735],"about_ca_topic_score_codex":0.00009655057,"about_ca_topic_score_gemma":0.0011128635,"teacher_disagreement_score":0.793943,"about_ca_system_score_codex":0.0006938961,"about_ca_system_score_gemma":0.0017727445,"threshold_uncertainty_score":0.88570553},"labels":[],"label_agreement":null},{"id":"W4391108653","doi":"10.3389/fimmu.2023.1307873","title":"Improved overall survival in patients with high-grade serous ovarian cancer is associated with CD16a+ immunologic neighborhoods containing NK cells, T cells and macrophages","year":2024,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Université de Montréal; Health Sciences Centre; University of Victoria; Centre Hospitalier de l’Université de Montréal; University of British Columbia; Beatrice Hunter Cancer Research Institute; Dalhousie University","funders":"Dalhousie University","keywords":"Immune system; Infiltration (HVAC); Serous carcinoma; Cancer research; Biology; Ovarian cancer; Medicine; Immunology; Cancer; Internal medicine","score_opus":0.0065091945458607674,"score_gpt":0.22011749463839259,"score_spread":0.21360830009253182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391108653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977418,0.018453293,0.00016592548,0.0006094358,0.0022339292,0.000802726,0.00012317288,0.00011004592,0.000083468716],"genre_scores_gemma":[0.99504584,0.002765159,0.0008742936,0.00046036838,0.00004023456,0.00009448962,0.00007785404,0.000077138335,0.00056459854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773115,0.00019307969,0.0004674345,0.00067680376,0.00020813114,0.00072338706],"domain_scores_gemma":[0.9992667,0.00009287488,0.0001640486,0.00034239262,0.00007677239,0.000057207926],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027374912,0.0004261652,0.00085431617,0.00044460926,0.00008277373,0.000067033405,0.00018425014,0.00040387764,0.00010459593],"category_scores_gemma":[0.000016593458,0.00032561625,0.00006767245,0.0006311598,0.00039732078,0.0001741599,0.00007370403,0.00074723765,0.0000017476865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039142214,0.0010985687,0.83073866,0.00030384277,0.006203912,0.0008142971,0.0052813496,0.00003492727,0.075735144,0.00008083267,0.0018810651,0.03868516],"study_design_scores_gemma":[0.029762896,0.0048796833,0.95036536,0.0011367736,0.0002553685,0.000017392213,0.00107222,0.000562345,0.0094863195,0.000099196644,0.0016211754,0.0007412865],"about_ca_topic_score_codex":0.0040310333,"about_ca_topic_score_gemma":0.00052226346,"teacher_disagreement_score":0.11962666,"about_ca_system_score_codex":0.00076822256,"about_ca_system_score_gemma":0.00029067756,"threshold_uncertainty_score":0.9999196},"labels":[],"label_agreement":null},{"id":"W4391383797","doi":"10.3390/curroncol31020053","title":"A Rare Case of Complete-Immunotherapy-Responsive Metastatic Non-Small Cell Lung Cancer with Long Lasting Progression-Free Survival: A Case Report","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Nivolumab; Gemcitabine; Lung cancer; Immunotherapy; Oncology; Internal medicine; Chemotherapy; Cisplatin; Disease; Cancer","score_opus":0.08046244627154339,"score_gpt":0.41599493658472986,"score_spread":0.33553249031318644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391383797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93827266,0.054832462,0.0019464432,0.0006398107,0.0019614648,0.0016016059,0.00017643439,0.000108786604,0.0004603352],"genre_scores_gemma":[0.9960914,0.00064461434,0.001885606,0.000098490986,0.00025946466,0.00045785127,0.000066756074,0.0000890173,0.00040674602],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99775785,0.0002361912,0.0007510827,0.0005454124,0.00027801917,0.00043144033],"domain_scores_gemma":[0.9978462,0.00067985745,0.00039624577,0.0005934931,0.00034090204,0.00014329769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007696908,0.0003291084,0.0007709972,0.00028086812,0.00013144476,0.00003134184,0.00014360694,0.000104249215,0.00031966195],"category_scores_gemma":[0.00009901115,0.00023471146,0.00022028325,0.0005828079,0.00027901476,0.000076756856,0.000093256895,0.00046306988,0.0000028109391],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007971034,0.0009133494,0.015499358,0.0046502366,0.0012979725,0.7937114,0.005365539,0.000021287586,0.008832685,0.000019257444,0.0029644172,0.15875341],"study_design_scores_gemma":[0.021276698,0.0052725305,0.0027850433,0.008647972,0.0027337936,0.86403054,0.0049168537,0.0072809816,0.005842928,0.000023314298,0.07621031,0.0009790641],"about_ca_topic_score_codex":0.00078356726,"about_ca_topic_score_gemma":0.002161056,"teacher_disagreement_score":0.15777434,"about_ca_system_score_codex":0.00041519827,"about_ca_system_score_gemma":0.0015516062,"threshold_uncertainty_score":0.95712554},"labels":[],"label_agreement":null},{"id":"W4391430347","doi":"10.1016/j.ejca.2024.113585","title":"Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Manchester Biomedical Research Centre; Array BioPharma; Ipsen; Genentech; Deutsche Krebshilfe; Eisai; National Institute for Health and Care Research; Italfarmaco; Seagen; Sanofi Pasteur; Galecto; SkylineDx; Cancer Research UK; NeraCare; Sun Pharma; Regeneron Pharmaceuticals; Sanofi; Pfizer; InflaRx; Les Laboratories Pierre Fabre; Daiichi Sankyo Europe; Bayer; Bristol-Myers Squibb; AstraZeneca; Amgen","keywords":"Medicine; Pembrolizumab; Placebo; Internal medicine; Hazard ratio; Adverse effect; Incidence (geometry); Melanoma; Gastroenterology; Clinical trial; Surgery; Oncology; Cancer; Immunotherapy; Confidence interval; Pathology","score_opus":0.012444828162958286,"score_gpt":0.2935422822969203,"score_spread":0.28109745413396203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391430347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912768,0.005636235,0.000056452394,0.00032736614,0.0009814437,0.00084298686,0.000080453785,0.00000876112,0.0007895204],"genre_scores_gemma":[0.99698365,0.0022313017,0.000031682626,0.00003543699,0.00056578225,0.000009655295,0.0000047164017,0.00003818742,0.00009957387],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99714065,0.00074849103,0.001077419,0.00021093254,0.0005856547,0.00023683812],"domain_scores_gemma":[0.99853915,0.00041810342,0.00059510843,0.0002237197,0.00014547659,0.000078468336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024537216,0.00020087631,0.00058673613,0.0003981805,0.00003401354,0.000030241601,0.00022487281,0.00005125393,0.00006961651],"category_scores_gemma":[0.00015315662,0.00013548647,0.0001617515,0.00041563937,0.00023184021,0.00016093971,0.00004284077,0.00061980344,7.06454e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92412496,0.00045258377,0.0056664166,0.00039613148,0.0010475686,0.0012819985,0.015207723,0.00020539942,0.01849623,0.000020749034,0.0007915982,0.03230862],"study_design_scores_gemma":[0.71699834,0.017312339,0.24372631,0.0040650447,0.0008741931,0.000104367726,0.0033309471,0.001569595,0.008372558,0.000010499104,0.0033316303,0.00030417586],"about_ca_topic_score_codex":0.00020307391,"about_ca_topic_score_gemma":0.00006204055,"teacher_disagreement_score":0.23805991,"about_ca_system_score_codex":0.00016311281,"about_ca_system_score_gemma":0.00052223477,"threshold_uncertainty_score":0.5524978},"labels":[],"label_agreement":null},{"id":"W4391509144","doi":"10.1016/j.athoracsur.2024.01.024","title":"The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer","year":2024,"lang":"en","type":"review","venue":"The Annals of Thoracic Surgery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"Daiichi Sankyo Europe; Intuitive Surgical; Gilead Sciences; National Cancer Institute; Regeneron Pharmaceuticals; National Institutes of Health; Eisai; Genentech; Coherus Biosciences; Seagen; G1 Therapeutics; Pfizer; Incyte; Mirati Therapeutics; Spectrum Pharmaceuticals; Boston Scientific Corporation; Teva Pharmaceutical Industries; AstraZeneca; Invitae; Atara Biotherapeutics; Sanofi; Bristol-Myers Squibb; Amgen; GlaxoSmithKline","keywords":"Medicine; Immunotherapy; Lung cancer; Oncology; Internal medicine; Cancer","score_opus":0.09316936616059317,"score_gpt":0.42932139022085725,"score_spread":0.33615202406026407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391509144","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034278212,0.993104,0.0000010556215,0.00071271876,0.0006558625,0.0009307602,0.000052405045,0.000020516924,0.0010948976],"genre_scores_gemma":[0.0008180433,0.9962855,0.000006136074,0.00013421723,0.00023247181,0.00023261018,0.00001986835,0.00010243624,0.0021686987],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969924,0.0004013665,0.0013690692,0.00032970015,0.00039942202,0.0005080168],"domain_scores_gemma":[0.9965575,0.0014342447,0.0008134162,0.0009982914,0.00014927736,0.000047320795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004219939,0.00041714933,0.002023463,0.0004405583,0.000097180964,0.000033806133,0.00049217494,0.0002300075,0.00013805645],"category_scores_gemma":[0.00006605366,0.0002106787,0.0015523664,0.0013093844,0.00019191671,0.00004763476,0.00010260552,0.0006173342,0.0000074211644],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010022498,0.00007023916,0.00011371755,0.020618998,0.0010565879,0.00001185964,0.0003685001,0.000001365112,0.00028866265,0.00000367997,0.009077532,0.9673866],"study_design_scores_gemma":[0.00008157395,0.000038283655,0.000034403147,0.0573695,0.00067422277,0.000014756718,0.00022411675,0.000030227504,0.0028760743,0.000048656893,0.93837005,0.00023814462],"about_ca_topic_score_codex":0.00161281,"about_ca_topic_score_gemma":0.00012885145,"teacher_disagreement_score":0.9671485,"about_ca_system_score_codex":0.00007695897,"about_ca_system_score_gemma":0.0011245648,"threshold_uncertainty_score":0.8591228},"labels":[],"label_agreement":null},{"id":"W4391556186","doi":"10.3390/diagnostics14030336","title":"Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review","year":2024,"lang":"en","type":"review","venue":"Diagnostics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Sherbrooke; Université Laval","funders":"","keywords":"Uveitis; Medicine; Context (archaeology); Intensive care medicine; Multidisciplinary approach; Immunology; Political science","score_opus":0.029598632518869065,"score_gpt":0.3224623922047083,"score_spread":0.2928637596858392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391556186","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009806068,0.996293,0.000005721495,0.00077329663,0.0004337163,0.0018278232,0.00010907365,0.00015303738,0.000394508],"genre_scores_gemma":[0.000008086333,0.9976378,0.00008901959,0.0007085694,0.00030405953,0.0003116595,0.00051075895,0.00016437251,0.00026566023],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758863,0.0001066094,0.001005839,0.0005535699,0.0003532475,0.00039207473],"domain_scores_gemma":[0.9980082,0.0008808056,0.00043579217,0.00044360457,0.00009060969,0.00014098366],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005613485,0.0006140041,0.0024376204,0.00022340803,0.00008482721,0.000100057565,0.000116810756,0.0002835989,0.00006238257],"category_scores_gemma":[0.0010669113,0.00041937295,0.0005653836,0.0007750033,0.00016717565,0.0000558684,0.00011620342,0.00072380295,0.0000430183],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012584197,0.0000759218,0.000021994347,0.12052921,0.001169406,0.0008377321,0.000045346147,8.064422e-9,4.126076e-7,0.000008285956,0.010676939,0.86662215],"study_design_scores_gemma":[0.00030769972,0.0001651645,0.000028137416,0.44694817,0.0072506275,0.00027679317,0.000009008707,8.479014e-7,0.0000026501018,0.000007558886,0.5447157,0.00028765696],"about_ca_topic_score_codex":0.000059080623,"about_ca_topic_score_gemma":0.000017237651,"teacher_disagreement_score":0.8663345,"about_ca_system_score_codex":0.00036017408,"about_ca_system_score_gemma":0.00034134605,"threshold_uncertainty_score":0.99982584},"labels":[],"label_agreement":null},{"id":"W4391600565","doi":"10.3390/cancers16040708","title":"CXCL13 Positive Cells Localization Predict Response to Anti-PD-1/PD-L1 in Pulmonary Non-Small Cell Carcinoma","year":2024,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières; Centre Hospitalier de l’Université de Montréal; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval","keywords":"CXCL13; Medicine; Nivolumab; Lung cancer; Tumor microenvironment; Immunohistochemistry; Internal medicine; Oncology; Immune system; Immunotherapy; Cancer; Cancer research; Pathology; Immunology; Chemokine","score_opus":0.009624451137397043,"score_gpt":0.2470425316997677,"score_spread":0.23741808056237065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391600565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98825824,0.0034622636,0.0007661841,0.00096286123,0.0010589293,0.00090716715,0.000108186636,0.00008447974,0.004391709],"genre_scores_gemma":[0.9946813,0.00029850905,0.00008815671,0.0017879638,0.00021510749,0.00007546483,0.000050578874,0.00005434442,0.0027485723],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99851817,0.00008736075,0.00031226213,0.0004882,0.00022575581,0.0003682723],"domain_scores_gemma":[0.9993333,0.00009824862,0.000040834748,0.00029348632,0.00006305571,0.00017103227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035449985,0.00021978862,0.00027729018,0.00036010478,0.00005433168,0.000040273855,0.000118366705,0.00013961658,0.00016456375],"category_scores_gemma":[0.000015157286,0.00020828887,0.000121811216,0.0008697815,0.000081680395,0.00008856513,0.00003557447,0.00021062217,0.00005258086],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031036222,0.00010765209,0.016492832,0.00085700135,0.00014028602,0.0022336189,0.006948949,0.003105283,0.90016913,0.000009005685,0.025718862,0.013181167],"study_design_scores_gemma":[0.004842131,0.0023144518,0.31115162,0.0027654956,0.000243342,0.00012757743,0.0030029898,0.02556582,0.5638986,0.00001859239,0.08515375,0.00091558014],"about_ca_topic_score_codex":0.0016236628,"about_ca_topic_score_gemma":0.00010268141,"teacher_disagreement_score":0.33627048,"about_ca_system_score_codex":0.0023763517,"about_ca_system_score_gemma":0.0013504814,"threshold_uncertainty_score":0.84937733},"labels":[],"label_agreement":null},{"id":"W4391614640","doi":"10.1007/s10637-023-01410-2","title":"CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial","year":2024,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; Jewish General Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Randomized controlled trial; Pembrolizumab; Medicine; Antagonist; Internal medicine; Cancer; Immunotherapy; Receptor","score_opus":0.012628129560671114,"score_gpt":0.30921781692091993,"score_spread":0.2965896873602488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391614640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867374,0.0010956035,0.00015862673,0.007933629,0.00027672885,0.0020459273,0.000014901451,0.000101221245,0.0016360099],"genre_scores_gemma":[0.99608344,0.00006552525,0.000988243,0.0009345713,0.00022004815,0.00024397857,0.00028729957,0.000032481214,0.0011444173],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981795,0.00015074348,0.0006245434,0.00036097923,0.00044167758,0.00024256008],"domain_scores_gemma":[0.9992317,0.00034614588,0.000102965154,0.00013577857,0.00005924534,0.0001241623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067990524,0.00020776369,0.000553653,0.00038918835,0.000042973857,0.000072243245,0.00007845514,0.000083335915,0.000113321476],"category_scores_gemma":[0.00018675352,0.00016645005,0.00011622969,0.00090020045,0.00025744233,0.00024287596,0.000011217571,0.00029408347,0.000014834344],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9712556,0.0004260075,0.00009174923,0.00011395617,0.00013073169,0.00013890686,0.0019346777,0.00007730411,0.0110960575,0.004893171,0.0009870504,0.008854807],"study_design_scores_gemma":[0.97563785,0.00090222346,0.00034216882,0.001185005,0.000054949636,0.000092182185,0.000094433526,0.0058513125,0.0058056135,0.007830329,0.001978552,0.00022537293],"about_ca_topic_score_codex":0.00069407525,"about_ca_topic_score_gemma":0.00017499411,"teacher_disagreement_score":0.009346083,"about_ca_system_score_codex":0.00036217616,"about_ca_system_score_gemma":0.0020047287,"threshold_uncertainty_score":0.67876357},"labels":[],"label_agreement":null},{"id":"W4391618586","doi":"10.1111/bph.16313","title":"The impact of Foxp3 <sup>+</sup> regulatory T‐cells on CD8 <sup>+</sup> T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors","year":2024,"lang":"en","type":"article","venue":"British Journal of Pharmacology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"FOXP3; CD8; Immune checkpoint; Immunotherapy; Cytotoxic T cell; T cell; Immune system; Tumor microenvironment; Cancer research; Biology; Cancer immunotherapy; Immunology; In vitro; Biochemistry","score_opus":0.009283471492484615,"score_gpt":0.28131938985731253,"score_spread":0.27203591836482793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391618586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761146,0.021070957,0.000009184415,0.0016761156,0.00053585274,0.00046388464,0.000037653044,0.000012873532,0.00007890694],"genre_scores_gemma":[0.9907662,0.00738013,0.00006517938,0.00045939803,0.0004362279,0.000012825242,0.000003383795,0.00004443662,0.0008321657],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99760246,0.000366817,0.0010287019,0.0002782693,0.00033007233,0.00039368292],"domain_scores_gemma":[0.9990273,0.00032456848,0.000281494,0.0001167999,0.00007668219,0.00017313508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014551432,0.00023355248,0.0005090898,0.00040570533,0.00010974026,0.00005719622,0.00016644294,0.00013880174,0.00033279683],"category_scores_gemma":[0.000056578945,0.00019392004,0.00038276488,0.00030264066,0.00025762347,0.00014025084,0.000065053864,0.0006726874,0.000013101213],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012628823,0.00035959433,0.00076888193,0.00009810707,0.0004394753,0.00090301066,0.00063903286,0.001193228,0.93327075,4.920768e-7,0.02271126,0.026987344],"study_design_scores_gemma":[0.013250529,0.006400473,0.10746666,0.0019441599,0.00040655132,0.0071850214,0.0011388843,0.0011163747,0.8427807,0.000041265022,0.017891087,0.00037827],"about_ca_topic_score_codex":0.00030313816,"about_ca_topic_score_gemma":0.0000060905045,"teacher_disagreement_score":0.10669778,"about_ca_system_score_codex":0.0005962351,"about_ca_system_score_gemma":0.0003130193,"threshold_uncertainty_score":0.790783},"labels":[],"label_agreement":null},{"id":"W4391683708","doi":"10.3390/cancers16040732","title":"Tumor Copy Number Alteration Burden as a Predictor for Resistance to Immune Checkpoint Blockade across Different Cancer Types","year":2024,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vitalité Health Network; Atlantic Cancer Research Institute; Dr. Georges-L.-Dumont University Hospital Centre; Université de Moncton; Beatrice Hunter Cancer Research Institute","funders":"Mitacs; Dalhousie University; Fondation de la recherche en santé du Nouveau-Brunswick","keywords":"Immune checkpoint; Immunotherapy; Blockade; Medicine; Oncology; Cancer; Immune system; Internal medicine; Tumor microenvironment; Biomarker; Proportional hazards model; Multivariate analysis; CD8; Cancer immunotherapy; Cancer research; Immunology; Biology; Receptor; Genetics","score_opus":0.014992663064054999,"score_gpt":0.33091324026849606,"score_spread":0.31592057720444106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391683708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755237,0.012593102,0.00043442578,0.0059013697,0.0023520524,0.0014940524,0.00042331443,0.00019479667,0.0010831968],"genre_scores_gemma":[0.97147775,0.00063079136,0.00019245896,0.0009148476,0.0013690717,0.0012103518,0.000054225304,0.000064036096,0.02408646],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850804,0.000016486058,0.0003609331,0.0004483338,0.00025773296,0.0004084774],"domain_scores_gemma":[0.9993273,0.000054721808,0.000063208936,0.0002884823,0.00011014935,0.00015614856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015111855,0.00023130522,0.00033135334,0.000047852725,0.00012401886,0.000101552716,0.0001159519,0.00007469496,0.0008345778],"category_scores_gemma":[0.000041269257,0.00018793168,0.00021141424,0.00025460366,0.00008049929,0.00007964905,0.000021632455,0.00014542034,0.000052719064],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021103531,0.0000526196,0.001733961,0.0023338667,0.0016116205,0.00008647651,0.0102354,0.00032115888,0.8950613,0.00021498647,0.044848096,0.022396948],"study_design_scores_gemma":[0.0029313539,0.00038091466,0.0041189515,0.0022149927,0.00019857704,0.000025796302,0.00043437086,0.000755046,0.3673813,0.00013676591,0.621033,0.00038890194],"about_ca_topic_score_codex":0.0011260253,"about_ca_topic_score_gemma":0.00068232924,"teacher_disagreement_score":0.5761849,"about_ca_system_score_codex":0.0023959577,"about_ca_system_score_gemma":0.00075921573,"threshold_uncertainty_score":0.9138041},"labels":[],"label_agreement":null},{"id":"W4391686101","doi":"10.1016/j.vaccine.2024.01.023","title":"The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data","year":2024,"lang":"en","type":"article","venue":"Vaccine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Institut National de Santé Publique du Québec; McGill University; Western University; Dalhousie University; University of Toronto; University Health Network; Université de Sherbrooke; London Health Sciences Centre; Public Health Ontario","funders":"","keywords":"Medicine; Vaccination; Adverse effect; Discontinuation; Incidence (geometry); Poisson regression; Internal medicine; Influenza vaccine; Pediatrics; Immunology; Population; Environmental health","score_opus":0.033900462398424897,"score_gpt":0.3317175345143609,"score_spread":0.297817072115936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391686101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98851246,0.007465063,0.000024574081,0.00066285726,0.0003851013,0.0026166607,0.000113365655,0.00011946867,0.000100476944],"genre_scores_gemma":[0.998975,0.00020308472,0.00017612324,0.000028650717,0.00028266115,0.0000674473,0.00005930769,0.0000339319,0.00017378866],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99782246,0.00017675164,0.0009835156,0.00042780171,0.00034418408,0.00024529314],"domain_scores_gemma":[0.9983678,0.00025478553,0.00026416598,0.000800973,0.00023826028,0.00007402979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012792934,0.0002570145,0.0005259459,0.000116177376,0.00023136853,0.00009366861,0.00021125542,0.000084138686,0.00011739597],"category_scores_gemma":[0.00023137541,0.00016069516,0.0001698688,0.00051792135,0.000022901919,0.00046958012,0.00016761229,0.00024893804,0.000002084109],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5796323,0.00656458,0.1504058,0.0032091993,0.02580818,0.008883013,0.053070482,0.000049474227,0.07588228,0.0002233876,0.0029584502,0.09331287],"study_design_scores_gemma":[0.18043284,0.012889763,0.605021,0.004997547,0.006101909,0.009964642,0.058153354,0.06602106,0.040798884,0.00008628585,0.013958614,0.0015740728],"about_ca_topic_score_codex":0.0006734503,"about_ca_topic_score_gemma":0.0010179738,"teacher_disagreement_score":0.45461524,"about_ca_system_score_codex":0.00017228613,"about_ca_system_score_gemma":0.00038171856,"threshold_uncertainty_score":0.65529585},"labels":[],"label_agreement":null},{"id":"W4391741180","doi":"10.3389/fonc.2024.1330271","title":"Case report: A rare case of immunotherapy induced isolated left CN VI palsy in a patient with unresectable melanoma","year":2024,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Edinburgh; Institute of Genetics; Cancer Research UK","keywords":"Medicine; Immunotherapy; Palsy; Melanoma; Dermatology; Pediatrics; Radiology; Internal medicine; Pathology; Cancer; Cancer research; Alternative medicine","score_opus":0.014194500508513614,"score_gpt":0.2934396290407531,"score_spread":0.2792451285322395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391741180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985507,0.00992217,0.0003889331,0.0006065789,0.0011698825,0.000881879,0.000019988729,0.000049032416,0.0014545091],"genre_scores_gemma":[0.9967918,0.00035547893,0.0020542934,0.000303467,0.00004254667,0.00008118825,0.000025023131,0.00004476595,0.0003014513],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9980628,0.00019268856,0.000776316,0.0004330043,0.00015266877,0.00038250952],"domain_scores_gemma":[0.9991675,0.00010599726,0.00018269625,0.00039716667,0.00007311731,0.000073521376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005208722,0.00022509831,0.00071308966,0.0006374543,0.000039304097,0.000015063206,0.00008058554,0.0003144958,0.00025727757],"category_scores_gemma":[0.000047237867,0.00017852827,0.00010859032,0.0007690134,0.00014298657,0.00009128762,0.000030174806,0.00045269006,0.0000017063543],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0110548185,0.00038547756,0.010347589,0.0001536396,0.00042531156,0.8386063,0.006325149,0.000007245209,0.006977279,0.000005290943,0.0040093563,0.12170257],"study_design_scores_gemma":[0.010056256,0.008671377,0.0009198953,0.0008603924,0.000096908116,0.93620574,0.0077349273,0.0020663613,0.004008572,0.00008464886,0.028934982,0.000359935],"about_ca_topic_score_codex":0.004186304,"about_ca_topic_score_gemma":0.004346887,"teacher_disagreement_score":0.12134263,"about_ca_system_score_codex":0.0006985079,"about_ca_system_score_gemma":0.00080910925,"threshold_uncertainty_score":0.7280171},"labels":[],"label_agreement":null},{"id":"W4391779877","doi":"10.1038/s41591-024-02808-y","title":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; William Osler Health System; Centre Hospitalier de l’Université de Montréal; University of Toronto; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"Daiichi Sankyo Europe; Chugai Pharmaceutical; University of Texas MD Anderson Cancer Center; EMD Serono; Foundation Medicine; Karl Landsteiner Privatuniversität für Gesundheitswissenschaften; Universitätsklinikum Heidelberg; Ipsen; Deutsches Zentrum für Lungenforschung; Ottawa Hospital Research Institute; Seoul National University Hospital; Eisai; Universität Wien; PharmaMar; Institut Bergonié; Seoul National University; University of Toronto; Sanofi; Sungkyunkwan University; College of Medicine, Seoul National University; Genentech; Institut Gustave-Roussy; EpicentRx; Pfizer; Incyte; Mirati Therapeutics; Teva Pharmaceutical Industries; University of Ottawa; Johns Hopkins University; Nationales Centrum für Tumorerkrankungen Heidelberg; Amgen; Deutsches Krebsforschungszentrum; Université de Montréal; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Regeneron Pharmaceuticals","keywords":"Durvalumab; Medicine; Immunotherapy; Oncology; Internal medicine; Lung cancer; Cancer; Immunology; Cancer research; Nivolumab","score_opus":0.018031032367021232,"score_gpt":0.3536915487600901,"score_spread":0.3356605163930689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391779877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7134558,0.2697655,0.000051210933,0.005736144,0.0050016786,0.002588364,0.000043190343,0.00040029254,0.0029578228],"genre_scores_gemma":[0.96859723,0.021185772,0.00025263938,0.0028770033,0.0018585996,0.00037770264,0.00027931613,0.00012774585,0.004443959],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99685127,0.00013350206,0.0008173528,0.00085316185,0.00070602726,0.00063868915],"domain_scores_gemma":[0.9986008,0.00029358096,0.00015264917,0.00054847816,0.00016680553,0.00023771911],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008416325,0.00053435774,0.0010149312,0.00075102376,0.00008512279,0.000030333971,0.0002566779,0.0006976107,0.0015026821],"category_scores_gemma":[0.0001532567,0.000377121,0.0002690921,0.0022603886,0.00019446794,0.000099592915,0.00003129353,0.0015023483,0.000009969606],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2572039,0.00079184835,0.00030912142,0.000923552,0.0007784345,0.0010371967,0.0022902063,0.000005079828,0.45424882,0.000010763134,0.04646213,0.23593892],"study_design_scores_gemma":[0.65898085,0.0058768396,0.0038194582,0.0060750013,0.00056418293,0.00013493022,0.00047216128,0.015733264,0.042537745,0.000031078205,0.26486203,0.0009124464],"about_ca_topic_score_codex":0.0010474458,"about_ca_topic_score_gemma":0.00025876975,"teacher_disagreement_score":0.4117111,"about_ca_system_score_codex":0.0007451063,"about_ca_system_score_gemma":0.0010572021,"threshold_uncertainty_score":0.9998681},"labels":[],"label_agreement":null},{"id":"W4391786157","doi":"10.1007/s00262-023-03623-z","title":"INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors","year":2024,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"MacroGenics; AstraZeneca; Eli Lilly and Company; Astellas Pharma; Bristol-Myers Squibb","keywords":"Tremelimumab; Medicine; Tolerability; Discontinuation; Adverse effect; Oncology; Internal medicine; Response Evaluation Criteria in Solid Tumors; Cancer; Phases of clinical research; Clinical trial; Immunotherapy; Ipilimumab","score_opus":0.023970639687783277,"score_gpt":0.34388055676956547,"score_spread":0.3199099170817822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391786157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98077035,0.014343114,0.000011682701,0.0004340762,0.00045555676,0.0036720347,0.000032466778,0.00007740693,0.00020331061],"genre_scores_gemma":[0.9966601,0.0014669336,0.000108987806,0.00029842972,0.000022498893,0.001026072,0.00007371738,0.00011150831,0.00023171645],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971132,0.00019394897,0.0009826559,0.0007552519,0.00038157887,0.0005733238],"domain_scores_gemma":[0.9985998,0.00007798415,0.00031608314,0.00074089953,0.000218658,0.00004657079],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041232063,0.0004773883,0.001082271,0.0007808985,0.0001193407,0.000053682867,0.0004684289,0.0001599187,0.00029302292],"category_scores_gemma":[0.000012497189,0.00036815388,0.0000541442,0.0017044839,0.00033456684,0.0005116539,0.000085102765,0.0006369477,0.0000034382492],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23056115,0.039488867,0.08012408,0.00016393962,0.0032434273,0.00019857298,0.01465914,0.00007920349,0.095811166,0.000079354235,0.00011339144,0.5354777],"study_design_scores_gemma":[0.53946275,0.1146864,0.31911656,0.0044758487,0.00019953238,0.00004378107,0.003668487,0.0001666075,0.0129036335,0.00005827462,0.004168616,0.0010495012],"about_ca_topic_score_codex":0.001511472,"about_ca_topic_score_gemma":0.0012747103,"teacher_disagreement_score":0.5344282,"about_ca_system_score_codex":0.00081438,"about_ca_system_score_gemma":0.00074510195,"threshold_uncertainty_score":0.99987704},"labels":[],"label_agreement":null},{"id":"W4391873641","doi":"10.1093/jcag/gwad061.197","title":"A197 A ROLE FOR NOD2 IN INTESTINAL T CELL MEMORY DEVELOPMENT AND FUNCTION","year":2024,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"NOD2; Function (biology); Cognitive science; Psychology; Biology; Cell biology; Genetics","score_opus":0.008216286071313124,"score_gpt":0.22270931331308058,"score_spread":0.21449302724176747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391873641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903761,0.00023410756,0.00008297898,0.008514229,0.00050212257,0.000119035234,0.0000054641478,0.0000017426273,0.00016423431],"genre_scores_gemma":[0.99808455,0.00001190771,0.00039025996,0.00089918775,0.00007574198,0.0000030292758,0.0000015236823,0.000005641606,0.0005281479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993743,0.000046537447,0.00028943815,0.00005360723,0.00010094131,0.00013520045],"domain_scores_gemma":[0.9995391,0.00004791107,0.00021424475,0.000036225607,0.000100340476,0.00006221766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006912053,0.00004866744,0.00014911148,0.00021210092,0.000029917252,0.00001009884,0.000045117224,0.000052953455,0.000016636997],"category_scores_gemma":[0.0000713003,0.00003635544,0.00007458839,0.000053674306,0.000019260502,0.000034854053,0.0000059575646,0.00014332857,3.987383e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004121914,0.00006519133,0.96172005,0.00017477635,0.00040745645,0.000017019547,0.001202724,0.000025626568,0.010868583,0.000032086555,0.009145043,0.012219539],"study_design_scores_gemma":[0.004123957,0.001581229,0.9493245,0.00035621168,0.0001407426,0.0002139762,0.00031809826,0.00023785619,0.001627656,0.00012028939,0.04190892,0.00004659846],"about_ca_topic_score_codex":0.0010291267,"about_ca_topic_score_gemma":0.16683123,"teacher_disagreement_score":0.1658021,"about_ca_system_score_codex":0.0009870741,"about_ca_system_score_gemma":0.0005476159,"threshold_uncertainty_score":0.8483719},"labels":[],"label_agreement":null},{"id":"W4391982709","doi":"10.7150/jca.92502","title":"Overcoming the limitations of immunotherapy in pancreatic ductal adenocarcinoma: Combining radiotherapy and metabolic targeting therapy","year":2024,"lang":"en","type":"article","venue":"Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Government of Jiangsu Province; National Natural Science Foundation of China","keywords":"Immunotherapy; Medicine; Radiation therapy; Tumor microenvironment; Cancer research; Pancreatic cancer; Immune system; Cancer; Cancer immunotherapy; Reprogramming; Oncology; Immunology; Cell; Internal medicine; Biology","score_opus":0.03282549217305439,"score_gpt":0.3060167920674948,"score_spread":0.27319129989444046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391982709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5705482,0.4269967,0.00006211125,0.0019302461,0.0002829768,0.00012291693,0.0000020376615,0.000005040906,0.000049784787],"genre_scores_gemma":[0.7590947,0.23968646,0.0004791841,0.00040381157,0.00025042178,0.0000095414,5.2440157e-7,0.00002362914,0.000051704992],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987607,0.00009045574,0.0006012108,0.00011413774,0.00026714115,0.00016635943],"domain_scores_gemma":[0.9991185,0.0003838966,0.0002470406,0.00011711816,0.00009404899,0.000039371756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007243489,0.0001387143,0.0004381999,0.00024388646,0.000055508426,0.000044247965,0.000100755744,0.00005480693,0.00008563123],"category_scores_gemma":[0.00003480707,0.00008395035,0.00019851403,0.00039826604,0.00013030843,0.00017359527,0.000007418102,0.00031740533,1.9619446e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047347336,0.00015102775,0.22473934,0.00011744971,0.0026757652,0.00009720287,0.015249683,0.00007726618,0.53045,0.00044134233,0.0008079183,0.2204583],"study_design_scores_gemma":[0.012214646,0.001163044,0.8657954,0.0022634524,0.00034414508,0.00074344024,0.0028730754,0.0012152885,0.018343067,0.00039719054,0.09434146,0.0003058356],"about_ca_topic_score_codex":0.0001829878,"about_ca_topic_score_gemma":0.000020662674,"teacher_disagreement_score":0.641056,"about_ca_system_score_codex":0.00011157725,"about_ca_system_score_gemma":0.00029932146,"threshold_uncertainty_score":0.3423396},"labels":[],"label_agreement":null},{"id":"W4392014388","doi":"10.1016/j.esmoop.2024.102254","title":"A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Principia Biopharma; Loxo Oncology; Chugai Pharmaceutical; EMD Serono; Genentech; Sierra Oncology; Astellas Pharma; Cancer Research UK; Seagen; MacroGenics; Ascentage Pharma; Menarini Group; F-star Therapeutics; Symphogen; Moderna; Pfizer; Innovent Biologics; Incyte; Mersana Therapeutics; Agios Pharmaceuticals; BeiGene; Bristol-Myers Squibb; Constellation Pharmaceuticals; GlaxoSmithKline; Tizona Therapeutics; Helsinn; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Novartis Farmacéutica; Alexion Pharmaceuticals; Servier; Gilead Sciences; Sanofi; Helsinn Therapeutics; Amgen; Jounce Therapeutics; LAM Therapeutics; Celgene; Carrick Therapeutics; AstraZeneca; Onyx Pharmaceuticals; Eli Lilly and Company","keywords":"Monoclonal antibody; Antibody; Solid tumor; Dosing; Cancer research; Medicine; Monoclonal; Internal medicine; Immunology; Cancer","score_opus":0.013214786902607927,"score_gpt":0.3212640118319691,"score_spread":0.3080492249293612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392014388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950339,0.00013978714,7.105732e-7,0.000464168,0.00020024093,0.0028222965,0.00001533505,0.000019496087,0.0013040187],"genre_scores_gemma":[0.99907535,0.0000114077375,0.000030761894,0.00015089451,0.000031410113,0.00014576975,0.000017139537,0.000033372216,0.00050390424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985534,0.00006889529,0.00045076094,0.0003565966,0.00033457042,0.0002357553],"domain_scores_gemma":[0.99929583,0.000036136727,0.00009624658,0.00048462918,0.000043090247,0.00004408212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032205065,0.00017667738,0.0003894576,0.00014190622,0.000073241834,0.00004889165,0.0003433824,0.000046866015,0.00022396578],"category_scores_gemma":[0.000021578868,0.00011029194,0.000057684283,0.0006569244,0.00008707761,0.00019249042,0.00017096991,0.00025449906,0.000004912733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031665117,0.017064083,0.8924798,0.00051018206,0.00050621765,0.00037819767,0.022444334,0.00008283034,0.0018617713,0.000065648244,0.0022905234,0.030651296],"study_design_scores_gemma":[0.043146115,0.0069948463,0.9370839,0.0029630568,0.00006953928,0.0000054180337,0.0018430516,0.00006775911,0.0029532593,0.00003651063,0.0045863343,0.0002501957],"about_ca_topic_score_codex":0.0024587752,"about_ca_topic_score_gemma":0.005828758,"teacher_disagreement_score":0.044604115,"about_ca_system_score_codex":0.00020316897,"about_ca_system_score_gemma":0.00014745582,"threshold_uncertainty_score":0.4497575},"labels":[],"label_agreement":null},{"id":"W4392022357","doi":"10.1016/j.rdc.2024.01.006","title":"Patient Voices in Rheumatic Immune-related Adverse Events","year":2024,"lang":"en","type":"review","venue":"Rheumatic Disease Clinics of North America","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Centre de Santé et de Services Sociaux de la Montagne","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Rheumatology Research Foundation","keywords":"Medicine; Adverse effect; Myositis; Physical therapy; Joint pain; Arthritis; Rheumatoid arthritis; Immune system; Internal medicine; Intensive care medicine; Immunology","score_opus":0.02270900662678647,"score_gpt":0.3389964886485681,"score_spread":0.3162874820217816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392022357","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011483638,0.9846429,0.0000037480104,0.000052241357,0.00086964684,0.0023256645,0.0003667744,0.000087276254,0.00016806503],"genre_scores_gemma":[0.0044507887,0.993643,0.00012624208,0.00007772014,0.0000168886,0.0002890446,0.000990622,0.00013330823,0.00027239646],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99354887,0.00027924578,0.0043129786,0.00068418076,0.0007002196,0.00047450053],"domain_scores_gemma":[0.9957433,0.00052758644,0.0020908695,0.0011604527,0.00009504832,0.00038276383],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038143768,0.0007514869,0.0037015907,0.00065621,0.000044276116,0.000011050048,0.0003796193,0.00020919049,0.00038093398],"category_scores_gemma":[0.00054797647,0.00056730316,0.0023735214,0.0014899056,0.0002829821,0.00009527633,0.00016958089,0.00068615685,0.00051967235],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032098935,0.000800126,0.0013436802,0.078520186,0.0017895872,0.00009335732,0.0002616796,0.0000065709046,8.380818e-9,0.00000208604,0.00026530848,0.9165964],"study_design_scores_gemma":[0.002943381,0.00082941493,0.010890966,0.39505342,0.011143327,0.00003821703,0.00024109053,0.0007283535,2.4566017e-8,0.00012932566,0.5767462,0.0012562878],"about_ca_topic_score_codex":0.00015072593,"about_ca_topic_score_gemma":0.000022197653,"teacher_disagreement_score":0.9153401,"about_ca_system_score_codex":0.00029203942,"about_ca_system_score_gemma":0.0017058671,"threshold_uncertainty_score":0.99967784},"labels":[],"label_agreement":null},{"id":"W4392058002","doi":"10.1007/s10238-024-01301-7","title":"Immune checkpoint inhibitors and risk of immune-mediated adverse events: a cohort study comparing extended versus standard interval administration","year":2024,"lang":"en","type":"article","venue":"Clinical and Experimental Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Santé et de Services Sociaux de la Vieille-Capitale; Université Laval; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec","funders":"","keywords":"Medicine; Hazard ratio; Poisson regression; Internal medicine; Confidence interval; Retrospective cohort study; Incidence (geometry); Adverse effect; Cohort; Cohort study; Proportional hazards model; Population","score_opus":0.03899465358422806,"score_gpt":0.39109130936787945,"score_spread":0.3520966557836514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392058002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98217624,0.014532928,0.000013010742,0.00036854012,0.0016993898,0.0008562472,0.000013634118,0.00006052286,0.00027948027],"genre_scores_gemma":[0.99750274,0.0019494048,0.00005772084,0.0000351427,0.00027536886,0.00003924654,0.000049432656,0.000020412928,0.00007055167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975637,0.0001358383,0.0013584935,0.00042019377,0.0003495481,0.00017221898],"domain_scores_gemma":[0.99906373,0.0002840006,0.00019917394,0.00022632269,0.000049253667,0.00017749415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014315057,0.00022101228,0.00081103283,0.00009857989,0.00006908881,0.0000073774027,0.000059083166,0.0001028814,0.00017130846],"category_scores_gemma":[0.00026370352,0.00015579358,0.00017328752,0.00017239086,0.00067842024,0.000091123286,0.00008846456,0.0003312647,0.0000034244918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11491893,0.0024647927,0.79375947,0.00037531517,0.00393211,0.00020149075,0.005215936,2.6073047e-7,0.06178282,0.000026340038,0.0002924978,0.017030044],"study_design_scores_gemma":[0.037633285,0.03795099,0.8755327,0.001957384,0.0010076251,0.00006654807,0.019129388,0.0004976707,0.025021981,0.000019046443,0.0008982382,0.00028515043],"about_ca_topic_score_codex":0.00035877284,"about_ca_topic_score_gemma":0.00002800085,"teacher_disagreement_score":0.08177323,"about_ca_system_score_codex":0.000071496754,"about_ca_system_score_gemma":0.00007707764,"threshold_uncertainty_score":0.6353077},"labels":[],"label_agreement":null},{"id":"W4392094247","doi":"10.1016/j.rdc.2024.01.007","title":"De novo Connective Tissue Disorders as Immune-related Adverse Events","year":2024,"lang":"en","type":"review","venue":"Rheumatic Disease Clinics of North America","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Connective tissue; Immune system; Medicine; Adverse effect; Immunology; Pathology; Internal medicine","score_opus":0.019016305810919502,"score_gpt":0.3606146564005634,"score_spread":0.3415983505896439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392094247","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026318072,0.99308765,0.00003633878,0.00012212411,0.0007406505,0.0021225123,0.00051164266,0.00012200342,0.0006252626],"genre_scores_gemma":[0.0022953374,0.99469185,0.00011837797,0.00015363164,0.00003881228,0.00018782372,0.0009921223,0.00015576939,0.0013662911],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99591124,0.0002345947,0.0022328445,0.00065110775,0.0004972607,0.00047294507],"domain_scores_gemma":[0.99653375,0.0005833358,0.0013143161,0.0009791412,0.000105309584,0.00048416475],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032669332,0.0006841556,0.0028159865,0.00034502614,0.00007046753,0.000011177884,0.00039615334,0.00022894566,0.00078146637],"category_scores_gemma":[0.00080092775,0.0005456926,0.0021225705,0.0010127628,0.00040597437,0.00006855676,0.00013163732,0.00059598737,0.00075774454],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054496893,0.0005640233,0.00035247,0.033924438,0.0037828758,0.00009160602,0.00022496465,0.000003660628,4.205397e-8,0.000011419812,0.00033805246,0.9601615],"study_design_scores_gemma":[0.0019078497,0.0008230445,0.0018609236,0.06540071,0.01342162,0.000058217916,0.00016613834,0.000089600966,5.9133058e-8,0.00035933623,0.91516787,0.0007446585],"about_ca_topic_score_codex":0.00015910421,"about_ca_topic_score_gemma":0.000013853592,"teacher_disagreement_score":0.9594168,"about_ca_system_score_codex":0.00029840198,"about_ca_system_score_gemma":0.0028308493,"threshold_uncertainty_score":0.9996995},"labels":[],"label_agreement":null},{"id":"W4392105530","doi":"10.3389/fonc.2024.1325610","title":"Immunotherapy and radiotherapy for older patients with locally advanced rectal cancer unfit for surgery or decline surgery: a practical proposal by the International Geriatric Radiotherapy Group","year":2024,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Radiation therapy; Colorectal cancer; Immunotherapy; Quality of life (healthcare); Cancer; Surgery; Oncology; Internal medicine; Nursing","score_opus":0.01252717282075464,"score_gpt":0.3223171875146566,"score_spread":0.30979001469390194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392105530","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41349584,0.11317581,0.33473846,0.10904545,0.016938932,0.011693537,0.0005944608,0.00025315498,0.00006437751],"genre_scores_gemma":[0.17905684,0.23753873,0.48303366,0.059445072,0.006463095,0.022219101,0.002368973,0.0012807014,0.008593827],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979791,0.00012397762,0.00059332774,0.0005621601,0.00027897637,0.0004624325],"domain_scores_gemma":[0.99707603,0.002299539,0.00020262749,0.00020552777,0.00013560192,0.000080662634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010306225,0.0003034041,0.0007592134,0.00031459657,0.00010547813,0.000075644886,0.00014203934,0.0002460602,0.00014743271],"category_scores_gemma":[0.00014986985,0.00018269631,0.00022683808,0.00041111614,0.00029433615,0.00019991474,0.000015735672,0.00024767674,1.9701606e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09797072,0.0005053892,0.02940406,0.0001500578,0.0013493508,0.000028219432,0.00035268712,0.000002874908,0.0009536425,0.000027236561,0.27240837,0.5968474],"study_design_scores_gemma":[0.017840004,0.0027870853,0.015491307,0.0003246707,0.00012346997,0.00012209019,0.00019616676,0.0023525294,0.0002010975,0.00013016927,0.9600248,0.00040663444],"about_ca_topic_score_codex":0.00009728637,"about_ca_topic_score_gemma":0.00023016542,"teacher_disagreement_score":0.6876164,"about_ca_system_score_codex":0.0010261346,"about_ca_system_score_gemma":0.0017652488,"threshold_uncertainty_score":0.7450139},"labels":[],"label_agreement":null},{"id":"W4392110421","doi":"10.1038/s41467-024-45357-1","title":"Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial","year":2024,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Labex Immuno-Oncology; Fondation Gustave Roussy; Institut Gustave-Roussy; Radboud Universitair Medisch Centrum; Institut Universitaire de France; Ligue Contre le Cancer; Fondation pour la Recherche Médicale; ZonMw; Institut National Du Cancer; Institut National de la Santé et de la Recherche Médicale; Agence Nationale de la Recherche; Université de Paris; Direction Générale de l’offre de Soins; Seerave Foundation; Association pour la Recherche sur le Cancer; European Commission; Centre National de la Recherche Scientifique; Radboud Universiteit; Equipex","keywords":"Faecalibacterium prausnitzii; Melanoma; Randomized controlled trial; Medicine; Internal medicine; Adjuvant; Microbiome; Placebo; Oncology; Metabolomics; Immune system; Immunotherapy; Gastroenterology; Immunology; Gut flora; Cancer research; Bioinformatics; Biology; Pathology","score_opus":0.025959426830327464,"score_gpt":0.34669711386952307,"score_spread":0.3207376870391956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392110421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762173,0.01889216,0.0000041499875,0.0026954385,0.00020641396,0.0017671806,0.000101996186,0.000034982488,0.0000803759],"genre_scores_gemma":[0.99714345,0.00040159674,0.00095538376,0.00097314897,0.000031878815,0.00011208014,0.00033308918,0.000022688993,0.000026704914],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99752855,0.000842484,0.00092356646,0.0002685088,0.00026896902,0.00016792097],"domain_scores_gemma":[0.99387205,0.0041232673,0.00025972122,0.0015322987,0.00016909232,0.000043559205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015242252,0.00016952597,0.00073138153,0.00010301853,0.00009592954,0.000032970587,0.0005415931,0.00030748945,0.000018352157],"category_scores_gemma":[0.001109695,0.00009872643,0.00035261587,0.0005886491,0.00041009623,0.00004428223,0.00006534817,0.0012933546,0.0000057836314],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58414406,0.0037582526,0.39743733,0.000045097895,0.0016501035,0.0000088183515,0.00080072146,0.00003269761,0.0010167452,0.0001686996,0.0005571642,0.010380306],"study_design_scores_gemma":[0.48527145,0.00061677926,0.5035479,0.0007004172,0.00092105597,5.662668e-7,0.00005745861,0.00020837868,0.00047836517,0.000015155221,0.008001227,0.0001812579],"about_ca_topic_score_codex":0.00032354993,"about_ca_topic_score_gemma":0.00050934445,"teacher_disagreement_score":0.10611055,"about_ca_system_score_codex":0.000079817284,"about_ca_system_score_gemma":0.00022994446,"threshold_uncertainty_score":0.5619054},"labels":[],"label_agreement":null},{"id":"W4392111425","doi":"10.3390/cancers16050911","title":"Breast Tumor Metastasis and Its Microenvironment: It Takes Both Seed and Soil to Grow a Tumor and Target It for Treatment","year":2024,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; University of Manitoba; CancerCare Manitoba; Saskatchewan Cancer Agency; University of Saskatchewan; University of Alberta; University of Calgary","funders":"","keywords":"Breast cancer; Tumor microenvironment; Metastasis; Medicine; Immunotherapy; Metastatic breast cancer; Cancer research; Cancer; CA15-3; Primary tumor; Oncology; Melanoma; Internal medicine","score_opus":0.016979100332149173,"score_gpt":0.2631717073181842,"score_spread":0.246192606986035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392111425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9360592,0.051443346,0.00006409456,0.009915989,0.00021347887,0.0011803253,0.0008491162,0.00004575729,0.00022870481],"genre_scores_gemma":[0.98905903,0.00335711,0.00071763893,0.0035670446,0.00018145173,0.00035140014,0.000032488697,0.000052334257,0.0026815112],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99903345,0.000014283355,0.00017208704,0.0004169114,0.0001004542,0.0002628009],"domain_scores_gemma":[0.9995947,0.000046653164,0.00003275883,0.00011619724,0.000011876323,0.00019781243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010586421,0.00021626242,0.00031430306,0.00009005083,0.00008896771,0.00006166706,0.00003171408,0.000028880475,0.00010580854],"category_scores_gemma":[0.0000059714494,0.00016913013,0.000070271264,0.00010064193,0.00009603131,0.000077605844,0.00001592138,0.00003994847,0.000003262199],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020035816,0.00021509119,0.0063225334,0.004193733,0.005659294,0.0006144408,0.015930569,0.00006213133,0.6770669,0.00015298488,0.063703224,0.20604324],"study_design_scores_gemma":[0.012644945,0.0036708964,0.013741932,0.0013861798,0.0015358162,0.002258999,0.004723326,0.002553398,0.0771197,0.0000524596,0.87943345,0.00087891344],"about_ca_topic_score_codex":0.0003404864,"about_ca_topic_score_gemma":0.00015626532,"teacher_disagreement_score":0.8157302,"about_ca_system_score_codex":0.0006447926,"about_ca_system_score_gemma":0.00018887759,"threshold_uncertainty_score":0.6896926},"labels":[],"label_agreement":null},{"id":"W4392121206","doi":"10.3390/curroncol31030089","title":"Unlocking the Potential of Therapy-Induced Cytokine Responses: Illuminating New Pathways in Cancer Precision Medicine","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health","keywords":"Precision medicine; Cancer Medicine; Medicine; Cancer; Cancer therapy; Computational biology; Cytokine; Personalized medicine; Bioinformatics; Immunology; Biology; Internal medicine; Pathology","score_opus":0.16210766150954822,"score_gpt":0.43787459659118466,"score_spread":0.2757669350816364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392121206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9285921,0.058568038,0.00020178774,0.008146788,0.003394892,0.0005904715,0.000009658393,0.00004610788,0.00045017462],"genre_scores_gemma":[0.98984605,0.0086953975,0.000040149647,0.00022883691,0.0009310467,0.00004665448,0.000010818544,0.000023012448,0.00017802087],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983796,0.00020901735,0.0005611523,0.00029862084,0.00029868938,0.00025294741],"domain_scores_gemma":[0.9990176,0.00045361771,0.00013949876,0.00024536764,0.000081767954,0.00006214554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009943828,0.00016618354,0.00040459816,0.00028049684,0.000052546195,0.000008995346,0.00016111687,0.00012681152,0.0004694992],"category_scores_gemma":[0.00018066035,0.00009708521,0.00012293716,0.00060650526,0.00017466827,0.000051965602,0.000049601626,0.0004163685,0.0000034441925],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026518973,0.000111245114,0.0006672485,0.000077512246,0.0000634357,0.00003865342,0.0029639294,0.000003512832,0.28535053,0.00005359165,0.0017507289,0.7062677],"study_design_scores_gemma":[0.023094727,0.0085581755,0.104254715,0.0097203,0.00037243846,0.00037401044,0.005088514,0.0054787225,0.06792726,0.0010839516,0.77347296,0.00057420396],"about_ca_topic_score_codex":0.00057435356,"about_ca_topic_score_gemma":0.00015678233,"teacher_disagreement_score":0.77172226,"about_ca_system_score_codex":0.00036978422,"about_ca_system_score_gemma":0.00086855,"threshold_uncertainty_score":0.5140687},"labels":[],"label_agreement":null},{"id":"W4392121221","doi":"10.4103/jrms.jrms_166_23","title":"Effectiveness of PD1/PD-L1 combined with anti-angiogenic drugs in patients with advanced nonsmall cell lung cancer: A systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Journal of Research in Medical Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Publication bias; Meta-analysis; Funnel plot; Hazard ratio; Confidence interval; Lung cancer; Oncology; Randomized controlled trial","score_opus":0.06815456063393,"score_gpt":0.4515420033291474,"score_spread":0.3833874426952174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392121221","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0055311928,0.9909046,0.0000032672567,0.00048441728,0.00003964829,0.0029820283,0.00001649382,0.000002811997,0.000035496538],"genre_scores_gemma":[0.010843411,0.98876464,0.00009074182,0.00003476426,0.00001170985,0.00020372847,0.0000036402532,0.000016576998,0.000030788477],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99110824,0.002381056,0.0015879017,0.00044285276,0.0040263752,0.00045355494],"domain_scores_gemma":[0.9962382,0.0018677878,0.0008869692,0.000280359,0.00041809012,0.00030862272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022353305,0.00031780655,0.0070307995,0.0019107406,0.000057643065,0.000045360408,0.00064810464,0.00015324703,0.00013148213],"category_scores_gemma":[0.00044839073,0.00012967938,0.0010063027,0.008071082,0.0010239806,0.00013359207,0.00009671439,0.0011139755,6.357503e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005398626,0.0002875934,0.001699058,0.9643546,0.02997975,0.00017928967,0.00005816181,0.0000015889646,5.0591876e-7,0.0000028941893,0.00002829441,0.0028684423],"study_design_scores_gemma":[0.0023664613,0.0031598662,0.00076629716,0.68330777,0.30964386,0.00006813869,0.00007432809,0.000018094937,0.0000029870025,0.0000052526857,0.00037571348,0.00021123461],"about_ca_topic_score_codex":0.00017803485,"about_ca_topic_score_gemma":0.00007999475,"teacher_disagreement_score":0.28104678,"about_ca_system_score_codex":0.00037411402,"about_ca_system_score_gemma":0.0028744428,"threshold_uncertainty_score":0.7747254},"labels":[],"label_agreement":null},{"id":"W4392124874","doi":"10.1158/1055-9965.epi-23-1466","title":"Large-Scale Cancer Genomic Analysis Reveals Significant Disparities between Microsatellite Instability and Tumor Mutational Burden","year":2024,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"National Cancer Institute; Korea Health Industry Development Institute","keywords":"Microsatellite instability; Lung cancer; Colorectal cancer; ARID1A; Cancer; Oncology; Proportional hazards model; Immunotherapy; Internal medicine; Medicine; Hazard ratio; Cancer research; Biology; Mutation; Gene; Confidence interval; Genetics; Allele; Microsatellite","score_opus":0.04128417481279157,"score_gpt":0.36529854711059206,"score_spread":0.3240143722978005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392124874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88163245,0.1037555,0.003915168,0.008447623,0.0005581677,0.0007844991,0.000725455,0.00012828702,0.00005286341],"genre_scores_gemma":[0.9876957,0.007229779,0.0013540293,0.0008145811,0.00054060726,0.00042571584,0.000746362,0.000040776387,0.00115246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99653816,0.0006382302,0.0010789386,0.000976195,0.00016946776,0.00059898547],"domain_scores_gemma":[0.9983021,0.0007322371,0.00028357148,0.00036115074,0.00010896891,0.00021194902],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029328014,0.0003457232,0.0010223216,0.00041168559,0.00018905278,0.00004049499,0.00013045988,0.00025209697,0.0007798251],"category_scores_gemma":[0.000115634095,0.00030106836,0.00059871096,0.0007521545,0.0005566889,0.000177887,0.00007092782,0.00029008824,0.000010916512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010387304,0.00005122537,0.9415672,0.00064697064,0.0076591275,0.000016081585,0.0005046688,0.000031988802,0.018099662,0.00010329336,0.00224307,0.028038021],"study_design_scores_gemma":[0.0010687979,0.0001294607,0.9758407,0.0004969618,0.0034150188,0.000015141134,0.00024293867,0.001542506,0.0005226598,0.0033764706,0.013010511,0.00033881777],"about_ca_topic_score_codex":0.002304301,"about_ca_topic_score_gemma":0.00070255826,"teacher_disagreement_score":0.10606325,"about_ca_system_score_codex":0.0006302674,"about_ca_system_score_gemma":0.000378579,"threshold_uncertainty_score":0.99994415},"labels":[],"label_agreement":null},{"id":"W4392246441","doi":"10.1016/j.esmoop.2024.102358","title":"30P OSE279, a PD-1-blocking monoclonal antibody, as future backbone of a bifunctional checkpoint inhibitor platform: Preliminary results of a first-in-human (FIH) study in subjects with advanced malignancies","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; Genentech; Sierra Oncology; Daiichi Sankyo Europe; Servier; Eisai; Astellas Pharma; Basilea Pharmaceutica; PharmaMar; European Society for Medical Oncology; Pfizer; Incyte; Boston Pharmaceuticals; Agios Pharmaceuticals; Ipsen; Eisai Canada; BeiGene; Clovis Oncology; Les Laboratories Pierre Fabre; Loxo Oncology; Astex Pharmaceuticals; Bayer HealthCare; Exelixis; Sanofi; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Monoclonal antibody; Blocking (statistics); Bifunctional; Medicine; Cancer research; Blocking antibody; Antibody; Immunology; Chemistry; Computer science","score_opus":0.020554862663627372,"score_gpt":0.31619361572736215,"score_spread":0.29563875306373477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392246441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99437654,0.0011940608,0.000004166629,0.00068188604,0.00023072648,0.0019169978,0.00004844975,0.00002612346,0.0015210413],"genre_scores_gemma":[0.99840647,0.00010384096,0.00041813188,0.000056061446,0.00013554125,0.00012153373,0.000098183766,0.00003547337,0.0006247801],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99799836,0.000045575354,0.0007517592,0.00048235222,0.0004462825,0.00027567722],"domain_scores_gemma":[0.9992131,0.00009767319,0.00019209246,0.00034435358,0.00009441222,0.00005835429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007385117,0.0002486403,0.0005806064,0.0003701011,0.000063995634,0.00003737425,0.0002251688,0.00010964276,0.00013835673],"category_scores_gemma":[0.00003966849,0.00019082884,0.00010199266,0.00084202376,0.00012388089,0.0003195428,0.00017316308,0.00029135396,0.0000032917635],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44416842,0.008536345,0.3190948,0.0035880771,0.0019979766,0.004042048,0.047585655,0.00050177606,0.15412952,0.00040803498,0.0028206413,0.013126701],"study_design_scores_gemma":[0.024947673,0.015264151,0.90262586,0.007634132,0.000116454416,0.00022004911,0.009951081,0.00020888404,0.036124285,0.00013071325,0.0023816875,0.0003950588],"about_ca_topic_score_codex":0.00491582,"about_ca_topic_score_gemma":0.006317617,"teacher_disagreement_score":0.583531,"about_ca_system_score_codex":0.00017307232,"about_ca_system_score_gemma":0.00038296139,"threshold_uncertainty_score":0.77817744},"labels":[],"label_agreement":null},{"id":"W4392284368","doi":"10.1016/j.urology.2024.02.035","title":"Immune Checkpoint Inhibitors for Kidney and Bladder Cancer: Adrenotoxic Consequences","year":2024,"lang":"en","type":"letter","venue":"Urology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Kidney cancer; Bladder cancer; Urothelial cancer; Cancer; Immune system; Kidney; Oncology; Immunology; Cancer research; Internal medicine","score_opus":0.017475398086929654,"score_gpt":0.2812512543244319,"score_spread":0.2637758562375022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392284368","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026163936,0.04394832,0.00001667175,0.94836813,0.0030471487,0.0009350922,0.00035681704,0.00010203466,0.0006093749],"genre_scores_gemma":[0.0063439133,0.0036462552,0.00007486897,0.9742913,0.005491549,0.0005777035,0.00048391364,0.00010566026,0.008984822],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99829316,0.000048370883,0.0004755608,0.00057812384,0.00015081739,0.00045393954],"domain_scores_gemma":[0.9992662,0.00013210085,0.00015861008,0.0002908967,0.00006472283,0.000087458815],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001968167,0.00034480402,0.0006418007,0.00023251325,0.00006624752,0.000031250405,0.00011217555,0.0010070631,0.0007485505],"category_scores_gemma":[0.00007037647,0.00027535876,0.00028903384,0.00012168448,0.00073906867,0.000025087476,0.000050387465,0.0010218329,0.0000250693],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008282556,0.000012764685,0.000038340364,0.00072560436,0.0009568849,0.000304831,0.00014917647,1.4237636e-7,0.018168528,0.000011223158,0.9748046,0.0039996863],"study_design_scores_gemma":[0.0016333575,0.0008548253,0.000044553297,0.00018771194,0.0006821078,0.0004919831,0.0000138647465,0.000023601635,0.0053829905,0.00045482878,0.9899573,0.00027289166],"about_ca_topic_score_codex":0.00049812015,"about_ca_topic_score_gemma":0.00003452828,"teacher_disagreement_score":0.040302064,"about_ca_system_score_codex":0.00009859159,"about_ca_system_score_gemma":0.0006735419,"threshold_uncertainty_score":0.99996984},"labels":[],"label_agreement":null},{"id":"W4392291849","doi":"10.3389/fimmu.2024.1256766","title":"CD5 blockade, a novel immune checkpoint inhibitor, enhances T cell anti-tumour immunity and delays tumour growth in mice harbouring poorly immunogenic 4T1 breast tumour homografts","year":2024,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"King Saud bin Abdulaziz University for Health Science; Canadian Institutes of Health Research; King Abdullah International Medical Research Center","keywords":"CD5; Cytotoxic T cell; Cancer research; Immune checkpoint; Immune system; T cell; CD8; Immunology; Biology; Antibody; Antigen; Medicine; Immunotherapy; In vitro","score_opus":0.006578469980590995,"score_gpt":0.22027884826934777,"score_spread":0.21370037828875676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392291849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8452332,0.14879446,0.0004823842,0.0013036723,0.002783306,0.00077503326,0.000068768255,0.000187194,0.00037200286],"genre_scores_gemma":[0.9855673,0.01098862,0.002372152,0.000125518,0.00022340719,0.00013763999,0.00007109998,0.00013669957,0.00037761612],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9955089,0.0002681973,0.0015279178,0.0010527578,0.00035570288,0.0012865319],"domain_scores_gemma":[0.9987878,0.0001321669,0.00030221805,0.0005040882,0.00013514412,0.00013854711],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011660556,0.00076925516,0.0013798675,0.0016330456,0.00022332897,0.00016174231,0.00058925844,0.00055779377,0.000074312156],"category_scores_gemma":[0.00007929321,0.00076364743,0.00042768483,0.0016285103,0.0007308338,0.00047041537,0.0003625255,0.0018886894,0.000025916592],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022925013,0.0005612399,0.009251312,0.00049391633,0.000538482,0.00042950257,0.0018377118,0.0000033660156,0.98076206,0.000026263819,0.0002550545,0.0035485607],"study_design_scores_gemma":[0.010100122,0.0007640044,0.34005725,0.002161114,0.00023334721,0.0021834464,0.003744388,0.0006320051,0.6377693,0.0002458106,0.0010702147,0.0010389881],"about_ca_topic_score_codex":0.0044941637,"about_ca_topic_score_gemma":0.0001807874,"teacher_disagreement_score":0.34299278,"about_ca_system_score_codex":0.00074246235,"about_ca_system_score_gemma":0.00053488615,"threshold_uncertainty_score":0.99948144},"labels":[],"label_agreement":null},{"id":"W4392357794","doi":"10.3899/jrheum.2023-0969","title":"Immune Checkpoint Inhibitor–Associated Remitting Seronegative Symmetrical Synovitis With Pitting Edema: Description of a New Entity by CanRIO","year":2024,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Alberta; Dalhousie University","funders":"","keywords":"Medicine; Synovitis; Immune system; Edema; Immunology; Internal medicine; Arthritis","score_opus":0.01574940949110821,"score_gpt":0.25585851560089695,"score_spread":0.24010910610978875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392357794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98190874,0.013214417,0.0015656281,0.002600676,0.00042592816,0.00014895834,0.000004466915,0.000022091946,0.00010907537],"genre_scores_gemma":[0.997603,0.001614135,0.0003716879,0.000056056797,0.000028759365,0.0000011035996,0.0000034474378,0.000021436435,0.00030035072],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998224,0.00021327374,0.0008942733,0.00011298145,0.00032461336,0.00023081276],"domain_scores_gemma":[0.99842095,0.00041257145,0.0007439067,0.00013011247,0.00021358875,0.000078844474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015279702,0.00014540632,0.00060146133,0.00021308006,0.000079519625,0.000022127946,0.00012564393,0.00012565663,0.00005468137],"category_scores_gemma":[0.00049793796,0.00008754197,0.00017537444,0.0006459643,0.00018101213,0.00013952196,0.000032528773,0.00052937795,0.0000022184622],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013263697,0.0006601753,0.2337278,0.001023294,0.0072140163,0.00018656733,0.018069442,0.000017405056,0.65995955,0.00019796226,0.032589138,0.033090975],"study_design_scores_gemma":[0.04889075,0.021195235,0.2592083,0.056069925,0.0065618493,0.11168934,0.028941281,0.0028939936,0.45173213,0.0018435468,0.009131288,0.0018423719],"about_ca_topic_score_codex":0.00397752,"about_ca_topic_score_gemma":0.0001938031,"teacher_disagreement_score":0.20822741,"about_ca_system_score_codex":0.00031293568,"about_ca_system_score_gemma":0.0005062202,"threshold_uncertainty_score":0.6012847},"labels":[],"label_agreement":null},{"id":"W4392376557","doi":"10.1158/1538-7445.ovarian23-a074","title":"Abstract A074: Maveropepimut-S, a DPX-based immune-educating therapy, combined with Pembrolizumab and Cyclophosphamide in recurrent ovarian cancer, results from the Phase 1/2 PESCO Trial","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Cyclophosphamide; Oncology; Internal medicine; Ovarian cancer; Cancer; Gynecology; Chemotherapy; Immunotherapy","score_opus":0.08518002733598602,"score_gpt":0.42276661610663885,"score_spread":0.33758658877065284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392376557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9151186,0.06747556,0.000003792418,0.013273978,0.00085079303,0.0023406597,0.00035469554,0.00006521001,0.00051673746],"genre_scores_gemma":[0.98241705,0.014832795,0.00004114209,0.00033467184,0.0007309802,0.0010378441,0.00012680652,0.000072495255,0.0004062457],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966887,0.00029792805,0.0006423172,0.0007896867,0.0008724504,0.0007088984],"domain_scores_gemma":[0.9977488,0.0011101214,0.0001100574,0.000657324,0.00019365478,0.00018004602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020336425,0.00030831777,0.0004642066,0.00025241976,0.00028391936,0.0002756398,0.00032702918,0.00013479021,0.0006492592],"category_scores_gemma":[0.00016102561,0.00019039144,0.00012291502,0.0011434988,0.00045990996,0.00012689327,0.000058598187,0.0012632548,0.0000083496925],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6722487,0.00065533083,0.00086574716,0.00018789507,0.00042429465,0.00020565976,0.0031863737,0.000013786612,0.023890283,0.000030143996,0.0040000314,0.29429176],"study_design_scores_gemma":[0.7107136,0.011048299,0.117705904,0.013860772,0.00018086664,0.000031258078,0.0028431194,0.0013778479,0.035885073,0.00027595347,0.10497725,0.0011000071],"about_ca_topic_score_codex":0.04915741,"about_ca_topic_score_gemma":0.0037169345,"teacher_disagreement_score":0.29319173,"about_ca_system_score_codex":0.00084515096,"about_ca_system_score_gemma":0.003437705,"threshold_uncertainty_score":0.95717436},"labels":[],"label_agreement":null},{"id":"W4392379123","doi":"10.1158/1538-7445.ovarian23-b016","title":"Abstract B016: Repurposing nelfinavir for re-sensitizing platinum-resistant high grade serous ovarian cancer cells","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Repurposing; Medicine; Ovarian cancer; Serous fluid; Cancer; Oncology; Internal medicine; Nelfinavir; Serous ovarian cancer; Cancer research; Biology; Immunology","score_opus":0.10763554771106329,"score_gpt":0.41796062062802514,"score_spread":0.3103250729169619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392379123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9426075,0.035716634,0.00014131945,0.014637023,0.002247386,0.002262415,0.00045855227,0.00028070773,0.0016484204],"genre_scores_gemma":[0.9872212,0.0039321254,0.0006037352,0.0005977412,0.0017113319,0.0006639219,0.00004541537,0.00013680603,0.0050877286],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99680644,0.00008298259,0.00047366318,0.00076684885,0.00082780275,0.0010422354],"domain_scores_gemma":[0.9982938,0.00048016393,0.00006582147,0.00052802137,0.00032425858,0.0003079338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015442848,0.00026373443,0.0004047041,0.00036285,0.00040767813,0.00027038643,0.00020159416,0.0002090698,0.0008258022],"category_scores_gemma":[0.000092964714,0.00022630351,0.00020176369,0.00086733705,0.0002385805,0.0001631547,0.00006681048,0.00079183,0.000029320267],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038055198,0.00005661451,0.000047667465,0.0012129637,0.00034855233,0.00046231545,0.0008584004,0.000033372886,0.8882896,0.00020764959,0.03650304,0.06817435],"study_design_scores_gemma":[0.0036691353,0.0006491559,0.0038397359,0.0051830392,0.00016146441,0.000056379038,0.0008053922,0.00050948194,0.6065271,0.0005515084,0.3775027,0.0005448959],"about_ca_topic_score_codex":0.010983246,"about_ca_topic_score_gemma":0.0011291832,"teacher_disagreement_score":0.34099966,"about_ca_system_score_codex":0.0015421162,"about_ca_system_score_gemma":0.0017301934,"threshold_uncertainty_score":0.9956027},"labels":[],"label_agreement":null},{"id":"W4392481691","doi":"10.1016/j.ebiom.2024.105043","title":"A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies","year":2024,"lang":"en","type":"article","venue":"EBioMedicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"H2020 Marie Skłodowska-Curie Actions; Astellas Pharma; Oncolytics Biotech; Incyte; Gilead Sciences; GlaxoSmithKline; Fundación Científica Asociación Española Contra el Cáncer; Veracyte; Daiichi Sankyo Europe; European Commission; Breast Cancer Research Foundation; Instituto de Salud Carlos III; Amgen; Pfizer; Les Laboratories Pierre Fabre; Fundación Fero; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Triple-negative breast cancer; Medicine; Oncology; Internal medicine; Breast cancer; Immune system; Cohort; Stage (stratigraphy); Survival analysis; Proportional hazards model; Cancer; Immunology; Biology","score_opus":0.014369535668383579,"score_gpt":0.3121454258346046,"score_spread":0.297775890166221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392481691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89177674,0.10025269,0.000038316222,0.005598414,0.0006748034,0.0006646577,0.00054710486,0.00007891849,0.00036834585],"genre_scores_gemma":[0.98652804,0.004871132,0.00007446058,0.00045477983,0.00022312757,0.00007669429,0.00010347889,0.000036680744,0.0076315925],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978425,0.000081134516,0.00074352184,0.0004718196,0.00050433085,0.00035669998],"domain_scores_gemma":[0.9989398,0.00020436927,0.00017211521,0.00037792348,0.000202697,0.000103054976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060078583,0.00030876257,0.0012013188,0.001526036,0.00004008388,0.000012118746,0.00014399659,0.00016689143,0.00073951244],"category_scores_gemma":[0.00004926829,0.00021759611,0.0003909674,0.0051581017,0.00034562254,0.00008743804,0.00005293389,0.0003905483,0.0000060917687],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010477281,0.000858208,0.010419485,0.0020185094,0.03865682,0.0013958425,0.042185552,0.000058932255,0.864334,0.00002581704,0.0048324573,0.024737116],"study_design_scores_gemma":[0.03231319,0.0025277229,0.7983065,0.0065411846,0.018085156,0.000101201804,0.014868457,0.0026375074,0.11452781,0.00009483148,0.008868151,0.0011282357],"about_ca_topic_score_codex":0.0031045992,"about_ca_topic_score_gemma":0.0005525116,"teacher_disagreement_score":0.7878871,"about_ca_system_score_codex":0.0003627734,"about_ca_system_score_gemma":0.00024385503,"threshold_uncertainty_score":0.8873312},"labels":[],"label_agreement":null},{"id":"W4392595625","doi":"10.1016/j.rdc.2024.02.005","title":"Imaging in Rheumatic Immune-related Adverse Events","year":2024,"lang":"en","type":"review","venue":"Rheumatic Disease Clinics of North America","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Immune system; Adverse effect; Rheumatic disease; Disease; Autoimmune disease; Organ system; Immunology; Intensive care medicine; Internal medicine","score_opus":0.02404032654710837,"score_gpt":0.3500884621076946,"score_spread":0.32604813556058626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392595625","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022804132,0.9943586,0.000011997876,0.00008466505,0.00079950044,0.0018962474,0.00024896316,0.00010431945,0.00021526859],"genre_scores_gemma":[0.0027506968,0.9953113,0.00014934021,0.0000871864,0.00002173934,0.00020337946,0.0009029207,0.00015678276,0.00041662934],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.993953,0.0002474392,0.0040068906,0.0006860138,0.0006028993,0.000503747],"domain_scores_gemma":[0.996202,0.0004695816,0.0016808609,0.0011934128,0.00008637694,0.00036778598],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005430119,0.00074009097,0.0035950216,0.0007412155,0.000043951455,0.000012018995,0.00045185394,0.0001440798,0.0003895833],"category_scores_gemma":[0.00058453635,0.0005839898,0.0024643282,0.0015045285,0.00031041767,0.000106238534,0.00016699378,0.00070915034,0.0005101088],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000225638,0.0004985435,0.0027723857,0.07008029,0.0011079614,0.00013962129,0.00012622021,0.0000036034737,1.3576637e-8,0.000002802358,0.00029442692,0.9247485],"study_design_scores_gemma":[0.0042664534,0.00032216214,0.020308603,0.48913017,0.014039878,0.00008823922,0.00019042396,0.0018094304,1.6773752e-8,0.00022678684,0.46811873,0.0014991276],"about_ca_topic_score_codex":0.00012070524,"about_ca_topic_score_gemma":0.000010244865,"teacher_disagreement_score":0.92324936,"about_ca_system_score_codex":0.00031919935,"about_ca_system_score_gemma":0.0018975075,"threshold_uncertainty_score":0.99966115},"labels":[],"label_agreement":null},{"id":"W4392631993","doi":"10.1136/ijgc-2024-esgo.34","title":"639 Management of immune-related adverse events in patients with primary advanced or recurrent endometrial cancer: dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial","year":2024,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Chemotherapy; Oncology; Medicine; Endometrial cancer; Adverse effect; Internal medicine; Cancer; Immune system; Immunology","score_opus":0.018033520643407783,"score_gpt":0.3126615419709289,"score_spread":0.2946280213275211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392631993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99035627,0.0031850163,0.00003684134,0.0025785044,0.0017670459,0.0018077232,0.000055553184,0.000015715435,0.00019730862],"genre_scores_gemma":[0.99154496,0.0067689354,0.00038096946,0.00073521107,0.00020697164,0.00017529332,0.000036888956,0.00003058218,0.00012015867],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99659336,0.00015359781,0.0012969908,0.00032481938,0.0013245014,0.00030672754],"domain_scores_gemma":[0.99832153,0.00037283121,0.00071085076,0.00018285311,0.00034290206,0.00006904423],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008046577,0.00030184496,0.00078056735,0.00046493483,0.00003206552,0.000019787498,0.00051421585,0.00012434549,0.00124107],"category_scores_gemma":[0.000043836862,0.00015611779,0.0002760384,0.0008547921,0.00014874383,0.00022146721,0.000039087772,0.00058177335,0.0000013700763],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8073884,0.0024633312,0.041921142,0.00014293886,0.0031091063,0.00044521995,0.0012421786,0.000678674,0.00033851317,0.000025077738,0.0001989654,0.14204645],"study_design_scores_gemma":[0.32079923,0.007526664,0.6623093,0.0025414608,0.00019432207,0.0000389351,0.0004016024,0.00011203317,0.0002769209,0.000047313635,0.005469777,0.0002824703],"about_ca_topic_score_codex":0.00016728797,"about_ca_topic_score_gemma":0.00021681089,"teacher_disagreement_score":0.62038815,"about_ca_system_score_codex":0.0019403938,"about_ca_system_score_gemma":0.0005811341,"threshold_uncertainty_score":0.99967194},"labels":[],"label_agreement":null},{"id":"W4392662409","doi":"10.26685/urncst.517","title":"The Role of Regulatory T Cells (Tregs) in Tumorigenesis: A Comprehensive Literature Review","year":2024,"lang":"en","type":"article","venue":"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Carcinogenesis; Regulatory T cell; Cancer research; Immunology; Biology; Political science; T cell; Cancer; Genetics; Immune system; IL-2 receptor","score_opus":0.03209022437642192,"score_gpt":0.40240192248916323,"score_spread":0.37031169811274134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392662409","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3689826,0.5732846,2.3679117e-7,0.05706503,0.00020656135,0.00025656656,0.0000011350368,0.000012624861,0.00019057778],"genre_scores_gemma":[0.57807976,0.42160422,0.000032550113,0.000119431614,0.000040316296,0.000004447382,2.4142622e-7,0.0000034693262,0.0001155747],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99758935,0.00021382314,0.0006337327,0.0003634937,0.0007038172,0.0004957807],"domain_scores_gemma":[0.9984288,0.0006477164,0.00008364577,0.00021339473,0.00048546997,0.00014097123],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.006072889,0.00011938592,0.00035319175,0.0007319922,0.00031442445,0.00012993994,0.00032901517,0.00016927389,0.0000042119837],"category_scores_gemma":[0.00044893345,0.00006240384,0.00008377764,0.003975443,0.0037327874,0.00017995853,0.00017243112,0.0022905215,0.000002384236],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059006666,0.0001541129,0.009909908,0.0006641769,0.00009308189,0.0006923722,0.00006354229,1.01958825e-7,0.041581873,0.0073790615,0.0015669649,0.93730474],"study_design_scores_gemma":[0.008430478,0.005924553,0.10265214,0.09994261,0.00017551918,0.012010269,0.006227506,0.0033586207,0.02393502,0.4590729,0.27730873,0.00096169475],"about_ca_topic_score_codex":0.000019228293,"about_ca_topic_score_gemma":0.00003935709,"teacher_disagreement_score":0.936343,"about_ca_system_score_codex":0.00013438342,"about_ca_system_score_gemma":0.0006400395,"threshold_uncertainty_score":0.9989785},"labels":[],"label_agreement":null},{"id":"W4392662969","doi":"10.1186/s12894-024-01446-3","title":"Survival and clinicopathological significance of B7-H3 in bladder cancer: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"BMC Urology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Bladder cancer; Meta-analysis; Pathological; Oncology; Hazard ratio; Odds ratio; Internal medicine; Biomarker; Confidence interval; Clinical significance; Cancer","score_opus":0.1901244223981984,"score_gpt":0.4301301184501599,"score_spread":0.2400056960519615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392662969","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011671594,0.99685353,0.0000135108185,0.00034504198,0.000079994934,0.0024725646,0.00013089941,0.000017449405,0.00007533495],"genre_scores_gemma":[0.0003615554,0.9974036,0.000060155762,0.0005811255,0.000026943864,0.0010174445,0.000025232592,0.000027834612,0.0004960826],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99607056,0.0011924909,0.0016553514,0.0006803464,0.00017003264,0.0002311986],"domain_scores_gemma":[0.9980004,0.00073658815,0.0006276051,0.0005153127,0.000049885515,0.00007024597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018964519,0.00041439355,0.011407663,0.0003565193,0.000014378871,0.000009772943,0.00014069802,0.00039393568,0.00033348237],"category_scores_gemma":[0.00023151761,0.00023039448,0.0017460603,0.0009058775,0.0002867863,0.000016147098,0.00008133648,0.00037078105,0.0000052902815],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006086205,0.00004615133,0.000090828085,0.9693338,0.028957324,0.000060214952,0.000018359693,9.5708195e-8,3.0731428e-7,0.000037272017,0.00010558737,0.0012891915],"study_design_scores_gemma":[0.00023092606,0.00022511624,0.000068348774,0.0059035453,0.9620351,0.00015544794,0.000009857149,0.0000042542165,4.1079577e-8,0.000011642142,0.03116597,0.00018973873],"about_ca_topic_score_codex":0.00010782332,"about_ca_topic_score_gemma":0.00047908176,"teacher_disagreement_score":0.9634303,"about_ca_system_score_codex":0.000041232215,"about_ca_system_score_gemma":0.0002450463,"threshold_uncertainty_score":0.93952143},"labels":[],"label_agreement":null},{"id":"W4392735304","doi":"10.21037/actr-23-42","title":"CheckMate 817: expanding the pool of patients eligible for immune checkpoint inhibitor therapy in advanced non-small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"AME Clinical Trials Review","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Cancer; Immune checkpoint; Oncology; Immune system; Immunotherapy; Cancer research; Internal medicine; Immunology","score_opus":0.12454750418736286,"score_gpt":0.47863540940110255,"score_spread":0.3540879052137397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392735304","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41462576,0.574674,0.0000715953,0.0028698104,0.0015763633,0.0059854,0.000057564557,0.000030263134,0.00010921791],"genre_scores_gemma":[0.21855089,0.77713937,0.00020598683,0.0022541145,0.00047271943,0.0009631581,0.000033360822,0.000048694124,0.00033170456],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950845,0.00055185566,0.003373847,0.0004377808,0.00023609966,0.0003158717],"domain_scores_gemma":[0.99599755,0.0025696156,0.0007411172,0.00047254868,0.0001484996,0.0000706826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010686203,0.00026010038,0.0019523992,0.00007638269,0.000042187625,0.000025048521,0.00021153805,0.00015176159,0.00024772744],"category_scores_gemma":[0.0017627691,0.00014397498,0.0014118172,0.0004880015,0.00010286083,0.00007357522,0.000046120895,0.00033322256,0.000008812993],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007525524,0.0007388028,0.006831231,0.018563552,0.00077661604,0.0000058505443,0.00027350092,0.0000026766204,0.0319943,0.000009696884,0.00547458,0.9278037],"study_design_scores_gemma":[0.06456523,0.0057773343,0.04023758,0.1763603,0.0026062357,0.000005015182,0.00018032055,0.0005404399,0.16997182,0.00022539972,0.53829604,0.00123426],"about_ca_topic_score_codex":0.000101348705,"about_ca_topic_score_gemma":0.000008979527,"teacher_disagreement_score":0.9265694,"about_ca_system_score_codex":0.00011041593,"about_ca_system_score_gemma":0.0003499724,"threshold_uncertainty_score":0.5871129},"labels":[],"label_agreement":null},{"id":"W4392782970","doi":"10.1101/2024.02.14.580308","title":"Exploitation of CD3ζ to enhance TCR expression levels and antigen-specific T cell function","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"T-cell receptor; Function (biology); CD3; Expression (computer science); Antigen; T cell; Cell biology; Biology; Computer science; Immunology; Immune system; CD8","score_opus":0.02026877485404971,"score_gpt":0.2557107562074382,"score_spread":0.2354419813533885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392782970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784184,0.015690887,0.002748012,0.00026601905,0.0015977864,0.000938614,0.00012386317,0.00018825779,0.000028172219],"genre_scores_gemma":[0.9933454,0.002146742,0.0036734596,0.00018897981,0.00037177742,0.00013999149,5.633326e-7,0.00010149946,0.00003158741],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978435,0.00006192232,0.000554166,0.0008611935,0.0003886218,0.00029056479],"domain_scores_gemma":[0.9983904,0.00004169618,0.000268691,0.0007740672,0.0003357842,0.00018940195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043210242,0.00038949898,0.0005139539,0.00038488873,0.00007148502,0.00007886328,0.00014112431,0.00037799752,0.00010413243],"category_scores_gemma":[0.00003196787,0.00037841994,0.0001449752,0.00047539076,0.00008261336,0.00008278939,0.00025402015,0.00046311523,0.0000442353],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066953665,0.00010037948,0.0007851829,0.001125935,0.00009414714,0.000015227663,0.00006479581,0.000004855624,0.995345,0.00003173888,0.0017016199,0.00006158896],"study_design_scores_gemma":[0.00046308376,0.00021693867,0.09029175,0.0020263724,0.00006945546,2.02266e-8,0.00001365385,0.00001749163,0.89150256,0.00000359339,0.015051791,0.00034326213],"about_ca_topic_score_codex":0.000024195895,"about_ca_topic_score_gemma":8.4851956e-7,"teacher_disagreement_score":0.10384241,"about_ca_system_score_codex":0.0001893264,"about_ca_system_score_gemma":0.00029388856,"threshold_uncertainty_score":0.9998668},"labels":[],"label_agreement":null},{"id":"W4392797262","doi":"10.1016/j.ijrobp.2024.01.075","title":"A Phase 2 Clinical Trial of Pembrolizumab with Radiation Following Progression on anti-PD-1 Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","year":2024,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Head and neck; Radiation therapy; Internal medicine; Basal cell; Head and neck squamous-cell carcinoma; Head and neck cancer; Radiology; Surgery; Immunotherapy; Cancer","score_opus":0.03808368005064678,"score_gpt":0.39839984509046333,"score_spread":0.36031616503981656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392797262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99608666,0.0008895597,0.0001466373,0.0006422279,0.0014256034,0.0007324244,0.00003338125,0.0000065843496,0.000036954447],"genre_scores_gemma":[0.998732,0.00036712506,0.0003410238,0.00017189451,0.0003179486,0.000012388524,0.000033226625,0.00001832638,0.000006080283],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981512,0.0003059868,0.0008641004,0.0001895128,0.00036693196,0.0001222592],"domain_scores_gemma":[0.9982001,0.00044884763,0.0009411914,0.000119890734,0.00024057427,0.000049358423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058448256,0.00015405731,0.00049496425,0.00017302358,0.000030759733,0.000013796251,0.00015169215,0.000102401544,0.000010824905],"category_scores_gemma":[0.00010631212,0.00008059697,0.00020361434,0.00024581995,0.00017267202,0.00013778904,0.00001662674,0.00033954653,3.5306098e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2083145,0.0041976986,0.35247156,0.000033428798,0.00045035614,0.000026793425,0.0004920386,0.00003459171,0.0005554879,0.00007721342,0.000071146176,0.4332752],"study_design_scores_gemma":[0.42127085,0.1037203,0.46705928,0.00072534225,0.00030092793,0.000045139346,0.000077425626,0.001100809,0.0034762528,0.00016250253,0.0018862763,0.00017486433],"about_ca_topic_score_codex":0.000012146619,"about_ca_topic_score_gemma":0.0000051037355,"teacher_disagreement_score":0.4331003,"about_ca_system_score_codex":0.00025236173,"about_ca_system_score_gemma":0.0007920179,"threshold_uncertainty_score":0.3286649},"labels":[],"label_agreement":null},{"id":"W4392824195","doi":"10.1016/j.ijrobp.2024.01.095","title":"Lenvatinib ± Pembrolizumab Versus Chemotherapy for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Progressed after Platinum and Immunotherapy: The Phase 2 LEAP-009 Study","year":2024,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Lenvatinib; Oncology; Immunotherapy; Head and neck squamous-cell carcinoma; Internal medicine; Chemotherapy; Head and neck cancer; Head and neck; Radiation therapy; Cancer; Surgery","score_opus":0.035723128275939334,"score_gpt":0.3679507956196816,"score_spread":0.33222766734374226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392824195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780324,0.013535428,0.0008509819,0.0040569208,0.0022514851,0.0010663979,0.000100216566,0.000031505988,0.00007467724],"genre_scores_gemma":[0.99613416,0.0011214071,0.0007019698,0.0007031986,0.0010739679,0.00010405753,0.000050758405,0.00004644452,0.000064043714],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998395,0.00018114405,0.00062094163,0.00030282125,0.00026285418,0.00023722897],"domain_scores_gemma":[0.99819696,0.00078960974,0.00050246494,0.00015946648,0.00027229587,0.000079193655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060185656,0.00026687284,0.00045698698,0.00015772284,0.00010722994,0.00010643536,0.00021114244,0.0001221658,0.000060646427],"category_scores_gemma":[0.000060569684,0.00018595546,0.00021763607,0.00014579928,0.0002454563,0.00022662105,0.000030327574,0.00039312584,0.0000023556397],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07928811,0.0022077456,0.07254952,0.00010184903,0.0017878828,0.00009526931,0.0064021116,0.0000073490783,0.0059628487,0.00032271066,0.0013137759,0.8299608],"study_design_scores_gemma":[0.4341566,0.10107531,0.17738748,0.00048473233,0.0017993653,0.0013382806,0.003978903,0.011379287,0.01058584,0.004149337,0.2523801,0.0012847707],"about_ca_topic_score_codex":0.000018953431,"about_ca_topic_score_gemma":0.000012376552,"teacher_disagreement_score":0.82867604,"about_ca_system_score_codex":0.0003278196,"about_ca_system_score_gemma":0.0004105619,"threshold_uncertainty_score":0.75830436},"labels":[],"label_agreement":null},{"id":"W4392851109","doi":"10.1016/b978-0-12-823912-4.00024-4","title":"Neurologic manifestations of autoimmunity with immune checkpoint inhibitors","year":2024,"lang":"en","type":"article","venue":"Handbook of clinical neurology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Adverse effect; Discontinuation; Immune system; Immune checkpoint; Hypophysitis; Autoimmunity; Immunology; Immunotherapy; Internal medicine; Hormone","score_opus":0.04808008482026665,"score_gpt":0.36418675477954005,"score_spread":0.3161066699592734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392851109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99003553,0.003718669,0.00017149336,0.0037797007,0.0006412772,0.00030295536,0.000009799644,0.00007794411,0.0012626225],"genre_scores_gemma":[0.9971459,0.0011715528,0.00030518114,0.0010389088,0.00009946316,0.000011963313,0.000011200672,0.000022708371,0.00019313421],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99791074,0.00022338939,0.0012259329,0.00028202255,0.00017505018,0.0001828419],"domain_scores_gemma":[0.9983677,0.0008384913,0.00025028578,0.00038243798,0.00009639475,0.00006467156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071837293,0.00014081923,0.0006104086,0.00012950943,0.000030445495,0.0000050882595,0.000117583775,0.00019671558,0.00024665231],"category_scores_gemma":[0.00021984885,0.00009843758,0.00034518394,0.0002179464,0.0008575951,0.000043425887,0.000050069906,0.0005721885,0.000012573105],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.107309364,0.004664976,0.21999253,0.0032172066,0.0026179843,0.0054026204,0.0012509577,0.000098662196,0.4822683,0.0017921265,0.0024713005,0.16891398],"study_design_scores_gemma":[0.0082496675,0.03278467,0.88820475,0.00074843917,0.00062051165,0.0018807224,0.00003920011,0.0007784181,0.043135233,0.0009401125,0.022311728,0.00030652652],"about_ca_topic_score_codex":0.00008927495,"about_ca_topic_score_gemma":0.00001615899,"teacher_disagreement_score":0.66821223,"about_ca_system_score_codex":0.000004658652,"about_ca_system_score_gemma":0.00025276927,"threshold_uncertainty_score":0.4014168},"labels":[],"label_agreement":null},{"id":"W4392895230","doi":"10.1007/s10928-024-09903-0","title":"Predicting efficacy assessment of combined treatment of radiotherapy and nivolumab for NSCLC patients through virtual clinical trials using QSP modeling","year":2024,"lang":"en","type":"article","venue":"Journal of Pharmacokinetics and Pharmacodynamics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal","funders":"Syneos Health; Natural Sciences and Engineering Research Council of Canada; Pfizer","keywords":"Medicine; Clinical trial; Nivolumab; Precision medicine; Clinical study design; Oncology; Medical physics; Cancer; Internal medicine; Immunotherapy; Pathology","score_opus":0.12589357957786707,"score_gpt":0.48887468086589436,"score_spread":0.3629811012880273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392895230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9578891,0.0076252082,0.03212295,0.00017505125,0.0012613552,0.0007576733,0.00014467728,0.000008623153,0.000015403668],"genre_scores_gemma":[0.9491348,0.042783357,0.007439444,0.00008037356,0.00049538567,0.0000035031017,0.000013912338,0.000037491744,0.000011717262],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9972034,0.0002079066,0.0018968072,0.00019469617,0.0003097771,0.00018741649],"domain_scores_gemma":[0.99785066,0.00082752056,0.0007922952,0.00008651705,0.00030628065,0.00013674486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018391408,0.00021711501,0.0010345863,0.00016307643,0.000052803483,0.000030355857,0.00006918884,0.00009112274,0.000017490194],"category_scores_gemma":[0.00006405757,0.00016140266,0.0004697432,0.00014333638,0.000116148905,0.000115046256,0.00001776235,0.0001980813,1.2400503e-8],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028792715,0.003856218,0.022484444,0.0012933562,0.009311028,0.000031912554,0.0021129558,0.01091695,0.42411104,0.00013506899,0.0001612495,0.49679306],"study_design_scores_gemma":[0.036322005,0.0066291755,0.00096144056,0.00055590714,0.0022962943,0.000043658023,0.00009096784,0.9484662,0.0034360832,0.000033800305,0.0010293613,0.00013512609],"about_ca_topic_score_codex":0.000019954383,"about_ca_topic_score_gemma":4.7861687e-7,"teacher_disagreement_score":0.93754923,"about_ca_system_score_codex":0.00015823972,"about_ca_system_score_gemma":0.00028183247,"threshold_uncertainty_score":0.6581809},"labels":[],"label_agreement":null},{"id":"W4392918992","doi":"10.3390/pharmaceutics16030411","title":"Fundamentals and Applications of Focused Ultrasound-Assisted Cancer Immune Checkpoint Inhibition for Solid Tumors","year":2024,"lang":"en","type":"article","venue":"Pharmaceutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Institute of Cancer Research; Fonds de Recherche du Québec - Santé; Université de Montréal; Fondation du CHUM","keywords":"Solid tumor; Cancer research; Immune checkpoint; Cancer; Immune system; Medicine; Immunotherapy; Immunology; Internal medicine","score_opus":0.05258040174166183,"score_gpt":0.3901669921570622,"score_spread":0.33758659041540034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392918992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92639166,0.057354454,0.006962742,0.0036941404,0.0005213118,0.0032609203,0.0006609037,0.0001905477,0.00096329657],"genre_scores_gemma":[0.99460256,0.003478327,0.0004451688,0.00032493533,0.00015903443,0.00043993583,0.00007436634,0.000024853529,0.00045080914],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99921995,0.000011607508,0.0003315372,0.00017275334,0.00011616473,0.00014796745],"domain_scores_gemma":[0.99959433,0.00009497305,0.00007445799,0.00011238681,0.00006369943,0.000060181097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019760286,0.00010784131,0.00019906675,0.000088856366,0.000058634876,0.000024819608,0.000030255009,0.00004411803,0.00016770152],"category_scores_gemma":[0.000008850133,0.000096063115,0.000113303875,0.00022125883,0.00011648567,0.00005296695,0.000012832615,0.00009440295,0.0000028068662],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049795135,0.000097561424,0.00037826152,0.0009198076,0.000265533,0.0000017739682,0.0002960116,0.0000013205262,0.89258796,0.00009528298,0.00030302012,0.104555525],"study_design_scores_gemma":[0.0024987382,0.00012994329,0.0028450165,0.00040789854,0.0003612348,0.000060651993,0.00017453024,0.00065115455,0.9087851,0.00018795273,0.08377038,0.00012741398],"about_ca_topic_score_codex":0.00005635362,"about_ca_topic_score_gemma":0.000008311973,"teacher_disagreement_score":0.10442811,"about_ca_system_score_codex":0.00012225428,"about_ca_system_score_gemma":0.00011113466,"threshold_uncertainty_score":0.391734},"labels":[],"label_agreement":null},{"id":"W4392936715","doi":"10.1016/j.it.2024.02.005","title":"Regulation and impact of tumor-specific CD4+ T cells in cancer and immunotherapy","year":2024,"lang":"en","type":"review","venue":"Trends in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Institutes of Health, Pakistan; National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Immunotherapy; Immune system; Immunology; Cancer immunotherapy; Acquired immune system; T cell; Immunity; Cancer; Biology; Cancer research; Medicine","score_opus":0.04923839839203931,"score_gpt":0.3815598350564089,"score_spread":0.3323214366643696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392936715","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015687892,0.9831803,4.2661824e-7,0.000056454544,0.0003628419,0.0003328692,0.0000715747,0.000019827416,0.00028782076],"genre_scores_gemma":[0.0034662078,0.99531883,0.000038332455,0.000013127233,0.000054618296,0.000085887834,0.00006782238,0.000060139464,0.00089503557],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99820113,0.00012459954,0.00083485397,0.0004489167,0.00009588223,0.00029462774],"domain_scores_gemma":[0.99922836,0.00008728545,0.00026543034,0.00037129066,0.000020870655,0.000026791935],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026673454,0.00040234954,0.0018170587,0.001532412,0.00001652558,0.000015112497,0.00010322363,0.00037703093,0.00044979082],"category_scores_gemma":[0.0000036782951,0.00029329583,0.0003235739,0.0009805728,0.00032524823,0.000047483445,0.00005207546,0.00053801655,0.000003796363],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006918822,0.00007062875,0.00016697783,0.0019429637,0.0005983972,0.000034799108,0.00028932517,2.7200497e-7,0.0018668672,0.00003316605,0.00038015173,0.99392456],"study_design_scores_gemma":[0.004113763,0.0009938021,0.034593713,0.019032458,0.00043533902,0.00044678932,0.000048251943,0.000009252443,0.00007925802,0.000085949505,0.9396636,0.0004978641],"about_ca_topic_score_codex":0.0012452599,"about_ca_topic_score_gemma":0.00016700546,"teacher_disagreement_score":0.9934267,"about_ca_system_score_codex":0.00050083926,"about_ca_system_score_gemma":0.0002180805,"threshold_uncertainty_score":0.9999519},"labels":[],"label_agreement":null},{"id":"W4392948986","doi":"10.1007/s13402-024-00930-0","title":"Multi-dimensional characterization of apoptosis in the tumor microenvironment and therapeutic relevance in melanoma","year":2024,"lang":"en","type":"article","venue":"Cellular Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Key Research and Development Program of China; China Postdoctoral Science Foundation; China Pharmaceutical University; Central South University; Ministry of Industry and Information Technology of the People's Republic of China; National Natural Science Foundation of China","keywords":"Immune system; Melanoma; Tumor microenvironment; Apoptosis; Cancer research; Immunotherapy; Immune checkpoint; Blockade; Medicine; Biology; Immunology; Receptor; Internal medicine","score_opus":0.0168501748956919,"score_gpt":0.2666293070641862,"score_spread":0.2497791321684943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392948986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99191785,0.0055802055,0.000056346267,0.0019811767,0.00012971852,0.00028913817,0.00000391196,0.000005418909,0.000036241832],"genre_scores_gemma":[0.9981635,0.0005816245,0.00018804497,0.00087390427,0.000023938344,0.000028369726,0.000020741341,0.000008369723,0.00011146807],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9993761,0.00008999226,0.00020894584,0.0001507815,0.00007190631,0.00010224714],"domain_scores_gemma":[0.9997419,0.00010236248,0.000037450125,0.00010029572,0.0000049757755,0.000013007939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028053808,0.00006909694,0.00015934462,0.00008345303,0.000011987519,0.000003827356,0.000040795658,0.00005492896,0.00005643175],"category_scores_gemma":[0.0000069122,0.000047632915,0.000032223477,0.00012762978,0.000100826226,0.000017431816,0.000013313279,0.00011614976,0.0000043626655],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037363498,0.00016738678,0.0032959417,0.00006715163,0.000023241819,0.000056943063,0.00088466157,0.0000010019028,0.9774505,0.000018913339,0.000009319096,0.017651286],"study_design_scores_gemma":[0.005032882,0.0013381494,0.48611513,0.00041363918,0.00009361949,0.00020337096,0.00044826276,0.0037398848,0.41559565,0.000052981606,0.086777754,0.00018869307],"about_ca_topic_score_codex":0.000031627744,"about_ca_topic_score_gemma":0.000020322312,"teacher_disagreement_score":0.56185484,"about_ca_system_score_codex":0.000107155516,"about_ca_system_score_gemma":0.000054555574,"threshold_uncertainty_score":0.19424139},"labels":[],"label_agreement":null},{"id":"W4392982551","doi":"10.1038/s41571-024-00882-2","title":"Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges","year":2024,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Microbiome; Melanoma; Computational biology; Gut flora; Gut microbiome; Identification (biology); Immunology; Biology; Medicine; Bioinformatics; Ecology; Cancer research","score_opus":0.13806588119189953,"score_gpt":0.4500587480147986,"score_spread":0.31199286682289906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392982551","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015263508,0.9953792,6.0871866e-7,0.00095255807,0.00080343796,0.0024067953,0.00005979338,0.000020804306,0.00022413766],"genre_scores_gemma":[0.00013630641,0.9986867,0.00016777456,0.00028229918,0.00012453187,0.000111022164,0.00017569741,0.000057754252,0.00025795077],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99499077,0.0008102747,0.003050167,0.00071940676,0.00019476884,0.0002346049],"domain_scores_gemma":[0.996712,0.0008490441,0.001682379,0.00053025567,0.00012867406,0.00009760507],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0030428832,0.00046401512,0.0046432163,0.00038133326,0.000021978223,0.000012985359,0.00022450855,0.0023306564,0.000036960486],"category_scores_gemma":[0.00058873766,0.00027035133,0.00070783944,0.00034598674,0.00033752937,0.0000482934,0.00008679689,0.0023739631,0.000008382706],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035459115,0.00030001954,0.000049794653,0.04988186,0.00047935545,0.00002725114,0.000026650985,2.5863498e-9,8.223335e-7,0.000040095278,0.0008444229,0.9479951],"study_design_scores_gemma":[0.0011249569,0.0013616286,0.0036168452,0.05333071,0.002660584,0.000024093815,0.000014026096,9.1702054e-7,8.142905e-8,0.00001110934,0.9376214,0.00023360846],"about_ca_topic_score_codex":0.0000039690394,"about_ca_topic_score_gemma":0.00017903974,"teacher_disagreement_score":0.94776154,"about_ca_system_score_codex":0.0002813013,"about_ca_system_score_gemma":0.0006454368,"threshold_uncertainty_score":0.99997485},"labels":[],"label_agreement":null},{"id":"W4393007701","doi":"10.14293/p2199-8442.1.sop-.p6seu2.v1","title":"Investigating the Correlation between Immune Infiltrate and Treatment Response in Triple Negative Breast Cancer Patients","year":2024,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Immune system; Breast cancer; Correlation; Triple-negative breast cancer; Triple negative; Medicine; Oncology; Cancer; Internal medicine; Immunology; Mathematics","score_opus":0.02677803446897607,"score_gpt":0.30016837902974536,"score_spread":0.27339034456076927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393007701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99019307,0.0016402445,0.0000037496377,0.0055466676,0.00040604742,0.0014580797,0.00029349208,0.000046083594,0.00041254918],"genre_scores_gemma":[0.99699944,0.00066378305,0.000068303394,0.00022361647,0.00012444223,0.00024661492,0.000119136246,0.000029470668,0.0015251964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985669,0.00021384275,0.0004782478,0.0003700363,0.00018941051,0.00018156199],"domain_scores_gemma":[0.99914324,0.00029035987,0.0001800744,0.00025647483,0.000068164954,0.00006169144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043815986,0.0002716674,0.00039873424,0.00016414197,0.00007096496,0.00006427905,0.00005521654,0.00020046024,0.00008968447],"category_scores_gemma":[0.000060178823,0.00016045115,0.00010912833,0.0002578444,0.0001612989,0.000035384444,0.00015768845,0.00049602106,0.000005304477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013502469,0.00020239821,0.81879187,0.0003140422,0.0015094177,0.000015282907,0.015891038,0.000116851385,0.0023826344,0.000024379722,0.000546909,0.1467027],"study_design_scores_gemma":[0.0034457464,0.00036303015,0.99192333,0.0012500021,0.000229895,0.0000061449837,0.0003581164,0.0007339642,0.0009055501,0.0004500829,0.00015790775,0.00017623973],"about_ca_topic_score_codex":0.012447649,"about_ca_topic_score_gemma":0.0005756884,"teacher_disagreement_score":0.17313145,"about_ca_system_score_codex":0.000715669,"about_ca_system_score_gemma":0.0005201584,"threshold_uncertainty_score":0.9941285},"labels":[],"label_agreement":null},{"id":"W4393043011","doi":"10.14740/wjon1790","title":"Predictors of Immunotherapy Efficacy in Metastatic Non-Small Cell Lung Cancer: Lung Immune Prognostic Index and Immune-Related Toxicity","year":2024,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Common Terminology Criteria for Adverse Events; Gastroenterology; Immune system; Adverse effect; Response Evaluation Criteria in Solid Tumors; Absolute neutrophil count; Toxicity; Progressive disease; Disease; Immunology; Neutropenia","score_opus":0.010425758795583604,"score_gpt":0.2996332837192387,"score_spread":0.2892075249236551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393043011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84638625,0.14993817,0.00008800526,0.0011493292,0.001180629,0.0006399635,0.000008071963,0.00001699295,0.00059261086],"genre_scores_gemma":[0.9882755,0.0105567705,0.00028026392,0.00013004726,0.000111807574,0.000020247126,0.0000039390925,0.00004337884,0.0005779893],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973435,0.0002011706,0.001615034,0.00022659606,0.00026511514,0.00034858455],"domain_scores_gemma":[0.99831665,0.00057537557,0.0006644756,0.0001947884,0.00014137893,0.000107351756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00123137,0.0002556163,0.0010469421,0.00092211424,0.000044497436,0.000023138555,0.00019487085,0.00014046264,0.00031771738],"category_scores_gemma":[0.000053628304,0.00020084332,0.00033290967,0.00094070676,0.00023759907,0.000121475474,0.000043584314,0.00084388943,9.4324264e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016085245,0.0025891224,0.32776695,0.0020955808,0.005836081,0.0016735117,0.008446743,0.0003867151,0.50298566,0.000048449732,0.0013246723,0.13076125],"study_design_scores_gemma":[0.03184055,0.004882665,0.9143769,0.006460817,0.0016327482,0.001256818,0.0005176753,0.004358187,0.02438308,0.00006634248,0.009754485,0.00046972377],"about_ca_topic_score_codex":0.00030117616,"about_ca_topic_score_gemma":0.00018410847,"teacher_disagreement_score":0.58660996,"about_ca_system_score_codex":0.0005798095,"about_ca_system_score_gemma":0.0011633497,"threshold_uncertainty_score":0.81901526},"labels":[],"label_agreement":null},{"id":"W4393085665","doi":"10.1158/1538-7445.am2024-3973","title":"Abstract 3973: Cancer B cell blueprint reveals dysfunctional extra-follicular dominance with therapeutic opportunity","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Dysfunctional family; Blueprint; Dominance (genetics); Cancer; Biology; Medicine; Genetics; Gene","score_opus":0.11333548300662961,"score_gpt":0.4031269207504355,"score_spread":0.2897914377438059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393085665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8728768,0.10925381,0.00010166384,0.005898376,0.0006055249,0.0011107876,0.000102465034,0.0001358819,0.009914655],"genre_scores_gemma":[0.9639807,0.019564305,0.00007351768,0.00071204145,0.0006275813,0.0008592367,0.000019506644,0.00007403073,0.01408913],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970787,0.00010454281,0.0003272349,0.0006672066,0.0011251097,0.00069718086],"domain_scores_gemma":[0.9985087,0.0001751146,0.00005329307,0.00054484233,0.0003937092,0.00032436417],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013292936,0.00025209796,0.00032969363,0.00018163437,0.00023687605,0.0001288876,0.00022740077,0.00015037964,0.011059736],"category_scores_gemma":[0.00001898787,0.00018003103,0.00016899376,0.00074334425,0.00040868524,0.00019291368,0.00005092714,0.0008709767,0.00008109967],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006882867,0.00032628037,0.0039306735,0.0018988115,0.0008957823,0.00068113324,0.000664704,0.000049038532,0.7519584,0.0004990231,0.025374603,0.2068387],"study_design_scores_gemma":[0.0050643836,0.0010636753,0.1446066,0.0042821425,0.00024778576,0.00016153717,0.000875399,0.00018429148,0.14857523,0.0006227006,0.69350356,0.00081271265],"about_ca_topic_score_codex":0.004367485,"about_ca_topic_score_gemma":0.00062909204,"teacher_disagreement_score":0.6681289,"about_ca_system_score_codex":0.0012828091,"about_ca_system_score_gemma":0.0027138393,"threshold_uncertainty_score":0.98984426},"labels":[],"label_agreement":null},{"id":"W4393087932","doi":"10.1158/1538-7445.am2024-5179","title":"Abstract 5179: Tumor microenvironment (TME) biomarkers of TIGIT and PD-L1 immune checkpoint blockade in cervical cancer: An exploratory biomarker analysis from SKYSCRAPER-04 (SKY04) study","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"TIGIT; Immune checkpoint; Blockade; Tumor microenvironment; Biomarker; Medicine; Cancer; Cervical cancer; Cancer research; PD-L1; Immunotherapy; Oncology; Internal medicine; Receptor; Chemistry","score_opus":0.060043761568762906,"score_gpt":0.37937197225120045,"score_spread":0.31932821068243755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393087932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93795794,0.058684886,0.00000448978,0.0014241387,0.00021418421,0.0012533953,0.00029874133,0.000052060324,0.00011014071],"genre_scores_gemma":[0.9918205,0.0069614486,0.000044711436,0.000084816376,0.0001614453,0.0006148001,0.00007653041,0.000079750374,0.00015600002],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99552596,0.00036530566,0.0010058356,0.0011646741,0.001158097,0.0007801487],"domain_scores_gemma":[0.99824625,0.0002410221,0.0001231941,0.00090206903,0.0001281449,0.00035929773],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020336583,0.00039513718,0.00090061536,0.0013963605,0.0001328783,0.00012681654,0.00037277638,0.0001723965,0.0034426358],"category_scores_gemma":[0.000033392495,0.00033814195,0.0003246114,0.0026228682,0.00069478096,0.00024850736,0.00022751432,0.00073073944,0.000019033405],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006597436,0.0012375707,0.13327718,0.00042801772,0.0054634144,0.0004582161,0.0039705425,0.000015124893,0.8114902,0.0000010592861,0.00029374118,0.03676755],"study_design_scores_gemma":[0.0038150172,0.00066024804,0.9086615,0.00075674366,0.0006698508,0.0000065275403,0.007019277,0.0004857145,0.07398402,0.000028302607,0.0035302353,0.00038259255],"about_ca_topic_score_codex":0.032983836,"about_ca_topic_score_gemma":0.008250617,"teacher_disagreement_score":0.7753843,"about_ca_system_score_codex":0.001169688,"about_ca_system_score_gemma":0.00070370693,"threshold_uncertainty_score":0.9999071},"labels":[],"label_agreement":null},{"id":"W4393092712","doi":"10.1158/1538-7445.am2024-1058","title":"Abstract 1058: Immune biomarkers for recurrence in stage II and III melanoma to guide patient stratification","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Stratification (seeds); Stage (stratigraphy); Risk stratification; Melanoma; Immune system; Internal medicine; Oncology; Immunology; Cancer research; Biology","score_opus":0.07857506064394973,"score_gpt":0.43118707141041235,"score_spread":0.35261201076646265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393092712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97343355,0.017352697,0.000056152705,0.0056486046,0.00030143786,0.0017327057,0.00010759997,0.000032879994,0.0013343852],"genre_scores_gemma":[0.9945896,0.0018240135,0.00022023602,0.00009469696,0.00008477082,0.00081994507,0.000036616457,0.00002364085,0.0023064786],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984116,0.000039840474,0.0003677852,0.00042830454,0.00036754535,0.0003849584],"domain_scores_gemma":[0.99923676,0.0001673449,0.000028042272,0.0002775735,0.00016482196,0.00012542991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001190717,0.00011635239,0.00017752202,0.00038818448,0.00013525416,0.00007923073,0.00010972312,0.000077188946,0.00032709117],"category_scores_gemma":[0.00009420091,0.00009965052,0.00005552862,0.0006909956,0.00012490609,0.00010043277,0.000054798278,0.00023789646,0.000007981903],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026979921,0.000077413155,0.00051559496,0.0005491882,0.00011339398,0.000026840089,0.002674367,0.0000031181055,0.5006933,0.00024360983,0.012180808,0.48022434],"study_design_scores_gemma":[0.0039375033,0.0028175528,0.06823598,0.003549906,0.000031329448,0.000015271879,0.0051651294,0.00053558714,0.21979809,0.00023918961,0.6952041,0.0004703724],"about_ca_topic_score_codex":0.0033768208,"about_ca_topic_score_gemma":0.0007295908,"teacher_disagreement_score":0.6830233,"about_ca_system_score_codex":0.0005527492,"about_ca_system_score_gemma":0.0006092506,"threshold_uncertainty_score":0.5104765},"labels":[],"label_agreement":null},{"id":"W4393093393","doi":"10.1158/1538-7445.am2024-3467","title":"Abstract 3467: Tumor immune and microbial characteristics of colorectal cancer according to age at diagnosis and detailed anatomical location","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Colorectal cancer; Cancer; Medicine; Immune system; Oncology; Internal medicine; Immunology","score_opus":0.04519978848637372,"score_gpt":0.38324866362877774,"score_spread":0.338048875142404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393093393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827987,0.014554967,0.000002850431,0.0015792585,0.00025962092,0.00061902835,0.00011467832,0.000023165903,0.00004772974],"genre_scores_gemma":[0.99257815,0.0065466305,0.00002946089,0.00009819789,0.00019388326,0.0003330925,0.000017622848,0.000029921253,0.00017301962],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987489,0.00004142633,0.00028194176,0.0003350452,0.0002783436,0.00031433912],"domain_scores_gemma":[0.9993106,0.00020223594,0.00003709754,0.0001315036,0.00017353853,0.00014498658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005088839,0.00012302372,0.00029736682,0.00024087247,0.00010737997,0.000070996706,0.000079170495,0.00007443292,0.00034641073],"category_scores_gemma":[0.00009267679,0.00010648934,0.000048278125,0.00048827025,0.00028259004,0.00006884597,0.00012078351,0.00028038814,0.000006798877],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029818045,0.000037396607,0.07399905,0.00083472836,0.00014492734,0.00007823944,0.0005637249,4.1208034e-7,0.8640671,0.00000952225,0.0011337311,0.05614939],"study_design_scores_gemma":[0.0010134212,0.00024009611,0.6555742,0.0015766742,0.000051000312,0.000027946224,0.00020027114,0.00005702594,0.33493793,0.000006577413,0.0061716055,0.00014324635],"about_ca_topic_score_codex":0.0020937016,"about_ca_topic_score_gemma":0.000654415,"teacher_disagreement_score":0.58157516,"about_ca_system_score_codex":0.00057160633,"about_ca_system_score_gemma":0.00037075,"threshold_uncertainty_score":0.43425092},"labels":[],"label_agreement":null},{"id":"W4393093418","doi":"10.1158/1538-7445.am2024-3460","title":"Abstract 3460: Predicting cessation of immune checkpoint inhibitor therapy due to severe adverse events with an integrated autoimmune disease polygenic risk score","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Adverse effect; Disease; Immune system; Oncology; Internal medicine; Cancer; Immunology","score_opus":0.044160872160162894,"score_gpt":0.3637827662763959,"score_spread":0.319621894116233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393093418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862869,0.010590244,0.0000542795,0.0009431009,0.00031411025,0.0013464023,0.00023883734,0.00012243811,0.00010373256],"genre_scores_gemma":[0.9963155,0.0021305722,0.00009388285,0.00004654658,0.00027152474,0.00029518778,0.0001210925,0.00007437275,0.0006513383],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973176,0.0001739757,0.00052639615,0.00052637025,0.0009653726,0.0004902979],"domain_scores_gemma":[0.9984516,0.00009637546,0.00011213962,0.000578864,0.00045793838,0.00030306558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001426275,0.00023305681,0.00034081,0.00046108107,0.00018088684,0.00003710473,0.0002332505,0.00010593408,0.0009003986],"category_scores_gemma":[0.00010532384,0.00016672423,0.00016950049,0.0013923147,0.00018931959,0.0002863805,0.00005685829,0.0007450281,0.000018512723],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06719932,0.00066224,0.06357991,0.0013376313,0.001318721,0.00029324985,0.0046748524,0.00032318835,0.6223134,0.000011782364,0.0004888443,0.23779687],"study_design_scores_gemma":[0.0043578087,0.0017634066,0.91275644,0.005316064,0.00008402859,0.000024482875,0.0015051605,0.0006340667,0.07046805,0.000044605815,0.0027511946,0.00029467142],"about_ca_topic_score_codex":0.0075017535,"about_ca_topic_score_gemma":0.00031845362,"teacher_disagreement_score":0.8491765,"about_ca_system_score_codex":0.0006666273,"about_ca_system_score_gemma":0.0018279294,"threshold_uncertainty_score":0.99910736},"labels":[],"label_agreement":null},{"id":"W4393200069","doi":"10.1038/s41467-023-44512-4","title":"Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis","year":2024,"lang":"en","type":"review","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Princess Margaret Cancer Centre","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institutes of Health; National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; Vanderbilt Institute for Clinical and Translational Research; National Center for Advancing Translational Sciences; National Human Genome Research Institute; Memorial Sloan-Kettering Cancer Center; Vanderbilt University; Vanderbilt University Medical Center; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Princess Margaret Cancer Foundation; National Center for Research Resources; Georgia Clinical and Translational Science Alliance; Larry L. Hillblom Foundation","keywords":"Medicine; Internal medicine; Ulcerative colitis; Adverse effect; Meta-analysis; Gastroenterology; Colitis; Colorectal cancer; Cancer; Cohort; Oncology; Immune system; Lung cancer; Disease; Immunology","score_opus":0.04280840570516917,"score_gpt":0.360680529419318,"score_spread":0.31787212371414886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393200069","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020139643,0.98238504,0.000009723901,0.001394714,0.0012334468,0.005612237,0.0075805094,0.00031759313,0.0014465873],"genre_scores_gemma":[0.0009434684,0.9812006,0.0010444893,0.0002836262,0.0006254694,0.0029063693,0.0110084,0.00020544269,0.001782141],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99650145,0.00047943695,0.0014389367,0.0006608524,0.00038994895,0.00052936515],"domain_scores_gemma":[0.99403864,0.0011250707,0.0007528663,0.0033810816,0.00047698585,0.0002253662],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0008162717,0.0007322361,0.002056046,0.00032006096,0.0005122035,0.00012416668,0.0012181019,0.0018040448,0.00008600083],"category_scores_gemma":[0.0007714043,0.00058540807,0.0018540658,0.0013136483,0.0005033329,0.0000963085,0.00046824853,0.004112362,0.00011764201],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012323791,0.00061688654,0.000020528405,0.024189569,0.007877881,0.000023462455,0.00071711803,4.1655166e-8,0.000028035778,0.002026236,0.12034767,0.8429202],"study_design_scores_gemma":[0.001487571,0.0003081242,0.0005636723,0.023630463,0.0054637217,0.00016005534,0.00007317142,0.00003217325,0.000010386948,0.00008402278,0.9676984,0.00048821373],"about_ca_topic_score_codex":0.00017699161,"about_ca_topic_score_gemma":0.0010896345,"teacher_disagreement_score":0.8473508,"about_ca_system_score_codex":0.0009887387,"about_ca_system_score_gemma":0.0020183097,"threshold_uncertainty_score":0.9996597},"labels":[],"label_agreement":null},{"id":"W4393230681","doi":"10.1136/jitc-2023-008694","title":"Poor clinical outcomes and immunoevasive contexture in CD161<sup>+</sup>CD8<sup>+</sup> T cells barren human pancreatic cancer","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"Program of Shanghai Academic Research Leader; Shanghai Key Laboratory of Molecular Imaging; Fujian Medical University; China Postdoctoral Science Foundation; Fudan University; National Natural Science Foundation of China; Beijing Xisike Clinical Oncology Research Foundation; Shanghai Municipal Health Commission","keywords":"Pancreatic cancer; Cytotoxic T cell; Cancer; Cancer research; Medicine; Biology; Internal medicine; Biochemistry","score_opus":0.02980560795441357,"score_gpt":0.3826889662164464,"score_spread":0.3528833582620328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393230681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83109474,0.16093874,0.00008255232,0.004636214,0.0013504428,0.0013807466,0.00031270157,0.000060613078,0.00014322503],"genre_scores_gemma":[0.89655906,0.090279646,0.00042837995,0.0040296814,0.0012457867,0.00036429852,0.00003199324,0.0002138401,0.006847342],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956953,0.0002192359,0.0020473443,0.0006390974,0.0006429446,0.00075606105],"domain_scores_gemma":[0.9977259,0.00067472935,0.0005262273,0.00049159257,0.0003518791,0.00022966006],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015405554,0.0006329518,0.0017349219,0.00053228426,0.00028685288,0.00020169874,0.00038809748,0.00044845158,0.0017574632],"category_scores_gemma":[0.00007001952,0.00046988888,0.0012117204,0.00046284866,0.00048243327,0.00036510482,0.00004517873,0.001169924,0.000005838299],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031707954,0.001078538,0.18315443,0.0021648845,0.018183002,0.00021480303,0.013844646,0.00091093086,0.1435407,0.00022138236,0.049318343,0.55566037],"study_design_scores_gemma":[0.06436341,0.0058248565,0.1374088,0.01295364,0.0024802224,0.00051680533,0.0054220897,0.005213831,0.019488638,0.0011929185,0.7428388,0.0022959826],"about_ca_topic_score_codex":0.0021603745,"about_ca_topic_score_gemma":0.0002533188,"teacher_disagreement_score":0.6935205,"about_ca_system_score_codex":0.00068300474,"about_ca_system_score_gemma":0.0010754704,"threshold_uncertainty_score":0.9997753},"labels":[],"label_agreement":null},{"id":"W4393261672","doi":"10.12890/2024_004370","title":"Haemophagocytic lymphohistiocytosis following the anti-PD-1 nivolumab in a patient with gastric cancer and ankylosing spondylitis","year":2024,"lang":"en","type":"article","venue":"European Journal of Case Reports in Internal Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"McGill University Health Centre; McGill University","keywords":"Medicine; Pancytopenia; Hemophagocytic lymphohistiocytosis; Ankylosing spondylitis; Internal medicine; Gastroenterology; Cancer; Autoimmune hepatitis; Pneumonitis; Liver biopsy; Nivolumab; Rash; Hepatitis; Bone marrow; Dermatology; Biopsy; Immunotherapy","score_opus":0.014125053068566998,"score_gpt":0.277648435878344,"score_spread":0.263523382809777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393261672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9533515,0.042209964,0.00020163458,0.0016244149,0.001170638,0.00018458953,0.0000035024793,0.000011096704,0.0012426791],"genre_scores_gemma":[0.9976198,0.0012707425,0.00014546927,0.00039683035,0.00039235852,0.000002939438,0.0000012240511,0.000039001803,0.00013160387],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99773395,0.00018718567,0.0011514103,0.00023563873,0.0004655449,0.00022624414],"domain_scores_gemma":[0.99907076,0.00014712368,0.0003888862,0.00018661199,0.00008176282,0.0001248602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018276589,0.00019292987,0.0004640809,0.00054321875,0.00004571547,0.000044106855,0.000054844953,0.000022166736,0.00010984054],"category_scores_gemma":[0.00019275758,0.00010582373,0.000116836185,0.0005181999,0.00018719453,0.00013432391,0.00003263609,0.00045125058,4.0160853e-7],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014048304,0.00003988842,0.016247574,0.00011917897,0.0002664596,0.8771764,0.0026829962,0.000018095487,0.0016120198,0.0000016382348,0.0004255892,0.10000533],"study_design_scores_gemma":[0.003489856,0.0020427967,0.026230816,0.018873055,0.00033105654,0.93746173,0.0014090912,0.00017769766,0.0003782096,0.000009490507,0.0094660325,0.00013018916],"about_ca_topic_score_codex":0.00089721906,"about_ca_topic_score_gemma":0.00009147713,"teacher_disagreement_score":0.099875145,"about_ca_system_score_codex":0.00049713696,"about_ca_system_score_gemma":0.00024632312,"threshold_uncertainty_score":0.43153664},"labels":[],"label_agreement":null},{"id":"W4393343265","doi":"10.1007/s00262-024-03654-0","title":"Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours","year":2024,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Centre Hospitalier de l’Université de Montréal","funders":"National Institute for Health and Care Research; Boehringer Ingelheim","keywords":"Medicine; Adverse effect; Pharmacokinetics; Internal medicine; Maximum tolerated dose; Gastroenterology","score_opus":0.009003923693406368,"score_gpt":0.3100422142431986,"score_spread":0.30103829054979225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393343265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92633814,0.06875535,0.00010476755,0.0012323443,0.0016163065,0.0011243738,0.000069785645,0.00036586396,0.00039308646],"genre_scores_gemma":[0.98115283,0.01573699,0.00030671214,0.0014571393,0.00014033601,0.00024562082,0.0003130932,0.00020185317,0.00044539938],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99678475,0.00014472735,0.0007425047,0.000966595,0.0003916814,0.00096972956],"domain_scores_gemma":[0.9984631,0.00007125413,0.00017520154,0.0009899224,0.00019625275,0.00010425482],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030409129,0.00062193203,0.0009403289,0.00064161327,0.00016535207,0.000105094674,0.00042975575,0.00035408314,0.0010049324],"category_scores_gemma":[0.000011456037,0.0005006949,0.000233899,0.0010721913,0.0005939625,0.00062820944,0.00004508842,0.00078070856,0.000050451268],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036437526,0.0015366448,0.22453956,0.00020698807,0.0025880802,0.000228673,0.0021694829,0.00006450949,0.40585905,0.00018369393,0.00040513492,0.32578063],"study_design_scores_gemma":[0.01974919,0.0047538984,0.9297491,0.0012257121,0.000114735754,0.000073175834,0.00033159586,0.000095732095,0.015123042,0.00006600642,0.027887054,0.0008308018],"about_ca_topic_score_codex":0.0004655237,"about_ca_topic_score_gemma":0.00009708535,"teacher_disagreement_score":0.7052095,"about_ca_system_score_codex":0.00067057647,"about_ca_system_score_gemma":0.0006964633,"threshold_uncertainty_score":0.99990827},"labels":[],"label_agreement":null},{"id":"W4393377211","doi":"10.3390/curroncol31040140","title":"Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia; Pancreas Centre (Canada); Canada's Michael Smith Genome Sciences Centre","funders":"Genome British Columbia; Genome Canada","keywords":"Medicine; Adverse effect; Germline; Cancer; Human leukocyte antigen; Genetic predisposition; Family history; Pneumonitis; Oncology; Immune checkpoint; Internal medicine; Immune system; Immunotherapy; Immunology; Disease; Gene; Antigen; Genetics","score_opus":0.024386537896456353,"score_gpt":0.33216085252112115,"score_spread":0.3077743146246648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393377211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784234,0.019919846,0.00001750639,0.000089448804,0.0007818025,0.0006538902,0.00003997772,0.000026822827,0.000047317666],"genre_scores_gemma":[0.9873962,0.012272502,0.000025993213,0.0000028876173,0.000019071025,0.00007542919,0.00012613561,0.000020038839,0.0000617856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985022,0.0000903396,0.0008611084,0.00024020036,0.00014472533,0.00016142862],"domain_scores_gemma":[0.99923,0.00007287397,0.0003889315,0.00013550797,0.00013216534,0.000040500894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024473827,0.00016507051,0.00047433624,0.00025046337,0.000020720483,0.0000010547952,0.000042611,0.00012488873,0.00006287763],"category_scores_gemma":[0.000042154898,0.00012278951,0.00011366322,0.0004747612,0.0001584735,0.00016068794,0.000027103006,0.00025834772,0.000001779343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008700856,0.0011500812,0.80553824,0.00052360777,0.00049445085,0.000009296456,0.0025459123,0.00010021323,0.023008792,0.000008390241,0.000019201323,0.15790094],"study_design_scores_gemma":[0.019639118,0.0052336645,0.9378134,0.004306193,0.0005782059,0.000010863789,0.0005610815,0.0019553665,0.027952902,0.000057238867,0.0016374912,0.00025446923],"about_ca_topic_score_codex":0.00038235882,"about_ca_topic_score_gemma":0.00013459033,"teacher_disagreement_score":0.15764648,"about_ca_system_score_codex":0.00025445377,"about_ca_system_score_gemma":0.00016775646,"threshold_uncertainty_score":0.5007211},"labels":[],"label_agreement":null},{"id":"W4393385792","doi":"10.1016/j.clcc.2024.03.002","title":"Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E","year":2024,"lang":"en","type":"article","venue":"Clinical Colorectal Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université de Montréal; Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Pembrolizumab; Colorectal cancer; Internal medicine; Oncology; Family medicine; Cancer","score_opus":0.057807141311088314,"score_gpt":0.4013327436419324,"score_spread":0.34352560233084406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393385792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97660905,0.012556427,0.00018651705,0.0047713765,0.0018348657,0.0027552492,0.0007344561,0.00029124154,0.00026079055],"genre_scores_gemma":[0.98310727,0.0069275955,0.001517232,0.0039749285,0.00083157764,0.0016991607,0.000096486176,0.00017599891,0.0016697266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965305,0.00013818545,0.0010321777,0.0011625806,0.0004993259,0.00063723384],"domain_scores_gemma":[0.9968312,0.0020278196,0.00025352938,0.000305357,0.00019826148,0.0003838485],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006649263,0.00058574794,0.0017574917,0.00014284486,0.00016896865,0.00015065921,0.00020342709,0.00030423127,0.0020625868],"category_scores_gemma":[0.0002030486,0.00036655535,0.0004893781,0.00047470565,0.0007596399,0.00016689648,0.000059061953,0.00056601234,0.000012273316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32342353,0.00059074996,0.41627258,0.0009672081,0.009457949,0.00021225477,0.0014546283,0.000011714888,0.0053882045,0.000037087433,0.016895803,0.22528832],"study_design_scores_gemma":[0.080498934,0.019883117,0.7331568,0.0029477042,0.005211363,0.00020636893,0.00086655846,0.010505931,0.013633238,0.00027046527,0.13057616,0.002243384],"about_ca_topic_score_codex":0.002643167,"about_ca_topic_score_gemma":0.0039323512,"teacher_disagreement_score":0.3168842,"about_ca_system_score_codex":0.00046711523,"about_ca_system_score_gemma":0.0019112681,"threshold_uncertainty_score":0.99987864},"labels":[],"label_agreement":null},{"id":"W4393445514","doi":"10.5281/zenodo.5513853","title":"Immune signatures predict development of autoimmune toxicity in immune-checkpoint-inhibitor-treated cancer patients","year":2021,"lang":"fr","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immune system; Immune checkpoint; Toxicity; Cancer; Immunology; Medicine; Cancer research; Immunotherapy; Internal medicine","score_opus":0.019110403669832122,"score_gpt":0.25380765264012756,"score_spread":0.23469724897029542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393445514","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30914605,0.044707716,0.0000748677,0.00062070205,0.00276436,0.004099637,0.6334251,0.000549799,0.0046117734],"genre_scores_gemma":[0.10894585,0.005965555,0.00014842789,0.00010198102,0.00033387987,9.877775e-7,0.88146865,0.0017795734,0.0012550757],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99399006,0.0009214058,0.0020032767,0.0009796476,0.001118976,0.000986647],"domain_scores_gemma":[0.99630594,0.000073623574,0.0008567485,0.0011059202,0.0014089512,0.00024882855],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015035341,0.0006424574,0.001071401,0.00072541257,0.0013100866,0.00031499116,0.0012266799,0.000585851,0.034823008],"category_scores_gemma":[0.00093493925,0.0006726881,0.0003035161,0.0016771904,0.0005295963,0.00024303915,0.001908273,0.001292777,0.0013337065],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004679433,0.0049852678,0.0001608863,0.003549687,0.00191954,0.00019282421,0.0031113685,0.000071024224,0.27863148,0.00001848512,0.5326873,0.1699927],"study_design_scores_gemma":[0.0050422573,0.000723401,0.041786674,0.004006866,0.00015587677,0.000029897115,0.00041216952,0.000057337,0.037488595,0.0000021143057,0.90972805,0.00056674],"about_ca_topic_score_codex":0.0007336155,"about_ca_topic_score_gemma":0.000025757516,"teacher_disagreement_score":0.37704077,"about_ca_system_score_codex":0.0019580962,"about_ca_system_score_gemma":0.00015090563,"threshold_uncertainty_score":0.99999005},"labels":[],"label_agreement":null},{"id":"W4393591544","doi":"10.5281/zenodo.4831758","title":"barechey/PredictIO.data:","year":2022,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Computer science","score_opus":0.06776145570151468,"score_gpt":0.2967323649363808,"score_spread":0.2289709092348661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393591544","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003770235,0.00060710585,0.000040123843,0.0007997964,0.0004474388,0.00066449365,0.98612964,0.0005614033,0.010712316],"genre_scores_gemma":[0.00007938302,0.0020451408,0.000031075244,0.00067510566,0.00043796154,9.0559084e-8,0.99401575,0.0013306127,0.0013848632],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99737686,0.00033472828,0.00037997236,0.0007538587,0.0007570753,0.00039749683],"domain_scores_gemma":[0.9973407,0.000028124534,0.00017871222,0.001967395,0.00027927046,0.00020579335],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010506421,0.00025284084,0.00032636087,0.0003852591,0.0020153155,0.00041813139,0.001992884,0.0001805651,0.5240974],"category_scores_gemma":[0.0005212651,0.00026217615,0.000111029134,0.00066942925,0.00019371191,0.00016253571,0.0032245694,0.00094394427,0.0041361493],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005730717,0.0002357351,2.6858953e-7,0.00021741992,0.00026123106,0.000076661345,0.00006091346,0.0000010538424,0.00018967148,0.000007910443,0.96598494,0.032391112],"study_design_scores_gemma":[0.0012231917,0.00059063936,0.00007205131,0.0000649604,0.00014914286,0.0006081276,0.00014024341,0.00001512496,0.000016252998,0.0000060421667,0.9968729,0.00024131747],"about_ca_topic_score_codex":0.00014298016,"about_ca_topic_score_gemma":0.000001139754,"teacher_disagreement_score":0.51996124,"about_ca_system_score_codex":0.00046911684,"about_ca_system_score_gemma":0.000024025303,"threshold_uncertainty_score":0.9999831},"labels":[],"label_agreement":null},{"id":"W4393793706","doi":"10.5281/zenodo.5503752","title":"Immune signatures predict development of autoimmune toxicity in immune-checkpoint-inhibitor-treated cancer patients","year":2021,"lang":"fr","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immune system; Immune checkpoint; Toxicity; Cancer; Immunology; Medicine; Immunotherapy; Internal medicine","score_opus":0.019110403669832122,"score_gpt":0.25380765264012756,"score_spread":0.23469724897029542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393793706","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30914605,0.044707716,0.0000748677,0.00062070205,0.00276436,0.004099637,0.6334251,0.000549799,0.0046117734],"genre_scores_gemma":[0.10894585,0.005965555,0.00014842789,0.00010198102,0.00033387987,9.877775e-7,0.88146865,0.0017795734,0.0012550757],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99399006,0.0009214058,0.0020032767,0.0009796476,0.001118976,0.000986647],"domain_scores_gemma":[0.99630594,0.000073623574,0.0008567485,0.0011059202,0.0014089512,0.00024882855],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015035341,0.0006424574,0.001071401,0.00072541257,0.0013100866,0.00031499116,0.0012266799,0.000585851,0.034823008],"category_scores_gemma":[0.00093493925,0.0006726881,0.0003035161,0.0016771904,0.0005295963,0.00024303915,0.001908273,0.001292777,0.0013337065],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004679433,0.0049852678,0.0001608863,0.003549687,0.00191954,0.00019282421,0.0031113685,0.000071024224,0.27863148,0.00001848512,0.5326873,0.1699927],"study_design_scores_gemma":[0.0050422573,0.000723401,0.041786674,0.004006866,0.00015587677,0.000029897115,0.00041216952,0.000057337,0.037488595,0.0000021143057,0.90972805,0.00056674],"about_ca_topic_score_codex":0.0007336155,"about_ca_topic_score_gemma":0.000025757516,"teacher_disagreement_score":0.37704077,"about_ca_system_score_codex":0.0019580962,"about_ca_system_score_gemma":0.00015090563,"threshold_uncertainty_score":0.99999005},"labels":[],"label_agreement":null},{"id":"W4393859830","doi":"10.1002/adhm.202400235","title":"Antibody‐Conjugated Nanogel with Two Immune Checkpoint Inhibitors for Enhanced Cancer Immunotherapy","year":2024,"lang":"en","type":"article","venue":"Advanced Healthcare Materials","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"National Research Foundation of Korea","keywords":"Immunotherapy; Monoclonal antibody; Immune system; Antibody; Cancer research; Cancer; Cancer immunotherapy; Antigen; Medicine; Cancer cell; Breast cancer; Immunology; Cytotoxic T cell; Metastatic breast cancer; In vitro; Biology; Internal medicine; Biochemistry","score_opus":0.01587229500458322,"score_gpt":0.3596063736358575,"score_spread":0.3437340786312743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393859830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95508784,0.028204445,0.0012192278,0.007651903,0.0033218032,0.0033101751,0.00032950987,0.0007949505,0.00008014349],"genre_scores_gemma":[0.98636764,0.006308059,0.0025420883,0.0013305346,0.0006834829,0.0012715531,0.0005326785,0.00025549444,0.0007084939],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997245,0.00006501984,0.0009736374,0.00070535863,0.0003013844,0.0007095563],"domain_scores_gemma":[0.9987335,0.000078074,0.00023843291,0.0005132033,0.0002871569,0.0001496192],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047766542,0.0004518924,0.0008619381,0.00019347659,0.00016589621,0.00011099918,0.00013857993,0.00016982897,0.00029122707],"category_scores_gemma":[0.000013638994,0.00033837,0.00022357717,0.00044405437,0.00014719117,0.0002489981,0.000025055328,0.0001789887,0.000015540596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019699164,0.00005957903,0.000035215642,0.0016109286,0.00038460537,0.000024836132,0.0006162095,0.0000058513206,0.92855525,0.00017277348,0.00004666814,0.048788924],"study_design_scores_gemma":[0.0088318065,0.0013387958,0.0006797361,0.0030201527,0.000073378666,0.000056851703,0.00017050507,0.0000073287138,0.9472476,0.00017052978,0.037989516,0.00041375362],"about_ca_topic_score_codex":0.0018900218,"about_ca_topic_score_gemma":0.0002367414,"teacher_disagreement_score":0.04837517,"about_ca_system_score_codex":0.00043030622,"about_ca_system_score_gemma":0.0006528888,"threshold_uncertainty_score":0.99990684},"labels":[],"label_agreement":null},{"id":"W4393969650","doi":"10.1016/j.isci.2024.109668","title":"The diversity of inhibitory receptor co-expression patterns of exhausted CD8+ T cells in oropharyngeal carcinoma","year":2024,"lang":"en","type":"article","venue":"iScience","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"West China Hospital, Sichuan University; Sichuan University; Department of Science and Technology of Sichuan Province; National Natural Science Foundation of China","keywords":"Inhibitory postsynaptic potential; CD8; Diversity (politics); Receptor; Chemistry; Cytotoxic T cell; Cancer research; Cell biology; Biology; Immunology; Biochemistry; Immune system; Sociology; Neuroscience; In vitro","score_opus":0.019171205269106137,"score_gpt":0.27065241641143206,"score_spread":0.2514812111423259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393969650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99707824,0.0017058229,0.00001701177,0.0001797214,0.00045884313,0.00014277919,0.000026679898,0.00001022628,0.00038067825],"genre_scores_gemma":[0.9991869,0.00022237469,0.000024711084,0.000038435825,0.00003253641,0.000001964771,0.0000017220899,0.0000034611933,0.00048789423],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992409,0.000030185452,0.00017155525,0.000154589,0.00027987044,0.00012290502],"domain_scores_gemma":[0.99964726,0.000077900826,0.000047493828,0.00016512001,0.000030872878,0.000031344018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032752534,0.0000578426,0.00011530172,0.00007149472,0.00007320477,0.000008037553,0.0001537156,0.000034990022,0.00009802932],"category_scores_gemma":[0.000010574683,0.000035997982,0.00005381262,0.00025455933,0.00022929085,0.00007452763,0.00009673603,0.00008944326,0.0000042342945],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000288461,0.000035273737,0.06814258,0.000104281346,0.0000047908825,0.00001105764,0.0013906832,9.200189e-7,0.9205791,0.000005021325,0.0015278097,0.007910074],"study_design_scores_gemma":[0.00048698654,0.00018102449,0.18026687,0.00038365478,0.000007434453,0.0000027280612,0.00054390286,0.00008484923,0.8149141,0.000004075029,0.0030776297,0.000046753492],"about_ca_topic_score_codex":0.0004879568,"about_ca_topic_score_gemma":0.000029121713,"teacher_disagreement_score":0.112124294,"about_ca_system_score_codex":0.000062527084,"about_ca_system_score_gemma":0.000104621344,"threshold_uncertainty_score":0.14679551},"labels":[],"label_agreement":null},{"id":"W4393986694","doi":"10.1158/1538-7445.am2024-lb395","title":"Abstract LB395: NetraAI-driven discovery of novel biomarkers in MSI-high colon cancer for precision immunotherapy","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Cancer; Medicine; Immunotherapy; Colorectal cancer; Microsatellite instability; Oncology; Biomarker discovery; Cancer immunotherapy; Internal medicine; Cancer research; Biology; Genetics; Proteomics","score_opus":0.08902612866333698,"score_gpt":0.4406809275490307,"score_spread":0.35165479888569373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393986694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95746887,0.035455983,0.00023895726,0.0029713383,0.00093211746,0.0019569786,0.00052637496,0.00004157715,0.00040779114],"genre_scores_gemma":[0.9815409,0.014717535,0.0002686292,0.00012479245,0.00034247144,0.0010666695,0.000042094114,0.000079667734,0.0018172453],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99744457,0.000056908262,0.0005416552,0.00057292316,0.0007484883,0.0006354391],"domain_scores_gemma":[0.9985616,0.0005965301,0.000074376854,0.0004185054,0.0002587645,0.00009018839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001310096,0.00021691516,0.00044444622,0.0006808688,0.00008985303,0.00010192286,0.00028415074,0.00021019466,0.0005972084],"category_scores_gemma":[0.00006746727,0.00017521798,0.00024363287,0.0012586217,0.00035325854,0.00027750278,0.00005241298,0.0004765392,0.0000043607934],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014581394,0.00029101357,0.0021815158,0.0009983693,0.00066520326,0.000020364452,0.0005361928,0.000060414608,0.8700449,0.00014646379,0.007502078,0.10297212],"study_design_scores_gemma":[0.025522448,0.0029893687,0.23857202,0.0142439455,0.00013908735,0.00002532572,0.0009636243,0.0023350022,0.54067725,0.00051110913,0.17305677,0.0009640492],"about_ca_topic_score_codex":0.011043818,"about_ca_topic_score_gemma":0.0017027797,"teacher_disagreement_score":0.3293676,"about_ca_system_score_codex":0.0010581969,"about_ca_system_score_gemma":0.0014490089,"threshold_uncertainty_score":0.99554175},"labels":[],"label_agreement":null},{"id":"W4393988417","doi":"10.1158/1538-7445.am2024-ct104","title":"Abstract CT104: Results from a phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously treated advanced solid tumors","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Antibody; Monoclonal antibody; Cancer research; Oncology; Virology; Internal medicine; Immunotherapy; Immunology; Cancer","score_opus":0.04156949515434699,"score_gpt":0.394824790099123,"score_spread":0.35325529494477603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393988417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98952246,0.0050111283,0.0000018930981,0.00037710316,0.00032358282,0.003446064,0.0010783748,0.0000596994,0.0001796721],"genre_scores_gemma":[0.99818677,0.0006770123,0.000012241673,0.000050376,0.000090312366,0.0002457762,0.00022735563,0.000072545394,0.0004375933],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9959116,0.00025178373,0.00085697835,0.00081444276,0.0014307817,0.00073443487],"domain_scores_gemma":[0.99827063,0.0001999959,0.00013620556,0.0008704885,0.0003776672,0.00014500579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072143006,0.0003337562,0.00068930746,0.00037900615,0.0001628483,0.000064559754,0.0004780635,0.000121382254,0.0002442767],"category_scores_gemma":[0.000063502725,0.00021253075,0.00016843369,0.0016509383,0.0003599272,0.0001997526,0.000073096824,0.00094583526,0.000008287123],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37435457,0.01071815,0.117372856,0.0010378758,0.002701146,0.0008463595,0.028174637,0.0005515655,0.39830175,0.000003480582,0.002407823,0.06352978],"study_design_scores_gemma":[0.09114268,0.005894102,0.8758842,0.0043018777,0.00016300753,0.000007241995,0.0018493844,0.00022035874,0.017770482,0.000009296016,0.0023882948,0.00036912478],"about_ca_topic_score_codex":0.011648814,"about_ca_topic_score_gemma":0.0014016597,"teacher_disagreement_score":0.7585113,"about_ca_system_score_codex":0.00085423706,"about_ca_system_score_gemma":0.0013470812,"threshold_uncertainty_score":0.9949327},"labels":[],"label_agreement":null},{"id":"W4393988485","doi":"10.1158/1538-7445.am2024-ct207","title":"Abstract CT207: Association of gene expression profiles and clinical outcomes in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma treated with pembrolizumab in KEYNOTE-629","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University","funders":"","keywords":"Pembrolizumab; Medicine; Oncology; Basal cell; Internal medicine; Cancer research; Gene; Cancer; Dermatology; Biology; Immunotherapy; Genetics","score_opus":0.038568933583159284,"score_gpt":0.37899535634632797,"score_spread":0.3404264227631687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393988485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99663264,0.0015288403,0.0000033064334,0.00014959692,0.00006783134,0.0014064785,0.00008338739,0.00002029992,0.000107600514],"genre_scores_gemma":[0.99850804,0.00044819992,0.0001846775,0.00002081088,0.000024343643,0.00015132288,0.000043485063,0.000038587463,0.0005805376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976415,0.00019312478,0.00052447314,0.00045475786,0.0007750284,0.00041110817],"domain_scores_gemma":[0.99867755,0.00061661465,0.0001210235,0.00022223804,0.00025788217,0.00010466398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057937694,0.0001822032,0.0004778112,0.00036553617,0.000038487557,0.0000313822,0.00009468779,0.000110829475,0.00011281472],"category_scores_gemma":[0.00014357308,0.00010925132,0.000051697978,0.00066479115,0.00015001568,0.00010971254,0.000028024331,0.0005638048,0.0000022746678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05239146,0.0006359851,0.9120466,0.00075044343,0.00006618626,0.0002775743,0.0003488443,0.000013905005,0.005875022,3.2659185e-7,0.000107714826,0.0274859],"study_design_scores_gemma":[0.015618982,0.0045070853,0.9621211,0.0012099358,0.000044234956,0.0000066559087,0.00020345894,0.00008875781,0.015955117,0.0000026612001,0.000086336106,0.00015564516],"about_ca_topic_score_codex":0.00085937616,"about_ca_topic_score_gemma":0.0010801156,"teacher_disagreement_score":0.050074488,"about_ca_system_score_codex":0.0007844336,"about_ca_system_score_gemma":0.000790017,"threshold_uncertainty_score":0.44551393},"labels":[],"label_agreement":null},{"id":"W4393988692","doi":"10.1158/1538-7445.am2024-ct114","title":"Abstract CT114: Phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously untreated advanced head and neck squamous cell carcinoma (HNSCC) or non-small cell lung cancer (NSCLC)","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ottawa Hospital","funders":"","keywords":"Pembrolizumab; Head and neck squamous-cell carcinoma; Medicine; Antibody; Monoclonal antibody; Head and neck; Cancer research; Internal medicine; Oncology; Head and neck cancer; Cancer; Immunotherapy; Immunology; Surgery","score_opus":0.03041345447476762,"score_gpt":0.3604095163433503,"score_spread":0.32999606186858266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393988692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96766543,0.025715094,0.000004034242,0.0001997335,0.00041759055,0.0053807683,0.00032868536,0.000046199006,0.00024244002],"genre_scores_gemma":[0.9962051,0.0017073927,0.000021055363,0.00007667725,0.00009526883,0.00052105106,0.00005204194,0.00011970284,0.0012017373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958862,0.00021503467,0.000752076,0.00097254384,0.0011487032,0.0010254078],"domain_scores_gemma":[0.9982333,0.00016810335,0.00014862661,0.000779973,0.00043677958,0.00023321233],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005057122,0.00049414206,0.0007990637,0.00044226047,0.00024603002,0.00009291969,0.00047617155,0.0001833081,0.000376226],"category_scores_gemma":[0.000015563553,0.00031360725,0.00015597961,0.0016435302,0.0003580347,0.00020937763,0.000114469505,0.0010786214,0.0000032062608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11783467,0.005881659,0.65543604,0.00527105,0.00051183713,0.00057127513,0.016706742,0.00040715776,0.18127508,8.517539e-7,0.0010708565,0.015032771],"study_design_scores_gemma":[0.095884435,0.0074970867,0.86577016,0.0024958067,0.00032573263,0.000013308663,0.0016619458,0.0006430643,0.02417746,0.000001069292,0.001011877,0.00051806186],"about_ca_topic_score_codex":0.016857084,"about_ca_topic_score_gemma":0.004449227,"teacher_disagreement_score":0.21033412,"about_ca_system_score_codex":0.0010929032,"about_ca_system_score_gemma":0.0027272138,"threshold_uncertainty_score":0.9999316},"labels":[],"label_agreement":null},{"id":"W4393988798","doi":"10.1158/1538-7445.am2024-ct281","title":"Abstract CT281: The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non-small-cell lung cancer (NSCLC)","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University","funders":"","keywords":"Pembrolizumab; Medicine; non-small cell lung cancer (NSCLC); Lung cancer; Internal medicine; Placebo; Oncology; Stage (stratigraphy); Cancer; Immunotherapy; Biology; Pathology","score_opus":0.11472892218302619,"score_gpt":0.4371691381645255,"score_spread":0.3224402159814993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393988798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92795783,0.050179653,0.0006543211,0.0019479826,0.0012821518,0.015795445,0.0006006753,0.00030813258,0.0012738347],"genre_scores_gemma":[0.9587426,0.0152294,0.000092925504,0.0004438497,0.0013959708,0.010438924,0.000077536504,0.0003527336,0.013226027],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99201345,0.00086670014,0.0011687381,0.0016821983,0.0021636512,0.0021052563],"domain_scores_gemma":[0.9952683,0.0016250492,0.00025428412,0.0014258045,0.00091306027,0.00051354524],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004478771,0.00086388265,0.0011757264,0.0009674663,0.0010767741,0.0009057802,0.0015202806,0.00043700705,0.0039921957],"category_scores_gemma":[0.0001675774,0.00060845376,0.0006355133,0.0020049422,0.00065425603,0.000344788,0.0003341192,0.0023328306,0.000079230405],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4894679,0.0024488484,0.0023181003,0.0034097387,0.007397752,0.0013653326,0.06533045,0.0003272087,0.21880966,0.0000332697,0.119327165,0.08976459],"study_design_scores_gemma":[0.4309006,0.024967644,0.033106305,0.00854959,0.0018088951,0.0001613347,0.017209103,0.028223775,0.20248857,0.0001311413,0.2484525,0.004000516],"about_ca_topic_score_codex":0.012511409,"about_ca_topic_score_gemma":0.0017273562,"teacher_disagreement_score":0.12912534,"about_ca_system_score_codex":0.003300037,"about_ca_system_score_gemma":0.007519818,"threshold_uncertainty_score":0.9999688},"labels":[],"label_agreement":null},{"id":"W4393988990","doi":"10.1177/10781552241243042","title":"The relationship between immune-related adverse events during ipilimumab monotherapy and survival outcomes among melanoma patients: A systematic review","year":2024,"lang":"en","type":"review","venue":"Journal of Oncology Pharmacy Practice","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Ipilimumab; Medicine; Adverse effect; Internal medicine; Discontinuation; Oncology; Hazard ratio; Incidence (geometry); Melanoma; Clinical trial; Confounding; Cancer; Immunotherapy; Confidence interval","score_opus":0.07369751300540853,"score_gpt":0.44483823801374756,"score_spread":0.37114072500833906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393988990","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035311326,0.9896791,0.0000013974216,0.0020251048,0.0016008829,0.0028834045,0.000016210925,0.000025289502,0.00023747169],"genre_scores_gemma":[0.0019143118,0.99655974,0.000044638968,0.0002690263,0.00019210434,0.000101262565,0.000017991733,0.000089920395,0.0008110132],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918017,0.0029748573,0.0039397134,0.00030333851,0.00065355113,0.00032685863],"domain_scores_gemma":[0.9834709,0.009216396,0.0062890565,0.00043378185,0.00040303497,0.00018683191],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0059820805,0.00054355105,0.0040373937,0.00033543684,0.00029006656,0.000034650417,0.00038964313,0.0002867451,0.000036296206],"category_scores_gemma":[0.0045605623,0.0002921258,0.0014272678,0.0005490601,0.00016022201,0.0005789914,0.00009120395,0.0023269234,0.000040813185],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022430667,0.0005360271,0.03582183,0.85467315,0.028626757,0.00062213215,0.00039959713,9.666379e-8,8.1140445e-7,0.000016349177,0.0006416781,0.076418534],"study_design_scores_gemma":[0.008850988,0.0006683844,0.01296495,0.4248449,0.07528842,0.002438161,0.00015009702,7.0247137e-7,2.8368146e-7,0.00001391318,0.47443086,0.0003483567],"about_ca_topic_score_codex":0.000020442629,"about_ca_topic_score_gemma":0.0000022681695,"teacher_disagreement_score":0.4737892,"about_ca_system_score_codex":0.0010807388,"about_ca_system_score_gemma":0.0009699061,"threshold_uncertainty_score":0.9999747},"labels":[],"label_agreement":null},{"id":"W4394078250","doi":"10.6084/m9.figshare.20046957","title":"Additional file 2 of Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Signature (topology); Immunotherapy; Colorectal cancer; Gene signature; Identification (biology); Cancer research; Cancer stem cell; Stem cell; Gene; Cancer immunotherapy; Computational biology; Oncology; Biology; Medicine; Cancer; Internal medicine; Gene expression; Genetics; Botany; Mathematics","score_opus":0.011665600639401828,"score_gpt":0.24137854812254195,"score_spread":0.2297129474831401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394078250","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033431917,0.00086791976,4.6313147e-8,0.000014704786,0.000055854864,0.0009280421,0.99478036,0.0000053027234,0.0000045836837],"genre_scores_gemma":[0.0007582114,0.00018580012,0.0000066625694,0.000046456727,0.000046237135,0.0021261272,0.9966695,0.000019458974,0.00014156576],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987073,0.00005336142,0.0005486667,0.00024816807,0.0003299043,0.0001125898],"domain_scores_gemma":[0.99855554,0.0002943111,0.0007394983,0.0001940485,0.00018505676,0.000031523898],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000049613587,0.00016838593,0.00042680305,0.0002600071,0.000023524151,0.0000071720942,0.0001395822,0.00018259473,0.97264034],"category_scores_gemma":[0.000084653584,0.00016172492,0.00008080765,0.00038212267,0.000014183476,0.00004626449,0.00005068587,0.00018722855,0.000010061054],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010456978,0.0001571494,0.00001484857,0.001868586,0.00008051745,0.0000044112817,0.00007446934,0.0000022352813,0.0796345,1.1463962e-8,0.9158146,0.0013029987],"study_design_scores_gemma":[0.00090215215,0.0003843509,0.033383366,0.00479965,0.00003510784,0.000006451553,0.000038673985,0.000011124514,0.017374488,1.8002831e-7,0.9429071,0.00015735456],"about_ca_topic_score_codex":0.000028560631,"about_ca_topic_score_gemma":0.00003143766,"teacher_disagreement_score":0.9726303,"about_ca_system_score_codex":0.00007204516,"about_ca_system_score_gemma":0.00033892528,"threshold_uncertainty_score":0.6594951},"labels":[],"label_agreement":null},{"id":"W4394125839","doi":"10.6084/m9.figshare.2074264.v1","title":"Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modelling approaches to estimate and extrapolate survival outcomes","year":2016,"lang":"en","type":"dataset","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nivolumab; Oncology; Second line; Line (geometry); Environmental science; Overall survival; Medicine; Internal medicine; First line; Mathematics; Cancer; Immunotherapy","score_opus":0.2267399441904804,"score_gpt":0.3687933685431805,"score_spread":0.1420534243527001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394125839","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028853353,0.003936877,0.000005537758,0.000062483225,0.00007367818,0.0016560857,0.96540487,0.0000020033106,0.0000051019806],"genre_scores_gemma":[0.14670774,0.00005941226,0.000053615186,0.000007648252,0.000022277742,0.00038459117,0.85273206,0.000014546606,0.000018077852],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99885005,0.000029420265,0.0005588935,0.00021963846,0.0001966655,0.00014531675],"domain_scores_gemma":[0.99870086,0.00041806346,0.00043245056,0.00033332058,0.00007860254,0.00003669249],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001499668,0.00019582079,0.00076829543,0.00009442671,0.000020138119,0.000003340315,0.00010596156,0.000084177635,0.0025011238],"category_scores_gemma":[0.00006210062,0.0001258407,0.00010386284,0.000044426313,0.000012732136,0.000026163729,0.000016377544,0.00004715892,8.001982e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011638927,0.000759584,0.0013917552,0.0058363792,0.0017666509,0.0000024649846,0.00085914286,0.0607029,0.00022526634,0.0000015873753,0.7218245,0.1949908],"study_design_scores_gemma":[0.05495282,0.0060236757,0.031460725,0.013448023,0.00239314,0.000009194472,0.0010293092,0.3587637,0.009689862,0.000032994198,0.5208956,0.0013009735],"about_ca_topic_score_codex":0.101260014,"about_ca_topic_score_gemma":0.7475787,"teacher_disagreement_score":0.6463187,"about_ca_system_score_codex":0.0006351009,"about_ca_system_score_gemma":0.0011765003,"threshold_uncertainty_score":0.9984107},"labels":[],"label_agreement":null},{"id":"W4394130103","doi":"10.6084/m9.figshare.20400961","title":"Additional file 1 of Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer","year":2022,"lang":"en","type":"dataset","venue":"Open MIND","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Chemotherapy; Lung cancer; Immune checkpoint; Medicine; Cancer research; Immune system; Oncology; Internal medicine; Immunotherapy; Immunology","score_opus":0.014008215650277194,"score_gpt":0.2687919651748504,"score_spread":0.25478374952457317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394130103","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09579022,0.00024941153,1.4939823e-7,0.000083731495,0.00007783306,0.0015661259,0.90209454,0.0000021810915,0.00013578532],"genre_scores_gemma":[0.0012803571,0.000062192266,0.00033688443,0.00035978542,0.000036120782,0.0009646395,0.9961207,0.000055929722,0.0007834101],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971466,0.0001386058,0.001116168,0.0006073326,0.00060813536,0.00038316852],"domain_scores_gemma":[0.9969989,0.00053426577,0.0014765589,0.00070823065,0.00017399724,0.00010805359],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046584793,0.0005008448,0.0015388145,0.00031832652,0.00007723962,0.00003577686,0.00059492746,0.00030697536,0.92010987],"category_scores_gemma":[0.000117983014,0.0004296688,0.00035645964,0.00069752726,0.00019307461,0.00007610835,0.0001541814,0.00059420563,0.000005959192],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039282814,0.0015404335,0.00048250024,0.00028227994,0.0013311536,0.0000707567,0.00009104241,0.000025700247,0.0015695774,2.3655045e-9,0.9903634,0.00031485732],"study_design_scores_gemma":[0.03214408,0.0016433488,0.020626713,0.0059459014,0.0011299191,0.000017301209,0.00023062526,0.00014880819,0.1069803,3.726629e-7,0.83005285,0.001079799],"about_ca_topic_score_codex":0.015063725,"about_ca_topic_score_gemma":0.0046844915,"teacher_disagreement_score":0.9201039,"about_ca_system_score_codex":0.0006165444,"about_ca_system_score_gemma":0.0033587357,"threshold_uncertainty_score":0.9998155},"labels":[],"label_agreement":null},{"id":"W4394148468","doi":"10.6084/m9.figshare.19534810.v2","title":"Identification of immune-related genes prognostic index for predicting survival and immunotherapy in colorectal carcinoma","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunotherapy; Immune system; Oncology; Medicine; Colorectal cancer; Gene; Identification (biology); Internal medicine; Immunology; Biology; Cancer; Genetics","score_opus":0.02238846123587179,"score_gpt":0.27913559657663145,"score_spread":0.25674713534075966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394148468","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027125128,0.00969922,1.2193951e-7,0.000026397727,0.00023610004,0.0019029757,0.9609821,0.000021815229,0.000006170825],"genre_scores_gemma":[0.041782748,0.00023212706,0.000002101913,0.000015290694,0.000052969386,0.0012689268,0.9565679,0.00003629637,0.00004163412],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982546,0.0000766081,0.0008192512,0.0003577165,0.00027200193,0.00021984903],"domain_scores_gemma":[0.9986692,0.0002932605,0.00059233414,0.00029949355,0.000112118905,0.0000336129],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027655903,0.00023595596,0.0005006989,0.00028211155,0.0000873938,0.000024788358,0.0001918329,0.0002771247,0.06353751],"category_scores_gemma":[0.00047052684,0.00023793719,0.00017582977,0.00031913686,0.000026367416,0.000055327328,0.0000830263,0.00032384254,0.0000041292146],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038422784,0.00025916737,0.0053635743,0.0036419698,0.0004931134,0.00002907835,0.00027113038,0.0000053862946,0.009891975,2.5241425e-7,0.9713059,0.00489617],"study_design_scores_gemma":[0.008644949,0.0012385009,0.40545547,0.0031147087,0.00018001079,0.00008845415,0.00036880275,0.0003970883,0.00261931,0.0000068206605,0.577353,0.00053289265],"about_ca_topic_score_codex":0.00031684426,"about_ca_topic_score_gemma":0.00010163367,"teacher_disagreement_score":0.4000919,"about_ca_system_score_codex":0.00014257393,"about_ca_system_score_gemma":0.00027936968,"threshold_uncertainty_score":0.97027963},"labels":[],"label_agreement":null},{"id":"W4394149314","doi":"10.6084/m9.figshare.19386194","title":"Transcriptome_COVID19_Cytokine_Mathmodel.xlsx","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Transcriptome; Coronavirus disease 2019 (COVID-19); Virology; Biology; Medicine; Internal medicine; Gene expression; Genetics; Gene","score_opus":0.04632998122319057,"score_gpt":0.30105255777805495,"score_spread":0.2547225765548644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394149314","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[7.540524e-7,0.0025215975,5.1913037e-8,0.00024068226,0.00025634008,0.00051721267,0.9957669,0.00008759043,0.00060891465],"genre_scores_gemma":[0.0000027923886,0.000134289,0.000004832606,0.0032389993,0.0002780631,0.00066931336,0.9944164,0.00004216749,0.0012131269],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984981,0.00003452737,0.00028646906,0.00040736498,0.00048434976,0.00028923445],"domain_scores_gemma":[0.9989205,0.0000481565,0.00012842058,0.00073887676,0.00005595417,0.0001080798],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000049422597,0.00031120636,0.00043603833,0.00018929322,0.00010959299,0.00003620157,0.00033174382,0.00024130958,0.988342],"category_scores_gemma":[0.00013529547,0.00029042878,0.00039351973,0.0002943994,0.00000804102,0.000040023948,0.0001145461,0.00066121365,0.0015208832],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039576617,0.00009133978,1.3542758e-7,0.0012477543,0.00015623686,0.00022012544,0.0000115849225,6.7744526e-7,0.000026976844,7.542467e-8,0.9968391,0.0010102299],"study_design_scores_gemma":[0.0011022808,0.00025869856,0.00003562799,0.0011378723,0.00010823179,0.00013630792,0.000008951684,0.0000032013995,0.000024178065,0.0000015397575,0.9968804,0.00030269698],"about_ca_topic_score_codex":0.00006689328,"about_ca_topic_score_gemma":0.000015027534,"teacher_disagreement_score":0.9868211,"about_ca_system_score_codex":0.00024267843,"about_ca_system_score_gemma":0.0004451071,"threshold_uncertainty_score":0.99995476},"labels":[],"label_agreement":null},{"id":"W4394220321","doi":"10.6084/m9.figshare.22605457","title":"Additional file 1 of Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape","year":2023,"lang":"en","type":"dataset","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"Tumor microenvironment; Immune system; Tumour heterogeneity; Biology; Immune escape; Cell; Renal cell carcinoma; Clear cell renal cell carcinoma; Cancer research; Tumor heterogeneity; Immunology; Medicine; Pathology; Cancer; Genetics","score_opus":0.016642187203799057,"score_gpt":0.22409059785615107,"score_spread":0.207448410652352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394220321","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044045068,0.00032859965,4.7767344e-8,0.000064591,0.00010899753,0.0006528976,0.9983493,0.00001331959,0.000041760544],"genre_scores_gemma":[0.0009652809,0.000008717498,0.000060719118,0.00013269244,0.00023166534,0.00037297263,0.9976052,0.00003667329,0.0005860953],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998232,0.00007768754,0.00056867674,0.00036378016,0.00050247635,0.0002554013],"domain_scores_gemma":[0.9982993,0.00018991805,0.0005815705,0.0007537387,0.00008674686,0.00008874024],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00005075564,0.00028329142,0.0004390042,0.0001334019,0.00006922997,0.000009472792,0.00037876872,0.00040679614,0.8963203],"category_scores_gemma":[0.00019043802,0.0002330937,0.00042191957,0.00027611403,0.000045027748,0.000030505837,0.0002699198,0.000532821,0.0022504448],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005096673,0.00016480929,0.0000036757501,0.0009440798,0.00005068327,0.000012024137,0.000011673078,0.0000046058167,0.0027210827,4.3183417e-9,0.99546957,0.000108142165],"study_design_scores_gemma":[0.0005930556,0.000513946,0.029178344,0.003525106,0.00005531388,0.00000972087,0.000020274581,0.000008326369,0.012896629,4.2326224e-7,0.9530027,0.00019614527],"about_ca_topic_score_codex":0.00037631855,"about_ca_topic_score_gemma":0.0001339696,"teacher_disagreement_score":0.89406985,"about_ca_system_score_codex":0.00032782304,"about_ca_system_score_gemma":0.0004123177,"threshold_uncertainty_score":0.9985264},"labels":[],"label_agreement":null},{"id":"W4394292051","doi":"10.6084/m9.figshare.21879057","title":"Tumor-infiltrating lymphocyte: features and prognosis of lymphocytes infiltration on colorectal cancer","year":2023,"lang":"en","type":"dataset","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Infiltration (HVAC); Tumor-infiltrating lymphocytes; Colorectal cancer; Lymphocyte; Medicine; Lymphocytic infiltration; Pathology; Immunology; Cancer; Immune system; Internal medicine; Immunotherapy; Geography","score_opus":0.029120738899421208,"score_gpt":0.3021351892000041,"score_spread":0.2730144503005829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394292051","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016720574,0.003555401,2.8652432e-9,0.000076189135,0.00017115613,0.00076121854,0.99361235,0.000071710376,0.000079922516],"genre_scores_gemma":[0.00065833604,0.0007967208,0.000009469171,0.00043760106,0.00035227806,0.00077179726,0.99683875,0.00004177008,0.00009325955],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99854887,0.000037705162,0.00036938404,0.00039795844,0.0003962211,0.00024984512],"domain_scores_gemma":[0.9989047,0.00024595766,0.00038271426,0.00024361821,0.00013859617,0.00008443482],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000643308,0.00033320603,0.0005104529,0.00021206986,0.00008758081,0.00005158651,0.00013773446,0.00030047563,0.011331402],"category_scores_gemma":[0.0005487662,0.000284293,0.00014878178,0.0003517968,0.000032738088,0.000060175356,0.00005836589,0.00023215139,0.00019031475],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009965419,0.000050611423,0.000044479133,0.0021063094,0.00022974468,0.00004102002,0.000036292637,0.0000020004984,0.00071269256,1.41834e-7,0.9909604,0.0048197256],"study_design_scores_gemma":[0.00275106,0.0009983103,0.024711762,0.021985587,0.00020133614,0.00014413278,0.00007451045,0.000020040827,0.02671235,0.0000013809515,0.9219254,0.00047408955],"about_ca_topic_score_codex":0.0011413804,"about_ca_topic_score_gemma":0.0005457638,"teacher_disagreement_score":0.069035,"about_ca_system_score_codex":0.00029828039,"about_ca_system_score_gemma":0.00077703473,"threshold_uncertainty_score":0.9999609},"labels":[],"label_agreement":null},{"id":"W4394297416","doi":"10.6084/m9.figshare.22617403","title":"Additional file 3 of Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing","year":2023,"lang":"en","type":"dataset","venue":"Open MIND","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Defence Research and Development Canada","funders":"","keywords":"Tumor microenvironment; Immunotherapy; RNA; Cancer research; Cell; Lung cancer; Cancer immunotherapy; Cancer; Biology; Medicine; Oncology; Internal medicine; Gene; Tumor cells; Genetics","score_opus":0.019581754380247406,"score_gpt":0.2615060547118234,"score_spread":0.24192430033157603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394297416","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0067399316,0.0023102313,0.0000019506076,0.00006314912,0.00017999513,0.0014610427,0.9889391,0.0000023626333,0.00030222142],"genre_scores_gemma":[0.000039109298,0.0012840594,0.0026039514,0.00046464696,0.00014613994,0.0009928938,0.9850623,0.00008621659,0.009320704],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973541,0.00007595061,0.00094366854,0.0007510137,0.00039281568,0.000482464],"domain_scores_gemma":[0.9982194,0.00030946278,0.0006265002,0.0006937074,0.000049316575,0.00010163664],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027442432,0.00047790687,0.0008603552,0.00023129933,0.000059644666,0.00006396258,0.00052941014,0.0002770103,0.59047484],"category_scores_gemma":[0.000024487757,0.00046075575,0.00023376204,0.0002669384,0.00010152972,0.000093894836,0.00020513446,0.0005380388,0.0004541529],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016036689,0.00027743823,0.00000892494,0.0003102153,0.00012221742,0.0001780055,0.00012219144,0.000015871541,0.064017504,2.7546979e-10,0.9290717,0.0042722113],"study_design_scores_gemma":[0.0030309362,0.00022468275,0.00013894742,0.0064154905,0.00011761916,0.00001821739,0.00015799771,0.00013321664,0.0074153338,3.4254236e-7,0.98186845,0.00047874366],"about_ca_topic_score_codex":0.0036327431,"about_ca_topic_score_gemma":0.0008580051,"teacher_disagreement_score":0.5900207,"about_ca_system_score_codex":0.0011787344,"about_ca_system_score_gemma":0.00076029287,"threshold_uncertainty_score":0.9997844},"labels":[],"label_agreement":null},{"id":"W4394384392","doi":"10.6084/m9.figshare.23435188","title":"Additional file 1 of Analyzing molecular typing and clinical application of immunogenic cell death-related genes in hepatocellular carcinoma","year":2023,"lang":"en","type":"dataset","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Hepatocellular carcinoma; Gene; Typing; Biology; Computational biology; Virology; Cancer research; Genetics","score_opus":0.03146490582267175,"score_gpt":0.28873590716389824,"score_spread":0.2572710013412265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394384392","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000620844,0.003073991,1.3255698e-7,0.000004978419,0.000018383555,0.00038528218,0.99586767,0.000011734608,0.000017005812],"genre_scores_gemma":[0.00038173326,0.00018142132,0.0000502304,0.000023577422,0.000038971593,0.0003331347,0.9989189,0.00002431118,0.00004774759],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99864954,0.000055693894,0.0006849306,0.0003063514,0.00016295015,0.00014051533],"domain_scores_gemma":[0.99843395,0.0005721431,0.00046981266,0.00037196255,0.000107531036,0.000044590393],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007760715,0.00017064753,0.0004693131,0.00022181845,0.000019859797,0.000005099149,0.00013817596,0.00036391005,0.62005836],"category_scores_gemma":[0.00042320375,0.00017537248,0.00023254528,0.0003594377,0.000024038976,0.000021750711,0.00008839126,0.00027105503,0.0003235137],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012646602,0.00006742236,0.00015075886,0.00089922646,0.00015201219,0.000034292738,0.000003275025,6.7100797e-7,0.00044950703,3.4287417e-8,0.9970577,0.0010586465],"study_design_scores_gemma":[0.0008418664,0.00013119142,0.017710747,0.005049723,0.000108501365,0.000013336461,0.000011165354,0.0004401528,0.00039739747,0.0000028420552,0.9751163,0.00017679141],"about_ca_topic_score_codex":0.00025381704,"about_ca_topic_score_gemma":0.000028452789,"teacher_disagreement_score":0.6197348,"about_ca_system_score_codex":0.000051226747,"about_ca_system_score_gemma":0.0002426703,"threshold_uncertainty_score":0.7151482},"labels":[],"label_agreement":null},{"id":"W4394414143","doi":"10.6084/m9.figshare.19534810","title":"Identification of immune-related genes prognostic index for predicting survival and immunotherapy in colorectal carcinoma","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunotherapy; Immune system; Colorectal cancer; Identification (biology); Gene; Index (typography); Oncology; Medicine; Biology; Internal medicine; Immunology; Genetics; Cancer; Ecology; Computer science; World Wide Web","score_opus":0.02238846123587179,"score_gpt":0.27913559657663145,"score_spread":0.25674713534075966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394414143","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027125128,0.00969922,1.2193951e-7,0.000026397727,0.00023610004,0.0019029757,0.9609821,0.000021815229,0.000006170825],"genre_scores_gemma":[0.041782748,0.00023212706,0.000002101913,0.000015290694,0.000052969386,0.0012689268,0.9565679,0.00003629637,0.00004163412],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982546,0.0000766081,0.0008192512,0.0003577165,0.00027200193,0.00021984903],"domain_scores_gemma":[0.9986692,0.0002932605,0.00059233414,0.00029949355,0.000112118905,0.0000336129],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027655903,0.00023595596,0.0005006989,0.00028211155,0.0000873938,0.000024788358,0.0001918329,0.0002771247,0.06353751],"category_scores_gemma":[0.00047052684,0.00023793719,0.00017582977,0.00031913686,0.000026367416,0.000055327328,0.0000830263,0.00032384254,0.0000041292146],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038422784,0.00025916737,0.0053635743,0.0036419698,0.0004931134,0.00002907835,0.00027113038,0.0000053862946,0.009891975,2.5241425e-7,0.9713059,0.00489617],"study_design_scores_gemma":[0.008644949,0.0012385009,0.40545547,0.0031147087,0.00018001079,0.00008845415,0.00036880275,0.0003970883,0.00261931,0.0000068206605,0.577353,0.00053289265],"about_ca_topic_score_codex":0.00031684426,"about_ca_topic_score_gemma":0.00010163367,"teacher_disagreement_score":0.4000919,"about_ca_system_score_codex":0.00014257393,"about_ca_system_score_gemma":0.00027936968,"threshold_uncertainty_score":0.97027963},"labels":[],"label_agreement":null},{"id":"W4394415747","doi":"10.6084/m9.figshare.22617394","title":"Additional file 1 of Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing","year":2023,"lang":"en","type":"dataset","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Defence Research and Development Canada","funders":"","keywords":"Immunotherapy; Tumor microenvironment; Cancer research; Lung cancer; RNA; Cell; Cancer; Medicine; Biology; Oncology; Internal medicine; Gene; Genetics","score_opus":0.018865407463805973,"score_gpt":0.23741896672988075,"score_spread":0.21855355926607478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394415747","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012251946,0.0062529016,1.4502086e-7,0.000031554107,0.00010047669,0.000967054,0.9924176,0.000029016135,0.00007874011],"genre_scores_gemma":[0.000011794614,0.000577159,0.00018676423,0.00096115796,0.00023889395,0.0033864316,0.9919372,0.00011673611,0.0025838201],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99748397,0.00005654416,0.00082537555,0.00066105707,0.00044991085,0.00052311434],"domain_scores_gemma":[0.9981068,0.00044823138,0.0006202599,0.00064216787,0.00007698747,0.00010560366],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00007135959,0.0005209607,0.0007501699,0.0002666673,0.00005374772,0.000029236899,0.00032578898,0.00034435556,0.95281744],"category_scores_gemma":[0.000108466484,0.0005156394,0.00033659462,0.00029625348,0.000025718455,0.000063051,0.000121128025,0.0006450864,0.001089507],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006159683,0.00017343182,0.0000017819549,0.0024062882,0.000094293995,0.00019590415,0.000050032024,0.000018449447,0.011044826,1.6537949e-10,0.98493636,0.0004626404],"study_design_scores_gemma":[0.0017379281,0.00015437974,0.0002034387,0.036476973,0.00005391736,0.000015437483,0.00004581257,0.0001701472,0.0018306944,2.2583983e-7,0.9588283,0.0004828011],"about_ca_topic_score_codex":0.00076946896,"about_ca_topic_score_gemma":0.00022951425,"teacher_disagreement_score":0.9517279,"about_ca_system_score_codex":0.0012513177,"about_ca_system_score_gemma":0.00060775806,"threshold_uncertainty_score":0.9997295},"labels":[],"label_agreement":null},{"id":"W4394425166","doi":"10.6084/m9.figshare.19534810.v3","title":"Identification of immune-related genes prognostic index for predicting survival and immunotherapy in colorectal carcinoma","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunotherapy; Immune system; Oncology; Medicine; Colorectal cancer; Gene; Identification (biology); Internal medicine; Immunology; Biology; Cancer; Genetics","score_opus":0.02238846123587179,"score_gpt":0.27913559657663145,"score_spread":0.25674713534075966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394425166","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027125128,0.00969922,1.2193951e-7,0.000026397727,0.00023610004,0.0019029757,0.9609821,0.000021815229,0.000006170825],"genre_scores_gemma":[0.041782748,0.00023212706,0.000002101913,0.000015290694,0.000052969386,0.0012689268,0.9565679,0.00003629637,0.00004163412],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982546,0.0000766081,0.0008192512,0.0003577165,0.00027200193,0.00021984903],"domain_scores_gemma":[0.9986692,0.0002932605,0.00059233414,0.00029949355,0.000112118905,0.0000336129],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027655903,0.00023595596,0.0005006989,0.00028211155,0.0000873938,0.000024788358,0.0001918329,0.0002771247,0.06353751],"category_scores_gemma":[0.00047052684,0.00023793719,0.00017582977,0.00031913686,0.000026367416,0.000055327328,0.0000830263,0.00032384254,0.0000041292146],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038422784,0.00025916737,0.0053635743,0.0036419698,0.0004931134,0.00002907835,0.00027113038,0.0000053862946,0.009891975,2.5241425e-7,0.9713059,0.00489617],"study_design_scores_gemma":[0.008644949,0.0012385009,0.40545547,0.0031147087,0.00018001079,0.00008845415,0.00036880275,0.0003970883,0.00261931,0.0000068206605,0.577353,0.00053289265],"about_ca_topic_score_codex":0.00031684426,"about_ca_topic_score_gemma":0.00010163367,"teacher_disagreement_score":0.4000919,"about_ca_system_score_codex":0.00014257393,"about_ca_system_score_gemma":0.00027936968,"threshold_uncertainty_score":0.97027963},"labels":[],"label_agreement":null},{"id":"W4394439721","doi":"10.6084/m9.figshare.22617406","title":"Additional file 4 of Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing","year":2023,"lang":"en","type":"dataset","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Defence Research and Development Canada","funders":"","keywords":"Tumor microenvironment; Immunotherapy; Cancer research; Lung cancer; RNA; Cell; Cancer immunotherapy; Biology; Cancer; Medicine; Oncology; Internal medicine; Gene; Tumor cells; Genetics","score_opus":0.018696563356716867,"score_gpt":0.2374403310939279,"score_spread":0.21874376773721102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394439721","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012284268,0.006307018,1.4673468e-7,0.00003135419,0.00010053239,0.0009678905,0.9923622,0.000029019451,0.00007899716],"genre_scores_gemma":[0.000012217056,0.00058519334,0.00018480548,0.0009613884,0.00023919673,0.003324967,0.9920315,0.000116692165,0.0025440275],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99748355,0.000056483714,0.0008260233,0.00066084013,0.00044997255,0.000523133],"domain_scores_gemma":[0.99811095,0.00044519492,0.0006204592,0.0006415602,0.00007623867,0.000105600484],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00007138408,0.0005209246,0.0007504181,0.00026670177,0.000053769392,0.000029310846,0.0003258233,0.00034435545,0.95094556],"category_scores_gemma":[0.00010695359,0.0005156069,0.00033659913,0.0002961091,0.000025724765,0.00006310743,0.00012108767,0.00064493815,0.0010791409],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006259979,0.00017346765,0.0000017885449,0.00242801,0.0000942361,0.00019892241,0.000050092975,0.000018206376,0.010909162,1.7026024e-10,0.98503107,0.00046901856],"study_design_scores_gemma":[0.0017548911,0.00015676804,0.00020322153,0.036492933,0.000053846783,0.000015454805,0.00004574376,0.00017102064,0.0018321972,2.2877556e-7,0.95879066,0.00048303913],"about_ca_topic_score_codex":0.00077123643,"about_ca_topic_score_gemma":0.00023196544,"teacher_disagreement_score":0.9498664,"about_ca_system_score_codex":0.0012514351,"about_ca_system_score_gemma":0.000605856,"threshold_uncertainty_score":0.9997296},"labels":[],"label_agreement":null},{"id":"W4394447216","doi":"10.6084/m9.figshare.12383498","title":"Data and metadata supporting the published article: Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer","year":2020,"lang":"en","type":"dataset","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cyclophosphamide; Medicine; Oncology; Metadata; Metastatic breast cancer; Breast cancer; Breast tumor; Internal medicine; Cancer; Chemotherapy; World Wide Web; Computer science","score_opus":0.035689091383983906,"score_gpt":0.30626215945556867,"score_spread":0.27057306807158477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394447216","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018675437,0.014427665,1.2888371e-7,0.0011401804,0.000068977184,0.00096731324,0.96468866,0.000024913455,0.000006746573],"genre_scores_gemma":[0.0059276395,0.0012761108,0.000052812786,0.0018771355,0.000111188216,0.0001483606,0.9905324,0.000040920215,0.000033437136],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977153,0.0001167022,0.00065166777,0.00086228596,0.00027001384,0.00038400822],"domain_scores_gemma":[0.99770725,0.00036012245,0.00047502495,0.0012365733,0.000057220685,0.00016378105],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004075336,0.00040728407,0.00085202715,0.00014478927,0.0001134769,0.00034473347,0.00046627357,0.000107669526,0.009055493],"category_scores_gemma":[0.00066177227,0.0002982353,0.000051912728,0.00032151822,0.00007801356,0.00071145274,0.0010186434,0.0006228418,0.0000123368245],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030821306,0.00006736679,0.0011535246,0.0018006745,0.0005609347,0.00025850785,0.000023993405,5.018274e-7,0.00023362426,1.3531483e-7,0.9931295,0.0024630437],"study_design_scores_gemma":[0.002759333,0.000053360924,0.30627817,0.0018635071,0.00055320084,0.0003463946,0.00007605663,0.00016090079,0.00003862475,0.0000018114208,0.6875331,0.00033558693],"about_ca_topic_score_codex":0.00077750516,"about_ca_topic_score_gemma":0.00036845042,"teacher_disagreement_score":0.3055964,"about_ca_system_score_codex":0.00011192653,"about_ca_system_score_gemma":0.00059536076,"threshold_uncertainty_score":0.99994695},"labels":[],"label_agreement":null},{"id":"W4394480002","doi":"10.6084/m9.figshare.20071677","title":"Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Immune system; PD-L1; Oncology; Internal medicine; Medicine; Cancer research; Immunotherapy; Immunology","score_opus":0.04021346038055574,"score_gpt":0.3279294465176014,"score_spread":0.2877159861370457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394480002","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009133318,0.0007796139,3.8018177e-7,0.000009763281,0.00006690516,0.0015369187,0.996572,0.000024719435,0.000096340176],"genre_scores_gemma":[0.0027213288,0.0000075502003,0.00006754644,0.000038641207,0.00006712178,0.0006412107,0.9963643,0.000034374825,0.000057931393],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985595,0.000046528316,0.00046641284,0.00031697625,0.00039560712,0.00021500462],"domain_scores_gemma":[0.9982653,0.0003466095,0.0007145731,0.00044233128,0.00018367586,0.00004746669],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000039049777,0.00029324548,0.00065224833,0.00011816814,0.00014760108,0.000029881967,0.00021665046,0.00015969694,0.26425928],"category_scores_gemma":[0.00024910367,0.00021921672,0.00020391434,0.00018156235,0.00002045198,0.000081921666,0.00009174271,0.00031230107,0.000011376547],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007906561,0.00045349874,0.000026231573,0.001415317,0.00022470535,0.0000026640184,0.00026597205,0.000008213366,0.0001187676,5.8206066e-8,0.9874001,0.0021779153],"study_design_scores_gemma":[0.008501797,0.0025058014,0.005642631,0.010777755,0.00016557353,0.0000013083956,0.0009875069,0.0000067302412,0.0015499543,0.0000010633312,0.96955884,0.00030103888],"about_ca_topic_score_codex":0.00011201764,"about_ca_topic_score_gemma":0.000022573902,"teacher_disagreement_score":0.26424792,"about_ca_system_score_codex":0.00011021638,"about_ca_system_score_gemma":0.00030247774,"threshold_uncertainty_score":0.8939398},"labels":[],"label_agreement":null},{"id":"W4394508907","doi":"10.6084/m9.figshare.2074264","title":"Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes","year":2016,"lang":"en","type":"dataset","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nivolumab; Second line; Oncology; Line (geometry); Medicine; Internal medicine; First line; Mathematics; Cancer; Immunotherapy","score_opus":0.21451910555488263,"score_gpt":0.37484657950285544,"score_spread":0.1603274739479728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394508907","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.040109377,0.0037606899,0.000002996218,0.000071325216,0.00007471661,0.0016135604,0.9543602,0.0000020586006,0.0000050814874],"genre_scores_gemma":[0.20784469,0.000042959437,0.000034919132,0.000008140357,0.00002100043,0.0003753862,0.7916476,0.000013313565,0.00001200449],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9988284,0.00003603007,0.00057485624,0.00021877456,0.00019735916,0.00014455953],"domain_scores_gemma":[0.9988443,0.0003251766,0.0003718861,0.0003365694,0.00008552768,0.000036497237],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015445251,0.00019447558,0.00076577294,0.00009561464,0.000020193618,0.0000033262868,0.00010737681,0.00008339497,0.002488631],"category_scores_gemma":[0.00010684213,0.0001245037,0.00010338166,0.000043073815,0.000010317238,0.000026617005,0.000018789944,0.000046684476,7.447302e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012118158,0.000775978,0.0015213385,0.0059943413,0.001876254,0.00000243617,0.0008590405,0.04019694,0.00032462203,0.0000012017763,0.66176957,0.27456012],"study_design_scores_gemma":[0.062192634,0.0063128793,0.034133177,0.01479939,0.002576318,0.000010761492,0.0014691962,0.5888248,0.005942739,0.000030457837,0.2823094,0.0013982512],"about_ca_topic_score_codex":0.109354205,"about_ca_topic_score_gemma":0.8206318,"teacher_disagreement_score":0.71127754,"about_ca_system_score_codex":0.00066411344,"about_ca_system_score_gemma":0.0012767739,"threshold_uncertainty_score":0.9984232},"labels":[],"label_agreement":null},{"id":"W4394690662","doi":"10.1136/jitc-2023-007675","title":"Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Université de Montréal","funders":"National Center for Advancing Translational Sciences; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Cancer Institute; Eli Lilly Canada; National Institutes of Health; Bausch Health; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Galderma; Amryt Pharma; Incyte; Novocure; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre","keywords":"Medicine; CLARITY; Delphi method; Adverse effect; Grading (engineering); Usability; Medical diagnosis; Family medicine; Disease; Psoriasis; MEDLINE; Vitiligo; Alternative medicine; Dermatology; Internal medicine; Pathology; Artificial intelligence; Computer science","score_opus":0.04581985567053431,"score_gpt":0.340229610841648,"score_spread":0.2944097551711137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394690662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59782946,0.38427255,0.0022303686,0.010324257,0.00217454,0.0016487117,0.0014522551,0.00004832667,0.00001952901],"genre_scores_gemma":[0.93369454,0.060736597,0.0022100855,0.0016182375,0.00031669546,0.001169215,0.000060103946,0.00009583698,0.000098690776],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978573,0.0000711552,0.0011056648,0.00025644084,0.00037362712,0.00033582313],"domain_scores_gemma":[0.99695086,0.0016581332,0.0005601045,0.00037082928,0.00036214,0.00009789871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005849618,0.0002964111,0.00060828193,0.00020897869,0.00029497867,0.00002694808,0.00023654441,0.00012356779,0.00054583995],"category_scores_gemma":[0.000113139155,0.00019038559,0.001448618,0.0002819312,0.00027223598,0.000086718435,0.000011717974,0.00026329342,0.0000017795143],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17121848,0.0022781675,0.07314874,0.002411228,0.019476505,0.000053606844,0.003309738,0.0011571147,0.28954265,0.0012035249,0.017080927,0.4191193],"study_design_scores_gemma":[0.049577575,0.0036011885,0.09597601,0.010903757,0.002260369,0.00009498449,0.0013663894,0.004234824,0.47040263,0.0071258033,0.35340807,0.0010484052],"about_ca_topic_score_codex":0.00025816722,"about_ca_topic_score_gemma":0.000023234683,"teacher_disagreement_score":0.41807088,"about_ca_system_score_codex":0.00019606529,"about_ca_system_score_gemma":0.0010384892,"threshold_uncertainty_score":0.77636987},"labels":[],"label_agreement":null},{"id":"W4394813416","doi":"10.1038/s41416-024-02677-9","title":"Blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses","year":2024,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research; EMD Serono; Government of Canada; Merck KGaA","keywords":"Ovarian cancer; Immunotherapy; Cancer research; Cytotoxic T cell; Immune system; Medicine; CD8; Perforin; Immunology; Cancer; Transforming growth factor; Tumor microenvironment; Biology; Internal medicine","score_opus":0.02035811710824899,"score_gpt":0.32039403510583647,"score_spread":0.3000359179975875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394813416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7447517,0.25292113,0.000028896207,0.0014274701,0.00029963086,0.0002901969,0.00021995492,0.000010188294,0.000050813906],"genre_scores_gemma":[0.9471509,0.051840488,0.00014058681,0.000114935865,0.0002629039,0.00002412246,0.0000040316304,0.000036658355,0.00042538202],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981329,0.0002247269,0.00075695524,0.00027598892,0.00034795955,0.00026146026],"domain_scores_gemma":[0.9990364,0.0003616605,0.00024227482,0.0000838363,0.00011419928,0.00016167627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013746409,0.00016171783,0.0005636558,0.00011765211,0.000041983734,0.00009270621,0.00008654377,0.00014720121,0.00012132451],"category_scores_gemma":[0.00012383984,0.00015609931,0.00011577931,0.00021666469,0.00018681776,0.00020200139,0.000029664745,0.00048342967,1.5953201e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065523144,0.00031638236,0.014996547,0.0018096728,0.000526451,0.0004232595,0.00093879347,0.000009006885,0.46898842,0.0000022447687,0.005902601,0.4995343],"study_design_scores_gemma":[0.05043527,0.007892807,0.1931245,0.074775055,0.0022000556,0.0075560478,0.00068809034,0.011979943,0.5701961,0.0006442703,0.07845,0.002057878],"about_ca_topic_score_codex":0.002955832,"about_ca_topic_score_gemma":0.0007425505,"teacher_disagreement_score":0.49747643,"about_ca_system_score_codex":0.00011835584,"about_ca_system_score_gemma":0.00044358513,"threshold_uncertainty_score":0.6365545},"labels":[],"label_agreement":null},{"id":"W4394853357","doi":"10.5858/arpa.2023-0536-cp","title":"Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation","year":2024,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Association for Molecular Pathology; LUNGevity Foundation","keywords":"Medicine; Guideline; Lung cancer; Companion diagnostic; Intensive care medicine; Cancer; Grading (engineering); Immunotherapy; Clinical trial; Oncology; Biomarker; Internal medicine; Pathology","score_opus":0.010769709461361441,"score_gpt":0.30780218869109494,"score_spread":0.29703247922973347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394853357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821137,0.0071384283,0.003041539,0.0022150713,0.0002564739,0.0034003526,0.0018142528,0.000017116621,0.00000303373],"genre_scores_gemma":[0.99415445,0.0008214404,0.0036072887,0.00010249874,0.00016958891,0.0008108951,0.00029448175,0.000029062388,0.000010296652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792063,0.00024255383,0.0010076661,0.0003487138,0.00029103586,0.00018938386],"domain_scores_gemma":[0.9943523,0.0024566937,0.0018018847,0.00016640416,0.0011971452,0.000025574092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016925564,0.00019663428,0.0006772789,0.00012389358,0.000097485674,0.0000043257223,0.000115966395,0.000098093966,0.0000028992295],"category_scores_gemma":[0.0011198426,0.00012577916,0.00011000535,0.00036272226,0.0005626329,0.00007097433,0.00004138248,0.00014995557,3.9344465e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003511405,0.000343493,0.5446437,0.0007012123,0.0014557983,0.000005226849,0.008465932,0.00003249899,0.4224551,0.00004202886,0.00007204784,0.018271567],"study_design_scores_gemma":[0.010400801,0.006318558,0.93235964,0.0010195232,0.0026181738,0.000011317104,0.0068462226,0.012943754,0.026808472,0.00028686997,0.00020379925,0.00018286162],"about_ca_topic_score_codex":0.00066030084,"about_ca_topic_score_gemma":0.00019278098,"teacher_disagreement_score":0.39564663,"about_ca_system_score_codex":0.00017390566,"about_ca_system_score_gemma":0.00031058156,"threshold_uncertainty_score":0.5129125},"labels":[],"label_agreement":null},{"id":"W4394913953","doi":"10.1016/j.jpainsymman.2024.02.524","title":"Inpatient and ED Use Among Melanoma and Lung Cancer Patients Receiving Immune Checkpoint Inhibitors (GP133)","year":2024,"lang":"en","type":"article","venue":"Journal of Pain and Symptom Management","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Population and Public Health","funders":"","keywords":"Medicine; Lung cancer; Melanoma; Oncology; Cancer; Nivolumab; Immune checkpoint; Internal medicine; Immunotherapy; Cancer research","score_opus":0.006293204074424255,"score_gpt":0.24417285769033797,"score_spread":0.23787965361591373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394913953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815642,0.016520556,0.000086133914,0.0007006723,0.00058718293,0.0003301488,0.0000026454122,0.00001366572,0.00019479929],"genre_scores_gemma":[0.98700297,0.011914168,0.00018387476,0.00024348199,0.00012978342,0.000009580708,0.0000025579818,0.000018389299,0.00049517385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987777,0.00007809815,0.0005248174,0.0001777686,0.00027641744,0.00016521323],"domain_scores_gemma":[0.99947935,0.000077018136,0.00017748088,0.0000890315,0.000060896084,0.00011620373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009759317,0.00015337976,0.00026901328,0.00023797032,0.00007109366,0.00015016462,0.0000375673,0.000052702668,0.000034012228],"category_scores_gemma":[0.000029961519,0.00011209469,0.00008796661,0.00013078636,0.00007633387,0.00022177023,0.00006972305,0.00016505526,2.0397495e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007390763,0.00014926257,0.7170428,0.0014701674,0.0016168411,0.00016312014,0.0028039315,0.0000023981136,0.0015566279,0.000042479278,0.005084577,0.26932874],"study_design_scores_gemma":[0.002723208,0.0007525725,0.9790182,0.003579173,0.00036218812,0.000022982676,0.000554432,0.0010976652,0.00026949306,0.000019388628,0.011430133,0.00017057094],"about_ca_topic_score_codex":0.00009992166,"about_ca_topic_score_gemma":0.0000144112255,"teacher_disagreement_score":0.26915818,"about_ca_system_score_codex":0.00014867744,"about_ca_system_score_gemma":0.000022116714,"threshold_uncertainty_score":0.45710889},"labels":[],"label_agreement":null},{"id":"W4394984090","doi":"10.2196/53792","title":"Online Patient Attitudes Toward Cutaneous Immune-Related Adverse Events Attributed to Nivolumab and Pembrolizumab: Sentiment Analysis","year":2024,"lang":"en","type":"article","venue":"JMIR Dermatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pembrolizumab; Nivolumab; Adverse effect; Medicine; Sentiment analysis; Immune system; Internal medicine; Oncology; Psychology; Immunotherapy; Natural language processing; Immunology; Computer science","score_opus":0.011741957975764961,"score_gpt":0.29802483024540805,"score_spread":0.2862828722696431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394984090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901036,0.004011088,0.00012500372,0.0042858673,0.00035493926,0.0007424585,0.00008917675,0.0001975833,0.00009028798],"genre_scores_gemma":[0.99783415,0.00026332322,0.00020410438,0.000732909,0.000019638832,0.000068818976,0.00026493103,0.000029326864,0.00058277964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982171,0.000082548104,0.0006083568,0.00047635115,0.00023930152,0.00037632065],"domain_scores_gemma":[0.9992891,0.000055010012,0.000079067846,0.00033101847,0.00007256133,0.00017325496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000055157296,0.00025033712,0.00062553835,0.00053818664,0.0000732833,0.00001453158,0.000092325135,0.00019348011,0.00047077134],"category_scores_gemma":[0.000013877738,0.00021686427,0.00033523067,0.00097300054,0.000087036766,0.000056153815,0.0001018353,0.00021644846,0.00010034017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027297959,0.00758958,0.54988086,0.0043711425,0.08208903,0.030270537,0.019840201,0.00053938455,0.10159154,0.0004433151,0.030891335,0.1451951],"study_design_scores_gemma":[0.015465732,0.002649456,0.7731103,0.0012923749,0.0074619474,0.03245924,0.001330762,0.012314214,0.012217769,0.00011187781,0.139839,0.0017473495],"about_ca_topic_score_codex":0.00016510411,"about_ca_topic_score_gemma":0.00007306039,"teacher_disagreement_score":0.22322941,"about_ca_system_score_codex":0.000202615,"about_ca_system_score_gemma":0.000095073825,"threshold_uncertainty_score":0.8843468},"labels":[],"label_agreement":null},{"id":"W4394984330","doi":"10.1101/2024.04.18.590189","title":"Spatial mapping reveals unique cellular interactions and enhanced tertiary lymphoid structures in responders to anti-PD-1 therapy in mucosal head and neck cancers","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Cancer Institute NSW; Sanofi; Medical Research Council; National Health and Medical Research Council; Servier; AstraZeneca","keywords":"Head and neck squamous-cell carcinoma; CD8; Tumor microenvironment; Mass cytometry; Immune system; Flow cytometry; Head and neck; Cancer research; Chemotherapy; Lymphatic system; Medicine; PD-L1; Internal medicine; Pathology; Oncology; Immunology; Head and neck cancer; Biology; Radiation therapy; Immunotherapy; Surgery; Phenotype","score_opus":0.014784405350819343,"score_gpt":0.2613168752103548,"score_spread":0.24653246985953545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394984330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988644,0.006973352,0.00021560288,0.0013550943,0.0010318825,0.001530476,0.00011085558,0.00012979312,0.000008947459],"genre_scores_gemma":[0.9938378,0.003193407,0.0012366916,0.00110812,0.0002683109,0.00023282653,0.0000012095109,0.000111343135,0.000010343311],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997291,0.0001783427,0.0006912319,0.0010836747,0.00025505468,0.00050066394],"domain_scores_gemma":[0.998775,0.000075492404,0.00018312888,0.00062262424,0.00010904216,0.00023468166],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051747804,0.0005493891,0.0007501026,0.0010546449,0.00007437843,0.00014869307,0.00018126343,0.0004042351,0.000040620955],"category_scores_gemma":[0.00007343674,0.00054932776,0.0001046391,0.0007228673,0.00013813139,0.00009714232,0.00027632064,0.0009092296,0.0000028574395],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012934215,0.000052639956,0.03668412,0.00060314493,0.00019735415,0.00017968228,0.0002833986,0.000021014026,0.9603656,0.000021650127,0.00012996244,0.00016803895],"study_design_scores_gemma":[0.002611429,0.00015759186,0.6386277,0.0035165932,0.00004319351,4.0004187e-7,0.00004225663,0.00018096314,0.35248566,0.000014685589,0.0016973659,0.0006221603],"about_ca_topic_score_codex":0.0038499127,"about_ca_topic_score_gemma":0.000529544,"teacher_disagreement_score":0.60787994,"about_ca_system_score_codex":0.0010878309,"about_ca_system_score_gemma":0.0010244342,"threshold_uncertainty_score":0.99969584},"labels":[],"label_agreement":null},{"id":"W4395020893","doi":"10.1016/j.esmoop.2024.103004","title":"Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Sanofi; AstraZeneca","keywords":"Medicine; Internal medicine; Discontinuation; Retrospective cohort study; Oncology; Lung cancer; Adverse effect; Cancer; Cohort; Kidney cancer; Progression-free survival; Chemotherapy","score_opus":0.01840575878252875,"score_gpt":0.3167468201235399,"score_spread":0.2983410613410111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395020893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793876,0.00326528,0.0000032807532,0.014328692,0.00047166622,0.00095999264,0.00002358156,0.00003564102,0.0015242692],"genre_scores_gemma":[0.9934311,0.0034484733,0.00003599083,0.0006580096,0.000052427902,0.00010818308,0.00003889479,0.000023417655,0.0022035022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990751,0.000033347096,0.0003044345,0.00025147415,0.0001383527,0.00019729811],"domain_scores_gemma":[0.9996539,0.000027423674,0.00003229607,0.00022119995,0.000027092652,0.00003811292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005969025,0.00012544416,0.00023827856,0.000083085106,0.00006667372,0.00009837057,0.00019608457,0.0000651935,0.0005739944],"category_scores_gemma":[0.000008750117,0.0000787885,0.000040189898,0.000577816,0.00010012601,0.00008538334,0.000063654734,0.00023812664,0.00001225933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073786397,0.0002698909,0.6253703,0.00026977307,0.0021591496,0.000625542,0.010408272,0.0000034119462,0.12293927,0.00018568344,0.011077631,0.21931243],"study_design_scores_gemma":[0.0031774347,0.00018774136,0.8481821,0.0016839042,0.00013124669,0.00015289901,0.00031727293,0.00021878869,0.039839994,0.00004753492,0.10584546,0.00021566407],"about_ca_topic_score_codex":0.013489794,"about_ca_topic_score_gemma":0.0009852648,"teacher_disagreement_score":0.22281176,"about_ca_system_score_codex":0.00012810808,"about_ca_system_score_gemma":0.00019717947,"threshold_uncertainty_score":0.9930795},"labels":[],"label_agreement":null},{"id":"W4395029062","doi":"10.1101/2024.04.19.590271","title":"Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the <i>cis</i> CD80 / PD-L1 interaction","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; Wellcome Trust","keywords":"Bivalent (engine); CD80; CTLA-4; Chemistry; Cell biology; Biology; Biochemistry; Metal; Cytotoxic T cell; In vitro","score_opus":0.02200513654026923,"score_gpt":0.2798517107552144,"score_spread":0.25784657421494517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395029062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.961198,0.0028367622,0.0006967663,0.022183254,0.008517216,0.003156541,0.00056620064,0.00071627257,0.00012902224],"genre_scores_gemma":[0.9888666,0.00058143586,0.0009566639,0.0066951397,0.0016385217,0.00069484353,0.0000015388604,0.00027606788,0.0002891789],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99552417,0.0001388767,0.0009888731,0.0016255669,0.00085935014,0.00086316216],"domain_scores_gemma":[0.9963321,0.000098878074,0.00034660447,0.0022268768,0.00042683925,0.00056870375],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010637805,0.00087693986,0.00087717635,0.00074512104,0.00028315818,0.0005075644,0.0007159701,0.0005391493,0.0002978421],"category_scores_gemma":[0.00019033479,0.00069860654,0.00055065897,0.0016486136,0.00012345842,0.00013248566,0.0010357864,0.0013607531,0.0011526624],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018041648,0.00018168785,0.0008519234,0.00087808014,0.0009211709,0.00015319584,0.00024073958,0.000016764709,0.96204317,0.00007970913,0.03268212,0.00014726294],"study_design_scores_gemma":[0.0013014958,0.00051255134,0.013791541,0.0055984952,0.0007853522,6.6803204e-7,0.00004778364,0.0002077496,0.6449438,0.00000451743,0.33142266,0.0013834476],"about_ca_topic_score_codex":0.00032225263,"about_ca_topic_score_gemma":0.000013752487,"teacher_disagreement_score":0.31709942,"about_ca_system_score_codex":0.0014450286,"about_ca_system_score_gemma":0.00074305834,"threshold_uncertainty_score":0.999625},"labels":[],"label_agreement":null},{"id":"W4395055509","doi":"10.5114/pm.2024.138609","title":"Cardiovascular adverse effects of immune checkpoint inhibitors","year":2024,"lang":"en","type":"article","venue":"Medycyna Paliatywna","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Adverse effect; Medicine; Immune system; Pharmacology; Immunology","score_opus":0.0076547753398757655,"score_gpt":0.24302094440537417,"score_spread":0.2353661690654984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395055509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86816275,0.122921236,0.00025083838,0.0006695882,0.0032634828,0.00088293967,0.000011326814,0.0002571781,0.003580673],"genre_scores_gemma":[0.9965659,0.0014241148,0.00017035927,0.00009641552,0.00033527642,0.00004637277,0.000019245403,0.000046835314,0.0012955307],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983489,0.000059715687,0.0005054335,0.0003277833,0.00048306846,0.00027510835],"domain_scores_gemma":[0.9991389,0.00008087228,0.000058019454,0.0005692183,0.00005432041,0.000098690594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000565759,0.00021202934,0.000537199,0.00019412821,0.000036377693,0.000012166442,0.00009725003,0.00013097395,0.00018171649],"category_scores_gemma":[0.00008679949,0.00016775505,0.0013034138,0.00048767487,0.00013519212,0.000071667666,0.000040152456,0.00020922409,0.00008000135],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001400697,0.00035622265,0.0039131506,0.009607965,0.00915832,0.0014716228,0.0026898796,0.000015723086,0.79055506,0.00022123082,0.005058372,0.17555177],"study_design_scores_gemma":[0.004123307,0.000603931,0.03504714,0.0028353268,0.0012446254,0.00013445786,0.00021479125,0.0001522616,0.7241827,0.00007478777,0.23101658,0.00037009086],"about_ca_topic_score_codex":0.0003585154,"about_ca_topic_score_gemma":0.000004487694,"teacher_disagreement_score":0.2259582,"about_ca_system_score_codex":0.00013329773,"about_ca_system_score_gemma":0.00014019608,"threshold_uncertainty_score":0.68408525},"labels":[],"label_agreement":null},{"id":"W4395663602","doi":"10.1158/2767-9764.crc-23-0459","title":"First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study","year":2024,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre","funders":"Merck KGaA; Pfizer","keywords":"Javelin; Avelumab; Chemotherapy; Medicine; Solid tumor; Oncology; Internal medicine; Cancer; Immunotherapy; Pembrolizumab; Physics","score_opus":0.08169363019912536,"score_gpt":0.4397402393431038,"score_spread":0.35804660914397846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395663602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9297812,0.01527088,0.00003737511,0.049615566,0.000119622,0.003994785,0.00055611134,0.0001316342,0.0004928254],"genre_scores_gemma":[0.9784301,0.017783662,0.0003741957,0.00087801286,0.00017256623,0.0012683991,0.0004155276,0.00009250629,0.0005850301],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99667263,0.0004035322,0.0007186824,0.0006221544,0.0010083171,0.0005746647],"domain_scores_gemma":[0.99498785,0.0010482804,0.000114469396,0.0031695412,0.00052712834,0.0001527165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016243516,0.00029148854,0.00046301653,0.00023808949,0.00074866816,0.00013520767,0.0013500277,0.00009770129,0.000345199],"category_scores_gemma":[0.00020290457,0.00019363366,0.00011170305,0.0017924776,0.0006526016,0.00020541062,0.00030414294,0.0012644636,0.000021596512],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1309828,0.018571971,0.01845906,0.00022201169,0.0033255809,0.0000700007,0.10358294,0.00033991312,0.0038865244,0.00014738922,0.03378359,0.6866282],"study_design_scores_gemma":[0.21380337,0.013015369,0.2690086,0.0076063676,0.00020280259,0.000007434064,0.0100956205,0.0125165535,0.0029255045,0.0005391414,0.46903348,0.0012457626],"about_ca_topic_score_codex":0.005475398,"about_ca_topic_score_gemma":0.008188788,"teacher_disagreement_score":0.6853825,"about_ca_system_score_codex":0.0012042049,"about_ca_system_score_gemma":0.0011864817,"threshold_uncertainty_score":0.8277201},"labels":[],"label_agreement":null},{"id":"W4395674419","doi":"10.1016/j.ijrobp.2024.04.065","title":"Longitudinal Assessment of Tumor-Infiltrating Lymphocytes in Primary Breast Cancer Following Neoadjuvant Radiation Therapy","year":2024,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"NIHR Maudsley Biomedical Research Centre; National Institute for Health and Care Research; Breast Cancer Now","keywords":"Radiation therapy; Medicine; Breast cancer; Oncology; Neoadjuvant therapy; Cancer; Tumor-infiltrating lymphocytes; Internal medicine; Immunotherapy","score_opus":0.02060610690134712,"score_gpt":0.35872723518315247,"score_spread":0.33812112828180535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395674419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820431,0.008188557,0.0019426387,0.003129498,0.0038158738,0.0002533761,0.00007953778,0.000032138556,0.0005152736],"genre_scores_gemma":[0.99221665,0.0040762057,0.0011725002,0.000752886,0.0016544273,0.000018823812,0.00006394467,0.000027587037,0.000016952597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980566,0.00015689191,0.0009789616,0.00023001303,0.00037407334,0.0002034535],"domain_scores_gemma":[0.99841475,0.00036467402,0.0007374637,0.00010798312,0.00031015679,0.00006497974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008440056,0.00019394147,0.00053103187,0.00031631114,0.00004026339,0.00003807377,0.00022217317,0.00014223694,0.00012241107],"category_scores_gemma":[0.000044560664,0.00016175206,0.00037904596,0.00032139377,0.0001053395,0.00038479964,0.000025596186,0.0003763021,0.0000020980137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007869288,0.00024399626,0.5643151,0.000025428813,0.0009490834,0.00009831313,0.00031041307,0.00039339165,0.040734872,0.00080016523,0.00017125567,0.39117107],"study_design_scores_gemma":[0.0111683635,0.0011163659,0.964302,0.00074264046,0.0001498057,0.00066573254,0.000116986055,0.007933659,0.006022265,0.0010654792,0.006473815,0.00024285847],"about_ca_topic_score_codex":0.0001303179,"about_ca_topic_score_gemma":0.000008871723,"teacher_disagreement_score":0.39998695,"about_ca_system_score_codex":0.0024204296,"about_ca_system_score_gemma":0.002192485,"threshold_uncertainty_score":0.65960574},"labels":[],"label_agreement":null},{"id":"W4396213011","doi":"10.1101/2024.04.28.591549","title":"PD-1 endocytosis unleashes the cytolytic potential of check-point blockade in tumor immunity","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Canadian Institutes of Health Research","keywords":"Blockade; Endocytosis; Effector; Cytolysis; Cancer research; Perforin; Immune checkpoint; CD8; Cell biology; Cytotoxic T cell; Granzyme; Antibody; Biology; Chemistry; Immunology; Immune system; Receptor; Biochemistry","score_opus":0.012457081005632491,"score_gpt":0.23352579833548084,"score_spread":0.22106871732984834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396213011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98430514,0.010865327,0.00003448344,0.0016460681,0.0013958748,0.001303981,0.00020421675,0.00020585918,0.00003903106],"genre_scores_gemma":[0.9973148,0.0010305559,0.00041535916,0.0003440652,0.00050548225,0.00023022047,5.8262776e-7,0.00014030297,0.000018641724],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99679124,0.00021240195,0.0010197479,0.00080010475,0.00058817765,0.0005883353],"domain_scores_gemma":[0.9972573,0.00010020316,0.0004410837,0.0017556509,0.00028340437,0.00016238689],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011408579,0.00062069355,0.0009840563,0.00046861183,0.00010671629,0.00011047683,0.00064461,0.0003982102,0.00016971996],"category_scores_gemma":[0.00018685026,0.00048766757,0.00053748826,0.0009349867,0.00040179983,0.00005818311,0.0007590977,0.0017899864,0.000043678865],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096656964,0.00033435147,0.0032358589,0.001789872,0.0007623095,0.00029664367,0.000055240544,0.000026909462,0.9920047,0.00008832323,0.00042843277,0.000010820959],"study_design_scores_gemma":[0.0021859393,0.00018660053,0.1989316,0.003185204,0.0007692688,6.0022586e-7,0.000049382328,0.00050102366,0.7914466,0.000012504054,0.0020606231,0.00067063194],"about_ca_topic_score_codex":0.00093030365,"about_ca_topic_score_gemma":0.0000194193,"teacher_disagreement_score":0.20055805,"about_ca_system_score_codex":0.0006087497,"about_ca_system_score_gemma":0.0015141242,"threshold_uncertainty_score":0.99975747},"labels":[],"label_agreement":null},{"id":"W4396219640","doi":"10.1186/s12969-024-00983-3","title":"Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first","year":2024,"lang":"en","type":"article","venue":"Pediatric Rheumatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Arthritis; Inflammatory arthritis; Rheumatology; Surgery; Cancer; Dermatology; Oncology; Immunotherapy","score_opus":0.008030772535538733,"score_gpt":0.24112896441234022,"score_spread":0.23309819187680147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396219640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91721135,0.07664925,0.00005959785,0.002620964,0.0018956157,0.00075333787,0.000025548503,0.00037383664,0.00041049218],"genre_scores_gemma":[0.9432849,0.054632425,0.000267871,0.00051603676,0.0007327464,0.00017737522,0.000019373172,0.00009759882,0.00027162852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99721664,0.0000763388,0.0010077736,0.00076690654,0.00030536103,0.0006269916],"domain_scores_gemma":[0.99873257,0.00027503606,0.00014407196,0.0004596739,0.00008877356,0.00029985447],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051649765,0.0004109132,0.0008130844,0.0009010282,0.00019171055,0.00010131215,0.0001637514,0.00038090322,0.00067037105],"category_scores_gemma":[0.00011454301,0.00039060018,0.00023833608,0.00094099744,0.00009456627,0.00019015055,0.000113107526,0.00058486214,0.0002871124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009200333,0.0007310849,0.53862536,0.008991827,0.0012412359,0.0017156431,0.012110676,0.0000034302063,0.014366767,0.00071347435,0.10251774,0.30978242],"study_design_scores_gemma":[0.044196118,0.0073346035,0.6175524,0.0015406806,0.0009178946,0.015671464,0.001307496,0.0003932944,0.0048071314,0.0010101825,0.30096847,0.0043002362],"about_ca_topic_score_codex":0.00031411712,"about_ca_topic_score_gemma":0.00016472866,"teacher_disagreement_score":0.30548218,"about_ca_system_score_codex":0.00018272414,"about_ca_system_score_gemma":0.0008034852,"threshold_uncertainty_score":0.99985456},"labels":[],"label_agreement":null},{"id":"W4396587176","doi":"10.1158/1538-7445.sabcs23-ps14-08","title":"Abstract PS14-08: Safety evaluation from the KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Chemotherapy; Oncology; Internal medicine; Breast cancer; Placebo; Triple-negative breast cancer; Metastatic breast cancer; Recurrent breast cancer; Cancer; Immunotherapy; Pathology","score_opus":0.058025912391397545,"score_gpt":0.3928854851214807,"score_spread":0.33485957273008315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396587176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806077,0.006482062,0.0000176707,0.0025225265,0.00028550197,0.009411742,0.0004660646,0.0000483748,0.00015836529],"genre_scores_gemma":[0.9917131,0.0050375317,0.000032663327,0.0003330963,0.0001868959,0.0018898175,0.000099765064,0.00010745909,0.0005996717],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9945123,0.00072338065,0.00083021785,0.0008868623,0.0022981472,0.0007490576],"domain_scores_gemma":[0.997156,0.0007206439,0.00019644956,0.00072389556,0.0010397964,0.00016318662],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023567076,0.00043971164,0.0008347993,0.00035292542,0.0002115076,0.00013172823,0.0004349165,0.00012817839,0.0059003807],"category_scores_gemma":[0.000100152734,0.00025046416,0.00012673005,0.0019443526,0.0003655786,0.00025497426,0.000057904388,0.0009695476,0.000014862341],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58139694,0.002043552,0.021848358,0.00065562985,0.0033696822,0.000052774667,0.029046813,0.0012823262,0.00087036437,0.000003832276,0.004583395,0.35484633],"study_design_scores_gemma":[0.17308743,0.0067084515,0.7975634,0.005979676,0.00052310847,0.00001143111,0.005984462,0.0050678113,0.0021247366,0.000045404813,0.0022503033,0.0006537802],"about_ca_topic_score_codex":0.035940625,"about_ca_topic_score_gemma":0.019657627,"teacher_disagreement_score":0.77571505,"about_ca_system_score_codex":0.00452998,"about_ca_system_score_gemma":0.005437479,"threshold_uncertainty_score":0.99999475},"labels":[],"label_agreement":null},{"id":"W4396590541","doi":"10.1158/1538-7445.sabcs23-gs01-02","title":"Abstract GS01-02: Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Placebo; Oncology; Breast cancer; Adjuvant; Internal medicine; Chemotherapy; Cancer; Stage (stratigraphy); Immunotherapy; Pathology","score_opus":0.056719152750950644,"score_gpt":0.4144835822188015,"score_spread":0.35776442946785086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396590541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95801944,0.02025519,0.00014683045,0.0027719883,0.0012530071,0.011234098,0.005757159,0.00034091822,0.00022139546],"genre_scores_gemma":[0.93676066,0.033744212,0.000056298275,0.00028679168,0.0011577836,0.005506496,0.00017006128,0.00043228554,0.021885412],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9912776,0.00046713577,0.0015844546,0.0019474798,0.0024987725,0.0022245527],"domain_scores_gemma":[0.99511695,0.0012612788,0.0004499322,0.0015787671,0.00089567906,0.00069737574],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019896494,0.0010808704,0.002017835,0.0009159729,0.00061845226,0.0003433096,0.0010866829,0.0003960925,0.009121306],"category_scores_gemma":[0.0001343268,0.00075541047,0.00064426893,0.0018513644,0.00065989577,0.00043997413,0.00019588119,0.001766624,0.0000366752],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64183456,0.0025800583,0.0006516579,0.001550064,0.003808249,0.00080984697,0.005544664,0.00016617423,0.078960225,0.000011679404,0.047513507,0.2165693],"study_design_scores_gemma":[0.60147715,0.039188642,0.017873777,0.0041949116,0.0010408121,0.00042629015,0.007855192,0.0038835553,0.10434441,0.00004783711,0.21687278,0.0027946327],"about_ca_topic_score_codex":0.05922796,"about_ca_topic_score_gemma":0.005642845,"teacher_disagreement_score":0.21377467,"about_ca_system_score_codex":0.0032733402,"about_ca_system_score_gemma":0.006161891,"threshold_uncertainty_score":0.99948967},"labels":[],"label_agreement":null},{"id":"W4396591128","doi":"10.1158/1538-7445.sabcs23-po2-03-07","title":"Abstract PO2-03-07: Immune Landscape in PD-L1-positive and TROP2-positive Triple-Negative Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Canadian Navy","funders":"","keywords":"Triple-negative breast cancer; Medicine; Breast cancer; Cancer; Triple negative; Immune system; Oncology; Internal medicine; Immunology","score_opus":0.03418732605383803,"score_gpt":0.38823520985278925,"score_spread":0.35404788379895125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396591128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93069327,0.04759584,0.000004027108,0.009212033,0.0003913927,0.001316892,0.0009202866,0.000060291615,0.009805961],"genre_scores_gemma":[0.9851876,0.01115294,0.000019674928,0.00036400193,0.0005419628,0.00049579545,0.000054307253,0.000054455682,0.0021292784],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99723065,0.00022167483,0.0003756291,0.00065877114,0.00078136945,0.00073192903],"domain_scores_gemma":[0.9987158,0.00049012806,0.00004619728,0.0002765774,0.0002919306,0.00017931928],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011276613,0.00026739627,0.00045172256,0.00060275727,0.00016406669,0.0001746276,0.00018679435,0.00018275932,0.0031493355],"category_scores_gemma":[0.000047076657,0.00021537366,0.00014340896,0.0012253905,0.00041232945,0.00025630344,0.00006890033,0.001101144,0.00007753775],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047992487,0.00093325396,0.021222606,0.0022239478,0.0024249323,0.003855552,0.02967477,0.000010606523,0.38538694,0.0005680706,0.045720387,0.45998645],"study_design_scores_gemma":[0.005703264,0.0006301225,0.9590144,0.0038760542,0.00008508817,0.00023999123,0.0034799334,0.00013202387,0.021343112,0.00017418416,0.004925177,0.00039661193],"about_ca_topic_score_codex":0.01483252,"about_ca_topic_score_gemma":0.0014451925,"teacher_disagreement_score":0.9377918,"about_ca_system_score_codex":0.0008233416,"about_ca_system_score_gemma":0.0009560267,"threshold_uncertainty_score":0.9977619},"labels":[],"label_agreement":null},{"id":"W4396591833","doi":"10.1158/1538-7445.sabcs23-ps03-04","title":"Abstract PS03-04: Tumor immune microenvironment modulates resistance to estrogen suppression in ER+ breast cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Tumor microenvironment; Breast cancer; Estrogen; Immune system; Cancer; Medicine; Cancer research; Estrogen receptor; Internal medicine; Oncology; Immunology","score_opus":0.03220530550140412,"score_gpt":0.3696461242090047,"score_spread":0.3374408187076006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396591833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92031854,0.06340288,0.0000032674038,0.014140607,0.00038423855,0.0009362166,0.00025823782,0.000055597135,0.00050040573],"genre_scores_gemma":[0.9876126,0.0054735104,0.00007808965,0.00030721992,0.00034893714,0.0007489234,0.000020117517,0.000071681956,0.005338933],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99720126,0.00008091642,0.0004237006,0.00068526104,0.0007954833,0.0008133738],"domain_scores_gemma":[0.9990227,0.000095876254,0.000033205677,0.0005235406,0.00008344322,0.000241216],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008214876,0.00022954529,0.00033746037,0.00041683952,0.00012662944,0.0001034719,0.00028167924,0.00009799947,0.0037734378],"category_scores_gemma":[0.000020018279,0.0001893592,0.00013561604,0.0008827104,0.00020365187,0.0001311235,0.00013034567,0.00069099537,0.0001324634],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004922082,0.00013229593,0.0060747964,0.00063597003,0.00013499954,0.00036609842,0.00056892575,0.000068313224,0.93545,0.00002203316,0.023174347,0.028450137],"study_design_scores_gemma":[0.0020874578,0.0001515473,0.46611208,0.006789936,0.000031102554,0.000052233347,0.00032673727,0.00008449387,0.34585416,0.00009329821,0.17803158,0.00038537162],"about_ca_topic_score_codex":0.004474693,"about_ca_topic_score_gemma":0.0010950213,"teacher_disagreement_score":0.58959585,"about_ca_system_score_codex":0.0018076833,"about_ca_system_score_gemma":0.0005847776,"threshold_uncertainty_score":0.99713725},"labels":[],"label_agreement":null},{"id":"W4396597402","doi":"10.51731/cjht.2024.882","title":"Nivolumab and Relatlimab (Opdualag)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nivolumab; Medicine; Internal medicine; Cancer; Immunotherapy","score_opus":0.020883726419394413,"score_gpt":0.2905325456342415,"score_spread":0.2696488192148471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396597402","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19664255,0.67526793,0.00007372021,0.12653044,0.0006302989,0.00015235007,0.00000974217,0.0001439776,0.00054898474],"genre_scores_gemma":[0.99340796,0.0053125885,0.00037222647,0.00063012267,0.000015567006,0.0000014881085,7.944872e-7,0.0000123849195,0.0002468902],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992109,0.000015696094,0.0003323661,0.00009666577,0.00008875956,0.00025560614],"domain_scores_gemma":[0.9996391,0.000030332763,0.00008325238,0.00012426212,0.000047973477,0.00007509476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045194672,0.00007931881,0.00023105166,0.0005584503,0.00010653899,0.00004362572,0.00008074337,0.00011211234,0.000033578086],"category_scores_gemma":[0.0001072714,0.00006089711,0.00006261236,0.00027766815,0.00022314712,0.00007936019,0.000007140483,0.00038342393,0.000004155731],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049335944,0.000004347952,0.0012738633,0.00021826685,0.0000824344,0.00034602135,0.00028400918,1.2996257e-7,0.00018721036,0.00083333603,0.01743248,0.9792886],"study_design_scores_gemma":[0.0007559644,0.0009981373,0.010715871,0.0012802265,0.000030016383,0.004085099,0.00246871,0.000016969378,0.00032214032,0.0019513412,0.97727937,0.00009613276],"about_ca_topic_score_codex":0.0023446095,"about_ca_topic_score_gemma":0.0011868434,"teacher_disagreement_score":0.97919244,"about_ca_system_score_codex":0.00035032284,"about_ca_system_score_gemma":0.002602121,"threshold_uncertainty_score":0.4616051},"labels":[],"label_agreement":null},{"id":"W4396597768","doi":"10.1158/1538-7445.sabcs23-po1-13-04","title":"Abstract PO1-13-04: Distinct immune signatures discriminate between patients defined as exceptional survivors of metastatic breast cancer compared to those with rapidly progressing treatment resistant breast cancers","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Breast cancer; Medicine; Oncology; Metastatic breast cancer; Immune system; Internal medicine; Cancer; Immunology","score_opus":0.06736305483458309,"score_gpt":0.3995147834842628,"score_spread":0.3321517286496797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396597768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784938,0.01213766,0.00001071754,0.0029485258,0.00026591434,0.0018922323,0.0037834095,0.0000768295,0.000390928],"genre_scores_gemma":[0.99671394,0.0007492303,0.00011881365,0.000048067326,0.00026413015,0.00096630293,0.00036956253,0.00010298177,0.000667001],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99580795,0.00022087949,0.00066953024,0.0008002822,0.0016081064,0.0008932315],"domain_scores_gemma":[0.9978894,0.0003305335,0.0001590611,0.0005008963,0.00072677986,0.0003933107],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007261702,0.0004485044,0.0007935136,0.00055484765,0.0002971122,0.00015639089,0.00029205313,0.00009858447,0.0011818272],"category_scores_gemma":[0.000028530992,0.00029980755,0.00023732107,0.0013459815,0.0006277434,0.00018713517,0.00008360297,0.00048893,0.000014794647],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.087077364,0.0015964225,0.18406396,0.0045230985,0.0069748694,0.0004137939,0.007270978,0.00040446394,0.13674144,0.00009147457,0.0036427632,0.56719935],"study_design_scores_gemma":[0.0045882114,0.0014798553,0.97672343,0.006057768,0.00041703426,0.000021272775,0.00081782846,0.000042611307,0.006889327,0.00004052626,0.002486257,0.00043586735],"about_ca_topic_score_codex":0.06996439,"about_ca_topic_score_gemma":0.011005962,"teacher_disagreement_score":0.79265946,"about_ca_system_score_codex":0.0028992014,"about_ca_system_score_gemma":0.002833112,"threshold_uncertainty_score":0.9999454},"labels":[],"label_agreement":null},{"id":"W4396605939","doi":"10.1097/md.0000000000038019","title":"Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Oncology; Adverse effect; Internal medicine; Cochrane Library; Systematic review; PD-L1; MEDLINE; Cancer; Intensive care medicine; Immunotherapy","score_opus":0.08504672712497115,"score_gpt":0.3899065085987458,"score_spread":0.3048597814737747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396605939","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017427128,0.98973596,0.0000018247422,0.0038075708,0.00011182862,0.006125099,0.000109597684,0.0000098677265,0.00008081703],"genre_scores_gemma":[0.00023740559,0.9982962,0.0000135335495,0.00014536308,0.00007577231,0.00081674365,0.00010821305,0.000030973744,0.00027577122],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99537796,0.0005455574,0.0029169861,0.00047607152,0.00048320944,0.00020020084],"domain_scores_gemma":[0.9974178,0.0004330832,0.0011389538,0.0008570712,0.000074845564,0.00007821813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022283297,0.000580971,0.012268715,0.0005733403,0.000028373945,0.0000068116815,0.00015952441,0.00015096544,0.00025328257],"category_scores_gemma":[0.00013332514,0.000231206,0.0018640612,0.0019047767,0.00030123515,0.000017479662,0.000031929718,0.00024968,0.0000011140585],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018274633,0.00020172038,0.0000013927092,0.8068414,0.13365896,0.000023861896,0.0011069836,2.872978e-8,0.0000027824685,0.000010338999,0.00013619217,0.05783359],"study_design_scores_gemma":[0.0012569702,0.0008430062,0.00002789005,0.2209107,0.6849512,0.00006510702,0.00009052821,0.0000011392908,0.0000021279532,0.0000017525732,0.091725186,0.00012440083],"about_ca_topic_score_codex":0.0012504581,"about_ca_topic_score_gemma":0.0001332872,"teacher_disagreement_score":0.5859307,"about_ca_system_score_codex":0.00024836735,"about_ca_system_score_gemma":0.00018469305,"threshold_uncertainty_score":0.9428307},"labels":[],"label_agreement":null},{"id":"W4396607282","doi":"10.1016/j.esmoop.2024.102964","title":"The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Stichting Tegen Kanker; Fonds De La Recherche Scientifique - FNRS; Gilead Sciences","keywords":"Pembrolizumab; Medicine; Immunotherapy; Oncology; Cancer; Breast cancer; Triple-negative breast cancer; Internal medicine","score_opus":0.013643132587179488,"score_gpt":0.29238551692852194,"score_spread":0.27874238434134246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396607282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99433595,0.0006484501,0.00022607557,0.00085714564,0.00005846022,0.0021695753,0.001491168,0.000025050953,0.00018812118],"genre_scores_gemma":[0.9984449,0.00017921143,0.00037866458,0.00012536238,0.000028462202,0.00030515212,0.00013783984,0.000039506325,0.00036090554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988045,0.00004811124,0.000252482,0.00042798943,0.00024123384,0.00022566579],"domain_scores_gemma":[0.99911505,0.00020286265,0.00012670753,0.00029132984,0.00019380137,0.00007022862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020899439,0.00021170334,0.0005110179,0.00022606007,0.00019651884,0.00018125222,0.00018404168,0.00005184033,0.00017094257],"category_scores_gemma":[0.000017661114,0.00011293806,0.00011527025,0.001345029,0.00017596787,0.00016767376,0.00004330097,0.0000805267,4.4321268e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07027316,0.00009581806,0.8215988,0.000028222214,0.028710283,0.000006201287,0.0025607138,0.0000060942602,0.0006067874,0.000021895972,0.00034335253,0.07574863],"study_design_scores_gemma":[0.007365489,0.000931228,0.986906,0.0004958501,0.0017705096,0.000002934588,0.00051680504,0.00019447481,0.0012755577,0.000017427727,0.00034774415,0.00017598702],"about_ca_topic_score_codex":0.04444474,"about_ca_topic_score_gemma":0.014831046,"teacher_disagreement_score":0.16530715,"about_ca_system_score_codex":0.00029747232,"about_ca_system_score_gemma":0.00017405025,"threshold_uncertainty_score":0.9619184},"labels":[],"label_agreement":null},{"id":"W4396752643","doi":"10.7150/jca.93306","title":"Immunotherapeutic Strategies for Intra-cranial Metastatic Melanoma - a Meta-analysis and Systematic Review","year":2024,"lang":"en","type":"article","venue":"Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"National Institute for Health and Care Excellence","keywords":"Medicine; Immunotherapy; Melanoma; Radiation therapy; Oncology; Clinical trial; Internal medicine; Combination therapy; Ipilimumab; Surgery; Cancer; Cancer research","score_opus":0.05497794002866691,"score_gpt":0.37559026483955044,"score_spread":0.32061232481088353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396752643","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003202931,0.9865405,0.004036159,0.005084105,0.00022346954,0.00081696396,0.000034173216,0.0000120240775,0.000049701644],"genre_scores_gemma":[0.76343393,0.2228925,0.0024836166,0.008751104,0.00037783408,0.00045823483,0.0000065101153,0.000075905475,0.0015203375],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99845856,0.00009124942,0.00087008777,0.00013145355,0.00030825174,0.00014039893],"domain_scores_gemma":[0.999021,0.00021443861,0.0003509322,0.00015965296,0.00019187582,0.00006209543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001044627,0.00016716757,0.0018330207,0.00027376795,0.00003430852,0.00011072049,0.00008440481,0.000032776363,0.0005254227],"category_scores_gemma":[0.000030019059,0.00009236469,0.0016992779,0.00050094177,0.00005205966,0.00018164894,0.0000052034384,0.00013850117,0.000001157694],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009506831,0.00005181876,0.00001336872,0.28155535,0.7087352,0.000099983285,0.00054739654,0.00000565207,0.0045116115,0.00037101758,0.0009257077,0.0022321625],"study_design_scores_gemma":[0.001095286,0.00057771,0.00008625835,0.01641503,0.9757728,0.0005831577,0.000274961,0.0002010464,0.0003074767,0.00043395886,0.0040974044,0.00015488928],"about_ca_topic_score_codex":0.00004395216,"about_ca_topic_score_gemma":0.00005004494,"teacher_disagreement_score":0.763648,"about_ca_system_score_codex":0.00009380343,"about_ca_system_score_gemma":0.00040189654,"threshold_uncertainty_score":0.575301},"labels":[],"label_agreement":null},{"id":"W4396776045","doi":"10.1016/s2468-1253(24)00091-8","title":"Clinical significance of combined tumour-infiltrating lymphocytes and microsatellite instability status in colorectal cancer: a systematic review and network meta-analysis","year":2024,"lang":"en","type":"review","venue":"˜The œLancet. Gastroenterology & hepatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Deutsche Forschungsgemeinschaft","keywords":"Microsatellite instability; Colorectal cancer; Oncology; Medicine; Meta-analysis; Internal medicine; Cancer; Tumor-infiltrating lymphocytes; DNA mismatch repair; Biology; Microsatellite; Immunotherapy; Gene; Genetics","score_opus":0.07815559779266261,"score_gpt":0.37243686710292223,"score_spread":0.2942812693102596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396776045","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010575933,0.9840089,0.000014297395,0.000741702,0.00027125297,0.0040010754,0.0003355925,0.00003994288,0.000011282862],"genre_scores_gemma":[0.019596815,0.97640127,0.00015015583,0.0021438259,0.00011599478,0.0014224352,0.000099570716,0.000050012142,0.000019910463],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99027145,0.0037472907,0.0036900588,0.0011261281,0.00020026058,0.0009647941],"domain_scores_gemma":[0.9957063,0.0014219929,0.0017904976,0.0008002177,0.00011849379,0.00016247714],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.003842545,0.0007753762,0.019522894,0.00027989288,0.00007809159,0.000028132603,0.00037622947,0.00047338862,0.0000703405],"category_scores_gemma":[0.00014807754,0.000464048,0.0022185883,0.0009878663,0.0014010941,0.000038542712,0.00021943256,0.0010485557,0.000002583983],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019496003,0.00016055898,0.11777097,0.7217534,0.15271533,0.00010804673,0.000099974066,9.4815357e-7,0.0000088424495,0.000013254601,0.00036110636,0.0050579607],"study_design_scores_gemma":[0.0027754558,0.0016097323,0.0038681484,0.045906384,0.9312206,0.0009660365,0.000034405264,0.00015083414,0.0000013676298,0.00002946109,0.013024485,0.0004130956],"about_ca_topic_score_codex":0.0007105291,"about_ca_topic_score_gemma":0.006166881,"teacher_disagreement_score":0.77850527,"about_ca_system_score_codex":0.0002604025,"about_ca_system_score_gemma":0.0005256641,"threshold_uncertainty_score":0.99978113},"labels":[],"label_agreement":null},{"id":"W4396813958","doi":"10.1158/1078-0432.ccr-24-0268","title":"Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial","year":2024,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Ottawa; Ottawa Hospital; University of British Columbia","funders":"BC Cancer Foundation; Michael Smith Health Research BC; AstraZeneca","keywords":"Durvalumab; Medicine; Colorectal cancer; Microsatellite instability; Tremelimumab; Internal medicine; Pembrolizumab; Immunotherapy; Oncology; Biomarker; Cancer; Gastroenterology; Ipilimumab; Biology; Allele; Microsatellite","score_opus":0.1396367048201123,"score_gpt":0.5080197485062736,"score_spread":0.3683830436861613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396813958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99071527,0.0018179395,9.089186e-7,0.0037142173,0.0007221998,0.0025267904,0.00018640945,0.000024748495,0.00029151211],"genre_scores_gemma":[0.99820775,0.0003348892,0.00003353548,0.00010253269,0.0002595177,0.0007901775,0.00003247869,0.000048598104,0.00019051663],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9943232,0.0018700762,0.0009836829,0.0005739765,0.0017231953,0.00052584975],"domain_scores_gemma":[0.99286354,0.0063007483,0.00011660861,0.00031145738,0.000278316,0.00012930857],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0069105453,0.00020438759,0.00057847897,0.0005224383,0.00007864849,0.000059292295,0.00033462228,0.00011814418,0.0012019775],"category_scores_gemma":[0.0014618989,0.00013199655,0.0001615265,0.0015760432,0.0009426455,0.000106874504,0.000051124505,0.00092786085,0.000034588782],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9587912,0.00048356666,0.0049294108,0.0001640847,0.0005635133,0.00032908734,0.0011728451,0.000057452315,0.00038926615,0.000018519635,0.0014536494,0.031647414],"study_design_scores_gemma":[0.46440715,0.040495142,0.47143745,0.0019638787,0.00028025467,0.000018520339,0.002861397,0.0017462963,0.0016547813,0.000091314854,0.014562686,0.00048111007],"about_ca_topic_score_codex":0.004990965,"about_ca_topic_score_gemma":0.0026146222,"teacher_disagreement_score":0.49438405,"about_ca_system_score_codex":0.0010720583,"about_ca_system_score_gemma":0.005022617,"threshold_uncertainty_score":0.99971104},"labels":[],"label_agreement":null},{"id":"W4396921377","doi":"10.1016/j.annonc.2024.04.001","title":"IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Chugai Pharmaceutical; Daiichi Sankyo Europe; Gilead Sciences; Servier; Seagen; Genentech; Veracyte; Jazz Pharmaceuticals; Ipsen; Queen Mary University of London; Clovis Oncology; Eisai; Natera; Baxalta; Les Laboratories Pierre Fabre; F. Hoffmann-La Roche; Amgen; Breast Cancer Research Foundation; Ariad Pharmaceuticals; Bayer HealthCare; Sanofi; Stryker; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Atezolizumab; Triple-negative breast cancer; Oncology; Metastatic breast cancer; Internal medicine; Chemotherapy; Double blind; Breast cancer; Cancer; Immunotherapy; Placebo; Pathology","score_opus":0.09997999724582605,"score_gpt":0.4500273928235163,"score_spread":0.3500473955776902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396921377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799965,0.0019661675,0.0025256404,0.0057564448,0.0007359181,0.008034606,0.00024797785,0.00006328493,0.00067347905],"genre_scores_gemma":[0.98908395,0.0026423084,0.002110794,0.0006587532,0.00024171175,0.001188832,0.000029074794,0.000079557205,0.003965039],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99777,0.00012625319,0.0009354115,0.0004175327,0.0003207415,0.0004300482],"domain_scores_gemma":[0.9977302,0.00081056927,0.00051432115,0.00027408585,0.0005310642,0.00013978098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083002314,0.00029852698,0.001460096,0.00028249098,0.000075822405,0.00002089472,0.00014388694,0.00016174403,0.0008402985],"category_scores_gemma":[0.000083592786,0.00016850738,0.0003249732,0.00067958207,0.00035204296,0.00021242257,0.00001668013,0.00020785387,0.0000010126603],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77873176,0.0010128669,0.000008121407,0.0003637357,0.002166163,0.000046499135,0.0012267035,0.000010936909,0.015528261,0.000015859676,0.0015265925,0.1993625],"study_design_scores_gemma":[0.89051795,0.04454109,0.000028505028,0.0012898422,0.0005448023,0.00013913114,0.00044426034,0.0005438744,0.05362711,0.00006422933,0.00804388,0.00021533323],"about_ca_topic_score_codex":0.0008285587,"about_ca_topic_score_gemma":0.0004939258,"teacher_disagreement_score":0.19914716,"about_ca_system_score_codex":0.0001499349,"about_ca_system_score_gemma":0.0032109544,"threshold_uncertainty_score":0.9200679},"labels":[],"label_agreement":null},{"id":"W4396935701","doi":"10.1016/j.clcc.2024.05.002","title":"A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer","year":2024,"lang":"en","type":"article","venue":"Clinical Colorectal Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University Health Network; Princess Margaret Cancer Centre","funders":"Institute of Genetics; Genentech; Servier; Astellas Pharma; Eisai; Seagen; Sociedad Española de Oncología Médica; Mirati Therapeutics; Regeneron Pharmaceuticals; Array BioPharma; Karyopharm Therapeutics; Daiichi Sankyo Europe; Iterion Therapeutics; Sanofi; GlaxoSmithKline; Celgene; Symphogen; Bristol-Myers Squibb; American Association for Cancer Research; AstraZeneca; Pfizer; Amgen","keywords":"Medicine; Olaparib; Durvalumab; Colorectal cancer; Oncology; Randomized controlled trial; Internal medicine; Open label; Cetuximab; Nivolumab; Cancer","score_opus":0.059311103470402006,"score_gpt":0.41037805715196785,"score_spread":0.3510669536815658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396935701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98535484,0.001905029,0.000011377478,0.0006343209,0.0015565985,0.009625539,0.00023994644,0.00014663054,0.0005257421],"genre_scores_gemma":[0.99222773,0.0012784078,0.0004587549,0.0005569993,0.00035561307,0.0033397146,0.000067667665,0.00009871882,0.0016163901],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99516135,0.0004913287,0.0019005759,0.0010254321,0.0008283668,0.0005929237],"domain_scores_gemma":[0.996998,0.0014924767,0.00047985162,0.0004027468,0.00036073296,0.00026619897],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021535528,0.0005035782,0.0025464615,0.00019916079,0.00013805914,0.00007497646,0.00033963725,0.000321446,0.001819559],"category_scores_gemma":[0.00063711137,0.00026195677,0.00034537027,0.0013947244,0.00097377365,0.00021313068,0.00014976857,0.00065612636,0.000004894655],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9636096,0.009090897,0.007208614,0.00045242964,0.0020491558,0.00016082064,0.0006069546,0.000004176427,0.0002613066,0.000012861557,0.002044963,0.014498229],"study_design_scores_gemma":[0.9080386,0.078771815,0.0044944137,0.0029726054,0.0014084544,0.000013786887,0.00010208554,0.0012172274,0.00068971945,0.0000068993763,0.0018403158,0.00044406246],"about_ca_topic_score_codex":0.0020445667,"about_ca_topic_score_gemma":0.003741364,"teacher_disagreement_score":0.069680914,"about_ca_system_score_codex":0.00059538934,"about_ca_system_score_gemma":0.0036431588,"threshold_uncertainty_score":0.99998325},"labels":[],"label_agreement":null},{"id":"W4396994187","doi":"10.1681/asn.20213210s1576c","title":"Immune-Checkpoint Inhibitor Use in Patients with ESKD","year":2021,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Immune checkpoint; Immune system; Immunotherapy; Immunology","score_opus":0.01180260379598397,"score_gpt":0.25055535207191904,"score_spread":0.23875274827593507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396994187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933477,0.00031768647,0.00002395296,0.006116104,0.000091001,0.0000817222,0.0000030427927,0.0000022974941,0.00001646225],"genre_scores_gemma":[0.98822796,0.00027329626,0.0029979434,0.00830583,0.0000882764,8.3534377e-7,0.0000012380051,0.000012237573,0.000092396804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989526,0.00009828721,0.00045613296,0.000088595414,0.0002498821,0.00015445576],"domain_scores_gemma":[0.9985821,0.000080493206,0.00080959126,0.00022450968,0.0002647248,0.00003857398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021832314,0.000091492984,0.00046404192,0.000032626343,0.00002697633,0.000005390059,0.00011133428,0.00004219668,0.000035830515],"category_scores_gemma":[0.000036145007,0.000054502118,0.0004393729,0.00038693822,0.00052901165,0.000065661516,0.000046937123,0.00029917617,4.1143036e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009753646,0.0007264908,0.6523373,0.00003672445,0.0010115074,0.000022672877,0.0010024256,0.000016954533,0.3192529,0.0000023674168,0.009736085,0.0061009056],"study_design_scores_gemma":[0.004450098,0.001430583,0.9781446,0.000104668026,0.000078798286,0.00011597225,0.0006479283,0.000006982799,0.005755098,0.000010517501,0.009198245,0.000056526736],"about_ca_topic_score_codex":0.00014909734,"about_ca_topic_score_gemma":0.000020535319,"teacher_disagreement_score":0.32580727,"about_ca_system_score_codex":0.00011224435,"about_ca_system_score_gemma":0.00026378018,"threshold_uncertainty_score":0.22225319},"labels":[],"label_agreement":null},{"id":"W4396997576","doi":"10.1681/asn.20203110s1663a","title":"Immune Checkpoint Inhibitor-Associated Glomerular Disease: A Systematic Review and Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"Journal of the American Society of Nephrology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University Health Network","funders":"","keywords":"Meta-analysis; Medicine; Immune system; Disease; Immunology; Internal medicine","score_opus":0.04202208376080097,"score_gpt":0.33158511938009766,"score_spread":0.2895630356192967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396997576","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000034956603,0.98618084,0.000015356678,0.012494523,0.000033745095,0.0011528749,0.00007689138,0.000007661727,0.0000031203374],"genre_scores_gemma":[0.00008352153,0.9880053,0.00018883357,0.011441218,0.00007364344,0.000035382676,0.000010083217,0.000036976213,0.00012507074],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99532044,0.0010790705,0.002559043,0.00025845188,0.00054501044,0.00023800673],"domain_scores_gemma":[0.98921645,0.00030174825,0.009401527,0.0006246659,0.00027243156,0.00018317642],"candidate_categories":["metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.001525237,0.00044564702,0.015627736,0.00011374395,0.000065418004,0.000012104776,0.00046430863,0.00013426023,0.00009474882],"category_scores_gemma":[0.00025007236,0.00022441536,0.020098632,0.0019028792,0.0007834292,0.000037846134,0.00014568567,0.00070906454,0.0000014999788],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010569956,0.00009730176,0.0000035624505,0.4095114,0.58557224,0.000017513596,0.00007084566,1.658007e-7,0.000053505373,5.4770203e-7,0.003245221,0.0013219838],"study_design_scores_gemma":[0.000302093,0.00033394393,0.00012873256,0.022237245,0.8224471,0.00024535868,0.000054280365,0.0000021545973,7.9805295e-7,0.0000031451962,0.15409788,0.00014724705],"about_ca_topic_score_codex":0.000036581412,"about_ca_topic_score_gemma":0.0000013264962,"teacher_disagreement_score":0.38727415,"about_ca_system_score_codex":0.00024265396,"about_ca_system_score_gemma":0.00056000287,"threshold_uncertainty_score":0.9989863},"labels":[],"label_agreement":null},{"id":"W4397007022","doi":"10.1016/j.esmoop.2024.103282","title":"261TiP TROPION-Breast05: Phase (Ph) III study of datopotamab deruxtecan (Dato-DXd) ± durvalumab (D) vs chemotherapy (CT) + pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Durvalumab; Medicine; Chemotherapy; Metastatic melanoma; Docetaxel; Internal medicine; Oncology; Radiology; Immunotherapy; Cancer","score_opus":0.0240032643173013,"score_gpt":0.335595626129557,"score_spread":0.3115923618122557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397007022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898342,0.00062986877,0.000099202545,0.001048845,0.00046195879,0.006785533,0.00046611973,0.000079004916,0.0005952487],"genre_scores_gemma":[0.9956026,0.0004504707,0.0003229284,0.00046985692,0.00008474581,0.000843531,0.0001682382,0.00013909957,0.0019185458],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957022,0.0003935433,0.0011932575,0.0011027119,0.0009171512,0.000691119],"domain_scores_gemma":[0.99801093,0.00016373931,0.00035105878,0.0008821746,0.00033575748,0.00025632512],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005828113,0.00066860346,0.001416205,0.0004548067,0.00017479366,0.00021067106,0.00074360106,0.00008657663,0.0044673905],"category_scores_gemma":[0.00004567673,0.00045548455,0.00016858862,0.0016546032,0.0002396953,0.0006637625,0.00020538586,0.0005734742,0.0000208658],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5100307,0.024385178,0.027870405,0.0010325118,0.00538512,0.001034245,0.01376991,0.00008178585,0.0003244002,0.000053139483,0.0061595677,0.40987307],"study_design_scores_gemma":[0.51109266,0.038292784,0.4086646,0.0074973973,0.0018184416,0.0007919291,0.010169187,0.003321268,0.0034658718,0.00008628256,0.012681684,0.0021178997],"about_ca_topic_score_codex":0.03314261,"about_ca_topic_score_gemma":0.0162644,"teacher_disagreement_score":0.40775517,"about_ca_system_score_codex":0.00093854626,"about_ca_system_score_gemma":0.0017816991,"threshold_uncertainty_score":0.9997897},"labels":[],"label_agreement":null},{"id":"W4397007854","doi":"10.1016/j.esmoop.2024.103035","title":"27P Impact of chemotherapy (CT) use and stromal tumor-infiltrating lymphocytes (sTILs) in stage I triple-negative breast cancer (TNBC)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Triple-negative breast cancer; Stage (stratigraphy); Triple negative; Stromal cell; Chemotherapy; Breast cancer; Medicine; Oncology; Cancer; Pathology; Internal medicine; Biology","score_opus":0.028841999122971765,"score_gpt":0.34957971962111506,"score_spread":0.3207377204981433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397007854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966127,0.0010572494,0.000005953196,0.00040028038,0.000108037406,0.00080687634,0.00034322706,0.000028187666,0.0006374492],"genre_scores_gemma":[0.9977025,0.00050278485,0.00025954205,0.00022752663,0.000071818286,0.000049455102,0.000014995324,0.00003536454,0.0011360325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988778,0.00005424136,0.0003368131,0.00031402442,0.00016669383,0.0002504153],"domain_scores_gemma":[0.99941224,0.00015625503,0.000096207594,0.00020596545,0.000046363344,0.00008295616],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030622867,0.0002025072,0.00041654977,0.00013398929,0.000041616207,0.00017120784,0.00014816673,0.000039424613,0.0017190377],"category_scores_gemma":[0.000035776986,0.00015231423,0.00011479287,0.00038678467,0.0001285871,0.00048104828,0.00005728713,0.00015299949,0.0000022633683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015297769,0.00031682133,0.8363314,0.00047460108,0.0015956404,0.00065726065,0.004665973,0.000051517203,0.056469508,0.00013635232,0.0031816293,0.08082148],"study_design_scores_gemma":[0.006597418,0.00042571747,0.97590697,0.0011012704,0.000039734397,0.00016038172,0.00047651966,0.0012105219,0.013139913,0.000023360059,0.0007190177,0.00019915194],"about_ca_topic_score_codex":0.09624132,"about_ca_topic_score_gemma":0.0023678166,"teacher_disagreement_score":0.13957554,"about_ca_system_score_codex":0.00042808152,"about_ca_system_score_gemma":0.0007294133,"threshold_uncertainty_score":0.99919355},"labels":[],"label_agreement":null},{"id":"W4398131449","doi":"10.1093/oncolo/oyae089","title":"Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapy","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Immunotherapy; Melanoma; Medicine; Oncology; Targeted therapy; Internal medicine; Cancer research; Cancer","score_opus":0.013438049135509457,"score_gpt":0.2830156575480475,"score_spread":0.26957760841253803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398131449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99234223,0.0036265575,0.00037051374,0.0016126815,0.00029730718,0.0013284674,0.000015027479,0.000097873024,0.00030936653],"genre_scores_gemma":[0.9939441,0.00017520359,0.0048070336,0.00040462083,0.00009790434,0.00013491827,0.000036333247,0.000044265194,0.00035562785],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99909395,0.00005263356,0.00022568264,0.00024657336,0.00014332429,0.00023782907],"domain_scores_gemma":[0.9993186,0.00034333905,0.000064600055,0.00019851427,0.000046211408,0.0000287179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005428873,0.00016236478,0.0002747293,0.0000668567,0.00011601432,0.000051371182,0.00009465473,0.00006934875,0.000075724136],"category_scores_gemma":[0.00004355287,0.00009000428,0.000055615455,0.00022780006,0.00017401928,0.00007947394,0.000015073132,0.00015724046,0.0000041265803],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023672296,0.00028448453,0.07310575,0.00011467244,0.0004291553,0.000015563633,0.0014012066,0.00012952667,0.015776865,0.00003239355,0.00043979287,0.8845983],"study_design_scores_gemma":[0.021646298,0.007391433,0.9391516,0.0008504188,0.00006091687,0.000018401548,0.00018219418,0.0153860785,0.0007442899,0.00025333208,0.013872835,0.00044222086],"about_ca_topic_score_codex":0.0001147384,"about_ca_topic_score_gemma":0.00008503678,"teacher_disagreement_score":0.88415605,"about_ca_system_score_codex":0.00016439059,"about_ca_system_score_gemma":0.00011682908,"threshold_uncertainty_score":0.3670268},"labels":[],"label_agreement":null},{"id":"W4398145149","doi":"10.1097/cji.0000000000000527","title":"False-positive Findings of Large Vessel Vasculitis on FDG-PET in Patients Treated With Immune Checkpoint Inhibitors","year":2024,"lang":"en","type":"article","venue":"Journal of Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Alberta","funders":"","keywords":"Medicine; Discontinuation; Vasculitis; Positron emission tomography; Radiology; Retrospective cohort study; Immunosuppression; Internal medicine; Nuclear medicine","score_opus":0.005921378093618918,"score_gpt":0.251044565208188,"score_spread":0.2451231871145691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398145149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916877,0.0067437277,0.000022988608,0.00053571834,0.00032192492,0.00033623347,0.00004209109,0.000018239001,0.0002913772],"genre_scores_gemma":[0.9972876,0.0019629647,0.00013251248,0.0002475745,0.000091678085,0.0000049382706,0.000024245825,0.000056136047,0.00019237117],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979472,0.000084171515,0.0009874984,0.00018780495,0.0005251282,0.00026816863],"domain_scores_gemma":[0.99907565,0.00009739829,0.00033264523,0.00022040127,0.00021439123,0.000059530266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006788137,0.0002492765,0.00064155355,0.0005568332,0.000037192207,0.000036159585,0.00013148034,0.0000916965,0.00019255956],"category_scores_gemma":[0.000020851303,0.00016701693,0.00034739298,0.0005753266,0.00009266437,0.00019208527,0.000010169342,0.0004433667,0.000006873124],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11257155,0.0064668464,0.18016408,0.0006513694,0.008746666,0.0016321908,0.008051095,0.000022261951,0.5924046,0.00022923954,0.0031560147,0.08590405],"study_design_scores_gemma":[0.027722122,0.0113672195,0.6951792,0.0080916565,0.00014535997,0.00031307503,0.00033823226,0.000018190938,0.24821633,0.000029320447,0.008248102,0.00033115342],"about_ca_topic_score_codex":0.00016553672,"about_ca_topic_score_gemma":0.000006118062,"teacher_disagreement_score":0.5150151,"about_ca_system_score_codex":0.00034891852,"about_ca_system_score_gemma":0.00019182186,"threshold_uncertainty_score":0.6810753},"labels":[],"label_agreement":null},{"id":"W4398221087","doi":"10.1136/bcr-2023-258701","title":"Immune checkpoint inhibitor-induced hypophysitis with transient ACTH-dependent hypercortisolism","year":2024,"lang":"en","type":"article","venue":"BMJ Case Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Hypophysitis; Medicine; Adrenal insufficiency; Adrenal crisis; Adrenocorticotropic hormone; Nivolumab; Ipilimumab; Hydrocortisone; Internal medicine; Primary Adrenal Insufficiency; Hypothalamic disease; Endocrinology; Immunotherapy; Pituitary gland; Hypogonadotropic hypogonadism; Hormone; Cancer","score_opus":0.019827115086133756,"score_gpt":0.2889869624247889,"score_spread":0.2691598473386551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398221087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903253,0.0033459754,0.000081698185,0.0011652202,0.0012478954,0.0010689162,0.000007307675,0.0002594475,0.0024982905],"genre_scores_gemma":[0.9973156,0.00016174892,0.00016085649,0.00018222735,0.0005192484,0.00014557313,0.00002829414,0.00007250546,0.0014139598],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9977553,0.000032010834,0.0007677264,0.0005706971,0.00052260567,0.00035167928],"domain_scores_gemma":[0.99890894,0.000027266711,0.00014893859,0.0006499898,0.00008673607,0.00017813646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038957308,0.00028187037,0.00042497017,0.00015000832,0.00009766093,0.000080047656,0.000027015725,0.00013106586,0.00028202593],"category_scores_gemma":[0.000019766076,0.00021009495,0.00030148067,0.0003185521,0.00006792144,0.0001449625,0.000023300096,0.00029745605,0.000029481402],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047044377,0.0001066068,0.000036367004,0.00019561432,0.00027937687,0.6095777,0.00047014718,0.0000013233065,0.33130568,0.000003415109,0.00029063522,0.05726269],"study_design_scores_gemma":[0.001036375,0.0006351478,0.0038128833,0.0008791429,0.00027806117,0.8514817,0.00030676177,0.000044332643,0.13112006,0.000013120152,0.010076869,0.00031558215],"about_ca_topic_score_codex":0.0011542641,"about_ca_topic_score_gemma":0.0001104847,"teacher_disagreement_score":0.24190398,"about_ca_system_score_codex":0.00024860847,"about_ca_system_score_gemma":0.000461855,"threshold_uncertainty_score":0.8567424},"labels":[],"label_agreement":null},{"id":"W4399057096","doi":"10.1016/j.prp.2024.155370","title":"The tumor microenvironment’s in pancreatic cancer: Effects on immunotherapy success and novel strategies to overcome the hostile environment","year":2024,"lang":"en","type":"article","venue":"Pathology - Research and Practice","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Tumor microenvironment; Medicine; Immunotherapy; Radiation therapy; Cancer; Pancreatic cancer; Cancer immunotherapy; Internal medicine","score_opus":0.035604366107800746,"score_gpt":0.38008167665078063,"score_spread":0.34447731054297986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399057096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9017268,0.04935193,0.0000451471,0.04678241,0.00016132595,0.0010893386,0.000020019797,0.000014200288,0.00080881594],"genre_scores_gemma":[0.93627256,0.060297985,0.000097028525,0.001985355,0.00010564969,0.0004554348,0.000002965737,0.000023329374,0.0007597038],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998183,0.00055336056,0.00017414191,0.0003626077,0.00031133238,0.00041554516],"domain_scores_gemma":[0.99373484,0.0058210613,0.000032399006,0.00031732352,0.00001556943,0.00007881484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026020329,0.00014398537,0.00017613076,0.000107686654,0.0003267941,0.00021192283,0.00012956762,0.00005773335,0.00006343189],"category_scores_gemma":[0.0002597586,0.000072338866,0.000027773729,0.00018830327,0.00052598695,0.00015442626,0.00008786822,0.0006116882,0.00002097926],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025777778,0.00052164186,0.010657491,0.00047314737,0.0005043787,0.0016282019,0.006761575,0.000009346378,0.7828909,0.0017351622,0.0019081981,0.1671322],"study_design_scores_gemma":[0.0033227946,0.0046615456,0.53379744,0.00061640237,0.000090182206,0.0013573576,0.0050733397,0.00008651556,0.009082112,0.00073476974,0.44090104,0.0002764909],"about_ca_topic_score_codex":0.00080597034,"about_ca_topic_score_gemma":0.00010873363,"teacher_disagreement_score":0.7738088,"about_ca_system_score_codex":0.00015394877,"about_ca_system_score_gemma":0.00010931133,"threshold_uncertainty_score":0.29498932},"labels":[],"label_agreement":null},{"id":"W4399060913","doi":"10.1016/j.ebiom.2024.105167","title":"A computational pipeline for identifying gene targets and signalling pathways in cancer cells to improve lymphocyte infiltration and immune checkpoint therapy efficacy","year":2024,"lang":"en","type":"article","venue":"EBioMedicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research; Alberta Innovates; Alberta Heritage Foundation for Medical Research","keywords":"Immune system; Infiltration (HVAC); Lymphocyte; Signalling pathways; Immune checkpoint; Gene; Immunology; Medicine; Immunotherapy; Cancer research; Biology; Computational biology; Genetics","score_opus":0.032900037531015634,"score_gpt":0.3169921492942237,"score_spread":0.2840921117632081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399060913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9018628,0.06577074,0.02627869,0.003679238,0.0007396747,0.0015007957,0.00007322186,0.00007313073,0.00002169664],"genre_scores_gemma":[0.99160755,0.003399063,0.0030364455,0.00097571505,0.0005295708,0.00013934956,0.00013334284,0.000036283243,0.00014266296],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986841,0.000018012015,0.0004775613,0.00038146295,0.00020534033,0.00023351832],"domain_scores_gemma":[0.9995032,0.00015251059,0.00006121717,0.000097142045,0.00007528744,0.00011062788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053547375,0.00018746227,0.00032778707,0.00032108303,0.00006556781,0.000049179696,0.000041934854,0.00007555798,0.00004354597],"category_scores_gemma":[0.000023819093,0.00014936527,0.000062492705,0.000352385,0.000083551575,0.00008357196,0.000021071435,0.00010318958,0.0000019336876],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015712947,0.000058218957,0.000044736214,0.0002557105,0.00009054094,0.000019961966,0.0019952166,0.00007669363,0.83355063,0.0000148406525,0.00013574318,0.16218643],"study_design_scores_gemma":[0.02440223,0.0017435363,0.016305635,0.0023495257,0.00013812727,0.000096625896,0.00047362215,0.09284932,0.8501221,0.00057043333,0.010456854,0.00049196935],"about_ca_topic_score_codex":0.0003714366,"about_ca_topic_score_gemma":0.000022977789,"teacher_disagreement_score":0.16169445,"about_ca_system_score_codex":0.00018024731,"about_ca_system_score_gemma":0.00018215521,"threshold_uncertainty_score":0.6090939},"labels":[],"label_agreement":null},{"id":"W4399133791","doi":"10.21037/map-24-ab073","title":"AB073. SOH24AB_228. Immunomodulatory effect of epigenetic modification on T cell phenotype and checkpoint receptor expression in oesophageal adenocarcinoma","year":2024,"lang":"en","type":"article","venue":"Mesentery and Peritoneum","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Epigenetics; Phenotype; Cancer research; Biology; Genetics; Gene","score_opus":0.010471552562360938,"score_gpt":0.2659507681958198,"score_spread":0.2554792156334589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399133791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96622413,0.032468572,0.0000152216035,0.00024953854,0.00035339245,0.00033419585,0.0000117750615,0.00002488329,0.0003183128],"genre_scores_gemma":[0.9981336,0.0012822427,0.00004189336,0.000051972525,0.00009804239,0.000030269515,0.000023328193,0.000020815482,0.00031782282],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99905515,0.00009969105,0.00026260637,0.00030294398,0.00013193555,0.00014768631],"domain_scores_gemma":[0.99961555,0.00007984138,0.000041240874,0.00019521019,0.000012347493,0.000055780685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026460766,0.00015973226,0.00027122375,0.000149341,0.000039207207,0.000023274852,0.000042255,0.000097675475,0.00006311191],"category_scores_gemma":[0.000007962655,0.00012221631,0.0000722649,0.00011042232,0.00010132798,0.000059631115,0.00002607643,0.00016545661,0.0000060257603],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029575492,0.000095701624,0.021153487,0.00094336114,0.00003307772,0.00001802463,0.0011432803,0.0000020883676,0.94958186,0.0000051281513,0.00015676199,0.023909697],"study_design_scores_gemma":[0.0016398879,0.0016102011,0.2580015,0.00075737067,0.00003859967,0.000023230108,0.00016680648,0.0004847889,0.7360902,0.0000139757,0.0010347534,0.0001386646],"about_ca_topic_score_codex":0.0000597946,"about_ca_topic_score_gemma":0.0000024952033,"teacher_disagreement_score":0.23684803,"about_ca_system_score_codex":0.000041598203,"about_ca_system_score_gemma":0.000028388267,"threshold_uncertainty_score":0.49838364},"labels":[],"label_agreement":null},{"id":"W4399295832","doi":"10.3389/fimmu.2024.1372837","title":"Regulatory and memory T lymphocytes infiltrating prostate tumors predict long term clinical outcomes","year":2024,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Prostate Cancer Canada; Movember Foundation","keywords":"FOXP3; Tumor-infiltrating lymphocytes; Prostate cancer; Proportional hazards model; Oncology; Medicine; Prostate; CD3; Immune system; Immunohistochemistry; Cancer research; Pathology; Cancer; Biology; Internal medicine; Immunology; Immunotherapy; CD8","score_opus":0.013180876642920487,"score_gpt":0.2926513112457384,"score_spread":0.2794704346028179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399295832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94657457,0.048311833,0.00012343028,0.0006651064,0.00322056,0.0004317471,0.000008354597,0.00015351975,0.00051087],"genre_scores_gemma":[0.9926368,0.0031387114,0.0015303078,0.00044933052,0.0001318877,0.000048814396,0.00002536876,0.00004061485,0.0019981824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983074,0.0001255737,0.0006668698,0.0004230255,0.00012884988,0.00034828685],"domain_scores_gemma":[0.99939585,0.00014208788,0.0000835981,0.0002965007,0.000024345483,0.000057613375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006218693,0.00020665691,0.00055895647,0.00030654424,0.00005930562,0.000036706377,0.00010720352,0.0002287568,0.000039903152],"category_scores_gemma":[0.00010195966,0.00017031649,0.00015287093,0.00022106337,0.00068608095,0.00013765505,0.0000652587,0.00039586297,0.000005257964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010456076,0.00004949321,0.8331017,0.00014319322,0.0005745149,0.00024995944,0.0005580019,4.349129e-7,0.0012880411,0.000020145559,0.002489021,0.16047989],"study_design_scores_gemma":[0.0031360688,0.00040659454,0.9920743,0.00051094283,0.00007111651,0.00026513464,0.0005498272,0.00015457634,0.00079132343,0.000104827224,0.0017559404,0.00017932376],"about_ca_topic_score_codex":0.000069770846,"about_ca_topic_score_gemma":0.000014628541,"teacher_disagreement_score":0.16030057,"about_ca_system_score_codex":0.00021695778,"about_ca_system_score_gemma":0.00033284075,"threshold_uncertainty_score":0.6945305},"labels":[],"label_agreement":null},{"id":"W4399304812","doi":"10.1016/j.jemermed.2024.03.031","title":"The lethal M triad of myocarditis, myositis, and myasthenia gravis post immune checkpoint inhibitors therapy: A systematic review","year":2024,"lang":"en","type":"review","venue":"Journal of Emergency Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Myasthenia gravis; Myositis; Myocarditis; Medicine; Triad (sociology); Immunology; Internal medicine","score_opus":0.050355506643320336,"score_gpt":0.3767140708078898,"score_spread":0.3263585641645695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399304812","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004760834,0.9884053,0.0000035889586,0.0030738318,0.0056034094,0.0026357688,0.00003386093,0.000014198284,0.00018244458],"genre_scores_gemma":[0.0000566159,0.9971251,0.000013174966,0.0001212406,0.0016336605,0.00007014139,0.000027807822,0.00009872185,0.00085355906],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9908599,0.0006437314,0.0066618077,0.00031080257,0.0011766537,0.00034707857],"domain_scores_gemma":[0.9936387,0.00035690822,0.0043858457,0.00069956924,0.00069544214,0.00022354936],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0059146746,0.00070103054,0.006702329,0.00045466708,0.00011284339,0.000012094044,0.0004399008,0.00026344342,0.0003951323],"category_scores_gemma":[0.0010758796,0.00030676182,0.0027537527,0.0009848245,0.00032123356,0.00007646266,0.00006549986,0.0010889444,0.000008070619],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034868627,0.000075897726,0.0000012718882,0.8358201,0.0061305785,0.00015574713,0.00029308785,4.1546246e-9,0.0002083337,0.000018515606,0.022548312,0.13439949],"study_design_scores_gemma":[0.001049433,0.001596344,0.000009469318,0.594924,0.014800386,0.0026904962,0.00014994625,1.9230953e-7,0.0000067074666,0.000020286376,0.3845759,0.00017685829],"about_ca_topic_score_codex":0.00009334285,"about_ca_topic_score_gemma":0.0000043509904,"teacher_disagreement_score":0.3620276,"about_ca_system_score_codex":0.00018023635,"about_ca_system_score_gemma":0.0007209553,"threshold_uncertainty_score":0.9999384},"labels":[],"label_agreement":null},{"id":"W4399305588","doi":"10.1200/jco.2024.42.16_suppl.12047","title":"Delayed immune-related adverse events in patients with advanced melanoma treated with immune checkpoint inhibitors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC","funders":"","keywords":"Medicine; Adverse effect; Immune system; Ipilimumab; Nivolumab; Melanoma; Immune checkpoint; Immunotherapy; Immunology; Oncology; Cancer research; Internal medicine","score_opus":0.02067868592833625,"score_gpt":0.35588459403834966,"score_spread":0.3352059081100134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399305588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99449515,0.0019016295,0.00001544127,0.0014045247,0.00095457776,0.000461598,0.000004548258,0.000027187722,0.00073534495],"genre_scores_gemma":[0.9980721,0.0004750288,0.0006720601,0.00022965056,0.00015025989,0.000007785235,0.000018724539,0.000041394782,0.00033299244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953312,0.00028317544,0.0033691826,0.0002707221,0.00044323102,0.00030248714],"domain_scores_gemma":[0.9974475,0.0004758971,0.0013159576,0.00022911078,0.00032510285,0.00020643746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00197407,0.00024008779,0.0014380118,0.00029137617,0.00003139229,0.0000044401445,0.00014348849,0.0003990289,0.00019213559],"category_scores_gemma":[0.0002822838,0.00013802577,0.0005541592,0.00056503754,0.00021319126,0.000225209,0.00002971843,0.0012284017,0.000017707505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24276434,0.0041788835,0.57441014,0.000088711255,0.0037730907,0.0021322526,0.00032133993,0.00006979166,0.0020112018,0.000010181582,0.0001659025,0.17007418],"study_design_scores_gemma":[0.04714789,0.04594634,0.8980376,0.0013636487,0.0004560171,0.00024389222,0.00011829068,0.00006110498,0.0005521582,0.000021967455,0.0058676098,0.00018349355],"about_ca_topic_score_codex":0.00008482819,"about_ca_topic_score_gemma":0.000056233286,"teacher_disagreement_score":0.32362747,"about_ca_system_score_codex":0.0004598744,"about_ca_system_score_gemma":0.0013207678,"threshold_uncertainty_score":0.56285274},"labels":[],"label_agreement":null},{"id":"W4399318772","doi":"10.1200/jco.23.02736","title":"Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"North York General Hospital","funders":"Cilag; Genentech; Sirtex Medical; Daiichi Sankyo Europe; Servier; Eli Lilly and Company; Ono Pharmaceutical; Eisai; Chugai Pharmaceutical; Seagen; Daiichi Sankyo Company; BeiGene; Halozyme; Mirati Therapeutics; Taiho Pharmaceutical; Array BioPharma; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Les Laboratories Pierre Fabre; PharmaMar; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Colorectal cancer; Lenvatinib; Oncology; Internal medicine; Open label; Randomized controlled trial; Cancer; Immunotherapy; Thyroid cancer","score_opus":0.19670539736259515,"score_gpt":0.5371934962452657,"score_spread":0.3404880988826705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399318772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843343,0.009293864,0.00012035559,0.0013355978,0.0016283318,0.0027456186,0.00021295277,0.000007023627,0.0003219939],"genre_scores_gemma":[0.9967122,0.0021306237,0.00047654356,0.00014090062,0.00020512249,0.00009981297,0.000012721557,0.000021182996,0.00020086684],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941066,0.0011160721,0.0037490958,0.00026642415,0.0005340234,0.00022777764],"domain_scores_gemma":[0.9893932,0.006651673,0.0026122935,0.0002607792,0.0009450411,0.00013706088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056819627,0.00020833481,0.0050350926,0.0002895565,0.00007399489,0.000023981269,0.00045283203,0.00017302588,0.00025099007],"category_scores_gemma":[0.0024949997,0.00011428937,0.0017043719,0.0008420236,0.0005448619,0.00010349582,0.00008564073,0.0005328043,2.7418218e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86867243,0.0022117705,0.0007474287,0.0001921846,0.03196254,0.00009386642,0.0017756736,0.00006922037,0.000265685,0.000028210736,0.0009577854,0.09302319],"study_design_scores_gemma":[0.8390634,0.10083578,0.001373465,0.00038769876,0.047167875,0.000031050673,0.0019576887,0.0014625163,0.00051112886,0.000018976327,0.0070724986,0.00011794198],"about_ca_topic_score_codex":0.0004395726,"about_ca_topic_score_gemma":0.0024323987,"teacher_disagreement_score":0.098624006,"about_ca_system_score_codex":0.0005132034,"about_ca_system_score_gemma":0.005666661,"threshold_uncertainty_score":0.99997026},"labels":[],"label_agreement":null},{"id":"W4399322010","doi":"10.1038/s41416-024-02730-7","title":"Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer","year":2024,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"Ono Pharmaceutical; Hirosaki University","keywords":"Nivolumab; Microsatellite instability; Medicine; Colorectal cancer; Internal medicine; Chemoradiotherapy; Gastroenterology; Oncology; Cancer; Surgery; Immunotherapy; Microsatellite","score_opus":0.009738101648636052,"score_gpt":0.2845658555059519,"score_spread":0.2748277538573159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399322010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7366583,0.26169854,0.00008141099,0.0005169846,0.00047790958,0.00035694678,0.00013869614,0.000012768982,0.000058476155],"genre_scores_gemma":[0.88394517,0.11365025,0.0012268247,0.00036827353,0.00018152804,0.000029261062,0.000006778655,0.000055004348,0.00053688826],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981037,0.000051946186,0.0008492131,0.00032086772,0.00035084388,0.00032343643],"domain_scores_gemma":[0.9991073,0.00007489429,0.00023824634,0.00014937739,0.00031316228,0.00011700348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045600973,0.00022869153,0.000892637,0.00018139037,0.000049980186,0.00011093076,0.00013301743,0.00013007215,0.00052404415],"category_scores_gemma":[0.000027569415,0.0002134071,0.00020914784,0.00043567055,0.0002993168,0.00036382693,0.000025229434,0.00047007634,6.761922e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008091464,0.00020994007,0.1640629,0.00091278,0.0011094621,0.00048388774,0.0019715214,0.000108111635,0.14302647,0.000016418486,0.00031645483,0.6796906],"study_design_scores_gemma":[0.019339211,0.0011900526,0.8296674,0.014197969,0.00026003696,0.0011141605,0.0005515646,0.00016274804,0.10230368,0.00019999298,0.03040824,0.00060497684],"about_ca_topic_score_codex":0.0066130315,"about_ca_topic_score_gemma":0.011904359,"teacher_disagreement_score":0.6790856,"about_ca_system_score_codex":0.0006837033,"about_ca_system_score_gemma":0.0010888774,"threshold_uncertainty_score":0.99969697},"labels":[],"label_agreement":null},{"id":"W4399325142","doi":"10.1200/jco.2024.42.16_suppl.2564","title":"Circulating metabolic profiling as a biomarker for immune checkpoint blockade efficacy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; National Research Council Canada; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Blockade; Immune checkpoint; Biomarker; Profiling (computer programming); Immune system; Oncology; Cancer research; Immunology; Internal medicine; Receptor; Biology; Genetics","score_opus":0.14986171696981546,"score_gpt":0.4940249751471281,"score_spread":0.34416325817731264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399325142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9551138,0.023855494,0.0008893013,0.012947188,0.0042039375,0.00055067684,0.000004366041,0.00004072834,0.0023944783],"genre_scores_gemma":[0.98569643,0.00127685,0.008807643,0.001126857,0.002508897,0.000013671877,0.0000044385065,0.000040169034,0.0005250245],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957672,0.00020841426,0.0031866184,0.00024200554,0.00030219997,0.0002935666],"domain_scores_gemma":[0.9959605,0.0023123804,0.0010025753,0.00019067021,0.00030262917,0.00023126566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068387757,0.00016613788,0.0014175753,0.00021058267,0.000056332516,0.000030107863,0.00015024217,0.00039425713,0.000231047],"category_scores_gemma":[0.004173114,0.000112520465,0.0017667577,0.0002855997,0.00017781311,0.00009613246,0.000034745408,0.0008028696,0.000019323808],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015154481,0.0010241698,0.0009998078,0.0002276882,0.0034080755,0.0010384618,0.0001988343,0.0000052112778,0.20468345,0.0002488202,0.0009444876,0.77206653],"study_design_scores_gemma":[0.02834827,0.014848904,0.11517008,0.0013024511,0.002676654,0.006944019,0.00036256335,0.004161592,0.027886927,0.0011470328,0.7967789,0.00037259265],"about_ca_topic_score_codex":0.000017746584,"about_ca_topic_score_gemma":0.0000022928855,"teacher_disagreement_score":0.7958344,"about_ca_system_score_codex":0.00012662327,"about_ca_system_score_gemma":0.002238333,"threshold_uncertainty_score":0.49959087},"labels":[],"label_agreement":null},{"id":"W4399452407","doi":"10.1200/jco.2024.42.17_suppl.lba8007","title":"Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Perioperative; Nivolumab; Adjuvant; Oncology; Stock options; Cancer; Surgery; Immunotherapy","score_opus":0.0700768060127514,"score_gpt":0.4588425139649711,"score_spread":0.3887657079522197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399452407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99091214,0.0007478841,0.00007560279,0.0037109896,0.0016309551,0.00095919456,0.00028274936,0.000032345244,0.0016481606],"genre_scores_gemma":[0.9918552,0.0007551467,0.0004994314,0.0019193171,0.00079314294,0.000015657562,0.000048453647,0.00005266209,0.0040610093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928155,0.0012911678,0.0038686632,0.00057881186,0.00094814826,0.000497723],"domain_scores_gemma":[0.99099004,0.00563864,0.0017214026,0.0005129656,0.0006627155,0.0004742167],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005623192,0.0003452574,0.0020802026,0.00009182425,0.00017345481,0.00010693276,0.00035004673,0.0003747828,0.0003253341],"category_scores_gemma":[0.0020061182,0.0001574856,0.0005797513,0.00034040838,0.00096541806,0.0003332661,0.00008659991,0.0023359107,0.000016098254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23433739,0.008595224,0.6574806,0.000014842758,0.004848337,0.0012858235,0.002336421,0.000005140948,0.00004488257,0.0000034907857,0.016120072,0.07492776],"study_design_scores_gemma":[0.12856022,0.08370527,0.6256258,0.0003590049,0.0008767541,0.000026575502,0.0033321707,0.00011154498,0.000020211135,0.0000035033304,0.15715961,0.00021934639],"about_ca_topic_score_codex":0.0017828228,"about_ca_topic_score_gemma":0.002242338,"teacher_disagreement_score":0.14103954,"about_ca_system_score_codex":0.00033124976,"about_ca_system_score_gemma":0.0028655482,"threshold_uncertainty_score":0.9999657},"labels":[],"label_agreement":null},{"id":"W4399452838","doi":"10.1200/jco.2024.42.17_suppl.lba9516","title":"Phase III randomized trial evaluating tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with advanced refractory melanoma (ILLUMINATE 301).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ipilimumab; Medicine; Clinical endpoint; Internal medicine; Hazard ratio; Adverse effect; Melanoma; Refractory (planetary science); Oncology; Randomized controlled trial; Surgery; Immunotherapy; Gastroenterology; Confidence interval; Cancer; Cancer research","score_opus":0.06765289190333494,"score_gpt":0.45780414285497767,"score_spread":0.3901512509516427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399452838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99284524,0.00097391655,0.000063135616,0.0011504575,0.0023822354,0.001729709,0.000003032765,0.000016274687,0.0008359922],"genre_scores_gemma":[0.997847,0.00045078548,0.0010101079,0.00023731621,0.00027674492,0.00004994846,0.000016459322,0.00003179554,0.000079823185],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943486,0.0011619511,0.0031636304,0.00031958907,0.00071000535,0.00029626084],"domain_scores_gemma":[0.99297374,0.004738277,0.001530516,0.00019679828,0.00039835833,0.0001622818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007885243,0.00022715334,0.0024388544,0.00043903996,0.000032919404,0.00001874681,0.00013598237,0.0003267537,0.00012818525],"category_scores_gemma":[0.0022653635,0.00013977448,0.00038115197,0.00043918204,0.00034800055,0.0003093771,0.00002272896,0.0012483066,0.0000037374662],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7239008,0.005375352,0.00047868106,0.00003481782,0.00051025295,0.00033666223,0.00027492805,0.000011658873,0.0000660846,0.000009488628,0.000050601604,0.2689507],"study_design_scores_gemma":[0.82889205,0.15989126,0.007335715,0.0006227647,0.0004610395,0.000025559075,0.00014919351,0.0008847591,0.000025282756,0.000048838614,0.0015245941,0.0001389527],"about_ca_topic_score_codex":0.000038429294,"about_ca_topic_score_gemma":0.00013953961,"teacher_disagreement_score":0.26881173,"about_ca_system_score_codex":0.0007181987,"about_ca_system_score_gemma":0.0021822408,"threshold_uncertainty_score":0.5699838},"labels":[],"label_agreement":null},{"id":"W4399481444","doi":"10.1136/annrheumdis-2024-eular.5963","title":"OP0334 OUTCOMES IN PATIENTS WITH PRE-EXISTING AUTOIMMUNE DISEASE ON IMMUNE CHECKPOINT INHIBITOR THERAPY FOR TREATMENT OF CANCER","year":2024,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Canada","funders":"","keywords":"Medicine; Cancer; Disease; Immune checkpoint; Immune system; Immunotherapy; Autoimmune disease; Immunology; Oncology; Internal medicine","score_opus":0.04090105439869998,"score_gpt":0.3494708122231483,"score_spread":0.3085697578244483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399481444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973836,0.021684984,0.000002841667,0.0022082243,0.00021547149,0.0016187318,0.00037961156,0.000027688646,0.00002645499],"genre_scores_gemma":[0.99690396,0.0020976143,0.00002370169,0.00013227672,0.000017965285,0.0003288139,0.00003638633,0.000032062493,0.0004272359],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998728,0.000039237653,0.0005320113,0.00020100645,0.00030398765,0.00019576063],"domain_scores_gemma":[0.999021,0.0001984109,0.00020565197,0.00041679427,0.00009165724,0.000066496636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098816396,0.00020877249,0.00051670446,0.00010752025,0.000043986136,0.000016156191,0.00011360703,0.0000234139,0.00005918565],"category_scores_gemma":[0.00008482334,0.00010502997,0.00043571918,0.00020200333,0.00012153568,0.000060658604,0.000016686774,0.000029696033,6.767083e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036245305,0.0066853235,0.5219693,0.0026083202,0.0028984984,0.0000043180185,0.0013905889,0.00014303945,0.00044227464,0.00010902556,0.00028018042,0.4272238],"study_design_scores_gemma":[0.005267614,0.0016928659,0.982223,0.0055296607,0.00017881804,1.2850188e-7,0.00004930532,0.0002464223,0.004192399,0.00013812113,0.0003605268,0.0001211675],"about_ca_topic_score_codex":0.00043542866,"about_ca_topic_score_gemma":0.000011595379,"teacher_disagreement_score":0.46025363,"about_ca_system_score_codex":0.00007764817,"about_ca_system_score_gemma":0.00024931235,"threshold_uncertainty_score":0.42829978},"labels":[],"label_agreement":null},{"id":"W4399491057","doi":"10.1186/s13058-024-01848-z","title":"Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer","year":2024,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Center for Advancing Translational Sciences; National Institute of General Medical Sciences; National Cancer Institute","keywords":"Surgical oncology; Medicine; Breast cancer; Immunophenotyping; Oncology; Peripheral blood; Chemotherapy; Internal medicine; Neoadjuvant therapy; Cancer; Immunology; Flow cytometry","score_opus":0.02805176045585458,"score_gpt":0.3806595941316745,"score_spread":0.35260783367581994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399491057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9321848,0.03274362,0.0000056908025,0.03295994,0.00025231618,0.001284839,0.00029420378,0.000086820335,0.0001877373],"genre_scores_gemma":[0.9783263,0.011488247,0.00010857161,0.0007084446,0.0004697434,0.0011746942,0.0000078535195,0.00009648767,0.007619662],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99711305,0.00026050542,0.0003562076,0.00076788384,0.0006135928,0.00088874775],"domain_scores_gemma":[0.9989099,0.00013446988,0.000022684379,0.00045097136,0.00019275064,0.0002892582],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012160443,0.0003069766,0.0004350643,0.0005351535,0.00020026075,0.00024066768,0.00018473601,0.00013509097,0.002255542],"category_scores_gemma":[0.000012544016,0.00023847572,0.00011148848,0.0012443237,0.00020448561,0.00018126944,0.000092462644,0.00045603403,0.000019780593],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06946821,0.00040189544,0.01797868,0.0002649455,0.0005890994,0.00028709235,0.0054886597,0.000041914478,0.370429,0.000018019873,0.0010547675,0.5339777],"study_design_scores_gemma":[0.011311775,0.0013033553,0.919059,0.0041515776,0.00008611924,0.001539358,0.0009139884,0.0008384835,0.0095658135,0.000022706705,0.05066253,0.00054529187],"about_ca_topic_score_codex":0.04064451,"about_ca_topic_score_gemma":0.001974264,"teacher_disagreement_score":0.9010803,"about_ca_system_score_codex":0.00217015,"about_ca_system_score_gemma":0.0018034531,"threshold_uncertainty_score":0.9986565},"labels":[],"label_agreement":null},{"id":"W4399518019","doi":"10.1101/2024.06.10.24308518","title":"Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events","year":2024,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Institutes of Health; Vanderbilt Institute for Clinical and Translational Research; Memorial Sloan-Kettering Cancer Center; Vanderbilt University; Princess Margaret Cancer Foundation; Larry L. Hillblom Foundation","keywords":"Medicine; Discontinuation; Adverse effect; Internal medicine; Disease; Lung cancer; Oncology; Immune checkpoint; Proportional hazards model; Logistic regression; Cancer; Immunotherapy","score_opus":0.01805258202191015,"score_gpt":0.2810370835805886,"score_spread":0.2629845015586785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399518019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833744,0.0071326294,0.0003335016,0.0012816271,0.004567293,0.0023495194,0.0004657388,0.00016376526,0.0003315345],"genre_scores_gemma":[0.9929266,0.00066911784,0.0004202056,0.000023998542,0.00044985788,0.00034797387,0.0013116419,0.00008776459,0.0037628182],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99706846,0.00005878277,0.0016805863,0.0005434326,0.00038847647,0.00026026176],"domain_scores_gemma":[0.99829566,0.000051455496,0.0006872921,0.0006620888,0.00023506541,0.000068459165],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001132318,0.0003568204,0.0007395431,0.00030599826,0.000048932525,0.000008694829,0.00016264968,0.0004767544,0.00017378891],"category_scores_gemma":[0.00015567722,0.0003032792,0.0010877528,0.00024898304,0.000105489344,0.000050776962,0.00025250774,0.00061270763,0.000019697201],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060773063,0.00079159567,0.011774981,0.0046781315,0.0028842455,0.00001685706,0.0016699781,0.000075542106,0.9588075,0.00007047743,0.00046521044,0.012688126],"study_design_scores_gemma":[0.014681766,0.001765843,0.52396935,0.014862676,0.0028942346,0.000056023826,0.0003792733,0.0077289487,0.42380175,0.0031947377,0.005846885,0.0008184982],"about_ca_topic_score_codex":0.00013141985,"about_ca_topic_score_gemma":0.000008651255,"teacher_disagreement_score":0.5350058,"about_ca_system_score_codex":0.00025040348,"about_ca_system_score_gemma":0.00029529197,"threshold_uncertainty_score":0.99994195},"labels":[],"label_agreement":null},{"id":"W4399519585","doi":"10.1200/jco.2024.42.16_suppl.tps8116","title":"The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non–small-cell lung cancer (NSCLC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Pembrolizumab; Medicine; Placebo; Oncology; Lung cancer; Stage (stratigraphy); Internal medicine; non-small cell lung cancer (NSCLC); Cancer; Immunotherapy; Pathology","score_opus":0.13317905615974068,"score_gpt":0.4799944488978683,"score_spread":0.3468153927381276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399519585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9567841,0.023906395,0.0032788345,0.004548409,0.0056215106,0.0048800255,0.00006737678,0.000083568055,0.00082973833],"genre_scores_gemma":[0.96695054,0.020939633,0.0009838324,0.0020180906,0.0030733831,0.00041264968,0.000009857427,0.00015786465,0.0054541538],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9913767,0.0018063792,0.0042708633,0.00070564175,0.0009380312,0.0009023573],"domain_scores_gemma":[0.987822,0.008136028,0.0020817837,0.00059918896,0.00080646144,0.00055451825],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009519619,0.00057878654,0.0026036121,0.00040252178,0.00039516453,0.00024232123,0.00097448274,0.00075107184,0.0006395228],"category_scores_gemma":[0.0012684561,0.00035283118,0.0016238443,0.0005652435,0.00049182225,0.00023791204,0.00015530441,0.0023839972,0.000019022304],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7199179,0.0040016305,0.002915206,0.00025744893,0.0078118225,0.0020519865,0.006979298,0.00007316454,0.0032398698,0.000017197704,0.043219376,0.20951514],"study_design_scores_gemma":[0.43343723,0.122795545,0.020518292,0.0012747247,0.0033287979,0.0006085139,0.0027372374,0.013424057,0.00194049,0.00010934426,0.39893755,0.0008882009],"about_ca_topic_score_codex":0.00035574194,"about_ca_topic_score_gemma":0.00040113463,"teacher_disagreement_score":0.35571817,"about_ca_system_score_codex":0.0012913459,"about_ca_system_score_gemma":0.010460326,"threshold_uncertainty_score":0.99991757},"labels":[],"label_agreement":null},{"id":"W4399553361","doi":"10.1080/14796694.2024.2342224","title":"Real-world comparative effectiveness and safety of pembrolizumab for PD-L1≥50% metastatic non-small-cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Health Sciences Centre; Canada Research Chairs; University of Toronto; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Oncology; Internal medicine; PD-L1; Immunotherapy; Cancer; Intensive care medicine","score_opus":0.0218372023544261,"score_gpt":0.36493949076044885,"score_spread":0.34310228840602275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399553361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91923946,0.048107445,0.0024281952,0.0031423834,0.003471662,0.005224495,0.00034967615,0.00009882925,0.01793787],"genre_scores_gemma":[0.99113053,0.003967036,0.0017152838,0.00034520592,0.00069006736,0.0005875306,0.000058120477,0.000039294224,0.0014669205],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988893,0.00015519888,0.0003139161,0.0003189863,0.000093663526,0.00022888098],"domain_scores_gemma":[0.9987994,0.00077979866,0.0001037025,0.00015341306,0.00009239887,0.000071288545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043624258,0.00018783873,0.0007256477,0.00015533816,0.00006104935,0.00000967919,0.000064160486,0.000108600994,0.00017689914],"category_scores_gemma":[0.0000063485572,0.00014217816,0.00015549787,0.00025686613,0.0001351557,0.000040684874,0.000025161795,0.00018378515,0.0000017358428],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25138935,0.001675205,0.011660294,0.055850763,0.010315273,0.00035612166,0.019450556,0.00009822539,0.39733627,0.0055043343,0.061199825,0.18516378],"study_design_scores_gemma":[0.048907325,0.008198408,0.26187968,0.006189446,0.0047058524,0.00024507035,0.0027139876,0.0042459564,0.06471058,0.0002655146,0.5970162,0.00092197635],"about_ca_topic_score_codex":0.00042221494,"about_ca_topic_score_gemma":0.0015326062,"teacher_disagreement_score":0.5358164,"about_ca_system_score_codex":0.00037431795,"about_ca_system_score_gemma":0.00070190284,"threshold_uncertainty_score":0.5797857},"labels":[],"label_agreement":null},{"id":"W4399577197","doi":"10.2139/ssrn.4857103","title":"A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Cancer","year":2024,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Partnership Against Cancer; Princess Margaret Cancer Centre; Western University; University of Toronto; Ottawa Hospital; University Health Network; CancerCare Manitoba; University of British Columbia Hospital; Juravinski Hospital; Hôpital Notre-Dame; University of Ottawa; University of British Columbia; Hospital for Sick Children","funders":"","keywords":"Durvalumab; Tremelimumab; Phase (matter); Medicine; Cancer; Oncology; Internal medicine; Chemistry; Immunotherapy; Nivolumab","score_opus":0.008403775660196117,"score_gpt":0.29399981144013504,"score_spread":0.2855960357799389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399577197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9678675,0.030368911,0.0000065228787,0.0002898116,0.00024897736,0.001114829,0.000027273807,0.000017326956,0.00005887728],"genre_scores_gemma":[0.9902234,0.009155169,0.000015738942,0.00003648991,0.00009753555,0.00006142273,0.000015423075,0.00005178107,0.00034305023],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975662,0.00007051047,0.0005355788,0.00039946276,0.0004626363,0.00096558605],"domain_scores_gemma":[0.9991875,0.000013712244,0.0003117834,0.00026475367,0.00015274655,0.00006944734],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005571961,0.00030532375,0.00063391175,0.00034472608,0.0000735745,0.000022408025,0.00013580592,0.00013133312,0.000038816517],"category_scores_gemma":[0.000012861851,0.00022094583,0.00010960673,0.00025171743,0.000058088845,0.00004722559,0.00016757724,0.0030621248,3.7577328e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.076754525,0.011703034,0.05249676,0.000652885,0.0054060286,0.00007155285,0.0068180994,0.00008718128,0.00061938417,0.00008981546,0.00006445886,0.8452363],"study_design_scores_gemma":[0.510912,0.26209587,0.15851428,0.013684327,0.0046841367,0.00052829436,0.028010972,0.00027398492,0.00058829976,0.017374022,0.0011101577,0.0022236821],"about_ca_topic_score_codex":0.0005603085,"about_ca_topic_score_gemma":0.005213488,"teacher_disagreement_score":0.8430126,"about_ca_system_score_codex":0.0016294292,"about_ca_system_score_gemma":0.0039408384,"threshold_uncertainty_score":0.99923784},"labels":[],"label_agreement":null},{"id":"W4399627762","doi":"10.1200/jco.2024.42.16_suppl.12031","title":"Molecular predictors and mechanisms of immune checkpoint inhibitor-induced myocarditis: A case-control study with translational correlates.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Christie (Canada); McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Myocarditis; Immune system; Immune checkpoint; Translational research; Internal medicine; Cancer research; Immunology; Oncology; Immunotherapy; Pathology","score_opus":0.03469830852134992,"score_gpt":0.3690755164760821,"score_spread":0.3343772079547322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399627762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99002606,0.0028409672,0.0033537722,0.0020398214,0.0010927059,0.0004599464,0.00001279056,0.000012477822,0.00016143973],"genre_scores_gemma":[0.9987519,0.00014396317,0.00049166224,0.00026695133,0.00030362402,0.0000062122317,8.9647494e-7,0.000020123312,0.000014664146],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968867,0.00031143267,0.002104764,0.00018050623,0.00037991974,0.00013671088],"domain_scores_gemma":[0.99788624,0.00093420653,0.00066766137,0.0001204537,0.00022908027,0.00016236871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032779877,0.0001380694,0.0011309859,0.0001474231,0.000025766047,0.000010957966,0.000059254064,0.00025878867,0.000077415716],"category_scores_gemma":[0.00022581797,0.000088595756,0.0004784359,0.00016471837,0.00015807373,0.000086480744,0.000009197574,0.00074550667,8.2742264e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13598406,0.00797135,0.06011771,0.000500317,0.033221398,0.11849134,0.0039076777,0.0001313515,0.15161093,0.00081586634,0.00036158046,0.4868864],"study_design_scores_gemma":[0.087775946,0.19971518,0.6336209,0.0016049986,0.0077297706,0.05423491,0.0031413333,0.0018131146,0.007050742,0.0014072831,0.0014916604,0.00041416488],"about_ca_topic_score_codex":0.000027939983,"about_ca_topic_score_gemma":0.000018649967,"teacher_disagreement_score":0.5735032,"about_ca_system_score_codex":0.00005881399,"about_ca_system_score_gemma":0.0010217868,"threshold_uncertainty_score":0.361283},"labels":[],"label_agreement":null},{"id":"W4399662556","doi":"10.1200/jco.2024.42.16_suppl.2645","title":"Comprehensive whole genome and transcriptome analysis of patients with advanced solid tumor treated with immune checkpoint inhibitor therapy in the pan-cancer cohorts from the Marathon of Hope Cancer Centres Network Study (MOHCCN).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Cancer; Transcriptome; Immune checkpoint; Genome; Solid tumor; Oncology; Cancer therapy; Internal medicine; Immunotherapy; Gene; Genetics; Biology; Gene expression","score_opus":0.038149946340332565,"score_gpt":0.3825682155830793,"score_spread":0.3444182692427467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399662556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9697767,0.027091999,0.000006832101,0.0018482415,0.0002795548,0.000877109,0.000101086946,0.000004243766,0.000014245099],"genre_scores_gemma":[0.9901245,0.008663393,0.00007298239,0.0007938681,0.00026382186,0.00003164135,0.000015595986,0.000019368057,0.000014809914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965164,0.00065736845,0.0019068685,0.00024860087,0.0004595429,0.0002112068],"domain_scores_gemma":[0.9967602,0.0012890955,0.0012273486,0.0002491612,0.00040495457,0.00006927468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011760263,0.0002061835,0.0018740036,0.0001330394,0.00004092556,0.000015592886,0.0001856573,0.00010491528,0.00010518607],"category_scores_gemma":[0.000036317684,0.00008616425,0.0003769357,0.00079717033,0.00041294994,0.00008634346,0.000018182602,0.00058048,1.5490855e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07894097,0.0023578438,0.8427448,0.00003427077,0.011857842,0.00015829227,0.0038225285,0.0006210748,0.007088363,3.911618e-7,0.000099267556,0.052274354],"study_design_scores_gemma":[0.014331669,0.016515225,0.9588532,0.0004158716,0.0028878134,0.0000057280913,0.001688126,0.00007833261,0.00015596938,0.000004161091,0.0049660685,0.000097824755],"about_ca_topic_score_codex":0.000979661,"about_ca_topic_score_gemma":0.0018269185,"teacher_disagreement_score":0.11610841,"about_ca_system_score_codex":0.00010208503,"about_ca_system_score_gemma":0.00052063074,"threshold_uncertainty_score":0.3513676},"labels":[],"label_agreement":null},{"id":"W4399763539","doi":"10.1200/jco.2024.42.16_suppl.2649","title":"Development of a novel risk stratification model for immune-related adverse events for patients with advanced melanoma and non-small cell lung cancer treated with immune checkpoint inhibitors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Melanoma; Lung cancer; Immune system; Adverse effect; Risk stratification; Oncology; Ipilimumab; Nivolumab; Immune checkpoint; Cancer research; Programmed cell death 1; Internal medicine; Immunotherapy; Immunology; PD-L1","score_opus":0.034133324472548104,"score_gpt":0.36361954555162995,"score_spread":0.3294862210790819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399763539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98344547,0.0010899054,0.013518898,0.00023443412,0.00030326858,0.0013212316,0.000047900125,0.000008392028,0.000030509016],"genre_scores_gemma":[0.94278586,0.00051227474,0.0563128,0.00003375674,0.00006106209,0.00008853559,0.000029794159,0.000030671257,0.00014524946],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969257,0.000038909326,0.0024232129,0.00023184974,0.00019611041,0.00018418318],"domain_scores_gemma":[0.99681467,0.00041561745,0.0019541613,0.00012399036,0.00057436916,0.000117176416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012926923,0.0001793554,0.000909324,0.00012000716,0.000056991263,0.000004270122,0.000079177655,0.00024051,0.000007702543],"category_scores_gemma":[0.000115938434,0.0001104511,0.00029657574,0.00014330972,0.00010026326,0.000109655106,0.000014376059,0.00033014742,1.3378374e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2815483,0.01073516,0.154804,0.0021343036,0.008639318,0.000022154942,0.004512499,0.0024730081,0.094908305,0.00001979465,0.00013886644,0.44006428],"study_design_scores_gemma":[0.15725711,0.04230765,0.6516148,0.0043037166,0.0039790943,0.00003735023,0.00061763846,0.10553511,0.03165843,0.00003883325,0.0020861086,0.00056416047],"about_ca_topic_score_codex":0.000021880795,"about_ca_topic_score_gemma":0.000069128386,"teacher_disagreement_score":0.4968108,"about_ca_system_score_codex":0.00024372042,"about_ca_system_score_gemma":0.0022044799,"threshold_uncertainty_score":0.45040652},"labels":[],"label_agreement":null},{"id":"W4399781621","doi":"10.3390/curroncol31060258","title":"A Review of Immunotherapy in Non-Small-Cell Lung Cancer","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University; St Mary's Hospital Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Immunotherapy; Lung cancer; Cancer immunotherapy; Intensive care medicine; Cancer; Radiological weapon; Adverse effect; Oncology; Internal medicine; Surgery","score_opus":0.1253930419812161,"score_gpt":0.4812198287059368,"score_spread":0.35582678672472073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399781621","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001079315,0.9922939,0.0000051573325,0.00021355803,0.0032045557,0.0028394696,0.00007702495,0.000026356984,0.0013291609],"genre_scores_gemma":[5.873267e-7,0.9974303,0.000035858062,0.00044060193,0.00034864742,0.0010941545,0.00012971493,0.00007990987,0.00044017422],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973578,0.00020322361,0.0014252383,0.0004978418,0.00016348551,0.0003524205],"domain_scores_gemma":[0.9986433,0.000116930954,0.00058188394,0.00049687276,0.00009035373,0.00007070631],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00064019044,0.00047734263,0.0034701524,0.00041762265,0.000014955426,0.000005888952,0.000280919,0.00039711208,0.00073662563],"category_scores_gemma":[0.000019667552,0.00033607567,0.0011383124,0.0008700502,0.0001076841,0.000019100937,0.00007447317,0.0009428681,0.00003975068],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062607214,0.00023118437,0.000018035269,0.39597943,0.00025890584,0.000019438487,0.000055329772,4.5936672e-9,0.0000041860626,0.0000018539945,0.02263639,0.58073264],"study_design_scores_gemma":[0.00086310203,0.00016947635,0.000005291601,0.4035433,0.0017816828,0.00003915772,0.000003996606,0.0000021091337,0.000001284458,0.0000012188472,0.59342664,0.0001627195],"about_ca_topic_score_codex":0.000090056266,"about_ca_topic_score_gemma":0.000040118142,"teacher_disagreement_score":0.5805699,"about_ca_system_score_codex":0.0012117622,"about_ca_system_score_gemma":0.0027298727,"threshold_uncertainty_score":0.9999091},"labels":[],"label_agreement":null},{"id":"W4399781695","doi":"10.3390/curroncol31060260","title":"Outcome of an Accelerated Treatment Algorithm for Patients Developing Diarrhea as a Complication of Ipilimumab-Based Cancer Immunotherapy in a Community Practice","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health","keywords":"Ipilimumab; Medicine; Diarrhea; Internal medicine; Infliximab; Complication; Gastroenterology; Combination therapy; Adverse effect; Cancer; Immunotherapy; Tumor necrosis factor alpha","score_opus":0.18448064705461514,"score_gpt":0.4984345271680976,"score_spread":0.31395388011348246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399781695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99051625,0.0039168512,0.0022400764,0.00089503516,0.00069472747,0.0015085868,0.00011772088,0.000050187704,0.000060574697],"genre_scores_gemma":[0.9926203,0.0012807365,0.0047498774,0.00027925754,0.000044580614,0.0006232982,0.00035962873,0.0000330199,0.000009308201],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99865675,0.0002805467,0.0005972412,0.00017863128,0.00011949817,0.0001673123],"domain_scores_gemma":[0.99860215,0.0005858569,0.0002208991,0.00024327307,0.00031057379,0.000037251728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004242784,0.0001472012,0.0004457823,0.00019988243,0.000042736447,0.000007651744,0.00010152031,0.00009998249,0.000027641303],"category_scores_gemma":[0.0000688828,0.000121745325,0.000107552936,0.00034268998,0.00009800735,0.000098016404,0.000012226671,0.0001755729,8.301188e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041453834,0.0038506594,0.016227856,0.0003783122,0.00021447845,0.0000015840131,0.0015947204,0.0000050180943,0.0027370113,0.00003922764,0.000035949313,0.9707698],"study_design_scores_gemma":[0.071861185,0.033619985,0.34317425,0.0027926837,0.0006919093,0.000027662021,0.0015373359,0.033008426,0.043207206,0.00026941783,0.46903163,0.0007783129],"about_ca_topic_score_codex":0.0019767736,"about_ca_topic_score_gemma":0.00033504388,"teacher_disagreement_score":0.9699915,"about_ca_system_score_codex":0.0011792931,"about_ca_system_score_gemma":0.00079129625,"threshold_uncertainty_score":0.49646303},"labels":[],"label_agreement":null},{"id":"W4399787571","doi":"10.1093/neuonc/noae064.023","title":"BIOM-03. IMMUNO-ONCOLOGIC PROFILING OF PEDIATRIC BRAIN TUMORS REVEALS MAJOR CLINICAL SIGNIFICANCE OF THE TUMOR IMMUNE MICROENVIRONMENT","year":2024,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Hospital for Sick Children","funders":"","keywords":"Profiling (computer programming); Tumor microenvironment; Immune system; Medicine; Cancer research; Biology; Immunology; Computer science","score_opus":0.028606927554040353,"score_gpt":0.32830821660162207,"score_spread":0.2997012890475817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399787571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796292,0.00941409,0.000023387784,0.006347197,0.0021339483,0.0016008015,0.000059327478,0.00006262399,0.0007293899],"genre_scores_gemma":[0.9944815,0.0014583142,0.0007816337,0.0023282275,0.0005066421,0.00010792264,0.0000113052465,0.00005324377,0.000271215],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962021,0.0007076585,0.001736564,0.00058396603,0.0003423915,0.00042733358],"domain_scores_gemma":[0.99681073,0.0016367051,0.00068540714,0.00070773286,0.000068240675,0.00009116316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017674587,0.00028157333,0.00097634934,0.00018511341,0.00007842531,0.000010412349,0.00044102306,0.00024493758,0.00025474536],"category_scores_gemma":[0.00054586824,0.00019172014,0.0006388608,0.00073175726,0.0007794521,0.000051543495,0.00020555506,0.0006900248,0.000037316317],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020628637,0.00054277276,0.019899063,0.00046282844,0.00017936174,0.00018596713,0.00017117789,0.0000032108057,0.96430767,0.00005865613,0.003694793,0.00843163],"study_design_scores_gemma":[0.0073797433,0.010252654,0.18523805,0.00040072133,0.00095738715,0.0007891101,0.00055870006,0.00012680386,0.70001215,0.00020460639,0.09359927,0.00048081175],"about_ca_topic_score_codex":0.00006215302,"about_ca_topic_score_gemma":0.00000503629,"teacher_disagreement_score":0.26429555,"about_ca_system_score_codex":0.0003324116,"about_ca_system_score_gemma":0.0009952559,"threshold_uncertainty_score":0.781812},"labels":[],"label_agreement":null},{"id":"W4399879795","doi":"10.1200/jco.2024.42.16_suppl.3587","title":"Artemin and immune checkpoint inhibitor (ICI) efficacy in metastatic colorectal cancer (mCRC): A correlative analysis of the Canadian Cancer Trials Group (CCTG) CO.26 trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital du Sacré-Cœur de Montréal; Juravinski Cancer Centre; Cancer Care Nova Scotia; Jewish General Hospital; Hôpital Charles-Le Moyne; St. John’s Health Sciences Centre; Hôtel-Dieu de Québec; Genome British Columbia; Saskatchewan Cancer Agency; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; Queen's University; Moncton Hospital","funders":"","keywords":"Medicine; Colorectal cancer; Oncology; Internal medicine; Cancer; Immune checkpoint; Cancer research; Immunotherapy","score_opus":0.16106508784645318,"score_gpt":0.49620621256832026,"score_spread":0.3351411247218671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399879795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716436,0.014724953,0.0000088956,0.00887418,0.0034707687,0.00087916024,0.00007622452,0.000006241889,0.00031592834],"genre_scores_gemma":[0.99466616,0.0037128099,0.00009662746,0.00062629476,0.00063962064,0.00004028155,0.000003664398,0.000022156786,0.0001923879],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9927663,0.0016272134,0.00464981,0.00025835732,0.00041714628,0.00028112758],"domain_scores_gemma":[0.99072737,0.0063404744,0.002253425,0.00016404505,0.00022130187,0.0002933588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01305837,0.00019822593,0.0032877955,0.0006655123,0.00005910823,0.000023358676,0.0001693219,0.00034809153,0.00064014463],"category_scores_gemma":[0.004607397,0.00011328346,0.0016145234,0.0012861332,0.00064102304,0.000087754495,0.00002932318,0.0011796785,0.0000018595375],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47904038,0.003947308,0.05607304,0.00030521696,0.05659293,0.0010904623,0.0052747917,0.00028380973,0.024721382,0.00019583676,0.007001662,0.36547318],"study_design_scores_gemma":[0.12649058,0.012278321,0.79884756,0.0016188116,0.017631777,0.000110374975,0.0008505875,0.0018190318,0.002147936,0.00013672764,0.03777535,0.00029295],"about_ca_topic_score_codex":0.045020897,"about_ca_topic_score_gemma":0.3526789,"teacher_disagreement_score":0.7427745,"about_ca_system_score_codex":0.0010301259,"about_ca_system_score_gemma":0.007290591,"threshold_uncertainty_score":0.99833715},"labels":[],"label_agreement":null},{"id":"W4399881301","doi":"10.1002/cncr.35387","title":"Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study","year":2024,"lang":"en","type":"article","venue":"Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Eisai","keywords":"Triple-negative breast cancer; Medicine; Pembrolizumab; Breast cancer; Oncology; Internal medicine; Lenvatinib; Cohort; Cancer; Triple negative; Immunotherapy","score_opus":0.015201761805717761,"score_gpt":0.3078492838161655,"score_spread":0.29264752201044775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399881301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9399721,0.007331841,0.000022094202,0.00391991,0.0015327933,0.010430845,0.036428813,0.00011788428,0.00024369993],"genre_scores_gemma":[0.98815256,0.002987071,0.000036846646,0.0007069127,0.00074132514,0.0045707813,0.00018522928,0.00013515797,0.0024840983],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9962007,0.0002144056,0.0009750854,0.0010827046,0.0008641033,0.0006630085],"domain_scores_gemma":[0.99694777,0.0005856476,0.0006339502,0.0009351178,0.0007312494,0.00016624935],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036224793,0.00065161305,0.0010110023,0.000108324995,0.00036840697,0.000080429265,0.0005029308,0.00015848076,0.0005775983],"category_scores_gemma":[0.00009999231,0.000341109,0.00039566724,0.0011593645,0.00056528725,0.00030284474,0.00008406688,0.0004978841,0.0000028279192],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34829953,0.0025287564,0.20168266,0.00050830096,0.010768071,0.000026958951,0.024742903,0.00033160252,0.0011304162,0.00001986058,0.028120369,0.38184056],"study_design_scores_gemma":[0.14954124,0.0027898063,0.82258797,0.005051195,0.003605634,0.000026350097,0.0036121823,0.0007176599,0.0033864717,0.00004854348,0.0077557503,0.0008771958],"about_ca_topic_score_codex":0.03128068,"about_ca_topic_score_gemma":0.01280964,"teacher_disagreement_score":0.6209053,"about_ca_system_score_codex":0.0017488291,"about_ca_system_score_gemma":0.0020671664,"threshold_uncertainty_score":0.9999041},"labels":[],"label_agreement":null},{"id":"W4399881422","doi":"10.1200/jco.2024.42.16_suppl.4040","title":"Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Gastroesophageal Junction; Internal medicine; Cancer; Esophageal cancer; Gastric adenocarcinoma; Esophageal adenocarcinoma; Chemotherapy; Adenocarcinoma; Gastroenterology; Oncology; Immunotherapy","score_opus":0.06582602180490636,"score_gpt":0.4236906571408252,"score_spread":0.35786463533591883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399881422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95854896,0.020550257,0.00066797575,0.01127726,0.007354833,0.0011464811,0.00009910532,0.0000643746,0.000290775],"genre_scores_gemma":[0.96026075,0.026803946,0.002905475,0.00154819,0.0041670976,0.00014083882,0.000029464927,0.00011199583,0.004032223],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99466413,0.00017111964,0.0032782827,0.00061621884,0.0006188973,0.00065137853],"domain_scores_gemma":[0.9955438,0.0009924691,0.0019514449,0.00039565194,0.00065577275,0.0004608602],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016686738,0.00050123694,0.0026413754,0.00035508044,0.00011560074,0.000029791225,0.00031417806,0.0006479074,0.00095695304],"category_scores_gemma":[0.00039277435,0.00037818408,0.0019278674,0.00057079195,0.00034390925,0.00024473658,0.000040360883,0.00082726375,0.000013689665],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17714034,0.0023623726,0.027256409,0.0005872036,0.004624123,0.0005450647,0.0005062303,0.0001460816,0.008687113,0.000041671286,0.010150689,0.7679527],"study_design_scores_gemma":[0.25429985,0.18191986,0.20829001,0.0028659555,0.0061573316,0.0019099566,0.0006019492,0.0028767404,0.050839104,0.00057157234,0.28864062,0.001027069],"about_ca_topic_score_codex":0.0005716289,"about_ca_topic_score_gemma":0.00040714783,"teacher_disagreement_score":0.76692563,"about_ca_system_score_codex":0.001979813,"about_ca_system_score_gemma":0.0041899253,"threshold_uncertainty_score":0.9999563},"labels":[],"label_agreement":null},{"id":"W4399985868","doi":"10.1016/j.jconrel.2024.06.041","title":"Resiquimod-loaded cationic liposomes cure mice with peritoneal carcinomatosis and induce specific anti-tumor immunity","year":2024,"lang":"en","type":"article","venue":"Journal of Controlled Release","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; National Organization for Rare Disorders; Canadian Cancer Society; NanoMedicines Innovation Network","keywords":"Peritoneal cavity; Immune system; Medicine; Cancer research; CD8; Immunogenic cell death; Immunology; Cationic liposome; Immunotherapy; Biology; Cell culture; Transfection; Surgery","score_opus":0.010595158605645378,"score_gpt":0.2496937554307744,"score_spread":0.23909859682512902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399985868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9231897,0.06961438,0.000041268704,0.0060864342,0.00032603482,0.0003950751,0.0000069037064,0.000024969755,0.00031526285],"genre_scores_gemma":[0.99457526,0.003984062,0.00017386932,0.0003240046,0.00046938617,0.000009703624,0.0000028225593,0.000030281912,0.00043060735],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985348,0.00013310873,0.0005871932,0.00016944695,0.00036860802,0.00020681732],"domain_scores_gemma":[0.99886256,0.00019289396,0.00028183585,0.00020593705,0.00026745268,0.00018931166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004791506,0.00019810036,0.0007114656,0.00030387644,0.00012475903,0.0001259395,0.00010621275,0.0000849823,0.00009214476],"category_scores_gemma":[0.000054020806,0.00012508241,0.0002563574,0.00030915454,0.00014473616,0.00020855272,0.000014809835,0.0005836021,0.000004398054],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10692515,0.0006775627,0.0077394308,0.0007663155,0.003990239,0.0032979778,0.0027626536,0.000014709005,0.8473681,0.0002370046,0.0096267415,0.016594062],"study_design_scores_gemma":[0.26559913,0.014353534,0.3603465,0.011144404,0.0069274018,0.045838375,0.0085387975,0.002035499,0.14143758,0.00030895066,0.14145733,0.0020124966],"about_ca_topic_score_codex":0.000071915005,"about_ca_topic_score_gemma":0.000008329466,"teacher_disagreement_score":0.7059306,"about_ca_system_score_codex":0.00014281506,"about_ca_system_score_gemma":0.0006970381,"threshold_uncertainty_score":0.5100713},"labels":[],"label_agreement":null},{"id":"W4400036601","doi":"10.1200/jco.2024.42.16_suppl.8578","title":"Association of RNA-sequencing signatures with clinical outcomes of pembrolizumab + chemotherapy in patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) enrolled in the phase 2 KEYNOTE-782 trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Lung cancer; Internal medicine; Chemotherapy; Clinical trial; Cancer; Immunotherapy","score_opus":0.05323586654378033,"score_gpt":0.43941106518965284,"score_spread":0.3861751986458725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400036601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933747,0.0012076641,0.000100903875,0.0030903297,0.0007629933,0.0011868356,0.000012603614,0.000004754106,0.00025923338],"genre_scores_gemma":[0.9959388,0.0009909396,0.0008668415,0.0017919642,0.00024280432,0.000022578533,0.000003383416,0.000026515698,0.0001162146],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99399716,0.001058504,0.003747232,0.0002396081,0.0006978837,0.00025961807],"domain_scores_gemma":[0.9898271,0.00651439,0.0029519428,0.00021213439,0.00039704965,0.000097361604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008050024,0.00021088061,0.002284052,0.00029292284,0.000019000447,0.000012599205,0.0002431109,0.0003575348,0.000087262786],"category_scores_gemma":[0.0011661485,0.000105727166,0.00064120116,0.0004817129,0.00018145393,0.00010268773,0.000014571473,0.0014259559,3.943746e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48819724,0.006632529,0.46330458,0.00020329742,0.0023860333,0.00023434142,0.0010675716,0.00011027059,0.00023538138,0.0000036408612,0.000788021,0.036837105],"study_design_scores_gemma":[0.41872606,0.037742436,0.53963864,0.00071649166,0.0013278059,0.000009091203,0.0003108144,0.00040549765,0.00017805847,0.00002178094,0.0007769763,0.00014634395],"about_ca_topic_score_codex":0.00021151324,"about_ca_topic_score_gemma":0.0005644103,"teacher_disagreement_score":0.076334074,"about_ca_system_score_codex":0.0005233297,"about_ca_system_score_gemma":0.0037455158,"threshold_uncertainty_score":0.6644384},"labels":[],"label_agreement":null},{"id":"W4400151493","doi":"10.1016/j.annonc.2024.05.333","title":"419P Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4-year (y) follow-up (FU) of CheckMate 649","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Cancer; Gastroesophageal Junction; Internal medicine; Oncology; Chemotherapy; Esophageal adenocarcinoma; Esophageal cancer; Adenocarcinoma; Immunotherapy","score_opus":0.08238964688085516,"score_gpt":0.40254935799563096,"score_spread":0.3201597111147758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400151493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94980675,0.033589166,0.00046978664,0.006357937,0.0015819676,0.0015311594,0.00603702,0.00014692415,0.0004792968],"genre_scores_gemma":[0.9707504,0.018507859,0.0021551664,0.0013004724,0.0013188377,0.0009074639,0.001988408,0.000111307636,0.0029600952],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99694073,0.000077739314,0.0010381797,0.00081825873,0.0004680145,0.0006570649],"domain_scores_gemma":[0.9978482,0.00041532156,0.00056640717,0.00045626692,0.00050046947,0.00021332114],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024611314,0.00053442025,0.0013957852,0.0004242621,0.00013250846,0.000021870757,0.0002347882,0.0003712366,0.006953865],"category_scores_gemma":[0.00006880804,0.0004713435,0.0009152661,0.00071657076,0.0003125489,0.00020271278,0.000039168932,0.00023893233,0.00001845451],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.098995246,0.002453728,0.005552453,0.0010506588,0.009147392,0.00028220148,0.001310716,0.0002825994,0.13166793,0.00008925751,0.098761894,0.65040594],"study_design_scores_gemma":[0.05313973,0.034959566,0.060676165,0.0015151048,0.00230899,0.00017271488,0.000459689,0.0026378173,0.66441596,0.0005727919,0.17828932,0.00085217255],"about_ca_topic_score_codex":0.0048623695,"about_ca_topic_score_gemma":0.0013405507,"teacher_disagreement_score":0.6495538,"about_ca_system_score_codex":0.0008883171,"about_ca_system_score_gemma":0.0015388564,"threshold_uncertainty_score":0.9997738},"labels":[],"label_agreement":null},{"id":"W4400192714","doi":"10.1136/gutjnl-2024-bsg.147","title":"P65 Two-year efficacy and safety of mirikizumab following 104 weeks of continuous treatment: interim results from the LUCENT-3 open-label extension study","year":2024,"lang":"en","type":"article","venue":"Poster presentations","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; St. Thomas Hospital","funders":"","keywords":"Interim; Extension (predicate logic); Open label; Interim analysis; Medicine; Computer science; Clinical trial; Programming language; Internal medicine; Political science","score_opus":0.06323462172925366,"score_gpt":0.38097449143337175,"score_spread":0.3177398697041181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400192714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991901,0.0019773648,0.000025764924,0.001893895,0.00032248127,0.0016834097,0.0002782796,0.000024151497,0.0018936701],"genre_scores_gemma":[0.998581,0.00012852755,0.00018116945,0.00008083343,0.00004953073,0.000029925583,0.0001292467,0.000018587873,0.0008011862],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988564,0.00012495095,0.0004530698,0.00027830136,0.00017290344,0.00011437393],"domain_scores_gemma":[0.99889815,0.00052809215,0.00009072182,0.0003853353,0.000057779176,0.000039943883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019621814,0.00012543621,0.00028814297,0.000062177445,0.00007970965,0.00006386588,0.00012745913,0.000030734293,0.00004265922],"category_scores_gemma":[0.000062918385,0.000079981575,0.00007888384,0.00018215274,0.00008137324,0.00012108444,0.000111164336,0.00007334692,0.000004364542],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1457856,0.0110174995,0.048149228,0.00019525793,0.012324515,0.0003612664,0.17929757,0.000007839853,0.34225553,0.00027167905,0.009348084,0.25098595],"study_design_scores_gemma":[0.11850028,0.0065862807,0.8197428,0.0017687522,0.0024293147,0.000044336946,0.024384715,0.0002763194,0.020637225,0.00009204966,0.005204951,0.00033299864],"about_ca_topic_score_codex":0.0042298906,"about_ca_topic_score_gemma":0.0002948947,"teacher_disagreement_score":0.7715936,"about_ca_system_score_codex":0.00003723273,"about_ca_system_score_gemma":0.00006622604,"threshold_uncertainty_score":0.6394357},"labels":[],"label_agreement":null},{"id":"W4400246525","doi":"10.1186/s40001-024-01901-9","title":"Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer","year":2024,"lang":"en","type":"review","venue":"European journal of medical research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Alberta Cancer Foundation","keywords":"CTLA-4; Medicine; Cytotoxic T cell; Immunotherapy; Immunology; Breast cancer; Cancer immunotherapy; Antigen; Immune system; Cancer; Monoclonal antibody; Antibody; Tumor microenvironment; Cancer research; Oncology; T cell; Internal medicine; Biology; In vitro","score_opus":0.13396649630770588,"score_gpt":0.47501211322706655,"score_spread":0.34104561691936064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400246525","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018336704,0.9928174,0.00000634227,0.0041439156,0.00084359467,0.00039067183,0.00002688807,0.000014910712,0.0015729159],"genre_scores_gemma":[0.00025196376,0.99549997,0.00003391004,0.00018949367,0.003097652,0.000008304428,0.000009931267,0.00014827795,0.0007605054],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98967725,0.0029615667,0.0018877891,0.00039870996,0.0043178666,0.0007568399],"domain_scores_gemma":[0.9977687,0.0004501499,0.00037352636,0.00031027838,0.00034979096,0.0007475268],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.025155354,0.00035070573,0.0017269126,0.0014000097,0.0000765193,0.00011274859,0.0010625457,0.00024291642,0.0028056696],"category_scores_gemma":[0.0010417346,0.00021238478,0.0007816543,0.001609814,0.00039921157,0.0000699943,0.00034892955,0.0044631977,0.00035134808],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004498292,0.000102777696,0.000015211998,0.009638048,0.0005073932,0.019331325,0.00009167912,9.860614e-8,0.000042252217,0.0000041810463,0.036469802,0.9333474],"study_design_scores_gemma":[0.0014312551,0.00023794382,0.00007197628,0.13136052,0.00019426699,0.004421096,0.000048019083,0.000013512002,0.000002267392,0.000003092882,0.8620588,0.00015721674],"about_ca_topic_score_codex":0.000111956586,"about_ca_topic_score_gemma":0.000004769761,"teacher_disagreement_score":0.93319017,"about_ca_system_score_codex":0.0012445931,"about_ca_system_score_gemma":0.007164445,"threshold_uncertainty_score":0.998464},"labels":[],"label_agreement":null},{"id":"W4400272135","doi":"10.1200/jco.2024.42.16_suppl.9554","title":"Pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): Long-term results of the phase 2 KEYNOTE-629 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Basal cell; Dermatology; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.09897449490993147,"score_gpt":0.47161280875271777,"score_spread":0.3726383138427863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98691195,0.0038009163,0.00043106618,0.0025093388,0.004094318,0.0013932367,0.000075232696,0.000018486671,0.0007654301],"genre_scores_gemma":[0.9958477,0.0005513544,0.0008267345,0.00057398085,0.0007012115,0.000020116935,0.0000060180314,0.0000452573,0.0014276183],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.993977,0.00082168856,0.003894761,0.0003797949,0.0005722383,0.00035450718],"domain_scores_gemma":[0.9889197,0.007932099,0.0019234414,0.00045090544,0.0005106832,0.0002632113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033501673,0.0002724593,0.0016870296,0.00018060373,0.00006958832,0.000024596462,0.00043436445,0.0002808972,0.000112177106],"category_scores_gemma":[0.003519552,0.00014889475,0.0012297736,0.00036377137,0.00039964207,0.0000980867,0.000074086194,0.0011133587,0.000004639889],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39895722,0.008847238,0.0021014411,0.00061827333,0.0006114543,0.003982794,0.0005695745,0.000016239184,0.0022173428,0.0000063065895,0.0046792296,0.5773929],"study_design_scores_gemma":[0.3617483,0.41206524,0.08030622,0.0017275218,0.005732208,0.0110171735,0.0012107763,0.0012947593,0.003820036,0.00018432608,0.1202486,0.00064483733],"about_ca_topic_score_codex":0.000015452633,"about_ca_topic_score_gemma":0.00012953597,"teacher_disagreement_score":0.5767481,"about_ca_system_score_codex":0.00027483495,"about_ca_system_score_gemma":0.0042104702,"threshold_uncertainty_score":0.74691933},"labels":[],"label_agreement":null},{"id":"W4400272169","doi":"10.1200/jco.2024.42.16_suppl.9559","title":"Lenvatinib (len) plus pembrolizumab (pembro) in patients with advanced melanoma that progressed on anti–PD-(L)1 therapy: Over 4 years of follow-up from the phase 2 LEAP-004 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Lenvatinib; Oncology; Melanoma; Internal medicine; Phases of clinical research; Clinical trial; Dermatology; Immunotherapy; Cancer; Cancer research","score_opus":0.07907522718799255,"score_gpt":0.43508881363543866,"score_spread":0.35601358644744613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933909,0.0022292612,0.0000067574692,0.0014956379,0.0017002083,0.00090675335,0.00002375105,0.000013758434,0.00023298412],"genre_scores_gemma":[0.9973052,0.00085194735,0.00014821003,0.0011778129,0.0003663172,0.000013406485,0.00000965523,0.000036192145,0.0000912595],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99645245,0.00055436156,0.0017411166,0.00029987947,0.0007050779,0.00024709318],"domain_scores_gemma":[0.99586695,0.0023794256,0.0011198968,0.00033774128,0.00017679362,0.000119216944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018556566,0.00021007204,0.0013877007,0.00014921607,0.000030395116,0.00002002971,0.00028025097,0.00024654926,0.00025329093],"category_scores_gemma":[0.0004188306,0.00011432851,0.00044973055,0.0003135584,0.0002589745,0.00015629015,0.000034560322,0.0009906224,0.000004863298],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21427904,0.005722803,0.26525503,0.000019968571,0.0014273426,0.00042565516,0.0011193962,0.000007845361,0.00019492596,0.0000072796965,0.000976633,0.5105641],"study_design_scores_gemma":[0.12626988,0.05698656,0.79265785,0.0005195203,0.00020629767,0.000011219342,0.00036065603,0.000027555065,0.00011738296,0.000029291514,0.022700882,0.00011290057],"about_ca_topic_score_codex":0.0000903538,"about_ca_topic_score_gemma":0.00012831237,"teacher_disagreement_score":0.5274028,"about_ca_system_score_codex":0.0002044947,"about_ca_system_score_gemma":0.0013574614,"threshold_uncertainty_score":0.46621814},"labels":[],"label_agreement":null},{"id":"W4400272471","doi":"10.1200/jco.2024.42.16_suppl.e20618","title":"Sex influence on cancer immunotherapy efficacy and safety in advanced non-small cell lung cancer (NSCLC): A Canadian institution real-world experience.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Oncology; Lung cancer; Internal medicine; Immunotherapy; Cancer immunotherapy; non-small cell lung cancer (NSCLC); Cancer","score_opus":0.04161408321969619,"score_gpt":0.43972808171603295,"score_spread":0.3981139984963368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793346,0.009015558,0.000018878987,0.0059582237,0.002277374,0.00044766042,0.000009677457,0.000017951412,0.0029200655],"genre_scores_gemma":[0.9444608,0.049517483,0.00023909482,0.004574294,0.00055346574,0.00003563411,0.0000011805862,0.000028592298,0.00058946444],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971986,0.00017118864,0.0017250997,0.00031578646,0.00023504678,0.00035427487],"domain_scores_gemma":[0.99804157,0.0007781632,0.0004810051,0.00018205782,0.0001413706,0.00037585694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014987454,0.0001996778,0.00096821494,0.00043758043,0.00006187836,0.000025592177,0.00016096,0.000297853,0.0001656429],"category_scores_gemma":[0.00017020818,0.00014967124,0.00022681971,0.00047566925,0.000264912,0.00017760533,0.000017808143,0.0010859991,0.0000021300161],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025980853,0.0005172152,0.23881282,0.00016017974,0.00039716336,0.0011218786,0.002981046,0.000696096,0.008071099,0.00006552195,0.0011489815,0.7200472],"study_design_scores_gemma":[0.013154397,0.0030230286,0.78609157,0.0021198548,0.00010234998,0.000055702803,0.00019881997,0.00040508082,0.00062251923,0.000014693361,0.1940079,0.0002040716],"about_ca_topic_score_codex":0.059345204,"about_ca_topic_score_gemma":0.15175606,"teacher_disagreement_score":0.7198431,"about_ca_system_score_codex":0.001630083,"about_ca_system_score_gemma":0.0075698975,"threshold_uncertainty_score":0.99805623},"labels":[],"label_agreement":null},{"id":"W4400408753","doi":"10.1200/jco.2024.42.16_suppl.e21518","title":"Long term outcomes of patients with advanced/unresectable melanoma treated with immune checkpoint inhibitors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC","funders":"","keywords":"Medicine; Oncology; Ipilimumab; Pembrolizumab; Melanoma; Internal medicine; Nivolumab; PD-L1; Immune checkpoint; Immunotherapy; Cancer; Cancer research","score_opus":0.0408201708393422,"score_gpt":0.3967738527287622,"score_spread":0.35595368188942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400408753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99433595,0.0021659324,0.000041654737,0.0014234663,0.00065680314,0.0002538372,0.0000066358352,0.0000149321,0.0011008014],"genre_scores_gemma":[0.9976324,0.00045902556,0.0009262813,0.00022659615,0.00022757635,0.000003938576,0.000006959658,0.000027057184,0.00049016887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969757,0.00012687466,0.0021042384,0.00018013114,0.00040528283,0.00020776017],"domain_scores_gemma":[0.99739367,0.0007127565,0.00114148,0.00019358785,0.00039554338,0.00016296674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011635592,0.00016857691,0.0014478011,0.00016460559,0.000024062818,0.000010778881,0.000117604526,0.00021534231,0.0002414261],"category_scores_gemma":[0.00028992654,0.000084706924,0.00046313953,0.0002593449,0.00028571076,0.00016423118,0.00002536883,0.00062102015,0.000003899701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037817296,0.0012779234,0.80752695,0.00010098572,0.0016923812,0.00048681523,0.0000660974,0.0000021496437,0.00074965204,0.0000040128616,0.000203178,0.15007254],"study_design_scores_gemma":[0.016186763,0.034927852,0.9398645,0.0007102557,0.00046828267,0.00012819827,0.000050148632,0.000005320352,0.0022113337,0.0000073236897,0.0053387336,0.00010130047],"about_ca_topic_score_codex":0.00003489851,"about_ca_topic_score_gemma":0.00004523433,"teacher_disagreement_score":0.14997125,"about_ca_system_score_codex":0.00014050824,"about_ca_system_score_gemma":0.0009998316,"threshold_uncertainty_score":0.34542483},"labels":[],"label_agreement":null},{"id":"W4400644133","doi":"10.3390/antib13030056","title":"Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data","year":2024,"lang":"en","type":"article","venue":"Antibodies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Atezolizumab; Adverse effect; Medicine; Immune system; Adverse Event Reporting System; Pharmacovigilance; Immunology; Nivolumab; Internal medicine; Oncology; Immunotherapy","score_opus":0.030119052346939075,"score_gpt":0.32354702952838066,"score_spread":0.2934279771814416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400644133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97421294,0.015059018,0.0000094168445,0.00068670197,0.0006268493,0.00032692408,0.0003423173,0.0004157472,0.008320055],"genre_scores_gemma":[0.98145926,0.00626197,0.00007116177,0.00026251646,0.000113703594,0.000007166704,0.0026481668,0.000047704547,0.009128354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850047,0.000055915138,0.0003780484,0.000493528,0.00030805258,0.00026396356],"domain_scores_gemma":[0.9990325,0.000126013,0.000102805694,0.00061515864,0.000058006295,0.000065506414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001313711,0.00024086701,0.00037663587,0.00015936514,0.00011666272,0.000022877337,0.00025154304,0.00008150837,0.00027753005],"category_scores_gemma":[0.000025829122,0.00017139268,0.000105355415,0.0005461443,0.0001398899,0.0002747753,0.00010670727,0.00025895098,0.00014927541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012439767,0.0011259704,0.4944446,0.00083742745,0.030876547,0.0050389105,0.006677955,0.000026000045,0.30521187,0.0010932304,0.10954458,0.032683153],"study_design_scores_gemma":[0.008089609,0.00030125177,0.88623387,0.006661173,0.0013957937,0.00003472933,0.0002930554,0.003150458,0.015610165,0.0005377109,0.07689549,0.00079669413],"about_ca_topic_score_codex":0.0014287696,"about_ca_topic_score_gemma":0.0005006879,"teacher_disagreement_score":0.3917893,"about_ca_system_score_codex":0.00013158636,"about_ca_system_score_gemma":0.00017586653,"threshold_uncertainty_score":0.69891906},"labels":[],"label_agreement":null},{"id":"W4400647185","doi":"10.21203/rs.3.rs-4497628/v1","title":"Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistance","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Organoid; Colorectal cancer; Cancer; Immunotherapy; Immunity; Medicine; Cancer research; Cancer immunotherapy; Immunology; Oncology; Biology; Immune system; Internal medicine; Genetics","score_opus":0.038330515142430174,"score_gpt":0.3585101392720304,"score_spread":0.3201796241296002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400647185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91677785,0.06747723,0.000006024089,0.002378996,0.0012487121,0.0048311036,0.0020482088,0.00037990944,0.004851987],"genre_scores_gemma":[0.93985146,0.04313845,0.00010467332,0.00017831686,0.00054815126,0.0026282906,0.0015752008,0.0004058184,0.011569663],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99241996,0.0005989423,0.0009513009,0.0014803767,0.0028784606,0.001670943],"domain_scores_gemma":[0.99519897,0.0005557201,0.00041573882,0.0012713575,0.0021700016,0.00038821396],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019517535,0.0009315789,0.0013320294,0.0009265651,0.0006856361,0.00043522852,0.00087105104,0.0010045618,0.0037541834],"category_scores_gemma":[0.00018296264,0.00076240103,0.00042868382,0.0020907915,0.0010368616,0.00013786733,0.000793861,0.0050188005,0.00007295848],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17245147,0.0057457625,0.058129527,0.015552196,0.022317583,0.0013723772,0.017839385,0.00009223016,0.34740195,0.00022953669,0.21351136,0.14535663],"study_design_scores_gemma":[0.02287865,0.0063303737,0.5536181,0.050753325,0.0005432052,0.000018965768,0.003496094,0.000095372765,0.13319612,0.0011190092,0.2244411,0.0035097168],"about_ca_topic_score_codex":0.005638701,"about_ca_topic_score_gemma":0.0068843234,"teacher_disagreement_score":0.49548855,"about_ca_system_score_codex":0.006568846,"about_ca_system_score_gemma":0.0040690047,"threshold_uncertainty_score":0.9994827},"labels":[],"label_agreement":null},{"id":"W4400653397","doi":"10.3390/cells13141193","title":"Peptide Blockers of PD-1-PD-L1 Interaction Reinvigorate PD-1-Suppressed T Cells and Curb Tumor Growth in Mice","year":2024,"lang":"en","type":"article","venue":"Cells","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Cancer immunotherapy; PD-L1; Immunotherapy; Cancer research; Immune system; T cell; Immune checkpoint; Cancer cell; Monoclonal antibody; Peptide; Antibody; Cancer; Medicine; Immunology; Biology; Internal medicine; Biochemistry","score_opus":0.010585498052542084,"score_gpt":0.2553061714960941,"score_spread":0.244720673443552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400653397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99245685,0.0026153543,0.000024415012,0.0009778631,0.000929189,0.00038991173,0.00003140833,0.000053742708,0.0025212734],"genre_scores_gemma":[0.9952209,0.0010064199,0.00031505374,0.00043023523,0.00012321351,0.00001475581,0.00001612348,0.000034958677,0.002838331],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99880034,0.00005470685,0.00039253262,0.00034512283,0.00017525503,0.000232074],"domain_scores_gemma":[0.9994515,0.00013508231,0.000094241295,0.00018275957,0.00005373558,0.00008267064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024263092,0.00018568782,0.0003080786,0.000231617,0.000025695414,0.00003926646,0.00008264785,0.00008228172,0.00028539807],"category_scores_gemma":[0.000015499383,0.00016392581,0.00010759737,0.00035462817,0.00012017376,0.00014297015,0.00003416209,0.00025986304,0.00005017265],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015334375,0.000086310014,0.00041796672,0.0007741624,0.00010296918,0.00013790803,0.0009638623,0.000005171735,0.9752906,0.000013044097,0.01939149,0.0012830626],"study_design_scores_gemma":[0.0015616483,0.00026400338,0.001636412,0.0009973585,0.000095423726,0.000040516243,0.0005556315,0.0008949772,0.96118575,0.000060372135,0.03252443,0.00018347528],"about_ca_topic_score_codex":0.0005624052,"about_ca_topic_score_gemma":0.000040759718,"teacher_disagreement_score":0.014104865,"about_ca_system_score_codex":0.00010693177,"about_ca_system_score_gemma":0.00009408385,"threshold_uncertainty_score":0.66847},"labels":[],"label_agreement":null},{"id":"W4400677411","doi":"10.1038/s41698-024-00630-w","title":"Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy","year":2024,"lang":"en","type":"article","venue":"npj Precision Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Agence Nationale de la Recherche; National Cancer Institute; Royal College of Physicians and Surgeons of Canada; Damon Runyon Cancer Research Foundation; Parker Institute for Cancer Immunotherapy; Canadian Institutes of Health Research; Cancer Research Society; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Chemotherapy; Immunotherapy; Lung cancer; Antibiotics; Oncology; Cancer; Internal medicine; Intensive care medicine","score_opus":0.01202962443715131,"score_gpt":0.31800853617788605,"score_spread":0.3059789117407347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400677411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993771,0.002967798,0.00002726969,0.0016822775,0.00018579136,0.00081940455,0.000032084627,0.000096834694,0.00041750446],"genre_scores_gemma":[0.9943557,0.0028144543,0.00019119462,0.0011321311,0.00003026234,0.000019634035,0.000031663472,0.00005833802,0.0013666342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998598,0.000093743576,0.00033851495,0.00040939657,0.00026363836,0.00029674222],"domain_scores_gemma":[0.99919546,0.0002823461,0.00013412366,0.00020068321,0.00011630918,0.00007109434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002422077,0.00025395805,0.0006002954,0.00025772207,0.000053501397,0.00003789041,0.00007575213,0.00025243047,0.00026988378],"category_scores_gemma":[0.000029807681,0.0001530768,0.00006212498,0.00055284525,0.00015001306,0.00009514629,0.000015887543,0.00027684876,0.0000022494098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008137588,0.0006095174,0.89393276,0.000040690356,0.00065464573,0.00011219029,0.00064463663,0.0000035133487,0.0013864519,0.0000031163866,0.0007182063,0.09375665],"study_design_scores_gemma":[0.013751719,0.0027317924,0.97336763,0.0012455692,0.00009525862,0.000018586352,0.00008810995,0.00040141348,0.0010634279,0.000006961555,0.0070073255,0.00022222436],"about_ca_topic_score_codex":0.00025112738,"about_ca_topic_score_gemma":0.0010126549,"teacher_disagreement_score":0.09353443,"about_ca_system_score_codex":0.00061807776,"about_ca_system_score_gemma":0.00023933951,"threshold_uncertainty_score":0.62422913},"labels":[],"label_agreement":null},{"id":"W4400724181","doi":"10.3390/antib13030059","title":"Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database","year":2024,"lang":"en","type":"article","venue":"Antibodies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Adverse effect; CTLA-4; PD-L1; Immune system; Database; Medicine; Immunology; Computer science; Pharmacology; Immunotherapy; T cell","score_opus":0.014978496399803282,"score_gpt":0.2970432694413767,"score_spread":0.2820647730415734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400724181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946833,0.0037750036,0.000015212215,0.00036026334,0.0003881706,0.00028738193,0.00019630072,0.00003211618,0.00026225124],"genre_scores_gemma":[0.9967879,0.002023115,0.00012633273,0.00008674987,0.00006671172,0.000006226474,0.00014389749,0.000020373465,0.0007387093],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99845207,0.00007933801,0.000579405,0.0003178247,0.0003673812,0.00020397051],"domain_scores_gemma":[0.9989812,0.00005867771,0.00019098264,0.0006165231,0.00009014466,0.00006250145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046575943,0.00020169248,0.0005148149,0.0003254963,0.00007485858,0.0000035323394,0.00015015832,0.000078654135,0.00020634217],"category_scores_gemma":[0.000056667992,0.00013481747,0.0004764081,0.000812724,0.00025387495,0.00022685941,0.00013922647,0.0001407646,0.000005623265],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022315835,0.0005646042,0.30915353,0.0012916222,0.0076049464,0.000044758075,0.00403701,0.00003149054,0.66890323,0.00007502849,0.00038216604,0.005680038],"study_design_scores_gemma":[0.0019694474,0.00031497917,0.8296615,0.0018594499,0.0037043213,0.00001990482,0.002639652,0.0010428018,0.15613958,0.00004577947,0.0023443955,0.0002581934],"about_ca_topic_score_codex":0.0014787302,"about_ca_topic_score_gemma":0.0002450619,"teacher_disagreement_score":0.52050793,"about_ca_system_score_codex":0.000049849852,"about_ca_system_score_gemma":0.00010391436,"threshold_uncertainty_score":0.5497697},"labels":[],"label_agreement":null},{"id":"W4400763069","doi":"10.1038/s41698-024-00641-7","title":"Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab","year":2024,"lang":"en","type":"article","venue":"npj Precision Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Biomarker; Oncology; Immune system; Internal medicine; Immunotherapy; CD8; Immunology; Biology","score_opus":0.028346497684524297,"score_gpt":0.32552860822423163,"score_spread":0.29718211053970733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400763069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838928,0.007877267,0.000077555604,0.003289951,0.0004956314,0.0009967919,0.00009341883,0.00012644536,0.0031501683],"genre_scores_gemma":[0.99440575,0.0017317494,0.00058524526,0.00028040094,0.000094199575,0.000078058045,0.00012159572,0.00004209141,0.0026609362],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985169,0.00017119435,0.0003656511,0.00042259673,0.00026643672,0.00025720336],"domain_scores_gemma":[0.9982011,0.0011714615,0.0001312465,0.0003042959,0.00009545326,0.000096449585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000625792,0.00023782007,0.00059913757,0.00029340803,0.00006548567,0.000018526518,0.000077484336,0.00024103731,0.00066643313],"category_scores_gemma":[0.00017081443,0.00015200047,0.000106655396,0.00040385503,0.00022518313,0.00003746662,0.000036719328,0.00015264848,0.000018806211],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026273353,0.0008484573,0.00027647827,0.000085608146,0.0017611117,0.00028115013,0.00095668074,0.0000055780265,0.06395921,0.000040967632,0.006017077,0.89949435],"study_design_scores_gemma":[0.08465634,0.12290061,0.11885972,0.006847992,0.0020575228,0.0007560412,0.0011759797,0.007979397,0.15372895,0.00009301924,0.49976394,0.0011805008],"about_ca_topic_score_codex":0.00023250643,"about_ca_topic_score_gemma":0.00024530178,"teacher_disagreement_score":0.8983138,"about_ca_system_score_codex":0.0009123667,"about_ca_system_score_gemma":0.0004977563,"threshold_uncertainty_score":0.7296975},"labels":[],"label_agreement":null},{"id":"W4400775784","doi":"10.1016/j.ccell.2024.06.015","title":"Tumor-infiltrating lymphocytes: A new hope","year":2024,"lang":"en","type":"review","venue":"Cancer Cell","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Dr. Alfred E. Deacon Medical Research Foundation; Aimmune Therapeutics; Aeglea BioTherapeutics; Moffitt Cancer Center; Swim Across America; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Donald D. Hammill Foundation","keywords":"Tumor-infiltrating lymphocytes; Cancer research; Biology; Immunology; Immunotherapy; Immune system","score_opus":0.05665786257990523,"score_gpt":0.3648065729113019,"score_spread":0.3081487103313967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400775784","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000002684757,0.9761086,0.0000060436996,0.000070333364,0.0016597381,0.0008559149,0.00007102507,0.00015492593,0.02107074],"genre_scores_gemma":[0.0000019864303,0.9596279,0.00013948792,0.0007723726,0.0020204836,0.00018374903,0.000070297414,0.0001511342,0.03703254],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981,0.00003615786,0.0006290001,0.00058816327,0.00025603647,0.000390661],"domain_scores_gemma":[0.9989423,0.000050581533,0.0002450493,0.00051052135,0.000034634486,0.0002169035],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012970972,0.0005428984,0.0015603806,0.00011322031,0.00004978042,0.00007973625,0.00021186615,0.00023793553,0.0024907524],"category_scores_gemma":[0.000009915368,0.00038464155,0.0009666831,0.0004896469,0.00005640389,0.00005470347,0.0000547199,0.00039486107,0.00043707705],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050998504,0.000017317721,8.036746e-7,0.038454615,0.00034829514,0.00011761638,0.00008916935,5.757703e-8,0.000016973127,0.000004223489,0.089396395,0.87150353],"study_design_scores_gemma":[0.00071665365,0.000103465805,4.6313573e-7,0.046910662,0.0031277451,0.00018152218,0.00003484741,0.0000032127198,0.00005374051,0.000004323977,0.94848204,0.00038135666],"about_ca_topic_score_codex":0.0015001683,"about_ca_topic_score_gemma":0.00009033917,"teacher_disagreement_score":0.8711222,"about_ca_system_score_codex":0.0016085737,"about_ca_system_score_gemma":0.005478894,"threshold_uncertainty_score":0.9998605},"labels":[],"label_agreement":null},{"id":"W4400874984","doi":"10.1200/jco.23.01488","title":"Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non–Small-Cell Lung Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Royal College of Physicians and Surgeons of Canada; Damon Runyon Cancer Research Foundation; LUNGevity Foundation; Parker Institute for Cancer Immunotherapy; Canadian Institutes of Health Research; Cancer Research Society; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Chemoimmunotherapy; Hazard ratio; Oncology; Internal medicine; Escherichia coli; Cohort; Lung cancer; H&E stain; Cancer; Cancer research; Immunotherapy; Immunohistochemistry; Biology; Confidence interval","score_opus":0.035084792224519386,"score_gpt":0.36301542237589723,"score_spread":0.32793063015137786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400874984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99250954,0.00080068817,0.00019271506,0.0040576095,0.001498763,0.0005810516,0.000011140649,0.000016257021,0.00033221018],"genre_scores_gemma":[0.99604094,0.0001991946,0.0013071715,0.0018576772,0.00029682775,0.000018835737,0.0000103675475,0.000038719863,0.00023027784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969721,0.00020021228,0.0018666468,0.00028159647,0.00035856222,0.0003209122],"domain_scores_gemma":[0.99789244,0.00034989163,0.0009196668,0.00014634678,0.0004480713,0.00024361117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017585497,0.00021213524,0.0011762984,0.00016666761,0.000028465854,0.000026642065,0.000083539024,0.0002705838,0.00012575062],"category_scores_gemma":[0.00028784265,0.00013522209,0.00027532212,0.00053134956,0.0001002946,0.00013791231,0.000033055177,0.0010502758,0.0000025304282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20171638,0.012092439,0.42503205,0.00040934602,0.0035155346,0.0021221284,0.002148719,0.0001688526,0.1292449,0.0000037476225,0.0017081549,0.22183776],"study_design_scores_gemma":[0.036744256,0.048603512,0.9005551,0.0023347905,0.0005888914,0.000026387412,0.00020769566,0.00048647434,0.0070615243,0.0000068848685,0.0030787284,0.00030581106],"about_ca_topic_score_codex":0.000107248205,"about_ca_topic_score_gemma":0.00052541855,"teacher_disagreement_score":0.475523,"about_ca_system_score_codex":0.00094148243,"about_ca_system_score_gemma":0.0018597668,"threshold_uncertainty_score":0.5514197},"labels":[],"label_agreement":null},{"id":"W4400892363","doi":"10.1136/jitc-2024-009427","title":"Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee","year":2024,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Kite Pharma; Moderna; EMD Serono; Ribon Therapeutics; Regeneron Pharmaceuticals; Gilead Sciences; Genentech; Society for Immunotherapy of Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Biomarker; Medicine; Immunotherapy; PD-L1; Biomarker discovery; Immune system; Oncology; Bioinformatics; Immunology; Biology","score_opus":0.08405559566590562,"score_gpt":0.3973262209989202,"score_spread":0.31327062533301453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400892363","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014602001,0.9863213,0.00031991565,0.003517127,0.0035780661,0.004532285,0.0014453373,0.00005272135,0.00008726333],"genre_scores_gemma":[0.000014705293,0.9908858,0.0029287983,0.0012655244,0.001101071,0.0015032351,0.00028727832,0.0002677524,0.0017458467],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954621,0.0001888421,0.0024988041,0.000593996,0.0006253444,0.00063091953],"domain_scores_gemma":[0.9959581,0.00112351,0.0015850622,0.0006629691,0.0005205758,0.0001498059],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016110681,0.00091919996,0.002806382,0.0003753217,0.00050628674,0.00018351561,0.00048050773,0.0005542822,0.0006912531],"category_scores_gemma":[0.00005101976,0.00053272385,0.0032507663,0.00063320954,0.00039607167,0.00006953733,0.000053234253,0.00068790663,0.000013756005],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004012865,0.000112662114,0.000005150357,0.007843366,0.016203936,0.00001609522,0.00032213578,9.017722e-8,0.0003372576,0.000016707523,0.1337627,0.83736706],"study_design_scores_gemma":[0.00494217,0.00040754277,0.00004351959,0.04903783,0.0042921226,0.00036768665,0.000119514785,0.000004463681,0.00021051298,0.00017642313,0.939813,0.0005851983],"about_ca_topic_score_codex":0.00017455402,"about_ca_topic_score_gemma":0.00010136272,"teacher_disagreement_score":0.83678186,"about_ca_system_score_codex":0.0010600421,"about_ca_system_score_gemma":0.0033058075,"threshold_uncertainty_score":0.9997124},"labels":[],"label_agreement":null},{"id":"W4400892533","doi":"10.1136/jitc-2024-009309","title":"Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors?","year":2024,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Adverse effect; Medicine; Osteoporosis; Immune system; Bone remodeling; Intensive care medicine; Bioinformatics; Internal medicine; Oncology; Immunology","score_opus":0.03742799908571104,"score_gpt":0.4110232161316989,"score_spread":0.37359521704598786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400892533","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011988195,0.99093604,0.000056398694,0.00017545141,0.0046185004,0.002563199,0.00034915443,0.000031863725,0.00007059639],"genre_scores_gemma":[0.00028901285,0.9953764,0.0005113684,0.00012544944,0.0012066661,0.0002885888,0.00011253399,0.0002692971,0.0018206534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99425685,0.00016737552,0.0038705114,0.00047538176,0.0007321436,0.00049771543],"domain_scores_gemma":[0.9950271,0.00015974496,0.0033840532,0.0007252317,0.0005247322,0.00017912559],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016946028,0.0008096019,0.004053831,0.00076453417,0.00012042217,0.000040971692,0.0004688576,0.00061355205,0.0013913146],"category_scores_gemma":[0.000066591776,0.0005414472,0.0056836796,0.0005711321,0.00023550665,0.00019279595,0.000037320533,0.0010645582,0.000006939257],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049929284,0.00034713186,0.0000030162291,0.026914634,0.0067740157,0.000017175264,0.0005630652,0.0000023532643,0.0038647444,0.0000042716133,0.0012248814,0.9552918],"study_design_scores_gemma":[0.0056039793,0.0021017164,0.00003341037,0.06794796,0.0048341937,0.00038503495,0.00016737956,0.0000050678686,0.0028397553,0.00011083332,0.9154757,0.0004949438],"about_ca_topic_score_codex":0.00023712506,"about_ca_topic_score_gemma":0.00002804205,"teacher_disagreement_score":0.95479685,"about_ca_system_score_codex":0.0007706435,"about_ca_system_score_gemma":0.0026454472,"threshold_uncertainty_score":0.9997037},"labels":[],"label_agreement":null},{"id":"W4400929921","doi":"10.1016/j.esmoop.2024.103646","title":"Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Incyte; Mirati Therapeutics; Jounce Therapeutics; Regeneron Pharmaceuticals; Daiichi-Sankyo; Amgen; Pfizer; EMD Serono; Mersana Therapeutics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Tremelimumab; Durvalumab; Head and neck squamous-cell carcinoma; Medicine; CTLA-4; Oncology; PD-L1; Immunotherapy; Cytotoxic T cell; Internal medicine; Cancer research; Head and neck cancer; T cell; Immunology; Cancer; Immune system; Ipilimumab; Nivolumab; Biology","score_opus":0.04684865456165723,"score_gpt":0.38269544008808287,"score_spread":0.33584678552642566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400929921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962186,0.00069210114,0.000009786093,0.00037295467,0.00012579544,0.0021225347,0.000028918093,0.000012898422,0.0004164134],"genre_scores_gemma":[0.99937254,0.00010840079,0.00016305874,0.00006342116,0.000015675725,0.000027257745,0.000011439498,0.000020300702,0.00021789115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866295,0.0002132935,0.00041521306,0.00038414262,0.00016094118,0.00016347996],"domain_scores_gemma":[0.9993391,0.00021761606,0.00008003396,0.00024579198,0.000030397645,0.00008704891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071463507,0.0001601919,0.00052820577,0.00009052154,0.000037631125,0.000051099014,0.00009468596,0.00003929311,0.000076654025],"category_scores_gemma":[0.000031293086,0.00011497583,0.00004889101,0.00021044129,0.00013055369,0.00014423007,0.00010765236,0.00023108147,0.0000017316762],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30096132,0.01510527,0.4936641,0.00078561937,0.0004087401,0.0006618766,0.004203075,4.2567063e-7,0.000510587,0.0000060824796,0.00025198536,0.18344095],"study_design_scores_gemma":[0.10358849,0.024729447,0.8675109,0.0003220751,0.0003354462,0.000028686469,0.00085435447,0.0013222944,0.00040276337,0.0000036852887,0.0007347643,0.00016709915],"about_ca_topic_score_codex":0.0030560782,"about_ca_topic_score_gemma":0.0032911103,"teacher_disagreement_score":0.37384683,"about_ca_system_score_codex":0.00006024133,"about_ca_system_score_gemma":0.00015037102,"threshold_uncertainty_score":0.46885782},"labels":[],"label_agreement":null},{"id":"W4400931289","doi":"10.1101/2024.07.22.24310819","title":"Spatially-resolved tumour infiltrating immune cells and prognosis in breast cancer","year":2024,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Sinai Health System; University of Calgary; Lunenfeld-Tanenbaum Research Institute","funders":"National Institute for Health and Care Research","keywords":"CD20; Immune system; Breast cancer; Medicine; Stromal cell; CD163; FOXP3; Internal medicine; Tissue microarray; CD8; Oncology; CD68; Cancer; Pathology; Immunohistochemistry; Immunology; Biology; Gene","score_opus":0.016968233867617904,"score_gpt":0.27722614302995535,"score_spread":0.26025790916233743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400931289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747139,0.0146128945,0.000005512033,0.007778713,0.0011474935,0.0008965687,0.0001385501,0.00010222927,0.0006041432],"genre_scores_gemma":[0.9948571,0.003426951,0.0002449522,0.00026334135,0.00039497027,0.00031304348,0.000027218084,0.00006888338,0.00040356518],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99810976,0.000065014516,0.0005975428,0.00061017356,0.0002842728,0.00033325213],"domain_scores_gemma":[0.9993155,0.000048376092,0.00016639763,0.00030427933,0.0000668396,0.00009862482],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045203796,0.0003583947,0.0006105403,0.00025509775,0.00003956882,0.000100641846,0.00014925037,0.000286187,0.0002895681],"category_scores_gemma":[0.000015836835,0.0003015824,0.00018418429,0.0002611908,0.000116329065,0.000031091695,0.00037753503,0.0009886804,0.0000114689055],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012625613,0.00019455377,0.29533806,0.0035691473,0.00058320136,0.0003635249,0.0021657555,0.000031382704,0.64817154,0.00001276083,0.0005533278,0.04775417],"study_design_scores_gemma":[0.0029621806,0.00017452799,0.8567647,0.0114345355,0.0004908395,0.00018415561,0.00032013535,0.0017999099,0.122775935,0.00026561762,0.001986899,0.000840566],"about_ca_topic_score_codex":0.004410209,"about_ca_topic_score_gemma":0.0008043905,"teacher_disagreement_score":0.56142664,"about_ca_system_score_codex":0.0001858418,"about_ca_system_score_gemma":0.00043904773,"threshold_uncertainty_score":0.9999436},"labels":[],"label_agreement":null},{"id":"W4401029773","doi":"10.1016/j.lungcan.2024.107900","title":"Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLC","year":2024,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Internal medicine; Neoadjuvant therapy; Chemotherapy; Cancer","score_opus":0.017030840922792504,"score_gpt":0.30625259375077823,"score_spread":0.28922175282798573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401029773","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.060766146,0.43961066,0.00041140107,0.4718026,0.010191202,0.010179677,0.001319503,0.00028750525,0.005431306],"genre_scores_gemma":[0.0417027,0.027260173,0.001863531,0.8606778,0.00948222,0.007963058,0.0014619491,0.0010644171,0.0485242],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974615,0.000060062208,0.00074120064,0.00064196024,0.00054168154,0.00055359537],"domain_scores_gemma":[0.99883354,0.00012612517,0.00028678248,0.00059548963,0.000110798246,0.0000472498],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020762434,0.00043764253,0.00086751865,0.00037841263,0.000044027027,0.000027316537,0.00020020909,0.0007090655,0.0008118925],"category_scores_gemma":[0.000012863174,0.00035056076,0.0004968507,0.00033791657,0.000101384205,0.00005814934,0.000041814106,0.0010413678,0.0000031131442],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005331671,0.00010082731,0.00012065108,0.003404315,0.00049279083,0.00011000458,0.0012586813,0.000010703679,0.07511333,0.0000012989468,0.8963619,0.01769383],"study_design_scores_gemma":[0.0043780874,0.00055985106,0.00028260265,0.008867143,0.00018539952,0.000016418766,0.00009729455,0.00015095352,0.04279099,0.00004240838,0.9422214,0.00040746032],"about_ca_topic_score_codex":0.0010265748,"about_ca_topic_score_gemma":0.00015094462,"teacher_disagreement_score":0.41235048,"about_ca_system_score_codex":0.0013093001,"about_ca_system_score_gemma":0.00074816536,"threshold_uncertainty_score":0.9998946},"labels":[],"label_agreement":null},{"id":"W4401029882","doi":"10.1016/j.lungcan.2024.107898","title":"Treatment patterns and outcomes in KRAS‐positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"William Osler Health System; London Health Sciences Centre; Brampton Civic Hospital; CancerCare Manitoba; Ottawa Hospital; University Health Network; Occupational Cancer Research Centre; Juravinski Cancer Centre; University of Ottawa; Jewish General Hospital; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; University of Calgary; Centre Hospitalier de l’Université de Montréal; Hamilton Health Sciences","funders":"Canadian Institutes of Health Research; Amgen Canada; Amgen","keywords":"Medicine; Oncology; Retrospective cohort study; Internal medicine; Cohort; KRAS; Center (category theory); Cancer","score_opus":0.005912470398139684,"score_gpt":0.28135253948923683,"score_spread":0.27544006909109714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401029882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925798,0.0020761422,0.000005281336,0.00041012253,0.0003319274,0.0040476583,0.00025584674,0.00007483136,0.00021835687],"genre_scores_gemma":[0.9954332,0.001472125,0.000022499646,0.0001209394,0.000045184937,0.0009999828,0.00010323261,0.00006148259,0.0017413138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980298,0.000068356756,0.00048141295,0.0006583812,0.00036900022,0.00039302488],"domain_scores_gemma":[0.9993056,0.000056971516,0.00011870676,0.00029429732,0.00010672956,0.00011771616],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000097041906,0.00039433036,0.0007091919,0.00017937463,0.000069509326,0.000042523396,0.000057377176,0.00005162208,0.000045789493],"category_scores_gemma":[0.0000118373455,0.0002681023,0.00009741121,0.0003927668,0.000054729306,0.00011891342,0.000029900615,0.00018626494,5.5917945e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026951951,0.0012508779,0.9853532,0.00010028522,0.0017313958,0.00027118248,0.0020951966,0.0000022877969,0.00014290922,5.3149563e-7,0.00006163556,0.00629533],"study_design_scores_gemma":[0.018392898,0.0015664328,0.97589505,0.0014687255,0.00040374897,0.0000052605137,0.00037356018,0.00010148577,0.0013063547,2.2381457e-7,0.00020174091,0.0002844928],"about_ca_topic_score_codex":0.8132924,"about_ca_topic_score_gemma":0.90820587,"teacher_disagreement_score":0.09491344,"about_ca_system_score_codex":0.0061438344,"about_ca_system_score_gemma":0.0004957684,"threshold_uncertainty_score":0.9999771},"labels":[],"label_agreement":null},{"id":"W4401036743","doi":"10.1111/bcp.16188","title":"Model‐based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer","year":2024,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Nivolumab; Medicine; Adjuvant; Gastroesophageal Junction; Regimen; Oncology; Internal medicine; Clinical trial; Population; Dosing; Cancer; Pharmacology; Immunotherapy; Adenocarcinoma","score_opus":0.07829050037331493,"score_gpt":0.45938455436871917,"score_spread":0.38109405399540425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401036743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98249865,0.015108104,0.00039016007,0.0008302982,0.00045872593,0.0006426848,0.000053561547,0.000013214691,0.000004617613],"genre_scores_gemma":[0.99167717,0.0066211903,0.0006857662,0.00042113187,0.00036319045,0.00002345338,0.00001475204,0.000024432482,0.00016891675],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99774855,0.000445395,0.0011332603,0.00027085966,0.00019895617,0.00020296103],"domain_scores_gemma":[0.9980369,0.0012260253,0.00034066587,0.00005700443,0.00017793075,0.00016143893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001113184,0.0001536949,0.0007639982,0.00024912678,0.000048339876,0.000020634394,0.000047340167,0.000121300465,0.00013080805],"category_scores_gemma":[0.00018077371,0.000117536365,0.0001762228,0.00025370234,0.0001809675,0.00010899912,0.000010254593,0.00030528306,1.1200021e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60265744,0.0008416699,0.012523795,0.00023531697,0.0010704012,0.0022606985,0.00011778083,0.0032577743,0.035680145,5.348614e-7,0.00060830463,0.34074613],"study_design_scores_gemma":[0.099970534,0.025278129,0.8035656,0.0013149357,0.0023708802,0.0026441053,0.000053434025,0.05683764,0.0071794544,0.00001799866,0.0005791423,0.00018810888],"about_ca_topic_score_codex":0.000378819,"about_ca_topic_score_gemma":0.00033190535,"teacher_disagreement_score":0.79104185,"about_ca_system_score_codex":0.00017274647,"about_ca_system_score_gemma":0.00082169194,"threshold_uncertainty_score":0.47929937},"labels":[],"label_agreement":null},{"id":"W4401188844","doi":"10.1002/path.6338","title":"Changes in the tumour microenvironment mark the transition from serous borderline tumour to low‐grade serous carcinoma","year":2024,"lang":"en","type":"article","venue":"The Journal of Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; University of British Columbia; BC Cancer Agency","funders":"BC Cancer Foundation; VGH and UBC Hospital Foundation; U.S. Department of Defense","keywords":"Serous fluid; Serous carcinoma; Medicine; Carcinoma; Pathology; Transition (genetics); Oncology; Internal medicine; Chemistry; Cancer","score_opus":0.014658593947080474,"score_gpt":0.2590219060938736,"score_spread":0.24436331214679313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401188844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86953324,0.00840494,0.00030986778,0.1209588,0.00041608594,0.000316292,0.000024894189,0.000007524511,0.000028374907],"genre_scores_gemma":[0.98895127,0.0014540928,0.000100318124,0.008702286,0.0006789942,0.0000107020205,0.000006104337,0.000021028043,0.0000752117],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99851227,0.000504343,0.00036044468,0.00013111345,0.0002534607,0.00023835486],"domain_scores_gemma":[0.99934757,0.00023686419,0.000107208,0.00024235423,0.000022585786,0.000043427848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014439654,0.0001550346,0.00026665174,0.000110552195,0.00008430612,0.00002411537,0.00030092837,0.00007022428,0.00009852102],"category_scores_gemma":[0.000015560418,0.00006859183,0.0001253803,0.00021763323,0.00012582913,0.000034167435,0.00002374646,0.00052384124,0.000017082602],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031966525,0.0002003204,0.00064726284,0.000049057588,0.00013684032,0.0035398467,0.029716516,0.000075221564,0.9452455,0.000008329282,0.0041294107,0.013055034],"study_design_scores_gemma":[0.005912324,0.0055041397,0.83389604,0.00097057805,0.001186623,0.042362012,0.022205424,0.0003857409,0.06110804,0.0008387549,0.025213799,0.0004165537],"about_ca_topic_score_codex":0.00020314415,"about_ca_topic_score_gemma":0.00060317287,"teacher_disagreement_score":0.88413745,"about_ca_system_score_codex":0.000115099785,"about_ca_system_score_gemma":0.000060734317,"threshold_uncertainty_score":0.27970934},"labels":[],"label_agreement":null},{"id":"W4401200698","doi":"10.2478/jtim-2024-0003","title":"A bibliometric analysis of immune-related adverse events in cancer patients and a meta-analysis of immune-related adverse events in patients with hepatocellular carcinoma.","year":2024,"lang":"en","type":"article","venue":"PubMed","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adverse effect; Hepatocellular carcinoma; Meta-analysis; Internal medicine; Immune system; Oncology; Nephrology; Cancer; Immunology","score_opus":0.02181469213862733,"score_gpt":0.2506950503261446,"score_spread":0.22888035818751726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401200698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98590964,0.011396402,0.0000028623037,0.000055492743,0.00012436284,0.002114847,0.00030990122,0.000027114582,0.000059389098],"genre_scores_gemma":[0.99805045,0.00040089572,0.000013356277,0.000033051998,0.0000025664538,0.00073291553,0.00047190033,0.0000461546,0.0002487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953284,0.00024460632,0.0021485423,0.00070832996,0.0010003669,0.0005697036],"domain_scores_gemma":[0.99813116,0.00012878288,0.0007485718,0.0005751615,0.00025713362,0.00015918558],"candidate_categories":["metaepi_narrow","bibliometrics"],"consensus_categories":["bibliometrics"],"category_scores_codex":[0.0010486975,0.00042979873,0.0024178037,0.076830275,0.000034005036,0.0000041463522,0.00022210894,0.0002441458,0.00034332045],"category_scores_gemma":[0.00010687649,0.00032736576,0.0017699962,0.1910595,0.00013301699,0.00027293593,0.000097802185,0.00032109753,0.0000013671723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017989521,0.0009612324,0.8115795,0.00018117674,0.18247366,0.00001499828,0.0005385032,0.00033325137,0.000089172565,0.0000012232382,0.0000020301766,0.0020262436],"study_design_scores_gemma":[0.006271545,0.00017077231,0.8023168,0.000042754687,0.18856138,3.246462e-7,0.000059884034,0.002071373,0.00025332737,0.0000030655112,0.000007783572,0.00024103817],"about_ca_topic_score_codex":0.00863685,"about_ca_topic_score_gemma":0.0004780891,"teacher_disagreement_score":0.114229225,"about_ca_system_score_codex":0.00039460778,"about_ca_system_score_gemma":0.00012516903,"threshold_uncertainty_score":0.99991786},"labels":[],"label_agreement":null},{"id":"W4401304201","doi":"10.1016/j.jgo.2024.101838","title":"Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study","year":2024,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"Deutsche Forschungsgemeinschaft; Baden-Württemberg Stiftung; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Ipilimumab; Post-hoc analysis; Quality of life (healthcare); Oncology; Internal medicine; Esophageal squamous cell carcinoma; Cancer; Esophageal cancer; Immunotherapy","score_opus":0.016047500563594438,"score_gpt":0.3244036981527508,"score_spread":0.30835619758915633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401304201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98582804,0.012712681,0.000020086381,0.00023412437,0.0005269204,0.00057161564,0.00008160286,0.0000044290405,0.000020480034],"genre_scores_gemma":[0.99867296,0.00080881873,0.00010021946,0.00020375928,0.00009478811,0.000010891863,0.0000079771835,0.000015948273,0.00008462324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977464,0.00033347806,0.0011100933,0.00020959774,0.00040283476,0.00019759817],"domain_scores_gemma":[0.9980321,0.00040475756,0.00088377064,0.0001709043,0.00041881492,0.00008963675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007409847,0.00016062138,0.00085889775,0.0005615743,0.000037001533,0.000010387329,0.00008352604,0.00009011197,0.00056161307],"category_scores_gemma":[0.0000728478,0.00009582624,0.00024823216,0.001104042,0.00010486928,0.00012151019,0.000030063144,0.00032293017,1.515093e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11331377,0.00737307,0.8048451,0.00024515315,0.002806377,0.000026925429,0.004392913,0.0002445537,0.008571837,4.687373e-7,0.00013174959,0.058048062],"study_design_scores_gemma":[0.052479725,0.009809381,0.9347784,0.000052186573,0.0009535093,0.000003637469,0.0012071269,0.00015416458,0.00020169985,9.1355e-7,0.0002727205,0.000086551554],"about_ca_topic_score_codex":0.00045735744,"about_ca_topic_score_gemma":0.0013580265,"teacher_disagreement_score":0.12993327,"about_ca_system_score_codex":0.0003689287,"about_ca_system_score_gemma":0.00092701777,"threshold_uncertainty_score":0.6149269},"labels":[],"label_agreement":null},{"id":"W4401324171","doi":"10.1200/jco.23.01448","title":"Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"EMD Serono; Genentech; Seagen; Ono Pharmaceutical; Apollomics; BeiGene; Five Prime Therapeutics; Regeneron Pharmaceuticals; Array BioPharma; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AtriCure; GlaxoSmithKline; Astellas Pharma; Celldex Therapeutics; Relay Therapeutics; Amgen; Pfizer","keywords":"Medicine; Ipilimumab; Nivolumab; Adjuvant; Systemic therapy; Internal medicine; Oncology; Melanoma; Adjuvant therapy; Overall survival; Progression-free survival; Surgery; Chemotherapy; Immunotherapy; Cancer; Cancer research","score_opus":0.13032674529911756,"score_gpt":0.4726604284343066,"score_spread":0.3423336831351891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401324171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786798,0.011956316,0.000061464765,0.0059689586,0.0024938432,0.00064569,0.00000911433,0.000021533757,0.00016332149],"genre_scores_gemma":[0.99415636,0.0034565744,0.0009786168,0.00046296095,0.00060414744,0.00003739133,0.000004757177,0.000026218195,0.0002729684],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996893,0.00021590201,0.0021215002,0.00024216638,0.0002640552,0.00026339258],"domain_scores_gemma":[0.9972021,0.0016627731,0.0006491997,0.00016438955,0.00015772427,0.00016383443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023455694,0.00019577803,0.0015730471,0.00021072208,0.00002722739,0.000021299496,0.00011216056,0.00027027496,0.000031660413],"category_scores_gemma":[0.00047268998,0.00010222853,0.00091250445,0.00022500737,0.00008853843,0.00010322808,0.000011607299,0.00044776118,0.0000041236563],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07138339,0.0018385076,0.12842889,0.0001973323,0.003329159,0.002920891,0.000845656,0.000005075566,0.013195362,0.000023755012,0.0006569008,0.77717507],"study_design_scores_gemma":[0.1102002,0.16290744,0.60743475,0.007754704,0.0010717871,0.0024306446,0.0012499694,0.00049137126,0.007737965,0.00018166905,0.09799635,0.00054316333],"about_ca_topic_score_codex":0.00005574526,"about_ca_topic_score_gemma":0.000115528106,"teacher_disagreement_score":0.7766319,"about_ca_system_score_codex":0.00056587247,"about_ca_system_score_gemma":0.0020824913,"threshold_uncertainty_score":0.41687584},"labels":[],"label_agreement":null},{"id":"W4401382527","doi":"10.1056/nejmc2407267","title":"Perioperative Nivolumab in Resectable Lung Cancer","year":2024,"lang":"en","type":"letter","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Nivolumab; Medicine; Perioperative; Lung cancer; Oncology; Cancer; Internal medicine; Surgery; Immunotherapy","score_opus":0.01965534194072127,"score_gpt":0.3210302090008643,"score_spread":0.30137486706014305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401382527","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009682102,0.113959625,0.000017939532,0.86854947,0.003700944,0.00030303156,0.000012448524,0.0000139133845,0.0037604969],"genre_scores_gemma":[0.014020055,0.02757368,0.00018390609,0.73631924,0.13007633,0.0000192971,0.00007217427,0.00016978002,0.09156552],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99745554,0.00013104793,0.0009352154,0.00026246975,0.00084921747,0.00036648536],"domain_scores_gemma":[0.9988609,0.00017407918,0.00034660453,0.00022972596,0.00023874968,0.00014993186],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00090463297,0.0003367678,0.0011729267,0.0007392066,0.000033620196,0.000026011565,0.00019528017,0.0004239242,0.0028331697],"category_scores_gemma":[0.00015166074,0.00020481,0.00020389282,0.00046314427,0.0001489118,0.000087802546,0.00002397453,0.0035819411,0.0000053867457],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029660752,0.000017843617,0.0007881459,0.0005758102,0.00063880056,0.00778716,0.002635207,0.000003574473,0.0013370791,0.0000017827508,0.95340395,0.029844556],"study_design_scores_gemma":[0.047764678,0.0014748373,0.00047345177,0.01064904,0.00061604346,0.0027140318,0.00015963621,0.000041628773,0.00011941875,0.000039362418,0.9357644,0.0001835085],"about_ca_topic_score_codex":0.0021621187,"about_ca_topic_score_gemma":0.0005434509,"teacher_disagreement_score":0.13223024,"about_ca_system_score_codex":0.000631154,"about_ca_system_score_gemma":0.0015104382,"threshold_uncertainty_score":0.99871683},"labels":[],"label_agreement":null},{"id":"W4401406952","doi":"10.1136/jitc-2024-008872","title":"Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Eisai; Department of Science and Technology, Ministry of Science and Technology, India; MacroGenics; Genentech; Actuate Therapeutics; Pfizer; Incyte; Mylan; BeiGene; Clovis Oncology; National Medical Research Council; Exelixis; Karyopharm Therapeutics; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; GlaxoSmithKline; Amgen; Astex Pharmaceuticals; Medical Research Council; Les Laboratories Pierre Fabre; AstraZeneca; Samsung; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Metastatic melanoma; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.031156298007487766,"score_gpt":0.38733140100864477,"score_spread":0.356175103001157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401406952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830283,0.009431964,0.0004883254,0.00024784077,0.0006323524,0.005899199,0.0002356837,0.00001959673,0.000016746319],"genre_scores_gemma":[0.9930383,0.0019878603,0.0027277633,0.00016425406,0.00010418825,0.0006691697,0.000027345674,0.00013675596,0.0011443614],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958058,0.00023247972,0.002199579,0.0004248468,0.0009287426,0.0004085441],"domain_scores_gemma":[0.9968712,0.0005452753,0.0013580893,0.0003941681,0.00073779287,0.00009351686],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011574856,0.0004448255,0.002377942,0.0006302031,0.000113007976,0.00007260801,0.00048285152,0.00006811255,0.0013512402],"category_scores_gemma":[0.000077389595,0.00027230626,0.0002972491,0.00079585373,0.0003199609,0.00050520024,0.000030483834,0.00033464975,6.60258e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87526554,0.004210545,0.00020752805,0.0005023167,0.0051388717,0.000060945782,0.0051081153,0.0007111194,0.0053627766,0.00001834993,0.00015315064,0.10326077],"study_design_scores_gemma":[0.9519186,0.03310514,0.0012551519,0.0030976576,0.0006304051,0.00008595141,0.0025355169,0.0013804609,0.0045137154,0.00018971677,0.000887756,0.00039990642],"about_ca_topic_score_codex":0.0018654929,"about_ca_topic_score_gemma":0.00041793453,"teacher_disagreement_score":0.10286086,"about_ca_system_score_codex":0.00055725087,"about_ca_system_score_gemma":0.002232803,"threshold_uncertainty_score":0.99997294},"labels":[],"label_agreement":null},{"id":"W4401420128","doi":"10.1016/j.cell.2024.07.004","title":"Anti-LAG-3 boosts CD8 T cell effector function","year":2024,"lang":"en","type":"letter","venue":"Cell","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Moderna; Foghorn Therapeutics; Mallinckrodt Pharmaceuticals; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Biology; Effector; Lag; Blockade; Immune system; CD8; Function (biology); Melanoma; Immune checkpoint; Immunology; Cancer research; Immunotherapy; Cell biology; Genetics; Receptor","score_opus":0.011343826324746328,"score_gpt":0.23689574855993445,"score_spread":0.2255519222351881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401420128","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06481455,0.08511563,0.0001277547,0.61295366,0.033800423,0.003536347,0.00037374577,0.0011750829,0.1981028],"genre_scores_gemma":[0.015226496,0.0009017614,0.000041341053,0.7050569,0.011306672,0.000058167432,0.0013201683,0.00021167923,0.26587683],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99841076,0.000051542193,0.00028008322,0.0005288169,0.0003508644,0.00037793224],"domain_scores_gemma":[0.9992008,0.000073921954,0.00010303817,0.0005167326,0.00004481382,0.000060655664],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00011611396,0.0003738968,0.0004810759,0.00020448225,0.000047845526,0.000060616643,0.00011987638,0.0008306222,0.0016370022],"category_scores_gemma":[0.0000042663146,0.0003025835,0.00041083831,0.00020508433,0.00006737312,0.000033805056,0.00003702074,0.0014120325,0.0031991322],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025727984,0.000037587262,0.00003597367,0.002657437,0.000118977754,0.00057397876,0.00003623245,8.187014e-8,0.12310949,8.120406e-8,0.87174577,0.0014271304],"study_design_scores_gemma":[0.0012898608,0.00043245815,0.00026455987,0.00043349242,0.0005501888,0.00003744197,0.000007734879,0.000006394503,0.037933953,0.000007644185,0.95872915,0.00030713293],"about_ca_topic_score_codex":0.000058058726,"about_ca_topic_score_gemma":0.000001956243,"teacher_disagreement_score":0.09210323,"about_ca_system_score_codex":0.00018377848,"about_ca_system_score_gemma":0.00014380152,"threshold_uncertainty_score":0.9999426},"labels":[],"label_agreement":null},{"id":"W4401503118","doi":"10.1016/s1470-2045(24)00338-3","title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"MSD K.K.; Merck","keywords":"Pembrolizumab; Medicine; Quality of life (healthcare); Adjuvant; Internal medicine; Oncology; Placebo; Stage (stratigraphy); Melanoma; Clinical trial; Cancer; Surgery; Immunotherapy; Alternative medicine; Pathology; Nursing","score_opus":0.1603378670695152,"score_gpt":0.4411800088781165,"score_spread":0.2808421418086013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401503118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9568441,0.012426714,0.00005028813,0.015511239,0.0033176225,0.007380259,0.0005129447,0.00020520031,0.0037516486],"genre_scores_gemma":[0.9925885,0.0022409232,0.00005338677,0.0009823198,0.0014844949,0.00059096655,0.0007374968,0.00006147403,0.0012604463],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9924228,0.0024638025,0.0029326703,0.0007541334,0.000567971,0.00085862755],"domain_scores_gemma":[0.9915921,0.0060148374,0.0009973324,0.0010333423,0.00012301921,0.0002393579],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.007118465,0.0004405721,0.0036116273,0.0003643669,0.00013855849,0.00005078653,0.0004910315,0.00051876553,0.0006938407],"category_scores_gemma":[0.0010689445,0.00029392843,0.00054622587,0.0007269134,0.0004278005,0.000105778905,0.000102336955,0.0011629043,0.00004052561],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9777774,0.0008627199,0.000063469495,0.00020581634,0.0022137386,0.0004077575,0.003265407,0.000020220175,0.0032155514,0.0002342171,0.0034999978,0.008233669],"study_design_scores_gemma":[0.98354334,0.00710475,0.0009265474,0.00039237025,0.00032755866,0.000026800622,0.00033459254,0.0005861746,0.00027391274,0.00004727656,0.0061470866,0.00028957194],"about_ca_topic_score_codex":0.008174799,"about_ca_topic_score_gemma":0.006743172,"teacher_disagreement_score":0.03574441,"about_ca_system_score_codex":0.00086565287,"about_ca_system_score_gemma":0.0026615416,"threshold_uncertainty_score":0.9999513},"labels":[],"label_agreement":null},{"id":"W4401583589","doi":"10.3390/cancers16162839","title":"Potentiating Salvage Radiotherapy in Radiorecurrent Prostate Cancer Through Anti-CTLA4 Therapy: Implications from a Syngeneic Model","year":2024,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Movember Canada; Prostate Cancer Canada; Sunnybrook Foundation; Canadian Institutes of Health Research; Sunnybrook Research Institute; Movember Foundation","keywords":"Prostate cancer; CD8; Medicine; Immune system; Cancer research; Radiation therapy; Immune checkpoint; T cell; Cancer; Isotype; Immunotherapy; Oncology; Internal medicine; Immunology; Antibody","score_opus":0.034762114926286204,"score_gpt":0.3329525595968342,"score_spread":0.29819044467054795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401583589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76882046,0.22124432,0.0018499925,0.0053046723,0.0008452063,0.0009994607,0.00032441053,0.00020483711,0.00040661867],"genre_scores_gemma":[0.8854847,0.10926226,0.0012394813,0.0025873668,0.00036900642,0.0005499631,0.00009519381,0.00008912428,0.00032290688],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9983033,0.00003969579,0.00040792988,0.00059672724,0.00022259037,0.00042976858],"domain_scores_gemma":[0.9993355,0.00004822581,0.000083079874,0.0003960996,0.0000477743,0.0000892846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014083234,0.00028006948,0.0003939653,0.00015153959,0.00010031577,0.00008151761,0.0001561048,0.00011188904,0.0002954154],"category_scores_gemma":[0.000006084599,0.00023714775,0.00021052104,0.0006770234,0.000121196,0.00021275647,0.000016291615,0.00029070544,0.000005870218],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017156372,0.00012253772,0.01591465,0.00032175018,0.0015819988,0.000065985885,0.016962409,0.013635153,0.440006,0.0002535831,0.016626868,0.4927934],"study_design_scores_gemma":[0.024635041,0.00089986663,0.13090982,0.007341352,0.0006409788,0.000094423776,0.0018367445,0.42300147,0.048679657,0.002561703,0.35649133,0.0029076058],"about_ca_topic_score_codex":0.00580014,"about_ca_topic_score_gemma":0.00035703447,"teacher_disagreement_score":0.4898858,"about_ca_system_score_codex":0.0027212757,"about_ca_system_score_gemma":0.0015997991,"threshold_uncertainty_score":0.96706045},"labels":[],"label_agreement":null},{"id":"W4401590090","doi":"10.1186/s12890-024-03180-w","title":"The impact of chronic obstructive pulmonary disease on the risk of immune-related pneumonitis in lung cancer patients undergoing immunotherapy: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"BMC Pulmonary Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; COPD; Meta-analysis; Internal medicine; Pneumonitis; Cochrane Library; Oncology; Immunotherapy; Cancer; Intensive care medicine; Lung","score_opus":0.03409256884076189,"score_gpt":0.3476004732719449,"score_spread":0.313507904431183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401590090","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037484788,0.9910244,0.0000012375006,0.00046360042,0.00014102731,0.0072743096,0.00058165216,0.000021793692,0.00011718056],"genre_scores_gemma":[0.018683968,0.9789193,0.0000016765765,0.00005721966,0.000043261443,0.0014897025,0.00019074706,0.00010451772,0.00050959975],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99282503,0.0018412588,0.003412853,0.000683874,0.0008090049,0.00042796446],"domain_scores_gemma":[0.9925105,0.0028384042,0.002824687,0.0014929809,0.0001959137,0.00013751112],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023987992,0.0009476335,0.00856382,0.00067045336,0.00015283567,0.000015895419,0.0005209087,0.00019041159,0.00035813518],"category_scores_gemma":[0.00059352576,0.00036165662,0.0053361095,0.0028275382,0.0006621742,0.00006859289,0.00011094048,0.0008858026,0.0000025122213],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004499275,0.00024717988,0.0007323033,0.73951685,0.25204068,0.00007167889,0.00011541977,0.000007454988,0.0000025133822,0.000023269622,0.000067261586,0.0067254435],"study_design_scores_gemma":[0.0004944883,0.0004174517,0.005133998,0.25109383,0.7417979,0.00005811734,0.00006586457,0.00027122075,2.1653037e-7,0.000051311268,0.00031691245,0.0002986582],"about_ca_topic_score_codex":0.001468595,"about_ca_topic_score_gemma":0.000087827786,"teacher_disagreement_score":0.48975724,"about_ca_system_score_codex":0.0009920786,"about_ca_system_score_gemma":0.001118838,"threshold_uncertainty_score":0.99988353},"labels":[],"label_agreement":null},{"id":"W4401715289","doi":"10.1111/crj.13823","title":"Comparative Efficacy and Safety of Immunotherapy on Non–Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Network Meta‐Analysis","year":2024,"lang":"en","type":"review","venue":"The Clinical Respiratory Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"China-Japan Friendship Hospital","keywords":"Immunotherapy; Medicine; Meta-analysis; Lung cancer; Oncology; Internal medicine; Cancer; Cancer immunotherapy","score_opus":0.12758550664168572,"score_gpt":0.4425277277774258,"score_spread":0.31494222113574005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401715289","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017460548,0.99469906,0.000030676165,0.00020663209,0.000129456,0.0045712637,0.00013797346,0.000010551819,0.000039760936],"genre_scores_gemma":[0.00005697862,0.9955309,0.00005727301,0.0037735526,0.00017061333,0.00017936146,0.00001327382,0.00006012118,0.00015790323],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99233174,0.0031157369,0.0031992109,0.0005096586,0.0005248147,0.00031880787],"domain_scores_gemma":[0.9924096,0.003780428,0.00261378,0.0007145701,0.00024604183,0.00023559218],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.007248318,0.0006663643,0.010657269,0.00022366393,0.00018747835,0.00007658627,0.00033686453,0.00021601614,0.00016027766],"category_scores_gemma":[0.0001593535,0.00027532442,0.0027988637,0.0010331931,0.000395852,0.00004291752,0.00007438283,0.0015279179,0.000003717501],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020351084,0.00034282493,0.000061801504,0.49111724,0.48730016,0.000025760857,0.00012998193,0.0000051978877,1.8043524e-7,0.0000047489734,0.0030836023,0.015893396],"study_design_scores_gemma":[0.0021154573,0.0014146643,0.00010774782,0.23871033,0.6828692,0.000022660004,0.000011766459,0.0000031820107,1.646427e-7,0.0000018632903,0.07448549,0.00025745848],"about_ca_topic_score_codex":0.0000075255784,"about_ca_topic_score_gemma":0.000013857133,"teacher_disagreement_score":0.25240692,"about_ca_system_score_codex":0.000115164155,"about_ca_system_score_gemma":0.0007188573,"threshold_uncertainty_score":0.9999699},"labels":[],"label_agreement":null},{"id":"W4401796073","doi":"10.1136/bmjonc-2024-000539","title":"Unlocking the predictive power of imaging biomarkers: predicting immune checkpoint therapy response in non-small cell lung cancer through baseline tumour vessel perfusions","year":2024,"lang":"en","type":"editorial","venue":"BMJ Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Lung cancer; Internal medicine; Cancer; Immune checkpoint; Immunotherapy","score_opus":0.015061676464857742,"score_gpt":0.3441257980389995,"score_spread":0.3290641215741418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401796073","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21456717,0.0925383,0.0004158615,0.01207027,0.6690382,0.006940706,0.0010380305,0.0002186529,0.0031728281],"genre_scores_gemma":[0.5049333,0.03503227,0.0010804118,0.001344896,0.450023,0.003553303,0.00065713475,0.0007118901,0.002663786],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99411196,0.0011595188,0.0019854787,0.0010533505,0.00084665074,0.0008430398],"domain_scores_gemma":[0.9929041,0.004323456,0.0011498496,0.0009297528,0.00058437994,0.000108443084],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0064907586,0.0007542736,0.0015599038,0.00055421167,0.00021026384,0.00004970239,0.00062039314,0.0011017818,0.0003796615],"category_scores_gemma":[0.0012975285,0.00053941045,0.000694002,0.0010127627,0.00052364136,0.00011913228,0.0003552441,0.0024477667,0.0000065861504],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.098195404,0.00082985393,0.0017689129,0.0011360642,0.0017058823,0.00082885625,0.02144478,0.00006258933,0.17493951,0.0000010513189,0.6947981,0.0042889984],"study_design_scores_gemma":[0.02262925,0.0044842027,0.0097096525,0.01367856,0.0016171582,0.00019347097,0.014942766,0.008598127,0.020812403,0.00003653257,0.9020216,0.0012763096],"about_ca_topic_score_codex":0.004871692,"about_ca_topic_score_gemma":0.00030147866,"teacher_disagreement_score":0.29036614,"about_ca_system_score_codex":0.0019499876,"about_ca_system_score_gemma":0.0064704437,"threshold_uncertainty_score":0.9998536},"labels":[],"label_agreement":null},{"id":"W4401803980","doi":"10.1200/po.24.00100","title":"Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"Genentech; Merck Canada; CRIS Cancer Foundation; Sociedad Española de Oncología Médica; Natera; Gilead Sciences; Eli Lilly and Company","keywords":"Pembrolizumab; Internal medicine; Oncology; Medicine; Biomarker; Immunotherapy; Progression-free survival; Cancer research; Cancer; Biology; Overall survival","score_opus":0.033039067890378006,"score_gpt":0.37552085143387254,"score_spread":0.3424817835434945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401803980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965356,0.00067590235,0.00017833989,0.001077412,0.00014130349,0.0006412751,0.000020253816,0.00013135209,0.0005985402],"genre_scores_gemma":[0.99832505,0.00013788794,0.00065986416,0.00028412754,0.000030075771,0.00007381349,0.000047700785,0.00004186904,0.0003996364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972928,0.0002603408,0.00093825965,0.0007394312,0.00035345068,0.00041570194],"domain_scores_gemma":[0.9981662,0.0010605735,0.00020960378,0.0002938001,0.00010978737,0.00016005654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009235855,0.00032126153,0.001444169,0.00068314356,0.000081968734,0.00005470298,0.0001032388,0.0002042105,0.00018078292],"category_scores_gemma":[0.00012908816,0.00020198636,0.00030976403,0.0014867716,0.0002701687,0.00015216599,0.000029420344,0.00038619287,0.0000052965383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022118734,0.0005182004,0.9257437,0.000060132283,0.0032714324,0.0012401991,0.00033690676,0.000022459746,0.0043874998,0.000010364007,0.000059569098,0.042230792],"study_design_scores_gemma":[0.013443105,0.0047562625,0.97593,0.00037998985,0.0013317765,0.00024649414,0.0002387614,0.0026633635,0.00022138686,0.00002801845,0.00049455353,0.0002663176],"about_ca_topic_score_codex":0.00020723157,"about_ca_topic_score_gemma":0.00081917964,"teacher_disagreement_score":0.050186258,"about_ca_system_score_codex":0.0003970658,"about_ca_system_score_gemma":0.00033811695,"threshold_uncertainty_score":0.82367647},"labels":[],"label_agreement":null},{"id":"W4401827050","doi":"10.1136/bmjonc-2024-000398","title":"Increase in major osteoporotic fractures after therapy with immune checkpoint inhibitors","year":2024,"lang":"en","type":"article","venue":"BMJ Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Alberta","funders":"National Cancer Institute; National Institute of Allergy and Infectious Diseases; University of Texas MD Anderson Cancer Center; Duncan Family Institute for Cancer Prevention and Risk Assessment","keywords":"Medicine; Immune system; Oncology; Internal medicine; Immunology","score_opus":0.012195266938984954,"score_gpt":0.3278814866012611,"score_spread":0.31568621966227617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401827050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97385186,0.013741619,0.000009204164,0.007960947,0.00045348782,0.0010873867,0.0000058144574,0.00007175849,0.002817925],"genre_scores_gemma":[0.9952991,0.00034095507,0.00031943838,0.002370814,0.00037112075,0.00040297236,0.000019513924,0.000037904596,0.0008381609],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987457,0.00008648509,0.00042228255,0.0002962851,0.00016903778,0.0002802573],"domain_scores_gemma":[0.9994583,0.000105818726,0.00006364252,0.00026283023,0.00003223446,0.000077140925],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004808793,0.00018729268,0.00037982242,0.0002332381,0.000023592196,0.00002176646,0.00006574317,0.00019474648,0.001344192],"category_scores_gemma":[0.000027185926,0.00012153136,0.00013179568,0.00032928746,0.00015383406,0.00006781117,0.000024492409,0.00032658665,0.00005946606],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15548497,0.0018011379,0.050064333,0.0007507949,0.0014090703,0.020879323,0.008198352,0.000006565181,0.19875412,0.000069323345,0.008377451,0.5542046],"study_design_scores_gemma":[0.016764073,0.0073184185,0.58436,0.0012460309,0.00014239635,0.00239661,0.0008323326,0.00006672658,0.045877375,0.00018404577,0.3402881,0.0005238816],"about_ca_topic_score_codex":0.000954107,"about_ca_topic_score_gemma":0.0006811871,"teacher_disagreement_score":0.55368066,"about_ca_system_score_codex":0.00033001916,"about_ca_system_score_gemma":0.0006007286,"threshold_uncertainty_score":0.9995687},"labels":[],"label_agreement":null},{"id":"W4401903524","doi":"10.17504/protocols.io.5qpvok9j7l4o/v1","title":"Mitochondrial Antigen Presentation (MitAP) to 2CZ CD8+ T cell hybridoma v1","year":2024,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Presentation (obstetrics); Antigen; Antigen presentation; CD8; Mitochondrion; T cell; Chemistry; Molecular biology; Biology; Cell biology; Immunology; Medicine; Immune system","score_opus":0.019985048113558824,"score_gpt":0.30658613163649767,"score_spread":0.28660108352293884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401903524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85785276,0.0046102675,0.0012992165,0.010019543,0.013839945,0.0038439531,0.00017064209,0.00051295816,0.1078507],"genre_scores_gemma":[0.82357776,0.0012474881,0.012509957,0.0042359466,0.0065939957,0.00043411055,0.00065770216,0.00021974344,0.15052328],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979537,0.00004346809,0.00047203896,0.00074363523,0.00047205554,0.00031506535],"domain_scores_gemma":[0.99889606,0.000043550863,0.00009127166,0.0006781042,0.00010769463,0.00018333616],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00013042014,0.00034515496,0.00045450657,0.00029089948,0.000045731285,0.00013582163,0.00021122453,0.00028751054,0.0016521879],"category_scores_gemma":[0.000025026236,0.00028720635,0.00040902584,0.00022596357,0.000047150268,0.00002954169,0.00047482623,0.00053623936,0.0008458535],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049830447,0.00022464585,0.0007005723,0.0015031133,0.00081096106,0.00022652643,0.0011586072,0.00003776216,0.38698006,0.00006639779,0.5760607,0.027247583],"study_design_scores_gemma":[0.00667748,0.0010744395,0.009806007,0.0018125911,0.00086186937,0.00011128746,0.0005314872,0.0006126181,0.4660846,0.0021873368,0.5088142,0.0014260879],"about_ca_topic_score_codex":0.0011631649,"about_ca_topic_score_gemma":0.000099093675,"teacher_disagreement_score":0.07910456,"about_ca_system_score_codex":0.00021184323,"about_ca_system_score_gemma":0.00041037655,"threshold_uncertainty_score":0.99995804},"labels":[],"label_agreement":null},{"id":"W4401908628","doi":"10.3390/curroncol31090367","title":"Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients with PD-L1 &lt; 50% Treated with First-Line Chemoimmunotherapy","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chemoimmunotherapy; Medicine; Lung cancer; Oncology; Internal medicine; Cancer; First line; Immunotherapy","score_opus":0.036499530791051685,"score_gpt":0.36601821203926105,"score_spread":0.3295186812482094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401908628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870725,0.00840314,0.000084921194,0.0005044711,0.0014735947,0.0018094084,0.00028312273,0.00009429075,0.00027449618],"genre_scores_gemma":[0.9953015,0.003028037,0.00033541303,0.00029424834,0.00012695944,0.00031572185,0.00037911918,0.00008593455,0.00013307156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99721456,0.000118404096,0.0011152206,0.0006699602,0.00039568712,0.00048619934],"domain_scores_gemma":[0.998221,0.0005632363,0.0004093891,0.00042091685,0.00023289758,0.00015259493],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037907469,0.000446761,0.0012327919,0.00033186591,0.00005504737,0.000016108032,0.00021102486,0.00025068258,0.0002829158],"category_scores_gemma":[0.000034760724,0.000298399,0.000273106,0.0006218222,0.00041920078,0.000076534634,0.00002790627,0.00045000043,0.00000463333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028202102,0.0038669014,0.9485271,0.00090375607,0.001513457,0.000050911487,0.00026686897,0.00004617198,0.0011840285,0.0000011128755,0.00054946414,0.014888156],"study_design_scores_gemma":[0.054932304,0.010374078,0.86675304,0.0022904812,0.0009237306,0.0000068941276,0.000060394374,0.0009614256,0.0013505229,0.0000011160199,0.06191961,0.000426373],"about_ca_topic_score_codex":0.0003949192,"about_ca_topic_score_gemma":0.0012321761,"teacher_disagreement_score":0.081774,"about_ca_system_score_codex":0.0004197361,"about_ca_system_score_gemma":0.001439701,"threshold_uncertainty_score":0.99994683},"labels":[],"label_agreement":null},{"id":"W4401922562","doi":"10.21037/actr-24-34","title":"Chemo-immunotherapy on localized gastroesophageal/gastric adenocarcinoma—hope or delusion?","year":2024,"lang":"en","type":"article","venue":"AME Clinical Trials Review","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Delusion; Immunotherapy; Gastroesophageal Junction; Cancer; Medicine; Adenocarcinoma; Internal medicine; Gastroenterology; Psychiatry","score_opus":0.2471063106414863,"score_gpt":0.5112828568609188,"score_spread":0.2641765462194325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401922562","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005014534,0.9683046,0.0006804323,0.01810942,0.0024999212,0.003906354,0.000060091123,0.00037502064,0.0010496238],"genre_scores_gemma":[0.018740265,0.92658436,0.0013557605,0.04639907,0.0019816414,0.00020956804,0.00008229361,0.000116549956,0.0045305095],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9923567,0.0020425632,0.0036280365,0.00087379286,0.0006056959,0.00049318303],"domain_scores_gemma":[0.9931573,0.004855075,0.0005015701,0.0010379122,0.00011679689,0.00033134196],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.014592099,0.00046789722,0.0030545644,0.00016028169,0.000088949295,0.00008139803,0.00032911327,0.00028456593,0.008987016],"category_scores_gemma":[0.0055553536,0.00026731667,0.0022055132,0.0010798647,0.00024486115,0.00008751613,0.000064638334,0.00078889943,0.0011717811],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010707411,0.0004120506,0.00038928504,0.0026130425,0.0009752739,0.00042669338,0.000014388133,1.7752639e-7,0.0005097302,0.000052175383,0.108117,0.8757828],"study_design_scores_gemma":[0.010349135,0.004317336,0.0025080922,0.029973056,0.001185345,0.00033896777,0.0000093956,0.000059219863,0.00018085528,0.000083798186,0.95065135,0.00034346813],"about_ca_topic_score_codex":0.000024902794,"about_ca_topic_score_gemma":0.0000024340598,"teacher_disagreement_score":0.8754393,"about_ca_system_score_codex":0.000167555,"about_ca_system_score_gemma":0.00066631765,"threshold_uncertainty_score":0.9999779},"labels":[],"label_agreement":null},{"id":"W4401927532","doi":"10.1007/978-3-031-64636-2_5","title":"Divergent Expression of PD-1 as Challenges and Chances of Immunotherapy Targeting PD-1 or PD-L1 in Cancer","year":2024,"lang":"en","type":"book-chapter","venue":"Lecture notes in computer science","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Immunotherapy; Cancer immunotherapy; PD-L1; Cancer; Expression (computer science); Computer science; Cancer research; Medicine; Internal medicine; Programming language","score_opus":0.030861637491737374,"score_gpt":0.30400736867853073,"score_spread":0.27314573118679336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401927532","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13510032,0.8336435,0.017047387,0.003908488,0.0046518603,0.0020219467,0.000060708964,0.00009754558,0.003468248],"genre_scores_gemma":[0.82433486,0.16512221,0.008256604,0.00068535295,0.00050556194,0.000026717053,0.0000066994044,0.00006685578,0.0009951212],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99782115,0.000020224763,0.0005608101,0.0007108404,0.00058167096,0.00030532648],"domain_scores_gemma":[0.99898416,0.00019776968,0.00028577453,0.0003610407,0.00011185493,0.00005937296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054558815,0.0003403518,0.0006858195,0.00055831455,0.000048880698,0.000022334127,0.0003603475,0.00024295639,0.00019002474],"category_scores_gemma":[0.000029073348,0.00023574955,0.0001134608,0.0002602494,0.0006723515,0.00010140485,0.00022995903,0.000398991,0.0000014033152],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020270126,0.000085037966,0.00025693703,0.0012291757,0.00010360314,0.00007251606,0.008763637,0.00029997888,0.094943516,0.00022912207,0.00002336327,0.8919661],"study_design_scores_gemma":[0.009868981,0.0068785497,0.011047502,0.08709774,0.00023204043,0.00022125104,0.00012123079,0.010694223,0.7977402,0.035303187,0.03789349,0.0029015702],"about_ca_topic_score_codex":0.00028110054,"about_ca_topic_score_gemma":0.0002563851,"teacher_disagreement_score":0.88906455,"about_ca_system_score_codex":0.00017138716,"about_ca_system_score_gemma":0.0003715682,"threshold_uncertainty_score":0.9613588},"labels":[],"label_agreement":null},{"id":"W4402087465","doi":"10.1016/bs.adgen.2024.08.005","title":"Construction of an immune gene expression meta signature to assess the prognostic risk of colorectal cancer patients","year":2024,"lang":"en","type":"article","venue":"Advances in genetics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill Genome Centre","funders":"","keywords":"Biology; Colorectal cancer; Meta-analysis; Gene; Immune system; Signature (topology); Gene expression; Expression (computer science); Gene signature; Oncology; Cancer; Internal medicine; Genetics; Bioinformatics; Cancer research","score_opus":0.013112090000516314,"score_gpt":0.3107940481446185,"score_spread":0.29768195814410214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402087465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92142,0.07707279,0.00021336152,0.000041742656,0.00058592303,0.00050720805,0.00009465208,0.000010283578,0.00005405023],"genre_scores_gemma":[0.982312,0.010794025,0.006710945,0.000025808222,0.000041887757,0.000070753464,0.000017292137,0.000013495096,0.000013799519],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99912775,0.000074541946,0.00030344463,0.0001575619,0.0002236789,0.000113033326],"domain_scores_gemma":[0.99946374,0.00011502299,0.00011510319,0.00016882658,0.00010821921,0.000029111363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015826884,0.00010567022,0.00023614774,0.00009650556,0.000025374438,0.000006645333,0.00010159887,0.00006538285,0.00004719662],"category_scores_gemma":[0.000047925616,0.00006486285,0.00008279694,0.00041385717,0.00012760653,0.000071495066,0.00002882593,0.00013715464,3.53042e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015511236,0.00022218357,0.18623349,0.00030785875,0.00050208514,0.0000036158408,0.0011318859,0.002030324,0.6602998,0.000021994605,0.000023457764,0.14767218],"study_design_scores_gemma":[0.0006892278,0.00083574146,0.12200218,0.0003235157,0.000518096,0.000004559198,0.00023256689,0.00039075475,0.87244356,0.00013988576,0.0023231134,0.00009682977],"about_ca_topic_score_codex":0.000032692056,"about_ca_topic_score_gemma":0.00006261654,"teacher_disagreement_score":0.21214372,"about_ca_system_score_codex":0.000039860533,"about_ca_system_score_gemma":0.00007638318,"threshold_uncertainty_score":0.264503},"labels":[],"label_agreement":null},{"id":"W4402167552","doi":"10.1200/jco.24.00326","title":"Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Foghorn Therapeutics; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Mallinckrodt Pharmaceuticals; Massachusetts General Hospital; Eli Lilly and Company","keywords":"Medicine; Myocarditis; Pneumonitis; Internal medicine; Adverse effect","score_opus":0.07668197061795526,"score_gpt":0.46318749518581037,"score_spread":0.38650552456785514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402167552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99662596,0.0018760164,0.00044873127,0.00035219363,0.00036944164,0.000122236,0.000016291624,0.000002453035,0.00018667136],"genre_scores_gemma":[0.9986616,0.0007667111,0.00045966898,0.000043597724,0.000027325408,0.0000020858138,0.000009296245,0.0000036869676,0.000026021518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704313,0.0003166785,0.002253926,0.00012216011,0.00018748421,0.00007663221],"domain_scores_gemma":[0.99747705,0.0012142183,0.0010148627,0.00007802533,0.00015760692,0.000058249338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025190779,0.000065511325,0.00076208054,0.00052033307,0.000007882508,0.0000017021329,0.000060533366,0.00012236346,0.00006328388],"category_scores_gemma":[0.00071611407,0.00004959267,0.00030703328,0.00045682144,0.000053982454,0.00013512652,0.000027188122,0.0003649677,2.3561067e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07390465,0.004388165,0.46300527,0.00028291836,0.007220445,0.0003585474,0.019122606,0.005834799,0.03813341,0.0001690247,0.000043586315,0.38753656],"study_design_scores_gemma":[0.005000862,0.0018828767,0.88926953,0.0012193089,0.00066382124,0.000014880665,0.0042830184,0.09678687,0.00045909462,0.0002324962,0.00012188339,0.00006536467],"about_ca_topic_score_codex":0.00006800156,"about_ca_topic_score_gemma":0.0005629641,"teacher_disagreement_score":0.42626423,"about_ca_system_score_codex":0.00018405159,"about_ca_system_score_gemma":0.00034351708,"threshold_uncertainty_score":0.20223303},"labels":[],"label_agreement":null},{"id":"W4402266378","doi":"10.1158/1538-7445.pediatric24-b015","title":"Abstract B015: Transcriptome-based assessment of immune infiltration for molecular selection of pediatric patients with solid tumors for combination immune checkpoint inhibitor therapy","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; Ontario Institute for Cancer Research; BC Children's Hospital; University Health Network; Université Laval; Princess Margaret Cancer Centre; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Immune system; Transcriptome; Immune checkpoint; Medicine; Solid tumor; Selection (genetic algorithm); Cancer research; Immunotherapy; Immunology; Cancer; Biology; Internal medicine; Genetics; Gene; Gene expression; Computer science","score_opus":0.03721209823249799,"score_gpt":0.3925980597563694,"score_spread":0.3553859615238714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402266378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98956835,0.0027743613,0.0036629853,0.00046756418,0.00019730159,0.0031487052,0.00011210294,0.000028017732,0.000040625455],"genre_scores_gemma":[0.9977083,0.00032815337,0.0004325613,0.000017326336,0.00010848927,0.0010913176,0.00022644513,0.00004562401,0.000041772033],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981875,0.000050862058,0.000569663,0.00026447012,0.0006547214,0.00027278776],"domain_scores_gemma":[0.9983508,0.00014129894,0.00015209489,0.0001688204,0.0011403438,0.000046615864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010792401,0.00014005005,0.0003112483,0.00047207644,0.00008020981,0.000029555507,0.0000865298,0.00008986378,0.00007985977],"category_scores_gemma":[0.000031776985,0.00011197012,0.00021162763,0.00078247243,0.00010342847,0.00011993992,0.000004908782,0.00021296777,2.2458944e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074331253,0.00059632695,0.0045451988,0.002261035,0.00024694199,6.62893e-7,0.00019236121,0.00008217543,0.9742536,0.00007090738,0.000110694185,0.010206954],"study_design_scores_gemma":[0.008816723,0.004533449,0.16423495,0.00049981225,0.00006379363,3.474065e-7,0.00005929714,0.0012322976,0.820089,0.000054954253,0.00029780145,0.000117569434],"about_ca_topic_score_codex":0.00020920724,"about_ca_topic_score_gemma":0.0000124761045,"teacher_disagreement_score":0.15968975,"about_ca_system_score_codex":0.000403078,"about_ca_system_score_gemma":0.001260601,"threshold_uncertainty_score":0.4566009},"labels":[],"label_agreement":null},{"id":"W4402267050","doi":"10.1158/1538-7445.pediatric24-b075","title":"Abstract B075: The Open Single-cell Pediatric Cancer Atlas project: Collaborative analysis of pediatric tumor data","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Atlas (anatomy); Medicine; Cancer; Pediatric cancer; Oncology; Internal medicine; Anatomy","score_opus":0.19898528304021526,"score_gpt":0.4741819545754963,"score_spread":0.27519667153528105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402267050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8803942,0.10622957,0.0000047761005,0.002905573,0.00048078987,0.0023798968,0.0023106392,0.0000463073,0.0052482407],"genre_scores_gemma":[0.96721655,0.027268613,0.000045683413,0.00014983429,0.0013676591,0.0005661409,0.00018503972,0.000053456908,0.0031470214],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967869,0.00021144959,0.00050941965,0.00079466176,0.0011332013,0.00056436314],"domain_scores_gemma":[0.99718386,0.00065047113,0.0001432481,0.0011957935,0.00070844183,0.00011820327],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023254573,0.00021279552,0.0005149659,0.001102098,0.0002200408,0.0003113306,0.0015042765,0.000092696624,0.0019984888],"category_scores_gemma":[0.00014054803,0.00013625588,0.00015602296,0.013130076,0.00026747788,0.0003178657,0.00067573006,0.00068281294,0.000023230794],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009602892,0.0014757903,0.08128186,0.0043633454,0.00946737,0.0004535651,0.007775536,0.0001770322,0.08201166,0.00014754073,0.76566124,0.037582166],"study_design_scores_gemma":[0.010505466,0.002663891,0.2085157,0.0011421132,0.021643497,0.000020018388,0.010884211,0.003047423,0.03836481,0.00008497231,0.70126134,0.0018665752],"about_ca_topic_score_codex":0.013400979,"about_ca_topic_score_gemma":0.0037453952,"teacher_disagreement_score":0.12723385,"about_ca_system_score_codex":0.0005466005,"about_ca_system_score_gemma":0.005948273,"threshold_uncertainty_score":0.9996871},"labels":[],"label_agreement":null},{"id":"W4402267375","doi":"10.1158/1538-7445.pediatric24-b009","title":"Abstract B009: The Dutch childhood cancer genome project: Data-driven precision medicine and research","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Childhood cancer; Precision medicine; Cancer; Medicine; Genome; Family medicine; Computational biology; Genetics; Biology; Internal medicine; Pathology","score_opus":0.26822439667909415,"score_gpt":0.521125321111974,"score_spread":0.2529009244328798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402267375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6530453,0.25945768,0.000007869234,0.07469127,0.0008153217,0.003626613,0.0004199963,0.00013994935,0.007796041],"genre_scores_gemma":[0.89034146,0.09892461,0.000040805033,0.00042104526,0.002902531,0.00077941496,0.000120670644,0.0000917853,0.006377705],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950335,0.00034387724,0.00041892644,0.0010271759,0.002235013,0.00094150647],"domain_scores_gemma":[0.99667346,0.0011191315,0.000037025093,0.0013960201,0.0005588601,0.00021550921],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007003074,0.00022381192,0.0003561097,0.00070953683,0.0006163668,0.00023782074,0.0007541402,0.00016949943,0.002643552],"category_scores_gemma":[0.00040220912,0.00012657202,0.00006552079,0.0022223261,0.0014445202,0.00025803078,0.0006555485,0.0020281696,0.000054718705],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028821963,0.00019849185,0.0008271802,0.0013943836,0.00090907037,0.0003613221,0.012008494,0.0000053287213,0.19563879,0.0002742037,0.3117993,0.47370127],"study_design_scores_gemma":[0.0019796914,0.00063923013,0.08110123,0.003124335,0.00007728171,0.000106031126,0.002212915,0.00043942314,0.001487306,0.0003191686,0.9082806,0.00023279393],"about_ca_topic_score_codex":0.012048641,"about_ca_topic_score_gemma":0.0011417352,"teacher_disagreement_score":0.5964813,"about_ca_system_score_codex":0.00062908186,"about_ca_system_score_gemma":0.0023839918,"threshold_uncertainty_score":0.9982682},"labels":[],"label_agreement":null},{"id":"W4402268369","doi":"10.1158/1538-7445.pediatric24-a046","title":"Abstract A046 Expression of novel immune checkpoints HHLA2 and B7x on circulating tumor cells (CTCs) of pediatric, adolescent and young adult solid tumors","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immune system; Cancer research; Medicine; Biology; Immunology","score_opus":0.05861498227172625,"score_gpt":0.3849851087447797,"score_spread":0.32637012647305347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402268369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98672736,0.011747924,0.00000811089,0.00024636032,0.00022117475,0.00050018646,0.00008529867,0.000020478827,0.0004430876],"genre_scores_gemma":[0.99576026,0.0036099125,0.00006887191,0.000035262907,0.00027458512,0.00003477166,0.0000051863753,0.00003620495,0.00017492264],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99807745,0.000040704756,0.00047718326,0.00038127304,0.000672686,0.0003506911],"domain_scores_gemma":[0.9991174,0.00012959843,0.00011052019,0.00026313055,0.00025451664,0.00012484952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077842834,0.00015683232,0.00035553897,0.00031627397,0.000079358346,0.00003270762,0.00010181419,0.00007809694,0.00015214997],"category_scores_gemma":[0.00008487277,0.0001257079,0.0000892168,0.00038631522,0.00024086499,0.0000788343,0.000091265385,0.00049058703,0.0000024058058],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014201431,0.00016155755,0.0039366554,0.003193904,0.000051187828,0.00004159852,0.00082183763,0.0000054653806,0.98343617,0.000012916106,0.00053017423,0.0063883793],"study_design_scores_gemma":[0.0021663855,0.00033289293,0.15277778,0.004599325,0.000036475714,0.000026620392,0.0006010123,0.00025698636,0.8389519,0.000011129184,0.000099686615,0.00013985117],"about_ca_topic_score_codex":0.0010746848,"about_ca_topic_score_gemma":0.000020947087,"teacher_disagreement_score":0.14884111,"about_ca_system_score_codex":0.00016003338,"about_ca_system_score_gemma":0.00032326012,"threshold_uncertainty_score":0.51262194},"labels":[],"label_agreement":null},{"id":"W4402378820","doi":"10.3390/pharmaceutics16091181","title":"Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer","year":2024,"lang":"en","type":"review","venue":"Pharmaceutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke; St. Michael's Hospital","funders":"Canada Research Chairs; Cancer Research Society","keywords":"Immunotherapy; PD-L1; Immune system; Immune checkpoint; Oncolytic virus; Cancer research; Medicine; Cancer immunotherapy; Cancer; T cell; CD8; Immunology; Internal medicine","score_opus":0.16734434960377784,"score_gpt":0.46740316388305997,"score_spread":0.30005881427928216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402378820","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000121265875,0.9937842,0.00023172674,0.00042363149,0.002053962,0.0027361137,0.00020761731,0.00009275578,0.0003487186],"genre_scores_gemma":[0.0006123064,0.996071,0.00023270401,0.00050707336,0.0008787822,0.0009446485,0.00010300042,0.00020258814,0.00044790053],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970671,0.00013501821,0.0012716852,0.0005387388,0.00033918602,0.0006482791],"domain_scores_gemma":[0.99862486,0.00028984266,0.00046338994,0.00041596548,0.00013242017,0.00007349754],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009796493,0.000705094,0.0014951051,0.0002618539,0.00015176366,0.00017113633,0.00047498263,0.00026982068,0.00014738887],"category_scores_gemma":[0.000024341505,0.000451867,0.0010587771,0.0006048378,0.0001948147,0.00011131257,0.00014087255,0.0012862937,0.000023212464],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061996706,0.00011538045,0.000003560603,0.030886594,0.0033965863,0.000046066245,0.0017038777,0.000042087577,0.0011010162,0.00016470127,0.0002522159,0.96166795],"study_design_scores_gemma":[0.0014771966,0.000094121104,0.0000024777344,0.015931534,0.00386582,0.000050024366,0.00048466277,0.0018030655,0.0007453436,0.0001772976,0.97487295,0.0004954927],"about_ca_topic_score_codex":0.0006013883,"about_ca_topic_score_gemma":0.000050826384,"teacher_disagreement_score":0.97462076,"about_ca_system_score_codex":0.00094526977,"about_ca_system_score_gemma":0.0011257605,"threshold_uncertainty_score":0.9997933},"labels":[],"label_agreement":null},{"id":"W4402416181","doi":"10.3390/curroncol31090394","title":"Low CD8+ Density Variation and R1 Surgical Margin as Independent Predictors of Early Post-Resection Recurrence in HCC Patients Meeting Milan Criteria","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Lietuvos Mokslo Taryba","keywords":"Medicine; Milan criteria; CD8; Biopsy; Pathological; Internal medicine; Surgical margin; Liver transplantation; Oncology; Surgery; Radiology; Gastroenterology; Resection; Immune system; Transplantation","score_opus":0.0298272298987155,"score_gpt":0.35503836230945135,"score_spread":0.32521113241073585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402416181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99402624,0.0018331427,0.000015749816,0.0002406268,0.00320139,0.00040563723,0.000023606883,0.000028317878,0.00022529838],"genre_scores_gemma":[0.99900395,0.0006459747,0.000022255568,0.000023507866,0.00017736283,0.000020497004,0.00007189353,0.000009874626,0.00002467732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998726,0.00017677304,0.00038860078,0.0002984674,0.0002251447,0.00018497901],"domain_scores_gemma":[0.99945664,0.00013809619,0.00009693088,0.00010377984,0.00013488649,0.000069683454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050736027,0.000120794175,0.00027617704,0.00022627706,0.000032031683,0.00001792803,0.00004992773,0.00015868641,0.000092567614],"category_scores_gemma":[0.00012787875,0.00010693078,0.00006113598,0.00024150503,0.00008373826,0.000095766125,0.000048828402,0.00027783227,0.0000053372773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008800277,0.0010163141,0.8089129,0.00085939886,0.0001227379,0.00008149513,0.0063302005,8.2155776e-7,0.012012318,0.00004622948,0.0005469162,0.1612704],"study_design_scores_gemma":[0.0032447623,0.0024931917,0.98616844,0.0009168598,0.00005968929,0.000053167663,0.00009938991,0.00030791922,0.0013854799,0.000057089543,0.005099977,0.000114023904],"about_ca_topic_score_codex":0.0004495023,"about_ca_topic_score_gemma":0.00019772402,"teacher_disagreement_score":0.17725556,"about_ca_system_score_codex":0.0003122116,"about_ca_system_score_gemma":0.00019609636,"threshold_uncertainty_score":0.43605107},"labels":[],"label_agreement":null},{"id":"W4402468774","doi":"10.1016/j.jim.2024.113757","title":"Comparative analysis of LAG3 antibodies shows differential binding patterns by flow cytometry","year":2024,"lang":"en","type":"article","venue":"Journal of Immunological Methods","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Flow cytometry; Antibody; Molecular biology; Biology; Chemistry; Cancer research; Immunology","score_opus":0.06329614873648484,"score_gpt":0.42947509446799864,"score_spread":0.36617894573151377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402468774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8928682,0.019440448,0.08641102,0.0002639135,0.00063556037,0.000087339584,0.00007863143,0.000021584216,0.00019327668],"genre_scores_gemma":[0.9562852,0.002468461,0.040841322,0.00006115001,0.00009560205,0.000001937655,0.00001771253,0.000009071064,0.00021956488],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99793017,0.0004920025,0.0008529731,0.00018220989,0.00032948935,0.00021316439],"domain_scores_gemma":[0.9984435,0.000805046,0.0003522554,0.00016992493,0.00016312681,0.0000661841],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011646503,0.00019216361,0.0012617634,0.00090909714,0.000048780254,0.00004965659,0.00018782007,0.00016772166,0.0014066887],"category_scores_gemma":[0.00016202506,0.00011428122,0.0009436017,0.001275724,0.00019270724,0.000107810476,0.000055179535,0.0005334328,0.0000019406336],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016059282,0.00022777217,0.007625899,0.00007023399,0.012389904,0.000058477464,0.00045051577,0.000005240595,0.8832051,0.000017171495,0.0003510225,0.09399269],"study_design_scores_gemma":[0.0028408018,0.003995919,0.34497333,0.0010780233,0.008857436,0.00027936164,0.0023363787,0.003370482,0.6241444,0.00008809554,0.0076021417,0.00043367856],"about_ca_topic_score_codex":0.00001320825,"about_ca_topic_score_gemma":0.0000010946986,"teacher_disagreement_score":0.33734742,"about_ca_system_score_codex":0.00011704115,"about_ca_system_score_gemma":0.000054789638,"threshold_uncertainty_score":0.9995062},"labels":[],"label_agreement":null},{"id":"W4402494964","doi":"10.1038/s41523-024-00679-7","title":"Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC","year":2024,"lang":"en","type":"article","venue":"npj Breast Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Breast Cancer Foundation; Breast Cancer Research Foundation","keywords":"Pembrolizumab; Oncology; Medicine; Internal medicine; Chemotherapy; Randomized controlled trial; Immunotherapy; Cancer","score_opus":0.008130626764051447,"score_gpt":0.27269681275941676,"score_spread":0.2645661859953653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402494964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98356164,0.0023171129,0.0001711635,0.006785038,0.00067169365,0.004439123,0.0013802991,0.00008932005,0.0005846266],"genre_scores_gemma":[0.99722683,0.00023702491,0.00013750826,0.0008879655,0.00032811536,0.00058811676,0.00011281582,0.000063363834,0.00041823197],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99830115,0.000079651465,0.0004895122,0.00044464524,0.00043022903,0.0002548303],"domain_scores_gemma":[0.9987448,0.00033710207,0.00017541742,0.00046845048,0.00021036017,0.000063908315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029061222,0.00025317914,0.0006805791,0.000061783896,0.00008140607,0.00003550354,0.00016261949,0.00007589122,0.0002512049],"category_scores_gemma":[0.000030134548,0.00013452153,0.00022883214,0.00026891282,0.00016063005,0.00009175974,0.000017059188,0.00015810186,0.0000023502414],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79609656,0.00038572671,0.0011788341,0.00006573508,0.0016233115,0.0000048304305,0.0042622644,0.000021095384,0.00030025849,0.0000077380555,0.0022464804,0.19380715],"study_design_scores_gemma":[0.8057844,0.0011803115,0.1784491,0.0008398788,0.0006991841,0.000007966366,0.0010655369,0.00042070827,0.0004471594,0.000046078956,0.010775531,0.00028412385],"about_ca_topic_score_codex":0.0021519146,"about_ca_topic_score_gemma":0.0003851362,"teacher_disagreement_score":0.19352302,"about_ca_system_score_codex":0.00024766824,"about_ca_system_score_gemma":0.0003430797,"threshold_uncertainty_score":0.5485629},"labels":[],"label_agreement":null},{"id":"W4402507417","doi":"10.1016/j.humimm.2024.110872","title":"Reconstitution of T cells at three months after stem cell transplant influences the discovery of predictive markers of relapse","year":2024,"lang":"en","type":"article","venue":"Human Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Stem cell; Medicine; Oncology; Cancer research; Immunology; Biology; Cell biology","score_opus":0.011610589878754672,"score_gpt":0.23442971164377044,"score_spread":0.22281912176501575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402507417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97602373,0.020949759,0.00007626193,0.000085774984,0.00042890958,0.0003891355,0.00014211168,0.000017921688,0.0018864071],"genre_scores_gemma":[0.99771917,0.0014061069,0.000013441056,0.000022775921,0.000019838146,0.000032084095,0.000011797322,0.000011076592,0.00076371274],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99895966,0.00007394768,0.0004897476,0.00018966914,0.00013933577,0.00014763052],"domain_scores_gemma":[0.99932647,0.00013163245,0.0001660501,0.0003155939,0.00004736551,0.000012898581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022846085,0.00012926501,0.0003236522,0.00012856365,0.000043518558,0.000005142737,0.00012955652,0.0001303939,0.00017375198],"category_scores_gemma":[0.0000021526198,0.000083855346,0.00020124984,0.00014508178,0.0011651386,0.0001036153,0.00003227,0.00016048801,0.0000036983065],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015391118,0.00012115579,0.009277323,0.00062948174,0.00093349366,0.00002600881,0.0028977182,0.000011697654,0.967761,0.00034658625,0.00020500469,0.0023994541],"study_design_scores_gemma":[0.0023545912,0.00343413,0.24674807,0.0017908864,0.00062514713,0.00007030544,0.0012790341,0.000053263593,0.7415238,0.00022263973,0.0017146963,0.00018342388],"about_ca_topic_score_codex":0.00033270774,"about_ca_topic_score_gemma":0.00017768765,"teacher_disagreement_score":0.23747076,"about_ca_system_score_codex":0.00007998749,"about_ca_system_score_gemma":0.00012197918,"threshold_uncertainty_score":0.4293002},"labels":[],"label_agreement":null},{"id":"W4402510707","doi":"10.1158/1055-9965.epi-24-0263","title":"Associations of Prostate Tumor Immune Landscape with Vigorous Physical Activity and Prostate Cancer Progression","year":2024,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill; National Cancer Institute; University of North Carolina at Chapel Hill; China Scholarship Council","keywords":"Prostate cancer; Medicine; Prostatectomy; Tumor microenvironment; Immune system; Prostate; Oncology; Cancer; Internal medicine; Tumor-infiltrating lymphocytes; Immunotherapy; Cancer research; Immunology","score_opus":0.03036564266910135,"score_gpt":0.38130270786343373,"score_spread":0.3509370651943324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402510707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94803554,0.044957735,0.00011519205,0.004882523,0.00037769967,0.0012574843,0.00015387284,0.0001184843,0.00010147358],"genre_scores_gemma":[0.99381864,0.0039179167,0.0005646772,0.00011518772,0.00015796465,0.0006127765,0.0001150676,0.00004133776,0.0006564087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812245,0.00033002874,0.0004408159,0.0005453176,0.0001727158,0.00038866873],"domain_scores_gemma":[0.99885315,0.00028937685,0.00040944852,0.00022763372,0.0001188684,0.00010151791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010080087,0.0002619424,0.00070615544,0.00015362163,0.00011196174,0.000015294294,0.000065825756,0.00013259715,0.00006894659],"category_scores_gemma":[0.0000795888,0.00018410811,0.00020797345,0.00040780156,0.00037600484,0.00020264377,0.000041677093,0.00025667567,0.0000022027282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007829452,0.00040934674,0.47323614,0.0009891636,0.0027139806,0.000027136879,0.00077238376,0.000010470612,0.070660815,0.00010081541,0.0020772922,0.441173],"study_design_scores_gemma":[0.0028806394,0.0012436953,0.97477585,0.0031057128,0.00077867374,0.0000514245,0.00010311724,0.0025190422,0.011598548,0.00070072105,0.001930906,0.00031167147],"about_ca_topic_score_codex":0.00077877124,"about_ca_topic_score_gemma":0.00020707268,"teacher_disagreement_score":0.5015397,"about_ca_system_score_codex":0.00023857619,"about_ca_system_score_gemma":0.00043709707,"threshold_uncertainty_score":0.7507711},"labels":[],"label_agreement":null},{"id":"W4402533801","doi":"10.1038/s41588-024-01899-0","title":"Five latent factors underlie response to immunotherapy","year":2024,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Ministerio de Economía y Competitividad; Centres de Recerca de Catalunya; Generalitat de Catalunya; European Commission; Institute for Research in Biomedicine","keywords":"Biology; Immunotherapy; Tumor microenvironment; Immune system; Oncology; Transcriptome; Cohort; Immunology; Computational biology; Cancer research; Bioinformatics; Internal medicine; Medicine; Genetics; Gene; Gene expression","score_opus":0.014919407951357636,"score_gpt":0.30722133498530424,"score_spread":0.2923019270339466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402533801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95111156,0.040981147,0.00013901034,0.0053739953,0.0014339132,0.00037784997,0.00003338565,0.00013671692,0.00041242305],"genre_scores_gemma":[0.9870068,0.0012853752,0.0009007489,0.0036107418,0.000213798,0.000009703657,0.00002010186,0.00004857732,0.0069041625],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989645,0.000040051487,0.00018336484,0.0002883565,0.00028632444,0.00023741234],"domain_scores_gemma":[0.99937296,0.00010091879,0.000018574547,0.0003380419,0.00006115778,0.00010835687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002099113,0.00017597656,0.00017806183,0.00017751583,0.00004985212,0.000055495733,0.0001121178,0.00032077273,0.00028316645],"category_scores_gemma":[0.000030821444,0.00013204127,0.0001619357,0.0004067241,0.000039331433,0.000019793037,0.000023965009,0.0004567524,0.00006786649],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023149185,0.00018725176,0.007306699,0.0001790057,0.0012837268,0.00029065987,0.006212441,0.000051278308,0.74046856,0.00010554628,0.07280129,0.14796436],"study_design_scores_gemma":[0.001090174,0.0009574979,0.17715548,0.00019387882,0.000060667546,0.000046842306,0.00018147904,0.00008309904,0.05230403,0.000104824074,0.76757544,0.00024657912],"about_ca_topic_score_codex":0.000012072041,"about_ca_topic_score_gemma":0.000008456376,"teacher_disagreement_score":0.69477415,"about_ca_system_score_codex":0.0001959267,"about_ca_system_score_gemma":0.00020338592,"threshold_uncertainty_score":0.5384487},"labels":[],"label_agreement":null},{"id":"W4402538375","doi":"10.1007/s10637-024-01461-z","title":"A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors","year":2024,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; MAPK/ERK pathway; Internal medicine; Pharmacology; Chemistry; Kinase; Immunotherapy; Cancer","score_opus":0.010907936607217268,"score_gpt":0.2797415372715782,"score_spread":0.2688336006643609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402538375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967935,0.00027565044,0.0000029895732,0.0013588599,0.0002486617,0.0009554428,0.000024476501,0.000034780664,0.00030563903],"genre_scores_gemma":[0.9985539,0.0000031456696,0.00013008495,0.00056516123,0.000119096665,0.00004262715,0.000033471737,0.00002412573,0.0005284102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985721,0.000044152475,0.0003799486,0.0002570318,0.0005879686,0.000158781],"domain_scores_gemma":[0.99944913,0.000052424697,0.000096946715,0.00022277854,0.0000812841,0.00009743266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109195695,0.00015381697,0.0002334903,0.00013369987,0.000047889655,0.00001969794,0.000110199784,0.00003922433,0.00004466946],"category_scores_gemma":[0.000045289456,0.00009822514,0.00006430607,0.00062492373,0.0001638509,0.00012671167,0.00003178002,0.00018809666,0.0000057413617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08954956,0.03971073,0.36529216,0.0024434465,0.0038239516,0.00034963895,0.16911326,0.003439579,0.0848235,0.0037812665,0.04626213,0.19141077],"study_design_scores_gemma":[0.20837918,0.010405254,0.74108815,0.005062025,0.00032201307,0.00003710401,0.0036214131,0.0012324449,0.021946304,0.0022134855,0.0049394243,0.0007532263],"about_ca_topic_score_codex":0.00024381292,"about_ca_topic_score_gemma":0.00006906859,"teacher_disagreement_score":0.37579596,"about_ca_system_score_codex":0.00020973178,"about_ca_system_score_gemma":0.0010960349,"threshold_uncertainty_score":0.40055048},"labels":[],"label_agreement":null},{"id":"W4402543961","doi":"10.1016/s0140-6736(24)01756-2","title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"National Cancer Institute; Genentech; Eisai; Daiichi-Sankyo; Chugai Pharmaceutical; Seagen; Incyte; BeiGene; Regeneron Pharmaceuticals; National Institutes of Health; Helsinn; Merck KGaA; Gilead Sciences; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Chemotherapy; Oncology; Stage (stratigraphy); Internal medicine; Lung cancer; Adjuvant; Neoadjuvant therapy; Placebo; Adjuvant chemotherapy; Cancer; Immunotherapy; Pathology; Breast cancer","score_opus":0.01784361033734386,"score_gpt":0.29256561267169545,"score_spread":0.27472200233435157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402543961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9685688,0.008112867,0.000498944,0.0034059796,0.0007053925,0.016958551,0.0003271058,0.00030775953,0.0011145946],"genre_scores_gemma":[0.98752505,0.0019409992,0.00017113429,0.002051534,0.0011022913,0.0029464469,0.00031345137,0.00030727862,0.0036417975],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99450326,0.00025524467,0.0012940696,0.001279744,0.0011969124,0.0014707667],"domain_scores_gemma":[0.9971208,0.00032018404,0.00054820086,0.001479393,0.00020240704,0.00032901525],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010600468,0.0011546256,0.003437875,0.00036934295,0.00026451182,0.0003516096,0.00078764994,0.00032754525,0.00068525947],"category_scores_gemma":[0.00001342384,0.00066512683,0.00057290867,0.0010188455,0.00034412256,0.00027920207,0.00006015766,0.0011107447,0.000021283779],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97208744,0.0015484282,0.0023130786,0.00040572992,0.002325994,0.00016905888,0.0035011761,0.00019864626,0.003097383,0.0000048790907,0.010468334,0.0038798503],"study_design_scores_gemma":[0.97394663,0.0044394317,0.0016361248,0.0013297573,0.0008800133,0.000024578685,0.00017963763,0.006547946,0.002673332,0.0000033126273,0.007358652,0.0009805729],"about_ca_topic_score_codex":0.0024063704,"about_ca_topic_score_gemma":0.0006525022,"teacher_disagreement_score":0.018956263,"about_ca_system_score_codex":0.00089782395,"about_ca_system_score_gemma":0.0011662841,"threshold_uncertainty_score":0.99957997},"labels":[],"label_agreement":null},{"id":"W4402552559","doi":"10.1016/j.annonc.2024.08.2330","title":"Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Hexal AG; Pharmacyclics; Genentech; Eisai; Pfizer; Innovent Biologics; Incyte; Moderna; SkylineDx; BeiGene; Les Laboratories Pierre Fabre; Sun Pharma; Regeneron Pharmaceuticals; Array BioPharma; Qbiotics; NGM Biopharmaceuticals; Daiichi Sankyo Europe; Gilead Sciences; Exelixis; Sanofi; Bristol-Myers Squibb; AstraZeneca; Amgen; GlaxoSmithKline","keywords":"Medicine; Ipilimumab; Pembrolizumab; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.07706815044565193,"score_gpt":0.41984728697892937,"score_spread":0.3427791365332774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402552559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98544776,0.0027793609,0.000026321257,0.0030926417,0.0019193842,0.0012759943,0.00007636872,0.000034769808,0.005347376],"genre_scores_gemma":[0.9964216,0.00021894026,0.00007245052,0.00025659965,0.0001429798,0.00009582729,0.000015756394,0.000025621333,0.002750246],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99869555,0.00008068111,0.00048870477,0.00026840207,0.00021112336,0.0002555508],"domain_scores_gemma":[0.9987817,0.00038930326,0.0001686063,0.0003894388,0.00022004747,0.000050915394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043713424,0.00015267803,0.00053736987,0.00011136405,0.000056015306,0.000005648382,0.0001941547,0.00012621598,0.00035088373],"category_scores_gemma":[0.00014857594,0.00010500513,0.00039791898,0.00028757472,0.00017800648,0.00005689032,0.00005268038,0.0001270633,0.0000068914524],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48491842,0.0036799433,0.00023603147,0.0004292964,0.0028368984,0.00004920513,0.0034607071,0.0000063083085,0.052664425,0.00053763035,0.053895243,0.39728588],"study_design_scores_gemma":[0.2688699,0.08788957,0.0022915385,0.00027520285,0.0008842009,0.00003284321,0.003848188,0.00013630392,0.061225556,0.0002815464,0.5739687,0.00029643776],"about_ca_topic_score_codex":0.00007907221,"about_ca_topic_score_gemma":0.0001304891,"teacher_disagreement_score":0.5200735,"about_ca_system_score_codex":0.00007221654,"about_ca_system_score_gemma":0.00049183145,"threshold_uncertainty_score":0.4281985},"labels":[],"label_agreement":null},{"id":"W4402559951","doi":"10.1016/j.annonc.2024.08.799","title":"737P Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Lenvatinib; Oncology; Internal medicine; Cancer; Immunotherapy; Thyroid cancer","score_opus":0.06545529475976408,"score_gpt":0.38070123633921205,"score_spread":0.31524594157944796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99035627,0.0004744457,0.0000078912835,0.0069600497,0.00012996119,0.00085103343,0.000026210915,0.000022695556,0.0011714557],"genre_scores_gemma":[0.9976709,0.0002067609,0.000019304473,0.0014543806,0.00008054046,0.00007932549,0.000028492386,0.000019235073,0.00044107225],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99837506,0.0004642085,0.00047933563,0.00022344924,0.00025609924,0.00020183122],"domain_scores_gemma":[0.9989522,0.00040644995,0.00017431425,0.00030100415,0.00013566343,0.000030335937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015083819,0.00013496817,0.00043494123,0.0002517363,0.00002806656,0.000010085688,0.00015595277,0.000077927456,0.0001481649],"category_scores_gemma":[0.00009609467,0.00008480638,0.00007693663,0.0005016055,0.00016070147,0.00008206881,0.000024340243,0.0002046089,0.00000651294],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35802913,0.0050209225,0.012026118,0.0006814739,0.0010337674,0.001224218,0.037666924,0.00000775074,0.47731557,0.0002615131,0.0032810457,0.10345158],"study_design_scores_gemma":[0.0145017905,0.030836673,0.8415105,0.00044354497,0.00014868482,0.00032332778,0.004380159,0.00013154415,0.011018234,0.000025035075,0.096487924,0.00019259604],"about_ca_topic_score_codex":0.0002026659,"about_ca_topic_score_gemma":0.00016186033,"teacher_disagreement_score":0.82948434,"about_ca_system_score_codex":0.00006216461,"about_ca_system_score_gemma":0.0006449936,"threshold_uncertainty_score":0.34583038},"labels":[],"label_agreement":null},{"id":"W4402560107","doi":"10.1016/j.annonc.2024.08.687","title":"620P Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with tumor mutational burden-high (TMB-H) and/or microsatellite instability-high (MSI-H) cancers: Results from an expansion cohort","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Microsatellite instability; Antibody; Cancer research; Oncology; Microsatellite; Genetics; Immunology; Gene; Allele","score_opus":0.019729019020304182,"score_gpt":0.3282027910193738,"score_spread":0.3084737719990696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942362,0.0014819839,0.0000058924365,0.0023440812,0.0001867076,0.0008340835,0.0007771985,0.000020242102,0.00011366084],"genre_scores_gemma":[0.9963868,0.0019687042,0.0003212186,0.00040582547,0.00006315266,0.000013197398,0.00078285363,0.000025737969,0.000032459728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770755,0.00015734868,0.0009293127,0.0006080425,0.0002926763,0.00030509403],"domain_scores_gemma":[0.9985967,0.0005522881,0.00025016637,0.00029236986,0.00020100916,0.00010743427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067056244,0.00023752841,0.0008293258,0.000298898,0.000043397988,0.000014990706,0.00009922371,0.00018672486,0.0000837791],"category_scores_gemma":[0.00011425345,0.00018084039,0.000058843456,0.0004511713,0.0005217122,0.00018683141,0.00005270223,0.0002329438,0.0000010571255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22349542,0.0028432775,0.6422626,0.00087209715,0.0008543722,0.00057990494,0.008500878,0.00028767416,0.016228702,0.00010463512,0.00037118755,0.103599265],"study_design_scores_gemma":[0.015647372,0.005853973,0.9674438,0.0013159075,0.0000676184,0.00002014242,0.00027659917,0.00021776158,0.0026054669,0.000059928654,0.006292559,0.00019884444],"about_ca_topic_score_codex":0.016788088,"about_ca_topic_score_gemma":0.005314083,"teacher_disagreement_score":0.32518125,"about_ca_system_score_codex":0.00016507703,"about_ca_system_score_gemma":0.00068824785,"threshold_uncertainty_score":0.9897592},"labels":[],"label_agreement":null},{"id":"W4402560186","doi":"10.1016/j.annonc.2024.08.1645","title":"1583P Trial-level surrogacy of intermediate endpoints in adjuvant or neoadjuvant use of immune checkpoint blockade","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Blockade; Immune checkpoint; Adjuvant; Oncology; Surrogate endpoint; Internal medicine; Neoadjuvant therapy; Cancer","score_opus":0.2130049803754344,"score_gpt":0.4213249497223415,"score_spread":0.20831996934690714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907993,0.0044853175,0.000016415268,0.0025313206,0.0008907759,0.00065887754,0.00011558414,0.00002113806,0.00048125745],"genre_scores_gemma":[0.9934981,0.0048741302,0.00028248178,0.00027459543,0.00010343717,0.000028669509,0.000025405707,0.000027507744,0.0008857065],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973756,0.00016077422,0.0016174157,0.00028001206,0.0002465116,0.00031968276],"domain_scores_gemma":[0.99831426,0.000593749,0.00044611088,0.0003782411,0.00019176585,0.00007586756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011986725,0.00019568107,0.0011638146,0.0004778851,0.000010222163,0.000005624022,0.00016735497,0.00022986202,0.0005506962],"category_scores_gemma":[0.0005279461,0.00014417787,0.0004262181,0.00046841823,0.00037210638,0.00011525409,0.0000892025,0.00025929083,0.000007607545],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23779835,0.0019468926,0.0011641071,0.001015093,0.0008909317,0.00051461277,0.002589173,0.0000050068024,0.44982243,0.00006919337,0.0021431795,0.30204102],"study_design_scores_gemma":[0.055036683,0.021131624,0.06710034,0.0024825253,0.00019617744,0.00014139317,0.000632051,0.00018983612,0.78869927,0.0001488266,0.063968636,0.00027264914],"about_ca_topic_score_codex":0.001098992,"about_ca_topic_score_gemma":0.00038084763,"teacher_disagreement_score":0.3388768,"about_ca_system_score_codex":0.000076657314,"about_ca_system_score_gemma":0.0008341151,"threshold_uncertainty_score":0.60297376},"labels":[],"label_agreement":null},{"id":"W4402560614","doi":"10.1016/j.annonc.2024.08.1481","title":"1415P Real-world data on the use of nivolumab plus chemotherapy for patients with metastatic GC/GEJC/EAC: A Canadian perspective","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Bristol-Myers Squibb (Canada); Princess Margaret Cancer Centre; BC Cancer Agency; University Health Network; Capital District Health Authority; Centre Hospitalier de l’Université de Montréal","funders":"Pfizer","keywords":"Medicine; Nivolumab; Oncology; Chemotherapy; Perspective (graphical); Internal medicine; Cancer; Immunotherapy; Artificial intelligence","score_opus":0.19213163807173256,"score_gpt":0.41356165648760523,"score_spread":0.22143001841587268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9099945,0.00091380556,0.000066045126,0.07969277,0.00034987723,0.0025042242,0.0018443485,0.0000350288,0.0045993854],"genre_scores_gemma":[0.9910248,0.0006796423,0.0008070866,0.006187259,0.000068418296,0.000051435192,0.00016048153,0.00003770187,0.0009831726],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99898213,0.00006803072,0.00025965084,0.00027640694,0.00016777229,0.0002460113],"domain_scores_gemma":[0.9983449,0.0005949038,0.0001359627,0.0005357501,0.00030753165,0.00008092632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034420536,0.0001301278,0.00039772352,0.00023150853,0.00004556706,0.000012004361,0.00019659878,0.000041981362,0.00013018133],"category_scores_gemma":[0.000118519,0.0000794507,0.00009374613,0.00035982468,0.00027983572,0.00008583356,0.000018835106,0.00011838439,0.0000025104239],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06273467,0.0018812708,0.0058077797,0.00050689356,0.008757014,0.000107229986,0.009896794,0.000023684725,0.0006901183,0.014258089,0.58053917,0.31479728],"study_design_scores_gemma":[0.0079244105,0.018446714,0.03595185,0.00049504463,0.00038042897,0.000011333091,0.0013917572,0.0008672019,0.001186896,0.00049182185,0.93260944,0.00024310588],"about_ca_topic_score_codex":0.1475653,"about_ca_topic_score_gemma":0.24019574,"teacher_disagreement_score":0.35207027,"about_ca_system_score_codex":0.0002792914,"about_ca_system_score_gemma":0.0014469667,"threshold_uncertainty_score":0.85811114},"labels":[],"label_agreement":null},{"id":"W4402560620","doi":"10.1016/j.annonc.2024.08.1444","title":"1389P Safety and effectiveness of immune checkpoint inhibitor therapy in patients with lung cancer and pre-existing autoimmune disease","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"Canadian Association of Medical Oncologists; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Disease; Autoimmune disease; Immunotherapy; Cancer; Immunology; Oncology; Immune system; Internal medicine","score_opus":0.022144275947253687,"score_gpt":0.3535493462548458,"score_spread":0.3314050703075921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96255136,0.035709053,0.000008432997,0.00081230665,0.0001234877,0.00059884985,0.00003203927,0.000013057758,0.00015143288],"genre_scores_gemma":[0.99355245,0.0062062074,0.000031282587,0.00008579188,0.000023853263,0.000035523495,0.00001549074,0.00001619869,0.000033198696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905634,0.00010172338,0.0003713068,0.00020554382,0.00011293104,0.00015215432],"domain_scores_gemma":[0.9994,0.00020585592,0.00011769536,0.00012337243,0.00010342045,0.00004962043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005774659,0.0001213927,0.00043532657,0.000119211814,0.000023487206,0.000005142529,0.000034966542,0.00007284432,0.000022474018],"category_scores_gemma":[0.00003419368,0.00008762293,0.000057678317,0.00019069582,0.000224943,0.000067170215,0.000031117375,0.00012102952,7.638781e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.092751004,0.0006435602,0.61819154,0.0029199454,0.0007108706,0.000027975948,0.0012680321,0.000010690454,0.035884436,0.000075043245,0.00003181487,0.24748506],"study_design_scores_gemma":[0.006103993,0.002943154,0.9798754,0.0022574808,0.00004722985,0.0000022544577,0.000024543178,0.00012165172,0.006974489,0.0000220509,0.0015384624,0.00008930438],"about_ca_topic_score_codex":0.00051849394,"about_ca_topic_score_gemma":0.000022408069,"teacher_disagreement_score":0.36168382,"about_ca_system_score_codex":0.00006089838,"about_ca_system_score_gemma":0.00024528886,"threshold_uncertainty_score":0.35731593},"labels":[],"label_agreement":null},{"id":"W4402560691","doi":"10.1016/j.annonc.2024.08.1111","title":"1053P The prognostic value of systemic inflammatory markers among patients receiving immune checkpoint inhibitors (ICIs): A population-based study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Population; Oncology; Value (mathematics); Immunology; Statistics","score_opus":0.024932605650777723,"score_gpt":0.31985794587829397,"score_spread":0.29492534022751626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994116,0.0020750714,0.000005905647,0.0007452056,0.0007196539,0.0018868892,0.000008657536,0.000045552762,0.00039708219],"genre_scores_gemma":[0.9994232,0.00007346651,0.000017620228,0.0001344257,0.000080128804,0.00015202747,0.000023904002,0.000028488885,0.00006672887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977371,0.00033162037,0.0011157247,0.00024481185,0.00034412506,0.00022660288],"domain_scores_gemma":[0.9983957,0.0005547792,0.00043056268,0.0003308524,0.00023811922,0.000049981496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016018848,0.00017030802,0.0004880957,0.00023461772,0.000057740446,0.000011285674,0.00014289832,0.00014244457,0.00004776581],"category_scores_gemma":[0.00033946056,0.000117779025,0.00029452387,0.0003977125,0.0001497622,0.00007237501,0.000042312502,0.00021350363,0.000003297293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021102678,0.00070669025,0.9532528,0.00080134574,0.00068432535,0.000026999329,0.0016151032,0.000076997734,0.0030008012,0.000012950339,0.0004826017,0.03722913],"study_design_scores_gemma":[0.00188966,0.0034920336,0.9892166,0.0015727616,0.00018663943,0.0000067981923,0.0010724739,0.00032196217,0.0017842834,0.000017396545,0.00033010298,0.00010926948],"about_ca_topic_score_codex":0.00082578225,"about_ca_topic_score_gemma":0.000093228125,"teacher_disagreement_score":0.037119858,"about_ca_system_score_codex":0.00013750183,"about_ca_system_score_gemma":0.00034232927,"threshold_uncertainty_score":0.48028895},"labels":[],"label_agreement":null},{"id":"W4402560830","doi":"10.1016/j.annonc.2024.08.917","title":"855P Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care South East; Northeast Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Head and neck squamous-cell carcinoma; TIGIT; Head and neck; Head and neck cancer; Oncology; Immunotherapy; Cancer research; Internal medicine; Cancer; Surgery","score_opus":0.03000376623706928,"score_gpt":0.3450944541369353,"score_spread":0.315090687899866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841198,0.010417181,0.0000023591788,0.0022798108,0.00008673238,0.001744025,0.0002481516,0.000043447435,0.0010584984],"genre_scores_gemma":[0.99717385,0.0020723334,0.0000650851,0.00034662124,0.000040188504,0.000021451897,0.00012637615,0.00003702227,0.000117092066],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9976675,0.0002033528,0.00093645044,0.0005569003,0.00023673399,0.00039905607],"domain_scores_gemma":[0.99817145,0.00080813136,0.0002970647,0.000463379,0.0001462939,0.00011369037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047315113,0.00031091148,0.0009546427,0.00020307674,0.00009778328,0.000015313834,0.00014613448,0.00018205127,0.000030890656],"category_scores_gemma":[0.000104259816,0.00020252845,0.00009688155,0.00056781457,0.0003611571,0.000112268615,0.00009362755,0.0003069118,0.0000012183489],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5841632,0.012395926,0.035489783,0.0005911011,0.0010902087,0.0013006919,0.02661639,0.00010512026,0.049375642,0.00003213485,0.0013165018,0.28752333],"study_design_scores_gemma":[0.26986384,0.100189626,0.5817933,0.0009179688,0.0006946524,0.00026799814,0.0020455392,0.0008527411,0.02063358,0.000024683588,0.022216348,0.0004996936],"about_ca_topic_score_codex":0.0030697118,"about_ca_topic_score_gemma":0.0016701544,"teacher_disagreement_score":0.5463035,"about_ca_system_score_codex":0.0000779085,"about_ca_system_score_gemma":0.00044823586,"threshold_uncertainty_score":0.825887},"labels":[],"label_agreement":null},{"id":"W4402560938","doi":"10.1016/j.annonc.2024.08.1268","title":"1209MO Neoadjuvant nivolumab and nivolumab+ipilimumab in resectable non-small cell lung cancer: Combined analysis of 5-year outcomes from NEOSTAR and CA209-159","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Nivolumab; Medicine; Ipilimumab; Oncology; Internal medicine; Lung cancer; Neoadjuvant therapy; Cancer; Immunotherapy","score_opus":0.031859783692050475,"score_gpt":0.3459355386364147,"score_spread":0.31407575494436424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96688586,0.027927548,0.00001008228,0.0029830383,0.00021248058,0.00037740407,0.00020391868,0.000020645626,0.0013790454],"genre_scores_gemma":[0.9872052,0.011351402,0.0002070027,0.00050682534,0.000037455986,0.000025418105,0.000052479707,0.000024319925,0.0005898762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828017,0.00009752207,0.0006469271,0.0004322307,0.00018668234,0.00035648147],"domain_scores_gemma":[0.99886084,0.00040050398,0.00018249387,0.00031472428,0.0001288345,0.0001125963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047409977,0.00020813507,0.0011883964,0.0006490263,0.000036502006,0.000016191903,0.00011602082,0.0002260086,0.00032549028],"category_scores_gemma":[0.000037125727,0.0001823416,0.0002172632,0.0007925237,0.00023186274,0.00008121514,0.00008620578,0.00023358302,0.0000010972213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010092708,0.0008295701,0.83271927,0.0011806476,0.007422696,0.0002891968,0.006073961,0.000060292707,0.05803295,0.00006569994,0.011134151,0.07209886],"study_design_scores_gemma":[0.016207792,0.005110312,0.93279505,0.0007265964,0.002852604,0.000008301904,0.0018612666,0.010106994,0.018943055,0.000155989,0.010790346,0.00044167822],"about_ca_topic_score_codex":0.030588994,"about_ca_topic_score_gemma":0.011769976,"teacher_disagreement_score":0.100075796,"about_ca_system_score_codex":0.000117219075,"about_ca_system_score_gemma":0.00046013045,"threshold_uncertainty_score":0.9758664},"labels":[],"label_agreement":null},{"id":"W4402561058","doi":"10.1016/j.annonc.2024.08.1064","title":"1005P Microbial ecosystem therapeutics 4 (MET4) treatment mediates a humoral response in patients treated with immune checkpoint inhibition (ICI)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Immune system; Pharmacology; Immunology","score_opus":0.051608571652888215,"score_gpt":0.33943059212143134,"score_spread":0.2878220204685431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930984,0.0018989611,0.000001854805,0.0038019135,0.00015436062,0.00062009954,0.000071053786,0.000046116824,0.00030723534],"genre_scores_gemma":[0.99832517,0.00073111407,0.000055157092,0.00040910777,0.000057528818,0.000053685704,0.00012076074,0.000028125656,0.00021937597],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99854845,0.00023428845,0.00055708544,0.00025245608,0.0001395073,0.00026823825],"domain_scores_gemma":[0.99934494,0.00015586197,0.00013939866,0.00019041203,0.00011889847,0.000050475428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004912766,0.0001956885,0.00051884307,0.0003205915,0.00002666756,0.000011651013,0.00004529811,0.00016811452,0.00008952397],"category_scores_gemma":[0.000012656478,0.00013384447,0.00016442094,0.00035495398,0.000103421655,0.00006168707,0.000013979549,0.000113315764,0.000014191818],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27013707,0.004365137,0.025987454,0.00034326923,0.0019599474,0.00067969016,0.0052547483,0.000008137674,0.5717373,0.000026078818,0.0005844144,0.118916765],"study_design_scores_gemma":[0.022896415,0.082050845,0.23453344,0.0012572801,0.00032369036,0.00013784204,0.00049395184,0.00010616176,0.60289073,0.00003213141,0.054919925,0.0003575881],"about_ca_topic_score_codex":0.00027317714,"about_ca_topic_score_gemma":0.00028837755,"teacher_disagreement_score":0.24724065,"about_ca_system_score_codex":0.0003941342,"about_ca_system_score_gemma":0.00039228663,"threshold_uncertainty_score":0.54580194},"labels":[],"label_agreement":null},{"id":"W4402561069","doi":"10.1016/j.annonc.2024.08.1055","title":"996MO Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/metastatic solid tumors: Data from phase I dose escalation","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Solid tumor; Phase (matter); Oncology; Nuclear medicine; Internal medicine; Cancer; Immunotherapy","score_opus":0.06164670606560626,"score_gpt":0.3922550541486538,"score_spread":0.33060834808304757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995673,0.00141207,0.00012914829,0.0015463411,0.00006946765,0.00063164823,0.00014328804,0.00002184427,0.00037319874],"genre_scores_gemma":[0.9972342,0.0004501581,0.0008062583,0.00036855476,0.000020541947,0.00002910327,0.0010357376,0.000022833854,0.00003259636],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986152,0.000100901605,0.0004496928,0.00040024932,0.00021479915,0.00021913585],"domain_scores_gemma":[0.999161,0.00019561267,0.0001637538,0.00031764168,0.0001035159,0.000058487007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033478145,0.0001614509,0.00047482466,0.00028611175,0.000021305405,0.000014839521,0.00010748932,0.000068282236,0.000056507964],"category_scores_gemma":[0.00006819942,0.00012400639,0.000020504755,0.0004306225,0.00015903886,0.00035161915,0.0000494045,0.00018273373,0.0000031138354],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10822943,0.0070790565,0.061588854,0.0006261285,0.00045182678,0.0006322208,0.0019316652,0.000085666084,0.006946282,0.00006729377,0.0014565578,0.81090504],"study_design_scores_gemma":[0.11799198,0.03807082,0.8185046,0.0032653082,0.00022784078,0.00009932813,0.00057410885,0.01121471,0.0034977633,0.0006673004,0.0054221116,0.00046416355],"about_ca_topic_score_codex":0.00042805675,"about_ca_topic_score_gemma":0.00084477384,"teacher_disagreement_score":0.81044084,"about_ca_system_score_codex":0.00008512429,"about_ca_system_score_gemma":0.00025510378,"threshold_uncertainty_score":0.50568336},"labels":[],"label_agreement":null},{"id":"W4402561187","doi":"10.1016/j.annonc.2024.08.1126","title":"1068P Phase II trial of fecal microbiota transplantation (FMT) plus immune checkpoint inhibition (ICI) in advanced non-small cell lung cancer and cutaneous melanoma (FMT-LUMINate)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Royal Victoria Hospital; McGill University Health Centre; Hôtel-Dieu de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Fecal bacteriotherapy; Melanoma; Immune checkpoint; Cancer; Transplantation; Internal medicine; Oncology; Lung cancer; Immunotherapy; Cancer research","score_opus":0.02559648026178742,"score_gpt":0.35027308941468865,"score_spread":0.32467660915290125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868083,0.008770934,0.00005032848,0.0019794619,0.00048128664,0.000972476,0.00010160088,0.000018788165,0.0008167953],"genre_scores_gemma":[0.98809606,0.01095881,0.00015244848,0.00018856031,0.00009815432,0.000061345185,0.00009612123,0.000022455803,0.00032605918],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99853176,0.000066499924,0.00074619893,0.0002945057,0.00011169762,0.00024936287],"domain_scores_gemma":[0.99938977,0.00011478576,0.00021056403,0.00013718099,0.00009293804,0.000054735974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037323756,0.00017877684,0.00059842394,0.00025871096,0.000034755743,0.00000621749,0.00005625089,0.00023684533,0.00010696297],"category_scores_gemma":[0.000013185661,0.00016383873,0.0001698294,0.00025014364,0.00016027474,0.00007273105,0.000022005475,0.00021048899,0.0000010955662],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12721841,0.0008418205,0.00004067198,0.0011420747,0.00013546107,0.0003738968,0.0032323352,0.000013668642,0.7981698,0.000008680032,0.00018496429,0.06863821],"study_design_scores_gemma":[0.10053504,0.021617547,0.00070815923,0.0012827836,0.0002558212,0.00037546144,0.0003587808,0.00079659704,0.8699051,0.000024795128,0.0039274995,0.00021241436],"about_ca_topic_score_codex":0.0008082099,"about_ca_topic_score_gemma":0.00042335427,"teacher_disagreement_score":0.071735285,"about_ca_system_score_codex":0.00015092736,"about_ca_system_score_gemma":0.0004685812,"threshold_uncertainty_score":0.66811496},"labels":[],"label_agreement":null},{"id":"W4402561191","doi":"10.1016/j.annonc.2024.08.1077","title":"1018P Leveraging innate and adaptive immunity with AFM24 and atezolizumab in metastatic gastric cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"","keywords":"Atezolizumab; Medicine; Innate immune system; Acquired immune system; Cancer; Immunity; Immunology; Oncology; Immunotherapy; Internal medicine; Immune system; Nivolumab","score_opus":0.09142715196903854,"score_gpt":0.3835679807072185,"score_spread":0.2921408287381799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96535075,0.029158676,0.00003395198,0.0039274027,0.00006261608,0.00019494635,0.0000132040705,0.0000142197305,0.0012442414],"genre_scores_gemma":[0.9906873,0.008080877,0.00030076923,0.00071191415,0.000019759449,0.000020693062,0.0000030773904,0.0000116092115,0.00016396368],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992889,0.00007859925,0.0001988659,0.00017087656,0.000082677594,0.00018003854],"domain_scores_gemma":[0.9996224,0.00013084162,0.000054733606,0.00008541092,0.000059703743,0.00004689141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032040037,0.000104264145,0.00032001772,0.00022405779,0.000024564602,0.000008863015,0.000032139975,0.000045871333,0.00006318906],"category_scores_gemma":[0.000014992187,0.00007688769,0.000028326562,0.0003201577,0.00020759233,0.00007552516,0.000028527718,0.00018209801,7.5838767e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010880691,0.00023974774,0.010001942,0.00056247925,0.0011271491,0.00060340547,0.007398876,0.000012984636,0.009865066,0.00027561173,0.0011506319,0.9578814],"study_design_scores_gemma":[0.022416674,0.031039959,0.80990416,0.0043286546,0.00083027425,0.0028867775,0.010684798,0.0033914375,0.015114811,0.0019630059,0.09657727,0.00086217234],"about_ca_topic_score_codex":0.002268033,"about_ca_topic_score_gemma":0.00058759085,"teacher_disagreement_score":0.95701927,"about_ca_system_score_codex":0.000055101962,"about_ca_system_score_gemma":0.0003164092,"threshold_uncertainty_score":0.34286028},"labels":[],"label_agreement":null},{"id":"W4402561249","doi":"10.1016/j.annonc.2024.08.1005","title":"944TiP Petosemtamab plus pembrolizumab vs. pembrolizumab alone for first-line (1L) treatment of recurrent/metastatic (r/m) PD-L1–positive head and neck squamous cell carcinoma (HNSCC): A randomized, open-label, phase III trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Genentech; Oncolytics Biotech; Coherus Biosciences; Celgene; Rakuten Medical; Pfizer; Incyte; Break Through Cancer; Relay Therapeutics; Seagen; Agios Pharmaceuticals; BeiGene; Tizona Therapeutics; Eisai; Eli Lilly and Company; National Comprehensive Cancer Network; Sanofi; Exelixis; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; Gilead Sciences; AbbVie; Amgen; AstraZeneca; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Head and neck squamous-cell carcinoma; Oncology; Internal medicine; Open label; Head and neck; Head and neck cancer; Immunotherapy; Randomized controlled trial; Cancer; Surgery","score_opus":0.10361793668828055,"score_gpt":0.41855865730273056,"score_spread":0.31494072061445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9497259,0.03402924,0.00018924601,0.004814763,0.0008816429,0.008035898,0.00069992687,0.00004089894,0.0015824311],"genre_scores_gemma":[0.9893983,0.0066198255,0.00056894217,0.00050611177,0.00031983218,0.0010773275,0.0003545314,0.00007038642,0.0010847637],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99643326,0.00038411445,0.0015352594,0.00073287217,0.0003102482,0.0006042246],"domain_scores_gemma":[0.99635434,0.0019908622,0.00059371063,0.00045239212,0.0003672324,0.00024143621],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008941889,0.00051939173,0.003094041,0.00040162035,0.00013632546,0.000045332803,0.0002400368,0.00024361895,0.00017353134],"category_scores_gemma":[0.00019047108,0.00040278825,0.0005950039,0.00036576384,0.00056452147,0.00016564899,0.000092915485,0.0001867191,0.000005401442],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9021807,0.00805424,0.000005871255,0.00094824,0.0011509409,0.0002533984,0.0024164324,0.0000034941097,0.0021425146,0.00014875094,0.0036556798,0.07903976],"study_design_scores_gemma":[0.8311668,0.1318666,0.00003944016,0.0002924083,0.0016685768,0.00026525863,0.00015337043,0.002059632,0.013201222,0.00023742343,0.018753413,0.00029582714],"about_ca_topic_score_codex":0.0014122832,"about_ca_topic_score_gemma":0.0003574168,"teacher_disagreement_score":0.12381236,"about_ca_system_score_codex":0.00035592326,"about_ca_system_score_gemma":0.0014088036,"threshold_uncertainty_score":0.9998424},"labels":[],"label_agreement":null},{"id":"W4402561315","doi":"10.1016/j.annonc.2024.08.970","title":"909P Immunoscore-IC predicts nivolumab efficacy as adjuvant treatment after salvage surgery in head and neck cancer squamous cell carcinoma: The ADJORL1 trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Nivolumab; Head and neck cancer; Salvage surgery; Oncology; Adjuvant; Head and neck squamous-cell carcinoma; Basal cell; Squamous cell cancer; Salvage therapy; Internal medicine; Head and neck; Surgery; Cancer; Immunotherapy; Radiation therapy; Chemotherapy","score_opus":0.05736057747459269,"score_gpt":0.3652727655285547,"score_spread":0.30791218805396203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89362603,0.096835844,3.8296116e-7,0.00616277,0.001008608,0.0009525985,0.00004645325,0.000029832127,0.0013374472],"genre_scores_gemma":[0.9890334,0.007973431,0.000006594037,0.0013274127,0.00035722114,0.00029401606,0.000020837653,0.000031866108,0.0009551973],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99826497,0.00018447726,0.000585288,0.00037144817,0.00019168686,0.0004021037],"domain_scores_gemma":[0.99867666,0.00072932645,0.00011926028,0.00032845765,0.000055962344,0.00009033932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004562482,0.00023999326,0.0007104953,0.00021255575,0.000045568228,0.000019354935,0.00008774084,0.00019992942,0.00031457038],"category_scores_gemma":[0.000051943614,0.00015511175,0.00029328154,0.0002891863,0.00025808573,0.00006429253,0.000041541272,0.00021442251,0.000013189862],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38843834,0.0035426975,0.03652952,0.00058306084,0.00058781455,0.0023636508,0.007461785,0.0000052092187,0.007621559,0.000018563649,0.021333102,0.5315147],"study_design_scores_gemma":[0.095514126,0.02970228,0.643413,0.0006102393,0.00047054683,0.00021385284,0.000443115,0.00007688734,0.0144787,0.00006306409,0.21460216,0.00041199982],"about_ca_topic_score_codex":0.006593576,"about_ca_topic_score_gemma":0.0014095287,"teacher_disagreement_score":0.6068835,"about_ca_system_score_codex":0.00023514128,"about_ca_system_score_gemma":0.0011423599,"threshold_uncertainty_score":0.99675584},"labels":[],"label_agreement":null},{"id":"W4402565510","doi":"10.1016/j.annonc.2024.08.2291","title":"LBA50 Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Eli Lilly Japan; MSD K.K.; Chugai Pharmaceutical; Novartis Pharma; University of Texas MD Anderson Cancer Center; EMD Serono; Bristol-Myers Squibb; Samsung; Genentech; European Society for Medical Oncology; Seagen; Pfizer; Moderna; Mirati Therapeutics; Les Laboratories Pierre Fabre; Eli Lilly and Company; Ono Pharmaceutical; Jazz Pharmaceuticals; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Regeneron Pharmaceuticals; AstraZeneca; American Society of Clinical Oncology; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Spectrum Pharmaceuticals; Amgen; Takeda Pharmaceutical Company","keywords":"Medicine; Nivolumab; Internal medicine; Perioperative; Placebo; Oncology; Phases of clinical research; Clinical trial; Surgery; Cancer; Immunotherapy; Pathology","score_opus":0.0800987718462758,"score_gpt":0.44196014387362176,"score_spread":0.361861372027346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877048,0.0014524775,0.000008629839,0.0058872174,0.00046027807,0.0013241037,0.000072331204,0.00003446521,0.003055661],"genre_scores_gemma":[0.9957154,0.0006929882,0.000059939113,0.0024608648,0.00018084722,0.00008683126,0.00006221846,0.000028737051,0.0007121701],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976882,0.00047282944,0.0007616962,0.00045409775,0.00028835333,0.0003348286],"domain_scores_gemma":[0.99867344,0.00048073335,0.00015945859,0.0004033755,0.00020071883,0.00008226388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012305103,0.00020296838,0.0006928745,0.00010511197,0.00008018165,0.000029123326,0.00021033143,0.00016743103,0.0006589789],"category_scores_gemma":[0.000120692755,0.00012207571,0.00013787801,0.00039419753,0.00033702044,0.00012914439,0.000077983386,0.000491187,0.000037406116],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30123362,0.016358607,0.15179226,0.00008641701,0.003888652,0.0007302275,0.020527756,0.00000854518,0.0016672417,0.00009456264,0.061976038,0.4416361],"study_design_scores_gemma":[0.18768452,0.09993023,0.2800829,0.0010355831,0.00052825303,0.000028357981,0.010435665,0.0005747787,0.0027509192,0.000077231896,0.416262,0.00060955225],"about_ca_topic_score_codex":0.0018145465,"about_ca_topic_score_gemma":0.0020997496,"teacher_disagreement_score":0.4410265,"about_ca_system_score_codex":0.0000967955,"about_ca_system_score_gemma":0.0006301419,"threshold_uncertainty_score":0.7215357},"labels":[],"label_agreement":null},{"id":"W4402565645","doi":"10.1016/j.annonc.2024.08.2285","title":"LBA44 Pembrolizumab vs ipilimumab in advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Ipilimumab; Oncology; Melanoma; Internal medicine; Phases of clinical research; Immunotherapy; Cancer research; Chemotherapy; Cancer","score_opus":0.047359941220065,"score_gpt":0.39199009921779376,"score_spread":0.3446301579977288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98451656,0.0029410687,0.0000035620956,0.003410596,0.00075558637,0.00081253354,0.00002757127,0.000027741507,0.007504755],"genre_scores_gemma":[0.99618375,0.000376941,0.00002731121,0.00048572037,0.000080109545,0.000048123027,0.000008426279,0.000023146013,0.0027664953],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99837136,0.00016489695,0.00063377497,0.00029502352,0.00025712364,0.00027784347],"domain_scores_gemma":[0.9990204,0.00019945072,0.00016658056,0.00042919343,0.00013374309,0.00005064615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005845426,0.00016544989,0.0006439754,0.0002013663,0.000033521563,0.0000055416203,0.00021839143,0.00014358725,0.00059048785],"category_scores_gemma":[0.00009782741,0.00011490479,0.00027589628,0.0005329609,0.00019241024,0.000069992675,0.000074650445,0.00022487949,0.000015057528],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2888442,0.011419751,0.010312871,0.00071521435,0.0023510803,0.00054516684,0.01294975,0.00001920403,0.11012305,0.0005174463,0.06373679,0.49846548],"study_design_scores_gemma":[0.25842094,0.08479277,0.088899866,0.0011537861,0.0006617111,0.00017521212,0.007562038,0.000225002,0.09053717,0.0006907311,0.4662353,0.00064547325],"about_ca_topic_score_codex":0.0003091084,"about_ca_topic_score_gemma":0.00047795865,"teacher_disagreement_score":0.49782002,"about_ca_system_score_codex":0.00009232125,"about_ca_system_score_gemma":0.0005165167,"threshold_uncertainty_score":0.6465428},"labels":[],"label_agreement":null},{"id":"W4402565731","doi":"10.1016/j.annonc.2024.08.2284","title":"LBA43 10-y survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.09439874432614945,"score_gpt":0.4237533734174347,"score_spread":0.3293546290912852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97854316,0.0043489323,0.000011311621,0.009351766,0.0012942608,0.00062140485,0.00010479567,0.000030543342,0.005693811],"genre_scores_gemma":[0.9965186,0.0011685384,0.00006341286,0.0007230716,0.00019105613,0.000041220126,0.000046203542,0.000020245394,0.0012276174],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983563,0.00016886035,0.0007330763,0.0002564617,0.00023150095,0.0002538155],"domain_scores_gemma":[0.9985706,0.0007502846,0.00019573329,0.00034774444,0.0000887679,0.0000468452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078207627,0.00016155338,0.00085992157,0.00011928724,0.000025378518,0.000006848468,0.00019098379,0.00017047368,0.00085305236],"category_scores_gemma":[0.00014308917,0.000107402615,0.00030151897,0.00027392147,0.00022661759,0.00006895565,0.000048561054,0.00019171415,0.000013708101],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5101073,0.001477329,0.00077050674,0.00011993158,0.0012253718,0.00017364544,0.0022979989,0.0000062760373,0.027274895,0.0002325025,0.009869128,0.44644514],"study_design_scores_gemma":[0.5512246,0.023478867,0.01702151,0.0004903271,0.00029956343,0.0000221098,0.0017336432,0.00033816314,0.030604994,0.0006343339,0.37379807,0.0003538334],"about_ca_topic_score_codex":0.0012679714,"about_ca_topic_score_gemma":0.0006285516,"teacher_disagreement_score":0.4460913,"about_ca_system_score_codex":0.00009169126,"about_ca_system_score_gemma":0.0005745297,"threshold_uncertainty_score":0.9340325},"labels":[],"label_agreement":null},{"id":"W4402566013","doi":"10.1016/j.annonc.2024.08.1940","title":"1845P The impact of body mass index (BMI) on immune-related adverse events (irAEs) and acute care use among patients receiving immune checkpoint inhibitors (ICIs): A population-based study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; University Health Network","funders":"Sanofi; AstraZeneca; Ipsen; Pfizer","keywords":"Medicine; Body mass index; Adverse effect; Immune system; Population; Oncology; Internal medicine; Immunology; Environmental health","score_opus":0.025331950189818757,"score_gpt":0.35034321842931576,"score_spread":0.325011268239497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402566013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970436,0.0006312117,0.0000018210185,0.00028908244,0.0004113155,0.0013856323,0.000048703434,0.000033483633,0.00015512716],"genre_scores_gemma":[0.999489,0.00013227599,0.000008630966,0.00007547725,0.000029257086,0.000048463393,0.000106839194,0.000035619836,0.00007440524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978143,0.00025045272,0.0010410558,0.00030661383,0.0003178504,0.00026971684],"domain_scores_gemma":[0.9985631,0.0002461295,0.0004788911,0.0003886961,0.00025328825,0.000069906586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060536177,0.00024700185,0.0005938606,0.0003151049,0.00008362557,0.0000099715335,0.00012459836,0.00021237493,0.000058729005],"category_scores_gemma":[0.00013314222,0.00016409374,0.00048836134,0.0004493021,0.00012728326,0.00014852338,0.000051641146,0.00032700208,0.0000021548533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054487097,0.0008238548,0.97003484,0.000101485464,0.0018636645,0.000036329395,0.001706591,0.00019035292,0.0045156246,0.0000016138625,0.00012747105,0.015149464],"study_design_scores_gemma":[0.004687179,0.007859264,0.98315215,0.000557534,0.00023529973,0.0000034163115,0.0008576755,0.00031903372,0.0021141386,0.000014509425,0.00005782637,0.00014198302],"about_ca_topic_score_codex":0.0053271563,"about_ca_topic_score_gemma":0.00015832386,"teacher_disagreement_score":0.015007481,"about_ca_system_score_codex":0.00024062755,"about_ca_system_score_gemma":0.00022179441,"threshold_uncertainty_score":0.8053102},"labels":[],"label_agreement":null},{"id":"W4402600880","doi":"10.3332/ecancer.2024.1771","title":"Liver metastasis and resistance to immunotherapy in microsatellite stable colorectal cancer. A literature review","year":2024,"lang":"en","type":"review","venue":"ecancermedicalscience","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Colorectal cancer; Metastasis; Immunotherapy; Microsatellite instability; Cancer; Oncology; Internal medicine; Microsatellite; Cancer research; Gene; Genetics; Biology","score_opus":0.024928137271133965,"score_gpt":0.35711540833666866,"score_spread":0.3321872710655347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402600880","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003116433,0.9938884,0.0000065449663,0.0018085685,0.00069635373,0.0026028,0.0003939983,0.00006963779,0.0005025491],"genre_scores_gemma":[0.000004144011,0.99099874,0.0006666609,0.0036853852,0.00023294445,0.0011215406,0.00004609232,0.000079372876,0.0031651012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957362,0.00019516637,0.0011352974,0.0013674711,0.0007810309,0.0007848663],"domain_scores_gemma":[0.9984993,0.00015562946,0.0002706345,0.00056558405,0.00011056416,0.00039831456],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015090081,0.0007096851,0.0026683921,0.000532415,0.00011360858,0.00016761827,0.0005330132,0.00033814515,0.00046552328],"category_scores_gemma":[0.00014916559,0.00048638217,0.00048659972,0.004622321,0.00059296144,0.00016337213,0.0001646037,0.0009990892,0.00005435879],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018875858,0.00004861063,0.000007214766,0.10479858,0.00018405836,0.00038809355,0.00033997663,1.500956e-8,0.000066460496,0.00002694627,0.02043961,0.8735117],"study_design_scores_gemma":[0.00028278597,0.00009012178,0.00003092032,0.33385646,0.0004649511,0.00018639186,0.0000057197153,0.000001495047,0.000013437363,0.000011101121,0.6647205,0.0003361586],"about_ca_topic_score_codex":0.0001592974,"about_ca_topic_score_gemma":0.0004283243,"teacher_disagreement_score":0.8731755,"about_ca_system_score_codex":0.0009954445,"about_ca_system_score_gemma":0.0021536024,"threshold_uncertainty_score":0.9997588},"labels":[],"label_agreement":null},{"id":"W4402625008","doi":"10.1016/j.canrad.2024.07.002","title":"Combination of radiotherapy and immunotherapy in duality with the protumoral action of radiation","year":2024,"lang":"en","type":"review","venue":"Cancer/Radiothérapie","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Fonds de Recherche du Québec - Santé","keywords":"Radiation therapy; Duality (order theory); Action (physics); Immunotherapy; Radiation; Medicine; Cancer research; Immunology; Physics; Radiology; Mathematics; Immune system; Pure mathematics; Optics","score_opus":0.04364176768618127,"score_gpt":0.3728817033667376,"score_spread":0.3292399356805563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402625008","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032459619,0.9929254,0.00005166768,0.0005936243,0.00030428375,0.0026934731,0.00006839466,0.000029344807,0.00008784915],"genre_scores_gemma":[0.0030646024,0.9957635,0.000078334146,0.00007512926,0.00017076937,0.00049465895,0.00005535647,0.0000791007,0.00021855558],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980617,0.00020063715,0.0007797256,0.00039431514,0.00034968057,0.00021392592],"domain_scores_gemma":[0.99861735,0.000114866714,0.000711813,0.00043531926,0.000078263736,0.00004238231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006137745,0.00039200234,0.0016172209,0.0003953204,0.000041825424,0.000025879546,0.00015288529,0.00025367198,0.000070230206],"category_scores_gemma":[0.000009652464,0.00023222438,0.0003146249,0.0009729855,0.0003733996,0.000104910425,0.000012558657,0.00043304465,4.36739e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010529706,0.00012746385,0.00014226776,0.019198079,0.0010526475,0.000005185816,0.00063355826,0.0000011195114,0.000428429,0.00016170123,0.00051298254,0.9766836],"study_design_scores_gemma":[0.0053139906,0.0012837631,0.002343875,0.020594522,0.0013619495,0.00013857428,0.00010626436,0.00006757363,0.00046777428,0.00003688368,0.9678707,0.00041409075],"about_ca_topic_score_codex":0.00042143796,"about_ca_topic_score_gemma":0.00008974813,"teacher_disagreement_score":0.9762695,"about_ca_system_score_codex":0.00074898347,"about_ca_system_score_gemma":0.00081535487,"threshold_uncertainty_score":0.9469835},"labels":[],"label_agreement":null},{"id":"W4402642160","doi":"10.3390/curroncol31090407","title":"Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Under-Represented by Clinical Trials","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"CancerCare Manitoba Foundation; Canadian Institutes of Health Research; Jazz Pharmaceuticals; Genome Canada; AstraZeneca; Manitoba Medical Service Foundation; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Clinical trial; Lung cancer; Immunotherapy; Oncology; Internal medicine; Disease; Cancer; ROS1; Adenocarcinoma","score_opus":0.20640421944252138,"score_gpt":0.5402252695100284,"score_spread":0.33382105006750695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402642160","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021848422,0.98535335,0.000069978945,0.00018968972,0.0060317987,0.005539162,0.00028201737,0.000066255314,0.0002829072],"genre_scores_gemma":[0.000050900544,0.99619794,0.000060560753,0.00021170803,0.0004927408,0.0012459749,0.0008837554,0.00014944705,0.00070698594],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.993715,0.0013793047,0.0028930278,0.0010723491,0.00034671757,0.0005936049],"domain_scores_gemma":[0.9967565,0.000957764,0.0012684094,0.000686594,0.00014623521,0.00018449398],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021891904,0.00076058996,0.0054698344,0.00039633331,0.00004503853,0.000030630974,0.00035448882,0.00083067705,0.0003839503],"category_scores_gemma":[0.00010929607,0.00048057467,0.0012786112,0.0007458336,0.00021132176,0.00004998459,0.00009567547,0.0017365484,0.000039409446],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003523768,0.001963971,0.002650739,0.0102837365,0.0014678651,0.000016742491,0.00005579244,3.711581e-7,0.0000033518854,0.0000012356624,0.029365275,0.95066714],"study_design_scores_gemma":[0.017694257,0.0016669877,0.00046399463,0.022764232,0.0031336811,0.000005421467,0.000021650618,0.000011438968,0.0000019820297,0.000002476943,0.95375735,0.00047650907],"about_ca_topic_score_codex":0.00006996584,"about_ca_topic_score_gemma":0.00006448186,"teacher_disagreement_score":0.95019066,"about_ca_system_score_codex":0.0015036211,"about_ca_system_score_gemma":0.0026485706,"threshold_uncertainty_score":0.9997646},"labels":[],"label_agreement":null},{"id":"W4402713089","doi":"10.1101/2024.09.12.612675","title":"A Comprehensive Proteogenomic and Spatial Analysis of Innate and Acquired Resistance of Metastatic Melanoma to Immune Checkpoint Blockade Therapies","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Blockade; Metastatic melanoma; Immune checkpoint; Innate immune system; Melanoma; Medicine; Cancer research; Immune system; Immunology; Internal medicine; Receptor","score_opus":0.015726420577999896,"score_gpt":0.24648262711532226,"score_spread":0.23075620653732237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402713089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95926154,0.0378711,0.00016210103,0.00055756007,0.00016602369,0.0014239961,0.0004965798,0.00005821171,0.0000028633706],"genre_scores_gemma":[0.9944853,0.0014792276,0.0036708303,0.000067878806,0.000051339266,0.0001636069,9.365505e-7,0.0000708199,0.000010042176],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99762416,0.00011451984,0.00092927186,0.0007373188,0.0003171194,0.0002776056],"domain_scores_gemma":[0.99799377,0.00007173228,0.000541798,0.0008307815,0.00041552048,0.00014642994],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004488205,0.00044553023,0.0014764037,0.0008645734,0.000048579113,0.0000504631,0.00017876201,0.0001958469,0.00003337593],"category_scores_gemma":[0.000054835706,0.00040560454,0.00029997173,0.001024852,0.00031869064,0.000029308974,0.00039124105,0.000255104,0.0000014160199],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018110421,0.00008703768,0.0021934628,0.0029178332,0.009016603,0.000034532906,0.00025567503,0.0000081994,0.9836193,0.000023601817,0.0000065343766,0.000026225787],"study_design_scores_gemma":[0.0011685404,0.00022761761,0.360242,0.0012747565,0.0036013292,5.980337e-8,0.000028231241,0.00024457282,0.63223433,0.000004685614,0.00061586953,0.00035797452],"about_ca_topic_score_codex":0.0006570042,"about_ca_topic_score_gemma":0.0000416783,"teacher_disagreement_score":0.35804856,"about_ca_system_score_codex":0.00013253956,"about_ca_system_score_gemma":0.00036482234,"threshold_uncertainty_score":0.9998396},"labels":[],"label_agreement":null},{"id":"W4402737357","doi":"10.14740/wjon1924","title":"Prognostic Implications of Timing of Immunotherapy in Stage IV Non-Small Cell Lung Cancer","year":2024,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Novocure; Gilead Sciences","keywords":"Medicine; Stage (stratigraphy); Immunotherapy; Lung cancer; Oncology; Internal medicine; Cancer; Intensive care medicine","score_opus":0.026579638611842836,"score_gpt":0.3532163511755857,"score_spread":0.3266367125637429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402737357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95493644,0.03585535,0.00043835802,0.0035816915,0.0005427763,0.0003679688,0.000015496309,0.0000061266915,0.0042557768],"genre_scores_gemma":[0.99306935,0.0041015684,0.001168766,0.00024107726,0.00012040166,0.00001589068,0.0000015099574,0.000018880657,0.0012625617],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988198,0.00005018737,0.0007576046,0.000099988625,0.000114105474,0.00015826015],"domain_scores_gemma":[0.9990284,0.00025234185,0.0004014805,0.00013002055,0.00014460053,0.000043189877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004885631,0.00009476469,0.0004399021,0.0005205448,0.000015629756,0.000005033581,0.00012432395,0.00006514132,0.00051988184],"category_scores_gemma":[0.000015067533,0.00007562004,0.00017576992,0.0005306793,0.000089699024,0.000048355338,0.000014247251,0.00029370526,7.091037e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029799608,0.00067573437,0.2116173,0.00091631344,0.0006193514,0.00014332995,0.0027961158,0.000107572814,0.6205135,0.00010291286,0.0036459297,0.15588199],"study_design_scores_gemma":[0.011436408,0.0036324642,0.7785362,0.0047237063,0.00054932595,0.00033381453,0.0006803188,0.00096275733,0.044761375,0.00012444245,0.15398164,0.000277517],"about_ca_topic_score_codex":0.00018661315,"about_ca_topic_score_gemma":0.00047520097,"teacher_disagreement_score":0.5757521,"about_ca_system_score_codex":0.0003360272,"about_ca_system_score_gemma":0.0010546829,"threshold_uncertainty_score":0.5692342},"labels":[],"label_agreement":null},{"id":"W4402908971","doi":"10.1016/j.ijrobp.2024.07.2293","title":"Cross-Cancer Analysis Reveals Distinct Pattern of Immune Modulation during Curative Radiotherapy","year":2024,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Immune modulation; Radiation therapy; Immune system; Cancer; Medicine; Biology; Oncology; Internal medicine; Immunology","score_opus":0.01929195928742256,"score_gpt":0.37555521398864367,"score_spread":0.3562632547012211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402908971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95319414,0.0059964033,0.0361846,0.0020697312,0.002075938,0.00018222621,0.00014639941,0.000032688913,0.00011789796],"genre_scores_gemma":[0.9945944,0.0027175231,0.0004890302,0.00023560441,0.0016539737,0.000012679492,0.00010415219,0.000026619879,0.00016603064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802047,0.0001508221,0.0011131805,0.0002344316,0.00031194123,0.00016914537],"domain_scores_gemma":[0.9977539,0.0002589975,0.0010627935,0.00015299296,0.00070727384,0.000064036096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055883883,0.00018848373,0.00061939296,0.00040143842,0.000054856162,0.0000449263,0.00024010905,0.00018329649,0.00047430542],"category_scores_gemma":[0.0000746577,0.00015492969,0.0006669144,0.00054277346,0.00021776426,0.00033982657,0.000025680796,0.00032792173,0.000004250329],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015878038,0.00021704653,0.58346784,0.000042822005,0.00865919,0.000031059044,0.0010367669,0.0017904389,0.13299686,0.00033369,0.00011038587,0.26972613],"study_design_scores_gemma":[0.005673746,0.0007887808,0.9514801,0.00028001828,0.0007724285,0.000115743846,0.00005983775,0.019350437,0.014221491,0.0011227482,0.005911172,0.0002235119],"about_ca_topic_score_codex":0.00009701253,"about_ca_topic_score_gemma":0.000008074942,"teacher_disagreement_score":0.36801225,"about_ca_system_score_codex":0.0009746309,"about_ca_system_score_gemma":0.00033697925,"threshold_uncertainty_score":0.631785},"labels":[],"label_agreement":null},{"id":"W4402909416","doi":"10.1016/j.ijrobp.2024.07.1081","title":"Enhancing Radiotherapy Response via Intratumoral Injection of the TLR9 Agonist CpG to Stimulate CD8 T Cells in an Autochthonous Mouse Model of Sarcoma","year":2024,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"TLR9; Agonist; CD8; Cancer research; CpG site; Sarcoma; Cytotoxic T cell; Biology; Chemistry; Medicine; Immunology; Internal medicine; Receptor; Immune system; Pathology; Gene; Genetics; In vitro","score_opus":0.019556917208545462,"score_gpt":0.3348380867185227,"score_spread":0.31528116950997725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402909416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9547211,0.00037775098,0.041009225,0.0017418012,0.0017513989,0.00028884242,0.00006503516,0.000020023908,0.000024824565],"genre_scores_gemma":[0.99540627,0.00017362149,0.0030996206,0.0006551157,0.00053062604,0.00000909212,0.00001112851,0.00002805257,0.000086478554],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980845,0.00035864563,0.00092429324,0.0001968541,0.00026537044,0.0001703457],"domain_scores_gemma":[0.99847853,0.00028573576,0.00059210614,0.00018553618,0.00038563745,0.00007247399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010841418,0.00016391282,0.00042913205,0.00033363,0.000037609894,0.00002232691,0.00032239684,0.00017874948,0.000027211443],"category_scores_gemma":[0.0000916309,0.00012713454,0.0002433726,0.0003361509,0.00017186897,0.00022073276,0.00003246564,0.00041160744,0.0000017593878],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009040255,0.0003590413,0.0071848864,0.00001979649,0.00035523094,0.000012360685,0.0021391278,0.0305399,0.9105446,0.00041886017,0.00012436773,0.039261606],"study_design_scores_gemma":[0.008478438,0.0070304526,0.02111062,0.00043061402,0.00015557371,0.00031456197,0.00019797275,0.19381034,0.76240873,0.0036667448,0.0020850524,0.0003108949],"about_ca_topic_score_codex":0.000079420686,"about_ca_topic_score_gemma":0.0000393127,"teacher_disagreement_score":0.16327044,"about_ca_system_score_codex":0.0010456201,"about_ca_system_score_gemma":0.0010197439,"threshold_uncertainty_score":0.5184396},"labels":[],"label_agreement":null},{"id":"W4402924504","doi":"10.51731/cjht.2024.991","title":"Nivolumab (Opdivo)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nivolumab; Medicine; Immunology; Immunotherapy; Immune system","score_opus":0.026593800618034187,"score_gpt":0.3047002063446103,"score_spread":0.27810640572657613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402924504","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.102199644,0.7154124,0.00026773685,0.17882282,0.001624999,0.00021611688,0.000016093492,0.00026066133,0.0011795774],"genre_scores_gemma":[0.9960825,0.00223659,0.0003444117,0.00093054445,0.000024458119,0.0000018894958,0.0000010884795,0.000013032081,0.0003654994],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991077,0.000015624133,0.00037652263,0.00008976397,0.000110431676,0.00029994376],"domain_scores_gemma":[0.99958694,0.000023811777,0.00009194314,0.00015477286,0.00006826985,0.0000742724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046237392,0.000081129685,0.00024089457,0.00066745526,0.00009954905,0.000040198895,0.00013866863,0.00010504624,0.00010658065],"category_scores_gemma":[0.000106110754,0.000061737606,0.00011231452,0.000385692,0.00017467952,0.000073316696,0.0000055972496,0.00037635985,0.000015193139],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037732843,0.0000047394615,0.00063294306,0.00017694541,0.00007838321,0.00047188002,0.00016665041,2.790457e-7,0.00016635822,0.0005118225,0.037326615,0.9604257],"study_design_scores_gemma":[0.00041593375,0.0006840576,0.0035711208,0.00090414006,0.000017265042,0.0019323933,0.0014524957,0.000010639897,0.00063998287,0.0011772577,0.9891231,0.00007158982],"about_ca_topic_score_codex":0.003518141,"about_ca_topic_score_gemma":0.0018042212,"teacher_disagreement_score":0.9603541,"about_ca_system_score_codex":0.0005619194,"about_ca_system_score_gemma":0.004960285,"threshold_uncertainty_score":0.8799333},"labels":[],"label_agreement":null},{"id":"W4402940732","doi":"10.2196/64950","title":"Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non–Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study","year":2024,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Cryoablation; Lung cancer; Chemotherapy; Protocol (science); Internal medicine; Pathology; Alternative medicine","score_opus":0.168095333762312,"score_gpt":0.4938573384575615,"score_spread":0.3257620046952495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402940732","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33857557,0.00006499665,0.000042191885,0.0005049477,0.0000028767702,0.6607011,0.000021026022,0.00001827521,0.000069036236],"genre_scores_gemma":[0.30434334,0.000017218877,0.00018142606,0.000034291632,0.000033875076,0.6952855,0.00000543083,0.000036983183,0.00006190058],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9979257,0.00017867281,0.0005602926,0.00048081766,0.00046379404,0.00039073298],"domain_scores_gemma":[0.99872875,0.00044773926,0.00015561454,0.00037474005,0.00022662316,0.000066553104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009170743,0.0002684973,0.0004970516,0.00028291563,0.0001764581,0.00007250097,0.0001335469,0.00006762792,0.000034353863],"category_scores_gemma":[0.0000142169765,0.00015833689,0.00007067107,0.0006152804,0.00026225302,0.00010877439,0.000033057193,0.00020280594,8.815942e-8],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40891033,0.09761379,0.012321018,0.004482881,0.00036032303,0.00003393905,0.02162772,0.000016485994,0.10357353,0.0000052732694,0.00017290951,0.3508818],"study_design_scores_gemma":[0.3658649,0.48749787,0.0074571595,0.0101873595,0.00003480741,0.000023963854,0.0012559226,0.0017285368,0.043110374,0.00001646151,0.0825052,0.00031742718],"about_ca_topic_score_codex":0.000107783664,"about_ca_topic_score_gemma":0.00019220867,"teacher_disagreement_score":0.38988408,"about_ca_system_score_codex":0.00025488128,"about_ca_system_score_gemma":0.0002866692,"threshold_uncertainty_score":0.64567906},"labels":[],"label_agreement":null},{"id":"W4403012138","doi":"10.1038/s41467-024-52553-6","title":"Caspase-1-dependent spatiality in triple-negative breast cancer and response to immunotherapy","year":2024,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Cancer Society Research Institute","keywords":"Triple-negative breast cancer; Cancer research; Tumor microenvironment; CD8; Immunotherapy; Immune checkpoint; Immune system; Estrogen receptor; Blockade; Breast cancer; Apoptosis; Cancer immunotherapy; Biology; Cancer; Immunology; Medicine; Receptor; Internal medicine; Genetics","score_opus":0.02101630678845738,"score_gpt":0.3579804086337036,"score_spread":0.3369641018452462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403012138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7454982,0.10639411,0.000033781773,0.14500818,0.0004658131,0.0012020409,0.00050026405,0.0001379325,0.0007596981],"genre_scores_gemma":[0.9858065,0.009921061,0.0007922566,0.0025232031,0.00005201463,0.00020157908,0.000022240789,0.000025175548,0.0006559467],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99892235,0.00022239536,0.0002591816,0.0002491133,0.00017748491,0.00016945631],"domain_scores_gemma":[0.99835044,0.00043728322,0.000034977467,0.0010014019,0.000093956805,0.00008195189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066937273,0.00014354812,0.00021079202,0.00021377855,0.000115037794,0.000056651515,0.0002766366,0.00020126328,0.00013005454],"category_scores_gemma":[0.00009171418,0.00012236339,0.000070588685,0.00067516917,0.00013289874,0.00008825817,0.00010862048,0.0008303438,0.000009719403],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06709486,0.0013186014,0.04661022,0.00027820392,0.001585189,0.0001503515,0.024235584,0.000011110478,0.33638516,0.0036012435,0.03641888,0.4823106],"study_design_scores_gemma":[0.0032669862,0.00017669507,0.901923,0.000661891,0.00006156192,0.00017857514,0.0005643129,0.00036719686,0.0019038216,0.00017155027,0.0904394,0.0002849896],"about_ca_topic_score_codex":0.0026728476,"about_ca_topic_score_gemma":0.007920664,"teacher_disagreement_score":0.8553128,"about_ca_system_score_codex":0.00042820006,"about_ca_system_score_gemma":0.00032609588,"threshold_uncertainty_score":0.49898344},"labels":[],"label_agreement":null},{"id":"W4403059101","doi":"10.58931/crt.2024.1147","title":"Management of Rheumatologic Immune-Related Adverse Events (Rh-irAEs) – An Overview of Immunosuppressive Therapies","year":2024,"lang":"en","type":"article","venue":"Canadian rheumatology today.","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; University of British Columbia; University of Alberta; Arthritis Research Centre of Canada; Research Canada","funders":"","keywords":"Adverse effect; Medicine; Immune system; Dermatology; Intensive care medicine; Immunology; Internal medicine","score_opus":0.02310762077008318,"score_gpt":0.29550128567420286,"score_spread":0.2723936649041197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403059101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8696194,0.12539665,0.000007938747,0.00096408447,0.0009219988,0.0005856438,0.00009330736,0.0000800502,0.0023309235],"genre_scores_gemma":[0.977298,0.021466728,0.00021169458,0.000106306026,0.0000032778705,0.000045278357,0.00011309764,0.000044286917,0.0007113209],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977959,0.000139694,0.00096999377,0.00040631718,0.00020586434,0.0004822331],"domain_scores_gemma":[0.9986881,0.00007278261,0.00023828761,0.000680805,0.000101058584,0.0002189846],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035127538,0.00029190816,0.0008190747,0.0005135943,0.00008361753,0.0000058108194,0.0003240119,0.00030121382,0.0022119123],"category_scores_gemma":[0.00001717674,0.00025391378,0.00035700877,0.000541689,0.0003717613,0.00014146052,0.000044434008,0.00023958746,0.000060576156],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071836747,0.0017538338,0.26888302,0.032060396,0.04559812,0.0068277307,0.026258502,0.000096193406,0.023923155,0.28006652,0.013389012,0.29395983],"study_design_scores_gemma":[0.024146337,0.0039416733,0.74923253,0.04695359,0.0026031642,0.009275704,0.020368403,0.0015499662,0.015753305,0.011601506,0.11145284,0.0031209663],"about_ca_topic_score_codex":0.02829061,"about_ca_topic_score_gemma":0.003252261,"teacher_disagreement_score":0.4803495,"about_ca_system_score_codex":0.00020066423,"about_ca_system_score_gemma":0.0005598363,"threshold_uncertainty_score":0.9999913},"labels":[],"label_agreement":null},{"id":"W4403112417","doi":"10.1016/j.nmd.2024.07.648","title":"506VP Long-term efficacy and safety of ravulizumab in adults with AChR-Ab+ gMG: final results from the phase 3 CHAMPION MG open-label extension","year":2024,"lang":"en","type":"article","venue":"Neuromuscular Disorders","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; London Health Sciences Centre","funders":"","keywords":"Champion; Open label; Extension (predicate logic); Phase (matter); Term (time); Chemistry; Medicine; Pharmacology; Computer science; Physics; Political science; Adverse effect; Organic chemistry; Programming language","score_opus":0.028310510345714145,"score_gpt":0.31106835358567053,"score_spread":0.2827578432399564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403112417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98555654,0.008769226,0.00009221305,0.0037201978,0.00018835819,0.0013692448,0.000075005846,0.000042554682,0.00018664336],"genre_scores_gemma":[0.99299574,0.0061086733,0.00006676243,0.00040822604,0.0000496286,0.00002518383,0.00023464883,0.00004346912,0.00006766349],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99826354,0.00012977619,0.00041782172,0.0006162692,0.00032967317,0.00024292647],"domain_scores_gemma":[0.99897957,0.00025262125,0.00009579357,0.00056215393,0.000040046034,0.00006980787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029140478,0.00024203095,0.0003426837,0.00009712356,0.00008913063,0.00006037413,0.00021731805,0.00009161567,0.000040435334],"category_scores_gemma":[0.000094654846,0.0001540626,0.00007183526,0.00043614896,0.00022107064,0.00014173449,0.000095751086,0.00030983612,0.000003790557],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21114658,0.0025149442,0.0041911774,0.0005217269,0.00046588702,0.00051848957,0.004422506,0.000026383248,0.03999086,0.000026047364,0.00097349717,0.7352019],"study_design_scores_gemma":[0.16691086,0.0050751013,0.8104485,0.005797683,0.0003159048,0.00009592736,0.0004698806,0.001957323,0.0010003272,0.000036232825,0.007436858,0.00045538],"about_ca_topic_score_codex":0.001013142,"about_ca_topic_score_gemma":0.00079272175,"teacher_disagreement_score":0.80625737,"about_ca_system_score_codex":0.0000381892,"about_ca_system_score_gemma":0.00012754953,"threshold_uncertainty_score":0.628249},"labels":[],"label_agreement":null},{"id":"W4403116868","doi":"10.1016/j.heliyon.2024.e38888","title":"Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer","year":2024,"lang":"en","type":"review","venue":"Heliyon","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Trinity College Dublin; Irish Cancer Society","keywords":"Serous ovarian cancer; Ovarian cancer; Medicine; Immune checkpoint; Oncology; Serous fluid; Internal medicine; Cancer; Immunotherapy","score_opus":0.17910906659934342,"score_gpt":0.40488318181232913,"score_spread":0.2257741152129857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403116868","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032728357,0.99339277,0.000016074042,0.0014566979,0.001529131,0.0030959032,0.000050597362,0.00007679305,0.000054750417],"genre_scores_gemma":[0.00015211794,0.99394244,0.00010961184,0.00045751932,0.00089432934,0.0022639672,0.00005027811,0.00013243567,0.001997296],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99761087,0.000150758,0.00091241807,0.0006034263,0.00028580613,0.00043673057],"domain_scores_gemma":[0.9984703,0.00042586602,0.00028523745,0.0007112917,0.000051105533,0.00005619836],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010563459,0.0005058341,0.0014924696,0.00023013332,0.000085124615,0.00007924794,0.000336736,0.0003565494,0.00018046823],"category_scores_gemma":[0.00007717591,0.0002767668,0.0006657493,0.00070274767,0.00009146426,0.000065365035,0.00005910773,0.0006839747,0.000034651668],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004466945,0.000045269047,0.000012355908,0.034742303,0.0005626148,0.00003301152,0.00032118117,2.4187992e-7,0.0002417961,0.000021970476,0.00032013806,0.9632524],"study_design_scores_gemma":[0.0011715421,0.00035136263,0.0003512832,0.1698873,0.00082365016,0.00007623344,0.0000513196,0.0000029610696,0.00008464525,0.000013750238,0.82689816,0.00028777192],"about_ca_topic_score_codex":0.00090169563,"about_ca_topic_score_gemma":0.00020788025,"teacher_disagreement_score":0.96296465,"about_ca_system_score_codex":0.00060543464,"about_ca_system_score_gemma":0.00081693305,"threshold_uncertainty_score":0.99996847},"labels":[],"label_agreement":null},{"id":"W4403151694","doi":"10.1210/jendso/bvae163.2283","title":"8657 Thymic Neoplasia in a Pediatric Patient With LI-Fraumeni Syndrome: A Case Report","year":2024,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"WiLAN (Canada)","funders":"","keywords":"Li–Fraumeni syndrome; Medicine; Pediatrics; Genetics; Biology; Mutation","score_opus":0.006801243565216463,"score_gpt":0.25517945862903,"score_spread":0.24837821506381355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403151694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880208,0.0054570953,0.000023724431,0.0052741435,0.0007303389,0.0002252139,0.0000029587945,0.000017451366,0.00024828152],"genre_scores_gemma":[0.9967928,0.0009123893,0.0005286382,0.00047730285,0.0002752494,0.000006294271,8.280489e-7,0.00002405705,0.0009824584],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9986644,0.00003917531,0.00053743925,0.00014516078,0.00039629146,0.00021756241],"domain_scores_gemma":[0.99929136,0.00006632242,0.00025148244,0.00023690898,0.00007800418,0.00007594381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033069606,0.00014248968,0.0002772519,0.00007927815,0.00005764307,0.000035093293,0.00009625576,0.000037993497,0.000060937356],"category_scores_gemma":[0.000034265082,0.00007491461,0.0005153377,0.0006307937,0.000052767875,0.000106370564,0.00004223612,0.0005793601,0.000001970784],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014573684,0.0004571737,0.04994425,0.0006783402,0.0012644575,0.86318153,0.0056263725,0.00009282303,0.0012355342,0.000012957394,0.06712378,0.008925407],"study_design_scores_gemma":[0.0019752898,0.00078857254,0.012601788,0.00039841142,0.00032157663,0.96362054,0.0010256559,0.00010380211,0.00035434624,0.000025936442,0.018678697,0.00010536272],"about_ca_topic_score_codex":0.00007214796,"about_ca_topic_score_gemma":0.000027532542,"teacher_disagreement_score":0.10043903,"about_ca_system_score_codex":0.000293628,"about_ca_system_score_gemma":0.00047224393,"threshold_uncertainty_score":0.30549294},"labels":[],"label_agreement":null},{"id":"W4403218311","doi":"10.1101/2024.10.07.24314963","title":"Comparative effectiveness of first line pembrolizumab vs. chemotherapy in aNSCLC: A Norwegian Population-Based Cohort Study","year":2024,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nordic Life Science Pipeline (Canada)","funders":"","keywords":"Norwegian; Pembrolizumab; Cohort; Medicine; Internal medicine; Oncology; Family medicine; Cancer","score_opus":0.02110825425589407,"score_gpt":0.3208080593060255,"score_spread":0.29969980505013144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403218311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928446,0.0008633763,0.000047159952,0.00041118456,0.0006043055,0.004500319,0.000062741936,0.00008392105,0.00058240484],"genre_scores_gemma":[0.99873096,0.0001167178,0.00004722178,0.00008404029,0.00011855019,0.00053836557,0.00022693857,0.000065217995,0.00007201459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740016,0.00033754238,0.00073855865,0.00076430244,0.0005022518,0.00025715414],"domain_scores_gemma":[0.998438,0.00031441834,0.00025229473,0.000762695,0.00015432273,0.00007828707],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011721615,0.00045370052,0.0015410543,0.00049654127,0.000040442526,0.000027407485,0.00022752945,0.00027528222,0.00016403368],"category_scores_gemma":[0.00003944628,0.00038755624,0.00033962005,0.00057334686,0.00010200728,0.000025180496,0.00010558918,0.00074195,0.000009006097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01594781,0.001427715,0.97601867,0.0026529871,0.00093398785,0.000062035484,0.0011167061,0.0005750001,0.0008574565,0.0000055326423,0.000022539372,0.00037954655],"study_design_scores_gemma":[0.008110362,0.000995105,0.98286086,0.0029861256,0.00026936855,0.0000044259896,0.000077272394,0.0014129733,0.002744274,0.00011537887,0.00010815337,0.00031567272],"about_ca_topic_score_codex":0.0036185572,"about_ca_topic_score_gemma":0.0016552754,"teacher_disagreement_score":0.007837448,"about_ca_system_score_codex":0.00051384204,"about_ca_system_score_gemma":0.00035975504,"threshold_uncertainty_score":0.9998576},"labels":[],"label_agreement":null},{"id":"W4403241169","doi":"10.17615/4kv9-et07","title":"A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies","year":2024,"lang":"en","type":"article","venue":"UNC Libraries","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"H2020 Marie Skłodowska-Curie Actions; Astellas Pharma; Oncolytics Biotech; Incyte; Gilead Sciences; GlaxoSmithKline; Fundación Científica Asociación Española Contra el Cáncer; Veracyte; Daiichi Sankyo Europe; European Commission; Breast Cancer Research Foundation; Instituto de Salud Carlos III; Amgen; Pfizer; Les Laboratories Pierre Fabre; Fundación Fero; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Triple-negative breast cancer; Signature (topology); Breast cancer; Gene signature; Immune system; Oncology; Gene; Cancer research; Biology; Medicine; Internal medicine; Cancer; Immunology; Gene expression; Genetics; Mathematics","score_opus":0.015995823538262767,"score_gpt":0.2796969989070755,"score_spread":0.2637011753688127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403241169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8729701,0.12137869,0.000032625794,0.0031431876,0.00039329522,0.0005163024,0.0007355684,0.00011221247,0.00071802625],"genre_scores_gemma":[0.987293,0.001254075,0.0003821211,0.00032621028,0.000090987,0.00006872,0.000061760766,0.0000326202,0.010490518],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985363,0.000078674944,0.00048332254,0.0003511455,0.0002886157,0.00026196073],"domain_scores_gemma":[0.99920565,0.00023759402,0.00011915465,0.0002867366,0.0000973055,0.000053554086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020279105,0.00024384567,0.00079894013,0.00071034284,0.00005006727,0.000061071885,0.00013269535,0.00014354606,0.0005690039],"category_scores_gemma":[0.000037880938,0.00018083701,0.00037431656,0.0028192347,0.00027967282,0.0003334604,0.000072125295,0.00028628623,0.000003415834],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043094907,0.0018911342,0.07518719,0.005224653,0.13165365,0.0017094612,0.26518592,0.0005997496,0.42570132,0.0084832255,0.013795022,0.027473755],"study_design_scores_gemma":[0.015387837,0.0010690293,0.5103599,0.0031001316,0.011362384,0.000025933223,0.023391863,0.0017167884,0.42151508,0.0038236133,0.0069108936,0.0013365471],"about_ca_topic_score_codex":0.0015118852,"about_ca_topic_score_gemma":0.00044737328,"teacher_disagreement_score":0.4351727,"about_ca_system_score_codex":0.00012738245,"about_ca_system_score_gemma":0.00036911416,"threshold_uncertainty_score":0.73743194},"labels":[],"label_agreement":null},{"id":"W4403243250","doi":"10.1038/s41586-024-07943-7","title":"CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors","year":2024,"lang":"en","type":"article","venue":"Nature","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health","keywords":"Blockade; Cancer research; Medicine; Pharmacology; Chemistry; Internal medicine; Receptor","score_opus":0.0045210119927173555,"score_gpt":0.2722805946640456,"score_spread":0.2677595826713282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403243250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7967706,0.12216011,0.000007125063,0.055670608,0.0037471943,0.0007472629,0.000053629275,0.00067240186,0.020171097],"genre_scores_gemma":[0.95814955,0.00031779445,0.0003037913,0.003367897,0.00052193674,0.00001944611,0.000033333687,0.00004474569,0.03724149],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987468,0.000020986095,0.0002423644,0.00038004635,0.00032812104,0.0002816491],"domain_scores_gemma":[0.9994231,0.000060461334,0.000027871574,0.00028773732,0.00006813969,0.00013271786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018532731,0.00018726489,0.00021509749,0.00018529447,0.000068222966,0.00005660327,0.000113878305,0.0009810141,0.0004874684],"category_scores_gemma":[0.000069778594,0.00014604552,0.0001696974,0.0008918595,0.000054464697,0.00006724959,0.000028621627,0.0016732932,0.00018254977],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002329474,0.00009649919,0.00083770335,0.00045952416,0.0005699456,0.00051882,0.0015888503,0.0000028592508,0.24570099,0.00097492983,0.7253195,0.021600934],"study_design_scores_gemma":[0.00085390627,0.0001352298,0.0039951866,0.0011210081,0.00007922623,0.000052195202,0.00010558328,0.000016936616,0.06260387,0.0002379898,0.930596,0.0002028599],"about_ca_topic_score_codex":0.000019425237,"about_ca_topic_score_gemma":0.000064908956,"teacher_disagreement_score":0.20527652,"about_ca_system_score_codex":0.00017535013,"about_ca_system_score_gemma":0.00012786762,"threshold_uncertainty_score":0.7566479},"labels":[],"label_agreement":null},{"id":"W4403248837","doi":"10.1002/cam4.70262","title":"Temporal Effect on <scp>PD</scp>‐<scp>L1</scp> Detection and Novel Insights Into Its Clinical Implications in Non–Small Cell Lung Cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Research Nova Scotia; Nova Scotia Health Authority; Merck Canada; Dalhousie University","keywords":"Hazard ratio; Confidence interval; Lung cancer; Oncology; Internal medicine; Medicine; Cancer; Lung; Stage (stratigraphy); Cohort; Pathology; Biology","score_opus":0.027275957553489487,"score_gpt":0.3512805910904356,"score_spread":0.3240046335369461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403248837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9322967,0.05837588,0.00062081264,0.0025052517,0.0026250165,0.0015362718,0.000026292992,0.00014604883,0.0018677391],"genre_scores_gemma":[0.9816566,0.009799282,0.000038602997,0.0023908832,0.0020983585,0.0007468037,0.000039488008,0.00008375636,0.0031462244],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973363,0.00010504124,0.0008267873,0.0008890343,0.00036349954,0.00047928112],"domain_scores_gemma":[0.99756944,0.0013157895,0.00018346423,0.00044768883,0.0001350304,0.00034860414],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007794564,0.00043574595,0.0007906056,0.00049056916,0.00013832071,0.00003569564,0.0001707533,0.0003581472,0.00004296622],"category_scores_gemma":[0.00039391516,0.00032005823,0.0001615896,0.0010554615,0.0002954382,0.00012895273,0.00005478101,0.000859859,0.00001462556],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008164246,0.0004713152,0.13086691,0.0042382875,0.0008846856,0.00015175334,0.008109508,0.00003524458,0.6423967,0.00012896351,0.037267722,0.1746325],"study_design_scores_gemma":[0.020079613,0.0056080394,0.57817036,0.008829905,0.0013094768,0.000084161766,0.0007682944,0.006506445,0.06435139,0.00012070497,0.31388298,0.00028865653],"about_ca_topic_score_codex":0.002535543,"about_ca_topic_score_gemma":0.0028308053,"teacher_disagreement_score":0.5780453,"about_ca_system_score_codex":0.00069127773,"about_ca_system_score_gemma":0.0004732729,"threshold_uncertainty_score":0.99992514},"labels":[],"label_agreement":null},{"id":"W4403251516","doi":"10.1016/j.ygyno.2024.07.020","title":"Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy among patients with high-risk, locally advanced cervical cancer","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Placebo; Chemoradiotherapy; Oncology; Internal medicine; Chemotherapy; Cancer; Immunotherapy; Alternative medicine","score_opus":0.019305037816924935,"score_gpt":0.3229214523200555,"score_spread":0.30361641450313054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403251516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764234,0.0032744533,0.00021049366,0.0012349047,0.002774362,0.015451148,0.00012430818,0.00021353348,0.00029341102],"genre_scores_gemma":[0.9929711,0.00074133393,0.00011783606,0.0010955638,0.00018936722,0.004429289,0.00017990696,0.00007867905,0.00019688113],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99428695,0.0010232652,0.002094141,0.001056702,0.0008226997,0.00071621663],"domain_scores_gemma":[0.9924189,0.004725238,0.0013921063,0.00079264666,0.00044482562,0.00022627697],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011598271,0.00073985907,0.0038930916,0.00022337331,0.00025163003,0.000060023493,0.00039813056,0.0004734418,0.0023334452],"category_scores_gemma":[0.0003862132,0.0003880201,0.0006394881,0.0005597039,0.0008585491,0.00015355894,0.0001097784,0.0009287104,0.000008336223],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84958935,0.0045948317,0.037546936,0.000043663393,0.008356987,0.00019994624,0.00359649,0.00028611286,0.000090506044,0.000014771318,0.0004934768,0.09518695],"study_design_scores_gemma":[0.93518615,0.012843434,0.04382448,0.00013316849,0.0031393638,0.000008644818,0.0014560346,0.0010072754,0.00015973064,0.00002474418,0.0017717716,0.00044517856],"about_ca_topic_score_codex":0.005809713,"about_ca_topic_score_gemma":0.0047101374,"teacher_disagreement_score":0.09474178,"about_ca_system_score_codex":0.0012581706,"about_ca_system_score_gemma":0.001305907,"threshold_uncertainty_score":0.9998572},"labels":[],"label_agreement":null},{"id":"W4403254218","doi":"10.1016/j.ygyno.2024.07.015","title":"Overall survival and progression-free survival by PD-L1 status among endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG GY018 trial","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Carboplatin; Paclitaxel; Oncology; Internal medicine; Pembrolizumab; Placebo; Endometrial cancer; Progression-free survival; Overall survival; Chemotherapy; Cancer; Cisplatin; Immunotherapy; Pathology","score_opus":0.025459327438658953,"score_gpt":0.33373437308985604,"score_spread":0.30827504565119707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403254218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97759855,0.002279243,0.0000059026092,0.0016204555,0.0027950385,0.0065201153,0.00049808196,0.00018794027,0.008494699],"genre_scores_gemma":[0.99556357,0.0003973595,0.00012390372,0.00061692594,0.0005036741,0.0016251525,0.00033066212,0.00007793374,0.0007607932],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99417377,0.0012264858,0.0011140282,0.0011630718,0.0010442416,0.0012783884],"domain_scores_gemma":[0.99423295,0.0041361116,0.00036252342,0.0006630069,0.0001973694,0.00040801952],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001631438,0.0007030341,0.0016515079,0.0005150836,0.00025100593,0.00015724168,0.000466085,0.00063276425,0.00054035254],"category_scores_gemma":[0.001548911,0.00044289816,0.00022370288,0.0012562296,0.00061177794,0.00017711383,0.00023229285,0.0009059489,0.0000146111415],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7685038,0.0018891119,0.17700954,0.00026044788,0.0014641682,0.0010779203,0.005985174,0.00009965308,0.0009393197,0.00016349749,0.018425891,0.024181515],"study_design_scores_gemma":[0.49339157,0.040746763,0.4237768,0.00043064184,0.0007896819,0.00007305928,0.0028167877,0.00085919694,0.00015568557,0.00013101335,0.035665486,0.0011632809],"about_ca_topic_score_codex":0.0118072955,"about_ca_topic_score_gemma":0.014358208,"teacher_disagreement_score":0.27511218,"about_ca_system_score_codex":0.0030158928,"about_ca_system_score_gemma":0.0020328204,"threshold_uncertainty_score":0.9998023},"labels":[],"label_agreement":null},{"id":"W4403410372","doi":"10.1016/j.jtho.2024.09.073","title":"OA14.04 Efficacy and Safety of Olomorasib with Pembrolizumab + Chemotherapy as First-Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Medicine; Pembrolizumab; KRAS; Oncology; Chemotherapy; Internal medicine; Cancer; Immunotherapy","score_opus":0.010375457593587985,"score_gpt":0.3512811453665129,"score_spread":0.3409056877729249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992229,0.0027030085,0.000060785733,0.0036855582,0.00019631813,0.00060296885,0.000010174676,0.000013254535,0.0004989712],"genre_scores_gemma":[0.9958404,0.0024961529,0.0010961381,0.00024747566,0.00009500187,0.0000083850955,0.0000068333156,0.000034172415,0.00017545147],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99854827,0.00008141659,0.0006353192,0.00021823439,0.0002881017,0.00022867593],"domain_scores_gemma":[0.9989628,0.0001954807,0.00038802615,0.000176096,0.0001601172,0.00011745066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028966911,0.00023094016,0.0008014714,0.0002851683,0.000035962017,0.000011571001,0.000080946695,0.00012928712,0.00012619547],"category_scores_gemma":[0.000023015786,0.00013045814,0.00010638517,0.0003474629,0.00018008178,0.00011595022,0.00001233249,0.00025991286,0.0000017667146],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29632673,0.0019141732,0.021042265,0.00020187155,0.0010288658,0.00064308994,0.0015300558,0.000063847016,0.0025520008,0.0000102546355,0.0000450029,0.67464185],"study_design_scores_gemma":[0.09414659,0.15412593,0.6512111,0.004524064,0.0010926864,0.0029527075,0.0005866097,0.00008683207,0.012483115,0.00007911908,0.07824323,0.00046802466],"about_ca_topic_score_codex":0.000044396536,"about_ca_topic_score_gemma":0.00012310962,"teacher_disagreement_score":0.67417383,"about_ca_system_score_codex":0.0007173044,"about_ca_system_score_gemma":0.00068661326,"threshold_uncertainty_score":0.53199285},"labels":[],"label_agreement":null},{"id":"W4403410382","doi":"10.1016/j.jtho.2024.09.051","title":"OA08.06 Sacituzumab Govitecan vs Docetaxel in Patients with mNSCLC Non-responsive to Last Anti-PD-(L)1-containing Regimen: EVOKE-01","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"Medicine; Docetaxel; Regimen; Internal medicine; Oncology; Pharmacology; Chemotherapy","score_opus":0.012242057141337833,"score_gpt":0.3590807503979023,"score_spread":0.34683869325656447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98792493,0.00090723945,0.00024203233,0.008225151,0.0009428099,0.00048003645,0.000012886355,0.000023589282,0.0012413375],"genre_scores_gemma":[0.99526143,0.00007819315,0.0017832211,0.001821902,0.0003913565,0.000012157187,0.0000074412997,0.000045723293,0.00059858145],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99777126,0.00019487822,0.0008171947,0.00031000315,0.00046593387,0.00044073781],"domain_scores_gemma":[0.99854696,0.00026036118,0.00038750228,0.0002581491,0.000302175,0.0002448552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011049282,0.00025986566,0.000870239,0.0008812856,0.000062865714,0.000053077194,0.00020882374,0.00021236105,0.00015034332],"category_scores_gemma":[0.00014595734,0.000186491,0.00020749068,0.0008151901,0.00011608229,0.00024286854,0.000053430736,0.0007412773,0.000035785088],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32243586,0.0019281412,0.1356562,0.0006615011,0.0024474694,0.008204652,0.010002338,0.00019164245,0.026780581,0.000062839084,0.025759574,0.4658692],"study_design_scores_gemma":[0.010949142,0.028814506,0.778042,0.0039750156,0.00055656856,0.0017384483,0.0022096334,0.000083295,0.0031496647,0.000061444254,0.16990946,0.000510816],"about_ca_topic_score_codex":0.000051302235,"about_ca_topic_score_gemma":0.00014346343,"teacher_disagreement_score":0.6423858,"about_ca_system_score_codex":0.0014226851,"about_ca_system_score_gemma":0.001345749,"threshold_uncertainty_score":0.7604883},"labels":[],"label_agreement":null},{"id":"W4403411452","doi":"10.1016/j.jtocrr.2024.100737","title":"CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer; Centre Technologique des Résidus Industriels; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Lung cancer; Medicine; Cancer; Immunotherapy; Cancer research; Lung; Oncology; Internal medicine","score_opus":0.09651927422717367,"score_gpt":0.4826450913431923,"score_spread":0.3861258171160186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403411452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933657,0.0035360707,0.0000084945195,0.0011846356,0.0001633633,0.0013635616,8.2206765e-7,0.000018644376,0.00035870948],"genre_scores_gemma":[0.9968574,0.0023862687,0.000032593507,0.00004489989,0.00004546467,0.00018808471,0.0000036759295,0.000016897746,0.00042472777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997718,0.00022304643,0.0008019427,0.00038682672,0.0006618511,0.00020836631],"domain_scores_gemma":[0.99901867,0.00037084037,0.0000933049,0.0002266222,0.00023740433,0.000053153686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039892117,0.00009429265,0.00033020784,0.00036974263,0.000036771104,0.000026235306,0.000037948936,0.0000633597,0.000053085965],"category_scores_gemma":[0.00022710954,0.0000623415,0.000033235036,0.000957153,0.0001917407,0.00012651908,0.000026232938,0.00054758013,2.2929498e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015547352,0.004218889,0.8547332,0.0002641556,0.00017886683,0.00086081884,0.0008501554,0.000006807494,0.009167294,0.000025926689,0.00017998296,0.11396652],"study_design_scores_gemma":[0.0063604685,0.008733421,0.9811403,0.0012200022,0.000011870498,0.000033027787,0.00046882787,0.0003393131,0.000351924,0.00017836425,0.0010778521,0.00008461068],"about_ca_topic_score_codex":0.0030916154,"about_ca_topic_score_gemma":0.0014584092,"teacher_disagreement_score":0.12640709,"about_ca_system_score_codex":0.00014149252,"about_ca_system_score_gemma":0.0004147636,"threshold_uncertainty_score":0.46736184},"labels":[],"label_agreement":null},{"id":"W4403420185","doi":"10.1016/j.jtho.2024.09.022","title":"OA01.03 Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Perioperative; Stage (stratigraphy); Oncology; Internal medicine; Association (psychology); Surgery; Cancer; Immunotherapy","score_opus":0.029266082196785063,"score_gpt":0.4199902217130759,"score_spread":0.3907241395162908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995007,0.0011332226,0.0001164704,0.002218867,0.0003048921,0.00066710316,0.000010241328,0.000004761808,0.00053745566],"genre_scores_gemma":[0.9984073,0.00015858865,0.00042175458,0.00013655148,0.00012753853,0.000020595257,0.0000018709312,0.000011824874,0.0007139487],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99826175,0.00047679216,0.0006445102,0.00012672877,0.0003420243,0.00014818786],"domain_scores_gemma":[0.99833935,0.0005111369,0.0006983603,0.00013743792,0.00028602252,0.000027714297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022380678,0.00011505578,0.0005613989,0.00022999845,0.00004014048,0.00001398461,0.00013661386,0.00014852067,0.000040908453],"category_scores_gemma":[0.00018827255,0.000056731675,0.00015164295,0.00031820164,0.00006877605,0.000098694785,0.000015474237,0.00037475454,4.8036105e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26271138,0.008473851,0.18083416,0.0014516893,0.0028417585,0.0034023286,0.16525011,0.000186226,0.122091636,0.0001319095,0.0026250577,0.24999991],"study_design_scores_gemma":[0.02940671,0.15964317,0.68841565,0.0033951337,0.0020283635,0.0017954218,0.08041399,0.00061697536,0.013329681,0.00015037374,0.02040703,0.00039749377],"about_ca_topic_score_codex":0.000048270023,"about_ca_topic_score_gemma":0.0001537315,"teacher_disagreement_score":0.5075815,"about_ca_system_score_codex":0.00040102084,"about_ca_system_score_gemma":0.000422843,"threshold_uncertainty_score":0.23134504},"labels":[],"label_agreement":null},{"id":"W4403473591","doi":"10.1016/j.jtho.2024.09.1011","title":"EP.07C.15 Neoadjuvant Immuno-Chemotherapy in Resectable Non-Small Cell Lung Cancer - A Retrospective Cohort Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Oncology; Retrospective cohort study; Chemotherapy; Internal medicine; Cohort; Lung cancer; Neoadjuvant therapy; Cancer; Breast cancer","score_opus":0.014091477278933964,"score_gpt":0.3929191152399555,"score_spread":0.37882763796102153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403473591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9666491,0.022913104,0.00009054123,0.0030384685,0.002271879,0.0011064359,0.000008238638,0.00002551571,0.0038966865],"genre_scores_gemma":[0.9898715,0.004115199,0.0005265995,0.00061209383,0.00071381306,0.000064061474,0.0000021334192,0.00005629667,0.0040382794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975499,0.00024948103,0.0009800055,0.00035283042,0.00043924194,0.0004285773],"domain_scores_gemma":[0.99871826,0.00016270287,0.00040719422,0.0002986957,0.000284622,0.00012850986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023755098,0.00025693924,0.0010480271,0.0005864968,0.00006661583,0.000053143616,0.00024699507,0.00024071372,0.00091023283],"category_scores_gemma":[0.000043200613,0.00019578064,0.00031034613,0.0007778375,0.000091985065,0.00016575737,0.000046957517,0.0011528417,0.000009348532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028593292,0.0025674368,0.79064,0.00041039745,0.002229432,0.0048663765,0.008138279,0.00003743671,0.07289926,0.0000034751083,0.02013429,0.06948032],"study_design_scores_gemma":[0.0072873263,0.009967876,0.9355164,0.0013777015,0.0008667019,0.0011176488,0.0028809973,0.00071204326,0.007996001,0.000084363135,0.03183999,0.0003529639],"about_ca_topic_score_codex":0.0010079154,"about_ca_topic_score_gemma":0.0006922813,"teacher_disagreement_score":0.14487639,"about_ca_system_score_codex":0.0028857163,"about_ca_system_score_gemma":0.0016439483,"threshold_uncertainty_score":0.99664116},"labels":[],"label_agreement":null},{"id":"W4403584964","doi":"10.3390/cells13201739","title":"Contemporaneous Inflammatory, Angiogenic, Fibrogenic, and Angiostatic Cytokine Profiles of the Time-to-Tumor Development by Cancer Cells to Orchestrate Tumor Neovascularization, Progression, and Metastasis","year":2024,"lang":"en","type":"article","venue":"Cells","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; Queen's University","funders":"Harvard Stem Cell Institute; Natural Sciences and Engineering Research Council of Canada; Queen's University; York University","keywords":"Proinflammatory cytokine; Angiogenesis; Metastasis; Cytokine; Tumor progression; Cancer research; Tumor necrosis factor alpha; Pancreatic cancer; Tumor microenvironment; Cancer; Immunology; Neovascularization; Medicine; Biology; Immune system; Inflammation; Internal medicine","score_opus":0.00731992171905156,"score_gpt":0.24411930907528376,"score_spread":0.2367993873562322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403584964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98245966,0.014207132,0.00006863049,0.001115281,0.00012632021,0.0017589905,0.00015803048,0.00005113112,0.00005482426],"genre_scores_gemma":[0.99138767,0.00025753572,0.003189653,0.0012435601,0.00007592872,0.0003050498,0.0000443716,0.000089695335,0.0034065356],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99866974,0.000060473827,0.00040574052,0.00035725377,0.00027717932,0.00022959872],"domain_scores_gemma":[0.9993464,0.00005488914,0.00009113521,0.000234691,0.00010206523,0.0001708548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027985804,0.00021898412,0.00032350922,0.000104701496,0.000082836,0.000056850382,0.000100451136,0.000042553016,0.00018301228],"category_scores_gemma":[0.000016077216,0.00014472265,0.00010118673,0.00039469948,0.000113916176,0.000047457208,0.00007263851,0.0000762749,0.000024600653],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039722526,0.00004380571,0.00062503957,0.0007134103,0.0005273906,0.000044041084,0.0011949253,0.000008082215,0.9700911,0.000003345639,0.013633607,0.012718018],"study_design_scores_gemma":[0.0006538644,0.00015446648,0.0013784424,0.00076670275,0.00019698156,0.00005409616,0.000072280185,0.00007871729,0.90521306,0.000003723125,0.09124119,0.00018647646],"about_ca_topic_score_codex":0.00003971224,"about_ca_topic_score_gemma":0.000010804589,"teacher_disagreement_score":0.07760758,"about_ca_system_score_codex":0.00006734804,"about_ca_system_score_gemma":0.0003935399,"threshold_uncertainty_score":0.59016186},"labels":[],"label_agreement":null},{"id":"W4403646047","doi":"10.3390/curroncol31100473","title":"Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Vancouver General Hospital; Women's College Hospital; University of British Columbia; University of Toronto; University Health Network; Toronto General Hospital; William Osler Health System","funders":"","keywords":"Medicine; Multidisciplinary approach; Adverse effect; Intensive care medicine; Multidisciplinary team; MEDLINE; Medical emergency; Nursing; Internal medicine","score_opus":0.04444790754044044,"score_gpt":0.37068814393593713,"score_spread":0.3262402363954967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403646047","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008135573,0.98576635,8.2409144e-7,0.000071234834,0.002417391,0.0026560659,0.000027645572,0.00013794567,0.00078697025],"genre_scores_gemma":[0.0020270443,0.99550736,0.0000111657155,0.000013523141,0.00012947855,0.00033331715,0.0012027753,0.00014089583,0.0006344594],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959863,0.00032512523,0.0019356643,0.0007899399,0.00033164406,0.0006313275],"domain_scores_gemma":[0.9984762,0.000066966844,0.00073149905,0.00049839116,0.00010225309,0.0001246692],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005287146,0.000775231,0.0027328266,0.0009579394,0.000059134778,0.0000066328025,0.00023722855,0.000588737,0.00016359017],"category_scores_gemma":[0.0000347768,0.00053072954,0.0009990499,0.0015896993,0.00014514395,0.000069932226,0.00013333767,0.0015172324,0.00021835064],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011129553,0.0010623127,0.0025370864,0.013907667,0.0013939239,0.00012809022,0.00018388394,3.024764e-7,0.0000039232605,0.0000026963864,0.00029797255,0.97936916],"study_design_scores_gemma":[0.007710593,0.002013799,0.0029089916,0.063462906,0.0037065935,0.0001264111,0.000036515983,0.000011769961,0.000008787009,0.000008206058,0.9194026,0.0006028535],"about_ca_topic_score_codex":0.00010279944,"about_ca_topic_score_gemma":0.000025274176,"teacher_disagreement_score":0.9787663,"about_ca_system_score_codex":0.0027564617,"about_ca_system_score_gemma":0.00092181057,"threshold_uncertainty_score":0.99971443},"labels":[],"label_agreement":null},{"id":"W4403646049","doi":"10.3390/curroncol31100472","title":"Exploring the Frequency and Risk Factors of Hyperprogressive Disease in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Melanoma; Internal medicine; Oncology; Multivariate analysis; Disease; Pembrolizumab; Clinical significance; Metastatic melanoma; Cancer; Gastroenterology; Immunotherapy; Cancer research","score_opus":0.042144913101330624,"score_gpt":0.3089766241009799,"score_spread":0.2668317109996493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403646049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871391,0.01170215,0.0000032317937,0.0001112967,0.0003159365,0.000627398,0.000032468168,0.00002863923,0.00003975956],"genre_scores_gemma":[0.99784005,0.0019050922,0.000033063017,0.0000035335077,0.000031093074,0.00012229935,0.000041099087,0.000018571518,0.000005204421],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990952,0.000066859255,0.00027994427,0.00023752915,0.00014562844,0.00017485186],"domain_scores_gemma":[0.99948794,0.00008951805,0.000121689925,0.000170284,0.000058392998,0.00007215086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000097431934,0.00015959282,0.00028764337,0.00012104992,0.000040492498,0.000008123775,0.00005079756,0.000029665742,0.000015716063],"category_scores_gemma":[0.000029966004,0.00007861946,0.00005564895,0.00030836157,0.00025269613,0.00011383892,0.000021208547,0.00022466398,6.8880513e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004132646,0.00030431693,0.85957694,0.00013007414,0.00014935012,0.000023131346,0.0011046466,0.0000022258341,0.00026268983,0.000006220026,0.0000031831823,0.1343046],"study_design_scores_gemma":[0.0039274488,0.0026448378,0.9894759,0.00095454924,0.00020343663,0.0000026664795,0.00037115478,0.000021648111,0.0013846756,0.000008111763,0.00089738803,0.00010815053],"about_ca_topic_score_codex":0.00017703549,"about_ca_topic_score_gemma":0.000045537276,"teacher_disagreement_score":0.13419645,"about_ca_system_score_codex":0.00017439948,"about_ca_system_score_gemma":0.00015588403,"threshold_uncertainty_score":0.32060087},"labels":[],"label_agreement":null},{"id":"W4403646280","doi":"10.3390/curroncol31100469","title":"Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Nivolumab vs. Pembrolizumab in Resectable Non-Small Cell Lung Cancer: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pembrolizumab; Nivolumab; Medicine; Oncology; Lung cancer; Internal medicine; Immunotherapy; Ipilimumab; Cancer","score_opus":0.07256722957929775,"score_gpt":0.42346918906028863,"score_spread":0.3509019594809909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403646280","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025696112,0.9879234,0.000012252573,0.00009702564,0.0006296484,0.010370229,0.0001000755,0.000031824242,0.00057861995],"genre_scores_gemma":[0.00012580004,0.9974509,0.000045393543,0.00007241447,0.00009516443,0.0016435226,0.0001103547,0.000079613426,0.00037682147],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9958945,0.0006115773,0.0020021396,0.00071925437,0.00029608427,0.00047646055],"domain_scores_gemma":[0.99749947,0.00041656356,0.0011489488,0.00065790286,0.00016135578,0.000115749084],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00081802503,0.000717086,0.008249233,0.00043393244,0.00005220736,0.000019180603,0.00030835628,0.0003259466,0.00010155755],"category_scores_gemma":[0.00002510158,0.0004491906,0.0004995955,0.00093374983,0.00024798105,0.00004260372,0.0000946756,0.0010360046,0.000010946297],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025156927,0.0004509524,0.000023202538,0.8922168,0.001143626,0.00005686297,0.0007140287,2.3830496e-7,0.0000046503974,0.000005137231,0.0020173353,0.10085145],"study_design_scores_gemma":[0.005653606,0.001296785,0.000018631608,0.64449507,0.0066332705,0.00022186985,0.00004538314,0.000033810495,0.0000022049117,5.7846455e-7,0.34129542,0.0003033792],"about_ca_topic_score_codex":0.00020935724,"about_ca_topic_score_gemma":0.00020065538,"teacher_disagreement_score":0.3392781,"about_ca_system_score_codex":0.0014750145,"about_ca_system_score_gemma":0.0027459122,"threshold_uncertainty_score":0.999796},"labels":[],"label_agreement":null},{"id":"W4403668052","doi":"10.1016/j.kint.2024.09.017","title":"Diagnosis and management of immune checkpoint inhibitor–associated nephrotoxicity: a position statement from the American Society of Onco-nephrology","year":2024,"lang":"en","type":"article","venue":"Kidney International","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Institutes of Health; Amgen; Janssen Canada; Mayo Clinic","keywords":"Position statement; Medicine; Nephrology; Nephrotoxicity; Internal medicine; Intensive care medicine; Kidney; Family medicine","score_opus":0.01602110498128461,"score_gpt":0.29879670719635676,"score_spread":0.28277560221507214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403668052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9536278,0.00081560586,0.00017086662,0.04398679,0.0002812644,0.00036761965,0.0004627438,0.000024315766,0.00026298867],"genre_scores_gemma":[0.98991287,0.005171229,0.00080047705,0.0034730397,0.00010432407,0.00008916593,0.00029641428,0.000011231409,0.0001412582],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99906576,0.00003241261,0.00038132526,0.00015708224,0.0002722861,0.00009113138],"domain_scores_gemma":[0.99952066,0.00008340571,0.0001825648,0.00010768526,0.00006703514,0.000038662114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022812907,0.00008937052,0.00017978354,0.000041087573,0.000025565056,0.000016006856,0.00008101337,0.000030929863,0.0002595854],"category_scores_gemma":[0.000013909034,0.00006537221,0.00017087813,0.00014563547,0.00021035326,0.000044963297,0.00006427127,0.000087045155,0.000002009406],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027639144,0.0010167299,0.029757569,0.0005145675,0.016829021,0.000038485283,0.0036200334,0.000003574533,0.6853031,0.00077724527,0.1895741,0.0698017],"study_design_scores_gemma":[0.0046383627,0.0008584588,0.6608404,0.0027050942,0.00059194677,0.000015825051,0.0013879889,0.001936526,0.14325568,0.00062217435,0.18293609,0.00021143688],"about_ca_topic_score_codex":0.0011589355,"about_ca_topic_score_gemma":0.000017859455,"teacher_disagreement_score":0.63108283,"about_ca_system_score_codex":0.00019618684,"about_ca_system_score_gemma":0.000069487476,"threshold_uncertainty_score":0.2842278},"labels":[],"label_agreement":null},{"id":"W4403734664","doi":"10.1186/s12885-024-12841-2","title":"Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC","year":2024,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Pemetrexed; Carboplatin; Canakinumab; Gemcitabine; Internal medicine; Cisplatin; Oncology; Chemotherapy; non-small cell lung cancer (NSCLC); Lung cancer; Gastroenterology; Pharmacology; Disease","score_opus":0.01733966717411547,"score_gpt":0.28542543706690204,"score_spread":0.2680857698927866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403734664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959211,0.00089630304,0.00030248085,0.00037117573,0.00010524593,0.0017034282,0.00003332029,0.00008719527,0.0005797569],"genre_scores_gemma":[0.9962988,0.00009503847,0.0010174186,0.00048222987,0.000042150525,0.00040388163,0.000102614074,0.00009781226,0.0014600938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981184,0.000055481676,0.00034749715,0.0005064582,0.0005518597,0.00042027605],"domain_scores_gemma":[0.9993425,0.00005688444,0.000111887195,0.00028183954,0.00012171508,0.00008519937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015601172,0.00033388071,0.0005144497,0.00034880583,0.000042478656,0.00006904145,0.00009636512,0.00006776274,0.0006028818],"category_scores_gemma":[0.000006682478,0.00019653059,0.00003920121,0.0014485967,0.00012140057,0.00022059234,0.000008071482,0.00026662636,0.000005215961],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12992601,0.0005349015,0.84355325,0.00064374396,0.0006163698,0.00015598026,0.00249605,0.000150455,0.00017233014,0.00005427175,0.0009610852,0.02073555],"study_design_scores_gemma":[0.08076456,0.00583447,0.8934425,0.0055641453,0.000285939,0.00009466624,0.00045518868,0.0019764244,0.001284571,0.000015828797,0.009475354,0.0008063062],"about_ca_topic_score_codex":0.009736159,"about_ca_topic_score_gemma":0.15563904,"teacher_disagreement_score":0.14590289,"about_ca_system_score_codex":0.00083379593,"about_ca_system_score_gemma":0.0015106626,"threshold_uncertainty_score":0.9968581},"labels":[],"label_agreement":null},{"id":"W4403758188","doi":"10.2196/53443","title":"Development of an Educational Website for Patients With Cancer and Preexisting Autoimmune Diseases Considering Immune Checkpoint Blockers: Usability and Acceptability Study","year":2024,"lang":"en","type":"article","venue":"JMIR Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Usability; Cancer; Immune checkpoint; Immune system; Medicine; Computer science; Immunology; Immunotherapy; Internal medicine; Human–computer interaction","score_opus":0.02194450951102862,"score_gpt":0.3393978026661669,"score_spread":0.3174532931551383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403758188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914746,0.005820328,0.0000069815255,0.0003902045,0.00016113916,0.0019692725,0.00012922767,0.000035900535,0.000012303662],"genre_scores_gemma":[0.99595237,0.00004740674,0.0024068097,0.00002746583,0.00006377803,0.0013696243,0.00003373802,0.000021764617,0.0000770411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998803,0.000021497435,0.00040358026,0.0004007244,0.00019999218,0.00017119176],"domain_scores_gemma":[0.99938446,0.00009495187,0.00009827856,0.00019810059,0.00014353982,0.000080666054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020605352,0.0001675552,0.00029962495,0.000056756497,0.00012244088,0.000040439674,0.000044237542,0.000035987156,0.00027281317],"category_scores_gemma":[0.000030760675,0.0001272618,0.00004480038,0.00013736669,0.00018784325,0.0001582518,0.000045442204,0.00007922178,1.309554e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002352983,0.00081877474,0.862255,0.0012471789,0.0004305385,5.6272216e-7,0.004964958,0.0000016604237,0.0026281944,0.0000030135652,0.000020082092,0.12527706],"study_design_scores_gemma":[0.0027405743,0.00038966865,0.9917594,0.00045067136,0.00014766284,0.0000015700988,0.0009027777,0.00014302623,0.0009869742,0.0000168047,0.0023003994,0.00016046257],"about_ca_topic_score_codex":0.0005365981,"about_ca_topic_score_gemma":0.0005689394,"teacher_disagreement_score":0.12950441,"about_ca_system_score_codex":0.00026980165,"about_ca_system_score_gemma":0.0007723827,"threshold_uncertainty_score":0.5189585},"labels":[],"label_agreement":null},{"id":"W4403848417","doi":"10.1093/jncics/pkae102","title":"Patient-reported outcome measure (PROM) programs for monitoring symptoms among patients treated with immunotherapy: a scoping review","year":2024,"lang":"en","type":"review","venue":"JNCI Cancer Spectrum","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Université de Montréal; Université de Sherbrooke; McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; Hôpital Charles-Le Moyne; McGill University; Hôpital Maisonneuve-Rosemont; St Mary's Hospital Centre","funders":"Bristol-Myers Squibb Canada; AstraZeneca Canada; Merck Canada; Bristol-Myers Squibb; AstraZeneca; Fonds de Recherche du Québec - Santé; Roche Canada","keywords":"Prom; Medicine; Patient-reported outcome; MEDLINE; Mood; Rash; Nausea; Physical therapy; Quality of life (healthcare); Internal medicine; Psychiatry; Nursing","score_opus":0.05447837718064114,"score_gpt":0.3601444576062425,"score_spread":0.30566608042560134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403848417","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010326832,0.97783464,0.000008342358,0.00011460259,0.0015626285,0.018766537,0.00010680086,0.0004139935,0.00015975564],"genre_scores_gemma":[0.0003146148,0.98678553,0.000078101286,0.00015019414,0.00062602106,0.010450171,0.00039711036,0.00043477194,0.00076350855],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9945946,0.000101543344,0.0021454827,0.0012775417,0.00093458896,0.00094628177],"domain_scores_gemma":[0.99693626,0.0000525983,0.0014324521,0.0010704502,0.00027836437,0.00022987617],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038306654,0.0012627511,0.0039973566,0.0003482979,0.00017326634,0.00015321109,0.00028750394,0.00045243942,0.00012189116],"category_scores_gemma":[0.00003502159,0.0008060855,0.0016372573,0.0013878471,0.00014838969,0.0001560396,0.000058345286,0.0007546441,0.0000138562355],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048490864,0.00020965384,0.016317658,0.19102737,0.004029828,0.000054638636,0.000056567733,3.4001314e-8,8.5238753e-7,7.2990633e-7,0.00033234092,0.7874854],"study_design_scores_gemma":[0.0024511425,0.0015261295,0.000667935,0.7545433,0.008897874,0.00006539179,0.000007933719,8.7789516e-7,0.000018674491,0.0000015373915,0.23092814,0.0008910762],"about_ca_topic_score_codex":0.00059277326,"about_ca_topic_score_gemma":0.00012839104,"teacher_disagreement_score":0.78659433,"about_ca_system_score_codex":0.0018520375,"about_ca_system_score_gemma":0.0013711624,"threshold_uncertainty_score":0.999439},"labels":[],"label_agreement":null},{"id":"W4403852334","doi":"10.1172/jci179501","title":"Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's Health Research Institute; BC Cancer Agency; Foothills Medical Centre; Vancouver General Hospital; University of Calgary; University of Victoria; University of British Columbia","funders":"Medical Research and Materiel Command; Congressionally Directed Medical Research Programs; National Cancer Institute; Instituto de Salud Carlos III; Cancer Council Tasmania; Cancer Council Victoria; National Center for Advancing Translational Sciences; Medical Research Council; Foundation Medicine; National Institutes of Health; Peter MacCallum Foundation; Canadian Institutes of Health Research; Cancer Institute NSW; Terry Fox Research Institute; Cancer Council Western Australia; Cancer Australia; Bundesministerium für Bildung und Forschung; National Institute for Health and Care Research; Cancer Council NSW; Marshfield Clinic Research Foundation; Ovarian Cancer Australia; Genome British Columbia; Fred C. and Katherine B. Andersen Foundation; Mayo Foundation for Medical Education and Research; Deutsche Forschungsgemeinschaft; VGH and UBC Hospital Foundation; Friedrich-Alexander-Universität Erlangen-Nürnberg; Cancer Council South Australia; Deutsches Krebsforschungszentrum; Cancer Council Queensland; Ministerio de Economía y Competitividad; University of Pittsburgh; Victorian Cancer Agency; National Health and Medical Research Council; AstraZeneca; Pfizer; National Center for Research Resources; BC Cancer Foundation; Oak Foundation; Cancer Research UK; Minnesota Ovarian Cancer Alliance; U.S. Department of Defense","keywords":"Term (time); Cancer; Ovarian cancer; Tumor microenvironment; Cancer research; Medicine; Oncology; Biology; Immunology; Bioinformatics; Internal medicine","score_opus":0.03837565036358295,"score_gpt":0.35037581692255637,"score_spread":0.31200016655897345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403852334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841081,0.01192785,0.000042649943,0.0033683279,0.00039768545,0.00011949621,0.0000071137088,0.0000018981384,0.000026908236],"genre_scores_gemma":[0.9971042,0.0020724603,0.0003494604,0.0003446449,0.00007855308,0.000001058132,0.000001126268,0.000006494956,0.000041961055],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984464,0.00015149287,0.0009986489,0.00008733589,0.00025394495,0.00006218578],"domain_scores_gemma":[0.99889505,0.0001970683,0.0006552867,0.00012539457,0.000075820455,0.0000513948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008804167,0.000071946924,0.00037388125,0.000051061674,0.00001163114,0.0000053769163,0.00008787245,0.00008663577,0.000051244457],"category_scores_gemma":[0.00022864097,0.000040261948,0.00026436488,0.00012396008,0.00063083327,0.000043282093,0.000027524991,0.00027821586,1.1799022e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012728422,0.00012831796,0.29697755,0.00033797824,0.00054947706,0.000026971944,0.00019968976,0.00000826561,0.6752661,0.0001279391,0.00016921165,0.024935683],"study_design_scores_gemma":[0.0008241082,0.0005059241,0.81088185,0.0010787384,0.00018809475,0.000063028565,0.000025861113,0.000012235561,0.18601415,0.0002468407,0.00012836902,0.000030774532],"about_ca_topic_score_codex":0.00007782727,"about_ca_topic_score_gemma":0.000012324828,"teacher_disagreement_score":0.51390433,"about_ca_system_score_codex":0.000025311736,"about_ca_system_score_gemma":0.00018608324,"threshold_uncertainty_score":0.23243314},"labels":[],"label_agreement":null},{"id":"W4403866180","doi":"10.61173/67aqtk89","title":"Exploring the Synergy of Immunotherapy and Conventional Treatments in Cancer Therapy","year":2024,"lang":"en","type":"article","venue":"MedScien","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Markham Stouffville Hospital","funders":"","keywords":"Immunotherapy; Cancer immunotherapy; Cancer therapy; Medicine; Cancer; Oncology; Internal medicine","score_opus":0.0906523406850735,"score_gpt":0.3305187646000317,"score_spread":0.23986642391495822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403866180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.960734,0.03622426,0.000007506041,0.0019845956,0.0003641308,0.00019185127,0.0000065141253,0.000016072134,0.00047103316],"genre_scores_gemma":[0.9732852,0.02511049,0.00002521662,0.00022543233,0.000052056464,0.000121725505,0.0000028045724,0.000010353533,0.0011667435],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9994162,0.000023436522,0.00014681616,0.0001377476,0.00016247417,0.00011335128],"domain_scores_gemma":[0.9997784,0.00005393041,0.000020069347,0.00011242072,0.000015522968,0.00001965223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023617511,0.000073207535,0.00012153811,0.00009944959,0.000033077904,0.000016911279,0.000053634903,0.000017425536,0.00021373341],"category_scores_gemma":[0.000003272053,0.000040918512,0.000060023718,0.0002962985,0.00013220786,0.00008488491,0.000008731894,0.0000578384,0.0000014680832],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012107411,0.00013691517,0.019482756,0.000056854184,0.00044762014,0.000020194635,0.0030211795,0.0000033987517,0.20185032,0.0005410983,0.00031871285,0.7729102],"study_design_scores_gemma":[0.005788113,0.00054844585,0.78503555,0.00090773427,0.000039356448,0.00003716356,0.0005166232,0.00037622443,0.06496185,0.00027648668,0.14134383,0.0001686024],"about_ca_topic_score_codex":0.0007815138,"about_ca_topic_score_gemma":0.000051682055,"teacher_disagreement_score":0.7727416,"about_ca_system_score_codex":0.000066061555,"about_ca_system_score_gemma":0.00009055296,"threshold_uncertainty_score":0.2340231},"labels":[],"label_agreement":null},{"id":"W4403882077","doi":"10.1101/2024.10.23.619890","title":"Anti-PTHrP blockade limits CD8+ T-cell exhaustion in anti-cancer immunotherapy","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; McGill University Health Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Immunotherapy; Immunosurveillance; Cancer research; Blocking antibody; CD8; Blockade; Immunology; Medicine; Cancer; Immune system; Tumor microenvironment; Immune checkpoint; Melanoma; Cancer immunotherapy; Antigen; Internal medicine; Receptor","score_opus":0.01707283115261731,"score_gpt":0.25823209440767675,"score_spread":0.24115926325505943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403882077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.952898,0.03957118,0.000055236032,0.0016848611,0.0031336192,0.0015667338,0.00020483024,0.0008370013,0.00004852135],"genre_scores_gemma":[0.9731128,0.023397746,0.00073012465,0.0007417718,0.0010332552,0.00042620348,0.0000014599883,0.0004236467,0.0001329994],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995787,0.00012491787,0.0010431535,0.0015217646,0.0006490452,0.0008741076],"domain_scores_gemma":[0.997405,0.00005061239,0.00043214526,0.0015490252,0.00032074415,0.00024245733],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007796092,0.0009324229,0.001275566,0.00086713093,0.00009599572,0.00022948181,0.0004965983,0.0010853489,0.00023467364],"category_scores_gemma":[0.000038300834,0.0008415429,0.00047723553,0.0012081229,0.00020061056,0.00011747451,0.00028655998,0.0019125657,0.00010982373],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000534663,0.0004923969,0.016448965,0.0016990557,0.00051334716,0.000220215,0.000033473625,0.000050262686,0.97863615,0.00002590225,0.0012916366,0.000053963573],"study_design_scores_gemma":[0.003825316,0.00016381247,0.14983818,0.003667985,0.00031651225,1.359341e-7,0.0000075114954,0.00028352786,0.8105392,0.0000029605492,0.030179705,0.001175162],"about_ca_topic_score_codex":0.0004934688,"about_ca_topic_score_gemma":0.0000123034415,"teacher_disagreement_score":0.16809693,"about_ca_system_score_codex":0.0009515105,"about_ca_system_score_gemma":0.0014355745,"threshold_uncertainty_score":0.99940354},"labels":[],"label_agreement":null},{"id":"W4403912394","doi":"10.1016/j.celrep.2024.114907","title":"PD-1 endocytosis unleashes the cytolytic potential of checkpoint blockade in tumor immunity","year":2024,"lang":"en","type":"article","venue":"Cell Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health; Foundation for the National Institutes of Health","keywords":"Blockade; Endocytosis; Cytolysis; Immunity; Cancer research; Cell biology; Immune checkpoint; Immunology; Biology; Immune system; Cytotoxicity; Receptor; Genetics","score_opus":0.011239151766757749,"score_gpt":0.2507950787865516,"score_spread":0.23955592701979386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403912394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853592,0.0070893113,0.000017555889,0.00069777836,0.00056048384,0.0003287097,0.0000025636873,0.00004532294,0.0058990614],"genre_scores_gemma":[0.99803644,0.00023782402,0.000041653802,0.00010515521,0.00011751919,0.000020522048,0.0000066624557,0.000020488967,0.0014137358],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987521,0.0000423126,0.0005435335,0.0002198762,0.00024586983,0.00019626183],"domain_scores_gemma":[0.9992627,0.000055998564,0.00012657445,0.00047516884,0.000035334273,0.00004424618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005155263,0.000128427,0.00024789097,0.000108777174,0.000040582392,0.000023038769,0.00007235846,0.000050012775,0.00031104442],"category_scores_gemma":[0.000048043643,0.00008377106,0.00022268412,0.00032348928,0.00013659752,0.000039291033,0.000043108914,0.00024940117,0.000007503743],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004623874,0.00020710201,0.004488303,0.00046704005,0.00013012691,0.004804983,0.0006554776,0.000014563817,0.9830267,0.000008337645,0.000877089,0.00485791],"study_design_scores_gemma":[0.0007537391,0.00018260737,0.04917323,0.000542444,0.00019096865,0.0027770987,0.0006653541,0.0002558268,0.9325561,0.00021189735,0.012530871,0.00015985113],"about_ca_topic_score_codex":0.00081682735,"about_ca_topic_score_gemma":0.000029187975,"teacher_disagreement_score":0.050470565,"about_ca_system_score_codex":0.000108487206,"about_ca_system_score_gemma":0.00028201775,"threshold_uncertainty_score":0.34160846},"labels":[],"label_agreement":null},{"id":"W4403957774","doi":"10.1111/gtc.13177","title":"Immunotherapy‐induced reprogramming of cancer‐associated fibroblasts can promote tumor progression","year":2024,"lang":"en","type":"article","venue":"Genes to Cells","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Mental Health Association; Ministry of Education, Culture, Sports, Science and Technology; Takeda Science Foundation","keywords":"Cancer-Associated Fibroblasts; Biology; Cancer research; Immunotherapy; Reprogramming; Cancer immunotherapy; Tumor microenvironment; Tumor progression; Tumor necrosis factor alpha; Melanoma; Immune system; Cancer; Context (archaeology); Crosstalk; Immunology; Cell","score_opus":0.017081900321769254,"score_gpt":0.3187999496728293,"score_spread":0.30171804935106006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403957774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98484284,0.012091409,0.00001666755,0.00089087564,0.0007747003,0.0010272827,0.000035354904,0.00017788718,0.00014296838],"genre_scores_gemma":[0.9961573,0.00048355074,0.00088290527,0.00027894907,0.00017715065,0.0001420967,0.00002030619,0.0000672389,0.0017905125],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984673,0.000040339317,0.00039980942,0.00041264558,0.00032079624,0.00035907188],"domain_scores_gemma":[0.9993174,0.000028377295,0.00009277507,0.00034821368,0.000101611826,0.00011159782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029643608,0.00020647854,0.0003456171,0.00015707462,0.000060313865,0.000043348424,0.00012386299,0.00009416996,0.00018889345],"category_scores_gemma":[0.00001399999,0.00016463401,0.00019590076,0.00064582325,0.000045311284,0.00004117716,0.00003901544,0.00013236965,0.000013291753],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004964914,0.000071111346,0.00034973308,0.00019941974,0.00021390188,0.000031988846,0.0006819208,0.0000042526885,0.6339463,0.0000010394524,0.0003932527,0.3636106],"study_design_scores_gemma":[0.0009227373,0.0010981488,0.0022672713,0.002169608,0.00006917475,0.000014076032,0.000083918065,0.00016724959,0.9493163,0.000005940409,0.04368699,0.00019854965],"about_ca_topic_score_codex":0.0015762033,"about_ca_topic_score_gemma":0.00034557175,"teacher_disagreement_score":0.36341205,"about_ca_system_score_codex":0.0002193024,"about_ca_system_score_gemma":0.00032444214,"threshold_uncertainty_score":0.671358},"labels":[],"label_agreement":null},{"id":"W4404004861","doi":"10.1016/j.anai.2024.10.023","title":"Corrigendum to ‘A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology’ [Annals of Allergy, Asthma &amp; Immunology 133/3 (2024) 286-94]","year":2024,"lang":"en","type":"erratum","venue":"Annals of Allergy Asthma & Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; McMaster University; St. Joseph’s Healthcare Hamilton; Impact","funders":"National Institutes of Health","keywords":"Medicine; Dupilumab; Delphi; Position paper; Asthma; Delphi method; Immunology; Family medicine; Allergy; Artificial intelligence; Pathology","score_opus":0.05092848590061554,"score_gpt":0.30891570771168547,"score_spread":0.2579872218110699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404004861","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49888065,0.418951,0.000016998747,0.06210265,0.00986059,0.007402964,0.0019193456,0.00007511848,0.00079068827],"genre_scores_gemma":[0.15642616,0.82305634,0.00039348513,0.00973706,0.00016777385,0.000598117,0.0010208425,0.00034139698,0.008258838],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919865,0.0020741294,0.0036864446,0.00094717497,0.0005483401,0.0007574171],"domain_scores_gemma":[0.9915037,0.00079508394,0.00425731,0.0017201974,0.0016338292,0.00008988196],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013879299,0.00095003244,0.0040906905,0.00108771,0.00013193158,0.000015816497,0.0007354169,0.0008156089,0.00039710314],"category_scores_gemma":[0.001329739,0.0006792713,0.0006868993,0.0013875051,0.0014903649,0.00014147014,0.0006254156,0.0011408828,0.000004857407],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031778138,0.0032596388,0.00010445288,0.041244164,0.047891185,0.000042444368,0.004861239,0.000016382104,0.04213107,0.0017247089,0.81167144,0.015275152],"study_design_scores_gemma":[0.0047845347,0.013564099,0.088211685,0.11817027,0.00018095857,0.00039015678,0.00319343,0.000033626588,0.005127284,0.00015369042,0.76489395,0.0012963131],"about_ca_topic_score_codex":0.0033659127,"about_ca_topic_score_gemma":0.0025860071,"teacher_disagreement_score":0.40410534,"about_ca_system_score_codex":0.00011894858,"about_ca_system_score_gemma":0.0004757494,"threshold_uncertainty_score":0.99956584},"labels":[],"label_agreement":null},{"id":"W4404024879","doi":"10.1007/s11523-024-01111-7","title":"Durvalumab Following Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Differences in Survival Based on Age and Post-Progression Systemic Therapy","year":2024,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia; University of Victoria","funders":"AstraZeneca","keywords":"Medicine; Durvalumab; Chemoradiotherapy; Stage (stratigraphy); Oncology; Systemic therapy; Lung cancer; Internal medicine; Cancer; Pathology; Immunotherapy","score_opus":0.021619840625903716,"score_gpt":0.32708693537086064,"score_spread":0.3054670947449569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404024879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96288157,0.031426653,0.0003710811,0.0013759095,0.0015460739,0.0018825157,0.00005681872,0.00011218074,0.0003472235],"genre_scores_gemma":[0.99395674,0.0029819424,0.00051771535,0.0009953172,0.00021983591,0.00048573446,0.000073470605,0.000061245664,0.0007079839],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99828655,0.00014138674,0.00041430094,0.00052555784,0.00020344736,0.0004287338],"domain_scores_gemma":[0.99910474,0.00042885228,0.000103072016,0.0002203996,0.00004514397,0.000097796226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006022924,0.00029379645,0.0007763236,0.00028631804,0.000093969196,0.000043215936,0.00012178289,0.00028889635,0.00014000345],"category_scores_gemma":[0.000015096546,0.0002201629,0.00021845345,0.00028930185,0.00008034671,0.00005040903,0.000013508694,0.00027246683,0.0000010834077],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02539829,0.0006223256,0.042235292,0.001956106,0.0005432815,0.0009859779,0.0039523803,0.0000282805,0.8025211,0.000027587357,0.00063131005,0.121098064],"study_design_scores_gemma":[0.22151147,0.04134141,0.31515518,0.01392116,0.0009545745,0.00013300018,0.00619163,0.22549248,0.12167833,0.00007286698,0.050039712,0.0035081967],"about_ca_topic_score_codex":0.0006351239,"about_ca_topic_score_gemma":0.00022595437,"teacher_disagreement_score":0.68084276,"about_ca_system_score_codex":0.0005685231,"about_ca_system_score_gemma":0.0006530057,"threshold_uncertainty_score":0.89779824},"labels":[],"label_agreement":null},{"id":"W4404053084","doi":"10.1136/jitc-2024-sitc2024.0716","title":"716 A randomized phase II window of opportunity clinical trial of PD-1 +/- IL-4 inhibition in early-stage ER+ HER2- breast cancer","year":2024,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; McMaster University; Ontario Institute for Cancer Research","funders":"","keywords":"Breast cancer; Stage (stratigraphy); Oncology; Window of opportunity; Window (computing); Internal medicine; Medicine; Cancer; Computer science; Biology; Real-time computing","score_opus":0.045850144807708965,"score_gpt":0.3498682161185697,"score_spread":0.3040180713108608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404053084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937434,0.0015521665,0.000009212943,0.0022159927,0.00071402773,0.0011956977,0.0002868631,0.00004456102,0.00023808186],"genre_scores_gemma":[0.99691737,0.001826043,0.00008972763,0.00026167868,0.00029551133,0.000056774483,0.000051413343,0.000030728424,0.00047072803],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973335,0.00025103215,0.0013899973,0.00037520428,0.00040048404,0.00024973406],"domain_scores_gemma":[0.99864763,0.00018876612,0.00034628581,0.00028247226,0.000104260485,0.0004305657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025556784,0.00023758462,0.0010679758,0.00022076053,0.00004759421,0.000027606056,0.00005716856,0.00026827323,0.000104035695],"category_scores_gemma":[0.0004416378,0.00018973942,0.00042347432,0.00030589927,0.0009570604,0.00018188774,0.000036771307,0.0003720216,0.0000012023085],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88354725,0.0019772418,0.0033810262,0.0015871747,0.0011037085,0.000434129,0.0016797878,0.00000929029,0.0850994,0.0003550321,0.00185769,0.018968288],"study_design_scores_gemma":[0.8894608,0.0023509972,0.046514776,0.0036545894,0.0007042165,0.00019510457,0.00020144922,0.00029098915,0.051276226,0.00049397233,0.004441597,0.00041526128],"about_ca_topic_score_codex":0.0023669212,"about_ca_topic_score_gemma":0.00011900964,"teacher_disagreement_score":0.04313375,"about_ca_system_score_codex":0.00007476315,"about_ca_system_score_gemma":0.001190333,"threshold_uncertainty_score":0.7737349},"labels":[],"label_agreement":null},{"id":"W4404065332","doi":"10.1136/jitc-2024-sitc2024.0878","title":"878 The immunomodulatory impact of chemotherapy when combined with PD-1 blockade in resectable lung cancers","year":2024,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; McGill University Health Centre","funders":"","keywords":"Blockade; Medicine; Chemotherapy; Lung; Oncology; Internal medicine; Cancer research; Receptor","score_opus":0.009662269831908502,"score_gpt":0.2611179576055441,"score_spread":0.25145568777363564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404065332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836194,0.01302637,0.000004514209,0.0019498111,0.00018244657,0.00055707956,0.000017873575,0.000060645736,0.0005818856],"genre_scores_gemma":[0.99804246,0.00064596056,0.00013289147,0.00028118564,0.00009671856,0.00003022683,0.000015706284,0.0000513612,0.0007034995],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985015,0.000051626044,0.0004070488,0.00034126235,0.0003382237,0.00036038388],"domain_scores_gemma":[0.99913675,0.00006421341,0.000105945626,0.0004239327,0.0000583847,0.00021078483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005405844,0.00026708044,0.00041200576,0.00016844978,0.000077973375,0.00007285511,0.00013443535,0.00013538566,0.00006598151],"category_scores_gemma":[0.00003724237,0.00016014109,0.00016881974,0.00037880166,0.0004923165,0.0001600389,0.000020410289,0.00034902064,0.0000017658949],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015193017,0.00030573722,0.23116462,0.002133165,0.004499128,0.000499393,0.013282619,0.0008453207,0.69792855,0.00031517603,0.027390933,0.0064423177],"study_design_scores_gemma":[0.006326087,0.001697069,0.9012707,0.002319674,0.00025069332,0.00046162523,0.0005472015,0.0021297275,0.076905,0.00053192343,0.0070593925,0.0005009191],"about_ca_topic_score_codex":0.004796182,"about_ca_topic_score_gemma":0.000314445,"teacher_disagreement_score":0.67010605,"about_ca_system_score_codex":0.0004408092,"about_ca_system_score_gemma":0.0014151733,"threshold_uncertainty_score":0.7250424},"labels":[],"label_agreement":null},{"id":"W4404067466","doi":"10.1136/jitc-2024-sitc2024.1488","title":"1488 A multicenter phase 2 trial of lifileucel plus pembrolizumab in patients with checkpoint inhibitor-naive metastatic NSCLC: updated results","year":2024,"lang":"en","type":"article","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Oncology; Medicine; Internal medicine; Computer science; Immunotherapy; Cancer","score_opus":0.01740966404119063,"score_gpt":0.2987447312813352,"score_spread":0.28133506724014457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404067466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99444044,0.00020461272,0.00006810298,0.0005044127,0.00046320172,0.0017853221,0.00017954694,0.00007277643,0.002281601],"genre_scores_gemma":[0.99755406,0.000026886044,0.00043088334,0.00022009535,0.00008118844,0.00005002531,0.0003476034,0.000033499568,0.0012557317],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980994,0.00007000282,0.0007657307,0.0003763653,0.00042592888,0.00026258203],"domain_scores_gemma":[0.9992841,0.00007261723,0.00012426099,0.00030366136,0.00012353143,0.00009183465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003022831,0.00022008693,0.00045857977,0.00029879838,0.000019942492,0.000028345357,0.00007468742,0.0000668136,0.00043239706],"category_scores_gemma":[0.00006229859,0.00014269803,0.00014800383,0.0004978693,0.00010577448,0.00013410466,0.000027686981,0.00020331588,0.000025023326],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97901744,0.0021429858,0.00016146667,0.00021731999,0.00057377986,0.000089723166,0.0011078822,0.0000023199204,0.0025964247,0.0000110499195,0.0054043974,0.00867522],"study_design_scores_gemma":[0.95272726,0.013165126,0.004193749,0.0014137704,0.0003625571,0.000008309197,0.00042714493,0.002184138,0.01804981,0.000006955396,0.007145869,0.000315291],"about_ca_topic_score_codex":0.00054147514,"about_ca_topic_score_gemma":0.00011753293,"teacher_disagreement_score":0.02629015,"about_ca_system_score_codex":0.0002488254,"about_ca_system_score_gemma":0.00031942103,"threshold_uncertainty_score":0.58190566},"labels":[],"label_agreement":null},{"id":"W4404067494","doi":"10.1136/jitc-2024-sitc2024.1475","title":"1475 Combination of LND101, a healthy donor microbiome transplantation product, to doublet immunotherapy or immunotherapy combined with targeted therapy in metastatic renal cell carcinoma patients","year":2024,"lang":"en","type":"article","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St Joseph's Health Care; London Health Sciences Centre; National Research Council Canada; Western University","funders":"","keywords":"Immunotherapy; Medicine; Renal cell carcinoma; Transplantation; Oncology; Adoptive immunotherapy; Colon carcinoma; Internal medicine; Cancer research; Colorectal cancer; Cancer","score_opus":0.014501595157358936,"score_gpt":0.2636816590910579,"score_spread":0.24918006393369896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404067494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897738,0.0032021478,0.0005648062,0.0020393105,0.00030784807,0.0036766413,0.000096326636,0.00010998747,0.00022912011],"genre_scores_gemma":[0.99284303,0.0016900627,0.0021840697,0.0014797782,0.000029507057,0.0002081036,0.00046805415,0.00009619674,0.0010012191],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974213,0.00016496779,0.0009098337,0.00060342246,0.0004498243,0.00045063245],"domain_scores_gemma":[0.9989325,0.00010166012,0.00017744342,0.00044300783,0.00024446883,0.000100962505],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049495633,0.00041677576,0.00067261717,0.0008381879,0.000067578585,0.000060210125,0.00018507747,0.000084863015,0.0005559078],"category_scores_gemma":[0.0000044138233,0.00027571493,0.00016094126,0.0017048415,0.00010645623,0.0002387726,0.000008093841,0.00022655832,0.000012133438],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21842195,0.0027666774,0.009478491,0.0009958533,0.00051089877,0.000063250416,0.007472893,0.000011939224,0.7280551,0.00004637779,0.0010534729,0.031123085],"study_design_scores_gemma":[0.08686353,0.03938733,0.19894455,0.00085214217,0.000119708966,0.00009062429,0.0004769975,0.00018413572,0.66509145,0.00004510474,0.0070855627,0.00085888844],"about_ca_topic_score_codex":0.0013846263,"about_ca_topic_score_gemma":0.00031447763,"teacher_disagreement_score":0.18946606,"about_ca_system_score_codex":0.00029771644,"about_ca_system_score_gemma":0.0005378005,"threshold_uncertainty_score":0.9999695},"labels":[],"label_agreement":null},{"id":"W4404070394","doi":"10.7759/cureus.73049","title":"Pembrolizumab-Induced Insulin-Dependent Diabetes Mellitus in a Patient With Triple-Negative Breast Cancer: A Rare Immune-Related Adverse Event","year":2024,"lang":"en","type":"article","venue":"Cureus","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brandon Regional Health Authority","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Diabetic ketoacidosis; Adverse effect; Polyuria; Diabetes mellitus; Insulin; Oncology; Cancer; Endocrinology; Immunotherapy","score_opus":0.008620476424740953,"score_gpt":0.25461894001103147,"score_spread":0.24599846358629052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404070394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9588699,0.036894046,0.0000032690334,0.0012562465,0.00081695657,0.0011370025,0.00015300418,0.00014411488,0.00072550913],"genre_scores_gemma":[0.99643385,0.0024819945,0.000024712495,0.00021310455,0.00008012075,0.00030094996,0.00004053476,0.0000574117,0.0003672907],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979468,0.00008711237,0.0006009758,0.00049729354,0.00041200704,0.00045581197],"domain_scores_gemma":[0.9991884,0.0000688098,0.00012938674,0.000368011,0.00010390061,0.00014148124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018663978,0.00032584716,0.0004656898,0.0001995842,0.000065659115,0.000031688232,0.00012740029,0.00016562719,0.00076100195],"category_scores_gemma":[0.000024030265,0.00023804579,0.00021623398,0.00069934677,0.000088614914,0.00017169485,0.00004728678,0.0004360925,0.00003221997],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04434076,0.0033905122,0.025055097,0.0019815678,0.008583901,0.006209135,0.046104457,0.00030453302,0.1479088,0.00034065812,0.0020043608,0.71377623],"study_design_scores_gemma":[0.100841165,0.013042806,0.6474425,0.026887652,0.002406912,0.0029146879,0.015337281,0.008167351,0.16145651,0.00078223896,0.016565664,0.004155215],"about_ca_topic_score_codex":0.002657225,"about_ca_topic_score_gemma":0.00080514955,"teacher_disagreement_score":0.709621,"about_ca_system_score_codex":0.0010175136,"about_ca_system_score_gemma":0.0006018673,"threshold_uncertainty_score":0.97072256},"labels":[],"label_agreement":null},{"id":"W4404124672","doi":"10.3390/biomedicines12112547","title":"Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review","year":2024,"lang":"en","type":"review","venue":"Biomedicines","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre; Université de Sherbrooke","funders":"","keywords":"Immune system; Immune checkpoint; Medicine; Cancer research; Immunology; Immunotherapy","score_opus":0.028150863673996128,"score_gpt":0.353460425107117,"score_spread":0.3253095614331209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404124672","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008334667,0.99332744,0.0000046270366,0.00095160335,0.0023968962,0.0028944793,0.000024218472,0.00011993949,0.00027248354],"genre_scores_gemma":[0.000004019673,0.997173,0.00008628419,0.0004636397,0.0010904806,0.00022879543,0.00027436056,0.00012583805,0.00055354077],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99621606,0.0001414474,0.002087873,0.0005968109,0.00058492314,0.0003728615],"domain_scores_gemma":[0.9978368,0.00021895613,0.0007863788,0.00081790023,0.00019054383,0.00014942086],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043707952,0.0007533556,0.0045299693,0.00068215415,0.00003997082,0.000011105389,0.0002318416,0.0003327067,0.00007076327],"category_scores_gemma":[0.00018832332,0.00046094935,0.002217204,0.0016615717,0.00035657262,0.000038004517,0.00013103025,0.00045638834,0.0000939856],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025459984,0.000046157762,1.7908484e-7,0.46820843,0.0012447205,0.00021285427,0.000037635,7.72655e-10,0.001108624,0.0000023086652,0.0069979816,0.52211565],"study_design_scores_gemma":[0.0005078825,0.0002737438,0.00000390587,0.42878708,0.007301281,0.00029664056,0.000015720216,2.8591555e-7,0.00018920781,0.0000030362069,0.56240726,0.00021398613],"about_ca_topic_score_codex":0.00013137626,"about_ca_topic_score_gemma":7.7761945e-7,"teacher_disagreement_score":0.55540925,"about_ca_system_score_codex":0.00019308076,"about_ca_system_score_gemma":0.00047226384,"threshold_uncertainty_score":0.99978423},"labels":[],"label_agreement":null},{"id":"W4404174330","doi":"10.4049/jimmunol.212.supp.0377.6071","title":"PD-1 endocytosis unleashes the cytolytic potential of check-point blockade in tumor immunity","year":2024,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Cytolysis; Endocytosis; Blockade; Immunity; Immunology; Biology; Cell biology; Virology; Immune system; Cytotoxicity; Genetics; Cell; Receptor","score_opus":0.01262385101484843,"score_gpt":0.2635879586380225,"score_spread":0.25096410762317406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404174330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9505997,0.038982764,0.000065646105,0.009139962,0.0007220709,0.00017900058,0.000003925049,0.000011031137,0.00029593759],"genre_scores_gemma":[0.9952309,0.0040602125,0.00004118845,0.00028108803,0.00017511102,0.0000029440748,8.31356e-7,0.00001759815,0.00019012643],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998385,0.0003536447,0.0007208127,0.00007916583,0.00022178196,0.00023956943],"domain_scores_gemma":[0.9988756,0.00035259503,0.00028618838,0.000356583,0.00010414341,0.000024894965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015019539,0.00014327191,0.00041776712,0.0002304468,0.000072586714,0.000015217338,0.00041232543,0.00007293439,0.00028081462],"category_scores_gemma":[0.00011766129,0.00007040567,0.0002847143,0.00038752914,0.00050365104,0.00007649439,0.00007874076,0.00084166456,0.000010571985],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075660534,0.00017675306,0.00032314556,0.00007904308,0.0012522497,0.00020465393,0.002256491,0.00002782795,0.9765631,0.000085981424,0.0006054959,0.01085921],"study_design_scores_gemma":[0.010945603,0.005136624,0.2126522,0.0024547284,0.0018571825,0.032093693,0.017036466,0.0005748878,0.7008721,0.0019426906,0.014026207,0.00040757502],"about_ca_topic_score_codex":0.00040556272,"about_ca_topic_score_gemma":0.000029225906,"teacher_disagreement_score":0.27569097,"about_ca_system_score_codex":0.00015236894,"about_ca_system_score_gemma":0.00034970674,"threshold_uncertainty_score":0.36566603},"labels":[],"label_agreement":null},{"id":"W4404186508","doi":"10.51731/cjht.2024.1023","title":"Elranatamab (Elrexfio)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.02548443029172805,"score_gpt":0.3087367537867053,"score_spread":0.28325232349497725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404186508","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.071524225,0.738882,0.00028369704,0.18621607,0.0016182237,0.00021443523,0.000020475625,0.00024277628,0.0009980722],"genre_scores_gemma":[0.9953836,0.0029732343,0.000350226,0.0010224014,0.000026160229,0.0000019466345,0.0000015560556,0.000013911237,0.00022696739],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990579,0.000016678214,0.00040120457,0.00009534829,0.000119372824,0.00030949182],"domain_scores_gemma":[0.99956316,0.000028630882,0.00009386205,0.00016612302,0.00007055156,0.000077645665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005174067,0.00008730246,0.000255871,0.00074769364,0.000100103854,0.00004119905,0.0001503362,0.00010942634,0.00011169904],"category_scores_gemma":[0.00011667177,0.000065092725,0.00011878881,0.00043643994,0.00017649976,0.00008029871,0.000005489566,0.00040587253,0.00001402562],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044712895,0.0000051998986,0.000520561,0.00020885703,0.00009599334,0.00060393487,0.0001726288,3.6198946e-7,0.00018163555,0.00073080894,0.036414847,0.96102047],"study_design_scores_gemma":[0.0004269265,0.0005395197,0.0033741477,0.0008930421,0.000018901226,0.0018867219,0.0014214001,0.000010608215,0.00077424827,0.0011443216,0.98943716,0.00007299445],"about_ca_topic_score_codex":0.0029435367,"about_ca_topic_score_gemma":0.0015328174,"teacher_disagreement_score":0.96094745,"about_ca_system_score_codex":0.0005196596,"about_ca_system_score_gemma":0.0047122478,"threshold_uncertainty_score":0.83593255},"labels":[],"label_agreement":null},{"id":"W4404275600","doi":"10.1080/14796694.2024.2421151","title":"Inflammatory markers correlate with lymphocytes infiltrating and predict immunotherapy prognosis for esophageal cancer","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Government of Jiangsu Province","keywords":"Medicine; Tumor-infiltrating lymphocytes; Esophageal cancer; Immunotherapy; Oncology; Immunology; Cancer; Internal medicine; Pathology","score_opus":0.008220770756086012,"score_gpt":0.2852142627647132,"score_spread":0.27699349200862716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404275600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89483315,0.08844684,0.00032192492,0.008304857,0.0026503715,0.0023811867,0.00009037671,0.00037631183,0.0025949716],"genre_scores_gemma":[0.9701318,0.012559021,0.005006748,0.003654263,0.00353627,0.0020088982,0.00009054922,0.00016417244,0.0028482736],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99887854,0.00005316308,0.00028531378,0.00034721335,0.00013385672,0.0003019185],"domain_scores_gemma":[0.99939835,0.00022629106,0.00008570032,0.0001388633,0.00006685194,0.000083970255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034576145,0.00021700075,0.0003422743,0.00011923602,0.00011597229,0.000043312768,0.00006363391,0.00025401296,0.00019986641],"category_scores_gemma":[0.000011518963,0.00015236741,0.000103341525,0.000194398,0.0001981547,0.00010366566,0.000014161008,0.00021349572,0.0000023881905],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02694799,0.00012039866,0.045211367,0.0011990131,0.0024163814,0.00027830154,0.0026303402,0.0000067092305,0.01906952,0.00041004806,0.018482553,0.88322735],"study_design_scores_gemma":[0.012194446,0.004959446,0.106569245,0.0010034487,0.0004503753,0.0009019874,0.0010236638,0.0015525096,0.0021375255,0.00004491584,0.868771,0.00039144576],"about_ca_topic_score_codex":0.00006574555,"about_ca_topic_score_gemma":0.00012201004,"teacher_disagreement_score":0.8828359,"about_ca_system_score_codex":0.00036027777,"about_ca_system_score_gemma":0.0008970477,"threshold_uncertainty_score":0.6213363},"labels":[],"label_agreement":null},{"id":"W4404312631","doi":"10.1007/s40265-024-02111-7","title":"The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab","year":2024,"lang":"en","type":"review","venue":"Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Merck","keywords":"Pembrolizumab; Medicine; Oncology; Internal medicine; Pharmacotherapy; Intensive care medicine; Immunotherapy; Cancer","score_opus":0.12585733132406987,"score_gpt":0.4139733711353599,"score_spread":0.2881160398112901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404312631","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016611438,0.9793614,1.8488815e-7,0.000059238027,0.00040908117,0.0023285768,0.000023528934,0.000012956549,0.0011935993],"genre_scores_gemma":[0.047991894,0.95115346,0.0000016141801,0.000024969331,0.000052628446,0.0001621543,0.0000149986145,0.000030912783,0.0005673482],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983622,0.0003427916,0.00072948734,0.00021208187,0.00022234592,0.0001311138],"domain_scores_gemma":[0.9989289,0.00016392121,0.00035612125,0.00046147147,0.000070769696,0.000018782961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058998505,0.00019534091,0.0009002714,0.00012465048,0.000050419105,0.000010904415,0.00019085575,0.00017891203,0.000013318877],"category_scores_gemma":[0.000040678315,0.00008619826,0.00029474037,0.0009709594,0.00011650238,0.000014929889,0.0000791221,0.00036585104,0.0000020569844],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024410081,0.00038177692,0.000006582359,0.004955279,0.00038526664,0.0001993562,0.0033397372,1.2394462e-7,0.000005235201,0.00001871151,0.0003463639,0.9901175],"study_design_scores_gemma":[0.0019577355,0.0005027645,0.00001563855,0.0053640828,0.00096364494,0.00080951763,0.006647028,0.000015354064,0.000016843367,0.000005915359,0.9836034,0.00009803849],"about_ca_topic_score_codex":0.00057905045,"about_ca_topic_score_gemma":0.00048323412,"teacher_disagreement_score":0.99001944,"about_ca_system_score_codex":0.00022128176,"about_ca_system_score_gemma":0.0010588268,"threshold_uncertainty_score":0.35150632},"labels":[],"label_agreement":null},{"id":"W4404332614","doi":"10.1177/10815589241270439","title":"Radiation therapy in combination with immune checkpoint inhibitors in metastatic lung cancer: Effect of fractionation","year":2024,"lang":"en","type":"article","venue":"Journal of Investigative Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; NOSM University; Essar Steel Algoma (Canada); Sault Area Hospital","funders":"","keywords":"Medicine; Radiation therapy; Lung cancer; Oncology; Internal medicine; Immune checkpoint; Cancer; Immunotherapy; Chemotherapy; Abscopal effect","score_opus":0.01866388687900485,"score_gpt":0.3179749477513162,"score_spread":0.29931106087231135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404332614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95724446,0.030838663,0.000113962604,0.010809471,0.00040381434,0.0005017233,0.0000017173472,0.0000072662274,0.00007890268],"genre_scores_gemma":[0.99628913,0.003225693,0.00012378125,0.00013034734,0.00014918498,0.000023514154,0.000010953845,0.000016097158,0.000031312837],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981839,0.0002142087,0.00087798876,0.00011646075,0.0005012112,0.000106223895],"domain_scores_gemma":[0.9988341,0.00031757753,0.0005200212,0.00007193529,0.00019951495,0.000056894805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018913542,0.00014487836,0.0005350446,0.00089236256,0.000015377884,0.0000064891765,0.000048135593,0.00004618809,0.00008378632],"category_scores_gemma":[0.0003172843,0.00008496614,0.000080640246,0.0010654645,0.00031845964,0.00026794377,0.0000038104245,0.00037560516,2.6570885e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074688513,0.00024493728,0.14372556,0.0011203492,0.0008591839,0.0001822386,0.008991924,0.00027476085,0.69933206,0.00015663212,0.0006219583,0.13702156],"study_design_scores_gemma":[0.021377819,0.00968347,0.49688187,0.011651353,0.00023149962,0.00013792327,0.00058337994,0.002851201,0.45546398,0.0004862353,0.0005161516,0.00013514012],"about_ca_topic_score_codex":0.0007136494,"about_ca_topic_score_gemma":0.00005474768,"teacher_disagreement_score":0.3531563,"about_ca_system_score_codex":0.00055400684,"about_ca_system_score_gemma":0.00035553199,"threshold_uncertainty_score":0.34648186},"labels":[],"label_agreement":null},{"id":"W4404348107","doi":"10.1016/j.fander.2024.09.433","title":"Efficacité en vie réelle du risankizumab chez les patients participant à l’étude observationnelle post-commercialisation internationale VALUE","year":2024,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; NOSM University","funders":"","keywords":"Medicine; Political science; Gynecology","score_opus":0.07033101344788731,"score_gpt":0.3336405952660817,"score_spread":0.2633095818181944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404348107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8858533,0.03634335,0.0027720672,0.068647794,0.003709771,0.0007912891,0.00026279077,0.00049572025,0.0011239421],"genre_scores_gemma":[0.9645267,0.02318197,0.001241889,0.008419169,0.0006908779,0.0001984181,0.0007902879,0.00009613863,0.0008545635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950202,0.0012669124,0.0011441062,0.00077612937,0.0005490735,0.0012435667],"domain_scores_gemma":[0.99616665,0.002426491,0.00028998495,0.0005347344,0.0003262876,0.00025585055],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017739511,0.0006072625,0.0007290469,0.0003520754,0.00031445656,0.0002645199,0.0006313997,0.00080253073,0.000837114],"category_scores_gemma":[0.0022851778,0.0005760869,0.00052746607,0.00059344346,0.0005757841,0.0005180817,0.00026777675,0.0008656723,0.00038582334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002580099,0.0025558134,0.68494165,0.0022113745,0.0030965244,0.0016807958,0.022129819,0.0021917056,0.006648546,0.014684743,0.11729658,0.13998234],"study_design_scores_gemma":[0.0035850436,0.0008150701,0.75451124,0.0017663453,0.00082152017,0.00059678487,0.0031268927,0.018448507,0.009048553,0.0021645117,0.20419563,0.00091987115],"about_ca_topic_score_codex":0.0013223432,"about_ca_topic_score_gemma":0.00040167637,"teacher_disagreement_score":0.13906246,"about_ca_system_score_codex":0.0011709061,"about_ca_system_score_gemma":0.0013066677,"threshold_uncertainty_score":0.9996691},"labels":[],"label_agreement":null},{"id":"W4404348185","doi":"10.1016/j.fander.2024.09.402","title":"Résultats du suivi à 10 ans de l’association nivolumab plus ipilimumab dans le mélanome avancé issus de l’essai de phase 3, CheckMate 067","year":2024,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Medicine; Ipilimumab; Immunotherapy; Cancer; Internal medicine","score_opus":0.032336796612697026,"score_gpt":0.3436773771465514,"score_spread":0.3113405805338544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404348185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82342505,0.08847096,0.014354765,0.06005264,0.0026572503,0.0009862767,0.00068333605,0.0013947432,0.007974964],"genre_scores_gemma":[0.9221223,0.047371004,0.002344963,0.0066474397,0.0008872953,0.0002716573,0.0003996069,0.0002027887,0.019752964],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9906533,0.0019062636,0.0012710547,0.001137695,0.0005706909,0.004461021],"domain_scores_gemma":[0.9953954,0.0021537673,0.0005006315,0.00088257104,0.0002719357,0.0007956599],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0053065456,0.0009670236,0.0013143655,0.00048542192,0.0005089906,0.00046125698,0.00096290174,0.0017019798,0.0006973971],"category_scores_gemma":[0.0029790096,0.0010199487,0.0007922277,0.001014858,0.00076714635,0.00064038165,0.00025920305,0.0015590794,0.00048305452],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011140017,0.0039911433,0.17650072,0.0060599945,0.006148915,0.035255425,0.029122982,0.002040492,0.13160521,0.005033156,0.5442883,0.048813667],"study_design_scores_gemma":[0.030715346,0.0025250614,0.062852435,0.0035645743,0.0025710687,0.018650211,0.015026629,0.06789962,0.119572885,0.008618322,0.66473556,0.0032683057],"about_ca_topic_score_codex":0.0029798443,"about_ca_topic_score_gemma":0.0016092408,"teacher_disagreement_score":0.120447256,"about_ca_system_score_codex":0.011385355,"about_ca_system_score_gemma":0.011635004,"threshold_uncertainty_score":0.99959403},"labels":[],"label_agreement":null},{"id":"W4404353106","doi":"10.1016/j.fander.2024.09.162","title":"Efficacité spectaculaire de l’association ipilimumab-nivolumab dans un carcinome épidermoïde métastatique","year":2024,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Immunotherapy; Cancer","score_opus":0.024136403528885294,"score_gpt":0.3249018666719037,"score_spread":0.3007654631430184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404353106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7746893,0.14045505,0.008435782,0.06486395,0.003333001,0.0009381682,0.00042070157,0.001246032,0.0056180055],"genre_scores_gemma":[0.94653034,0.03628082,0.0025915897,0.0076043596,0.0007472728,0.00016854788,0.00022725265,0.00016800966,0.0056818225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921425,0.0018170581,0.0011849651,0.001117138,0.00059935625,0.003138978],"domain_scores_gemma":[0.9953929,0.0025997218,0.0003760173,0.0008557915,0.00020562609,0.00056994474],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0031129373,0.0008883813,0.0011562284,0.00046206068,0.00034994836,0.00038473835,0.00073159,0.001516588,0.00067588896],"category_scores_gemma":[0.0019132099,0.0008951677,0.00090323447,0.0010930168,0.00064353767,0.00045967213,0.00022649035,0.0018429302,0.0005138766],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027940643,0.0014728241,0.4874412,0.0054725413,0.006355893,0.038403906,0.02029086,0.00082122773,0.048920766,0.011741972,0.26414767,0.112137064],"study_design_scores_gemma":[0.0072752545,0.0015458154,0.6170036,0.004099687,0.0023608839,0.019448185,0.009064218,0.016149288,0.070982754,0.011649174,0.2377966,0.0026244903],"about_ca_topic_score_codex":0.001118361,"about_ca_topic_score_gemma":0.0007276271,"teacher_disagreement_score":0.17184103,"about_ca_system_score_codex":0.007467311,"about_ca_system_score_gemma":0.00467854,"threshold_uncertainty_score":0.99977964},"labels":[],"label_agreement":null},{"id":"W4404374201","doi":"10.3390/cancers16223833","title":"Validation of the Scottish Inflammatory Prognostic Score (SIPS) in NSCLC Patients Treated with First-Line Pembrolizumab","year":2024,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics; Cancer Research UK; NHS Health Scotland","keywords":"Pembrolizumab; Medicine; Oncology; Internal medicine; Second line; First line; Cancer; Immunotherapy","score_opus":0.012220813742263328,"score_gpt":0.24139174484645817,"score_spread":0.22917093110419484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404374201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997015,0.0011631715,0.000006579062,0.000199314,0.00022945511,0.00074123085,0.000019001092,0.000039696235,0.0005865776],"genre_scores_gemma":[0.9992983,0.00018620389,0.0000083596115,0.000088276545,0.0000510503,0.000070047456,0.000031585532,0.000022856217,0.0002433197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918234,0.00002460086,0.00022898433,0.00018892412,0.00022539654,0.00014973937],"domain_scores_gemma":[0.9995821,0.00004475376,0.00006752993,0.00019873289,0.000072379604,0.000034481785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000077499266,0.00011663336,0.00016043025,0.0001011933,0.000032669985,0.000014997469,0.00007526055,0.000056346355,0.00007312371],"category_scores_gemma":[0.000037210197,0.000073175404,0.00006432814,0.00052985025,0.00012786473,0.00007793512,0.000013121371,0.000118381824,0.0000029615053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033254398,0.000048516147,0.9763402,0.00083543366,0.00019075551,0.000024301566,0.000830202,0.0004501666,0.001690959,0.000019035619,0.0012258695,0.0150191495],"study_design_scores_gemma":[0.007147578,0.0008507532,0.95758116,0.006981355,0.00019441886,0.00001446413,0.00009195603,0.0006064762,0.023089284,0.000016504722,0.0032204464,0.00020559362],"about_ca_topic_score_codex":0.00044995235,"about_ca_topic_score_gemma":0.0005801879,"teacher_disagreement_score":0.021398326,"about_ca_system_score_codex":0.0008890706,"about_ca_system_score_gemma":0.00080135657,"threshold_uncertainty_score":0.29840064},"labels":[],"label_agreement":null},{"id":"W4404395566","doi":"10.1158/1078-0432.ccr-24-2983","title":"Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i> Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade","year":2024,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McGill University; McGill University Health Centre","funders":"Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; Swim Across America; American Lung Association; Mark Foundation For Cancer Research; Bristol-Myers Squibb; LUNGevity Foundation; National Cancer Institute; National Institutes of Health; Conquer Cancer Foundation","keywords":"KRAS; Immune checkpoint; Medicine; Lung cancer; Cancer research; Oncology; Context (archaeology); Cancer; Immunotherapy; Neoadjuvant therapy; Internal medicine; STK11; Biology; Colorectal cancer; Breast cancer","score_opus":0.1293539012176479,"score_gpt":0.506675577321772,"score_spread":0.37732167610412415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404395566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9564636,0.030989809,0.00001774466,0.0071651973,0.0022206176,0.0015587558,0.00009833435,0.00013685212,0.001349095],"genre_scores_gemma":[0.9788418,0.018361032,0.00009535482,0.0010521169,0.0003448111,0.00037159864,0.00005247802,0.000075733304,0.00080508547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99291486,0.0011180275,0.002063549,0.0012681655,0.0013508053,0.0012846155],"domain_scores_gemma":[0.99520576,0.0032725302,0.00014922878,0.0007444982,0.00019301672,0.00043493757],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009678103,0.0003840039,0.0011562051,0.0005214691,0.00027394577,0.0001721305,0.00030889525,0.00046357192,0.00065542076],"category_scores_gemma":[0.0015312704,0.0002914808,0.0007559352,0.0012170303,0.0009279653,0.00016477962,0.00018703041,0.0027055198,0.00004413663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02269432,0.0010271728,0.83778983,0.00070824183,0.0013385508,0.0023043435,0.00050491444,0.00021091384,0.01839528,0.000048458776,0.0034145922,0.11156336],"study_design_scores_gemma":[0.029384289,0.0064433427,0.8550793,0.0051300307,0.00034501223,0.000027160137,0.0011023121,0.021920577,0.014102508,0.00024688893,0.06521,0.0010085987],"about_ca_topic_score_codex":0.00741546,"about_ca_topic_score_gemma":0.0007747945,"teacher_disagreement_score":0.11055476,"about_ca_system_score_codex":0.0015585567,"about_ca_system_score_gemma":0.002762086,"threshold_uncertainty_score":0.99995375},"labels":[],"label_agreement":null},{"id":"W4404406224","doi":"10.1016/j.ejca.2024.115119","title":"Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health; Ono Pharmaceutical; National Cancer Institute; National Institute for Health and Care Research; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Oncology; Internal medicine; Term (time); Immunotherapy; Cancer","score_opus":0.015403915778306266,"score_gpt":0.28854883820832294,"score_spread":0.2731449224300167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404406224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99470824,0.0018836559,0.00007540584,0.0015348087,0.0008953712,0.00047141837,0.000032539865,0.00002410479,0.00037445527],"genre_scores_gemma":[0.9928438,0.0003825867,0.0000617878,0.0013908854,0.00023538774,0.000010167685,0.000006128627,0.00008465043,0.0049846284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973239,0.00029103569,0.0009965247,0.00032387587,0.00074902445,0.00031568678],"domain_scores_gemma":[0.99867594,0.00009461813,0.00038578454,0.000395681,0.00027862834,0.00016931912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094162795,0.00028459006,0.0006406541,0.0007292364,0.00010167829,0.00015569408,0.00039252936,0.00004657046,0.00072638487],"category_scores_gemma":[0.000098583114,0.0001661044,0.0004727735,0.0013774233,0.00010266041,0.00022017573,0.00006301316,0.00044376674,0.000034970544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015213763,0.00017317882,0.9414897,0.000060570634,0.0031065901,0.00033451343,0.005569398,0.00025248047,0.000028314555,0.0000013553991,0.0034848957,0.030285234],"study_design_scores_gemma":[0.009822411,0.0011886461,0.97990835,0.0009866321,0.0008677556,0.000005385634,0.00017796722,0.00012724611,0.000049368056,0.0000014519693,0.0066511305,0.0002136536],"about_ca_topic_score_codex":0.00022635015,"about_ca_topic_score_gemma":0.0026208714,"teacher_disagreement_score":0.038418647,"about_ca_system_score_codex":0.00074669055,"about_ca_system_score_gemma":0.0003057493,"threshold_uncertainty_score":0.7953405},"labels":[],"label_agreement":null},{"id":"W4404442920","doi":"10.23977/socmhm.2024.050213","title":"A Comparative Evaluation of Survival Analysis Methods for Tumor Immunotherapy Combination Regimens","year":2024,"lang":"en","type":"article","venue":"Social Medicine and Health Management","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Immunotherapy; Medicine; Oncology; Internal medicine; Cancer","score_opus":0.22680271223509946,"score_gpt":0.5510632175777614,"score_spread":0.324260505342662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404442920","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16212487,0.20321688,0.27691314,0.29845035,0.0041461564,0.01963574,0.00007692084,0.00036093095,0.03507501],"genre_scores_gemma":[0.9881063,0.0025707162,0.005626924,0.002415231,0.00028079096,0.00031127137,0.00014614091,0.000018277498,0.0005243446],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986397,0.00022365167,0.0004071782,0.0002149063,0.0003628653,0.00015166662],"domain_scores_gemma":[0.99941766,0.000113070826,0.00014380703,0.00010283002,0.00017900142,0.000043604974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050500706,0.00010618218,0.00057398883,0.0003805353,0.00013078291,0.000008729007,0.000034487777,0.000029879184,0.00009704473],"category_scores_gemma":[0.0000110863375,0.00008311424,0.00013101046,0.0007459117,0.000115952425,0.000032218784,0.000010173444,0.00006500092,3.6836934e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012847001,0.00018809817,0.0003071368,0.0022542055,0.007273088,0.0000015372563,0.021313768,0.0000026217488,0.00063962414,0.02816445,0.011500027,0.92707074],"study_design_scores_gemma":[0.046583194,0.009324954,0.40627623,0.0024627415,0.022286102,0.0000084239755,0.06086184,0.063860625,0.0005044083,0.023194348,0.36389855,0.0007385926],"about_ca_topic_score_codex":0.00027847997,"about_ca_topic_score_gemma":0.00004970844,"teacher_disagreement_score":0.9263322,"about_ca_system_score_codex":0.00023042777,"about_ca_system_score_gemma":0.00012435664,"threshold_uncertainty_score":0.33893004},"labels":[],"label_agreement":null},{"id":"W4404451153","doi":"10.1158/1538-7445.tumbody-pr018","title":"Abstract PR018: Inflammation-induced mechanotransduction is necessary and sufficient to create pre-cancerous squamous lung metaplasias and necessary to drive progression to dysplasia","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Inflammation; Mechanotransduction; Medicine; Lung; Dysplasia; Pathology; Cancer research; Internal medicine; Biology; Neuroscience","score_opus":0.04279189732606305,"score_gpt":0.4011355353077976,"score_spread":0.3583436379817346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404451153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9694431,0.0061250324,0.00021195448,0.02004079,0.00048012022,0.0031499965,0.000060617196,0.00012063546,0.0003677491],"genre_scores_gemma":[0.99551606,0.0011045141,0.0003104688,0.00051127345,0.00047461205,0.0011833123,0.000017426806,0.000065785294,0.00081654923],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969174,0.00009848691,0.00040885308,0.0009159362,0.000993634,0.0006656881],"domain_scores_gemma":[0.9985028,0.00016570436,0.00004046008,0.00037634667,0.00032559506,0.0005891262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010142162,0.00028538745,0.00036320972,0.0007512717,0.00030270073,0.0002949725,0.00016648577,0.00016766904,0.0003705233],"category_scores_gemma":[0.00009136903,0.00023551172,0.000067155874,0.0014415527,0.00009559671,0.00026354066,0.00013397064,0.00050477777,0.000033869528],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055650156,0.000070650916,0.00083072245,0.0012052472,0.00022349518,0.00009339651,0.013850015,0.00006534119,0.7871626,0.000042075866,0.009239412,0.18165204],"study_design_scores_gemma":[0.0025140375,0.0034253413,0.08175315,0.004638749,0.00020945306,0.00013206934,0.0023147648,0.00096235494,0.86430466,0.00007536048,0.038948584,0.00072148157],"about_ca_topic_score_codex":0.0015972104,"about_ca_topic_score_gemma":0.000490645,"teacher_disagreement_score":0.18093055,"about_ca_system_score_codex":0.0007214335,"about_ca_system_score_gemma":0.0005431712,"threshold_uncertainty_score":0.9603889},"labels":[],"label_agreement":null},{"id":"W4404567325","doi":"10.1136/jitc-2024-010143","title":"Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Alberta Health Services; Université Laval; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; CD8; Cytokine; Oncology; Response Evaluation Criteria in Solid Tumors; Melanoma; Aldesleukin; Adverse effect; Cancer; Interleukin 2; Gastroenterology; Immunotherapy; Immunology; Phases of clinical research; Toxicity; Cancer research; Immune system","score_opus":0.007401104382701864,"score_gpt":0.30071899791223383,"score_spread":0.29331789352953197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404567325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784475,0.018378196,0.0006067713,0.00084888603,0.000337177,0.0010666156,0.000067619425,0.00004000096,0.00020725073],"genre_scores_gemma":[0.9912219,0.005862959,0.00087390834,0.0006515873,0.0001490337,0.0001718052,0.000015167866,0.00012723132,0.0009263943],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99796236,0.00003677321,0.00071003725,0.00038191635,0.000469537,0.00043938137],"domain_scores_gemma":[0.9989746,0.00007457905,0.00031353583,0.00027983586,0.00024158705,0.00011583405],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025674858,0.00037708436,0.00071700104,0.0003951941,0.00010456496,0.00010795991,0.00016507291,0.00011310346,0.00019302047],"category_scores_gemma":[0.000008424989,0.00025117712,0.00019281411,0.00040134016,0.00022148975,0.0003423923,0.000011139701,0.00041142895,8.111066e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30384728,0.0006473728,0.03368223,0.00066870276,0.0029258386,0.0001138298,0.0031174824,0.00042803728,0.06396857,0.00015294515,0.0007108245,0.5897369],"study_design_scores_gemma":[0.21735704,0.047501,0.51988524,0.019262819,0.00064702734,0.0015326524,0.0011391612,0.0019900638,0.06763128,0.0011813515,0.11954308,0.0023292718],"about_ca_topic_score_codex":0.00028699098,"about_ca_topic_score_gemma":0.00013951081,"teacher_disagreement_score":0.5874076,"about_ca_system_score_codex":0.00040361297,"about_ca_system_score_gemma":0.0006042251,"threshold_uncertainty_score":0.99999404},"labels":[],"label_agreement":null},{"id":"W4404583166","doi":"10.1200/go.24.00122","title":"Low-Dose Anti-PD(L)1 for the Treatment of Solid Malignancies","year":2024,"lang":"en","type":"article","venue":"JCO Global Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbotsford Veterinary Clinic","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Melanoma; Gastroenterology; Immunotherapy; Cancer","score_opus":0.028308349610660567,"score_gpt":0.36967437103347206,"score_spread":0.34136602142281147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404583166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92163545,0.045045488,0.0006248012,0.019815661,0.003924307,0.0018544534,0.0005488914,0.00012610754,0.006424848],"genre_scores_gemma":[0.99254847,0.0042067403,0.00026572673,0.0009395541,0.0003790374,0.00011913378,0.0000169977,0.000010981512,0.0015133657],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993109,0.00001939677,0.0002251766,0.00016260681,0.00008547837,0.00019641563],"domain_scores_gemma":[0.9995191,0.00016946494,0.000046208446,0.00018042739,0.00004905317,0.000035732046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011226134,0.00010736104,0.0002990654,0.000025089968,0.000041967276,0.000007254835,0.00006553144,0.000101350735,0.00010696292],"category_scores_gemma":[0.000013852945,0.00005929155,0.00024745506,0.00016452494,0.00016508553,0.000020593767,0.000009580659,0.000029097278,0.00001663201],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007208695,0.0015174589,0.0016209417,0.0003407864,0.0018966357,0.0002166645,0.0010237566,0.000010545251,0.056817774,0.0031687552,0.056050304,0.8701277],"study_design_scores_gemma":[0.0030738579,0.006249712,0.015503421,0.00008489108,0.0003226934,0.00014795533,0.0002515634,0.00022115547,0.011651902,0.00021179159,0.96220726,0.00007377556],"about_ca_topic_score_codex":0.00013425658,"about_ca_topic_score_gemma":0.00010320722,"teacher_disagreement_score":0.90615696,"about_ca_system_score_codex":0.0004983342,"about_ca_system_score_gemma":0.00038408075,"threshold_uncertainty_score":0.24178392},"labels":[],"label_agreement":null},{"id":"W4404590925","doi":"10.3390/curroncol31110544","title":"Sex-Related Differences in Immunotherapy Outcomes of Patients with Advanced Non-Small Cell Lung Cancer","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Immunotherapy; Lung cancer; Cancer immunotherapy; Oncology; Cancer; Internal medicine; Bioinformatics; Biology","score_opus":0.028661081720803373,"score_gpt":0.3500210382420645,"score_spread":0.3213599565212611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404590925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97356665,0.023369085,0.000041029398,0.0002722324,0.0015019084,0.0006987682,0.000031330273,0.000037260186,0.00048171103],"genre_scores_gemma":[0.99588513,0.00334981,0.000074694886,0.0000738271,0.000025945705,0.00012240744,0.000031912903,0.000024558434,0.00041169944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884266,0.00005031201,0.00041802353,0.00028257276,0.00015921531,0.0002472187],"domain_scores_gemma":[0.9994794,0.00011654974,0.00011842009,0.0001759928,0.00006500394,0.000044622986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001172616,0.00018999679,0.0005548423,0.00019957949,0.000021536049,0.000007367972,0.00010702456,0.0001119802,0.0003032494],"category_scores_gemma":[0.000005374224,0.00012519879,0.0001057569,0.00032873085,0.00011472743,0.000051071318,0.000020271666,0.00027372426,0.0000030145234],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012230385,0.0006775549,0.82597655,0.0003114486,0.0002274352,0.000008054108,0.0017766391,0.0000027305823,0.0012810403,0.000006212957,0.00014893938,0.16836038],"study_design_scores_gemma":[0.009200729,0.0011688045,0.9789115,0.0005955925,0.00009582594,0.0000012644924,0.00017969229,0.00027195,0.0008776896,0.000011835366,0.008514104,0.00017097009],"about_ca_topic_score_codex":0.00009326261,"about_ca_topic_score_gemma":0.00008828422,"teacher_disagreement_score":0.1681894,"about_ca_system_score_codex":0.00030019795,"about_ca_system_score_gemma":0.00036154644,"threshold_uncertainty_score":0.51054585},"labels":[],"label_agreement":null},{"id":"W4404597670","doi":"10.1186/s12885-024-13210-9","title":"Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC","year":2024,"lang":"en","type":"erratum","venue":"BMC Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Surgical oncology; Canakinumab; Oncology; Chemotherapy; Internal medicine; non-small cell lung cancer (NSCLC); Lung cancer; Disease","score_opus":0.01569121093584851,"score_gpt":0.2786271051415368,"score_spread":0.2629358942056883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404597670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87261856,0.017725807,0.00078509975,0.002390597,0.03945416,0.02379592,0.0008463032,0.0009606043,0.04142293],"genre_scores_gemma":[0.53656876,0.0016890864,0.0012405023,0.0020247449,0.0011890312,0.0032720882,0.0037979006,0.00094736734,0.4492705],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9965081,0.00010322306,0.0006639516,0.0009960225,0.0010735138,0.00065515435],"domain_scores_gemma":[0.9984725,0.00006630982,0.00045044534,0.00054969854,0.00032673066,0.00013430743],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019797591,0.0008108451,0.0013083956,0.00074338604,0.00007742052,0.00011214047,0.00019053802,0.000322792,0.0010254675],"category_scores_gemma":[0.00001591351,0.00050617475,0.000093833856,0.0021975692,0.00020603961,0.00019463505,0.000019089503,0.0012867807,0.000010439729],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23130076,0.0010316907,0.23762476,0.0022320063,0.0020070733,0.00031157525,0.0024475155,0.00013025115,0.000010356832,0.000008897582,0.5084503,0.014444766],"study_design_scores_gemma":[0.12770449,0.01458549,0.4437544,0.035147052,0.0016347391,0.00035830942,0.0008672908,0.0022308081,0.00020091214,0.000012622643,0.37075162,0.0027522605],"about_ca_topic_score_codex":0.020375837,"about_ca_topic_score_gemma":0.41641647,"teacher_disagreement_score":0.40784755,"about_ca_system_score_codex":0.002317986,"about_ca_system_score_gemma":0.0053239344,"threshold_uncertainty_score":0.9998877},"labels":[],"label_agreement":null},{"id":"W4404635574","doi":"10.1016/j.canlet.2024.217327","title":"Local ablation disrupts immune evasion in pancreatic cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Letters","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Pancreatic cancer; Immune system; Evasion (ethics); Ablation; Cancer; Cancer research; Pancreas; Immunology; Biology; Medicine; Oncology; Internal medicine","score_opus":0.01599945257544297,"score_gpt":0.3028483277664044,"score_spread":0.28684887519096147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404635574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93044114,0.0424351,0.0017162837,0.023096513,0.0013404835,0.00041896632,0.000017224404,0.00011104177,0.0004232618],"genre_scores_gemma":[0.99025613,0.0032651534,0.000055344164,0.005218722,0.00030983172,0.00021125296,0.000023484195,0.00003538076,0.00062472204],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99891454,0.000028705626,0.00027535058,0.00030052243,0.00021516657,0.00026572472],"domain_scores_gemma":[0.9996593,0.000040412597,0.00003512319,0.00019150804,0.000018725123,0.000054911485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014842654,0.00015692861,0.00023739423,0.00016946808,0.000035901918,0.00003342018,0.00006223024,0.00007172019,0.0007577234],"category_scores_gemma":[0.0000058734436,0.000129859,0.0001173465,0.00045589084,0.00010434296,0.00013211087,0.000014527081,0.00021068049,0.000033263223],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014985815,0.000038521157,0.020929364,0.00067667523,0.00029031993,0.00022888856,0.0012707583,0.00047978343,0.6636395,0.000033568387,0.013493881,0.29742017],"study_design_scores_gemma":[0.006624524,0.000258589,0.7020897,0.009853038,0.0005219163,0.00009010739,0.0003491155,0.013631662,0.058917854,0.00007777587,0.20669357,0.0008920839],"about_ca_topic_score_codex":0.0028604874,"about_ca_topic_score_gemma":0.00034339676,"teacher_disagreement_score":0.6811604,"about_ca_system_score_codex":0.0008876962,"about_ca_system_score_gemma":0.00017648735,"threshold_uncertainty_score":0.829654},"labels":[],"label_agreement":null},{"id":"W4404694754","doi":"10.1084/jem.20231106","title":"Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer","year":2024,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Institutes of Health, Pakistan; Stand Up To Cancer; National Research Foundation of Korea; National Cancer Institute; National Institutes of Health; Yale University; Mark Foundation For Cancer Research; American Cancer Society; National Research Foundation; American Association for Cancer Research","keywords":"Lung cancer; Cancer research; Hypoxia (environmental); Nivolumab; Immune system; Immune checkpoint; Medicine; MSH2; Immunotherapy; Cancer; Internal medicine; Immunology; Colorectal cancer; Chemistry; DNA mismatch repair","score_opus":0.01951833274377372,"score_gpt":0.34129110991328104,"score_spread":0.3217727771695073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404694754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7814064,0.15420197,0.00003228362,0.06150813,0.0016102655,0.00048826993,0.0000035468163,0.000016815446,0.0007322858],"genre_scores_gemma":[0.990877,0.0013041125,0.00017022854,0.0047111064,0.0011575791,0.000024413504,9.683531e-7,0.000034359673,0.0017202682],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99803984,0.000063407555,0.000899776,0.00016691866,0.0005612574,0.00026880653],"domain_scores_gemma":[0.99922085,0.00009243066,0.00014029277,0.00025410866,0.000080513404,0.00021183335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010581798,0.00020049402,0.00047880178,0.0003495761,0.000051794123,0.000015154521,0.00022026703,0.00005968004,0.0008963613],"category_scores_gemma":[0.00006423577,0.00011436711,0.00014240918,0.00075826095,0.00012392785,0.00009254562,0.000053138465,0.00024051737,0.00001107987],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067137596,0.00007647961,0.00013601076,0.00007142801,0.00018628473,0.0001223524,0.020070339,0.000003117135,0.9437209,0.0000073303304,0.026581636,0.0023103913],"study_design_scores_gemma":[0.0055707227,0.002465002,0.0141238645,0.012966539,0.00021499698,0.00030732248,0.008492895,0.000059943064,0.89548874,0.000029283015,0.06001919,0.0002614748],"about_ca_topic_score_codex":0.00038757385,"about_ca_topic_score_gemma":0.000045919896,"teacher_disagreement_score":0.20947054,"about_ca_system_score_codex":0.0007211963,"about_ca_system_score_gemma":0.00016956584,"threshold_uncertainty_score":0.98145276},"labels":[],"label_agreement":null},{"id":"W4404713118","doi":"10.3390/curroncol31120552","title":"The Potential of PD-1 and PD-L1 as Prognostic and Predictive Biomarkers in Colorectal Adenocarcinoma Based on TILs Grading","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Universitas Hasanuddin","keywords":"Medicine; Grading (engineering); Colorectal cancer; Malignancy; Oncology; Tumor-infiltrating lymphocytes; PD-L1; Adenocarcinoma; Immunohistochemistry; Colorectal adenocarcinoma; Internal medicine; Tumor microenvironment; Immunotherapy; Cancer research; Cancer; Biology","score_opus":0.029254488612752823,"score_gpt":0.34419445350344857,"score_spread":0.31493996489069576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404713118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97368836,0.022558171,0.000042241434,0.0013919929,0.0010866367,0.0006933495,0.000023048866,0.000024462897,0.000491723],"genre_scores_gemma":[0.9988284,0.000888959,0.000021825304,0.00005470415,0.000093534174,0.000067153334,0.000017059054,0.000012903955,0.000015478396],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989829,0.00012212877,0.00025836218,0.0002760231,0.00014769202,0.00021287796],"domain_scores_gemma":[0.9992018,0.0005449925,0.000059656733,0.000091434886,0.00003320144,0.000068910354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003978793,0.00013124291,0.00023746764,0.00018803444,0.00006478289,0.000020715883,0.000054561617,0.000100528116,0.000023999015],"category_scores_gemma":[0.00012164209,0.00008987097,0.00006350285,0.00023020236,0.0004408193,0.000033795503,0.000030963,0.00022368325,0.0000019914046],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044543117,0.0009250062,0.3555265,0.0011261407,0.0009002303,0.00048033957,0.0022599122,0.000010523764,0.030491995,0.0003778034,0.0033125249,0.5600459],"study_design_scores_gemma":[0.0054376763,0.0073512103,0.9452496,0.0010196493,0.0003068455,0.00025313196,0.00076519034,0.028381804,0.0015785595,0.00025635815,0.0092299245,0.00017004953],"about_ca_topic_score_codex":0.000026529837,"about_ca_topic_score_gemma":0.00002182059,"teacher_disagreement_score":0.5897231,"about_ca_system_score_codex":0.00017242075,"about_ca_system_score_gemma":0.0002827866,"threshold_uncertainty_score":0.36648315},"labels":[],"label_agreement":null},{"id":"W4404749043","doi":"10.1016/j.immuni.2024.10.014","title":"Impaired development of memory B cells and antibody responses in humans and mice deficient in PD-1 signaling","year":2024,"lang":"en","type":"article","venue":"Immunity","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill Genome Centre","funders":"Vermont Agency of Natural Resources; National Institutes of Health; New South Wales Government; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases; Glenn Foundation for Medical Research; Honjo International Scholarship Foundation; Universidad de Antioquia; National Health and Medical Research Council; SCOR Corporate Foundation for Science; Ministério da Ciência, Tecnologia e Inovação; Institut National de la Santé et de la Recherche Médicale; Fondation pour la Recherche Médicale; National Institute on Handicapped Research; Université Paris-Saclay; National Center for Research Resources; National Institute of Allergy and Infectious Diseases; Australian Government; Agence Nationale de la Recherche; Tasmanian Department of Health; Rockefeller University; Research England; Icahn School of Medicine at Mount Sinai; Ministerio de Ciencia, Tecnología, Conocimiento e Innovación; Diabetes UK; Ministry of Health, Labour and Welfare; St. Giles Foundation; National Center for Advancing Translational Sciences; Medical Research Council; Leona M. and Harry B. Helmsley Charitable Trust; Immune Deficiency Foundation; Ministerio de Ciencia, Tecnología e Innovación","keywords":"Biology; Antibody; Signal transduction; Immunology; Cell biology","score_opus":0.02729393616749533,"score_gpt":0.3143739235201,"score_spread":0.2870799873526047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404749043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892603,0.010228763,0.000015858306,0.00008127568,0.0000689993,0.00018899264,0.0000052900396,0.0000152013545,0.00013532642],"genre_scores_gemma":[0.9990697,0.00032199174,0.00043030578,0.000049229126,0.0000058633236,0.000005029676,0.000006584247,0.000008417674,0.00010286131],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99927497,0.00009146128,0.00028154472,0.00013045527,0.00009431127,0.00012726361],"domain_scores_gemma":[0.9996634,0.00015467418,0.000028159668,0.00011125119,0.000017056173,0.000025421326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008484927,0.000086950786,0.00018136627,0.00024240765,0.000041132505,0.000014685422,0.000039736973,0.000048617334,0.00002386245],"category_scores_gemma":[0.000023283774,0.000076301185,0.000022940223,0.00023207578,0.000093913666,0.000040727533,0.000041677875,0.00015477551,9.162138e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012194067,0.000100541656,0.009934144,0.0003257106,0.000031784424,0.00003226251,0.010832706,0.0000015987749,0.967063,0.000003623729,0.000009902987,0.01044532],"study_design_scores_gemma":[0.0016539512,0.00016592669,0.5692101,0.0012754896,0.000019683202,0.000018314488,0.0035715813,0.0000943624,0.42306927,0.000016992177,0.0007738776,0.00013043454],"about_ca_topic_score_codex":0.0008205459,"about_ca_topic_score_gemma":0.00030475095,"teacher_disagreement_score":0.559276,"about_ca_system_score_codex":0.00007956133,"about_ca_system_score_gemma":0.0001756935,"threshold_uncertainty_score":0.3111472},"labels":[],"label_agreement":null},{"id":"W4404756549","doi":"10.1016/j.esmogo.2024.100107","title":"PD-L1 as a response biomarker to chemotherapy plus immune checkpoint inhibitors in operable gastroesophageal adenocarcinoma: a meta-analysis of neoadjuvant clinical trials","year":2024,"lang":"en","type":"article","venue":"ESMO Gastrointestinal Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research","funders":"NIHR Oxford Biomedical Research Centre; AstraZeneca","keywords":"Meta-analysis; Medicine; Oncology; Biomarker; Chemotherapy; Internal medicine; Neoadjuvant therapy; Complete response; Immune checkpoint; Clinical trial; Immunotherapy; Cancer; Biology; Breast cancer","score_opus":0.17252356598905416,"score_gpt":0.4599136091919914,"score_spread":0.28739004320293726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404756549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96811515,0.00916563,0.0013093344,0.018437631,0.0005198515,0.0017741148,0.00008111287,0.00012385656,0.00047330806],"genre_scores_gemma":[0.98240745,0.00009817489,0.012938607,0.0019961596,0.00021868378,0.00023824077,0.000045631466,0.00007903407,0.0019780218],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99035215,0.0030400793,0.004181332,0.001074369,0.0005499831,0.0008020835],"domain_scores_gemma":[0.99415594,0.0037444138,0.0006334255,0.0007935635,0.00024743573,0.0004252137],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.021391971,0.00055709,0.0050613782,0.0018715216,0.00005959637,0.00005311095,0.00035495756,0.00026402576,0.0030328922],"category_scores_gemma":[0.0036481365,0.00041540148,0.004483565,0.002820145,0.0004315206,0.00011473073,0.00014339288,0.00083804264,0.00009054213],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44797996,0.0029490027,0.03088714,0.00026443342,0.13910383,0.01076056,0.0022708212,0.0003954873,0.32740593,0.00007329313,0.0054870117,0.032422516],"study_design_scores_gemma":[0.024766644,0.038546495,0.76125664,0.00076103705,0.1296512,0.0070263217,0.0013258996,0.0066961413,0.012286082,0.00006253901,0.016745098,0.0008759074],"about_ca_topic_score_codex":0.0016262605,"about_ca_topic_score_gemma":0.00024652795,"teacher_disagreement_score":0.7303695,"about_ca_system_score_codex":0.000960199,"about_ca_system_score_gemma":0.0021636225,"threshold_uncertainty_score":0.99982977},"labels":[],"label_agreement":null},{"id":"W4404759453","doi":"10.3390/biom14121513","title":"Sex-Related Differences in the Immune System Drive Differential Responses to Anti-PD-1 Immunotherapy","year":2024,"lang":"en","type":"article","venue":"Biomolecules","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Immunotherapy; Immune system; Systems biology; Immunology; Biology; Medicine; Computational biology","score_opus":0.01517234786502456,"score_gpt":0.27806725269771176,"score_spread":0.2628949048326872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404759453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97611,0.017297074,0.00034044345,0.0038475068,0.00069275114,0.0007435291,0.00003657821,0.00020117156,0.000730937],"genre_scores_gemma":[0.99795693,0.0004347103,0.000053966716,0.00027819627,0.000100052916,0.00008647314,0.000022983788,0.000036605798,0.0010300507],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99817824,0.00026761327,0.00046721962,0.00038919778,0.00036325265,0.00033444937],"domain_scores_gemma":[0.99924386,0.00018227247,0.000049112703,0.00043850546,0.000030469646,0.000055793796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039500603,0.0002609245,0.0004013652,0.00035908632,0.00010401842,0.00016925433,0.00029415227,0.00013392945,0.00012247452],"category_scores_gemma":[0.000018120714,0.00015577138,0.00023233843,0.0007686445,0.00018632012,0.000050859206,0.000038380247,0.00020310935,0.00007553478],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025527235,0.00021211432,0.0035689285,0.00023240916,0.00060409337,0.0005774542,0.005960062,2.0906903e-7,0.95878065,0.0034340234,0.00048853736,0.02358882],"study_design_scores_gemma":[0.005618004,0.001994161,0.7347615,0.003802729,0.00024769205,0.0008938291,0.011706054,0.0005790908,0.2237794,0.00012449005,0.0155439265,0.00094914227],"about_ca_topic_score_codex":0.00039200857,"about_ca_topic_score_gemma":0.000017675151,"teacher_disagreement_score":0.7350012,"about_ca_system_score_codex":0.00013062269,"about_ca_system_score_gemma":0.00011783366,"threshold_uncertainty_score":0.63521725},"labels":[],"label_agreement":null},{"id":"W4404789377","doi":"10.1126/sciadv.adq8122","title":"Identification of VISTA regulators in macrophages mediating cancer cell survival","year":2024,"lang":"en","type":"article","venue":"Science Advances","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Immune system; Tumor microenvironment; Cancer research; CD8; Cytotoxic T cell; Immune checkpoint; Proinflammatory cytokine; Biology; Cancer immunotherapy; Gene knockdown; Immunotherapy; Immunology; Cell biology; Inflammation; Cell culture; In vitro; Genetics","score_opus":0.010343345633309207,"score_gpt":0.3296429746166859,"score_spread":0.3192996289833767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404789377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9645947,0.03320911,0.000047320755,0.00030551234,0.0010498966,0.00012378306,0.000015380185,0.000027286462,0.00062700786],"genre_scores_gemma":[0.99800205,0.0012946127,0.00011979545,0.000025680893,0.000057099638,0.000011928782,0.0000017890349,0.0000055806863,0.00048143658],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989759,0.000011592685,0.0002507877,0.0002421107,0.00036270326,0.00015691554],"domain_scores_gemma":[0.9996669,0.000043941087,0.00006788896,0.0001384125,0.000050346007,0.000032474793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069575186,0.00006121594,0.00011264598,0.00012849063,0.00004696298,0.000031543274,0.00012419265,0.000018316188,0.000062134735],"category_scores_gemma":[0.000041729243,0.000048230868,0.000033543492,0.0010123577,0.00039840833,0.00047009237,0.000017045046,0.00005195966,0.000002375691],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049944734,0.000017666216,0.007481718,0.00017521303,0.0000035075007,0.0000039192937,0.00056313653,0.00002706788,0.934219,0.00007407285,0.000015356822,0.057369407],"study_design_scores_gemma":[0.00026535027,0.000049245078,0.045376226,0.00021950617,0.000010186461,0.0000020389232,0.0010442232,0.00061960495,0.95027626,0.00012179204,0.0019408982,0.00007467762],"about_ca_topic_score_codex":0.00020977794,"about_ca_topic_score_gemma":0.00018649014,"teacher_disagreement_score":0.05729473,"about_ca_system_score_codex":0.00014799483,"about_ca_system_score_gemma":0.00027235228,"threshold_uncertainty_score":0.19667977},"labels":[],"label_agreement":null},{"id":"W4404890341","doi":"10.1007/978-3-031-66754-1_12","title":"Can Understanding and Utilizing the Tumor Microenvironment Enhance the Therapeutic Efficacy of Focal Therapy?","year":2024,"lang":"en","type":"book-chapter","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Tumor microenvironment; Medicine; Psychology; Cancer research; Tumor cells","score_opus":0.05064346929223574,"score_gpt":0.27675493033735055,"score_spread":0.22611146104511481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404890341","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008243335,0.19008662,0.0001882124,0.042301882,0.000804513,0.003365508,0.00005881494,0.00013743417,0.7548137],"genre_scores_gemma":[0.7741273,0.016876386,0.000017901484,0.0040580016,0.00018047211,0.000017488816,0.000007984942,0.00009562151,0.20461883],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99870723,0.000020514444,0.00037070405,0.0003566815,0.00032617923,0.00021870703],"domain_scores_gemma":[0.9990301,0.00026312814,0.00014642731,0.0005030712,0.000012445361,0.00004482764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030394836,0.00033763918,0.00038543146,0.0000668897,0.00014418674,0.000040252202,0.00016943981,0.00011882418,0.0006222607],"category_scores_gemma":[0.0000027210954,0.00015629281,0.0002702241,0.00004071875,0.00074009306,0.000014581273,0.00006623224,0.0004460531,0.000008621799],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007756948,0.00021937297,0.00010843798,0.00089705474,0.009774292,0.00013183377,0.007118184,0.0000020030916,0.10223379,0.6681278,0.0057064276,0.1979239],"study_design_scores_gemma":[0.0056406497,0.0021700421,0.001815659,0.003918893,0.0019736784,0.0005971414,0.007783384,0.0000968649,0.025368243,0.048172757,0.9012754,0.0011873047],"about_ca_topic_score_codex":0.00007779428,"about_ca_topic_score_gemma":0.00007373696,"teacher_disagreement_score":0.89556897,"about_ca_system_score_codex":0.00024968377,"about_ca_system_score_gemma":0.00009126077,"threshold_uncertainty_score":0.6813318},"labels":[],"label_agreement":null},{"id":"W4405070240","doi":"10.3390/curroncol31120564","title":"Longitudinal Assessment of FT3 to FT4 Conversion Ratio in Predicting the Efficacy of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small Cell Lung Cancer: A Propensity-Score Matching Analysis of Data from the National Drug Monitoring Agency","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Propensity score matching; Cohort; Lung cancer; Cancer; Immunotherapy","score_opus":0.143381387266406,"score_gpt":0.4313357433631788,"score_spread":0.2879543560967728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405070240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99084187,0.0054923375,0.0009621075,0.0008291809,0.0006172492,0.0010347957,0.00017319324,0.000009320961,0.00003995542],"genre_scores_gemma":[0.9977728,0.0015500755,0.00025358298,0.000032748616,0.00013608352,0.000072358765,0.00016443459,0.000011716527,0.00000619317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982758,0.0001666906,0.0006603473,0.00036844634,0.00036247968,0.00016622688],"domain_scores_gemma":[0.998155,0.0010243952,0.00027864292,0.00034822733,0.00016311064,0.000030601128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009912901,0.00014758311,0.0005134607,0.00029818536,0.000052481813,0.000010108021,0.00036535962,0.000054214277,0.00008091276],"category_scores_gemma":[0.000054230768,0.000093820905,0.00012994834,0.0010605657,0.000077153214,0.00008516888,0.00012544084,0.00031836357,1.7063061e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021662062,0.000555405,0.9471863,0.0003265455,0.0004907015,0.0000056367135,0.0037512896,0.011095063,0.016592452,0.0000023141151,0.00009983477,0.017728265],"study_design_scores_gemma":[0.004136371,0.00026496814,0.8941903,0.0012558609,0.00040469473,4.97627e-7,0.00034159684,0.09518785,0.0038931554,0.0000031642949,0.00024300523,0.00007853796],"about_ca_topic_score_codex":0.002093642,"about_ca_topic_score_gemma":0.0019941845,"teacher_disagreement_score":0.08409279,"about_ca_system_score_codex":0.00042243584,"about_ca_system_score_gemma":0.0008857915,"threshold_uncertainty_score":0.38259053},"labels":[],"label_agreement":null},{"id":"W4405200272","doi":"10.1080/1750743x.2024.2436838","title":"Musculoskeletal immune-related adverse events of PD-(L)1 inhibitors in melanoma: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Research Canada; Dalhousie University","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; American Academy of Allergy Asthma and Immunology","keywords":"Adverse effect; Medicine; Immune system; Melanoma; Pembrolizumab; Incidence (geometry); Meta-analysis; Oncology; Ipilimumab; Internal medicine; Immunotherapy; Immunology; Cancer research","score_opus":0.03227925669359021,"score_gpt":0.35404011530669366,"score_spread":0.32176085861310344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405200272","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005051981,0.9934629,0.000002289606,0.00015844146,0.0001608934,0.005872201,0.000122030244,0.000058927013,0.0001118],"genre_scores_gemma":[0.00018465504,0.99601513,0.000044648965,0.00015992184,0.000016884786,0.0009629939,0.00016927363,0.00013940308,0.002307061],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.993595,0.0007127228,0.0040218155,0.00075507036,0.0005284726,0.00038691724],"domain_scores_gemma":[0.9968201,0.00019268387,0.0015001873,0.001309348,0.00009694297,0.00008077289],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0019266279,0.00097287877,0.014617138,0.0013581854,0.000039639686,0.000013376704,0.00034806508,0.00051810866,0.0005859232],"category_scores_gemma":[0.00006171026,0.000587514,0.010972455,0.0032200245,0.00016067446,0.00009688615,0.00007490842,0.0006930108,0.000055376564],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004865154,0.00011866935,0.0000017234645,0.652312,0.3415019,0.000035309447,0.00010964664,7.73574e-8,0.0000073513424,0.000015325984,0.000030254003,0.005819112],"study_design_scores_gemma":[0.0008916709,0.00020814236,0.000009894321,0.14811352,0.8225788,0.00014648552,0.000027541246,0.0000019863967,0.0000015980577,0.000010077336,0.02755729,0.00045299742],"about_ca_topic_score_codex":0.0002528082,"about_ca_topic_score_gemma":0.000021382126,"teacher_disagreement_score":0.5041985,"about_ca_system_score_codex":0.00029133074,"about_ca_system_score_gemma":0.0003072262,"threshold_uncertainty_score":0.99965763},"labels":[],"label_agreement":null},{"id":"W4405215161","doi":"10.1016/j.eclinm.2024.102991","title":"Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial","year":2024,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; BC Cancer Agency; Cancer Care Ontario; McGill University; McGill University Health Centre; Juravinski Cancer Centre; University Health Network; Ottawa Hospital; CancerCare Manitoba; BC Studies; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Hamilton Health Sciences","funders":"Canadian Cancer Society Research Institute; Canadian Cancer Society; AstraZeneca","keywords":"Durvalumab; Medicine; Tremelimumab; Open label; Cancer; Internal medicine; Clinical trial; Immunotherapy; Pembrolizumab","score_opus":0.06434953328348646,"score_gpt":0.41233806921970856,"score_spread":0.3479885359362221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405215161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838654,0.0047833123,0.00004454435,0.0064934855,0.0011839721,0.0031896322,0.000093443596,0.00008042877,0.0002657737],"genre_scores_gemma":[0.9919726,0.0020548443,0.0010901417,0.0022584246,0.00048157052,0.0001799538,0.00015481726,0.00007138323,0.0017362684],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99723506,0.00008034735,0.0009617677,0.00079772423,0.00048434,0.0004407327],"domain_scores_gemma":[0.99869925,0.00027389175,0.00015558681,0.00046522214,0.00012413636,0.00028190046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007320672,0.00034808976,0.0009320351,0.0002261879,0.00010833487,0.00004751875,0.00021701457,0.00018393545,0.00059018214],"category_scores_gemma":[0.00026149908,0.00023519603,0.00007443115,0.00066855125,0.00026753484,0.00022276319,0.0001420438,0.0005431778,0.000009750953],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48385075,0.0077989674,0.016099926,0.00023323332,0.00041954892,0.00020144682,0.0006225323,8.017631e-7,0.0002477597,0.0000054538814,0.0041555287,0.48636404],"study_design_scores_gemma":[0.9106899,0.021101402,0.037848637,0.0035763984,0.00033739145,0.0000091888705,0.00016597722,0.0016206139,0.00006235451,0.000011718687,0.024212405,0.00036400385],"about_ca_topic_score_codex":0.0002969429,"about_ca_topic_score_gemma":0.0003061647,"teacher_disagreement_score":0.48600003,"about_ca_system_score_codex":0.00018996508,"about_ca_system_score_gemma":0.00054581993,"threshold_uncertainty_score":0.95910156},"labels":[],"label_agreement":null},{"id":"W4405319926","doi":"10.1002/jha2.1062","title":"Characteristics of relapsed/refractory diffuse large B‐cell lymphoma patients with durable responses to maveropepimut‐S, pembrolizumab, and cyclophosphamide: Long‐term follow‐up from the SPiReL trial","year":2024,"lang":"en","type":"article","venue":"eJHaem","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Health Sciences Centre; Sunnybrook Hospital; Baker Hughes (Canada); McGill University Health Centre; Sunnybrook Health Science Centre","funders":"Merck Canada; McGill University Health Centre; Ottawa Hospital Research Institute; London Health Sciences Centre; McGill University","keywords":"Pembrolizumab; Medicine; Regimen; Cyclophosphamide; Internal medicine; Oncology; Immunotherapy; Clinical trial; ELISPOT; Lymphoma; Chemotherapy; Immune system; Immunology; T cell; Cancer","score_opus":0.01066533123460231,"score_gpt":0.24273796992625502,"score_spread":0.2320726386916527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405319926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937845,0.0029067204,0.000030711548,0.00036341642,0.0012351808,0.00095605396,0.00048746046,0.0000654454,0.00017054167],"genre_scores_gemma":[0.99380547,0.00075443415,0.000046425055,0.0006516832,0.00025196595,0.000038853555,0.00012762313,0.000060962477,0.004262614],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.998354,0.000091760296,0.00043531085,0.00039801333,0.00040726436,0.0003136488],"domain_scores_gemma":[0.9987822,0.00033960812,0.00013348574,0.00051980035,0.00008433301,0.00014058177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024006718,0.00026246518,0.00043187072,0.00008687591,0.000118661934,0.000073801515,0.00015735603,0.00011973914,0.0001709501],"category_scores_gemma":[0.00010316093,0.00016197437,0.00012907908,0.00025223652,0.00012197922,0.000111851696,0.000077723584,0.00015794356,0.00003064209],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54465944,0.0024927221,0.38772768,0.00029701958,0.00062172266,0.00030971604,0.0038853805,3.9735397e-8,0.0038019267,0.000019386585,0.0072211255,0.048963875],"study_design_scores_gemma":[0.10772568,0.0019143169,0.86210495,0.0005589325,0.00023472784,0.000008007936,0.00007234635,0.0000051033853,0.0013435024,0.0000053269146,0.025814962,0.00021211412],"about_ca_topic_score_codex":0.0002882567,"about_ca_topic_score_gemma":0.00006574321,"teacher_disagreement_score":0.4743773,"about_ca_system_score_codex":0.0001301904,"about_ca_system_score_gemma":0.00022571385,"threshold_uncertainty_score":0.6605123},"labels":[],"label_agreement":null},{"id":"W4405374502","doi":"10.1016/j.iotech.2024.101027","title":"LBA3 Perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) in early-stage non-small-cell lung cancer (NSCLC): A 4-year update of KEYNOTE-671","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Chugai Pharmaceutical; EMD Serono; Berlin Institute of Health; Sun Pharma; Teijin Pharma; Medizinische Universität Innsbruck; Freie Universität Berlin; Hôpitaux Universitaires de Genève; Humboldt-Universität zu Berlin; Astellas Pharma; Eisai; Daiichi-Sankyo; Sanofi; Sungkyunkwan University; BeiGene; Mirati Therapeutics; University of Queensland; Helsinn; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Pfizer; Incyte; Universität Innsbruck; Merck KGaA; Taiho Pharmaceutical; Revolution Medicines; Regeneron Pharmaceuticals; Japan Surgical Society; Yuhan; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Amgen; Celgene; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Oncology; Stage (stratigraphy); Perioperative; Chemotherapy; Lung cancer; Internal medicine; Cancer; Radiology; Immunotherapy; Biology","score_opus":0.008401937325614091,"score_gpt":0.2975276717874244,"score_spread":0.2891257344618103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9538506,0.031387355,0.00037144154,0.0074490355,0.0009803334,0.0016425486,0.00007230524,0.0003907369,0.0038556175],"genre_scores_gemma":[0.9826371,0.010584964,0.0014091125,0.0009315917,0.00012483932,0.00056891446,0.0000335995,0.00014022538,0.0035696693],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99669546,0.00011494269,0.0010587415,0.00093811285,0.00026218494,0.0009305739],"domain_scores_gemma":[0.9983726,0.00012756136,0.0002781515,0.0009291123,0.0002011029,0.00009143542],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047597112,0.000584134,0.0014048062,0.0012563753,0.000113598384,0.00003782164,0.0006123501,0.0012840069,0.0012064788],"category_scores_gemma":[0.000039443094,0.00052552886,0.00034093083,0.0016453004,0.0009833997,0.00015069476,0.00022117811,0.0012893677,0.00005802807],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01550478,0.00075160543,0.018373124,0.00086296705,0.0014738712,0.0010278407,0.0073607108,0.000035234283,0.8715518,0.0009370385,0.0016895554,0.080431476],"study_design_scores_gemma":[0.06894076,0.006397613,0.024920778,0.0026400962,0.00067275064,0.0007967437,0.005767145,0.0052729226,0.6718852,0.00022528227,0.2106531,0.0018276236],"about_ca_topic_score_codex":0.0017257218,"about_ca_topic_score_gemma":0.00062751205,"teacher_disagreement_score":0.20896354,"about_ca_system_score_codex":0.0017959962,"about_ca_system_score_gemma":0.002252915,"threshold_uncertainty_score":0.9997196},"labels":[],"label_agreement":null},{"id":"W4405374533","doi":"10.1016/j.iotech.2024.100886","title":"2O TILs and PD-L1 early dynamics in the randomized Neo-CheckRay phase II trial evaluating neo-adjuvant immuno-radiation and adenosine pathway blockade for early-stage, high risk ER+/HER2- breast cancer (BC)","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Japanese Respiratory Society; Japan Agency for Medical Research and Development","keywords":"Adenosine; Adjuvant; Blockade; Oncology; Stage (stratigraphy); Medicine; Internal medicine; Breast cancer; Randomized controlled trial; Receptor; Biology; Cancer","score_opus":0.014716830822621232,"score_gpt":0.34418831218317414,"score_spread":0.32947148136055293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94806594,0.029264767,0.00024063565,0.01538151,0.0013974588,0.0049108393,0.0003970997,0.00026261885,0.000079110105],"genre_scores_gemma":[0.98678374,0.008799524,0.0006527899,0.00036212453,0.00033841722,0.0023873837,0.00011298551,0.00008291085,0.00048014475],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963822,0.0005982318,0.0011978535,0.0007980119,0.0002971221,0.0007266283],"domain_scores_gemma":[0.9972821,0.0013577389,0.0005030677,0.0006182518,0.00017231888,0.000066511755],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032631631,0.0005042808,0.0014560838,0.0007675019,0.00045078393,0.00010348777,0.00034989955,0.0010382923,0.00012539727],"category_scores_gemma":[0.0005230275,0.0003680139,0.0002698172,0.0008818909,0.0012252297,0.00018693498,0.00015984986,0.001115911,0.000003811676],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44509342,0.00056243315,0.00088537193,0.00010886605,0.0010848505,0.000081191465,0.0024535486,0.0000031139507,0.019651666,0.0008057876,0.00016912626,0.52910066],"study_design_scores_gemma":[0.931918,0.020356894,0.008997117,0.0005406157,0.0018532277,0.00084529567,0.0022678333,0.0115722185,0.0034116337,0.0026150516,0.014854561,0.00076749944],"about_ca_topic_score_codex":0.0067451308,"about_ca_topic_score_gemma":0.0010850126,"teacher_disagreement_score":0.5283331,"about_ca_system_score_codex":0.00087084,"about_ca_system_score_gemma":0.000681272,"threshold_uncertainty_score":0.99987715},"labels":[],"label_agreement":null},{"id":"W4405374998","doi":"10.1016/j.iotech.2024.100749","title":"120MO Inupadenant combined with chemotherapy in patients with non-squamous NSCLC progressing on or after immune checkpoint inhibitor therapy: Results from dose-finding part of the A2A-005 trial","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Brampton Civic Hospital","funders":"","keywords":"Medicine; Oncology; Chemotherapy; Internal medicine; Immune checkpoint; Immune system; Immunotherapy; Immunology; Cancer","score_opus":0.012900915253423132,"score_gpt":0.2756339601567856,"score_spread":0.26273304490336247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850742,0.002128243,0.000005973027,0.0078759445,0.0011149641,0.0033122916,0.00004588827,0.0002164441,0.00022604542],"genre_scores_gemma":[0.9978413,0.00025503803,0.00038634907,0.00045678217,0.00015415586,0.00059223827,0.000046670713,0.00010264091,0.00016481221],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968365,0.00015697039,0.0011827615,0.0007612402,0.0004284193,0.0006341292],"domain_scores_gemma":[0.9979235,0.0003183671,0.00052335416,0.0010757435,0.00011212428,0.000046945464],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005615745,0.0005039791,0.0010453414,0.0006208147,0.0001241115,0.00004506138,0.00043992265,0.00079232606,0.00010251972],"category_scores_gemma":[0.00009746202,0.00025884548,0.00019711153,0.0014588216,0.0011305609,0.00012976002,0.00011082441,0.0009977422,0.0000068691406],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80108917,0.0021043038,0.009345733,0.000051163977,0.000793136,0.00020489552,0.0015799048,0.0000012167127,0.029247042,0.000013165947,0.00014273783,0.15542755],"study_design_scores_gemma":[0.51788604,0.0735526,0.16620405,0.0060225953,0.0002726664,0.00009871741,0.0011199513,0.00004715142,0.2101209,0.00013213098,0.023645222,0.0008979644],"about_ca_topic_score_codex":0.00018844026,"about_ca_topic_score_gemma":0.00019709155,"teacher_disagreement_score":0.2832031,"about_ca_system_score_codex":0.0006580031,"about_ca_system_score_gemma":0.00087075133,"threshold_uncertainty_score":0.99998635},"labels":[],"label_agreement":null},{"id":"W4405375144","doi":"10.1016/j.iotech.2024.100750","title":"121MO Anti-IL-8 (BMS-986253) in combination with nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with advanced melanoma: Final analysis from the randomized part 2 of the phase I/II CA027-002 study","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; PharmaMar; European Society for Medical Oncology","keywords":"Nivolumab; Ipilimumab; Medicine; Metastatic melanoma; Internal medicine; Melanoma; Oncology; Cancer research; Immunotherapy; Cancer","score_opus":0.008657859952414042,"score_gpt":0.2774406519264998,"score_spread":0.2687827919740858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405375144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896531,0.0030458174,0.000079164296,0.0032607294,0.00039522527,0.0031874157,0.000053991007,0.000119713804,0.00020485253],"genre_scores_gemma":[0.9985675,0.00027420413,0.00013449232,0.00014558382,0.000019901285,0.00057368434,0.000083308056,0.000037921352,0.0001633964],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99693644,0.0005634896,0.0009990287,0.0006499258,0.00039575784,0.0004553576],"domain_scores_gemma":[0.99776137,0.00058373535,0.00043428259,0.0010120905,0.00018050734,0.000028017335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093123905,0.0003755923,0.001661643,0.0009428537,0.00017424881,0.00001788176,0.0005633139,0.00041050353,0.0001457919],"category_scores_gemma":[0.00014280349,0.0002049609,0.0002466351,0.0037403808,0.0013130399,0.00012346229,0.00018759488,0.0008224278,0.0000036450328],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51140743,0.013228859,0.3235366,0.00007118074,0.0108641125,0.00035865026,0.007967453,0.00020417642,0.0053844415,0.00033396983,0.00029753233,0.12634557],"study_design_scores_gemma":[0.8140933,0.02113009,0.14566065,0.00054523954,0.0036322807,0.000051791623,0.006122132,0.0013651956,0.0028458168,0.00026627613,0.0038123068,0.0004749108],"about_ca_topic_score_codex":0.0016522892,"about_ca_topic_score_gemma":0.006222238,"teacher_disagreement_score":0.30268586,"about_ca_system_score_codex":0.0008154055,"about_ca_system_score_gemma":0.00061028474,"threshold_uncertainty_score":0.8358063},"labels":[],"label_agreement":null},{"id":"W4405456399","doi":"10.3899/jrheum.2024-0603","title":"Effect of Age on Rheumatic Immune-Related Adverse Events: Experience From the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)","year":2024,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Research Canada; University of Ottawa; Western University; Hôtel-Dieu de Montréal; Dalhousie University; McGill University; University of Calgary; Université de Montréal; University of Alberta; University of British Columbia","funders":"Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Rheumatology; Internal medicine; Adverse effect; Oncology; Immune system; Physical therapy; Immunology","score_opus":0.02185581844969822,"score_gpt":0.345155962516855,"score_spread":0.3233001440671568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405456399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98222417,0.0127183525,0.000008610494,0.0028970563,0.0012484896,0.00054433226,0.000011358118,0.00000955655,0.00033809053],"genre_scores_gemma":[0.9933852,0.0064177504,0.000030469004,0.00006678254,0.000004725618,0.000019627789,0.000007495946,0.000030215435,0.00003771822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994024,0.0029180793,0.0018141475,0.00019907673,0.00050954125,0.000535191],"domain_scores_gemma":[0.9919012,0.006588012,0.0006323848,0.00059343595,0.00017153978,0.000113399954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007016963,0.00023634094,0.0012480834,0.0007300399,0.00015688763,0.000006709016,0.0007874592,0.00034601786,0.00042056543],"category_scores_gemma":[0.0010103476,0.00012734225,0.000329734,0.0008859575,0.0013135363,0.00009163389,0.000084768624,0.0013122805,0.000020991316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07084523,0.0010984532,0.6153672,0.0024029762,0.007582196,0.0013523289,0.14454079,0.00018826047,0.07502165,0.0064539425,0.005244982,0.069902],"study_design_scores_gemma":[0.0777347,0.07225838,0.5528605,0.07391693,0.0020942453,0.093847916,0.062823094,0.0031485232,0.029472744,0.0101926355,0.019694319,0.0019560286],"about_ca_topic_score_codex":0.3046239,"about_ca_topic_score_gemma":0.11157865,"teacher_disagreement_score":0.19304524,"about_ca_system_score_codex":0.00065030117,"about_ca_system_score_gemma":0.0011917369,"threshold_uncertainty_score":0.90463275},"labels":[],"label_agreement":null},{"id":"W4405518490","doi":"10.47363/jccsr/2024(6)339","title":"Survival and Concomitant Antitumor Immunity in Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Case Studies Reviews & Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Concomitant; Immunity; Medicine; Cancer; Oncology; Internal medicine; Immunology; Immune system","score_opus":0.21006144512195593,"score_gpt":0.5250063895870541,"score_spread":0.31494494446509824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405518490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54220015,0.45423207,0.0000020941927,0.0010196378,0.0020988667,0.00020090069,0.0000015254353,0.000004742792,0.00024002611],"genre_scores_gemma":[0.56636375,0.43262693,0.00011731203,0.00024204185,0.00048004964,0.0000065069207,3.014462e-7,0.000009244959,0.0001538746],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99569994,0.00032529622,0.0033783843,0.00020303787,0.00023566686,0.00015766504],"domain_scores_gemma":[0.9977946,0.0007187852,0.00092069514,0.00021947117,0.00022110589,0.00012530231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008924058,0.00016045698,0.0017240475,0.00010068003,0.000049538838,0.00002250219,0.000033916618,0.00007123316,0.00006955419],"category_scores_gemma":[0.0019244908,0.00009361982,0.00053807267,0.00025855438,0.0002507891,0.00010591523,0.00005316161,0.00065843604,0.0000013032326],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010990138,0.00023193295,0.10728332,0.0017169013,0.001331227,0.3554274,0.0004538651,2.5587136e-7,0.00014857107,0.0000114753575,0.010396726,0.5218993],"study_design_scores_gemma":[0.0019465187,0.0011804042,0.050698638,0.008339504,0.0008397512,0.2874615,0.00093676546,0.0000094247625,0.000038921873,0.00010939496,0.64823157,0.00020763752],"about_ca_topic_score_codex":0.000115076735,"about_ca_topic_score_gemma":0.00025146606,"teacher_disagreement_score":0.6378348,"about_ca_system_score_codex":0.000101064965,"about_ca_system_score_gemma":0.00033167677,"threshold_uncertainty_score":0.38177055},"labels":[],"label_agreement":null},{"id":"W4405596303","doi":"10.1016/j.ijcha.2024.101581","title":"Cardiac magnetic resonance imaging in patients with suspected myocarditis from immune checkpoint inhibitor therapy – A real-world observational study","year":2024,"lang":"en","type":"article","venue":"IJC Heart & Vasculature","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute; Artificial Intelligence in Medicine (Canada)","funders":"National Institutes of Health; Deutsche Forschungsgemeinschaft; Medizinische Fakultät, Universität Duisburg-Essen; European Commission","keywords":"Medicine; Myocarditis; Magnetic resonance imaging; Observational study; Cardiac magnetic resonance imaging; Radiology; Internal medicine","score_opus":0.014846608439359255,"score_gpt":0.26465123384734607,"score_spread":0.2498046254079868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405596303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9453279,0.050621852,0.0000010760215,0.0013877334,0.0006726788,0.0015090621,0.0000987901,0.00015423869,0.00022667157],"genre_scores_gemma":[0.9973938,0.0005123742,0.00029898656,0.0004330125,0.0005125693,0.00012772586,0.00030322096,0.00007376363,0.00034458208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977129,0.00014719862,0.00045145166,0.00062059006,0.0007110214,0.00035681293],"domain_scores_gemma":[0.99906063,0.00008971457,0.000042521595,0.00056387106,0.0001577408,0.00008549489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003353052,0.00030785543,0.0005503631,0.00021707639,0.000081010214,0.00010186378,0.000091386915,0.000094344614,0.0002834998],"category_scores_gemma":[0.000018436524,0.00023558887,0.00031260925,0.0010714787,0.00008291387,0.00018443447,0.000033600678,0.0005095366,0.000015599298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020332031,0.0004131884,0.96788555,0.000026203492,0.0002599868,0.00009402897,0.0011167164,0.0000018229264,0.005853895,0.0000073187985,0.0023654597,0.019942638],"study_design_scores_gemma":[0.0059963707,0.00045019086,0.9420637,0.00067165523,0.00007819321,0.0000031453678,0.00012963006,0.00003493181,0.0003365869,0.000025293526,0.0499492,0.000261125],"about_ca_topic_score_codex":0.0036969401,"about_ca_topic_score_gemma":0.00035094804,"teacher_disagreement_score":0.052065868,"about_ca_system_score_codex":0.00030755476,"about_ca_system_score_gemma":0.00024464665,"threshold_uncertainty_score":0.96070355},"labels":[],"label_agreement":null},{"id":"W4405624081","doi":"10.1016/j.clon.2024.103742","title":"Tumour-infiltrating Lymphocytes and Radiation Therapy in Rectal Cancer: Systematic Review and Meta-analysis","year":2024,"lang":"en","type":"review","venue":"Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Colorectal cancer; Radiation therapy; Meta-analysis; Oncology; Tumor-infiltrating lymphocytes; Internal medicine; Cancer; Cancer research; Immunotherapy","score_opus":0.24810544212626318,"score_gpt":0.5180020289484688,"score_spread":0.26989658682220563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405624081","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027669268,0.9952953,7.4766234e-7,0.0014714061,0.00019139341,0.0028108733,0.000039915147,0.000028631492,0.00013408602],"genre_scores_gemma":[0.000039916362,0.99560213,0.00005902446,0.002734806,0.00015024722,0.0009794512,0.000050108665,0.000034539687,0.00034975025],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99469644,0.0014292402,0.0028615831,0.0006508007,0.00015018646,0.00021173609],"domain_scores_gemma":[0.9961313,0.0023298587,0.0010358259,0.00032949029,0.000049851424,0.0001236954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035941112,0.00040120064,0.013100827,0.000296304,0.000032736567,0.000028655135,0.000109205845,0.0005579746,0.00021606663],"category_scores_gemma":[0.00064616825,0.00022526187,0.0025516755,0.00090407353,0.0001858954,0.00003789097,0.000043299984,0.00057736976,0.000009975504],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006038842,0.000067739085,0.000022094226,0.51645476,0.13118476,0.000055132747,0.000028470877,1.7304455e-8,1.938591e-7,0.000005839336,0.00041228466,0.35170835],"study_design_scores_gemma":[0.00072455866,0.0006642103,0.000037994,0.035290886,0.7997108,0.00014306845,0.00000977308,0.000008482696,1.168338e-7,0.000005988086,0.16320279,0.00020133518],"about_ca_topic_score_codex":0.00016469722,"about_ca_topic_score_gemma":0.00018076287,"teacher_disagreement_score":0.66852605,"about_ca_system_score_codex":0.0003856942,"about_ca_system_score_gemma":0.0010126325,"threshold_uncertainty_score":0.91859126},"labels":[],"label_agreement":null},{"id":"W4405694105","doi":"10.3389/fimmu.2024.1505896","title":"Association between somatic microsatellite instability, hypermutation status, and specific T cell subsets in colorectal cancer tumors","year":2024,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Sinai Health System; Lunenfeld-Tanenbaum Research Institute","funders":"Office of Research Infrastructure Programs, National Institutes of Health; Harvard T.H. Chan School of Public Health; Ontario Ministry of Research and Innovation; Prevent Cancer Foundation; Cancer Research UK; National Health and Medical Research Council; Medical Research Council; Canadian Institutes of Health Research; National Institutes of Health; Fred Hutchinson Cancer Research Center; National Cancer Institute; Brigham and Women's Hospital; Centers for Disease Control and Prevention","keywords":"Microsatellite instability; Stromal cell; Colorectal cancer; Biology; Odds ratio; CD8; Oncology; Pathology; Cancer research; Internal medicine; Medicine; Immune system; Immunology; Cancer; Genetics; Microsatellite","score_opus":0.009443010117499666,"score_gpt":0.25058868517138494,"score_spread":0.24114567505388526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405694105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9388371,0.05862669,0.00005103656,0.00062309875,0.001134597,0.00044833968,0.000042453255,0.000044037108,0.00019260964],"genre_scores_gemma":[0.9883702,0.010562969,0.00055722875,0.00004670522,0.000055934324,0.00005461693,0.00009814662,0.000023592003,0.00023060056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986109,0.00013195281,0.00043095672,0.00032350703,0.00012443548,0.00037823446],"domain_scores_gemma":[0.999632,0.00011652559,0.00008274659,0.00010638185,0.00002825871,0.000034084856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037178103,0.0001553132,0.0003923725,0.000424094,0.000033337386,0.00003688245,0.000058941274,0.00021629651,0.000058527716],"category_scores_gemma":[0.00002869831,0.00015388167,0.00005533157,0.0004982994,0.00013535778,0.00012973805,0.000027232574,0.00034897035,0.000007965416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005533213,0.000055242916,0.88208485,0.00017208602,0.00016474076,0.000025782701,0.0023495657,0.0000017157662,0.06956195,0.0000060420048,0.0005938876,0.04443085],"study_design_scores_gemma":[0.0020889575,0.00014421954,0.97361654,0.00023532019,0.00004565994,0.0000073282595,0.00075190613,0.00011120647,0.01577962,0.00039945482,0.0066646626,0.00015513641],"about_ca_topic_score_codex":0.0006732975,"about_ca_topic_score_gemma":0.00027917876,"teacher_disagreement_score":0.09153171,"about_ca_system_score_codex":0.0015329402,"about_ca_system_score_gemma":0.00017675372,"threshold_uncertainty_score":0.62751126},"labels":[],"label_agreement":null},{"id":"W4405748686","doi":"10.1016/j.jval.2024.10.090","title":"CO13 Impact on Health Outcomes and Productive Work of Anti-PD-(L)1 Inhibitors to Treat Early-Stage Cancers in England","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Stage (stratigraphy); Medicine; Oncology; Internal medicine; Biology","score_opus":0.03250610740754499,"score_gpt":0.35414556125140906,"score_spread":0.32163945384386405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405748686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97757804,0.007408068,0.0000015801822,0.013221893,0.00038426288,0.0012565932,0.00006264636,0.000030372474,0.000056542107],"genre_scores_gemma":[0.99673045,0.0020530657,0.00007824985,0.0007927559,0.000100856465,0.000027023594,0.000007070048,0.000026494661,0.00018405073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831116,0.00016887738,0.00052113464,0.0003835707,0.00022200825,0.0003932309],"domain_scores_gemma":[0.9993056,0.00017387318,0.00009168057,0.00021856875,0.00001834679,0.00019193986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097325514,0.00018788388,0.0005920733,0.0004937978,0.000033041855,0.00001532546,0.00004521691,0.000059409882,0.000013359544],"category_scores_gemma":[0.000056616696,0.0001354649,0.00007179528,0.0009043789,0.000059658225,0.000053481675,0.000014988961,0.00025522927,0.0000021817186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037790993,0.00016286212,0.9032182,0.0017361894,0.00007861433,0.00004127252,0.02767752,0.0009119811,0.00020154392,0.00002684213,0.0011698558,0.060996037],"study_design_scores_gemma":[0.0024601137,0.0026291998,0.98695433,0.0030644329,0.0000054762268,0.0000067496335,0.0003913286,0.000061293256,0.0004713497,0.000013207744,0.0038150374,0.00012747677],"about_ca_topic_score_codex":0.089272246,"about_ca_topic_score_gemma":0.0012025341,"teacher_disagreement_score":0.08806971,"about_ca_system_score_codex":0.0015858673,"about_ca_system_score_gemma":0.0011791777,"threshold_uncertainty_score":0.9167924},"labels":[],"label_agreement":null},{"id":"W4405751176","doi":"10.1161/jaha.124.035689","title":"Myocarditis in Patients Starting Combination Checkpoint Inhibitor Therapy: Analysis of a Commercial Claims Database","year":2024,"lang":"en","type":"article","venue":"Journal of the American Heart Association","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Heart, Lung, and Blood Institute; Hamilton Health Sciences Foundation; National Institutes of Health; Brigham and Women's Hospital","keywords":"Medicine; Myocarditis; Database; Internal medicine; Intensive care medicine","score_opus":0.013634450882456623,"score_gpt":0.29392774575202196,"score_spread":0.28029329486956533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405751176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99597895,0.00024571008,0.000019443538,0.0031606068,0.00039510595,0.00014235057,0.000030956082,0.000005874043,0.000020980502],"genre_scores_gemma":[0.9988747,0.00017788786,0.00006997238,0.00071081426,0.0001227863,0.0000018746604,0.000012394328,0.000009149861,0.000020382413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846417,0.00020801104,0.0005845088,0.000080836835,0.00054734194,0.000115163384],"domain_scores_gemma":[0.9988109,0.00018482009,0.00063337147,0.00011927274,0.00022232624,0.00002930499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013592608,0.0000735054,0.000500374,0.0003845401,0.000035444365,0.000021966633,0.000061597806,0.000030500483,0.000019774472],"category_scores_gemma":[0.00020650965,0.00005151548,0.0004927897,0.0015715985,0.000041367348,0.000134338,0.00001712886,0.00022679195,7.5964095e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071540324,0.00021781216,0.96590006,0.000013624232,0.0014000419,0.0000012465007,0.0005963875,0.000017616901,0.012581094,0.0000017483525,0.0025532732,0.016001703],"study_design_scores_gemma":[0.0013249828,0.0005188956,0.9930958,0.00017745516,0.00043301264,0.0000011562785,0.0001457492,0.00042497812,0.002951127,0.000017731227,0.0008600627,0.00004901827],"about_ca_topic_score_codex":0.0003624294,"about_ca_topic_score_gemma":0.00005787622,"teacher_disagreement_score":0.027195781,"about_ca_system_score_codex":0.00075965666,"about_ca_system_score_gemma":0.00012669328,"threshold_uncertainty_score":0.21007402},"labels":[],"label_agreement":null},{"id":"W4405808029","doi":"10.1186/s13256-024-04852-1","title":"Immune checkpoint inhibitor-associated diabetic ketoacidosis and insulin-dependent diabetes: a case report","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Case Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"","keywords":"Medicine; Diabetic ketoacidosis; Nivolumab; Diabetes mellitus; Ketoacidosis; Insulin; Intensive care medicine; Internal medicine; Pediatrics; Immunotherapy; Type 1 diabetes; Cancer; Endocrinology","score_opus":0.013596287157302506,"score_gpt":0.2860385175075496,"score_spread":0.2724422303502471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405808029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94648904,0.04559201,0.000032318967,0.005410626,0.0020414125,0.00022834295,0.0000050724784,0.00005295721,0.00014823455],"genre_scores_gemma":[0.99669147,0.0019136702,0.000070473776,0.00034025687,0.00072479545,0.000010043887,0.0000068811355,0.00004248029,0.00019993147],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99512315,0.00011569637,0.0023315472,0.00034761455,0.0017180797,0.00036394148],"domain_scores_gemma":[0.9975664,0.00024879034,0.0008620826,0.0003377833,0.00027779097,0.00070717506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063580945,0.00025435473,0.00078885676,0.00031511218,0.00010241978,0.000100814046,0.000046445453,0.00036930802,0.00047005722],"category_scores_gemma":[0.002583821,0.00018092208,0.0004702514,0.00038988393,0.00021155564,0.0001564636,0.00008199959,0.0010124563,0.0000019830472],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016559387,0.00028310218,0.0022997577,0.00033838858,0.0009055391,0.95699394,0.00037224276,2.3168629e-7,0.0040270025,0.0000010152036,0.0009033814,0.033709794],"study_design_scores_gemma":[0.0016998795,0.0007046104,0.0015790276,0.0026394767,0.000625733,0.9821713,0.00037192818,0.0001515549,0.005659805,0.000055677596,0.0041559585,0.00018502238],"about_ca_topic_score_codex":0.00023279258,"about_ca_topic_score_gemma":0.000041068615,"teacher_disagreement_score":0.05020244,"about_ca_system_score_codex":0.00037776705,"about_ca_system_score_gemma":0.0010824827,"threshold_uncertainty_score":0.73777884},"labels":[],"label_agreement":null},{"id":"W4405842373","doi":"10.1101/2024.12.27.630504","title":"Combinations of genomic alterations and immune microenvironmental features associate with patient survival in multiple cancer types","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Immune system; Cancer; Computational biology; Biology; Medicine; Cancer research; Immunology; Genetics","score_opus":0.008909773209531995,"score_gpt":0.21722878166462042,"score_spread":0.20831900845508844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405842373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98058236,0.017092701,0.0000058592045,0.00050836656,0.00044907682,0.00071324676,0.0005952015,0.000043791693,0.0000093701965],"genre_scores_gemma":[0.99761415,0.0016039459,0.0004065791,0.000074849115,0.00005543953,0.0001680644,0.000002129523,0.00006165815,0.000013177662],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99873173,0.00005614328,0.00037151517,0.0004257016,0.00020081004,0.00021412314],"domain_scores_gemma":[0.9992525,0.000041155792,0.00021303054,0.0003455889,0.000080748236,0.00006698836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016731324,0.00026762503,0.00043850538,0.00020739593,0.00006480964,0.000048637135,0.00008832768,0.00018756393,0.000029942626],"category_scores_gemma":[0.000016681272,0.00024273747,0.000084300125,0.00018809215,0.00015044525,0.00003457896,0.00015020947,0.00045440567,0.0000034623488],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033310885,0.00035529278,0.056593496,0.0003564644,0.00058315153,0.00002618298,0.00009562928,0.0000394643,0.9414766,0.00005399113,0.00007098765,0.00001563825],"study_design_scores_gemma":[0.0019689314,0.00013383193,0.77127606,0.00082452426,0.00020505014,5.1683884e-8,0.00001463929,0.00007265777,0.22480117,0.000001443053,0.0004455584,0.0002560735],"about_ca_topic_score_codex":0.0009115495,"about_ca_topic_score_gemma":0.00017391832,"teacher_disagreement_score":0.7166754,"about_ca_system_score_codex":0.00047843403,"about_ca_system_score_gemma":0.00034937475,"threshold_uncertainty_score":0.98985463},"labels":[],"label_agreement":null},{"id":"W4405850130","doi":"10.1186/s12979-024-00487-4","title":"CD57+ EMRA CD8+ T cells in cancer patients over 70: associations with prior chemotherapy and response to anti-PD-1/PD-L1 therapy","year":2024,"lang":"en","type":"article","venue":"Immunity & Ageing","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"CD8; Medicine; Cytotoxic T cell; Immunotherapy; T cell; Immune system; PD-L1; Chemotherapy; Senescence; Cancer; Immunology; Flow cytometry; Internal medicine; Biology","score_opus":0.015464896586561175,"score_gpt":0.3011403148865382,"score_spread":0.285675418299977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405850130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935979,0.0024280178,0.000017655846,0.0025081523,0.0002574378,0.00078542496,0.00004536783,0.00009330712,0.0002667081],"genre_scores_gemma":[0.9931371,0.003162775,0.00014961296,0.0022845985,0.00007430523,0.000055378856,0.000018815723,0.000058311634,0.0010590518],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985634,0.00021441987,0.00029069453,0.00028355976,0.0003054991,0.0003424029],"domain_scores_gemma":[0.9991938,0.0002455345,0.0000705289,0.0003086118,0.0000849508,0.00009659077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006772405,0.00021858861,0.00031706056,0.0002980005,0.0002900879,0.00009762453,0.00011328659,0.000119916636,0.000200388],"category_scores_gemma":[0.000039574945,0.00018320758,0.000081445134,0.00073509855,0.00008390031,0.00017977359,0.000041952644,0.00037173915,0.0000061529345],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019860487,0.0008849937,0.10693462,0.00015232756,0.0009166062,0.00017573881,0.0664954,0.000018348408,0.6668682,0.000012289615,0.0015907143,0.13609028],"study_design_scores_gemma":[0.0050535467,0.0006039185,0.9279771,0.00084448594,0.000037941776,0.0000031369075,0.000510918,0.000039537128,0.016060105,0.000008865858,0.048583116,0.00027735258],"about_ca_topic_score_codex":0.0045167683,"about_ca_topic_score_gemma":0.0006042725,"teacher_disagreement_score":0.8210425,"about_ca_system_score_codex":0.0005165109,"about_ca_system_score_gemma":0.00032867322,"threshold_uncertainty_score":0.7470988},"labels":[],"label_agreement":null},{"id":"W4405850907","doi":"10.1101/2024.12.23.629453","title":"Characterizing postoperative T and B cell dysfunction in cancer surgery patients, using COVID-19 as a model antigen","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Immune system; CD8; Antigen; Medicine; Disease; Surgical stress; T cell; Antibody; Immunology; Cell; Cancer; Cytotoxic T cell; Coronavirus disease 2019 (COVID-19); B cell; Internal medicine; Biology; In vitro","score_opus":0.03100196050033171,"score_gpt":0.27226867307268743,"score_spread":0.2412667125723557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405850907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891731,0.0070468597,0.00013590857,0.00092192716,0.0011917326,0.001042974,0.00031597906,0.0001648237,0.000006705961],"genre_scores_gemma":[0.9921644,0.004084446,0.0004227678,0.0028126778,0.00020766525,0.00016413725,0.0000023980165,0.00012877905,0.000012742706],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975443,0.00009894375,0.0005976063,0.0009836697,0.00033220372,0.000443312],"domain_scores_gemma":[0.9986069,0.000060051687,0.00028772312,0.0004985839,0.00024006629,0.0003066635],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005387636,0.0005110605,0.0007241173,0.0006045933,0.00012991445,0.00015566367,0.000104991705,0.00047494145,0.00006130249],"category_scores_gemma":[0.000110678164,0.00051097956,0.00017044923,0.00051538134,0.00011211481,0.00013399597,0.0002768813,0.00077008293,0.000009049261],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009706774,0.00020988897,0.09417249,0.0018536159,0.00022527376,0.00011755246,0.00016471118,0.00017111828,0.90182644,0.000013764233,0.00025762746,0.000016846836],"study_design_scores_gemma":[0.0070362943,0.00030301884,0.5190784,0.00876356,0.0009388992,4.1562586e-7,0.00005510462,0.04166802,0.40845323,0.000010187196,0.010435632,0.0032572877],"about_ca_topic_score_codex":0.0018569558,"about_ca_topic_score_gemma":0.000021717713,"teacher_disagreement_score":0.49337322,"about_ca_system_score_codex":0.0014567999,"about_ca_system_score_gemma":0.0034461946,"threshold_uncertainty_score":0.99973416},"labels":[],"label_agreement":null},{"id":"W4405954953","doi":"10.3390/pharma4010001","title":"Hepatobiliary Adverse Events Associated with Pembrolizumab: A Pharmacovigilance Study from the FDA Adverse Event Reporting System (FAERS) Database","year":2024,"lang":"en","type":"article","venue":"Pharmacoepidemiology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"U.S. Food and Drug Administration","keywords":"Adverse Event Reporting System; Pharmacovigilance; Adverse effect; Medicine; Pembrolizumab; Database; Pharmacology; Internal medicine; Computer science","score_opus":0.06011235360401502,"score_gpt":0.3816651777446038,"score_spread":0.3215528241405888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405954953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869701,0.0055382317,0.0004141316,0.0020487213,0.0018300083,0.0020393552,0.0003985558,0.0005532143,0.00020766466],"genre_scores_gemma":[0.99419194,0.0005207513,0.000099760255,0.0031771548,0.0007236337,0.00025308682,0.0007315929,0.00007921614,0.0002228606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99408245,0.0016206013,0.0019223498,0.0012170904,0.0004689355,0.0006885503],"domain_scores_gemma":[0.99512327,0.0022314712,0.0011340264,0.0011626395,0.00011760044,0.00023099317],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006902767,0.00046424018,0.001001942,0.00010783357,0.0002445626,0.000008917723,0.000546211,0.00012184535,0.0004693771],"category_scores_gemma":[0.0013730248,0.0002853743,0.00029497364,0.00056617847,0.00016523014,0.00026825012,0.0002720836,0.0008783595,0.00010475094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007745267,0.00075153256,0.93724805,0.00032687708,0.006078189,0.004060334,0.0012181706,0.0001735627,0.012065575,0.000010267876,0.026330832,0.00399135],"study_design_scores_gemma":[0.03854387,0.0018077418,0.7208355,0.006623715,0.010397826,0.0018603298,0.009512552,0.14744754,0.0019295402,0.000031133433,0.05913453,0.0018756998],"about_ca_topic_score_codex":0.0031573842,"about_ca_topic_score_gemma":0.00027410168,"teacher_disagreement_score":0.21641251,"about_ca_system_score_codex":0.00059845886,"about_ca_system_score_gemma":0.00046857444,"threshold_uncertainty_score":0.9999598},"labels":[],"label_agreement":null},{"id":"W4406020721","doi":"10.14740/gr1768","title":"Risk Factors Predicting Outcomes in Advanced Upper Gastrointestinal Cancers Treated With Immune Checkpoint Inhibitors","year":2024,"lang":"en","type":"article","venue":"Gastroenterology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Immune system; Immune checkpoint; Oncology; Internal medicine; Immunology; Immunotherapy","score_opus":0.0245041089004575,"score_gpt":0.33125044938423537,"score_spread":0.30674634048377786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406020721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971177,0.0004935623,0.000049600014,0.001068866,0.00015450224,0.00071319693,0.000042457294,0.00014592026,0.0002142053],"genre_scores_gemma":[0.9985355,0.00016182737,0.0004182347,0.00004686036,0.00007690673,0.00013250065,0.0000403391,0.00005605396,0.0005317422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968748,0.00031402888,0.00054575637,0.0006203829,0.00053784635,0.0011072002],"domain_scores_gemma":[0.9990039,0.00024002689,0.000075372365,0.00036102574,0.00014190498,0.00017776182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011391583,0.0002885132,0.0005099317,0.00078850007,0.00013713066,0.000049296406,0.00017088592,0.000089249756,0.00019317838],"category_scores_gemma":[0.00018160195,0.00019787971,0.00019362284,0.00065513374,0.0005252307,0.00014325147,0.00008864079,0.0014051534,0.000016082322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00930342,0.000120879384,0.9706168,0.000082478866,0.0002635322,0.00035566668,0.00037888275,0.000051121853,0.017478194,0.0000014356244,0.00010081785,0.001246726],"study_design_scores_gemma":[0.0039620297,0.0045294785,0.98484296,0.0009143805,0.000043193944,0.0004343583,0.0013311087,0.0006004143,0.003110851,0.0000051891748,0.00012747654,0.00009857144],"about_ca_topic_score_codex":0.0041669738,"about_ca_topic_score_gemma":0.0012090812,"teacher_disagreement_score":0.014367343,"about_ca_system_score_codex":0.00087845395,"about_ca_system_score_gemma":0.00030194226,"threshold_uncertainty_score":0.80693},"labels":[],"label_agreement":null},{"id":"W4406158653","doi":"10.1200/jco-24-02239","title":"Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Nivolumab; Medicine; Ipilimumab; Internal medicine; Lung cancer; Chemotherapy; Oncology; Cancer; Surgery; Immunotherapy","score_opus":0.08983224065365615,"score_gpt":0.5073074975597608,"score_spread":0.41747525690610465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406158653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93530065,0.012944723,0.000091369075,0.02976457,0.0065306267,0.0003114338,0.000002456043,0.000012587106,0.01504161],"genre_scores_gemma":[0.96959925,0.015626436,0.0008565042,0.007866669,0.0012009903,0.000012659637,0.0000013340152,0.000020861293,0.0048152967],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99687564,0.00025152942,0.0021060347,0.00019968908,0.00027413518,0.00029298026],"domain_scores_gemma":[0.99719197,0.001344807,0.0008313184,0.00021831928,0.00026784505,0.00014572684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027045952,0.00013658569,0.0013799676,0.0002517204,0.00003643794,0.000009852499,0.0002104281,0.0004219743,0.0006275794],"category_scores_gemma":[0.0009979511,0.000102483114,0.00049677555,0.000420282,0.00017740807,0.00009372609,0.00003490554,0.0010599635,0.0000031504796],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3318319,0.0013375807,0.04893854,0.000096974625,0.0014446316,0.0004879193,0.00023331644,0.000057872094,0.0013168807,0.00008928798,0.0508724,0.5632927],"study_design_scores_gemma":[0.17982075,0.011580329,0.26443213,0.00093976856,0.00039815728,0.00007969334,0.00037871563,0.001228879,0.0005513282,0.00016465648,0.5402332,0.00019239368],"about_ca_topic_score_codex":0.0004064173,"about_ca_topic_score_gemma":0.00095848885,"teacher_disagreement_score":0.5631003,"about_ca_system_score_codex":0.001149051,"about_ca_system_score_gemma":0.005615494,"threshold_uncertainty_score":0.99616456},"labels":[],"label_agreement":null},{"id":"W4406175284","doi":"10.1016/j.jtho.2024.10.010","title":"Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy","year":2025,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Chemoimmunotherapy; Medicine; Adjuvant; Complete response; Immunotherapy; Neoadjuvant therapy; Oncology; Internal medicine; Cancer; Chemotherapy","score_opus":0.02937301994842129,"score_gpt":0.3933514504140159,"score_spread":0.36397843046559464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406175284","genre_codex":"empirical","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57597005,0.0032725928,0.00016719502,0.020804487,0.39648005,0.002480057,0.0005240384,0.000061309496,0.00024018262],"genre_scores_gemma":[0.2764957,0.012091715,0.031007366,0.06891323,0.5891745,0.0006957531,0.0015440044,0.0014216009,0.018656118],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99324757,0.0011998364,0.0022704203,0.00066067284,0.0018439543,0.00077754736],"domain_scores_gemma":[0.9933522,0.002212338,0.0019969,0.00091066695,0.0012861075,0.00024181475],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0045740013,0.00080745784,0.0032792115,0.0016904973,0.000113127324,0.00006374516,0.0008490428,0.0017107045,0.00025392382],"category_scores_gemma":[0.00091931265,0.00057532714,0.00067970285,0.00095381466,0.00027511516,0.0001450254,0.000109056324,0.0029345325,0.000008812668],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5820737,0.0015667581,0.0011639904,0.0001621411,0.00097526226,0.0013176508,0.0010534724,0.00001162951,0.013854468,6.5723793e-7,0.30032703,0.09749327],"study_design_scores_gemma":[0.022906085,0.027652021,0.040080976,0.0021032314,0.00033916638,0.00011810498,0.00017874864,0.0000027346891,0.0005527679,0.0000104026385,0.9054993,0.00055647315],"about_ca_topic_score_codex":0.00009590001,"about_ca_topic_score_gemma":0.000092361304,"teacher_disagreement_score":0.6051723,"about_ca_system_score_codex":0.002913457,"about_ca_system_score_gemma":0.0046731806,"threshold_uncertainty_score":0.9996698},"labels":[],"label_agreement":null},{"id":"W4406211711","doi":"10.1016/j.ejcped.2025.100215","title":"The safety and efficacy of immune checkpoint blockade in children, adolescents, and young adults: A systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"EJC Paediatric Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Meta-analysis; Blockade; Medicine; Psychology; Immune checkpoint; Developmental psychology; Internal medicine","score_opus":0.01666592770795787,"score_gpt":0.32008331152794756,"score_spread":0.30341738381998967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406211711","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000039098315,0.9938381,0.0000031741101,0.0004439997,0.00006592439,0.0054560667,0.000088194596,0.000012951934,0.00005253722],"genre_scores_gemma":[0.0002230374,0.99885416,0.000039419545,0.0001546968,0.000044926655,0.00029623864,0.000057175712,0.000021357348,0.00030901612],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9952694,0.0010431564,0.0026111337,0.0005618804,0.00021554194,0.00029884104],"domain_scores_gemma":[0.99672484,0.0009961028,0.001455024,0.00065312686,0.000077926656,0.00009300205],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002496805,0.00048978406,0.009565514,0.00055337173,0.000090281785,0.000016231386,0.00020910866,0.00038417248,0.00002458204],"category_scores_gemma":[0.0007059202,0.0002669167,0.0016976363,0.0017217003,0.0002409163,0.000024954526,0.00018414335,0.00051468133,0.0000010658591],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030056038,0.00015531521,0.0003104441,0.8434621,0.08390295,0.000010647978,0.00007873355,2.497214e-8,1.3823995e-7,0.0000041816234,0.00003353847,0.07174137],"study_design_scores_gemma":[0.002502888,0.00026608972,0.0028832057,0.052086294,0.92591107,0.00031173514,0.0000332524,0.0000014974648,1.4827357e-7,0.0000014584972,0.015746975,0.0002554088],"about_ca_topic_score_codex":0.00020553137,"about_ca_topic_score_gemma":0.00010104456,"teacher_disagreement_score":0.8420081,"about_ca_system_score_codex":0.00019689309,"about_ca_system_score_gemma":0.00041810542,"threshold_uncertainty_score":0.9999783},"labels":[],"label_agreement":null},{"id":"W4406221897","doi":"10.1038/s43018-024-00896-w","title":"Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma","year":2025,"lang":"en","type":"article","venue":"Nature Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Dana-Farber/Harvard Cancer Center; Cancer Prevention and Research Institute of Texas; Deutsche Forschungsgemeinschaft; U.S. Department of Health and Human Services","keywords":"Cytotoxic T cell; Immunotherapy; Immune checkpoint; Cancer research; Clear cell renal cell carcinoma; Immune system; Biology; T cell; Immunology; Transcriptome; Renal cell carcinoma; Medicine; Internal medicine; Genetics","score_opus":0.008044944259330734,"score_gpt":0.29560474154355687,"score_spread":0.28755979728422615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406221897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985526,0.0117513975,0.00000981201,0.0013700842,0.00040630065,0.0004025571,0.00004833981,0.000011390679,0.0004740869],"genre_scores_gemma":[0.9968679,0.00016278402,0.0001471977,0.0008766439,0.000071515526,0.000071997165,0.000013262033,0.0000132311425,0.0017754529],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989187,0.000057454345,0.00041571126,0.00023855208,0.00017497654,0.00019458446],"domain_scores_gemma":[0.99946105,0.00004607994,0.00009690177,0.00024979326,0.00010737523,0.000038802496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039683675,0.00013551627,0.00028838185,0.0003489631,0.000031796797,0.000006124945,0.00006722145,0.0002517609,0.00029521403],"category_scores_gemma":[0.000043800588,0.00012342511,0.0001364865,0.0005084184,0.00005690576,0.000040438816,0.00003968448,0.00035756582,0.0000049808145],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027763797,0.00008668047,0.015421602,0.000106871994,0.000020981768,0.00002618615,0.0002488404,0.00000874419,0.9496044,0.0000040423306,0.0005504133,0.0061574406],"study_design_scores_gemma":[0.002484426,0.00013292457,0.5027522,0.00037267772,0.00001752051,0.000007246272,0.00004126819,0.000008380059,0.490288,0.000014718541,0.0038106719,0.00006998705],"about_ca_topic_score_codex":0.0003757594,"about_ca_topic_score_gemma":0.00019739245,"teacher_disagreement_score":0.4873306,"about_ca_system_score_codex":0.00062131666,"about_ca_system_score_gemma":0.0005570144,"threshold_uncertainty_score":0.503313},"labels":[],"label_agreement":null},{"id":"W4406246448","doi":"10.1016/j.ypdi.2013.01.036","title":"10.1016/j.ypdi.2013.01.036","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Antibody; Cancer; Oncology; Internal medicine; Cancer research; Immunology","score_opus":0.007582914566176218,"score_gpt":0.20463577827652318,"score_spread":0.19705286371034697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406246448","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027418241,0.0004847821,3.4152438e-7,0.0020234908,0.0000029331277,0.00025681386,0.000010151258,0.0001171591,0.99436253],"genre_scores_gemma":[0.00031430039,0.0000045474167,0.00008767446,0.000393101,0.0002037777,0.000016703994,0.000024449893,0.000025500674,0.9989299],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99922824,0.000017897983,0.00016629702,0.00018764022,0.00017007408,0.00022984082],"domain_scores_gemma":[0.9995025,0.000020616742,0.00002067658,0.00029888295,0.000026672933,0.00013064308],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00011002539,0.00012195217,0.00018429349,0.000062766,0.00004885,0.000016949305,0.000092782204,0.00006585835,0.9986487],"category_scores_gemma":[0.000009524754,0.000103914186,0.00009527536,0.00019703912,0.00004172249,0.00004511753,0.000012657241,0.00008818817,0.9861282],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013315148,0.000048182286,2.6602518e-7,0.000006869076,0.00004318496,0.00000788543,0.000016208367,0.0000010562019,0.0007824265,7.637624e-8,0.42720333,0.570559],"study_design_scores_gemma":[0.0011907653,0.00042805477,0.0002729398,0.000050059178,0.000035628676,0.000038930782,0.0000016667615,0.000029266006,0.00047160938,0.0000017044972,0.9973455,0.00013386823],"about_ca_topic_score_codex":0.00011756111,"about_ca_topic_score_gemma":6.3980235e-7,"teacher_disagreement_score":0.57042515,"about_ca_system_score_codex":0.000056581674,"about_ca_system_score_gemma":0.000040203395,"threshold_uncertainty_score":0.42374977},"labels":[],"label_agreement":null},{"id":"W4406268174","doi":"10.1016/j.esmoop.2024.104107","title":"Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer study","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre","funders":"Ono Pharmaceutical; National Cancer Institute; Celgene; Agilent Technologies; Bristol-Myers Squibb","keywords":"Gastroesophageal Junction; Medicine; Cancer; Internal medicine; Nivolumab; Gastroenterology; Oncology; Adenocarcinoma; Immunotherapy","score_opus":0.009857846797699509,"score_gpt":0.31018671636702405,"score_spread":0.30032886956932453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406268174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99504405,0.0007108507,0.00010330611,0.0010107824,0.0002685176,0.0025712205,0.000009520501,0.000020566824,0.00026118846],"genre_scores_gemma":[0.99777126,0.00038035322,0.000060416238,0.00039655517,0.00002821607,0.0005297867,0.000028536855,0.000013755693,0.0007911176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989931,0.000089133035,0.0002267848,0.00028571548,0.00021850306,0.00018676388],"domain_scores_gemma":[0.99949706,0.000028809853,0.00013372605,0.00021078614,0.00009860656,0.000031009436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023234192,0.0001556934,0.00024320812,0.00022596946,0.0002843255,0.00006349149,0.00012997753,0.000038316062,0.00014778794],"category_scores_gemma":[0.00001000069,0.00010266408,0.000024526591,0.0008810322,0.000061774175,0.00031165552,0.00006860543,0.0001906831,5.4256026e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010297381,0.0015810659,0.5897164,0.000012171747,0.00018081887,0.0000021811727,0.00046410205,0.000018844687,0.000087724446,0.0000047648928,0.00043658138,0.39719796],"study_design_scores_gemma":[0.034937598,0.0042538624,0.95761245,0.00015594992,0.00011496535,0.0000013351497,0.0008725893,0.00008803625,0.00010176143,0.000013047058,0.001766636,0.00008176709],"about_ca_topic_score_codex":0.0067678667,"about_ca_topic_score_gemma":0.002846011,"teacher_disagreement_score":0.3971162,"about_ca_system_score_codex":0.00036758857,"about_ca_system_score_gemma":0.0001712745,"threshold_uncertainty_score":0.99984616},"labels":[],"label_agreement":null},{"id":"W4406431740","doi":"10.1016/j.ysur.2016.03.158","title":"10.1016/j.ysur.2016.03.158","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Ipilimumab; Metastatic melanoma; Oncology; Melanoma; Phase (matter); Internal medicine; Term (time); Phases of clinical research; Clinical trial; Cancer research; Cancer; Immunotherapy","score_opus":0.007305788158671702,"score_gpt":0.20380239780777903,"score_spread":0.19649660964910734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406431740","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026696182,0.00042946485,2.9406337e-7,0.0011720025,0.000002865704,0.0002438153,0.000010747752,0.000108133216,0.99536306],"genre_scores_gemma":[0.00030859569,0.000003243045,0.00007730957,0.00038157383,0.00020394447,0.000010636084,0.000018888508,0.00002505971,0.99897075],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99921954,0.000018852315,0.0001689572,0.00018971247,0.00017143725,0.00023147772],"domain_scores_gemma":[0.9994898,0.000025280819,0.000021173757,0.00029904465,0.00003303573,0.00013170094],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00012603049,0.00012226528,0.00018783806,0.00006197501,0.000043652442,0.000016667245,0.00009171545,0.00006528112,0.99864745],"category_scores_gemma":[0.000013328098,0.00010293536,0.00009614566,0.00019836442,0.00004215075,0.000043669515,0.00001221694,0.00008564818,0.9922737],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014781469,0.00005002215,3.1826443e-7,0.0000071278237,0.000047492635,0.000009166292,0.000016125807,9.288061e-7,0.0011008793,8.480204e-8,0.4004488,0.5968409],"study_design_scores_gemma":[0.0012027966,0.0004459997,0.00028746197,0.000062650666,0.000035550198,0.000035412115,0.0000014196945,0.0000208623,0.000734965,0.0000015275132,0.9970364,0.00013495122],"about_ca_topic_score_codex":0.00006485575,"about_ca_topic_score_gemma":2.5703764e-7,"teacher_disagreement_score":0.596706,"about_ca_system_score_codex":0.000059729515,"about_ca_system_score_gemma":0.000065374414,"threshold_uncertainty_score":0.41975823},"labels":[],"label_agreement":null},{"id":"W4406471500","doi":"10.1002/cac2.12661","title":"Bioequivalence of alternative pembrolizumab dosing regimens: current practice and future perspectives","year":2025,"lang":"en","type":"article","venue":"Cancer Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bioequivalence; Dosing; Pembrolizumab; Medicine; Medical physics; Psychology; Pharmacology; Internal medicine; Pharmacokinetics; Cancer; Immunotherapy","score_opus":0.03932492012326258,"score_gpt":0.4011608327392284,"score_spread":0.3618359126159658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406471500","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.035119332,0.86458033,0.00035926537,0.07968725,0.00043397053,0.00060817105,0.00005077178,0.000050855084,0.019110076],"genre_scores_gemma":[0.6054515,0.3918733,0.0018873132,0.00040034892,0.00009332086,0.00007604025,0.0000075377493,0.0000075710936,0.00020303823],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993739,0.00008820642,0.00018853683,0.00015493075,0.00009937794,0.000095022806],"domain_scores_gemma":[0.9985255,0.00017797212,0.00014558915,0.0008131248,0.00030761518,0.000030210615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012946958,0.00008836461,0.00016354775,0.00008577974,0.0001453744,0.000014107958,0.00023119086,0.00003520553,0.000034158827],"category_scores_gemma":[0.000065627806,0.000079596255,0.0000541363,0.00033717032,0.00042178415,0.00012443327,0.0001283166,0.00020236317,6.2709915e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004446347,0.0013200148,0.0047049453,0.00069740735,0.0017014795,0.000002480319,0.029928235,0.0000043242308,0.0251926,0.10181245,0.00856057,0.82162917],"study_design_scores_gemma":[0.0037413568,0.00015434572,0.01721484,0.0013653818,0.00050742476,0.000023815064,0.019394297,0.00034408056,0.0029469486,0.00051980803,0.9536049,0.00018281299],"about_ca_topic_score_codex":0.0003662595,"about_ca_topic_score_gemma":0.000035929384,"teacher_disagreement_score":0.94504434,"about_ca_system_score_codex":0.00018456626,"about_ca_system_score_gemma":0.00026598808,"threshold_uncertainty_score":0.3245841},"labels":[],"label_agreement":null},{"id":"W4406520144","doi":"10.1016/s0765-2046(97)87022-0","title":"10.1016/s0765-2046(97)87022-0","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medical emergency; Medicine; Immunology","score_opus":0.00916746643308356,"score_gpt":0.20960663466578255,"score_spread":0.200439168232699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406520144","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018787654,0.00048256607,3.960415e-7,0.0012227601,0.000002783447,0.00027002834,0.000010842984,0.0001015474,0.99603033],"genre_scores_gemma":[0.00023125677,0.000002891321,0.000091738424,0.0004249916,0.0002273229,0.000020017122,0.00002025496,0.000026591504,0.99895495],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991627,0.000019533882,0.0001791005,0.00020435205,0.00018876094,0.00024558805],"domain_scores_gemma":[0.99946517,0.000023436454,0.000022085254,0.00031711865,0.0000326637,0.00013952909],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00012069039,0.00013173728,0.00019719034,0.00006876087,0.000054845772,0.000018388291,0.00009980614,0.000068886155,0.99921674],"category_scores_gemma":[0.000011737592,0.000113979266,0.00010483455,0.00022703777,0.000042784504,0.000045488203,0.000013468211,0.00009788812,0.9939276],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017058789,0.000060985567,4.79587e-7,0.000009365683,0.00005524685,0.000012159959,0.000020351583,0.000001280391,0.0008093636,1.1558086e-7,0.28657165,0.71075314],"study_design_scores_gemma":[0.0013596261,0.000462684,0.00020164195,0.00005337692,0.000040209008,0.00004239623,0.0000018504874,0.00002446779,0.0007475673,0.0000020323412,0.9969194,0.00014478149],"about_ca_topic_score_codex":0.000059623668,"about_ca_topic_score_gemma":3.4617673e-7,"teacher_disagreement_score":0.71060836,"about_ca_system_score_codex":0.00006951369,"about_ca_system_score_gemma":0.000054878084,"threshold_uncertainty_score":0.46479395},"labels":[],"label_agreement":null},{"id":"W4406520963","doi":"10.1016/s0765-2046(97)80162-1","title":"10.1016/s0765-2046(97)80162-1","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Blockade; CTLA-4; Signalling; Immunology; Medicine; Biology; Cell biology; Receptor; T cell; Immune system; Genetics","score_opus":0.00910331262587049,"score_gpt":0.20931907687155185,"score_spread":0.20021576424568135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406520963","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016725656,0.0004703836,4.345084e-7,0.0012612861,0.0000027610502,0.00027218083,0.0000109595785,0.0001028647,0.9962066],"genre_scores_gemma":[0.00022365387,0.000002944976,0.0000970801,0.00042297097,0.00022674522,0.00001925647,0.000019315794,0.00002687949,0.99896115],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991548,0.000019518817,0.0001816376,0.00020686985,0.00018804814,0.00024909162],"domain_scores_gemma":[0.99945796,0.00002408672,0.000022738734,0.0003194613,0.00003364633,0.00014213551],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00012076898,0.00013380357,0.00019979714,0.000070243535,0.000054262975,0.000018667262,0.00010098335,0.00007090375,0.99921477],"category_scores_gemma":[0.000012122841,0.00011455606,0.00010615975,0.0002236988,0.000043807093,0.000046482186,0.0000135994205,0.00009664376,0.9946347],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017405391,0.000060309605,3.8804743e-7,0.0000094625775,0.000055614863,0.000012247214,0.000020119815,0.0000010978682,0.0008416978,1.1431467e-7,0.29219595,0.70506245],"study_design_scores_gemma":[0.0014178014,0.00046369297,0.00018890004,0.000059094997,0.000040571907,0.000042278036,0.00000176141,0.000022435912,0.00076717534,0.0000021515932,0.99684745,0.0001466672],"about_ca_topic_score_codex":0.000059353697,"about_ca_topic_score_gemma":3.4633385e-7,"teacher_disagreement_score":0.7049158,"about_ca_system_score_codex":0.000071053975,"about_ca_system_score_gemma":0.000057737023,"threshold_uncertainty_score":0.46714607},"labels":[],"label_agreement":null},{"id":"W4406525793","doi":"10.3390/curroncol32010046","title":"Treatment Options for Advanced Non-Small Cell Lung Cancer After Failure of Previous Immune Checkpoint Inhibitors and Chemotherapy: Meta-Analysis of Five Randomized Controlled Trials","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chemotherapy; Oncology; Lung cancer; Meta-analysis; Randomized controlled trial; Internal medicine; Immune system; Cancer; Nivolumab; Immunotherapy; Bioinformatics; Immunology","score_opus":0.08355211196076115,"score_gpt":0.4365381157456695,"score_spread":0.3529860037849083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406525793","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027884697,0.97530127,0.0005085426,0.0003160627,0.00063043623,0.021886542,0.0010187386,0.00001331563,0.000046258],"genre_scores_gemma":[0.00015104508,0.96976537,0.0009528727,0.00002568059,0.00011605976,0.027576858,0.00036337614,0.000037852897,0.0010108685],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.993072,0.0013923893,0.0044538,0.0006086989,0.00017988254,0.0002932484],"domain_scores_gemma":[0.9893956,0.00529978,0.0043205866,0.0005177343,0.0003813026,0.00008498627],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0028103965,0.0007446789,0.0373718,0.0009497525,0.000040770083,0.00001013406,0.00014156263,0.00046791986,0.00052719895],"category_scores_gemma":[0.0004413845,0.00040298444,0.022378897,0.00064159237,0.00024717438,0.000025513391,0.00004078196,0.00021091162,1.7941247e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1630043,0.0010121098,0.0000040003524,0.025141057,0.52164984,0.0000021224707,0.00048257486,0.00002516699,0.00005289108,0.000002892643,0.000107033324,0.28851599],"study_design_scores_gemma":[0.23963138,0.0004892318,0.0000010698952,0.0021115306,0.6235911,0.0000018152246,0.00003736404,0.00012536831,0.00009726562,0.0000017986503,0.1337196,0.00019245935],"about_ca_topic_score_codex":0.00009695223,"about_ca_topic_score_gemma":0.00008241969,"teacher_disagreement_score":0.28832352,"about_ca_system_score_codex":0.00057220354,"about_ca_system_score_gemma":0.0016213403,"threshold_uncertainty_score":0.9998422},"labels":[],"label_agreement":null},{"id":"W4406546556","doi":"10.1016/s1541-9800(10)70419-1","title":"10.1016/s1541-9800(10)70419-1","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Etanercept; Cancer; Medicine; Internal medicine; Tumor necrosis factor alpha","score_opus":0.007399447189526858,"score_gpt":0.2032648321355352,"score_spread":0.19586538494600833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406546556","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024693005,0.00040746774,3.3813683e-7,0.0013053351,0.0000028841575,0.00026639146,0.000013011507,0.00012526351,0.99541],"genre_scores_gemma":[0.00029984585,0.0000025655916,0.000078889396,0.00036050513,0.00022449227,0.000020032834,0.000028058696,0.000028957902,0.9989567],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991114,0.000021306912,0.00019229625,0.0002169393,0.00019879687,0.0002592227],"domain_scores_gemma":[0.9994281,0.000025754187,0.000024619712,0.00033835732,0.00003910545,0.00014406655],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00013198378,0.00014133636,0.00021164931,0.00007272729,0.00005732593,0.000019953943,0.000107746295,0.00007555992,0.99942446],"category_scores_gemma":[0.000015805617,0.00012200177,0.00011255727,0.0002366281,0.00004776455,0.000047975893,0.000014986381,0.00009377649,0.99176645],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001884907,0.00005523185,1.9644907e-7,0.000008443517,0.000051122806,0.00001109825,0.00001713753,0.0000011101603,0.00091384107,8.362245e-8,0.4895707,0.5074861],"study_design_scores_gemma":[0.0014393384,0.00050922733,0.00022790353,0.00005714715,0.000043590422,0.000041066894,0.0000017735953,0.000027775977,0.0010004215,0.0000016926484,0.99649554,0.00015449084],"about_ca_topic_score_codex":0.00006114283,"about_ca_topic_score_gemma":3.6864301e-7,"teacher_disagreement_score":0.5073316,"about_ca_system_score_codex":0.00007272737,"about_ca_system_score_gemma":0.000060383583,"threshold_uncertainty_score":0.4975088},"labels":[],"label_agreement":null},{"id":"W4406547111","doi":"10.1016/s1541-9800(06)71260-1","title":"10.1016/s1541-9800(06)71260-1","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Etanercept; Medicine; Pharmacology; Internal medicine; Tumor necrosis factor alpha","score_opus":0.007106642923194629,"score_gpt":0.20269304344624012,"score_spread":0.1955864005230455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406547111","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00315303,0.00039613358,4.4248165e-7,0.0013160617,0.0000020473026,0.00026951905,0.0000123200025,0.00012374611,0.9947267],"genre_scores_gemma":[0.0003976482,0.0000028795673,0.000085163934,0.00043826253,0.00021297704,0.000018929633,0.000029559087,0.000027441069,0.99878716],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991512,0.000019870926,0.00018138513,0.00020672633,0.00018994494,0.00025088963],"domain_scores_gemma":[0.99945575,0.00002339497,0.000021781574,0.00032057034,0.000033522247,0.00014498357],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00012581972,0.00013331989,0.00020067899,0.00006994822,0.000054364817,0.0000188519,0.000101693004,0.00007104015,0.99872357],"category_scores_gemma":[0.000013574033,0.0001149451,0.000106760555,0.00022685174,0.00004468028,0.00004597771,0.000013997061,0.000097313365,0.990076],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011896695,0.00005541546,4.8349807e-7,0.000008638606,0.000050952727,0.000011040099,0.000019753152,0.0000012859781,0.0010251622,1.1111536e-7,0.4833853,0.5142522],"study_design_scores_gemma":[0.0013047548,0.0003987619,0.0003291318,0.00005652617,0.000040619376,0.00004697201,0.0000017742116,0.000027694578,0.00074683246,0.0000018803361,0.9968987,0.00014634129],"about_ca_topic_score_codex":0.0000526558,"about_ca_topic_score_gemma":2.8289622e-7,"teacher_disagreement_score":0.51410586,"about_ca_system_score_codex":0.00007023012,"about_ca_system_score_gemma":0.000057663707,"threshold_uncertainty_score":0.4687325},"labels":[],"label_agreement":null},{"id":"W4406547907","doi":"10.1016/s1541-9800(05)70225-8","title":"10.1016/s1541-9800(05)70225-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Belimumab; Rituximab; Medicine; Immunology; Antibody; B cell","score_opus":0.007188887444192017,"score_gpt":0.20328530229057098,"score_spread":0.19609641484637896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406547907","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026847457,0.00036480319,3.9463072e-7,0.0014640332,0.0000035916623,0.00026837707,0.000012140929,0.00012297387,0.9950789],"genre_scores_gemma":[0.0003374764,0.0000026462278,0.00008791792,0.0004821525,0.00022417773,0.000019574787,0.000023691095,0.000027362927,0.998795],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991544,0.000020042226,0.00017941785,0.00020575928,0.00019089482,0.00024948677],"domain_scores_gemma":[0.99946094,0.000022855736,0.000022134363,0.00031994513,0.000032704767,0.00014141141],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00012542024,0.00013241633,0.00019761224,0.000070174734,0.00005567939,0.000018261955,0.00010161867,0.000068959875,0.9989256],"category_scores_gemma":[0.000012737051,0.00011425183,0.000106676955,0.00022805925,0.000044080014,0.000046097462,0.000013851256,0.00009772699,0.9852837],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013738849,0.00005131817,2.5739757e-7,0.0000064989486,0.000045900513,0.000013084824,0.000018467641,0.0000010338341,0.00093276304,1.03089846e-7,0.41852376,0.57903296],"study_design_scores_gemma":[0.0013311062,0.00051115395,0.00023172458,0.000058250094,0.000039893508,0.000060352857,0.0000020255798,0.00002544045,0.0007797256,0.0000015542141,0.99681354,0.00014521058],"about_ca_topic_score_codex":0.00006451812,"about_ca_topic_score_gemma":3.891611e-7,"teacher_disagreement_score":0.57888776,"about_ca_system_score_codex":0.00007310934,"about_ca_system_score_gemma":0.00005654666,"threshold_uncertainty_score":0.46590546},"labels":[],"label_agreement":null},{"id":"W4406551477","doi":"10.1016/s1541-9800(12)70375-7","title":"10.1016/s1541-9800(12)70375-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Adalimumab; Term (time); Medicine; Internal medicine; Physics; Tumor necrosis factor alpha","score_opus":0.00756653204183358,"score_gpt":0.20044340959266652,"score_spread":0.19287687755083294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406551477","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022384063,0.00033599982,3.9258455e-7,0.001239221,0.0000029115165,0.00026909309,0.000011335747,0.00012202078,0.99578065],"genre_scores_gemma":[0.0003338858,0.0000027573526,0.000091199574,0.00043186243,0.00021824225,0.000018835235,0.00002244119,0.000027394863,0.9988534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999155,0.000019678537,0.00018130215,0.00020613155,0.00018912532,0.0002488044],"domain_scores_gemma":[0.99946356,0.000023393439,0.000022230037,0.00032039048,0.000028815111,0.00014161687],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00012381152,0.00013312243,0.00020000017,0.00006885459,0.000054235687,0.000018446099,0.000100594974,0.000069856425,0.99886996],"category_scores_gemma":[0.000013014859,0.00011470638,0.00010422763,0.00018147742,0.00004462222,0.000044823744,0.000013782658,0.00009794721,0.985086],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015906636,0.000054042295,4.2419356e-7,0.000008269029,0.000050504037,0.00001149208,0.000019061134,0.0000011404352,0.0009942538,9.5481965e-8,0.40418795,0.59308213],"study_design_scores_gemma":[0.0013283747,0.0004764685,0.0003605443,0.000055942717,0.000040809893,0.000047406287,0.0000016534136,0.000025329982,0.00075419224,0.0000019001333,0.99676144,0.0001459394],"about_ca_topic_score_codex":0.0000645436,"about_ca_topic_score_gemma":5.223395e-7,"teacher_disagreement_score":0.59293616,"about_ca_system_score_codex":0.000069466136,"about_ca_system_score_gemma":0.00005532821,"threshold_uncertainty_score":0.46775904},"labels":[],"label_agreement":null},{"id":"W4406579675","doi":"10.1016/s1541-9800(08)70398-3","title":"10.1016/s1541-9800(08)70398-3","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Golimumab; Medicine; Internal medicine; Adalimumab","score_opus":0.007113218524848933,"score_gpt":0.20264706158580528,"score_spread":0.19553384306095634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579675","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025349152,0.00041860118,4.1667866e-7,0.001298179,0.000002887804,0.00027181895,0.000011365121,0.00012302632,0.9953388],"genre_scores_gemma":[0.0003194091,0.0000029223738,0.00009138621,0.00044678937,0.00021837669,0.000019309651,0.000022277458,0.000027430986,0.9988521],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991525,0.000019982053,0.0001815005,0.00020711687,0.00018953996,0.00024935688],"domain_scores_gemma":[0.99945724,0.000023568518,0.000022253891,0.0003216369,0.00003340826,0.00014187065],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00012457775,0.0001334419,0.00020088494,0.00006982725,0.000054329605,0.000018626926,0.00010133532,0.000070767834,0.99903196],"category_scores_gemma":[0.000012959375,0.00011505598,0.00010697616,0.00022574131,0.000045361707,0.000046449837,0.000013853134,0.00009815731,0.9902052],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014544723,0.00005366858,3.358586e-7,0.00000823705,0.000049207432,0.000011396155,0.000018528415,0.0000011366226,0.0010030792,9.593691e-8,0.43060398,0.5667959],"study_design_scores_gemma":[0.0013586914,0.00045100306,0.00028731104,0.000057152647,0.00004067739,0.000047672645,0.0000017248092,0.000025353109,0.00084700884,0.00000193653,0.9967351,0.00014637728],"about_ca_topic_score_codex":0.000053802756,"about_ca_topic_score_gemma":3.0627675e-7,"teacher_disagreement_score":0.5666495,"about_ca_system_score_codex":0.00007059425,"about_ca_system_score_gemma":0.000058022797,"threshold_uncertainty_score":0.46918464},"labels":[],"label_agreement":null},{"id":"W4406737410","doi":"10.1093/ecco-jcc/jjae190.0981","title":"P0807 Impact of Risankizumab on Patient-reported Outcomes and Biomarkers Over Time: Post-Hoc Analysis of Phase 3 INSPIRE and COMMAND Studies","year":2025,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Post-hoc analysis; Post hoc; Phase (matter); Intensive care medicine; Internal medicine","score_opus":0.014937492608910734,"score_gpt":0.348940909953184,"score_spread":0.33400341734427325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406737410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98742247,0.011721909,0.0000020125956,0.0003856014,0.000055566223,0.00015076673,0.0000913579,0.0000027436556,0.00016757453],"genre_scores_gemma":[0.99580926,0.0038085487,0.000032837117,0.00023011155,0.00000962875,0.000001308634,0.000004599449,0.0000056469976,0.00009805337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988224,0.00004600713,0.0006893116,0.00011432426,0.00021120615,0.000116778196],"domain_scores_gemma":[0.9987194,0.00017936024,0.0005902629,0.00013146755,0.00029871275,0.000080821694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024250912,0.00014225405,0.00087178656,0.0005554735,0.00005671571,0.0000173948,0.000033323162,0.000059972488,0.00006188361],"category_scores_gemma":[0.00008239762,0.00009306341,0.00029039397,0.00038106943,0.00027252882,0.00007905719,0.000028353179,0.00008703138,2.9995725e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14277579,0.0011142506,0.47715923,0.00046278755,0.07916377,0.00031745608,0.0028792082,0.000003173006,0.00673896,0.00003809177,0.0040910994,0.28525618],"study_design_scores_gemma":[0.009519214,0.0047401367,0.9807239,0.0003768277,0.0028100898,0.00006647766,0.00063509843,0.000046347846,0.0005567451,0.000035704223,0.00041082402,0.00007862099],"about_ca_topic_score_codex":0.00028619426,"about_ca_topic_score_gemma":0.00003574352,"teacher_disagreement_score":0.50356466,"about_ca_system_score_codex":0.00006456772,"about_ca_system_score_gemma":0.000121135134,"threshold_uncertainty_score":0.37950158},"labels":[],"label_agreement":null},{"id":"W4406756255","doi":"10.1016/j.modpat.2025.100718","title":"Digital Profiling of Immune Biomarkers in Breast Cancer: Relation to Anthracycline Benefit","year":2025,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; BC Cancer Agency; Queen's University; University of British Columbia","funders":"British Columbia Knowledge Development Fund; Sichuan Province Science and Technology Support Program; BC Cancer Foundation; University of British Columbia; Canada Foundation for Innovation; National Natural Science Foundation of China; Cancer Research Society; Eli Lilly Canada; Canadian Cancer Society; AstraZeneca","keywords":"Profiling (computer programming); Anthracycline; Breast cancer; Medicine; Pathology; Immune system; Oncology; Internal medicine; Cancer; Immunology; Computer science","score_opus":0.010347739563760406,"score_gpt":0.28911128029166605,"score_spread":0.27876354072790566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406756255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98944694,0.0018881472,0.0018092678,0.0045720637,0.00022445113,0.0003959302,0.00009144251,0.000028993978,0.0015427701],"genre_scores_gemma":[0.998452,0.00020126878,0.0004976729,0.0003660233,0.00002268824,0.00004090929,0.000044269662,0.000012566038,0.00036260477],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989925,0.000018135172,0.00044530895,0.0002599396,0.00009031457,0.0001937708],"domain_scores_gemma":[0.9995326,0.000034820612,0.00008702948,0.000246612,0.00006757986,0.000031393498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018796351,0.00011298814,0.00031269487,0.00031683868,0.000025454156,0.0000064841574,0.000073935546,0.00012210556,0.000033595723],"category_scores_gemma":[0.00002868473,0.00010459828,0.00008541324,0.00041158506,0.00008164759,0.000070696515,0.000044516386,0.00010603716,0.0000026945916],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041309213,0.00017897926,0.25614598,0.00008876951,0.00011776271,0.00003868593,0.0002965514,0.0001328681,0.49224705,0.00008075559,0.000034979195,0.24650669],"study_design_scores_gemma":[0.0031841462,0.00014716465,0.9706804,0.00041468165,0.000043275064,0.00008498831,0.000116780975,0.001993417,0.022527471,0.00049313327,0.0001874415,0.00012705736],"about_ca_topic_score_codex":0.00016720901,"about_ca_topic_score_gemma":0.000055747958,"teacher_disagreement_score":0.71453446,"about_ca_system_score_codex":0.00012502444,"about_ca_system_score_gemma":0.00009922109,"threshold_uncertainty_score":0.4265394},"labels":[],"label_agreement":null},{"id":"W4406818361","doi":"10.1016/s0140-6736(24)02848-4","title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":179,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Open label; Colorectal cancer; Microsatellite instability; Oncology; Internal medicine; Metastatic melanoma; Phases of clinical research; Cancer; Randomized controlled trial; Immunotherapy; Clinical trial; Microsatellite; Gene; Biology","score_opus":0.06751625483083432,"score_gpt":0.38417249245568763,"score_spread":0.3166562376248533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406818361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811325,0.0055391146,0.000028099292,0.0039610993,0.0018158585,0.004765747,0.00021347601,0.00008561218,0.0024585081],"genre_scores_gemma":[0.9928327,0.0018513465,0.00034787488,0.0016003543,0.00042451455,0.0010261136,0.0001219243,0.000042783686,0.0017523627],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972744,0.00042842186,0.00078648556,0.0005514989,0.00030322667,0.0006559804],"domain_scores_gemma":[0.99833214,0.0004376382,0.0002174093,0.00083015114,0.0000978045,0.00008482852],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015730134,0.00035386212,0.001441769,0.00015936773,0.00021172185,0.00016690086,0.0007730353,0.00012136694,0.00047927804],"category_scores_gemma":[0.00021796352,0.0002536544,0.00015776254,0.00088911725,0.00036985008,0.00017637806,0.00020752072,0.0004965821,0.000023209694],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9463237,0.0010015855,0.000107069245,0.00017575729,0.0007416015,0.000037415964,0.0007335337,0.000008252884,0.020188741,0.000121473415,0.0035210047,0.02703985],"study_design_scores_gemma":[0.96502644,0.0017964486,0.00063568464,0.00047740372,0.00043711264,0.0000101933,0.00027319806,0.0004357963,0.0076839784,0.00023541918,0.022699038,0.00028929874],"about_ca_topic_score_codex":0.0048111393,"about_ca_topic_score_gemma":0.0035663592,"teacher_disagreement_score":0.026750552,"about_ca_system_score_codex":0.0008951838,"about_ca_system_score_gemma":0.0011015185,"threshold_uncertainty_score":0.9999916},"labels":[],"label_agreement":null},{"id":"W4406869106","doi":"10.1200/jco.2025.43.4_suppl.602","title":"Pembrolizumab and stereotactic radiotherapy combined in subjects with advanced HCC: A phase II study (PEMRAD).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Stereotactic radiotherapy; Oncology; Hepatocellular carcinoma; Radiosurgery; Radiation therapy; Internal medicine; Nuclear medicine; Radiology; Cancer; Immunotherapy","score_opus":0.051706459951020634,"score_gpt":0.46676355530399066,"score_spread":0.41505709535297003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893925,0.0022138671,0.000056007208,0.0064015863,0.00061075715,0.00057664636,7.4017606e-7,0.000008235839,0.00073961914],"genre_scores_gemma":[0.9941061,0.001622809,0.0007959792,0.0029304237,0.0001418781,0.000008653396,5.038908e-7,0.00001279934,0.00038081052],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972582,0.00043302524,0.0016815263,0.0002063776,0.00022053748,0.00020032238],"domain_scores_gemma":[0.9974852,0.0011598563,0.00084555196,0.00019333669,0.00016333841,0.0001526903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020790962,0.0001513816,0.0015238909,0.00026702296,0.000050122017,0.00001016272,0.00011452451,0.0001795136,0.000059683818],"category_scores_gemma":[0.00049240777,0.00009862694,0.00017458762,0.00031722712,0.0001980921,0.00011228673,0.000026686248,0.00075510464,3.4563487e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3731815,0.015147972,0.14147748,0.000046881767,0.0013839462,0.0013743101,0.0007042458,0.0000025978138,0.0011703258,0.000023226195,0.00046987578,0.46501765],"study_design_scores_gemma":[0.2687643,0.23509291,0.47415033,0.00030745796,0.000338709,0.00043010782,0.00071817567,0.000071086615,0.00006419437,0.000070698574,0.019872649,0.000119410935],"about_ca_topic_score_codex":0.000030958556,"about_ca_topic_score_gemma":0.0001851167,"teacher_disagreement_score":0.46489823,"about_ca_system_score_codex":0.00021374242,"about_ca_system_score_gemma":0.0015007171,"threshold_uncertainty_score":0.40218896},"labels":[],"label_agreement":null},{"id":"W4406869723","doi":"10.1200/jco.2025.43.4_suppl.lba248","title":"Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: The phase 3, randomized KEYFORM-007 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Merck","keywords":"Medicine; Pembrolizumab; Colorectal cancer; Oncology; Internal medicine; Standard of care; Cancer; Immunotherapy","score_opus":0.06375081820030999,"score_gpt":0.49278144716634126,"score_spread":0.4290306289660313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835267,0.007880615,0.000045635286,0.0018100968,0.0013566293,0.0027029617,0.000052546802,0.0000118601065,0.0026129773],"genre_scores_gemma":[0.99408746,0.0048366343,0.00013478554,0.0005692991,0.00015892106,0.00007055526,0.000013603903,0.000018946643,0.00010977225],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930937,0.0018554602,0.0039050106,0.00025440313,0.0005372554,0.00035414443],"domain_scores_gemma":[0.98951364,0.007148196,0.0022064978,0.00022977775,0.00074406894,0.00015782488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005933662,0.00027195088,0.003969336,0.00032353456,0.00008786789,0.000016537015,0.00029443458,0.00027716655,0.00018804148],"category_scores_gemma":[0.0025720298,0.00015296953,0.0011679741,0.0005468669,0.00065122393,0.000110316556,0.000040624403,0.001099453,0.0000018146889],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86564523,0.0021494878,0.0024476266,0.00007066214,0.0048956685,0.00044577205,0.0019199529,0.00003882053,0.0001425565,0.000025969148,0.00041884097,0.12179944],"study_design_scores_gemma":[0.8946962,0.078624904,0.012569436,0.00051250693,0.0039808415,0.00008541623,0.0037661914,0.00029064005,0.0011682973,0.000037308502,0.0041240784,0.00014419087],"about_ca_topic_score_codex":0.00042400265,"about_ca_topic_score_gemma":0.0012800957,"teacher_disagreement_score":0.12165525,"about_ca_system_score_codex":0.0013008405,"about_ca_system_score_gemma":0.0051540835,"threshold_uncertainty_score":0.91431224},"labels":[],"label_agreement":null},{"id":"W4406875658","doi":"10.1200/jco.2025.43.4_suppl.398","title":"Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Gastroesophageal Junction; Cancer; Chemotherapy; Internal medicine; Esophageal adenocarcinoma; Adenocarcinoma; Oncology; Esophageal cancer; Gastroenterology; Immunotherapy","score_opus":0.060370747793238394,"score_gpt":0.41646542137251774,"score_spread":0.3560946735792794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406875658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9572986,0.008009459,0.0007252255,0.023709493,0.007917384,0.0013745807,0.00025963518,0.0000671107,0.0006385325],"genre_scores_gemma":[0.95328885,0.022966977,0.0048202337,0.005556891,0.004530226,0.00018361316,0.00011023557,0.000091375834,0.008451619],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936306,0.0002468938,0.0039575864,0.00082883204,0.00057496055,0.0007611148],"domain_scores_gemma":[0.99352926,0.0016586144,0.0029208947,0.00058873935,0.00080759224,0.0004949243],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001685661,0.00058831146,0.0029045774,0.00035133454,0.00022413656,0.000038162856,0.00042662089,0.00084021897,0.0005084886],"category_scores_gemma":[0.0010616663,0.00046327763,0.0017008398,0.00060546806,0.0003182119,0.00022856239,0.000059310398,0.00096275366,0.000014182765],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40510342,0.0024226916,0.03260641,0.00010222222,0.0035232257,0.00029717878,0.00030674625,0.00014052619,0.0032213593,0.000014507027,0.017703943,0.53455776],"study_design_scores_gemma":[0.35552478,0.057383183,0.34219965,0.0011929586,0.0033639478,0.00020377323,0.00036676714,0.00092588126,0.018866228,0.00048827264,0.21886265,0.00062190276],"about_ca_topic_score_codex":0.0022350452,"about_ca_topic_score_gemma":0.0014758576,"teacher_disagreement_score":0.5339359,"about_ca_system_score_codex":0.002764399,"about_ca_system_score_gemma":0.0047428575,"threshold_uncertainty_score":0.9997819},"labels":[],"label_agreement":null},{"id":"W4406946202","doi":"10.1093/ofid/ofae631.2229","title":"P-2073. COVID-19 Vaccine Effectiveness in Patients with Lung Cancer and Mesothelioma in the Omicron Era","year":2025,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Coronavirus disease 2019 (COVID-19); Mesothelioma; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Internal medicine; Oncology; Virology; Pathology; Disease","score_opus":0.005112034313937074,"score_gpt":0.3023880507623091,"score_spread":0.29727601644837204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406946202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991126,0.0027230706,0.00001578786,0.0023435378,0.000100165016,0.0024033904,0.000055363595,0.000022682192,0.0012100027],"genre_scores_gemma":[0.9935287,0.00021373128,0.0000024356648,0.005591239,0.000010667249,0.00052413635,0.00003459206,0.000015135106,0.0000793693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990123,0.00014334603,0.00018742646,0.00029503278,0.00012363076,0.000238267],"domain_scores_gemma":[0.99938965,0.00019302378,0.0000611904,0.00024553208,0.00003776718,0.00007284379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023689732,0.00017080604,0.00030434388,0.00022054689,0.00013713498,0.00009360006,0.0001531474,0.000050995804,0.00008545342],"category_scores_gemma":[0.000067823166,0.000108110915,0.00004345311,0.00065237976,0.00005694259,0.00015845659,0.000089248664,0.00012280751,7.8250946e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008713059,0.00055937155,0.98068684,0.00027185935,0.00015019781,0.00001570782,0.00014243225,0.000024939141,0.00006249927,0.0001221822,0.0016609139,0.0075900094],"study_design_scores_gemma":[0.019227846,0.0003563562,0.9771258,0.000475089,0.00012025496,0.000004646268,0.00011439269,0.000025695057,0.00006209925,0.00016446106,0.0021875822,0.00013574705],"about_ca_topic_score_codex":0.0075904843,"about_ca_topic_score_gemma":0.0064073275,"teacher_disagreement_score":0.010514786,"about_ca_system_score_codex":0.00045025308,"about_ca_system_score_gemma":0.00041040962,"threshold_uncertainty_score":0.9990181},"labels":[],"label_agreement":null},{"id":"W4407003843","doi":"10.1016/bs.mie.2024.12.001","title":"Biochemical assays for AID/APOBECs and the identification of AID/APOBEC inhibitors","year":2025,"lang":"en","type":"article","venue":"Methods in enzymology on CD-ROM/Methods in enzymology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"APOBEC; Identification (biology); Computational biology; Biology; Virology; Genetics; Genome; Gene","score_opus":0.03638555992644005,"score_gpt":0.4317852567152089,"score_spread":0.39539969678876885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407003843","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66721296,0.013787759,0.291839,0.014046769,0.005210204,0.0043557547,0.000054998505,0.00013870318,0.0033538535],"genre_scores_gemma":[0.1706732,0.0009294712,0.82290626,0.0032257338,0.00018706478,0.0009034529,0.000036909325,0.000068234396,0.0010696691],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9895877,0.006377947,0.0020080116,0.0010802749,0.00020549433,0.00074052584],"domain_scores_gemma":[0.9856186,0.01246736,0.00061866734,0.0010271898,0.00018276313,0.000085426575],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.019375661,0.00048725383,0.0017165632,0.001182704,0.00013151453,0.000018208317,0.0005003358,0.0011368714,0.000062164],"category_scores_gemma":[0.008154088,0.0003834384,0.00037015707,0.0013202319,0.0024348209,0.00006706393,0.0002195106,0.0010342995,0.0000019612473],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014690759,0.00063255633,0.006856258,0.00036546055,0.00038074437,0.000024555487,0.0009716845,0.000022847898,0.77767766,0.028552314,0.0021011487,0.16772401],"study_design_scores_gemma":[0.035137113,0.0017295404,0.10506154,0.0005649982,0.00046981368,0.00038021937,0.001123073,0.00095983467,0.712753,0.09722242,0.043798447,0.0007999961],"about_ca_topic_score_codex":0.0003756789,"about_ca_topic_score_gemma":0.00020527783,"teacher_disagreement_score":0.53106725,"about_ca_system_score_codex":0.0003212233,"about_ca_system_score_gemma":0.00027332478,"threshold_uncertainty_score":0.9998618},"labels":[],"label_agreement":null},{"id":"W4407086441","doi":"10.1080/14712598.2025.2456485","title":"Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challenges","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Melanoma; Immunotherapy; Nivolumab; Immune checkpoint; Immune system; Medicine; Ipilimumab; Term (time); Cancer research; Pembrolizumab; Immunology","score_opus":0.11995718681064713,"score_gpt":0.39524859417414226,"score_spread":0.2752914073634951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407086441","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0047987415,0.99046963,0.00000125785,0.002680278,0.0003739867,0.0015697132,0.000019268233,0.000040379262,0.000046758316],"genre_scores_gemma":[0.0028452638,0.99621964,0.000067709516,0.00024944,0.00015237396,0.00034499817,0.00008113037,0.000030649466,0.000008793484],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976913,0.00024335047,0.0010276443,0.0005546392,0.00019367122,0.00028939339],"domain_scores_gemma":[0.99843603,0.0005788701,0.0004600353,0.00044154047,0.000036006015,0.00004752714],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000692792,0.0005515521,0.00189295,0.00010596733,0.00009312713,0.000029695899,0.00022806095,0.00052034203,0.00003991124],"category_scores_gemma":[0.000053884112,0.00025693545,0.00047493982,0.00025224383,0.0005149508,0.00003234701,0.00010062471,0.0006399835,6.610988e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006804577,0.00033126364,0.0021155735,0.0009688167,0.00043153757,0.0000033780636,0.00046139702,5.5311995e-9,0.00012198756,0.00009979408,0.000006631594,0.99477917],"study_design_scores_gemma":[0.0070082173,0.0031863637,0.07081991,0.05447104,0.000011716909,0.00010198829,0.0004289543,0.0000010411802,0.00019478214,0.000032461452,0.86304086,0.0007026596],"about_ca_topic_score_codex":0.00003680928,"about_ca_topic_score_gemma":0.0000023004704,"teacher_disagreement_score":0.9940765,"about_ca_system_score_codex":0.00005385775,"about_ca_system_score_gemma":0.00008865816,"threshold_uncertainty_score":0.99998826},"labels":[],"label_agreement":null},{"id":"W4407107658","doi":"10.1038/s41591-024-03441-5","title":"Immunotherapy boosts responses in hormone receptor-positive breast cancers","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Immunotherapy; Breast cancer; Hormone receptor; Medicine; Receptor; Hormone; Internal medicine; Oncology; Cancer research; Biology; Immunology; Cancer","score_opus":0.005904414978881192,"score_gpt":0.30041446424171564,"score_spread":0.2945100492628345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407107658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74305123,0.16162273,0.00006133358,0.06913394,0.0018241127,0.0011513554,0.00007151528,0.00014262431,0.02294114],"genre_scores_gemma":[0.96679413,0.0074806903,0.00015698887,0.016446289,0.00039201824,0.000049835904,0.000087121225,0.000031119187,0.008561825],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99828166,0.000112768495,0.00044142833,0.0004026365,0.00039756685,0.00036397084],"domain_scores_gemma":[0.99900144,0.00023265682,0.00009879232,0.0004191713,0.00016164247,0.00008629026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061854435,0.00027371183,0.0005721416,0.0005816145,0.00007837395,0.000009124029,0.00016775176,0.0004374041,0.0004585548],"category_scores_gemma":[0.00015869658,0.00020208137,0.00010898391,0.0012568678,0.00033799707,0.00006932726,0.000023760424,0.0010059965,0.000008891492],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07546803,0.00020319103,0.013875546,0.000104912375,0.00068248925,0.00016764506,0.0015289428,9.674757e-7,0.5771378,0.0005827098,0.12290383,0.2073439],"study_design_scores_gemma":[0.019885158,0.0009993457,0.7634251,0.0025681413,0.000096191514,0.00018250596,0.00077960466,0.00001682022,0.016407432,0.00013749489,0.19519888,0.00030332585],"about_ca_topic_score_codex":0.0011878524,"about_ca_topic_score_gemma":0.00016055415,"teacher_disagreement_score":0.74954957,"about_ca_system_score_codex":0.0009192822,"about_ca_system_score_gemma":0.0005178967,"threshold_uncertainty_score":0.8240639},"labels":[],"label_agreement":null},{"id":"W4407164318","doi":"10.1002/cam4.71888","title":"A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours","year":2025,"lang":"en","type":"review","venue":"Cancer Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Charlie Teo Foundation","keywords":"Meta-analysis; Oncology; Internal medicine; Medicine; Mutation; Biology; Genetics; Gene","score_opus":0.08177186639492394,"score_gpt":0.4428087307960202,"score_spread":0.3610368644010962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407164318","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000512082,0.99489605,0.0000018090923,0.0012300811,0.00010721107,0.003303751,0.00022618436,0.00000659615,0.00017712216],"genre_scores_gemma":[0.0014970987,0.99673486,0.0000018408452,0.00032862014,0.000029916004,0.0004366456,0.000051502386,0.000021425523,0.00089809246],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9965661,0.0005162321,0.0018979681,0.00033345053,0.00050821976,0.00017799353],"domain_scores_gemma":[0.9967385,0.00074679276,0.0015723251,0.00070643687,0.0001753711,0.00006057374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013061006,0.00044989787,0.014283472,0.00075010204,0.00001949681,0.0000029392907,0.00024651826,0.00012773553,0.0004007479],"category_scores_gemma":[0.00075761584,0.00018319178,0.0031648192,0.0023371025,0.00019145821,0.00001995142,0.000035208228,0.00027779143,3.630482e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004623614,0.000038232323,0.000056255863,0.80395454,0.19318327,0.000006527966,0.00014980549,0.000006391036,0.0000032665346,0.000006075714,0.00019238531,0.0023569958],"study_design_scores_gemma":[0.0005325605,0.00017991096,0.000872779,0.2879186,0.7101551,0.0000073202305,0.000047102076,0.000004538751,0.0000014400603,0.000002219899,0.00017285497,0.000105517815],"about_ca_topic_score_codex":0.0025231875,"about_ca_topic_score_gemma":0.00017838113,"teacher_disagreement_score":0.5169719,"about_ca_system_score_codex":0.0003529919,"about_ca_system_score_gemma":0.00068265223,"threshold_uncertainty_score":0.9763896},"labels":[],"label_agreement":null},{"id":"W4407240950","doi":"10.1016/j.ejcskn.2025.100284","title":"Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma","year":2025,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Medicine; Placebo; Internal medicine; Type 2 diabetes; Cancer; Oncology; Body mass index; Index (typography); Diabetes mellitus; Alternative medicine; Pathology; Endocrinology; Immunotherapy; Computer science","score_opus":0.03411272885735226,"score_gpt":0.36545527000434735,"score_spread":0.3313425411469951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407240950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911839,0.0054420554,0.0000061962273,0.0002138168,0.00014472117,0.0026121112,0.0002515467,0.000004729582,0.00014093259],"genre_scores_gemma":[0.9943203,0.005145538,0.000018398427,0.000010788002,0.00007451814,0.00029079372,0.00002965102,0.000015064154,0.00009500197],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9986244,0.0002629916,0.0004138317,0.0002704363,0.00022844966,0.00019991027],"domain_scores_gemma":[0.99867284,0.00075318775,0.00020720666,0.00019227904,0.00014432434,0.000030162932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007888112,0.00013154176,0.00038749087,0.00023010618,0.00004694987,0.000009711947,0.00006671017,0.000071788905,0.000031196727],"category_scores_gemma":[0.00015930225,0.000094324736,0.000026568732,0.00043659584,0.0002878711,0.000048711794,0.000024394714,0.000120584584,2.305391e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5122072,0.00048038998,0.45105946,0.00026115202,0.00044591466,0.0000059020185,0.0030151797,0.0000090067115,0.0133942105,0.00002595236,0.00012356596,0.018972028],"study_design_scores_gemma":[0.3212743,0.009606963,0.6453196,0.0004162713,0.00020122735,3.3260804e-7,0.0012796103,0.0006832901,0.020747863,0.000078204306,0.00029374575,0.000098588775],"about_ca_topic_score_codex":0.004411623,"about_ca_topic_score_gemma":0.004476662,"teacher_disagreement_score":0.19426012,"about_ca_system_score_codex":0.00024675895,"about_ca_system_score_gemma":0.00036096558,"threshold_uncertainty_score":0.6669083},"labels":[],"label_agreement":null},{"id":"W4407271869","doi":"10.1101/2025.02.03.636144","title":"Essential role of NLRC5 in cancer immune surveillance and cancer immunoediting","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Immunoediting; Cancer; Immune system; Medicine; Immunology; Internal medicine; Immunotherapy","score_opus":0.008689026718897975,"score_gpt":0.253715606278475,"score_spread":0.24502657955957702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407271869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8962445,0.10059271,0.00002124806,0.00041996443,0.0012983446,0.00076119736,0.00053804816,0.00009325292,0.0000306988],"genre_scores_gemma":[0.9757592,0.022944335,0.0003332276,0.00013997649,0.00039302002,0.00033789125,7.697263e-7,0.000062242434,0.00002932388],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974341,0.0001077959,0.0008653569,0.00077244977,0.00033853902,0.00048176188],"domain_scores_gemma":[0.99804777,0.00008155808,0.0005521435,0.0008150894,0.00039823516,0.000105213796],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062732724,0.00047623974,0.001045458,0.00038888722,0.00007505411,0.000049334158,0.00028677244,0.00048428922,0.00013439193],"category_scores_gemma":[0.00008977999,0.00049930974,0.00019562258,0.00063113356,0.00022472753,0.000081538805,0.0003579132,0.00074343034,0.0000011392367],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074256025,0.00013949828,0.1363452,0.0015317192,0.00048325225,0.000018675635,0.00003845416,0.000026333018,0.8604221,0.000048611237,0.00006298892,0.0001406182],"study_design_scores_gemma":[0.0021561247,0.00004691313,0.5837443,0.003730251,0.00013734044,2.5306331e-8,0.000012535397,0.00027973112,0.40588275,0.0000013613552,0.0035355645,0.00047310232],"about_ca_topic_score_codex":0.006683579,"about_ca_topic_score_gemma":0.00013840967,"teacher_disagreement_score":0.45453936,"about_ca_system_score_codex":0.00045852835,"about_ca_system_score_gemma":0.0015442168,"threshold_uncertainty_score":0.999931},"labels":[],"label_agreement":null},{"id":"W4407285903","doi":"10.1093/jcag/gwae059.127","title":"A127 PEMBROLIZUMAB-ASSOCIATED IMMUNE CHECKPOINT INHIBITOR GASTRITIS AND DUODENITIS: A CASE REPORT","year":2025,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Duodenitis; Gastritis; Immune system; Immunology; Gastroenterology; Immunotherapy; Helicobacter pylori","score_opus":0.006489614014807178,"score_gpt":0.23665871612396125,"score_spread":0.23016910210915406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407285903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729896,0.00023404406,0.00001080453,0.025425237,0.0008099803,0.00016995736,0.000040098,0.000004259514,0.00031600776],"genre_scores_gemma":[0.9970923,0.00007551169,0.00006027094,0.0012698986,0.000085420616,0.0000028129962,0.0000046251257,0.000009199379,0.0013999612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998289,0.00021402247,0.0008751965,0.000105836254,0.00022627889,0.00028969298],"domain_scores_gemma":[0.9977682,0.000060768223,0.0013413379,0.00015974016,0.0005237748,0.00014614315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011263685,0.000111635876,0.00047137568,0.0003271612,0.00013451769,0.000021658043,0.00010152029,0.000160903,0.00003803556],"category_scores_gemma":[0.00084296387,0.00009179174,0.0002866435,0.00019647686,0.00009850776,0.000060969258,0.000028188619,0.00035276238,3.139577e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023657044,0.00011620441,0.97259945,0.00005063194,0.0015075022,0.006983929,0.00022521667,0.0000029849016,0.004640282,0.000014629906,0.010877621,0.0006158718],"study_design_scores_gemma":[0.009988657,0.0010818961,0.91694087,0.00047273375,0.00044229277,0.06735306,0.00021397775,0.000019798217,0.0008156843,0.00007536759,0.0025324153,0.0000632401],"about_ca_topic_score_codex":0.015333144,"about_ca_topic_score_gemma":0.31236374,"teacher_disagreement_score":0.2970306,"about_ca_system_score_codex":0.0018826936,"about_ca_system_score_gemma":0.00085080083,"threshold_uncertainty_score":0.9912238},"labels":[],"label_agreement":null},{"id":"W4407296520","doi":"10.1158/2767-9764.crc-24-0407","title":"Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors","year":2025,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bayer","keywords":"Nivolumab; Medicine; Tolerability; Adverse effect; Oncology; Internal medicine; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Cancer; Clinical trial; Immunotherapy","score_opus":0.04313230397912114,"score_gpt":0.43944991981068704,"score_spread":0.3963176158315659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407296520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931879,0.0023714148,0.000015209704,0.0013370994,0.000009837899,0.0023707063,0.000020172041,0.000011523698,0.00067615224],"genre_scores_gemma":[0.9977062,0.0015952364,0.00017427719,0.00004135142,0.0000020556427,0.00032941572,0.000044804896,0.000012163958,0.00009449316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985916,0.0002971826,0.00034534535,0.00020480448,0.00034874148,0.0002123141],"domain_scores_gemma":[0.9981881,0.00031071494,0.00007798345,0.00094641256,0.00042950222,0.00004731072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068986666,0.00009516373,0.00029029412,0.00043169432,0.00013771767,0.000014477071,0.00030119464,0.0000317445,0.00001692664],"category_scores_gemma":[0.00011162482,0.0000770924,0.000015927018,0.0016060885,0.00048376527,0.00010591019,0.00014490765,0.00040517238,3.1398852e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03964227,0.009688966,0.8305689,0.00012764249,0.00017334118,0.000003758913,0.0031783425,0.000036721525,0.00070394285,0.00027235315,0.0000828999,0.11552087],"study_design_scores_gemma":[0.053669833,0.0031144388,0.9391959,0.0011838406,0.000021001939,3.4922024e-7,0.0016150606,0.00020179665,0.0001844626,0.000019268451,0.0007162889,0.00007780995],"about_ca_topic_score_codex":0.002018167,"about_ca_topic_score_gemma":0.007643855,"teacher_disagreement_score":0.115443066,"about_ca_system_score_codex":0.0004518909,"about_ca_system_score_gemma":0.0005991712,"threshold_uncertainty_score":0.42654505},"labels":[],"label_agreement":null},{"id":"W4407380418","doi":"10.18502/ijhoscr.v19i1.17819","title":"Pre-Treatment Peripheral Blood Parameters as Prognostic Biomarkers in Cancer Patients Receiving Immune Checkpoint Inhibitors","year":2025,"lang":"en","type":"article","venue":"International Journal of Hematology-Oncology and Stem Cell Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Algoma University; Essar Steel Algoma (Canada); Sault Area Hospital; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Nivolumab; Internal medicine; Oncology; Cancer; Ipilimumab; Lung cancer; Kidney cancer; Immune checkpoint; Immunotherapy","score_opus":0.02893273820637796,"score_gpt":0.3807658527763268,"score_spread":0.3518331145699488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407380418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98174405,0.010720667,0.0000062038207,0.0041968585,0.0010799535,0.00053050707,0.0000040054438,0.000007065499,0.0017106886],"genre_scores_gemma":[0.9944848,0.0043970547,0.00017443,0.00014240788,0.000051956602,0.000068904694,0.0000050482977,0.000011302499,0.0006641264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976561,0.000368078,0.0008998017,0.0002568632,0.00046790554,0.00035126967],"domain_scores_gemma":[0.9981064,0.0006926043,0.0003057386,0.000116317155,0.0006746554,0.000104249855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012193657,0.00016447064,0.0005042807,0.0008420444,0.00008873381,0.00003515953,0.0002303267,0.00024377316,0.00008378149],"category_scores_gemma":[0.00015143173,0.00012603446,0.00017342289,0.0003063013,0.00036907376,0.000103530954,0.00009615191,0.00051190174,0.00000241015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013514796,0.0026790912,0.8536388,0.00015380754,0.0024696144,0.0009860108,0.0018494047,0.000010504742,0.016908579,0.000058934354,0.00042878327,0.10730163],"study_design_scores_gemma":[0.042736974,0.014511519,0.71226007,0.003635034,0.00041715286,0.002267932,0.004361671,0.0002013357,0.20734572,0.00063531386,0.011201736,0.00042553473],"about_ca_topic_score_codex":0.0004601425,"about_ca_topic_score_gemma":0.00019016315,"teacher_disagreement_score":0.19043714,"about_ca_system_score_codex":0.0009886542,"about_ca_system_score_gemma":0.0011001591,"threshold_uncertainty_score":0.5139536},"labels":[],"label_agreement":null},{"id":"W4407388488","doi":"10.1093/bioinformatics/btaf060","title":"ImmunoTar—integrative prioritization of cell surface targets for cancer immunotherapy","year":2025,"lang":"en","type":"article","venue":"Bioinformatics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Spinal Cord Injury BC","funders":"National Cancer Institute; Cancer Research UK; National Institutes of Health; Michael Smith Health Research BC; Mark Foundation For Cancer Research","keywords":"Identification (biology); Chimeric antigen receptor; Prioritization; Immunotherapy; Computational biology; Cancer immunotherapy; Cancer; Computer science; Proteomics; Bioinformatics; Biology; Gene","score_opus":0.010638015712514907,"score_gpt":0.29056213018331295,"score_spread":0.27992411447079807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407388488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5891412,0.046063215,0.31960988,0.0035679922,0.003420579,0.00788907,0.00070834626,0.0005027901,0.029096952],"genre_scores_gemma":[0.7964291,0.015053126,0.1699719,0.0034185175,0.00010753521,0.00019992265,0.00033683205,0.00009871749,0.014384357],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99904734,0.000011238266,0.00053183467,0.00008825021,0.00014181445,0.00017952922],"domain_scores_gemma":[0.9991382,0.00007787947,0.00022318315,0.00023723903,0.00029863615,0.00002489676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018095516,0.00015309323,0.00031779366,0.00009850412,0.000059249953,0.000015896445,0.00010077798,0.00010305806,0.00005207249],"category_scores_gemma":[0.000025301424,0.000119010925,0.00017365061,0.00030032004,0.00008310223,0.000118450254,0.000014460894,0.00007828797,0.0000018353443],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010726666,0.0007079027,0.007956355,0.0045749685,0.001622956,0.0000010812489,0.011986193,0.00015234016,0.80014735,0.0018173667,0.031684864,0.12862198],"study_design_scores_gemma":[0.010127745,0.00069284765,0.0087929135,0.0009844825,0.00019167068,0.00000314293,0.0028274232,0.013516694,0.80644715,0.00023389186,0.15584393,0.0003380899],"about_ca_topic_score_codex":0.00010991929,"about_ca_topic_score_gemma":0.000014280268,"teacher_disagreement_score":0.20728791,"about_ca_system_score_codex":0.000113793845,"about_ca_system_score_gemma":0.0003778651,"threshold_uncertainty_score":0.48531246},"labels":[],"label_agreement":null},{"id":"W4407392510","doi":"10.1158/1078-0432.ccr-24-1818","title":"AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Durvalumab; Medicine; Tolerability; Combination therapy; Adverse effect; Internal medicine; Toxicity; Pharmacology; Cancer; Urology; Oncology; Gastroenterology; Immunotherapy","score_opus":0.06226559789994827,"score_gpt":0.4923652683580123,"score_spread":0.430099670458064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407392510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952103,0.00062596524,0.00001026456,0.001335805,0.00013579662,0.0024183008,0.00000975956,0.000026562553,0.00022725771],"genre_scores_gemma":[0.99755275,0.0011318851,0.00021385324,0.0005460755,0.0000801552,0.00022998771,0.000029210807,0.00003579434,0.00018028918],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99688643,0.0005740284,0.0007707508,0.00063292845,0.000618106,0.0005177391],"domain_scores_gemma":[0.9985761,0.0004522218,0.00013383098,0.0003359436,0.00033163372,0.0001702755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002612173,0.00019014637,0.0006029956,0.00044953957,0.0001182894,0.000052874668,0.0001435298,0.00013295093,0.0000736006],"category_scores_gemma":[0.0004057465,0.00014396927,0.00005587591,0.0010611389,0.00051134074,0.00020930609,0.000044026016,0.0008007901,0.0000019094648],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6068077,0.0034121135,0.28174362,0.00007791559,0.00008817635,0.00007009446,0.00025470878,0.000012338508,0.00072244834,0.000020822858,0.00014511775,0.10664493],"study_design_scores_gemma":[0.47409567,0.019849926,0.50130725,0.0012360933,0.0000224799,0.0000015742412,0.0003612527,0.00047999964,0.0012118662,0.00013994533,0.0010598715,0.00023404564],"about_ca_topic_score_codex":0.0013231034,"about_ca_topic_score_gemma":0.0013049728,"teacher_disagreement_score":0.21956366,"about_ca_system_score_codex":0.00031175115,"about_ca_system_score_gemma":0.00085588824,"threshold_uncertainty_score":0.58708966},"labels":[],"label_agreement":null},{"id":"W4407565194","doi":"10.3390/curroncol32020110","title":"Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Ministero della Salute","keywords":"Medicine; Perioperative; Immunotherapy; Lung cancer; Oncology; Lung; Cancer; Internal medicine; Cancer research; Surgery","score_opus":0.09466145182697121,"score_gpt":0.4285470982025178,"score_spread":0.3338856463755466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407565194","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00069351436,0.97814095,0.000036389865,0.00021421471,0.0039246716,0.0043120547,0.00015398623,0.000075603675,0.012448592],"genre_scores_gemma":[0.00007944666,0.9898162,0.00022063582,0.00041884207,0.00094960834,0.0033211622,0.0005247965,0.00014487602,0.0045244633],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99514824,0.0004974477,0.0016957069,0.0012418086,0.000347422,0.0010694029],"domain_scores_gemma":[0.9975482,0.0004265164,0.00072670024,0.00082503835,0.00027491443,0.00019860866],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007200763,0.0010646051,0.003935782,0.00078654604,0.00020794332,0.00006115386,0.0006339497,0.0010752283,0.00094083406],"category_scores_gemma":[0.000082387785,0.00088197365,0.0009934371,0.0014053781,0.0002331597,0.00008791511,0.0001985913,0.0015430617,0.000024704206],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000942249,0.0007815626,0.0002710067,0.019995717,0.0006623781,0.00009050566,0.0026290952,9.2420987e-7,0.0011663261,0.0000012951573,0.00985157,0.9636074],"study_design_scores_gemma":[0.0067062806,0.00047327855,0.00006223877,0.058331996,0.00061598857,0.000040715026,0.00039659592,0.00007640182,0.0003611157,4.8554125e-7,0.9321833,0.0007515628],"about_ca_topic_score_codex":0.0010566859,"about_ca_topic_score_gemma":0.0006278908,"teacher_disagreement_score":0.9628558,"about_ca_system_score_codex":0.0038602678,"about_ca_system_score_gemma":0.0063644876,"threshold_uncertainty_score":0.99997246},"labels":[],"label_agreement":null},{"id":"W4407621635","doi":"10.1016/j.ijgc.2024.100432","title":"Randomized Study Evaluating Optimal Dose, Efficacy And Safety Of E7386 + Lenvatinib Versus Treatment Of Physicians’ Choice In Advanced/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Eisai","keywords":"Medicine; Lenvatinib; Immunotherapy; Oncology; Internal medicine; Randomized controlled trial; Gynecology; Sorafenib; Cancer; Hepatocellular carcinoma","score_opus":0.046844560633795926,"score_gpt":0.3959338950705721,"score_spread":0.34908933443677614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407621635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902464,0.006995762,0.000044384316,0.00035545928,0.00063337694,0.0015449321,0.000018182991,0.000005620904,0.0001558375],"genre_scores_gemma":[0.99562025,0.003578359,0.00049360155,0.000054589393,0.0001169063,0.00007751136,0.000005893802,0.000010195187,0.00004269999],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976199,0.00029784848,0.0011506971,0.00022259404,0.0005349801,0.00017397646],"domain_scores_gemma":[0.995973,0.0023389373,0.0009349119,0.0001201618,0.00059753994,0.000035475678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072579726,0.00021572734,0.0012287957,0.00037835047,0.000030071578,0.000014158746,0.00017599661,0.00006954855,0.00016477058],"category_scores_gemma":[0.00058824266,0.00013374686,0.00026366004,0.0003972242,0.00021185551,0.000093393544,0.00002526997,0.00016014506,1.00105254e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6555302,0.0024591035,0.12716964,0.000020709045,0.0025119677,0.000033342585,0.00052796333,0.0004754915,0.006276023,0.000009483447,0.000004873638,0.20498118],"study_design_scores_gemma":[0.5119477,0.015300698,0.46873555,0.00040863748,0.00034741955,0.000007650499,0.0002283149,0.0001467472,0.0026085242,0.000003395486,0.00017662495,0.00008872301],"about_ca_topic_score_codex":0.00034987842,"about_ca_topic_score_gemma":0.00011775363,"teacher_disagreement_score":0.3415659,"about_ca_system_score_codex":0.00063117774,"about_ca_system_score_gemma":0.00035939872,"threshold_uncertainty_score":0.54540384},"labels":[],"label_agreement":null},{"id":"W4407635325","doi":"10.1111/his.15432","title":"Comparative performance of <scp>PD</scp>‐<scp>L1</scp> scoring by pathologists and <scp>AI</scp> algorithms","year":2025,"lang":"en","type":"article","venue":"Histopathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"HORIZON EUROPE Framework Programme; Austrian Science Fund; European Commission","keywords":"Concordance; Kappa; Medicine; Cohen's kappa; Lung cancer; Algorithm; Nuclear medicine; Oncology; Internal medicine; Machine learning; Computer science; Mathematics","score_opus":0.018123305675911597,"score_gpt":0.28602004879017356,"score_spread":0.267896743114262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407635325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95943093,0.02142994,0.0007853115,0.00018294345,0.0012010017,0.00064137427,0.00008411245,0.00014936696,0.016095031],"genre_scores_gemma":[0.97028255,0.0025986333,0.0014639392,0.0019555364,0.00016908081,0.00012945296,0.0001001176,0.00005105904,0.023249628],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9969645,0.00023471705,0.00083106285,0.0008585289,0.00032741253,0.00078376377],"domain_scores_gemma":[0.9976325,0.000827947,0.00043272707,0.0006781676,0.00025224258,0.0001764163],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000753511,0.0005049253,0.0012304442,0.00044516768,0.0002772545,0.000028732247,0.00032689638,0.00045739854,0.000012676929],"category_scores_gemma":[0.0005490857,0.0004737163,0.00020755151,0.0006230389,0.001319586,0.00017554492,0.00018942756,0.00067729113,0.000033645774],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000298435,0.000955231,0.21090397,0.0012947294,0.00024596063,0.0006379131,0.015428801,0.000022022692,0.5840214,0.00050498085,0.17052943,0.015157135],"study_design_scores_gemma":[0.006384405,0.0025632102,0.5492599,0.00059173343,0.0003703624,0.0010038619,0.0033073258,0.00071308954,0.088888384,0.00017627224,0.34661523,0.00012625041],"about_ca_topic_score_codex":0.000097453885,"about_ca_topic_score_gemma":0.000024575236,"teacher_disagreement_score":0.495133,"about_ca_system_score_codex":0.00029547777,"about_ca_system_score_gemma":0.00028522065,"threshold_uncertainty_score":0.9997715},"labels":[],"label_agreement":null},{"id":"W4407640511","doi":"10.3390/cancers17040674","title":"Correction: Girard et al. Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis. Cancers 2024, 16, 2492","year":2025,"lang":"en","type":"erratum","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Meta-analysis; Oncology; Nivolumab; Lung cancer; Internal medicine; Chemotherapy; Cancer; Immunotherapy","score_opus":0.044281678100344765,"score_gpt":0.3500285111328434,"score_spread":0.3057468330324986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407640511","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029837494,0.9686248,0.000054269884,0.0012455555,0.013730555,0.005700148,0.00073982304,0.000040711147,0.009565767],"genre_scores_gemma":[0.0029970075,0.7162683,0.00014608976,0.008319269,0.0004496436,0.0031874178,0.0023355195,0.00010585951,0.2661909],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9951689,0.0005506883,0.0016818417,0.0012159296,0.0007211037,0.00066153094],"domain_scores_gemma":[0.9963751,0.00044474212,0.0015221504,0.000924417,0.0005106969,0.00022289065],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00076680037,0.001018927,0.0075077876,0.0006208253,0.00015951734,0.00008913861,0.00036056121,0.00046784402,0.0011632765],"category_scores_gemma":[0.000033673245,0.00083790673,0.0020049657,0.0034371663,0.00024552474,0.0001267768,0.00006718113,0.0013015735,0.0000021192766],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0050936365,0.00007204931,0.00011291703,0.04219347,0.13446881,0.000028830555,0.00057610514,0.0024439944,0.0000074384675,0.00000272645,0.81496406,0.000035957433],"study_design_scores_gemma":[0.041203395,0.0014068548,0.00082623854,0.17301148,0.5429221,0.0000394486,0.0006769345,0.011734994,0.000103146085,0.0000025395302,0.22630976,0.001763092],"about_ca_topic_score_codex":0.0069845873,"about_ca_topic_score_gemma":0.009453853,"teacher_disagreement_score":0.5886543,"about_ca_system_score_codex":0.010278317,"about_ca_system_score_gemma":0.0077596363,"threshold_uncertainty_score":0.9997498},"labels":[],"label_agreement":null},{"id":"W4407642528","doi":"10.3390/curroncol32020114","title":"TM7SF2 as a Potential Biomarker in Colorectal Cancer: Implications for Metastasis","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Education","keywords":"Colorectal cancer; Medicine; Biomarker; Metastasis; Cancer; Oncology; Cancer research; Bioinformatics; Internal medicine; Biology; Genetics","score_opus":0.08717726137538856,"score_gpt":0.461499572745184,"score_spread":0.37432231136979544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407642528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94657826,0.016506579,0.0018715668,0.027900666,0.0029307823,0.0018601624,0.00018078671,0.00006461804,0.0021065627],"genre_scores_gemma":[0.9954113,0.0018954091,0.00023551873,0.0006692118,0.00008725723,0.0013046664,0.000099315956,0.000012102285,0.00028523852],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99903876,0.000051170227,0.0003155049,0.0002760964,0.000055784203,0.00026266315],"domain_scores_gemma":[0.99951327,0.00010945274,0.00007771712,0.00013942046,0.00010652121,0.00005359293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021778159,0.00012028279,0.00031925517,0.00025647972,0.0000704829,0.000008810817,0.000099445046,0.00011245127,0.00018127503],"category_scores_gemma":[0.00006663561,0.00010820248,0.00017646773,0.0004431098,0.000117212185,0.000030643,0.000035014655,0.0001236317,0.0000058789606],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056546,0.0008016927,0.028475326,0.00013461617,0.00033980026,0.000003822454,0.000107813554,0.0000019964268,0.072415,0.0007340215,0.023930797,0.8674005],"study_design_scores_gemma":[0.0072108083,0.000449787,0.42617646,0.000101227095,0.0002732216,0.000027846736,0.00010197377,0.00017733638,0.0032705767,0.0006964867,0.56139135,0.00012290779],"about_ca_topic_score_codex":0.00018344964,"about_ca_topic_score_gemma":0.0003789093,"teacher_disagreement_score":0.8672776,"about_ca_system_score_codex":0.00053955073,"about_ca_system_score_gemma":0.0008113402,"threshold_uncertainty_score":0.44123694},"labels":[],"label_agreement":null},{"id":"W4407694297","doi":"10.1186/s12885-025-13712-0","title":"Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review","year":2025,"lang":"en","type":"review","venue":"BMC Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"University of Electronic Science and Technology of China; Department of Science and Technology of Sichuan Province","keywords":"Surgical oncology; Medicine; Oncology; Solid tumor; Immune checkpoint; Internal medicine; Immune system; Cancer research; Intensive care medicine; Immunology; Immunotherapy; Cancer","score_opus":0.04872387703076278,"score_gpt":0.37742546688196715,"score_spread":0.32870158985120435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407694297","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010997843,0.97063255,0.000052660358,0.000099706565,0.00080933206,0.027377043,0.0006652214,0.00012414243,0.00012936843],"genre_scores_gemma":[0.000017998424,0.9555987,0.00044035437,0.0004187495,0.00031288384,0.030619085,0.00044338967,0.00017528211,0.011973516],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99296886,0.00034952819,0.0040831487,0.0011689592,0.00047106043,0.0009584292],"domain_scores_gemma":[0.9959583,0.00045182498,0.0018220597,0.0012618,0.00028991268,0.00021606253],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013048028,0.0012165449,0.008253644,0.0005567453,0.00008977587,0.000058263162,0.00047243724,0.0005283932,0.0009314487],"category_scores_gemma":[0.00049706263,0.0008239615,0.0025132147,0.0014715364,0.000119323624,0.00014239624,0.00010357014,0.00063401647,0.000014622495],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0021093334,0.000117670395,0.0000031554332,0.9259358,0.001123289,0.000041798052,0.000109415676,0.000006009329,0.000028720671,0.0000021192138,0.00063286134,0.06988983],"study_design_scores_gemma":[0.0035313682,0.00065689074,0.0000054316706,0.78446925,0.0061332574,0.00006150559,0.000036334746,0.000013357756,0.00019792811,9.2908954e-7,0.20419736,0.00069640577],"about_ca_topic_score_codex":0.0011158827,"about_ca_topic_score_gemma":0.0037012813,"teacher_disagreement_score":0.2035645,"about_ca_system_score_codex":0.0056478237,"about_ca_system_score_gemma":0.007280648,"threshold_uncertainty_score":0.9999818},"labels":[],"label_agreement":null},{"id":"W4407700130","doi":"10.1002/acr2.70002","title":"Chronicity of Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis After Immunotherapy Discontinuation: Results From the Canadian Research Group of Rheumatology in Immuno‐Oncology Database","year":2025,"lang":"en","type":"article","venue":"ACR Open Rheumatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Research Canada; University of Alberta; Université de Montréal; Western University; Dalhousie University; University of Toronto; University of British Columbia; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Hazard ratio; Discontinuation; Internal medicine; Rheumatology; Immunosuppression; Oncology; Cohort; Arthritis; Inflammatory arthritis; Cancer; Database; Confidence interval","score_opus":0.027386656652737772,"score_gpt":0.3377344668949266,"score_spread":0.3103478102421888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971244,0.015945975,0.000008309427,0.008317868,0.00063158484,0.0017772262,0.00038925136,0.000016953887,0.0016688819],"genre_scores_gemma":[0.99056786,0.00790752,0.00016380711,0.00027365217,0.000008577327,0.00033273068,0.0005695153,0.000031501728,0.00014484259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942363,0.0014854847,0.0025444715,0.0006173493,0.0003426184,0.0007738141],"domain_scores_gemma":[0.9956042,0.0017406736,0.0007409454,0.0013835185,0.00043543163,0.000095228905],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0054406878,0.00029876552,0.0015042057,0.00055885635,0.00025804457,0.000044437067,0.0010679174,0.0005953786,0.00044654164],"category_scores_gemma":[0.0013544544,0.00024669865,0.00021505043,0.0010968752,0.001596632,0.00023763347,0.00052445586,0.00086387846,0.00001254365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0745702,0.0026510851,0.72498465,0.00037997295,0.0037499825,0.00033140776,0.024577336,0.0000052628384,0.08343439,0.0067266636,0.010980789,0.06760829],"study_design_scores_gemma":[0.042138882,0.0011810246,0.90317273,0.00583198,0.00005900859,0.0001648294,0.0052255094,0.000088323184,0.015532729,0.0011802076,0.02496073,0.00046406503],"about_ca_topic_score_codex":0.77353436,"about_ca_topic_score_gemma":0.88997203,"teacher_disagreement_score":0.17818809,"about_ca_system_score_codex":0.0009975533,"about_ca_system_score_gemma":0.0038657025,"threshold_uncertainty_score":0.9999985},"labels":[],"label_agreement":null},{"id":"W4407778016","doi":"10.1097/cji.0000000000000551","title":"The Impact of Chronic Obstructive Pulmonary Disease on Immune Checkpoint Inhibitor Effectiveness in Non-small Cell Lung Cancer: A Population Health Study","year":2025,"lang":"en","type":"article","venue":"Journal of Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; COPD; Internal medicine; Contraindication; Hazard ratio; Lung cancer; Population; Proportional hazards model; Odds ratio; Oncology; Confidence interval; Pathology","score_opus":0.007702180697183973,"score_gpt":0.32121194922370455,"score_spread":0.31350976852652057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407778016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94016373,0.057130404,0.00004672821,0.00048485314,0.0005251196,0.0016006499,0.000008515861,0.000006289502,0.000033718563],"genre_scores_gemma":[0.99319166,0.0064359526,0.000014099071,0.000066056185,0.00013680354,0.00005424025,0.0000033792003,0.000028489585,0.00006933406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771166,0.00038407271,0.0011169595,0.00018710499,0.00031157373,0.0002886251],"domain_scores_gemma":[0.9981596,0.00024582222,0.0009579004,0.00037078926,0.00019133516,0.00007458527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014619308,0.00024891898,0.0007062346,0.00037647647,0.00014241014,0.000026234196,0.0002134929,0.000055314413,0.000020908017],"category_scores_gemma":[0.000028104596,0.000153363,0.00055694336,0.0005798353,0.00006902469,0.00010054585,0.000019465975,0.00044119533,2.3875094e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07925184,0.0034172034,0.65668607,0.000511311,0.0014548665,0.00006170313,0.0012829045,0.0012800494,0.13791555,0.000004375744,0.000051599756,0.11808254],"study_design_scores_gemma":[0.009991894,0.003467668,0.9771944,0.0026657437,0.000060282546,0.000013013501,0.00040943726,0.00033231862,0.005667448,0.000048267768,0.000034579636,0.00011494329],"about_ca_topic_score_codex":0.0041564987,"about_ca_topic_score_gemma":0.00009370912,"teacher_disagreement_score":0.32050836,"about_ca_system_score_codex":0.0029241752,"about_ca_system_score_gemma":0.0015118239,"threshold_uncertainty_score":0.7646616},"labels":[],"label_agreement":null},{"id":"W4407789762","doi":"10.1038/s43018-024-00894-y","title":"Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial","year":2025,"lang":"en","type":"article","venue":"Nature Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Microsatellite instability; Microsatellite; Medicine; Oncology; Computational biology; Internal medicine; Biology; Genetics; Cancer; Immunotherapy","score_opus":0.006391366082573252,"score_gpt":0.29939753500547384,"score_spread":0.2930061689229006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407789762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973793,0.019350545,0.000001676688,0.0032530925,0.0012562807,0.0012914134,0.00017408576,0.0000483632,0.00083153415],"genre_scores_gemma":[0.99624944,0.0008153682,0.00009157984,0.0015819528,0.00008900422,0.000045739274,0.000041612075,0.000016664493,0.0010686626],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982062,0.00009665194,0.0006500326,0.00046950238,0.00028066838,0.00029697278],"domain_scores_gemma":[0.99892443,0.00008799536,0.00019527294,0.0005743394,0.00016972084,0.000048243037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038888727,0.00022049616,0.0005107665,0.00014755197,0.00006568506,0.00001429673,0.00016863066,0.00034667863,0.00004651337],"category_scores_gemma":[0.00017427948,0.0001486517,0.00019851771,0.00085447315,0.0002442719,0.000053633365,0.000070811766,0.0006751615,6.308303e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7639748,0.0008214181,0.005810192,0.00075662497,0.00042558985,0.000023707644,0.0016222654,0.00008876961,0.18309449,0.00040156968,0.0076858825,0.035294678],"study_design_scores_gemma":[0.31733334,0.0010029244,0.1983335,0.004445322,0.00030600367,0.000021834487,0.0005943936,0.00019630813,0.29232553,0.00041262925,0.18443683,0.0005913889],"about_ca_topic_score_codex":0.00067619095,"about_ca_topic_score_gemma":0.0007065738,"teacher_disagreement_score":0.44664147,"about_ca_system_score_codex":0.0003536973,"about_ca_system_score_gemma":0.0005422724,"threshold_uncertainty_score":0.606184},"labels":[],"label_agreement":null},{"id":"W4407819338","doi":"10.1016/j.clcc.2025.02.003","title":"A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1)","year":2025,"lang":"en","type":"article","venue":"Clinical Colorectal Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Colorectal cancer; Stage (stratigraphy); Oncology; Internal medicine; Open label; Cancer; Adverse effect","score_opus":0.0939701663074966,"score_gpt":0.4541728769110935,"score_spread":0.3602027106035969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407819338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98751813,0.0029058184,0.00006383228,0.0017693614,0.00057007466,0.0054490804,0.00012793306,0.00015527058,0.0014405141],"genre_scores_gemma":[0.98899573,0.0010621832,0.00039590755,0.0033541475,0.00013619968,0.0024054698,0.000030782114,0.00010269436,0.0035168692],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952062,0.00035138035,0.0014359357,0.0014023856,0.00055841776,0.0010457311],"domain_scores_gemma":[0.99769145,0.00042007444,0.00046174377,0.00066081237,0.0004047945,0.0003611085],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009774881,0.00066696573,0.0016432618,0.00024698183,0.00027218452,0.00012286124,0.0005280824,0.00025022106,0.0010014935],"category_scores_gemma":[0.00011017648,0.00047117504,0.00013560092,0.0018877786,0.00064806506,0.00034769523,0.00020668253,0.00086321746,0.0000039569063],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6027512,0.04660546,0.15111704,0.00008422348,0.0024006325,0.0005598812,0.0012782264,0.00013895522,0.013778291,0.00001259167,0.0007224551,0.18055104],"study_design_scores_gemma":[0.7077603,0.1786144,0.06921323,0.003851065,0.0013323146,0.000022270156,0.0029308249,0.0018726407,0.017854432,0.000029901064,0.014815816,0.0017028197],"about_ca_topic_score_codex":0.0073540765,"about_ca_topic_score_gemma":0.06424794,"teacher_disagreement_score":0.17884822,"about_ca_system_score_codex":0.0010766377,"about_ca_system_score_gemma":0.0024924518,"threshold_uncertainty_score":0.9999117},"labels":[],"label_agreement":null},{"id":"W4407835402","doi":"10.3390/curroncol32030121","title":"CD8+CD28+PD1− T Cells as a Prognostic Biomarker in Endometrial Cancer","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Key Research and Development Program of China; Peking University Third Hospital; Peking University","keywords":"CD28; CD8; Medicine; Immune system; Cytotoxic T cell; Tumor microenvironment; T cell; Cancer research; Immunology; Internal medicine; Biology","score_opus":0.09884957968863138,"score_gpt":0.4436260913546609,"score_spread":0.3447765116660295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407835402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93782884,0.028373368,0.00006672048,0.0039150324,0.010884612,0.0016321362,0.000024133526,0.00007722364,0.017197955],"genre_scores_gemma":[0.9918245,0.0049802326,0.000063707164,0.0007939544,0.0002639194,0.0004083509,0.000027274753,0.000017325763,0.0016207362],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850124,0.00013162819,0.0004560567,0.0003623762,0.00016418136,0.00038453224],"domain_scores_gemma":[0.9990524,0.0004531317,0.00010520131,0.0002255709,0.00008060008,0.00008307334],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037094956,0.00018260012,0.00047369936,0.00059106067,0.000050610037,0.00001302504,0.00013319612,0.0001833175,0.0009622647],"category_scores_gemma":[0.00033856067,0.00015535652,0.0001601011,0.0011298195,0.0001642692,0.000038095095,0.000061892664,0.00028969144,0.000059097383],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009510236,0.0015030418,0.12124297,0.000339439,0.00028232296,0.00009359746,0.0002506588,0.0000011571626,0.043031376,0.00015388118,0.026028955,0.79756236],"study_design_scores_gemma":[0.0153806135,0.00065892,0.1036862,0.00057409576,0.00016809307,0.000018417883,0.00008087865,0.00007517078,0.004664541,0.00011169651,0.8744085,0.00017286632],"about_ca_topic_score_codex":0.0003193981,"about_ca_topic_score_gemma":0.00047834692,"teacher_disagreement_score":0.84837955,"about_ca_system_score_codex":0.0007254588,"about_ca_system_score_gemma":0.0011510458,"threshold_uncertainty_score":0.999951},"labels":[],"label_agreement":null},{"id":"W4407866630","doi":"10.1158/2326-6074.io2025-b054","title":"Abstract B054: Immune checkpoint inhibitor-induced myocarditis and myocarditis-myositis overlap syndrome: identifying distinct molecular pathways for targeted therapeutic interventions","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Christie (Canada); McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"","keywords":"Myocarditis; Myositis; Medicine; Immunotherapy; Immune checkpoint; Immunology; Immune system; Internal medicine","score_opus":0.08281328274867114,"score_gpt":0.39597794455155993,"score_spread":0.3131646618028888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407866630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.881064,0.11122635,0.00071580836,0.0023218915,0.00141322,0.0019374345,0.00020582518,0.00012470502,0.0009907467],"genre_scores_gemma":[0.9929703,0.004127016,0.00008372535,0.00022337091,0.00010901055,0.0016465106,0.00016574064,0.00007129919,0.00060306047],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99660784,0.00029095946,0.00085485575,0.0008061336,0.00045522343,0.0009849918],"domain_scores_gemma":[0.9980001,0.00037039688,0.00017353243,0.0007696949,0.0005642969,0.000122010424],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015383553,0.00036423042,0.0008336758,0.0007224782,0.00064822397,0.00015563649,0.0003568882,0.00041112743,0.00031667078],"category_scores_gemma":[0.00024625854,0.00036104655,0.0007453365,0.0008884077,0.00077658315,0.00018573663,0.00028290568,0.0010398906,0.00001647155],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015762406,0.00018536168,0.0017884909,0.0009908827,0.0031786172,0.00022211265,0.00020785461,8.661187e-7,0.8925881,0.0005466023,0.0005430241,0.098171845],"study_design_scores_gemma":[0.007977495,0.0011679747,0.7222688,0.0034173601,0.0003376991,0.00032996715,0.0010875223,0.000035299832,0.25769168,0.001914898,0.003324209,0.00044705844],"about_ca_topic_score_codex":0.00092185347,"about_ca_topic_score_gemma":0.000054077726,"teacher_disagreement_score":0.7204803,"about_ca_system_score_codex":0.0008098987,"about_ca_system_score_gemma":0.0007034612,"threshold_uncertainty_score":0.9998841},"labels":[],"label_agreement":null},{"id":"W4407920409","doi":"10.1016/j.modpat.2025.100730","title":"Consistent Patterns of Immune-Related Adverse Events in Postmortem and Real-World Data on Immune Checkpoint Inhibitors","year":2025,"lang":"en","type":"letter","venue":"Modern Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Immune system; Medicine; Pathology; Immunology","score_opus":0.02855300140879461,"score_gpt":0.2933299929755666,"score_spread":0.264776991566772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407920409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8405856,0.002030827,0.000020751968,0.15242559,0.0012763661,0.0014260745,0.0009013033,0.000067281886,0.0012662251],"genre_scores_gemma":[0.8912968,0.0029952284,0.00009488476,0.090888195,0.0003356939,0.00007791114,0.0060512205,0.00012371957,0.008136347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964464,0.00029270657,0.0015593315,0.00093610416,0.00030979438,0.0004557067],"domain_scores_gemma":[0.9972481,0.00014791336,0.00069817505,0.0017924316,0.0000698268,0.00004352434],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007031427,0.00046639028,0.0013375265,0.00074553466,0.0000393066,0.000003144148,0.00037146194,0.00072250754,0.00006662803],"category_scores_gemma":[0.000059809245,0.000423357,0.00028656723,0.0002586932,0.0002635065,0.00004909876,0.00041028208,0.0014970596,0.000006323352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027258165,0.0033887562,0.5572333,0.01114921,0.0075101163,0.03609714,0.0056928075,0.000033135282,0.1402662,0.00007847889,0.11927013,0.092022575],"study_design_scores_gemma":[0.016969783,0.0016614527,0.93238854,0.007950688,0.0009999182,0.0007271819,0.0001871402,0.00046175378,0.004288507,0.00025786887,0.032964483,0.001142697],"about_ca_topic_score_codex":0.0031557584,"about_ca_topic_score_gemma":0.0007055175,"teacher_disagreement_score":0.37515524,"about_ca_system_score_codex":0.00024033719,"about_ca_system_score_gemma":0.00023973353,"threshold_uncertainty_score":0.99982184},"labels":[],"label_agreement":null},{"id":"W4407995068","doi":"10.3390/curroncol32030140","title":"Enhancing Care Through a Virtual Canadian Community of Practice for Managing Immune-Related Adverse Events","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre; University of Alberta; McGill University; St Mary's Hospital Centre; Jewish General Hospital","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Adverse effect; Health professionals; Peer support; Health care; Medical education; Nursing; Internal medicine","score_opus":0.04689113779857027,"score_gpt":0.4112837444175529,"score_spread":0.3643926066189826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407995068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9258173,0.020505344,0.002822654,0.004609679,0.00686933,0.002461388,0.00011058383,0.0000805214,0.036723215],"genre_scores_gemma":[0.9978639,0.0005407615,0.00051192555,0.0005630492,0.000033946428,0.00006530444,0.00013611779,0.000012573678,0.00027242006],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988143,0.00022758027,0.00045853067,0.00014463459,0.000085495725,0.0002694635],"domain_scores_gemma":[0.9987692,0.00040154738,0.00019778473,0.00030411984,0.00026553872,0.00006176888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004820372,0.00012409133,0.0003472727,0.00016915967,0.00021644647,0.0000019043715,0.00014671945,0.00013834515,0.000051027782],"category_scores_gemma":[0.0003402404,0.00012285214,0.00017308116,0.0002793341,0.00010318122,0.00009022193,0.000048825856,0.00041192252,0.0000038215585],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01845448,0.0034284368,0.015560406,0.0043464056,0.0039325003,0.00005633466,0.08905421,0.0000706672,0.0302557,0.00854344,0.006602666,0.81969476],"study_design_scores_gemma":[0.01648201,0.0029637783,0.013249758,0.0020478512,0.0010644504,0.000048934,0.07696502,0.00010363259,0.008148691,0.00066537893,0.8779432,0.00031727366],"about_ca_topic_score_codex":0.03437174,"about_ca_topic_score_gemma":0.051518116,"teacher_disagreement_score":0.8713406,"about_ca_system_score_codex":0.0010305577,"about_ca_system_score_gemma":0.0013087709,"threshold_uncertainty_score":0.9720585},"labels":[],"label_agreement":null},{"id":"W4408027112","doi":"10.1038/s41598-025-91401-5","title":"Immunogenic cell death signature predicts survival and reveals the role of VEGFA + Mast cells in lung adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Innovation-Driven Project of Central South University; National Natural Science Foundation of China","keywords":"Mast cell; Mast (botany); Signature (topology); Adenocarcinoma; Lung; Biology; Cell survival; Cancer research; Immunology; Medicine; Cell culture; Internal medicine; Genetics; Cancer","score_opus":0.007008614003886718,"score_gpt":0.2347050065350133,"score_spread":0.22769639253112658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408027112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9600756,0.031037156,0.0000062822573,0.00017670175,0.0024321736,0.0005991963,0.0000067035076,0.000017211856,0.0056489464],"genre_scores_gemma":[0.9926065,0.000121395286,0.000058292637,0.000047704798,0.000029508625,0.000015155577,0.000017597793,0.000009995498,0.007093836],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983115,0.000071218914,0.00053732505,0.00046897586,0.0003610624,0.0002499027],"domain_scores_gemma":[0.99882585,0.00006291156,0.00021783193,0.0007451283,0.00009971647,0.000048546375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016127767,0.00013616792,0.00027529115,0.00019711572,0.00012813204,0.000059917584,0.000119696306,0.000109197696,0.00006094717],"category_scores_gemma":[0.000038971255,0.00009422014,0.000108728265,0.00066264154,0.00026016746,0.000058243422,0.00008070616,0.00019666969,9.1154504e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000249846,0.00008371439,0.23882389,0.00016010244,0.000057442747,0.000113406386,0.0005014613,0.0000037718835,0.7561763,0.000027281463,0.0026171359,0.001185676],"study_design_scores_gemma":[0.0013189189,0.00009313131,0.45109585,0.0005330325,0.00015750207,0.00013244117,0.0010979365,0.00017239705,0.5279225,0.0016447542,0.015658515,0.00017303822],"about_ca_topic_score_codex":0.00012517741,"about_ca_topic_score_gemma":0.00003054002,"teacher_disagreement_score":0.22825378,"about_ca_system_score_codex":0.000072706614,"about_ca_system_score_gemma":0.00029670232,"threshold_uncertainty_score":0.38421857},"labels":[],"label_agreement":null},{"id":"W4408032454","doi":"10.3390/curroncol32030143","title":"Breast Cancer and Tumor Microenvironment: The Crucial Role of Immune Cells","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Tumor microenvironment; Medicine; Immune system; Cancer; Breast cancer; Carcinogenesis; Tumor progression; Immune checkpoint; Immunotherapy; Cancer research; Immunology; Bioinformatics; Internal medicine; Biology","score_opus":0.03953669708822205,"score_gpt":0.37976655162819783,"score_spread":0.3402298545399758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408032454","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015018957,0.99648505,9.667176e-7,0.0002275132,0.0014221543,0.00097392,0.00034890152,0.00000843095,0.00038285297],"genre_scores_gemma":[0.00004075837,0.9989715,0.000008407498,0.000061509265,0.00032165513,0.00018906324,0.000039684648,0.000018859593,0.0003485486],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99863446,0.00013137594,0.000622095,0.0002863898,0.000110479545,0.00021519899],"domain_scores_gemma":[0.999028,0.00015494332,0.0004367518,0.00030846725,0.000025714207,0.00004609621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020544592,0.00026608037,0.0014454235,0.0001050797,0.000057860885,0.0000059445165,0.00018608505,0.0001640481,0.000323264],"category_scores_gemma":[0.0000063107304,0.00016108011,0.00042885076,0.00016219335,0.0003618471,0.000012749589,0.00013068676,0.00039078476,0.0000069636176],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024123344,0.00019151285,0.000028057124,0.010990502,0.00030636342,0.0000035703965,0.000070123715,1.6522987e-8,0.00017549179,0.000008013305,0.0013400948,0.98664504],"study_design_scores_gemma":[0.00092497375,0.0001268788,0.00028504553,0.012079082,0.0016662857,0.00018970271,0.00004013363,6.7306917e-7,0.00005140653,0.0000054120615,0.9845076,0.00012279367],"about_ca_topic_score_codex":0.00008886785,"about_ca_topic_score_gemma":0.000016472297,"teacher_disagreement_score":0.9865222,"about_ca_system_score_codex":0.00032319393,"about_ca_system_score_gemma":0.0008003377,"threshold_uncertainty_score":0.6568656},"labels":[],"label_agreement":null},{"id":"W4408037006","doi":"10.1080/2162402x.2025.2473163","title":"Humanized mouse models of <i>KRAS</i> -mutated colorectal and pancreatic cancers with HLA-class-I match for pre-clinical evaluation of cancer immunotherapies","year":2025,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research; Ontario Institute for Cancer Research","keywords":"KRAS; Colorectal cancer; Medicine; Pancreatic cancer; Human leukocyte antigen; Cancer; Immunotherapy; Cancer research; Immunology; Immune system; Oncology; Internal medicine; Antigen","score_opus":0.03291333261453035,"score_gpt":0.37823464790956546,"score_spread":0.3453213152950351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408037006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97596055,0.020774523,0.00027991142,0.00043751372,0.00020645598,0.0016243717,0.000063136344,0.000033486638,0.0006200677],"genre_scores_gemma":[0.99278635,0.0048154388,0.000657436,0.00022446936,0.000020354119,0.00048878475,0.000042215583,0.000029003562,0.00093594677],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983247,0.00018181924,0.00071882823,0.00031340355,0.00022715407,0.00023407437],"domain_scores_gemma":[0.99835366,0.0002974501,0.00039763298,0.000313616,0.00061306654,0.000024553156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008105724,0.00020045567,0.0008464422,0.00015995245,0.00006671198,0.000007307189,0.000118299824,0.00021798663,0.00011137492],"category_scores_gemma":[0.000064340566,0.00015838075,0.00013206486,0.00026947632,0.00070221204,0.00007613442,0.00002887138,0.0001545522,2.4245404e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10577389,0.0006366377,0.02524934,0.0008470558,0.009540235,0.0000019141844,0.0033480756,0.00038149464,0.73865324,0.0006667444,0.0007334099,0.11416798],"study_design_scores_gemma":[0.17323525,0.017830212,0.3258291,0.003835606,0.009666099,0.000069284644,0.0048079346,0.03669015,0.41851276,0.0035628972,0.0047661774,0.001194552],"about_ca_topic_score_codex":0.0040264972,"about_ca_topic_score_gemma":0.0012797153,"teacher_disagreement_score":0.32014048,"about_ca_system_score_codex":0.00031944757,"about_ca_system_score_gemma":0.0013519678,"threshold_uncertainty_score":0.64585793},"labels":[],"label_agreement":null},{"id":"W4408061392","doi":"10.1038/s41586-025-08767-9","title":"Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors","year":2025,"lang":"en","type":"erratum","venue":"Nature","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Blockade; Cancer research; STK11; Chemistry; Pharmacology; Medicine; Internal medicine; Cancer; Biochemistry; Receptor","score_opus":0.005600839806160557,"score_gpt":0.28064526027656145,"score_spread":0.2750444204704009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408061392","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017900383,0.17194283,0.000009997435,0.08522588,0.41420767,0.0028326537,0.00037130833,0.0010209751,0.32259864],"genre_scores_gemma":[0.0041290275,0.001082864,0.00017680271,0.005565233,0.0041248333,0.00008164846,0.0009198638,0.00009848586,0.9838212],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99690235,0.00008475797,0.00068345614,0.00096040615,0.0007983958,0.0005706151],"domain_scores_gemma":[0.99806935,0.000112534726,0.0002896621,0.00087207,0.0004073138,0.0002490982],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00032724638,0.0006542794,0.00092019286,0.00061443396,0.0002470869,0.00007995248,0.0003656638,0.008412779,0.0008552809],"category_scores_gemma":[0.00046133998,0.000577878,0.00052421534,0.0018303217,0.00011799596,0.00006311042,0.000098747456,0.010520467,0.00008787286],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023440341,0.00009039654,0.00007241982,0.00047144573,0.00060876936,0.000117999894,0.0002833841,9.610043e-7,0.0009263339,0.000026908641,0.9899015,0.0051558735],"study_design_scores_gemma":[0.0014251822,0.0002229151,0.0016492099,0.0055663516,0.00037186776,0.000051296087,0.0001368815,0.000009369348,0.0030597677,0.000052225016,0.9869251,0.0005297877],"about_ca_topic_score_codex":0.00008387699,"about_ca_topic_score_gemma":0.0005020427,"teacher_disagreement_score":0.66122264,"about_ca_system_score_codex":0.00076619186,"about_ca_system_score_gemma":0.0011144319,"threshold_uncertainty_score":0.9996673},"labels":[],"label_agreement":null},{"id":"W4408072614","doi":"10.1016/j.celrep.2025.115365","title":"The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma","year":2025,"lang":"en","type":"article","venue":"Cell Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; University of Manitoba; Université de Montréal; McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"Fonds de recherche du Québec – Nature et technologies; Fonds de Recherche du Québec - Santé; Melanoma Research Alliance; Canadian Institutes of Health Research; Canada Foundation for Innovation; University of Texas MD Anderson Cancer Center; Canada Research Chairs","keywords":"Evasion (ethics); Suppressor; Immune system; Melanoma; Cancer research; PD-L1; Biology; Immunology; Immunotherapy; Cancer; Genetics","score_opus":0.006220866787223441,"score_gpt":0.24220240211219612,"score_spread":0.23598153532497268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408072614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9627682,0.018231153,0.0000019452327,0.0012077008,0.0004073617,0.0003380034,5.197629e-7,0.000023188244,0.017021902],"genre_scores_gemma":[0.986227,0.00045966406,0.00003282464,0.00022039821,0.000026888705,0.000020862955,0.000006502774,0.000009081486,0.0129968105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999101,0.000029628149,0.00037041295,0.00021241466,0.000117953015,0.00016858416],"domain_scores_gemma":[0.9993391,0.00008449254,0.000111513946,0.0004020871,0.000031934836,0.00003086123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047356286,0.00009779904,0.00018093883,0.0000645192,0.00009626114,0.00002706599,0.00004135087,0.000051460513,0.000050266102],"category_scores_gemma":[0.00006501949,0.000062748775,0.00006199708,0.0001600147,0.00009852706,0.00003057651,0.00004357097,0.00010508436,0.0000013413751],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025591166,0.00016736885,0.051657084,0.0002480765,0.00010197335,0.0019018875,0.00039243107,0.0000015244399,0.9088507,0.00004750905,0.010310999,0.023761323],"study_design_scores_gemma":[0.0012449892,0.000105005,0.4085984,0.0002980881,0.000044795393,0.00044314825,0.00019822312,0.000036501187,0.499241,0.000517645,0.0891719,0.000100333265],"about_ca_topic_score_codex":0.00019599611,"about_ca_topic_score_gemma":0.000035063535,"teacher_disagreement_score":0.40960974,"about_ca_system_score_codex":0.000050115752,"about_ca_system_score_gemma":0.00009724567,"threshold_uncertainty_score":0.25588208},"labels":[],"label_agreement":null},{"id":"W4408099016","doi":"10.1136/jitc-2024-009364","title":"Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Internal medicine; Metastasis; Adverse effect; Retrospective cohort study; Oncology; Cancer; Cardiology; Surgery","score_opus":0.012594358853010409,"score_gpt":0.32544774661509596,"score_spread":0.31285338776208554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408099016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9560997,0.037983138,0.00059242,0.0007312559,0.00079717,0.003479813,0.00028614243,0.000004470424,0.000025921234],"genre_scores_gemma":[0.963101,0.03573225,0.00044549152,0.00006629826,0.00007643173,0.00021097866,0.000009720628,0.000025406605,0.0003323761],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986157,0.000041418738,0.0007549065,0.0001619408,0.0002812875,0.0001447561],"domain_scores_gemma":[0.99816215,0.00019967141,0.0006573067,0.00024386036,0.0007151411,0.00002184835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041357073,0.00018541352,0.0006692554,0.00014289912,0.00011220648,0.000014002085,0.00013309547,0.0000419789,0.000058717287],"category_scores_gemma":[0.000019674264,0.00009867452,0.0005179394,0.00015100007,0.0001626184,0.00006170189,0.000007570748,0.00007374239,1.7510741e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2895166,0.004364946,0.24782355,0.000066606124,0.02748209,2.651152e-7,0.0047503267,0.000020478466,0.02156751,0.000022674369,0.00006118112,0.40432376],"study_design_scores_gemma":[0.066807576,0.009458477,0.86542404,0.00023779873,0.0006100993,6.5480765e-7,0.00092093454,0.000023988798,0.027786046,0.00001627954,0.028623017,0.00009107343],"about_ca_topic_score_codex":0.00024107848,"about_ca_topic_score_gemma":0.000022247556,"teacher_disagreement_score":0.6176005,"about_ca_system_score_codex":0.000276482,"about_ca_system_score_gemma":0.00017085267,"threshold_uncertainty_score":0.402383},"labels":[],"label_agreement":null},{"id":"W4408099258","doi":"10.1182/bloodadvances.2024015086","title":"Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC; University Health Network","funders":"","keywords":"Nivolumab; Medicine; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.007325588110520284,"score_gpt":0.2586844360969415,"score_spread":0.25135884798642116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408099258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788196,0.013340343,0.00017129075,0.000719821,0.00028688647,0.0024913398,0.000037619702,0.00011332924,0.0040197885],"genre_scores_gemma":[0.980077,0.00051128725,0.006641813,0.00035974476,0.000035860765,0.00045210193,0.000057442667,0.00003505915,0.0118296435],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987154,0.000033809913,0.0003356632,0.0003721816,0.00021824197,0.00032470957],"domain_scores_gemma":[0.99923646,0.00018845766,0.000147383,0.0002758643,0.00011004219,0.000041785155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000124783,0.00020460463,0.00038529615,0.00016703129,0.00010850235,0.000020728468,0.00010667452,0.00009883993,0.000028625042],"category_scores_gemma":[0.00009854103,0.00014065491,0.000085306754,0.0005500953,0.00013012522,0.00022791288,0.000023909768,0.00015788886,0.0000021675207],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11683046,0.007118469,0.79118806,0.002888304,0.0007085412,0.00012766046,0.0017212917,0.00004458536,0.004114202,0.00057418173,0.0020948106,0.07258943],"study_design_scores_gemma":[0.25918475,0.017275112,0.28168786,0.0063153803,0.0011483519,0.000025169671,0.0019214675,0.00018247537,0.029679975,0.0009136504,0.40033364,0.0013321681],"about_ca_topic_score_codex":0.00002147378,"about_ca_topic_score_gemma":0.00017109982,"teacher_disagreement_score":0.5095002,"about_ca_system_score_codex":0.00011266348,"about_ca_system_score_gemma":0.0003173559,"threshold_uncertainty_score":0.57357407},"labels":[],"label_agreement":null},{"id":"W4408179056","doi":"10.1200/jco.24.00727","title":"Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Biotech (Canada); University of Alberta; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Ipilimumab; Medicine; Refractory (planetary science); Internal medicine; Melanoma; Oncology; Open label; Randomized controlled trial; Cancer; Cancer research; Immunotherapy","score_opus":0.062457962405469206,"score_gpt":0.44722081190433793,"score_spread":0.38476284949886874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408179056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943108,0.0003422253,0.00002658818,0.0007146553,0.0007460694,0.002279545,0.0000025391982,0.00000501377,0.0015725874],"genre_scores_gemma":[0.99865574,0.00033777652,0.00048890855,0.0003089164,0.000031486426,0.000045246194,0.000007519178,0.000017285442,0.00010710391],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99477535,0.001032317,0.0031940981,0.00029002587,0.0004708536,0.00023733925],"domain_scores_gemma":[0.9940516,0.0026231639,0.0023157503,0.00029391583,0.00060059055,0.000115018265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041937637,0.00021036144,0.0029759381,0.0004717492,0.000033735723,0.000010089982,0.000314034,0.00025784352,0.00005165614],"category_scores_gemma":[0.0011672182,0.00013491261,0.0001314855,0.0005825666,0.00036746153,0.00028401785,0.00007418906,0.00087266014,7.198737e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81566554,0.04662152,0.027349096,0.000032328342,0.0008826369,0.00017856849,0.00040103085,0.000009787861,0.000049818467,0.000014948303,0.00007549452,0.10871923],"study_design_scores_gemma":[0.7504681,0.12128948,0.1256725,0.00039163732,0.00039134687,0.000005923063,0.00085211295,0.000051615785,0.000034271965,0.000026405436,0.0007147002,0.00010192298],"about_ca_topic_score_codex":0.00019129952,"about_ca_topic_score_gemma":0.0010072455,"teacher_disagreement_score":0.10861731,"about_ca_system_score_codex":0.00047722345,"about_ca_system_score_gemma":0.0015153579,"threshold_uncertainty_score":0.55015767},"labels":[],"label_agreement":null},{"id":"W4408213392","doi":"10.1136/jitc-2024-010928","title":"Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Queen's University","funders":"National Cancer Institute","keywords":"Medicine; Immunotherapy; Biomarker; Clinical trial; Cancer immunotherapy; Oncology; Cancer; Immunology; Internal medicine; Biology","score_opus":0.048968913838723954,"score_gpt":0.4640198424156276,"score_spread":0.4150509285769036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408213392","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6525933,0.13039035,0.046406966,0.029835237,0.014493358,0.12095403,0.004615071,0.00023222895,0.00047943208],"genre_scores_gemma":[0.21813394,0.33039236,0.12980415,0.04867888,0.009565,0.21383682,0.00057106424,0.0023958513,0.046621922],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99382406,0.00015814208,0.0035755634,0.0007370495,0.0007467374,0.0009584209],"domain_scores_gemma":[0.9935378,0.0011674602,0.0025826185,0.0008571212,0.0017071858,0.00014781032],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032090165,0.00074694457,0.0020470796,0.0004180203,0.0005450031,0.00009838596,0.0006475257,0.0005317619,0.0005654575],"category_scores_gemma":[0.000090007845,0.0006110111,0.004340297,0.0005448534,0.00074820174,0.00014204468,0.000027937404,0.0005033403,5.885144e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20086716,0.0014855656,0.0030891458,0.0011803694,0.020071084,0.0000012570437,0.00060933054,0.00007099845,0.3783579,0.0002432016,0.064529985,0.32949403],"study_design_scores_gemma":[0.08348555,0.008057379,0.006295837,0.0031232082,0.0005867454,0.0000119148735,0.0005278224,0.00043467333,0.19845329,0.0010273558,0.6973066,0.0006896485],"about_ca_topic_score_codex":0.00041018057,"about_ca_topic_score_gemma":0.0000914853,"teacher_disagreement_score":0.6327766,"about_ca_system_score_codex":0.00090890337,"about_ca_system_score_gemma":0.0029923085,"threshold_uncertainty_score":0.99963415},"labels":[],"label_agreement":null},{"id":"W4408236029","doi":"10.1038/s41591-025-03575-0","title":"Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Oncology; Randomized controlled trial; Biomarker; Internal medicine; Chemotherapy; Cancer; Immunotherapy; Biology","score_opus":0.03941585590825022,"score_gpt":0.41721392243320377,"score_spread":0.37779806652495357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408236029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8865091,0.09216908,0.00039447023,0.0122708455,0.0026740122,0.003921,0.000036103324,0.000103040344,0.0019223009],"genre_scores_gemma":[0.98816925,0.0048174085,0.000187234,0.003916796,0.00050263846,0.00029941986,0.000057711233,0.00003280928,0.0020167546],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971001,0.0002856331,0.0011981912,0.0004576514,0.0005953991,0.00036298786],"domain_scores_gemma":[0.9983071,0.0005026146,0.0003598282,0.00049215584,0.00022815097,0.000110162204],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015246893,0.0003576475,0.0022773843,0.0009497453,0.00005581945,0.000007207811,0.00021037883,0.00041746406,0.0011801359],"category_scores_gemma":[0.00067705405,0.0002160742,0.00040230775,0.0017459183,0.0007436215,0.00007815616,0.00002633755,0.0006658376,9.644823e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90276706,0.0005335658,0.000103452556,0.00024435355,0.001254641,0.00009436757,0.00052273914,0.0000010925655,0.05035022,0.000020758613,0.010254481,0.03385324],"study_design_scores_gemma":[0.96667534,0.0014472969,0.00046815956,0.0015837171,0.0007426307,0.0000117531545,0.00044788208,0.00039639196,0.024949621,0.000046273533,0.0030841662,0.00014674343],"about_ca_topic_score_codex":0.00068020844,"about_ca_topic_score_gemma":0.00022210088,"teacher_disagreement_score":0.10166008,"about_ca_system_score_codex":0.00040137215,"about_ca_system_score_gemma":0.000989019,"threshold_uncertainty_score":0.9997329},"labels":[],"label_agreement":null},{"id":"W4408266096","doi":"10.1016/j.lungcan.2025.108491","title":"Establishing survival benchmarks in the era of peri-operative immunotherapy","year":2025,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Immunotherapy; Peri; Internal medicine; Oncology; Intensive care medicine; Cancer","score_opus":0.012279643713661387,"score_gpt":0.3195714229083646,"score_spread":0.3072917791947032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408266096","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01232941,0.044455927,0.000035632474,0.91302687,0.0031963289,0.0018087658,0.0003039997,0.000032571836,0.024810478],"genre_scores_gemma":[0.01440424,0.011861465,0.00013097255,0.9596183,0.0038249334,0.00057705643,0.0007471418,0.000084480824,0.008751445],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977402,0.0002701798,0.00055999396,0.0004339307,0.0005883319,0.0004073581],"domain_scores_gemma":[0.998538,0.00040412307,0.00022572874,0.00067072955,0.00014309336,0.000018337681],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054581685,0.00037560108,0.00077381136,0.00018480695,0.00008403963,0.000077716635,0.0004658052,0.0005797918,0.0021542066],"category_scores_gemma":[0.00003873047,0.00025196775,0.00032088195,0.00060887047,0.0001799376,0.00011367413,0.000038189464,0.0025882868,7.5050383e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009904554,0.00005690012,0.0033651097,0.0006523042,0.00074849534,0.00011950661,0.004152991,0.0000063328907,0.0010831526,0.000020333833,0.97389686,0.014907573],"study_design_scores_gemma":[0.0026616945,0.00013937529,0.008295172,0.002582905,0.00019522164,0.000011467765,0.0005164428,0.00005943401,0.00039012887,0.00001641585,0.9848089,0.00032279312],"about_ca_topic_score_codex":0.006940096,"about_ca_topic_score_gemma":0.000670472,"teacher_disagreement_score":0.04659138,"about_ca_system_score_codex":0.00050214084,"about_ca_system_score_gemma":0.0009764457,"threshold_uncertainty_score":0.99999326},"labels":[],"label_agreement":null},{"id":"W4408326441","doi":"10.1158/1538-7445.genfunc25-a044","title":"Abstract A044: Immune profiling tools for adult and pediatric cancer: From whole genome and transcriptome sequencing to immunotherapy clinical trial design","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; BC Children's Hospital; University Health Network; Hospital for Sick Children; Université Laval; Princess Margaret Cancer Centre; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Transcriptome; Immunotherapy; Computational biology; Cancer immunotherapy; Profiling (computer programming); Genome; Immune system; Clinical trial; Medicine; Cancer; Biology; Bioinformatics; Immunology; Genetics; Internal medicine; Gene; Computer science; Gene expression","score_opus":0.2122654958545585,"score_gpt":0.4736261182405916,"score_spread":0.2613606223860331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408326441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9422943,0.046340864,0.001035387,0.0046596006,0.00065649545,0.004600541,0.00028954193,0.000046609424,0.00007665156],"genre_scores_gemma":[0.93666625,0.052119892,0.0031924865,0.0018148444,0.0018734162,0.0031045787,0.000059884078,0.000080462145,0.0010881902],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972333,0.00019380702,0.00078944815,0.00071555784,0.0004229734,0.00064496946],"domain_scores_gemma":[0.997561,0.0011907873,0.000093006165,0.00039479457,0.000550763,0.0002096829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026316755,0.00023736982,0.00063446217,0.00036454076,0.00031749913,0.00020631625,0.00022881375,0.00023932046,0.00012450168],"category_scores_gemma":[0.0004201704,0.0002076118,0.00017634402,0.0006360441,0.00021774271,0.0001866689,0.000050879295,0.0006096701,0.0000031811646],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15142438,0.00008954755,0.0015947311,0.000341226,0.00040835174,0.000008453712,0.0005877145,0.000009548432,0.7176037,0.000018784574,0.0007263628,0.12718722],"study_design_scores_gemma":[0.42976433,0.013665033,0.26273298,0.003333142,0.0009830088,0.000013742593,0.0052326927,0.0005613587,0.17870836,0.0014780439,0.10136497,0.002162334],"about_ca_topic_score_codex":0.0029140557,"about_ca_topic_score_gemma":0.00012018973,"teacher_disagreement_score":0.5388953,"about_ca_system_score_codex":0.0005456849,"about_ca_system_score_gemma":0.0018035113,"threshold_uncertainty_score":0.8466163},"labels":[],"label_agreement":null},{"id":"W4408376647","doi":"10.1136/ejhpharm-2025-eahp.312","title":"5PSQ-013 Economic evaluation of the pembrolizumab dosing regimen by body weight in a second-level private hospital","year":2025,"lang":"en","type":"article","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dosing; Pembrolizumab; Regimen; Medicine; Internal medicine; Cancer","score_opus":0.013999329691548613,"score_gpt":0.28368143944869284,"score_spread":0.26968210975714424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408376647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97014457,0.00096624024,0.000025248111,0.0029551813,0.00034002218,0.0006827236,0.000013421937,0.000013051008,0.024859559],"genre_scores_gemma":[0.9925051,0.00006188771,0.000072684714,0.00044873694,0.000026127163,0.000032456912,0.000011172341,0.0000085453785,0.006833339],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999129,0.00006629109,0.00031080702,0.00018598602,0.00016754506,0.00014036152],"domain_scores_gemma":[0.99949807,0.00003232727,0.00010149932,0.00030702646,0.000042624815,0.00001845371],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00049854215,0.000100571786,0.000188119,0.00008948174,0.00003518026,0.000012011395,0.00011356824,0.00007051786,0.0010259937],"category_scores_gemma":[0.000021864229,0.000069358684,0.00009167489,0.00015292982,0.0000662915,0.00007390248,0.00003767312,0.00009473702,0.000005539337],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005816008,0.0009235861,0.119973965,0.0004128961,0.0014671108,0.0000031022496,0.002339478,0.000024171812,0.5771335,0.0046223616,0.20302767,0.08425618],"study_design_scores_gemma":[0.023790067,0.00031603308,0.7403683,0.00059795193,0.0002859854,0.000008826866,0.00034818993,0.0066041066,0.19633865,0.0012217654,0.029833434,0.00028669386],"about_ca_topic_score_codex":0.00033513943,"about_ca_topic_score_gemma":0.00021817688,"teacher_disagreement_score":0.62039435,"about_ca_system_score_codex":0.00045640225,"about_ca_system_score_gemma":0.00036974024,"threshold_uncertainty_score":0.9998872},"labels":[],"label_agreement":null},{"id":"W4408380357","doi":"10.18502/ijaai.v24i2.18141","title":"Predictive Value of the Lung Immune Prognostic Index for Immune Checkpoint Inhibitor Therapy Outcomes in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis","year":2025,"lang":"en","type":"review","venue":"Iranian Journal of Allergy Asthma and Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Meta-analysis; Medicine; Oncology; Lung cancer; Internal medicine; Cochrane Library","score_opus":0.018263321887128075,"score_gpt":0.29928179261456234,"score_spread":0.28101847072743424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408380357","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00071239664,0.99220717,0.00017311724,0.0007702414,0.00028160523,0.0057315505,0.00009917029,0.00000605972,0.000018712302],"genre_scores_gemma":[0.0026508367,0.99585795,0.000094469084,0.00018814292,0.000032585787,0.0006404007,0.000012190438,0.00004868253,0.0004747128],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99442935,0.0008422548,0.003635652,0.00042090137,0.00028111317,0.0003907435],"domain_scores_gemma":[0.9944371,0.0007002141,0.0037363209,0.0006485726,0.00040764007,0.000070138645],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015919263,0.0007226651,0.011536303,0.0008651894,0.00010428733,0.000028532006,0.0005304195,0.0004507678,0.00006164948],"category_scores_gemma":[0.00022351375,0.00038473489,0.0047038314,0.0010146328,0.0002696081,0.00008817428,0.00013495935,0.0008333727,1.2227116e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009595457,0.00034522102,0.00021082211,0.55876106,0.4344011,0.000023287434,0.00062374014,0.0000049136725,0.000087257715,0.000010375167,0.000029116904,0.0045435946],"study_design_scores_gemma":[0.008656405,0.0021125283,0.008259029,0.285974,0.68603426,0.0005933855,0.00033846023,0.000078126635,0.00009074843,0.00001493885,0.0070877075,0.0007604385],"about_ca_topic_score_codex":0.00015065933,"about_ca_topic_score_gemma":0.000035693152,"teacher_disagreement_score":0.27278703,"about_ca_system_score_codex":0.00020988948,"about_ca_system_score_gemma":0.00089211226,"threshold_uncertainty_score":0.99986047},"labels":[],"label_agreement":null},{"id":"W4408391104","doi":"10.1101/2025.03.08.642085","title":"GSK-3 regulates CD4-CD8 cooperation needed to generate super-armed CD8+ cytolytic T cells against tumors","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Cytolysis; Cytotoxic T cell; CD8; Cell biology; Cancer research; Virology; Biology; Immunology; Immune system; Genetics; In vitro","score_opus":0.013939978311584797,"score_gpt":0.23448389764350666,"score_spread":0.22054391933192186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408391104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890962,0.0019226611,0.00046873296,0.0022162995,0.0026036766,0.0026031912,0.00040890032,0.0006184975,0.00006179696],"genre_scores_gemma":[0.9874253,0.0009942091,0.0033215636,0.0062150382,0.0010409049,0.0004450644,0.000007946356,0.0001815429,0.00036838272],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99562806,0.00020035262,0.0011359461,0.0015380111,0.00060049543,0.0008971307],"domain_scores_gemma":[0.99615836,0.00008014294,0.00035248062,0.0019479628,0.00092523807,0.0005358174],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077601784,0.0009835246,0.0012565962,0.0007477762,0.00029763512,0.0003369129,0.0005790142,0.00078178954,0.00015638661],"category_scores_gemma":[0.00018455226,0.0009941388,0.00038874542,0.0013571178,0.00017036217,0.00014949459,0.0004072401,0.00088272034,0.00012637541],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009062522,0.00021878876,0.0005373865,0.0007629485,0.00052578194,0.00011716518,0.00004902046,0.00042600837,0.9877684,0.000058124,0.008610806,0.000019276262],"study_design_scores_gemma":[0.002302352,0.00020369684,0.006503504,0.0020493108,0.00032456702,7.06333e-8,0.000015563977,0.0011203262,0.9694998,4.3398109e-7,0.016919862,0.0010605075],"about_ca_topic_score_codex":0.00032698855,"about_ca_topic_score_gemma":0.000015302538,"teacher_disagreement_score":0.018268637,"about_ca_system_score_codex":0.0010384754,"about_ca_system_score_gemma":0.002417145,"threshold_uncertainty_score":0.9992509},"labels":[],"label_agreement":null},{"id":"W4408555231","doi":"10.1055/s-0045-1804654","title":"Efficacy and Safety of Olomorasib with Pembrolizumab+Chemotherapy as First Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC","year":2025,"lang":"en","type":"article","venue":"Pneumologie","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Alberta Health Services","funders":"","keywords":"Pembrolizumab; KRAS; Medicine; Chemotherapy; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.009384943681118335,"score_gpt":0.27139573102595643,"score_spread":0.26201078734483807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408555231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995064,0.0006706437,0.00002749756,0.0017706268,0.00004823241,0.001158882,0.000015664322,0.00004018409,0.0012042766],"genre_scores_gemma":[0.9976078,0.0013881598,0.00024487168,0.0003986434,0.000009939639,0.00005154742,0.0000321759,0.000018715245,0.0002481356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989455,0.000030180048,0.0002907717,0.00033286086,0.00015542423,0.00024529625],"domain_scores_gemma":[0.9993169,0.00013920022,0.0001068337,0.0003192517,0.00006730153,0.0000505666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007014799,0.00023658096,0.00048230603,0.00013901824,0.000049878337,0.0000067373458,0.00007361796,0.000084607345,0.000044805045],"category_scores_gemma":[0.000030663432,0.00014219554,0.000045274657,0.00034527754,0.00019258693,0.000043817672,0.000019272898,0.000096481905,0.000001387005],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16531658,0.0019655384,0.6278624,0.00014457734,0.00055879867,0.000067051624,0.00045794417,0.00005870665,0.004217012,0.000044815173,0.000016367947,0.19929023],"study_design_scores_gemma":[0.053857423,0.009884818,0.92325956,0.0005669964,0.00008874724,0.000013432448,0.00007223345,0.000008911135,0.009411403,0.000027643624,0.002642531,0.00016632205],"about_ca_topic_score_codex":0.00018440874,"about_ca_topic_score_gemma":0.00017410245,"teacher_disagreement_score":0.29539716,"about_ca_system_score_codex":0.00024283622,"about_ca_system_score_gemma":0.00020488912,"threshold_uncertainty_score":0.5798566},"labels":[],"label_agreement":null},{"id":"W4408678990","doi":"10.1097/nm9.0000000000000024","title":"Deceptive Hypermetabolic Cutaneous/Subcutaneous Manifestations in a Melanoma Patient Post Nivolumab Immunotherapy on 18F-FDG PET/CT Scan","year":2025,"lang":"en","type":"article","venue":"Clinical nuclear medicine open.","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Health Sciences Centre; Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Nivolumab; Medicine; Immunotherapy; Melanoma; Nuclear medicine; Internal medicine; Cancer research; Cancer","score_opus":0.02439269737379119,"score_gpt":0.359412590094757,"score_spread":0.33501989272096583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408678990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9280095,0.0009912801,0.0000035051517,0.017589463,0.00112953,0.0017751406,0.00003453883,0.000093313494,0.050373696],"genre_scores_gemma":[0.9615555,0.002589842,0.00044368196,0.032093205,0.00018526202,0.000047672915,0.0000642516,0.000087340915,0.002933248],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963166,0.0003452259,0.0015417967,0.00081979187,0.00045690904,0.00051967974],"domain_scores_gemma":[0.9974783,0.00083895086,0.00030104996,0.00093390385,0.00020416704,0.00024364352],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00068565476,0.00040833076,0.0011354476,0.00040243202,0.00022492459,0.000058349393,0.000594873,0.00006547825,0.003317683],"category_scores_gemma":[0.0006876695,0.0003231076,0.00030377824,0.0007326476,0.0006985796,0.000105934625,0.00016547336,0.0008192641,0.000266065],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074862584,0.0057411673,0.0140342545,0.0001871579,0.0017767666,0.03197526,0.0022916174,0.000013516722,0.009535162,0.003680603,0.0727796,0.7831223],"study_design_scores_gemma":[0.042617984,0.031190306,0.18787573,0.0047109006,0.00057270547,0.016772248,0.01016115,0.000556586,0.00017251472,0.0007233199,0.70348924,0.001157273],"about_ca_topic_score_codex":0.0019117506,"about_ca_topic_score_gemma":0.00046278368,"teacher_disagreement_score":0.781965,"about_ca_system_score_codex":0.00033543765,"about_ca_system_score_gemma":0.0004262763,"threshold_uncertainty_score":0.9999221},"labels":[],"label_agreement":null},{"id":"W4408758370","doi":"10.21203/rs.3.rs-6185818/v1","title":"Maveropepimut-S, Pembrolizumab and Low-dose Cyclophosphamide in Patients with Metastatic Ovarian Cancer: Final Results from Phase 1/2 PESCO trial","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Cyclophosphamide; Oncology; Internal medicine; Ovarian cancer; Phase (matter); Cancer; Chemotherapy; Physics; Immunotherapy","score_opus":0.057437981718616075,"score_gpt":0.3983253528339085,"score_spread":0.34088737111529244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408758370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817168,0.0037848293,0.000011947604,0.0011502726,0.00043629654,0.005443465,0.0067189955,0.000046848087,0.0006905102],"genre_scores_gemma":[0.98939574,0.0039704083,0.00040503585,0.0001425861,0.00031300128,0.0007452817,0.0031103527,0.00006031018,0.0018572728],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948616,0.0006470412,0.0008783788,0.0012403298,0.0015714351,0.0008011984],"domain_scores_gemma":[0.9972969,0.0005822626,0.0002389399,0.001047898,0.00054251566,0.00029144503],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013500976,0.0004762075,0.0010165583,0.00073901104,0.00017025329,0.00015456887,0.00035598536,0.00030272422,0.00033741124],"category_scores_gemma":[0.0005114621,0.0003790408,0.00017006604,0.00077841734,0.00034155336,0.00009823017,0.0005111415,0.001952243,0.0000069167463],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91628605,0.0022850798,0.011601606,0.0014796571,0.0008098659,0.00037297036,0.0010474811,0.00003775279,0.00005017499,0.000010783801,0.002115282,0.06390331],"study_design_scores_gemma":[0.6927172,0.005505754,0.28181323,0.012237803,0.00028045737,0.0000025969177,0.00030846815,0.0004513874,0.0003223072,0.00023105931,0.0055178013,0.0006119214],"about_ca_topic_score_codex":0.02649048,"about_ca_topic_score_gemma":0.00196938,"teacher_disagreement_score":0.27021164,"about_ca_system_score_codex":0.0009894547,"about_ca_system_score_gemma":0.0031742486,"threshold_uncertainty_score":0.9998661},"labels":[],"label_agreement":null},{"id":"W4408796372","doi":"10.1016/j.labinv.2024.103240","title":"1006 Identifying H&amp;E-based Immune Patterns in Endometrial Carcinoma and Their Association with Clinicopathologic Variables, Tumor Mutational Landscape, and Survival","year":2025,"lang":"en","type":"article","venue":"Laboratory Investigation","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Carcinoma; Immune system; Biology; Cancer research; Oncology; Internal medicine; Medicine; Genetics","score_opus":0.020931220590330507,"score_gpt":0.2681628652019789,"score_spread":0.2472316446116484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408796372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99715436,0.0009993627,0.00046174353,0.00062297186,0.00023771706,0.00034186515,0.00007490348,0.00003552132,0.00007158918],"genre_scores_gemma":[0.9982258,0.000034359786,0.00050414633,0.0008373943,0.00006835976,0.000042557625,0.00022643748,0.000010736463,0.0000501848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998858,0.00021806726,0.00034634207,0.00025502226,0.00017487179,0.00014773505],"domain_scores_gemma":[0.99905896,0.00040194215,0.00020814085,0.00012401458,0.00015956369,0.000047378933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011113628,0.0001381959,0.00026758967,0.0002953466,0.00008436299,0.00006175855,0.000035912475,0.00010449646,0.000025121755],"category_scores_gemma":[0.00038125066,0.000112595306,0.000023277924,0.0007619771,0.000076439224,0.00013433116,0.000014433494,0.00017384569,8.396862e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006862402,0.00003356289,0.96276665,0.00012291994,0.000039986724,0.000009164507,0.00023326107,0.000008947408,0.035622757,0.000096093,0.000041678006,0.00033875136],"study_design_scores_gemma":[0.00725961,0.00013686303,0.97983956,0.0002572231,0.00005325695,0.0000044458498,0.00031762483,0.00027787258,0.011269702,0.00023399081,0.00023029845,0.000119576966],"about_ca_topic_score_codex":0.00015930712,"about_ca_topic_score_gemma":0.00023745527,"teacher_disagreement_score":0.024353055,"about_ca_system_score_codex":0.00015841251,"about_ca_system_score_gemma":0.00043490247,"threshold_uncertainty_score":0.45915034},"labels":[],"label_agreement":null},{"id":"W4408881986","doi":"10.1136/jitc-2024-010791","title":"Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Oxaliplatin; Cancer research; Colorectal cancer; Tumor microenvironment; Immune system; Antibody; Cancer; Immunology; Internal medicine","score_opus":0.02051684446937839,"score_gpt":0.31750323658377405,"score_spread":0.29698639211439565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408881986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85254985,0.14040127,0.00004731797,0.0044664177,0.00026707165,0.002222808,0.000015429874,0.0000078203775,0.000021985323],"genre_scores_gemma":[0.948624,0.050123774,0.00003574288,0.0008525292,0.00006387787,0.00024710866,0.0000067247893,0.000022043241,0.0000241984],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99840504,0.00021540165,0.0006391788,0.00024579107,0.00022471989,0.0002698632],"domain_scores_gemma":[0.99900717,0.0002452014,0.0004246508,0.00013462747,0.00015258197,0.000035772246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012244735,0.00024792523,0.0006834547,0.00036902537,0.00017055319,0.00006865697,0.00012145194,0.0001206697,0.000004436503],"category_scores_gemma":[0.000023557674,0.0001742968,0.00008063379,0.00029358172,0.00024829857,0.00014161294,0.000017101827,0.00034216864,3.9526856e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01116636,0.00024298215,0.03598367,0.00052174716,0.0003007997,0.0000132240575,0.0026707696,0.0000023540608,0.9052878,0.00010644712,0.000041652187,0.043662164],"study_design_scores_gemma":[0.061426997,0.0033414268,0.74042594,0.004877629,0.000085947184,0.0003311653,0.004627981,0.0003712063,0.18183367,0.0002953081,0.0019463977,0.00043630763],"about_ca_topic_score_codex":0.00046794218,"about_ca_topic_score_gemma":0.0003395255,"teacher_disagreement_score":0.7234542,"about_ca_system_score_codex":0.00018375603,"about_ca_system_score_gemma":0.00014529064,"threshold_uncertainty_score":0.7107617},"labels":[],"label_agreement":null},{"id":"W4408922776","doi":"10.1136/jitc-2024-011273","title":"Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Research Resources; National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; National Center for Advancing Translational Sciences; National Human Genome Research Institute; National Institute of Diabetes and Digestive and Kidney Diseases; NIH Office of the Director; National Heart, Lung, and Blood Institute; U.S. Food and Drug Administration; Fiona and Stanley Druckenmiller Center for Lung Cancer Research; National Cancer Institute; National Institutes of Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Princess Margaret Cancer Foundation; Larry L. Hillblom Foundation","keywords":"Discontinuation; Adverse effect; Immune system; Medicine; Immune checkpoint; Immunology; Immunotherapy; Internal medicine","score_opus":0.01334862461884169,"score_gpt":0.3210786169146588,"score_spread":0.3077299922958171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408922776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9459625,0.0378329,0.007065926,0.002260632,0.0040540043,0.0023431177,0.00028706534,0.00003236945,0.00016151006],"genre_scores_gemma":[0.97990507,0.009781707,0.0017616226,0.00018244213,0.00033628548,0.00032012555,0.00009899478,0.00006605462,0.0075476873],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972458,0.000041003248,0.0019354122,0.00020319349,0.00030115806,0.00027345956],"domain_scores_gemma":[0.9975762,0.0001018296,0.0012871646,0.000295007,0.0006975284,0.000042300064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001074119,0.00023074755,0.0007016828,0.000353571,0.00016159577,0.000007838291,0.00016427756,0.00019105151,0.0002086896],"category_scores_gemma":[0.00008282791,0.0001901438,0.0011693097,0.00034711993,0.00012193144,0.00020057865,0.000014414413,0.00021595124,3.446987e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026327299,0.00046772402,0.0035529984,0.00036833406,0.0024335324,3.8713353e-7,0.00049451244,0.00006679554,0.8854724,0.00007833978,0.0005962763,0.08014138],"study_design_scores_gemma":[0.04833641,0.003082829,0.17191195,0.0041966317,0.0007302514,0.00002901671,0.00046754288,0.0009175247,0.72421515,0.0012367246,0.044592664,0.0002832975],"about_ca_topic_score_codex":0.00012099824,"about_ca_topic_score_gemma":0.00001097354,"teacher_disagreement_score":0.16835895,"about_ca_system_score_codex":0.00034147056,"about_ca_system_score_gemma":0.00049618934,"threshold_uncertainty_score":0.7753839},"labels":[],"label_agreement":null},{"id":"W4408924510","doi":"10.3390/curroncol32040195","title":"Incidence Rates of Cutaneous Immune-Related Adverse Events in Patients with Lung Cancer: A Systematic Review and Meta-Analysis","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Medicine; Meta-analysis; Lung cancer; Incidence (geometry); Adverse effect; Systematic review; Immune system; Dermatology; Intensive care medicine; MEDLINE; Oncology; Internal medicine; Immunology","score_opus":0.06634603413999687,"score_gpt":0.430820477855994,"score_spread":0.36447444371599713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408924510","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011255602,0.99340135,0.0000024529138,0.00005038193,0.00015860265,0.0061090873,0.00012716162,0.000011451011,0.000026956192],"genre_scores_gemma":[0.00022882641,0.9980696,0.000013839714,0.00006416029,0.000004232093,0.0011434285,0.0002147294,0.00001940828,0.00024176142],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99610794,0.0007503762,0.0021409155,0.00048027388,0.00027914872,0.00024132388],"domain_scores_gemma":[0.99691087,0.00041092953,0.001838938,0.0005452456,0.00022914648,0.00006488541],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005908447,0.00046693234,0.011267722,0.0006219909,0.000028350674,0.0000017959734,0.00022352653,0.00024338666,0.00026779034],"category_scores_gemma":[0.00018539312,0.00027509674,0.0016341346,0.0018363979,0.0001134231,0.000038909027,0.00008551852,0.000416982,0.0000018391737],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012995498,0.0002764744,0.0017935311,0.8660067,0.121351995,0.000012552812,0.000042516585,5.1331733e-7,1.7374528e-8,0.0000014165554,0.000032610853,0.0103517305],"study_design_scores_gemma":[0.0009372506,0.00023358759,0.0002071292,0.2507255,0.7429867,0.000023213182,0.0000057709262,0.0000038796047,6.489059e-8,6.6050313e-7,0.0046887454,0.00018752771],"about_ca_topic_score_codex":0.000113431015,"about_ca_topic_score_gemma":0.000106636704,"teacher_disagreement_score":0.62163466,"about_ca_system_score_codex":0.00064588216,"about_ca_system_score_gemma":0.00094096555,"threshold_uncertainty_score":0.99997014},"labels":[],"label_agreement":null},{"id":"W4408942933","doi":"10.6004/jnccn.2024.7252","title":"TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy","year":2025,"lang":"en","type":"article","venue":"Journal of the National Comprehensive Cancer Network","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Lenvatinib; Medicine; Immunotherapy; Oncology; Endometrial cancer; Internal medicine; Randomized controlled trial; Carcinoma; Cancer","score_opus":0.049249119791007004,"score_gpt":0.3769303939944209,"score_spread":0.3276812742034139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408942933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96326363,0.03314748,0.00003458995,0.0003387201,0.0007090183,0.0023892515,0.000020775515,0.000004481476,0.000092025264],"genre_scores_gemma":[0.99555343,0.0032648044,0.00052840315,0.0001201723,0.00040746335,0.000058167818,0.00000601947,0.000017681421,0.000043850083],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971298,0.0005570313,0.0011554783,0.00021894964,0.00072315655,0.00021558236],"domain_scores_gemma":[0.9944662,0.002712475,0.0013571756,0.00016915219,0.001263237,0.00003179951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006213981,0.00026389732,0.0013961572,0.0002777766,0.000097214244,0.000012707036,0.00016565452,0.000058568272,0.000023789638],"category_scores_gemma":[0.00023064938,0.00016107057,0.00034377925,0.0011080324,0.00024211488,0.00008426765,0.000029612733,0.00021354533,5.5822312e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8684163,0.0013660901,0.053087894,0.00008474557,0.0044960417,0.00000473065,0.0010612151,0.025324522,0.005835702,0.00001925387,0.00014048713,0.04016301],"study_design_scores_gemma":[0.55714536,0.0070134304,0.43006206,0.0016047925,0.0008779678,0.000010814238,0.0002626503,0.0010018983,0.0010140479,0.000013895059,0.00084659253,0.00014648766],"about_ca_topic_score_codex":0.00015858928,"about_ca_topic_score_gemma":0.000043375854,"teacher_disagreement_score":0.37697417,"about_ca_system_score_codex":0.0006106244,"about_ca_system_score_gemma":0.0006260665,"threshold_uncertainty_score":0.6568267},"labels":[],"label_agreement":null},{"id":"W4408943423","doi":"10.1136/jitc-2024-010419","title":"SITC strategic vision: prevention, premalignant immunity, host and environmental factors","year":2025,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Western University; Lawson Health Research Institute; Ontario Institute for Cancer Research","funders":"University of Texas MD Anderson Cancer Center; Society for Immunotherapy of Cancer","keywords":"Immune system; Immunotherapy; Medicine; Immunology; Cancer; Immunity; Cancer immunotherapy; Microbiome; Bioinformatics; Internal medicine; Biology","score_opus":0.047144551982480264,"score_gpt":0.3938186957324736,"score_spread":0.34667414374999334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408943423","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025650852,0.9939005,0.000040728763,0.00007913237,0.0010506052,0.0018290476,0.00036804256,0.0000163367,0.00015054981],"genre_scores_gemma":[0.00035250536,0.9931792,0.00013523185,0.000077112105,0.00022921072,0.00012727163,0.00016946945,0.00008270269,0.0056473045],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99738556,0.0001534452,0.0013621086,0.00033867703,0.00040361352,0.00035660318],"domain_scores_gemma":[0.99791837,0.00022112892,0.0012397813,0.0004248424,0.00008656252,0.00010934714],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005365209,0.0005814038,0.0021326756,0.00040234387,0.0002936977,0.000087371525,0.00029726303,0.00040383718,0.00064586796],"category_scores_gemma":[0.000011219955,0.00040399216,0.0015808087,0.00023345336,0.00022626453,0.00014235212,0.00004762517,0.0005772696,6.3706887e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015647989,0.00033826526,0.00008357645,0.013838879,0.0040658433,0.000005522354,0.00020611112,2.6555423e-7,0.0016132399,0.000020683274,0.00069119636,0.9775716],"study_design_scores_gemma":[0.0036996321,0.0016972458,0.0003017238,0.042465262,0.0018598121,0.00021061114,0.00029590796,0.0000015158224,0.000247136,0.00014210187,0.94866085,0.00041822123],"about_ca_topic_score_codex":0.000056815563,"about_ca_topic_score_gemma":0.000012272482,"teacher_disagreement_score":0.9771534,"about_ca_system_score_codex":0.00046457333,"about_ca_system_score_gemma":0.0012159022,"threshold_uncertainty_score":0.9998412},"labels":[],"label_agreement":null},{"id":"W4408979201","doi":"10.1016/s1556-0864(25)00220-5","title":"25P: Durvalumab with or without tremelimumab plus chemotherapy as first-line treatment for metastatic NSCLC: Results from the phase III POSEIDON extended China cohort","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Durvalumab; Tremelimumab; Oncology; Chemotherapy; Cohort; Internal medicine; Phase (matter); China; Cancer; Immunotherapy","score_opus":0.036060204868246334,"score_gpt":0.4327114401567048,"score_spread":0.39665123528845847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9462226,0.0027226144,0.0034041468,0.04294094,0.00079784176,0.0024151676,0.00013540167,0.000034146276,0.0013271222],"genre_scores_gemma":[0.97937226,0.0029260556,0.00626335,0.0034692269,0.00056108297,0.00010435363,0.00007544093,0.000048433474,0.0071797855],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99754864,0.00023439355,0.0011547229,0.0003462265,0.0003663767,0.0003496587],"domain_scores_gemma":[0.99715257,0.000882569,0.0010345596,0.0004915357,0.00030146708,0.00013728645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012099063,0.0003507106,0.001343342,0.00018852527,0.00023214998,0.000037756825,0.00026541945,0.00015129986,0.00020006752],"category_scores_gemma":[0.00020213333,0.00016826847,0.0004109025,0.0003548836,0.00021255015,0.000103169456,0.000018498497,0.00031010914,0.0000027281874],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5745711,0.001985366,0.00015986922,0.000038169495,0.00434178,0.0002538695,0.0017023383,0.000035263405,0.0017622206,0.000008574694,0.0028706468,0.4122708],"study_design_scores_gemma":[0.4329488,0.11989191,0.016301828,0.0020436803,0.011218412,0.0034662252,0.003196841,0.003400772,0.02013099,0.0007701332,0.38597533,0.00065506337],"about_ca_topic_score_codex":0.00071476004,"about_ca_topic_score_gemma":0.0011286158,"teacher_disagreement_score":0.41161576,"about_ca_system_score_codex":0.001328297,"about_ca_system_score_gemma":0.0024303594,"threshold_uncertainty_score":0.6861789},"labels":[],"label_agreement":null},{"id":"W4408979626","doi":"10.1016/s1556-0864(25)00323-5","title":"128TiP: ABBIL1TY NSCLC-06: A global, randomized, open-label, phase III trial of acasunlimab in combination with pembrolizumab (Pembro) vs docetaxel in checkpoint inhibitor (CPI)-experienced patients with PD-L1+ metastatic non-small cell lung cancer (mNSCLC)","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Docetaxel; Oncology; Internal medicine; Open label; Randomized controlled trial; Chemotherapy; Immunotherapy; Cancer","score_opus":0.019421263798491486,"score_gpt":0.39840942607270036,"score_spread":0.3789881622742089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905021,0.0013826042,0.00073805096,0.0010823649,0.0006732731,0.004412983,0.000026379732,0.000008146975,0.0011740514],"genre_scores_gemma":[0.99472046,0.0004961041,0.0037156788,0.0004442996,0.000071515846,0.0003161196,0.000019986677,0.000026517739,0.00018931561],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99562955,0.00073333643,0.0021804718,0.00040532846,0.0005924438,0.000458857],"domain_scores_gemma":[0.99635255,0.00032779147,0.0021694282,0.0003188493,0.00068065024,0.00015072999],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023651195,0.0003922975,0.0025518325,0.00063183805,0.000070628164,0.000048504895,0.0004481209,0.00022216268,0.00008541934],"category_scores_gemma":[0.00020826487,0.00026320422,0.00020995323,0.0012705554,0.00036746822,0.00039763676,0.00010756778,0.0006249822,6.8640435e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9615209,0.012636343,0.00312066,0.00043674916,0.00067509344,0.00017892118,0.0015427909,0.000043143766,0.002723138,0.000014549359,0.0002345781,0.016873142],"study_design_scores_gemma":[0.97082895,0.014756488,0.0041495464,0.0026137829,0.0010606479,0.000072473056,0.0008445533,0.00077751296,0.0042655068,0.00005208119,0.00030838716,0.00027006617],"about_ca_topic_score_codex":0.0008458757,"about_ca_topic_score_gemma":0.00091023534,"teacher_disagreement_score":0.016603075,"about_ca_system_score_codex":0.0018943447,"about_ca_system_score_gemma":0.0033842584,"threshold_uncertainty_score":0.999982},"labels":[],"label_agreement":null},{"id":"W4408979978","doi":"10.1016/s1556-0864(25)00334-x","title":"138P: Outcomes by treatment (tx) cycles (cyc) with perioperative nivolumab (NIVO) in patients (pts) with resectable NSCLC from CheckMate 77 T study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Nivolumab; Perioperative; Oncology; Internal medicine; Surgery; Cancer; Immunotherapy","score_opus":0.013623294942393761,"score_gpt":0.3809814202040986,"score_spread":0.3673581252617048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935449,0.0008379819,0.000026302821,0.0025076966,0.00024297061,0.0007884919,0.000022582246,0.000011992731,0.0020171234],"genre_scores_gemma":[0.9950521,0.00014064745,0.0007585837,0.00050055457,0.000047506535,0.00003444921,0.000012330414,0.000022256474,0.0034315651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981792,0.0002926039,0.00064492156,0.0002656429,0.00033165878,0.00028597194],"domain_scores_gemma":[0.9988413,0.00014345336,0.0004220678,0.00025279948,0.00024879145,0.0000915834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003432978,0.0002615018,0.0009770511,0.00028764503,0.000098415,0.000032982818,0.00015441782,0.00012520247,0.00017732619],"category_scores_gemma":[0.000034976598,0.00014790302,0.00011127189,0.000336314,0.00012862482,0.00016271895,0.000029934714,0.0003250867,0.000003334564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08285118,0.005897842,0.80186003,0.000020291947,0.0020694875,0.00033916766,0.0036944714,0.000017494614,0.0015256559,0.0000012205337,0.0009844713,0.100738674],"study_design_scores_gemma":[0.036058947,0.04223633,0.8956613,0.0005026718,0.00070404983,0.00004752088,0.008344861,0.000019322648,0.0028091127,0.000010598703,0.013383349,0.00022192014],"about_ca_topic_score_codex":0.0016713925,"about_ca_topic_score_gemma":0.0031549097,"teacher_disagreement_score":0.10051675,"about_ca_system_score_codex":0.0016224646,"about_ca_system_score_gemma":0.0007741998,"threshold_uncertainty_score":0.603131},"labels":[],"label_agreement":null},{"id":"W4408980189","doi":"10.1016/s1556-0864(25)00348-x","title":"154P: Prognostic significance of T cell subtypes in the tumour microenvironment for recurrence following curative-intent resection in early-stage NSCLC","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver Coastal Health Research Institute; University of British Columbia; University of British Columbia Hospital; Vancouver General Hospital","funders":"Cancer Research Institute","keywords":"Medicine; Stage (stratigraphy); Oncology; Resection; Surgical resection; Internal medicine; Surgery","score_opus":0.02709275367169702,"score_gpt":0.3813607072995867,"score_spread":0.3542679536278897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408980189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991873,0.0020231225,0.00093234313,0.0035765893,0.00052059727,0.0007581728,0.0000036152794,0.0000017579823,0.0003108048],"genre_scores_gemma":[0.99790406,0.00034155417,0.0011542026,0.0002399182,0.000045349687,0.00003967937,0.0000012669994,0.0000057329867,0.000268214],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986037,0.00028492333,0.0006448749,0.00012814577,0.0001654204,0.00017295782],"domain_scores_gemma":[0.9988611,0.0005035869,0.00043570236,0.00010972509,0.000066396555,0.000023487743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016645213,0.00009558184,0.00037204442,0.0002512149,0.000032312957,0.000007626051,0.00015661075,0.000083144485,0.000009863196],"category_scores_gemma":[0.00021774299,0.00006509493,0.00018129827,0.00030835893,0.00008138751,0.00007119599,0.000016311755,0.00033653385,5.2215034e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038510203,0.002064084,0.17536499,0.0006767269,0.0002230722,0.0003196833,0.005810786,0.00008632427,0.71731615,0.000030763553,0.0010834252,0.05851378],"study_design_scores_gemma":[0.0068997582,0.0114124445,0.6895608,0.0029995972,0.00034792782,0.00010797205,0.011330937,0.00017697141,0.25751606,0.00037766137,0.019065691,0.00020421567],"about_ca_topic_score_codex":0.00008578771,"about_ca_topic_score_gemma":0.00021619248,"teacher_disagreement_score":0.5141958,"about_ca_system_score_codex":0.00042754077,"about_ca_system_score_gemma":0.0003252143,"threshold_uncertainty_score":0.26544943},"labels":[],"label_agreement":null},{"id":"W4408980834","doi":"10.1016/s1556-0864(25)00386-7","title":"192P: Differential effect of proton pump inhibitors (PPIs) and antibiotics (ATB) on clinical outcomes from immunotherapy or placebo in patients with locally advanced, unresectable NSCLC who have not progressed following chemoradiation therapy (cCTRT): A post-hoc analysis of the PACIFIC trial","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Placebo; Immunotherapy; Internal medicine; Oncology; Antibiotics; Chemoradiotherapy; Chemotherapy; Cancer; Pathology; Alternative medicine","score_opus":0.01471447977675807,"score_gpt":0.3835884075308421,"score_spread":0.36887392775408406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408980834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950258,0.00030552558,0.000033626144,0.00083747075,0.00066675106,0.0030632168,0.000026172584,0.000005816722,0.000035636098],"genre_scores_gemma":[0.9991466,0.00032240088,0.0001663876,0.00017627308,0.0000721217,0.000016406348,0.000016219165,0.00002137699,0.00006224882],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9965644,0.0008900237,0.0014983019,0.0002733719,0.00054270495,0.00023120754],"domain_scores_gemma":[0.99651015,0.0012924392,0.001565699,0.00033933745,0.00023259148,0.00005975995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014747382,0.00027015808,0.0018393587,0.0005811279,0.00007352155,0.000022312417,0.00021016822,0.00030165876,0.000032331893],"category_scores_gemma":[0.0003066867,0.00013778164,0.0006472583,0.0008458956,0.00023680831,0.00011367313,0.000033235407,0.0005018795,9.828349e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5042197,0.0010020642,0.38308284,0.00004987173,0.0031631726,0.0000092659,0.00019814706,0.000012853133,0.003552093,3.4399562e-7,0.00000781458,0.10470185],"study_design_scores_gemma":[0.1669585,0.05429251,0.7370738,0.0010015481,0.001575722,0.0000020369134,0.00022747587,0.00017280517,0.03834588,0.0000036604656,0.00018766958,0.00015844245],"about_ca_topic_score_codex":0.000054925567,"about_ca_topic_score_gemma":0.00009117115,"teacher_disagreement_score":0.3539909,"about_ca_system_score_codex":0.00025102834,"about_ca_system_score_gemma":0.0005459163,"threshold_uncertainty_score":0.5618572},"labels":[],"label_agreement":null},{"id":"W4408989062","doi":"10.1016/s1556-0864(25)00538-6","title":"346P: Multi-omics approach to identify factors underlying antibiotics (ABX)-mediated immunosuppression in a prospective trial of cancer immunotherapy","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"ABX test; Medicine; Immunosuppression; Immunotherapy; Omics; Cancer; Cancer immunotherapy; Oncology; Immunology; Internal medicine; Bioinformatics","score_opus":0.05866612740197183,"score_gpt":0.47835019139768215,"score_spread":0.41968406399571034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408989062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918672,0.0027280264,0.0014302145,0.0008077096,0.0017692916,0.001079158,0.000013395445,0.0000167362,0.0002882642],"genre_scores_gemma":[0.9933379,0.0018182738,0.0042060814,0.00029209835,0.00009058165,0.000006706285,0.0000059435197,0.000030395162,0.00021197172],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99774015,0.00025041215,0.0012237849,0.00021824909,0.00028924705,0.00027817473],"domain_scores_gemma":[0.9982686,0.00027030558,0.0008353081,0.00023416693,0.0003154758,0.00007612397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010022171,0.00021224878,0.0010066387,0.00078994717,0.00005026815,0.000019344145,0.0002573926,0.0003254065,0.000021459024],"category_scores_gemma":[0.00024441862,0.00015933112,0.0003044803,0.00078062207,0.00014074067,0.00011963874,0.000052870393,0.0005738388,5.351216e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28699505,0.0030103382,0.05395821,0.00022452457,0.0011132458,0.00003237158,0.004237361,0.00010588647,0.59606606,0.000010613151,0.0002564609,0.053989865],"study_design_scores_gemma":[0.09685722,0.0061757723,0.7552941,0.0017918905,0.000383669,0.00007244211,0.00719005,0.0003901835,0.12723976,0.00011388955,0.004148264,0.00034274173],"about_ca_topic_score_codex":0.00031882085,"about_ca_topic_score_gemma":0.00007818727,"teacher_disagreement_score":0.7013359,"about_ca_system_score_codex":0.0010308992,"about_ca_system_score_gemma":0.0010581553,"threshold_uncertainty_score":0.6497334},"labels":[],"label_agreement":null},{"id":"W4409009786","doi":"10.2139/ssrn.5188639","title":"Low Ft3/Ft4 Ratio as a Proxy for Muscle Wasting in Patients with Advanced Non-Small Cell Lung Cancer Treated with Upfront Pembrolizumab","year":2025,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Pembrolizumab; Wasting; Proxy (statistics); Lung cancer; Business; Internal medicine; Oncology; Medicine; Computer science; Cancer","score_opus":0.004282499487013814,"score_gpt":0.24345521749845403,"score_spread":0.23917271801144022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409009786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98457277,0.0057145306,0.0046984856,0.0002698239,0.00021367602,0.003888337,0.000049440452,0.000045387824,0.0005475597],"genre_scores_gemma":[0.9910645,0.0033948196,0.00063025084,0.00018385552,0.00021259533,0.0007167343,0.00014439528,0.00009619454,0.00355667],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99613905,0.00006638459,0.0006366132,0.0006718801,0.0004166684,0.0020693885],"domain_scores_gemma":[0.9983897,0.000047818754,0.0006012756,0.0003863796,0.00045407834,0.000120698],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005342516,0.0005641386,0.0007898362,0.00035072045,0.0001865248,0.00007084935,0.0002806226,0.00026858656,0.00003710407],"category_scores_gemma":[0.00002444145,0.0004103754,0.00022162903,0.000323676,0.000054644705,0.00011011056,0.00006777805,0.0027292583,6.595574e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.1476503,0.0030669118,0.61277527,0.0052289106,0.005990009,0.000071996474,0.0030650422,0.009971709,0.003725377,0.00012885797,0.00027018265,0.20805544],"study_design_scores_gemma":[0.42389646,0.049011808,0.38006824,0.06698997,0.007486114,0.00043968396,0.0073680347,0.025803069,0.027907003,0.002090012,0.0021785721,0.0067610187],"about_ca_topic_score_codex":0.000782496,"about_ca_topic_score_gemma":0.004187716,"teacher_disagreement_score":0.27624616,"about_ca_system_score_codex":0.0044577452,"about_ca_system_score_gemma":0.0151070105,"threshold_uncertainty_score":0.99983484},"labels":[],"label_agreement":null},{"id":"W4409144909","doi":"10.1016/j.ejcskn.2025.100586","title":"A Phase 3 trial of fixed-dose combination of fianlimab + cemiplimab vs relatlimab + nivolumab in patients with unresectable or metastatic melanoma","year":2025,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Nivolumab; Medicine; Oncology; Melanoma; Internal medicine; Phase (matter); Metastatic melanoma; Radiology; Cancer research; Immunotherapy; Cancer; Physics","score_opus":0.01461065501911946,"score_gpt":0.3161808704942925,"score_spread":0.30157021547517304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409144909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953731,0.00090195733,0.00005052413,0.0004029711,0.00034500938,0.0015640196,0.00011213481,0.000016734184,0.0012335572],"genre_scores_gemma":[0.99761164,0.0001720433,0.00027370607,0.00015501653,0.00002253813,0.00018199738,0.000071298375,0.000023645613,0.0014881069],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983095,0.00008806966,0.0006250029,0.00028577188,0.00043940573,0.0002522364],"domain_scores_gemma":[0.99891907,0.00015729167,0.0003117111,0.0003608894,0.00021023827,0.000040798004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030256915,0.00018937892,0.00063683034,0.0003538756,0.000037393744,0.00000993798,0.00013526775,0.00008450796,0.0005231688],"category_scores_gemma":[0.000099466066,0.00014115393,0.00011202696,0.0010046231,0.00013031159,0.0001207782,0.000033582444,0.00016811724,0.0000012821523],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.914375,0.008241073,0.025925254,0.0006999059,0.0007816792,0.000016349628,0.00078660337,0.000016226857,0.0011097743,0.00007950501,0.002396537,0.045572106],"study_design_scores_gemma":[0.8661351,0.01687494,0.093892924,0.0019276697,0.00049857155,0.0000022583906,0.00024723407,0.00027571316,0.015710112,0.00008042104,0.0040824823,0.0002725315],"about_ca_topic_score_codex":0.0012759982,"about_ca_topic_score_gemma":0.0005614326,"teacher_disagreement_score":0.06796767,"about_ca_system_score_codex":0.0003916392,"about_ca_system_score_gemma":0.00076158444,"threshold_uncertainty_score":0.575609},"labels":[],"label_agreement":null},{"id":"W4409178690","doi":"10.1080/1750743x.2025.2485012","title":"Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data","year":2025,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; McMaster University; Pancreas Centre (Canada); University Health Network; Kingston Health Sciences Centre; Canadian Partnership Against Cancer","funders":"Canadian Cancer Society Research Institute; AstraZeneca","keywords":"Immune system; Medicine; Immunology; Oncology; Cancer research","score_opus":0.012069763549505152,"score_gpt":0.29527718584675666,"score_spread":0.2832074222972515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409178690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840057,0.013351852,0.00009287428,0.0009635772,0.00038781404,0.00078910706,0.00021078947,0.00003843765,0.00015988086],"genre_scores_gemma":[0.99730206,0.00076004374,0.00019273383,0.0008204681,0.000026303744,0.000042742307,0.00020810176,0.000028914985,0.00061861053],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975007,0.00026211055,0.0009864919,0.00042823766,0.0005504226,0.00027199642],"domain_scores_gemma":[0.99735975,0.00037906485,0.0004213465,0.0016342606,0.00016214678,0.000043437412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009790375,0.00027284812,0.0009430433,0.0010258108,0.00006242008,0.000016491102,0.0005383129,0.0001714846,0.00011699402],"category_scores_gemma":[0.00019224104,0.0002247218,0.00046692367,0.0021809347,0.0002246307,0.00007453616,0.00012858352,0.00021418525,0.0000023382897],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043664318,0.00094946113,0.0009871456,0.00017390875,0.014180031,0.000010317421,0.0011662347,0.000009600095,0.8600155,0.000048594186,0.00069253304,0.07810236],"study_design_scores_gemma":[0.0069011576,0.001857529,0.33549947,0.0005395888,0.0020426635,0.0000021480914,0.00017551977,0.000093751434,0.6441413,0.000011212905,0.008563307,0.00017236055],"about_ca_topic_score_codex":0.0005498447,"about_ca_topic_score_gemma":0.000017991973,"teacher_disagreement_score":0.33451232,"about_ca_system_score_codex":0.00014787311,"about_ca_system_score_gemma":0.00039805289,"threshold_uncertainty_score":0.9163889},"labels":[],"label_agreement":null},{"id":"W4409252004","doi":"10.1136/jitc-2024-011049","title":"Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Project Data Sphere","keywords":"Medicine; Uveitis; Delphi method; Adverse effect; Family medicine; Disease; Usability; Ophthalmology; Internal medicine; Artificial intelligence; Computer science","score_opus":0.025072726287116723,"score_gpt":0.3355969537691115,"score_spread":0.31052422748199476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409252004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91747516,0.07263742,0.0005043221,0.0035197935,0.0029607622,0.0020474012,0.0004665713,0.000029584287,0.00035900998],"genre_scores_gemma":[0.98462635,0.0102765,0.0012966458,0.00027849124,0.00012187706,0.00030027857,0.000049431066,0.0000681942,0.0029822006],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99711823,0.000053231637,0.0019350534,0.00023175334,0.0002962163,0.00036548695],"domain_scores_gemma":[0.99744475,0.00023268162,0.0011496787,0.0003955624,0.0006749346,0.000102374295],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007336498,0.0002859204,0.00078502187,0.00041576492,0.00024443265,0.000008123684,0.00021548533,0.00015954862,0.00033656813],"category_scores_gemma":[0.00013716544,0.00024656358,0.0017737322,0.00041182528,0.00026483386,0.00008094838,0.000020095862,0.0002547786,8.719715e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06341969,0.000959314,0.0061963894,0.0010983375,0.0054630907,0.000006646085,0.00048385837,0.00015824966,0.8899759,0.0005831886,0.0015677129,0.030087616],"study_design_scores_gemma":[0.09795777,0.0036297431,0.20974962,0.011238313,0.002529563,0.00021497255,0.0013561617,0.0004805392,0.5955756,0.014841457,0.06138962,0.0010366874],"about_ca_topic_score_codex":0.00016782836,"about_ca_topic_score_gemma":0.000006586546,"teacher_disagreement_score":0.29440036,"about_ca_system_score_codex":0.00033439277,"about_ca_system_score_gemma":0.0012030365,"threshold_uncertainty_score":0.9999987},"labels":[],"label_agreement":null},{"id":"W4409292902","doi":"10.1038/s41598-025-89308-2","title":"Integrating bioinformatics with experimental validation unveils immunological and prognostic significance of PVRIG in pan-cancer","year":2025,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Clinical Research Institute","funders":"","keywords":"Cancer; Bioinformatics; Computational biology; Medicine; Biology; Internal medicine","score_opus":0.01620304025687713,"score_gpt":0.2963370912280751,"score_spread":0.280134050971198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409292902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99546117,0.0018108389,0.00025348508,0.00011009662,0.00059340824,0.00060552824,0.0000012945766,0.00001976507,0.0011443886],"genre_scores_gemma":[0.99754244,0.000031818265,0.001785306,0.000030246865,0.0000064942037,0.000071302195,0.000015624215,0.000003857162,0.000512893],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99891317,0.000020330446,0.0004722865,0.0002559378,0.00019945431,0.00013884254],"domain_scores_gemma":[0.9993948,0.000037971146,0.00021658656,0.00024121588,0.00008738424,0.000022055094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005346338,0.00009382543,0.0001978072,0.000170444,0.00006643878,0.00005418236,0.00003781532,0.000048126472,0.000044314762],"category_scores_gemma":[0.00008253051,0.00006274147,0.000031569412,0.00057423825,0.00038875715,0.000110827845,0.000024939405,0.00008407768,3.4268683e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005250932,0.0002483655,0.28332102,0.00021186465,0.00007205737,0.0000590179,0.0013325079,0.000009518456,0.68459725,0.00006324859,0.00029753766,0.029262483],"study_design_scores_gemma":[0.0010995412,0.00030117237,0.08641081,0.0013246167,0.000040580388,0.00009930066,0.0028494045,0.0003428456,0.9057319,0.0002257573,0.0014363133,0.00013775955],"about_ca_topic_score_codex":0.00013642077,"about_ca_topic_score_gemma":0.00003397733,"teacher_disagreement_score":0.22113462,"about_ca_system_score_codex":0.00008709328,"about_ca_system_score_gemma":0.00025704823,"threshold_uncertainty_score":0.2558523},"labels":[],"label_agreement":null},{"id":"W4409349036","doi":"10.1016/j.jhep.2025.03.033","title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","year":2025,"lang":"en","type":"article","venue":"Journal of Hepatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"AstraZeneca; AstraZeneca United States","keywords":"Durvalumab; Tremelimumab; Medicine; Oncology; Internal medicine; Cancer; Immunotherapy; Nivolumab","score_opus":0.017698643337023697,"score_gpt":0.30068675652392984,"score_spread":0.28298811318690614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409349036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99176824,0.0022027951,0.000016876094,0.004014877,0.0008476902,0.00024326987,0.000007842601,0.0000048254306,0.00089360063],"genre_scores_gemma":[0.99831235,0.00050638977,0.00007734253,0.00070027745,0.00008828124,0.0000031379384,0.0000028143897,0.000009811992,0.00029956893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828416,0.00033990064,0.00075533014,0.00014382918,0.00027219407,0.00020461173],"domain_scores_gemma":[0.99883133,0.00035235958,0.00034267217,0.00027978074,0.00015797252,0.00003590782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006828279,0.00012538361,0.0007218159,0.00020275448,0.000041155672,0.000009498142,0.00025277276,0.000099185265,0.00030663845],"category_scores_gemma":[0.00014200002,0.00008081447,0.00015573858,0.00028758217,0.000088231725,0.0000640196,0.000058068126,0.00037243526,0.000003077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0264985,0.0009658114,0.9541121,0.00003266143,0.0010808829,0.00027062662,0.0017011015,0.000044092787,0.0044204122,0.000091481765,0.008260339,0.0025219843],"study_design_scores_gemma":[0.05536264,0.0032672875,0.9175663,0.00039075653,0.00047161983,0.00016331434,0.00575453,0.0003492504,0.0018727911,0.00063383736,0.013983924,0.00018375966],"about_ca_topic_score_codex":0.004149214,"about_ca_topic_score_gemma":0.0032940288,"teacher_disagreement_score":0.03654582,"about_ca_system_score_codex":0.00019946854,"about_ca_system_score_gemma":0.0005013536,"threshold_uncertainty_score":0.62723976},"labels":[],"label_agreement":null},{"id":"W4409361702","doi":"10.58931/cot.2025.2131","title":"Clinical Considerations for the Management of Advanced PD-L1 ≥50% Non-small Cell Lung Cancer In 2025: Should All Patients Be Treated the Same?","year":2025,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Lung cancer; Medicine; Intensive care medicine; Cancer; Oncology; Internal medicine","score_opus":0.04781192108716303,"score_gpt":0.3763830102409679,"score_spread":0.32857108915380484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409361702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82386047,0.00946243,0.00010718566,0.122450896,0.0029141554,0.010105205,0.0005808539,0.000029964302,0.030488854],"genre_scores_gemma":[0.9487644,0.0035166352,0.0006296555,0.037785422,0.00007907786,0.0011647098,0.00006164191,0.000024433939,0.007974054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987037,0.00008992559,0.0005292363,0.00026017215,0.00007756055,0.00033939],"domain_scores_gemma":[0.998485,0.000802457,0.00012373463,0.0003551998,0.000120870005,0.00011270904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004266228,0.000141882,0.0003477594,0.00013381822,0.00014848958,0.000009231816,0.00016044149,0.0001922381,0.00035913914],"category_scores_gemma":[0.000050727864,0.000094049356,0.00014675247,0.00023140373,0.00021419935,0.000022222752,0.00002614417,0.00023028118,0.0000012570945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052671833,0.00090066274,0.38415745,0.0008055039,0.0033785165,0.00010944177,0.0023120951,0.00041862126,0.00049486925,0.0010108263,0.36260888,0.23853597],"study_design_scores_gemma":[0.0136625655,0.0006563818,0.57734096,0.00065383926,0.0009689108,0.0000018575158,0.0013378082,0.00066589075,0.00036497493,0.00010866541,0.4040394,0.00019873884],"about_ca_topic_score_codex":0.03551166,"about_ca_topic_score_gemma":0.5729484,"teacher_disagreement_score":0.5374367,"about_ca_system_score_codex":0.0007836101,"about_ca_system_score_gemma":0.0017896469,"threshold_uncertainty_score":0.97091097},"labels":[],"label_agreement":null},{"id":"W4409456948","doi":"10.3390/curroncol32040230","title":"LAG3, TIM3 and TIGIT: New Targets for Immunotherapy and Potential Associations with Radiotherapy","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"TIGIT; Medicine; Immunotherapy; Cancer research; Immune system; Radiation therapy; Tumor microenvironment; Immune checkpoint; T cell; Immunology; Internal medicine","score_opus":0.07425760266375032,"score_gpt":0.43064802544469577,"score_spread":0.35639042278094546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409456948","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018424897,0.9937174,0.0017993675,0.0007023575,0.0010315723,0.0022950238,0.00018892575,0.00004716221,0.00019977907],"genre_scores_gemma":[0.0000021799106,0.99492687,0.0013725339,0.0002495888,0.0005879692,0.0002392997,0.00042940822,0.000049370206,0.0021427593],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99848396,0.00010889595,0.0004954524,0.00046435086,0.00013009754,0.00031726295],"domain_scores_gemma":[0.99886,0.0003239763,0.00037209835,0.00023847615,0.00008603631,0.00011938866],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002449789,0.00039277526,0.0017780733,0.00024117793,0.00013642253,0.00003976349,0.000105163555,0.00041008843,0.000084430074],"category_scores_gemma":[0.00003308445,0.0002848787,0.00031352823,0.00021737115,0.00015799225,0.000044504446,0.00002517545,0.00033441975,0.0000014029806],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006796274,0.00015825452,0.00005458275,0.00463337,0.0011312629,0.000004614529,0.00010769499,4.078811e-8,0.0000067578603,0.000049908238,0.01603166,0.9771422],"study_design_scores_gemma":[0.006247038,0.0012083679,0.00014273662,0.0036393888,0.0010399501,0.00011978317,0.000010830819,0.0000062019017,8.266445e-7,0.00004289522,0.98727196,0.00027003099],"about_ca_topic_score_codex":0.00001840767,"about_ca_topic_score_gemma":0.000017802358,"teacher_disagreement_score":0.9768722,"about_ca_system_score_codex":0.00042480347,"about_ca_system_score_gemma":0.0018414737,"threshold_uncertainty_score":0.99996036},"labels":[],"label_agreement":null},{"id":"W4409461225","doi":"10.3390/curroncol32040229","title":"Long-Term Outcomes in Patients with Locally Advanced and Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pembrolizumab; Immunotherapy; Oncology; Internal medicine; Lung cancer; Survival rate; Cancer","score_opus":0.021537836444417528,"score_gpt":0.3489395867033526,"score_spread":0.3274017502589351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409461225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937655,0.0035548308,0.0006146585,0.00031446695,0.0005002039,0.001064923,0.000013029085,0.000018654986,0.00015377086],"genre_scores_gemma":[0.9978617,0.00059159665,0.0006326973,0.00032073786,0.000016370122,0.00020833171,0.000039544215,0.000016697211,0.0003123208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989666,0.000050494687,0.0002652428,0.0003232109,0.00013647361,0.00025801323],"domain_scores_gemma":[0.9994422,0.00007948723,0.00012872633,0.00019133293,0.000089818794,0.000068406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007859707,0.00019830739,0.00047943485,0.00015682032,0.000042690768,0.000008937347,0.00007611392,0.00006056257,0.000058959744],"category_scores_gemma":[0.000007798173,0.00012416345,0.000033449327,0.00020104588,0.000114929935,0.00006008118,0.000043555403,0.0002073958,7.8812207e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008608599,0.00082897674,0.92554504,0.00052423327,0.00010749985,0.000019513867,0.0002289815,0.000011038616,0.000597889,0.0000021236783,0.00015522128,0.06337087],"study_design_scores_gemma":[0.02457542,0.0013671239,0.97011584,0.0013130204,0.00020071128,0.0000015845591,0.000055286175,0.00002711451,0.0013305281,0.0000029710234,0.000859607,0.00015078408],"about_ca_topic_score_codex":0.000059126964,"about_ca_topic_score_gemma":0.00048464525,"teacher_disagreement_score":0.06322008,"about_ca_system_score_codex":0.00029506913,"about_ca_system_score_gemma":0.00035551382,"threshold_uncertainty_score":0.5063238},"labels":[],"label_agreement":null},{"id":"W4409472865","doi":"10.1016/j.jaccao.2025.01.020","title":"Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction","year":2025,"lang":"fr","type":"article","venue":"JACC CardioOncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Institutes of Health; European Research Area Network on Cardiovascular Diseases; Eisai; Novo Nordisk; Daiichi-Sankyo; UVA Cancer Center; Ipsen; BeiGene; Andrew Sabin Family Foundation; Regeneron Pharmaceuticals; Cancer Prevention and Research Institute of Texas; National Heart, Lung, and Blood Institute; Pfizer; Austrian Science Fund; National Cancer Institute; Kiniksa Pharmaceuticals; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Myocarditis; Cardiology; Internal medicine; Medicine","score_opus":0.007959516920727803,"score_gpt":0.2547766380695204,"score_spread":0.2468171211487926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409472865","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24093533,0.6457231,0.0013345804,0.024489217,0.04644759,0.0017494697,0.00008945669,0.00016363255,0.03906762],"genre_scores_gemma":[0.9483124,0.021676507,0.00013758433,0.0017502293,0.004088187,0.00009519391,0.000075088705,0.000054849257,0.02380996],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972767,0.0004299183,0.0006993108,0.0006177011,0.0002533403,0.0007230177],"domain_scores_gemma":[0.9986703,0.00023473805,0.00019431782,0.0005562526,0.00018092174,0.00016347949],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009921667,0.00038369835,0.001185775,0.0003580492,0.00022593352,0.00005240421,0.000120569566,0.00073434354,0.00041992852],"category_scores_gemma":[0.00019487781,0.00039357826,0.00067462894,0.0005214236,0.0005357914,0.00012509759,0.00016195436,0.00052184716,0.000105672945],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065220804,0.00072528195,0.039268903,0.004351347,0.014412425,0.0042547113,0.0011426527,0.00006232014,0.08743331,0.0022716369,0.13843186,0.7011235],"study_design_scores_gemma":[0.007502672,0.00082628615,0.116132006,0.0010994679,0.0019677232,0.0026558212,0.00088777003,0.00012808543,0.008689119,0.00010641556,0.85967267,0.00033196254],"about_ca_topic_score_codex":0.0006358265,"about_ca_topic_score_gemma":0.000059843278,"teacher_disagreement_score":0.7212408,"about_ca_system_score_codex":0.0013324077,"about_ca_system_score_gemma":0.0005342943,"threshold_uncertainty_score":0.9998516},"labels":[],"label_agreement":null},{"id":"W4409527523","doi":"10.1158/1055-9965.epi-25-0287","title":"Density of T-cell Subsets in Colorectal Cancer in Relation to Disease-Specific Survival","year":2025,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Lunenfeld-Tanenbaum Research Institute","funders":"Office of Research Infrastructure Programs, National Institutes of Health; Division of Loan Repayment; Canadian Institutes of Health Research; National Health and Medical Research Council; National Cancer Institute; Cancer Research UK; National Institutes of Health; National Heart, Lung, and Blood Institute; Brigham and Women's Hospital","keywords":"Colorectal cancer; Disease; Cancer; Relation (database); Medicine; Oncology; Internal medicine; Computer science","score_opus":0.04414321729365135,"score_gpt":0.3575087324032376,"score_spread":0.31336551510958627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409527523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751957,0.016432313,0.0007352084,0.004940685,0.0012097562,0.0011016084,0.000029795025,0.00002672051,0.00032818856],"genre_scores_gemma":[0.99394053,0.0043869726,0.00037004246,0.00042328797,0.000055176988,0.00029661544,0.00006909533,0.00001570777,0.00044255098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997343,0.0006540859,0.0009447643,0.00054806547,0.00012219678,0.00038787795],"domain_scores_gemma":[0.9988968,0.00038305373,0.00026370017,0.00025190142,0.00009133952,0.00011325197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019482952,0.00020969281,0.0006786345,0.0005385753,0.00004063233,0.0000030145573,0.00011990717,0.00024338553,0.00020903753],"category_scores_gemma":[0.00021961876,0.00020849098,0.00021613094,0.0009600393,0.00016924509,0.00008194653,0.000047629695,0.00021110999,0.000004966105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011864278,0.00020498583,0.8983511,0.00017128237,0.00014674253,0.000008722697,0.00009655313,0.00011490317,0.06706456,0.00014539134,0.0020521507,0.019779366],"study_design_scores_gemma":[0.0032110005,0.000104660896,0.98739296,0.0011050226,0.000077515615,7.974861e-7,0.00006821852,0.00027946453,0.005361373,0.001051292,0.0011866372,0.000161073],"about_ca_topic_score_codex":0.0016795719,"about_ca_topic_score_gemma":0.006125949,"teacher_disagreement_score":0.08904188,"about_ca_system_score_codex":0.00093649083,"about_ca_system_score_gemma":0.00044909285,"threshold_uncertainty_score":0.85020155},"labels":[],"label_agreement":null},{"id":"W4409530136","doi":"10.1038/s41467-025-58999-6","title":"Peritoneal resident macrophages constitute an immunosuppressive environment in peritoneal metastasized colorectal cancer","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Oncode Institute; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; ZonMw; New York Stem Cell Foundation","keywords":"Colorectal cancer; Peritoneum; Medicine; Cancer research; Peritoneal carcinomatosis; Cancer; Immunology; Pathology; Internal medicine","score_opus":0.01489519238558577,"score_gpt":0.3430940063174875,"score_spread":0.3281988139319017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409530136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7921445,0.1834861,0.00001791269,0.01840207,0.0005407189,0.0012262193,0.0002154771,0.000088817695,0.0038782165],"genre_scores_gemma":[0.97149193,0.02385381,0.0025429022,0.00095604314,0.00004119038,0.00040902084,0.00022208743,0.000016732298,0.00046626138],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986197,0.00023394407,0.0003874112,0.00029736923,0.0002130989,0.00024850547],"domain_scores_gemma":[0.9983019,0.00014672444,0.00010150748,0.0013024054,0.000075819575,0.000071642935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024886595,0.00019830033,0.00035318022,0.00017168287,0.00029763766,0.000045387278,0.0006197928,0.0002852718,0.00030266607],"category_scores_gemma":[0.000052295072,0.00018285535,0.00013141263,0.00034759977,0.0005757904,0.00013268348,0.00025430002,0.0010440074,0.000006569666],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010068743,0.0025610388,0.07369863,0.00016882044,0.0019472592,0.00012101806,0.004648105,0.00006703844,0.83914673,0.008748365,0.016170288,0.042653937],"study_design_scores_gemma":[0.010151242,0.00034098714,0.5868998,0.0005841607,0.00051524554,0.0000840913,0.00241796,0.0007089923,0.065409616,0.000173253,0.33214566,0.0005689511],"about_ca_topic_score_codex":0.0011603433,"about_ca_topic_score_gemma":0.0024382567,"teacher_disagreement_score":0.77373713,"about_ca_system_score_codex":0.00045342345,"about_ca_system_score_gemma":0.00043342405,"threshold_uncertainty_score":0.7456625},"labels":[],"label_agreement":null},{"id":"W4409565762","doi":"10.1080/14796694.2025.2485015","title":"STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Royal Ottawa Mental Health Centre","funders":"Exelixis; American Society of Clinical Oncology","keywords":"Pembrolizumab; Medicine; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.01271133484206635,"score_gpt":0.32109144347390917,"score_spread":0.30838010863184284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409565762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848655,0.00067797134,0.000008267715,0.0007262509,0.0016846606,0.0016889025,0.0000196408,0.000044632965,0.0102841845],"genre_scores_gemma":[0.9980012,0.00007836375,0.00009733869,0.00043603816,0.00023568464,0.000071110175,0.00007792454,0.00002712802,0.00097518245],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99797434,0.00015059182,0.0006638868,0.00046489734,0.00034764563,0.0003986717],"domain_scores_gemma":[0.9987823,0.0001143821,0.0002671482,0.0005376574,0.00021266383,0.00008584317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022591896,0.0002916528,0.00094377546,0.00039885947,0.000103418075,0.0000073631813,0.0002108689,0.00030561013,0.00036413138],"category_scores_gemma":[0.00003069098,0.0002290514,0.00011236482,0.000771148,0.00015235296,0.000061234365,0.000099699995,0.00041434192,0.0000037284453],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8727134,0.017708294,0.02253571,0.00015603587,0.0013597333,0.00015225778,0.0054146433,0.000014053107,0.00051705044,0.000105302635,0.00634996,0.07297358],"study_design_scores_gemma":[0.7384975,0.06428271,0.105936095,0.000178809,0.0005594638,0.000014332106,0.0052059432,0.000029494286,0.00043297277,0.0000071626364,0.08454674,0.00030879737],"about_ca_topic_score_codex":0.000399049,"about_ca_topic_score_gemma":0.0015492641,"teacher_disagreement_score":0.13421589,"about_ca_system_score_codex":0.0006189631,"about_ca_system_score_gemma":0.00083438645,"threshold_uncertainty_score":0.9340445},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W4409626118","doi":"10.1158/1538-7445.am2025-2123","title":"Abstract 2123: KJ-103: First-in-class naked anti-TROP2 HCAb with immune modulatory mechanisms and tumor regression potential in clinical trials","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute","funders":"","keywords":"Immune system; Medicine; Class (philosophy); Oncology; Internal medicine; Immunology; Computer science","score_opus":0.1037997744454655,"score_gpt":0.4694513717600073,"score_spread":0.3656515973145418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409626118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860586,0.0070572826,0.000046750058,0.004486887,0.00039210296,0.0014107048,0.000018423692,0.000022583807,0.00050666666],"genre_scores_gemma":[0.9946073,0.0038936513,0.0001342964,0.00035093309,0.00018105452,0.0002097554,0.000014564501,0.000028536688,0.0005798678],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99609876,0.0008170971,0.0010506195,0.00063275575,0.000796557,0.0006042332],"domain_scores_gemma":[0.99837136,0.00064463366,0.00016066706,0.0005192484,0.0001731501,0.00013093525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0100229075,0.00021951862,0.0009279409,0.0006487779,0.00014321343,0.00006806932,0.000248968,0.00023117573,0.00029243968],"category_scores_gemma":[0.000484312,0.00015266659,0.00016623402,0.0008691823,0.0003575145,0.00011313342,0.00008886221,0.0010992185,0.0000059180516],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06810941,0.0017587992,0.051074848,0.0017843551,0.00067754503,0.0029322866,0.0007228857,0.00007047123,0.7314543,0.00050748984,0.0076622795,0.13324533],"study_design_scores_gemma":[0.025348654,0.001052323,0.93309474,0.00468836,0.0000659294,0.000033245495,0.0009946902,0.00039633218,0.027945075,0.00044156518,0.005627435,0.0003116362],"about_ca_topic_score_codex":0.0022901625,"about_ca_topic_score_gemma":0.00087496394,"teacher_disagreement_score":0.8820199,"about_ca_system_score_codex":0.00037302537,"about_ca_system_score_gemma":0.0009231806,"threshold_uncertainty_score":0.62255627},"labels":[],"label_agreement":null},{"id":"W4409627440","doi":"10.1158/1538-7445.am2025-2276","title":"Abstract 2276: Whole exome sequencing of immune-mediated colitis in cancer patients treated with immune checkpoint inhibitors","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Exome sequencing; Immune system; Medicine; Immune checkpoint; Cancer; Colitis; Cancer research; Exome; Colorectal cancer; Microsatellite instability; Immunology; Mutation; Internal medicine; Biology; Immunotherapy; Genetics; Gene","score_opus":0.041526528618500085,"score_gpt":0.36221733324230776,"score_spread":0.32069080462380767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409627440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98888636,0.0068073464,6.6002906e-7,0.000921881,0.00016867388,0.0011787496,0.00013287428,0.000035085322,0.0018683972],"genre_scores_gemma":[0.99557877,0.0018717032,0.000010485841,0.00007860878,0.00005657917,0.00052787387,0.000093516086,0.00003886885,0.0017435885],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99723285,0.000109428,0.0008053817,0.0004298098,0.0007360712,0.00068648247],"domain_scores_gemma":[0.9984482,0.00014642747,0.00016859766,0.00042711268,0.0006968405,0.00011281459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088548067,0.00022464026,0.0005605948,0.0006085979,0.00010725685,0.00002914038,0.00021839622,0.00017233886,0.0005403965],"category_scores_gemma":[0.000121440324,0.00018097414,0.00013255353,0.00222023,0.00045049202,0.00013328088,0.00007983475,0.00065657555,0.000008750358],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00878056,0.00038573396,0.22905038,0.00080774474,0.00036704206,0.000059383365,0.0009115177,0.00002120894,0.7475716,0.0000067771152,0.00059368904,0.01144435],"study_design_scores_gemma":[0.0063844216,0.0004204235,0.6699832,0.0032604104,0.00002373177,0.0000012546391,0.0005352821,0.00001793446,0.31749317,0.00000832805,0.0017233,0.00014853658],"about_ca_topic_score_codex":0.06069937,"about_ca_topic_score_gemma":0.0030318967,"teacher_disagreement_score":0.4409328,"about_ca_system_score_codex":0.002578746,"about_ca_system_score_gemma":0.0020679287,"threshold_uncertainty_score":0.9455555},"labels":[],"label_agreement":null},{"id":"W4409627977","doi":"10.1158/1538-7445.am2025-2010","title":"Abstract 2010: A spatial profiling approach to evaluating the prognostic impact of heterogeneity in the triple-negative breast cancer immune microenvironment","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Associated Medical Services; Institute of Cancer Research; University of Toronto","funders":"","keywords":"Triple-negative breast cancer; Breast cancer; Tumor microenvironment; Immune system; Medicine; Profiling (computer programming); Spatial heterogeneity; Triple negative; Cancer; Oncology; Biology; Immunology; Internal medicine; Computer science; Ecology","score_opus":0.10893323240046233,"score_gpt":0.45839632555839627,"score_spread":0.34946309315793395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409627977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885052,0.0041756085,0.000033846267,0.0027344322,0.00012238542,0.003903364,0.00012677867,0.000007465413,0.0003909326],"genre_scores_gemma":[0.99689627,0.00050292746,0.00008686089,0.00016853603,0.00012007233,0.0020016083,0.000010573313,0.000018190156,0.00019496182],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99737436,0.0004549207,0.00044636228,0.00038060173,0.0008028778,0.000540892],"domain_scores_gemma":[0.99868286,0.00042255037,0.000103094586,0.0005347721,0.00019532348,0.00006139241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033614405,0.00018053332,0.0003189105,0.00021917626,0.00020829441,0.00004436611,0.00043050817,0.000075952375,0.00016858029],"category_scores_gemma":[0.00020168362,0.00009569175,0.00019900323,0.0010061095,0.00035164764,0.00004825044,0.00011989639,0.00067187793,0.0000033675506],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01265826,0.0006834713,0.19770442,0.00038483724,0.00065732584,0.0000056023414,0.0030799177,0.00090915384,0.71279275,0.000009073741,0.00069755,0.07041761],"study_design_scores_gemma":[0.0021868835,0.0003923814,0.95680463,0.0005965841,0.000046948622,0.000008810524,0.00091668003,0.0005131214,0.03839727,0.000020976328,0.000025520822,0.00009021522],"about_ca_topic_score_codex":0.050264344,"about_ca_topic_score_gemma":0.0012395413,"teacher_disagreement_score":0.7591002,"about_ca_system_score_codex":0.0011173009,"about_ca_system_score_gemma":0.0012372818,"threshold_uncertainty_score":0.95606005},"labels":[],"label_agreement":null},{"id":"W4409629417","doi":"10.1158/1538-7445.am2025-6061","title":"Abstract 6061: Dual PD-L1 blockade and VEGF-A neutralization with the bispecific antibody BNT327/PM8002 shows potent antitumor activity in preclinical models","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Optech (Canada)","funders":"","keywords":"Blockade; Bispecific antibody; Medicine; Neutralization; Antibody; Cancer research; VEGF receptors; Pharmacology; Immunology; Internal medicine; Receptor; Monoclonal antibody","score_opus":0.12705428417367967,"score_gpt":0.4546985707906712,"score_spread":0.3276442866169915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409629417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824979,0.003433423,0.0001135375,0.010962815,0.00012644037,0.001014027,0.00002290947,0.000028287131,0.0018006929],"genre_scores_gemma":[0.9936912,0.004361011,0.000020257363,0.00023302597,0.00014468456,0.00013678474,0.000011231047,0.000022182023,0.0013796289],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980244,0.00017825705,0.0002627976,0.00048747592,0.00056775333,0.00047932635],"domain_scores_gemma":[0.9989925,0.00025122619,0.000055778633,0.00042105417,0.00018203443,0.00009737415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012584165,0.00016580538,0.0003018898,0.00027749303,0.00020936568,0.00009678292,0.00016177996,0.00012962219,0.00012322517],"category_scores_gemma":[0.000037582628,0.00010674464,0.00006275124,0.00089276565,0.00053257437,0.00016424783,0.00008371975,0.00077024923,0.0000030069823],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03411384,0.0011571961,0.06408732,0.00095543225,0.00053834065,0.00027021172,0.0014602485,0.00080461305,0.80014956,0.0006719252,0.007474281,0.088317014],"study_design_scores_gemma":[0.0063835913,0.0006090769,0.93159765,0.0012088275,0.00006130583,0.000027723012,0.00061577343,0.0025069732,0.046333082,0.00020422935,0.010175391,0.0002763514],"about_ca_topic_score_codex":0.001610793,"about_ca_topic_score_gemma":0.0015575755,"teacher_disagreement_score":0.8675104,"about_ca_system_score_codex":0.00027701486,"about_ca_system_score_gemma":0.00068129407,"threshold_uncertainty_score":0.435292},"labels":[],"label_agreement":null},{"id":"W4409629542","doi":"10.1093/ibd/izaf065","title":"Rethinking the Use of Biologics in Inflammatory Bowel Disease Patients With Malignancy: Insights From the Treatment of Immune Checkpoint Inhibitor-Induced Colitis","year":2025,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Inflammatory bowel disease; Medicine; Malignancy; Colitis; Colorectal cancer; Immune system; Disease; Cancer; Immune checkpoint; Immunology; Immunotherapy; Internal medicine","score_opus":0.020035732868162032,"score_gpt":0.2378642406112335,"score_spread":0.21782850774307147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409629542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912233,0.00601265,0.0000028329168,0.00036882926,0.00026558124,0.001728055,0.00031340847,0.000049919483,0.000035459736],"genre_scores_gemma":[0.9982512,0.00087407307,0.000025859294,0.00032868807,0.0000776243,0.00020865412,0.0001518183,0.000028865556,0.000053203064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976369,0.00027755433,0.0009939816,0.0003809832,0.00042190903,0.0002886618],"domain_scores_gemma":[0.9976676,0.00051027536,0.0004946195,0.000983042,0.0002248182,0.000119663855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000111113586,0.0003648559,0.00047223712,0.00015729679,0.00015751556,0.000041432257,0.000256165,0.00013102754,0.000034277906],"category_scores_gemma":[0.00017167829,0.00019114182,0.00034411935,0.000299991,0.0005475414,0.0001796579,0.000073858544,0.00015091631,0.0000019022586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013832609,0.0009977116,0.97595394,0.00023863548,0.0005800515,0.00010004258,0.0020220631,0.00003990063,0.0029809098,0.00021256437,0.00009604238,0.0029455428],"study_design_scores_gemma":[0.005660137,0.0004093256,0.9845416,0.0019269965,0.00035864196,3.6079462e-7,0.00024985048,0.00004871927,0.004374351,0.00043186184,0.001795038,0.00020313005],"about_ca_topic_score_codex":0.0006329978,"about_ca_topic_score_gemma":0.00034132058,"teacher_disagreement_score":0.008587661,"about_ca_system_score_codex":0.00029464025,"about_ca_system_score_gemma":0.00070959295,"threshold_uncertainty_score":0.77945375},"labels":[],"label_agreement":null},{"id":"W4409632105","doi":"10.1158/1538-7445.am2025-5813","title":"Abstract 5813: Evolution of the tumor immune microenvironment (TIME) in hepatocellular carcinoma (HCC) with liver metastases treated with atezolizumab-bevacizumab (INTEGRATE)","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Atezolizumab; Bevacizumab; Hepatocellular carcinoma; Medicine; Tumor microenvironment; Immune system; Cancer research; Oncology; Internal medicine; Cancer; Immunotherapy; Immunology; Chemotherapy; Nivolumab","score_opus":0.022800772796388785,"score_gpt":0.2918862055551203,"score_spread":0.26908543275873154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409632105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807218,0.016363982,0.000011836809,0.0006903669,0.000029007935,0.0013551178,0.000053760225,0.000015423264,0.0007587267],"genre_scores_gemma":[0.995427,0.0006080993,0.000035722558,0.00004322398,0.000020680469,0.00022839375,0.000017993514,0.0000297306,0.0035891386],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99787956,0.00020196501,0.0003697233,0.00041167208,0.00064245675,0.0004946272],"domain_scores_gemma":[0.99889916,0.0000818227,0.00010767157,0.00064173795,0.000202487,0.000067144945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056870497,0.00022644927,0.00043574127,0.00034530283,0.00013777897,0.000022879092,0.00027912273,0.00006908415,0.0006473326],"category_scores_gemma":[0.000020646417,0.00012746656,0.00011910422,0.0011960014,0.0006978886,0.00006276223,0.000078182726,0.0004986425,0.00001311544],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026659781,0.00044990017,0.22408994,0.00053975807,0.000528914,0.00027743488,0.00031506352,0.00004309445,0.7407024,0.000050949377,0.0011317709,0.005211019],"study_design_scores_gemma":[0.005196608,0.0005384214,0.5159016,0.0017763816,0.00009771416,0.000032375698,0.00048812776,0.00016767,0.47415805,0.000010700604,0.0014994376,0.00013285129],"about_ca_topic_score_codex":0.022580378,"about_ca_topic_score_gemma":0.0010210249,"teacher_disagreement_score":0.2918117,"about_ca_system_score_codex":0.0020344025,"about_ca_system_score_gemma":0.0011450859,"threshold_uncertainty_score":0.9839283},"labels":[],"label_agreement":null},{"id":"W4409632149","doi":"10.1158/1538-7445.am2025-7288","title":"Abstract 7288: Targeted degradation of mobile immune checkpoints to advance cancer therapy","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cancer; Cancer therapy; Immune system; Computational biology; Cancer research; Biology; Medicine; Immunology; Genetics","score_opus":0.05268197465200714,"score_gpt":0.43817405838256285,"score_spread":0.3854920837305557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409632149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94642645,0.04670117,0.000050837476,0.0028477414,0.0003777431,0.0014177313,0.000045883135,0.00003609995,0.002096334],"genre_scores_gemma":[0.97134274,0.017103538,0.00016580806,0.00048068014,0.000116696545,0.0013929434,0.000019069907,0.000029087887,0.009349408],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811256,0.00006414371,0.00042283398,0.0003703886,0.0005781035,0.00045198898],"domain_scores_gemma":[0.99857366,0.00010589965,0.000079973506,0.00050400523,0.00062933954,0.00010711916],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007992667,0.00015242684,0.0003540934,0.0003989014,0.0001232874,0.00002098755,0.00025386165,0.00010360824,0.0020657794],"category_scores_gemma":[0.00007407932,0.00012891684,0.00012424444,0.00148076,0.00015471852,0.000095420575,0.000056195644,0.00035924604,0.000018587625],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004390632,0.00013358965,0.0029843822,0.00017771298,0.00017440878,0.0000033086678,0.00023586198,0.00003444325,0.7768243,0.000027021755,0.00528641,0.20972796],"study_design_scores_gemma":[0.0024009377,0.0002857714,0.111939825,0.0007062061,0.0000105593235,7.2614097e-7,0.0002542701,0.000011052274,0.7825653,0.000049570914,0.10166183,0.00011392933],"about_ca_topic_score_codex":0.0054021124,"about_ca_topic_score_gemma":0.00033176286,"teacher_disagreement_score":0.20961402,"about_ca_system_score_codex":0.0005824933,"about_ca_system_score_gemma":0.0010491877,"threshold_uncertainty_score":0.9988465},"labels":[],"label_agreement":null},{"id":"W4409822007","doi":"10.1158/1538-7445.am2025-ct251","title":"Abstract CT251: Phase 3 INTerpath-009 study: Individualized neoantigen therapy V940 (mRNA-4157) plus pembrolizumab for resected stage II-IIIB (N2) NSCLC with incomplete pathological response to neoadjuvant immunochemotherapy","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Pembrolizumab; Medicine; Oncology; Internal medicine; Stage (stratigraphy); Neoadjuvant therapy; Cancer; Immunotherapy; Biology; Breast cancer","score_opus":0.10595116221389714,"score_gpt":0.46931895725833533,"score_spread":0.36336779504443817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409822007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97885454,0.004384932,0.00035274008,0.00580879,0.00027425934,0.008950412,0.00046548102,0.00020650163,0.0007023529],"genre_scores_gemma":[0.984542,0.0013673567,0.0005363306,0.0019123305,0.00023547636,0.0031881856,0.0000856619,0.00013214863,0.00800047],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938325,0.0009311501,0.00094488764,0.0013408958,0.0014713815,0.0014791762],"domain_scores_gemma":[0.9960324,0.0009361176,0.00020437216,0.0013435957,0.0010951222,0.00038837275],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0047346847,0.00061233196,0.0011677839,0.001260619,0.0009970022,0.0002432792,0.0010074957,0.0003109802,0.00193061],"category_scores_gemma":[0.00043872977,0.0004482985,0.00032307458,0.002222683,0.000606592,0.00016488027,0.0003165387,0.0011740106,0.00001983093],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44452572,0.001535691,0.0008025155,0.00010047978,0.0008784521,0.0002685651,0.0053508403,0.0000068888744,0.44442824,0.000016534412,0.0038356634,0.09825041],"study_design_scores_gemma":[0.25138423,0.053715914,0.17073755,0.0024042802,0.0001526314,0.000065023705,0.0081038615,0.00012119766,0.106610745,0.00015377539,0.40516064,0.0013901631],"about_ca_topic_score_codex":0.0015010539,"about_ca_topic_score_gemma":0.00044519643,"teacher_disagreement_score":0.40132496,"about_ca_system_score_codex":0.0014923232,"about_ca_system_score_gemma":0.0030763336,"threshold_uncertainty_score":0.99979687},"labels":[],"label_agreement":null},{"id":"W4409822021","doi":"10.1158/1538-7445.am2025-ct198","title":"Abstract CT198: A first-in-human study evaluating safety, tolerability and efficacy of TEV-56278, as monotherapy and in combination with pembrolizumab in participants with locally advanced or metastatic solid tumors","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Pembrolizumab; Tolerability; Medicine; Oncology; Solid tumor; Internal medicine; Response Evaluation Criteria in Solid Tumors; Medical physics; Adverse effect; Cancer; Clinical trial; Immunotherapy; Phases of clinical research","score_opus":0.09054043081958066,"score_gpt":0.47378039338914774,"score_spread":0.38323996256956705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409822021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950552,0.00096583884,0.0000066016396,0.0006715655,0.000010749008,0.0031709168,0.000004106019,0.000008958671,0.000106090105],"genre_scores_gemma":[0.9988747,0.00036101858,0.00007972233,0.000042597163,0.000005019714,0.00053127616,0.0000029845542,0.000018851793,0.000083785744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768555,0.00027591514,0.00058697816,0.00046050272,0.0005593118,0.00043176505],"domain_scores_gemma":[0.9988061,0.0005325355,0.00010093875,0.00027776146,0.00020776507,0.00007489812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023341603,0.0001672333,0.0005729294,0.00046427033,0.00009230468,0.000027864122,0.000100642625,0.00004006874,0.000074405725],"category_scores_gemma":[0.00022132679,0.000116718445,0.000018010927,0.0010821722,0.00034629068,0.00011827096,0.000039910752,0.00038917654,2.0222268e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19334102,0.0032238462,0.6769013,0.0010918358,0.00024217632,0.00016119066,0.009355024,0.0012383262,0.022890095,0.000016103493,0.000004266426,0.091534816],"study_design_scores_gemma":[0.050001714,0.0063257418,0.9319836,0.0026151591,0.00002635358,0.000004822327,0.0040151547,0.0008278988,0.0039794357,0.00008645554,0.00000858601,0.00012509443],"about_ca_topic_score_codex":0.006249073,"about_ca_topic_score_gemma":0.038117908,"teacher_disagreement_score":0.25508228,"about_ca_system_score_codex":0.00051855337,"about_ca_system_score_gemma":0.00094358245,"threshold_uncertainty_score":0.97943395},"labels":[],"label_agreement":null},{"id":"W4409822055","doi":"10.1158/1538-7445.am2025-ct148","title":"Abstract CT148: Phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab plus chemotherapy in patients with advanced solid tumors","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Pembrolizumab; Medicine; Monoclonal antibody; Chemotherapy; Antibody; Pharmacokinetics; Internal medicine; Oncology; Cancer research; Pharmacology; Immunotherapy; Cancer; Immunology","score_opus":0.031174710965164075,"score_gpt":0.4027522681327222,"score_spread":0.37157755716755814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409822055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99267346,0.0021861747,0.000010605891,0.0007554248,0.00035964622,0.0034556908,0.00009784888,0.000030996325,0.00043018354],"genre_scores_gemma":[0.99795353,0.0006180163,0.000018000794,0.00030173536,0.00005192256,0.0002623567,0.000030918112,0.00005281095,0.0007107265],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99641514,0.00018529315,0.00070950517,0.0006231339,0.0013070576,0.00075986783],"domain_scores_gemma":[0.9982247,0.00009731391,0.00016392153,0.0008958391,0.0005109864,0.00010723915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006692195,0.00032709553,0.00076783786,0.00045361774,0.00024022335,0.000035551766,0.00062138983,0.00012459168,0.00030618583],"category_scores_gemma":[0.00003348547,0.00022275292,0.00016490452,0.0018080169,0.00048459476,0.00015251331,0.000078571145,0.0008891382,0.0000029611197],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25848562,0.012325089,0.2930505,0.0011840177,0.0019743124,0.00012600765,0.0104138395,0.0008631687,0.34375197,0.00001964877,0.0020448687,0.075760946],"study_design_scores_gemma":[0.1018274,0.0029935993,0.8681705,0.0013566825,0.000056014742,0.0000029193725,0.0019737186,0.00008169252,0.021142108,0.000011581049,0.0021243806,0.0002593771],"about_ca_topic_score_codex":0.002417422,"about_ca_topic_score_gemma":0.0004778782,"teacher_disagreement_score":0.57512003,"about_ca_system_score_codex":0.0011333814,"about_ca_system_score_gemma":0.0021145814,"threshold_uncertainty_score":0.90836006},"labels":[],"label_agreement":null},{"id":"W4409822130","doi":"10.1158/1538-7445.am2025-ct074","title":"Abstract CT074: Discovery and preliminary clinical findings of MK-6598, a potent and selective inhibitor of the immune checkpoint IL4I1","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Immune system; Pharmacology; Immune checkpoint; Biology; Medicine; Immunology; Immunotherapy","score_opus":0.053503192831385375,"score_gpt":0.4208308633784346,"score_spread":0.36732767054704923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409822130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804458,0.014858532,0.0000039281085,0.0030603271,0.00016131815,0.00066447566,0.000026352183,0.000005062485,0.00077422656],"genre_scores_gemma":[0.99332345,0.0049275397,0.000018374481,0.00006597293,0.00006707973,0.00004204758,0.0000014963492,0.000010407287,0.001543638],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998567,0.00011803335,0.00046335702,0.00026562644,0.00035621593,0.00022976003],"domain_scores_gemma":[0.99900794,0.0003444109,0.000090637324,0.0002761631,0.0002293338,0.000051519277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012555587,0.00009900488,0.0003273535,0.00013631309,0.000090464,0.000017884466,0.00012355589,0.00011170736,0.000026792472],"category_scores_gemma":[0.00025974022,0.0000645399,0.00013116201,0.00045037363,0.0010002435,0.00007146475,0.00020620125,0.0004940562,3.623726e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021521313,0.00044512,0.12719914,0.0014557188,0.00067966065,0.000011482177,0.0011036195,9.792452e-7,0.7771785,0.000113754024,0.0035066279,0.066784024],"study_design_scores_gemma":[0.001861907,0.00056446396,0.71248245,0.0010727285,0.00003654455,0.000005861772,0.00037366635,0.000007348099,0.28283536,0.00009230163,0.00062042597,0.00004693368],"about_ca_topic_score_codex":0.0011676295,"about_ca_topic_score_gemma":0.00005250913,"teacher_disagreement_score":0.58528334,"about_ca_system_score_codex":0.00013928748,"about_ca_system_score_gemma":0.0006645039,"threshold_uncertainty_score":0.36854386},"labels":[],"label_agreement":null},{"id":"W4409822192","doi":"10.1158/1538-7445.am2025-ct039","title":"Abstract CT039: Results of a first-in-human phase 1 trial of anchored IL-12 drug conjugate (ANK-101)","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Conjugate; Medicine; Drug; Pharmacology; Computational biology; Biology; Mathematics","score_opus":0.07401649993922951,"score_gpt":0.4467763592428601,"score_spread":0.37275985930363054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409822192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98318964,0.0017357452,0.0000014842255,0.0028073068,0.00029564896,0.0014170778,0.00024488522,0.00001639901,0.010291834],"genre_scores_gemma":[0.9946025,0.0013092986,0.000014557206,0.00006189753,0.00017722577,0.00017271773,0.000033718297,0.000018121176,0.003609933],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975618,0.00012803404,0.00081196916,0.00037999146,0.0006683479,0.0004498718],"domain_scores_gemma":[0.99847955,0.00032024935,0.0001577675,0.00059502857,0.0003513642,0.00009602379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002256215,0.00014527702,0.00052671065,0.0005867309,0.000089194415,0.0000155419,0.0002707827,0.000117197844,0.00042117195],"category_scores_gemma":[0.00029015657,0.00012649229,0.0001696347,0.00088403013,0.0005299861,0.000065440916,0.00006692297,0.00047472105,0.0000029189723],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5292449,0.0013841095,0.0012171174,0.0010592716,0.0003361025,0.000054337957,0.0014791648,0.00000647873,0.40590322,0.000093881055,0.037099894,0.022121528],"study_design_scores_gemma":[0.42227757,0.0023963547,0.017569242,0.0030695542,0.00006160513,0.0000016898316,0.00076659536,0.0000415674,0.4586439,0.00025999648,0.094688594,0.00022330652],"about_ca_topic_score_codex":0.0076700905,"about_ca_topic_score_gemma":0.002649607,"teacher_disagreement_score":0.10696732,"about_ca_system_score_codex":0.000363169,"about_ca_system_score_gemma":0.0008319726,"threshold_uncertainty_score":0.9989379},"labels":[],"label_agreement":null},{"id":"W4409875572","doi":"10.21037/tcr-2024-2477","title":"Will phenotype help guide immunotherapy in prostate cancer?","year":2025,"lang":"en","type":"letter","venue":"Translational Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Université du Québec en Outaouais","funders":"","keywords":"Immunotherapy; Prostate cancer; Cancer; Medicine; Prostate; Phenotype; Oncology; Cancer research; Internal medicine; Biology; Genetics; Gene","score_opus":0.06685955315953036,"score_gpt":0.4231772309204071,"score_spread":0.35631767776087675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409875572","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013158823,0.0684771,0.000025403682,0.9188521,0.0006527228,0.0022438676,0.0007781662,0.00006810684,0.0075866636],"genre_scores_gemma":[0.004967728,0.112548314,0.0005206145,0.7249579,0.008777104,0.0043188366,0.0021334675,0.00030763535,0.1414684],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99492866,0.00033751657,0.0007914157,0.0008500505,0.0020606804,0.0010316976],"domain_scores_gemma":[0.9981386,0.00039261547,0.000109649474,0.0005768757,0.00070408266,0.00007817163],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011544925,0.0004374829,0.00071631814,0.0011122129,0.00019365312,0.00007833335,0.0004409331,0.0006361228,0.0050578634],"category_scores_gemma":[0.00002414921,0.00040178327,0.00029839325,0.0016159862,0.0003948088,0.00020351405,0.00003203686,0.0036394638,0.000023674853],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065805274,0.00009408261,0.0021390668,0.00090231036,0.0005749085,0.00024320371,0.0005919062,0.000046487978,0.0034182186,0.00005011154,0.8895151,0.095844045],"study_design_scores_gemma":[0.005015658,0.0001690942,0.006076471,0.0020141944,0.00003437645,0.0000076063748,0.000023533205,0.000058126996,0.0004884449,0.00066012866,0.9850827,0.0003696924],"about_ca_topic_score_codex":0.022101138,"about_ca_topic_score_gemma":0.0025845778,"teacher_disagreement_score":0.1938942,"about_ca_system_score_codex":0.0013340386,"about_ca_system_score_gemma":0.005627579,"threshold_uncertainty_score":0.9998434},"labels":[],"label_agreement":null},{"id":"W4409921856","doi":"10.3390/curroncol32050259","title":"Does Pre-Existing Chronic Obstructive Pulmonary Disease Increase the Risk of Checkpoint Inhibitor Pneumonitis in Advanced/Metastatic Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors?","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Pneumonitis; Lung cancer; Cancer; Pulmonary disease; Lung; Immune checkpoint; Nivolumab; Disease; Cancer research; Immunotherapy; Immunology; Oncology; Internal medicine","score_opus":0.0161648387825138,"score_gpt":0.3208377972133749,"score_spread":0.3046729584308611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409921856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9659948,0.029557655,0.00006714644,0.0005583061,0.00095442246,0.0020680036,0.0001559354,0.0000418566,0.0006019271],"genre_scores_gemma":[0.9935367,0.004689927,0.0001440072,0.000039448565,0.00021169313,0.0008517985,0.0000720417,0.000038472375,0.00041589633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973789,0.00031432376,0.0010003952,0.0005731531,0.00022889143,0.0005043774],"domain_scores_gemma":[0.9980995,0.00033058276,0.00070145243,0.0005058152,0.00021447825,0.00014819215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045915137,0.00040178842,0.0007809097,0.00028437443,0.00014928242,0.000015056969,0.00021317748,0.0001012723,0.00007235388],"category_scores_gemma":[0.00014243487,0.00022340432,0.00027310755,0.0007778532,0.0004963758,0.00010386772,0.0001390928,0.0006811743,0.0000012955124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016338617,0.001990781,0.74491346,0.0035013028,0.0005186355,0.0002189364,0.0013466274,0.00025641383,0.060953166,0.000008220595,0.0000641847,0.16988967],"study_design_scores_gemma":[0.009927346,0.0008697915,0.92646164,0.004518109,0.0013075327,0.000021137,0.0011768901,0.0028315645,0.049809016,0.000082297265,0.0026087589,0.0003859123],"about_ca_topic_score_codex":0.0023079328,"about_ca_topic_score_gemma":0.00088828796,"teacher_disagreement_score":0.18154821,"about_ca_system_score_codex":0.0016573154,"about_ca_system_score_gemma":0.0016654547,"threshold_uncertainty_score":0.9110164},"labels":[],"label_agreement":null},{"id":"W4409995180","doi":"10.1016/j.xcrm.2025.102101","title":"Low T cell diversity associates with poor outcome in bladder cancer: A comprehensive longitudinal analysis of the T cell receptor repertoire","year":2025,"lang":"en","type":"article","venue":"Cell Reports Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Lundbeckfonden; Aarhus Universitets Forskningsfond; Novo Nordisk Fonden; Kræftens Bekæmpelse; Aarhus Universitet; AstraZeneca","keywords":"T-cell receptor; Immunotherapy; Biology; Repertoire; Immune system; Cytotoxic T cell; Immunology; T cell; Bladder cancer; Cancer immunotherapy; Cancer; Cancer research; Genetics","score_opus":0.01692413662152232,"score_gpt":0.27345009259291947,"score_spread":0.25652595597139716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409995180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851731,0.0045362203,0.000022503558,0.003212174,0.00060238264,0.0005935687,0.000014827842,0.00002780345,0.00581743],"genre_scores_gemma":[0.98357844,0.0006800646,0.00004123273,0.0012876763,0.000055869485,0.000017404729,0.000037841513,0.000015562366,0.014285878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759424,0.00008026147,0.00086085877,0.000520614,0.00062913506,0.0003148702],"domain_scores_gemma":[0.99793535,0.00016958824,0.00076054106,0.0007006985,0.00034044217,0.00009334763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043055767,0.00027332923,0.0010671142,0.00043519997,0.00017051099,0.0000062544214,0.00017232711,0.00014370693,0.00067893666],"category_scores_gemma":[0.000067088855,0.00016062157,0.00031501983,0.0022631793,0.0004160394,0.000043172702,0.00016244536,0.0003271174,7.99548e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008550426,0.00034807558,0.9460646,0.00035741713,0.0010788792,0.00026361263,0.0009726507,0.00007904583,0.042525966,6.046943e-7,0.006890707,0.00056341634],"study_design_scores_gemma":[0.004590319,0.00034827238,0.9066424,0.0007969871,0.005047921,0.000015129099,0.0019379152,0.000098637785,0.074742176,0.000005870558,0.005540842,0.00023356613],"about_ca_topic_score_codex":0.0067249774,"about_ca_topic_score_gemma":0.0010026369,"teacher_disagreement_score":0.039422218,"about_ca_system_score_codex":0.00040926112,"about_ca_system_score_gemma":0.00032133685,"threshold_uncertainty_score":0.9998893},"labels":[],"label_agreement":null},{"id":"W4410004223","doi":"10.3390/curroncol32050262","title":"The Spatial Proximity of CD8+ FoxP3+PD-1+ Cells to Tumor Cells: A More Accurate Predictor of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung Cancer","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China; Shanghai Municipal Health Commission","keywords":"Medicine; Immunotherapy; Lung cancer; FOXP3; CD8; Cancer immunotherapy; Cancer research; Cytotoxic T cell; Immunology; Oncology; Immune system; Biology; Genetics","score_opus":0.0297147764869609,"score_gpt":0.37780252265039155,"score_spread":0.34808774616343063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410004223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836084,0.008359167,0.0005038057,0.0015534977,0.0031038304,0.0024447963,0.00011737756,0.00002186307,0.00028724506],"genre_scores_gemma":[0.9939319,0.0039007145,0.00030446367,0.00052205514,0.000087227214,0.0005944218,0.00001131376,0.00002801,0.00061992375],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980219,0.00012367468,0.00087392604,0.00035678552,0.00021747037,0.0004062723],"domain_scores_gemma":[0.9984975,0.00033095607,0.00041126876,0.00047955223,0.00020881418,0.000071939714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040677673,0.0002619981,0.00080624555,0.00021152406,0.00006417174,0.000007759625,0.0003580887,0.0001217528,0.000079659476],"category_scores_gemma":[0.000046544734,0.00018192545,0.00023319163,0.00046059914,0.00022417502,0.000047741047,0.0001023655,0.0003179608,0.0000015784343],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01591707,0.0023233942,0.24465996,0.0013623767,0.0004894507,0.000012377895,0.0033607834,0.00013358326,0.544559,0.000017657154,0.0033214132,0.18384296],"study_design_scores_gemma":[0.027438184,0.002369192,0.33388832,0.0017914723,0.0003095969,0.0000028994248,0.0012527378,0.0019416168,0.53502905,0.00004193974,0.09547326,0.0004617251],"about_ca_topic_score_codex":0.0006406068,"about_ca_topic_score_gemma":0.00096206623,"teacher_disagreement_score":0.18338123,"about_ca_system_score_codex":0.0004665955,"about_ca_system_score_gemma":0.0011150902,"threshold_uncertainty_score":0.7418705},"labels":[],"label_agreement":null},{"id":"W4410011276","doi":"10.1177/08465371251334929","title":"<sup>18</sup> F-FDG PET/CT for the Detection of Immune-Related Adverse Events in Patients With Metastatic Melanoma Receiving Immunotherapy","year":2025,"lang":"en","type":"article","venue":"Canadian Association of Radiologists Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Women's College Hospital; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Adverse effect; Immunotherapy; Melanoma; Immune system; Metastatic melanoma; Oncology; Internal medicine; Nuclear medicine; Cancer research; Immunology","score_opus":0.008207627089336427,"score_gpt":0.2435623975525454,"score_spread":0.235354770463209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410011276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961819,0.0010559002,0.00058542524,0.0008585483,0.00030277323,0.00081805687,0.0000440397,0.000006915,0.00014643431],"genre_scores_gemma":[0.9988965,0.00026056185,0.00019148785,0.00014971629,0.00001802394,0.0000229645,0.000021588343,0.000014180876,0.00042497728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844754,0.00017889094,0.0007406955,0.00013052349,0.00021578083,0.00028659086],"domain_scores_gemma":[0.9982588,0.0003642407,0.00082008686,0.00016951615,0.0003200694,0.00006725201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015416181,0.00013839205,0.00039997307,0.00042420204,0.00016197599,0.0000062769636,0.00015027114,0.000040306884,0.000074832016],"category_scores_gemma":[0.0005381438,0.000098021286,0.00022774382,0.00046559056,0.00007008792,0.00009047197,0.0000048521097,0.00028429885,5.6404787e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025180785,0.000094066614,0.97122073,0.000051145013,0.0021484694,0.000012961955,0.00026698402,0.00077056483,0.0006535186,0.000019787372,0.00029611477,0.02194759],"study_design_scores_gemma":[0.009833394,0.0005231711,0.9864933,0.00025993204,0.00016572075,0.000057324618,0.00026785958,0.0006665883,0.0002611152,0.0000997913,0.0012758318,0.00009600804],"about_ca_topic_score_codex":0.0064221695,"about_ca_topic_score_gemma":0.012859302,"teacher_disagreement_score":0.021851582,"about_ca_system_score_codex":0.0020803818,"about_ca_system_score_gemma":0.0007860974,"threshold_uncertainty_score":0.9708442},"labels":[],"label_agreement":null},{"id":"W4410031582","doi":"10.1016/j.jval.2025.04.2159","title":"Cost-Utility Analysis of Durvalumab and Tremelimumab Versus Best Supportive Care in Refractory Metastatic Colorectal Cancer","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Queen's University; Sunnybrook Health Science Centre; Kingston Health Sciences Centre","funders":"","keywords":"Durvalumab; Tremelimumab; Refractory (planetary science); Colorectal cancer; Medicine; Oncology; Internal medicine; Cancer; Immunotherapy; Nivolumab; Biology","score_opus":0.06745000253906976,"score_gpt":0.3929510278730196,"score_spread":0.32550102533394987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410031582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97872794,0.019198315,0.000006877808,0.00063463725,0.00020722345,0.00072033465,0.00015242869,0.000008828584,0.00034340308],"genre_scores_gemma":[0.99638575,0.0031766028,0.00009092424,0.00018512875,0.000007986487,0.000060169463,0.00004872314,0.0000069658518,0.000037719747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842006,0.00026023522,0.00060146215,0.0002863163,0.00018624884,0.00024566214],"domain_scores_gemma":[0.9992155,0.0002799917,0.00016910746,0.0001859637,0.00008153868,0.00006792987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000616711,0.00012260757,0.0006541423,0.0006319159,0.00003430648,0.0000044998483,0.00005257872,0.0000581878,0.00010128599],"category_scores_gemma":[0.000110262765,0.00011369432,0.00010272122,0.0015242359,0.00012269773,0.00004008479,0.000020345704,0.00018418377,3.4109985e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038247112,0.00081246765,0.71955574,0.0024125224,0.002400138,0.00003927419,0.014776081,0.0006910642,0.0007394915,0.00005809575,0.00012922185,0.22013882],"study_design_scores_gemma":[0.010013263,0.001239498,0.9733811,0.00058816886,0.0006480076,9.4596373e-7,0.00796521,0.004411217,0.0006006305,0.000012916432,0.001025314,0.00011371673],"about_ca_topic_score_codex":0.07168014,"about_ca_topic_score_gemma":0.03449343,"teacher_disagreement_score":0.2538254,"about_ca_system_score_codex":0.00102833,"about_ca_system_score_gemma":0.0013799778,"threshold_uncertainty_score":0.98312455},"labels":[],"label_agreement":null},{"id":"W4410121985","doi":"10.1186/s12967-025-06487-2","title":"Computational analysis of whole slide images predicts PD-L1 expression and progression-free survival in immunotherapy-treated non-small cell lung cancer patients","year":2025,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; Centre hospitalier de l'Université Laval","funders":"Fonds de Recherche du Québec - Santé; Institut de Valorisation des Données","keywords":"Immunotherapy; Feature selection; Lung cancer; Medicine; Oncology; Cancer; Biomarker; Linear discriminant analysis; Cancer immunotherapy; Immune checkpoint; Artificial intelligence; Computational biology; Internal medicine; Computer science; Biology","score_opus":0.008728546698041514,"score_gpt":0.2957744690951082,"score_spread":0.28704592239706667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410121985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98091906,0.01187217,0.0023285542,0.0037728478,0.00025513401,0.00039175965,0.000092232905,0.000006453467,0.00036180412],"genre_scores_gemma":[0.99686414,0.0008264278,0.0017567998,0.00021622627,0.000085539454,0.000009840401,0.00010575765,0.000012391561,0.00012289146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785435,0.00008486941,0.0010159974,0.00017594523,0.0007174711,0.00015136493],"domain_scores_gemma":[0.99843067,0.00034156945,0.0004914915,0.00013637927,0.00051893346,0.000080936865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056532654,0.00017549585,0.0007004685,0.0010254958,0.000050550403,0.0000076158312,0.0001381144,0.00009867359,0.00014553826],"category_scores_gemma":[0.00005562532,0.000122317,0.0001753555,0.0009709776,0.0001579449,0.000116990464,0.000014586639,0.00022721833,6.663614e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061588534,0.0005229003,0.9121386,0.00028228518,0.001443126,0.000013773952,0.0009832323,0.001850837,0.06700267,0.0000048544966,0.0011488292,0.008450047],"study_design_scores_gemma":[0.0180977,0.00047434296,0.96961004,0.0026220984,0.0010940484,0.0000033018894,0.00011342982,0.0035387552,0.004022864,0.000100527766,0.00023040237,0.00009249488],"about_ca_topic_score_codex":0.00012236688,"about_ca_topic_score_gemma":0.000038264716,"teacher_disagreement_score":0.0629798,"about_ca_system_score_codex":0.000079777805,"about_ca_system_score_gemma":0.000272757,"threshold_uncertainty_score":0.49879426},"labels":[],"label_agreement":null},{"id":"W4410268064","doi":"10.1136/jitc-2024-010548","title":"The cold immunological landscape of ATM-deficient cancers","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Telesta Therapeutics (Canada)","funders":"National Cancer Institute; Starr Cancer Consortium","keywords":"Cancer research; Biology; DNA repair; Olaparib; Immune system; Immune checkpoint; Tumor-infiltrating lymphocytes; PARP inhibitor; DNA damage; Immunotherapy; Immunology; Poly ADP ribose polymerase; Gene; DNA; Polymerase; Genetics","score_opus":0.015149643538691459,"score_gpt":0.3357400251105151,"score_spread":0.3205903815718236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410268064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64894587,0.3370047,0.0008841707,0.0064591365,0.003366511,0.0010604317,0.00005965897,0.000024296045,0.0021952207],"genre_scores_gemma":[0.8853357,0.103281,0.00052724255,0.0013100124,0.00020428924,0.00016260719,0.0000032745393,0.000036576224,0.009139312],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984443,0.000044496806,0.000751404,0.00014801505,0.00030558984,0.00030615123],"domain_scores_gemma":[0.99846715,0.00025141123,0.00049751636,0.000315173,0.00043246403,0.000036266974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067822717,0.00017008382,0.00047998902,0.00013884406,0.00030243685,0.000029598368,0.00028971324,0.00011795355,0.00021564374],"category_scores_gemma":[0.000043738546,0.00010026128,0.00054130686,0.0003698029,0.00032788873,0.000048543796,0.000018615932,0.00024832334,3.8976052e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03505886,0.00022597967,0.006943918,0.00017159645,0.003208723,0.0000024033072,0.00039562624,0.00011009607,0.6304763,0.0018734204,0.01731975,0.30421332],"study_design_scores_gemma":[0.011083698,0.0015548802,0.02550656,0.0007729915,0.00020215889,0.000036451507,0.0007085785,0.00010512751,0.11889513,0.00039906727,0.84056157,0.0001737922],"about_ca_topic_score_codex":0.0002025725,"about_ca_topic_score_gemma":0.000048445214,"teacher_disagreement_score":0.82324183,"about_ca_system_score_codex":0.00033056235,"about_ca_system_score_gemma":0.0009248399,"threshold_uncertainty_score":0.40885362},"labels":[],"label_agreement":null},{"id":"W4410316719","doi":"10.1007/s11912-025-01676-0","title":"Effectiveness and Safety of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review of Real-World Studies","year":2025,"lang":"en","type":"review","venue":"Current Oncology Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"University of Sydney","keywords":"Medicine; Oncology; Internal medicine; Adverse effect; Colorectal cancer; Observational study; Clinical trial; MEDLINE; Pembrolizumab; Systematic review; Cancer; Intensive care medicine; Immunotherapy","score_opus":0.05090221844015739,"score_gpt":0.43792020817865035,"score_spread":0.38701798973849294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410316719","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005067067,0.9894038,3.7683353e-7,0.00003605315,0.0019108277,0.007835856,0.000027761618,0.000016331216,0.00026232496],"genre_scores_gemma":[0.00027034857,0.99766463,0.000007441263,0.000007744879,0.00004310317,0.0018808377,0.000051683182,0.000022647533,0.00005153634],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9937856,0.0008922662,0.004336724,0.0005069556,0.00025436297,0.00022406192],"domain_scores_gemma":[0.99426496,0.0011214698,0.003829587,0.00043100357,0.00030138573,0.00005160397],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0037653367,0.0004434321,0.0094764,0.0005119671,0.000028779094,0.000002024387,0.00009008281,0.00023583093,0.000014052181],"category_scores_gemma":[0.0010520765,0.00030763383,0.00089293957,0.0010272394,0.00037000407,0.000027350128,0.00015115652,0.00042786298,2.1894577e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018795647,0.00021678452,0.00041651592,0.78152657,0.0013517957,0.00012680357,0.00007357468,2.1110258e-8,0.000016798951,0.0000039267306,0.00007013501,0.2160091],"study_design_scores_gemma":[0.00073536223,0.0003216231,0.0008393527,0.9538251,0.006856079,0.0004029364,0.000029636152,8.411216e-8,0.00010068354,0.000005859355,0.03671599,0.00016724797],"about_ca_topic_score_codex":0.00020026762,"about_ca_topic_score_gemma":0.00012688774,"teacher_disagreement_score":0.21584184,"about_ca_system_score_codex":0.0014417731,"about_ca_system_score_gemma":0.0025854988,"threshold_uncertainty_score":0.9999376},"labels":[],"label_agreement":null},{"id":"W4410349213","doi":"10.1016/j.lungcan.2025.108583","title":"Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; AstraZeneca (Canada); Institut universitaire de cardiologie et de pneumologie de Québec; Dalhousie University; Université Laval; Queen Elizabeth II Health Sciences Centre; Université de Montréal; University of Calgary; Centre Hospitalier de l’Université de Montréal; BC Cancer Agency; Ottawa Hospital","funders":"AstraZeneca","keywords":"Durvalumab; Medicine; Stage (stratigraphy); Oncology; Internal medicine; Overall survival; Relevance (law); Cancer; Immunotherapy; Nivolumab","score_opus":0.008585620769715262,"score_gpt":0.2952468966671313,"score_spread":0.286661275897416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410349213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968266,0.00050269376,0.0000040820505,0.00009867973,0.00008843139,0.0017782126,0.00015589077,0.000014717273,0.0005307294],"genre_scores_gemma":[0.99533397,0.0004524716,0.000005130778,0.000051055198,0.000012298692,0.00021696437,0.000028771778,0.000025209889,0.0038741338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850595,0.00011218452,0.00032808766,0.0003447804,0.00041077536,0.00029821417],"domain_scores_gemma":[0.9990933,0.00012928099,0.00017752856,0.0004390495,0.00009426596,0.00006658649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012458916,0.00027620053,0.0005637563,0.000121036,0.00008299531,0.00001611952,0.00009999404,0.00003362347,0.00009761658],"category_scores_gemma":[0.0000073694255,0.00013174959,0.000050430917,0.0004978275,0.00007188913,0.00007745242,0.000029514948,0.00013324474,3.2694167e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012812487,0.0003486591,0.98230517,0.0000757433,0.0008575045,0.00002860864,0.00042527923,0.00009941343,0.00009484534,6.62494e-7,0.00020545664,0.0027461788],"study_design_scores_gemma":[0.017688114,0.0009878989,0.9788708,0.00089570944,0.00021215517,2.4843314e-7,0.0005631728,0.00006779981,0.00050012954,1.494282e-7,0.00007006136,0.00014377311],"about_ca_topic_score_codex":0.988673,"about_ca_topic_score_gemma":0.9918272,"teacher_disagreement_score":0.004875628,"about_ca_system_score_codex":0.0028573396,"about_ca_system_score_gemma":0.0014605793,"threshold_uncertainty_score":0.74718434},"labels":[],"label_agreement":null},{"id":"W4410381125","doi":"10.3389/fimmu.2025.1550003","title":"Tumor-infiltrating immune cells state-implications for various breast cancer subtypes","year":2025,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"Southwest Medical University; Department of Science and Technology of Sichuan Province","keywords":"Immune system; Tumor microenvironment; Breast cancer; Carcinogenesis; Cancer research; Biology; Cancer; Immunology; Medicine","score_opus":0.016926078270882727,"score_gpt":0.3139244618772906,"score_spread":0.2969983836064079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410381125","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018837634,0.9896139,0.0014762408,0.0006469942,0.0040277974,0.0026037572,0.0011915019,0.000083740895,0.00033726552],"genre_scores_gemma":[0.000018179138,0.99111575,0.0027593113,0.00023696794,0.00012655722,0.0019596838,0.00038627198,0.00008000504,0.0033172637],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972845,0.00015359913,0.0011767677,0.00065349595,0.00008749218,0.0006442],"domain_scores_gemma":[0.99821293,0.0002613851,0.00055885327,0.00078200334,0.00013545624,0.00004936565],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029964466,0.00053458806,0.0025109358,0.000736496,0.00014898916,0.00003442166,0.0004459852,0.00045987574,0.00008174932],"category_scores_gemma":[0.00005400128,0.00047557615,0.00070451846,0.0008231523,0.00026978343,0.00006579268,0.00008246839,0.0006508025,0.0000060099105],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000559321,0.00012297457,0.00019591361,0.00897885,0.0016009673,0.000008331232,0.00009695538,0.0000011023147,0.00014131365,0.000045271983,0.01025805,0.9779909],"study_design_scores_gemma":[0.0017654494,0.00014804563,0.0011585171,0.011693203,0.0010046173,0.00018048777,0.0000962818,0.0000047189574,0.000041453888,0.00019872919,0.98325825,0.00045025386],"about_ca_topic_score_codex":0.0005870095,"about_ca_topic_score_gemma":0.00008518576,"teacher_disagreement_score":0.9775407,"about_ca_system_score_codex":0.00094032934,"about_ca_system_score_gemma":0.0021066663,"threshold_uncertainty_score":0.99976957},"labels":[],"label_agreement":null},{"id":"W4410424571","doi":"10.1016/j.esmoop.2025.105051","title":"First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Chugai Pharmaceutical; Genentech; Ipsen; Servier; Astellas Pharma; Eisai; Daiichi-Sankyo; Karyopharm Therapeutics; Gilead Sciences; Daiichi Sankyo Europe; Iterion Therapeutics; Sanofi; GlaxoSmithKline; Amgen; Novartis Pharmaceuticals Corporation; Pfizer; Les Laboratories Pierre Fabre; Symphogen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Monoclonal antibody; Medicine; Antibody; Programmed cell death 1; Monoclonal; Cancer research; PD-L1; Oncology; Immunology; Immunotherapy; Internal medicine; Cancer","score_opus":0.014801016748825375,"score_gpt":0.30766719638374646,"score_spread":0.29286617963492106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410424571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99582624,0.00014182509,0.000011095348,0.00020456257,0.000056901725,0.0034810186,0.000012271106,0.000019223477,0.0002468834],"genre_scores_gemma":[0.9991521,0.00007414393,0.00028934688,0.000079347825,0.00000563699,0.00013027852,0.00016606573,0.000028852483,0.000074200034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807125,0.000098641154,0.0005759995,0.00055051345,0.00034312747,0.00036043616],"domain_scores_gemma":[0.9991683,0.000038430502,0.00020292374,0.00040755575,0.00011772189,0.000065062944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000386842,0.00028905508,0.0007987818,0.00043227733,0.00010196719,0.000075508324,0.00026708416,0.0000954549,0.000019166806],"category_scores_gemma":[0.000017220385,0.0002304203,0.000028408005,0.0008509355,0.00015426152,0.0004480659,0.00012724992,0.00019024464,4.1463977e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007188028,0.0043179397,0.9836506,0.00014449643,0.0001428632,0.00008372658,0.0014095453,0.00006960652,0.00095101347,0.000058075137,0.000009519544,0.0019745645],"study_design_scores_gemma":[0.046425983,0.00391216,0.943867,0.0012561489,0.0000638832,0.0000046839496,0.0012496706,0.00008087129,0.0027689934,0.000032304026,0.00008205665,0.00025624508],"about_ca_topic_score_codex":0.009448296,"about_ca_topic_score_gemma":0.026978957,"teacher_disagreement_score":0.039783623,"about_ca_system_score_codex":0.00012197558,"about_ca_system_score_gemma":0.00013473783,"threshold_uncertainty_score":0.99714786},"labels":[],"label_agreement":null},{"id":"W4410506512","doi":"10.1097/hep.0000000000001385","title":"Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial","year":2025,"lang":"en","type":"article","venue":"Hepatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Calgary","funders":"","keywords":"Durvalumab; Tremelimumab; Hepatocellular carcinoma; Medicine; Adverse effect; Internal medicine; Randomized controlled trial; Oncology; Clinical trial; Immune system; Immunotherapy; Gastroenterology; Nivolumab; Immunology; Cancer; Ipilimumab","score_opus":0.028084133891120192,"score_gpt":0.35534630136162054,"score_spread":0.32726216747050035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410506512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899657,0.004129024,0.00020538067,0.0013342605,0.000830601,0.0027528012,0.000016410771,0.0000716742,0.0006941474],"genre_scores_gemma":[0.9909432,0.006743874,0.00017985572,0.00088823837,0.00008689645,0.00022582762,0.00007236963,0.000037378843,0.000822389],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995868,0.0012693981,0.0013747205,0.0006996647,0.00026239047,0.00052579754],"domain_scores_gemma":[0.9975919,0.0014246684,0.0003088496,0.00043661814,0.00009372244,0.00014421635],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025427323,0.0003808419,0.0023989864,0.00036885476,0.00010997294,0.000013722811,0.00012985374,0.00040202006,0.00019981476],"category_scores_gemma":[0.00043938306,0.00029340386,0.00025605844,0.00037623927,0.0006472633,0.000117005555,0.00006904548,0.00046988815,0.00000407634],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9514833,0.00078601047,0.040094,0.000076186814,0.0009593518,0.00015154292,0.00026498875,0.0000011575214,0.0006122294,0.000140462,0.00013007346,0.0053007095],"study_design_scores_gemma":[0.9795768,0.0021971725,0.009527954,0.00019940965,0.00030168105,0.00008103825,0.00014323449,0.0054201423,0.0001198602,0.00014285119,0.0020058912,0.00028391255],"about_ca_topic_score_codex":0.0021586437,"about_ca_topic_score_gemma":0.00087848323,"teacher_disagreement_score":0.030566044,"about_ca_system_score_codex":0.00019320547,"about_ca_system_score_gemma":0.0007734484,"threshold_uncertainty_score":0.99995184},"labels":[],"label_agreement":null},{"id":"W4410529901","doi":"10.1016/j.critrevonc.2025.104768","title":"Immunotherapy in primary hormone-receptor positive breast cancer: A systematic review","year":2025,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Texas MD Anderson Cancer Center; National and Kapodistrian University of Athens; McGill University","keywords":"Breast cancer; Oncology; Hormone receptor; Medicine; Immunotherapy; Internal medicine; Cancer","score_opus":0.03134749409604915,"score_gpt":0.41323372093724725,"score_spread":0.3818862268411981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410529901","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[5.893144e-7,0.97687083,0.000019290956,0.0050636264,0.0008446862,0.014163269,0.00024052874,0.00006155126,0.0027356083],"genre_scores_gemma":[0.0000011386819,0.97480094,0.00035907107,0.012145738,0.00011498931,0.011807071,0.00024546043,0.000099279125,0.000426334],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9873708,0.0040039034,0.005785338,0.0013270396,0.00036094585,0.0011519837],"domain_scores_gemma":[0.99268067,0.0044756844,0.0010306614,0.0013511748,0.00022492502,0.00023689326],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003508282,0.0012500344,0.021226298,0.00088131684,0.00007815854,0.00002298423,0.00082026643,0.0016651874,0.0006875551],"category_scores_gemma":[0.002844165,0.0009034337,0.002110281,0.00206487,0.00073255424,0.0001117896,0.00020340548,0.0020772824,0.00027491315],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025529062,0.0005265691,0.000006746266,0.6357394,0.00029786534,0.00033241895,0.000028020315,1.4087511e-9,0.000002413631,0.0008432079,0.006447019,0.35552105],"study_design_scores_gemma":[0.0010966576,0.00023962972,0.000012176338,0.59629935,0.0021268171,0.0025743155,0.000009541737,2.8775213e-7,3.5140667e-7,0.000027511678,0.39718378,0.0004295935],"about_ca_topic_score_codex":0.00007394631,"about_ca_topic_score_gemma":0.00005481841,"teacher_disagreement_score":0.39073676,"about_ca_system_score_codex":0.004028348,"about_ca_system_score_gemma":0.0037638885,"threshold_uncertainty_score":0.999795},"labels":[],"label_agreement":null},{"id":"W4410595792","doi":"10.1016/j.trim.2025.102242","title":"Successful use of cemiplimab in a high immunologic risk kidney transplant recipient with metastatic squamous cell carcinoma","year":2025,"lang":"en","type":"article","venue":"Transplant Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; University of Alberta","funders":"Bristol-Myers Squibb Foundation","keywords":"Medicine; Basal cell; Kidney transplant; Kidney; Pathology; Oncology; Kidney transplantation; Internal medicine","score_opus":0.01315609118440378,"score_gpt":0.23245622439831595,"score_spread":0.21930013321391217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410595792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99171597,0.0048116366,0.00063141895,0.00060544966,0.0003071428,0.00090283155,0.0005799312,0.00006905837,0.0003765489],"genre_scores_gemma":[0.9947489,0.0035254273,0.0006708186,0.00036838348,0.000008004661,0.00010367076,0.0002254957,0.000032387885,0.00031690404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99748963,0.0002944208,0.00085640483,0.0005314551,0.00021102569,0.0006170506],"domain_scores_gemma":[0.9985448,0.000402395,0.00024676707,0.000645832,0.0000884368,0.000071749855],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029175336,0.0004106197,0.0009861087,0.0006447486,0.00009366854,0.000014497779,0.0002816104,0.00024404182,0.00020005931],"category_scores_gemma":[0.000023866964,0.00030966447,0.00020462686,0.00077530195,0.00048396603,0.00011643168,0.000018693745,0.00061874406,0.0000076215756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10703274,0.0026458541,0.5700888,0.0014036457,0.0014330735,0.0013172441,0.0036825817,0.0001168587,0.30741274,0.0004499781,0.00013486933,0.004281629],"study_design_scores_gemma":[0.038016677,0.0046861134,0.78548414,0.0011471068,0.0017526585,0.00063443265,0.0005317692,0.00012465483,0.16510199,0.000090288166,0.0018226537,0.0006075435],"about_ca_topic_score_codex":0.007793389,"about_ca_topic_score_gemma":0.0005409073,"teacher_disagreement_score":0.21539533,"about_ca_system_score_codex":0.00017701011,"about_ca_system_score_gemma":0.0004779599,"threshold_uncertainty_score":0.99993557},"labels":[],"label_agreement":null},{"id":"W4410599138","doi":"10.1080/2162402x.2025.2507856","title":"Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference","year":2025,"lang":"en","type":"review","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Weill Cornell Medical College; Pfizer","keywords":"Immunotherapy; Medicine; Radiation therapy; Medical physics; Cancer; Internal medicine","score_opus":0.02578443872472441,"score_gpt":0.34544427869642474,"score_spread":0.31965983997170033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410599138","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013563986,0.98652434,0.00001392623,0.00049670885,0.000780562,0.0019965076,0.0002528664,0.00014905045,0.009650393],"genre_scores_gemma":[0.00007497328,0.98768216,0.000447792,0.00040243473,0.000086213935,0.00036919213,0.00030941074,0.00010326137,0.0105245495],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967608,0.00012534049,0.001481279,0.00074359955,0.00034660782,0.0005423802],"domain_scores_gemma":[0.99717426,0.00040652198,0.0010827375,0.0007350506,0.0005472351,0.00005416892],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046088645,0.0008341712,0.0037728588,0.0010895089,0.00014402253,0.000043276552,0.00076920545,0.0010219592,0.0006298465],"category_scores_gemma":[0.00009059602,0.0006766186,0.0010572274,0.0011144971,0.0006895122,0.00012916322,0.000090430316,0.0009781533,0.000040913823],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015300532,0.00095845584,0.000010873176,0.009508616,0.0031471737,0.000009072125,0.00032727278,2.5885557e-8,0.0005561991,0.004893555,0.005060408,0.9739983],"study_design_scores_gemma":[0.004353836,0.0024485025,0.00008216921,0.025552219,0.0006409159,0.00018594149,0.0002403525,7.212959e-7,0.00015917663,0.00013232842,0.9657026,0.00050122297],"about_ca_topic_score_codex":0.0000799743,"about_ca_topic_score_gemma":0.000002804218,"teacher_disagreement_score":0.9734971,"about_ca_system_score_codex":0.00060144585,"about_ca_system_score_gemma":0.0015449859,"threshold_uncertainty_score":0.9995685},"labels":[],"label_agreement":null},{"id":"W4410646356","doi":"10.51731/cjht.2025.1133","title":"Durvalumab (Imfinzi)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Durvalumab; Medicine; Internal medicine; Cancer","score_opus":0.020596970468108097,"score_gpt":0.31009797314778254,"score_spread":0.28950100267967444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410646356","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22531915,0.39269194,0.00059298094,0.3738513,0.0016995159,0.00045509794,0.000013837761,0.00017929492,0.005196881],"genre_scores_gemma":[0.994768,0.0013454988,0.00044543965,0.002888781,0.000007745305,0.000002363712,8.4714856e-7,0.0000059968534,0.0005352877],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99908173,0.000022517836,0.00043876996,0.000078966135,0.00008767438,0.0002903186],"domain_scores_gemma":[0.99941146,0.000025133799,0.00018693897,0.00020274588,0.00012258918,0.00005112155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049150846,0.00007943733,0.00029911203,0.00075280684,0.00014876139,0.000016316018,0.00017778501,0.0001136128,0.0000463355],"category_scores_gemma":[0.00026353463,0.00006341475,0.000097351265,0.00045852887,0.00020003773,0.000042187054,0.000007812162,0.00030873262,0.000003325551],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011371474,0.000012192795,0.0075268773,0.00011772961,0.000100666664,0.00009596291,0.000079240956,5.982445e-7,0.0001664347,0.0010052852,0.03553923,0.9552421],"study_design_scores_gemma":[0.0014232778,0.00050262694,0.046557654,0.00075650366,0.000022550916,0.0003701732,0.002001002,0.000003049937,0.0014534462,0.0022706876,0.9445645,0.00007451022],"about_ca_topic_score_codex":0.003637112,"about_ca_topic_score_gemma":0.002622017,"teacher_disagreement_score":0.95516753,"about_ca_system_score_codex":0.00056202,"about_ca_system_score_gemma":0.0060324734,"threshold_uncertainty_score":0.9996024},"labels":[],"label_agreement":null},{"id":"W4410708315","doi":"10.1016/j.jtho.2025.05.016","title":"Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Incorporated; Merck Sharp and Dohme; Eisai Canada; Eisai; Merck; Eli Lilly and Company","keywords":"Medicine; Pemetrexed; Pembrolizumab; Oncology; Lenvatinib; Lung cancer; Internal medicine; Atezolizumab; Nivolumab; Cancer; Chemotherapy; Immunotherapy; Cisplatin","score_opus":0.04779553451295115,"score_gpt":0.4649378753724637,"score_spread":0.4171423408595126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410708315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97935474,0.007071299,0.0021564201,0.007826606,0.00081936264,0.0017855074,0.00002170495,0.000021265909,0.00094309234],"genre_scores_gemma":[0.99162924,0.0009887961,0.0029829706,0.001958699,0.0002928981,0.000076231125,0.000007856759,0.000030323014,0.002032991],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99785,0.0002189771,0.001057916,0.00026375585,0.0002918376,0.00031751592],"domain_scores_gemma":[0.99763155,0.000887563,0.00072148634,0.0002518984,0.0003702204,0.000137301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001496612,0.00026156465,0.0010833693,0.0005369784,0.00018185207,0.000034899993,0.00018409234,0.00013336314,0.00019225672],"category_scores_gemma":[0.00038615667,0.00019208888,0.0003018846,0.0004129095,0.00015473469,0.000122051206,0.000039668717,0.00040325584,0.0000028757142],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2104396,0.005113285,0.0013144097,0.00025805947,0.0022769198,0.00047120635,0.0022666561,0.000017517428,0.0053946017,0.000030816096,0.006612649,0.7658043],"study_design_scores_gemma":[0.30925307,0.20735767,0.015339289,0.0011003288,0.005086113,0.0061832773,0.013629876,0.0019100956,0.00846167,0.0019980045,0.4287861,0.00089451845],"about_ca_topic_score_codex":0.0000674577,"about_ca_topic_score_gemma":0.000143048,"teacher_disagreement_score":0.76490974,"about_ca_system_score_codex":0.00038371186,"about_ca_system_score_gemma":0.0011555848,"threshold_uncertainty_score":0.7833157},"labels":[],"label_agreement":null},{"id":"W4410712213","doi":"10.1136/jitc-2024-011404","title":"IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against pancreatic cancer in mice with obesity","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute of Neurological Disorders and Stroke; National Institute of Mental Health; National Cancer Institute; Ludwig Institute for Cancer Research; National Foundation for Cancer Research","keywords":"Medicine; Pancreatic cancer; Oncology; FOLFIRINOX; Immune checkpoint; Internal medicine; Blockade; Cancer; Cardiotoxicity; Chemoimmunotherapy; Chemotherapy; Immunotherapy; Receptor","score_opus":0.007628141211374882,"score_gpt":0.28763999250250477,"score_spread":0.2800118512911299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410712213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9243543,0.070866294,0.00006495145,0.0030409652,0.00023595602,0.0013347889,0.000043680855,0.000009092358,0.000049956718],"genre_scores_gemma":[0.9211237,0.07701588,0.00040263592,0.0006043638,0.00009217268,0.0001196138,0.000001690334,0.000037309263,0.00060267764],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982226,0.00007632729,0.00083220174,0.00026664056,0.00028378333,0.00031848333],"domain_scores_gemma":[0.99868566,0.00019734073,0.00059051294,0.0002844851,0.0001842503,0.00005774543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075239554,0.0002910235,0.0008576682,0.00020018086,0.0001650835,0.00003131228,0.00018944395,0.00012868464,0.000028906368],"category_scores_gemma":[0.000027079977,0.00018425657,0.0002910512,0.00036753455,0.0004373741,0.0000958177,0.000024187548,0.00033632055,2.862513e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02181773,0.00027453728,0.044787597,0.00048329448,0.0027624017,0.0000021431724,0.0015464372,0.000029706918,0.77621436,0.000005907636,0.00009546423,0.15198043],"study_design_scores_gemma":[0.02354024,0.00085796835,0.58340514,0.0027911249,0.0003640763,0.000037991587,0.0005490566,0.0001457144,0.38177812,0.000083579915,0.006199053,0.0002479645],"about_ca_topic_score_codex":0.0014811687,"about_ca_topic_score_gemma":0.00021476901,"teacher_disagreement_score":0.5386175,"about_ca_system_score_codex":0.0002442642,"about_ca_system_score_gemma":0.0005088304,"threshold_uncertainty_score":0.7513765},"labels":[],"label_agreement":null},{"id":"W4410795637","doi":"10.1200/jco.2025.43.16_suppl.2636","title":"Biological determinants of immune exclusion in non-small cell lung cancer: An analysis of the precision medicine BIP study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Lung cancer; Immune system; Precision medicine; Cancer; Oncology; Internal medicine; Cancer research; Immunology; Pathology","score_opus":0.08986989931342658,"score_gpt":0.4881347278346573,"score_spread":0.3982648285212307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942169,0.0026940464,0.000049070877,0.0013098222,0.0010555371,0.00040821466,0.000003116111,0.0000018375955,0.0002614423],"genre_scores_gemma":[0.99536896,0.0037693768,0.00016069648,0.00044867172,0.00013441594,0.000004173761,8.675533e-7,0.000005025382,0.000107836866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945416,0.0008646017,0.003935354,0.00019551095,0.00030907438,0.0001538791],"domain_scores_gemma":[0.9946608,0.0019482453,0.002587956,0.00035515692,0.00036413572,0.000083693194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068963147,0.00012713468,0.0023477485,0.0005015845,0.00003176078,0.0000016312025,0.0004044199,0.00034024895,0.00014847907],"category_scores_gemma":[0.0013513874,0.00006220528,0.0007085456,0.0011807694,0.00034247962,0.00003785026,0.00013304506,0.00057087495,1.00377996e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012973191,0.0027977128,0.8498607,0.000040731975,0.0007298248,0.000041918967,0.00044947662,0.0000480545,0.011679012,7.654991e-7,0.000082104605,0.1212965],"study_design_scores_gemma":[0.010921385,0.012174994,0.97038597,0.0005551708,0.0021235147,0.000006240422,0.00072179164,0.0013058685,0.0012758068,0.000017984532,0.00046083963,0.000050428],"about_ca_topic_score_codex":0.0010023866,"about_ca_topic_score_gemma":0.0018012432,"teacher_disagreement_score":0.12124607,"about_ca_system_score_codex":0.00016184794,"about_ca_system_score_gemma":0.0008176712,"threshold_uncertainty_score":0.26243114},"labels":[],"label_agreement":null},{"id":"W4410802882","doi":"10.1200/jco.2025.43.16_suppl.2545","title":"Validation of an optimized tissue-agnostic genome-wide methylome enrichment assay to predict clinical outcomes in patients treated with pembrolizumab.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; DNA methylation; Genome; Oncology; Computational biology; Internal medicine; Bioinformatics; Cancer; Genetics; Gene; Biology; Immunotherapy; Gene expression","score_opus":0.05140425094792985,"score_gpt":0.43893779500628,"score_spread":0.38753354405835017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99468535,0.00009813456,0.00060439087,0.002531148,0.00077806314,0.0006959434,0.000008365554,0.00000919645,0.0005893781],"genre_scores_gemma":[0.9910562,0.00029333966,0.0058008926,0.0023407824,0.00014616647,0.000011839887,0.000018225594,0.000015215153,0.00031734107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934473,0.0013282561,0.0042662746,0.0002734088,0.0004528507,0.00023193409],"domain_scores_gemma":[0.9917999,0.005315305,0.0016935964,0.00030275213,0.00058631797,0.0003021204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006176122,0.00018311797,0.002249524,0.0004081237,0.000023036084,0.000008204368,0.00022652365,0.00039028408,0.00011185791],"category_scores_gemma":[0.0070108357,0.000117574265,0.00039837373,0.00041384835,0.00017432406,0.000107621476,0.000046278856,0.0006267888,0.0000034114057],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.073171325,0.0049780826,0.86945724,0.000025882213,0.0010067823,0.00008838725,0.000059198912,0.0002454147,0.00012894356,0.0000029037394,0.0003171624,0.050518658],"study_design_scores_gemma":[0.04376357,0.040658012,0.9100452,0.00016753889,0.0005840178,0.000008269035,0.00003443755,0.000034848403,0.00039153107,0.000026230104,0.0041918387,0.00009452196],"about_ca_topic_score_codex":0.000074799456,"about_ca_topic_score_gemma":0.00002477793,"teacher_disagreement_score":0.050424136,"about_ca_system_score_codex":0.00030198082,"about_ca_system_score_gemma":0.001233666,"threshold_uncertainty_score":0.8393132},"labels":[],"label_agreement":null},{"id":"W4410803209","doi":"10.1200/jco.2025.43.16_suppl.8611","title":"Interim results of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in patients with NSCLC in a phase 1 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; non-small cell lung cancer (NSCLC); Oncology; Internal medicine; Interim; Lung cancer","score_opus":0.07753471214883798,"score_gpt":0.4760811882307938,"score_spread":0.3985464760819558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924624,0.00029447585,0.00007016704,0.004197032,0.0010840666,0.00051126356,0.0000073762976,0.000004368947,0.0013688633],"genre_scores_gemma":[0.996251,0.00008694323,0.0012611058,0.0020903037,0.00020123484,0.0000063368902,0.000008099989,0.000010672397,0.00008429472],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944529,0.00061303517,0.0041924324,0.00020802938,0.0003037589,0.00022985772],"domain_scores_gemma":[0.9948939,0.002228126,0.0022168872,0.00019041698,0.0003549817,0.0001156688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005506293,0.00014299189,0.001608278,0.00043972908,0.000014523402,0.0000051731467,0.00017812895,0.00030945384,0.000064307715],"category_scores_gemma":[0.005941436,0.00009737024,0.0003605471,0.0004987696,0.000221907,0.00006466174,0.000029465149,0.0009012028,0.0000010870073],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80742145,0.00865796,0.058010504,0.000050652114,0.00021007315,0.00014246626,0.0001119947,0.000016079746,0.0002700965,0.0000027052822,0.0023105894,0.12279541],"study_design_scores_gemma":[0.6691703,0.059641507,0.24612054,0.0016966829,0.00014979915,0.00000422703,0.0001379222,0.00013952762,0.00037934192,0.000027560773,0.022427548,0.00010501296],"about_ca_topic_score_codex":0.00010915191,"about_ca_topic_score_gemma":0.00020159999,"teacher_disagreement_score":0.18811004,"about_ca_system_score_codex":0.00027043768,"about_ca_system_score_gemma":0.0027006795,"threshold_uncertainty_score":0.7112883},"labels":[],"label_agreement":null},{"id":"W4410804010","doi":"10.1200/jco.2025.43.16_suppl.6033","title":"Initial safety and efficacy of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in combination with pembrolizumab in patients with recurrent or metastatic (R/M) HNSCC.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.0502117729583029,"score_gpt":0.4221898160640512,"score_spread":0.37197804310574833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962839,0.0003273678,0.00022856022,0.002062953,0.00031886212,0.00048389807,0.0000047436606,0.000003611889,0.000286143],"genre_scores_gemma":[0.9968398,0.00018582036,0.0021212962,0.0007608239,0.00004711012,0.0000042837555,0.000010322221,0.000010568355,0.000019952748],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99646974,0.0005790119,0.002256353,0.0001816501,0.000324266,0.00018900313],"domain_scores_gemma":[0.99544036,0.0025896993,0.0014090723,0.00011082231,0.00035198795,0.00009807057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025266358,0.00014305998,0.0012677009,0.0003534517,0.000024103676,0.000005843238,0.00009366679,0.00014559984,0.0000549713],"category_scores_gemma":[0.002003633,0.00008579186,0.00012558208,0.00045133106,0.00025990102,0.00007638851,0.000021027312,0.00067181396,3.016891e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5047111,0.005520203,0.29449776,0.0001756994,0.00033012478,0.00014267201,0.00016843005,0.0000664816,0.00002328902,0.000023203313,0.00013406623,0.19420695],"study_design_scores_gemma":[0.13520941,0.03298365,0.82772297,0.0012978633,0.00024151089,0.000014570324,0.00010908651,0.00026694723,0.00005130769,0.000025882617,0.0019913728,0.0000854299],"about_ca_topic_score_codex":0.00005276922,"about_ca_topic_score_gemma":0.00032111243,"teacher_disagreement_score":0.5332252,"about_ca_system_score_codex":0.00024035246,"about_ca_system_score_gemma":0.0023411566,"threshold_uncertainty_score":0.4153111},"labels":[],"label_agreement":null},{"id":"W4410804953","doi":"10.1200/jco.2025.43.16_suppl.tps9604","title":"TeLuRide-006: An adaptive phase 2/3 study of EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, in combination with pembrolizumab in patients with advanced melanoma.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Agonist; TLR7; TLR9; Toll-like receptor; Cancer research; Receptor; Toll-Like Receptor 9; Oncology; Internal medicine; Immunotherapy; Cancer; Gene; Innate immune system; Genetics","score_opus":0.04008054253250323,"score_gpt":0.4177264549160286,"score_spread":0.3776459123835254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997228,0.00013344162,0.000052987052,0.00069508044,0.0004258666,0.0008672319,0.0000047366634,0.000005286399,0.00058736367],"genre_scores_gemma":[0.99823266,0.00007252915,0.0010310046,0.00047243419,0.00005158233,0.000016196514,0.000007703977,0.000013636105,0.000102231796],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99648595,0.0005621671,0.002120991,0.00024188838,0.00039145758,0.00019753638],"domain_scores_gemma":[0.9970674,0.0006212955,0.0014793179,0.00021387934,0.00049793924,0.00012019183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015559235,0.0001646929,0.0014036425,0.00039821645,0.000026168298,0.0000056762005,0.00016181532,0.0002031327,0.000044446668],"category_scores_gemma":[0.00028617255,0.0001084055,0.00011718526,0.0005105332,0.00018865292,0.00020125542,0.000023973824,0.00068964914,5.743134e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39872244,0.03515841,0.394383,0.000023846069,0.000436922,0.00015561754,0.00052240735,0.00002938484,0.00007832665,0.000017349328,0.00017301863,0.17029928],"study_design_scores_gemma":[0.17447142,0.18479341,0.636981,0.0003214342,0.00015517343,0.000012210964,0.0013153452,0.00004312502,0.00005349066,0.000025506482,0.0017397819,0.00008808813],"about_ca_topic_score_codex":0.0001134992,"about_ca_topic_score_gemma":0.0013152554,"teacher_disagreement_score":0.24259798,"about_ca_system_score_codex":0.00039200974,"about_ca_system_score_gemma":0.001529301,"threshold_uncertainty_score":0.4420648},"labels":[],"label_agreement":null},{"id":"W4410805015","doi":"10.1200/jco.2025.43.16_suppl.e20555","title":"Molecular profiling of metastatic lung squamous cell carcinoma (mLUSC) to identify patients with differential response to immune checkpoint inhibitor (ICI) therapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Lung; Oncology; Immune system; Cancer research; Basal cell; Lung cancer; Carcinoma; Pathology; Internal medicine; Immunology","score_opus":0.0405326169658677,"score_gpt":0.409315266569293,"score_spread":0.3687826496034253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99203795,0.00092087005,0.0015574958,0.0031964926,0.0012382683,0.00088660355,0.000008198607,0.0000069757225,0.00014714006],"genre_scores_gemma":[0.9949894,0.000035475343,0.0029389418,0.0016983104,0.0001398387,0.000013505832,0.0000033086553,0.000024534542,0.00015670138],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99532706,0.0007612647,0.0028563295,0.0002546254,0.00052279315,0.0002779447],"domain_scores_gemma":[0.9962246,0.0011408889,0.0012875099,0.0003228375,0.00074918236,0.00027499915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028337378,0.00020753087,0.0015076395,0.00039652298,0.000040684212,0.00001278822,0.00024486578,0.00019130357,0.00007884201],"category_scores_gemma":[0.001498148,0.000138368,0.0006275652,0.00042945895,0.00013335707,0.000059483245,0.0000855249,0.0005885537,0.0000031378554],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3468289,0.0039752233,0.06242119,0.00017186311,0.0007164105,0.00028492368,0.00041044253,0.000034589833,0.5646119,0.0000055641867,0.000424526,0.020114457],"study_design_scores_gemma":[0.031486522,0.031322982,0.7484748,0.00028115298,0.0005325114,0.000018966683,0.00022739601,0.00002578776,0.1855894,0.000017727853,0.0018694354,0.00015335163],"about_ca_topic_score_codex":0.000039037222,"about_ca_topic_score_gemma":0.0000071171125,"teacher_disagreement_score":0.6860536,"about_ca_system_score_codex":0.00024339852,"about_ca_system_score_gemma":0.0016003492,"threshold_uncertainty_score":0.5642484},"labels":[],"label_agreement":null},{"id":"W4410805568","doi":"10.1200/jco.2025.43.16_suppl.e20585","title":"PD-1 inhibitors versus PD-L1 inhibitors in PD-L1–negative advanced non-small cell lung cancer: A meta-analysis of survival outcomes.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Oncology; PD-L1; Internal medicine; Programmed cell death 1; Meta-analysis; Cancer; Cancer research; Immunotherapy","score_opus":0.11961093292082893,"score_gpt":0.4749252272377434,"score_spread":0.35531429431691447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97193986,0.0063591576,0.00008601566,0.010166405,0.005707324,0.0005765462,0.000037376,0.000011517924,0.0051158047],"genre_scores_gemma":[0.9917,0.0029122776,0.001252375,0.0023521022,0.0003804082,0.000031519176,0.0000064651676,0.000026993042,0.001337887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923236,0.0008509924,0.005280047,0.00045847768,0.00064347615,0.00044344383],"domain_scores_gemma":[0.9882528,0.0066805235,0.003613297,0.00042572513,0.0007403908,0.0002872302],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005160872,0.00037529884,0.006460983,0.001110733,0.000051923085,0.000012261742,0.00038070456,0.0006565897,0.00044864143],"category_scores_gemma":[0.0023431578,0.00026298867,0.0050286874,0.0019776989,0.00039907312,0.00014764826,0.0001182745,0.0014944822,0.0000024288345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.119481154,0.004939424,0.535896,0.0003151914,0.284145,0.0005302461,0.0012295016,0.00139678,0.002690115,0.00003871365,0.007841776,0.041496105],"study_design_scores_gemma":[0.06827001,0.009575272,0.64607126,0.00027103606,0.23471853,0.0000074988284,0.0019485293,0.00048678202,0.004926145,0.00007789518,0.033103656,0.0005434092],"about_ca_topic_score_codex":0.0010689878,"about_ca_topic_score_gemma":0.004232257,"teacher_disagreement_score":0.110175245,"about_ca_system_score_codex":0.00078452955,"about_ca_system_score_gemma":0.0031694311,"threshold_uncertainty_score":0.99998224},"labels":[],"label_agreement":null},{"id":"W4410809228","doi":"10.1200/jco.2025.43.16_suppl.570","title":"MHC class I expression and outcomes in breast cancer in the real-world clinico-genomic data and the FinXX trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology","funders":"","keywords":"Medicine; Breast cancer; Cancer; Oncology; Class (philosophy); Internal medicine","score_opus":0.1336709002924435,"score_gpt":0.5140138831179181,"score_spread":0.3803429828254746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8523353,0.0022223701,0.000002753451,0.1426092,0.0011133458,0.00041245008,0.000016114664,0.0000019256854,0.0012865765],"genre_scores_gemma":[0.96319425,0.023005577,0.00008092322,0.012800485,0.0004640445,0.0000105401205,0.0000015104223,0.0000059225745,0.00043673042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99628216,0.0011349958,0.0020748423,0.00019403223,0.00016740551,0.00014655675],"domain_scores_gemma":[0.9909488,0.0077340677,0.0008357282,0.00037367732,0.000050822946,0.000056893572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011394425,0.00010291502,0.0011432626,0.00013886938,0.000040287305,0.000017557493,0.00036494053,0.00019850385,0.000051018058],"category_scores_gemma":[0.0011638214,0.000044611956,0.00015596539,0.00018861861,0.00048359123,0.00007873012,0.00015969796,0.0009690399,4.1875836e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25540692,0.00064457866,0.54080236,0.000022775022,0.00018742384,0.00006744396,0.00020235394,0.0000011256402,0.000101644575,0.000086735316,0.006774311,0.19570237],"study_design_scores_gemma":[0.122521654,0.0007272344,0.8272706,0.00018660726,0.00015818629,0.00003505498,0.00029243194,0.000089055335,0.0000019550646,0.0003296843,0.04834543,0.00004206651],"about_ca_topic_score_codex":0.00051741104,"about_ca_topic_score_gemma":0.003580697,"teacher_disagreement_score":0.2864683,"about_ca_system_score_codex":0.00008833465,"about_ca_system_score_gemma":0.0010299634,"threshold_uncertainty_score":0.421005},"labels":[],"label_agreement":null},{"id":"W4410810717","doi":"10.1200/jco.2025.43.16_suppl.2632","title":"Validation of ENLIGHT, an AI predictor of immune checkpoint blockade (ICB) response and resistance, across the treatment span.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University; University Health Network","funders":"","keywords":"Medicine; Blockade; Immune checkpoint; Oncology; Internal medicine; Receptor","score_opus":0.06131153850967042,"score_gpt":0.4603479341100242,"score_spread":0.3990363956003538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97873276,0.0027418442,0.00005761184,0.017266454,0.0005942551,0.00022528715,0.000014595817,0.0000036022764,0.00036360315],"genre_scores_gemma":[0.99430424,0.003258203,0.00056858937,0.000511113,0.00023226693,0.000003965342,0.0000019555816,0.0000066622983,0.0011130193],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9964359,0.0006916255,0.002409331,0.00012716945,0.0002052868,0.00013072249],"domain_scores_gemma":[0.9957403,0.001979467,0.0015798389,0.0002742279,0.00034026915,0.00008589219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005540929,0.000102305385,0.0009861531,0.00007894106,0.000047027384,0.000005796525,0.00012865583,0.00023468096,0.00003811581],"category_scores_gemma":[0.0011867993,0.000056273944,0.00041880563,0.00016762222,0.0004924862,0.00006191282,0.000023686825,0.00030172314,2.8298098e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60299265,0.0066396478,0.065103754,0.00017486796,0.0032396705,0.00011988898,0.003211055,0.000011327033,0.21581496,0.00018012675,0.0016413698,0.10087069],"study_design_scores_gemma":[0.018277306,0.024138149,0.7733887,0.00030395394,0.00055424444,0.000055980956,0.0006156764,0.00002404965,0.07549528,0.00055724615,0.10652761,0.00006184637],"about_ca_topic_score_codex":0.000033500306,"about_ca_topic_score_gemma":0.00005411307,"teacher_disagreement_score":0.7082849,"about_ca_system_score_codex":0.00014388049,"about_ca_system_score_gemma":0.0011937824,"threshold_uncertainty_score":0.22947848},"labels":[],"label_agreement":null},{"id":"W4410820763","doi":"10.1200/jco.2025.43.16_suppl.tps5632","title":"Randomized study evaluating optimal dose, efficacy and safety of E7386 + lenvatinib versus treatment of physicians’ choice in advanced/recurrent endometrial carcinoma previously treated with anti–PD-(L)1 immunotherapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lenvatinib; Immunotherapy; Oncology; Internal medicine; Randomized controlled trial; Endometrial cancer; Gynecology; Carcinoma; Cancer; Sorafenib; Hepatocellular carcinoma","score_opus":0.11555544957277976,"score_gpt":0.4839434033552135,"score_spread":0.3683879537824338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410820763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98894584,0.007173933,0.00003062701,0.00039195578,0.0007118892,0.0024358612,0.0000051110674,0.00000545561,0.0002993442],"genre_scores_gemma":[0.99355334,0.0045876447,0.0014923535,0.000065748114,0.00020237925,0.000031148527,0.0000035108064,0.000016251672,0.00004760467],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99369526,0.0015641642,0.003813145,0.00028477263,0.0004009213,0.0002417567],"domain_scores_gemma":[0.98415816,0.012107794,0.002966597,0.00025840724,0.00043585792,0.00007317329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004551567,0.00025684916,0.0040579196,0.00039824133,0.00003694235,0.0000061165247,0.00014017757,0.0001875826,0.000030237215],"category_scores_gemma":[0.002792454,0.000160751,0.0006081362,0.0006413559,0.00044138767,0.000084313244,0.000025407171,0.00037938717,1.6156879e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5707983,0.0059449617,0.07177015,0.000035966725,0.0021908106,0.00003104733,0.00045677688,0.000059438775,0.00124727,0.0000024515482,0.000005258881,0.3474576],"study_design_scores_gemma":[0.5802949,0.09738566,0.3194635,0.00039434657,0.0010550665,0.00001001964,0.00031752288,0.000093044975,0.00044425108,0.0000016542123,0.00046304244,0.000076988166],"about_ca_topic_score_codex":0.0002394216,"about_ca_topic_score_gemma":0.00010202622,"teacher_disagreement_score":0.3473806,"about_ca_system_score_codex":0.00030567634,"about_ca_system_score_gemma":0.0013209688,"threshold_uncertainty_score":0.6555236},"labels":[],"label_agreement":null},{"id":"W4410822180","doi":"10.1200/jco.2025.43.16_suppl.3129","title":"Using single-cell sequencing to identify endothelial expression of immune checkpoint ligands in advanced hepatocellular carcinoma, pre- and post- atezolizumab plus bevacizumab in the phase II INTEGRATE study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canada's Michael Smith Genome Sciences Centre; Princess Margaret Cancer Centre; University Health Network; University of British Columbia","funders":"","keywords":"Atezolizumab; Medicine; Bevacizumab; Hepatocellular carcinoma; Cancer research; Immune checkpoint; Vascular endothelial growth factor; Oncology; Immune system; VEGF receptors; Immunotherapy; Internal medicine; Immunology; Nivolumab; Chemotherapy","score_opus":0.1036887650843341,"score_gpt":0.4531016664911236,"score_spread":0.3494129014067895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543613,0.0018983373,0.00011894436,0.0009473291,0.00061352743,0.0008200148,0.00000477643,0.0000037222303,0.0001572137],"genre_scores_gemma":[0.99829024,0.000199726,0.0007932015,0.0005013775,0.000120571385,0.000009048989,0.0000013946976,0.000013256169,0.000071198134],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99535924,0.00053654116,0.0032895058,0.00025221435,0.000314427,0.00024806225],"domain_scores_gemma":[0.9972807,0.0008164655,0.0012614358,0.00027089857,0.00026946652,0.00010102192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047254246,0.00018721937,0.0014197615,0.0004141088,0.00006103881,0.000013792717,0.00025984045,0.0002404336,0.000014912845],"category_scores_gemma":[0.0012297272,0.00012014358,0.00033598067,0.00041713635,0.00014711676,0.00012844398,0.00013280506,0.0009013248,2.6596118e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05960339,0.003305787,0.024843458,0.00007763072,0.00007704064,0.0005794162,0.0051454348,0.00004611292,0.8781112,0.00000138039,0.000010865938,0.0281983],"study_design_scores_gemma":[0.14126134,0.07655283,0.25891235,0.0026180726,0.00051776116,0.00044870155,0.018892797,0.0013722214,0.4980871,0.00008812733,0.0009492261,0.00029947015],"about_ca_topic_score_codex":0.0006085114,"about_ca_topic_score_gemma":0.00017149273,"teacher_disagreement_score":0.38002408,"about_ca_system_score_codex":0.00065748964,"about_ca_system_score_gemma":0.0017540896,"threshold_uncertainty_score":0.48993132},"labels":[],"label_agreement":null},{"id":"W4410869103","doi":"10.21037/tlcr-2024-1204","title":"Combination of immune checkpoint inhibitors with multi-targeted tyrosine kinase inhibitors for second- or later-line therapy of non-small cell lung cancer: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Translational Lung Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Tyrosine kinase; Lung cancer; Targeted therapy; Oncology; Bioinformatics; Cancer; Cancer research; Internal medicine; Receptor; Biology","score_opus":0.09839336803857801,"score_gpt":0.4268929602947006,"score_spread":0.3284995922561226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410869103","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019924762,0.98085314,0.0002882323,0.00062406913,0.000059160608,0.015844863,0.0020957128,0.000017969502,0.000017608296],"genre_scores_gemma":[0.0019819462,0.98748595,0.0005234847,0.00006184173,0.00004460485,0.006761148,0.0007858235,0.000081149665,0.0022740592],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99471724,0.00055145647,0.0025799884,0.0007183066,0.0009996468,0.00043335653],"domain_scores_gemma":[0.9955998,0.0009311261,0.0012040259,0.00061596005,0.0015254992,0.00012357188],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002803947,0.00061864,0.006744312,0.0012623235,0.0001352949,0.00002975202,0.00029592315,0.00030894898,0.0007430188],"category_scores_gemma":[0.00005766587,0.00037243165,0.0023172093,0.0031513227,0.0002557679,0.000099299265,0.000033867997,0.0005425819,2.3923621e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014276587,0.0003628777,0.00004539107,0.90406245,0.08945624,0.0000033209647,0.00022976757,0.000012845493,0.00053366553,0.0000045543566,0.00009600561,0.0037652415],"study_design_scores_gemma":[0.009785488,0.0011589188,0.00012826668,0.30373308,0.6700979,0.000008947721,0.000044478464,0.0008559107,0.007995606,0.000003745904,0.0053727166,0.0008149551],"about_ca_topic_score_codex":0.0009336251,"about_ca_topic_score_gemma":0.0007469007,"teacher_disagreement_score":0.60032934,"about_ca_system_score_codex":0.00035203167,"about_ca_system_score_gemma":0.0027360138,"threshold_uncertainty_score":0.99987274},"labels":[],"label_agreement":null},{"id":"W4410900800","doi":"10.5489/cuaj.9073","title":"Adjuvant pembrolizumab following kidney cancer surgery","year":2025,"lang":"en","type":"letter","venue":"Canadian Urological Association Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; University of British Columbia; University of Toronto; Dalhousie University; McGill University; Kidney Foundation of Canada; McMaster University","funders":"","keywords":"Pembrolizumab; Medicine; Kidney cancer; Adjuvant; Cancer; Surgery; Oncology; General surgery; Internal medicine; Immunotherapy","score_opus":0.016257898273092593,"score_gpt":0.2516237017278577,"score_spread":0.2353658034547651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410900800","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038858228,0.0031628706,0.0000073118536,0.98361284,0.005253759,0.00026015975,0.00031005754,0.000048393285,0.0034588068],"genre_scores_gemma":[0.011181719,0.001327197,0.000019677182,0.9606666,0.007362122,0.000036983878,0.00039377442,0.000037180347,0.018974744],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967918,0.00030211764,0.00072997925,0.00038673222,0.00074771466,0.0010416966],"domain_scores_gemma":[0.9977296,0.00044372174,0.0005737664,0.00021654951,0.0002899121,0.00074642216],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0008938678,0.00036929146,0.00096699473,0.0006640876,0.0003952331,0.00018007045,0.0002213625,0.001825799,0.0030647719],"category_scores_gemma":[0.0013303447,0.00030663292,0.0012325853,0.0004239039,0.000036139838,0.00008329069,0.000017720346,0.0037152132,0.000038027578],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00013079119,0.000010217115,0.08614,0.000037634258,0.0010125649,0.0018098026,0.000020153944,6.7500963e-7,0.000011498684,0.0000010125085,0.9055387,0.0052869543],"study_design_scores_gemma":[0.0011536704,0.000059540333,0.044284824,0.00032582175,0.00048658036,0.00020303365,0.00000666107,0.0000074159943,0.000005346448,0.00007613196,0.9530965,0.00029448987],"about_ca_topic_score_codex":0.0076075774,"about_ca_topic_score_gemma":0.00079507724,"teacher_disagreement_score":0.047557786,"about_ca_system_score_codex":0.0058806874,"about_ca_system_score_gemma":0.00956292,"threshold_uncertainty_score":0.99993855},"labels":[],"label_agreement":null},{"id":"W4410918597","doi":"10.1136/jitc-2025-011682","title":"Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto; St. Thomas Hospital; University Health Network","funders":"Guy's and St Thomas' Charity; British Skin Foundation; Royal Society; Cancer Research UK; Wellcome Trust","keywords":"Immunology; Antibody; Medicine; Melanoma; Memory B cell; Immune system; Immunoglobulin E; B cell; Toxicity; Immunotherapy; Immune checkpoint; Cancer research; Internal medicine","score_opus":0.017328475149311004,"score_gpt":0.3499550727543015,"score_spread":0.33262659760499047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410918597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97589225,0.021044249,0.00020503752,0.00055133697,0.0005229189,0.0014695874,0.000076904675,0.0000142356575,0.00022350257],"genre_scores_gemma":[0.99328285,0.0045338725,0.0012216517,0.00020986254,0.0001002938,0.0001147997,0.00000849243,0.000035068475,0.00049309287],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982129,0.000053340485,0.000917625,0.00027180862,0.00024277173,0.00030158917],"domain_scores_gemma":[0.99881816,0.00010214884,0.0005206475,0.00025672835,0.00023447436,0.000067849214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042145376,0.0002675007,0.00081248995,0.00039762256,0.000099280245,0.00001928759,0.00011437528,0.0001312805,0.00006134329],"category_scores_gemma":[0.000025943471,0.00021375639,0.00031678323,0.00034710535,0.00013568053,0.00014094001,0.000021003581,0.0001706277,1.4432305e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009773259,0.00040152986,0.05059868,0.00029850448,0.00060609373,0.000005061211,0.0013697944,0.00006149926,0.8656253,0.000012923631,0.00006446205,0.07118288],"study_design_scores_gemma":[0.0103162555,0.0017265971,0.35152414,0.0015289371,0.00008112772,0.000018603747,0.0005120584,0.000103695136,0.6303405,0.000061040795,0.0036344663,0.00015260077],"about_ca_topic_score_codex":0.00039881625,"about_ca_topic_score_gemma":0.00004240375,"teacher_disagreement_score":0.30092546,"about_ca_system_score_codex":0.0006749621,"about_ca_system_score_gemma":0.0006499942,"threshold_uncertainty_score":0.8716732},"labels":[],"label_agreement":null},{"id":"W4410920998","doi":"10.37766/inplasy2025.5.0098","title":"Prognostic and clinicopathological value of soluble programmed cell death ligand-1 (sPD-L1) in patients with colorectal cancer: a meta-analysis","year":2025,"lang":"en","type":"report","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Colorectal cancer; Meta-analysis; Internal medicine; Oncology; Value (mathematics); Medicine; Ligand (biochemistry); Cancer; Cancer research; Receptor; Mathematics; Statistics","score_opus":0.05424989589088398,"score_gpt":0.3389824153760737,"score_spread":0.28473251948518974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410920998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97408307,0.01306382,0.00002564458,0.00017845372,0.00020011234,0.0036888656,0.0001659605,0.000059938015,0.00853413],"genre_scores_gemma":[0.98587215,0.0035113604,0.0012255503,0.00017074523,0.0000388397,0.00075133215,0.0004634783,0.00003542065,0.007931105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966295,0.00012911457,0.0011282547,0.0007948325,0.00091581175,0.00040252466],"domain_scores_gemma":[0.99801713,0.000236083,0.00064861664,0.0003762003,0.0006005675,0.0001214005],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010259254,0.00047123534,0.00312251,0.00055846333,0.00004124871,0.000028072363,0.00013797835,0.0004936626,0.00025526845],"category_scores_gemma":[0.00014567701,0.00027386638,0.0010909585,0.0011590614,0.00020571583,0.000035870078,0.00009025925,0.00044996798,4.6829e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00443056,0.0013354402,0.9503523,0.00084518787,0.039133217,0.00005394592,0.0000669701,0.0000046155424,0.0000269687,0.0000025312672,0.00040984896,0.003338406],"study_design_scores_gemma":[0.004617827,0.0031660767,0.74070424,0.00018995021,0.24831614,0.000008276,0.000034421635,0.00003590394,0.00046311042,0.0000055507385,0.0021048298,0.00035367676],"about_ca_topic_score_codex":0.0042697717,"about_ca_topic_score_gemma":0.0015676059,"teacher_disagreement_score":0.20964807,"about_ca_system_score_codex":0.00025060147,"about_ca_system_score_gemma":0.0018960471,"threshold_uncertainty_score":0.99997133},"labels":[],"label_agreement":null},{"id":"W4410943999","doi":"10.1056/nejmoa2502931","title":"Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer","year":2025,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Oncology; Chemotherapy; Neoadjuvant therapy; Internal medicine; Lung cancer; Cancer; Immunotherapy; Breast cancer","score_opus":0.010919927386611931,"score_gpt":0.29994164088623754,"score_spread":0.28902171349962563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410943999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90700084,0.02377729,0.001059653,0.062292047,0.0013953061,0.00030684777,0.0000017861952,0.000014913231,0.0041513443],"genre_scores_gemma":[0.98105055,0.007251556,0.00028034174,0.004395116,0.002315144,0.0000032596135,0.000003019553,0.000022161254,0.0046788724],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986057,0.00005441123,0.00053313014,0.00014772612,0.0004339598,0.00022505442],"domain_scores_gemma":[0.99920654,0.00010917018,0.000225712,0.00016961145,0.00014814372,0.00014083281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007055432,0.00017231988,0.00066965364,0.00032324757,0.000028948483,0.000008251043,0.00012056439,0.000071620176,0.00052967825],"category_scores_gemma":[0.00005294125,0.0001007489,0.00007524068,0.00036689822,0.000105279105,0.00007157133,0.00000877726,0.0003989623,3.1721393e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.097118646,0.00023031849,0.18729648,0.00034883892,0.001461044,0.0010023471,0.0037807403,0.00018969656,0.01826952,0.00019219409,0.05581637,0.6342938],"study_design_scores_gemma":[0.5192209,0.0032346495,0.24171525,0.0078091393,0.00045164855,0.0008024131,0.0004848949,0.0005086955,0.0013064074,0.00020241982,0.2240072,0.0002564032],"about_ca_topic_score_codex":0.0019590112,"about_ca_topic_score_gemma":0.0008567018,"teacher_disagreement_score":0.6340374,"about_ca_system_score_codex":0.00035624727,"about_ca_system_score_gemma":0.0010026918,"threshold_uncertainty_score":0.5799605},"labels":[],"label_agreement":null},{"id":"W4410979871","doi":"10.1016/j.jtho.2025.05.020","title":"LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–Programmed Cell Death Protein 1 or Anti–Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Eisai Canada; Eisai; MSD","keywords":"Medicine; Pembrolizumab; Lenvatinib; Oncology; Chemotherapy; Platinum; Internal medicine; PD-L1; Immunotherapy; Cancer; Hepatocellular carcinoma; Sorafenib","score_opus":0.05813767730453691,"score_gpt":0.3986231119463125,"score_spread":0.3404854346417756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410979871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806815,0.0039441166,0.0034326797,0.0054224893,0.00085161545,0.005080484,0.000042558815,0.000102491314,0.00044207275],"genre_scores_gemma":[0.9472289,0.00038885273,0.045982894,0.00169281,0.0004563417,0.00058992085,0.000052575342,0.00012770631,0.003479962],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995383,0.0004473093,0.0016754611,0.0006844789,0.000690682,0.001119045],"domain_scores_gemma":[0.99625826,0.0003757339,0.0016547455,0.00064049434,0.0006449402,0.00042583048],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019528858,0.000706348,0.0021176925,0.00066102215,0.00029972175,0.00024260879,0.000568048,0.00053669413,0.00018642028],"category_scores_gemma":[0.0001300819,0.0005030554,0.00076067663,0.00068828516,0.00037413248,0.00039270154,0.000073610165,0.0008849551,0.000005649431],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30749452,0.006307545,0.0064134984,0.0036577347,0.0023951724,0.0019178797,0.0037156693,0.000025713995,0.12876175,0.000018493207,0.0025548649,0.53673714],"study_design_scores_gemma":[0.11608797,0.05006564,0.020766538,0.0033695449,0.004303855,0.0026676925,0.004464914,0.0023331244,0.55679166,0.0005597987,0.23673303,0.0018562111],"about_ca_topic_score_codex":0.00008005095,"about_ca_topic_score_gemma":0.00010011286,"teacher_disagreement_score":0.53488094,"about_ca_system_score_codex":0.0010004669,"about_ca_system_score_gemma":0.0044740303,"threshold_uncertainty_score":0.9997421},"labels":[],"label_agreement":null},{"id":"W4411019010","doi":"10.1371/journal.pone.0325760","title":"Immune-mediated enterocolitis is associated with immune checkpoint inhibitors: A pharmacovigilance study from the FDA Adverse Event Reporting System (FAERS) database","year":2025,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Atezolizumab; Tremelimumab; Ipilimumab; Nivolumab; Adverse Event Reporting System; Durvalumab; Adverse effect; Pharmacovigilance; Enterocolitis; Immune system; Immunology; Internal medicine; Oncology; Immunotherapy","score_opus":0.03281173711406441,"score_gpt":0.2827332776375355,"score_spread":0.24992154052347107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411019010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924756,0.0021799665,0.000019076078,0.001363803,0.00022551478,0.002972042,0.0002282928,0.00024752572,0.00028812845],"genre_scores_gemma":[0.9971508,0.00015618915,0.00006548951,0.0009652696,0.00017039824,0.0003404551,0.00040942797,0.00004391438,0.0006981003],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9962138,0.0002259664,0.0017796118,0.0005636825,0.0007833281,0.0004336078],"domain_scores_gemma":[0.9969959,0.00025752882,0.0014758433,0.0009101781,0.00026449614,0.00009603305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013528462,0.00033650306,0.0008560274,0.00010241602,0.00024839715,0.00004365412,0.00026035894,0.000091040914,0.00021828535],"category_scores_gemma":[0.0005904589,0.00023403628,0.00022785895,0.00068445026,0.00010093268,0.00014067326,0.00015171789,0.00047286577,0.000030264271],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066312407,0.0074482886,0.28364968,0.0005399328,0.014217264,0.00074378256,0.005125887,0.0000012810874,0.6800196,0.0000014962511,0.0010688149,0.00055270264],"study_design_scores_gemma":[0.03135243,0.0012407156,0.47627336,0.026477862,0.0044946,0.000028096694,0.021875072,0.0007794548,0.43607095,0.0000021082137,0.00070542865,0.0006999345],"about_ca_topic_score_codex":0.0032826767,"about_ca_topic_score_gemma":0.00016908166,"teacher_disagreement_score":0.2439487,"about_ca_system_score_codex":0.0006787462,"about_ca_system_score_gemma":0.00028828322,"threshold_uncertainty_score":0.9543723},"labels":[],"label_agreement":null},{"id":"W4411025723","doi":"10.1200/jco.2025.43.17_suppl.lba8010","title":"Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: Updated survival and biomarker analyses from CheckMate 77T.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Nivolumab; Perioperative; Internal medicine; Oncology; Placebo; Cisplatin; Biomarker; Surgery; Chemotherapy; Cancer; Immunotherapy; Pathology","score_opus":0.09496438120777968,"score_gpt":0.45888745761025634,"score_spread":0.3639230764024767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411025723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98743045,0.00086911826,0.000064685366,0.0037329358,0.0008199367,0.0002863975,0.000013657901,0.000008767445,0.0067740525],"genre_scores_gemma":[0.9958846,0.00057514297,0.0009383378,0.0013653883,0.00014287721,0.0000046825976,0.000017020926,0.000015471956,0.0010564523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99654806,0.00071647053,0.0018519358,0.0002943851,0.0003263085,0.00026285986],"domain_scores_gemma":[0.99719226,0.0010968585,0.0008527921,0.00020549279,0.00047667508,0.00017590077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020591936,0.00019491944,0.0015751146,0.00028762253,0.00007302636,0.000027902382,0.00015150734,0.0003626851,0.00034591166],"category_scores_gemma":[0.0009413853,0.00012635929,0.00022458204,0.00047661277,0.0004189705,0.00016918489,0.00006258493,0.000748318,0.0000035930568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29683754,0.0020077992,0.6192509,0.000029031,0.0024034095,0.00028955322,0.00022677642,0.0000062095123,0.0025706717,0.000023533605,0.004447606,0.07190701],"study_design_scores_gemma":[0.061947104,0.008505392,0.910935,0.00035592387,0.00038047408,0.000016592778,0.00049577403,0.00017282869,0.00038235332,0.000035999714,0.016637016,0.00013558687],"about_ca_topic_score_codex":0.00091194385,"about_ca_topic_score_gemma":0.0013111058,"teacher_disagreement_score":0.2916841,"about_ca_system_score_codex":0.0002702048,"about_ca_system_score_gemma":0.0014692172,"threshold_uncertainty_score":0.5152782},"labels":[],"label_agreement":null},{"id":"W4411027965","doi":"10.1200/jco.2025.43.17_suppl.lba109","title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Triple-negative breast cancer; Breast cancer; Chemotherapy; Cancer; Oncology; Internal medicine; Immunotherapy","score_opus":0.03209540618474122,"score_gpt":0.4260614781526635,"score_spread":0.39396607196792227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411027965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9556617,0.0032462436,0.00014244801,0.031763006,0.002025554,0.0043822248,0.0003229972,0.00004415007,0.0024116442],"genre_scores_gemma":[0.9748184,0.009077577,0.00055406056,0.012937799,0.0009782027,0.0001379835,0.000058610025,0.00006248835,0.0013748606],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9876548,0.0038016303,0.0061657694,0.0008386762,0.0008333923,0.0007057039],"domain_scores_gemma":[0.9798602,0.013914084,0.0041737515,0.00073853513,0.0009509299,0.00036252599],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00747749,0.0006406613,0.005336875,0.00035588056,0.0001769743,0.000054962315,0.00069744955,0.00071146997,0.00035438768],"category_scores_gemma":[0.0047881,0.00039613538,0.0016295608,0.0010517648,0.0009976447,0.00028142091,0.00011755235,0.0023895963,0.0000068109516],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7455861,0.0064753345,0.0033095784,0.000032719825,0.004094665,0.0004496476,0.0019233625,0.000020386482,0.0009704404,0.000006933592,0.0035143194,0.23361649],"study_design_scores_gemma":[0.72516847,0.008061945,0.25682265,0.001157753,0.0015631025,0.00010870039,0.0009819665,0.00021180186,0.00047663663,0.00017944038,0.0049581826,0.00030935078],"about_ca_topic_score_codex":0.0037635684,"about_ca_topic_score_gemma":0.0021421327,"teacher_disagreement_score":0.25351307,"about_ca_system_score_codex":0.0023460733,"about_ca_system_score_gemma":0.006185792,"threshold_uncertainty_score":0.9999119},"labels":[],"label_agreement":null},{"id":"W4411037230","doi":"10.1038/s41591-025-03725-4","title":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Jewish General Hospital","funders":"Genentech; Japanese Society of Medical Oncology; Eisai; Astellas Pharma; Sanofi; Kyowa Hakko Kirin; Natera; Les Laboratories Pierre Fabre; Teva Pharmaceutical Industries; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; F. Hoffmann-La Roche; Vifor Pharma; Chugai Pharmaceutical; Seagen; OncoSec Medical; Roche; Amgen; Pfizer; G1 Therapeutics; Celgene; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Atezolizumab; Breast cancer; Randomized controlled trial; Medicine; Stage (stratigraphy); Oncology; Triple-negative breast cancer; Perioperative; Internal medicine; Peri; Cancer; Surgery; Biology; Immunotherapy","score_opus":0.031178275962015434,"score_gpt":0.4133979229228024,"score_spread":0.382219646960787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411037230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9123863,0.022518318,0.000047413378,0.058893204,0.0012085878,0.0027317011,0.0006265021,0.000041115312,0.0015468319],"genre_scores_gemma":[0.98738897,0.0039866813,0.00006233112,0.003826558,0.0009029769,0.00021142527,0.0001486087,0.000017021242,0.003455434],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973281,0.0005414379,0.00082205044,0.0005333788,0.00047499215,0.00030003808],"domain_scores_gemma":[0.9972858,0.0017677464,0.00025441192,0.00038939912,0.00019310697,0.00010956583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012020464,0.0003493686,0.0013293101,0.0002736175,0.00018047231,0.000030641357,0.00017718143,0.00034756865,0.0004892954],"category_scores_gemma":[0.0016525792,0.00017032928,0.00020129976,0.00093452487,0.0008102137,0.000096086114,0.000047735237,0.001166066,0.0000011349146],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96210885,0.00019931406,0.00031220354,0.000023169647,0.0008472064,0.00006798514,0.003972379,0.0000010116166,0.006018216,0.00005563785,0.00965731,0.016736735],"study_design_scores_gemma":[0.96224004,0.0008192391,0.02389415,0.001374446,0.0006911852,0.000013407364,0.0015629848,0.0003450047,0.0031896934,0.00011720475,0.005575178,0.00017743773],"about_ca_topic_score_codex":0.01537341,"about_ca_topic_score_gemma":0.00157072,"teacher_disagreement_score":0.07500264,"about_ca_system_score_codex":0.0002427414,"about_ca_system_score_gemma":0.0004635015,"threshold_uncertainty_score":0.9911833},"labels":[],"label_agreement":null},{"id":"W4411156042","doi":"10.3390/curroncol32060335","title":"Increased Pre-Operative Lung Immune Prognostic Index Score Is a Prognostic Factor in Cases of Pathological T3 Renal Cell Carcinoma","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pathological; Renal cell carcinoma; Lung; Carcinoma; Pathology; Immune system; Oncology; Internal medicine; Immunology","score_opus":0.05689549478183623,"score_gpt":0.37674676837216176,"score_spread":0.3198512735903255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411156042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834902,0.013327999,0.0001017754,0.00032815067,0.00052054855,0.0017004443,0.0000635847,0.000031106505,0.0004361671],"genre_scores_gemma":[0.99902034,0.00021210514,0.000068664194,0.00018335687,0.00006001484,0.00026937644,0.000069599206,0.000012843765,0.0001036966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808514,0.00027807066,0.00067064044,0.000424173,0.00018191923,0.00036007617],"domain_scores_gemma":[0.9987237,0.0005546481,0.00019923797,0.00026964594,0.0001706902,0.00008208308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023415255,0.0002478106,0.00068668113,0.0003025014,0.00005409481,0.000009843233,0.00014283492,0.00023871928,0.00030516935],"category_scores_gemma":[0.0004559626,0.00019185965,0.00016743863,0.0005088098,0.00031370507,0.000049228525,0.00010177519,0.0004547136,0.0000033742601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004298846,0.0019037878,0.9498928,0.0005460572,0.000063165615,0.00028958084,0.0012969277,0.0000010117117,0.021566281,0.000020815465,0.0006142482,0.019506484],"study_design_scores_gemma":[0.0066402503,0.0024996158,0.97530776,0.0006713374,0.00015669933,0.000080716076,0.00024400154,0.00033500046,0.011635291,0.000025039695,0.0022341758,0.00017009009],"about_ca_topic_score_codex":0.00025880084,"about_ca_topic_score_gemma":0.000092863644,"teacher_disagreement_score":0.025414988,"about_ca_system_score_codex":0.00038859926,"about_ca_system_score_gemma":0.0010119127,"threshold_uncertainty_score":0.782381},"labels":[],"label_agreement":null},{"id":"W4411176534","doi":"10.1016/j.lungcan.2025.108621","title":"Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative Non-Small Cell Lung Cancer (NSCLC) – A meta-analysis based on reconstructed individual participant data","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Lung cancer; Oncology; Meta-analysis; non-small cell lung cancer (NSCLC); Internal medicine; Cancer; PD-L1; Immune system; Immunotherapy; Immunology; A549 cell","score_opus":0.07116806147672569,"score_gpt":0.35294685240541346,"score_spread":0.28177879092868774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411176534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9433658,0.044534378,0.00022351673,0.0041650645,0.0008670542,0.0031536557,0.0015611278,0.00007528323,0.0020541358],"genre_scores_gemma":[0.9959565,0.0006073572,0.00040285135,0.0012716679,0.00008754662,0.00069927156,0.0002607019,0.000039022038,0.0006750846],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9964291,0.00020722108,0.0014380526,0.0008801746,0.00050234457,0.00054314634],"domain_scores_gemma":[0.99727476,0.00040238784,0.0006122798,0.0014184907,0.00017464264,0.000117452895],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009936995,0.0004343378,0.001776044,0.0008358632,0.00008099677,0.000037250535,0.0005206285,0.00020576105,0.0019525422],"category_scores_gemma":[0.0001236071,0.00034618564,0.0010610034,0.0027950844,0.00021151928,0.00011536689,0.00017593158,0.00047028178,0.0000013634233],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043551374,0.0045048483,0.20639364,0.003765005,0.6139685,0.00013385457,0.009205577,0.01724226,0.051672965,0.00003457699,0.015939463,0.033587925],"study_design_scores_gemma":[0.02219162,0.00034651216,0.3397929,0.0014652231,0.41507396,0.0000014182332,0.00069724076,0.054859985,0.16313939,0.000010167801,0.0014862159,0.0009353694],"about_ca_topic_score_codex":0.016199451,"about_ca_topic_score_gemma":0.005448587,"teacher_disagreement_score":0.19889456,"about_ca_system_score_codex":0.0004081255,"about_ca_system_score_gemma":0.0012135776,"threshold_uncertainty_score":0.999899},"labels":[],"label_agreement":null},{"id":"W4411202089","doi":"10.1007/s40487-025-00350-6","title":"Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer","year":2025,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Lung cancer; Medicine; Oncology; Chemotherapy; Complete response; Internal medicine; Duration (music); Cancer; Immunotherapy","score_opus":0.028651675311576492,"score_gpt":0.36962959291600705,"score_spread":0.3409779176044306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411202089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98989135,0.0046672714,0.00008558413,0.0030872093,0.00027926796,0.0017255227,0.000030915664,0.000034445067,0.00019842027],"genre_scores_gemma":[0.9770621,0.019781258,0.00007536931,0.0014214478,0.00009040084,0.00033320847,0.000009034534,0.000037762955,0.0011894141],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.998185,0.00038252582,0.0004787973,0.0004264516,0.00013010431,0.00039715416],"domain_scores_gemma":[0.99772274,0.0014496649,0.0002704995,0.00030095264,0.00014236929,0.00011374209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016012725,0.00030297547,0.0006731246,0.00024073993,0.0002285756,0.000024271685,0.00009712749,0.00024872166,0.0001432532],"category_scores_gemma":[0.00011823443,0.00022916829,0.00019366689,0.00026072378,0.00026421656,0.00007356053,0.000015212521,0.0002001995,4.8558655e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68179774,0.0005781352,0.096631944,0.00007843295,0.0008395981,0.000016515067,0.0028034612,0.000019963101,0.16839243,0.00001243206,0.0004050624,0.04842428],"study_design_scores_gemma":[0.047304932,0.013383323,0.891129,0.00031031217,0.00008173063,0.000014896946,0.00019796315,0.0012189226,0.04277011,0.00007276091,0.0032717672,0.00024424947],"about_ca_topic_score_codex":0.000487406,"about_ca_topic_score_gemma":0.00018861775,"teacher_disagreement_score":0.7944971,"about_ca_system_score_codex":0.00039718577,"about_ca_system_score_gemma":0.0012490718,"threshold_uncertainty_score":0.9345212},"labels":[],"label_agreement":null},{"id":"W4411260891","doi":"10.1080/1750743x.2025.2518913","title":"Time toxicity of nivolumab in metastatic head and neck squamous cell carcinoma patients: a single-institution experience","year":2025,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; Population Health Research Institute; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Nivolumab; Medicine; Head and neck; Toxicity; Basal cell; Oncology; Head and neck squamous-cell carcinoma; Radiation therapy; Internal medicine; Carcinoma; Head and neck cancer; Surgery; Cancer; Immunotherapy","score_opus":0.013062482689831033,"score_gpt":0.2701643034079915,"score_spread":0.2571018207181605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411260891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929902,0.0048557944,0.00011869785,0.0001347304,0.00013274106,0.0005368319,0.000010162223,0.000023889943,0.0011969316],"genre_scores_gemma":[0.99832207,0.00013420699,0.0003862734,0.0005703162,0.000008872521,0.000031261832,0.000010417841,0.000012585267,0.0005239721],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989254,0.000054144668,0.00041690716,0.00024041563,0.0001627391,0.00020038182],"domain_scores_gemma":[0.99945045,0.000053861586,0.00010948733,0.00028605817,0.000071448325,0.00002869949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012166718,0.0001613217,0.00034775084,0.0001976856,0.000052380998,0.000014407014,0.0000895707,0.00006428218,0.00008069468],"category_scores_gemma":[0.000025888447,0.00014461047,0.00008395285,0.00038744998,0.00024170913,0.00011624022,0.000018735926,0.00009780186,0.000003015882],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009619029,0.002403673,0.121115915,0.0002842371,0.00007554504,0.000015422484,0.00551717,0.0000063295665,0.8080187,0.000064666085,0.0001601826,0.05271912],"study_design_scores_gemma":[0.036322307,0.0033787428,0.6431766,0.0004954142,0.000056124758,0.000014666296,0.0007005959,0.00055919937,0.30856353,0.000079081175,0.0062779887,0.0003757212],"about_ca_topic_score_codex":0.00062690646,"about_ca_topic_score_gemma":0.000053252676,"teacher_disagreement_score":0.5220607,"about_ca_system_score_codex":0.00019080463,"about_ca_system_score_gemma":0.00012576443,"threshold_uncertainty_score":0.5897044},"labels":[],"label_agreement":null},{"id":"W4411281412","doi":"10.1080/14796694.2025.2511470","title":"LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research","funders":"Genentech; Astellas Pharma; Eisai; EMD Serono; Rakuten Medical; Daiichi Sankyo Europe; Sanofi; Exelixis; Amgen; Relay Therapeutics; Gilead Sciences; Pfizer; Break Through Cancer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Agios Pharmaceuticals","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.04745932149046059,"score_gpt":0.42577289509448113,"score_spread":0.3783135736040205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411281412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9517723,0.028146386,0.00020433532,0.011315425,0.0019212763,0.0020466438,0.00007957502,0.000056438177,0.004457651],"genre_scores_gemma":[0.9713837,0.017272567,0.0023363335,0.0045083784,0.00074011576,0.0003367219,0.00008786706,0.00005336408,0.0032809705],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972036,0.0005336538,0.0013082328,0.0004195468,0.00019165673,0.00034330008],"domain_scores_gemma":[0.9983431,0.0006644195,0.00045136214,0.0003598979,0.00009495906,0.000086278094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015084147,0.00028705908,0.0017369377,0.0005379044,0.00005524331,0.000013329849,0.00014288342,0.00024606928,0.0007028147],"category_scores_gemma":[0.00023323405,0.0002011276,0.00025994633,0.0006342083,0.00018424248,0.00006226351,0.000037606784,0.00033400024,0.0000029630169],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22236313,0.002517056,0.00029257004,0.0004900023,0.0010658216,0.00021448304,0.0021942032,6.7605646e-7,0.05838554,0.00071067415,0.01077268,0.7009932],"study_design_scores_gemma":[0.20735209,0.010173896,0.0036891364,0.00062552805,0.00073169504,0.00027362668,0.0027560245,0.000120733464,0.017232183,0.00038208227,0.75630283,0.00036015833],"about_ca_topic_score_codex":0.00013807794,"about_ca_topic_score_gemma":0.00052857294,"teacher_disagreement_score":0.7455302,"about_ca_system_score_codex":0.0003104381,"about_ca_system_score_gemma":0.0010705311,"threshold_uncertainty_score":0.8201745},"labels":[],"label_agreement":null},{"id":"W4411284824","doi":"10.1158/1557-3265.sabcs24-ps19-04","title":"Abstract PS19-04: Exploring the broad societal value of pembrolizumab in triple-negative breast cancer in Canada","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Triple-negative breast cancer; Pembrolizumab; Breast cancer; Medicine; Cancer; Value (mathematics); Oncology; Gynecology; Internal medicine; Immunotherapy; Statistics","score_opus":0.17892154257603307,"score_gpt":0.4915326437501494,"score_spread":0.3126111011741163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411284824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747601,0.003685902,7.072761e-7,0.01803067,0.00078464916,0.00082840247,0.00013039832,0.000007575328,0.0017715987],"genre_scores_gemma":[0.9895044,0.008256932,0.000007168076,0.0007522892,0.00021275786,0.00047900723,0.000002789153,0.000018379727,0.0007662879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99670386,0.00039317517,0.0009992352,0.0004528348,0.0008267317,0.0006241843],"domain_scores_gemma":[0.99725956,0.0017887398,0.00011483208,0.000434876,0.00028543844,0.00011654979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027859414,0.00016299379,0.0005752475,0.00020570416,0.00009588178,0.000017860826,0.00039721566,0.00011569061,0.000724375],"category_scores_gemma":[0.00045533988,0.00011607258,0.00019852731,0.0015220657,0.0005875453,0.0000952825,0.00013179812,0.0015898821,0.0000022531328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023369065,0.00047426787,0.5738235,0.0005617485,0.00050199707,0.00009740206,0.00085590064,0.00020316603,0.0017521108,0.0001408556,0.018460419,0.37975955],"study_design_scores_gemma":[0.0069979713,0.0000912433,0.98632175,0.0011324013,0.000018905885,0.0000024077167,0.0015550065,0.00023515084,0.0011512942,0.0001298039,0.0022565126,0.000107528685],"about_ca_topic_score_codex":0.95693946,"about_ca_topic_score_gemma":0.94289416,"teacher_disagreement_score":0.41249827,"about_ca_system_score_codex":0.0027059263,"about_ca_system_score_gemma":0.013500922,"threshold_uncertainty_score":0.9920916},"labels":[],"label_agreement":null},{"id":"W4411289211","doi":"10.1158/1557-3265.sabcs24-p4-02-02","title":"Abstract P4-02-02: Hospitalizations and emergency visits for Ontario breast cancer patients undergoing neoadjuvant chemotherapy with pembrolizumab: A population-based analysis","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pembrolizumab; Breast cancer; Chemotherapy; Oncology; Cancer; Population; Neoadjuvant therapy; Internal medicine; Immunotherapy","score_opus":0.053933127609821885,"score_gpt":0.4515621291709281,"score_spread":0.3976290015611062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411289211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99114734,0.0011545483,0.00041163867,0.0052366434,0.00025117304,0.001318129,0.0001762861,0.0000355672,0.00026870446],"genre_scores_gemma":[0.99513215,0.0016814197,0.00013504128,0.000611129,0.00014747422,0.00042389578,0.00017945275,0.0000345816,0.001654858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746716,0.00008763857,0.0007375186,0.00065009727,0.0005765385,0.00048104158],"domain_scores_gemma":[0.99787915,0.0004726166,0.00016824166,0.00039287872,0.0008838503,0.00020325894],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00073332794,0.00021240974,0.0005551826,0.00043604677,0.00036447585,0.000061390645,0.00016073702,0.00017830604,0.0016500038],"category_scores_gemma":[0.00011458287,0.00016690514,0.0002990689,0.0014794598,0.0001557366,0.000102578044,0.000033806038,0.00040175483,0.0000014460948],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008484713,0.00047610386,0.96094346,0.0002111864,0.0016004007,0.0000018694923,0.00011637503,0.00013527928,0.000041651336,0.000029777393,0.001600754,0.026358414],"study_design_scores_gemma":[0.009410996,0.0006229345,0.98654276,0.0004147427,0.00045622824,3.258893e-7,0.000036449186,0.00066729455,0.000048985945,0.00007878494,0.0015346103,0.0001859023],"about_ca_topic_score_codex":0.07285593,"about_ca_topic_score_gemma":0.26765242,"teacher_disagreement_score":0.1947965,"about_ca_system_score_codex":0.00087166287,"about_ca_system_score_gemma":0.0021048216,"threshold_uncertainty_score":0.99926263},"labels":[],"label_agreement":null},{"id":"W4411295011","doi":"10.1038/s41698-025-00955-0","title":"Deep learning-based quantification of eosinophils and lymphocytes shows complementary prognostic effects in colorectal cancer patients","year":2025,"lang":"en","type":"article","venue":"npj Precision Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"University of Bern; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Colorectal cancer; Medicine; Oncology; Cancer; Internal medicine","score_opus":0.01443900021978422,"score_gpt":0.3259482730794852,"score_spread":0.311509272859701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411295011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955046,0.001861735,0.00051147334,0.00044814777,0.0003375669,0.0010978108,0.0000072238927,0.000018458368,0.0002129541],"genre_scores_gemma":[0.9986465,0.00021693953,0.00041306874,0.0004392807,0.000014242307,0.00015554558,0.00007156007,0.000008437882,0.000034433935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885714,0.00020060442,0.0003878356,0.0002522057,0.00014457126,0.00015765871],"domain_scores_gemma":[0.99866855,0.0009379479,0.0001501112,0.00009262165,0.000114391965,0.000036374033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028367998,0.0001124265,0.00034617286,0.00024909768,0.00004915575,0.0000058726587,0.0000647869,0.00012715784,0.00011137901],"category_scores_gemma":[0.00025619258,0.00009755814,0.000047894657,0.00028556774,0.00012440214,0.00003292852,0.00003433675,0.00011742615,0.0000015017355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006667352,0.000596246,0.6606142,0.00018704173,0.000058236303,0.000004332047,0.00018099246,0.00011559385,0.05779969,0.000015757003,0.00027188368,0.2734887],"study_design_scores_gemma":[0.010390847,0.0025354028,0.94086826,0.00043176685,0.00007819295,0.0000016239219,0.000052808773,0.0060893325,0.03689814,0.00006128398,0.0025095684,0.00008276222],"about_ca_topic_score_codex":0.00033485054,"about_ca_topic_score_gemma":0.00058894564,"teacher_disagreement_score":0.2802541,"about_ca_system_score_codex":0.00041729113,"about_ca_system_score_gemma":0.0002795769,"threshold_uncertainty_score":0.39783055},"labels":[],"label_agreement":null},{"id":"W4411306400","doi":"10.14740/wjon2520","title":"Anti-Programmed Cell Death-1 Versus Anti-Programmed Death-Ligand 1 (PD-L1) in PD-L1-Negative Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis","year":2025,"lang":"en","type":"review","venue":"World Journal of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Programmed cell death 1; Medicine; PD-L1; Meta-analysis; Programmed cell death; Lung cancer; Oncology; Programmed instruction; Cell; Cancer research; Cancer; Internal medicine; Apoptosis; Immunotherapy","score_opus":0.06408386717853286,"score_gpt":0.39423353728396143,"score_spread":0.33014967010542856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411306400","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024927236,0.9899554,0.000046242763,0.0009149994,0.00066612783,0.007055952,0.00008438089,0.000025713369,0.0010018562],"genre_scores_gemma":[0.00063647993,0.9925767,0.0021327508,0.0009426283,0.00012802742,0.0010505986,0.00005570684,0.00009077262,0.0023863274],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99126035,0.0015233245,0.004678384,0.0009328119,0.00063758146,0.00096756953],"domain_scores_gemma":[0.99021435,0.0022009774,0.0056319446,0.00087916694,0.0006337909,0.00043974977],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.003012612,0.001248041,0.021743834,0.0024321778,0.00014241699,0.00008458468,0.0007474988,0.0005888002,0.00022907017],"category_scores_gemma":[0.0003392765,0.0008436153,0.0057739248,0.0041879253,0.00020524708,0.0001447982,0.00016874539,0.0017909271,0.00000448988],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001298687,0.00077724166,0.00015632765,0.79432184,0.14851671,0.0011552145,0.0002086434,0.0000062211384,0.000013439961,0.0000039420843,0.0006557508,0.052885983],"study_design_scores_gemma":[0.0073887706,0.0011786403,0.00005185694,0.08810545,0.7741284,0.00025251738,0.00011911729,0.00000967001,0.000026890852,0.0000029223927,0.12808797,0.0006477872],"about_ca_topic_score_codex":0.00033088523,"about_ca_topic_score_gemma":0.0015310455,"teacher_disagreement_score":0.7062164,"about_ca_system_score_codex":0.001778654,"about_ca_system_score_gemma":0.0029375444,"threshold_uncertainty_score":0.99940145},"labels":[],"label_agreement":null},{"id":"W4411312487","doi":"10.1016/j.phymed.2025.156968","title":"Gegen Qinlian Tablets attenuate immune-related adverse events in NSCLC patients: A multi-center randomized controlled trial in China","year":2025,"lang":"en","type":"article","venue":"Phytomedicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Capital Health","keywords":"Medicine; Adverse effect; Randomized controlled trial; Immune system; Oncology; Center (category theory); Internal medicine; Pharmacology; Immunology; Chemistry","score_opus":0.0063650086590269096,"score_gpt":0.27505033561011427,"score_spread":0.2686853269510874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411312487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98053765,0.0021993278,0.000041327203,0.0028494173,0.0020760125,0.009948359,0.000010766847,0.000056998753,0.0022801117],"genre_scores_gemma":[0.9941467,0.00053574686,0.000042865526,0.0011108427,0.00009698467,0.0008333388,0.00015036277,0.000030282426,0.0030528896],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99633896,0.0004142146,0.0018807955,0.0004434477,0.0004119572,0.00051060994],"domain_scores_gemma":[0.9987853,0.00024295118,0.00037202882,0.0004020578,0.00009852909,0.00009911794],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019440346,0.0003701391,0.0025027744,0.000862701,0.00004818793,0.0000036850513,0.00017048222,0.00018800692,0.00026090557],"category_scores_gemma":[0.0007300259,0.00025816224,0.00055025547,0.0009912831,0.00018491119,0.000106231884,0.00005228209,0.00045969756,0.000022747485],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9655094,0.0028507214,0.026838785,0.000091280934,0.0007680616,0.0000426613,0.00055789633,0.0000048788884,0.0009800511,0.000003343999,0.00020180955,0.0021511132],"study_design_scores_gemma":[0.8586015,0.00037384345,0.13736504,0.001827487,0.00023286014,0.0000027938618,0.00006266806,0.00078315154,0.00008544833,0.000032258635,0.0004581807,0.00017477112],"about_ca_topic_score_codex":0.0006684804,"about_ca_topic_score_gemma":0.000110439396,"teacher_disagreement_score":0.11052626,"about_ca_system_score_codex":0.00037032447,"about_ca_system_score_gemma":0.00019318666,"threshold_uncertainty_score":0.99998707},"labels":[],"label_agreement":null},{"id":"W4411456337","doi":"10.3390/curroncol32060365","title":"KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja","keywords":"Medicine; Meta-analysis; KRAS; Oncology; Internal medicine; Bioinformatics; Cancer; Biology; Colorectal cancer","score_opus":0.12303551172139553,"score_gpt":0.45843501088305455,"score_spread":0.335399499161659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411456337","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000026634473,0.980026,0.0006735393,0.0013326455,0.00038955532,0.016915003,0.00050606136,0.00005105524,0.00010349654],"genre_scores_gemma":[0.0000108917575,0.981875,0.0002601709,0.0003023405,0.000052920725,0.016085602,0.0009137359,0.00005135303,0.000447979],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9950257,0.0006209696,0.0028148128,0.0008909467,0.00023841362,0.00040917643],"domain_scores_gemma":[0.9958344,0.0015141547,0.0015038992,0.0007486464,0.0002690549,0.00012985467],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014497768,0.00075194734,0.011869157,0.0011630264,0.0001047606,0.000021786327,0.00025123483,0.00042424785,0.0002021794],"category_scores_gemma":[0.0006584865,0.0005195285,0.0046010613,0.0020887458,0.00019396906,0.00007353869,0.000056054923,0.0004520641,0.000007147839],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005888488,0.00042332144,8.5604023e-7,0.7504752,0.15152733,0.000008350441,0.00010931007,7.9484437e-7,7.9840123e-7,0.000015582753,0.00014890965,0.09670067],"study_design_scores_gemma":[0.0026219105,0.0008798867,0.0000027096116,0.11433648,0.66068405,0.000039954168,0.00004395704,0.00002188924,0.000001953445,0.000047095888,0.22098671,0.0003334071],"about_ca_topic_score_codex":0.00003490883,"about_ca_topic_score_gemma":0.00016117694,"teacher_disagreement_score":0.63613874,"about_ca_system_score_codex":0.00087682507,"about_ca_system_score_gemma":0.0012089373,"threshold_uncertainty_score":0.99972564},"labels":[],"label_agreement":null},{"id":"W4411500165","doi":"10.1007/s40273-025-01512-0","title":"Innovation Headroom for a Highly Accurate PD-L1 Companion Diagnostic in Non-small Cell Lung Cancer","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care; University of British Columbia Hospital; Polytechnique Montréal; University of British Columbia","funders":"NanoMedicines Innovation Network","keywords":"Medicine; Lung cancer; Oncology","score_opus":0.02262593603436821,"score_gpt":0.3470991397382342,"score_spread":0.324473203703866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411500165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900065,0.0016202566,0.001537634,0.0032012148,0.0012016492,0.0013786991,0.00007250546,0.000033924447,0.00094758195],"genre_scores_gemma":[0.99025404,0.0014919688,0.0002661146,0.006537761,0.0001908573,0.0004330446,0.000097254815,0.000022756643,0.0007062078],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998985,0.00001568695,0.00046427542,0.0002587161,0.000033478096,0.00024285485],"domain_scores_gemma":[0.9993555,0.00025685783,0.00013741446,0.00013889656,0.00007641791,0.000034919813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002514055,0.00015498402,0.000278655,0.00028477612,0.000053804426,0.000029427227,0.000100104575,0.00006801815,0.00009329142],"category_scores_gemma":[0.000025270841,0.00016325653,0.000073646974,0.0003394121,0.00002534795,0.000102057325,0.000025442823,0.00014353369,0.0000057635093],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010809096,0.0009286337,0.37462717,0.0030729314,0.0007825734,0.000016355418,0.0011317731,0.0026125708,0.4239407,0.00076584244,0.10990711,0.07140525],"study_design_scores_gemma":[0.04546555,0.0002497835,0.30614,0.0010521695,0.0005885444,0.000006408911,0.00022969989,0.14610144,0.3540509,0.00026804092,0.14499126,0.0008561693],"about_ca_topic_score_codex":0.0004301352,"about_ca_topic_score_gemma":0.00014358881,"teacher_disagreement_score":0.14348887,"about_ca_system_score_codex":0.0005093652,"about_ca_system_score_gemma":0.0002998165,"threshold_uncertainty_score":0.6657408},"labels":[],"label_agreement":null},{"id":"W4411534009","doi":"10.1136/jitc-2024-010739","title":"SITC perspective: leveraging patient enrichment biomarkers to accelerate early phase IO drug development","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Clinical trial; Drug development; Biomarker; Medicine; Drug; Immunotherapy; Intensive care medicine; Cancer; Oncology; Internal medicine; Pharmacology","score_opus":0.021173314319618167,"score_gpt":0.36744862160887887,"score_spread":0.3462753072892607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411534009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95771474,0.025784697,0.0034608871,0.008699095,0.002038614,0.0014651127,0.000024589648,0.000036743022,0.0007755295],"genre_scores_gemma":[0.978532,0.003240542,0.005294786,0.0072755916,0.00022518098,0.00034864465,0.0000067879146,0.000072352595,0.0050040763],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978038,0.000049524944,0.0008847486,0.00033841244,0.0004598487,0.00046366442],"domain_scores_gemma":[0.9984584,0.000070031485,0.00037568036,0.00028109673,0.00066986895,0.00014491405],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053811894,0.00031268588,0.00055044907,0.0005450658,0.00035986607,0.000090190144,0.00023182674,0.00007887134,0.00039896852],"category_scores_gemma":[0.000023528131,0.00025949164,0.00040227498,0.00054934784,0.00007218648,0.0001458296,0.000032911707,0.00023676504,0.000002784453],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034581605,0.0007792042,0.0020005049,0.00012554017,0.004786877,0.000011561474,0.012930974,0.0000460132,0.3401602,0.00006079717,0.023566471,0.58095026],"study_design_scores_gemma":[0.021159803,0.0014502344,0.015097811,0.0012830618,0.00016939949,0.000027170405,0.0028131912,0.000032100485,0.31072298,0.00017369051,0.6466377,0.00043286802],"about_ca_topic_score_codex":0.00045886278,"about_ca_topic_score_gemma":0.000038340786,"teacher_disagreement_score":0.62307125,"about_ca_system_score_codex":0.0016401041,"about_ca_system_score_gemma":0.0011327125,"threshold_uncertainty_score":0.99998575},"labels":[],"label_agreement":null},{"id":"W4411604374","doi":"10.1158/1078-0432.ccr-24-3720","title":"Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; York University","keywords":"Immune system; Computer science; Immune checkpoint; Artificial intelligence; Computational biology; Immunology; Medicine; Biology; Immunotherapy","score_opus":0.19196513426731834,"score_gpt":0.5307325766693138,"score_spread":0.3387674424019955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411604374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90734273,0.005288927,0.003096231,0.07640884,0.0029898616,0.0022582852,0.000053936375,0.00020912154,0.002352041],"genre_scores_gemma":[0.9851229,0.0018456235,0.0014888112,0.0021465356,0.0013018985,0.00046592153,0.0000103505745,0.00004203393,0.0075759017],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99560004,0.00075907324,0.0013603056,0.0006939405,0.00088423083,0.00070241606],"domain_scores_gemma":[0.9966085,0.0015506687,0.00007414479,0.0007702468,0.0006197323,0.00037670947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011220572,0.00018207933,0.00049986405,0.0005077609,0.00023065142,0.00006932039,0.00038612486,0.00027505672,0.0006111479],"category_scores_gemma":[0.0035324583,0.00015426443,0.00034735654,0.0020229106,0.0007351615,0.000058474707,0.00032070975,0.0012335668,0.0002137657],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047865875,0.0004744127,0.0018221724,0.00007511549,0.00020256145,0.000064815125,0.00021605084,0.000003892863,0.041382533,0.000067369576,0.012810156,0.89501506],"study_design_scores_gemma":[0.0029258872,0.006590549,0.18243128,0.0029759281,0.00012176969,0.000016190743,0.0013972522,0.001581647,0.35754758,0.0028572986,0.4409474,0.00060721004],"about_ca_topic_score_codex":0.0007927431,"about_ca_topic_score_gemma":0.00009535506,"teacher_disagreement_score":0.8944078,"about_ca_system_score_codex":0.0005621387,"about_ca_system_score_gemma":0.0020420197,"threshold_uncertainty_score":0.6691641},"labels":[],"label_agreement":null},{"id":"W4411621161","doi":"10.1007/s00262-025-04105-0","title":"Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor-resistant tumors resulting in complete responses","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Tumor microenvironment; Immune system; Cancer research; Melanoma; Immunotherapy; Cytotoxic T cell; Chemokine; Acquired immune system; Interleukin 12; Cancer; Immunology; Cancer immunotherapy; Biology; Medicine; Internal medicine; In vitro","score_opus":0.030743658589663967,"score_gpt":0.30224594091405105,"score_spread":0.27150228232438706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411621161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9613868,0.03264972,0.00002064268,0.0040098676,0.00045030395,0.00073016295,0.00005717537,0.00008075228,0.00061460683],"genre_scores_gemma":[0.99172795,0.0059719346,0.00029381298,0.0010890844,0.00005331938,0.00031827946,0.000034346805,0.000044757213,0.0004665393],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9970994,0.00034984114,0.0010790505,0.0006588138,0.00018332318,0.00062954973],"domain_scores_gemma":[0.9987804,0.00025733974,0.00031521023,0.00047320337,0.0001263945,0.000047396727],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00076417427,0.00043403293,0.00080994546,0.000980399,0.00016516208,0.000059228732,0.00021496067,0.00030242585,0.00009392519],"category_scores_gemma":[0.00010859266,0.00041319287,0.00013022778,0.001198493,0.00062826154,0.00023216679,0.000070075235,0.0007965362,0.0000023887214],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0786932,0.00023444105,0.015848491,0.000058827438,0.00032537122,0.00012884496,0.0016621755,0.000003856056,0.8531828,0.00048743477,0.00006715326,0.049307387],"study_design_scores_gemma":[0.0153283365,0.0015624758,0.7857646,0.0020027598,0.0000271604,0.000064062144,0.0020612483,0.0001398913,0.18743564,0.0004992322,0.0046362225,0.00047841904],"about_ca_topic_score_codex":0.0018335301,"about_ca_topic_score_gemma":0.0010308124,"teacher_disagreement_score":0.76991606,"about_ca_system_score_codex":0.00090958265,"about_ca_system_score_gemma":0.0008828528,"threshold_uncertainty_score":0.999832},"labels":[],"label_agreement":null},{"id":"W4411823524","doi":"10.3390/cancers17132199","title":"Tumour- and Non-Tumour-Associated Factors That Modulate Response to PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer","year":2025,"lang":"en","type":"review","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Sanofi; AstraZeneca; Pfizer","keywords":"PD-L1; Immunotherapy; Biomarker; Medicine; Lung cancer; Immune system; Cancer; Antigen; Immune checkpoint; Cancer research; Tumor microenvironment; Oncology; Antibody; Cell; Atezolizumab; Durvalumab; Immunology; Internal medicine; Nivolumab; Biology","score_opus":0.024541895871474827,"score_gpt":0.3122262527405105,"score_spread":0.2876843568690357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411823524","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15144514,0.8425236,0.00000657068,0.00019665793,0.0016303782,0.0032336877,0.00038234948,0.00007179897,0.00050982024],"genre_scores_gemma":[0.037058536,0.95648,0.000026506099,0.0005708125,0.0001851562,0.00066014694,0.00013141421,0.00015472468,0.004732687],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961583,0.00029437768,0.0010083709,0.0011480482,0.00044626484,0.00094463077],"domain_scores_gemma":[0.99783623,0.00046830665,0.0005798619,0.00058410584,0.00011294216,0.00041854056],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007961992,0.0010246347,0.0028311783,0.0010723785,0.00014673555,0.00008179482,0.00037069898,0.000737096,0.00012662339],"category_scores_gemma":[0.00014834676,0.0008748445,0.0006901754,0.0016714389,0.00013776423,0.00009761573,0.00016856153,0.0009521416,0.000007240362],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.019852111,0.00038414332,0.023994481,0.13346094,0.004694003,0.0010594426,0.00969087,0.00031296868,0.0075778505,0.0000015845698,0.06846677,0.7305049],"study_design_scores_gemma":[0.00824532,0.00068322814,0.026957374,0.18852735,0.003417671,0.000018721428,0.000776409,0.00013989734,0.002163879,0.0000025921183,0.76648986,0.0025776927],"about_ca_topic_score_codex":0.008499123,"about_ca_topic_score_gemma":0.0024025703,"teacher_disagreement_score":0.72792715,"about_ca_system_score_codex":0.010560063,"about_ca_system_score_gemma":0.0064825127,"threshold_uncertainty_score":0.9993702},"labels":[],"label_agreement":null},{"id":"W4411846646","doi":"10.3899/jrheum.2025-0314.30","title":"Description of Immune Checkpoint Inhibitor Associated Sicca-Like Syndrome from the Canadian Research Group of Rheumatology in Immuno-Oncology Database: A Case Series","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University; McMaster University; St Joseph's Health Centre; University of British Columbia; University of Toronto; Western University; Jewish General Hospital; Dalhousie University; Research Canada; University of Calgary; Arthritis Research Centre of Canada; University of Alberta","funders":"","keywords":"Medicine; Rheumatology; Internal medicine; Sicca syndrome; Oncology; Dermatology; Disease","score_opus":0.03629778674810735,"score_gpt":0.3175308483439862,"score_spread":0.28123306159587885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411846646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801637,0.010173185,0.000024148787,0.008088347,0.00096526253,0.000404299,0.00006395725,0.0000059494496,0.000111134075],"genre_scores_gemma":[0.995283,0.004344927,0.00011510278,0.00011920967,0.0000042820707,0.000011003786,0.000029231303,0.000017245944,0.00007599327],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99532866,0.0018663447,0.0018334481,0.00016174262,0.00032793908,0.00048184276],"domain_scores_gemma":[0.9960323,0.0017710727,0.0009936603,0.0005509363,0.0005680522,0.00008398019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063596983,0.0001859131,0.0011666195,0.00069893844,0.00023776852,0.00001218797,0.00049334933,0.00035220364,0.00015044864],"category_scores_gemma":[0.0011657306,0.000117143805,0.00020647135,0.0009476554,0.0013095972,0.00014840171,0.00014125078,0.0010584457,0.0000025360637],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031389534,0.0013021859,0.71911037,0.000676,0.004874875,0.003152065,0.01617841,0.0000146042985,0.20728663,0.0019642215,0.009766442,0.0042846757],"study_design_scores_gemma":[0.031196646,0.007652085,0.4024985,0.011011052,0.0010134254,0.47098804,0.049837567,0.00022696199,0.011218112,0.0038998444,0.009859484,0.00059827976],"about_ca_topic_score_codex":0.5706839,"about_ca_topic_score_gemma":0.6678551,"teacher_disagreement_score":0.46783596,"about_ca_system_score_codex":0.00079211075,"about_ca_system_score_gemma":0.0022676338,"threshold_uncertainty_score":0.48252654},"labels":[],"label_agreement":null},{"id":"W4411962974","doi":"10.3389/fimmu.2025.1601377","title":"Health impact of using anti-PD-(L)1 agents to treat early-stage cancers in Switzerland: a modeling study","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"Merck","keywords":"Medicine; Oncology; Internal medicine; Adjuvant; Renal cell carcinoma; Adverse effect; Population; Breast cancer; Stage (stratigraphy); Melanoma; Cancer; Triple-negative breast cancer; Adjuvant therapy; Cancer research","score_opus":0.02932403438758861,"score_gpt":0.36145106250513725,"score_spread":0.33212702811754863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411962974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906113,0.0045146598,0.0026376855,0.00021936483,0.0006971251,0.0011302487,0.000019193594,0.000018186065,0.00015221348],"genre_scores_gemma":[0.9980296,0.00053444324,0.0009435916,0.00019007291,0.000012810613,0.00002937965,0.000007725959,0.0000189043,0.00023345984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982916,0.00016507733,0.0006199088,0.0003386223,0.0001165698,0.0004682055],"domain_scores_gemma":[0.99939877,0.000016484624,0.00011682798,0.000379747,0.000038955182,0.000049218954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039639336,0.00020090728,0.00088036223,0.0011220019,0.000046409255,0.000008052601,0.00016390391,0.00012013299,0.000021721105],"category_scores_gemma":[0.00003157192,0.0001824102,0.00013944267,0.0009789224,0.000068253205,0.0000607319,0.00005787165,0.00024613738,5.9990026e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006469187,0.00038519915,0.9642683,0.000070215654,0.00051409146,0.00003720114,0.0047622905,0.007084759,0.0035122018,0.0000020538232,0.00039138636,0.0125030875],"study_design_scores_gemma":[0.010951861,0.0021022032,0.9630923,0.00062112155,0.00005586976,0.000007732829,0.006427734,0.016047852,0.00028209508,0.000029643994,0.0001573835,0.00022418097],"about_ca_topic_score_codex":0.07967984,"about_ca_topic_score_gemma":0.001517967,"teacher_disagreement_score":0.07816187,"about_ca_system_score_codex":0.0023931875,"about_ca_system_score_gemma":0.00093543704,"threshold_uncertainty_score":0.92644864},"labels":[],"label_agreement":null},{"id":"W4412009832","doi":"10.3390/cancers17132228","title":"Impact of Proton Pump Inhibitor Use on Progression-Free and Overall Survival in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis of Recent Studies","year":2025,"lang":"en","type":"review","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"European Commission","keywords":"Meta-analysis; Medicine; Oncology; Internal medicine; Proton-pump inhibitor; Immune system; Cancer; Immunology","score_opus":0.12542605258845071,"score_gpt":0.4190691176070379,"score_spread":0.29364306501858717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412009832","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046266234,0.98320854,1.2996531e-7,0.000089206835,0.00012352581,0.011499912,0.00042692403,0.000011997727,0.000013155379],"genre_scores_gemma":[0.00048803445,0.9959353,0.000014200018,0.000099990335,0.000018399245,0.003245984,0.00005740609,0.00004160709,0.000099086516],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99585074,0.00053505495,0.0021749418,0.0006031282,0.00055074313,0.00028536146],"domain_scores_gemma":[0.996138,0.0006197626,0.0019739121,0.0007984751,0.00038407143,0.000085827305],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009506453,0.0006671615,0.010293363,0.0007165768,0.000041825475,0.000021392341,0.00017577717,0.00020062563,0.000076406366],"category_scores_gemma":[0.00075166,0.000373165,0.0020913272,0.0014828121,0.00019520208,0.000097643926,0.00012842484,0.00029557792,1.0367396e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005702763,0.0001231381,0.00040513233,0.7959056,0.19302377,0.000002710269,0.00020032804,0.0000024921908,0.000005800765,0.0000010844703,0.000056045898,0.00970364],"study_design_scores_gemma":[0.0028510906,0.0013353103,0.00050348556,0.5572907,0.43604788,0.0000014774149,0.00004541302,0.0000021029805,0.000055050008,0.000002563766,0.0014540604,0.00041090604],"about_ca_topic_score_codex":0.0010227131,"about_ca_topic_score_gemma":0.0003345832,"teacher_disagreement_score":0.24302411,"about_ca_system_score_codex":0.0026201953,"about_ca_system_score_gemma":0.0018780943,"threshold_uncertainty_score":0.999872},"labels":[],"label_agreement":null},{"id":"W4412012626","doi":"10.3389/fmed.2025.1593933","title":"Fingolimod synergizes with anti-PD-1 radioimmunotherapy in an experimental multiple sclerosis model through enhanced lymph node retention and CD8+ T cell depletion","year":2025,"lang":"en","type":"article","venue":"Frontiers in Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cameco (Canada); University of Saskatchewan","funders":"","keywords":"Medicine; Multiple sclerosis; Fingolimod; Experimental autoimmune encephalomyelitis; Immune system; Radioimmunotherapy; Immunology; CD8; Pharmacology; Antibody","score_opus":0.02256851623169468,"score_gpt":0.26838596720570407,"score_spread":0.2458174509740094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412012626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9457666,0.014582684,0.03719724,0.0008616725,0.00041662916,0.00059740944,0.00000394292,0.000052033865,0.00052174483],"genre_scores_gemma":[0.97774816,0.0048721116,0.01549063,0.0013841521,0.00005668754,0.00009726232,0.000061789324,0.000033873865,0.00025535934],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983655,0.000080750586,0.00045750244,0.0004962763,0.00027456434,0.0003253871],"domain_scores_gemma":[0.99940133,0.000030422967,0.000112938695,0.00035415718,0.000044361957,0.000056801888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031777055,0.00027080972,0.00064862636,0.00037803798,0.00008681422,0.00001632058,0.000108442444,0.0001610358,0.000024430392],"category_scores_gemma":[0.000020818425,0.00021685925,0.000050463506,0.0005237483,0.0003350829,0.00024314785,0.00001907523,0.00019006031,3.0609803e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008983862,0.0004477247,0.11980115,0.00016398319,0.00009437948,0.000013457522,0.0043858164,0.00045150396,0.85796124,0.0000152585435,0.001225086,0.0064565665],"study_design_scores_gemma":[0.10016102,0.002172668,0.35876155,0.0070451484,0.00024904765,0.000022611956,0.015891815,0.110711575,0.40313455,0.00029203616,0.00063910405,0.0009188819],"about_ca_topic_score_codex":0.00072802184,"about_ca_topic_score_gemma":0.000058700498,"teacher_disagreement_score":0.45482668,"about_ca_system_score_codex":0.00037907253,"about_ca_system_score_gemma":0.00009916316,"threshold_uncertainty_score":0.88432634},"labels":[],"label_agreement":null},{"id":"W4412091581","doi":"10.1002/cam4.71023","title":"Tumor‐Infiltrating Lymphocytes in Breast and Female Genital Tract Cancers: Overlooked Potential and Unexplored Frontiers","year":2025,"lang":"en","type":"review","venue":"Cancer Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Javna Agencija za Raziskovalno Dejavnost RS; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"Tumor-infiltrating lymphocytes; Medicine; Immunotherapy; Oncology; Breast cancer; Ovarian cancer; Tumor microenvironment; Internal medicine; Endometrial cancer; Microsatellite instability; Cancer; Biology","score_opus":0.024011402895506483,"score_gpt":0.31881048553266733,"score_spread":0.29479908263716087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412091581","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028880704,0.99334294,0.000016497108,0.0005393219,0.001224008,0.0012665128,0.00018193366,0.00005174154,0.00048896],"genre_scores_gemma":[0.0014034638,0.99569595,0.000101859085,0.00064956635,0.00094912003,0.0003087974,0.00014991658,0.000065702756,0.0006756127],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99730045,0.000104460014,0.00094811345,0.0007833344,0.00036772896,0.00049593206],"domain_scores_gemma":[0.9988177,0.00013527025,0.0003806737,0.00034837835,0.0000734768,0.0002445281],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034633625,0.0006562061,0.0026719328,0.0005621938,0.00010055006,0.000031616164,0.00014518818,0.00029277746,0.00021046652],"category_scores_gemma":[0.000071358714,0.0004937713,0.00022494911,0.00067686464,0.0005510868,0.00012926749,0.00005774592,0.0005035849,8.046881e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006518905,0.00003584543,0.001158977,0.020581344,0.0005132381,0.00029214157,0.00050475076,5.964368e-7,0.000041758838,0.000003305998,0.0028514806,0.97336465],"study_design_scores_gemma":[0.018620664,0.00071843073,0.00535388,0.20869812,0.0059889476,0.0032065506,0.0032032696,0.00013219836,0.000017156372,0.000020659398,0.7527564,0.0012837126],"about_ca_topic_score_codex":0.002988614,"about_ca_topic_score_gemma":0.00016225467,"teacher_disagreement_score":0.97208095,"about_ca_system_score_codex":0.0012837846,"about_ca_system_score_gemma":0.002264337,"threshold_uncertainty_score":0.9997514},"labels":[],"label_agreement":null},{"id":"W4412104478","doi":"10.1177/10668969251350264","title":"Small Samples, Big Insights: PD-L1 Experience of a Tertiary Institution","year":2025,"lang":"en","type":"article","venue":"International Journal of Surgical Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"","keywords":"Concordance; Medicine; Lung cancer; non-small cell lung cancer (NSCLC); Internal medicine; PD-L1; Resection; Oncology; Immunotherapy; Radiology; Pathology; Cancer; Surgery","score_opus":0.04042536100022873,"score_gpt":0.31421888189204805,"score_spread":0.2737935208918193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412104478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98854893,0.0022113398,0.0023900557,0.0025879976,0.0019388688,0.000063124084,0.0000057827538,0.000006675648,0.002247206],"genre_scores_gemma":[0.99694145,0.0012583763,0.00052654085,0.0008390237,0.00022816277,0.0000029013827,0.0000054114003,0.0000036028878,0.00019450852],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99891555,0.000058995225,0.0005912976,0.00010695927,0.00023627725,0.00009088896],"domain_scores_gemma":[0.999097,0.000110019,0.0002559479,0.000093394396,0.00039988116,0.00004376822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020543238,0.00008157158,0.00025725,0.0003301179,0.000019752331,0.000007693687,0.00020239598,0.000094921816,0.00009848457],"category_scores_gemma":[0.0000956582,0.000059699676,0.00018482121,0.00013993858,0.00026297153,0.00006324095,0.00004477795,0.00017696677,0.0000017212743],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03395274,0.0019870026,0.18413989,0.00011930451,0.0015450774,0.0134090055,0.0030124004,0.00004705049,0.38598618,0.015203297,0.0014444966,0.35915354],"study_design_scores_gemma":[0.015331768,0.001001115,0.5283207,0.0012890728,0.00013621901,0.012558491,0.0006364756,0.000053806656,0.05892504,0.0025116687,0.3790043,0.0002313247],"about_ca_topic_score_codex":0.000043309898,"about_ca_topic_score_gemma":0.000010432764,"teacher_disagreement_score":0.37755978,"about_ca_system_score_codex":0.00010653559,"about_ca_system_score_gemma":0.00022074553,"threshold_uncertainty_score":0.24344821},"labels":[],"label_agreement":null},{"id":"W4412124266","doi":"10.1093/oncolo/oyaf145","title":"Moving the needle on immune checkpoint inhibitors with novel targets: are we being TIMid or LAGging behind?","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lagging; Immune system; Computer science; Cancer research; Medicine; Immunology; Pathology","score_opus":0.026379924789962164,"score_gpt":0.297026984113279,"score_spread":0.27064705932331684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412124266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6496676,0.005899184,0.0011905127,0.27751902,0.0018646673,0.0026802043,0.000031130578,0.00044629327,0.0607014],"genre_scores_gemma":[0.98406106,0.00037780084,0.00028542057,0.00530118,0.00027987806,0.00008109632,0.000006800278,0.000027215146,0.009579537],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99880874,0.000060009028,0.00033701325,0.00024191814,0.00023308996,0.00031924987],"domain_scores_gemma":[0.99884975,0.0003379984,0.00021008067,0.00051253283,0.00005523302,0.000034408436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076953904,0.00021063114,0.0003149558,0.00008058181,0.000496519,0.000056193447,0.00027860978,0.000095195086,0.0001148638],"category_scores_gemma":[0.000126694,0.000089220244,0.00013452709,0.00034488548,0.00041551582,0.000048770922,0.00010222516,0.00044274435,0.000008747344],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09504159,0.0041143633,0.018435791,0.0012762223,0.0051138722,0.0006604215,0.028175026,0.0021831142,0.49300992,0.0032904074,0.07663673,0.27206254],"study_design_scores_gemma":[0.023430137,0.00577545,0.09589778,0.0094049405,0.0011847306,0.00034270214,0.048692014,0.0021361012,0.22299536,0.00049966294,0.58841175,0.0012293968],"about_ca_topic_score_codex":0.0006564368,"about_ca_topic_score_gemma":0.00041275044,"teacher_disagreement_score":0.511775,"about_ca_system_score_codex":0.00040869566,"about_ca_system_score_gemma":0.0002628471,"threshold_uncertainty_score":0.3818873},"labels":[],"label_agreement":null},{"id":"W4412166680","doi":"10.1017/cjn.2025.10189","title":"P.005 Real-world evidence of Lecanemab use in the United Statese","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"","keywords":"Real world evidence; Political science; Medicine; Internal medicine","score_opus":0.08033780067696561,"score_gpt":0.33894224834786296,"score_spread":0.25860444767089735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412166680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98220474,0.0019199844,0.000011669629,0.013295508,0.00046716016,0.00022258169,0.0000051376264,0.000007047605,0.0018661903],"genre_scores_gemma":[0.98835343,0.0018573697,0.0004214162,0.009212593,0.00007008615,0.000002450205,2.3118046e-7,0.000005238257,0.000077192984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956896,0.0012129659,0.0010826708,0.0003598839,0.0007444387,0.00091044913],"domain_scores_gemma":[0.99617434,0.0019264091,0.0006563727,0.00021353587,0.00043111233,0.00059822603],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0066498397,0.00024199949,0.0005071582,0.0024522007,0.0009768605,0.00039606588,0.0017160136,0.00011865357,0.000103105864],"category_scores_gemma":[0.003119094,0.00013452383,0.00024256679,0.005317833,0.0065745176,0.0007916719,0.00004147812,0.0011224641,5.032792e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008361186,0.00005032807,0.98921514,0.000021523709,0.000022104938,0.0034523252,0.0004716135,0.0010552608,0.00021517297,0.0010925984,0.001311968,0.002255858],"study_design_scores_gemma":[0.0007613749,0.04333216,0.93575126,0.0004179664,0.000085109,0.0071708094,0.0005891126,0.000751441,0.0002326971,0.0042676195,0.0064281668,0.00021228386],"about_ca_topic_score_codex":0.02725775,"about_ca_topic_score_gemma":0.40704167,"teacher_disagreement_score":0.37978393,"about_ca_system_score_codex":0.00030249933,"about_ca_system_score_gemma":0.0056877625,"threshold_uncertainty_score":0.99994904},"labels":[],"label_agreement":null},{"id":"W4412196006","doi":"10.3390/curroncol32070392","title":"Cancer Immunotherapy: The Role of Nursing in Patient Education, Assessment, Monitoring, and Support","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Alberta Health Services; University of Alberta; Sunnybrook Hospital; York University","funders":"","keywords":"Medicine; Immunotherapy; Cancer; Cancer immunotherapy; Oncology nursing; Intensive care medicine; Life expectancy; Adverse effect; Cancer treatment; Health care; Nursing; Oncology; Internal medicine; Nurse education; Population","score_opus":0.07836355431715991,"score_gpt":0.49962962304572756,"score_spread":0.42126606872856764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412196006","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032193563,0.9927965,0.0000017030461,0.00014731524,0.0031527088,0.001138326,0.000019906629,0.000013430977,0.002408175],"genre_scores_gemma":[0.000258795,0.99866354,0.000044833567,0.000029204926,0.00021583367,0.0005852973,0.00003921954,0.000024316885,0.00013896072],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985959,0.00018813774,0.0006431774,0.00025603527,0.00012869868,0.00018806229],"domain_scores_gemma":[0.99901646,0.00015629896,0.0004245126,0.00028178917,0.000086276064,0.00003466041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022014773,0.00022279621,0.0010324756,0.00023938806,0.000036073532,0.000008365713,0.00012929067,0.00018782982,0.00007269102],"category_scores_gemma":[0.000015684698,0.00014762841,0.00020060652,0.0003249482,0.00016576442,0.000023367302,0.000030396022,0.0004237622,4.8812933e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007472975,0.0006701598,0.0022935031,0.0034350182,0.00015087977,8.28422e-7,0.0005564425,2.101145e-8,0.000008191272,0.000042387735,0.0007546892,0.99201316],"study_design_scores_gemma":[0.00043066198,0.00026317226,0.0012301357,0.029079068,0.00041709762,0.000028483424,0.00042852244,5.162974e-7,0.000010750118,0.00004594407,0.96795654,0.0001091321],"about_ca_topic_score_codex":0.00008654769,"about_ca_topic_score_gemma":0.000009066847,"teacher_disagreement_score":0.991904,"about_ca_system_score_codex":0.0011485909,"about_ca_system_score_gemma":0.005749924,"threshold_uncertainty_score":0.9998866},"labels":[],"label_agreement":null},{"id":"W4412387662","doi":"10.1080/13696998.2025.2530862","title":"Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of early-stage non-small cell lung cancer following complete resection and platinum-based chemotherapy in Canada","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Pembrolizumab; Stage (stratigraphy); Chemotherapy; Oncology; Lung cancer; Adjuvant chemotherapy; Adjuvant; Cancer; Internal medicine; Resection; Surgery; Immunotherapy","score_opus":0.024088500101018588,"score_gpt":0.3212812795561362,"score_spread":0.29719277945511763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412387662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974524,0.0011906842,0.00025321054,0.0004726223,0.00022869761,0.00030828922,0.00003010249,0.0000012524627,0.000062743464],"genre_scores_gemma":[0.9976982,0.001889417,0.00007120337,0.00026281615,0.000032464384,0.000010068341,0.0000072642088,0.000009074674,0.000019506211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987635,0.00007878854,0.0006796379,0.00014142487,0.00019864611,0.00013800457],"domain_scores_gemma":[0.9990056,0.0002513759,0.00041031913,0.00013513422,0.00006244024,0.00013513755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005699927,0.00012191256,0.00085631217,0.0003751096,0.000022686352,0.0000070543642,0.000091564434,0.00009415429,0.00010870405],"category_scores_gemma":[0.000022643591,0.0001002871,0.00022869433,0.00027342726,0.000048354963,0.00004675845,0.000007948622,0.00013743066,1.8277067e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020672059,0.0005322053,0.9079855,0.00040909066,0.004686347,0.00009956548,0.000717509,0.0057111327,0.0042975526,0.000008753331,0.000024586314,0.0548557],"study_design_scores_gemma":[0.030443257,0.0017227933,0.8639997,0.00074755895,0.001203327,0.000007356284,0.0005492263,0.08563504,0.01489507,0.0000061730693,0.00066287536,0.00012760461],"about_ca_topic_score_codex":0.49344268,"about_ca_topic_score_gemma":0.5400901,"teacher_disagreement_score":0.07992391,"about_ca_system_score_codex":0.0015916497,"about_ca_system_score_gemma":0.003906207,"threshold_uncertainty_score":0.69294435},"labels":[],"label_agreement":null},{"id":"W4412393529","doi":"10.3390/curroncol32070403","title":"MET Exon 14 Skipping Mutations in Lung Cancer: Clinical–Pathological Characteristics and Immune Microenvironment","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Key Research and Development Program of China","keywords":"CD20; Immune system; Tumor microenvironment; FOXP3; CD8; Medicine; Cancer research; Lung cancer; Oncology; Biology; Immunology; Immunohistochemistry","score_opus":0.07635815516201744,"score_gpt":0.44753020373991503,"score_spread":0.3711720485778976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412393529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718095,0.02344382,0.00022036461,0.0021141223,0.0016763023,0.00043482604,0.000019590925,0.000020296813,0.00026114943],"genre_scores_gemma":[0.97485197,0.023626441,0.00033623632,0.000688043,0.00012594975,0.0001317239,0.0000622975,0.000007697741,0.0001696711],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987043,0.00015078999,0.0005932928,0.00028050624,0.000065081076,0.00020603316],"domain_scores_gemma":[0.9994556,0.00018415114,0.00013154597,0.00015545443,0.00002185133,0.00005141063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047437934,0.000114771225,0.00044550127,0.00012275769,0.00004764105,0.000008225576,0.00006494936,0.00014524968,0.00012251028],"category_scores_gemma":[0.00010241837,0.000102996884,0.00008782442,0.00015291608,0.0002520359,0.000024249905,0.000073057636,0.00034403274,0.0000027009626],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007086722,0.0005922458,0.4409747,0.000119949495,0.00008002434,0.000046910423,0.00024795494,4.980533e-7,0.0052989214,0.00006227675,0.00047471415,0.55139315],"study_design_scores_gemma":[0.0035326148,0.000301489,0.8899403,0.00028589112,0.0001379338,0.000017600109,0.000105313025,0.00016491018,0.00012424348,0.000037082926,0.10526551,0.00008706226],"about_ca_topic_score_codex":0.000022703764,"about_ca_topic_score_gemma":0.000024224692,"teacher_disagreement_score":0.55130607,"about_ca_system_score_codex":0.00035643327,"about_ca_system_score_gemma":0.00015995553,"threshold_uncertainty_score":0.4200091},"labels":[],"label_agreement":null},{"id":"W4412416997","doi":"10.2147/itt.s485643","title":"Combination of Radioligand Therapy and Immunotherapy: How to Make It Work in Clinic?","year":2025,"lang":"en","type":"article","venue":"ImmunoTargets and Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Radioligand; Immunotherapy; Work (physics); Medicine; Psychology; Internal medicine; Receptor; Cancer; Thermodynamics; Physics","score_opus":0.02110832415621605,"score_gpt":0.29465481262908294,"score_spread":0.2735464884728669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412416997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9028185,0.083710454,0.000049787363,0.011274727,0.00028648129,0.0009253821,0.0000060382677,0.000027045224,0.0009016087],"genre_scores_gemma":[0.89962876,0.09418881,0.0003573705,0.0038803353,0.00002959067,0.00005598098,0.00001013297,0.000026504045,0.0018225403],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986626,0.00008570476,0.00045740762,0.00034719543,0.00017048014,0.00027659873],"domain_scores_gemma":[0.9992174,0.00014458242,0.00012494817,0.000365594,0.00009086127,0.0000566137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060954527,0.00025528984,0.0005776308,0.0003494952,0.000088942856,0.00005452446,0.00011647804,0.0001548651,0.00010441049],"category_scores_gemma":[0.000021517502,0.00020427341,0.00011479001,0.000591578,0.00017424735,0.00007680546,0.000027172277,0.00018661021,0.0000013340888],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025593247,0.00055075035,0.061806057,0.00005861683,0.00064990245,0.000007755069,0.0028250357,4.104717e-7,0.11526823,0.00026317916,0.0015816587,0.7913951],"study_design_scores_gemma":[0.021015087,0.0014600665,0.7374951,0.0005106876,0.000014974763,0.000011821887,0.00044661315,0.000011251349,0.018278489,0.0005778922,0.21988235,0.00029564925],"about_ca_topic_score_codex":0.00014412467,"about_ca_topic_score_gemma":0.000015786576,"teacher_disagreement_score":0.7910995,"about_ca_system_score_codex":0.000047043446,"about_ca_system_score_gemma":0.00008745546,"threshold_uncertainty_score":0.8330028},"labels":[],"label_agreement":null},{"id":"W4412417362","doi":"10.1186/s12969-025-01127-x","title":"Immune checkpoint inhibitors and the pediatric rheumatologist: a pediatric needs assessment","year":2025,"lang":"en","type":"article","venue":"Pediatric Rheumatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Research Canada; Arthritis Research Centre of Canada; University of Alberta; BC Children's Hospital","funders":"","keywords":"Medicine; Adverse effect; Rheumatology; Internal medicine; Family medicine; Context (archaeology); Demographics; Pediatrics; Demography","score_opus":0.007525620554503233,"score_gpt":0.2681353607393864,"score_spread":0.26060974018488314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412417362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9235555,0.06071141,0.00043943754,0.008966828,0.0019996986,0.0011623533,0.000008580669,0.00022163763,0.0029345462],"genre_scores_gemma":[0.9074415,0.09046753,0.0003750291,0.00045153248,0.0002478779,0.00023479373,0.000019195812,0.000038400784,0.0007241473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961538,0.00032868053,0.0017631407,0.00060464273,0.00039871372,0.00075102533],"domain_scores_gemma":[0.9971569,0.0010954163,0.00065154245,0.0007623868,0.00017286958,0.00016086164],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017485714,0.000494919,0.0014179201,0.0012390685,0.0004083249,0.00007761401,0.0003674987,0.0004286609,0.00015223198],"category_scores_gemma":[0.0005128157,0.00033843768,0.00046428663,0.0025863382,0.00048112147,0.00011104353,0.00030624215,0.0007572059,0.000038559472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016099615,0.00022263806,0.98270917,0.00093014666,0.00020555446,0.00002360204,0.00039767515,0.0000017896059,0.000026346263,0.0050181234,0.007135551,0.0017194394],"study_design_scores_gemma":[0.049832933,0.0006716274,0.92964214,0.000104429724,0.0035891829,0.0025554022,0.0016893528,0.0006592694,0.00014083627,0.0028067753,0.007054536,0.001253537],"about_ca_topic_score_codex":0.00073351956,"about_ca_topic_score_gemma":0.000012959669,"teacher_disagreement_score":0.053067055,"about_ca_system_score_codex":0.00016738742,"about_ca_system_score_gemma":0.0010133195,"threshold_uncertainty_score":0.9999068},"labels":[],"label_agreement":null},{"id":"W4412426006","doi":"10.21203/rs.3.rs-7090131/v1","title":"Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trial","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Les Laboratories Pierre Fabre; SkylineDx; Regeneron Pharmaceuticals; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Nivolumab; Ipilimumab; Oncology; Medicine; Stage (stratigraphy); Internal medicine; Melanoma; Survival analysis; Overall survival; Immunotherapy; Cancer; Cancer research; Biology","score_opus":0.04338473399575225,"score_gpt":0.36499740457591007,"score_spread":0.3216126705801578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412426006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691297,0.01605273,0.00006751914,0.0050784852,0.0012413292,0.0055578575,0.0022344566,0.000079921956,0.00055801263],"genre_scores_gemma":[0.98133504,0.009773384,0.000047640504,0.00015689549,0.0007118418,0.0009894137,0.0013822234,0.00008777181,0.0055158003],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9893635,0.003497348,0.0012250341,0.0018035404,0.0026513017,0.0014592676],"domain_scores_gemma":[0.99286294,0.002503504,0.0003201196,0.0033906272,0.0006236099,0.0002991847],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0073534744,0.0007672869,0.0017197347,0.0011939397,0.0005441008,0.0006238357,0.0013287759,0.0007869688,0.0018527473],"category_scores_gemma":[0.0005797484,0.00047593072,0.00079328875,0.0030309537,0.0010190088,0.00016230962,0.0027822857,0.003244371,0.000032339],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6954367,0.001419222,0.2615414,0.0019891912,0.013457916,0.00162871,0.003589277,0.000110418536,0.0006500747,0.00012908987,0.0027237246,0.017324243],"study_design_scores_gemma":[0.08231189,0.00065404683,0.9069167,0.002182658,0.0011349239,0.000003773762,0.00211204,0.00071937917,0.00015052361,0.00019962058,0.002914843,0.00069964334],"about_ca_topic_score_codex":0.05245576,"about_ca_topic_score_gemma":0.04789692,"teacher_disagreement_score":0.64537525,"about_ca_system_score_codex":0.0012472443,"about_ca_system_score_gemma":0.0023584648,"threshold_uncertainty_score":0.9997692},"labels":[],"label_agreement":null},{"id":"W4412427378","doi":"10.3899/jrheum.2025-0108","title":"Necrotizing and Nonnecrotizing Granulomatous Reactions in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Literature Review","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Immune system; Dermatology; Immunology; Internal medicine","score_opus":0.0056043589144226654,"score_gpt":0.24445222674598188,"score_spread":0.23884786783155923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412427378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8498689,0.14717075,0.000023381359,0.0020379059,0.00008201628,0.0007678213,0.0000016445684,0.000008859133,0.000038724884],"genre_scores_gemma":[0.93369377,0.06583951,0.00009150561,0.00027801952,0.0000035814503,0.000025528103,0.0000023513292,0.00001407849,0.000051662428],"study_design_codex":"observational","study_design_gemma":"systematic_review","domain_scores_codex":[0.9985381,0.000200749,0.00083681144,0.0000988788,0.00015655458,0.0001689308],"domain_scores_gemma":[0.998697,0.00015737316,0.0006502048,0.00020328452,0.00025269718,0.000039443392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006433822,0.00016386303,0.0008475825,0.0002421779,0.00008397402,0.000018484183,0.00007365842,0.000067814675,0.000008962301],"category_scores_gemma":[0.000085324566,0.000077227465,0.00007357945,0.0006363126,0.000109648536,0.00010305763,0.000016712163,0.0003582997,3.2520282e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0105579365,0.00030057566,0.8786923,0.10406688,0.0015945968,0.000104178675,0.0019423531,0.0000065982877,0.0012379849,0.00003528799,0.00031780728,0.0011434436],"study_design_scores_gemma":[0.0101399645,0.0009481319,0.11663363,0.8586588,0.0009808507,0.011208475,0.00059804035,0.000017705084,0.00048107025,0.000013250728,0.00014834313,0.00017171992],"about_ca_topic_score_codex":0.0003682088,"about_ca_topic_score_gemma":0.00017150752,"teacher_disagreement_score":0.76205873,"about_ca_system_score_codex":0.00011442219,"about_ca_system_score_gemma":0.0001373708,"threshold_uncertainty_score":0.31492445},"labels":[],"label_agreement":null},{"id":"W4412428663","doi":"10.1001/jamanetworkopen.2025.18440","title":"Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non–Small Cell Lung Cancer","year":2025,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"AstraZeneca","keywords":"Durvalumab; Medicine; Internal medicine; Clinical endpoint; Oncology; Lung cancer; Population; Randomized controlled trial; Chemoradiotherapy; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.029436128722467782,"score_gpt":0.32191538299884936,"score_spread":0.2924792542763816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412428663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8952047,0.0047503826,0.014441877,0.010480642,0.0019909537,0.017634442,0.00036448968,0.00015515594,0.054977365],"genre_scores_gemma":[0.5543896,0.0007980289,0.005412743,0.011546005,0.00057349296,0.0013468703,0.0002103898,0.00009606041,0.42562684],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99834716,0.00004008653,0.00039238782,0.00045089656,0.00020285387,0.00056660874],"domain_scores_gemma":[0.9988554,0.00017986458,0.00018525276,0.000504775,0.00016211238,0.000112595],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00067913625,0.0002593689,0.00059099286,0.00006604491,0.0002617434,0.00019306637,0.00046607933,0.00014749206,0.0009740744],"category_scores_gemma":[0.000019427538,0.00018335812,0.00010185448,0.00066017505,0.00005883532,0.00015866048,0.0002124134,0.00020623849,0.0000025297823],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2658233,0.0010200081,0.060867313,0.0014244505,0.0027081394,0.000074551455,0.0006422405,0.0020234033,0.004644339,0.000209039,0.650984,0.009579211],"study_design_scores_gemma":[0.17484416,0.003419725,0.1103433,0.0056200335,0.0012268,0.000013587519,0.00064628123,0.025949663,0.008826316,0.000028272925,0.6681245,0.00095737603],"about_ca_topic_score_codex":0.0036435525,"about_ca_topic_score_gemma":0.0038073566,"teacher_disagreement_score":0.3706495,"about_ca_system_score_codex":0.00027880605,"about_ca_system_score_gemma":0.0009211463,"threshold_uncertainty_score":0.99993914},"labels":[],"label_agreement":null},{"id":"W4412535807","doi":"10.1016/j.breast.2025.104545","title":"Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer","year":2025,"lang":"en","type":"review","venue":"The Breast","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Santé Montérégie","funders":"","keywords":"Medicine; Breast cancer; Oncology; Cancer; Immune system; Cancer research; Internal medicine; Immunology","score_opus":0.016240443658560786,"score_gpt":0.31449669898182714,"score_spread":0.29825625532326633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412535807","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012229525,0.9903863,8.383514e-7,0.005657648,0.00023298066,0.0013692881,0.0006000781,0.000021664986,0.00050823216],"genre_scores_gemma":[0.00095165044,0.9962218,0.000038991846,0.00014239004,0.00009093914,0.00020688731,0.000016862516,0.000041273906,0.0022892407],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977486,0.00034433368,0.0009427023,0.0004052295,0.00025360176,0.0003055466],"domain_scores_gemma":[0.9984911,0.00032148833,0.0003290108,0.0006906661,0.00007800966,0.00008971295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013854365,0.00038630338,0.0014860935,0.0004619641,0.000056414716,0.000017253396,0.0002650403,0.00021097584,0.000091811664],"category_scores_gemma":[0.000057459118,0.00024376277,0.0004120828,0.0013095953,0.00025752303,0.00003214579,0.00013735663,0.0003014331,0.0000045265438],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019909235,0.00008925738,0.00013041875,0.016569627,0.00063080434,0.000023941577,0.000241324,5.730858e-8,0.00077841996,0.000010272308,0.0016114757,0.96000516],"study_design_scores_gemma":[0.0020723476,0.00007955575,0.035568964,0.17760327,0.00096314837,0.0007764595,0.00017059306,3.4338973e-7,0.00008524868,0.000013188143,0.78221256,0.00045429743],"about_ca_topic_score_codex":0.0010530697,"about_ca_topic_score_gemma":0.00024572772,"teacher_disagreement_score":0.95955086,"about_ca_system_score_codex":0.00040603807,"about_ca_system_score_gemma":0.0009968688,"threshold_uncertainty_score":0.9940357},"labels":[],"label_agreement":null},{"id":"W4412558988","doi":"10.1016/j.jtho.2025.07.115","title":"Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Roche","keywords":"Medicine; Post hoc; Post-hoc analysis; Platinum; Phase (matter); Internal medicine; Oncology","score_opus":0.028948815020603615,"score_gpt":0.4481591844504088,"score_spread":0.4192103694298052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412558988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99033797,0.000860706,0.00014032883,0.0066791703,0.0007119776,0.00049738394,0.00001069584,0.000005208579,0.00075655855],"genre_scores_gemma":[0.9986269,0.00006382877,0.00026892783,0.0006782347,0.00016821793,0.000005094721,0.0000107190035,0.000005842122,0.00017225138],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99782383,0.00037011906,0.0012890351,0.00015153184,0.00024572597,0.00011978255],"domain_scores_gemma":[0.9978073,0.0004888778,0.0009969096,0.00032770558,0.00034140304,0.000037767746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024875705,0.00010276357,0.0005771498,0.00017604811,0.000039519375,0.0000090567155,0.0001591448,0.000116805124,0.00013475402],"category_scores_gemma":[0.00056430325,0.000066045824,0.00016157638,0.00037715174,0.000105298976,0.00008442845,0.000040597562,0.00037243657,6.344153e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15150705,0.007864297,0.1875158,0.000073858784,0.0012522109,0.0017232565,0.0063549457,0.000018720773,0.09321089,0.000008663163,0.005575111,0.5448952],"study_design_scores_gemma":[0.035882816,0.014728277,0.87973374,0.00076706905,0.001126851,0.0010448229,0.011562689,0.000058531437,0.032867238,0.0006256235,0.021413667,0.00018869633],"about_ca_topic_score_codex":0.00061938044,"about_ca_topic_score_gemma":0.00039347223,"teacher_disagreement_score":0.69221795,"about_ca_system_score_codex":0.00032181822,"about_ca_system_score_gemma":0.00089347834,"threshold_uncertainty_score":0.26932707},"labels":[],"label_agreement":null},{"id":"W4412565794","doi":"10.2196/64900","title":"Impact of Immune Checkpoint Inhibitors on Second Primary Cancer Risk in Patients With Metastatic Lung Cancer Using Real-World Data From the TriNetX Network: Retrospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"JMIR Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Preprint; Lung cancer; Medicine; Oncology; Cancer; Internal medicine; Computer science; World Wide Web","score_opus":0.021636578919132763,"score_gpt":0.35574702328995067,"score_spread":0.3341104443708179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412565794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98994017,0.003383792,0.0000031108773,0.000106567575,0.00050283107,0.0041703056,0.0015269016,0.000024524483,0.0003418152],"genre_scores_gemma":[0.99696946,0.0013194389,0.000037030917,0.0002108734,0.000249864,0.00063570245,0.00016786958,0.000051899962,0.0003578364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972499,0.00021140775,0.0008110031,0.0007129103,0.0005706619,0.0004441088],"domain_scores_gemma":[0.9976762,0.00015407613,0.0007098228,0.0011983888,0.00019936469,0.00006217548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006593899,0.00038243024,0.0010123522,0.00019217255,0.00012738521,0.000029158824,0.000345188,0.00005379673,0.0008005249],"category_scores_gemma":[0.000020534273,0.00023378321,0.0001669224,0.0015601186,0.00018504071,0.0001674949,0.00017212814,0.0005362465,3.9566598e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014922274,0.0006799717,0.96973646,0.00007758908,0.0044588773,0.000004494913,0.00045269207,0.0010287823,0.00022023555,4.3347885e-7,0.0033232837,0.005094887],"study_design_scores_gemma":[0.0100724,0.0006120364,0.98546803,0.0015456139,0.0010147704,1.3359892e-7,0.000087289714,0.00063906406,0.00017485232,0.000003577397,0.00014055698,0.00024167169],"about_ca_topic_score_codex":0.27072588,"about_ca_topic_score_gemma":0.11056695,"teacher_disagreement_score":0.16015892,"about_ca_system_score_codex":0.0037959605,"about_ca_system_score_gemma":0.00129112,"threshold_uncertainty_score":0.9926305},"labels":[],"label_agreement":null},{"id":"W4412595186","doi":"10.1016/j.annonc.2025.07.009","title":"From epigenetic alterations to clinical impact: the role of DNMT3A in modulating immunotherapy response","year":2025,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Epigenetics; Immunotherapy; Oncology; Immunology; Immune system; Genetics; Gene","score_opus":0.05085911907880081,"score_gpt":0.4710971843933706,"score_spread":0.4202380653145698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412595186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68630624,0.012386562,0.00004930994,0.009646028,0.28830153,0.0013691954,0.00087201234,0.000019633808,0.0010494716],"genre_scores_gemma":[0.56161755,0.011283017,0.001228809,0.0033974466,0.41995192,0.00022393219,0.00055396045,0.000102577564,0.00164079],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967415,0.0008903089,0.0014340366,0.00033981673,0.0003250257,0.0002693474],"domain_scores_gemma":[0.99175245,0.0065118256,0.00056624954,0.0006846193,0.00041947683,0.00006536177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026214796,0.0002234546,0.0011279209,0.00029290363,0.000041106065,0.000008771312,0.00033207404,0.0008414932,0.00018871126],"category_scores_gemma":[0.002177062,0.00016107039,0.00049977755,0.00037144765,0.00020182518,0.00002429504,0.00007219263,0.00064695167,0.0000037992766],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06176946,0.0007048651,0.0020319885,0.000035106044,0.0010966131,0.000012994268,0.0020250527,0.0000661569,0.026795767,0.0000046287005,0.65858227,0.24687509],"study_design_scores_gemma":[0.003245264,0.0066243364,0.030653885,0.0004975567,0.000073980336,0.0000010741087,0.00023342695,0.000057225243,0.0032896379,0.00042649676,0.95475364,0.00014349405],"about_ca_topic_score_codex":0.004047996,"about_ca_topic_score_gemma":0.00046564324,"teacher_disagreement_score":0.29617134,"about_ca_system_score_codex":0.00012698521,"about_ca_system_score_gemma":0.0028325447,"threshold_uncertainty_score":0.656826},"labels":[],"label_agreement":null},{"id":"W4412626262","doi":"10.1038/s41523-025-00796-x","title":"The untapped potential of radiation and immunotherapy for hormone receptor-positive breast cancer","year":2025,"lang":"en","type":"review","venue":"npj Breast Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Cancer Institute; Office of Defense Programs; Cancer Research UK; National Institutes of Health; Royal Marsden NHS Foundation Trust; Breast Cancer Research Foundation; U.S. Department of Defense","keywords":"Breast cancer; Immunotherapy; Hormone receptor; Hormone; Oncology; Cancer; Medicine; Internal medicine; Receptor; Cancer immunotherapy; Cancer research","score_opus":0.010740190256175721,"score_gpt":0.3146805826261346,"score_spread":0.30394039236995885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412626262","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005861722,0.98730534,0.00007782123,0.0020637843,0.0009830309,0.0025218693,0.006842847,0.000031345662,0.000115314906],"genre_scores_gemma":[0.00019751335,0.99527764,0.000033341545,0.0002870741,0.00086417113,0.0013882695,0.00028293347,0.00007736641,0.0015916864],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979452,0.00011955909,0.0007416744,0.0004932253,0.00030613292,0.00039421726],"domain_scores_gemma":[0.9983516,0.00022493134,0.00063441816,0.00041385088,0.00029163592,0.0000835847],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027826036,0.0004910467,0.0014520735,0.00016614526,0.0002546992,0.000051830695,0.00021693861,0.00037577518,0.00025299663],"category_scores_gemma":[0.00000876843,0.00032043643,0.0006862047,0.00041516137,0.00028077193,0.00008053698,0.00004104127,0.0002936832,0.0000016242816],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005148477,0.0000571251,0.000027185104,0.0045562363,0.0022431337,9.0685666e-7,0.000058385947,3.5684334e-7,0.00036980995,0.000024905778,0.0057660094,0.98174745],"study_design_scores_gemma":[0.004493607,0.00016770803,0.007872995,0.016784007,0.0022540165,0.00018707133,0.000047705846,0.000009834596,0.000063947926,0.0000121869,0.9676824,0.0004245092],"about_ca_topic_score_codex":0.0017780585,"about_ca_topic_score_gemma":0.0000730447,"teacher_disagreement_score":0.98132294,"about_ca_system_score_codex":0.0006794745,"about_ca_system_score_gemma":0.0016328403,"threshold_uncertainty_score":0.9999248},"labels":[],"label_agreement":null},{"id":"W4412629771","doi":"10.1007/s40487-025-00357-z","title":"The Health Impact of Using Anti-PD-1 Agents to Treat Early-Stage Cancer in Belgium","year":2025,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"Merck","keywords":"Stage (stratigraphy); Cancer; Medicine; Internal medicine; Biology","score_opus":0.04550332840947906,"score_gpt":0.4467312410999579,"score_spread":0.4012279126904788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412629771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842258,0.010304539,0.000013749225,0.0040724254,0.00018685433,0.00041557485,0.000017926777,0.0000066460652,0.0007564816],"genre_scores_gemma":[0.97631323,0.020825356,0.000029716482,0.0018332318,0.000030918007,0.000016689695,0.0000015054655,0.0000066439784,0.00094273454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993144,0.00009557099,0.00020309289,0.00013263518,0.00005370559,0.00020057986],"domain_scores_gemma":[0.9996455,0.000073268704,0.00006998942,0.0001395149,0.000024338853,0.000047429512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031754604,0.000090715526,0.00029625933,0.000100747886,0.00010470297,0.000006209523,0.00005544456,0.000076633645,0.00008231838],"category_scores_gemma":[0.000005369643,0.000054560227,0.00007272709,0.00026846092,0.00010161163,0.000021285514,0.000013033913,0.00009687622,3.8520577e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009949729,0.0002243113,0.5199478,0.000033632015,0.00031119797,0.000010840706,0.0017032215,0.000014880779,0.02216636,0.00007979133,0.00092213065,0.4446361],"study_design_scores_gemma":[0.0038289754,0.001600991,0.958703,0.00011045126,0.000011752758,0.000004563486,0.00014124297,0.00004379205,0.0017031287,0.0000350649,0.03375924,0.000057801524],"about_ca_topic_score_codex":0.0076779723,"about_ca_topic_score_gemma":0.00080271065,"teacher_disagreement_score":0.4445783,"about_ca_system_score_codex":0.00029282708,"about_ca_system_score_gemma":0.000595432,"threshold_uncertainty_score":0.99893},"labels":[],"label_agreement":null},{"id":"W4412645886","doi":"10.3389/fimmu.2025.1557461","title":"Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Education and Child Care","funders":"Guangdong Medical Research Foundation; China Postdoctoral Science Foundation; National Natural Science Foundation of China","keywords":"Tumor microenvironment; Immunotherapy; Oncology; Medicine; Proportional hazards model; Biomarker; Cancer; Internal medicine; Computational biology; Bioinformatics; Biology; Genetics","score_opus":0.00740063996022426,"score_gpt":0.26321096499111757,"score_spread":0.2558103250308933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412645886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92382896,0.062154967,0.0004980806,0.011100457,0.000832331,0.0013737372,0.000025295409,0.00001949594,0.00016665412],"genre_scores_gemma":[0.9891139,0.008860366,0.00033479912,0.00091739214,0.00008946782,0.00031827597,0.000015703756,0.000017636712,0.00033241662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985755,0.00024757726,0.0004873429,0.0002817015,0.00013543402,0.00027240597],"domain_scores_gemma":[0.99921864,0.00016334554,0.00021813034,0.00035148568,0.000031725518,0.000016659233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047980796,0.00019339012,0.0005314047,0.00018443611,0.00010247445,0.000016224165,0.0002663,0.00009271299,0.000043512013],"category_scores_gemma":[0.000043327866,0.00011121125,0.000119901764,0.00028894327,0.0013460949,0.00005158555,0.00008517874,0.00030078256,0.000001030879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013766018,0.00017277931,0.6091373,0.00014554712,0.003385332,0.000020573973,0.006410754,0.000008951137,0.03129798,0.00008261969,0.007208401,0.32836375],"study_design_scores_gemma":[0.012512595,0.0004511989,0.9249187,0.00042744086,0.00023397032,0.000027236329,0.003188144,0.00012475601,0.027106052,0.00040589063,0.030457014,0.00014697343],"about_ca_topic_score_codex":0.00075848226,"about_ca_topic_score_gemma":0.000018104693,"teacher_disagreement_score":0.3282168,"about_ca_system_score_codex":0.00015851443,"about_ca_system_score_gemma":0.000117266376,"threshold_uncertainty_score":0.4959743},"labels":[],"label_agreement":null},{"id":"W4412662528","doi":"10.14740/wjon2613","title":"Efficacy of Infliximab Versus Vedolizumab in the Management of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review and Meta-Analysis","year":2025,"lang":"en","type":"review","venue":"World Journal of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Vedolizumab; Medicine; Infliximab; Meta-analysis; Colitis; Internal medicine; Systematic review; Gastroenterology; MEDLINE; Ulcerative colitis; Tumor necrosis factor alpha; Disease","score_opus":0.0909168812666085,"score_gpt":0.40535162715995315,"score_spread":0.31443474589334464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412662528","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037700713,0.99512047,0.0000021031885,0.00068245945,0.0001606213,0.0027726323,0.000012764129,0.0000022869147,0.0012089527],"genre_scores_gemma":[0.00092321547,0.9982268,0.00016522696,0.00018023404,0.00002906069,0.00014082006,0.000007639539,0.000014258873,0.0003127268],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.993583,0.0012406153,0.0043280185,0.0002071199,0.0004403493,0.00020089546],"domain_scores_gemma":[0.99347883,0.0011631717,0.0044838265,0.00060868775,0.0002151106,0.000050382798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039089965,0.00034807666,0.01166522,0.0012237272,0.000023661994,0.000008679092,0.00043090803,0.00015734756,0.00012705299],"category_scores_gemma":[0.00017480802,0.00018746163,0.0042663426,0.0023460127,0.00012270779,0.000034186738,0.00009158603,0.0005640839,8.057747e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012245402,0.00033877976,1.957322e-7,0.71816444,0.2435646,0.00017136322,0.00010659682,2.0493844e-7,0.0000012521594,0.0000664027,0.000079516445,0.036282122],"study_design_scores_gemma":[0.0043757013,0.0008952607,0.000053434364,0.16631897,0.78385395,0.00023963854,0.00012635972,1.3790951e-7,0.0000032286825,0.0000032127273,0.04401856,0.000111566595],"about_ca_topic_score_codex":0.00003662489,"about_ca_topic_score_gemma":0.00006622889,"teacher_disagreement_score":0.55184543,"about_ca_system_score_codex":0.00045262708,"about_ca_system_score_gemma":0.0006402726,"threshold_uncertainty_score":0.79741114},"labels":[],"label_agreement":null},{"id":"W4412871508","doi":"10.1101/2025.07.16.663652","title":"Age-dependent tumor-immune interactions underlie immunotherapy response in pediatric cancer","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Health and Medical Research Council; Stan Perron Charitable Foundation","keywords":"Immune system; Immunotherapy; Cancer immunotherapy; Cancer; Medicine; Immunology; Internal medicine","score_opus":0.018376026430650384,"score_gpt":0.2792116682294223,"score_spread":0.2608356417987719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412871508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677435,0.023888176,0.00023245499,0.0018512658,0.0037772555,0.0017124712,0.00031441782,0.00041928815,0.00006113282],"genre_scores_gemma":[0.9846164,0.011539845,0.0007422248,0.0011992991,0.0005732001,0.0008739294,0.0000010174933,0.00014774628,0.00030631255],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9959759,0.00039195686,0.0011793923,0.0011760065,0.00054302096,0.00073369173],"domain_scores_gemma":[0.9968708,0.00024288568,0.00056409254,0.0017670853,0.0003590096,0.00019613237],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012596077,0.000773503,0.0010955611,0.0013097877,0.00017016503,0.0001696158,0.0005853687,0.0004974913,0.00040660257],"category_scores_gemma":[0.0001779037,0.00081413495,0.00045479782,0.0012859803,0.0001407109,0.0001449903,0.0003426501,0.001790816,0.00004024623],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018824304,0.0010268806,0.0405864,0.001344901,0.0010576011,0.0008858399,0.00009015689,0.00014605807,0.93485755,0.000058677106,0.0010786656,0.000042985183],"study_design_scores_gemma":[0.005865164,0.00024102385,0.88367534,0.0023358597,0.00041736153,2.2657449e-7,0.00001586142,0.0001108803,0.0848626,0.000002871682,0.021314332,0.0011584578],"about_ca_topic_score_codex":0.0011362034,"about_ca_topic_score_gemma":0.000090118774,"teacher_disagreement_score":0.84999496,"about_ca_system_score_codex":0.0021863873,"about_ca_system_score_gemma":0.0033933434,"threshold_uncertainty_score":0.99943095},"labels":[],"label_agreement":null},{"id":"W4412881332","doi":"10.3389/fonc.2025.1615795","title":"Systematic literature review of real-world evidence on overall survival in cancer patients before and after the approval of anti-PD-(L)1 therapy","year":2025,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Clinical trial; Internal medicine; Observational study; MEDLINE; Oncology; Lung cancer; Targeted therapy; Cancer; Systematic review","score_opus":0.026098769747252788,"score_gpt":0.3654676237432321,"score_spread":0.3393688539959793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412881332","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047332075,0.9929332,0.0000016936859,0.00028811826,0.0013917107,0.0045334348,0.00008258119,0.000005427037,0.00029051077],"genre_scores_gemma":[0.00012040479,0.99770075,0.00009568135,0.00067171996,0.00006218966,0.0008400221,0.00004305672,0.00002534127,0.00044083354],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99646693,0.0010468898,0.0015286651,0.00040934354,0.00030069545,0.0002474913],"domain_scores_gemma":[0.9978649,0.0005143644,0.0009197072,0.0005339815,0.0001317886,0.000035250123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001279652,0.00037999297,0.0041014594,0.000548669,0.000016226943,0.000006921639,0.00029139378,0.00036730888,0.00002178446],"category_scores_gemma":[0.0002443499,0.00021200508,0.00041810094,0.0010232804,0.00021222632,0.000049571376,0.00006032324,0.0005733636,2.1864844e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011067891,0.00020672851,0.008755248,0.7006979,0.00038239482,0.00002223338,0.0003045537,4.476369e-8,2.1324436e-7,0.00001060816,0.002028123,0.28648514],"study_design_scores_gemma":[0.0013137157,0.0007278534,0.00712611,0.9014926,0.0005271605,0.0000059542976,0.00001865399,0.0000011807772,6.4451655e-7,0.000012065996,0.088633746,0.0001403199],"about_ca_topic_score_codex":0.00018184942,"about_ca_topic_score_gemma":0.00043898623,"teacher_disagreement_score":0.28634483,"about_ca_system_score_codex":0.0007115553,"about_ca_system_score_gemma":0.0008318601,"threshold_uncertainty_score":0.86453164},"labels":[],"label_agreement":null},{"id":"W4412881860","doi":"10.21203/rs.3.rs-7159624/v1","title":"Neoadjuvant immune-modulating SBRT and anti-CD73 to increase response to anti-PD-L1 and chemotherapy in early ER+/HER2- breast cancer: primary endpoint and translational results from the randomized Neo-CheckRay trial","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Saint-Luc","funders":"AstraZeneca","keywords":"Clinical endpoint; Medicine; Breast cancer; Internal medicine; Oncology; Population; Chemotherapy; Immune system; Cancer; Gastroenterology; Randomized controlled trial; Immunology","score_opus":0.027833594532196686,"score_gpt":0.3643697789119888,"score_spread":0.3365361843797921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412881860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93548465,0.007985862,0.000047358495,0.044845093,0.00021038312,0.008240448,0.002981592,0.000047577734,0.00015704162],"genre_scores_gemma":[0.98868257,0.0075448225,0.000769548,0.0010098477,0.0004956181,0.0007202319,0.00030456847,0.00006321076,0.00040960283],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99280137,0.0026492768,0.001280581,0.0013353159,0.001205813,0.0007276387],"domain_scores_gemma":[0.99309266,0.0050188396,0.00021573984,0.0008969881,0.00038191903,0.00039387864],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.01077601,0.00054658396,0.0017084464,0.0007431574,0.00034024077,0.0003174278,0.00034186244,0.0004597745,0.000079587306],"category_scores_gemma":[0.001411923,0.00040277874,0.00027777688,0.0007433872,0.000535757,0.00010723333,0.0005594334,0.0015427431,0.0000018320657],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92610854,0.0001861434,0.0053747008,0.00033638012,0.00046446195,0.000059969698,0.008268797,0.000040302795,0.012150334,0.000007232174,0.00038633432,0.04661678],"study_design_scores_gemma":[0.3350219,0.00036189682,0.6573081,0.003940656,0.00007811184,0.000017156959,0.0003776289,0.0003916536,0.0003910981,0.00011079934,0.0016559265,0.00034505752],"about_ca_topic_score_codex":0.03983911,"about_ca_topic_score_gemma":0.000733866,"teacher_disagreement_score":0.6519334,"about_ca_system_score_codex":0.00036159594,"about_ca_system_score_gemma":0.0016041861,"threshold_uncertainty_score":0.9998424},"labels":[],"label_agreement":null},{"id":"W4412928838","doi":"10.1038/s41590-025-02260-1","title":"Author Correction: LARP4-mediated hypertranslation drives T cell dysfunction in tumors","year":2025,"lang":"en","type":"erratum","venue":"Nature Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Cancer research; Medicine; Computational biology; Internal medicine; Biology","score_opus":0.006225730067251254,"score_gpt":0.2577558056034281,"score_spread":0.25153007553617684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412928838","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013614951,0.306066,0.00018060084,0.020980842,0.45598462,0.0030949288,0.00018238195,0.0008280605,0.19906762],"genre_scores_gemma":[0.06734779,0.007037176,0.000116784104,0.002580009,0.0017755312,0.0001470214,0.0062891627,0.000102033955,0.9146045],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779916,0.00018890559,0.00063220516,0.0006519696,0.00028732637,0.00044040708],"domain_scores_gemma":[0.9987879,0.00016994192,0.00028161306,0.0005182179,0.00019785829,0.00004447116],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0002651515,0.0004596786,0.00084144576,0.0010547363,0.00010634568,0.000022693475,0.00019500386,0.004435059,0.000507088],"category_scores_gemma":[0.00020564448,0.00042633404,0.00028306645,0.0010711654,0.00017104195,0.00008533014,0.000036306243,0.0055288365,0.00004812947],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045307935,0.00026146864,0.0007030393,0.00030279977,0.00038882846,0.000104564904,0.00026931867,0.0000019300278,0.01385267,0.000015494235,0.9567729,0.022796169],"study_design_scores_gemma":[0.0039549605,0.00056362577,0.04272876,0.001027495,0.00018325701,0.00012281873,0.00017878262,0.00014340777,0.0014638604,0.000030995365,0.949239,0.00036300585],"about_ca_topic_score_codex":0.00028346488,"about_ca_topic_score_gemma":0.0004309753,"teacher_disagreement_score":0.7155369,"about_ca_system_score_codex":0.000537925,"about_ca_system_score_gemma":0.0010401503,"threshold_uncertainty_score":0.99981886},"labels":[],"label_agreement":null},{"id":"W4412940298","doi":"10.1136/jitc-2025-012659","title":"Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; London Health Sciences Centre; Lawson Health Research Institute; Western University","funders":"Canadian Cancer Society; Lotte and John Hecht Memorial Foundation; London Health Sciences Centre","keywords":"Medicine; Internal medicine; Transplantation; Melanoma; Post-hoc analysis; Oncology; Fecal bacteriotherapy; Gastroenterology; Progression-free survival; Surgery; Overall survival; Clostridium difficile; Antibiotics; Cancer research","score_opus":0.0198921299049257,"score_gpt":0.33525427973694233,"score_spread":0.3153621498320166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412940298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956546,0.0009383441,0.0002676868,0.0004985293,0.00041744622,0.0020208755,0.00018349779,0.000004627329,0.000014419345],"genre_scores_gemma":[0.9982721,0.0010244825,0.00035230213,0.00013523588,0.00002698224,0.000045593373,0.000041942476,0.000022784601,0.00007857929],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99838555,0.00011901783,0.0008562556,0.0001897466,0.00022247744,0.0002269752],"domain_scores_gemma":[0.99877334,0.00009023167,0.00068209023,0.00017082434,0.00025934508,0.000024171137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004293419,0.00018511814,0.0005181423,0.00029776833,0.00008704769,0.000014156012,0.00012355876,0.000095725765,0.000008906025],"category_scores_gemma":[0.000013559367,0.00011620493,0.0001413212,0.0005702282,0.000109093955,0.00013283348,0.000003632542,0.00022791828,1.06772955e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6826872,0.0011146617,0.02487733,0.00014470326,0.00025134787,0.0000018147808,0.00039572595,0.00010213433,0.26266533,0.0000016965874,0.000012823292,0.02774522],"study_design_scores_gemma":[0.6819404,0.011011449,0.21701494,0.0022023988,0.00015527257,0.00001581212,0.00013299643,0.00051417307,0.08640488,0.000007348073,0.0004237338,0.00017659584],"about_ca_topic_score_codex":0.0015904054,"about_ca_topic_score_gemma":0.0017404951,"teacher_disagreement_score":0.19213761,"about_ca_system_score_codex":0.00045348177,"about_ca_system_score_gemma":0.0007035941,"threshold_uncertainty_score":0.47386995},"labels":[],"label_agreement":null},{"id":"W4412940313","doi":"10.1136/jitc-2024-010777","title":"Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"American Society of Clinical Oncology","keywords":"Medicine; Pembrolizumab; Renal cell carcinoma; Melanoma; Pharmacodynamics; Internal medicine; Pharmacokinetics; Clinical endpoint; Oncology; Adverse effect; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Cancer; Clinical trial; Gastroenterology; Immunotherapy; Cancer research","score_opus":0.00830114669991602,"score_gpt":0.29845379804716465,"score_spread":0.29015265134724866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412940313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774645,0.016127408,0.0005160617,0.001847106,0.0007776154,0.0028035967,0.00027706256,0.000008998822,0.00017765132],"genre_scores_gemma":[0.9914329,0.0051505924,0.000944557,0.0011162402,0.00026114224,0.00025050243,0.00005420205,0.000044792803,0.0007450881],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977364,0.00014066177,0.0011272436,0.0003218276,0.00035407627,0.00031982054],"domain_scores_gemma":[0.99796885,0.0006147589,0.0007297738,0.00039130435,0.00023277008,0.000062558014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086229644,0.00030476265,0.000978582,0.00017521449,0.00017733734,0.00005366618,0.00022125678,0.00013311715,0.00008620942],"category_scores_gemma":[0.000052155283,0.00017914923,0.00033974432,0.00029432698,0.000336013,0.00014402605,0.000013628577,0.00035262288,1.9769149e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8797854,0.0005515186,0.0028792587,0.000025186155,0.00065930287,0.0000033722117,0.00090415456,0.000016119639,0.015531855,0.0000043139953,0.0012898698,0.098349646],"study_design_scores_gemma":[0.93437696,0.003448522,0.030085826,0.0004961749,0.00020567111,0.000002420006,0.00015944595,0.00010384354,0.015617081,0.00014976054,0.015151164,0.00020315927],"about_ca_topic_score_codex":0.00089172897,"about_ca_topic_score_gemma":0.00013547952,"teacher_disagreement_score":0.09814648,"about_ca_system_score_codex":0.00021084827,"about_ca_system_score_gemma":0.0005043895,"threshold_uncertainty_score":0.73054934},"labels":[],"label_agreement":null},{"id":"W4412940509","doi":"10.3390/curroncol32080432","title":"Immunologic Alteration After Total En-Bloc Spondylectomy with Anterior Spinal Column Reconstruction with Frozen Tumor-Containing Bone Autologous Grafts: A Case Report in a Prospective Study","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Immune system; T-cell receptor; Pathology; Transplantation; Surgery; T cell; Immunology","score_opus":0.018665968931990927,"score_gpt":0.3442957593661884,"score_spread":0.3256297904341975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412940509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938516,0.0021236164,0.00018331339,0.00026629466,0.00086806563,0.0024342001,0.0000056721033,0.00008354411,0.00018372113],"genre_scores_gemma":[0.9981519,0.000024356808,0.00041817588,0.000074593445,0.000100743426,0.0010919654,0.000011282362,0.000015883514,0.00011111243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810666,0.00023305367,0.0006091449,0.0005824946,0.00013999574,0.00032864095],"domain_scores_gemma":[0.9991682,0.000053292468,0.0002880159,0.00028064635,0.00016381765,0.0000460177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047352831,0.00025428808,0.0006529241,0.0003989967,0.00010739539,0.0000323673,0.000049297945,0.00010947557,0.000057602658],"category_scores_gemma":[0.000068375404,0.00019354856,0.00006612922,0.0005626826,0.00024177182,0.00013019497,0.00004139716,0.00048716928,0.000002108844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08768044,0.0017090577,0.7194523,0.000092862465,0.00039493473,0.10538296,0.0024601626,0.000002635347,0.0011266916,0.000003933235,0.000018008217,0.08167598],"study_design_scores_gemma":[0.016118886,0.020522976,0.7183394,0.0009224021,0.00025270594,0.2372561,0.005543377,0.00014094384,0.00020510158,0.000014095818,0.00044227985,0.00024175711],"about_ca_topic_score_codex":0.0004266667,"about_ca_topic_score_gemma":0.0027595772,"teacher_disagreement_score":0.13187315,"about_ca_system_score_codex":0.0012382941,"about_ca_system_score_gemma":0.0007060663,"threshold_uncertainty_score":0.78926814},"labels":[],"label_agreement":null},{"id":"W4412954991","doi":"10.1111/jop.70012","title":"Inverse Regulation of <scp>TLR4</scp> and <scp>PD</scp> ‐ <scp>L1</scp> Shapes the Inflammatory Tumor Microenvironment in Oral Squamous Cell Carcinomas","year":2025,"lang":"en","type":"article","venue":"Journal of Oral Pathology and Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"European Commission; Università degli Studi di Foggia","keywords":"Tumor microenvironment; TLR4; Immunohistochemistry; Immune system; CD8; Medicine; Lymph node; Cancer research; T cell; Tissue microarray; Immunotherapy; Cancer; Pathology; Internal medicine; Immunology","score_opus":0.012121821213886193,"score_gpt":0.24879489069926486,"score_spread":0.23667306948537867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412954991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98037314,0.016005335,0.000042831864,0.0016945658,0.00042407864,0.00042223043,0.00000615437,0.0000106608095,0.0010209726],"genre_scores_gemma":[0.9931062,0.0023655286,0.00026634548,0.0021499929,0.0001950107,0.000008233508,0.000008109786,0.000021600554,0.001878976],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976534,0.00028325472,0.0010448167,0.00029225685,0.00034267225,0.00038355283],"domain_scores_gemma":[0.99794006,0.00079564296,0.0007314367,0.00024121748,0.000117216085,0.00017442489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017175976,0.00030452706,0.00087165035,0.00050056825,0.0001284697,0.000010501836,0.00016854418,0.0002399377,0.00002064338],"category_scores_gemma":[0.00078692,0.00019805765,0.00013212334,0.00031171204,0.0011369245,0.00014020185,0.00008657537,0.00064467627,0.0000015852678],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000560829,0.00039774014,0.3166763,0.00065279595,0.00022235731,0.0014475615,0.008773993,0.000033056127,0.628477,0.00008224976,0.037940923,0.004735253],"study_design_scores_gemma":[0.011770845,0.0021457258,0.9201545,0.00053607044,0.0005217603,0.0017837617,0.007839769,0.00012145112,0.0154672405,0.00035803032,0.039264098,0.00003675763],"about_ca_topic_score_codex":0.00006995726,"about_ca_topic_score_gemma":0.000084011284,"teacher_disagreement_score":0.6130097,"about_ca_system_score_codex":0.00012194736,"about_ca_system_score_gemma":0.00020377114,"threshold_uncertainty_score":0.80765563},"labels":[],"label_agreement":null},{"id":"W4412963982","doi":"10.1007/978-3-031-91334-1_85","title":"Exploring Novel PD-L1 Inhibitors Through Molecular Docking: A Promising Approach in Cancer Immunotherapy","year":2025,"lang":"en","type":"book-chapter","venue":"Lecture notes in networks and systems","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bishop's University","funders":"","keywords":"Cancer immunotherapy; Immunotherapy; Docking (animal); Computational biology; PD-L1; Cancer; Medicine; Cancer research; Biology; Internal medicine","score_opus":0.06051747563783376,"score_gpt":0.28110996061384075,"score_spread":0.22059248497600698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412963982","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03810535,0.7487974,0.13728254,0.0011472948,0.0073055127,0.008866508,0.000048723723,0.00040930908,0.058037344],"genre_scores_gemma":[0.9641903,0.029304253,0.0005313837,0.0010224887,0.0016498454,0.00059715024,0.00008146627,0.00028206033,0.0023410309],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974311,0.000049312257,0.0008895696,0.0007826614,0.00033998943,0.000507373],"domain_scores_gemma":[0.9989515,0.00015557991,0.0002975829,0.00047045734,0.00006671536,0.00005816553],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004146955,0.0006428937,0.0012324901,0.0003436002,0.00007135003,0.00010905472,0.00014784209,0.00077000493,0.000011185571],"category_scores_gemma":[0.000016280686,0.0005433974,0.00023872264,0.0002842657,0.00011592446,0.00010597153,0.00005824441,0.0011560086,1.908365e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013910397,0.000732201,0.008588793,0.010983084,0.0051047564,0.0006557292,0.013135386,0.4471433,0.014839444,0.010118762,0.00067292707,0.47411522],"study_design_scores_gemma":[0.0521288,0.0020645019,0.0034354553,0.20251127,0.0013762596,0.0009340278,0.0006565264,0.23794834,0.0029362522,0.0031806445,0.48343796,0.009389981],"about_ca_topic_score_codex":0.0018539287,"about_ca_topic_score_gemma":0.00017542003,"teacher_disagreement_score":0.926085,"about_ca_system_score_codex":0.00051599706,"about_ca_system_score_gemma":0.0001922064,"threshold_uncertainty_score":0.99970174},"labels":[],"label_agreement":null},{"id":"W4413006781","doi":"10.51731/cjht.2025.1185","title":"Nivolumab","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nivolumab; Computer science; Medicine; Internal medicine; Cancer; Immunotherapy","score_opus":0.017837409268314727,"score_gpt":0.3032496467341336,"score_spread":0.2854122374658189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413006781","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20986685,0.43464628,0.0006964072,0.34752172,0.0014763774,0.0003752419,0.000009542309,0.00015582569,0.0052517736],"genre_scores_gemma":[0.9955683,0.0010401808,0.00041241726,0.0024079538,0.000005712865,0.0000015697299,5.485055e-7,0.000004486149,0.0005588808],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992629,0.00001512913,0.00035384583,0.00006245678,0.0000660502,0.00023956847],"domain_scores_gemma":[0.9995259,0.000017501367,0.00015002761,0.00016496546,0.000101019505,0.000040566087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034705523,0.00006207761,0.00024369425,0.0006592807,0.00012327064,0.000012834578,0.00014501739,0.00009256697,0.00003502332],"category_scores_gemma":[0.00018199344,0.000049896247,0.0000778288,0.000389813,0.00016707517,0.000035285604,0.0000058724445,0.00025372903,0.0000023642656],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007985959,0.0000081902335,0.005785979,0.00008265994,0.00006867276,0.00006486128,0.00005656628,3.0217907e-7,0.0001258801,0.000715892,0.03402064,0.9589905],"study_design_scores_gemma":[0.0012104932,0.00047112218,0.029660773,0.00064206717,0.000016289914,0.00029685404,0.0019512209,0.0000023245118,0.0013100072,0.0019159855,0.96246576,0.000057091802],"about_ca_topic_score_codex":0.003952862,"about_ca_topic_score_gemma":0.0026720995,"teacher_disagreement_score":0.9589334,"about_ca_system_score_codex":0.0004935394,"about_ca_system_score_gemma":0.0053537264,"threshold_uncertainty_score":0.9497281},"labels":[],"label_agreement":null},{"id":"W4413008967","doi":"10.1097/ppo.0000000000000782","title":"Modulating T-cell Responses to Enhance the Effects of Radiotherapy","year":2025,"lang":"en","type":"review","venue":"The Cancer Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Immune system; Immunotherapy; Radiation therapy; Cytotoxic T cell; Cancer research; Context (archaeology); Medicine; Immunology; T cell; Cancer immunotherapy; Biology; Internal medicine; In vitro","score_opus":0.02081548869882613,"score_gpt":0.3906668593936176,"score_spread":0.36985137069479146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413008967","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000413346,0.99540055,0.00027111717,0.0011602051,0.0012200716,0.0012568623,0.0000147626015,0.000012208961,0.00025085057],"genre_scores_gemma":[0.00010396972,0.99154615,0.00013543296,0.0013381747,0.0009462524,0.00013453503,0.000001300036,0.000041614374,0.0057525868],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979346,0.0005323263,0.0006770753,0.00021987397,0.00035045095,0.00028567715],"domain_scores_gemma":[0.99720144,0.001376945,0.00061562576,0.000620546,0.00010691289,0.00007855201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001082242,0.00031400562,0.001190169,0.00017128073,0.00024296404,0.000045663564,0.00062651496,0.000128159,0.00014704],"category_scores_gemma":[0.0002030565,0.00013937913,0.00073894655,0.0006139046,0.00011761031,0.000026744914,0.000051426967,0.00078194187,0.000002562034],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007251253,0.00002701778,0.0000061144488,0.01191367,0.000664443,0.000012514036,0.00035728767,0.0000027223093,0.001031914,0.0000025279487,0.008122618,0.97713405],"study_design_scores_gemma":[0.00056731387,0.00029928208,0.000038676917,0.053731814,0.0010960499,0.00018218224,0.000025698799,0.0000022910149,0.0013427486,0.000015014654,0.94254154,0.00015738247],"about_ca_topic_score_codex":0.000059409995,"about_ca_topic_score_gemma":0.000005983267,"teacher_disagreement_score":0.97697663,"about_ca_system_score_codex":0.00042332156,"about_ca_system_score_gemma":0.0015052,"threshold_uncertainty_score":0.5683716},"labels":[],"label_agreement":null},{"id":"W4413032234","doi":"10.20944/preprints202508.0162.v1","title":"Kinome-Wide Screening Identifies FAK as a Novel Post-Translational Regulator of PD-L1 Stability and Immune Evasion in Triple Negative Breast Cancer","year":2025,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Kinome; Regulator; Evasion (ethics); Triple-negative breast cancer; Immune system; Breast cancer; Cancer research; PD-L1; Computational biology; Biology; Medicine; Cancer; Gene; Internal medicine; Immunology; Immunotherapy; Genetics","score_opus":0.07635442655713204,"score_gpt":0.35090571370067286,"score_spread":0.2745512871435408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413032234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911962,0.001924145,0.00013469027,0.0029798956,0.00039958316,0.001683822,0.0007762147,0.00004992606,0.00085551455],"genre_scores_gemma":[0.9975806,0.00056078477,0.0002917452,0.00018799021,0.000063170024,0.00019448972,0.0001343256,0.00002583609,0.00096106716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997046,0.00014048409,0.0010487919,0.0009566421,0.00051136623,0.00029672257],"domain_scores_gemma":[0.99783236,0.0002612932,0.00047178357,0.0008519818,0.00048669163,0.00009586332],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011121999,0.00038403968,0.00086473033,0.0003759521,0.00008188128,0.000018522871,0.0002668132,0.00037136543,0.001471278],"category_scores_gemma":[0.0003308386,0.00038012263,0.00032380695,0.00035279695,0.00034822305,0.00014472123,0.0006189729,0.0007297697,0.000004838301],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01111915,0.0003343892,0.7645287,0.0012364084,0.00059820164,0.000004132947,0.0029659856,0.00007521775,0.21659873,0.000039339902,0.0000061409205,0.0024936192],"study_design_scores_gemma":[0.0037495082,0.000030992807,0.86774963,0.002491994,0.00014866135,0.000013623735,0.00048824705,0.00013771575,0.12446199,0.00038639968,0.0000848255,0.00025642838],"about_ca_topic_score_codex":0.019707685,"about_ca_topic_score_gemma":0.0011082683,"teacher_disagreement_score":0.103220925,"about_ca_system_score_codex":0.00028419247,"about_ca_system_score_gemma":0.0009767917,"threshold_uncertainty_score":0.99986506},"labels":[],"label_agreement":null},{"id":"W4413049571","doi":"10.1016/j.jpi.2025.100465","title":"Neighborhood clustering analysis to define epithelial–stromal interface for tumor infiltrating lymphocyte evaluation","year":2025,"lang":"en","type":"article","venue":"Journal of Pathology Informatics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs","funders":"Medical Center, University of Rochester","keywords":"Stromal cell; Computer science; Cluster analysis; Lymphocyte; Interface (matter); Information retrieval; Computational biology; Pathology; Medicine; Artificial intelligence; Immunology; Biology","score_opus":0.0189739855435667,"score_gpt":0.33792917964851604,"score_spread":0.3189551941049493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413049571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74885654,0.0003352431,0.2483904,0.00082231103,0.00043904613,0.0003550672,0.000014921935,0.000009553272,0.0007769232],"genre_scores_gemma":[0.95621365,0.000041364812,0.041085795,0.0024827647,0.000094580864,0.00001602042,0.000008725071,0.000007313395,0.000049777922],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99831676,0.00004741789,0.0011533648,0.000059901216,0.00023454361,0.00018800463],"domain_scores_gemma":[0.99847305,0.0001257903,0.0006372757,0.00017128907,0.00052667357,0.00006594942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016589619,0.00012407958,0.00046783753,0.00067528966,0.000070158814,0.000030390986,0.00012372805,0.00007517813,0.000036521764],"category_scores_gemma":[0.00051092636,0.000099644356,0.00028204574,0.0005824784,0.00003490262,0.00016332685,0.00003607306,0.00014319614,0.000002717615],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0247364,0.0005832688,0.061244994,0.0015061505,0.013846592,0.00015365146,0.025590243,0.056914385,0.23501761,0.00027889636,0.0039757616,0.576152],"study_design_scores_gemma":[0.058483656,0.012433431,0.13947013,0.0021731898,0.025174884,0.008324544,0.017460614,0.6392422,0.07891975,0.0008378484,0.016365202,0.0011145927],"about_ca_topic_score_codex":0.0000034074442,"about_ca_topic_score_gemma":0.00001232737,"teacher_disagreement_score":0.5823278,"about_ca_system_score_codex":0.00029486621,"about_ca_system_score_gemma":0.0003889597,"threshold_uncertainty_score":0.4063379},"labels":[],"label_agreement":null},{"id":"W4413100200","doi":"10.1177/12034754251364847","title":"Neoadjuvant Immune Checkpoint Inhibitors in CSCC: A Systematic Review and Meta-Analysis","year":2025,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Meta-analysis; Immune system; Oncology; Immunology; Internal medicine","score_opus":0.062121457434870984,"score_gpt":0.34588358326614327,"score_spread":0.2837621258312723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413100200","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009030169,0.9955798,0.0000046318787,0.0028227,0.00018779481,0.0012441444,0.000010044037,0.0000077632785,0.00013409302],"genre_scores_gemma":[0.00003937858,0.9969944,0.000021867296,0.001659573,0.00012206391,0.000040443578,0.000016953472,0.00002806299,0.0010773089],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99311525,0.00056395057,0.005115287,0.00032217236,0.00060097466,0.00028234077],"domain_scores_gemma":[0.99378616,0.0024465665,0.0028684328,0.0004525964,0.00023252916,0.00021370516],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0042772926,0.00058786036,0.021995991,0.0022153216,0.000042488282,0.00002112225,0.00012894087,0.0002614089,0.00024869156],"category_scores_gemma":[0.0015577826,0.00030047426,0.0047403197,0.0017162438,0.00017286718,0.000058893915,0.000041855783,0.0007343036,9.376538e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000085774715,0.000054642802,0.000005262956,0.8521241,0.12263046,0.0025351006,0.00007537233,4.524202e-8,0.0000013099921,0.000001122781,0.0016652623,0.020821527],"study_design_scores_gemma":[0.00021283289,0.00014152881,0.0000013277922,0.33655643,0.59315217,0.013423851,0.000059147987,4.2404739e-7,3.6375468e-7,0.0000039601196,0.056286998,0.00016094862],"about_ca_topic_score_codex":0.000087138884,"about_ca_topic_score_gemma":0.00001740208,"teacher_disagreement_score":0.51556766,"about_ca_system_score_codex":0.00014900323,"about_ca_system_score_gemma":0.0006627302,"threshold_uncertainty_score":0.99994475},"labels":[],"label_agreement":null},{"id":"W4413107688","doi":"10.1136/jitc-2025-011475","title":"First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Immunogenicity; CD8; Pharmacokinetics; Pharmacodynamics; Cytotoxic T cell; Agonist; Tolerability; Adverse effect; Pharmacology; Receptor; Antibody; CD28; T cell; Internal medicine; Immune system; Immunology; In vitro; Chemistry","score_opus":0.011388662550833616,"score_gpt":0.34751192627272615,"score_spread":0.33612326372189255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413107688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948098,0.0019075811,0.00002764095,0.00064361724,0.00057571556,0.0018018584,0.00003246819,0.000007342761,0.00019398988],"genre_scores_gemma":[0.9981919,0.00039869768,0.000046997862,0.0004972735,0.00004414401,0.00012815851,0.000002678596,0.000032172375,0.00065798644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983446,0.000047185473,0.00075173465,0.0001934483,0.0004125411,0.00025049626],"domain_scores_gemma":[0.99862266,0.00006894916,0.0005955986,0.00039519017,0.00028382576,0.000033779783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002558531,0.00021250873,0.0005756457,0.00022844756,0.0002567588,0.000018061011,0.00026526002,0.000055627046,0.00010561174],"category_scores_gemma":[0.0000175254,0.00012711635,0.00025529714,0.0004090403,0.00013909965,0.000077757635,0.0000136329345,0.00027484415,1.0826651e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26120016,0.024367196,0.32067025,0.00063583633,0.0047040684,0.000011909746,0.0061714943,0.0015304348,0.09640766,0.000104246115,0.0017952131,0.28240156],"study_design_scores_gemma":[0.18010166,0.026318397,0.7200613,0.0043430603,0.00028862222,0.000007323389,0.0015478098,0.000053379565,0.046833288,0.00014861624,0.019953396,0.00034316987],"about_ca_topic_score_codex":0.00019206913,"about_ca_topic_score_gemma":0.0003499985,"teacher_disagreement_score":0.39939103,"about_ca_system_score_codex":0.00034512047,"about_ca_system_score_gemma":0.000298699,"threshold_uncertainty_score":0.51836544},"labels":[],"label_agreement":null},{"id":"W4413131513","doi":"10.21203/rs.3.rs-7180379/v1","title":"Ex vivo culture to evaluate dynamic changes in the tumor microenvironment following durvalumab treatment","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"AstraZeneca","keywords":"Ex vivo; Durvalumab; Tumor microenvironment; Cancer research; Immune system; Immunotherapy; Prostate cancer; In vivo; Flow cytometry; Biology; Immunology; Myeloid; Macrophage; Cancer; Medicine; In vitro; Internal medicine","score_opus":0.055295110832635753,"score_gpt":0.4226824593361084,"score_spread":0.3673873485034726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413131513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94326466,0.016009115,0.0000137411325,0.027619598,0.00047433717,0.00877784,0.00034581,0.00005526822,0.003439611],"genre_scores_gemma":[0.9627083,0.008485278,0.00031463362,0.0014463027,0.0002856483,0.0032268865,0.00030804652,0.000057280697,0.023167636],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99584347,0.00080478226,0.0003345153,0.0008139541,0.001440264,0.0007630243],"domain_scores_gemma":[0.99835366,0.00017860458,0.00005980471,0.0011906559,0.00008491297,0.00013235469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022038938,0.00038874333,0.0005680805,0.0005287661,0.00019451647,0.00010867418,0.0005000586,0.00021998004,0.0003076898],"category_scores_gemma":[0.000108735425,0.00024197812,0.00041387556,0.0005709151,0.000096899734,0.000020738024,0.00046625064,0.0009624421,0.000058076563],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029495226,0.009124432,0.028840795,0.013647938,0.007820536,0.007588043,0.13787496,0.00088311324,0.29007202,0.00007478854,0.07616907,0.39840907],"study_design_scores_gemma":[0.020278312,0.011028438,0.1629576,0.025195517,0.00088869274,0.00012154592,0.030448975,0.0014762382,0.022428956,0.00047663564,0.72302836,0.0016707586],"about_ca_topic_score_codex":0.0013996764,"about_ca_topic_score_gemma":0.0025635676,"teacher_disagreement_score":0.6468593,"about_ca_system_score_codex":0.003365661,"about_ca_system_score_gemma":0.0005910528,"threshold_uncertainty_score":0.9867582},"labels":[],"label_agreement":null},{"id":"W4413282746","doi":"10.3390/curroncol32080466","title":"Chemoradiotherapy Strategies for Immunotherapy-Sensitive Multi-Metastatic Nasopharyngeal Carcinoma: A Comparative Case Report and Literature Review","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Immunotherapy; Radiation therapy; Chemotherapy; Nasopharyngeal carcinoma; Oncology; Internal medicine; Chemoradiotherapy; Immune system; Immunology; Cancer","score_opus":0.16903534014457985,"score_gpt":0.4873841004516819,"score_spread":0.318348760307102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413282746","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047153,0.9898065,0.00037497838,0.00019001482,0.0013603995,0.007376458,0.00056851545,0.000060507267,0.00021547629],"genre_scores_gemma":[0.000015413027,0.99371284,0.0016473847,0.0005696294,0.00031171186,0.0015576438,0.0015418641,0.000061339946,0.00058215193],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99648523,0.0004902818,0.0014419493,0.0009503607,0.00017114037,0.00046101972],"domain_scores_gemma":[0.99698925,0.00081266445,0.0009938936,0.00060709583,0.0004491663,0.00014795335],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007254352,0.00086237217,0.005414267,0.00034998215,0.00016896789,0.00006920341,0.00014822537,0.00038346645,0.000038918024],"category_scores_gemma":[0.00007253049,0.00064121914,0.0010965905,0.00063618895,0.0003621735,0.000112328686,0.00004771884,0.0008396566,0.0000023500404],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006993341,0.00045043556,0.0000013765564,0.18719926,0.0013137441,0.023671487,0.00092172093,1.2034178e-8,0.0000036933257,0.00003136335,0.0070563722,0.7786512],"study_design_scores_gemma":[0.004330242,0.0007524271,0.0000030282233,0.09359134,0.0024955492,0.13787009,0.00026489908,0.000010184002,0.0000021369294,0.000007586972,0.76027334,0.00039920167],"about_ca_topic_score_codex":0.000021471884,"about_ca_topic_score_gemma":0.000031252304,"teacher_disagreement_score":0.778252,"about_ca_system_score_codex":0.00060010195,"about_ca_system_score_gemma":0.0029820013,"threshold_uncertainty_score":0.9996039},"labels":[],"label_agreement":null},{"id":"W4413305591","doi":"10.1136/bcr-2025-265370","title":"Discordance between biochemical and histological severity in persistent immune checkpoint inhibitor induced liver injury","year":2025,"lang":"en","type":"article","venue":"BMJ Case Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Immunosuppression; Medicine; Liver injury; Nivolumab; Ipilimumab; Liver biopsy; Prednisone; Elevated liver enzymes; Histopathology; Biopsy; Hepatitis; Internal medicine; Immune system; Gastroenterology; Pathology; Immunology; Immunotherapy; Biology","score_opus":0.028699754903709452,"score_gpt":0.3139512443864932,"score_spread":0.2852514894827837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413305591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943296,0.0031800724,0.000008278104,0.0011466618,0.00023143108,0.0006300761,0.0000040091427,0.00003539862,0.0004345093],"genre_scores_gemma":[0.9990841,0.00010261426,0.00016457091,0.00019153628,0.00009228997,0.000052256906,0.000015392661,0.000008755305,0.0002884422],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998512,0.00004546571,0.0006678036,0.00040389167,0.0001562972,0.00021450243],"domain_scores_gemma":[0.99930876,0.000041924235,0.00016667342,0.000352404,0.000042434374,0.00008779934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048457962,0.00016534822,0.0004203886,0.00011527492,0.000058145844,0.000014145955,0.000023910734,0.0001769181,0.000041716652],"category_scores_gemma":[0.00018503319,0.00013670024,0.0001775943,0.00024424715,0.00015579858,0.00004799769,0.00007615979,0.00027146042,0.0000011557305],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00303257,0.00051006075,0.1508461,0.0005826115,0.0003566933,0.30520374,0.00049747765,8.724985e-8,0.47626445,0.000008359303,0.0015041939,0.061193652],"study_design_scores_gemma":[0.0025908777,0.0006839306,0.64494336,0.0011989794,0.00029070608,0.19422166,0.0004997156,0.000035163892,0.15073462,0.000062991865,0.004232026,0.00050597335],"about_ca_topic_score_codex":0.00081229815,"about_ca_topic_score_gemma":0.00003096272,"teacher_disagreement_score":0.49409726,"about_ca_system_score_codex":0.00030818512,"about_ca_system_score_gemma":0.000194831,"threshold_uncertainty_score":0.55744743},"labels":[],"label_agreement":null},{"id":"W4413345437","doi":"10.51731/cjht.2025.1190","title":"Nivolumab","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.017837409268314727,"score_gpt":0.3032496467341336,"score_spread":0.2854122374658189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413345437","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20986685,0.43464628,0.0006964072,0.34752172,0.0014763774,0.0003752419,0.000009542309,0.00015582569,0.0052517736],"genre_scores_gemma":[0.9955683,0.0010401808,0.00041241726,0.0024079538,0.000005712865,0.0000015697299,5.485055e-7,0.000004486149,0.0005588808],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992629,0.00001512913,0.00035384583,0.00006245678,0.0000660502,0.00023956847],"domain_scores_gemma":[0.9995259,0.000017501367,0.00015002761,0.00016496546,0.000101019505,0.000040566087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034705523,0.00006207761,0.00024369425,0.0006592807,0.00012327064,0.000012834578,0.00014501739,0.00009256697,0.00003502332],"category_scores_gemma":[0.00018199344,0.000049896247,0.0000778288,0.000389813,0.00016707517,0.000035285604,0.0000058724445,0.00025372903,0.0000023642656],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007985959,0.0000081902335,0.005785979,0.00008265994,0.00006867276,0.00006486128,0.00005656628,3.0217907e-7,0.0001258801,0.000715892,0.03402064,0.9589905],"study_design_scores_gemma":[0.0012104932,0.00047112218,0.029660773,0.00064206717,0.000016289914,0.00029685404,0.0019512209,0.0000023245118,0.0013100072,0.0019159855,0.96246576,0.000057091802],"about_ca_topic_score_codex":0.003952862,"about_ca_topic_score_gemma":0.0026720995,"teacher_disagreement_score":0.9589334,"about_ca_system_score_codex":0.0004935394,"about_ca_system_score_gemma":0.0053537264,"threshold_uncertainty_score":0.9497281},"labels":[],"label_agreement":null},{"id":"W4413380844","doi":"10.3389/fonc.2025.1642564","title":"A non-small cell lung cancer fragile elderly patient treated with immunotherapy and non-ablative radiation therapy: a case report of a winning combination","year":2025,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Abscopal effect; Radiation therapy; Immunotherapy; Lung cancer; Ablative case; Regimen; Oncology; Cancer; Pembrolizumab; Internal medicine; Surgery","score_opus":0.006363924506145745,"score_gpt":0.273659283785251,"score_spread":0.26729535927910525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413380844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849981,0.0079167895,0.003195816,0.00042211032,0.00033902162,0.0012596989,0.0000065855243,0.00001655121,0.0018453395],"genre_scores_gemma":[0.99503493,0.0016522787,0.002286473,0.0003848351,0.000017116257,0.00025351386,0.000025215712,0.00001877556,0.00032683485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989169,0.000075774034,0.0004338999,0.00028375754,0.000098142926,0.00019148487],"domain_scores_gemma":[0.99925697,0.0000583094,0.00033073407,0.00019047857,0.00013028526,0.00003323097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023182546,0.00016667316,0.00048118964,0.00036280378,0.000065474895,0.000009710294,0.00004318337,0.00017908785,0.000025705629],"category_scores_gemma":[0.0000086272585,0.00013839554,0.000054871532,0.00048495893,0.00013420766,0.000076117496,0.000011260685,0.00017760188,5.974708e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012626719,0.0010383666,0.62322456,0.00013439791,0.00086135743,0.0037965474,0.013658593,0.000059308473,0.008427173,0.000005034761,0.0038937023,0.33227426],"study_design_scores_gemma":[0.14333437,0.036837082,0.63564676,0.0023230796,0.0008407907,0.004687714,0.023464171,0.025779549,0.08255764,0.00024268076,0.042950258,0.0013359234],"about_ca_topic_score_codex":0.0028815037,"about_ca_topic_score_gemma":0.0001997639,"teacher_disagreement_score":0.33093834,"about_ca_system_score_codex":0.0005761853,"about_ca_system_score_gemma":0.0006019379,"threshold_uncertainty_score":0.5643606},"labels":[],"label_agreement":null},{"id":"W4413427043","doi":"10.1177/17588359251361883","title":"The role of immunotherapy in resectable non-small-cell lung cancer","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Medicine; Immunotherapy; Lung cancer; Oncology; Cancer; Internal medicine","score_opus":0.01845210998458962,"score_gpt":0.4051781740363202,"score_spread":0.3867260640517306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413427043","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000044302404,0.9849603,0.000060471786,0.00050951954,0.0009312448,0.0019363955,0.0000118763455,0.000019647718,0.011526238],"genre_scores_gemma":[0.000102571656,0.9965735,0.000104291874,0.0008278004,0.000190497,0.0010726731,0.000016662301,0.000053603453,0.0010583694],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99582946,0.00066700455,0.0017146476,0.00052807096,0.00054973137,0.00071109534],"domain_scores_gemma":[0.99569076,0.0028548616,0.0006146308,0.00065896666,0.00007437291,0.00010639263],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019934627,0.0004802812,0.0028433218,0.00040879424,0.000078524194,0.000008790767,0.00088247954,0.00096165424,0.00055572554],"category_scores_gemma":[0.000114063456,0.00029537803,0.00048147404,0.0012568759,0.00065061526,0.00005605991,0.0001153305,0.001568742,0.0000036003428],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015152248,0.00037848085,0.0002909074,0.0075560277,0.00029191296,0.000051671068,0.00019626421,0.0000013439411,0.00001913222,0.00010777511,0.000050544077,0.9895407],"study_design_scores_gemma":[0.0038042315,0.00044927633,0.000032711323,0.026284961,0.00028879286,0.00003124112,0.0001923264,0.00007354904,0.000030211646,0.00035418212,0.96821713,0.00024136233],"about_ca_topic_score_codex":0.00038845552,"about_ca_topic_score_gemma":0.001542708,"teacher_disagreement_score":0.98929936,"about_ca_system_score_codex":0.0010851428,"about_ca_system_score_gemma":0.00595046,"threshold_uncertainty_score":0.9999498},"labels":[],"label_agreement":null},{"id":"W4413593066","doi":"10.1101/2025.08.25.668405","title":"A fibroblast-centric network drives cold fibrosis in the tumor microenvironment of lung squamous cell carcinoma","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill Genome Centre; McGill University; McGill University Health Centre; Montreal General Hospital","funders":"National Cancer Institute; Israel Science Foundation; United States-Israel Binational Science Foundation; Council for Higher Education; Cancer Research UK","keywords":"Tumor microenvironment; Stromal cell; Fibrosis; Myofibroblast; Cancer research; Stroma; Desmoplasia; Biology; Transdifferentiation; Pathology; Tumor progression; Cancer-Associated Fibroblasts; Pulmonary fibrosis; Autocrine signalling; Cancer; Medicine; Stem cell; Cell biology; Cell culture; Immunohistochemistry","score_opus":0.006950257795319565,"score_gpt":0.20411758338463892,"score_spread":0.19716732558931935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413593066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847372,0.011770646,0.000102124366,0.00037585903,0.0004652706,0.002168473,0.00027062508,0.000070731025,0.000039065373],"genre_scores_gemma":[0.99690497,0.0005069834,0.0011488774,0.0007331535,0.00030969977,0.0002934678,0.0000010490616,0.00006902997,0.000032788834],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9967734,0.00026029837,0.0008966256,0.0008677874,0.0005034535,0.00069842435],"domain_scores_gemma":[0.9974604,0.00021012753,0.00056457886,0.0015162026,0.00011322533,0.00013544735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063732,0.00060561654,0.0008731432,0.0003323284,0.00011743862,0.00006623441,0.00064462353,0.00037089124,0.000081646256],"category_scores_gemma":[0.000045883568,0.0005210669,0.0003895725,0.0009750344,0.00021210383,0.000052031137,0.00038177555,0.0008079217,0.0000071205827],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012507428,0.0008450398,0.18526658,0.0040537245,0.00020007063,0.00017117448,0.0001045202,0.00033599694,0.8021821,0.00005510934,0.005532791,0.0000021511098],"study_design_scores_gemma":[0.0032470683,0.00028830973,0.6182017,0.0022476178,0.00038134432,8.625498e-8,0.000018035926,0.000324206,0.36679938,4.561884e-7,0.00790275,0.00058907893],"about_ca_topic_score_codex":0.00025582605,"about_ca_topic_score_gemma":0.0000076244773,"teacher_disagreement_score":0.4353827,"about_ca_system_score_codex":0.0006233707,"about_ca_system_score_gemma":0.0007983912,"threshold_uncertainty_score":0.9997241},"labels":[],"label_agreement":null},{"id":"W4413722628","doi":"10.1016/j.celrep.2025.116190","title":"T cell receptor repertoire in cell-free DNA as a proxy for tumor infiltrates in patients treated with pembrolizumab","year":2025,"lang":"en","type":"article","venue":"Cell Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"Ontario Ministry of Economic Development, Job Creation and Trade; Terry Fox Research Institute; Canada Research Chairs; Ontario Ministry of Research and Innovation; Princess Margaret Cancer Foundation; Dana-Farber Cancer Institute; Canada Foundation for Innovation; Ontario Institute for Cancer Research; Department of Medical Biophysics, University of Toronto; Leukemia and Lymphoma Society","keywords":"Pembrolizumab; Repertoire; Receptor; Cell; DNA; Cell-free fetal DNA; Cancer research; Medicine; Internal medicine; Biology; Immunotherapy; Cancer; Biochemistry; Genetics","score_opus":0.0050256551399602105,"score_gpt":0.22516813264793603,"score_spread":0.22014247750797583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413722628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708877,0.0006349177,0.0000024606397,0.00018122458,0.00018807809,0.0020907645,0.000008773478,0.000054301912,0.025951732],"genre_scores_gemma":[0.982789,0.000051797586,0.00021155537,0.00037582894,0.000026637203,0.0003213404,0.00013023368,0.00003910888,0.016054492],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981112,0.000034685698,0.00070098136,0.0005485473,0.0002304974,0.0003740803],"domain_scores_gemma":[0.9987576,0.00005511994,0.00028832577,0.0006849435,0.00013520602,0.000078785524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022360717,0.00025929106,0.00043943577,0.0002901082,0.000053502183,0.000025606245,0.00009940809,0.00012618177,0.000105021754],"category_scores_gemma":[0.000090185975,0.00020377827,0.000108583044,0.0005799676,0.00007028443,0.00007898107,0.00003289855,0.00017299851,0.0000033385716],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013251047,0.0017859403,0.9082113,0.0008746926,0.000045186403,0.0007508741,0.0005004816,0.0000049916475,0.05837045,0.0000018701229,0.014613433,0.0015897427],"study_design_scores_gemma":[0.027468164,0.002888469,0.123669654,0.0012357658,0.00011981606,0.0000868332,0.00039533604,0.000047765025,0.8061766,0.00008713819,0.037300393,0.0005240908],"about_ca_topic_score_codex":0.00069160206,"about_ca_topic_score_gemma":0.000104644816,"teacher_disagreement_score":0.78454167,"about_ca_system_score_codex":0.000321519,"about_ca_system_score_gemma":0.00056852633,"threshold_uncertainty_score":0.8309837},"labels":[],"label_agreement":null},{"id":"W4413745708","doi":"10.51731/cjht.2025.1210","title":"Durvalumab (Imfinzi)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Durvalumab; Medicine; Immunology; Immune system","score_opus":0.020596970468108097,"score_gpt":0.31009797314778254,"score_spread":0.28950100267967444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413745708","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22531915,0.39269194,0.00059298094,0.3738513,0.0016995159,0.00045509794,0.000013837761,0.00017929492,0.005196881],"genre_scores_gemma":[0.994768,0.0013454988,0.00044543965,0.002888781,0.000007745305,0.000002363712,8.4714856e-7,0.0000059968534,0.0005352877],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99908173,0.000022517836,0.00043876996,0.000078966135,0.00008767438,0.0002903186],"domain_scores_gemma":[0.99941146,0.000025133799,0.00018693897,0.00020274588,0.00012258918,0.00005112155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049150846,0.00007943733,0.00029911203,0.00075280684,0.00014876139,0.000016316018,0.00017778501,0.0001136128,0.0000463355],"category_scores_gemma":[0.00026353463,0.00006341475,0.000097351265,0.00045852887,0.00020003773,0.000042187054,0.000007812162,0.00030873262,0.000003325551],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011371474,0.000012192795,0.0075268773,0.00011772961,0.000100666664,0.00009596291,0.000079240956,5.982445e-7,0.0001664347,0.0010052852,0.03553923,0.9552421],"study_design_scores_gemma":[0.0014232778,0.00050262694,0.046557654,0.00075650366,0.000022550916,0.0003701732,0.002001002,0.000003049937,0.0014534462,0.0022706876,0.9445645,0.00007451022],"about_ca_topic_score_codex":0.003637112,"about_ca_topic_score_gemma":0.002622017,"teacher_disagreement_score":0.95516753,"about_ca_system_score_codex":0.00056202,"about_ca_system_score_gemma":0.0060324734,"threshold_uncertainty_score":0.9996024},"labels":[],"label_agreement":null},{"id":"W4413766549","doi":"10.1186/s13046-025-03521-5","title":"Vinburnine potentiates anti-PD1 immunotherapy in melanoma through IL-24 secretion via P38/MAPK/ATF3 signaling","year":2025,"lang":"en","type":"article","venue":"Journal of Experimental & Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Project 211; Xiangya Hospital, Central South University; Higher Education Discipline Innovation Project; Natural Science Foundation of Hunan Province; Central South University; National Natural Science Foundation of China","keywords":"Nivolumab; p38 mitogen-activated protein kinases; Secretion; Cancer research; MAPK/ERK pathway; Medicine; Melanoma; Signal transduction; Apoptosis; Immunotherapy; Pharmacology; Immunology; Chemistry; Immune system; Cell biology; Biology; Internal medicine","score_opus":0.1130832919598193,"score_gpt":0.5070031900593935,"score_spread":0.39391989809957423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413766549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94066936,0.052309953,0.00022616234,0.0037628247,0.0013960638,0.000522727,0.000008193537,0.000016006876,0.001088741],"genre_scores_gemma":[0.9848544,0.011924674,0.0005922525,0.001187266,0.0007109171,0.000038281076,0.000007959182,0.00003857869,0.00064568967],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9953962,0.00060612516,0.001871527,0.00040812665,0.0011245218,0.00059349847],"domain_scores_gemma":[0.99803203,0.0005469711,0.00041364043,0.00035254483,0.00048857613,0.0001662111],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0040042438,0.00025056064,0.00089629594,0.0004920531,0.00018051293,0.0000848301,0.00040960766,0.0002804249,0.0017318053],"category_scores_gemma":[0.0001729115,0.00019846756,0.0005890772,0.0009960512,0.0004943415,0.00026390972,0.00011745922,0.0015860149,0.00001098234],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017554095,0.0013017551,0.043732613,0.00005538689,0.0006926053,0.00022051933,0.0005290289,0.0000139927115,0.917812,0.00008551901,0.0028272388,0.015175257],"study_design_scores_gemma":[0.024617143,0.006800258,0.090551734,0.0028842925,0.000089984205,0.00016539343,0.0028181477,0.00021601068,0.8301899,0.0008484643,0.040403504,0.0004151604],"about_ca_topic_score_codex":0.0009964004,"about_ca_topic_score_gemma":0.00003628687,"teacher_disagreement_score":0.087622076,"about_ca_system_score_codex":0.0008539548,"about_ca_system_score_gemma":0.00083694526,"threshold_uncertainty_score":0.99918073},"labels":[],"label_agreement":null},{"id":"W4413801718","doi":"10.1016/j.annonc.2025.08.008","title":"Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Sharp and Dohme; Eisai Canada","keywords":"Pembrolizumab; Medicine; Lenvatinib; Placebo; Oncology; Internal medicine; Double blind; Phases of clinical research; Metastatic melanoma; Immunotherapy; Clinical trial; Cancer; Pathology","score_opus":0.19559295964400839,"score_gpt":0.4627367715875191,"score_spread":0.26714381194351067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413801718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97285205,0.003112957,0.00087297754,0.0034613,0.0011056891,0.010011822,0.000103901126,0.000058623515,0.008420696],"genre_scores_gemma":[0.99168575,0.0010772193,0.0003094747,0.00055737223,0.00013110219,0.001491869,0.00010790387,0.000047146204,0.004592137],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962081,0.00037981238,0.0017905702,0.00057021267,0.000421455,0.0006298675],"domain_scores_gemma":[0.99426556,0.0033729144,0.00088954985,0.00067773904,0.000654612,0.00013965683],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001985939,0.00043101882,0.0029682368,0.00061813986,0.00017398768,0.000016890703,0.00037946072,0.0002551454,0.00055301277],"category_scores_gemma":[0.0007422862,0.0003270959,0.00060199416,0.0007759813,0.00045028926,0.00013049174,0.00011733707,0.00028581833,0.0000038414914],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9664676,0.0044590514,0.000024757046,0.0007245907,0.005644785,0.00006982342,0.0018275513,0.00022295344,0.0003805258,0.00034662412,0.007089798,0.01274194],"study_design_scores_gemma":[0.9288563,0.03602507,0.000017625958,0.00019637984,0.0017599397,0.00003253652,0.0024998847,0.0015631983,0.00606309,0.00010072998,0.022634909,0.00025032324],"about_ca_topic_score_codex":0.001723098,"about_ca_topic_score_gemma":0.0028415634,"teacher_disagreement_score":0.037611287,"about_ca_system_score_codex":0.00027294792,"about_ca_system_score_gemma":0.0021367474,"threshold_uncertainty_score":0.9999181},"labels":[],"label_agreement":null},{"id":"W4413803778","doi":"10.1038/s41523-025-00821-z","title":"Prognostic and predictive capacity of tumor infiltrating lymphocytes in the MA.20 regional node radiotherapy trial","year":2025,"lang":"en","type":"article","venue":"npj Breast Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University; University Health Network; Queen's University; University of British Columbia","funders":"Göteborgs Universitet; Canadian Cancer Society","keywords":"Radiation therapy; Node (physics); Medicine; Oncology; Internal medicine; Engineering","score_opus":0.017702037874718975,"score_gpt":0.2820940149337266,"score_spread":0.26439197705900763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413803778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99045545,0.0028920914,0.00008953691,0.0046461276,0.00019891707,0.00091295777,0.00010897659,0.000015900949,0.0006800203],"genre_scores_gemma":[0.996404,0.00036439707,0.00019526217,0.0024919587,0.00024380043,0.00021469625,0.000007662734,0.000009695881,0.00006853647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990678,0.00007997074,0.0002747501,0.0001986563,0.00021200826,0.00016680175],"domain_scores_gemma":[0.9994494,0.00018489729,0.00010529392,0.00016494561,0.000067982444,0.00002747871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028127342,0.00012784338,0.00026410285,0.00009199196,0.000053657855,0.000015206464,0.00008933898,0.00005852995,0.00007170214],"category_scores_gemma":[0.000032480624,0.00008550357,0.00007277102,0.0002977152,0.0002473099,0.00005850324,0.000009782046,0.00013439333,1.5618072e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28029376,0.00071004784,0.6011011,0.0006075755,0.00089203013,0.000024370227,0.005003531,0.00005610001,0.04823222,0.0002965507,0.0040910398,0.05869168],"study_design_scores_gemma":[0.054782245,0.00041401666,0.93740207,0.0010690952,0.00013008526,0.0002401238,0.00057378237,0.0008374758,0.0015058764,0.000084704174,0.00282048,0.00014005577],"about_ca_topic_score_codex":0.0015179608,"about_ca_topic_score_gemma":0.00019500044,"teacher_disagreement_score":0.33630097,"about_ca_system_score_codex":0.00022323418,"about_ca_system_score_gemma":0.00046580937,"threshold_uncertainty_score":0.34867343},"labels":[],"label_agreement":null},{"id":"W4413810973","doi":"10.3390/cancers17172827","title":"Liposomal Doxorubicin, but Not Platinum-Taxane, Supports MHC-II Expression and Immune Maturation in the Ovarian Tumor Microenvironment","year":2025,"lang":"en","type":"article","venue":"Cancers","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Institutes of Health; National Cancer Institute; Ovarian Cancer Research Alliance","keywords":"Taxane; Cancer research; Tumor microenvironment; Immune system; Medicine; Doxorubicin; Major histocompatibility complex; Ovarian cancer; Immunology; Internal medicine; Chemotherapy; Cancer; Breast cancer","score_opus":0.006951648161436234,"score_gpt":0.23788893995169852,"score_spread":0.2309372917902623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413810973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916057,0.0023025207,0.000034630782,0.0035169416,0.0003576874,0.0006009091,0.00001635013,0.00001961801,0.0015456291],"genre_scores_gemma":[0.9945697,0.0003651047,0.00016762184,0.003320279,0.00008668378,0.000075832075,0.000038663075,0.000011242546,0.001364848],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990038,0.000047522335,0.00029792736,0.00025872805,0.0001748791,0.00021712031],"domain_scores_gemma":[0.999523,0.00004176077,0.00009804056,0.00028900092,0.000012210556,0.000035979516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021616493,0.00015260646,0.00020709087,0.000092819326,0.00015130865,0.000026425192,0.00009102334,0.00006918251,0.00017579313],"category_scores_gemma":[0.000015756432,0.00010637138,0.00005792376,0.00016454936,0.00011731954,0.000075055446,0.00004307077,0.00018602503,0.000002250874],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044235056,0.00003542604,0.0018153678,0.00008724876,0.000047309408,0.000056203262,0.0014709248,0.000020151818,0.97860336,0.000036531736,0.0040304153,0.009373565],"study_design_scores_gemma":[0.006687865,0.000423511,0.40718898,0.0009619451,0.00010081771,0.00014148856,0.0031626255,0.00021942257,0.53523827,0.000058530575,0.04553985,0.00027673194],"about_ca_topic_score_codex":0.0008619215,"about_ca_topic_score_gemma":0.000105394756,"teacher_disagreement_score":0.4433651,"about_ca_system_score_codex":0.0005621231,"about_ca_system_score_gemma":0.0002301544,"threshold_uncertainty_score":0.43376988},"labels":[],"label_agreement":null},{"id":"W4413832409","doi":"10.3390/vaccines13090921","title":"ImmuniT Platform for Improved Neoantigen Prediction in Lung Cancer","year":2025,"lang":"en","type":"article","venue":"Vaccines","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; U.S. Department of Defense","keywords":"Lung cancer; Cancer; Medicine; Computational biology; Computer science; Oncology; Biology; Internal medicine","score_opus":0.01374189330591971,"score_gpt":0.3089914094098673,"score_spread":0.2952495161039476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413832409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841931,0.008244972,0.0004381708,0.0034388541,0.0008934597,0.0011521868,0.000046256257,0.00007414062,0.0015188452],"genre_scores_gemma":[0.98106146,0.0017696106,0.00028283393,0.0013290062,0.00026907967,0.00044944414,0.000079800644,0.000022172067,0.014736585],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9994427,0.00000474898,0.00021617686,0.0001375067,0.000037554655,0.00016130279],"domain_scores_gemma":[0.99968374,0.000037576443,0.0000382661,0.00016249272,0.0000586084,0.000019326457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000117680276,0.00009164223,0.00017147837,0.0001695195,0.000053211912,0.000011399469,0.000058643876,0.00007369817,0.00019132772],"category_scores_gemma":[0.000023827783,0.000074628864,0.00007534781,0.00029161604,0.000007843611,0.000070955175,0.000014923171,0.000073224954,0.0000010313192],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020342909,0.00027252472,0.24438408,0.001204333,0.00084183604,0.000003302122,0.00068956224,0.000020013873,0.33220807,0.0002123262,0.059372406,0.34044862],"study_design_scores_gemma":[0.017675383,0.00034450638,0.7073575,0.0009599262,0.00024266097,0.000007327385,0.00031942525,0.0163531,0.04026355,0.00024805404,0.21599318,0.00023536175],"about_ca_topic_score_codex":0.0007975097,"about_ca_topic_score_gemma":0.00044430155,"teacher_disagreement_score":0.46297345,"about_ca_system_score_codex":0.00012291595,"about_ca_system_score_gemma":0.00013683568,"threshold_uncertainty_score":0.30432767},"labels":[],"label_agreement":null},{"id":"W4413843148","doi":"10.37766/inplasy2025.8.0091","title":"Impact of Age on the Efficacy of Immune Checkpoint Inhibitors (ICIs) in Cancer Treatment: A Protocol for a Systematic Review and Meta-Analysis","year":2025,"lang":"en","type":"report","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Meta-analysis; Protocol (science); Medicine; Cancer; Oncology; Internal medicine; Alternative medicine; Pathology","score_opus":0.1298024426406854,"score_gpt":0.44603927069828764,"score_spread":0.3162368280576022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413843148","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00056127895,0.09298351,0.00000577023,0.0009605545,0.000026832098,0.9001956,0.00045787674,0.000018973687,0.0047896183],"genre_scores_gemma":[0.0067406297,0.008823847,0.000023376504,0.00012938268,0.000023474595,0.96633184,0.00006636452,0.00003436547,0.017826729],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9964755,0.0001743473,0.002382052,0.00034728713,0.00044545913,0.0001753558],"domain_scores_gemma":[0.9965858,0.00051057996,0.0017019492,0.00087191514,0.00029406208,0.00003572834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018488502,0.000434323,0.0062271627,0.00046798497,0.00002204044,0.000009476467,0.000117734504,0.00016216953,0.00069050764],"category_scores_gemma":[0.00040166342,0.00017041694,0.0062921224,0.0009644056,0.00008301673,0.000015374751,0.000023992061,0.0001269428,1.5474855e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015364881,0.0007143324,0.000065219625,0.5504333,0.44576913,0.000005949558,0.00011924351,0.0000023846276,0.00015573317,0.0000034596578,0.00090716645,0.00028761727],"study_design_scores_gemma":[0.004434756,0.0018759159,0.0018861218,0.07252786,0.9168289,0.000009389675,0.000032366126,0.0000065589866,0.0014466218,0.0000032671448,0.00071446487,0.0002338092],"about_ca_topic_score_codex":0.015211813,"about_ca_topic_score_gemma":0.00073721533,"teacher_disagreement_score":0.47790542,"about_ca_system_score_codex":0.00079441356,"about_ca_system_score_gemma":0.0010712795,"threshold_uncertainty_score":0.991346},"labels":[],"label_agreement":null},{"id":"W4413923563","doi":"10.1016/j.jtocrr.2025.100892","title":"Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]","year":2025,"lang":"en","type":"erratum","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Pembrolizumab; Chemotherapy; Medicine; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.17758127873716026,"score_gpt":0.5096313038910896,"score_spread":0.33205002515392934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413923563","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83629656,0.013115649,0.00082443317,0.04569636,0.05048003,0.035898764,0.0023915896,0.00037355357,0.014923097],"genre_scores_gemma":[0.21898809,0.030880751,0.036714762,0.0059483577,0.023059819,0.00451564,0.005925381,0.0010515763,0.67291564],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98573554,0.0013482146,0.0046267756,0.0023918261,0.0045733494,0.0013243164],"domain_scores_gemma":[0.97523046,0.009363962,0.001600883,0.0011832948,0.01134911,0.0012722743],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.024022713,0.0007050808,0.0030481552,0.0008169511,0.0006421065,0.00022552877,0.00024219805,0.00096457545,0.00024224365],"category_scores_gemma":[0.028585708,0.00049044745,0.00055070186,0.0010222972,0.00418843,0.00016970339,0.00025961996,0.0034054832,0.000004136965],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07455786,0.0014607279,0.1667454,0.0014194277,0.006672083,0.0034314538,0.00057245255,0.0000025631348,0.000014834335,0.000070996044,0.69890046,0.046151765],"study_design_scores_gemma":[0.024236923,0.014338796,0.44825774,0.0012979632,0.00057370623,0.0005848739,0.00058550684,0.00016510932,0.000018198978,0.00077982154,0.5084995,0.0006618328],"about_ca_topic_score_codex":0.0016641367,"about_ca_topic_score_gemma":0.00091858924,"teacher_disagreement_score":0.65799254,"about_ca_system_score_codex":0.00041358077,"about_ca_system_score_gemma":0.013814766,"threshold_uncertainty_score":0.9997547},"labels":[],"label_agreement":null},{"id":"W4413940136","doi":"10.3390/curroncol32090493","title":"Tumor Immune Microenvironment and Current Status of Immune Checkpoint Inhibitor Therapy in Colorectal Cancer Liver Metastasis","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Science and Technology Major Project","keywords":"Medicine; Colorectal cancer; Tumor microenvironment; Immune system; Metastasis; Cancer research; Cancer; Immune checkpoint; Immunotherapy; Oncology; Immunology; Internal medicine","score_opus":0.08041887487997817,"score_gpt":0.40571105596643714,"score_spread":0.32529218108645896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413940136","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015298349,0.97876877,0.0000029558823,0.00006340404,0.0025886209,0.0028075862,0.00039311478,0.000020211837,0.000056987607],"genre_scores_gemma":[0.000471276,0.99794304,0.000060460374,0.000021744583,0.00018695899,0.0009644531,0.00025502587,0.000050608767,0.000046402958],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99598956,0.00043177593,0.0019089582,0.000708272,0.00027162986,0.0006898101],"domain_scores_gemma":[0.998115,0.0002628767,0.0010161588,0.00037939864,0.00007102021,0.00015554075],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005462024,0.00067311776,0.0035853703,0.00059243065,0.00005173582,0.000012057612,0.00021503877,0.00027803023,0.0004399929],"category_scores_gemma":[0.000060014318,0.00052193593,0.000920793,0.00052461406,0.0004734342,0.000047164318,0.00023738593,0.0009367613,0.0000070770557],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014543786,0.0014832382,0.00035829045,0.023104684,0.0006757571,0.00002673415,0.0002763823,8.7233964e-8,0.0007807328,0.0000036880033,0.00026111046,0.9715749],"study_design_scores_gemma":[0.0050299778,0.0011314091,0.0043105353,0.026068233,0.0011182665,0.000054467673,0.000056620327,0.0000023993898,0.001131766,0.0000024065228,0.96071136,0.0003825651],"about_ca_topic_score_codex":0.00038105232,"about_ca_topic_score_gemma":0.00008161353,"teacher_disagreement_score":0.97119236,"about_ca_system_score_codex":0.0020511982,"about_ca_system_score_gemma":0.0020792224,"threshold_uncertainty_score":0.9997232},"labels":[],"label_agreement":null},{"id":"W4413975452","doi":"10.2196/73576","title":"Prognostic Value of Dynamic Lactate Dehydrogenase Trends in Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma: Retrospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"JMIR Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Preprint; Medicine; Esophageal squamous cell carcinoma; Retrospective cohort study; Immunotherapy; Oncology; Internal medicine; Basal cell; Cohort; Lactate dehydrogenase; Cohort study; Carcinoma; Cancer; Biology; Computer science","score_opus":0.006682319289167792,"score_gpt":0.3127377121835508,"score_spread":0.306055392894383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413975452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889068,0.005703393,0.00004070987,0.00020063823,0.00033034614,0.0038680802,0.00010412507,0.00004440999,0.0008015046],"genre_scores_gemma":[0.9932865,0.00011233096,0.00010841178,0.00020801295,0.00003340098,0.0029111388,0.000039877035,0.00004307629,0.0032572418],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998286,0.00006147481,0.0005243862,0.00050321856,0.0002573496,0.00036758912],"domain_scores_gemma":[0.9991178,0.00008545673,0.00019014617,0.00041586466,0.00014149939,0.0000492554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026481817,0.00026982938,0.00065526436,0.00041766043,0.00006386162,0.000010912369,0.00014653172,0.000104185914,0.000116658564],"category_scores_gemma":[0.000017466506,0.00024287729,0.00023224081,0.00091650116,0.00009483333,0.000069383954,0.000023460707,0.00019442548,8.125335e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01093127,0.001560688,0.93195724,0.00022826632,0.00024302005,0.00003379152,0.0011696375,0.00004326722,0.036211852,0.000016618744,0.00029263494,0.017311707],"study_design_scores_gemma":[0.018558087,0.0017284447,0.9674484,0.00009298005,0.00016567335,0.0000024463372,0.0003223696,0.0006966293,0.010481063,0.000039775303,0.00026559684,0.00019849207],"about_ca_topic_score_codex":0.0009051968,"about_ca_topic_score_gemma":0.00085453765,"teacher_disagreement_score":0.035491195,"about_ca_system_score_codex":0.0010010727,"about_ca_system_score_gemma":0.00031435175,"threshold_uncertainty_score":0.9904248},"labels":[],"label_agreement":null},{"id":"W4414040436","doi":"10.1126/sciimmunol.aeb8333","title":"Loss-of-function mutations ensure that response to immune checkpoint therapy is NOD2 be denied","year":2025,"lang":"en","type":"article","venue":"Science Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Blockade; NOD2; Immune checkpoint; Mutation; Immune system; Action (physics)","score_opus":0.026926551850366704,"score_gpt":0.3246018849135136,"score_spread":0.2976753330631469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414040436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97360533,0.0028229014,0.0005023264,0.02026127,0.0010317697,0.00048361893,0.000008232101,0.00005394672,0.0012305975],"genre_scores_gemma":[0.9941928,0.00031869664,0.00041111893,0.0024587133,0.00001565061,0.00004545708,0.0000053851595,0.00000947494,0.0025427178],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985173,0.000089501336,0.00036441608,0.0003860068,0.00028618806,0.00035660676],"domain_scores_gemma":[0.9987661,0.00014076958,0.00012073145,0.0006365995,0.00028686167,0.000048923157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012091032,0.00015056362,0.0002919568,0.0006852645,0.00026888103,0.000026675341,0.00033344078,0.00012142347,0.00037672409],"category_scores_gemma":[0.0002638793,0.00012523208,0.00014355945,0.0018888926,0.001309473,0.00013969728,0.00008154945,0.00017633864,0.00002807992],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01484548,0.000102128615,0.0026165708,0.000008094838,0.00013212083,0.000004163588,0.0013884163,0.0000018743568,0.95654666,0.00015388879,0.0001331371,0.024067434],"study_design_scores_gemma":[0.0021109278,0.0008451078,0.42544347,0.00006865774,0.000025292562,0.00003248168,0.00084114267,0.000011419868,0.5509135,0.0002423118,0.019366352,0.00009931068],"about_ca_topic_score_codex":0.00026580406,"about_ca_topic_score_gemma":0.0000114470595,"teacher_disagreement_score":0.4228269,"about_ca_system_score_codex":0.00020770455,"about_ca_system_score_gemma":0.00093047274,"threshold_uncertainty_score":0.51068157},"labels":[],"label_agreement":null},{"id":"W4414056195","doi":"10.1016/j.xcrm.2025.102322","title":"Modulation of fibronectin extracellular matrix enhances anti-tumor efficacy of immune checkpoint blockade","year":2025,"lang":"en","type":"article","venue":"Cell Reports Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Genentech; Canadian Institutes of Health Research; Sunnybrook Research Institute","keywords":"Atezolizumab; Extracellular matrix; Fibronectin; Integrin; Blockade; Immune system; Immunotherapy; Immune checkpoint; Extracellular","score_opus":0.009814796805649614,"score_gpt":0.284267018472474,"score_spread":0.27445222166682437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414056195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96372074,0.029453525,0.0010216498,0.00075176964,0.00071294256,0.0006107669,0.0000013270064,0.000040497936,0.003686752],"genre_scores_gemma":[0.9912341,0.0004928886,0.0003830651,0.000026650425,0.00012791067,0.00000907134,0.000035463672,0.000018840814,0.007671959],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99737966,0.000037423193,0.0016216363,0.00033440097,0.00041931952,0.00020755664],"domain_scores_gemma":[0.997957,0.0001244364,0.0010017346,0.00065731525,0.00019558817,0.00006391188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089252094,0.00020067958,0.000792399,0.00028919347,0.000042545857,0.0000027694346,0.00008104596,0.00009886947,0.00050957093],"category_scores_gemma":[0.00030787254,0.00015442402,0.0002231411,0.0005574792,0.00030625245,0.000040558767,0.00003123473,0.0001584955,0.0000012193877],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077748974,0.00029588703,0.0040932284,0.000957312,0.00014166535,0.00014969398,0.00033167304,0.000033238714,0.98896164,0.0000123981,0.0002738068,0.0039719776],"study_design_scores_gemma":[0.002950052,0.00044729374,0.096337296,0.001559458,0.0002665617,0.00013598666,0.0002897559,0.00016625543,0.89309335,0.0000567608,0.004590691,0.00010654061],"about_ca_topic_score_codex":0.00041732806,"about_ca_topic_score_gemma":0.0000023227376,"teacher_disagreement_score":0.09586828,"about_ca_system_score_codex":0.00006499826,"about_ca_system_score_gemma":0.0002203734,"threshold_uncertainty_score":0.6297229},"labels":[],"label_agreement":null},{"id":"W4414091396","doi":"10.3390/biom15091304","title":"A Comprehensive Oncological Biomarker Framework Guiding Precision Medicine","year":2025,"lang":"en","type":"review","venue":"Biomolecules","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen's University","funders":"Roswell Park Cancer Institute","keywords":"Precision medicine; Biomarker; Immunotherapy; Personalized medicine; Liquid biopsy; Microbiome; Cancer","score_opus":0.1573413837309701,"score_gpt":0.4366868579186391,"score_spread":0.279345474187669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414091396","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000060724356,0.9896146,0.001282128,0.0008048447,0.0011043069,0.0016650282,0.000049189555,0.00016573767,0.0053080637],"genre_scores_gemma":[0.0000108661025,0.9942156,0.002442615,0.0010878855,0.00041202165,0.00015679847,0.00027872607,0.00005742912,0.0013380375],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99679303,0.00031975578,0.0011050977,0.0008199788,0.0005179411,0.00044416648],"domain_scores_gemma":[0.9970581,0.0013884291,0.00039736813,0.000801121,0.00017477649,0.00018023305],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034607982,0.00070467556,0.0027929188,0.00062324555,0.00013622893,0.000033654716,0.00038052152,0.0010874213,0.0007052069],"category_scores_gemma":[0.0005143629,0.0004392766,0.0010057022,0.0013220774,0.0005956304,0.000028266377,0.0002098435,0.00036570875,0.00007956645],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003710278,0.00011008364,0.0000017117338,0.015287213,0.00076535903,0.00022128008,0.000027525917,5.325022e-9,0.00018963125,0.00032583787,0.023216968,0.9594834],"study_design_scores_gemma":[0.0008003776,0.0004649411,0.000032458727,0.10845792,0.0015102443,0.00023375837,0.000041325304,0.0000015166589,0.000016191112,0.0001497263,0.88793516,0.00035636194],"about_ca_topic_score_codex":0.000046092835,"about_ca_topic_score_gemma":0.0000018116565,"teacher_disagreement_score":0.959127,"about_ca_system_score_codex":0.00038216164,"about_ca_system_score_gemma":0.00060811563,"threshold_uncertainty_score":0.9998059},"labels":[],"label_agreement":null},{"id":"W4414171558","doi":"10.1101/2025.09.10.675342","title":"Binding of inhibitory checkpoints to CD18 in <i>cis</i> hinders anti-cancer immune responses","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Inhibitory postsynaptic potential; Immune system; Phagocytosis; CD47; Receptor; Function (biology); Integrin; CD18","score_opus":0.01869467342635854,"score_gpt":0.27295802966277516,"score_spread":0.2542633562364166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414171558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889592,0.0058511486,0.00008256578,0.0010845842,0.0018578648,0.0014737267,0.00048088684,0.00017265278,0.000037386486],"genre_scores_gemma":[0.99524814,0.0019944727,0.0012134132,0.0007373196,0.00025518914,0.00030019868,7.383458e-7,0.00010075058,0.00014978583],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963732,0.00018340483,0.001204056,0.0010395311,0.00055577315,0.0006440498],"domain_scores_gemma":[0.9973321,0.00011910669,0.0005331501,0.0013837736,0.00040962227,0.00022222279],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012432036,0.0006286331,0.0012904505,0.0013699305,0.00008577324,0.000056285382,0.0004949591,0.000678978,0.00011659094],"category_scores_gemma":[0.00028969845,0.0006687704,0.0003699486,0.001459615,0.00020034998,0.00010687888,0.0004919136,0.000951698,0.000017865796],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026295106,0.000273222,0.029901192,0.0013592073,0.00040901898,0.00005513039,0.00005281306,0.000023496586,0.96441436,0.000017494955,0.00084622385,0.000018353781],"study_design_scores_gemma":[0.002219573,0.0001121775,0.18827885,0.005319363,0.0001339832,2.20266e-8,0.0000148824365,0.00001526724,0.798225,2.808079e-7,0.005150935,0.0005296751],"about_ca_topic_score_codex":0.00061473827,"about_ca_topic_score_gemma":0.000017896167,"teacher_disagreement_score":0.16618936,"about_ca_system_score_codex":0.00097111624,"about_ca_system_score_gemma":0.002265279,"threshold_uncertainty_score":0.99957633},"labels":[],"label_agreement":null},{"id":"W4414205664","doi":"10.3899/jrheum.2025-0481","title":"Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 1: Preexisting Inflammatory Arthritides","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université de Montréal; Dalhousie University; McMaster University; University of British Columbia; Alberta Hospital Edmonton; Western University; University of Toronto; Alberta Bone and Joint Health Institute; McGill University; University of Ottawa; University of Manitoba; Research Canada; Arthritis Research Centre of Canada; University of Calgary; University of Alberta","funders":"Canadian Rheumatology Association","keywords":"Rheumatology; Immunosuppression; Guideline; Baseline (sea); Immune system; MEDLINE","score_opus":0.03994353635059864,"score_gpt":0.3451663644676846,"score_spread":0.30522282811708595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414205664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976011,0.014068036,0.0001338394,0.0074557313,0.0007437887,0.0012763734,0.000052076666,0.000021843205,0.00023732816],"genre_scores_gemma":[0.9932479,0.0046899565,0.0015795402,0.00018414817,0.00001735598,0.00014214171,0.000041811767,0.000057860958,0.000039230614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9901883,0.0025891988,0.0048692157,0.0003936435,0.0005582263,0.0014014341],"domain_scores_gemma":[0.9827898,0.011787381,0.002654502,0.00056253374,0.0019156131,0.00029012928],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.018049499,0.0004350962,0.0021420822,0.0030887902,0.00050343206,0.000045585508,0.00070845825,0.00061352825,0.00009273009],"category_scores_gemma":[0.02622156,0.00033823078,0.0002785667,0.0013257404,0.00056503795,0.00031139428,0.00017791202,0.0013061778,0.0000022092581],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001523149,0.0002119107,0.98148006,0.0011446552,0.0006705479,0.000029903564,0.0031402889,0.00013246306,0.0009419402,0.0003644209,0.0013577505,0.009002895],"study_design_scores_gemma":[0.038283393,0.0053185876,0.7441889,0.13035603,0.00085306267,0.0141081475,0.043859206,0.0059041893,0.0019134382,0.004273181,0.009189624,0.001752256],"about_ca_topic_score_codex":0.44066054,"about_ca_topic_score_gemma":0.7002844,"teacher_disagreement_score":0.25962391,"about_ca_system_score_codex":0.0023770449,"about_ca_system_score_gemma":0.007258304,"threshold_uncertainty_score":0.99990696},"labels":[],"label_agreement":null},{"id":"W4414255524","doi":"10.3389/fimmu.2025.1662216","title":"225Actinium-armed antibody targeting CCR8+ regulatory T cells synergizes with immunotherapy to promote tumor rejection in syngeneic colorectal cancer models","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"College of Pharmacy and Nutrition, University of Saskatchewan; Colorectal Cancer Alliance","keywords":"Immunotherapy; TIGIT; Colorectal cancer; Cancer immunotherapy; Antibody; Monoclonal antibody","score_opus":0.005934798003847293,"score_gpt":0.25778601693988173,"score_spread":0.25185121893603446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414255524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97652125,0.015455538,0.002269546,0.0008583721,0.0027800822,0.0014100617,0.000010780011,0.000102682636,0.00059170066],"genre_scores_gemma":[0.98842376,0.0030694492,0.006021189,0.00082815747,0.00007181839,0.00041864422,0.000030216837,0.0000666915,0.0010700846],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976028,0.00018616162,0.0006603576,0.0006646296,0.00020298222,0.0006830247],"domain_scores_gemma":[0.9992001,0.000044439883,0.00018952254,0.00040726582,0.000106358195,0.000052336734],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050265476,0.00036127688,0.0008118657,0.0010629927,0.00011577647,0.000025271826,0.00024768853,0.00026828735,0.000054425273],"category_scores_gemma":[0.000030143638,0.00032573106,0.00011773552,0.0013743066,0.00026292296,0.0001762018,0.00005745654,0.0005349682,0.0000029096225],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023548113,0.00039163392,0.033488464,0.00011359604,0.0007757043,0.00007767491,0.0016000897,0.0010039303,0.91632026,0.000039738785,0.0023137168,0.020327069],"study_design_scores_gemma":[0.022330677,0.0025930975,0.22602159,0.0025821254,0.00016341287,0.00008041265,0.004322325,0.003779453,0.7126639,0.00033870756,0.0239408,0.001183516],"about_ca_topic_score_codex":0.0018229667,"about_ca_topic_score_gemma":0.00040988793,"teacher_disagreement_score":0.20365639,"about_ca_system_score_codex":0.00113642,"about_ca_system_score_gemma":0.0006087158,"threshold_uncertainty_score":0.9999195},"labels":[],"label_agreement":null},{"id":"W4414280768","doi":"10.1158/0008-5472.can-24-3095","title":"Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"Fondation contre le Cancer; Kom op tegen Kanker; Vrije Universiteit Brussel; Stichting Tegen Kanker; Fonds Wetenschappelijk Onderzoek","keywords":"Immunotherapy; Cancer immunotherapy; Construct (python library); Cancer; Immune system; Antibody; Autoimmune disease","score_opus":0.03325473000837953,"score_gpt":0.3706434265754012,"score_spread":0.3373886965670217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414280768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889672,0.0058047925,0.000031390413,0.0012269461,0.00020485526,0.0012353898,0.00001819036,0.00005294607,0.0024582811],"genre_scores_gemma":[0.9972749,0.00062280195,0.00039276638,0.00053193956,0.0001770849,0.0001171588,0.000008452166,0.000047525242,0.0008273868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972278,0.00036079556,0.00048412677,0.00047365887,0.0008235655,0.00063004595],"domain_scores_gemma":[0.9978203,0.00047717494,0.0001643176,0.00094350154,0.0004958453,0.00009887265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018694081,0.00022434187,0.00044780356,0.0002741906,0.00045665438,0.000066961795,0.00042785538,0.00009509112,0.00033192453],"category_scores_gemma":[0.00007831925,0.00014633009,0.000119201344,0.0011424244,0.0012760676,0.00010764876,0.000070456255,0.00064850115,0.0000038813514],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065455036,0.0001397979,0.017543403,0.00026811694,0.00038482773,0.000024379819,0.0007117028,0.000023299914,0.9303152,0.00023074831,0.0010577076,0.04275534],"study_design_scores_gemma":[0.007841534,0.0010580561,0.09370789,0.0019144714,0.000058259193,0.00004889788,0.0022267858,0.00008795579,0.8838449,0.000041691394,0.00891322,0.00025633452],"about_ca_topic_score_codex":0.0016756373,"about_ca_topic_score_gemma":0.0001408151,"teacher_disagreement_score":0.076164484,"about_ca_system_score_codex":0.0002973358,"about_ca_system_score_gemma":0.001716958,"threshold_uncertainty_score":0.59671676},"labels":[],"label_agreement":null},{"id":"W4414287004","doi":"10.14740/wjon2612","title":"Demographic Variations in Immune Checkpoint Inhibitor Adverse Events: A Real-World Study","year":2025,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Adverse effect; Obesity; Immune system; Anemia; MEDLINE","score_opus":0.016575028186691116,"score_gpt":0.33706776836287444,"score_spread":0.32049274017618334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414287004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9725038,0.00126023,0.00010437533,0.0104728695,0.0018468463,0.0007020633,0.0000021827402,0.000017359896,0.013090307],"genre_scores_gemma":[0.994084,0.00047218878,0.0006948677,0.00066906546,0.0001945827,0.000019784513,0.0000017672439,0.000011249299,0.0038525076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99798983,0.00024222945,0.0011920589,0.00014838208,0.00020471257,0.00022275839],"domain_scores_gemma":[0.9988497,0.00018684407,0.0004983857,0.00021340253,0.00017853286,0.00007316201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014458509,0.00013735918,0.0006005767,0.0019407581,0.00006382274,0.0000040718337,0.00014723779,0.000067588946,0.00026099358],"category_scores_gemma":[0.0000947289,0.00011423927,0.00028594295,0.0020074963,0.00007046442,0.00008962276,0.000042794883,0.00053605996,0.000004082071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015796412,0.007022487,0.9104608,0.00007407778,0.0017412385,0.0008396762,0.0017918235,0.000027186094,0.017376,0.00053505145,0.0028871512,0.04144809],"study_design_scores_gemma":[0.015264218,0.0018969533,0.9313843,0.00042213956,0.0002887082,0.00008039564,0.0008579799,0.000015521398,0.00026458778,0.00033605288,0.049093883,0.00009524138],"about_ca_topic_score_codex":0.0004573738,"about_ca_topic_score_gemma":0.010406882,"teacher_disagreement_score":0.04620673,"about_ca_system_score_codex":0.0007442752,"about_ca_system_score_gemma":0.0008370321,"threshold_uncertainty_score":0.5807284},"labels":[],"label_agreement":null},{"id":"W4414306402","doi":"10.1080/1120009x.2025.2561969","title":"Characterizing pulmonary adverse events associated with the immune checkpoint inhibitor avelumab: a FAERS-based pharmacovigilance study from 2013 to 2024","year":2025,"lang":"en","type":"article","venue":"Journal of Chemotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Pneumonitis; Adverse effect; Pneumonia; Pharmacovigilance; Respiratory distress; Respiratory failure; Pulmonary edema; Lung cancer; Pulmonary toxicity","score_opus":0.011283008644933243,"score_gpt":0.28717363617491565,"score_spread":0.2758906275299824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414306402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97401077,0.0012831469,0.00017555199,0.022898419,0.0006106679,0.00083056034,0.000015834019,0.00002228882,0.00015273575],"genre_scores_gemma":[0.9895045,0.0002119099,0.00015662915,0.008200853,0.00031300075,0.000025134706,0.000007003813,0.000036488123,0.0015444773],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99822545,0.00011644623,0.0006551454,0.00021674357,0.00052516523,0.0002610446],"domain_scores_gemma":[0.9986723,0.00012622988,0.0005587778,0.00029455882,0.0002453928,0.0001027502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007356409,0.00025597416,0.0005587912,0.00019630091,0.00011255283,0.000022451053,0.000271819,0.00007510775,0.0003262171],"category_scores_gemma":[0.000030717736,0.00015550262,0.00029639454,0.0005699376,0.000052957006,0.00012618296,0.000021041154,0.00045117846,0.0000063175175],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027936358,0.0019171011,0.0499252,0.000033580898,0.0027739482,0.0001680077,0.0015521089,0.00002054363,0.9002729,2.0047739e-7,0.0037010505,0.0116989855],"study_design_scores_gemma":[0.02547164,0.0021530346,0.7022122,0.0023249104,0.00045991282,0.000034098477,0.0014654981,0.0001765385,0.23955125,0.00001157512,0.025802933,0.00033641272],"about_ca_topic_score_codex":0.00008568193,"about_ca_topic_score_gemma":0.000019313324,"teacher_disagreement_score":0.66072166,"about_ca_system_score_codex":0.00035543356,"about_ca_system_score_gemma":0.00035972142,"threshold_uncertainty_score":0.6341213},"labels":[],"label_agreement":null},{"id":"W4414338300","doi":"10.1016/j.jjcc.2025.09.010","title":"Cardiovascular-related hospital visits amongst oncology patients receiving immune checkpoint inhibitors: a population-based cohort study","year":2025,"lang":"en","type":"article","venue":"Journal of Cardiology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Toronto Rehabilitation Institute; University Health Network; Women's College Hospital; Cancer Care Ontario; Western University; St. Michael's Hospital; Canadian Centre for Applied Research in Cancer Control","funders":"","keywords":"Incidence (geometry); Cohort study; Disease; Cohort; Cancer; Retrospective cohort study","score_opus":0.0058091682719058416,"score_gpt":0.26261770694184755,"score_spread":0.2568085386699417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414338300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99070674,0.0027445748,0.00020988572,0.0006576757,0.003224684,0.0009560451,0.0000027701342,0.000024182344,0.0014734345],"genre_scores_gemma":[0.99915564,0.00012793462,0.00008461324,0.00012832349,0.0003504989,0.00002139165,0.00002199033,0.000020699279,0.000088886074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99721295,0.000494521,0.001335194,0.00026496494,0.0004187632,0.00027363913],"domain_scores_gemma":[0.99818283,0.0001526635,0.0005781777,0.00038777708,0.0006112614,0.00008728753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019610166,0.00021500139,0.0014643153,0.0004244618,0.00009719372,0.000015454434,0.00015304724,0.00029248075,0.00002250553],"category_scores_gemma":[0.0004227584,0.00017389799,0.0013320317,0.00043421795,0.00007454606,0.00008720343,0.000045849527,0.0005330041,0.0000034945563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014658051,0.00035207893,0.9708247,0.000027868184,0.007072377,0.00017582907,0.00016544052,0.00040023596,0.0005038865,0.0000013095631,0.00059610663,0.018414322],"study_design_scores_gemma":[0.010781728,0.0032755022,0.97910935,0.00018181039,0.0011320317,0.00008818953,0.00021527767,0.0000183245,0.00021753095,0.000021831484,0.004813968,0.0001444465],"about_ca_topic_score_codex":0.00018588941,"about_ca_topic_score_gemma":0.000009527511,"teacher_disagreement_score":0.018269876,"about_ca_system_score_codex":0.00080681255,"about_ca_system_score_gemma":0.00041763583,"threshold_uncertainty_score":0.7091354},"labels":[],"label_agreement":null},{"id":"W4414371835","doi":"10.1016/j.ijrobp.2025.08.039","title":"Cross-Cancer Analysis Reveals a Distinct Pattern of Immune Modulation During Curative Radiation Therapy","year":2025,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Terry Fox Research Institute; Canada Foundation for Innovation; Princess Margaret Cancer Foundation; Pfizer; Bristol-Myers Squibb","keywords":"Immune system; Myeloid cells; Immune modulation; Myeloid; Effector; Radiation therapy; Immunotherapy","score_opus":0.01912560161991737,"score_gpt":0.37286284462614355,"score_spread":0.35373724300622617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414371835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97373945,0.0026701614,0.019362504,0.0021344752,0.0014763587,0.00026909294,0.00009696442,0.000020802077,0.00023019413],"genre_scores_gemma":[0.9951044,0.0031233216,0.00022356388,0.0004729587,0.0007335096,0.00002101499,0.000143024,0.000015626136,0.0001626151],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978599,0.00020743265,0.0012455009,0.00022850248,0.0002872087,0.00017144425],"domain_scores_gemma":[0.99646384,0.00027290656,0.0019004522,0.00018427626,0.0011272551,0.00005128105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005869857,0.00019430072,0.000664913,0.0004881333,0.00008389857,0.00002984451,0.00027135032,0.00020908476,0.00021740011],"category_scores_gemma":[0.0001575268,0.00016635051,0.0005817089,0.00067985745,0.00019899137,0.00030864167,0.00003338602,0.0002886073,0.0000023807079],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021070326,0.00026029025,0.6542356,0.00001386641,0.0044549946,0.0000042360643,0.00043489426,0.001062168,0.053175304,0.00023418968,0.00005967771,0.28395775],"study_design_scores_gemma":[0.0084275035,0.0004319626,0.9637471,0.00010627348,0.00038636956,0.000013939003,0.000045475706,0.003818814,0.019415092,0.0011857455,0.0022892707,0.00013249314],"about_ca_topic_score_codex":0.00014150528,"about_ca_topic_score_gemma":0.000010942531,"teacher_disagreement_score":0.30951145,"about_ca_system_score_codex":0.00088340393,"about_ca_system_score_gemma":0.00041590145,"threshold_uncertainty_score":0.67835766},"labels":[],"label_agreement":null},{"id":"W4414385509","doi":"10.1038/s44276-025-00174-x","title":"Evaluating the significance of combining PD-L1 and TILs as biomarkers in non-small cell lung cancer patients treated with immunotherapy: a systematic review","year":2025,"lang":"en","type":"review","venue":"BJC Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biomarker; Lung cancer; Overall survival; Predictive value; Immunotherapy; Tumor-infiltrating lymphocytes; Meta-analysis","score_opus":0.029570729500780206,"score_gpt":0.3550188290732884,"score_spread":0.3254480995725082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414385509","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054074368,0.97902656,0.0000019198178,0.000027474474,0.00014838712,0.014547878,0.000017172732,0.000024325424,0.00079883094],"genre_scores_gemma":[0.0016030605,0.99399346,0.000053820906,0.00022171564,0.00001561372,0.0030199697,0.0000763668,0.00007184231,0.0009441441],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9954431,0.0005136295,0.0024552047,0.00068285124,0.00056129385,0.0003439022],"domain_scores_gemma":[0.995161,0.00049618795,0.0030006662,0.0010205049,0.0002555821,0.00006606567],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021146256,0.0006067753,0.0037189943,0.00026295515,0.00008624597,0.00003281917,0.00018804376,0.0002145362,0.000046683002],"category_scores_gemma":[0.00023288016,0.00033770647,0.0004431167,0.0011093294,0.00013344898,0.00004684485,0.000051542716,0.00033084126,6.1946827e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026569684,0.0001611453,0.002397849,0.9293102,0.0017564239,0.00011508445,0.00019150348,3.011768e-7,0.000028916478,2.6831026e-7,0.00013752407,0.06563506],"study_design_scores_gemma":[0.0014548101,0.0005372348,0.00051556824,0.9868754,0.0071062995,0.0001718831,0.000044633445,0.000013534023,0.000023665481,0.0000010294283,0.002882406,0.0003735395],"about_ca_topic_score_codex":0.0012958321,"about_ca_topic_score_gemma":0.00004006364,"teacher_disagreement_score":0.06526153,"about_ca_system_score_codex":0.0003736656,"about_ca_system_score_gemma":0.0015071647,"threshold_uncertainty_score":0.9999075},"labels":[],"label_agreement":null},{"id":"W4414403649","doi":"10.1101/2025.09.21.677465","title":"Spatial statistics for identifying and scoring immune clusters in high-plex profiles of primary prostate cancer","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Tumor microenvironment; Immune system; Prostate cancer; Prostate; T cell; Prostatectomy; Antibody; Cell; Acquired immune system","score_opus":0.019748316623336506,"score_gpt":0.2688035782816692,"score_spread":0.24905526165833267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414403649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791224,0.009663225,0.0038246925,0.00024224994,0.0014444684,0.003062669,0.0025492555,0.00008767446,0.0000033483316],"genre_scores_gemma":[0.9771929,0.0041067954,0.01740814,0.00015233572,0.0002036366,0.00081930176,0.000005998451,0.000080914666,0.000030008025],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997624,0.000064245476,0.00087525643,0.00071065116,0.0002976466,0.0004282425],"domain_scores_gemma":[0.99826807,0.00011188538,0.0005460442,0.0005833288,0.00039345864,0.00009720815],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058078376,0.00042031924,0.00094710564,0.0004396808,0.00008064035,0.00006738931,0.00019846033,0.00031489832,0.000017400576],"category_scores_gemma":[0.00010390847,0.00044092213,0.00011689559,0.0003308786,0.00018109794,0.00008891739,0.00030197372,0.00045187987,4.2138703e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003295651,0.00019563903,0.08183834,0.017977664,0.0006693925,0.000033875534,0.00009440029,0.00004184856,0.89515394,0.00013522853,0.00019660778,0.00036741572],"study_design_scores_gemma":[0.0052378178,0.00016141181,0.7355473,0.0075736637,0.00038986068,2.4197863e-8,0.00001303371,0.0005408289,0.24931744,0.000004825462,0.00064781687,0.00056596514],"about_ca_topic_score_codex":0.0023128153,"about_ca_topic_score_gemma":0.00007827271,"teacher_disagreement_score":0.653709,"about_ca_system_score_codex":0.00057243,"about_ca_system_score_gemma":0.0014810712,"threshold_uncertainty_score":0.99980426},"labels":[],"label_agreement":null},{"id":"W4414406645","doi":"10.3390/jcm14186680","title":"Immune Checkpoint Inhibitors Beyond Progression in Various Solid Tumors: A Systematic Review and Pooled Analysis","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Discontinuation; Post-hoc analysis; Lung cancer; Pooled analysis; Cochrane Library; Retrospective cohort study; Nivolumab; Meta-analysis; Clinical trial","score_opus":0.041928000387947466,"score_gpt":0.457901205958175,"score_spread":0.41597320557022754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414406645","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020369045,0.9934516,0.000023684708,0.0029231478,0.00062693434,0.0026521673,0.00000520442,0.000011640893,0.00028523323],"genre_scores_gemma":[0.00009738549,0.9974611,0.00016830409,0.0011800037,0.0006608881,0.00006035284,0.000025985786,0.000032395426,0.0003136197],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9842359,0.0012257125,0.0129404655,0.00042741364,0.00086164504,0.00030888713],"domain_scores_gemma":[0.9888815,0.0022205405,0.0074939984,0.0006549181,0.00039899038,0.00035001876],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.013415929,0.0005669734,0.019489571,0.0014547055,0.000038172395,0.000016748285,0.0003387558,0.000521364,0.00013982125],"category_scores_gemma":[0.0102927685,0.0002902664,0.0030071263,0.0025333785,0.00032814656,0.00007109007,0.00009829908,0.0019081079,0.0000026949508],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029293704,0.00026628043,0.000056651952,0.7427694,0.0074531366,0.0004541295,0.00003712576,2.234757e-8,0.000001318251,0.0000018124124,0.0004372036,0.24822995],"study_design_scores_gemma":[0.0029565962,0.0016633833,0.00016985285,0.83888847,0.13795777,0.0007651452,0.000033407876,0.0000029254845,7.996928e-7,0.000020234493,0.017348815,0.00019257674],"about_ca_topic_score_codex":0.00002373527,"about_ca_topic_score_gemma":0.000008648841,"teacher_disagreement_score":0.24803737,"about_ca_system_score_codex":0.000211103,"about_ca_system_score_gemma":0.0012752491,"threshold_uncertainty_score":0.99995494},"labels":[],"label_agreement":null},{"id":"W4414422193","doi":"10.1016/j.semcancer.2025.09.005","title":"Microorganisms in cancer tertiary lymphoid structure formation","year":2025,"lang":"en","type":"review","venue":"Seminars in Cancer Biology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fundamental Research Funds for the Central Universities; Canadian Space Agency; National Key Research and Development Program of China; Wuhan University; National Natural Science Foundation of China","keywords":"Cancer; Immune system; Microorganism; Tumor microenvironment; Immune checkpoint; Signal transduction; Immunotherapy; Cancer immunotherapy","score_opus":0.021592149810844143,"score_gpt":0.3712726332593259,"score_spread":0.3496804834484818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414422193","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00081965333,0.99525535,0.0000054436487,0.00035369297,0.0015105897,0.0012250595,0.0005833741,0.000028922006,0.00021793251],"genre_scores_gemma":[0.00021073985,0.9964417,0.000101492726,0.0011149825,0.00025666918,0.00052049215,0.000618299,0.000041195606,0.0006943989],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779695,0.00017292211,0.00088615686,0.00056740915,0.00009562896,0.00048095098],"domain_scores_gemma":[0.99907494,0.00012347856,0.00032125332,0.00039035644,0.00004007316,0.000049931765],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001987654,0.0004793657,0.0016851977,0.00069245405,0.000035916226,0.000010748362,0.00028222776,0.0009779853,0.0006302115],"category_scores_gemma":[0.00002796605,0.00037570027,0.0002714068,0.00089358015,0.00014412425,0.000057071444,0.00009087023,0.0005573185,0.0000041197864],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018655516,0.00004193053,0.0021439,0.013389249,0.00013751378,0.00002389576,0.00016901814,5.133077e-7,0.0010452002,0.0000062101967,0.0025442105,0.9803118],"study_design_scores_gemma":[0.001384391,0.00010046624,0.00027840515,0.055982817,0.0002912946,0.00013772919,0.000036494064,0.0000026903876,0.0006193062,0.0000684696,0.94072974,0.00036821584],"about_ca_topic_score_codex":0.0020852955,"about_ca_topic_score_gemma":0.0036342277,"teacher_disagreement_score":0.9799436,"about_ca_system_score_codex":0.002472861,"about_ca_system_score_gemma":0.00175106,"threshold_uncertainty_score":0.99986947},"labels":[],"label_agreement":null},{"id":"W4414422951","doi":"10.1016/j.oraloncology.2025.107704","title":"Resectable locally advanced head and neck squamous cell carcinoma: cut first or immune checkpoint inhibitors first?","year":2025,"lang":"en","type":"article","venue":"Oral Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group; McMaster University","funders":"","keywords":"Head and neck; Perioperative; Immune system; Immune checkpoint; Squamous cell cancer; Disease; Clinical trial","score_opus":0.01565594410085482,"score_gpt":0.2968284873554002,"score_spread":0.2811725432545454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414422951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96579415,0.007422966,0.000031174965,0.0102026975,0.000885974,0.0007248604,0.000008117191,0.000074537624,0.014855528],"genre_scores_gemma":[0.9838536,0.0005591825,0.00083233055,0.0013274257,0.00011637916,0.00007984404,0.000019092546,0.000026916583,0.013185232],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983823,0.000054094817,0.0005441882,0.00041864006,0.00013883386,0.00046197328],"domain_scores_gemma":[0.99910617,0.00018333757,0.00013523117,0.00035881487,0.00009550983,0.00012096235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002761561,0.00024012866,0.0006128152,0.00016275395,0.00021075486,0.00001931871,0.00012616756,0.00028518852,0.00038214255],"category_scores_gemma":[0.00010285338,0.00018788378,0.00013957132,0.0004380161,0.00024173064,0.0000884641,0.00012374691,0.00031635177,0.000022939408],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24663138,0.0054715173,0.15496396,0.004603343,0.0005532438,0.0030116753,0.0039230087,0.000105931824,0.2614291,0.0002715308,0.11780789,0.20122744],"study_design_scores_gemma":[0.0292317,0.008497243,0.061586764,0.00029263913,0.00015094627,0.00016479575,0.0005089199,0.00016681019,0.061412625,0.000060169335,0.837584,0.00034337814],"about_ca_topic_score_codex":0.0020496922,"about_ca_topic_score_gemma":0.0073756063,"teacher_disagreement_score":0.71977615,"about_ca_system_score_codex":0.00056667294,"about_ca_system_score_gemma":0.0006661582,"threshold_uncertainty_score":0.7661678},"labels":[],"label_agreement":null},{"id":"W4414465177","doi":"10.1158/2326-6074.cimm25-b008","title":"Abstract B008: Unraveling the sexually dimorphic immune microenvironment in gastric cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Immune system; CD8; Cytotoxic T cell; Antigen; Sexual dimorphism; Immunotherapy; Tumor microenvironment; CDH1","score_opus":0.05364733650164636,"score_gpt":0.3832631809748934,"score_spread":0.32961584447324704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414465177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8040209,0.17221624,0.000014603588,0.020410316,0.00066219515,0.00092990964,0.000017525805,0.00003040721,0.0016979004],"genre_scores_gemma":[0.9429727,0.04961391,0.000027063183,0.000901006,0.00013571016,0.0008683063,0.00001424775,0.000033138887,0.0054339226],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972076,0.0002567904,0.0005846457,0.0005422332,0.00042357517,0.0009851982],"domain_scores_gemma":[0.9985539,0.00035005625,0.00009284008,0.0007962347,0.00015232372,0.000054681335],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016615748,0.00024333509,0.0004374988,0.00063577486,0.0003564547,0.000044663902,0.0005680221,0.00024776705,0.0018457386],"category_scores_gemma":[0.00009549037,0.00017799769,0.00013688099,0.0014904091,0.0010441528,0.00006879397,0.00026074832,0.0016500375,0.000052650394],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045012888,0.0002863288,0.05158738,0.00018182116,0.0008566188,0.000075227224,0.00072326825,0.000064620035,0.7610808,0.000082212806,0.0028026663,0.17775777],"study_design_scores_gemma":[0.0040935287,0.000210823,0.9197121,0.000901961,0.000048015223,0.000027393535,0.0013463384,0.000044303488,0.026350833,0.00010362852,0.046972424,0.00018864262],"about_ca_topic_score_codex":0.0060574687,"about_ca_topic_score_gemma":0.0007421452,"teacher_disagreement_score":0.8681247,"about_ca_system_score_codex":0.0014747878,"about_ca_system_score_gemma":0.0013014121,"threshold_uncertainty_score":0.9990667},"labels":[],"label_agreement":null},{"id":"W4414465186","doi":"10.1158/2326-6074.cimm25-a009","title":"Abstract A009: Novel roles of the nuclear autoantigen LEDGF/p75 in modulating prostate cancer related inflammatory pathways and cancer patient response to immunotherapy","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Downregulation and upregulation; Prostate cancer; Cancer; Gene silencing; Gene knockdown; Immunotherapy; Transcription factor; Autoantibody","score_opus":0.029976874850282574,"score_gpt":0.34496921669977226,"score_spread":0.3149923418494897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414465186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94417495,0.045130223,6.8381365e-7,0.008053605,0.00047170345,0.0017238052,0.000075036456,0.000054527536,0.00031544184],"genre_scores_gemma":[0.9857461,0.012166066,0.000048874677,0.0005254001,0.000028697494,0.0006537755,0.0000025097956,0.000056402274,0.00077221147],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99702775,0.0003887103,0.00081125734,0.00057054195,0.0004523118,0.0007494268],"domain_scores_gemma":[0.99825233,0.00029566803,0.00021162855,0.00072239805,0.00044212947,0.0000758513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015921877,0.00027628834,0.0005394845,0.0006738769,0.00032987935,0.000036225283,0.00040477444,0.00031739508,0.00028192587],"category_scores_gemma":[0.0001939968,0.0002134819,0.00013408877,0.0014324551,0.00073125423,0.00011106091,0.0003146271,0.0010472803,0.0000039339757],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018666865,0.00016687556,0.0480501,0.00016418114,0.0006089802,0.000010789245,0.010817916,0.0001593072,0.8032685,0.000085509746,0.0002779169,0.117723055],"study_design_scores_gemma":[0.0055678706,0.0003574227,0.9103497,0.002496261,0.000027679205,0.000008067305,0.0021377103,0.00023094089,0.052201238,0.00007560927,0.026308166,0.00023927975],"about_ca_topic_score_codex":0.004183611,"about_ca_topic_score_gemma":0.00087531225,"teacher_disagreement_score":0.8622997,"about_ca_system_score_codex":0.0010962569,"about_ca_system_score_gemma":0.0020163178,"threshold_uncertainty_score":0.8705539},"labels":[],"label_agreement":null},{"id":"W4414465201","doi":"10.1158/2326-6074.cimm25-a008","title":"Abstract A008: Relationship between CD4+ T cells and cancer stem cells in squamous cancers of the oro-esophageal tract","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Q & T Research; Université de Sherbrooke","funders":"","keywords":"Cancer stem cell; CDKN2A; Tumor microenvironment; Stem cell; Flow cytometry; Cancer; Context (archaeology); Carcinogenesis; Immunotherapy","score_opus":0.07941855897713583,"score_gpt":0.3902459849650642,"score_spread":0.31082742598792834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414465201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9485118,0.045104437,0.0000020283446,0.0032106962,0.0006627944,0.0009826162,0.00013603515,0.000021148926,0.0013684669],"genre_scores_gemma":[0.98930764,0.0048197107,0.000009952184,0.00018573145,0.00009708926,0.00026147865,0.0000043718096,0.000027730559,0.0052862656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746954,0.00036141637,0.00061026256,0.00048068175,0.00041522604,0.00066284585],"domain_scores_gemma":[0.99772507,0.0011944058,0.00015697502,0.0006130734,0.00023953353,0.000070971684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012436465,0.00022071497,0.00053413544,0.0005071115,0.00025352015,0.000024380037,0.00041647037,0.00037485783,0.00025773913],"category_scores_gemma":[0.00006895215,0.00016999799,0.00013375303,0.0014247535,0.0014563488,0.00009774893,0.00015186821,0.0014354116,0.0000059413405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020066774,0.00011437086,0.79453945,0.00047892772,0.00031474486,0.000021187067,0.0010030782,0.000045959692,0.15030566,0.00012384848,0.00234809,0.048698],"study_design_scores_gemma":[0.0029421032,0.00014406603,0.8680474,0.0005481365,0.000060505776,0.0000034160228,0.0005134054,0.000010314321,0.12212933,0.000121914345,0.0053561954,0.00012322707],"about_ca_topic_score_codex":0.013283601,"about_ca_topic_score_gemma":0.0014455616,"teacher_disagreement_score":0.073507935,"about_ca_system_score_codex":0.0013429043,"about_ca_system_score_gemma":0.0023627563,"threshold_uncertainty_score":0.993287},"labels":[],"label_agreement":null},{"id":"W4414465206","doi":"10.1158/2326-6074.cimm25-b007","title":"Abstract B007: Tissue-Specific B Cell Differentiation Limits Anti-Tumor Efficacy of Radiation and Immunotherapy","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunotherapy; Myeloid; Tumor microenvironment; Immune system; B cell; T cell; Context (archaeology); CD40; Blockade","score_opus":0.04515627670786234,"score_gpt":0.37673717325141115,"score_spread":0.33158089654354883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414465206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8828518,0.11262201,0.00007105761,0.0013514445,0.0004790741,0.00075126707,0.000014437168,0.000033972472,0.0018249581],"genre_scores_gemma":[0.9514675,0.046738416,0.000032885422,0.00011541041,0.00008857712,0.00009239087,0.00003253412,0.000023973162,0.0014082772],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982567,0.00016185986,0.0004590012,0.00039278023,0.0003003312,0.00042934602],"domain_scores_gemma":[0.99869156,0.00035949654,0.00014043365,0.0004790444,0.0002843084,0.000045178323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006407037,0.00017520663,0.000427756,0.00059651653,0.00019644137,0.00003374232,0.00019804205,0.0001952387,0.0005687307],"category_scores_gemma":[0.000054338754,0.00015820666,0.000090332935,0.0007218222,0.00056186575,0.000089277935,0.00005018653,0.00051606545,0.000013910533],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00356014,0.0002405577,0.00910904,0.00014638758,0.00027740138,0.000005462949,0.00028499277,0.0000013713741,0.7394333,0.00011638703,0.0015684526,0.2452565],"study_design_scores_gemma":[0.005045824,0.000270595,0.59358895,0.00017860849,0.000018434772,0.0000045125926,0.00012939204,0.000009198519,0.37305582,0.000040938732,0.027571112,0.000086606895],"about_ca_topic_score_codex":0.00032710226,"about_ca_topic_score_gemma":0.000011808582,"teacher_disagreement_score":0.5844799,"about_ca_system_score_codex":0.00026197766,"about_ca_system_score_gemma":0.00037786766,"threshold_uncertainty_score":0.64514804},"labels":[],"label_agreement":null},{"id":"W4414465996","doi":"10.1158/2326-6074.cimm25-pr-14","title":"Abstract PR-14: Unraveling the sexually dimorphic immune microenvironment in gastric cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Immune system; CD8; Cytotoxic T cell; Antigen; Sexual dimorphism; Immunotherapy; Tumor microenvironment; CDH1","score_opus":0.05215571832167075,"score_gpt":0.38088370511138075,"score_spread":0.32872798678971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414465996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8182487,0.15700097,0.000015583613,0.021052243,0.0007449546,0.0010993691,0.000019900965,0.000033497843,0.001784776],"genre_scores_gemma":[0.94783795,0.043058157,0.000029838717,0.0008839571,0.0001427808,0.0009999545,0.000015960972,0.000036063426,0.006995349],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9970743,0.00027260048,0.0006092454,0.0005674195,0.00045290065,0.0010235141],"domain_scores_gemma":[0.998491,0.0003525699,0.00010089299,0.0008216703,0.0001765603,0.000057330715],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017641899,0.00025532386,0.0004536515,0.0006400325,0.00036242112,0.00004796529,0.0005866564,0.00026458802,0.0018285009],"category_scores_gemma":[0.00011042452,0.0001869399,0.00013899998,0.0014643931,0.0010577994,0.00007352836,0.00027266028,0.001735752,0.000053803793],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051167523,0.00032799604,0.052227225,0.00020231685,0.0009523684,0.00007936685,0.000813273,0.00006954621,0.7600099,0.00008355394,0.0034843928,0.17663334],"study_design_scores_gemma":[0.0045204144,0.00024238268,0.90955704,0.0008862627,0.000053217023,0.000029479137,0.0012041392,0.000042804364,0.02755732,0.0001048217,0.055597402,0.00020468679],"about_ca_topic_score_codex":0.0051391064,"about_ca_topic_score_gemma":0.0007112092,"teacher_disagreement_score":0.85732985,"about_ca_system_score_codex":0.0015333856,"about_ca_system_score_gemma":0.001387966,"threshold_uncertainty_score":0.99908394},"labels":[],"label_agreement":null},{"id":"W4414466036","doi":"10.1158/2326-6074.cimm25-pr-07","title":"Abstract PR-07: Immunosuppressive γδ T cells limit anti-tumor immunity in ICI-resistant tumors from autoimmune-prone mice","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Autoimmunity; Immune system; Immunotherapy; Immunity; T cell; Nod; Tumor microenvironment; Genetic predisposition; Phenotype","score_opus":0.042586539552492586,"score_gpt":0.36277736093828655,"score_spread":0.32019082138579397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414466036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9035192,0.08448392,0.0000066316093,0.0033246942,0.0011767792,0.0016644833,0.0001873255,0.0001314497,0.0055054943],"genre_scores_gemma":[0.9867733,0.0075940927,0.00009378532,0.000621329,0.00013697993,0.00071247877,0.00012849402,0.00008451698,0.0038550054],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9944178,0.0007784224,0.0012965822,0.0010789793,0.000732822,0.0016954084],"domain_scores_gemma":[0.9960869,0.0010289737,0.000295672,0.0017828523,0.00067539106,0.0001301952],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018992681,0.00056415,0.0012810552,0.0012271504,0.00058470893,0.0001226429,0.0012866253,0.000535992,0.002617502],"category_scores_gemma":[0.00035642946,0.00052926294,0.00033398217,0.0019523957,0.0018203838,0.00025842644,0.0006176082,0.0032621655,0.0002587058],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014061895,0.0007607908,0.006667489,0.00025122028,0.001218241,0.00044861317,0.0009011747,0.00001143214,0.96126264,0.00007957376,0.0038575386,0.010479404],"study_design_scores_gemma":[0.007386403,0.000429722,0.62943554,0.002219351,0.000078820354,0.00001788459,0.0025009234,0.0000534114,0.34018153,0.0002457556,0.017021893,0.0004287879],"about_ca_topic_score_codex":0.031690106,"about_ca_topic_score_gemma":0.00079362205,"teacher_disagreement_score":0.62276804,"about_ca_system_score_codex":0.0017450739,"about_ca_system_score_gemma":0.0028460205,"threshold_uncertainty_score":0.99971586},"labels":[],"label_agreement":null},{"id":"W4414490996","doi":"10.1158/2326-6074.cimm25-ia02","title":"Abstract IA02: Mechanisms of TCF1 regulation of stem-like T cells in cancer and autoimmunity","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Autoimmunity; Cancer immunotherapy; Priming (agriculture); Immunotherapy; T cell; Tumor microenvironment; Cytotoxic T cell; Cancer; Peripheral tolerance","score_opus":0.06277460242488528,"score_gpt":0.39214207110304544,"score_spread":0.32936746867816014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414490996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9649868,0.031604227,0.000023925235,0.0012567737,0.00036965136,0.0005872638,0.000036953694,0.000014010643,0.0011203984],"genre_scores_gemma":[0.9869888,0.009847273,0.000059635306,0.00007591018,0.000013009528,0.00012729976,0.0000066724924,0.000013702948,0.0028677296],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984409,0.00016971765,0.00049796066,0.0002686815,0.00027149584,0.0003512163],"domain_scores_gemma":[0.9987895,0.00023131522,0.00013244756,0.00044307747,0.00037399263,0.000029681845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011705982,0.00012802792,0.00045938033,0.0006473402,0.00007804443,0.0000070516376,0.00019455723,0.00024435166,0.00041647072],"category_scores_gemma":[0.000024186636,0.00011753771,0.00006938238,0.00090259645,0.0007903493,0.000070029295,0.0001225167,0.0005521042,0.0000015243307],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003586106,0.00015614094,0.0065950714,0.00048154223,0.00030451064,0.0000033947479,0.00046882467,0.000009525278,0.9111439,0.0007238974,0.0003443984,0.07618271],"study_design_scores_gemma":[0.0028895137,0.00026239458,0.50576615,0.00090359146,0.000027122589,0.0000026000334,0.0007384342,0.000051939962,0.48648277,0.0008669175,0.0019265572,0.000081997205],"about_ca_topic_score_codex":0.009680237,"about_ca_topic_score_gemma":0.00081565307,"teacher_disagreement_score":0.49917108,"about_ca_system_score_codex":0.00037738236,"about_ca_system_score_gemma":0.00096084276,"threshold_uncertainty_score":0.9969144},"labels":[],"label_agreement":null},{"id":"W4414491675","doi":"10.1158/2326-6074.cimm25-b009","title":"Abstract B009: Targeting PAR-2 improves tumor antigen presentation and primes the immune system for anti-PD-1 immunotherapy","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Espace pour la vie","funders":"","keywords":"Immunotherapy; Immune system; Tumor microenvironment; Flow cytometry; Cancer; Myeloid; Cancer immunotherapy; Cytokine; Downregulation and upregulation","score_opus":0.03480508903454207,"score_gpt":0.38543541415212335,"score_spread":0.3506303251175813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414491675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7861344,0.20392147,0.00008337247,0.0055507114,0.0007978189,0.002449498,0.000030503132,0.0000910955,0.0009410936],"genre_scores_gemma":[0.98577785,0.010756272,0.00015797824,0.00021972127,0.00020319797,0.0010701197,0.000037672136,0.000044635883,0.0017325603],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99757904,0.00023474898,0.00059663015,0.0005242663,0.0003010974,0.00076419825],"domain_scores_gemma":[0.9979953,0.000669679,0.00017440933,0.00059907784,0.00051518914,0.000046298457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020049345,0.00024904733,0.000509746,0.0003293421,0.0009271264,0.00012367762,0.00033528593,0.00019308188,0.000074464595],"category_scores_gemma":[0.00017246128,0.00017510053,0.00018095937,0.0006039625,0.0010106286,0.00014511822,0.00013248583,0.00062459346,0.000005295213],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053312154,0.00008077266,0.0070124515,0.0005708154,0.0011974163,0.000010160301,0.00053303305,9.836309e-7,0.929844,0.0004116137,0.00243444,0.0525731],"study_design_scores_gemma":[0.0048815385,0.0003458643,0.50127816,0.000571497,0.000052805306,0.000034898567,0.003305384,0.00012345168,0.44783524,0.00011596335,0.041262392,0.0001928432],"about_ca_topic_score_codex":0.0014316508,"about_ca_topic_score_gemma":0.000019155346,"teacher_disagreement_score":0.49426568,"about_ca_system_score_codex":0.00033529507,"about_ca_system_score_gemma":0.0007847024,"threshold_uncertainty_score":0.71403927},"labels":[],"label_agreement":null},{"id":"W4414491882","doi":"10.1158/2326-6074.cimm25-b019","title":"Abstract B019: CCR5 inhibition with leronlimab is associated with enhanced PD-L1 expression, ICI response, and long-term survival in metastatic TNBC.","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Attodyne (Canada)","funders":"","keywords":"Immunotherapy; Metastatic breast cancer; Clinical trial; Metastasis; Breast cancer; Adverse effect; Cancer; Antibody; Breast cancer metastasis","score_opus":0.05078881003570925,"score_gpt":0.3867239364335297,"score_spread":0.33593512639782047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414491882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98498654,0.009571912,0.000053109514,0.0035626465,0.00011454446,0.00093865866,0.000039158465,0.00004726743,0.0006861822],"genre_scores_gemma":[0.9938537,0.0023263136,0.000041433177,0.00032341166,0.000022495375,0.00040386236,0.000052537376,0.00003752417,0.0029387507],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99710065,0.00060462503,0.0004175662,0.0006209939,0.00051240326,0.00074375956],"domain_scores_gemma":[0.99808246,0.0007617699,0.00012749482,0.00048151283,0.0004674778,0.0000792974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016930315,0.00026747858,0.0005925574,0.00072405755,0.00023611645,0.000053139425,0.00016422986,0.00022370464,0.00048007202],"category_scores_gemma":[0.00024728742,0.00019860947,0.00005292719,0.0013160718,0.0010647522,0.00017302015,0.000099359124,0.0009799341,0.000006887439],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12089628,0.00049394416,0.064834,0.00022722663,0.0011096457,0.0003864534,0.0012812015,0.0000024537344,0.7980391,0.000014835738,0.00059238647,0.012122487],"study_design_scores_gemma":[0.011645471,0.0011438158,0.82196987,0.0026962569,0.000054937416,0.000022927843,0.000763266,0.0000033613344,0.16123517,0.00003258346,0.00024307393,0.0001892903],"about_ca_topic_score_codex":0.0005234728,"about_ca_topic_score_gemma":0.001535733,"teacher_disagreement_score":0.75713587,"about_ca_system_score_codex":0.00075353927,"about_ca_system_score_gemma":0.0014145616,"threshold_uncertainty_score":0.80990595},"labels":[],"label_agreement":null},{"id":"W4414491903","doi":"10.1158/2326-6074.cimm25-ia01","title":"Abstract IA01: B cell checkpoints as regulators of tumor immunity and self-tolerance","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immune system; TIGIT; Cancer immunotherapy; Immunity; Melanoma; B cell; Cancer; Immune checkpoint; Immunotherapy","score_opus":0.029520254604255947,"score_gpt":0.36995281460628293,"score_spread":0.340432560002027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414491903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94082844,0.043917704,0.0000017389323,0.0018395813,0.00030234575,0.00054997957,0.0000119257165,0.00004944737,0.012498862],"genre_scores_gemma":[0.98835754,0.0073710857,0.00008985328,0.00027023396,0.00004511124,0.00011627269,0.0000060566504,0.000022122758,0.0037217273],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99816287,0.00017185218,0.00043101632,0.00038246563,0.0003126401,0.0005391784],"domain_scores_gemma":[0.9985122,0.00020393658,0.000110257075,0.0006817498,0.0004186566,0.000073179675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011093151,0.00018262037,0.0004685306,0.00043509147,0.00022691018,0.000019296536,0.0002996078,0.00020743016,0.0004728322],"category_scores_gemma":[0.000106784355,0.00016552312,0.00011342705,0.00082719006,0.00091261877,0.000082351544,0.00018584424,0.0008533694,0.00002087756],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007985974,0.00068883924,0.03286778,0.0010839495,0.00088247634,0.0000476662,0.0011353825,0.0000011162252,0.92423135,0.00032004953,0.0037678122,0.026987603],"study_design_scores_gemma":[0.0046671866,0.0004817077,0.5087386,0.0005854432,0.000050391434,0.000035683235,0.0010661336,0.000016344584,0.4638003,0.00041373522,0.019985396,0.00015912474],"about_ca_topic_score_codex":0.0024854522,"about_ca_topic_score_gemma":0.000055004977,"teacher_disagreement_score":0.47587076,"about_ca_system_score_codex":0.0003046147,"about_ca_system_score_gemma":0.0011712727,"threshold_uncertainty_score":0.6749837},"labels":[],"label_agreement":null},{"id":"W4414492865","doi":"10.1158/2326-6074.cimm25-b006","title":"Abstract B006: Immunosuppressive γδ T cells limit anti-tumor immunity in ICI-resistant tumors from autoimmune-prone mice","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Autoimmunity; Immune system; Immunotherapy; Immunity; T cell; Nod; Tumor microenvironment; Genetic predisposition; Phenotype","score_opus":0.04207406639913272,"score_gpt":0.3629962655184762,"score_spread":0.3209221991193435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414492865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.904387,0.08391209,0.0000067811116,0.0032037252,0.0011502096,0.0014886898,0.00018440999,0.00012650914,0.0055405935],"genre_scores_gemma":[0.9872568,0.007488435,0.00008971008,0.0006379886,0.00013128814,0.0006323082,0.00012714663,0.00008073347,0.0035555493],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.994584,0.00074305024,0.0012640475,0.0010478414,0.0007073089,0.0016537108],"domain_scores_gemma":[0.9961811,0.0010241977,0.00027846041,0.0017431526,0.00064739777,0.0001256921],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018433762,0.00054694136,0.001254423,0.0012861677,0.000572366,0.00011815,0.001252565,0.0005209458,0.0021572174],"category_scores_gemma":[0.00033111288,0.00051469577,0.00032933845,0.0021156478,0.0017884609,0.00024935845,0.0005985112,0.0031883977,0.00017606169],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013285885,0.00071328686,0.0067122863,0.00022215862,0.0011482838,0.00044019762,0.0008146505,0.000011223805,0.9614994,0.00008006791,0.0036582958,0.01141427],"study_design_scores_gemma":[0.007068012,0.00038132808,0.6168175,0.0020210939,0.000072376984,0.000015952275,0.0024162128,0.000051010713,0.35559255,0.00024469412,0.014917818,0.00040148795],"about_ca_topic_score_codex":0.03569729,"about_ca_topic_score_gemma":0.0009260206,"teacher_disagreement_score":0.61010516,"about_ca_system_score_codex":0.0016934886,"about_ca_system_score_gemma":0.0026232079,"threshold_uncertainty_score":0.99973047},"labels":[],"label_agreement":null},{"id":"W4414514026","doi":"10.1038/s41467-025-63465-4","title":"Oncogenic driver mutations underlie the spatial tumour immune landscape of non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill Genome Centre; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec; McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Fonds de Recherche du Québec - Santé; Québec Consortium for Drug Discovery; McGill University","keywords":"KRAS; Lung cancer; Mutation; Immune system; Adenocarcinoma; Tumor microenvironment; Cancer; Tumour heterogeneity; Gene","score_opus":0.01156153493076511,"score_gpt":0.30936023552919245,"score_spread":0.29779870059842733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414514026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5129467,0.36128286,0.0018664282,0.0639458,0.0012421538,0.002612313,0.00021537193,0.00014097379,0.055747386],"genre_scores_gemma":[0.9895317,0.006536881,0.0009064717,0.0010019521,0.00004275152,0.0001187658,0.00012479934,0.000014107369,0.0017225891],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99918157,0.00008293258,0.00031830402,0.00013719466,0.00013561815,0.00014439067],"domain_scores_gemma":[0.99790096,0.00031177746,0.00015260921,0.0013694239,0.00023528353,0.000029926505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018798524,0.00012330784,0.00021208444,0.00010379723,0.0003008008,0.000016505739,0.00068862824,0.00019303347,0.00015283405],"category_scores_gemma":[0.00003798473,0.000089784655,0.00019100649,0.0005775216,0.00020581418,0.0000336519,0.00016833327,0.0007522157,0.000005180299],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015321197,0.0021818802,0.19793142,0.00065606105,0.0032421437,0.000006033662,0.0052611674,0.00018830194,0.62377524,0.005365208,0.12237233,0.037488118],"study_design_scores_gemma":[0.005456241,0.0001146879,0.8499814,0.0006043417,0.0013861594,0.000010725836,0.0014835653,0.007102292,0.036819663,0.00015498785,0.09658493,0.00030099714],"about_ca_topic_score_codex":0.0008510537,"about_ca_topic_score_gemma":0.0020474752,"teacher_disagreement_score":0.65205,"about_ca_system_score_codex":0.00010782281,"about_ca_system_score_gemma":0.0005697417,"threshold_uncertainty_score":0.3661312},"labels":[],"label_agreement":null},{"id":"W4414535538","doi":"10.1126/sciimmunol.adv6870","title":"Inhibitory immune checkpoints in cancer immunotherapy","year":2025,"lang":"en","type":"review","venue":"Science Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; Montreal Clinical Research Institute","funders":"","keywords":"Immune system; Monoclonal antibody; Cancer immunotherapy; Immunotherapy; Inhibitory postsynaptic potential; Cancer; Antibody","score_opus":0.0346951688554065,"score_gpt":0.39084656888804925,"score_spread":0.35615140003264273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414535538","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027883408,0.9923725,0.0000029377238,0.00030350607,0.0030691724,0.0014383082,0.000015274527,0.00014295561,0.0023765191],"genre_scores_gemma":[0.000081551974,0.99568796,0.000085507294,0.00028813447,0.00012528445,0.0005264701,0.00002229378,0.00006898112,0.0031138216],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960787,0.00017236911,0.0013104539,0.0010260425,0.00042614675,0.0009862774],"domain_scores_gemma":[0.99792594,0.0001598243,0.00046702678,0.0012170675,0.00015753185,0.000072583745],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013284024,0.00061139744,0.0025481756,0.002133682,0.00017175457,0.000055866774,0.0010794736,0.0006301252,0.0003939603],"category_scores_gemma":[0.0001590237,0.00048815398,0.0007070807,0.0041110134,0.002264732,0.00020351612,0.0002704707,0.001111064,0.0000602379],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025161155,0.00015733049,0.000026643858,0.003388881,0.00023985238,0.000035226258,0.00011377582,7.587901e-8,0.0030379356,0.000064961525,0.00013170484,0.992552],"study_design_scores_gemma":[0.0017774822,0.00022320462,0.00085589045,0.029716006,0.00017361771,0.00015816388,0.000061099636,0.0000010077066,0.00046600835,0.000033616157,0.9660698,0.00046410688],"about_ca_topic_score_codex":0.0010854498,"about_ca_topic_score_gemma":0.000066498396,"teacher_disagreement_score":0.9920879,"about_ca_system_score_codex":0.0018837987,"about_ca_system_score_gemma":0.008412918,"threshold_uncertainty_score":0.999757},"labels":[],"label_agreement":null},{"id":"W4414553066","doi":"10.3390/biomedicines13102351","title":"Tumour SNPs Associated with Immune-Related Hepatitis in Patients with Melanoma Receiving Immune Checkpoint Inhibitors","year":2025,"lang":"en","type":"article","venue":"Biomedicines","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Universidad Europea de Madrid","keywords":"Genotype; Single-nucleotide polymorphism; Genotyping; SNP; Melanoma; Hepatitis; Allele; Hepatitis C","score_opus":0.0045501593037339475,"score_gpt":0.21757156022685367,"score_spread":0.21302140092311972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414553066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928547,0.0021563235,0.00001702902,0.0020502412,0.00054199185,0.00088597526,0.000012848778,0.00012590959,0.0013549405],"genre_scores_gemma":[0.9982216,0.0001210361,0.000080258076,0.00023711442,0.000051209347,0.00005164254,0.00024104939,0.000041459833,0.00095464155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784416,0.00006398381,0.00083205366,0.00039372212,0.0004444466,0.0004216221],"domain_scores_gemma":[0.9989546,0.000093116265,0.0003038442,0.00034234277,0.00022373805,0.00008234427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046576414,0.00032766227,0.00066807284,0.0006253133,0.000103347724,0.000021283095,0.00013422933,0.00019271534,0.00013076942],"category_scores_gemma":[0.00016824588,0.00021612606,0.00010804049,0.001971834,0.00031100996,0.00010777544,0.00004142908,0.00029256137,0.000006188029],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028720966,0.00045081243,0.9693663,0.000096505144,0.0006360515,0.00005894443,0.00035139185,8.024744e-7,0.016567716,0.0000067109754,0.00039151628,0.009201126],"study_design_scores_gemma":[0.015980408,0.0015764472,0.9704968,0.004933486,0.00016870313,0.000008312723,0.00015800455,0.000034355882,0.005693077,0.000016855794,0.0006794657,0.00025413034],"about_ca_topic_score_codex":0.0026257746,"about_ca_topic_score_gemma":0.0008457632,"teacher_disagreement_score":0.013108311,"about_ca_system_score_codex":0.00042129107,"about_ca_system_score_gemma":0.00025390706,"threshold_uncertainty_score":0.8813365},"labels":[],"label_agreement":null},{"id":"W4414565022","doi":"10.1093/ndt/gfaf191","title":"Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors–related AKI","year":2025,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University Health Network; University of Toronto; London Health Sciences Centre; Lawson Health Research Institute; Sunnybrook Health Science Centre; Western University","funders":"Schulich School of Medicine and Dentistry; Ontario Ministry of Health and Long-Term Care; Academic Medical Organization of Southwestern Ontario; Lawson Health Research Institute","keywords":"Cancer; Immune checkpoint; MEDLINE; Risk assessment; Kidney cancer; Immune system","score_opus":0.008728560338538315,"score_gpt":0.2880612367116571,"score_spread":0.2793326763731188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414565022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913662,0.00055932085,0.00028811494,0.006882882,0.00025458593,0.0003684149,0.000016454967,0.000034032866,0.00022997979],"genre_scores_gemma":[0.9918002,0.0045618936,0.00018728233,0.0030944864,0.000015033102,0.00007893989,0.00017195166,0.000009699417,0.000080526435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880725,0.00010752483,0.000529289,0.00025477863,0.00011941848,0.0001817263],"domain_scores_gemma":[0.99948174,0.00017539342,0.00013491674,0.00010435383,0.00007939012,0.000024226603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025165267,0.00014308633,0.0003394106,0.00031379817,0.000060360835,0.000012626905,0.00004135353,0.00017330788,0.00004337733],"category_scores_gemma":[0.000040902712,0.00012716712,0.00008401594,0.00036288906,0.000057704827,0.00015202312,0.000008190599,0.00016976031,0.0000023407163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026071374,0.00021702526,0.9606033,0.00018001146,0.000715059,0.000020575617,0.0021819063,0.000009411059,0.014325989,0.000049346367,0.000014926725,0.019075328],"study_design_scores_gemma":[0.0066897967,0.000096691176,0.9845657,0.00018245804,0.00057843566,0.0000072297294,0.000108798435,0.00004218905,0.006844445,0.000036834917,0.00073331513,0.0001141282],"about_ca_topic_score_codex":0.002179291,"about_ca_topic_score_gemma":0.0014915868,"teacher_disagreement_score":0.023962395,"about_ca_system_score_codex":0.0001388051,"about_ca_system_score_gemma":0.00010246122,"threshold_uncertainty_score":0.51857245},"labels":[],"label_agreement":null},{"id":"W4414568013","doi":"10.1016/b978-0-128-24465-4.00514-7","title":"Personalized Immunotherapy Targeting the Cancer Mutanome","year":2016,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; BC Cancer Agency","funders":"","keywords":"Immunotherapy; Cancer; Epitope; Major histocompatibility complex; DNA sequencing; Immune system; Cancer immunotherapy; Mutation","score_opus":0.017198142251058087,"score_gpt":0.2708084778627952,"score_spread":0.2536103356117371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414568013","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001419059,0.060290225,0.0000046156038,0.0026406802,0.00085111306,0.0010954913,0.00009500298,0.00010394943,0.934777],"genre_scores_gemma":[0.00065992237,0.008756519,0.000074962016,0.00477236,0.001503376,0.00015762761,0.000018104412,0.00020494108,0.9838522],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997816,0.00004075695,0.0005998216,0.0005653183,0.0005309538,0.00044709764],"domain_scores_gemma":[0.99845797,0.00008906843,0.00039871104,0.0007939059,0.00015354417,0.00010680657],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048165466,0.0005767618,0.000774394,0.000118139294,0.0002512265,0.000048629263,0.00037030232,0.00038389725,0.008351494],"category_scores_gemma":[0.000011284168,0.00031605162,0.000777084,0.000019941204,0.00058060145,0.000031148353,0.00006382942,0.0005516365,0.00017016896],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013092828,0.00000770113,0.000016403845,0.00008168616,0.0011895192,0.000036775076,0.0005072756,1.4378733e-8,0.009614125,0.0014031299,0.0012233609,0.98461074],"study_design_scores_gemma":[0.0025610852,0.000121705474,0.000043165473,0.0014371799,0.00024268977,0.00006315106,0.000023300028,6.6726017e-7,0.000380737,0.0012342652,0.9934441,0.00044799194],"about_ca_topic_score_codex":0.000004259936,"about_ca_topic_score_gemma":0.000012253581,"teacher_disagreement_score":0.9922207,"about_ca_system_score_codex":0.00040360112,"about_ca_system_score_gemma":0.00046284878,"threshold_uncertainty_score":0.99992913},"labels":[],"label_agreement":null},{"id":"W4414568095","doi":"10.1101/2025.09.24.676875","title":"Reinvigoration of translational activity in dysfunctional T cells initiates the early intratumoral response to PD-1 blockade","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Oncode Institute; Ministerie van Volksgezondheid, Welzijn en Sport; Melanoma Research Alliance","keywords":"Effector; Blockade; Immune system; Cytotoxic T cell; T cell; CD8; Dysfunctional family; Immunity; Immunotherapy","score_opus":0.015657747275057872,"score_gpt":0.24558345326157607,"score_spread":0.2299257059865182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414568095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929002,0.000421586,0.0006426736,0.0036030533,0.0007727925,0.0011642729,0.00040967733,0.000070706454,0.000015041395],"genre_scores_gemma":[0.99795353,0.0000758664,0.0010612115,0.00043493605,0.00022182407,0.00019246995,8.9261204e-7,0.000033502572,0.000025786732],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997741,0.00032264172,0.00057968847,0.0005727987,0.00048574316,0.00029814948],"domain_scores_gemma":[0.9982986,0.0002661839,0.00026662738,0.00068962877,0.00037042258,0.00010855865],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00120087,0.00034702802,0.0004965922,0.0004771054,0.000091173184,0.000057453653,0.0002541952,0.00037465748,0.00007091507],"category_scores_gemma":[0.00015424562,0.00030670158,0.00018905126,0.000908382,0.00014998605,0.00010103712,0.000101539925,0.000747399,0.000008053951],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011947685,0.00022446984,0.010186883,0.0002518344,0.00018993019,0.000018927387,0.00006319292,0.00019682747,0.9765971,0.00007932136,0.00023224055,0.000011587594],"study_design_scores_gemma":[0.001056287,0.00015081956,0.54653263,0.0005216192,0.00007269026,1.496307e-8,0.0000028017887,0.00015879094,0.45021302,0.0000027777537,0.001088221,0.00020033045],"about_ca_topic_score_codex":0.000219413,"about_ca_topic_score_gemma":0.000021151398,"teacher_disagreement_score":0.5363457,"about_ca_system_score_codex":0.00029388056,"about_ca_system_score_gemma":0.0018359206,"threshold_uncertainty_score":0.9999385},"labels":[],"label_agreement":null},{"id":"W4414703658","doi":"10.1186/s41927-025-00528-5","title":"Immune checkpoint inhibitor associated vasculitis and polymyalgia rheumatica: a case series and systematic review","year":2025,"lang":"en","type":"review","venue":"BMC Rheumatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Western University; University of Calgary; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Vasculitis; Polymyalgia rheumatica; Immune system; Nivolumab; Disease; Cutaneous Vasculitis; Immunotherapy; Clinical trial","score_opus":0.019640707616744572,"score_gpt":0.30035621618356556,"score_spread":0.280715508566821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414703658","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013496958,0.9945774,0.000011492269,0.00019782205,0.00033604042,0.004430197,0.000082850296,0.000113917034,0.000115307295],"genre_scores_gemma":[0.000040287756,0.9974656,0.0001677927,0.00009756683,0.000008409549,0.00085654843,0.000143196,0.00006113701,0.0011594241],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9953084,0.00087917724,0.0025125984,0.00064125174,0.00020926757,0.00044928468],"domain_scores_gemma":[0.9968989,0.0009544656,0.0011020002,0.00077094574,0.0001147555,0.00015893075],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011869705,0.0007209509,0.0080843475,0.00030650647,0.0001806338,0.000051991057,0.00013867705,0.00065280293,0.000098084034],"category_scores_gemma":[0.0021417239,0.0005263709,0.00079748826,0.00051111897,0.00036414232,0.00007744438,0.00018683154,0.00043211578,0.000017540879],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005624972,0.000051677453,0.000021638534,0.97950476,0.0017516442,0.00041559042,0.000076176184,4.699462e-10,3.7317142e-7,0.000116893854,0.0003758437,0.017629169],"study_design_scores_gemma":[0.0012650294,0.0001760705,0.0000073410556,0.8510893,0.0066049574,0.13015996,0.000091568916,0.0000015781447,7.140244e-7,0.000012920349,0.010202994,0.00038758817],"about_ca_topic_score_codex":0.00029789552,"about_ca_topic_score_gemma":0.00011112229,"teacher_disagreement_score":0.12974437,"about_ca_system_score_codex":0.00019563265,"about_ca_system_score_gemma":0.0007614205,"threshold_uncertainty_score":0.9997188},"labels":[],"label_agreement":null},{"id":"W4414710091","doi":"10.1016/j.esmoop.2025.105598","title":"20MO Hallmarks of gut health influence toxicity and survival outcomes after immune-checkpoint inhibitors","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Toxicity; Disease; Immune system; Population; Clinical trial","score_opus":0.014115074469789716,"score_gpt":0.3278406466024053,"score_spread":0.3137255721326156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414710091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98275566,0.0013497339,0.000018245597,0.009253577,0.0002782352,0.0006951787,0.000013728894,0.000016523201,0.0056190914],"genre_scores_gemma":[0.99416184,0.00033526172,0.0002977297,0.0026709884,0.00001633392,0.000036761066,0.000007283818,0.00000996056,0.0024638074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988117,0.000073699455,0.00052214536,0.00023545485,0.00015954553,0.00019744913],"domain_scores_gemma":[0.9993033,0.0000688637,0.00014209721,0.00035684276,0.00005999777,0.00006892865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007699479,0.00014150405,0.0005273586,0.00009039519,0.00006334346,0.000035852772,0.00018366288,0.000075549986,0.0001743428],"category_scores_gemma":[0.00007962203,0.00011153697,0.00010481031,0.00019404068,0.00015052459,0.00013168245,0.0002638638,0.00014313594,0.0000032476428],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004017963,0.00032854604,0.9593943,0.0004288356,0.00042672243,0.0000147033725,0.0009663315,0.0000011379203,0.0074488884,0.00021433548,0.0018302602,0.02492798],"study_design_scores_gemma":[0.0028221023,0.00017925417,0.97982144,0.00047459264,0.000023813473,0.00000389561,0.00018665123,0.0000040145446,0.007723419,0.00008667477,0.008573982,0.000100140685],"about_ca_topic_score_codex":0.0138024045,"about_ca_topic_score_gemma":0.0014835183,"teacher_disagreement_score":0.02482784,"about_ca_system_score_codex":0.000093380884,"about_ca_system_score_gemma":0.00029928618,"threshold_uncertainty_score":0.9927648},"labels":[],"label_agreement":null},{"id":"W4414710139","doi":"10.1016/j.esmoop.2025.105597","title":"19MO Desaminotyrosine is a key driver of the success of immunotherapy with fecal microbial transplantation in cancer","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; London Health Sciences Centre","funders":"","keywords":"Immunotherapy; Cancer; Fecal bacteriotherapy; Transplantation; Key (lock); Cancer immunotherapy","score_opus":0.013192074235955316,"score_gpt":0.3068517226223231,"score_spread":0.29365964838636777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414710139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950184,0.0005117477,0.00007334929,0.002263821,0.00011461058,0.000735803,0.00004572355,0.0000036047602,0.00123292],"genre_scores_gemma":[0.99666756,0.0007453194,0.00020804386,0.0010884675,0.000011011974,0.000034984198,0.00000947203,0.0000090373505,0.0012261028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993595,0.000039999435,0.0002435732,0.00013738441,0.00011617764,0.00010339509],"domain_scores_gemma":[0.99959445,0.0000257543,0.000098990466,0.00021244596,0.00005748404,0.000010867263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013409992,0.00009103977,0.00024930187,0.00006983917,0.000031040498,0.0000115376715,0.0002540951,0.00005556393,0.0003327977],"category_scores_gemma":[0.0000021525518,0.000056787645,0.000061340375,0.00040021894,0.00014715514,0.00007399257,0.00002392096,0.00008717894,3.706599e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02740349,0.00044103427,0.54946584,0.00039245875,0.00052326324,0.000008362146,0.0059937844,0.000021387252,0.38750988,0.00014241027,0.0016934456,0.026404671],"study_design_scores_gemma":[0.0063734427,0.000118164906,0.6289694,0.0010051847,0.000053716933,0.0000044624853,0.0000500451,0.000009755485,0.36093923,0.000011025903,0.0024108568,0.00005470535],"about_ca_topic_score_codex":0.029407807,"about_ca_topic_score_gemma":0.008272588,"teacher_disagreement_score":0.07950358,"about_ca_system_score_codex":0.00006974082,"about_ca_system_score_gemma":0.00029538714,"threshold_uncertainty_score":0.97705543},"labels":[],"label_agreement":null},{"id":"W4414751930","doi":"10.1016/j.ymthe.2025.09.047","title":"BiTE-secreting T cells rationally combine with PD-1 blockade and vaccine boosting to reshape antitumor immunity in ovarian cancer","year":2025,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"National Cancer Institute; Ovarian Cancer Research Alliance; U.S. Department of Defense; Ovarian Cancer Research Fund Alliance; Roswell Park Alliance Foundation, Roswell Park Cancer Institute; Roswell Park Cancer Institute","keywords":"Ovarian cancer; Immune system; Blockade; T cell; Myeloid-derived Suppressor Cell; Boosting (machine learning); Epitope; Cytotoxic T cell; Tumor microenvironment; Immunotherapy","score_opus":0.008522708736843989,"score_gpt":0.2740198302919888,"score_spread":0.2654971215551448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414751930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98544383,0.005385709,0.0010691163,0.0066392445,0.00007845587,0.00072105695,0.0000070661335,0.000032162257,0.0006233799],"genre_scores_gemma":[0.9900671,0.00072941394,0.0016022112,0.0070491093,0.000031947733,0.00006436874,0.000020447846,0.000027165552,0.0004081838],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989431,0.000078088946,0.0002743943,0.0002852585,0.00017756275,0.00024163036],"domain_scores_gemma":[0.9994564,0.000055198052,0.00006653815,0.0002661638,0.00008980641,0.00006589179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032962105,0.00018324133,0.00028778028,0.00023214478,0.00010583511,0.000039659135,0.000097688935,0.00006355801,0.00010625218],"category_scores_gemma":[0.000024845405,0.00015099155,0.000044813765,0.00063765765,0.00003527832,0.00003955217,0.00003451617,0.00020271356,0.0000015438526],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049176253,0.00010487922,0.020981174,0.000050548322,0.00017613545,0.00008284526,0.00030907508,0.00006695933,0.96613616,0.000083540515,0.00009305861,0.0069980253],"study_design_scores_gemma":[0.014595921,0.0007243413,0.23264067,0.001213032,0.00004923915,0.000024928462,0.00017351094,0.00042625924,0.74090517,0.000084867315,0.008826344,0.00033574345],"about_ca_topic_score_codex":0.0011462575,"about_ca_topic_score_gemma":0.00027734885,"teacher_disagreement_score":0.22523098,"about_ca_system_score_codex":0.000087040076,"about_ca_system_score_gemma":0.00018950186,"threshold_uncertainty_score":0.61572564},"labels":[],"label_agreement":null},{"id":"W4414799658","doi":"10.1093/neuonc/noaf193.014","title":"JS07.6.A AGE-APPROPRIATE MODELS OF PAEDIATRIC BRAIN TUMOURS REVEAL THE INFLUENCE OF AGE ON TUMOUR-IMMUNE INTERACTION.","year":2025,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill Genome Centre; Jewish General Hospital","funders":"","keywords":"Immune system; CD8; Tumor microenvironment; Juvenile; Immunotherapy; Cytotoxic T cell; Major histocompatibility complex; Cancer; Genetically modified mouse","score_opus":0.01980280638120635,"score_gpt":0.30412466016659784,"score_spread":0.2843218537853915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414799658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809816,0.00054274,0.000048608905,0.010609796,0.0006854975,0.0006302315,0.0000112931775,0.00003567726,0.006454556],"genre_scores_gemma":[0.9937625,0.00041867694,0.00010212254,0.005111136,0.00009063148,0.00004511845,0.00000791076,0.000018959827,0.00044297823],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981845,0.00034165257,0.00070688885,0.00029005395,0.00022882072,0.00024806889],"domain_scores_gemma":[0.9978924,0.0010602614,0.00041019346,0.00046590425,0.00012590417,0.00004534512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059255864,0.00018239196,0.00056972733,0.00028008936,0.00006614518,0.0000074696804,0.0002877462,0.00015597994,0.000033490585],"category_scores_gemma":[0.00039579283,0.00013008577,0.0002302217,0.00061345665,0.00032617155,0.00007399718,0.0000903276,0.00051276345,0.0000058738183],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063365726,0.00036415184,0.000499415,0.00014160396,0.00012238508,0.00014336455,0.00074823765,0.0014254276,0.96325463,0.0005263679,0.0053533223,0.021084545],"study_design_scores_gemma":[0.031165127,0.017614221,0.32613915,0.0013995484,0.0012767882,0.00058226526,0.002189149,0.0019462793,0.4662622,0.0072765583,0.14323686,0.0009118732],"about_ca_topic_score_codex":0.00028423694,"about_ca_topic_score_gemma":0.000033500633,"teacher_disagreement_score":0.4969924,"about_ca_system_score_codex":0.00017542203,"about_ca_system_score_gemma":0.00039862504,"threshold_uncertainty_score":0.5304744},"labels":[],"label_agreement":null},{"id":"W4414813522","doi":"10.1007/s10120-025-01660-4","title":"Comparative efficacy and safety of tislelizumab and other programmed cell death protein 1 inhibitors in first-line treatment of advanced gastroesophageal cancers: a systematic review and network meta-analysis","year":2025,"lang":"en","type":"review","venue":"Gastric Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Pembrolizumab; Nivolumab; Chemotherapy; Programmed cell death 1; Adverse effect; Incidence (geometry); Surgical oncology; Gastroesophageal Junction","score_opus":0.06392817142680882,"score_gpt":0.3591512268560754,"score_spread":0.29522305542926663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414813522","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017201433,0.9871331,0.000026164576,0.00004794819,0.00002630392,0.012165422,0.0003818796,0.000011634807,0.00003557611],"genre_scores_gemma":[0.0011097479,0.99408245,0.000596319,0.000045150347,0.000036155034,0.0037204288,0.000052315263,0.000028268341,0.0003291847],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99670744,0.00032794187,0.0017390428,0.0006193324,0.00026147914,0.0003447657],"domain_scores_gemma":[0.99772054,0.00028378554,0.0013347161,0.0004431418,0.00010052404,0.00011728111],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038155032,0.0006341002,0.010146487,0.00040007755,0.00004544613,0.000012909908,0.00008887127,0.00015181495,0.000074863085],"category_scores_gemma":[0.000025998452,0.0004023349,0.0009504655,0.0018321262,0.00016337565,0.000035005603,0.00004515752,0.0001624002,1.4871567e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008413302,0.00027003736,0.00011043319,0.8281017,0.068293065,0.00001200321,0.00023603477,0.000043944823,0.0000012321502,0.0000021468688,0.00003581833,0.10205223],"study_design_scores_gemma":[0.0061656623,0.0018137501,0.00011522275,0.29172826,0.6801607,0.000033384105,0.000045935085,0.000020342426,0.000011779024,0.0000015994616,0.019518323,0.0003850477],"about_ca_topic_score_codex":0.0013516423,"about_ca_topic_score_gemma":0.0011467579,"teacher_disagreement_score":0.6118676,"about_ca_system_score_codex":0.00059964595,"about_ca_system_score_gemma":0.00055095105,"threshold_uncertainty_score":0.9998428},"labels":[],"label_agreement":null},{"id":"W4414813924","doi":"10.2196/70553","title":"Unpacking Genomic Biomarkers for Programmed Cell Death Receptor-1 Immunotherapy Success in Non–Small Cell Lung Cancer Using Deep Neural Networks: Quantitative Study","year":2025,"lang":"en","type":"article","venue":"JMIR Bioinformatics and Biotechnology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immunotherapy; Lung cancer; Cancer immunotherapy; Biomarker; Gene; Cancer; PD-L1; Cell","score_opus":0.01774519493910206,"score_gpt":0.31694999156510784,"score_spread":0.2992047966260058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414813924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9721988,0.005088315,0.016638495,0.00060911704,0.00034543537,0.004928455,0.000019382165,0.00009498207,0.00007704949],"genre_scores_gemma":[0.9768049,0.0016861507,0.02039438,0.00044080112,0.000030186658,0.00051956053,0.000035197427,0.00003768111,0.000051142833],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9981607,0.000035770485,0.00076713465,0.00033748313,0.000105107916,0.00059379754],"domain_scores_gemma":[0.99909985,0.0000922378,0.00032527855,0.0003387396,0.00008890473,0.00005498738],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039793618,0.00034917827,0.00057484495,0.00069581275,0.00019644953,0.000084935076,0.00024241737,0.00046026683,0.000010246933],"category_scores_gemma":[0.000010707176,0.00029363457,0.0001340673,0.0008734813,0.00019625487,0.000114485156,0.00010938524,0.00034215298,3.8337154e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012092904,0.002061065,0.36511588,0.003348713,0.0018221193,0.000025402162,0.007784666,0.00079329096,0.14466132,0.00018674343,0.00028266147,0.46182525],"study_design_scores_gemma":[0.014765832,0.0017837513,0.017747374,0.00036090493,0.00020828913,0.0000114029,0.010063016,0.94421834,0.00918669,0.000020038771,0.0010785068,0.0005558426],"about_ca_topic_score_codex":0.00056689663,"about_ca_topic_score_gemma":0.00038506667,"teacher_disagreement_score":0.94342506,"about_ca_system_score_codex":0.00030643665,"about_ca_system_score_gemma":0.00013721845,"threshold_uncertainty_score":0.9999516},"labels":[],"label_agreement":null},{"id":"W4414890034","doi":"10.1007/978-3-032-00773-5_316","title":"Advancing Cancer Immunotherapy Through Integrating Molecular and Computational Approaches","year":2025,"lang":"en","type":"book-chapter","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Immunotherapy; Cancer immunotherapy; Context (archaeology); Modalities; Personalized medicine; Precision medicine; Scope (computer science); Profiling (computer programming)","score_opus":0.02494767725680407,"score_gpt":0.28662845054673436,"score_spread":0.2616807732899303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414890034","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045385532,0.058065534,0.025380235,0.0034487518,0.00030365208,0.0009088978,0.00004283316,0.00022808867,0.91116816],"genre_scores_gemma":[0.010810412,0.01325353,0.07911431,0.013718651,0.00039948447,0.00013594124,0.00035958947,0.00031288306,0.8818952],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988265,0.000010212695,0.00035705644,0.00039089928,0.00023426073,0.00018105198],"domain_scores_gemma":[0.99945796,0.00007506803,0.00014014631,0.00020472359,0.00008302282,0.00003906322],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010720597,0.00033457568,0.00048502724,0.00010666543,0.00006753737,0.0000325518,0.00006884013,0.00023548162,0.00056779484],"category_scores_gemma":[0.000007307352,0.00027225394,0.00018923375,0.000041612493,0.00014593001,0.00005924014,0.00003655863,0.00033497144,0.0000017675576],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017835476,0.00006449931,0.00017817675,0.0008464159,0.003508638,0.00006537802,0.00094285473,0.000101040074,0.005237126,0.29456842,0.008043571,0.6846603],"study_design_scores_gemma":[0.007102589,0.000428774,0.00025945326,0.0061919736,0.00061240897,0.00016900094,0.0004950646,0.0024025035,0.0030790893,0.044917077,0.93293774,0.0014042978],"about_ca_topic_score_codex":0.00024292385,"about_ca_topic_score_gemma":0.000054192176,"teacher_disagreement_score":0.9248942,"about_ca_system_score_codex":0.00018972771,"about_ca_system_score_gemma":0.00034290535,"threshold_uncertainty_score":0.99997294},"labels":[],"label_agreement":null},{"id":"W4414904246","doi":"10.1016/j.esmoop.2025.105846","title":"Critical insights on real-life PD-L1 histopathological workflow and assessment in esophageal, esophagogastric junction, and gastric carcinoma in Italy","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Ministero della Salute","keywords":"Workflow; Reliability (semiconductor); Cancer; Selection (genetic algorithm); Clinical Practice; Patient care","score_opus":0.026522509209520297,"score_gpt":0.34086700075067344,"score_spread":0.3143444915411531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414904246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98159033,0.0017949201,0.000048418024,0.003373333,0.0002243523,0.0006605395,0.0000025291104,0.00001846022,0.0122871185],"genre_scores_gemma":[0.9961422,0.00057251495,0.0006058345,0.0017967619,0.000040411658,0.000086517,0.000011943316,0.000010323044,0.0007335127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986127,0.0001492674,0.0003649913,0.00046238053,0.00016250298,0.00024816653],"domain_scores_gemma":[0.9993783,0.0001938204,0.000039603456,0.00023386245,0.000037309648,0.00011708039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041054765,0.00017896076,0.00040240277,0.0004152241,0.00008287516,0.00008180168,0.0001255251,0.00013853714,0.00010506021],"category_scores_gemma":[0.00016963847,0.0001473041,0.000035429573,0.00067691854,0.00016519282,0.00014600699,0.00014494828,0.00038038593,0.0000031958198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043129222,0.0007262321,0.95967853,0.000106283405,0.000032249303,0.0011794819,0.0003385967,0.0000039769952,0.00025889894,0.004495197,0.0023699515,0.026497703],"study_design_scores_gemma":[0.0045071105,0.00063284254,0.9922869,0.0002055713,0.000029382883,0.000050278453,0.00016529343,0.00014549213,0.0000455957,0.00039715422,0.0014265132,0.00010784344],"about_ca_topic_score_codex":0.0015595641,"about_ca_topic_score_gemma":0.0003629037,"teacher_disagreement_score":0.032608416,"about_ca_system_score_codex":0.00031343408,"about_ca_system_score_gemma":0.00034086514,"threshold_uncertainty_score":0.6006887},"labels":[],"label_agreement":null},{"id":"W4414907048","doi":"10.1158/2159-8290.cd-24-1213","title":"Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"European Commission; Israel Science Foundation; Melanoma Research Alliance; HORIZON EUROPE European Research Council; Israel Cancer Research Fund","keywords":"Prostate cancer; Immunotherapy; Acquired resistance; Receptor; Cancer; Antigen; Antibody; Chimeric antigen receptor","score_opus":0.015552155243449838,"score_gpt":0.29154342184336024,"score_spread":0.2759912665999104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414907048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8151155,0.18105143,0.000012262512,0.0012846516,0.0008608353,0.00085592427,0.00025285335,0.000027821823,0.00053868484],"genre_scores_gemma":[0.86571836,0.1233234,0.000024623756,0.0005600121,0.00004784724,0.00052158686,0.000049417995,0.000030433044,0.009724278],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99856126,0.0000678723,0.00040343855,0.00045562992,0.0001184449,0.0003933385],"domain_scores_gemma":[0.99940914,0.00006416222,0.00011964769,0.00029294938,0.00004538378,0.00006869266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013398631,0.00031677043,0.0005080516,0.00020598607,0.000088223685,0.00006628907,0.000083798775,0.000057512527,0.00015159756],"category_scores_gemma":[0.000008295552,0.00022190319,0.00017027852,0.00049904693,0.00016208919,0.00017091754,0.00003779579,0.00014317136,0.000002419473],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025717545,0.00097568956,0.075099476,0.0012057802,0.00239097,0.000067658686,0.0045102816,0.00004469065,0.31244415,0.00008161049,0.004014449,0.5734477],"study_design_scores_gemma":[0.04520298,0.0025559873,0.12636337,0.007033719,0.0015616791,0.000020944712,0.005941413,0.00033762638,0.41534242,0.0005145243,0.3935308,0.0015945561],"about_ca_topic_score_codex":0.0036681453,"about_ca_topic_score_gemma":0.002866895,"teacher_disagreement_score":0.57185316,"about_ca_system_score_codex":0.0008655322,"about_ca_system_score_gemma":0.00086157705,"threshold_uncertainty_score":0.90489495},"labels":[],"label_agreement":null},{"id":"W4414923280","doi":"10.3389/fonc.2025.1657282","title":"The effect of tislelizumab on complete and pathological complete response in non-small cell lung cancer: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Lanzhou University","keywords":"Chemotherapy; Pathological; Complete response; Lung; Lung cancer; Cell","score_opus":0.03995955632827896,"score_gpt":0.3655107284278476,"score_spread":0.32555117209956863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414923280","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000081349106,0.9923878,0.000058480575,0.000490749,0.00016991126,0.0064837853,0.00018053192,0.000007702488,0.00013969275],"genre_scores_gemma":[0.000073658324,0.9966075,0.00026324636,0.0005448153,0.000008759179,0.0020341345,0.00003202507,0.000018688954,0.00041719753],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9922757,0.0051299073,0.0015424928,0.0005623454,0.00017404403,0.0003154687],"domain_scores_gemma":[0.9941331,0.0043182033,0.00083008764,0.0006186196,0.000038337042,0.000061624094],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0043610847,0.0004801525,0.01247579,0.0006632427,0.000062795116,0.000012426702,0.00028152022,0.00039662197,0.00002446233],"category_scores_gemma":[0.00043529092,0.00024682152,0.0012936528,0.0010577721,0.0003128044,0.000011662985,0.00010776061,0.0005806099,5.705163e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003422046,0.00005874373,0.00015675345,0.9288722,0.03886744,0.00018210313,0.00007536919,8.5930697e-7,0.0000012438991,0.0000020933378,0.0020454982,0.026315613],"study_design_scores_gemma":[0.002698665,0.0029391109,0.00021401515,0.086881556,0.81026316,0.00007722017,0.00003515252,0.00007587361,4.681589e-7,0.0000033831225,0.09648973,0.00032168915],"about_ca_topic_score_codex":0.00009983608,"about_ca_topic_score_gemma":0.00013310273,"teacher_disagreement_score":0.8419907,"about_ca_system_score_codex":0.0006300436,"about_ca_system_score_gemma":0.00031928695,"threshold_uncertainty_score":0.9999984},"labels":[],"label_agreement":null},{"id":"W4414924557","doi":"10.1101/2025.10.07.680325","title":"Unveiling the temporal impact: Exploring dynamic changes in the paediatric solid tumour immune microenvironment through time","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université de Sherbrooke; Centre Hospitalier Universitaire Sainte-Justine; Centre hospitalier de l'Université Laval; McGill University Health Centre; Centre hospitalier universitaire de Québec","funders":"Fonds de Recherche du Québec - Santé; Fondation Charles-Bruneau; Université Laval","keywords":"Immune system; Transcriptome; Immunotherapy; Tumor microenvironment; T cell; Downregulation and upregulation; Tumour heterogeneity; Immune dysregulation; Acquired immune system","score_opus":0.01922835306527458,"score_gpt":0.2542863902035183,"score_spread":0.2350580371382437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414924557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97146523,0.021045297,0.00008734821,0.004053796,0.0009533691,0.0020057077,0.00020547284,0.0001652346,0.000018553805],"genre_scores_gemma":[0.99112105,0.0062467684,0.00045171112,0.0009326276,0.00049866945,0.0006159798,0.0000024930528,0.000095923344,0.000034763092],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99671924,0.000296903,0.000768567,0.00089176785,0.00055978197,0.0007637339],"domain_scores_gemma":[0.9974325,0.00016627822,0.00047165985,0.0017423935,0.00009423173,0.00009295909],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015299829,0.00074123946,0.0008505562,0.00032098294,0.00027059633,0.00016535234,0.0008929612,0.00037223927,0.0001222388],"category_scores_gemma":[0.00008354392,0.0004867563,0.00045219276,0.00096326385,0.00020782852,0.00012738987,0.00049759436,0.0014017274,0.000055822577],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008498622,0.0004625294,0.010881662,0.0008761015,0.00086908403,0.0002078913,0.0005910221,0.00018885071,0.9843472,0.000017352522,0.0006671431,0.000041247236],"study_design_scores_gemma":[0.004239412,0.00045871173,0.7912273,0.0031796794,0.00095212436,7.316521e-7,0.0002610906,0.0013673903,0.18586576,0.000004706972,0.0108243795,0.0016187365],"about_ca_topic_score_codex":0.00038993367,"about_ca_topic_score_gemma":0.000017161086,"teacher_disagreement_score":0.79848146,"about_ca_system_score_codex":0.001083197,"about_ca_system_score_gemma":0.000706648,"threshold_uncertainty_score":0.9997584},"labels":[],"label_agreement":null},{"id":"W4414928659","doi":"10.1007/s10198-025-01827-x","title":"Pembrolizumab vs. chemotherapy in the first-line setting of PD-L1 ≥ 50% metastatic non-small cell lung cancer: a real-world cost-effectiveness analysis","year":2025,"lang":"en","type":"article","venue":"The European Journal of Health Economics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Sunnybrook Hospital; University of Toronto; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Chemotherapy; Lung cancer; Lung; Immunotherapy; Survival analysis; Exploratory analysis","score_opus":0.026576715111655727,"score_gpt":0.32690748248087725,"score_spread":0.30033076736922154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414928659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97691286,0.005485328,0.0012472805,0.012912301,0.00025251613,0.0011818015,0.00001978269,0.000006228144,0.001981876],"genre_scores_gemma":[0.97831655,0.016893275,0.0002177053,0.0043024607,0.00012122465,0.000014032858,0.000004933089,0.00003097009,0.00009887748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968658,0.0011714939,0.0013782798,0.00017957579,0.00010602434,0.00029880676],"domain_scores_gemma":[0.997504,0.00058561284,0.0013477716,0.00040576802,0.00009611284,0.000060731265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008528274,0.00019479549,0.0009208935,0.00048874924,0.00014275157,0.000030263338,0.00042301984,0.00001755364,0.000032161686],"category_scores_gemma":[0.000020471729,0.00012162271,0.0003844969,0.00076479604,0.00007949873,0.00005825755,0.000033544704,0.0003961919,9.2655614e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06326852,0.0020189786,0.42982072,0.010675051,0.01365962,0.0001479373,0.029074311,0.07649965,0.0007266468,0.00016290651,0.0040389113,0.36990675],"study_design_scores_gemma":[0.013632651,0.00081387843,0.9684467,0.0021382722,0.0013063016,0.000046081077,0.0008088739,0.0057149814,0.000640495,0.000047896017,0.006208811,0.0001950623],"about_ca_topic_score_codex":0.001444447,"about_ca_topic_score_gemma":0.0022485896,"teacher_disagreement_score":0.53862596,"about_ca_system_score_codex":0.0005220789,"about_ca_system_score_gemma":0.0007837656,"threshold_uncertainty_score":0.495963},"labels":[],"label_agreement":null},{"id":"W4414933795","doi":"10.1097/mot.0000000000001254","title":"Use of molecular mismatch to guide induction therapy","year":2025,"lang":"en","type":"article","venue":"Current Opinion in Organ Transplantation","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Vancouver Coastal Health Research Institute; University of British Columbia","funders":"","keywords":"Genotyping; Compatibility (geochemistry); Immune system; Antibody therapy; Induction therapy; Selection (genetic algorithm)","score_opus":0.06139018206235605,"score_gpt":0.3660401430430476,"score_spread":0.3046499609806915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414933795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98400193,0.0016960631,0.010113548,0.0013361564,0.002142282,0.0005790038,0.000019403475,0.000028784892,0.00008283284],"genre_scores_gemma":[0.9828726,0.015622058,0.0007637713,0.00026958992,0.000066835746,0.000039336905,0.00027030194,0.000015260475,0.000080241334],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992381,0.00003850737,0.00031798705,0.00016188294,0.000136527,0.00010699567],"domain_scores_gemma":[0.99969727,0.000026564425,0.000047569745,0.0001343674,0.00006633316,0.00002788658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011457207,0.00008948259,0.0001410058,0.00028311822,0.00001954774,0.000009489197,0.000043406602,0.000054548556,0.000037812053],"category_scores_gemma":[0.000011823842,0.00008419785,0.00005126166,0.0005295416,0.000022068272,0.00007634639,0.0000030236629,0.00008196811,0.0000029446462],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038660357,0.00033843805,0.035940826,0.0011271527,0.000080773585,0.0000016727182,0.0018904047,0.00007659462,0.7220867,0.00040496766,0.0026131417,0.23157327],"study_design_scores_gemma":[0.004793576,0.0002775823,0.4093779,0.002639818,0.000039474264,0.00001345242,0.00014685739,0.00004027194,0.5270092,0.0000811799,0.05539844,0.00018223774],"about_ca_topic_score_codex":0.00009742448,"about_ca_topic_score_gemma":0.0000052884607,"teacher_disagreement_score":0.37343708,"about_ca_system_score_codex":0.00007231509,"about_ca_system_score_gemma":0.00009298007,"threshold_uncertainty_score":0.34334886},"labels":[],"label_agreement":null},{"id":"W4415069879","doi":"10.1016/j.jhepr.2025.101630","title":"Navigating second-line therapy after immunotherapy in advanced HCC☆","year":2025,"lang":"en","type":"article","venue":"JHEP Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Immunotherapy; Hepatocellular carcinoma; Clinical trial; Sorafenib; Disease; Systemic therapy; Tyrosine kinase; Therapeutic approach","score_opus":0.009116866115393253,"score_gpt":0.31641623419048914,"score_spread":0.3072993680750959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415069879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774215,0.015049063,0.000040482533,0.0012805264,0.0006750042,0.000636918,0.0000024477645,0.000082454186,0.004811571],"genre_scores_gemma":[0.99005026,0.0009769469,0.0005275,0.004448673,0.00008287231,0.00018521541,0.000019183353,0.000029605106,0.0036797242],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99838483,0.000032462343,0.00070311717,0.00039350253,0.00019240599,0.0002936957],"domain_scores_gemma":[0.99909,0.000042450596,0.0001852952,0.00057183043,0.00006696013,0.000043471144],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004197949,0.00020444187,0.00040260967,0.00008833343,0.000052875865,0.000025740228,0.00006168272,0.00012419395,0.0011778488],"category_scores_gemma":[0.000028354447,0.00017170724,0.00017942753,0.0004661024,0.000067956884,0.00010941205,0.000020358171,0.00034552813,0.0000042572865],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070402795,0.000405974,0.16859636,0.000102348306,0.00025171513,0.0017064301,0.0007768317,0.000005548826,0.17887853,0.000010917986,0.0005340038,0.6416911],"study_design_scores_gemma":[0.0076163895,0.00047563098,0.6597312,0.0014354115,0.000019819476,0.0004988309,0.0002512614,0.00004145798,0.0817659,0.00057728484,0.24717836,0.00040845812],"about_ca_topic_score_codex":0.00012589281,"about_ca_topic_score_gemma":0.00008610089,"teacher_disagreement_score":0.6412826,"about_ca_system_score_codex":0.00017235882,"about_ca_system_score_gemma":0.0001844481,"threshold_uncertainty_score":0.99973524},"labels":[],"label_agreement":null},{"id":"W4415113293","doi":"10.14309/crj.0000000000001847","title":"Refractory Immune Checkpoint Inhibitor Colitis Treated With Biologics, Janus Kinase Inhibition, Plasma Exchange, and Fecal Microbiota Transplantation","year":2025,"lang":"en","type":"article","venue":"ACG Case Reports Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Dalhousie University","funders":"","keywords":"Refractory (planetary science); Enterocolitis; Adverse effect; Fecal bacteriotherapy; Immune dysregulation; Vedolizumab; Colorectal cancer; Immune system; Ulcerative colitis","score_opus":0.010113429516820493,"score_gpt":0.25092248019294505,"score_spread":0.24080905067612457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415113293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940198,0.0037719072,0.00007600879,0.00078005326,0.0003077781,0.00039585825,0.000030411748,0.0000434185,0.0005747446],"genre_scores_gemma":[0.99469197,0.0037229434,0.00026391854,0.00025998973,0.0001779604,0.000016278138,0.00009723924,0.000018657116,0.00075104524],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.998473,0.00008060963,0.00072323304,0.00030072767,0.00015406152,0.00026836153],"domain_scores_gemma":[0.9989879,0.0000468413,0.00039144835,0.00020774355,0.00022025658,0.00014579366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051328435,0.00022723262,0.00035705307,0.0002579668,0.00027879392,0.00007377273,0.000017881583,0.00017956791,0.00013550464],"category_scores_gemma":[0.00004114543,0.00016437724,0.00012399307,0.0002622799,0.0002022099,0.00014235654,0.000014219744,0.00036895077,9.777241e-7],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009114745,0.0003545904,0.009378431,0.00039029212,0.0005541471,0.43010056,0.00052809267,8.5535925e-7,0.521784,0.0000041462517,0.0016909314,0.026099196],"study_design_scores_gemma":[0.005461028,0.00095741585,0.041521177,0.0011719138,0.00035182567,0.74244356,0.0003535156,0.000004781369,0.19860817,0.000020234475,0.008891325,0.00021504823],"about_ca_topic_score_codex":0.00035516656,"about_ca_topic_score_gemma":0.00014177784,"teacher_disagreement_score":0.32317582,"about_ca_system_score_codex":0.0002383124,"about_ca_system_score_gemma":0.00026519314,"threshold_uncertainty_score":0.670311},"labels":[],"label_agreement":null},{"id":"W4415273737","doi":"10.3389/fimmu.2025.1719075","title":"Editorial: Community series in immune responses against tumors - from the bench to the bedside, volume II","year":2025,"lang":"en","type":"editorial","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Immune system; Cancer; Immune checkpoint; Immunotherapy; Autoantibody; Lung cancer; Breast cancer; Antibody; Ipilimumab","score_opus":0.007259985025241081,"score_gpt":0.25658124776282315,"score_spread":0.24932126273758207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415273737","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015167368,0.025162727,0.000025039944,0.015201547,0.9417509,0.0014171146,0.00075258256,0.00008088255,0.00044185878],"genre_scores_gemma":[0.0013616086,0.008915629,0.00051630597,0.0013739312,0.9666689,0.0006415942,0.0020516037,0.000114799725,0.018355597],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940683,0.0024971669,0.0013108851,0.0006145863,0.0006794592,0.00082959153],"domain_scores_gemma":[0.99513197,0.0016462669,0.00040222312,0.0024792387,0.00028405033,0.000056259032],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.002949106,0.00067620195,0.0015956187,0.0006338156,0.00079339306,0.00008368464,0.0021189584,0.0017709765,0.00006632807],"category_scores_gemma":[0.0049380776,0.0004680788,0.00035397246,0.0012461961,0.0010162079,0.00013502507,0.001012866,0.0058768303,0.000015067001],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020097068,0.00019948937,0.0013318346,0.00004196152,0.0007411253,0.000028764212,0.004135313,0.0000051044076,0.0006052883,0.0000044379194,0.9667933,0.0060162963],"study_design_scores_gemma":[0.0033680578,0.00082256645,0.013468449,0.0010795571,0.00011907414,0.000003236304,0.005237043,0.0000033335125,0.00015059189,0.0002418916,0.9750932,0.00041302663],"about_ca_topic_score_codex":0.027294794,"about_ca_topic_score_gemma":0.0073998403,"teacher_disagreement_score":0.024918051,"about_ca_system_score_codex":0.0012607338,"about_ca_system_score_gemma":0.0021762757,"threshold_uncertainty_score":0.9997771},"labels":[],"label_agreement":null},{"id":"W4415280627","doi":"10.3390/ijms262010108","title":"Kinome-Wide Screening Identifies FAK as a Novel Post-Translational Regulator of PD-L1 Stability and Immune Evasion in Triple-Negative Breast Cancer","year":2025,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Focal adhesion; Regulator; Immune system; Immune checkpoint; Breast cancer; Blockade; Kinase; Cell","score_opus":0.016658270645152184,"score_gpt":0.3186201008663937,"score_spread":0.3019618302212415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415280627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848189,0.0027857872,0.0017872889,0.009813932,0.00037871063,0.00013446169,0.0000345577,0.000002636471,0.0002437287],"genre_scores_gemma":[0.9981792,0.00016795921,0.0011504628,0.00042031085,0.000026940821,0.0000026390069,0.000002005035,0.0000031975721,0.00004727805],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99840164,0.000047315007,0.000551354,0.00015843919,0.00073950965,0.000101737816],"domain_scores_gemma":[0.9987335,0.00014496905,0.0003144192,0.00006610773,0.00070416316,0.000036844584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008995897,0.00008971148,0.00021664232,0.0004606933,0.000046085424,0.00004438732,0.0002357935,0.000041726595,0.000106931875],"category_scores_gemma":[0.00020808198,0.000071339586,0.00013232775,0.0003625242,0.0004070109,0.00027261776,0.000040760493,0.00012607912,1.3337379e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049057696,0.00020077798,0.09020532,0.000036910125,0.00038258053,0.000031757547,0.0008047252,0.00015977885,0.8894696,0.00062142964,0.000013569493,0.0131677585],"study_design_scores_gemma":[0.003064345,0.00014702306,0.8364853,0.0008812205,0.00003507574,0.0001506487,0.0007892178,0.0002982233,0.15712447,0.00091442995,0.0000426487,0.000067366505],"about_ca_topic_score_codex":0.0009566188,"about_ca_topic_score_gemma":0.0001147131,"teacher_disagreement_score":0.74628,"about_ca_system_score_codex":0.000084788524,"about_ca_system_score_gemma":0.00058911886,"threshold_uncertainty_score":0.2909144},"labels":[],"label_agreement":null},{"id":"W4415313449","doi":"10.1056/nejmoa2504966","title":"Nivolumab for Resected Stage III or IV Melanoma at 9 Years","year":2025,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Nivolumab; Melanoma; Stage (stratigraphy); Immunotherapy; Overall survival","score_opus":0.024212305849784867,"score_gpt":0.3193465216509392,"score_spread":0.29513421580115434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415313449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9671668,0.0066842358,0.0011629482,0.019209182,0.001775648,0.00046677995,0.000009912906,0.000023732606,0.0035008024],"genre_scores_gemma":[0.8716748,0.0015615793,0.0009066916,0.002888823,0.0035802359,0.000004856033,0.000017858403,0.000026668715,0.119338535],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987182,0.000044504744,0.0005696383,0.00012692275,0.00033476128,0.00020596091],"domain_scores_gemma":[0.99885905,0.00032714516,0.00025144932,0.0001899874,0.00020125738,0.00017111935],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008090917,0.0001289729,0.0005199662,0.00028923343,0.000059873397,0.0000069724206,0.00012822884,0.00008647384,0.0012073653],"category_scores_gemma":[0.00042158432,0.00007746085,0.00012585877,0.00030176458,0.000103047285,0.000046327805,0.000019927087,0.00021724108,0.0000017043152],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12988646,0.00010293545,0.003323263,0.00020015375,0.0009232431,0.00052460085,0.0013107049,0.0000027344556,0.05909645,0.00010737303,0.35721692,0.44730514],"study_design_scores_gemma":[0.17730415,0.0046394872,0.015433806,0.0010038512,0.00029956922,0.00060116156,0.00029393955,0.000034243876,0.0025589569,0.00010573006,0.7976394,0.000085666295],"about_ca_topic_score_codex":0.00018504696,"about_ca_topic_score_gemma":0.0002852929,"teacher_disagreement_score":0.4472195,"about_ca_system_score_codex":0.00019502454,"about_ca_system_score_gemma":0.00050318596,"threshold_uncertainty_score":0.9997057},"labels":[],"label_agreement":null},{"id":"W4415346010","doi":"10.3389/fmed.2025.1649353","title":"Impact of glucocorticoid administration on therapeutic outcomes of immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Frontiers in Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Glucocorticoid; Immune system; Lung; Immunotherapy; Lung cancer; Glucocorticoid receptor; Cell","score_opus":0.03536524621330041,"score_gpt":0.37044857371657,"score_spread":0.3350833275032696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415346010","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014985529,0.99245507,0.00008238274,0.00031275905,0.0002029669,0.0066164257,0.00006338864,0.000006934366,0.00011019663],"genre_scores_gemma":[0.0025564716,0.9957737,0.00010414132,0.00019184474,0.000015245723,0.0006631705,0.00009362254,0.000031690797,0.0005701462],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.994746,0.00039785972,0.003667767,0.0004853938,0.00043814516,0.0002648316],"domain_scores_gemma":[0.99654895,0.00030891818,0.0021197456,0.00084723224,0.00010446109,0.000070712624],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0017176531,0.0006273886,0.017381087,0.0016630548,0.000013438895,0.0000045490597,0.00023142359,0.00027317746,0.00012192127],"category_scores_gemma":[0.00020232431,0.0003481074,0.0031045515,0.0023281458,0.00015287871,0.000031526983,0.000030623884,0.00043657908,2.3928268e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016033808,0.00019100051,0.003271081,0.87902933,0.110607915,0.000011645037,0.0001650481,0.0000019023543,0.0000075934,6.306255e-7,0.000155974,0.0063975165],"study_design_scores_gemma":[0.0015553948,0.0007143274,0.0017843777,0.26744506,0.727921,0.0000048802526,0.00010256921,0.000029100194,0.00001732166,0.0000018598732,0.00018489039,0.00023923052],"about_ca_topic_score_codex":0.0009631571,"about_ca_topic_score_gemma":0.000074765856,"teacher_disagreement_score":0.6173131,"about_ca_system_score_codex":0.00056708313,"about_ca_system_score_gemma":0.00079020014,"threshold_uncertainty_score":0.9998971},"labels":[],"label_agreement":null},{"id":"W4415383364","doi":"10.30683/1927-7229.2025.14.09","title":"Immune Evasion and Resistance in Cancer Progression: Overcoming Checkpoint Inhibition Challenges with Personalized Immunotherapy Guided by PD-L1 Expression","year":2025,"lang":"","type":"article","venue":"Journal of Analytical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immunotherapy; Immune checkpoint; Immune system; Cancer; Epigenetics; Biomarker; Evasion (ethics); Cancer immunotherapy; Tumor microenvironment","score_opus":0.03179083295147103,"score_gpt":0.36893797011637247,"score_spread":0.3371471371649014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415383364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5103214,0.43902972,0.00028413493,0.0459923,0.00053828966,0.00060556916,0.0000082060305,0.000010214686,0.003210167],"genre_scores_gemma":[0.74264055,0.25220978,0.0017500282,0.0011415088,0.00031714982,0.000030113773,0.0000050037675,0.00004402111,0.0018618432],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.995216,0.00064281194,0.0022625872,0.00054046407,0.00073701603,0.0006011275],"domain_scores_gemma":[0.99696857,0.00052377634,0.0014349412,0.00032245126,0.0005190819,0.00023119351],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002539477,0.00048116804,0.0018093605,0.00062463747,0.00018705061,0.00005470153,0.00020609052,0.00063213165,0.0005780265],"category_scores_gemma":[0.000208221,0.0003374457,0.000450219,0.0006829639,0.0008519287,0.00031815984,0.00008647035,0.0012043049,8.80425e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27242562,0.0040416503,0.0037665071,0.0017480796,0.002732085,0.0012444988,0.0058947564,0.000008243496,0.5508406,0.0008108886,0.01278113,0.14370589],"study_design_scores_gemma":[0.18105525,0.025111705,0.1131336,0.102841444,0.0030349588,0.0013007364,0.012452584,0.0008972315,0.0963231,0.002279893,0.45971966,0.0018498517],"about_ca_topic_score_codex":0.00007725015,"about_ca_topic_score_gemma":0.00016869011,"teacher_disagreement_score":0.45451754,"about_ca_system_score_codex":0.0020450733,"about_ca_system_score_gemma":0.001624378,"threshold_uncertainty_score":0.99990773},"labels":[],"label_agreement":null},{"id":"W4415438746","doi":"10.51731/cjht.2025.1261","title":"Nivolumab Plus Ipilimumab (Opdivo Plus Yervoy)","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ipilimumab; Nivolumab; Colorectal cancer; Microsatellite instability; Drug; Metastatic melanoma; Systemic therapy; Disease","score_opus":0.024514835644645905,"score_gpt":0.30273002263953375,"score_spread":0.27821518699488784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415438746","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036131073,0.7716913,0.0008075512,0.18088555,0.0060358327,0.0010866384,0.0000867602,0.0001765499,0.003098744],"genre_scores_gemma":[0.9684234,0.022892468,0.00034262842,0.0044599427,0.00008055366,0.000013738741,0.0000050017125,0.00004704012,0.0037352187],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99464595,0.00020253594,0.0024779735,0.00047066624,0.00045691043,0.0017459472],"domain_scores_gemma":[0.9964507,0.00017549406,0.0014403249,0.000994908,0.00059825805,0.00034027136],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020412495,0.0005445104,0.0017319742,0.0032088237,0.0009690822,0.00015432529,0.0012893671,0.0008460782,0.0004068838],"category_scores_gemma":[0.0010521811,0.00050524075,0.0005295792,0.002091069,0.001443902,0.00024734554,0.00008613549,0.0020253884,0.000031963384],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0015176369,0.000050825125,0.0014303668,0.0012590368,0.00084893504,0.00066236255,0.00093054184,0.00003323968,0.00009171468,0.0013938824,0.0661473,0.92563415],"study_design_scores_gemma":[0.012729748,0.0027581386,0.006779752,0.009676116,0.00023935291,0.00076807255,0.023762716,0.00014500723,0.00087807083,0.0023077964,0.93942696,0.0005282419],"about_ca_topic_score_codex":0.035187677,"about_ca_topic_score_gemma":0.02550165,"teacher_disagreement_score":0.93229234,"about_ca_system_score_codex":0.010238504,"about_ca_system_score_gemma":0.068845116,"threshold_uncertainty_score":0.99973994},"labels":[],"label_agreement":null},{"id":"W4415444243","doi":"10.1158/1535-7163.targ-25-c072","title":"Abstract C072: Comparing and combining existing radiological criteria for hyperprogressive disease in patients receiving immune-oncology therapy: Building towards a sensitive and conservative method to assess the presence of hyperprogressive disease","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Queen's University; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre","funders":"","keywords":"Radiological weapon; Disease; Incidence (geometry); Cancer; Lung cancer; Colorectal cancer","score_opus":0.08760377124632727,"score_gpt":0.41821971517671414,"score_spread":0.33061594393038685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97320765,0.016546166,0.005717284,0.0023017253,0.00017290456,0.0019089967,0.000055342898,0.000021760461,0.00006814419],"genre_scores_gemma":[0.9897471,0.00082774414,0.0066242195,0.0023492987,0.000024989155,0.00037824333,0.00001505672,0.000026282909,0.000007037976],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981421,0.00038263758,0.00047334784,0.0004660205,0.00019784164,0.00033804093],"domain_scores_gemma":[0.99825335,0.0007947812,0.00026106043,0.00025151123,0.0003088732,0.00013041116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006919931,0.00027175507,0.00062831753,0.0001250127,0.00017376512,0.000052067608,0.00014667037,0.00009777168,0.0000031258837],"category_scores_gemma":[0.00024320316,0.00019811392,0.00011437804,0.00031049785,0.00036703356,0.00006436008,0.00012667921,0.00022657978,3.730758e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029609168,0.00044397137,0.33658114,0.00053578033,0.0012900103,0.00010312117,0.0047742287,0.0001538642,0.19834058,0.0003544815,0.000015216489,0.42779842],"study_design_scores_gemma":[0.006493025,0.00055499293,0.9627966,0.0022158986,0.000346604,0.0000045014276,0.00096637884,0.0059011886,0.019073538,0.00036553762,0.0009739789,0.00030774888],"about_ca_topic_score_codex":0.00013819791,"about_ca_topic_score_gemma":0.000009308193,"teacher_disagreement_score":0.62621546,"about_ca_system_score_codex":0.0001766194,"about_ca_system_score_gemma":0.00037384377,"threshold_uncertainty_score":0.80788517},"labels":[],"label_agreement":null},{"id":"W4415519280","doi":"10.1016/j.jtho.2025.09.124","title":"MA04.04 Perioperative Pembrolizumab in Non-Small Cell Cancer (NSCLC): 4-Year Outcomes by Nodal Status in the KEYNOTE-671 Study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Pembrolizumab; NODAL; Perioperative; Cancer; Squamous cell cancer","score_opus":0.016777693247040492,"score_gpt":0.4030823295487934,"score_spread":0.38630463630175293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98143286,0.0024859936,0.000032948188,0.009975531,0.0007727676,0.00078435417,0.00001334879,0.0000051627003,0.004497037],"genre_scores_gemma":[0.99352944,0.0007438085,0.00020388704,0.0032918563,0.000097072305,0.000046573645,0.0000022236113,0.000016278467,0.0020688905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768233,0.00054481707,0.00086630933,0.0002160295,0.0002964192,0.00039407166],"domain_scores_gemma":[0.9988809,0.0002957364,0.00035524118,0.00023744153,0.00015705235,0.00007358465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001292474,0.00021711887,0.00080890907,0.00039882993,0.0000675735,0.00003319059,0.00030810913,0.00017310686,0.00019722396],"category_scores_gemma":[0.00007771227,0.00013416613,0.00018929833,0.00052928866,0.00011129528,0.00009320216,0.000051147475,0.00089729356,0.00000454433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033915777,0.0046110773,0.8364337,0.00012690047,0.00054513087,0.0010702026,0.022023516,0.00005177447,0.012034125,0.0000078708845,0.008107476,0.08107244],"study_design_scores_gemma":[0.016718172,0.0047580027,0.91446275,0.00026484687,0.00026540132,0.0000770598,0.028930563,0.00003691613,0.0012312217,0.000018283887,0.03304931,0.0001874886],"about_ca_topic_score_codex":0.0011939221,"about_ca_topic_score_gemma":0.0033679705,"teacher_disagreement_score":0.08088495,"about_ca_system_score_codex":0.0010800414,"about_ca_system_score_gemma":0.0014336384,"threshold_uncertainty_score":0.5471136},"labels":[],"label_agreement":null},{"id":"W4415519518","doi":"10.1016/j.jtho.2025.09.1419","title":"EP.07.38 Immune Checkpoint Inhibitors May Not Fully Mitigate the Adverse Prognostic Impact of PD-L1 Expression in Early Lung Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Lung cancer; Adverse effect; Immune system; Immune checkpoint; Expression (computer science); Immunotherapy","score_opus":0.01477407890474573,"score_gpt":0.4031859119925588,"score_spread":0.3884118330878131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838642,0.007221729,0.000024177729,0.006560752,0.0009114264,0.0005033813,0.000010119054,0.00000787335,0.0008963574],"genre_scores_gemma":[0.99753094,0.00065168494,0.00026695474,0.00026103802,0.00023447469,0.000023265065,0.0000017675038,0.00001728137,0.0010126213],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976514,0.00031882356,0.0012491631,0.00016421375,0.00030270516,0.00031366805],"domain_scores_gemma":[0.9980454,0.0002972248,0.0010283942,0.00025648504,0.00027958083,0.000092902286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014340265,0.00020003534,0.00073435856,0.00039215194,0.00006242756,0.000010901654,0.0002433539,0.00022685205,0.0005970456],"category_scores_gemma":[0.00025930363,0.00011723704,0.00058796874,0.00048718095,0.00023284923,0.00014074214,0.00007243481,0.0006984879,0.0000038600947],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.068709806,0.00084062957,0.09867285,0.0004534522,0.0011830265,0.00050263695,0.002482357,0.0002165921,0.74552166,0.0000050228064,0.0038745073,0.07753748],"study_design_scores_gemma":[0.0040787067,0.0031604418,0.84091485,0.0035980535,0.0004738354,0.00031389846,0.00066845724,0.00011857261,0.1425441,0.000036611298,0.003940189,0.00015227549],"about_ca_topic_score_codex":0.00041126323,"about_ca_topic_score_gemma":0.000040755007,"teacher_disagreement_score":0.742242,"about_ca_system_score_codex":0.0010190763,"about_ca_system_score_gemma":0.0016680268,"threshold_uncertainty_score":0.65372306},"labels":[],"label_agreement":null},{"id":"W4415519763","doi":"10.1016/j.jtho.2025.09.045","title":"OA05.04 A Randomized Phase 3 Study of Niraparib Plus Pembrolizumab as Maintenance Therapy for Advanced/Metastatic NSCLC: ZEAL-1L","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Pembrolizumab; Maintenance therapy; Phases of clinical research; Antibody therapy; Phase (matter)","score_opus":0.028295237195804103,"score_gpt":0.45493130491482714,"score_spread":0.426636067719023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759851,0.007630679,0.005095289,0.005089845,0.0013742463,0.0032145593,0.000013397954,0.000016879421,0.0015799849],"genre_scores_gemma":[0.99009615,0.002101979,0.0032842394,0.0016968048,0.0001509111,0.00015418892,0.0000044706367,0.000028032999,0.0024831947],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99686116,0.00057748856,0.0016278712,0.0002442345,0.00034589416,0.00034332505],"domain_scores_gemma":[0.9961633,0.0012000527,0.0015068979,0.00032921796,0.0006861857,0.000114357485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026483142,0.0002569794,0.0022075016,0.000495034,0.000087563705,0.000014554063,0.0002792521,0.00012678279,0.00013860097],"category_scores_gemma":[0.0006833327,0.00017447163,0.0007261213,0.00043166766,0.00026950668,0.00012262318,0.000030067851,0.00037315703,0.0000017880803],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70469725,0.0032994829,0.000033733504,0.00014706363,0.0020429178,0.00013907904,0.0012834988,0.000022654835,0.008206297,0.000052283256,0.0029213582,0.2771544],"study_design_scores_gemma":[0.91002643,0.035739373,0.00032252102,0.00073088985,0.0017205368,0.0007838745,0.004994239,0.00029917926,0.005588886,0.0020928462,0.037489932,0.00021130264],"about_ca_topic_score_codex":0.000048417787,"about_ca_topic_score_gemma":0.000024293011,"teacher_disagreement_score":0.2769431,"about_ca_system_score_codex":0.0004918112,"about_ca_system_score_gemma":0.0017035389,"threshold_uncertainty_score":0.71147466},"labels":[],"label_agreement":null},{"id":"W4415519843","doi":"10.1016/j.jtho.2025.09.033","title":"OA02.03 Overall Survival (OS) with Neoadjuvant Nivolumab Plus Chemotherapy by Surgical Outcomes in the Phase 3 CheckMate 816 Study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Trinity College","funders":"","keywords":"Nivolumab; Overall survival; Chemotherapy; Phases of clinical research; Neoadjuvant therapy","score_opus":0.021321537285763765,"score_gpt":0.43101578009003844,"score_spread":0.4096942428042747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97534764,0.0012906906,0.000068257956,0.019529471,0.0006142589,0.0006558283,0.0000070568867,0.000013207295,0.002473619],"genre_scores_gemma":[0.994352,0.00043966385,0.00015885929,0.002585637,0.0001597414,0.000016909938,0.0000039483994,0.000020125037,0.0022631404],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99755454,0.0005414877,0.0008588619,0.0002259122,0.00048348898,0.0003357105],"domain_scores_gemma":[0.9985824,0.00038429143,0.0004769546,0.00032488606,0.00014773093,0.000083706895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023224533,0.00024047968,0.0010824071,0.00024224569,0.000079712256,0.00003587273,0.00034801904,0.00016026897,0.00022192848],"category_scores_gemma":[0.000047800524,0.00012840243,0.00024335414,0.00038114973,0.00015613779,0.00010422742,0.000029299683,0.0006774239,0.000003868186],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32914728,0.023236396,0.1661891,0.00018312731,0.0043120836,0.008900373,0.0076575866,0.00002908166,0.0073315823,0.000058705074,0.030175926,0.4227788],"study_design_scores_gemma":[0.18936177,0.043623626,0.24953254,0.0006310803,0.0013031324,0.0041464847,0.012705197,0.00018089749,0.0021017212,0.00019134043,0.49555826,0.0006639665],"about_ca_topic_score_codex":0.00015762693,"about_ca_topic_score_gemma":0.00018607627,"teacher_disagreement_score":0.46538234,"about_ca_system_score_codex":0.0006064766,"about_ca_system_score_gemma":0.0007867931,"threshold_uncertainty_score":0.5236099},"labels":[],"label_agreement":null},{"id":"W4415519856","doi":"10.1016/j.jtho.2025.09.109","title":"MA02.06 Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; KRAS; MEDLINE; Immunotherapy; PD-L1","score_opus":0.018901264307362615,"score_gpt":0.3817211829039664,"score_spread":0.3628199185966038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817583,0.0073684365,0.000077057965,0.0071635647,0.0005037707,0.00033965346,0.00005559333,0.00000928679,0.002724354],"genre_scores_gemma":[0.99317175,0.0044960664,0.001002308,0.0006427821,0.00018476315,0.0000023709617,0.000012777483,0.000015675725,0.0004715226],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975844,0.0002919792,0.0013245655,0.00027215588,0.00024499622,0.0002819289],"domain_scores_gemma":[0.9979209,0.0007970092,0.0007348288,0.00025499603,0.00015363347,0.00013867908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012189191,0.00021274196,0.0010789804,0.00044879396,0.000055232627,0.000015531275,0.0001583457,0.0003150674,0.00008498976],"category_scores_gemma":[0.0003764489,0.00016595244,0.000135944,0.00038424818,0.00031965296,0.00010217872,0.00007819201,0.00056150235,0.0000017336256],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41830412,0.001191733,0.013633637,0.00030929074,0.0011458735,0.001412561,0.0031231092,0.00003488777,0.084752604,0.000054715085,0.004408732,0.47162873],"study_design_scores_gemma":[0.08073179,0.0071168165,0.7993732,0.0033611334,0.0011271451,0.001955498,0.0022661937,0.00031118406,0.012243372,0.00067238306,0.09040718,0.00043407216],"about_ca_topic_score_codex":0.00037115105,"about_ca_topic_score_gemma":0.00032217553,"teacher_disagreement_score":0.7857396,"about_ca_system_score_codex":0.00055309274,"about_ca_system_score_gemma":0.0010064207,"threshold_uncertainty_score":0.6767344},"labels":[],"label_agreement":null},{"id":"W4415520534","doi":"10.1016/j.jtho.2025.09.261","title":"P1.07.18 Peri-Operative Immune Cell Profiling in Lung Cancer Resection: A Longitudinal Study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Lung cancer; Immune system; Profiling (computer programming); Longitudinal study; Respiratory disease","score_opus":0.039609317922157015,"score_gpt":0.47541152227669464,"score_spread":0.43580220435453765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771832,0.012890506,0.00012412839,0.0032408354,0.0016433015,0.0006200422,0.0000020971042,0.000008905845,0.0042869393],"genre_scores_gemma":[0.99484867,0.00068838015,0.00074682094,0.00029672746,0.00034706198,0.000042990105,0.0000010190397,0.000012503367,0.0030158393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981653,0.00032243622,0.0008396675,0.00019948295,0.00023209071,0.00024100984],"domain_scores_gemma":[0.9989467,0.00012087158,0.00039104902,0.00017061816,0.00030977806,0.000060937404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013571567,0.00015509731,0.00066163647,0.0004586703,0.00010093969,0.000022316255,0.0001477611,0.00014591352,0.00060218683],"category_scores_gemma":[0.000070936374,0.00011920636,0.00017683089,0.0005781569,0.00008717464,0.00013209782,0.00004999609,0.00073113764,0.000002288811],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.091454305,0.0046117897,0.72907066,0.00065952743,0.0017093082,0.0021707048,0.0057737753,0.00017601899,0.09176736,0.000014349246,0.0043953247,0.06819688],"study_design_scores_gemma":[0.017136797,0.014868095,0.87431717,0.0019715305,0.0012839205,0.0009875231,0.019544592,0.0005220686,0.055779602,0.000055447264,0.013148295,0.00038497397],"about_ca_topic_score_codex":0.0002614938,"about_ca_topic_score_gemma":0.00045629952,"teacher_disagreement_score":0.1452465,"about_ca_system_score_codex":0.0013677938,"about_ca_system_score_gemma":0.0014438519,"threshold_uncertainty_score":0.65935236},"labels":[],"label_agreement":null},{"id":"W4415526381","doi":"10.1097/md.0000000000045224","title":"Combined laboratory and imaging indicators to construct risk models for predicting immunotherapy efficacy and prognosis in non-small cell lung cancer: An observational study (STROBE compliant)","year":2025,"lang":"en","type":"article","venue":"Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"","keywords":"Nomogram; Receiver operating characteristic; Univariate; Logistic regression; Proportional hazards model; Univariate analysis; Area under the curve; Lung cancer; Multivariate analysis","score_opus":0.029837997996699978,"score_gpt":0.3266258564698695,"score_spread":0.2967878584731696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415526381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98830783,0.004214904,0.0009972949,0.0024787213,0.00021302629,0.0035975133,0.000067214656,0.000051373067,0.000072096926],"genre_scores_gemma":[0.99630994,0.00052333216,0.0011581318,0.0013747521,0.00009501728,0.0004385715,0.000033689532,0.000028798075,0.000037798192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984221,0.00008091536,0.00053407764,0.00047044634,0.00020424051,0.00028824032],"domain_scores_gemma":[0.9990858,0.00025900942,0.00016506219,0.00022214862,0.00013162263,0.00013635997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080366636,0.00024121336,0.00053385843,0.00046236554,0.00018137343,0.000025014077,0.00011274769,0.000061688945,0.000016488455],"category_scores_gemma":[0.000062724466,0.00020359119,0.000027635573,0.0007007538,0.00019094377,0.00010609461,0.000040940784,0.00021889241,6.6797014e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002412214,0.00033737544,0.95864594,0.0002306142,0.00019025255,0.0000066859407,0.0038729322,0.000033679193,0.008232601,0.00001934699,0.00037204518,0.025646327],"study_design_scores_gemma":[0.027857812,0.0013729836,0.9494062,0.0010053861,0.00024869427,0.0000027027254,0.003119,0.015838534,0.00069085235,0.000034710967,0.00024039659,0.00018275062],"about_ca_topic_score_codex":0.0011253202,"about_ca_topic_score_gemma":0.00016578627,"teacher_disagreement_score":0.025463575,"about_ca_system_score_codex":0.00013830536,"about_ca_system_score_gemma":0.00024488923,"threshold_uncertainty_score":0.8302208},"labels":[],"label_agreement":null},{"id":"W4415615711","doi":"10.1186/s40364-025-00850-7","title":"THSD4 is a novel mediator of T cell exclusion and anti-PD-1 resistance in hormone receptor-positive breast cancer","year":2025,"lang":"en","type":"article","venue":"Biomarker Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Beatrice Hunter Cancer Research Institute; Nova Scotia Health Authority; Acadia University; Dalhousie University","funders":"Killam Trusts; Canadian Cancer Society; Dalhousie University; Faculty of Medicine, Dalhousie University; Canadian Institutes of Health Research; Cancer Research Society; Dalhousie Medical Research Foundation; Research Nova Scotia; Beatrice Hunter Cancer Research Institute","keywords":"Breast cancer; Pembrolizumab; Immune system; Immunotherapy; Tumor microenvironment; Immune checkpoint; T cell; Antibody","score_opus":0.03566022618823507,"score_gpt":0.3629876044686055,"score_spread":0.32732737828037045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415615711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95996314,0.022588078,0.00002349668,0.00955081,0.00012183548,0.000825661,0.00043145125,0.000016934684,0.0064785695],"genre_scores_gemma":[0.98639417,0.008670627,0.0002928521,0.00027284323,0.000046686055,0.00007451567,0.000020361775,0.000022123466,0.004205849],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99789554,0.00014856836,0.00039199137,0.00046444545,0.000651508,0.0004479726],"domain_scores_gemma":[0.998857,0.00023429954,0.0000747092,0.00036189452,0.00035776326,0.00011430727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013594102,0.00016756136,0.0003697176,0.00061993755,0.000118883225,0.00002457812,0.00017218209,0.00017998052,0.00029068557],"category_scores_gemma":[0.000058895075,0.00014142365,0.00007961042,0.0016181443,0.0004829196,0.00008374304,0.00015755439,0.00029362278,0.0000045584857],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011522396,0.0003605304,0.023624673,0.00040256343,0.00012060944,0.000012542044,0.00070387294,1.6022378e-8,0.92400956,0.000039075458,0.033144224,0.0060599404],"study_design_scores_gemma":[0.0058949618,0.000113626986,0.80824167,0.0012189031,0.00002442401,0.000005343477,0.00047427887,0.0000322205,0.17193817,0.000029919842,0.011871244,0.00015523615],"about_ca_topic_score_codex":0.0016711031,"about_ca_topic_score_gemma":0.0003345108,"teacher_disagreement_score":0.784617,"about_ca_system_score_codex":0.0003597675,"about_ca_system_score_gemma":0.0005534336,"threshold_uncertainty_score":0.5767089},"labels":[],"label_agreement":null},{"id":"W4415619203","doi":"10.51731/cjht.2025.1266","title":"Durvalumab (Imfinzi) and Tremelimumab (Imjudo)","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Durvalumab; Tremelimumab; Vinorelbine; Epidermal growth factor receptor; Drug; Clinical Oncology; Reimbursement; Lymphoma; Discontinuation","score_opus":0.020021908016387844,"score_gpt":0.2969294342109829,"score_spread":0.276907526194595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415619203","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08774944,0.74057305,0.00015671625,0.16750143,0.0023518906,0.0005112237,0.000038960647,0.0000654639,0.0010518171],"genre_scores_gemma":[0.9442743,0.051545512,0.00022264774,0.0030653537,0.000033460463,0.0000054166867,0.0000018288795,0.000024381166,0.00082707644],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99649155,0.0001545159,0.0017078787,0.00033180424,0.000262658,0.0010515965],"domain_scores_gemma":[0.9978263,0.00014695675,0.0009081951,0.0005403959,0.000351856,0.00022628874],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018887677,0.00036548264,0.0011460634,0.0023130097,0.0006877704,0.000117314295,0.0005331032,0.0005248937,0.00014405831],"category_scores_gemma":[0.0009082657,0.00032529497,0.00023745987,0.0011920183,0.0012807882,0.00016597316,0.00004886639,0.0011801765,0.000005724611],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004638985,0.000035155936,0.0060028457,0.00069862045,0.00045227195,0.00022396939,0.00049603794,9.854085e-7,0.00013136401,0.0010050979,0.018620893,0.9718689],"study_design_scores_gemma":[0.0074193534,0.0028531183,0.05753404,0.0070259375,0.0002491947,0.0009721464,0.018950647,0.00003316996,0.0010786288,0.0043776217,0.89909786,0.00040828015],"about_ca_topic_score_codex":0.01430227,"about_ca_topic_score_gemma":0.011811309,"teacher_disagreement_score":0.9714606,"about_ca_system_score_codex":0.0017757135,"about_ca_system_score_gemma":0.019128524,"threshold_uncertainty_score":0.9999199},"labels":[],"label_agreement":null},{"id":"W4415652714","doi":"10.14740/jocmr6255","title":"A Challenging Case of Immune-Related Organizing Pneumonitis Following Programmed Cell Death 1 Inhibitor Therapy in Non-Small Cell Lung Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Ministero della Salute","keywords":"Pembrolizumab; Pneumonitis; Lung cancer; Adverse effect; Pneumonia; Targeted therapy; Immunotherapy; Lung; Immune system","score_opus":0.09799068155448581,"score_gpt":0.47777578375609236,"score_spread":0.37978510220160655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415652714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9477594,0.04212742,0.000046878104,0.006455187,0.001104005,0.0009407353,0.0000013091566,0.000011446283,0.0015536324],"genre_scores_gemma":[0.9737708,0.02469026,0.0002654808,0.00017626987,0.00054109556,0.000024103836,0.0000016116119,0.000040985316,0.0004894037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940641,0.0006543141,0.003405904,0.00032813541,0.00091295247,0.0006346214],"domain_scores_gemma":[0.99519116,0.002459179,0.0007579494,0.00036610843,0.0009343729,0.00029124078],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.012875114,0.00023514924,0.0014952943,0.0011484917,0.00012400855,0.000018753612,0.0003190469,0.00034145117,0.00013688502],"category_scores_gemma":[0.0014935374,0.00016409685,0.0006007362,0.0017934525,0.0002937025,0.00009743806,0.000092872455,0.0025337308,0.0000010170277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009597738,0.0027115908,0.46015817,0.001966887,0.0016013205,0.015988445,0.0048462027,0.000012993544,0.21216193,0.000014997456,0.0011221713,0.28981754],"study_design_scores_gemma":[0.2416225,0.03609439,0.38720605,0.08267122,0.0017662462,0.003202419,0.035356127,0.005116139,0.19852388,0.0004249445,0.006722107,0.0012939739],"about_ca_topic_score_codex":0.0015016751,"about_ca_topic_score_gemma":0.000077070195,"teacher_disagreement_score":0.28852358,"about_ca_system_score_codex":0.0003015978,"about_ca_system_score_gemma":0.0015377125,"threshold_uncertainty_score":0.9997675},"labels":[],"label_agreement":null},{"id":"W4415655717","doi":"10.1136/jitc-2025-012355","title":"Acetaminophen interactions with immune checkpoint inhibitors: guilt by association?","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Acetaminophen; Immune system; Immune checkpoint; Causality (physics); Drug; Nivolumab","score_opus":0.009689728968450075,"score_gpt":0.3244373792283184,"score_spread":0.31474765025986834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415655717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8648072,0.08020848,0.0027322231,0.041995645,0.004617436,0.0016865177,0.00015551965,0.00007936285,0.0037176346],"genre_scores_gemma":[0.84095806,0.021208366,0.0042510964,0.0044388743,0.0010592205,0.0005239255,0.000052182175,0.00014771296,0.12736054],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983311,0.000037996673,0.00081032026,0.00017903907,0.00034521826,0.00029631535],"domain_scores_gemma":[0.998137,0.0001306872,0.00075073563,0.00035697882,0.0005715291,0.000053074382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000543262,0.0002099445,0.00051050686,0.00021904573,0.0002208897,0.000059283608,0.00023127197,0.000113301976,0.00058951986],"category_scores_gemma":[0.00007062474,0.0001567054,0.00046559295,0.00036160144,0.000078512174,0.00019143488,0.000019020526,0.00035373177,0.0000015086696],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013002664,0.0003618759,0.014790799,0.00011907911,0.0044281716,0.0000016318874,0.00044100865,0.00001084513,0.8116966,0.000025240734,0.095294505,0.059827592],"study_design_scores_gemma":[0.012899347,0.0010216091,0.015316847,0.001053483,0.00029429028,0.000038011578,0.00029364138,0.00002399478,0.29974768,0.00020929273,0.6688913,0.00021050463],"about_ca_topic_score_codex":0.00030093777,"about_ca_topic_score_gemma":0.000051414503,"teacher_disagreement_score":0.5735968,"about_ca_system_score_codex":0.0010539643,"about_ca_system_score_gemma":0.00053573336,"threshold_uncertainty_score":0.6454829},"labels":[],"label_agreement":null},{"id":"W4415689904","doi":"10.3389/fphar.2025.1613120","title":"Impact on health outcomes and productive work of adding anti-PD-1 agents to treat early-stage cancers in the United Kingdom: a modelling study","year":2025,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"National Institute for Health and Care Excellence","keywords":"Productivity; Work (physics); Perioperative; Investment (military); Work productivity; Health economics; Adjuvant","score_opus":0.05757833665835817,"score_gpt":0.40741500886024984,"score_spread":0.3498366722018917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415689904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99362624,0.0004932415,0.00023974261,0.0027305589,0.00070976914,0.0020762754,0.000018588784,0.000011568055,0.00009401265],"genre_scores_gemma":[0.9963439,0.00027477482,0.0002703794,0.0028232876,0.00002687654,0.00010300559,0.00000634081,0.000011799411,0.00013962325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859625,0.00031432157,0.00033497965,0.0003087642,0.00013483231,0.0003108307],"domain_scores_gemma":[0.9995565,0.00009836905,0.00010061609,0.00016576775,0.000027979595,0.00005078437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060806103,0.0001719842,0.0005311018,0.0008336566,0.000058648922,0.000007864489,0.00012917694,0.000049102928,0.000015516938],"category_scores_gemma":[0.000017709712,0.00011723226,0.0000585163,0.0013279531,0.00008097727,0.000035685556,0.000028568744,0.00025947002,2.1442925e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010006803,0.0005679926,0.945349,0.000067746754,0.0004998787,0.000035522415,0.013622079,0.008808081,0.00017132242,0.0000029017438,0.014005147,0.006863564],"study_design_scores_gemma":[0.008875084,0.001581599,0.9805478,0.00022315382,0.000121133606,0.0000012731267,0.0045032636,0.0014452026,0.00034816796,0.000009056645,0.0022044687,0.00013983878],"about_ca_topic_score_codex":0.005589062,"about_ca_topic_score_gemma":0.0000681109,"teacher_disagreement_score":0.035198797,"about_ca_system_score_codex":0.00071207806,"about_ca_system_score_gemma":0.00020816132,"threshold_uncertainty_score":0.8449027},"labels":[],"label_agreement":null},{"id":"W4415790827","doi":"10.4103/crst.crst_15_25","title":"Excellence in oncology care (EIOC) consensus guidelines on integrating immunotherapy (IO) in resectable non-small cell lung cancer (NSCLC) for the Middle East and Indian subcontinent","year":2025,"lang":"en","type":"article","venue":"Cancer Research Statistics and Treatment","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"","keywords":"Pembrolizumab; Lung cancer; Atezolizumab; Immunotherapy; Excellence; Chemotherapy; Adjuvant; Disease; Cancer","score_opus":0.1184238318118911,"score_gpt":0.4289081210910559,"score_spread":0.3104842892791648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415790827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8435726,0.14234087,0.00026003178,0.008239803,0.00028548556,0.0036832574,0.0009845826,0.000009841085,0.0006235345],"genre_scores_gemma":[0.915326,0.07789249,0.0014377143,0.0004302716,0.00008146616,0.002788054,0.000051220904,0.000025162542,0.0019676243],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843603,0.00010634511,0.00039463962,0.00040699015,0.00018167352,0.00047431904],"domain_scores_gemma":[0.99838305,0.00089621544,0.000071307484,0.0002315817,0.00034222926,0.000075626434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048457686,0.00020717016,0.0003706755,0.00027627824,0.00023991629,0.000055633027,0.00009240061,0.00009361693,0.00003592408],"category_scores_gemma":[0.00007990689,0.00013464289,0.000041067655,0.00032189695,0.00027317795,0.000013847653,0.00003929584,0.000264164,2.8980017e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013273965,0.00048830087,0.061335113,0.0010919207,0.00046250207,0.00021286368,0.02304693,0.00011457216,0.0071661165,0.00042642158,0.005278386,0.8871029],"study_design_scores_gemma":[0.18367861,0.02424302,0.16960378,0.02443327,0.0007953807,0.000051440136,0.20705448,0.046482105,0.037824694,0.00127997,0.30230498,0.0022482348],"about_ca_topic_score_codex":0.04061965,"about_ca_topic_score_gemma":0.048896603,"teacher_disagreement_score":0.8848547,"about_ca_system_score_codex":0.0013587603,"about_ca_system_score_gemma":0.0013942572,"threshold_uncertainty_score":0.96845853},"labels":[],"label_agreement":null},{"id":"W4415820304","doi":"10.3390/curroncol32110612","title":"Docetaxel and Ramucirumab as Subsequent Treatment After First-Line Immunotherapy-Based Treatment for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Study and Literature Review","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ramucirumab; Docetaxel; Retrospective cohort study; Regimen; Concordance; Adverse effect; Randomized controlled trial; Progression-free survival; Clinical trial","score_opus":0.04300020199165179,"score_gpt":0.40386227970921,"score_spread":0.36086207771755824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415820304","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45728576,0.5328309,0.00013100404,0.0031400353,0.0004317085,0.005956465,0.00013558888,0.000025943276,0.000062572595],"genre_scores_gemma":[0.521094,0.46808982,0.0003067509,0.001360648,0.00010874462,0.008015222,0.00011236929,0.000036296322,0.0008761218],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99826956,0.00012817283,0.00050103577,0.0006365369,0.000120129676,0.00034454107],"domain_scores_gemma":[0.9990095,0.00014159695,0.00018964453,0.00037440826,0.00017631521,0.00010854721],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025590515,0.00043454338,0.0010690365,0.00018351129,0.00014168174,0.000039890456,0.00006765962,0.00009501883,0.00008911447],"category_scores_gemma":[0.000019328469,0.00029890117,0.00025178897,0.0003132882,0.00010844318,0.000041665102,0.000023974222,0.0001432345,9.731156e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037450776,0.018199395,0.19023432,0.012669394,0.0052590473,0.00041679607,0.008275362,0.0000033236543,0.0010410732,0.00003052994,0.0022580402,0.7241619],"study_design_scores_gemma":[0.2235889,0.07508414,0.11913257,0.02248667,0.014768949,0.00020704235,0.0009222367,0.0014273883,0.0026763985,0.00017117098,0.53817356,0.0013609645],"about_ca_topic_score_codex":0.00015877999,"about_ca_topic_score_gemma":0.00069285545,"teacher_disagreement_score":0.72280097,"about_ca_system_score_codex":0.0019437273,"about_ca_system_score_gemma":0.0006732259,"threshold_uncertainty_score":0.9999463},"labels":[],"label_agreement":null},{"id":"W4415823352","doi":"10.1073/pnas.2409553122","title":"Structural immunotherapy: Harnessing chemical design to build powerful next-generation therapeutics","year":2025,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Institute for Nanotechnology","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Component (thermodynamics); Immunotherapy; Key (lock); Identity (music)","score_opus":0.09432806512571795,"score_gpt":0.3519092072471223,"score_spread":0.25758114212140437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415823352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98210627,0.0009467329,0.000057408528,0.014886013,0.000065457876,0.00037729144,0.0000033216954,0.000014988168,0.0015425453],"genre_scores_gemma":[0.9906318,0.00004363272,0.005296044,0.0036815517,0.00008669115,0.000006935395,1.8410118e-7,0.000004462217,0.00024865477],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99864775,0.0000071316854,0.00031978244,0.000206313,0.00068213354,0.00013691786],"domain_scores_gemma":[0.99944735,0.00006385539,0.00019283552,0.000011623069,0.0002620844,0.000022261462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008098459,0.000101395766,0.0001679551,0.0001800358,0.0001515213,0.000044786557,0.00039052457,0.00008932513,0.000021435599],"category_scores_gemma":[0.00011513057,0.00006488045,0.00009189625,0.0009606837,0.0004516956,0.00023799895,0.000048483074,0.00013023708,4.976412e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028698397,0.00002057851,0.001316855,0.000023870449,0.000058952544,2.5894031e-9,0.0001831239,0.000022291568,0.9865006,0.002411922,0.00065927295,0.008515507],"study_design_scores_gemma":[0.00049214857,0.00006999113,0.017990952,0.0001701351,0.00002741175,0.000007090946,0.00009575273,0.0023343572,0.9744475,0.0037350124,0.0005582657,0.00007142209],"about_ca_topic_score_codex":0.0000056511944,"about_ca_topic_score_gemma":2.2300581e-8,"teacher_disagreement_score":0.016674098,"about_ca_system_score_codex":0.00008805669,"about_ca_system_score_gemma":0.00010594274,"threshold_uncertainty_score":0.2645748},"labels":[],"label_agreement":null},{"id":"W4415881820","doi":"10.1101/2025.11.02.25338835","title":"Spatial Structure of Tumor and Immune Cells Shape Outcomes in ER⁺HER2⁻ and Triple-Negative Breast Cancer","year":2025,"lang":"","type":"preprint","venue":"medRxiv","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Universitair Medisch Centrum Groningen","keywords":"Immune system; Breast cancer; Stromal cell; Tumor-infiltrating lymphocytes; Disease; Multiplex; Infiltration (HVAC); FOXP3","score_opus":0.009797015333511853,"score_gpt":0.2728490755084563,"score_spread":0.2630520601749444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415881820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97994566,0.010451509,0.00001630527,0.0015255032,0.002473057,0.0020118332,0.0034051149,0.000021139867,0.00014986588],"genre_scores_gemma":[0.9890127,0.008919985,0.00014977476,0.00039367823,0.0002041356,0.000066892724,0.00002851932,0.00004825172,0.0011760326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958469,0.00032419272,0.0015727812,0.001155058,0.0005122683,0.0005887437],"domain_scores_gemma":[0.99757206,0.00040679303,0.00088036514,0.00072056503,0.000233792,0.00018641238],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00051513896,0.000892776,0.0023312797,0.00053613406,0.00010703288,0.00005217065,0.0003640575,0.0005289755,0.002425922],"category_scores_gemma":[0.000107433,0.0007422476,0.00030658743,0.0004932978,0.00084225734,0.000097504446,0.0005583181,0.001238179,0.0000010140636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009431988,0.00026263145,0.78429663,0.0033064026,0.0018421549,0.00006606916,0.0044016493,0.000015129154,0.12642835,0.000014277868,0.00004052575,0.06989416],"study_design_scores_gemma":[0.01008416,0.00023246436,0.92403686,0.0034842775,0.0005167869,0.000036943668,0.000660608,0.00068690686,0.05937052,0.00015707484,0.00016052224,0.00057285046],"about_ca_topic_score_codex":0.029846637,"about_ca_topic_score_gemma":0.005009608,"teacher_disagreement_score":0.13974023,"about_ca_system_score_codex":0.00029350375,"about_ca_system_score_gemma":0.0009002396,"threshold_uncertainty_score":0.99950284},"labels":[],"label_agreement":null},{"id":"W4415900319","doi":"10.1136/jitc-2025-sitc2025.0173","title":"173 Androgen receptor stratifies immune-cold triple negative breast cancer: meta-analysis of chemotherapy response to guide precision immunotherapy","year":2025,"lang":"","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chemotherapy; Immunotherapy; Complete response; Androgen receptor; Androgen suppression; Androgen","score_opus":0.0224521765230527,"score_gpt":0.30189445328839937,"score_spread":0.27944227676534666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415900319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8897115,0.08199908,0.00012984798,0.020916862,0.0012925391,0.0032083758,0.002272386,0.00009960443,0.00036980226],"genre_scores_gemma":[0.9528079,0.017832085,0.002198858,0.004562654,0.00020329193,0.00044049995,0.00009709243,0.00016428786,0.021693304],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9921082,0.00096259994,0.0031690975,0.0015554392,0.0012140272,0.0009906017],"domain_scores_gemma":[0.9944227,0.0006746363,0.0013328908,0.0018291473,0.0008776944,0.00086297415],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0041217487,0.0012092049,0.0042198347,0.0016843831,0.0004916879,0.0002962208,0.0006974333,0.0007290941,0.0015496738],"category_scores_gemma":[0.00062653876,0.001030735,0.0028309233,0.0042160098,0.0011977768,0.00043103244,0.00013201639,0.00058432645,0.000011107863],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036356144,0.00050704484,0.002151074,0.00032825608,0.25825715,0.000024507648,0.0041914796,0.00034165772,0.6793912,0.00011572262,0.010614124,0.0077216434],"study_design_scores_gemma":[0.008507378,0.0010290495,0.15519033,0.0008328472,0.10591944,0.000035600813,0.0017027038,0.0002509331,0.6723296,0.00014571626,0.052849676,0.0012067129],"about_ca_topic_score_codex":0.0066109877,"about_ca_topic_score_gemma":0.00043921938,"teacher_disagreement_score":0.15303926,"about_ca_system_score_codex":0.0006895177,"about_ca_system_score_gemma":0.0030953381,"threshold_uncertainty_score":0.999388},"labels":[],"label_agreement":null},{"id":"W4415900424","doi":"10.1136/jitc-2025-sitc2025.0116","title":"116 Application of a comprehensive multi-omic immune profiling strategy achieves superior checkpoint immunotherapy response prediction in lung cancer","year":2025,"lang":"","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Standards Association","funders":"","keywords":"Lung cancer; Profiling (computer programming); Immunotherapy; Cancer immunotherapy; Nivolumab; Immune checkpoint","score_opus":0.0161937421815287,"score_gpt":0.2976826542388666,"score_spread":0.2814889120573379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415900424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9093173,0.08464494,0.00029194565,0.001865239,0.00086143427,0.0026841688,0.0002134048,0.00007083809,0.0000507024],"genre_scores_gemma":[0.98856586,0.009025426,0.000603322,0.0003500083,0.00012844203,0.0003642743,0.00009569046,0.00007871732,0.00078828103],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99516827,0.00047146797,0.0022108385,0.00096922356,0.00047245788,0.0007077478],"domain_scores_gemma":[0.9975822,0.00019644634,0.0007571669,0.0008091407,0.00034251442,0.0003125305],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001515575,0.0006982875,0.0012273642,0.0006551904,0.00025933312,0.00010692659,0.00028425618,0.0006370758,0.000041622578],"category_scores_gemma":[0.00018064756,0.00069625874,0.00034003047,0.00092222064,0.0011320454,0.0003530447,0.00006648367,0.00076950557,0.0000034716236],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015184963,0.0004294671,0.068684995,0.0019447607,0.0009248098,0.000020503816,0.0015663303,0.0006119946,0.90292376,0.000071669056,0.00008779747,0.007548915],"study_design_scores_gemma":[0.008323277,0.00034945196,0.6248491,0.0029561121,0.0002862469,0.000033744953,0.0018210427,0.009936326,0.34997475,0.000041734038,0.0010414391,0.00038679637],"about_ca_topic_score_codex":0.0044949064,"about_ca_topic_score_gemma":0.00019839464,"teacher_disagreement_score":0.5561641,"about_ca_system_score_codex":0.0007813847,"about_ca_system_score_gemma":0.002615499,"threshold_uncertainty_score":0.99954885},"labels":[],"label_agreement":null},{"id":"W4415932910","doi":"10.1016/j.athoracsur.2025.10.016","title":"Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671","year":2025,"lang":"en","type":"article","venue":"The Annals of Thoracic Surgery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"MSD K.K.; MSD","keywords":"Pembrolizumab; Perioperative; Chemotherapy; Neoadjuvant therapy; MEDLINE","score_opus":0.08783236430065533,"score_gpt":0.4306494457087039,"score_spread":0.34281708140804856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415932910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952755,0.0010670429,0.0000032602484,0.0025147002,0.00026902914,0.00020549858,0.000021297159,0.00000855421,0.00063511607],"genre_scores_gemma":[0.995808,0.00310473,0.00001696622,0.0006155743,0.00002981181,0.000006918571,0.000014662673,0.000008672023,0.00039466846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829227,0.00031703102,0.0008587515,0.00017185851,0.00018621216,0.00017387471],"domain_scores_gemma":[0.99747926,0.0017690269,0.00024696867,0.00028018918,0.00018455608,0.00004001612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018934403,0.00012683589,0.0007894388,0.00016904746,0.000037432917,0.000008914276,0.000083109466,0.00009705643,0.000052706433],"category_scores_gemma":[0.0008421277,0.00008106016,0.0002489792,0.00028543043,0.00029967466,0.00005325031,0.00006222083,0.00017877294,8.4836023e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006698979,0.00023927083,0.81716627,0.00012676674,0.000166099,0.000007639313,0.00020229572,1.11737485e-7,0.00006308555,0.000017765342,0.0002587998,0.17505294],"study_design_scores_gemma":[0.0005357487,0.000089715555,0.99504536,0.00048664416,0.00003870926,0.0000023860232,0.000099754936,0.000023278339,0.0014372922,0.000025681667,0.0021428906,0.00007251018],"about_ca_topic_score_codex":0.00006878037,"about_ca_topic_score_gemma":0.000012028663,"teacher_disagreement_score":0.17787914,"about_ca_system_score_codex":0.000012281493,"about_ca_system_score_gemma":0.0001411656,"threshold_uncertainty_score":0.33055377},"labels":[],"label_agreement":null},{"id":"W4415940216","doi":"10.1016/j.annonc.2025.08.2325","title":"1698eP Incidence of chronic immune related adverse events (irAEs) in patients with advanced melanoma treated with immune checkpoint inhibitors in British Columbia","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Abbotsford Veterinary Clinic; BC Cancer Agency","funders":"","keywords":"Adverse effect; Incidence (geometry); Immune system; Melanoma; Pembrolizumab; Immune checkpoint; Clinical trial","score_opus":0.00811521122977008,"score_gpt":0.2754361221465436,"score_spread":0.2673209109167735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995535,0.0022698084,0.000001336491,0.0002960499,0.000092899325,0.0010070604,0.00001591886,0.00001739108,0.00076454587],"genre_scores_gemma":[0.9984654,0.0007591996,0.00008642562,0.00010977839,0.0000059272456,0.00005722967,0.000060634804,0.000020253898,0.00043513966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783057,0.000128453,0.0011485829,0.00032375587,0.00022538997,0.00034325058],"domain_scores_gemma":[0.99872094,0.000071109505,0.00055657496,0.00032151464,0.00028434742,0.000045509096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043949994,0.0001584822,0.0008594392,0.00025556513,0.000029493649,0.0000031575196,0.00014900017,0.00022276823,0.00012365532],"category_scores_gemma":[0.000078458375,0.00017958155,0.00012139986,0.0011315244,0.00029435309,0.00013609415,0.000054136177,0.0002656314,0.000001361341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010681364,0.0017019977,0.9053813,0.00018424785,0.0003159996,0.00010871356,0.00020567724,0.000048550974,0.0076482785,0.0000015351673,0.000064004256,0.07365833],"study_design_scores_gemma":[0.024267644,0.011049193,0.9524224,0.0031707305,0.000050537692,0.000016411408,0.00020206161,0.000017943965,0.00825478,0.000018790002,0.00037587297,0.00015367642],"about_ca_topic_score_codex":0.031078655,"about_ca_topic_score_gemma":0.064561434,"teacher_disagreement_score":0.07350466,"about_ca_system_score_codex":0.00039145042,"about_ca_system_score_gemma":0.00071570935,"threshold_uncertainty_score":0.97537345},"labels":[],"label_agreement":null},{"id":"W4415940764","doi":"10.1016/j.annonc.2025.08.2037","title":"1405P AI informed virtual immunocyte profiling from H&amp;E images predicts immunotherapy response (VIPER) in head and neck squamous cell carcinoma","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Dental and Craniofacial Research; Institute of Aging; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute","keywords":"Immunotherapy; Head and neck squamous-cell carcinoma; Head and neck; Immunohistochemistry; CD68; Immune system; Head and neck cancer; Basal cell; Monoclonal antibody","score_opus":0.038570153056316406,"score_gpt":0.36590476161951335,"score_spread":0.32733460856319696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742024,0.015507137,0.00003023359,0.0054318276,0.00030693755,0.0006501146,0.000064376516,0.000037958354,0.0037690361],"genre_scores_gemma":[0.9880027,0.0022741247,0.0006228107,0.007597958,0.00005420122,0.000056884757,0.000057643076,0.000023683475,0.0013099853],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99801373,0.00026013504,0.0007824022,0.00034521212,0.00018086156,0.00041764393],"domain_scores_gemma":[0.9982773,0.00081201777,0.0002150546,0.00044542225,0.00017561209,0.00007458779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075138576,0.000251306,0.00071260147,0.00043743703,0.000069559916,0.000018529756,0.00018115918,0.0003267534,0.00009491108],"category_scores_gemma":[0.0002594415,0.00022910173,0.00015461238,0.0003831738,0.00034709094,0.00015200804,0.0000826412,0.0003651052,0.000006210735],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17803289,0.00088770676,0.08266651,0.00018838933,0.00021977993,0.000097422075,0.002751189,0.0000080457185,0.6404655,0.000052069987,0.0062247324,0.08840577],"study_design_scores_gemma":[0.022356788,0.0072239223,0.6161487,0.00025379827,0.00004886486,0.000029336106,0.00081325497,0.000044703153,0.22113305,0.0001896182,0.13150226,0.00025570596],"about_ca_topic_score_codex":0.0018465683,"about_ca_topic_score_gemma":0.00030025252,"teacher_disagreement_score":0.5334822,"about_ca_system_score_codex":0.00015559822,"about_ca_system_score_gemma":0.0012959177,"threshold_uncertainty_score":0.93424976},"labels":[],"label_agreement":null},{"id":"W4415941010","doi":"10.1016/j.annonc.2025.08.3640","title":"3025eP LINC01929 mediates breast cancer immunosuppression and is a target to increase antigen presentation","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Prince Edward Island; Acadia University; Dalhousie University","funders":"","keywords":"Immunosuppression; Presentation (obstetrics); Breast cancer; Antigen presentation; Antigen; Tumor associated antigen","score_opus":0.030296408452998844,"score_gpt":0.4052150594016355,"score_spread":0.37491865094863663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93998337,0.006513375,0.000025929932,0.049880713,0.00024799298,0.00038055077,0.00011066109,0.00001803018,0.0028393741],"genre_scores_gemma":[0.9784009,0.00810548,0.00035444467,0.011963622,0.000099373625,0.00005321584,0.000028351224,0.000009449045,0.0009851631],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99916136,0.00006527838,0.00028454335,0.00019768305,0.0001135865,0.00017756724],"domain_scores_gemma":[0.99934965,0.000106011306,0.000099432684,0.00016440933,0.00019729645,0.00008322326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023559468,0.00010334646,0.0003129077,0.00017632305,0.00004825971,0.000006760236,0.00007374483,0.00012642375,0.00048875576],"category_scores_gemma":[0.00005297227,0.00008473581,0.00006687959,0.00023596021,0.000102701444,0.000062451065,0.00006518638,0.00008244727,0.000003984379],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015808173,0.0005282248,0.16245301,0.00025265053,0.0006562375,0.000022621545,0.0019425831,0.000003746828,0.25721034,0.00005090659,0.18295877,0.37811273],"study_design_scores_gemma":[0.003314519,0.0010753772,0.6825693,0.00036954126,0.000070776754,0.000028546885,0.00035267673,0.00007242244,0.11404377,0.0002710047,0.19770819,0.0001238516],"about_ca_topic_score_codex":0.002824365,"about_ca_topic_score_gemma":0.00007714395,"teacher_disagreement_score":0.5201163,"about_ca_system_score_codex":0.000037247362,"about_ca_system_score_gemma":0.0003370103,"threshold_uncertainty_score":0.5351533},"labels":[],"label_agreement":null},{"id":"W4415941031","doi":"10.1016/j.annonc.2025.08.1525","title":"956P Encouraging antitumor activity of PDL1V (PF-08046054) monotherapy, an ADC targeting PD-L1, correlates with antigen expression in patients with NSCLC","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"Seagen; Pfizer","keywords":"Antigen; Tumor associated antigen; Cancer; Tumor antigen; Over expression","score_opus":0.021225442824662086,"score_gpt":0.33215999920335976,"score_spread":0.31093455637869766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99622416,0.0007200297,0.00021184159,0.0007159858,0.000113457514,0.0004859501,0.000010727552,0.000021314494,0.0014965314],"genre_scores_gemma":[0.9980618,0.00043256686,0.0008463657,0.0005133825,0.000022371014,0.0000151939685,0.000020814685,0.000019260577,0.00006826024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986523,0.00013961966,0.00040100544,0.000301817,0.00021329535,0.0002920124],"domain_scores_gemma":[0.9989157,0.000121990786,0.00038858905,0.0002735318,0.0002443192,0.0000558955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042625994,0.0001844462,0.0006083299,0.0002837443,0.000054503882,0.000005790558,0.00013374245,0.00014280782,0.00006614598],"category_scores_gemma":[0.000035853405,0.00013216611,0.0000701263,0.00040339955,0.00021906734,0.00019308152,0.000032511674,0.00020917425,5.7254425e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035459064,0.0016296471,0.7369183,0.00013419871,0.00022899124,0.000021337948,0.0010152663,0.000047582434,0.1101731,0.000009195754,0.00059092924,0.113772444],"study_design_scores_gemma":[0.008749858,0.0066536474,0.80081373,0.0011305353,0.000036294565,0.0000035020241,0.0003599568,0.000111148314,0.1796898,0.000023626679,0.0022599238,0.0001679507],"about_ca_topic_score_codex":0.00037389493,"about_ca_topic_score_gemma":0.00010947596,"teacher_disagreement_score":0.11360449,"about_ca_system_score_codex":0.000054074113,"about_ca_system_score_gemma":0.00036015845,"threshold_uncertainty_score":0.5389578},"labels":[],"label_agreement":null},{"id":"W4415941228","doi":"10.1016/j.annonc.2025.08.642","title":"209eP Genome and transcriptome analysis on 235 patients treated with immune checkpoint inhibitors: Leveraging multi-omics data in the quest for biomarkers","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"Transcriptome; Genome; Immune checkpoint; Immune system; Nivolumab; Immunotherapy","score_opus":0.07195616759296611,"score_gpt":0.36691651554819377,"score_spread":0.29496034795522763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907308,0.0014362489,0.00019267653,0.0062370375,0.000059177102,0.0008197269,0.00015921946,0.0000111552445,0.00035390686],"genre_scores_gemma":[0.9963673,0.000711046,0.0004437342,0.0018288784,0.000018683724,0.000044627017,0.0005097679,0.00001074962,0.0000652427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987398,0.0001066386,0.00048434574,0.000333377,0.000114054295,0.00022178842],"domain_scores_gemma":[0.99901456,0.00018340605,0.000165806,0.00048697132,0.00011783698,0.000031428408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008789142,0.00015221859,0.0005105557,0.00045601756,0.00005553282,0.000011531931,0.00020837484,0.00011082038,0.000007957193],"category_scores_gemma":[0.000059806596,0.00009956083,0.00012500364,0.0007606062,0.00018186127,0.00006746088,0.000030177873,0.00011415229,2.6880502e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07951498,0.007557014,0.5303477,0.0007752577,0.019279312,0.00007232453,0.0072274134,0.00004010287,0.11617359,0.000077181845,0.002107386,0.23682773],"study_design_scores_gemma":[0.015639815,0.004525671,0.9417497,0.00019350594,0.0010376644,0.0000049553723,0.0009805858,0.0007202031,0.0071118358,0.000013935875,0.027832298,0.00018985574],"about_ca_topic_score_codex":0.0009976439,"about_ca_topic_score_gemma":0.00046967916,"teacher_disagreement_score":0.41140196,"about_ca_system_score_codex":0.000066191074,"about_ca_system_score_gemma":0.00012872409,"threshold_uncertainty_score":0.40599728},"labels":[],"label_agreement":null},{"id":"W4415941497","doi":"10.1016/j.annonc.2025.08.2714","title":"3208P 10-year outcomes from clinical trials of pembrolizumab (pembro) monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Clinical trial; Lung cancer; Immunotherapy; Cancer; Chemotherapy","score_opus":0.19313410227825825,"score_gpt":0.51311728074028,"score_spread":0.31998317846202173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95123845,0.014546714,0.007659979,0.014304785,0.0018466727,0.00462333,0.00081832346,0.00005293038,0.004908835],"genre_scores_gemma":[0.90063727,0.030616986,0.024545016,0.025555523,0.00048024827,0.0011106788,0.00016462902,0.00013248873,0.01675717],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961349,0.00051808386,0.002355436,0.00043910154,0.00018492395,0.0003675681],"domain_scores_gemma":[0.9929258,0.004832931,0.0011579846,0.00047852047,0.00049769203,0.000107059976],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028364768,0.00027500058,0.0025737442,0.00021542663,0.00004198612,0.000006788366,0.0002772639,0.00029059814,0.00133307],"category_scores_gemma":[0.0010472113,0.00019471048,0.0010146738,0.0002651547,0.00023588823,0.000054884295,0.000041319214,0.00018577899,0.0000030601557],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25037813,0.0023799746,0.013430451,0.00097092445,0.006293665,0.000021116226,0.00048008448,0.000042973854,0.038383372,0.00008592447,0.062571146,0.6249623],"study_design_scores_gemma":[0.24334334,0.029207442,0.084277205,0.0020599344,0.0037283336,0.0000047727535,0.0012913534,0.0013662844,0.1873273,0.000990524,0.44552463,0.00087888876],"about_ca_topic_score_codex":0.0004695379,"about_ca_topic_score_gemma":0.00031650715,"teacher_disagreement_score":0.62408334,"about_ca_system_score_codex":0.00007648016,"about_ca_system_score_gemma":0.0022776513,"threshold_uncertainty_score":0.99957985},"labels":[],"label_agreement":null},{"id":"W4415941544","doi":"10.1016/j.annonc.2025.08.1957","title":"1325MO Retifanlimab (Anti–PD-1 mAb) alone or in combination with Anti-LAG3 ± Anti-TIM3 mAbs In previously untreated, recurrent and/or metastatic (R/M) PD-L1+ HNSCC: A double-blind randomised controlled phase II trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Incyte","keywords":"Blockade; Phases of clinical research; Clinical trial; Immunotherapy; Immune checkpoint; Chemotherapy","score_opus":0.0900878328807049,"score_gpt":0.4193750796481191,"score_spread":0.32928724676741417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97745836,0.0029862395,0.000033272558,0.009869499,0.0003334351,0.008349968,0.000024426794,0.00003023182,0.0009145878],"genre_scores_gemma":[0.9904668,0.0067256344,0.00023599375,0.0010603404,0.000044102948,0.0006142463,0.00011782381,0.000025853096,0.0007092207],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965158,0.00062861777,0.0015357047,0.0005222178,0.00030423424,0.0004934002],"domain_scores_gemma":[0.99770546,0.00089462835,0.00066051877,0.00033383336,0.00030200547,0.000103574166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023627684,0.00035664553,0.0024488806,0.0008864338,0.00008586776,0.000023751354,0.00015338788,0.00024317145,0.00031239726],"category_scores_gemma":[0.00044611134,0.00023294122,0.00020901128,0.0010937144,0.00030773046,0.00014502674,0.000053394735,0.00032440305,0.0000021540395],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93696725,0.008577154,0.0003779406,0.0003012141,0.0009993652,0.0004005079,0.0006646668,0.0000064733567,0.0033682382,0.000061917715,0.0010877588,0.047187526],"study_design_scores_gemma":[0.95350266,0.03633551,0.0012600189,0.0010068254,0.000598333,0.00010199985,0.00028016442,0.00036510578,0.0036951813,0.00006282843,0.002560332,0.00023105893],"about_ca_topic_score_codex":0.000423578,"about_ca_topic_score_gemma":0.0010096962,"teacher_disagreement_score":0.04695647,"about_ca_system_score_codex":0.00014680419,"about_ca_system_score_gemma":0.0011954815,"threshold_uncertainty_score":0.9499067},"labels":[],"label_agreement":null},{"id":"W4415941668","doi":"10.1016/j.annonc.2025.08.2237","title":"1609P Final, 9-year results from the CheckMate 238 phase III trial of adjuvant nivolumab vs ipilimumab in resected stage IIIB–C or IV melanoma","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Italfarmaco; Sun Pharma; Istituto Oncologico Veneto; Medizinische Universität Wien; Pfizer; Incyte; Odense Universitetshospital; Novo Nordisk; Astellas Pharma; Eisai; American Society of Clinical Oncology; Universität Wien; BeiGene; Regeneron Pharmaceuticals; Mylan; Helsinn; Les Laboratories Pierre Fabre; Society for Immunotherapy of Cancer; Daiichi Sankyo Europe; Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu; Hospices Civils de Lyon; Gilead Sciences; Univerzita Karlova v Praze; Melanoma Research Alliance; AstraZeneca; Associazione Italiana di Oncologia Medica; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; Sanofi; Johns Hopkins University; Melanoma Institute Australia; Amgen","keywords":"Ipilimumab; Nivolumab; Adjuvant; Melanoma; Stage (stratigraphy); Phases of clinical research","score_opus":0.11395194068233609,"score_gpt":0.42176272067913306,"score_spread":0.30781077999679696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97900367,0.0010710022,0.0000061199053,0.011367482,0.0005135416,0.0010106727,0.00045009286,0.000022725879,0.0065546785],"genre_scores_gemma":[0.9905727,0.0021754429,0.000105468214,0.0015681911,0.0001618869,0.000043724955,0.00012242293,0.00001570841,0.0052344473],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99755514,0.00034126538,0.0011754396,0.00034471112,0.00025201033,0.00033144778],"domain_scores_gemma":[0.9976415,0.00096061965,0.0004898145,0.0006295128,0.00022531452,0.000053254833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012722122,0.00018397416,0.0009268123,0.00021119561,0.000054004206,0.0000068761797,0.00030339166,0.00027173382,0.0005746379],"category_scores_gemma":[0.0007987412,0.00012207298,0.00021196579,0.000607435,0.00033452432,0.000055593722,0.00008778326,0.00029920178,0.00000559787],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8748996,0.0017735442,0.0001617371,0.00005576692,0.00045567728,0.00010068421,0.0010876742,0.0000018957692,0.02112079,0.000055146535,0.058250148,0.042037304],"study_design_scores_gemma":[0.63962567,0.026821716,0.012721812,0.00059373333,0.00016243303,0.00000639257,0.0014605358,0.00013222829,0.052676033,0.00016381947,0.2654398,0.00019582466],"about_ca_topic_score_codex":0.0042528026,"about_ca_topic_score_gemma":0.0027392462,"teacher_disagreement_score":0.23527397,"about_ca_system_score_codex":0.0000956466,"about_ca_system_score_gemma":0.0011685643,"threshold_uncertainty_score":0.64289933},"labels":[],"label_agreement":null},{"id":"W4415942084","doi":"10.1016/j.annonc.2025.08.571","title":"137P OST: An immune-related adverse event (irAE) grading tool and its prognostic value in cancer patients","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Grading (engineering); Cancer; Value (mathematics); Event (particle physics); Adverse effect","score_opus":0.03860606023844163,"score_gpt":0.3777800509033372,"score_spread":0.33917399066489556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894837,0.006151338,0.0000011543387,0.002167986,0.00035754172,0.0006964847,0.000013672534,0.000015730133,0.0011123931],"genre_scores_gemma":[0.9959746,0.0024337955,0.00002055607,0.0011568969,0.000017284694,0.000060721293,0.00002398967,0.00000968992,0.00030245126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987588,0.000109463894,0.00057647895,0.00021507451,0.00010670615,0.00023345875],"domain_scores_gemma":[0.99940944,0.000105358915,0.00017348363,0.00012879768,0.00013567509,0.000047220197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041393618,0.000119297,0.0003645907,0.00021129868,0.000037203747,0.0000027559613,0.00007272289,0.00015808131,0.00008608835],"category_scores_gemma":[0.00014609264,0.00010722171,0.00009142058,0.0003128057,0.000079227255,0.000086742104,0.000038417787,0.00014952806,0.0000020734883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009766146,0.002950949,0.48663774,0.0005131949,0.00083431485,0.00007888904,0.0023943079,0.000077733304,0.0366672,0.001059611,0.0012928735,0.45772702],"study_design_scores_gemma":[0.011682449,0.004255554,0.958836,0.00076850253,0.00011766637,0.000008156907,0.00020195763,0.00058748125,0.009429067,0.00023167416,0.013715733,0.00016571312],"about_ca_topic_score_codex":0.000499019,"about_ca_topic_score_gemma":0.00010298996,"teacher_disagreement_score":0.47219828,"about_ca_system_score_codex":0.00010590172,"about_ca_system_score_gemma":0.0003089055,"threshold_uncertainty_score":0.43723744},"labels":[],"label_agreement":null},{"id":"W4415942595","doi":"10.1016/j.annonc.2025.08.3674","title":"3061eP Transcriptomically inferred communications between immune cells &amp; endothelial cells (ECs) via the TIGIT pathway in non-small cell lung cancer (NSCLC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia Hospital; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Roche; Eli Lilly and Company","keywords":"TIGIT; Immune system; Downregulation and upregulation; Immune checkpoint; Receptor; Endothelial stem cell; Transcriptome; Lung cancer","score_opus":0.050762098319055884,"score_gpt":0.3568711593010113,"score_spread":0.30610906098195545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93198925,0.012793381,0.00069661747,0.025996165,0.00082506397,0.0017974306,0.00038038514,0.000047626116,0.0254741],"genre_scores_gemma":[0.9886041,0.0054646004,0.00047467943,0.00282692,0.000102129125,0.00015869905,0.00005309802,0.000027062648,0.002288682],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979122,0.00028775563,0.0009295825,0.00028705632,0.00015625687,0.00042709545],"domain_scores_gemma":[0.99778014,0.0006338965,0.000283323,0.0010320763,0.00019470036,0.000075859134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077630737,0.00023686954,0.00073567225,0.00023234397,0.00010872523,0.000014753888,0.0007415358,0.0003092717,0.00018684582],"category_scores_gemma":[0.000018087212,0.00018709495,0.00032781807,0.00047899786,0.00043562922,0.000054839224,0.00012592302,0.00053059426,0.00001659228],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016281715,0.000681109,0.006082963,0.00017644808,0.000402305,0.000005402002,0.002105951,0.000012778764,0.9114445,0.00003330073,0.00530521,0.07212187],"study_design_scores_gemma":[0.0058268276,0.00058131776,0.02233767,0.00031831226,0.00017352366,0.0000024419685,0.00017219313,0.000119164644,0.48308462,0.000114060604,0.48705158,0.0002182936],"about_ca_topic_score_codex":0.0027913777,"about_ca_topic_score_gemma":0.0016690397,"teacher_disagreement_score":0.48174638,"about_ca_system_score_codex":0.00013876808,"about_ca_system_score_gemma":0.0009659265,"threshold_uncertainty_score":0.762951},"labels":[],"label_agreement":null},{"id":"W4415942647","doi":"10.1016/j.annonc.2025.08.2475","title":"1851MO Pembrolizumab plus chemotherapy (PEM + CT) versus pembrolizumab (PEM) as first-line therapy for advanced NSCLC with PD-L1 tumor proportion score (TPS) ≥50%: Open-label, phase III, randomized trial (PAULIEN)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Pembrolizumab; Chemotherapy; Randomized controlled trial; Phases of clinical research; Chemotherapy regimen","score_opus":0.08929967220707699,"score_gpt":0.4317234721105517,"score_spread":0.3424237999034747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95203686,0.0057984274,0.0014219885,0.014405461,0.0014955229,0.017461382,0.00006607321,0.0001351735,0.00717912],"genre_scores_gemma":[0.96975595,0.010686969,0.0016932283,0.00978819,0.0005323018,0.003830467,0.00031870147,0.00012444181,0.0032697616],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99571526,0.00031487143,0.0017126906,0.00093590235,0.0005059056,0.00081539626],"domain_scores_gemma":[0.99581414,0.0010177324,0.0013005954,0.0008314796,0.00082334026,0.00021270291],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017997957,0.0006424964,0.0029714317,0.00040568702,0.00032004257,0.000065296306,0.0006192621,0.0002756514,0.0004748004],"category_scores_gemma":[0.00044422617,0.00047977982,0.00054087216,0.0006823701,0.0008001743,0.0003403371,0.00008550095,0.00037920842,0.0000070891992],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78163326,0.0041005868,0.0000038748954,0.00015611533,0.0018923824,0.000070733746,0.00030215227,0.000018177458,0.0036789335,0.00036475094,0.0036533528,0.20412567],"study_design_scores_gemma":[0.7775152,0.05530007,0.00002927526,0.00036465694,0.00034065518,0.00009267919,0.00014071928,0.0003584897,0.019003266,0.0004483743,0.14602698,0.0003796587],"about_ca_topic_score_codex":0.00040762895,"about_ca_topic_score_gemma":0.00017927442,"teacher_disagreement_score":0.20374602,"about_ca_system_score_codex":0.00039069387,"about_ca_system_score_gemma":0.0035035997,"threshold_uncertainty_score":0.9997654},"labels":[],"label_agreement":null},{"id":"W4415943874","doi":"10.1016/j.esmoop.2025.105833","title":"Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure","year":2025,"lang":"en","type":"review","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Clinical trial; Nivolumab; Immunotherapy; Immune checkpoint; Cancer; PD-L1; Immune system; Antibody therapy","score_opus":0.04539532483745746,"score_gpt":0.37766122912169303,"score_spread":0.3322659042842356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415943874","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005995678,0.9930403,0.000005943344,0.00062026014,0.00023088703,0.0033877038,0.00015279361,0.000040063325,0.001922479],"genre_scores_gemma":[0.0014907323,0.99332273,0.0003360594,0.00014633547,0.00020382725,0.0012671406,0.00034899972,0.000064334694,0.0028198694],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981038,0.00014032592,0.00059999904,0.0005987043,0.00022825958,0.00032893906],"domain_scores_gemma":[0.99887854,0.00007450919,0.00032220667,0.00055756804,0.00008053451,0.00008663587],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039758577,0.00052172254,0.0015523492,0.00010805542,0.00014271164,0.0001871973,0.00022481872,0.00038344442,0.00034132655],"category_scores_gemma":[0.000015825513,0.00033726246,0.00028264898,0.00032908702,0.00019278169,0.00018160288,0.0002035958,0.0004049673,0.000008382388],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029342861,0.000078124474,0.00009620208,0.00794343,0.001875644,0.000117067604,0.001006941,3.7900733e-8,0.000003425007,0.000009936078,0.0003275031,0.9856074],"study_design_scores_gemma":[0.0033251552,0.0006504612,0.0009288673,0.045072224,0.00089200615,0.00012230792,0.0003410981,2.4180852e-7,0.000078721736,0.000013108336,0.94816315,0.0004126842],"about_ca_topic_score_codex":0.0017417991,"about_ca_topic_score_gemma":0.0028155851,"teacher_disagreement_score":0.98519474,"about_ca_system_score_codex":0.00081218674,"about_ca_system_score_gemma":0.0010377963,"threshold_uncertainty_score":0.9999079},"labels":[],"label_agreement":null},{"id":"W4416017497","doi":"10.1016/j.lungcan.2025.108834","title":"MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Durvalumab; Chemotherapy; Lung cancer; Disease; Cancer","score_opus":0.009759950064900491,"score_gpt":0.3044476110311205,"score_spread":0.29468766096622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416017497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9511831,0.042738255,0.00015309348,0.0022924822,0.00019818661,0.0015052343,0.000038725128,0.000043514596,0.0018474414],"genre_scores_gemma":[0.9644739,0.020805202,0.00068932574,0.0018905582,0.00009973715,0.00059233594,0.000015398631,0.00006367453,0.011369836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985496,0.000042947548,0.0002740668,0.00054430345,0.00017963296,0.00040948033],"domain_scores_gemma":[0.9993782,0.000036617144,0.000113085676,0.0003065473,0.000054467502,0.000111066365],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012255393,0.000365576,0.0006292503,0.00019434353,0.000087664346,0.000055461245,0.000077480414,0.000089637964,0.00022743864],"category_scores_gemma":[0.000002993572,0.0002667961,0.000067255154,0.00038582398,0.00015708643,0.000071794624,0.000023988485,0.00017291866,6.2140106e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0148504935,0.00040797633,0.84119064,0.0022517177,0.0029905648,0.000106293635,0.008132141,0.00009172468,0.019354638,0.000015743959,0.0021901075,0.108417965],"study_design_scores_gemma":[0.1735264,0.0025059823,0.71312046,0.0071639144,0.0045843883,0.00014182492,0.0030006198,0.0322195,0.043725837,0.000045580025,0.018044384,0.0019211338],"about_ca_topic_score_codex":0.010530213,"about_ca_topic_score_gemma":0.008200501,"teacher_disagreement_score":0.15867591,"about_ca_system_score_codex":0.000934607,"about_ca_system_score_gemma":0.0007475236,"threshold_uncertainty_score":0.9999784},"labels":[],"label_agreement":null},{"id":"W4416075617","doi":"10.1136/jitc-2025-sitc2025.1069","title":"1069 Real-world experience with durvalumab amongst older patients","year":2025,"lang":"","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Durvalumab; Disease; MEDLINE; Population; Incidence (geometry)","score_opus":0.00956199840565414,"score_gpt":0.25784839890166195,"score_spread":0.2482864004960078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416075617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794339,0.0035856734,0.000016520296,0.0021909985,0.0018918967,0.0013908084,0.000047296482,0.00012888353,0.011314046],"genre_scores_gemma":[0.97992295,0.0020253104,0.00025357783,0.0021233012,0.00025100025,0.00010003103,0.00007555417,0.00008431731,0.015163927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954536,0.00015056774,0.0011931021,0.0012372768,0.00093235855,0.0010331165],"domain_scores_gemma":[0.996887,0.000100312245,0.0004967331,0.0010458286,0.00040148917,0.001068584],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005242626,0.0008313536,0.00096758903,0.00045403835,0.00057871436,0.00030127895,0.0003405366,0.00038681243,0.00017220204],"category_scores_gemma":[0.00025894874,0.00070358923,0.00023248843,0.0011787583,0.0021240413,0.00048365502,0.0001296696,0.0006109456,0.000025604559],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031697294,0.00083089207,0.9504196,0.0014009974,0.0012731715,0.0002232817,0.005013603,0.0000126453915,0.0067288983,0.0006130553,0.017514652,0.012799483],"study_design_scores_gemma":[0.008021093,0.0005642254,0.9298219,0.0040618684,0.00056452944,0.000032708173,0.0010981559,0.00006123859,0.023072338,0.00011448765,0.031803574,0.0007838787],"about_ca_topic_score_codex":0.0030976757,"about_ca_topic_score_gemma":0.00078798615,"teacher_disagreement_score":0.02059769,"about_ca_system_score_codex":0.00045072616,"about_ca_system_score_gemma":0.0014532057,"threshold_uncertainty_score":0.9995415},"labels":[],"label_agreement":null},{"id":"W4416088303","doi":"10.3390/curroncol32110630","title":"Antibiotic Exposure Does Not Impact Anti-BRAF/Anti-MEK Targeted Therapy Outcome in Patients with Advanced Melanoma","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Weston Family Foundation; Seerave Foundation; Cancer Research Society","keywords":"Antibiotics; Targeted therapy; Melanoma; Microbiome; Biomarker; Overall survival; Antibiotic therapy; Survival analysis","score_opus":0.030167447041363364,"score_gpt":0.3693269337114862,"score_spread":0.33915948667012286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416088303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929325,0.0029377877,0.000023948947,0.00082830444,0.0018883446,0.0010319136,0.000047641766,0.000065924505,0.00024364167],"genre_scores_gemma":[0.9981803,0.00078652793,0.00011340124,0.0005836612,0.000059907175,0.000020178635,0.000118565185,0.000025573161,0.00011188203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981798,0.0001292857,0.00056851364,0.00044115804,0.00021755132,0.0004636776],"domain_scores_gemma":[0.999086,0.00010874865,0.00020018854,0.00038137383,0.00013552739,0.00008813123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022414431,0.00030720644,0.0008011388,0.00035192812,0.00006631692,0.000015821766,0.00016913346,0.00018018352,0.00017383687],"category_scores_gemma":[0.000052246993,0.00018037896,0.00017753591,0.0005435681,0.00017071792,0.00010403465,0.000036852416,0.000364189,0.000009842858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006479614,0.0013926452,0.83025604,0.00008288316,0.0002129107,0.00001971426,0.00017918074,0.0000041324556,0.0046010385,0.000008873176,0.0002459015,0.15651706],"study_design_scores_gemma":[0.023513569,0.0032331063,0.9567738,0.0002326241,0.000052911953,0.000003706259,0.00008566732,0.000014641383,0.003460023,0.0000075281932,0.012405558,0.00021681956],"about_ca_topic_score_codex":0.00005052903,"about_ca_topic_score_gemma":0.000041354386,"teacher_disagreement_score":0.15630023,"about_ca_system_score_codex":0.00042146625,"about_ca_system_score_gemma":0.00036425798,"threshold_uncertainty_score":0.73556405},"labels":[],"label_agreement":null},{"id":"W4416140208","doi":"10.25251/gmn1ta26","title":"Lebrikizumab Patients Treated in the Real World: First North American data from the PPD&lt;sup&gt;TM&lt;/sup&gt; CorEvitas&lt;sup&gt;TM&lt;/sup&gt; AD Registry","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Probity Medical Research; Foothills Medical Centre; University of Calgary","funders":"Eli Lilly and Company","keywords":"MEDLINE; Disease; Epidemiology; Incidence (geometry); Data collection","score_opus":0.01739020930894231,"score_gpt":0.27928569984755447,"score_spread":0.26189549053861216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8554866,0.06826945,0.00010439511,0.059046287,0.0035951484,0.004367953,0.002293965,0.00012593913,0.006710294],"genre_scores_gemma":[0.88286245,0.09706369,0.00013345448,0.00910803,0.004291277,0.000055029017,0.0014478992,0.0003026295,0.0047355522],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9789004,0.0037776884,0.006866507,0.0020928406,0.0055141496,0.0028484468],"domain_scores_gemma":[0.9751571,0.008795728,0.0059691784,0.0075906124,0.0014963751,0.0009910369],"candidate_categories":["metaepi_narrow","sts","open_science","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","sts"],"category_scores_codex":[0.006536957,0.0026448788,0.004912609,0.0014610619,0.0018737607,0.00035837115,0.0090851635,0.00066901994,0.002416926],"category_scores_gemma":[0.0036697313,0.0014418209,0.001178816,0.007328173,0.005862256,0.00063494244,0.0011788192,0.0049369466,0.00011458174],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.082241505,0.004115664,0.056536276,0.0007674275,0.010953173,0.011081761,0.02788627,0.00073129224,0.0016090327,0.000071914175,0.57573825,0.22826743],"study_design_scores_gemma":[0.033153042,0.010482984,0.14289388,0.016069543,0.0125082815,0.0084590595,0.0124983555,0.004860418,0.0001687998,0.00026132623,0.7563453,0.002299017],"about_ca_topic_score_codex":0.008106152,"about_ca_topic_score_gemma":0.03804028,"teacher_disagreement_score":0.2259684,"about_ca_system_score_codex":0.0021732464,"about_ca_system_score_gemma":0.0021704086,"threshold_uncertainty_score":0.99942565},"labels":[],"label_agreement":null},{"id":"W4416142812","doi":"10.34133/cbsystems.0468","title":"Reviving Dormant Immunity: Millimeter Waves Reprogram the Immunosuppressive Microenvironment to Potentiate Immunotherapy without Obvious Side Effects","year":2025,"lang":"en","type":"article","venue":"Cyborg and Bionic Systems","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Alberta Museum; University of Calgary","funders":"","keywords":"Immune system; Tumor microenvironment; Reprogramming; Immunotherapy; Cancer immunotherapy; Cancer; Cancer treatment; Cancer cell","score_opus":0.007359271706251875,"score_gpt":0.2570746753895443,"score_spread":0.24971540368329245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416142812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86698425,0.12680124,0.00025929676,0.0017889455,0.0010971441,0.0022723947,0.0000091177935,0.00008324735,0.0007043771],"genre_scores_gemma":[0.98553246,0.00864316,0.000112860354,0.0015975592,0.0001184037,0.00022271888,0.000018799934,0.000033182532,0.0037208535],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981094,0.00025002245,0.00053355447,0.00043978984,0.00024218218,0.00042507274],"domain_scores_gemma":[0.9986132,0.0001383916,0.00017137166,0.00093823735,0.000054422588,0.00008437539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068680325,0.00031832146,0.00052918703,0.00014728481,0.000411576,0.00017291708,0.00023224037,0.00013534061,0.000011001105],"category_scores_gemma":[0.00003520942,0.00019168694,0.00020855285,0.00031200887,0.00020442411,0.00006196302,0.00013383059,0.00024887495,0.000021988724],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021343243,0.00023934984,0.008923653,0.0007707277,0.001954478,0.000048123347,0.0017192428,0.0000050758217,0.8502943,0.000037667163,0.001452524,0.13242054],"study_design_scores_gemma":[0.012209347,0.0025358647,0.4316826,0.013037125,0.0010725146,0.0010397658,0.0047923014,0.00024910615,0.15655337,0.000042095864,0.37558192,0.0012039861],"about_ca_topic_score_codex":0.0008991382,"about_ca_topic_score_gemma":0.00001046088,"teacher_disagreement_score":0.6937409,"about_ca_system_score_codex":0.00017657143,"about_ca_system_score_gemma":0.000085413085,"threshold_uncertainty_score":0.78167665},"labels":[],"label_agreement":null},{"id":"W4416194118","doi":"10.1001/jamaoncol.2025.4543","title":"Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic Effects","year":2025,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; Toronto General Hospital; Population Health Research Institute","funders":"","keywords":"Myocarditis; Pericarditis; Cardiotoxicity; Disease; Cancer; Acute pericarditis; Heart disease","score_opus":0.008894360964312868,"score_gpt":0.2788533286064106,"score_spread":0.26995896764209776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416194118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9238559,0.02268698,0.00015669435,0.008482334,0.002321466,0.0008504335,0.0000043816453,0.00017512609,0.04146671],"genre_scores_gemma":[0.9916082,0.0006196447,0.00014624892,0.003491744,0.00025241953,0.00009454008,0.00002817781,0.000018942827,0.0037400508],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99864507,0.00020451809,0.00037134704,0.0002809708,0.00018301982,0.00031507935],"domain_scores_gemma":[0.99913824,0.00019467766,0.00008515994,0.0004199107,0.00010080876,0.00006119987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080301036,0.00016049224,0.0006677849,0.00015949243,0.000082501196,0.000015824624,0.00010381811,0.0004050667,0.00010284415],"category_scores_gemma":[0.00039465496,0.00013959713,0.0006683348,0.00045417438,0.000121451536,0.000044157092,0.000065336644,0.00032610405,0.00004348661],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043436657,0.00092428667,0.003647043,0.00044439413,0.0069526336,0.000574542,0.00045214023,0.000005301504,0.39909172,0.0001810889,0.023661563,0.55972165],"study_design_scores_gemma":[0.018287241,0.0014845426,0.20519854,0.00047443967,0.00069006643,0.00007679645,0.00012858234,0.000044732074,0.130602,0.00015951015,0.6426445,0.00020902806],"about_ca_topic_score_codex":0.0002793078,"about_ca_topic_score_gemma":0.000039326867,"teacher_disagreement_score":0.618983,"about_ca_system_score_codex":0.0008869737,"about_ca_system_score_gemma":0.00043651415,"threshold_uncertainty_score":0.5692606},"labels":[],"label_agreement":null},{"id":"W4416247422","doi":"10.51731/cjht.2025.1286","title":"Belzutifan (Welireg)","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Drug approval; MEDLINE; Drug; Clinical trial","score_opus":0.02073411329293563,"score_gpt":0.3122605198815232,"score_spread":0.2915264065885876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416247422","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018083444,0.7137969,0.000387107,0.26071557,0.004270312,0.00045361114,0.000031573585,0.000071024755,0.0021904453],"genre_scores_gemma":[0.9676023,0.025222732,0.0003133842,0.005248791,0.000039589584,0.00000488771,0.0000022751453,0.00002209289,0.0015439207],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99649256,0.00012749975,0.0017579731,0.00026401322,0.00025168862,0.0011062598],"domain_scores_gemma":[0.99753433,0.00011027359,0.000982061,0.0006178151,0.00055929687,0.0001962307],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018100342,0.00031849561,0.0010251999,0.0024695424,0.0006595084,0.00008572845,0.00077658123,0.0005333355,0.00023904338],"category_scores_gemma":[0.0011247927,0.00028163203,0.0002957043,0.0019914284,0.001052798,0.00013600162,0.000037278383,0.0012818855,0.000015129099],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002463654,0.000034144112,0.005499676,0.00052474975,0.00044639513,0.00019406127,0.00033685687,0.0000015730324,0.00011502613,0.0014962229,0.04852746,0.9425775],"study_design_scores_gemma":[0.0022639188,0.0012856851,0.018438505,0.0050552697,0.00011699776,0.00034439703,0.010113916,0.000006389498,0.0011489228,0.0024460924,0.95856553,0.00021436755],"about_ca_topic_score_codex":0.017960893,"about_ca_topic_score_gemma":0.01170799,"teacher_disagreement_score":0.94951886,"about_ca_system_score_codex":0.0022986606,"about_ca_system_score_gemma":0.035836466,"threshold_uncertainty_score":0.9999636},"labels":[],"label_agreement":null},{"id":"W4416247829","doi":"10.3899/jrheum.2025-0696","title":"Arthroplasty Joint Histology and Surgical Outcomes in Patients on Immune Checkpoint Inhibitors: A Single-Center Case Series","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Rheumatology Research Foundation","keywords":"Arthritis; Joint arthroplasty; Inflammatory arthritis; Osteoarthritis; Arthroplasty; Inflammation; Joint replacement; Cancer","score_opus":0.01234585046719754,"score_gpt":0.24966825861916808,"score_spread":0.23732240815197053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416247829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903332,0.0010747138,0.0000048313127,0.0074927397,0.0007671337,0.00016434435,0.0000021980877,0.00000592907,0.00015493574],"genre_scores_gemma":[0.9990404,0.00054366427,0.00003517439,0.00022748433,0.0000050777194,0.0000021197445,0.0000010335962,0.0000073920764,0.00013762075],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9986312,0.00019814186,0.0007922362,0.00009160478,0.00010568961,0.00018113948],"domain_scores_gemma":[0.99922776,0.00018906905,0.00031383257,0.00014894766,0.00008035706,0.000040045208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046019055,0.00013239101,0.0006132376,0.00024114286,0.00006015671,0.000006411352,0.00005006616,0.00010419604,0.000043949447],"category_scores_gemma":[0.00012966756,0.00007640187,0.00012256482,0.00011181259,0.00031123185,0.00005089392,0.00004559039,0.00031609822,0.0000019042108],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013321231,0.0008002649,0.9773734,0.00007013087,0.000293576,0.00076745055,0.00077129086,9.758431e-7,0.00046906725,0.00011131036,0.00057880866,0.0054424875],"study_design_scores_gemma":[0.053151015,0.010033542,0.38957614,0.0023008836,0.00024868327,0.517688,0.0021831354,0.000016341552,0.0029080405,0.00038726573,0.021120975,0.00038601042],"about_ca_topic_score_codex":0.00016383163,"about_ca_topic_score_gemma":0.00021457084,"teacher_disagreement_score":0.5877973,"about_ca_system_score_codex":0.00013313227,"about_ca_system_score_gemma":0.00007838177,"threshold_uncertainty_score":0.31155777},"labels":[],"label_agreement":null},{"id":"W4416298995","doi":"10.1016/j.isci.2025.113977","title":"CD2 costimulation strength: A key regulator of T cell function and anti-tumor immunity that is epigenetically regulated","year":2025,"lang":"en","type":"article","venue":"iScience","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Society for the History of Medicine","keywords":"Jurkat cells; Downregulation and upregulation; T cell; Regulator; Histone deacetylase; Transcriptome; Chimeric antigen receptor; Function (biology); Peripheral tolerance","score_opus":0.014657555900589148,"score_gpt":0.2638407592579826,"score_spread":0.24918320335739347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416298995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99517846,0.0014961351,0.0009095215,0.00064912677,0.00016806222,0.0002302475,0.0000070183673,0.000024028825,0.0013374164],"genre_scores_gemma":[0.9980883,0.00010867104,0.00042196174,0.0005396217,0.000010088269,0.000002904421,0.000004530873,0.0000043657196,0.0008195593],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992145,0.000031255902,0.00019945217,0.00021124801,0.00020669357,0.00013689241],"domain_scores_gemma":[0.99943554,0.000058680336,0.00008822123,0.00027787118,0.00009424823,0.000045427554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026059727,0.00008848955,0.00016263558,0.00011249897,0.000102896964,0.000019033501,0.00007807056,0.00005216546,0.000095094234],"category_scores_gemma":[0.00003958641,0.00007404777,0.000044757613,0.00047591337,0.00030006922,0.00008356299,0.000037205242,0.00007323586,0.0000017293063],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006134194,0.00010481701,0.031830058,0.00007739114,0.00002508128,0.0000011380802,0.00019343011,0.000009211793,0.94860804,0.0001020963,0.00037717886,0.018058147],"study_design_scores_gemma":[0.0011512517,0.0001841178,0.7051709,0.00013899055,0.000054282875,0.000002672737,0.00009024589,0.0018418054,0.2901696,0.00022739492,0.0009041056,0.000064594606],"about_ca_topic_score_codex":0.00010507433,"about_ca_topic_score_gemma":0.000006566003,"teacher_disagreement_score":0.6733409,"about_ca_system_score_codex":0.000038142647,"about_ca_system_score_gemma":0.00013371395,"threshold_uncertainty_score":0.30195802},"labels":[],"label_agreement":null},{"id":"W4416312954","doi":"10.3390/molecules30224445","title":"Comparative In Vitro and In Vivo Evaluation of Anti-CCR8 Full-Sized IgG and Its Fab Fragments in Murine Colorectal Cancer Models","year":2025,"lang":"en","type":"article","venue":"Molecules","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Colorectal Cancer Alliance; University of Saskatchewan","keywords":"In vivo; Biodistribution; Radioimmunotherapy; Immunotherapy; Colorectal cancer; Antibody; Monoclonal antibody; In vitro; Kidney","score_opus":0.03210305850647515,"score_gpt":0.3381144461301452,"score_spread":0.30601138762367003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416312954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910235,0.00753845,0.000018082304,0.00034286868,0.000037988662,0.0006211278,0.000022927727,0.0000036920271,0.00039137076],"genre_scores_gemma":[0.99908835,0.0006013281,0.00007638543,0.000104660234,0.000004120609,0.000085388136,0.000008518424,0.0000043374994,0.000026934425],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992192,0.00009236142,0.00023541418,0.00017698544,0.00016474497,0.000111343674],"domain_scores_gemma":[0.9997731,0.000033941902,0.000049613296,0.00006863645,0.000056968474,0.000017752656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028446742,0.00009313305,0.0003062274,0.00023176904,0.00001150815,0.0000054183856,0.00003570216,0.000053594213,0.000025464738],"category_scores_gemma":[0.000023355262,0.00008548699,0.000017687093,0.00028184438,0.000050196046,0.000051810508,0.000032345364,0.000076777804,9.631829e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005305779,0.00014772342,0.00803641,0.00008236326,0.000057623773,0.000006068804,0.0012346725,0.00058449217,0.9815368,0.000010887428,0.00003128977,0.0029658605],"study_design_scores_gemma":[0.013027775,0.000100720696,0.24008793,0.00047875664,0.000043518135,0.0000021373446,0.00035411463,0.10354563,0.6420165,0.00023611615,0.000013001937,0.000093842944],"about_ca_topic_score_codex":0.00079863507,"about_ca_topic_score_gemma":0.001870473,"teacher_disagreement_score":0.33952036,"about_ca_system_score_codex":0.00012994191,"about_ca_system_score_gemma":0.00013190672,"threshold_uncertainty_score":0.3486058},"labels":[],"label_agreement":null},{"id":"W4416329987","doi":"10.1016/j.xcrm.2025.102450","title":"The tumor microenvironment of 14,837 breast cancers is associated with clinical outcome independently of genomic subtypes","year":2025,"lang":"en","type":"article","venue":"Cell Reports Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"UK Research and Innovation; Winston Churchill Foundation of the United States; European Association for Cancer Research","keywords":"Tumor microenvironment; Stromal cell; Gene expression profiling; Immunotherapy; Breast cancer; Biomarker; Tumour heterogeneity","score_opus":0.015031737755106881,"score_gpt":0.29077265717368894,"score_spread":0.2757409194185821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416329987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986435,0.0055872397,0.000021850445,0.002271433,0.00068226125,0.0005227917,0.000010777936,0.00001504269,0.0044536064],"genre_scores_gemma":[0.98842406,0.0010806435,0.000021717913,0.0011918134,0.00006737231,0.0000110822,0.000017540251,0.000018608815,0.009167166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975207,0.000059964754,0.0014137061,0.00031385917,0.0004601381,0.00023162464],"domain_scores_gemma":[0.997916,0.00021780262,0.0010390816,0.00061216694,0.00012756523,0.000087408065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013951572,0.0001812094,0.00071351865,0.000089164016,0.00006666296,0.0000033220629,0.000120297445,0.00009200378,0.0003088147],"category_scores_gemma":[0.00012690606,0.000101236576,0.00015952751,0.0002099321,0.00083915755,0.00001764526,0.00004181826,0.00024397453,0.0000012660842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027722558,0.00024792066,0.93554455,0.00019986893,0.0009236955,0.00034932845,0.00028543224,0.0000032906285,0.04468445,0.000004207497,0.010148293,0.004836712],"study_design_scores_gemma":[0.004689481,0.00077054737,0.9626877,0.0008118909,0.00063474785,0.00026162498,0.00061485224,0.000009179211,0.014461251,0.000022189699,0.014916657,0.0001198917],"about_ca_topic_score_codex":0.00071304844,"about_ca_topic_score_gemma":0.0001277464,"teacher_disagreement_score":0.0302232,"about_ca_system_score_codex":0.0003003781,"about_ca_system_score_gemma":0.0005081984,"threshold_uncertainty_score":0.41283077},"labels":[],"label_agreement":null},{"id":"W4416385639","doi":"10.1038/s44276-025-00185-8","title":"Tumor cell-intrinsic PD-1 regulates chemotherapy resistance in colorectal cancer cells by activating downstream MAPK signaling","year":2025,"lang":"en","type":"article","venue":"BJC Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"BC Cancer Agency; BC Cancer Foundation; Canada's Michael Smith Genome Sciences Centre; Cancer Research Society","keywords":"Colorectal cancer; Chemotherapy; MAPK/ERK pathway; Signal transduction; Protein kinase B; Cell growth; Drug resistance; PI3K/AKT/mTOR pathway","score_opus":0.004939381807737897,"score_gpt":0.24792388219144595,"score_spread":0.24298450038370806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416385639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98613024,0.0055383504,0.000016954507,0.0009442947,0.00043623688,0.0006243765,0.000007900878,0.000082333136,0.0062192935],"genre_scores_gemma":[0.9920143,0.00035464863,0.0005053242,0.00082372077,0.00009222173,0.00009959145,0.000018168517,0.000032363412,0.006059679],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99815357,0.00003674897,0.0006655695,0.00051319116,0.0002636318,0.00036726738],"domain_scores_gemma":[0.9991041,0.000086668646,0.0003518783,0.00031277473,0.00007874991,0.00006583156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035485486,0.000238756,0.00043396596,0.00015671024,0.000093368915,0.000037539725,0.00007447168,0.000113447706,0.00025420176],"category_scores_gemma":[0.000033162338,0.00021772832,0.0001341136,0.00059337995,0.00008685269,0.0000787707,0.000023045002,0.00022207285,0.0000014687544],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018140355,0.00016212341,0.015196734,0.00019494141,0.000093445415,0.0004255806,0.00026663102,0.000007714644,0.9548476,0.0000029168052,0.017139817,0.009848472],"study_design_scores_gemma":[0.0016698359,0.000056586643,0.024192847,0.0008143031,0.000026091991,0.000035009532,0.00014520877,0.000010590899,0.94782335,0.00008111017,0.024939673,0.0002054058],"about_ca_topic_score_codex":0.00084040774,"about_ca_topic_score_gemma":0.00019417462,"teacher_disagreement_score":0.009643066,"about_ca_system_score_codex":0.00043562351,"about_ca_system_score_gemma":0.00039511462,"threshold_uncertainty_score":0.8878703},"labels":[],"label_agreement":null},{"id":"W4416387202","doi":"10.3389/fimmu.2025.1655258","title":"Baseline AHR expression shapes immune response to pharmacological modulation in PBMCs from pancreatic cancer patients","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Lietuvos Sveikatos Mokslų Universitetas","keywords":"Immune system; Peripheral blood mononuclear cell; Immunotherapy; Pancreatic cancer; Biomarker; Immune modulation; Gene expression profiling","score_opus":0.010836349170672456,"score_gpt":0.29188601788294105,"score_spread":0.2810496687122686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416387202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98432535,0.0089591155,0.0017558343,0.0022371085,0.0017577346,0.00079661375,0.000034995912,0.000042836466,0.00009043197],"genre_scores_gemma":[0.99354225,0.0012231732,0.002995424,0.001306679,0.000042201395,0.0002634826,0.00008446291,0.00001658323,0.0005257596],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980431,0.00046364544,0.00058965536,0.00041505854,0.00013887112,0.0003496211],"domain_scores_gemma":[0.9993777,0.00020136416,0.000095831456,0.00022050779,0.0000639324,0.000040609983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004450788,0.00020373781,0.00053825433,0.0006246072,0.000053358857,0.000009911909,0.0001793813,0.00025851562,0.0003492048],"category_scores_gemma":[0.0003085002,0.00018063352,0.00008370654,0.00066661485,0.000103150494,0.000079978105,0.00009312317,0.00031205054,0.0000068525696],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07235257,0.0005065518,0.26309234,0.000017905963,0.00020509244,0.000021268492,0.00052609306,0.00012663036,0.57970065,0.0000018656674,0.0049733054,0.07847571],"study_design_scores_gemma":[0.009601296,0.00034399444,0.9585358,0.0005134459,0.00005502761,6.209903e-7,0.00026698565,0.001827526,0.021550791,0.00018638143,0.0069430103,0.0001751092],"about_ca_topic_score_codex":0.0010495203,"about_ca_topic_score_gemma":0.00006232565,"teacher_disagreement_score":0.69544345,"about_ca_system_score_codex":0.0007151396,"about_ca_system_score_gemma":0.00016776836,"threshold_uncertainty_score":0.7366021},"labels":[],"label_agreement":null},{"id":"W4416387689","doi":"10.1016/j.annonc.2025.09.040","title":"LBA29 Nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): New results from CheckMate 8HW","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Colorectal cancer; Metastatic melanoma; Chemotherapy; Phases of clinical research","score_opus":0.05744008029439762,"score_gpt":0.37715881685172103,"score_spread":0.3197187365573234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416387689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9646294,0.014291718,0.00040075937,0.014125988,0.0014602013,0.0023243143,0.0013076193,0.00019700674,0.0012629912],"genre_scores_gemma":[0.96453345,0.009113557,0.007060222,0.008560035,0.0003637702,0.00044193075,0.0006673649,0.000115376344,0.009144274],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957977,0.0002584938,0.0017103715,0.0010408731,0.0003638013,0.00082879176],"domain_scores_gemma":[0.9968588,0.00076705427,0.00071264943,0.00085265416,0.0005875637,0.00022130707],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011659883,0.00050254865,0.0016611806,0.00032575548,0.0001964407,0.000034417684,0.00037577437,0.00041068674,0.0003988598],"category_scores_gemma":[0.00027642748,0.0004648854,0.0007818337,0.000657646,0.00048324026,0.00013956991,0.00009903472,0.00034668285,0.000016293647],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37650082,0.0029253957,0.0016603499,0.00085509144,0.0055793063,0.0000780525,0.008675622,0.00022312076,0.1588329,0.0004208882,0.11604104,0.32820743],"study_design_scores_gemma":[0.076009504,0.010988189,0.018404743,0.0010508753,0.0008583637,0.0000315442,0.0013380637,0.0014181614,0.17270537,0.0023279607,0.71404797,0.0008192738],"about_ca_topic_score_codex":0.023637902,"about_ca_topic_score_gemma":0.0051975166,"teacher_disagreement_score":0.5980069,"about_ca_system_score_codex":0.00076343905,"about_ca_system_score_gemma":0.0032330703,"threshold_uncertainty_score":0.9997803},"labels":[],"label_agreement":null},{"id":"W4416391584","doi":"10.1016/j.annonc.2025.09.032","title":"LBA22 Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in patients (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) in the phase III ASCENT-04/KEYNOTE-D19 study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Eisai; Gilead Sciences; AstraZeneca; Gilead UK and Ireland Corporate Contributions; Pfizer","keywords":"Pembrolizumab; Metastatic breast cancer; Chemotherapy; Breast cancer; Phases of clinical research; Chemotherapy regimen","score_opus":0.027596952817562605,"score_gpt":0.36601590485305335,"score_spread":0.33841895203549077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872939,0.0003628099,0.00001738273,0.0048350706,0.00015734689,0.006382287,0.00014785102,0.00005232727,0.0007509993],"genre_scores_gemma":[0.9933976,0.0003026532,0.00008942907,0.0048085083,0.000022658323,0.00082409737,0.000102852435,0.00006453407,0.00038764934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99511105,0.0007126739,0.001616205,0.00088862324,0.00080203835,0.00086942286],"domain_scores_gemma":[0.99681413,0.00041766712,0.001099866,0.000881965,0.00064645347,0.0001399196],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00083714625,0.0006966988,0.001984965,0.00070677436,0.00013243142,0.000036713165,0.0004092928,0.00020689526,0.00024132778],"category_scores_gemma":[0.00012380547,0.00042678203,0.00024464872,0.0020752246,0.0004647818,0.0002207571,0.00006190872,0.00059447915,0.0000021604947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32335654,0.022013212,0.5144186,0.0002473533,0.004074095,0.00037359708,0.013675945,0.0000387432,0.00033148605,0.000014185716,0.0014119571,0.12004426],"study_design_scores_gemma":[0.21612296,0.02565881,0.7483878,0.00061283016,0.000669632,0.00007943407,0.0050824108,0.000073227995,0.0016220768,0.00003094794,0.001193873,0.0004659913],"about_ca_topic_score_codex":0.012537387,"about_ca_topic_score_gemma":0.012434019,"teacher_disagreement_score":0.2339692,"about_ca_system_score_codex":0.00079461193,"about_ca_system_score_gemma":0.0016739941,"threshold_uncertainty_score":0.9998184},"labels":[],"label_agreement":null},{"id":"W4416391729","doi":"10.1016/j.annonc.2025.09.079","title":"LBA67 Perioperative pembrolizumab in early-stage non-small- cell lung cancer (NSCLC): 5-year follow-up from KEYNOTE- 671","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Lung cancer; Perioperative; Respiratory disease; Cancer","score_opus":0.032199601494794144,"score_gpt":0.35926907952241294,"score_spread":0.32706947802761877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.954295,0.0042866217,0.00005114159,0.0048056114,0.00070876774,0.00063142576,0.00008892042,0.000021878646,0.03511068],"genre_scores_gemma":[0.9792007,0.0025839882,0.0001940667,0.0045785327,0.00012261374,0.000110575325,0.000026501635,0.000023736879,0.013159249],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984056,0.00012410889,0.0005257269,0.00039306606,0.00015655802,0.0003949867],"domain_scores_gemma":[0.99903667,0.00016649738,0.00016921728,0.00034291265,0.00020258148,0.000082124054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026669988,0.00022291942,0.000712939,0.00025001052,0.000058766294,0.0000137714,0.00019948081,0.00030381797,0.00088120543],"category_scores_gemma":[0.000044913217,0.00020199237,0.00022895132,0.00038679744,0.00017077928,0.00007491142,0.000074732045,0.00032928016,0.000013265482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10005285,0.0023692206,0.44333053,0.0008886558,0.0026925784,0.0005238049,0.033138957,0.00009100497,0.265068,0.00040336399,0.050068446,0.1013726],"study_design_scores_gemma":[0.054943033,0.0046779,0.5815893,0.0011970262,0.00032520815,0.000004657266,0.0049071386,0.00049914914,0.21045688,0.000074160635,0.1407032,0.00062236877],"about_ca_topic_score_codex":0.022993246,"about_ca_topic_score_gemma":0.005282841,"teacher_disagreement_score":0.13825876,"about_ca_system_score_codex":0.00020623504,"about_ca_system_score_gemma":0.0012623656,"threshold_uncertainty_score":0.9835127},"labels":[],"label_agreement":null},{"id":"W4416391742","doi":"10.1016/j.annonc.2025.09.077","title":"LBA65 Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: Interim analysis (IA) of the phase II MDT-BRIDGE study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; AstraZeneca (Canada); Kingston General Hospital","funders":"Jiangsu Cancer Hospital; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; University of Chicago Medicine; Betta Pharmaceuticals; State Key Laboratory of Molecular Oncology; Guangxi Medical University; Xiamen University; School of Medicine, Stanford University; Tianjin Medical University; Weill Cornell Medical College; Peking University; Directorate for Biological Sciences; Universidad de Las Palmas de Gran Canaria; Université de Montréal; University of Chinese Academy of Sciences; Zhejiang University; Chinese Academy of Medical Sciences; Tongji University; Peking Union Medical College; Huazhong University of Science and Technology; Dalian University of Technology; Shandong University; Sichuan University; Sun Yat-sen University; McGill University; McGill University Health Centre; Chinese Academy of Sciences; West China Hospital, Sichuan University; Lanzhou University; Stanford Cancer Institute; Harbin Medical University; Memorial Sloan-Kettering Cancer Center; Deutsches Zentrum für Lungenforschung; AstraZeneca","keywords":"Durvalumab; Interim; Neoadjuvant therapy; Chemotherapy; Adjuvant; Stage (stratigraphy)","score_opus":0.05451174183621708,"score_gpt":0.40424994759058586,"score_spread":0.34973820575436876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945737,0.0013741177,0.000034992077,0.0019639793,0.00009579672,0.0015607745,0.00010582149,0.0000121689245,0.00027866545],"genre_scores_gemma":[0.99522275,0.0011695295,0.00004172109,0.0008325314,0.000012979939,0.00008864931,0.00005539452,0.000023384606,0.002553047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976597,0.0003883558,0.0008629167,0.00044372847,0.00030207686,0.0003432258],"domain_scores_gemma":[0.99820554,0.00042710756,0.0004964653,0.00048103178,0.00032042098,0.000069413734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013076963,0.0002496782,0.001236771,0.0004965357,0.000116769144,0.000015115187,0.00014772436,0.00010930143,0.00034712185],"category_scores_gemma":[0.0002594262,0.00014965357,0.00013408846,0.001456378,0.00034322953,0.0001259591,0.00010751446,0.00019433364,1.7651365e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21993667,0.014332372,0.5892256,0.00032445038,0.0051747574,0.00007820138,0.0027697582,0.000010258514,0.022529766,0.000005725554,0.017805083,0.12780736],"study_design_scores_gemma":[0.10375405,0.05793654,0.7449174,0.000994279,0.00139319,0.00002376726,0.0035340046,0.00039676658,0.049804714,0.000013187931,0.036676437,0.0005556362],"about_ca_topic_score_codex":0.0025052465,"about_ca_topic_score_gemma":0.00457959,"teacher_disagreement_score":0.15569182,"about_ca_system_score_codex":0.0000873492,"about_ca_system_score_gemma":0.00060895586,"threshold_uncertainty_score":0.61026955},"labels":[],"label_agreement":null},{"id":"W4416391839","doi":"10.1016/j.annonc.2025.09.080","title":"LBA68 CCTG BR.31: Adjuvant durvalumab (D) in resected non-small-cell lung cancer (NSCLC): Final overall survival (OS) and minimal residual disease (MRD) analyses","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Cancer Society; Dalhousie University; Ottawa Hospital","funders":"Daiichi Sankyo Europe; National Cancer Institute; Eli Lilly Japan; MSD K.K.; Chugai Pharmaceutical; Chinese Society of Clinical Oncology; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Eisai; Daiichi-Sankyo; Seagen; Astellas Foundation for Research on Metabolic Disorders; Taiho Pharmaceutical; Boehringer Ingelheim Japan; International Association for the Study of Lung Cancer; BeiGene; AstraZeneca; Associazione Italiana di Oncologia Medica; Novocure; Pfizer; Incyte; Ono Pharmaceutical; Eli Lilly and Company; European SocieTy for Radiotherapy and Oncology; Bristol-Myers Squibb; American Society of Clinical Oncology; Regeneron Pharmaceuticals; Sanofi; Amgen","keywords":"Durvalumab; Overall survival; Adjuvant; Lung cancer; Disease; Survival analysis; Proportional hazards model; Lung","score_opus":0.09800486052716045,"score_gpt":0.4299573125928187,"score_spread":0.33195245206565827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9684644,0.015041649,0.000012047462,0.008987258,0.00032172995,0.0005490137,0.00011107153,0.000022570988,0.0064903037],"genre_scores_gemma":[0.9883937,0.005475637,0.00013719853,0.0021124282,0.00015968688,0.0000712419,0.00005371077,0.0000210671,0.0035752815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978447,0.00023806051,0.0006828451,0.0004907225,0.00025012688,0.0004935334],"domain_scores_gemma":[0.9986537,0.0003450858,0.00022793568,0.00034951235,0.00024656072,0.00017717411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060951675,0.00025792426,0.0008291364,0.00044424992,0.00007188759,0.000015412154,0.00018033053,0.00022350077,0.00026020646],"category_scores_gemma":[0.0001700421,0.0002320568,0.00018510393,0.00049590424,0.0002788431,0.00007934339,0.0001176563,0.00030507203,0.0000018804458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14409085,0.003730187,0.44926098,0.0022443288,0.0021780103,0.0013535476,0.0015693167,0.00008989117,0.19171551,0.00014265717,0.13796405,0.06566067],"study_design_scores_gemma":[0.015309502,0.0018755934,0.9586679,0.00066063716,0.00039465073,0.000008880226,0.00025579362,0.00052768586,0.009978125,0.00007852625,0.011970507,0.00027221686],"about_ca_topic_score_codex":0.0043848506,"about_ca_topic_score_gemma":0.0038010045,"teacher_disagreement_score":0.50940686,"about_ca_system_score_codex":0.0001535049,"about_ca_system_score_gemma":0.0021170264,"threshold_uncertainty_score":0.9463002},"labels":[],"label_agreement":null},{"id":"W4416410553","doi":"10.1016/j.annonc.2025.11.008","title":"Emerging options and future strategies in immunotherapy for advanced lung squamous-cell carcinoma","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University of Texas MD Anderson Cancer Center; Rexanna's Foundation; University of Texas at Austin; Cancer Prevention and Research Institute of Texas","keywords":"Immunotherapy; Lung cancer; Immune system; Carcinoma; Immune checkpoint; Nivolumab; Tumor microenvironment","score_opus":0.023821984828242136,"score_gpt":0.37509629284134677,"score_spread":0.3512743080131046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416410553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9428684,0.032818027,0.00018068514,0.014713026,0.00027421478,0.00052147475,0.000011361091,0.00001428734,0.0085985055],"genre_scores_gemma":[0.99186826,0.0049853413,0.0008821301,0.0016003526,0.00007443743,0.00007229964,0.000011968519,0.000009328794,0.00049586804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99929684,0.000033338514,0.00028125066,0.00015828872,0.00004565987,0.00018464767],"domain_scores_gemma":[0.9995454,0.00011581492,0.00008556883,0.0001381486,0.00009298739,0.000022106718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021418619,0.000097075674,0.00030180396,0.0001870443,0.000045231653,0.0000057843113,0.000056515117,0.00012068561,0.000038662223],"category_scores_gemma":[0.000009700602,0.000088300694,0.00008863265,0.00019219842,0.00009433041,0.00007054479,0.00001240479,0.000094706076,1.7875129e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017831795,0.00092049845,0.011390509,0.0009301921,0.00019337308,0.000022053015,0.0027720092,0.00004227966,0.31463856,0.008616483,0.008606958,0.6340353],"study_design_scores_gemma":[0.02590125,0.0056352387,0.19280446,0.00013572007,0.00008032658,0.000021500315,0.01117854,0.00034667237,0.035267618,0.0020975515,0.7262417,0.00028944225],"about_ca_topic_score_codex":0.000092319504,"about_ca_topic_score_gemma":0.00009533838,"teacher_disagreement_score":0.71763474,"about_ca_system_score_codex":0.00003789662,"about_ca_system_score_gemma":0.00029868577,"threshold_uncertainty_score":0.3600798},"labels":[],"label_agreement":null},{"id":"W4416446900","doi":"10.1093/jimmun/vkaf283.1708","title":"Tumor microenvironmental stress modulates membrane trafficking to regulate T cell receptor complex aggregation in Epithelial Ovarian Cancer 3967","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Endosome; T cell; T-cell receptor; Cytotoxic T cell; Ovarian cancer; Cancer cell; Tumor microenvironment; Immune system","score_opus":0.01060142853113596,"score_gpt":0.25462127807168194,"score_spread":0.24401984954054598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416446900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98711246,0.004311964,0.00006421108,0.007510457,0.0005971949,0.00028284112,0.000016824071,0.0000077841105,0.000096268675],"genre_scores_gemma":[0.99627686,0.0018650513,0.00033621275,0.00094240665,0.000105975385,0.000004890991,0.0000055904693,0.000014691795,0.00044832588],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988012,0.00017826406,0.0005418758,0.00011325519,0.00013164071,0.00023378906],"domain_scores_gemma":[0.99935627,0.00008269727,0.00028586204,0.00019701698,0.000045802797,0.000032321488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044169428,0.0001411766,0.00035258278,0.00025303217,0.00008078299,0.000011351676,0.000227036,0.00007012073,0.00037649914],"category_scores_gemma":[0.000018647144,0.0000986449,0.00010421413,0.00025408147,0.0001490913,0.000060137016,0.000044696728,0.00030494155,0.00000699056],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0081487745,0.000148219,0.0010510571,0.000029064135,0.00024896648,0.000015223323,0.0011225614,0.0006139616,0.9597267,0.000007097619,0.00031291042,0.028575493],"study_design_scores_gemma":[0.006854253,0.0005836048,0.16411376,0.00071730337,0.00014094489,0.00020178604,0.0012385156,0.00017504972,0.8179985,0.000031226504,0.0078082075,0.00013680372],"about_ca_topic_score_codex":0.00040705974,"about_ca_topic_score_gemma":0.000107572836,"teacher_disagreement_score":0.1630627,"about_ca_system_score_codex":0.00035032808,"about_ca_system_score_gemma":0.00011837034,"threshold_uncertainty_score":0.41224018},"labels":[],"label_agreement":null},{"id":"W4416448019","doi":"10.1093/jimmun/vkaf283.872","title":"Defining molecular determinants of T cell spatial localization and clonal response throughout PDAC malignant progression 3030","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network","funders":"","keywords":"Tumor microenvironment; Cytotoxic T cell; Phenotype; Immune system; T cell; CD8; Cancer; Cell; Immunotherapy","score_opus":0.008186848809717467,"score_gpt":0.30409046378195814,"score_spread":0.29590361497224066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416448019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749252,0.0199797,0.003947088,0.00069103955,0.00023900036,0.00012810873,0.0000020252057,0.000004033155,0.0000837554],"genre_scores_gemma":[0.9975704,0.0016039197,0.00046451754,0.0002693562,0.000014517876,0.0000012339409,0.0000010710537,0.000008033941,0.00006696043],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99887437,0.0003172849,0.00047086983,0.00006865138,0.00013939271,0.00012941203],"domain_scores_gemma":[0.99910206,0.00017006071,0.0004131767,0.00015278884,0.00014440084,0.000017490509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009216698,0.00009194209,0.00028554993,0.00013908256,0.000066827546,0.000005230578,0.000108723085,0.00009598861,0.0000204802],"category_scores_gemma":[0.00010666354,0.00005515095,0.0000741963,0.00015468484,0.0002543531,0.0000382152,0.000050932438,0.00016776346,7.0318976e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04497997,0.00010552324,0.008913541,0.000060389506,0.00017616438,0.000056748147,0.0006011205,0.000007974346,0.89982545,0.000041879888,0.00006378328,0.045167442],"study_design_scores_gemma":[0.0045957374,0.002423074,0.080172904,0.00085355726,0.0002566944,0.0008721327,0.00047711248,0.0002322278,0.908586,0.00019106132,0.0012638977,0.00007555729],"about_ca_topic_score_codex":0.000043112428,"about_ca_topic_score_gemma":0.00000413936,"teacher_disagreement_score":0.071259364,"about_ca_system_score_codex":0.000043652115,"about_ca_system_score_gemma":0.00024937905,"threshold_uncertainty_score":0.22489904},"labels":[],"label_agreement":null},{"id":"W4416448296","doi":"10.1093/jimmun/vkaf283.1370","title":"Rasal1 regulates stemness and exhaustion of CD8 T-cells for more effective anti-PD-1 tumor immunity 3588","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Blockade; Signal transduction; Immune system; Downregulation and upregulation; Phosphorylation; Intracellular; Cytotoxic T cell; CD8; PD-L1","score_opus":0.008383202551762566,"score_gpt":0.27971940378901794,"score_spread":0.2713362012372554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416448296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843338,0.0126832975,0.00047313413,0.0014078879,0.0005119363,0.00051202084,0.0000066498687,0.0000067951883,0.00006445242],"genre_scores_gemma":[0.9979275,0.0014380582,0.00014383948,0.00019525288,0.000044417815,0.0000068488353,0.0000019304587,0.000010206974,0.00023197818],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99902207,0.00020147607,0.00045934497,0.00007379808,0.00009119997,0.00015214256],"domain_scores_gemma":[0.998419,0.00057444395,0.00045109904,0.00023107596,0.00030581476,0.000018584406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010760956,0.000121673045,0.00048684436,0.0001905759,0.000103388214,0.000006047906,0.00016095706,0.000090055386,0.00001771728],"category_scores_gemma":[0.0001105144,0.000075071344,0.00013906442,0.00018964276,0.00046919772,0.00006203658,0.000045511566,0.00025979805,3.5913592e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014275515,0.00012643321,0.0009293373,0.00019055116,0.0010605023,0.0000046218947,0.00064335275,0.000008695001,0.9688703,0.00006823262,0.00042841543,0.013394054],"study_design_scores_gemma":[0.007446444,0.001914666,0.24028027,0.00071841606,0.00056093547,0.0005039816,0.0022487126,0.00004139264,0.74468297,0.0004432164,0.0010715518,0.00008742639],"about_ca_topic_score_codex":0.00008601692,"about_ca_topic_score_gemma":0.0000031202312,"teacher_disagreement_score":0.23935094,"about_ca_system_score_codex":0.00007149563,"about_ca_system_score_gemma":0.00012382356,"threshold_uncertainty_score":0.30613205},"labels":[],"label_agreement":null},{"id":"W4416452822","doi":"10.33696/immunology.7.235","title":"Mechanisms and Therapeutic Strategies to Overcome Immune Checkpoint Inhibitor Resistance in Melanoma, Head and Neck, and Triple-Negative Breast Cancers","year":2025,"lang":"en","type":"article","venue":"Journal of Cellular Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; York University","keywords":"Immunotherapy; Context (archaeology); Nivolumab; Melanoma; Head and neck squamous-cell carcinoma; Cancer; Acquired resistance; Immune system; Breast cancer","score_opus":0.008955093749801885,"score_gpt":0.258282814271548,"score_spread":0.2493277205217461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416452822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91693705,0.07808299,0.00049923063,0.0035328497,0.00033157662,0.00030453003,0.0000061747965,0.0000069841526,0.00029862166],"genre_scores_gemma":[0.9945993,0.0035300255,0.0009941446,0.00036286307,0.000030746905,0.000008125702,0.0000010726492,0.000013856603,0.00045985542],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99868906,0.00011381005,0.0006174827,0.0002060284,0.00012906728,0.00024458094],"domain_scores_gemma":[0.99933827,0.00009411853,0.00024169865,0.00015794563,0.000103689075,0.00006427655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004526373,0.00019507704,0.00060284237,0.00039058682,0.00007175642,0.000043966244,0.00008583952,0.00014838102,0.000026136508],"category_scores_gemma":[0.00003137825,0.00015973768,0.00007615853,0.0002882585,0.00023389517,0.00012312717,0.000054200213,0.00036499396,4.1744357e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013822039,0.00007575795,0.0013370964,0.00013018968,0.0006322201,0.000119976416,0.002076347,0.000001466985,0.9713231,0.001932799,0.000025085585,0.008523972],"study_design_scores_gemma":[0.023848869,0.0032331503,0.8140436,0.0022985146,0.0002674538,0.0012581075,0.00782437,0.00003135572,0.12925008,0.013900072,0.0036155197,0.00042890912],"about_ca_topic_score_codex":0.00044343242,"about_ca_topic_score_gemma":0.00047761473,"teacher_disagreement_score":0.84207296,"about_ca_system_score_codex":0.0002512839,"about_ca_system_score_gemma":0.0003594297,"threshold_uncertainty_score":0.6513914},"labels":[],"label_agreement":null},{"id":"W4416454169","doi":"10.20944/preprints202511.1463.v1","title":"Am-Bivalent Copper: Mechanistically Distinct Immune Effects Driving Innovation in Cancer Nanomedicine","year":2025,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Immune system; Context (archaeology); Nanomedicine; Cancer; Immune modulation; Mechanism (biology); Immunotherapy; Cancer cell; Cell","score_opus":0.06015958961675965,"score_gpt":0.3676880844001029,"score_spread":0.30752849478334326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416454169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796366,0.002082287,0.0006972609,0.0041198763,0.0027058509,0.0024506785,0.00005293785,0.00021575205,0.0080387285],"genre_scores_gemma":[0.99167526,0.0016531553,0.00023202672,0.00096058345,0.0003654101,0.00083293667,0.00025280044,0.000053104006,0.0039747274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99584395,0.00017663294,0.0016035754,0.0011905668,0.0006284937,0.00055675575],"domain_scores_gemma":[0.99734706,0.0002537684,0.00057371054,0.0013378481,0.00037209617,0.00011549443],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016634277,0.00057491043,0.0011587414,0.0007631248,0.000096983706,0.000028908722,0.0004861495,0.00059670536,0.0010764628],"category_scores_gemma":[0.0013726492,0.000540501,0.0002544079,0.0010204277,0.00017961112,0.0000722388,0.0012169998,0.0015813018,0.00007122945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021108354,0.0006071955,0.76194674,0.0042235786,0.00075856457,0.00013191302,0.0007041867,0.00003537538,0.20820393,0.00080406544,0.00021201016,0.020261604],"study_design_scores_gemma":[0.004060697,0.00012203467,0.90618753,0.01043797,0.0003048049,0.000012980518,0.000049765727,0.00023854882,0.07229415,0.00072140037,0.005082269,0.0004878588],"about_ca_topic_score_codex":0.0020358374,"about_ca_topic_score_gemma":0.00019913158,"teacher_disagreement_score":0.14424077,"about_ca_system_score_codex":0.0014052184,"about_ca_system_score_gemma":0.0009914408,"threshold_uncertainty_score":0.9998367},"labels":[],"label_agreement":null},{"id":"W4416607719","doi":"10.1038/s41598-025-28810-z","title":"Expression of carcinoma ecotypes in the tumor microenvironment predicts response to neoadjuvant therapy in early-stage breast cancer","year":2025,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Beatrice Hunter Cancer Research Institute; Nova Scotia Health Authority; Dalhousie University","funders":"Canadian Institutes of Health Research; Dalhousie University","keywords":"Breast cancer; Immunotherapy; Neoadjuvant therapy; Chemotherapy; Transcriptome; Tumor microenvironment; Breast carcinoma","score_opus":0.010820789995896174,"score_gpt":0.2652666542845977,"score_spread":0.25444586428870153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416607719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99418646,0.0015346457,0.0000029432356,0.0020684502,0.001123906,0.00091179006,0.000014468345,0.000011380913,0.00014596536],"genre_scores_gemma":[0.9971426,0.000051910414,0.00003554613,0.00042242857,0.000018165047,0.000106048974,0.0000057828183,0.000008404175,0.002209123],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982293,0.00014157999,0.00051905715,0.00046534932,0.0004019237,0.00024274878],"domain_scores_gemma":[0.9989439,0.00005022548,0.00014968643,0.0007725907,0.00003642435,0.000047164827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020939126,0.00012451188,0.00022763354,0.00035647422,0.00006746416,0.000038449078,0.0001385586,0.00004282159,0.00011729247],"category_scores_gemma":[0.00003757904,0.00008003886,0.00007732394,0.00070320745,0.00017123893,0.00005628722,0.000047677302,0.00011569761,0.0000016674229],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004330409,0.00018855922,0.39084485,0.0000286428,0.00000866985,0.00038150977,0.0022887702,0.000024681542,0.5962577,7.0756374e-7,0.0032457514,0.0023997973],"study_design_scores_gemma":[0.0008958465,0.00010284463,0.8058077,0.00041825214,0.000005795788,0.000055525237,0.00036206163,0.000006441098,0.17783725,0.000019400353,0.014426944,0.000061909945],"about_ca_topic_score_codex":0.001119752,"about_ca_topic_score_gemma":0.00029773795,"teacher_disagreement_score":0.4184204,"about_ca_system_score_codex":0.00018839035,"about_ca_system_score_gemma":0.00032101534,"threshold_uncertainty_score":0.32638898},"labels":[],"label_agreement":null},{"id":"W4416619436","doi":"10.5256/f1000research.25082.r75094","title":"Referee report. For: Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry [version 1; peer review: 2 approved]","year":2020,"lang":"en","type":"article","venue":"Faculty of 1000 Research Ltd","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Servier; Regeneron Pharmaceuticals; Mersana Therapeutics; Karyopharm Therapeutics; PTC Therapeutics; Princess Margaret Cancer Foundation; Sanofi; GlaxoSmithKline; Amgen; Pfizer; MorphoSys; Celgene; Symphogen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Toxicity; Autoantibody; Mass spectrometry; Drug; Immune system","score_opus":0.0841799796860403,"score_gpt":0.3973060153578921,"score_spread":0.3131260356718518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416619436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91214144,0.0029255822,0.00090071105,0.0812366,0.000071413546,0.0012786282,0.0010724094,0.00006124273,0.0003119502],"genre_scores_gemma":[0.97231334,0.0016697077,0.011727702,0.001334629,0.00037281323,0.000048514812,0.0015938001,0.00006916781,0.010870295],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99629,0.00033898858,0.00064913597,0.00058790523,0.0016920508,0.0004419003],"domain_scores_gemma":[0.9968904,0.00037221142,0.00021045948,0.00044399456,0.0018432065,0.0002396912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057867956,0.00019145578,0.0005313835,0.0002466134,0.0002930602,0.00006377809,0.00015638368,0.00014423163,0.00017881363],"category_scores_gemma":[0.0074443477,0.00016927558,0.00017877317,0.0006970229,0.00019241803,0.0001904899,0.00020820966,0.0004259619,0.000011340312],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011398955,0.000048561717,0.0018760966,0.00095311366,0.00016048463,0.00006151137,0.00061290385,9.748484e-7,0.9188369,0.0000023840075,0.06509864,0.0009494501],"study_design_scores_gemma":[0.004105128,0.0020475732,0.07008352,0.006418397,0.00017887045,0.000083228544,0.0020189246,0.0005924392,0.72356737,0.000092395676,0.19044003,0.00037211285],"about_ca_topic_score_codex":0.000759794,"about_ca_topic_score_gemma":0.00002855577,"teacher_disagreement_score":0.19526954,"about_ca_system_score_codex":0.00034750235,"about_ca_system_score_gemma":0.00027365042,"threshold_uncertainty_score":0.8912117},"labels":[],"label_agreement":null},{"id":"W4416630659","doi":"10.1016/j.jlb.2025.100356","title":"Assessment of PD-L1 Expression on Circulating Tumor Cells and Clusters in Gastric Cancer Patients","year":2025,"lang":"en","type":"article","venue":"The Journal of Liquid Biopsy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"","keywords":"Cancer; Circulating tumor cell; Expression (computer science); Tumor cells; Circulating tumor DNA; Cancer cell","score_opus":0.012122174551012447,"score_gpt":0.3046841229067879,"score_spread":0.2925619483557755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416630659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998114,0.0005743137,0.000045516263,0.00048357947,0.0002648071,0.0001581657,0.000004801379,0.000001928534,0.0003529205],"genre_scores_gemma":[0.9989327,0.00034250782,0.00022014962,0.00041226854,0.00004247059,0.0000016330439,5.9307854e-7,0.000005542038,0.000042090574],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99909616,0.00008395281,0.0004213349,0.00006469588,0.0002269541,0.00010690777],"domain_scores_gemma":[0.99934155,0.000091816415,0.0003515303,0.00010070435,0.00008258507,0.00003180657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004917962,0.00008197505,0.00021948248,0.00018791418,0.00003250089,0.000005287861,0.00007952184,0.00002990614,0.00002530457],"category_scores_gemma":[0.00001879031,0.000047143632,0.00005999834,0.00022503185,0.000051526556,0.000038156002,0.000027225893,0.0001772533,9.8873976e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006657654,0.00023219298,0.052724723,0.00012017519,0.000082432416,0.000011348522,0.00036449847,0.00010698603,0.9368606,0.0000026527644,0.00027536438,0.0025613748],"study_design_scores_gemma":[0.0060150567,0.002279921,0.85963786,0.0040055085,0.00012611042,0.000053770593,0.0006250123,0.00023455617,0.12672229,0.0000083847735,0.0002033473,0.00008820363],"about_ca_topic_score_codex":0.00005881407,"about_ca_topic_score_gemma":0.0000033213842,"teacher_disagreement_score":0.8101383,"about_ca_system_score_codex":0.00013957708,"about_ca_system_score_gemma":0.00013381,"threshold_uncertainty_score":0.19224615},"labels":[],"label_agreement":null},{"id":"W4416639186","doi":"10.1183/13993003.congress-2025.pa4572","title":"Win ratio analysis of dupilumab efficacy in patients with chronic obstructive pulmonary disease and type 2 inflammation: BOREAS and NOTUS","year":2025,"lang":"","type":"article","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Q & T Research; Université de Sherbrooke","funders":"","keywords":"Dupilumab; Placebo; COPD; Clinical endpoint; Odds ratio; Clinical trial; Population; Post-hoc analysis","score_opus":0.004528216123794517,"score_gpt":0.23465174363476868,"score_spread":0.23012352751097417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416639186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98971874,0.0080485325,0.000041897005,0.0004151961,0.00009693615,0.000887918,0.000040638097,0.000009997382,0.0007401376],"genre_scores_gemma":[0.99819946,0.0009788926,0.000037510526,0.000067580455,0.000034488316,0.000013148473,0.00016524356,0.000010835124,0.0004928619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984432,0.00008366324,0.0005652825,0.00042827087,0.00026241588,0.00021720042],"domain_scores_gemma":[0.99899334,0.00013344955,0.0001886445,0.00034600298,0.00021589028,0.00012270003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001360097,0.0002473757,0.0005737146,0.0006682723,0.00007478883,0.000029362745,0.00006533345,0.00009360998,0.00031780486],"category_scores_gemma":[0.000068020585,0.00019743489,0.00007685426,0.002273578,0.0003840153,0.00018202438,0.00005592619,0.00012989587,5.693731e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02335584,0.00036906532,0.87860924,0.0003343838,0.003337259,0.000012410979,0.00040772572,0.00009405009,0.00036169548,0.00014835194,0.000015010921,0.09295497],"study_design_scores_gemma":[0.006817169,0.000503353,0.9837995,0.00042881625,0.003758035,3.843629e-7,0.00014553298,0.0039006236,0.0002783589,0.000017582905,0.00016069326,0.00018991005],"about_ca_topic_score_codex":0.00051508757,"about_ca_topic_score_gemma":0.0005479585,"teacher_disagreement_score":0.10519031,"about_ca_system_score_codex":0.00026062125,"about_ca_system_score_gemma":0.000538879,"threshold_uncertainty_score":0.8051161},"labels":[],"label_agreement":null},{"id":"W4416752515","doi":"10.2196/preprints.88273","title":"Treatment Options After PD-1/PD-L1 Inhibitors in dMMR/MSI-H Colorectal Cancer: A Systematic Review (Preprint)","year":2025,"lang":"","type":"article","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bevacizumab; Cohort; Retrospective cohort study; Observational study; Chemotherapy; Cohort study; Critical appraisal; Colorectal cancer; Cancer","score_opus":0.009987053383389557,"score_gpt":0.3010131752181235,"score_spread":0.2910261218347339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416752515","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11504606,0.84615177,0.000045662586,0.011572806,0.0023151329,0.015061094,0.000082194114,0.00011832255,0.00960696],"genre_scores_gemma":[0.6035867,0.3651999,0.000062733634,0.002887927,0.00013317668,0.0078041255,0.000014430166,0.000037182377,0.020273881],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9950188,0.0005089027,0.0023126574,0.0009664,0.00044705014,0.00074620644],"domain_scores_gemma":[0.9979482,0.0002908087,0.00037503496,0.0009970614,0.00017733734,0.00021152127],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008613388,0.00073146523,0.0023601553,0.00049166154,0.00014343392,0.0000813506,0.00026183037,0.00030478887,0.006461083],"category_scores_gemma":[0.0001627145,0.0005429977,0.00086141616,0.001683801,0.00023331099,0.00015287807,0.00012782063,0.00034191302,0.00019604144],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0106382035,0.0038615994,0.02359244,0.9196928,0.0066755842,0.00042651675,0.0032799584,0.000020228903,0.003647481,0.00044975855,0.00814519,0.019570235],"study_design_scores_gemma":[0.011464424,0.0016952291,0.016182497,0.94679433,0.0063882736,0.000092787006,0.0017757165,0.00041921416,0.0059226383,0.00004074786,0.008253457,0.00097065675],"about_ca_topic_score_codex":0.005167162,"about_ca_topic_score_gemma":0.005169524,"teacher_disagreement_score":0.4885406,"about_ca_system_score_codex":0.004298755,"about_ca_system_score_gemma":0.001458556,"threshold_uncertainty_score":0.99970216},"labels":[],"label_agreement":null},{"id":"W4416775676","doi":"10.3389/fimmu.2025.1740320","title":"Editorial: Community series in reducing adverse effects of cancer immunotherapy, volume II","year":2025,"lang":"en","type":"editorial","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Adverse effect; Discontinuation; Cancer; Vomiting; Nausea; Cardiotoxicity; Dexamethasone; Pembrolizumab; QT interval","score_opus":0.004234099806614664,"score_gpt":0.26252313392017435,"score_spread":0.2582890341135597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416775676","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012181604,0.053519074,0.000026170113,0.00036768548,0.9323472,0.0010779147,0.00013682319,0.00010026415,0.00024326716],"genre_scores_gemma":[0.0013057332,0.05930961,0.0010649223,0.00011128488,0.9235268,0.0006837613,0.00054925226,0.00021696983,0.013231633],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99613094,0.000842453,0.0012664085,0.00054370484,0.00050871546,0.0007077917],"domain_scores_gemma":[0.99738866,0.00038737681,0.00061683374,0.0012492911,0.00031419558,0.00004363081],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0010104376,0.00062598195,0.002178003,0.0013204556,0.00016081381,0.000011729531,0.0007556721,0.0025871568,0.000049791397],"category_scores_gemma":[0.0010222413,0.0006527192,0.0003844311,0.00097602856,0.00081470166,0.00016769517,0.000314015,0.003974508,9.605153e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015274519,0.0005255224,0.0022311446,0.0014840125,0.0015130913,0.000026098032,0.0020179788,0.0000075231983,0.0065412233,0.000002565211,0.95717585,0.013200496],"study_design_scores_gemma":[0.010459978,0.0014147667,0.0036212513,0.004670896,0.00019000849,0.0000023659197,0.0007589804,0.000004825565,0.0021552476,0.00011125051,0.9761496,0.00046081425],"about_ca_topic_score_codex":0.029095955,"about_ca_topic_score_gemma":0.0014264559,"teacher_disagreement_score":0.027669499,"about_ca_system_score_codex":0.0018034505,"about_ca_system_score_gemma":0.0023065833,"threshold_uncertainty_score":0.9995924},"labels":[],"label_agreement":null},{"id":"W4416782943","doi":"10.3390/curroncol32120663","title":"Steroid-Refractory Cholestatic Immune-Mediated Hepatitis Following Nivolumab Therapy in an Elderly Patient with Metastatic Melanoma: A Rare and Challenging Presentation","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Nivolumab; Context (archaeology); Immunosuppression; Hepatitis; Cholestasis; Hepatitis C; Liver biopsy; Adverse effect","score_opus":0.041700468078373916,"score_gpt":0.3595213697676956,"score_spread":0.3178209016893217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416782943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777764,0.019837841,0.0003208831,0.0004301107,0.0004997639,0.0009540391,0.000008527827,0.000041895848,0.00013054593],"genre_scores_gemma":[0.99615836,0.0030878482,0.00018082265,0.00016757869,0.000019973606,0.00020554355,0.0001261785,0.000019638432,0.00003407081],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99853975,0.00024888298,0.0004379209,0.0003277564,0.00017612378,0.0002695664],"domain_scores_gemma":[0.999319,0.00019007215,0.00015107689,0.0002071797,0.00006328943,0.00006938466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020846972,0.0001952993,0.00045798373,0.0003190778,0.00007926483,0.000031677835,0.000069619295,0.00007051114,0.000027028815],"category_scores_gemma":[0.0000345164,0.00015989134,0.00006900318,0.00030235286,0.00008563847,0.0002538965,0.000021614358,0.00024932754,0.0000012671638],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003656178,0.0012759402,0.14589918,0.00025251217,0.00035761605,0.00016995033,0.006377818,0.000005795229,0.006422129,0.000016282122,0.0000586779,0.8355079],"study_design_scores_gemma":[0.05518285,0.020508697,0.89485973,0.0018516858,0.0003213371,0.00009731469,0.008462977,0.0024397883,0.0011532597,0.00011958771,0.014382399,0.00062035304],"about_ca_topic_score_codex":0.0003189267,"about_ca_topic_score_gemma":0.00079533196,"teacher_disagreement_score":0.83488756,"about_ca_system_score_codex":0.00031394552,"about_ca_system_score_gemma":0.0002573562,"threshold_uncertainty_score":0.65201795},"labels":[],"label_agreement":null},{"id":"W4416794994","doi":"10.1007/s12672-025-04144-0","title":"Research progress and frontier trends in liver cancer immunotherapy in the post-COVID-19 era (2020–2024): a visualization analysis based on bibliometric methods","year":2025,"lang":"en","type":"article","venue":"Discover Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Natural Science Foundation of Ningxia Province","keywords":"Multidisciplinary approach; Frontier; Translational research; Pandemic; Liver cancer; Immunotherapy; Visualization; Cancer immunotherapy; 2019-20 coronavirus outbreak","score_opus":0.05701420962065415,"score_gpt":0.5152336314925254,"score_spread":0.45821942187187126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416794994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8780962,0.052123323,0.00689123,0.05435435,0.0007860864,0.0020810028,0.000072541254,0.00007026629,0.0055249976],"genre_scores_gemma":[0.97618175,0.004699247,0.0008546326,0.016098637,0.000062698986,0.0006351106,0.000100664576,0.000027148726,0.001340109],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99652505,0.0018034753,0.0004142857,0.0004835752,0.00039140816,0.00038223376],"domain_scores_gemma":[0.9983587,0.0009842356,0.00009250481,0.0003897043,0.00011403137,0.000060810395],"candidate_categories":["bibliometrics"],"consensus_categories":["bibliometrics"],"category_scores_codex":[0.0038313977,0.00017598936,0.0005133979,0.037676446,0.00009306984,0.00007388176,0.00020983959,0.00022037292,0.0006738422],"category_scores_gemma":[0.00019300093,0.00011935461,0.00015978196,0.0919062,0.00031052786,0.0000967209,0.000041583702,0.00044527208,8.978283e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011608295,0.0010531959,0.3458446,0.00009574414,0.00068288407,0.00011603282,0.002593711,0.00015920441,0.00069801835,0.00019037782,0.006245474,0.63071245],"study_design_scores_gemma":[0.006514888,0.0010878928,0.9061417,0.000060122384,0.0002098069,0.000003818092,0.0009822586,0.0075618355,0.00012507445,0.000054052154,0.07712388,0.0001346566],"about_ca_topic_score_codex":0.0076970183,"about_ca_topic_score_gemma":0.005003846,"teacher_disagreement_score":0.6305778,"about_ca_system_score_codex":0.0010364315,"about_ca_system_score_gemma":0.0010482407,"threshold_uncertainty_score":0.9989108},"labels":[{"model":"gemma","categories":["bibliometrics"],"domain":null,"study_design":"not_applicable","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["bibliometrics"],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W4416808481","doi":"10.1016/j.jtho.2025.11.018","title":"Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Alberta Health Services","funders":"National Cancer Institute; National Institutes of Health; Eli Lilly and Company","keywords":"Pembrolizumab; KRAS; Immunotherapy; Adverse effect; PD-L1","score_opus":0.009457525746142717,"score_gpt":0.35428404019241183,"score_spread":0.3448265144462691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416808481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974279,0.0007497353,0.00005002959,0.00084882404,0.00007725182,0.00044586087,0.0000041025687,0.0000017783085,0.00039451715],"genre_scores_gemma":[0.99861795,0.0005455875,0.0007302058,0.00004711073,0.0000070027145,0.000004491371,0.0000041161024,0.0000061731766,0.00003735714],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989646,0.0001076162,0.000568827,0.00009826697,0.00015089731,0.000109796936],"domain_scores_gemma":[0.9990367,0.0001463083,0.00051531265,0.000097548305,0.00017189093,0.00003221924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022103144,0.00010358163,0.00061297714,0.00036718947,0.0000124515045,0.0000017366028,0.000045116412,0.000077069184,0.0000122519095],"category_scores_gemma":[0.000029644903,0.00006392817,0.00004160743,0.00034265826,0.00012260381,0.00006222773,0.000008164804,0.00011019033,6.109047e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3012947,0.0035292963,0.24425296,0.00012505837,0.00025821067,0.00007848817,0.0008493267,0.00004448281,0.0041640755,0.00002165287,0.0000058383816,0.4453759],"study_design_scores_gemma":[0.04704072,0.023596939,0.92144376,0.0009054685,0.00015924242,0.000053222324,0.00031628713,0.000015276108,0.005540214,0.000030494346,0.00084264093,0.000055712666],"about_ca_topic_score_codex":0.00004032988,"about_ca_topic_score_gemma":0.00019018736,"teacher_disagreement_score":0.67719084,"about_ca_system_score_codex":0.0005299524,"about_ca_system_score_gemma":0.00042960417,"threshold_uncertainty_score":0.26069152},"labels":[],"label_agreement":null},{"id":"W4416816321","doi":"10.1093/ckj/sfaf373","title":"Rituximab for the treatment of immune checkpoint inhibitor–induced glomerulonephritis","year":2025,"lang":"en","type":"article","venue":"Clinical Kidney Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"University of Texas MD Anderson Cancer Center; National Institutes of Health","keywords":"Rituximab; Proteinuria; Glomerulonephritis; Kidney disease; Renal biopsy; Corticosteroid; Creatinine","score_opus":0.05210318626898471,"score_gpt":0.3920331136168702,"score_spread":0.3399299273478855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416816321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88580257,0.030038266,0.0017389095,0.07127265,0.007611658,0.0017852673,0.000076202086,0.00004413221,0.0016303658],"genre_scores_gemma":[0.95589334,0.032539904,0.0014948423,0.00466709,0.002034288,0.000072681854,0.000016281843,0.000031095627,0.0032505058],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980222,0.00007764301,0.0013196213,0.00017487339,0.00017544723,0.00023020775],"domain_scores_gemma":[0.99832124,0.0006228077,0.0003191303,0.00032982024,0.0001973684,0.00020965112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010573462,0.00014765373,0.00060880627,0.00007756582,0.0001887565,0.000029663359,0.0001348787,0.00015376974,0.00019728104],"category_scores_gemma":[0.00077758427,0.00008496172,0.0011405008,0.00019494804,0.00021170297,0.000038511833,0.00001684548,0.0002686913,0.000005408041],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014479471,0.004270186,0.006899216,0.00014009395,0.002624548,0.000029311062,0.00022792346,2.3079828e-7,0.05108262,0.0000982398,0.025392894,0.89475524],"study_design_scores_gemma":[0.06557829,0.008778495,0.10526087,0.001254221,0.0010916094,0.00025034838,0.00035286267,0.000118371034,0.07000896,0.00061116565,0.74648935,0.00020543214],"about_ca_topic_score_codex":0.00003546388,"about_ca_topic_score_gemma":0.0000037978537,"teacher_disagreement_score":0.89454985,"about_ca_system_score_codex":0.00014450272,"about_ca_system_score_gemma":0.00078251795,"threshold_uncertainty_score":0.34646383},"labels":[],"label_agreement":null},{"id":"W4416816600","doi":"10.1177/12034754251403189","title":"Immune Checkpoint Inhibitor-Associated Squamous Cell Carcinoma: A Systematic Review","year":2025,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Immune system; Immune checkpoint; Immunotherapy; Basal cell; Cell; Squamous cell cancer; Nivolumab; Cell cycle checkpoint","score_opus":0.014505122796873023,"score_gpt":0.25950247207633087,"score_spread":0.24499734927945785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416816600","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41985792,0.5668867,0.00001652008,0.009928297,0.0008649016,0.0005521838,0.0000017708886,0.000019505525,0.0018721882],"genre_scores_gemma":[0.96325296,0.029599685,0.000011672001,0.00512903,0.00018179086,0.0000058674736,0.0000048075963,0.000016720038,0.0017974449],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99706775,0.00017048183,0.0019062001,0.00014436984,0.00047002808,0.00024119306],"domain_scores_gemma":[0.99720854,0.001036108,0.0009740222,0.00024495326,0.00038866993,0.0001476988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002000142,0.00021972829,0.0019868389,0.00039896506,0.00007236054,0.000011632871,0.0000834233,0.00011166651,0.00010375202],"category_scores_gemma":[0.0018128768,0.00013812294,0.00046530005,0.00047732194,0.00012845157,0.000051194995,0.000019090632,0.00034668436,0.0000019460556],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040151137,0.00097396085,0.009317799,0.7696711,0.0011266893,0.010665854,0.0011401393,4.754813e-7,0.051372483,0.00001545179,0.14980586,0.0018951087],"study_design_scores_gemma":[0.011375571,0.003810346,0.00565377,0.9014345,0.01237341,0.044311084,0.0026177259,0.000052765845,0.009205453,0.00015011858,0.008260287,0.0007549769],"about_ca_topic_score_codex":0.00006441076,"about_ca_topic_score_gemma":0.000004380099,"teacher_disagreement_score":0.5433951,"about_ca_system_score_codex":0.00017343232,"about_ca_system_score_gemma":0.00043608085,"threshold_uncertainty_score":0.563249},"labels":[],"label_agreement":null},{"id":"W4416827100","doi":"10.1136/jitc-2025-013214","title":"JAK inhibitors for the treatment of life-threatening and refractory immune-related adverse events secondary to immune checkpoint inhibitors: a prospective cohort study","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; St Mary's Hospital Centre; Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Adverse effect; Prospective cohort study; Refractory (planetary science); Immune checkpoint; Cohort study; Clinical trial; Immune system; Safety profile","score_opus":0.011013981859586493,"score_gpt":0.31381246585524136,"score_spread":0.30279848399565484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416827100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91081333,0.07951264,0.00015411907,0.0011249778,0.0016743417,0.006573477,0.00005950931,0.0000195435,0.00006804314],"genre_scores_gemma":[0.9812207,0.014599157,0.00024865326,0.00015312481,0.00022208886,0.0012484752,0.00000704905,0.000064201406,0.0022365148],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99730283,0.00006971717,0.0016120671,0.0003383348,0.00033474318,0.00034228797],"domain_scores_gemma":[0.99783665,0.00026082635,0.0008901108,0.0004103738,0.0005122899,0.00008975925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010354214,0.00036114544,0.0010196064,0.0003395942,0.00036126067,0.000018118666,0.00017502902,0.00014474077,0.00011235204],"category_scores_gemma":[0.00006423178,0.00023645669,0.0008280388,0.00039870763,0.00016672123,0.00014094057,0.000024385658,0.00024578228,3.3193908e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08666905,0.0031227537,0.26587227,0.00032813716,0.021983923,0.0000042379243,0.012684195,0.00008562171,0.37683594,0.0000129446535,0.00044996594,0.23195097],"study_design_scores_gemma":[0.04760064,0.014519282,0.7929598,0.0014900048,0.0012440031,0.00002311585,0.005018161,0.00005006012,0.1055862,0.00017347037,0.030969141,0.00036608492],"about_ca_topic_score_codex":0.00089529593,"about_ca_topic_score_gemma":0.000077347766,"teacher_disagreement_score":0.52708757,"about_ca_system_score_codex":0.0007673393,"about_ca_system_score_gemma":0.0007573205,"threshold_uncertainty_score":0.9642424},"labels":[],"label_agreement":null},{"id":"W4416930596","doi":"10.1002/cnr2.70422","title":"Immunotherapy‐Related Gastritis in Small Cell Lung Cancer Treatment With Durvalumab—A Case Report","year":2025,"lang":"en","type":"article","venue":"Cancer Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Essar Steel Algoma (Canada); McMaster University","funders":"","keywords":"Immunotherapy; Gastritis; Cancer; Lung cancer; Curative treatment; Cancer treatment","score_opus":0.010672016629074226,"score_gpt":0.28984711797259777,"score_spread":0.2791751013435235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416930596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9414182,0.04862602,0.000042583837,0.0011765993,0.00088650093,0.0014321984,0.00001772816,0.00010636699,0.0062938267],"genre_scores_gemma":[0.96674085,0.006209804,0.00016417833,0.00061184703,0.00008581763,0.0011276739,0.00004276409,0.00005897033,0.02495812],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99766606,0.000045709614,0.00092632516,0.0007108566,0.00019230202,0.00045875376],"domain_scores_gemma":[0.99852973,0.000029685574,0.00041088107,0.00077843736,0.00014301104,0.00010822563],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028141332,0.0003550212,0.0006223092,0.00026054104,0.00011264188,0.000034072647,0.00005373417,0.00017101315,0.00078099745],"category_scores_gemma":[0.00000904707,0.00028022288,0.00019408955,0.00074790337,0.000117266645,0.00007196956,0.000018781664,0.00022361797,7.8622617e-7],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021798068,0.00043307655,0.43589044,0.00025072525,0.00094774895,0.48722216,0.0006376927,0.000089311456,0.008108764,0.0000029737225,0.0018018741,0.06243542],"study_design_scores_gemma":[0.03859336,0.0021757938,0.20575757,0.0068425895,0.0019301799,0.4782413,0.001090857,0.00041555442,0.07142299,0.00008177039,0.19169647,0.0017515892],"about_ca_topic_score_codex":0.03020234,"about_ca_topic_score_gemma":0.00857888,"teacher_disagreement_score":0.23013286,"about_ca_system_score_codex":0.001954217,"about_ca_system_score_gemma":0.0019177807,"threshold_uncertainty_score":0.999965},"labels":[],"label_agreement":null},{"id":"W4416933958","doi":"10.1038/s41467-025-66803-8","title":"Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche; Roche","keywords":"Atezolizumab; Immunotherapy; Lung cancer; Transcriptome; Adenocarcinoma; Immune system; Cancer; Lung","score_opus":0.011730141408747105,"score_gpt":0.33282554861203034,"score_spread":0.3210954072032832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416933958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7898367,0.15330453,0.00040542328,0.045045733,0.00024429287,0.001746577,0.000057403227,0.000119991615,0.009239358],"genre_scores_gemma":[0.98036855,0.011621087,0.0027706288,0.0035414728,0.000011775085,0.00042717147,0.00005741019,0.0000153633,0.0011865135],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992591,0.000067695946,0.00021073438,0.00022475558,0.0000855696,0.00015212712],"domain_scores_gemma":[0.9981333,0.00013592078,0.00004737615,0.0014428808,0.00017562554,0.00006487484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001442891,0.00015331668,0.00021989908,0.00012781356,0.00028761147,0.00003289762,0.00029813367,0.00018288044,0.00002847562],"category_scores_gemma":[0.00002241943,0.00013230935,0.000100427984,0.00049554097,0.00010651971,0.00003238027,0.00009184348,0.0003583377,0.0000020583807],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019828437,0.005751785,0.34361783,0.00035413879,0.0023982336,0.0000075342514,0.0046021794,0.00003989859,0.46101573,0.014374449,0.03520273,0.13065264],"study_design_scores_gemma":[0.009313618,0.0005071566,0.51624715,0.00036486203,0.0005324373,0.000007231178,0.00035701558,0.0014232376,0.053615123,0.00029168467,0.41688377,0.00045671273],"about_ca_topic_score_codex":0.00053805177,"about_ca_topic_score_gemma":0.0009828582,"teacher_disagreement_score":0.4074006,"about_ca_system_score_codex":0.0003296667,"about_ca_system_score_gemma":0.00026322613,"threshold_uncertainty_score":0.5395419},"labels":[],"label_agreement":null},{"id":"W4416934403","doi":"10.3389/fonc.2025.1659304","title":"Unraveling the synergy of radiotherapy and immune checkpoint inhibitors in NSCLC: emerging clinical evidence and novel therapeutic strategies","year":2025,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Natural Sciences and Engineering Research Council of Canada; Fonds de recherche du Québec – Nature et technologies; Health Canada; Pfizer Canada; Pfizer","keywords":"Abscopal effect; Radiation therapy; Clinical trial; Chemotherapy; Immunotherapy; Immune system; Lung cancer; Immune checkpoint","score_opus":0.063233346140609,"score_gpt":0.4164298494710535,"score_spread":0.3531965033304445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416934403","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045761766,0.99446833,0.0013914906,0.00078096846,0.0015963378,0.0010780997,0.0000046761384,0.000012061605,0.00021043714],"genre_scores_gemma":[0.0011055624,0.9965873,0.0016979503,0.00022457622,0.00014938999,0.00009364599,0.0000060022353,0.00003017923,0.00010539425],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99666786,0.00054325146,0.0018185485,0.00050052046,0.00015179664,0.00031804098],"domain_scores_gemma":[0.9976394,0.0012907521,0.0006088068,0.0003733909,0.000041539464,0.00004609512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025248758,0.000362921,0.0026445913,0.00052550813,0.000048319325,0.0000213441,0.00023655644,0.0006352588,0.00001064541],"category_scores_gemma":[0.00021821322,0.00024340137,0.00035591502,0.0006258821,0.00075416267,0.00007855599,0.00008810362,0.0008741149,1.0270327e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074396894,0.0001419403,0.00097332144,0.0051702443,0.0005149486,0.000018711715,0.00046572406,0.0000016475902,0.00006969921,0.00010518816,0.0001123742,0.99168223],"study_design_scores_gemma":[0.006088928,0.0014859692,0.0039750147,0.074385755,0.0009910649,0.00017484729,0.003611746,0.0002592677,0.00001592215,0.00029789447,0.90818125,0.0005323525],"about_ca_topic_score_codex":0.00034400998,"about_ca_topic_score_gemma":0.000121457364,"teacher_disagreement_score":0.9911499,"about_ca_system_score_codex":0.00044713693,"about_ca_system_score_gemma":0.0016934895,"threshold_uncertainty_score":0.992562},"labels":[],"label_agreement":null},{"id":"W4416953579","doi":"10.3389/fonc.2025.1581275","title":"Unraveling the complexity of PD-L1 assays: a descriptive review of the methodology, scoring, and practical implications","year":2025,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"MEDLINE","score_opus":0.3150428719101887,"score_gpt":0.4828072276279616,"score_spread":0.16776435571777287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416953579","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000021322758,0.9854115,0.0034202074,0.006164125,0.0009289727,0.0020039731,0.000054275137,0.000006253989,0.0020085257],"genre_scores_gemma":[0.0000035407832,0.9656485,0.032691527,0.0012145848,0.000047080048,0.00020005056,0.00001686621,0.0000126751465,0.00016520686],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99626786,0.0021051248,0.0010069292,0.00030173786,0.00012304957,0.00019531857],"domain_scores_gemma":[0.9967231,0.0015818794,0.0009093279,0.00061145663,0.00014138328,0.00003284727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027870685,0.00021598926,0.0023157818,0.00016210087,0.00006504432,0.0000028666325,0.00026297598,0.00034688943,0.000026316178],"category_scores_gemma":[0.0023213546,0.00011685635,0.00044493072,0.0006766483,0.0017513044,0.000021022934,0.00018795166,0.0007239665,2.8055592e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023239733,0.00013132613,0.00031147554,0.06572767,0.00076508103,0.0000035928626,0.00020878951,2.481697e-8,0.000005355335,0.0019367172,0.026763141,0.90391445],"study_design_scores_gemma":[0.0004634916,0.00017714026,0.00064804294,0.06299383,0.0018678083,0.00019081155,0.00023653815,0.0000019876013,0.000004060455,0.0012354553,0.93209213,0.00008869865],"about_ca_topic_score_codex":0.00013749489,"about_ca_topic_score_gemma":0.000050257953,"teacher_disagreement_score":0.905329,"about_ca_system_score_codex":0.00045127954,"about_ca_system_score_gemma":0.0021971315,"threshold_uncertainty_score":0.6452754},"labels":[],"label_agreement":null},{"id":"W4417144082","doi":"10.1186/s43556-025-00361-9","title":"Gastrointestinal cancer: molecular pathogenesis and targeted therapy","year":2025,"lang":"en","type":"article","venue":"Molecular Biomedicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Natural Science Foundation of China","keywords":"Targeted therapy; Epigenetics; Immunotherapy; Tumor microenvironment; Cancer; Immune system; Histone; Immune checkpoint; Disease","score_opus":0.0075742001838341,"score_gpt":0.27542428880733066,"score_spread":0.2678500886234966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417144082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92274487,0.05260247,0.009513384,0.0132913785,0.00020993681,0.0005950404,0.000018992574,0.00010980051,0.0009141198],"genre_scores_gemma":[0.98412603,0.0023402858,0.0023612003,0.010314972,0.00006575573,0.000080932245,0.00005895561,0.000035792866,0.00061606144],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99863666,0.000049461192,0.00030592864,0.00040547704,0.00027639387,0.00032606276],"domain_scores_gemma":[0.9992881,0.000022573535,0.00006878871,0.0003569744,0.000119139266,0.00014445567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020047459,0.0002514375,0.00037874424,0.00032669565,0.000070153816,0.000016962782,0.000100339945,0.00006254533,0.00016335206],"category_scores_gemma":[0.00004232781,0.00020010944,0.00012332332,0.0007408101,0.00036674525,0.000022595555,0.000041181214,0.0001357144,0.0000027788965],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010717999,0.00009315538,0.009552228,0.000083954685,0.00023129147,0.00053554773,0.000030099502,7.2354e-7,0.91321456,0.000111027235,0.0009951275,0.07408049],"study_design_scores_gemma":[0.017454326,0.002142135,0.13157445,0.0017945766,0.00043455392,0.00095536513,0.00020367377,0.0003285145,0.7896366,0.00031966512,0.054614317,0.00054182607],"about_ca_topic_score_codex":0.00025689293,"about_ca_topic_score_gemma":0.0000045055112,"teacher_disagreement_score":0.12357796,"about_ca_system_score_codex":0.00008164317,"about_ca_system_score_gemma":0.00020261829,"threshold_uncertainty_score":0.81602263},"labels":[],"label_agreement":null},{"id":"W4417183636","doi":"10.1155/jskc/2561307","title":"Prognostic Potential of Baseline Eosinophils at the Initiation of Immune Checkpoint Inhibitor Treatment of Metastatic Melanoma: A Systematic Review and Meta‐Analysis","year":2025,"lang":"en","type":"article","venue":"Journal of Skin Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Eosinophil; Funnel plot; Hazard ratio; Melanoma; Meta-analysis; Publication bias; Cohort; Adverse effect; Inclusion and exclusion criteria","score_opus":0.02388754609807292,"score_gpt":0.31565320158077526,"score_spread":0.29176565548270234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417183636","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15765516,0.83705926,0.00030835465,0.0035521958,0.0000891461,0.0012276398,0.00008411359,0.0000018280873,0.000022302595],"genre_scores_gemma":[0.94021255,0.059164554,0.00019887608,0.00015700854,0.000025428242,0.000057663772,0.000005957626,0.0000072271646,0.00017070817],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99763393,0.00022235999,0.0016379162,0.000095038326,0.000323633,0.00008711942],"domain_scores_gemma":[0.99718916,0.00023030321,0.0018686242,0.00022088684,0.0004598079,0.0000312083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010416907,0.00014144923,0.0020189462,0.00025313947,0.00002665716,0.0000045833553,0.000069024834,0.000031410862,0.00026054503],"category_scores_gemma":[0.00012022338,0.000070948176,0.001064592,0.0005974942,0.00010729186,0.00004975525,0.000016723703,0.000057532387,1.3585016e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040009473,0.0015160899,0.0014216192,0.304647,0.59401083,0.000044402812,0.0010520867,0.00017902331,0.091447465,0.00001982825,0.00026962173,0.0013910594],"study_design_scores_gemma":[0.003223918,0.0011099783,0.0061405255,0.014911502,0.8899436,0.000097593256,0.00019732238,0.000093074246,0.084136814,0.00002335236,0.000037130143,0.000085189895],"about_ca_topic_score_codex":0.00023277459,"about_ca_topic_score_gemma":0.000058741236,"teacher_disagreement_score":0.7825574,"about_ca_system_score_codex":0.00016163573,"about_ca_system_score_gemma":0.00023308223,"threshold_uncertainty_score":0.28931826},"labels":[],"label_agreement":null},{"id":"W4417209037","doi":"10.1038/s43018-025-01055-5","title":"Antibiotic-related dysbiosis in cancer immunotherapy: from preclinical insights to practice-changing evidence","year":2025,"lang":"en","type":"article","venue":"Nature Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé","keywords":"Dysbiosis; Microbiome; Antimicrobial stewardship; Cancer; Psychological intervention; Human microbiome","score_opus":0.023106391987853678,"score_gpt":0.3988190701112689,"score_spread":0.3757126781234152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417209037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6347313,0.3110818,0.000060069244,0.04715077,0.004286709,0.0011710916,0.000034334105,0.00017435124,0.001309584],"genre_scores_gemma":[0.9385767,0.02519741,0.0006577725,0.033105902,0.00029393236,0.00010820743,0.000010031524,0.000051471277,0.0019985563],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99786067,0.0001271685,0.00056175,0.00066050387,0.0003621741,0.0004277257],"domain_scores_gemma":[0.9983355,0.000647584,0.00016099475,0.000517787,0.0002349258,0.00010320949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040421195,0.00028094125,0.0005315841,0.0004757204,0.00007809648,0.000046852,0.00024735922,0.000689873,0.00044918875],"category_scores_gemma":[0.00059486076,0.00023399791,0.00017588183,0.0019809552,0.000081033904,0.00025787883,0.00007347941,0.0011649801,0.000012339947],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032760914,0.0009289441,0.12160642,0.0003596992,0.0034482884,0.00019824239,0.007912212,0.00014427952,0.32203293,0.00040545582,0.03451041,0.4756922],"study_design_scores_gemma":[0.008535636,0.00040180425,0.2875566,0.016203087,0.0005223785,0.000008078963,0.0007184021,0.00027141717,0.068824194,0.00019176259,0.6160315,0.0007351516],"about_ca_topic_score_codex":0.0031541882,"about_ca_topic_score_gemma":0.001548206,"teacher_disagreement_score":0.5815211,"about_ca_system_score_codex":0.00089509785,"about_ca_system_score_gemma":0.0007019228,"threshold_uncertainty_score":0.95421576},"labels":[],"label_agreement":null},{"id":"W4417209144","doi":"10.1016/j.ygyno.2025.12.003","title":"Evaluating the clinical utility and impact on healthcare utilization of serial troponin T monitoring in gynecologic cancer patients receiving immune checkpoint inhibitors – A single centre experience","year":2025,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; Sunnybrook Health Science Centre","funders":"","keywords":"Gynecologic cancer; Biomarker; Gynecologic oncology; Pembrolizumab; Cancer; Immunotherapy; Myocarditis; Chemotherapy","score_opus":0.11915230043243598,"score_gpt":0.4678452331041466,"score_spread":0.34869293267171064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417209144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99248314,0.0013174943,0.0000027916599,0.0021618258,0.002429956,0.0012365123,0.000009021003,0.000031473854,0.00032779586],"genre_scores_gemma":[0.99857175,0.00063706446,0.00017749179,0.0003160016,0.000108767585,0.00011673435,0.000010861505,0.000009997712,0.00005135544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996702,0.0009854841,0.0012007615,0.00048347365,0.00021384448,0.0004144303],"domain_scores_gemma":[0.997248,0.0016659693,0.0005228234,0.00028759957,0.00020641182,0.000069217174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020689508,0.00022231198,0.00070537627,0.00014023992,0.00016150787,0.000013291951,0.00014776179,0.00040251776,0.00017057132],"category_scores_gemma":[0.0029915413,0.0001442195,0.00018010511,0.0005145672,0.00037199593,0.000063782325,0.00012636384,0.00045058248,8.6916543e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041695763,0.0008319998,0.7158851,0.00006226959,0.000054907017,0.000004272575,0.0011268108,0.000029234432,0.005868231,0.0000050995154,0.00002828391,0.2719342],"study_design_scores_gemma":[0.004950014,0.0070519913,0.97975576,0.00027698523,0.00004657193,0.0000015405953,0.0019497925,0.0004139671,0.0052128225,0.00006300829,0.00016839472,0.000109137145],"about_ca_topic_score_codex":0.00080514903,"about_ca_topic_score_gemma":0.0007672066,"teacher_disagreement_score":0.27182508,"about_ca_system_score_codex":0.0013666425,"about_ca_system_score_gemma":0.0007122059,"threshold_uncertainty_score":0.5881101},"labels":[],"label_agreement":null},{"id":"W4417221218","doi":"10.3389/fimmu.2025.1730817","title":"Peri-tumoural lymphocyte neighbourhoods predict longer survival in pancreatic ductal adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Beatrice Hunter Cancer Research Institute; Nova Scotia Health Authority; Dalhousie University","funders":"Canadian Cancer Society","keywords":"Immune system; Pancreatic ductal adenocarcinoma; Lymphocyte; Lymphocyte subsets; Immunotherapy; Adenocarcinoma; Immune escape","score_opus":0.00808988216114777,"score_gpt":0.243897797349179,"score_spread":0.2358079151880312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417221218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93788755,0.05176017,0.0003721822,0.0009885184,0.0043562837,0.0004918544,0.000009145329,0.0000619443,0.004072361],"genre_scores_gemma":[0.9936726,0.0020440095,0.0009740463,0.00043042086,0.000089484995,0.00008370033,0.00003940461,0.00002842623,0.002637887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998016,0.00020157036,0.000574331,0.00044896358,0.00015521448,0.00060391915],"domain_scores_gemma":[0.9992953,0.000059950406,0.00008841217,0.00047116043,0.000039881612,0.000045285207],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003291804,0.0002727903,0.00074755744,0.0007442073,0.000058955466,0.000018919254,0.00025631848,0.00030713048,0.00019186285],"category_scores_gemma":[0.0000958077,0.0002611485,0.00015954542,0.0007832291,0.00040270737,0.00010617823,0.00008835102,0.00041647555,0.000009856474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006867854,0.0001833456,0.97517776,0.000069808644,0.00049384724,0.0002992409,0.00063363445,0.0000036365902,0.0047039385,0.00013854235,0.00223029,0.009198122],"study_design_scores_gemma":[0.0098357815,0.00034144951,0.98314464,0.00025162773,0.00008657574,0.00012792983,0.002087307,0.00035690644,0.00086158124,0.00026352736,0.0024274013,0.00021528246],"about_ca_topic_score_codex":0.00078131066,"about_ca_topic_score_gemma":0.00015276525,"teacher_disagreement_score":0.055785082,"about_ca_system_score_codex":0.0009635258,"about_ca_system_score_gemma":0.0005242986,"threshold_uncertainty_score":0.9999841},"labels":[],"label_agreement":null},{"id":"W4417230978","doi":"10.1172/jci188458","title":"CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"National Cancer Institute; National Institutes of Health; Seagen; Puma Biotechnology; Susan G. Komen; Cancer Prevention and Research Institute of Texas; Daiichi Sankyo Europe; U.S. Department of Defense; Breast Cancer Research Foundation; Sanofi; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; NightstaRx; University of Texas Southwestern Medical Center; Susan G. Komen for the Cure; Pfizer; Amgen","keywords":"Tumor microenvironment; Stromal cell; CXCL11; Letrozole; Immune system; CXCL10; CXCR3; Chemokine; Cytotoxic T cell","score_opus":0.044219122027332795,"score_gpt":0.37366916011851287,"score_spread":0.32945003809118006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417230978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8473263,0.00053756713,0.000011956977,0.15142448,0.00033374896,0.00033082932,0.0000038286994,0.0000018688492,0.00002941783],"genre_scores_gemma":[0.9670017,0.001964895,0.00015327043,0.030496472,0.00018895626,0.000015956673,5.7293715e-7,0.000006309363,0.00017187215],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9977302,0.0006760295,0.0010781982,0.00012006757,0.00025927002,0.00013621394],"domain_scores_gemma":[0.9985316,0.00083684514,0.00030885972,0.00021039962,0.00004999731,0.000062291416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039798403,0.00009390854,0.00028565474,0.00013845785,0.000037466223,0.00002124211,0.00019281765,0.000043353593,0.000056475736],"category_scores_gemma":[0.00023999682,0.000047215966,0.00015151304,0.00038991586,0.00015903969,0.000060399576,0.000017238795,0.00044870403,0.000002973912],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05348589,0.00061453425,0.33184525,0.000033966055,0.00019931182,0.00014516046,0.0016755858,0.00079998147,0.5428048,0.000031402924,0.010664076,0.05770007],"study_design_scores_gemma":[0.0040394105,0.00046217942,0.96942335,0.0004445738,0.000025557247,0.00005463824,0.00020010445,0.0001077776,0.009110578,0.00027358995,0.0158086,0.00004963717],"about_ca_topic_score_codex":0.00017185361,"about_ca_topic_score_gemma":0.000102621525,"teacher_disagreement_score":0.6375781,"about_ca_system_score_codex":0.00013429935,"about_ca_system_score_gemma":0.00031963593,"threshold_uncertainty_score":0.19494207},"labels":[],"label_agreement":null},{"id":"W4417288638","doi":"10.1111/ijd.70199","title":"Lichen Planopilaris Induced by Checkpoint Inhibitors: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"International Journal of Dermatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Scarring alopecia; Pembrolizumab; Nivolumab; Malignancy; Adverse effect; Biopsy; Cancer","score_opus":0.024546263347057392,"score_gpt":0.3613092318101155,"score_spread":0.3367629684630581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417288638","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000002886821,0.9916745,0.000030116507,0.005205913,0.001660549,0.0009342461,0.000035872563,0.000013427594,0.00044249298],"genre_scores_gemma":[0.00003075582,0.99759465,0.000055610104,0.001504255,0.00023119687,0.000058089878,0.00009576904,0.000024934965,0.00040475387],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9960341,0.0003098351,0.0027294522,0.00018977233,0.0005596007,0.00017727872],"domain_scores_gemma":[0.9963305,0.00034431482,0.002447033,0.00025937692,0.0005230106,0.000095762385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026263238,0.00033965538,0.0036154354,0.0005440535,0.000021335823,0.000031841108,0.0006145058,0.00037629853,0.000100818834],"category_scores_gemma":[0.0006498726,0.00023074006,0.0013380207,0.00023111604,0.00004795279,0.000078337114,0.00007875787,0.00068938406,0.000024748608],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010544792,0.0001425383,0.000003530913,0.9163925,0.005203107,0.0014689476,0.00002943046,1.800791e-9,0.000020770838,0.000022479162,0.03474738,0.041863874],"study_design_scores_gemma":[0.00052029366,0.000050329203,1.8613885e-7,0.53719807,0.0026166877,0.041655112,0.000006302333,1.4780947e-7,0.000029056564,0.000006613906,0.4178143,0.000102864105],"about_ca_topic_score_codex":0.000008128291,"about_ca_topic_score_gemma":0.0000011650187,"teacher_disagreement_score":0.38306692,"about_ca_system_score_codex":0.00039413496,"about_ca_system_score_gemma":0.0011361636,"threshold_uncertainty_score":0.94093066},"labels":[],"label_agreement":null},{"id":"W4417299894","doi":"10.1080/13696998.2025.2599670","title":"Impact of pembrolizumab on health outcomes and productivity in earlier-stage cancers within the US Medicare population","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Canada; Merck","keywords":"Pembrolizumab; Productivity; Population; Investment (military); Work productivity; Exploratory analysis","score_opus":0.016483279543900966,"score_gpt":0.34714052042635307,"score_spread":0.33065724088245213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417299894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9633151,0.0008437,0.000010479563,0.03515609,0.00039712738,0.00017328702,0.000007818471,0.0000022185075,0.000094153256],"genre_scores_gemma":[0.9966645,0.0014960844,0.000029261257,0.001661622,0.000087607375,0.0000015007648,0.0000019185118,0.0000058021064,0.000051676834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987772,0.00008124028,0.0006740937,0.000104345294,0.00024399484,0.00011912714],"domain_scores_gemma":[0.99904984,0.00014409161,0.00050203333,0.00014559909,0.00003530405,0.00012311009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018465624,0.0000908099,0.00047501057,0.00013272109,0.000032424286,0.00000858215,0.00011292083,0.00008955702,0.000053222597],"category_scores_gemma":[0.00046387914,0.000051567276,0.00013555257,0.000105807405,0.00013403334,0.000058840982,0.000019524257,0.00040333995,1.2121299e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004521062,0.00016410086,0.8978665,0.00015413844,0.00046754666,0.000011877974,0.0007190118,0.0005699722,0.000020278418,0.00032877116,0.0010417461,0.094135016],"study_design_scores_gemma":[0.0045188027,0.00072453136,0.9925435,0.00042958473,0.000022421495,0.000044051416,0.00021639175,0.0006895771,0.00002514015,0.00012250942,0.0006217664,0.000041728792],"about_ca_topic_score_codex":0.0034823988,"about_ca_topic_score_gemma":0.0018827755,"teacher_disagreement_score":0.094677016,"about_ca_system_score_codex":0.0008388226,"about_ca_system_score_gemma":0.0020183395,"threshold_uncertainty_score":0.52643687},"labels":[],"label_agreement":null},{"id":"W4417479777","doi":"10.1016/j.jval.2025.09.648","title":"EE264 Cost-Effectiveness of Nivolumab Plus Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable NSCLC in Greece","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thermo Fisher Scientific (Canada)","funders":"","keywords":"Nivolumab; Chemotherapy; Platinum; Complete response","score_opus":0.05804817109753496,"score_gpt":0.3793686892482297,"score_spread":0.32132051815069473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417479777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97901314,0.009118531,0.00030634008,0.0032202855,0.00040081586,0.0063472274,0.000043872336,0.00003396451,0.0015158447],"genre_scores_gemma":[0.99501425,0.001875921,0.00055764447,0.0007436262,0.000047369515,0.0006593538,0.000042971315,0.000029221206,0.0010296217],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983003,0.00022363498,0.0005646941,0.0003381723,0.0001636727,0.0004095375],"domain_scores_gemma":[0.9988778,0.00052563223,0.00014121315,0.00033260218,0.000057135065,0.00006561028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012363701,0.00018075855,0.0006794494,0.00032712417,0.000052897805,0.000008007124,0.00009181941,0.00011715398,0.00003539875],"category_scores_gemma":[0.00005576421,0.00015668847,0.0001195249,0.00061511603,0.000058057198,0.00004396673,0.000013121814,0.0001257105,0.00000159498],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23828983,0.0034546913,0.06572621,0.009459933,0.0006912948,0.000062356004,0.0059984303,0.0062283347,0.03010216,0.0035637612,0.0018086573,0.63461435],"study_design_scores_gemma":[0.36524168,0.025751678,0.29334888,0.028050428,0.000111703725,0.00008506547,0.0019761978,0.031187763,0.14128679,0.0050139623,0.106881775,0.0010640556],"about_ca_topic_score_codex":0.05414676,"about_ca_topic_score_gemma":0.0009996238,"teacher_disagreement_score":0.6335503,"about_ca_system_score_codex":0.0023315887,"about_ca_system_score_gemma":0.0018230763,"threshold_uncertainty_score":0.9521518},"labels":[],"label_agreement":null},{"id":"W4417481590","doi":"10.1016/j.jval.2025.09.209","title":"CO107 Evaluating the Health Impact of Anti-PD-(L)1 Agents for Early Stage Cancer Treatment in the Czech Republic","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Czech; Stage (stratigraphy); Renal cell carcinoma; Cancer; Cancer treatment; Breast cancer; Disease; Cancer stage","score_opus":0.17715392520786227,"score_gpt":0.4943118286976621,"score_spread":0.31715790348979983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417481590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9674122,0.007406285,0.00002544922,0.021363256,0.00020064805,0.0033722557,0.0001090255,0.000012122535,0.00009876445],"genre_scores_gemma":[0.993126,0.002710617,0.00011371447,0.0031122742,0.000052693973,0.00032980702,0.000018418466,0.0000140077445,0.00052248593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773735,0.0006143577,0.0006973935,0.00024590208,0.00026678943,0.00043819204],"domain_scores_gemma":[0.9987058,0.00043428468,0.0003018722,0.00044901404,0.000055675628,0.000053348467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004009602,0.00014797277,0.00044915144,0.00019673315,0.0001391415,0.00001872004,0.00015775762,0.000051849063,0.000040387124],"category_scores_gemma":[0.00011412207,0.000077484285,0.00017820107,0.00074634526,0.000057286285,0.000039184597,0.000014316051,0.00016112968,3.6162442e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005421599,0.0011056598,0.65709984,0.0015863057,0.00046731235,0.000005023493,0.027699996,0.0018655034,0.0005285665,0.00046450843,0.0044971453,0.29925856],"study_design_scores_gemma":[0.0050363485,0.00544182,0.9779615,0.0009170318,0.000020667738,0.0000031596785,0.0011994487,0.0054200343,0.00010032521,0.000099357036,0.003725123,0.00007520582],"about_ca_topic_score_codex":0.26721358,"about_ca_topic_score_gemma":0.002331696,"teacher_disagreement_score":0.32086167,"about_ca_system_score_codex":0.0019571616,"about_ca_system_score_gemma":0.0040793368,"threshold_uncertainty_score":0.73766613},"labels":[],"label_agreement":null},{"id":"W4417506867","doi":"10.1158/1078-0432.ccr-25-3541","title":"Investigating Early Kinetics in Plasma ctDNA and Peripheral T-cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck Squamous Cell Carcinoma","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"Eisai; Genentech; AstraZeneca; Canada Research Chairs; Genomic Health; Natera; Menarini Silicon Biosystems","keywords":"Repertoire; Head and neck; Head and neck squamous-cell carcinoma; T-cell receptor; Peripheral; Head and neck cancer; Receptor","score_opus":0.0896926933238834,"score_gpt":0.4311432024017427,"score_spread":0.3414505090778593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417506867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840954,0.00213686,8.513271e-7,0.011022825,0.00028602642,0.0015526494,0.000025573803,0.000021211748,0.0008586148],"genre_scores_gemma":[0.99350834,0.00049613114,0.0004927229,0.0012012081,0.0001588359,0.00032709813,0.0000056264385,0.000030112851,0.0037799173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970691,0.00032209558,0.00084342813,0.00074828346,0.00041585695,0.00060123316],"domain_scores_gemma":[0.99822515,0.0007736009,0.000051316485,0.00037286535,0.000114245624,0.0004628127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010727514,0.00023464438,0.0006094365,0.00038829035,0.0000965607,0.00006702105,0.00013949514,0.00022870259,0.000059854414],"category_scores_gemma":[0.00063306524,0.00019089789,0.00008952567,0.0008299881,0.00033753167,0.000051926716,0.0001915245,0.0006171527,0.0000048246015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028767493,0.000437764,0.9401551,0.00017556851,0.000016798655,0.000032978478,0.0016392061,0.000009444396,0.011172028,0.0000019955373,0.0019462749,0.041536123],"study_design_scores_gemma":[0.011294292,0.0057093543,0.96299446,0.0005108062,0.00001664362,0.0000015272383,0.0005832541,0.0001408939,0.007789566,0.000013588499,0.010754653,0.0001909917],"about_ca_topic_score_codex":0.011012365,"about_ca_topic_score_gemma":0.006690133,"teacher_disagreement_score":0.04134513,"about_ca_system_score_codex":0.0008546787,"about_ca_system_score_gemma":0.0006120396,"threshold_uncertainty_score":0.9955734},"labels":[],"label_agreement":null},{"id":"W6901562744","doi":"10.60692/ajst5-65a26","title":"Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis","year":2020,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dysgeusia; Peripheral neuropathy; Cancer; Clinical trial; Chemotherapy-induced peripheral neuropathy; Chemotherapy","score_opus":0.04807721148996214,"score_gpt":0.2475622360720401,"score_spread":0.19948502458207795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901562744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786595,0.014768812,0.00010000855,0.0017806726,0.00009900407,0.003759653,0.00028701726,0.00012067838,0.00042462331],"genre_scores_gemma":[0.99726844,0.000055438784,0.00001152797,0.002372752,0.0000060337647,0.00022146544,0.000024716082,0.00000696784,0.00003267556],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9974663,0.0001670529,0.0017542663,0.00015095863,0.0003131802,0.00014819988],"domain_scores_gemma":[0.9987658,0.000015017729,0.00074722583,0.00023056078,0.00016772943,0.00007366178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041101544,0.00019791278,0.0018305567,0.00025694532,0.00003159528,0.000027608636,0.000086903965,0.00010150141,0.00013255673],"category_scores_gemma":[0.0000603006,0.00012235322,0.0005323004,0.0008612966,0.00004983014,0.00024412878,0.000037198588,0.00011115324,0.00001598315],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014851505,0.000036455338,0.17941535,0.6219626,0.098166585,0.000011659399,0.098559305,0.00009799344,0.000017564067,0.00004037092,0.00015948823,0.000047483925],"study_design_scores_gemma":[0.011923206,0.0021032803,0.22969115,0.01893983,0.7133279,0.000065334796,0.017630866,0.00399366,0.0009964225,8.769263e-7,0.00009544511,0.0012320695],"about_ca_topic_score_codex":0.000043699678,"about_ca_topic_score_gemma":6.531033e-7,"teacher_disagreement_score":0.61516124,"about_ca_system_score_codex":0.00005497076,"about_ca_system_score_gemma":0.000026638838,"threshold_uncertainty_score":0.49894196},"labels":[],"label_agreement":null},{"id":"W6901633038","doi":"10.60692/rzzf3-ch046","title":"Defining the critical hurdles in cancer immunotherapy","year":2011,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Université de Montréal; Ontario Institute for Cancer Research; BC Cancer Agency; McMaster University","funders":"","keywords":"Clinical trial; Cancer immunotherapy; Immunotherapy; Alternative medicine; Cancer; Cancer treatment; China","score_opus":0.049332188755081156,"score_gpt":0.2732868618096176,"score_spread":0.22395467305453642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901633038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98288524,0.00042775148,0.0016914521,0.0005150687,0.0007366517,0.00058325386,0.000035837875,0.00024908024,0.012875643],"genre_scores_gemma":[0.9986046,0.000003902261,0.00018915831,0.0009727561,0.000039419923,0.00012178421,0.0000028217328,0.000012334881,0.00005322047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990567,0.000040573337,0.00044373432,0.00008164979,0.00018007404,0.0001972845],"domain_scores_gemma":[0.9995372,0.000011230705,0.00009321024,0.00025126213,0.00007216056,0.000034906887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033497994,0.00011386407,0.00017351069,0.00013770438,0.00006915408,0.000041001156,0.00009563237,0.00007567016,0.00014950059],"category_scores_gemma":[0.000012511401,0.00006878353,0.00007661387,0.00019689143,0.00007136657,0.00025917866,0.000014267826,0.00010846068,0.0001169115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024974595,0.000009563647,0.6820773,0.0003929001,0.0001451135,0.000010132831,0.30164793,0.0000030385052,0.00002873117,0.0025333522,0.00021378872,0.0104406625],"study_design_scores_gemma":[0.0036404324,0.00015855806,0.9543331,0.0007439587,0.000038642716,0.00013882645,0.034389094,0.0003678568,0.0020613142,0.000003872375,0.003904837,0.00021949878],"about_ca_topic_score_codex":0.00021695998,"about_ca_topic_score_gemma":0.0000020322636,"teacher_disagreement_score":0.27225578,"about_ca_system_score_codex":0.00012814073,"about_ca_system_score_gemma":0.00006332545,"threshold_uncertainty_score":0.28049108},"labels":[],"label_agreement":null},{"id":"W6901686223","doi":"10.60692/hrpf8-ccm77","title":"Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3","year":2020,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Immunotherapy; CD8; T cell; Antibody; Cancer; Cancer immunotherapy; Clinical trial; Tumor-infiltrating lymphocytes; Cell","score_opus":0.040903460049549895,"score_gpt":0.24594236968970395,"score_spread":0.20503890964015406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901686223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98581284,0.000032059546,0.010797276,0.00015809423,0.00013716868,0.0002954072,0.00004261153,0.000079503494,0.0026450087],"genre_scores_gemma":[0.999033,0.0000020063903,0.00040357982,0.00043967177,0.00006621088,0.000008131931,0.00002374738,0.0000058800238,0.000017794076],"study_design_codex":"qualitative","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999136,0.000031812924,0.00047286865,0.000075938224,0.00016840205,0.00011502732],"domain_scores_gemma":[0.9994762,0.0000036962408,0.00024090608,0.00012592471,0.00010407609,0.00004918596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016195983,0.00009985125,0.00023815768,0.000043280368,0.00007069276,0.000029787754,0.000051229934,0.000055304357,0.00004297232],"category_scores_gemma":[0.000018555857,0.000079262114,0.0000623921,0.00014959172,0.000047317117,0.00035031472,0.000032233613,0.00007345664,0.000034834942],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0083068935,0.0000140554575,0.09840168,0.010812627,0.00078024925,0.000015356187,0.8236547,0.000030366504,0.053419717,0.00030798046,0.0007589623,0.0034973752],"study_design_scores_gemma":[0.017446568,0.0011571936,0.11121647,0.0016599586,0.0002834554,0.00017071379,0.12653664,0.002669609,0.73431236,0.0000015991781,0.003847874,0.00069754885],"about_ca_topic_score_codex":0.000029798066,"about_ca_topic_score_gemma":5.4574258e-8,"teacher_disagreement_score":0.6971181,"about_ca_system_score_codex":0.00003302626,"about_ca_system_score_gemma":0.000038777995,"threshold_uncertainty_score":0.3232215},"labels":[],"label_agreement":null},{"id":"W6901699600","doi":"10.60692/t0vj9-13p85","title":"Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3","year":2020,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Immunotherapy; CD8; T cell; Antibody; Cancer; Cancer immunotherapy; Clinical trial; Tumor-infiltrating lymphocytes; Cell","score_opus":0.040903460049549895,"score_gpt":0.24594236968970395,"score_spread":0.20503890964015406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901699600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98581284,0.000032059546,0.010797276,0.00015809423,0.00013716868,0.0002954072,0.00004261153,0.000079503494,0.0026450087],"genre_scores_gemma":[0.999033,0.0000020063903,0.00040357982,0.00043967177,0.00006621088,0.000008131931,0.00002374738,0.0000058800238,0.000017794076],"study_design_codex":"qualitative","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999136,0.000031812924,0.00047286865,0.000075938224,0.00016840205,0.00011502732],"domain_scores_gemma":[0.9994762,0.0000036962408,0.00024090608,0.00012592471,0.00010407609,0.00004918596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016195983,0.00009985125,0.00023815768,0.000043280368,0.00007069276,0.000029787754,0.000051229934,0.000055304357,0.00004297232],"category_scores_gemma":[0.000018555857,0.000079262114,0.0000623921,0.00014959172,0.000047317117,0.00035031472,0.000032233613,0.00007345664,0.000034834942],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0083068935,0.0000140554575,0.09840168,0.010812627,0.00078024925,0.000015356187,0.8236547,0.000030366504,0.053419717,0.00030798046,0.0007589623,0.0034973752],"study_design_scores_gemma":[0.017446568,0.0011571936,0.11121647,0.0016599586,0.0002834554,0.00017071379,0.12653664,0.002669609,0.73431236,0.0000015991781,0.003847874,0.00069754885],"about_ca_topic_score_codex":0.000029798066,"about_ca_topic_score_gemma":5.4574258e-8,"teacher_disagreement_score":0.6971181,"about_ca_system_score_codex":0.00003302626,"about_ca_system_score_gemma":0.000038777995,"threshold_uncertainty_score":0.3232215},"labels":[],"label_agreement":null},{"id":"W6901782992","doi":"10.6084/m9.figshare.12153999.v1","title":"Additional file 1 of Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Adverse effect; Funnel plot; Meta-analysis; Event (particle physics); Table (database); Subgroup analysis; Melanoma; Survival analysis","score_opus":0.024824514945219422,"score_gpt":0.2426240007786332,"score_spread":0.21779948583341377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901782992","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025096494,0.011362497,1.883225e-8,0.00040176982,0.0000020491332,0.0015719897,0.9841102,0.000011625209,0.000030245967],"genre_scores_gemma":[0.34078228,0.000044630444,0.000012327833,0.00051969517,0.000005506819,0.0018652371,0.65647525,0.000029271481,0.00026578284],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99849325,0.00011920136,0.0007114793,0.00018700206,0.00037289094,0.000116193114],"domain_scores_gemma":[0.99778056,0.00044518814,0.0012297601,0.0002280446,0.0002719228,0.000044508066],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008469346,0.00017162011,0.001451144,0.00007082566,0.00002856032,0.000002247274,0.00010293177,0.000055508528,0.77689576],"category_scores_gemma":[0.0014300293,0.000089087865,0.00051209,0.0011708699,0.00002557667,0.00004931385,0.000033375472,0.0001399478,0.000010575763],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017473618,0.00072549784,0.0008301073,0.1255226,0.25759333,0.000015890602,0.00085930835,0.000061322404,0.000023368146,1.0831042e-7,0.612594,0.000027081627],"study_design_scores_gemma":[0.0061981967,0.00078445586,0.5896689,0.21240248,0.18889475,0.0000022819959,0.00026838496,0.00006395605,0.00012552328,2.3815886e-7,0.0012244773,0.00036631263],"about_ca_topic_score_codex":0.000037251393,"about_ca_topic_score_gemma":0.000043206324,"teacher_disagreement_score":0.7768852,"about_ca_system_score_codex":0.000062210245,"about_ca_system_score_gemma":0.00010118414,"threshold_uncertainty_score":0.36328977},"labels":[],"label_agreement":null},{"id":"W6901798590","doi":"10.60692/hxhem-pdx27","title":"Additional file 1 of Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Lung cancer; Table (database); Univariate analysis; Immunotherapy; Univariate; Chemotherapy; Gene; Mutation; Biomarker","score_opus":0.011345593160163512,"score_gpt":0.20567431509543418,"score_spread":0.19432872193527068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901798590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8694868,0.000014788381,0.00003167723,0.000041766274,0.000068453686,0.00080109964,0.12920722,0.00004046662,0.00030773287],"genre_scores_gemma":[0.98995113,2.620674e-7,0.00012351906,0.00035629826,0.000016443813,0.0009352565,0.008438709,0.000021642532,0.00015670642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789643,0.00008255059,0.0010993358,0.0001665033,0.0005131763,0.00024200966],"domain_scores_gemma":[0.99823314,0.00006599067,0.0011167744,0.00030075788,0.00022033595,0.0000629794],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003490723,0.00023210993,0.00063165,0.00036068095,0.00008987527,0.000018308256,0.00013354848,0.00008916008,0.046196744],"category_scores_gemma":[0.00002489736,0.00018919724,0.00021505401,0.0005992222,0.00006026372,0.00014666126,0.000033837194,0.00018127022,0.0000043181312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017453074,0.00058239256,0.8189784,0.0059978366,0.0036545717,0.000047791927,0.06203809,0.004130319,0.0019671067,0.0000013594068,0.08480333,0.0003456776],"study_design_scores_gemma":[0.034602754,0.00094576646,0.83369076,0.0035240552,0.00029122314,0.000039162423,0.008329647,0.013093133,0.10413821,1.1818215e-7,0.00070738647,0.00063779566],"about_ca_topic_score_codex":0.00058180076,"about_ca_topic_score_gemma":0.000010642529,"teacher_disagreement_score":0.120768525,"about_ca_system_score_codex":0.0005853003,"about_ca_system_score_gemma":0.0006233473,"threshold_uncertainty_score":0.95467514},"labels":[],"label_agreement":null},{"id":"W6901808310","doi":"10.60692/m634h-5x732","title":"Additional file 1 of Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Lung cancer; Table (database); Univariate analysis; Immunotherapy; Univariate; Chemotherapy; Gene; Mutation; Biomarker","score_opus":0.011345593160163512,"score_gpt":0.20567431509543418,"score_spread":0.19432872193527068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901808310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8694868,0.000014788381,0.00003167723,0.000041766274,0.000068453686,0.00080109964,0.12920722,0.00004046662,0.00030773287],"genre_scores_gemma":[0.98995113,2.620674e-7,0.00012351906,0.00035629826,0.000016443813,0.0009352565,0.008438709,0.000021642532,0.00015670642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789643,0.00008255059,0.0010993358,0.0001665033,0.0005131763,0.00024200966],"domain_scores_gemma":[0.99823314,0.00006599067,0.0011167744,0.00030075788,0.00022033595,0.0000629794],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003490723,0.00023210993,0.00063165,0.00036068095,0.00008987527,0.000018308256,0.00013354848,0.00008916008,0.046196744],"category_scores_gemma":[0.00002489736,0.00018919724,0.00021505401,0.0005992222,0.00006026372,0.00014666126,0.000033837194,0.00018127022,0.0000043181312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017453074,0.00058239256,0.8189784,0.0059978366,0.0036545717,0.000047791927,0.06203809,0.004130319,0.0019671067,0.0000013594068,0.08480333,0.0003456776],"study_design_scores_gemma":[0.034602754,0.00094576646,0.83369076,0.0035240552,0.00029122314,0.000039162423,0.008329647,0.013093133,0.10413821,1.1818215e-7,0.00070738647,0.00063779566],"about_ca_topic_score_codex":0.00058180076,"about_ca_topic_score_gemma":0.000010642529,"teacher_disagreement_score":0.120768525,"about_ca_system_score_codex":0.0005853003,"about_ca_system_score_gemma":0.0006233473,"threshold_uncertainty_score":0.95467514},"labels":[],"label_agreement":null},{"id":"W6901829170","doi":"10.6084/m9.figshare.14446709.v1","title":"Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nivolumab; Docetaxel; Population; Lung cancer; Clinical trial; Cost-effectiveness analysis; Cost effectiveness; Chemotherapy","score_opus":0.033196546306340856,"score_gpt":0.2882468545764554,"score_spread":0.25505030827011455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901829170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9440845,0.0037707426,8.9845236e-7,0.000044717955,0.00003388626,0.00071868283,0.05117378,0.0000055579003,0.0001672253],"genre_scores_gemma":[0.9859576,0.00011545206,0.000037596827,0.00013659587,0.000023837467,0.000119287135,0.013549631,0.000024219069,0.000035760833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897975,0.0000633805,0.00018673281,0.00039702922,0.00015026712,0.00022283885],"domain_scores_gemma":[0.99921423,0.00011568332,0.00007243746,0.00042691905,0.00007956377,0.00009115545],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000980309,0.00015071759,0.00032720453,0.00006315302,0.000024006775,0.000017918968,0.00012513885,0.000065018,0.0034615987],"category_scores_gemma":[0.00004780749,0.00013556727,0.000012428863,0.0002671747,0.000014044041,0.00011582161,0.000115295545,0.00016532141,9.0287847e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007346251,0.00044708635,0.9262479,0.011435785,0.00016174057,0.0023548272,0.001244145,0.00019513475,0.014637408,4.2750955e-7,0.016408421,0.019520892],"study_design_scores_gemma":[0.008802512,0.00020174934,0.971293,0.00414867,0.000040825285,0.000047531023,0.0005760464,0.0018300118,0.011070695,4.771497e-7,0.0017302913,0.00025819158],"about_ca_topic_score_codex":0.53357905,"about_ca_topic_score_gemma":0.95860523,"teacher_disagreement_score":0.42502615,"about_ca_system_score_codex":0.00029304562,"about_ca_system_score_gemma":0.0019162407,"threshold_uncertainty_score":0.9974494},"labels":[],"label_agreement":null},{"id":"W6902072599","doi":"10.6084/m9.figshare.26630134","title":"Additional file 10 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Immune system; Immune checkpoint; Pembrolizumab; Immunotherapy; Adverse effect","score_opus":0.014032393180212462,"score_gpt":0.23166796609119886,"score_spread":0.2176355729109864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902072599","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16295484,0.00028924496,1.3080583e-8,0.000024364695,0.000030140573,0.0003447931,0.8343195,0.000048671038,0.0019884876],"genre_scores_gemma":[0.4502317,0.000003321039,0.000013191519,0.000018288965,0.00003720104,0.00020629284,0.5477469,0.000021373731,0.0017217054],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99883974,0.0000231196,0.00045644882,0.00020406512,0.0003162513,0.00016037194],"domain_scores_gemma":[0.99926883,0.00020089459,0.0001450406,0.00019900336,0.00014347982,0.000042767388],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00003387091,0.00015498369,0.00030669017,0.00017319302,0.00001729491,0.000008139716,0.00007863561,0.00010992667,0.94858605],"category_scores_gemma":[0.00036662648,0.000118019365,0.00015126973,0.0004914305,0.000034648852,0.00009255876,0.00003349165,0.00014187105,0.0001922976],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016445452,0.0003754284,0.0006422611,0.00071471895,0.00026367366,0.000027812788,0.00022544297,0.0000015509066,0.0029408613,3.092121e-7,0.98984087,0.003322521],"study_design_scores_gemma":[0.00237244,0.0018010511,0.68801725,0.027124977,0.000035100158,0.00001203434,0.00005626408,0.00006504918,0.04868575,0.0000024721894,0.2316352,0.0001924346],"about_ca_topic_score_codex":0.000082227954,"about_ca_topic_score_gemma":0.000007502851,"teacher_disagreement_score":0.94839376,"about_ca_system_score_codex":0.00011777154,"about_ca_system_score_gemma":0.00026593835,"threshold_uncertainty_score":0.481269},"labels":[],"label_agreement":null},{"id":"W6902144407","doi":"10.6084/m9.figshare.29558120","title":"Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of early-stage non-small cell lung cancer following complete resection and platinum-based chemotherapy in Canada","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pembrolizumab; Lung cancer; Chemotherapy; Clinical trial; Adjuvant; Stage (stratigraphy); Survival analysis; Disease","score_opus":0.04008640671312782,"score_gpt":0.3255141357660614,"score_spread":0.2854277290529336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902144407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781941,0.0013017987,0.000005287926,0.000026384905,0.000037495865,0.00094547507,0.019291282,0.000006792301,0.0001913526],"genre_scores_gemma":[0.9942642,0.000038859667,0.000015176703,0.00009264963,0.00000849357,0.00029193528,0.0051865783,0.00001261383,0.00008949507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913096,0.000063105734,0.00025604575,0.00024121652,0.00015078502,0.00015786226],"domain_scores_gemma":[0.9993778,0.00015232437,0.00012870137,0.00022010793,0.0000727563,0.000048321494],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005312009,0.00014781232,0.0005295817,0.00028554822,0.000034069413,0.0000073762612,0.000054155815,0.00005895182,0.0032133579],"category_scores_gemma":[0.000015860522,0.00013156128,0.0001474883,0.00071756844,0.000007666043,0.000034733526,0.000008572078,0.00005607191,1.9276423e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02111875,0.0006232509,0.87357956,0.003330624,0.0047671245,0.000109616354,0.0016526325,0.0037574368,0.059031162,8.237958e-7,0.0005964836,0.03143256],"study_design_scores_gemma":[0.010210716,0.0005682996,0.90941894,0.0019302687,0.00040612303,3.1954602e-7,0.00016437125,0.0141611565,0.062092945,3.0789343e-7,0.00092805136,0.00011847988],"about_ca_topic_score_codex":0.73187125,"about_ca_topic_score_gemma":0.7358041,"teacher_disagreement_score":0.035839427,"about_ca_system_score_codex":0.0009899567,"about_ca_system_score_gemma":0.0012841192,"threshold_uncertainty_score":0.99769783},"labels":[],"label_agreement":null},{"id":"W6902168106","doi":"10.6084/m9.figshare.26378046","title":"Additional file 1 of Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study","year":2024,"lang":"en","type":"article","venue":"Open MIND","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Pembrolizumab; Placebo; Lung cancer; Immunotherapy; Phases of clinical research; PD-L1","score_opus":0.0844648644612435,"score_gpt":0.3801801566212285,"score_spread":0.295715292159985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902168106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.741737,0.0015710728,0.0001796313,0.00024255094,0.00026168296,0.024859773,0.22934745,0.000012290093,0.0017885385],"genre_scores_gemma":[0.933142,0.00016483714,0.007251805,0.000025994745,0.00019196353,0.022478048,0.022246156,0.00012663445,0.014372579],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99747044,0.00008380966,0.00084022497,0.0006797128,0.00048186406,0.0004439567],"domain_scores_gemma":[0.99651974,0.0022171899,0.0004103067,0.00040222277,0.00026581707,0.0001847344],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034725814,0.00048564968,0.0015244558,0.00024395288,0.00012304613,0.000116226496,0.00025732355,0.00010167739,0.17010224],"category_scores_gemma":[0.00006650165,0.00033168858,0.00038504484,0.0004053046,0.00020736332,0.00016964873,0.00006802201,0.00015267977,0.000018613755],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95052326,0.0022386515,0.0000027289968,0.0005057291,0.0056876037,0.0001748062,0.0033370634,0.00014615651,0.00015898015,0.0000033402393,0.013628913,0.023592789],"study_design_scores_gemma":[0.9341443,0.012419228,0.00001829787,0.0014690775,0.004531098,0.00005881672,0.0011274441,0.0032129122,0.01123788,0.0000053550752,0.03140584,0.00036975657],"about_ca_topic_score_codex":0.002292265,"about_ca_topic_score_gemma":0.001897708,"teacher_disagreement_score":0.2071013,"about_ca_system_score_codex":0.000698211,"about_ca_system_score_gemma":0.0033427768,"threshold_uncertainty_score":0.9999135},"labels":[],"label_agreement":null},{"id":"W6902175935","doi":"10.6084/m9.figshare.26378046.v1","title":"Additional file 1 of Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Pembrolizumab; Placebo; Lung cancer; Immunotherapy; Phases of clinical research; PD-L1","score_opus":0.07809445917721287,"score_gpt":0.3548470916386028,"score_spread":0.2767526324613899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902175935","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.035058014,0.0022284302,0.000014334381,0.00009201446,0.00010884307,0.012044346,0.9499759,0.00006923004,0.00040888938],"genre_scores_gemma":[0.41921574,0.000056710785,0.0006258873,0.000034919995,0.00021607937,0.04244034,0.53391033,0.000116930154,0.0033830807],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976304,0.00006284578,0.0007279886,0.0005941952,0.0005240528,0.00046048604],"domain_scores_gemma":[0.995739,0.0029337846,0.0003955362,0.00036671854,0.00038133067,0.0001836621],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000107341,0.0005069484,0.0013186536,0.0002668597,0.00011025074,0.000058311685,0.00016642468,0.000118304575,0.66465557],"category_scores_gemma":[0.00022719635,0.00035332315,0.0005109982,0.0004265201,0.00006204176,0.00011806485,0.000042230316,0.00017222691,0.00003736957],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.776763,0.0011909168,5.129144e-7,0.002420651,0.0037947053,0.00015569985,0.0013390579,0.0001411039,0.000032091,0.0000017783043,0.2106026,0.0035578588],"study_design_scores_gemma":[0.92844146,0.009786496,0.000032567918,0.007148458,0.0024636253,0.00005378118,0.00041931059,0.004556911,0.003897597,0.000004032742,0.042799115,0.00039664237],"about_ca_topic_score_codex":0.00055303355,"about_ca_topic_score_gemma":0.000593622,"teacher_disagreement_score":0.6646182,"about_ca_system_score_codex":0.00072237826,"about_ca_system_score_gemma":0.0028715853,"threshold_uncertainty_score":0.9998919},"labels":[],"label_agreement":null},{"id":"W6902189100","doi":"10.6084/m9.figshare.25010378","title":"Additional file 1 of Negative prognostic behaviour of PD-L1 expression in tongue and larynx squamous cell carcinoma and its significant predictive power in combination with PD-1 expression on TILs","year":2024,"lang":"en","type":"article","venue":"Open MIND","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Larynx; Tongue; Basal cell; Expression (computer science); Immunohistochemistry; Epidermoid carcinoma; Carcinoma","score_opus":0.015059482470031745,"score_gpt":0.26290649099262664,"score_spread":0.2478470085225949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902189100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97508746,0.00020572064,0.0000015191719,0.000038756247,0.000018883215,0.0010179414,0.021794673,0.0000013490306,0.0018336708],"genre_scores_gemma":[0.99695295,0.000006781687,0.00035574668,0.000008627878,0.0000068173345,0.0001837713,0.0020132703,0.000011300588,0.00046076215],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99915266,0.00006016748,0.00022504137,0.00026847495,0.00019276098,0.00010088141],"domain_scores_gemma":[0.99914736,0.0005731334,0.00009435212,0.00008541391,0.000057999558,0.000041758885],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000107189095,0.00011194252,0.00020681722,0.00015611308,0.000019569856,0.000017393228,0.000053181062,0.000074376665,0.038755316],"category_scores_gemma":[0.00007968062,0.00008291236,0.000018232973,0.00017232599,0.00007641244,0.00015147298,0.000045550478,0.00013178952,0.0000023880532],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047007408,0.0054956377,0.04563117,0.0010164893,0.00008383998,0.00076907396,0.028729891,0.000022402854,0.72071457,0.0000094088655,0.13040255,0.02011756],"study_design_scores_gemma":[0.0045297462,0.0037559927,0.5978979,0.0054009855,0.000032782722,0.000014700799,0.0018588703,0.00035898027,0.38510656,0.000013666365,0.00088535965,0.00014445529],"about_ca_topic_score_codex":0.000059083333,"about_ca_topic_score_gemma":0.000030160038,"teacher_disagreement_score":0.5522667,"about_ca_system_score_codex":0.000049701823,"about_ca_system_score_gemma":0.00014637868,"threshold_uncertainty_score":0.9621234},"labels":[],"label_agreement":null},{"id":"W6902222018","doi":"10.6084/m9.figshare.26630104","title":"Additional file 1 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Antigen; Immune system; Immunotherapy; Pembrolizumab; Immune checkpoint; Antibody","score_opus":0.013490730881090608,"score_gpt":0.22879322136168445,"score_spread":0.21530249048059386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902222018","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10526852,0.00023613834,1.2094445e-8,0.000021571606,0.000028507537,0.00033193806,0.89245796,0.00004662382,0.0016087434],"genre_scores_gemma":[0.37210912,0.0000029368903,0.000015357024,0.000019420006,0.000033640164,0.0002473776,0.62672555,0.000019609422,0.0008269812],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9988863,0.000021655444,0.00043880512,0.00019548503,0.00030320536,0.00015457296],"domain_scores_gemma":[0.999251,0.0002517844,0.00014111787,0.00018940383,0.00012578217,0.00004091742],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00002849051,0.00014808634,0.00029548712,0.00016859571,0.000016348466,0.0000075633952,0.00007446199,0.00010357483,0.96118516],"category_scores_gemma":[0.0004059718,0.00011243382,0.00014653282,0.00048719646,0.000033073273,0.00008878714,0.000031752566,0.00014641978,0.00014576699],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001056225,0.0003043814,0.0006147651,0.000595399,0.00021925454,0.000024349341,0.0001960956,0.0000013241582,0.002307919,2.2635628e-7,0.99181944,0.002860639],"study_design_scores_gemma":[0.0017972938,0.0013930685,0.7074816,0.029287867,0.000027598413,0.000011617717,0.000053380725,0.000052806623,0.0354827,0.0000018646475,0.22424528,0.00016491833],"about_ca_topic_score_codex":0.000080470716,"about_ca_topic_score_gemma":0.0000070101587,"teacher_disagreement_score":0.9610394,"about_ca_system_score_codex":0.00011334053,"about_ca_system_score_gemma":0.00026684272,"threshold_uncertainty_score":0.45849183},"labels":[],"label_agreement":null},{"id":"W6902244894","doi":"10.6084/m9.figshare.8252117","title":"Additional file 5: of Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis","year":2019,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Programmed cell death 1; Adverse effect; Programmed cell death; Table (database); Cell; Systematic review; Lung cancer","score_opus":0.020570530816070375,"score_gpt":0.24940532129240808,"score_spread":0.2288347904763377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902244894","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011797355,0.025979921,6.3785717e-7,0.00006383311,0.000010429775,0.018595183,0.94329536,0.00006209774,0.00019517737],"genre_scores_gemma":[0.10077835,0.00021528424,0.0013504156,0.00027640408,0.000025677455,0.050257593,0.82951677,0.00013635306,0.017443158],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9976006,0.00010876938,0.0009414688,0.0005374006,0.00040077808,0.00041096035],"domain_scores_gemma":[0.99716336,0.00046944668,0.0013378111,0.0003940002,0.00046783328,0.00016752369],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023459832,0.00042478397,0.0020124563,0.0001717157,0.00009018622,0.00002278254,0.00014044256,0.00021407488,0.27777213],"category_scores_gemma":[0.0003182678,0.00029416644,0.00085606414,0.0006765229,0.000019672481,0.00010060089,0.00005680555,0.00020573844,0.000017751609],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076661306,0.001192619,0.0005845486,0.6632645,0.08036868,0.000025809348,0.000486651,0.000004281773,0.0008703118,1.964204e-7,0.25235927,0.00007650553],"study_design_scores_gemma":[0.020430326,0.004518715,0.007221243,0.3099859,0.6200393,0.000043357977,0.00046276956,0.0021133597,0.014120296,0.000004927297,0.018660266,0.0023995503],"about_ca_topic_score_codex":0.000055592038,"about_ca_topic_score_gemma":0.00003871282,"teacher_disagreement_score":0.5396706,"about_ca_system_score_codex":0.0001322016,"about_ca_system_score_gemma":0.00034333853,"threshold_uncertainty_score":0.99995106},"labels":[],"label_agreement":null},{"id":"W6902249325","doi":"10.6084/m9.figshare.26630125.v1","title":"Additional file 7 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Immunotherapy; Immune system; Immune checkpoint; Pembrolizumab","score_opus":0.013269466913538029,"score_gpt":0.22864619081191945,"score_spread":0.21537672389838142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902249325","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10602438,0.00023834669,1.2230845e-8,0.00002156507,0.000028545926,0.0003322976,0.8916959,0.00004665813,0.0016123003],"genre_scores_gemma":[0.37582746,0.0000029775867,0.000015136972,0.000019381816,0.000033596927,0.00024162998,0.62302274,0.000019550687,0.0008175149],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99888587,0.000021644444,0.0004391658,0.0001954642,0.00030327283,0.00015460423],"domain_scores_gemma":[0.99925375,0.0002494568,0.0001411527,0.00018918386,0.00012555196,0.000040924206],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00002851537,0.00014810178,0.00029564803,0.00016862398,0.000016356686,0.000007584406,0.00007444964,0.0001035773,0.95893496],"category_scores_gemma":[0.00039724555,0.00011243994,0.00014654716,0.00048711113,0.000033087246,0.00008888329,0.00003174553,0.00014641507,0.00014358759],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010763692,0.0003100677,0.00062566396,0.00061795977,0.00022316341,0.00002520528,0.00020012286,0.0000013489858,0.0023434602,2.372614e-7,0.9915986,0.0029778155],"study_design_scores_gemma":[0.001824963,0.0014064707,0.709566,0.02977969,0.000027723145,0.000011694526,0.000053579963,0.000053365522,0.03614764,0.0000019000069,0.220961,0.00016596843],"about_ca_topic_score_codex":0.00008148618,"about_ca_topic_score_gemma":0.000007120033,"teacher_disagreement_score":0.9587914,"about_ca_system_score_codex":0.000113398266,"about_ca_system_score_gemma":0.00026635325,"threshold_uncertainty_score":0.45851678},"labels":[],"label_agreement":null},{"id":"W6902258681","doi":"10.6084/m9.figshare.26630125","title":"Additional file 7 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Immunotherapy; Immune system; Immune checkpoint; Pembrolizumab","score_opus":0.013269466913538029,"score_gpt":0.22864619081191945,"score_spread":0.21537672389838142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902258681","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10602438,0.00023834669,1.2230845e-8,0.00002156507,0.000028545926,0.0003322976,0.8916959,0.00004665813,0.0016123003],"genre_scores_gemma":[0.37582746,0.0000029775867,0.000015136972,0.000019381816,0.000033596927,0.00024162998,0.62302274,0.000019550687,0.0008175149],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99888587,0.000021644444,0.0004391658,0.0001954642,0.00030327283,0.00015460423],"domain_scores_gemma":[0.99925375,0.0002494568,0.0001411527,0.00018918386,0.00012555196,0.000040924206],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00002851537,0.00014810178,0.00029564803,0.00016862398,0.000016356686,0.000007584406,0.00007444964,0.0001035773,0.95893496],"category_scores_gemma":[0.00039724555,0.00011243994,0.00014654716,0.00048711113,0.000033087246,0.00008888329,0.00003174553,0.00014641507,0.00014358759],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010763692,0.0003100677,0.00062566396,0.00061795977,0.00022316341,0.00002520528,0.00020012286,0.0000013489858,0.0023434602,2.372614e-7,0.9915986,0.0029778155],"study_design_scores_gemma":[0.001824963,0.0014064707,0.709566,0.02977969,0.000027723145,0.000011694526,0.000053579963,0.000053365522,0.03614764,0.0000019000069,0.220961,0.00016596843],"about_ca_topic_score_codex":0.00008148618,"about_ca_topic_score_gemma":0.000007120033,"teacher_disagreement_score":0.9587914,"about_ca_system_score_codex":0.000113398266,"about_ca_system_score_gemma":0.00026635325,"threshold_uncertainty_score":0.45851678},"labels":[],"label_agreement":null},{"id":"W6902262676","doi":"10.6084/m9.figshare.26630128","title":"Additional file 8 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Immune system; Pembrolizumab; Immune checkpoint; Immunotherapy; Nivolumab","score_opus":0.013254414913963529,"score_gpt":0.22859643274929495,"score_spread":0.2153420178353314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902262676","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10638764,0.00023848726,1.2239732e-8,0.000021586993,0.000028533314,0.00033224552,0.8913207,0.000046320307,0.0016244871],"genre_scores_gemma":[0.37720233,0.0000029378327,0.000015155969,0.000019396508,0.00003360359,0.00024201006,0.6216381,0.000019532637,0.00082693493],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9988859,0.000021650303,0.00043915727,0.00019543714,0.00030320472,0.00015459533],"domain_scores_gemma":[0.9992535,0.00024969084,0.00014116196,0.00018917494,0.00012556247,0.000040921208],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00002851633,0.00014809729,0.0002956457,0.00016857406,0.000016355763,0.000007583327,0.00007443966,0.000103575694,0.95953673],"category_scores_gemma":[0.00040165894,0.00011243421,0.00014654585,0.00048681145,0.00003308409,0.00008886789,0.000031737552,0.00014641049,0.00014448758],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010718979,0.00030869516,0.00061900145,0.00060983247,0.00022221795,0.000025098492,0.00019922992,0.000001343781,0.002307111,2.3537544e-7,0.9916427,0.002992625],"study_design_scores_gemma":[0.0018238157,0.0014062005,0.710199,0.029481879,0.000027709357,0.000011692506,0.000053569922,0.000053383625,0.03647979,0.0000018997157,0.22029518,0.00016587957],"about_ca_topic_score_codex":0.00008132667,"about_ca_topic_score_gemma":0.0000071114605,"teacher_disagreement_score":0.9593922,"about_ca_system_score_codex":0.00011339237,"about_ca_system_score_gemma":0.0002663827,"threshold_uncertainty_score":0.4584934},"labels":[],"label_agreement":null},{"id":"W6902282177","doi":"10.6084/m9.figshare.26716219.v1","title":"Additional file 1 of Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Loss of heterozygosity; Prostate cancer; Immune system; Major histocompatibility complex; Tumor microenvironment; Prostate","score_opus":0.01849760743748261,"score_gpt":0.25961295894818087,"score_spread":0.24111535151069827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902282177","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032045394,0.0014632134,1.1681851e-8,0.00028832923,0.000023062341,0.00032801618,0.96559715,0.000012561423,0.00024227654],"genre_scores_gemma":[0.42914593,0.00007273821,0.00001268804,0.00018775971,0.0000383927,0.0006808851,0.5691394,0.000018534372,0.0007036735],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992914,0.000028212993,0.00021867092,0.00014423935,0.00018839633,0.00012908992],"domain_scores_gemma":[0.99935406,0.00033854356,0.00008844336,0.00016817694,0.000023293793,0.000027463493],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000030024385,0.000099907134,0.00015186796,0.000058313188,0.000021580754,0.0000073280653,0.00007020397,0.000049154405,0.9743701],"category_scores_gemma":[0.0001313597,0.000063018546,0.000098259516,0.00015238172,0.000025704103,0.00004046676,0.000035935896,0.00013594939,0.0001357998],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058389816,0.00008205246,0.000015783538,0.00035758995,0.000049003942,0.000024245825,0.00021707664,0.0000061303954,0.050247863,1.2060428e-7,0.94668657,0.0017296462],"study_design_scores_gemma":[0.00079632306,0.00031948707,0.09660593,0.051802617,0.0000120807545,0.000015920365,0.000070986775,0.00008304151,0.28850082,0.000005654701,0.56166095,0.00012621662],"about_ca_topic_score_codex":0.000041013693,"about_ca_topic_score_gemma":0.000010932521,"teacher_disagreement_score":0.97423434,"about_ca_system_score_codex":0.00011916937,"about_ca_system_score_gemma":0.000109449604,"threshold_uncertainty_score":0.25698218},"labels":[],"label_agreement":null},{"id":"W6902304492","doi":"10.6084/m9.figshare.26630137","title":"Additional file 11 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Immune system; Antibody; Immunotherapy; Immune checkpoint; Adverse effect","score_opus":0.013724982179416069,"score_gpt":0.22986317838547815,"score_spread":0.2161381962060621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902304492","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22673182,0.00024222075,1.6815696e-8,0.000025561872,0.000032460823,0.00033132028,0.77161795,0.000045645087,0.0009730191],"genre_scores_gemma":[0.5117049,0.0000031929355,0.000013383871,0.000019690548,0.000034256012,0.00019107816,0.4873446,0.000019862573,0.00066904427],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9988285,0.000023488032,0.00046156245,0.00020540919,0.00031788068,0.00016317068],"domain_scores_gemma":[0.99928445,0.00019654093,0.00014605191,0.0001992517,0.00013043877,0.000043285047],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000034080113,0.00015619559,0.00031060376,0.0001753066,0.000017584875,0.000008030419,0.00007919997,0.00010814938,0.8896201],"category_scores_gemma":[0.00032487485,0.00011893827,0.00015253037,0.00049709,0.000034824403,0.000094383315,0.000033706707,0.00013706768,0.00010470783],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012390612,0.00045683965,0.0024495085,0.0008880607,0.00026785216,0.00003669979,0.00031457242,0.0000023821417,0.0037599623,5.4179145e-7,0.9876708,0.0029137451],"study_design_scores_gemma":[0.002014866,0.0011994662,0.78372127,0.024147438,0.000029951916,0.0000114473405,0.00005784333,0.000052740044,0.043461412,0.0000018349598,0.14513876,0.00016295194],"about_ca_topic_score_codex":0.00014674837,"about_ca_topic_score_gemma":0.000016916072,"teacher_disagreement_score":0.88951546,"about_ca_system_score_codex":0.00011830416,"about_ca_system_score_gemma":0.00026027244,"threshold_uncertainty_score":0.4850162},"labels":[],"label_agreement":null},{"id":"W6910116650","doi":"10.3899/jrheum.2025-0314.4","title":"Immune Checkpoint Inhibitors in Patients with Pre-Existing Rheumatic Disease and the Impact of Immunosuppression: Data from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McMaster University; University of Toronto; Western University; Dalhousie University; McGill University; University of Ottawa; Jewish General Hospital; University of Alberta; University of Calgary; Centre Hospitalier de l’Université de Montréal; Arthritis Research Centre of Canada; Montreal Clinical Research Institute; University of British Columbia; St Joseph's Health Centre; Research Canada","funders":"","keywords":"Rheumatology; Prospective cohort study; Retrospective cohort study; Inflammatory arthritis; Arthritis; Adverse effect; Cohort study; Cohort","score_opus":0.031078748573775537,"score_gpt":0.34765171783582416,"score_spread":0.31657296926204864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6910116650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97883016,0.015812244,0.0000091423235,0.004172413,0.00022589898,0.0008013041,0.000043794676,0.0000026731755,0.000102393744],"genre_scores_gemma":[0.99581397,0.004015631,0.000057225312,0.000041051557,0.0000034942,0.000011837462,0.000030959087,0.000017179655,0.000008663891],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99505323,0.002080951,0.0018128512,0.00020507256,0.00038844277,0.00045948007],"domain_scores_gemma":[0.9935706,0.0038368483,0.0010856277,0.0010796329,0.0003271271,0.00010012518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061947554,0.00021709703,0.0011766803,0.0005140883,0.0002170338,0.000017377182,0.0010972192,0.0001707532,0.00006796522],"category_scores_gemma":[0.0017707448,0.00009510413,0.00013967896,0.0007506318,0.0021882195,0.00013199462,0.00038047638,0.001021676,5.1669366e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041973334,0.0002884196,0.9475093,0.00014015127,0.000876895,0.000009474757,0.0046241554,0.000028097256,0.00038680644,0.00015207347,0.0005060225,0.0035053089],"study_design_scores_gemma":[0.01677057,0.0007959462,0.974479,0.0038787955,0.0001338365,0.0002843535,0.0022565727,0.00041690492,0.00004560621,0.00076825236,0.000078460725,0.00009170591],"about_ca_topic_score_codex":0.5630943,"about_ca_topic_score_gemma":0.17273544,"teacher_disagreement_score":0.39035887,"about_ca_system_score_codex":0.0004461923,"about_ca_system_score_gemma":0.0025265652,"threshold_uncertainty_score":0.84235996},"labels":[],"label_agreement":null},{"id":"W6920181522","doi":"10.60692/jej1y-j9243","title":"LAG3's Enigmatic Mechanism of Action","year":2021,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Mechanism (biology); Endocytosis; Immune system; Disease; Infectious disease (medical specialty); Action (physics)","score_opus":0.041315843471991104,"score_gpt":0.24448433067988046,"score_spread":0.20316848720788935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920181522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97345,0.00001311174,0.01806043,0.00012302883,0.00050601835,0.00026521913,0.000028664175,0.00009830208,0.007455193],"genre_scores_gemma":[0.99895567,7.220348e-7,0.00029986745,0.0002450307,0.000037241687,0.000015484751,0.00002179998,0.0000049250807,0.00041925197],"study_design_codex":"qualitative","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99919623,0.000026919422,0.00041199208,0.00005968508,0.00021329877,0.00009187889],"domain_scores_gemma":[0.99936825,0.000003237916,0.0001921313,0.00022264924,0.00017772865,0.000036023815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015979224,0.000075621996,0.00018437897,0.00010683814,0.000035469955,0.000023360188,0.00003128134,0.0000583459,0.00011797141],"category_scores_gemma":[0.000010442981,0.000061225044,0.000090186244,0.00018019768,0.000012022625,0.00021000444,0.000012323802,0.000043927615,0.00012344249],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009819067,0.00010338331,0.19164574,0.04422831,0.0039839135,0.00016041874,0.63677627,0.00010597284,0.0383643,0.014312421,0.0031180761,0.05738215],"study_design_scores_gemma":[0.014452155,0.00051055703,0.1200911,0.0026081533,0.00038996415,0.0018481555,0.1371516,0.00483991,0.7128136,0.000017508042,0.0046764333,0.0006008736],"about_ca_topic_score_codex":0.0000051232882,"about_ca_topic_score_gemma":1.847605e-7,"teacher_disagreement_score":0.6744493,"about_ca_system_score_codex":0.00008601424,"about_ca_system_score_gemma":0.00007308401,"threshold_uncertainty_score":0.2496685},"labels":[],"label_agreement":null},{"id":"W6920244738","doi":"10.60692/jqgzp-ypg75","title":"Defining the critical hurdles in cancer immunotherapy","year":2011,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Université de Montréal; Ontario Institute for Cancer Research; BC Cancer Agency; McMaster University","funders":"","keywords":"Clinical trial; Cancer immunotherapy; Immunotherapy; Alternative medicine; Cancer; Cancer treatment; China","score_opus":0.049332188755081156,"score_gpt":0.2732868618096176,"score_spread":0.22395467305453642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920244738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98288524,0.00042775148,0.0016914521,0.0005150687,0.0007366517,0.00058325386,0.000035837875,0.00024908024,0.012875643],"genre_scores_gemma":[0.9986046,0.000003902261,0.00018915831,0.0009727561,0.000039419923,0.00012178421,0.0000028217328,0.000012334881,0.00005322047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990567,0.000040573337,0.00044373432,0.00008164979,0.00018007404,0.0001972845],"domain_scores_gemma":[0.9995372,0.000011230705,0.00009321024,0.00025126213,0.00007216056,0.000034906887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033497994,0.00011386407,0.00017351069,0.00013770438,0.00006915408,0.000041001156,0.00009563237,0.00007567016,0.00014950059],"category_scores_gemma":[0.000012511401,0.00006878353,0.00007661387,0.00019689143,0.00007136657,0.00025917866,0.000014267826,0.00010846068,0.0001169115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024974595,0.000009563647,0.6820773,0.0003929001,0.0001451135,0.000010132831,0.30164793,0.0000030385052,0.00002873117,0.0025333522,0.00021378872,0.0104406625],"study_design_scores_gemma":[0.0036404324,0.00015855806,0.9543331,0.0007439587,0.000038642716,0.00013882645,0.034389094,0.0003678568,0.0020613142,0.000003872375,0.003904837,0.00021949878],"about_ca_topic_score_codex":0.00021695998,"about_ca_topic_score_gemma":0.0000020322636,"teacher_disagreement_score":0.27225578,"about_ca_system_score_codex":0.00012814073,"about_ca_system_score_gemma":0.00006332545,"threshold_uncertainty_score":0.28049108},"labels":[],"label_agreement":null},{"id":"W6920289923","doi":"10.60692/v4rm6-ws749","title":"Distribution, vocalization and taxonomic status of hypsiboas roraima and h. angelicus (Amphibia: Anura: Hylidae)","year":2011,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ontario Museum","funders":"","keywords":"Amazon rainforest; Synonym (taxonomy); Nomenclature; Distribution (mathematics)","score_opus":0.0370284489424744,"score_gpt":0.21171213066996197,"score_spread":0.17468368172748758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920289923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98950297,0.000092541406,0.007949664,0.000019219551,0.00012112363,0.0004241645,0.00026103924,0.000057313347,0.001571971],"genre_scores_gemma":[0.9995319,0.000010007111,0.00020612706,0.00006242513,0.000024722583,0.000020986716,0.00010920589,0.0000060073107,0.00002859837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910766,0.000024456886,0.00047425646,0.000101869155,0.00012337597,0.00016837686],"domain_scores_gemma":[0.9993296,0.0000039274883,0.00026340512,0.0001682316,0.00013842435,0.000096360105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016737907,0.00011871834,0.00021896098,0.00010797346,0.000060499464,0.000030092831,0.000028853101,0.000085871114,0.0000184361],"category_scores_gemma":[0.000014387259,0.000094897696,0.000036011163,0.0001322149,0.00008123779,0.00034255697,0.000020934975,0.000040109182,0.000015501966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016105382,0.000007766431,0.9516845,0.0010565917,0.00014616345,0.0000023288437,0.03799234,0.0000012318686,0.000092292066,0.00030045945,0.00038453753,0.0067212847],"study_design_scores_gemma":[0.003194298,0.00022455212,0.9812281,0.00024643596,0.000082056744,0.000105600084,0.008311613,0.00045852637,0.003516698,0.000001275232,0.0024829304,0.0001479146],"about_ca_topic_score_codex":0.00011121535,"about_ca_topic_score_gemma":0.0000010933197,"teacher_disagreement_score":0.029680729,"about_ca_system_score_codex":0.00010292578,"about_ca_system_score_gemma":0.000042739273,"threshold_uncertainty_score":0.38698158},"labels":[],"label_agreement":null},{"id":"W6920576303","doi":"10.6084/m9.figshare.14446709","title":"Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nivolumab; Docetaxel; Population; Lung cancer; Clinical trial; Cost-effectiveness analysis; Cost effectiveness; Chemotherapy","score_opus":0.033196546306340856,"score_gpt":0.2882468545764554,"score_spread":0.25505030827011455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920576303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9440845,0.0037707426,8.9845236e-7,0.000044717955,0.00003388626,0.00071868283,0.05117378,0.0000055579003,0.0001672253],"genre_scores_gemma":[0.9859576,0.00011545206,0.000037596827,0.00013659587,0.000023837467,0.000119287135,0.013549631,0.000024219069,0.000035760833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897975,0.0000633805,0.00018673281,0.00039702922,0.00015026712,0.00022283885],"domain_scores_gemma":[0.99921423,0.00011568332,0.00007243746,0.00042691905,0.00007956377,0.00009115545],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000980309,0.00015071759,0.00032720453,0.00006315302,0.000024006775,0.000017918968,0.00012513885,0.000065018,0.0034615987],"category_scores_gemma":[0.00004780749,0.00013556727,0.000012428863,0.0002671747,0.000014044041,0.00011582161,0.000115295545,0.00016532141,9.0287847e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007346251,0.00044708635,0.9262479,0.011435785,0.00016174057,0.0023548272,0.001244145,0.00019513475,0.014637408,4.2750955e-7,0.016408421,0.019520892],"study_design_scores_gemma":[0.008802512,0.00020174934,0.971293,0.00414867,0.000040825285,0.000047531023,0.0005760464,0.0018300118,0.011070695,4.771497e-7,0.0017302913,0.00025819158],"about_ca_topic_score_codex":0.53357905,"about_ca_topic_score_gemma":0.95860523,"teacher_disagreement_score":0.42502615,"about_ca_system_score_codex":0.00029304562,"about_ca_system_score_gemma":0.0019162407,"threshold_uncertainty_score":0.9974494},"labels":[],"label_agreement":null},{"id":"W6920601812","doi":"10.6084/m9.figshare.26630137.v1","title":"Additional file 11 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Immune system; Antibody; Immunotherapy; Immune checkpoint; Adverse effect","score_opus":0.013724982179416069,"score_gpt":0.22986317838547815,"score_spread":0.2161381962060621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920601812","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22673182,0.00024222075,1.6815696e-8,0.000025561872,0.000032460823,0.00033132028,0.77161795,0.000045645087,0.0009730191],"genre_scores_gemma":[0.5117049,0.0000031929355,0.000013383871,0.000019690548,0.000034256012,0.00019107816,0.4873446,0.000019862573,0.00066904427],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9988285,0.000023488032,0.00046156245,0.00020540919,0.00031788068,0.00016317068],"domain_scores_gemma":[0.99928445,0.00019654093,0.00014605191,0.0001992517,0.00013043877,0.000043285047],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000034080113,0.00015619559,0.00031060376,0.0001753066,0.000017584875,0.000008030419,0.00007919997,0.00010814938,0.8896201],"category_scores_gemma":[0.00032487485,0.00011893827,0.00015253037,0.00049709,0.000034824403,0.000094383315,0.000033706707,0.00013706768,0.00010470783],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012390612,0.00045683965,0.0024495085,0.0008880607,0.00026785216,0.00003669979,0.00031457242,0.0000023821417,0.0037599623,5.4179145e-7,0.9876708,0.0029137451],"study_design_scores_gemma":[0.002014866,0.0011994662,0.78372127,0.024147438,0.000029951916,0.0000114473405,0.00005784333,0.000052740044,0.043461412,0.0000018349598,0.14513876,0.00016295194],"about_ca_topic_score_codex":0.00014674837,"about_ca_topic_score_gemma":0.000016916072,"teacher_disagreement_score":0.88951546,"about_ca_system_score_codex":0.00011830416,"about_ca_system_score_gemma":0.00026027244,"threshold_uncertainty_score":0.4850162},"labels":[],"label_agreement":null},{"id":"W6920667839","doi":"10.6084/m9.figshare.29558120.v2","title":"Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of early-stage non-small cell lung cancer following complete resection and platinum-based chemotherapy in Canada","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pembrolizumab; Lung cancer; Chemotherapy; Clinical trial; Adjuvant; Stage (stratigraphy); Survival analysis; Disease","score_opus":0.04008640671312782,"score_gpt":0.3255141357660614,"score_spread":0.2854277290529336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920667839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781941,0.0013017987,0.000005287926,0.000026384905,0.000037495865,0.00094547507,0.019291282,0.000006792301,0.0001913526],"genre_scores_gemma":[0.9942642,0.000038859667,0.000015176703,0.00009264963,0.00000849357,0.00029193528,0.0051865783,0.00001261383,0.00008949507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913096,0.000063105734,0.00025604575,0.00024121652,0.00015078502,0.00015786226],"domain_scores_gemma":[0.9993778,0.00015232437,0.00012870137,0.00022010793,0.0000727563,0.000048321494],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005312009,0.00014781232,0.0005295817,0.00028554822,0.000034069413,0.0000073762612,0.000054155815,0.00005895182,0.0032133579],"category_scores_gemma":[0.000015860522,0.00013156128,0.0001474883,0.00071756844,0.000007666043,0.000034733526,0.000008572078,0.00005607191,1.9276423e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02111875,0.0006232509,0.87357956,0.003330624,0.0047671245,0.000109616354,0.0016526325,0.0037574368,0.059031162,8.237958e-7,0.0005964836,0.03143256],"study_design_scores_gemma":[0.010210716,0.0005682996,0.90941894,0.0019302687,0.00040612303,3.1954602e-7,0.00016437125,0.0141611565,0.062092945,3.0789343e-7,0.00092805136,0.00011847988],"about_ca_topic_score_codex":0.73187125,"about_ca_topic_score_gemma":0.7358041,"teacher_disagreement_score":0.035839427,"about_ca_system_score_codex":0.0009899567,"about_ca_system_score_gemma":0.0012841192,"threshold_uncertainty_score":0.99769783},"labels":[],"label_agreement":null},{"id":"W6920684683","doi":"10.6068/dp14ba87e4dd299","title":"Trend 2000 - 2005. Statistics Canada. CANSIM: Health - Health Care Services | Country: Canada | Table: Patient satisfaction with most recent hospital care received in the past 12 months, by age group and sex, household population aged 15 and over, Canadian Community Health Survey (CCHS 1.1, 2.1 and 3.1) | Variable: 55 to 64 years, Very or somewhat satisfied with hospital care received, Males | Units: , 2000-2005. Data-Planet™ Statistical Ready Reference by Conquest Systems, Inc. Dataset-ID: 075-001-112.","year":2015,"lang":"en","type":"other","venue":"Data Planet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Health care; Health statistics; Census; Population; Socioeconomic status; Population statistics; Medical prescription; Official statistics","score_opus":0.017688826228001022,"score_gpt":0.24110485277541546,"score_spread":0.22341602654741444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920684683","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001102715,0.027035005,5.0674913e-7,0.000027947408,0.0002816345,0.0025257133,0.96895,0.000035007655,0.00004147612],"genre_scores_gemma":[0.0030224232,0.016278291,0.0001122091,0.0021251715,0.0000671422,0.000035558318,0.97808534,0.00018330505,0.00009058007],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949691,0.0013802629,0.00078852434,0.0009464054,0.0009302707,0.0009853819],"domain_scores_gemma":[0.99629897,0.00030671945,0.00072644686,0.0015332587,0.00004930442,0.0010853215],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006753901,0.0007296485,0.0011534552,0.00016580675,0.000497514,0.00027343153,0.00045514887,0.000295606,0.00013738262],"category_scores_gemma":[0.000015346337,0.00057943456,3.1398517e-7,0.0003605022,0.0001745154,0.00023821913,0.00014013087,0.0009577008,1.9282899e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011347183,0.000056098568,0.012463598,0.0015859624,0.00021547722,0.00017729442,0.0007490884,0.000009842314,1.2050712e-7,0.0000013981881,0.9801058,0.003500563],"study_design_scores_gemma":[0.0026473799,0.0015472833,0.022412311,0.0004489856,0.000112551614,0.0000794624,0.021493783,0.000015838557,3.3477747e-9,1.439848e-8,0.950601,0.0006413749],"about_ca_topic_score_codex":0.9999959,"about_ca_topic_score_gemma":0.99999946,"teacher_disagreement_score":0.029504828,"about_ca_system_score_codex":0.0030051444,"about_ca_system_score_gemma":0.022684643,"threshold_uncertainty_score":0.99966574},"labels":[],"label_agreement":null},{"id":"W6920772499","doi":"10.6084/m9.figshare.26630110","title":"Additional file 3 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Immunotherapy; Immune checkpoint; Immune system; Adverse effect; Pembrolizumab","score_opus":0.013245027715023356,"score_gpt":0.22844305981447646,"score_spread":0.2151980320994531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920772499","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10597366,0.00023739798,1.2165157e-8,0.000021464288,0.000028789638,0.00033190844,0.8917417,0.000046558507,0.0016185377],"genre_scores_gemma":[0.3745214,0.0000029809014,0.000015169953,0.000019405237,0.000034045817,0.00024258594,0.6243009,0.000019608944,0.0008438937],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9988861,0.000021633701,0.00043900847,0.00019539609,0.00030326957,0.0001545605],"domain_scores_gemma":[0.99925244,0.00024946188,0.00014114068,0.0001891073,0.0001269383,0.00004091369],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000028477058,0.00014806462,0.00029551858,0.00016853705,0.000016347,0.0000075795906,0.000074413176,0.000103565646,0.9602046],"category_scores_gemma":[0.00040585824,0.00011240396,0.00014652307,0.00048700816,0.000033075725,0.000088858345,0.000031728647,0.0001463886,0.00014742848],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010747357,0.0003076373,0.0006225303,0.00061277393,0.0002215184,0.000024931622,0.00019830243,0.0000013394314,0.0023398465,2.2739957e-7,0.99165916,0.0029369886],"study_design_scores_gemma":[0.0018189618,0.0013877895,0.7035375,0.029156234,0.000027275997,0.000011477828,0.000052992666,0.00005277084,0.03618212,0.0000018659601,0.22760645,0.00016455188],"about_ca_topic_score_codex":0.00008142288,"about_ca_topic_score_gemma":0.000007059815,"teacher_disagreement_score":0.96005714,"about_ca_system_score_codex":0.000113809205,"about_ca_system_score_gemma":0.00026699645,"threshold_uncertainty_score":0.45837006},"labels":[],"label_agreement":null},{"id":"W6920788676","doi":"10.6084/m9.figshare.26630107.v1","title":"Additional file 2 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Immunotherapy; Pembrolizumab; Immune system; Immune checkpoint; Ipilimumab","score_opus":0.013012443286969854,"score_gpt":0.2282902159117537,"score_spread":0.21527777262478384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920788676","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10475655,0.00024035087,1.184173e-8,0.000021484573,0.000028716822,0.0003317624,0.89292574,0.000046673285,0.001648698],"genre_scores_gemma":[0.36969945,0.0000030251476,0.000015049225,0.000019473657,0.00003424741,0.00024313694,0.62913394,0.000019634077,0.00083204306],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99888635,0.000021647851,0.00043900812,0.0001953336,0.00030312693,0.00015451407],"domain_scores_gemma":[0.9992551,0.00024810788,0.0001413207,0.00018902669,0.00012549225,0.0000409109],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00002832985,0.0001480377,0.00029556183,0.0001684817,0.000016349702,0.000007580353,0.00007441918,0.00010357545,0.96044534],"category_scores_gemma":[0.00040091298,0.000112395865,0.00014650355,0.00048680542,0.0000330728,0.00008884999,0.000031747953,0.00014638496,0.00014416098],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010547065,0.00030555838,0.0005971469,0.000603499,0.00022017864,0.000025143314,0.00019709182,0.0000013363286,0.0022349118,2.3144136e-7,0.9918047,0.002955472],"study_design_scores_gemma":[0.0018099598,0.0013932828,0.70058197,0.028920298,0.000027494681,0.000011644135,0.000052817035,0.000052441093,0.035257984,0.0000018799512,0.2317257,0.00016455782],"about_ca_topic_score_codex":0.00008130849,"about_ca_topic_score_gemma":0.000007053022,"teacher_disagreement_score":0.9603012,"about_ca_system_score_codex":0.00011337407,"about_ca_system_score_gemma":0.00026561637,"threshold_uncertainty_score":0.458337},"labels":[],"label_agreement":null},{"id":"W6920806833","doi":"10.6084/m9.figshare.28733333","title":"Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Cannabinoid; Adverse effect; Durvalumab; Cancer; Cannabis; Immune system; Chemotherapy","score_opus":0.02223533990352406,"score_gpt":0.29641626165412427,"score_spread":0.2741809217506002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920806833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81621796,0.0039274707,6.562018e-7,0.00046332294,0.000111537,0.0007048516,0.17825268,0.000030119405,0.0002913973],"genre_scores_gemma":[0.94359255,0.000010666973,0.000020857638,0.00029548138,0.00001981195,0.00006232093,0.05565405,0.000010882985,0.000333389],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99864966,0.00010719939,0.00046490275,0.00027084307,0.00035400773,0.00015338021],"domain_scores_gemma":[0.99848205,0.0002747568,0.00023482347,0.0008323612,0.00013372896,0.000042275064],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019763305,0.00014070702,0.00048092104,0.0005253463,0.000029432826,0.000008426841,0.00030039944,0.000106348925,0.008258405],"category_scores_gemma":[0.0014835168,0.00011774472,0.00022875628,0.0014135912,0.000020860074,0.000042024694,0.00023339814,0.00012966203,0.000012093009],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032418743,0.0014174655,0.00060028164,0.0034743985,0.017714161,0.00006926218,0.0014782702,0.000022260903,0.5423865,0.000004601495,0.33663037,0.0637837],"study_design_scores_gemma":[0.0025869557,0.0008805017,0.43066671,0.0048843515,0.0019407549,0.0000010903107,0.00009520962,0.000091206195,0.53729,0.0000011226448,0.021438895,0.00012322218],"about_ca_topic_score_codex":0.00008416528,"about_ca_topic_score_gemma":0.000016496053,"teacher_disagreement_score":0.43006644,"about_ca_system_score_codex":0.00007908024,"about_ca_system_score_gemma":0.00029613415,"threshold_uncertainty_score":0.9926482},"labels":[],"label_agreement":null},{"id":"W6920827909","doi":"10.6084/m9.figshare.12331688","title":"Additional file 1 of MHC-I genotype and tumor mutational burden predict response to immunotherapy","year":2020,"lang":"en","type":"article","venue":"Open MIND","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Institute for Advanced Research","funders":"","keywords":"Immunotherapy; Cohort; Univariate; Multivariate analysis; Blockade; Table (database); Pembrolizumab; Nivolumab","score_opus":0.025680803766721112,"score_gpt":0.29076515506471867,"score_spread":0.26508435129799757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920827909","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4657098,0.0002782524,0.000023504912,0.010877306,0.000057513626,0.0013246641,0.5135379,0.0000061239693,0.008184933],"genre_scores_gemma":[0.5865847,0.00007781211,0.1770033,0.026316633,0.0022022934,0.001696597,0.14871277,0.00024579334,0.05716013],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992883,0.000039845952,0.00019626119,0.00019551576,0.00018258674,0.000097441225],"domain_scores_gemma":[0.9992273,0.00042119512,0.00006893254,0.00011024778,0.00006901969,0.00010332356],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011297848,0.00008403318,0.00017165218,0.000042164862,0.000041435404,0.000025926824,0.000116935524,0.00003096893,0.87155724],"category_scores_gemma":[0.00029073164,0.00007518939,0.000042526044,0.00016132549,0.000066958164,0.00006433924,0.000049698065,0.00005952875,0.00019919922],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030159673,0.00003862301,0.000020350333,0.000009079063,0.00013015638,0.000031811673,0.0012064336,0.0000025910492,0.04594932,6.076893e-7,0.8555307,0.06692067],"study_design_scores_gemma":[0.0016791453,0.0009068019,0.022669388,0.00012580318,0.000012434765,0.0000491865,0.00024093561,0.00006783048,0.0025097418,0.0000050238427,0.9716479,0.000085798536],"about_ca_topic_score_codex":0.000023062616,"about_ca_topic_score_gemma":0.0000036487825,"teacher_disagreement_score":0.87135804,"about_ca_system_score_codex":0.00002615326,"about_ca_system_score_gemma":0.00033900182,"threshold_uncertainty_score":0.30661345},"labels":[],"label_agreement":null},{"id":"W6920869499","doi":"10.6084/m9.figshare.26630140.v1","title":"Additional file 12 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Immune system; Adverse effect; Immunotherapy; Immune checkpoint; Pembrolizumab","score_opus":0.014373405944739253,"score_gpt":0.22932093499629738,"score_spread":0.21494752905155812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920869499","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13923772,0.0002919578,2.34785e-8,0.00002543815,0.00003697831,0.0003741387,0.8581412,0.00005059769,0.0018419448],"genre_scores_gemma":[0.49779657,0.0000040095806,0.000012678413,0.000020810805,0.00003721153,0.00019928665,0.5011034,0.000020588905,0.0008054377],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99882895,0.000023514784,0.00046040217,0.00020375263,0.00031936966,0.00016399457],"domain_scores_gemma":[0.99929905,0.0001989317,0.00014553721,0.00019826839,0.000114631286,0.00004357404],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00003416825,0.0001560078,0.000309279,0.00017292202,0.000017621487,0.0000080415075,0.000078298435,0.000109238244,0.8967953],"category_scores_gemma":[0.00032109537,0.000118738804,0.00015226976,0.00040937713,0.000034595738,0.00009604703,0.00003357212,0.00015315502,0.0001135371],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017051754,0.00045820256,0.0016049227,0.0008916213,0.00033044108,0.00003491435,0.00033907886,0.000002862123,0.0039579957,4.1987755e-7,0.9870614,0.0036129917],"study_design_scores_gemma":[0.0021734303,0.0015165401,0.78336877,0.026196511,0.00003285947,0.000012263726,0.000058032034,0.00006506526,0.040187955,0.0000021594149,0.14620957,0.00017685586],"about_ca_topic_score_codex":0.000105167885,"about_ca_topic_score_gemma":0.000011686459,"teacher_disagreement_score":0.8966818,"about_ca_system_score_codex":0.000120888624,"about_ca_system_score_gemma":0.00025759125,"threshold_uncertainty_score":0.4842028},"labels":[],"label_agreement":null},{"id":"W6920910392","doi":"10.6084/m9.figshare.28733333.v1","title":"Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Cannabinoid; Adverse effect; Durvalumab; Cancer; Cannabis; Immune system; Chemotherapy","score_opus":0.02223533990352406,"score_gpt":0.29641626165412427,"score_spread":0.2741809217506002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920910392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81621796,0.0039274707,6.562018e-7,0.00046332294,0.000111537,0.0007048516,0.17825268,0.000030119405,0.0002913973],"genre_scores_gemma":[0.94359255,0.000010666973,0.000020857638,0.00029548138,0.00001981195,0.00006232093,0.05565405,0.000010882985,0.000333389],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99864966,0.00010719939,0.00046490275,0.00027084307,0.00035400773,0.00015338021],"domain_scores_gemma":[0.99848205,0.0002747568,0.00023482347,0.0008323612,0.00013372896,0.000042275064],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019763305,0.00014070702,0.00048092104,0.0005253463,0.000029432826,0.000008426841,0.00030039944,0.000106348925,0.008258405],"category_scores_gemma":[0.0014835168,0.00011774472,0.00022875628,0.0014135912,0.000020860074,0.000042024694,0.00023339814,0.00012966203,0.000012093009],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032418743,0.0014174655,0.00060028164,0.0034743985,0.017714161,0.00006926218,0.0014782702,0.000022260903,0.5423865,0.000004601495,0.33663037,0.0637837],"study_design_scores_gemma":[0.0025869557,0.0008805017,0.43066671,0.0048843515,0.0019407549,0.0000010903107,0.00009520962,0.000091206195,0.53729,0.0000011226448,0.021438895,0.00012322218],"about_ca_topic_score_codex":0.00008416528,"about_ca_topic_score_gemma":0.000016496053,"teacher_disagreement_score":0.43006644,"about_ca_system_score_codex":0.00007908024,"about_ca_system_score_gemma":0.00029613415,"threshold_uncertainty_score":0.9926482},"labels":[],"label_agreement":null},{"id":"W6920982771","doi":"10.6084/m9.figshare.26630116","title":"Additional file 4 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Autoantibody; Immunotherapy; Ipilimumab; Immune system; Immune checkpoint; Pembrolizumab","score_opus":0.013352675244357218,"score_gpt":0.22882044623816986,"score_spread":0.21546777099381265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920982771","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10560219,0.00023849455,1.2255298e-8,0.000021440419,0.000028543796,0.00033247055,0.89211476,0.00004666122,0.0016154348],"genre_scores_gemma":[0.3778342,0.000002965398,0.00001510807,0.00001932625,0.00003351445,0.0002413434,0.6210248,0.000019501924,0.0008092469],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9988859,0.00002163075,0.0004391727,0.0001954166,0.00030324978,0.00015457887],"domain_scores_gemma":[0.9992543,0.00024996191,0.00014116452,0.00018921024,0.00012447614,0.000040915605],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000028500943,0.00014807537,0.00029559145,0.00016861895,0.000016355498,0.0000075838034,0.00007447036,0.00010357479,0.9595254],"category_scores_gemma":[0.0003999361,0.00011242626,0.00014653492,0.0004869432,0.00003308193,0.000088871915,0.00003174128,0.00014638386,0.00014428665],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010902797,0.00030889717,0.0006262082,0.0006099298,0.0002223127,0.000025111449,0.00019921958,0.0000013246339,0.0023106814,2.3690109e-7,0.9916607,0.002945072],"study_design_scores_gemma":[0.0018244112,0.0014225929,0.71051323,0.029436814,0.000027687176,0.000011685351,0.000053541375,0.000053341122,0.035677597,0.0000018992471,0.22081144,0.00016576723],"about_ca_topic_score_codex":0.00008066805,"about_ca_topic_score_gemma":0.0000070900683,"teacher_disagreement_score":0.95938116,"about_ca_system_score_codex":0.000113351896,"about_ca_system_score_gemma":0.00026595165,"threshold_uncertainty_score":0.45846102},"labels":[],"label_agreement":null},{"id":"W6921001904","doi":"10.6084/m9.figshare.26630131","title":"Additional file 9 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Immune system; Immunotherapy; Antibody; Immune checkpoint; Pembrolizumab","score_opus":0.013260552224482894,"score_gpt":0.22862720852338045,"score_spread":0.21536665629889756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921001904","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10600633,0.00023855975,1.2256979e-8,0.000021597192,0.000028547018,0.00033229383,0.8917101,0.000046663885,0.0016158655],"genre_scores_gemma":[0.37678215,0.0000029765345,0.000015145643,0.000019409028,0.000033631823,0.00024039217,0.6220655,0.000019560552,0.0008212507],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9988859,0.000021649432,0.00043915468,0.00019541399,0.00030324576,0.00015458149],"domain_scores_gemma":[0.99925363,0.0002496507,0.00014114365,0.0001891175,0.00012555468,0.0000409156],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000028510303,0.00014807905,0.00029559733,0.00016861485,0.000016356698,0.0000075817666,0.000074384414,0.000103558166,0.95935535],"category_scores_gemma":[0.00040163784,0.000112420545,0.00014654222,0.00048708447,0.00003308331,0.00008887979,0.000031728665,0.0001463565,0.00014386773],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010717534,0.00030867392,0.0006238813,0.0006097022,0.00022214692,0.000025090152,0.00019920005,0.000001343397,0.0023254156,2.3200084e-7,0.99169743,0.0029151335],"study_design_scores_gemma":[0.001817881,0.0013994859,0.7112125,0.029396923,0.000027627322,0.000011658466,0.00005343045,0.00005323256,0.035891652,0.000001894701,0.21996832,0.00016537607],"about_ca_topic_score_codex":0.00007972896,"about_ca_topic_score_gemma":0.0000071001664,"teacher_disagreement_score":0.9592115,"about_ca_system_score_codex":0.00011336831,"about_ca_system_score_gemma":0.00026622645,"threshold_uncertainty_score":0.45843768},"labels":[],"label_agreement":null},{"id":"W6921097281","doi":"10.6084/m9.figshare.26593118.v1","title":"Additional file 1 of Inter-rater and intra-rater agreement of [99mTc]-labelled NM-01, a single-domain programmed death-ligand 1 (PD-L1) antibody, using quantitative SPECT/CT in non-small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Lung cancer; Table (database); Cancer; Data file; Cell","score_opus":0.03957580237805473,"score_gpt":0.3099875358194086,"score_spread":0.27041173344135383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921097281","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23332009,0.0022202004,0.0000053282874,0.000075575954,0.00006356415,0.0008219822,0.7628187,0.000019509553,0.00065506523],"genre_scores_gemma":[0.5992848,0.00005132242,0.0030649034,0.00020952726,0.0001574851,0.0008728332,0.39540684,0.00007396699,0.00087831274],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986721,0.000046543515,0.00045431842,0.0003472708,0.0001989279,0.0002807891],"domain_scores_gemma":[0.9991601,0.00034345023,0.00016332921,0.00015859884,0.000107532,0.00006700327],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007390495,0.000230155,0.000396545,0.00022767835,0.00003221703,0.00004187723,0.000083830484,0.00004900211,0.69473296],"category_scores_gemma":[0.00009665959,0.00018939468,0.00012168425,0.0003539813,0.000047319954,0.00010025448,0.000070580354,0.00017316885,0.000026641888],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014892822,0.0004985686,0.00068476406,0.0047813193,0.0005587482,0.00051182363,0.0021301056,0.000005001433,0.12411992,0.0000022877914,0.8615023,0.0037158995],"study_design_scores_gemma":[0.012882191,0.0036361474,0.024719622,0.18997474,0.00043835855,0.0003763837,0.002974773,0.01405582,0.38052312,0.00007148138,0.36871055,0.0016368022],"about_ca_topic_score_codex":0.00020755177,"about_ca_topic_score_gemma":0.0003414992,"teacher_disagreement_score":0.6947063,"about_ca_system_score_codex":0.00018448397,"about_ca_system_score_gemma":0.0002729736,"threshold_uncertainty_score":0.7723291},"labels":[],"label_agreement":null},{"id":"W6921120202","doi":"10.6084/m9.figshare.26630119.v1","title":"Additional file 5 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Autoimmune disease; Disease; Immunotherapy; Immune system; Pembrolizumab; Immune checkpoint","score_opus":0.013250662893149983,"score_gpt":0.22859026048532674,"score_spread":0.21533959759217675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921120202","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.106054105,0.00023814848,1.2213333e-8,0.000021556702,0.00002854028,0.00033233463,0.8916664,0.00004665627,0.0016122186],"genre_scores_gemma":[0.3767115,0.000002972695,0.000015145385,0.000019387726,0.00003360319,0.00024193685,0.6221383,0.000019554049,0.0008176144],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9988859,0.000021649787,0.00043915794,0.00019544267,0.0003032685,0.00015457484],"domain_scores_gemma":[0.9992536,0.00024963066,0.00014115761,0.00018917443,0.00012553169,0.00004091991],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000028515935,0.00014809068,0.00029564445,0.00016861186,0.000016356285,0.000007580305,0.00007444109,0.00010358004,0.95951444],"category_scores_gemma":[0.00040161624,0.00011242845,0.00014655558,0.00048710726,0.0000330821,0.00008887177,0.000031742962,0.00014640184,0.00014327341],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010703932,0.00030828558,0.0006226677,0.0006088527,0.00022185639,0.000025058494,0.00019869827,0.0000013390455,0.0023239444,2.365451e-7,0.9916749,0.00294378],"study_design_scores_gemma":[0.0018141365,0.0013957844,0.71343905,0.029311147,0.000027558777,0.000011627979,0.000053301053,0.000052682186,0.035779435,0.0000018792448,0.21794844,0.0001649596],"about_ca_topic_score_codex":0.00008143363,"about_ca_topic_score_gemma":0.0000071166837,"teacher_disagreement_score":0.95937115,"about_ca_system_score_codex":0.00011337779,"about_ca_system_score_gemma":0.0002662639,"threshold_uncertainty_score":0.45846993},"labels":[],"label_agreement":null},{"id":"W6921246929","doi":"10.6084/m9.figshare.29578728","title":"Additional file 1 of Immune checkpoint inhibitors and the pediatric rheumatologist: a pediatric needs assessment","year":2025,"lang":"en","type":"article","venue":"Open MIND","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Alberta; University of British Columbia","funders":"","keywords":"Needs assessment; MEDLINE; Immune system; Pediatric oncology; PD-L1","score_opus":0.013624006766865048,"score_gpt":0.29012188368283354,"score_spread":0.2764978769159685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921246929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6698578,0.007781248,0.000030515617,0.007650499,0.0007592145,0.0039822133,0.12828843,0.000013233717,0.18163683],"genre_scores_gemma":[0.912276,0.003279621,0.013510272,0.0006167982,0.00057970727,0.0016164727,0.021944094,0.000046513003,0.046130497],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99907327,0.000050917177,0.0004356905,0.00015584174,0.00015768164,0.00012658736],"domain_scores_gemma":[0.99866873,0.0008134125,0.00020738016,0.00021654653,0.00006285268,0.000031089483],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034261408,0.00010800936,0.0002988031,0.0001647127,0.00008908818,0.000041750256,0.00016364008,0.000068203815,0.44030702],"category_scores_gemma":[0.00021677189,0.00006964511,0.000121702695,0.0005770345,0.00017100695,0.000059145295,0.00016294022,0.00013996797,0.000026585662],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001352465,0.00018164304,0.004636664,0.00008862027,0.00015432961,0.0000051391926,0.0002606114,3.1198658e-7,0.00009673872,0.000038654114,0.9641253,0.029059524],"study_design_scores_gemma":[0.0116568245,0.0003163371,0.16781212,0.00036508526,0.00043185963,0.00008201576,0.0015351736,0.00009770669,0.0006703082,0.000115342984,0.8166671,0.00025014885],"about_ca_topic_score_codex":0.000106769476,"about_ca_topic_score_gemma":0.000007684317,"teacher_disagreement_score":0.44028044,"about_ca_system_score_codex":0.0000437632,"about_ca_system_score_gemma":0.0005254106,"threshold_uncertainty_score":0.5602046},"labels":[],"label_agreement":null},{"id":"W6925218224","doi":"10.17605/osf.io/gxe9d","title":"COVID-19 Vaccine Hesitancy among Marginalized Populations in the U.S. and Canada: Protocol for a Scoping Review","year":2022,"lang":"en","type":"other","venue":"Open Science Framework","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Conceptualization; Context (archaeology); Thematic analysis; Systematic review; Protocol (science); Population; Grey literature","score_opus":0.09914269969944273,"score_gpt":0.445404417278345,"score_spread":0.3462617175789023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6925218224","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027282627,0.010771136,0.00035853183,0.036482826,0.00034100408,0.8845064,0.00008893203,0.000045330064,0.067378566],"genre_scores_gemma":[0.000052101583,0.0012840945,0.009936547,0.055837646,0.00019109833,0.88330024,0.000053651405,0.00017034948,0.04917426],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982141,0.00009947324,0.00034281833,0.00050445617,0.0005377644,0.0003013424],"domain_scores_gemma":[0.99864805,0.00016494184,0.00029080827,0.000703714,0.000030132347,0.000162355],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020555486,0.00018791511,0.0004850374,0.00015227866,0.00039853813,0.00013120136,0.0010383347,0.00008458078,0.0102993185],"category_scores_gemma":[0.0013005056,0.00012569192,0.000049403152,0.0010964958,0.00016170996,0.000088613226,0.00020547613,0.0002952241,6.3943133e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004965237,0.00007053175,0.017204575,0.009988176,0.00002572497,0.00003790278,0.00017760452,5.727804e-7,0.0000036482738,0.000798751,0.96723145,0.003964514],"study_design_scores_gemma":[0.0018707869,0.000110204186,0.005709867,0.050261382,0.000044567005,0.000027503482,0.00012752277,0.0000052971877,7.833001e-7,0.00025945532,0.9413667,0.00021596023],"about_ca_topic_score_codex":0.37340865,"about_ca_topic_score_gemma":0.68791157,"teacher_disagreement_score":0.31450292,"about_ca_system_score_codex":0.00061387237,"about_ca_system_score_gemma":0.0072308774,"threshold_uncertainty_score":0.99839723},"labels":[],"label_agreement":null},{"id":"W6926775008","doi":"10.25549/wpacards-c8-148917","title":"WPA household census for 1133 S RECORD AVE, Los Angeles County","year":2014,"lang":"en","type":"dataset","venue":"University of Southern California Digital Library","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Census; Population; Statistical analysis; Quarter (Canadian coin); Data collection","score_opus":0.013445191104384625,"score_gpt":0.1877717953905526,"score_spread":0.17432660428616797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6926775008","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013253152,0.00024459168,0.000041395655,0.00015954867,0.00009850405,0.00046005799,0.9967829,0.00011133841,0.00077635195],"genre_scores_gemma":[0.00010210063,0.00021866143,0.00017597062,0.00043410025,0.00025986735,7.858708e-7,0.9977099,0.00006073337,0.0010378999],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987073,0.00002369582,0.00028998917,0.00039953672,0.00027981264,0.0002996664],"domain_scores_gemma":[0.9988139,0.00011802527,0.0003380522,0.00050120417,0.000049752165,0.00017902198],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00006968841,0.00034022913,0.000603854,0.00019726693,0.00010794564,0.00006113514,0.00037266244,0.00039266897,0.00032987364],"category_scores_gemma":[0.00002159669,0.00032639335,0.00048614058,0.00015309217,0.00030916888,0.00014304924,0.00013796543,0.0002446753,0.00008399772],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004273344,0.00017047607,0.00070888415,0.0006971485,0.00023398531,0.000046333138,0.0000033063568,3.3615038e-7,0.000009504906,9.953993e-7,0.99074614,0.0031095406],"study_design_scores_gemma":[0.0020057522,0.0001584534,0.00002306902,0.000447335,0.00025404073,0.00001655184,0.00028191268,0.000007131964,0.00002776927,0.00006127962,0.9963784,0.0003382789],"about_ca_topic_score_codex":0.00012658983,"about_ca_topic_score_gemma":0.0000139233425,"teacher_disagreement_score":0.00563228,"about_ca_system_score_codex":0.00007004962,"about_ca_system_score_gemma":0.00021733953,"threshold_uncertainty_score":0.9999188},"labels":[],"label_agreement":null},{"id":"W6929263955","doi":"10.48448/v9cf-ft96","title":"U-CREAT: Unsupervised Case Retrieval using Events extrAcTion","year":2022,"lang":"en","type":"other","venue":"Underline Science Inc.","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Relevance (law); Ranking (information retrieval); Task (project management); Benchmark (surveying); Baseline (sea); Domain (mathematical analysis); Pipeline (software); Document retrieval","score_opus":0.042884237845912714,"score_gpt":0.3545571221210988,"score_spread":0.3116728842751861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929263955","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29758802,0.011840805,0.0021744922,0.0024136268,0.012960966,0.0060893847,0.00063913764,0.0017962733,0.6644973],"genre_scores_gemma":[0.1723074,0.0012689137,0.015507269,0.0025179717,0.0025236607,0.000018815399,0.00043017324,0.0010696044,0.8043562],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977424,0.000049020462,0.00030229124,0.000606519,0.00090045226,0.00039927277],"domain_scores_gemma":[0.99893135,0.000029959496,0.00022434443,0.0005728529,0.00007303943,0.00016844457],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00069457095,0.00026375035,0.00032903976,0.0007865178,0.00037958001,0.00004013072,0.00024223274,0.00017002774,0.0193126],"category_scores_gemma":[0.00007116378,0.00023725776,0.0001212105,0.0013110329,0.0004378517,0.00012089641,0.00010842255,0.00038821183,0.00003194884],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008216276,0.0029953406,0.005881468,0.0012540111,0.0016133812,0.02194601,0.0014849239,0.00011795942,0.61131376,0.00033957837,0.20612474,0.13871254],"study_design_scores_gemma":[0.0056546824,0.00086422823,0.0004578506,0.0005265679,0.00053548574,0.021862198,0.0016146147,0.005961429,0.0025520609,0.000054651136,0.9589261,0.0009901768],"about_ca_topic_score_codex":0.0017772212,"about_ca_topic_score_gemma":0.00012794859,"teacher_disagreement_score":0.7528013,"about_ca_system_score_codex":0.0009085022,"about_ca_system_score_gemma":0.001150197,"threshold_uncertainty_score":0.9815839},"labels":[],"label_agreement":null},{"id":"W6930731103","doi":"10.5281/zenodo.14976069","title":"Phytomyza plantaginis Robineau-Desvoidy 1851","year":2025,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Range (aeronautics); Selective sweep; Decapoda; Sweep frequency response analysis; Taxonomy (biology)","score_opus":0.022611002344184585,"score_gpt":0.2631615211996419,"score_spread":0.24055051885545733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930731103","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004604421,0.001172598,0.0007662535,0.0009796795,0.00030881376,0.00076252664,0.0008251751,0.0016273302,0.99351156],"genre_scores_gemma":[0.003166991,0.0017675651,0.00036835004,0.0010859254,0.00074571156,1.1324601e-7,0.0070288093,0.009059945,0.9767766],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99829346,0.00014777365,0.00027120218,0.0005271695,0.00038184607,0.00037852448],"domain_scores_gemma":[0.9987857,0.000014656014,0.00015080997,0.0006871311,0.00020608952,0.00015561964],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00029823484,0.00027180722,0.00035578018,0.0005712091,0.00078056124,0.0004079993,0.0006191776,0.00022273716,0.109686986],"category_scores_gemma":[0.00013329768,0.0002680235,0.00014009264,0.00053664204,0.00025208044,0.00004764033,0.00047373003,0.00042034953,0.008313415],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040389565,0.00012100304,0.000001742385,0.00030653065,0.0003120428,0.000041460193,0.00014801697,4.5398946e-7,0.00092378794,0.0003521957,0.9246771,0.07271177],"study_design_scores_gemma":[0.001608,0.0002565626,0.00011655094,0.00050373236,0.000085807354,0.00015195236,0.00007991146,0.000012641064,0.00025640134,0.000016682361,0.99666446,0.00024731224],"about_ca_topic_score_codex":0.0001441851,"about_ca_topic_score_gemma":0.0000016647444,"teacher_disagreement_score":0.10137357,"about_ca_system_score_codex":0.00020244443,"about_ca_system_score_gemma":0.000027747043,"threshold_uncertainty_score":0.9999772},"labels":[],"label_agreement":null},{"id":"W6931120122","doi":"10.5281/zenodo.4250011","title":"Regarder Monster Hunter (2020) Film Complet en HD Streaming VF Entier Français cka","year":2020,"lang":"fr","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Monster; Hum; Dislocation","score_opus":0.028716752303418462,"score_gpt":0.2515173883628411,"score_spread":0.22280063605942263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931120122","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13609648,0.033058885,0.016084975,0.14585873,0.0042673107,0.004832204,0.0038139191,0.0032059378,0.65278155],"genre_scores_gemma":[0.9480781,0.0026645923,0.0005572716,0.0070960093,0.0030709894,1.6151157e-7,0.0031252608,0.0036252367,0.031782392],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967296,0.0006206421,0.0005526163,0.00071513985,0.00062734715,0.0007546515],"domain_scores_gemma":[0.99827707,0.000058796115,0.00015894072,0.000575266,0.00045539983,0.00047449992],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006357298,0.00032962396,0.0003995366,0.00015682339,0.0012813293,0.00067341264,0.0008341481,0.00019643946,0.16976666],"category_scores_gemma":[0.0004912643,0.0003492459,0.00020455683,0.0007562678,0.00042331737,0.0003225788,0.0009916928,0.00066832924,0.021989834],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010259956,0.00021755687,0.000068985806,0.00042388416,0.00043784827,0.00014891365,0.010048529,0.000024417714,0.012358626,0.0002403217,0.7469468,0.22805808],"study_design_scores_gemma":[0.0027351193,0.0007484215,0.004314801,0.00033040732,0.00012575343,0.00022102418,0.0020520857,0.0015044184,0.0008151003,0.000011702055,0.98679084,0.00035034816],"about_ca_topic_score_codex":0.00013968002,"about_ca_topic_score_gemma":0.0000012588298,"teacher_disagreement_score":0.8119816,"about_ca_system_score_codex":0.0002886741,"about_ca_system_score_gemma":0.000015246155,"threshold_uncertainty_score":0.99989593},"labels":[],"label_agreement":null},{"id":"W6931160817","doi":"10.5281/zenodo.4359195","title":"FIGURE 6 in Liogenys Guérin-Méneville, 1831 (Coleoptera: Scarabaeidae: Melolonthinae) from the southern South American Transition Zone and boundaries: taxonomic overview with four new species","year":2020,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Museum of Nature","funders":"","keywords":"Holotype; Paratype; Transition (genetics); Hybrid zone; Taxonomy (biology)","score_opus":0.033952179466952184,"score_gpt":0.22625452476453706,"score_spread":0.1923023452975849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931160817","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.043260183,0.029818637,0.0054853265,0.045249626,0.0005123865,0.008671572,0.008917515,0.0029200304,0.8551647],"genre_scores_gemma":[0.39045066,0.024246465,0.0034113273,0.013097571,0.005650391,0.0000029486052,0.01686273,0.026801657,0.51947623],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814487,0.00026056953,0.0003023502,0.00059032365,0.000378752,0.00032314402],"domain_scores_gemma":[0.99896425,0.000025117937,0.0002547565,0.0004933377,0.00008044956,0.00018211782],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00022937654,0.00033282756,0.00049711956,0.00020395538,0.0006140888,0.00068218337,0.00045356827,0.00012263194,0.023392357],"category_scores_gemma":[0.00006966555,0.00025466926,0.00009810249,0.0006191174,0.0006695035,0.000071097355,0.00021316325,0.00046483544,0.0011531819],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002649344,0.00008688872,0.00010229793,0.00026201826,0.00066769926,0.00010218892,0.012659391,0.0000037424247,0.0004101991,0.0000795566,0.88997525,0.09300144],"study_design_scores_gemma":[0.0022459864,0.000532364,0.0037799275,0.00066313625,0.00012109224,0.00004904227,0.0028767027,0.000025051513,0.000019446587,0.0000061058954,0.9893969,0.00028422588],"about_ca_topic_score_codex":0.0044342782,"about_ca_topic_score_gemma":0.0002807869,"teacher_disagreement_score":0.34719047,"about_ca_system_score_codex":0.000175425,"about_ca_system_score_gemma":0.000048080587,"threshold_uncertainty_score":0.9999906},"labels":[],"label_agreement":null},{"id":"W6931563702","doi":"10.5281/zenodo.6829940","title":"Rapport concernant le sondage sur les stratégies institutionnelles","year":2022,"lang":"fr","type":"report","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; University of Guelph","funders":"","keywords":"Mars Exploration Program; Documentation; West germany; Qualitative analysis","score_opus":0.09960187767505292,"score_gpt":0.2783744935327296,"score_spread":0.17877261585767668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931563702","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023429368,0.07030832,0.0032320556,0.008389033,0.0058397297,0.0039023778,0.005877886,0.002567068,0.8764542],"genre_scores_gemma":[0.66538554,0.089159556,0.00022081453,0.0004841016,0.0039312057,0.0000011026801,0.038016565,0.00874723,0.19405387],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950432,0.00067496736,0.000984864,0.0009943226,0.0013996008,0.00090303045],"domain_scores_gemma":[0.9966976,0.00006524125,0.0006066747,0.0009524042,0.0013189932,0.00035910716],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002308064,0.0005281622,0.0006904991,0.00048192748,0.006328099,0.00059482816,0.0013528313,0.0003233233,0.14573696],"category_scores_gemma":[0.0009898464,0.00056360004,0.00038070025,0.00089728576,0.0012255488,0.00034175886,0.0016201027,0.0012617162,0.0023323328],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008639038,0.0005984469,0.000026216823,0.0011009168,0.00085307896,0.0005224492,0.0017893197,0.000117120224,0.00796005,0.0034993615,0.5465891,0.43608004],"study_design_scores_gemma":[0.002253909,0.0008494495,0.0014212527,0.00054262386,0.0001847698,0.0017263814,0.005388101,0.000116099145,0.0004546138,0.000028323586,0.98646694,0.00056750857],"about_ca_topic_score_codex":0.0018107119,"about_ca_topic_score_gemma":0.00001087879,"teacher_disagreement_score":0.6824003,"about_ca_system_score_codex":0.0014358126,"about_ca_system_score_gemma":0.00048055543,"threshold_uncertainty_score":0.99968153},"labels":[],"label_agreement":null},{"id":"W6931826491","doi":"10.5683/sp3/yuss1p","title":"Enquête sur la population active, juin 2014 [Canada] [Remanié 2025]","year":2023,"lang":"fr","type":"dataset","venue":"Borealis","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Statistics Canada","funders":"","keywords":"Population; Publics; Research methodology; Ethnic community","score_opus":0.016173689982173417,"score_gpt":0.2755544814156549,"score_spread":0.2593807914334815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931826491","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034965886,0.003698666,0.00000459783,0.002367076,0.0029960945,0.0007826967,0.98812884,0.00008340983,0.0015889524],"genre_scores_gemma":[0.00012589955,0.0112313405,0.000021182925,0.0010808279,0.001913542,0.00008927811,0.97277445,0.00011248294,0.012650977],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99659604,0.00030955116,0.0007532696,0.0007141683,0.00089059427,0.00073635],"domain_scores_gemma":[0.9974654,0.0005907003,0.0004437222,0.0010753007,0.00014964907,0.00027526458],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00055745005,0.0006026446,0.0008384714,0.00024615595,0.0001812084,0.000075308715,0.000408144,0.00067851937,0.0010423193],"category_scores_gemma":[0.00028346674,0.0005937242,0.00029121788,0.0004140177,0.0001514015,0.00014521883,0.00010908719,0.0006583405,0.00038088087],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013451512,0.00010968894,0.00044731377,0.0005968765,0.00075642817,0.0004855411,0.000037395224,0.000006695245,0.0001087226,0.00003767237,0.9661065,0.029962063],"study_design_scores_gemma":[0.0017335933,0.0001512555,0.12016812,0.0010630508,0.0004788893,0.00004753874,0.000087273795,0.000040328865,0.00009318142,0.000020422527,0.87560785,0.00050848874],"about_ca_topic_score_codex":0.99569875,"about_ca_topic_score_gemma":0.9952539,"teacher_disagreement_score":0.1197208,"about_ca_system_score_codex":0.0013331443,"about_ca_system_score_gemma":0.0013821825,"threshold_uncertainty_score":0.99987084},"labels":[],"label_agreement":null},{"id":"W6932025061","doi":"10.5683/sp3/ovy379","title":"Peterbell Ontario. 1:50,000. Map Sheet 042B11, ed. 2, 1979","year":2021,"lang":"en","type":"dataset","venue":"Borealis","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Georeference; General partnership; Raster graphics; Natural (archaeology); Digital mapping; Geographic information system; Aerial photography; Orthophoto","score_opus":0.01586588410387985,"score_gpt":0.265964080674865,"score_spread":0.25009819657098514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6932025061","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000053617376,0.0053034527,0.000002423053,0.0009025431,0.0010485764,0.0004577193,0.9893282,0.00006139761,0.0028420878],"genre_scores_gemma":[0.000003419397,0.0034927747,0.00015689088,0.0040703155,0.0010694118,0.00007243749,0.98437744,0.00005596717,0.006701356],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99752265,0.00007362694,0.0005734432,0.0006923697,0.00060340227,0.0005345219],"domain_scores_gemma":[0.9977017,0.00006214091,0.00023535361,0.0016299298,0.00012607223,0.00024478463],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024758923,0.00053412386,0.0008699662,0.00018860011,0.000105340514,0.00009534835,0.0003688707,0.00058545766,0.009546197],"category_scores_gemma":[0.00003780976,0.00046991455,0.0004953175,0.00015003687,0.0001385339,0.00006171352,0.00013508227,0.000711973,0.00009189866],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000923233,0.00021400247,0.000081931714,0.00042648133,0.00060934573,0.0007189725,0.000073498646,1.4994002e-7,0.00009723594,0.0000013643347,0.9952289,0.0016249135],"study_design_scores_gemma":[0.0019452453,0.00029110574,0.0024918474,0.0007360502,0.0005553941,0.000214841,0.00004208284,3.6512498e-7,0.00012747053,0.0000072961875,0.99307936,0.0005089627],"about_ca_topic_score_codex":0.72340006,"about_ca_topic_score_gemma":0.62564945,"teacher_disagreement_score":0.097750604,"about_ca_system_score_codex":0.0006431223,"about_ca_system_score_gemma":0.0010247725,"threshold_uncertainty_score":0.99977523},"labels":[],"label_agreement":null},{"id":"W6938899133","doi":"10.60692/2fdcp-wq260","title":"Tumor-infiltrating lymphocyte: features and prognosis of lymphocytes infiltration on colorectal cancer","year":2023,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Tumor-infiltrating lymphocytes; Colorectal cancer; CD8; Infiltration (HVAC); Tumor microenvironment; Lymphocyte; Lymphocytic infiltration; Gene; T lymphocyte","score_opus":0.024612733996309855,"score_gpt":0.2462413706469743,"score_spread":0.22162863665066443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6938899133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99729866,0.000039857205,0.000025320667,0.000089475914,0.00022870634,0.0005652179,0.000096355914,0.00020687259,0.0014495243],"genre_scores_gemma":[0.9993881,0.000006991845,0.00004810758,0.0002062827,0.000072639225,0.00016217842,0.000040158924,0.000010719485,0.000064836335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888873,0.000029920282,0.00048190865,0.00012263354,0.00029978104,0.00017700838],"domain_scores_gemma":[0.9993734,0.000017929047,0.00029249108,0.0001266073,0.00013189974,0.000057695474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002436085,0.00015189905,0.00025687987,0.00030007315,0.00010006431,0.00006243939,0.000048491856,0.00008203505,0.00001688278],"category_scores_gemma":[0.000024298639,0.000116876916,0.00007060167,0.00044259816,0.00005314364,0.0002675418,0.000017011778,0.000052317064,0.00003324329],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050665867,0.0000091692045,0.8951627,0.0029318368,0.00038990483,0.000010903612,0.070318125,0.00015530373,0.0028579407,0.00014321881,0.0010813582,0.021872977],"study_design_scores_gemma":[0.0040863603,0.00039094323,0.8676319,0.0010886646,0.00006482086,0.00016237382,0.010056683,0.0019454624,0.114193015,3.4932518e-7,0.00019195829,0.00018744558],"about_ca_topic_score_codex":0.00007802022,"about_ca_topic_score_gemma":0.000001253012,"teacher_disagreement_score":0.11133508,"about_ca_system_score_codex":0.00022113323,"about_ca_system_score_gemma":0.00014542349,"threshold_uncertainty_score":0.4766102},"labels":[],"label_agreement":null},{"id":"W6939005502","doi":"10.60692/5pmve-bq984","title":"The effect of blocking immune checkpoints LAG-3 and PD-1 on human invariant Natural Killer T cell function","year":2023,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Immune system; Blockade; Peripheral blood mononuclear cell; T cell; Flow cytometry; Cell; Antibody; Natural killer T cell; Cell growth","score_opus":0.019410652831889846,"score_gpt":0.2335713157249754,"score_spread":0.21416066289308555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939005502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967281,0.00003254051,0.000027838034,0.00008674311,0.00073068717,0.00048198385,0.0000055395726,0.00010121974,0.0018053302],"genre_scores_gemma":[0.99911535,0.0000012472068,0.0000023738028,0.0000556101,0.000052247975,0.000032821616,0.000024820636,0.000008233431,0.0007073022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903786,0.000060628532,0.0004319447,0.00008355421,0.00023508917,0.00015090592],"domain_scores_gemma":[0.99943,0.000027403086,0.00023283881,0.00023422609,0.000045672554,0.000029857696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071846956,0.00012326214,0.00020144931,0.00016367702,0.00021309186,0.000055561963,0.00005492803,0.000068907335,0.00000902728],"category_scores_gemma":[0.000012646358,0.0000693967,0.0000831727,0.00022501218,0.000040042385,0.00013019312,0.000028632288,0.0001017684,0.000101357466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05705858,0.000027512242,0.59772474,0.018437967,0.0029547203,0.000050138842,0.2382185,0.00017150254,0.033328682,0.0007395066,0.0063721323,0.044916034],"study_design_scores_gemma":[0.0121973865,0.0018167305,0.90717757,0.0013415586,0.00017949444,0.000070526214,0.007967076,0.0018496687,0.065015085,9.545487e-7,0.002104966,0.000278999],"about_ca_topic_score_codex":0.000018988456,"about_ca_topic_score_gemma":2.7240466e-7,"teacher_disagreement_score":0.30945283,"about_ca_system_score_codex":0.00006236928,"about_ca_system_score_gemma":0.000012004572,"threshold_uncertainty_score":0.28299153},"labels":[],"label_agreement":null},{"id":"W6939067383","doi":"10.60692/gwtqe-9mj61","title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Nivolumab; Ipilimumab; Chemotherapy; Cancer; Randomized controlled trial; Confidence interval","score_opus":0.02919931414851835,"score_gpt":0.2486175563615745,"score_spread":0.21941824221305617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939067383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99578947,0.000048931903,0.00036368764,0.00034745169,0.00061563577,0.00084238144,0.0001561812,0.00015944333,0.0016768087],"genre_scores_gemma":[0.99658614,0.0000018899796,0.00006657834,0.0013475696,0.000099584206,0.00043050438,0.00003294587,0.000017545402,0.0014172252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848354,0.00005776209,0.0005948111,0.00015291527,0.00042256055,0.00028840607],"domain_scores_gemma":[0.9993582,0.0000046778914,0.00021673522,0.00029581104,0.000056642966,0.000067943576],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003327102,0.00017077,0.00031702552,0.00032213877,0.00015633405,0.000047210404,0.00013200231,0.000057348898,0.0011162256],"category_scores_gemma":[0.0000032888897,0.0001350897,0.0001019886,0.00046066198,0.000028268601,0.00026261396,0.00004523124,0.00018382665,0.00006454463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04405904,0.000035873145,0.67813766,0.0014804432,0.0004414479,0.00013774182,0.25211614,0.00083426695,0.00008993741,0.0000316433,0.0047272225,0.01790861],"study_design_scores_gemma":[0.09784299,0.0020741543,0.7115866,0.0008913303,0.00013859214,0.0015205145,0.12710506,0.015137302,0.002266202,7.958078e-7,0.0403947,0.0010417358],"about_ca_topic_score_codex":0.00017167254,"about_ca_topic_score_gemma":0.000004079374,"teacher_disagreement_score":0.12501107,"about_ca_system_score_codex":0.0013634377,"about_ca_system_score_gemma":0.0002953028,"threshold_uncertainty_score":0.99979687},"labels":[],"label_agreement":null},{"id":"W6939070843","doi":"10.60692/cknes-bp696","title":"Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis","year":2020,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dysgeusia; Peripheral neuropathy; Cancer; Clinical trial; Chemotherapy-induced peripheral neuropathy; Chemotherapy","score_opus":0.04807721148996214,"score_gpt":0.2475622360720401,"score_spread":0.19948502458207795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939070843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786595,0.014768812,0.00010000855,0.0017806726,0.00009900407,0.003759653,0.00028701726,0.00012067838,0.00042462331],"genre_scores_gemma":[0.99726844,0.000055438784,0.00001152797,0.002372752,0.0000060337647,0.00022146544,0.000024716082,0.00000696784,0.00003267556],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9974663,0.0001670529,0.0017542663,0.00015095863,0.0003131802,0.00014819988],"domain_scores_gemma":[0.9987658,0.000015017729,0.00074722583,0.00023056078,0.00016772943,0.00007366178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041101544,0.00019791278,0.0018305567,0.00025694532,0.00003159528,0.000027608636,0.000086903965,0.00010150141,0.00013255673],"category_scores_gemma":[0.0000603006,0.00012235322,0.0005323004,0.0008612966,0.00004983014,0.00024412878,0.000037198588,0.00011115324,0.00001598315],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014851505,0.000036455338,0.17941535,0.6219626,0.098166585,0.000011659399,0.098559305,0.00009799344,0.000017564067,0.00004037092,0.00015948823,0.000047483925],"study_design_scores_gemma":[0.011923206,0.0021032803,0.22969115,0.01893983,0.7133279,0.000065334796,0.017630866,0.00399366,0.0009964225,8.769263e-7,0.00009544511,0.0012320695],"about_ca_topic_score_codex":0.000043699678,"about_ca_topic_score_gemma":6.531033e-7,"teacher_disagreement_score":0.61516124,"about_ca_system_score_codex":0.00005497076,"about_ca_system_score_gemma":0.000026638838,"threshold_uncertainty_score":0.49894196},"labels":[],"label_agreement":null},{"id":"W6939368869","doi":"10.60692/7msch-mkc18","title":"Considerations for treatment duration in responders to immune checkpoint inhibitors","year":2021,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Immunotherapy; Clinical trial; Duration (music); Limiting; Cancer; Cancer immunotherapy; Toxicity","score_opus":0.049225208506716626,"score_gpt":0.2633598408821824,"score_spread":0.21413463237546576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939368869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907389,0.000020252019,0.0037288156,0.0023524784,0.0004282729,0.0014323292,0.00009217468,0.0000848531,0.0011218879],"genre_scores_gemma":[0.9975445,6.1240746e-7,0.0011027077,0.0004394302,0.00006288155,0.00033981242,0.00008174768,0.000008428542,0.00041983207],"study_design_codex":"qualitative","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99876314,0.000037041125,0.0007719649,0.00012534388,0.00014238496,0.00016014914],"domain_scores_gemma":[0.99933594,0.000017799479,0.000139451,0.00023847762,0.00020429734,0.00006401959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026490717,0.00012455556,0.00023821965,0.00026548497,0.00009090611,0.00008456045,0.000019324572,0.00007770883,0.000045554436],"category_scores_gemma":[0.0000750268,0.00010389212,0.00012679644,0.00025696598,0.000012359541,0.00023465595,0.000009626673,0.000027875845,0.00007635361],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018732963,0.00013192148,0.111430235,0.0025672805,0.0011599342,0.00014126573,0.81481504,0.00080422167,0.03439787,0.001273604,0.002370864,0.012174765],"study_design_scores_gemma":[0.03356937,0.0016383865,0.25543037,0.0015879889,0.00020504881,0.0007128745,0.12858237,0.0024630274,0.5595818,0.000012894111,0.015428768,0.0007870589],"about_ca_topic_score_codex":0.00002588651,"about_ca_topic_score_gemma":0.000008684791,"teacher_disagreement_score":0.6862327,"about_ca_system_score_codex":0.00058993045,"about_ca_system_score_gemma":0.0002280084,"threshold_uncertainty_score":0.42365977},"labels":[],"label_agreement":null},{"id":"W6939586340","doi":"10.6084/m9.figshare.12667688","title":"Additional file 1 of Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre; McMaster University; Hamilton Health Sciences","funders":"","keywords":"Table (database); Checklist; Clinical trial; Outcome (game theory); Inclusion (mineral); MEDLINE","score_opus":0.24920793919315729,"score_gpt":0.4244891323188327,"score_spread":0.1752811931256754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939586340","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00209299,0.0021376298,1.4898046e-8,0.0006311731,0.00005495616,0.002751203,0.99207526,0.000023691553,0.00023309265],"genre_scores_gemma":[0.027660277,0.00008628159,0.00011075935,0.0043169376,0.000094267416,0.0034671924,0.964176,0.000025060996,0.00006322498],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.99458534,0.00074823765,0.003969159,0.00024503033,0.0002968946,0.00015532714],"domain_scores_gemma":[0.9950195,0.0028970737,0.0016434931,0.0002465727,0.0000930975,0.00010029452],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00086704147,0.00015026635,0.0019786889,0.00008877134,0.000010828384,0.0000056076406,0.000102147234,0.00016653238,0.92238367],"category_scores_gemma":[0.07825677,0.000116390125,0.00051681534,0.00040405712,0.000014927488,0.000057793688,0.00005910728,0.0002892096,0.00033792434],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055474177,0.00026327636,0.00024913813,0.068491295,0.0001560189,0.0000908066,0.00009233804,5.412803e-8,0.000064256994,5.1512163e-8,0.92888975,0.0011482843],"study_design_scores_gemma":[0.005706585,0.0009587051,0.010660668,0.84803265,0.00012936576,0.000032759446,0.00015927774,0.000040035007,0.00016361641,0.0000016532765,0.1339199,0.00019479265],"about_ca_topic_score_codex":0.000009752562,"about_ca_topic_score_gemma":0.0000124489725,"teacher_disagreement_score":0.9220457,"about_ca_system_score_codex":0.00016177865,"about_ca_system_score_gemma":0.00044283448,"threshold_uncertainty_score":0.92950743},"labels":[],"label_agreement":null},{"id":"W6939652914","doi":"10.6084/m9.figshare.26630110.v1","title":"Additional file 3 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Immunotherapy; Immune checkpoint; Immune system; Adverse effect; Pembrolizumab","score_opus":0.013245027715023356,"score_gpt":0.22844305981447646,"score_spread":0.2151980320994531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939652914","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10597366,0.00023739798,1.2165157e-8,0.000021464288,0.000028789638,0.00033190844,0.8917417,0.000046558507,0.0016185377],"genre_scores_gemma":[0.3745214,0.0000029809014,0.000015169953,0.000019405237,0.000034045817,0.00024258594,0.6243009,0.000019608944,0.0008438937],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9988861,0.000021633701,0.00043900847,0.00019539609,0.00030326957,0.0001545605],"domain_scores_gemma":[0.99925244,0.00024946188,0.00014114068,0.0001891073,0.0001269383,0.00004091369],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000028477058,0.00014806462,0.00029551858,0.00016853705,0.000016347,0.0000075795906,0.000074413176,0.000103565646,0.9602046],"category_scores_gemma":[0.00040585824,0.00011240396,0.00014652307,0.00048700816,0.000033075725,0.000088858345,0.000031728647,0.0001463886,0.00014742848],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010747357,0.0003076373,0.0006225303,0.00061277393,0.0002215184,0.000024931622,0.00019830243,0.0000013394314,0.0023398465,2.2739957e-7,0.99165916,0.0029369886],"study_design_scores_gemma":[0.0018189618,0.0013877895,0.7035375,0.029156234,0.000027275997,0.000011477828,0.000052992666,0.00005277084,0.03618212,0.0000018659601,0.22760645,0.00016455188],"about_ca_topic_score_codex":0.00008142288,"about_ca_topic_score_gemma":0.000007059815,"teacher_disagreement_score":0.96005714,"about_ca_system_score_codex":0.000113809205,"about_ca_system_score_gemma":0.00026699645,"threshold_uncertainty_score":0.45837006},"labels":[],"label_agreement":null},{"id":"W6939830656","doi":"10.6084/m9.figshare.7806605.v2","title":"Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)","year":2019,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Atezolizumab; Docetaxel; Nivolumab; Lung cancer; Clinical trial; Overall survival","score_opus":0.028780955760814915,"score_gpt":0.2970891464970044,"score_spread":0.2683081907361895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939830656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89121246,0.002820079,0.000002518016,0.000036921083,0.00022379003,0.003405194,0.101165764,0.000011371321,0.0011219202],"genre_scores_gemma":[0.9870801,0.000021328326,0.000033369975,0.00023026354,0.00003939577,0.0005539712,0.011344468,0.000030796415,0.0006663376],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991409,0.0000224327,0.00022780604,0.00023338285,0.00012073401,0.00025474382],"domain_scores_gemma":[0.9992549,0.00021235866,0.00011613414,0.0002238821,0.0001355017,0.000057238383],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000060217215,0.00014518025,0.00035333657,0.00005698838,0.000015496036,0.0000041242392,0.00010616959,0.00006626953,0.042943686],"category_scores_gemma":[0.000039202187,0.00013253372,0.00008845879,0.00016863381,0.000003445045,0.00004693364,0.000023869326,0.00010709782,0.000011763839],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0466414,0.0006295261,0.07875693,0.08197217,0.00086982956,0.00013295088,0.0014874123,0.0029074477,0.52943367,0.0000036672934,0.1616853,0.09547968],"study_design_scores_gemma":[0.030245274,0.0006734056,0.32747087,0.021376397,0.000060700702,0.00000913479,0.00038469478,0.0025065788,0.5376192,0.0000028592174,0.07906679,0.0005841165],"about_ca_topic_score_codex":0.124654226,"about_ca_topic_score_gemma":0.5317439,"teacher_disagreement_score":0.40708965,"about_ca_system_score_codex":0.0007990645,"about_ca_system_score_gemma":0.0021548967,"threshold_uncertainty_score":0.9579312},"labels":[],"label_agreement":null},{"id":"W6939869185","doi":"10.6084/m9.figshare.27300421","title":"Additional file 1 of Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC","year":2024,"lang":"en","type":"article","venue":"Open MIND","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Chemotherapy; Canakinumab; Adjuvant chemotherapy; Metastasis; Cancer","score_opus":0.017908020018459314,"score_gpt":0.27753600720897775,"score_spread":0.25962798719051844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939869185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95911354,0.00005019769,0.000021892462,0.00021815729,0.000027370883,0.002472079,0.03244487,0.0000074992677,0.0056443843],"genre_scores_gemma":[0.9517453,0.000005239589,0.0100852,0.00014117341,0.000017044087,0.0005058767,0.032953076,0.00006577684,0.0044813645],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99867713,0.000041914536,0.00030829656,0.00034741423,0.00040302108,0.00022223115],"domain_scores_gemma":[0.9993107,0.00019686359,0.00013238889,0.00019546754,0.00011187982,0.00005270121],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010237746,0.0002042075,0.0004054263,0.00023058172,0.000028434872,0.00006477315,0.0001266247,0.0000458187,0.3569582],"category_scores_gemma":[0.00001967022,0.00012420976,0.000023798706,0.0009257314,0.00011372401,0.0002504163,0.000013711578,0.00016427651,0.000022586899],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30319116,0.004380299,0.042288072,0.0005086255,0.0023587425,0.0006992419,0.0065070284,0.0000610313,0.00020128167,0.000020478788,0.36164343,0.2781406],"study_design_scores_gemma":[0.09921241,0.018573327,0.4522695,0.017342808,0.0002916912,0.0002809689,0.0013730603,0.0015412678,0.0021168396,0.000019522893,0.40583828,0.0011403438],"about_ca_topic_score_codex":0.0010386078,"about_ca_topic_score_gemma":0.017570311,"teacher_disagreement_score":0.40998143,"about_ca_system_score_codex":0.00020731606,"about_ca_system_score_gemma":0.0010389014,"threshold_uncertainty_score":0.9804646},"labels":[],"label_agreement":null},{"id":"W6939949471","doi":"10.6084/m9.figshare.8252117.v1","title":"Additional file 5: of Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis","year":2019,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Programmed cell death 1; Adverse effect; Programmed cell death; Table (database); Cell; Systematic review; Lung cancer","score_opus":0.020570530816070375,"score_gpt":0.24940532129240808,"score_spread":0.2288347904763377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939949471","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011797355,0.025979921,6.3785717e-7,0.00006383311,0.000010429775,0.018595183,0.94329536,0.00006209774,0.00019517737],"genre_scores_gemma":[0.10077835,0.00021528424,0.0013504156,0.00027640408,0.000025677455,0.050257593,0.82951677,0.00013635306,0.017443158],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9976006,0.00010876938,0.0009414688,0.0005374006,0.00040077808,0.00041096035],"domain_scores_gemma":[0.99716336,0.00046944668,0.0013378111,0.0003940002,0.00046783328,0.00016752369],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023459832,0.00042478397,0.0020124563,0.0001717157,0.00009018622,0.00002278254,0.00014044256,0.00021407488,0.27777213],"category_scores_gemma":[0.0003182678,0.00029416644,0.00085606414,0.0006765229,0.000019672481,0.00010060089,0.00005680555,0.00020573844,0.000017751609],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076661306,0.001192619,0.0005845486,0.6632645,0.08036868,0.000025809348,0.000486651,0.000004281773,0.0008703118,1.964204e-7,0.25235927,0.00007650553],"study_design_scores_gemma":[0.020430326,0.004518715,0.007221243,0.3099859,0.6200393,0.000043357977,0.00046276956,0.0021133597,0.014120296,0.000004927297,0.018660266,0.0023995503],"about_ca_topic_score_codex":0.000055592038,"about_ca_topic_score_gemma":0.00003871282,"teacher_disagreement_score":0.5396706,"about_ca_system_score_codex":0.0001322016,"about_ca_system_score_gemma":0.00034333853,"threshold_uncertainty_score":0.99995106},"labels":[],"label_agreement":null},{"id":"W6939975215","doi":"10.6084/m9.figshare.26630128.v1","title":"Additional file 8 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Immune system; Pembrolizumab; Immune checkpoint; Immunotherapy; Nivolumab","score_opus":0.013254414913963529,"score_gpt":0.22859643274929495,"score_spread":0.2153420178353314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939975215","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10638764,0.00023848726,1.2239732e-8,0.000021586993,0.000028533314,0.00033224552,0.8913207,0.000046320307,0.0016244871],"genre_scores_gemma":[0.37720233,0.0000029378327,0.000015155969,0.000019396508,0.00003360359,0.00024201006,0.6216381,0.000019532637,0.00082693493],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9988859,0.000021650303,0.00043915727,0.00019543714,0.00030320472,0.00015459533],"domain_scores_gemma":[0.9992535,0.00024969084,0.00014116196,0.00018917494,0.00012556247,0.000040921208],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00002851633,0.00014809729,0.0002956457,0.00016857406,0.000016355763,0.000007583327,0.00007443966,0.000103575694,0.95953673],"category_scores_gemma":[0.00040165894,0.00011243421,0.00014654585,0.00048681145,0.00003308409,0.00008886789,0.000031737552,0.00014641049,0.00014448758],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010718979,0.00030869516,0.00061900145,0.00060983247,0.00022221795,0.000025098492,0.00019922992,0.000001343781,0.002307111,2.3537544e-7,0.9916427,0.002992625],"study_design_scores_gemma":[0.0018238157,0.0014062005,0.710199,0.029481879,0.000027709357,0.000011692506,0.000053569922,0.000053383625,0.03647979,0.0000018997157,0.22029518,0.00016587957],"about_ca_topic_score_codex":0.00008132667,"about_ca_topic_score_gemma":0.0000071114605,"teacher_disagreement_score":0.9593922,"about_ca_system_score_codex":0.00011339237,"about_ca_system_score_gemma":0.0002663827,"threshold_uncertainty_score":0.4584934},"labels":[],"label_agreement":null},{"id":"W6943875816","doi":"10.15789/1563-0625-dav-3188","title":"Development and validation of an ELISA-based method for determining neutralizing antibodies to pembrolizumab in human serum based on inhibition of the drug binding to its PD-1 target","year":2025,"lang":"en","type":"article","venue":"Medical Immunology (Russia)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"L'Alliance Boviteq","funders":"","keywords":"Pembrolizumab; Antibody; Drug; Neutralizing antibody; Neutralization; Monoclonal antibody; Immune system","score_opus":0.02490205132908989,"score_gpt":0.3502839253548138,"score_spread":0.3253818740257239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6943875816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99027795,0.00009749022,0.0038397263,0.0047397926,0.0002104772,0.00070340105,0.000011491799,0.000019650688,0.00010003124],"genre_scores_gemma":[0.9838415,0.0000044867375,0.014198313,0.0017574418,0.000015788153,0.000087136556,0.000034441397,0.000013210349,0.000047690362],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984934,0.00020268802,0.0005438843,0.00027393777,0.0002453854,0.00024076054],"domain_scores_gemma":[0.99931884,0.00021485613,0.00013658436,0.00020899091,0.000060909326,0.00005984869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011305382,0.00014738925,0.00038801666,0.00047054264,0.00012743425,0.000008094856,0.00012827168,0.000157264,0.0000371183],"category_scores_gemma":[0.00032931467,0.00011302364,0.00006664241,0.00040301456,0.000105531675,0.000044474393,0.00005217061,0.00017556574,3.7162593e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045667225,0.00035595734,0.011417064,0.0004825411,0.00012772776,0.000010817301,0.0023397547,0.00014351512,0.9374646,0.000255332,0.000098502016,0.042737477],"study_design_scores_gemma":[0.0043880013,0.00038507552,0.09164505,0.001776797,0.00003214288,0.0000034393788,0.0003618117,0.00179339,0.89902335,0.00002399516,0.00046364582,0.0001032796],"about_ca_topic_score_codex":0.000047943773,"about_ca_topic_score_gemma":0.000058170004,"teacher_disagreement_score":0.080227986,"about_ca_system_score_codex":0.00012779549,"about_ca_system_score_gemma":0.00035596793,"threshold_uncertainty_score":0.46089703},"labels":[],"label_agreement":null},{"id":"W6957977225","doi":"10.6084/m9.figshare.26593124","title":"Additional file 3 of Inter-rater and intra-rater agreement of [99mTc]-labelled NM-01, a single-domain programmed death-ligand 1 (PD-L1) antibody, using quantitative SPECT/CT in non-small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Limits of agreement; Time to peak; Lung cancer; Time perception; Response time; Time point","score_opus":0.039124837487540295,"score_gpt":0.30965494828177087,"score_spread":0.27053011079423056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6957977225","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2350982,0.0022258551,0.0000053274243,0.00007509175,0.0000638731,0.00081952143,0.7610362,0.000019377332,0.0006565489],"genre_scores_gemma":[0.60443085,0.000051691073,0.0030215378,0.00020878,0.00015854748,0.00085405895,0.39030954,0.00007353917,0.0008914667],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986794,0.000046217017,0.00045201293,0.0003452561,0.00019788097,0.00027921796],"domain_scores_gemma":[0.9991671,0.00033873116,0.00016240185,0.00015743215,0.00010781305,0.00006656262],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007343263,0.00022879985,0.00039444107,0.00022619292,0.0000320244,0.000041713327,0.00008324319,0.000048690785,0.68985647],"category_scores_gemma":[0.00009603139,0.00018820116,0.00012092915,0.00035177355,0.000047016096,0.00009972476,0.00007009379,0.00017212419,0.000026733751],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015247526,0.0005065187,0.000697776,0.0049438025,0.00056788157,0.0005261037,0.0021732743,0.000005071306,0.12709042,0.0000023020723,0.85812616,0.0038359142],"study_design_scores_gemma":[0.012850666,0.0035761092,0.024255482,0.18709435,0.00042707712,0.00036610264,0.0029176923,0.013859501,0.3833522,0.00007033736,0.36962208,0.0016084109],"about_ca_topic_score_codex":0.00020898996,"about_ca_topic_score_gemma":0.00034307194,"teacher_disagreement_score":0.68982977,"about_ca_system_score_codex":0.00018424791,"about_ca_system_score_gemma":0.0002716661,"threshold_uncertainty_score":0.767462},"labels":[],"label_agreement":null},{"id":"W6958030631","doi":"10.6084/m9.figshare.26630107","title":"Additional file 2 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Immunotherapy; Pembrolizumab; Immune system; Immune checkpoint; Ipilimumab","score_opus":0.013012443286969854,"score_gpt":0.2282902159117537,"score_spread":0.21527777262478384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958030631","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10475655,0.00024035087,1.184173e-8,0.000021484573,0.000028716822,0.0003317624,0.89292574,0.000046673285,0.001648698],"genre_scores_gemma":[0.36969945,0.0000030251476,0.000015049225,0.000019473657,0.00003424741,0.00024313694,0.62913394,0.000019634077,0.00083204306],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99888635,0.000021647851,0.00043900812,0.0001953336,0.00030312693,0.00015451407],"domain_scores_gemma":[0.9992551,0.00024810788,0.0001413207,0.00018902669,0.00012549225,0.0000409109],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00002832985,0.0001480377,0.00029556183,0.0001684817,0.000016349702,0.000007580353,0.00007441918,0.00010357545,0.96044534],"category_scores_gemma":[0.00040091298,0.000112395865,0.00014650355,0.00048680542,0.0000330728,0.00008884999,0.000031747953,0.00014638496,0.00014416098],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010547065,0.00030555838,0.0005971469,0.000603499,0.00022017864,0.000025143314,0.00019709182,0.0000013363286,0.0022349118,2.3144136e-7,0.9918047,0.002955472],"study_design_scores_gemma":[0.0018099598,0.0013932828,0.70058197,0.028920298,0.000027494681,0.000011644135,0.000052817035,0.000052441093,0.035257984,0.0000018799512,0.2317257,0.00016455782],"about_ca_topic_score_codex":0.00008130849,"about_ca_topic_score_gemma":0.000007053022,"teacher_disagreement_score":0.9603012,"about_ca_system_score_codex":0.00011337407,"about_ca_system_score_gemma":0.00026561637,"threshold_uncertainty_score":0.458337},"labels":[],"label_agreement":null},{"id":"W6958185608","doi":"10.6084/m9.figshare.26593124.v1","title":"Additional file 3 of Inter-rater and intra-rater agreement of [99mTc]-labelled NM-01, a single-domain programmed death-ligand 1 (PD-L1) antibody, using quantitative SPECT/CT in non-small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Limits of agreement; Time to peak; Lung cancer; Time perception; Response time; Time point","score_opus":0.039124837487540295,"score_gpt":0.30965494828177087,"score_spread":0.27053011079423056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958185608","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2350982,0.0022258551,0.0000053274243,0.00007509175,0.0000638731,0.00081952143,0.7610362,0.000019377332,0.0006565489],"genre_scores_gemma":[0.60443085,0.000051691073,0.0030215378,0.00020878,0.00015854748,0.00085405895,0.39030954,0.00007353917,0.0008914667],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986794,0.000046217017,0.00045201293,0.0003452561,0.00019788097,0.00027921796],"domain_scores_gemma":[0.9991671,0.00033873116,0.00016240185,0.00015743215,0.00010781305,0.00006656262],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007343263,0.00022879985,0.00039444107,0.00022619292,0.0000320244,0.000041713327,0.00008324319,0.000048690785,0.68985647],"category_scores_gemma":[0.00009603139,0.00018820116,0.00012092915,0.00035177355,0.000047016096,0.00009972476,0.00007009379,0.00017212419,0.000026733751],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015247526,0.0005065187,0.000697776,0.0049438025,0.00056788157,0.0005261037,0.0021732743,0.000005071306,0.12709042,0.0000023020723,0.85812616,0.0038359142],"study_design_scores_gemma":[0.012850666,0.0035761092,0.024255482,0.18709435,0.00042707712,0.00036610264,0.0029176923,0.013859501,0.3833522,0.00007033736,0.36962208,0.0016084109],"about_ca_topic_score_codex":0.00020898996,"about_ca_topic_score_gemma":0.00034307194,"teacher_disagreement_score":0.68982977,"about_ca_system_score_codex":0.00018424791,"about_ca_system_score_gemma":0.0002716661,"threshold_uncertainty_score":0.767462},"labels":[],"label_agreement":null},{"id":"W6958541172","doi":"10.6084/m9.figshare.26630104.v1","title":"Additional file 1 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Antigen; Immune system; Immunotherapy; Pembrolizumab; Immune checkpoint; Antibody","score_opus":0.013490730881090608,"score_gpt":0.22879322136168445,"score_spread":0.21530249048059386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958541172","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10526852,0.00023613834,1.2094445e-8,0.000021571606,0.000028507537,0.00033193806,0.89245796,0.00004662382,0.0016087434],"genre_scores_gemma":[0.37210912,0.0000029368903,0.000015357024,0.000019420006,0.000033640164,0.0002473776,0.62672555,0.000019609422,0.0008269812],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9988863,0.000021655444,0.00043880512,0.00019548503,0.00030320536,0.00015457296],"domain_scores_gemma":[0.999251,0.0002517844,0.00014111787,0.00018940383,0.00012578217,0.00004091742],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00002849051,0.00014808634,0.00029548712,0.00016859571,0.000016348466,0.0000075633952,0.00007446199,0.00010357483,0.96118516],"category_scores_gemma":[0.0004059718,0.00011243382,0.00014653282,0.00048719646,0.000033073273,0.00008878714,0.000031752566,0.00014641978,0.00014576699],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001056225,0.0003043814,0.0006147651,0.000595399,0.00021925454,0.000024349341,0.0001960956,0.0000013241582,0.002307919,2.2635628e-7,0.99181944,0.002860639],"study_design_scores_gemma":[0.0017972938,0.0013930685,0.7074816,0.029287867,0.000027598413,0.000011617717,0.000053380725,0.000052806623,0.0354827,0.0000018646475,0.22424528,0.00016491833],"about_ca_topic_score_codex":0.000080470716,"about_ca_topic_score_gemma":0.0000070101587,"teacher_disagreement_score":0.9610394,"about_ca_system_score_codex":0.00011334053,"about_ca_system_score_gemma":0.00026684272,"threshold_uncertainty_score":0.45849183},"labels":[],"label_agreement":null},{"id":"W6958543424","doi":"10.6084/m9.figshare.23636295.v2","title":"Boreal forest foliar chemistry data","year":2024,"lang":"en","type":"dataset","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Balsam; Boreal; Taiga; Black spruce; Ammonium nitrate; Nitrogen; Nitrate","score_opus":0.06059757147681092,"score_gpt":0.3286159921826701,"score_spread":0.2680184207058592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958543424","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.8744258e-7,0.0053520845,1.0859339e-8,0.00020116624,0.00018045044,0.00025823803,0.9917587,0.00007520657,0.0021737618],"genre_scores_gemma":[0.0000036053673,0.00023086193,0.000005486172,0.0005512757,0.0014293969,0.000101950165,0.99578786,0.00004110844,0.0018484792],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986727,0.0000068961285,0.00023164458,0.0005465278,0.00029516453,0.00024703838],"domain_scores_gemma":[0.997811,0.00004005596,0.000091426264,0.001903756,0.00004470608,0.000109044915],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00004322143,0.0002769107,0.00031999292,0.000045796416,0.000032555003,0.00007093744,0.00069013255,0.00042051735,0.3346063],"category_scores_gemma":[0.00029414837,0.00023162916,0.00014064908,0.00015715449,0.000011996564,0.00005124019,0.00050698913,0.0005534606,0.015311281],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013649621,0.000033648394,8.011131e-7,0.004522145,0.00025455665,0.0004055447,0.0000020918362,1.3681298e-8,0.0000078379435,2.2407011e-8,0.99323905,0.0013977692],"study_design_scores_gemma":[0.00044802937,0.000038166978,0.0001463458,0.00869486,0.00019870787,0.00015209633,0.0000051283314,0.000010860694,0.00004842571,0.0000038157536,0.9900161,0.0002374845],"about_ca_topic_score_codex":0.00014278128,"about_ca_topic_score_gemma":0.00017732481,"teacher_disagreement_score":0.31929502,"about_ca_system_score_codex":0.000092195296,"about_ca_system_score_gemma":0.0004758928,"threshold_uncertainty_score":0.9854554},"labels":[],"label_agreement":null},{"id":"W6958750093","doi":"10.6084/m9.figshare.26630119","title":"Additional file 5 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Autoimmune disease; Disease; Immunotherapy; Immune system; Pembrolizumab; Immune checkpoint","score_opus":0.013250662893149983,"score_gpt":0.22859026048532674,"score_spread":0.21533959759217675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958750093","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.106054105,0.00023814848,1.2213333e-8,0.000021556702,0.00002854028,0.00033233463,0.8916664,0.00004665627,0.0016122186],"genre_scores_gemma":[0.3767115,0.000002972695,0.000015145385,0.000019387726,0.00003360319,0.00024193685,0.6221383,0.000019554049,0.0008176144],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9988859,0.000021649787,0.00043915794,0.00019544267,0.0003032685,0.00015457484],"domain_scores_gemma":[0.9992536,0.00024963066,0.00014115761,0.00018917443,0.00012553169,0.00004091991],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000028515935,0.00014809068,0.00029564445,0.00016861186,0.000016356285,0.000007580305,0.00007444109,0.00010358004,0.95951444],"category_scores_gemma":[0.00040161624,0.00011242845,0.00014655558,0.00048710726,0.0000330821,0.00008887177,0.000031742962,0.00014640184,0.00014327341],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010703932,0.00030828558,0.0006226677,0.0006088527,0.00022185639,0.000025058494,0.00019869827,0.0000013390455,0.0023239444,2.365451e-7,0.9916749,0.00294378],"study_design_scores_gemma":[0.0018141365,0.0013957844,0.71343905,0.029311147,0.000027558777,0.000011627979,0.000053301053,0.000052682186,0.035779435,0.0000018792448,0.21794844,0.0001649596],"about_ca_topic_score_codex":0.00008143363,"about_ca_topic_score_gemma":0.0000071166837,"teacher_disagreement_score":0.95937115,"about_ca_system_score_codex":0.00011337779,"about_ca_system_score_gemma":0.0002662639,"threshold_uncertainty_score":0.45846993},"labels":[],"label_agreement":null},{"id":"W6959000150","doi":"10.6084/m9.figshare.29558120.v1","title":"Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of early-stage non-small cell lung cancer following complete resection and platinum-based chemotherapy in Canada","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pembrolizumab; Lung cancer; Chemotherapy; Clinical trial; Adjuvant; Stage (stratigraphy); Survival analysis; Disease","score_opus":0.04008640671312782,"score_gpt":0.3255141357660614,"score_spread":0.2854277290529336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6959000150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781941,0.0013017987,0.000005287926,0.000026384905,0.000037495865,0.00094547507,0.019291282,0.000006792301,0.0001913526],"genre_scores_gemma":[0.9942642,0.000038859667,0.000015176703,0.00009264963,0.00000849357,0.00029193528,0.0051865783,0.00001261383,0.00008949507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913096,0.000063105734,0.00025604575,0.00024121652,0.00015078502,0.00015786226],"domain_scores_gemma":[0.9993778,0.00015232437,0.00012870137,0.00022010793,0.0000727563,0.000048321494],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005312009,0.00014781232,0.0005295817,0.00028554822,0.000034069413,0.0000073762612,0.000054155815,0.00005895182,0.0032133579],"category_scores_gemma":[0.000015860522,0.00013156128,0.0001474883,0.00071756844,0.000007666043,0.000034733526,0.000008572078,0.00005607191,1.9276423e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02111875,0.0006232509,0.87357956,0.003330624,0.0047671245,0.000109616354,0.0016526325,0.0037574368,0.059031162,8.237958e-7,0.0005964836,0.03143256],"study_design_scores_gemma":[0.010210716,0.0005682996,0.90941894,0.0019302687,0.00040612303,3.1954602e-7,0.00016437125,0.0141611565,0.062092945,3.0789343e-7,0.00092805136,0.00011847988],"about_ca_topic_score_codex":0.73187125,"about_ca_topic_score_gemma":0.7358041,"teacher_disagreement_score":0.035839427,"about_ca_system_score_codex":0.0009899567,"about_ca_system_score_gemma":0.0012841192,"threshold_uncertainty_score":0.99769783},"labels":[],"label_agreement":null},{"id":"W6976516305","doi":"10.6084/m9.figshare.12667688.v1","title":"Additional file 1 of Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre; McMaster University; Hamilton Health Sciences","funders":"","keywords":"Table (database); Checklist; Clinical trial; Outcome (game theory); Inclusion (mineral); MEDLINE","score_opus":0.24920793919315729,"score_gpt":0.4244891323188327,"score_spread":0.1752811931256754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976516305","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00209299,0.0021376298,1.4898046e-8,0.0006311731,0.00005495616,0.002751203,0.99207526,0.000023691553,0.00023309265],"genre_scores_gemma":[0.027660277,0.00008628159,0.00011075935,0.0043169376,0.000094267416,0.0034671924,0.964176,0.000025060996,0.00006322498],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.99458534,0.00074823765,0.003969159,0.00024503033,0.0002968946,0.00015532714],"domain_scores_gemma":[0.9950195,0.0028970737,0.0016434931,0.0002465727,0.0000930975,0.00010029452],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00086704147,0.00015026635,0.0019786889,0.00008877134,0.000010828384,0.0000056076406,0.000102147234,0.00016653238,0.92238367],"category_scores_gemma":[0.07825677,0.000116390125,0.00051681534,0.00040405712,0.000014927488,0.000057793688,0.00005910728,0.0002892096,0.00033792434],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055474177,0.00026327636,0.00024913813,0.068491295,0.0001560189,0.0000908066,0.00009233804,5.412803e-8,0.000064256994,5.1512163e-8,0.92888975,0.0011482843],"study_design_scores_gemma":[0.005706585,0.0009587051,0.010660668,0.84803265,0.00012936576,0.000032759446,0.00015927774,0.000040035007,0.00016361641,0.0000016532765,0.1339199,0.00019479265],"about_ca_topic_score_codex":0.000009752562,"about_ca_topic_score_gemma":0.0000124489725,"teacher_disagreement_score":0.9220457,"about_ca_system_score_codex":0.00016177865,"about_ca_system_score_gemma":0.00044283448,"threshold_uncertainty_score":0.92950743},"labels":[],"label_agreement":null},{"id":"W6976578424","doi":"10.60692/gs9jy-wm417","title":"Considerations for treatment duration in responders to immune checkpoint inhibitors","year":2021,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Immunotherapy; Clinical trial; Duration (music); Limiting; Cancer; Cancer immunotherapy; Toxicity","score_opus":0.049225208506716626,"score_gpt":0.2633598408821824,"score_spread":0.21413463237546576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976578424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907389,0.000020252019,0.0037288156,0.0023524784,0.0004282729,0.0014323292,0.00009217468,0.0000848531,0.0011218879],"genre_scores_gemma":[0.9975445,6.1240746e-7,0.0011027077,0.0004394302,0.00006288155,0.00033981242,0.00008174768,0.000008428542,0.00041983207],"study_design_codex":"qualitative","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99876314,0.000037041125,0.0007719649,0.00012534388,0.00014238496,0.00016014914],"domain_scores_gemma":[0.99933594,0.000017799479,0.000139451,0.00023847762,0.00020429734,0.00006401959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026490717,0.00012455556,0.00023821965,0.00026548497,0.00009090611,0.00008456045,0.000019324572,0.00007770883,0.000045554436],"category_scores_gemma":[0.0000750268,0.00010389212,0.00012679644,0.00025696598,0.000012359541,0.00023465595,0.000009626673,0.000027875845,0.00007635361],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018732963,0.00013192148,0.111430235,0.0025672805,0.0011599342,0.00014126573,0.81481504,0.00080422167,0.03439787,0.001273604,0.002370864,0.012174765],"study_design_scores_gemma":[0.03356937,0.0016383865,0.25543037,0.0015879889,0.00020504881,0.0007128745,0.12858237,0.0024630274,0.5595818,0.000012894111,0.015428768,0.0007870589],"about_ca_topic_score_codex":0.00002588651,"about_ca_topic_score_gemma":0.000008684791,"teacher_disagreement_score":0.6862327,"about_ca_system_score_codex":0.00058993045,"about_ca_system_score_gemma":0.0002280084,"threshold_uncertainty_score":0.42365977},"labels":[],"label_agreement":null},{"id":"W6976884885","doi":"10.6084/m9.figshare.26593118","title":"Additional file 1 of Inter-rater and intra-rater agreement of [99mTc]-labelled NM-01, a single-domain programmed death-ligand 1 (PD-L1) antibody, using quantitative SPECT/CT in non-small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Lung cancer; Table (database); Cancer; Data file; Cell","score_opus":0.03957580237805473,"score_gpt":0.3099875358194086,"score_spread":0.27041173344135383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976884885","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23332009,0.0022202004,0.0000053282874,0.000075575954,0.00006356415,0.0008219822,0.7628187,0.000019509553,0.00065506523],"genre_scores_gemma":[0.5992848,0.00005132242,0.0030649034,0.00020952726,0.0001574851,0.0008728332,0.39540684,0.00007396699,0.00087831274],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986721,0.000046543515,0.00045431842,0.0003472708,0.0001989279,0.0002807891],"domain_scores_gemma":[0.9991601,0.00034345023,0.00016332921,0.00015859884,0.000107532,0.00006700327],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007390495,0.000230155,0.000396545,0.00022767835,0.00003221703,0.00004187723,0.000083830484,0.00004900211,0.69473296],"category_scores_gemma":[0.00009665959,0.00018939468,0.00012168425,0.0003539813,0.000047319954,0.00010025448,0.000070580354,0.00017316885,0.000026641888],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014892822,0.0004985686,0.00068476406,0.0047813193,0.0005587482,0.00051182363,0.0021301056,0.000005001433,0.12411992,0.0000022877914,0.8615023,0.0037158995],"study_design_scores_gemma":[0.012882191,0.0036361474,0.024719622,0.18997474,0.00043835855,0.0003763837,0.002974773,0.01405582,0.38052312,0.00007148138,0.36871055,0.0016368022],"about_ca_topic_score_codex":0.00020755177,"about_ca_topic_score_gemma":0.0003414992,"teacher_disagreement_score":0.6947063,"about_ca_system_score_codex":0.00018448397,"about_ca_system_score_gemma":0.0002729736,"threshold_uncertainty_score":0.7723291},"labels":[],"label_agreement":null},{"id":"W6977128088","doi":"10.6084/m9.figshare.26593121.v1","title":"Additional file 2 of Inter-rater and intra-rater agreement of [99mTc]-labelled NM-01, a single-domain programmed death-ligand 1 (PD-L1) antibody, using quantitative SPECT/CT in non-small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Limits of agreement; Lung cancer; Agreement; Predictive value of tests","score_opus":0.038540518039930666,"score_gpt":0.30951311674757426,"score_spread":0.27097259870764356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977128088","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23356597,0.0022551008,0.000005213404,0.00007531669,0.00006386806,0.00082097255,0.7625253,0.000019461437,0.0006687914],"genre_scores_gemma":[0.5961985,0.000052491392,0.0030074064,0.00020992356,0.00015975183,0.0008577891,0.39855787,0.00007379597,0.00088247197],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99867964,0.00004624371,0.0004520126,0.00034515862,0.00019779878,0.0002791439],"domain_scores_gemma":[0.99916965,0.00033710827,0.0001625851,0.00015737326,0.00010672815,0.00006655878],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000073097384,0.00022876314,0.00039449206,0.00022612733,0.000032029075,0.000041717034,0.00008324912,0.000048694852,0.691049],"category_scores_gemma":[0.000094997195,0.00018818918,0.00012091492,0.0003516442,0.000047012425,0.000099716475,0.00007013144,0.00017212042,0.000026209855],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014951786,0.00050199975,0.00067059277,0.00486324,0.00056317006,0.0005284701,0.0021551338,0.0000050458993,0.12188651,0.000002331217,0.86348253,0.0038457918],"study_design_scores_gemma":[0.012838816,0.0036010344,0.0241657,0.18640555,0.00043158795,0.00037206587,0.0029192276,0.013830862,0.3761986,0.00007104794,0.3775515,0.0016140309],"about_ca_topic_score_codex":0.00020873075,"about_ca_topic_score_gemma":0.00034278055,"teacher_disagreement_score":0.6910228,"about_ca_system_score_codex":0.00018362583,"about_ca_system_score_gemma":0.0002704259,"threshold_uncertainty_score":0.7674132},"labels":[],"label_agreement":null},{"id":"W6977155980","doi":"10.6084/m9.figshare.29578728.v1","title":"Additional file 1 of Immune checkpoint inhibitors and the pediatric rheumatologist: a pediatric needs assessment","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Alberta; University of British Columbia","funders":"","keywords":"Needs assessment; MEDLINE; Immune system; Pediatric oncology; PD-L1","score_opus":0.012335721172136672,"score_gpt":0.25880040087526784,"score_spread":0.24646467970313118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977155980","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012234284,0.0028901792,2.889657e-7,0.00051928445,0.000056667075,0.00036431808,0.98867846,0.000032037122,0.006235357],"genre_scores_gemma":[0.079080485,0.00036125325,0.00024653628,0.00043612134,0.00030074653,0.0018840971,0.9142438,0.000019384835,0.0034275276],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991464,0.00003613449,0.0003701646,0.000131921,0.00017976199,0.00013559971],"domain_scores_gemma":[0.99824196,0.0012273669,0.00020112078,0.00019607907,0.00010189863,0.000031591528],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007590324,0.0001164332,0.00025211432,0.00019029134,0.00007932307,0.000016923921,0.00009224488,0.000084335414,0.93764085],"category_scores_gemma":[0.0011425011,0.00007698527,0.000180637,0.00062684907,0.00003696463,0.00003714997,0.000087126056,0.00016768352,0.00006891461],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021443055,0.000046035042,0.00034350975,0.00039648314,0.000052291733,0.0000025162183,0.00003784126,1.6571009e-7,0.000007006848,0.000012202529,0.99789214,0.0009953842],"study_design_scores_gemma":[0.004719231,0.0001466731,0.1981559,0.0019432514,0.00013060405,0.000050962,0.0002825167,0.000097046075,0.00011281209,0.00006139563,0.7941171,0.00018254666],"about_ca_topic_score_codex":0.000018370207,"about_ca_topic_score_gemma":0.0000016650831,"teacher_disagreement_score":0.9375719,"about_ca_system_score_codex":0.000045536694,"about_ca_system_score_gemma":0.00040105733,"threshold_uncertainty_score":0.31393683},"labels":[],"label_agreement":null},{"id":"W6977159763","doi":"10.6084/m9.figshare.12153999","title":"Additional file 1 of Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Adverse effect; Funnel plot; Meta-analysis; Event (particle physics); Table (database); Subgroup analysis; Melanoma; Survival analysis","score_opus":0.024824514945219422,"score_gpt":0.2426240007786332,"score_spread":0.21779948583341377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977159763","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025096494,0.011362497,1.883225e-8,0.00040176982,0.0000020491332,0.0015719897,0.9841102,0.000011625209,0.000030245967],"genre_scores_gemma":[0.34078228,0.000044630444,0.000012327833,0.00051969517,0.000005506819,0.0018652371,0.65647525,0.000029271481,0.00026578284],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99849325,0.00011920136,0.0007114793,0.00018700206,0.00037289094,0.000116193114],"domain_scores_gemma":[0.99778056,0.00044518814,0.0012297601,0.0002280446,0.0002719228,0.000044508066],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008469346,0.00017162011,0.001451144,0.00007082566,0.00002856032,0.000002247274,0.00010293177,0.000055508528,0.77689576],"category_scores_gemma":[0.0014300293,0.000089087865,0.00051209,0.0011708699,0.00002557667,0.00004931385,0.000033375472,0.0001399478,0.000010575763],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017473618,0.00072549784,0.0008301073,0.1255226,0.25759333,0.000015890602,0.00085930835,0.000061322404,0.000023368146,1.0831042e-7,0.612594,0.000027081627],"study_design_scores_gemma":[0.0061981967,0.00078445586,0.5896689,0.21240248,0.18889475,0.0000022819959,0.00026838496,0.00006395605,0.00012552328,2.3815886e-7,0.0012244773,0.00036631263],"about_ca_topic_score_codex":0.000037251393,"about_ca_topic_score_gemma":0.000043206324,"teacher_disagreement_score":0.7768852,"about_ca_system_score_codex":0.000062210245,"about_ca_system_score_gemma":0.00010118414,"threshold_uncertainty_score":0.36328977},"labels":[],"label_agreement":null},{"id":"W6977300923","doi":"10.6084/m9.figshare.26593121","title":"Additional file 2 of Inter-rater and intra-rater agreement of [99mTc]-labelled NM-01, a single-domain programmed death-ligand 1 (PD-L1) antibody, using quantitative SPECT/CT in non-small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Limits of agreement; Lung cancer; Agreement; Predictive value of tests","score_opus":0.038540518039930666,"score_gpt":0.30951311674757426,"score_spread":0.27097259870764356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977300923","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23356597,0.0022551008,0.000005213404,0.00007531669,0.00006386806,0.00082097255,0.7625253,0.000019461437,0.0006687914],"genre_scores_gemma":[0.5961985,0.000052491392,0.0030074064,0.00020992356,0.00015975183,0.0008577891,0.39855787,0.00007379597,0.00088247197],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99867964,0.00004624371,0.0004520126,0.00034515862,0.00019779878,0.0002791439],"domain_scores_gemma":[0.99916965,0.00033710827,0.0001625851,0.00015737326,0.00010672815,0.00006655878],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000073097384,0.00022876314,0.00039449206,0.00022612733,0.000032029075,0.000041717034,0.00008324912,0.000048694852,0.691049],"category_scores_gemma":[0.000094997195,0.00018818918,0.00012091492,0.0003516442,0.000047012425,0.000099716475,0.00007013144,0.00017212042,0.000026209855],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014951786,0.00050199975,0.00067059277,0.00486324,0.00056317006,0.0005284701,0.0021551338,0.0000050458993,0.12188651,0.000002331217,0.86348253,0.0038457918],"study_design_scores_gemma":[0.012838816,0.0036010344,0.0241657,0.18640555,0.00043158795,0.00037206587,0.0029192276,0.013830862,0.3761986,0.00007104794,0.3775515,0.0016140309],"about_ca_topic_score_codex":0.00020873075,"about_ca_topic_score_gemma":0.00034278055,"teacher_disagreement_score":0.6910228,"about_ca_system_score_codex":0.00018362583,"about_ca_system_score_gemma":0.0002704259,"threshold_uncertainty_score":0.7674132},"labels":[],"label_agreement":null},{"id":"W6977306647","doi":"10.6084/m9.figshare.26630116.v1","title":"Additional file 4 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Autoantibody; Immunotherapy; Ipilimumab; Immune system; Immune checkpoint; Pembrolizumab","score_opus":0.013352675244357218,"score_gpt":0.22882044623816986,"score_spread":0.21546777099381265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977306647","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10560219,0.00023849455,1.2255298e-8,0.000021440419,0.000028543796,0.00033247055,0.89211476,0.00004666122,0.0016154348],"genre_scores_gemma":[0.3778342,0.000002965398,0.00001510807,0.00001932625,0.00003351445,0.0002413434,0.6210248,0.000019501924,0.0008092469],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9988859,0.00002163075,0.0004391727,0.0001954166,0.00030324978,0.00015457887],"domain_scores_gemma":[0.9992543,0.00024996191,0.00014116452,0.00018921024,0.00012447614,0.000040915605],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000028500943,0.00014807537,0.00029559145,0.00016861895,0.000016355498,0.0000075838034,0.00007447036,0.00010357479,0.9595254],"category_scores_gemma":[0.0003999361,0.00011242626,0.00014653492,0.0004869432,0.00003308193,0.000088871915,0.00003174128,0.00014638386,0.00014428665],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010902797,0.00030889717,0.0006262082,0.0006099298,0.0002223127,0.000025111449,0.00019921958,0.0000013246339,0.0023106814,2.3690109e-7,0.9916607,0.002945072],"study_design_scores_gemma":[0.0018244112,0.0014225929,0.71051323,0.029436814,0.000027687176,0.000011685351,0.000053541375,0.000053341122,0.035677597,0.0000018992471,0.22081144,0.00016576723],"about_ca_topic_score_codex":0.00008066805,"about_ca_topic_score_gemma":0.0000070900683,"teacher_disagreement_score":0.95938116,"about_ca_system_score_codex":0.000113351896,"about_ca_system_score_gemma":0.00026595165,"threshold_uncertainty_score":0.45846102},"labels":[],"label_agreement":null},{"id":"W6977426405","doi":"10.6084/m9.figshare.12331688.v1","title":"Additional file 1 of MHC-I genotype and tumor mutational burden predict response to immunotherapy","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Institute for Advanced Research","funders":"","keywords":"Immunotherapy; Cohort; Univariate; Multivariate analysis; Blockade; Table (database); Pembrolizumab; Nivolumab","score_opus":0.023216138773270473,"score_gpt":0.2558465334466755,"score_spread":0.23263039467340504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977426405","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002133554,0.00021378402,3.426287e-7,0.0015582852,0.000008887534,0.00025416067,0.9952396,0.00003275624,0.00055859087],"genre_scores_gemma":[0.012334366,0.000002052284,0.00071354466,0.0048082285,0.0002938207,0.0005024978,0.9803313,0.000026121515,0.000988081],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993325,0.00002751906,0.00016389665,0.00016467346,0.00020752958,0.000103907965],"domain_scores_gemma":[0.9989966,0.00062199635,0.00006576103,0.00009788017,0.00011049742,0.0001072341],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000023850977,0.000090055546,0.00014339625,0.000047807618,0.000035883313,0.0000102031745,0.000064281994,0.00003789691,0.99265045],"category_scores_gemma":[0.001558241,0.00008291192,0.000062328196,0.00017263109,0.000013632452,0.000039785537,0.00002627703,0.00007054862,0.0005336684],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006772494,0.0000139153635,0.0000019921597,0.00006022694,0.000062174266,0.000022969378,0.0002853542,0.0000017258278,0.0044504083,2.1716647e-7,0.98401254,0.004315952],"study_design_scores_gemma":[0.0008788691,0.000580453,0.035629697,0.0009093137,0.000004886478,0.00004107361,0.000057883615,0.00010153125,0.00048723115,0.0000025870995,0.96122205,0.000084443775],"about_ca_topic_score_codex":0.000003826149,"about_ca_topic_score_gemma":7.4679184e-7,"teacher_disagreement_score":0.9921168,"about_ca_system_score_codex":0.000026898697,"about_ca_system_score_gemma":0.0002530314,"threshold_uncertainty_score":0.68594056},"labels":[],"label_agreement":null},{"id":"W6977432714","doi":"10.6084/m9.figshare.7806605","title":"Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)","year":2019,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Atezolizumab; Docetaxel; Nivolumab; Lung cancer; Clinical trial; Overall survival","score_opus":0.028780955760814915,"score_gpt":0.2970891464970044,"score_spread":0.2683081907361895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977432714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89121246,0.002820079,0.000002518016,0.000036921083,0.00022379003,0.003405194,0.101165764,0.000011371321,0.0011219202],"genre_scores_gemma":[0.9870801,0.000021328326,0.000033369975,0.00023026354,0.00003939577,0.0005539712,0.011344468,0.000030796415,0.0006663376],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991409,0.0000224327,0.00022780604,0.00023338285,0.00012073401,0.00025474382],"domain_scores_gemma":[0.9992549,0.00021235866,0.00011613414,0.0002238821,0.0001355017,0.000057238383],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000060217215,0.00014518025,0.00035333657,0.00005698838,0.000015496036,0.0000041242392,0.00010616959,0.00006626953,0.042943686],"category_scores_gemma":[0.000039202187,0.00013253372,0.00008845879,0.00016863381,0.000003445045,0.00004693364,0.000023869326,0.00010709782,0.000011763839],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0466414,0.0006295261,0.07875693,0.08197217,0.00086982956,0.00013295088,0.0014874123,0.0029074477,0.52943367,0.0000036672934,0.1616853,0.09547968],"study_design_scores_gemma":[0.030245274,0.0006734056,0.32747087,0.021376397,0.000060700702,0.00000913479,0.00038469478,0.0025065788,0.5376192,0.0000028592174,0.07906679,0.0005841165],"about_ca_topic_score_codex":0.124654226,"about_ca_topic_score_gemma":0.5317439,"teacher_disagreement_score":0.40708965,"about_ca_system_score_codex":0.0007990645,"about_ca_system_score_gemma":0.0021548967,"threshold_uncertainty_score":0.9579312},"labels":[],"label_agreement":null},{"id":"W6977617874","doi":"10.6084/m9.figshare.26630131.v1","title":"Additional file 9 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Toxicity; Immune system; Immunotherapy; Antibody; Immune checkpoint; Pembrolizumab","score_opus":0.013260552224482894,"score_gpt":0.22862720852338045,"score_spread":0.21536665629889756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977617874","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10600633,0.00023855975,1.2256979e-8,0.000021597192,0.000028547018,0.00033229383,0.8917101,0.000046663885,0.0016158655],"genre_scores_gemma":[0.37678215,0.0000029765345,0.000015145643,0.000019409028,0.000033631823,0.00024039217,0.6220655,0.000019560552,0.0008212507],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9988859,0.000021649432,0.00043915468,0.00019541399,0.00030324576,0.00015458149],"domain_scores_gemma":[0.99925363,0.0002496507,0.00014114365,0.0001891175,0.00012555468,0.0000409156],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000028510303,0.00014807905,0.00029559733,0.00016861485,0.000016356698,0.0000075817666,0.000074384414,0.000103558166,0.95935535],"category_scores_gemma":[0.00040163784,0.000112420545,0.00014654222,0.00048708447,0.00003308331,0.00008887979,0.000031728665,0.0001463565,0.00014386773],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010717534,0.00030867392,0.0006238813,0.0006097022,0.00022214692,0.000025090152,0.00019920005,0.000001343397,0.0023254156,2.3200084e-7,0.99169743,0.0029151335],"study_design_scores_gemma":[0.001817881,0.0013994859,0.7112125,0.029396923,0.000027627322,0.000011658466,0.00005343045,0.00005323256,0.035891652,0.000001894701,0.21996832,0.00016537607],"about_ca_topic_score_codex":0.00007972896,"about_ca_topic_score_gemma":0.0000071001664,"teacher_disagreement_score":0.9592115,"about_ca_system_score_codex":0.00011336831,"about_ca_system_score_gemma":0.00026622645,"threshold_uncertainty_score":0.45843768},"labels":[],"label_agreement":null},{"id":"W6978069090","doi":"10.6084/m9.figshare.27300421.v1","title":"Additional file 1 of Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Chemotherapy; Canakinumab; Adjuvant chemotherapy; Metastasis; Cancer","score_opus":0.01623155574711108,"score_gpt":0.24861168810694484,"score_spread":0.23238013235983376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6978069090","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033287544,0.00007677909,0.0000013664902,0.00007735966,0.000010689971,0.0011288986,0.96428746,0.00005408384,0.0010758177],"genre_scores_gemma":[0.32040322,0.0000014233385,0.00058816536,0.00017445635,0.000017156655,0.00096281385,0.67697,0.00005413464,0.00082862587],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99870276,0.00003122684,0.00026854099,0.00030613868,0.00045325427,0.00023809452],"domain_scores_gemma":[0.99919456,0.00027519368,0.00012796477,0.00018045079,0.00016802168,0.000053824413],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000028592905,0.00021936945,0.0003525921,0.00026315506,0.000025514131,0.000030800562,0.00007929314,0.000055418583,0.8681554],"category_scores_gemma":[0.00007866603,0.0001362212,0.000033104167,0.001000968,0.00003078477,0.00017219983,0.000008225432,0.00019372336,0.000050875537],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021448204,0.00045842916,0.0015676456,0.00059216726,0.0003044535,0.00013182011,0.00046512124,0.000012045007,0.000006895928,0.0000021011783,0.96949524,0.0055158897],"study_design_scores_gemma":[0.041636355,0.009060696,0.47068313,0.06462343,0.00009460103,0.00016917501,0.00029358978,0.0013785558,0.000405265,0.000009003544,0.41084856,0.00079764205],"about_ca_topic_score_codex":0.00023549743,"about_ca_topic_score_gemma":0.005102905,"teacher_disagreement_score":0.8681045,"about_ca_system_score_codex":0.00021997718,"about_ca_system_score_gemma":0.00083273003,"threshold_uncertainty_score":0.55549395},"labels":[],"label_agreement":null},{"id":"W6980201643","doi":"","title":"The Belgian system of party and campaign finance: an analysis from a comparative perspective","year":2008,"lang":"nl","type":"article","venue":"Lirias (KU Leuven)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Holy See; European union; Erasmus+","score_opus":0.034153462436854305,"score_gpt":0.2957848251362067,"score_spread":0.2616313626993524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6980201643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9566083,0.03847736,0.00014480713,0.00078875554,0.0005172189,0.00064587075,0.00043573295,0.000040418232,0.0023415238],"genre_scores_gemma":[0.9939152,0.0029919317,0.00011432828,0.00013728913,0.00038338502,0.00003729022,0.000056662568,0.000024189367,0.0023396998],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.99718225,0.00053069735,0.00071364694,0.0006393261,0.00049026514,0.0004438422],"domain_scores_gemma":[0.9975766,0.00052675634,0.0005347792,0.00086386426,0.00033415557,0.00016385646],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053388026,0.00038619054,0.0011830543,0.00017593513,0.0006486364,0.000045978537,0.00027266066,0.00022165537,0.00021827882],"category_scores_gemma":[0.00004697731,0.00027034094,0.0004188258,0.0011062964,0.0010746348,0.00017881971,0.000056541554,0.0003311276,0.000048522033],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056329813,0.0030731317,0.21731718,0.00067163014,0.067934476,0.00089400145,0.59618914,0.0007023068,0.01092276,0.01454126,0.022106012,0.009318305],"study_design_scores_gemma":[0.0091885775,0.0025638058,0.64996386,0.0008682089,0.0061651333,0.000086655215,0.30095613,0.010508647,0.0034366462,0.00017585371,0.015235575,0.0008508995],"about_ca_topic_score_codex":0.0163706,"about_ca_topic_score_gemma":0.002673336,"teacher_disagreement_score":0.4326467,"about_ca_system_score_codex":0.0005079192,"about_ca_system_score_gemma":0.0003588885,"threshold_uncertainty_score":0.9999749},"labels":[],"label_agreement":null},{"id":"W6980684961","doi":"","title":"Comportamiento de la generación diaria de desechos sólidos en la Ciudadela el Maestro, Cantón Pasaje","year":2024,"lang":"es","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reinforced concrete; Quarter (Canadian coin); Population","score_opus":0.11356259683549913,"score_gpt":0.5541385444811135,"score_spread":0.4405759476456144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6980684961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8058645,0.18312563,0.0007710839,0.0011154071,0.0015555427,0.00089004607,0.00019697852,0.00011847103,0.006362336],"genre_scores_gemma":[0.87824327,0.11748261,0.00032593936,0.0008673015,0.001183897,0.00009372393,0.000048015972,0.00019476426,0.0015604929],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993598,0.0017502505,0.0015489372,0.000869602,0.0011460673,0.0010871371],"domain_scores_gemma":[0.9959528,0.0014748093,0.00075917644,0.0008249674,0.00023692341,0.0007513529],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005748104,0.00078373554,0.0013818722,0.0013121978,0.00033906611,0.0038332366,0.0026090192,0.0006310974,0.010945365],"category_scores_gemma":[0.0003853966,0.0007067304,0.00069740514,0.0015531279,0.00060022424,0.0014397731,0.0007294119,0.0016904069,0.00005841152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018403963,0.0005853578,0.5000095,0.0010825212,0.002493772,0.0022886866,0.0015502633,0.00008710594,0.35994476,0.0004587785,0.06483018,0.064828716],"study_design_scores_gemma":[0.0023248384,0.00006293769,0.7221223,0.0062631993,0.0010558404,0.00071577146,0.00033017556,0.0008908948,0.039364174,0.0018527317,0.22411098,0.00090613513],"about_ca_topic_score_codex":0.011178387,"about_ca_topic_score_gemma":0.00014050196,"teacher_disagreement_score":0.32058057,"about_ca_system_score_codex":0.0010592332,"about_ca_system_score_gemma":0.0021919147,"threshold_uncertainty_score":0.99953836},"labels":[],"label_agreement":null},{"id":"W6981668081","doi":"","title":"Etude sur l'entremêlement des concepts d'histoire et de fiction dans la littérature historique et fantastique en Chine","year":2003,"lang":"fr","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Period (music); Theme (computing); Feature (linguistics)","score_opus":0.009557383411464693,"score_gpt":0.27270231970474634,"score_spread":0.2631449362932817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6981668081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8410925,0.027186913,0.000024752899,0.00039687075,0.0060575795,0.0020566336,0.002854926,0.00037747197,0.11995234],"genre_scores_gemma":[0.9080966,0.02879848,0.0019297272,0.0028230776,0.0002888901,0.0004599974,0.004915158,0.0004896357,0.052198447],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9907735,0.0035602,0.0015982949,0.0015781317,0.0010949137,0.0013949635],"domain_scores_gemma":[0.99597615,0.000747523,0.0010027611,0.00096319185,0.000615299,0.00069505896],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0036260595,0.0015669672,0.0013984195,0.00046518192,0.0015888547,0.00014488191,0.0006131374,0.002244129,0.000985775],"category_scores_gemma":[0.0012981404,0.0016419573,0.00092416245,0.0009701196,0.00042821048,0.00081120344,0.000092477974,0.0038062364,0.0000674849],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050872774,0.002009494,0.0019678697,0.0026470872,0.002192058,0.0007855763,0.0021006726,0.00024281215,0.7697749,0.08561485,0.0002802443,0.12729715],"study_design_scores_gemma":[0.0074524595,0.0012146649,0.025689904,0.006029851,0.0012745076,0.0007750947,0.004751679,0.000044711665,0.12570114,0.0011757375,0.82374763,0.002142621],"about_ca_topic_score_codex":0.0049232077,"about_ca_topic_score_gemma":0.018238287,"teacher_disagreement_score":0.8234674,"about_ca_system_score_codex":0.01447095,"about_ca_system_score_gemma":0.0009826982,"threshold_uncertainty_score":0.99992746},"labels":[],"label_agreement":null},{"id":"W6987672446","doi":"","title":"Tumor Infiltrating Effector Memory Antigen-Specific CD8&lt;sup&gt;+&lt;/sup&gt; T Cells Predict Response to Immune Checkpoint Therapy","year":2020,"lang":"en","type":"article","venue":"UWA Profiles and Research Repository (University of Western Australia)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Global Health Research","funders":"","keywords":"Immune system; Effector; Immune checkpoint; Nivolumab; Immunotherapy; Tumor-infiltrating lymphocytes; Cytotoxic T cell; Pembrolizumab","score_opus":0.05976505121425801,"score_gpt":0.29900861564767467,"score_spread":0.23924356443341666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6987672446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99341685,0.0014837391,0.000039302315,0.0027713992,0.00014702596,0.001716227,0.000067335415,0.000091707516,0.00026643896],"genre_scores_gemma":[0.991335,0.0010422448,0.0005526309,0.00007829606,0.0003054963,0.000007045862,0.00002143758,0.000042673826,0.0066152215],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964221,0.00072180846,0.00045562614,0.0007315954,0.0010045866,0.00066426676],"domain_scores_gemma":[0.9980339,0.0002683414,0.00020548177,0.000566555,0.0003424315,0.0005833383],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015045226,0.00031821054,0.00063377694,0.0002984334,0.0005795312,0.00010869055,0.0004548648,0.0002071934,0.0002441502],"category_scores_gemma":[0.000051691473,0.0003075982,0.0002903782,0.0006311032,0.0007055273,0.0002575376,0.00024457855,0.0006096141,0.000051256957],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023444384,0.00017691453,0.008494634,0.0003854994,0.00027175972,0.0006846726,0.0052177897,0.0000123952095,0.95640266,0.000003094478,0.0031197583,0.0017864386],"study_design_scores_gemma":[0.0046243924,0.004169425,0.26105994,0.00067874265,0.000030278092,0.00012911114,0.0039520743,0.00015361533,0.68820995,0.000001422819,0.03662793,0.00036314866],"about_ca_topic_score_codex":0.0004923181,"about_ca_topic_score_gemma":0.0000057179914,"teacher_disagreement_score":0.26819274,"about_ca_system_score_codex":0.00016875507,"about_ca_system_score_gemma":0.00026514468,"threshold_uncertainty_score":0.9999376},"labels":[],"label_agreement":null},{"id":"W6991509866","doi":"","title":"Harper Government Supports Renewable Energy Project and Innovation in British Columbia\\n| Reuters","year":2012,"lang":"en","type":"other","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Renewable energy; Energy policy; Energy (signal processing); Subsidy","score_opus":0.012158912960178115,"score_gpt":0.24249215542772093,"score_spread":0.2303332424675428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6991509866","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032061648,0.0033822744,0.000057455225,0.00019502515,0.0004750242,0.0007058445,0.00007258222,0.00010688977,0.99179876],"genre_scores_gemma":[0.0036116487,0.002140946,0.00047461197,0.0014521917,0.00021651997,0.00007064013,0.00014424167,0.00017064133,0.99171853],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99889916,0.000018940002,0.00030001684,0.00027414545,0.00027591182,0.00023183833],"domain_scores_gemma":[0.9995925,0.0000074166696,0.00014455584,0.00020567623,0.000016454536,0.00003341401],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018451274,0.00012509087,0.0002960147,0.00013542174,0.000017721708,0.00006892008,0.000038940376,0.00025023677,0.009325187],"category_scores_gemma":[0.000009660353,0.00016875223,0.00003438721,0.00039930726,0.00005538659,0.000045878125,0.000028886661,0.00008077293,0.0000018539704],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072067865,0.00008704205,0.020951103,0.000116524476,0.000097120195,0.000032992044,0.00002344,1.2469431e-8,0.00047419866,0.0000054431744,0.93862647,0.03951359],"study_design_scores_gemma":[0.001580872,0.00009965888,0.0076211416,0.0005845485,0.000031690066,0.00010077833,0.0000869046,0.0000016770092,0.0001122816,0.000005097403,0.9895766,0.000198747],"about_ca_topic_score_codex":0.44185504,"about_ca_topic_score_gemma":0.47972065,"teacher_disagreement_score":0.05095014,"about_ca_system_score_codex":0.00021745378,"about_ca_system_score_gemma":0.00012013784,"threshold_uncertainty_score":0.9915804},"labels":[],"label_agreement":null},{"id":"W6994032710","doi":"","title":"kinesis_2000_02_06","year":2000,"lang":"en","type":"other","venue":"cIRcle (University of British Columbia)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"","score_opus":0.006963467433078488,"score_gpt":0.1843230033786526,"score_spread":0.1773595359455741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6994032710","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.042840656,0.0052041644,0.000017614244,0.00010370568,0.00021897483,0.00045808,0.00050833967,0.00024932073,0.95039916],"genre_scores_gemma":[0.040376257,0.0066062757,0.0002847784,0.00017231047,0.00015683395,4.1046002e-7,0.00010448524,0.00019507675,0.95210356],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99908066,0.00002178667,0.000109928886,0.00035166313,0.00023547738,0.0002004578],"domain_scores_gemma":[0.9993584,0.000008561444,0.00014208394,0.0003645864,0.000026903657,0.00009946186],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000046211087,0.00006334059,0.00047812168,0.00009875037,0.000053014293,0.000024446328,0.00017972523,0.00032464316,0.018257117],"category_scores_gemma":[0.0000026575547,0.0002456555,0.00028274342,0.00022442955,0.00027741704,0.000035711462,0.000028396991,0.00013943379,0.0001219581],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065472406,0.00008342973,0.0005850975,0.00014532341,0.00015857253,0.00022118328,0.000012189223,2.4903352e-8,0.00007068505,2.0561423e-8,0.5390261,0.45963192],"study_design_scores_gemma":[0.0018125193,0.000088142006,0.4505429,0.0011864987,0.00013744076,0.00013538694,0.00006514433,0.0000014051204,2.550993e-7,0.0000035046107,0.54585016,0.0001766619],"about_ca_topic_score_codex":0.24444664,"about_ca_topic_score_gemma":0.32742494,"teacher_disagreement_score":0.45945525,"about_ca_system_score_codex":0.00004985378,"about_ca_system_score_gemma":0.00013500087,"threshold_uncertainty_score":0.9999996},"labels":[],"label_agreement":null},{"id":"W6994589766","doi":"","title":"Guest editorial","year":2012,"lang":"en","type":"article","venue":"Canadian acoustics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"","score_opus":0.013574674200211516,"score_gpt":0.2545503314234408,"score_spread":0.24097565722322928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6994589766","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31357935,0.0029363225,0.00021032774,0.002753589,0.6285821,0.0006065064,0.0002111188,0.00014089524,0.05097977],"genre_scores_gemma":[0.8133564,0.000044255314,0.00020139357,0.0016321955,0.18324919,0.000003923816,0.000027671442,0.00001656505,0.0014684163],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99935955,0.0000063142056,0.000092073395,0.0000654529,0.00012281477,0.00035377636],"domain_scores_gemma":[0.9991684,0.000015665611,0.000017192559,0.00015659994,0.00005115129,0.00059098715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109521316,0.00007096104,0.00009154845,0.00007551498,0.00005841446,0.000010553363,0.00004302611,0.00010921127,0.0002806788],"category_scores_gemma":[0.00006103125,0.00006621377,0.000041378204,0.00010252854,0.00004543372,0.000041324052,0.000004089463,0.00011043914,0.00013414667],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006431141,0.0000170559,0.0058844956,0.000013661171,0.000033348224,0.000010150385,0.000108871915,3.4352868e-7,0.01889446,0.00002979863,0.97357094,0.0013725623],"study_design_scores_gemma":[0.00056527724,0.000048753558,0.04903707,0.000015255161,0.00005418006,0.000032842607,0.0000681031,0.000007171768,0.00021688652,0.0000039360543,0.9498605,0.00009000865],"about_ca_topic_score_codex":0.015303804,"about_ca_topic_score_gemma":0.0017427668,"teacher_disagreement_score":0.49977702,"about_ca_system_score_codex":0.0003136973,"about_ca_system_score_gemma":0.0004978113,"threshold_uncertainty_score":0.9912534},"labels":[],"label_agreement":null},{"id":"W6995615246","doi":"","title":"Personalising Adjuvant Therapy in Common Solid Tumours Using Data from the Add-Aspirin Trial","year":2022,"lang":"en","type":"dissertation","venue":"UCL Discovery (University College London)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Colorectal cancer; Cancer; Randomized controlled trial; Clinical trial; Population; Stage (stratigraphy); Adverse effect; Adjuvant","score_opus":0.054166713927490166,"score_gpt":0.31198217989577615,"score_spread":0.257815465968286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6995615246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821006,0.0042751585,0.000008218492,0.00053754344,0.001727391,0.0017665026,0.00841449,0.000046067566,0.001124043],"genre_scores_gemma":[0.9493808,0.0022321811,0.00008697867,0.0009107371,0.0005734533,0.000007174478,0.027653659,0.00011651762,0.019038482],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99709785,0.00039926375,0.00042203104,0.00087155204,0.0007740206,0.00043527444],"domain_scores_gemma":[0.9978253,0.00030297684,0.0004598349,0.0012672953,0.000056071498,0.00008851609],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004922451,0.00046104196,0.00095144426,0.00035071556,0.0006774031,0.00008770784,0.0011921176,0.0002778173,0.0019440406],"category_scores_gemma":[0.000025932293,0.00042394738,0.0004041411,0.000921575,0.00013408008,0.0008130776,0.00028945928,0.00095762894,0.000007581467],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92563057,0.0016929024,0.007690481,0.00018959852,0.0022336994,0.0029359346,0.009505887,0.00007495484,0.008217602,0.0002906778,0.031813666,0.0097240135],"study_design_scores_gemma":[0.35075307,0.0036116436,0.18767114,0.0035675964,0.0030613414,0.00014423925,0.28509104,0.008058435,0.00084637216,0.00020471269,0.15363333,0.0033570784],"about_ca_topic_score_codex":0.018322619,"about_ca_topic_score_gemma":0.027523018,"teacher_disagreement_score":0.5748775,"about_ca_system_score_codex":0.0009929392,"about_ca_system_score_gemma":0.0013307674,"threshold_uncertainty_score":0.99982125},"labels":[],"label_agreement":null},{"id":"W6995777618","doi":"","title":"PodCamp Montreal 2008 - Sylvain Carle","year":2008,"lang":"en","type":"other","venue":"Bulletin of Miscellaneous Information (Royal Gardens Kew)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Social media; Tone (literature); Focus (optics); Georgia tech","score_opus":0.005959720136783304,"score_gpt":0.1921603232357021,"score_spread":0.18620060309891878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6995777618","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000086781496,0.0032199735,2.0530847e-7,0.00025015496,0.0003283178,0.0006181918,0.00020384527,0.00021230475,0.99508023],"genre_scores_gemma":[0.0003274091,0.004243353,0.00047836755,0.0007210213,0.00031524998,0.0000183325,0.00035605277,0.00016683993,0.9933734],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982846,0.00004395054,0.0006352321,0.0002159054,0.0004903877,0.00032993677],"domain_scores_gemma":[0.9987415,0.000049382703,0.0004772089,0.00046621126,0.00011737707,0.000148284],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00012470897,0.00037472707,0.00060694636,0.00012100265,0.000059810085,0.000018970606,0.00018687425,0.000511598,0.43777874],"category_scores_gemma":[0.000048291156,0.000343012,0.00031594082,0.000011636016,0.00020955609,1.1713234e-7,0.00004118895,0.0002804437,0.006812361],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078297977,0.00007806393,0.0000079534375,0.0004450196,0.00024860562,0.00009542201,0.00016811307,0.000008220048,0.0000018234505,0.0000014969827,0.9914568,0.006705487],"study_design_scores_gemma":[0.0019969943,0.00030818424,0.00008444727,0.00045187556,0.000103515675,0.0005957187,0.00007257849,0.0000055403593,0.000017595454,0.0000010813527,0.99604076,0.0003217118],"about_ca_topic_score_codex":0.032746732,"about_ca_topic_score_gemma":0.0030131915,"teacher_disagreement_score":0.43096638,"about_ca_system_score_codex":0.00010910215,"about_ca_system_score_gemma":0.00011004697,"threshold_uncertainty_score":0.9999022},"labels":[],"label_agreement":null},{"id":"W6995969911","doi":"","title":"PScout: Analyzing the Android Permission Specification","year":2013,"lang":"en","type":"dissertation","venue":"TSpace","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; Strong","keywords":"Permission; Android (operating system); Redundancy (engineering); Static analysis; Android application","score_opus":0.026499396389412438,"score_gpt":0.35485404816030075,"score_spread":0.3283546517708883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6995969911","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8919236,0.028369261,0.000044346805,0.0037766944,0.0010367193,0.0010927384,0.0000029180508,0.00010349663,0.07365025],"genre_scores_gemma":[0.45580336,0.008485242,0.00020945109,0.0005462847,0.0009239915,0.000101906786,0.001384432,0.00009331287,0.53245205],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99914175,0.00002934601,0.00020415105,0.00023583835,0.00023374514,0.00015515342],"domain_scores_gemma":[0.9992008,0.000030818817,0.00018649384,0.00041941385,0.0001071655,0.000055271765],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015497496,0.0001770624,0.00022167857,0.000088897934,0.00013325144,0.000048017722,0.00011060902,0.00018267821,0.003351936],"category_scores_gemma":[0.00002828928,0.00010975923,0.00015050064,0.00019728292,0.000029511993,0.00003825953,0.0000057704588,0.00027102634,0.00015345516],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032454662,0.000153202,0.0005545142,0.00053169153,0.0004684168,0.0000125972665,0.019357333,0.0000011065949,0.48408636,0.00012982666,0.13870984,0.35274965],"study_design_scores_gemma":[0.0027002206,0.00036865636,0.21260263,0.0016189809,0.00075134856,0.000059990794,0.02996564,0.00020949602,0.08361869,0.00008724332,0.66730034,0.00071675703],"about_ca_topic_score_codex":0.00025897697,"about_ca_topic_score_gemma":0.00003419939,"teacher_disagreement_score":0.5285905,"about_ca_system_score_codex":0.00010283485,"about_ca_system_score_gemma":0.0001225337,"threshold_uncertainty_score":0.99755913},"labels":[],"label_agreement":null},{"id":"W6995978823","doi":"","title":"Pteragen Canada Inc. obtains regulatory approval for its 120 MW Peace Butte Wind Power Project in Alberta","year":2013,"lang":"en","type":"other","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Butte; Wind power; Power (physics); Environmental impact statement; Global Positioning System","score_opus":0.012514242081127731,"score_gpt":0.25035913096368284,"score_spread":0.23784488888255512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6995978823","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0077352147,0.004324174,0.000022027309,0.002248458,0.0011657727,0.0066043003,0.00019143957,0.0001094814,0.97759914],"genre_scores_gemma":[0.0070642233,0.00016447729,0.000312032,0.0023452593,0.0003815907,0.00018136055,0.00024936054,0.00042073027,0.988881],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981618,0.000042104737,0.0003912211,0.0005549428,0.00035138286,0.0004985432],"domain_scores_gemma":[0.9990138,0.00006836992,0.00019073703,0.00055742724,0.000060989452,0.00010870486],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017027828,0.0004379769,0.0006318344,0.00029191587,0.000034891422,0.000024039258,0.00021001254,0.00041813796,0.0060553746],"category_scores_gemma":[0.000035655365,0.00034557286,0.00013818344,0.00018683715,0.000058197562,0.000042065156,0.000041229752,0.00024486915,0.000029526922],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051252637,0.00006952033,0.0002778837,0.00035293063,0.0003901559,0.000019345955,0.00018256747,2.0019287e-7,0.00041194688,0.00007619671,0.9956259,0.0020807972],"study_design_scores_gemma":[0.0031570585,0.00017425879,0.001394007,0.00038407886,0.00006113086,0.000025374382,0.00015313836,0.000041736577,0.000258408,0.0000013492572,0.9939123,0.0004371547],"about_ca_topic_score_codex":0.8587358,"about_ca_topic_score_gemma":0.91627884,"teacher_disagreement_score":0.057543,"about_ca_system_score_codex":0.00054375775,"about_ca_system_score_gemma":0.0023324867,"threshold_uncertainty_score":0.9998996},"labels":[],"label_agreement":null},{"id":"W6996055425","doi":"","title":"Prostatectomía transcervical","year":2017,"lang":"es","type":"article","venue":"LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computed tomography; Arterial disease; Ideal (ethics)","score_opus":0.025005227900300707,"score_gpt":0.2768144312833264,"score_spread":0.2518092033830257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6996055425","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31879848,0.0071819783,0.0013940504,0.20379345,0.006644028,0.0033794923,0.00056049833,0.0009862517,0.45726177],"genre_scores_gemma":[0.9925925,0.00212627,0.0008338876,0.00065120554,0.00199812,0.00023789832,0.00016969089,0.00013485414,0.0012555784],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944966,0.00040061885,0.0011803352,0.0012498151,0.0012990882,0.0013735681],"domain_scores_gemma":[0.9954132,0.00020298947,0.00088012934,0.0020181304,0.0005629505,0.0009226237],"candidate_categories":["metaepi_narrow","sts","scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.0011161282,0.00086577213,0.0010236189,0.00044841482,0.0024537859,0.0011735441,0.0013940387,0.0011109151,0.0003511582],"category_scores_gemma":[0.00065882737,0.00080375205,0.0007488128,0.00039345128,0.00014678683,0.000744365,0.00028955642,0.0012898323,0.00008428815],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011534501,0.0030240356,0.011296182,0.0016445651,0.0023160141,0.001970051,0.0037224954,0.000011474628,0.04713597,0.86765796,0.0041149766,0.04557175],"study_design_scores_gemma":[0.0062511927,0.00037228307,0.10622802,0.0010114481,0.00040013954,0.0017156104,0.00025743523,0.00022675017,0.0045273844,0.00016191423,0.87803996,0.0008078845],"about_ca_topic_score_codex":0.000011027036,"about_ca_topic_score_gemma":0.00015974138,"teacher_disagreement_score":0.873925,"about_ca_system_score_codex":0.0011249982,"about_ca_system_score_gemma":0.0016487151,"threshold_uncertainty_score":0.9998633},"labels":[],"label_agreement":null},{"id":"W6996320642","doi":"","title":"Royal Bank of Canada Upgrades General Electric (GE) to “Outperform”","year":2018,"lang":"en","type":"other","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Charter; Work (physics); Section (typography)","score_opus":0.007503389579160898,"score_gpt":0.23594870604281754,"score_spread":0.22844531646365665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6996320642","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0069356835,0.001370213,0.000028844794,0.0004331493,0.00055672496,0.00043639305,0.000022682263,0.00005665918,0.99015963],"genre_scores_gemma":[0.005187504,0.00010724545,0.0006600943,0.0016310011,0.00090126874,0.000012854823,0.000023367827,0.00018765991,0.991289],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888617,0.000012874766,0.00023267916,0.0002393191,0.0003259108,0.00030304206],"domain_scores_gemma":[0.9993877,0.000010257696,0.00009350473,0.00033301717,0.000044133973,0.0001314251],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007570536,0.00022206693,0.00041807495,0.00021178962,0.000021709558,0.0000055672376,0.00012815262,0.00017510107,0.032912284],"category_scores_gemma":[0.000011730338,0.00016424441,0.00010015638,0.0002468213,0.000034703015,0.000004816528,0.00001849226,0.00008599786,0.000038275673],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003513788,0.000024556266,0.0004884421,0.00009321916,0.00030170343,0.0000075352023,0.000016147045,1.2429307e-7,0.0019570787,0.000021434744,0.99240357,0.0043347897],"study_design_scores_gemma":[0.000807577,0.00043185486,0.0018673374,0.00016129312,0.00006623961,0.000011127825,0.000011690156,0.000017845587,0.006635171,0.0000014581116,0.9897847,0.00020368981],"about_ca_topic_score_codex":0.7254117,"about_ca_topic_score_gemma":0.6447705,"teacher_disagreement_score":0.080641225,"about_ca_system_score_codex":0.0002202192,"about_ca_system_score_gemma":0.0012287474,"threshold_uncertainty_score":0.96797174},"labels":[],"label_agreement":null},{"id":"W6996463720","doi":"","title":"Space Link Extension Application Program Interface for Return Channel Frames Service - CCSDS 915.2-M-1","year":2008,"lang":"en","type":"article","venue":"Biblioteca Digital da Memória Científica do INPE (National Institute for Space Research)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Nuclear Physics; National Institute of Information and Communications Technology; Japan Aerospace Exploration Agency; Canadian Space Agency; National Commission for Science and Technology; Iran Telecommunication Research Center; European Space Agency; Agenzia Spaziale Italiana; European Organization for the Exploitation of Meteorological Satellites; Korea Aerospace Research Institute; National Oceanic and Atmospheric Administration; China National Space Administration; National Space Organization; Belgian Federal Science Policy Office; Chinese Academy of Sciences; U.S. Geological Survey; Indian Space Research Organisation; Centre National d’Etudes Spatiales; Commonwealth Scientific and Industrial Research Organisation; National Aeronautics and Space Administration","keywords":"Nucleofection; Diafiltration; Gestational period; TSG101; Fusible alloy; Articular cartilage damage; Proteogenomics; Hyporeflexia; Dysgeusia","score_opus":0.10326408125402313,"score_gpt":0.3906987572139271,"score_spread":0.28743467595990396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6996463720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42778718,0.009482457,0.2022723,0.26329553,0.0042183413,0.047985684,0.008558325,0.0026483831,0.03375181],"genre_scores_gemma":[0.9834436,0.000840105,0.0072976705,0.00052021246,0.0012058923,0.0019116323,0.0019209894,0.00013517478,0.0027247106],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99549025,0.00004582666,0.0006020597,0.0010392016,0.0019050026,0.00091764657],"domain_scores_gemma":[0.99483943,0.0004269922,0.00023487021,0.0006739924,0.0034653032,0.00035943647],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013597958,0.0004082526,0.00047684557,0.0030323677,0.00085214945,0.0005100622,0.00056172843,0.00042355384,0.000044962497],"category_scores_gemma":[0.0014655351,0.00036611088,0.0003697029,0.006721471,0.00065566547,0.0013578702,0.00023691464,0.00054432236,0.00007936645],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041369516,0.0078727165,0.00050852634,0.0032798,0.0017419762,0.00008051745,0.0031790694,0.001474582,0.18007992,0.062046587,0.5038639,0.19450289],"study_design_scores_gemma":[0.0038298883,0.001517573,0.0009790078,0.0004223123,0.000036835925,0.00017563757,0.00033307687,0.00886046,0.011892687,0.0020907354,0.96938604,0.00047571695],"about_ca_topic_score_codex":0.000081832506,"about_ca_topic_score_gemma":0.00007426456,"teacher_disagreement_score":0.55565643,"about_ca_system_score_codex":0.00060703297,"about_ca_system_score_gemma":0.00090698176,"threshold_uncertainty_score":0.99987906},"labels":[],"label_agreement":null},{"id":"W6997080782","doi":"","title":"Understanding the rapid expression of lymphocyte activation gene 3 (LAG-3) on healthy human T cells","year":2015,"lang":"en","type":"dissertation","venue":"Mspace (University of Manitoba)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Immune system; Cytokine; Lymphocyte; T lymphocyte; T cell; TCIRG1; Cytotoxic T cell; CD69; Jurkat cells; Antigen-presenting cell","score_opus":0.06897191866484083,"score_gpt":0.2729339127926604,"score_spread":0.20396199412781957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6997080782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896439,0.00040864598,0.00028995573,0.00066656055,0.00041816387,0.00060792506,0.00002419318,0.000032690445,0.007908021],"genre_scores_gemma":[0.9971543,0.00070205017,0.00014220901,0.00008594694,0.000089335874,5.731936e-7,0.0003871508,0.000029392035,0.0014090203],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99883235,0.00008979046,0.00015414672,0.0002446044,0.000515732,0.00016336194],"domain_scores_gemma":[0.99879545,0.00005873898,0.000555879,0.0003644665,0.00015800085,0.00006744701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028149234,0.00018736397,0.00037439965,0.00025680993,0.00026729083,0.000007312628,0.00019733573,0.00025676144,0.000044755547],"category_scores_gemma":[0.000008711856,0.00017287506,0.00018309665,0.00022143131,0.000105850275,0.00008204036,0.00002423671,0.00020700724,0.000005476373],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023243532,0.00030386026,0.0004260786,0.00091802445,0.00031987624,0.000015829592,0.0040056817,0.000038953855,0.94389606,0.00013607433,0.023242248,0.0034537888],"study_design_scores_gemma":[0.013972454,0.003691324,0.06713748,0.0039038206,0.00064618787,0.000007454157,0.25165528,0.00011911519,0.64657307,0.00031466866,0.011311215,0.0006679439],"about_ca_topic_score_codex":0.0011984139,"about_ca_topic_score_gemma":0.010770727,"teacher_disagreement_score":0.297323,"about_ca_system_score_codex":0.00099224,"about_ca_system_score_gemma":0.0003216506,"threshold_uncertainty_score":0.70496404},"labels":[],"label_agreement":null},{"id":"W6999764013","doi":"","title":"Dissecting tumour-immune interactions in mesothelioma for identifying responders to immune checkpoint blockade","year":2020,"lang":"en","type":"article","venue":"UWA Profiles and Research Repository (University of Western Australia)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Nurses in Oncology","funders":"","keywords":"Blockade; Mesothelioma; Immune checkpoint; Immune system; Immunotherapy; PD-L1","score_opus":0.16352282938996754,"score_gpt":0.3917658712430928,"score_spread":0.22824304185312527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6999764013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929256,0.0002543344,0.00014252607,0.0055032773,0.00011584509,0.0008661254,0.0000145883005,0.000026457647,0.00015129065],"genre_scores_gemma":[0.9900005,0.000049562223,0.0006155932,0.000016666538,0.00009591889,0.00000538531,0.000009710479,0.000016559092,0.009190095],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99860173,0.00010280807,0.00028958943,0.0003490565,0.00031956713,0.00033726415],"domain_scores_gemma":[0.99915874,0.0001261286,0.00011065377,0.00018711224,0.00021820527,0.00019914412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005876775,0.00012190938,0.00031115074,0.00031344467,0.00031345646,0.00004978353,0.00018985903,0.000070445865,0.00004169286],"category_scores_gemma":[0.000087212626,0.0001298922,0.00015810627,0.00048630591,0.00019958867,0.00018401322,0.0001466175,0.00035116452,0.000005541248],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00497466,0.00008160462,0.011973999,0.000512398,0.00012015436,0.00012232503,0.0058906837,0.0000042645884,0.9756957,0.000012299867,0.000110304,0.0005015853],"study_design_scores_gemma":[0.0027918748,0.0008621931,0.3033443,0.0009623162,0.000051053954,0.00008250006,0.032970157,0.00020199918,0.6559679,0.000016185444,0.0025600994,0.00018942481],"about_ca_topic_score_codex":0.0022401048,"about_ca_topic_score_gemma":0.00008212597,"teacher_disagreement_score":0.31972784,"about_ca_system_score_codex":0.0001322689,"about_ca_system_score_gemma":0.000081251506,"threshold_uncertainty_score":0.529685},"labels":[],"label_agreement":null},{"id":"W7017699952","doi":"","title":"Changement de pratiques au CHU Ste-Justine (Montréal) : mise en place des perfusions rapides de rituximab dans une population pédiatrique","year":2014,"lang":"fr","type":"other","venue":"OpenGrey (Institut de l'Information Scientifique et Technique)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Population; Rituximab; Gestational period","score_opus":0.013472638139337719,"score_gpt":0.27149950727126176,"score_spread":0.258026869131924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7017699952","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057684727,0.003096856,0.6858548,0.008391114,0.0021812387,0.025847973,0.00056540227,0.0011849856,0.21519291],"genre_scores_gemma":[0.40368268,0.027328312,0.25308448,0.010846167,0.0034526174,0.015060925,0.0064646387,0.000893874,0.2791863],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99415946,0.0011181186,0.001679421,0.0007333879,0.00089379534,0.001415789],"domain_scores_gemma":[0.99616927,0.00029362878,0.001237706,0.001153892,0.0005326884,0.0006128437],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009898162,0.00095589,0.0010174912,0.001259748,0.0010372382,0.0006432147,0.00085452833,0.0012378058,0.0025749505],"category_scores_gemma":[0.0012867168,0.00092542387,0.00042812788,0.0012452409,0.00066119386,0.0018468831,0.00028629188,0.0010379481,0.0002799981],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033844246,0.0017046954,0.0122271115,0.013666232,0.0008852542,0.00017602967,0.10606605,0.0026716504,0.080084205,0.014260344,0.17454325,0.5903308],"study_design_scores_gemma":[0.004156043,0.00043723045,0.017563408,0.00948685,0.0004465036,0.0003641314,0.002538274,0.0069584693,0.024968918,0.00033089943,0.9314733,0.0012759856],"about_ca_topic_score_codex":0.030095108,"about_ca_topic_score_gemma":0.047613606,"teacher_disagreement_score":0.75693005,"about_ca_system_score_codex":0.007194562,"about_ca_system_score_gemma":0.0032179453,"threshold_uncertainty_score":0.9993196},"labels":[],"label_agreement":null},{"id":"W7017924297","doi":"","title":"Characterizing the melanoma brain metastasis microenvironment using CyTOF IMC and the adenosine pathway in melanoma","year":2023,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research","keywords":"Melanoma; Tumor microenvironment; Hematopoietic cell; Mass cytometry","score_opus":0.00935781335537833,"score_gpt":0.194392643052442,"score_spread":0.18503482969706367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7017924297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8930601,0.098037176,0.000024883906,0.005310779,0.0014449686,0.0010309607,0.00012168466,0.00003806249,0.00093137706],"genre_scores_gemma":[0.9631436,0.008421396,0.00014031099,0.0008237278,0.00043186426,0.00007461813,0.00043593935,0.00007874831,0.026449798],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9969238,0.00050723186,0.0006698579,0.00065606844,0.0006362921,0.00060674094],"domain_scores_gemma":[0.998188,0.0005290254,0.0005424693,0.00049680355,0.00006647717,0.00017723432],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0009162285,0.0005541517,0.00068868796,0.0003111747,0.00462186,0.00009089318,0.00038588428,0.00036470403,0.00006763764],"category_scores_gemma":[0.000077074714,0.00041288047,0.00041502,0.0005078929,0.0009690829,0.00021892483,0.00020878678,0.0006476389,0.000028629342],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024091536,0.00041751133,0.02407369,0.0007479347,0.0037783182,0.006133471,0.17699479,0.00050404086,0.7129989,0.0060125757,0.0003186314,0.043928597],"study_design_scores_gemma":[0.017702982,0.0004545469,0.5813124,0.0033607401,0.002156368,0.0044294447,0.2134739,0.004430291,0.06502266,0.00014093846,0.106185324,0.0013303778],"about_ca_topic_score_codex":0.073697545,"about_ca_topic_score_gemma":0.011041828,"teacher_disagreement_score":0.6479762,"about_ca_system_score_codex":0.005638689,"about_ca_system_score_gemma":0.0010384232,"threshold_uncertainty_score":0.99983233},"labels":[],"label_agreement":null},{"id":"W7020799900","doi":"","title":"A measure of well-being: An anthropometric study of living conditions in Canada at the turn of the twentieth century","year":2007,"lang":"en","type":"dissertation","venue":"The Atrium (University of Guelph)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Anthropometry; Census; Standard of living; Secular variation; Order (exchange)","score_opus":0.012887554234367842,"score_gpt":0.25368845605635687,"score_spread":0.24080090182198902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7020799900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956859,0.0014237991,0.0000014506818,0.00017025402,0.00042226096,0.0007268021,0.000064591244,0.0000037672817,0.0015011709],"genre_scores_gemma":[0.99811184,0.00047924748,0.0000043370046,0.00001802771,0.000017764067,3.1822358e-7,0.000047890007,0.000013241227,0.0013073387],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99844056,0.00021101645,0.00032221503,0.00017249418,0.0006916149,0.00016210762],"domain_scores_gemma":[0.9979617,0.00031774302,0.000797691,0.00060098903,0.00028670486,0.000035176214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005878018,0.00015300095,0.00046185206,0.00033524973,0.00018969148,0.000001934694,0.0005382733,0.00010917271,0.00038992084],"category_scores_gemma":[0.00007164833,0.000102391314,0.00021313333,0.0012880039,0.00026506808,0.000050745857,0.00007518754,0.00029415786,3.2679125e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0149294315,0.0045015677,0.34947523,0.0026446134,0.0048349085,0.000067402536,0.19486786,0.00018437527,0.4154956,0.00009597278,0.006569754,0.0063332645],"study_design_scores_gemma":[0.0009179804,0.000337826,0.8040235,0.0005004455,0.0005528346,0.0000034779375,0.1920974,0.000011927459,0.0012528015,0.0000040015098,0.00021657403,0.00008121837],"about_ca_topic_score_codex":0.8015473,"about_ca_topic_score_gemma":0.9226956,"teacher_disagreement_score":0.45454827,"about_ca_system_score_codex":0.0003731281,"about_ca_system_score_gemma":0.0008494064,"threshold_uncertainty_score":0.42693597},"labels":[],"label_agreement":null},{"id":"W7021125281","doi":"","title":"Novel treatments and biomarkers for immune-related adverse events secondary to cancer immune checkpoint inhibitor therapy","year":2019,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fondation de l'Hôpital général juif; Jewish General Hospital; McGill University Health Centre","keywords":"Adverse effect; Immune system; Cancer; Immunotherapy; Nivolumab; Pembrolizumab; Clinical trial","score_opus":0.016762819700549325,"score_gpt":0.27650730044222277,"score_spread":0.25974448074167344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7021125281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726485,0.008363283,2.8549115e-7,0.00012013248,0.0037403787,0.0058850218,0.0039717862,0.00018458506,0.005085999],"genre_scores_gemma":[0.9449605,0.006355869,0.0007842027,0.0008056815,0.00010343046,0.001851136,0.004828149,0.0005875428,0.039723504],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9949817,0.00011835444,0.0017210398,0.0015193858,0.00070799503,0.00095148996],"domain_scores_gemma":[0.99702126,0.00015622386,0.0009433236,0.000977487,0.0004569248,0.00044477507],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008354365,0.0012360095,0.0015619053,0.0006952071,0.00070952903,0.00003410963,0.00038549912,0.0011684666,0.00068481755],"category_scores_gemma":[0.0001485162,0.0011428563,0.0011570482,0.00067442947,0.00008032457,0.0004473902,0.0000889605,0.00095298624,0.000090265334],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018063605,0.0005650909,0.00013445782,0.0006474558,0.004738499,0.000015365758,0.00005775985,0.0000024376925,0.72831756,0.000080663434,0.000010319973,0.24736677],"study_design_scores_gemma":[0.052810177,0.0035154193,0.094135806,0.0056163147,0.0018323598,0.0001255327,0.0012324199,0.000024930494,0.7596925,0.00037077503,0.077903256,0.0027405429],"about_ca_topic_score_codex":0.0018667114,"about_ca_topic_score_gemma":0.00038789105,"teacher_disagreement_score":0.24462624,"about_ca_system_score_codex":0.0016717315,"about_ca_system_score_gemma":0.00035033454,"threshold_uncertainty_score":0.9991022},"labels":[],"label_agreement":null},{"id":"W7021511238","doi":"","title":"Our Contributors","year":2006,"lang":"en","type":"article","venue":"Archivaria","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"","score_opus":0.012129129545076542,"score_gpt":0.27269385386076067,"score_spread":0.2605647243156841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7021511238","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4843628,0.00076969905,0.0030917407,0.015402999,0.0009004378,0.00060509134,0.000041376188,0.0002802346,0.4945456],"genre_scores_gemma":[0.99492276,0.00001010466,0.00069369015,0.0006335444,0.00030675158,0.0000061593655,0.0000344611,0.000009211162,0.0033833068],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9995223,0.000014481582,0.00011771524,0.00010268169,0.000092572474,0.00015024489],"domain_scores_gemma":[0.99976265,0.00001673231,0.000024515633,0.00014757464,0.000014220588,0.00003427323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007983463,0.000061798644,0.000106305575,0.00003891533,0.000037905666,0.000009249951,0.00003829444,0.000023374709,0.0000818071],"category_scores_gemma":[0.000010737231,0.000049163114,0.00007215882,0.00007499094,0.00001824683,0.000018848905,0.000010315712,0.0000635582,0.00006137181],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044710217,0.00050754385,0.09781584,0.000061397026,0.0003342292,0.00019960498,0.0002043999,0.000005309346,0.40282077,0.2657924,0.18309605,0.044691436],"study_design_scores_gemma":[0.0045566484,0.000222464,0.70875037,0.000044855686,0.000054905577,0.000111330555,0.00004314359,0.00007195903,0.009465793,0.015759883,0.26076567,0.00015294916],"about_ca_topic_score_codex":0.00054118154,"about_ca_topic_score_gemma":0.0000063262783,"teacher_disagreement_score":0.61093456,"about_ca_system_score_codex":0.000023372706,"about_ca_system_score_gemma":0.000045181514,"threshold_uncertainty_score":0.20048136},"labels":[],"label_agreement":null},{"id":"W7027532342","doi":"","title":"Conceptual Approaches to Environmental Quality and Livability in Smaller Cities","year":2019,"lang":"en","type":"article","venue":"RAF (Faculty of Architecture, University of Belgrade)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Population; Quality (philosophy); Context (archaeology); Government (linguistics); Gloom","score_opus":0.07634074206365946,"score_gpt":0.2472938868094365,"score_spread":0.17095314474577705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7027532342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99691665,0.00019503383,0.000091084534,0.0013463142,0.000023381444,0.0004733654,0.00013360052,0.000012979446,0.00080761133],"genre_scores_gemma":[0.9973009,0.000034380406,0.0019203512,0.000091371956,0.000009029782,2.9296535e-7,0.000042380085,0.0000066899383,0.0005945754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901575,0.00007983703,0.00020964789,0.0002832427,0.00024238763,0.00016911715],"domain_scores_gemma":[0.99948907,0.00007868849,0.00010284027,0.00023099843,0.000009986261,0.00008842418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022996587,0.00013631981,0.00041278312,0.00012977122,0.000036332032,0.000002543747,0.00012292215,0.00009732195,0.00019610424],"category_scores_gemma":[0.000012325386,0.00013479161,0.00013294432,0.00012008195,0.00064999954,0.0000383161,0.000098703866,0.00016543239,0.0000029627547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008611366,0.0006826383,0.85280454,0.0005213193,0.00041665992,0.000008872637,0.05497347,0.00021808514,0.05239643,0.00072618993,0.00018253863,0.028457873],"study_design_scores_gemma":[0.003742135,0.0005194033,0.9752592,0.00008596803,0.0000307232,0.0000080633945,0.0121822925,0.000014619164,0.0035086446,0.00010831978,0.0043784278,0.00016222257],"about_ca_topic_score_codex":0.0011408025,"about_ca_topic_score_gemma":0.00023926723,"teacher_disagreement_score":0.12245463,"about_ca_system_score_codex":0.00008423897,"about_ca_system_score_gemma":0.000046554203,"threshold_uncertainty_score":0.54966426},"labels":[],"label_agreement":null},{"id":"W7036882484","doi":"","title":"Couplage d'un procédé biologique sur charbon actif en poudre à un procédé membranaire pour le traitement des eaux potables","year":2009,"lang":"fr","type":"other","venue":"PolyPublie (École Polytechnique de Montréal)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Water Network","keywords":"Filtration (mathematics); Human physiology; Quality of Life Research","score_opus":0.010008330248664772,"score_gpt":0.22663394994585362,"score_spread":0.21662561969718885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7036882484","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27108777,0.35555246,0.20850742,0.05499628,0.002659726,0.028410291,0.0020857793,0.0064947787,0.070205495],"genre_scores_gemma":[0.5943916,0.072524354,0.05887696,0.012920312,0.004159177,0.004261011,0.0010816325,0.0021287194,0.24965623],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9914021,0.00088711735,0.001948684,0.0019552282,0.0009406908,0.002866175],"domain_scores_gemma":[0.99508846,0.00040800957,0.0012985234,0.0018855914,0.0003697565,0.0009496763],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002377694,0.00217728,0.002373729,0.0012921293,0.0007523325,0.00032371382,0.0014289528,0.0030483108,0.0038052662],"category_scores_gemma":[0.0005551711,0.002032466,0.0010575473,0.0013526403,0.00072626554,0.00052760006,0.00027188333,0.002014895,0.00011887294],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004649815,0.0033657642,0.00514814,0.0019073578,0.00249102,0.0007550464,0.0016395213,0.00022471865,0.28334612,0.0044947052,0.010194416,0.6817834],"study_design_scores_gemma":[0.017020958,0.0046435706,0.14945297,0.011189402,0.0018056474,0.0020838992,0.0021753707,0.01602729,0.40277898,0.0027208466,0.38423836,0.0058627026],"about_ca_topic_score_codex":0.036264684,"about_ca_topic_score_gemma":0.017737724,"teacher_disagreement_score":0.67592067,"about_ca_system_score_codex":0.0036112536,"about_ca_system_score_gemma":0.003900385,"threshold_uncertainty_score":0.99909675},"labels":[],"label_agreement":null},{"id":"W7042754944","doi":"","title":"Quantification of the PD-1/PD-L1 Axis in Various Cancer Types by Immuno-Multiple Reaction Monitoring","year":2025,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Allegheny Health Network; Genome Canada; McGill University","keywords":"Cancer; Cancer detection; Disease monitoring","score_opus":0.020131879275434937,"score_gpt":0.28225610505656024,"score_spread":0.2621242257811253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7042754944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97994167,0.005468172,1.5752467e-7,0.00007398325,0.0036424363,0.001093006,0.00065494835,0.00008359421,0.00904204],"genre_scores_gemma":[0.98244,0.0042799017,0.00005216609,0.00007587024,0.0000551587,0.00027146938,0.00078653573,0.00007382096,0.011965105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99703586,0.00022142974,0.0010026993,0.0007058351,0.0006343519,0.00039984167],"domain_scores_gemma":[0.9977251,0.00019922586,0.0007451893,0.00086739095,0.00038865284,0.00007442093],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063236523,0.000481699,0.00069295155,0.00037119407,0.00042276536,0.000031104344,0.00040705755,0.0007169695,0.000074972624],"category_scores_gemma":[0.0004304399,0.00041927912,0.00037794854,0.0010347205,0.000056848807,0.0002658549,0.000039875253,0.001202258,0.000008804835],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030064313,0.0002491884,0.0018657169,0.0005948654,0.00038885293,0.0000035089945,0.000028204044,0.000009369683,0.8458648,0.0002849781,0.000018844225,0.14768529],"study_design_scores_gemma":[0.0022133617,0.00011414032,0.10895892,0.0030943702,0.0003860395,0.0000067547617,0.00039900767,0.000015351521,0.8443223,0.0003077211,0.039722662,0.0004593236],"about_ca_topic_score_codex":0.014302703,"about_ca_topic_score_gemma":0.0049413578,"teacher_disagreement_score":0.14722598,"about_ca_system_score_codex":0.001489795,"about_ca_system_score_gemma":0.00023004663,"threshold_uncertainty_score":0.9998259},"labels":[],"label_agreement":null},{"id":"W7083899401","doi":"","title":"Grand River Walter Bean Trail Chicopee Sims Estate Vignette, Kitchener ON Canada","year":2025,"lang":"en","type":"other","venue":"Internet Archive (Internet Archive)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Real estate; Estate; Spanish Civil War; World War II; Civilization; World heritage","score_opus":0.009234835122827748,"score_gpt":0.23554059311245773,"score_spread":0.22630575798962999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7083899401","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001937732,0.0006690493,0.002153248,0.0010778331,0.0022392543,0.0015342,0.00249207,0.00028904842,0.98760754],"genre_scores_gemma":[0.01066268,0.0010379216,0.00091752026,0.0066287704,0.0009056277,0.00011326002,0.0017436928,0.00066987966,0.9773207],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99538237,0.00028997607,0.0009279529,0.0015080284,0.0008431517,0.0010485097],"domain_scores_gemma":[0.9975419,0.00035212582,0.00045953607,0.001120898,0.00005439139,0.00047111532],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017653352,0.0012622917,0.0014072557,0.0008581355,0.000050337876,0.000096867414,0.0009636621,0.00028128407,0.017204085],"category_scores_gemma":[0.00005554535,0.0010523727,0.00073099654,0.00019455873,0.0007018253,0.000050083163,0.0003583825,0.0013416521,0.00040753462],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048863324,0.0002636607,0.00033962747,0.00037333855,0.0019768546,0.00072687137,0.001591586,0.000002450182,0.0005132476,0.00019049583,0.97603357,0.013101985],"study_design_scores_gemma":[0.0047915657,0.0008757056,0.0018772836,0.004319091,0.0002935283,0.000088021014,0.00004866487,0.00024777855,0.0013654592,0.0002212315,0.9848701,0.0010015861],"about_ca_topic_score_codex":0.8240516,"about_ca_topic_score_gemma":0.8905716,"teacher_disagreement_score":0.06651994,"about_ca_system_score_codex":0.0003242614,"about_ca_system_score_gemma":0.0011064403,"threshold_uncertainty_score":0.99919266},"labels":[],"label_agreement":null},{"id":"W7084097741","doi":"10.6084/m9.figshare.30038716.v1","title":"Appendix 3_ Articles Included in Review - Included.pdf","year":2025,"lang":"en","type":"dataset","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"","keywords":"Psychological intervention; Supervisor; Transfer of training; Transfer of learning; Organizational culture; Intervention (counseling); Work (physics); Knowledge transfer","score_opus":0.03654090684444704,"score_gpt":0.3325496104885456,"score_spread":0.29600870364409854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7084097741","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000019890838,0.06254961,9.349341e-9,0.00086325867,0.0001047289,0.00099791,0.9346182,0.000032895532,0.0008314159],"genre_scores_gemma":[0.000002836575,0.011397161,0.000007551049,0.009695716,0.00015512807,0.0004083896,0.976824,0.000012807957,0.0014964191],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99824154,0.00007862371,0.0005865242,0.00041823144,0.00035350618,0.0003215982],"domain_scores_gemma":[0.9986787,0.00012152,0.00021089564,0.0008231945,0.00007480578,0.0000909086],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015544066,0.00032803608,0.0007696131,0.00025154572,0.00005499456,0.000028247967,0.0003808607,0.00033039585,0.4878742],"category_scores_gemma":[0.0009801555,0.00028622494,0.00023237367,0.00064410735,0.000013379791,0.000057693702,0.00033248967,0.00057315675,0.004354064],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016521168,0.00013151465,0.0000028870536,0.016942339,0.00009600282,0.00017847733,0.0000075775297,3.0199317e-8,0.000010480581,7.4675675e-8,0.97753257,0.0049328106],"study_design_scores_gemma":[0.0009925314,0.00007327129,0.00019326535,0.13304228,0.000096086966,0.000027558932,0.000005898933,7.9973614e-7,0.000085135165,0.0000030183016,0.8652483,0.0002318186],"about_ca_topic_score_codex":0.00024974372,"about_ca_topic_score_gemma":0.0005884531,"teacher_disagreement_score":0.48352015,"about_ca_system_score_codex":0.00026271027,"about_ca_system_score_gemma":0.0005135785,"threshold_uncertainty_score":0.999959},"labels":[],"label_agreement":null},{"id":"W7087387414","doi":"10.1016/j.colsurfa.2025.138617","title":"Investigation on the amphiphobic silica nanoparticles emulsion delivery system for enhancing oil recovery in low-permeability reservoirs","year":2025,"lang":"en","type":"article","venue":"Colloids and Surfaces A Physicochemical and Engineering Aspects","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Natural Science Foundation of China","keywords":"Emulsion; Silane; Wetting; Contact angle; Hexadecane; Nanoparticle; Fourier transform infrared spectroscopy; Viscosity","score_opus":0.010932110812068765,"score_gpt":0.2123310239959709,"score_spread":0.20139891318390213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7087387414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99764156,0.0010981492,0.000009724785,0.0007947393,0.00008698572,0.00021472691,0.000005556562,0.000044129065,0.00010439917],"genre_scores_gemma":[0.99947166,0.00016661282,0.00006690218,0.00011957621,0.00003471706,0.00006170908,0.0000049406094,0.000008909944,0.00006494556],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99929523,0.00001657318,0.00019120578,0.00023808247,0.000085561565,0.00017335433],"domain_scores_gemma":[0.99942356,0.0003310232,0.000025818637,0.00013597487,0.000032407912,0.000051188505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019182815,0.00012827148,0.00021835901,0.000046639663,0.00007889333,0.000034513578,0.00004104682,0.00006446263,9.754998e-7],"category_scores_gemma":[0.000093515206,0.00009245379,0.000053759726,0.00024192229,0.000064192114,0.000047796788,0.000026316797,0.00010659602,2.6089916e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005954287,0.000028431094,0.0004246829,0.0008666276,0.000031304437,9.208986e-7,0.00014719427,0.00029618817,0.9959518,0.00028446122,0.000056649358,0.0013163219],"study_design_scores_gemma":[0.0012233775,0.00015669987,0.009452768,0.0021692708,0.000026487465,0.0000021124242,0.00039406258,0.017636357,0.9684418,0.0002208882,0.00013751099,0.00013866663],"about_ca_topic_score_codex":0.00006586593,"about_ca_topic_score_gemma":0.000023368722,"teacher_disagreement_score":0.02750999,"about_ca_system_score_codex":0.00011850357,"about_ca_system_score_gemma":0.000033076587,"threshold_uncertainty_score":0.37701562},"labels":[],"label_agreement":null},{"id":"W7097476457","doi":"","title":"Reviewed by:","year":2015,"lang":"en","type":"article","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Clinical trial; Immunotherapy; Antibody therapy; Heading (navigation); Tumor immunology; Clinical immunology; Cancer therapy; Cancer treatment","score_opus":0.04721849151230851,"score_gpt":0.3172801045989864,"score_spread":0.2700616130866779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7097476457","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14137976,0.04788173,0.00060301204,0.024303839,0.0005787875,0.0005682307,0.0000041878156,0.0002308404,0.78444964],"genre_scores_gemma":[0.75974065,0.0024177134,0.0023110323,0.030371202,0.0002651473,0.000021315518,0.000038129878,0.000023710492,0.20481111],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997563,0.000005873804,0.00006275488,0.00004996702,0.000072345676,0.000052767053],"domain_scores_gemma":[0.9998074,0.0000033500874,0.00000966749,0.00009447798,0.000025995578,0.000059104917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109468136,0.000029234603,0.00007029319,0.000008769221,0.000005570036,0.000003024601,0.000017341683,0.000016200933,0.00060765137],"category_scores_gemma":[0.000016824053,0.000018919618,0.000028009617,0.000055891247,0.0000138972255,0.00001530977,0.0000038492713,0.000021161786,0.00012413228],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024619885,0.00002400329,0.0010233339,0.000010501105,0.000019720634,0.0000021972523,0.000030637122,3.6303165e-9,0.0076902136,0.000041316882,0.9478516,0.0430603],"study_design_scores_gemma":[0.001183286,0.0001149624,0.0005261768,0.000020144738,0.000009974167,0.000015061748,0.000036699977,0.0000035985754,0.004152829,0.000020671698,0.99388635,0.000030213785],"about_ca_topic_score_codex":0.000051930063,"about_ca_topic_score_gemma":0.0000021151652,"teacher_disagreement_score":0.6183609,"about_ca_system_score_codex":0.000024555622,"about_ca_system_score_gemma":0.000036043362,"threshold_uncertainty_score":0.6653356},"labels":[],"label_agreement":null},{"id":"W7098487387","doi":"","title":"DRUG NAME: Nivolumab SYNONYM(S): COMMON TRADE NAME(S): OPDIVO®","year":2015,"lang":"en","type":"article","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nivolumab; Monoclonal antibody; Antibody; Drug; Immunotherapy; Blocking (statistics); Receptor; Immunity","score_opus":0.024751517655274627,"score_gpt":0.2857633716842759,"score_spread":0.2610118540290013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7098487387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8380686,0.005814654,0.000125721,0.017686944,0.0009772727,0.0006509264,0.000014680465,0.00039528369,0.13626592],"genre_scores_gemma":[0.97263485,0.00013929319,0.00058572175,0.0042419843,0.00022068512,0.000020348125,0.000024923984,0.000035173114,0.022097012],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99866116,0.000049615126,0.0003107151,0.0002648055,0.00039379444,0.000319904],"domain_scores_gemma":[0.99912953,0.00004148905,0.00006592399,0.00044984394,0.00004030408,0.00027293392],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034683407,0.00019223016,0.00034803365,0.00007724471,0.00006615592,0.00003374229,0.00015431641,0.000102972896,0.0014968255],"category_scores_gemma":[0.000023277407,0.00015117039,0.00016366346,0.00017867534,0.00010327051,0.00010724506,0.00003551335,0.00020626083,0.00020017163],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007196342,0.0009341644,0.020728512,0.00016044716,0.0006452978,0.00025483806,0.0034572782,0.0000039515244,0.0101032285,0.0007728928,0.64339644,0.31234658],"study_design_scores_gemma":[0.014402688,0.0010413671,0.013627398,0.00019202239,0.00016852822,0.00048397534,0.0027339065,0.0005009209,0.021542303,0.00034915342,0.9443925,0.00056524517],"about_ca_topic_score_codex":0.0010620692,"about_ca_topic_score_gemma":0.00018185921,"teacher_disagreement_score":0.31178135,"about_ca_system_score_codex":0.00022914735,"about_ca_system_score_gemma":0.0002114741,"threshold_uncertainty_score":0.99941593},"labels":[],"label_agreement":null},{"id":"W7099282230","doi":"","title":"Science Across Borders: 5th Annual Natural Health Product","year":2010,"lang":"en","type":"article","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Popularity; Product (mathematics); Natural (archaeology); Natural resource; Public health","score_opus":0.013351839159606511,"score_gpt":0.38275656136355746,"score_spread":0.36940472220395093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7099282230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776206,0.00068605423,0.000010962817,0.017242955,0.0013885195,0.00031463252,0.000009894398,0.00009751327,0.0026288875],"genre_scores_gemma":[0.98815,0.00003902421,0.00137503,0.0046526203,0.00024669597,0.00000363988,0.0000046446007,0.000008073977,0.0055202944],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988761,0.000006820653,0.00014765884,0.00028253632,0.0002929646,0.00039393496],"domain_scores_gemma":[0.99936473,0.00000900514,0.00004380565,0.00032526333,0.00013729847,0.00011988913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069214666,0.00008689137,0.00013282897,0.00007052513,0.00023268763,0.000036662408,0.00013734712,0.000014830199,0.00019878513],"category_scores_gemma":[0.00007542061,0.00005925032,0.00004464726,0.00059161236,0.0005660473,0.00018914351,0.00003508593,0.0002546295,0.000019687577],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011525888,0.00026105245,0.013454998,0.00007978328,0.00004520654,0.000008506311,0.0039940784,9.7482555e-8,0.51422,0.00072146504,0.031150313,0.4349119],"study_design_scores_gemma":[0.0037172206,0.00073260046,0.4434502,0.000058670474,0.000008140747,0.00035083992,0.0024584555,0.00006878045,0.07373049,0.000029789595,0.47507423,0.0003205845],"about_ca_topic_score_codex":0.0008905338,"about_ca_topic_score_gemma":0.0008860003,"teacher_disagreement_score":0.44392392,"about_ca_system_score_codex":0.000056545818,"about_ca_system_score_gemma":0.001023375,"threshold_uncertainty_score":0.2416158},"labels":[],"label_agreement":null},{"id":"W7099335039","doi":"","title":"The Annual Carbon Budget for Fen and Forest in a Wetland at Arctic Treeline","year":2001,"lang":"en","type":"article","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Subarctic climate; Tundra; Carbon fibers; Carbon cycle; Arctic; Wetland; Carbon flux; Total organic carbon","score_opus":0.011340101774935447,"score_gpt":0.2658635384214789,"score_spread":0.2545234366465435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7099335039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870209,0.0016812299,0.000018308321,0.007994136,0.00006949973,0.0004207336,0.0000050654007,0.000014028876,0.002776071],"genre_scores_gemma":[0.98649335,0.0009302849,0.00007861651,0.00062891276,0.00010685647,0.000039945462,0.000009961369,0.000009429849,0.011702624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995185,0.000009753933,0.00013123524,0.00011275934,0.000067893016,0.00015986984],"domain_scores_gemma":[0.99968517,0.00011303018,0.000021441578,0.00011472102,0.00002905798,0.00003656565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018086682,0.000068629146,0.00010946188,0.000032178523,0.000052070507,0.000009696242,0.000030799358,0.0000379199,0.00002111599],"category_scores_gemma":[0.00003096327,0.00003836552,0.000033481123,0.000080290345,0.00005812434,0.000018612185,0.0000144862215,0.000041069587,5.9916164e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01614362,0.00010144269,0.92132044,0.00006478931,0.000109642635,0.000026994914,0.0005957527,0.0000012370521,0.0034868864,0.00015228504,0.0050118635,0.052985057],"study_design_scores_gemma":[0.011875802,0.0009067239,0.6701209,0.00007395286,0.000048805774,0.00020260735,0.00080911536,0.0012559365,0.00038393214,0.00033899405,0.31383443,0.00014880624],"about_ca_topic_score_codex":0.0012091155,"about_ca_topic_score_gemma":0.029187681,"teacher_disagreement_score":0.30882257,"about_ca_system_score_codex":0.00006126008,"about_ca_system_score_gemma":0.000022925495,"threshold_uncertainty_score":0.9885271},"labels":[],"label_agreement":null},{"id":"W7102389118","doi":"10.6084/m9.figshare.30473409.v1","title":"Additional file 1 of THSD4 is a novel mediator of T cell exclusion and anti-PD-1 resistance in hormone receptor-positive breast cancer","year":2025,"lang":"","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Beatrice Hunter Cancer Research Institute; Nova Scotia Health Authority; Acadia University; Dalhousie University","funders":"","keywords":"Mediator; Breast cancer; T cell; Hormone; Acquired resistance; Cancer","score_opus":0.01107910673864246,"score_gpt":0.2459342636211803,"score_spread":0.23485515688253783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7102389118","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001474785,0.015947701,2.5518713e-7,0.00064450473,0.00007953354,0.000545338,0.9782822,0.000008339012,0.0030173128],"genre_scores_gemma":[0.059628908,0.0019349911,0.00026915458,0.00080775504,0.0002168342,0.00079410366,0.9311429,0.00004012474,0.005165187],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980927,0.00005091028,0.0006691959,0.0004708375,0.00040792525,0.00030841088],"domain_scores_gemma":[0.99760276,0.0010868283,0.0005057758,0.0002863679,0.0004248967,0.00009334328],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000064252614,0.00028849248,0.0006097671,0.0002589677,0.00007959113,0.000012816686,0.00017970364,0.0002793878,0.9790441],"category_scores_gemma":[0.0004100097,0.0002859989,0.00015710897,0.0008750029,0.000104445906,0.0001286118,0.00013483982,0.00026646585,0.000047019184],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002927478,0.0003510708,0.000036424113,0.0016587321,0.00015552982,0.00000504163,0.0006857622,1.9534923e-7,0.041433226,0.0000010750599,0.95113546,0.0016100293],"study_design_scores_gemma":[0.005513663,0.00019109545,0.25056085,0.09063067,0.00007803062,0.00000436345,0.0005105857,0.000047750415,0.03791817,0.000007049822,0.6141565,0.00038128055],"about_ca_topic_score_codex":0.0001267743,"about_ca_topic_score_gemma":0.00016264846,"teacher_disagreement_score":0.97899705,"about_ca_system_score_codex":0.00024740718,"about_ca_system_score_gemma":0.00110055,"threshold_uncertainty_score":0.99995923},"labels":[],"label_agreement":null},{"id":"W7102390830","doi":"10.6084/m9.figshare.30473409","title":"Additional file 1 of THSD4 is a novel mediator of T cell exclusion and anti-PD-1 resistance in hormone receptor-positive breast cancer","year":2025,"lang":"","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Beatrice Hunter Cancer Research Institute; Nova Scotia Health Authority; Acadia University; Dalhousie University","funders":"","keywords":"Mediator; Breast cancer; T cell; Hormone; Acquired resistance; Cancer","score_opus":0.01107910673864246,"score_gpt":0.2459342636211803,"score_spread":0.23485515688253783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7102390830","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001474785,0.015947701,2.5518713e-7,0.00064450473,0.00007953354,0.000545338,0.9782822,0.000008339012,0.0030173128],"genre_scores_gemma":[0.059628908,0.0019349911,0.00026915458,0.00080775504,0.0002168342,0.00079410366,0.9311429,0.00004012474,0.005165187],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980927,0.00005091028,0.0006691959,0.0004708375,0.00040792525,0.00030841088],"domain_scores_gemma":[0.99760276,0.0010868283,0.0005057758,0.0002863679,0.0004248967,0.00009334328],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000064252614,0.00028849248,0.0006097671,0.0002589677,0.00007959113,0.000012816686,0.00017970364,0.0002793878,0.9790441],"category_scores_gemma":[0.0004100097,0.0002859989,0.00015710897,0.0008750029,0.000104445906,0.0001286118,0.00013483982,0.00026646585,0.000047019184],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002927478,0.0003510708,0.000036424113,0.0016587321,0.00015552982,0.00000504163,0.0006857622,1.9534923e-7,0.041433226,0.0000010750599,0.95113546,0.0016100293],"study_design_scores_gemma":[0.005513663,0.00019109545,0.25056085,0.09063067,0.00007803062,0.00000436345,0.0005105857,0.000047750415,0.03791817,0.000007049822,0.6141565,0.00038128055],"about_ca_topic_score_codex":0.0001267743,"about_ca_topic_score_gemma":0.00016264846,"teacher_disagreement_score":0.97899705,"about_ca_system_score_codex":0.00024740718,"about_ca_system_score_gemma":0.00110055,"threshold_uncertainty_score":0.99995923},"labels":[],"label_agreement":null},{"id":"W7102399395","doi":"10.6084/m9.figshare.30473412.v1","title":"Additional file 2 of THSD4 is a novel mediator of T cell exclusion and anti-PD-1 resistance in hormone receptor-positive breast cancer","year":2025,"lang":"","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Beatrice Hunter Cancer Research Institute; Nova Scotia Health Authority; Acadia University; Dalhousie University","funders":"","keywords":"Mediator; Breast cancer; T cell; Acquired resistance; Hormone; Cancer","score_opus":0.010673785258703862,"score_gpt":0.24538711640832425,"score_spread":0.2347133311496204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7102399395","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014635941,0.016207783,2.4925075e-7,0.00064068893,0.00007999321,0.00054407405,0.9779663,0.000008333323,0.0030889828],"genre_scores_gemma":[0.058577638,0.0019873648,0.00026260418,0.00080700254,0.00022003657,0.0007771411,0.93215,0.000040025338,0.0051781503],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998093,0.000050891922,0.00066951534,0.00047046208,0.0004078168,0.00030829],"domain_scores_gemma":[0.9976199,0.0010705093,0.0005065337,0.00028578538,0.00042389525,0.00009332961],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006387925,0.00028839486,0.00060992595,0.00025878724,0.00007959735,0.0000128463025,0.00017959716,0.00027938953,0.9786245],"category_scores_gemma":[0.00040474525,0.00028589938,0.00015707663,0.00087427936,0.00010444437,0.00012870562,0.00013481962,0.00026640057,0.000046485333],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029134317,0.00035129423,0.00003523037,0.0016763628,0.00015568438,0.0000051937577,0.00068705325,1.9654208e-7,0.04001159,0.0000010962892,0.9525033,0.0016595311],"study_design_scores_gemma":[0.005498476,0.00018922884,0.24439098,0.088606685,0.00007695683,0.0000043302616,0.0005000181,0.0000469392,0.037296705,0.0000070388883,0.623006,0.0003766454],"about_ca_topic_score_codex":0.00012813468,"about_ca_topic_score_gemma":0.00016367332,"teacher_disagreement_score":0.97857803,"about_ca_system_score_codex":0.00024748262,"about_ca_system_score_gemma":0.0010953422,"threshold_uncertainty_score":0.9999593},"labels":[],"label_agreement":null},{"id":"W7102419227","doi":"10.6084/m9.figshare.30473412","title":"Additional file 2 of THSD4 is a novel mediator of T cell exclusion and anti-PD-1 resistance in hormone receptor-positive breast cancer","year":2025,"lang":"","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Beatrice Hunter Cancer Research Institute; Nova Scotia Health Authority; Acadia University; Dalhousie University","funders":"","keywords":"Mediator; Breast cancer; T cell; Acquired resistance; Hormone; Cancer","score_opus":0.010673785258703862,"score_gpt":0.24538711640832425,"score_spread":0.2347133311496204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7102419227","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014635941,0.016207783,2.4925075e-7,0.00064068893,0.00007999321,0.00054407405,0.9779663,0.000008333323,0.0030889828],"genre_scores_gemma":[0.058577638,0.0019873648,0.00026260418,0.00080700254,0.00022003657,0.0007771411,0.93215,0.000040025338,0.0051781503],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998093,0.000050891922,0.00066951534,0.00047046208,0.0004078168,0.00030829],"domain_scores_gemma":[0.9976199,0.0010705093,0.0005065337,0.00028578538,0.00042389525,0.00009332961],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006387925,0.00028839486,0.00060992595,0.00025878724,0.00007959735,0.0000128463025,0.00017959716,0.00027938953,0.9786245],"category_scores_gemma":[0.00040474525,0.00028589938,0.00015707663,0.00087427936,0.00010444437,0.00012870562,0.00013481962,0.00026640057,0.000046485333],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029134317,0.00035129423,0.00003523037,0.0016763628,0.00015568438,0.0000051937577,0.00068705325,1.9654208e-7,0.04001159,0.0000010962892,0.9525033,0.0016595311],"study_design_scores_gemma":[0.005498476,0.00018922884,0.24439098,0.088606685,0.00007695683,0.0000043302616,0.0005000181,0.0000469392,0.037296705,0.0000070388883,0.623006,0.0003766454],"about_ca_topic_score_codex":0.00012813468,"about_ca_topic_score_gemma":0.00016367332,"teacher_disagreement_score":0.97857803,"about_ca_system_score_codex":0.00024748262,"about_ca_system_score_gemma":0.0010953422,"threshold_uncertainty_score":0.9999593},"labels":[],"label_agreement":null},{"id":"W7104177269","doi":"10.1016/j.annonc.2025.08.751","title":"322P Immune profiling across blood, tumour and lymph nodes to guide patient stratification for neoadjuvant immunotherapy in early-stage TNBC","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Immunotherapy; Lymph; Profiling (computer programming); Stratification (seeds); Risk stratification; Immune system","score_opus":0.04273266134237628,"score_gpt":0.40000602601828655,"score_spread":0.35727336467591025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104177269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886089,0.0035062549,0.00027582454,0.0054363823,0.00016942763,0.0010900183,0.000049724767,0.000018095543,0.00084537413],"genre_scores_gemma":[0.9932918,0.0011564557,0.0023141105,0.0022450516,0.000028053782,0.0002021672,0.000026012518,0.000015311034,0.0007210513],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99857277,0.000057712736,0.00069271337,0.00027467718,0.000099149096,0.00030298645],"domain_scores_gemma":[0.9991393,0.00015303493,0.00019940453,0.00024966424,0.000214275,0.000044304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006409372,0.00014215708,0.0004447578,0.00015525326,0.00006742651,0.000015566553,0.0001016938,0.000139253,0.000013094782],"category_scores_gemma":[0.00010803801,0.00012829925,0.00010484019,0.00024622004,0.0001051446,0.00005906789,0.000034477176,0.00008188619,0.0000010237526],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066424916,0.00050508353,0.016472407,0.00015904882,0.00021355429,0.000013293792,0.002519589,0.0000128799875,0.7128147,0.00045370017,0.00023492785,0.25995833],"study_design_scores_gemma":[0.008698129,0.0039280243,0.32610965,0.00035991892,0.000036450016,0.000013108454,0.002503915,0.00011354719,0.6235511,0.00023980808,0.03424667,0.0001996809],"about_ca_topic_score_codex":0.0009744754,"about_ca_topic_score_gemma":0.000097829696,"teacher_disagreement_score":0.30963725,"about_ca_system_score_codex":0.00006868977,"about_ca_system_score_gemma":0.00031033432,"threshold_uncertainty_score":0.5231891},"labels":[],"label_agreement":null},{"id":"W7108689459","doi":"10.71781/32645","title":"La synergie entre l’immunothérapie et la radiothérapie dans le traitement du cancer du poumon non à petites cellules : analyse d’études cliniques réelles et virtuelles","year":2025,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer; Natural Sciences and Engineering Research Council of Canada; Health Canada; Pfizer Canada; Fonds de recherche du Québec – Nature et technologies; Université de Montréal","keywords":"Lung disease; Colonic disease; Negative therapeutic reaction","score_opus":0.017312568590589654,"score_gpt":0.33117963111931376,"score_spread":0.3138670625287241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108689459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8433616,0.04691795,0.0003395391,0.0045194044,0.0015779318,0.002421372,0.00095070765,0.000025495403,0.099885985],"genre_scores_gemma":[0.82802844,0.13785164,0.0035818852,0.00054831005,0.00049635716,0.00048187803,0.0039777053,0.00017205192,0.024861732],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941457,0.0014533742,0.0016210526,0.0013682491,0.0006698685,0.0007417503],"domain_scores_gemma":[0.9961236,0.0015702805,0.00096108223,0.000800925,0.00030754658,0.00023655454],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002821704,0.0011746939,0.0016879584,0.00054709555,0.0005085807,0.0008387881,0.001247665,0.000973923,0.0054822406],"category_scores_gemma":[0.0001347358,0.0011015012,0.0008549513,0.0006655391,0.00045857075,0.0005220427,0.00024439336,0.0009820716,0.00005418461],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010466794,0.0044205575,0.013973124,0.0017286314,0.010626973,0.0008543371,0.0707002,0.0006121011,0.23339902,0.0025143235,0.0039544962,0.64674944],"study_design_scores_gemma":[0.013499926,0.0010564121,0.060374893,0.019222127,0.004372153,0.000074191616,0.09558555,0.0016905837,0.15095256,0.000073730174,0.6507924,0.0023054385],"about_ca_topic_score_codex":0.020510197,"about_ca_topic_score_gemma":0.044331554,"teacher_disagreement_score":0.64683795,"about_ca_system_score_codex":0.0005918771,"about_ca_system_score_gemma":0.0041202996,"threshold_uncertainty_score":0.99914354},"labels":[],"label_agreement":null},{"id":"W7111493484","doi":"","title":"INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)","year":2023,"lang":"en","type":"article","venue":"Research Explorer (The University of Manchester)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Interim analysis; Cetuximab; Head and neck cancer; Hazard ratio; Clinical endpoint; Head and neck squamous-cell carcinoma; Placebo; Confidence interval; Cancer; Chemotherapy","score_opus":0.06625848813984087,"score_gpt":0.33060152368220236,"score_spread":0.2643430355423615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7111493484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996346,0.0007133218,0.000004620468,0.0002801065,0.000007528932,0.002593807,0.000014695709,0.000032052907,0.000007845097],"genre_scores_gemma":[0.99952924,0.00019776532,0.0000891851,0.000013272404,0.0000133736075,0.000045428635,0.000026158386,0.00004132468,0.000044269153],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9975313,0.00035057514,0.0003235808,0.00053763186,0.0007426146,0.00051430665],"domain_scores_gemma":[0.99869454,0.00013434174,0.00017793696,0.00055191095,0.00017292748,0.00026831782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006295176,0.00027805183,0.0005474294,0.00040047467,0.00014726548,0.000024533363,0.0001843551,0.000031554897,0.000035374833],"category_scores_gemma":[0.000013158127,0.000174798,0.00004997722,0.00073694304,0.00076822314,0.00021466055,0.00010713265,0.0003493549,0.0000018424865],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52101654,0.011927185,0.2836234,0.001574063,0.0003362875,0.0027291453,0.14617118,0.000024220088,0.0056665926,0.0000014052775,0.000033317596,0.026896706],"study_design_scores_gemma":[0.12651566,0.0663098,0.7012983,0.0031725222,0.000305361,0.000042015385,0.09377402,0.0013597296,0.0067816866,0.000008575973,0.000053934313,0.00037838117],"about_ca_topic_score_codex":0.0002185495,"about_ca_topic_score_gemma":0.0001699883,"teacher_disagreement_score":0.41767493,"about_ca_system_score_codex":0.00015079719,"about_ca_system_score_gemma":0.00018550978,"threshold_uncertainty_score":0.71280557},"labels":[],"label_agreement":null},{"id":"W7115703867","doi":"10.1097/js9.0000000000004403","title":"TB-MIL: deep learning-based identification of TMB status in bladder cancer from histopathological images","year":2025,"lang":"en","type":"article","venue":"International Journal of Surgery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Education and Child Care","funders":"","keywords":"Bladder cancer; Deep learning; Immunotherapy; Cancer; Metastasis; Pathological; Deep sequencing; Identification (biology)","score_opus":0.022241040359431717,"score_gpt":0.3229329389516773,"score_spread":0.3006918985922456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7115703867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889035,0.005153947,0.0015500103,0.0027100125,0.0014468712,0.00004832477,0.00002105807,0.000006608589,0.0001596359],"genre_scores_gemma":[0.99734414,0.0016616187,0.00010865901,0.00045772275,0.00012685882,0.0000043141704,0.000021128635,0.0000059613826,0.00026962886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986386,0.00007358171,0.0007274551,0.000102783866,0.0003589434,0.00009868836],"domain_scores_gemma":[0.9985876,0.0003721998,0.00048421923,0.00007066153,0.000453185,0.000032133572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052230875,0.000074906995,0.00026341795,0.0004798897,0.00001329618,0.00001590594,0.00010284281,0.000059332342,0.0004935767],"category_scores_gemma":[0.00037189786,0.000062153136,0.00020010614,0.00016143834,0.00008193941,0.000088874214,0.000012870489,0.00020292103,0.0000016856048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042181243,0.00029963258,0.78822577,0.000020756508,0.0003232273,0.00021328327,0.00012558063,0.0004741784,0.12604919,0.00001052056,0.0020536848,0.07798604],"study_design_scores_gemma":[0.0013131875,0.000032590597,0.9610865,0.0003992108,0.000047283236,0.0000139847825,0.000105999694,0.00026031525,0.030727534,0.00011167234,0.005845091,0.00005660863],"about_ca_topic_score_codex":0.00040754417,"about_ca_topic_score_gemma":0.000040266743,"teacher_disagreement_score":0.17286074,"about_ca_system_score_codex":0.00030023055,"about_ca_system_score_gemma":0.00035375037,"threshold_uncertainty_score":0.54043186},"labels":[],"label_agreement":null},{"id":"W7116059631","doi":"10.14740/wjon2660","title":"Neurotoxicity of Immunotherapy: Immune Checkpoint Inhibitor-Related Encephalitis vs. Immune Effector Cell-Associated Neurotoxicity Syndrome","year":2025,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Neurotoxicity; Immune system; Neuroinflammation; Autoimmune encephalitis; Immunotherapy; Effector; Chimeric antigen receptor; Encephalitis; Clinical trial","score_opus":0.009042363038994158,"score_gpt":0.2788033727400038,"score_spread":0.26976100970100964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116059631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820144,0.008093888,0.00005429097,0.0033763028,0.0023494083,0.0010400768,0.000020406871,0.00004685071,0.0030043789],"genre_scores_gemma":[0.99443984,0.0016020025,0.00015943525,0.00092596904,0.000075357,0.000026109692,0.000009994769,0.000046650646,0.0027146416],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9952158,0.0007844142,0.0026582957,0.0003194164,0.00049354,0.00052853965],"domain_scores_gemma":[0.9961412,0.0006032943,0.0021599843,0.00046515494,0.00048306733,0.00014731126],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020561155,0.00039526328,0.001887322,0.0009451238,0.00014022461,0.000022371425,0.00045999335,0.00034129995,0.0007822322],"category_scores_gemma":[0.00030696683,0.0003418465,0.0010789115,0.001578761,0.00046164132,0.0001532142,0.00010598311,0.0012559895,0.000009949871],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011574302,0.002008058,0.0074599185,0.00021920372,0.001243177,0.0007876767,0.00028946841,0.00001292416,0.9601911,0.000039594644,0.00079975114,0.015374866],"study_design_scores_gemma":[0.027307993,0.010990962,0.5192661,0.0018527632,0.00046841076,0.0015947989,0.00009205324,0.00004344132,0.4160148,0.00015011254,0.021852525,0.00036602747],"about_ca_topic_score_codex":0.00027878693,"about_ca_topic_score_gemma":0.000047169742,"teacher_disagreement_score":0.5441763,"about_ca_system_score_codex":0.00085133803,"about_ca_system_score_gemma":0.0010224773,"threshold_uncertainty_score":0.9999034},"labels":[],"label_agreement":null},{"id":"W7116427045","doi":"10.1016/j.compbiomed.2025.111388","title":"Patient-derived geometry-integrated multiphysics framework: Computational optimization of immunotherapeutic nanoparticle delivery via tumor microenvironment reprogramming in prostate cancer","year":2025,"lang":"en","type":"article","venue":"Computers in Biology and Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Balsillie School of International Affairs","funders":"","keywords":"Tumor microenvironment; Stromal cell; Immune system; Prostate cancer; Extracellular matrix; Cytotoxic T cell; Cancer cell; Prostate; Reprogramming","score_opus":0.009001785654914619,"score_gpt":0.28774944320348406,"score_spread":0.27874765754856945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116427045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9579231,0.007521068,0.03252543,0.0012636363,0.0002698918,0.00047163322,0.000004512715,0.000014709513,0.0000059798717],"genre_scores_gemma":[0.98305005,0.0012905876,0.013895617,0.001647832,0.000015794603,0.000035335746,0.00005220019,0.000007464585,0.000005096954],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989723,0.00007452034,0.0004394493,0.0002604817,0.00006390966,0.00018931841],"domain_scores_gemma":[0.9995209,0.00015259886,0.00012512096,0.00012680444,0.000045285702,0.000029305002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017320616,0.00013244635,0.00034890286,0.0002400354,0.00003574518,0.0000027387819,0.000048675098,0.00007144833,0.000023840725],"category_scores_gemma":[0.00002269091,0.00010651435,0.000030326159,0.00044987994,0.0004059719,0.000028845205,0.000035336307,0.0001660268,1.8294952e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045297523,0.00052122236,0.26880813,0.00021038922,0.00030080907,0.000026218293,0.0025544914,0.0155706955,0.29196283,0.00013746909,0.000042503572,0.41533548],"study_design_scores_gemma":[0.033736426,0.0039199386,0.5596022,0.0093410555,0.00025718537,0.00007019622,0.0023642296,0.32859358,0.05649733,0.0030834333,0.0018535055,0.00068093266],"about_ca_topic_score_codex":0.00044945691,"about_ca_topic_score_gemma":0.000016714866,"teacher_disagreement_score":0.41465455,"about_ca_system_score_codex":0.00012499996,"about_ca_system_score_gemma":0.00005938101,"threshold_uncertainty_score":0.4343529},"labels":[],"label_agreement":null},{"id":"W7116681136","doi":"10.1158/1078-0432.ccr-25-1197","title":"INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Princess Margaret Cancer Centre","funders":"EMD Serono; Genentech; Foundation Medicine; MacroGenics; BeiGene; Astellas Pharma; Mylan; Regeneron Pharmaceuticals; Gilead Sciences; Merck KGaA; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Head and neck squamous-cell carcinoma; Head and neck; Placebo; Basal cell; Phases of clinical research; Head and neck cancer; Carcinoma","score_opus":0.10950279646438475,"score_gpt":0.4662303413668743,"score_spread":0.35672754490248954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116681136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98988897,0.003845174,0.00000760254,0.00064490584,0.00020802679,0.004920195,0.000031985826,0.00001445656,0.00043871487],"genre_scores_gemma":[0.99812204,0.00053412764,0.00003136442,0.00012380038,0.00005917257,0.0005233062,0.000022594817,0.000025897176,0.0005576931],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957428,0.0009039599,0.0013377585,0.00066394004,0.0008303004,0.00052122696],"domain_scores_gemma":[0.9968175,0.0016866892,0.00020689695,0.000566067,0.0005285285,0.00019428115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030282831,0.00024288641,0.0014686545,0.00050843647,0.00017090437,0.00002441974,0.00022384916,0.00012634425,0.00017412746],"category_scores_gemma":[0.00073437457,0.00017236618,0.00016352595,0.0012085716,0.0007204784,0.00007072143,0.00020586795,0.001007184,0.0000011375863],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7546133,0.01231772,0.20578848,0.00043085616,0.00020317592,0.000034225523,0.001308894,0.0000040630885,0.000017386821,0.0000033707033,0.00047076444,0.024807768],"study_design_scores_gemma":[0.81729,0.024989963,0.15530498,0.00048424187,0.00022087527,9.0695556e-7,0.00055679464,0.000562849,0.0000838289,0.000027154374,0.00032549098,0.00015289088],"about_ca_topic_score_codex":0.005210857,"about_ca_topic_score_gemma":0.0032539684,"teacher_disagreement_score":0.06267673,"about_ca_system_score_codex":0.00037109712,"about_ca_system_score_gemma":0.0010681234,"threshold_uncertainty_score":0.78772914},"labels":[],"label_agreement":null},{"id":"W7116874115","doi":"10.1111/cas.70300","title":"Perioperative Nivolumab in Resectable Non‐Small Cell Lung Cancer: A Subanalysis of Japanese Patients From <scp>CheckMate 77T</scp>","year":2025,"lang":"en","type":"article","venue":"Cancer Science","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Nivolumab; Perioperative; Placebo; Adverse effect; Lung cancer; Randomized controlled trial; Chemotherapy; Neoadjuvant therapy","score_opus":0.008503494123921478,"score_gpt":0.28156415758175146,"score_spread":0.27306066345783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116874115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857739,0.007939884,0.00003153472,0.00016512004,0.00046651036,0.00052773196,0.00008256912,0.000017736867,0.004995014],"genre_scores_gemma":[0.9933005,0.0013198054,0.00016836706,0.00043172028,0.000039272407,0.00013828924,0.000010023903,0.000012622493,0.004579395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793506,0.00004278513,0.00043828058,0.0006326958,0.00046659214,0.00048459246],"domain_scores_gemma":[0.9987023,0.000087495944,0.0001771915,0.0004842498,0.00043539,0.00011341279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003855739,0.00020500836,0.000492456,0.00044352337,0.00016868323,0.000057192035,0.00047714272,0.00008452616,0.00014651136],"category_scores_gemma":[0.00011465864,0.00017801167,0.000118241114,0.0031533968,0.00052968215,0.00024303231,0.00012051998,0.00019738438,0.000002377092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004741117,0.00028087283,0.70008343,0.0002894376,0.00015867793,0.0000088847755,0.018737284,0.00031106378,0.27258307,0.0000050196927,0.0011439458,0.005924204],"study_design_scores_gemma":[0.007883595,0.0002601026,0.60433805,0.0014168652,0.00028578978,4.8741646e-7,0.005037856,0.013373501,0.365107,0.000006843243,0.0020995892,0.00019032553],"about_ca_topic_score_codex":0.046593342,"about_ca_topic_score_gemma":0.0059806,"teacher_disagreement_score":0.09574539,"about_ca_system_score_codex":0.0010064695,"about_ca_system_score_gemma":0.0019311236,"threshold_uncertainty_score":0.9597555},"labels":[],"label_agreement":null},{"id":"W7116904528","doi":"10.64898/2025.12.19.695247","title":"NLRC5 expression in tumor cells is critical to activate adaptive and innate antitumor immune responses","year":2025,"lang":"","type":"article","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Alliance de recherche numérique du Canada; Université de Sherbrooke","keywords":"Immune system; Cytotoxic T cell; Tumor microenvironment; Cancer immunotherapy; Chemokine; Acquired immune system; Downregulation and upregulation; Innate immune system; CD8","score_opus":0.012483773926855072,"score_gpt":0.2624374701881693,"score_spread":0.24995369626131425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116904528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97870964,0.013543282,0.00035473765,0.004077618,0.0014364985,0.0014313739,0.00029440163,0.00011945122,0.00003297402],"genre_scores_gemma":[0.99188775,0.0018000167,0.0018173255,0.0039870148,0.00018270263,0.00015021865,6.682797e-8,0.00010203146,0.00007289793],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99547464,0.0004479626,0.0011208147,0.0013654259,0.00048379204,0.0011073558],"domain_scores_gemma":[0.99722433,0.00053465116,0.00022470394,0.0011167518,0.00043873274,0.000460834],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011404544,0.00074222474,0.001059403,0.0010748387,0.0003357844,0.00020447416,0.00038846745,0.00035586266,0.00027325144],"category_scores_gemma":[0.0007431425,0.0007560005,0.00017481067,0.0021299075,0.0005457286,0.0004154308,0.00035110206,0.0007575008,0.00006265977],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013437396,0.0004840695,0.006637838,0.0005377374,0.00017155692,0.0004270974,0.0000825179,7.672085e-7,0.97707576,0.0002611275,0.00085622485,0.000027893642],"study_design_scores_gemma":[0.0030923958,0.00050110125,0.22741723,0.0047878125,0.00011685073,7.113011e-8,0.00009601566,0.00008983569,0.75388163,0.0000011177577,0.009442598,0.00057332724],"about_ca_topic_score_codex":0.00021003693,"about_ca_topic_score_gemma":0.0000047008502,"teacher_disagreement_score":0.22319414,"about_ca_system_score_codex":0.0005724349,"about_ca_system_score_gemma":0.001141352,"threshold_uncertainty_score":0.9994891},"labels":[],"label_agreement":null},{"id":"W7116910451","doi":"10.1016/j.annonc.2025.10.607","title":"LBA9 Perioperative pembrolizumab in early-stage non–small-cell lung cancer (NSCLC): 5-year follow-up from the KEYNOTE-671 global study and Asian subgroup","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Lung cancer; Subgroup analysis; Perioperative; MEDLINE","score_opus":0.030612822902916614,"score_gpt":0.3650202672501153,"score_spread":0.3344074443471987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116910451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97448957,0.0042531025,0.000018295472,0.007861178,0.00042081473,0.0011892327,0.00009867724,0.000015024383,0.011654117],"genre_scores_gemma":[0.99404633,0.0011661681,0.00004714058,0.0025112866,0.00008910641,0.00010751057,0.0000102316335,0.000013387924,0.002008826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984448,0.00023422173,0.00043821023,0.00038688493,0.00016532691,0.00033055944],"domain_scores_gemma":[0.9991657,0.0001521031,0.00013921174,0.00033768272,0.00013713392,0.000068161055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039581978,0.00021418829,0.00059431914,0.0000816206,0.00009811868,0.000024935889,0.00020870988,0.00018702827,0.00019847487],"category_scores_gemma":[0.000046105364,0.00015661208,0.00012841524,0.0003937982,0.00021464886,0.000063840744,0.000110798435,0.0002667917,0.0000028984146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016018648,0.001033812,0.9217279,0.00007868362,0.00095515244,0.00012309762,0.013521977,0.0000031662096,0.0035902313,0.00010504941,0.0041544638,0.03868784],"study_design_scores_gemma":[0.020620756,0.0031182938,0.9531775,0.0001827382,0.00019226769,0.0000031469895,0.008555739,0.000067249726,0.0013024166,0.00002755514,0.012587817,0.00016449788],"about_ca_topic_score_codex":0.019179521,"about_ca_topic_score_gemma":0.025729919,"teacher_disagreement_score":0.038523342,"about_ca_system_score_codex":0.00018158476,"about_ca_system_score_gemma":0.00074344175,"threshold_uncertainty_score":0.99204797},"labels":[],"label_agreement":null},{"id":"W7116923068","doi":"10.1016/j.annonc.2025.10.140","title":"313P Characteristics, treatment patterns, and outcomes with first-line nivolumab plus chemotherapy vs chemotherapy in CheckMate 649 patients by regions","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Chemotherapy; Nivolumab; Chemotherapy regimen; Chemoimmunotherapy; Cyclophosphamide","score_opus":0.026630085028864887,"score_gpt":0.33765457265372445,"score_spread":0.31102448762485957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116923068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9622376,0.00052920164,0.00005380327,0.03586135,0.00011265863,0.00065604504,0.000083946274,0.000023895753,0.0004414756],"genre_scores_gemma":[0.9728445,0.01605212,0.00007960131,0.00879562,0.000027913387,0.00007135793,0.00011680062,0.000025340332,0.0019867732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987802,0.00004259021,0.00046318356,0.00030540282,0.00012050307,0.00028811727],"domain_scores_gemma":[0.9992011,0.00010952647,0.00022511737,0.0002837948,0.00011254306,0.000067893234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012869164,0.0002410077,0.0008027474,0.00016525335,0.000048702164,0.000008881686,0.00008617541,0.00016817306,0.00008100065],"category_scores_gemma":[0.000019629348,0.00017700353,0.000100132595,0.00017049727,0.00016951335,0.00004682525,0.00001713387,0.00009852895,0.0000012399282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014846338,0.0018059181,0.8194282,0.00016263676,0.00062498735,0.000017419434,0.00073246815,3.4045823e-7,0.00025345696,0.0000136381905,0.006896131,0.15521844],"study_design_scores_gemma":[0.025131928,0.0069304644,0.85911983,0.00028641056,0.00004839909,0.0000060742614,0.000089559784,0.00001995979,0.0033172406,0.000024976878,0.104868285,0.00015688637],"about_ca_topic_score_codex":0.0014247276,"about_ca_topic_score_gemma":0.0010865501,"teacher_disagreement_score":0.15506154,"about_ca_system_score_codex":0.00021215326,"about_ca_system_score_gemma":0.00024447936,"threshold_uncertainty_score":0.7217995},"labels":[],"label_agreement":null},{"id":"W7116948267","doi":"10.1016/j.annonc.2025.10.758","title":"1047P Pembrolizumab (Pembro) monotherapy for locally advanced or metastatic non–small-cell lung cancer (NSCLC): 10-year outcomes from clinical trials","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Clinical trial; Lung cancer; Cancer; Immunotherapy; Respiratory disease","score_opus":0.20408833573306595,"score_gpt":0.5220085272068498,"score_spread":0.3179201914737838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116948267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9142394,0.020269884,0.011879318,0.034142368,0.0033206376,0.0074364166,0.00077320647,0.00013140115,0.007807338],"genre_scores_gemma":[0.76388776,0.05407966,0.03523722,0.08457204,0.0012800056,0.0032083236,0.00033193242,0.00027082107,0.057132214],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99602425,0.00062047533,0.002097019,0.0005700904,0.00020561434,0.00048256057],"domain_scores_gemma":[0.9929369,0.0050395965,0.00087045314,0.0005455288,0.00045793044,0.00014956597],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002981068,0.00033967535,0.0024787413,0.00022220178,0.00007539728,0.00001568023,0.000313493,0.00034588366,0.0019682364],"category_scores_gemma":[0.0011838116,0.0002405021,0.0010355084,0.0002982203,0.00022635695,0.0000733243,0.000049466118,0.00024626698,0.000009547089],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21407537,0.001893016,0.007669554,0.0004918611,0.005990579,0.00003558141,0.00033147485,0.000027954518,0.015156598,0.00007867595,0.085845225,0.6684041],"study_design_scores_gemma":[0.2170058,0.020524679,0.04527727,0.0012892069,0.0033761223,0.0000069576317,0.00092916,0.0015273816,0.05021569,0.0008798992,0.65807515,0.000892665],"about_ca_topic_score_codex":0.00046298347,"about_ca_topic_score_gemma":0.0004330753,"teacher_disagreement_score":0.66751146,"about_ca_system_score_codex":0.00011755628,"about_ca_system_score_gemma":0.0025452129,"threshold_uncertainty_score":0.9989441},"labels":[],"label_agreement":null},{"id":"W7117306841","doi":"10.1016/j.iotech.2025.101399","title":"402P TMEM33 loss enhances CD8+ T cell functionality and tumour control","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"T cell; Cytotoxic T cell; Immune system; T lymphocyte; Cell","score_opus":0.006170921108255087,"score_gpt":0.28137488002997735,"score_spread":0.2752039589217223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117306841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9301664,0.021355433,0.0011002071,0.031890936,0.0012500915,0.0006786098,0.00001940486,0.00039503528,0.013143873],"genre_scores_gemma":[0.99185497,0.0014584201,0.00040555128,0.0031954888,0.00006923207,0.00016465096,0.000013066091,0.000016012502,0.0028226129],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843514,0.00008575983,0.00047320305,0.00046856957,0.000114382274,0.00042292435],"domain_scores_gemma":[0.99896616,0.00021878838,0.00016684725,0.00045061068,0.00015288021,0.000044736607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040017007,0.00024259751,0.0006345022,0.0004661756,0.00019757183,0.000013121156,0.0002145889,0.00070920476,0.00031196815],"category_scores_gemma":[0.000104406274,0.00021483195,0.00012347224,0.00058835046,0.0012924058,0.00006088508,0.00010497674,0.0004811604,0.000035176494],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004382222,0.00046113975,0.030876553,0.00011013343,0.0006021964,0.00010725708,0.000066660024,4.7462171e-7,0.88473064,0.0029830884,0.0047557177,0.07092391],"study_design_scores_gemma":[0.020702332,0.0027799855,0.06511848,0.00014737307,0.0004871635,0.00078919646,0.0009891632,0.000035422716,0.2785891,0.007435215,0.6224901,0.0004364222],"about_ca_topic_score_codex":0.000088184,"about_ca_topic_score_gemma":0.00006601346,"teacher_disagreement_score":0.61773443,"about_ca_system_score_codex":0.00029734834,"about_ca_system_score_gemma":0.00045799112,"threshold_uncertainty_score":0.8760593},"labels":[],"label_agreement":null},{"id":"W7117315492","doi":"10.1016/j.iotech.2025.101210","title":"126P Neoadjuvant (neoadj) nivolumab (N) + chemotherapy (C) in patients (pts) with resectable NSCLC: Outcomes by subsequent immunotherapy (IO) in CheckMate 816","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College; McGill University Health Centre","funders":"","keywords":"Nivolumab; Chemotherapy; Immunotherapy; Chemoimmunotherapy; Neoadjuvant therapy; MEDLINE","score_opus":0.005142110023032019,"score_gpt":0.27443932435254625,"score_spread":0.26929721432951426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117315492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96725565,0.0096400045,0.00007240554,0.016357113,0.00057049084,0.0020566464,0.000022960598,0.0003527425,0.0036719863],"genre_scores_gemma":[0.98771495,0.0031160328,0.00064785156,0.0043903864,0.000016452805,0.0006706323,0.000088231514,0.000106545274,0.003248896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99598306,0.00018206447,0.0012848692,0.00095752033,0.00034138156,0.0012510841],"domain_scores_gemma":[0.997905,0.00015428699,0.00037981648,0.0012947518,0.00019999781,0.00006611829],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006362041,0.00065246754,0.0016289442,0.0018329356,0.00015131406,0.000031580683,0.0007561306,0.0012632665,0.00036167735],"category_scores_gemma":[0.00008671473,0.00054757396,0.0002027672,0.002414639,0.0009075335,0.00018227907,0.00014913664,0.0011524019,0.000029685594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023946173,0.003122571,0.6367442,0.00007176663,0.00082999736,0.00014741767,0.0005202562,0.00000338154,0.09507343,0.00028536087,0.0037061016,0.23554932],"study_design_scores_gemma":[0.13335238,0.009217094,0.5455231,0.0010615283,0.00010367742,0.00012986736,0.0014071031,0.00005318451,0.061849695,0.0010865208,0.24497262,0.0012432087],"about_ca_topic_score_codex":0.0018457714,"about_ca_topic_score_gemma":0.001368285,"teacher_disagreement_score":0.24126652,"about_ca_system_score_codex":0.0026243974,"about_ca_system_score_gemma":0.000840112,"threshold_uncertainty_score":0.99969757},"labels":[],"label_agreement":null},{"id":"W7117359197","doi":"10.1093/jnci/djaf373","title":"Impact of age and frailty on acute care use during immune checkpoint inhibitor treatment","year":2025,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Health Services and Policy Research; Princess Margaret Cancer Centre; Institute for Work & Health; Institute for Clinical Evaluative Sciences; Toronto General Hospital; University Health Network; University of Toronto","funders":"Conquer Cancer Foundation","keywords":"Acute toxicity; Acute care; MEDLINE; Disease; Immune system; Risk assessment; Immunotherapy","score_opus":0.044157447381334924,"score_gpt":0.3691085736606888,"score_spread":0.32495112627935385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117359197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952153,0.0023855406,0.000003267273,0.00079871074,0.0008764129,0.0001912063,0.000106249194,0.0000029665432,0.00042034683],"genre_scores_gemma":[0.99734545,0.0013666279,0.0000944612,0.00015312865,0.0002830105,0.0000059864046,0.0000038194257,0.0000062488484,0.00074126566],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990205,0.000020301182,0.00040010762,0.00009129618,0.00037251724,0.00009526301],"domain_scores_gemma":[0.9991531,0.000029781946,0.0003060961,0.0001011353,0.00036815627,0.000041760144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009736033,0.00012221343,0.00026930662,0.00017342936,0.0000926595,0.000019704416,0.000087025845,0.000054734286,0.00003042],"category_scores_gemma":[0.00006270769,0.00006824308,0.00037651506,0.00020844316,0.00011569908,0.00015503846,0.000025442097,0.00015430167,2.7275016e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023778362,0.00052941404,0.050459284,0.00022661289,0.007208388,0.0001260622,0.0019199906,0.0017322458,0.88421863,0.00012819824,0.0012872525,0.028385544],"study_design_scores_gemma":[0.006419668,0.00061967847,0.85359275,0.0010973064,0.00027798355,0.00010077508,0.00003893435,0.000008302459,0.1313898,0.000034186287,0.006344724,0.00007590033],"about_ca_topic_score_codex":0.0004015282,"about_ca_topic_score_gemma":0.00011475502,"teacher_disagreement_score":0.8031334,"about_ca_system_score_codex":0.0017170695,"about_ca_system_score_gemma":0.00097394746,"threshold_uncertainty_score":0.44900772},"labels":[],"label_agreement":null},{"id":"W7127739281","doi":"","title":"Effects of Programmed Death-Ligand 1 Expression and Clinicopathological Features on the Survival Outcomes of Patients with Colorectal Cancer: A Meta-Analysis.","year":2025,"lang":"en","type":"article","venue":"PubMed","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Expression (computer science); Colorectal cancer; Survival analysis; Overall survival; Immunohistochemistry; Disease; Over expression","score_opus":0.03308135554603011,"score_gpt":0.2943115272078515,"score_spread":0.2612301716618214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7127739281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952039,0.0020752456,0.0000063883363,0.0007315063,0.000066874054,0.0017024972,0.000023029534,0.000012712433,0.00017782152],"genre_scores_gemma":[0.9979931,0.00008984103,0.000039779217,0.0002892196,0.0000063541343,0.0014351797,0.000007591492,0.0000054876164,0.00013343034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895525,0.00014727162,0.00025418308,0.00021072713,0.00026645648,0.00016610327],"domain_scores_gemma":[0.998863,0.0006811859,0.0001774701,0.00017056162,0.00006590547,0.00004189249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003596597,0.00013718822,0.00087036,0.0001013127,0.00003834079,0.000008567826,0.000078484416,0.000074953845,0.0000072392677],"category_scores_gemma":[0.00019767579,0.000056633467,0.00036539367,0.0003522599,0.00016889823,0.000016944621,0.00003174827,0.00010792294,2.7942999e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065643806,0.00046931705,0.9614231,0.00011451098,0.01930404,0.0000029004661,0.00007443562,8.100372e-7,0.00075207755,0.00003823058,0.000052313968,0.011203898],"study_design_scores_gemma":[0.0023706292,0.00026653876,0.92906284,0.000012735275,0.026337894,1.55388e-7,0.000017288166,5.291638e-7,0.04182444,0.000010538758,0.000045093468,0.000051341558],"about_ca_topic_score_codex":0.00007461647,"about_ca_topic_score_gemma":0.00004299958,"teacher_disagreement_score":0.041072365,"about_ca_system_score_codex":0.000016534066,"about_ca_system_score_gemma":0.000027440365,"threshold_uncertainty_score":0.23094457},"labels":[],"label_agreement":null},{"id":"W7131829076","doi":"10.5376/cge.2024.12.0029","title":"Efficacy of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer: Current Status and Future Directions","year":2024,"lang":"","type":"article","venue":"Cancer Genetics and Epigenetics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Current (fluid); Immune system; Breast cancer; Ipilimumab; Immunotherapy; Nivolumab; Disease; Immune checkpoint","score_opus":0.01382460128385707,"score_gpt":0.3010479881999563,"score_spread":0.2872233869160992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7131829076","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46540284,0.5268876,0.000009728772,0.001369296,0.0047430512,0.00070644164,0.00082047714,0.000016679065,0.00004385405],"genre_scores_gemma":[0.4627093,0.5356647,0.000053487205,0.000028395762,0.0013053684,0.000076572265,0.000013431033,0.000053294003,0.000095497235],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99634135,0.000120027406,0.0014447612,0.00088111544,0.00040839444,0.00080435316],"domain_scores_gemma":[0.9985013,0.00014846989,0.00030681927,0.0004178889,0.00022876592,0.0003967651],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035349297,0.0006140065,0.0008940296,0.0004652568,0.00016684881,0.00012317213,0.00013404078,0.00032892276,0.00035349923],"category_scores_gemma":[0.000020633632,0.0005745437,0.00027847104,0.0012423344,0.0007743879,0.00006436484,0.00015390907,0.00068763166,0.0000016056199],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013924133,0.00029920976,0.03607233,0.0019007336,0.00072579103,0.000011204257,0.00786365,0.000082581086,0.008711398,0.000033394565,0.00018603767,0.94272125],"study_design_scores_gemma":[0.0064616967,0.0005524631,0.7501946,0.0045374543,0.0009296255,0.000024209075,0.001446998,0.0020264562,0.020776933,0.00013118741,0.21218015,0.00073818775],"about_ca_topic_score_codex":0.0037407808,"about_ca_topic_score_gemma":0.0014831433,"teacher_disagreement_score":0.94198304,"about_ca_system_score_codex":0.00054070505,"about_ca_system_score_gemma":0.0013575193,"threshold_uncertainty_score":0.9996706},"labels":[],"label_agreement":null},{"id":"W7131843051","doi":"10.5376/cge.2025.13.0030","title":"Advances in the Efficacy and Safety of Immune Checkpoint Inhibitors in Solid Tumors","year":2025,"lang":"","type":"article","venue":"Cancer Genetics and Epigenetics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immune system; Immunotherapy; Nivolumab; Immune checkpoint; CHEK1; Cancer immunotherapy; Cancer; Pembrolizumab","score_opus":0.01052422037669654,"score_gpt":0.29975501311867714,"score_spread":0.2892307927419806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7131843051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5448137,0.45198599,0.00004475711,0.0011568294,0.00051172473,0.0007708873,0.000028549417,0.0000030555934,0.0006845218],"genre_scores_gemma":[0.55554944,0.44395742,0.00006478348,0.00022454064,0.0000884131,0.000032982858,0.0000038417475,0.00001573956,0.00006282871],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99676776,0.00016642212,0.001681443,0.0005368974,0.0002955682,0.0005518967],"domain_scores_gemma":[0.9986915,0.0002587274,0.00034475597,0.00051113975,0.000103466795,0.00009039843],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009388657,0.00040456,0.0008306639,0.00032907337,0.000118148324,0.00004386716,0.00026924635,0.00023635825,0.00004049609],"category_scores_gemma":[0.000079040154,0.00032874936,0.00012393993,0.0009727078,0.00085845124,0.00004184382,0.00015956322,0.00041960308,4.0064134e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038584264,0.00046969252,0.1762027,0.0017090108,0.00018213502,0.00002389808,0.0071513816,0.0013224379,0.023331556,0.000166502,0.00005414848,0.7855281],"study_design_scores_gemma":[0.010484487,0.0009585734,0.89303225,0.0051386175,0.00026267162,0.000008904768,0.0036407632,0.0012535591,0.04934273,0.00062293775,0.03476532,0.0004891579],"about_ca_topic_score_codex":0.0005528582,"about_ca_topic_score_gemma":0.0012358683,"teacher_disagreement_score":0.78503895,"about_ca_system_score_codex":0.00015296788,"about_ca_system_score_gemma":0.00052408467,"threshold_uncertainty_score":0.99991643},"labels":[],"label_agreement":null},{"id":"W7131874418","doi":"10.5376/ijmms.2025.15.0023","title":"Survival Benefit Analysis of PD-1/PD-L1 Inhibitors Combined with Chemotherapy in Non-Small Cell Lung Cancer","year":2025,"lang":"","type":"article","venue":"International Journal of Molecular Medical Science","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chemotherapy; Lung cancer; Survival analysis; Cancer; Clinical trial; Cell","score_opus":0.005677117345958002,"score_gpt":0.2994359624547976,"score_spread":0.2937588451088396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7131874418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726998,0.004235054,0.006431617,0.01289216,0.0025192467,0.00028252005,0.000015782236,0.0000039553074,0.00091982674],"genre_scores_gemma":[0.99430645,0.0027192433,0.00035141606,0.0022339583,0.00016237199,0.0000052822297,0.0000039677357,0.00001525296,0.00020205254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928764,0.00009792451,0.0016159035,0.00047132347,0.0044552255,0.00048322554],"domain_scores_gemma":[0.996302,0.00023077664,0.0010480178,0.00030208356,0.0017095642,0.00040755287],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00324395,0.0003100518,0.00096675777,0.002406771,0.00006901032,0.00008371205,0.0017934561,0.00020764061,0.0009614517],"category_scores_gemma":[0.00033392356,0.00023650308,0.0005283674,0.005029162,0.0012927436,0.00020373602,0.00016452081,0.000691746,5.7702636e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02767388,0.003550294,0.50991005,0.00031136055,0.013960213,0.0022495997,0.0028159944,0.0051171198,0.34156743,0.00054234883,0.0003993301,0.09190241],"study_design_scores_gemma":[0.034639604,0.0022767943,0.6255828,0.010394174,0.0035702656,0.00007287589,0.0012597444,0.04387957,0.2761231,0.00011263286,0.0013540821,0.00073437253],"about_ca_topic_score_codex":0.001089835,"about_ca_topic_score_gemma":0.0004977231,"teacher_disagreement_score":0.11567276,"about_ca_system_score_codex":0.0009931817,"about_ca_system_score_gemma":0.0044553867,"threshold_uncertainty_score":0.9999518},"labels":[],"label_agreement":null},{"id":"W7131887932","doi":"10.5376/cge.2025.13.0019","title":"Survival Benefit Analysis of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer","year":2025,"lang":"","type":"article","venue":"Cancer Genetics and Epigenetics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lung cancer; Survival analysis; Cancer; Disease; Clinical trial","score_opus":0.012046076689336388,"score_gpt":0.2889984297806939,"score_spread":0.2769523530913575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7131887932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6744596,0.3199634,0.0003937088,0.0004783263,0.002384735,0.0008117049,0.0004548775,0.000009472658,0.0010441951],"genre_scores_gemma":[0.6484366,0.348632,0.0001838655,0.00039233128,0.00027416236,0.00010132249,0.00003460104,0.00005366559,0.0018914507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953014,0.00010822515,0.0018657636,0.0011393494,0.0005423208,0.0010429197],"domain_scores_gemma":[0.99742997,0.0001902809,0.0005986508,0.00096607534,0.00048323453,0.00033179115],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058912416,0.0007716746,0.0018333651,0.0014219733,0.00017747932,0.00008561537,0.0004504213,0.0006459288,0.0005493188],"category_scores_gemma":[0.00001988105,0.0008136769,0.00060004386,0.0042008758,0.0005001354,0.000034564084,0.0002887431,0.0005047287,0.0000010397147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012747649,0.00039252767,0.8619987,0.0018999145,0.005474648,0.000014055855,0.0022038224,0.020106152,0.022209212,0.000027506818,0.00051603554,0.08388267],"study_design_scores_gemma":[0.0055992864,0.00039354304,0.8621938,0.0017917661,0.012455281,4.3077793e-7,0.0009877741,0.03917282,0.06644803,0.000055757457,0.00999975,0.0009017419],"about_ca_topic_score_codex":0.008779979,"about_ca_topic_score_gemma":0.020366749,"teacher_disagreement_score":0.08298092,"about_ca_system_score_codex":0.0006209598,"about_ca_system_score_gemma":0.0013652641,"threshold_uncertainty_score":0.99943143},"labels":[],"label_agreement":null},{"id":"W7131901876","doi":"10.5376/cge.2025.13.0018","title":"Identification and Management of Immune-Related Adverse Events -A Case Study in Lung Cancer","year":2025,"lang":"","type":"article","venue":"Cancer Genetics and Epigenetics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Adverse effect; Lung cancer; Identification (biology); Cancer; Event (particle physics); Disease","score_opus":0.014430002766770002,"score_gpt":0.32997602119159414,"score_spread":0.31554601842482416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7131901876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7114559,0.28501588,0.000079589445,0.00023526244,0.0011314781,0.0019386478,0.00006073237,0.000006569933,0.000075931865],"genre_scores_gemma":[0.64099336,0.357589,0.0000458884,0.000047346108,0.000026053021,0.00016570027,0.000004181982,0.000024404317,0.0011040956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99685574,0.00012922684,0.0015999549,0.00069573784,0.00028843366,0.000430886],"domain_scores_gemma":[0.9986359,0.000039519786,0.00043642166,0.000586232,0.00017748379,0.00012447915],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057938264,0.00039201442,0.0006226991,0.0003600518,0.00016742478,0.000021360656,0.0001614558,0.00022015409,0.00010311717],"category_scores_gemma":[0.000006271719,0.0004184984,0.00011264062,0.000854304,0.0002673747,0.00003822796,0.00022622144,0.000227568,4.644487e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087494275,0.0008129867,0.8078044,0.003995054,0.0031319011,0.00045614247,0.005208934,0.0011632368,0.004885175,0.000037172398,0.00006280389,0.17156728],"study_design_scores_gemma":[0.010982363,0.00041083776,0.9561072,0.0030561367,0.0030275125,0.00003617604,0.01141078,0.009359246,0.0043740384,0.00007882381,0.0006850073,0.0004718564],"about_ca_topic_score_codex":0.003447014,"about_ca_topic_score_gemma":0.0020481793,"teacher_disagreement_score":0.17109542,"about_ca_system_score_codex":0.00030954127,"about_ca_system_score_gemma":0.0002885394,"threshold_uncertainty_score":0.99982667},"labels":[],"label_agreement":null},{"id":"W7131902183","doi":"10.5376/cge.2025.13.0024","title":"Correlation Analysis of Postoperative Recurrence in Hepatocellular Carcinoma Patients and the Dynamic Evolution of the Tumor Immune Microenvironment","year":2025,"lang":"","type":"article","venue":"Cancer Genetics and Epigenetics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Hepatocellular carcinoma; Tumor microenvironment; Immune system; Disease; Carcinoma","score_opus":0.005210133322119081,"score_gpt":0.22759550461053832,"score_spread":0.22238537128841923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7131902183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7730798,0.22441556,0.0005290049,0.0004839988,0.000410512,0.0009130036,0.00014484744,8.455468e-7,0.000022416492],"genre_scores_gemma":[0.9262147,0.07344666,0.000038575316,0.00012742207,0.000007129373,0.000033647724,0.000016277581,0.00001060184,0.00010496486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799246,0.0002491789,0.00091812795,0.0003532819,0.00025806282,0.00022890707],"domain_scores_gemma":[0.9987393,0.00010868934,0.0004926554,0.0004548026,0.00016492873,0.000039633098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036664214,0.00024219092,0.0006255014,0.00023670976,0.0001396355,0.000014970651,0.0001832552,0.00011525141,0.00002401011],"category_scores_gemma":[0.00003671812,0.00016571383,0.0001895071,0.0011225401,0.0012266081,0.000016965801,0.00017033935,0.0001968896,1.0191121e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001238773,0.00013912625,0.96871877,0.00016259079,0.00087648706,3.7963864e-7,0.0022286286,0.0028445208,0.008822781,0.00007560796,0.000007021925,0.014885287],"study_design_scores_gemma":[0.0036764662,0.00020138132,0.8294023,0.00036699633,0.0022664268,3.1698795e-7,0.00050962984,0.1566085,0.0066079823,0.00008006054,0.00015963601,0.00012027463],"about_ca_topic_score_codex":0.0015923022,"about_ca_topic_score_gemma":0.00064939767,"teacher_disagreement_score":0.15376398,"about_ca_system_score_codex":0.00036702483,"about_ca_system_score_gemma":0.00029874285,"threshold_uncertainty_score":0.6757614},"labels":[],"label_agreement":null},{"id":"W7132859359","doi":"","title":"Preclinical Radiobiological and Immunological Characterization of Syngeneic Head/Neck and Prostate Cancer Tumor Models","year":2024,"lang":"","type":"dissertation","venue":"TSpace","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Prostate cancer; Downregulation and upregulation; Immune system; Lung cancer; Prostate; Radiation therapy; CXCR4; Cancer","score_opus":0.04295040377847445,"score_gpt":0.37833180489196017,"score_spread":0.3353814011134857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132859359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89033365,0.10542071,0.000017524218,0.001164499,0.001046015,0.0015895959,0.00016084113,0.0000647251,0.0002024408],"genre_scores_gemma":[0.86491966,0.12803395,0.00009016406,0.00021721884,0.00023480125,0.0002261555,0.0007378786,0.00006639481,0.0054737944],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9966973,0.00022075925,0.0011301773,0.0011197281,0.00032335447,0.0005086941],"domain_scores_gemma":[0.99847966,0.00017649775,0.00059023843,0.0003581508,0.00020199768,0.00019342457],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005283367,0.00065783184,0.0013754672,0.00019701128,0.00013359076,0.00008056544,0.0001513282,0.0007820649,0.00045185967],"category_scores_gemma":[0.000094162635,0.0004960782,0.00024041045,0.00034253873,0.0006613186,0.00013615467,0.00009939587,0.00083432486,0.0000071254753],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026064351,0.00040837034,0.004038906,0.004004499,0.0014066387,0.00007340777,0.01699978,0.0000057986676,0.86340255,0.00017825695,0.00005713024,0.08336032],"study_design_scores_gemma":[0.016969424,0.014255473,0.82111317,0.025221607,0.004937536,0.0005649949,0.014598393,0.017350636,0.07190982,0.0008548493,0.0090465,0.0031776025],"about_ca_topic_score_codex":0.00048740295,"about_ca_topic_score_gemma":0.00005134392,"teacher_disagreement_score":0.81707424,"about_ca_system_score_codex":0.000140583,"about_ca_system_score_gemma":0.00043158073,"threshold_uncertainty_score":0.99974906},"labels":[],"label_agreement":null},{"id":"W7132929879","doi":"","title":"Spatial Heterogeneity and Immune Microenvironment of Early Invasive ER+ Breast Cancer","year":2022,"lang":"","type":"dissertation","venue":"TSpace","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Ontario Institute for Cancer Research","keywords":"Breast cancer; Tumor microenvironment; Immune system; Immunotherapy; Cancer; Tumour heterogeneity; Tumor heterogeneity; Adjuvant","score_opus":0.012233089785925256,"score_gpt":0.30165890853659594,"score_spread":0.2894258187506707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132929879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9436388,0.052435283,0.0000076241495,0.00069674465,0.0012908245,0.0011603332,0.0004948157,0.00001421549,0.00026133773],"genre_scores_gemma":[0.95919937,0.03510832,0.000025542078,0.00016341198,0.00021120672,0.00019099511,0.00050660607,0.00009250874,0.0045020645],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99712723,0.00018432246,0.00079956267,0.000744488,0.0006623128,0.00048209843],"domain_scores_gemma":[0.9980988,0.00008887952,0.0009576498,0.0005957556,0.00008584767,0.00017305987],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028335355,0.000597766,0.0010171733,0.00019963595,0.00026281583,0.000028958199,0.00024332492,0.0003031225,0.010307997],"category_scores_gemma":[0.000014107891,0.000616159,0.00038041524,0.00023422381,0.00033355498,0.0000679058,0.00014149961,0.0005700137,0.000009591465],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024306787,0.00047953823,0.046959188,0.0015275535,0.002280392,0.000044456076,0.022861764,0.000009289924,0.8576797,0.0000035125838,0.00015401035,0.043693792],"study_design_scores_gemma":[0.00444243,0.0011568171,0.7760895,0.001001578,0.00090252876,0.00006726159,0.009722494,0.000009986166,0.20465732,0.0000027998549,0.0014355236,0.0005117478],"about_ca_topic_score_codex":0.06649284,"about_ca_topic_score_gemma":0.0056678955,"teacher_disagreement_score":0.7291303,"about_ca_system_score_codex":0.0005829865,"about_ca_system_score_gemma":0.0006160062,"threshold_uncertainty_score":0.99962896},"labels":[],"label_agreement":null},{"id":"W7133056225","doi":"","title":"Investigating T Cell Phenotypes Associated with Clinical Response to PD-1 blockade","year":2024,"lang":"","type":"dissertation","venue":"TSpace","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Canada","keywords":"Pembrolizumab; T cell; TIGIT; Immune system; Immune checkpoint; CD8; Immunotherapy; Blockade; Tumor microenvironment","score_opus":0.03657215983028017,"score_gpt":0.3883125261810324,"score_spread":0.35174036635075223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7133056225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767352,0.0068255737,0.000017785263,0.0064568594,0.0026829331,0.0015115634,0.00003682471,0.00023490832,0.0054983837],"genre_scores_gemma":[0.8172053,0.00040295237,0.00059889967,0.0021254304,0.00084473874,0.00010006906,0.00043377443,0.00027210504,0.17801669],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9945099,0.00091181014,0.0013653934,0.0013296262,0.0010137273,0.0008695591],"domain_scores_gemma":[0.99557126,0.0018125607,0.00074212544,0.0007795189,0.00041095668,0.0006835729],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034819772,0.000877128,0.0013181292,0.00043291255,0.00028643518,0.00018953462,0.00036394305,0.0010571376,0.00096097606],"category_scores_gemma":[0.00254163,0.0007453056,0.00047769325,0.0016798119,0.00029262152,0.00006379303,0.00006865859,0.0018400338,0.00068658625],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17405154,0.0015533685,0.00918151,0.0025881901,0.006278563,0.00068072695,0.18791033,0.000086778215,0.56155187,0.000018368246,0.040015843,0.016082915],"study_design_scores_gemma":[0.03283828,0.030151848,0.36395553,0.06721569,0.013041493,0.00006748182,0.17640518,0.0017354467,0.15715872,0.00012902475,0.1506425,0.006658807],"about_ca_topic_score_codex":0.00071073964,"about_ca_topic_score_gemma":0.0008275335,"teacher_disagreement_score":0.40439314,"about_ca_system_score_codex":0.0005855452,"about_ca_system_score_gemma":0.0028098861,"threshold_uncertainty_score":0.99995226},"labels":[],"label_agreement":null},{"id":"W7162146681","doi":"10.82308/38452","title":"The single-cell spatial landscape of non-small cell lung cancer reveals mechanisms of anti-tumor immunity and response to immune checkpoint inhibitors","year":2025,"lang":"en","type":"dissertation","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lung cancer; KRAS; Cancer; Mutation","score_opus":0.00899515326511915,"score_gpt":0.26033399288969256,"score_spread":0.25133883962457343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7162146681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869088,0.0066440646,0.00018002042,0.0002655621,0.00092079,0.001485698,0.000086453125,0.000022219763,0.0034864212],"genre_scores_gemma":[0.9773676,0.0011243568,0.0003493867,0.00010619278,0.000059110025,0.00008663307,0.00013932944,0.00004668976,0.020720696],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99776495,0.00017227403,0.0010826488,0.00034662313,0.00034081494,0.00029269414],"domain_scores_gemma":[0.99790704,0.00033245495,0.0007024588,0.0005991231,0.0003727408,0.000086153676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011831633,0.000369167,0.0008634088,0.0003089008,0.0001404823,0.00002612571,0.00023783043,0.0002619037,0.0001618074],"category_scores_gemma":[0.000110721514,0.00026180854,0.0003058046,0.0004021139,0.00005494121,0.000028958191,0.00007292035,0.00033995428,8.628497e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023764221,0.00022431315,0.00040465273,0.0017971012,0.00021468003,0.0000052632654,0.0014342391,0.0000021653425,0.96844625,0.000003415069,0.0004468622,0.0032568201],"study_design_scores_gemma":[0.0029480185,0.0008534977,0.03275882,0.0022053462,0.00038123288,0.0000026550676,0.003648693,0.000046580215,0.95659053,0.0000135831315,0.00029620875,0.00025480482],"about_ca_topic_score_codex":0.005962352,"about_ca_topic_score_gemma":0.0017097625,"teacher_disagreement_score":0.032354165,"about_ca_system_score_codex":0.0001298473,"about_ca_system_score_gemma":0.0007756391,"threshold_uncertainty_score":0.99998343},"labels":[],"label_agreement":null}]}